-DOCSTART- -X- O O

Comparison NNP N
of IN N
quality NN o
of IN o
life NN o
, , o
work NN o
productivity NN o
and CC N
medical JJ o
resource NN o
utilization NN o
of IN N
peginterferon NN i
alpha NN i
2a CD i
vs IN N
the DT N
combination NN N
of IN N
interferon NN i
alpha NN i
2b CD i
plus CC i
ribavirin VB i
as IN N
initial JJ N
treatment NN N
in IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
The DT N
on-treatment JJ N
impact NN N
of IN N
interferon-based JJ N
therapies NNS N
on IN N
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
, , o
work NN o
productivity NN o
, , o
and CC o
medical JJ o
resource NN o
utilization NN o
has VBZ N
not RB N
been VBN N
systematically RB N
studied VBN N
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
treatment NN N
with IN N
peginterferon NN i
alpha NN i
( ( i
pegIFNalpha NN i
) ) i
2a CD i
monotherapy NN i
and CC N
the DT N
combination NN i
of IN i
interferon NN i
alpha NN i
( ( i
IFNalpha NNP i
) ) i
2b CD i
plus CC i
ribavirin NN i
( ( i
RBV NNP i
) ) i
on IN N
health-related JJ o
QOL NNP o
, , o
work NN o
productivity NN o
and CC o
resource NN o
utilization NN o
. . o

A DT N
total NN N
of IN N
412 CD p
patients NNS p
with IN p
hepatitis NN p
C NNP p
infection NN p
were VBD N
randomized VBN N
to TO N
open-label JJ i
treatment NN i
with IN i
either DT i
pegIFNalpha NN i
2a CD i
( ( i
n JJ i
= NNP i
206 CD i
) ) i
or CC i
IFNalpha $ i
2b/RBV CD i
( ( i
n JJ i
= NNP i
206 CD i
) ) i
. . i

PegIFNalpha $ i
2a CD i
was VBD N
administered VBN N
subcutaneously RB N
at IN N
a DT N
dose NN N
of IN N
180 CD N
microg NN N
once RB N
weekly JJ N
for IN N
48 CD N
weeks NNS N
; : N
and CC N
IFNalpha $ i
2b/RBV CD i
at IN N
doses NNS N
of IN N
3 CD N
MU NNP N
thrice JJ N
weekly RB N
subcutaneously RB N
and CC N
1000-1200 JJ N
mg/day NN N
orally RB N
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
SF-36 NNP o
Health NNP o
Survey NNP o
Questionnaire NNP o
and CC o
additional JJ o
generic NN o
and CC o
specific JJ o
scales NNS o
. . o

During IN N
treatment NN N
, , N
for IN N
all DT N
SF-36 NNP N
summary NN N
and CC N
Hepatitis NNP o
Quality NNP o
of IN o
Life NNP o
Questionnaire NNP o
( ( o
HQLQ NNP o
) ) o
-specific NN o
scales NNS o
, , N
the DT N
pegIFNalpha NN i
2a CD i
group NN N
experienced VBD N
less JJR N
impairment JJ N
than IN N
did VBD N
the DT N
IFNalpha NNP i
2b/RBV CD i
patients NNS N
. . N

The DT N
between-treatment JJ N
differences NNS N
were VBD N
significant JJ N
for IN N
many JJ N
of IN N
the DT N
scores NNS N
particularly RB N
in IN N
the DT N
first JJ N
24 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Across IN N
all DT N
measures NNS N
of IN N
work NN N
functioning NN N
and CC N
productivity NN N
at IN N
each DT N
visit NN N
, , N
patients NNS N
randomized VBD N
to TO N
pegIFNalpha VB i
2a CD i
treatment NN N
showed VBD N
less RBR N
impairment JJ o
relative NN N
to TO N
the DT N
group NN N
treated VBD N
with IN N
IFNalpha NNP i
2b/RBV CD i
. . i

Hence NNP N
treatment NN N
with IN N
pegIFNalpha JJ i
2a CD i
relative JJ N
to TO N
IFNalpha NNP i
2b/RBV CD i
minimizes VBZ N
the DT N
adverse JJ N
impact NN N
of IN N
therapy NN N
on IN N
health-related JJ o
QOL NNP o
. . o

Patients NNS N
randomized VBD N
to TO N
pegIFNalpha VB i
2a CD i
had VBD N
improved VBN N
work NN o
productivity NN o
, , o
less JJR o
activity NN o
impairment NN o
, , o
decreased VBD o
need NN o
for IN o
prescription NN o
drugs NNS o
to TO o
treat VB o
adverse JJ o
effects NNS o
, , o
and CC o
better JJR o
adherence NN o
to TO o
therapy NN o
. . o

-DOCSTART- -X- O O

Role NNP N
of IN N
the DT N
placebo NN i
effect NN i
in IN N
evaluating VBG p
antidepressant JJ o
efficacy NN o
. . o

-DOCSTART- -X- O O

Evidence NN N
of IN N
radiographic JJ o
benefit NN o
of IN N
treatment NN N
with IN N
infliximab JJ i
plus JJ i
methotrexate NN i
in IN N
rheumatoid JJ p
arthritis NN p
patients NNS p
who WP p
had VBD p
no DT p
clinical JJ p
improvement NN p
: : p
a DT N
detailed JJ N
subanalysis NN N
of IN N
data NNS N
from IN N
the DT N
anti-tumor JJ N
necrosis NN N
factor NN N
trial NN N
in IN N
rheumatoid JJ N
arthritis NN N
with IN N
concomitant JJ N
therapy NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB o
the DT o
relationship NN o
between IN N
inflammation NN N
and CC N
joint JJ N
destruction NN N
in IN N
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
patients NNS p
who WP p
have VBP p
not RB p
responded VBN p
clinically RB p
to TO p
treatment NN p
. . p

METHODS NNP N
Changes NNP N
from IN N
baseline NN N
to TO N
week NN N
54 CD N
in IN N
clinical JJ o
variables NNS o
and CC o
measures NNS o
of IN o
radiographic JJ o
progression NN o
were VBD N
compared VBN N
between IN N
patients NNS N
who WP N
received VBD N
infliximab NN i
( ( N
3 CD N
mg/kg NN N
or CC N
10 CD N
mg/kg NN N
every DT N
4 CD N
or CC N
8 CD N
weeks NNS N
) ) N
plus CC N
methotrexate NN i
( ( i
MTX NNP i
) ) i
and CC N
those DT N
who WP N
received VBD N
MTX NNP i
plus CC i
placebo NN i
in IN N
the DT N
Anti-Tumor NNP N
Necrosis NNP N
Factor NNP N
Trial NNP N
in IN N
RA NNP N
with IN N
Concomitant NNP N
Therapy NNP N
trial NN N
. . N

RESULTS NN N
At IN N
week NN N
54 CD N
, , N
patients NNS p
who WP N
did VBD N
not RB N
show VB N
20 CD N
% NN N
improvement NN o
by IN o
American NNP o
College NNP o
of IN o
Rheumatology NNP o
criteria NNS o
( ( N
ACR20 NNP N
nonresponders NNS N
) ) N
while IN N
receiving VBG N
infliximab JJ i
plus CC i
MTX NNP i
exhibited VBD N
mild JJ N
but CC N
statistically RB N
significant JJ N
improvement NN N
in IN N
clinical JJ N
variables NNS N
, , N
including VBG N
the DT N
28-joint JJ o
Disease NNP o
Activity NNP o
Score NNP o
( ( o
DAS28 NNP o
) ) o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
tender NN o
joint NN o
count NN o
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
, , N
swollen JJ o
joint NN o
count NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
level NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Whereas IN N
the DT N
clinical JJ N
and CC N
CRP NNP N
changes NNS N
among IN N
ACR20 NNP N
nonresponders NNS N
to TO N
infliximab VB i
plus JJ i
MTX NNP i
were VBD N
small JJ N
and CC N
much JJ N
lower JJR N
than IN N
among IN N
ACR20 NNP N
responders NNS N
to TO N
this DT N
treatment NN N
, , N
radiographic JJ o
progression NN o
among IN N
ACR20 NNP N
nonresponders NNS N
to TO N
infliximab VB i
plus JJ i
MTX NNP i
was VBD N
significantly RB N
inhibited VBN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
compared VBN N
with IN N
ACR20 NNP N
nonresponders NNS N
to TO N
MTX NNP N
plus CC N
placebo NN N
. . N

Radiographic JJ N
progression NN N
was VBD N
much RB N
greater JJR N
in IN N
patients NNS N
receiving VBG N
MTX NNP i
plus CC i
placebo NN i
than IN N
in IN N
patients NNS N
receiving VBG N
infliximab JJ N
plus CC N
MTX NNP N
, , N
irrespective NN N
of IN N
ACR NNP o
response NN o
status NN o
( ( o
mean JJ o
change NN o
in IN o
modified JJ o
Sharp/van NNP o
der NN o
Heijde NNP o
score VBD o
6.0 CD N
in IN N
ACR20 NNP N
responders NNS N
and CC N
7.2 CD N
in IN N
ACR20 NNP N
nonresponders NNS N
in IN N
the DT N
MTX NNP i
plus CC N
placebo-treated JJ N
group NN N
, , N
versus VBZ N
0.1 CD N
in IN N
ACR20 NNP N
responders NNS N
and CC N
1.2 CD N
in IN N
ACR20 NNP N
nonresponders NNS N
in IN N
the DT N
infliximab JJ i
plus CC i
MTX-treated JJ i
group NN N
) ) N
. . N

Furthermore UH N
, , N
among IN N
patients NNS N
who WP N
were VBD N
ACR20 NNP N
nonresponders NNS N
through IN N
week NN N
54 CD N
, , N
patients NNS N
who WP N
were VBD N
DAS NNP N
nonresponders NNS N
at IN N
weeks NNS N
30 CD N
and CC N
54 CD N
, , N
and CC N
patients NNS N
without IN N
any DT N
improvement NN N
in IN N
individual JJ N
clinical JJ N
variables NNS N
, , N
those DT N
receiving VBG N
infliximab JJ i
plus CC i
MTX NNP i
still RB N
demonstrated VBD N
inhibition NN N
of IN N
structural JJ N
damage NN N
that WDT N
was VBD N
statistically RB N
significant JJ N
compared VBN N
with IN N
inhibition NN N
in IN N
patients NNS N
who WP N
received VBD N
MTX NNP i
plus CC i
placebo NN i
( ( N
P NNP N
< VBZ N
0.05 CD N
to TO N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Even RB N
in IN N
patients NNS p
without IN N
clinical JJ o
improvement NN o
, , N
treatment NN N
with IN N
infliximab JJ i
plus CC i
MTX NNP i
provided VBD N
significant JJ N
benefit NN N
with IN N
regard NN N
to TO N
the DT N
destructive JJ N
process NN N
, , N
suggesting VBG N
that IN N
in IN N
such JJ N
patients NNS N
these DT N
2 CD N
measures NNS N
of IN N
disease NN N
are VBP N
dissociated VBN N
. . N

-DOCSTART- -X- O O

Design NN N
and CC N
subject JJ N
characteristics NNS N
in IN N
the DT N
federally-funded JJ N
citalopram NN i
trial NN N
in IN N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

The DT N
Studies NNPS N
to TO N
Advance NNP N
Autism NNP N
Research NNP N
and CC N
Treatment NNP N
Network NNP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
with IN N
citalopram NN i
in IN N
children NNS p
with IN p
Pervasive NNP p
developmental NN p
disorders NNS p
( ( p
PDDs NNP p
) ) p
. . p

We PRP N
present VBD N
the DT N
rationale NN N
, , N
design NN N
and CC N
sample JJ N
characteristics NNS N
of IN N
the DT N
citalopram JJ i
trial NN N
. . N

Subjects NNS p
( ( p
128 CD p
boys NNS p
, , p
21 CD p
girls NNS p
) ) p
had VBD p
a DT p
mean JJ p
age NN p
of IN p
9.3 CD p
( ( p
?3.12 NN p
) ) p
years NNS p
; : p
132 CD p
( ( p
88.6 CD p
% NN p
) ) p
were VBD p
diagnosed VBN p
with IN p
autistic JJ p
disorder NN p
( ( p
4.7 CD p
% NN p
with IN p
Asperger NNP p
's POS p
Disorder NNP p
; : p
6.7 CD p
% NN p
with IN p
PDD-not NNP p
otherwise RB p
specified VBD p
) ) p
. . p

Less JJR p
than IN p
half NN p
of IN p
the DT p
subjects NNS p
were VBD o
intellectually RB o
disabled VBN o
; : o
117 CD p
( ( p
78.5 CD p
% NN p
) ) p
were VBD p
rated VBN p
Moderate NNP p
or CC p
Marked VBN p
on IN p
the DT o
Clinical NNP o
Global NNP o
Impression NNP o
for IN o
Severity NNP o
. . o

Study NNP N
measures NNS N
were VBD N
similar JJ N
to TO N
previous JJ N
Research NNP N
Units NNP N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
trials NNS N
. . N

Subjects NNS p
in IN p
this DT p
trial NN p
were VBD p
slightly RB p
older JJR p
and CC p
more RBR p
likely JJ p
to TO p
have VB p
complaints NNS p
of IN o
repetitive JJ o
behavior NN o
than IN N
participants NNS N
in IN N
RUPP NNP N
trials NNS N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
randomized NN N
study NN N
concerning VBG N
the DT N
point NN N
A NNP N
dose NN N
in IN N
high-dose JJ i
rate NN i
intracavitary JJ i
therapy NN i
for IN N
carcinoma NN p
of IN p
the DT p
uterine JJ p
cervix NN p
. . p

The DT N
final JJ N
results NNS N
. . N

PURPOSE NNP N
High-dose JJ i
rate NN i
( ( i
HDR NNP i
) ) i
remote VBP i
afterloading VBG i
intracavitary JJ i
therapy NN i
has VBZ N
been VBN N
recognized VBN N
as IN N
an DT N
effective JJ N
and CC N
safe JJ N
treatment NN N
modality NN N
for IN N
carcinoma NN p
of IN p
the DT p
uterine JJ p
cervix NN p
. . p

Since IN N
1983 CD N
, , N
a DT N
prospective JJ N
randomized NN N
study NN N
was VBD N
started VBN N
in IN N
order NN N
to TO N
investigate VB N
the DT N
more RBR N
advantageous JJ N
treatment NN N
schedule NN N
with IN N
keeping VBG N
the DT N
local JJ N
control NN N
rate NN N
. . N

This DT N
paper NN N
reports VBZ N
the DT N
final JJ N
results NNS N
in IN N
terms NNS N
of IN N
survival NN N
, , N
local JJ N
control NN N
and CC N
complications NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP p
January NNP p
1983 CD p
and CC p
February NNP p
1989 CD p
, , p
a DT p
total NN p
of IN p
165 CD p
patients NNS p
with IN p
carcinoma NN p
of IN p
the DT p
uterine JJ p
cervix NN p
was VBD p
entered VBN p
in IN p
a DT p
prospective JJ p
randomized NN p
study NN p
concerning VBG p
the DT p
point NN p
A NNP p
dose NN i
of IN i
HDR NNP i
therapy NN i
( ( i
6 CD i
Gy/fraction NNP i
vs FW i
7.5 CD i
Gy/fraction NNP i
) ) i
and CC i
external JJ i
irradiation NN i
dose NN i
at IN i
Department NNP i
of IN i
Radiation NNP i
Therapy NNP i
, , p
The DT p
Center NNP p
for IN p
Adult NNP p
Diseases NNP p
, , p
Osaka NNP p
. . p

UICC NNP p
[ VBD p
20 CD p
] JJ p
stage NN p
distribution NN p
of IN p
patients NNS p
was VBD p
as IN p
follows VBZ p
: : p
stage NN p
IA NNP p
= NNP p
4 CD p
, , p
stage NN p
IB NNP p
= NNP p
33 CD p
, , p
stage NN p
IIA NNP p
= NNP p
18 CD p
, , p
stage NN p
IIB NNP p
= NNP p
38 CD p
, , p
stage NN p
III NNP p
= NNP p
57 CD p
, , p
stage NN p
IV NNP p
= VBZ p
15 CD p
. . p

RESULTS VB N
Overall JJ N
5-year JJ o
cause NN o
specific JJ o
survivals NNS o
were VBD N
as IN N
follows VBZ N
: : N
stage NN N
IA NNP N
= VBZ N
100 CD N
% NN N
, , N
stage NN N
IB NNP N
= VBZ N
96 CD N
% NN N
, , N
stage NN N
IIA NNP N
= VBZ N
92 CD N
% NN N
, , N
stage NN N
IIB NNP N
= VBZ N
79 CD N
% NN N
, , N
stage NN N
III NNP N
= VBZ N
57 CD N
% NN N
, , N
stage NN N
IV NNP N
= VBZ N
27 CD N
% NN N
. . N

In IN N
each DT N
stage NN N
, , N
5-year JJ o
survival NN o
rates NNS o
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
were VBD N
100 CD N
% NN N
, , N
93 CD N
% NN N
in IN N
stage NN N
I PRP N
, , N
82 CD N
% NN N
and CC N
85 CD N
% NN N
in IN N
stage NN N
II NNP N
, , N
62 CD N
% NN N
and CC N
52 CD N
% NN N
in IN N
stage NN N
II NNP N
and CC N
22 CD N
% NN N
and CC N
31 CD N
% NN N
in IN N
stage NN N
IV NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
among IN N
these DT N
survival JJ N
curves NNS N
in IN N
each DT N
stage NN N
. . N

Five-year JJ o
local JJ o
failure NN o
rates NNS o
were VBD N
16 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
16 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p JJ N
= NNP N
0.9096 CD N
) ) N
, , N
and CC N
corresponding VBG N
distant JJ N
failure NN N
rates NNS N
were VBD N
23 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
19 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p JJ N
= NNP N
0.2955 CD N
) ) N
. . N

Moderate-to-severe JJ o
complications NNS o
requiring VBG N
treatment NN N
( ( N
Kottmeier NNP N
's POS N
grade NN N
2 CD N
or CC N
more JJR N
) ) N
were VBD N
noted VBN N
in IN N
6 CD N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
in IN N
group NN N
A NNP N
and CC N
6 CD N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
in IN N
group NN N
B NNP N
. . N

All DT N
of IN N
the DT N
bladder NN o
and CC o
rectal JJ o
complications NNS o
needed VBD N
medical JJ N
treatment NN N
( ( N
Kottmeier NNP N
's POS N
grade NN N
2 CD N
) ) N
. . N

Severe JJ o
complications NNS o
receiving VBG N
surgery NN N
were VBD N
noted VBN N
in IN N
4 CD N
patients NNS N
( ( N
A DT N
: : N
1 CD N
; : N
B NNP N
: : N
3 CD N
) ) N
, , N
i.e. FW N
, , N
small JJ N
intestine NN N
3 CD N
and CC N
sigmoid JJ N
colon NN N
1 CD N
patient NN N
. . N

Another DT N
1 CD N
patient NN N
( ( N
A DT N
) ) N
was VBD N
dead JJ o
of IN N
ileus NN N
. . N

CONCLUSIONS NNP N
There EX N
were VBD N
no DT N
statistically RB o
significant JJ o
differences NNS o
between IN o
2 CD o
treatment NN o
schedules NNS o
in IN o
survival NN o
rates NNS o
, , o
failure NN o
patterns NNS o
and CC o
complications NNS o
rates NNS o
. . o

This DT N
fact NN N
suggests VBZ N
that IN N
small JJ N
number NN N
of IN N
fractions NNS N
( ( N
7.5 CD N
Gy/fraction NNP N
) ) N
may MD N
be VB N
advantageous JJ N
because IN N
of IN N
short JJ N
duration NN N
and CC N
a DT N
low JJ N
load NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Gastric JJ p
carcinoma NN p
: : p
expression NN o
of IN o
c-erbB-2/neu JJ o
oncoprotein NN o
, , o
epidermal JJ o
growth NN o
factor NN o
receptor NN o
, , o
cathepsin NN o
D NNP o
, , o
progesterone NN o
receptor NN o
and CC o
tumor NN o
associated VBN o
glycoprotein-72 JJ o
in IN N
different JJ N
histological JJ N
types NNS N
. . N

OBJECTIVE NNP N
Gastric NNP p
carcinoma NN p
can MD N
be VB N
divided VBN N
into IN N
two CD N
main JJ N
histological JJ N
and CC N
clinical JJ N
types NNS N
: : N
diffuse NN p
and CC p
intestinal JJ p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
expression NN o
of IN o
neu/c-erbB-2 JJ o
oncoprotein NN o
, , o
epidermal JJ o
growth NN o
factor NN o
receptor NN o
( ( o
EGFR NNP o
) ) o
, , o
cathepsin JJ o
D NNP o
( ( o
catD NN o
) ) o
, , o
progesterone JJ o
receptor NN o
( ( o
PR NNP o
) ) o
and CC o
tumor-associated JJ o
glycoprotein-72 NN o
( ( o
TAG-72 NNP o
) ) o
in IN N
gastric JJ N
carcinoma NN N
of IN N
these DT N
histological JJ N
types NNS N
. . N

METHOD NN N
In IN N
this DT N
randomized VBN N
, , N
prospective JJ N
study NN N
we PRP N
analyzed VBD N
85 CD p
biopsy NN i
samples NNS i
from IN p
patients NNS p
with IN p
gastric JJ p
adenocarcinoma NN p
. . p

The DT N
control NN p
group NN p
consisted VBD p
of IN p
40 CD p
specimens NNS p
from IN p
normal JJ i
gastric JJ i
mucosa NN i
. . i

Neu NNP o
oncoprotein NN o
and CC o
PR NNP o
were VBD N
determined VBN N
by IN N
ELISA NNP o
. . o

CatD NNP o
and CC o
TAG-72 NNP o
were VBD N
quantified VBN N
with IN N
immunoradiometric JJ o
( ( o
IRMA NNP o
) ) o
methods NNS o
, , N
and CC N
EGFR NNP o
were VBD o
studied VBN o
by IN o
radioimmunoassay NN o
( ( o
RIA NNP o
) ) o
. . o

RESULTS NNP N
Neu NNP o
, , o
EGFR NNP o
, , o
catD NN o
and CC o
TAG-72 JJ o
concentrations NNS o
were VBD N
higher JJR N
in IN N
the DT N
tumoral JJ N
group NN N
( ( N
p JJ N
= NN N
0.02 CD N
, , N
p NN N
= VBD N
0.00001 CD N
, , N
p NN N
= VBD N
0.002 CD N
and CC N
p VB N
= JJ N
0.007 CD N
, , N
respectively RB N
) ) N
. . N

In IN N
diffuse NN N
adenocarcinomas NN N
, , N
catD NN o
and CC o
PR NNP o
expression NN o
was VBD N
increased VBN N
( ( N
p JJ N
= NN N
0.01 CD N
and CC N
p VB N
= JJ N
0.04 CD N
respectively RB N
) ) N
, , N
whereas JJ N
TAG-72 NNP o
concentration NN o
, , N
which WDT N
correlated VBD N
with IN N
neu NN o
( ( N
r JJ N
= NNP N
0.57 CD N
) ) N
, , N
was VBD N
higher RBR N
in IN N
the DT N
intestinal JJ N
type NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
EGFR NNP o
and CC o
neu JJ o
concentrations NNS o
were VBD N
seen VBN N
between IN N
the DT N
two CD N
histological JJ N
types NNS N
. . N

CONCLUSIONS VB N
The DT N
higher JJR N
PR NNP o
and CC o
catD JJ o
concentrations NNS o
in IN N
diffuse NN N
adenocarcinomas NN N
, , N
and CC N
the DT N
overexpression NN N
of IN N
TAG-72 NNP o
in IN N
the DT N
intestinal JJ N
type NN N
, , N
support VB N
the DT N
existence NN N
of IN N
two CD N
modes NNS N
of IN N
gastric JJ N
carcinogenesis NN N
. . N

-DOCSTART- -X- O O

Older JJR p
patients NNS p
with IN p
chronic JJ p
myeloid NN p
leukemia NN p
( ( p
?65 CD p
years NNS p
) ) p
profit NN p
more RBR N
from IN N
higher JJR i
imatinib NN i
doses NNS i
than IN p
younger JJR p
patients NNS p
: : p
a DT p
subanalysis NN N
of IN N
the DT N
randomized JJ N
CML-Study NNP N
IV NNP N
. . N

The DT N
impact NN N
of IN N
imatinib NN i
dose NN i
on IN N
response NN N
rates NNS N
and CC N
survival NN N
in IN N
older JJR p
patients NNS p
with IN p
chronic JJ p
myeloid NN p
leukemia NN p
in IN p
chronic JJ p
phase NN p
has VBZ p
not RB N
been VBN N
studied VBN N
well RB N
. . N

We PRP N
analyzed VBD N
data NNS N
from IN N
the DT N
German JJ N
CML-Study NNP N
IV NNP N
, , N
a DT N
randomized JJ p
five-arm JJ p
treatment NN p
optimization NN p
study NN p
in IN p
newly RB p
diagnosed VBN p
BCR-ABL-positive JJ p
chronic JJ p
myeloid NN p
leukemia NN p
in IN p
chronic JJ p
phase NN p
. . p

Patients NNS p
randomized VBD p
to TO p
imatinib VB i
400 CD i
mg/day NN p
( ( p
IM400 NNP p
) ) p
or CC p
imatinib $ i
800 CD i
mg/day NN p
( ( p
IM800 NNP p
) ) p
and CC p
stratified VBD p
according VBG p
to TO p
age NN p
( ( p
?65 CD p
years NNS p
vs. FW p
< RB p
65 CD p
years NNS p
) ) p
were VBD p
compared VBN N
regarding VBG N
dose RB N
, , N
response NN N
, , N
adverse JJ N
events NNS N
, , N
rates NNS N
of IN N
progression NN N
, , N
and CC N
survival NN N
. . N

The DT N
full JJ N
800 CD N
mg NN N
dose NN N
was VBD N
given VBN N
after IN N
a DT N
6-week JJ N
run-in JJ N
period NN N
with IN N
imatinib JJ i
400 CD i
mg/day NN N
. . N

The DT N
dose NN N
could MD N
then RB N
be VB N
reduced VBN N
according VBG N
to TO N
tolerability NN p
. . p

A DT p
total NN p
of IN p
828 CD p
patients NNS p
were VBD p
randomized VBN p
to TO p
IM400 NNP N
or CC N
IM800 NNP p
. . p

Seven NNP p
hundred VBD p
eighty-four JJ p
patients NNS p
were VBD p
evaluable JJ p
( ( p
IM400 NNP p
, , p
382 CD p
; : p
IM800 NNP p
, , p
402 CD p
) ) p
. . p

One CD p
hundred VBD p
ten JJ p
patients NNS p
( ( p
29 CD p
% NN p
) ) p
on IN p
IM400 NNP p
and CC p
83 CD p
( ( p
21 CD p
% NN p
) ) p
on IN p
IM800 NNP p
were VBD p
?65 JJ p
years NNS p
. . N

The DT o
median JJ o
dose JJ o
per IN o
day NN o
was VBD o
lower JJR N
for IN N
patients NNS N
?65 CD N
years NNS N
on IN N
IM800 NNP N
, , N
with IN N
the DT N
highest JJS N
median JJ N
dose NN N
in IN N
the DT N
first JJ N
year NN N
( ( N
466 CD N
mg/day NN N
for IN N
patients NNS N
?65 CD N
years NNS N
vs. FW N
630 CD N
mg/day NN N
for IN N
patients NNS N
< JJ N
65 CD N
years NNS N
) ) N
. . N

Older JJR N
patients NNS N
on IN N
IM800 NNP N
achieved VBD o
major JJ o
molecular JJ o
remission NN o
and CC o
deep JJ o
molecular JJ o
remission NN o
as IN N
fast NN N
as IN N
younger JJR N
patients NNS N
, , N
in IN N
contrast NN N
to TO N
standard VB N
dose JJ N
imatinib NN N
with IN N
which WDT N
older JJR p
patients NNS p
achieved VBD o
remissions NNS o
much RB o
later RBR o
than IN o
younger JJR o
patients NNS o
. . o

Grades NNP o
3 CD o
and CC o
4 CD o
adverse JJ o
events NNS o
were VBD o
similar JJ N
in IN N
both DT N
age NN N
groups NNS N
. . o

Five-year JJ o
relative JJ o
survival NN o
for IN N
older JJR N
patients NNS N
was VBD N
comparable JJ N
to TO N
that DT N
of IN N
younger JJR N
patients NNS N
. . N

We PRP N
suggest VBP N
that IN N
the DT N
optimal JJ N
dose NN N
for IN N
older JJR N
patients NNS N
is VBZ N
higher JJR N
than IN N
400 CD N
mg/day NN N
. . N

ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00055874 NN N
-DOCSTART- -X- O O

Over IN N
time NN N
relationships NNS N
between IN N
early JJ p
adolescent NN p
and CC p
peer NN o
substance NN o
use NN N
. . N

Peer NNP N
and CC N
adolescent JJ N
substance NN N
use NN N
are VBP N
highly RB N
correlated VBN N
, , N
but CC N
this DT N
relationship NN N
is VBZ N
not RB N
fully RB N
understood JJ N
. . N

In IN N
particular JJ N
, , N
the DT N
relative JJ N
contributions NNS N
of IN N
selection NN N
and CC N
socialization NN N
to TO N
substance VB N
use NN N
progression NN N
have VBP N
not RB N
been VBN N
established VBN N
. . N

Students NNS p
( ( p
n=2453 NN p
) ) p
in IN p
the DT p
seven CD p
middle JJ p
schools NNS p
in IN p
one CD p
school NN p
district NN p
were VBD p
assessed VBN p
at IN p
school NN p
at IN p
the DT p
beginning NN p
and CC p
end NN p
of IN p
the DT p
sixth JJ p
, , p
seventh JJ p
, , p
eighth JJ p
grade NN p
and CC p
beginning NN p
of IN p
the DT p
9th CD p
grade NN p
. . p

Self-reported JJ o
smoking NN o
and CC o
drinking NN o
and CC p
the DT p
number NN p
of IN p
substance NN p
using VBG p
friends NNS p
were VBD p
assessed VBN p
5 CD p
times NNS p
over IN p
3 CD p
years NNS p
. . p

The DT N
relationship NN i
between IN i
peer NN o
and CC o
adolescent NN o
substance NN o
use NN o
were VBD i
assessed VBN i
in IN i
parallel JJ i
processes NNS i
as IN i
part NN i
of IN i
an DT i
autoregressive JJ i
latent NN i
trajectory NN i
model NN i
. . i

Substance NNP o
use NN o
and CC N
the DT o
number NN o
of IN o
substance NN o
using VBG N
friends NNS N
increased VBN N
in IN N
linear JJ N
fashion NN N
from IN N
T1 NNP N
to TO N
T5 NNP N
. . N

Initial NNP N
substance NN N
use NN N
predicted VBD N
an DT N
increase NN N
in IN N
the DT N
number NN o
of IN o
substance NN o
using VBG o
friends NNS o
over IN o
time NN o
, , N
indicating VBG N
an DT N
effect NN N
of IN N
selection NN N
, , N
and CC N
the DT N
initial JJ N
number NN N
of IN N
substance NN N
using VBG N
friends NNS N
predicted VBD N
substance NN o
use NN o
progression NN N
, , N
providing VBG N
evidence NN N
of IN N
socialization NN N
. . N

The DT N
magnitudes NNS N
of IN N
these DT N
relationships NNS N
were VBD N
similar JJ N
. . N

Bivariate NNP N
, , N
lagged VBD N
autoregressive JJ N
analyses NNS N
of IN N
the DT N
successive JJ N
relationships NNS N
from IN N
one CD N
assessment NN N
to TO N
the DT N
next JJ N
showed JJ N
consistent NN N
, , N
significant JJ N
associations NNS N
from IN N
peer NN o
use NN o
to TO o
adolescent VB o
substance NN o
use NN o
. . o

The DT N
association NN N
from IN N
adolescent NN o
to TO o
peer VB o
use NN o
was VBD N
significant JJ N
only RB N
from IN N
7th CD N
to TO N
8th CD N
grade NN N
. . N

The DT N
findings NNS N
provide VBP N
evidence NN N
of IN N
reciprocal JJ N
influences NNS N
, , N
but CC N
socialization NN N
was VBD N
a DT N
more RBR N
consistent JJ N
influence NN N
than IN N
selection NN N
. . N

-DOCSTART- -X- O O

Evolution NN N
of IN N
coronary JJ N
stenoses NNS N
is VBZ N
related VBN N
to TO N
baseline VB N
severity NN N
-- : N
a DT N
prospective JJ N
quantitative JJ N
angiographic JJ N
analysis NN N
in IN N
patients NNS p
with IN p
moderate JJ p
coronary JJ p
disease NN p
. . p

INTACT JJ N
Investigators NNPS N
. . N

International NNP N
Nifedipine NNP N
Trial NNP N
on IN N
Antiatherosclerotic NNP N
Therapy NNP N
. . N

A DT N
correlation NN N
of IN N
the DT N
angiographic JJ N
evolution NN N
of IN N
coronary JJ N
stenoses NNS N
( ( N
stenosis NN N
diameter NN N
> NN N
or CC N
= VB N
20 CD N
% NN N
) ) N
with IN N
morphological JJ N
stenosis NN N
parameters NNS N
at IN N
baseline NN N
could MD N
help VB N
to TO N
identify VB o
the DT o
risk NN o
of IN o
progressive JJ o
stenoses NNS o
. . o

Therefore RB N
, , N
the DT N
data NN N
of IN N
the DT N
prospective JJ N
INTACT NNP N
study NN N
( ( N
International NNP N
Nifedipine NNP N
Trial NNP N
on IN N
Antiatherosclerotic NNP N
Therapy NNP N
) ) N
were VBD N
reviewed VBN N
. . N

In IN N
348 CD p
patients NNS p
with IN p
moderate JJ p
coronary JJ p
artery NN p
disease NN p
, , p
standardized VBD i
coronary JJ i
angiograms NNS i
were VBD p
taken VBN p
3 CD p
years NNS p
apart RB p
and CC N
were VBD N
quantitatively RB N
analysed VBN N
. . N

Changes NNS N
in IN N
the DT N
minimal JJ o
diameter NN o
of IN N
the DT N
1063 CD N
preexisting VBG N
coronary JJ N
stenoses NNS N
compared VBN N
between IN N
both DT N
angiograms NNS N
were VBD N
set VBN N
in IN N
relation NN N
to TO N
a DT N
number NN o
of IN o
conventional JJ o
stenosis NN o
parameters NNS o
at IN N
baseline NN N
. . N

Regression NNP N
analysis NN N
demonstrated VBD N
a DT N
significant JJ N
correlation NN o
of IN N
the DT N
changes NNS o
in IN o
minimal JJ o
diameter NN o
with IN N
baseline NN o
% NN o
diameter NN o
stenosis NN o
( ( N
r JJ N
= VBZ N
0.30 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
minimal JJ o
diameter NN o
( ( N
r JJ N
= NNP N
-0.28 NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
reference NN o
diameter NN o
of IN o
stenoses NNS o
( ( N
r NN N
= NNP N
-0.14 NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
changes NNS o
were VBD o
not RB o
correlated VBN o
with IN N
stenosis NN o
length NN o
and CC o
plaque JJ o
area NN o
. . o

The DT N
baseline NN N
parameters NNS N
of IN N
22 CD N
preexisting VBG N
stenoses NNS N
progressing VBG o
to TO o
occlusions NNS o
differed VBN N
from IN N
those DT N
remaining VBG o
patent NN o
only RB N
with IN N
regard NN N
to TO N
the DT N
% NN o
diameter NN o
stenosis NN o
( ( N
43 CD N
+/- JJ N
9 CD N
% NN N
vs JJ N
39 CD N
+/- JJ N
11 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Additional JJ N
progression NN o
of IN o
coronary JJ o
disease NN o
became VBD N
manifest JJS N
through IN N
development NN N
of IN N
228 CD N
stenoses NNS o
and CC N
19 CD N
occlusions NNS o
at IN N
arterial JJ N
sites NNS N
free VBP N
from IN N
definitive JJ N
stenoses NNS N
in IN N
the DT N
baseline NN N
angiograms NN N
. . N

Thus RB N
, , N
progression NN o
of IN o
atherosclerosis NN o
predominantly RB o
occurred VBD o
in IN N
mild NN N
preexisting VBG N
coronary JJ N
stenoses NNS N
and CC N
developed VBN N
at IN N
previously RB N
angiographically RB N
normal JJ N
sites NNS N
. . N

Since IN N
the DT N
conventional JJ N
angiographic JJ N
parameters NNS N
analysed VBN N
in IN N
this DT N
study NN N
failed VBD N
to TO N
identify VB N
individual JJ N
arterial JJ N
sites NNS N
with IN N
an DT N
increased VBN N
risk NN N
for IN N
progression NN N
, , N
definition NN N
of IN N
new JJ N
angiographic JJ N
parameters NNS N
or CC N
application NN N
of IN N
new JJ N
techniques NNS N
seem VBP N
mandatory JJ N
to TO N
this DT N
end NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
phase NN N
II NNP N
study NN N
of IN N
two CD N
doses NNS N
of IN N
pemetrexed JJ i
as IN N
first-line JJ N
chemotherapy NN N
for IN N
advanced JJ p
breast NN p
cancer NN p
. . p

PURPOSE NNP N
Pemetrexed NNP i
has VBZ N
shown VBN N
varied JJ N
response NN N
rates NNS N
in IN N
advanced JJ p
breast NN p
cancer NN p
. . p

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
phase NN N
II NNP N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
two CD N
doses NNS N
of IN N
pemetrexed NN i
in IN N
a DT N
homogeneous JJ N
population NN N
. . N

A DT N
secondary JJ N
objective NN N
was VBD N
to TO N
identify VB N
molecular JJ N
biomarkers NNS N
correlating VBG N
with IN N
response NN o
and CC o
toxicity NN o
. . o

EXPERIMENTAL NNP N
DESIGN NNP N
Patients NNPS p
with IN p
newly RB p
diagnosed VBN p
metastatic JJ p
breast NN p
cancer NN p
or CC p
locally RB p
recurrent JJ p
breast NN p
cancer NN p
received VBD N
600 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( i
P600 NNP i
arm NN N
) ) N
or CC N
900 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( i
P900 NNP i
arm NN N
) ) N
of IN N
pemetrexed NN i
on IN N
day NN N
1 CD N
of IN N
a DT N
21-day JJ N
cycle NN N
. . N

All DT N
patients NNS N
received VBD N
folic JJ i
acid NN i
and CC i
vitamin NN i
B NNP i
( ( i
12 CD i
) ) i
supplementation NN i
. . i

RESULTS VB N
The DT p
P600 NNP p
( ( p
47 CD p
patients NNS p
) ) p
and CC p
P900 NNP p
( ( p
45 CD p
patients NNS p
) ) p
arms NNS N
had VBD N
response NN o
rates NNS o
of IN N
17.0 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
7.7-30.8 CD N
% NN N
) ) N
and CC N
15.6 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
6.5-29.5 CD N
% NN N
) ) N
with IN N
approximately RB N
50 CD N
% NN N
stable JJ N
disease NN N
per IN N
arm NN N
, , N
median JJ o
progression-free JJ o
survival NN o
of IN N
4.2 CD N
and CC N
4.1 CD N
months NNS N
, , N
and CC N
median JJ o
times NNS o
to TO o
tumor VB o
progression NN o
of IN N
4.2 CD N
and CC N
4.6 CD N
months NNS N
, , N
respectively RB N
. . N

Both DT N
arms NNS N
exhibited VBD N
minimal JJ o
toxicity NN o
( ( N
grade JJ N
3/4 CD N
neutropenia JJ o
< RB N
20 CD N
% NN N
, , N
leukopenia NN o
< VBD N
9 CD N
% NN N
, , N
and CC N
other JJ o
toxicities NNS o
< VBP N
5 CD N
% NN N
) ) N
. . N

Tumor NN N
samples NNS N
from IN N
49 CD N
patients NNS N
were VBD N
assessed VBN N
for IN N
the DT N
expression NN N
levels NNS N
of IN N
12 CD N
pemetrexed-related JJ i
genes NNS N
. . N

Folylpolyglutamate NNP N
synthetase NN N
and CC N
thymidine JJ N
phosphorylase NN N
correlated VBN N
with IN N
efficacy NN o
. . o

Best JJS o
response NN o
rates NNS o
and CC o
median JJ o
time NN o
to TO o
tumor VB o
progression NN o
for IN N
high JJ N
versus NN N
low JJ N
thymidine NN N
phosphorylase NN N
expression NN N
were VBD N
27.6 CD N
% NN N
versus IN N
6.3 CD N
% NN N
( ( N
P NNP N
= NNP N
0.023 CD N
) ) N
and CC N
5.4 CD N
versus NN N
1.9 CD N
months NNS N
( ( N
P NNP N
= NNP N
0.076 CD N
) ) N
, , N
and CC N
for IN N
folylpolyglutamate JJ N
synthetase NN N
were VBD N
37.5 CD N
% NN N
versus IN N
10.0 CD N
% NN N
( ( N
P NNP N
= NNP N
0.115 CD N
) ) N
and CC N
8.6 CD N
versus NN N
3.0 CD N
months NNS N
( ( N
P NNP N
= NNP N
0.019 CD N
) ) N
, , N
respectively RB N
. . N

gamma-Glutamyl JJ N
hydrolase NN N
expression NN N
correlated VBN N
with IN N
grade JJ o
3/4 CD o
toxicities NNS o
: : o
78.6 CD N
% NN N
for IN N
high JJ N
versus NN N
27.3 CD N
% NN N
for IN N
low JJ N
gamma-glutamyl JJ N
hydrolase NN N
( ( N
P NNP N
= NNP N
0.024 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
two CD N
pemetrexed JJ i
doses NNS N
yielded VBD N
similar JJ N
efficacy NN o
and CC o
safety NN o
profiles NNS N
. . N

Exploratory NNP N
biomarker NN N
analysis NN N
identified VBN N
efficacy NN o
and CC o
toxicity NN o
correlations NNS N
and CC N
warrants NNS N
further JJ N
evaluation NN N
. . N

-DOCSTART- -X- O O

Endoscopic NNP i
versus NN i
operative JJ i
gastrostomy NN i
: : i
final JJ N
results NNS N
of IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

This DT p
study NN p
compared VBN p
operative JJ i
gastrostomy NN i
( ( i
OG NNP i
) ) i
( ( p
by IN p
surgeons NNS p
) ) p
with IN i
endoscopic NN i
gastrostomy NN i
( ( i
PEG NNP i
) ) i
( ( p
by IN p
physicians NNS p
) ) p
in IN N
a DT N
prospective JJ N
randomized VBN N
fashion NN N
to TO N
determine VB N
whether IN N
one CD N
technique NN N
was VBD N
superior JJ N
. . N

PEG NNP i
( ( i
Sachs-Vine NNP i
) ) i
and CC i
OG NNP i
( ( i
Stamm NNP i
) ) i
were VBD N
done VBN N
using VBG N
local JJ i
anesthesia NN i
. . i

Patients NNS p
were VBD p
assessed VBN p
for IN p
complications NNS o
, , o
mortality NN o
, , o
tube NN o
function NN o
, , o
and CC o
cost NN o
. . o

Groups NNP p
were VBD p
equally RB p
matched VBN p
for IN p
indications NNS p
and CC p
underlying JJ p
disease NN p
. . p

Fifty-seven NNP p
had VBD p
OG NNP p
and CC p
64 CD p
had VBD p
attempted VBN p
PEG NNP p
. . p

Complications NNS o
occurred VBD N
in IN N
26 CD N
% NN N
of IN N
OG NNP N
patients NNS N
and CC N
9 CD N
% NN N
died VBD o
. . o

Complications NNS o
occurred VBD N
in IN N
25 CD N
% NN N
of IN N
PEG NNP N
patients NNS N
and CC N
12 CD N
% NN N
died VBD o
. . o

Tube NNP N
feeding NN N
was VBD N
initiated VBN N
in IN N
both DT N
groups NNS N
within IN N
a DT N
mean NN N
of IN N
29 CD N
( ( N
24 CD N
to TO N
72 CD N
) ) N
hours NNS N
of IN N
the DT N
gastrostomy JJ N
placement NN N
. . N

OG NNP o
cost VBD o
$ $ N
1675 CD N
and CC N
PEG NNP N
$ $ N
979 CD N
to TO N
perform VB N
. . N

Twenty-one CD N
PEG NNP i
patients NNS N
required VBD N
endoscopic JJ o
tube NN o
change NN o
which WDT N
raised VBD o
their PRP$ o
total JJ o
cost NN o
to TO N
$ $ N
1574 CD N
. . N

We PRP N
conclude VBP N
there EX N
is VBZ N
no DT N
difference NN N
between IN N
OG NNP N
( ( N
using VBG N
local JJ N
anesthesia NN N
) ) N
and CC N
PEG NNP i
with IN N
regard NN N
to TO N
morbidity NN o
, , o
mortality NN o
, , o
or CC o
tube NN o
function NN o
. . o

The DT N
endoscopic NN N
technique NN N
does VBZ N
appear VB N
to TO N
have VB N
economic JJ o
advantage NN o
. . o

-DOCSTART- -X- O O

Using VBG N
repeated JJ N
measures NNS N
of IN N
symptom NN N
score NN N
, , N
uroflowmetry NN N
and CC N
prostate NN N
specific JJ N
antigen NN N
in IN N
the DT N
clinical JJ N
management NN N
of IN N
prostate NN p
disease NN p
. . p

Benign NNP p
Prostatic NNP p
Hyperplasia NNP p
Treatment NNP N
Outcomes NNP N
Study NNP N
Group NNP N
. . N

Measurements NNS i
of IN i
American NNP o
Urological NNP o
Association NNP o
symptom VBD o
score RB o
, , o
peak JJ o
urine JJ o
flow NN o
rate NN o
and CC i
prostate NN o
specific JJ o
antigen NN o
( ( o
PSA NNP o
) ) o
are VBP i
often RB i
followed VBN i
over RP i
time NN i
in IN i
urological JJ i
management NN i
. . i

However RB N
, , N
their PRP$ N
interpretation NN N
is VBZ N
confounded VBN N
by IN N
within-patient JJ N
variability NN N
due JJ N
to TO N
chance NN N
. . N

Data NNP N
from IN N
2 CD N
clinical JJ N
trials NNS N
are VBP N
used VBN N
to TO N
examine VB N
the DT N
magnitude NN N
of IN N
this DT N
variation NN N
. . N

When WRB N
these DT N
measures NNS N
are VBP N
repeated VBN N
at IN N
a DT N
short JJ N
interval NN N
variation NN N
is VBZ N
modest JJ N
and CC N
might MD N
easily RB N
be VB N
misinterpreted VBN N
as IN N
a DT N
true JJ N
change NN N
in IN N
patient JJ N
condition NN N
. . N

For IN N
example NN N
, , N
approximately RB p
20 CD p
% NN p
of IN p
patients NNS p
might MD N
be VB N
expected VBN N
to TO N
have VB N
a DT N
chance NN N
increase NN N
or CC N
decrease NN N
in IN N
symptom NN N
score NN N
by IN N
at IN N
least JJS N
4.9 CD N
points NNS N
, , N
in IN N
peak JJ N
urine JJ N
flow NN N
rate NN N
by IN N
at IN N
least JJS N
4.1 CD N
ml NN N
. . N

per IN N
second NN N
or CC N
in IN N
PSA NNP N
by IN N
at IN N
least JJS N
1.6 CD N
ng./ml NN N
. . N

Clinicians NNS N
can MD N
use VB N
these DT N
data NNS N
to TO N
help VB N
interpret VB N
repeated JJ N
measures NNS N
of IN N
these DT N
variables NNS N
in IN N
patients NNS N
, , N
and CC N
can MD N
consider VB N
obtaining VBG N
paired JJ N
measurements NNS N
to TO N
decrease VB N
the DT N
effect NN N
of IN N
chance NN N
variation NN N
when WRB N
they PRP N
plan VBP N
on IN N
following VBG N
them PRP N
over IN N
time NN N
. . N

-DOCSTART- -X- O O

A DT N
study NN N
of IN N
a DT N
Self-Care JJ i
Rehabilitation NNP i
Program NNP i
in IN N
pediatric JJ p
asthma NN p
. . p

The DT N
Self-Care JJ i
Rehabilitation NNP i
in IN N
Pediatric NNP N
Asthma NNP N
( ( N
SCRPA NNP N
) ) N
project NN N
was VBD N
designed VBN N
to TO N
ascertain VB N
the DT N
level NN N
to TO N
which WDT N
children NNS p
with IN p
asthma NN p
are VBP p
able JJ p
to TO p
acquire VB p
the DT p
asthma NN p
knowledge NN p
and CC p
skills NNS p
presented VBN p
in IN p
a DT p
self-management JJ p
training NN p
program NN p
conducted VBN p
by IN p
the DT p
American NNP p
Lung NNP p
Association NNP p
of IN p
Utah NNP p
and CC N
the DT N
effect NN N
of IN N
such JJ N
training NN N
on IN N
the DT N
asthma JJ N
experience NN N
. . N

The DT N
preschool NN p
SCRPA NNP N
Curriculum NNP N
( ( p
ages VBZ p
2-5 CD p
) ) p
consisted VBN N
of IN N
six CD i
1-hour JJ i
classes NNS i
scheduled VBN i
twice RB i
a DT i
week NN i
for IN i
3 CD i
weeks NNS i
. . i

The DT N
first JJ N
and CC N
last JJ N
classes NNS N
were VBD N
for IN N
one CD p
or CC p
both DT p
parents NNS p
only RB N
, , N
and CC N
the DT N
middle JJ N
four CD N
sessions NNS N
were VBD N
for IN N
the DT N
child NN p
and CC p
parent NN p
( ( p
s NN p
) ) p
. . p

The DT N
school-age JJ N
SCRPA NNP N
curriculum NN N
( ( p
ages IN p
6-14 NN p
) ) p
consisted VBD N
of IN N
eight CD i
90-minute JJ i
classes NNS i
for IN i
both DT i
child NN i
and CC i
parent NN i
( ( i
s PRP i
) ) i
scheduled VBN i
twice RB N
a DT N
week NN N
for IN N
4 CD N
weeks NNS N
. . N

Private JJ p
physicians NNS p
referred VBD p
21 CD p
preschool NN p
children NNS p
and CC p
38 CD p
school-age JJ p
children NNS p
into IN p
the DT p
program NN p
. . p

The DT N
school-age JJ p
children NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
study NN N
or CC N
control NN N
group NN N
, , N
and CC N
the DT N
preschool NN p
children NNS p
served VBD N
as IN N
their PRP$ N
own JJ N
controls NNS N
. . N

A DT N
comparison NN N
of IN N
asthma JJ N
episodes NNS N
during IN N
the DT N
3 CD N
months NNS N
before IN N
and CC N
after IN N
training NN N
showed VBD N
a DT N
statistically RB N
significant JJ N
decrease NN o
in IN o
the DT o
number NN o
of IN o
episodes NNS o
but CC N
no DT N
change NN N
in IN N
severity NN o
in IN N
the DT N
preschool NN N
, , N
school NN N
study NN N
, , N
and CC N
school NN N
control NN N
groups NNS N
. . N

The DT N
decrease NN N
in IN N
episodes NNS o
for IN N
the DT N
control NN N
groups NNS N
suggest VBP N
that IN N
the DT N
family NN N
record NN N
keeping VBG N
required VBN N
of IN N
all DT N
subjects NNS N
may MD N
have VB N
a DT N
beneficial JJ N
effect NN N
, , N
a DT N
phenomenon NN N
worth IN N
further JJ N
investigation NN N
. . N

Also RB N
, , N
the DT N
school-age NN N
group NN N
, , N
in IN N
pre- JJ N
and CC N
posttesting NN N
, , N
demonstrated VBD N
that IN N
the DT N
SCRPA NNP i
curriculum NN N
increased VBD N
knowledge NN o
and CC o
skills NNS o
in IN N
the DT N
study NN N
group NN N
, , N
changes VBZ N
not RB N
found VBN N
in IN N
the DT N
control NN N
group NN N
. . N

-DOCSTART- -X- O O

Pre-medication NN N
with IN N
pronase NN i
reduces NNS N
artefacts VBZ o
during IN N
endoscopic NN N
ultrasonography NN i
. . i

BACKGROUND NNP N
Gastric NNP N
mucus NN N
usually RB N
induces VBZ N
artefacts NNS o
during IN N
endoscopic JJ N
ultrasonography NN N
. . N

AIM NNP N
To TO N
investigate VB N
the DT N
effectiveness NN N
of IN N
pre-medication NN N
with IN N
the DT N
proteolytic JJ i
enzyme NN i
, , i
pronase NN i
, , N
before IN N
endoscopic JJ i
ultrasonography NN i
. . i

METHODS NNP N
Out-patients NNS p
scheduled VBN p
for IN p
endoscopic NN p
ultrasonography NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
oral JJ p
pre-medication NN i
with IN i
the DT i
anti-foam JJ i
agent NN i
, , i
dimethylpolysiloxane NN i
, , i
alone RB i
( ( i
treatment NN i
A NNP i
; : i
n JJ i
= NNP i
29 CD i
) ) i
, , i
with IN i
dimethylpolysiloxane JJ i
plus CC i
sodium JJ i
bicarbonate NN i
( ( i
treatment NN i
B NNP i
; : i
n CC i
= VB i
29 CD i
) ) i
or CC i
with IN i
dimethylpolysiloxane NN i
, , i
sodium NN i
bicarbonate NN i
and CC i
pronase NN i
( ( i
treatment NN i
C NNP i
; : i
n CC p
= VB p
29 CD p
) ) p
. . p

All DT N
drinks NNS N
were VBD N
given VBN N
about IN N
10 CD N
min NN N
before IN N
the DT N
start NN N
of IN N
the DT N
procedure NN N
. . N

After IN N
insertion NN N
of IN N
the DT N
endoscope NN N
, , N
endoscopists VBZ N
recorded JJ N
visibility NN N
scores NNS N
before IN N
the DT N
procedure NN N
, , N
imaging VBG N
scores NNS N
at IN N
endoscopic NN N
ultrasonography NN N
and CC N
the DT N
numbers NNS N
of IN N
high-echo JJ N
spots NNS N
in IN N
the DT N
gastric JJ N
cavity NN N
and CC N
on IN N
the DT N
gastric NN N
wall NN N
surface NN N
after IN N
the DT N
procedure NN N
. . N

RESULTS VB N
Pre-medication JJ N
with IN N
pronase NN i
( ( N
treatment NN N
C NNP i
) ) i
significantly RB N
reduced VBN N
( ( N
both DT N
at IN N
P NNP N
< NNP N
0.05 CD N
) ) N
the DT N
visibility NN o
score NN o
( ( N
score RB N
4 CD N
, , N
46 CD N
% NN N
) ) N
in IN N
comparison NN N
with IN N
that DT N
obtained VBN N
for IN N
pre-medication NN N
without IN N
pronase NN i
( ( N
10 CD N
% NN N
for IN N
both DT N
treatments NNS i
A DT i
and CC i
B NNP i
) ) i
. . N

Treatment NN N
with IN N
pronase NN i
significantly RB N
reduced VBN N
( ( N
both DT N
at IN N
P NNP N
< NNP N
0.05 CD N
) ) N
the DT o
endoscopic NN o
ultrasonography NN o
score NN o
in IN N
the DT N
gastric JJ N
cavity NN N
( ( N
score RB N
4 CD N
, , N
34 CD N
% NN N
) ) N
in IN N
comparison NN N
with IN N
that DT N
found NN N
for IN N
treatments NNS N
A NNP N
( ( N
7 CD N
% NN N
) ) N
and CC N
B NNP N
( ( N
0 CD N
% NN N
) ) N
. . N

It PRP N
also RB N
significantly RB N
reduced VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
the DT N
endoscopic NN o
ultrasonography NN o
score NN o
on IN N
the DT N
gastric NN N
wall NN N
surface NN N
( ( N
score RB N
4 CD N
, , N
14 CD N
% NN N
) ) N
in IN N
comparison NN N
with IN N
that DT N
observed VBD N
for IN N
treatment NN N
A NNP N
( ( N
3 CD N
% NN N
) ) N
. . N

The DT o
numbers NNS o
of IN o
high-echo JJ o
spots NNS o
in IN o
the DT o
gastric JJ o
cavity NN o
and CC o
on IN o
the DT o
gastric NN o
wall NN o
surface NN o
were VBD N
significantly RB N
less JJR N
( ( N
both DT N
at IN N
P NNP N
< NNP N
0.001 CD N
) ) N
for IN N
pre-medication NN N
with IN N
pronase NN i
( ( i
treatment NN i
C NNP i
) ) i
than IN N
for IN N
pre-medication NN N
with IN N
treatments NNS i
A NNP i
and CC i
B NNP i
. . i

There EX N
were VBD N
no DT o
complications NNS o
associated VBN N
with IN N
the DT N
solutions NNS N
. . N

CONCLUSIONS NNP N
Pre-treatment JJ N
with IN N
pronase NN i
reduced VBD N
the DT N
artefacts NNS o
during IN N
endoscopic JJ N
ultrasonography NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
acupuncture NN i
on IN N
T-lymphocyte NNP o
and CC o
its PRP$ o
subsets NNS o
from IN N
the DT N
peripheral JJ N
blood NN N
of IN N
patients NNS p
with IN p
malignant JJ p
neoplasm NN p
] NN p
. . N

Effect NN N
of IN N
acupuncture NN i
on IN N
the DT N
T-lymphocyte NNP o
and CC N
its PRP$ N
subsets NNS o
from IN N
the DT N
peripheral JJ N
blood NN N
of IN N
patients NNS p
with IN p
malignant JJ p
neoplasm NN p
has VBZ N
been VBN N
researched VBN N
in IN N
this DT N
study NN N
. . N

51 CD p
patients NNS p
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
one CD N
in IN N
acupuncture NN i
treatment NN i
and CC N
the DT N
other JJ N
without IN N
any DT N
treatment NN N
. . N

48 CD p
healthy JJ p
adults NNS p
were VBD p
also RB p
studied VBN p
as IN p
normal JJ p
control NN p
group NN p
. . p

The DT N
results NNS N
showed VBD N
that IN N
the DT N
percentages NNS o
of IN o
OKT3+ NNP o
, , o
OKT4+ NNP o
, , o
OKT8+ NNP o
cells NNS o
in IN o
the DT o
peripheral JJ o
blood NN o
of IN N
the DT N
51 CD N
patients NNS N
were VBD N
lower JJR N
than IN N
those DT N
of IN N
the DT N
normal JJ N
adults NNS N
respectively RB N
. . N

After IN N
the DT N
acupuncture NN i
treatment NN N
, , N
the DT N
percentages NNS o
of IN o
OKT3+ NNP o
, , o
OKT4+ NNP o
, , o
OKT8+ NNP o
cells NNS o
were VBD N
obviously RB N
higher JJR N
than IN N
those DT N
before IN N
acupuncture NN i
; : i
the DT N
control NN N
group NN N
of IN N
patients NNS N
showed VBD N
no DT N
significant JJ N
variation NN N
. . N

This DT N
result NN N
revealed VBD N
that IN N
acupuncture NN i
seemed VBD N
to TO N
have VB N
more JJR N
affect NN N
on IN N
OKT4+ NNP o
cells NNS o
than IN N
on IN N
OKT8+ NNP o
cells NNS o
. . o

From IN N
our PRP$ N
study NN N
we PRP N
believe VBP N
that IN N
acupuncture NN i
can MD N
be VB N
used VBN N
as IN N
one CD N
of IN N
the DT N
many JJ N
treatments NNS N
for IN N
patients NNS p
with IN p
cancer NN p
. . p

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
phenytoin NN i
for IN N
the DT N
prevention NN N
of IN N
early JJ N
posttraumatic JJ N
seizures NNS N
in IN N
children NNS N
with IN N
moderate JJ N
to TO N
severe VB N
blunt NN N
head JJ N
injury NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
We PRP N
determine VBP N
the DT N
efficacy NN N
of IN N
prophylactic JJ N
phenytoin NN i
in IN N
preventing VBG N
early JJ N
posttraumatic JJ N
seizures NNS N
in IN N
children NNS N
with IN N
moderate JJ N
to TO N
severe VB N
blunt NN N
head JJ N
injury NN N
. . N

METHODS NNP N
Children NNP p
younger JJR p
than IN p
16 CD p
years NNS p
and CC p
experiencing VBG p
moderate JJ p
to TO p
severe VB p
blunt NN p
head JJ p
injury NN p
were VBD N
randomized VBN N
to TO N
receive VB N
phenytoin NN i
or CC i
placebo NN i
within IN N
60 CD N
minutes NNS N
of IN N
presentation NN N
at IN N
3 CD N
pediatric JJ N
trauma NN N
centers NNS N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
posttraumatic JJ o
seizures NNS o
within IN N
48 CD N
hours NNS N
; : N
secondary JJ N
endpoints NNS N
were VBD N
survival JJ N
and CC N
neurologic JJ N
outcome NN N
30 CD N
days NNS N
after IN N
injury NN N
. . N

A DT N
Bayesian JJ N
decision-theoretic JJ N
clinical JJ N
trial NN N
design NN N
was VBD N
used VBN N
to TO N
determine VB N
the DT N
probability NN N
of IN N
remaining VBG N
posttraumatic JJ N
seizure NN N
free JJ N
for IN N
each DT N
treatment NN N
group NN p
. . p

RESULTS NNP N
One CD p
hundred VBD p
two CD p
patients NNS p
were VBD p
enrolled VBN p
, , p
with IN p
a DT p
median JJ p
age NN p
of IN p
6.1 CD p
years NNS p
. . p

Sixty-eight JJ p
percent NN p
were VBD p
boys NNS p
. . p

The DT N
2 CD p
treatment NN p
groups NNS p
were VBD N
well RB N
matched VBN N
. . N

During IN N
the DT N
48-hour JJ N
observation NN N
period NN N
, , N
3 CD p
( ( p
7 CD p
% NN p
) ) p
of IN p
46 CD p
patients NNS p
given VBN N
phenytoin NNS i
and CC N
3 CD p
( ( p
5 CD p
% NN p
) ) p
of IN p
56 CD p
patients NNS p
given VBN N
placebo NNS i
experienced VBD N
a DT N
posttraumatic JJ o
seizure NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS p
in IN N
survival NN o
or CC o
neurologic JJ o
outcome NN o
after IN N
30 CD N
days NNS N
. . N

According VBG N
to TO N
these DT N
results NNS N
, , N
the DT N
probability NN N
that WDT N
phenytoin NN i
has VBZ N
the DT N
originally RB N
hypothesized VBN N
effect NN N
of IN N
reducing VBG N
the DT N
rate NN o
of IN o
early JJ o
posttraumatic JJ o
seizures NNS o
by IN N
12.5 CD N
% NN N
is VBZ N
0.0053 CD N
. . N

The DT N
probability NN N
that WDT N
phenytoin NN i
has VBZ N
any DT N
prophylactic JJ o
efficacy NN o
is VBZ N
0.383 CD N
. . N

The DT N
median JJ N
effect NN N
size NN N
in IN N
this DT N
trial NN N
was VBD N
-0.015 NNP N
( ( p
seizure JJ p
rate NN p
increased VBN p
by IN p
1.5 CD p
% NN p
in IN p
the DT p
phenytoin NN i
group NN p
) ) p
, , N
95 CD N
% NN N
probability NN N
interval NN N
-0.127 NN N
to TO N
0.091 CD N
( ( N
12.7 CD N
% NN N
higher JJR N
rate NN N
of IN N
posttraumatic JJ o
seizures NNS o
to TO N
a DT N
9.1 CD N
% NN N
lower JJR N
rate NN N
of IN N
posttraumatic JJ N
seizures NNS N
with IN N
phenytoin NN i
) ) i
. . N

CONCLUSION VB N
The DT N
rate NN N
of IN N
early JJ N
posttraumatic JJ N
seizures NNS N
in IN N
children NNS p
may MD p
be VB p
much RB p
lower JJR N
than IN N
previously RB N
reported VBN N
. . N

Phenytoin VB i
did VBD N
not RB N
substantially RB N
reduce VB N
that DT N
rate NN N
. . N

-DOCSTART- -X- O O

Efficacy NN o
of IN N
prepackaged VBN i
, , i
low JJ i
residual JJ i
test NN i
meals NNS i
with IN i
4L CD i
polyethylene NN i
glycol NN i
versus IN i
a DT i
clear JJ i
liquid NN i
diet NN i
with IN i
4L CD i
polyethylene NN i
glycol NN i
bowel NN i
preparation NN i
: : i
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIMS NNP N
A NNP N
prepackaged VBD N
low JJ N
residue JJ N
one-day JJ N
diet NN N
( ( N
breakfast NN N
, , N
lunch NN N
and CC N
dinner NN N
) ) N
has VBZ N
been VBN N
recently RB N
developed VBN N
to TO N
improve VB N
patient NN o
tolerance NN o
for IN o
bowel NN o
preparation NN o
prior RB N
to TO N
colonoscopy VB N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC N
tolerability NN o
of IN N
bowel NN N
preparation NN N
protocols NNS N
based VBN N
on IN N
a DT N
low JJ i
residue JJ i
diet NN i
and CC N
4L CD i
polyethylene NN i
glycol NN i
( ( i
PEG NNP i
) ) i
solution NN i
, , N
and CC N
to TO N
compare VB N
these DT N
new JJ N
options NNS N
with IN N
the DT N
traditional JJ i
liquid NN i
diet NN i
and CC i
the DT i
PEG NNP i
4L CD i
lavage NN i
. . i

METHODS NNP N
A NNP p
total NN p
of IN p
214 CD p
patients NNS p
( ( p
mean JJ p
age NN p
: : p
54.1 CD p
years NNS p
; : p
120 CD p
male NN p
, , p
94 CD p
female NN p
) ) p
from IN p
four CD p
university NN p
hospitals NNS p
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
clear JJ i
liquid NN i
diet NN i
and CC i
the DT i
PEG NNP i
4L CD i
regimen NNS i
( ( p
106 CD p
patients NNS p
) ) p
or CC N
the DT N
low JJ i
residue JJ i
test NN i
meals NNS i
and CC i
the DT i
PEG NNP i
4L CD i
regimen NNS i
( ( i
TM-PEG JJ i
4L CD N
, , N
108 CD N
patients NNS N
) ) N
. . N

The DT N
colon NN o
cleansing VBG o
efficacy NN o
of IN N
the DT N
different JJ N
preparations NNS N
was VBD N
rated VBN N
using VBG N
the DT N
Ottawa NNP o
bowel NN o
preparation NN o
scale NN o
. . o

RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
treatment NN N
groups NNS N
according VBG N
to TO N
the DT N
Ottawa NNP o
cleansing VBG o
scale JJ o
findings NNS N
( ( N
PEG NNP N
4L CD N
: : N
2.97 CD N
vs IN N
TM-PEG JJ N
4L CD N
: : N
2.46 CD N
, , N
P NNP N
= NNP N
0.063 CD N
) ) N
. . N

The DT N
overall JJ o
tolerability NN o
was VBD N
higher RBR N
in IN N
the DT N
TM-PEG NNP N
4L CD N
group NN N
than IN N
in IN N
the DT N
PEG NNP N
4L CD N
group NN N
( ( N
P NNP N
= NNP N
0.036 CD N
) ) N
. . N

No DT N
difference NN N
was VBD N
found VBN N
when WRB N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
with IN N
regard NN N
to TO N
adverse JJ o
events NNS o
( ( N
P NNP N
= NNP N
0.599 CD N
) ) N
. . N

CONCLUSIONS VB N
A DT N
prepackaged JJ N
low JJ N
residue JJ N
one-day JJ N
diet NN N
provided VBD N
cleansing VBG o
efficacy NN o
similar JJ N
to TO N
that DT N
of IN N
a DT N
clear JJ N
liquid NN N
diet NN N
and CC N
offered VBD N
the DT N
benefit NN N
of IN N
improved JJ o
tolerability NN o
compared VBN N
to TO N
the DT N
conventional JJ N
PEG NNP N
4L CD N
regimen NNS N
. . N

-DOCSTART- -X- O O

Calcium NNP i
chloride NN i
before IN i
i.v NN i
. . i

diltiazem NN i
in IN N
the DT N
management NN o
of IN o
atrial JJ o
fibrillation NN o
. . o

Diltiazem NNP i
is VBZ N
commonly RB N
used VBN N
to TO N
treat VB N
atrial JJ p
fibrillation NN p
or CC p
flutter NN p
( ( p
AFF NNP p
) ) p
with IN N
rapid JJ N
ventricular JJ N
response NN N
( ( N
RVR NNP N
) ) N
. . N

Although IN N
it PRP N
is VBZ N
very RB N
effective JJ N
for IN N
rate NN o
control NN o
, , N
up RB N
to TO N
an DT N
18 CD N
% NN N
prevalence NN N
of IN N
reported VBN N
diltiazem-induced JJ o
hypotension NN o
[ NN o
defined VBN o
by IN o
systolic JJ o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
< VBD o
90 CD o
mm NN o
Hg NNP o
] NNP o
, , N
and CC N
a DT N
mean NN N
of IN N
9.7 CD N
% NN N
hypotension NN o
have VBP N
been VBN N
reported VBN N
from IN N
several JJ N
studies NNS N
totaling VBG N
over IN p
450 CD p
patients NNS p
. . p

This DT N
hypotension NN o
may MD N
complicate VB N
therapy NN N
. . N

Our PRP$ N
objective NN N
was VBD N
to TO N
determine VB N
if IN N
calcium JJ i
chloride NN i
( ( i
CaCl NNP i
( ( i
2 CD i
) ) i
) ) i
pre-treatment NN N
would MD N
blunt VB N
a DT N
SBP NNP o
drop NN o
after IN N
i.v NN N
. . N

diltiazem NN N
, , N
while IN N
allowing VBG N
diltiazem NN i
to TO N
maintain VB N
its PRP$ N
efficacy NN N
. . N

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
conducted VBN N
. . N

Seventy-eight JJ p
patients NNS p
with IN p
AFF NNP p
and CC p
a DT p
ventricular JJ p
rate NN p
of IN p
> NNP p
/= NNP p
120 CD p
beats NNS p
per IN p
minute NN p
were VBD p
enrolled VBN p
. . p

Half NNP N
received VBD N
i.v JJ N
. . N

CaCl NNP i
( ( i
2 CD i
) ) i
pre-treatment NN N
; : N
the DT N
other JJ N
half NN N
received VBD N
placebo NN i
. . i

All DT N
patients NNS N
then RB N
received VBD N
i.v NN N
. . N

diltiazem NN i
in IN N
a DT N
standard NN N
, , N
weight-based JJ N
dose NN N
. . N

A DT N
second JJ N
dose NN N
of IN N
CaCl NNP N
( ( N
2 CD N
) ) N
pre-treatment NN N
or CC N
placebo NN i
and CC N
diltiazem NN i
was VBD N
given VBN N
if IN N
clinically RB N
indicated VBN N
for IN N
additional JJ N
rate NN N
control NN N
. . N

Both DT N
CaCl NNP N
( ( N
2 CD N
) ) N
and CC N
placebo JJ i
pre-treatment JJ N
groups NNS N
had VBD N
equal JJ N
lowering NN N
of IN N
heart NN o
rate NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
adverse JJ o
events NNS o
in IN N
the DT N
calcium NN N
pre-treatment NN N
study NN N
arm NN N
. . N

One CD p
patient NN p
in IN p
the DT p
placebo NN p
group NN p
became VBD N
paradoxically RB N
more JJR N
tachycardic JJ o
and CC o
apneic NN o
after IN N
the DT N
diltiazem JJ N
infusion NN N
. . N

Although IN N
i.v NN N
. . N

CaCl NNP N
( ( N
2 CD N
) ) N
seems VBZ N
to TO N
be VB N
equally RB N
safe JJ N
compared VBN N
to TO N
placebo VB N
as IN N
a DT N
pre-treatment NN N
in IN N
the DT N
management NN N
of IN N
AFF NNP N
with IN N
RVR NNP N
, , N
we PRP N
were VBD N
unable JJ N
to TO N
find VB N
a DT N
statistically RB N
significant JJ N
blunting NN o
of IN o
SBP NNP o
drop NN o
with IN N
CaCl NNP N
( ( N
2 CD N
) ) N
i.v NN N
. . N

pre-treatment NN N
. . N

Until IN N
further JJ N
research NN N
determines VBZ N
a DT N
benefit NN N
exists VBZ N
, , N
we PRP N
can MD N
not RB N
recommend VB N
i.v NN N
. . N

CaCl NNP i
( ( i
2 CD i
) ) i
pre-treatment NN N
before IN N
diltiazem NN i
in IN N
the DT N
treatment NN N
of IN N
AFF NNP N
with IN N
RVR NNP N
. . N

-DOCSTART- -X- O O

Aminocaproic NNP i
acid VBZ i
versus FW N
prednisone NN i
for IN N
the DT N
treatment NN N
of IN N
traumatic JJ p
hyphema NN p
. . p

A DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

One CD p
hundred VBD p
twelve NN p
patients NNS p
who WP p
sustained VBD p
hyphema NN p
after IN p
blunt NN p
trauma NN p
were VBD p
enrolled VBN p
in IN N
a DT N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
to TO N
determine VB N
the DT N
relative JJ N
efficacies NNS N
of IN N
aminocaproic JJ i
acid NN i
( ( i
Amicar NNP i
) ) i
and CC N
systemic JJ i
prednisone NN i
for IN N
reducing VBG N
the DT N
rate NN o
of IN o
secondary JJ o
hemorrhage NN o
. . o

Fifty-six JJ N
patients NNS N
received VBD N
an DT N
oral JJ i
dosage NN i
of IN i
50 CD i
mg/kg NN i
of IN i
aminocaproic JJ i
acid NN i
every DT N
4 CD N
hours NNS N
for IN N
5 CD N
days NNS N
, , N
up RB N
to TO N
a DT N
maximum NN N
of IN N
30 CD N
g JJ N
daily JJ N
, , N
and CC N
56 CD N
patients NNS N
received VBD N
an DT N
oral JJ i
dosage NN i
of IN i
40 CD i
mg NN i
of IN i
prednisone JJ i
daily JJ i
( ( N
adjusted VBN N
for IN N
weight NN N
) ) N
in IN N
two CD N
divided JJ N
doses NNS N
. . N

Placebo NNP i
pills NNS N
and CC N
liquids NNS N
were VBD N
given VBN N
to TO N
each DT N
patient NN N
to TO N
mask VB N
the DT N
treatment NN N
schedules NNS N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
patient NN N
populations NNS N
for IN N
any DT N
demographic JJ N
or CC N
clinical JJ N
characteristic NN N
( ( N
e.g. JJ N
, , N
visual JJ o
acuity NN o
, , o
intraocular JJ o
pressure NN o
[ NNP o
IOP NNP o
] NNP o
, , o
initial JJ o
hyphema NN o
size NN o
) ) o
measured VBN N
in IN N
the DT N
study NN N
. . N

Blacks NNS p
comprised VBD p
53 CD p
% NN p
of IN p
the DT p
study NN p
population NN p
, , p
and CC p
the DT p
mean JJ p
age NN p
of IN p
the DT p
patients NNS p
was VBD p
23.5 CD p
years NNS p
. . p

Four CD N
patients NNS N
in IN N
each DT N
of IN N
the DT N
treatment NN N
groups NNS N
experienced VBD N
a DT N
secondary JJ o
hemorrhage NN o
; : o
the DT N
rebleed NN o
rate NN o
was VBD N
7.1 CD N
% NN N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
nifedipine NN i
on IN N
gastric JJ o
acid JJ o
secretion NN o
and CC p
gastrin NN o
release NN o
in IN p
man NN p
. . p

As IN N
calcium NN N
is VBZ N
important JJ N
in IN N
the DT N
regulation NN N
of IN N
gastric JJ N
acid JJ N
secretion NN N
and CC N
gastrin NN N
release NN N
, , N
we PRP N
have VBP N
examined VBN N
the DT N
effect NN N
of IN N
the DT N
calcium NN N
antagonist NN N
nifedipine NN i
on IN N
these DT N
processes NNS N
in IN N
man NN p
. . p

Nifedipine CC i
30 CD N
mg NNS N
orally RB N
inhibited VBN N
basal NN N
acid NN N
output NN N
by IN N
37 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.025 CD N
) ) N
and CC N
that IN N
stimulated VBN N
by IN N
low JJ N
infusion NN N
rates NNS N
of IN N
pentagastrin NN i
-- : i
that WDT i
is VBZ N
, , N
0.031 CD N
and CC N
0.062 CD N
microgram/kg/h NN N
by IN N
44 CD N
% NN N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
and CC N
39 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
respectively RB N
. . N

On IN N
increasing VBG N
the DT N
pentagastrin JJ i
infusion NN N
rate NN N
the DT N
inhibition NN N
was VBD N
surmounted VBN N
suggesting VBG N
it PRP N
was VBD N
competitive JJ N
in IN N
type NN N
. . N

Nifedipine NNP i
did VBD N
not RB N
affect VB N
basal NN o
or CC o
Oxo NNP o
meal NN o
stimulated VBD o
gastrin JJ o
concentrations NNS o
in IN N
normal JJ p
volunteers NNS p
nor CC N
did VBD N
it PRP N
affect VB N
resting VBG o
serum JJ o
gastrin NN o
or CC o
calcium NN o
stimulated JJ o
increase NN o
in IN o
gastrin NN o
in IN N
a DT N
single JJ p
patient NN p
with IN p
Zollinger-Ellison NNP p
syndrome NN p
. . p

These DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
the DT N
transmembrane NN N
flux NN N
of IN N
calcium NN N
ions NNS N
being VBG N
involved VBN N
in IN N
basal NN N
and CC N
pentagastrin NN p
stimulated VBD p
acid JJ p
secretion NN p
in IN p
man NN p
. . p

-DOCSTART- -X- O O

Study NNP N
protocol NN N
: : N
Phase NNP N
III NNP N
single-blinded JJ N
fast-track JJ N
pragmatic NN N
randomised VBD N
controlled JJ N
trial NN N
of IN N
a DT N
complex JJ N
intervention NN N
for IN N
breathlessness NN o
in IN o
advanced JJ o
disease NN o
. . o

BACKGROUND NNP N
Breathlessness NNP N
in IN N
advanced JJ N
disease NN N
causes VBZ N
significant JJ N
distress NN o
to TO o
patients NNS o
and CC N
carers NNS N
and CC N
presents NNS N
management NN o
challenges VBZ o
to TO o
health NN o
care NN o
professionals NNS o
. . o

The DT N
Breathlessness NNP i
Intervention NNP i
Service NNP i
( ( i
BIS NNP i
) ) i
seeks VBZ N
to TO N
improve VB N
the DT N
care NN o
of IN o
breathless NN o
patients NNS o
with IN p
advanced JJ p
disease NN p
( ( p
regardless NN p
of IN p
cause NN p
) ) p
through IN N
the DT N
use NN N
of IN N
evidence-based JJ N
practice NN N
and CC N
working VBG N
with IN N
other JJ N
healthcare NN N
providers NNS N
. . N

BIS NNP i
delivers VBZ N
a DT i
complex JJ i
intervention NN i
( ( i
of IN i
non-pharmacological JJ i
and CC i
pharmacological JJ i
treatments NNS i
) ) i
via IN N
a DT N
multi-professional JJ N
team NN N
. . N

BIS NNP i
is VBZ N
being VBG N
continuously RB N
developed VBN N
and CC N
its PRP$ N
impact NN N
evaluated VBN N
using VBG N
the DT N
MRC NNP N
's POS N
framework NN N
for IN N
complex JJ N
interventions NNS N
( ( N
PreClinical NNP N
, , N
Phase NNP N
I PRP N
and CC N
Phase NNP N
II NNP N
completed VBD N
) ) N
. . N

This DT N
paper NN N
presents VBZ N
the DT N
protocol NN N
for IN N
Phase NNP N
III NNP N
. . N

METHODS/DESIGN NNP N
Phase NNP N
III NNP N
comprises VBZ N
a DT N
pragmatic JJ N
, , N
fast-track JJ N
, , N
single-blind JJ N
randomised VBD N
controlled JJ N
trial NN N
of IN N
BIS NNP i
versus FW N
standard NN i
care NN i
. . i

Due NNP N
to TO N
differing VBG N
disease NN N
trajectories NNS N
, , N
the DT N
service NN N
uses VBZ N
two CD i
broad JJ i
service NN i
models NNS i
: : i
one CD N
for IN N
patients NNS p
with IN p
malignant JJ p
disease NN p
( ( p
intervention NN p
delivered VBN p
over IN p
two CD p
weeks NNS p
) ) p
and CC p
one CD p
for IN p
patients NNS p
with IN p
non-malignant JJ p
disease NN p
( ( p
intervention NN p
delivered VBN p
over IN p
four CD p
weeks NNS p
) ) p
. . p

The DT N
Phase NNP N
III NNP N
trial NN N
therefore NN N
consists VBZ N
of IN N
two CD N
sub-protocols NNS N
: : N
one CD N
for IN N
patients NNS p
with IN p
malignant JJ p
conditions NNS p
( ( p
four CD p
week NN p
protocol NN p
) ) p
and CC p
one CD p
for IN p
patients NNS p
with IN p
non-malignant JJ p
conditions NNS p
( ( N
eight CD N
week NN N
protocol NN N
) ) N
. . N

Mixed JJ i
method NN i
interviews NNS i
are VBP N
conducted VBN N
with IN N
patients NNS N
and CC N
their PRP$ N
lay NN N
carers NNS N
at IN N
three CD N
to TO N
five CD N
measurement NN N
points NNS N
depending VBG N
on IN N
randomisation NN N
and CC N
sub-protocol NN N
. . N

Qualitative JJ N
interviews NNS N
are VBP N
conducted VBN N
with IN N
referring VBG N
and CC N
non-referring JJ N
health NN N
care NN N
professionals NNS N
( ( N
malignant JJ N
disease NN N
protocol NN N
only RB N
) ) N
. . N

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
'patient JJ o
distress NN o
due JJ o
to TO o
breathlessness VB o
' '' o
measured VBN o
on IN o
a DT o
numerical JJ o
rating NN o
scale NN o
( ( o
0-10 JJ o
) ) o
. . o

The DT N
trial NN N
includes VBZ N
economic JJ o
evaluation NN o
. . o

Analysis NN N
will MD N
be VB N
on IN N
an DT N
intention NN N
to TO N
treat VB N
basis NN N
. . N

DISCUSSION NNP N
This DT N
is VBZ N
the DT N
first JJ N
evaluation NN N
of IN N
a DT N
breathlessness NN N
intervention NN N
for IN N
advanced JJ N
disease NN N
to TO N
have VB N
followed VBN N
the DT N
MRC NNP N
framework NN N
and CC N
one CD N
of IN N
the DT N
first JJ N
palliative JJ N
care NN N
trials NNS N
to TO N
use VB N
fast JJ N
track NN N
methodology NN N
and CC N
single-blinding NN N
. . N

The DT N
results NNS N
will MD N
provide VB N
evidence NN N
of IN N
the DT N
clinical JJ o
and CC o
cost-effectiveness NN o
of IN o
the DT o
service NN o
, , N
informing VBG N
its PRP$ N
longer JJR N
term NN N
development NN N
and CC N
implementation NN N
of IN N
the DT N
model NN N
in IN N
other JJ N
centres NNS N
nationally RB N
and CC N
internationally RB N
. . N

It PRP N
adds VBZ N
to TO N
methodological JJ N
developments NNS N
in IN N
palliative JJ i
care NN i
research NN N
where WRB N
complex JJ N
interventions NNS N
are VBP N
common JJ N
but CC N
evidence NN N
sparse NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT00678405ISRCTN NN N
: : N
ISRCTN04119516 NNP N
. . N

-DOCSTART- -X- O O

Cardiovascular JJ o
risk NN o
markers NNS o
during IN N
treatment NN N
with IN N
estradiol NN i
and CC i
trimegestone NN i
or CC i
dydrogesterone NN i
. . N

OBJECTIVE UH N
To TO N
study VB N
cardiovascular JJ o
risk NN o
markers NNS o
in IN N
women NNS p
taking VBG p
estradiol/trimegestone NN i
or CC i
estradiol/dydrogesterone NN i
. . i

DESIGN NNP N
Multicenter NNP N
, , N
randomized VBD N
, , N
prospective JJ N
, , N
double-blind JJ N
study NN N
of IN N
184 CD p
healthy JJ p
post-menopausal JJ p
women NNS p
randomized VBD N
to TO N
6 CD i
cycles NNS i
of IN i
either DT i
estradiol NN i
( ( i
2mg CD i
) ) i
+trimegestone NN i
( ( i
0.5mg CD i
) ) i
( ( i
T-group NNP i
) ) i
or CC i
estradiol NN i
( ( i
2mg CD i
) ) i
+dydrogesterone NN i
( ( i
10mg CD i
) ) i
( ( i
DYDR NNP i
group NN i
) ) i
. . i

Cardiovascular JJ o
risk NN o
markers NNS o
were VBD i
measured VBN i
before IN i
, , i
after IN i
cycle NN i
1 CD i
, , i
3 CD i
and CC i
6 CD i
and CC i
at IN i
4 CD i
weeks NNS i
post-treatment JJ i
. . i

RESULTS NNP N
Fibrinogen NNP o
was VBD N
reduced VBN N
in IN N
both DT N
groups NNS N
but CC N
more JJR N
markedly RB N
in IN N
the DT N
DYDR NNP N
group NN N
. . N

Factor NNP o
VIIc NNP o
activity NN o
levels NNS o
decreased VBN N
in IN N
both DT N
groups NNS N
with IN N
a DT N
greater JJR N
change NN N
in IN N
the DT N
T-group NNP N
. . N

Factor NNP o
VII NNP o
antigen NN o
was VBD N
increased VBN N
in IN N
both DT N
groups NNS N
with IN N
a DT N
greater JJR N
increase NN N
in IN N
the DT N
DYDR NNP N
group NN N
. . N

Factor NNP o
VIIa NNP o
was VBD N
increased VBN N
in IN N
the DT N
DYDR NNP N
group NN N
only RB N
. . N

Plasminogen NN o
levels NNS o
were VBD N
also RB N
increased VBN N
in IN N
both DT N
groups NNS N
with IN N
a DT N
greater JJR N
increase NN N
in IN N
the DT N
T-group NNP N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
changes NNS N
in IN N
lipid JJ o
variables NNS o
between IN N
the DT N
different JJ N
regimens NNS N
. . N

Changes NNS N
in IN N
total JJ o
cholesterol NN o
and CC o
LDL NNP o
cholesterol NN o
were VBD N
correlated VBN N
positively RB N
with IN N
changes NNS N
in IN N
factor NN o
VIIc NNP o
in IN N
the DT N
DYDR NNP N
group NN N
and CC N
negatively RB N
with IN N
changes NNS N
in IN N
factor NN o
VIIc NNP o
in IN N
the DT N
T-group NNP N
. . N

Trigemestone NN N
was VBD N
associated VBN N
with IN N
a DT N
better JJR N
bleeding NN o
pattern NN o
. . o

CONCLUSIONS NNP N
Trimegestone NNP N
was VBD N
associated VBN N
with IN N
less RBR N
procoagulant JJ o
changes NNS o
in IN o
factor NN o
VIIa NNP o
and CC N
factor NN o
VIIc NNP o
activity NN o
and CC N
larger JJR N
decrease NN N
in IN N
PAI-1 NNP o
activity NN o
compared VBN N
with IN N
the DT N
dydrogesterone NN N
preparation NN N
. . N

These DT N
results NNS N
reflect VBP N
less JJR N
androgenic JJ o
properties NNS o
of IN N
the DT N
trimegestone NN N
preparation NN N
. . N

The DT N
fibrinogen NN o
level NN o
and CC N
Lp NNP o
( ( o
a DT o
) ) o
were VBD N
more JJR N
decreased JJ N
during IN N
dydrogesterone NN N
treatment NN N
. . N

Further JJ N
investigation NN N
is VBZ N
required VBN N
to TO N
clarify VB N
the DT N
relative JJ N
importance NN N
of IN N
beneficial JJ N
effects NNS N
with IN N
respect NN N
to TO N
cardiovascular JJ N
risk NN N
. . N

-DOCSTART- -X- O O

The DT N
nature NN N
of IN N
placebo NN i
response NN N
in IN N
clinical JJ N
studies NNS N
of IN N
major JJ p
depressive JJ p
disorder NN p
. . p

OBJECTIVE NNP N
To TO N
review VB N
factors NNS N
influencing VBG N
placebo NN i
response NN N
and CC N
clinical JJ N
trial NN N
outcome NN N
in IN N
depression NN p
, , N
and CC N
suggest VBP N
ways NNS N
to TO N
optimize VB N
trial NN N
success NN N
in IN N
mood NN N
disorders NNS N
. . N

DATA NNP N
SOURCES NNP N
PubMed NNP N
searches NNS N
were VBD N
conducted VBN N
by IN N
cross-referencing VBG N
the DT N
terms NNS N
depression NN N
, , N
depressive JJ N
with IN N
placebo NN i
, , N
clinical JJ N
trial NN N
, , N
and CC N
clinical JJ N
trials NNS N
for IN N
studies NNS p
published VBN p
in IN p
English NNP p
between IN p
1970 CD p
and CC p
September NNP p
2013 CD p
. . p

STUDY NNP N
SELECTION NNP N
Relevant NNP N
abstracts NNS N
were VBD N
identified VBN N
in IN N
PubMed NNP N
, , N
including VBG N
clinical JJ N
trials NNS N
, , N
quantitative JJ N
studies NNS N
, , N
and CC N
qualitative JJ N
research NN N
. . N

We PRP N
obtained VBD N
and CC N
reviewed VBD N
relevant JJ N
articles NNS N
and CC N
utilized VBD N
their PRP$ N
information NN N
to TO N
synthesize VB N
the DT N
present JJ N
review NN N
. . N

DATA NNP N
EXTRACTION NNP N
Included VBD N
articles NNS N
were VBD N
grouped VBN N
in IN N
the DT N
following JJ N
areas NNS N
of IN N
relevance NN N
: : N
( ( N
1 CD N
) ) N
biological JJ N
validity NN N
of IN N
illness NN N
, , N
( ( N
2 CD N
) ) N
baseline NN N
severity NN N
of IN N
illness NN N
, , N
( ( N
3 CD N
) ) N
chronicity NN N
of IN N
the DT N
index NN N
episode NN N
of IN N
depression NN N
, , N
( ( N
4 CD N
) ) N
age NN N
of IN N
participants NNS N
, , N
( ( N
5 CD N
) ) N
medical JJ N
and CC N
psychiatric JJ N
comorbidity NN N
, , N
( ( N
6 CD N
) ) N
probability NN N
of IN N
receiving VBG i
placebo NN i
, , N
( ( N
7 CD N
) ) N
use NN N
of IN N
prospective JJ N
treatment NN N
phases NNS N
( ( N
lead-in NN N
) ) N
( ( N
8 CD N
) ) N
dosing NN N
schedule NN N
, , N
( ( N
9 CD N
) ) N
trial NN N
duration NN N
, , N
( ( N
10 CD N
) ) N
frequency NN N
of IN N
follow-up JJ N
assessments NNS N
, , N
and CC N
( ( N
11 CD N
) ) N
study NN N
outcome JJ N
measure NN N
. . N

RESULTS NNP N
Several JJ N
key JJ N
elements NNS N
emerge VBP N
as RB N
critical JJ N
to TO N
the DT N
ultimate JJ N
success NN N
of IN N
a DT N
clinical JJ N
trial NN N
, , N
including VBG N
the DT N
probability NN o
of IN o
receiving VBG o
placebo NN o
, , o
study NN o
duration NN o
, , o
dosing VBG o
schedule NN o
, , o
visit NN o
frequency NN o
, , o
the DT o
use NN o
of IN o
blinded JJ o
lead-in JJ o
phases NNS o
, , o
the DT o
use NN o
of IN o
centralized JJ o
raters NNS o
, , o
illness JJ o
severity NN o
and CC o
duration NN o
, , o
and CC o
comorbid NN o
anxiety NN o
. . o

CONCLUSIONS NNP N
Our PRP$ N
increasing VBG N
understanding NN N
of IN N
the DT N
placebo NN i
response NN p
in IN p
clinical JJ p
trials NNS p
of IN N
major JJ p
depressive JJ p
disorder NN p
lends VBZ N
to TO N
a DT N
, , N
gradually RB N
, , N
more RBR N
predictable JJ N
phenomenon NN N
and CC N
, , N
hopefully RB N
, , N
to TO N
one CD N
that WDT N
becomes VBZ N
lesser JJR N
in IN N
magnitude NN N
and CC N
variability NN N
. . N

Several JJ N
elements NNS N
have VBP N
emerged VBN N
that WDT N
seem VBP N
to TO N
play VB N
a DT N
critical JJ N
role NN N
in IN N
trial NN N
success NN N
, , N
gradually RB N
reshaping VBG N
the DT N
design NN N
of IN N
clinical JJ N
, , N
translational JJ N
, , N
as RB N
well RB N
as IN N
mechanistic JJ N
studies NNS N
in IN N
depression NN N
. . N

-DOCSTART- -X- O O

A DT N
home-based JJ i
exercise NN i
program NN i
to TO N
improve VB N
function NN o
, , o
fatigue NN o
, , o
and CC o
sleep JJ o
quality NN o
in IN N
patients NNS p
with IN p
Stage NNP p
IV NNP p
lung NN p
and CC p
colorectal JJ p
cancer NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

CONTEXT NNP N
Exercise NNP N
benefits NNS N
patients NNS p
with IN p
cancer NN p
, , N
but CC N
studies NNS N
of IN N
home-based JJ N
approaches NNS N
, , N
particularly RB N
among IN N
those DT p
with IN p
Stage NNP p
IV NNP p
disease NN p
, , N
remain VBP N
small JJ N
and CC N
exploratory JJ N
. . N

OBJECTIVES NNP N
To TO N
conduct VB N
an DT N
adequately RB N
powered JJ N
trial NN N
of IN N
a DT N
home-based JJ i
exercise NN i
intervention NN i
that WDT N
can MD N
be VB N
facilely RB N
integrated VBN N
into IN N
established VBN N
delivery NN N
and CC N
reimbursement NN N
structures NNS N
. . N

METHODS NNP N
Sixty-six JJ p
adults NNS p
with IN p
Stage NNP p
IV NNP p
lung NN p
or CC p
colorectal JJ p
cancer NN p
were VBD p
randomized VBN p
, , N
in IN N
an DT N
eight-week JJ N
trial NN N
, , N
to TO N
usual JJ i
care NN i
or CC i
incremental JJ i
walking NN i
and CC i
home-based JJ i
strength NN i
training NN i
. . i

The DT N
exercising VBG N
participants NNS N
were VBD N
instructed VBN N
during IN N
a DT N
single JJ N
physiotherapy NN i
visit NN N
and CC N
subsequently RB N
exercised VBN N
four CD N
days NNS N
or CC N
more JJR N
per IN N
week NN N
; : N
training NN N
and CC N
step-count NN N
goals NNS N
were VBD N
advanced VBN N
during IN N
bimonthly RB N
telephone NN N
calls VBZ N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
mobility NN o
assessed VBN N
with IN N
the DT N
Ambulatory NNP o
Post NNP o
Acute NNP o
Care NNP o
Basic NNP o
Mobility NNP o
Short NNP o
Form NNP o
. . o

Secondary JJ N
outcomes NNS N
included VBD o
ratings NNS o
of IN o
pain NN o
and CC o
sleep JJ o
quality NN o
as RB N
well RB N
as IN N
the DT o
ability NN o
to TO o
perform VB o
daily JJ o
activities NNS o
( ( N
Ambulatory NNP N
Post NNP N
Acute NNP N
Care NNP N
Daily NNP N
Activities NNP N
Short NNP N
Form NNP N
) ) N
, , N
quality NN o
of IN o
life NN o
( ( N
Functional NNP N
Assessment NNP N
of IN N
Cancer NNP N
Therapy-General NNP N
) ) N
, , N
and CC o
fatigue NN o
( ( N
Functional NNP N
Assessment NNP N
of IN N
Cancer NNP N
Therapy-Fatigue NNP N
) ) N
. . N

RESULTS NNP p
Three CD p
participants NNS p
dropped VBD p
out RP p
and CC p
seven CD o
died VBD o
( ( N
five CD N
in IN N
the DT N
intervention NN N
and CC N
two CD N
in IN N
the DT N
control NN N
group NN N
, , N
P=0.28 NNP N
) ) N
. . N

At IN N
Week JJ N
8 CD N
, , N
the DT N
intervention NN N
group NN N
reported VBD N
improved JJ o
mobility NN o
( ( N
P=0.01 NNP N
) ) N
, , N
fatigue NN o
( ( N
P=0.02 NNP N
) ) N
, , N
and CC o
sleep JJ o
quality NN o
( ( N
P=0.05 NNP N
) ) N
compared VBN N
with IN N
the DT N
usual JJ N
care NN N
group NN N
, , N
but CC N
did VBD N
not RB N
differ VB N
on IN N
the DT N
other JJ N
measures NNS N
. . N

CONCLUSION VB i
A DT i
home-based JJ i
exercise NN i
program NN i
seems VBZ N
capable JJ N
of IN N
improving VBG N
the DT o
mobility NN o
, , o
fatigue NN o
, , o
and CC o
sleep JJ o
quality NN o
of IN p
patients NNS p
with IN p
Stage NNP p
IV NNP p
lung NN p
and CC p
colorectal JJ p
cancer NN p
. . p

-DOCSTART- -X- O O

Systematic JJ i
approach NN i
to TO N
benign VB p
paroxysmal JJ p
positional JJ p
vertigo NN p
in IN p
the DT p
elderly JJ p
. . p

OBJECTIVE IN N
We PRP N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
a DT N
management NN N
approach NN N
that WDT N
combines VBZ N
the DT N
canalith NN i
repositioning VBG i
maneuver NN i
( ( i
CRM NNP i
) ) i
and CC i
vestibular JJ i
rehabilitation NN i
( ( i
VR NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
benign JJ p
positional JJ p
paroxysmal NN p
vertigo NN p
( ( p
BPPV NNP p
) ) p
in IN p
elderly JJ p
persons NNS p
. . p

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
Forty-seven JJ p
patients NNS p
( ( p
> JJ p
/=70 CD p
years NNS p
old JJ p
) ) p
with IN p
the DT p
diagnosis NN p
of IN p
unilateral JJ p
posterior JJ p
semicircular JJ p
canal NN p
BPPV NNP p
formed VBD N
the DT N
study NN N
population NN N
. . N

This DT N
study NN N
has VBZ N
2 CD N
parts NNS N
. . N

In IN N
the DT N
first JJ N
part NN N
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
groups NNS N
: : N
the DT i
CRM NNP i
and CC i
avoidance NN i
( ( i
no DT i
treatment NN i
) ) i
. . i

Patients NNS N
were VBD N
evaluated VBN N
1 CD N
month NN N
after IN N
the DT N
first JJ N
visit NN N
. . N

Those DT N
patients NNS N
not RB N
responding VBG N
to TO N
treatment NN N
were VBD N
enrolled VBN N
in IN N
the DT N
second JJ N
part NN N
of IN N
the DT N
study NN N
, , N
treated VBN N
with IN N
an DT i
individualized JJ i
combination NN i
of IN i
CRM NNP i
and CC i
VR NNP i
, , N
and CC N
then RB N
reevaluated VBD N
3 CD N
months NNS N
later RB N
. . N

RESULTS NNP N
Statistically NNP N
significant JJ N
improvement NN o
of IN o
vertigo NN o
and CC o
provoked VBD o
nystagmus NNS o
in IN N
64 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
CRM NNP N
group NN N
compared VBN N
with IN N
the DT N
no-treatment JJ N
group NN N
. . N

After IN N
the DT N
addition NN N
of IN N
VR NNP o
, , N
77 CD N
% NN N
of IN N
all DT N
patients NNS N
improved VBN N
. . N

CONCLUSION VB N
A DT N
combination NN N
of IN N
CRM NNP N
and CC N
VR NNP N
improves VBZ N
BPPV NNP o
in IN p
the DT p
elderly JJ p
. . p

SIGNIFICANCE NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
although IN N
CRM NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
no DT N
treatment NN N
, , N
VR NNP N
can MD N
be VB N
added VBN N
to TO N
improve VB N
the DT N
results NNS N
in IN N
the DT N
treatment NN N
of IN N
BPPV NNP N
. . N

-DOCSTART- -X- O O

Age NNP N
and CC N
autonomic JJ N
effects NNS N
on IN N
interrelationships NNS N
between IN N
lung NN N
volume NN N
and CC N
heart NN N
rate NN N
. . N

To TO N
determine VB N
effects NNS N
of IN N
aging VBG N
and CC N
autonomic JJ N
input NN N
on IN N
interrelationships NNS N
between IN N
respiratory NN N
and CC N
heart NN N
rate NN N
variability NN N
, , N
we PRP N
collected VBD N
5 CD N
min NN N
of IN N
lung NN N
volume NN N
of IN N
R-R NNP N
interval NN N
data NNS N
from IN N
7 CD p
young JJ p
[ $ p
27 CD p
+/- JJ p
3 CD p
( ( p
SD NNP p
) ) p
yr NN p
] NN p
and CC p
10 CD p
older JJR p
( ( p
69 CD p
+/- JJ p
6 CD p
yr NN p
) ) p
healthy JJ p
supine NN p
humans NNS p
before IN p
and CC p
after IN p
double JJ p
pharmacological JJ p
autonomic NN p
blockade NN p
with IN p
propranolol NN i
( ( p
0.2 CD p
mg/kg RB p
iv NN p
) ) p
and CC p
atropine NN i
( ( p
0.04 CD p
mg/kg RB p
iv NN p
) ) p
. . p

Estimates NNS N
of IN N
respiratory NN N
and CC N
heart NN N
rate NN N
power NN N
spectra NN N
and CC N
linear JJ N
transfer NN N
functions NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
generated VBN N
by IN N
Fourier NNP N
analysis NN N
. . N

Age NNP N
, , N
double JJ N
blockade NN N
effects NNS N
, , N
the DT N
age-drug JJ N
interactions NNS N
were VBD N
determined VBN N
by IN N
analysis NN N
of IN N
variance NN N
for IN N
repeated JJ N
measures NNS N
. . N

Basal NNP N
R-R JJ N
intervals NNS N
were VBD N
unaffected VBN N
by IN N
age NN N
. . N

Double JJ N
blockade NN N
decreased VBD N
R-R JJ o
intervals NNS o
and CC o
variability NN o
in IN N
both DT N
age NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
but CC N
R-R NNP N
intervals NNS N
decreased VBD N
less RBR N
in IN N
older JJR N
than IN N
in IN N
young JJ N
subjects NNS N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
basal JJ o
respiratory NN o
intervals NNS o
and CC N
standard JJ N
deviation NN N
were VBD N
greater JJR N
in IN N
older JJR N
subjects NNS N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
were VBD N
unaffected VBN N
by IN N
double JJ N
blockade NN N
in IN N
young JJ p
and CC p
older JJR p
subjects NNS p
. . p

Lung NNP o
volume-to-heart JJ o
rate NN o
spectral JJ o
coherence NN o
was VBD N
highest JJS N
at IN N
frequencies NNS N
associated VBN N
with IN N
respiration NN N
and CC N
greater JJR N
in IN N
young JJ N
than IN N
in IN N
older JJR N
subjects NNS N
( ( N
P NNP N
< NNP N
0.07 CD N
) ) N
. . N

Double JJ N
blockade NN N
decreased VBD N
lung JJ o
volume-to-heart JJ o
rate NN o
variability NN o
transfer NN o
function NN o
magnitude NN o
( ( N
P NNP N
< NNP N
0.007 CD N
) ) N
and CC N
increased JJ N
phase NN o
angle NN o
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
without IN N
age NN N
effects NNS N
or CC N
age-drug JJ N
interactions NNS N
. . N

In IN N
conclusion NN N
, , N
heart NN o
rate NN o
, , o
respiration NN o
, , o
and CC o
respiration-heart JJ o
rate NN o
interrelations NNS o
are VBP N
altered VBN N
by IN N
aging VBG N
, , N
and CC N
double JJ N
autonomic JJ N
pharmacological JJ N
blockade NN N
does VBZ N
not RB N
eliminate VB N
all DT N
age-related JJ N
differences NNS N
. . N

-DOCSTART- -X- O O

Combination NNP N
therapy NN N
with IN N
methotrexate NN i
and CC i
hydroxychloroquine NN i
for IN N
rheumatoid JJ p
arthritis NN p
increases NNS N
exposure VBP N
to TO N
methotrexate VB N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
bioavailability NN N
of IN N
methotrexate NN i
( ( i
MTX NNP i
) ) i
in IN N
the DT N
presence NN N
of IN N
hydroxychloroquine NN i
( ( i
HCQ NNP i
) ) i
, , N
and CC N
vice NN N
versa NN N
, , N
to TO N
determine VB N
a DT N
possible JJ N
pharmacokinetic JJ N
explanation NN N
for IN N
the DT N
observation NN N
that IN N
combination NN N
treatment NN N
of IN N
rheumatoid JJ N
arthritis NN N
with IN N
MTX NNP i
and CC N
HCQ NNP i
has VBZ N
been VBN N
shown VBN N
, , N
clinically RB N
, , N
to TO N
be VB N
more RBR N
potent JJ N
than IN N
MTX NNP i
used VBD N
alone RB N
. . N

METHODS NNP N
In IN N
a DT N
randomized VBN N
crossover NN N
study NN N
, , N
10 CD p
healthy JJ p
subjects NNS p
received VBN p
, , N
on IN N
each DT N
of IN N
5 CD N
dosing VBG N
occasions NNS N
, , N
MTX NNP i
alone RB N
as IN N
tablets NNS N
or CC N
intravenous JJ N
solution NN N
, , N
HCQ NNP i
alone RB N
as IN N
a DT N
tablet NN N
or CC N
oral JJ N
solution NN N
, , N
or CC N
a DT N
coadministered JJ N
dose NN N
of IN N
MTX NNP i
tablets NNS N
with IN N
an DT N
HCQ NNP i
tablet NN N
. . N

The DT N
area NN N
under IN N
the DT N
concentration-time JJ o
curve NN o
( ( o
AUC NNP o
) ) o
was VBD N
determined VBN N
for IN N
each DT N
subject NN N
, , N
on IN N
each DT N
dosing VBG N
occasion NN N
, , N
for IN N
each DT N
compound NN N
. . N

RESULTS VB N
The DT N
mean JJ o
AUC NNP o
for IN o
MTX NNP o
was VBD N
increased VBN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
and CC N
the DT N
maximum JJ o
MTX NNP o
concentration NN o
( ( o
Cmax NNP o
) ) o
decreased VBD N
( ( N
p JJ N
= NNP N
0.025 CD N
) ) N
when WRB N
MTX NNP i
was VBD N
coadministered VBN N
with IN N
HCQ NNP i
, , N
compared VBN N
to TO N
MTX NNP i
administered VBD N
alone RB N
. . N

The DT N
time NN o
to TO o
reach VB o
Cmax NNP o
for IN o
MTX NNP o
administration NN o
, , o
tmax NN o
, , N
was VBD N
also RB N
increased VBN N
during IN N
the DT N
coadministration NN N
with IN N
HCQ NNP i
( ( N
p JJ N
= NNP N
0.072 CD N
) ) N
. . N

The DT N
AUC NNP N
of IN N
HCQ NNP i
showed VBD N
no DT N
significant JJ N
difference NN o
( ( N
p JJ N
= NNP N
0.957 CD N
) ) N
between IN N
any DT N
of IN N
the DT N
dosing NN N
occasions NNS N
. . N

CONCLUSION NNP N
These DT N
results NNS N
may MD N
explain VB N
the DT N
increased JJ N
potency NN N
of IN N
the DT N
MTX-HCQ NNP i
combination NN N
over RB N
MTX NNP i
as IN N
a DT N
single JJ N
agent NN N
and CC N
also RB N
the DT N
sustained JJ N
effects NNS N
of IN N
MTX NNP i
when WRB N
administered VBN N
with IN N
HCQ NNP i
. . i

In IN N
addition NN N
, , N
the DT N
reduced JJ N
Cmax NNP N
of IN N
MTX NNP i
observed VBD N
during IN N
the DT N
coadministration NN N
may MD N
explain VB N
diminution NN N
of IN N
acute JJ N
liver JJ N
adverse JJ N
effects NNS N
. . N

Extra NNP N
vigilance NN N
for IN N
MTX NNP i
adverse JJ N
effects NNS N
during IN N
combination NN N
therapy NN N
with IN N
HCQ NNP i
is VBZ N
recommended VBN N
, , N
especially RB N
if IN N
renal JJ N
function NN N
is VBZ N
known VBN N
to TO N
be VB N
decreased VBN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
the DT N
effect NN N
of IN N
topical JJ i
agents NNS i
on IN N
radiation-induced JJ o
skin NN o
disease NN o
by IN N
reflectance NN N
spectrophotometry NN N
. . N

OBJECTIVES NNP N
Radiotherapy NNP N
may MD N
cause VB N
severe JJ N
skin NN N
changes NNS N
that WDT N
significantly RB N
interfere VBZ N
with IN N
the DT N
patient NN N
's POS N
quality NN N
of IN N
life NN N
and CC N
reduce VB N
radiotherapy NN N
effectiveness NN N
. . N

Many JJ N
skin NN N
care NN N
instructions NNS N
and CC N
various JJ N
topical JJ N
agents NNS N
are VBP N
recommended VBN N
to TO N
help VB N
patients NNS N
in IN N
the DT N
management NN N
of IN N
radiation NN N
skin NN N
reactions NNS N
, , N
but CC N
evidence NN N
to TO N
support VB N
the DT N
value NN N
of IN N
the DT N
topical JJ N
treatments NNS N
of IN N
the DT N
irradiated JJ N
skin NN N
is VBZ N
lacking VBG N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
topical JJ i
agents NNS i
used VBN N
as IN N
supportive JJ N
care NN N
to TO N
minimise VB N
radiation-induced JJ o
skin NN o
disease NN o
using VBG N
an DT N
instrumental JJ N
method NN N
. . N

METHODS NNP N
Subjects NNPS p
who WP p
were VBD p
undergoing VBG p
a DT p
planned JJ p
course NN p
of IN p
radiation NN p
therapy NN p
after IN p
breast-conserving JJ p
surgery NN p
were VBD N
randomised VBN N
to TO N
treatment NN N
( ( N
using VBG N
one CD N
of IN N
two CD N
topical JJ i
agents NNS i
) ) i
or CC i
non-treatment JJ i
( ( i
control NN i
) ) i
groups NNS N
and CC N
monitored VBD N
over IN N
8 CD N
weeks NNS N
. . N

The DT N
intensity NN o
of IN o
skin NN o
erythema NN o
was VBD N
evaluated VBN N
once RB N
per IN N
week NN N
by IN N
non-invasive JJ N
instrumental JJ N
reflectance NN N
spectrophotometry NN N
in IN N
comparison NN N
with IN N
a DT N
visual JJ N
scoring NN N
system NN N
. . N

KEY NNP N
FINDINGS NNP N
Examination NNP N
of IN N
the DT N
erythema JJ o
time NN o
course NN o
by IN N
a DT N
sensitive JJ N
spectrophotometric JJ N
reflectance NN N
method NN N
showed VBD N
a DT N
significant JJ N
increase NN N
of IN N
skin JJ o
reactions NNS o
in IN N
the DT N
non-treated JJ N
group NN N
after IN N
the DT N
second JJ N
week NN N
of IN N
treatment NN N
and CC N
maximal JJ N
alterations NNS N
between IN N
the DT N
fourth JJ N
and CC N
sixth JJ N
week NN N
. . N

CONCLUSIONS NN N
From IN N
the DT N
results NNS N
obtained VBD N
, , N
we PRP N
observed VBD N
that DT N
application NN N
of IN N
topical JJ i
agents NNS i
used VBN N
in IN N
radio-induced JJ N
skin JJ N
disease NN N
were VBD N
able JJ N
to TO N
significantly RB N
reduce VB N
the DT N
erythema NN o
extent NN N
compared VBN N
to TO N
the DT N
non-treated JJ N
group NN N
. . N

-DOCSTART- -X- O O

Randomised VBN N
controlled VBD N
study NN N
of IN N
clinical JJ N
outcome NN N
following VBG N
trophic JJ i
feeding VBG i
. . i

AIMS NNP N
To TO N
determine VB N
the DT N
effect NN N
of IN N
trophic JJ i
feeding VBG i
on IN N
clinical JJ N
outcome NN N
in IN N
ill JJ p
preterm JJ p
infants NNS p
. . p

METHODS NNP N
A DT N
randomised VBN N
, , N
controlled VBN N
, , N
prospective JJ N
study NN N
of IN N
100 CD p
preterm JJ p
infants NNS p
, , p
weighing VBG p
less JJR p
than IN p
1750 CD p
g NN p
at IN p
birth NN p
and CC p
requiring VBG p
ventilatory JJ p
support NN p
and CC p
parenteral JJ p
nutrition NN p
, , N
was VBD N
performed VBN N
. . N

Group NNP N
TF NNP N
( ( N
48 CD N
infants NNS N
) ) N
received VBD N
trophic JJ i
feeding VBG i
from IN i
day NN i
3 CD i
( ( i
0.5-1 JJ i
ml/h NN i
) ) i
along IN i
with IN i
parenteral JJ i
nutrition NN i
until IN N
ventilatory JJ i
support NN i
finished VBD N
. . N

Group NNP N
C NNP N
( ( N
52 CD N
infants NNS N
) ) N
received VBD N
parenteral JJ i
nutrition NN i
alone RB i
. . i

Nutritive JJ i
milk NN i
feeding NN i
was VBD N
then RB N
introduced VBN N
to TO N
both DT N
groups NNS N
. . N

Clinical JJ N
outcomes NNS N
measured VBN N
included VBD N
total JJ o
energy NN o
intake NN o
and CC o
growth NN o
over IN o
the DT o
first JJ o
six CD o
postnatal JJ o
weeks NNS o
, , o
sepsis NN o
incidence NN o
, , o
liver NN o
function NN o
, , o
milk NN o
tolerance NN o
, , o
duration NN o
of IN o
respiratory JJ o
support NN o
, , o
duration NN o
of IN o
hospital NN o
stay NN o
and CC o
complication NN o
incidence NN o
. . o

RESULTS JJ N
Groups NNP N
were VBD N
well RB N
matched VBN N
for IN N
birthweight NN N
, , N
gestation NN N
and CC N
CRIB NNP N
scores NNS N
. . N

Infants NNS N
in IN N
group NN N
TF NNP N
had VBD N
significantly RB N
greater JJR N
energy NN o
intake NN o
, , N
mean JJ N
difference NN N
41.4 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
9 CD N
, , N
73.7 CD N
) ) N
kcal/kg NN N
p=0.02 NN N
; : N
weight JJ o
gain NN o
, , N
130 CD N
( ( N
CI NNP N
1 CD N
, , N
250 CD N
) ) N
g NN N
p NN N
= VBZ N
0.02 CD N
; : N
head NN o
circumference NN o
gain NN o
, , N
mean JJ N
difference NN N
0.7 CD N
( ( N
CI NNP N
0.1 CD N
, , N
1.3 CD N
) ) N
cm NN N
, , N
p NN N
= VBD N
0.04 CD N
; : N
fewer JJR N
episodes NNS o
of IN o
culture NN o
confirmed VBN o
sepsis NN o
, , N
mean JJ N
difference NN N
-0.7 NNP N
( ( N
-1.3 NNP N
, , N
-0.2 NNP N
) ) N
episodes VBZ N
, , N
p VB N
= JJ N
0.04 CD N
; : N
less JJR N
parenteral JJ o
nutrition NN o
, , N
mean JJ N
difference NN N
-11.5 NNP N
( ( N
CI NNP N
-20 NNP N
, , N
-3 NNP N
) ) N
days NNS N
, , N
p VBP N
= JJ N
0 CD N
. . N

03 CD N
; : N
tolerated VBN o
full JJ o
milk NN o
feeds NNS o
( ( N
165 CD N
ml/kg/day NN N
) ) N
earlier RBR N
, , N
mean JJ N
difference NN N
-11.2 NNP N
( ( N
CI NNP N
-19 NNP N
, , N
-3 NNP N
) ) N
days NNS N
, , N
p VBP N
= JJ N
0.03 CD N
; : N
reduced VBN N
requirement NN o
for IN o
supplemental JJ o
oxygen NN o
, , N
mean JJ N
difference NN N
-22.4 NNP N
( ( N
CI-41.5 NNP N
, , N
-3.3 NNP N
) ) N
days NNS N
, , N
p VBP N
= JJ N
0.02 CD N
; : N
and CC N
were VBD N
discharged VBN o
home NN o
earlier RBR N
, , N
mean JJ N
difference NN N
-22.1 NNP N
( ( N
CI NNP N
-42.1 NNP N
, , N
-2.2 NNP N
) ) N
days NNS N
, , N
p VBP N
= JJ N
0.04 CD N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
relative JJ N
risk NN o
of IN o
any DT o
complication NN o
. . o

CONCLUSIONS NNP N
Trophic NNP i
feeding VBG i
improves NNS N
clinical JJ N
outcome NN N
in IN N
ill JJ p
preterm JJ p
infants NNS p
requiring VBG p
parenteral JJ i
nutrition NN i
. . i

-DOCSTART- -X- O O

Acute JJ N
effects NNS N
of IN N
static JJ i
active JJ i
or CC i
dynamic JJ i
active JJ i
stretching VBG i
on IN N
eccentric-exercise-induced JJ o
hamstring NN o
muscle NN o
damage NN o
. . o

OBJECTIVES UH N
To TO N
examine VB N
whether IN N
an DT N
acute NN N
bout NN N
of IN N
active JJ i
or CC i
dynamic JJ i
hamstring-stretching JJ i
exercises NNS i
would MD N
reduce VB N
the DT N
amount NN N
of IN N
muscle NN N
damage NN N
observed VBD N
after IN N
a DT N
strenuous JJ N
eccentric JJ N
task NN N
and CC N
to TO N
determine VB N
whether IN N
the DT N
stretching NN N
protocols VBZ N
elicit JJ N
similar JJ N
responses NNS N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

METHODS NNP N
Thirty-six NNP p
young JJ p
male NN p
students NNS p
performed VBD p
5 CD p
min NN p
of IN p
jogging NN i
as IN p
a DT p
warm-up JJ p
and CC p
were VBD p
allocated VBN p
to TO p
1 CD p
of IN p
3 CD p
groups NNS p
: : p
3 CD i
min NN i
of IN i
static JJ i
active JJ i
stretching NN i
( ( i
SAS NNP i
) ) i
, , i
3 CD i
min NN i
of IN i
dynamic JJ i
active JJ i
stretching NN i
( ( i
DAS NNP i
) ) i
, , i
or CC i
control NN i
( ( i
CON NNP i
) ) i
. . i

All DT N
subjects NNS p
performed VBN p
eccentric JJ i
exercise NN i
immediately RB p
after IN p
stretching VBG p
. . p

Heart NNP N
rate NN N
, , N
core NN N
temperature NN N
, , N
maximal JJ N
voluntary JJ N
isometric JJ N
contraction NN N
, , N
passive JJ N
hip NN N
flexion NN N
, , N
passive JJ N
hamstring NN N
stiffness NN N
( ( N
PHS NNP N
) ) N
, , N
plasma JJ N
creatine JJ N
kinase NN N
activity NN N
, , N
and CC N
myoglobin NNS N
were VBD N
recorded VBN N
at IN N
prestretching NN N
, , N
at IN N
poststretching NN N
, , N
and CC N
every DT N
day NN N
after IN N
the DT N
eccentric JJ N
exercises NNS N
for IN N
5 CD N
d. NN N
RESULTS NNP N
After IN N
stretching VBG i
, , N
the DT N
change NN o
in IN o
hip NN o
flexion NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
SAS NNP i
( ( N
5? CD N
) ) N
and CC i
DAS NNP i
( ( N
10.8? CD N
) ) N
groups NNS N
than IN N
in IN N
the DT i
CON NNP i
( ( i
-4.1? NNP N
) ) N
group NN N
. . N

The DT N
change NN N
in IN N
PHS NNP o
was VBD o
significantly RB N
higher JJR N
in IN N
the DT N
DAS NNP i
( ( i
5.6 CD i
% NN N
) ) N
group NN N
than IN N
in IN N
the DT N
CON NNP i
( ( i
-5.7 NNP i
% NN N
) ) N
and CC N
SAS NNP N
( ( N
-6.7 NNP N
% NN N
) ) N
groups NNS N
. . N

Furthermore NNP o
, , o
changes NNS o
in IN o
muscle-damage NN o
markers NNS o
were VBD o
smaller JJR N
in IN N
the DT N
SAS NNP i
group NN i
than IN N
in IN N
the DT N
DAS NNP i
and CC i
CON NNP i
groups NNS i
. . N

CONCLUSIONS NNP N
Prior NNP N
active JJ N
stretching NN N
could MD N
be VB N
useful JJ N
for IN N
attenuating VBG N
the DT N
symptoms NNS N
of IN N
muscle NN N
damage NN N
after IN N
eccentric JJ N
exercise NN i
. . i

SAS NNP i
is VBZ i
recommended VBN N
over RP i
DAS NNP i
as IN i
a DT N
stretching VBG N
protocol NN N
in IN N
terms NNS N
of IN N
strength NN N
, , N
hamstring VBG N
range NN N
of IN N
motion NN N
, , N
and CC N
damage NN N
markers NNS N
. . N

-DOCSTART- -X- O O

Induction NNP i
chemotherapy NN i
in IN N
head NN p
and CC p
neck NN p
cancer NN p
: : p
results NNS N
of IN N
a DT N
phase NN N
III NNP N
trial NN N
. . N

Between IN p
December NNP p
1982 CD p
and CC p
October NNP p
1986 CD p
, , p
131 CD p
patients NNS p
with IN p
stage JJ p
II-III-IV NNP p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
oropharynx NN p
or CC p
oral JJ p
cavity NN p
were VBD N
randomized VBN N
to TO N
induction VB i
chemotherapy NN i
, , i
consisting VBG i
of IN i
bleomycin NN i
( ( i
10 CD i
mg/m2/day NN i
in IN i
continuous JJ i
infusion NN i
from IN i
day NN i
1 CD i
to TO i
day NN i
5 CD i
) ) i
, , i
methotrexate NN i
( ( i
120 CD i
mg/m2 NN i
on IN i
day NN i
2 CD i
) ) i
followed VBN i
by IN i
folinic JJ i
acid NN i
, , i
5-fluorouracil JJ i
( ( i
5 CD i
FU NNP i
) ) i
( ( i
600 CD i
mg/m2 NN i
on IN i
day NN i
2 CD i
) ) i
, , i
and CC i
cisplatin NN i
( ( i
120 CD i
mg/m2 NN i
on IN i
day NN i
4 CD i
) ) i
every DT i
4 CD i
weeks NNS i
for IN i
a DT i
total NN i
of IN i
three CD i
cycles NNS i
followed VBN i
by IN i
definitive JJ i
locoregional JJ i
treatment NN i
versus IN i
locoregional JJ i
treatment NN i
alone RB i
. . i

The DT N
modalities NNS N
of IN N
definitive JJ N
treatment NN N
( ( i
radiotherapy JJ i
+/- JJ i
surgery NN i
) ) i
were VBD N
chosen VBN N
prior RB N
to TO N
randomization NN N
. . N

A DT p
total NN p
of IN p
116 CD p
patients NNS p
were VBD p
evaluable JJ p
. . p

Of IN N
55 CD N
patients NNS N
in IN N
the DT N
chemotherapy NN i
arm NN N
, , N
four CD N
( ( N
7 CD N
% NN N
) ) N
had VBD N
a DT N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
and CC N
23 CD N
( ( N
42 CD N
% NN N
) ) N
a DT N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
following VBG N
the DT N
induction NN N
regimen NNS N
. . N

At IN N
the DT N
completion NN N
of IN N
locoregional JJ N
treatment NN N
, , N
76 CD N
% NN N
( ( N
42 CD N
of IN N
55 CD N
) ) N
of IN N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
were VBD N
in IN N
CR NNP N
compared VBN N
to TO N
89 CD N
% NN N
( ( N
54 CD N
of IN N
61 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
survival NN o
, , o
cause-specific JJ o
survival NN o
, , o
and CC o
pattern NN o
of IN o
relapse NN o
between IN N
both DT N
groups NNS N
. . N

The DT N
median JJ o
survival NN o
was VBD N
22 CD N
months NNS N
in IN N
the DT N
chemotherapy NN N
group NN N
and CC N
29 CD N
months NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Responders NNS N
to TO N
chemotherapy VB N
did VBD N
not RB N
fare VB N
better JJR N
than IN N
nonresponders NNS N
. . N

Chemotherapy-related JJ o
toxicities NNS o
were VBD N
few JJ N
and CC N
most JJS N
of IN N
them PRP N
related VBN N
to TO N
cisplatin VB N
which WDT N
was VBD N
reduced VBN N
to TO N
100 CD N
mg/m2 NN N
for IN N
35 CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
treatment-related JJ N
deaths NNS o
and CC N
, , N
in IN N
the DT N
experimental JJ N
arm NN N
of IN N
the DT N
trial NN N
, , N
no DT N
increased VBN N
morbidity NN o
from IN N
locoregional JJ N
treatment NN N
. . N

This DT N
induction NN N
regimen NN N
does VBZ N
not RB N
offer VB N
any DT N
advantages NNS N
over IN N
standard JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Oral JJ N
magnesium NN i
supplementation NN i
in IN N
children NNS p
with IN p
cystic JJ p
fibrosis NN p
improves VBZ N
clinical JJ o
and CC o
functional JJ o
variables NNS o
: : o
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
. . N

BACKGROUND NNP N
Magnesium NNP N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
important JJ N
minerals NNS N
in IN N
the DT N
body NN N
. . N

Although IN N
some DT N
studies NNS N
reported VBD N
that IN N
patients NNS N
with IN N
cystic JJ N
fibrosis NN N
( ( N
CF NNP N
) ) N
lack NN N
magnesium NN N
, , N
no DT N
international JJ N
study NN N
has VBZ N
assessed VBN N
the DT N
importance NN N
of IN N
oral JJ N
magnesium NN N
supplementation NN N
in IN N
CF NNP N
patients NNS N
. . N

OBJECTIVE IN N
We PRP N
prospectively RB N
investigated VBD N
the DT N
long-term JJ N
effect NN N
of IN N
oral JJ N
magnesium NN i
supplementation NN N
on IN N
respiratory JJ o
muscle NN o
strength NN o
by IN N
using VBG N
manuvacuometry NN N
and CC N
the DT N
Shwachman-Kulczycki NNP o
( ( o
SK NNP o
) ) o
score NN o
among IN N
children NNS p
and CC p
adolescents NNS p
with IN p
CF NNP p
. . p

DESIGN NNP N
This DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
included VBD N
44 CD p
CF NNP p
patients NNS p
( ( p
aged VBN p
7-19 CD p
y NN p
; : p
20 CD p
males NNS p
) ) p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
magnesium NN i
( ( p
n JJ p
= VBZ p
22 CD p
; : p
300 CD p
mg/d NN p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= NNP p
22 CD p
) ) p
for IN p
8 CD p
wk NN p
with IN p
a DT p
4-wk JJ p
washout NN p
period NN p
between IN p
trials NNS p
. . p

All DT N
patients NNS N
were VBD N
undergoing JJ N
conventional JJ N
treatment NN N
of IN N
CF NNP N
. . N

The DT N
experimental JJ N
protocol NN N
included VBD N
clinical JJ N
evaluation NN N
, , N
assessment NN N
of IN N
urinary JJ N
concentration NN N
of IN N
magnesium NN N
, , N
and CC N
manuvacuometric JJ N
measurements NNS N
[ VBP o
maximal JJ o
inspiratory JJ o
pressure NN o
( ( o
MIP NNP o
) ) o
and CC N
maximal JJ o
expiratory NN o
pressure NN o
( ( o
MEP NNP o
) ) o
] NN o
. . N

MIP NNP o
was VBD N
the DT N
primary JJ N
outcome NN N
. . N

RESULTS NNP N
Urinary JJ o
magnesium NN o
increased VBD N
after IN N
the DT N
administration NN N
of IN N
magnesium NN N
( ( N
change NN N
: : N
36.38 CD N
mg/d NN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.72 CD N
mg/d NNS N
after IN N
placebo NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Moreover RB N
, , N
MIP NNP o
and CC o
MEP NNP o
significantly RB N
improved VBD N
only RB N
after IN N
magnesium NN i
administration NN N
( ( N
change NN N
in IN N
MIP NNP N
: : N
11 CD N
% NN N
predicted VBN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.5 CD N
% NN N
predicted VBN N
after IN N
placebo NN N
; : N
change NN N
in IN N
MEP NNP N
: : N
11.9 CD N
% NN N
predicted VBN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.8 CD N
% NN N
predicted VBN N
after IN N
placebo NN N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
) ) N
. . N

Magnesium NNP N
administration NN N
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
clinical JJ N
variables NNS N
assessed VBN N
by IN N
the DT N
SK NNP o
score NN o
( ( N
change NN N
: : N
4.48 CD N
points NNS N
after IN N
magnesium NN N
compared VBN N
with IN N
-1.30 NNP N
points NNS N
after IN N
placebo NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Oral NNP N
magnesium NN i
supplementation NN N
helped VBD N
improve VB N
both DT N
the DT N
SK NNP o
score NN o
and CC o
respiratory JJ o
muscle NN o
strength NN o
in IN N
pediatric JJ N
patients NNS N
with IN N
CF NNP N
. . N

-DOCSTART- -X- O O

Participant JJ N
characteristics NNS N
and CC N
intervention NN N
processes NNS N
associated VBN N
with IN N
reductions NNS N
in IN N
television NN o
viewing NN o
in IN N
the DT N
High NNP N
Five NNP N
for IN N
Kids NNP p
study NN N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
High NNP i
Five NNP i
for IN i
Kids NNP i
intervention NN i
effect NN N
on IN N
television NN o
within IN N
subgroups NNS N
, , N
examine NN N
participant NN N
characteristics NNS N
associated VBN N
with IN N
process NN N
measures NNS N
and CC N
assess NN N
perceived VBD N
helpfulness NN N
of IN N
television NN N
intervention NN N
components NNS N
. . N

METHOD NNP N
High NNP p
Five NNP p
( ( p
randomized VBN p
controlled VBN p
trial NN p
of IN p
445 CD p
overweight/obese JJ p
2-7 JJ p
year-olds NNS p
in IN p
Massachusetts NNP p
[ NNP p
2006-2008 JJ p
] NN p
) ) p
reduced VBD i
television NN i
by IN i
0.36 CD i
h/day NN i
. . i

1-year JJ N
effects NNS N
on IN N
television NN N
viewing NN N
, , N
stratified VBN N
by IN N
subgroup NN N
, , N
were VBD N
assessed VBN N
using VBG N
linear JJ N
regression NN N
. . N

Among IN p
intervention NN p
participants NNS p
( ( p
n=253 NN p
) ) p
, , N
associations NNS N
of IN N
intervention NN i
component NN i
helpfulness NN N
with IN N
television NN o
reduction NN N
were VBD N
examined VBN N
using VBG N
linear JJ N
regression NN N
and CC N
associations NNS N
of IN N
participant JJ N
characteristics NNS N
with IN N
processes NNS N
linked VBN N
to TO N
television NN N
reduction NN N
( ( N
choosing VBG N
television NN N
and CC N
completing VBG N
intervention NN N
visits NNS N
) ) N
were VBD N
examined VBN N
using VBG N
logistic JJ N
regression NN N
. . N

RESULTS NNP N
High NNP N
Five NNP N
reduced VBD N
television NN N
across IN N
subgroups NNS N
. . N

Parents NNS p
of IN p
Latino NNP p
( ( p
versus IN p
white JJ p
) ) p
children NNS p
had VBD N
lower JJR N
odds NNS N
of IN N
completing VBG o
?2 NNP o
study NN o
visits NNS o
( ( o
Odds NNPS N
Ratio NNP N
: : N
0.39 CD N
[ $ N
95 CD N
% NN N
Confidence NN N
Interval NNP N
: : N
0.18 CD N
, , N
0.84 CD p
] NN p
) ) p
. . p

Parents NNS p
of IN p
black JJ p
( ( p
versus IN p
white JJ p
) ) p
children NNS p
had VBD p
higher JJR N
odds NNS N
of IN N
choosing VBG o
television NN o
( ( o
Odds NNP N
Ratio NNP N
: : N
2.23 CD N
[ $ N
95 CD N
% NN N
Confidence NN N
Interval NNP N
: : N
1.08 CD N
, , N
4.59 CD N
] NN N
) ) N
, , N
as IN N
did VBD p
parents NNS p
of IN p
obese JJ p
( ( p
versus JJ p
overweight NN p
) ) p
children NNS p
and CC p
children NNS p
watching VBG p
?2 NN p
h/day NN p
( ( p
versus JJ p
< NNP p
2 CD p
) ) p
at IN p
baseline NN p
. . p

Greater NNP p
perceived VBD o
helpfulness NN o
was VBD o
associated VBN N
with IN N
greater JJR N
television NN N
reduction NN N
. . N

CONCLUSION NNP i
Clinic-based JJ i
motivational JJ i
interviewing NN i
reduces NNS o
television NN o
viewing NN o
in IN o
children NNS i
. . i

Low JJ i
cost NN i
education NN i
approaches NNS i
( ( i
e.g. NN i
, , N
printed JJ N
materials NNS N
) ) N
may MD N
be VB N
well-received JJ N
. . N

Parents NNS p
of IN p
children NNS p
at IN p
higher JJR p
obesity NN p
risk NN p
could MD p
be VB N
more RBR N
motivated JJ N
to TO N
reduce VB o
television NN o
. . o

-DOCSTART- -X- O O

Association NNP N
of IN N
PAX4 NNP N
genetic JJ N
variants NNS N
with IN N
oral JJ i
antidiabetic JJ i
drugs NNS i
efficacy NN N
in IN N
Chinese NNP p
type NN p
2 CD p
diabetes VBZ p
patients NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
association NN N
of IN N
PAX4 NNP i
variants NNS i
with IN N
therapeutic JJ N
effect NN N
of IN N
oral JJ i
antidiabetic JJ i
drugs NNS i
in IN N
Chinese NNP p
type NN p
2 CD p
diabtes NNS p
mellitus FW p
( ( p
T2DM NNP p
) ) p
patients NNS p
. . p

A DT p
total NN p
of IN p
209 CD p
newly RB p
diagnosed VBN p
T2DM NNP p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
repaglinide NN i
or CC i
rosiglitazone NN i
for IN N
48 CD N
weeks NNS N
, , N
and CC N
the DT N
therapeutic JJ N
effects NNS N
were VBD N
compared VBN N
. . N

In IN N
the DT N
rosiglitazone NN N
cohort NN N
, , N
rs6467136 VB N
GA+AA NNP N
carriers NNS N
showed VBD N
greater JJR N
decrease NN N
in IN N
2-h JJ o
glucose NN o
levels NNS o
( ( N
P=0.0063 NNP N
) ) N
and CC N
higher JJR N
cumulative JJ N
attainment NN N
rates NNS o
of IN o
target NN o
2-h JJ o
glucose NN o
levels NNS o
( ( N
Plog NNP N
rank=0.0093 NN N
) ) N
than IN N
GG NNP N
homozygotes NNS N
. . N

In IN N
the DT N
subgroup NN N
with IN N
defective JJ N
?-cell JJ N
function NN N
, , N
rs6467136 VB N
GA+AA NNP N
carriers NNS N
exhibited VBD N
greater JJR N
decrements NNS N
of IN o
2-h JJ o
glucose JJ o
level NN o
and CC N
improvement NN N
of IN o
homeostasis NN o
model NN o
assessment NN o
of IN o
insulin NN o
resistance NN o
( ( N
P=0.0143 NNP N
) ) N
. . N

Moreover RB N
, , N
GA+AA NNP N
carriers NNS N
were VBD N
more RBR N
likely JJ N
to TO N
attain VB N
the DT o
target NN o
fasting NN o
and CC o
2-h JJ o
glucose JJ o
level NN o
( ( N
Plog NNP N
rank=0.0091 NN N
and CC N
0.007 CD N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
these DT N
single-nucleotide JJ N
polymorphisms NN N
showed VBD N
no DT N
effect NN N
on IN o
repaglinide NN o
efficacy NN o
. . o

In IN N
conclusion NN N
, , N
PAX4 NNP N
variant NN N
rs6467136 NN N
was VBD N
associated VBN N
with IN N
the DT N
therapeutic JJ N
effect NN N
of IN i
rosiglitazone NN i
in IN p
Chinese JJ p
T2DM NNP p
patients NNS p
. . p

-DOCSTART- -X- O O

Randomised VBN N
clinical JJ N
trial NN N
of IN N
physiotherapy NN i
after IN N
open JJ N
abdominal JJ N
surgery NN N
in IN N
high JJ p
risk NN p
patients NNS p
. . p

Postoperative NNP i
physiotherapy NN i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB o
the DT o
incidence NN o
of IN N
postoperative JJ N
pulmonary JJ N
complications NNS N
after IN N
open JJ N
abdominal JJ N
surgery NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
determine VB N
if IN N
the DT N
addition NN N
of IN N
deep JJ i
breathing NN i
exercises NNS i
and CC N
secretion NN i
clearing NN i
techniques NNS i
to TO N
a DT N
standardised JJ i
physiotherapist-directed JJ i
program NN i
of IN N
early JJ N
mobilisation NN N
improved VBD N
clinical JJ N
outcomes NNS N
in IN N
patients NNS p
undergoing VBG p
open JJ p
abdominal JJ p
surgery NN p
. . p

Fifty-six JJ p
patients NNS p
undergoing VBG p
open JJ i
abdominal JJ i
surgery NN i
, , p
at IN p
high JJ p
risk NN p
of IN p
developing VBG p
postoperative JJ p
pulmonary JJ p
complications NNS p
, , N
were VBD N
randomised VBN i
before IN i
operation NN i
to TO i
an DT i
early JJ i
mobilisation-only JJ i
group NN i
or CC i
an DT i
early JJ i
mobilisation-plus-deep JJ i
breathing NN i
and CC i
coughing VBG i
group NN i
. . i

Mobility NNP o
duration NN o
, , o
frequency NN o
and CC o
intensity NN o
of IN o
breathing VBG o
interventions NNS o
were VBD i
quantified VBN i
for IN i
both DT i
groups NNS i
. . i

All DT i
outcomes NNS i
were VBD i
assessed VBN i
by IN i
a DT i
blinded JJ i
outcomes NN i
researcher NN i
using VBG i
a DT i
standardised JJ i
outcomes NNS i
measurement JJ i
tool NN i
developed VBD i
specifically RB i
for IN i
this DT i
population NN i
. . i

Outcomes CC o
included VBD o
incidence NN o
of IN o
clinically RB o
significant JJ o
postoperative JJ o
pulmonary JJ o
complications NNS o
, , o
fever RB o
, , o
length NN o
of IN o
stay NN o
, , o
and CC o
restoration NN o
of IN o
mobility NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
mean JJ o
age NN o
, , o
anaesthetic JJ o
time NN o
, , o
perioperative JJ o
morbidity NN o
, , o
or CC o
postoperative JJ o
mobility NN o
. . o

Outcome NNP N
data NNS N
were VBD N
available JJ N
for IN N
89 CD N
% NN N
of IN N
enrolled JJ N
subjects NNS N
. . N

Overall JJ N
incidence NN N
of IN N
postoperative JJ o
pulmonary JJ o
complications NNS o
was VBD N
16 CD N
% NN N
. . N

The DT N
incidence NN N
of IN N
postoperative JJ o
pulmonary JJ o
complications NNS o
in IN N
the DT N
non-deep JJ N
breathing NN N
and CC N
coughing VBG N
group NN N
was VBD N
14 CD N
% NN N
, , N
and CC N
the DT N
incidence NN N
of IN N
postoperative JJ o
pulmonary JJ o
complications NNS o
in IN N
the DT N
deep JJ N
breathing NN N
and CC N
coughing VBG N
group NN N
was VBD N
17 CD N
% NN N
, , N
( ( N
absolute JJ N
risk NN N
reduction NN N
-3 NNP N
% NN N
, , N
95 CD N
% NN N
C1 NNP N
-22 NNP N
to TO N
19 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
incidence NN N
of IN N
fever NN o
, , o
physiotherapist JJ o
time NN o
, , o
or CC o
the DT o
number NN o
of IN o
treatments NNS o
. . o

This DT N
study NN N
suggests VBZ N
that IN N
, , N
in IN N
this DT N
clinical JJ N
setting NN N
, , N
the DT N
addition NN N
of IN N
deep JJ i
breathing NN i
and CC i
coughing NN i
exercises NNS i
to TO N
a DT N
physiotherapist-directed JJ N
program NN N
of IN N
early JJ N
mobilisation NN N
does VBZ N
not RB N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
clinically RB N
significant JJ N
postoperative JJ N
pulmonary JJ N
complications NNS N
in IN N
high JJ p
risk NN p
open JJ p
abdominal JJ p
surgery NN p
subjects NNS p
. . p

-DOCSTART- -X- O O

The DT N
additional JJ N
value NN N
of IN N
a DT N
night NN i
splint NN i
to TO i
eccentric VB i
exercises NNS i
in IN N
chronic JJ p
midportion NN p
Achilles NNP p
tendinopathy NN p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

AIM NNP N
To TO N
assess VB N
whether IN N
the DT N
use NN i
of IN i
a DT i
night NN i
splint NN i
is VBZ N
of IN N
added JJ N
benefit NN N
on IN N
functional JJ N
outcome NN N
in IN N
treating VBG N
chronic JJ p
midportion NN p
Achilles NNP p
tendinopathy NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
single-blind JJ N
, , N
prospective JJ N
, , N
single JJ N
centre NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
set NN N
in IN N
the DT N
Sports NNP p
Medical NNP p
Department NNP p
, , p
The DT p
Hague NNP p
Medical NNP p
Centre NNP p
, , p
The DT p
Netherlands NNP p
. . p

Inclusion NNP p
criteria NNS p
were VBD p
: : p
age NN p
18-70 CD p
years NNS p
, , p
active JJ p
participation NN p
in IN p
sports NNS p
, , p
and CC p
tendon VB p
pain NN p
localised VBN p
at IN p
2-7 JJ p
cm NN p
from IN p
distal JJ p
insertion NN p
. . p

Exclusion NN p
criteria NNS p
were VBD p
: : p
insertional JJ p
disorders NNS p
, , p
partial JJ p
or CC p
complete JJ p
ruptures NNS p
, , p
or CC p
systemic JJ p
illness NN p
. . p

70 CD p
tendons NNS p
were VBD p
included VBN p
and CC N
randomised VBN N
into IN N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
: : N
eccentric JJ i
exercises NNS i
with IN i
a DT i
night NN i
splint NN i
( ( N
night NN N
splint NN N
group NN N
, , N
n RB N
= VBZ N
36 CD N
) ) N
or CC N
eccentric JJ i
exercises NNS i
only RB i
( ( N
eccentric JJ N
group NN N
, , N
n RB N
= VBZ N
34 CD N
) ) N
. . N

INTERVENTIONS NNP N
Both DT N
groups NNS N
completed VBD N
a DT N
12-week JJ N
heavy-load NN i
eccentric JJ i
training NN i
programme NN i
. . i

One CD N
group NN N
received VBD N
a DT N
night NN i
splint NN i
in IN i
addition NN i
to TO i
eccentric JJ i
exercises NNS i
. . i

At IN N
baseline NN N
and CC N
follow-up NN N
at IN N
12 CD N
weeks NNS N
, , N
patient JJ o
satisfaction NN o
, , o
Victorian NNP o
Institute NNP o
of IN o
Sport NNP o
Assessment-Achilles NNP o
questionnaire NN o
( ( o
VISA-A NNP o
) ) o
score NN o
and CC o
reported VBD o
compliance NN o
were VBD N
recorded VBN N
by IN N
a DT N
single-blind NN N
trained JJ N
researcher NN N
who WP N
was VBD N
blinded VBN N
to TO N
the DT N
treatment NN N
. . N

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
, , N
patient JJ o
satisfaction NN o
in IN N
the DT N
eccentric JJ N
group NN N
was VBD N
63 CD N
% NN N
compared VBN N
with IN N
48 CD N
% NN N
in IN N
the DT N
night NN i
splint NN i
group NN N
. . N

The DT N
VISA-A NNP o
score NN o
significantly RB N
improved VBN N
in IN N
both DT N
groups NNS N
; : N
in IN N
the DT N
eccentric JJ p
group NN p
from IN p
50.1 CD p
to TO p
68.8 CD p
( ( p
p NN p
= RB p
0.001 CD p
) ) p
and CC N
in IN N
the DT N
night NN p
splint NN p
group NN p
from IN p
49.4 CD p
to TO p
67.0 CD p
( ( p
p NN p
< RB p
0.001 CD p
) ) p
. . p

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
VISA-A NNP o
score NN o
( ( N
p JJ N
= NNP N
0.815 CD N
) ) N
and CC N
patient JJ o
satisfaction NN o
( ( N
p JJ N
= NNP N
0.261 CD N
) ) N
. . N

CONCLUSION VB N
A DT N
night NN i
splint NN i
is VBZ N
not RB N
beneficial JJ N
in IN N
addition NN N
to TO N
eccentric VB N
exercises NNS N
in IN N
the DT N
treatment NN N
of IN N
chronic JJ N
midportion NN N
Achilles NNP N
tendinopathy NN N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
premature JJ N
labor NN N
by IN N
17 CD i
alpha-hydroxyprogesterone JJ i
caproate NN i
. . i

Eighty NNP p
pregnant JJ p
women NNS p
at IN p
high JJ p
risk NN p
of IN p
giving VBG p
birth NN p
prematurely RB p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

Treatment NN N
with IN N
either DT N
17 CD i
alpha-hydroxyprogesterone NN i
caproate NN i
, , i
250 CD i
mg NN i
by IN i
intramuscular JJ i
injection NN i
once RB i
a DT i
week NN i
, , i
or CC i
a DT i
placebo NN i
was VBD N
given VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
. . N

Imminent JJ N
premature NN N
labor NN N
occurred VBD N
in IN N
29.0 CD N
% NN N
of IN N
the DT N
treated VBN N
group NN N
and CC N
in IN N
59.4 CD N
% NN N
of IN N
the DT N
control NN i
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.025 CD N
) ) N
. . N

The DT N
rate NN o
of IN o
premature NN o
deliveries NNS o
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
treated JJ N
group NN N
( ( N
16.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
37.82 CD N
% NN N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
cases NNS N
of IN N
perinatal JJ o
death NN o
or CC o
fetal JJ o
malformations NNS o
in IN N
either DT N
group NN N
. . N

The DT N
mean JJ o
birth NN o
weight NN o
of IN N
all DT N
infants NNS N
of IN N
the DT N
treated JJ N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
those DT N
of IN N
the DT N
control NN N
group NN N
( ( N
3111.9 CD N
+/- JJ N
905 CD N
gm NN N
versus NN N
2680 CD N
+/- JJ N
813.4 CD N
gm NN N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
results NNS N
support VB N
treatment NN N
with IN N
progesterone NN i
caproate NN i
for IN N
the DT N
prevention NN N
of IN N
premature JJ N
labor NN N
. . N

-DOCSTART- -X- O O

Drug NNP N
therapy NN N
of IN N
ventricular JJ p
tachycardia NN p
: : p
a DT N
cost NN N
comparison NN N
of IN N
randomized JJ N
noninvasive JJ i
and CC i
invasive JJ i
approaches NNS i
. . i

OBJECTIVE NNP N
Economic NNP o
evaluation NN o
of IN N
noninvasive JJ i
( ( i
suppression NN i
of IN i
ventricular JJ i
arrhythmias NNS i
detected VBN i
by IN i
ambulatory JJ i
monitoring NN i
) ) i
and CC N
invasive JJ i
( ( i
suppression NN i
of IN i
arrhythmias NNS i
induced VBN i
by IN i
programmed JJ i
stimulation NN i
) ) i
approaches VBZ N
to TO N
antiarrhythmic VB N
drug NN N
selection NN N
for IN N
ventricular JJ N
tachyarrhythmias NN N
. . N

DESIGN/SETTING NNP N
Randomized NNP N
clinical JJ N
trial/tertiary-care JJ N
hospital NN N
. . N

PATIENTS NNP N
Of IN N
124 CD p
consecutive JJ p
patients NNS p
referred VBD p
for IN p
treatment NN p
of IN p
symptomatic JJ p
ventricular NN p
tachyarrhythmias NN p
, , p
57 CD p
consenting NN p
patients NNS p
were VBD p
eligible JJ p
to TO p
have VB p
drug NN p
therapy NN p
selected VBN p
by IN p
either DT p
noninvasive JJ i
or CC i
invasive JJ i
approaches NNS i
. . i

MEASUREMENTS NNP N
Costs NNPS o
of IN o
initial JJ o
and CC o
follow-up JJ o
( ( N
26 CD N
+/- JJ N
15 CD N
months NNS N
) ) N
admissions NNS N
for IN N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
. . N

This DT N
economic JJ o
evaluation NN o
also RB N
considered VBN N
relative JJ N
efficacies NNS o
of IN N
the DT N
approaches NNS N
using VBG N
the DT N
primary JJ o
outcome NN o
variable NN o
of IN N
symptomatic JJ o
, , o
sustained VBD o
ventricular JJ o
tachyarrhythmia NN o
recurrence NN o
( ( o
including VBG o
sudden JJ o
death NN o
) ) o
. . o

RESULTS NNP N
Initial JJ o
hospitalization NN o
for IN N
therapy NN N
selection NN N
was VBD N
less RBR N
costly JJ o
by IN N
the DT N
noninvasive JJ N
approach NN N
( ( N
$ $ N
6,869 CD N
+/- JJ N
4,019 CD N
) ) N
than IN N
by IN N
the DT N
invasive JJ i
approach NN i
( ( N
$ $ N
13,164 CD N
+/- JJ N
6,740 CD N
) ) N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

However RB N
, , N
the DT N
noninvasive JJ i
approach NN i
generated VBD N
higher JJR N
follow-up JJ o
hospital NN o
costs NNS o
( ( N
$ $ N
9,204 CD N
+/- JJ N
9,217 CD N
) ) N
than IN N
the DT N
invasive JJ N
approach NN N
( ( N
$ $ N
3,784 CD N
+/- JJ N
4,944 CD N
) ) N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

Thus RB N
, , N
total JJ o
hospital NN o
costs NNS o
of IN N
the DT N
noninvasive JJ N
( ( N
$ $ N
16,073 CD N
+/- JJ N
9,423 CD N
) ) N
and CC N
invasive JJ N
approaches NNS N
( ( N
$ $ N
16,949 CD N
+/- JJ N
7,174 CD N
) ) N
were VBD N
equivalent JJ N
. . N

The DT N
two-year JJ o
actuarial JJ o
probability NN o
of IN o
a DT o
recurrent NN o
, , o
sustained VBN o
, , o
symptomatic JJ o
ventricular NN o
tachyarrhythmia NN o
was VBD N
greater JJR N
in IN N
noninvasive JJ i
( ( N
0.50 CD N
+/- JJ N
0.10 CD N
) ) N
than IN N
in IN N
invasive JJ i
( ( N
0.20 CD N
+/- JJ N
0.08 CD N
) ) N
approach NN N
patients NNS N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
lower JJR N
initial JJ o
hospital NN o
costs NNS o
of IN N
the DT N
noninvasive JJ N
approach NN N
are VBP N
offset VBN N
by IN N
greater JJR N
follow-up NN o
costs NNS o
. . o

Within IN N
two CD N
years NNS N
the DT N
costs NNS o
of IN N
the DT N
two CD N
approaches NNS N
are VBP N
equivalent JJ N
. . N

Thus RB N
, , N
greater JJR N
antiarrhythmic JJ o
efficacy NN o
can MD N
be VB N
achieved VBN N
by IN N
the DT N
invasive JJ i
approach NN i
to TO N
drug NN N
selection NN N
without IN N
increasing VBG N
total JJ o
hospital NN o
costs NNS o
. . o

-DOCSTART- -X- O O

Evaluating VBG o
erectile JJ p
dysfunction NN p
: : p
oral JJ N
sildenafil NN N
versus NN N
intracavernosal JJ N
injection NN N
of IN N
papaverine NN N
. . N

BACKGROUND NNP N
Intracavernosal NNP N
injection NN N
of IN N
vasoactive JJ N
drugs NNS N
is VBZ N
an DT N
established JJ N
method NN N
of IN N
evaluating VBG N
erectile JJ N
dysfunction NN N
. . N

However RB N
, , N
it PRP N
is VBZ N
invasive JJ N
and CC N
may MD N
be VB N
associated VBN N
with IN N
pain NN N
and CC N
priapism NN N
. . N

We PRP N
investigated VBD N
the DT N
use NN N
of IN N
oral JJ N
sildenafil NN N
as IN N
a DT N
possible JJ N
substitute NN N
for IN N
intracavernosal JJ N
agents NNS N
. . N

METHODS NNP N
Men NNP p
with IN p
erectile JJ p
dysfunction NN p
were VBD p
randomized VBN p
into IN p
two CD p
groups NNS p
of IN p
25 CD p
each DT p
. . p

One CD N
group NN N
of IN N
25 CD p
men NNS p
received VBN N
injection NN i
papaverine NN i
initially RB i
followed VBN i
by IN i
oral JJ i
sildenafil NN i
, , N
and CC N
another DT N
25 CD N
received VBD N
oral JJ i
sildenafil NN i
followed VBN i
by IN i
injection NN i
papaverine NN i
. . i

Genital JJ N
self-stimulation NN N
was VBD N
used VBN N
in IN N
both DT N
the DT N
groups NNS N
. . N

Penile NNP o
length NN o
and CC o
circumference NN o
as RB o
well RB o
as IN o
angle NN o
of IN o
erection NN o
, , N
before IN N
and CC N
after IN N
each DT N
medication NN N
, , N
were VBD N
recorded VBN N
. . N

Two CD N
days NNS N
later RB N
, , N
the DT N
intervention NN N
arms NNS N
were VBD N
crossed VBN N
over IN N
. . N

Subjective JJ o
responses NNS o
were VBD N
obtained VBN N
. . N

The DT N
effect NN N
of IN N
medication NN N
on IN N
each DT N
outcome NN N
variable NN N
was VBD N
studied VBN N
by IN N
using VBG N
analysis NN o
of IN o
variance NN o
models NNS o
in IN N
relation NN N
to TO N
patient VB N
, , N
period NN N
and CC N
medication NN N
. . N

RESULTS NNP N
There EX N
was VBD N
statistically RB N
significant JJ N
improvement NN N
from IN N
the DT N
baseline NN N
value NN N
in IN N
both CC N
the DT N
arms NNS N
, , N
i.e JJ N
injection NN N
papaverine NN N
and CC N
oral JJ N
sildenafil NN N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
for IN N
both DT N
penile JJ o
length NN o
and CC o
circumference NN o
. . o

No DT N
significant JJ N
difference NN o
was VBD N
observed VBN N
between IN N
the DT N
two CD N
medications NNS N
in IN N
the DT N
outcome NN N
measures NNS N
. . N

CONCLCUSION NN N
: : N
Oral JJ N
sildenafil NN N
was VBD N
as RB N
effective JJ N
as IN N
injection NN N
papaverine NN N
in IN N
evaluating VBG N
erectile JJ p
dysfunction NN p
. . p

-DOCSTART- -X- O O

0.1 CD N
% NN N
bupivacaine NN i
does VBZ N
not RB N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
infusion NN N
after IN p
major JJ p
abdominal JJ p
surgery NN p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Although IN N
local JJ N
anesthesia NN N
has VBZ N
been VBN N
demonstrated VBN N
to TO N
potentiate VB N
spinal JJ N
morphine NN N
analgesia NN N
in IN N
animal JJ N
studies NNS N
, , N
results NNS N
comparing VBG N
epidural JJ N
local JJ N
anesthesia/opioid NN N
mixtures NNS N
with IN N
opioid JJ N
alone NN N
are VBP N
contradictory JJ N
in IN N
clinical JJ N
studies NNS N
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
, , N
although IN N
the DT N
concentration NN N
of IN N
bupivacaine NN i
( ( N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
to TO N
minimize VB N
its PRP$ N
adverse JJ N
effects NNS N
, , N
if IN N
the DT N
infusion NN N
rate NN N
of IN N
a DT N
fentanyl/bupivacaine JJ i
solution NN N
was VBD N
closely RB N
adjusted VBN N
according VBG N
to TO N
need NN N
, , N
the DT N
presence NN N
bupivacaine NN N
would MD N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
. . N

METHODS NNP N
Forty NNP p
patients NNS p
were VBD N
randomly RB N
assigned VBN i
to TO i
receive VB i
either DT i
fentanyl NN i
( ( i
10 CD i
micrograms/mL NN i
) ) i
or CC i
a DT i
fentanyl/bupivacaine NN i
( ( i
0.1 CD i
% NN i
) ) i
mixture NN i
epidurally RB i
corresponding VBG i
to TO i
the DT i
dermatome NN i
of IN i
the DT i
surgical JJ i
incision NN i
in IN i
a DT i
double-blind JJ i
fashion NN i
for IN i
the DT i
first JJ i
18 CD i
hours NNS i
after IN i
major JJ i
abdominal JJ i
surgery NN i
. . i

The DT i
infusion NN i
was VBD i
titrated VBN i
for IN i
each DT i
patient NN i
to TO i
the DT i
rate NN i
required VBN i
for IN i
pain NN i
relief NN i
during IN i
forced VBN i
inspiration NN i
( ( i
pain NN i
score NN i
< NN i
or CC i
= $ i
2 CD i
, , i
maximum JJ i
10 CD i
) ) i
. . i

Pain NN N
scores NNS N
, , N
the DT N
fentanyl JJ N
doses NNS N
required VBN N
, , N
plasma JJ N
concentrations NNS N
of IN N
fentanyl NN N
at IN N
18 CD N
hours NNS N
, , N
and CC N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ o
effects NNS o
were VBD N
recorded VBN N
. . N

RESULTS JJ N
Patients NNPS N
reported VBD N
similar JJ N
median JJ o
pain NN o
scores NNS o
and CC N
were VBD N
equally RB N
satisfied VBN N
with IN N
pain NN o
relief NN o
in IN N
both DT N
groups NNS N
. . N

The DT N
mean NN o
required VBN o
post-operative JJ o
fentanyl JJ o
infusion NN o
rate NN o
( ( N
57.7 CD N
+/- JJ N
19.5 CD N
micrograms/h NN N
) ) N
and CC N
the DT N
plasma NN o
concentrations NNS o
( ( N
0.84 CD N
+/- JJ N
0.36 CD N
ng/mL NN N
) ) N
in IN N
the DT N
fentanyl NN N
group NN N
were VBD N
comparable JJ N
to TO N
the DT N
infusion NN o
rate NN o
( ( N
54.4 CD N
+/- JJ N
19.2 CD N
micrograms/h NN N
) ) N
and CC N
the DT N
plasma NN o
concentrations NNS o
( ( N
0.86 CD N
+/- JJ N
0.36 CD N
ng/mL NN N
) ) N
in IN N
the DT N
fentanyl/bupivacaine NN N
group NN N
. . N

Respiratory NNP o
and CC o
cardiovascular JJ o
functions NNS o
were VBD N
preserved VBN N
, , N
and CC N
the DT N
incidence NN o
of IN o
nausea NN o
, , o
pruritus NN o
, , o
and CC o
periods NNS o
of IN o
drowsiness NN o
or CC o
sleep NN o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
low JJ N
concentrations NNS N
( ( N
0.1 CD N
% NN N
) ) N
, , N
bupivacaine NN i
did VBD N
not RB N
reduce VB N
the DT N
titrated JJ N
dose NN N
of IN N
epidural JJ N
fentanyl NN N
required VBN N
for IN N
adequate JJ N
pain NN N
relief NN N
during IN N
forced VBN N
inspiration NN N
after IN N
major JJ N
abdominal JJ N
surgery NN N
. . N

The DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
effects NNS N
were VBD N
also RB N
comparable JJ N
whether IN N
or CC N
not RB N
low-dose JJ N
bupivacaine NN i
infusion NN N
was VBD N
used VBN N
. . N

-DOCSTART- -X- O O

Oral JJ o
estrogen NN o
antagonizes VBZ o
the DT o
metabolic JJ o
actions NNS o
of IN o
growth NN o
hormone NN o
in IN o
growth NN o
hormone-deficient JJ o
women NNS o
. . o

We PRP N
have VBP N
determined VBN N
whether IN N
oral JJ i
estrogen NN i
reduces VBZ N
the DT N
biological JJ N
effects NNS N
of IN N
growth NN N
hormone NN N
( ( N
GH NNP N
) ) N
in IN N
GH-deficient NNP p
( ( p
GHD NNP p
) ) p
women NNS p
compared VBN N
with IN N
transdermal JJ i
estrogen NN i
treatment NN N
. . N

In IN p
two CD p
separate JJ p
studies NNS p
, , p
eight CD p
GHD NNP p
women NNS p
randomly RB N
received VBD N
either CC N
oral JJ i
or CC i
transdermal JJ i
estrogen NN i
for IN N
8 CD N
wk NN N
before IN N
crossing VBG N
over IN N
to TO N
the DT N
alternate JJ N
route NN N
of IN N
administration NN N
. . N

The DT N
first JJ N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
incremental JJ N
doses NNS N
of IN N
GH NNP N
( ( N
0.5 CD N
, , N
1.0 CD N
, , N
2.0 CD N
IU/day NNP N
for IN N
1 CD N
wk NNS N
each DT N
) ) N
on IN N
insulin-like JJ N
growth NN N
factor NN N
I PRP N
( ( N
IGF-I NNP N
) ) N
levels NNS N
during IN N
each DT N
estrogen NN i
treatment NN i
phase NN N
. . N

The DT N
second JJ N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
GH NNP N
( ( N
2 CD N
IU/day NNP N
) ) N
on IN N
lipid JJ N
oxidation NN N
and CC N
on IN N
protein NN N
metabolism NN N
using VBG N
the DT N
whole JJ N
body NN N
leucine JJ N
turnover NN N
technique NN N
. . N

Mean JJ o
IGF-I JJ o
level NN o
was VBD o
significantly RB o
lower JJR o
during IN o
oral JJ o
estrogen NN o
treatment NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
rose VBD o
dose NNS o
dependently RB o
during IN o
GH NNP o
administration NN o
by IN N
a DT N
lesser JJR N
magnitude NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
compared VBN N
with IN N
transdermal JJ i
treatment NN i
. . i

Postprandial NNP o
lipid JJ o
oxidation NN o
was VBD o
significantly RB o
lower JJR o
with IN o
oral JJ o
estrogen NN o
treatment NN N
, , N
both DT N
before IN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
during IN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
GH NNP N
administration NN N
, , N
compared VBN N
with IN N
transdermal JJ N
treatment NN N
. . N

Protein NNP o
synthesis NN o
was VBD N
lower JJR N
during IN N
oral JJ N
estrogen NN i
both DT N
before IN N
and CC N
during IN N
GH NNP i
administration NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Oral JJ i
estrogen NN i
antagonizes VBZ o
several JJ o
of IN o
the DT o
metabolic JJ o
actions NNS o
of IN o
GH NNP o
. . o

It PRP N
may MD N
aggravate VB o
body NN o
composition NN o
abnormalities NNS o
already RB N
present JJ N
in IN N
GHD NNP p
women NNS p
and CC N
attenuate VB o
the DT o
beneficial JJ o
effects NNS o
of IN o
GH NNP o
therapy NN o
. . o

Estrogen NNP i
replacement NN i
in IN N
GHD NNP p
women NNS p
should MD o
be VB o
administered VBN o
by IN o
a DT o
nonoral JJ o
route NN o
. . o

-DOCSTART- -X- O O

Differential JJ N
effect NN N
of IN N
aspirin NN i
on IN N
thromboxane NN o
and CC o
prostaglandin JJ o
biosynthesis NN o
in IN p
man NN p
. . p

1 CD N
. . N

Effects NNS N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
aspirin NN i
( ( N
600 CD N
mg NN N
) ) N
on IN N
bradykinin-stimulated JJ o
prostaglandin NN o
( ( o
PG NNP o
) ) o
and CC o
on IN o
thromboxane NN o
( ( o
TX NNP o
) ) o
biosynthesis NN o
were VBD N
determined VBN N
in IN N
nine CD p
healthy JJ p
male NN p
volunteers NNS p
. . p

Plasma NNP N
concentrations NNS N
of IN N
6-oxo-PGF1 JJ N
alpha NN N
and CC N
13,14-dihydro-15-oxo-PGF2 JJ N
alpha NN N
were VBD N
measured VBN N
in IN N
samples NNS N
obtained VBN N
during IN N
repeated JJ N
10 CD N
min NN N
intravenous JJ N
infusions NNS N
of IN N
bradykinin NN N
before IN N
and CC N
up RB N
to TO N
6 CD N
h NN N
after IN N
the DT N
dose NN N
of IN N
aspirin NN i
. . i

TXB2 NNP o
was VBD o
measured VBN o
in IN o
serum NN o
from IN N
blood NN N
allowed VBN N
to TO N
clot VB N
at IN N
37 CD N
degrees NNS N
C. NNP N
2 CD N
. . N

Aspirin NNP o
inhibited VBD o
bradykinin NN o
stimulated VBN o
PG NNP o
and CC N
platelet VB N
TX NNP N
biosynthesis NN N
0.5 CD N
h NN N
after IN N
the DT N
dose NN N
. . N

Serum NNP o
TXB2 NNP o
remained VBD o
low JJ o
, , N
whereas JJ N
PG NNP o
synthesis NN o
recovered VBD o
within IN N
6 CD N
h. JJ N
3 CD N
. . N

Effects NNS N
of IN N
intravenous JJ i
sodium NN i
salicylate NN i
( ( N
600 CD N
mg NN N
) ) N
were VBD N
studied VBN N
identically RB N
in IN N
eight CD N
subjects NNS N
. . N

Prostanoid NNP o
biosynthesis NN o
was VBD N
not RB N
inhibited VBN N
. . N

4 CD N
. . N

Biosynthesis NN o
of IN o
prostacyclin NN o
and CC o
TXA2 NNP o
under IN N
basal NN N
conditions NNS N
was VBD N
studied VBN N
in IN N
eight CD N
subjects NNS N
by IN N
measuring VBG o
2,3-dinor-6-oxo-PGF1 JJ o
alpha NN o
and CC o
2,3-dinor-TXB2 JJ o
in IN N
hourly JJ N
urine JJ N
samples NNS N
obtained VBN N
during IN N
and CC N
after IN N
intravenous JJ N
infusion NN i
of IN i
aspirin NN i
and CC N
, , N
on IN N
a DT N
separate JJ N
occasion NN N
, , N
of IN N
vehicle NN N
. . N

5 CD N
. . N

Aspirin NNP i
infusion NN i
reduced VBD o
urinary JJ o
excretion NN o
of IN N
both DT N
metabolites NNS N
greater JJR N
than IN N
90 CD N
% NN N
, , N
but CC N
excretion NN N
of IN N
2,3-dinor-6-oxo-PGF1 JJ o
alpha NN o
recovered VBD o
more RBR o
rapidly RB o
than IN N
did VBD N
that IN N
of IN N
2,3-dinor-TXB2 JJ N
. . N

6 CD N
. . N

We PRP N
conclude VBP N
that DT N
cyclo-oxygenase NN N
is VBZ N
rapidly RB o
synthesised VBN o
in IN o
bradykinin-responsive JJ o
tissues NNS o
in IN N
vivo NN N
and CC N
that IN N
this DT N
reflects VBZ N
similarly RB N
rapid JJ N
enzyme JJ N
biosynthesis NN N
in IN N
tissues NNS N
that WDT N
produce VBP N
PGI2 NNP N
under IN N
basal NN N
conditions NNS N
. . N

-DOCSTART- -X- O O

Safety NN o
and CC N
efficacy NN o
of IN N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
Logiparin NNP N
) ) N
versus NN N
dextran NN N
as IN N
prophylaxis NN N
against IN N
thrombosis NN o
after IN N
total JJ p
hip NN p
replacement NN p
. . p

In IN N
order NN N
to TO N
study VB N
the DT N
plasma NN N
levels NNS N
of IN N
factor NN N
XaI NNP N
and CC N
IIaI NNP N
activity NN N
an DT N
enzymatically RB i
depolymerized VBN i
low JJ i
molecular JJ i
weight NN i
heparin NN i
( ( i
LMW-heparin NNP i
; : i
Logiparin NNP i
) ) i
was VBD N
given VBN N
s.c. NN N
in IN N
a DT N
dose NN N
of IN N
35 CD N
XaI NNP N
mu/kg NN N
b.w NN N
. . N

once RB N
daily JJ N
for IN N
7 CD N
days NNS N
to TO N
10 CD p
patients NNS p
undergoing JJ p
total JJ p
hip NN p
replacement NN p
( ( p
THR NNP p
) ) p
in IN N
a DT N
pilot NN N
study NN N
. . N

The DT N
XaI NN N
activity NN N
was VBD N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.24 CD N
XaI NNP N
units/ml NN N
and CC N
the DT N
IIaI NNP N
activity NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.043 CD N
IIaI NNP N
mu/ml NN N
. . N

No DT N
accumulation NN N
of IN N
the DT N
activities NNS N
were VBD N
seen VBN N
. . N

No DT N
phlebographically RB o
verified VBN o
thrombi NN o
or CC N
any DT N
bleeding JJ o
complications NNS o
were VBD N
registered VBN N
. . N

From IN N
this DT N
study NN N
it PRP N
was VBD N
concluded VBN N
that IN N
the DT N
given VBN N
dose NN N
of IN N
Logiparin NNP N
was VBD N
safe JJ N
with IN N
regard NN N
to TO N
bleeding VBG N
complications NNS N
. . N

Based VBN N
on IN N
these DT N
data NNS N
, , N
an DT N
open JJ N
, , N
randomized VBD N
controlled VBN N
trial NN N
was VBD N
started VBN N
. . N

In IN N
this DT N
main JJ N
study NN N
the DT N
thromboprophylactic JJ o
effect NN o
of IN N
the DT N
LMW-heparin NNP N
( ( N
Logiparin NNP N
) ) N
in IN N
a DT N
dose NN N
of IN N
35 CD N
XaI NNP N
mu/kg NN N
b.w NN N
. . N

once RB N
daily JJ N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
dextran NN N
70 CD N
in IN N
patients NNS p
undergoing JJ p
THR NNP p
. . p

100 CD p
patients NNS p
were VBD p
randomized VBN p
. . p

The DT N
over-all JJ o
thrombosis NN o
rate NN o
was VBD N
28 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
LMW-heparin NNP N
and CC N
39 CD N
% NN N
in IN N
those DT N
given VBN N
dextran NN N
, , N
a DT N
non-significant JJ N
difference NN N
. . N

No UH N
bleeding VBG o
complications NNS o
, , o
deaths NNS o
or CC o
pulmonary JJ o
embolism NN o
were VBD N
recorded VBN N
in IN N
either DT N
group NN N
. . N

Peroperative JJ o
blood NN o
loss NN o
and CC o
transfusion NN o
requirements NNS o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
the DT N
investigated JJ N
LMW-heparin NNP N
( ( N
Logiparin NNP N
) ) N
is VBZ N
safe JJ N
and CC N
effective JJ N
in IN N
preventing VBG N
postoperative JJ N
thromboembolism NN N
in IN N
patients NNS p
undergoing JJ p
total JJ p
hip NN p
replacement NN p
, , N
but CC N
the DT N
dosage NN N
can MD N
probably RB N
be VB N
optimized VBN N
. . N

-DOCSTART- -X- O O

B-type JJ i
natriuretic JJ i
peptide NN i
for IN N
acute JJ N
dyspnea NN N
in IN N
patients NNS p
with IN p
kidney JJ p
disease NN p
: : p
insights NNS N
from IN N
a DT N
randomized JJ N
comparison NN N
. . N

BACKGROUND NNP N
B-type NNP o
natriuretic JJ o
peptide NN o
( ( o
BNP NNP o
) ) o
levels NNS o
are VBP N
reliably RB N
elevated VBN N
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
and CC N
therefore RB N
helpful JJ N
in IN N
its PRP$ N
diagnosis NN N
. . N

However RB N
, , N
kidney FW N
disease NN N
results NNS N
in IN N
elevated JJ N
BNP NNP N
levels NNS N
independently RB N
of IN N
CHF NNP N
. . N

Accordingly RB N
, , N
the DT N
impact NN N
of IN N
kidney NN N
disease NN N
on IN N
the DT N
benefit NN N
of IN N
BNP NNP i
testing VBG N
needs NNS N
to TO N
be VB N
scrutinized VBN N
. . N

METHODS NNP N
This DT N
study NN N
evaluated VBD N
patients NNS p
with IN p
and CC p
without IN p
kidney NN p
disease NN p
[ NNP p
glomerular JJ p
filtration NN p
rate NN p
( ( p
GFR NNP p
) ) p
less JJR p
than IN p
60 CD p
mL/min/1.73 JJ p
m NN p
( ( p
2 CD p
) ) p
) ) p
presenting VBG p
with IN p
acute JJ p
dyspnea NN p
. . p

A DT N
total NN N
of IN N
452 CD p
consecutive JJ p
patients NNS p
( ( p
240 CD p
with IN p
kidney NN p
disease NN p
and CC p
212 CD p
without IN p
kidney NN p
disease NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
diagnostic JJ i
strategy NN i
with IN i
( ( i
BNP NNP i
group NN i
) ) i
or CC i
without IN i
( ( i
control NN i
group NN i
) ) i
the DT i
use NN i
of IN i
BNP NNP i
levels NNS i
provided VBN i
by IN i
a DT i
rapid JJ i
bedside NN i
assay NN i
. . i

RESULTS JJ N
Patients NNS p
with IN p
kidney JJ p
disease NN p
were VBD p
older JJR p
, , p
more RBR p
often RB p
had VBD p
CHF NNP o
as IN o
the DT o
cause NN o
of IN o
acute JJ o
dyspnea NN o
, , p
and CC p
more RBR p
often RB p
died JJ p
in-hospital JJ p
or CC p
within IN p
30 CD p
days NNS p
as RB p
compared VBN p
to TO p
patients NNS p
without IN p
kidney NN p
disease NN p
. . N

In IN N
patients NNS N
without IN N
kidney NN N
disease NN N
, , N
BNP NNP i
testing VBG i
significantly RB N
reduced VBN N
median JJ o
time NN o
to TO o
discharge VB o
( ( N
from IN N
9.5 CD N
days NNS N
to TO N
2.5 CD N
days NNS N
) ) N
( ( N
P= NNP N
0.003 CD N
) ) N
and CC N
total JJ o
cost NN o
of IN o
treatment NN o
( ( N
from IN N
7184 CD N
dollars NNS N
to TO N
4151 CD N
dollars NNS N
) ) N
( ( N
P= NNP N
0.004 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
in IN N
patients NNS N
with IN N
kidney NN N
disease NN N
, , N
time NN N
to TO N
discharge VB N
and CC N
total JJ N
cost NN N
of IN N
treatment NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
When WRB N
applying VBG N
BNP NNP i
cut-off NN N
values NNS N
without IN N
adjustment NN N
for IN N
the DT N
presence NN N
of IN N
kidney NN N
disease NN N
, , N
the DT N
use NN N
of IN N
BNP NNP o
levels NNS o
does VBZ N
significantly RB N
improve VB N
the DT N
management NN N
of IN N
patients NNS N
without IN N
kidney NN N
disease NN N
, , N
but CC N
not RB N
of IN N
those DT N
with IN N
kidney JJ N
disease NN N
. . N

-DOCSTART- -X- O O

Double-blind NNP N
comparison NN N
of IN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
trandolapril JJ i
2 CD N
mg NN N
and CC N
hydrochlorothiazide VB i
25 CD N
mg NNS N
in IN N
patients NNS p
with IN p
mild-to-moderate JJ p
essential JJ p
hypertension NN p
. . p

Investigator NNP N
Study NNP N
Group NNP N
. . N

This DT N
multicenter NN N
international JJ N
trial NN N
recruited VBD N
205 CD p
patients NNS p
from IN p
16 CD p
investigators NNS p
. . p

After IN N
a DT N
4-week JJ N
, , N
single-blind JJ i
placebo NN i
run-in NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
16 CD N
weeks NNS N
of IN N
trandolapril JJ i
2 CD N
mg/day NN N
( ( N
68 CD N
patients NNS N
) ) N
, , N
hydrochlorothiazide RB i
( ( i
HCTZ NNP i
) ) i
25 CD N
mg/day NN N
( ( N
68 CD N
patients NNS N
) ) N
, , N
or CC i
the DT i
combination NN i
( ( N
69 CD N
patients NNS N
) ) N
. . N

Morning VBG o
predosing VBG o
supine NN o
diastolic JJ o
blood NN o
pressure NN o
( ( o
DBP NNP o
) ) o
was VBD N
the DT N
primary JJ N
efficacy NN N
measurement NN N
. . N

Intention-to-treat JJ N
analysis NN N
showed VBD N
significant JJ N
decreases NNS N
in IN N
all DT N
three CD N
groups NNS N
in IN N
mean JJ N
( ( N
+/- JJ N
SEM NNP N
) ) N
supine NN o
DBP NNP o
throughout IN N
the DT N
study NN N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
at IN N
week NN N
16 CD N
between IN N
trandolapril NN N
( ( N
-10.6 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
and CC N
HCTZ NNP N
( ( N
-10.9 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
. . N

The DT N
combination NN N
gave VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
than IN N
either DT N
drug NN N
alone RB N
( ( N
-15.1 JJ N
+/- JJ N
1.13 CD N
mm NN N
Hg NNP N
) ) N
. . N

Blood NNP o
pressure NN o
was VBD N
normalized VBN N
in IN N
the DT N
combination NN N
group NN N
in IN N
67 CD N
% NN N
of IN N
patients NNS N
, , N
a DT N
significantly RB N
higher JJR N
proportion NN N
than IN N
either DT N
trandolapril NN N
( ( N
63 CD N
% NN N
) ) N
or CC N
HCTZ NNP N
( ( N
60 CD N
% NN N
; : N
p CC N
= VB N
0.04 CD N
) ) N
. . N

Each DT N
treatment NN N
was VBD N
well RB N
tolerated VBN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ o
events NNS o
was VBD N
similar JJ N
in IN N
all DT N
three CD N
groups NNS N
. . N

Trandolapril NNP N
2 CD N
mg NN N
once RB N
daily JJ N
is VBZ N
an DT N
effective JJ N
antihypertensive JJ N
agent NN N
, , N
comparable JJ N
to TO N
HCTZ NNP N
. . N

Furthermore NNP N
, , N
the DT N
combination NN N
of IN N
the DT N
two CD N
drugs NNS N
was VBD N
shown VBN N
to TO N
enhance VB N
the DT N
antihypertensive JJ o
effect NN o
of IN N
the DT N
two CD N
compounds NNS N
alone RB N
. . N

-DOCSTART- -X- O O

Anemia NNP N
and CC N
associated VBN N
clinical JJ N
outcomes NNS N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
due JJ p
to TO p
reduced VB p
left JJ p
ventricular JJ p
systolic JJ p
function NN p
. . p

BACKGROUND NNP N
Anemia NNP N
is VBZ N
associated VBN N
with IN N
decreased JJ N
functional JJ N
capacity NN N
, , N
reduced VBD N
quality NN N
of IN N
life NN N
, , N
and CC N
worsened VBD N
outcomes NNS N
among IN N
patients NNS p
with IN p
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
due JJ p
to TO p
reduced VB p
left JJ p
ventricular JJ p
ejection NN p
fraction NN p
( ( p
HFREF NNP p
) ) p
. . p

We PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
independent JJ N
effect NN N
of IN N
anemia NN N
on IN N
clinical JJ N
outcomes NNS N
among IN N
those DT p
with IN p
HFREF NNP p
. . p

HYPOTHESIS NNP N
Anemia NNP N
is VBZ N
associated VBN N
with IN N
cardiovascular JJ N
events NNS N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
. . p

METHODS PDT N
The DT N
HF-ACTION NNP N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
exercise NN i
therapy NN i
vs NN i
usual JJ i
care NN i
in IN N
2331 CD p
patients NNS p
with IN p
HFREF NNP p
. . p

Patients NNS p
with IN p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
II NNP p
to TO p
IV NNP p
HF NNP p
and CC p
left VBD p
ventricular JJ p
ejection NN p
fractions NNS p
of IN p
? . p
35 CD p
% NN p
were VBD p
recruited VBN o
. . o

Hemoglobin NNP o
( ( o
Hb NNP o
) ) o
was VBD o
measured VBN N
up RB N
to TO N
1 CD N
year NN N
prior RB N
to TO N
entry NN N
and CC N
was VBD N
stratified VBN N
by IN N
quintile NN o
. . o

Anemia NNP o
was VBD o
defined VBN N
as IN N
baseline NN p
Hb NNP p
< VBZ p
13 CD p
g/dL NN p
and CC p
< $ p
12 CD p
g/dL NN p
in IN p
men NNS p
and CC p
women NNS p
, , p
respectively RB o
. . o

Hemoglobin NNP o
was VBD o
assessed VBN N
in IN N
2 CD N
models NNS N
: : N
a DT N
global JJ N
prediction NN N
model NN N
that WDT N
had VBD N
been VBN N
previously RB N
developed VBN N
, , N
and CC N
a DT N
modified JJ N
model NN N
including VBG N
variables NNS N
associated VBN N
with IN N
anemia NN N
and CC N
the DT N
studied JJ N
outcomes NNS N
. . N

RESULTS NNP o
Hemoglobin NNP o
was VBD o
available JJ N
at IN N
baseline NN N
in IN N
1763 CD p
subjects NNS p
( ( p
76 CD p
% NN p
of IN p
total JJ p
study NN p
population NN p
) ) p
; : p
their PRP$ p
median JJ p
age NN p
was VBD p
59.0 CD p
years NNS p
, , p
73 CD p
% NN p
were VBD p
male JJ p
, , p
and CC p
62 CD p
% NN p
were VBD p
Caucasian JJ p
. . p

The DT N
prevalence NN N
of IN N
anemia NN N
was VBD N
515/1763 CD N
( ( N
29 CD N
% NN N
) ) N
. . N

Older JJR N
age NN N
, , N
female JJ N
sex NN N
, , N
African JJ N
American NNP N
race NN N
, , N
diabetes VBZ N
, , N
hypertension NN N
, , N
and CC N
lower JJR N
estimated VBN N
glomerular JJ N
filtration NN N
rates NNS N
were VBD N
all DT N
more RBR N
frequent JJ N
in IN N
lower JJR N
Hb NNP N
quintiles NNS N
. . N

Over IN N
a DT N
median JJ N
follow-up NN N
of IN N
30 CD N
months NNS N
, , N
the DT N
primary JJ N
outcome NN N
of IN N
all-cause JJ o
mortality NN o
or CC o
all-cause JJ o
hospitalization NN o
occurred VBD o
in IN N
78 CD N
% NN N
of IN N
those DT N
with IN N
anemia NN N
and CC N
64 CD N
% NN N
in IN N
those DT N
without IN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
secondary JJ N
outcomes NNS N
of IN N
all-cause JJ o
mortality NN o
alone RB o
, , o
cardiovascular JJ o
( ( o
CV NNP o
) ) o
mortality NN o
or CC o
CV NNP o
hospitalization NN o
, , o
and CC o
CV NNP o
mortality NN o
or CC o
HF NNP o
hospitalization NN o
occurred VBD o
in IN N
23 CD N
% NN N
vs JJ N
15 CD N
% NN N
, , N
67 CD N
% NN N
vs JJ N
54 CD N
% NN N
, , N
and CC N
44 CD N
vs NNS N
29 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD o
) ) o
. . o

Heart NNP o
failure NN o
hospitalizations NNS o
occurred VBD o
in IN N
36 CD N
% NN N
vs JJ N
22 CD N
% NN N
, , N
and CC o
urgent JJ o
outpatient NN o
visits NNS o
for IN o
HF NNP o
exacerbations NNS o
occurred VBD o
in IN N
67 CD N
% NN N
and CC N
55 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
the DT N
global JJ N
model NN N
, , N
there EX N
was VBD N
an DT N
association NN N
observed VBD N
for IN N
anemia NN N
and CC o
all-cause JJ o
mortality NN o
or CC o
hospitalization NN o
( ( o
adjusted VBN N
hazard RB N
ratio JJ N
[ NNP N
HR NNP N
] NN N
: : N
1.15 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
1.01-1.32 JJ N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
but CC N
other JJ N
outcomes NNS N
were VBD N
not RB N
significant JJ N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

In IN N
the DT N
modified JJ N
model NN N
, , N
the DT N
adjusted JJ o
HR NNP o
for IN o
anemia NN N
and CC N
the DT N
primary JJ N
outcome NN N
of IN N
all-cause JJ N
mortality NN N
or CC N
all-cause JJ N
hospitalization NN N
was VBD N
1.25 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
1.10-1.42 JJ N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
independent JJ N
associations NNS N
between IN o
anemia NN o
and CC o
all-cause JJ o
death NN o
( ( o
HR NNP N
: : N
1.11 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.87-1.42 JJ N
, , N
P NNP N
= NNP N
0.38 CD o
) ) o
, , o
CV NNP o
death NN o
or CC o
CV NNP o
hospitalization NN o
( ( o
HR NNP N
: : N
1.16 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01-1.33 JJ N
, , N
P NNP N
= NNP N
0.035 CD N
) ) N
, , N
and CC N
CV NNP N
death NN N
and CC o
HF NNP o
hospitalization NN o
( ( o
HR NNP N
: : N
1.27 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.06-1.51 JJ N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

CONCLUSIONS NNP N
Anemia NNP N
modestly RB N
is VBZ N
associated VBN N
with IN N
increased JJ N
rates NNS N
of IN N
death NN N
, , N
hospitalization NN N
, , N
and CC N
HF NNP N
exacerbation NN N
in IN N
patients NNS p
with IN p
chronic JJ p
HFREF NNP p
. . p

After IN N
adjusting VBG N
for IN N
other JJ N
important JJ N
covariates NNS N
, , N
anemia NN N
is VBZ N
independently RB N
associated VBN N
with IN N
an DT N
excess JJ N
hazard NN N
for IN N
all-cause JJ N
mortality NN N
and CC N
all-cause JJ N
hospitalization NN N
. . N

Anemia NNP N
is VBZ N
also RB N
associated VBN N
with IN N
combinations NNS N
of IN N
CV NNP N
death NN N
and CC N
CV/HF NNP N
hospitalizations NNS N
as IN N
composite JJ N
endpoints NNS N
. . N

-DOCSTART- -X- O O

Thiabendazole NN i
for IN N
the DT N
prophylaxis NN N
of IN N
strongyloidiasis NN N
in IN N
immunosuppressed JJ p
patients NNS p
with IN p
hematological JJ p
diseases NNS p
: : p
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ i
study NN N
. . N

-DOCSTART- -X- O O

Future NNP N
therapeutic JJ N
directions NNS N
for IN N
factor NN N
Xa NNP N
inhibition NN N
in IN N
the DT N
prophylaxis NN N
and CC N
treatment NN N
of IN N
thrombotic JJ p
disorders NNS p
. . p

The DT N
targeted JJ N
mechanism NN N
of IN N
factor NN N
Xa NNP N
inhibition NN N
has VBZ N
been VBN N
studied VBN N
extensively RB N
, , N
initially RB N
as IN N
prophylaxis NN N
for IN N
venous JJ p
thromboembolism NN p
( ( p
VTE NNP p
) ) p
in IN p
the DT p
orthopedic JJ p
surgical JJ p
setting NN p
. . p

Future NNP N
therapeutic JJ N
directions NNS N
for IN N
selective JJ N
factor NN N
Xa NNP N
inhibition NN N
in IN N
the DT N
management NN N
of IN N
other JJ N
thrombotic JJ N
diseases NNS N
are VBP N
discussed VBN N
. . N

Thromboembolic JJ N
diseases NNS N
can MD N
occur VB N
in IN N
the DT N
venous JJ N
or CC N
arterial JJ N
sides NNS N
of IN N
the DT N
circulatory NN N
system NN N
. . N

Factor NNP N
Xa NNP N
inhibition NN N
is VBZ N
a DT N
targeted JJ N
approach NN N
to TO N
anticoagulation VB N
that IN N
resulted VBD N
from IN N
significant JJ N
advances NNS N
in IN N
our PRP$ N
understanding NN N
of IN N
the DT N
coagulation NN N
cascade NN N
. . N

The DT N
factor NN i
Xa NNP i
inhibitor NN i
fondaparinux NN i
has VBZ N
been VBN N
studied VBN N
extensively RB N
in IN N
the DT N
orthopedic JJ N
surgical JJ N
setting NN N
for IN N
the DT N
prophylaxis NN N
of IN N
VTE NNP N
. . N

Current NNP N
investigations NNS N
that WDT N
are VBP N
under IN N
way NN N
or CC N
completed VBN N
evaluate VBP N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
fondaparinux NN N
for IN N
the DT N
management NN N
of IN N
various JJ N
thrombotic JJ N
diseases NNS N
. . N

The DT N
future NN N
development NN N
of IN N
fondaparinux NN N
resides NNS N
primarily RB N
in IN N
three CD N
therapeutic JJ N
areas NNS N
: : N
prevention NN N
of IN N
VTE NNP N
, , N
treatment NN N
of IN N
VTE NNP N
, , N
and CC N
treatment NN N
of IN N
acute JJ o
coronary JJ o
syndromes NNS o
. . o

For IN N
the DT N
prevention NN N
of IN N
VTE NNP N
, , N
fondaparinux NN i
has VBZ N
been VBN N
studied VBN N
as IN N
extended JJ N
prophylaxis NN N
following VBG N
hip NN N
fracture NN N
surgery NN N
( ( N
PENTHIFRA NNP N
Plus NNP N
) ) N
, , N
for IN N
use NN N
in IN N
high-risk JJ N
abdominal JJ N
surgical JJ N
patients NNS N
( ( N
PEGASUS NNP N
and CC N
APOLLO NNP N
) ) N
, , N
and CC N
for IN N
use NN N
in IN N
medical JJ N
patients NNS N
( ( N
ARTEMIS NNP N
) ) N
. . N

Studies NNPS N
evaluating VBG N
fondaparinux NN i
for IN N
the DT N
treatment NN N
of IN N
VTE NNP N
are VBP N
part NN N
of IN N
the DT N
large JJ N
MATISSE NNP N
clinical JJ N
program NN N
( ( N
MATISSE NNP N
DVT NNP N
and CC N
MATISSE NNP N
PE NNP N
) ) N
. . N

Fondaparinux NNP i
was VBD N
investigated VBN N
in IN N
phase NN N
2 CD N
studies NNS N
for IN N
the DT N
treatment NN N
of IN N
acute JJ p
coronary JJ p
syndromes NNS p
, , N
including VBG N
acute JJ o
ST-segment JJ o
myocardial JJ o
infarction NN o
( ( o
PENTALYSE NNP o
) ) o
and CC o
unstable JJ o
angina NN o
( ( o
PENTUA NNP o
) ) o
. . o

Encouraging VBG N
data NNS N
from IN N
these DT N
trials NNS N
are VBP N
the DT N
basis NN N
for IN N
phase NN N
3 CD N
programs NNS N
in IN N
this DT N
area NN N
( ( N
MICHELANGELO NNP N
) ) N
. . N

The DT N
orthopedic JJ N
prophylactic JJ N
and CC N
nonorthopedic JJ N
clinical JJ N
programs NNS N
for IN N
fondaparinux NN N
in IN N
the DT N
management NN N
of IN N
thrombosis NN N
support NN N
the DT N
concept NN N
that WDT N
targeted VBD o
inhibition NN o
of IN o
coagulation NN o
is VBZ N
an DT N
effective JJ o
advance NN o
in IN o
antithrombotic JJ o
therapy NN o
. . o

-DOCSTART- -X- O O

[ VB N
A NNP N
randomized JJ N
study NN N
of IN N
prophylactic JJ N
intravesical JJ N
instillation NN N
of IN N
pirarubicin NN i
( ( i
THP NNP i
) ) i
prior RB N
to TO N
transurethral JJ p
resection NN p
of IN p
superficial JJ o
bladder NN o
cancer NN o
] NNP o
. . N

A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
prophylactic JJ p
intravesical JJ i
instillation NN i
of IN i
pirarubicin NN i
( ( i
THP NNP i
) ) i
prior RB p
to TO p
transurethral JJ o
resection NN o
( ( o
TUR NNP o
) ) o
of IN o
superficial JJ o
bladder NN o
cancer NN o
. . o

A DT N
total NN N
of IN N
63 CD p
patients NNS p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
THP NNP i
group NN N
and CC N
the DT N
control NN N
group NN N
. . N

In IN N
the DT N
THP NNP N
group NN N
, , N
30 CD N
mg NN N
of IN N
THP NNP N
dissolved VBD N
in IN N
50 CD i
ml NNS i
saline NN i
was VBD N
administered VBN N
4 CD N
times NNS N
intravesically RB N
for IN N
4 CD N
consecutive JJ N
days NNS N
before IN N
TUR NNP N
. . N

In IN N
the DT N
control NN N
group NN N
, , N
no DT i
instillation NN i
was VBD i
performed VBN i
before IN i
TUR NNP i
. . i

The DT N
patients NNS N
were VBD N
followed VBN N
by IN N
cystoscopy NN N
and CC N
urinary JJ N
cytology NN N
every DT N
3 CD N
months NNS N
. . N

The DT N
non-recurrence JJ o
rates NNS o
in IN N
the DT N
THP NNP N
group NN N
and CC N
control NN N
group NN N
were VBD N
54.1 CD N
% NN N
versus IN N
37.6 CD N
% NN N
at IN N
1 CD N
year NN N
and CC N
40.4 CD N
% NN N
versus IN N
26.8 CD N
% NN N
at IN N
2 CD N
years NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.086 CD N
) ) N
. . N

Time NN o
to TO o
recurrence VB o
for IN o
tumors NNS o
larger JJR o
than IN o
1 CD o
cm NN o
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
THP NNP N
group NN N
( ( N
P NNP N
= NNP N
0.0137 CD N
) ) N
. . N

Time NN o
to TO o
recurrence VB o
for IN o
single JJ o
and CC o
grade VBD o
1+2 CD o
tumors NNS o
tended VBD N
to TO N
be VB N
longer RBR N
in IN N
the DT N
THP NNP N
group NN N
( ( N
P NNP N
= NNP N
0.09 CD N
, , N
P NNP N
= NNP N
0.079 CD N
) ) N
. . N

No DT N
significant JJ N
adverse JJ o
effects NNS o
were VBD N
observed VBN N
in IN N
any DT N
patient NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
intravesical JJ N
THP NNP N
instillation NN N
prior RB N
to TO N
TUR NNP N
would MD N
be VB N
effective JJ o
for IN N
patients NNS N
with IN N
single JJ o
, , o
low JJ o
grade NN o
lesions NNS o
larger JJR o
than IN o
1 CD o
cm NN o
of IN N
superficial JJ o
bladder NN o
cancer NN o
. . o

-DOCSTART- -X- O O

Using VBG N
dietetic JJ i
assistants NNS i
to TO N
improve VB N
the DT N
outcome NN N
of IN N
hip JJ p
fracture NN p
: : p
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
nutritional JJ N
support NN N
in IN N
an DT N
acute NN p
trauma NN p
ward NN p
. . p

OBJECTIVE UH N
To TO N
examine VB N
how WRB N
improved JJ N
attention NN N
to TO N
nutritional JJ o
status NN o
and CC o
dietary JJ o
intake NN o
, , N
achieved VBN N
through IN N
the DT N
employment NN N
of IN N
dietetic JJ i
assistants NNS i
( ( i
DAs NNP i
) ) i
, , N
will MD N
affect VB N
postoperative JJ o
clinical JJ o
outcome NN o
among IN N
elderly JJ p
women NNS p
with IN p
hip JJ p
fracture NN p
. . p

DESIGN NNP N
Open NNP N
prospective NN N
randomised VBD N
controlled VBN N
trial NN N
, , N
comparing VBG N
conventional JJ i
nursing NN i
care NN i
with IN N
the DT N
additional JJ i
nutritional JJ i
support NN i
provided VBN i
by IN i
DA NNP i
. . i

SETTING NNP N
Thirty-eight NNP p
bedded VBD p
acute JJ p
trauma NN p
ward NN p
in IN p
a DT p
teaching JJ p
hospital NN p
. . p

PARTICIPANTS VB N
All DT p
but CC p
11 CD p
of IN p
344 CD p
consecutive JJ p
admissions NNS p
with IN p
acute JJ p
nonpathological JJ p
hip NN p
fracture NN p
were VBD p
approached VBN p
. . p

Three CD p
hundred VBD p
and CC p
eighteen JJ p
( ( p
93 CD p
% NN p
) ) p
agreed VBD p
to TO p
inclusion NN p
. . p

Sixteen NNP p
were VBD p
ineligible JJ p
as IN N
they PRP N
were VBD N
immediately RB N
transferred VBN N
to TO N
another DT N
acute NN N
ward NN N
, , N
were VBD N
managed VBN N
conservatively RB N
or CC N
died VBD N
preoperatively RB N
. . N

PRIMARY NNP N
OUTCOME NNP N
MEASURE NNP N
Postoperative NNP o
mortality NN o
in IN N
the DT N
acute JJ N
trauma NN N
unit NN N
. . N

SECONDARY NNP N
OUTCOME NNP N
MEASURES NNP N
Postoperative NNP o
mortality NN o
at IN o
4 CD o
months NNS o
after IN o
fracture NN o
, , o
length NN o
of IN o
stay NN o
, , o
energy NN o
intake NN o
and CC N
nutritional JJ o
status NN o
. . o

RESULTS NNP N
DA-supported JJ N
participants NNS N
were VBD N
less RBR N
likely JJ o
to TO o
die VB o
in IN N
the DT N
acute JJ N
ward NN N
( ( N
4.1 CD N
versus RB N
10.1 CD N
% NN N
, , N
P NNP N
= NNP N
0.048 CD N
) ) N
. . N

This DT N
effect NN N
was VBD N
still RB N
apparent JJ N
at IN N
4 CD N
month NN N
follow-up NN N
( ( N
13.1 CD N
versus RB N
22.9 CD N
% NN N
, , N
P NNP N
= NNP N
0.036 CD N
) ) N
. . N

DA-supported JJ N
subjects NNS N
had VBD N
significantly RB N
better RBR N
mean JJ o
daily JJ o
energy NN o
intake NN o
( ( N
1,105 CD N
kcal JJ N
versus NN N
756 CD N
kcal/24 NN N
h NN N
, , N
95 CD N
% NN N
CI NNP N
259-440 JJ N
kcal/24 NN N
h NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
significantly RB N
smaller JJR N
reduction NN N
in IN N
mid-arm JJ N
circumference NN N
during IN N
their PRP$ N
inpatient JJ N
stay NN N
( ( N
0.39 CD N
cm NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
and CC N
nonsignificantly RB N
favourable JJ N
results NNS N
for IN N
other JJ N
anthropometric JJ o
and CC o
laboratory JJ o
measurements NNS o
. . o

CONCLUSION NNP N
Dietetic NNP i
or CC i
nutrition NN i
assistants NNS i
are VBP N
being VBG N
introduced VBN N
in IN N
units NNS N
across IN p
the DT p
UK NNP p
. . p

This DT N
, , N
the DT N
largest JJS N
ever RB N
study NN N
of IN N
nutritional JJ N
support NN N
after IN N
hip NN N
fracture NN N
, , N
shows VBZ N
that IN N
their PRP$ N
employment NN N
significantly RB N
reduced VBD N
patients NNS o
' POS o
risk NN o
of IN o
dying VBG o
in IN N
the DT N
acute JJ N
trauma NN N
unit NN N
; : N
an DT N
effect NN N
that WDT N
persisted VBD N
at IN N
4 CD N
month NN N
follow-up NN N
. . N

-DOCSTART- -X- O O

A DT N
chinese JJ N
mind-body NN N
exercise NN N
improves VBZ N
self-control NN o
of IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Self-control JJ o
problems NNS N
commonly RB N
manifest VBP N
as IN N
temper NN N
outbursts NNS N
and CC N
repetitive/rigid/impulsive JJ N
behaviors NNS N
, , N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
, , N
which WDT N
often RB N
contributes VBZ N
to TO N
learning VBG N
difficulties NNS N
and CC N
caregiver NN N
burden NN N
. . N

The DT N
present JJ N
study NN N
aims NNS N
to TO N
compare VB N
the DT N
effect NN N
of IN N
a DT N
traditional JJ i
Chinese JJ i
Chan-based JJ i
mind-body NN i
exercise NN i
, , i
Nei NNP i
Yang NNP i
Gong NNP i
, , N
with IN N
that DT N
of IN N
the DT N
conventional JJ i
Progressive NNP i
Muscle NNP i
Relaxation NNP i
( ( i
PMR NNP i
) ) i
technique NN i
in IN N
enhancing VBG N
the DT N
self-control NN o
of IN N
children NNS p
with IN p
ASD NNP p
. . p

Forty-six NNP p
age- JJ p
and CC p
IQ-matched JJ p
ASD NNP p
children NNS p
were VBD N
randomly RB i
assigned VBN i
to TO i
receive VB i
group NN i
training NN i
in IN i
Nei NNP i
Yang NNP i
Gong NNP i
( ( i
experimental JJ i
group NN i
) ) i
or CC i
PMR NNP i
( ( i
control VB i
group NN i
) ) i
twice RB i
per IN i
week NN i
for IN i
four CD i
weeks NNS i
. . i

The DT N
participants NNS N
' POS N
self-control NN N
was VBD N
measured VBN i
by IN i
three CD i
neuropsychological JJ o
tests NNS o
and CC i
parental JJ o
rating NN o
on IN o
standardized JJ o
questionnaires NNS o
, , i
and CC i
the DT i
underlying JJ i
neural JJ i
mechanism NN i
was VBD i
assessed VBN i
by IN i
the DT i
participants NNS i
' POS i
brain NN i
EEG NNP i
activity NN i
during IN i
an DT i
inhibitory-control JJ i
task NN i
before IN i
and CC i
after IN i
intervention NN i
. . i

The DT N
results NNS N
show VBP N
that IN N
the DT N
experimental JJ N
group NN N
demonstrated VBD N
significantly RB N
greater JJR N
improvement NN o
in IN o
self-control NN o
than IN N
the DT N
control NN N
group NN N
, , N
which WDT N
concurs VBZ N
with IN N
the DT N
parental JJ N
reports NNS N
of IN N
reduced VBN N
autistic JJ o
symptoms NNS o
and CC N
increased VBD N
control NN o
of IN o
temper NN o
and CC o
behaviors NNS o
. . o

In IN N
addition NN N
, , N
the DT N
experimental JJ N
group NN N
showed VBD N
enhanced JJ o
EEG NNP o
activity NN o
in IN N
the DT N
anterior JJ N
cingulate NN N
cortex NN N
, , N
a DT N
region NN N
that WDT N
mediates VBZ N
self-control NN N
, , N
whereas IN N
the DT N
PMR NNP N
group NN N
did VBD N
not RB N
. . N

The DT N
present JJ N
findings NNS N
support VBP N
the DT N
potential JJ N
application NN N
of IN N
Chinese JJ N
Chan-based JJ i
mind-body NN i
exercises NNS i
as IN N
a DT N
form NN N
of IN N
neuropsychological JJ N
rehabilitation NN N
for IN N
patients NNS p
with IN p
self-control JJ o
problems NNS p
. . p

Chinese JJ N
Clinical JJ N
Trial NNP N
Registry NNP N
; : N
Registration NNP N
No NNP N
. . N

: : N
ChiCTR-TRC-12002561 JJ N
; : N
URL NNP N
: : N
www.chictr.org NN N
. . N

-DOCSTART- -X- O O

Relationship NN N
between IN N
baseline NN N
blood NN N
pressure NN N
parameters NNS N
( ( N
including VBG N
mean JJ N
pressure NN N
, , N
pulse JJ N
pressure NN N
, , N
and CC N
variability NN N
) ) N
and CC N
early JJ N
outcome NN N
after IN N
stroke NN p
: : p
data NN N
from IN N
the DT N
Tinzaparin NNP i
in IN i
Acute NNP i
Ischaemic NNP i
Stroke NNP i
Trial NNP i
( ( p
TAIST NNP p
) ) p
. . p

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
High NNP p
blood NN p
pressure NN p
( ( p
BP NNP p
) ) p
in IN p
acute JJ p
stroke NN p
is VBZ N
associated VBN N
independently RB N
with IN N
a DT N
poor JJ N
outcome NN N
. . N

Recent JJ N
evidence NN N
suggests VBZ N
that IN N
other JJ N
hemodynamic JJ N
parameters NNS N
may MD N
also RB N
be VB N
associated VBN N
with IN N
outcomes NNS N
following VBG N
stroke NN N
. . N

METHODS NNP N
The DT N
relationship NN N
between IN N
baseline NN N
BP NNP N
, , N
heart NN N
rate NN N
, , N
and CC N
other JJ N
hemodynamic JJ N
parameters NNS N
, , N
and CC N
early RB N
outcomes NNS N
were VBD N
assessed VBN N
using VBG p
data NNS p
from IN p
TAIST NNP p
trial NN p
. . p

RESULTS NNP N
Death NNP o
or CC o
neurological JJ o
deterioration NN o
at IN o
day NN o
10 CD o
was VBD N
associated VBN N
, , N
both DT N
in IN N
unadjusted JJ N
and CC N
adjusted JJ N
analyses NNS N
, , N
with IN N
systolic JJ o
BP NNP o
( ( N
adjusted VBN N
OR NNP N
, , N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.03 JJ N
) ) N
, , N
mean JJ o
arterial JJ o
pressure NN o
( ( N
OR NNP N
, , N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.04 JJ N
) ) N
, , N
pulse JJ o
pressure NN o
( ( N
OR NNP N
, , N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.03 JJ N
) ) N
, , N
and CC N
BP NNP o
variability NN o
( ( N
OR NNP N
, , N
1.03 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.05 JJ N
) ) N
. . N

Similar JJ N
relationships NNS N
were VBD N
noted VBN N
for IN N
deterioration NN o
alone RB o
, , o
and CC o
recurrent JJ o
stroke NN o
. . o

CONCLUSIONS NNP N
Early JJ N
death NN o
or CC N
neurologic JJ o
deterioration NN o
, , o
deterioration NN o
, , N
and CC N
recurrent JJ o
stroke NN o
are VBP N
associated VBN N
independently RB N
with IN N
high JJ o
systolic JJ o
BP NNP o
, , o
mean JJ o
arterial JJ o
pressure NN o
, , o
pulse JJ o
pressure NN o
, , o
and CC o
BP NNP o
variability NN o
. . o

These DT N
measures NNS N
offer VBP N
potential JJ N
therapeutic JJ i
targets NNS i
for IN N
improving VBG N
early JJ N
outcome NN N
after IN N
acute JJ p
ischemic JJ p
stroke NN p
. . p

-DOCSTART- -X- O O

Pazopanib NNP i
in IN N
locally RB p
advanced JJ p
or CC p
metastatic JJ p
renal NN p
cell NN p
carcinoma NN p
: : p
results NNS N
of IN N
a DT N
randomized JJ N
phase NN N
III NNP N
trial NN N
. . N

PURPOSE NNP N
Pazopanib NNP i
is VBZ N
an DT N
oral JJ i
angiogenesis NN i
inhibitor NN i
targeting VBG N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
receptor NN N
, , N
platelet-derived JJ N
growth NN N
factor NN N
receptor NN N
, , N
and CC N
c-Kit NN N
. . N

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
phase NN N
III NNP N
study NN N
evaluated VBD N
efficacy NN N
and CC N
safety NN N
of IN N
pazopanib JJ i
monotherapy NN i
in IN N
treatment-naive JJ p
and CC p
cytokine-pretreated JJ i
patients NNS p
with IN p
advanced JJ p
renal JJ p
cell NN p
carcinoma NN p
( ( p
RCC NNP p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Adult NNP p
patients NNS p
with IN p
measurable JJ p
, , p
locally RB p
advanced JJ p
, , p
and/or JJ p
metastatic JJ p
RCC NNP p
were VBD N
randomly RB N
assigned VBN N
2:1 CD N
to TO N
receive VB i
oral JJ i
pazopanib NN i
or CC i
placebo NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . o

Secondary JJ N
end NN N
points NNS N
included VBD N
overall JJ o
survival NN o
, , o
tumor NN o
response NN o
rate NN o
( ( o
Response NNP o
Evaluation NNP o
Criteria NNP o
in IN o
Solid NNP o
Tumors NNP o
) ) o
, , o
and CC o
safety NN o
. . o

Radiographic JJ N
assessments NNS N
of IN N
tumors NNS N
were VBD N
independently RB N
reviewed VBN N
. . N

Results NNS N
Of IN p
435 CD p
patients NNS p
enrolled VBD p
, , p
233 CD p
were VBD p
treatment NN p
naive JJ p
( ( p
54 CD p
% NN p
) ) p
and CC p
202 CD p
were VBD p
cytokine NN p
pretreated VBN p
( ( p
46 CD p
% NN p
) ) p
. . p

PFS NNP o
was VBD N
significantly RB N
prolonged VBN N
with IN N
pazopanib NNS i
compared VBN N
with IN N
placebo NN i
in IN N
the DT N
overall JJ N
study NN N
population NN N
( ( N
median JJ N
, , N
PFS NNP N
9.2 CD N
v NN N
4.2 CD N
months NNS N
; : N
hazard PRP$ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.46 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.34 CD N
to TO N
0.62 CD N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
the DT N
treatment-naive JJ i
subpopulation NN N
( ( N
median JJ N
PFS NNP N
11.1 CD N
v NN N
2.8 CD N
months NNS N
; : N
HR NNP N
, , N
0.40 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.27 CD N
to TO N
0.60 CD N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
and CC N
the DT N
cytokine-pretreated JJ N
subpopulation NN N
( ( N
median JJ N
PFS NNP N
, , N
7.4 CD N
v NN N
4.2 CD N
months NNS N
; : N
HR NNP N
, , N
0.54 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.35 CD N
to TO N
0.84 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
objective JJ o
response NN o
rate NN o
was VBD N
30 CD N
% NN N
with IN N
pazopanib NN i
compared VBN N
with IN N
3 CD N
% NN N
with IN N
placebo NN i
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
median JJ o
duration NN o
of IN o
response NN o
was VBD N
longer JJR N
than IN N
1 CD N
year NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD N
diarrhea RB o
, , o
hypertension NN o
, , o
hair NN o
color NN o
changes NNS o
, , o
nausea NN o
, , o
anorexia NN o
, , o
and CC o
vomiting VBG o
. . o

There EX N
was VBD N
no DT N
evidence NN N
of IN N
clinically RB N
important JJ N
differences NNS N
in IN N
quality NN N
of IN N
life NN N
for IN N
pazopanib JJ i
versus NN i
placebo NN i
. . i

CONCLUSION NNP N
Pazopanib NNP i
demonstrated VBD N
significant JJ N
improvement NN N
in IN N
PFS NNP N
and CC N
tumor NN N
response NN N
compared VBN N
with IN N
placebo NN i
in IN N
treatment-naive JJ p
and CC p
cytokine-pretreated JJ i
patients NNS p
with IN p
advanced JJ p
and/or NNS p
metastatic JJ p
RCC NNP p
. . p

-DOCSTART- -X- O O

Disorder-dissociated JJ N
effects NNS N
of IN N
fluoxetine NN i
on IN N
brain NN N
function NN N
of IN N
working VBG N
memory NN N
in IN N
attention NN p
deficit NN p
hyperactivity NN p
disorder NN p
and CC p
autism NN p
spectrum NN p
disorder NN p
. . p

BACKGROUND NNP N
Attention NNP N
deficit NN N
hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
and CC N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
are VBP N
often RB N
co-morbid JJ N
and CC N
share NN N
performance NN N
and CC N
brain NN N
dysfunctions NNS N
during IN N
working VBG N
memory NN N
( ( N
WM NNP N
) ) N
. . N

Serotonin JJ N
agonists NNS N
modulate VBP N
WM NNP N
and CC N
there EX N
is VBZ N
evidence NN N
of IN N
positive JJ N
behavioural JJ N
effects NNS N
in IN N
both DT N
disorders NNS N
. . N

We PRP N
therefore VBP N
used JJ N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
fMRI NN N
) ) N
to TO N
investigate VB N
shared VBN N
and CC N
disorder-specific JJ N
brain NN N
dysfunctions NNS N
of IN N
WM NNP N
in IN N
these DT N
disorders NNS N
, , N
and CC N
the DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
the DT N
selective JJ N
serotonin NN i
reuptake NN i
inhibitor NN i
( ( i
SSRI NNP i
) ) i
fluoxetine NN i
. . i

METHOD NNP N
Age-matched JJ p
boys NNS p
with IN p
ADHD NNP p
( ( p
n JJ p
= NNP p
17 CD p
) ) p
, , p
ASD NNP p
( ( p
n JJ p
= NNP p
17 CD p
) ) p
and CC p
controls NNS p
( ( p
n JJ p
= NNP p
22 CD p
) ) p
were VBD p
compared VBN N
using VBG N
fMRI NN i
during IN N
an DT N
N-back JJ N
WM NNP N
task NN N
. . N

Patients NNS N
were VBD N
scanned VBN N
twice RB N
, , N
under IN N
either DT N
an DT N
acute NN N
dose NN N
of IN i
fluoxetine NN i
or CC i
placebo NN i
in IN i
a DT i
double-blind JJ N
, , N
placebo-controlled JJ N
randomized JJ N
design NN N
. . N

Repeated-measures JJ N
analyses NNS N
within IN N
patients NNS N
assessed JJ N
drug NN N
effects NNS N
on IN N
performance NN N
and CC N
brain NN N
function NN N
. . N

To TO N
test VB N
for IN N
normalization NN N
effects NNS N
of IN N
brain NN N
dysfunctions NNS N
, , N
patients NNS N
under IN N
each DT N
drug NN N
condition NN N
were VBD N
compared VBN N
to TO N
controls NNS N
. . N

RESULTS NNP N
Under IN N
placebo NN i
, , i
relative JJ i
to TO N
controls NNS N
, , N
both DT N
ADHD NNP N
and CC N
ASD NNP N
boys NNS N
shared VBD N
underactivation NN o
in IN o
the DT o
right JJ o
dorsolateral JJ o
prefrontal JJ o
cortex NN o
( ( o
DLPFC NNP o
) ) o
. . o

Fluoxetine NNP o
significantly RB N
normalized VBD o
the DT o
DLPFC NNP o
underactivation NN o
in IN o
ASD NNP o
relative NN N
to TO N
controls NNS N
whereas IN N
it PRP N
increased VBD o
posterior JJ o
cingulate NN o
cortex NN o
( ( o
PCC NNP o
) ) o
deactivation NN o
in IN o
ADHD NNP o
relative JJ N
to TO N
control VB N
boys NNS N
. . N

Within-patient JJ N
analyses NNS N
showed VBD N
inverse JJ N
effects NNS N
of IN N
fluoxetine NN N
on IN N
PCC NNP N
deactivation NN N
, , N
which WDT N
it PRP N
enhanced VBD N
in IN N
ADHD NNP N
and CC N
decreased VBN N
in IN N
ASD NNP N
. . N

CONCLUSIONS NNP N
The DT N
findings NNS N
show VBP N
that IN N
fluoxetine NN N
modulates NNS N
brain NN N
activation NN N
during IN N
WM NNP N
in IN N
a DT N
disorder-specific JJ N
manner NN N
by IN N
normalizing VBG N
task-positive JJ N
DLPFC NNP N
dysfunction NN p
in IN p
ASD NNP p
boys NNS p
and CC N
enhancing VBG N
task-negative JJ N
default NN N
mode NN N
network NN N
( ( N
DMN NNP N
) ) N
deactivation NN N
in IN N
ADHD NNP N
. . N

-DOCSTART- -X- O O

Breaking VBG N
it PRP N
down RP N
is VBZ N
better RBR N
: : N
haptic JJ i
decomposition NN i
of IN i
complex JJ i
movements NNS i
aids NNS N
in IN N
robot-assisted JJ i
motor NN o
learning NN o
. . o

Training VBG i
with IN i
haptic JJ i
guidance NN i
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
technique NN N
for IN N
learning VBG N
complex JJ N
movements NNS N
in IN N
rehabilitation NN N
and CC N
sports NNS N
, , N
but CC N
it PRP N
is VBZ N
unclear JJ N
how WRB N
to TO N
best VB N
deliver RB N
guidance-based JJ N
training NN N
. . N

Here RB N
, , N
we PRP N
hypothesized VBD N
that IN N
breaking VBG N
down RP N
a DT N
complex JJ N
movement NN N
, , N
similar JJ N
to TO N
a DT N
tennis NN N
backhand NN N
, , N
into IN N
simpler NN N
parts NNS N
and CC N
then RB N
using VBG N
haptic JJ i
feedback NN i
from IN i
a DT i
robotic JJ i
exoskeleton NN i
would MD N
help VB N
the DT N
motor NN N
system NN N
learn VBP N
the DT N
movement NN N
. . N

We PRP N
also RB N
examined VBD N
how WRB N
the DT N
particular JJ N
form NN N
of IN N
the DT N
decomposition NN N
affected VBD N
learning NN o
. . o

Three CD p
groups NNS p
of IN p
unimpaired JJ p
participants NNS p
trained VBN p
with IN p
the DT p
target NN p
arm JJ p
movement NN p
broken VBD p
down RB p
in IN p
three CD p
ways NNS p
: : p
1 CD p
) ) p
elbow NN i
flexion/extension NN i
and CC i
the DT i
unified JJ i
shoulder NN i
motion NN i
independently RB i
( ( i
anatomical JJ i
decomposition NN i
) ) i
, , i
2 CD i
) ) i
three CD i
component JJ i
shoulder NN i
motions NNS i
in IN i
Euler NNP i
coordinates NNS i
and CC i
elbow JJ i
flexion/extension NN i
( ( i
Euler NNP i
decomposition NN i
) ) i
, , i
or CC i
3 CD i
) ) i
the DT i
motion NN i
of IN i
the DT i
tip NN i
of IN i
the DT i
elbow NN i
and CC i
motion NN i
of IN i
the DT i
hand NN i
with IN i
respect NN i
to TO i
the DT i
elbow NN i
, , i
independently RB i
( ( i
visual JJ i
decomposition NN i
) ) i
. . i

A DT N
control NN N
group NN N
practiced VBD N
the DT N
same JJ N
number NN o
of IN o
movements NNS o
, , i
but CC i
experienced VBD i
the DT i
target NN o
motion NN o
only RB o
, , N
achieving VBG N
eight CD N
times NNS N
more RBR N
direct JJ o
practice NN o
with IN N
this DT N
motion NN N
. . N

Despite IN N
less JJR p
experience NN p
with IN p
the DT p
target NN p
motion NN p
, , N
part NN o
training NN o
was VBD N
better RBR N
, , N
but CC N
only RB N
when WRB N
the DT N
arm NN N
trajectory NN N
was VBD N
decomposed VBN N
into IN N
anatomical JJ N
components NNS N
. . N

Varying VBG N
robotic JJ N
movement NN N
training NN N
to TO N
include VB N
practice NN N
of IN N
simpler NN i
, , i
anatomically-isolated JJ i
motions NNS i
may MD N
enhance VB N
its PRP$ N
efficacy NN o
. . o

-DOCSTART- -X- O O

Veterans NNS p
Affairs VBP p
congestive JJ p
heart NN p
failure NN p
antiarrhythmic JJ N
trial NN N
. . N

CHF NNP N
STAT NNP N
Investigators NNP N
. . N

This DT N
is VBZ N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
antiarrhythmic JJ N
drug NN N
therapy NN N
on IN N
mortality NN o
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
and CC p
ventricular JJ p
arrhythmia NN p
. . p

Patients NNS N
will MD N
be VB N
assigned VBN N
to TO N
receive VB N
either CC N
amiodarone VB i
or CC i
placebo VB i
. . i

Eligible JJ p
patients NNS p
include VBP p
those DT p
with IN p
ischemic JJ p
and CC p
nonischemic JJ p
congestive JJ p
heart NN p
failure NN p
and CC p
with IN p
> NNP p
or CC p
= $ p
10 CD p
ventricular JJ p
premature NN p
beats NNS p
per IN p
hour NN p
. . p

All DT p
patients NNS p
must MD p
have VB p
shortness NN p
of IN p
breath NN p
with IN p
minimal JJ p
exertion NN p
or CC p
paroxysmal JJ p
nocturnal JJ p
dyspnea NN p
, , p
a DT p
left JJ p
ventricular JJ p
internal JJ p
dimension NN p
( ( p
LVIDd NNP p
) ) p
by IN p
echocardiogram NN p
of IN p
> NN p
or CC p
= $ p
55 CD p
mm NN p
or CC p
a DT p
cardiothoracic JJ p
ratio NN p
of IN p
> $ p
0.5 CD p
and CC p
an DT p
ejection NN p
fraction NN p
of IN p
< NN p
or CC p
= VB p
40 CD p
% NN p
. . p

All DT N
patients NNS N
will MD N
receive VB N
vasodilator NN N
therapy NN N
, , N
unless IN N
they PRP N
find VBP N
it PRP N
intolerable JJ N
. . N

Patients NNS p
will MD p
be VB p
entered VBN p
into IN p
the DT p
study NN p
for IN p
2.5 CD p
years NNS p
and CC p
followed VBD p
for IN p
an DT p
additional JJ p
2 CD p
years NNS p
. . p

Drug NNP N
therapy NN N
will MD N
be VB N
continued VBN N
for IN N
all DT N
patients NNS N
throughout IN N
the DT N
entire JJ N
study NN N
unless IN N
adverse JJ N
reactions NNS N
occur VBP N
that IN N
necessitate JJ N
individualized JJ N
treatment NN N
. . N

The DT N
expectation NN N
is VBZ N
that IN N
674 CD p
patients NNS p
will MD p
be VB p
entered VBN p
into IN p
the DT p
study NN p
from IN p
25 CD p
participating VBG p
centers NNS p
. . p

This DT N
sample JJ N
size NN N
will MD N
allow VB N
for IN N
the DT N
detection NN N
of IN N
a DT N
33 CD N
% NN N
decrease NN N
in IN N
2-year JJ o
mortality NN o
( ( N
20 CD N
% NN N
vs JJ N
30 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
patients NNS N
compared VBN N
with IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
, , N
with IN N
a DT N
power NN N
of IN N
0.90 CD N
and CC N
a DT N
2-sided JJ N
alpha JJ N
level NN N
of IN N
0.05 CD N
. . N

Intermittent JJ N
Holter NNP N
monitoring NN N
, , N
radionuclide JJ N
ventriculograms NN N
, , N
pulmonary JJ N
function NN N
tests NNS N
, , N
echocardiograms NNS N
, , N
and CC N
blood NN N
tests NNS N
, , N
including VBG N
arterial JJ N
blood NN N
gases NNS N
, , N
will MD N
be VB N
required VBN N
for IN N
each DT N
patient NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Effects NNS N
of IN N
short- JJ N
and CC N
long-term JJ N
risperidone NN i
treatment NN p
on IN p
prolactin NN o
levels NNS o
in IN p
children NNS p
with IN p
autism NN p
. . p

BACKGROUND IN N
The DT N
effects NNS N
of IN N
short- JJ N
and CC N
long-term JJ N
risperidone NN i
treatment NN N
on IN N
serum NN N
prolactin NN N
were VBD N
assessed VBN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
. . p

METHODS NNP N
Patients NNPS p
with IN p
autism NN p
( ( p
N NNP p
= NNP p
101 CD p
, , p
5-17 CD p
years NNS p
of IN p
age NN p
) ) p
were VBD N
randomized VBN N
to TO N
an DT N
8-week JJ N
trial NN N
of IN N
risperidone NN i
or CC i
placebo NN i
and CC N
63 CD p
then RB p
took VBD p
part NN p
in IN p
a DT p
4-month JJ p
open-label JJ p
follow-up JJ p
phase NN p
. . p

Serum NNP N
samples NNS N
were VBD N
obtained VBN N
at IN N
Baseline NNP N
and CC N
Week-8 NNP N
( ( N
N NNP N
= NNP N
78 CD N
) ) N
, , N
and CC N
at IN N
6-month JJ N
( ( N
N NNP N
= NNP N
43 CD N
) ) N
and CC N
22-month JJ N
( ( N
N NNP N
= NNP N
30 CD N
) ) N
follow-up NN N
. . N

Serum NNP N
prolactin NN N
was VBD N
determined VBN N
by IN N
immunoradiometric JJ N
assay NN N
; : N
dopamine JJ o
type-2 JJ o
receptor NN o
( ( o
DRD2 NNP o
) ) o
polymorphisms NNS o
were VBD o
genotyped VBN o
. . o

RESULTS NNP N
Baseline NNP o
prolactin NN o
levels NNS o
were VBD N
similar JJ N
in IN N
the DT N
risperidone NN i
( ( N
N NNP N
= NNP N
42 CD N
) ) N
and CC N
placebo NN i
( ( N
N NNP N
= NNP N
36 CD N
) ) N
groups NNS N
( ( N
9.3 CD N
+/- JJ N
7.5 CD N
and CC N
9.3 CD N
+/- JJ N
7.6 CD N
ng/ml NN N
, , N
respectively RB N
) ) N
. . N

After IN N
8 CD N
weeks NNS N
of IN N
risperidone NN i
, , N
prolactin NN o
increased VBD N
to TO N
39.0 CD N
+/- JJ N
19.2 CD N
ng/ml NN N
, , N
compared VBN N
with IN N
10.1 CD N
+/- JJ N
8.8 CD N
ng/ml NN N
for IN N
placebo NN N
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
. . N

Prolactin NN o
levels NNS o
were VBD N
also RB N
significantly RB N
increased VBN N
at IN N
6 CD N
months NNS N
( ( N
32.4 CD N
+/- JJ N
17.8 CD N
ng/ml NN N
; : N
N NNP N
= VBZ N
43 CD N
, , N
p NN N
< NNP N
.0001 NNP N
) ) N
and CC N
at IN N
22 CD N
months NNS N
( ( N
N NNP N
= NNP N
30 CD N
, , N
25.3 CD N
+/- JJ N
15.6 CD N
ng/ml NN N
, , N
p NN N
< NNP N
.0001 NNP N
) ) N
. . N

Prolactin NN o
levels NNS o
were VBD N
not RB N
associated VBN N
with IN N
adverse JJ N
effects NNS N
and CC N
DRD2 NNP N
alleles NNS N
( ( N
Taq1A NNP N
, , N
-141C NNP N
Ins/Del NNP N
, , N
C957T NNP N
) ) N
did VBD N
not RB N
significantly RB N
influence VB N
baseline NN N
levels NNS N
or CC N
risperidone-induced JJ N
increases NNS N
in IN N
prolactin NN N
. . N

CONCLUSIONS NNP N
Risperidone NNP i
treatment NN N
was VBD N
associated VBN N
with IN N
two- JJ N
to TO N
four-fold JJ N
mean NN N
increases NNS N
in IN N
serum NN N
prolactin NN N
in IN N
children NNS p
with IN p
autism NN p
. . p

Although IN N
risperidone-induced JJ N
increases NNS N
tended VBD N
to TO N
diminish VB N
with IN N
time NN N
, , N
further JJ N
research NN N
on IN N
the DT N
consequences NNS N
of IN N
long-term JJ N
prolactin NN N
elevations NNS N
in IN N
children NNS p
and CC p
adolescents NNS p
is VBZ N
needed VBN N
. . N

-DOCSTART- -X- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
risperidone NN i
in IN N
adults NNS p
with IN p
autistic JJ p
disorder NN p
and CC p
other JJ p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

BACKGROUND NNP N
Neurobiological NNP N
research NN N
has VBZ N
implicated VBN N
the DT N
dopamine NN N
and CC N
serotonin JJ N
systems NNS N
in IN N
the DT N
pathogenesis NN N
of IN N
autism NN p
. . p

Open-label JJ N
reports NNS N
suggest VBP N
that IN N
the DT N
serotonin2A-dopamine JJ i
D2 NNP i
antagonist NN i
risperidone NN i
may MD N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
reducing VBG N
the DT N
interfering NN N
symptoms NNS N
of IN N
patients NNS p
with IN p
autism NN p
. . p

METHODS NNP N
Thirty-one CD p
adults NNS p
( ( p
age NN p
[ VBZ p
mean+/-SD JJ p
] NNP p
, , p
28.1+/-7.3 JJ p
years NNS p
) ) p
with IN p
autistic JJ p
disorder NN p
( ( p
n=17 JJ p
) ) p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
not RB p
otherwise RB p
specified VBN p
( ( p
n=14 JJ p
) ) p
participated VBD p
in IN p
a DT p
12-week JJ p
double-blind NN p
, , p
placebo-controlled JJ i
trial NN p
of IN p
risperidone NN i
. . i

Patients NNS N
treated VBD N
with IN N
placebo NN N
subsequently RB N
received VBD N
a DT N
12-week JJ N
open-label JJ N
trial NN N
of IN N
risperidone NN i
. . i

RESULTS NNP N
For IN N
persons NNS N
completing VBG N
the DT N
study NN N
, , N
8 CD N
( ( N
57 CD N
% NN N
) ) N
of IN N
14 CD N
patients NNS N
treated VBN N
with IN N
risperidone NN i
were VBD N
categorized VBN N
as IN N
responders NNS N
( ( N
daily JJ N
dose VB N
[ JJ N
mean+/-SD JJ N
] NN N
, , N
2.9+/-1.4 JJ N
mg NN N
) ) N
compared VBN N
with IN N
none NN N
of IN N
16 CD N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
. . N

Risperidone NN i
was VBD N
superior JJ N
to TO N
placebo VB i
in IN N
reducing VBG N
repetitive JJ o
behavior NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
aggression NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
anxiety NN o
or CC o
nervousness NN o
( ( o
P NNP o
< NNP o
.02 NNP o
) ) o
, , o
depression NN o
( ( o
P NNP o
< NNP o
.03 NNP o
) ) o
, , o
irritability NN o
( ( o
P NNP o
< NNP o
.01 NNP o
) ) o
, , N
and CC N
the DT N
overall JJ o
behavioral JJ o
symptoms NNS o
of IN o
autism NN o
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

Objective NNP N
, , N
measurable JJ N
change NN N
in IN N
social JJ o
behavior NN o
and CC o
language NN o
did VBD N
not RB N
occur VB N
. . N

Nine NNP N
( ( N
60 CD N
% NN N
) ) N
of IN N
15 CD N
patients NNS N
who WP N
received VBD N
treatment NN N
with IN N
open-label JJ N
risperidone NN N
following VBG N
the DT N
double-blind JJ N
placebo NN i
phase NN N
responded VBD N
. . N

Other JJ N
than IN N
mild JJ o
, , o
transient JJ o
sedation NN o
, , N
risperidone NN N
was VBD N
well RB N
tolerated VBN o
, , N
with IN N
no DT N
evidence NN N
of IN N
extrapyramidal JJ o
effects NNS o
, , o
cardiac JJ o
events NNS o
, , o
or CC o
seizures NNS o
. . o

CONCLUSION NNP N
Risperidone NNP i
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN i
in IN N
the DT N
short-term JJ N
treatment NN N
of IN N
symptoms NNS N
of IN N
autism NN p
in IN p
adults NNS p
. . p

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
a DT N
short JJ i
nurse-based JJ i
and CC i
a DT i
long JJ i
multidisciplinary JJ i
version NN i
of IN i
structured JJ i
patient JJ i
education NN i
in IN N
irritable JJ p
bowel NN p
syndrome NN p
. . p

OBJECTIVE CC N
Structured NNP i
multidisciplinary JJ i
patient NN i
group NN i
education NN i
has VBZ N
positive JJ N
effects NNS N
on IN N
symptoms NNS N
, , N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
and CC N
disease-related JJ N
knowledge NN N
in IN N
patients NNS p
with IN p
irritable JJ p
bowel NN p
syndrome NN p
( ( p
IBS NNP p
) ) p
, , N
but CC N
few JJ N
studies NNS N
comparing VBG N
different JJ N
forms NNS N
of IN N
educational JJ N
interventions NNS N
are VBP N
available JJ N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
long JJ i
multidisciplinary JJ i
group NN i
education NN i
with IN N
a DT N
short JJ i
nurse-based JJ i
group NN i
education NN i
with IN N
regard NN N
to TO N
symptoms NNS N
, , N
knowledge NN N
, , N
quality NN N
of IN N
life NN N
, , N
and CC N
satisfaction NN N
with IN N
the DT N
intervention NN N
in IN N
IBS NNP p
patients NNS p
. . p

METHODS NNP N
Patients NNPS p
with IN p
IBS NNP p
according VBG p
to TO p
the DT p
Rome NNP p
II NNP p
criteria NNS p
were VBD N
randomized VBN N
to TO N
either DT N
short JJ i
nurse-based JJ i
or CC i
a DT i
long JJ i
multidisciplinary-based JJ i
education NN i
. . i

The DT N
effects NNS N
were VBD N
evaluated VBN N
by IN N
self-administered JJ i
questionnaires NNS i
at IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
baseline NN N
, , N
and CC N
compared VBN N
between IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
No NNP N
differences NNS N
in IN N
effects NNS N
were VBD N
detected VBN N
in IN N
the DT N
between-group JJ N
comparisons NNS N
at IN N
any DT N
of IN N
the DT N
follow-up JJ N
assessments NNS N
. . N

However RB N
, , N
positive JJ N
effects NNS N
on IN N
symptoms NNS o
, , o
knowledge NN o
, , o
quality NN o
of IN o
life NN o
, , o
and CC o
satisfaction NN o
with IN N
the DT N
intervention NN N
were VBD N
found VBN N
in IN N
both CC N
the DT N
short JJ N
and CC N
the DT N
long JJ N
version NN N
. . N

CONCLUSION VB N
A DT N
short JJ i
, , i
nurse-based JJ i
educational JJ i
intervention NN i
seems VBZ N
to TO N
be VB N
as RB N
efficacious JJ N
as IN N
a DT N
longer RBR i
multidisciplinary JJ i
version NN N
. . N

In IN N
both DT N
groups NNS N
, , N
positive JJ N
effects NNS N
on IN N
patients NNS N
' POS N
well-being NN N
were VBD N
found VBN N
to TO N
a DT N
similar JJ N
extent NN N
. . N

This DT N
is VBZ N
an DT N
important JJ N
finding NN N
that IN N
, , N
from IN N
a DT N
cost-effective JJ N
perspective NN N
, , N
could MD N
contribute VB N
toward IN N
an DT N
optimized JJ N
management NN N
of IN N
patients NNS N
with IN N
IBS NNP N
. . N

-DOCSTART- -X- O O

Intravitreal NNP N
ranibizumab VBZ i
versus FW N
isovolemic JJ i
hemodilution NN i
in IN N
the DT N
treatment NN N
of IN N
macular JJ p
edema NN p
secondary JJ p
to TO p
central JJ p
retinal JJ p
vein NN p
occlusion NN p
: : p
twelve-month JJ N
results NNS N
of IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
. . N

PURPOSE VB N
This DT N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR p
, , N
investigator-initiated JJ N
trial NN N
to TO N
evaluate VB N
the DT N
12-month JJ N
effectiveness NN N
of IN N
isovolemic JJ i
hemodilution NN i
( ( i
IH NNP i
) ) i
with IN N
prompt JJ N
versus NN N
deferred VBD N
intravitreal JJ N
injections NNS N
( ( N
IVI NNP N
) ) N
of IN N
ranibizumab NN i
0.5 CD i
mg NN i
for IN N
the DT N
treatment NN N
of IN N
macular JJ p
edema NN p
secondary JJ p
to TO p
early JJ p
central JJ p
retinal JJ p
vein NN p
occlusion NN p
( ( p
CRVO NNP p
) ) p
. . p

METHODS NNP N
Eyes NNP p
with IN p
macular JJ p
edema NNS p
due JJ p
to TO p
CRVO NNP p
having VBG p
occurred VBD p
not RB p
more JJR p
than IN p
8 CD p
weeks NNS p
previously RB p
received VBD N
either CC N
monthly JJ N
ranibizumab NN i
IVI NNP i
in IN N
combination NN N
with IN N
IH NNP i
( ( N
group NN N
I PRP N
, , N
n RB N
= VBZ N
28 CD N
) ) N
or CC N
IH NNP i
alone RB N
( ( N
group NN N
II NNP N
, , N
n JJ N
= NNP N
30 CD N
) ) N
. . N

From IN N
month NN N
2 CD N
to TO N
12 CD N
, , N
the DT N
patients NNS N
in IN N
both DT N
groups NNS N
could MD N
be VB N
treated VBN N
with IN N
monthly JJ N
intravitreal NN N
ranibizumab NN i
. . i

The DT N
main JJ N
outcome NN N
variables NNS N
were VBD N
gain NN o
of IN o
visual JJ o
acuity NN o
and CC o
the DT o
course NN o
of IN o
central JJ o
retinal JJ o
thickness NN o
as IN N
measured VBN N
with IN N
optical JJ N
coherence NN N
tomography NN N
. . N

RESULTS NNP N
At IN N
12 CD N
months NNS N
, , N
eyes NNS N
in IN N
group NN N
I PRP N
on IN N
average NN N
gained VBN N
+28.1 NNP N
( ( o
?19.3 NNP o
) ) o
letters NNS o
compared VBN N
to TO N
+25.2 VB N
( ( N
?20.9 NN N
) ) N
letters NNS N
in IN N
group NN N
II NNP N
( ( N
p JJ N
= NNP N
0.326 CD N
) ) N
. . N

This DT N
result NN N
was VBD N
achieved VBN N
with IN N
significantly RB N
fewer JJR N
injections NNS N
in IN N
group NN N
II NNP N
. . N

Additionally RB N
, , N
30 CD N
% NN N
of IN N
the DT N
eyes NNS N
in IN N
group NN N
II NNP N
did VBD N
not RB N
need VB i
ranibizumab JJ i
IVI NNP i
during IN N
the DT N
12 CD N
months NNS N
of IN N
the DT N
trial NN N
. . N

CONCLUSION NNP i
Ranibizumab NNP i
IVI NNP i
in IN N
addition NN N
to TO N
IH NNP N
proved VBD N
to TO N
be VB N
highly RB o
effective JJ o
in IN o
increasing VBG o
visual JJ o
acuity NN o
and CC o
reducing VBG o
macular JJ o
edema NN o
secondary JJ o
to TO o
CRVO NNP o
. . o

Initial NNP N
IH NNP N
in IN N
early JJ N
CRVO NNP N
may MD N
be VB N
a DT N
first JJ N
treatment NN N
option NN N
in IN N
patients NNS N
anxious JJ N
about IN N
IVI NNP N
. . N

-DOCSTART- -X- O O

Rationale NNP N
and CC N
design NN N
of IN N
a DT N
randomized JJ N
trial NN N
to TO N
evaluate VB N
an DT N
evidence-based JJ i
prescription NN i
drug NN i
label NN i
on IN p
actual JJ p
medication NN p
use NN p
. . p

BACKGROUND NNP N
Medication NNP N
errors NNS N
are VBP N
an DT N
important JJ N
public JJ N
health NN N
concern NN N
, , N
and CC N
poor JJ N
understanding NN N
of IN N
medication NN N
labels NNS N
are VBP N
a DT N
root NN N
cause NN N
. . N

Research NN N
shows VBZ N
that IN N
labels NNS N
are VBP N
variable JJ N
, , N
of IN N
poor JJ N
quality NN N
, , N
and CC N
not RB N
patient-centered JJ N
. . N

No DT N
real-world JJ N
trials NNS N
have VBP N
evaluated VBN N
whether IN N
improved JJ N
medication NN N
labels NNS N
can MD N
affect VB N
appropriate JJ N
medication NN N
use NN N
, , N
adherence NN N
or CC N
health NN N
outcomes NNS N
. . N

TRIAL NNP N
DESIGN NNP N
We PRP N
developed VBD N
an DT N
evidence-based JJ i
prescription NN i
label NN i
that WDT N
addresses VBZ N
both DT N
content NN N
and CC N
format NN N
. . N

The DT N
enhanced JJ i
label NN i
includes VBZ N
a DT N
universal JJ N
medication NN N
schedule NN N
( ( N
UMS NNP N
) ) N
that WDT N
standardizes VBZ N
the DT N
directions NNS N
for IN N
use NN N
incorporating VBG N
1 CD N
) ) N
standard NN N
time NN N
periods NNS N
for IN N
administration NN N
( ( N
morning NN N
, , N
noon NN N
, , N
evening NN N
, , N
and CC N
bedtime NN N
) ) N
, , N
2 CD N
) ) N
numeric JJ N
vs. FW N
alpha NN N
characters NNS N
, , N
3 CD N
) ) N
'carriage NN N
returns NNS N
' POS N
to TO N
separate VB N
daily JJ N
dose NN N
and CC N
4 CD N
) ) N
a DT N
graphic JJ N
aid NN N
to TO N
visually RB N
depict VB N
dose NN N
and CC N
frequency NN N
. . N

We PRP N
will MD N
evaluate VB N
the DT N
effect NN N
of IN N
providing VBG N
this DT N
label NN i
to TO N
randomly VB p
sampled VBN p
patients NNS p
who WP p
receive VBP p
their PRP$ p
care NN p
from IN p
free JJ p
clinics NNS p
, , p
mobile JJ p
vans NNS p
and CC p
federally RB p
qualified JJ p
health NN p
centers NNS p
( ( p
FQHCs NNP p
) ) p
in IN p
Northern NNP p
Virginia NNP p
. . p

We PRP N
will MD N
recruit VB N
patients NNS p
with IN p
diabetes NNS p
or CC p
hypertension NN p
; : p
these DT N
patients NNS N
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
receive VB N
all DT N
of IN N
their PRP$ N
medications NNS N
with IN N
improved JJ N
labels NNS N
or CC N
to TO N
receive VB N
prescriptions NNS N
with IN N
standard JJ N
labels NNS N
. . N

The DT N
primary JJ N
outcome NN N
will MD N
be VB N
the DT N
patient NN o
's POS o
ability NN o
to TO o
correctly RB o
demonstrate VB o
dosing VBG o
instructions NNS o
. . o

Other JJ N
outcomes NNS N
include VBP N
adherence NN o
, , o
error NN o
rates NNS o
and CC o
health NN o
outcomes NNS o
. . o

CONCLUSION NN N
To TO N
our PRP$ N
knowledge NN N
, , N
this DT N
trial NN N
is VBZ N
the DT N
first JJ N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prescription NN N
label NN N
improvement NN N
on IN N
understanding NN o
, , o
medication NN o
use NN o
and CC N
outcomes NNS N
in IN N
a DT N
clinical JJ N
setting NN N
. . N

If IN N
successful JJ N
, , N
these DT N
findings NNS N
could MD N
be VB N
implemented VBN N
broadly RB N
to TO N
promote VB N
safe JJ N
and CC N
appropriate JJ N
medication NN N
use NN N
and CC N
to TO N
support VB N
evidence-based JJ N
standards NNS N
in IN N
the DT N
development NN N
of IN N
labels NNS N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
the DT N
laryngeal JJ i
tube-S JJ i
and CC N
Proseal NNP i
laryngeal JJ i
mask NN i
during IN N
outpatient JJ p
surgical JJ p
procedures NNS p
. . p

BACKGROUND NNP N
AND CC N
OBJECTIVE NNP N
The DT N
Laryngeal NNP i
Tube NNP i
Sonda NNP i
( ( i
LTS NNP i
) ) i
and CC N
the DT N
ProSeal NNP i
Laryngeal NNP i
Mask NNP i
Airway NNP i
( ( i
PLMA NNP i
) ) i
are VBP N
two CD N
new JJ N
devices NNS N
introduced VBN N
for IN N
maintaining VBG N
the DT N
airway NN N
during IN N
controlled VBN N
ventilation NN N
under IN p
general JJ p
anaesthesia NN p
. . p

The DT N
present JJ N
investigation NN N
compared VBN N
their PRP$ N
performance NN N
in IN N
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

METHODS NNP N
One CD p
hundred VBD p
ASA NNP p
I-II NNP p
patients NNS p
, , p
aged VBN p
18-60 JJ p
yr NN p
undergoing VBG p
elective JJ p
minor JJ p
surgery NN p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
an DT N
LTS NNP i
( ( N
n JJ N
= NNP N
50 CD N
) ) N
or CC N
PLMA NNP i
( ( N
n JJ N
= NNP N
50 CD N
) ) N
for IN N
airway JJ N
management NN N
. . N

After IN N
induction NN N
of IN N
general JJ N
anaesthesia NN N
, , N
the DT N
devices NNS N
were VBD N
inserted VBN N
, , N
its PRP$ N
correct JJ N
placement NN N
was VBD N
verified VBN N
and CC N
airway RB N
leak JJ N
pressure NN N
was VBD N
measured VBN N
. . N

Ease NNP o
of IN o
insertion NN o
, , o
quality NN o
of IN o
airway NN o
seal NN o
, , o
fibre-optic JJ o
view NN o
and CC o
postoperative JJ o
pharyngeal NN o
morbidity NN o
were VBD N
examined VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
patient JJ N
characteristics NNS N
for IN N
both DT N
groups NNS N
. . N

First-time JJ o
and CC o
second-time JJ o
success NN o
rates NNS o
were VBD N
comparable JJ N
for IN N
both DT N
groups NNS N
( ( N
86 CD N
vs. FW N
88 CD N
% NN N
and CC N
96 CD N
vs. FW N
98 CD N
% NN N
in IN N
LTS NNP N
and CC N
PLMA NNP N
groups NNS N
, , N
respectively RB N
) ) N
. . N

The DT N
airway NN o
of IN N
one CD N
patient NN N
in IN N
each DT N
group NN N
could MD N
not RB N
be VB N
managed VBN N
with IN N
these DT N
devices NNS N
after IN N
three CD N
attempts NNS N
. . N

Time NNP o
until IN o
delivery NN o
of IN o
first JJ o
tidal JJ o
volume NN o
for IN N
LTS NNP N
and CC N
PLMA NNP N
was VBD N
24.5 CD N
+/- JJ N
6.9 CD N
and CC N
28.8 CD N
+/- JJ N
10.3 CD N
s. JJ N
Fixation NNP o
and CC o
manipulation NN o
time NN o
was VBD N
54.9 CD N
+/- JJ N
15.2 CD N
and CC N
73.2 CD N
+/- JJ N
25 CD N
s NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Airway NNP o
seal JJ o
pressure NN o
( ( N
cm JJ N
H NNP N
( ( N
2 CD N
) ) N
O NNP N
) ) N
for IN N
LTS NNP N
and CC N
PLMA NNP N
was VBD N
20 CD N
+/- JJ N
8.6 CD N
and CC N
24.1 CD N
+/- JJ N
10.8 CD N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Patients NNS N
were VBD N
questioned VBN N
on IN N
a DT N
variety NN N
of IN N
postoperative JJ o
pharyngeal NN o
morbidities NNS o
. . o

Only RB N
hoarseness NN o
was VBD N
more RBR N
frequent JJ N
in IN N
the DT N
LTS NNP N
group NN N
. . N

CONCLUSIONS NNP N
Both NNP N
devices NNS N
provide VBP N
a DT N
secure NN N
airway NN N
, , N
are VBP N
similar JJ N
in IN N
clinical JJ N
utility NN N
and CC N
are VBP N
easy JJ N
to TO N
insert VB N
. . N

Better NNP N
airway RB o
seal NN o
was VBD N
detected VBN N
in IN N
the DT N
PLMA NNP N
group NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Case-controll NNP N
study NN N
on IN N
the DT N
synergistic JJ o
effects NNS o
of IN N
electroacupuncture NN i
on IN N
knee NN N
osteoarthritis NN N
after IN N
arthroscopic JJ i
debridement NN i
] NN i
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
synergistic JJ o
effects NNS o
of IN N
electroacupuncture NN i
on IN N
the DT N
treatment NN N
of IN N
knee NN N
osteoarthritis NN N
after IN N
arthroscopic JJ i
debridement NN i
. . i

METHODS NNP N
From NNP N
May NNP p
2008 CD p
to TO p
July NNP p
2010 CD p
, , p
78 CD p
patients NNS p
with IN p
knee JJ p
osteoarthritis NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

There EX N
were VBD N
42 CD p
patients NNS p
in IN p
the DT p
experimental JJ p
group NN p
, , p
including VBG p
16 CD p
males NNS p
and CC p
26 CD p
females NNS p
, , p
ranging VBG p
in IN p
age NN p
from IN p
41 CD p
to TO p
63 CD p
years NNS p
, , p
with IN p
an DT p
average NN p
of IN p
( ( p
53.62 CD p
+/- JJ p
6.53 CD p
) ) p
years NNS p
; : p
the DT p
disease NN p
course NN p
ranged VBD p
from IN p
8 CD p
to TO p
24 CD p
months NNS p
, , p
with IN p
an DT p
average NN p
of IN p
( ( p
10.35 CD p
+/- JJ p
6.42 CD p
) ) p
months NNS p
. . p

The DT N
patients NNS N
were VBD N
treated VBN N
with IN N
arthroscopic JJ i
debridement NN i
combined VBN i
with IN i
electroacupuncture NN i
after IN i
operation NN i
. . i

There EX N
were VBD N
36 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
, , p
including VBG p
14 CD p
males NNS p
and CC p
22 CD p
females NNS p
, , p
ranging VBG p
in IN p
age NN p
from IN p
40 CD p
to TO p
62 CD p
years NNS p
, , p
with IN p
an DT p
average NN p
of IN p
( ( p
54.34 CD p
+/- JJ p
7.67 CD p
) ) p
years NNS p
; : p
the DT p
disease NN o
course NN o
ranged VBD p
from IN p
6 CD p
to TO p
25 CD p
months NNS p
, , p
with IN p
an DT p
average NN p
of IN p
( ( p
11.94 CD p
+/- JJ p
5.13 CD p
) ) p
months NNS p
. . p

Those DT N
patients NNS N
were VBD N
treated VBN N
only RB N
with IN N
arthroscopic JJ i
debridment NN i
. . i

All PDT N
the DT N
patients NNS N
performed VBD N
isometric JJ i
quadriceps NNS i
femoris JJ i
contraction NN i
exercise NN i
and CC i
knee NN i
flexion NN i
and CC i
extension NN i
activities NNS i
after IN i
operation NN i
. . i

The DT N
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
score NN o
and CC o
Lysholm NNP o
knee VBD o
score NN o
were VBD N
used VBN N
to TO N
evaluate VB N
the DT N
therapeutic JJ N
effects NNS N
. . N

RESULTS NNP N
All PDT N
the DT N
patients NNS N
were VBD N
followed VBN N
up RP N
, , N
and CC N
the DT N
duration NN N
ranged VBD N
from IN N
12 CD N
to TO N
30 CD N
months NNS N
, , N
with IN N
an DT N
average NN N
of IN N
15.6 CD N
months NNS N
. . N

At IN N
the DT N
final JJ N
follow-up NN N
, , N
VAS NNP o
score NN o
was VBD N
significantly RB N
decreased VBN N
, , N
and CC N
the DT N
Lysholm NNP o
score NN o
, , N
except IN N
for IN N
the DT N
item NN N
demanding VBG N
for IN N
support NN N
, , N
significantly RB N
increased VBN N
, , N
compared VBN N
with IN N
those DT N
before IN N
surgery NN N
respectively RB N
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
significant JJ N
difference NN N
in IN N
VAS NNP o
score NN o
between IN N
two CD N
groups NNS N
after IN N
treatment NN N
. . N

As IN N
to TO N
Lysholm NNP o
score NN o
, , N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
limp NN o
, , o
pain NN o
, , o
swelling VBG o
, , o
stair NN o
activity NN o
and CC o
squat NN o
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
items NNS N
of IN N
interlocking VBG o
and CC o
instability NN o
between IN N
two CD N
groups NNS N
after IN N
treatment NN N
. . N

CONCLUSION NNP N
Electroacupuncture NNP N
can MD N
effectively RB N
improve VB N
the DT N
clinical JJ o
symptoms NNS o
and CC N
knee VB N
joint NN N
's POS N
motor NN o
function NN o
of IN o
knee NN o
joints NNS o
in IN N
patients NNS N
with IN p
knee JJ p
osteoarthritis NN p
, , N
as RB N
well RB N
as IN N
the DT N
synergistic JJ N
effects NNS N
on IN N
the DT N
treatment NN N
of IN N
knee NN N
osteoarthritis NN N
after IN N
arthroscopic JJ N
debridement NN N
, , N
leading VBG N
to TO N
a DT N
much RB N
better JJR N
long-term JJ N
therapeutic JJ N
effect NN N
with IN N
respect NN N
of IN N
improving VBG N
the DT N
function NN N
of IN N
knee NN N
joint NN N
. . N

This DT N
therapy NN N
, , N
combined VBN N
with IN N
traditional JJ N
Chinese JJ N
medicine NN N
and CC N
Western JJ N
Medicine NNP N
, , N
is VBZ N
worth IN N
of IN N
clinical JJ N
application NN N
in IN N
the DT N
treatment NN N
of IN N
knee NN N
osteoarthritis NN N
. . N

-DOCSTART- -X- O O

Melatonin NNP i
versus NN i
placebo NN i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
conditions NNS p
and CC p
severe JJ p
sleep NN p
problems NNS p
not RB p
amenable JJ p
to TO p
behaviour VB p
management NN p
strategies NNS p
: : p
a DT N
randomised JJ N
controlled VBN N
crossover NN N
trial NN N
. . N

Twenty-two JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
who WP p
had VBD p
not RB p
responded VBN p
to TO p
supported VB p
behaviour JJ p
management NN p
strategies NNS p
for IN p
severe JJ p
dysomnias NN p
entered VBD N
a DT N
double JJ N
blind NN N
, , N
randomised VBN N
, , N
controlled VBD N
crossover RB N
trial NN N
involving VBG N
3 CD N
months NNS N
of IN N
placebo NN i
versus IN N
3 CD N
months NNS N
of IN N
melatonin NN i
to TO N
a DT N
maximum JJ N
dose NN N
of IN N
10 CD N
mg. NNS N
17 CD p
children NNS p
completed VBD p
the DT p
study NN p
. . p

There EX N
were VBD N
no DT o
significant JJ o
differences NNS o
between IN N
sleep JJ o
variables NNS o
at IN N
baseline NN N
. . N

Melatonin NNP i
significantly RB N
improved VBD o
sleep JJ o
latency NN o
( ( N
by IN N
an DT N
average NN N
of IN N
47 CD N
min NN N
) ) N
and CC N
total JJ o
sleep NN o
( ( N
by IN N
an DT N
average NN N
of IN N
52 CD N
min NN N
) ) N
compared VBN N
to TO N
placebo VB i
, , N
but CC N
not RB N
number NN N
of IN N
night NN N
wakenings NNS N
. . N

The DT N
side NN o
effect NN o
profile NN o
was VBD N
low JJ o
and CC o
not RB o
significantly RB o
different JJ o
between IN N
the DT N
two CD N
arms NNS N
. . N

-DOCSTART- -X- O O

[ JJ i
Cred? NNP i
's POS i
prevention NN i
method NN i
has VBZ N
lost VBN N
its PRP$ o
justification NN o
today NN N
] NNP N
. . N

-DOCSTART- -X- O O

Rituximab NNP i
plus CC i
concurrent JJ i
infusional JJ i
EPOCH NNP i
chemotherapy NN i
is VBZ N
highly RB N
effective JJ N
in IN p
HIV-associated JJ p
B-cell NNP p
non-Hodgkin JJ p
lymphoma NN p
. . p

Rituximab NNP N
plus CC N
intravenous JJ N
bolus NN N
chemotherapy NN N
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
immunocompetent JJ p
patients NNS p
with IN p
B-cell NNP p
non-Hodgkin JJ p
lymphoma NN p
( ( p
NHL NNP p
) ) p
. . p

Some DT N
studies NNS N
have VBP N
suggested VBN N
that IN N
rituximab NN N
is VBZ N
associated VBN N
with IN N
excessive JJ o
toxicity NN o
in IN N
HIV-associated NNP N
NHL NNP N
, , N
and CC N
that IN N
infusional JJ N
chemotherapy NN N
may MD N
be VB N
more RBR N
effective JJ N
. . N

We PRP N
performed VBD N
a DT N
randomized JJ N
phase NN N
2 CD N
trial NN N
of IN N
rituximab NN i
( ( i
375 CD i
mg/m NN i
( ( i
2 CD i
) ) i
) ) i
given VBN i
either CC i
concurrently RB i
before IN i
each DT i
infusional JJ i
etoposide NN i
, , i
vincristine NN i
, , i
doxorubicin NN i
, , i
cyclophosphamide NN i
, , i
and CC i
prednisone NN i
( ( i
EPOCH NNP i
) ) i
chemotherapy NN i
cycle NN i
or CC i
sequentially RB i
( ( i
weekly JJ i
for IN i
6 CD i
weeks NNS i
) ) i
after IN i
completion NN i
of IN i
all DT i
chemotherapy NN i
in IN i
HIV-associated NNP i
NHL NNP i
. . i

EPOCH NNP i
consisted VBD N
of IN N
a DT N
96-hour JJ N
intravenous JJ N
infusion NN N
of IN N
etoposide NN i
, , i
doxorubicin NN i
, , i
and CC i
vincristine JJ i
plus CC i
oral JJ i
prednisone NN i
followed VBN N
by IN N
intravenous JJ N
bolus JJ N
cyclophosphamide NN i
given VBN N
every DT N
21 CD N
days NNS N
for IN N
4 CD N
to TO N
6 CD N
cycles NNS N
. . N

In IN N
the DT N
concurrent NN N
arm NN N
, , N
35 CD N
of IN N
48 CD p
evaluable JJ p
patients NNS p
( ( N
73 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
58 CD N
% NN N
-85 NNP N
% NN N
) ) N
had VBD N
a DT N
complete JJ o
response NN o
. . o

In IN N
the DT N
sequential JJ N
arm NN N
, , N
29 CD N
of IN N
53 CD p
evaluable JJ p
patients NNS p
( ( N
55 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
41 CD N
% NN N
-68 CD N
% NN N
) ) N
had VBD N
a DT N
complete JJ N
response NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
met VBN N
for IN N
the DT N
concurrent NN N
arm NN N
only RB N
. . N

Toxicity NNP o
was VBD N
comparable JJ N
in IN N
the DT N
2 CD N
arms NNS N
, , N
although IN N
patients NNS N
with IN N
a DT N
baseline NN N
CD4 NNP o
count NN N
less JJR N
than IN N
50/microL CD N
had VBD N
a DT N
high JJ N
infectious JJ o
death NN o
rate NN o
in IN N
the DT N
concurrent NN N
arm NN N
. . N

We PRP N
conclude VBP N
that DT N
concurrent NN i
rituximab NN i
plus CC i
infusional JJ i
EPOCH NNP i
is VBZ N
an DT N
effective JJ N
regimen NNS N
for IN N
HIV-associated JJ p
lymphoma NN p
. . p

-DOCSTART- -X- O O

Epirubicin NNP i
and CC i
cyclophosphamide VB i
versus NN N
epirubicin NN i
and CC i
docetaxel NN i
as IN N
first-line JJ N
therapy NN N
for IN N
women NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
: : p
final JJ N
results NNS N
of IN N
a DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
. . N

BACKGROUND VB N
This DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
epirubicin NN i
and CC i
cyclophosphamide NN i
( ( i
EC NNP i
) ) i
with IN i
epirubicin NN i
and CC i
docetaxel NN i
( ( i
Taxotere NNP i
) ) i
( ( i
ED NNP i
) ) i
as IN N
first-line JJ N
chemotherapy NN N
for IN N
metastatic JJ p
breast NN p
cancer NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP p
( ( p
n JJ p
= NNP p
240 CD p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO N
receive VB N
either DT N
ED NNP i
( ( i
epirubicin JJ i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
and CC i
docetaxel $ i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
or CC N
EC NNP i
( ( i
epirubicin VBP i
90 CD N
mg/m NN N
( ( N
2 CD N
) ) N
and CC N
cyclophosphamide $ i
600 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
objective JJ o
response NN o
rate NN o
( ( o
ORR NNP o
) ) o
. . o

Secondary JJ N
end NN N
points NNS N
were VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
and CC o
safety NN o
. . o

RESULTS NNP N
ORR NNP o
for IN N
patients NNS N
randomly RB N
assigned VBN N
to TO N
receive VB N
EC NNP i
and CC N
ED NNP i
were VBD N
42 CD N
% NN N
and CC N
47 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.63 CD N
) ) N
. . N

Median JJ o
PFS NNP o
[ NNP N
10.1 CD N
versus NN N
10.3 CD N
months NNS N
; : N
hazard VBN N
ratio NN N
( ( N
HR NNP N
) ) N
0.98 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
0.38 CD N
] NN N
and CC N
OS NNP o
( ( N
19.9 CD N
versus NN N
30.0 CD N
months NNS N
; : N
HR NNP N
0.663 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
0.21 CD N
) ) N
were VBD N
comparable JJ N
in IN N
both DT N
arms NNS N
. . N

Although IN N
grade JJ o
3/4 CD o
leucopenia NN o
occurred VBD N
more RBR N
frequently RB N
with IN N
ED NNP i
( ( N
81 CD N
% NN N
versus IN N
73 CD N
% NN N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
febrile JJ o
neutropenia NN o
and CC o
grade VBD o
3/4 CD o
infections NNS o
. . o

Grade VB o
3/4 CD o
non-haematologic JJ o
toxicity NN o
was VBD N
infrequent JJ N
in IN N
both DT N
arms NNS N
. . N

Congestive JJ o
heart NN o
failure NN o
was VBD N
observed VBN N
in IN N
one CD N
patient NN N
in IN N
each DT N
arm NN N
. . N

CONCLUSION NN N
In IN N
this DT N
randomised JJ N
trial NN N
, , N
no DT N
differences NNS N
in IN N
the DT N
efficacy NN N
study VBD N
end JJ N
points NNS N
were VBD N
observed VBN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
. . N

-DOCSTART- -X- O O

Oxaprozin NNP i
versus NN N
diclofenac NN i
in IN N
NSAID-refractory NNP N
periarthritis NN N
pain NN N
of IN N
the DT N
shoulder NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
oxaprozin NN i
in IN N
comparison NN N
with IN N
diclofenac NN i
in IN N
patients NNS p
with IN p
periarthritis NN p
pain NN p
of IN p
the DT p
shoulder NN p
previously RB p
unsuccessfully RB p
treated VBN p
with IN p
nonsteroidal JJ p
anti-inflammatory JJ p
drugs NNS p
other JJ p
than IN p
diclofenac NNS p
and CC p
oxaprozin NN p
. . p

METHODS NNP N
In IN N
this DT N
open JJ N
, , N
multicentre NN N
, , N
randomised VBN N
, , N
controlled VBN N
study NN N
, , N
eligible JJ p
patients NNS p
with IN p
periarthritis NN p
of IN p
the DT p
shoulder NN p
were VBD N
randomised VBN N
to TO N
receive VB i
either RB i
oxaprozin JJ i
1200 CD i
mg NN i
once RB i
daily JJ i
( ( i
n JJ i
= NNP i
49 CD i
) ) i
or CC i
diclofenac $ i
50 CD i
mg NN i
three CD i
times NNS i
daily RB i
( ( i
n JJ i
= NNP i
47 CD i
) ) i
. . i

The DT N
treatment NN N
period NN N
was VBD N
15 CD N
+/- JJ N
1 CD N
days NNS N
. . N

The DT N
study NN N
was VBD N
planned VBN N
on IN N
a DT N
hypothesis NN N
of IN N
equivalence NN N
between IN N
the DT N
two CD N
study NN N
drugs NNS N
. . N

The DT N
primary JJ N
study NN N
endpoint NN N
was VBD N
the DT N
change NN o
from IN o
baseline NN o
at IN o
day NN o
15 CD o
in IN o
the DT o
patient-assessed JJ o
shoulder NN o
pain NN o
score NN o
. . o

Secondary JJ N
efficacy NN N
variables NNS N
included VBD N
investigator-assessed JJ o
shoulder NN o
function NN o
, , o
patient-assessed JJ o
quality NN o
of IN o
life NN o
on IN o
the DT o
Short-Form-36 NNP o
( ( o
SF-36 NNP o
) ) o
Acute NNP o
Health NNP o
Survey NNP o
and CC o
both DT o
patients NNS o
' POS o
and CC o
investigators NNS o
' POS o
overall JJ o
assessment NN o
of IN o
efficacy NN o
. . o

RESULTS NNP N
At IN N
day NN N
15 CD N
, , N
the DT N
mean NN N
changes NNS N
in IN N
shoulder NN o
pain NN o
score NN o
from IN N
baseline NN N
in IN N
the DT N
oxaprozin NN i
and CC N
diclofenac NN i
groups NNS N
were VBD N
-5.85 JJ N
+/- JJ N
SD NNP N
4.62 CD N
and CC N
-5.54 JJ N
+/- JJ N
SD NNP N
4.41 CD N
, , N
respectively RB N
. . N

The DT N
difference NN o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
, , N
confirming VBG N
the DT N
hypothesis NN N
of IN N
the DT N
study NN N
that IN N
oxaprozin NN i
is VBZ N
as RB N
effective JJ N
as IN N
diclofenac NN i
. . i

Investigator-assessed JJ o
shoulder NN o
function NN o
improved VBN N
in IN N
both DT N
groups NNS N
but CC N
more JJR N
so RB N
in IN N
the DT N
oxaprozin NN N
group NN N
( ( N
p JJ N
= RB N
0.028 CD N
at IN N
day NN N
15 CD N
) ) N
. . N

Quality NN o
of IN o
life NN o
as IN o
measured VBN o
by IN o
SF-36 NNP o
total JJ o
score NN o
was VBD N
also RB N
improved VBN N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
with IN N
a DT N
trend NN N
toward IN N
greater JJR N
improvement NN N
in IN N
the DT N
oxaprozin NN i
group NN N
. . N

Furthermore RB N
, , N
a DT N
significantly RB N
more RBR N
favourable JJ N
effect NN o
on IN N
the DT N
SF-36 NNP o
'mental NNP o
health NN o
' '' o
item NN o
was VBD N
observed VBN N
in IN N
oxaprozin NN N
compared VBN N
with IN N
diclofenac-treated JJ N
patients NNS N
at IN N
day NN N
15 CD N
( ( N
p NN N
= RB N
0.0202 CD N
) ) N
. . N

As IN N
assessed VBN N
by IN N
investigators NNS N
, , N
the DT N
overall JJ N
efficacy NN N
of IN N
oxaprozin NN i
was VBD N
superior JJ N
to TO N
that DT N
for IN N
diclofenac NN i
at IN N
visit NN N
3 CD N
( ( N
8 CD N
+/- JJ N
1 CD N
days NNS N
) ) N
( ( N
p JJ N
= NNP N
0.0067 CD N
) ) N
. . N

Patients NNS p
also RB p
assessed VBD p
the DT p
overall JJ p
efficacy NN o
of IN p
oxaprozin NN i
as IN p
superior JJ p
to TO p
that DT p
of IN p
diclofenac NN i
at IN N
visits NNS N
3 CD N
( ( N
8 CD N
+/- JJ N
1 CD N
days NNS N
) ) N
( ( N
p JJ N
= NNP N
0.0235 CD N
) ) N
and CC N
4 CD N
( ( N
15 CD N
+/- JJ N
1 CD N
days NNS N
) ) N
( ( N
p JJ N
= NNP N
0.0272 CD N
) ) N
. . N

Only RB N
six CD N
adverse JJ o
events NNS o
, , N
all DT N
of IN N
which WDT N
were VBD N
mild NNS N
or CC N
moderate VB N
in IN N
intensity NN N
and CC N
occurred VBD N
in IN N
four CD N
diclofenac NN i
recipients NNS N
, , N
were VBD N
observed VBN N
in IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
As IN N
expected VBN N
, , N
once-daily JJ N
oxaprozin NN i
proved VBD N
to TO N
be VB N
as RB N
effective JJ N
as IN N
diclofenac NN i
three CD N
times NNS N
daily RB N
in IN N
reducing VBG N
the DT N
primary JJ N
efficacy NN N
variable NN N
of IN N
patient-assessed JJ o
shoulder NN o
pain NN o
score NN o
in IN N
patients NNS p
with IN p
periarthritis NN p
of IN p
the DT p
shoulder NN p
refractory NN p
to TO N
previous JJ N
treatments NNS N
with IN N
other JJ N
NSAIDs NNP N
. . N

Oxaprozin NNP i
was VBD N
shown VBN N
to TO N
be VB N
superior JJ N
to TO N
diclofenac VB i
in IN N
improving VBG N
shoulder NN o
function NN o
and CC N
was VBD N
considered VBN N
by IN N
investigators NNS N
and CC N
patients NNS N
to TO N
have VB N
greater JJR N
overall JJ N
efficacy NN N
than IN N
diclofenac NN i
. . i

In IN N
addition NN N
, , N
oxaprozin NN i
showed VBD N
a DT N
trend NN N
toward IN N
superior JJ N
results NNS N
in IN N
improving VBG N
patients NNS N
' POS N
quality NN o
of IN o
life NN o
compared VBN N
with IN N
diclofenac NN i
. . i

A DT N
trend NN N
towards VBZ N
better JJR N
tolerability NN o
results NNS o
for IN N
oxaprozin JJ i
compared VBN N
with IN N
diclofenac NN i
was VBD N
also RB N
noted VBN N
. . N

-DOCSTART- -X- O O

Parents NNS N
' POS N
Adoption NN N
of IN N
Social NNP i
Communication NNP i
Intervention NNP i
Strategies NNS i
: : i
Families NNS N
Including VBG N
Children NNP p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
Who NNP p
are VBP p
Minimally NNP p
Verbal NNP p
. . p

Notably RB N
absent NN N
from IN N
the DT N
intervention NN N
literature NN N
are VBP N
parent JJ N
training VBG N
programs NNS N
targeting VBG N
school-aged JJ p
children NNS p
with IN p
autism NN p
who WP p
have VBP p
limited VBN p
communication NN p
skills NNS p
( ( N
Tager-Flusberg NNP N
and CC N
Kasari NNP N
in IN N
Autism NNP N
Res NNP N
6:468-478 CD N
, , N
2013 CD N
) ) N
. . N

Sixty-one JJ p
children NNS p
with IN p
autism NN p
age NN p
5-8 JJ p
with IN p
minimal JJ p
spontaneous JJ p
communication NN p
received VBD p
a DT p
6-month JJ i
social JJ i
communication NN i
intervention NN i
including VBG i
parent NN i
training NN i
. . i

Parent-child JJ p
play NN p
interactions NNS p
were VBD N
coded VBN N
for IN N
parents NNS N
' POS N
strategy NN o
implementation NN o
and CC N
children NNS N
's POS N
time NN N
jointly RB o
engaged VBN o
( ( N
Adamson NNP N
et RB N
al RB N
. . N

in IN N
J NNP N
Autism NNP N
Dev NNP N
Disord NNP N
39:84-96 CD N
, , N
2009 CD N
) ) N
. . N

Parents NNS p
mastered VBD o
an DT N
average NN N
of IN N
70 CD N
% NN N
of IN N
the DT N
strategies NNS N
. . N

Further JJ N
analyses NNS N
indicated VBD N
some DT N
gains NNS o
in IN o
implementation NN o
occurred VBD N
from IN N
mere JJ N
observation NN N
of IN N
sessions NNS N
, , N
while IN N
the DT N
greatest JJS N
gains NNS o
occurred VBD N
in IN N
the DT N
first JJ N
month NN N
of IN N
active JJ N
coaching NN N
and CC N
workshops NNS N
. . N

Children NNP p
's POS p
joint JJ o
engagement NN o
was VBD N
associated VBN N
with IN N
parents NNS N
' POS N
implementation NN o
success NN o
across IN N
time NN N
demonstrating VBG N
parents NNS p
' POS p
implementation NN p
was VBD N
relevant JJ N
to TO N
children NNS p
's POS p
social JJ o
engagement NN o
. . o

-DOCSTART- -X- O O

Initial JJ N
clinical JJ N
experience NN N
with IN N
implantation NN i
of IN i
left JJ i
ventricular JJ i
lead NN i
guided VBN i
by IN i
Overlay NNP i
Ref NNP i
for IN N
the DT N
treatment NN N
of IN N
congestive JJ N
heart NN N
failure NN N
. . N

BACKGROUND NNP N
Cardiac NNP i
resynchronization NN i
therapy NN i
( ( i
CRT NNP i
) ) i
improves VBZ N
clinical JJ N
outcome NN o
in IN N
selected VBN p
patients NNS p
with IN p
advanced JJ p
congestive JJ p
heart NN p
failure NN p
. . p

The DT N
Overlay NNP N
Ref NNP N
technique NN N
may MD N
facilitate VB N
the DT N
procedure NN N
for IN N
implanting VBG N
left JJ N
ventricular NN N
( ( N
LV NNP N
) ) N
pacing VBG N
leads NNS N
to TO N
deliver VB N
CRT NNP i
. . i

AIM NNP N
To TO N
assess VB N
the DT N
feasibility NN N
of IN N
deploying VBG N
a DT N
LV NNP N
pacing VBG N
lead NN N
into IN N
a DT N
coronary JJ N
sinus NN N
side NN N
branch NN N
guided VBN N
by IN N
Overlay NNP i
Ref NNP i
. . i

METHODS NNP N
Data NNP N
from IN N
88 CD p
consecutive JJ p
patients NNS p
who WP p
met VBD p
the DT p
CRT NNP i
implantation NN p
criteria NNS p
in IN p
our PRP$ p
hospital NN p
between IN p
28 CD p
November NNP p
2007 CD p
and CC p
30 CD p
December NNP p
2009 CD p
were VBD p
randomly RB p
assigned VBN p
to TO p
two CD p
groups NNS p
. . p

Forty-four CD p
patients NNS p
underwent JJ p
CRT NNP i
device NN i
implantation NN i
using VBG i
Overlay NNP i
Ref NNP i
to TO i
guide VB i
target NN i
vein JJ i
selection NN i
and CC i
advance VB i
a DT i
specifically RB i
designed VBN i
pacing VBG i
lead NN i
into IN i
the DT i
target NN i
vein NN i
( ( i
Overlay NNP i
Ref NNP i
group NN i
) ) i
; : i
44 CD i
patients NNS i
were VBD i
conventionally RB i
implanted VBN i
( ( i
control VB i
group NN i
) ) i
. . i

RESULTS NNP N
LV NNP i
lead JJ i
implantation NN i
was VBD N
successful JJ N
in IN N
all DT N
patients NNS N
. . N

Mean NNP N
CRT NNP o
total JJ o
procedure NN o
times NNS o
( ( o
skin-to-skin JJ o
) ) o
were VBD N
: : N
Overlay NNP i
Ref NNP i
group NN N
, , N
80.7 CD N
? . N
18.0 CD N
min NN N
; : N
control NN N
group NN N
, , N
98.5 CD N
? . N
32.2 CD N
min NN N
; : N
p CC N
= $ N
0.029 CD N
. . N

Mean JJ o
placement NN o
of IN o
LV NNP o
pacing VBG o
lead NN o
into IN o
target NN o
vein JJ o
times NNS o
were VBD o
: : i
Overlay NNP i
Ref NNP i
group NN i
, , N
16.2 CD N
? . N
7.7 CD N
min NN N
; : N
control NN N
group NN N
, , N
36.4 CD N
? . N
23.4 CD N
min NN N
; : N
p=0.004 NN N
. . N

Mean NNP N
total JJ o
fluoroscopy NN o
times NNS o
were VBD o
: : i
Overlay NNP i
Ref NNP i
group NN N
, , N
13.6 CD N
? . N
4.3 CD N
min NN N
; : N
control NN N
group NN N
, , N
23.8 CD N
? . N
15.7 CD N
min NN N
; : N
p=0.007 NN N
. . N

Mean NNP N
LV NNP o
lead NN o
fluoroscopy NN o
times NNS o
were VBD N
: : N
Overlay NNP i
Ref NNP i
group NN i
, , N
5.7 CD N
? . N
2.9 CD N
min NN N
; : N
control NN N
group NN N
, , N
14.4 CD N
? . N
4.6 CD N
min NN N
; : N
p=0.003 NN N
. . N

No DT N
major JJ N
complications NNS o
occurred VBD o
. . N

CONCLUSIONS NNP i
Overlay NNP i
Ref NNP i
facilitates VBZ i
location NN N
of IN N
and CC N
entry NN N
into IN N
the DT N
coronary JJ N
sinus NN N
, , N
and CC N
shortens VBZ N
the DT o
duration NN o
of IN o
LV NNP o
pacing VBG o
lead JJ o
implantation NN o
into IN o
the DT o
target NN N
vein NN N
. . N

-DOCSTART- -X- O O

Reliance NN N
on IN N
visual JJ o
information NN o
after IN N
stroke NN N
. . N

Part NNP N
II NNP N
: : N
Effectiveness NN N
of IN N
a DT N
balance NN N
rehabilitation NN i
program NN i
with IN N
visual JJ i
cue NN i
deprivation NN i
after IN p
stroke NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
balance NN N
rehabilitation NN i
with IN i
visual JJ i
cue NN i
deprivation NN i
improves VBZ N
balance NN o
more RBR N
effectively RB N
than IN N
rehabilitation NN i
with IN i
free JJ i
vision NN i
. . i

DESIGN NNP N
Single-blind NNP N
, , N
randomized VBD N
controlled VBN N
trial NN N
. . N

SETTING NNP N
Public NNP p
rehabilitation NN p
center NN p
in IN p
France NNP p
. . p

PARTICIPANTS NNP N
Twenty NNP p
patients NNS p
with IN p
hemiplegia NN p
after IN p
a DT p
single-hemisphere JJ p
stroke NN p
that WDT p
occurred VBD p
at IN p
least JJS p
12 CD p
months NNS p
before IN p
the DT p
study NN p
. . p

INTERVENTION NNP N
Patients NNPS i
were VBD i
randomly RB i
assigned VBN i
to TO i
1 CD i
of IN i
2 CD i
balance NN i
rehabilitation NN i
programs-with NN i
and CC i
without IN i
visual JJ i
cue NN i
deprivation NN i
. . i

In IN i
all DT i
other JJ i
respects NNS i
, , i
the DT i
programs NNS i
were VBD i
identical JJ i
. . i

Each DT N
lasted VBD N
for IN N
1 CD N
hour NN N
and CC N
was VBD N
implemented VBN N
5 CD N
days NNS N
a DT N
week NN N
for IN N
4 CD N
weeks NNS N
. . N

All DT p
patients NNS p
completed VBD p
the DT p
program NN p
. . p

Mean NNP N
outcome JJ N
measures NNS N
Balance NNP o
under IN N
6 CD N
sensory JJ N
conditions NNS N
was VBD N
assessed VBN N
by IN N
computerized JJ N
dynamic JJ o
posturography NN o
( ( o
EquiTest NNP o
) ) o
, , o
gait JJ o
velocity NN o
, , o
timed VBD o
stair NN o
climbing NN o
, , o
and CC o
self-assessment NN o
of IN o
ease NN o
of IN o
gait NN o
before IN o
and CC o
after IN o
program NN o
completion NN o
. . o

RESULTS NNP N
After IN N
completing VBG N
the DT N
program NN N
, , N
balance NN o
, , o
gait JJ o
velocity NN o
, , o
and CC o
self-assessment NN o
of IN o
gait NN o
improved VBN N
significantly RB N
in IN N
all DT N
patients NNS N
. . N

The DT N
improvements NNS N
in IN N
gait NN o
velocity NN o
( ( N
P= NNP N
.03 NNP N
) ) N
and CC N
timed VBD o
stair NN o
climbing VBG o
( ( N
P= NNP N
.01 NNP N
) ) N
correlated VBD N
significantly RB N
with IN N
improved JJ N
balance NN N
. . N

Balance NNP o
improved VBD N
more RBR N
in IN N
the DT N
vision-deprived JJ N
group NN N
than IN N
in IN N
the DT N
free-vision NN N
group NN N
. . N

CONCLUSIONS NNP N
Balance NNP o
improved VBD N
more RBR N
after IN N
rehabilitation NN N
with IN N
visual JJ i
deprivation NN i
than IN N
with IN N
free JJ i
vision NN i
. . i

Visual JJ N
overuse NN N
may MD N
be VB N
a DT N
compensatory NN N
strategy NN N
for IN N
coping VBG N
with IN N
initial JJ N
imbalance NN N
exacerbated VBN N
by IN N
traditional JJ N
rehabilitation NN N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
canine JJ p
parvoviral JJ N
enteritis NN N
with IN N
interferon-omega JJ i
in IN N
a DT N
placebo-controlled JJ N
challenge NN N
trial NN N
. . N

Canine NNP p
parvoviral JJ p
enteritis NN p
continues VBZ N
to TO N
cause VB N
significant JJ N
morbidity NN N
and CC N
mortality NN N
in IN N
dogs NNS p
worldwide RB N
, , N
and CC N
efficacious JJ N
antiviral JJ i
therapies NNS i
are VBP N
lacking VBG N
. . N

The DT N
present JJ N
trial NN N
was VBD N
aimed VBN N
at IN N
evaluating VBG N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
a DT N
recombinant JJ i
feline NN i
interferon NN i
( ( i
type JJ i
omega NN i
) ) i
preparation NN N
in IN N
the DT N
treatment NN N
of IN N
parvoviral JJ p
enteritis NN p
in IN p
dogs NNS p
. . p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
challenge NN N
trial NN N
was VBD N
performed VBN N
in IN N
beagle NN p
pups NNS p
( ( p
8-9 JJ p
weeks NNS p
) ) p
; : p
clinical JJ N
signs NNS N
, , N
body NN N
weight NN N
, , N
hematologic JJ N
parameters NNS N
, , N
and CC N
mortality NN N
were VBD N
monitored VBN N
for IN N
a DT N
period NN N
of IN N
14 CD N
days NNS N
after IN N
challenge NN N
. . N

Fourteen JJ p
animals NNS p
were VBD p
inoculated VBN i
with IN i
virulent JJ i
canine NN i
parvovirus NN i
; : i
10 CD p
animals NNS p
that WDT p
developed VBD p
clinical JJ p
signs NNS p
thereby RB p
meeting VBG p
the DT p
inclusion NN p
criteria NNS p
were VBD p
admitted VBN p
to TO p
the DT p
treatment NN p
phase NN p
in IN N
two CD N
randomly RB N
selected VBN N
groups NNS N
( ( i
placebo NN i
and CC N
IFN NNP i
) ) i
of IN N
equal JJ N
size NN N
. . N

The DT N
IFN NNP N
group NN N
received VBD N
daily RB N
intravenous JJ N
injections NNS N
of IN N
rFeIFN-omega JJ i
( ( N
2.5 CD N
MU/kg NNP N
) ) N
for IN N
three CD N
consecutive JJ N
days NNS N
. . N

The DT N
placebo NN i
group NN N
received VBD N
daily JJ N
injections NNS N
of IN N
saline NN i
without IN N
IFN NNP N
. . N

Both DT N
groups NNS N
of IN N
animals NNS N
received VBN N
individual JJ N
supportive JJ N
treatment NN N
consisting VBG N
of IN N
adjusted VBN N
diet NN N
and CC N
electrolyte JJ N
solution NN N
. . N

All DT N
five CD N
dogs NNS N
in IN N
the DT N
placebo NN N
group NN N
developed VBD N
fulminating VBG o
enteritis NN o
with IN o
typical JJ o
clinical JJ o
signs NNS o
and CC o
died VBD o
within IN N
10 CD N
days NNS N
post-inoculation NN N
( ( N
or CC N
6 CD N
days NNS N
post-treatment JJ N
) ) N
. . N

In IN N
the DT N
IFN-treated NNP N
group NN N
, , N
one CD N
animal NN N
died VBD o
on IN N
day NN N
2 CD N
after IN N
the DT N
treatment NN N
was VBD N
started VBN N
, , N
whereas IN N
the DT N
other JJ N
four CD N
dogs NNS N
survived VBD o
the DT N
challenge NN N
and CC N
gradually RB N
recovered VBN o
. . o

Our PRP$ N
data NNS N
confirm VBP N
that IN N
the DT N
rFeIFN-omega JJ i
can MD N
exert VB N
a DT N
significant JJ N
therapeutic JJ N
effect NN N
on IN N
dogs NNS p
with IN p
parvoviral JJ p
enteritis NN p
by IN N
improving VBG N
clinical JJ N
signs NNS N
and CC N
reducing VBG N
mortality NN N
. . N

-DOCSTART- -X- O O

The DT N
impact NN N
of IN N
a DT N
psychological JJ i
intervention NN i
on IN N
quality NN o
of IN o
life NN o
in IN N
non-metastatic JJ p
breast NN p
cancer NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
psychological JJ i
intervention NN i
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
quality NN o
of IN o
life NN o
and CC o
behaviour NN o
of IN N
women NNS p
diagnosed VBN p
with IN p
breast NN p
cancer NN p
. . p

36 CD p
consecutive JJ p
patients NNS p
with IN p
non-metastatic JJ p
breast NN p
cancer NN p
assigned VBD p
to TO p
surgery VB p
and CC p
systemic VB p
chemotherapy NN p
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
psychological JJ i
intervention NN i
( ( i
weekly JJ i
cognitive VBP i
individual JJ i
psychotherapy NN i
and CC i
bimonthly JJ i
family NN i
counselling VBG i
) ) i
or CC N
standard JJ i
follow-up NN i
. . i

Personality NNP o
( ( o
16-PF JJ o
and CC o
IIQ NNP o
) ) o
, , o
quality NN o
of IN o
life NN o
( ( o
FLIC NNP o
) ) o
, , o
and CC o
depression NN o
( ( o
BDI NNP o
) ) o
scores NNS o
were VBD N
the DT N
endpoints NNS N
for IN N
this DT N
study NN N
, , N
and CC N
the DT N
questionnaires NNS N
were VBD N
completed VBN N
by IN N
the DT N
patients NNS N
at IN N
diagnosis NN N
, , N
and CC N
up RB N
to TO N
9 CD N
months NNS N
after IN N
diagnosis NN N
. . N

Cognitive JJ N
psychotherapy NN N
and CC N
family NN N
counselling NN N
improved VBD N
both DT N
depression NN o
and CC o
quality NN o
of IN o
life NN o
indexes NNS o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Better NNP N
emotional JJ o
coping NN o
behaviours NNS o
were VBD N
also RB N
revealed VBN N
by IN N
some DT N
changes NNS N
in IN N
personality NN N
traits NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

-DOCSTART- -X- O O

Adjuvant NNP N
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vincristine NN i
, , i
and CC i
prednisone NN i
chemotherapy NN i
after IN N
radiation NN N
therapy NN N
in IN N
stage NN p
I PRP p
low-grade JJ p
and CC p
intermediate-grade JJ p
non-Hodgkin JJ p
lymphoma NN p
. . p

Results NNS N
of IN N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

BACKGROUND NNP N
In IN N
a DT N
prospective JJ N
randomized NN N
manner NN N
, , N
this DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
adjuvant JJ i
chemotherapy NN i
( ( i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vincristine NN i
, , i
and CC i
prednisone NN i
; : i
CHOP NNP i
) ) i
in IN N
patients NNS p
with IN p
Stage NNP p
I PRP p
non-Hodgkin JJ p
lymphoma NN p
( ( p
NHL NNP p
) ) p
who WP p
have VBP p
achieved VBN p
a DT p
complete JJ p
response NN p
( ( p
CR NNP p
) ) p
after IN p
radiation NN p
therapy NN p
( ( p
RT NNP p
) ) p
. . p

METHODS NNP N
Forty-four JJ p
patients NNS p
with IN p
clinical JJ p
or CC p
pathologic JJ p
Stage NN p
I PRP p
intermediate-grade VBP p
or CC p
low-grade JJ p
NHL NNP p
were VBD N
randomized VBN N
to TO N
receive VB i
regional JJ i
RT NNP i
alone RB i
( ( i
median JJ i
dose NN i
, , i
40 CD i
Gy NNP i
) ) i
or CC i
regional JJ i
RT NNP i
followed VBN i
by IN i
six CD i
cycles NNS i
of IN i
CHOP NNP i
chemotherapy NN i
. . i

There EX N
were VBD N
no DT N
differences NNS N
in IN N
clinical JJ N
and CC N
pathologic JJ N
characteristics NNS o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

RESULTS VB N
The DT N
median JJ o
follow-up NN o
was VBD N
7 CD N
years NNS N
( ( N
range NN N
, , N
2-10 JJ N
years NNS N
) ) N
. . N

The DT N
actuarial JJ o
relapse-free JJ o
survival NN o
( ( o
RFS NNP o
) ) o
rate NN o
for IN N
the DT N
RT NNP N
plus CC N
CHOP NNP N
group NN N
at IN N
7 CD N
years NNS N
was VBD N
83 CD N
% NN N
compared VBN N
with IN N
47 CD N
% NN N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
for IN N
the DT N
RT-alone NNP N
group NN N
. . N

The DT N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
for IN N
the DT N
two CD N
groups NNS N
was VBD N
88 CD N
% NN N
and CC N
66 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.2 CD N
) ) N
. . N

In IN N
patients NNS N
with IN N
intermediate-grade JJ N
NHL NNP N
, , N
the DT N
7-year JJ o
actuarial JJ o
RFS NNP o
for IN N
RT NNP N
and CC N
CHOP NNP N
was VBD N
86 CD N
% NN N
compared VBN N
with IN N
20 CD N
% NN N
for IN N
RT NNP N
alone RB N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
corresponding JJ o
actuarial JJ o
survival NN o
rates NNS o
were VBD N
92 CD N
% NN N
and CC N
47 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.08 CD N
) ) N
. . N

In IN N
patients NNS N
with IN N
low-grade JJ N
histologic JJ N
findings NNS N
, , N
the DT N
addition NN N
of IN N
adjuvant JJ N
CHOP NNP i
did VBD N
not RB N
improve VB N
RFS NNP o
( ( N
P NNP N
= NNP N
0.6 CD N
) ) N
or CC N
OS NNP N
. . N

All DT N
relapses VBZ N
in IN N
this DT N
study NN N
were VBD N
at IN N
sites NNS N
remote VBP N
from IN N
the DT N
initially RB N
involved JJ N
areas NNS N
, , N
and CC N
in IN N
5 CD N
of IN N
11 CD N
patients NNS N
( ( N
45 CD N
% NN N
) ) N
, , N
there EX N
were VBD N
recurrences NNS N
5 CD N
years NNS N
or CC N
longer JJR N
after IN N
initial JJ N
treatment NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
showed VBD N
that IN N
adjuvant JJ N
CHOP NNP i
chemotherapy NN i
significantly RB N
improves VBZ N
RFS NNP N
in IN N
patients NNS N
with IN N
Stage NNP N
I PRP N
intermediate-grade VBP N
NHL NNP N
who WP N
achieve VBP N
a DT N
CR NNP N
after IN N
regional-field JJ N
RT NNP N
. . N

The DT N
chemotherapeutic JJ N
regimen NNS N
favorably RB N
affected VBD N
their PRP$ N
probability NN o
of IN N
survival NN o
. . o

-DOCSTART- -X- O O

Nizatidine NNP i
versus NN N
ranitidine NN i
in IN N
the DT N
treatment NN N
of IN N
peptic JJ N
ulcer JJ N
disease NN N
: : N
report NN N
on IN N
the DT N
Dutch JJ N
investigation NN N
as IN N
part NN N
of IN N
a DT N
European NNP p
multicentre NN p
trial NN p
. . p

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
nizatidine NN i
was VBD N
evaluated VBN N
in IN N
comparison NN N
with IN N
ranitidine NN i
in IN N
230 CD p
patients NNS p
with IN p
endoscopically RB p
documented VBN p
gastric NN p
( ( p
71 CD p
) ) p
or CC p
duodenal JJ p
( ( p
159 CD p
) ) p
ulcers NNS p
. . p

Gastric NNP p
ulcer JJ p
patients NNS p
who WP p
satisfied VBD p
all DT p
criteria NNS p
for IN p
inclusion NN p
and CC p
exclusion NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
nizatidine VB i
300 CD i
mg NN i
nocte NN i
, , i
150 CD i
mg NN i
b.d NN i
. . i

or CC i
ranitidine VB i
150 CD i
mg NN i
b.d. NN N
, , N
duodenal JJ N
ulcer NN N
patients NNS N
to TO N
nizatidine VB i
300 CD i
mg JJ i
nocte NN i
or CC i
ranitidine VB i
300 CD i
mg NN i
nocte NN i
. . i

Endoscopic NNP o
healing NN o
was VBD N
defined VBN N
as IN N
complete JJ o
epithelialisation NN o
of IN o
all DT o
mucosal JJ o
lesions NNS o
. . o

Endoscopy NNP N
was VBD N
performed VBN N
at IN N
4 CD N
and CC N
, , N
if IN N
not RB N
healed VBN N
, , N
at IN N
8 CD N
weeks NNS N
. . N

Healing VBG o
rates NNS o
were VBD N
shown VBN N
to TO N
be VB N
comparable JJ N
for IN N
all DT N
treatment NN N
regimens NNS N
. . N

In IN N
both DT N
duodenal JJ N
ulcer NN N
treatment NN N
groups NNS N
, , N
and CC N
with IN N
both DT N
drugs NNS N
, , N
healing NN o
was VBD N
negatively RB N
influenced VBN N
by IN N
ulcer JJ o
size NN o
, , o
ulcer JJ o
number NN o
, , o
smoking VBG o
habits NNS o
and CC o
a DT o
disease NN o
duration NN o
of IN N
5 CD N
years NNS N
or CC N
more JJR N
. . N

Few JJ o
side NN o
effects NNS o
were VBD N
noted VBN N
. . N

Nizatidine NNP i
, , N
administered VBD N
as IN N
a DT N
300 CD N
mg NN N
nocte NN N
and CC N
as IN N
a DT N
150 CD N
mg NN N
b.d NN N
. . N

dose VB N
appeared VBD N
to TO N
be VB N
a DT N
safe JJ N
H2 NNP N
antagonist NN N
and CC N
was VBD N
as RB N
effective JJ o
as IN N
ranitidine NN i
in IN N
the DT N
treatment NN p
of IN p
duodenal JJ p
and CC p
gastric JJ p
ulceration NN p
. . p

-DOCSTART- -X- O O

Double-blind NNP N
comparison NN N
of IN N
liquid NN i
antacid NN i
and CC i
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
symptomatic JJ p
reflux NN p
esophagitis NN p
. . p

Although IN N
antacids NNS i
have VBP N
been VBN N
the DT N
mainstay NN N
of IN N
pharmacologic JJ N
therapy NN N
for IN N
reflux NN N
esophagitis NN N
, , N
their PRP$ N
effectiveness NN N
has VBZ N
not RB N
been VBN N
tested VBN N
in IN N
a DT N
placebo-controlled JJ i
double-blind JJ N
trial NN N
. . N

We PRP N
report VBP N
a DT N
double-blind JJ N
comparison NN N
of IN N
liquid JJ i
antacid NN i
vs NN i
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
reflux NN N
esophagitis NN N
in IN N
32 CD p
patients NNS p
with IN p
chronic JJ p
heartburn NN p
. . p

Entry NN p
criteria NNS p
included VBD p
the DT p
presence NN p
of IN p
symptomatic JJ p
gastroesophageal NN p
reflux NN p
confirmed VBN p
by IN p
both DT p
an DT p
acid JJ p
perfusion NN p
( ( p
Bernstein NNP p
) ) p
test NN p
and CC p
by IN p
intraesophageal JJ p
pH NN p
probe NN p
. . p

Drug NNP N
treatment NN N
consisted VBD N
of IN N
15 CD N
ml NN N
( ( N
80 CD N
mEq NN N
) ) N
doses VBZ N
of IN N
antacid NN i
( ( i
Maalox NNP i
Therapeutic NNP i
Concentration NNP i
, , N
William NNP N
H. NNP N
Rorer NNP N
) ) N
or CC N
placebo VB i
taken VBN N
7 CD N
times NNS N
daily RB N
, , N
ie NN N
, , N
1 CD N
and CC N
3 CD N
hr NN N
after IN N
meals NNS N
and CC N
at IN N
bedtime NN N
. . N

Both DT N
groups NNS N
showed VBD N
significant JJ N
improvement NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
in IN N
both DT N
frequency NN o
and CC o
severity NN o
of IN o
heartburn NN o
. . o

The DT N
time NN o
to TO o
reproduce VB o
heartburn NN o
with IN N
the DT N
timed JJ N
Bernstein NNP N
test NN N
was VBD N
increased VBN N
with IN N
both DT N
active JJ i
drug NN i
and CC N
placebo NN i
therapy NN i
. . i

The DT N
mean JJ N
increase NN N
was VBD N
402 CD N
% NN N
( ( N
41 CD N
+/- JJ N
20 CD N
sec NN N
to TO N
169 CD N
+/- JJ N
66 CD N
sec NN N
) ) N
for IN N
the DT N
placebo NN N
group NN N
and CC N
286 CD N
% NN N
( ( N
42 CD N
+/- JJ N
16 CD N
to TO N
120 CD N
+/- JJ N
57 CD N
sec NN N
) ) N
in IN N
the DT N
antacid NN N
group NN N
. . N

Both CC N
the DT N
antacid NN i
and CC N
placebo NN i
groups NNS N
showed VBD N
improvement NN N
in IN N
the DT N
degree NN o
of IN o
esophagitis NN o
as IN N
assessed VBN N
endoscopically RB N
. . N

The DT N
current JJ N
study NN N
asked VBD N
: : N
does VBZ N
regular JJ N
antacid NN N
therapy NN N
have VBP N
a DT N
favorable JJ N
influence NN N
on IN N
the DT N
natural JJ N
history NN N
of IN N
symptomatic JJ o
reflux NN o
esophagitis NN o
, , N
ie NN N
, , N
does VBZ N
therapy VB N
heal NN N
or CC N
otherwise RB N
change NN N
esophagitis NN N
so IN N
that DT N
painful JJ N
episodes NNS N
are VBP N
either RB N
less RBR N
frequent JJ N
, , N
less RBR N
severe JJ N
, , N
or CC N
both DT N
? . N
We PRP N
found VBD N
that IN N
the DT N
natural JJ o
history NN o
of IN o
symptomatic JJ o
reflux NN o
esophagitis NN o
was VBD N
to TO N
improve VB N
with IN N
either DT N
antacid NN i
or CC N
placebo NN i
. . i

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
antacid NN i
or CC N
placebo NN i
on IN N
the DT N
( ( N
short-term JJ N
) ) N
natural JJ o
history NN o
of IN o
the DT o
disease NN o
. . o

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
application NN N
of IN N
irradiated JJ N
drug-containing JJ i
porcine-cornea NN i
to TO N
patients NNS p
with IN p
ocular JJ p
burns NNS p
] FW p
. . N

OBJECTIVE UH N
To TO N
explore VB N
a DT N
new JJ N
method NN N
for IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
ocular JJ p
burns NNS p
. . p

METHODS NNP N
Fifty-five JJ p
cases NNS p
of IN p
patients NNS p
with IN p
ocular JJ p
burns NNS p
( ( p
in IN p
88 CD p
eyes NNS p
) ) p
were VBD N
randomly RB N
divided VBN N
into IN N
treatment NN N
and CC N
control NN N
groups NNS N
. . N

Thirty NNP N
cases NNS N
in IN N
treatment NN N
group NN N
with IN N
49 CD p
eyes NNS p
were VBD p
transplanted VBN p
with IN N
irradiated JJ i
drug-containing NN i
( ( i
ofloxacin UH i
, , i
acetyl JJ i
cysteine NN i
and CC i
reduced JJ i
glutathione NN i
) ) i
porcine-cornea NN i
. . i

25 CD N
cases NNS N
in IN N
control NN N
group NN N
with IN N
39 CD N
eyes NNS N
were VBD N
treated VBN N
with IN N
routine JJ N
program NN N
. . N

RESULTS NNP N
Thirty-two JJ N
eyes NNS o
were VBD o
rescued VBN o
in IN N
treatment NN N
group NN N
with IN N
the DT N
cure NN N
rate NN N
of IN N
65.3 CD N
% NN N
. . N

But CC N
only RB N
17 CD N
eyes NNS o
were VBD o
saved VBN o
in IN N
control NN N
group NN N
with IN N
the DT N
cure NN N
rate NN N
of IN N
43.59 CD N
% NN N
, , N
indicating VBG N
significant JJ N
difference NN N
of IN N
the DT N
cure NN o
rate NN o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Irradiated VBD N
drug-containing JJ N
porcine-cornea NN i
might MD N
well RB N
be VB N
an DT N
ideal JJ N
therapeutic JJ N
material NN N
for IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
ocular JJ p
burns NNS p
. . p

-DOCSTART- -X- O O

Once-daily JJ N
versus NN N
twice-daily RB N
intravenous JJ N
administration NN N
of IN N
vancomycin NN i
for IN N
infections NNS p
in IN p
hospitalized JJ p
patients NNS p
. . p

The DT N
efficacy NN N
and CC N
toxicity NN N
of IN N
once-daily JJ N
( ( N
od MD N
) ) N
versus VB N
twice-daily JJ N
( ( N
bd NN N
) ) N
dosing NN N
of IN N
vancomycin NN i
was VBD N
compared VBN N
in IN N
121 CD p
hospitalized JJ p
patients NNS p
. . p

Eighteen JJ p
patients NNS p
were VBD p
then RB p
withdrawn VBN p
from IN p
the DT p
study NN p
. . p

Clinical NNP N
and CC N
bacteriological JJ N
responses NNS N
were VBD N
evaluated VBN N
in IN N
all DT N
patients NNS p
( ( p
n JJ p
= NNP p
103 CD p
) ) p
. . N

Nephrotoxicity NNP o
was VBD N
assessed VBN N
in IN N
patients NNS N
who WP N
did VBD N
not RB N
receive VB N
nephrotoxic JJ N
agents NNS N
( ( N
n JJ N
= NNP N
76 CD N
) ) N
. . N

Ototoxicity NN o
was VBD N
assessed VBN N
in IN N
patients NNS N
who WP N
completed VBD N
two CD N
audiograms NNS N
and CC N
were VBD N
not RB N
receiving VBG N
ototoxic JJ N
agents NNS N
( ( N
n JJ N
= NNP N
63 CD N
) ) N
. . N

No DT o
significant JJ o
difference NN o
was VBD o
found VBN o
between IN o
the DT o
two CD o
groups NNS o
for IN o
favourable JJ o
clinical JJ o
response NN o
: : o
47/51 CD N
( ( N
92.1 CD N
% NN N
) ) N
and CC N
49/52 CD N
( ( N
94.2 CD N
% NN N
) ) N
in IN N
the DT N
od NN N
and CC N
bd NN N
groups NNS N
, , N
respectively RB N
. . N

In IN N
34 CD N
patients NNS N
vancomycin NN i
was VBD N
the DT N
only JJ o
effective JJ o
antibiotic JJ o
. . o

Fifteen NNP N
of IN N
18 CD N
( ( N
83.3 CD N
% NN N
) ) N
evaluated VBD N
episodes NNS N
in IN N
the DT N
od NN N
and CC N
12/16 CD N
( ( N
75.0 CD N
% NN N
) ) N
evaluated VBD N
episodes NNS N
in IN N
the DT N
bd NN N
group NN N
showed VBD N
a DT N
favourable JJ o
bacteriological JJ o
response NN o
. . o

There EX N
were VBD N
no DT o
significant JJ o
differences NNS o
between IN N
the DT N
od NN N
and CC N
bd NN N
groups NNS N
for IN N
all DT o
adverse JJ o
events NNS o
. . o

Nephrotoxicity NNP o
developed VBD o
in IN N
4/37 CD N
( ( N
10.8 CD N
% NN N
) ) N
and CC N
3/39 CD N
( ( N
7.7 CD N
% NN N
) ) N
patients NNS N
, , N
respectively RB N
. . N

Hearing NNP o
loss NN o
developed VBD N
in IN N
1/31 CD N
( ( N
3.2 CD N
% NN N
) ) N
and CC N
5/32 CD N
( ( N
15.6 CD N
% NN N
) ) N
. . N

Phlebitis NN o
occurred VBD N
in IN N
7/51 CD N
( ( N
13.7 CD N
% NN N
) ) N
and CC N
12/52 CD N
( ( N
23.0 CD N
% NN N
) ) N
. . N

Red JJ o
man NN o
syndrome NN o
occurred VBD N
in IN N
7/51 CD N
( ( N
13.7 CD N
% NN N
) ) N
and CC N
5/52 CD N
( ( N
9.6 CD N
% NN N
) ) N
in IN N
od NN N
and CC N
bd NN N
groups NNS N
, , N
respectively RB N
. . N

The DT N
efficacy NN o
and CC o
safety NN o
profile NN o
of IN o
od JJ N
administration NN N
of IN N
vancomycin NN i
is VBZ N
similar JJ o
to TO N
that DT N
of IN N
the DT N
customary JJ N
, , N
but CC N
less RBR N
convenient JJ N
, , N
bd JJ N
administration NN N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
of IN N
melphalan NN i
and CC i
cis-platinum JJ i
versus NN N
hexamethylmelamine NN i
, , i
adriamycin NN i
, , i
and CC i
cyclophosphamide NN i
in IN N
advanced JJ p
ovarian JJ p
cancer NN p
. . p

From CD N
May NNP p
1978 CD p
until IN p
November NNP p
1980 CD p
, , p
169 CD p
previously RB p
untreated JJ p
patients NNS p
with IN p
advanced JJ p
epithelial JJ p
ovarian JJ p
cancer NN p
were VBD N
entered VBN N
into IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
comparing VBG N
the DT N
combination NN N
of IN N
hexamethylmelamine NN i
, , i
Adriamycin NNP i
, , i
and CC i
cyclophosphamide NN i
( ( i
HAC NNP i
) ) i
to TO i
a DT i
combination NN i
of IN i
melphalan NN i
and CC i
cis-platinum NN i
. . i

Eleven JJ p
patients NNS p
were VBD N
excluded VBN N
from IN N
analysis NN N
and CC N
another DT N
5 CD N
patients NNS N
were VBD N
excluded VBN N
from IN N
response NN N
analysis NN N
. . N

Of IN N
153 CD p
patients NNS p
evaluable JJ p
for IN p
response NN p
, , p
there EX p
were VBD p
47 CD p
, , p
or CC p
30.7 CD p
% NN p
, , p
complete JJ o
responders NNS o
( ( o
all DT o
determined VBN o
surgically RB o
) ) o
, , N
6 CD N
partial JJ N
responders NNS N
, , N
and CC N
100 CD N
nonresponders NNS N
. . N

The DT N
response NN o
rate NN o
for IN N
the DT N
HAC NNP i
group NN N
was VBD N
31 CD N
% NN N
and CC N
for IN N
the DT N
melphalan-platinum JJ i
group NN N
was VBD N
37.8 CD N
% NN N
. . N

The DT N
overall JJ N
response NN N
rate NN N
was VBD N
34.6 CD N
% NN N
. . N

Residual JJ N
tumor NN N
diameter NN N
( ( N
less JJR N
than IN N
or CC N
greater JJR N
than IN N
2 CD N
cm NN N
) ) N
exerted VBD N
a DT N
statistically RB N
significant JJ N
effect NN N
on IN N
response NN N
-- : N
47.8 CD N
vs JJ N
24.4 CD N
% NN N
. . N

Of IN N
the DT N
47 CD N
complete JJ N
responders NNS N
, , N
7 CD N
, , N
or CC N
14.9 CD N
% NN N
, , N
have VBP N
relapsed VBN N
, , N
with IN N
the DT N
median JJ N
duration NN N
of IN N
remission NN N
of IN N
44+ CD N
months NNS N
. . N

Of IN N
the DT N
158 CD p
patients NNS p
evaluable JJ N
for IN N
survival NN o
, , N
90 CD N
patients NNS N
have VBP N
died VBN N
, , N
with IN N
a DT N
median JJ o
survival NN o
time NN o
of IN N
27.9 CD N
months NNS N
( ( i
HAC NNP i
= VBZ N
26.4 CD N
months NNS N
, , N
melphalan-platinum JJ i
= NN N
29.6 CD N
months NNS N
) ) N
. . N

Age NNP N
, , N
FIGO NNP N
stage NN N
, , N
histologic JJ N
grade NN N
, , N
and CC N
residual JJ N
disease NN N
all DT N
exerted VBD N
a DT N
significant JJ N
effect NN N
on IN N
survival JJ N
time NN N
. . N

Second-line JJ N
therapy NN N
in IN N
the DT N
treatment NN N
failures NNS N
was VBD N
of IN N
no DT N
benefit NN N
. . N

Hematologic NNP o
toxicity NN o
was VBD N
greater JJR N
in IN N
the DT N
melphalan-platinum JJ i
group NN N
. . N

Gastrointestinal NNP o
toxicity NN o
was VBD N
severe JJ N
in IN N
both DT N
groups NNS N
. . N

Other JJ o
toxicities NNS o
were VBD N
minor JJ N
and CC N
infrequent NN N
. . N

-DOCSTART- -X- O O

A DT N
possible JJ N
link NN N
between IN N
early JJ N
probiotic JJ i
intervention NN i
and CC N
the DT N
risk NN o
of IN o
neuropsychiatric JJ o
disorders NNS o
later RB p
in IN p
childhood NN p
: : p
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Recent NNP N
experimental JJ N
evidence NN N
suggests VBZ N
that IN N
gut NN N
microbiota NN N
may MD N
alter VB N
function NN N
within IN N
the DT N
nervous JJ N
system NN N
providing VBG N
new JJ N
insight NN N
on IN N
the DT N
mechanism NN N
of IN N
neuropsychiatric JJ N
disorders NNS N
. . N

METHODS NNP N
Seventy-five JJ p
infants NNS p
who WP p
were VBD p
randomized VBN p
to TO p
receive VB p
Lactobacillus NNP i
rhamnosus NN i
GG NNP i
( ( i
ATCC NNP i
53103 CD i
) ) i
or CC i
placebo NN i
during IN p
the DT p
first JJ p
6 CD p
mo NN p
of IN p
life NN p
were VBD p
followed-up JJ p
for IN p
13 CD p
y NN p
. . p

Gut NNP o
microbiota NN o
was VBD N
assessed VBN N
at IN N
the DT N
age NN N
of IN N
3 CD N
wk NN N
, , N
3 CD N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
24 CD N
mo NN N
, , N
and CC N
13 CD N
y NN N
using VBG i
fluorescein NN i
in IN i
situ JJ i
hybridization NN i
( ( i
FISH NNP N
) ) N
and CC N
qPCR $ N
, , N
and CC N
indirectly RB N
by IN N
determining VBG N
the DT o
blood NN o
group NN o
secretor NN o
type NN o
at IN o
the DT N
age NN N
of IN N
13 CD N
y NN N
. . N

The DT N
diagnoses NNS N
of IN N
attention NN o
deficit NN o
hyperactivity NN o
disorder NN o
( ( o
ADHD NNP o
) ) o
and CC o
Asperger NNP o
syndrome VBP o
( ( o
AS IN o
) ) o
by IN o
a DT N
child JJ N
neurologist NN N
or CC N
psychiatrist NN N
were VBD N
based VBN N
on IN N
ICD-10 NNP N
diagnostic JJ N
criteria NNS N
. . N

RESULTS NN N
At IN N
the DT N
age NN N
of IN N
13 CD N
y NNS N
, , N
ADHD NNP o
or CC o
AS NNP o
was VBD o
diagnosed VBN N
in IN N
6/35 CD N
( ( N
17.1 CD N
% NN N
) ) N
children NNS N
in IN N
the DT N
placebo NN N
and CC N
none NN N
in IN N
the DT N
probiotic JJ N
group NN N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

The DT o
mean NN o
( ( o
SD NNP o
) ) o
numbers NNS o
of IN o
Bifidobacterium NNP o
species NNS o
bacteria VBP o
in IN o
feces NNS o
during IN o
the DT o
first JJ o
6 CD o
mo NN o
of IN o
life NN o
was VBD o
lower JJR N
in IN N
affected JJ N
children NNS N
8.26 CD N
( ( N
1.24 CD N
) ) N
log NN N
cells/g NN N
than IN N
in IN N
healthy JJ N
children NNS N
9.12 CD N
( ( N
0.64 CD N
) ) N
log NN N
cells/g NN N
; : N
P NNP N
= VBD N
0.03 CD N
. . N

CONCLUSION NNP i
Probiotic NNP i
supplementation NN i
early RB i
in IN N
life NN N
may MD N
reduce VB N
the DT o
risk NN o
of IN o
neuropsychiatric JJ o
disorder NN o
development NN o
later RB o
in IN p
childhood NN p
possible JJ p
by IN N
mechanisms NNS N
not RB N
limited VBN N
to TO N
gut VB N
microbiota JJ N
composition NN N
. . N

-DOCSTART- -X- O O

International NNP p
Czech NNP i
and CC i
Slovak NNP i
cooperation NN i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
differentiated JJ p
thyroid NN p
cancer NN p
. . p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
paper NN N
is VBZ N
to TO N
present VB N
our PRP$ N
experience NN N
concerning VBG N
cooperation NN N
in IN N
the DT N
treatment NN N
of IN N
Slovak NNP p
patients NNS p
with IN p
differentiated JJ p
thyroid NN p
cancer NN p
in IN p
Slovak NNP p
and CC p
Czech NNP p
hospitals NNS p
. . p

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
demonstrate VB N
the DT N
means NNS o
of IN o
this DT o
cooperation NN o
and CC N
the DT N
results NNS o
of IN N
therapy NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
From NNP p
September NNP p
1991 CD p
to TO p
October NNP p
2005 CD p
in IN p
the DT p
Department NNP p
of IN p
Nuclear NNP p
Medicine NNP p
in IN p
Ostrava NNP p
357 CD p
patients NNS p
from IN p
the DT p
Slovak NNP p
Republic NNP p
with IN p
differentiated VBN p
thyroid NN p
cancers NNS p
( ( p
follicular JJ p
and CC p
papillary JJ p
) ) p
underwent NN p
complex JJ i
therapy NN i
. . i

They PRP p
were VBD p
diagnosed VBN p
and CC p
operated VBN p
due JJ p
to TO p
the DT p
cancer NN p
( ( p
near-total JJ p
thyroidectomy NN p
and CC p
removal NN p
of IN p
lymph JJ p
node JJ p
metastases NNS p
) ) p
in IN p
Slovak NNP p
hospitals NNS p
. . p

Then RB p
they PRP p
were VBD p
sent VBN p
to TO p
the DT p
Department NNP p
of IN p
Nuclear NNP p
Medicine NNP p
in IN p
Ostrava NNP p
in IN p
the DT p
Czech NNP p
Republic NNP p
. . p

In IN N
this DT N
department NN N
a DT N
radioiodine JJ i
ablation NN N
of IN N
thyroid JJ N
remnants NNS N
, , N
by IN N
means NNS N
of IN N
the DT N
treatment NN i
amount NN N
of IN N
radioiodine NN i
of IN N
a DT N
standard JJ N
activity NN N
of IN N
3.7 CD N
GBq NNP N
, , N
was VBD N
performed VBN N
, , N
and CC N
then RB N
a DT N
suppression NN N
and CC N
substitution NN i
therapy NN i
of IN N
thyroid JJ N
hormones NNS N
was VBD N
started VBN N
. . N

After IN N
3-6 JJ N
months NNS N
some DT N
patients NNS N
were VBD N
examined VBN N
by IN N
means NNS N
of IN N
diagnostic JJ o
whole JJ o
body NN o
scintigraphy NN o
after IN N
application NN N
of IN N
300 CD N
MBq NNP N
131I CD N
. . N

Some DT N
patients NNS N
were VBD N
treated VBN N
by IN N
means NNS N
of IN N
a DT N
standard JJ N
activity NN N
of IN N
7.4 CD N
GBq NNP N
131I CD N
and CC N
after IN N
5 CD N
days NNS N
whole JJ N
body NN N
scintigraphy NN N
( ( N
WBS NNP N
) ) N
was VBD N
performed VBN N
. . N

In IN N
both DT N
of IN N
these DT N
groups NNS N
of IN N
patients NNS N
the DT N
diagnostic JJ N
or CC N
therapeutic JJ N
radioiodine NN i
application NN N
was VBD N
done VBN N
after IN N
withdrawal NN N
of IN N
thyroid JJ N
hormone NN N
treatment NN N
. . N

If IN N
thyroglobulin JJ o
levels NNS o
were VBD N
low JJ N
and CC N
WBSs NNP o
were VBD N
negative JJ N
, , N
patients NNS N
were VBD N
followed VBN N
up RP N
in IN N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Martin NNP N
. . N

Patients NNS N
with IN N
radioiodine NN N
accumulated VBN N
metastases NNS N
were VBD N
again RB N
treated VBN N
with IN N
radioiodine NN i
in IN N
Ostrava NNP N
. . N

If IN N
indicated VBN N
, , N
external JJ N
radiation NN i
therapy NN i
targeted VBN N
on IN N
the DT N
neck NN N
and CC N
upper JJ N
mediastinum NN N
was VBD N
performed VBN N
in IN N
the DT N
Slovak NNP p
Republic NNP p
, , p
in IN p
the DT p
University NNP p
Hospital NNP p
in IN p
Martin NNP p
. . p

Newly RB N
formed VBN N
lymph JJ N
node NN N
metastases NNS N
were VBD N
surgically RB N
treated VBN N
in IN N
Slovakia NNP N
, , N
too RB N
. . N

Generally RB N
we PRP N
have VBP N
very RB N
good JJ o
treatment NN o
results NNS o
. . o

Also RB N
, , N
economically RB N
our PRP$ N
partnership NN N
is VBZ N
cost VBN o
effective JJ o
. . o

Our PRP$ N
collaboration NN N
also RB N
successfully RB N
continues VBZ N
after IN N
entrance NN N
of IN N
the DT N
Slovak NNP N
Republic NNP N
and CC N
the DT N
Czech NNP N
Republic NNP N
to TO N
the DT N
European NNP N
Union NNP N
in IN N
2004 CD N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
multi-centre JJ N
study NN N
show NN N
that IN N
international JJ N
Czech NNP N
and CC N
Slovak NNP N
cooperation NN i
in IN N
the DT N
complex JJ N
therapy NN N
of IN N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancers NNS N
is VBZ N
successful JJ N
, , N
with IN N
high JJ N
efficacy NN N
. . N

The DT N
treatment NN N
results NNS N
were VBD N
very RB N
similar JJ N
to TO N
therapeutic JJ N
results NNS N
in IN N
our PRP$ N
patients NNS N
from IN N
the DT N
Czech NNP N
Republic NNP N
. . N

-DOCSTART- -X- O O

[ JJ N
Psychoexperimental NNP N
studies NNS N
on IN N
the DT N
effect NN N
of IN N
a DT N
valepotriate JJ i
combination NN i
as RB p
well RB p
as IN p
the DT p
combined JJ p
effects NNS p
of IN p
valtratum NN i
and CC i
alcohol NN i
] NN i
. . N

-DOCSTART- -X- O O

Injection NN o
pain NN o
with IN N
propofol NN i
. . i

Reduction NN N
with IN N
aspiration NN N
of IN N
blood NN N
. . N

A DT N
randomised JJ N
, , N
controlled VBN N
, , N
single-blind NN N
study NN N
was VBD N
performed VBN N
on IN N
100 CD p
patients NNS p
to TO N
investigate VB N
a DT N
new JJ N
method NN N
of IN N
reducing VBG N
pain NN o
on IN N
propofol NN i
injection NN N
. . N

Aspiration NNP N
of IN N
2 CD N
ml NN N
of IN N
the DT N
patient NN N
's POS N
blood NN N
into IN N
a DT N
syringe NN N
of IN N
propofol NN i
immediately RB N
before IN N
injection NN N
was VBD N
compared VBN N
with IN N
the DT N
addition NN N
of IN N
lignocaine NN i
20 CD i
mg NN i
or CC i
normal JJ i
saline JJ i
2 CD i
ml NN i
to TO i
the DT i
propofol NN i
before IN i
injection NN i
. . i

The DT N
addition NN N
of IN N
blood NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
in IN N
reducing VBG o
pain NN o
on IN o
injection NN o
than IN N
the DT N
addition NN N
of IN N
saline NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
was VBD N
not RB N
significantly RB N
more RBR N
effective JJ o
than IN N
the DT N
addition NN N
of IN N
lignocaine NN N
. . N

-DOCSTART- -X- O O

Results NNS N
of IN N
a DT N
phase NN N
I/II NNP N
trial NN N
of IN N
recombinant JJ i
human JJ i
granulocyte-macrophage NN i
colony-stimulating NN i
factor NN i
in IN N
very RB p
low JJ p
birthweight NN p
neonates NNS p
: : p
significant JJ N
induction NN N
of IN N
circulatory NN N
neutrophils NNS N
, , N
monocytes NNS N
, , N
platelets NNS N
, , N
and CC N
bone NN N
marrow NN N
neutrophils NNS N
. . N

Neonates NNS N
, , N
especially RB N
those DT p
of IN p
very RB p
low JJ p
birthweight NN p
( ( p
VLBW NNP p
) ) p
, , N
have VBP N
an DT N
increased VBN N
risk NN N
of IN N
nosocomial JJ N
infections NNS N
secondary JJ N
to TO N
deficiencies NNS N
in IN N
development NN N
. . N

We PRP N
previously RB N
demonstrated VBD N
that IN N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( N
GM-CSF NNP N
) ) N
production NN N
and CC N
mRNA JJ N
expression NN N
from IN N
stimulated VBN N
neonatal JJ N
mononuclear JJ N
cells NNS N
are VBP N
significantly RB N
less JJR N
than IN N
that DT N
from IN N
adult NN N
cells NNS N
. . N

Recombinant JJ i
murine JJ i
GM-CSF NNP i
administration NN i
to TO N
neonatal JJ N
rats NNS N
has VBZ N
resulted VBN N
in IN N
neutrophilia JJ N
, , N
increased JJ N
neutrophil NN N
production NN N
, , N
and CC N
increased VBD N
survival NN N
of IN N
pups NNS N
during IN N
experimental JJ N
Staphylococcus NNP N
aureus NN N
sepsis NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
sought VBD N
to TO N
determine VB N
the DT N
safety NN N
and CC N
biologic JJ N
response NN N
of IN N
recombinant JJ i
human JJ i
( ( i
rhu NN i
) ) i
GM-CSF NNP i
in IN N
VLBW NNP N
neonates NNS N
. . N

Twenty NNP p
VLBW NNP p
neonates NNS p
( ( p
500 CD p
to TO p
1,500 CD p
g NN p
) ) p
, , p
aged VBD p
< JJ p
72 CD p
hours NNS p
, , p
were VBD p
randomized VBN p
to TO N
receive VB N
either DT N
placebo NN i
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
rhuGM-CSF NN i
at IN N
5.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
, , N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
, , N
or CC N
10 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
given VBN N
via IN N
2-hour JJ N
intravenous JJ N
infusion NN N
for IN N
7 CD N
days NNS N
. . N

Complete JJ N
blood NN N
counts NNS N
, , N
differential NN N
, , N
and CC N
platelet NN N
counts NNS N
were VBD N
obtained VBN N
, , N
and CC N
tibial JJ N
bone NN N
marrow NN N
aspirate NN N
was VBD N
performed VBN N
on IN N
day NN N
8 CD N
. . N

Neutrophil NNP N
C3bi NNP N
receptor NN N
expression NN N
was VBD N
measured VBN N
at IN N
0 CD N
and CC N
24 CD N
hours NNS N
. . N

GM-CSF JJ o
levels NNS o
were VBD N
measured VBN N
by IN N
a DT N
sandwich JJ N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
at IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
rhuGM-CSF NN i
. . i

At IN N
all DT N
doses NNS N
, , N
rhuGM-CSF NN i
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
grade NN o
III NNP o
or CC o
IV NNP o
toxicity NN o
. . o

Within IN N
48 CD N
hours NNS N
of IN N
administration NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
circulating VBG o
absolute JJ o
neutrophil NN o
count NN o
( ( o
ANC NNP o
) ) o
at IN N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
and CC N
10.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
, , N
which WDT N
continued VBD N
for IN N
at IN N
least JJS N
24 CD N
hours NNS N
after IN N
discontinuation NN N
of IN N
rhuGM-CSF NN i
. . i

When WRB N
the DT N
ANC NNP N
was VBD N
normalized VBN N
for IN N
each DT N
patient NN N
's POS N
first JJ N
ANC NNP N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
ANC NNP o
on IN N
days NNS N
6 CD N
and CC N
7 CD N
at IN N
each DT N
dose JJ N
level NN N
. . N

By IN N
day NN N
7 CD N
, , N
all DT N
tested JJ N
doses NNS N
of IN N
rhuGM-CSF NN i
resulted VBD N
in IN N
an DT N
increase NN N
in IN N
the DT N
absolute NN o
monocyte NN o
count NN o
( ( o
AMC NNP o
) ) o
compared VBN N
with IN N
placebo-treated JJ N
neonates NNS N
. . N

In IN N
those DT N
receiving VBG N
rhuGM-CSF JJ i
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
, , N
there EX N
was VBD N
additionally RB N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
day NN o
7 CD o
and CC o
8 CD o
platelet NN o
count NN o
. . o

Tibial NNP N
bone NN N
marrow NN N
aspirates VBZ N
demonstrated VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
bone NN o
marrow NN o
neutrophil JJ o
storage NN o
pool NN o
( ( o
BM NNP o
NSP NNP o
) ) o
at IN N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
and CC N
10.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
. . N

Neutrophil NNP o
C3bi NNP o
receptor NN o
expression NN o
was VBD N
significantly RB N
increased VBN N
24 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
rhuGM-CSF NN i
at IN N
5.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
. . N

The DT N
elimination NN N
half-life NN N
( ( N
T1/2 NNP N
) ) N
of IN N
rhuGM-CSF NN N
was VBD N
1.4 CD N
+/- JJ N
0.8 CD N
to TO N
3.9 CD N
+/- JJ N
2.8 CD N
hours NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Cross-modal JJ N
attention-switching NN N
is VBZ N
impaired VBN N
in IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

This DT N
investigation NN N
aimed VBN N
to TO N
determine VB N
if IN N
children NNS p
with IN p
ASD NNP p
are VBP N
impaired VBN N
in IN N
their PRP$ N
ability NN N
to TO N
switch VB N
attention NN N
between IN N
different JJ N
tasks NNS N
, , N
and CC N
whether IN N
performance NN N
is VBZ N
further RB N
impaired JJ N
when WRB N
required VBN N
to TO N
switch VB N
across IN N
two CD N
separate JJ N
modalities NNS N
( ( N
visual JJ N
and CC N
auditory NN N
) ) N
. . N

Eighteen JJ p
children NNS p
with IN p
ASD NNP p
( ( p
9-13 CD p
years NNS p
old JJ p
) ) p
were VBD p
compared VBN p
with IN p
18 CD p
typically-developing JJ p
children NNS p
matched VBN p
with IN p
the DT p
ASD NNP p
group NN p
for IN p
mental JJ p
age NN p
, , p
and CC p
also RB p
with IN p
18 CD p
subjects NNS p
with IN p
learning VBG p
difficulties NNS p
matched VBN p
with IN p
the DT p
ASD NNP p
group NN p
for IN p
mental JJ p
and CC p
chronological JJ p
age NN p
. . p

Individuals NNS N
alternated VBD N
between IN N
two CD i
different JJ i
visual JJ i
tasks NNS i
, , i
and CC i
between IN i
a DT i
different JJ i
visual JJ i
task NN i
and CC i
an DT i
auditory JJ i
task NN i
. . i

Children NNP N
with IN N
ASD NNP N
performed VBD o
worse JJR o
than IN N
both DT N
comparison JJ N
groups NNS N
at IN N
both DT N
switching VBG o
tasks NNS o
. . o

Moreover RB N
, , N
children NNS N
with IN N
ASD NNP N
had VBD N
greater JJR o
difficulty NN o
when WRB o
different JJ o
modalities NNS o
were VBD o
required VBN o
than IN o
where WRB o
only RB o
one CD o
modality NN o
was VBD o
required VBN o
in IN o
the DT o
switching NN o
task NN o
in IN N
comparison NN N
with IN N
participants NNS N
matched VBN N
in IN N
terms NNS N
of IN N
mental NN N
and CC N
chronological JJ N
age NN N
. . N

-DOCSTART- -X- O O

Torasemide NNP i
versus NN N
furosemide NN i
in IN N
cirrhosis NN p
: : p
a DT N
long-term JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
clinical JJ N
study NN N
. . N

The DT N
effects NNS N
of IN N
long-term JJ N
therapy NN N
( ( N
70 CD N
days NNS N
) ) N
with IN N
torasemide NN i
( ( N
20 CD N
mg/day NN N
) ) N
, , N
a DT N
new JJ N
loop NN N
diuretic JJ N
, , N
were VBD N
compared VBN N
with IN N
those DT N
of IN N
furosemide NN i
( ( N
50 CD N
mg/day NN N
) ) N
in IN N
a DT N
randomized JJ N
double-blind JJ N
trial NN N
. . N

Both DT N
drugs NNS N
were VBD N
administered VBN N
in IN N
association NN N
with IN N
spironolactone NN i
( ( N
200 CD N
mg/day NN N
) ) N
in IN N
28 CD p
nonazotemic JJ p
cirrhotic JJ p
patients NNS p
with IN p
controlled JJ p
ascites NNS p
. . p

The DT N
treatments NNS N
did VBD N
not RB N
modify VB N
creatinine JJ o
clearance NN o
and CC N
exhibited VBD N
a DT N
similar JJ N
effect NN N
on IN N
body NN o
weight NN o
, , o
urinary JJ o
volume NN o
, , N
and CC N
fractional JJ o
excretion NN o
of IN o
uric JJ o
acid NN o
, , o
sodium NN o
, , o
and CC o
chloride NN o
. . o

The DT N
effect NN N
of IN N
torasemide NN i
on IN N
fractional JJ o
potassium NN o
excretion NN o
was VBD N
lower JJR N
than IN N
that DT N
of IN N
furosemide NN i
. . i

Torasemide VB i
showed VBD N
higher JJR N
sparing VBG o
effect NN o
than IN N
furosemide NN i
on IN N
calcium NN o
, , o
inorganic JJ o
phosphate NN o
, , o
and CC o
magnesium NN o
excretion NN o
and CC N
stronger JJR N
action NN N
on IN N
free JJ o
water NN o
clearance NN o
. . o

No DT N
changes NNS N
in IN N
serum NN o
parameters NNS o
were VBD N
induced VBN N
by IN N
either DT N
treatment NN N
. . N

Two CD N
episodes NNS N
of IN N
hepatic JJ o
encephalopathy NN o
occurred VBD N
in IN N
the DT N
torasemide NN i
group NN N
. . N

In IN N
view NN N
of IN N
its PRP$ N
effects NNS o
on IN o
sodium NN o
and CC o
water NN o
excretion NN o
and CC N
on IN o
other JJ o
urinary JJ o
parameters NNS o
, , N
torasemide NN i
can MD N
represent VB N
an DT N
alternative JJ N
tool NN N
for IN N
the DT N
long-term JJ N
treatment NN N
of IN N
ascites NNS p
. . p

-DOCSTART- -X- O O

Reversal NNP N
of IN N
skeletal JJ N
effects NNS o
of IN N
endocrine NN i
treatments NNS i
in IN N
the DT N
Intergroup NNP N
Exemestane NNP N
Study NNP N
. . N

The DT N
adjuvant JJ N
use NN N
of IN N
aromatase NN i
inhibitors NNS i
in IN N
breast NN N
cancer NN N
is VBZ N
associated VBN N
with IN N
adverse JJ N
effects NNS N
on IN N
bone NN N
health NN N
. . N

We PRP N
previously RB N
reported VBD N
a DT N
decline NN N
in IN N
bone JJ N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
following VBG N
the DT N
switch NN N
from IN N
tamoxifen NN i
to TO N
exemestane VB i
in IN N
the DT N
Intergroup NNP N
Exemestane NNP N
Study NNP N
( ( N
IES NNP N
) ) N
. . N

Here RB N
we PRP N
report VBP N
effects NNS N
of IN N
endocrine JJ i
treatment NN i
withdrawal NN N
on IN N
BMD NNP N
, , N
bone NN N
turnover NN N
markers NNS N
( ( N
BTM NNP N
) ) N
and CC N
fracture JJ N
rates NNS N
. . N

4,724 CD p
patients NNS p
took VBD p
part NN p
in IN p
IES NNP p
, , p
and CC p
206 CD p
patients NNS p
were VBD p
included VBN p
in IN p
a DT p
bone NN p
sub-study NN p
. . p

BMD NNP N
and CC N
BTM NNP N
were VBD N
assessed VBN N
pre-randomization NN N
, , N
during IN N
and CC N
after IN N
the DT N
end NN N
of IN N
treatment NN N
( ( N
EOT NNP N
) ) N
. . N

To TO N
evaluate VB N
treatment NN N
withdrawal NN N
effects NNS N
, , N
12- JJ N
and CC N
24-month JJ N
post NN N
EOT NNP N
BMD NNP N
results NNS N
are VBP N
available JJ N
for IN N
122 CD N
and CC N
126 CD N
patients NNS N
, , N
respectively RB N
. . N

Similar JJ N
patient NN N
numbers NNS N
had VBD N
BTM NNP N
measured VBD N
post NN N
EOT NNP N
. . N

Following VBG N
treatment NN N
withdrawal NN N
, , N
the DT N
differences NNS N
in IN N
BMD NNP N
observed VBD N
between IN N
the DT N
two CD N
endocrine NN N
strategies NNS N
were VBD N
partially RB N
reversed VBN N
. . N

At IN N
24 CD N
months NNS N
from IN N
EOT NNP N
, , N
spine JJ o
BMD NNP o
increased VBN o
by IN N
1.53 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
0.63-2.43 CD N
; : N
p CC N
= VB N
0.001 CD N
) ) N
after IN N
stopping VBG N
exemestane NN N
and CC N
fell VBD N
by IN N
1.93 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-2.91 NNP N
to TO N
0.95 CD N
; : N
p NN N
= VBZ N
0.0002 CD N
) ) N
following VBG N
tamoxifen NN i
withdrawal NN N
. . N

A DT N
similar JJ N
pattern NN N
of IN N
changes NNS N
was VBD N
observed VBN N
at IN N
the DT N
hip NN N
. . N

At IN N
2 CD N
years NNS N
post RB N
EOT NNP N
, , N
BMD NNP o
changes NNS o
from IN o
baseline NN o
were VBD N
similar JJ N
with IN N
both DT N
treatment NN N
strategies NNS N
. . N

Corresponding VBG N
inverse JJ o
changes NNS o
in IN o
BTM NNP o
were VBD N
seen VBN N
, , N
with IN N
an DT N
increase NN N
following VBG N
tamoxifen JJ N
withdrawal NN N
and CC N
a DT N
reduction NN N
after IN N
exemestane NN N
. . N

A DT N
higher JJR N
number NN o
of IN o
fractures NNS o
occurred VBD o
during IN N
exemestane NN i
treatment NN N
, , N
but CC N
fracture NN o
rates NNS o
were VBD N
similar JJ N
after IN N
treatment NN N
withdrawal NN N
. . N

With IN N
the DT N
switch NN N
strategy NN N
used VBN N
in IN N
IES NNP N
, , N
the DT N
on IN N
treatment NN N
adverse JJ o
bone NN o
effects NNS o
of IN N
exemestane NN i
are VBP N
reversed VBN N
. . N

Ongoing VBG N
monitoring NN N
of IN N
BMD NNP N
is VBZ N
therefore RB N
not RB N
routinely RB N
required VBN N
. . N

-DOCSTART- -X- O O

Bilateral NNP i
transversus NN i
abdominis NN i
plane NN i
block NN i
does VBZ N
not RB N
decrease VB N
postoperative JJ N
pain NN N
after IN N
laparoscopic NN N
cholecystectomy NN N
when WRB N
compared VBN N
with IN N
local JJ i
anesthetic JJ i
infiltration NN i
of IN i
trocar NN i
insertion NN i
sites NNS i
. . i

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Transversus NNP i
abdominis NN i
plane NN i
( ( i
TAP NNP i
) ) i
block NN i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
pain NN N
and CC N
analgesic JJ N
requirements NNS N
after IN N
abdominal JJ N
surgery NN N
. . N

Our PRP$ N
hypothesis NN N
was VBD N
that IN N
bilateral JJ i
TAP NNP i
blocks NNS i
decrease NN N
pain NN N
after IN N
laparoscopic NN N
cholecystectomy NN N
when WRB N
compared VBN N
with IN N
local JJ i
anesthetic JJ i
infiltration NN i
of IN N
trocar NN N
insertion NN N
sites NNS N
. . N

METHODS NNP N
Eighty NNP p
patients NNS p
undergoing VBG p
laparoscopic JJ p
cholecystectomy NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
bilateral JJ i
TAP NNP i
blocks NNS i
or CC i
local JJ i
anesthetic JJ i
infiltration NN i
of IN i
trocar NN i
insertion NN i
sites VBZ i
with IN i
ropivacaine JJ i
0.5 CD i
% NN i
. . i

Postoperative JJ o
pain NN o
scores NNS N
and CC N
analgesic JJ N
use NN N
for IN N
the DT N
first JJ N
24 CD N
hrs NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Eighty NNP p
patients NNS p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

After IN N
exclusions NNS N
, , N
data NNS N
were VBD N
analyzed VBN N
on IN N
39 CD N
patients NNS N
in IN N
group NN N
T NNP N
( ( N
bilateral JJ N
TAP NNP i
block NN i
) ) i
and CC N
35 CD N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
infiltration NN N
) ) N
. . N

There EX N
was VBD N
no DT N
statistically RB o
significant JJ o
difference NN o
in IN N
pain NN o
scores NNS o
on IN o
the DT o
numeric JJ o
analog NN o
scale NN o
( ( N
0-10 JJ N
) ) N
between IN N
the DT N
groups NNS N
at IN N
4 CD N
hrs NN N
after IN N
surgery NN N
( ( N
P NNP N
= NNP N
0.18 CD N
) ) N
or CC N
during IN N
the DT N
24 CD N
hrs NN N
after IN N
surgery NN N
( ( N
P NNP N
= NNP N
0.23 CD N
) ) N
. . N

The DT N
time NN o
interval NN o
from IN o
anesthesia JJ o
start NN o
to TO o
surgery VB o
start NN o
was VBD N
greater JJR N
in IN N
group NN N
T NNP N
than IN N
group NN N
I PRP N
( ( N
48 CD N
vs RB N
35 CD N
mins NNS N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ o
difference NN o
found VBD N
in IN N
analgesic JJ o
use NN o
during IN N
the DT N
first JJ N
24 CD N
hrs NN N
after IN N
surgery NN N
. . N

CONCLUSIONS NNP N
Bilateral NNP i
ultrasound-guided JJ i
TAP NNP i
block NN i
is VBZ N
equivalent JJ N
to TO N
local JJ i
anesthetic JJ i
infiltration NN i
of IN N
trocar NN N
insertion NN N
sites VBZ N
for IN N
overall JJ N
postoperative JJ o
pain NN o
in IN N
a DT N
heterogeneous JJ N
group NN N
of IN N
patients NNS N
undergoing VBG N
laparoscopic JJ N
cholecystectomy NN N
. . N

-DOCSTART- -X- O O

Acceptability NNP N
of IN N
an DT N
Electronic JJ i
Self-Report JJ i
Assessment NNP i
Program NNP i
for IN N
patients NNS p
with IN p
cancer NN p
. . p

Eliciting VBG N
symptom NN N
and CC N
quality NN N
of IN N
life NN N
information NN N
from IN N
patients NNS N
is VBZ N
an DT N
important JJ N
component NN N
of IN N
medical JJ N
and CC N
nursing NN N
care NN N
processes VBZ N
. . N

Traditionally RB N
, , N
this DT N
information NN N
has VBZ N
been VBN N
collected VBN N
with IN N
paper NN N
and CC N
pencil NN N
. . N

However RB N
, , N
this DT N
approach NN N
presents VBZ N
several JJ N
barriers NNS N
, , N
including VBG N
delays NNS N
in IN N
receiving VBG N
information NN N
, , N
difficulty NN N
in IN N
integrating VBG N
responses NNS N
with IN N
electronic JJ N
records NNS N
, , N
and CC N
the DT N
time NN N
required VBN N
to TO N
manually RB N
score VB N
questionnaires NNS N
for IN N
measurement NN N
purposes NNS N
. . N

One CD N
solution NN N
that WDT N
addresses VBZ N
many JJ N
of IN N
these DT N
barriers NNS N
is VBZ N
the DT N
adoption NN i
of IN i
computerized JJ i
screening NN i
for IN i
symptom NN i
and CC i
quality-of-life JJ i
information NN i
. . i

This DT N
research NN N
explored VBD N
the DT N
acceptability NN o
of IN N
asking VBG N
symptom NN N
and CC N
quality-of-life JJ N
questions NNS N
using VBG i
the DT i
Electronic NNP i
Self NNP i
Report NNP i
Assessment-Cancer NNP i
program NN i
on IN i
wireless NN i
laptops NNS i
equipped VBN i
with IN i
touch-screen JJ i
format NN i
. . i

Acceptability NNP o
data NNS o
were VBD N
explored VBN N
with IN N
respect NN N
to TO N
whether IN N
any DT N
differences NNS N
may MD N
be VB N
attributed VBN N
to TO N
demographics NNS N
and CC N
symptom NN N
and CC N
quality-of-life NN o
levels NNS o
, , N
such JJ N
as IN N
depression NN o
and CC o
cognitive JJ o
and CC o
emotional JJ o
functioning NN o
. . o

This DT N
evaluation NN N
used VBN N
descriptive JJ N
and CC N
univariate JJ N
statistics NNS N
to TO N
examine VB N
data NNS N
from IN N
342 CD p
participants NNS p
from IN p
the DT p
ongoing JJ p
ESRA-C NNP i
randomized VBD p
clinical JJ p
trial NN p
. . p

Research NN p
participants NNS p
for IN p
the DT p
ESRA-C NNP i
study NN p
were VBD p
recruited VBN p
from IN p
the DT p
Seattle NNP p
Cancer NNP p
Care NNP p
Alliance NNP p
, , p
a DT p
consortium NN p
among IN p
the DT p
University NNP p
of IN p
Washington NNP p
Medical NNP p
Center NNP p
, , p
Fred NNP p
Hutchinson NNP p
Cancer NNP p
Research NNP p
Center NNP p
, , p
and CC p
Children NNP p
's POS p
Hospital NNP p
and CC p
Regional NNP p
Medical NNP p
Center NNP p
in IN p
Seattle NNP p
, , p
WA NNP p
. . p

The DT N
sample NN N
consisted VBD N
of IN N
342 CD p
adult NN p
participants NNS p
who WP p
completed VBD p
both DT p
baseline NN p
and CC p
follow-up JJ p
survey NN p
sessions NNS p
. . p

Medical NNP N
oncology NN N
represented VBD N
the DT N
largest JJS N
recruitment NN p
group NN p
( ( N
45.3 CD N
% NN N
) ) N
, , N
followed VBN N
by IN N
stem NN N
cell NN N
transplant NN N
( ( N
34.5 CD N
% NN N
) ) N
and CC N
radiation NN N
oncology NN N
( ( N
20.2 CD N
% NN N
) ) N
. . N

The DT N
primary JJ N
finding NN N
was VBD N
that IN N
patients NNS N
were VBD N
generally RB N
able JJ o
to TO o
use VB o
ESRA-C JJ o
quickly RB o
and CC N
without IN N
difficulty NN N
in IN N
a DT N
real-world JJ N
clinical JJ N
setting NN N
and CC N
that IN N
they PRP N
were VBD N
overall JJ N
quite RB N
satisfied VBN o
with IN o
the DT o
ESRA-C JJ o
program NN o
. . o

Significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
several JJ N
acceptability NN o
areas NNS o
with IN N
respect NN N
to TO N
demographics NNS N
and CC N
quality NN N
of IN N
life NN N
measures NNS N
such JJ N
as IN N
age NN N
, , N
sex NN N
, , N
and CC N
severe JJ N
distress NN N
. . N

This DT N
analysis NN N
confirms VBZ N
that IN N
the DT N
ESRA-C NNP i
application NN i
for IN i
collecting VBG i
symptom NN i
and CC i
quality NN i
of IN i
life NN i
information NN i
is VBZ N
easy JJ N
for IN N
patients NNS N
to TO N
use VB N
and CC N
acceptable JJ N
across IN N
a DT N
range NN N
of IN N
user JJ N
characteristics NNS N
. . N

We PRP N
intend VBP N
to TO N
build VB N
on IN N
our PRP$ N
work NN N
by IN N
using VBG N
the DT N
survey NN N
platform NN N
in IN N
other JJ N
modalities NNS N
while IN N
ensuring VBG N
that IN N
the DT N
patient NN N
's POS N
preferences NNS N
are VBP N
considered VBN N
at IN N
all DT N
times NNS N
. . N

-DOCSTART- -X- O O

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
fenfluramine NN i
in IN N
autistic JJ p
children NNS p
: : p
preliminary JJ N
analysis NN N
of IN N
a DT N
double-blind JJ N
study NN N
. . N

-DOCSTART- -X- O O

Double-blind NNP N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
on IN N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN o
a DT o
physostigmine JJ o
patch NN o
in IN N
patients NNS p
with IN p
senile JJ p
dementia NN p
of IN p
the DT p
Alzheimer NNP p
type NN p
. . p

Owing VBG N
to TO N
the DT N
pharmacokinetic JJ N
properties NNS N
of IN N
physostigmine NN N
when WRB N
administered VBN N
by IN N
conventional JJ N
routes NNS N
, , N
long-term JJ N
cholinergic JJ N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
is VBZ N
difficult JJ N
to TO N
manage VB N
. . N

In IN N
order NN N
to TO N
overcome VB N
the DT N
problems NNS N
associated VBN N
with IN N
the DT N
oral JJ N
and CC N
intravenous JJ N
application NN N
of IN N
physostigmine NN N
, , N
and CC N
to TO N
improve VB N
patients NNS o
' POS o
compliance NN o
, , N
a DT N
transdermal JJ N
therapeutic JJ N
system NN N
was VBD N
developed VBN N
. . N

The DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
this DT N
system NN N
were VBD N
evaluated VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
multicenter RBR N
study NN N
comparing VBG N
patches NNS N
containing VBG N
30 CD i
mg NN i
and CC i
60 CD i
mg NNS i
physostigmine NN i
with IN i
a DT i
placebo NN i
patch NN i
. . i

The DT N
clinical JJ N
trial NN N
followed VBD N
the DT N
basic JJ N
principles NNS N
of IN N
the DT N
various JJ N
guidelines NNS N
on IN N
the DT N
evaluation NN N
of IN N
anti-dementia JJ N
drugs NNS N
, , N
and CC N
included VBD N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
probable JJ p
Alzheimer NNP p
's POS p
disease NN p
. . p

A DT p
total NN p
of IN p
204 CD p
patients NNS p
with IN p
probable JJ p
Alzheimer NNP p
's POS p
disease NN p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Of IN p
these DT p
, , p
136 CD p
patients NNS p
were VBD p
eligible JJ p
for IN p
the DT p
according-to-protocol JJ p
analysis NN p
of IN p
efficacy NN p
, , p
167 CD p
subjects NNS p
for IN p
the DT p
intention-to-treat JJ p
analysis NN p
of IN p
efficacy NN p
, , p
and CC p
181 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
safety NN p
analysis NN p
. . p

In IN N
contrast NN N
to TO N
the DT N
hypothesis NN N
to TO N
be VB N
tested VBN N
, , N
the DT N
efficacy NN o
of IN N
physostigmine NN N
was VBD N
not RB N
superior JJ N
to TO N
that DT N
of IN N
placebo NN N
after IN N
a DT N
treatment NN N
period NN N
of IN N
24 CD N
weeks NNS N
. . N

On IN N
the DT N
contrary JJ N
, , N
there EX N
was VBD N
even RB N
a DT N
slight NN N
, , N
but CC N
not RB N
statistically RB N
significant JJ N
, , N
trend NN N
toward IN N
a DT N
better JJR N
outcome NN N
in IN N
the DT N
placebo NN p
group NN p
. . p

Median JJ o
physostigmine NN o
plasma NN o
concentrations NNS o
of IN N
approximately RB N
100 CD N
pg/ml NNS N
were VBD N
measured VBN N
, , N
showing VBG N
a DT N
high JJ N
degree NN N
of IN N
interindividual JJ N
variability NN N
and CC N
no DT N
linear JJ N
dose NN N
relationship NN N
between IN N
the DT N
30 CD N
mg NN N
and CC N
60 CD N
mg NN N
dosages NNS N
. . N

Plasma NNP o
cholinesterase NN o
activity NN o
was VBD N
not RB N
significantly RB N
affected VBN N
by IN N
physostigmine NN N
. . N

The DT N
physostigmine JJ N
patch NN N
application NN N
in IN N
doses NNS N
of IN N
30 CD N
mg NNS N
and CC N
60 CD N
mg NNS N
apparently RB N
did VBD N
not RB N
lead VB N
to TO N
physostigmine VB o
plasma JJ o
concentrations NNS o
that WDT N
were VBD N
sufficient JJ N
to TO N
compensate VB N
for IN N
cholinergic JJ N
deficiencies NNS N
in IN N
affected JJ N
brain NN N
areas NNS N
and CC N
produce VB N
clinical JJ N
benefits NNS N
. . N

Both CC N
the DT N
drug NN N
and CC N
the DT N
transdermal JJ N
system NN N
were VBD N
generally RB N
well RB o
tolerated VBN o
under IN N
the DT N
study NN N
conditions NNS N
. . N

Modifications NNS N
of IN N
the DT N
patch NN N
system NN N
may MD N
perhaps RB N
make VB N
it PRP N
possible JJ N
to TO N
achieve VB N
higher JJR N
physostigmine NN o
plasma NN o
concentrations NNS o
, , N
which WDT N
seem VBP N
to TO N
be VB N
required VBN N
to TO N
induce VB N
the DT N
expected JJ N
beneficial JJ o
effects NNS o
during IN N
long-term JJ N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
. . N

-DOCSTART- -X- O O

Lack NN N
of IN N
benefit NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
in IN N
the DT N
treatment NN N
of IN N
autism NN p
and CC p
pervasive JJ p
developmental JJ p
disorder NN p
. . p

BACKGROUND NNP N
Secretin NNP i
is VBZ N
a DT N
peptide JJ N
hormone NN N
that WDT N
stimulates VBZ N
pancreatic JJ N
secretion NN N
. . N

After IN N
recent JJ N
publicity NN N
about IN N
a DT N
child NN N
with IN N
autism NN N
whose WP$ N
condition NN N
markedly RB N
improved VBN N
after IN N
a DT N
single JJ N
dose NN N
of IN N
secretin NN i
, , N
thousands NNS p
of IN p
children NNS p
with IN p
autistic JJ p
disorders NNS p
may MD N
have VB N
received VBN N
secretin JJ i
injections NNS i
. . i

METHODS NNP N
We PRP N
conducted VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
in IN N
60 CD p
children NNS p
( ( p
age NN p
, , p
3 CD p
to TO p
14 CD p
years NNS p
) ) p
with IN p
autism NN p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
. . p

The DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
an DT N
intravenous JJ N
infusion NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
( ( N
0.4 CD N
microg NN N
per IN N
kilogram NN N
of IN N
body NN N
weight NN N
) ) N
or CC N
saline JJ i
placebo NN i
. . i

We PRP N
used VBD N
standardized JJ N
behavioral JJ N
measures NNS N
of IN N
the DT N
primary JJ N
and CC N
secondary JJ N
features NNS N
of IN N
autism NN N
, , N
including VBG N
the DT N
Autism NNP N
Behavior NNP N
Checklist NNP N
, , N
to TO N
assess VB N
the DT N
degree NN N
of IN N
impairment NN N
at IN N
base NN N
line NN N
and CC N
over IN N
the DT N
course NN N
of IN N
a DT N
four-week JJ N
period NN N
after IN N
treatment NN N
. . N

RESULTS NNP N
Of IN N
the DT N
60 CD p
children NNS p
, , p
4 CD p
could MD p
not RB p
be VB p
evaluated VBN p
- : N
2 CD N
received VBD N
secretin NN i
outside IN N
the DT N
study NN N
, , N
and CC N
2 CD N
did VBD N
not RB N
return VB N
for IN N
follow-up JJ N
. . N

Thus NNP N
, , N
56 CD p
children NNS p
( ( p
28 CD p
in IN p
each DT p
group NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

As IN N
compared VBN N
with IN N
placebo NN i
, , i
secretin FW i
treatment NN N
was VBD N
not RB N
associated VBN N
with IN N
significant JJ o
improvements NNS o
in IN o
any DT o
of IN o
the DT o
outcome NN o
measures NNS o
. . o

Among IN N
the DT N
children NNS N
in IN N
the DT N
secretin NN i
group NN N
, , N
the DT N
mean JJ o
total NN o
score NN o
on IN o
the DT o
Autism NNP o
Behavior NNP o
Checklist NNP o
at IN N
base NN N
line NN N
was VBD N
59.0 CD N
( ( N
range NN N
of IN N
possible JJ N
values NNS N
, , N
0 CD N
to TO N
158 CD N
, , N
with IN N
a DT N
larger JJR N
value NN N
corresponding VBG N
to TO N
greater JJR N
impairment NN N
) ) N
, , N
and CC N
among IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
it PRP N
was VBD N
63.2 CD N
. . N

The DT N
mean JJ o
decreases NNS o
in IN o
scores NNS o
over IN N
the DT N
four-week JJ N
period NN N
were VBD N
8.9 CD N
in IN N
the DT N
secretin NN i
group NN N
and CC N
17.8 CD N
in IN N
the DT N
placebo NN i
group NN N
( ( N
mean JJ N
difference NN N
, , N
-8.9 NNP N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
-19.4 VBP N
to TO N
1.6 CD N
; : N
P=0.11 NNP N
) ) N
. . N

None NN N
of IN N
the DT N
children NNS p
had VBD N
treatment-limiting JJ o
adverse JJ o
effects NNS o
. . o

After IN N
they PRP N
were VBD N
told VBN N
the DT N
results NNS N
, , N
69 CD N
percent NN N
of IN N
the DT N
parents NNS N
of IN N
the DT N
children NNS N
in IN N
this DT N
study NN N
said VBD N
they PRP N
remained VBD N
interested JJ N
in IN N
secretin NN i
as IN N
a DT N
treatment NN N
for IN N
their PRP$ N
children NNS N
. . N

CONCLUSIONS VB N
A DT N
single JJ N
dose NN N
of IN N
synthetic JJ N
human JJ i
secretin NN i
is VBZ N
not RB o
an DT o
effective JJ o
treatment NN o
for IN N
autism NN N
or CC N
pervasive JJ N
developmental JJ N
disorder NN N
. . N

-DOCSTART- -X- O O

Percutaneous JJ i
tracheostomy NN i
in IN N
critically RB p
ill JJ p
patients NNS p
: : p
a DT N
prospective JJ N
, , N
randomized JJ N
comparison NN N
of IN N
two CD N
techniques NNS N
. . N

OBJECTIVE NNP N
To TO N
prospectively RB N
compare VB N
two CD N
commonly RB N
used VBD N
methods NNS N
for IN N
percutaneous JJ i
dilational JJ i
tracheostomy NN i
( ( i
PDT NNP i
) ) i
in IN p
critically RB p
ill JJ p
patients NNS p
. . p

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
clinical JJ N
trial NN N
. . N

SETTING NN N
Trauma NNP p
and CC p
general JJ p
intensive JJ p
care NN p
units NNS p
of IN p
a DT p
university NN p
tertiary JJ p
teaching NN p
hospital NN p
, , p
which WDT p
is VBZ p
also RB p
a DT p
level NN p
1 CD p
trauma NN p
center NN p
. . p

PATIENTS VB N
One CD p
hundred VBN p
critically RB p
ill JJ p
patients NNS p
with IN p
an DT p
indication NN p
for IN p
PDT NNP i
. . i

INTERVENTIONS NNP N
PDT NNP i
with IN i
the DT i
Ciaglia NNP i
technique NN i
using VBG i
the DT i
Ciaglia NNP i
PDT NNP i
introducer NN i
set NN i
and CC i
the DT i
Griggs NNP i
technique NN i
using VBG i
a DT i
Griggs NNP i
PDT NNP i
kit NN i
and CC i
guidewire NN i
dilating NN i
forceps NNS i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Surgical NNP o
time NN o
, , o
difficulties NNS o
, , o
and CC o
surgical JJ o
and CC o
anesthesia JJ o
complications NNS o
were VBD N
measured VBN N
at IN N
0-2 JJ N
hrs NN N
, , N
24 CD N
hrs NN N
, , N
and CC N
7 CD N
days NNS N
postprocedure NN N
. . N

Groups NNP N
were VBD N
well RB N
matched VBN N
, , N
and CC N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
two CD N
methods NNS N
in IN N
surgical JJ o
time NN o
or CC N
in IN N
anesthesia JJ o
complications NNS o
. . o

Major JJ o
bleeding VBG o
complications NNS o
were VBD N
4.4 CD N
times NNS N
more RBR N
frequent JJ N
with IN N
the DT N
Griggs NNP i
PDT NNP i
kit NN N
. . N

With IN N
the DT N
Ciaglia NNP i
PDT NNP i
kit NN N
, , N
both DT N
intraoperative JJ N
and CC N
at IN N
2 CD N
and CC N
24 CD N
hrs NN N
, , N
surgical JJ o
complications NNS o
were VBD N
less JJR N
common JJ N
( ( N
p JJ N
= NNP N
.023 NNP N
) ) N
and CC N
the DT N
procedure NN N
was VBD N
more RBR N
often RB N
completed VBN N
without IN N
expert JJ N
assistance NN N
( ( N
p JJ N
= NNP N
.013 NNP N
) ) N
. . N

Tracheostomy NNP o
bleeding NN o
was VBD N
not RB N
associated VBN N
with IN N
either DT N
anticoagulant JJ N
therapy NN N
or CC N
an DT N
abnormal JJ N
clotting NN N
profile NN N
. . N

Multivariate NNP o
analysis NN o
identified VBD N
the DT N
predictors NNS N
of IN N
PDT NNP N
complications NNS N
as IN N
the DT N
Griggs NNP N
PDT NNP N
kit NN N
( ( N
p JJ N
= NNP N
.027 NNP N
) ) N
and CC N
the DT N
Acute NNP o
Physiology NNP o
and CC o
Chronic NNP o
Health NNP o
Evaluation NNP o
( ( o
APACHE NNP o
) ) o
II NNP o
score NN o
( ( N
p JJ N
= NNP N
.041 NNP N
) ) N
. . N

The DT N
significant JJ N
predictors NNS N
of IN N
time NN N
required VBN N
to TO N
complete VB N
PDT NNP i
were VBD N
the DT N
APACHE NNP o
II NNP o
score NN o
( ( N
p JJ N
= NNP N
.041 NNP N
) ) N
, , N
a DT N
less RBR N
experienced JJ N
operator NN N
( ( N
p JJ N
= NNP N
.0001 NNP N
) ) N
, , N
and CC N
a DT N
female JJ N
patient NN N
( ( N
p JJ N
= NNP N
.013 NNP N
) ) N
. . N

CONCLUSIONS JJ N
Patients NNPS p
experiencing VBG p
PDT NNP i
with IN N
the DT N
Ciaglia NNP N
PDT NNP N
kit NN N
had VBD N
a DT N
lower JJR o
surgical JJ o
complication NN o
rate NN o
( ( N
2 CD N
% NN N
vs. FW N
25 CD N
% NN N
) ) N
, , N
less RBR o
operative JJ o
and CC o
postoperative JJ o
bleeding NN o
, , N
and CC N
less RBR N
overall JJ o
technical JJ o
difficulties NNS o
than IN N
did VBD N
patients NNS p
undergoing VBG p
PDT NNP p
with IN N
the DT N
Griggs NNP i
PDT NNP i
kit NN N
. . N

Ciaglia NNP i
PDT NNP i
is VBZ N
, , N
therefore RB N
, , N
the DT N
preferred JJ N
technique NN N
for IN N
percutaneous JJ p
tracheostomy NN p
in IN p
critically RB p
ill JJ p
patients NNS p
. . p

-DOCSTART- -X- O O

Nicotinic JJ i
acid NN i
as IN N
therapy NN N
for IN N
dyslipidemia NN N
in IN N
non-insulin-dependent JJ p
diabetes NNS p
mellitus NN p
. . p

Recently RB N
, , N
nicotinic JJ i
acid NN i
has VBZ N
been VBN N
recommended VBN N
as IN N
a DT N
first-line JJ N
hypolipidemic JJ N
drug NN N
. . N

To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
nicotinic JJ N
acid NN N
in IN N
dyslipidemic JJ p
patients NNS p
with IN p
non-insulin-dependent JJ p
diabetes NNS p
mellitus VBP p
, , p
13 CD p
patients NNS p
were VBD p
treated VBN p
in IN p
a DT p
randomized JJ p
crossover NN p
trial NN p
. . p

Patients NNS N
received VBD N
either RB N
nicotinic JJ i
acid NN i
( ( N
1.5 CD N
g NN N
three CD N
times NNS N
daily RB N
) ) N
or CC N
no DT i
therapy NN i
( ( N
control JJ N
period NN N
) ) N
for IN N
8 CD N
weeks NNS N
each DT N
. . N

Compared VBN N
with IN N
the DT N
control NN N
period NN N
, , N
nicotinic JJ i
acid NN i
therapy NN N
reduced VBD N
the DT N
plasma NN o
total JJ o
cholesterol NN o
level NN o
by IN N
24 CD N
% NN N
, , N
plasma JJ o
triglyceride IN o
level NN o
by IN N
45 CD N
% NN N
, , N
very-low-density NN o
lipoprotein NN o
cholesterol NN o
level NN o
by IN N
58 CD N
% NN N
, , N
and CC N
low-density NN o
lipoprotein NN o
cholesterol NN o
level NN o
by IN N
15 CD N
% NN N
, , N
and CC N
it PRP N
increased VBD N
the DT N
high-density NN o
lipoprotein NN o
cholesterol NN o
level NN o
by IN N
34 CD N
% NN N
. . N

However RB N
, , N
nicotinic JJ i
acid NN i
therapy NN N
resulted VBD N
in IN N
the DT N
deterioration NN o
of IN o
glycemic JJ o
control NN o
, , N
as IN N
evidenced VBN N
by IN N
a DT N
16 CD N
% NN N
increase NN N
in IN N
mean JJ o
plasma NN o
glucose JJ o
concentrations NNS o
, , N
a DT N
21 CD N
% NN N
increase NN N
in IN N
glycosylated JJ o
hemoglobin NN o
levels NNS o
, , N
and CC N
the DT N
induction NN N
of IN N
marked JJ o
glycosuria NN o
in IN N
some DT N
patients NNS N
. . N

Furthermore NNP N
, , N
a DT N
consistent JJ N
increase NN N
in IN N
plasma JJ o
uric JJ o
acid NN o
levels NNS o
was VBD N
observed VBN N
. . N

Therefore RB N
, , N
despite IN N
improvement NN N
in IN N
lipid JJ o
and CC o
lipoprotein JJ o
concentrations NNS o
, , N
because IN N
of IN N
worsening VBG N
hyperglycemia NN o
and CC N
the DT N
development NN N
of IN N
hyperuricemia NN o
, , N
nicotinic JJ N
acid NN N
must MD N
be VB N
used VBN N
with IN N
caution NN N
in IN N
patients NNS p
with IN N
non-insulin-dependent JJ N
diabetes NNS N
mellitus VBP N
with IN N
dyslipidemia NN N
. . N

We PRP N
suggest VBP N
that IN N
the DT N
drug NN N
not RB N
be VB N
used VBN N
as IN N
a DT N
first-line JJ N
hypolipidemic JJ N
drug NN N
in IN N
patients NNS p
with IN p
non-insulin-dependent JJ p
diabetes NNS p
mellitus NN p
. . p

-DOCSTART- -X- O O

Treatment NN N
of IN N
brain NN N
metastases NNS N
of IN N
small-cell JJ N
lung NN N
cancer NN N
: : N
comparing NN N
teniposide NN i
and CC N
teniposide NN i
with IN i
whole-brain JJ i
radiotherapy NN i
-- : i
a DT i
phase NN N
III NNP N
study NN N
of IN N
the DT N
European JJ N
Organization NNP N
for IN N
the DT N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
Lung NNP N
Cancer NNP N
Cooperative NNP N
Group NNP N
. . N

PURPOSE NNP N
Approximately RB N
60 CD N
% NN N
of IN N
patients NNS p
with IN p
small-cell JJ p
lung NN p
cancer NN p
( ( p
SCLC NNP p
) ) p
develop VB N
brain NN N
metastases NNS N
. . N

Whole-brain JJ i
radiotherapy NN i
( ( i
WBRT NNP i
) ) i
gives VBZ N
symptomatic JJ N
improvement NN N
in IN N
more JJR N
than IN N
50 CD N
% NN N
of IN N
these DT N
patients NNS N
. . N

Because IN N
brain NN N
metastases NNS N
are VBP N
a DT N
sign NN N
of IN N
systemic JJ N
progression NN N
, , N
and CC N
chemotherapy NN N
was VBD N
found VBN N
to TO N
be VB N
effective JJ N
as IN N
well RB N
, , N
it PRP N
becomes VBZ N
questionable JJ N
whether IN N
WBRT NNP i
is VBZ N
the DT N
only JJ N
appropriate JJ N
therapy NN N
in IN N
this DT N
situation NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
phase NN N
III NNP N
study NN N
, , N
SCLC NNP p
patients NNS p
with IN p
brain NN p
metastases NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
teniposide NN i
with IN N
or CC N
without IN N
WBRT NNP i
. . i

Teniposide NNP i
120 CD N
mg/m NN N
( ( N
2 CD N
) ) N
was VBD N
given VBN N
intravenously RB N
three CD N
times NNS N
a DT N
week NN N
, , N
every DT N
3 CD N
weeks NNS N
. . N

WBRT NNP i
( ( N
10 CD N
fractions NNS N
of IN N
3 CD N
Gy NNP N
) ) N
had VBD N
to TO N
start VB N
within IN N
3 CD N
weeks NNS N
from IN N
the DT N
start NN N
of IN N
chemotherapy NN i
. . i

Response NNP N
was VBD N
measured VBN N
clinically RB o
and CC N
by IN N
computed JJ o
tomography NN o
of IN o
the DT o
brain NN o
. . o

RESULTS NNP N
One CD p
hundred VBD p
twenty NN p
eligible JJ p
patients NNS p
were VBD N
randomized VBN N
. . N

A DT N
57 CD N
% NN N
response NN o
rate NN o
was VBD N
seen VBN N
in IN N
the DT N
combined-modality NN N
arm NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
43 CD N
% NN N
to TO N
69 CD N
% NN N
) ) N
, , N
and CC N
a DT N
22 CD N
% NN N
response NN o
rate NN o
was VBD N
seen VBN N
in IN N
the DT N
teniposide-alone JJ i
arm NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
12 CD N
% NN N
to TO N
34 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Time NN o
to TO o
progression NN o
in IN o
the DT o
brain NN o
was VBD N
longer RBR o
in IN N
the DT N
combined-modality NN N
group NN N
( ( N
P=.005 NNP N
) ) N
. . N

Clinical JJ o
response NN o
and CC N
response NN o
outside IN N
the DT N
brain NN N
were VBD N
not RB N
different JJ N
. . N

The DT N
median JJ o
survival NN o
time NN o
was VBD N
3.5 CD N
months NNS N
in IN N
the DT N
combined-modality NN N
arm NN N
and CC N
3.2 CD N
months NNS N
in IN N
the DT N
teniposide-alone JJ i
arm NN N
. . N

Overall JJ o
survival NN o
in IN N
both DT N
groups NNS N
was VBD N
not RB N
different JJ N
( ( N
P=.087 NNP N
) ) N
. . N

CONCLUSION NNP N
Adding NNP N
WBRT NNP i
to TO N
teniposide VB N
results NNS N
in IN N
a DT N
much RB N
higher JJR N
response NN o
rate NN o
of IN N
brain NN N
metastases NNS N
and CC N
in IN N
a DT N
longer JJR N
time NN N
to TO N
progression NN N
of IN N
brain NN N
metastases NNS N
than IN N
teniposide RB i
alone JJ N
. . N

Survival NNP o
was VBD N
poor JJ N
in IN N
both DT N
groups NNS N
and CC N
not RB N
significantly RB N
different JJ N
. . N

-DOCSTART- -X- O O

Noradrenergic NNP N
moderation NN o
of IN N
working VBG N
memory NN N
impairments NNS N
in IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

In IN N
addition NN N
to TO N
having VBG N
difficulties NNS N
with IN N
social JJ N
communications NNS N
, , N
individuals NNS p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
often RB N
also RB N
experience JJ N
impairment NN o
in IN o
higher-order NN o
, , o
executive NN o
skills NNS o
. . o

The DT N
present JJ N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
pharmacological JJ N
modulation NN N
of IN N
the DT N
norepinephrine NN N
system NN N
on IN N
the DT N
severity NN N
of IN N
such JJ N
impairments NNS N
. . N

A DT N
sample NN N
of IN N
14 CD p
high-functioning JJ p
adults NNS p
with IN p
ASD NNP p
and CC p
a DT p
demographically-matched JJ p
comparison NN p
group NN p
of IN p
13 CD p
typically RB p
developing VBG p
individuals NNS p
participated VBN p
. . p

An DT N
AX NNP o
continuous JJ o
performance NN o
test NN o
( ( o
AX-CPT NNP o
) ) o
was VBD N
used VBN N
to TO N
evaluate VB N
working VBG N
memory NN N
and CC N
inhibitory NN N
control NN N
. . N

AX-CPT JJ o
performance NN o
was VBD N
assessed VBN N
following VBG N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
propranolol NN i
( ( i
a DT i
beta NN i
adrenergic JJ i
antagonist NN i
) ) i
and CC i
following VBG i
placebo NN i
( ( N
sugar NN N
pill NN N
) ) N
administration NN N
. . N

Individuals NNS p
with IN p
ASD NNP p
performed VBD o
more RBR N
poorly RB N
than IN N
non-ASD JJ N
individuals NNS N
in IN N
the DT N
working JJ N
memory NN N
condition NN N
( ( N
BX NNP N
trials NNS N
) ) N
. . N

Importantly RB N
, , N
administration NN N
of IN N
propranolol NN i
attenuated VBN o
this DT o
impairment NN o
, , N
with IN N
the DT N
ASD NNP N
group NN N
performing VBG o
significantly RB N
better RBR N
in IN N
the DT N
propranolol NN N
condition NN N
than IN N
the DT N
placebo JJ N
condition NN N
. . N

Working VBG o
memory NN o
performance NN o
of IN N
the DT N
non-ASD JJ N
group NN N
was VBD N
unaffected VBN N
by IN N
propranolol/placebo JJ N
administration NN N
. . N

No DT N
group NN N
or CC N
medication NN N
effects NNS o
were VBD N
observed VBN N
for IN N
the DT N
inhibition NN o
condition NN o
( ( N
AY NNP N
trials NNS N
) ) N
. . N

The DT N
present JJ N
findings NNS N
suggest VBP N
that IN N
norepinephrine NN N
may MD N
play VB N
a DT N
role NN N
in IN N
some DT N
, , N
but CC N
not RB N
necessarily RB N
all RB N
, , N
cognitive JJ o
impairments NNS o
associated VBN N
with IN N
ASD NNP N
. . N

Additional NNP N
research NN N
is VBZ N
needed VBN N
to TO N
fully RB N
understand VB N
whether IN N
this DT N
role NN N
is VBZ N
primarily RB N
causal JJ N
or CC N
compensatory NN N
in IN N
nature NN N
. . N

-DOCSTART- -X- O O

Letter NN N
by IN N
Begg NNP N
et CC N
al NN N
regarding VBG N
article NN N
, , N
The DT N
effects NNS N
of IN N
vitamin NN i
d NN i
supplementation NN i
on IN N
physical JJ o
function NN o
and CC o
quality NN o
of IN o
life NN o
in IN N
older JJR p
heart NN p
failure NN p
patients NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
of IN N
genetic JJ i
and CC i
environmental JJ i
risk NN i
assessment NN i
( ( i
GERA NNP i
) ) i
for IN N
colorectal JJ N
cancer NN N
risk NN N
in IN N
primary JJ N
care NN N
: : N
trial NN N
design NN N
and CC N
baseline NN N
findings NNS N
. . N

PURPOSE VB N
This DT N
paper NN N
describes VBZ N
an DT N
ongoing JJ N
randomized NN N
controlled VBD N
trial NN N
designed VBN N
to TO N
assess VB N
the DT N
impact NN o
of IN N
genetic JJ i
and CC i
environmental JJ i
risk NN i
assessment NN i
( ( i
GERA NNP i
) ) i
on IN N
colorectal JJ p
cancer NN p
( ( p
CRC NNP p
) ) p
screening NN N
. . N

METHODS NNP N
The DT N
trial NN N
includes VBZ N
asymptomatic JJ p
patients NNS p
who WP p
are VBP p
50-79years NNS p
and CC p
are VBP p
not RB p
up-to-date JJ p
with IN p
CRC NNP p
screening VBG p
guidelines NNS p
. . p

Patients NNS N
who WP N
responded VBD N
to TO N
a DT N
baseline NN N
telephone NN o
survey NN o
are VBP N
randomized VBN N
to TO N
a DT N
GERA NNP i
or CC i
Control NNP i
group NN i
. . i

GERA NNP i
group NN i
participants NNS i
meet VBP i
with IN i
a DT i
nurse NN i
, , i
decide VB i
whether IN i
to TO i
have VB i
a DT i
GERA NNP i
blood NN i
test NN i
( ( i
a DT i
combination NN i
of IN i
genetic JJ i
polymorphism NN i
and CC i
folate NN i
) ) i
, , i
and CC i
, , i
if IN i
tested VBN i
, , i
receive VBP i
GERA NNP i
feedback NN i
. . i

Follow-up NNP i
telephone NN o
surveys NNS o
are VBP i
conducted VBN i
at IN i
1 CD i
and CC i
6months CD i
. . i

A DT i
chart NN o
audit NN o
is VBZ i
performed VBN i
at IN i
6months CD i
. . i

RESULTS NNP N
Of IN p
2,223 CD p
eligible JJ p
patients NNS p
, , p
562 CD p
( ( p
25 CD p
% NN p
) ) p
have VBP p
enrolled VBN p
. . p

Patients NNS p
who WP p
enrolled VBD p
in IN p
the DT p
study NN p
were VBD p
significantly RB p
younger JJR p
than IN p
those DT p
who WP p
did VBD p
not RB p
( ( p
p JJ p
< NNP p
0.001 CD p
) ) p
. . p

Participants NNS p
tended VBD p
to TO p
be VB p
50-59years JJ p
( ( p
64 CD p
% NN p
) ) p
, , p
female JJ p
( ( p
58 CD p
% NN p
) ) p
, , p
white JJ p
( ( p
52 CD p
% NN p
) ) p
, , p
married VBD p
( ( p
51 CD p
% NN p
) ) p
, , p
and CC p
have VBP p
more JJR p
than IN p
a DT p
high JJ p
school NN p
education NN p
( ( p
67 CD p
% NN p
) ) p
. . p

At IN N
baseline NN N
, , N
most JJS N
participants NNS N
had VBD N
some DT N
knowledge NN o
of IN o
CRC NNP o
screening NN o
and CC o
GERA NNP i
, , N
viewed VBD N
CRC NNP N
screening VBG N
favorably RB N
, , N
and CC N
reported VBD N
that IN N
they PRP N
had VBD N
decided VBN N
to TO N
do VB N
screening VBG N
. . N

Almost NNP N
half NN N
had VBD N
worries NNS o
and CC o
concerns NNS o
about IN N
CRC NNP N
. . N

CONCLUSIONS NNP N
One CD p
in IN p
four CD p
eligible JJ p
primary JJ p
care NN p
patients NNS p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

Age NNP N
was VBD N
negatively RB N
associated VBN N
with IN N
enrollment NN N
. . N

Prospective JJ N
analyses NNS N
using VBG N
data NNS N
for IN N
all DT N
participants NNS N
will MD N
provide VB N
more RBR N
definitive JJ N
information NN N
on IN N
GERA NNP i
uptake NN N
and CC N
the DT N
impact NN N
of IN N
GERA NNP i
feedback NN N
. . N

-DOCSTART- -X- O O

Mediation NN N
analysis NN N
demonstrates VBZ N
that IN N
trans-eQTLs NN o
are VBP N
often RB N
explained VBN N
by IN N
cis-mediation NN N
: : N
a DT N
genome-wide JJ N
analysis NN N
among IN N
1,800 CD p
South NNP p
Asians NNPS p
. . p

A DT N
large JJ N
fraction NN N
of IN N
human JJ N
genes NNS N
are VBP N
regulated VBN N
by IN N
genetic JJ N
variation NN N
near IN N
the DT N
transcribed JJ N
sequence NN N
( ( N
cis-eQTL JJ N
, , N
expression JJ N
quantitative JJ N
trait NN N
locus NN N
) ) N
, , N
and CC N
many JJ N
cis-eQTLs NNS N
have VBP N
implications NNS N
for IN N
human JJ N
disease NN N
. . N

Less NNP N
is VBZ N
known VBN N
regarding VBG N
the DT N
effects NNS N
of IN N
genetic JJ N
variation NN N
on IN N
expression NN o
of IN o
distant JJ o
genes NNS o
( ( o
trans-eQTLs NN o
) ) o
and CC N
their PRP$ N
biological JJ N
mechanisms NNS N
. . N

In IN N
this DT N
work NN N
, , N
we PRP N
use VBP N
genome-wide JJ i
data NNS i
on IN i
SNPs NNP i
and CC N
array-based JJ i
expression NN i
measures NNS i
from IN N
mononuclear JJ N
cells NNS N
obtained VBN N
from IN N
a DT N
population-based JJ N
cohort NN N
of IN N
1,799 CD p
Bangladeshi NNP p
individuals NNS p
to TO N
characterize VB N
cis- JJ o
and CC o
trans-eQTLs JJ o
and CC N
determine VB N
if IN N
observed VBN N
trans-eQTL JJ o
associations NNS o
are VBP N
mediated VBN N
by IN N
expression NN N
of IN N
transcripts NNS N
in IN N
cis NN N
with IN N
the DT N
SNPs NNP N
showing VBG N
trans-association NN N
, , N
using VBG N
Sobel NNP o
tests NNS o
of IN o
mediation NN o
. . o

We PRP N
observed VBD N
434 CD p
independent JJ p
trans-eQTL JJ o
associations NNS o
at IN N
a DT N
false-discovery JJ N
rate NN N
of IN N
0.05 CD N
, , N
and CC N
189 CD N
of IN N
these DT N
trans-eQTLs NNS o
were VBD N
also RB N
cis-eQTLs JJ N
( ( N
enrichment JJ N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Among IN N
these DT N
189 CD p
trans-eQTL NN o
associations NNS o
, , p
39 CD p
were VBD p
significantly RB p
attenuated VBN p
after IN N
adjusting VBG N
for IN N
a DT N
cis-mediator NN N
based VBN N
on IN N
Sobel NNP N
P NNP N
< NNP N
10-5 JJ N
. . N

We PRP N
attempted VBD N
to TO N
replicate VB N
21 CD N
of IN N
these DT N
mediation NN N
signals NNS N
in IN N
two CD N
European JJ N
cohorts NNS N
, , N
and CC N
while IN N
only RB N
7 CD N
trans-eQTL JJ o
associations NNS o
were VBD N
present JJ N
in IN N
one CD N
or CC N
both DT N
cohorts NNS N
, , N
6 CD N
showed VBD N
evidence NN N
of IN N
cis-mediation NN N
. . N

Analyses NNS N
of IN N
simulated JJ N
data NNS N
show VBP N
that IN N
complete JJ N
mediation NN N
will MD N
be VB N
observed VBN N
as IN N
partial JJ N
mediation NN N
in IN N
the DT N
presence NN N
of IN N
mediator NN N
measurement NN N
error NN N
or CC N
imperfect JJ N
LD NNP N
between IN N
measured VBN N
and CC N
causal JJ N
variants NNS N
. . N

Our PRP$ N
data NNS N
demonstrates VBZ N
that IN N
trans-associations NNS N
can MD N
become VB N
significantly RB N
stronger JJR N
or CC N
switch VB N
directions NNS N
after IN N
adjusting VBG N
for IN N
a DT N
potential JJ N
mediator NN N
. . N

Using VBG N
simulated JJ N
data NNS N
, , N
we PRP N
demonstrate VBP N
that IN N
this DT N
phenomenon NN N
is VBZ N
expected VBN N
in IN N
the DT N
presence NN N
of IN N
strong JJ N
cis-trans NNS N
confounding NN N
and CC N
when WRB N
the DT N
measured VBN N
cis-transcript NN N
is VBZ N
correlated VBN N
with IN N
the DT N
true JJ N
( ( N
unmeasured JJ N
) ) N
mediator NN N
. . N

In IN N
conclusion NN N
, , N
by IN N
applying VBG N
mediation NN N
analysis NN N
to TO N
eQTL VB N
data NNS N
, , N
we PRP N
show VBP N
that IN N
a DT N
substantial JJ N
fraction NN N
of IN N
observed JJ N
trans-eQTL JJ o
associations NNS o
can MD N
be VB N
explained VBN N
by IN N
cis-mediation NN N
. . N

Future JJ N
studies NNS N
should MD N
focus VB N
on IN N
understanding VBG N
the DT N
mechanisms JJ N
underlying JJ N
widespread JJ N
cis-mediation NN N
and CC N
their PRP$ N
relevance NN N
to TO N
disease VB N
biology NN N
, , N
as RB N
well RB N
as IN N
using VBG N
mediation NN N
analysis NN N
to TO N
improve VB N
eQTL NN N
discovery NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
magnesium NN i
sulfate NN i
and CC i
nimodipine NN i
for IN N
the DT N
prevention NN o
of IN o
eclampsia NN o
. . o

-DOCSTART- -X- O O

The DT N
impact NN N
of IN N
daily JJ N
sodium NN i
intake NN N
on IN N
posttransplant JJ o
hypertension NN o
in IN p
kidney NN p
allograft NN p
recipients NNS p
. . p

INTRODUCTION NNP N
Posttransplant NNP o
hypertension NN o
is VBZ N
a DT N
well-known JJ N
risk NN N
factor NN N
for IN N
long-term JJ N
allograft NN N
failure NN N
and CC N
mortality NN N
in IN N
kidney NN p
recipients NNS p
. . p

Although IN N
dietary JJ N
sodium NN N
restriction NN N
is VBZ N
a DT N
widely RB N
recommended JJ N
nonpharmacological JJ N
measure NN N
for IN N
control NN N
of IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
, , N
no DT N
detailed JJ N
investigation NN N
has VBZ N
been VBN N
conducted VBN N
regarding VBG N
the DT N
impact NN N
of IN N
dietary JJ N
sodium NN N
restriction NN N
on IN N
this DT N
condition NN N
. . N

METHODS NNP N
Thirty-two JJ p
patients NNS p
on IN p
antihypertensive JJ p
treatment NN p
completed VBD p
the DT p
study NN p
. . p

They PRP N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
controls NNS i
( ( N
group NN N
1 CD N
) ) N
versus NN i
strict JJ i
sodium NN i
diet NN i
( ( N
group NN N
2 CD N
; : N
80 CD N
to TO N
100 CD N
mmol NNS N
sodium JJ i
daily RB N
) ) N
. . N

After IN N
randomization NN N
, , N
24-hour JJ o
urine NN o
for IN o
sodium NN o
measurement NN o
, , o
BP NNP o
, , o
and CC o
allograft NN o
functions NNS o
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
after IN N
3 CD N
months NNS N
. . N

BP NNP N
treatment NN N
was VBD N
reevaluated VBN N
at IN N
each DT N
visit NN N
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
age NN N
, , N
sex NN o
, , o
serum JJ o
creatinine NN o
, , o
systolic JJ o
and CC o
diastolic JJ o
BP NNP o
, , o
antihypertensive JJ o
drugs NNS o
, , o
or CC o
24-hour JJ o
urinary JJ o
sodium NN o
levels NNS o
between IN N
the DT N
groups NNS N
. . N

After IN N
3 CD N
months NNS N
, , N
daily JJ o
urinary JJ o
sodium NN o
excretion NN o
( ( N
from IN N
190+/-75 CD N
to TO N
106+/-48 JJ N
mEq/d NN N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
systolic JJ o
BP NNP o
( ( N
from IN N
146+/-21 CD N
to TO N
116+/-11 CD N
mm NNS N
Hg NNP N
) ) N
, , N
and CC N
diastolic JJ o
BP NNP o
( ( N
from IN N
89+/-8 CD N
to TO N
72+/-10 CD N
mm NNS N
Hg NNP N
) ) N
had VBD N
significantly RB N
decreased VBN N
in IN N
group NN N
2 CD N
, , N
while IN N
no DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
group NN N
1 CD N
. . N

CONCLUSION NNP N
Low NNP N
sodium NN N
intake NN N
in IN N
combination NN N
with IN N
antihypertensive JJ N
treatment NN N
appears VBZ N
to TO N
efficiently VB N
control NN o
BP NNP o
in IN N
kidney NN p
allograft NN p
recipients NNS p
with IN N
hypertension NN N
. . N

Twenty-four-hour JJ N
urinary JJ N
sodium NN N
excretion NN N
should MD N
be VB N
checked VBN N
regularly RB N
in IN N
these DT N
patients NNS N
as IN N
a DT N
useful JJ N
marker NN N
to TO N
indicate VB N
whether IN N
the DT N
patient NN N
complies NNS N
with IN N
low JJ N
sodium NN N
intake NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
open-label JJ N
non-comparative JJ N
multicenter NN N
phase NN N
II NNP N
trial NN N
of IN N
sequential JJ N
erlotinib NN i
and CC i
docetaxel NN i
versus NN i
docetaxel NN i
alone RB i
in IN N
patients NNS p
with IN p
non-small-cell JJ p
lung NN p
cancer NN p
after IN p
failure NN p
of IN p
first-line JJ p
chemotherapy NN p
: : p
GFPC NNP N
10.02 CD N
study NN N
. . N

BACKGROUND NNP N
Concomitant NNP i
administration NN i
of IN i
erlotinib NN i
with IN i
standard JJ i
chemotherapy NN i
does VBZ N
not RB N
appear VB N
to TO N
improve VB N
survival NN o
among IN N
patients NNS p
with IN p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
, , N
but CC N
preliminary JJ N
studies NNS N
suggest VBP N
that IN N
sequential JJ N
administration NN N
might MD N
be VB N
effective JJ N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
second-line JJ N
sequential JJ N
administration NN N
of IN N
erlotinib NN i
and CC i
docetaxel NN i
in IN N
advanced JJ N
NSCLC NNP N
. . N

METHODS NNP N
In IN N
an DT N
open-label JJ N
phase NN N
II NNP N
trial NN N
, , N
patients NNS p
with IN p
advanced JJ p
NSCLC NNP p
, , p
EGFR NNP p
wild-type NN p
or CC p
unknown JJ p
, , p
PS NNP p
0-2 CD p
, , p
in IN p
whom WP p
initial JJ p
cisplatin-based JJ p
chemotherapy NN p
had VBD p
failed VBN p
were VBD N
randomized VBN N
to TO N
sequential JJ i
erlotinib NN i
150 CD i
mg/d NN i
( ( i
day NN i
2-16 CD i
) ) i
+docetaxel NN i
( ( i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
d1 NN i
) ) i
( ( i
arm JJ i
ED NNP i
) ) i
or CC i
docetaxel NN i
( ( i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
d1 NN i
) ) i
alone RB i
( ( N
arm JJ N
D NNP N
) ) N
( ( N
21-day JJ N
cycle NN N
) ) N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
progression-free JJ o
survival NN o
rate NN o
at IN N
15 CD N
weeks NNS N
( ( N
PFS NNP N
15 CD N
) ) N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
PFS NNP o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
the DT o
overall JJ o
response NN o
rate NN o
( ( o
ORR NNP o
) ) o
and CC o
tolerability NN o
. . o

Based VBN N
on IN N
a DT N
Simon NNP N
optimal JJ N
two-stage NN N
design NN N
, , N
the DT N
ED NNP i
strategy NN N
was VBD N
rejected VBN N
if IN N
the DT N
primary JJ N
endpoint NN N
was VBD N
below IN N
33/66 CD N
patients NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
two CD N
Simon NNP N
stages NNS N
. . N

RESULTS VB N
147 CD p
patients NNS p
were VBD p
randomized VBN p
( ( p
median JJ p
age NN p
: : p
60?8 CD p
years NNS p
, , p
PS NNP p
0/1/2 CD p
: : p
44/83/20 CD p
patients NNS p
; : p
males NNS p
: : p
78 CD p
% NN p
) ) p
. . p

The DT i
ED NNP i
strategy NN N
was VBD N
rejected VBN N
, , N
with IN N
only RB N
18 CD N
of IN N
73 CD N
patients NNS N
achieving VBG o
PFS15 NNP o
in IN o
arm NN o
ED NN o
at IN N
the DT N
end NN N
of IN N
stage NN N
2 CD N
and CC N
17 CD N
of IN N
74 CD N
patients NNS N
in IN N
arm JJ N
D. NNP N
In IN N
arms NNS i
ED NNP i
and CC i
D NNP i
, , i
respectively RB N
, , N
median JJ o
PFS NNP o
was VBD N
2.2 CD N
and CC N
2.5 CD N
months NNS N
and CC o
median JJ o
OS NNP o
was VBD N
6.5 CD N
and CC N
8.3 CD N
months NNS N
. . N

CONCLUSION NNP i
Sequential NNP i
erlotinib NN i
and CC i
docetaxel NN i
was VBD N
not RB N
more RBR o
effective JJ o
than IN i
docetaxel RB i
alone JJ i
as IN N
second-line JJ N
treatment NN N
for IN N
advanced JJ N
NSCLC NNP N
with IN N
wild-type JJ N
or CC N
unknown JJ o
EGFR NNP o
status NN o
. . o

-DOCSTART- -X- O O

Effects NNS N
of IN N
antihypertensive JJ i
drugs NNS N
on IN N
cognitive JJ o
function NN o
in IN N
adolescents NNS p
. . p

The DT N
effects NNS N
of IN N
clonidine NN i
and CC N
hydrochlorothiazide NN i
on IN N
cognitive JJ o
function NN o
were VBD N
studied VBN N
in IN N
hypertensive JJ p
adolescents NNS p
requiring VBG p
pharmacologic JJ p
therapy NN p
for IN p
blood NN p
pressure NN p
control NN p
. . p

Twenty-four JJ p
adolescents NNS p
with IN p
persistent JJ p
blood NN o
pressure NN o
elevation NN p
( ( p
greater JJR p
than IN p
95th CD p
% NN p
) ) p
on IN p
placebo NN i
were VBD N
randomized VBN N
double JJ N
blind NN N
to TO N
clonidine VB i
or CC i
hydrochlorothiazide VB i
treatment NN N
. . N

A DT N
battery NN N
of IN N
cognitive JJ o
tests NNS o
were VBD N
performed VBN N
during IN N
the DT N
placebo NN N
phase NN N
and CC N
after IN N
16 CD N
weeks NNS N
of IN N
active JJ N
therapy NN N
. . N

Antihypertensive JJ i
therapy NN i
resulted VBD N
in IN N
significant JJ N
blood NN o
pressure NN o
reduction NN o
( ( N
p NN N
less JJR N
than IN N
.01 NN N
) ) N
. . N

A DT N
slight JJ N
interactive JJ N
effect NN N
was VBD N
observed VBN N
in IN N
arithmetic JJ o
performance NN o
( ( N
p NN N
less JJR N
than IN N
.05 NN N
) ) N
. . N

All DT N
other JJ N
parameters NNS N
of IN N
cognitive JJ o
function NN o
were VBD N
not RB N
affected VBN N
by IN N
either DT N
treatment NN N
. . N

-DOCSTART- -X- O O

A DT N
scanning NN N
electron NN N
microscopic NN N
study NN N
of IN N
different JJ N
caries NNS p
removal VBP o
techniques NNS o
on IN p
human JJ p
dentin NN p
. . p

Scanning VBG N
electron NN N
microscopy NN N
( ( N
SEM NNP N
) ) N
evaluated VBD N
the DT N
effect NN o
of IN o
different JJ o
caries NNS o
removal VBP o
techniques NNS o
on IN p
human JJ p
dentin NN p
topography NN p
. . p

Thirty-six NNP p
extracted VBD p
human JJ p
carious JJ p
mandibular NN p
molars NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
six CD p
groups NNS p
according VBG p
to TO p
caries NNS p
removal NN p
technique NN p
. . p

Carious JJ N
tissue NN N
was VBD N
removed VBN N
by IN N
hand NN o
excavation NN o
, , o
bur JJ o
excavation NN o
, , o
air-abrasion NN o
, , o
laser JJR o
ablation NN o
, , o
chemomechanical JJ o
methods NNS o
and CC o
sono-abrasion NN o
. . o

The DT N
remaining VBG N
dentin NN N
surfaces NNS N
were VBD N
replicated VBN i
and CC i
gold-coated JJ i
. . i

The DT N
surfaces NNS N
were VBD N
examined VBN N
using VBG N
SEM NNP N
and CC N
distinct JJ N
differences NNS N
in IN N
appearance NN N
were VBD N
observed VBN N
among IN N
specimens NNS N
treated VBN N
with IN N
different JJ N
caries NNS N
removal NN N
techniques NNS N
. . N

While IN N
hand-excavated JJ N
, , N
bur-excavated JJ N
and CC N
air-abraded JJ N
carious JJ N
dentin NN N
surfaces NNS N
were VBD N
covered VBN N
with IN N
a DT N
residual JJ o
smear NN o
layer NN o
, , N
sono-abrasion NN N
with IN N
patent JJ N
dentinal JJ N
tubules NNS N
completely RB N
removed VBD N
the DT N
smear JJ N
layer NN N
. . N

A DT N
few JJ N
patent NN o
orifices NNS o
of IN o
dentinal JJ o
tubules NNS o
were VBD N
observed VBN N
in IN N
dentin NN N
subjected VBN N
to TO N
laser VB N
ablation NN N
and CC N
chemo-mechanical JJ N
caries NNS N
removal NN N
. . N

-DOCSTART- -X- O O

Focal NNP o
therapeutic JJ o
efficacy NN o
of IN N
transcatheter NN N
arterial JJ N
infusion NN N
of IN N
styrene NN i
maleic NN i
acid NN i
neocarzinostatin NN N
for IN N
hepatocellular JJ N
carcinoma NN N
. . N

We PRP N
evaluated VBD N
the DT N
focal JJ o
therapeutic JJ o
effect NN o
of IN N
oily RB i
carcinostatic JJ i
agents NNS i
administered VBN N
by IN N
transcatheter NN N
arterial JJ N
infusion NN N
( ( N
TAI NNP N
) ) N
as IN N
the DT N
initial JJ N
therapy NN N
in IN N
patients NNS p
with IN p
hepatocellular JJ p
carcinoma NN p
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

Group NNP p
A NNP p
( ( p
19 CD p
patients NNS p
) ) p
received VBD N
4 CD i
mg NN i
of IN i
styrene NN i
maleic NN i
acid NN i
neocarzinostatin NN i
in IN i
4 CD i
ml NN i
of IN i
Lipiodol NNP i
, , N
and CC N
group NN p
B NNP p
( ( p
18 CD p
patients NNS p
) ) p
received VBD N
100 CD i
mg NN i
of IN i
epirubicin NN i
in IN i
4 CD i
ml NN i
of IN i
Lipiodol NNP i
via IN N
the DT N
tumor NN N
feeding VBG N
arteries NNS N
as RB N
peripherally RB N
as IN N
possible JJ N
. . N

The DT N
grade NN N
of IN N
Lipiodol NNP N
accumulation NN N
and CC N
the DT N
tumor NN N
regression NN N
rate NN N
were VBD N
determined VBN N
2 CD N
weeks NNS N
after IN N
TAI NNP N
by IN N
computerized JJ N
tomography NN N
. . N

Adverse JJ N
effects NNS N
within IN N
2 CD N
weeks NNS N
after IN N
TAI NNP N
were VBD N
evaluated VBN N
by IN N
subjective JJ N
signs NNS N
and CC N
symptoms NNS N
such JJ N
as IN N
fever NN o
( ( o
maximum JJ o
body NN o
temperature NN o
) ) o
and CC N
the DT N
frequency NN o
of IN o
shaking VBG o
chills NNS o
and CC o
abdominal JJ o
pain NN o
, , o
and CC o
by IN o
biochemical JJ o
parameters NNS o
such JJ o
as IN o
albumin NN o
, , o
prothrombin JJ o
time NN o
, , o
and CC o
aspartate NN o
and CC o
alanine NN o
aminotransferases NNS o
. . o

Lipiodol NNP o
accumulation NN o
in IN o
the DT o
tumor NN o
was VBD N
significantly RB N
greater JJR N
in IN N
group NN N
A NNP N
( ( N
12/19 CD N
; : N
63.2 CD N
% NN N
showing VBG N
grade JJ N
IV NNP N
Lipiodol NNP N
accumulation NN N
) ) N
than IN N
in IN N
group NN N
B NNP N
( ( N
3/18 CD N
; : N
16.7 CD N
% NN N
showing VBG N
grade JJ N
IV NNP N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
tumor NN o
regression NN o
rate NN o
was VBD N
also RB N
significantly RB N
greater JJR N
in IN N
group NN N
A NNP N
( ( N
8/17 CD N
; : N
47.1 CD N
% NN N
showing VBG N
more JJR N
than IN N
25 CD N
% NN N
tumor NN N
regression NN N
) ) N
than IN N
in IN N
group NN N
B NNP N
( ( N
1/13 CD N
; : N
7.7 CD N
% NN N
showing VBG N
more JJR N
than IN N
25 CD N
% NN N
tumor NN N
regression NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Although IN N
clinically RB N
significant JJ N
elevations NNS o
of IN o
aminotransferases NNS o
and CC N
reductions NNS o
of IN o
cholinesterase NN o
, , N
and CC N
shaking VBG o
chills NNS o
were VBD N
observed VBN N
more RBR N
often RB N
in IN N
group NN N
A NNP N
than IN N
in IN N
group NN N
B NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
these DT N
factors NNS N
had VBD N
little JJ N
influence NN N
on IN N
the DT N
clinical JJ N
outcome NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
styrene NN i
maleic NN i
acid NN i
neocarzinostatin NN i
in IN N
Lipiodol NNP N
exerts VBZ N
a DT N
more RBR o
favorable JJ o
focal JJ o
therapeutic JJ o
effect NN o
than IN N
does VBZ N
epirubicin VB i
in IN N
Lipiodol NNP i
in IN N
the DT N
initial JJ N
treatment NN N
of IN N
hepatocellular JJ N
carcinoma NN N
. . N

-DOCSTART- -X- O O

Effectiveness NN o
of IN N
written VBN N
guidelines NNS N
on IN N
the DT N
appropriateness NN N
of IN N
thromboprophylaxis JJ i
prescriptions NNS i
for IN p
medical JJ p
patients NNS p
: : p
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN o
of IN N
providing VBG N
doctors NNS N
with IN N
written VBN N
thromboprophylaxis JJ i
prescription NN i
aids NNS i
based VBN N
on IN N
current JJ N
recommendations NNS N
. . N

DESIGN VB N
A DT N
prospective JJ N
trial NN N
of IN N
specific JJ N
anticoagulant JJ N
prescription NN N
forms NNS N
: : N
a DT N
1-day JJ N
survey NN N
before IN N
and CC N
after IN N
the DT N
intervention NN N
in IN N
each DT N
centre NN N
. . N

SETTING CC N
30 CD p
Internal NNP p
Medicine NNP p
departments NNS p
of IN p
Assistance NNP p
Publique-H?pitaux NNP p
de IN p
Paris NNP p
. . p

SUBJECTS NNP p
All DT p
inpatients NNS p
were VBD p
included VBN p
, , p
except IN p
those DT p
who WP p
were VBD p
either RB p
admitted VBN p
or CC p
discharged VBN p
on IN p
the DT p
day NN p
of IN p
the DT p
survey NN p
, , p
and CC p
those DT p
receiving VBG p
curative JJ i
anticoagulant JJ i
treatment NN p
. . p

INTERVENTIONS VBZ N
The DT N
study NN N
included VBD N
three CD N
parts NNS N
: : N
( ( N
i NN N
) ) N
a DT N
1-day JJ N
baseline NN N
survey NN N
; : N
( ( N
ii NN N
) ) N
over IN N
the DT N
following JJ N
3-month JJ N
period NN N
, , N
departments NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
all DT N
practitioners NNS N
in IN N
wards NNS N
allocated VBN N
to TO N
the DT N
intervention NN N
group NN N
were VBD N
required VBN N
to TO N
systematically RB N
use VB N
specific JJ i
anticoagulant JJ i
prescription NN N
forms NNS N
, , N
whilst NN N
doctors NNS N
in IN N
the DT N
control NN N
group NN N
continued VBD N
prescribing VBG N
according VBG N
to TO N
their PRP$ i
usual JJ i
practices NNS i
and CC N
( ( N
iii NN N
) ) N
a DT N
1-day JJ N
postintervention NN N
survey NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP o
The DT o
proportion NN o
of IN o
prescriptions NNS o
in IN o
accordance NN o
with IN o
the DT o
recommendations NNS o
. . o

RESULTS VB p
1,469 CD p
patients NNS p
were VBD p
included VBN p
. . p

The DT N
intervention NN N
produced VBD N
a DT N
significant JJ o
reduction NN o
in IN N
the DT o
frequency NN o
of IN o
over-prescriptions NNS o
, , o
from IN N
25 CD N
% NN N
to TO N
14 CD N
% NN N
of IN N
the DT N
patients NNS N
who WP N
did VBD N
not RB N
meet VB N
the DT N
guideline NN N
criteria NNS N
( ( N
adjusted VBN N
OR NNP N
: : N
0.3 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.1-0.8 NN N
) ) N
. . N

Using VBG o
specific JJ o
forms NNS o
did VBD N
not RB o
improve VB o
under-prescription NN o
of IN o
anticoagulants NNS o
. . o

A DT N
little JJ N
over IN N
60 CD N
% NN N
of IN N
the DT N
patients NNS N
who WP N
met VBD N
guideline NN N
criteria NNS N
for IN N
thromboprophylaxis NN N
were VBD o
prescribed JJ o
anticoagulants NNS o
in IN N
both DT N
intervention NN N
and CC N
control NN N
wards NNS N
, , N
either RB N
at IN N
baseline NN N
or CC N
after IN N
intervention NN N
. . N

CONCLUSIONS NNP i
Multitargeted VBD i
interventions NNS i
using VBG N
a DT N
variety NN N
of IN N
means NNS N
and CC N
strategies NNS N
should MD N
still RB N
be VB N
considered VBN N
to TO o
improve VB o
prescriptions NNS o
that WDT N
may MD N
have VB N
a DT N
significant JJ o
impact NN o
on IN o
health NN o
expenses NNS o
and CC N
, , N
most RBS N
importantly RB N
, , N
on IN o
patients NNS o
outcomes NNS o
. . o

-DOCSTART- -X- O O

Behavioral NNP o
and CC o
physiological JJ o
effects NNS o
of IN N
remifentanil NN i
and CC i
alfentanil NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

BACKGROUND IN N
The DT o
subjective JJ o
and CC o
psychomotor JJ o
effects NNS o
of IN N
remifentanil NNS i
have VBP N
not RB N
been VBN N
evaluated VBN N
. . N

Accordingly RB N
, , N
the DT N
authors NNS N
used VBD N
mood NN N
inventories NNS N
and CC N
psychomotor NN N
tests NNS N
to TO N
characterize VB N
the DT N
effects NNS N
of IN N
remifentanil NN i
in IN N
healthy JJ p
, , p
non-drug-abusing JJ p
volunteers NNS p
. . p

Alfentanil NNP N
was VBD N
used VBN N
as IN N
a DT N
comparator NN N
drug NN N
. . N

METHODS NNP N
Ten NNP p
healthy JJ p
volunteers NNS p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ i
, , N
crossover JJ N
trial NN N
in IN N
which WDT N
they PRP N
received VBD N
an DT N
infusion NN N
of IN N
saline NN i
, , i
remifentanil NN i
, , i
or CC i
alfentanil NN i
for IN i
120 CD i
min NN i
. . i

The DT N
age- JJ i
and CC i
weight-adjusted JJ i
infusions NNS i
( ( i
determined VBN i
with IN i
STANPUMP NNP i
, , i
a DT i
computer NN i
modeling VBG i
software NN i
package NN i
) ) i
were VBD N
given VBN N
to TO N
achieve VB N
three CD N
predicted VBN N
constant JJ N
plasma NN N
levels NNS N
for IN N
40 CD i
min NNS i
each DT i
of IN i
remifentanil NN i
( ( i
0.75 CD i
, , i
1.5 CD i
, , i
and CC i
3 CD i
ng/ml NN i
) ) i
and CC i
alfentanil NN i
( ( i
16 CD i
, , i
32 CD i
, , i
and CC i
64 CD i
ng/ml NN i
) ) i
. . i

Mood NN N
forms NNS N
and CC N
psychomotor NN N
tests NNS N
were VBD N
completed VBN N
, , N
and CC N
miosis NN N
was VBD N
assessed VBN N
, , N
during IN N
and CC N
after IN N
the DT N
infusions NNS N
. . N

In IN N
addition NN N
, , N
analgesia NN N
was VBD N
tested VBN N
at IN N
each DT N
dose JJ N
level NN N
using VBG N
a DT N
cold-pressor JJ N
test NN N
. . N

RESULTS NNP N
Remifentanil NNP i
had VBD N
prototypic VBN o
micro-like JJ o
opioid JJ o
subjective JJ o
effects NNS o
, , o
impaired JJ o
psychomotor NN o
performance NN o
, , o
and CC o
produced VBD o
analgesia NN o
. . o

Alfentanil NNP N
at IN N
the DT N
dose JJ N
range NN N
tested VBD N
had VBD N
more RBR N
mild JJ N
effects NNS N
on IN N
these DT N
measures NNS N
, , N
and CC N
the DT N
analgesia NN o
data NNS N
indicated VBD N
that IN N
a DT N
40:1 CD N
potency NN N
ratio NN N
, , N
rather RB N
than IN N
the DT N
20:1 CD N
ratio NN N
we PRP N
used VBD N
, , N
may MD N
exist VB N
between IN N
remifentanil NN N
and CC N
alfentanil NN N
. . N

A DT N
psychomotor NN N
test NN N
administered VBD N
60 CD N
min NN N
after IN N
the DT N
remifentanil NN N
infusion NN N
was VBD N
discontinued VBN N
showed VBD N
that IN N
the DT N
volunteers NNS N
were VBD N
still RB N
impaired VBN N
, , N
although IN N
they PRP N
reported VBD N
feeling VBG N
no DT N
drug NN N
effects NNS N
. . N

CONCLUSIONS VB N
The DT N
notion NN N
that IN N
the DT N
pharmacodynamic JJ o
effects NNS o
of IN N
remifentanil NN i
are VBP N
extremely RB N
short-lived JJ N
after IN N
the DT N
drug NN N
is VBZ N
no DT N
longer RB N
administered VBN N
must MD N
be VB N
questioned VBN N
given VBN N
our PRP$ N
findings NNS N
that IN N
psychomotor NN o
effects NNS o
were VBD N
still RB N
apparent JJ N
1 CD N
h NN N
after IN N
the DT N
infusion NN N
was VBD N
discontinued VBN N
. . N

-DOCSTART- -X- O O

Development NNP N
of IN N
an DT N
adaptive JJ i
low-pass NN i
filtered VBD i
speech JJ i
test NN i
for IN N
the DT N
identification NN N
of IN N
auditory NN o
processing NN o
disorders NNS o
. . o

OBJECTIVE CC N
One CD N
type NN N
of IN N
test NN N
commonly RB N
used VBD N
to TO N
examine VB N
auditory JJ p
processing NN p
disorders NNS p
( ( p
APD NNP p
) ) p
is VBZ N
the DT N
low-pass NN i
filtered VBD i
speech JJ i
test NN i
( ( N
LPFST NNP N
) ) N
, , N
of IN N
which WDT N
there EX N
are VBP N
various JJ N
versions NNS N
. . N

In IN N
LPFSTs NNP N
, , N
a DT N
monaural JJ N
, , N
low-redundancy JJ N
speech NN N
sample NN N
is VBZ N
distorted VBN N
by IN N
using VBG N
filtering VBG N
to TO N
modify VB N
its PRP$ N
frequency NN N
content NN N
. . N

Due JJ N
to TO N
the DT N
richness NN N
of IN N
the DT N
neural JJ N
pathways NNS N
in IN N
the DT N
auditory NN N
system NN N
and CC N
the DT N
redundancy NN N
of IN N
acoustic JJ N
information NN N
in IN N
spoken JJ N
language NN N
, , N
a DT N
normal JJ N
listener NN N
is VBZ N
able JJ N
to TO N
recognize VB N
speech NN N
even RB N
when WRB N
parts NNS N
of IN N
the DT N
signal NN N
are VBP N
missing VBG N
, , N
whereas IN N
this DT N
ability NN N
is VBZ N
often RB N
impaired VBN N
in IN N
listeners NNS p
with IN p
APD NNP p
. . p

One CD N
limitation NN N
of IN N
the DT N
various JJ N
versions NNS N
of IN N
the DT N
LPFST NNP i
is VBZ N
that IN N
they PRP N
are VBP N
carried VBN N
out IN N
using VBG N
a DT N
constant JJ N
level NN N
of IN N
low-pass JJ N
filtering NN N
( ( N
e.g NN N
. . N

a DT N
fixed JJ N
1kHz CD N
corner NN N
frequency NN N
) ) N
which WDT N
makes VBZ N
them PRP N
prone VB N
to TO N
ceiling NN N
and CC N
floor NN N
effects NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
counter VB N
these DT N
effects NNS N
by IN N
modifying VBG N
the DT N
LPFST NNP N
using VBG N
a DT N
computer-based JJ N
adaptive JJ N
procedure NN N
, , N
and CC N
to TO N
evaluate VB N
the DT N
performance NN N
of IN N
normal-hearing JJ p
participants NNS p
of IN p
varying VBG p
ages NNS p
on IN N
the DT N
test NN N
. . N

METHODS NNP N
In IN N
this DT N
preliminary JJ N
study NN N
, , N
33 CD p
adults NNS p
and CC p
30 CD p
children NNS p
( ( p
aged VBN p
8-11 CD p
years NNS p
) ) p
with IN p
no DT p
known JJ p
history NN p
of IN p
listening VBG p
difficulties NNS p
were VBD N
tested VBN N
. . N

The DT i
University NNP i
of IN i
Canterbury NNP i
Adaptive NNP i
Speech NNP i
Test NNP i
( ( i
UCAST NNP i
) ) i
platform NN i
was VBD i
used VBN i
to TO i
administer VB i
a DT i
four-alternative JJ i
forced-choice JJ i
adaptive JJ i
test NN i
that WDT i
altered VBD i
a DT i
low-pass JJ i
filter NN i
( ( i
LPF NNP i
) ) i
to TO i
track VB i
the DT i
corner NN i
frequency NN i
at IN i
which WDT i
participants NNS i
correctly RB i
identified VBN i
a DT i
certain JJ i
percentage NN i
of IN i
the DT i
word NN i
stimuli NN i
. . i

RESULTS NNP N
Findings NNP N
on IN N
the DT N
University NNP o
of IN o
Canterbury NNP o
Adaptive NNP o
Speech NNP o
Test-Filtered NNP o
Words NNP o
( ( o
UCAST-FW NNP o
) ) o
indicated VBD N
a DT N
significant JJ o
maturational JJ o
effect NN o
. . o

Adult NN p
participants NNS p
performed VBD N
significantly RB N
better RBR N
on IN N
the DT N
UCAST-FW NNP o
in IN N
comparison NN N
to TO N
the DT N
child NN p
participants NNS p
. . p

The DT N
UCAST-FW JJ i
test NN N
was VBD N
reliable JJ N
over IN N
repeated JJ N
administrations NNS N
. . N

CONCLUSIONS NNP N
An DT N
adaptive JJ N
low-pass NN N
filtered VBD N
speech JJ N
test NN N
such JJ N
as IN N
the DT N
UCAST-FW NNP o
is VBZ N
sensitive JJ N
to TO N
maturational JJ o
changes NNS o
in IN o
auditory NN o
processing NN o
ability NN o
. . o

-DOCSTART- -X- O O

Zoledronic JJ i
acid NN i
combined VBN i
with IN i
adjuvant JJ i
endocrine JJ i
therapy NN i
of IN i
tamoxifen JJ i
versus NN N
anastrozol NN i
plus CC i
ovarian JJ i
function NN i
suppression NN i
in IN N
premenopausal NN p
early JJ p
breast NN p
cancer NN p
: : p
final JJ N
analysis NN N
of IN N
the DT N
Austrian JJ p
Breast NNP p
and CC p
Colorectal NNP p
Cancer NNP p
Study NNP p
Group NNP p
Trial NNP p
12 CD p
. . p

BACKGROUND NNP N
Zoledronic NNP i
acid NN i
( ( i
ZOL NNP i
) ) i
plus CC i
adjuvant JJ i
endocrine NN i
therapy NN i
significantly RB N
improved VBN N
disease-free JJ o
survival NN o
( ( N
DFS NNP N
) ) N
at IN N
48- JJ N
and CC N
62-month JJ N
follow-up NN N
in IN N
the DT N
ABCSG-12 NNP N
trial NN N
. . N

We PRP N
present JJ N
efficacy JJ N
results NNS N
of IN N
a DT N
final JJ N
additional JJ N
analysis NN N
after IN N
94.4 CD N
months NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
were VBD p
premenopausal JJ p
women NNS p
who WP p
had VBD p
undergone JJ p
primary JJ p
surgery NN p
for IN p
stage NN p
I/II NNP p
estrogen-receptor-positive JJ p
and/or NN p
progesterone-receptor-positive JJ p
breast NN p
cancer NN p
with IN p
< $ p
10 CD p
positive JJ p
lymph NN p
nodes NNS p
, , p
and CC p
were VBD p
scheduled VBN p
for IN p
standard JJ p
goserelin NN p
therapy NN p
. . p

All DT N
1803 CD p
patients NNS p
received VBN p
goserelin NNS i
( ( i
3.6 CD i
mg NN i
every DT i
28 CD i
days NNS i
) ) i
and CC i
were VBD i
randomized VBN i
to TO i
tamoxifen VB i
( ( i
20 CD i
mg/days NNS i
) ) i
or CC i
anastrozole JJ i
( ( i
1 CD i
mg/days NNS i
) ) i
, , i
both DT i
with IN i
or CC i
without IN i
ZOL NNP i
( ( i
4 CD i
mg NN i
every DT i
6 CD i
months NNS i
) ) i
for IN i
3 CD i
years NNS i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
DFS NNP o
; : o
recurrence-free JJ o
survival NN o
and CC o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
were VBD N
secondary JJ N
end NN N
points NNS N
. . N

RESULTS NNP N
After IN N
94.4-month JJ N
median JJ N
follow-up NN N
( ( N
range NN N
, , N
0-114 JJ N
months NNS N
) ) N
, , N
relative JJ o
risks NNS o
of IN o
disease NN o
progression NN o
[ NNP o
hazard NN o
ratio NN o
( ( o
HR NNP o
) ) o
= VBZ N
0.77 CD N
; : N
95 CD N
% NN N
confidence NN o
interval NN o
( ( N
CI NNP N
) ) N
0.60-0.99 NN N
; : N
P NNP N
= VBD N
0.042 CD N
] NNP N
and CC N
of IN N
death NN o
( ( N
HR NNP N
= NNP N
0.66 CD N
; : N
95 CD N
% NN N
CI NNP N
0.43-1.02 CD N
; : N
P NNP N
= NNP N
0.064 CD N
) ) N
are VBP N
still RB N
reduced VBN N
by IN N
ZOL NNP N
although IN N
no RB N
longer RBR N
significant JJ N
at IN N
the DT N
predefined JJ N
significance NN N
level NN N
. . N

Overall JJ N
, , N
251 CD N
DFS NNP o
events NNS o
and CC N
86 CD N
deaths NNS o
were VBD N
reported VBN N
. . N

Absolute NNP o
risk NN o
reductions NNS o
with IN N
ZOL NNP N
were VBD N
3.4 CD N
% NN N
for IN N
DFS NNP N
and CC N
2.2 CD N
% NN N
for IN N
OS NNP N
. . N

There EX N
was VBD N
no DT N
DFS NNP o
difference NN o
between IN N
tamoxifen NN N
alone RB N
versus JJ N
anastrozole JJ N
alone RB N
, , N
but CC N
there RB N
was VBD N
a DT N
pronounced JJ N
higher JJR o
risk NN o
of IN o
death NN o
for IN N
anastrozole-treated JJ N
patients NNS N
( ( N
HR NNP N
= NNP N
1.63 CD N
; : N
95 CD N
% NN N
CI NNP N
1.05-1.45 CD N
; : N
P NNP N
= NNP N
0.030 CD N
) ) N
. . N

Treatments NNS N
were VBD N
generally RB N
well RB N
tolerated VBN o
, , N
with IN N
no DT o
reports NNS o
of IN o
renal JJ o
failure NN o
or CC o
osteonecrosis NN o
of IN o
the DT o
jaw NN o
. . o

CONCLUSION NNP N
These DT N
final JJ N
results NNS N
from IN N
ABCSG NNP N
12 CD N
suggest NN N
that IN N
twice-yearly JJ N
ZOL NNP i
enhances VBZ N
the DT N
efficacy NN N
of IN N
adjuvant JJ N
endocrine NN N
treatment NN N
, , N
and CC N
this DT N
benefit NN N
is VBZ N
maintained VBN N
long-term JJ N
. . N

CLINICALTRIALSGOV NNP N
NCT00295646 NNP N
( ( N
http NN N
: : N
//www.clinicaltrials.gov/ct2/results NNS N
? . N
term=00295646 NN N
) ) N
. . N

-DOCSTART- -X- O O

Enrollment NN N
of IN N
racial JJ p
and CC p
ethnic JJ p
minorities NNS p
in IN p
the DT p
Prostate NNP p
, , p
Lung NNP p
, , p
Colorectal NNP p
and CC p
Ovarian JJ p
Cancer NNP p
Screening NNP p
Trial NNP p
. . p

BACKGROUND NNP N
Minority NNP p
populations NNS p
in IN p
the DT p
United NNP p
States NNPS p
, , p
especially RB p
blacks NNS p
and CC p
Hispanics NNPS p
, , N
are VBP N
generally RB N
underrepresented VBN N
among IN N
participants NNS N
in IN N
clinical JJ N
trials NNS N
. . N

Here RB N
, , N
we PRP N
report VBP N
the DT N
experience NN N
of IN N
enrolling VBG N
ethnic JJ p
minorities NNS p
in IN N
a DT N
large JJ N
cancer NN N
screening VBG N
trial NN N
. . N

METHODS NNP N
The DT N
Prostate NNP i
, , i
Colorectal NNP i
, , i
Lung NNP i
and CC i
Ovarian NNP i
( ( i
PLCO NNP i
) ) i
Cancer NNP i
Screening NNP i
Trial NNP N
is VBZ N
a DT N
multicenter NN N
randomized VBN N
trial NN N
designed VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN p
of IN p
screening VBG i
for IN i
the DT i
PLCO NNP i
cancers NNS i
. . i

Subjects NNS p
were VBD p
recruited VBN p
at IN p
10 CD p
U.S. NNP p
centers NNS p
between IN p
1993 CD p
and CC p
2001 CD p
. . p

One CD N
screening NN N
center NN N
had VBD N
a DT N
major JJ N
special JJ i
recruitment NN i
effort NN i
for IN i
blacks NNS i
and CC N
another DT N
center NN N
had VBD N
a DT N
major JJ N
special JJ i
recruitment NN i
effort NN i
for IN i
Hispanics NNPS i
. . i

RESULTS NNP N
Among IN N
almost RB N
155,000 CD p
subjects NNS p
enrolled VBN p
in IN p
PLCO NNP p
, , p
minority NN p
enrollment NN p
was VBD p
as IN p
follows VBZ p
: : p
black JJ p
( ( p
5.0 CD p
% NN p
) ) p
, , p
Hispanic NNP p
( ( p
1.8 CD p
% NN p
) ) p
and CC p
Asian NNP p
( ( p
3.6 CD p
% NN p
) ) p
. . p

This DT N
compares VBZ N
to TO N
an DT N
age-eligible JJ N
population NN N
in IN N
the DT N
combined JJ N
catchment JJ N
areas NNS N
of IN N
the DT N
PLCO NNP p
centers NNS p
that WDT p
was VBD p
14.0 CD p
% NN p
black JJ p
, , p
2.9 CD p
% NN p
Hispanic NNP p
and CC p
5.4 CD p
% NN p
Asian JJ p
, , p
and CC p
an DT p
age-eligible JJ p
population NN p
across IN p
the DT p
U.S. NNP p
that WDT p
was VBD p
9.5 CD p
% NN p
black JJ p
, , p
6.5 CD p
% NN p
Hispanic NNP p
and CC p
3.0 CD p
% NN p
Asian JJ p
. . p

About IN N
half NN N
( ( p
45 CD p
% NN p
) ) p
of IN p
Hispanics NNPS p
were VBD p
recruited VBN o
at IN p
the DT p
center NN p
with IN p
the DT p
special JJ p
Hispanic JJ p
recruitment NN p
effort NN p
. . p

Seventy NNP p
percent NN p
of IN p
blacks NNS p
were VBD p
recruited VBN o
at IN p
two CD p
centers NNS p
; : p
the DT p
one NN p
with IN p
the DT p
major JJ p
special JJ p
recruitment NN p
effort NN N
and CC N
a DT N
center NN N
in IN N
Detroit NNP N
whose WP$ N
catchment JJ N
area NN N
was VBD N
20 CD N
% NN N
black JJ N
among IN N
age-eligibles NNS N
. . N

Blacks NNS N
, , N
Hispanics NNPS N
and CC N
( ( N
non-Hispanic JJ N
) ) N
whites NNS N
were VBD N
all DT N
more RBR N
highly RB N
educated VBN N
, , N
less RBR N
likely JJ N
to TO N
currently RB o
smoke VB o
and CC N
more RBR N
likely JJ N
to TO N
get VB N
regular JJ o
exercise NN o
than IN N
their PRP$ N
counterparts NNS N
in IN N
the DT N
general JJ N
population NN N
. . N

CONCLUSION NNP N
Significant NNP N
efforts NNS N
were VBD N
made VBN N
to TO N
recruit VB N
racial/ NN N
ethnic JJ N
minorities NNS N
into IN N
PLCO NNP N
, , N
and CC N
these DT N
efforts NNS N
resulted VBD N
in IN N
enrollment NN N
levels NNS N
that WDT N
were VBD N
comparable JJ N
to TO N
those DT N
seen VBN N
in IN N
many JJ N
recent JJ N
cancer NN N
screening NN N
or CC N
prevention NN N
trials NNS N
. . N

Blacks NNS N
and CC N
Hispanics NNPS N
were VBD N
nonetheless RB N
underrepresented VBN N
in IN N
PLCO NNP N
compared VBN N
to TO N
their PRP$ N
levels NNS N
among IN N
age-eligibles NNS N
in IN N
the DT N
overall JJ N
U.S. NNP N
population NN N
or CC N
in IN N
the DT N
aggregate JJ N
PLCO NNP N
catchment NN N
areas NNS N
. . N

-DOCSTART- -X- O O

Falls NNS o
and CC o
mobility NN o
in IN N
Parkinson NNP p
's POS p
disease NN p
: : p
protocol NN N
for IN N
a DT N
randomised VBN N
controlled JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
physical JJ i
therapy NN i
and CC i
falls VBZ i
prevention NN i
education NN i
are VBP N
argued VBN N
to TO N
reduce VB N
falls NNS o
and CC o
disability NN o
in IN N
people NNS N
with IN N
idiopathic JJ N
Parkinson NNP p
's POS p
disease NN p
, , N
this DT N
has VBZ N
not RB N
yet RB N
been VBN N
confirmed VBN N
with IN N
a DT N
large JJ N
scale NN N
randomised VBD N
controlled JJ N
clinical JJ N
trial NN N
. . N

The DT N
study NN N
will MD N
investigate VB N
the DT N
effects NNS N
on IN N
falls NNS o
, , o
mobility NN o
and CC o
quality NN o
of IN o
life NN o
of IN N
( ( N
i NN N
) ) N
movement NN i
strategy NN i
training NN i
combined VBN i
with IN i
falls NNS i
prevention JJ i
education NN i
, , i
( ( i
ii NN i
) ) i
progressive NN i
resistance NN i
strength NN i
training NN i
combined VBN i
with IN i
falls NNS i
prevention JJ i
education NN i
, , i
( ( i
iii NN i
) ) i
a DT i
generic JJ i
life-skills JJ i
social JJ i
program NN i
( ( i
control VB i
group NN i
) ) i
. . i

METHODS/DESIGN JJ N
People NNS p
with IN p
idiopathic JJ p
Parkinson NNP p
's POS p
disease NN p
who WP p
live VBP p
at IN p
home NN p
will MD N
be VB N
recruited VBN N
and CC N
randomly RB N
allocated VBD N
to TO N
one CD N
of IN N
three CD N
groups NNS N
. . N

Each DT N
person NN N
shall MD N
receive VB N
therapy NN i
in IN N
an DT N
out-patient JJ N
setting NN N
in IN N
groups NNS N
of IN N
3-4 JJ N
. . N

Each DT N
group NN N
shall MD N
be VB N
scheduled VBN N
to TO N
meet VB N
once RB N
per IN N
week NN N
for IN N
2 CD N
hours NNS N
for IN N
8 CD N
consecutive JJ N
weeks NNS N
. . N

All DT N
participants NNS N
will MD N
also RB N
have VB N
a DT N
structured JJ N
2 CD N
hour NN N
home NN i
practice NN i
program NN i
for IN N
each DT N
week NN N
during IN N
the DT N
8 CD N
week NN N
intervention NN N
phase NN N
. . N

Assessments NNS N
will MD N
occur VB N
before IN N
therapy NN N
, , N
after IN N
the DT N
8 CD N
week NN N
therapy NN N
program NN N
, , N
and CC N
at IN N
3 CD N
and CC N
12 CD N
months NNS N
after IN N
the DT N
intervention NN N
. . N

A DT N
falls JJ N
calendar NN N
will MD N
be VB N
kept VBN N
by IN N
each DT N
participant NN N
for IN N
12 CD N
months NNS N
after IN N
outpatient JJ N
therapy.Consistent NN N
with IN N
the DT N
recommendations NNS N
of IN N
the DT N
Prevention NNP N
of IN N
Falls NNP N
Network NNP N
Europe NNP N
group NN N
, , N
three CD N
falls NNS o
variables NNS N
will MD N
be VB N
used VBN N
as IN N
the DT N
primary JJ N
outcome NN N
measures NNS N
: : N
the DT o
number NN o
of IN o
fallers NNS o
, , o
the DT o
number NN o
of IN o
multiple JJ o
fallers NNS o
and CC o
the DT o
falls JJ o
rate NN o
. . o

In IN N
addition NN N
to TO N
quantifying VBG N
falls NNS o
, , N
we PRP N
shall MD N
measure VB N
mobility NN o
, , o
activity NN o
limitations NNS o
and CC o
quality NN o
of IN o
life NN o
as IN N
secondary JJ N
outcomes NNS N
. . N

DISCUSSION NNP N
This DT N
study NN N
has VBZ N
the DT N
potential NN N
to TO N
determine VB N
whether IN N
outpatient JJ N
movement NN N
strategy NN N
training NN N
combined VBN N
with IN N
falls NNS N
prevention JJ N
education NN N
or CC N
progressive JJ N
resistance NN N
strength NN N
training NN N
combined VBN N
with IN N
falls NNS N
prevention JJ N
education NN N
are VBP N
effective JJ N
for IN N
reducing VBG o
falls NNS o
and CC N
improving VBG o
mobility NN o
and CC o
life NN o
quality NN o
in IN N
people NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
who WP p
live VBP p
at IN p
home NN p
. . p

TRIAL NNP N
REGISTRATION NNP N
Australia NNP N
and CC N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Register NNP N
( ( N
ANZCTR NNP N
) ) N
: : N
ACTRN12606000344594 NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effects NNS N
of IN N
transcutaneous JJ i
electrical JJ i
stimulation NN i
of IN i
auricular JJ i
Shenmen NNP i
point NN i
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
in IN N
cesarean JJ p
section NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
transcutaneous JJ N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNP N
point NN N
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
in IN N
cesarean JJ N
section NN N
. . N

METHODS NNP N
After IN N
IRB NNP N
approval NN N
and CC N
informed JJ N
consent NN N
, , N
one CD p
hundred CD p
and CC p
eighty VB p
singleton NN p
primiparas IN p
undergoing VBG p
elective JJ p
cesarean JJ p
section NN p
, , p
in IN p
Qingdao NNP p
Municipal NNP p
Hospital NNP p
, , p
and CC p
Qingdao NNP p
Hiser NNP p
Medical NNP p
Center NNP p
, , p
from IN p
November NNP p
2011 CD p
to TO p
March NNP p
2012 CD p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO N
three CD N
groups NNS N
: : N
transcutaneous JJ i
electrical JJ i
stimulation NN i
of IN i
auricular JJ i
Shenmen NNP i
point NN i
group NN i
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
, , N
transcutaneous JJ i
electrical JJ i
stimulation NN i
of IN i
auricular JJ i
Eye NNP i
point NN i
group NN i
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
and CC N
control NN i
group NN i
( ( N
group NN N
C NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
. . N

Women NNP N
of IN N
group NN N
A NNP N
received VBD N
transcutaneous JJ i
electrical JJ i
stimulation NN i
of IN N
auricular JJ N
Shenmen NNP N
point NN N
( ( N
frequency NN N
1.5 CD N
HZ NNP N
) ) N
at IN N
the DT N
time NN N
of IN N
preoperation NN N
, , N
4 CD N
, , N
10 CD N
and CC N
22 CD N
hours NNS N
of IN N
postoperation NN N
for IN N
30 CD N
minutes NNS N
. . N

The DT N
strength NN N
was VBD N
controlled VBN N
by IN N
themselves PRP N
. . N

Women NNP N
of IN N
group NN N
B NNP N
received VBD N
stimulation NN N
of IN N
auricular JJ N
Eye NNP N
point NN N
as IN N
group NN N
A NNP N
. . N

Women NNP N
of IN N
group NN N
C NNP N
received VBD N
pressurization NN i
and CC i
connected VBN i
line NN i
were VBD i
the DT i
same JJ i
with IN i
group NN i
A NNP i
, , i
but CC i
without IN i
electrical JJ i
stimulation NN i
. . i

The DT N
following JJ N
indexes NNS N
was VBD N
observed VBN N
: : N
the DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
for IN N
48 CD N
hours NNS N
; : N
the DT N
rate NN N
of IN N
metoclopramide NN N
; : N
the DT o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
score NN o
of IN o
rest NN o
pain NN o
, , o
uterine JJ o
contration NN o
pain NN o
and CC o
dynamic JJ o
pain NN o
at IN o
the DT o
time NN o
of IN o
postoperation NN o
for IN o
6 CD o
, , o
12 CD o
, , o
24 CD o
and CC o
48 CD o
hours NNS o
( ( o
T NNP o
( ( o
1 CD o
) ) o
-T NN o
( ( o
4 CD o
) ) o
) ) o
; : o
the DT o
total JJ o
number NN o
and CC o
effective JJ o
compressions NNS o
number NN o
of IN o
patient-controlled JJ o
epidural JJ o
analgesia NN o
( ( o
PCEA NNP o
) ) o
; : o
the DT o
dose NN o
of IN o
analgesia JJ o
mixture NN o
; : o
the DT o
anal JJ o
exhaust JJ o
time NN o
; : o
the DT o
volume NN o
of IN o
postoperative JJ o
bleeding NN o
for IN o
6 CD o
hours NNS o
of IN o
postoperation NN o
and CC o
the DT o
other JJ o
side NN o
effects NNS o
. . o

RESULTS NNP N
Compared NNP N
with IN N
group NN N
B NNP N
and CC N
group NN N
C NNP N
, , N
the DT N
incidence NN o
of IN o
PONV NNP o
, , o
the DT o
rate NN o
of IN o
metoclopramide NN o
, , o
the DT o
VAS NNP o
score NN o
at IN N
the DT N
time NN N
T NNP N
( ( N
1 CD N
) ) N
-T NN N
( ( N
4 CD N
) ) N
, , N
the DT N
total JJ o
number NN o
and CC o
effective JJ o
compressions NNS o
number NN o
of IN o
PCEA NNP o
, , o
the DT o
ratio NN o
of IN o
the DT o
total JJ o
number NN o
with IN o
effective JJ o
compressions NNS o
number NN o
and CC o
the DT o
dose NN o
of IN o
analgesia JJ o
mixture NN o
were VBD N
decreased VBN N
in IN N
group NN N
A NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
no DT N
difference NN N
compared VBN N
group NN N
B NNP N
with IN N
group NN N
C NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
anal JJ o
exhaust NN o
time NN o
and CC o
the DT o
volume NN o
of IN o
postoperative JJ o
bleeding NN o
for IN N
6 CD N
hours NNS N
of IN N
postoperation NN N
were VBD N
no DT N
difference NN N
in IN N
the DT N
three CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

No UH N
other JJ N
side NN o
effects NNS o
were VBD N
observed VBN N
. . N

CONCLUSION NNP N
Transcutaneous NNP N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNS N
point NN N
can MD N
reduce VB N
the DT N
incidence NN o
of IN o
PONV NNP o
and CC o
improves VBZ o
analgesia JJ o
effect NN o
of IN o
PCEA NNP o
in IN o
postoperation NN o
of IN o
cesarean JJ o
section NN o
. . o

-DOCSTART- -X- O O

Abrasive JJ o
wear NN o
on IN N
eroded JJ p
root NN p
dentine NN p
after IN N
different JJ N
periods NNS N
of IN N
exposure NN N
to TO N
saliva VB i
in IN N
situ NN N
. . N

The DT N
effect NN N
of IN N
salivary JJ i
exposure NN N
time NN N
on IN N
the DT N
abrasive JJ o
wear NN o
of IN N
acid-eroded JJ p
dentine NN p
was VBD N
evaluated VBN N
in IN N
situ NN N
. . N

One-hundred JJ p
and CC p
twenty JJ p
bovine NN p
root NN p
dentine NN p
slabs NN p
were VBD N
randomly RB N
assigned VBN N
into IN N
six CD N
groups NNS N
( ( N
A-F NNP N
) ) N
and CC N
placed VBN N
in IN N
intraoral JJ N
palatal JJ N
devices NNS N
, , N
which WDT N
were VBD N
worn VBN N
by IN N
10 CD p
volunteers NNS p
for IN N
4 CD N
d. NN N
On IN N
the DT N
first JJ N
day NN N
, , N
no DT N
erosive/abrasive JJ N
procedures NNS N
were VBD N
carried VBN N
out RP N
. . N

On IN N
the DT N
following VBG N
3 CD N
d NN N
, , N
erosive JJ i
challenges NNS i
were VBD N
performed VBN N
extraorally RB N
, , N
two CD N
times NNS N
per IN N
day NN N
, , N
by IN N
immersing VBG N
the DT N
device NN N
for IN N
90 CD N
s NN N
in IN N
a DT N
soft JJ N
drink NN N
. . N

Subsequently RB N
, , N
the DT N
group NN N
A DT N
specimens NNS N
were VBD N
immediately RB N
brushed VBN N
( ( N
40 CD N
strokes NNS N
) ) N
, , N
and CC N
the DT N
others NNS N
were VBD N
brushed VBN N
after IN N
the DT N
following JJ N
times NNS N
: : N
B NNP N
, , N
20 CD N
min NN N
; : N
C NNP N
, , N
40 CD N
min NN N
; : N
and CC N
D NNP N
, , N
60 CD N
min NN N
. . N

Group NNP N
E NNP N
specimens NNS N
were VBD N
only RB N
acid-eroded JJ N
and CC N
those DT N
of IN N
group NN N
F NNP N
were VBD N
only RB N
brushed VBN N
. . N

Dentine NNP o
wear NN o
was VBD N
measured VBN N
with IN N
a DT N
profilometer NN N
. . N

anova NN N
and CC N
Dunnett NNP N
's POS N
test NN N
showed VBD N
that IN N
groups NNS N
A-D NNP N
did VBD N
not RB N
differ VB N
statistically RB N
from IN N
the DT N
control NN N
group NN N
E NNP N
but CC N
differed VBD N
from IN N
the DT N
control NN N
group NN N
F. NNP N
The DT N
lowest JJS N
mean JJ N
value NN N
was VBD N
found VBN N
for IN N
group NN N
F. NNP N
Regression NNP N
analysis NN N
was VBD N
unable JJ N
to TO N
show VB N
salivary JJ i
effect NN N
on IN N
dentine NN o
wear NN o
reduction NN o
. . o

The DT N
data NN N
suggest NN N
that IN N
the DT N
exposure NN N
time NN N
of IN N
saliva NN N
of IN N
up IN N
to TO N
60 CD N
min NN N
has VBZ N
no DT N
effect NN N
on IN N
reducing VBG N
the DT N
eroded JJ o
dentine NN o
wear NN o
by IN N
toothbrushing VBG N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
use NN N
of IN N
pyridostigmine NN i
and CC N
requirement NN N
of IN N
vecuronium NN i
in IN N
patients NNS p
with IN p
myasthenia JJ p
gravis NN p
. . p

CONTEXT NNP N
Patients NNPS p
with IN p
myasthenia NNP p
gravis FW p
receive JJ p
pyridostigmine NN i
, , p
an DT p
anticholinesterase NN i
agent NN i
, , N
as IN N
a DT N
part NN N
of IN N
therapy NN N
. . N

These DT N
patients NNS N
demonstrate VBP N
a DT N
heightened JJ N
sensitivity NN N
towards IN N
non-depolarising JJ N
muscle NN N
relaxants NNS N
. . N

Continuing VBG N
pyridostigmine NN i
till IN N
the DT N
day NN N
of IN N
the DT N
surgery NN N
or CC N
omitting VBG N
it PRP N
on IN N
the DT N
night NN N
before IN N
surgery NN N
could MD N
provide VB N
variable JJ N
results NNS N
with IN N
regards NNS N
to TO N
the DT N
effect NN N
of IN N
vecuronium NN i
. . i

AIMS NNP N
Myographic NNP N
evaluation NN N
of IN N
a DT N
dose NN N
of IN N
vecuronium NN N
in IN N
patients NNS p
with IN p
myasthenia JJ p
gravis NN p
on IN p
pyridostigmine NN p
therapy NN p
. . p

SETTING NN N
AND CC N
DESIGN NNP N
A NNP N
randomised JJ N
, , N
double-blind JJ N
, , N
clinical JJ N
study NN N
conducted VBN N
in IN N
a DT N
teaching JJ N
hospital NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Medically NNP p
( ( i
oral JJ i
pyridostigmine NN i
) ) i
well-controlled JJ p
adult NN p
patients NNS p
with IN p
myasthenia JJ p
gravis NNS p
who WP p
were VBD p
posted VBN p
for IN p
thymectomy NN i
, , N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

Patients NNS N
in IN N
Group NNP N
1 CD N
received VBD N
their PRP$ N
last JJ N
dose NN N
of IN N
pyridostigmine NN i
on IN i
the DT i
night NN i
before IN i
surgery NN i
while IN N
those DT N
in IN N
Group NNP N
2 CD N
received VBD N
even RB N
the DT N
morning NN i
dose NN i
of IN i
the DT i
drug NN i
on IN i
the DT i
day NN i
of IN i
surgery NN i
. . i

Neostigmine NNP i
( ( N
1-2 JJ N
mg NN N
) ) N
intravenously RB N
was VBD N
used VBN N
as IN N
rescue JJ N
medication NN N
. . N

Vecuronium NNP i
( ( N
0.01 CD N
mg/kg NN N
) ) N
was VBD N
used VBN N
for IN N
intubation NN N
and CC N
muscle NN N
relaxation NN N
during IN N
trans-sternal JJ i
thymectomy NN i
and CC N
its PRP$ N
effect NN N
was VBD N
reversed VBN N
using VBG N
neostigmine NN N
and CC N
atropine NN N
. . N

RESULTS NNP N
Fourteen JJ p
patients NNS p
( ( N
7 CD N
in IN N
each DT N
group NN N
) ) N
belonging NN N
to TO N
both DT N
sexes NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

The DT N
intubating VBG N
dose NN N
of IN N
vecuronium NN N
showed VBD N
quicker JJR N
onset JJ o
time NN o
( ( N
155 CD N
sec NN N
or CC N
2.7 CD N
min NN N
approx NN N
. . N

) ) N
and CC N
peak JJ o
effect NN o
( ( N
99 CD N
% NN N
T1 NNP N
suppression NN N
) ) N
in IN N
patients NNS N
belonging VBG N
to TO N
Group NNP N
1 CD N
, , N
and CC N
3/7 CD N
( ( N
43 CD N
% NN N
) ) N
complained VBD N
of IN N
respiratory JJ N
discomfort NN N
while IN N
waiting VBG N
for IN N
surgery NN N
. . N

By IN N
giving VBG N
the DT N
morning NN N
dose NN N
of IN N
pyridostigmine NN i
( ( N
Group NNP N
2 CD N
) ) N
, , N
an DT N
identical JJ N
intubating NN N
dose NN N
of IN N
vecuronium NN i
showed VBD N
relative JJ o
resistance NN o
( ( N
peak JJ N
effect-97 NN N
% NN N
T1 NNP N
suppression NN N
) ) N
and CC N
delayed VBN o
onset NN o
time NN o
( ( N
198 CD N
sec NN N
approx. NN N
) ) N
. . N

However RB N
, , N
the DT N
reversal NN N
was VBD N
complete JJ N
at IN N
the DT N
end NN N
of IN N
surgery NN N
in IN N
both CC N
the DT N
regimens NNS N
. . N

CONCLUSIONS NNP N
Omission NNP N
of IN N
the DT N
pyridostigmine NN i
dose NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
predisposed VBN N
patients NNS N
with IN N
myasthenia JJ p
gravis NN p
to TO N
the DT N
possibility NN N
of IN N
respiratory JJ N
discomfort NN N
and CC N
sensitivity NN N
to TO N
vecuronium NN i
. . i

Continued VBN N
administration NN N
significantly RB N
prolonged VBD N
the DT N
onset JJ N
time NN N
of IN N
vecuronium NN i
and CC N
the DT N
patients NNS N
required VBD N
a DT N
higher JJR N
dose NN N
of IN N
vecuronium NN i
. . i

-DOCSTART- -X- O O

A DT N
web-based JJ i
approach NN i
to TO N
address VB N
cardiovascular JJ o
risks NNS o
in IN p
managers NNS p
: : p
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
examine VB N
whether IN N
a DT N
Web-based JJ i
health NN i
and CC i
leadership NN i
development NN i
program NN i
-- : i
designed VBN i
specifically RB N
for IN N
managers NNS p
-- : p
was VBD p
associated VBN N
with IN N
changes NNS N
in IN N
self-reported JJ o
and CC o
biometric JJ o
indicators NNS o
of IN o
cardiovascular JJ o
disease NN o
within IN N
the DT N
context NN N
of IN N
a DT N
randomized VBN N
control NN N
trial NN N
. . N

METHODS VB N
A DT N
total NN N
of IN N
145 CD p
managers NNS p
from IN p
8 CD p
organizations NNS p
participated VBN N
in IN N
a DT N
6-month JJ i
Internet-based JJ i
program NN i
or CC i
a DT i
control JJ i
condition NN i
. . i

They PRP N
completed VBD N
pre- NN N
and CC N
posttest NN N
assessments NNS N
that WDT N
included VBD N
both DT N
self-reported JJ o
attitudes NNS o
( ( o
on IN o
diet NN o
, , o
exercise NN o
, , o
and CC o
mental JJ o
health NN o
) ) o
and CC N
biometric JJ o
measures NNS o
( ( o
eg NN o
, , o
body NN o
weight NN o
, , o
waist JJ o
circumference NN o
) ) o
. . o

RESULTS VB N
The DT N
intervention NN i
was VBD N
associated VBN N
with IN N
improvements NNS N
in IN N
dietary JJ o
attitudes NNS o
, , o
dietary JJ o
self-efficacy NN o
, , o
and CC o
exercise NN o
, , o
and CC o
reductions NNS o
in IN o
distress NN o
symptoms NNS o
. . o

Women NNS N
in IN N
the DT N
program NN N
reduced VBD N
their PRP$ N
waist NN o
circumference NN o
significantly RB N
more RBR N
than IN N
controls NNS N
. . N

CONCLUSIONS VB N
The DT N
program NN N
showed VBD N
promise NN N
for IN N
reducing VBG N
cardiovascular JJ o
disease NN o
risk NN o
factors NNS o
. . o

Similar JJ N
results NNS N
across IN N
diverse JJ N
organizations NNS N
suggest VBP N
the DT N
program NN N
may MD N
be VB N
useful JJ N
across IN N
industry NN N
types NNS N
. . N

-DOCSTART- -X- O O

Extracorporeal NNP i
shock NN i
wave NN i
therapy NN i
( ( i
ESWT NNP i
) ) i
in IN N
patients NNS p
with IN p
chronic JJ p
proximal JJ p
plantar NN p
fasciitis NN p
: : p
a DT N
2-year JJ N
follow-up NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
extracorporeal NN i
shock NN i
wave VBP i
therapy NN i
( ( N
ESWT NNP N
) ) N
in IN N
patients NNS N
with IN N
chronically RB p
painful JJ p
proximal JJ p
plantar NN p
fasciitis NN p
with IN N
a DT N
further JJ N
conventional JJ N
conservative JJ N
treatment NN N
. . N

Forty-seven JJ p
patients NNS p
( ( p
49 CD p
feet NNS p
) ) p
with IN p
a DT p
previously RB p
unsuccessful JJ p
nonsurgical JJ p
treatment NN p
of IN p
at IN p
least JJS p
6 CD p
months NNS p
were VBD p
randomized VBN p
to TO p
two CD p
groups NNS p
. . p

Heel NNP i
cups NNS i
had VBD N
to TO N
be VB N
worn VBN N
throughout IN N
the DT N
study NN N
. . N

Group NNP p
1 CD p
( ( p
25 CD p
heels NNS p
) ) p
was VBD N
treated VBN N
immediately RB N
with IN N
three CD N
sessions NNS N
of IN N
ESWT NNP i
( ( i
3000 CD i
shock NN i
waves/session NN i
of IN i
0.2 CD i
mJ/mm2 NN i
) ) i
at IN i
weekly JJ i
intervals NNS i
. . i

The DT N
patients NNS N
of IN N
group NN p
2 CD p
( ( p
24 CD p
heels NNS p
) ) p
continued VBD N
nonsurgical JJ i
treatment NN i
( ( i
iontophoresis NN i
with IN i
diclofenac NN i
and CC i
an DT i
oral JJ i
nonsteroidal JJ i
anti-inflammatory JJ i
drug NN i
) ) i
for IN N
12 CD N
weeks NNS N
. . N

After IN N
this DT N
period NN N
they PRP N
were VBD N
treated VBN N
using VBG N
the DT N
protocol NN N
of IN N
group NN N
1 CD N
. . N

No DT N
significant JJ N
difference NN N
of IN N
pain NN o
and CC o
walking NN o
time NN o
after IN N
further JJ N
nonsurgical JJ N
treatment NN N
( ( N
3 CD N
months NNS N
) ) N
was VBD N
seen VBN N
in IN N
group NN N
2 CD N
. . N

At IN N
12 CD N
weeks NNS N
after IN N
ESWT NNP N
, , N
the DT N
pain NN o
estimation NN o
on IN o
the DT o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
for IN o
activities NNS o
of IN o
daily JJ o
living NN o
diminished VBN N
significantly RB N
by IN N
62.9 CD N
% NN N
in IN N
group NN N
1 CD N
and CC N
by IN N
63.0 CD N
% NN N
in IN N
group NN N
2 CD N
. . N

The DT N
comfortable JJ o
walking NN o
time NN o
had VBD N
increased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
. . N

Two CD N
years NNS N
after IN N
ESWT NNP N
, , N
pain NN o
during IN o
activities NNS o
of IN o
daily JJ o
living NN o
decreased VBN N
by IN N
94 CD N
% NN N
in IN N
group NN N
1 CD N
and CC N
by IN N
90 CD N
% NN N
in IN N
group NN N
2 CD N
on IN N
the DT N
VAS NNP N
and CC N
the DT N
comfortable JJ o
walking NN o
time NN o
had VBD N
increased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -X- O O

Acute NNP N
pressor NN N
and CC N
hormonal JJ N
effects NNS N
of IN N
beta-endorphin NN i
at IN N
high JJ N
doses NNS N
in IN N
healthy JJ p
and CC p
hypertensive JJ p
subjects NNS p
: : p
role NN N
of IN N
opioid JJ N
receptor NN N
agonism NN N
. . N

CONTEXT VB N
The DT N
opioid NN N
system NN N
is VBZ N
involved VBN N
in IN N
blood NN N
pressure NN N
regulation NN N
in IN N
both DT N
normal JJ p
humans NNS p
and CC p
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
a DT N
high-dose JJ N
infusion NN N
of IN N
beta-endorphin NN i
, , N
an DT N
opioid JJ N
peptide NN N
, , N
on IN N
blood NN N
pressure NN N
and CC N
on IN N
the DT N
hormonal JJ N
profile NN N
in IN N
healthy JJ p
subjects NNS p
and CC p
in IN p
hypertensive JJ p
patients NNS p
and CC N
the DT N
mediation NN N
played VBN N
by IN N
opioid JJ N
receptor NN N
agonism NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
According VBG N
to TO N
a DT N
randomized VBN N
double-blind NN N
design NN N
, , N
11 CD p
healthy JJ p
subjects NNS p
( ( p
controls NNS p
) ) p
and CC p
12 CD p
hypertensive JJ p
inpatients NNS p
( ( p
mean JJ p
age NN p
, , p
38.9 CD p
and CC p
40.4 CD p
yr NN p
, , p
respectively RB p
) ) p
received VBD N
1-h JJ i
iv JJ i
infusion NN i
of IN i
beta-endorphin JJ i
( ( i
250 CD i
mug/h NN i
) ) i
and CC i
, , i
on IN i
another DT i
occasion NN i
, , i
the DT i
same JJ i
infusion NN i
protocol NN i
preceded VBN i
by IN i
the DT i
opioid JJ i
antagonist NN i
naloxone NN i
( ( i
8 CD i
mg NN i
) ) i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Hemodynamic NNP o
and CC o
hormonal JJ o
measurements NNS o
were VBD N
performed VBN N
at IN N
established VBN N
times NNS N
during IN N
the DT N
infusion NN N
protocols NNS N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
circulating VBG o
beta-endorphin JJ o
, , o
norepinephrine JJ o
, , o
and CC o
endothelin-1 NN o
in IN N
hypertensive JJ N
patients NNS N
were VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
higher JJR N
than IN N
in IN N
controls NNS N
. . N

In IN N
controls NNS N
, , N
beta-endorphin JJ N
reduced VBD N
blood NN o
pressure NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
circulating VBG o
norepinephrine NN o
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
and CC N
increased VBD N
plasma JJ o
atrial JJ o
natriuretic JJ o
factor NN o
( ( N
P NNP N
< NNP N
0.003 CD N
) ) N
and CC N
GH NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
hypertensive JJ N
patients NNS N
, , N
beta-endorphin JJ i
decreased JJ N
systemic JJ o
vascular NN o
resistance NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
blood NN o
pressure NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
plasma JJ o
norepinephrine NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
endothelin-1 JJ o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
raised VBD N
circulating VBG o
atrial JJ o
natriuretic JJ o
factor NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
GH NNP o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
IGF-I NNP o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

These DT N
hemodynamic JJ o
and CC o
hormonal JJ o
responses NNS o
to TO N
beta-endorphin JJ N
in IN N
hypertensive JJ N
patients NNS N
were VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
greater JJR N
than IN N
in IN N
controls NNS N
but CC N
were VBD N
annulled VBN N
in IN N
all DT N
individuals NNS N
when WRB N
naloxone NN N
preceded VBD N
beta-endorphin JJ N
infusion NN N
. . N

CONCLUSIONS NNP N
High NNP N
doses NNS N
of IN N
beta-endorphin JJ i
induce NN N
hypotensive NN N
and CC N
beneficial JJ N
hormonal JJ N
effects NNS N
in IN N
humans NNS N
, , N
which WDT N
are VBP N
enhanced VBN N
in IN N
essential JJ N
hypertension NN N
and CC N
are VBP N
mediated VBN N
by IN N
opioid JJ N
receptors NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
clinical JJ N
context NN N
on IN N
simulator-based JJ N
assessment NN N
of IN N
blood NN o
pressure NN o
taking VBG p
- : N
a DT N
pilot NN N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
Blood NNP N
pressure NN N
measurement NN N
is VBZ N
an DT N
essential JJ N
clinical JJ N
skill NN N
that WDT N
can MD N
readily RB N
be VB N
assessed VBN N
in IN N
objective JJ N
structured JJ N
clinical JJ N
examination NN N
( ( N
OSCE NNP N
) ) N
. . N

While IN N
the DT N
use NN N
of IN N
simulators NNS i
can MD N
enhance VB N
test NN N
validity NN N
and CC N
reliability NN N
, , N
the DT N
given VBN N
clinical JJ N
context NN N
may MD N
also RB N
affect VB N
student NN N
performance NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
impact NN N
of IN N
variations NNS N
in IN N
clinical JJ N
context NN N
on IN N
blood NN N
pressure NN N
measurement NN N
in IN N
a DT N
simulator-based JJ i
OSCE NNP i
. . i

METHOD NNP N
We PRP N
randomized VBD p
162 CD p
first-year JJ p
medical JJ p
students NNS p
into IN p
four CD p
groups NNS p
that WDT p
received VBD p
different JJ p
lead-in JJ p
statements NNS p
before IN p
measuring VBG p
blood NN o
pressure NN o
on IN p
a DT p
manikin JJ i
simulator NN i
. . i

These DT N
statements NNS N
described VBD N
hypothetical JJ N
patients NNS N
with IN N
different JJ N
likelihoods NNS N
of IN N
having VBG N
systemic JJ o
hypertension NN o
. . o

RESULTS VB N
The DT N
lead-in JJ N
that WDT N
described VBD N
the DT N
highest JJS N
likelihood NN o
of IN o
hypertension NN o
was VBD N
associated VBN N
with IN N
significantly RB N
higher JJR N
reported VBD o
readings NNS o
and CC o
lower JJR o
accuracy NN o
. . o

The DT N
lead-in NN N
that WDT N
suggested VBD N
normality NN N
yielded VBN N
the DT N
best JJS N
performance NN N
. . N

CONCLUSION NNP N
Student NNP p
performance NN N
in IN N
simulator-based JJ i
OSCE NNP i
may MD N
be VB N
affected VBN N
by IN N
the DT N
clinical JJ N
context NN N
provided VBN N
. . N

However RB N
, , N
we PRP N
argue VBP N
that IN N
construct NN N
validity NN N
should MD N
be VB N
viewed VBN N
in IN N
light NN N
of IN N
the DT N
application NN N
of IN N
a DT N
test NN N
, , N
in IN N
that DT N
patients NNS N
may MD N
also RB N
present VB N
with IN N
different JJ N
cues NNS N
and CC N
likelihoods NNS N
of IN N
having VBG N
hypertension NN N
. . N

Variations NNS N
in IN N
construct NN N
design NN N
should MD N
be VB N
further RB N
explored VBN N
to TO N
enhance VB N
the DT N
training NN N
and CC N
assessment NN N
of IN N
clinical JJ N
competence NN N
that WDT N
reflects VBZ N
the DT N
unpredictability NN N
encountered VBN N
in IN N
daily JJ N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

Immune NNP o
status NN o
of IN p
infants NNS p
fed VBN p
soy-based JJ i
formulas NNS i
with IN p
or CC p
without IN p
added JJ i
nucleotides NNS i
for IN p
1 CD p
year NN p
: : p
part NN N
2 CD N
: : N
immune NN N
cell NN N
populations NNS N
. . N

BACKGROUND NNP N
Infants NNPS p
fed VBD p
a DT p
soy JJ i
protein NN i
isolate-based JJ i
formula NN i
have VBP N
immunization NN o
responses NNS o
similar JJ N
to TO N
breast-fed JJ N
infants NNS N
. . N

However RB N
, , N
cellular JJ o
aspects NNS o
of IN o
the DT o
immunologic JJ o
development NN o
of IN N
soy-fed JJ p
infants NNS p
have VBP N
not RB N
been VBN N
studied VBN N
extensively RB N
. . N

Nucleotides NNP i
added VBD N
to TO N
milk-based JJ N
formula NN N
benefit NN N
infant NN N
immune NN N
status NN N
, , N
but CC N
reports NNS N
of IN N
the DT N
immunologic JJ o
effects NNS o
of IN N
adding VBG N
nucleotides NNS i
to TO N
soy-based JJ i
formula NN i
are VBP N
not RB N
available JJ N
. . N

This DT N
study NN N
examines VBZ N
immune RB o
cell JJ o
populations NNS o
of IN N
infants NNS p
fed VBN p
soy JJ i
protein NN i
isolate NN i
formulas NNS i
with IN p
and CC p
without IN p
added VBN p
nucleotides NNS i
for IN p
1 CD p
year NN p
. . p

METHODS NNP N
Newborn NNP p
, , p
term NN p
infants NNS p
studied VBN p
in IN p
a DT p
masked JJ p
12-month JJ p
feeding VBG p
trial NN p
were VBD N
assigned VBN i
randomly RB i
to TO i
soy VB i
formula NN i
groups NNS i
with IN i
and CC i
without IN i
added VBN i
nucleotides NNS i
( ( i
n JJ i
= NN i
94 CD i
, , i
n RB i
= VBZ i
92 CD i
) ) i
. . i

A DT N
nonrandomized JJ p
human JJ i
milk/formula-fed JJ i
cohort NN i
( ( i
n JJ i
= NNP i
81 CD i
) ) i
, , i
was VBD i
concurrently RB N
enrolled VBN N
. . N

Blood NN i
samples NNS i
were VBD i
collected VBN i
at IN i
6 CD i
, , i
7 CD i
, , i
and CC i
12 CD i
months NNS i
. . i

Thirty-two NNP o
immune NN o
cell NN o
populations NNS o
were VBD N
characterized VBN N
using VBG N
three-color JJ N
flow JJ N
cytometry NN N
. . N

Cellular JJ N
markers NNS N
were VBD N
chosen VBN N
to TO N
assess VB N
general JJ o
pediatric JJ o
immune NN o
status NN o
, , o
emphasizing VBG o
maturation NN o
and CC o
activation NN o
of IN o
B NNP o
, , o
T NNP o
, , o
and CC o
NK NNP o
lymphocytes NNS o
. . o

RESULTS NNP N
All NNP N
cell VBP N
populations NNS N
, , N
number NN N
and CC N
percentages NNS N
, , N
were VBD N
within IN N
age-related JJ N
normal JJ N
ranges NNS N
. . N

The DT N
only JJ N
significant JJ N
difference NN N
found VBD N
between IN N
soy JJ i
formula NN i
and CC p
human JJ i
milk/formula-fed JJ i
infants NNS p
was VBD N
the DT N
percentage NN o
of IN o
CD57 NNP o
+ NNP o
NK NNP o
T NNP o
cells NNS o
at IN N
12 CD N
months NNS N
( ( N
human JJ N
milk/formula NN N
> NNP N
soy NN N
formula NN N
, , N
P NNP N
= NNP N
0.034 CD N
) ) N
. . N

There EX N
were VBD N
significant JJ N
differences NNS N
at IN N
some DT N
time NN N
points NNS N
between IN N
human JJ N
milk/formula-fed JJ N
and CC N
nucleotide-supplemented JJ i
soy NN N
formula-fed JJ N
infants NNS N
in IN N
populations NNS o
of IN o
lymphocytes NNS o
, , o
eosinophils NNS o
, , o
total JJ o
T NNP o
, , o
helper NN o
T NNP o
, , o
naive JJ o
helper NN o
, , o
memory/effector NN o
helper NN o
, , o
CD57 NNP o
- : o
T NN o
, , o
and CC o
CD11b NNP o
+ NNP o
CD8 NNP o
+ NNP o
NK NNP o
cells NNS o
. . o

None NN N
of IN N
the DT N
cell NN o
populations NNS o
differed VBD N
between IN N
infants NNS p
fed VBN p
soy JJ p
formula NN p
versus NN N
soy NN N
plus CC N
nucleotides NNS i
. . i

CONCLUSIONS NNP N
Infants NNPS p
fed VBD p
this DT p
commercial JJ p
soy NN p
formula NN p
demonstrated VBD N
immune JJ o
cell NN o
status NN o
similar JJ N
to TO N
human JJ p
milk/formula-fed JJ p
infants NNS p
, , N
consistent JJ N
with IN N
normal JJ N
immune JJ o
system NN o
development NN o
. . o

The DT N
addition NN N
of IN N
nucleotides NNS i
to TO N
soy VB N
formula NN N
did VBD N
not RB N
significantly RB N
change VBP N
specific JJ N
individual JJ N
immune NN o
cell NN o
populations NNS o
but CC N
tended VBD N
to TO N
increase VB N
numbers NNS o
and CC o
percentages NNS o
of IN o
T NNP o
cells NNS o
and CC N
decreased JJ N
numbers NNS o
and CC o
percentages NNS o
of IN o
NK NNP o
cells NNS o
. . o

-DOCSTART- -X- O O

Treatment NN p
of IN p
hepatitis NN p
B NNP p
virus NN p
infection NN p
with IN p
interferon NN i
. . i

Factors NNS N
predicting VBG N
response NN N
to TO N
interferon VB i
. . i

Several JJ N
randomised VBD N
controlled VBN N
trials NNS N
have VBP N
been VBN N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
alpha-interferon NN i
in IN N
the DT N
therapy NN N
of IN N
chronic JJ N
hepatitis NN N
B NNP N
. . N

In IN N
patients NNS p
with IN p
HBe NNP p
antigen-positive JJ p
disease NN p
acquired VBD p
in IN p
adult NN p
life NN p
the DT N
response NN N
rates NNS N
vary VBP N
from IN N
25-50 CD N
% NN N
. . N

In IN N
those DT N
infected VBN N
at IN N
birth NN N
, , N
response NN N
rates NNS N
are VBP N
lower JJR N
. . N

Twenty-one CD p
pretreatment JJ p
variables NNS p
were VBD p
assessed VBN p
for IN p
their PRP$ p
significance NN p
in IN p
response NN o
prediction NN p
using VBG p
data NNS p
from IN p
114 CD p
patients NNS p
given VBN p
alpha-interferon NNS i
for IN p
chronic JJ p
hepatitis NN p
B NNP p
virus NN p
infection NN p
. . p

In IN N
those DT N
patients NNS N
who WP N
had VBD N
received VBN N
a DT N
minimum NN N
of IN N
90 CD N
million CD N
units NNS N
per IN N
m2 NN N
total NN N
dose NN N
over IN N
12 CD N
weeks NNS N
, , N
a DT N
negative JJ N
anti-human JJ o
immunodeficiency NN o
virus NN o
antibody NN o
status NN o
( ( N
p RB N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
chronic JJ o
active JJ o
hepatitis NN o
on IN o
liver NN o
biopsy NN o
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
, , N
high JJ N
AST NNP o
level NN o
( ( N
p RB N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
low JJ N
hepatitis NN o
B NNP o
virus NN o
DNA NNP o
level NN o
( ( N
p RB N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
a DT N
history NN N
of IN N
acute JJ o
hepatitis NN o
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
were VBD N
all DT N
associated VBN N
with IN N
an DT N
increased VBN N
likelihood NN N
of IN N
response NN N
on IN N
univariate JJ N
analysis NN N
. . N

On IN N
stepwise NN N
logistic JJ N
regression NN N
analysis NN N
, , N
hepatitis NN N
B NNP N
virus NN N
DNA NNP N
, , N
AST NNP N
and CC N
a DT N
history NN N
of IN N
acute JJ N
hepatitis NN N
predicted VBD N
response NN N
independently RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
most RBS N
reliable JJ N
combination NN N
of IN N
predictive JJ N
factors NNS N
was VBD N
a DT N
negative JJ N
anti-human JJ o
immunodeficiency NN o
virus NN o
antibody NN o
status NN o
, , N
with IN N
either DT N
a DT N
positive JJ N
history NN N
of IN N
acute JJ o
icteric JJ o
hepatitis NN o
and CC N
AST NNP N
greater JJR N
than IN N
45 CD N
IU NNP N
per IN N
liter NN N
or CC N
no DT N
history NN N
of IN N
acute JJ N
icteric JJ N
hepatitis NN N
and CC N
AST NNP N
greater JJR N
than IN N
85 CD N
IU NNP N
per IN N
liter NN N
, , N
which WDT N
predicted VBD N
response NN N
in IN N
77 CD N
% NN N
with IN N
a DT N
specificity NN N
of IN N
79 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
loss NN N
of IN N
HBsAg NNP o
in IN N
addition NN N
to TO N
HBeAg NNP o
and CC N
hepatitis NN o
B NNP o
virus NN o
DNA NN o
was VBD N
more RBR N
likely JJ N
to TO N
occur VB N
in IN N
patients NNS p
with IN N
chronic JJ N
infection NN N
of IN N
less JJR N
than IN N
2 CD N
years NNS N
duration NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

-DOCSTART- -X- O O

Prospective JJ N
randomized VBN N
evaluation NN N
of IN N
diode-laser NN N
and CC N
cryotherapy NN N
in IN N
prethreshold JJ o
retinopathy NN o
of IN p
prematurity NN p
. . p

PURPOSE NNP N
To TO N
study VB N
the DT N
efficacy NN N
of IN N
indirect JJ N
diode NN N
laser NN N
photocoagulation NN N
and CC N
cryotherapy NN N
in IN N
prethreshold JJ o
retinopathy NN o
of IN o
prematurity NN o
( ( o
ROP NNP o
) ) o
. . N

METHODS NNP N
Thirty-six JJ p
eyes NNS p
of IN p
18 CD p
premature NN p
infants NNS p
less RBR p
than IN p
34 CD p
weeks NNS p
gestational JJ p
age NN p
and/or NN p
less JJR p
than IN p
1600 CD p
g JJ p
birth NN p
weight NN p
with IN p
prethreshold JJ p
ROP NNP p
were VBD N
prospectively RB N
randomized VBN N
to TO N
treatment NN N
with IN N
either DT N
indirect JJ i
laser NN i
photocoagulation NN i
or CC i
cryotherapy NN i
. . i

Prethreshold NNP N
ROP NNP N
was VBD N
defined VBN N
as IN N
any DT N
stage NN N
of IN N
ROP NNP N
in IN N
zone NN N
I PRP N
with IN N
plus JJ N
disease NN N
; : N
or CC N
stage VB N
3 CD N
with IN N
three CD N
or CC N
more JJR N
contiguous JJ N
clock NN N
hours NNS N
or CC N
five CD N
or CC N
more JJR N
total JJ N
clock NN N
hours NNS N
of IN N
involvement NN N
of IN N
retina NN N
in IN N
zone NN N
II NNP N
with IN N
plus JJ N
disease NN N
but CC N
less JJR N
than IN N
threshold JJ N
disease NN N
. . N

Regression NN o
of IN o
the DT o
ROP NNP o
was VBD N
assessed VBN N
for IN N
a DT N
minimum JJ N
period NN N
of IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
Regression NNP o
of IN o
ROP NNP o
occurred VBD N
in IN N
all DT N
36 CD p
eyes NNS p
( ( N
100 CD N
% NN N
) ) N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Excellent JJ N
results NNS N
are VBP N
achieved VBN N
if IN N
ROP NNP o
is VBZ N
treated VBN N
at IN N
the DT N
prethreshold JJ N
stage NN N
with IN N
both DT N
indirect JJ N
laser NN N
photocoagulation NN N
and CC N
cryotherapy NN N
. . N

Although IN N
laser NN N
has VBZ N
definite VBN N
advantages NNS N
, , N
cryotherapy NN N
can MD N
be VB N
considered VBN N
as IN N
an DT N
alternative JJ N
modality NN N
of IN N
treatment NN N
in IN N
developing VBG N
countries NNS N
due JJ N
to TO N
economic JJ N
reasons NNS N
. . N

-DOCSTART- -X- O O

Pretreatment NN N
and CC N
co-administration NN N
of IN N
oral JJ i
anti-diabetic JJ i
agent NN i
with IN N
clomiphene JJ i
citrate NN i
or CC N
rFSH NN i
for IN N
ovulation NN N
induction NN N
in IN N
clomiphene-citrate-resistant JJ p
polycystic JJ p
ovary JJ p
syndrome NN p
. . p

AIM IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
explore VB N
the DT N
result NN N
of IN N
pretreatment NN N
and CC N
concomitant NN N
use NN N
of IN N
metformin NN i
with IN N
clomiphene JJ i
citrate NN i
( ( i
CC NNP i
) ) i
and CC N
rFSH NN i
for IN N
ovulation NN N
induction NN N
in IN N
clomiphene-citrate-resistant JJ p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
done VBN N
in IN N
the DT N
Dhaka NNP p
Medical NNP p
College NNP p
and CC p
Hospital NNP p
and CC p
the DT p
Infertility NNP p
Care NNP p
and CC p
Research NNP p
Centre NNP p
, , p
Dhaka NNP p
, , p
Bangladesh NNP p
. . p

A NNP N
total NN N
of IN N
165 CD p
infertile JJ p
patients NNS p
with IN p
CC-resistant JJ p
PCOS NNP p
who WP p
attended VBD p
for IN p
treatment NN p
were VBD p
the DT p
target NN p
population NN p
for IN p
this DT p
study NN p
. . p

Patients NNS N
were VBD N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
groups NNS N
A DT N
and CC N
B NNP N
were VBD N
given VBN N
metformin NNS i
and CC N
group NN N
C NNP N
was VBD N
the DT N
control NN i
. . i

Along IN N
with IN N
metformin NN i
, , N
group NN N
A NNP N
received VBD N
CC NNP i
and CC N
group NN N
B NNP N
received VBD N
rFSH NN i
. . i

Group NNP N
C NNP N
was VBD N
treated VBN N
with IN N
only RB N
rFSH NN i
. . i

Metformin NNP i
was VBD N
given VBN N
1500 CD N
mg JJ N
daily JJ N
for IN N
4 CD N
weeks NNS N
. . N

Afterwards NNS i
CC NNP i
or CC i
rFSH VB i
were VBD i
added VBN N
for IN N
induction NN N
of IN N
ovulation NN N
along IN N
with IN i
metformin NN i
. . i

Six NNP N
ovulatory JJ N
cycles NNS N
were VBD N
assessed VBN N
. . N

Treatment NNP N
was VBD N
terminated VBN N
when WRB N
there EX N
was VBD N
no DT N
response NN N
with IN N
maximum JJ N
dose NN N
of IN N
CC NNP i
and CC i
rFSH NN i
or CC i
after IN N
six CD N
ovulatory JJ N
cycles NNS N
without IN N
pregnancy NN N
or CC N
after IN N
achieving VBG N
pregnancy NN N
. . N

A DT N
P-value NNP N
of IN N
< NNP N
0.5 CD N
was VBD N
considered VBN N
as IN N
significant JJ N
. . N

RESULTS NNP o
Ovulation NNP o
( ( o
89.09 CD N
% NN N
) ) N
and CC o
pregnancy NN o
( ( o
54.55 CD N
% NN N
) ) N
rates NNS N
were VBD N
higher JJR N
in IN N
group NN N
B. NNP N
Ovulation NNP o
( ( o
74.55 CD N
% NN N
) ) N
and CC o
pregnancy NN o
( ( o
29.09 CD N
% NN N
) ) N
rates NNS N
were VBD N
also RB N
satisfactory JJ N
in IN N
group NN N
C NNP N
but CC N
a DT N
dose NN N
of IN N
rFSH JJ i
requirement NN i
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
= NNP N
0.000 CD N
) ) N
. . N

In IN N
group NN N
A NNP N
, , N
both DT N
ovulation NN o
and CC o
pregnancy NN o
rate NN o
were VBD N
much RB N
lower JJR N
than IN N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
27.27 CD N
% NN N
and CC N
12.73 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Use NNP N
of IN N
metformin NN i
increases VBZ i
the DT N
response NN N
of IN N
ovulation-inducing JJ N
agents NNS N
and CC N
can MD N
be VB N
used VBN N
safely RB N
in IN p
PCOS NNP p
. . p

-DOCSTART- -X- O O

Effectiveness NN N
and CC N
safety NN N
of IN N
inhaled JJ N
treprostinil NN i
for IN N
the DT N
treatment NN N
of IN N
pulmonary JJ p
arterial JJ p
hypertension NN p
in IN p
children NNS p
. . p

The DT N
introduction NN N
of IN N
prostanoid NN i
therapy NN i
has VBZ N
revolutionized VBN N
the DT N
treatment NN N
of IN N
pulmonary JJ N
arterial JJ N
hypertension NN N
( ( N
PAH NNP N
) ) N
. . N

However RB N
, , N
continuous JJ N
intravenous JJ N
prostacyclin NN i
infusion NN N
poses VBZ N
significant JJ N
risks NNS N
and CC N
challenges NNS N
, , N
particularly RB N
in IN N
children NNS p
. . p

Inhaled VBN N
treprostinil NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
efficacious JJ N
in IN N
adults NNS N
. . N

This DT N
study NN N
describes VBZ N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
inhaled JJ N
treprostinil NN i
in IN N
children NNS p
with IN p
PAH NNP p
. . p

A NNP N
retrospective JJ N
analysis NN N
of IN N
29 CD p
children NNS p
treated VBN p
with IN p
inhaled JJ p
treprostinil NN i
for IN p
?6 JJ p
weeks NNS p
was VBD p
performed VBN p
. . p

Effects NNS N
of IN N
inhaled JJ i
treprostinil NN i
on IN i
exercise NN N
capacity NN N
, , N
functional JJ N
class NN N
, , N
and CC N
echocardiographic JJ N
and CC N
hemodynamic JJ N
data NNS N
were VBD N
evaluated VBN N
. . N

Adverse JJ N
events NNS N
were VBD N
documented VBN N
. . N

Patients NNS N
received VBD N
3 CD N
to TO N
9 CD N
breaths NNS N
( ( N
6 CD N
?g/breath NN N
) ) N
of IN N
inhaled VBN i
treprostinil NN i
4 CD i
times/day NN N
. . N

All DT N
were VBD N
receiving VBG i
background NN i
PAH NNP i
therapy NN i
; : i
12 CD i
had VBD N
previously RB N
received VBN N
parenteral JJ N
prostanoid NN N
. . N

Inhaled VBD i
treprostinil NN i
was VBD i
discontinued VBN N
in IN N
4 CD p
patients NNS p
because IN p
of IN N
symptoms NNS N
including VBG o
cough NN o
and CC o
bronchospasm NN o
( ( o
n JJ o
= NNP N
3 CD N
) ) N
and CC N
progression NN o
of IN o
PAH NNP o
( ( o
n JJ o
= NNP N
1 CD N
) ) N
. . N

Mild JJ o
side JJ o
effects NNS o
including VBG o
cough NN o
( ( o
n JJ o
= NNP N
9 CD N
) ) N
and CC N
sore $ o
throat NN o
( ( o
n JJ o
= NNP N
6 CD N
) ) N
did VBD N
not RB N
require VB N
discontinuation NN N
of IN N
therapy NN o
. . o

World NNP o
Health NNP o
Organization NNP o
functional JJ o
class NN o
improved VBN o
in IN N
19 CD N
and CC N
was VBD N
unchanged JJ N
in IN N
10 CD N
; : N
exercise NN o
capacity NN o
significantly RB o
improved VBN N
with IN N
the DT N
6-minute JJ N
walk NN N
distance NN N
, , N
improving VBG N
on IN N
follow-up NN N
from IN N
455.7 CD N
? . N
71.5 CD N
to TO N
498 CD N
? . N
70 CD N
m NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
and CC o
peak JJ o
oxygen NN o
consumption NN o
increasing VBG o
from IN N
25.5 CD N
? . N
10.2 CD N
to TO N
27.4 CD N
? . N
10 CD N
( ( N
p NN N
= RB N
0.04 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
inhaled VBD N
treprostinil NN N
was VBD N
associated VBN N
with IN N
improvement NN o
in IN o
exercise NN o
capacity NN o
and CC o
World NNP o
Health NNP o
Organization NNP o
functional JJ o
class NN o
when WRB N
added VBD N
to TO N
background VB N
targeted JJ p
PAH NNP p
therapy NN p
in IN p
children NNS p
and CC p
had VBD p
an DT N
acceptable JJ N
safety NN N
profile NN N
. . N

Based VBN N
on IN N
these DT N
early JJ N
data NNS N
, , N
further JJ N
study NN N
of IN N
inhaled JJ N
treprostinil NN i
appears VBZ i
warranted VBN p
in IN p
pediatric JJ p
patients NNS p
with IN p
PAH NNP p
. . p

-DOCSTART- -X- O O

Effect NN N
of IN N
chronic JJ i
aerobic JJ i
exercise NN i
and CC i
progressive JJ i
relaxation NN i
on IN N
motor NN N
performance NN N
and CC N
affect NN N
following VBG N
acute JJ N
stress NN N
. . N

The DT N
effects NNS N
of IN N
a DT N
10-week JJ N
aerobic JJ i
exercise NN i
and CC i
progressive JJ i
relaxation NN i
training VBG N
program NN N
on IN N
somatic JJ N
, , N
emotional JJ N
, , N
and CC N
behavioral JJ N
responses NNS N
to TO N
acute VB N
stress NN N
, , N
as IN N
determined VBN N
by IN N
quality NN N
of IN N
motor NN N
performance NN N
and CC N
affect NN N
, , N
were VBD N
examined VBN N
. . N

The DT N
participants NNS N
consisted VBD N
of IN N
60 CD p
unfit JJ p
male NN p
university NN p
undergraduate JJ p
students NNS p
with IN p
no DT p
previous JJ p
training NN p
in IN p
stress JJ p
management NN p
who WP N
were VBD N
randomly RB N
and CC N
evenly RB N
assigned VBD N
to TO N
engage VB N
in IN N
one CD i
of IN i
four CD i
treatments NNS i
over IN i
10 CD i
weeks NNS i
: : i
( ( i
a DT i
) ) i
moderate NN i
aerobic JJ i
exercise NN i
, , i
( ( i
b NN i
) ) i
progressive NN i
relaxation NN i
, , i
( ( i
c NN i
) ) i
a DT i
placebo NN i
group NN i
that WDT i
engaged VBD i
in IN i
group NN i
discussion NN i
but CC i
did VBD i
experience VB i
acute NN i
stress NN i
, , i
and CC i
( ( i
d NN i
) ) i
a DT i
nonintervention NN i
control NN i
group NN i
that WDT i
did VBD i
not RB i
experience VB i
stress NN i
while IN i
performing VBG i
the DT i
motor NN i
task NN i
. . i

Acute NNP N
stress NN N
consisted VBD N
of IN N
losing VBG N
against IN N
a DT N
competitor NN N
of IN N
the DT N
opposite JJ N
sex NN N
on IN N
the DT N
criterion NN N
motor NN N
task NN N
while IN N
receiving VBG N
unpleasant JJ N
information NN N
about IN N
their PRP$ N
performance NN N
over IN N
30 CD N
preintervention NN N
and CC N
30 CD N
postintervention NN N
trials NNS N
. . N

Analyses NNS N
indicated VBD N
that IN N
aerobic JJ N
exercisers NNS N
, , N
in IN N
comparisons NNS N
with IN N
the DT N
other JJ N
groups NNS N
, , N
responded VBD N
to TO N
acute VB o
stress NN o
with IN N
more RBR N
positive JJ N
affect NN N
, , N
lower JJR o
stressor NN o
task JJ o
heart NN o
rate NN o
, , o
reduced VBN o
systolic JJ o
( ( o
but CC o
not RB o
diastolic JJ o
) ) o
blood NN o
pressure NN o
, , N
and CC N
superior JJ N
motor NN o
performance NN o
. . o

Progressive JJ N
relaxation NN N
markedly RB N
reduced VBD N
systolic JJ o
blood NN o
pressure NN o
but CC N
did VBD N
not RB N
favorably RB N
influence JJ N
performance NN N
or CC N
affect VB N
in IN N
response NN N
to TO N
acute VB o
stress NN o
. . o

Placebo NNP N
and CC N
control NN N
groups NNS N
were VBD N
statistically RB N
similar JJ N
on IN N
all DT N
measures NNS N
. . N

The DT N
findings NNS N
indicated VBD N
support NN N
for IN N
the DT N
use NN N
of IN N
chronic JJ N
aerobic JJ N
exercise NN N
as IN N
a DT N
strategy NN N
for IN N
improved JJ N
coping NN N
with IN N
acute JJ N
stress NN N
. . N

-DOCSTART- -X- O O

Short-term JJ N
effect NN N
of IN N
pitavastatin NN i
on IN N
the DT N
reactive JJ o
hyperemic JJ o
index NN o
in IN N
post-menopausal JJ p
women NNS p
with IN p
high JJ p
levels NNS p
in IN p
serum JJ p
LDL-cholesterol NNP p
. . p

-DOCSTART- -X- O O

Influence NN o
of IN N
bony NN p
defects NNS p
on IN N
implant JJ N
stability NN N
. . N

INTRODUCTION NNP N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyze VB N
the DT N
evolution NN N
of IN N
implant JJ N
mechanical JJ N
stability NN N
in IN N
different JJ N
types/sizes NNS N
of IN N
bony NN p
defects NNS p
using VBG N
both DT N
Periotest NNP i
and CC N
Osstell NNP i
devices NNS N
as IN N
objective JJ N
tools NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty-two NNP p
implants NNS p
were VBD p
randomly RB p
allocated VBN p
to TO N
one CD N
of IN N
the DT N
four CD p
types NNS p
of IN p
bone NN p
defects NNS p
: : p
marginal JJ p
bone NN p
loss NN p
, , p
peri-apical JJ p
bone NN p
defect NN p
, , p
constant JJ p
width NN p
dehiscence NN p
and CC p
constant JJ p
length NN p
dehiscences NNS p
. . p

Periotest/Osstell NNP o
measurements NNS o
were VBD N
completed VBN N
before IN N
and CC N
during IN N
staged VBN N
bone NN N
removal NN N
( ( N
to TO N
enlarge VB N
defect JJ N
size NN N
) ) N
. . N

RESULTS NNP N
Significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
initial JJ N
values NNS N
were VBD N
found VBN N
after IN N
a DT N
2 CD N
mm NN N
marginal JJ N
bone NN N
removal NN N
( ( N
Osstell/Periotest NNP N
) ) N
; : N
for IN N
a DT N
peri-apical JJ o
bone NN o
lesion NN o
, , N
after IN N
removal NN N
of IN N
5 CD N
mm NN N
( ( i
Osstell NNP i
) ) i
or CC N
8 CD N
mm NN N
( ( i
Periotest NNP i
) ) i
; : i
for IN N
a DT N
6-mm-long JJ N
dehiscence NN N
, , N
after IN N
removal NN N
up RB N
to TO N
180 CD N
degrees NNS N
of IN N
the DT N
implant JJ N
perimeter NN N
( ( N
Osstell/Periotest NNP N
) ) N
; : N
for IN N
a DT N
3-mm-wide JJ N
dehiscence NN N
, , N
after IN N
removal NN N
of IN N
10 CD N
mm NN N
( ( N
Osstell NNP N
) ) N
or CC N
6 CD N
mm NN N
( ( N
Periotest NNP N
) ) N
. . N

CONCLUSION NNP N
Periotest NNP o
and CC N
Osstell NNP o
are VBP N
in IN N
general JJ N
not RB N
very RB N
sensitive JJ N
in IN N
the DT N
identification NN N
of IN N
peri-implant JJ N
bone NN N
destruction NN N
, , N
except IN N
for IN N
marginal JJ N
bone NN N
loss NN N
. . N

-DOCSTART- -X- O O

Reducing VBG N
breast NN o
cancer NN o
recurrence NN o
with IN N
weight JJ N
loss NN N
, , N
a DT N
vanguard JJ N
trial NN N
: : N
the DT N
Exercise NNP N
and CC N
Nutrition NNP N
to TO N
Enhance VB N
Recovery NNP N
and CC N
Good NNP N
Health NNP N
for IN N
You PRP N
( ( N
ENERGY NNP N
) ) N
Trial NNP N
. . N

Breast NNP N
cancer NN N
is VBZ N
the DT N
most RBS N
common JJ N
invasive JJ N
cancer NN N
among IN N
women NNS N
in IN N
developed JJ N
countries NNS N
. . N

Obesity NN N
is VBZ N
a DT N
major JJ N
risk NN N
factor NN N
for IN N
breast NN N
cancer NN N
recurrence NN N
and CC N
mortality NN N
in IN N
both DT N
pre- JJ p
and CC p
postmenopausal JJ p
women NNS p
. . p

Co-morbid NNP N
medical JJ N
conditions NNS N
are VBP N
common JJ N
among IN N
breast JJ N
cancer NN N
survivors NNS N
. . N

The DT N
Exercise NN N
and CC N
Nutrition NN N
to TO N
Enhance VB N
Recovery NNP N
and CC N
Good NNP N
Health NNP N
for IN N
You PRP N
( ( N
ENERGY NNP N
) ) N
study NN N
is VBZ N
a DT N
4-year JJ N
randomized JJ N
clinical JJ N
trial NN N
of IN p
693 CD p
overweight/obese JJ p
women NNS p
aged VBN p
?21years NNS p
diagnosed VBD p
with IN p
any DT p
early JJ p
stage NN p
breast NN p
cancer NN p
( ( p
stages NNS p
I PRP p
[ VBP p
?1cm JJ p
] NNP p
-III NN p
) ) p
within IN p
the DT p
previous JJ p
five CD p
years NNS p
, , p
designed VBN p
to TO N
demonstrate VB N
the DT N
feasibility NN N
of IN N
achieving VBG N
sustained JJ N
weight JJ N
loss NN N
and CC N
to TO N
examine VB N
the DT N
impact NN N
of IN N
weight JJ N
loss NN N
on IN N
quality NN N
of IN N
life NN N
and CC N
co-morbidities NNS N
, , N
and CC N
to TO N
enable VB N
future JJ N
exploration NN N
of IN N
biochemical JJ N
mechanisms NNS N
linking VBG N
obesity NN N
to TO N
lower JJR N
likelihood NN N
of IN N
disease-free JJ N
survival NN N
. . N

This DT N
trial NN N
is VBZ N
strategically RB N
designed VBN N
as IN N
a DT N
vanguard NN N
for IN N
a DT N
fully-powered JJ N
trial NN N
of IN N
women NNS N
who WP N
will MD N
be VB N
evaluated VBN N
for IN N
breast NN o
cancer NN o
recurrence NN o
and CC o
disease-free JJ o
survival NN o
. . o

Participants NNS o
were VBD p
recruited VBN p
between IN p
2010 CD p
and CC p
2012 CD p
at IN p
four CD p
sites NNS p
, , p
had VBD p
completed VBN p
initial JJ p
therapies NNS p
, , p
and CC p
had VBD p
a DT o
body NN o
mass NN o
index NN o
between IN o
25 CD p
and CC p
45kg/m CD p
( ( p
2 CD p
) ) p
. . p

The DT p
intervention NN N
featured VBD i
a DT i
group-based JJ i
cognitive-behavioral JJ i
weight JJ i
loss NN i
program NN i
with IN i
telephone NN i
counseling NN i
and CC i
tailored VBD i
newsletters NNS i
to TO i
support VB i
initial JJ o
weight NN o
loss NN o
and CC o
subsequent JJ o
maintenance NN o
, , o
with IN o
the DT i
goal NN i
of IN i
7 CD i
% NN i
weight JJ i
loss NN i
at IN i
two CD i
years NNS i
. . i

This DT i
study NN N
has VBZ N
high JJ N
potential NN N
to TO N
have VB N
a DT N
major JJ N
impact NN N
on IN N
clinical JJ N
management NN N
and CC N
outcomes NNS N
after IN N
a DT N
breast NN N
cancer NN N
diagnosis NN N
. . N

This DT N
trial NN N
initiates VBZ N
the DT N
effort NN N
to TO N
establish VB N
weight NN N
loss NN N
support NN N
for IN N
overweight NN p
or CC p
obese JJ p
breast NN p
cancer NN p
survivors NNS p
as IN p
a DT N
new JJ N
standard NN N
of IN N
clinical JJ N
care NN N
. . N

-DOCSTART- -X- O O

Influence NN N
of IN N
two CD N
different JJ N
flap NNS N
designs NNS N
on IN N
the DT N
sequelae NN N
of IN N
mandibular JJ p
third JJ p
molar JJ p
surgery NN p
. . p

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
influence NN N
of IN N
triangular NN N
and CC N
envelope NN N
flaps NNS N
on IN N
trismus NN o
, , o
pain NN o
, , o
and CC o
facial JJ o
swelling NN o
after IN N
mandibular JJ p
third JJ p
molar JJ p
surgery NN p
. . p

METHODS NNP N
Twenty NNP p
healthy JJ p
patients NNS p
with IN p
bilateral JJ p
, , p
symmetrically RB p
impacted JJ p
mandibular JJ p
third JJ p
molars NNS p
were VBD N
included VBN N
in IN N
this DT N
double-blinded JJ N
, , N
prospective JJ N
, , N
cross-over JJ N
, , N
randomized VBN N
study NN N
. . N

The DT N
patients NNS N
were VBD N
operated VBN i
with IN i
envelope NN i
flap NN i
on IN i
one CD i
side NN i
and CC i
triangular JJ i
flap NN i
on IN i
the DT i
other JJ i
side NN i
. . i

Trismus NNP o
was VBD i
determined VBN i
by IN i
measuring VBG i
maximum JJ i
interincisal JJ i
opening NN i
, , i
and CC i
facial JJ o
swelling NN o
was VBD i
evaluated VBN i
using VBG i
a DT i
tape NN i
measuring VBG i
method NN i
. . i

Pain NNP o
was VBD N
determined VBN N
using VBG N
visual JJ i
analog NN i
scale NN i
( ( i
VAS NNP i
) ) i
and CC i
recording VBG i
the DT i
number NN i
of IN i
pain NN i
pills NNS i
taken VBN i
. . i

RESULTS VB N
The DT N
facial JJ o
swelling NN o
measurements NNS o
and CC o
VAS NNP o
scores NNS o
were VBD N
lower JJR N
in IN N
the DT N
envelope NN N
flap NN N
group NN N
compared VBN N
to TO N
the DT N
triangular JJ N
flap NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
flap NN N
designs NNS N
in IN N
operation NN o
time NN o
, , o
maximum JJ o
interincisal NN o
opening NN o
, , o
and CC o
the DT o
number NN o
of IN o
analgesics NNS o
taken VBN o
. . o

CONCLUSION NNP N
Envelope NNP N
flap VBP N
yields NNS N
to TO N
less VB N
facial JJ o
swelling NN o
and CC N
reduced JJ N
VAS NNP o
scores NNS o
in IN N
comparison NN N
to TO N
triangular VB N
flap NN N
. . N

There EX N
is VBZ N
no DT N
clinical JJ N
difference NN N
in IN N
trismus NN N
between IN N
the DT N
two CD N
flap NN N
designs NNS N
. . N

Despite IN N
the DT N
higher JJR N
VAS NNP N
scores NNS N
with IN N
triangular JJ N
flap NN N
, , N
no DT N
additional JJ N
doses NNS N
of IN N
analgesics NNS N
were VBD N
required VBN N
in IN N
triangular JJ N
flap NN N
. . N

-DOCSTART- -X- O O

Comparative JJ N
efficacy NN N
and CC N
safety NN N
of IN N
calcium NN i
carbasalate NN i
plus CC i
metoclopramide JJ i
versus NN i
ergotamine NN i
tartrate NN i
plus CC i
caffeine NN i
in IN N
the DT N
treatment NN N
of IN N
acute JJ p
migraine NN p
attacks NNS p
. . p

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
multicenter NN p
, , N
parallel-group JJ N
study NN N
aimed VBN N
at IN N
comparing VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
calcium NN i
carbasalate NN i
( ( i
equivalent JJ i
to TO i
900 CD i
mg NNS i
aspirin RB i
) ) i
plus CC i
metoclopramide $ i
10 CD i
mg NN i
( ( i
CM NNP i
) ) i
with IN i
ergotamine JJ i
tartrate NN i
1 CD i
mg NN i
plus CC i
caffeine JJ i
100 CD i
mg NN i
( ( i
EC NNP i
) ) i
administered VBN N
in IN N
the DT N
treatment NN N
of IN N
2 CD N
acute JJ N
migraine NN N
attacks NNS N
. . N

A DT N
total NN N
of IN N
296 CD p
patients NNS p
fulfilling VBG p
the DT p
International NNP p
Headache NNP p
Society NNP p
diagnostic JJ p
criteria NNS p
for IN p
migraine NN p
were VBD p
enrolled VBN p
. . p

In IN N
total JJ N
, , N
one CD N
or CC N
two CD N
migraine NN N
attacks NNS N
were VBD N
treated VBN N
in IN N
268 CD N
and CC N
235 CD N
patients NNS N
, , N
respectively RB N
. . N

The DT N
primary JJ N
endpoint NN N
for IN N
the DT N
first JJ N
treated VBD N
attack NN N
was VBD N
headache NN N
relief NN N
, , N
with IN N
intensity NN N
decreasing VBG N
from IN N
moderate JJ N
or CC N
severe JJ N
to TO N
mild VB N
or CC N
absent VB N
2 CD N
h NN N
after IN N
drug NN N
intake NN N
. . N

Usual JJ N
secondary JJ N
efficacy NN N
endpoints NNS N
were VBD N
assessed VBN N
. . N

A DT N
superiority NN N
of IN N
CM NNP i
over IN N
EC NNP i
was VBD N
observed VBN N
for IN N
both DT N
treated JJ N
attacks NNS N
for IN N
the DT N
main JJ N
endpoint NN N
: : N
success NN N
in IN N
54 CD N
versus NN N
36 CD N
% NN N
, , N
p NN N
= VBD N
0.003 CD N
for IN N
the DT N
first JJ N
attack NN N
and CC N
60 CD N
versus NN N
44 CD N
% NN N
, , N
p NN N
= VBD N
0.02 CD N
for IN N
the DT N
second JJ N
attack NN N
. . N

CM NNP o
was VBD o
also RB o
significantly RB o
superior JJ o
to TO o
EC NNP o
during IN o
the DT o
first JJ o
attack NN o
for IN o
complete JJ o
headache NN o
relief NN o
( ( o
20 CD o
vs. FW o
8 CD o
% NN o
, , o
p NN o
= NNP o
0.006 CD o
) ) o
, , o
nausea NN o
( ( o
42 CD o
vs. FW o
63 CD o
% NN o
, , o
p NN o
= VBD o
0 CD o
. . o

007 CD o
) ) o
and CC o
willingness NN o
to TO o
take VB o
the DT o
drug NN o
again RB o
( ( o
90 CD o
vs. FW o
80 CD o
% NN o
, , o
p NN o
= NNP o
0.043 CD o
) ) o
. . o

The DT o
global JJ o
efficacy NN o
evaluation NN o
, , o
rated VBN o
by IN o
the DT o
investigators NNS o
, , o
was VBD o
significantly RB o
more RBR o
favorable JJ o
to TO o
CM NNP o
for IN o
both DT o
attacks NNS o
( ( o
p VB o
= $ o
0.001 CD o
for IN o
the DT o
first JJ o
attack NN o
and CC o
p NN o
= VBP o
0.02 CD o
for IN o
the DT o
second JJ o
) ) o
. . o

The DT o
patients NNS o
' POS o
evaluation NN o
was VBD o
significant JJ o
for IN o
the DT o
first JJ o
attack NN o
( ( o
p JJ o
= NNP o
0.002 CD o
) ) o
. . o

The DT o
global JJ o
incidence NN o
of IN o
adverse JJ o
events NNS o
was VBD o
45 CD o
% NN o
higher JJR o
with IN o
EC NNP o
, , o
though IN o
not RB o
significant JJ o
( ( o
32 CD o
vs. FW o
22 CD o
% NN o
, , o
p NN o
= NNP o
0.075 CD o
) ) o
. . o

They PRP o
were VBD o
most RBS o
often RB o
unspecific JJ o
and CC o
mild JJ o
to TO o
moderate VB o
in IN o
intensity NN o
. . o

Gastrointestinal JJ o
side NN o
effects NNS o
were VBD o
significantly RB o
less RBR o
frequent JJ o
with IN o
CM NNP o
than IN o
EC NNP o
( ( o
7 CD o
vs. FW o
21 CD o
% NN o
, , o
p NN o
= NNP o
0.001 CD o
) ) o
. . o

Thus RB o
, , o
CM NNP o
is VBZ o
more RBR o
effective JJ o
and CC o
has VBZ o
a DT o
better JJR o
gastrointestinal JJ o
safety NN o
than IN o
EC NNP o
in IN o
the DT o
acute JJ o
treatment NN o
of IN o
migraine NN o
attacks NNS o
. . o

-DOCSTART- -X- O O

Antifungal NNP N
prophylaxis NN N
during IN N
remission NN p
induction NN p
therapy NN p
for IN p
acute JJ p
leukemia NN p
fluconazole JJ N
versus NN i
intravenous JJ i
amphotericin NN i
B NNP i
. . i

BACKGROUND NNP N
Fungal NNP N
infection NN N
is VBZ N
a DT N
frequent JJ N
and CC N
often RB N
fatal JJ N
complication NN N
in IN N
patients NNS p
undergoing JJ p
remission NN p
induction NN p
therapy NN p
for IN p
acute JJ p
leukemia NN p
. . p

Although IN N
candidiasis NN N
is VBZ N
the DT N
most RBS N
common JJ N
infection NN N
, , N
mold JJ N
infections NNS N
are VBP N
increasing VBG N
in IN N
frequency NN N
. . N

Fluconazole NNP i
( ( i
FLU NNP i
) ) i
is VBZ N
a DT N
new JJ N
antifungal JJ N
agent NN N
that WDT N
has VBZ N
been VBN N
used VBN N
successfully RB N
to TO N
treat VB N
Candida NNP N
infections NNS N
and CC N
has VBZ N
modest JJ N
activity NN N
against IN N
aspergillosis NN N
in IN N
animal JJ N
models NNS N
. . N

Subtherapeutic JJ N
doses NNS N
of IN N
amphotericin NN i
B NNP i
( ( i
AMB NNP i
) ) i
have VBP N
been VBN N
considered VBN N
effective JJ N
as IN N
prophylaxis NN N
in IN N
these DT N
patients NNS N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
efficacy NN o
and CC o
toxicity NN o
of IN N
these DT N
agents NNS N
as IN N
antifungal JJ N
prophylaxis NN N
. . N

METHODS NNP N
Adults NNP p
with IN p
acute JJ p
leukemia NN p
undergoing VBG p
remission NN p
induction NN p
chemotherapy NN p
randomly NN N
were VBD N
assigned VBN N
to TO N
receive VB i
antifungal JJ i
prophylaxis NN i
with IN i
AMB NNP i
( ( i
0.5 CD i
mg/kg NN i
three CD i
times NNS i
weekly JJ i
) ) i
or CC i
FLU NNP i
( ( i
400 CD i
mg NNS i
daily RB i
) ) i
. . i

Trimethoprim-sulfamethoxazole NN i
was VBD i
administered VBN i
as IN i
an DT i
antibacterial JJ i
prophylaxis NN i
. . i

Prophylaxis NNP i
was VBD i
continued VBN i
until IN i
the DT i
patient NN i
achieved VBD i
complete JJ i
remission NN i
or CC i
was VBD i
treated VBN i
for IN i
8 CD i
weeks NNS i
without IN i
antileukemic JJ i
response NN i
. . i

Prophylaxis NNP N
was VBD N
discontinued VBN N
if IN N
the DT N
patient NN N
experienced VBD N
a DT N
possible JJ N
or CC N
proven JJ N
fungal JJ N
infection NN N
or CC N
a DT N
serious JJ N
toxicity NN N
. . N

RESULTS NNP N
Overall NNP N
, , N
58 CD N
% NN N
of IN N
the DT N
36 CD p
patients NNS p
assigned VBN N
to TO N
AMB NNP i
successfully RB N
completed VBD N
prophylaxis NNS N
compared VBN N
with IN N
80 CD N
% NN N
of IN N
the DT N
41 CD p
patients NNS p
assigned VBN N
to TO N
FLU NNP i
( ( N
< NNP N
0.05 CD N
) ) N
. . N

Proven NNP o
, , o
probable JJ o
, , o
or CC o
possible JJ o
fungal JJ o
infections NNS o
occurred VBD N
in IN N
31 CD N
% NN N
and CC N
17 CD N
% NN N
of IN N
the DT N
patients NNS N
, , N
respectively RB N
. . N

The DT N
risk NN N
of IN N
discontinuing VBG N
prophylaxis NN N
due JJ N
to TO N
fungal JJ o
infection NN o
or CC N
toxicity NN o
increased VBN N
with IN N
time NN N
in IN N
the DT N
study NN N
and CC N
was VBD N
significantly RB N
greater JJR N
for IN N
AMB NNP N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS NN N
At IN N
the DT N
dose NN N
used VBN N
in IN N
this DT N
study NN N
, , N
AMB NNP i
was VBD N
no DT N
more RBR N
effective JJ o
and CC N
was VBD N
more JJR N
toxic JJ o
than IN N
FLU NNP i
for IN N
prophylaxis NN N
of IN N
fungal JJ o
infections NNS o
in IN N
patients NNS p
undergoing JJ p
remission NN p
induction NN p
chemotherapy NN p
for IN p
acute JJ p
leukemia NN p
. . p

-DOCSTART- -X- O O

A DT N
randomized VBN N
study NN N
on IN N
hormone-resistant JJ p
prostatic JJ p
cancer NN p
: : p
estramustine JJ i
phosphate NN i
versus NN N
low JJ i
dose JJ i
epirubicin NN i
with IN i
or CC i
without IN i
medroxyprogesterone JJ i
acetate NN i
. . i

A DT N
Norwegian JJ N
multicenter NN N
study NN N
. . N

A DT N
prospective JJ N
randomized NN N
study NN N
has VBZ N
been VBN N
carried VBN N
out RP N
in IN N
order NN N
to TO N
compare VB N
three CD N
different JJ N
treatment NN N
modalities NNS N
for IN N
symptomatic JJ p
metastatic JJ p
hormone-resistant JJ p
prostatic JJ p
cancer NN p
. . p

A DT N
total NN p
of IN p
79 CD p
patients NNS p
were VBD p
included VBN p
. . p

One CD N
group NN N
was VBD N
treated VBN i
with IN i
estramustine JJ i
phosphate NN i
, , i
another DT i
with IN i
Epirubicin NNP i
plus CC i
Medroxyprogesterone NNP i
acetate NN i
( ( i
MPA NNP i
) ) i
, , i
while IN i
the DT i
third JJ i
arm NN i
consisted VBD i
of IN i
Epirubicin NNP i
plus CC i
placebo NN i
. . i

Best JJS o
palliation NN o
was VBD N
obtained VBN N
by IN N
the DT N
combination NN N
of IN N
Epirubicin NNP i
and CC i
MPA NNP i
. . i

This DT N
combination NN N
also RB N
seemed VBD N
to TO N
be VB N
associated VBN N
with IN N
the DT N
longest JJS N
response NN N
duration NN N
. . N

-DOCSTART- -X- O O

NSAID NNP i
Pretreatment NNP N
Inhibits NNP N
Prostaglandin NNP o
Release NNP o
in IN N
Femtosecond NNP i
Laser-Assisted NNP i
Cataract NNP i
Surgery NNP i
. . i

PURPOSE NNP N
To TO N
investigate VB N
whether IN N
short-term JJ N
nonsteroidal JJ i
anti-inflammatory JJ i
drug NN i
( ( i
NSAID NNP i
) ) i
pretreatment NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
inhibits NNS N
prostaglandin VBP o
release NN o
. . o

Previous JJ N
studies NNS N
detected VBN N
elevated JJ N
prostaglandin NN o
levels NNS o
after IN N
femtosecond NN i
laser NN i
treatment NN i
and CC N
identified VBD N
them PRP N
as IN N
a DT N
potential JJ N
mediator NN N
for IN N
laser-induced JJ N
miosis NN N
. . N

METHODS NNP N
Patients NNPS p
underwent JJ p
either CC p
image-guided JJ i
femtosecond NN i
laser NN i
cataract NN i
surgery NN i
or CC i
conventional JJ i
cataract NN i
surgery NN i
( ( p
n JJ p
= NNP p
75 CD p
) ) p
. . p

Half NN N
of IN N
the DT N
eyes NNS N
per IN N
group NN N
received VBD N
topical JJ i
NSAID NNP i
treatment NN i
on IN N
the DT N
day NN N
of IN N
surgery NN N
. . N

Aqueous JJ N
humor NN N
was VBD N
collected VBN N
from IN N
all DT p
patients NNS p
. . p

ELISA JJ N
measurements NNS N
were VBD N
performed VBN N
to TO N
detect VB N
aqueous JJ o
humor NN o
prostaglandin NN o
levels NNS o
. . o

RESULTS NNP N
Femtosecond NNP i
laser NNP i
cataract NN i
surgery NN i
led VBD N
to TO N
higher JJR N
prostaglandin NN o
levels NNS o
than IN N
conventional JJ i
cataract NN i
surgery NN i
( ( N
P NNP N
= NNP N
.007 NNP N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
NSAID NNP i
pretreatment NN i
led VBD N
to TO N
reduced VBN N
prostaglandin NN o
release NN o
. . o

In IN N
the DT N
femtosecond NN p
laser NN p
group NN p
, , p
patients NNS p
pretreated VBD i
with IN i
NSAIDs NNP i
had VBD N
significantly RB N
lower JJR N
prostaglandin NN o
values NNS o
( ( N
65.3 CD N
? . N
13.2 CD N
pg/mL NN N
) ) N
than IN p
patients NNS i
not RB i
pretreated VBN i
with IN i
NSAIDs NNP i
( ( N
294.4 CD N
? . N
66.5 CD N
pg/mL NN N
) ) N
( ( N
P NNP N
= NNP N
.0009 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
short-term JJ i
NSAID NNP i
treatment NN i
prevented VBD o
prostaglandin JJ o
release NN o
in IN o
patients NNS p
treated VBN p
with IN i
image-guided JJ i
femtosecond NN i
laser NN i
. . i

Therefore RB N
, , N
it PRP N
has VBZ N
potential JJ N
to TO N
limit VB N
intraoperative JJ N
laser-induced JJ N
miosis NN N
. . N

-DOCSTART- -X- O O

[ JJ i
Afala NNP i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
BPH NNP p
: : p
efficacy NN N
and CC N
safety NN N
] NN N
. . N

The DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
clinical JJ N
trial NN N
involving VBG N
94 CD p
patients NNS p
has VBZ N
evaluated VBN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
domestic JJ N
preparation NN N
afala NN i
in IN N
patients NNS p
with IN p
symptoms NNS p
of IN p
I-II NNP p
stages NNS p
benign VBP p
prostatic JJ p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
. . p

It PRP N
was VBD N
shown VBN N
that IN N
a DT N
6-month JJ N
course NN N
of IN N
treatment NN N
with IN N
afala NN i
at IN i
a DT i
dose NN i
of IN i
2 CD i
tablets NNS i
4 CD i
times NNS i
a DT i
day NN i
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
severity NN N
of IN N
urinary JJ N
disorders NNS N
, , N
estimated VBN N
by IN N
total JJ N
IPSS NNP N
score NN N
, , N
relative JJ N
to TO N
baseline VB N
values NNS N
and CC N
compared VBN N
to TO N
placebo VB i
therapy NN N
. . N

The DT N
most RBS N
pronounced JJ N
therapeutic JJ N
effects NNS N
of IN N
the DT N
drug NN N
were VBD N
registered VBN N
in IN N
respect NN N
of IN N
irritative JJ N
symptoms NNS N
of IN N
BPH NNP N
. . N

According VBG N
uroflowmetry NN N
, , N
peak JJ o
flow NN o
rate NN o
after IN o
6 CD N
months NNS N
of IN N
treatment NN N
was VBD N
increased VBN N
by IN N
more JJR N
than IN N
50 CD N
% NN N
. . N

Significant JJ N
clinical JJ N
benefit NN N
persisted VBD N
not RB N
only RB N
within IN N
the DT N
6-month JJ N
course NN N
of IN N
therapy NN N
, , N
but CC N
3 CD N
months NNS N
after IN N
. . N

Long-term JJ N
therapy NN N
had VBD N
no DT N
effect NN N
on IN N
the DT N
concentration NN o
of IN o
total JJ o
, , o
free JJ o
and CC o
complex JJ o
PSA NNP o
, , o
testosterone NN o
( ( o
total JJ o
and CC o
free JJ o
) ) o
, , o
dihydrotestosterone NN o
, , o
and CC o
prolactin NN o
in IN o
the DT o
blood NN o
. . o

Absence NN o
of IN o
adverse JJ o
effects NNS o
, , o
biochemical JJ o
abnormalities NNS o
, , o
changes NNS o
in IN o
clinical JJ o
blood NN o
and CC o
urine NN o
confirmed VBD N
the DT N
safety NN N
of IN N
6-month JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

Children NNP N
's POS N
Yale-Brown JJ N
Obsessive NNP N
Compulsive NNP N
Scale NNP N
modified VBD N
for IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
psychometric JJ N
properties NNS N
of IN N
the DT N
Children NNP i
's POS i
Yale-Brown JJ i
Obsessive NNP i
Compulsive NNP i
Scales NNP i
( ( i
CYBOCS NNP i
) ) i
modified VBD i
for IN i
pervasive JJ i
developmental NN i
disorders NNS i
( ( i
PDDs NNP i
) ) i
. . i

METHOD NNP N
Raters NNPS N
from IN N
five CD N
Research NNP N
Units NNS N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
( ( N
RUPP NNP N
) ) N
Autism NNP N
Network NNP N
were VBD N
trained VBN N
to TO N
reliability NN N
. . N

The DT N
modified JJ N
scale NN N
( ( i
CYBOCS-PDD NNP i
) ) i
, , N
which WDT N
contains VBZ N
only RB N
the DT N
five CD i
Compulsion NNP i
severity NN i
items NNS i
( ( N
range VB N
0-20 NN N
) ) N
, , N
was VBD N
administered VBN p
to TO p
172 CD p
medication-free JJ p
children NNS p
( ( p
mean JJ p
8.2 CD p
+/- JJ p
2.6 CD p
years NNS p
) ) p
with IN p
PDD NNP p
( ( p
autistic JJ p
disorder NN p
, , p
n JJ p
= VBP p
152 CD p
; : p
Asperger NNP p
's POS p
disorder NN p
, , p
n JJ p
= VBP p
6 CD p
; : p
PDD NNP p
not RB p
otherwise RB p
specified VBN p
, , p
n JJ p
= NNP p
14 CD p
) ) p
participating NN p
in IN p
RUPP NNP p
clinical JJ p
trials NNS p
. . p

Reliability NNP o
was VBD N
assessed VBN N
by IN N
intraclass NN N
correlation NN N
coefficient NN N
( ( N
ICC NNP N
) ) N
and CC N
internal JJ N
consistency NN N
by IN N
Cronbach NNP N
's POS N
alpha JJ N
coefficient NN N
. . N

Correlations NNS N
with IN N
ratings NNS N
of IN N
repetitive JJ N
behavior NN N
and CC N
disruptive JJ N
behavior NN N
were VBD N
examined VBN N
for IN N
validity NN N
. . N

RESULTS NNP N
Eleven NNP N
raters NNS N
showed VBD N
excellent JJ N
reliability NN o
( ( N
ICC NNP N
= NNP N
0.97 CD N
) ) N
. . N

The DT N
mean JJ o
CYBOCS NNP o
score NN o
was VBD N
14.4 CD N
( ( N
+/- JJ N
3.86 CD N
) ) N
with IN N
excellent JJ N
internal JJ o
consistency NN o
( ( N
alpha JJ N
= NNP N
.85 NNP N
) ) N
. . N

Correlations NNS N
with IN N
other JJ N
measures NNS N
of IN N
repetitive JJ N
behavior NN N
ranged VBD N
from IN N
r NN N
= $ N
0.11 CD N
to TO N
r VB N
= JJ N
0.28 CD N
and CC N
were VBD N
similar JJ N
to TO N
correlations NNS N
with IN N
measures NNS o
of IN o
irritability NN o
( ( N
r JJ N
= NNP N
0.24 CD N
) ) N
and CC N
hyperactivity NN o
( ( N
r JJ N
= NNP N
0.25 CD N
) ) N
. . N

Children NNP p
with IN p
higher JJR p
scores NNS p
on IN N
the DT N
CYBOCS-PDD NNP N
had VBD N
higher JJR N
levels NNS N
of IN N
maladaptive JJ o
behaviors NNS o
and CC o
lower JJR o
adaptive JJ o
functioning NN o
. . o

CONCLUSIONS VB N
The DT N
five-item JJ N
CYBOCS-PDD NNP N
is VBZ N
reliable JJ N
, , N
distinct JJ N
from IN N
other JJ N
measures NNS N
of IN N
repetitive JJ N
behavior NN N
, , N
and CC N
sensitive JJ N
to TO N
change VB N
. . N

-DOCSTART- -X- O O

The DT N
SNRI NNP i
venlafaxine NN i
improves VBZ N
emotional JJ o
unawareness NN o
in IN N
patients NNS p
with IN p
post-stroke JJ p
depression NN p
. . p

OBJECTIVE CC N
Patients NNPS p
with IN p
stroke NNS p
have VBP N
a DT N
high JJ N
prevalence NN N
of IN N
depression NN N
and CC N
unawareness NN N
of IN N
emotions NNS N
or CC N
alexithymia NN o
. . o

Here RB N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
the DT N
serotoninergic NN i
and CC i
noradrenergic JJ i
reuptake NN i
inhibitor NN i
( ( i
SNRI NNP i
) ) i
venlafaxine NN i
in IN N
comparison NN N
with IN N
the DT N
SSRI NNP i
fluoxetine NN i
on IN N
alexithymia NN o
severity NN N
in IN N
patients NNS p
with IN p
DSM-IV NNP p
post-stroke JJ p
major JJ p
depressive-like JJ p
episode NN p
( ( p
PSD NNP p
) ) p
. . p

METHODS NNP N
Fifty NNP p
inpatients NNS p
with IN p
first-ever JJ p
stroke NN p
and CC p
PSD NNP p
were VBD p
consecutively RB p
enrolled VBN p
in IN N
this DT N
randomized JJ N
open-label NN N
study NN N
. . N

Twenty-five JJ N
were VBD N
treated VBN N
with IN N
the DT N
SNRI NNP i
venlafaxine NN i
SR NNP N
( ( N
75-150 JJ N
mg/die NN N
) ) N
, , N
and CC N
25 CD N
with IN N
the DT N
SSRI NNP i
fluoxetine NN i
( ( N
20-40 JJ N
mg/die NN N
) ) N
. . N

All DT N
patients NNS N
were VBD N
assessed VBN N
at IN N
day NN N
0 CD N
, , N
and CC N
after IN N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
8 CD N
weeks NNS N
, , N
using VBG N
the DT N
Mini-Mental JJ o
State NNP o
Examination NNP o
, , o
the DT o
Hamilton NNP o
Depression NNP o
Rating NNP o
Scale NNP o
, , o
and CC o
the DT o
Toronto NNP o
Alexithymia NNP o
Scale NNP o
( ( N
TAS-20 NNP N
) ) N
. . N

RESULTS JJ N
Patients NNS N
treated VBN N
with IN N
fluoxetine NN N
and CC N
those DT N
treated VBN N
with IN N
venlafaxine NN N
showed VBD N
similar JJ N
improvement NN N
in IN N
depressive JJ o
symptoms NNS o
. . o

However RB N
, , N
patients NNS N
treated VBD N
with IN N
venlafaxine NN N
had VBD N
a DT N
greater JJR N
improvement NN N
on IN N
alexithymia NN o
severity NN o
than IN N
those DT N
treated VBN N
with IN N
fluoxetine NN N
. . N

The DT N
effect NN N
of IN N
venlafaxine NN N
on IN N
unawareness NN o
of IN o
emotions NNS o
was VBD N
evident JJ N
in IN N
patients NNS N
with IN N
alexithymia NN N
( ( N
TAS-20 NNP N
> NNP N
or= IN N
61 CD N
) ) N
at IN N
the DT N
baseline NN N
and CC N
in IN N
those DT N
without IN N
alexithymia NN N
( ( N
TAS-20 NNP N
< NNP N
61 CD N
) ) N
. . N

CONCLUSIONS JJ N
Antidepressants NNPS N
acting VBG N
on IN N
both CC N
the DT N
serotoninergic NN N
and CC N
noradrenergic JJ N
systems NNS N
might MD N
represent VB N
a DT N
valid JJ N
resource NN N
not RB N
only RB N
for IN N
the DT N
treatment NN N
of IN N
depression NN N
but CC N
also RB N
for IN N
improving VBG N
emotional JJ o
unawareness NN o
in IN N
stroke NN p
patients NNS p
. . p

-DOCSTART- -X- O O

Perioperative JJ i
enteral JJ i
nutrition NN i
and CC N
quality NN o
of IN o
life NN o
of IN N
severely RB p
malnourished VBN p
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
This DT N
study NN N
evaluated VBD N
the DT N
use NN N
of IN N
perioperative JJ i
nutritional JJ i
support NN i
on IN N
Quality NN o
of IN o
Life NNP o
( ( o
QOL NNP o
) ) o
in IN N
malnourished VBN p
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
undergoing VBG p
surgery NN p
. . p

METHODS NNP N
49 CD p
Malnourished NNP p
( ( p
weight JJ p
loss NN p
> VBZ p
10 CD p
% NN p
) ) p
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
who WP p
were VBD p
included VBN p
in IN p
a DT p
nutrition NN p
intervention NN p
trial NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
no DT i
preoperative JJ i
and CC i
standard JJ i
postoperative JJ i
tube-feeding NN i
( ( i
group NN i
I PRP i
) ) i
, , i
standard JJ i
preoperative NN i
and CC i
postoperative JJ i
tube-feeding NN i
( ( i
group NN i
II NNP i
) ) i
or CC N
arginine-supplemented JJ i
preoperative NN i
and CC i
postoperative JJ i
tube-feeding NN i
( ( N
group NN N
III NNP N
) ) N
. . N

Of IN N
these DT N
patients NNS p
, , N
31 CD N
completed VBD N
a DT N
full JJ N
QOL NNP o
assessment NN o
on IN N
the DT N
first JJ N
day NN N
of IN N
preoperative JJ N
nutritional JJ N
support NN N
, , N
one CD N
day NN N
before IN N
surgery NN N
, , N
and CC N
6 CD N
months NNS N
after IN N
surgery NN N
. . N

Both CC N
a DT N
disease-specific NN N
( ( N
EORTC NNP N
QLQ-C30 NNP N
) ) N
and CC N
a DT N
generic JJ N
questionnaire NN N
( ( N
COOP-WONCA NNP N
) ) N
were VBD N
used VBN N
. . N

One CD N
way NN N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
and CC N
the DT N
Kruskal-Wallis NNP N
test NN N
were VBD N
applied VBN N
for IN N
testing VBG N
differences NNS N
in IN N
scores NNS N
between IN N
groups NNS N
. . N

RESULTS NNP N
Between NNP N
baseline NN N
and CC N
the DT N
day NN N
before IN N
surgery NN N
, , N
both DT N
preoperatively RB i
fed VBN i
groups NNS N
revealed VBD N
a DT N
positive JJ N
change NN N
for IN N
the DT N
dimensions NNS N
physical JJ o
and CC o
emotional JJ o
functioning NN o
and CC o
dyspnea NN o
( ( N
with IN N
significance NN N
in IN N
group NN N
II NNP N
, , N
P=0.050,0.031,0.045 NNP N
respectively RB N
) ) N
. . N

Group NNP N
III NNP N
showed VBD N
a DT N
negative JJ N
change NN N
in IN N
appetite NN o
( ( N
P=0.049 NNP N
) ) N
. . N

Between NNP N
baseline NN N
and CC N
6 CD N
months NNS N
after IN N
surgery NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
group NN N
I PRP N
and CC N
both DT i
pre-fed JJ i
groups NNS i
. . i

There EX N
were VBD N
no DT N
differences NNS N
in IN N
favour NN N
of IN N
group NN N
III NNP N
compared VBN N
to TO N
group NN N
II NNP N
. . N

CONCLUSION NNP N
Enteral NNP i
nutrition NN i
improves VBZ N
QOL NNP o
of IN N
severely RB N
malnourished VBN N
head NN N
and CC N
neck NN N
cancer NN N
patients NNS N
in IN N
the DT N
period NN N
preceding VBG N
surgery NN N
. . N

No DT N
benefit NN N
of IN N
preoperative JJ i
enteral JJ i
feeding NN i
on IN N
QOL NNP o
could MD N
be VB N
demonstrated VBN N
6 CD N
months NNS N
after IN N
surgery NN N
. . N

-DOCSTART- -X- O O

Fluvoxamine NNP i
as RB N
effective JJ N
as IN N
clomipramine NN i
against IN N
symptoms NNS N
of IN N
severe JJ o
depression NN o
: : o
results NNS N
from IN N
a DT N
multicentre NN N
, , N
double-blind NN N
study NN N
. . N

BACKGROUND NNP N
Although IN N
selective JJ N
serotonin NNS N
reuptake VBP N
inhibitors NNS N
( ( N
SSRIs NNP N
) ) N
are VBP N
better RBR N
tolerated VBN N
than IN N
tricyclic JJ N
antidepressants NNS N
, , N
their PRP$ N
efficacy NN o
in IN N
severe JJ N
depression NN N
remains VBZ N
to TO N
be VB N
further RB N
elucidated VBN N
. . N

METHOD VB N
A DT N
double-blind NN N
, , N
multicentre NN p
study NN p
was VBD p
conducted VBN p
in IN p
86 CD p
severely RB p
depressed JJ p
inpatients NNS p
( ( p
> JJ p
or= RB p
25 CD p
on IN p
the DT p
17-item JJ o
Hamilton NNP o
depression NN o
rating NN o
scale NN o
[ NNP o
HAMD NNP o
] NNP o
total JJ o
score NN o
) ) o
to TO N
compare VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
fluvoxamine NN i
with IN N
that DT N
of IN N
clomipramine NN i
. . i

Following VBG N
placebo JJ i
run-in JJ N
, , N
86 CD p
patients NNS p
were VBD N
randomised VBN N
to TO N
receive VB N
fluvoxamine NN i
or CC i
clomipramine NN i
( ( N
100-250 JJ N
mg/day NN N
) ) N
for IN N
8 CD N
weeks NNS N
. . N

RESULTS NNP N
Fluvoxamine NNP N
and CC N
clomipramine VB N
both DT N
resulted VBN N
in IN N
marked JJ N
improvements NNS o
; : o
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
them PRP N
on IN N
the DT N
17-item JJ o
HAMD NNP o
total NN o
score NN o
, , N
the DT N
clinical JJ o
global JJ o
impression NN o
severity NN o
of IN o
illness NN o
or CC N
global JJ o
improvement NN o
items NNS o
or CC o
the DT o
Montgomery-Asberg JJ o
depression NN o
rating NN o
scale NN o
, , N
at IN N
any DT N
visit NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
71 CD N
% NN N
in IN N
the DT N
fluvoxamine NN N
group NN N
and CC N
69 CD N
% NN N
in IN N
the DT N
clomipramine NN N
group NN N
were VBD N
responders NNS N
( ( N
> JJ N
or= RB N
50 CD N
% NN N
decrease NN N
in IN N
17-item JJ o
HAMD NNP o
total NN o
score NN o
) ) o
. . N

However RB N
, , N
fluvoxamine NN N
was VBD N
better RBR N
tolerated VBN o
than IN N
clomipramine NN N
. . N

Clomipramine NNP N
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
incidence NN N
of IN N
overall JJ N
and CC N
treatment-related JJ N
adverse JJ o
events NNS o
. . o

In IN N
addition NN N
, , N
the DT N
percentage NN N
of IN N
patients NNS N
discontinued VBN o
prematurely RB o
due JJ N
to TO N
adverse JJ o
events NNS o
was VBD N
more JJR N
than IN N
twice RB N
as IN N
high JJ N
with IN N
clomipramine NN N
than IN N
with IN N
fluvoxamine NN N
( ( N
24 CD N
% NN N
vs JJ N
11 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Fluvoxamine NNP N
and CC N
clomipramine NN N
are VBP N
equally RB N
effective JJ N
in IN N
severe JJ N
depression NN N
, , N
but CC N
fluvoxamine NN N
has VBZ N
a DT N
better JJR N
safety NN o
and CC N
tolerability NN o
profile NN N
. . N

-DOCSTART- -X- O O

Clinical JJ N
and CC N
prognostic JJ N
significance NN N
of IN N
serum NN N
magnesium NN N
concentration NN N
in IN N
patients NNS p
with IN p
severe JJ p
chronic JJ p
congestive JJ p
heart NN p
failure NN p
: : p
the DT N
PROMISE NNP N
Study NNP N
. . N

OBJECTIVES NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
prognostic JJ N
significance NN N
of IN N
alterations NNS N
in IN N
serum JJ N
magnesium NN N
in IN N
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
congestive JJ p
heart NN p
failure NN p
. . p

BACKGROUND NNP N
Reductions NNPS N
in IN N
serum NN N
magnesium NN N
have VBP N
been VBN N
postulated VBN N
to TO N
play VB N
a DT N
role NN N
in IN N
promoting VBG N
arrhythmias NN N
and CC N
to TO N
have VB N
an DT N
adverse JJ N
impact NN N
on IN N
survival NN N
in IN N
congestive JJ N
heart NN N
failure NN N
, , N
although IN N
support NN N
for IN N
this DT N
postulate NN N
is VBZ N
lacking VBG N
. . N

METHODS NNP N
Serum NNP o
magnesium NN o
levels NNS o
were VBD o
measured VBN o
in IN N
1,068 CD p
patients NNS p
enrolled VBN p
in IN p
a DT p
survival NN p
study NN p
of IN p
class NN p
III NNP p
or CC p
IV NNP p
heart NN p
failure NN p
at IN p
the DT p
time NN p
of IN p
double-blind JJ p
randomization NN p
to TO p
milrinone VB i
, , i
a DT i
phosphodiesterase NN i
inhibitor NN i
, , i
or CC i
placebo NN i
. . i

All DT N
patients NNS N
received VBD N
conventional JJ i
therapy NN i
with IN i
digoxin NN i
, , i
diuretic JJ i
drugs NNS i
and CC i
a DT i
converting VBG i
enzyme NN i
inhibitor NN i
throughout IN N
the DT N
trial NN N
. . N

The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
6.1 CD N
months NNS N
( ( N
range VB N
1 CD N
day NN N
to TO N
20 CD N
months NNS N
) ) N
. . N

RESULTS JJ N
Patients NNS N
with IN N
high JJ N
serum NN N
magnesium NN N
( ( N
defined VBN N
as IN N
> NN N
or CC N
= $ N
1.9 CD N
mEq/liter NN N
, , N
n JJ N
= NNP N
242 CD N
) ) N
were VBD N
less RBR N
likely JJ N
to TO N
survive VB o
than IN N
were VBD N
patients NNS N
with IN N
a DT N
normal JJ N
magnesium NN N
level NN N
( ( N
n JJ N
= NNP N
627 CD N
) ) N
( ( N
p JJ N
< NN N
0.05 CD N
, , N
risk NN N
ratio NN N
= NNP N
1.41 CD N
) ) N
. . N

Patients NNS N
with IN N
a DT N
low JJ N
magnesium NN N
level NN N
( ( N
defined VBN N
as IN N
< NN N
or CC N
= $ N
1.5 CD N
mEq/liter NN N
, , N
n JJ N
= NNP N
199 CD N
) ) N
had VBD N
no DT N
difference NN N
in IN N
survival NN o
compared VBN N
with IN N
the DT N
group NN N
with IN N
a DT N
normal JJ N
magnesium NN N
level NN N
( ( N
p JJ N
= NNP N
NS NNP N
, , N
risk NN N
ratio NN N
= NNP N
0.89 CD N
) ) N
. . N

At IN N
baseline NN N
, , N
the DT N
patients NNS N
in IN N
the DT N
high JJ N
magnesium NN N
group NN N
were VBD N
older JJR N
and CC N
had VBD N
more RBR N
severe JJ N
functional JJ o
and CC o
renal JJ o
impairment NN o
. . o

An DT N
analysis NN N
after IN N
adjustment NN N
for IN N
these DT N
variables NNS N
demonstrated VBD N
no DT N
difference NN N
in IN N
survival NN o
comparing VBG N
the DT N
low JJ N
, , N
normal JJ N
and CC N
high JJ N
magnesium NN N
groups NNS N
. . N

Although IN N
the DT N
three CD N
groups NNS N
had VBD N
no DT N
difference NN N
in IN N
frequency NN N
of IN N
ventricular JJ o
tachycardia NN o
, , o
length NN o
of IN o
longest JJS o
run NN o
or CC o
frequency NN o
of IN o
ventricular JJ o
premature NN o
beats NNS o
on IN N
baseline NN o
Holter NNP o
monitoring NN o
, , N
the DT N
group NN N
with IN N
hypomagnesemia NN N
had VBD N
more RBR N
frequent JJ N
ventricular JJ N
couplets NNS N
. . N

CONCLUSIONS NNP N
Serum NNP N
magnesium NN N
does VBZ N
not RB N
appear VB N
to TO N
be VB N
an DT N
independent JJ N
risk NN N
factor NN N
for IN N
either DT N
sudden JJ o
death NN o
or CC o
death NN o
due JJ N
to TO N
all DT N
causes NNS N
in IN N
patients NNS N
with IN N
moderate JJ N
to TO N
severe VB N
heart NN N
failure NN N
. . N

Hypomagnesemia NNP N
is VBZ N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
the DT N
frequency NN N
of IN N
certain JJ N
forms NNS N
of IN N
ventricular JJ o
ectopic NN o
activity NN o
, , N
but CC N
this DT N
is VBZ N
not RB N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
clinical JJ N
events NNS N
. . N

The DT N
higher JJR N
mortality NN N
rate NN N
among IN N
the DT N
patients NNS N
with IN N
hypermagnesemia NN N
is VBZ N
attributable JJ N
to TO N
older JJR N
age NN N
, , N
more RBR N
advanced JJ N
heart NN N
failure NN N
and CC N
renal JJ N
insufficiency NN N
. . N

-DOCSTART- -X- O O

Adjuvant NNP N
goserelin NN N
and CC N
ovarian JJ N
preservation NN N
in IN N
chemotherapy NN N
treated VBD N
patients NNS p
with IN p
early JJ p
breast NN p
cancer NN p
: : p
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
study NN N
was VBD N
to TO N
examine VB N
if IN N
goserelin JJ N
concomitant NN N
to TO N
CMF-chemotherapy NNP N
as IN N
adjuvant JJ N
treatment NN N
for IN N
premenopausal NN N
breast NN N
cancer NN N
, , N
protects VBZ o
the DT o
ovaries NNS o
from IN N
premature JJ N
failure NN N
. . N

A DT N
total NN N
of IN N
285 CD p
premenopausal NN p
breast NN p
cancer NN p
patients NNS p
, , p
in IN p
a DT p
randomized JJ p
adjuvant JJ p
trial NN p
( ( i
Zoladex NNP i
in IN p
premenopausal NN p
patients NNS p
( ( p
ZIPP NNP p
) ) p
) ) p
, , N
were VBD N
assigned VBN N
to TO N
a DT N
study NN N
on IN N
ovarian JJ N
function NN N
. . N

Node NNP p
positive JJ p
patients NNS p
were VBD N
assigned VBN N
to TO N
CMF- NNP i
( ( i
cyclophosphamide NN i
, , i
methotrexate NN i
and CC i
5-fluorouracil NN i
) ) i
chemotherapy NN i
in IN i
addition NN i
to TO i
endocrine VB i
therapy NN i
. . i

All DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
2 CD N
years NNS N
of IN N
goserelin NN i
, , i
goserelin NN i
plus CC i
tamoxifen NN i
, , i
tamoxifen VB i
alone RB i
or CC i
no DT i
endocrine JJ i
treatment NN i
. . i

We PRP N
studied VBD N
, , N
if IN N
menses NNS o
were VBD N
affected VBN N
in IN N
the DT N
treatment NN N
groups NNS N
, , N
up RB N
to TO N
36 CD N
months NNS N
after IN N
randomization NN N
. . N

One CD N
year NN N
after IN N
completed VBN N
CMF- NNP N
and CC N
endocrine JJ N
therapy NN N
, , N
36 CD N
% NN N
of IN N
the DT N
women NNS N
in IN N
the DT N
goserelin NN N
group NN N
reported VBD N
menses NNS o
, , N
compared VBN N
to TO N
7 CD N
% NN N
in IN N
the DT N
goserelin NN N
plus CC N
tamoxifen JJ N
group NN N
, , N
13 CD N
% NN N
in IN N
the DT N
tamoxifen NN N
group NN N
and CC N
10 CD N
% NN N
of IN N
the DT N
controls NNS N
. . N

Among IN N
women NNS N
treated VBN N
with IN N
goserelin NN N
, , N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
increase NN o
in IN N
the DT N
proportion NN o
of IN o
menstruating VBG o
women NNS o
, , N
1 CD N
year NN N
after IN N
completed VBN N
treatment NN N
compared VBN N
to TO N
at IN N
24 CD N
months NNS N
of IN N
treatment NN N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
, , N
in IN N
contrast NN N
to TO N
all DT N
other JJ N
treatment NN N
groups NNS N
, , N
who WP N
were VBD N
unchanged JJ N
or CC N
more RBR N
often RB N
amenorrheic JJ o
. . o

In IN N
our PRP$ N
study NN N
, , N
there EX N
is VBZ N
some DT N
evidence NN N
of IN N
protective JJ o
effect NN o
of IN o
goserelin NN o
on IN o
ovarian JJ o
function NN o
in IN N
CMF NNP N
treated VBD N
women NNS N
. . N

This DT N
effect NN N
was VBD N
not RB N
observed VBN N
in IN N
the DT N
combined JJ N
tamoxifen NN N
and CC N
goserelin NN N
treatment NN N
. . N

-DOCSTART- -X- O O

A DT N
comparative JJ N
analysis NN N
of IN N
the DT N
effects NNS N
of IN N
the DT N
fixed JJ N
combination NN i
of IN i
timolol NN i
and CC i
dorzolamide VB i
versus NN N
latanoprost NN i
plus CC i
timolol NN i
on IN N
ocular JJ o
hemodynamics NNS o
and CC o
visual JJ o
function NN o
in IN N
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
. . p

AIMS IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
fixed JJ N
combination NN N
of IN N
timolol NN i
and CC i
dorzolamide NN i
and CC i
latanoprost NN i
plus CC i
timolol NN i
on IN N
retinal JJ o
, , o
choroidal JJ o
, , o
and CC o
retrobulbar NN o
hemodynamics NNS o
and CC N
visual JJ o
function NN o
in IN N
primary JJ p
open-angle JJ p
glaucoma NN p
( ( p
OAG NNP p
) ) p
subjects VBZ p
. . p

METHODS NNP N
Sixteen NNP p
( ( p
16 CD p
) ) p
OAG NN p
patients NNS p
( ( p
age NN p
, , p
63.5 CD p
+/- JJ p
10.8 CD p
years NNS p
; : p
9 CD p
male NN p
) ) p
were VBD N
evaluated VBN N
in IN N
a DT N
randomized JJ N
, , N
crossover RB N
, , N
double-blind JJ N
study NN N
design NN N
after IN N
4 CD N
weeks NNS N
of IN N
treatment NN N
of IN N
latanoprost NN i
with IN i
timolol NN i
and CC N
fixed JJ N
combination NN N
of IN N
timolol NN i
and CC i
dorzolamide NN i
. . i

After IN N
randomization NN N
, , N
9 CD p
right JJ p
eyes NNS p
and CC p
7 CD p
left JJ p
eyes NNS p
were VBD N
included VBN N
in IN N
the DT N
hemodynamic JJ N
portion NN N
of IN N
the DT N
study NN N
. . N

Measurements NNS N
included VBD N
: : N
adverse JJ o
events NNS o
check NN o
, , o
visual JJ o
acuity NN o
, , o
contrast NN o
sensitivity NN o
, , o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
intraocular JJ o
pressure NN o
( ( o
IOP NNP o
) ) o
, , o
and CC o
fundus JJ o
examination NN o
. . o

Ocular JJ o
blood NN o
flow NN o
was VBD N
assessed VBN N
using VBG N
confocal JJ N
scanning VBG N
laser NN N
Doppler NNP N
flowmetry NN N
, , N
color NN N
Doppler NNP N
imaging NN N
, , N
and CC N
scanning VBG N
laser NN N
ophthalmoscopy NN N
. . N

RESULTS NNP N
Both NNP N
therapies NNS N
were VBD N
effective JJ N
at IN N
lowering VBG N
IOP NNP o
, , N
whereas IN N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
latanoprost NN i
plus CC i
timolol NN i
and CC N
the DT N
fixed JJ N
combination NN i
of IN i
timolol NN i
and CC i
dorzolamide NN i
( ( N
13.9 CD N
% NN N
and CC N
12.2 CD N
% NN N
reduction NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.5533 CD N
) ) N
. . N

Fixed VBN N
combination NN i
of IN i
timolol NN i
and CC i
dorzolamide VB i
significantly RB N
increased JJ N
central JJ o
retinal JJ o
artery NN o
end NN o
diastolic NN o
blood NN o
flow NN o
velocity NN o
( ( N
P NNP N
= NNP N
0.0168 CD N
) ) N
and CC N
lowered VBD N
resistance NN o
to TO o
flow VB o
( ( N
P NNP N
= NNP N
0.0279 CD N
) ) N
. . N

Temporal JJ o
posterior JJ o
ciliary JJ o
artery NN o
peak NN o
systolic NN o
and CC o
end VB o
diastolic JJ o
velocities NNS o
were VBD N
significantly RB N
increased VBN N
with IN N
the DT N
fixed JJ N
combination NN i
of IN i
timolol NN i
and CC i
dorzolamide NN i
( ( N
P NNP N
= NNP N
0.0125 CD N
and CC N
0.0238 CD N
, , N
respectively RB N
) ) N
. . N

Latanoprost NNP i
plus CC i
timolol NN i
had VBD N
no DT N
significant JJ N
effects NNS N
on IN N
ocular JJ o
blood NN o
flow NN o
during IN N
4 CD N
weeks NNS N
of IN N
treatment NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
adverse JJ o
events NNS o
, , o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
visual JJ o
acuity NN o
, , o
contrast NN o
sensitivity NN o
scanning VBG o
laser NN o
ophthalmoscopy NN o
, , o
or CC o
Heidelberg NNP o
Retinal NNP o
Flowmeter NNP o
for IN N
any DT N
treatment NN N
period NN N
. . N

CONCLUSIONS NNP N
Fixed NNP N
combination NN i
of IN i
timolol NN i
and CC i
dorzolamide JJ i
therapy NN N
might MD N
increase VB N
blood NN o
flow NN o
in IN N
OAG NNP p
patients NNS p
while IN N
attaining VBG N
a DT N
similar JJ N
IOP NNP o
reduction NN N
compared VBN N
to TO N
latanoprost VB i
plus JJ i
timolol NN i
. . i

Visual JJ o
function NN o
, , N
however RB N
, , N
was VBD N
not RB N
different JJ N
in IN N
this DT N
short-term JJ N
comparison NN N
between IN N
the DT N
two CD N
treatments NNS N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
tailored JJ N
skin NN p
cancer NN p
prevention NN p
for IN p
children NNS p
: : p
the DT N
Project NNP N
SCAPE NNP N
family NN p
study NN p
. . p

This DT N
study NN N
evaluated VBD N
a DT N
tailored VBN i
intervention NN i
to TO N
promote VB i
sun NN i
protection NN i
in IN N
parents NNS p
and CC p
their PRP$ p
children NNS p
, , N
hypothesizing VBG N
that IN N
the DT N
tailored VBN N
intervention NN N
would MD N
lead VB N
to TO N
improved JJ o
skin NN o
cancer NN o
prevention NN o
behaviors NNS o
compared VBN N
to TO N
generic JJ N
materials NNS N
. . N

Families NNS p
were VBD p
recruited VBN p
through IN p
schools NNS p
and CC p
community NN p
centers NNS p
and CC p
were VBD p
included VBN p
if IN p
there EX p
was VBD p
1 CD p
child NN p
in IN p
Grades NNP p
1-3 JJ p
at IN p
moderate JJ p
to TO p
high JJ p
risk NN p
for IN p
skin JJ p
cancer NN p
. . p

Participants NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
two CD N
intervention NN N
groups NNS N
: : N
a DT N
tailored JJ i
intervention NN i
, , i
in IN i
which WDT i
they PRP i
received VBD i
personalized JJ i
skin NN i
cancer NN i
education NN i
through IN i
the DT i
mail NN i
; : i
or CC i
a DT i
control NN i
group NN i
who WP i
received VBD i
generic JJ i
skin NN i
cancer NN i
information NN i
materials NNS i
. . i

Before IN N
and CC N
after IN N
intervention NN N
, , N
parents NNS N
completed VBD N
questionnaires NNS N
about IN N
their PRP$ N
and CC N
their PRP$ N
children NNS N
's POS N
skin NN N
cancer NN N
risk NN N
and CC N
prevention NN N
knowledge NN N
and CC N
behaviors NNS N
. . N

Parents NNS p
also RB N
completed VBD N
4-day JJ N
sun NN N
exposure NN N
and CC N
protection NN N
diaries NNS N
for IN N
their PRP$ N
child NN N
and CC N
themselves PRP N
. . N

Tailored VBN p
group NN p
participants NNS p
demonstrated VBD N
significantly RB o
greater JJR o
positive JJ o
changes NNS o
in IN o
prevention NN o
behavior NN o
after IN N
the DT N
intervention NN N
, , N
including VBG N
children NNS o
's POS o
use NN o
of IN o
sunscreen NN o
, , o
shirts NNS o
, , o
and CC o
hats NNS o
, , o
and CC o
parents NNS o
' POS o
use NN o
of IN o
shade NN o
, , o
and CC o
skin JJ o
examinations NNS o
. . o

Effect JJ o
sizes NNS o
were VBD N
small JJ o
and CC o
perceived JJ o
benefits NNS o
and CC o
social JJ o
norms NNS o
mediated VBN o
intervention NN o
effects NNS o
. . o

Findings NNS N
from IN N
this DT N
study NN N
support VBD N
the DT N
efficacy NN N
of IN N
focusing VBG N
tailored VBN N
communications NNS N
to TO N
families NNS p
in IN N
order NN N
to TO N
change VB N
skin JJ p
cancer NN p
prevention NN p
practices NNS p
in IN p
young JJ p
children NNS p
. . p

-DOCSTART- -X- O O

The DT N
need NN N
for IN N
chemotherapy NN i
after IN N
prolonged JJ p
complete JJ p
remission NN p
in IN p
acute JJ p
leukemia NN p
of IN p
childhood NN p
. . p

-DOCSTART- -X- O O

Milk NN o
production NN o
in IN N
cows NNS p
with IN p
endotoxin-induced JJ i
mastitis NN i
treated VBN N
with IN N
isotonic JJ i
or CC i
hypertonic JJ i
sodium NN i
chloride NN i
solution NN i
. . i

Milk NNP o
production NN o
was VBD N
monitored VBN N
in IN N
16 CD p
cows NNS p
for IN p
6 CD p
milkings NNS p
after IN N
intramammary JJ N
infusion NN N
of IN N
1 CD N
mg NN N
of IN N
endotoxin NN i
in IN N
a DT N
single JJ N
forequarter NN N
. . N

The DT N
cows NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
treatment NN N
groups NNS N
; : N
8 CD p
cows NNS p
were VBD p
treated VBN p
with IN p
isotonic JJ i
saline NN i
solution NN i
and CC N
8 CD p
cows NNS p
were VBD p
treated VBN p
with IN p
hypertonic JJ i
saline JJ i
solution NN i
. . i

Saline JJ i
solutions NNS N
were VBD N
administered VBN N
IV NNP N
( ( N
5 CD N
ml/kg NN N
of IN N
body NN N
weight NN N
) ) N
4 CD N
hours NNS N
after IN N
infusion NN N
of IN N
endotoxin NN i
. . i

Mean NNP o
cumulative JJ o
change NN o
in IN o
milk NN o
yield NN o
and CC o
interval JJ o
change NN o
in IN o
milk NN o
yield NN o
were VBD N
greater JJR N
in IN N
cows NNS p
treated VBN N
with IN N
isotonic JJ N
saline NN N
solution NN i
than IN N
in IN N
cows NNS N
treated VBN N
with IN N
hypertonic JJ i
saline JJ i
solution NN i
. . i

Significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
were VBD N
not RB N
detected VBN N
. . N

-DOCSTART- -X- O O

Comparative JJ N
evaluation NN N
of IN N
calcium NN i
hydroxide NN i
and CC i
zinc NN i
oxide RB i
eugenol RB i
as IN N
root JJ o
canal JJ o
filling NN o
materials NNS o
for IN p
primary JJ p
molars NNS p
: : p
a DT N
clinical JJ N
and CC N
radiographic JJ N
study NN N
. . N

Calcium NNP i
hydroxide NN i
, , N
a DT N
material NN N
widely RB N
used VBN N
for IN N
the DT N
treatment NN N
of IN N
permanent JJ N
teeth NN N
has VBZ N
not RB N
been VBN N
used VBN N
frequently RB N
for IN N
pulpectomy NN N
in IN N
primary JJ N
teeth NNS N
. . N

A DT N
comparative JJ N
evaluation NN N
of IN N
calcium NN i
hydroxide NN i
and CC i
zinc NN i
oxide NN i
eugenol NN i
used VBN i
as IN i
root JJ o
canal JJ o
filling NN o
materials NNS o
in IN N
primary JJ p
molars NNS p
is VBZ N
presented VBN N
. . N

-DOCSTART- -X- O O

Links NNS N
between IN N
multisensory NN o
processing NN o
and CC N
autism NN N
. . N

Autism NNP p
spectrum JJ p
disorder NN p
is VBZ N
typically RB N
associated VBN N
with IN N
social JJ N
deficits NNS N
and CC N
is VBZ N
often RB N
specifically RB N
linked VBN N
to TO N
difficulty VB N
with IN N
processing NN o
faces VBZ o
and CC o
other JJ o
socially RB o
relevant JJ o
stimuli NNS o
. . o

Emerging VBG N
research NN N
has VBZ N
suggested VBN N
that IN N
children NNS p
with IN p
autism NN p
might MD N
also RB N
have VB N
deficits NNS N
in IN N
basic JJ N
perceptual JJ N
abilities NNS N
including VBG N
multisensory NN N
processing NN N
( ( N
e.g. JJ N
, , N
simultaneously RB N
processing VBG N
visual JJ N
and CC N
auditory JJ N
inputs NNS N
) ) N
. . N

The DT N
current JJ N
study NN N
examined VBD N
the DT N
relationship NN o
between IN o
multisensory JJ o
temporal JJ o
processing NN o
( ( N
assessed JJ N
via IN N
a DT N
simultaneity NN i
judgment NN i
task NN i
wherein NN i
participants NNS i
were VBD i
to TO i
report VB i
whether IN i
a DT i
visual JJ i
stimulus NN i
and CC i
an DT i
auditory JJ i
stimulus NN i
occurred VBD i
at IN i
the DT i
same JJ i
time NN i
or CC i
at IN i
different JJ i
times NNS i
) ) i
and CC o
self-reported JJ o
symptoms NNS o
of IN o
autism NN o
( ( N
assessed JJ N
via IN N
the DT N
Autism NNP i
Spectrum NNP i
Quotient NNP i
questionnaire NN i
) ) i
. . N

Data NNS N
from IN N
over IN p
100 CD p
healthy JJ p
adults NNS p
revealed VBD N
a DT N
relationship NN N
between IN N
these DT N
two CD N
factors NNS N
as IN N
multisensory NN o
timing VBG o
perception NN o
correlated VBN o
with IN o
symptoms NNS o
of IN o
autism NN o
. . o

Specifically RB N
, , N
a DT N
stronger JJR N
bias NN o
to TO N
perceive VB N
auditory JJ o
stimuli NNS o
occurring VBG o
before IN N
visual JJ N
stimuli NN N
as IN N
simultaneous JJ N
was VBD N
associated VBN N
with IN N
greater JJR o
levels NNS o
of IN o
autistic JJ o
symptoms NNS o
. . o

Additional NNP N
data NN N
and CC N
analyses NNS N
confirm VBP N
that IN N
this DT N
relationship NN o
is VBZ o
specific JJ o
to TO o
multisensory JJ o
processing NN o
and CC o
symptoms NNS o
of IN o
autism NN o
. . o

These DT N
results NNS N
provide VBP N
insight RB N
into IN N
the DT N
nature NN N
of IN N
multisensory NN N
processing NN N
while IN N
also RB N
revealing VBG N
a DT N
continuum NN N
over IN N
which WDT N
perceptual JJ N
abilities NNS N
correlate VBP N
with IN N
symptoms NNS N
of IN N
autism NN N
and CC N
that IN N
this DT N
continuum NN N
is VBZ N
not RB N
just RB N
specific JJ N
to TO N
clinical JJ N
populations NNS N
but CC N
is VBZ N
present JJ N
within IN N
the DT N
general JJ p
population NN p
. . p

-DOCSTART- -X- O O

Warfarin NNP i
for IN N
atrial JJ p
fibrillation NN p
. . p

The DT N
patient NN N
's POS N
perspective NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
minimal JJ o
clinically RB o
important JJ o
difference NN o
( ( o
MCID NNP o
) ) o
of IN N
warfarin NN i
therapy NN i
for IN N
the DT N
treatment NN N
of IN N
nonvalvular JJ p
atrial JJ p
fibrillation NN p
from IN N
the DT N
perspective NN N
of IN N
patients NNS p
using VBG p
2 CD p
different JJ p
elicitation NN p
methods NNS p
. . p

DESIGN NNP N
All DT N
patients NNS N
completed VBD N
2 CD N
face-to-face JJ N
interviews NNS N
, , N
which WDT N
were VBD N
2 CD N
weeks NNS N
apart RB N
. . N

For IN N
each DT N
interview NN N
, , N
they PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
of IN N
2 CD N
elicitation NN N
methods NNS N
: : N
ping-ponging NN N
or CC N
starting VBG N
at IN N
the DT N
known JJ N
efficacy NN N
. . N

SETTING CC N
The DT N
practices NNS p
of IN p
2 CD p
university-affiliated JJ p
family NN p
medicine NN p
centers NNS p
( ( p
8 CD p
physicians NNS p
each DT p
) ) p
, , p
14 CD p
community-based JJ p
family NN p
physicians NNS p
, , p
and CC p
2 CD p
cardiologists NNS p
. . p

PATIENTS VB N
Sixty-four JJ p
patients NNS p
with IN p
nonvalvular JJ p
atrial JJ p
fibrillation NN p
who WP p
were VBD p
initiated VBN p
with IN p
warfarin JJ p
therapy NN p
at IN p
least JJS p
3 CD p
months NNS p
before IN p
the DT p
study NN p
. . p

INTERVENTION NNP N
During IN N
each DT N
interview NN N
, , N
the DT N
patients NNS N
' POS N
MCIDs NNP N
were VBD N
determined VBN N
by IN N
using VBG N
( ( N
1 CD N
) ) N
a DT o
pictorial JJ o
flip NN o
chart NN o
to TO o
describe VB o
atrial JJ o
fibrillation NN o
; : o
the DT o
consequences NNS o
of IN o
a DT o
minor JJ o
stroke NN o
, , o
a DT o
major JJ o
stroke NN o
, , o
and CC o
a DT o
major JJ o
bleeding NN o
episode NN o
; : o
the DT N
chance NN o
of IN o
stroke NN o
if IN o
not RB o
taking VBG o
warfarin NN o
; : o
the DT N
chance NN o
of IN o
a DT o
major JJ o
bleeding NN o
episode NN o
if IN o
taking VBG o
warfarin NN o
; : o
examples NNS N
of IN N
the DT N
inconvenience NN o
, , o
minor JJ o
side NN o
effects NNS o
, , o
and CC o
costs NNS o
of IN o
warfarin JJ o
therapy NN o
; : o
and CC N
then RB N
( ( N
2 CD N
) ) N
1 CD N
of IN N
the DT N
2 CD N
elicitation NN o
methods NNS o
to TO o
determine VB o
their PRP$ o
MCIDs NNP o
( ( o
the DT o
smallest JJS o
reduction NN o
in IN o
stroke NN o
risk NN o
at IN o
which WDT o
the DT o
patients NNS o
were VBD o
willing JJ o
to TO o
take VB o
warfarin NN o
) ) o
. . o

Patients NNS o
' POS o
knowledge NN o
of IN o
their PRP$ o
stroke NN o
risk NN o
, , o
acceptability NN o
of IN o
the DT o
interview NN o
process NN o
, , o
and CC o
factors NNS o
determining VBG o
their PRP$ o
preferences NNS o
were VBD N
also RB N
assessed VBN N
. . N

MAIN NNP N
RESULTS NNP N
Given NNP N
a DT N
baseline NN N
risk NN N
of IN N
having VBG N
a DT N
stroke NN N
in IN N
the DT N
next JJ N
2 CD N
years NNS N
, , N
if IN N
not RB N
taking VBG N
warfarin NN i
, , N
of IN N
10 CD N
of IN N
100 CD N
, , N
the DT N
mean JJ o
MCID NNP o
was VBD N
2.01 CD N
of IN N
100 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.60-2.42 JJ N
) ) N
. . N

Fifty-two JJ N
percent NN N
of IN N
the DT N
patients NNS N
would MD N
take VB N
warfarin NN i
for IN N
an DT N
absolute JJ N
decrease NN N
in IN N
stroke NN o
risk NN o
of IN N
1 CD N
% NN N
over IN N
2 CD N
years NNS N
. . N

Before IN N
eliciting VBG N
their PRP$ N
MCIDs NNP N
, , N
patients NNS N
showed VBD N
poor JJ N
knowledge NN o
of IN o
their PRP$ o
stroke NN o
risk NN o
, , N
which WDT N
improved VBD N
afterward RB N
. . N

The DT N
interview NN N
process NN N
was VBD N
well RB N
accepted VBN N
by IN N
the DT N
patients NNS N
. . N

The DT N
MCID NNP o
using VBG N
the DT N
ping-ponging JJ N
elicitation NN N
method NN N
was VBD N
1.015 CD N
of IN N
100 CD N
smaller JJR N
compared VBN N
with IN N
use NN N
of IN N
the DT N
starting NN N
at IN N
the DT N
known JJ N
efficacy NN N
method NN N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

CONCLUSIONS NN N
We PRP N
were VBD N
able JJ N
to TO N
determine VB N
the DT N
MCID NNP o
of IN N
warfarin NN i
therapy NN i
for IN N
the DT N
prevention NN N
of IN N
stroke NN N
from IN N
the DT N
perspective NN N
of IN N
patients NNS p
with IN p
nonvalvular JJ p
atrial JJ p
fibrillation NN p
. . p

Their PRP$ N
MCIDs NNPS N
were VBD N
much RB N
smaller JJR N
than IN N
those DT N
that WDT N
have VBP N
been VBN N
implied VBN N
by IN N
some DT N
experts NNS N
and CC N
clinicians NNS N
. . N

The DT N
interview NN N
process NN N
, , N
using VBG N
the DT N
flip JJ N
chart NN N
approach NN N
, , N
appeared VBD N
to TO N
improve VB N
the DT N
patients NNS o
' POS o
knowledge NN o
of IN o
their PRP$ o
disease NN o
and CC o
its PRP$ o
consequences NNS o
and CC o
treatment NN o
. . o

The DT N
method NN N
used VBN N
to TO N
elicit VB N
the DT N
patients NNS N
' POS N
MCIDs NNP o
can MD N
have VB N
a DT N
clinically RB N
important JJ N
effect NN N
on IN N
patient NN N
responses NNS N
. . N

The DT N
method NN N
used VBN N
in IN N
our PRP$ N
study NN N
can MD N
be VB N
generalized VBN N
to TO N
other JJ N
conditions NNS N
and CC N
, , N
thus RB N
, , N
could MD N
be VB N
helpful JJ N
in IN N
3 CD N
ways NNS N
: : N
( ( N
1 CD N
) ) N
from IN N
a DT N
clinical JJ N
decision-making NN N
perspective NN N
, , N
it PRP N
could MD N
facilitate VB N
patient-physician JJ N
communication NN N
; : N
( ( N
2 CD N
) ) N
it PRP N
could MD N
clarify VB N
the DT N
patient NN N
perspective NN N
when WRB N
interpreting VBG N
the DT N
results NNS N
of IN N
previously RB N
completed VBN N
trials NNS N
; : N
and CC N
( ( N
3 CD N
) ) N
it PRP N
could MD N
be VB N
used VBN N
to TO N
derive VB N
more RBR N
clinically RB N
relevant JJ N
sample NN N
sizes NNS N
for IN N
randomized JJ N
treatment NN N
trials NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
dietary JJ i
pyridoxine NN i
on IN N
haemato-immunological JJ o
responses NNS o
of IN N
Labeo NNP p
rohita JJ p
fingerlings NNS p
reared VBD p
at IN p
higher JJR p
water NN p
temperature NN p
. . p

A DT N
sixty-day JJ N
feeding NN N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
elucidate VB N
the DT N
effect NN N
of IN N
dietary JJ i
pyridoxine NN i
( ( i
PN NNP i
) ) i
on IN N
hemato-immunological JJ o
parameters NNS o
in IN N
Labeo NNP p
rohita VBP p
fingerlings NNS p
exposed VBN p
to TO p
an DT p
elevated JJ p
temperature NN p
( ( p
ET NNP p
) ) p
of IN p
33 CD p
?C NNS p
. . p

Two CD p
hundred VBD p
and CC p
seventy JJ p
fingerlings NNS p
( ( p
6.71 CD p
? . p
0.32 CD p
g NN p
) ) p
were VBD p
randomly RB N
distributed VBN N
into IN i
six CD i
treatments NNS i
in IN i
triplicates NNS i
( ( i
15 CD N
fish/tank NN N
) ) N
. . N

Five CD i
iso-nitrogenous JJ i
( ( i
356.3 CD i
? . i
2.7 CD i
g/kg JJ i
crude NN i
protein NN i
) ) i
purified VBD i
diets NNS i
were VBD i
prepared VBN N
with IN N
graded JJ N
levels NNS N
( ( N
0 CD N
, , N
10 CD N
, , N
50 CD N
, , N
100 CD N
and CC N
200 CD N
mg/kg NNS N
diet JJ N
) ) N
of IN N
PN NNP N
. . N

Six NNP N
treatment NN N
groups NNS N
were VBD N
P10T26 NNP N
( ( N
10 CD N
mg NN N
PN NNP N
+ NNP N
ambient JJ N
temperature NN N
( ( N
26 CD N
?C NN N
) ) N
, , N
P0T33 NNP N
( ( N
0 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
, , N
P10T33 NNP N
( ( N
10 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
, , N
P50T33 NNP N
( ( N
50 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
, , N
P100T33 NNP N
( ( N
100 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
and CC N
P200T33 NNP N
( ( N
200 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
. . N

The DT N
responses NNS p
of IN p
L. NNP p
rohita JJ p
fingerlings NNS p
to TO p
dietary JJ N
PN NNP N
were VBD N
assessed VBN N
in IN N
terms NNS o
of IN o
growth NN o
and CC o
by IN N
analysing VBG N
some DT N
hemato-immunological JJ N
parameters NNS N
. . N

When WRB N
PN NNP i
supplementation NN i
increased VBD i
from IN N
10 CD N
to TO N
200 CD N
mg/kg NNS N
diet JJ N
, , N
a DT N
significant JJ N
improvement NN o
in IN o
weight JJ o
gain NN o
percentage NN o
was VBD o
observed VBN o
. . o

Erythrocyte NNP o
( ( o
RBC NNP o
) ) o
count NN o
, , o
leucocyte NN o
( ( o
WBC NNP o
) ) o
count NN o
, , o
haemoglobin NN o
content NN o
and CC o
respiratory JJ o
burst NN o
activity NN o
were VBD o
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
in IN N
100 CD N
mg JJ i
PN/kg NNP i
diet-fed NN i
group NN i
than IN N
their PRP$ i
non-PN-fed JJ i
counterpart NN i
. . N

Also RB N
, , o
serum JJ o
albumin NN o
, , o
globulin NN o
and CC o
lysozyme JJ o
activity NN o
were VBD o
found VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
in IN N
PN-fed NNP N
groups NNS N
. . N

The DT N
overall JJ N
results NNS N
indicated VBD N
that IN N
dietary JJ i
PN NNP i
supplementation NN i
at IN i
100 CD N
mg/kg NNS N
diet JJ N
may MD N
reverse VB N
the DT N
negative JJ N
effects NNS N
caused VBN N
by IN N
ET NNP N
and CC N
may MD N
protect VB N
the DT N
haemato-immunological JJ o
status NN o
of IN o
L. NNP p
rohita JJ p
fingerlings NNS p
reared VBD p
at IN p
higher JJR p
water NN p
temperature NN p
. . p

-DOCSTART- -X- O O

Bronchodilator NNP N
effect NN N
of IN N
fenoterol NN i
and CC i
ipratropium NN i
bromide NN i
in IN N
infants NNS p
with IN p
acute JJ p
wheezing NN p
: : p
use NN N
of IN N
MDI NNP N
with IN N
a DT N
spacer NN N
device NN N
. . N

Twenty-eight JJ p
infants NNS p
admitted VBN p
to TO p
Exequiel NNP p
Gonz?lez NNP p
Cortes NNP p
Children NNP p
's POS p
Hospital NNP p
because IN p
of IN p
acute NN p
wheezing NN p
( ( p
AW NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
study NN N
groups NNS N
. . N

Fenoterol NNP i
( ( i
FNT NNP i
) ) i
, , i
ipratropium JJ i
bromide NN i
( ( i
IB NNP i
) ) i
, , i
and CC i
placebo NN i
were VBD N
administered VBN N
respectively RB N
to TO N
children NNS N
in IN N
the DT N
different JJ N
groups NNS N
by IN N
means NNS N
of IN N
metered VBN N
dose JJ N
inhalers NNS N
( ( N
MDI NNP N
) ) N
with IN N
spacers NNS N
, , N
using VBG N
doses NNS N
of IN N
3 CD N
puffs NNS N
every DT N
hour NN N
, , N
for IN N
4 CD N
hours NNS N
. . N

The DT N
degree NN N
of IN N
bronchial JJ N
obstruction NN N
was VBD N
assessed VBN N
clinically RB N
and CC N
scored VBN N
with IN N
the DT N
single-blind JJ N
method NN N
every DT N
hour NN N
prior RB N
to TO N
each DT N
treatment NN N
. . N

The DT N
criterion NN N
of IN N
a DT N
bronchodilator NN o
effect NN o
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
degree NN N
of IN N
bronchial JJ N
obstruction NN N
at IN N
subsequent JJ N
scorings NNS N
. . N

The DT o
scores NNS o
of IN o
the DT o
three CD o
groups NNS o
were VBD N
compared VBN N
using VBG N
the DT N
Student NN N
's POS N
t JJ N
test NN N
for IN N
matched JJ N
samples NNS N
. . N

The DT N
same JJ N
test NN N
was VBD N
also RB N
applied VBN N
to TO N
the DT N
independent JJ N
samples NNS N
for IN N
determining VBG N
the DT N
superiority NN N
of IN N
one CD N
treatment NN N
, , N
FNT NNP i
or CC i
IB NNP i
, , i
over IN N
the DT N
other JJ N
. . N

The DT N
results NNS N
indicated VBD N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
scores NNS N
of IN N
the DT N
groups NNS N
receiving VBG i
FNT NNP i
and CC i
IB NNP i
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
; : N
this DT N
did VBD N
not RB N
occur VB N
in IN N
the DT N
group NN N
in IN N
which WDT i
placebo NN i
was VBD N
used VBN N
. . N

FNT NNP i
produced VBD N
a DT N
more RBR N
rapid JJ N
and CC N
sustained VBD N
effect NN N
than IN i
IB NNP i
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Significant JJ N
bronchodilator NN N
effect NN N
was VBD N
obtained VBN N
in IN p
infants NNS p
with IN p
AW NNP p
when WRB N
repeated VBN N
doses NNS N
of IN i
FNT NNP i
or CC i
IB NNP i
were VBD N
administered VBN N
with IN N
MDI NNP N
and CC N
spacers NNS N
. . N

This DT N
effect NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
group NN N
treated VBD N
with IN i
FNT NNP i
. . i

-DOCSTART- -X- O O

Menopausal NNP o
quality NN o
of IN o
life NN o
: : o
RCT NNP i
of IN i
yoga NN i
, , i
exercise NN i
, , i
and CC i
omega-3 JJ i
supplements NNS i
. . i

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
3 CD i
nonhormonal JJ i
therapies NNS i
for IN N
the DT N
improvement NN N
of IN N
menopause-related JJ o
quality NN o
of IN o
life NN o
in IN N
women NNS p
with IN p
vasomotor NN p
symptoms NNS p
. . p

STUDY NNP N
DESIGN NNP N
We PRP N
conducted VBD N
a DT N
12-week JJ N
3 CD N
? . N
2 CD N
randomized VBD N
, , N
controlled VBD N
, , N
factorial JJ N
design NN N
trial NN N
. . N

Peri- NN p
and CC p
postmenopausal JJ p
women NNS p
, , p
40-62 JJ p
years NNS p
old JJ p
, , p
were VBD N
assigned VBN N
randomly RB N
to TO i
yoga VB i
( ( N
n JJ N
= NNP N
107 CD N
) ) N
, , N
exercise NN i
( ( N
n JJ N
= NNP N
106 CD N
) ) N
, , N
or CC i
usual JJ i
activity NN i
( ( N
n JJ N
= NNP N
142 CD N
) ) N
and CC N
also RB N
assigned VBD N
randomly RB N
to TO N
a DT N
double-blind JJ N
comparison NN N
of IN i
omega-3 JJ i
( ( N
n JJ N
= NNP N
177 CD i
) ) i
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
178 CD N
) ) N
capsules NNS N
. . N

We PRP N
performed VBD N
the DT N
following JJ N
interventions NNS N
: : N
( ( N
1 CD i
) ) i
weekly JJ i
90-minute CD i
yoga NN i
classes NNS i
with IN i
daily JJ i
at-home JJ i
practice NN i
, , i
( ( i
2 CD i
) ) i
individualized VBN i
facility-based JJ i
aerobic JJ i
exercise NN i
training NN i
3 CD i
times/week NN i
, , i
and CC N
( ( N
3 CD N
) ) N
0.615 CD N
g JJ N
omega-3 JJ i
supplement NN i
, , i
3 CD N
times/day NN N
. . N

The DT N
outcomes NNS N
were VBD N
assessed VBN N
with IN N
the DT N
following JJ N
scores NNS o
: : o
Menopausal NNP o
Quality NNP o
of IN o
Life NNP o
Questionnaire NNP o
( ( o
MENQOL NNP o
) ) o
total NN o
and CC o
domain NN o
( ( o
vasomotor NN o
symptoms NNS o
, , o
psychosocial JJ o
, , o
physical JJ o
and CC o
sexual JJ o
) ) o
. . o

RESULTS NNP p
Among IN p
355 CD p
randomly NNS p
assigned VBN p
women NNS p
who WP p
average VBP p
age NN p
was VBD p
54.7 CD p
years NNS p
, , p
338 CD p
women NNS p
( ( p
95 CD p
% NN p
) ) p
completed VBD p
12-week JJ p
assessments NNS p
. . p

Mean NNP o
baseline NN o
vasomotor NN o
symptoms JJ o
frequency NN o
was VBD N
7.6/day CD N
, , N
and CC N
the DT o
mean JJ o
baseline NN o
total JJ o
MENQOL NNP o
score NN o
was VBD N
3.8 CD N
( ( N
range NN N
, , N
1-8 CD N
from IN N
better JJR N
to TO N
worse VB N
) ) N
with IN N
no DT N
between-group JJ N
differences NNS N
. . N

For IN i
yoga NN i
compared VBN N
to TO N
usual JJ N
activity NN N
, , N
baseline NN N
to TO N
12-week JJ N
improvements NNS N
were VBD N
seen VBN N
for IN o
MENQOL NNP o
total JJ N
-0.3 NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-0.6 VBP N
to TO N
0 CD N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
, , N
vasomotor NN o
symptom NN o
domain NN o
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
, , N
and CC o
sexuality NN o
domain NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
scores VBZ N
. . N

For IN N
women NNS N
who WP N
underwent VBP i
exercise NN i
and CC i
omega-3 JJ i
therapy NN i
compared VBN N
with IN N
control NN N
subjects NNS N
, , N
improvements NNS N
in IN N
baseline NN N
to TO N
12-week JJ N
total JJ o
MENQOL NNP o
scores NNS o
were VBD N
not RB N
observed VBN N
. . N

Exercise NN N
showed VBD N
benefit NN N
in IN N
the DT o
MENQOL NNP o
physical JJ o
domain NN o
score NN o
at IN N
12 CD N
weeks NNS N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSION NNP N
All NNP N
women NNS N
become VBP N
menopausal JJ N
, , N
and CC N
many JJ N
of IN N
them PRP N
seek VBP N
medical JJ N
advice NN N
on IN N
ways NNS N
to TO N
improve VB o
quality NN o
of IN o
life NN o
; : o
little JJ N
evidence-based JJ N
information NN N
exists NNS N
. . N

We PRP N
found VBD N
that IN N
, , N
among IN p
healthy JJ p
sedentary JJ p
menopausal NN p
women NNS p
, , p
yoga NN i
appears VBZ N
to TO N
improve VB o
menopausal NN o
quality NN o
of IN o
life NN o
; : o
the DT N
clinical JJ N
significance NN N
of IN N
our PRP$ N
finding NN N
is VBZ N
uncertain JJ N
because IN N
of IN N
the DT N
modest JJ N
effect NN N
. . N

-DOCSTART- -X- O O

Tight-fitting JJ i
underwear JJ i
and CC p
sperm JJ o
quality NN o
. . o

-DOCSTART- -X- O O

Assessment NN N
of IN N
osteopontin NN N
in IN N
early JJ p
breast NN p
cancer NN p
: : p
correlative JJ N
study NN N
in IN N
a DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

INTRODUCTION NNP N
Osteopontin NNP i
( ( N
OPN NNP N
) ) N
is VBZ N
a DT N
malignancy-associated JJ N
glycoprotein NN N
that WDT N
contributes VBZ N
functionally RB N
to TO N
tumor VB N
aggressiveness NN N
. . N

In IN N
metastatic JJ N
breast NN N
cancer NN N
, , N
we PRP N
previously RB N
demonstrated VBD N
that IN N
elevated VBD N
OPN NNP N
in IN N
primary JJ N
tumor NN N
and CC N
blood NN N
was VBD N
associated VBN N
with IN N
poor JJ N
prognosis NN N
. . N

METHODS NNP N
We PRP N
measured VBD N
OPN NNP i
in IN N
plasma NN N
by IN N
ELISA NNP N
, , N
and CC N
in IN N
tumors NNS N
by IN N
immunohistochemistry NN i
, , N
in IN p
624 CD p
( ( p
94 CD p
% NN p
) ) p
and CC p
462 CD p
( ( p
69 CD p
% NN p
) ) p
, , p
respectively RB p
, , p
of IN p
667 CD p
postmenopausal JJ p
women NNS p
with IN p
hormone NN p
responsive VBP p
early JJ p
breast NN p
cancer NN p
treated VBN p
by IN p
surgery NN i
followed VBN p
by IN p
adjuvant JJ p
treatment NN p
with IN p
tamoxifen JJ i
+/- JJ i
octreotide NN i
in IN p
a DT p
randomized JJ p
trial NN p
( ( p
NCIC NNP p
CTG NNP p
MA.14 NNP p
; : p
National NNP p
Cancer NNP p
Institute NNP p
of IN p
Canada NNP p
Clinical NNP p
Trials NNP p
Group NNP p
Mammary.14 NNP p
) ) p
. . p

RESULTS NNP N
Plasma NNP o
OPN NNP o
was VBD N
measured VBN N
in IN N
2,540 CD p
samples NNS p
; : p
688 CD p
at IN p
baseline NN p
and CC p
1,852 CD p
collected VBN p
during IN N
follow-up JJ N
. . N

Mean NNP o
baseline NN o
plasma NN o
OPN NNP o
was VBD N
46 CD N
ng/ml NN N
( ( N
range VB N
22.6 CD N
to TO N
290 CD N
) ) N
which WDT N
did VBD N
not RB N
differ VB N
from IN N
normal JJ N
levels NNS N
. . N

Mean NNP o
percentage NN o
OPN NNP o
tumor NN o
cell NN o
positivity NN o
was VBD N
33.9 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
30.2 CD N
to TO N
37.9 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
correlation NN N
between IN o
plasma NN o
and CC o
tumor NN o
OPN NNP o
values NNS o
. . o

In IN N
multivariate JJ N
analysis NN N
, , N
neither DT N
was VBD N
associated VBN N
with IN o
event-free JJ o
survival NN o
( ( o
EFS NNP o
) ) o
, , o
relapse-free JJ o
survival NN o
( ( o
RFS NNP o
) ) o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
bone JJ o
RFS NNP o
or CC o
non-bone JJ o
RFS NNP o
. . o

An DT N
exploratory JJ N
analysis NN N
in IN N
patients NNS N
with IN N
recurrence NN N
showed VBD N
higher JJR o
mean JJ o
OPN NNP o
plasma NN o
levels NNS o
60.7 CD N
ng/ml NN N
( ( N
23.9 CD N
to TO N
543 CD N
) ) N
in IN N
the DT N
recurrence NN N
period NN N
compared VBN N
with IN N
baseline NN N
levels NNS N
. . N

CONCLUSIONS VB N
The DT N
hypothesis NN N
that WDT o
OPN NNP o
tumor NN o
expression NN o
would MD o
have VB N
independent JJ N
prognostic JJ N
value NN N
in IN N
early JJ N
breast NN N
cancer NN N
was VBD N
not RB N
supported VBN N
by IN N
multivariate JJ N
analysis NN N
of IN N
this DT N
study NN N
population NN o
. . o

Plasma NNP o
OPN NNP o
levels NNS o
in IN o
women NNS p
with IN p
hormone NN p
responsive VBP p
early JJ p
breast NN p
cancer NN p
in IN p
the DT N
MA.14 NNP N
trial NN N
were VBD N
not RB N
elevated VBN N
and CC N
there EX N
was VBD N
no DT N
evidence NN N
for IN N
prognostic JJ N
value NN N
of IN N
plasma JJ N
OPN NNP N
in IN N
this DT N
defined JJ N
group NN N
of IN N
patients NNS N
. . N

However RB N
, , N
our PRP$ N
finding NN N
of IN N
elevated JJ o
mean JJ o
OPN NNP o
plasma NN o
level NN o
around IN o
the DT N
time NN N
of IN N
recurrence NN N
warrants NNS N
further RBR N
study NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NCT00002864 NNP N
, , N
http NN N
: : N
//clinicaltrials.gov/show/NCT00002864 NN N
. . N

-DOCSTART- -X- O O

Enhancing VBG N
caregiver NN N
health NN N
: : N
findings NNS N
from IN N
the DT N
resources NNS N
for IN N
enhancing VBG N
Alzheimer NNP p
's POS p
caregiver NN p
health NN p
II NNP p
intervention NN p
. . p

OBJECTIVES NNP N
To TO N
examine VB N
the DT N
relationships NNS N
between IN N
changes NNS N
from IN N
baseline NN N
to TO N
post-Resources NNS i
for IN i
Enhancing VBG i
Alzheimer NNP i
's POS i
Caregiver NNP i
Health NNP i
( ( i
REACH NNP i
) ) i
intervention NN i
in IN N
caregiver NN N
( ( N
CG NNP N
) ) N
self-reported JJ N
health NN N
, , N
burden NN N
, , N
and CC N
bother RB N
. . N

DESIGN NNP N
Randomized NNP N
, , N
multisite RB N
clinical JJ N
trial NN N
. . N

SETTING NN N
CG NNP p
and CC p
care VB p
recipient NN p
( ( p
CR NNP p
) ) p
homes NNS p
in IN p
five CD p
U.S. NNP p
cities NNS p
. . p

PARTICIPANTS VB N
Four CD p
hundred CD p
ninety-five JJ p
dementia NN p
CG NNP p
and CC p
CR NNP p
dyads NNS p
( ( p
169 CD p
Hispanic NNP p
, , p
160 CD p
white JJ p
, , p
and CC p
166 CD p
African JJ p
American NNP p
) ) p
receiving VBG p
intervention NN p
and CC p
their PRP$ p
controls NNS p
. . p

INTERVENTION NNP N
CGs NNP N
were VBD N
assigned VBN N
to TO N
the DT N
REACH NNP i
intervention NN i
or CC i
a DT i
no-treatment JJ i
control NN i
group NN i
. . i

Intervention NNP N
subjects VBZ N
received VBN N
individual JJ N
risk NN N
profiles NNS N
and CC N
the DT N
REACH NNP i
intervention NN i
through IN i
nine CD N
in-home JJ i
and CC N
three CD N
telephone NN i
sessions NNS i
over IN N
6 CD N
months NNS N
. . N

Control NNP N
subjects VBZ N
received VBN N
two CD N
brief JJ N
check-in JJ i
telephone NN i
calls VBZ i
during IN N
this DT N
6-month JJ N
period NN N
. . N

MEASUREMENTS PDT N
The DT N
primary JJ N
outcome NN N
was VBD N
change NN o
in IN o
CG NNP o
health NN o
status NN o
from IN N
baseline NN N
to TO N
after IN N
the DT N
intervention NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
CG NNP o
burden NN o
and CC o
bother NN o
after IN o
the DT o
intervention NN o
. . o

RESULTS NNP N
After IN N
the DT N
intervention NN N
, , N
CGs NNP N
reported VBD N
better RBR N
self-rated JJ o
health NN o
, , o
sleep VBP o
quality NN o
, , o
physical JJ o
health NN o
, , o
and CC o
emotional JJ o
health NN o
, , N
which WDT N
was VBD N
related VBN N
to TO N
less JJR N
burden JJ N
and CC N
bother NN N
with IN N
their PRP$ N
caregiving NN N
role NN N
than IN N
for IN N
CGs NNP N
not RB N
receiving VBG N
the DT N
intervention NN N
. . N

Changes NNS N
in IN N
depression NN o
appeared VBD N
to TO N
mediate VB N
these DT N
relationships NNS N
. . N

Several JJ N
racial JJ N
and CC N
ethnic JJ N
group NN N
differences NNS N
existed VBD N
in IN N
physical JJ o
and CC o
emotional JJ o
health NN o
, , N
as RB N
well RB N
as IN N
in IN N
total JJ o
frustration NN o
with IN o
caregiving NN o
, , o
emotional JJ o
burden NN o
, , o
and CC o
CG-rated JJ o
bother NN o
with IN N
CR NNP N
's POS N
activities NNS N
of IN N
daily JJ N
living NN N
and CC N
instrumental JJ N
activities NNS N
of IN N
daily JJ N
living NN N
at IN N
baseline NN N
and CC N
at IN N
follow-up JJ N
, , N
although IN N
differences NNS N
between IN N
baseline NN N
and CC N
posttest NN N
did VBD N
not RB N
vary JJ N
according VBG N
to TO N
race NN N
. . N

CONCLUSION VB N
A DT N
structured JJ N
, , N
multicomponent JJ N
skills NNS N
training VBG N
intervention NN N
that WDT N
targeted VBD N
CG NNP N
self-care JJ N
behaviors NNS N
as IN N
one CD N
of IN N
five CD N
target NN N
areas NNS N
, , N
improved VBN N
self-reported JJ o
health NN o
status NN o
, , N
and CC N
decreased VBD N
burden NN o
and CC N
bother NN N
in IN N
racially RB p
and CC p
ethnically RB p
diverse JJ p
CGs NNP p
of IN p
people NNS p
with IN p
dementia NN p
. . p

-DOCSTART- -X- O O

Chlorhexidine NNP i
swabbing VBG N
applications NNS N
under IN N
various JJ N
conditions NNS N
of IN N
use NN N
in IN N
preventive JJ N
oral JJ N
care NN N
for IN N
persons NNS p
with IN p
disabilities NNS p
. . p

A DT N
sample NN N
of IN N
44 CD p
adults NNS p
with IN p
severe JJ p
disabilities NNS p
completed VBD N
a DT N
randomized JJ N
single-blind JJ N
cross-over NN N
study NN N
testing VBG N
chlorhexidine NN i
swabbing VBG N
under IN N
various JJ N
conditions NNS N
: : N
with/without NN N
prior RB N
dental JJ N
prophylaxis NN N
, , N
reduced VBD N
frequency NN N
of IN N
application NN N
( ( N
2 CD N
vs. NN N
5 CD N
times NNS N
per IN N
week NN N
) ) N
, , N
and CC N
prolonged VBN N
use NN N
( ( N
42 CD N
weeks NNS N
) ) N
. . N

All DT N
subjects NNS N
received VBN N
therapeutic JJ N
doses NNS N
of IN N
10 CD i
mL NNS i
0.12 CD i
% NN i
chlorhexidine NN i
gluconate NN i
( ( N
Peridex NNP N
, , N
Procter NNP N
& CC N
Gamble NNP N
) ) N
and CC N
10 CD i
mL NNS i
0.05 CD i
% NN i
NaF NNP i
applied VBN i
with IN i
a DT i
Toothette NNP i
( ( N
Sage NNP N
Products NNPS N
) ) N
. . N

Clinical JJ o
effectiveness NN o
of IN N
chlorhexidine NN i
swabbing NN N
compared VBN N
with IN N
placebo NN i
was VBD N
previously RB N
reported VBN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
while IN N
initial JJ N
benefits NNS N
were VBD N
observed VBN N
to TO N
be VB N
independent JJ N
of IN N
dental JJ N
prophylaxis NN N
, , N
significant JJ N
reductions NNS N
in IN N
periodontal JJ o
scores NNS o
were VBD N
sustained VBN N
by IN N
a DT N
combination NN N
of IN N
dental JJ N
prophylaxis NN N
and CC N
swabbing VBG N
protocol NN N
, , N
at IN N
reduced JJ N
frequency NN N
of IN N
application NN N
and CC N
over IN N
prolonged JJ N
time NN N
. . N

High JJ N
levels NNS N
of IN N
acceptance NN o
and CC o
compliance NN o
by IN N
subjects/caregivers NNS N
were VBD N
maintained VBN N
. . N

Subjects/caregivers NNS N
reported VBD N
improvements NNS o
in IN o
dental JJ o
health NN o
as RB o
well RB o
as IN o
in IN o
attitude NN o
, , o
quality NN o
of IN o
life NN o
, , o
and CC o
smile NN o
. . o

Chlorhexidine VB i
swabbing VBG N
at IN N
maintenance NN N
frequency NN N
, , N
combined VBN N
with IN N
periodic JJ N
dental JJ N
prophylaxis NN N
, , N
may MD N
offer VB N
an DT N
effective JJ N
and CC N
pragmatic JJ N
long-term JJ o
preventive JJ o
regimen NNS o
for IN N
persons NNS N
with IN N
disabilities NNS N
. . N

-DOCSTART- -X- O O

Parecoxib NNP i
for IN N
analgesia NN p
after IN p
craniotomy NN p
. . p

BACKGROUND NNP N
Pain NNP o
after IN N
craniotomy NN N
is VBZ N
often RB N
under-treated JJ N
. . N

Opiates VBZ N
carry VBP N
distinct JJ N
disadvantages NNS N
. . N

Non-steroidal JJ N
anti-inflammatory JJ N
drugs NNS N
have VBP N
an DT N
anti-platelet JJ N
action NN N
and CC N
carry VBP N
a DT N
bleeding NN N
risk NN N
. . N

Cyclo-oxygenase JJ N
2 CD N
inhibitors NNS N
such JJ N
as IN N
parecoxib NNS N
are VBP N
not RB N
associated VBN N
with IN N
a DT N
bleeding NN N
risk NN N
and CC N
would MD N
be VB N
welcome JJ N
analgesics NNS N
if IN N
shown VBN N
to TO N
be VB N
effective JJ N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
, , N
we PRP N
investigated VBD N
the DT N
analgesic JJ N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
parecoxib NN i
40 CD i
mg NN i
given VBN N
at IN N
dural JJ N
closure NN N
in IN N
82 CD p
patients NNS p
undergoing JJ p
elective JJ p
craniotomies NNS p
. . p

Remifentanil NNP i
was VBD N
used VBN N
intraoperatively RB N
, , N
and CC N
i.v NN i
. . i

morphine NN i
was VBD N
titrated VBN N
to TO N
the DT N
requirement NN N
in IN N
the DT N
post-anaesthetic JJ N
unit NN N
. . N

On IN N
the DT N
ward NN N
, , N
i.m NN i
. . i

morphine VB i
5 CD i
mg NNS i
as IN N
required VBN N
and CC N
regular JJ N
acetaminophen NN i
was VBD N
prescribed VBN N
. . N

Morphine NNP i
use NN N
and CC N
visual JJ o
analogue NN o
pain NN o
scores NNS o
were VBD N
recorded VBN N
at IN N
1 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
h NN N
after IN N
surgery NN N
. . N

RESULTS NNP N
Parecoxib NNP N
reduced VBD o
pain NN o
scores NNS o
at IN N
6 CD N
h NN N
and CC N
morphine NN N
use NN N
at IN N
6 CD N
and CC N
12 CD N
h NN N
after IN N
operation NN N
. . N

However RB N
, , N
overall JJ N
, , N
it PRP N
had VBD N
only RB N
minimal JJ N
impact NN N
on IN N
postoperative JJ o
analgesia NN o
. . o

We PRP N
found VBD N
a DT N
wide JJ N
variability NN N
in IN N
analgesic JJ N
requirements NNS N
where WRB N
11 CD N
% NN N
of IN N
patients NNS N
required VBN N
no DT N
opioids NNS N
and CC N
16 CD N
% NN N
required VBN N
more JJR N
than IN N
15 CD N
mg JJ N
i.v NN N
. . N

morphine VB N
1 CD N
h NN N
after IN N
the DT N
surgery NN N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
only RB N
limited JJ N
evidence NN N
to TO N
support VB N
parecoxib NN N
as IN N
an DT N
analgesic JJ N
after IN N
craniotomy NN N
. . N

-DOCSTART- -X- O O

The DT N
neuropeptide JJ i
oxytocin NN i
modulates NNS N
consumer NN N
brand NN N
relationships NNS N
. . N

Each DT N
year NN N
, , N
companies NNS N
invest VBP N
billions NNS N
of IN N
dollars NNS N
into IN N
marketing NN N
activities NNS N
to TO N
embellish VB N
brands NNS N
as IN N
valuable JJ N
relationship NN N
partners NNS N
assuming VBG N
that IN N
consumer NN N
brand NN N
relationships NNS N
( ( N
CBRs NNP N
) ) N
and CC N
interpersonal JJ N
relationships NNS N
rest VBP N
upon IN N
the DT N
same JJ N
neurobiological JJ N
underpinnings NNS N
. . N

Given VBN N
the DT N
crucial JJ N
role NN N
of IN N
the DT N
neuropeptide JJ i
oxytocin NN i
( ( i
OXT NNP i
) ) i
in IN N
social JJ N
bonding NN N
, , N
this DT N
study NN N
tests VBZ N
whether IN N
OXT-based JJ N
mechanisms NNS N
also RB N
determine VBP N
the DT N
bond NN N
between IN N
consumers NNS p
and CC N
brands NNS N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
placebo-controlled JJ N
study NN N
involving VBG N
101 CD p
subjects NNS p
and CC N
analyzed VBD N
the DT N
effect NN N
of IN N
intranasal NN i
OXT NNP i
on IN N
consumers NNS o
' POS o
attribution NN o
of IN o
relationship NN o
qualities NNS o
to TO o
brands NNS o
, , N
brands NNS N
paired VBD N
with IN N
human JJ N
celebrity NN N
endorsers NNS N
, , N
and CC N
familiar JJ N
persons NNS N
. . N

OXT NNP o
indeed RB N
promoted VBD N
the DT N
attribution NN o
of IN o
relationship NN o
qualities NNS o
not RB N
only RB N
in IN N
the DT N
case NN N
of IN N
social JJ N
and CC N
semi-social JJ N
stimuli NNS N
, , N
but CC N
also RB N
brands NNS N
. . N

Intriguingly RB N
, , N
for IN N
subjects NNS p
scoring VBG p
high JJ p
on IN p
autistic-like JJ p
traits NNS p
, , N
the DT N
effect NN N
of IN N
OXT NNP i
was VBD N
completely RB N
reversed VBN N
, , N
evident JJ N
in IN N
even RB N
lower JJR N
relationship NN o
qualities NNS o
across IN N
all DT N
stimulus JJ N
categories NNS N
. . N

The DT N
importance NN N
of IN N
OXT NNP i
in IN N
a DT N
CBR NNP N
context NN N
is VBZ N
further RB N
corroborated VBN N
by IN N
a DT N
three-fold JJ N
increase NN N
in IN N
endogenous JJ o
release NN o
of IN o
OXT NNP o
following VBG N
exposure NN N
to TO N
one CD N
's POS N
favorite JJ N
brand NN N
and CC N
positive JJ N
associations NNS N
between IN N
baseline JJ N
peripheral JJ N
OXT NNP i
concentrations NNS N
and CC N
brand NN N
relationship NN N
qualities NNS N
. . N

Collectively RB N
, , N
our PRP$ N
findings NNS N
indicate VBP N
that IN N
OXT NNP i
not RB N
only RB N
plays VBZ N
a DT N
fundamental JJ N
role NN N
in IN N
developing VBG N
interpersonal JJ o
relationships NNS o
, , N
but CC N
also RB N
enables VBZ N
relationship NN N
formation NN N
with IN N
objects NNS N
such JJ N
as IN N
brands NNS N
. . N

-DOCSTART- -X- O O

Patient NN N
positioning VBG N
influences NNS N
oxygen JJ o
saturation NN o
in IN N
the DT N
acute JJ p
phase NN p
of IN p
stroke NN p
. . p

We PRP N
evaluated VBD N
arterial JJ o
oxygen NN o
saturation NN o
( ( o
SaO NNP o
( ( o
2 CD o
) ) o
) ) o
and CC o
heart NN o
rate NN o
in IN N
acute JJ p
stroke NN p
patients NNS p
to TO N
determine VB N
whether IN N
routine JJ N
positioning NN N
affected VBD N
these DT N
physiological JJ N
parameters NNS N
. . N

Measurements NNS N
were VBD N
recorded VBN N
at IN N
the DT N
bedside JJ N
non-invasively RB N
in IN N
five CD i
different JJ i
positions NNS i
assigned VBN N
in IN N
random JJ N
order NN N
each DT N
maintained VBD N
for IN N
10 CD N
min NN N
. . N

One CD p
hundred CD p
and CC p
twenty-nine JJ p
patients NNS p
examined VBD p
within IN p
a DT p
median NN i
of IN p
72 CD p
h NN p
, , p
lying VBG i
on IN i
the DT i
left JJ i
side NN i
resulted VBD p
in IN p
slightly RB p
lower JJR p
SaO NNP o
( ( o
2 CD o
) ) o
than IN p
lying VBG i
on IN i
the DT i
right JJ i
side NN i
, , p
which WDT p
was VBD p
statistically RB p
significant JJ p
in IN p
the DT p
patients NNS p
with IN p
a DT p
right NN p
( ( p
n JJ p
= NNP p
66 CD p
) ) p
, , p
but CC p
not RB p
left VBD p
, , p
hemiparesis NN p
. . p

Patients NNS N
able JJ N
to TO N
sit VB i
in IN i
a DT i
chair NN i
( ( N
n JJ N
= NNP N
65 CD N
) ) N
, , N
who WP N
mostly RB N
had VBD N
less RBR N
severe JJ N
strokes NNS N
, , N
had VBD N
a DT N
significantly RB N
higher JJR N
mean JJ o
SaO NNP o
( ( o
2 CD o
) ) o
and CC o
heart NN o
rate NN o
when WRB N
sitting VBG N
in IN N
the DT N
chair NN N
than IN N
when WRB N
placed VBN N
in IN N
any DT N
other JJ N
position NN N
. . N

About IN N
10 CD N
% NN N
of IN N
patients NNS N
, , N
especially RB N
those DT N
with IN N
a DT N
severe JJ N
stroke NN N
, , N
with IN N
right JJ N
hemiparesis NN N
and CC N
concomitant JJ N
chest NN N
disease NN N
, , N
experienced VBD N
falls NNS N
in IN N
SaO NNP o
( ( o
2 CD o
) ) o
to TO N
90 CD N
% NN N
or CC N
less JJR N
for IN N
> NN N
/=2 NNP N
min NN N
in IN N
certain JJ N
positions NNS N
; : N
the DT N
hypoxia NN o
was VBD N
more RBR N
likely JJ N
when WRB N
they PRP N
were VBD N
lying VBG i
on IN i
their PRP$ i
left JJ i
side NN i
. . i

These DT N
results NNS N
may MD N
have VB N
implications NNS N
for IN N
current JJ N
practice NN N
and CC N
for IN N
future JJ N
patient JJ N
positioning VBG N
strategies NNS N
to TO N
improve VB N
outcome NN N
after IN N
stroke NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Total NNP N
parenteral JJ o
nutrition NN o
in IN N
colon NN i
surgery NN i
] NN i
. . N

-DOCSTART- -X- O O

Everolimus NNP i
for IN N
subependymal JJ N
giant NN N
cell NN N
astrocytoma NN N
in IN N
patients NNS p
with IN p
tuberous JJ p
sclerosis NN p
complex NN p
: : p
2-year JJ N
open-label JJ N
extension NN N
of IN N
the DT N
randomised JJ N
EXIST-1 NNP N
study NN N
. . N

BACKGROUND NNP N
In IN N
the DT N
EXIST-1 NNP N
trial NN N
, , N
initiated VBN N
on IN N
Aug NNP N
10 CD N
, , N
2009 CD N
, , N
more JJR N
than IN N
35 CD N
% NN N
of IN N
patients NNS p
with IN p
subependymal JJ p
giant NN p
cell NN p
astrocytoma NN p
( ( p
SEGA NNP p
) ) p
associated VBN p
with IN p
tuberous JJ p
sclerosis NN p
complex NN p
had VBD N
at IN N
least JJS N
50 CD N
% NN N
reduction NN N
in IN N
SEGA NNP N
volume NN N
after IN N
9?6 CD N
months NNS N
of IN N
treatment NN N
with IN N
everolimus NN N
. . N

In IN N
this DT N
Article NNP N
, , N
we PRP N
report VBP N
interim JJ N
data NNS p
( ( p
up IN p
to TO p
Jan NNP p
11 CD p
, , p
2013 CD p
) ) p
to TO N
support VB N
longer-term JJ N
tolerability NN N
and CC N
efficacy NN N
of IN i
everolimus NN i
from IN N
the DT N
continuing VBG N
4-year JJ N
extension NN N
phase NN N
of IN N
EXIST-1 NNP N
. . N

METHODS NNP N
We PRP N
assessed VBD N
data NNS N
from IN N
a DT N
prospective JJ N
, , N
open-label JJ N
extension NN N
of IN N
a DT N
multicentre NN N
, , N
phase NN N
3 CD N
, , N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
in IN p
patients NNS p
with IN p
tuberous JJ p
sclerosis NN p
complex NN p
who WP p
had VBD p
SEGA NNP p
that WDT p
was VBD p
growing VBG p
and CC p
needed VBN p
treatment NN p
. . p

In IN N
this DT N
extension NN N
study NN N
, , N
we PRP N
included VBD p
all DT p
patients NNS p
who WP p
had VBD p
been VBN p
assigned VBN i
everolimus RBR i
during IN p
the DT p
double-blind NN p
, , p
randomised VBD p
phase NN p
of IN p
the DT p
trial NN p
and CC p
those DT p
patients NNS p
who WP p
crossed VBD p
over IN p
from IN p
the DT i
placebo NN i
group NN p
to TO p
receive VB i
everolimus NN i
during IN p
the DT p
randomised JJ p
phase NN p
or CC p
at IN p
the DT p
start NN p
of IN p
the DT p
extension NN p
phase NN p
. . p

All DT N
patients NNS N
received VBD N
oral JJ i
everolimus NN i
at IN N
a DT N
starting VBG N
dose NN N
of IN N
4?5 CD N
mg/m NN N
( ( N
2 CD N
) ) N
per IN N
day NN i
. . i

Everolimus NNP i
dose NN i
was VBD N
subsequently RB N
adjusted VBN N
subject NN N
to TO N
tolerability NN N
to TO N
attain VB o
blood NN o
trough IN o
concentrations NNS o
of IN o
5-15 JJ N
ng/mL NN N
. . N

An DT N
independent JJ N
central JJ N
radiology NN N
review NN N
team NN N
assessed VBD N
SEGA NNP N
response NN N
( ( N
at IN N
least JJS N
a DT N
50 CD N
% NN N
reduction NN N
from IN N
baseline NN N
in IN N
total JJ N
volume NN N
of IN N
all DT N
target NN N
SEGAs NNP N
; : N
the DT N
primary JJ N
endpoint NN N
) ) N
by IN N
MRI NNP N
at IN N
12 CD N
, , N
24 CD N
, , N
and CC N
48 CD N
weeks NNS N
, , N
then RB N
every DT N
year NN N
thereafter RB N
in IN N
all DT N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
one CD N
dose NN N
of IN N
everolimus NN N
. . N

This DT N
study NN N
was VBD N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00789828 NNP N
. . N

FINDINGS NNP N
Of IN N
the DT p
original JJ p
117 CD p
randomly RB p
assigned VBN p
patients NNS p
, , p
111 CD p
were VBD p
given VBN p
everolimus NNS p
between IN p
Aug NNP p
20 CD p
, , p
2009 CD p
, , p
and CC p
Jan NNP p
11 CD p
, , p
2013 CD p
( ( p
date NN N
of IN N
data NNS N
cutoff NN N
) ) N
; : N
we PRP N
included VBD N
these DT N
patients NNS N
in IN N
our PRP$ N
longer-term JJ N
analysis NN N
. . N

Median JJ N
duration NN N
of IN N
everolimus NN N
exposure NN N
was VBD N
29?3 CD N
months NNS N
( ( N
IQR NNP N
19?4-33?8 CD N
) ) N
. . N

Median JJ N
follow-up NN N
was VBD N
28?3 CD N
months NNS N
( ( N
IQR NNP N
19?3-33?0 CD N
) ) N
. . N

54 CD N
( ( N
49 CD N
% NN N
) ) N
patients NNS N
had VBD N
a DT N
response NN N
of IN N
50 CD N
% NN N
or CC N
greater JJR N
reduction NN o
in IN o
SEGA NNP o
volume NN o
( ( N
95 CD N
% NN N
CI NNP N
39?0-58?3 CD o
) ) o
, , o
and CC o
duration NN o
of IN o
response NN o
was VBD N
between IN N
2?1 CD N
and CC N
31?1 CD N
months NNS N
( ( N
median JJ N
not RB N
reached VBN N
) ) N
. . o

SEGA JJ o
volume NN o
was VBD N
reduced VBN N
by IN N
50 CD N
% NN N
or CC N
more JJR N
in IN N
39 CD N
( ( N
37 CD N
% NN N
) ) N
of IN N
105 CD N
patients NNS N
at IN N
24 CD N
weeks NNS N
, , N
48 CD N
( ( N
46 CD N
% NN N
) ) N
of IN N
104 CD N
patients NNS N
at IN N
48 CD N
weeks NNS N
, , N
36 CD N
( ( N
47 CD N
% NN N
) ) N
of IN N
76 CD N
patients NNS N
at IN N
96 CD N
weeks NNS N
, , N
and CC N
11 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
29 CD N
patients NNS N
at IN N
144 CD N
weeks NNS N
. . o

Stomatitis NNP o
( ( N
48 CD N
[ RB N
43 CD N
% NN N
] JJ N
patients NNS N
) ) N
and CC o
mouth JJ o
ulceration NN o
( ( N
33 CD N
[ RB N
30 CD N
% NN N
] JJ N
patients NNS N
) ) N
were VBD N
the DT N
most RBS N
frequent JJ N
treatment-related JJ N
adverse JJ N
events NNS o
; : o
infections NNS o
were VBD N
the DT N
most RBS N
commonly RB N
reported VBD N
treatment-related JJ N
serious JJ N
adverse JJ N
event NN N
, , N
occurring VBG N
in IN N
15 CD N
( ( N
14 CD N
% NN N
) ) N
patients NNS N
. . N

35 CD N
( ( N
32 CD N
% NN N
) ) N
patients NNS N
reported VBD N
treatment-related JJ N
grade NN N
3 CD N
or CC N
4 CD N
adverse JJ o
events NNS o
, , o
the DT o
most RBS N
common JJ N
of IN N
which WDT N
were VBD o
stomatitis NN o
( ( N
nine CD N
[ RB N
8 CD N
% NN N
] NN N
) ) N
and CC o
pneumonia NN o
( ( o
nine CD N
[ RB N
8 CD N
% NN N
] NN N
) ) N
. . N

18 CD N
( ( N
16 CD N
% NN N
) ) N
patients NNS N
had VBD N
treatment-related JJ o
serious JJ o
adverse JJ o
events NNS o
. . o

Six NNP o
( ( N
5 CD N
% NN N
) ) N
patients NNS N
withdrew VBD N
because IN o
of IN o
adverse JJ o
events NNS o
. . o

INTERPRETATION NNP o
These DT N
results NNS N
support VBD N
the DT N
longer-term JJ N
use NN N
of IN N
everolimus NN N
in IN p
patients NNS p
who WP p
have VBP p
few JJ p
treatment NN p
options NNS p
and CC p
who WP p
need VBP p
continued VBN p
treatment NN p
for IN p
tuberous JJ p
sclerosis NN p
complex NN p
and CC p
its PRP$ N
varied JJ N
manifestations NNS o
. . o

Reduction NN o
or CC o
stabilisation NN o
of IN o
tumour JJ o
volume NN o
with IN o
everolimus NN i
will MD N
hopefully RB N
provide VB N
long-term JJ N
clinical JJ N
benefit NN N
in IN N
patients NNS N
with IN N
SEGA NNP N
. . N

FUNDING NN N
Novartis NN N
Pharmaceuticals NNP N
. . N

-DOCSTART- -X- O O

[ JJ N
Effects NNS N
of IN N
simvastatin NN i
on IN N
plasma NN o
lipids NNS o
, , o
lipoproteins NNS o
and CC N
apoproteins NNS o
( ( N
A1 NNP N
and CC N
B NNP N
) ) N
. . N

24 CD N
cases NNS N
of IN N
major JJ N
primary JJ N
hypercholesterolemia NN p
] NN p
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
simvastatin NN i
( ( i
MK NNP i
733 CD i
) ) i
, , N
a DT N
new JJ N
competitive JJ N
inhibitor NN N
of IN N
HMG NNP i
CoA NNP i
reductase NN i
, , i
alone RB i
and CC i
in IN i
combination NN i
with IN i
a DT i
bile JJ i
acid NN i
sequestrant NN i
, , i
cholestyramine NN i
, , N
on IN N
serum NN N
levels NNS N
of IN N
lipoproteins NNS N
and CC N
apoproteins NNS N
A1 NNP N
and CC N
B NNP N
, , N
in IN N
24 CD p
patients NNS p
with IN p
familial JJ p
hypercholesterolemia NN p
. . p

After IN N
simvastatin JJ i
treatment NN i
( ( N
40 CD N
mg/day NN N
) ) N
alone RB N
for IN N
12 CD N
weeks NNS N
, , N
serum JJ N
total NN N
and CC N
low JJ o
density NN o
lipoprotein NN o
cholesterol NN o
decreased VBN N
by IN N
31 CD N
and CC N
36 CD N
percent NN N
respectively RB N
. . N

With IN N
the DT N
addition NN N
of IN N
cholestyramine NN i
, , N
there EX N
was VBD N
a DT N
41 CD N
per IN N
cent NN N
total JJ N
decrease NN N
in IN N
serum NN o
cholesterol NN o
from IN N
the DT N
control NN N
value NN N
and CC N
a DT N
50 CD N
percent NN N
decrease NN N
in IN N
low JJ o
density NN o
lipoprotein NN o
cholesterol NN o
. . o

After IN N
cholestyramine JJ i
treatment NN i
alone RB N
for IN N
12 CD N
weeks NNS N
, , N
serum JJ o
total NN o
and CC o
low JJ o
density NN o
lipoprotein NN o
cholesterol NN o
decreased VBN N
by IN N
20 CD N
percent NN N
and CC N
29 CD N
percent NN N
respectively RB N
. . N

With IN N
the DT N
addition NN N
of IN N
simvastatin NN i
( ( N
20 CD N
mg NNS N
per IN N
day NN N
) ) N
, , N
there EX N
was VBD N
a DT N
32 CD N
percent NN N
total JJ N
decrease NN N
in IN N
serum NN o
cholesterol NN o
from IN N
the DT N
control NN N
value NN N
and CC N
a DT N
43 CD N
percent NN N
decrease NN N
in IN N
low JJ N
density NN o
lipoprotein NN o
cholesterol NN o
. . o

High JJ o
density NN o
lipoprotein VBP o
cholesterol NN o
remained VBD N
unchanged JJ N
. . N

No DT N
major JJ o
adverse JJ o
effect NN o
was VBD N
observed VBN N
. . N

If IN N
long JJ N
term NN N
safety NN N
can MD N
be VB N
confirmed VBN N
, , N
the DT N
simvastatin-cholestyramine JJ i
regimen NNS i
may MD N
prove VB N
useful JJ N
in IN N
heterozygous JJ p
familial JJ p
hypercholesterolemia NN p
. . p

-DOCSTART- -X- O O

[ JJ o
Therapeutic NNP o
efficacy NN o
of IN N
youdujing VBG i
preparation NN i
in IN N
treating VBG N
cervical JJ p
high-risk JJ p
human JJ p
papilloma NN p
virus NN p
infection NN p
patients NNS p
] VBP p
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
mechanisms NN N
of IN N
Youdujing NNP i
( ( i
YDJ NNP i
) ) i
preparation NN i
in IN N
treating VBG N
the DT N
cervical JJ p
high-risk JJ p
human JJ p
papilloma NN p
virus NN p
( ( p
HR-HPV NNP p
) ) p
infection NN p
. . p

METHODS NNP N
Totally RB p
HR-HPV NNP p
infection NN p
70 CD p
patients NNS p
were VBD N
assigned VBN N
to TO N
the DT N
treatment NN i
group NN N
and CC N
the DT N
control NN i
group NN N
using VBG N
random JJ N
single JJ N
blind NN N
method NN N
, , N
35 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

YDJ NNP i
external JJ i
lotion NN i
and CC i
YDJ NNP i
cream NN i
were VBD N
applied VBN N
to TO N
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
, , N
while IN N
normal JJ i
saline NN i
was VBD N
applied VBN N
for IN N
those DT N
in IN N
the DT N
control NN i
group NN N
. . N

HR-HPV NNP o
DNA NNP o
detection NN o
was VBD N
performed VBN N
by IN N
the DT N
end NN N
of IN N
the DT N
1st CD N
menstruation NN N
after IN N
3 CD N
menstrual JJ N
cycles NNS N
. . N

The DT N
cervical JJ N
biopsy NN N
and CC N
cervical JJ N
smear NN N
were VBD N
performed VBN N
using VBG N
vaginoscope NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

The DT N
mRNA JJ o
expression NN o
of IN o
human JJ o
telomerase NN o
reverse NN o
transcriptase NN o
( ( o
hTERT NN o
) ) o
was VBD N
detected VBN N
from IN N
fresh JJ N
tissues NNS N
of IN N
the DT N
cervical JJ N
lesion NN N
. . N

RESULTS VB N
The DT N
total JJ o
effective JJ o
rate NN o
was VBD N
96.6 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
, , N
higher JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
( ( N
70.00 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Before IN N
treatment NN N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
pathological JJ o
results NNS o
of IN o
the DT o
cervix NN o
and CC N
the DT N
mRNA JJ o
expression NN o
of IN o
hTERT NN o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
mRNA JJ o
expression NN o
of IN o
hTERT NN o
decreased VBN N
in IN N
the DT N
two CD N
groups NNS N
after IN N
treatment NN N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Better JJR N
effects NNS N
on IN N
the DT N
pathological JJ N
results NNS N
of IN N
the DT N
cervix NN o
and CC N
the DT N
mRNA JJ o
expression NN o
of IN o
hTERT NN o
were VBD N
obtained VBN N
in IN N
the DT N
treatment NN N
group NN N
after IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
YDJ NNP i
played VBD N
a DT N
role NN N
in IN N
clearing VBG N
HR-HPV NNP o
infection NN o
and CC N
reversing VBG N
the DT N
cervical JJ o
precancerous JJ o
changes NNS o
possibly RB N
through IN N
down-regulating NN N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
and CC N
lowering VBG N
the DT N
telomerase NN N
activation NN N
. . N

-DOCSTART- -X- O O

A DT N
cost-benefit JJ o
comparison NN N
of IN N
intensive JJ i
diabetes NNS i
management NN i
with IN i
implantable JJ i
pumps NNS i
versus IN N
multiple JJ i
subcutaneous JJ i
injections NNS i
in IN N
patients NNS p
with IN p
type NN p
I PRP p
diabetes VBZ p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
if IN N
intraperitoneal JJ i
( ( i
IP NNP i
) ) i
insulin NN i
infusion NN i
via IN i
programmable JJ i
implantable JJ i
pumps NNS i
is VBZ N
a DT N
potential JJ N
alternative NN N
to TO N
subcutaneous JJ i
( ( i
SC NNP i
) ) i
insulin NN i
via IN i
multiple JJ i
injections NNS i
. . i

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
We PRP N
compared VBN N
the DT N
cost-benefits NNS o
of IN N
the DT N
two CD N
methods NNS N
using VBG N
a DT N
randomized VBN N
, , N
prospective JJ N
, , N
6-month JJ N
, , N
crossover JJ N
design NN N
in IN N
10 CD p
adult NN p
type NN p
I PRP p
diabetic JJ p
patients NNS p
. . p

RESULTS NNP N
When WRB N
judged VBN N
on IN N
the DT N
last JJ N
month NN N
of IN N
IP NNP N
versus NN N
SC NNP N
periods NNS N
in IN N
the DT N
nine CD N
patients NNS N
who WP N
completed VBD N
the DT N
study NN N
, , N
metabolic JJ o
data NN o
showed VBD N
better JJR N
glycemic JJ o
control NN o
( ( N
HbA1c NNP N
: : N
7.2 CD N
+/- JJ N
0.2 CD N
IP NNP N
vs. FW N
8.5 CD N
+/- JJ N
0.7 CD N
% NN N
SC NNP N
, , N
mean JJ N
+/- JJ N
SE NNP N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
reduced VBN o
glycemic JJ o
fluctuations NNS o
( ( N
SD NNP N
of IN N
capillary JJ N
glucose JJ N
values NNS N
: : N
3.4 CD N
+/- JJ N
0.2 CD N
IP NNP N
vs. FW N
4.6 CD N
+/- JJ N
0.2 CD N
mM NN N
SC NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
fewer JJR N
mild JJ o
hypoglycemic JJ o
events NNS o
( ( N
5.7 CD N
+/- JJ N
2.0 CD N
IP NNP N
vs. FW N
10.0 CD N
+/- JJ N
3.1 CD N
events/month JJ N
SC NNP N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Quality NN o
of IN o
life NN o
, , o
judged VBN o
by IN o
Diabetes NNP o
Control NNP o
and CC o
Complications NNP o
Trial NNP o
questionnaires NNS o
, , N
was VBD N
unaffected VBN N
by IN N
pump NN i
therapy NN N
. . N

Direct JJ o
costs NNS o
, , o
including VBG o
pump JJ o
acquisition NN o
, , o
implantation NN o
, , o
and CC o
follow-up NN o
, , N
were VBD N
2.6-fold JJ N
higher JJR N
with IN N
IP NNP N
than IN N
with IN N
SC NNP N
delivery NN N
. . N

CONCLUSIONS VB N
The DT N
implantable JJ i
pump NN i
is VBZ N
more RBR o
effective JJ o
in IN N
the DT N
short JJ N
term NN N
, , N
equally RB N
accepted VBN o
, , N
but CC N
more RBR N
costly JJ o
than IN N
multiple JJ i
injections NNS i
and CC N
should MD N
be VB N
limited VBN N
to TO N
patients NNS N
with IN N
unsatisfactory JJ N
glycemic JJ o
control NN o
despite IN N
intensive JJ N
diabetes NNS N
management NN N
with IN N
SC NNP N
insulin NN N
. . N

In IN N
addition NN N
, , N
longer-term JJ N
, , N
larger-scale JJ N
, , N
and CC N
comparative JJ N
evaluation NN N
is VBZ N
required VBN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
alcohol NN i
on IN N
the DT N
pharmacokinetics NNS o
of IN N
morphine NN i
sulfate NN i
and CC N
naltrexone NN i
hydrochloride NN i
extended VBD N
release NN N
capsules NNS N
. . N

Although IN N
contraindicated VBN N
, , N
coingestion NN N
of IN N
alcohol NN N
and CC N
opioids NNS i
by IN N
patients NNS N
or CC N
drug NN N
abusers NNS N
is VBZ N
a DT N
major JJ N
health NN N
concern NN N
because IN N
of IN N
dangerous JJ N
additive JJ N
and CC N
potentially RB N
life-threatening JJ N
sedative JJ N
and CC N
respiratory JJ N
effects NNS N
. . N

In IN N
addition NN N
, , N
alcohol NN N
has VBZ N
been VBN N
shown VBN N
to TO N
disrupt VB N
the DT N
extended-release JJ N
characteristics NNS N
of IN N
certain JJ N
extended-release JJ N
opioid NN N
formulations NNS N
, , N
releasing VBG N
a DT N
hazardous JJ N
amount NN N
of IN N
opioid NN N
over IN N
a DT N
short JJ N
time NN N
period NN N
. . N

Morphine NNP i
sulfate NN i
and CC i
naltrexone NN i
hydrochloride NN i
extended VBD i
release NN i
capsules NNS i
( ( i
MS-sNT NNP i
) ) i
, , N
which WDT N
contain VBP N
naltrexone RB N
sequestered VBN N
in IN N
each DT N
pellet NN N
core NN N
, , N
are VBP N
indicated VBN N
for IN N
management NN N
of IN N
chronic NN N
, , N
moderate VB N
to TO N
severe VB N
pain NN N
. . N

Sequestered NNP N
naltrexone NN N
is VBZ N
designed VBN N
for IN N
release NN N
upon IN N
product NN N
tampering NN N
( ( N
crushing VBG N
) ) N
to TO N
potentially RB N
mitigate VB N
morphine-induced JJ N
subjective JJ N
effects NNS N
. . N

This DT N
open-label JJ N
, , N
single-dose JJ N
, , N
4-way JJ N
crossover NN N
, , N
pharmacokinetic JJ N
drug NN N
interaction NN N
study NN N
compared VBN N
the DT N
relative JJ o
bioavailability NN o
of IN o
morphine NN o
and CC o
naltrexone NN o
when WRB o
MS-sNT NNP o
is VBZ o
administered VBN o
( ( o
under IN o
fasting VBG o
conditions NNS o
) ) o
with IN o
increasing VBG o
doses NNS o
of IN o
alcohol NN o
. . o

Thirty-two NNP p
healthy JJ p
, , p
opioid-naive JJ p
adults NNS p
were VBD N
randomized VBN N
to TO N
MS-sNT NNP i
administered VBN N
with IN N
240 CD N
mL NNS N
of IN N
4 CD N
% NN N
, , N
20 CD N
% NN N
, , N
or CC N
40 CD N
% NN N
alcohol NN i
or CC N
water NN N
. . N

No DT N
drug NN o
interaction NN o
was VBD N
found VBN N
between IN N
morphine NN N
in IN N
MS-sNT NNP N
and CC N
4 CD N
% NN N
or CC N
20 CD N
% NN N
alcohol NN N
. . N

Administration NN N
with IN N
40 CD N
% NN N
alcohol NN N
did VBD N
not RB N
affect VB N
overall JJ o
morphine NN o
exposure NN o
but CC N
was VBD N
associated VBN N
with IN N
a DT N
2-fold JJ N
increase NN N
in IN N
C NNP o
( ( o
max NN o
) ) o
and CC N
reduction NN N
of IN N
t NN o
( ( o
max NN o
) ) o
from IN N
9 CD N
to TO N
4 CD N
hours NNS N
versus IN N
MS-sNT NNP N
taken VBN N
with IN N
water NN N
. . N

Naltrexone CD o
sequestering NN o
was VBD o
successful JJ o
in IN N
all DT N
treatment NN N
arms NNS N
and CC N
not RB N
affected VBN N
by IN N
coadministration NN N
with IN N
alcohol NN N
over IN N
the DT N
dose JJ N
range NN N
tested VBD N
. . N

-DOCSTART- -X- O O

Long-term JJ o
results NNS o
of IN N
the DT N
MRC NNP i
AML10 NNP i
trial NN p
. . p

-DOCSTART- -X- O O

Effect NN N
of IN N
ginseng NN i
extract JJ i
supplementation NN i
on IN N
testicular JJ o
functions NNS o
in IN N
diabetic JJ p
rats NNS p
. . p

OBJECTIVE IN N
It PRP N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
standardized JJ N
ginseng NN i
extract NN i
on IN N
fertility NN o
parameters NNS o
in IN N
diabetic JJ p
rats NNS p
. . p

METHODS NNP N
Thirty NNP p
male NN p
rats NNS p
were VBD N
randomly RB N
allocated VBN N
into IN N
three CD N
groups NNS N
of IN N
10 CD N
rats NNS N
each DT N
: : N
1. CD N
controls NNS N
, , N
2. CD N
diabetes NNS N
( ( N
D NNP N
) ) N
and CC N
3. CD N
diabetes NNS N
+ JJ N
ginseng NN N
( ( N
DG NNP N
) ) N
. . N

The DT N
latter JJ N
two CD N
groups NNS N
were VBD N
rendered VBN N
diabetic JJ N
by IN N
i.p NN N
. . N

injection NN N
of IN N
streptozotocin NN i
( ( N
STZ NNP N
; : N
50 CD N
mg/kg NN N
) ) N
. . N

Standardized VBN i
ginseng NN i
extract NN i
( ( N
Dansk NNP N
Droge NNP N
A/S NNP N
, , N
Copenhagen NNP N
, , N
Denmark NNP N
) ) N
was VBD N
administered VBN N
per IN N
os NN N
( ( N
100 CD N
mg/kg RB N
BW NNP N
) ) N
by IN N
stomach NN N
tube NN N
daily RB N
for IN N
90 CD N
days NNS N
starting VBG N
one CD N
week NN N
after IN N
STZ NNP N
. . N

Ninety NNP N
days NNS N
post NN N
STZ VBP N
the DT N
rats NNS N
were VBD N
sacrificed VBN N
, , N
and CC N
testis NN o
, , o
epididymis NN o
, , o
prostate NN o
, , o
and CC o
seminal JJ o
vesicles NNS o
were VBD o
weighed VBN o
and CC o
subjected VBN o
to TO o
histological JJ o
examination NN o
. . o

In IN N
addition NN N
, , N
spermiogram NN o
, , o
testicular JJ o
enzyme NN o
markers NNS o
, , o
intratesticular JJ o
steroid JJ o
hormonal NN o
profile NN o
and CC o
testicular JJ o
antioxidant NN o
status NN o
were VBD N
estimated VBN N
. . N

RESULTS VB N
The DT N
administration NN N
of IN N
ginseng JJ i
extract NN i
resulted VBD N
in IN N
a DT N
significant JJ N
improvement NN N
of IN N
fertility NN o
parameters NNS o
and CC o
testicular JJ o
antioxidants NNS o
together RB o
with IN N
a DT N
decrease NN o
in IN o
malondialdehyde NN o
and CC o
testicular JJ o
pathological JJ o
signs NNS o
including VBG o
degenerative JJ o
changes NNS o
of IN o
the DT o
seminiferous JJ o
tubules NNS o
. . o

CONCLUSION NNP N
Ginseng NNP i
extract NN i
may MD N
be VB N
a DT N
beneficial JJ N
adjuvant NN N
therapy NN N
for IN N
diabetics NNS N
suffering VBG N
from IN N
infertility NN o
as IN N
a DT N
complication NN N
. . N

-DOCSTART- -X- O O

Mastication NN o
and CC o
late JJ o
mandibular NN o
fracture NN o
after IN N
surgery NN i
of IN N
impacted JJ p
third JJ p
molars NNS p
associated VBN p
with IN p
no DT p
gross JJ p
pathology NN p
. . p

PURPOSE VB N
This DT N
study NN N
was VBD N
undertaken VBN N
with IN N
the DT N
null JJ N
hypothesis NN N
that IN N
in IN N
patients NNS p
, , p
fully RB p
denate VB p
or CC p
with IN p
1 CD p
or CC p
2 CD p
teeth NNS p
missing VBG p
and CC p
older JJR p
than IN p
25 CD p
years NNS p
, , N
mastication NN N
does VBZ N
not RB N
affect VB N
late JJ N
mandibular JJ o
fracture NN o
after IN p
surgical JJ i
removal NN i
of IN p
impacted JJ p
third JJ p
molars NNS p
( ( p
M3s NNP p
) ) p
associated VBN p
with IN p
no DT p
gross JJ p
pathology NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Five NNP p
hundred VBD p
sixty NN p
patients NNS p
, , p
fully RB p
dentate VB p
or CC p
with IN p
1 CD p
or CC p
2 CD p
teeth NNS p
missing VBG p
and CC p
older JJR p
than IN p
25 CD p
years NNS p
who WP p
had VBD p
no DT p
gross JJ p
pathology NN p
associated VBN p
with IN p
their PRP$ p
impacted VBN p
lower JJR p
M3s NNP p
, , N
were VBD N
recruited VBN N
in IN N
this DT N
study NN N
. . N

They PRP N
were VBD N
operated VBN i
on IN i
under IN N
local JJ i
anesthesia NN i
using VBG N
a DT N
standard NN N
technique NN N
and CC N
randomly RB N
assigned VBN N
into IN N
2 CD N
groups NNS N
for IN N
nonroutine NN N
( ( N
NR NNP N
group NN N
) ) N
and CC N
routine JJ N
( ( N
R NNP N
group NN N
) ) N
postoperative NN N
instructions NNS N
. . N

In IN N
the DT N
NR NNP N
group NN N
, , N
patients NNS N
were VBD N
postoperatively RB N
educated VBN N
in IN N
the DT N
possibility NN N
of IN N
mandibular JJ o
fracture NN o
and CC N
were VBD N
given VBN N
an DT N
emphasis NN N
on IN N
the DT N
necessity NN N
of IN N
limiting VBG o
mastication NN o
to TO N
a DT N
soft JJ N
diet NN N
for IN N
4 CD N
weeks NNS N
. . N

In IN N
the DT N
R NNP N
group NN N
, , N
patients NNS N
were VBD N
given VBN N
no DT N
such JJ N
education NN N
or CC N
emphasis NN N
. . N

Patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
2 CD N
months NNS N
, , N
and CC N
data NNS o
concerning VBG o
patients NNS o
' POS o
age NN o
and CC o
gender NN o
; : o
tooth CC o
position NN o
, , o
angulation NN o
, , o
and CC o
depth NN o
; : o
date NN o
and CC o
site NN o
of IN o
surgery NN o
; : o
and CC o
occurrence NN o
of IN o
late JJ o
mandibular JJ o
fracture NN o
were VBD o
recorded VBN o
and CC N
statistically RB N
analyzed VBN N
. . N

A DT N
value NN N
of IN N
P NNP N
less JJR N
than IN N
.05 NN N
was VBD N
considered VBN N
statistically RB N
significant JJ N
. . N

RESULTS NNP N
In IN N
no DT N
patient NN N
group NN N
was VBD N
there RB N
a DT N
late JJ o
mandibular JJ o
fracture NN o
recorded VBN N
. . N

All DT N
patients NNS N
completed VBD N
the DT N
follow-up JJ N
period NN N
, , N
and CC N
most JJS N
of IN N
the DT N
R NNP N
group NN N
patients NNS N
had VBD N
normal JJ N
eating JJ N
habits NNS N
10 CD N
to TO N
14 CD N
days NNS N
after IN N
surgery NN N
. . N

In IN N
no DT N
patient NN N
group NN N
was VBD N
there RB N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
relation NN N
to TO N
gender VB N
( ( N
P NNP N
= NNP N
.735 NNP N
) ) N
, , N
site NN N
of IN N
surgery NN N
( ( N
P NNP N
= NNP N
.552 NNP N
) ) N
, , N
class NN N
horizontal JJ N
space NN N
available JJ N
( ( N
P NNP N
= NNP N
.427 NNP N
) ) N
, , N
class NN N
highest JJS N
portion NN N
of IN N
the DT N
M3 NNP N
crown NN N
( ( N
P NNP N
= NNP N
.424 NNP N
) ) N
, , N
angulations NNS N
of IN N
the DT N
teeth NN N
( ( N
P NNP N
= NNP N
.925 NNP N
) ) N
, , N
and CC N
severity NN o
of IN o
impaction NN o
( ( N
P NNP N
= NNP N
.445 NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
, , p
fully RB p
dentate VB p
or CC p
with IN p
1 CD p
or CC p
2 CD p
teeth NNS p
missing VBG p
and CC p
older JJR p
than IN p
25 CD p
years NNS p
who WP p
have VBP p
no DT p
jawbone NN p
atrophy NN p
and CC p
no DT p
systemic JJ p
problems NNS p
that WDT p
may MD p
impair VB o
bone NN o
strength NN o
, , N
mastication NN N
seems VBZ N
not RB N
to TO N
affect VB N
late JJ o
mandibular JJ o
fracture NN o
after IN N
surgical JJ N
removal NN N
of IN N
impacted JJ N
M3s NNP N
associated VBN N
with IN N
no DT N
gross JJ N
pathology NN N
. . N

The DT N
remote JJ N
possible JJ N
risk NN N
of IN N
the DT N
late JJ o
fracture NN o
shown VBN N
in IN N
our PRP$ N
patients NNS N
indicates VBZ N
the DT N
need NN N
for IN N
no DT N
special JJ N
precautions NNS N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
a DT N
leptin JJ N
single JJ N
nucleotide NN N
polymorphism NN N
and CC N
zilpaterol NN i
hydrochloride NN i
on IN N
growth NN N
and CC N
carcass NN N
characteristics NNS N
in IN N
finishing VBG p
steers NNS p
. . p

A DT p
total NN p
of IN p
4,178 CD p
steers NNS p
( ( p
mean JJ p
initial JJ p
BW NNP p
= NN p
403.9 CD p
? . p
16.04 CD p
kg NN p
) ) p
were VBD p
used VBN p
to TO p
test VB p
the DT N
interactive JJ N
effects NNS N
, , N
if IN N
any DT N
, , N
of IN i
leptin JJ i
R25C NNP i
genotypes NNS i
( ( N
CC NNP N
, , N
CT NNP N
, , N
or CC N
TT NNP N
) ) N
and CC i
zilpaterol $ i
hydrochloride NN i
( ( i
ZH NNP i
) ) i
feeding VBG N
duration NN N
on IN N
growth NN N
performance NN N
and CC N
carcass NN N
traits NNS N
. . N

Steers NNS N
were VBD N
blocked VBN N
by IN N
arrival NN N
at IN N
the DT N
feed NN N
yard NN N
, , N
genotyped VBD N
for IN N
the DT N
leptin NN N
SNP NNP N
, , N
allotted VBD N
to TO N
genotype-specific JJ N
pens NNS N
( ( N
90 CD N
steers/pen NN N
) ) N
, , N
and CC N
assigned VBD N
randomly RB N
within IN N
genotype NN N
and CC N
block NN N
to TO N
0 CD N
or CC N
21 CD N
d NN N
of IN N
dietary JJ N
ZH NNP N
. . N

All DT N
pens NNS N
within IN N
a DT N
block NN N
were VBD N
slaughtered VBN N
on IN N
the DT N
same JJ N
day NN N
( ( N
132.1 CD N
? . N
10.9 CD N
d NN N
on IN N
feed NN N
) ) N
. . N

Final NNP N
BW NNP N
of IN N
steers NNS N
fed VBP N
ZH NNP N
was VBD N
6.0 CD N
kg NN N
heavier NN N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
, , N
and CC N
ZH-fed NNP N
steers NNS N
had VBD N
greater JJR N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
ADG NNP N
than IN N
steers NNS N
not RB N
fed VBN N
ZH NNP N
. . N

Feeding VBG N
ZH NNP N
decreased VBD o
DMI NNP o
in IN o
steers NNS N
with IN N
increased JJ N
frequency NN N
of IN N
the DT N
T NNP N
allele NN N
( ( N
9.67 CD N
, , N
9.53 CD N
, , N
and CC N
9.28 CD N
kg/d NN N
for IN N
CC NNP N
, , N
CT NNP N
, , N
and CC N
TT NNP N
, , N
respectively RB N
) ) N
, , N
but CC o
DMI NNP o
increased VBD o
with IN N
the DT N
frequency NN N
of IN N
the DT N
T NNP N
allele NN N
( ( N
9.68 CD N
, , N
9.90 CD N
, , N
and CC N
10.1 CD N
kg NN N
for IN N
CC NNP N
, , N
CT NNP N
, , N
and CC N
TT NNP N
, , N
respectively RB N
) ) N
when WRB N
ZH NNP N
was VBD N
not RB N
fed VBN N
( ( N
leptin JJ N
genotype NN N
? . N
ZH NNP N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
. . N

At IN N
the DT N
conclusion NN N
of IN N
the DT N
study NN o
, , o
ultrasonic JJ o
fat NN o
was VBD o
greatest JJS N
for IN N
TT NNP N
steers NNS N
( ( N
11.4 CD N
? . N
0.28 CD N
mm NN N
) ) N
and CC N
least JJS N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
for IN N
CC NNP N
steers NNS N
( ( N
11.0 CD N
? . N
0.25 CD N
mm NN N
) ) N
. . N

Regardless NNP N
of IN N
ZH-feeding NNP N
duration NN N
, , N
TT NNP N
steers NNS N
produced VBD N
a DT N
greater JJR N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
percentage NN o
of IN o
USDA NNP o
yield NN o
grade NN o
( ( o
YG NNP o
) ) o
4 CD N
or CC N
higher JJR N
carcasses NNS N
( ( N
5.4 CD N
vs. FW N
2.7 CD N
% NN N
) ) N
and CC N
a DT N
lesser JJR N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
percentage NN N
of IN N
YG NNP N
1 CD N
carcasses NNS N
( ( N
17.7 CD N
vs. FW N
26.8 CD N
% NN N
) ) N
than IN N
CC NNP N
steers NNS N
. . N

In IN N
addition NN N
, , N
ZH-fed NNP N
steers NNS N
produced VBD N
a DT N
greater JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
percentage NN o
of IN o
USDA NNP o
YG NNP o
1 CD o
carcasses NNS o
( ( o
25.9 CD o
vs. FW N
16.2 CD N
% NN N
) ) N
and CC N
a DT N
lesser JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
percentage NN N
of IN N
YG NNP N
4 CD N
or CC N
higher JJR N
carcasses NNS N
( ( N
1.6 CD N
vs. FW N
6.0 CD N
% NN N
) ) N
than IN N
steers NNS N
fed VBP N
the DT N
control NN N
diet NN N
. . N

Marbling VBG o
scores NNS o
and CC o
the DT o
percentage NN o
of IN o
carcasses NNS o
grading VBG o
USDA NNP o
Choice NNP o
and CC o
Prime NNP o
were VBD o
greater JJR N
in IN N
TT NNP N
than IN N
CC NNP N
steers NNS N
when WRB N
fed VBN N
diets NNS N
devoid VBP N
of IN N
ZH NNP N
, , N
but CC N
both DT N
marbling NN o
and CC o
quality NN o
grades NNS o
did VBD o
not RB N
differ VB N
among IN N
leptin JJ N
genotypes NNS N
when WRB N
fed VBN N
ZH NNP N
for IN N
21 CD N
d NN N
( ( N
leptin JJ N
genotype NN N
? . N
ZH NNP N
, , N
P NNP N
? . N
0.03 CD N
) ) N
. . N

The DT o
amount NN o
of IN o
HCW NNP o
gain NN o
tended VBD o
to TO N
be VB N
less JJR N
( ( N
P NNP N
= NNP N
0.095 CD N
) ) N
for IN N
steers NNS N
of IN N
the DT N
TT NNP N
genotype NN N
( ( N
12.7 CD N
kg NN N
) ) N
than IN N
either DT N
CC NNP N
( ( N
16.3 CD N
kg NN N
) ) N
or CC N
CT NNP N
( ( N
17.0 CD N
kg NN N
) ) N
genotypes NNS N
. . N

Results NNS N
indicated VBD N
that IN N
leptin NN N
R25C NNP N
genotype NN N
impacted VBD N
most RBS N
traits NNS N
associated VBN N
with IN N
fatness JJ N
whereas NNS N
feeding VBG N
ZH NNP N
for IN N
21 CD N
d NN N
affected VBD N
HCW NNP N
and CC N
ADG NNP N
positively RB N
but CC N
impacted VBD N
feed NN N
intake NN N
, , N
marbling NN N
, , N
and CC N
USDA NNP N
quality NN N
grades NNS N
negatively RB N
. . N

-DOCSTART- -X- O O

The DT N
long-term JJ N
effects NNS N
of IN N
auditory JJ i
training NN i
on IN N
children NNS p
with IN p
autism NN p
. . p

Eighty NNP p
children NNS p
, , p
3-17 JJ p
years NNS p
of IN p
age NN p
, , p
with IN p
autism NN p
or CC p
Asperger NNP p
syndrome NN p
and CC p
mild NN p
to TO p
severe VB p
distress NN p
in IN p
the DT p
presence NN p
of IN p
some DT p
sounds NNS p
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
. . N

The DT N
experimental JJ N
group NN N
received VBD N
auditory JJ i
training NN i
and CC i
the DT i
control NN i
group NN i
listened VBD i
to TO i
the DT i
same JJ i
unmodified JJ i
music NN i
under IN i
the DT i
same JJ i
conditions NNS i
. . i

Significant JJ N
improvements NNS N
in IN N
behavior NN o
and CC o
severity NN o
of IN o
autism NN o
were VBD N
maintained VBN N
for IN N
12 CD N
months NNS N
by IN N
both DT N
groups NNS N
. . N

Informal NNP N
data NN N
suggested VBD N
that IN N
a DT N
range NN o
of IN o
abnormal JJ o
responses NNS o
to TO N
sound VB o
and CC o
other JJ o
sensory JJ o
abnormalities NNS o
may MD N
also RB N
have VB N
improved VBN N
. . N

Verbal NNP o
and CC o
performance NN o
IQ NNP o
increased VBD N
significantly RB N
3 CD N
to TO N
12 CD N
months NNS N
after IN N
interventions NNS N
. . N

Findings NNS N
suggest VBP N
that IN N
some DT N
aspect NN N
of IN N
both DT N
auditory JJ i
training NN i
and CC i
listening VBG i
to TO N
selected VBN N
unmodified JJ N
music NN N
may MD N
have VB N
a DT N
beneficial JJ o
effect NN o
on IN N
children NNS p
with IN p
autism NN p
and CC p
sound JJ p
sensitivity NN p
, , N
and CC N
indicate VBP N
a DT N
need NN N
for IN N
further JJ N
research NN N
into IN N
the DT N
effects NNS N
that WDT N
led VBD N
to TO N
these DT N
changes NNS N
and CC N
the DT N
mechanisms NNS N
involved VBN N
in IN N
the DT N
sensory JJ N
abnormalities NNS N
commonly RB N
associated VBN N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O

Modified VBN i
constraint-induced JJ i
therapy NN i
combined VBN N
with IN N
mental JJ i
practice NN i
: : i
thinking NN N
through IN N
better JJR N
motor NN N
outcomes NNS N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Modified NNP i
constraint-induced JJ i
therapy NN i
( ( i
mCIT NN i
) ) i
is VBZ N
an DT N
outpatient JJ N
therapy NN N
encouraging VBG N
repetitive JJ N
, , N
task-specific JJ N
practice NN N
with IN N
the DT N
affected JJ N
arm NN N
. . N

mCIT NN i
has VBZ N
shown VBN N
efficacy NN o
in IN N
all DT N
stages NNS N
poststroke VBP N
. . N

Given VBN N
its PRP$ N
efficacy NN N
when WRB N
combined VBN N
with IN N
other JJ N
therapy NN N
regimens NNS N
, , N
the DT N
current JJ N
study NN N
examined VBD N
the DT N
efficacy NN o
of IN N
mental JJ i
practice NN i
when WRB N
combined VBN N
with IN N
mCIT JJ i
versus NN N
mCIT NN i
only RB i
using VBG N
randomized VBN N
, , N
controlled VBN N
methods NNS N
. . N

METHOD NNP N
Ten CD p
patients NNS p
with IN p
chronic JJ p
stroke NN p
( ( p
7 CD p
males NNS p
; : p
mean JJ p
age NN p
, , p
61.4+/-3.02 JJ p
years NNS p
; : p
age NN p
range NN p
, , p
48 CD p
to TO p
79 CD p
years NNS p
; : p
mean JJ p
time NN p
since IN p
stroke NN p
, , p
28.5 CD p
months NNS p
; : p
range NN p
, , p
13 CD p
to TO p
42 CD p
months NNS p
) ) p
exhibiting VBG p
stable JJ p
, , p
affected JJ p
arm NN p
motor NN p
deficits NNS p
were VBD N
administered VBN N
mCIT NN i
, , N
consisting VBG N
of IN N
: : N
( ( N
1 CD N
) ) N
structured VBD N
therapy NN N
emphasizing VBG N
affected JJ N
arm NN N
use NN N
in IN N
functional JJ N
activities NNS N
3 CD N
days/week NN N
for IN N
10 CD N
weeks NNS N
; : N
and CC N
( ( N
2 CD N
) ) N
less RBR N
affected JJ N
arm NN N
restraint NN N
5 CD N
days/week NN N
for IN N
5 CD N
hours NNS N
. . N

Both DT N
of IN N
these DT N
components NNS N
were VBD N
administered VBN N
during IN N
a DT N
10-week JJ N
period NN N
. . N

Subjects NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
mCIT+mental JJ i
practice NN i
experimental JJ N
condition NN N
also RB N
received VBD N
30-minute JJ N
mental JJ N
practice NN N
sessions NNS N
provided VBD N
directly RB N
after IN N
therapy NN N
sessions NNS N
. . N

These DT N
mental JJ i
practice NN i
sessions NNS N
required VBN N
daily RB N
cognitive JJ N
rehearsal NN N
of IN N
the DT N
activities NNS N
of IN N
daily JJ N
living NN N
practiced VBD N
during IN N
mCIT JJ i
clinical JJ N
sessions NNS N
. . N

RESULTS NNP N
No NNP N
pre-existing JJ N
differences NNS N
were VBD N
found VBN N
between IN N
groups NNS N
on IN N
any DT N
demographic JJ N
variable NN N
or CC N
movement NN N
scale NN N
. . N

All DT N
subjects NNS N
exhibited VBN N
marked JJ N
reductions NNS N
in IN N
affected JJ o
arm NN o
impairment NN o
and CC o
functional JJ o
limitation NN o
. . o

However RB N
, , N
subjects NNS N
in IN N
the DT N
mCIT+mental JJ i
practice NN i
group NN N
exhibited VBD N
significantly RB N
larger JJR N
changes NNS N
on IN N
both DT N
movement NN o
measures NNS o
after IN N
intervention NN N
: : N
Action NNP N
Research NNP N
Arm NNP N
Test NNP N
, , N
+15.4-point JJ N
change NN N
versus IN N
+8.4-point JJ N
change NN N
for IN N
mCIT NN i
only RB i
subjects VBZ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
Fugl-Meyer NNP N
, , N
+7.8-point JJ N
change NN N
versus IN N
+4.1-point JJ N
change NN N
for IN N
the DT N
mCIT NN i
only RB i
subjects VBZ N
( ( N
P=0.01 NNP N
) ) N
. . N

These DT N
changes NNS N
were VBD N
sustained VBN N
3 CD N
months NNS N
after IN N
intervention NN N
. . N

CONCLUSIONS NNP N
mCIT NN i
remains VBZ N
a DT N
promising JJ N
motor NN N
intervention NN N
. . N

However RB N
, , N
its PRP$ N
efficacy NN o
appears VBZ N
to TO N
be VB N
enhanced VBN N
by IN N
use NN N
of IN N
mental JJ i
practice NN i
provided VBD N
directly RB N
after IN N
mCIT JJ i
clinical JJ N
sessions NNS N
. . N

-DOCSTART- -X- O O

A DT N
phase NN N
II NNP N
randomized VBD N
trial NN N
comparing VBG N
radiotherapy NN i
with IN N
concurrent JJ N
weekly JJ N
cisplatin NN i
or CC N
weekly JJ N
paclitaxel NN i
in IN N
patients NNS p
with IN p
advanced JJ p
cervical JJ p
cancer NN p
. . p

PURPOSE/OBJECTIVE VB N
This DT N
is VBZ N
a DT N
prospective JJ N
comparison NN N
of IN N
weekly JJ N
cisplatin NN i
to TO N
weekly VB N
paclitaxel NN i
as IN N
concurrent JJ N
chemotherapy NN N
with IN N
standard JJ i
radiotherapy NN i
for IN N
locally RB N
advanced JJ p
cervical JJ p
carcinoma NN p
. . p

MATERIALS/METHODS NNP N
Between NNP p
May NNP p
2000 CD p
and CC p
May NNP p
2004 CD p
, , p
31 CD p
women NNS p
with IN p
FIGO NNP p
stage NN p
IB2-IVA NNP p
cervical JJ p
cancer NN p
or CC p
with IN p
postsurgical JJ p
pelvic JJ p
recurrence NN p
were VBD p
enrolled VBN p
into IN p
this DT p
phase NN p
II NNP p
study NN p
and CC N
randomized VBN N
to TO N
receive VB N
on IN N
a DT N
weekly JJ N
basis NN N
either CC N
40 CD i
mg/m? NN i
Cisplatin NNP i
( ( i
group NN i
I PRP i
; : i
16 CD i
patients NNS i
) ) i
or CC i
50 CD i
mg/m? NNS i
paclitaxel NN i
( ( i
group NN i
II NNP i
; : i
15 CD i
patients NNS i
) ) i
concurrently RB i
with IN i
radiotherapy NN i
. . i

Median JJ N
total NN N
dose NN N
to TO N
point VB N
A NNP N
was VBD N
74 CD N
Gy NNP N
( ( N
range NN N
: : N
66-92 JJ N
Gy NNP N
) ) N
for IN N
group NN N
I PRP N
and CC N
66 CD N
Gy NNP N
( ( N
range NN N
: : N
40-98 JJ N
Gy NNP N
) ) N
for IN N
group NN N
II NNP N
. . N

Median JJ N
follow-up JJ N
time NN N
was VBD N
46 CD N
months NNS N
. . N

RESULTS NNP p
Patient NNP p
and CC p
tumor NN p
characteristics NNS p
were VBD p
similar JJ N
in IN N
both DT N
groups NNS N
. . N

The DT o
mean JJ o
number NN o
of IN o
chemotherapy NN o
cycles NNS o
was VBD o
also RB N
comparable JJ N
with IN N
87 CD N
% NN N
and CC N
80 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
at IN N
least JJS N
4 CD N
doses NNS N
in IN N
groups NNS N
I PRP N
and CC N
II NNP N
, , N
respectively RB N
. . N

Seven JJ N
patients NNS N
( ( N
44 CD N
% NN N
) ) N
of IN N
group NN N
I PRP N
and CC N
8 CD N
patients NNS N
( ( N
53 CD N
% NN N
) ) N
of IN N
group NN N
II NNP N
developed VBD o
tumor NN o
recurrence NN o
. . o

The DT o
Median JJ o
Survival NNP o
time NN o
was VBD o
not RB N
reached VBN N
for IN N
Group NNP N
I PRP N
and CC N
53 CD N
months NNS N
for IN N
group NN N
II NNP N
. . N

The DT o
proportion NN o
of IN o
patients NNS o
surviving VBG o
at IN o
2 CD N
and CC N
5 CD N
years NNS N
was VBD N
78 CD N
% NN N
and CC N
54 CD N
% NN N
for IN N
group NN N
I PRP N
and CC N
73 CD N
% NN N
and CC N
43 CD N
% NN N
for IN N
group NN N
II NNP N
respectively RB N
. . N

CONCLUSIONS VB N
This DT N
small JJ N
prospective JJ N
study NN N
shows NNS N
that WDT N
weekly VBP i
paclitaxel NN i
does VBZ i
not RB N
provide VB N
any DT o
clinical JJ o
advantage NN o
over IN o
weekly JJ i
cisplatin NN i
for IN i
concurrent JJ i
chemoradiation NN i
for IN i
advanced JJ p
carcinoma NN p
of IN p
the DT p
cervix NN p
. . p

-DOCSTART- -X- O O

A DT N
single JJ N
dose NN N
of IN N
gabapentin NN i
reduces NNS N
acute VBP o
pain NN o
and CC N
allodynia NN o
in IN N
patients NNS p
with IN p
herpes NNS p
zoster NN p
. . p

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
measured VBD N
the DT N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
oral JJ i
gabapentin NN i
( ( N
900 CD N
mg NN N
) ) N
on IN N
pain NN o
and CC o
allodynia NN o
associated VBN o
with IN o
herpes NNS o
zoster NN o
. . o

Pain NNP o
severity NN o
decreased VBN N
by IN N
66 CD N
% NN N
with IN N
gabapentin NN i
compared VBN N
to TO N
33 CD N
% NN N
with IN N
placebo NN i
. . i

Reductions NNS N
in IN N
allodynia JJ o
area NN o
and CC o
severity NN o
, , o
and CC o
overall JJ o
pain NN o
relief NN o
, , N
were VBD N
also RB N
greater JJR N
with IN N
gabapentin NN i
. . i

-DOCSTART- -X- O O

Trials NNS o
and CC N
tribulations NNS o
in IN N
speech NN i
therapy NN i
. . i

-DOCSTART- -X- O O

Effects NNS N
of IN N
application NN N
in IN N
spring NN N
of IN N
urea JJ i
fertiliser NN i
on IN N
aspects NNS N
of IN N
reproductive JJ N
performance NN N
of IN N
pasture-fed JJ p
dairy NN p
cows NNS p
. . p

AIMS NNP N
To TO N
assess VB N
if IN N
raising VBG N
concentrations NNS N
of IN N
crude NN N
protein NN N
( ( N
CP NNP N
) ) N
in IN N
pasture NN N
in IN N
spring NN N
by IN N
the DT N
frequent JJ N
application NN N
of IN N
urea JJ i
fertiliser NN i
would MD N
affect VB N
ovarian JJ o
follicular JJ o
dynamics NNS o
, , o
luteal JJ o
function NN o
, , o
onset NN o
of IN o
oestrus NN o
and CC o
reproductive JJ o
performance NN o
of IN N
dairy NN p
cows NNS p
under IN p
farming VBG p
conditions NNS p
in IN p
New NNP p
Zealand NNP p
. . p

METHODS NNP N
Spring-calved JJ p
dairy NN p
cows NNS p
were VBD p
grazed VBN p
for IN p
101 CD p
days NNS p
in IN p
paddocks NNS p
that WDT p
were VBD p
either RB p
not RB i
fertilised VBN i
( ( p
Control NNP p
; : p
n=20 CC p
) ) p
during IN p
the DT p
course NN p
of IN p
the DT p
study NN p
, , p
or CC p
were VBD p
fertilised VBN i
with IN p
40-50 JJ i
kg NNS i
nitrogen NN i
( ( p
N NNP p
) ) p
/ha VBP p
every DT p
4-6 JJ p
weeks NNS p
( ( p
High-N NNP p
; : p
n=20 NN p
) ) p
. . p

Similar JJ N
generous JJ N
pasture NN N
allowances NNS N
were VBD N
offered VBN N
to TO N
both DT N
groups NNS N
. . N

Concentrations NNS o
of IN o
CP NNP o
in IN o
pasture NN o
, , o
urea JJ o
in IN o
serum NN o
and CC o
progesterone NN o
in IN o
milk NN o
were VBD N
measured VBN N
. . N

Ovarian JJ o
follicular NN o
and CC o
luteal JJ o
dynamics NNS o
were VBD N
determined VBN N
using VBG N
ultrasonography NN N
. . N

Oestrous JJ o
behaviour NN o
and CC o
the DT o
number NN o
, , o
time NN o
and CC o
outcome NN o
of IN o
inseminations NNS o
were VBD N
also RB N
recorded VBN N
. . N

RESULTS JJ N
Mean JJ o
concentrations NNS o
of IN o
CP NNP o
in IN o
pasture NN o
and CC o
urea NN o
in IN o
serum NN o
was VBD N
higher RBR N
in IN N
the DT N
High-N NNP N
than IN N
the DT N
Control NNP N
group NN N
( ( N
25.2 CD N
vs NN N
21.6 CD N
and CC N
8.3 CD N
vs NN N
5.4 CD N
mmol/L NN N
for IN N
CP NNP N
and CC N
urea JJ N
, , N
respectively RB N
; : N
p VB N
< $ N
0.001 CD N
) ) N
. . N

Intervals NNS o
between IN o
calving VBG o
and CC o
first JJ o
oestrus NN o
, , o
first JJ o
insemination NN o
and CC o
conception NN o
, , o
the DT o
time NN o
of IN o
first JJ o
emergence NN o
of IN o
a DT o
dominant JJ o
follicle NN o
, , o
milk NN o
progesterone NN o
concentration NN o
, , o
and CC o
the DT o
diameter NN o
of IN o
the DT o
corpus NN o
luteum NN o
( ( o
CL NNP o
) ) o
in IN o
the DT o
first JJ o
luteal JJ o
phase NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
groups NNS N
. . N

The DT N
interval NN o
from IN o
calving VBG o
to TO o
first JJ o
ovulation NN o
tended VBN N
( ( N
p=0.10 NN N
) ) N
to TO N
be VB N
lower JJR N
and CC N
the DT N
diameter NN o
of IN o
the DT o
dominant JJ o
follicle NN o
of IN o
the DT o
oestrous JJ o
cycle NN o
at IN o
which WDT o
cows VBZ o
conceived VBN o
was VBD N
greater JJR N
( ( N
p=0.02 NN N
) ) N
in IN N
Control NNP N
than IN N
High-N NNP N
cows NNS N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
large JJ N
amounts NNS N
of IN N
urea JJ i
fertiliser NN i
during IN N
spring NN N
and CC N
the DT N
consequent NN N
increases NNS N
in IN N
concentrations NNS o
of IN o
CP NNP o
in IN o
pasture NN o
and CC o
urea NN o
in IN o
serum NN o
did VBD N
not RB N
negatively RB N
affect JJ N
any DT N
of IN N
the DT N
parameters NNS N
of IN N
reproductive JJ o
performance NN o
of IN N
pasture-fed JJ p
dairy NN p
cows NNS p
that WDT N
were VBD N
assessed VBN N
in IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O

Double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
pentoxifylline NN i
added VBN i
to TO i
risperidone VB i
: : i
effects NNS N
on IN N
aberrant JJ o
behavior NN o
in IN o
children NNS o
with IN o
autism NN o
. . o

BACKGROUND IN N
There EX N
are VBP N
several JJ N
lines NNS N
of IN N
evidence NN N
to TO N
indicate VB N
that IN N
the DT N
immune NN N
system NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
the DT N
pathophysiology NN N
of IN N
autism NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
access NN N
the DT N
effects NNS N
of IN N
pentoxifylline NN i
plus CC i
risperidone NN i
in IN N
the DT N
treatment NN o
of IN o
autistic JJ o
disorder NN o
. . o

METHODS NNP N
Forty NNP p
children NNS p
between IN p
the DT p
ages NNS p
4 CD p
and CC p
12 CD p
years NNS p
with IN p
a DT p
DSM NNP p
IV-TR NNP p
clinical JJ p
diagnosis NN p
of IN p
autism NN p
were VBD p
recruited VBN p
. . p

The DT p
children NNS p
presented VBN p
with IN p
a DT p
chief JJ p
complaint NN p
of IN p
severely RB p
disruptive JJ p
symptoms NNS p
related VBN p
to TO p
autistic JJ p
disorder NN p
. . p

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
pentoxifylline+risperidone VB i
or CC i
placebo+risperidone VB i
for IN N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN i
was VBD N
titrated VBN N
up RB N
to TO N
3 CD N
mg/day NN N
, , N
pentoxifylline NN i
was VBD N
titrated VBN N
to TO N
600 CD N
mg/day NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
and CC N
10 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
. . N

The DT N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
. . o

RESULTS VB N
The DT N
difference NN N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
the DT N
group NN N
that WDT N
received VBD N
pentoxifylline NN i
had VBD N
greater JJR N
reduction NN N
in IN N
ABC-C NNP o
subscale NN o
scores NNS o
for IN o
Irritability NNP o
, , o
Lethargy/Social NNP o
Withdrawal NNP o
, , o
Stereotypic NNP o
Behavior NNP o
, , o
Hyperactivity/Noncompliance NNP o
and CC o
Inappropriate NNP o
Speech NNP o
. . o

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
combination NN i
of IN i
atypical JJ i
antipsychotic JJ i
medications NNS i
and CC i
pentoxifylline NN i
might MD N
have VB N
synergistic JJ N
effects NNS N
in IN N
treatment NN N
of IN N
behavioral JJ o
problems NNS o
of IN o
children NNS o
with IN o
autism NN o
. . o

-DOCSTART- -X- O O

Efficacy NN o
and CC N
safety NN o
of IN N
repeated VBN N
use NN N
of IN N
ulipristal JJ i
acetate NN i
in IN N
uterine JJ p
fibroids NNS p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
repeated VBN N
12-week JJ N
courses NNS N
of IN N
5 CD N
or CC N
10 CD N
mg JJ N
daily NN N
of IN N
ulipristal JJ i
acetate NN i
for IN N
intermittent JJ N
treatment NN N
of IN N
symptomatic JJ p
uterine JJ p
fibroids NNS p
. . p

DESIGN NNP N
Double-blind NNP N
, , N
randomized JJ N
administration NN N
of IN N
two CD N
12-week JJ N
courses NNS N
of IN N
ulipristal JJ i
acetate NN i
. . i

SETTING NNP N
Gynecology NNP p
centers NNS p
. . p

PATIENT NNP N
( ( N
S NNP N
) ) N
A NNP N
total NN p
of IN p
451 CD p
patients NNS p
with IN p
symptomatic JJ p
uterine JJ p
fibroid NN p
( ( p
s NN p
) ) p
and CC p
heavy JJ p
bleeding NN p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Two CD N
repeated VBD N
12-week JJ N
treatment NN N
courses NNS N
of IN N
daily JJ N
5 CD i
or CC i
10 CD i
mg NN i
of IN i
ulipristal JJ i
acetate NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Amenorrhea NNP o
, , o
controlled VBD o
bleeding NN o
, , o
fibroid JJ o
volume NN o
, , o
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
, , o
pain NN o
. . o

RESULT NNP N
( ( N
S NNP N
) ) N
In IN N
the DT N
5- JJ N
and CC N
10-mg JJ N
treatment NN N
groups NNS N
( ( N
62 CD N
% NN N
and CC N
73 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
) ) N
achieved VBD N
amenorrhea NN o
during IN N
both DT N
treatment NN N
courses NNS N
. . N

Proportions NNS N
of IN N
patients NNS N
achieving VBG N
controlled VBD o
bleeding VBG o
during IN N
two CD N
treatment NN N
courses NNS N
were VBD N
> JJ N
80 CD N
% NN N
. . N

Menstruation NN o
resumed VBD o
after IN N
each DT N
treatment NN N
course NN N
and CC N
was VBD N
diminished VBN N
compared VBN N
with IN N
baseline NN N
. . N

After IN N
the DT N
second JJ N
treatment NN N
course NN N
, , N
median JJ o
reductions NNS o
from IN o
baseline NN o
in IN o
fibroid JJ o
volume NN o
were VBD N
54 CD N
% NN N
and CC N
58 CD N
% NN N
for IN N
the DT N
patients NNS N
receiving VBG N
5 CD N
and CC N
10 CD N
mg NN N
of IN N
ulipristal JJ N
acetate NN N
, , N
respectively RB N
. . N

Pain NN o
and CC o
QoL NNP o
improved VBN N
in IN N
both DT N
groups NNS N
. . N

Ulipristal JJ N
acetate NN N
was VBD N
well RB N
tolerated VBN o
with IN N
less JJR N
than IN N
5 CD N
% NN N
of IN N
patients NNS N
discontinuing VBG N
treatment NN N
due JJ N
to TO N
adverse JJ o
events NNS o
. . o

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Repeated VBD N
12-week JJ N
courses NNS N
of IN N
daily JJ N
oral JJ N
ulipristal JJ N
acetate NN N
( ( N
5 CD N
and CC N
10 CD N
mg NN N
) ) N
effectively RB N
control VBP N
bleeding VBG o
and CC o
pain NN o
, , N
reduce VB N
fibroid JJ o
volume NN o
, , N
and CC N
restore VB N
QoL NNP o
in IN N
patients NNS N
with IN N
symptomatic JJ N
fibroids NNS N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT01629563 NNP N
( ( N
PEARL NNP N
IV NNP N
) ) N
. . N

-DOCSTART- -X- O O

Behavioral JJ o
changes NNS o
in IN N
autistic JJ p
individuals NNS p
as IN N
a DT N
result NN N
of IN N
wearing VBG N
ambient JJ i
transitional JJ i
prism NN i
lenses NNS i
. . i

A DT N
double-blind JJ N
crossover NN N
design NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
wearing VBG i
ambient JJ i
lenses NNS i
to TO N
reduce VB N
the DT N
behavioral JJ N
symptoms NNS N
of IN N
autism NN N
. . N

Eighteen NNP p
autistic JJ p
individuals NNS p
, , p
ranging VBG p
in IN p
age NN p
from IN p
7 CD p
to TO p
18 CD p
years NNS p
, , N
participated VBD N
in IN N
the DT N
study NN N
. . N

Behavior NNP o
, , o
attention NN o
, , o
and CC o
orientation NN o
were VBD N
evaluated VBN N
at IN N
1 CD N
1/2 CD N
months NNS N
, , N
2 CD N
months NNS N
, , N
3 CD N
months NNS N
, , N
and CC N
4 CD N
months NNS N
. . N

Compared VBN N
to TO N
the DT N
placebo NN i
condition NN N
, , N
the DT N
results NNS N
showed VBD N
a DT N
decrease NN N
in IN N
behavior JJ o
problems NNS o
at IN N
the DT N
1 CD N
1/2 CD N
and CC N
2 CD N
month NN N
assessment NN N
periods NNS N
and CC N
a DT N
slight JJ N
loss NN N
of IN N
these DT N
benefits NNS N
at IN N
the DT N
3 CD N
and CC N
4 CD N
month NN N
assessment NN N
periods NNS N
. . N

These DT N
findings NNS N
support VBP N
the DT N
prediction NN N
that WDT N
ambient JJ i
lenses NNS i
, , N
worn VBN N
without IN N
engaging VBG N
in IN N
visual-motor NN N
exercises NNS N
, , N
have VBP N
positive JJ N
effects NNS N
on IN N
autistic JJ p
individuals NNS p
. . p

-DOCSTART- -X- O O

Five-year JJ N
outcome NN N
of IN N
surgical JJ N
treatment NN N
of IN N
migraine NN o
headaches NNS o
. . o

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
long-term JJ N
efficacy NN N
of IN N
surgical JJ N
deactivation NN N
of IN N
migraine NN o
headache NN o
trigger NN N
sites NNS N
. . N

METHODS NNP N
One CD p
hundred VBD p
twenty-five JJ p
volunteers NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
treatment NN p
( ( p
n JJ p
= NNP p
100 CD p
) ) p
or CC p
control VB p
group NN p
( ( p
n JJ p
= NNP p
25 CD p
) ) p
after IN p
examination NN p
by IN p
the DT p
team NN p
neurologist NN p
to TO p
ensure VB p
a DT p
diagnosis NN p
of IN p
migraine NN o
headache NN o
. . o

Patients NNS N
were VBD N
asked VBN N
to TO N
complete VB N
the DT N
Medical NNP o
Outcomes NNP o
Study NNP o
36-Item JJ o
Short NNP o
Form NNP o
Health NNP o
Survey NNP o
, , o
Migraine-Specific NNP o
Quality NNP o
of IN o
Life NNP o
, , o
and CC o
Migraine NNP o
Disability NNP o
Assessment NNP o
questionnaires VBZ o
before IN N
treatment NN N
and CC N
at IN N
12- JJ N
and CC N
60-month JJ N
postoperative JJ N
follow-up NN N
. . N

The DT N
treatment NN N
group NN N
received VBD N
botulinum RB i
toxin NN i
to TO N
confirm VB N
the DT N
trigger NN N
sites VBZ N
; : N
controls NNS N
received VBD N
saline JJ i
injections NNS i
. . i

Treated VBN N
patients NNS N
underwent JJ N
surgical JJ i
deactivation NN i
of IN N
trigger NN N
site NN N
( ( N
s JJ N
) ) N
. . N

Results NNS N
were VBD N
analyzed VBN N
at IN N
1 CD N
year NN N
( ( N
previously RB N
published VBN N
) ) N
and CC N
5 CD N
years NNS N
postoperatively RB N
( ( N
the DT N
subject NN N
of IN N
this DT N
report NN N
) ) N
. . N

RESULTS JJ N
Eighty-nine NNP N
of IN N
100 CD p
patients NNS p
in IN p
the DT p
treatment NN p
group NN p
underwent JJ N
surgery NN N
, , N
and CC N
79 CD N
were VBD N
followed VBN N
for IN N
5 CD N
years NNS N
. . N

Ten CD N
patients NNS N
underwent JJ N
deactivation NN i
of IN N
additional JJ N
( ( N
different JJ N
) ) N
trigger NN N
sites NNS N
during IN N
the DT N
follow-up JJ N
period NN N
and CC N
were VBD N
not RB N
included VBN N
in IN N
the DT N
data NN N
analysis NN N
. . N

The DT N
final JJ N
outcome NN N
with IN N
or CC N
without IN N
inclusion NN N
of IN N
these DT N
10 CD N
patients NNS N
was VBD N
not RB N
statistically RB N
different JJ N
. . N

Sixty-one NN N
( ( N
88 CD N
percent NN N
) ) N
of IN N
69 CD N
patients NNS N
have VBP N
experienced VBN N
a DT N
positive JJ o
response NN o
to TO N
the DT N
surgery NN N
after IN N
5 CD N
years NNS N
. . N

Twenty NNP N
( ( N
29 CD N
percent NN N
) ) N
reported VBD N
complete JJ o
elimination NN o
of IN o
migraine NN o
headache NN o
, , N
41 CD N
( ( N
59 CD N
percent NN N
) ) N
noticed VBD N
a DT N
significant JJ N
decrease NN N
, , N
and CC N
eight CD N
( ( N
12 CD N
percent NN N
) ) N
experienced VBD N
no DT N
significant JJ N
change NN N
. . N

When WRB N
compared VBN N
with IN N
the DT N
baseline NN N
values NNS N
, , N
all DT N
measured VBD N
variables NNS N
at IN N
60 CD N
months NNS N
improved VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
the DT N
5-year JJ N
follow-up JJ N
data NNS N
, , N
there EX N
is VBZ N
strong JJ N
evidence NN N
that IN N
surgical JJ N
manipulation NN N
of IN N
one CD N
or CC N
more JJR N
migraine JJ N
trigger NN N
sites NNS N
can MD N
successfully RB N
eliminate VB o
or CC o
reduce VB o
the DT o
frequency NN o
, , o
duration NN o
, , o
and CC o
intensity NN o
of IN o
migraine NN o
headache NN o
in IN N
a DT N
lasting JJ N
manner NN N
. . N

-DOCSTART- -X- O O

Prospective JJ N
randomized VBN N
comparison NN N
between IN N
transperitoneal JJ i
laparoscopic NN i
pyeloplasty NN i
and CC p
retroperitoneoscopic NN i
pyeloplasty NN i
for IN p
primary JJ p
ureteropelvic JJ p
junction NN p
obstruction NN p
. . p

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
To TO N
compare VB N
laparoscopic JJ i
transperitoneal JJ i
versus NN N
retroperitoneoscopic NN i
pyeloplasty NN i
for IN N
primary JJ p
ureteropelvic JJ p
junction NN p
obstruction NN p
in IN N
a DT N
prospective JJ N
randomized JJ N
manner NN N
and CC N
assess NN N
overall JJ N
results NNS N
with IN N
long-term JJ N
follow-up NN N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
study NN N
, , N
from IN p
2008 CD p
to TO p
2012 CD p
, , p
112 CD p
cases NNS p
of IN p
primary JJ p
ureteropelvic JJ p
junction NN p
obstruction NN p
were VBD p
randomized VBN p
in IN p
a DT p
1:1 CD p
ratio NN p
into IN p
2 CD p
groups NNS p
. . p

Group NNP i
I PRP i
included VBD i
patients NNS i
who WP i
underwent VBP i
transperitoneal JJ i
laparoscopic NN i
pyeloplasty NN i
, , i
and CC i
group NN i
II NNP i
consisted VBD i
of IN i
patients NNS i
who WP i
underwent VBP i
retroperitoneoscopic NN i
laparoscopic NN i
pyeloplasty NN i
. . i

Demographic NNP N
and CC N
clinical JJ N
characteristics NNS N
and CC N
postoperative JJ N
and CC N
operative JJ N
data NNS N
were VBD N
collected VBN N
and CC N
analyzed VBN N
. . N

The DT N
statistical JJ N
analysis NN N
was VBD N
performed VBN N
with IN N
the DT N
Fisher NNP N
exact JJ N
test NN N
, , N
?2 JJ N
test NN N
, , N
and CC N
Mann-Whitney NNP N
U NNP N
test NN N
for IN N
independent JJ N
groups NNS N
, , N
and CC N
P NNP N
< NNP N
.05 NNP N
was VBD N
considered VBN N
statistically RB N
significant JJ N
. . N

RESULTS VB N
The DT o
total JJ o
operative JJ o
time NN o
and CC o
intracorporeal VB o
suturing JJ o
time NN o
were VBD N
significantly RB N
higher JJR N
in IN N
group NN N
II NNP N
than IN N
in IN N
group NN N
I PRP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT o
visual JJ o
analog NN o
scale NN o
score NN o
for IN o
pain NN o
on IN N
postoperative JJ N
day NN N
1 CD N
and CC N
the DT N
requirement NN N
for IN N
tramadol NN N
were VBD N
significantly RB N
higher JJR N
in IN N
group NN N
I PRP N
than IN N
in IN N
group NN N
II NNP N
( ( N
P=.004 NNP N
) ) N
. . N

The DT o
hospital NN o
stay NN o
and CC o
the DT o
rate NN o
of IN o
temporary JJ o
ileus NNS o
were VBD N
significantly RB N
greater JJR N
( ( N
P NNP N
< NNP N
.036 NNP N
and CC N
P NNP N
< NNP N
.02 NNP N
, , N
respectively RB N
) ) N
in IN N
group NN N
I PRP N
than IN N
in IN N
group NN N
II NNP N
. . N

The DT o
success NN o
rate NN o
of IN i
transperitoneal NN i
laparoscopic NN i
pyeloplasty JJ i
versus NN i
retroperitoneoscopic NN i
laparoscopic NN i
pyeloplasty NN i
was VBD N
96.4 CD N
% NN N
versus IN N
96.6 CD N
% NN N
with IN N
a DT N
mean JJ N
follow-up JJ N
period NN N
of IN N
30.75?4.85 CD N
months NNS N
versus IN N
30.99?5.59 CD N
months NNS N
( ( N
P NNP N
< NNP N
.88 NNP N
) ) N
. . N

CONCLUSION NNP i
Transperitoneal NNP i
laparoscopic NN i
pyeloplasty NN i
is VBZ i
associated VBN N
with IN N
significantly RB N
greater JJR N
postoperative JJ N
pain NN N
, , N
a DT N
higher JJR N
tramadol NN N
dose NN N
, , N
a DT N
higher JJR N
rate NN N
of IN N
ileus NN N
, , N
and CC N
a DT N
longer JJR N
hospital JJ N
stay NN N
in IN N
comparison NN N
with IN N
retroperitoneoscopic NN N
laparoscopic NN N
pyeloplasty NN N
. . N

Although IN N
the DT N
operative JJ N
time NN N
for IN N
retroperitoneoscopic NN i
laparoscopic NN i
pyeloplasty NN i
is VBZ i
significantly RB N
longer RBR N
, , N
the DT N
success NN N
rate NN N
remains VBZ N
the DT N
same JJ N
for IN N
both DT N
procedures NNS N
. . N

-DOCSTART- -X- O O

The DT N
degrees NNS N
of IN N
UVB-induced NNP o
erythema NN o
and CC o
pigmentation NN o
correlate VBP N
linearly RB N
and CC N
are VBP N
reduced VBN N
in IN N
a DT N
parallel JJ N
manner NN N
by IN N
topical JJ i
anti-inflammatory JJ i
agents NNS i
. . i

To TO N
examine VB N
whether IN N
it PRP N
is VBZ N
possible JJ N
to TO N
evaluate VB N
the DT N
degree NN o
of IN o
ultraviolet NN o
B NNP o
( ( o
UVB NNP o
) ) o
-induced VBD o
inflammation NN o
by IN N
measuring VBG N
the DT N
degree NN o
of IN o
hyperpigmentation NN o
, , N
we PRP N
investigated VBD N
the DT N
relationship NN N
between IN N
UVB-induced NNP N
erythema NN N
and CC N
the DT N
subsequent JJ o
pigmentation NN o
quantitatively RB N
. . N

At IN N
24 CD N
h NN N
and CC N
7 CD N
d NN N
after IN N
irradiation NN N
with IN N
erythemogenic JJ N
doses NNS N
of IN N
UVB NNP N
to TO N
the DT N
backs NNS N
of IN N
16 CD p
Japanese JJ p
subjects NNS p
, , N
the DT N
degree NN o
of IN o
induced JJ o
erythema NN o
( ( o
delta JJ o
erythema VBP o
index NN o
) ) o
and CC N
that IN N
of IN N
pigmentation NN o
( ( o
delta JJ o
melanin NN o
index NN o
) ) o
were VBD N
examined VBN N
by IN N
an DT N
image NN i
analytic JJ i
method NN i
using VBG i
a DT i
videomicroscope NN i
interfaced VBN i
with IN i
a DT i
computer NN i
. . i

The DT N
relationship NN N
between IN N
two CD N
indices NNS N
was VBD N
linear JJ N
in IN N
each DT N
subject NN N
, , N
and CC N
the DT N
correlation NN N
coefficient NN N
was VBD N
0.83 CD N
when WRB N
evaluated VBN N
using VBG N
whole JJ N
data NNS N
. . N

The DT N
slope NN N
of IN N
the DT N
regression NN N
line NN N
for IN N
the DT N
delta NN o
melanin NN o
index NN o
against IN o
delta NN o
erythema NN o
index NN o
tended VBD N
to TO N
become VB N
steeper JJ N
as IN N
non-irradiated JJ N
skin NN N
color NN N
became VBD N
darker NN N
( ( N
r JJ N
= NNP N
0.63 CD N
) ) N
, , N
suggesting VBG N
that IN N
more RBR N
efficient JJ N
melanogenesis NN N
takes VBZ N
place NN N
after IN N
the DT N
same JJ N
level NN N
of IN N
inflammation NN N
in IN N
the DT N
subject NN N
with IN N
darker NN N
skin NN N
. . N

Both DT N
erythema NN o
and CC o
hyperpigmentation NN o
were VBD N
suppressed VBN N
significantly RB N
and CC N
in IN N
a DT N
parallel JJ N
manner NN N
by IN N
corticosteroids NNS i
and CC N
indomethacin NN i
applied VBN N
topically RB N
immediately RB N
after IN N
UVB NNP N
irradiation NN N
. . N

These DT N
results NNS N
imply VBP N
that IN N
the DT N
post-inflammatory JJ o
hyperpigmentation NN o
correlates NNS N
closely RB N
with IN N
the DT N
severity NN N
of IN N
the DT N
prior JJ N
inflammation NN N
and CC N
that DT N
chemical NN N
mediators NNS N
released VBN N
in IN N
the DT N
inflammatory NN N
process NN N
have VBP N
considerable JJ N
influence NN N
on IN N
the DT N
melanogenesis NN N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
measurement NN N
of IN N
UVB-induced JJ o
hyperpigmentation NN o
can MD N
be VB N
utilized VBN N
for IN N
the DT N
assessment NN N
of IN N
topical JJ i
anti-inflammatory JJ i
agents NNS i
, , N
unless IN N
these DT N
have VBP N
direct JJ N
actions NNS N
on IN N
the DT N
tyrosinase NN N
activity NN N
of IN N
melanocytes NNS N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
empagliflozin NN i
added VBN N
on IN N
to TO N
basal VB N
insulin NN N
in IN N
type NN p
2 CD p
diabetes NNS p
inadequately RB p
controlled VBN p
on IN p
basal NN p
insulin NN p
: : p
a DT N
78-week JJ N
randomized NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
empagliflozin NN i
added VBN N
to TO N
basal VB N
insulin-treated JJ N
type NN N
2 CD N
diabetes NNS N
. . N

METHODS NNP N
Patients NNPS p
inadequately RB p
controlled VBN p
[ NN p
glycated VBN p
haemoglobin NN p
( ( p
HbA1c NNP p
) ) p
> VBD p
7 CD p
to TO p
?10 VB p
% NN p
( ( p
> JJ p
53 CD p
to TO p
?86 VB p
mmol/mol NN p
) ) p
] NN p
on IN p
basal NN p
insulin NN p
( ( p
glargine NN p
, , p
detemir NN p
, , p
NPH NNP p
) ) p
were VBD p
randomized VBN i
to TO i
empagliflozin VB i
10 CD i
mg NN i
( ( p
n JJ p
= NNP p
169 CD p
) ) i
, , i
empagliflozin $ i
25 CD i
mg NN i
( ( i
n JJ i
= NNP i
155 CD i
) ) i
or CC i
placebo NN i
( ( i
n JJ i
= NNP i
170 CD i
) ) p
for IN p
78 CD p
weeks NNS p
. . p

The DT p
baseline NN p
characteristics NNS N
were VBD N
balanced VBN N
among IN N
the DT N
groups NNS N
[ VBP N
mean JJ N
HbA1c NNP N
8.2 CD N
% NN N
( ( N
67 CD N
mmol/mol NN N
) ) N
, , N
BMI NNP N
32.2 CD N
kg/m NN N
( ( N
2 CD N
) ) N
] NN N
. . N

The DT N
basal NN N
insulin NN N
dose NN N
was VBD N
to TO N
remain VB N
constant JJ N
for IN N
18 CD N
weeks NNS N
, , N
then RB N
could MD N
be VB N
adjusted VBN N
at IN N
investigator NN N
's POS N
discretion NN N
. . N

The DT N
primary JJ N
endpoint NN o
was VBD o
change NN o
from IN o
baseline NN o
in IN o
HbA1c NNP o
at IN N
week NN N
18 CD N
. . N

Key NNP N
secondary JJ N
endpoints NNS N
were VBD N
changes NNS o
from IN o
baseline NN o
in IN o
HbA1c NNP o
and CC o
insulin NN o
dose NN o
at IN o
week NN N
78 CD N
. . N

RESULTS NN N
At IN N
week NN N
18 CD N
, , N
the DT N
adjusted VBN N
mean NN N
? . N
standard JJ N
error NN N
changes NNS N
from IN N
baseline NN N
in IN N
HbA1c NNP N
were VBD N
0.0 CD N
? . N
0.1 CD N
% NN N
( ( N
-0.1 NNP N
? . N
0.8 CD N
mmol/mol NN N
) ) N
for IN N
placebo NN N
, , N
compared VBN N
with IN N
-0.6 NNP N
? . N
0.1 CD N
% NN N
( ( N
-6.2 NNP N
? . N
0.8 CD N
mmol/mol NN N
) ) N
and CC N
-0.7 $ N
? . N
0.1 CD N
% NN N
( ( N
-7.8 NNP N
? . N
0.8 CD N
mmol/mol NN N
) ) N
for IN N
empagliflozin $ N
10 CD N
and CC N
25 CD N
mg NN N
, , N
respectively RB N
( ( N
both DT N
p VBP N
< $ N
0.001 CD N
) ) N
. . N

At IN N
week NN N
78 CD N
, , N
empagliflozin VBD i
10 CD N
and CC N
25 CD N
mg NN N
significantly RB N
reduced VBN N
HbA1c NNP o
, , o
insulin NN o
dose NN N
and CC N
weight NN i
vs NN i
placebo NN i
( ( N
all DT N
p VBP N
< $ N
0.01 CD N
) ) N
, , N
and CC i
empagliflozin RB i
10 CD i
mg NNS N
significantly RB N
reduced VBN N
systolic JJ o
blood NN o
pressure NN o
vs NN o
placebo NN o
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

Similar JJ N
percentages NNS N
of IN N
patients NNS N
had VBD N
confirmed VBN N
hypoglycaemia NN o
in IN N
all DT N
groups NNS N
( ( N
35-36 CD N
% NN N
) ) N
. . N

Events NNS N
consistent JJ o
with IN o
urinary JJ o
tract NN o
infection NN o
were VBD o
reported VBN N
in IN N
9 CD N
, , N
15 CD N
and CC N
12 CD N
% NN N
of IN N
patients NNS N
on IN i
placebo NN i
, , i
empagliflozin CC i
10 CD i
and CC N
25 CD N
mg NN N
, , N
and CC N
events NNS N
consistent JJ N
with IN N
genital JJ o
infection NN o
were VBD o
reported VBN N
in IN N
2 CD N
, , N
8 CD N
and CC N
5 CD N
% NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP i
Empagliflozin NNP i
for IN i
78 CD N
weeks NNS N
added VBD N
to TO N
basal VB N
insulin NN N
improved JJ o
glycaemic JJ o
control NN o
and CC o
reduced JJ o
weight NN o
with IN o
a DT o
similar JJ o
risk NN o
of IN o
hypoglycaemia NN o
to TO o
placebo VB i
. . i

-DOCSTART- -X- O O

The DT N
patient JJ p
experience NN p
of IN N
community NN i
hospital NN i
-- : i
the DT i
process NN i
of IN i
care NN i
as IN N
a DT N
determinant NN N
of IN N
satisfaction NN N
. . N

AIMS NNP N
AND CC N
OBJECTIVES NNP N
We PRP N
report VBP N
findings NNS N
from IN N
a DT N
qualitative JJ N
study NN N
to TO N
identify VB N
patient JJ p
views NNS p
of IN p
community NN i
hospital NN i
care NN i
. . i

We PRP N
consider VBP N
how WRB N
far RB N
these DT N
were VBD N
in IN N
accord NN N
with IN N
the DT N
hospital NN N
staffs NNS N
' POS N
views NNS N
. . N

This DT N
constituted JJ N
part NN N
of IN N
a DT N
wider NN N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
. . N

The DT N
methodological JJ N
challenges NNS N
in IN N
seeking VBG N
to TO N
identify VB N
patient JJ N
satisfaction NN o
and CC N
in IN N
linking VBG N
qualitative JJ o
findings NNS o
with IN N
trial NN N
results NNS N
are VBP N
explored JJ N
. . N

DESIGN VB N
A DT p
sample NN p
of IN p
13 CD p
patients NNS p
randomized VBN p
to TO p
the DT p
community NN p
hospital NN p
arm NN p
of IN p
the DT p
RCT NNP p
joined VBD p
the DT p
qualitative JJ i
study NN i
. . i

Official JJ N
documentation NN N
from IN N
the DT N
hospital NN N
were VBD N
accessed VBN N
and CC N
six CD N
staff NN N
interviewed VBN N
to TO N
identify VB N
assumptions NNS N
underlying VBG N
practice NN N
. . N

RESULTS NNP N
Analysis NNP N
of IN N
interviews NNS i
identified VBN N
a DT N
complex JJ N
picture NN N
concerning VBG N
expectations NNS N
These DT N
could MD N
be VB N
classified VBN N
as IN N
ideal NN N
, , N
realistic JJ N
, , N
normative JJ N
and CC N
unformed JJ N
. . N

The DT N
hospital NN N
philosophy NN N
and CC N
staff NN o
views NNS o
about IN N
service NN N
delivery NN N
were VBD N
closely RB N
in IN N
harmony NN N
, , N
they PRP N
delivered VBD N
rehabilitation NN N
in IN N
a DT N
home-based JJ N
atmosphere NN N
. . N

The DT N
formal JJ o
, , o
or CC o
'hard POS o
' '' o
, , o
process NN o
of IN o
rehabilitation NN o
was VBD N
not RB N
well RB N
understood JJ N
by IN N
patients NNS N
. . N

They PRP N
were VBD N
primarily RB N
concerned VBN N
with IN N
'soft NNP N
' POS N
or CC N
process NN N
issues NNS N
-- : N
where WRB N
and CC N
how WRB N
care NN N
was VBD N
delivered VBN N
. . N

CONCLUSIONS NNP N
We PRP N
identify VBP N
a DT N
model NN N
of IN N
community NN N
hospital NN N
care NN N
that WDT N
incorporates VBZ N
technical JJ N
aspects NNS N
of IN N
rehabilitation NN N
within IN N
a DT N
human JJ N
approach NN N
that WDT N
is VBZ N
welcomed VBN N
by IN N
patients NNS p
. . p

If IN N
patients NNS p
are VBP N
to TO N
be VB N
able JJ N
to TO N
participate VB N
in IN N
making VBG N
informed JJ N
decisions NNS N
about IN N
care NN N
, , N
the DT N
rationale NN N
for IN N
the DT N
activities NNS N
of IN N
staff NN N
need NN N
to TO N
be VB N
more JJR N
clearly RB N
explained VBN N
. . N

Recommendations NNS N
are VBP N
made VBN N
about IN N
the DT N
appropriate JJ N
scope NN N
of IN N
qualitative JJ N
findings NNS N
in IN N
the DT N
context NN N
of IN N
trials NNS N
and CC N
about RB N
techniques NNS N
to TO N
access NN N
patient JJ p
views NNS N
in IN N
areas NNS N
where WRB N
they PRP N
have VBP N
difficulty NN N
in IN N
expressing VBG N
critical JJ N
impressions NNS N
. . N

-DOCSTART- -X- O O

Effect NN p
of IN p
resistance NN i
exercise NN i
contraction NN i
mode NN i
and CC p
protein JJ i
supplementation NN i
on IN p
members NNS p
of IN p
the DT p
STARS NNP p
signalling VBG p
pathway RB p
. . p

The DT N
striated JJ N
muscle NN N
activator NN N
of IN N
Rho NNP N
signalling VBG N
( ( N
STARS NNP N
) ) N
pathway NN N
is VBZ N
suggested VBN N
to TO N
provide VB N
a DT N
link NN N
between IN N
external JJ N
stress NN N
responses NNS N
and CC N
transcriptional JJ N
regulation NN N
in IN N
muscle NN N
. . N

However RB N
, , N
the DT N
sensitivity NN N
of IN N
STARS NNP N
signalling VBG N
to TO N
different JJ N
mechanical JJ N
stresses NNS N
has VBZ N
not RB N
been VBN N
investigated VBN N
. . N

In IN N
a DT N
comparative JJ N
study NN N
, , N
we PRP N
examined VBD N
the DT N
regulation NN N
of IN N
the DT N
STARS NNP N
signalling VBG N
pathway RB N
in IN N
response NN N
to TO N
unilateral JJ N
resistance NN i
exercise NN i
performed VBN N
as IN N
either DT N
eccentric JJ i
( ( i
ECC NNP i
) ) i
or CC i
concentric JJ i
( ( i
CONC NNP i
) ) i
contractions NNS i
as RB N
well RB N
as IN N
prolonged JJ i
training NN i
; : i
with IN p
and CC p
without IN p
whey JJ i
protein NN i
supplementation NN i
. . i

Skeletal JJ N
muscle NN N
STARS NNP N
, , N
myocardian-related JJ N
transcription NN N
factor-A NN N
( ( N
MRTF-A NNP N
) ) N
and CC N
serum JJ N
response NN N
factor NN N
( ( N
SRF NNP N
) ) N
mRNA NN N
and CC N
protein NN N
, , N
as RB N
well RB N
as IN N
muscle NN N
cross-sectional JJ N
area NN N
and CC N
maximal JJ N
voluntary JJ N
contraction NN N
, , N
were VBD N
measured VBN N
. . N

A DT N
single-bout NN N
of IN N
exercise NN i
produced VBN N
increases NNS N
in IN N
STARS NNP o
and CC o
SRF NNP o
mRNA NN o
and CC o
decreases NNS o
in IN o
MRTF-A NNP o
mRNA NN o
with IN o
both DT o
ECC NNP o
and CC o
CONC NNP o
exercise NN o
, , N
but CC N
with IN N
an DT N
enhanced JJ N
response NN N
occurring VBG N
following VBG N
ECC NNP i
exercise NN i
. . i

A DT N
31 CD N
% NN N
increase NN N
in IN N
STARS NNP o
protein NN o
was VBD N
observed VBN N
exclusively RB N
after IN N
CONC NNP i
exercise NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
while IN N
pSRF JJ o
protein NN N
levels NNS N
increased VBD N
similarly RB N
by IN N
48 CD N
% NN N
with IN N
both DT N
CONC NNP N
and CC N
ECC NNP N
exercise NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Prolonged VBN N
ECC NNP N
and CC N
CONC NNP N
training VBG N
equally RB N
stimulated VBN N
muscle NN N
hypertrophy NN N
and CC N
produced VBD N
increases NNS N
in IN N
MRTF-A NNP o
protein NN o
of IN N
125 CD N
% NN N
and CC N
99 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No UH N
changes NNS N
occurred VBD N
for IN N
total JJ o
SRF NNP o
protein NN o
. . o

There EX N
was VBD N
no DT N
effect NN N
of IN N
whey NN o
protein NN o
supplementation NN o
. . o

These DT N
results NNS N
show VBP N
that IN N
resistance NN N
exercise NN N
provides VBZ N
an DT N
acute JJ o
stimulation NN o
of IN o
the DT o
STARS NNP o
pathway NN o
that WDT N
is VBZ N
contraction JJ N
mode NN N
dependent NN N
. . N

The DT N
responses NNS N
to TO N
acute VB i
exercise NN i
were VBD N
more RBR N
pronounced JJ N
than IN N
responses NNS N
to TO N
accumulated JJ i
training NN i
, , N
suggesting VBG N
that IN N
STARS NNP N
signalling VBG N
is VBZ N
primarily RB N
involved VBN N
in IN N
the DT N
initial JJ N
phase NN N
of IN N
exercise-induced JJ N
muscle NN N
adaptations NNS N
. . N

-DOCSTART- -X- O O

A DT N
pilot NN N
study NN N
of IN N
the DT N
Tele-Airway NNP i
Management NNP i
System NNP i
in IN N
a DT N
hospital NN p
emergency NN p
department NN p
. . p

We PRP N
developed VBD N
a DT N
telemedicine NN N
system NN N
for IN N
remote JJ N
guidance NN N
of IN N
emergency NN N
airway NN N
management NN N
called VBD N
the DT N
Tele-Airway NNP i
Management NNP i
System NNP i
( ( N
TAMS NNP N
) ) N
. . N

In IN N
a DT N
pilot NN N
study NN N
we PRP N
examined VBD N
the DT N
usefulness NN N
of IN N
the DT N
TAMS NNP i
for IN N
intubations NNS N
of IN N
actual JJ N
patients NNS p
in IN p
a DT p
hospital NN p
emergency NN p
department NN p
. . p

Twenty-five JJ p
patients NNS p
were VBD p
allocated VBN p
randomly RB p
either DT p
to TO p
a DT p
TAMS NNP i
group NN i
or CC p
to TO p
an DT p
on-scene JJ i
directed NN i
( ( i
OSD NNP i
) ) i
group NN i
. . i

A DT N
total NN N
of IN N
12 CD p
were VBD p
intubated VBN p
using VBG N
the DT N
TAMS NNP i
. . i

The DT N
mean JJ o
time NN o
to TO o
intubation NN o
( ( i
TAMS NNP i
62 CD N
s NN N
vs. FW N
OSD NNP i
56 CD N
s NN N
) ) N
and CC N
the DT N
success NN o
rate NN o
was VBD N
not RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
two CD N
oesophageal JJ o
intubations NNS o
in IN N
the DT N
TAMS NNP i
group NN N
and CC N
four CD N
in IN N
the DT N
OSD NNP i
group NN N
, , N
but CC N
this DT N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
P NNP N
= NNP N
0.36 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
mechanical JJ o
or CC o
technical JJ o
errors NNS o
such JJ o
as IN o
disconnection NN o
during IN N
use NN N
of IN N
the DT N
TAMS NNP i
. . i

The DT N
pilot NN N
study NN N
demonstrated VBD N
the DT N
feasibility NN o
of IN N
the DT N
TAMS NNP N
as IN N
an DT N
alternative NN N
to TO N
OSD NNP i
. . i

However RB N
, , N
a DT N
larger JJR N
study NN N
will MD N
be VB N
required VBN N
to TO N
determine VB N
non-superiority NN N
or CC N
equivalence NN N
. . N

-DOCSTART- -X- O O

ACE NNP i
inhibitors NNS i
or CC i
AT-1 JJ i
antagonists NNS i
- : N
which WDT N
is VBZ N
OPTIMAAL NNP N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
? . N
OPTIMAAL NNP N
( ( N
Optimal NNP N
Trial NNP N
in IN N
Myocardial NNP N
Infarction NNP N
with IN N
the DT N
Angiotensin NNP N
II NNP N
Antagonist NNP N
Losartan NNP N
) ) N
is VBZ N
the DT N
first JJ N
major JJ N
study NN N
to TO N
compare VB N
an DT N
angiotensin NN i
II NNP i
Type NNP i
1 CD i
antagonist NN i
losartan NN i
( ( N
Cozaar NNP N
trade NN N
mark NN N
, , N
Merck NNP N
) ) N
with IN N
an DT N
ACE NNP N
inhibitor NN N
captonpril NN i
( ( N
Capoten NNP N
trade NN N
mark NN N
, , N
Elan NNP N
) ) N
after IN p
myocardial JJ p
infarction NN p
in IN p
patients NNS p
with IN p
left JJ p
ventricular JJ p
dysfunction NN p
. . p

Patients NNS p
were VBD N
assigned VBN N
to TO N
a DT N
target NN N
dose NN N
of IN N
losartan JJ i
50 CD N
mg/day NN N
and CC N
captopril NN i
50 CD N
mg NN N
t.i.d. NN N
, , N
as IN N
tolerated VBN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
all-cause JJ o
mortality NN o
and CC N
there EX N
were VBD N
499 CD N
( ( N
18 CD N
% NN N
) ) N
and CC N
447 CD N
( ( N
16 CD N
% NN N
) ) N
deaths NNS o
in IN N
the DT N
losartan NN i
and CC i
captopril NN i
group NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.07 CD N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
significantly RB N
more JJR N
cardiovascular JJ o
deaths NNS o
with IN N
losartan NN N
( ( N
420 CD N
, , N
15 CD N
% NN N
) ) N
than IN N
with IN N
captopril NN i
( ( N
363 CD N
, , N
13 CD N
% NN N
; : N
p CC N
= VB N
0.03 CD N
) ) N
. . N

Losartan NNP i
was VBD N
better RBR N
tolerated VBN o
than IN N
captopril NN i
with IN N
fewer JJR N
patients NNS o
discontinuing VBG o
medication NN o
( ( N
17 CD N
versus RB N
23 CD N
% NN N
for IN N
losartan NN i
and CC N
captopril NN i
, , N
respectively RB N
) ) N
. . N

In IN N
conclusion NN N
, , N
if IN N
tolerated VBN N
, , N
captopril NN i
should MD N
remain VB N
the DT N
preferred JJ N
treatment NN N
for IN N
patients NNS p
after IN N
complicated VBN N
acute JJ o
myocardial JJ o
infarction NN o
. . o

-DOCSTART- -X- O O

Randomized VBN N
Phase NNP N
II NNP N
trial NN N
assessing VBG N
estramustine NN i
and CC i
vinblastine JJ i
combination NN i
chemotherapy NN i
vs JJ i
estramustine NN i
alone RB i
in IN N
patients NNS p
with IN p
progressive JJ p
hormone-escaped JJ p
metastatic JJ p
prostate NN p
cancer NN p
. . p

Based VBN N
on IN N
the DT N
results NNS N
of IN N
combined JJ N
data NNS N
from IN N
three CD N
North JJ N
American JJ N
Phase NNP N
II NNP N
studies NNS N
, , N
a DT N
randomised JJ N
Phase NNP N
II NNP N
study NN N
in IN N
the DT N
same JJ N
patient JJ N
population NN N
was VBD N
performed VBN N
, , N
using VBG N
combination NN N
chemotherapy NN i
with IN i
estramustine JJ i
phosphate NN i
( ( i
EMP NNP i
) ) i
and CC i
vinblastine NN i
( ( i
VBL NNP i
) ) i
in IN N
hormone NN N
refractory NN N
prostate NN N
cancer NN N
patients NNS N
. . N

In IN N
all DT N
, , N
92 CD p
patients NNS p
were VBD p
randomised VBN p
into IN p
a DT p
Phase NNP p
II NNP p
study NN p
of IN N
oral JJ i
EMP NNP i
( ( i
10 CD i
mg NNS i
kg JJ i
day NN i
continuously RB i
) ) i
or CC i
oral JJ i
EMP NNP i
in IN i
combination NN i
with IN i
intravenous JJ i
VBL NNP i
( ( N
4 CD N
mg NN N
m NN N
( ( N
2 CD N
) ) N
week NN N
for IN N
6 CD N
weeks NNS N
, , N
followed VBN N
by IN N
2 CD N
weeks NNS N
rest NN N
) ) N
. . N

The DT N
end NN N
points NNS N
were VBD N
toxicity NN o
and CC o
PSA NNP o
response NN o
in IN N
both DT N
groups NNS N
, , N
with IN N
the DT N
option NN N
to TO N
continue VB N
the DT N
trial NN N
as IN N
a DT N
Phase NNP N
III NNP N
study NN N
with IN N
time NN o
to TO o
progression NN o
and CC N
survival NN o
as IN N
end NN N
points NNS N
, , N
if IN N
sufficient JJ N
responses NNS N
were VBD N
observed VBN N
. . N

Toxicity NNP o
was VBD N
unexpectedly RB N
high JJ N
in IN N
both DT N
treatment NN N
arms NNS N
and CC N
led VBD N
to TO N
treatment NN N
withdrawal NN N
or CC N
refusal NN N
in IN N
49 CD N
% NN N
of IN N
all DT N
patients NNS N
, , N
predominantly RB N
already RB N
during IN N
the DT N
first JJ N
treatment NN N
cycle NN N
. . N

The DT N
mean JJ o
treatment NN o
duration NN o
was VBD N
10 CD N
and CC N
14 CD N
weeks NNS N
, , N
median JJ o
time NN o
to TO o
PSA NNP o
progression NN o
was VBD N
27.2 CD N
and CC N
30.8 CD N
weeks NNS N
, , N
median JJ o
survival NN o
time NN o
was VBD N
44 CD N
and CC N
50.9 CD N
weeks NNS N
, , N
and CC N
PSA NNP o
response NN o
rate NN o
was VBD N
only RB N
24.6 CD N
and CC N
28.9 CD N
% NN N
in IN N
the DT N
EMP/VBL NNP i
and CC N
EMP NNP i
arms NNS N
, , N
respectively RB N
. . N

There EX N
was VBD N
no DT N
correlation NN N
between IN N
PSA NNP o
response NN o
and CC o
survival NN o
. . o

While IN N
the DT N
PSA NNP o
response NN o
in IN N
the DT N
patients NNS N
tested VBD N
was VBD N
less JJR N
than IN N
half NN N
that WDT N
recorded VBD N
in IN N
the DT N
North JJ N
American JJ N
studies NNS N
, , N
the DT N
toxicity NN o
of IN o
EMP NNP o
monotherapy NN o
or CC N
in IN N
combination NN N
with IN N
VBL NNP i
was VBD N
much RB N
higher JJR N
than IN N
expected VBN N
. . N

Further NNP N
research NN N
on IN N
more RBR N
effective JJ o
and CC N
less RBR N
toxic JJ o
treatment NN N
strategies NNS N
for IN N
hormone NN N
refractory NN N
prostate NN N
cancer NN N
is VBZ N
mandatory JJ N
. . N

-DOCSTART- -X- O O

Drug-drug JJ N
interaction NN N
study NN N
of IN N
ACT-178882 NNP N
, , N
a DT N
new JJ N
renin NN N
inhibitor NN N
, , N
and CC N
diltiazem NN N
in IN N
healthy JJ p
subjects NNS p
. . p

BACKGROUND NNP N
AND CC N
OBJECTIVE NNP N
The DT N
cytochrome NN N
P450 NNP N
( ( N
CYP NNP N
) ) N
enzyme NN N
, , N
CYP3A4 NNP N
, , N
metabolizes VBZ N
ACT-178882 NNP N
, , N
a DT N
new JJ N
direct JJ N
renin NN N
inhibitor NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
effect NN o
of IN N
diltiazem NN i
, , N
a DT N
moderate JJ N
inhibitor NN N
of IN N
CYP3A4 NNP N
, , N
on IN N
the DT N
single-dose JJ N
pharmacokinetics NNS N
of IN N
ACT-178882 NNP N
in IN N
healthy JJ p
subjects NNS p
. . p

METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
two-way JJ N
crossover NN N
, , N
drug-drug JJ N
interaction NN N
study NN N
, , N
healthy JJ p
young JJ p
male JJ p
subjects NNS p
received VBD N
treatments NNS N
A NNP N
and CC N
B NNP N
in IN N
a DT N
randomized JJ N
fashion NN N
. . N

Treatment VB N
A NNP N
consisted NN N
of IN N
a DT N
single JJ i
dose NN i
of IN i
100 CD i
mg JJ i
ACT-178882 NNP i
and CC i
treatment NN i
B NNP i
of IN i
diltiazem NN i
300 CD i
mg NN i
once RB i
a DT i
day NN i
for IN i
13 CD i
days NNS i
and CC i
a DT i
single JJ i
dose NN i
of IN i
100 CD i
mg JJ i
ACT-178882 JJ i
on IN i
day NN i
4 CD i
. . i

Serial JJ N
blood NN N
samples NNS N
for IN N
the DT N
measurement NN N
of IN N
ACT-178882 NNP N
were VBD N
drawn VBN N
pre-dose NN N
and CC N
up RB N
to TO N
120 CD N
h JJ N
post-dose JJ N
during IN N
treatment NN N
A NNP N
and CC N
pre-dose JJ N
ACT-178882 NNP N
and CC N
up RB N
to TO N
240 CD N
h JJ N
post-dose JJ N
during IN N
treatment NN N
B. NNP N
Trough NNP N
blood NN o
samples NNS o
for IN o
the DT o
measurement NN N
of IN N
diltiazem NN N
were VBD N
taken VBN N
on IN N
days NNS N
1-5 CD N
of IN N
dosing VBG N
during IN N
treatment NN o
B NNP o
. . o

Safety NNP o
was VBD o
assessed VBN o
by IN o
recording VBG o
of IN o
vital JJ o
signs NNS o
and CC o
electrocardiogram NN o
, , o
clinical JJ o
laboratory NN o
tests NNS o
and CC o
adverse JJ o
event NN o
reporting NN o
. . o

RESULTS NNP o
Fourteen JJ p
subjects NNS p
were VBD p
enrolled VBN p
and CC p
completed VBN p
the DT p
study NN p
. . N

In IN N
the DT N
absence NN N
of IN N
diltiazem NN N
, , N
the DT N
mean NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
) ) N
maximum NN N
concentration NN N
( ( N
Cmax NNP N
) ) N
and CC N
area NN N
under IN N
the DT N
curve NN N
from IN N
time NN N
zero CD N
to TO N
infinity NN N
( ( N
AUC? NNP N
) ) N
were VBD N
26.8 CD N
( ( N
20.1-35.8 JJ N
) ) N
ng/mL NN N
and CC N
454 CD N
( ( N
351-587 CD N
) ) N
ng?h/mL NN N
, , N
respectively RB N
. . N

In IN N
the DT N
presence NN N
of IN N
diltiazem NN N
these DT N
values NNS N
were VBD N
43.5 CD N
( ( N
36.8-51.4 CD N
) ) N
ng/mL NN N
and CC N
918 CD N
( ( N
781-1078 CD N
) ) N
ng?h/mL NN N
, , N
respectively RB o
. . o

The DT o
median JJ o
time NN o
to TO o
Cmax NNP o
( ( o
tmax NN o
) ) o
for IN o
ACT-178882 NNP N
was VBD N
prolonged VBN N
from IN N
3.5 CD N
to TO N
5.0 CD N
h NN N
by IN N
diltiazem JJ N
whereas NNS N
its PRP$ N
apparent JJ o
terminal JJ o
half-life NN o
( ( o
t? NN o
) ) o
was VBD o
unaffected VBN o
by IN N
diltiazem NN N
, , N
22.9 CD N
and CC N
24.2 CD N
h NN N
for IN N
treatments NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
. . N

Using VBG N
treatment NN N
A NNP N
as IN N
reference NN N
, , N
the DT o
geometric JJ o
mean NN o
ratio NN o
( ( o
90 CD N
% NN N
CI NNP N
) ) N
was VBD N
1.62 CD N
( ( N
1.36-1.94 CD N
) ) N
for IN o
Cmax NNP o
and CC o
2.02 CD N
( ( N
1.75-2.34 CD N
) ) N
for IN N
AUC? NNP N
, , N
indicating VBG N
a DT N
significant JJ N
interaction NN N
between IN N
ACT-178882 NNP N
and CC N
diltiazem NN N
. . N

One CD N
( ( N
7.1 CD N
% NN N
) ) N
and CC N
3 CD N
( ( N
21.3 CD N
% NN N
) ) N
of IN N
14 CD N
subjects NNS N
reported VBD o
an DT o
adverse JJ o
event NN o
during IN N
treatment NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
, , N
with IN o
headache NN o
being VBG N
the DT N
most RBS N
frequently RB N
reported VBN N
, , N
with IN N
three CD N
events NNS N
. . N

There EX N
were VBD N
no DT N
clinically RB N
relevant JJ N
effects NNS N
of IN N
treatments NNS N
on IN N
vital JJ N
signs NNS N
, , N
electrocardiogram NN N
or CC N
clinical JJ N
laboratory NN N
variables NNS N
. . N

CONCLUSION NNP N
Concomitant NNP N
administration NN N
of IN N
diltiazem NN N
doubled VBD N
the DT N
exposure NN N
to TO N
ACT-178882 NNP N
without IN N
affecting VBG N
t? NN N
. . N

The DT N
clinical JJ N
significance NN N
of IN N
this DT N
increase NN N
is VBZ N
at IN N
present JJ N
unknown JJ N
and CC N
will MD N
need VB N
to TO N
be VB N
investigated VBN N
in IN N
future JJ N
clinical JJ N
studies NNS N
. . N

Treatment NN N
with IN N
ACT-178882 NNP N
alone RB N
or CC N
in IN N
combination NN N
with IN N
diltiazem NN N
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

-DOCSTART- -X- O O

Predicting VBG N
Overall JJ o
Survival NNP o
After IN o
Stereotactic NNP o
Ablative NNP o
Radiation NNP o
Therapy NNP o
in IN N
Early-Stage NNP N
Lung NNP N
Cancer NNP N
: : N
Development NNP N
and CC N
External NNP N
Validation NNP N
of IN N
the DT N
Amsterdam NNP N
Prognostic NNP N
Model NNP N
. . N

PURPOSE VB N
A NNP N
prognostic JJ N
model NN N
for IN N
5-year JJ N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
, , N
consisting VBG N
of IN N
recursive JJ N
partitioning NN N
analysis NN N
( ( N
RPA NNP N
) ) N
and CC N
a DT N
nomogram NN N
, , N
was VBD N
developed VBN N
for IN N
patients NNS p
with IN p
early-stage JJ p
non-small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
ES-NSCLC NNP p
) ) p
treated VBD p
with IN p
stereotactic JJ i
ablative JJ i
radiation NN i
therapy NN i
( ( i
SABR NNP i
) ) i
. . i

METHODS NNP N
AND NNP N
MATERIALS NNP N
A NNP p
primary JJ p
dataset NN p
of IN p
703 CD p
ES-NSCLC JJ p
SABR NNP i
patients NNS p
was VBD N
randomly RB N
divided VBN N
into IN N
a DT N
training NN N
( ( N
67 CD N
% NN N
) ) N
and CC N
an DT N
internal JJ N
validation NN N
( ( N
33 CD N
% NN N
) ) N
dataset NN N
. . N

In IN N
the DT N
former JJ N
group NN N
, , N
21 CD N
unique JJ N
parameters NNS N
consisting VBG N
of IN N
patient NN o
, , o
treatment NN o
, , o
and CC o
tumor NN o
factors NNS o
were VBD N
entered VBN N
into IN N
an DT N
RPA NNP N
model NN N
to TO N
predict VB N
OS NNP N
. . N

Univariate NNP N
and CC N
multivariate NN N
models NNS N
were VBD N
constructed VBN N
for IN N
RPA-selected JJ N
factors NNS N
to TO N
evaluate VB N
their PRP$ N
relationship NN N
with IN N
OS NNP N
. . N

A DT N
nomogram NN N
for IN N
OS NNP N
was VBD N
constructed VBN N
based VBN N
on IN N
factors NNS N
significant JJ N
in IN N
multivariate NN N
modeling NN N
and CC N
validated VBN N
with IN N
calibration NN N
plots NNS N
. . N

Both CC N
the DT N
RPA NNP N
and CC N
the DT N
nomogram NN N
were VBD N
externally RB N
validated VBN N
in IN N
independent JJ N
surgical JJ N
( ( N
n JJ N
= NNP N
193 CD N
) ) N
and CC N
SABR NNP N
( ( N
n JJ N
= NNP N
543 CD N
) ) N
datasets NNS N
. . N

RESULTS NNP N
RPA NNP o
identified VBD o
2 CD o
distinct JJ o
risk NN o
classes NNS o
based VBN o
on IN o
tumor NN o
diameter NN o
, , o
age NN o
, , o
World NNP o
Health NNP o
Organization NNP o
performance NN o
status NN o
( ( o
PS NNP o
) ) o
and CC o
Charlson NNP o
comorbidity NN o
index NN o
. . o

This DT N
RPA NNP N
had VBD N
moderate JJ N
discrimination NN N
in IN N
SABR NNP N
datasets NNS N
( ( N
c-index NN N
range NN N
: : N
0.52-0.60 JJ N
) ) N
but CC N
was VBD N
of IN N
limited JJ N
value NN N
in IN N
the DT N
surgical JJ N
validation NN N
cohort NN N
. . N

The DT N
nomogram JJ N
predicting NN N
OS NNP N
included VBD N
smoking VBG N
history NN N
in IN N
addition NN N
to TO N
RPA-identified JJ N
factors NNS N
. . N

In IN N
contrast NN N
to TO N
RPA NNP N
, , N
validation NN N
of IN N
the DT N
nomogram NN N
performed VBN N
well RB N
in IN N
internal JJ N
validation NN N
( ( N
r NN N
( ( N
2 CD N
) ) N
= FW N
0.97 CD N
) ) N
and CC N
external JJ N
SABR NNP N
( ( N
r NN N
( ( N
2 CD N
) ) N
= FW N
0.79 CD N
) ) N
and CC N
surgical JJ N
cohorts NNS N
( ( N
r NN N
( ( N
2 CD N
) ) N
= FW N
0.91 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
Amsterdam NNP o
prognostic JJ o
model NN o
is VBZ N
the DT N
first JJ N
externally RB N
validated VBN N
prognostication NN N
tool NN N
for IN N
OS NNP N
in IN N
ES-NSCLC NNP N
treated VBD N
with IN N
SABR NNP N
available JJ N
to TO N
individualize VB N
patient JJ N
decision NN N
making NN N
. . N

The DT N
nomogram NN N
retained VBD N
strong JJ N
performance NN N
across IN N
surgical JJ N
and CC N
SABR NNP N
external JJ N
validation NN N
datasets NNS N
. . N

RPA NNP o
performance NN o
was VBD N
poor JJ N
in IN N
surgical JJ N
patients NNS N
, , N
suggesting VBG N
that IN N
2 CD N
different JJ N
distinct JJ N
patient NN N
populations NNS N
are VBP N
being VBG N
treated VBN N
with IN N
these DT N
2 CD N
effective JJ N
modalities NNS N
. . N

-DOCSTART- -X- O O

Clonidine NNP i
treatment NN N
of IN N
hyperactive JJ p
and CC p
impulsive JJ p
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

Many JJ N
autistic JJ p
children NNS p
have VBP N
associated VBN N
problems NNS N
of IN N
inattention NN o
, , o
impulsivity NN o
, , o
and CC o
hyperactivity NN o
that WDT N
limit VBZ N
the DT N
effectiveness NN N
of IN N
educational JJ N
and CC N
behavioral JJ N
interventions NNS N
. . N

Few NNP N
controlled VBD N
psychopharmacologic JJ N
trials NNS N
have VBP N
been VBN N
conducted VBN N
in IN N
autistic JJ p
children NNS p
to TO N
determine VB N
which WDT N
agents NNS N
may MD N
be VB N
effective JJ o
for IN N
these DT N
associated VBN N
features NNS N
. . N

Eight NNP p
male NN p
children NNS p
( ( p
8.1 CD p
+/- JJ p
2.8 CD p
years NNS p
) ) p
with IN p
autistic JJ p
disorder NN p
, , p
diagnosed VBN p
by IN p
DSM-III-R NNP p
criteria NNS p
, , N
completed VBD N
a DT N
placebo-controlled JJ i
, , N
double-blind JJ N
crossover NN N
trial NN N
of IN N
clonidine NN i
. . i

Subjects NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
if IN p
they PRP p
had VBD p
inattention NN p
, , p
impulsivity NN p
, , p
and CC p
hyperactivity NN p
that WDT p
was VBD p
excessive JJ p
for IN p
their PRP$ p
developmental JJ p
level NN p
. . p

Subjects NNS p
had VBD p
not RB p
tolerated VBN p
or CC p
responded VBN p
to TO p
other JJ p
psychopharmacologic JJ p
treatments NNS p
( ( i
neuroleptics NNS i
, , i
methylphenidate NN i
, , i
or CC i
desipramine NN i
) ) i
. . p

Teacher PRP$ o
ratings NNS o
on IN o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
irritability NN o
, , o
stereotypy NN o
, , o
hyperactivity NN o
, , o
and CC o
inappropriate JJ o
speech NN o
factors NNS o
were VBD N
lower JJR N
during IN N
treatment NN N
with IN N
clonidine NN i
than IN N
during IN N
treatment NN N
with IN N
placebo NN i
. . i

Attention NNP N
deficit NN N
disorder NN N
with IN N
hyperactivity NN N
: : N
Comprehensive NNP o
Teacher NNP o
's POS o
Rating NNP o
Scale NNP o
ratings NNS o
were VBD N
not RB N
significantly RB N
improved VBN N
during IN N
the DT N
study NN N
, , N
except IN N
for IN N
oppositional JJ N
behavior NN N
. . N

Parent NN o
Conners NNPS o
Abbreviated NNP o
Parent-Teacher NNP o
Questionnaire NNP o
ratings NNS o
significantly RB N
improved VBN N
during IN N
clonidine JJ i
treatment NN N
. . N

Clonidine NNP N
led VBD N
to TO N
increased VBN N
ratings NNS N
of IN N
the DT N
side NN o
effects NNS o
of IN o
drowsiness NN o
and CC o
decreased JJ o
activity NN o
. . o

Clinician JJ N
ratings NNS N
( ( o
Children NNP o
's POS o
Psychiatric NNP o
Rating NNP o
Scale NNP o
Autism NNP o
, , o
Hyperactivity NNP o
, , o
Anger NNP o
and CC o
Speech NNP o
Deviance NNP o
factors NNS o
; : o
Children NNP o
's POS o
Global NNP o
Assessment NNP o
Scale NNP o
; : o
Clinical NNP o
Global NNP o
Impressions NNP o
efficacy NN o
) ) o
of IN N
videotaped JJ N
sessions NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
clonidine NN i
and CC N
placebo NN i
. . i

Clonidine NNP i
was VBD N
modestly RB N
effective JJ N
in IN N
the DT N
short-term JJ N
treatment NN N
of IN N
irritability NN o
and CC o
hyperactivity NN o
in IN N
some DT N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

-DOCSTART- -X- O O

Double-blind NNP N
, , N
placebo-controlled JJ i
study NN N
of IN N
amantadine JJ i
hydrochloride NN i
in IN N
the DT N
treatment NN N
of IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
amantadine JJ i
hydrochloride NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
treatment NN N
for IN N
behavioral JJ o
disturbances NNS o
-- : o
for IN o
example NN N
, , N
hyperactivity NN o
and CC o
irritability NN o
-- : o
in IN o
children NNS p
with IN p
autism NN p
. . p

METHOD NNP N
Thirty-nine JJ p
subjects NNS p
( ( p
intent NN p
to TO p
treat VB p
; : p
5-19 CD p
years NNS p
old JJ p
; : p
IQ NNP p
> NNP p
35 CD p
) ) p
had VBD p
autism NN p
diagnosed VBN p
according VBG p
to TO p
DSM-IV NNP p
and CC p
ICD-10 NNP p
criteria NNS p
using VBG p
the DT p
Autism NNP p
Diagnostic NNP p
Interview-Revised JJ p
and CC p
the DT p
Autism NNP p
Diagnostic NNP p
Observation NNP p
Schedule-Generic NNP p
. . p

The DT N
Aberrant JJ o
Behavior NNP o
Checklist-Community NNP o
Version NNP o
( ( o
ABC-CV NNP o
) ) o
and CC o
Clinical JJ o
Global NNP o
Impressions NNP o
( ( o
CGI NNP o
) ) o
scale NN N
were VBD N
used VBN N
as IN N
outcome JJ N
variables NNS N
. . N

After IN N
a DT N
1-week JJ N
, , N
single-blind JJ N
placebo NN N
run-in NN N
, , N
patients NNS N
received VBD N
a DT N
single JJ i
daily JJ i
dose NN i
of IN i
amantadine NN i
( ( i
2.5 CD i
mg/kg NNS i
per IN i
day NN i
) ) i
or CC i
placebo NN i
for IN i
the DT i
next JJ i
week NN i
, , i
and CC i
then RB i
bid VB i
dosing VBG i
( ( i
5.0 CD i
mg/kg NNS i
per IN i
day NN i
) ) i
for IN i
the DT i
subsequent JJ i
3 CD i
weeks NNS i
. . i

RESULTS VB N
When WRB N
assessed VBN N
on IN N
the DT N
basis NN N
of IN N
parent-rated JJ o
ABC-CV NNP o
ratings NNS o
of IN o
irritability NN o
and CC o
hyperactivity NN o
, , N
the DT N
mean JJ N
placebo NN N
response NN N
rate NN N
was VBD N
37 CD N
% NN N
versus NN N
amantadine NN N
at IN N
47 CD N
% NN N
( ( N
not RB N
significant JJ N
) ) N
. . N

However RB N
, , N
in IN N
the DT N
amantadine-treated JJ i
group NN N
there EX N
were VBD N
statistically RB N
significant JJ N
improvements NNS N
in IN N
absolute JJ N
changes NNS N
in IN N
clinician-rated JJ N
ABC-CVs NNP o
for IN o
hyperactivity NN o
( ( N
amantadine JJ N
-6.4 NNP N
versus NN N
placebo NN N
-2.1 NNP N
; : N
p CC N
= NNP N
.046 NNP N
) ) N
and CC N
inappropriate JJ o
speech NN o
( ( N
-1.9 JJ N
versus NN N
0.4 CD N
; : N
p NN N
= NNP N
.008 NNP N
) ) N
. . N

CGI NNP o
scale JJ o
ratings NNS o
were VBD N
higher JJR N
in IN N
the DT N
amantadine NN N
group NN N
: : N
53 CD N
% NN N
improved JJ N
versus NN N
25 CD N
% NN N
( ( N
p JJ N
= NNP N
.076 NNP N
) ) N
. . N

Amantadine NNP i
was VBD N
well RB N
tolerated VBN N
. . N

CONCLUSIONS NNP N
Parents NNPS N
did VBD N
not RB N
report VB N
statistically RB N
significant JJ N
behavioral JJ o
change NN o
with IN N
amantadine NN N
. . N

However RB N
, , N
clinician-rated JJ o
improvements NNS o
in IN o
behavioral JJ o
ratings NNS o
following VBG N
treatment NN N
with IN N
amantadine JJ i
suggest VBP N
that IN N
further JJ N
studies NNS N
with IN N
this DT N
or CC N
other JJ N
drugs NNS N
acting VBG N
on IN N
the DT N
glutamatergic NN N
system NN N
are VBP N
warranted VBN N
. . N

The DT N
design NN N
of IN N
these DT N
and CC N
similar JJ N
drug NN N
trials NNS N
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
must MD N
take VB N
into IN N
account NN N
the DT N
possibility NN N
of IN N
a DT N
large JJ N
placebo NN N
response NN N
. . N

-DOCSTART- -X- O O

Generalizability NNP o
and CC o
durability NN o
of IN o
treatment NN o
effects NNS o
in IN N
an DT N
intervention NN i
program NN i
for IN N
coronary-prone NN p
( ( p
Type NNP p
A NNP p
) ) p
managers NNS p
. . p

To TO N
test VB N
the DT N
reliability NN o
and CC o
durability NN o
of IN o
positive JJ o
treatment NN o
effects NNS o
obtained VBN N
in IN N
a DT N
type NN i
A DT i
intervention NN i
project NN i
for IN p
healthy JJ p
managers NNS p
, , N
the DT N
analysis NN N
was VBD N
extended VBN N
to TO N
data NNS N
available JJ N
from IN N
a DT N
third JJ N
treatment NN N
group NN N
( ( i
a DT i
special JJ i
behavior JJ i
therapy NN i
group NN i
for IN N
participants NNS N
eliminated VBN N
from IN N
the DT N
main JJ N
sample NN N
because IN N
of IN N
manifestations NNS p
of IN p
clinical JJ p
CHD NNP p
) ) p
and CC N
to TO N
measures NNS N
obtained VBN N
6 CD N
months NNS N
following VBG N
the DT N
end NN N
of IN N
treatment NN N
. . N

Immediately RB N
after IN N
treatment NN N
all DT p
three CD p
groups NNS p
showed VBD N
a DT N
similar JJ N
pattern NN N
of IN N
improvement NN N
, , N
although IN N
the DT N
two CD N
behavior JJ i
therapy NN i
groups NNS N
did VBD N
show VB N
a DT N
greater JJR N
decrease NN N
in IN N
serum NN o
cholesterol NN o
levels NNS o
. . o

Six NNP N
months NNS N
after IN N
treatment NN N
the DT N
sample NN N
as IN N
a DT N
whole NN N
showed VBD N
good JJ o
maintenance NN o
of IN o
treatment NN o
effects NNS o
, , N
but CC N
the DT N
differences NNS N
between IN N
groups NNS N
had VBD N
become VBN N
somewhat RB N
sharper JJ N
, , N
with IN N
the DT N
special JJ i
behavior JJ i
therapy NN i
group NN N
faring VBG N
best JJS N
, , N
the DT N
regular JJ i
behavior NN i
therapy NN i
group NN N
intermediate NN N
, , N
and CC N
the DT N
psychotherapy NN i
group NN N
worst WDT N
. . N

The DT N
logical JJ N
consistency NN N
of IN N
these DT N
findings NNS N
increases VBZ N
our PRP$ N
confidence NN N
in IN N
the DT N
initial JJ N
treatment NN N
results NNS N
, , N
as RB N
well RB N
as IN N
permitting VBG N
cautious JJ N
optimism NN N
concerning VBG N
the DT N
possibility NN N
of IN N
developing VBG N
effective JJ N
intervention NN N
programs NNS N
for IN N
coronary-type NN N
( ( N
type VB N
A DT N
) ) N
behavior NN N
. . N

-DOCSTART- -X- O O

The DT N
use NN N
of IN N
the DT N
Antenatal NNP i
Psychosocial NNP i
Health NNP i
Assessment NNP i
( ( i
ALPHA NNP i
) ) i
tool NN i
in IN N
the DT N
detection NN N
of IN N
psychosocial JJ o
risk NN o
factors NNS o
for IN N
postpartum JJ N
depression NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE CC N
Eliciting VBG N
known VBN N
risk NN o
factors NNS o
for IN o
postpartum NN o
depression NN o
( ( N
PPD NNP N
) ) N
during IN N
pregnancy NN N
may MD N
enable VB N
primary JJ N
health NN N
care NN N
providers NNS N
to TO N
identify VB N
women NNS N
at IN N
increased JJ N
risk NN N
of IN N
becoming VBG N
depressed VBN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
how WRB N
well RB N
the DT N
Antenatal NNP i
Psychosocial NNP i
Health NNP i
Assessment NNP i
( ( i
ALPHA NNP i
) ) i
form NN N
identified VBN N
antenatal JJ N
risk NN N
factors NNS N
for IN N
PPD NNP N
, , N
compared VBN N
with IN N
routine JJ N
care NN N
, , N
in IN N
a DT N
sample NN N
of IN N
pregnant JJ p
women NNS p
. . p

METHODS VB N
A DT N
randomized NN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effectiveness NN o
of IN o
the DT o
ALPHA NNP o
form NN N
in IN N
detecting VBG N
antenatal JJ N
risk NN N
factors NNS N
associated VBN N
with IN N
the DT N
adverse JJ N
postpartum NN N
outcomes NNS N
of IN N
postpartum NN o
depression NN o
, , o
intimate NN o
partner NN o
violence NN o
, , o
child NN o
abuse NN o
, , o
and CC o
couple JJ o
dysfunction NN o
. . o

The DT p
participants NNS p
were VBD p
primary JJ p
antenatal JJ p
care NN p
providers NNS p
-- : p
family NN p
physicians NNS p
, , p
obstetricians NNS p
, , p
and CC p
midwives NNS p
-- : p
from IN p
four CD p
diverse NN p
communities NNS p
in IN p
Ontario NNP p
. . p

These DT N
providers NNS N
were VBD N
matched VBN i
and CC i
then RB i
randomly RB i
allocated VBN i
into IN i
the DT i
intervention NN i
group NN i
, , i
who WP i
used VBD i
the DT i
ALPHA NNP i
form NN i
, , i
or CC i
into IN i
the DT i
control NN i
group NN i
, , i
who WP i
administered VBD i
usual JJ i
care NN i
. . i

In IN p
total JJ p
, , p
227 CD p
pregnant JJ p
women NNS p
were VBD p
recruited VBN p
: : p
98 CD p
in IN p
the DT p
ALPHA NNP i
group NN p
and CC p
129 CD p
in IN p
the DT p
control NN p
group NN p
. . p

The DT N
data NN N
presented VBN N
in IN N
this DT N
paper NN N
are VBP N
from IN N
a DT N
secondary JJ N
analysis NN N
focusing VBG N
on IN N
PPD NNP N
as IN N
the DT N
outcome NN N
. . N

RESULTS JJ N
Providers NNPS N
randomized VBD N
to TO N
the DT N
ALPHA NNP N
group NN N
identified VBD N
a DT N
statistically RB N
significantly RB N
higher JJR N
proportion NN N
of IN N
women NNS N
with IN N
antenatal JJ o
psychosocial JJ o
risk NN o
factors NNS o
for IN o
PPD NNP o
( ( N
36 CD N
% NN N
vs. FW N
26 CD N
% NN N
) ) N
and CC N
a DT N
significantly RB N
higher JJR N
number NN N
of IN N
risk NN o
factors NNS o
per IN N
woman NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
mean JJ N
2.1 CD N
vs.1.8 NN N
) ) N
( ( N
z JJ N
= NNP N
-1.96 NNP N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

Providers NNS N
in IN N
the DT N
ALPHA NNP N
group NN N
also RB N
identified VBD N
significantly RB N
more JJR N
women NNS N
having VBG N
a DT N
previous JJ o
history NN o
of IN o
depression NN o
( ( N
16 CD N
% NN N
vs. FW N
6 CD N
% NN N
) ) N
( ( N
chi2 JJ N
= NN N
5.243 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
and CC N
[ $ o
having VBG o
] NNP o
witnessed VBD o
or CC o
experienced JJ o
abuse NN o
as IN o
a DT o
child NN o
( ( N
17 CD N
% NN N
vs. FW N
3 CD N
% NN N
) ) N
( ( N
chi2 JJ N
= NN N
12.488 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
P NNP N
= NNP N
0.0005 CD N
) ) N
, , N
which WDT N
are VBP N
both DT N
established VBN N
risk NN N
factors NNS N
for IN N
PPD NNP o
. . o

CONCLUSION NNP N
The DT N
ALPHA NNP i
provides VBZ N
a DT N
systematic JJ N
means NNS N
of IN N
eliciting VBG N
antenatal JJ N
psychosocial JJ N
risk NN N
factors NNS N
for IN N
PPD NNP N
for IN N
primary JJ N
care NN N
providers NNS N
, , N
and CC N
it PRP N
may MD N
be VB N
particularly RB N
useful JJ N
for IN N
raising VBG N
and CC N
discussing VBG N
sensitive JJ N
issues NNS N
. . N

The DT N
detection NN N
of IN N
depressive JJ o
symptomatology NN o
during IN N
pregnancy NN N
remains VBZ N
problematic JJ N
, , N
however RB N
, , N
and CC N
detection NN N
may MD N
be VB N
improved VBN N
by IN N
administering VBG N
a DT N
simple JJ N
standardized JJ N
measure NN N
of IN N
depressive JJ N
symptomatology NN N
during IN N
routine JJ N
antenatal JJ N
care NN N
. . N

-DOCSTART- -X- O O

New NNP i
mini-extracorporeal JJ i
circulation NN i
system NN i
( ( i
ECC.O NNP i
) ) i
is VBZ N
a DT N
safe JJ N
technique NN N
in IN N
coronary JJ N
surgery NN N
. . N

OBJECTIVES NNP N
Cardiopulmonary NNP i
bypass NN i
( ( i
CPB NNP i
) ) i
is VBZ N
known VBN N
to TO N
cause VB N
the DT N
systemic JJ N
inflammatory NN N
reaction NN N
after IN N
cardiac JJ N
surgery NN N
. . N

New NNP N
coated VBD N
and CC N
closed VBD N
loop NN N
circuit NN N
systems NNS N
may MD N
reduce VB N
this DT N
inflammation NN o
response NN o
and CC o
improve VB o
the DT o
surgical JJ o
outcome NN o
. . o

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
mini-extracorporeal JJ i
circulation NN i
system NN i
( ( i
ECC.O NNP i
) ) i
in IN N
CABG NNP p
patients NNS p
. . p

DESIGN NNP N
Forty NNP p
patients NNS p
undergoing VBG p
elective JJ p
coronary JJ p
surgery NN p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
ECC.O NNP i
group NN i
and CC i
the DT i
standard JJ i
CPB NNP i
group NN i
. . i

Routine NNP N
hemodynamic JJ N
monitoring NN N
and CC N
biochemical JJ N
measurements NNS N
were VBD N
registered VBN N
according VBG N
to TO N
the DT N
hospital NN N
practice NN N
. . N

RESULTS VB N
The DT N
clinical JJ N
outcome NN N
of IN N
the DT N
patients NNS N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
the DT N
duration NN o
of IN o
intubation NN o
following VBG o
surgery NN o
, , o
the DT o
length NN o
of IN o
intensive JJ o
care NN o
unit-stay JJ o
or CC o
the DT o
total JJ o
hospital NN o
stay NN o
. . o

The DT N
haemoglobin JJ o
level NN o
was VBD N
significantly RB N
higher JJR N
( ( N
p=0.0069 NN N
) ) N
during IN N
and CC N
after IN N
the DT N
perfusion NN N
in IN N
the DT N
ECC.O NNP i
group NN N
. . N

CONCLUSIONS VB N
The DT N
ECC.O NNP i
system NN N
can MD N
be VB N
safely RB N
used VBN N
in IN N
CABG NNP p
patients NNS p
and CC N
it PRP N
maintains VBZ N
haemoglobin JJ N
level NN N
better RBR N
than IN N
conventional JJ N
CPB NNP i
. . i

-DOCSTART- -X- O O

Capsaicin NNP i
jelly RB i
against IN N
migraine NN o
pain NN o
. . o

OBJECTIVE NNP N
Recent NNP N
studies NNS N
support VBP N
the DT N
role NN N
of IN N
extracranial JJ N
perivascular JJ N
afferents NNS N
in IN N
a DT N
substantial JJ N
percentage NN N
of IN N
migraineurs NNS p
. . p

Perivascular JJ N
afferent JJ N
fibres NNS N
of IN N
the DT N
superficial JJ N
temporal JJ N
artery NN N
contain NN N
peptides NNS N
, , N
like IN N
calcitonin JJ N
gene-related JJ N
peptide NN N
( ( N
CGRP NNP N
) ) N
and CC N
substance NN N
P NNP N
( ( N
SP NNP N
) ) N
. . N

CGRP NNP N
and CC N
SP NNP N
are VBP N
considered VBN N
relevant JJ N
in IN N
the DT N
genesis NN N
of IN N
migraine NN N
pain NN N
. . N

Capsaicin NNP i
is VBZ N
an DT N
agonist NN N
of IN N
the DT N
transient NN N
receptor NN N
potential JJ N
vanilloid NN N
type NN N
1 CD N
. . N

It PRP N
causes VBZ N
membrane JJ N
depolarisation NN N
of IN N
sensory JJ N
neurons NNS N
, , N
which WDT N
release VBP N
CGRP NNP N
, , N
SP NNP N
and CC N
other JJ N
pain NN N
peptides NNS N
; : N
excitation NN N
is VBZ N
followed VBN N
by IN N
a DT N
refractory NN N
state NN N
, , N
causing VBG N
inactivation NN N
. . N

Topical JJ i
capsaicin NN i
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
efficacious JJ N
in IN N
several JJ N
types NNS N
of IN N
neuropathic JJ o
pain NN o
. . o

We PRP N
attempted VBD N
to TO N
verify VB N
whether IN N
topical JJ i
periarterial JJ i
capsaicin NN i
could MD N
ameliorate VB N
pain NN o
in IN o
absence NN o
of IN o
and CC o
during IN o
a DT o
migraine JJ o
attack NN o
. . o

METHODS NNP N
On IN N
23 CD p
migraineurs NNS p
showing VBG p
pain NN p
at IN p
pressure NN p
on IN p
scalp NN p
arteries NNS p
, , N
we PRP N
administered VBD N
topical JJ i
capsaicin NN i
0.1 CD i
% NN i
or CC i
vaseline NN i
jelly RB i
on IN N
painful JJ N
arteries NNS N
in IN N
absence NN N
of IN N
migraine JJ N
attack NN N
. . N

In IN N
those DT N
having VBG N
pain NN N
reduction NN N
> VBD N
50 CD N
% NN N
, , N
we PRP N
made VBD N
the DT N
same JJ N
comparison NN N
during IN N
a DT N
migraine JJ N
attack NN N
. . N

RESULTS NNP N
Topical NNP i
capsaicin NN i
caused VBD N
> JJ N
50 CD N
% NN N
reduction NN N
of IN N
arterial JJ o
pain NN o
in IN N
absence NN N
of IN N
attack NN N
in IN N
17/23 CD N
patients NNS N
, , N
as IN N
opposed VBN N
to TO N
two CD N
with IN N
vaseline NN N
. . N

During IN N
attacks NNS N
of IN N
mild- NN N
to TO N
moderate-intensity NN N
, , N
> VB N
50 CD N
% NN N
improvement NN N
was VBD N
obtained VBN N
in IN N
11/17 CD N
with IN N
capsaicin NN i
and CC N
in IN N
one CD N
with IN N
vaseline NN i
. . i

CONCLUSIONS NNP N
Although IN N
referring VBG N
to TO N
a DT N
small JJ N
number NN N
of IN N
patients NNS N
, , N
our PRP$ N
data NNS N
show VBP N
that IN N
topical JJ i
capsaicin NN i
may MD N
relieve VB N
arterial JJ o
pain NN o
in IN N
absence NN N
of IN N
and CC N
during IN N
a DT N
migraine JJ N
attack NN N
in IN N
a DT N
substantial JJ N
number NN N
of IN N
patients NNS p
experiencing VBG p
scalp JJ p
arterial JJ p
tenderness NN p
. . p

More RBR N
active JJ N
capsacinoids NNS i
might MD N
be VB N
tried VBN N
in IN N
the DT N
future NN N
and CC N
could MD N
provide VB N
a DT N
new JJ N
method NN N
for IN N
treating VBG N
migraine NN N
attacks NNS N
. . N

-DOCSTART- -X- O O

Analgesic JJ N
efficacy NN N
of IN N
low-dose JJ N
diclofenac NN i
versus NN i
paracetamol NN i
and CC i
placebo NN i
in IN N
postoperative JJ p
dental NN p
pain NN p
. . p

AIMS NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
diclofenac-K NN i
( ( N
12.5 CD N
mg NN N
) ) N
vs NN N
paracetamol NN i
( ( N
500 CD N
mg NN N
) ) N
and CC N
placebo VB i
given VBN N
in IN N
a DT N
flexible JJ N
dosage NN N
regimen NNS N
to TO N
treat VB N
pain NN p
resulting VBG p
from IN p
extraction NN p
of IN p
impacted JJ p
third JJ p
molar JJ p
teeth NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
2-day JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ i
study NN N
of IN N
diclofenac-K NN i
( ( i
12.5 CD i
mg NN i
) ) i
tablets VBZ i
vs JJ i
paracetamol NN i
( ( N
500 CD N
mg NN N
) ) N
tablets NNS N
and CC N
placebo NN i
in IN N
patients NNS p
with IN p
moderate JJ p
or CC p
severe JJ p
pain NN p
within IN p
8 CD p
hours NNS p
of IN p
extraction NN p
of IN p
impacted JJ p
third JJ p
molars NNS p
. . p

RESULTS NNP N
After IN N
the DT N
first JJ N
2-tablet JJ N
dose NN N
, , N
patients NNS N
took VBD N
on IN N
average JJ N
2.5 CD N
additional JJ N
tablets NNS N
of IN N
diclofenac-K NN i
or CC N
2.4 CD N
tablets NNS N
of IN N
paracetamol NN i
, , N
almost RB N
all DT N
as IN N
1-tablet JJ N
doses NNS N
. . N

Most JJS N
placebo JJ i
patients NNS N
discontinued VBN N
by IN N
taking VBG N
rescue JJ o
medication NN o
( ( N
ibuprofen JJ N
200 CD N
mg NN N
) ) N
on IN N
the DT N
first JJ N
day NN N
. . N

Pain NNP o
relief NN o
after IN N
the DT N
initial JJ N
dose NN N
of IN N
diclofenac-K NN i
( ( N
2 CD N
x RB N
12.5 CD N
mg NN N
) ) N
was VBD N
superior JJ N
to TO N
placebo VB i
( ( N
P NNP N
< NNP N
.01 NNP N
for IN N
all DT N
efficacy NN N
outcomes NNS N
) ) N
and CC N
comparable JJ N
to TO N
paracetamol VB i
( ( N
2 CD N
x RB N
500 CD N
mg NN N
) ) N
. . N

About IN N
30 CD N
% NN N
of IN N
patients NNS N
in IN N
each DT N
active JJ N
treatment NN N
group NN N
took VBD N
rescue NN o
medication NN o
during IN N
the DT N
study NN N
, , N
compared VBN N
to TO N
78 CD N
% NN N
on IN N
placebo NN i
. . i

About IN N
70 CD N
% NN N
in IN N
each DT N
active JJ N
treatment NN N
group NN N
considered VBD N
the DT N
overall JJ o
pain NN o
relief NN o
to TO N
be VB N
some DT N
, , N
a DT N
lot NN N
, , N
or CC N
complete JJ N
compared VBN N
to TO N
only RB N
15 CD N
% NN N
on IN N
placebo NN i
. . i

The DT N
incidence NN o
of IN o
adverse JJ o
events NNS o
in IN N
each DT N
active JJ N
treatment NN N
group NN N
was VBD N
low JJ N
and CC N
comparable JJ N
between IN N
the DT N
treatments NNS N
. . N

CONCLUSION NNP N
An DT N
initial JJ N
double-dose NN N
of IN N
diclofenac-K NN i
( ( N
2 CD N
x RB N
12.5 CD N
mg NN N
) ) N
or CC N
paracetamol NN i
( ( N
2 CD N
x RB N
500 CD N
mg NNS N
) ) N
adequately RB N
relieved VBD N
the DT N
most RBS N
intense JJ N
postoperative NN o
pain NN o
, , N
and CC N
the DT N
flexible JJ N
multiple NN N
dose JJ N
regimen NNS N
( ( N
1 CD N
or CC N
2 CD N
tablets NNS N
) ) N
maintained VBD N
adequate JJ N
pain NN o
relief NN o
thereafter RB N
. . N

Most JJS N
patients NNS N
needed VBN N
only RB N
1-tablet JJ N
doses NNS N
following VBG N
the DT N
initial JJ N
2-tablet JJ N
dose NN N
. . N

-DOCSTART- -X- O O

Abdominoperineal NNP i
resection NN i
and CC N
anterior JJ i
resection NN i
in IN N
the DT N
treatment NN N
of IN N
rectal JJ p
cancer NN p
: : p
results NNS N
in IN N
relation NN N
to TO N
adjuvant VB i
preoperative JJ i
radiotherapy NN i
. . i

The DT N
outcome NN N
of IN N
patients NNS p
with IN p
rectal JJ p
cancer NN p
treated VBN p
by IN p
abdominoperineal NN i
or CC i
anterior JJ i
resection NN i
, , i
with IN i
or CC i
without IN i
preoperative JJ i
radiotherapy NN i
, , N
was VBD N
assessed VBN N
to TO N
detect VB N
any DT N
differences NNS N
attributable JJ N
to TO N
the DT N
operative JJ N
method NN N
and CC N
interactions NNS N
between IN N
radiotherapy NN N
and CC N
type NN N
of IN N
surgery NN N
. . N

The DT N
study NN N
was VBD N
based VBN N
on IN N
1292 CD p
patients NNS p
included VBN p
in IN p
two CD p
consecutive JJ p
controlled VBN p
randomized JJ p
trials NNS p
of IN p
preoperative JJ i
radiotherapy NN i
in IN p
operable JJ p
rectal JJ p
carcinoma NN p
. . p

The DT N
outcome NN N
was VBD N
not RB N
related VBN N
to TO N
surgical JJ N
method NN N
. . N

Radiotherapy NNP N
increased VBD N
postoperative JJ o
mortality NN o
and CC o
complications NNS o
and CC N
reduced JJ N
local JJ o
and CC o
distant JJ o
recurrence NN o
, , N
but CC N
had VBD N
no DT N
effect NN N
on IN N
overall JJ o
survival NN o
. . o

Effects NNS N
of IN N
radiotherapy NN i
were VBD N
similar JJ N
irrespective NN N
of IN N
the DT N
type NN N
of IN N
surgery NN N
, , N
except IN N
that IN N
the DT N
increase NN N
in IN N
postoperative JJ o
mortality NN o
in IN N
irradiated JJ N
patients NNS N
was VBD N
greater JJR N
in IN N
those DT N
treated VBN N
with IN N
abdominoperineal JJ N
resection NN N
. . N

Sphincter-saving JJ i
procedures NNS i
appear VBP N
to TO N
have VB N
no DT N
adverse JJ N
effects NNS N
on IN N
outcome NN N
of IN N
rectal JJ p
cancer NN p
, , N
but CC N
the DT N
optimum JJ N
use NN N
of IN N
radiotherapy NN N
is VBZ N
still RB N
to TO N
be VB N
defined VBN N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
venous JJ N
thromboembolism NN N
after IN N
knee NN p
arthroplasty NN p
. . p

A DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
comparing VBG N
enoxaparin NN i
with IN N
warfarin NN i
. . i

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effectiveness NN o
and CC o
safety NN o
of IN N
fixed-dose JJ i
enoxaparin NN i
and CC N
adjusted VBD i
dose JJ i
warfarin NN i
in IN N
preventing VBG N
venous JJ N
thromboembolism NN N
after IN p
knee NN p
arthroplasty NN p
. . p

DESIGN VB N
A DT N
randomized JJ N
, , N
double-blind JJ N
controlled VBN N
trial NN N
. . N

SETTING NN N
8 CD p
university NN p
hospitals NNS p
. . p

PATIENTS VB N
670 CD p
consecutive JJ p
patients NNS p
who WP p
had VBD p
knee VBN p
arthroplasty RB p
. . p

INTERVENTION NN N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
enoxaparin NN i
( ( i
30 CD i
mg NN i
subcutaneously RB i
every DT i
12 CD i
hours NNS i
) ) i
or CC i
adjusted-dose JJ i
warfarin NN i
( ( i
international JJ i
normalized VBN i
ratio NN i
, , i
2.0 CD i
to TO i
3.0 CD i
) ) i
. . N

Both DT N
regimens NNS N
were VBD N
started VBN N
after IN N
surgery NN N
. . N

MEASUREMENTS PDT N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
incidence NN o
of IN o
deep JJ o
venous JJ o
thrombosis NN o
in IN N
patients NNS p
with IN p
adequate JJ p
bilateral JJ p
venograms NNS p
; : p
the DT N
secondary JJ N
end NN N
point NN N
was VBD N
hemorrhage NN o
. . o

RESULTS NNP N
Among IN N
the DT N
417 CD p
patients NNS p
with IN p
adequate JJ p
venograms NNS p
, , N
109 CD N
of IN N
211 CD N
warfarin NN i
recipients NNS N
( ( N
51.7 CD N
% NN N
) ) N
had VBD N
deep JJ o
venous JJ o
thrombosis NN o
compared VBN N
with IN N
76 CD N
of IN N
206 CD N
enoxaparin NN i
recipients NNS N
( ( N
36.9 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

The DT N
absolute NN o
risk NN o
difference NN o
was VBD N
14.8 CD N
% NN N
in IN N
favor NN N
of IN N
enoxaparin NN i
( ( N
95 CD N
% NN N
Cl NNP N
, , N
5.3 CD N
% NN N
to TO N
24.1 CD N
% NN N
) ) N
Twenty-two NNP N
warfarin NN i
recipients NNS N
( ( N
10.4 CD N
% NN N
) ) N
and CC N
24 CD N
enoxaparin NN i
recipients NNS N
( ( N
11.7 CD N
% NN N
) ) N
had VBD N
proximal JJ N
venous JJ N
thrombosis NN N
( ( N
P NNP N
> NNP N
0.2 CD N
) ) N
. . N

The DT N
absolute NN o
risk NN o
difference NN o
was VBD N
1.2 CD N
% NN N
in IN N
favor NN N
of IN N
warfarin NN i
( ( N
Cl NNP N
, , N
-7.2 NNP N
% NN N
to TO N
4.8 CD N
% NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
major JJ o
bleeding NN o
was VBD N
1.8 CD N
% NN N
( ( N
6 CD N
of IN N
334 CD N
patients NNS N
) ) N
in IN N
the DT N
warfarin NN N
group NN N
and CC N
2.1 CD N
% NN N
( ( N
7 CD N
of IN N
336 CD N
patients NNS N
) ) N
in IN N
the DT N
enoxaparin NN N
group NN N
( ( N
P NNP N
> NNP N
0.2 CD N
) ) N
. . N

The DT N
absolute NN o
risk NN o
difference NN o
was VBD N
0.3 CD N
% NN N
in IN N
favor NN N
of IN N
warfarin NN N
( ( N
Cl NNP N
, , N
-2.4 NNP N
% NN N
to TO N
1.8 CD N
% NN N
) ) N
. . N

CONCLUSIONS VB N
A DT N
postoperative JJ N
, , N
fixed-dose JJ N
enoxaparin NN i
regimen NNS N
is VBZ N
more RBR N
effective JJ N
than IN N
adjusted-dose JJ N
warfarin NN i
in IN N
preventing VBG N
deep JJ N
venous JJ N
thrombosis NN N
after IN p
knee NN p
arthroplasty NN p
. . p

No DT N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
incidence NN N
of IN N
proximal JJ N
venous JJ N
thrombosis NN N
or CC N
clinically RB N
overt JJ N
hemorrhage NN N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
comparison NN N
of IN N
the DT N
multiplane NN i
probe NN i
with IN N
the DT N
biplane NN i
probe NN i
in IN N
structure NN o
visualization NN o
and CC o
Doppler NNP o
examination NN o
during IN p
transesophageal JJ p
echocardiography NN p
. . p

To TO N
compare VB N
the DT N
imaging JJ o
capability NN o
of IN N
the DT N
multiplane NN i
probe NN i
with IN N
that DT N
of IN N
the DT N
biplane NN i
probe NN i
, , N
317 CD p
consecutive JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
undergo VB N
transesophageal JJ i
echocardiography NN i
with IN i
either DT i
probe NN i
. . i

Images NNS N
of IN N
24 CD N
cardiac JJ N
structures NNS N
and CC N
nine CD o
Doppler NNP o
signals NNS o
were VBD N
graded VBN N
prospectively RB N
on IN N
a DT N
three-grade JJ N
system NN N
. . N

Both DT N
multiplane NN i
and CC i
biplane NN i
probes NNS i
provided VBD N
excellent JJ o
visualization NN o
of IN o
cardiac JJ o
structures NNS o
and CC N
Doppler NNP o
signals NNS o
, , N
but CC N
the DT N
multiplane NN i
probe NN i
was VBD N
significantly RB N
superior JJ N
to TO N
the DT N
biplane NN N
probe NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
number NN o
of IN o
attempts NNS o
at IN o
esophageal JJ o
intubation NN o
, , o
the DT o
amount NN o
of IN o
sedation NN o
used VBN o
, , o
and CC o
the DT o
examination NN o
time NN o
. . o

The DT N
number NN o
of IN o
complications NNS o
was VBD o
similar JJ o
, , N
although IN N
all DT N
failed VBD o
intubations NNS o
occurred VBD N
with IN N
the DT N
multiplane NN i
probe NN i
. . i

-DOCSTART- -X- O O

Risperidone NNP i
improves VBZ N
behavioral JJ o
symptoms NNS o
in IN N
children NNS p
with IN p
autism NN p
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

Subgroup NNP N
analysis NN N
of IN N
children NNS p
( ( p
5-12 CD p
years NNS p
) ) p
with IN p
autism NN p
enrolled VBN N
in IN N
an DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
risperidone NN i
for IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

The DT N
primary JJ N
efficacy NN N
measure NN N
was VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist-Irritability NNP o
( ( o
ABC-I NNP o
) ) o
subscale NN o
. . o

Data NNS N
were VBD N
available JJ N
for IN N
55 CD p
children NNS p
given VBN N
risperidone NN i
( ( N
n=27 JJ N
) ) N
or CC N
placebo NN i
( ( N
n=28 JJ N
) ) N
; : N
mean JJ N
baseline NN N
ABC-I NNP N
( ( N
+/- JJ N
SD NNP N
) ) N
was VBD N
20.6 CD N
( ( N
8.1 CD N
) ) N
and CC N
21.6 CD N
( ( N
10.2 CD N
) ) N
. . N

Risperidone NNP i
[ JJ N
mean NN N
dose NN N
( ( N
+/- JJ N
SD NNP N
) ) N
: : N
1.37 CD N
mg/day NN N
( ( N
0.7 CD N
) ) N
] NN N
resulted VBD N
in IN N
significantly RB N
greater JJR N
reduction NN N
from IN N
baseline NN N
to TO N
endpoint VB N
in IN N
ABC-I NNP o
versus NN N
placebo NN i
[ JJ N
mean JJ N
change NN N
( ( N
+/- JJ N
SD NNP N
) ) N
: : N
-13.4 NN N
( ( N
1.5 CD N
) ) N
vs. FW N
-7.2 NNP N
( ( N
1.4 CD N
) ) N
, , N
P NNP N
< NNP N
0.05 CD N
; : N
ES=-0.7 JJ N
] NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
effect NN N
with IN N
risperidone NN i
was VBD N
somnolence NN o
( ( N
74 CD N
% NN N
vs. FW N
7 CD N
% NN N
with IN N
placebo NN i
) ) i
. . N

Risperidone CD i
treatment NN N
was VBD N
well RB N
tolerated VBN o
and CC N
significantly RB N
improved VBN N
behavioral JJ o
problems NNS o
associated VBN N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O

[ NN N
Risk NN N
factors NNS N
for IN N
atherosclerotic JJ N
disease NN N
from IN N
the DT N
Japanese JJ p
Elderly NNP i
Diabetes NNPS i
Intervention NNP i
Trial NNP p
( ( p
J-EDIT NNP p
) ) p
] NN p
. . N

-DOCSTART- -X- O O

B-vitamins NNS i
reduce VB N
plasma NN o
levels NNS o
of IN N
beta NN N
amyloid NN N
. . N

Elevated VBN N
plasma JJ N
homocysteine NN N
( ( N
tHcy NN N
) ) N
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
Alzheimer NNP N
's POS N
disease NN N
( ( N
AD NNP N
) ) N
, , N
and CC N
thus RB N
B NNP i
vitamins NNS i
may MD N
have VB N
a DT N
role NN N
in IN N
the DT N
prevention NN N
of IN N
AD NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
tHcy JJ N
lowering NN N
vitamins NNS N
decrease VBP N
the DT N
circulating NN o
levels NNS o
of IN o
A-beta NNP o
protein NN o
1-40 JJ o
( ( o
A NNP o
beta RB o
40 CD o
) ) o
. . o

We PRP N
randomized VBD N
299 CD p
older JJR p
men NNS p
to TO N
treatment NN N
with IN N
2mg CD i
of IN i
folate NN i
, , i
plus CC i
25mg CD i
of IN i
B6 NNP i
and CC i
400 CD i
microg NN i
of IN i
B12 NNP i
, , i
or CC i
placebo NN i
. . i

After IN N
2 CD N
years NNS N
of IN N
treatment NN N
the DT N
mean NN o
( ( o
S.E NNP o
. . o

) ) o
increase NN o
of IN o
A NNP o
beta NN o
40 CD o
was VBD N
7.0 CD N
pg/ml NN N
( ( N
8.4 CD N
) ) N
in IN N
the DT N
vitamin NN N
group NN N
( ( N
4.9 CD N
% NN N
) ) N
, , N
and CC N
26.8 CD N
pg/ml NN N
( ( N
7.7 CD N
) ) N
( ( N
18.5 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
B NNP N
vitamins NNS N
may MD N
decrease VB N
the DT o
plasma JJ o
level NN o
of IN o
A NNP o
beta NN o
40 CD o
and CC N
have VBP N
a DT N
role NN N
in IN N
the DT N
prevention NN N
of IN N
AD NNP N
. . N

-DOCSTART- -X- O O

The DT N
protective JJ N
effects NNS N
of IN N
angiotensin NN N
II NNP N
blockade NN N
with IN N
olmesartan JJ i
medoxomil NN i
on IN N
resistance NN N
vessel NN N
remodeling VBG N
( ( N
The DT N
VIOS NNP N
study NN N
) ) N
: : N
rationale NN N
and CC N
baseline NN N
characteristics NNS N
. . N

BACKGROUND IN N
The DT N
VIOS NNP N
( ( N
Vascular JJ N
Improvement NN N
with IN N
Olmesartan NNP i
medoxomil NNP i
Study NNP N
) ) N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
parallel JJ N
study NN N
to TO N
determine VB N
the DT N
relative JJ N
effects NNS N
of IN N
suppressing VBG N
the DT N
renin-angiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
with IN N
the DT N
angiotensin NN N
receptor NN N
antagonist NN N
olmesartan IN i
medoxomil NN i
versus NN N
suppressing VBG N
sympathetic JJ N
drive NN N
with IN N
the DT N
beta-adrenoceptor JJ N
antagonist NN N
atenolol NN i
on IN N
remodeling NN N
of IN N
the DT N
subcutaneous JJ N
small JJ N
resistance NN N
vessel NN N
. . N

Remodeling VBG N
of IN N
small JJ N
resistance NN N
vessels NNS N
may MD N
be VB N
the DT N
earliest JJS N
pathologic NN N
finding VBG N
associated VBN N
with IN N
hypertension NN N
. . N

It PRP N
may MD N
predate VB N
the DT N
onset NN N
of IN N
clinically RB N
apparent JJ N
hypertension NN N
. . N

METHODS NNP N
In IN N
this DT N
study NN N
, , N
100 CD p
patients NNS p
with IN p
stage NN p
I PRP p
hypertension VBP p
are VBP p
characterized VBN p
at IN p
baseline NN p
before IN p
being VBG p
treated VBN p
for IN p
1 CD p
year NN p
to TO p
obtain VB p
a DT p
goal NN p
BP NNP p
of IN p
less JJR p
than IN p
140/90 CD p
mm JJ p
Hg NNP p
as IN N
defined VBN N
by IN N
Joint NNP N
National NNP N
Committee NNP N
( ( N
JNC NNP N
) ) N
-7 NN N
. . N

Resistance NNP N
vessel NN N
remodeling NN N
is VBZ N
determined VBN N
using VBG N
the DT N
gluteal NN i
fat JJ i
biopsy NN i
technique NN i
in IN N
the DT N
hypertensive JJ N
patients NNS N
and CC N
a DT N
group NN N
of IN N
normotensive JJ N
healthy JJ N
volunteers NNS N
. . N

Additionally RB N
, , N
efforts NNS N
will MD N
be VB N
made VBN N
to TO N
define VB N
whether IN N
noninvasive JJ o
hemodynamic JJ o
parameters NNS o
, , o
retinal JJ o
vessel FW o
measurement NN o
changes NNS N
, , N
or CC N
biologic JJ o
markers NNS o
may MD N
predict VB N
and CC N
track VB N
the DT N
underlying VBG N
vascular JJ o
morphologic NN o
and CC o
physiologic JJ o
changes NNS o
induced VBN N
by IN N
either DT N
regimen NNS N
during IN N
the DT N
12-month JJ N
treatment NN N
period NN N
. . N

RESULTS VB N
The DT N
primary JJ N
endpoint NN N
will MD N
be VB N
the DT N
degree NN o
of IN o
vascular JJ o
remodeling VBG o
as RB o
obtained VBN o
from IN o
percutaneous JJ o
biopsy NN o
of IN o
gluteal NN o
subcutaneous JJ o
resistance NN o
vessels NNS o
in IN N
each DT N
of IN N
two CD N
treatment NN N
arms NNS N
compared VBN N
with IN N
the DT N
normal JJ N
volunteers NNS N
. . N

The DT N
design NN N
of IN N
the DT N
study NN N
and CC N
the DT N
pertinent JJ N
baseline NN N
characteristics NNS N
of IN N
these DT N
patients NNS N
with IN N
uncomplicated JJ N
essential JJ N
hypertension NN N
are VBP N
presented VBN N
. . N

CONCLUSION VB N
The DT N
suppression NN N
of IN N
the DT N
RAS NNP N
by IN N
the DT N
blockade NN N
of IN N
angiotensin NN N
II NNP N
type NN N
1 CD N
( ( N
AT NNP N
( ( N
1 CD N
) ) N
) ) N
receptors NNS N
may MD N
demonstrate VB N
remodeling VBG N
effects NNS N
on IN N
the DT N
ubiquitous JJ N
small JJ N
resistance NN N
vessels NNS N
similar JJ N
to TO N
that DT N
seen VBN N
in IN N
the DT N
myocardium NN N
and CC N
renal JJ N
glomeruli NN N
, , N
thus RB N
affording VBG N
more JJR N
complete JJ N
end-organ JJ N
protection NN N
. . N

-DOCSTART- -X- O O

Analysis NN o
of IN o
treatment NN o
in IN N
childhood NN p
leukaemia NN p
. . p

I. NNP N
Predisposition NNP N
to TO N
methotrexate-induced JJ N
neutropenia NN N
after IN p
craniospinal JJ p
irradiation NN p
. . p

Report NNP N
to TO N
the DT N
Medical NNP N
Research NNP N
Council NNP N
of IN N
the DT N
Working NNP N
Party NNP N
on IN N
Leukaemia NNP p
in IN p
Childhood NNP p
. . p

The DT N
degree NN N
of IN N
drug-induced JJ N
neutropenia NNS o
resulting VBG N
from IN N
a DT N
controlled VBN N
trial NN N
( ( N
UKALL NNP N
I PRP N
) ) N
of IN N
treatment NN N
in IN N
acute JJ p
lymphoblastic JJ p
leukaemia NN p
was VBD N
analysed VBN N
. . N

The DT N
main JJ N
agent NN N
associated VBN N
with IN N
severe JJ o
neutropenia NN o
was VBD N
methotrexate NN i
, , N
and CC N
methotrexate-induced JJ o
neutropenia NN o
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS p
who WP p
had VBD p
received VBN p
craniospinal JJ p
irradiation NN p
. . p

The DT N
synergistic JJ o
toxic NN o
effect NN o
of IN o
irradiation NN o
followed VBN N
by IN N
methotrexate NN N
treatment NN N
seems VBZ N
to TO N
have VB N
contributed VBN N
to TO N
three CD N
of IN N
the DT N
five CD N
deaths NNS o
which WDT N
occurred VBD N
in IN N
complete JJ N
remission NN o
in IN N
this DT N
trial NN N
; : N
all DT N
deaths NNS N
in IN N
remission NN N
occurred VBD N
in IN N
patients NNS N
who WP N
had VBD N
received VBN N
central JJ N
nervous JJ N
system NN N
prophylaxis NN N
. . N

Analysis NN N
of IN N
patients NNS N
who WP N
subsequently RB N
relapsed VBD N
compared VBN N
with IN N
those DT N
still RB N
in IN N
remission NN N
after IN N
18 CD N
months NNS N
of IN N
treatment NN N
indicated VBD N
that IN N
the DT N
former JJ N
, , N
on IN N
average NN N
, , N
had VBD N
slightly RB N
lower JJR N
neutrophil NN o
counts NNS o
. . o

This DT N
suggests VBZ N
that IN N
the DT N
children NNS p
who WP N
relapsed VBD N
did VBD N
not RB N
receive VB N
any DT N
less RBR N
aggressive JJ N
treatment NN N
than IN N
those DT N
who WP N
remained VBD N
in IN N
remission NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
Low-Dose NNP i
Buspirone NNP i
for IN N
Restricted NNP N
and CC N
Repetitive NNP N
Behavior NNP N
in IN N
Young NNP p
Children NNP p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
: : p
A DT N
Randomized NNP N
Trial NNP N
. . N

OBJECTIVES NNP N
To TO N
determine VB N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
5HT1A CD i
serotonin NN i
partial JJ i
agonist NN i
buspirone NN i
on IN N
core NN N
autism NN N
and CC N
associated JJ N
features NNS N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

STUDY NNP N
DESIGN NNP N
Children NNP p
2-6 CD p
years NNS p
of IN p
age NN p
with IN p
ASD NNP p
( ( p
N NNP p
= NNP p
166 CD p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
placebo NN i
or CC N
2.5 CD N
or CC N
5.0 CD N
mg NN N
of IN N
buspirone NN i
twice JJ N
daily RB N
. . N

The DT N
primary JJ N
objective NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
24 CD N
weeks NNS N
of IN N
buspirone NN i
on IN N
the DT N
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
( ( o
ADOS NNP o
) ) o
Composite NNP o
Total NNP o
Score NNP o
. . o

Secondary JJ N
objectives NNS N
included VBD N
evaluating VBG N
the DT N
effects NNS N
of IN N
buspirone NN i
on IN N
social JJ o
competence NN o
, , o
repetitive JJ o
behaviors NNS o
, , o
language NN o
, , o
sensory JJ o
dysfunction NN o
, , o
and CC o
anxiety NN o
and CC o
to TO o
assess VB o
side JJ o
effects NNS o
. . o

Positron NNP o
emission NN o
tomography NN o
measures NNS o
of IN o
tryptophan NN o
metabolism NN o
and CC o
blood NN o
serotonin NN o
concentrations NNS o
were VBD N
assessed VBN N
as IN N
predictors NNS N
of IN N
buspirone NN i
efficacy NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
ADOS NNP o
Composite NNP o
Total NNP o
Score NNP o
between IN N
baseline NN N
and CC N
24 CD N
weeks NNS N
among IN N
the DT N
3 CD N
treatment NN N
groups NNS N
( ( N
P NNP N
= NNP N
.400 NNP N
) ) N
; : N
however RB N
, , N
the DT N
ADOS NNP o
Restricted NNP o
and CC o
Repetitive NNP o
Behavior NNP o
score NN o
showed VBD N
a DT N
time-by-treatment JJ N
effect NN N
( ( N
P NNP N
= NNP N
.006 NNP N
) ) N
; : N
the DT N
2.5-mg JJ N
buspirone NN i
group NN N
showed VBD N
significant JJ N
improvement NN N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
, , N
whereas JJ N
placebo NN i
and CC N
5.0-mg JJ N
buspirone NN i
groups NNS N
showed VBD N
no DT N
change NN N
. . N

Children NNP N
in IN N
the DT N
2.5-mg JJ N
buspirone NN i
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
improve VB N
if IN N
they PRP N
had VBD N
fewer JJR N
foci NN N
of IN N
increased JJ N
brain NN N
tryptophan NN N
metabolism NN N
on IN N
positron NN N
emission NN N
tomography NN N
( ( N
P NNP N
= NNP N
.018 NNP N
) ) N
or CC N
if IN N
they PRP N
showed VBD N
normal JJ N
levels NNS N
of IN N
blood NN N
serotonin NN N
( ( N
P NNP N
= NNP N
.044 NNP N
) ) N
. . N

Adverse JJ N
events NNS N
did VBD N
not RB N
differ VB N
significantly RB N
among IN N
treatment NN N
groups NNS N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
2.5 CD N
mg NNS N
of IN N
buspirone NN i
in IN N
young JJ p
children NNS p
with IN p
ASD NNP p
might MD N
be VB N
a DT N
useful JJ N
adjunct JJ N
therapy NN N
to TO N
target VB N
restrictive JJ N
and CC N
repetitive JJ N
behaviors NNS N
in IN N
conjunction NN N
with IN N
behavioral JJ N
interventions NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT00873509 NN N
. . N

-DOCSTART- -X- O O

Exercise NN i
for IN N
methamphetamine NN i
dependence NN p
: : p
rationale NN N
, , N
design NN N
, , N
and CC N
methodology NN N
. . N

BACKGROUND NNP N
Effective NNP N
pharmacotherapies NNS N
to TO N
treat VB N
methamphetamine NN N
( ( N
MA NNP N
) ) N
dependence NN N
have VBP N
not RB N
been VBN N
identified VBN N
, , N
and CC N
behavioral JJ N
therapies NNS N
are VBP N
marginally RB N
effective JJ N
. . N

Based VBN N
on IN N
behavioral JJ N
studies NNS N
demonstrating VBG N
the DT N
potential JJ N
efficacy NN N
of IN N
aerobic JJ i
exercise NN i
for IN N
improving VBG N
depressive JJ o
symptoms NNS o
, , o
anxiety NN o
, , o
cognitive JJ o
deficits NNS o
, , o
and CC o
substance NN o
use NN o
outcomes NNS o
, , N
the DT N
study NN N
described VBD N
here RB N
is VBZ N
examining VBG N
exercise NN i
as IN N
a DT N
potential JJ N
treatment NN N
for IN N
MA-dependent JJ p
individuals NNS p
. . p

METHODS NNP N
This DT N
study NN N
is VBZ N
randomizing VBG N
150 CD p
participants NNS p
with IN p
MA NNP p
dependence NN p
at IN p
a DT p
residential JJ p
treatment NN p
facility NN p
for IN p
addictive JJ p
disorders NNS p
to TO p
receive VB p
either RB p
a DT p
thrice-weekly JJ i
structured JJ i
aerobic NN i
and CC i
resistance NN i
exercise NN i
intervention NN i
or CC i
a DT i
health NN i
education NN i
condition NN i
. . i

Recruitment NNP N
commenced VBD N
in IN N
March NNP N
, , N
2010 CD N
. . N

Enrollment NN N
and CC N
follow-up JJ N
phases NNS N
are VBP N
ongoing VBG N
, , N
and CC N
recruitment NN N
is VBZ N
exceeding VBG N
targeted VBN N
enrollment JJ N
rates NNS N
. . N

CONCLUSIONS NNP N
Seeking NNP N
evidence NN N
for IN N
a DT N
possibly RB N
effective JJ N
adjunct NN N
to TO N
traditional JJ N
behavioral JJ N
approaches NNS N
for IN N
treatment NN N
of IN N
MA NNP o
dependence NN o
, , N
this DT N
study NN N
is VBZ N
assessing VBG N
the DT N
ability NN N
of IN N
an DT N
8-week JJ N
aerobic NN i
and CC i
resistance NN i
exercise NN i
protocol NN N
to TO N
reduce VB N
relapse NN o
to TO o
MA NNP o
use NN N
during IN N
a DT N
12-week JJ N
follow-up JJ N
period NN N
after IN N
discharge NN N
from IN N
residential-based JJ N
treatment NN N
. . N

The DT N
study NN N
also RB N
is VBZ N
evaluating VBG N
improvements NNS N
in IN N
health NN o
and CC o
functional JJ o
outcomes NNS o
during IN N
and CC N
after IN N
the DT N
protocol NN N
. . N

This DT N
paper NN N
describes VBZ N
the DT N
design NN N
and CC N
methods NNS N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O

Mending VBG N
the DT N
rhythm NN N
does VBZ N
not RB N
improve VB N
prognosis NN N
in IN N
patients NNS p
with IN p
persistent JJ p
atrial JJ p
fibrillation NN p
: : p
a DT N
subanalysis NN N
of IN N
the DT N
RACE NNP N
study NN N
. . N

AIMS NNP N
To TO N
compare VB N
outcome NN N
of IN N
AF NNP p
patients NNS p
with IN p
effective JJ p
rhythm NNS p
control NN p
with IN N
patients NNS p
treated VBN p
with IN p
rate NN p
control NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Out NNP N
of IN N
the DT N
266 CD p
AF NNP p
patients NNS p
randomized VBD p
to TO p
rhythm VB i
control NN i
in IN p
the DT p
RACE NNP p
study NN p
, , p
49 CD p
patients NNS p
turned VBD p
to TO p
long-term JJ i
sinus NN i
rhythm NN i
and CC p
were VBD p
continuously RB p
treated VBN p
with IN p
oral JJ i
anticoagulation NN i
. . i

The DT N
incidence NN N
of IN N
the DT N
primary JJ N
endpoint NN N
in IN N
these DT N
patients NNS N
was VBD N
compared VBN N
to TO N
that DT N
in IN N
178 CD N
patients NNS N
out IN N
of IN N
the DT N
initial JJ N
256 CD p
rate-control JJ p
patients NNS p
of IN p
RACE NNP p
who WP N
were VBD N
in IN N
AF NNP N
and CC N
using VBG N
oral JJ N
anticoagulation NN N
continuously RB N
. . N

Baseline NNP N
characteristics NNS N
of IN N
both DT N
groups NNS N
were VBD N
not RB N
different JJ N
. . N

After IN N
a DT N
mean JJ N
follow-up NN N
of IN N
2.3+/-0.6 CD N
years NNS N
, , N
the DT N
primary JJ N
endpoint NN N
( ( N
a DT N
composite NN o
of IN o
cardiovascular JJ o
mortality NN o
, , o
heart NN o
failure NN o
, , o
thrombo-embolic JJ o
complications NNS o
( ( o
TECs NNP o
) ) o
, , o
bleeding VBG o
, , o
serious JJ o
adverse JJ o
effects NNS o
of IN o
antiarrhythmic JJ o
drugs NNS o
and CC o
pacemaker NN o
implants NNS o
) ) o
was VBD N
22.4 CD N
% NN N
in IN N
the DT N
rhythm-control NN N
group NN N
vs. FW N
15.2 CD N
% NN N
in IN N
the DT N
rate-control NN N
group NN N
. . N

Multivariable JJ N
regression NN N
analysis NN N
indicated VBD N
coronary JJ o
artery NN o
disease NN o
, , o
heart NN o
failure NN o
, , o
and CC o
digitalis RB o
as IN N
independent JJ N
risk NN N
indicators NNS N
of IN N
cardiovascular JJ N
morbidity NN N
and CC N
mortality NN N
. . N

Chronic NNP o
sinus NN o
rhythm NN o
did VBD N
not RB N
matter NN N
. . N

CONCLUSION NNP N
Among IN N
patients NNS p
who WP p
remained VBD p
on IN p
warfarin NN i
, , N
those DT N
who WP N
mostly RB N
were VBD N
maintained VBN N
in IN N
sinus NN N
rhythm NN N
under IN N
a DT N
rhythm-control JJ N
strategy NN N
did VBD N
not RB N
have VB N
a DT N
superior JJ N
prognosis NN N
compared VBN N
to TO N
those DT N
who WP N
remained VBD N
in IN N
AF NNP N
under IN N
a DT N
rate-control JJ N
strategy NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
recent JJ p
bereavement NN p
on IN N
outcomes NNS N
in IN N
a DT N
primary JJ o
care NN o
depression NN o
intervention NN N
study NN N
. . N

OBJECTIVES NNP N
Although IN N
bereavement NN N
and CC N
depression NN N
are VBP N
both DT N
common JJ N
in IN N
older JJR N
primary JJ N
care NN N
patients NNS N
, , N
the DT N
effect NN N
of IN N
bereavement NN N
on IN N
depression NN o
intervention NN N
outcomes NNS N
is VBZ N
unknown JJ N
. . N

We PRP N
examined VBD N
whether IN N
standard JJ i
interventions NNS i
for IN N
depression NN N
in IN N
primary JJ N
care NN N
were VBD N
as IN N
effective JJ N
for IN N
bereaved VBN p
as IN p
for IN p
non-bereaved JJ p
depressed JJ p
patients NNS p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NN N
Twenty CD p
community-based JJ p
primary JJ p
care NN p
practices NNS p
in IN p
New NNP p
York NNP p
City NNP p
, , p
greater JJR p
Philadelphia NNP p
, , p
and CC p
Pittsburgh NNP p
. . p

Randomization NNP N
to TO N
either DT N
intervention NN i
or CC N
usual JJ i
care NN i
occurred VBN i
by IN i
practice NN i
. . i

PARTICIPANTS CC p
Patients NNPS p
aged VBD p
60 CD p
years NNS p
or CC p
older JJR p
who WP p
met VBD p
criteria NNS p
for IN p
major JJ p
depression NN p
or CC p
clinically RB p
significant JJ p
minor JJ p
depression NN p
( ( p
N NNP p
= NNP p
599 CD p
) ) p
. . p

Patients NNS p
who WP p
did VBD p
not RB p
complete VB p
the DT p
bereavement JJ p
measure NN p
or CC p
who WP p
were VBD p
missing VBG p
4-month JJ p
data NNS p
were VBD p
excluded VBN p
( ( p
final JJ p
N NNP p
= NNP p
417 CD p
) ) p
. . p

INTERVENTION NNP i
Study-trained JJ i
depression NN i
care NN i
managers NNS i
offered VBD i
guideline-concordant JJ i
recommendations NNS i
to TO i
primary VB i
care NN i
physicians NNS i
at IN i
intervention NN i
sites NNS i
and CC i
assisted VBD i
patients NNS i
with IN i
treatment NN i
adherence NN i
. . i

Patients NNS i
who WP i
did VBD i
not RB i
wish VB i
to TO i
take VB i
antidepressants NNS i
could MD i
receive VB i
interpersonal JJ i
psychotherapy NN i
. . i

MEASUREMENTS NNP o
Bereavement NNP o
was VBD o
captured VBN N
using VBG N
the DT o
Louisville NNP o
Older NNP o
Persons NNP o
Events NNP o
Schedule NNP o
. . o

Depression NNP o
severity NN o
was VBD o
assessed VBN N
using VBG N
the DT o
24-item JJ o
Hamilton NNP o
Depression NNP o
Rating NNP o
Scale NNP o
( ( o
HDRS NNP o
) ) o
. . o

Outcomes CC N
at IN N
4 CD N
months NNS N
were VBD o
remission NN o
( ( o
HDRS NNP o
?7 NNP o
) ) o
and CC o
response NN o
( ( o
HDRS NNP o
reduction NN N
?50 CD N
% NN N
from IN N
baseline NN N
) ) N
. . N

RESULTS NNP N
Logistic JJ N
regressions NNS N
indicated VBD N
that IN N
, , N
for IN N
non-bereaved JJ N
participants NNS o
, , o
response NN o
and CC o
remission NN o
were VBD o
higher JJR o
in IN N
intervention NN N
than IN N
usual JJ N
care NN N
. . N

However RB N
, , N
recently RB N
bereaved VBD N
older JJR N
adults NNS N
were VBD N
less RBR N
likely JJ N
to TO N
achieve VB N
response NN o
or CC o
remission NN o
at IN o
4 CD o
months NNS o
if IN N
treated VBN N
in IN N
the DT N
intervention NN N
condition NN N
. . N

CONCLUSIONS NNP N
Standard NNP N
depression NN N
care NN N
management NN N
appears VBZ N
to TO N
be VB N
ineffective JJ N
among IN N
recently RB N
bereaved VBN N
older JJR N
primary JJ N
care NN N
patients NNS N
. . N

Greater NNP N
attention NN N
should MD N
be VB N
paid VBN N
in IN N
primary JJ N
care NN N
to TO N
emotional JJ p
distress NN p
in IN p
the DT p
context NN p
of IN p
bereavement NN p
. . p

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
pentoxifylline NN i
for IN N
the DT N
treatment NN N
of IN N
recurrent NN p
aphthous JJ p
stomatitis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
pentoxifylline NN i
for IN N
the DT N
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
. . N

DESIGN VB N
A DT N
60-day JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
with IN N
a DT N
60-day JJ N
no DT N
treatment NN N
follow-up RB N
. . N

SETTING VBG N
An DT N
oral JJ N
medicine NN N
specialist NN N
referral JJ N
center NN N
in IN N
Manchester NNP N
. . N

PARTICIPANTS NNP N
Forty-nine JJ p
volunteers NNS p
who WP p
passed VBD p
the DT p
initial JJ p
assessment NN p
for IN p
recurrent NN p
aphthous JJ p
stomatitis NN p
entered VBD p
a DT p
pretrial JJ p
phase NN p
in IN p
which WDT p
their PRP$ p
eligibility NN p
for IN p
the DT p
trial NN p
phase NN p
of IN p
the DT p
study NN p
was VBD p
assessed VBN p
. . p

Sixteen JJ p
subjects NNS p
were VBD p
deemed VBN p
ineligible JJ p
, , N
and CC N
7 CD N
failed VBD N
to TO N
attend VB N
or CC N
withdrew VB N
. . N

The DT N
remaining VBG N
26 CD p
subjects NNS p
were VBD N
randomized VBN N
to TO N
placebo VB N
or CC N
treatment NN N
. . N

Six NNP N
subjects VBZ N
withdrew JJ N
because IN N
of IN N
adverse JJ N
effects NNS N
, , N
and CC N
1 CD N
was VBD N
unavailable JJ N
for IN N
follow-up NN N
. . N

INTERVENTION NNP N
Pentoxifylline NNP i
( ( N
also RB N
called VBN N
oxpentifylline NN N
) ) N
, , N
400 CD N
mg NN N
3 CD N
times NNS N
daily RB N
, , N
or CC N
matching VBG N
placebo NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
A NNP N
reduction NN N
in IN N
the DT N
median JJ o
pain NN o
score NN o
, , o
ulcer JJ o
size NN o
, , o
number NN o
of IN o
ulcers NNS o
, , o
or CC o
total JJ o
number NN o
of IN o
ulcer JJ o
episodes NNS o
. . o

RESULTS JJ N
Patients NNPS N
taking VBG N
pentoxifylline NN i
had VBD N
less JJR o
pain NN o
and CC N
reported VBD N
smaller JJR o
and CC o
fewer JJR o
ulcers NNS o
compared VBN N
with IN N
baseline NN N
. . N

Patients NNS N
taking VBG N
placebo NN i
reported VBD N
no DT o
improvement NN o
in IN N
these DT N
variables NNS N
. . N

Patients NNS N
taking VBG N
pentoxifylline NN i
also RB N
reported VBD N
more RBR o
ulcer-free JJ o
days NNS o
than IN N
those DT N
taking VBG N
placebo NN i
. . i

However RB N
, , N
the DT N
differences NNS o
were VBD o
small JJ o
and CC N
, , N
with IN N
the DT N
exception NN o
of IN o
median JJ o
ulcer NN o
size NN o
( ( N
P NNP N
= NNP N
.05 NNP N
) ) N
, , N
did VBD o
not RB o
reach VB o
statistical JJ o
significance NN o
. . o

Adverse JJ o
effects NNS o
were VBD N
common JJ N
with IN N
pentoxifylline NN i
, , N
but CC N
not RB o
significantly RB o
different JJ o
from IN N
those DT N
experienced VBN N
by IN N
patients NNS N
taking VBG N
placebo NN i
. . i

CONCLUSIONS NNP N
Although IN N
pentoxifylline NN i
may MD N
have VB N
some DT N
benefit NN N
in IN N
the DT N
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
, , N
the DT N
benefit NN N
is VBZ N
limited VBN N
. . N

It PRP N
may MD N
have VB N
a DT N
role NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
unresponsive JJ N
to TO N
other JJ N
treatments NNS N
, , N
but CC N
can MD N
not RB N
yet RB N
be VB N
recommended VBN N
as IN N
a DT N
first-line JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Risk NN i
factors NNS i
for IN i
fracture NN i
in IN p
a DT p
UK JJ p
population NN p
: : p
a DT N
prospective JJ N
cohort NN i
study NN i
. . i

BACKGROUND NNP N
Common NNP N
clinical JJ N
risk NN i
factors NNS i
for IN i
fracture NN i
in IN p
older JJR p
women NNS p
have VBP N
been VBN N
identified VBN N
. . N

To TO N
date NN N
, , N
most JJS N
of IN N
these DT N
risk NN N
factors NNS N
have VBP N
not RB N
been VBN N
confirmed VBN N
in IN N
a DT N
UK NNP p
population NN p
. . p

AIM NNP N
To TO N
confirm VB N
the DT N
important JJ N
risk NN i
factors NNS i
for IN i
fracture NN i
in IN p
older JJR p
women NNS p
. . p

DESIGN NNP N
Comprehensive NNP i
cohort NN i
study NN i
( ( i
CCS NNP i
) ) i
with IN N
a DT N
nested JJ N
randomized NN N
controlled VBD i
trial NN i
. . i

METHODS NNP N
The DT N
CCS NNP i
included VBD p
4292 CD p
women NNS p
aged VBD p
> JJ p
70 CD p
years NNS p
. . p

We PRP N
assessed VBD N
potential JJ N
risk NN i
factors NNS i
for IN i
fracture NN i
, , N
and CC N
followed-up JJ N
participants NNS N
for IN N
24 CD N
months NNS N
for IN N
incidence NN N
of IN N
non-vertebral JJ N
fractures NNS N
. . N

RESULTS NNP N
Odds NNP N
ratios NNS N
( ( N
ORs NNP N
) ) N
for IN N
predicting VBG N
any DT N
non-vertebral JJ N
fracture NN N
were VBD N
: : N
previous JJ o
fracture NN o
, , N
2.67 CD N
( ( N
95 CD N
% NN N
CI NNP N
2.10-3.40 CD N
) ) N
; : N
a DT o
fall NN o
in IN o
the DT o
last JJ o
12 CD o
months NNS o
, , N
2.06 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.63-2.59 CD N
) ) N
; : N
and CC N
age NN o
( ( N
per IN N
year NN N
increase NN N
) ) N
, , N
1.03 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.01-1.05 CD N
) ) N
. . N

ORs NNP N
for IN N
predicting VBG N
hip JJ N
fracture NN N
were VBD N
: : N
previous JJ o
fracture NN o
, , N
2.31 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.31-4.08 CD N
) ) N
; : N
low JJ o
body NN o
weight NN o
( ( N
< JJ N
58 CD N
kg NN N
) ) N
, , N
2.20 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.28-3.77 CD N
) ) N
; : N
maternal JJ o
history NN o
of IN o
hip NN o
fracture NN o
, , N
1.68 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.85-3.31 NN N
) ) N
; : N
a DT o
fall NN o
in IN o
the DT o
last JJ o
12 CD o
months NNS o
, , N
2.92 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.70-5.01 CD N
) ) N
; : N
and CC N
age NN o
( ( N
per IN N
year NN N
increase NN N
) ) N
, , N
1.09 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.04-1.13 CD N
) ) N
. . N

ORs NNP N
for IN N
predicting VBG N
wrist JJ N
fracture NN N
were VBD N
: : N
previous JJ o
fracture NN o
, , N
2.29 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.56-3.34 CD N
) ) N
; : N
and CC N
a DT o
fall NN o
in IN o
the DT o
last JJ o
12 CD o
months NNS o
, , N
1.60 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.10-2.31 CD N
) ) N
. . N

Being VBG N
a DT N
current JJ o
smoker NN o
was VBD N
not RB N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
risk NN N
, , N
and CC N
was VBD N
consistent JJ N
across IN N
all DT N
fracture NN N
types NNS N
. . N

DISCUSSION NNP N
Older NNP N
women NNS N
with IN N
the DT N
clinical JJ N
risk NN N
factors NNS N
identified VBN N
in IN N
this DT N
study NN N
should MD N
be VB N
investigated VBN N
for IN N
osteoporosis NN N
or CC N
offered VBN N
preventive JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

[ VB p
The DT p
CARESS-in-AMI NNP i
trial NN p
] NN p
. . N

-DOCSTART- -X- O O

Counselling NN i
of IN N
postnatal JJ N
depression NN N
: : N
a DT N
controlled VBN N
study NN N
on IN N
a DT N
population NN p
based VBN p
Swedish JJ p
sample NN p
. . p

In IN N
a DT N
two-stage JJ N
screening NN N
procedure NN N
using VBG N
the DT N
Edinburgh NNP o
Postnatal NNP o
Depression NNP o
Scale NNP o
( ( o
EPDS NNP o
) ) o
at IN N
8 CD N
and CC N
12 CD N
weeks NNS N
postpartum NN p
and CC N
the DT N
Montgomery-Asberg NNP o
Depression NNP o
Rating NNP o
Scale NNP o
( ( o
MADRS NNP o
) ) o
and CC N
DSM-III-R NNP o
at IN N
about RB N
13 CD N
weeks NNS N
postpartum NN N
, , N
41 CD p
women NNS p
identified VBN p
as IN p
depressed JJ p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
study NN N
and CC N
a DT N
control NN N
group NN N
. . N

The DT N
women NNS N
in IN N
the DT N
study NN N
group NN N
received VBD N
6 CD i
weekly JJ i
, , i
counselling VBG i
visits NNS i
by IN i
the DT i
Child NNP i
Health NNP i
Clinic NNP i
nurse NN i
and CC i
the DT i
control NN i
group NN i
received VBD i
routine JJ i
primary NN i
care NN i
. . i

Twelve NNP N
( ( N
80 CD N
% NN N
) ) N
of IN N
15 CD N
women NNS N
with IN N
major JJ N
depression NN N
in IN N
the DT N
study NN N
group NN N
were VBD N
fully RB o
recovered VBN o
after IN N
the DT N
intervention NN N
compared VBN N
to TO N
4 CD N
( ( N
25 CD N
% NN N
) ) N
of IN N
16 CD N
in IN N
the DT N
control NN N
group NN N
. . N

Counselling VBG i
by IN N
health NN N
nurses NNS N
is VBZ N
helpful JJ N
in IN N
managing VBG N
postnatal JJ N
depression NN N
and CC N
seems VBZ N
to TO N
work VB N
well RB N
within IN N
the DT N
Swedish JJ N
Primary NNP N
Health NNP N
Care NNP N
system NN N
. . N

-DOCSTART- -X- O O

Adherence NN N
to TO N
moderate-intensity NN i
exercise NN i
during IN N
breast NN i
cancer NN i
therapy NN i
. . i

PURPOSE VB N
The DT N
aims NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
the DT N
following JJ N
: : N
1 CD N
) ) N
to TO N
examine VB N
patterns NNS N
of IN N
adherence NN N
to TO N
a DT N
brisk JJ i
walking VBG i
program NN i
in IN N
women NNS p
receiving VBG p
adjuvant JJ i
chemotherapy NN i
or CC i
radiation NN i
therapy NN i
for IN p
newly RB p
diagnosed VBN p
breast NN p
cancer NN p
using VBG N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
experimental JJ N
design NN N
; : N
2 CD N
) ) N
to TO N
examine VB N
the DT N
influence NN N
of IN N
disease NN N
symptoms NNS N
and CC N
treatment NN N
side NN N
effects NNS N
on IN N
exercise NN i
levels NNS N
; : N
and CC N
3 CD N
) ) N
to TO N
suggest VB N
methods NNS N
that WDT N
may MD N
improve VB N
future NN N
clinical JJ N
trials NNS N
of IN N
moderate-intensity NN N
exercise NN N
in IN N
similar JJ N
populations NNS N
. . N

DESCRIPTION NNP N
OF IN N
STUDY NNP N
Fifty-two NNP p
patients NNS p
with IN p
newly RB p
diagnosed VBN p
breast NN p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatment NN N
arms NNS N
: : N
usual JJ i
care NN i
or CC N
usual JJ i
care NN i
plus CC i
exercise NN i
. . i

Those DT N
assigned VBN N
to TO N
the DT N
exercise NN i
group NN N
received VBD N
a DT N
standardized JJ i
, , i
self-administered JJ i
, , i
home-based JJ i
brisk NN i
walking VBG i
intervention NN i
in IN N
addition NN N
to TO N
usual JJ N
care NN N
. . N

Each DT N
day NN N
subjects VBZ N
completed VBN N
self-report JJ N
diary JJ N
forms NNS N
that WDT N
elicited VBD N
information NN N
about IN N
activity NN N
levels NNS N
, , N
and CC N
the DT N
occurrence NN N
of IN N
symptoms NNS N
and CC N
side JJ N
effects NNS N
during IN N
cancer NN N
treatment NN N
. . N

RESULTS NNP N
Analyses NNP N
of IN N
self-reported JJ N
daily JJ N
activity NN N
levels NNS N
revealed VBD N
a DT N
diffusion NN N
of IN N
treatment NN N
effect NN N
. . N

Fifty NNP N
percent NN N
of IN N
the DT N
usual-care JJ N
group NN N
reported VBD N
maintaining NN o
or CC o
increasing VBG o
their PRP$ o
physical JJ o
activity NN o
to TO o
a DT o
moderate-intensity JJ o
level NN o
, , N
while IN N
33 CD N
% NN N
of IN N
the DT N
exercise NN N
group NN N
did VBD N
not RB N
exercise NN N
at IN N
the DT N
prescribed NN N
levels NNS N
. . N

Analyses NNS N
of IN N
self-reported JJ o
disease NN o
symptoms NNS o
and CC o
treatment NN o
side NN o
effects NNS o
did VBD N
not RB N
reveal VB N
clinically RB N
meaningful JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

CLINICAL JJ N
IMPLICATIONS NNP N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
women NNS p
who WP N
exercised VBD N
regularly RB N
before RB N
receiving VBG N
a DT N
breast NN N
cancer NN N
diagnosis NN N
attempted VBD N
to TO N
maintain VB N
their PRP$ N
exercise NN i
programs NNS i
. . i

Women NNS p
who WP N
lead VBP N
sedentary JJ N
lifestyles NNS N
may MD N
benefit VB N
from IN N
a DT N
structured JJ i
exercise NN i
program NN i
that WDT N
includes VBZ N
information NN N
and CC N
support NN N
related VBN N
to TO N
exercise VB N
adherence NN N
strategies NNS N
. . N

-DOCSTART- -X- O O

Sunbathing VBG N
and CC N
sunbed VBN N
use NN N
related VBN N
to TO N
self-image NN N
in IN N
a DT N
randomized JJ N
sample NN N
of IN N
Swedish JJ p
adolescents NNS p
. . p

In IN N
1996 CD p
a DT p
randomized JJ p
sample NN p
of IN p
4,020 CD p
Swedish JJ p
adolescents NNS p
from IN p
three CD p
birth NN p
cohorts NNS p
were VBD N
sent VBN N
a DT N
questionnaire NN i
consisting NN N
of IN N
50 CD N
items NNS N
concerning VBG N
habitual JJ N
sun-related JJ N
behaviours NNS N
and CC N
attitudes NNS N
, , N
knowledge NN N
about IN N
melanoma NN N
, , N
risk NN N
perception NN N
and CC N
self-image NN N
. . N

A DT p
total NN p
of IN p
2,615 CD p
questionnaires NNS i
were VBD p
returned VBN p
. . p

Girls NNP p
sunbathed VBD N
and CC N
used VBD N
sunbeds NNS N
more RBR N
than IN N
boys NNS p
at IN N
all DT N
ages NNS N
. . N

Sunbathing VBG o
and CC o
sunbed VBN o
use NN o
increased VBN N
with IN N
age NN N
. . N

Boys NNS N
who WP N
were VBD N
most RBS o
satisfied JJ o
and CC N
girls NNS N
least JJS o
satisfied JJ o
with IN N
themselves PRP N
sunbathed VBD o
most JJS N
. . N

Those DT N
who WP N
were VBD N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
used VBD o
sunbeds NNS o
most RBS N
frequently RB N
. . N

Girls NNP N
reported VBD N
a DT N
higher JJR o
perceived JJ o
susceptibility NN o
to TO o
melanoma VB o
than IN N
did VBD N
boys VB N
. . N

The DT N
perception NN o
of IN o
susceptibility NN o
increased VBN N
with IN N
age NN N
. . N

Those DT N
who WP N
were VBD N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
reported VBD N
feeling VBG N
most RBS o
susceptible JJ o
. . o

The DT N
overall JJ N
main JJ N
reason NN o
for IN o
sunbathing NN o
was VBD N
appearance NN N
, , N
both DT N
for IN N
own JJ N
sunbathing NN N
, , N
and CC N
to TO N
an DT N
even RB N
higher JJR N
degree NN N
, , N
as IN N
a DT N
supposed JJ N
reason NN N
for IN N
other JJ N
adolescents NNS N
' POS N
behaviour NN N
, , N
and CC N
was VBD N
reported VBN N
most JJS N
frequently RB N
by IN N
girls NNS N
and CC N
the DT N
older JJR N
age NN N
groups NNS N
. . N

The DT N
second JJ N
most RBS N
'important JJ N
' POS N
reason NN N
for IN N
sunbathing NN N
was VBD N
'feeling VBG o
warm JJ o
and CC o
comfortable JJ o
' '' o
. . N

Preventive JJ N
programmes NNS N
aimed VBN N
at IN N
a DT N
change NN N
of IN N
sun NN N
related VBN N
behaviours NNS N
among IN N
Swedish JJ N
adolescents NNS N
have VBP N
to TO N
be VB N
tailored VBN N
to TO N
the DT N
climate NN N
and CC N
cultural JJ N
conditions NNS N
and CC N
must MD N
take VB N
into IN N
account NN N
that IN N
having VBG N
a DT N
tan NN N
, , N
and CC N
the DT N
warmth NN N
of IN N
the DT N
sun NN N
, , N
are VBP N
highly RB N
valued VBN N
by IN N
most JJS N
adolescents NNS N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
activated JJ N
charcoal NN N
in IN N
a DT N
simulated JJ N
poisoning NN p
with IN p
acetaminophen NN p
: : p
a DT N
new JJ N
loading NN N
dose NN N
for IN N
N-acetylcysteine NNP i
? . N
STUDY NNP N
OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
ability NN N
of IN N
a DT N
supranormal JJ N
dose NN N
of IN N
N-acetylcysteine NNP i
to TO N
overcome VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
N-acetylcysteine NNP N
bioavailability NN N
and CC N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
serum NN N
acetaminophen NN N
levels NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Ten NNP p
healthy JJ p
adult NN p
volunteers NNS p
participated VBD N
in IN N
a DT N
controlled JJ N
cross-over JJ N
experiment NN N
. . N

During IN N
phase NN N
I PRP N
( ( N
control NN N
) ) N
, , N
subjects VBZ N
ingested JJ N
3 CD i
g NN i
acetaminophen NN i
, , N
followed VBD N
one CD i
hour NN i
later RB i
by IN i
the DT i
normal JJ i
loading VBG i
dose NN i
of IN i
N-acetylcysteine NNP i
( ( N
140 CD N
mg/kg NN N
) ) N
. . N

During IN N
phase NN N
II NNP N
( ( N
charcoal NN N
) ) N
, , N
subjects VBZ N
ingested JJ N
3 CD i
g NN i
acetaminophen NN i
, , N
followed VBD N
one CD N
hour NN N
later RB N
by IN N
60 CD i
g NNS i
activated VBN i
charcoal NN i
and CC i
a DT i
supranormal JJ i
loading NN i
dose NN i
of IN i
N-acetylcysteine NNP i
( ( N
235 CD N
mg/kg NN N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Serum NNP o
levels NNS o
of IN o
N-acetylcysteine NNP o
were VBD N
measured VBN N
every DT N
30 CD N
minutes NNS N
for IN N
six CD N
hours NNS N
. . N

A DT N
serum NN o
acetaminophen NN o
level NN o
was VBD N
measured VBN N
at IN N
four CD N
hours NNS N
. . N

RESULTS VB N
The DT N
area NN o
under IN o
the DT o
curve NN o
for IN o
N-acetylcysteine NNP o
was VBD N
significantly RB N
higher JJR N
for IN N
phase NN N
II NNP N
than IN N
phase NN N
I PRP N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
two-tailed JJ N
paired VBD N
t-test NN N
) ) N
. . N

Peak VB o
N-acetylcysteine JJ o
and CC o
time NN o
to TO o
peak VB o
were VBD N
not RB N
significantly RB N
different JJ N
. . N

The DT N
four-hour JJ o
serum NN o
acetaminophen NN o
level NN o
was VBD N
significantly RB N
lower JJR N
for IN N
phase NN N
II NNP N
than IN N
phase NN N
I PRP N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
two-tailed JJ N
paired VBD N
t-test NN N
) ) N
. . N

Diarrhea NNP o
occurred VBD N
during IN N
both DT N
phases NNS N
, , N
but CC N
N-acetylcysteine NNP i
was VBD N
otherwise RB N
well RB N
tolerated VBN o
. . o

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
activated JJ N
charcoal NN N
can MD N
be VB N
used VBN N
safely RB N
for IN N
victims NNS p
of IN p
acetaminophen NN p
overdose NN p
. . p

A DT N
beneficial JJ N
effect NN N
in IN N
preventing VBG N
acetaminophen JJ N
absorption NN N
can MD N
be VB N
expected VBN N
if IN N
it PRP N
is VBZ N
given VBN N
within IN N
one CD N
hour NN N
after IN N
ingestion NN N
. . N

If IN N
N-acetylcysteine NNP i
is VBZ N
needed VBN N
because IN N
of IN N
a DT N
toxic JJ N
serum NN N
acetaminophen NN N
level NN N
, , N
bioavailability NN N
can MD N
be VB N
ensured VBN N
by IN N
increasing VBG N
the DT N
N-acetylcysteine JJ i
loading NN N
dose NN N
from IN N
140 CD N
mg/kg NNS N
to TO N
235 CD N
mg/kg NNS N
. . N

-DOCSTART- -X- O O

Perispinal JJ N
analgesia NN N
for IN N
labour NN p
followed VBN N
by IN N
patient-controlled JJ N
infusion NN N
with IN N
bupivacaine NN i
and CC N
sufentanil NN i
: : i
combined VBN i
spinal-epidural JJ i
vs. FW i
epidural JJ i
analgesia NN N
alone RB N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Combined NNP N
spinal-epidural JJ N
is VBZ N
an DT N
alternative JJ N
technique NN N
to TO N
epidural JJ N
analgesia NN N
for IN N
labour NN N
, , N
but CC N
its PRP$ N
benefits NNS N
are VBP N
not RB N
clearly RB N
identified VBN N
. . N

METHODS VB N
A DT N
prospective JJ N
, , N
blinded VBD N
, , N
randomized VBD N
study NN N
was VBD N
undertaken JJ N
involving VBG N
113 CD p
women NNS p
attending VBG p
a DT p
university NN p
hospital NN p
obstetric JJ p
department NN p
. . p

Analgesia NNP N
was VBD N
initiated VBN i
with IN i
intrathecal JJ i
bupivacaine NN i
0.25 CD i
% NN i
1 CD i
mL NN i
+ NNP i
sufentanil VBD i
5 CD i
microg NN i
in IN i
the DT i
combined JJ i
spinal-epidural JJ i
group NN i
( ( i
n JJ i
= NNP i
54 CD i
) ) i
, , i
and CC i
with IN i
bupivacaine JJ i
0.125 CD i
% NN i
+ JJ i
epinephrine NN i
2.5 CD i
microg NN i
mL NN i
( ( i
-1 NNP i
) ) i
+ VBD i
sufentanil $ i
7.5 CD i
microg NN i
in IN i
the DT i
epidural JJ i
group NN i
( ( i
n JJ i
= NNP i
59 CD i
) ) i
. . i

In IN i
both DT i
cases NNS i
this DT i
was VBD i
followed VBN i
by IN i
patient-controlled JJ i
epidural JJ i
analgesia NN i
with IN i
bupivacaine JJ i
0.125 CD i
% NN i
( ( i
+ JJ i
sufentanil NN i
0.25 CD i
microg NN i
mL NN i
( ( i
-1 NNP i
) ) i
) ) i
. . i

Duration NN N
of IN N
labour NN N
, , N
quality NN o
of IN o
analgesia NN o
and CC o
side-effects NNS o
were VBD N
compared VBN N
between IN N
groups NNS N
. . N

RESULTS NNP N
In IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
, , N
the DT N
onset NN o
of IN o
analgesia NN o
was VBD o
faster RBR o
( ( N
5 CD N
vs. FW N
15 CD N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
the DT N
consumption NN o
of IN o
bupivacaine NN o
was VBD o
lower JJR o
( ( N
7.5 CD N
vs. FW N
11.3 CD N
mg NN N
h NN N
( ( N
-1 NNP N
) ) N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
and CC N
there EX N
was VBD N
less JJR o
unilateral JJ o
analgesia NN o
( ( N
14.8 CD N
% NN N
vs. FW N
40.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
than IN N
in IN N
the DT N
epidural JJ N
group NN N
. . N

The DT p
characteristics NNS o
of IN o
labour NN o
were VBD p
similar JJ p
in IN p
both DT p
groups NNS p
. . p

However RB N
, , N
in IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
, , N
there EX N
was VBD N
a DT N
higher JJR o
incidence NN o
of IN o
posterior JJ o
presentation NN o
( ( N
25.9 CD N
% NN N
vs. FW N
10 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
pruritus NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
hypotension NN o
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
somnolence NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
nausea NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
one CD N
case NN N
of IN N
meningitis NN o
. . o

CONCLUSIONS VB N
The DT N
combined JJ N
spinal-epidural JJ N
technique NN N
provided VBD N
more RBR N
effective JJ N
analgesia NN N
during IN p
labour JJR p
than IN N
epidural JJ N
analgesia NN N
alone RB N
but CC N
offered VBN N
no DT N
other JJ N
advantage NN N
. . N

It PRP N
induced VBD N
more RBR N
adverse JJ N
effects NNS N
and CC N
this DT N
should MD N
be VB N
considered VBN N
before IN N
routinely RB N
using VBG N
the DT N
combined JJ N
spinal-epidural JJ N
technique NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Presentation NNP N
of IN N
a DT N
randomized JJ N
multicenter NN N
study NN N
protocol NN N
. . N

Evaluation NN N
of IN N
adjuvant JJ o
interferon NN o
effectiveness NN o
after IN N
radical JJ N
nephrectomy NN N
in IN N
kidney NN p
carcinoma NN p
with IN p
high JJ p
risk NN p
of IN p
relapse NN p
] NN p
. . N

-DOCSTART- -X- O O

A DT N
pilot NN N
study NN N
of IN N
extended JJ N
duration NN N
peginterferon NN i
alfa-2a NN i
for IN N
patients NNS p
with IN p
hepatitis NN p
B NNP p
e VBZ p
antigen-negative JJ p
chronic JJ p
hepatitis NN p
B NNP p
. . p

OBJECTIVES NNP N
Forty-eight JJ N
weeks NNS N
of IN N
peginterferon NN i
alfa-2a NN i
is VBZ N
the DT N
approved JJ N
regimen NNS N
for IN N
chronic JJ p
hepatitis NN p
B NNP p
( ( p
CHB NNP p
) ) p
. . p

Standard NNP N
interferon NN N
is VBZ N
more RBR N
effective JJ N
for IN N
hepatitis NN N
B NNP N
e NN N
antigen NN N
( ( N
HBeAg NNP N
) ) N
-negative VBP N
CHB NNP N
when WRB N
given VBN N
for IN N
longer JJR N
than IN N
1 CD N
yr NN N
. . N

This DT N
study NN N
evaluated VBD N
peginterferon JJ i
alfa-2a NN i
for IN N
60 CD N
wk NN N
, , N
alone RB N
or CC N
in IN N
combination NN N
with IN N
lamivudine NN N
. . N

METHODS NNP N
Thirteen NNP p
patients NNS p
with IN p
HBeAg-negative JJ p
CHB NNP p
received VBD N
peginterferon JJ i
alfa-2a JJ i
( ( N
180 CD N
microg/week NN N
) ) N
for IN N
60 CD N
wk NN N
or CC N
peginterferon VB i
alfa-2a JJ i
( ( N
180 CD N
microg/week NN N
) ) N
for IN N
12 CD N
wk NN N
followed VBN N
by IN N
48 CD N
wk NN N
of IN N
peginterferon NN i
alfa-2a JJ i
plus CC i
lamivudine JJ i
. . i

The DT N
primary JJ N
end NN N
point NN N
, , N
sustained VBD o
virologic JJ o
response NN o
( ( o
SVR NNP o
) ) o
, , N
was VBD N
defined VBN N
as IN N
a DT N
reduction NN N
in IN N
hepatitis NN o
B NNP o
virus NN o
deoxyribonucleic NN o
acid NN o
( ( o
HBV NNP o
DNA NNP o
) ) o
of IN N
> NNP N
or=2 FW N
log10 NN N
copies/mL NN N
and CC N
HBV NNP o
DNA NNP o
< VBD o
20,000 CD o
copies/mL NN N
at IN N
24 CD N
wk NN N
of IN N
follow-up NN N
( ( N
week NN N
84 CD N
) ) N
. . N

Hepatitis $ o
B NNP o
surface NN o
antigen NN o
( ( o
HBsAg NNP o
) ) o
concentrations NNS o
were VBD N
analyzed VBN N
and CC N
compared VBN N
to TO N
changes NNS N
in IN N
HBV NNP o
DNA NNP o
. . o

RESULTS NNP N
SVR NNP o
was VBD N
achieved VBN N
by IN N
9/13 CD N
patients NNS N
( ( N
69 CD N
% NN N
) ) N
. . N

At IN N
week NN N
84 CD N
, , N
HBV NNP o
DNA NNP o
was VBD N
undetectable JJ N
by IN N
polymerase NN N
chain NN N
reaction NN N
in IN N
5/13 CD N
( ( N
38 CD N
% NN N
) ) N
patients NNS N
, , N
and CC N
3 CD N
additional JJ N
patients NNS N
had VBD N
a DT N
sustained VBN N
2-3 CD N
log NN o
reduction NN o
in IN o
HBV NNP o
DNA NNP o
. . o

Five CD N
patients NNS N
demonstrated VBD N
a DT N
> JJ N
90 CD N
% NN N
decrease NN N
in IN N
HBsAg NNP o
concentration NN o
at IN N
week NN N
60 CD N
, , N
including VBG N
3 CD N
with IN N
undetectable JJ N
HBV NNP o
DNA NNP o
at IN N
week NN N
84 CD N
and CC N
a DT N
fourth JJ N
who WP N
met VBD N
criteria NNS N
for IN N
SVR NNP o
. . o

CONCLUSIONS NNP N
Sixty NNP N
weeks NNS N
of IN N
peginterferon NN i
alfa-2a NN i
with IN N
or CC N
without IN N
lamivudine JJ N
resulted VBN N
in IN N
a DT N
higher JJR N
rate NN N
of IN N
SVR NNP o
compared VBN N
to TO N
historical JJ N
controls NNS N
with IN N
HBeAg-negative JJ p
CHB NNP p
treated VBD N
with IN N
48 CD N
wk NN N
of IN N
pegylated JJ i
interferon NN i
. . i

Larger JJR N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
if IN N
longer JJR N
duration NN N
therapy NN N
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
standard JJ N
regimen NNS N
and CC N
results NNS N
in IN N
a DT N
greater JJR N
decline NN N
in IN N
HBsAg NNP o
concentration NN o
. . N

-DOCSTART- -X- O O

Evaluating VBG N
the DT N
impact NN N
of IN N
peer NN i
, , i
nurse JJ i
case-managed JJ i
, , i
and CC i
standard JJ i
HIV NNP i
risk-reduction NN i
programs NNS i
on IN N
psychosocial JJ o
and CC o
health-promoting JJ o
behavioral JJ o
outcomes NNS o
among IN N
homeless JJ p
women NNS p
. . p

Investigators NNS N
examined VBD N
the DT N
6-month JJ N
impact NN N
of IN N
three CD N
cognitive-behavioral JJ i
HIV NNP i
risk-reduction NN i
programs NNS i
on IN N
behavioral JJ o
factors NNS o
( ( N
substance NN N
use NN N
and CC N
sexual JJ N
risk NN N
behaviors NNS N
) ) N
and CC N
cognitive JJ o
and CC o
psychological JJ o
resources NNS o
of IN N
325 CD p
women NNS p
who WP p
resided VBD p
in IN p
emergency NN p
or CC p
sober-living NN p
shelters NNS p
and CC p
their PRP$ p
308 CD p
intimate JJ p
sexual JJ p
partners NNS p
. . p

Participants NNS N
were VBD N
randomized VBN N
by IN N
shelter NN N
to TO N
a DT N
peer-mentored JJ o
, , o
a DT o
nurse JJ o
case-managed JJ o
, , o
or CC o
a DT o
standard JJ o
care NN o
HIV NNP o
risk-reduction NN o
program NN i
. . i

Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
all DT N
groups NNS N
in IN N
all DT N
behavioral JJ o
factors NNS o
and CC o
cognitive JJ o
and CC o
psychological JJ o
resources NNS o
except IN N
for IN N
self-esteem NN o
. . o

Participants NNS N
in IN N
the DT N
peer-mentored JJ i
and CC i
nurse JJ i
case-managed JJ i
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
from IN N
the DT N
standard JJ i
group NN i
in IN N
self-esteem NN o
, , o
life NN o
satisfaction NN o
, , o
psychological JJ o
well-being NN o
, , o
use NN o
of IN o
noninjection NN o
drugs NNS o
, , o
sex NN o
with IN o
multiple JJ o
partners NNS o
, , o
and CC o
unprotected JJ o
sex NN o
at IN N
6 CD N
months NNS N
( ( N
n JJ N
= NNP N
633 CD N
) ) N
. . N

It PRP N
was VBD N
concluded VBN N
that IN N
a DT N
standard JJ N
approach NN N
by IN N
health NN N
care NN N
professionals NNS N
appears VBZ N
to TO N
effectively RB N
modify VB o
HIV NNP o
risk NN o
behaviors NNS o
for IN N
a DT N
majority NN N
of IN N
homeless JJ p
participants NNS p
and CC N
may MD N
have VB N
important JJ N
economic JJ N
and CC N
policy NN N
implications NNS N
. . N

Further NNP N
, , N
the DT N
impact NN N
of IN N
short-term JJ N
programs NNS N
that WDT N
address VBP N
psychological JJ N
vulnerabilities NNS N
of IN N
impoverished JJ p
populations NNS p
needs NNS N
to TO N
be VB N
studied VBN N
further JJ N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS o
of IN N
improvisational JJ i
music NN i
therapy NN i
on IN N
joint JJ N
attention NN N
behaviors NNS N
in IN N
autistic JJ p
children NNS p
: : p
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS o
of IN N
improvisational JJ i
music NN i
therapy NN i
on IN N
joint JJ N
attention NN N
behaviors NNS N
in IN N
pre-school JJ p
children NNS p
with IN p
autism NN p
. . p

It PRP N
was VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
employing VBG N
a DT N
single JJ N
subject NN N
comparison NN N
design NN N
in IN N
two CD N
different JJ N
conditions NNS N
, , N
improvisational JJ i
music NN i
therapy NN i
and CC i
play NN i
sessions NNS i
with IN i
toys NNS i
, , N
and CC N
using VBG N
standardized JJ N
tools NNS N
and CC N
DVD NNP N
analysis NN N
of IN N
sessions NNS N
to TO N
evaluate VB N
behavioral JJ N
changes NNS N
in IN N
children NNS p
with IN p
autism NN p
. . p

The DT N
overall JJ o
results NNS o
indicated VBD N
that IN N
improvisational JJ N
music NN N
therapy NN N
was VBD N
more RBR o
effective JJ o
at IN N
facilitating VBG o
joint JJ o
attention NN o
behaviors NNS o
and CC o
non-verbal JJ o
social JJ o
communication NN o
skills NNS o
in IN N
children NNS N
than IN N
play NN N
. . N

Session NN N
analysis NN N
showed VBD N
significantly RB o
more RBR o
and CC o
lengthier JJR o
events NNS o
of IN o
eye NN o
contact NN o
and CC o
turn-taking NN o
in IN N
improvisational JJ i
music NN i
therapy NN i
than IN N
play NN N
sessions NNS N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
further RBR N
. . N

-DOCSTART- -X- O O

Enhancing VBG N
the DT N
experience NN p
of IN p
carers NNS p
in IN p
the DT p
chemotherapy NN p
outpatient JJ p
setting NN p
: : p
an DT N
exploratory NN N
randomised VBD N
controlled VBN N
trial NN N
to TO N
test VB N
impact NN N
, , N
acceptability NN N
and CC N
feasibility NN N
of IN N
a DT N
complex JJ i
intervention NN i
co-designed VBN N
by IN N
carers NNS p
and CC p
staff NN p
. . p

PURPOSE NNP N
Supporting VBG N
someone NN N
through IN N
chemotherapy NN N
can MD N
be VB N
emotionally RB N
and CC N
physically RB N
demanding VBG N
. . N

However RB N
, , N
research NN N
has VBZ N
yet RB N
to TO N
establish VB N
the DT N
type NN N
of IN N
support NN N
carers NNS N
require VBP N
or CC N
the DT N
best JJS N
way NN N
to TO N
provide VB N
this DT N
. . N

This DT N
study NN N
tested VBD N
the DT N
feasibility NN N
and CC N
acceptability NN N
of IN N
a DT N
complex JJ N
intervention NN N
for IN N
carers NNS p
that WDT p
was VBD p
co-designed VBN p
by IN p
staff NN p
and CC p
carers NNS p
of IN p
patients NNS p
starting VBG p
chemotherapy NN i
. . i

METHODS NNP N
Forty-seven JJ p
carers NNS p
were VBD p
recruited VBN p
, , p
randomised VBN p
between IN p
the DT p
intervention NN i
( ( p
n JJ p
= NNP p
24 CD p
) ) p
and CC p
control NN i
( ( p
n JJ p
= NNP p
23 CD p
) ) p
groups NNS p
. . p

A DT N
questionnaire NN i
was VBD N
completed VBN N
pre- JJ N
and CC N
post-intervention JJ N
measuring NN N
knowledge NN N
of IN N
chemotherapy NN o
and CC N
its PRP$ N
side NN N
effects NNS N
, , N
experience NN N
of IN N
care NN N
, , N
satisfaction NN N
with IN N
outpatient NN N
services NNS N
, , N
coping VBG N
and CC N
emotional JJ N
wellbeing NN N
. . N

The DT N
intervention NN p
process NN p
was VBD N
evaluated VBN N
by IN N
carers NNS N
and CC N
healthcare NN N
professionals NNS N
( ( N
HCPs NNP N
) ) N
in IN N
focus NN p
groups NNS p
. . p

RESULTS NNP N
Recruitment NNP N
to TO N
the DT N
study NN N
was VBD N
unproblematic JJ N
and CC N
attrition NN N
from IN N
it PRP N
was VBD N
low JJ N
, , N
suggesting VBG N
the DT N
intervention NN N
and CC N
study NN N
processes NNS N
were VBD N
acceptable JJ N
to TO N
patients NNS N
and CC N
carers NNS N
. . N

Carers NNS N
in IN N
receipt NN N
of IN N
the DT N
'Take NNP N
Care NNP N
' POS N
intervention NN N
reported VBD N
statistically RB N
significantly RB N
better RBR N
understanding NN N
of IN N
symptoms NNS N
and CC N
side JJ N
effects NNS N
and CC N
their PRP$ N
information NN N
needs VBZ N
being VBG N
more RBR N
frequently RB N
met VBN N
than IN N
carers NNS N
in IN N
the DT N
control NN N
. . N

Confidence NN N
in IN N
coping VBG N
improved VBN N
between IN N
baseline NN N
and CC N
follow-up NN N
for IN N
the DT N
intervention NN N
group NN N
and CC N
declined VBD N
for IN N
the DT N
control NN N
although IN N
differences NNS N
were VBD N
insufficient JJ N
to TO N
achieve VB N
statistical JJ N
significance NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
' POS N
emotional JJ N
wellbeing NN N
. . N

HCP NNP N
and CC N
carer NN N
focus NN N
groups NNS N
confirmed VBD N
the DT N
feasibility NN o
and CC o
acceptability NN o
of IN N
the DT N
intervention NN N
. . N

CONCLUSIONS VB N
The DT N
'Take NNP N
Care NNP N
' POS N
intervention NN N
proved VBD N
acceptable JJ N
to TO N
carers NNS p
and CC p
HCPs NNP p
and CC N
demonstrates VBZ N
considerable JJ N
promise NN N
and CC N
utility NN N
in IN N
practice NN N
. . N

Study NNP N
findings NNS N
support VBP N
the DT N
conduct NN N
of IN N
a DT N
fully RB N
powered VBN N
RCT NNP N
to TO N
determine VB N
the DT N
intervention NN N
's POS N
effectiveness NN N
and CC N
cost-effectiveness NN N
. . N

-DOCSTART- -X- O O

Misoprostol NNP i
versus NN N
oxytocin NN i
for IN N
the DT N
reduction NN N
of IN N
postpartum NN o
blood NN o
loss NN o
. . o

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
400 CD N
mug NN N
of IN N
oral JJ i
misoprostol NN i
with IN N
5 CD N
U NNP N
of IN N
intravenous JJ i
oxytocin NNS i
in IN N
the DT N
reduction NN N
of IN N
postpartum NN o
blood NN o
loss NN o
and CC N
prevention NN N
of IN N
postpartum NN N
hemorrhage NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
controlled VBN N
trial NN p
conducted VBN p
in IN p
a DT p
tertiary JJ p
maternity NN p
hospital NN p
622 CD p
women NNS p
received VBD N
either RB N
400 CD N
mug NN N
of IN N
oral JJ i
misoprostol NN i
or CC N
5 CD N
U NNP N
of IN N
intravenous JJ i
oxytocin NNS i
after IN N
delivery NN N
of IN N
the DT N
anterior JJ N
shoulder NN N
or CC N
within IN N
1 CD N
min NNS N
of IN N
delivery NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
a DT N
hematocrit JJ o
drop NN o
of IN o
10 CD o
% NN o
or CC o
greater JJR o
24 CD o
h NN o
postpartum NN o
. . o

The DT N
secondary JJ N
outcomes NNS N
were VBD N
a DT N
hemoglobin JJ o
drop NN o
of IN o
30 CD o
mg/L NN o
or CC o
greater JJR o
, , o
the DT o
use NN o
of IN o
additional JJ o
oxytocin NN o
, , o
an DT o
estimated VBN o
blood NN o
loss NN o
greater JJR o
than IN o
1000 CD o
mL NN o
, , o
manual JJ o
removal NN o
of IN o
the DT o
placenta NN o
, , o
a DT o
blood NN o
transfusion NN o
, , o
and CC o
shivering VBG o
and CC o
fever NN o
( ( o
> JJ o
or=38 NN o
degrees NNS o
C NNP o
) ) o
as IN o
adverse JJ o
effects NNS o
of IN o
misoprostol NN o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
regarding VBG N
the DT N
primary JJ N
outcome NN N
( ( N
a DT N
> NN N
or=10 NN N
% NN N
hematocrit JJ o
drop NN o
occurred VBD N
in IN N
3.4 CD N
% NN N
and CC N
3.7 CD N
% NN N
of IN N
the DT N
participants NNS N
in IN N
the DT N
oxytocin NN i
and CC N
misoprostol NN i
groups NNS N
, , N
P=0.98 NNP N
) ) N
. . N

The DT N
rate NN N
of IN N
use NN o
of IN o
additional JJ o
oxytocin NN o
was VBD N
higher RBR N
in IN N
the DT N
misoprostol NN i
group NN N
( ( N
51 CD N
% NN N
versus IN N
40.5 CD N
% NN N
, , N
P=0.01 NNP N
) ) N
. . N

Shivering VBG o
was VBD N
confined VBN N
to TO N
the DT N
misoprostol NN i
group NN N
( ( N
6.8 CD N
% NN N
) ) N
, , N
and CC N
fever RB N
occurred VBD N
in IN N
12.5 CD N
% NN N
of IN N
the DT N
women NNS N
in IN N
the DT N
misoprostol NN i
group NN N
and CC N
0.3 CD N
% NN N
of IN N
the DT N
women NNS N
in IN N
the DT N
oxytocin NN i
group NN N
. . N

CONCLUSION NNP N
The DT N
routine JJ N
use NN N
of IN N
400 CD N
microg NN N
of IN N
oral JJ N
misoprostol NN i
was VBD N
no DT N
less RBR N
effective JJ N
than IN N
5 CD N
U NNP N
of IN N
intravenous JJ N
oxytocin NNS i
in IN N
reducing VBG N
blood NN o
loss NN o
after IN N
delivery NN N
, , N
as IN N
assessed VBN N
by IN N
change NN N
in IN N
postpartum NN N
hematocrit NN N
. . N

The DT N
adverse JJ N
effects NNS N
of IN N
misoprostol NN i
were VBD N
mild JJ N
and CC N
self-limiting JJ N
. . N

-DOCSTART- -X- O O

Blockade NN N
of IN N
cytotoxic JJ N
T-lymphocyte JJ N
antigen-4 NN N
by IN N
ipilimumab JJ i
results NNS N
in IN N
dysregulation NN N
of IN N
gastrointestinal JJ N
immunity NN N
in IN N
patients NNS p
with IN p
advanced JJ p
melanoma NN p
. . p

Blockade NNP N
of IN N
cytotoxic JJ N
T-lymphocyte JJ N
antigen-4 NN N
( ( N
CTLA-4 NNP N
) ) N
by IN N
ipilimumab NN N
leads NNS N
to TO N
immune-mediated JJ N
tumor NN N
regression NN N
and CC N
immune-related JJ N
adverse JJ N
events NNS N
( ( N
irAEs NN N
) ) N
, , N
including VBG N
diarrhea NN N
and CC N
colitis NN N
. . N

The DT N
current JJ N
analyses NNS N
were VBD N
undertaken JJ N
to TO N
promote VB N
an DT N
understanding NN N
of IN N
the DT N
underlying VBG N
mechanism NN N
of IN N
action NN N
and CC N
to TO N
identify VB N
potential JJ N
biomarkers NNS N
that WDT N
could MD N
help VB N
in IN N
the DT N
prediction NN N
and CC N
management NN N
of IN N
ipilimumab-induced JJ N
gastrointestinal JJ N
irAEs NN N
. . N

Treatment-na?ve CD p
or CC p
previously RB p
treated VBN p
patients NNS p
with IN p
unresectable JJ p
stage NN p
III/IV NNP p
melanoma NN p
( ( p
n JJ p
= NNP p
115 CD p
) ) p
received VBD i
open-label JJ i
ipilimumab NN i
( ( i
10 CD i
mg/kg NN i
every DT i
3 CD i
weeks NNS i
for IN i
four CD i
doses NNS i
) ) i
and CC i
were VBD i
randomized VBN i
to TO i
receive VB i
concomitant NN i
blinded VBN i
prophylactic JJ i
oral JJ i
budesonide NN i
( ( i
9 CD i
mg/d NN i
with IN i
gradual JJ i
taper NN i
through IN i
week NN i
16 CD i
) ) i
or CC i
placebo NN i
. . i

Outcome NNP i
measures NNS N
included VBD o
histologic JJ o
assessment NN o
of IN o
bowel NN o
biopsies NNS o
and CC o
assessment NN o
of IN o
serologic JJ o
markers NNS o
of IN o
inflammatory JJ o
bowel NN o
disease NN o
( ( o
IBD NNP o
) ) o
, , o
fecal JJ o
calprotectin NN o
levels NNS o
, , o
and CC o
polymorphisms NNS o
in IN o
immune-related JJ o
genes NNS o
. . o

Ipilimumab NNP o
resulted VBD i
in IN N
dysregulation NN N
of IN N
gastrointestinal JJ N
mucosal NN N
immunity NN N
as IN N
evidenced VBN N
by IN N
altered JJ N
antibody NN N
levels NNS o
to TO o
enteric VB o
flora NNS o
, , o
inflammatory NN o
cell NN o
infiltration NN o
into IN o
gastrointestinal JJ o
mucosa NN o
, , o
and CC o
increased VBD o
fecal JJ o
calprotectin NN o
associated VBN o
with IN o
diarrhea NN o
and CC o
clinical JJ o
evidence NN o
of IN o
colitis NN o
. . o

The DT o
pattern NN N
of IN N
ipilimumab-induced JJ N
antibody NN N
titers NNS N
to TO N
microbial JJ N
flora NN N
and CC N
the DT N
histologic NN N
features NNS N
and CC N
location NN N
of IN N
the DT N
inflammation NN N
were VBD N
distinct JJ N
from IN N
classic JJ N
IBD NNP N
. . N

Prophylactic NNP i
budesonide NN i
did VBD i
not RB N
prevent VB o
ipilimumab-induced JJ o
bowel NN o
inflammation NN o
. . o

Despite IN o
an DT N
observed JJ N
association NN N
between IN N
colonic JJ N
inflammation NN N
and CC N
grade VB N
2 CD N
or CC N
higher JJR N
diarrhea NN o
, , o
no DT o
baseline NN N
biomarkers NNS N
could MD N
reliably RB N
predict VB N
development NN N
of IN N
gastrointestinal JJ N
toxicity NN N
. . N

Although IN N
classic JJ N
IBD NNP N
and CC N
ipilimumab-related JJ N
gastrointestinal JJ N
toxicity NN N
are VBP N
both DT N
immune JJ N
mediated VBN N
, , N
the DT N
observed JJ N
pattern NN N
of IN N
biomarkers NNS N
suggests VBZ N
ipilimumab-related JJ N
gastrointestinal JJ N
toxicity NN N
may MD N
be VB N
a DT N
distinct JJ N
clinicopathologic NN N
entity NN N
. . N

-DOCSTART- -X- O O

Safety NN o
of IN N
the DT N
combination NN i
of IN i
valsartan NN i
and CC i
benazepril NN i
in IN N
patients NNS p
with IN p
chronic JJ p
renal JJ p
disease NN p
. . p

European JJ N
Group NNP N
for IN N
the DT N
Investigation NNP N
of IN N
Valsartan NNP i
in IN N
Chronic NNP N
Renal NNP N
Disease NNP N
. . N

OBJECTIVE NNP N
Several JJ N
experimental JJ N
and CC N
clinical JJ N
studies NNS N
indicate VBP N
that IN N
the DT N
renin NN N
system NN N
may MD N
play VB N
a DT N
pivotal JJ N
role NN N
in IN N
progressing VBG N
renal JJ N
disease NN N
. . N

The DT N
combination NN N
of IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
and CC N
an DT N
angiotensin NN N
receptor NN N
blocker NN N
could MD N
provide VB N
a DT N
higher JJR N
degree NN N
of IN N
blockade NN N
of IN N
the DT N
renin-angiotensin NN N
system NN N
than IN N
either DT N
agent JJ N
alone RB N
. . N

Such JJ N
enhanced JJ N
suppression NN N
might MD N
be VB N
of IN N
benefit NN N
for IN N
patients NNS p
exhibiting VBG p
a DT p
progressive JJ p
decline NN p
in IN p
renal JJ p
function NN p
because IN p
of IN p
chronic JJ p
renal JJ p
disease NN p
. . p

METHODS NNP N
A NNP N
pilot NN N
multinational NN N
, , N
multicentre NN N
, , N
randomized VBN N
, , N
active-controlled JJ N
, , N
parallel JJ N
group NN N
open-label JJ N
study NN N
has VBZ N
been VBN N
conducted VBN N
in IN N
a DT N
group NN p
of IN p
patients NNS p
with IN p
progressive JJ p
chronic JJ p
renal JJ p
failure NN p
( ( p
creatinine JJ p
clearance NN p
20-45 JJ p
ml/min NN p
) ) p
either CC p
with IN p
or CC p
without IN p
proteinuria NNS p
and CC p
hypertension NN p
. . p

The DT N
primary JJ N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
safety NN o
and CC o
tolerability NN o
of IN N
the DT N
combination NN i
of IN i
valsartan NN i
and CC i
benazepril NN i
. . i

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
group NN N
1 CD N
received VBD N
valsartan JJ i
160 CD i
mg NN i
once RB N
daily JJ N
( ( p
n JJ p
= NNP p
22 CD p
) ) p
; : p
group NN N
2 CD N
received VBD N
valsartan JJ i
80 CD i
mg NN i
once RB i
daily JJ i
plus CC i
benazepril JJ i
5 CD i
or CC i
10 CD i
mg NNS i
once RB i
daily JJ i
( ( p
n JJ p
= NNP p
42 CD p
) ) p
; : p
group NN N
3 CD N
received VBD N
valsartan JJ i
160 CD i
mg NN i
once RB N
daily JJ N
plus CC i
benazepril JJ i
5 CD i
or CC i
10 CD i
mg NNS i
once RB N
daily JJ N
( ( p
n JJ p
= NNP p
44 CD p
) ) p
. . N

The DT N
study NN N
lasted VBD N
for IN N
5 CD N
weeks NNS N
, , N
and CC N
in IN N
groups NNS N
2 CD N
and CC N
3 CD N
benazepril NN N
was VBD N
added VBN N
on IN N
top NN N
of IN N
valsartan NN N
after IN N
the DT N
first JJ N
week NN N
of IN N
therapy NN N
with IN N
the DT N
angiotensin NN N
receptor NN N
blocker NN N
. . N

RESULTS NNP N
Serum NNP o
creatinine NN o
increased VBN N
in IN N
all DT N
three CD N
groups NNS N
( ( N
mean JJ N
change NN N
within IN N
a DT N
group NN N
: : N
11 CD N
micromol/l NN N
in IN N
group NN N
1 CD N
, , N
P= NNP N
0.045 CD N
; : N
9 CD N
micromol/l NN N
in IN N
group NN N
2 CD N
, , N
P= NNP N
0.030 CD N
; : N
15 CD N
micromol/l NN N
in IN N
group NN N
3 CD N
, , N
P= NNP N
0.0006 CD N
) ) N
. . N

Serum NNP o
potassium NN o
also RB N
increased VBN N
in IN N
all DT N
three CD N
groups NNS N
of IN N
patients NNS N
( ( N
mean JJ N
change NN N
within IN N
a DT N
group NN N
: : N
0.28 CD N
mmol/l NN N
in IN N
group NN N
1 CD N
, , N
P= NNP N
0.28 CD N
; : N
0.48 CD N
mmol/l NN N
in IN N
group NN N
2 CD N
, , N
P= NNP N
0.0008 CD N
; : N
0.36 CD N
mmol/l NN N
in IN N
group NN N
3 CD N
, , N
P= NNP N
0.02 CD N
) ) N
. . N

After IN N
5 CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
largest JJS N
decrease NN N
in IN N
blood NN o
pressure NN o
was VBD N
observed VBN N
in IN N
group NN N
3 CD N
( ( N
the DT N
mean NN N
change NN N
from IN N
baseline NN N
in IN N
seated VBN o
diastolic JJ o
blood NN o
pressure NN o
( ( o
SDBP NNP o
) ) o
and CC N
seated VBN o
systolic JJ o
blood NN o
pressure NN o
( ( o
SSBP NNP o
) ) o
, , N
respectively RB N
, , N
were VBD N
: : N
-2.0 NN N
and CC N
-11.5 NNP N
mmHg NN N
in IN N
group NN N
1 CD N
; : N
-7.6 NNS N
and CC N
-15.4 NNP N
mmHg NN N
in IN N
group NN N
2 CD N
; : N
-12.6 NNS N
and CC N
-21.6 NNP N
mmHg NN N
in IN N
group NN N
3 CD N
) ) N
. . N

In IN N
addition NN N
, , N
both DT N
combination NN N
treatments NNS N
resulted VBD N
in IN N
the DT N
reduction NN N
of IN N
proteinuria NN o
. . o

The DT N
total JJ o
number NN o
of IN o
patients NNS o
with IN N
adverse JJ o
experiences NNS o
were VBD N
10 CD N
( ( N
45.5 CD N
% NN N
) ) N
, , N
14 CD N
( ( N
33.3 CD N
% NN N
) ) N
and CC N
11 CD N
( ( N
25 CD N
% NN N
) ) N
in IN N
groups NNS N
1,2 CD N
and CC N
3 CD N
, , N
respectively RB N
. . N

In IN N
six CD N
patients NNS N
( ( N
5.6 CD N
% NN N
) ) N
therapy NN N
was VBD N
discontinued VBN N
as IN N
a DT N
result NN N
of IN N
adverse JJ o
experiences NNS o
. . o

Only RB N
one CD N
patient NN N
in IN N
each DT N
of IN N
the DT N
combined JJ N
therapy NN N
groups NNS N
withdrew VBD N
from IN N
the DT N
study NN N
because IN N
of IN N
hyperkalaemia NN o
and CC N
no DT N
patients NNS N
were VBD N
forced VBN N
to TO N
withdraw VB N
because IN N
of IN N
an DT N
increase NN N
in IN N
serum JJ o
creatinine NN o
, , o
acute JJ o
renal JJ o
failure NN o
or CC o
hospitalization NN o
. . o

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN N
short-term JJ N
combination NN N
of IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
and CC N
an DT N
angiotensin NN N
receptor NN N
blocker NN N
is VBZ N
safe JJ o
and CC N
well RB o
tolerated VBN o
in IN N
patients NNS p
with IN p
moderate JJ p
chronic JJ p
renal JJ p
failure NN p
. . p

-DOCSTART- -X- O O

The DT N
impact NN N
of IN N
the DT N
amount NN N
of IN N
social JJ i
evaluation NN i
on IN N
psychobiological JJ N
responses NNS N
to TO N
a DT N
body NN p
image NN p
threat NN p
. . p

The DT N
present JJ N
study NN N
examined VBD N
the DT N
impact NN N
of IN N
amount NN N
of IN N
social-evaluative JJ N
body NN N
image NN N
threat NN N
on IN N
psychobiological JJ N
responses NNS N
. . N

Women NNP p
( ( p
N=123 NNP p
) ) p
were VBD p
randomized VBN p
into IN p
an DT p
individual-threat JJ p
, , p
group-threat JJ p
or CC p
no-threat JJ p
condition NN p
. . p

Participants NNS N
completed VBD N
a DT N
measure NN N
of IN N
state NN i
body NN i
shame NN i
and CC N
provided VBD N
a DT N
sample NN N
of IN N
saliva NN N
( ( N
to TO N
assess VB N
cortisol NN N
) ) N
at IN N
baseline NN N
and CC N
following VBG N
their PRP$ N
condition NN N
. . N

Both DT N
threat NN N
conditions NNS N
had VBD N
higher JJR N
baseline-adjusted JJ N
body NN N
shame NN N
following VBG N
the DT N
threat NN N
compared VBN N
to TO N
the DT N
no-threat JJ N
condition NN N
; : N
however RB N
, , N
no DT N
difference NN N
on IN N
baseline-adjusted JJ N
body NN N
shame NN N
between IN N
the DT N
threat NN N
conditions NNS N
was VBD N
found VBN N
. . N

The DT N
same JJ N
pattern NN N
of IN N
results NNS N
was VBD N
found VBN N
for IN N
cortisol NN N
- : N
both DT N
threat NN N
conditions NNS N
had VBD N
higher JJR N
baseline-adjusted JJ N
response NN N
cortisol NN N
than IN N
the DT N
no-threat JJ N
condition NN N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
threat NN N
groups NNS N
. . N

Findings NNS N
suggest VBP N
that IN N
the DT N
magnitude NN N
of IN N
psychobiological JJ N
responses NNS N
to TO N
a DT N
social-evaluative JJ N
body NN N
image NN N
threat NN N
does VBZ N
not RB N
differ VB N
with IN N
the DT N
amount NN N
of IN N
social-evaluative JJ N
threat NN N
( ( N
individual- JJ N
versus IN N
group-threat NN N
) ) N
. . N

These DT N
findings NNS N
provide VBP N
insight RB N
into IN N
the DT N
context NN N
of IN N
body NN N
image NN N
threats NNS N
of IN N
women NNS p
. . p

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
long-term JJ N
vitamin NN i
D NNP i
and CC N
calcium NN i
supplementation NN i
on IN N
falls NNS o
and CC o
parameters NNS o
of IN o
muscle NN o
function NN o
in IN N
community-dwelling JJ p
older NN p
individuals NNS p
. . p

UNLABELLED NN N
In IN N
242 CD p
community-dwelling JJ p
seniors NNS p
, , N
supplementation NN N
with IN N
either DT N
1000 CD N
mg NN N
of IN N
calcium NN i
or CC N
1000 CD N
mg NN N
of IN N
calcium NN i
plus CC i
vitamin NN i
D NNP i
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
the DT N
number NN N
of IN N
subjects NNS N
with IN N
first JJ N
falls NNS N
of IN N
27 CD N
% NN N
at IN N
month NN N
12 CD N
and CC N
39 CD N
% NN N
at IN N
month NN N
20 CD N
. . N

Additionally RB N
, , N
parameters NNS N
of IN N
muscle NN o
function NN o
improved VBD N
significantly RB N
. . N

INTRODUCTION NNP N
The DT N
efficacy NN N
of IN N
vitamin NN i
D NNP i
and CC N
calcium NN i
supplementation NN N
on IN N
risk NN o
of IN o
falling VBG o
in IN N
the DT N
elderly JJ N
is VBZ N
discussed VBN N
controversially RB N
. . N

Randomized NNP N
controlled VBD N
trials NNS N
using VBG N
falls NNS N
as IN N
primary JJ N
outcome NN N
are VBP N
needed VBN N
. . N

We PRP N
investigated VBD N
long-term JJ N
effects NNS N
of IN N
calcium NN i
and CC N
vitamin NN i
D NNP i
on IN N
falls NNS o
and CC o
parameters NNS o
of IN o
muscle NN o
function NN o
in IN N
community-dwelling JJ p
elderly JJ p
women NNS p
and CC p
men NNS p
. . p

METHODS NNP N
Our PRP$ N
study NN N
population NN N
consisted VBD N
of IN N
242 CD p
individuals NNS p
recruited VBN p
by IN p
advertisements NNS p
and CC p
mailing VBG p
lists NNS p
( ( p
mean JJ p
[ NNP p
+/- NN p
SD NNP p
] NNP p
age NN p
, , p
77 CD p
+/- JJ p
4 CD p
years NNS p
) ) p
. . p

All DT p
serum JJ p
25-hydroxyvitamin JJ p
D NNP p
( ( p
25 CD p
[ NNP p
OH NNP p
] NNP p
D NNP p
) ) p
levels NNS p
were VBD p
below IN p
78 CD p
nmol/l NN p
. . p

Individuals NNS N
received VBD N
in IN N
a DT N
double JJ N
blinded JJ N
fashion NN N
either DT N
1000 CD N
mg NN N
of IN N
calcium NN i
or CC N
1000 CD N
mg NN N
of IN N
calcium NN i
plus CC N
800 CD N
IU NNP N
of IN N
vitamin NNP i
D NNP i
per IN N
day NN N
over IN N
a DT N
treatment NN N
period NN N
of IN N
12 CD N
months NNS N
, , N
which WDT N
was VBD N
followed VBN N
by IN N
a DT N
treatment-free JJ N
but CC N
still RB N
blinded VBD N
observation JJ N
period NN N
of IN N
8 CD N
months NNS N
. . N

Falls NNP o
were VBD N
documented VBN N
using VBG N
diaries NNS N
. . N

The DT p
study NN p
took VBD p
place NN p
in IN p
Bad NNP p
Pyrmont NNP p
, , p
Germany NNP p
( ( p
latitude VBP p
52 CD p
degrees NNS p
) ) p
and CC p
Graz NNP p
, , p
Austria NNP p
( ( p
latitude VBP p
46 CD p
degrees NNS p
) ) p
. . p

RESULTS $ N
Compared VBD N
to TO N
calcium VB N
mono NN N
, , N
supplementation NN N
with IN N
calcium NN N
plus CC N
vitamin NN i
D NNP i
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
number NN N
of IN N
subjects NNS o
with IN o
first JJ o
falls NNS o
of IN N
27 CD N
% NN N
at IN N
month NN N
12 CD N
( ( N
RR NNP N
= NNP N
0.73 CD N
; : N
CI NNP N
= NNP N
0.54-0.96 NN N
) ) N
and CC N
39 CD N
% NN N
at IN N
month NN N
20 CD N
( ( N
RR NNP N
= NNP N
0.61 CD N
; : N
CI NNP N
= NNP N
0.34-0.76 NN N
) ) N
. . N

Concerning VBG N
secondary JJ N
endpoints NNS N
, , N
we PRP N
observed VBD N
significant JJ N
improvements NNS o
in IN o
quadriceps JJ o
strength NN o
of IN N
8 CD N
% NN N
, , N
a DT N
decrease NN N
in IN N
body NN o
sway NN o
of IN N
28 CD N
% NN N
, , N
and CC N
a DT N
decrease NN N
in IN N
time NN o
needed VBN o
to TO o
perform VB o
the DT o
TUG NNP o
test NN o
of IN N
11 CD N
% NN N
. . N

DISCUSSION NNP N
Combined NNP N
calcium NN i
and CC N
vitamin NN i
D NNP i
supplementation NN N
proved VBD N
superior JJ N
to TO N
calcium VB N
alone RB N
in IN N
reducing VBG N
the DT N
number NN o
of IN o
falls NNS o
and CC N
improving VBG N
muscle NN o
function NN o
in IN N
community-dwelling JJ p
older NN p
individuals NNS p
. . p

-DOCSTART- -X- O O

Antifibrinolytic JJ i
therapy NN i
for IN N
prevention NN N
of IN N
hemorrhage NN N
during IN N
surgery NN p
of IN p
the DT p
thyroid JJ p
gland NN p
. . p

The DT N
amount NN N
of IN N
fibrinolytic JJ N
activity NN N
in IN N
the DT N
thyroid JJ N
gland NN N
equals NNS N
that WDT N
of IN N
the DT N
prostate NN N
. . N

In IN N
order NN N
to TO N
examine VB N
the DT N
effect NN N
of IN N
the DT N
antifibrinolytic JJ i
drug NN i
tranexemic JJ i
acid NN i
on IN N
perioperative JJ o
bleeding NN o
saline NN i
or CC N
tranexemic JJ i
acid NN i
were VBD N
given VBN N
randomized VBN N
double JJ N
blind NN N
to TO N
76 CD p
consecutive JJ p
patients NNS p
who WP p
came VBD p
for IN p
scheduled VBN p
thyroid NN p
surgery NN p
. . p

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
perioperative JJ o
bleeding NN o
between IN N
patients NNS p
in IN p
the DT p
treatment NN p
group NN p
( ( p
n JJ p
= NNP p
39 CD p
) ) p
and CC p
control NN p
group NN p
( ( p
n JJ p
= NNP p
37 CD p
) ) p
. . N

-DOCSTART- -X- O O

Complementary JJ N
feeding NN N
with IN N
fortified JJ N
spread NN N
and CC N
incidence NN N
of IN N
severe JJ o
stunting VBG o
in IN N
6- JJ p
to TO p
18-month-old JJ p
rural JJ p
Malawians NNPS p
. . p

OBJECTIVE NNP N
To TO N
compare VB N
growth NN o
and CC N
incidence NN N
of IN N
malnutrition NN o
in IN N
infants NNS p
receiving VBG p
long-term JJ p
dietary JJ p
supplementation NN p
with IN p
ready-to-use NN p
fortified VBN i
spread NN i
( ( i
FS NNP i
) ) i
or CC p
micronutrient-fortified JJ i
maize-soy JJ i
flour NN i
( ( i
likuni JJ i
phala NN i
[ NNP p
LP NNP p
] NNP p
) ) p
. . p

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
, , N
single-blind JJ N
trial NN N
. . N

SETTING NNP N
Rural JJ N
Malawi NNP N
. . N

PARTICIPANTS VB N
A DT p
total NN p
of IN p
182 CD p
six-month-old JJ p
infants NNS p
. . p

INTERVENTION NN N
Participants NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
year NN N
of IN N
daily JJ N
supplementation NN N
with IN N
71 CD N
g NN N
of IN N
LP NNP i
( ( N
282 CD N
kcal NN N
) ) N
, , N
50 CD N
g NN N
of IN N
FS NNP i
( ( N
FS50 NNP N
) ) N
( ( N
256 CD N
kcal NN N
) ) N
, , N
or CC N
25 CD N
g NN N
of IN N
FS NNP i
( ( i
FS25 NNP i
) ) i
( ( N
130 CD N
[ RB N
corrected VBN N
] NNP N
kcal JJ N
) ) N
. . N

OUTCOME NNP N
MEASURES NNP N
Weight NNP o
and CC o
length NN o
gains NNS o
and CC o
the DT o
incidences NNS o
of IN o
severe JJ o
stunting NN o
, , o
underweight JJ o
, , o
and CC o
wasting VBG o
. . o

RESULTS NNP N
Mean NNP o
weight NN o
and CC o
length NN o
gains NNS o
in IN N
the DT N
LP NNP i
, , N
FS50 NNP N
, , N
and CC N
FS25 NNP N
groups NNS N
were VBD N
2.37 CD N
, , N
2.47 CD N
, , N
and CC N
2.37 CD N
kg NN N
( ( N
P NNP N
= NNP N
.66 NNP N
) ) N
and CC N
12.7 CD N
, , N
13.5 CD N
, , N
and CC N
13.2 CD N
cm NN N
( ( N
P NNP N
= NNP N
.23 NNP N
) ) N
, , N
respectively RB N
. . N

In IN N
the DT N
same JJ N
groups NNS N
, , N
the DT N
cumulative JJ N
12-month JJ N
incidence NN N
of IN N
severe JJ o
stunting NN o
was VBD N
13.3 CD N
% NN N
, , N
0.0 CD N
% NN N
, , N
and CC N
3.5 CD N
% NN N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
, , N
of IN N
severe JJ N
underweight NN o
was VBD N
15.0 CD N
% NN N
, , N
22.5 CD N
% NN N
, , N
and CC N
16.9 CD N
% NN N
( ( N
P NNP N
= NNP N
.71 NNP N
) ) N
, , N
and CC N
of IN N
severe JJ o
wasting NN o
was VBD N
1.8 CD N
% NN N
, , N
1.9 CD N
% NN N
, , N
and CC N
1.8 CD N
% NN N
( ( N
P NNP N
> NNP N
.99 NNP N
) ) N
. . N

Compared VBN N
with IN N
LP-supplemented JJ i
infants NNS N
, , N
those DT N
given VBN N
FS50 NNP N
gained VBD N
a DT N
mean NN N
of IN N
100 CD N
g NNS N
more JJR N
weight NN o
and CC N
0.8 CD N
cm NN N
more JJR N
length NN o
. . o

There EX N
was VBD N
a DT N
significant JJ N
interaction NN N
between IN N
baseline NN N
length NN N
and CC N
intervention NN N
( ( N
P NNP N
= NNP N
.04 NNP N
) ) N
; : N
in IN N
children NNS N
with IN N
below-median JJ N
length NN N
at IN N
enrollment NN N
, , N
those DT N
given VBN N
FS50 NNP N
gained VBD N
a DT N
mean NN N
of IN N
1.9 CD N
cm NNS N
more JJR N
than IN N
individuals NNS N
receiving VBG N
LP NNP i
. . i

CONCLUSION NNP N
One-year-long JJ N
complementary JJ N
feeding NN N
with IN N
FS NNP i
does VBZ N
not RB N
have VB N
a DT N
significantly RB N
larger JJR N
effect NN N
than IN N
LP NNP i
on IN N
mean JJ o
weight NN o
gain NN o
in IN N
all DT N
infants NNS N
, , N
but CC N
it PRP N
is VBZ N
likely JJ N
to TO N
boost VB N
linear JJ o
growth NN o
in IN N
the DT N
most RBS N
disadvantaged JJ N
individuals NNS N
and CC N
, , N
hence RB N
, , N
decrease VB N
the DT N
incidence NN o
of IN o
severe JJ o
stunting NN o
. . o

-DOCSTART- -X- O O

The DT N
individual JJ N
responsiveness NN N
to TO N
growth NN i
hormone NN i
( ( i
GH NNP i
) ) i
treatment NN i
in IN N
GH-deficient NNP p
adults NNS p
is VBZ N
dependent JJ N
on IN N
the DT N
level NN N
of IN N
GH-binding NNP N
protein NN N
, , N
body NN o
mass NN o
index NN o
, , N
age NN N
, , N
and CC N
gender NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
trial NN N
was VBD N
to TO N
study VB N
the DT N
individual JJ N
responsiveness NN N
to TO N
GH NNP i
treatment NN i
in IN N
terms NNS N
of IN N
body NN N
composition NN N
and CC N
to TO N
search VB N
for IN N
possible JJ N
predictors NNS N
of IN N
the DT N
response NN N
in IN N
GH-deficient NNP N
adults NNS N
. . N

Sixty-eight JJ p
patients NNS p
( ( p
44 CD p
men NNS p
and CC p
24 CD p
women NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
44.3 CD p
( ( p
1.2 CD p
) ) p
yr NN p
and CC p
verified VBD p
GH NNP p
deficiency NN p
participated VBD p
in IN p
a DT p
2-phase JJ p
treatment NN p
trial NN p
with IN N
an DT N
initial JJ N
randomized NN N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ i
, , N
6-month JJ N
period NN N
, , N
followed VBN N
by IN N
an DT N
open JJ N
treatment NN N
period NN N
, , N
thereby RB N
ensuring VBG N
all DT N
patients NNS p
12 CD p
months NNS p
of IN p
GH NNP p
treatment NN p
. . p

Recombinant JJ i
human JJ i
GH NNP i
was VBD N
administered VBN N
sc JJ N
daily RB N
at IN N
bedtime NN N
, , N
with IN N
a DT N
target NN N
dose NN N
of IN N
12 CD N
micrograms/kg NNS N
x JJ N
day NN N
. . N

GHBP NNP N
was VBD N
measured VBN N
by IN N
ligand-mediated JJ N
immunofunctional JJ N
assay NN N
, , N
and CC N
serum JJ N
insulin-like JJ N
growth NN N
factor NN N
I PRP N
( ( N
IGF-I NNP N
) ) N
was VBD N
determined VBN N
by IN N
RIA NNP N
after IN N
acid-ethanol JJ N
extraction NN N
, , N
using VBG N
a DT N
truncated JJ N
IGF-I JJ N
analog NN N
as IN N
the DT N
radioligand NN N
. . N

Lean JJ o
body NN o
mass NN o
( ( o
LBM NNP o
) ) o
and CC o
body NN o
fat NN o
( ( o
BF NNP o
) ) o
were VBD N
determined VBN N
by IN N
dual JJ N
energy NN N
x-ray JJ N
absorptiometry NN N
, , N
and CC N
total JJ N
body NN N
water NN N
( ( N
TBW NNP N
) ) N
was VBD N
determined VBN N
by IN N
bioelectrical JJ N
impedance NN N
. . N

During IN N
the DT N
placebo NN N
control NN N
period NN N
, , N
serum JJ o
IGF-I NNP o
, , o
LBM NNP o
, , o
and CC o
TBW NNP o
increased VBD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
BF NNP o
decreased VBD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
serum JJ o
GHBP NNP o
was VBD N
unchanged JJ N
in IN N
the DT N
group NN N
treated VBD N
with IN N
GH NNP N
compared VBN N
with IN N
the DT N
patients NNS N
treated VBN N
with IN N
placebo NN N
. . N

After IN N
12 CD N
months NNS N
of IN N
GH NNP N
treatment NN N
, , N
the DT N
individual JJ N
changes NNS N
in IN N
BF NNP o
ranged VBD N
from IN N
-12.5 NN N
to TO N
4.3 CD N
kg NNS N
and CC N
from IN N
-4.5 NNP N
to TO N
10.1 CD N
kg NNS N
in IN N
LBM NNP N
. . N

Age NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
baseline JJ o
GHBP NNP o
level NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
were VBD N
inversely RB N
correlated VBN N
with IN N
the DT N
increase NN N
in IN N
LBM NNP N
. . N

The DT N
GH-induced JJ o
increment NN o
in IN o
IGF-I NNP o
and CC o
TBW NNP o
was VBD N
greater JJR N
in IN N
men NNS N
than IN N
in IN N
women NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
whereas IN N
the DT N
decreases NNS N
in IN N
BF NNP o
were VBD N
similar JJ N
in IN N
men NNS N
and CC N
women NNS N
. . N

This DT N
trial NN N
demonstrates VBZ N
the DT N
variability NN N
in IN N
responsiveness NN N
to TO N
GH NNP i
administration NN N
in IN N
GH-deficient NNP N
adults NNS N
. . N

The DT N
best JJS N
response NN N
to TO N
GH NNP N
was VBD N
obtained VBN N
in IN N
younger JJR N
patients NNS N
with IN N
low JJ N
GHBP NNP N
levels NNS N
. . N

Furthermore RB N
, , N
men NNS N
responded VBD N
better RBR N
than IN N
women NNS N
. . N

-DOCSTART- -X- O O

Enamel NNP N
and CC N
dentin VB N
bond NN N
strength NN N
following VBG N
gaseous JJ i
ozone NN i
application NN i
. . i

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
gaseous JJ i
ozone NN i
application NN i
on IN N
enamel NN N
and CC N
dentin VB N
bond NN N
strength NN N
produced VBN N
by IN N
two CD N
self-etching JJ N
adhesive JJ N
systems NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
The DT N
shear JJ N
bond NN N
strength NN N
test NN N
was VBD N
conducted VBN N
to TO N
assess VB N
adhesion NN N
on IN N
enamel NN N
( ( N
protocol JJ N
1 CD N
) ) N
, , N
while IN N
the DT N
microtensile JJ N
bond NN N
strength NN N
test NN N
was VBD N
performed VBN N
on IN N
dentin NN N
( ( N
protocol JJ N
2 CD N
) ) N
. . N

Protocol $ N
1 CD N
: : N
96 CD p
bovine NN p
incisors NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
, , N
and CC N
enamel JJ N
surfaces NNS N
were VBD N
bonded VBN N
in IN N
accordance NN N
with IN N
the DT N
following JJ N
treatments NNS N
: : N
( ( i
1E CD i
) ) i
ozone NN i
+ NN i
Clearfil NNP i
Protect NNP i
Bond NNP i
; : i
( ( i
2E CD i
) ) i
Clearfil NNP i
Protect NNP i
Bond NNP i
( ( i
control NN i
) ) i
; : i
( ( i
3E CD i
) ) i
ozone NN i
+ JJ i
Xeno NNP i
III NNP i
; : i
( ( i
4E CD i
) ) i
Xeno NN i
III NNP i
( ( i
control NN i
) ) i
. . i

Ozone NNP i
gas NN i
was VBD N
applied VBN N
for IN N
80 CD N
s. JJ N
Shear NNP N
bond NN N
strength NN N
was VBD N
measured VBN N
with IN N
a DT N
universal JJ N
testing NN N
machine NN N
. . N

Protocol CC N
2 CD N
: : N
40 CD p
noncarious JJ p
human JJ p
molars NNS p
were VBD N
selected VBN N
. . N

Middle/deep NNP N
dentin NN N
was VBD N
exposed VBN N
and CC N
bonded VBN N
in IN N
accordance NN N
with IN N
the DT N
following JJ N
treatments NNS N
: : N
( ( i
1D CD i
) ) i
ozone+Clearfil NN i
Protect NNP i
Bond NNP i
; : i
( ( i
2D CD i
) ) i
Clearfil NNP i
Protect NNP i
Bond NNP i
( ( i
control NN i
) ) i
; : i
( ( i
3D CD i
) ) i
ozone+Xeno NN i
III NNP i
( ( i
4D CD i
) ) i
Xeno NN i
III NNP i
( ( i
control NN i
) ) i
. . i

Four-mm-thick JJ N
buildups NNS N
were VBD N
built VBN N
on IN N
the DT N
adhesives NNS N
, , N
then RB N
specimens NNS N
were VBD N
sectioned VBN N
in IN N
accordance NN N
with IN N
the DT N
nontrimming NN N
technique NN N
. . N

Specimens NNS N
were VBD N
stressed VBN N
until IN N
failure NN N
occurred VBD N
, , N
and CC N
failure NN N
modes NNS N
were VBD N
analyzed VBN N
. . N

Shear JJ o
bond NN o
and CC o
microtensile NN o
bond NN o
strength NN o
data NNS o
were VBD N
analyzed VBN N
using VBG N
two-way JJ N
ANOVA NNP N
and CC N
Tukey NNP N
's POS N
post-hoc JJ N
test NN N
. . N

RESULTS NNP N
No NNP N
statistical JJ N
differences NNS N
were VBD N
found VBN N
between IN N
ozone NN N
treated VBN N
specimens NNS N
and CC N
controls NNS N
, , N
neither CC N
on IN N
enamel JJ o
nor CC N
on IN N
dentin JJ o
irrespective NN N
of IN N
the DT N
tested JJ N
adhesive NN N
. . N

Clearfil NNP N
Protect NNP N
Bond NNP N
showed VBD N
higher JJR N
bond NN o
strength NN o
to TO N
enamel VB N
than IN N
Xeno NNP i
III NNP i
, , N
irrespective NN N
of IN N
the DT N
ozone NN i
treatment NN i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
use NN N
of IN N
ozone NN i
gas NN i
to TO N
disinfect VB N
the DT N
cavity NN N
before IN N
placing VBG N
a DT N
restoration NN N
had VBD N
no DT N
influence NN N
on IN N
immediate JJ N
enamel NN N
and CC N
dentin VB N
bond NN N
strength NN N
. . N

-DOCSTART- -X- O O

Gastric JJ p
ulcer NN p
treatment NN p
with IN N
intravenous JJ N
human JJ i
epidermal JJ i
growth NN i
factor NN i
: : i
a DT N
double-blind NN N
controlled VBN N
clinical JJ N
study NN N
. . N

We PRP N
introduced VBD N
a DT N
double-blind NN N
controlled VBN N
clinical JJ N
study NN N
to TO N
compare VB N
intravenous JJ i
human JJ i
epidermal JJ i
growth NN i
factor NN i
( ( i
hEGF NN i
) ) i
to TO N
cetraxate VB i
hydrochloride NN i
( ( i
CH NNP i
) ) i
, , N
an DT N
antiulcer JJ N
drug NN N
, , N
for IN N
their PRP$ N
healing NN N
effect NN N
on IN N
gastric JJ o
ulcers NNS o
. . o

We PRP N
also RB N
prospected VBD N
an DT N
oral JJ N
use NN N
of IN N
EGF NNP i
on IN N
the DT N
basis NN N
of IN N
our PRP$ N
experimental JJ N
evidence NN N
. . N

In IN N
the DT N
clinical JJ N
trial NN N
, , N
the DT N
rate NN o
of IN o
ulcer NN o
healing VBG o
within IN N
8 CD N
weeks NNS N
was VBD N
77.9 CD N
% NN N
( ( p
67/86 CD p
) ) p
in IN N
patients NNS p
receiving VBG p
6 CD p
micrograms NNS p
EGF NNP i
intravenously RB p
twice RB p
a DT p
week NN p
, , N
being VBG N
significantly RB N
greater JJR N
than IN N
51.7 CD N
% NN N
( ( N
45/87 CD N
) ) N
in IN N
those DT N
given VBN N
CH NNP i
. . i

Taking VBG N
together RB N
all DT N
aspects NNS N
assessed VBD N
including VBG N
the DT N
healing NN o
rate NN o
, , o
pain NN o
relief NN o
, , o
blood NN o
examination NN o
and CC o
adverse JJ o
reactions NNS o
, , N
we PRP N
judged VBD N
the DT N
hEGF NN i
to TO N
be VB N
a DT N
useful JJ N
and CC N
safe JJ N
anticuler NN N
drug NN N
. . N

In IN N
rats NNS N
, , N
50 CD N
micrograms/kg NN N
mouse NN N
EGF NNP N
( ( N
mEGF NN N
) ) N
and CC N
2 CD N
% NN N
hydroxypropyl NN i
cellulose NN i
( ( N
HPC NNP N
) ) N
or CC N
1.0 CD N
g/kg JJ N
sucralfate NN N
given VBN N
by IN N
gastric JJ N
intubation NN N
significantly RB N
raised VBD N
the DT N
residual JJ o
mEGF NN o
levels NNS o
in IN N
both DT N
gastric JJ N
luminal JJ N
content NN N
( ( N
HPC NNP N
: : N
x JJ N
30 CD N
; : N
sucralfate NN N
: : N
x RB N
300 CD N
as RB N
high JJ N
as IN N
those DT N
in IN N
EGF NNP N
alone RB N
) ) N
and CC N
tissue NN N
( ( N
HPC NNP N
: : N
x JJ N
60 CD N
; : N
sucralfate NN N
: : N
x JJ N
100 CD N
) ) N
. . N

In IN N
addition NN N
, , N
the DT N
combined JJ N
treatments NNS N
significantly RB N
promoted VBD N
healing NN o
of IN o
rat NN o
gastric JJ o
ulcers NNS o
whereas VBP N
each DT N
agent NN N
alone RB N
had VBD N
no DT N
significant JJ N
effect NN N
as IN N
compared VBN N
with IN N
control NN N
( ( N
saline NN N
) ) N
. . N

This DT N
indicated VBD N
the DT N
beneficial JJ N
effect NN N
on IN N
ulcers NNS N
of IN N
oral JJ N
administration NN N
of IN N
EGF NNP i
with IN N
agents NNS N
allowing VBG N
it PRP N
to TO N
remain VB N
at IN N
high JJ N
levels NNS N
in IN N
the DT N
stomach NN N
, , N
whereas IN N
most JJS N
reports NNS N
suggested VBD N
less RBR N
effect NN N
of IN N
oral JJ N
EGF NNP N
on IN N
healing NN N
of IN N
gastroduodenal JJ N
ulcers NNS N
. . N

Subsequent JJ N
to TO N
the DT N
clinical JJ N
study NN N
, , N
evaluation NN N
of IN N
oral JJ N
use NN N
of IN N
EGF NNP i
may MD N
be VB N
expected VBN N
as IN N
the DT N
next JJ N
step NN N
in IN N
the DT N
treatment NN N
of IN N
ulcers NNS N
. . N

The DT N
experimental JJ N
evidence NN N
above IN N
would MD N
possibly RB N
be VB N
a DT N
guide NN N
for IN N
such JJ N
trial NN N
. . N

-DOCSTART- -X- O O

Eltrombopag NNP N
dose JJ N
predictors NNS N
in IN N
thrombocytopenic JJ p
subjects NNS p
with IN p
hepatitis NN p
C NNP p
virus NN p
infection NN p
. . p

This DT N
study NN N
aims VBZ N
to TO N
identify VB N
patient JJ N
characteristics NNS N
that WDT N
predict VBP N
effective JJ N
eltrombopag NN N
dosage NN N
for IN N
the DT N
treatment NN N
of IN N
Hepatitis NNP N
C NNP N
virus NN N
( ( N
HCV NNP N
) ) N
-related VBD N
thrombocytopenia NN N
. . N

Demographic NNP N
, , N
clinical JJ N
and CC N
genetic JJ N
data NNS N
collected VBN N
from IN N
thrombocytopenic JJ p
patients NNS p
( ( p
n JJ p
= NN p
1463 CD p
, , p
age NN p
? . p
18 CD p
years NNS p
) ) p
with IN p
chronic JJ p
HCV NNP p
infection NN p
who WP p
were VBD p
able JJ p
to TO p
achieve VB p
a DT p
target NN p
platelet NN p
count NN p
of IN p
> $ p
90 CD p
? . p
10 CD p
( ( p
9 CD p
) ) p
/L NN p
following VBG i
eltrombopag JJ i
treatment NN i
. . p

Patients NNS p
were VBD N
categorized VBN N
into IN N
four CD N
groups NNS N
( ( N
25 CD N
, , N
50 CD N
, , N
75 CD N
, , N
and CC N
100 CD N
mg NN N
) ) N
based VBN N
on IN N
the DT N
eltrombopag NN i
dose NN i
needed VBN N
to TO N
achieve VB N
the DT N
target NN N
platelet NN N
count NN i
. . i

Eltrombopag NNP i
dose JJ i
predictors NNS N
were VBD N
identified VBN N
using VBG N
a DT N
two CD N
stage NN N
approach NN N
. . N

First NNP N
, , N
bivariate NN N
analysis NN N
, , N
using VBG N
anova NN N
for IN N
continuous JJ N
variables NNS N
and CC N
Chi-square NNP N
test NN N
for IN N
categorical JJ N
variables NNS N
, , N
was VBD N
performed VBN N
to TO N
identify VB N
possible JJ N
predictors NNS N
of IN N
eltrombopag NN N
dose NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Second JJ N
, , N
ordinal JJ N
logistic JJ N
regression NN N
with IN N
stepwise NN N
addition NN N
followed VBN N
by IN N
backward NN N
deletion NN N
was VBD N
then RB N
performed VBN N
using VBG N
predictors NNS N
identified VBN N
in IN N
bivariate NN N
analysis NN N
step NN N
to TO N
produce VB N
final JJ N
model NN N
containing VBG N
independent JJ N
predictors NNS N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

Ordinal NNP N
logistic JJ N
model NN N
identified VBD N
several JJ N
predictors NNS N
of IN N
eltrombopag NN N
dose NN N
. . N

Predictors NNS N
of IN N
higher JJR N
eltrombopag NN N
dose JJ N
include NN o
: : o
having VBG o
a DT o
HCV NNP o
genotype NN o
2 CD o
or CC o
3 CD o
, , o
being VBG o
Central/South NNP o
Asian NNP o
, , o
being VBG o
White NNP o
( ( o
Caucasian JJ o
or CC o
European JJ o
heritage NN o
) ) o
, , o
increased VBD o
weight NN o
, , o
and CC o
increased VBD o
spleen JJ o
length NN o
. . o

Predictors NNS o
of IN N
lower JJR N
eltrombopag NN N
dose JJ N
include NN o
: : o
female JJ o
gender NN o
, , o
increased VBN o
age NN o
, , o
having VBG o
a DT o
higher JJR o
ALP NNP o
plasma JJ o
concentration NN o
, , o
increased VBD o
creatinine JJ o
clearance NN o
, , o
increased VBD o
baseline NN o
lymphocytes NNS o
count NN o
, , o
and CC o
increased VBD o
baseline NN o
platelet NN o
count NN o
. . o

In IN o
conclusion NN N
, , N
this DT N
study NN N
identified VBD N
patient JJ N
characteristics NNS N
that WDT N
predict VBP N
effective JJ N
eltrombopag NN N
dose NN N
for IN N
the DT N
treatment NN N
of IN N
HCV-related NNP N
thrombocytopenia NN N
. . N

Early JJ N
selection NN N
of IN N
the DT N
optimal JJ N
eltrombopag NN N
dose NN N
expedites VBZ N
the DT N
initiation NN N
of IN N
antiviral JJ N
therapy NN N
. . N

This DT N
is VBZ N
expected VBN N
to TO N
improve VB N
the DT N
antiviral JJ N
therapy NN N
outcome NN N
before IN N
the DT N
patient NN N
progress NN N
into IN N
liver JJ N
decompensation NN N
. . N

-DOCSTART- -X- O O

Network NNP N
support NN N
for IN N
drinking NN N
, , N
Alcoholics NNP N
Anonymous NNP N
and CC N
long-term JJ N
matching NN N
effects NNS N
. . N

AIMS NNP N
( ( N
1 CD N
) ) N
To TO N
examine VB N
the DT N
matching JJ N
hypothesis NN N
that WDT N
Twelve NNP i
Step NNP i
Facilitation NNP i
Therapy NNP i
( ( i
TSF NNP i
) ) i
is VBZ N
more RBR N
effective JJ N
than IN N
Motivational NNP i
Enhancement NNP i
Therapy NNP i
( ( i
MET NNP i
) ) i
for IN N
alcohol-dependent JJ p
clients NNS p
with IN N
networks NNS N
highly RB N
supportive JJ N
of IN N
drinking VBG N
3 CD N
years NNS N
following VBG N
treatment NN N
; : N
( ( N
2 CD N
) ) N
to TO N
test VB N
a DT N
causal NN N
chain NN N
providing VBG N
the DT N
rationale NN N
for IN N
this DT N
effect NN N
. . N

DESIGN NN N
Outpatients NNPS p
were VBD N
re-interviewed JJ N
3 CD N
years NNS N
following VBG N
treatment NN N
. . N

ANCOVAs NNP N
tested VBD N
the DT N
matching JJ N
hypothesis NN N
. . N

SETTING NN N
Outpatients NNS p
from IN p
five CD p
clinical JJ p
research NN p
units NNS p
distributed VBN p
across IN p
the DT p
United NNP p
States NNPS p
. . p

PARTICIPANTS NNP N
Eight NNP p
hundred VBD p
and CC p
six CD p
alcohol-dependent JJ p
clients NNS p
. . p

INTERVENTION JJ N
Clients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
12-week JJ N
, , N
manually-guided JJ i
, , i
individual JJ i
treatments NNS i
: : i
TSF NNP i
, , i
MET NNP i
or CC i
Cognitive NNP i
Behavioral NNP i
Coping NNP i
Skills NNP i
Therapy NNP i
( ( i
CBT NNP i
) ) i
. . i

MEASUREMENTS NNP N
Network NNP o
support NN o
for IN o
drinking VBG o
prior JJ o
to TO o
treatment NN o
, , o
Alcoholics NNP o
Anonymous NNP o
( ( o
AA NNP o
) ) o
involvement NN o
during IN o
and CC o
following VBG o
treatment NN o
, , o
percentage NN o
of IN o
days NNS o
abstinent JJ o
and CC o
drinks NNS o
per IN o
drinking NN o
day NN o
during IN o
months NNS o
37-39 JJ o
. . o

FINDINGS NNP N
( ( N
1 CD N
) ) N
The DT N
a DT N
priori JJ N
matching NN N
hypothesis NN N
that IN N
TSF NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
MET NNP N
for IN N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
was VBD N
supported VBN N
at IN N
the DT N
3 CD N
year NN N
follow-up NN N
; : N
( ( N
2 CD N
) ) N
AA NNP N
involvement NN N
was VBD N
a DT N
partial JJ N
mediator NN N
of IN N
this DT N
effect NN N
; : N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
assigned VBN N
to TO N
TSF VB N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
involved VBN o
in IN o
AA NNP o
; : o
AA NNP o
involvement NN o
was VBD N
associated VBN N
with IN N
better JJR N
3-year JJ o
drinking NN o
outcomes NNS o
for IN N
such JJ N
clients NNS N
. . N

CONCLUSIONS NNP N
( ( N
1 CD N
) ) N
In IN N
the DT N
long-term JJ N
TSF NNP N
may MD N
be VB N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
alcohol-dependent JJ N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
; : N
( ( N
2 CD N
) ) N
involvement NN N
in IN N
AA NNP N
should MD N
be VB N
given VBN N
special JJ N
consideration NN N
for IN N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
, , N
irrespective NN N
of IN N
the DT N
therapy NN N
they PRP N
will MD N
receive VB N
. . N

-DOCSTART- -X- O O

Control NN N
of IN N
the DT N
lumbar NN N
neutral JJ N
zone NN N
decreases VBZ N
low JJ o
back RB o
pain NN o
and CC N
improves VBZ o
self-evaluated JJ o
work NN o
ability NN o
: : o
a DT N
12-month JJ N
randomized NN N
controlled VBD N
study NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized NN N
controlled VBD N
study NN N
with IN N
12 CD N
months NNS N
intervention NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effectiveness NN N
of IN N
a DT N
training NN i
intervention NN i
with IN i
emphases NNS i
on IN i
the DT i
control NN i
of IN i
lumbar JJ i
neutral JJ i
zone NN i
( ( N
NZ NNP N
) ) N
and CC N
behavior JJ i
modeling NN i
as IN N
secondary JJ N
prevention NN N
of IN N
low JJ o
back RB o
pain NN o
( ( o
LBP NNP o
) ) o
and CC o
disability NN o
. . o

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
Improving NNP N
the DT N
control NN N
of IN N
lumbar NN N
NZ NNP N
and CC N
enhancing VBG N
muscle NN N
activation NN N
patterns NNS N
ensuring VBG N
spinal JJ N
stability NN N
have VBP N
been VBN N
proposed VBN N
as IN N
means NNS N
for IN N
secondary JJ N
prevention NN N
of IN N
LBP NNP o
and CC o
disability NN o
. . o

In IN N
addition NN N
, , N
cognitive JJ i
behavior NN i
interventions NNS i
have VBP N
been VBN N
shown VBN N
to TO N
lower VB N
the DT N
risk NN N
of IN N
recurrence NN o
of IN o
LBP NNP o
and CC o
long-term JJ o
disability NN o
. . o

METHODS NNP N
Middle-aged JJ p
working VBG p
men NNS p
with IN p
recent JJ p
LBP NNP p
but CC p
without IN p
severe JJ p
disability NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
either VB N
a DT N
training NN i
( ( N
TG NNP N
, , N
n JJ N
= NNP N
52 CD N
) ) N
or CC N
control VB i
group NN i
( ( N
CG NNP N
, , N
n JJ N
= NNP N
54 CD N
) ) N
. . N

The DT N
aim NN N
was VBD N
to TO N
exercise VB N
twice RB N
a DT N
week NN N
for IN N
12 CD N
months NNS N
, , N
once RB N
guided VBN N
and CC N
once RB N
independently RB N
. . N

The DT N
outcome NN N
measures NNS N
were VBD N
the DT N
changes NNS o
in IN o
intensity NN o
of IN o
LBP NNP o
, , o
disability NN o
, , o
self-evaluated JJ o
future NN o
work NN o
ability NN o
, , o
and CC o
neuromuscular JJ o
fitness NN o
. . o

RESULTS VB N
The DT N
intensity NN o
of IN o
LBP NNP o
decreased VBD N
significantly RB N
more JJR N
( ( N
39 CD N
% NN N
) ) N
in IN N
the DT N
TG NNP N
than IN N
in IN N
CG NNP N
at IN N
12 CD N
months NNS N
. . N

The DT N
proportion NN o
of IN o
subjects NNS o
with IN o
negative JJ o
expectations NNS o
about IN o
their PRP$ o
future NN o
work NN o
ability NN o
decreased VBN N
in IN N
both DT N
groups NNS N
at IN N
6 CD N
and CC N
12 CD N
months NNS N
; : N
however RB N
, , N
the DT N
proportion NN N
was VBD N
significantly RB N
bigger JJR N
in IN N
TG NNP N
compared VBN N
with IN N
CG NNP N
( ( N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

There EX N
effects NNS N
on IN N
disability NN o
indexes NNS o
and CC o
fitness NN o
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

CONCLUSIONS NNP N
Controlling NNP N
lumbar NN N
NZ NNP N
is VBZ N
a DT N
specific JJ N
form NN N
of IN N
exercise NN i
and CC i
daily JJ i
self-care NN i
with IN N
potential JJ N
for IN N
prevention NN N
of IN N
recurrent NN N
nonspecific JJ N
LBP NNP p
and CC p
disability NN p
among IN p
middle JJ p
aged VBN p
working VBG p
men NNS p
. . p

-DOCSTART- -X- O O

Prospective JJ N
, , N
randomized JJ N
comparison NN N
of IN N
transperitoneal JJ i
versus NN i
retroperitoneal NN i
laparoscopic JJ i
adrenalectomy NN i
. . i

PURPOSE NNP N
We PRP N
report VBP N
a DT N
prospective JJ N
, , N
randomized JJ N
comparison NN N
of IN N
transperitoneal JJ i
laparoscopic JJ i
adrenalectomy NN i
( ( i
TLA NNP i
) ) i
vs FW i
retroperitoneal JJ i
laparoscopic NN i
adrenalectomy NN i
( ( i
RLA NNP i
) ) i
for IN N
adrenal JJ N
lesions NNS N
with IN N
long-term JJ N
followup NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Between NNP p
December NNP p
1997 CD p
and CC p
November NNP p
1999 CD p
, , p
57 CD p
consecutive JJ p
eligible JJ p
patients NNS p
with IN p
surgical JJ p
adrenal JJ p
disease NN p
were VBD N
prospectively RB i
randomized VBN i
to TO i
undergo VB i
TLA NNP i
( ( i
25 CD i
) ) i
or CC i
RLA NNP i
( ( i
32 CD i
) ) i
. . i

Study NNP p
exclusion NN p
criteria NNS p
were VBD p
patient JJ p
age NN p
greater JJR p
than IN p
80 CD p
years NNS p
, , p
body NN p
mass NN p
index NN p
greater JJR p
than IN p
40 CD p
, , p
bilateral JJ p
adrenalectomy NN p
and CC p
significant JJ p
prior JJ p
abdominal JJ p
surgery NN p
in IN p
the DT p
quadrant NN p
of IN p
interest NN p
. . p

Mean NNP N
followup NN N
was VBD N
5.96 CD N
years NNS N
in IN N
the DT N
2 CD N
groups NNS N
. . N

RESULTS VB N
The DT N
groups NNS N
were VBD N
matched VBN N
in IN N
regard NN N
to TO N
patient JJ N
age NN N
( ( N
p JJ N
= NNP N
0.84 CD N
) ) N
, , N
body JJ N
mass NN N
index NN N
( ( N
p JJ N
= NNP N
0.43 CD N
) ) N
, , N
American NNP N
Society NNP N
of IN N
Anesthesiologists NNP N
class NN N
( ( N
p JJ N
= NNP N
0.81 CD N
) ) N
and CC N
laterality NN N
( ( N
p JJ N
= NNP N
0.12 CD N
) ) N
. . N

Median JJ N
adrenal JJ o
mass NN o
size NN o
was VBD N
2.7 CD N
cm NN N
( ( N
range VB N
1 CD N
to TO N
9 CD N
) ) N
in IN N
the DT N
TLA NNP N
group NN N
and CC N
2.6 CD N
cm NN N
( ( N
range VB N
0.5 CD N
to TO N
6 CD N
) ) N
in IN N
the DT N
RLA NNP N
group NN N
( ( N
p JJ N
= NNP N
0.83 CD N
) ) N
. . N

TLA NNP N
was VBD N
comparable JJ N
to TO N
RLA NNP N
in IN N
terms NNS N
of IN N
operative JJ o
time NN o
( ( N
130 CD N
vs NN N
126.5 CD N
minutes NNS N
, , N
p VBP N
= RB N
0.64 CD N
) ) N
, , N
estimated VBN o
blood NN o
loss NN o
( ( N
p JJ N
= NNP N
0.92 CD N
) ) N
, , N
specimen NNS o
weight VBD o
( ( N
p JJ N
= NNP N
0.81 CD N
) ) N
, , N
analgesic JJ o
requirements NNS o
( ( N
p JJ N
= NNP N
0.25 CD N
) ) N
, , N
hospital JJ o
stay NN o
( ( N
p JJ N
= NNP N
0.56 CD N
) ) N
and CC N
the DT N
complication NN o
rate NN o
( ( N
p JJ N
= NNP N
0.58 CD N
) ) N
. . N

One CD N
case NN N
per IN N
group NN N
was VBD N
electively RB N
converted VBN N
to TO N
open VB o
surgery NN o
. . o

Pathology NNP N
data NNS N
on IN N
the DT N
intact JJ N
extracted JJ N
specimens NNS N
were VBD N
similar JJ N
between IN N
the DT N
groups NNS N
. . N

Averaged VBD N
convalescence NN o
was VBD N
4.7 CD N
weeks NNS N
in IN N
the DT N
TLA NNP N
group NN N
and CC N
2.3 CD N
weeks NNS N
in IN N
the DT N
RLA NNP N
group NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

During IN N
a DT N
mean JJ N
followup NN N
of IN N
6 CD N
years NNS N
2 CD N
patients NNS N
in IN N
the DT N
TLA NNP N
group NN N
had VBD N
a DT N
late JJ o
complication NN o
( ( o
port JJ o
site NN o
hernia NN o
) ) o
. . o

Mortality NN o
occurred VBD N
in IN N
5 CD N
patients NNS N
, , N
including VBG N
1 CD N
with IN N
TLA NNP N
and CC N
4 CD N
with IN N
RLA NNP N
, , N
during IN N
the DT N
6-year JJ N
followup NN N
. . N

CONCLUSIONS NNP N
For IN N
most JJS N
benign JJ N
adrenal JJ N
lesions NNS N
requiring VBG N
surgery NN N
laparoscopic NN i
adrenalectomy NN i
can MD N
be VB N
performed VBN N
safely RB o
and CC N
effectively RB o
by IN N
the DT N
transperitoneal NN N
or CC N
the DT N
retroperitoneal JJ N
approach NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
albuterol JJ i
solution NN i
nebulized VBN i
versus NN i
albuterol NN i
powder NN i
given VBN N
by IN N
breath NN N
activated VBN N
metered VBD N
dose JJ N
inhaler NN N
. . N

The DT N
goal NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
nebulized JJ i
vs NN i
powdered VBD i
albuterol NN i
in IN N
patients NNS p
with IN p
exacerbated JJ p
bronchial JJ p
asthma NN p
who WP p
required VBD p
hospitalization NN p
. . p

From IN p
January NNP p
to TO p
May NNP p
1990 CD p
known NN p
asthmatics NNS p
admitted VBN p
with IN p
acute JJ p
exacerbation NN p
were VBD p
included VBN p
by IN p
established VBN p
criteria NNS p
. . p

Two CD N
groups NNS N
were VBD N
randomized VBN N
. . N

Group NNP N
I PRP N
for IN N
Albuterol NNP i
powder NN i
200 CD N
micrograms NNS N
inhaled VBD N
q RB N
4 CD N
hours NNS N
. . N

Group NNP N
II NNP N
with IN N
Albuterol NNP i
nebulized JJ i
solution NN i
2.5 CD N
mg NN N
inhaled VBD N
q RB N
4 CD N
hrs NN N
. . N

Force NNP o
Vital NNP o
Capacity NNP o
and CC o
Force NNP o
Expiratory NNP o
Volume NN o
in IN N
one CD N
second NN N
were VBD N
measured VBN N
with IN N
a DT N
pressure NN N
differential JJ N
transducer NN N
upon IN N
admission NN N
, , N
30 CD N
minutes NNS N
and CC N
24-hours JJ N
following NN N
therapies NNS N
. . N

Absolute NNP o
FEV1 NNP o
improvement NN o
was VBD N
calculated VBN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
student NN N
's POS N
T-Test NNP N
and CC N
Fisher NNP N
's POS N
exact JJ N
Test NNP N
with IN N
significance NN N
established VBN N
at IN N
p NN N
> VBP N
0.01 CD N
% NN N
. . N

Fifteen JJ p
patients NNS p
enrolled VBN p
in IN p
both DT p
groups NNS p
, , p
two CD p
patients NNS p
of IN p
group NN p
I PRP p
were VBD p
excluded VBN p
from IN N
the DT N
statistic JJ N
analysis NN N
due JJ N
to TO N
refusal VB N
to TO N
continue VB N
with IN N
the DT N
therapy NN N
. . N

Both DT N
groups NNS N
were VBD N
comparable JJ N
with IN N
respect NN N
to TO N
sex NN N
, , N
asthma JJ N
exacerbations/year NN N
, , N
smoking VBG N
history NN N
and CC N
hospital JJ N
length NN N
of IN N
stay NN N
. . N

FVC NNP o
and CC o
FEV1 NNP o
were VBD N
comparable JJ N
also RB N
. . N

In IN N
contrast NN N
, , N
there EX N
were VBD N
significant JJ N
difference NN N
when WRB N
the DT N
absolute NN N
improvement NN N
were VBD N
compared VBN N
. . N

The DT N
mean JJ o
+/- JJ o
SE NNP o
for IN o
FEV1 NNP o
absolute JJ N
improvement NN N
at IN N
the DT N
first JJ N
30 CD N
min NN N
was VBD N
0.42 CD N
+/- JJ N
0.08 CD N
lts NNS N
for IN N
the DT N
Group NNP N
I PRP N
versus VBP N
0.65 CD N
+/- JJ N
0.6 CD N
lts NNS N
in IN N
the DT N
Group NNP N
II NNP N
. . N

In IN N
the DT N
next JJ N
24 CD N
hours NNS N
, , N
Group NNP N
I PRP N
was VBD N
0.16 CD N
+/- JJ N
0.2 CD N
lts NNS N
versus JJ N
0.30 CD N
+/- JJ N
0.7 CD N
lts NNS N
in IN N
Group NNP N
II NNP N
( ( N
p JJ N
> NNP N
.01 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
although IN N
the DT N
dose JJ N
equivalence NN N
of IN N
both DT N
delivery NN N
systems NNS N
have VBP N
not RB N
been VBN N
established VBN N
in IN N
our PRP$ N
study NN N
, , N
the DT N
nebulized JJ i
solution NN i
was VBD N
more RBR N
effective JJ N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
of IN N
hospitalization NN N
than IN N
the DT N
dry JJ i
powder NN i
. . i

-DOCSTART- -X- O O

Final JJ N
report NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
study NN N
with IN N
streptococcal JJ N
preparation NN N
OK-432 NNP i
as IN N
a DT N
supplementary JJ N
immunopotentiator NN N
for IN N
laryngeal JJ p
cancer NN p
. . p

We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
streptococcal JJ N
preparation NN N
OK-432 NNP i
on IN N
120 CD p
newly RB p
identified VBN p
cases NNS p
of IN p
laryngeal JJ p
squamous JJ p
cell NN p
carcinoma NN p
who WP p
were VBD p
registered VBN p
at IN p
10 CD p
participating VBG p
institutions NNS p
between IN p
November NNP p
1984 CD p
and CC p
October NNP p
1989 CD p
. . p

The DT N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
those DT N
in IN N
early JJ N
stages NNS N
( ( N
stage NN N
I PRP N
or CC N
II NNP N
) ) N
and CC N
those DT N
in IN N
advanced JJ N
stages NNS N
( ( N
stage NN N
III NNP N
or CC N
IV NNP N
) ) N
; : N
these DT N
groups NNS N
were VBD N
further RB N
subdivided VBN N
into IN N
an DT N
immunotherapy NN N
group NN N
( ( i
receiving VBG i
OK-432 NNP i
) ) i
and CC N
a DT N
control NN i
group NN N
( ( N
who WP N
did VBD N
not RB N
receive VB N
OK-432 NNP i
) ) i
. . N

The DT N
usefulness NN N
of IN N
OK-432 NNP N
was VBD N
studied VBN N
using VBG N
the DT N
sealed VBN N
envelope NN N
method NN N
. . N

The DT N
basic JJ N
therapy NN N
for IN N
all DT N
cases NNS N
was VBD N
radiotherapy NN N
and CC N
, , N
when WRB N
required VBN N
, , N
surgery NN N
. . N

As IN N
adjuvant JJ N
therapy NN N
, , N
5Fu CD N
or CC N
derivatives NNS N
were VBD N
administered VBN N
to TO N
all DT N
cases NNS N
from IN N
the DT N
beginning NN N
of IN N
the DT N
treatment NN N
period NN N
to TO N
one CD N
year NN N
after IN N
the DT N
basic JJ N
therapy NN N
, , N
with IN N
the DT N
exception NN N
of IN N
cases NNS N
in IN N
whom WP N
side NN N
effects NNS N
were VBD N
serious JJ N
enough RB N
to TO N
contraindicate VB N
use NN N
of IN N
the DT N
drug NN N
. . N

The DT N
target NN N
administration NN N
period NN N
was VBD N
5 CD N
years NNS N
. . N

Of IN p
the DT p
initial JJ p
120 CD p
cases NNS p
, , p
11 CD p
cases NNS p
were VBD p
disqualified VBN p
( ( p
3 CD p
cases NNS p
of IN p
double JJ p
cancer NN p
and CC p
8 CD p
of IN p
incomplete JJ p
primary JJ p
therapy NN p
) ) p
and CC p
the DT p
remaining VBG p
109 CD p
were VBD p
used VBN p
for IN p
evaluation NN p
. . p

The DT N
5-year JJ o
survival NN o
rate NN o
and CC o
the DT o
5-year JJ o
recurrence-free JJ o
rate NN o
were VBD N
76 CD N
% NN N
and CC N
84 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
immunized JJ N
groups NNS N
( ( N
both DT N
the DT N
early JJ N
and CC N
advanced JJ N
groups NNS N
) ) N
, , N
whereas VBP N
the DT N
same JJ N
rates NNS N
for IN N
the DT N
control NN N
groups NNS N
were VBD N
78 CD N
% NN N
and CC N
75 CD N
% NN N
. . N

There EX N
was VBD N
a DT N
tendency NN N
for IN N
the DT N
immunized JJ N
groups NNS N
to TO N
enjoy VB N
a DT N
slightly RB o
longer RBR o
recurrence-free JJ o
period NN o
. . o

Over IN N
a DT N
24-month JJ N
observation NN N
period NN N
the DT N
immunized JJ N
group NN N
always RB N
had VBD N
higher JJR N
levels NNS o
of IN o
peripheral JJ o
leukocytes NNS o
and CC o
peripheral JJ o
lymphocytes NNS o
; : o
this DT N
difference NN N
was VBD N
significant JJ N
for IN N
the DT N
first JJ N
21 CD N
months NNS N
. . N

Inhibition NN o
of IN o
bone NN o
marrow NN o
function NN o
is VBZ N
sometimes RB N
observed VBN N
with IN N
radiotherapy NN N
. . N

It PRP N
is VBZ N
hoped VBN N
that IN N
, , N
if IN N
this DT N
inhibition NN N
can MD N
be VB N
mitigated VBN N
, , N
it PRP N
will MD N
be VB N
possible JJ N
to TO N
assist VB N
the DT N
compromised VBN N
immune NN N
system NN N
and CC N
maintain VB N
a DT N
certain JJ o
level NN o
of IN o
immune JJ o
performance NN o
which WDT N
will MD N
prevent VB N
recurrence NN N
and CC N
improve VB o
survival NN o
rate NN o
. . o

In IN N
the DT N
present JJ N
study NN N
we PRP N
observed VBD N
a DT N
tendency NN N
of IN N
the DT N
lower JJR N
recurrence NN N
rate NN N
in IN N
the DT N
immunized JJ N
group NN N
, , N
and CC N
we PRP N
hypothesize VBP N
that IN N
OK-432 NNP i
is VBZ N
effective JJ N
in IN N
extending VBG N
the DT N
recurrence-free JJ N
period NN N
. . N

-DOCSTART- -X- O O

Pedantic JJ i
speaking NN i
style NN N
differentiates VBZ N
Asperger NNP N
syndrome NN N
from IN N
high-functioning JJ N
autism NN N
. . N

Asperger NNP N
syndrome NN N
( ( N
AS IN N
) ) N
is VBZ N
a DT N
pervasive JJ N
developmental NN N
disorder NN N
recently RB N
introduced VBD N
as IN N
a DT N
new JJ N
diagnostic JJ N
category NN N
in IN N
the DT N
ICD-10 NNP N
and CC N
the DT N
DSM-IV NNP N
. . N

Along IN N
with IN N
motor NN N
clumsiness NN N
, , N
pedantic JJ i
speech NN i
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
clinical JJ N
feature NN N
of IN N
AS NNP N
. . N

However RB N
, , N
few JJ N
attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
define VB N
and CC N
measure VB N
this DT N
symptom NN N
. . N

We PRP N
studied VBD N
17 CD p
patients NNS p
with IN p
AS NNP p
( ( p
ICD-10 NNP p
; : p
14 CD p
male NN p
, , p
3 CD p
female NN p
; : p
mean JJ p
age NN p
16.4 CD p
years NNS p
, , p
mean JJ p
full-scale JJ p
IQ NNP p
97 CD p
) ) p
and CC N
compared VBN p
them PRP p
with IN p
a DT p
control NN p
group NN p
of IN p
13 CD p
patients NNS p
with IN p
normal-intelligence JJ p
autism NN p
or CC p
high-functioning JJ p
autism NN p
( ( p
HFA NNP p
) ) p
( ( p
ICD-10/DSM-III-R NNP p
; : p
12 CD p
male NN p
, , p
1 CD p
female NN p
; : p
mean JJ p
age NN p
15.5 CD p
years NNS p
, , p
mean JJ p
full-scale JJ p
IQ NNP p
81.2 CD p
) ) p
. . p

An DT N
operational JJ N
definition NN N
of IN N
pedantic JJ N
speech NN N
was VBD N
formulated VBN N
and CC N
a DT N
rating NN N
scale NN N
devised VBD N
. . N

13 CD p
( ( p
76 CD p
% NN p
) ) p
of IN p
the DT p
AS NNP p
patients NNS p
were VBD N
rated VBN N
as IN N
pedantic JJ o
compared VBN N
to TO N
4 CD p
( ( p
31 CD p
% NN p
) ) p
of IN p
the DT p
HFA NNP p
group NN p
( ( N
chi JJ N
2 CD N
= JJ N
6.3 CD N
; : N
p NN N
= NNP N
.01 NNP N
) ) N
. . N

Results VB N
suggest JJS N
that IN N
pedantic JJ i
speech NN i
is VBZ N
common JJ N
in IN N
AS NNP N
and CC N
may MD N
help VB N
differentiate VB o
AS IN o
from IN o
high-functioning JJ o
autism NN o
. . o

-DOCSTART- -X- O O

[ JJ i
Prophylactic NNP i
intraaortic JJ i
balloon NN i
pumping VBG i
in IN N
high-risk JJ p
cardiac JJ p
surgery NN p
patients NNS p
] VBP p
. . N

BACKGROUND NNP N
We PRP N
examined VBD N
the DT N
impact NN N
of IN N
prophylactic JJ i
IABP NNP i
insertion NN i
in IN N
EuroSCORE-stratified JJ p
high-risk JJ p
cardiac NN p
surgery NN p
patients NNS p
with IN p
a DT p
score NN p
?8 NN p
. . p

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP N
randomized JJ N
trial NN N
with IN p
104 CD p
patients NNS p
either CC i
without IN i
prophylactic JJ i
IABP NNP i
insertion NN i
( ( i
group NN i
A NNP p
, , p
n=52 NN p
) ) p
or CC p
with IN p
IABP NNP i
( ( i
group NN i
B NNP p
, , p
n=52 NN p
) ) p
was VBD p
conducted VBN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
30-day JJ o
mortality NN o
. . o

RESULTS VB o
The DT p
median JJ p
age NN p
of IN p
the DT p
patients NNS p
was VBD p
74 CD p
years NNS p
and CC p
43 CD p
% NN p
of IN p
participants NNS p
were VBD p
females NNS o
. . o

The DT o
30-day JJ o
mortality NN o
did VBD o
not RB o
differ VB N
between IN N
group NN N
A NNP N
( ( N
17.3 CD N
% NN N
) ) N
and CC N
group NN N
B NNP N
( ( N
13.4 CD N
% NN N
; : N
p=0.78 NN N
) ) N
. . N

The DT o
median JJ o
hospital NN o
stay NN o
was VBD o
14 CD N
days NNS N
in IN N
both DT N
groups NNS N
. . N

Intra- NNP N
and CC N
postoperative JJ i
IABP NNP i
support NN i
was VBD N
required VBN N
by IN N
13 CD N
patients NNS N
( ( N
21 CD N
% NN N
) ) N
in IN N
group NN N
A NNP N
. . N

The DT o
median JJ o
ventilation NN o
time NN o
( ( o
14 CD o
hours NNS N
versus VBD N
13 CD N
hours NNS N
) ) N
, , N
median JJ o
catecholamine NN o
dose NN o
, , o
frequency NN o
of IN o
dialysis-dependent JJ o
acute JJ o
renal JJ o
failure NN o
( ( o
28 CD o
% NN N
versus IN N
18 CD N
% NN N
) ) N
, , N
cardiac JJ o
indices NNS o
, , o
and CC o
frequency NN o
of IN o
a DT o
low JJ o
cardiac JJ o
output NN o
syndrome NN o
( ( o
26 CD o
% NN N
versus IN N
25 CD N
% NN N
) ) N
did VBD N
not RB N
significantly RB N
differ VBP N
between IN N
groups NNS N
. . N

CONCLUSION NNP N
Prophylactic NNP i
preoperative JJ i
IABP NNP i
insertion NN i
in IN i
EuroSCORE-stratified JJ p
high-risk JJ p
patients NNS p
is VBZ p
not RB N
associated VBN N
with IN N
decreased JJ N
30-day JJ N
mortality NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Efficacy NNP N
of IN N
immunomodulating VBG i
treatment NN i
in IN N
patients NNS p
with IN p
different JJ p
degrees NNS p
of IN p
immunosuppression NN p
] NNP p
. . N

Immunodepression NNP N
is VBZ N
a DT N
common JJ N
condition NN N
in IN N
patients NNS N
undergoing JJ N
elective JJ N
operations NNS N
and CC N
it PRP N
constitutes VBZ N
a DT N
high JJ N
risk NN N
for IN N
the DT N
onset NN N
of IN N
postoperative JJ N
infective JJ N
complications NNS N
. . N

The DT N
use NN N
of IN N
immunomodulatory NN i
drugs NNS i
has VBZ N
proved VBN N
useful JJ N
in IN N
the DT N
prophylaxis NN N
of IN N
these DT N
complications NNS N
, , N
although IN N
the DT N
precise JJ N
indications NNS N
for IN N
each DT N
drug NN N
have VBP N
not RB N
yet RB N
been VBN N
clearly RB N
codified VBN N
. . N

The DT N
present JJ N
study NN N
aimed VBN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
thymostimulin NN i
in IN N
patients NNS p
with IN p
different JJ p
degrees NNS p
of IN p
immunodepression NN p
, , N
by IN N
evaluating VBG N
both PDT N
the DT N
incidence NN o
of IN o
postoperative JJ o
infections NNS o
and CC N
the DT N
changes NNS o
induced VBN o
in IN N
various JJ N
immunological JJ o
parameters NNS o
. . o

The DT N
results NNS N
obtained VBD N
indicated JJ N
that IN N
those DT N
subjects NNS N
with IN N
the DT N
highest JJS N
degree NN N
of IN N
immunodepression NN N
( ( N
hypo-anergic JJ N
) ) N
benefited VBD N
most JJS N
from IN N
drug NN i
therapy NN i
in IN N
comparison NN N
to TO N
those DT N
with IN N
a DT N
lesser JJR N
degree NN N
of IN N
immunodepression NN N
( ( N
relatively RB N
hypo-ergic NN N
) ) N
. . N

The DT N
advantages NNS N
were VBD N
evident JJ N
in IN N
hypo-anergic JJ N
subjects NNS N
both DT N
with IN N
regard NN N
to TO N
the DT N
frequency NN o
of IN o
early JJ o
postoperative JJ o
infections NNS o
, , N
and CC N
with IN N
regard NN N
to TO N
immunological JJ o
parameters NNS o
. . o

On IN N
the DT N
other JJ N
hand NN N
, , N
in IN N
relatively RB N
hypo-ergic JJ N
subjects NNS N
, , N
benefits NNS N
were VBD N
limited VBN N
to TO N
the DT N
improvement NN N
of IN N
some DT N
immunological JJ o
parameters NNS o
. . o

In IN N
our PRP$ N
opinion NN N
, , N
the DT N
use NN N
of IN N
thymostimulin NN i
is VBZ N
of IN N
particular JJ N
use NN N
only RB N
in IN N
those DT N
subjects NNS N
with IN N
marked JJ N
immunodepression NN N
since IN N
the DT N
incidence NN N
of IN N
post-operative JJ o
sepsis NN o
is VBZ N
highest JJS N
in IN N
this DT N
group NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
the DT N
efficacy NN o
of IN N
a DT N
heparin NN i
and CC i
vancomycin JJ i
solution NN i
in IN N
preventing VBG N
central JJ o
venous JJ o
catheter NN o
infections NNS o
in IN p
children NNS p
. . p

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
adding VBG N
vancomycin NN i
to TO i
central JJ i
venous JJ i
catheter NN i
( ( i
CVC NNP i
) ) i
flush NN i
solution NN N
would MD N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
bacteremia NN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
. . N

STUDY NNP N
DESIGN NNP N
Fifty-five JJ p
children NNS p
with IN p
cancer NN p
and CC p
eight CD p
children NNS p
given VBN p
total JJ p
parenteral JJ p
nutrition NN p
by IN p
the DT p
surgery NN p
or CC p
nutrition NN p
support NN p
services NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
heparin NN i
CVC NNP i
flush JJ i
solution NN i
( ( N
n JJ N
= NNP N
31 CD N
) ) N
or CC N
a DT N
heparin-vancomycin JJ i
CVC NNP i
flush NN i
solution NN i
( ( N
n JJ N
= NNP N
32 CD N
) ) N
. . N

RESULTS NNP N
During IN N
9158 CD N
catheter NN N
days NNS N
, , N
6.5 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
heparin NN N
group NN N
and CC N
15.6 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
heparin-vancomycin JJ N
group NN N
had VBD N
bacteremia VBN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
( ( N
p JJ N
= NNP N
0.43 CD N
) ) N
. . N

The DT N
mean JJ o
rates NNS o
of IN o
bacteremia NN o
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
were VBD N
0.6/1000 CD N
catheter NN N
days NNS N
in IN N
the DT N
heparin NN N
group NN N
and CC N
1.4/1000 CD N
catheter NN N
days NNS N
in IN N
the DT N
heparin-vancomycin JJ N
group NN N
( ( N
p JJ N
= NNP N
0.25 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
when WRB N
the DT N
time NN o
to TO o
the DT o
first JJ o
episode NN o
of IN o
bacteremia NN o
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
a DT N
vancomycin-susceptible JJ N
organism NN N
was VBD N
compared VBN N
by IN N
means NNS N
of IN N
Kaplan-Meier NNP N
survival NN N
estimates NNS N
. . N

Streptococcus NNP o
viridans NNPS o
infection NN o
was VBD N
not RB N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
vancomycin NN N
to TO N
heparin VB N
CVC NNP N
flush JJ N
solution NN N
did VBD N
not RB N
reduce VB N
bacteremia NN o
with IN N
vancomycin-susceptible JJ N
organisms NNS N
. . N

Bacteremia NNP o
with IN N
Streptococcus NNP N
viridans NNS N
was VBD N
not RB N
related VBN N
to TO N
the DT N
use NN N
of IN N
a DT N
CVC NNP N
. . N

-DOCSTART- -X- O O

Antiinflammatory JJ o
effects NNS o
of IN N
the DT N
phosphodiesterase-4 JJ i
inhibitor NN i
cilomilast NN i
( ( i
Ariflo NNP i
) ) i
in IN N
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
. . p

Cilomilast NNP i
( ( i
Ariflo NNP i
) ) i
, , N
a DT N
new JJ N
oral JJ i
phosphodiesterase-4 JJ i
selective JJ i
inhibitor NN i
, , N
improves VBZ N
lung JJ o
function NN o
in IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
. . N

We PRP N
have VBP N
evaluated VBN N
its PRP$ N
antiinflammatory JJ o
effects NNS o
in IN N
59 CD p
patients NNS p
with IN p
COPD NNP p
randomized VBD p
to TO N
receive VB N
cilomilast NN i
, , N
15 CD N
mg NN N
two CD N
times NNS N
a DT N
day NN N
, , N
or CC N
placebo NN i
for IN N
12 CD N
weeks NNS N
. . N

Induced NNP o
sputum JJ o
differential NN o
cell NN o
counts NNS o
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
five CD N
further JJ N
visits NNS N
. . N

Interleukin-8 NNP o
and CC o
neutrophil JJ o
elastase NN o
were VBD N
measured VBN N
in IN N
sputum NN N
supernatant NN N
. . N

Bronchial JJ N
biopsies NNS N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
Week NNP N
10 CD N
were VBD N
immunostained VBN N
and CC N
counted VBN N
for IN N
neutrophils NNS o
, , o
CD8+ NNP o
and CC o
CD4+ NNP o
T-lymphocyte NNP o
subsets NNS o
, , o
and CC o
CD68+ NNP o
macrophages NNS o
. . o

Cells NNP N
expressing VBG N
the DT N
genes NNS o
for IN o
interleukin-8 NN o
and CC o
tumor NN o
necrosis NN o
factor-alpha NN o
were VBD N
identified VBN N
by IN N
in IN N
situ JJ N
hybridization NN N
and CC N
quantified VBD N
. . N

Compared VBN N
with IN N
placebo NN i
, , N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
of IN N
the DT N
change NN N
from IN N
baseline NN N
showed VBD N
that IN N
cilomilast NN i
did VBD N
not RB N
alter VB N
any DT N
sputum JJ o
endpoint NN o
or CC o
FEV1 NNP o
. . o

However RB N
, , N
bronchial JJ N
biopsies NNS N
demonstrated VBD N
that IN N
cilomilast NN i
treatment NN N
was VBD N
associated VBN N
with IN N
reductions NNS o
in IN o
CD8+ NNP o
( ( N
p JJ N
= VBZ N
0.001 CD N
; : N
ANOVA NNP N
) ) N
and CC N
CD68+ NNP o
cells NNS o
( ( N
p JJ N
< VBZ N
0.05 CD N
; : N
ANOVA NNP N
) ) N
. . N

In IN N
addition NN N
, , N
by IN N
Poisson NNP N
analysis NN N
, , N
comparison NN N
of IN N
cell NN N
counts NNS N
analyzed VBN N
as IN N
a DT N
ratio NN N
of IN N
active JJ N
to TO N
placebo VB N
demonstrated JJ N
reductions NNS o
of IN o
CD8+ NNP o
( ( N
48 CD N
% NN N
p NN N
< NNP N
0.01 CD N
) ) N
and CC N
CD68+ NNP o
( ( N
47 CD N
% NN N
p NN N
= NNP N
0.001 CD N
) ) N
cells NNS N
. . N

This DT N
is VBZ N
the DT N
first JJ N
demonstration NN N
of IN N
reduction NN N
by IN N
any DT N
agent NN N
of IN N
airway JJ o
tissue NN o
inflammatory NN o
cells NNS o
characteristic JJ N
of IN N
COPD NNP N
. . N

Phosphodiesterase-4 JJ i
inhibitors NNS i
represent VBP N
a DT N
promising JJ N
new JJ N
class NN N
of IN N
substances NNS N
for IN N
use NN N
in IN N
antiinflammatory JJ N
treatment NN N
of IN N
this DT N
disease NN N
. . N

-DOCSTART- -X- O O

First-line JJ i
cisplatin NN i
with IN i
docetaxel NN i
or CC i
vinorelbine NN i
in IN N
patients NNS p
with IN p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
: : p
a DT N
quality NN p
of IN p
life NN p
directed VBN p
phase NN p
II NNP p
randomized VBD p
trial NN p
of IN p
Gruppo NNP p
Oncologico NNP p
Italia NNP p
Meridionale NNP p
. . p

BACKGROUND NNP N
Quality NNP o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
has VBZ N
gained VBN N
greater JJR N
importance NN N
in IN N
the DT N
management NN N
of IN N
metastatic JJ p
non-small-cell JJ p
lung NN p
cancer NN p
due JJ N
to TO N
the DT N
palliative JJ N
nature NN N
of IN N
treatment NN N
. . N

Docetaxel NNP i
( ( i
DCT NNP i
) ) i
and CC i
cisplatin NN i
( ( i
CDDP NNP i
) ) i
doublet NN i
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
associated VBN N
to TO N
a DT N
better JJR N
QoL NNP N
than IN N
the DT N
weekly JJ N
vinorelbine NN i
( ( i
VNR NNP i
) ) i
and CC i
CDDP NNP i
regimen NNS N
. . N

Recently RB N
a DT N
newer NN N
more RBR N
tolerated JJ N
schedule NN N
of IN N
the DT N
VNR/CDDP NNP i
regimen NN N
has VBZ N
been VBN N
published VBN N
and CC N
is VBZ N
widely RB N
employed VBN N
in IN N
medical JJ N
practice NN N
. . N

The DT N
impact NN N
of IN N
these DT N
regimens NNS N
on IN N
patients NNS N
' POS N
QoL NNP N
as RB N
well RB N
as IN N
symptoms NNS o
control NN o
and CC o
type NN o
and CC N
grading VBG N
chemo-related JJ N
side-effects NNS o
has VBZ N
been VBN N
compared VBN N
prospectically RB N
. . N

METHODS NNP N
Patients NNPS p
received VBD N
CDDP NNP i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
plus CC i
DCT NNP i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
on IN N
day NN N
1 CD N
every DT N
weeks NNS N
( ( N
arm IN N
A NNP N
) ) N
or CC N
CDDP $ i
80 CD i
mg/m NN i
( ( i
2 CD i
) ) i
on IN i
day NN i
1 CD i
plus CC i
VNR NNP i
30 CD i
mg/m NN i
( ( i
2 CD i
) ) i
day NN N
1 CD N
and CC N
8 CD N
every DT N
3 CD N
weeks NNS N
( ( N
arm NN N
B NNP N
) ) N
. . N

G-CSF NNP i
and/or JJ i
EPO NNP i
were VBD N
employed VBN N
as IN N
needed VBN N
. . N

Health-related JJ o
QoL NNP o
was VBD N
assessed VBN N
at IN N
entry NN N
and CC N
after IN N
every DT N
cycle NN N
by IN N
the DT N
EORTC-QLQ-C30 NNP N
and CC N
LC13 NNP o
questionnaires NNS o
, , o
toxicity NN o
by IN N
the DT N
NCI-NCCN NNP N
CTC NNP N
vs NN N
2 CD N
, , N
and CC N
intent-to-treat JJ N
objective JJ o
response NN o
by IN N
the DT N
Recist NNP N
criteria NNS N
. . N

RESULTS VB N
The DT N
QoL NNP o
questionnaires NNS o
were VBD N
completed VBN N
by IN N
37 CD p
pts NNS p
( ( p
88 CD p
% NN p
) ) p
in IN p
the DT p
DCT/CDDP NNP i
arm NN p
and CC N
39 CD p
pts NNS p
( ( p
87 CD p
% NN p
) ) p
in IN p
the DT p
VNR/CDDP NNP i
one NN p
. . p

Baseline JJ N
mean JJ N
scores NNS N
and CC N
rates NNS N
at IN N
which WDT N
pts NNS N
failed VBD N
to TO N
complete VB N
QoL NNP N
assessment NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
arms NNS N
. . N

Global NNP o
health NN o
status NN o
of IN N
the DT N
EORTC NNP o
QLQ-C30 NNP o
scale NN o
and CC N
specific JJ o
symptoms NNS o
control NN o
( ( N
LC13 NNP N
module NN N
) ) N
improved VBD N
during IN N
treatment NN N
without IN N
any DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
arms NNS N
. . N

Emotional JJ o
functioning NN o
remained VBD N
stable JJ N
in IN N
both DT N
groups NNS N
during IN N
treatment NN N
, , N
whereas JJ N
physical JJ o
and CC o
role NN o
improved VBN N
slightly RB N
. . N

In IN N
the DT N
DCT/CDDP NNP i
arm NN N
14 CD N
pts NNS N
( ( N
33 CD N
% NN N
; : N
95 CD N
% NN N
CL NNP N
24-40 CD N
% NN N
) ) N
had VBD N
PR NNP N
, , N
and CC N
10 CD N
( ( N
24 CD N
% NN N
) ) N
SD NNP N
for IN N
a DT N
57 CD N
% NN N
TGCR NNP N
. . N

In IN N
the DT N
VNR/CDDP NNP i
arm NN N
12 CD N
pts NNS N
( ( N
27 CD N
% NN N
) ) N
achieved VBD N
PR NNP o
, , N
18 CD N
( ( N
41 CD N
% NN N
) ) N
SD VBZ N
a DT N
68 CD N
% NN N
TGCR NNP N
. . N

Differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Median JJ o
time-to-progression NN o
was VBD N
4.2 CD N
months NNS N
in IN N
the DT N
DCT/CDDP NNP i
arm NN N
and CC N
4.5 CD N
months NNS N
in IN N
the DT N
VNR/CDDP NNP i
one CD N
, , N
and CC N
median JJ o
overall JJ o
survival NN o
was VBD N
12.1 CD N
( ( N
range VB N
1-26+ JJ N
months NNS N
) ) N
and CC N
12.5 CD N
months NNS N
( ( N
range VB N
1-28+ JJ N
months NNS N
) ) N
for IN N
DCT/CDDP NNP i
and CC N
VNR/CDDP NNP i
arms NNS N
, , N
respectively RB N
. . N

Febrile NNP o
neutropenia JJ o
rate NN o
was VBD N
higher RBR N
in IN N
the DT N
VNR/CDDP NNP i
arm NN N
( ( N
p=0.02 NN N
) ) N
as RB N
well RB N
as IN N
G3-4 NNP N
anemia NN o
( ( N
p=0.005 NN N
) ) N
and CC N
G-CSF/EPO NNP N
use NN N
( ( N
p=0.019 NN N
) ) N
. . N

CONCLUSIONS NNP N
Global NNP o
and CC o
specific JJ o
health-related JJ o
QoL NNP o
data NNS N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
with IN N
no DT N
statistically RB N
significant JJ N
difference NN N
. . N

Efficacy NN o
measures NNS o
, , o
overall JJ o
response NN o
rate NN o
, , o
time-to-progression NN o
and CC o
overall JJ o
survival NN o
were VBD N
equivalent JJ N
in IN N
both DT N
arms NNS N
. . N

However RB N
, , N
severe JJ o
anemia NN o
and CC o
febrile JJ o
neutropenia NN o
are VBP N
statistically RB N
more RBR N
frequent JJ N
in IN N
the DT N
VNR/CDDP NNP i
arm NN N
than IN N
in IN N
the DT N
DCT/CDDP NNP i
one NN N
. . N

These DT N
data NNS N
should MD N
be VB N
considered VBN N
in IN N
treatment NN N
decision-making NN N
for IN N
pts NNS p
with IN p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
and CC N
for IN N
the DT N
design NN N
of IN N
future JJ N
trials NNS N
with IN N
chemotherapy NN N
plus CC N
biologics NNS N
. . N

-DOCSTART- -X- O O

[ IN N
The DT N
effects NNS N
of IN N
tirofiban NN i
on IN N
acute JJ N
non-ST JJ N
segment NN N
elevation NN N
myocardial JJ o
infarction NN o
patients NNS p
not RB p
receiving VBG p
early JJ p
reperfusion NN p
intervention NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
tirofiban NN i
in IN N
patients NNS p
with IN p
acute JJ p
non-ST- JJ p
segment NN p
elevation NN p
myocardial JJ p
infarction NN p
( ( p
NSTEMI NNP p
) ) p
without IN p
early JJ p
reperfusion NN p
intervention NN p
. . p

METHODS NNP N
A NNP N
total NN p
of IN p
151 CD p
NSTEMI NNP p
patients NNS p
without IN p
early JJ p
reperfusion NN p
intervention NN p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
and CC N
randomized VBN N
to TO N
the DT N
tirofiban NN i
group NN N
( ( N
n JJ N
= NNP N
76 CD N
) ) N
and CC N
the DT N
control NN i
group NN i
( ( i
n JJ i
= NNP N
75 CD N
) ) N
. . N

Coronary JJ i
angiography NN i
was VBD N
performed VBN N
at IN N
day NN N
3 CD N
and CC N
day NN N
7 CD N
, , N
while IN N
percutaneous JJ N
coronary JJ N
intervention NN i
( ( N
PCI NNP N
) ) N
was VBD N
performed VBN N
when WRB N
necessary JJ N
. . N

Parameters NNS N
including VBG N
thrombolysis NN o
in IN o
myocardial JJ o
infarction NN o
( ( o
TIMI NNP o
) ) o
flow NN o
, , o
bleeding VBG o
complications NNS o
and CC o
clinic JJ o
events NNS o
within IN N
30 CD N
days NNS N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Before IN N
PCI NNP N
, , N
no DT N
increase NN N
in IN N
the DT N
percentage NN o
of IN o
patient NN o
with IN o
TIMI NNP o
flow VBP o
better JJR N
than IN N
TIMI-2 NNP N
was VBD N
observed VBN N
by IN N
the DT N
treatment NN N
of IN N
tirofiban NN i
( ( N
69.3 CD N
% NN N
vs JJ N
78.9 CD N
% NN N
, , N
P NNP N
= NNP N
0.10 CD N
) ) N
. . N

While IN N
after IN N
PCI NNP N
, , N
significant JJ N
increase NN N
in IN N
the DT N
percentage NN o
of IN o
patient NN o
with IN o
TIMI NNP o
flow VBP o
better JJR N
than IN N
TIMI-2 NNP N
was VBD N
manifested VBN N
in IN N
the DT N
tirofiban NN i
group NN N
( ( N
96.0 CD N
% NN N
vs JJ N
100.0 CD N
% NN N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Tirofiban NNP N
treatment NN N
also RB N
significantly RB N
decreased VBD o
the DT o
rate NN o
of IN o
poor JJ o
myocardial JJ o
perfusion NN o
after IN N
PCI NNP N
( ( N
19.7 CD N
% NN N
vs JJ N
34.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

There EX N
were VBD N
0 CD N
and CC N
4 CD N
major JJ o
adverse JJ o
cardiovascular NN o
events NNS o
( ( o
MACE NNP o
) ) o
within IN N
30 CD N
days NNS N
observed VBN N
in IN N
the DT N
tirofiban NN i
group NN N
and CC N
the DT N
control NN N
group NN N
( ( N
0.0 CD N
% NN N
vs JJ N
5.3 CD N
% NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

No DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
found VBN N
in IN N
the DT N
bleeding NN o
complications NNS o
within IN N
30 CD N
days NNS N
including VBG N
the DT N
mild JJ o
hemorrhage NN o
( ( N
5 CD N
vs RB N
4 CD N
cases NNS N
, , N
P NNP N
= NNP N
0.75 CD N
) ) N
, , N
severe JJ o
hemorrhage NN o
( ( N
2 CD N
vs RB N
1 CD N
cases NNS N
, , N
P NNP N
= NNP N
0.56 CD N
) ) N
or CC N
severe JJ o
thrombocytopenia NN o
( ( N
2 CD N
vs RB N
0 CD N
cases NNS N
, , N
P NNP N
= NNP N
0.49 CD N
) ) N
. . N

CONCLUSIONS NNP N
Tirofiban NNP N
treatment NN N
does VBZ N
not RB N
increase VB N
the DT N
bleeding JJ o
complications NNS o
in IN N
NSTEMI NNP p
patients NNS p
without IN p
early JJ p
PCI NNP p
. . p

Tirofiban NN N
can MD N
improve VB N
the DT N
TIMI NNP N
flow NN N
and CC N
the DT N
myocardial JJ N
perfusion NN N
after IN N
PCI NNP N
with IN N
less JJR N
MACE NNP N
within IN N
30 CD N
days NNS N
. . N

-DOCSTART- -X- O O

Comments NNS N
on IN N
Secretin NNP o
and CC N
autism NN o
: : o
a DT N
two-part JJ N
clinical JJ N
investigation NN N
by IN N
M.G NNP N
. . N

Chez NNP N
et CC N
al NN N
. . N

-DOCSTART- -X- O O

Rye NNP i
bran NN i
bread NN i
intake VB i
elevates NNS N
urinary JJ o
excretion NN o
of IN o
ferulic JJ o
acid NN o
in IN p
humans NNS p
, , N
but CC N
does VBZ N
not RB N
affect VB N
the DT N
susceptibility NN o
of IN o
LDL NNP o
to TO o
oxidation VB o
ex FW N
vivo FW N
. . N

BACKGROUND NNP N
Rye NNP i
bread NN i
contributes VBZ N
an DT N
important JJ N
part NN N
of IN N
the DT N
whole JJ N
grain NN N
intake NN N
in IN N
the DT N
Scandinavian JJ p
diet NN N
. . N

Ferulic NNP N
acid NN N
is VBZ N
the DT N
major JJ N
phenolic JJ N
compound NN N
in IN N
rye NN N
bran NN N
and CC N
is VBZ N
an DT N
antioxidant NN N
in IN N
vitro NN N
and CC N
may MD N
, , N
therefore RB N
, , N
contribute NN N
to TO N
cardioprotective JJ N
effects NNS N
of IN N
whole JJ N
grain NN N
consumption NN N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
Firstly NNP N
, , N
to TO N
evaluate VB N
the DT N
bioavailability NN o
and CC o
potential JJ o
antioxidative JJ o
effects NNS o
in IN N
humans NNS N
of IN N
ferulic JJ N
acid NN N
from IN N
rye NN N
. . N

Secondly RB N
, , N
to TO N
evaluate VB N
urine JJ o
levels NNS o
of IN o
ferulic JJ o
acid NN o
as IN N
a DT N
possible JJ N
biomarker NN N
of IN N
the DT N
ordinary JJ N
dietary JJ N
intake NN N
of IN N
ferulic JJ N
acid NN N
. . N

METHODS NNP N
We PRP N
determined VBD N
the DT N
urinary JJ o
excretion NN o
of IN o
ferulic JJ o
acid NN o
in IN N
18 CD p
postmenopausal JJ p
women NNS p
after IN p
a DT p
dietary JJ i
intake NN i
of IN i
rye NN i
bran NN i
or CC i
an DT i
inert JJ i
wheat NN i
bran NN i
( ( i
control NN i
) ) i
in IN p
a DT p
crossover NN p
study NN p
( ( p
2 CD p
x RB p
6 CD p
weeks NNS p
with IN p
4 CD p
weeks NNS p
washout NN p
) ) p
. . N

The DT N
potential JJ N
antioxidative JJ N
effect NN N
of IN N
the DT N
rye NN N
bran NN N
intervention NN N
was VBD N
investigated VBN N
by IN N
measuring VBG N
low-density NN o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
susceptibility NN o
to TO o
copper VB o
oxidation NN o
ex FW o
vivo NN o
. . o

The DT N
subjects NNS N
ingested VBN N
rye NN N
bran NN N
enriched VBD N
breads NNS N
equivalent JJ N
to TO N
approximately RB N
10.2 CD N
mg NNS N
ferulic JJ N
acid JJ N
per IN N
day NN N
. . N

RESULTS VB N
The DT N
urinary JJ o
excretion NN o
of IN o
ferulic JJ o
acid NNS o
averaged VBD N
approximately RB N
4.8 CD N
mg NNS N
per IN N
day NN N
during IN N
intervention NN N
with IN N
rye NN i
bran NN i
breads NNS i
and CC N
approximately RB N
1.9 CD N
mg NNS N
per IN N
day NN N
on IN N
the DT N
control NN i
breads VBZ i
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Rye NNP i
bran NN i
intervention NN i
had VBD N
no DT N
influence NN N
on IN N
lag NN o
time NN o
or CC o
propagation NN o
rate NN o
of IN o
the DT o
LDL NNP o
oxidation NN o
ex NN N
vivo NN N
. . N

CONCLUSIONS VB N
The DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
ferulic JJ N
acid NN N
from IN N
rye NN N
bran NN N
is VBZ N
bioavailable JJ N
and CC N
that IN N
the DT N
urinary JJ N
concentration NN N
of IN N
ferulic JJ N
acid NN N
reflects VBZ N
the DT N
dietary JJ N
intake NN N
of IN N
this DT N
hydroxycinnamic JJ N
acid NN N
. . N

Within IN N
the DT N
period NN N
of IN N
intervention NN N
, , N
the DT N
elevated JJ N
ferulic JJ N
acid NN N
did VBD N
not RB N
produce VB N
a DT N
measurable JJ N
antioxidative JJ o
effect NN o
on IN N
the DT N
subjects NNS N
' POS N
LDL NNP N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
the DT N
determination NN N
of IN N
ferulic JJ N
acid NN N
in IN N
urine NN N
is VBZ N
a DT N
useful JJ N
biomarker NN N
to TO N
assess VB N
the DT N
intake NN o
of IN o
ferulic JJ o
acid NN o
from IN N
a DT N
regular JJ N
diet NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
digoxin NN i
on IN N
muscle NN N
reflexes NNS N
in IN N
normal JJ p
humans NNS p
. . p

Blockade NNP N
of IN N
the DT N
skeletal JJ N
muscle NN N
Na NNP N
( ( N
+ NNP N
) ) N
-K NN N
( ( N
+ NNP N
) ) N
-ATPase NN N
pump NN N
by IN N
digoxin NN i
could MD N
result VB N
in IN N
a DT N
more RBR N
marked JJ N
hyperkaliema NN N
during IN N
a DT N
forearm JJ N
exercise NN N
, , N
which WDT N
in IN N
turn NN N
could MD N
stimulate VB N
the DT N
mechano- NN N
and CC N
metaboreceptors NNS N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
, , N
and CC N
cross-over-design NN N
study NN N
, , N
we PRP N
measured VBD N
mean JJ o
blood NN o
pressure NN o
( ( o
MBP NNP o
) ) o
, , o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
, , o
ventilation NN o
( ( o
V NNP o
( ( o
E NNP o
) ) o
) ) o
, , o
oxygen JJ o
saturation NN o
( ( o
SpO NNP o
( ( o
2 CD o
) ) o
) ) o
, , o
muscle FW o
sympathetic JJ o
nerve NN o
activity NN o
( ( o
MSNA NNP o
) ) o
, , o
venous JJ o
plasma NN o
potassium NN o
and CC o
lactic JJ o
acid NN o
during IN o
dynamic JJ o
handgrip NN o
exercises NNS o
, , o
and CC o
local JJ o
circulatory NN o
arrest NN o
in IN N
11 CD p
healthy JJ p
subjects NNS p
. . p

Digoxin NNP i
enhanced VBD N
MBP NNP o
during IN N
exercise NN N
but CC N
not RB N
during IN N
the DT N
post-handgrip JJ N
ischemia NN N
and CC N
had VBD N
no DT N
effect NN N
on IN N
HR NNP o
, , o
V NNP o
( ( o
E NNP o
) ) o
, , o
SpO NNP o
( ( o
2 CD o
) ) o
, , o
and CC o
MSNA NNP o
. . o

Venous NNP o
plasma JJ o
potassium NN o
and CC o
lactic JJ o
acid NN o
were VBD N
also RB N
not RB N
affected VBN N
by IN N
digoxin-induced JJ i
skeletal JJ N
muscle NN N
Na NNP N
( ( N
+ NNP N
) ) N
-K NN N
( ( N
+ NNP N
) ) N
-ATPase NN N
blockade NN N
. . N

We PRP N
conclude VBP N
that IN N
digoxin NN i
increased VBD N
MBP NNP N
during IN N
dynamic JJ N
exercise NN N
in IN N
healthy JJ p
humans NNS p
, , N
independently RB N
of IN N
changes NNS N
in IN N
potassium NN N
and CC N
lactic JJ N
acid NN N
. . N

A DT N
modest JJ N
direct JJ N
sensitization NN N
of IN N
the DT N
muscle NN N
mechanoreceptors NNS N
is VBZ N
unlikely JJ N
and CC N
other JJ N
mechanisms NNS N
, , N
independent JJ N
of IN N
muscle NN N
reflexes NNS N
and CC N
related VBN N
to TO N
the DT N
inotropic JJ N
effects NNS N
of IN N
digoxin NN i
, , N
might MD N
be VB N
implicated VBN N
. . N

-DOCSTART- -X- O O

Combining VBG N
afferent JJ i
stimulation NN i
and CC i
mirror NN i
therapy NN i
for IN N
rehabilitating VBG N
motor NN o
function NN o
, , o
motor NN o
control NN o
, , o
ambulation NN o
, , o
and CC o
daily JJ o
functions NNS o
after IN o
stroke NN o
. . o

BACKGROUND NNP N
Mirror NNP i
therapy NN i
( ( i
MT NNP i
) ) i
and CC i
mesh JJ i
glove NN i
( ( i
MG NNP i
) ) i
afferent NN i
stimulation NN i
may MD N
be VB N
effective JJ N
in IN N
reducing VBG N
motor NN N
impairment NN N
after IN N
stroke NN N
. . N

A DT N
hybrid JJ N
intervention NN N
of IN N
MT NNP i
combined VBD i
with IN i
MG NNP i
( ( i
MT NNP i
+ NNP i
MG NNP i
) ) i
may MD N
broaden VB N
aspects NNS N
of IN N
treatment NN N
benefits NNS N
. . N

OBJECTIVE NNP N
To TO N
demonstrate VB N
the DT N
comparative JJ N
effects NNS N
of IN N
MG NNP i
+ NNP i
MT NNP i
, , i
MT NNP i
, , N
and CC N
a DT N
control NN i
treatment NN i
( ( i
CT NNP i
) ) i
on IN N
the DT N
outcomes NNS N
of IN N
motor NN N
impairments NNS N
, , N
manual JJ N
dexterity NN N
, , N
ambulation NN N
function NN N
, , N
motor NN N
control NN N
, , N
and CC N
daily JJ N
function NN N
. . N

METHODS NNP N
Forty-three JJ p
chronic JJ p
stroke NN p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
upper JJ p
extremity NN p
impairment NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
MT NNP i
+ NNP i
MG NNP i
, , i
MT NNP i
, , N
or CC N
CT NNP i
for IN N
1.5 CD N
hours/day NN N
, , N
5 CD N
days/week NN N
for IN N
4 CD N
weeks NNS N
. . N

Outcome NNP N
measures NNS N
were VBD N
the DT N
Fugl-Meyer NNP o
Assessment NNP o
( ( o
FMA NNP o
) ) o
and CC o
muscle NN o
tone NN o
measured VBN o
by IN o
Myoton-3 NNP o
for IN o
motor NN o
impairment NN o
and CC N
the DT N
Box NNP o
and CC o
Block NNP o
Test NNP o
( ( o
BBT NNP o
) ) o
and CC N
10-Meter JJ o
Walk NNP o
Test NNP o
( ( o
10 CD o
MWT NNP o
) ) o
for IN N
motor NN N
function NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
kinematic JJ o
parameters NNS o
for IN o
motor NN o
control NN o
and CC N
the DT N
Motor NNP o
Activity NNP o
Log NNP o
and CC N
ABILHAND NNP o
Questionnaire NNP o
for IN o
daily JJ o
function NN o
. . o

RESULTS NNP N
FMA NNP o
total JJ o
scores NNS o
were VBD N
significantly RB N
higher JJR N
and CC N
synergistic JJ o
shoulder NN o
abduction NN o
during IN o
reach NN o
was VBD N
less RBR N
in IN N
the DT N
MT NNP i
+ NNP i
MG NNP i
and CC N
MT NNP i
groups NNS N
compared VBN N
with IN N
the DT N
CT NNP i
group NN N
. . N

Performance NN N
on IN N
the DT N
BBT NNP o
and CC N
the DT N
10 CD o
MWT NNP o
( ( N
velocity NN N
and CC N
stride JJ N
length NN N
in IN N
self-paced JJ N
task NN N
and CC N
velocity NN N
in IN N
as-quickly-as-possible JJ N
task NN N
) ) N
were VBD N
improved VBN N
after IN N
MT NNP i
+ NNP i
MG NNP i
compared VBN N
with IN N
MT NNP i
. . i

CONCLUSIONS NNP N
MT NNP i
+ NNP i
MG NNP i
improved VBD N
manual JJ o
dexterity NN o
and CC o
ambulation NN o
. . o

MT NNP i
+ NNP i
MG NNP i
and CC N
MT NNP i
reduced VBD N
motor NN o
impairment NN o
and CC o
synergistic JJ o
shoulder NN o
abduction NN o
more JJR N
than IN N
CT. NNP i
Future NNP N
studies NNS N
may MD N
integrate VB N
functional JJ N
task NN N
practice NN N
into IN N
treatments NNS N
to TO N
enhance VB N
functional JJ N
outcomes NNS N
in IN N
patients NNS N
with IN N
various JJ N
levels NNS N
of IN N
motor NN N
severity NN N
. . N

The DT N
long-term JJ N
effects NNS N
of IN N
MG NNP i
+ NNP i
MT NNP i
remain VBP N
to TO N
be VB N
evaluated VBN N
. . N

-DOCSTART- -X- O O

Cost-effectiveness NN o
of IN N
ablation NN i
surgery NN i
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
undergoing VBG p
cardiac JJ p
surgery NN p
. . p

This DT N
study NN N
was VBD N
performed VBN N
to TO N
assess VB N
the DT N
cost-effectiveness NN N
of IN N
concomitant JJ N
ablation NN i
surgery NN i
( ( i
AS IN i
) ) i
compared VBN N
to TO N
regular VB N
cardiac JJ i
surgery NN i
in IN N
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
patients NNS p
over IN N
a DT N
one-year JJ N
follow-up NN N
. . N

Cost NN o
analysis NN o
was VBD N
performed VBN N
from IN N
a DT N
societal JJ N
perspective NN N
alongside IN N
a DT N
prospective JJ N
, , N
randomised JJ N
, , N
double-blinded JJ N
, , N
multicentre JJ N
trial NN N
. . N

One CD p
hundred CD p
and CC p
fifty JJ p
patients NNS p
with IN p
documented JJ p
AF NNP p
were VBD N
randomly RB i
assigned VBN i
to TO i
undergo VB i
cardiac JJ i
surgery NN i
with IN i
or CC i
without IN i
AS NNP i
. . i

One CD p
hundred CD p
and CC p
thirty-two JJ p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
cost-effectiveness NN i
study NN p
. . p

All DT o
costs NNS o
( ( o
medical JJ o
and CC o
non-medical JJ o
) ) o
were VBD N
measured VBN N
during IN N
follow-up JJ N
. . N

Costs NNS o
data NNS o
were VBD N
combined VBN N
with IN N
quality NN o
adjusted VBN o
life NN o
years NNS o
( ( N
QALYs NNP N
) ) N
to TO N
obtain VB N
the DT N
incremental JJ N
costs NNS N
per IN N
QALY NNP N
. . N

Total JJ o
costs NNS o
of IN N
the DT N
AS NNP i
group NN N
were VBD N
significantly RB N
higher JJR N
compared VBN N
to TO N
the DT N
regular JJ N
cardiac NN N
surgery NN N
group NN N
[ VBZ N
cost NN N
difference NN N
bootstrap NN N
: : N
?4,724 NN N
; : N
95 CD N
% NN N
uncertainty NN N
interval NN N
( ( N
UI NNP N
) ) N
, , N
?2,770-?6,678 JJ N
] NN N
. . N

The DT N
bootstrapped JJ N
difference NN o
in IN o
QALYs NNP o
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
0.06 CD N
; : N
95 CD N
% NN N
UI NN N
: : N
-0.024 NN N
to TO N
0.14 CD N
) ) N
. . N

The DT N
incremental JJ N
cost-effectiveness JJ N
ratio NN N
is VBZ N
?73,359 JJ N
per IN N
QALY NNP o
. . o

The DT o
acceptability NN N
curve NN N
showed VBD N
that IN N
, , N
even RB N
in IN N
the DT N
case NN N
of IN N
a DT N
maximum JJ N
threshold JJ N
value NN N
of IN N
?80,000 NNP N
per IN o
QALY NNP o
gained VBD N
, , N
the DT N
probability NN i
of IN i
AS NNP i
being VBG i
more RBR N
cost-effective JJ N
than IN N
regular JJ N
cardiac JJ N
surgery NN N
did VBD N
not RB N
reach VB N
beyond IN N
50 CD N
% NN N
. . N

Concluding VBG N
that DT N
concomitant NN i
AS IN i
in IN i
AF NNP i
is VBZ N
not RB N
cost-effective JJ N
after IN N
a DT N
one-year JJ N
follow-up NN N
compared VBN N
to TO N
regular VB N
cardiac JJ N
surgery NN N
. . N

-DOCSTART- -X- O O

New NNP i
methods NNS i
applied VBN N
to TO N
the DT N
analysis NN N
and CC N
treatment NN N
of IN N
ovarian JJ p
cancer NN p
. . p

-DOCSTART- -X- O O

Improved NNP N
local JJ N
control NN N
of IN N
invasive JJ N
bladder NN N
cancer NN N
by IN N
concurrent NN i
cisplatin NN i
and CC i
preoperative NN i
or CC i
definitive JJ i
radiation NN i
. . i

The DT N
National NNP N
Cancer NNP N
Institute NNP N
of IN N
Canada NNP N
Clinical NNP N
Trials NNP N
Group NNP N
. . N

PURPOSE NNP N
A NNP N
prospective JJ N
randomized VBN N
trial NN N
was VBD N
conducted VBN N
to TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
concurrent NN i
cisplatin NN i
to TO i
preoperative VB i
or CC i
definitive JJ i
radiation NN i
therapy NN i
in IN N
patients NNS p
with IN p
muscle-invasive JJ p
bladder NN p
cancer NN p
improved VBD p
local JJ o
control NN o
or CC o
survival NN o
. . o

PATIENTS NNP N
AND CC N
METHODS NNP N
Ninety-nine NNP p
eligible JJ p
patients NNS p
with IN p
T2 NNP p
to TO p
T4b NNP p
transitional JJ p
cell NN p
bladder NN p
cancer NN p
participated VBD p
, , p
64 CD p
% NN p
with IN p
cT3b NN p
or CC p
cT4 NN p
. . p

Patients NNS N
and CC N
their PRP$ N
physicians NNS N
selected VBN N
either RB N
definitive JJ N
radiotherapy NN i
or CC i
precystectomy JJ i
radiotherapy NN i
; : i
patients NNS N
were VBD N
then RB N
randomly RB N
allocated VBN N
to TO N
receive VB N
intravenous JJ i
cisplatin NNS i
100 CD N
mg/m2 NNS N
at IN N
2-week JJ N
intervals NNS N
for IN N
three CD N
cycles NNS N
concurrent VBP i
with IN i
pelvic JJ i
radiation NN i
, , N
or CC N
to TO N
receive VB i
radiation NN i
without IN i
chemotherapy NN i
. . i

Patients NNS N
were VBD N
stratified VBN N
by IN N
clinical JJ N
tumor NN N
stage NN N
and CC N
by IN N
radiation NN N
plan NN N
. . N

The DT N
median JJ N
follow-up JJ N
duration NN N
is VBZ N
6.5 CD N
years NNS N
. . N

RESULTS VB N
The DT N
occurrence NN o
of IN o
distant JJ o
metastases NNS o
was VBD N
the DT N
same JJ N
in IN N
both DT N
study NN N
arms NNS N
. . N

However RB N
, , N
25 CD N
of IN N
48 CD N
control NN N
patients NNS N
have VBP N
had VBD N
a DT N
first JJ o
recurrence NN o
in IN N
the DT N
pelvis NN N
, , N
compared VBN N
with IN N
15 CD N
of IN N
51 CD N
cisplatin-treated JJ i
patients NNS N
( ( N
P NNP N
= NNP N
.036 NNP N
) ) N
. . N

The DT N
pelvic JJ o
relapse NN o
rate NN o
in IN N
the DT N
two CD N
groups NNS N
was VBD N
significantly RB N
reduced VBN N
by IN N
concurrent NN i
cisplatin NN i
( ( N
P NNP N
= NNP N
.038 NNP N
, , N
log-rank JJ N
test NN N
) ) N
and CC N
this DT N
effect NN N
was VBD N
preserved VBN N
in IN N
a DT N
stepwise NN N
Cox NNP N
regression NN N
model NN N
of IN N
prognostic JJ N
factors NNS N
( ( N
hazards NNS N
ratio NN N
, , N
0.50 CD N
; : N
90 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.29 CD N
to TO N
0.86 CD N
; : N
P NNP N
= NNP N
.036 NNP N
) ) N
. . N

The DT N
hazard NN o
reduction NN o
was VBD N
similar JJ N
for IN N
both DT N
radiation NN N
plans NNS N
. . N

Pretreatment NNP N
leukocytosis NN N
and CC N
high JJ N
clinical JJ N
stage NN N
were VBD N
independent JJ N
adverse JJ N
factors NNS N
in IN N
a DT N
Cox NNP N
model NN N
of IN N
overall JJ o
survival NN o
, , N
but CC N
the DT N
effect NN o
of IN N
cisplatin NN i
was VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Concurrent NNP i
cisplatin NN i
may MD N
improve VB N
pelvic NNS o
control NN o
of IN N
locally RB N
advanced JJ N
bladder NN N
cancer NN N
with IN N
preoperative JJ i
or CC i
definitive JJ i
radiation NN i
, , N
but CC N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
improve VB N
overall JJ o
survival NN o
. . o

The DT N
use NN N
of IN N
concurrent NN i
cisplatin NN i
had VBD N
no DT N
detectable JJ N
effect NN o
on IN N
distant JJ N
metastases NNS N
. . N

-DOCSTART- -X- O O

Oral JJ i
S-adenosylmethionine NNP i
in IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
intrahepatic JJ o
cholestasis NN o
. . o

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

Parenteral JJ N
S-adenosylmethionine JJ i
proved VBN N
to TO N
be VB N
effective JJ N
in IN N
reversing VBG N
intrahepatic JJ o
cholestasis NN o
in IN N
pregnant JJ N
women NNS N
. . N

Based VBN N
on IN N
these DT N
findings NNS N
, , N
a DT N
prospective JJ N
multicenter NN p
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
planned VBN N
to TO N
assess VB N
whether IN N
oral JJ i
S-adenosylmethionine NNP i
is VBZ N
effective JJ N
in IN N
cholestatic JJ o
patients NNS o
with IN p
chronic JJ p
liver NN p
disease NN p
. . p

Accordingly RB N
, , N
220 CD p
inpatients NNS p
( ( p
26 CD p
% NN p
chronic JJ p
active JJ p
hepatitis NN p
, , p
68 CD p
% NN p
cirrhosis NN p
, , p
6 CD p
% NN p
primary JJ p
biliary JJ p
cirrhosis NN p
) ) p
with IN p
stable JJ p
( ( p
1 CD p
month NN p
or CC p
more JJR p
) ) p
at IN p
least JJS p
twofold JJ p
increases NNS p
in IN p
serum JJ o
total NN o
and CC o
conjugated VBD o
bilirubin NN o
and CC o
alkaline JJ o
phosphatase NN o
volunteered VBD p
for IN p
the DT p
trial NN p
. . p

Serum NNP o
markers NNS o
of IN o
cholestasis NN o
significantly RB N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
decreased VBN N
after IN N
oral JJ N
S-adenosylmethionine JJ i
administration NN N
( ( N
1600 CD N
mg/day NN N
) ) N
, , N
and CC N
their PRP$ N
values NNS N
were VBD N
significantly RB N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
lower JJR N
than IN N
the DT N
corresponding JJ N
values NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

S-adenosylmethionine NNP i
significantly RB N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
improved VBN N
subjective JJ o
symptoms NNS o
such JJ o
as IN o
pruritus NN o
, , o
fatigue NN o
, , o
and CC o
feeling NN o
of IN o
being VBG o
unwell JJ o
, , N
whereas JJ N
placebo NN N
was VBD N
ineffective JJ N
. . N

Two CD N
patients NNS N
in IN N
the DT N
S-adenosylmethionine NNP i
group NN N
and CC N
9 CD N
controls NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
withdrew NN N
from IN N
the DT N
trial NN N
for IN N
reduced VBN N
compliance NN o
because IN N
of IN N
inefficacy NN o
of IN N
treatment NN N
. . N

Oral JJ N
S-adenosylmethionine NNP i
was VBD N
tolerated VBN o
to TO N
the DT N
same JJ N
extent NN N
as IN N
placebo NN N
. . N

In IN N
conclusion NN N
, , N
short-term JJ N
administration NN N
of IN N
oral JJ i
S-adenosylmethionine NNP i
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN i
in IN N
improving VBG N
clinical JJ o
and CC o
laboratory JJ o
measures NNS o
of IN o
intrahepatic JJ o
cholestasis NN o
and CC N
offers VBZ N
a DT N
new JJ N
therapeutic JJ N
modality NN N
for IN N
the DT N
symptomatic JJ o
management NN o
of IN N
this DT N
syndrome NN N
. . N

-DOCSTART- -X- O O

Cardiovascular JJ o
safety NN o
and CC o
gastrointestinal JJ o
tolerability NN o
of IN N
etoricoxib JJ i
vs NN i
diclofenac NN i
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
( ( N
The DT N
MEDAL NNP N
study NN N
) ) N
. . N

OBJECTIVE UH N
To TO N
compare VB N
cardiovascular JJ o
( ( o
CV NNP o
) ) o
and CC o
other JJ o
safety NN o
and CC o
efficacy NN o
parameters NNS o
of IN N
etoricoxib JJ i
60 CD N
and CC N
90 CD N
mg NN N
, , N
and CC N
diclofenac VBZ i
150 CD N
mg. NN N
METHODS NNP N
This DT N
double-blind NN N
study NN N
randomized VBD N
OA NNP p
patients NNS p
to TO N
etoricoxib VB i
90 CD N
mg NN N
, , N
then RB N
to TO N
60 CD N
mg NNS N
once RB N
daily JJ N
vs NNS N
diclofenac VBP i
75 CD N
mg JJ N
twice RB N
daily RB N
; : N
RA NNP p
patients NNS p
were VBD N
randomized VBN N
to TO N
etoricoxib VB i
90 CD N
mg NNS N
once RB N
daily JJ N
or CC N
diclofenac JJ i
75 CD N
mg JJ N
twice RB N
daily RB N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
non-inferiority NN N
of IN N
etoricoxib JJ i
vs NN N
diclofenac NN i
for IN N
thrombotic JJ N
CV NNP N
events NNS N
( ( N
95 CD N
% NN N
CI NNP N
upper JJ N
bound NN N
of IN N
hazard NN N
ratio NN N
< NNP N
1.30 CD N
) ) N
. . N

Other JJ o
safety NN o
and CC o
efficacy NN o
parameters NNS o
were VBD N
evaluated VBN N
in IN N
cohorts NNS N
of IN N
patients NNS N
based VBN N
on IN N
etoricoxib NN i
dose NN N
and CC N
disease NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
23 CD p
504 CD p
patients NNS p
were VBD N
randomized VBN N
with IN N
mean JJ N
treatment NN N
duration NN N
from IN N
19.4 CD N
to TO N
20.8 CD N
months NNS N
. . N

The DT N
thrombotic JJ o
CV NNP o
risk NN o
hazard NN o
ratio NN o
( ( o
HR NNP o
) ) o
( ( i
etoricoxib UH i
to TO N
diclofenac VB N
) ) N
was VBD N
0.96 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.81 CD N
, , N
1.15 CD N
) ) N
, , N
consistent JJ N
with IN N
non-inferiority NN N
of IN N
etoricoxib NN i
to TO N
diclofenac VB i
. . i

The DT N
cumulative JJ o
gastrointestinal NN o
( ( o
GI NNP o
) ) o
/liver VBP o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
discontinuation NN o
rate NN o
was VBD N
significantly RB N
lower JJR N
for IN N
etoricoxib JJR i
than IN N
diclofenac NN i
in IN N
each DT N
patient NN N
cohort NN N
; : N
HR NNP N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
of IN N
0.46 CD N
( ( N
0.39 CD N
, , N
0.54 CD N
) ) N
, , N
0.52 CD N
( ( N
0.42 CD N
, , N
0.63 CD N
) ) N
and CC N
0.49 CD N
( ( N
0.39 CD N
, , N
0.62 CD N
) ) N
for IN N
the DT N
60 CD N
mg NN N
OA NNP N
, , N
90 CD N
mg NN N
OA NNP N
and CC N
RA NNP N
cohorts NNS N
. . N

The DT N
maximum JJ o
average JJ o
change NN o
in IN o
systolic JJ o
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
with IN N
etoricoxib NN i
was VBD N
3.4-3.6 JJ N
mmHg NN N
( ( N
diastolic JJ N
BP NNP N
: : N
1.0-1.5 JJ N
mmHg NN N
) ) N
, , N
while IN N
diclofenac NN N
produced VBD N
a DT N
maximum JJ N
average JJ N
change NN N
of IN N
0.9-1.9 JJ N
mmHg NN N
( ( N
diastolic JJ N
BP NNP N
: : N
0.0-0.5 JJ N
mmHg NN N
) ) N
. . N

Both DT N
agents NNS N
resulted VBD N
in IN N
similar JJ N
efficacy NN o
regardless NN N
of IN N
etoricoxib NN N
dose NN N
. . N

CONCLUSION NNP N
Long-term NNP N
etoricoxib NN i
use NN N
is VBZ N
associated VBN N
with IN N
a DT N
risk NN o
of IN o
thrombotic JJ o
CV NNP o
events NNS o
comparable JJ N
with IN N
that DT N
of IN N
diclofenac NN i
. . i

Compared VBN N
with IN N
diclofenac NN i
, , i
etoricoxib RB i
demonstrated VBD N
a DT N
greater JJR N
risk NN o
of IN o
renovascular JJ o
AEs NNP o
, , N
but CC N
a DT N
more RBR N
favourable JJ N
GI/liver NNP o
tolerability NN o
profile NN o
. . o

-DOCSTART- -X- O O

Comparison NNP N
of IN N
yoga NNP i
versus NN i
stretching VBG i
for IN N
chronic JJ o
low JJ o
back RB o
pain NN o
: : o
protocol NN N
for IN N
the DT N
Yoga NNP N
Exercise NNP N
Self-care NNP N
( ( N
YES NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Back NNP o
pain NN o
, , N
one CD N
of IN N
the DT N
most RBS N
prevalent JJ N
conditions NNS N
afflicting VBG N
American JJ N
adults NNS N
, , N
is VBZ N
the DT N
leading VBG N
reason NN N
for IN N
using VBG N
complementary JJ i
and CC i
alternative JJ i
medicine NN i
( ( i
CAM NNP i
) ) i
therapies NNS i
. . i

Yoga NNP i
is VBZ N
an DT N
increasingly RB N
popular JJ N
mind-body NN N
CAM NNP N
therapy NN N
often RB N
used VBN N
for IN N
relieving VBG o
back RB o
pain NN o
and CC N
several JJ N
small JJ N
studies NNS N
have VBP N
found VBN N
yoga RB N
effective JJ N
for IN N
this DT N
condition NN N
. . N

This DT N
study NN N
will MD N
assess VB N
whether IN N
yoga NN i
is VBZ N
effective JJ N
for IN N
treating VBG N
chronic JJ o
low JJ o
back RB o
pain NN o
compared VBN N
with IN N
self PRP i
care NN i
and CC i
exercise NN i
and CC N
will MD N
explore VB N
the DT N
mechanisms NNS N
responsible JJ N
for IN N
any DT N
observed JJ N
benefits NNS N
. . N

METHODS/DESIGN NNP N
A NNP p
total NN p
of IN p
210 CD p
participants NNS p
with IN p
low JJ p
back RB p
pain NN p
lasting NN p
at IN p
least JJS p
3 CD p
months NNS p
will MD p
be VB p
recruited VBN p
from IN p
primary JJ p
care NN p
clinics NNS p
of IN p
a DT p
large JJ p
healthcare NN p
system NN p
based VBN p
in IN p
Seattle NNP p
. . p

They PRP N
will MD N
be VB N
randomized VBN N
in IN N
a DT N
2:2:1 CD N
ratio NN N
to TO N
receive VB N
12 CD i
weekly JJ i
yoga NN i
classes NNS i
, , i
12 CD i
weekly JJ i
conventional JJ i
therapeutic JJ i
exercise NN i
classes NNS i
of IN i
comparable JJ i
physical JJ i
exertion NN i
, , i
or CC i
a DT i
self-care JJ i
book NN i
. . i

Interviewers NNS N
masked VBD N
to TO N
participants NNS N
' POS N
treatment NN N
group NN N
will MD N
assess VB N
outcomes NNS N
at IN N
baseline NN N
and CC N
6 CD N
, , N
12 CD N
and CC N
26 CD N
weeks NNS N
after IN N
randomization NN N
. . N

Primary JJ N
outcomes NNS N
will MD N
be VB N
back-related JJ o
dysfunction NN o
and CC o
symptom NN o
bothersomeness NN o
. . o

In IN N
addition NN N
, , N
data NNS N
will MD N
be VB N
collected VBN N
on IN N
physical JJ o
measurements NNS o
( ( o
e.g. NN o
, , N
flexion NN o
) ) o
at IN N
baseline NN N
and CC N
12 CD N
weeks NNS N
and CC N
saliva NN N
samples NNS N
will MD N
be VB N
obtained VBN N
at IN N
baseline NN N
, , N
6 CD N
and CC N
12 CD N
weeks NNS N
. . N

Information NN N
will MD N
be VB N
collected VBN N
on IN N
specific JJ N
physical JJ N
, , N
psychological JJ N
, , N
and CC N
physiological JJ N
factors NNS N
to TO N
allow VB N
exploration NN N
of IN N
possible JJ N
mechanisms NNS N
of IN N
action NN N
through IN N
which WDT N
yoga NN i
could MD N
relieve VB o
back RB o
pain NN o
and CC o
dysfunction NN o
. . o

The DT N
effectiveness NN N
of IN N
yoga NN i
will MD N
be VB N
assessed VBN N
using VBG N
analysis NN N
of IN N
covariance NN N
( ( N
using VBG N
general JJ N
estimating VBG N
equations NNS N
- : N
GEE NNP N
) ) N
within IN N
an DT N
intention-to-treat JJ N
context NN N
. . N

If IN N
yoga NN i
is VBZ N
found VBN N
effective JJ N
, , N
further JJ N
analyses NNS N
will MD N
explore VB N
whether IN N
yoga NN N
's POS N
benefits NNS N
are VBP N
attributable JJ N
to TO N
physical JJ N
, , N
psychological JJ N
and/or NN N
physiological JJ N
factors NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
will MD N
provide VB N
the DT N
clearest JJS N
evidence NN N
to TO N
date NN N
about IN N
the DT N
value NN N
of IN N
yoga NN i
as IN N
a DT N
therapeutic JJ N
option NN N
for IN N
treating VBG N
chronic JJ o
back RB o
pain NN o
, , N
and CC N
if IN N
the DT N
results NNS N
are VBP N
positive JJ N
, , N
will MD N
help VB N
focus VB N
future JJ N
, , N
more RBR N
in-depth JJ N
, , N
research NN N
on IN N
the DT N
most RBS N
promising JJ N
potential JJ N
mechanisms NN N
of IN N
action NN N
identified VBN N
by IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O

Enhanced NNP N
inotropic NN N
state NN N
of IN N
the DT N
failing NN N
left VBD N
ventricle NN N
by IN N
cardiac JJ i
contractility NN i
modulation NN i
electrical JJ i
signals NNS i
is VBZ N
not RB N
associated VBN N
with IN N
increased JJ N
myocardial JJ o
oxygen NN o
consumption NN o
. . o

BACKGROUND NNP N
Previous NNP N
studies NNS N
in IN N
patients NNS p
and CC p
in IN p
dogs NNS p
with IN p
experimentally RB p
induced JJ p
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
showed VBD N
that IN N
electrical JJ i
signals NNS i
applied VBN N
to TO N
the DT N
failing VBG N
myocardium NN N
during IN N
the DT N
absolute JJ N
refractory NN N
period NN N
improved VBD N
left JJ o
ventricular NN o
( ( o
LV NNP o
) ) o
function NN o
. . o

We PRP N
examined VBD N
the DT N
effects NNS N
these DT N
same JJ N
cardiac NN i
contractility NN i
modulating NN i
( ( i
CCM NNP i
) ) i
electrical JJ i
signals NNS i
on IN N
myocardial JJ o
oxygen NN o
consumption NN o
( ( o
MVO NNP o
( ( o
2 CD o
) ) o
) ) o
in IN N
both DT p
patients NNS p
and CC p
dogs NNS p
with IN p
chronic JJ p
HF NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Six NNP p
dogs NNS p
with IN p
microembolizations-induced JJ i
HF NNP i
and CC p
9 CD p
HF NNP p
patients NNS p
underwent JJ p
CCM NNP i
leads NNS i
and CC i
generator NN i
( ( i
OPTIMIZER NNP i
II NNP i
) ) i
implantation NN i
. . i

After IN N
baseline NN N
measurements NNS N
, , N
CCM NNP i
signals NNS i
were VBD N
delivered VBN N
continuously RB N
for IN N
2 CD N
hours NNS N
in IN N
dogs NNS N
and CC N
for IN N
30 CD N
minutes NNS N
in IN N
patients NNS N
. . N

MVO NNP o
( ( o
2 CD o
) ) o
was VBD N
measured VBN N
before IN N
and CC N
after IN N
CCM NNP i
therapy NN i
. . i

In IN N
dogs NNS N
, , N
CCM NNP i
therapy NN i
increased VBD N
LV NNP o
ejection NN o
fraction NN o
at IN N
2 CD N
hours NNS N
( ( N
26 CD N
+/- JJ N
1 CD N
versus NN N
31 CD N
+/- JJ N
2 CD N
% NN N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
without IN N
increasing VBG N
MVO NNP o
( ( o
2 CD o
) ) o
( ( N
257 CD N
+/- JJ N
41 CD N
versus NN N
180 CD N
+/- JJ N
34 CD N
micromol/min NN N
) ) N
. . N

In IN N
patients NNS N
, , N
CCM NNP i
therapy NN i
increased VBD N
LV NNP o
peak NN o
+dP/dt NN o
by IN N
10.1 CD N
+/- JJ N
1.5 CD N
% NN N
. . N

As IN N
with IN N
dogs NNS N
, , N
the DT N
increase NN N
in IN N
LV NNP o
function NN o
after IN N
30 CD N
minutes NNS N
of IN N
CCM NNP i
therapy NN i
was VBD N
not RB N
associated VBN N
with IN N
increased VBN N
MVO NNP o
( ( o
2 CD o
) ) o
( ( N
13.6 CD N
+/- JJ N
9.7 CD N
versus NN N
12.5 CD N
+/- JJ N
7.2 CD N
mL NN N
O NNP N
( ( N
2 CD N
) ) N
/min NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
study NN N
results NNS N
suggest VBP N
that IN N
unlike IN N
cAMP-dependent JJ N
positive JJ N
inotropic NN N
drugs NNS N
, , N
the DT N
increase NN N
in IN N
LV NNP o
function NN o
during IN N
CCM NNP i
therapy NN i
is VBZ N
elicited VBN N
without IN N
increasing VBG N
MVO NNP o
( ( o
2 CD o
) ) o
. . o

-DOCSTART- -X- O O

The DT N
Pain NNP N
Course NNP N
: : N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
a DT N
clinician-guided JJ i
Internet-delivered JJ i
cognitive JJ i
behaviour NN i
therapy NN i
program NN i
for IN p
managing VBG p
chronic JJ p
pain NN p
and CC p
emotional JJ p
well-being NN p
. . p

The DT N
present JJ N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
a DT N
clinician-guided JJ i
Internet-delivered JJ i
cognitive JJ i
behaviour NN i
therapy NN i
( ( i
iCBT JJ i
) ) i
program NN i
, , N
the DT N
Pain NNP i
Course NNP i
, , N
to TO N
reduce VB N
disability NN o
, , o
anxiety NN o
, , N
and CC N
depression NN o
associated VBN N
with IN N
chronic JJ N
pain NN N
. . N

Sixty-three JJ p
adults NNS p
with IN p
chronic JJ p
pain NN p
were VBD p
randomised VBN p
to TO N
either VB N
a DT N
Treatment NNP i
Group NNP i
or CC i
waitlist VB i
Control NNP i
Group NNP i
. . i

Treatment NNP N
consisted VBD N
of IN N
5 CD i
iCBT-based JJ i
lessons NNS i
, , i
homework NN i
tasks NNS i
, , i
additional JJ i
resources NNS i
, , i
weekly JJ i
e-mail NN i
or CC i
telephone NN i
contact NN i
from IN i
a DT i
Clinical JJ i
Psychologist NN i
, , i
and CC i
automated VBD i
e-mails NNS i
. . i

Twenty-nine NN N
of IN N
31 CD p
Treatment NNP i
Group NNP i
participants NNS p
completed VBD N
the DT N
5 CD i
lessons NNS i
during IN N
the DT N
8-week JJ N
program NN N
, , N
and CC N
posttreatment NN N
and CC N
3-month JJ N
follow-up JJ N
data NNS N
were VBD N
collected VBN N
from IN N
30/31 CD N
and CC N
29/31 CD N
participants NNS N
, , N
respectively RB N
. . N

Treatment NNP i
Group NNP i
participants NNS N
obtained VBD N
significantly RB N
greater JJR N
improvements NNS N
than IN N
Control NNP i
Group NNP i
participants NNS N
in IN N
levels NNS o
of IN o
disability NN o
, , o
anxiety NN o
, , o
depression NN o
, , o
and CC o
average JJ o
pain NN o
levels NNS o
at IN N
posttreatment NN N
. . N

These DT N
improvements NNS N
corresponded VBD N
to TO N
small JJ N
to TO N
large JJ N
between-groups NNS N
effect NN N
sizes VBZ N
( ( N
Cohen NNP N
's POS N
d NN N
) ) N
at IN N
posttreatment NN N
for IN N
disability NN o
( ( N
d JJ N
= NNP N
.88 NNP N
) ) N
, , N
anxiety NN o
( ( N
d JJ N
= NNP N
.38 NNP N
) ) N
, , N
depression NN o
( ( N
d JJ N
= NNP N
.66 NNP N
) ) N
, , N
and CC N
average JJ o
pain NN o
( ( N
d JJ N
= NNP N
.64 NNP N
) ) N
, , N
respectively RB N
. . N

These DT N
outcomes NNS N
were VBD N
sustained VBN N
at IN N
follow-up NN N
and CC N
participants NNS N
rated VBD N
the DT N
program NN N
as IN N
highly RB N
acceptable JJ N
. . N

Overall JJ N
, , N
the DT N
clinician JJ N
spent NN N
a DT N
total JJ o
mean JJ o
time NN o
of IN N
81.54 CD N
minutes NNS N
( ( N
SD NNP N
30.91 CD N
minutes NNS N
) ) N
contacting VBG N
participants NNS N
during IN N
the DT N
program NN N
. . N

The DT N
results NNS N
appear VBP N
better JJR N
than IN N
those DT N
reported VBN N
in IN N
iCBT NN i
studies NNS N
to TO N
date NN N
and CC N
provide VB N
support NN N
for IN N
the DT N
potential NN N
of IN N
clinician-guided JJ i
iCBT NN i
in IN N
the DT N
treatment NN N
of IN N
disability NN o
, , o
anxiety NN o
, , o
and CC o
depression NN o
for IN o
people NNS o
with IN o
chronic JJ o
pain NN o
. . o

-DOCSTART- -X- O O

[ VB N
A NNP N
controlled JJ N
study NN N
of IN N
treating VBG N
haemophilia PRP N
A NNP N
on IN N
an DT N
out-patient JJ N
basis NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

For IN N
six CD N
months NNS N
36 CD i
U NNP i
factor NN i
VIII NNP i
concentrates VBZ i
per IN N
kg NN N
bodyweight NN N
and CC N
week NN N
were VBD N
administered VBN N
to TO N
six CD p
out-patients NNS p
with IN p
severe JJ p
haemophilia NN p
A NNP p
. . p

The DT N
injection NN N
regimen NN N
was VBD N
changed VBN N
in IN N
every DT N
patient NN N
every DT N
two CD N
months NNS N
, , N
from IN N
36 CD N
U/kg NNP N
once RB N
to TO N
18 CD N
U/kg NNP N
twice RB N
and CC N
12 CD N
U/kg NNP N
three CD N
times NNS N
, , N
intravenously RB N
. . N

The DT N
six CD N
possible JJ N
combinations NNS N
of IN N
these DT N
three CD N
dosage NN N
schedules NNS N
were VBD N
used VBN N
in IN N
the DT N
patients NNS N
in IN N
a DT N
strictly RB N
randomised JJ N
manner NN N
, , N
and CC N
all DT N
patients NNS N
were VBD N
treated VBN N
during IN N
the DT N
same JJ N
period NN N
. . N

In IN N
the DT N
pre-trial JJ N
period NN N
( ( N
treatment NN N
as IN N
needed VBN N
) ) N
there EX N
were VBD N
an DT N
average NN N
of IN N
35 CD N
bleedings NNS o
per IN N
two CD N
months NNS N
. . N

On IN N
continual JJ N
treatment NN N
there EX N
were VBD N
21 CD N
bleedings NNS o
on IN N
weekly JJ N
injections NNS N
of IN N
36 CD N
U NNP i
factor NN i
VIII NNP i
per IN N
kg NN N
, , N
14 CD N
on IN N
twice JJ N
weekly JJ N
18 CD N
U/kg NNP N
and CC N
none NN N
on IN N
12 CD N
U/kg NNP N
, , N
three CD N
times NNS N
weekly RB N
. . N

The DT N
differences NNS N
are VBP N
statistically RB N
significant JJ N
. . N

The DT N
absence NN o
of IN o
bleeding VBG o
on IN N
the DT N
last JJ N
dosage NN N
schedule NN N
was VBD N
achieved VBN N
during IN N
normal JJ N
working VBG N
. . N

Days NNPS o
lost VBD o
from IN o
work NN o
per IN o
patient JJ o
per IN o
month NN o
was VBD N
zero NN N
on IN N
three CD N
times NNS N
12 CD N
U/kg NNP N
, , N
0.4 CD N
day NN N
on IN N
twice RB N
18 CD N
U/kg NNP N
and CC N
once RB N
36 CD N
U/kg NNP N
, , N
while IN N
it PRP N
had VBD N
been VBN N
five CD N
days NNS N
in IN N
the DT N
pre-trial JJ N
period NN N
. . N

In IN N
addition NN N
to TO N
freedom NN o
from IN o
bleeding VBG o
and CC N
no DT N
lost JJ o
days NNS o
from IN N
work NN N
, , N
there EX N
was VBD N
increased VBN N
mobility NN o
and CC o
physical JJ o
capacity NN o
. . o

-DOCSTART- -X- O O

Olanzapine NNP i
versus NN i
haloperidol NN i
in IN N
children NNS p
with IN p
autistic JJ o
disorder NN o
: : o
an DT N
open JJ N
pilot NN N
study NN N
. . N

OBJECTIVES NNP N
Conventional NNP N
neuroleptics NNS i
ameliorate VBP N
symptoms NNS N
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
; : p
however RB N
, , N
they PRP N
are VBP N
known VBN N
to TO N
cause VB N
dyskinesias NN N
. . N

Atypical JJ i
neuroleptics NNS i
, , N
including VBG N
olanzapine NN N
, , N
may MD N
have VB N
less JJR N
risk NN N
for IN N
dyskinesia NN N
, , N
but CC N
their PRP$ N
efficacy NN N
in IN N
autistic JJ N
disorder NN N
is VBZ N
not RB N
established VBN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
safety NN N
and CC N
effectiveness NN N
of IN N
open-label JJ N
olanzapine NN i
as IN N
a DT N
treatment NN N
for IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
by IN N
using VBG N
haloperidol NN i
as IN N
a DT N
standard JJ N
comparator NN N
treatment NN N
. . N

METHOD NNP N
In IN N
a DT N
parallel JJ p
groups NNS p
design NN p
, , p
12 CD p
children NNS p
with IN p
DSM-IV NNP p
autistic JJ p
disorder NN p
( ( p
mean JJ p
age NN p
7.8+/-2.1 CD p
years NNS p
) ) p
were VBD p
randomized VBN p
to TO N
6 CD N
weeks NNS N
of IN N
open JJ i
treatment NN i
with IN i
olanzapine NN i
or CC i
haloperidol NN i
. . i

Mean NNP N
final JJ N
dosages NNS N
were VBD N
7.9+/-2.5 JJ N
mg/day NN N
for IN N
olanzapine NN i
and CC N
1.4+/-0.7 JJ N
mg/day NN N
for IN N
haloperidol NN i
. . i

Outcome NNP N
measures NNS N
included VBD N
the DT N
Clinical NNP o
Global NNP o
Impressions NNP o
( ( o
CGI NNP o
) ) o
and CC o
the DT o
Children NNP o
's POS o
Psychiatric NNP o
Rating NNP o
Scale NNP o
( ( o
CPRS NNP o
) ) o
. . o

RESULTS NNP N
Both NNP N
groups NNS N
had VBD N
symptom VBN o
reduction NN o
. . o

Five CD N
of IN N
six CD N
in IN N
the DT N
olanzapine NN i
group NN N
and CC N
three CD N
of IN N
six CD N
in IN N
the DT N
haloperidol NN i
group NN N
were VBD N
rated VBN N
as IN N
responders NNS N
according VBG N
to TO N
the DT N
CGI NNP o
Improvement NNP N
item NN N
. . N

Subjects NNS N
showed VBD N
improvement NN N
on IN N
the DT N
CPRS NNP o
Autism NNP o
Factor NNP o
( ( N
F1,9 NNP N
= NNP N
24.4 CD N
, , N
p NN N
= NNP N
.0008 NNP N
) ) N
. . N

Side JJ N
effects NNS N
included VBD N
drowsiness NN o
and CC o
weight JJ o
gain NN o
. . o

CONCLUSIONS VB N
The DT N
findings NNS N
suggest VBP N
that IN N
olanzapine NN i
is VBZ N
a DT N
promising JJ N
treatment NN o
for IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

Further JJ N
placebo-controlled JJ N
and CC N
long-term JJ N
studies NNS N
of IN N
olanzapine NN i
in IN N
autistic JJ N
disorder NN N
are VBP N
required VBN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
alpha JJ i
dihydroergocryptine NN i
in IN N
patients NNS p
with IN p
fibrocystic JJ p
breast NN p
disease NN p
] NNP p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
alpha JJ i
dihidroergocriptine NN i
in IN N
patients NNS p
with IN p
fibrocystic JJ p
mastopathy NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
diagnosis NN p
of IN p
fibrocystic JJ p
breast NN p
disease NN p
were VBD p
included VBN p
in IN N
a DT N
prospective JJ N
longitudinal JJ N
blind NN N
double NN N
, , N
controlled VBN N
with IN N
placebo NN i
study NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
: : N
of IN N
treatment NN N
group NN N
A DT N
: : N
Alpha NNP i
dihidroergocriptine VBP i
tablets NNS i
of IN i
10 CD i
mg NNS i
, , N
group NN N
B NNP N
: : N
Placebo NN i
, , N
during IN N
6 CD N
months NNS N
. . N

After IN N
to TO N
basal VB N
evaluation NN N
, , N
the DT N
patients NNS N
were VBD N
revised VBN N
in IN N
a DT N
monthly JJ N
way NN N
evaluating VBG N
the DT N
following NN N
symptoms NNS N
and CC N
signs NNS N
: : N
mastalgia NN o
, , o
mammary JJ o
tension NN o
, , o
presence NN o
of IN o
nodules NNS o
, , o
nipple JJ o
secretion NN o
, , o
and CC o
the DT o
presence NN o
of IN o
adverse JJ o
events NNS o
. . o

RESULTS NNP N
39 CD p
patients NNS p
with IN p
alpha JJ i
dihidroergocriptine NN i
and CC p
38 CD p
with IN p
placebo NN i
. . i

Mastodinia NNP o
, , N
a DT N
satisfactory JJ N
response NN N
was VBD N
observed VBN N
in IN N
100 CD N
% NN N
of IN N
alpha JJ i
dihidroergocriptine NN i
group NN N
vs VBD N
61.11 CD N
% NN N
of IN N
placebo NN i
group NN N
( ( N
p JJ N
= NNP N
0.0002 CD N
) ) N
. . N

Mastalgia NNP o
responded VBD N
in IN N
100 CD N
% NN N
of IN N
alpha JJ N
dihidroergocriptine NN N
group NN N
vs VBD N
64.86 CD N
% NN N
of IN N
placebo NN N
group NN N
( ( N
p JJ N
= NNP N
0.0003 CD N
) ) N
. . N

Galactorrea NNP o
responded VBD N
100 CD N
% NN N
of IN N
alpha JJ i
dihidroergocriptine NN i
group NN N
vs VBD N
93.33 CD N
% NN N
of IN N
the DT N
placebo NN N
. . N

The DT N
nodules NNS o
in IN N
the DT N
group NN N
alpha VBZ N
dihidroergocriptine NN N
disappeared VBD N
in IN N
23.1 CD N
% NN N
and CC N
in IN N
21.1 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
. . N

Ultrasound IN o
evaluation NN o
of IN o
the DT o
nodules NNS o
did VBD N
not RB N
show VB N
significant JJ N
differences NNS N
between IN N
both DT N
groups NNS N
. . N

Prolactin NNP o
levels NNS o
showed VBD N
a DT N
decrease NN N
in IN N
the DT N
group NN N
treated VBD N
with IN N
alpha JJ i
dihidroergocriptine NN i
with IN N
an DT N
important JJ N
difference NN N
between IN N
both DT N
groups NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
6 CD N
months NNS N
study JJ N
period NN N
. . N

There EX N
were VBD N
not RB N
differences NNS N
in IN N
the DT N
presence NN o
of IN o
adverse JJ o
events NNS o
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
Alpha NNP i
dihidroergocriptine NN i
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
fribrocystic JJ o
breast NN o
disease NN o
with IN N
minimum JJ N
adverse JJ N
events NNS N
when WRB N
compared VBN N
with IN N
similar JJ N
drugs NNS N
. . N

-DOCSTART- -X- O O

Differences NNS N
in IN N
quality NN o
of IN o
life NN o
outcomes NNS N
among IN N
depressed JJ p
spinal JJ p
cord NN p
injury NN p
trial NN p
participants NNS p
. . p

OBJECTIVE NN N
To TO N
assess VB N
the DT N
role NN N
that WDT N
treatment NN N
response NN N
plays VBZ N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
an DT N
antidepressant JJ i
among IN N
people NNS p
with IN p
spinal JJ p
cord NN p
injury NN p
( ( p
SCI NNP p
) ) p
diagnosed VBD p
with IN p
major JJ p
depressive JJ p
disorder NN p
( ( p
MDD NNP p
) ) p
in IN N
explaining VBG N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
, , N
assessed VBD N
both DT N
globally RB N
as IN N
life NN N
satisfaction NN N
and CC N
in IN N
terms NNS N
of IN N
physical JJ N
and CC N
mental JJ N
health-related JJ N
QOL NNP N
. . N

DESIGN NNP N
Multivariable JJ N
analyses NNS N
were VBD N
conducted VBN N
, , N
controlling VBG N
for IN N
demographic JJ N
, , N
neurologic JJ N
, , N
and CC N
participatory JJ N
factors NNS N
and CC N
perceived VBD N
functional JJ N
limitations NNS N
. . N

SETTING NN N
Rehabilitation NN N
centers NNS N
. . N

PARTICIPANTS NNS N
Of IN p
the DT p
133 CD p
persons NNS p
who WP p
were VBD p
randomized VBN p
into IN p
the DT p
Project NN i
to TO i
Improve VB i
Symptoms NNP i
and CC i
Mood NNP i
after IN p
Spinal NNP p
Cord NNP p
Injury NNP p
randomized VBD p
controlled VBN p
trial NN p
, , p
124 CD p
participated VBN p
in IN p
this DT p
study NN p
. . p

All DT p
participants NNS p
were VBD p
between IN p
the DT p
ages NNS p
of IN p
18 CD p
and CC p
64 CD p
years NNS p
, , p
at IN p
least JJS p
1 CD p
month NN p
post-SCI NN p
, , p
met VBD p
the DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
4th CD p
edition NN p
, , p
criteria NNS p
for IN p
MDD NNP p
, , p
and CC p
completed VBD p
the DT p
core NN p
measures NNS p
used VBN p
in IN p
this DT p
study NN p
. . p

INTERVENTIONS NNP N
Not RB N
applicable JJ N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT o
Satisfaction NNP o
with IN o
Life NNP o
Scale NNP o
and CC o
the DT o
physical JJ o
and CC o
mental JJ o
component NN o
summary JJ o
scores NNS o
of IN o
the DT o
Medical NNP o
Outcomes NNP o
Study NNP o
12-Item JJ o
Short-Form NNP o
Health NNP o
Survey NNP o
. . o

RESULTS NNP N
Reduction NNP o
in IN o
depressive JJ o
symptoms NNS o
over IN N
the DT N
course NN N
of IN N
a DT N
12-week JJ N
trial NN N
was VBD N
predictive JJ N
of IN N
increased JJ N
QOL NNP o
, , o
which WDT o
was VBD o
measured VBN o
as IN o
life NN o
satisfaction NN o
and CC o
mental JJ o
well-being NN o
, , N
within IN N
the DT N
context NN N
of IN N
other JJ N
explanatory JJ N
factors NNS N
. . N

However RB N
, , N
reduction NN o
in IN o
symptoms NNS o
did VBD N
not RB N
explain VB N
differences NNS N
in IN N
physical JJ N
well-being NN N
among IN N
those DT N
with IN N
MDD NNP N
. . N

Perceived NNP o
functional JJ o
disability NN o
explained VBD N
all DT N
3 CD N
indices NNS N
of IN N
QOL NNP N
. . N

CONCLUSIONS NNP N
Greater NNP N
recognition NN N
has VBZ N
been VBN N
given VBN N
to TO N
QOL NNP N
outcomes RB N
as IN N
endpoints NNS N
of IN N
clinical JJ N
trials NNS N
because IN N
these DT N
often RB N
reflect VBP N
participants NNS p
' POS p
reported VBN N
outcomes NNS N
. . N

Our PRP$ N
findings NNS N
support VB N
the DT N
association NN N
of IN N
QOL NNP N
to TO N
the DT N
reduction NN N
of IN N
depression NN N
symptoms NNS N
among IN N
trial NN p
participants NNS p
. . p

This DT N
association NN N
differs VBZ N
depending VBG N
on IN N
how WRB N
QOL NNP N
is VBZ N
defined VBN N
and CC N
measured VBN N
, , N
with IN N
stronger JJR N
relations NNS N
observed VBN N
with IN N
life NN N
satisfaction NN N
and CC N
mental JJ N
well-being NN N
among IN N
those DT N
diagnosed VBN N
with IN N
MDD NNP N
. . N

The DT N
lack NN N
of IN N
association NN N
between IN N
depression NN N
and CC N
physical JJ N
well-being NN N
may MD N
be VB N
explained VBN N
by IN N
participants NNS p
' POS p
subjective JJ N
interpretation NN N
of IN N
physical JJ N
well-being NN N
after IN N
SCI NNP N
and CC N
their PRP$ N
expectations NNS N
and CC N
perceptions NNS N
of IN N
improved JJ N
physical JJ N
health-related JJ N
QOL NNP N
based VBN N
on IN N
the DT N
use NN N
of IN N
assistive JJ N
technology NN N
. . N

Consistent JJ N
with IN N
our PRP$ N
findings NNS N
, , N
pain NN N
is VBZ N
likely JJ N
to TO N
play VB N
a DT N
role NN N
in IN N
decreasing VBG N
physical JJ N
QOL NNP N
among IN N
those DT p
with IN p
incomplete JJ p
injuries NNS p
. . p

Practicing VBG N
caution NN N
is VBZ N
suggested VBN N
in IN N
using VBG N
physical JJ N
well-being NN N
as IN N
an DT N
endpoint NN N
in IN N
trials NNS N
among IN N
people NNS p
with IN p
SCI NNP p
. . p

-DOCSTART- -X- O O

Compliance NN N
with IN N
depot NN i
medroxyprogesterone NN i
acetate NN i
: : i
a DT N
randomized NN N
, , N
controlled VBD N
trial NN N
of IN N
intensive JJ N
reminders NNS N
. . N

We PRP N
enrolled VBD N
women NNS p
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
to TO N
determine VB N
whether IN N
an DT N
intensive JJ N
reminder NN N
system NN N
would MD N
improve VB N
compliance NN N
in IN N
women NNS p
receiving VBG p
depot NN i
medroxyprogesterone NN i
injections NNS p
. . p

Women NNP N
selecting VBG N
this DT N
treatment NN N
were VBD N
assigned VBN N
to TO N
a DT N
group NN N
that WDT N
received VBD N
both DT N
mail NN i
and CC i
telephone NN i
reminders NNS i
or CC N
to TO N
a DT N
second JJ N
group NN N
that WDT N
received VBD N
only RB i
a DT i
scheduled JJ i
appointment NN i
at IN i
the DT i
time NN i
of IN i
the DT i
previous JJ i
injection NN i
. . i

The DT N
rate NN o
of IN o
continuation NN o
and CC N
the DT N
rate NN o
of IN o
on-time JJ o
injections NNS o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

Women NNS N
who WP N
had VBD N
prolonged VBN o
bleeding NN o
were VBD N
more RBR N
likely JJ N
to TO N
discontinue VB N
depot VB N
medroxyprogesterone JJ N
injections NNS N
. . N

-DOCSTART- -X- O O

Effectiveness NN o
of IN N
the DT N
school NN i
dental JJ i
screening VBG i
programme NN i
in IN N
stimulating VBG o
dental JJ o
attendance NN o
for IN N
children NNS p
in IN p
need NN p
of IN p
treatment NN p
in IN p
Northern NNP p
Ireland NNP p
. . p

UNLABELLED IN N
The DT N
school NN i
dental JJ i
screening NN i
programme NN i
has VBZ N
been VBN N
in IN N
existence NN N
from IN N
the DT N
beginning NN N
of IN N
the DT N
20th JJ N
century NN N
yet RB N
its PRP$ N
value NN N
in IN N
encouraging JJ N
attendance NN N
among IN N
children NNS p
with IN p
a DT p
dental JJ p
health NN p
need NN p
is VBZ N
not RB N
fully RB N
established VBN N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
school NN i
dental JJ i
screening NN i
in IN N
promoting VBG N
dental JJ o
attendance NN o
among IN N
children NNS p
with IN p
a DT p
treatment NN p
need NN p
and CC N
to TO N
examine VB N
the DT N
relative JJ N
importance NN N
of IN N
screening NN N
, , N
social JJ N
class NN N
and CC N
other JJ N
factors NNS N
in IN N
dental JJ o
attendance NN o
. . o

METHODS NNP N
Sixty-four JJ p
participating NN p
schools NNS p
were VBD N
assigned VBN N
to TO N
study VB N
and CC N
control VB N
groups NNS N
using VBG N
a DT N
stratified JJ N
, , N
blocked JJ N
randomisation NN N
technique NN N
. . N

The DT N
study NN N
group NN N
children NNS N
received VBD N
the DT N
standard JJ i
school NN i
dental JJ i
screening NN i
and CC N
the DT N
dental JJ o
attendance NN o
of IN N
those DT N
with IN N
a DT N
positive JJ N
screening NN o
result NN o
was VBD N
assessed VBN N
after IN N
2 CD N
months NNS N
by IN N
means NNS N
of IN N
a DT N
questionnaire NN N
issued VBN N
to TO N
the DT N
children NNS N
's POS N
parents NNS N
. . N

The DT N
control NN N
group NN i
children NNS i
were VBD i
not RB i
, , i
at IN i
this DT i
stage NN i
, , i
screened VBD i
, , N
yet CC N
their PRP$ N
parents NNS N
received VBD N
the DT N
same JJ i
questionnaire NN i
assessing VBG i
dental JJ o
attendance NN o
over IN i
the DT i
2-month JJ i
period NN i
. . i

However RB N
, , N
only RB N
questionnaires VBZ N
from IN N
control NN i
group NN N
children NNS N
who WP N
had VBD N
a DT N
positive JJ N
result NN N
at IN N
a DT N
subsequent JJ N
screening NN N
were VBD N
retained VBN N
for IN N
analysis NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
2,321 CD p
children NNS p
were VBD p
screened VBN p
, , p
with IN p
980 CD p
having VBG p
a DT p
positive JJ p
result NN p
. . p

The DT N
mean JJ N
dmft NN N
of IN N
those DT N
screening VBG N
positive JJ N
was VBD N
4.85 CD N
. . N

In IN N
all DT N
, , N
664 CD p
completed VBN p
questionnaires NNS p
were VBD N
returned VBN N
, , N
giving VBG N
a DT N
response NN N
rate NN N
of IN N
67.8 CD N
% NN N
. . N

Dental JJ o
attendance NN o
was VBD N
reported VBN N
among IN N
45.5 CD N
% NN N
of IN N
the DT N
study NN N
group NN N
( ( N
n=352 NN N
) ) N
in IN N
the DT N
2 CD N
months NNS N
following VBG N
screening NN N
. . N

In IN N
the DT N
same JJ N
period NN N
, , N
27.6 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
n=312 RB N
) ) N
claimed VBD N
attendance NN N
. . N

The DT N
effect NN N
was VBD N
found VBN N
to TO N
be VB N
significant JJ N
among IN N
the DT N
high JJ N
employed VBN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
the DT N
unemployed JJ N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
School NNP N
dental JJ N
screening NN N
was VBD N
capable JJ N
of IN N
stimulating VBG N
dental JJ o
attendance NN o
. . o

The DT N
strong JJ N
effect NN N
among IN N
the DT N
lowest JJS N
socio-economic JJ N
group NN N
shows VBZ N
that IN N
school NN N
dental JJ N
screening NN N
may MD N
be VB N
used VBN N
to TO N
decrease VB N
dental JJ o
health NN o
inequalities NNS o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
beta-alanine NN i
, , N
with IN N
and CC N
without IN N
sodium NN i
bicarbonate NN i
, , N
on IN N
2000-m JJ o
rowing NN o
performance NN o
. . o

PURPOSE NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
beta-alanine NN N
only RB N
and CC N
beta-alanine JJ i
with IN i
sodium NN i
bicarbonate NN i
supplementation NN i
on IN N
2,000-m JJ o
rowing NN o
performance NN o
. . o

METHODS NNP N
Twenty NNP p
well-trained JJ p
rowers NNS p
( ( p
age NN p
23 CD p
? . p
4 CD p
y NN p
; : p
height VBD p
1.85 CD p
? . p
0.08 CD p
m NN p
; : p
body NN p
mass NN p
82.5 CD p
? . p
8.9 CD p
kg NN p
) ) p
were VBD p
assigned VBN N
to TO N
either VB i
a DT i
placebo NN i
or CC i
beta-alanine NN i
( ( i
6.4 CD i
g NN N
? . N
d NN N
( ( N
-1 NNP N
) ) N
for IN N
4 CD N
weeks NNS N
) ) N
group NN o
. . o

A DT o
2,000-m JJ o
rowing NN o
time NN o
trial NN o
( ( o
TT NNP o
) ) o
was VBD o
performed VBN N
before IN i
supplementation NN i
( ( i
Baseline NNP i
) ) N
and CC N
after IN N
28 CD N
and CC N
30 CD N
days NNS N
of IN i
supplementation NN i
. . i

The DT i
post NN N
supplementation NN N
trials NNS N
involved VBN N
supplementation NN N
with IN N
either DT N
maltodextrin NN N
or CC N
sodium NN N
bicarbonate NN N
in IN N
a DT N
double-blind NN N
, , N
crossover NN N
design NN N
, , N
creating VBG N
four CD N
study NN N
conditions NNS i
( ( i
placebo NN i
with IN i
maltodextrin NN i
; : i
placebo NN i
with IN i
sodium JJ i
bicarbonate NN i
; : i
beta-alanine JJ i
with IN i
maltodextrin NN i
; : i
beta-alanine JJ i
with IN i
sodium JJ i
bicarbonate NN o
) ) o
. . o

Blood NNP o
lactate NN o
, , o
pH NN o
, , o
bicarbonate NN o
, , o
and CC o
base NN o
excess NN o
were VBD o
measured VBN N
pre-TT JJ N
, , N
immediately RB N
post-TT JJ N
and CC N
at IN N
TT+5 NNP N
min NN N
. . N

Performance NNP o
data NNS o
were VBD o
analyzed VBN N
using VBG o
magnitude NN o
based VBN o
inferences NNS o
. . o

RESULTS NNP o
Beta-alanine JJ i
supplementation NN i
was VBD i
very RB N
likely JJ N
to TO N
be VB N
beneficial JJ o
to TO o
2,000-m JJ o
rowing NN o
performance NN o
( ( o
6.4 CD o
? . N
8.1 CD N
s JJ N
effect NN N
compared VBN N
with IN N
placebo NN N
) ) N
, , N
with IN N
the DT N
effect NN N
of IN N
sodium NN N
bicarbonate NN N
having VBG N
a DT N
likely JJ N
benefit NN N
( ( N
3.2 CD N
? . N
8.8 CD N
s NN N
) ) N
. . N

There EX N
was VBD N
a DT N
small JJ N
( ( N
1.1 CD N
? . N
5.6 CD N
s NN N
) ) N
but CC N
possibly RB N
beneficial JJ o
additional JJ o
effect NN o
when WRB N
combining VBG N
chronic JJ N
beta-alanine JJ N
supplementation NN N
with IN N
acute JJ N
sodium NN N
bicarbonate NN N
supplementation NN N
compared VBN N
with IN N
chronic JJ N
beta-alanine JJ N
supplementation NN N
alone RB N
. . N

Sodium JJ N
bicarbonate NN N
ingestion NN N
led VBD N
to TO N
increases NNS o
in IN o
plasma NN o
pH NN o
, , o
base NN o
excess NN o
, , o
bicarbonate NN o
, , o
and CC o
lactate JJ o
concentrations NNS o
. . o

CONCLUSIONS NNP o
Both NNP i
chronic JJ i
beta-alanine NN i
and CC i
acute JJ i
sodium NN i
bicarbonate NN i
supplementation NN i
alone RB i
had VBD N
positive JJ N
effects NNS N
on IN o
2,000-m JJ o
rowing NN o
performance NN o
. . o

The DT o
addition NN o
of IN i
acute JJ i
sodium NN i
bicarbonate NN i
to TO i
chronic VB i
beta-alanine JJ i
supplementation NN i
may MD i
further VB i
enhance NN N
rowing VBG o
performance NN o
. . o

-DOCSTART- -X- O O

Evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
human JJ N
leukocyte JJ i
IFN-alpha NN i
on IN N
the DT N
immune JJ o
response NN o
to TO o
the DT o
HBV NNP o
vaccine NN o
in IN N
healthy JJ p
unvaccinated JJ p
individuals NNS p
. . p

HBV NNP i
vaccine NN i
needs VBZ N
3 CD N
injections NNS N
over IN N
6 CD N
months NNS N
to TO N
induce VB N
immunity NN N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
adjuvants NNS N
capable JJ N
of IN N
inducing VBG N
earlier JJR N
immune JJ N
protection NN N
would MD N
be VB N
highly RB N
desirable JJ N
. . N

Most JJS N
adjuvants NNS N
may MD N
act VB N
by IN N
inducing VBG N
cytokines NNS N
, , N
and CC N
among IN N
them PRP N
, , N
type NN N
I PRP N
interferons NNS N
( ( N
IFNs NNP N
) ) N
, , N
deserve VB N
a DT N
special JJ N
attention NN N
in IN N
view NN N
of IN N
the DT N
potent JJ N
immunomostimulatory NN N
activity NN N
observed VBN N
in IN N
mouse NN N
models NNS N
and CC N
on IN N
dendritic JJ N
cell NN N
functions NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
IFN-alpha NNP i
administered VBD N
as IN N
an DT N
adjuvant NN i
of IN i
HBV NNP i
vaccine NN i
in IN N
healthy JJ p
unvaccinated JJ p
individuals NNS p
. . p

No DT N
significant JJ N
enhancing VBG N
effect NN N
on IN N
the DT N
antibody NN o
response NN o
was VBD N
observed VBN N
, , N
in IN N
spite NN N
of IN N
an DT N
early JJ N
and CC N
transient JJ N
upregulation NN N
of IN N
costimulatory NN N
molecule NN N
expression NN N
on IN N
peripheral JJ o
blood NN o
mononuclear NN o
cells NNS o
, , N
which WDT N
may MD N
be VB N
suggestive JJ N
of IN N
an DT N
IFN-mediated JJ N
activation NN N
of IN N
antigen NN N
presenting VBG N
cells NNS N
. . N

We PRP N
conclude VBP N
that IN N
, , N
under IN N
the DT N
conditions NNS N
used VBN N
in IN N
this DT N
trial NN N
, , N
natural JJ N
IFN-alpha NNP i
does VBZ N
not RB N
act VB N
as IN N
an DT N
adjuvant NN N
of IN N
the DT N
HBV NNP N
vaccine NN N
in IN N
healthy JJ p
unvaccinated JJ p
individuals NNS p
. . p

-DOCSTART- -X- O O

Colonoscopic NNP N
miss JJ N
rates NNS N
of IN N
adenomas NN p
determined VBN N
by IN N
back-to-back JJ N
colonoscopies NNS N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
The DT N
miss JJ N
rate NN N
of IN N
colonoscopy NN N
for IN N
neoplasms NN N
is VBZ N
poorly RB N
understood JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
miss JJ N
rate NN N
of IN N
colonoscopy NN i
by IN N
same JJ N
day NN N
back-to-back JJ N
colonoscopy NN N
. . N

METHODS NNP N
Two CD N
consecutive JJ N
same JJ N
day NN N
colonoscopies NNS i
were VBD N
performed VBN N
in IN N
183 CD p
patients NNS p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
undergo VB N
the DT N
second JJ i
colonoscopy NN i
by IN N
the DT N
same JJ i
or CC i
a DT i
different JJ i
endoscopist NN i
and CC i
in IN i
the DT i
same JJ i
or CC i
different JJ i
position NN i
. . i

RESULTS VB N
The DT N
overall JJ o
miss NN o
rate NN o
for IN o
adenomas NN o
was VBD N
24 CD N
% NN N
, , N
27 CD N
% NN N
for IN N
adenomas JJ N
< NN N
or CC N
= $ N
5 CD N
mm NN N
, , N
13 CD N
% NN N
for IN N
adenomas JJ N
6-9 JJ N
mm NN N
, , N
and CC N
6 CD N
% NN N
for IN N
adenomas JJ N
> NN N
or CC N
= $ N
1 CD N
cm NN N
. . N

Patients NNS p
with IN p
two CD p
or CC p
more JJR p
adenomas NNS p
at IN N
the DT N
first JJ N
examination NN N
were VBD N
more RBR N
likely JJ N
than IN N
patients NNS p
with IN p
no DT p
or CC p
one CD p
adenoma NN p
detected VBN N
at IN N
the DT N
first JJ N
examination NN N
to TO N
have VB N
one CD N
or CC N
more JJR N
adenomas NNS o
at IN N
the DT N
second JJ N
examination NN N
( ( N
odds NNS N
ratio NN N
, , N
3.3 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.69-6.46 JJ N
) ) N
. . N

Right JJ N
colon NN N
adenomas NNS N
were VBD N
missed VBN o
more RBR N
often RB N
( ( N
27 CD N
% NN N
) ) N
than IN N
left VBN N
colon NN N
adenomas NN N
( ( N
21 CD N
% NN N
) ) N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

There EX N
was VBD N
evidence NN N
of IN N
variation NN o
in IN o
sensitivity NN o
between IN N
endoscopists NNS N
, , N
but CC N
significant JJ N
miss JJ o
rates NNS o
for IN o
small JJ N
adenomas NNS N
were VBD N
found VBN N
among IN N
essentially RB N
all DT N
endoscopists NNS N
. . N

CONCLUSIONS NNP N
Using NNP N
current JJ N
colonoscopic NN i
technology NN i
, , N
there EX N
are VBP N
significant JJ N
miss JJ o
rates NNS o
for IN N
adenomas JJ N
< $ N
1 CD N
cm NN N
even RB N
with IN N
meticulous JJ N
colonoscopy NN N
. . N

Miss JJ o
rates NNS o
are VBP N
low JJ N
for IN N
adenomas NN N
> NN N
or CC N
= $ N
1 CD N
cm NN N
. . N

The DT N
results NNS N
suggest VBP N
the DT N
need NN N
for IN N
improvements NNS N
in IN N
colonoscopic NN N
technology NN N
. . N

-DOCSTART- -X- O O

Temporal JJ i
judgements NNS i
of IN N
internal JJ N
and CC N
external JJ N
events NNS N
in IN N
persons NNS p
with IN p
and CC p
without IN p
autism NN p
. . p

When WRB N
participants NNS N
make VBP N
judgments NNS i
about IN N
the DT N
onset NN N
of IN N
self-initiated JJ N
movements NNS N
they PRP N
typically RB N
report VBP N
the DT N
movement NN N
occurred VBD N
earlier JJR N
than IN N
it PRP N
had VBD N
[ NNP N
Obhi NNP N
, , N
S. NNP N
S. NNP N
, , N
& CC N
Haggard NNP N
, , N
P. NNP N
( ( N
2004 CD N
) ) N
. . N

Free NNP N
will MD N
and CC N
free JJ N
wo MD N
n't RB N
. . N

American JJ N
Scientific NNP N
, , N
92 CD N
, , N
358-365. JJ N
] NN N
. . N

One CD N
interpretation NN N
is VBZ N
that IN N
feed-forward JJ N
processes NNS N
lead VBP N
to TO N
awareness NN N
of IN N
the DT N
movement NN N
prior RB N
to TO N
execution NN N
. . N

Because IN N
individuals NNS p
with IN p
autism NN p
experience NN N
reduced VBD N
preparatory JJ N
activity NN N
prior RB N
to TO N
a DT N
voluntary JJ N
movement NN N
, , N
the DT N
present JJ N
study NN N
sought VBD N
to TO N
determine VB N
whether IN N
these DT N
anticipatory JJ N
biases NNS N
are VBP N
exhibited VBN N
by IN N
persons NNS p
with IN p
autism NN p
. . p

Participants NNS i
watched VBD i
a DT i
dot JJ i
move NN i
in IN i
a DT i
circle NN i
and CC i
pressed VBD i
the DT i
spacebar NN i
any DT i
time NN i
after IN i
one CD i
revolution NN i
. . i

A DT N
tone NN N
either CC N
followed VBD N
the DT N
participants NNS N
' POS N
voluntary JJ N
movement NN N
or CC N
was VBD N
computer NN N
generated VBN N
. . N

Participants NNS N
in IN N
both DT N
groups NNS N
made VBD N
anticipatory JJ N
judgements NNS o
regarding VBG N
movement NN o
initiation NN o
( ( N
approximately RB N
100 CD N
ms NN N
) ) N
. . N

When WRB N
the DT N
movement NN N
and CC N
tone NN N
occurred VBD N
together RB N
this DT N
anticipatory NN N
bias NN N
was VBD N
also RB N
present JJ N
, , N
regardless RB N
of IN N
which WDT N
event NN N
participants NNS N
focused VBD N
on IN N
. . N

Individuals NNS p
with IN p
autism NN p
appear VBP N
to TO N
have VB N
access NN N
to TO N
a DT N
similar JJ N
representation NN N
of IN N
voluntary JJ o
movements NNS o
, , N
however RB N
this DT N
representation NN N
may MD N
be VB N
more RBR N
variable JJ N
. . N

-DOCSTART- -X- O O

Dietary NNP N
patterns NNS N
differ VBP N
between IN N
urban JJ p
and CC p
rural JJ p
older JJR p
, , p
long-term JJ p
survivors NNS p
of IN p
breast NN p
, , p
prostate NN p
, , p
and CC p
colorectal JJ p
cancer NN p
and CC N
are VBP N
associated VBN N
with IN N
body NN N
mass NN N
index NN N
. . N

BACKGROUND NNP N
Older NNP p
adult NN p
cancer NN p
survivors NNS p
are VBP N
at IN N
greater JJR N
risk NN N
of IN N
cancer NN o
recurrence NN o
and CC N
other JJ N
comorbidities NNS o
that WDT N
can MD N
be VB N
prevented VBN N
through IN N
improved VBN N
diet JJ N
and CC N
weight JJ N
management NN N
. . N

The DT N
tertiary JJ N
prevention NN N
needs NNS N
of IN N
rural-dwelling JJ N
survivors NNS N
can MD N
be VB N
even RB N
greater JJR N
, , N
yet RB N
little JJ N
is VBZ N
known VBN N
about IN N
rural JJ N
and CC N
urban JJ N
differences NNS N
in IN N
lifestyle JJ N
factors NNS N
among IN N
this DT N
high-risk JJ N
population NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB i
dietary JJ i
patterns NNS i
of IN N
urban JJ p
and CC p
rural JJ p
cancer NN p
survivors NNS p
and CC N
to TO N
examine VB N
associations NNS N
of IN N
dietary JJ o
patterns NNS o
with IN N
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
. . o

DESIGN VB N
A DT N
secondary JJ N
analysis NN N
was VBD N
performed VBN N
of IN N
baseline NN N
data NNS N
from IN N
the DT N
Reach NNP o
Out NNP o
to TO o
Enhance VB o
Wellness NNP o
( ( N
RENEW NNP N
) ) N
trial NN N
, , N
a DT N
diet JJ i
and CC i
exercise JJ i
intervention NN i
among IN N
overweight JJ N
, , N
long-term JJ N
( ( N
?5 CD N
years NNS N
) ) N
, , N
older JJR N
survivors NNS N
of IN N
colorectal NN N
, , N
breast NN N
, , N
and CC N
prostate NN N
cancer NN p
. . p

Survivors NNS p
in IN p
the DT p
present JJ p
analysis NN p
( ( p
n=729 JJ p
) ) p
underwent JJ i
two CD i
45- JJ i
to TO i
60-minute JJ i
telephone NN i
surveys NNS i
, , i
which WDT i
included VBD i
two CD i
24-hour JJ i
dietary JJ i
recalls NNS i
. . i

Principal JJ i
components NNS i
analysis NN i
and CC i
multivariable JJ i
general JJ i
linear JJ i
models NNS i
were VBD i
used VBN N
to TO N
derive VB o
dietary JJ o
patterns NNS o
and CC o
to TO N
evaluate VB N
associations NNS N
between IN o
dietary JJ o
patterns NNS o
and CC o
BMI NNP o
, , o
respectively RB N
. . N

RESULTS VB N
Principal JJ N
components NNS N
analysis NN N
identified VBD N
three CD o
primary JJ o
dietary JJ o
patterns NNS o
among IN o
rural JJ N
dwellers NNS N
( ( N
high JJ N
sweets NNS N
and CC N
starches NNS N
, , N
high JJ N
reduced-fat NN N
dairy NN N
, , N
cereal NN N
, , N
nuts NNS N
, , N
and CC N
fruits NNS N
, , N
and CC N
mixed JJ N
) ) N
and CC N
three CD N
among IN N
urban JJ N
dwellers NNS N
( ( N
high JJ N
fruits NNS N
and CC N
vegetables NNS N
, , N
high JJ N
meat NN N
and CC N
refined VBD N
grains NNS N
, , N
and CC N
high JJ N
sugar-sweetened JJ N
beverages NNS N
) ) N
. . N

Among IN p
rural JJ p
survivors NNS p
, , p
greater JJR N
adherence NN N
to TO N
the DT N
high JJ N
reduced-fat NN N
dairy NN N
, , N
cereal NN N
, , N
nuts NNS N
, , N
and CC N
fruits NNS N
pattern NN N
was VBD N
positively RB N
associated VBN N
with IN N
lower JJR o
BMI NNP o
( ( o
P NNP N
trend NN N
< NNP N
0.05 CD N
) ) N
, , N
whereas IN N
higher JJR N
scores NNS N
on IN N
the DT N
mixed JJ N
pattern NN N
was VBD N
associated VBN N
with IN N
greater JJR o
BMI NNP o
( ( o
P NNP N
trend NN N
< NNP N
0.05 CD N
) ) N
. . N

Greater NNP N
adherence NN N
to TO N
the DT N
high JJ N
fruits NNS N
and CC N
vegetables NNS N
pattern VBP N
among IN N
urban JJ N
survivors NNS N
was VBD N
inversely RB N
associated VBN N
with IN o
BMI NNP o
( ( o
P NNP N
trend NN N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Urban NNP N
and CC N
rural JJ N
differences NNS N
in IN N
dietary JJ N
intake NN N
behavior NN N
should MD N
be VB N
considered VBN N
in IN N
designing VBG N
public JJ N
health NN N
interventions NNS N
among IN N
the DT o
increasing VBG o
population NN o
of IN o
older JJR N
cancer NN N
survivors NNS N
. . N

In IN N
addition NN N
, , N
targeting VBG N
overall JJ N
dietary JJ N
patterns NNS N
might MD N
be VB N
one CD N
approach NN N
to TO N
help VB N
reduce VB N
the DT N
burden NN N
of IN N
obesity NN N
among IN N
this DT N
population NN N
. . N

-DOCSTART- -X- O O

Cardiopulmonary JJ i
exercise NN i
variables NNS N
in IN N
diastolic JJ p
versus NN p
systolic JJ p
heart NN p
failure NN p
. . p

The DT N
response NN N
to TO N
cardiopulmonary JJ i
exercise NN i
( ( i
CPX NNP i
) ) i
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
with IN p
normal JJ p
left JJ p
ventricular NN p
( ( p
LV NNP p
) ) p
ejection NN p
fractions NNS p
( ( p
EFs NNP p
) ) p
is VBZ N
not RB N
well RB N
characterized VBN N
. . N

To TO N
determine VB N
if IN N
CPX NNP i
testing VBG N
could MD N
distinguish VB N
between IN N
patients NNS p
with IN p
HF NNP p
with IN p
normal JJ p
EFs NNP p
( ( p
> VB p
50 CD p
% NN p
; : p
i.e. CC p
, , N
diastolic JJ p
HF NNP p
) ) p
and CC N
those DT N
with IN N
decreased JJ N
EFs NNP N
( ( N
> CD N
or CC N
=50 CD N
% NN N
; : N
i.e. CC N
, , N
systolic JJ N
HF NNP N
) ) N
, , N
CPX NNP i
responses NNS N
were VBD N
compared VBN N
between IN N
185 CD p
patients NNS p
with IN p
systolic JJ p
HF NNP p
( ( p
79 CD p
% NN p
men NNS p
, , p
mean JJ p
age NN p
62.6 CD p
+/- JJ p
10.9 CD p
years NNS p
) ) p
and CC p
43 CD p
with IN p
diastolic JJ p
HF NNP p
( ( p
54 CD p
% NN p
men NNS p
, , p
mean JJ p
age NN p
67.4 CD p
+/- JJ p
9.8 CD p
years NNS p
) ) p
enrolled VBD p
in IN p
a DT p
phase NN p
II NNP p
multicenter NN p
clinical JJ p
trial NN p
. . p

All DT N
patients NNS N
were VBD N
evaluated VBN N
with IN N
echocardiography NN i
and CC N
a DT N
standardized JJ i
CPX NNP i
test NN i
as IN N
part NN N
of IN N
the DT N
trial NN N
. . N

CPX NNP o
variables NNS o
, , N
including VBG N
oxygen NN o
uptake NN o
at IN o
peak NN o
exercise NN o
( ( o
peak JJ o
VO NNP o
( ( o
2 CD o
) ) o
) ) o
and CC o
the DT o
slope NN o
of IN o
the DT o
ventilation/carbon NN o
dioxide NN o
production NN o
ratio NN o
( ( o
VE/VCO NNP o
( ( o
2 CD o
) ) o
) ) o
, , N
were VBD N
determined VBN N
and CC N
analyzed VBN N
by IN N
core NN N
laboratory NN N
personnel NNS N
. . N

Echocardiographic JJ o
measurements NNS o
included VBD N
the DT N
LV NNP o
EF NNP o
, , o
the DT o
E/A NNP o
ratio NN o
, , o
filling VBG o
time NN o
, , o
cavity NN o
volumes NNS o
, , o
right JJ o
ventricular NN o
function NN o
, , o
and CC o
mitral JJ o
regurgitation NN o
. . o

Patients NNS p
in IN p
the DT p
diastolic JJ p
HF NNP p
group NN p
tended VBD p
to TO p
be VB p
older JJR p
( ( p
p JJ p
< NNP p
0.08 CD p
) ) p
, , p
with IN p
more JJR p
women NNS p
( ( p
p JJ p
< NNP p
0.006 CD p
) ) p
and CC p
with IN p
greater JJR p
body NN p
mass NN p
indexes NNS p
( ( p
p JJ p
< NNP N
0.02 CD N
) ) N
, , N
than IN N
those DT N
in IN N
the DT N
systolic JJ N
HF NNP N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
use NN o
of IN o
beta NN o
blockers NNS o
or CC o
the DT o
incidence NN o
of IN o
coronary JJ o
artery NN o
disease NN o
. . o

Patients NNS N
with IN N
diastolic JJ N
HF NNP N
had VBD N
decreased VBN N
E/A NNP o
ratios NNS o
( ( N
0.9 CD N
+/- JJ N
0.4 CD N
vs JJ N
1.4 CD N
+/- JJ N
1.1 CD N
, , N
p NN N
< VBD N
0.02 CD N
, , N
diastolic JJ N
HF NNP N
vs NN N
systolic JJ N
HF NNP N
) ) N
and CC N
increased VBD N
filling VBG o
times NNS o
( ( N
30.4 CD N
+/- JJ N
3.2 CD N
vs JJ N
26.5 CD N
+/- JJ N
4.7 CD N
ms NN N
, , N
p NN N
< VBD N
0.01 CD N
, , N
diastolic JJ N
HF NNP N
vs NN N
systolic JJ N
HF NNP N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
peak NN o
VO NNP o
( ( o
2 CD o
) ) o
( ( N
14.4 CD N
+/- JJ N
1.9 CD N
vs JJ N
15.6 CD N
+/- JJ N
3.2 CD N
ml/kg/min NN N
, , N
p NN N
= VBD N
0.06 CD N
, , N
diastolic JJ N
HF NNP N
vs NN N
systolic JJ N
HF NNP N
) ) N
were VBD N
observed VBN N
. . N

The DT N
VE/VCO NNP o
( ( o
2 CD o
) ) o
ratios NNS o
for IN N
the DT N
2 CD N
groups NNS N
were VBD N
abnormal JJ N
and CC N
comparable JJ N
( ( N
32 CD N
2 CD N
+/- JJ N
7.5 CD N
vs JJ N
34.0 CD N
+/- JJ N
8.3 CD N
, , N
p NN N
= VBD N
0.3 CD N
, , N
diastolic JJ N
HF NNP N
vs NN N
systolic JJ N
HF NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
CPX NNP o
response NN o
in IN N
patients NNS N
with IN N
diastolic JJ N
HF NNP N
and CC N
systolic JJ N
HF NNP N
is VBZ N
markedly RB N
abnormal JJ N
and CC N
indistinguishable JJ N
with IN N
regard NN N
to TO N
peak VB o
VO NNP o
( ( o
2 CD o
) ) o
and CC o
ventilation NN o
despite IN N
marked JJ N
differences NNS N
in IN N
the DT N
LV NNP N
EF NNP N
. . N

-DOCSTART- -X- O O

A DT N
pilot NN i
group NN i
therapy NN i
for IN N
functional JJ p
memory NN p
disorder NN p
. . p

-DOCSTART- -X- O O

Clinical JJ N
usefulness NN N
of IN N
serum NN i
prostate NN i
specific JJ i
antigen NN i
for IN N
the DT N
detection NN N
of IN N
prostate NN p
cancer NN p
is VBZ N
preserved VBN N
in IN N
men NNS p
receiving VBG p
the DT p
dual JJ i
5alpha-reductase JJ i
inhibitor NN i
dutasteride NN i
. . i

PURPOSE NNP N
We PRP N
determined VBD N
whether IN N
the DT N
decrease NN N
in IN N
serum NN N
PSA NNP N
seen VBN N
with IN N
5alpha-reductase JJ i
inhibitors NNS i
affects VBZ N
the DT N
clinical JJ N
usefulness NN N
of IN N
PSA NNP N
for IN N
prostate NN N
cancer NN N
screening VBG N
using VBG N
data NNS N
from IN N
2 CD N
dutasteride JJ N
benign JJ N
prostatic JJ N
hyperplasia NN N
studies NNS N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
2,802 CD p
men NNS p
50 CD p
years NNS p
or CC p
older JJR p
with IN p
a DT p
clinical JJ p
diagnosis NN p
of IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
, , p
no DT p
history NN p
of IN p
prostate NN p
cancer NN p
, , p
PSA NNP p
1.5 CD p
to TO p
10 CD p
ng/ml NNS p
, , p
prostate NN p
volume NN p
30 CD p
cc NN p
or CC p
greater JJR p
, , p
an DT p
American NNP p
Urological NNP p
Association NNP p
symptom VBD p
score NN p
of IN p
12 CD p
or CC p
greater JJR p
and CC p
peak JJ p
urinary JJ p
flow NN p
rate NN p
15 CD p
ml NN p
per IN p
second NN p
or CC p
less JJR p
were VBD p
randomized VBN p
to TO p
0.5 CD i
mg NNS i
dutasteride JJ i
daily RB i
or CC i
matching VBG i
placebo NN i
for IN N
24 CD N
months NNS N
. . N

Increases NNS N
in IN N
PSA NNP N
from IN N
baseline NN N
and CC N
the DT N
maximum JJ N
increase NN N
from IN N
nadir JJ N
to TO N
month NN N
24 CD N
were VBD N
compared VBN N
between IN N
the DT N
groups NNS N
and CC N
analyzed VBN N
by IN N
prostate NN N
cancer NN N
status NN N
, , N
as IN N
determined VBN N
by IN N
PSA NNP N
driven JJ N
biopsy NN N
and CC N
an DT N
advised JJ N
cutoff NN N
of IN N
more JJR N
than IN N
4 CD N
ng/ml NNS N
after IN N
doubling VBG N
to TO N
correct VB N
for IN N
dutasteride JJ i
treatment NN N
with IN N
sensitivity NN N
and CC N
specificity NN N
calculated VBN N
for IN N
each DT N
. . N

RESULTS NNP N
In IN N
placebo NN i
treated VBN N
men NNS N
without IN N
prostate NN N
cancer NN N
there EX N
was VBD N
an DT N
8.3 CD N
% NN N
median JJ o
increase NN o
in IN o
PSA NNP o
at IN o
month NN o
24 CD o
compared VBN N
with IN N
-59.5 CD N
% NN N
in IN N
those DT N
who WP N
received VBD N
dutasteride RB i
, , N
using VBG N
doubled VBD N
values NNS N
to TO N
correct VB N
for IN N
dutasteride JJ i
treatment NN N
. . N

In IN N
those DT N
with IN N
prostate JJ N
cancer NN N
these DT N
changes NNS N
were VBD N
23.8 CD N
% NN N
and CC N
-37.2 CD N
% NN N
, , N
respectively RB N
. . N

Using VBG o
the DT o
upper JJ o
PSA NNP o
limit NN o
of IN o
4 CD o
ng/ml JJ o
sensitivity NN o
for IN N
prostate NN N
cancer NN N
in IN N
men NNS N
receiving VBG N
dutasteride NN i
vs NN i
placebo NN i
was VBD N
0.737 CD N
vs NN N
0.804 CD N
, , N
while IN N
specificity NN o
was VBD N
0.671 CD N
vs JJ N
0.578 CD N
. . N

Using VBG o
a DT o
PSA NNP o
increase NN o
from IN o
nadir NN o
of IN o
0.8 CD o
ng/ml IN o
the DT N
sensitivity NN o
of IN N
dutasteride NN i
was VBD N
0.548 CD N
and CC N
its PRP$ N
specificity NN o
was VBD N
0.795 CD N
. . N

CONCLUSIONS VB N
A DT N
doubling JJ N
factor NN N
is VBZ N
effective JJ N
for IN N
maintaining VBG N
the DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
PSA NNP o
for IN N
prostate NN N
cancer NN N
detection NN N
in IN N
men NNS N
on IN N
dutasteride NN i
. . i

Increases VBZ N
in IN N
serum NN o
PSA NNP o
in IN N
men NNS N
receiving VBG N
dutasteride NN i
should MD N
be VB N
considered VBN N
suspicious JJ N
and CC N
serial JJ N
PSA NNP o
measurements NNS N
should MD N
be VB N
used VBN N
to TO N
evaluate VB N
changes NNS N
from IN N
nadir NN N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
vasculogenic JJ p
sexual JJ p
dysfunction NN p
with IN N
pentoxifylline NN i
. . i

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
use NN N
of IN N
pentoxifylline NN i
to TO N
treat VB N
impotence NN N
in IN N
men NNS p
with IN p
mild NN p
to TO p
moderate VB p
penile IN p
vascular JJ p
insufficiency NN p
. . p

DESIGN NNP N
Double-blind NNP N
randomized VBD N
clinical JJ N
trial NN N
. . N

SETTING NN N
Sexual JJ p
Dysfunction NNP p
Clinic NNP p
at IN p
VA NNP p
Medical NNP p
Center NNP p
, , p
Sepulveda NNP p
, , p
CA NNP p
. . p

PARTICIPANTS NNP N
Convenience NNP p
sample NN p
of IN p
couples NNS p
. . p

INTERVENTION NNP N
Twelve NNP N
weeks NNS N
of IN N
treatment NN N
with IN N
placebo NN i
or CC i
400 CD i
mg JJ i
tid NN i
of IN i
pentoxifylline NN i
. . i

MEASUREMENTS NNP N
( ( N
1 CD N
) ) N
Report NN o
of IN o
patient JJ o
verified VBN o
by IN o
partner NN o
as IN o
to TO o
number NN o
of IN o
coital JJ o
episodes NNS o
per IN o
month NN o
; : o
( ( N
2 CD N
) ) N
penile-brachial JJ o
pressure NN o
index NN o
determinations NNS o
. . o

RESULTS NNP N
Pentoxifylline NNP i
therapy VBZ i
regularly RB N
increased VBN N
the DT N
PBPI NNP o
in IN N
impotent JJ p
men NNS p
in IN N
comparison NN N
with IN N
the DT N
placebo NN N
, , N
frequently RB N
into IN N
the DT N
normal JJ N
range NN N
. . N

Pentoxifylline NNP N
therapy NN N
was VBD N
particularly RB N
useful JJ N
in IN N
restoring VBG o
the DT o
PBPI NNP o
in IN N
men NNS p
with IN p
the DT p
pelvic JJ p
steal JJ p
syndrome NN p
; : p
six CD N
of IN N
seven CD N
such JJ N
subjects NNS N
improved VBN N
into IN N
the DT N
normal JJ N
range NN N
. . N

During IN N
the DT N
pentoxifylline JJ N
treatment NN N
period NN N
, , N
in IN N
contrast NN N
with IN N
the DT N
control NN N
period NN N
, , N
nine CD N
men NNS N
were VBD N
able JJ N
to TO N
reestablish VB o
coital JJ o
function NN o
and CC N
three CD N
had VBD N
no DT N
improvement NN N
. . N

Six NNP N
couples NNS N
did VBD N
not RB N
attempt VB o
intercourse JJ o
despite IN N
a DT N
professed JJ N
interest NN N
in IN N
sexual JJ o
activity NN o
; : o
however RB N
five CD N
out IN N
of IN N
the DT N
six CD N
men NNS N
experienced VBD N
erections NNS o
during IN o
episodes NNS o
of IN o
fantasy NN o
or CC o
attempts NNS o
at IN o
masturbation NN o
during IN N
treatment NN N
. . N

There EX N
were VBD N
no DT N
complications NNS o
of IN N
therapy NN N
. . N

CONCLUSIONS NNP N
These DT N
promising VBG N
preliminary JJ N
results NNS N
suggest VBP N
a DT N
well RB N
tolerated JJ N
alternative JJ N
therapy NN N
for IN N
erectile JJ p
dysfunction NN p
in IN p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
penile IN p
vascular JJ p
disease NN p
. . p

-DOCSTART- -X- O O

Mechanical JJ o
efficiency NN o
and CC o
propulsion NN o
technique NN o
after IN N
7 CD N
weeks NNS N
of IN N
low-intensity JJ N
wheelchair NN N
training NN N
. . N

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
7-week JJ N
low-intensity NN N
hand NN N
rim VBZ N
wheelchair JJ N
training VBG N
on IN N
the DT N
submaximal JJ N
metabolic NN N
cost NN N
, , N
mechanical JJ o
efficiency NN o
and CC N
propulsion NN N
technique NN N
in IN N
able-bodied JJ p
participants NNS p
. . p

METHODS JJ N
Participants NNS p
were VBD N
randomly RB N
divided VBN N
over RP N
an DT N
experimental JJ N
group NN N
( ( p
n=14 CC p
) ) p
and CC p
a DT p
control NN p
group NN p
( ( p
n=7 RB p
) ) p
. . p

The DT N
experimental JJ N
group NN N
received VBD i
7 CD i
weeks NNS i
wheelchair JJ i
training NN i
( ( i
3 CD i
week NN i
( ( i
-1 NN i
) ) i
, , i
70 CD i
min NN i
) ) i
at IN i
a DT i
low JJ i
intensity NN i
( ( i
30 CD i
% NN i
of IN i
the DT i
heart NN i
rate NN i
reserve NN i
) ) i
, , i
whereas IN i
the DT i
control NN i
group NN i
did VBD i
not RB i
receive VB i
training NN i
. . i

During IN i
pre- JJ i
and CC i
post-tests NNS i
, , i
submaximal JJ i
exercise NN i
was VBD i
performed VBN i
on IN i
a DT i
stationary JJ i
wheelchair NN i
ergometer NN i
at IN i
fixed JJ i
levels NNS i
of IN i
power NN i
output NN i
. . i

Mechanical JJ o
efficiency NN o
, , o
oxygen NN o
uptake NN o
, , o
heart NN o
rate NN o
, , o
timing VBG o
parameters NNS o
and CC o
stroke NN o
angles NNS o
were VBD i
measured VBN i
. . i

Video NNP N
recordings NNS N
were VBD N
made VBN N
to TO N
determine VB N
the DT N
stroke NN o
pattern NN o
. . o

FINDINGS NNP N
Mechanical NNP o
efficiency NN o
increased VBD o
and CC o
metabolic JJ o
cost NN o
decreased VBN o
significantly RB N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Push NNP o
time NN o
increased VBD N
and CC N
cycle NN o
frequency NN o
decreased VBD N
as IN N
a DT N
result NN N
of IN N
training NN N
. . N

The DT N
stroke NN o
angle NN o
increased VBD N
in IN N
the DT N
experimental JJ N
group NN N
during IN N
the DT N
training NN N
period NN N
. . N

The DT N
experimental JJ N
group NN N
preferred VBD N
double-looping NN N
over IN N
propulsion NN N
, , N
while IN N
the DT N
control NN N
group NN N
mainly RB N
used VBD N
single-looping NN o
over IN o
propulsion NN o
patterns NNS N
during IN N
the DT N
post-test JJ N
. . N

INTERPRETATION VB N
A DT N
low-intensity NN N
, , N
7-week JJ N
training NN N
protocol NN N
has VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
mechanical JJ o
efficiency NN o
and CC o
metabolic JJ o
cost NN o
of IN N
wheelchair NN N
propulsion NN N
in IN N
able-bodied JJ p
participants NNS p
. . p

The DT N
improved JJ N
mechanical JJ N
efficiency NN N
seems VBZ N
to TO N
be VB N
the DT N
result NN N
of IN N
changes NNS N
in IN N
propulsion NN N
technique NN N
that WDT N
were VBD N
found VBN N
. . N

-DOCSTART- -X- O O

Gastrointestinal NNP o
safety NN o
of IN N
NO-aspirin NNP i
( ( i
NCX-4016 NNP i
) ) i
in IN N
healthy JJ p
human JJ p
volunteers NNS p
: : p
a DT N
proof NN N
of IN N
concept NN N
endoscopic NN N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
NCX-4016 NNP i
is VBZ N
a DT N
nitric JJ N
oxide-releasing JJ N
derivative NN N
of IN N
aspirin NN N
with IN N
antiplatelet NN o
activity NN o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
NCX-4016 NNP i
on IN N
gastrointestinal JJ N
mucosa NN N
and CC N
platelet NN o
functions NNS o
in IN N
healthy JJ p
human JJ p
volunteers NNS p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
parallel-group JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

Forty NNP p
healthy JJ p
subjects NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
7 CD N
days NNS N
of IN N
treatment NN N
with IN N
NCX-4016 NNP i
( ( i
400 CD i
and CC i
800 CD i
mg NN i
twice RB i
daily RB i
) ) i
, , i
equimolar JJ i
doses NNS i
of IN i
aspirin NN i
( ( i
200 CD i
and CC i
420 CD i
mg NN i
twice RB i
daily RB i
) ) i
, , i
or CC i
placebo NN i
. . i

Upper IN N
endoscopies NNS N
were VBD N
performed VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
, , N
and CC N
gastroduodenal JJ o
lesions NNS o
were VBD N
graded VBN N
using VBG N
a DT N
predefined VBN o
scoring NN o
system NN o
. . o

Basal NNP o
and CC o
posttreatment JJ o
platelet NN o
aggregation NN o
in IN N
response NN N
to TO N
arachidonic JJ N
acid NN N
( ( N
AA NNP N
) ) N
and CC N
serum JJ N
thromboxane NN N
( ( N
TX NNP N
) ) N
B NNP N
( ( N
2 CD N
) ) N
and CC N
AA-stimulated JJ N
platelet NN N
TXB NNP N
( ( N
2 CD N
) ) N
production NN N
were VBD N
investigated VBN N
. . N

RESULTS NNP N
Mucosal NNP o
endoscopic JJ o
injury NN o
score NN o
on IN N
day NN N
7 CD N
was VBD N
0.63 CD N
+/- JJ N
0.16 CD N
in IN N
the DT N
placebo NN N
group NN N
and CC N
11.0 CD N
+/- JJ N
3.0 CD N
and CC N
16.1 CD N
+/- JJ N
1.6 CD N
in IN N
healthy JJ p
volunteers NNS p
treated VBD N
with IN N
200 CD N
and CC N
420 CD N
mg NN N
aspirin JJ N
twice RB N
daily RB N
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. FW N
placebo NN N
) ) N
. . N

NCX-4016 NN N
was VBD N
virtually RB N
devoid JJ N
of IN N
gastric JJ o
and CC o
duodenal JJ o
toxicity NN o
, , N
resulting VBG N
in IN N
a DT N
total JJ o
gastric NN o
and CC o
duodenal JJ o
endoscopic NN o
score NN o
of IN N
1.38 CD N
+/- JJ N
0.3 CD N
and CC N
1.25 CD N
+/- JJ N
0.5 CD N
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. NN N
aspirin NN N
, , N
not RB N
significant JJ N
vs. FW N
placebo NN N
) ) N
. . N

NCX-4016 JJ N
inhibited JJ N
AA-induced JJ o
platelet NN o
aggregation NN o
as RB N
well RB N
as IN N
serum NN o
TXB NNP o
( ( o
2 CD o
) ) o
and CC N
platelet NN o
TXB NNP o
( ( o
2 CD o
) ) o
generation NN o
induced VBN N
by IN N
AA NNP N
to TO N
the DT N
same JJ N
extent NN N
as IN N
aspirin NN i
( ( N
not RB N
significant JJ N
vs. FW N
aspirin NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
we PRP N
have VBP N
proven VBN N
the DT N
concept NN N
that IN N
addition NN N
of IN N
an DT N
NO-donating JJ N
moiety NN N
to TO N
aspirin VB N
results NNS N
in IN N
a DT N
new JJ N
chemical NN N
entity NN N
that WDT N
maintains VBZ N
cyclooxygenase-1 NN N
and CC N
platelet VB N
inhibitory JJ N
activity NN N
while IN N
nearly RB N
avoiding VBG N
gastrointestinal JJ o
damage NN o
. . o

-DOCSTART- -X- O O

[ NN N
Combined VBD N
preoperative JJ i
xeloda NN i
and CC i
radiotherapy NN i
for IN N
lower JJR p
rectal NN p
cancer NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
combined JJ i
preoperative JJ i
xeloda NN i
and CC i
pelvic JJ i
radiotherapy NN i
on IN N
locally RB p
advanced VBN p
lower JJR p
rectal JJ p
cancer NN p
. . p

METHODS NNP N
Sixty NNP p
lower JJR p
rectal JJ p
cancer NN p
patients NNS p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

30 CD p
patients NNS p
( ( N
Group NNP N
A NNP N
) ) N
were VBD N
treated VBN N
with IN N
operation NN i
alone RB i
and CC N
30 CD N
patients NNS N
( ( N
Group NNP N
B NNP N
) ) N
were VBD N
treated VBN N
with IN N
xeloda NNP i
and CC i
radiotherapy NN i
before IN i
operation NN i
. . i

RESULTS VB N
The DT N
operative JJ o
resection NN o
, , o
anal JJ o
preservation NN o
and CC o
local JJ o
recurrence NN o
rates NNS o
were VBD N
86.66 CD N
% NN N
, , N
33.33 CD N
% NN N
, , N
15.38 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
100 CD N
% NN N
, , N
83.33 CD N
% NN N
, , N
0 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
and CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Combined VBD i
preoperative JJ i
xeloda NN i
and CC i
radiotherapy NN i
for IN N
lower JJR N
rectal NN N
cancer NN N
is VBZ N
able JJ N
to TO N
significantly RB N
improve VB N
the DT N
operative JJ N
resection NN N
, , N
anal JJ N
preservation NN N
and CC N
decrease VB N
the DT N
local JJ N
recurrence NN N
rates NNS N
. . N

-DOCSTART- -X- O O

A DT N
comparative JJ N
study NN N
of IN N
ofloxacin NN i
and CC N
amoxycillin/clavulanate NN i
in IN N
hospitalized JJ p
patients NNS p
with IN p
lower JJR o
respiratory NN o
tract JJ o
infections NNS o
. . o

We PRP N
conducted VBD N
an DT N
open JJ N
randomized VBN N
trial NN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
parenteral JJ N
and CC N
oral JJ N
ofloxacin NN i
with IN N
that DT N
of IN N
amoxycillin/clavulanate NN i
. . i

A DT N
total NN N
of IN N
121 CD p
patients NNS p
was VBD p
studied VBN p
; : p
92 CD p
were VBD p
clinically RB p
evaluable JJ p
. . p

Of IN N
these DT N
, , N
59 CD p
patients NNS p
were VBD p
treated VBN p
with IN p
ofloxacin NN i
and CC p
33 CD p
with IN p
the DT p
comparator NN p
drug NN p
. . p

Patients NNS N
were VBD N
given VBN N
the DT N
drugs NNS N
intravenously RB N
for IN N
a DT N
minimum NN N
of IN N
three CD N
days NNS N
followed VBN N
by IN N
oral JJ N
preparations NNS N
for IN N
the DT N
next JJ N
seven CD N
to TO N
ten VB N
days NNS N
. . N

Ofloxacin NNP i
was VBD N
usually RB N
administered VBN N
as IN N
a DT N
200 CD N
mg NN N
dose NN N
bd NN N
. . N

In IN N
the DT N
ofloxacin NN i
treated VBN N
group NN N
all DT N
patients NNS N
showed VBD N
clinical JJ o
improvement NN o
. . o

In IN N
the DT N
comparator NN N
group NN N
94 CD N
% NN N
improved VBN N
clinically RB N
( ( N
either CC N
a DT N
complete JJ N
or CC N
partial JJ N
response NN N
) ) N
, , N
while IN N
6 CD N
% NN N
were VBD N
clinical JJ N
failures NNS N
. . N

Of IN N
the DT N
bacteriologically RB N
evaluable JJ N
patients NNS N
19 CD N
of IN N
20 CD N
showed VBD N
a DT N
satisfactory JJ o
bacteriological JJ o
response NN o
in IN N
the DT N
ofloxacin NN N
treated VBD N
group NN N
, , N
while IN N
in IN N
the DT N
comparator NN N
group NN N
the DT N
bacteriological JJ N
response NN N
was VBD N
judged VBN N
satisfactory NN N
in IN N
14 CD N
of IN N
17 CD N
patients NNS N
. . N

A DT N
small JJ N
proportion NN N
of IN N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
treated VBD N
with IN N
ofloxacin NN i
suffered VBD N
mild JJ o
adverse JJ o
effects NNS o
( ( o
nausea NN o
, , o
vomiting VBG o
, , o
headache NN o
, , o
hypotension NN o
and CC o
rash NN o
) ) o
. . o

On IN N
the DT N
whole NN N
, , N
ofloxacin NN N
was VBD N
well RB N
tolerated VBN o
by IN N
our PRP$ N
patients NNS N
. . N

The DT N
two CD N
deaths NNS o
that IN N
occurred VBD N
were VBD N
in IN N
the DT N
comparator NN N
group NN N
. . N

We PRP N
conclude VBP N
that DT N
ofloxacin NN i
in IN N
both DT N
oral JJ N
and CC N
parenteral JJ N
forms NNS N
is VBZ N
an DT N
effective JJ o
and CC o
safe JJ o
drug NN N
in IN N
the DT N
treatment NN N
of IN N
lower JJR N
respiratory NN N
tract JJ N
infections NNS N
. . N

-DOCSTART- -X- O O

Results NNS N
of IN N
a DT N
multicenter NN N
, , N
8-week JJ N
, , N
parallel-group JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ i
maleate NN i
versus NN i
amlodipine NN i
besylate NN i
in IN N
Korean JJ p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
. . p

BACKGROUND NNP N
Recently RB N
, , N
amlodipine JJ i
maleate NN i
was VBD N
developed VBN N
and CC N
tested VBN N
in IN N
preclinical JJ N
and CC N
Phase NNP N
I PRP N
clinical JJ N
trials NNS N
in IN N
Korea NNP p
. . p

The DT N
studies NNS N
found VBD N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
similar JJ N
to TO N
those DT N
of IN N
amlodipine JJ i
besylate NN i
. . i

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ i
maleate NN i
with IN N
those DT N
of IN N
amlodipine JJ i
besylate NN i
in IN N
Korean JJ p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
8-week JJ N
, , N
parallel-group JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
. . N

Eligible JJ p
patients NNS p
were VBD p
Korean NNP p
, , p
aged VBD p
18 CD p
to TO p
75 CD p
years NNS p
, , p
had VBD p
hypertension NN p
, , p
and CC p
were VBD p
either RB p
taking VBG p
antihypertensive JJ p
medications NNS p
or CC p
had VBD p
a DT p
documented VBN p
sitting VBG p
diastolic JJ p
blood NN p
pressure NN p
of IN p
90 CD p
to TO p
109 CD p
mm NN p
Hg NNP p
. . p

After IN N
a DT N
washout JJ N
period NN N
of IN N
2 CD N
weeks NNS N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
amlodipine VB i
maleate NN i
or CC i
amlodipine NN i
besylate NN i
for IN N
8 CD N
weeks NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
medications NNS N
were VBD N
initiated VBN N
at IN N
5 CD N
mg NN N
QD NNP N
. . N

At IN N
day NN N
29 CD N
, , N
the DT N
medication NN N
dose NN N
was VBD N
increased VBN N
to TO N
10 CD N
mg NNS N
QD NNP N
if IN N
sitting VBG N
diastolic JJ N
blood NN N
pressure NN N
( ( N
SiDBP NNP N
) ) N
was VBD N
> JJ N
or CC N
= JJ N
90 CD N
mm NN N
Hg NNP N
. . N

RESULTS NNP N
One CD p
hundred VBD p
eighteen JJ p
patients NNS p
were VBD p
enrolled VBN p
. . p

Fifty-seven JJ N
patients NNS N
received VBD N
amlodipine JJ i
maleate NN i
( ( N
29 CD N
men NNS N
, , N
28 CD N
women NNS N
; : N
mean VB N
[ NNP N
SD NNP N
] NNP N
age NN N
, , N
49.0 CD N
[ NN N
11.4 CD N
] CD N
years NNS N
) ) N
and CC N
61 CD N
received VBD N
amlodipine JJ i
besylate NN i
( ( N
35 CD N
men NNS N
, , N
26 CD N
women NNS N
; : N
mean VB N
[ NNP N
SD NNP N
] NNP N
age NN N
, , N
51.6 CD N
[ NN N
9.4 CD N
] CD N
years NNS N
) ) N
. . N

Baseline JJ o
mean NN o
( ( o
SD NNP o
) ) o
values NNS o
for IN N
sitting VBG o
systolic JJ o
blood NN o
pressure NN o
and CC o
SiDBP NNP o
were VBD N
152.0 CD N
( ( N
12.2 CD N
) ) N
mm NN N
Hg NNP N
and CC N
98.1 CD N
( ( N
5.6 CD N
) ) N
mm NN N
Hg NNP N
, , N
respectively RB N
, , N
for IN N
the DT N
amlodipine JJ i
maleate NN i
group NN N
and CC N
153.4 CD N
( ( N
14.0 CD N
) ) N
mm NN N
Hg NNP N
and CC N
98.1 CD N
( ( N
5.5 CD N
) ) N
mm NN N
Hg NNP N
, , N
respectively RB N
, , N
for IN N
the DT N
amlodipine JJ i
besylate NN i
group NN N
. . N

In IN N
this DT N
population NN N
, , N
amlodipine JJ i
maleate NN i
was VBD N
not RB N
inferior JJ N
to TO N
amlodipine VB i
besylate NN i
: : i
the DT N
lower JJR N
limit NN N
of IN N
the DT N
2-sided JJ N
95 CD N
% NN N
CI NNP N
for IN N
the DT N
treatment NN N
difference NN N
in IN N
SiDBP NNP o
was VBD N
greater JJR N
than IN N
-4 JJR N
mm NN N
Hg NNP N
. . N

The DT N
between-group JJ N
difference NN N
in IN N
SiDBP NNP o
response NN o
rate NN o
( ( N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
experienced VBD N
adequate JJ N
SiDBP NNP N
reductions NNS N
) ) N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
: : N
85.7 CD N
% NN N
( ( N
42/49 CD N
) ) N
for IN N
the DT N
amlodipine JJ i
maleate NN i
group NN N
and CC N
91.8 CD N
% NN N
( ( N
45/49 CD N
) ) N
for IN N
the DT N
amlodipine JJ N
besylate NN N
group NN N
. . N

Compliance NN N
rates NNS N
were VBD N
similar JJ N
between IN N
groups NNS N
, , N
with IN N
mean NN o
( ( o
SD NNP o
) ) o
compliance NN o
rates NNS o
of IN N
97.4 CD N
% NN N
( ( N
2.8 CD N
% NN N
) ) N
and CC N
97.1 CD N
% NN N
( ( N
3.6 CD N
% NN N
) ) N
in IN N
the DT N
amlodipine NN i
maleate NN i
and CC N
amlodipine JJ i
besylate NN i
groups NNS N
, , N
respectively RB N
. . N

Also RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidences NNS N
of IN N
drug-related JJ N
clinical JJ N
and CC N
laboratory JJ N
adverse JJ N
events NNS N
; : N
the DT N
most RBS N
common JJ N
were VBD N
headache NN o
, , o
flushing NN o
, , o
facial JJ o
edema NN o
, , o
and CC o
paresthesia NN o
. . o

CONCLUSION NN N
In IN N
this DT N
population NN N
, , N
the DT N
efficacy NN N
and CC N
tolerability NN N
observed VBN N
with IN N
amlodipine JJ N
maleate NN N
were VBD N
similar JJ N
to TO N
those DT N
seen VBN N
with IN N
amlodipine JJ N
besylate NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
esmolol JJ i
pretreatment NN N
on IN N
EEG NNP o
seizure NN o
morphology NN o
in IN N
RUL NNP N
ECT NNP N
. . N

Intravenous JJ N
beta-blockers NNS N
are VBP N
an DT N
effective JJ N
means NNS N
of IN N
controlling VBG N
heart NN o
rate NN o
and CC o
blood NN o
pressure NN o
during IN N
electroconvulsive JJ i
therapy NN i
( ( i
ECT NNP i
) ) i
, , N
but CC N
have VBP N
been VBN N
shown VBN N
to TO N
decrease VB N
seizure NN N
duration NN N
. . N

While IN N
the DT N
importance NN N
of IN N
seizure NN N
duration NN N
to TO N
the DT N
antidepressant JJ N
response NN N
of IN N
ECT NNP N
grows VBZ N
less JJR N
certain JJ N
, , N
there EX N
is VBZ N
growing VBG N
evidence NN N
that IN N
seizure NN N
morphology NN N
predicts VBZ N
the DT N
antidepressant JJ N
effect NN N
of IN N
ECT NNP N
. . N

This DT N
study NN N
examined VBD N
the DT N
impact NN N
of IN N
esmolol JJ i
pretreatment NN N
on IN N
seizure NN o
morphology NN o
. . o

Eighteen NNP p
depressed VBD p
patients NNS p
( ( p
6 CD p
men NNS p
, , p
12 CD p
women NNS p
; : p
69 CD p
+/- JJ p
12.8 CD p
years NNS p
old JJ p
) ) p
received VBD p
ECT NNP i
with IN i
and CC i
without IN i
esmolol JJ i
pretreatment NN i
in IN N
a DT N
randomized JJ N
, , N
blinded VBD N
crossover NN N
design NN N
. . N

The DT N
seizures NNS N
were VBD N
blindly RB N
rated VBN N
for IN N
duration NN o
of IN o
motor NN o
convulsion NN o
, , o
duration NN o
of IN o
electroencephalogram NN o
( ( o
EEG NNP o
) ) o
seizure NN o
, , o
degree NN o
of IN o
seizure NN o
regularity NN o
, , o
and CC o
degree NN o
of IN o
postictal JJ o
EEG NNP o
suppression NN o
. . o

Esmolol NNP N
shortened VBD N
the DT N
duration NN N
of IN N
the DT N
motor NN N
convulsion NN N
and CC N
degraded VBD N
the DT N
quality NN o
of IN o
the DT o
ictal JJ o
regularity NN o
. . o

Routine JJ N
administration NN N
of IN N
intravenous JJ N
esmolol NN N
before IN N
ECT NNP N
may MD N
cause VB N
a DT N
decrease NN N
in IN N
ictal JJ o
regularity NN o
. . o

Careful JJ N
consideration NN N
should MD N
be VB N
given VBN N
to TO N
the DT N
potential JJ N
benefits NNS N
of IN N
esmolol NN N
versus IN N
the DT N
deleterious JJ N
effect NN N
on IN N
the DT N
electrophysiologic JJ N
process NN N
. . N

Esmolol NN N
may MD N
still RB N
be VB N
indicated VBN N
on IN N
a DT N
case-by-case JJ N
basis NN N
for IN N
extreme JJ N
tachycardia NN N
or CC N
hypertension NN N
associated VBN N
with IN N
ECT NNP N
, , N
and CC N
presumably RB N
poses VBZ N
no DT N
problem NN N
for IN N
the DT N
therapeutic JJ N
effect NN N
of IN N
ECT NNP N
if IN N
given VBN N
after IN N
the DT N
seizure NN N
is VBZ N
over IN N
. . N

-DOCSTART- -X- O O

Phase NNP N
III NNP N
study NN N
of IN N
the DT N
Eastern NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
( ( N
ECOG NNP N
2597 CD N
) ) N
: : N
induction NN i
chemotherapy NN i
followed VBN i
by IN i
either DT i
standard JJ i
thoracic NN i
radiotherapy NN i
or CC i
hyperfractionated VBN i
accelerated JJ i
radiotherapy NN i
for IN N
patients NNS p
with IN p
unresectable JJ p
stage NN p
IIIA NNP p
and CC p
B NNP p
non-small-cell JJ p
lung NN p
cancer NN p
. . p

PURPOSE NNP N
To TO N
compare VB N
once-daily JJ i
radiation NN i
therapy NN i
( ( i
qdRT NN i
) ) i
with IN N
hyperfractionated VBN i
accelerated JJ i
radiation NN i
therapy NN i
( ( i
HART NNP i
) ) i
after IN N
two CD N
cycles NNS N
of IN N
induction NN i
chemotherapy NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Eligible JJ p
patients NNS p
were VBD p
treatment NN p
naive JJ p
, , p
and CC p
had VBD p
stage NN p
IIIA NNP p
and CC p
B NNP p
unresectable JJ p
non-small-cell JJ p
lung NN p
cancer NN p
, , p
Eastern NNP p
Cooperative NNP p
Oncology NNP p
Group NNP p
performance NN p
status NN p
0/1 CD p
, , p
and CC p
normal JJ p
organ JJ p
function NN p
. . p

Induction NNP i
chemotherapy NN i
consisted VBD N
of IN N
two CD N
cycles NNS N
of IN N
carboplatin JJ i
area NN N
under IN N
time-concentration NN N
curve NN N
6 CD N
mg/mL NN N
. . N

min NN N
plus CC N
paclitaxel JJ i
225 CD N
mg/m2 NN N
on IN N
day NN N
1 CD N
. . N

RT NNP N
consisted VBD N
of IN N
arm NN N
1 CD N
( ( N
qdRT NN N
) ) N
, , N
64 CD N
Gy NNP N
( ( N
2 CD N
Gy/d NNP N
) ) N
, , N
versus JJ N
arm NN N
2 CD N
( ( N
HART NNP N
) ) N
, , N
57.6 CD N
Gy NNP N
( ( N
1.5 CD N
Gy NNP N
tid NN N
for IN N
2.5 CD N
weeks NNS N
) ) N
. . N

A DT N
total NN p
of IN p
388 CD p
patients NNS p
were VBD N
needed VBN N
to TO N
detect VB N
a DT N
50 CD N
% NN N
increase NN N
in IN N
median JJ N
survival NN N
from IN N
14 CD N
months NNS N
of IN N
qdRT NN i
to TO N
21 CD N
months NNS N
of IN N
HART NNP i
; : i
accrual NN N
was VBD N
not RB N
achieved VBN N
and CC N
the DT N
study NN N
closed VBD N
prematurely RB N
. . N

RESULTS NNP N
Of IN N
141 CD p
patients NNS p
enrolled VBD p
, , N
83 CD N
% NN N
were VBD N
randomly RB N
assigned VBN N
after IN N
chemotherapy NN N
to TO N
qdRT VB i
( ( N
n JJ N
= NNP N
59 CD N
) ) N
or CC N
HART NNP i
( ( N
n JJ N
= NNP N
60 CD N
) ) N
. . N

Median JJ o
survival NN o
was VBD N
20.3 CD N
and CC N
14.9 CD N
months NNS N
for IN N
HART NNP i
and CC N
qdRT NN i
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.28 NNP N
) ) N
. . N

Overall JJ o
response NN o
was VBD N
25 CD N
% NN N
and CC N
22 CD N
% NN N
for IN N
HART NNP i
and CC N
qdRT NN i
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.69 NNP N
) ) N
. . N

Two- JJ o
and CC o
3-year JJ o
survival NN o
was VBD N
44 CD N
% NN N
and CC N
34 CD N
% NN N
for IN N
HART NNP i
, , N
and CC N
24 CD N
% NN N
and CC N
14 CD N
% NN N
for IN N
qdRT NN i
, , N
respectively RB N
. . N

Grade VB o
> NN o
or CC o
= $ o
3 CD o
toxicities NNS o
included VBD N
esophagitis NN N
in IN N
14 CD N
v JJ N
nine CD p
patients NNS p
, , N
and CC N
pneumonitis NN N
in IN N
0 CD N
v NNS N
6 CD N
patients NNS N
for IN N
HART NNP i
and CC N
qdRT NN i
, , N
respectively RB N
. . N

Any DT N
subsequent JJ N
trials NNS N
of IN N
the DT N
HART NNP i
regimen NNS N
must MD N
address VB N
the DT N
issues NNS N
that WDT N
led VBD N
to TO N
early JJ N
closure NN N
, , N
including VBG N
slow JJ o
accrual NN o
, , o
logistics NNS o
of IN o
HART NNP o
, , o
mucosal NN o
toxicity NN o
, , N
and CC N
the DT N
fact NN N
that IN N
concurrent JJ N
chemoradiotherapy NN N
now RB N
seems VBZ N
more RBR N
effective JJ N
than IN N
sequential JJ N
treatment NN N
. . N

CONCLUSION NNP N
After IN N
two CD N
cycles NNS N
of IN N
induction NN i
chemotherapy NN i
with IN N
carboplatin-paclitaxel NN i
, , i
HART NNP i
is VBZ N
feasible JJ N
with IN N
an DT N
acceptable JJ N
toxicity NN N
profile NN N
. . N

Although IN N
statistical JJ N
significance NN N
was VBD N
not RB N
achieved VBN N
and CC N
the DT N
study NN N
closed VBD N
early RB N
, , N
there EX N
was VBD N
a DT N
positive JJ N
statistical JJ N
trend NN N
suggesting VBG N
a DT N
survival JJ N
advantage NN N
with IN N
the DT N
HART NNP i
regimen NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
flumazenil NN i
on IN N
cerebral JJ o
blood NN o
flow NN o
and CC N
oxygen NN o
consumption NN o
after IN N
midazolam NN i
anaesthesia NN N
for IN N
craniotomy NN i
. . i

Cerebral JJ o
blood NN o
flow NN o
( ( o
CBF NNP o
) ) o
and CC N
cerebral JJ o
metabolic NN o
rate NN o
for IN o
oxygen NN o
( ( o
CMRO2 NNP o
) ) o
were VBD N
measured VBN N
by IN N
a DT N
modification NN N
of IN N
the DT N
Kety-Schmidt NNP N
technique NN N
using VBG N
i.v JJ N
. . N

xenon-133 NN N
in IN N
20 CD p
patients NNS p
undergoing JJ p
craniotomy NN p
for IN p
supratentorial JJ p
cerebral JJ p
tumours NNS p
. . p

Anaesthesia NNP N
was VBD N
induced VBN N
and CC N
maintained VBN N
with IN N
midazolam NN i
, , i
fentanyl NN i
and CC i
nitrous JJ i
oxide NN i
. . i

Pancuronium NN i
was VBD N
given VBN N
for IN N
neuromuscular JJ N
block NN N
. . N

The DT N
lungs NNS N
were VBD N
ventilated VBN N
to TO N
normocapnia VB N
. . N

The DT N
first JJ N
flow NN N
measurements NNS N
were VBD N
performed VBN N
approximately RB N
1 CD N
h NNS N
after IN N
induction NN N
of IN N
anaesthesia NN N
. . N

At IN N
the DT N
end NN N
of IN N
operation NN N
the DT N
patients NNS N
were VBD N
allocated VBN N
to TO N
two CD N
groups NNS N
. . N

Ten CD N
patients NNS N
were VBD N
given VBN N
flumazenil JJ i
0.01 CD N
mg JJ N
kg-1 NN N
and CC N
5 CD N
min NN N
later RB N
the DT N
second JJ N
flow NN N
measurement NN N
was VBD N
performed VBN N
. . N

In IN N
the DT N
other JJ N
10 CD N
patients NNS N
the DT N
second JJ N
flow NN N
measurement NN N
was VBD N
performed VBN N
before IN N
the DT N
administration NN N
of IN N
flumazenil NN i
. . i

Plasma NNP o
concentrations NNS o
of IN o
midazolam NN o
were VBD N
measured VBN N
at IN N
the DT N
time NN N
of IN N
each DT N
measurement NN N
of IN N
CBF NNP N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
plasma JJ o
concentration NN o
of IN o
midazolam NN o
, , o
CBF NNP o
or CC o
CMRO2 NNP o
. . o

Flumazenil NNP i
had VBD N
no DT o
effect NN o
on IN o
CBF NNP o
and CC N
CMRO2 NNP o
. . o

-DOCSTART- -X- O O

Deficiency NN o
of IN o
serum NN o
ionized JJ o
magnesium NN o
in IN N
patients NNS p
receiving VBG p
hemodialysis NN p
or CC p
peritoneal JJ p
dialysis NN p
. . p

Serum NNP N
total JJ N
magnesium NN N
( ( N
TMg NNP N
) ) N
measurements NNS N
in IN N
dialysis NN p
patients NNS p
are VBP N
variable JJ N
, , N
with IN N
some DT N
groups NNS N
reporting VBG N
hypermagnesemia NN N
and CC N
some DT N
hypomagnesemia NN N
. . N

It PRP N
had VBD N
not RB N
been VBN N
possible JJ N
to TO N
measure VB N
the DT N
biologically RB N
active JJ N
fraction NN N
, , N
ionized JJ N
magnesium NN N
( ( N
IMg2+ NNP N
) ) N
. . N

The DT N
authors NNS N
utilized VBD N
an DT N
ion-selective JJ N
electrode NN N
to TO N
measure VB N
IMg NNP o
in IN N
26 CD p
hemodialysis NN p
patients NNS p
and CC p
10 CD p
peritoneal JJ p
dialysis NN p
( ( p
CAPD NNP p
) ) p
patients NNS p
and CC p
compared VBN p
the DT p
results NNS p
with IN p
those DT p
from IN p
66 CD p
age NN p
matched VBD p
control NN p
subjects NNS p
. . p

Dialysate NNP i
magnesium NN i
was VBD N
0.375 CD N
mM/L NN N
for IN N
the DT N
hemodialysis NN N
and CC N
0.25 CD N
mM/L NN N
for IN N
the DT N
CAPD NNP N
patients NNS N
. . N

When WRB N
compared VBN N
with IN N
control NN N
subjects NNS N
, , N
both DT N
hemodialysis NN N
and CC N
CAPD NNP N
patients NNS N
had VBD N
significantly RB N
lower JJR N
IMg2+ NNP o
( ( N
0.55 CD N
+/- JJ N
0.02 CD N
and CC N
0.50 CD N
+/- JJ N
0.02 CD N
vs. FW N
0.60 CD N
+/- JJ N
0.004 CD N
mM/L NN N
; : N
p CC N
< VB N
0.05 CD N
) ) N
and CC N
greater JJR o
or CC o
normal JJ o
TMg NNP o
values NNS o
( ( N
0.99 CD N
+/- JJ N
0.04 CD N
, , N
different JJ N
at IN N
the DT N
p NN N
< VBZ N
0.001 CD N
level NN N
, , N
and CC N
0.85 CD N
+/- JJ N
0.04 CD N
vs. FW N
0.84 CD N
+/- JJ N
0.008 CD N
) ) N
. . N

Ionized VBN o
calcium NN o
( ( o
ICa2+ NNP o
) ) o
values NNS o
were VBD N
similar JJ N
for IN N
all DT N
three CD p
groups NNS p
( ( N
1.15 CD N
+/- JJ N
0.02 CD N
and CC N
1.21 CD N
+/- JJ N
0.04 CD N
vs. FW N
1.17 CD N
+/- JJ N
0.01 CD N
) ) N
, , N
resulting VBG N
in IN N
increased VBN N
mean NN N
ICa2+/IMg2+ NNP o
ratios NNS o
( ( N
2.14 CD N
+/- JJ N
0.07 CD N
and CC N
2.42 CD N
+/- JJ N
0.06 CD N
vs. FW N
1.95 CD N
+/- JJ N
0.02 CD N
for IN N
the DT N
control NN N
subjects VBZ N
; : N
p VB N
< $ N
0.05 CD N
) ) N
. . N

The DT N
percent NN N
of IN N
total JJ o
magnesium NN o
that WDT N
was VBD N
ionized VBN o
( ( o
% NN o
IMg2+ NNP o
) ) o
was VBD N
low JJ N
in IN N
both DT N
the DT N
hemodialysis NN N
and CC N
CAPD NNP N
patients NNS N
( ( N
55.6 CD N
+/- JJ N
0.93 CD N
and CC N
59.2 CD N
+/- JJ N
1.05 CD N
) ) N
compared VBN N
with IN N
that DT N
of IN N
control NN N
subjects NNS N
( ( N
72 CD N
+/- JJ N
0.61 CD N
; : N
p NN N
< VBZ N
0.05 CD N
) ) N
. . N

IMg2+ NNP N
values NNS N
correlated VBN N
with IN N
TMg NNP N
values NNS N
in IN N
both DT N
hemodialysis NN N
( ( N
r JJ N
= VBZ N
0.93 CD N
; : N
p NN N
< VBZ N
0.0001 CD N
) ) N
and CC N
CAPD NNP N
( ( N
r VB N
= RB N
0.92 CD N
; : N
p NN N
< VBZ N
0.0001 CD N
) ) N
patients NNS N
did VBD N
not RB N
correlate VB N
with IN N
age NN N
, , N
time NN N
on IN N
dialysis NN N
, , N
weight NN N
, , N
fasting VBG N
cholesterol NN N
or CC N
triglyceride NN N
, , N
albumin NN N
, , N
blood NN N
urea JJ N
nitrogen NN N
( ( N
BUN NNP N
) ) N
, , N
creatinine NN N
, , N
hematocrit NN N
, , N
phosphate NN N
, , N
or CC N
PTH NNP N
values NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Effect NN N
of IN N
systemic JJ N
nitric JJ i
oxide IN i
synthase JJ i
inhibition NN N
on IN N
postexercise NN p
hypotension NN p
in IN p
humans NNS p
. . p

An DT N
acute JJ N
bout NN N
of IN N
aerobic JJ N
exercise NN N
results NNS N
in IN N
a DT N
reduced JJ N
blood NN o
pressure NN o
that WDT N
lasts VBZ N
several JJ N
hours NNS N
. . N

Animal NNP N
studies NNS N
suggest VBP N
this DT N
response NN N
is VBZ N
mediated VBN N
by IN N
increased JJ N
production NN N
of IN N
nitric JJ N
oxide NN N
. . N

We PRP N
tested VBD N
the DT N
extent NN N
to TO N
which WDT N
systemic JJ N
nitric JJ N
oxide IN N
synthase JJ N
inhibition NN N
[ NNP N
N NNP N
( ( N
G NNP N
) ) N
-monomethyl-L-arginine NN N
( ( N
L-NMMA NNP N
) ) N
] NN N
can MD N
reverse VB N
the DT N
drop NN N
in IN N
blood NN o
pressure NN o
that WDT p
occurs VBZ p
after IN p
exercise NN p
in IN p
humans NNS p
. . p

Eight NNP p
healthy JJ p
subjects NNS p
underwent JJ N
parallel JJ N
experiments NNS N
on IN N
2 CD N
separate JJ N
days NNS N
. . N

The DT N
order NN N
of IN N
the DT N
experiments NNS N
was VBD N
randomized VBN N
between IN N
sham NN N
( ( i
60 CD i
min NN i
of IN i
seated JJ i
upright JJ i
rest NN i
) ) i
and CC N
exercise NN N
( ( i
60 CD i
min NN i
of IN i
upright JJ i
cycling NN i
at IN i
60 CD i
% NN i
peak NN i
aerobic JJ i
capacity NN i
) ) i
. . N

After IN N
both DT N
sham NN N
and CC N
exercise NN N
, , N
subjects VBZ N
received VBN N
, , N
in IN N
sequence NN N
, , N
systemic JJ N
alpha-adrenergic JJ N
blockade NN N
( ( N
phentolamine NN N
) ) N
and CC N
L-NMMA NNP N
. . N

Phentolamine NNP N
was VBD N
given VBN N
first RB N
to TO N
isolate VB N
the DT N
contribution NN N
of IN N
nitric JJ N
oxide NN N
to TO N
postexercise VB N
hypotension NN N
by IN N
preventing VBG N
reflex JJ N
changes NNS N
in IN N
sympathetic JJ N
tone NN N
that WDT N
result NN N
from IN N
systemic JJ N
nitric JJ N
oxide IN N
synthase JJ N
inhibition NN N
and CC N
to TO N
control VB N
for IN N
alterations NNS N
in IN N
resting VBG N
sympathetic JJ N
activity NN N
after IN N
exercise NN N
. . N

During IN N
each DT N
condition NN N
, , N
systemic JJ o
and CC o
regional JJ o
hemodynamics NNS o
were VBD N
measured VBN N
. . N

Throughout IN N
the DT N
study NN N
, , N
arterial JJ o
pressure NN o
and CC o
vascular JJ o
resistances NNS o
remained VBD N
lower JJR N
postexercise NN N
vs. FW N
postsham NN N
despite IN N
nitric JJ o
oxide JJ o
synthase NN o
inhibition NN N
( ( N
e.g. JJ N
, , N
mean JJ o
arterial JJ o
pressure NN o
after IN o
L-NMMA NNP o
was VBD N
108.0+/-2.4 JJ N
mmHg NN N
postsham NN N
vs. FW N
102.1+/-3.3 JJ N
mmHg NN N
postexercise NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Thus VB N
it PRP N
does VBZ N
not RB N
appear VB N
that IN N
postexercise NN o
hypotension NN o
is VBZ N
dependent JJ N
on IN N
increased JJ N
production NN o
of IN o
nitric JJ o
oxide NN o
in IN N
humans NNS p
. . p

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
education NN N
for IN N
gastric JJ p
cancer NN p
patients NNS p
: : p
a DT N
controlled JJ N
prospective JJ N
trial NN N
comparing VBG N
interactive JJ i
vs. FW i
lecture-based JJ i
programs NNS i
. . i

OBJECTIVE CC N
Although IN N
patient JJ i
education NN i
may MD N
enhance VB N
knowledge NN N
, , N
coping VBG N
with IN N
illness NN N
, , N
and CC N
quality NN N
of IN N
life NN N
among IN N
cancer NN p
patients NNS p
, , N
it PRP N
is VBZ N
uncertain JJ N
which WDT N
didactic JJ N
method NN N
is VBZ N
most RBS N
effective JJ N
. . N

We PRP N
compared VBN N
the DT N
impact NN N
of IN N
an DT N
interactive JJ i
, , i
patient-oriented JJ i
group NN i
program NN i
to TO i
a DT i
lecture-based JJ i
, , i
information-only JJ i
program NN i
in IN N
gastric JJ p
cancer NN p
patients NNS p
. . p

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
controlled JJ N
trial NN N
, , N
121 CD p
gastric JJ p
cancer NN p
patients NNS p
attending VBG p
inpatient JJ p
rehabilitation NN p
after IN p
surgical JJ p
treatment NN p
received VBD N
either CC N
the DT N
interactive JJ i
intervention NN i
or CC i
lectures VBZ i
providing VBG i
information NN i
. . i

The DT N
outcomes NNS N
were VBD N
patients NNS o
' POS o
disease-related JJ o
knowledge NN o
, , o
active JJ o
coping VBG o
with IN o
illness NN o
, , o
and CC o
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
at IN N
the DT N
end NN N
of IN N
their PRP$ N
stay NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
thereafter RB N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
improved VBD o
their PRP$ o
knowledge NN o
and CC o
QoL NNP o
during IN o
rehabilitation NN o
; : o
however RB N
, , N
knowledge NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
interactive JJ N
group NN N
compared VBN N
to TO N
the DT N
lecture NN N
group NN N
. . N

This DT N
difference NN N
was VBD N
maintained VBN N
at IN N
the DT N
6- JJ N
and CC N
12-months JJ N
follow-ups NNS N
. . N

In IN N
addition NN N
, , N
the DT N
interactive JJ N
group NN N
proved VBD N
superior JJ N
to TO N
the DT N
lecture NN N
group NN N
regarding VBG N
active JJ o
coping NN o
with IN o
illness NN o
and CC N
QoL NNP o
at IN N
the DT N
end NN N
of IN N
rehabilitation NN N
, , N
but CC N
not RB N
during IN N
follow-up JJ N
. . N

CONCLUSIONS VB N
A DT N
structured JJ N
, , N
interactive JJ N
patient JJ N
education NN N
program NN N
proved VBD N
superior JJ N
to TO N
lecture-based JJ N
provision NN N
of IN N
information NN N
in IN N
regards NNS N
to TO N
short-term JJ N
and CC N
long-term JJ N
knowledge NN N
as RB N
well RB N
as IN N
short-term JJ N
coping NN N
and CC N
QoL NNP N
. . N

PRACTICE NNP N
IMPLICATIONS NNP N
In IN N
gastric JJ N
cancer NN N
patients NNS N
, , N
interactive JJ i
patient NN i
education NN i
seems VBZ N
preferable JJ N
over IN N
lectures NNS N
. . N

-DOCSTART- -X- O O

The DT N
role NN N
of IN N
treatment NN i
fidelity NN i
on IN N
outcomes NNS N
during IN N
a DT N
randomized JJ N
field NN N
trial NN N
of IN N
an DT N
autism NN p
intervention NN N
. . N

This DT N
randomized JJ N
field NN N
trial NN N
comparing VBG N
Strategies NNS N
for IN N
Teaching VBG i
based VBN N
on IN N
Autism NNP N
Research NNP N
and CC N
Structured NNP N
Teaching NNP N
enrolled VBD N
educators NNS N
in IN N
33 CD p
kindergarten-through-second-grade JJ p
autism NN p
support NN p
classrooms NNS p
and CC p
119 CD p
students NNS p
, , p
aged VBN p
5-8 CD p
years NNS p
in IN p
the DT p
School NNP p
District NNP p
of IN p
Philadelphia NNP p
. . p

Students NNS p
were VBD N
assessed VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
academic JJ N
year NN N
using VBG N
the DT N
Differential NNP N
Ability NNP N
Scales NNP N
. . N

Program NNP o
fidelity NN o
was VBD N
measured VBN N
through IN N
video NN i
coding NN i
and CC N
use NN N
of IN N
a DT N
checklist NN N
. . N

Outcomes CC N
were VBD N
assessed VBN N
using VBG N
linear JJ N
regression NN N
with IN N
random JJ N
effects NNS N
for IN N
classroom NN N
and CC N
student NN p
. . p

Average JJ o
fidelity NN o
was VBD N
57 CD N
% NN N
in IN N
Strategies NNP N
for IN N
Teaching NNP N
based VBN N
on IN N
Autism NNP N
Research NNP N
classrooms NNS N
and CC N
48 CD N
% NN N
in IN N
Structured NNP N
Teaching NNP N
classrooms NNS N
. . N

There EX N
was VBD N
a DT N
9.2-point JJ N
( ( N
standard JJ N
deviation NN N
= NNP N
9.6 CD N
) ) N
increase NN N
in IN N
Differential NNP o
Ability NNP o
Scales NNP o
score RB o
over IN N
the DT N
8-month JJ N
study NN N
period NN N
, , N
but CC N
no DT N
main JJ N
effect NN N
of IN N
program NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
interaction NN o
between IN o
fidelity NN o
and CC o
group NN o
. . o

In IN N
classrooms NNS N
with IN N
either DT N
low JJ N
or CC N
high JJ N
program NN N
fidelity NN N
, , N
students NNS p
in IN p
Strategies NNP p
for IN p
Teaching NNP p
based VBN p
on IN p
Autism NNP p
Research NNP p
experienced VBD N
a DT N
greater JJR N
gain NN N
in IN N
Differential NNP o
Ability NNP o
Scales NNP o
score RB o
than IN N
students NNS p
in IN p
Structured NNP p
Teaching NNP p
( ( N
11.2 CD N
vs. RB N
5.5 CD N
points NNS N
and CC N
11.3 CD N
vs. FW N
8.9 CD N
points NNS N
, , N
respectively RB N
) ) N
. . N

In IN N
classrooms NNS N
with IN N
moderate JJ N
fidelity NN o
, , o
students NNS o
in IN o
Structured NNP o
Teaching NNP o
experienced VBD o
a DT N
greater JJR N
gain NN N
than IN N
students NNS p
in IN p
Strategies NNP o
for IN o
Teaching NNP o
based VBN o
on IN o
Autism NNP o
Research NNP o
( ( N
10.1 CD N
vs. RB N
4.4 CD N
points NNS N
) ) N
. . N

The DT N
results NNS N
suggest VBP N
significant JJ N
variability NN N
in IN N
implementation NN N
of IN N
evidence-based JJ N
practices NNS N
, , N
even RB N
with IN N
supports NNS N
, , N
and CC N
also RB N
suggest VBP N
the DT N
need NN N
to TO N
address VB N
challenging VBG N
issues NNS N
related VBN N
to TO N
implementation VB N
measurement NN N
in IN N
community NN N
settings NNS N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
EORTC NNP N
target NN N
definition NN N
guidelines NNS N
for IN N
dose-intensified JJ N
salvage NN N
radiation NN N
therapy NN N
for IN N
recurrent JJ N
prostate NN N
cancer NN N
: : N
results NNS N
of IN N
the DT N
quality NN N
assurance NN N
program NN N
of IN N
the DT N
randomized JJ N
trial NN N
SAKK NNP N
09/10 CD N
. . N

PURPOSE NNP N
Different NNP N
international JJ N
target NN N
volume NN N
delineation NN N
guidelines NNS N
exist VBP N
and CC N
different JJ N
treatment NN N
techniques NNS N
are VBP N
available JJ N
for IN N
salvage NN N
radiation NN N
therapy NN N
( ( N
RT NNP N
) ) N
for IN N
recurrent NN N
prostate NN N
cancer NN N
, , N
but CC N
less JJR N
is VBZ N
known VBN N
regarding VBG N
their PRP$ N
respective JJ N
applicability NN N
in IN N
clinical JJ N
practice NN N
. . N

METHODS NNP N
AND NNP N
MATERIALS NNP N
A NNP N
randomized JJ N
phase NN N
III NNP N
trial NN N
testing VBG N
64 CD i
Gy NNP i
vs NN i
70 CD i
Gy NNP i
salvage NN i
RT NNP i
was VBD N
accompanied VBN N
by IN N
an DT N
intense JJ i
quality NN i
assurance NN i
program NN i
including VBG N
a DT N
site-specific JJ N
and CC N
study-specific JJ N
questionnaire NN N
and CC N
a DT N
dummy JJ i
run NN i
( ( i
DR NNP i
) ) i
. . i

Target NN N
volume NN N
delineation NN N
was VBD N
performed VBN N
according VBG N
to TO N
the DT N
European JJ N
Organisation NN N
for IN N
the DT N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
guidelines NNS N
, , N
and CC N
a DT N
DR-based JJ N
treatment NN N
plan NN N
was VBD N
established VBN N
for IN N
70 CD N
Gy NNP N
. . N

Major NNP N
and CC N
minor JJ N
protocol NN N
deviations NNS N
were VBD N
noted VBN N
, , N
interobserver JJ N
agreement NN N
of IN N
delineated JJ N
target NN N
contours NN N
was VBD N
assessed VBN N
, , N
and CC N
dose-volume JJ N
histogram NN N
( ( N
DVH NNP N
) ) N
parameters NNS N
of IN N
different JJ N
treatment NN N
techniques NNS N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Thirty NNP p
European JJ p
centers NNS p
participated VBD p
, , p
43 CD p
% NN p
of IN p
which WDT p
were VBD p
using VBG p
3-dimensional JJ i
conformal JJ i
RT NNP i
( ( i
3D-CRT JJ i
) ) i
, , p
with IN p
the DT p
remaining VBG p
centers NNS p
using VBG p
intensity NN i
modulated VBN i
RT NNP i
( ( i
IMRT NNP i
) ) i
or CC p
volumetric JJ i
modulated VBN i
arc NN i
technique NN i
( ( i
VMAT NNP i
) ) i
. . i

The DT N
first JJ N
submitted VBN N
version NN N
of IN N
the DT N
DR NNP N
contained VBD N
major JJ N
deviations NNS N
in IN N
21 CD N
of IN N
30 CD N
( ( N
70 CD N
% NN N
) ) N
centers NNS N
, , N
mostly RB N
caused VBN N
by IN N
inappropriately RB N
defined VBN N
or CC N
lack NN N
of IN N
prostate NN N
bed NN N
( ( N
PB NNP N
) ) N
. . N

All DT N
but CC N
5 CD p
centers NNS p
completed VBD p
the DT p
DR NNP p
successfully RB p
with IN N
their PRP$ N
second JJ N
submitted VBN N
version NN N
. . N

The DT N
interobserver JJ N
agreement NN N
of IN N
the DT N
PB NNP N
was VBD N
moderate JJ N
and CC N
was VBD N
improved VBN N
by IN N
the DT N
DR NNP N
review NN N
, , N
as IN N
indicated VBN N
by IN N
an DT N
increased VBN N
? . o
value NN o
( ( N
0.59 CD N
vs RB N
0.55 CD N
) ) N
, , N
mean JJ o
sensitivity NN o
( ( N
0.64 CD N
vs RB N
0.58 CD N
) ) N
, , N
volume NN o
of IN o
total JJ o
agreement NN o
( ( N
3.9 CD N
vs RB N
3.3 CD N
cm NN N
( ( N
3 CD N
) ) N
) ) N
, , N
and CC N
decrease NN N
in IN N
the DT o
union NN o
volume NN o
( ( N
79.3 CD N
vs RB N
84.2 CD N
cm NN N
( ( N
3 CD N
) ) N
) ) N
. . N

Rectal JJ o
and CC o
bladder VB o
wall NN o
DVH NNP o
parameters NNS o
of IN o
IMRT NNP o
and CC o
VMAT NNP o
vs VBP o
3D-CRT JJ o
plans NNS o
were VBD N
not RB N
significantly RB N
different JJ N
. . N

CONCLUSIONS VB N
The DT N
interobserver JJ N
agreement NN N
of IN N
PB NNP N
delineation NN N
was VBD N
moderate JJ N
but CC N
was VBD N
improved VBN N
by IN N
the DT N
DR. NNP N
Major NNP N
deviations NNS N
could MD N
be VB N
identified VBN N
for IN N
the DT N
majority NN N
of IN N
centers NNS N
. . N

The DT N
DR NNP N
has VBZ N
improved VBN N
the DT N
acquaintance NN N
of IN N
the DT N
participating VBG N
centers NNS N
with IN N
the DT N
trial NN N
protocol NN N
. . N

-DOCSTART- -X- O O

Relationship NN N
between IN N
subjective JJ N
effects NNS N
and CC N
drug NN p
preferences NNS p
: : p
ethanol NN i
and CC N
diazepam NN i
. . i

The DT N
relationship NN N
between IN N
subjective JJ N
effects NNS N
and CC N
drug NN N
preferences NNS N
in IN N
normal JJ p
volunteers NNS p
was VBD N
explored VBN N
in IN N
a DT N
meta-analysis NN N
of IN N
several JJ N
previously RB N
published VBN N
studies NNS N
. . N

Subjective JJ N
effects NNS N
of IN N
, , N
and CC N
preference NN N
for IN N
, , N
ethanol NN i
and CC i
diazepam NN i
vs. FW i
placebo NN i
were VBD N
measured VBN N
using VBG N
a DT N
choice NN N
procedure NN N
. . N

Subjects NNS N
were VBD N
grouped VBN N
according VBG N
to TO N
their PRP$ N
drug NN N
choices NNS N
: : N
'non-choosers NNS p
' POS p
never RB p
chose JJ p
drug NN p
, , p
whereas IN p
'choosers NNS p
' POS p
always RB p
chose JJ p
drug NN p
. . p

The DT N
two CD N
groups NNS N
were VBD N
compared VBN N
on IN N
their PRP$ N
subjective JJ N
responses NNS N
to TO N
drug NN N
and CC N
on IN N
demographic JJ N
variables NNS N
. . N

Ethanol NNP i
decreased VBD o
Arousal NNP o
, , o
Elation NNP o
, , o
Positive NNP o
Mood NNP o
and CC o
Vigor NNP o
, , N
and CC N
increased VBD o
Anxiety NNP o
, , o
Depression NNP o
and CC o
Fatigue NNP o
in IN N
the DT N
non-choosers NNS N
, , N
whereas IN N
it PRP N
increased VBD o
Arousal NNP o
and CC o
Vigor NNP o
in IN N
the DT N
choosers NNS N
. . N

Ethanol JJ i
choosers NNS N
were VBD N
also RB N
more RBR N
likely JJ o
to TO o
be VB o
males NNS o
and/or IN o
full-time JJ o
students NNS o
than IN N
non-choosers NNS N
. . N

Diazepam NNP i
produced VBD N
sedative-like JJ o
effects NNS o
in IN N
both DT N
choosers NNS N
and CC N
non-choosers NNS N
, , N
but CC N
markedly RB N
decreased VBD o
Anxiety NNP o
and CC o
increased VBD o
Friendliness NNP o
in IN N
choosers NNS N
only RB N
. . N

Diazepam NNP i
choice NN N
was VBD N
also RB N
associated VBN N
with IN N
more RBR o
frequent JJ o
recreational JJ o
use NN o
of IN o
marijuana NN o
and CC o
stimulants NNS o
. . o

Thus RB N
, , N
both DT N
demographic JJ o
variables NNS o
and CC o
subjective JJ o
drug NN o
effects NNS o
were VBD N
related VBN N
to TO N
drug NN N
preference NN N
. . N

-DOCSTART- -X- O O

Two CD N
large JJ N
preoperative JJ N
doses NNS N
of IN N
erythropoietin NN i
do VBP N
not RB N
reduce VB N
the DT N
systemic JJ p
inflammatory NN p
response NN p
to TO p
cardiac VB p
surgery NN p
. . p

OBJECTIVES NNP N
Cardiac NNP N
surgery NN N
and CC N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
induce VBP N
an DT N
inflammatory JJ N
reaction NN N
that WDT N
may MD N
lead VB N
to TO N
tissue VB N
injury NN N
. . N

Experimental JJ N
studies NNS N
suggest VBP N
that IN N
recombinant JJ i
human JJ i
erythropoietin NN i
( ( i
EPO NNP i
) ) i
independent JJ N
of IN N
its PRP$ N
erythropoietic JJ N
effect NN N
may MD N
be VB N
used VBN N
clinically RB N
as IN N
an DT N
anti-inflammatory JJ N
drug NN N
. . N

This DT N
study NN N
tested VBD N
the DT N
hypothesis NN N
that IN N
2 CD N
large JJ N
doses NNS N
of IN N
EPO NNP i
administered VBD N
shortly RB N
before IN N
CPB NNP N
ameliorate VBP N
the DT N
systemic JJ N
inflammatory NN N
response NN N
to TO N
CPB NNP N
. . N

DESIGN NNP N
AND NNP N
SETTING NNP N
A NNP N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
and CC N
randomized JJ N
study NN N
at IN N
a DT N
single JJ N
tertiary NN N
care NN N
hospital NN N
. . N

PARTICIPANTS CC N
Patients NNS p
scheduled VBN p
for IN p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
with IN p
CPB NNP p
. . p

INTERVENTIONS NNP N
EPO NNP i
( ( i
epoetin JJ i
alfa NN i
, , N
500 CD N
IU/kg NNP N
intravenously RB N
, , N
n JJ p
= NNP p
22 CD p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= NNP p
21 CD p
) ) p
was VBD N
administered VBN N
12 CD N
to TO N
18 CD N
hours NNS N
preoperatively RB N
and CC N
again RB N
at IN N
the DT N
induction NN N
of IN N
anesthesia NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
CPB NNP N
in IN N
both DT N
groups NNS N
greatly RB N
increased VBD N
plasma JJ o
concentrations NNS o
of IN o
tumor NN o
necrosis NN o
factor NN o
alpha NN o
( ( o
TNF-alpha NNP o
) ) o
, , o
interleukin FW o
( ( o
IL NNP o
) ) o
-1beta NN o
, , o
IL-1beta NNP o
receptor NN o
antagonist NN o
, , o
IL-6 NNP o
, , o
IL-10 NNP o
, , o
and CC o
N-terminal JJ o
probrain NN o
natriuretic JJ o
peptide NN o
( ( o
NT-proBNP NNP o
) ) o
. . o

Compared VBN N
with IN N
placebo NN i
, , i
EPO NNP i
at IN N
day NN N
3 CD N
after IN N
CPB NNP N
augmented VBD N
the DT N
TNF-alpha JJ o
response NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
2 CD N
hours NNS N
after IN N
CPB NNP N
increased VBD N
NT-proBNP NNP o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Also RB N
, , N
EPO NNP i
tended VBD N
to TO N
enhance VB N
the DT N
CPB-induced JJ N
increase NN N
in IN N
IL-1beta NNP o
receptor NN o
antagonist NN o
( ( N
p JJ N
= NNP N
0.057 CD N
) ) N
. . N

Otherwise UH N
, , N
EPO NNP i
had VBD N
no DT N
effect NN N
on IN N
pro- NN o
and CC o
antiinflammatory NN o
mediators NNS o
compared VBN N
with IN N
placebo NN N
. . N

CONCLUSIONS NNP N
Two CD N
large JJ N
doses NNS N
of IN N
EPO NNP i
given VBN N
shortly RB N
before IN N
CPB NNP N
do VBP N
not RB N
reduce VB N
perioperative JJ o
release NN o
of IN o
inflammatory JJ o
cytokines NNS o
. . o

In IN N
contrast NN N
, , N
EPO NNP i
may MD N
augment VB N
the DT N
TNF-alpha NNP N
and CC N
NT-proBNP NNP N
response NN N
. . N

Although IN N
the DT N
long-term JJ N
clinical JJ N
impact NN N
remains VBZ N
unknown JJ N
, , N
the DT N
findings NNS N
do VBP N
not RB N
support VB N
use NN N
of IN N
EPO NNP i
as IN N
an DT N
anti-inflammatory JJ N
drug NN N
in IN N
patients NNS p
undergoing JJ p
cardiac JJ p
surgery NN p
. . p

-DOCSTART- -X- O O

Assessment NN N
of IN N
global JJ o
functioning NN o
in IN N
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
utility NN N
of IN N
the DT N
Developmental NNP o
Disability-Child NNP o
Global NNP o
Assessment NNP o
Scale NNP o
. . o

Assessment NN N
of IN N
global JJ o
functioning NN o
is VBZ N
an DT N
important JJ N
consideration NN N
in IN N
treatment NN N
outcome NN N
research NN N
; : N
yet RB N
, , N
there EX N
is VBZ N
little JJ N
guidance NN N
on IN N
its PRP$ N
evidence-based JJ N
assessment NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
utility NN N
and CC N
validity NN N
of IN N
clinician-rated JJ N
global JJ o
functioning NN o
using VBG N
the DT N
Developmental NNP o
Disability-Child NNP o
Global NNP o
Assessment NNP o
Scale NNP o
in IN N
a DT N
sample NN p
of IN p
higher JJR p
functioning NN p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
comorbid NN p
anxiety NN p
disorders NNS p
enrolled VBD p
in IN p
a DT p
randomized NN p
controlled VBN i
trial NN p
( ( p
n JJ p
= NNP p
30 CD p
) ) p
. . p

Pretreatment JJ N
Developmental JJ o
Disability-Child JJ o
Global NNP o
Assessment NNP o
Scale NNP o
scores NNS N
correlated VBD N
with IN N
severity NN N
of IN N
autism NN N
spectrum NN N
disorders NNS N
core VBP N
symptoms NNS N
( ( N
r VB N
= NNP N
-.388 NNP N
, , N
p NN N
= NNP N
.034 NNP N
) ) N
, , N
pragmatic JJ N
communication NN N
( ( N
r JJ N
= NNP N
.407 NNP N
, , N
p NN N
= NNP N
.032 NNP N
) ) N
, , N
and CC N
verbal JJ N
ability NN N
( ( N
r JJ N
= NNP N
.449 NNP N
, , N
p NN N
= NNP N
.013 NNP N
) ) N
and CC N
did VBD N
not RB N
correlate VB N
with IN N
severity NN N
of IN N
anxiety NN o
symptoms NNS o
or CC N
with IN N
parent-reported JJ N
adaptive JJ N
behavior NN N
. . N

Change NN o
in IN o
Developmental NNP o
Disability-Child NNP o
Global NNP o
Assessment NNP o
Scale NNP o
scores VBZ o
during IN N
treatment NN N
was VBD N
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
symptomatic JJ o
improvement NN o
( ( N
r JJ N
= NNP N
.414 NNP N
, , N
p NN N
= NNP N
.040 NNP N
) ) N
and CC N
with IN N
improved JJ N
general JJ o
communication NN o
( ( N
r JJ N
= NNP N
.499 NNP N
, , N
p NN N
= NNP N
.013 NNP N
) ) N
. . N

Results JJ N
support NN N
the DT N
importance NN N
of IN N
assessing VBG N
global JJ o
functioning NN o
in IN N
addition NN N
to TO N
symptom VB o
change NN o
and CC N
treatment NN o
response NN o
in IN N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O

Iontophoretic JJ i
administration NN N
of IN N
dexamethasone NN i
sodium NN i
phosphate NN i
for IN N
acute JJ p
epicondylitis NN p
. . p

A DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

BACKGROUND NNP N
A NNP N
better RBR N
treatment NN N
modality NN N
is VBZ N
needed VBN N
to TO N
control VB N
the DT N
pain NN o
of IN p
medial NN o
or CC o
lateral JJ o
epicondylitis NN o
( ( o
tennis IN o
elbow NN o
) ) o
. . o

HYPOTHESIS NNP N
Dermal NNP N
iontophoretic JJ i
administration NN N
of IN N
dexamethasone NN i
sodium NN N
phosphate NN N
will MD N
be VB N
significantly RB N
more RBR N
effective JJ N
in IN N
controlling VBG N
pain NN o
than IN N
a DT N
placebo NN N
in IN N
patients NNS p
with IN p
medial JJ p
or CC p
lateral JJ p
elbow NN p
epicondylitis NN p
. . p

STUDY NNP N
DESIGN NNP N
Randomized NNP N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

METHODS NNP N
On IN N
six CD N
occasions NNS N
, , N
1 CD N
to TO N
3 CD N
days NNS N
apart RB N
within IN N
15 CD N
days NNS N
, , N
199 CD p
patients NNS p
with IN p
elbow JJ p
epicondylitis NN p
received VBD N
40 CD N
mA-minutes NNS N
of IN N
either DT N
active JJ N
or CC N
placebo JJ i
treatment NN N
. . N

RESULTS NNP N
Dexamethasone NNP i
produced VBD N
a DT N
significant JJ N
23-mm JJ N
improvement NN N
on IN N
the DT N
100-mm JJ o
patient NN o
visual JJ o
analog NN o
scale NN o
ratings NNS o
, , N
compared VBN N
with IN N
14 CD N
mm NNS N
for IN N
placebo NN i
at IN N
2 CD N
days NNS N
and CC N
24 CD N
mm NNS N
compared VBN N
with IN N
19 CD N
mm NNS N
at IN N
1 CD N
month NN N
. . N

More JJR N
patients NNS N
treated VBN N
with IN N
dexamethasone NN i
than IN N
those DT N
treated VBN N
with IN N
placebo NN i
scored VBN N
moderate JJ N
or CC N
better JJR N
on IN N
the DT N
investigator NN o
's POS o
global JJ o
improvement NN o
scale NN o
( ( N
52 CD N
% NN N
versus IN N
33 CD N
% NN N
) ) N
at IN N
2 CD N
days NNS N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
at IN N
1 CD N
month NN N
( ( N
54 CD N
% NN N
versus IN N
49 CD N
% NN N
) ) N
. . N

Investigator-rated JJ o
pain NN o
and CC o
tenderness NN o
scores NNS o
favored VBD N
dexamethasone NN N
over IN N
placebo NN N
at IN N
2 CD N
days NNS N
. . N

Patients NNS N
completing VBG N
six CD N
treatments NNS N
in IN N
10 CD N
days NNS N
or CC N
less JJR N
had VBD N
better RBR N
results NNS N
than IN N
those DT N
treated VBN N
over IN N
a DT N
longer JJR N
period NN N
. . N

CONCLUSIONS NNP N
Iontophoresis NNP i
treatment NN N
was VBD N
well RB N
tolerated VBN o
by IN N
most JJS N
patients NNS N
and CC N
was VBD N
effective JJ N
in IN N
reducing VBG N
symptoms NNS o
of IN o
epicondylitis NN o
at IN N
short-term JJ N
follow-up NN N
. . N

-DOCSTART- -X- O O

One CD i
quadrant JJ i
sub-Tenon NN i
's POS i
capsule NN i
anesthesia NN i
in IN N
anterior JJ p
segment NN p
surgery NN p
. . p

Reports NNS N
of IN N
complications NNS N
associated VBN N
with IN N
local JJ p
anesthesia NN p
in IN p
ophthalmic JJ p
surgery NN p
have VBP N
increased VBN N
conspicuously RB N
in IN N
recent JJ N
years NNS N
. . N

Sub-Tenon NNP i
's POS i
capsule NN i
anesthesia NN i
for IN N
anterior JJ N
segment NN N
surgery NN N
avoids IN N
the DT N
risks NNS N
of IN N
retrobulbar NN i
and CC N
peribulbar NN N
injections NNS N
. . N

This DT N
study NN N
compared VBN N
sub-Tenon NN i
's POS i
and CC N
retrobulbar NN i
anesthesia NN i
. . i

Patients NNS p
undergoing VBG p
various JJ p
anterior JJ p
segment NN p
surgery NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
sub-Tenon NN i
's POS i
or CC i
retrobulbar NN i
anesthesia NN i
; : i
300 CD p
were VBD p
operated VBN p
with IN p
1-quadrant JJ i
sub-Tenon NN i
's POS i
anesthesia NN i
( ( i
1-QST JJ i
) ) i
and CC p
the DT p
results NNS p
were VBD p
compared VBN p
with IN p
270 CD p
patients NNS p
operated VBN p
with IN p
retrobulbar NN i
anesthesia NN i
. . i

Retrobulbar NNP i
anesthesia NN i
consisted VBD N
of IN N
a DT N
2.5 CD N
ml NN N
injection NN N
of IN N
a DT N
1:1 CD N
mixture NN N
of IN N
2 CD N
% NN N
lidocaine NN i
without IN i
epinephrine NN i
and CC i
0.5 CD i
% NN i
bupivacaine NN i
. . i

Sub-Tenon NNP i
's POS i
anesthesia NN i
involved VBN N
direct JJ N
transconjunctival JJ N
infiltration NN N
of IN N
the DT N
same JJ N
local JJ N
anesthetic JJ N
directly RB N
into IN N
the DT N
sub-Tenon NN N
's POS N
space NN N
, , N
in IN N
the DT N
inferior-nasal JJ N
quadrant NN N
, , N
using VBG N
a DT N
blunt NN N
23-gauge JJ N
cannula NN N
. . N

Patients NNS p
undergoing VBG p
various JJ p
anterior JJ p
segment NN p
surgery NN p
procedures NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
1-QST CD i
or CC N
retrobulbar VB i
anesthesia NN i
; : i
300 CD N
patients NNS N
were VBD N
operated VBN N
with IN N
1-QST JJ N
and CC N
the DT N
results NNS N
were VBD N
compared VBN N
with IN N
270 CD N
patients NNS N
operated VBN N
with IN N
retrobulbar NN N
anesthesia NN N
. . N

Preinjection NN o
mean NN o
( ( o
+/- JJ o
SD NNP o
) ) o
IOP NNP o
wer $ N
12.9 CD N
+/- JJ N
3.7 CD N
mmHg NN N
in IN N
the DT N
retrobulbar NN i
and CC N
13.4 CD N
+/- JJ N
3.2 CD N
mmHg NN N
in IN N
the DT N
1-QST JJ i
patients NNS N
. . N

Preoperative JJ o
intraocular JJ o
pressures NNS o
were VBD N
8.7 CD N
+/- JJ N
3.0 CD N
mmHg NN N
in IN N
the DT N
retrobulbar NN i
and CC N
9.2 CD N
+/- JJ N
3.2 CD N
mmHg NN N
in IN N
1-QST JJ i
patients NNS N
. . N

Pre- NNP o
and CC o
postinjection NN o
IOP NNP o
for IN N
retrobulbar NN i
and CC N
1-QST JJ i
patients NNS N
were VBD N
similar JJ N
. . N

Pain NN o
scores NNS o
for IN o
delivery NN o
of IN o
the DT o
anesthetic JJ o
, , N
using VBG N
a DT N
numerical JJ o
rating NN o
scale NN o
, , N
produced VBD N
a DT N
median JJ N
score NN N
of IN N
1 CD N
for IN N
1-QST JJ N
and CC N
2 CD N
for IN N
the DT N
retrobulbar NN i
technique NN N
. . N

For IN N
the DT N
subsequent JJ N
operative JJ N
procedure NN N
, , N
the DT N
median JJ N
score NN N
was VBD N
1 CD N
for IN N
1-QST JJ i
and CC N
2 CD N
for IN N
the DT N
retrobulbar NN N
patients NNS N
. . N

Complete JJ o
akinesia NN o
was VBD N
achieved VBN N
in IN N
41 CD N
% NN N
with IN N
1-QST JJ i
and CC N
in IN N
69 CD N
% NN N
of IN N
retrobulbar NN N
patients NNS N
. . N

1-QST JJ i
patients NNS N
with IN N
incomplete JJ o
akinesia NN o
most RBS N
often RB N
had VBD N
lateral JJ o
muscle NN o
function NN o
which WDT N
did VBD N
not RB N
interfere VB N
with IN N
the DT N
operation NN N
. . N

We PRP N
found VBD N
the DT N
use NN N
of IN N
a DT N
blunt NN N
cannula NN N
to TO N
deliver VB N
anesthetic JJ N
into IN N
the DT N
sub-Tenon NN N
's POS N
space NN N
as IN N
a DT N
simple NN N
, , N
safe JJ N
and CC N
effective JJ N
alternative JJ N
approach NN N
to TO N
traditional JJ N
retrobulbar NN i
anesthesia NN i
in IN N
anterior JJ N
segment NN N
surgery NN N
. . N

-DOCSTART- -X- O O

Myocardial JJ N
extracellular JJ N
volume NN N
by IN N
cardiac JJ N
magnetic JJ N
resonance NN N
imaging NN N
in IN N
patients NNS p
treated VBN p
with IN p
anthracycline-based JJ p
chemotherapy NN p
. . p

We PRP N
aimed VBD N
to TO N
determine VB N
whether IN N
the DT N
myocardial JJ o
extracellular JJ o
volume NN o
( ( o
ECV NNP o
) ) o
, , N
measured VBN N
using VBG N
T1 NNP o
measurements NNS o
obtained VBD N
during IN N
cardiac JJ N
magnetic JJ N
resonance NN N
imaging NN N
were VBD N
increased VBN N
in IN N
patients NNS i
treated VBN i
with IN i
anthracyclines NNS i
. . i

We PRP N
performed VBD N
cardiac JJ i
magnetic JJ i
resonance NN i
imaging NN i
and CC i
echocardiography NN i
and CC i
measured VBD i
the DT i
ECV NNP o
in IN N
42 CD p
patients NNS p
treated VBN p
with IN p
anthracyclines NNS i
. . i

The DT N
data NN N
from IN N
the DT N
cardiac JJ N
magnetic JJ N
resonance NN N
study NN N
were VBD N
compared VBN N
to TO N
those DT N
from IN N
healthy JJ p
volunteers NNS p
. . p

The DT N
anthracycline-treated JJ N
cohort NN N
consisted VBD N
of IN N
21 CD p
men NNS p
and CC p
21 CD p
women NNS p
with IN p
a DT p
mean JJ p
age NN p
of IN p
55 CD p
? . p
17 CD p
years NNS p
, , p
who WP p
presented VBD p
a DT p
median NN p
of IN p
84 CD p
months NNS p
after IN p
chemotherapy NN p
with IN p
a DT p
cumulative JJ p
anthracycline NN p
exposure NN p
of IN p
282 CD p
? . p
65 CD p
mg/m NN p
( ( p
2 CD p
) ) p
and CC p
a DT p
mean NN o
left VBD o
ventricular JJ o
ejection NN o
fraction NN o
of IN o
52 CD p
? . p
12 CD p
% NN p
. . p

The DT p
ECV NNP o
was VBD o
elevated VBN N
in IN N
the DT N
anthracycline-treated JJ N
patients NNS N
compared VBN N
to TO N
the DT N
age- JJ N
and CC N
gender-matched JJ N
controls NNS N
( ( N
0.36 CD N
? . N
0.03 CD N
vs NN N
0.28 CD N
? . N
0.02 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

A NNP N
positive JJ N
association NN N
was VBD N
found VBN N
between IN o
the DT o
ECV NNP o
and CC N
left VBD N
atrial JJ N
volume NN o
( ( o
ECV NNP o
vs RB o
indexed VBD o
left JJ o
atrial JJ o
volume NN o
, , o
r NN o
= VBD o
0.65 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
negative JJ N
association NN N
was VBD N
found VBN N
between IN N
the DT N
ECV NNP N
and CC o
diastolic JJ o
function NN o
( ( o
E NNP o
' POS o
lateral NN N
, , N
r NN N
= NNP N
-0.64 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
myocardial JJ o
ECV NNP o
is VBZ N
elevated VBN p
in IN p
patients NNS p
with IN p
previous JJ p
anthracycline NN p
treatment NN p
and CC p
is VBZ N
associated VBN N
with IN N
the DT N
diastolic JJ N
function NN N
and CC N
increased VBD N
atrial JJ N
volumes NNS N
. . N

-DOCSTART- -X- O O

Comparative JJ o
efficacy NN o
and CC o
safety NN o
of IN N
lofexidine NN i
and CC i
clonidine VB i
given VBN N
alone RB N
or CC N
concomitantly RB N
with IN N
hydrochlorothiazide NN i
in IN N
hypertensive JJ p
outpatients NNS p
. . p

-DOCSTART- -X- O O

[ JJ i
Plasma NNP i
separation NN i
combined VBN N
with IN N
CVVHF NNP i
in IN N
septic JJ p
and CC p
SIRS JJ p
patients NNS p
] VBP p
. . N

In IN N
a DT N
prospective JJ N
non-randomized JJ N
trial NN N
, , N
59 CD p
patients NNS p
with IN p
sepsis NN p
( ( p
n JJ p
= NNP p
43 CD p
) ) p
and CC p
SIRS NNP p
( ( p
n JJ p
= NNP p
16 CD p
) ) p
were VBD N
treated VBN N
on IN N
a DT N
surgical JJ N
intensive JJ N
care NN N
unit NN N
. . N

In IN N
22 CD p
patients NNS p
plasmapheresis NN i
in IN i
combination NN i
with IN i
continuous JJ i
venovenous JJ i
hemofiltration NN i
( ( i
CVVHF NNP i
) ) i
was VBD N
administered VBN N
. . N

Lethality NNP o
was VBD o
56 CD o
% NN o
in IN o
the DT o
sepsis NN o
group NN o
; : o
in IN o
the DT o
therapy NN o
group NN o
lethality NN o
was VBD o
significantly RB o
lower JJR o
in IN o
patients NNS o
with IN o
plasmapheresis NN o
, , o
even RB o
though IN o
in IN o
this DT o
population NN o
the DT o
organic JJ o
failure NN o
rate NN o
was VBD o
higher JJR o
. . o

Finally RB N
the DT o
dependency NN o
of IN o
lethality NN o
and CC o
age NN o
was VBD o
similar JJ o
in IN o
both DT o
groups NNS o
. . o

Lethality NNP o
at IN o
22 CD o
% NN o
in IN o
the DT o
plasmapheresis NN o
group NN o
with IN o
double JJ o
organ JJ o
failure NN o
was VBD o
significantly RB o
lower JJR o
( ( o
P NNP o
> NNP o
0.01 CD o
) ) o
than IN o
in IN o
controls NNS o
. . o

Reduction NN o
of IN o
lethality NN o
seemed VBD o
to TO o
be VB o
as RB o
high JJ o
as IN o
18 CD o
% NN o
in IN o
patients NNS o
with IN o
sepsis NN o
, , o
while IN o
patients NNS o
with IN o
SIRS NNP o
did VBD o
not RB o
profit NN o
from IN o
the DT o
additional JJ o
therapy NN o
. . o

A DT N
prospective JJ N
randomized VBN N
trial NN N
in IN N
sepsis NN N
and CC N
double JJ N
organic JJ N
failure NN N
should MD N
be VB N
projected VBN N
. . N

-DOCSTART- -X- O O

Immunogenicity NN o
and CC N
reactogenicity NN o
of IN N
a DT N
group NN N
C NNP N
meningococcal JJ N
conjugate NN N
vaccine NN N
compared VBN N
with IN N
a DT N
group NN N
A+C NNP N
meningococcal JJ N
polysaccharide NN N
vaccine NN N
in IN N
adolescents NNS p
in IN N
a DT N
randomised JJ N
observer-blind NN N
controlled VBN N
trial NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
immunogenicity NN o
and CC N
reactogenicity NN o
of IN N
a DT N
group NN i
C NNP i
meningococcal JJ i
conjugate NN i
vaccine NN i
( ( i
MenC NNP i
) ) i
compared VBN i
with IN i
a DT i
group NN i
A+C NNP i
meningococcal JJ i
polysaccharide NN i
vaccine NN i
( ( i
MenPS NNP i
) ) i
in IN N
healthy JJ p
adolescents NNS p
. . p

Subjects NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
one CD N
dose NN N
of IN N
either DT N
MenC NNP i
( ( N
n=92 NN N
) ) N
or CC N
MenPS NNP i
( ( N
n=90 NN N
) ) N
. . N

Group NNP N
C NNP N
meningococcal JJ o
IgG NNP o
antibody NN o
concentrations NNS o
and CC o
bactericidal JJ o
titres NNS o
were VBD N
higher JJR N
in IN N
the DT N
MenC NNP N
group NN N
than IN N
the DT N
MenPS NNP N
group NN N
at IN N
1 CD N
month NN N
( ( N
22.8 CD N
U/ml NNP N
vs NN N
4.0 CD N
U/ml NNP N
, , N
p NN N
< VBD N
0.001 CD N
, , N
and CC N
87 CD N
vs NN N
20 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
and CC N
12 CD N
months NNS N
( ( N
6.1 CD N
U/ml NNP N
vs NN N
3.0 CD N
U/ml NNP N
, , N
p NN N
< VBD N
0.001 CD N
, , N
and CC N
81.3 CD N
vs NN N
20.2 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

No DT N
differences NNS N
in IN N
post NN o
immunisation NN o
reaction NN o
rates NNS o
were VBD N
noted VBN N
between IN N
the DT N
two CD N
vaccinated VBD N
groups NNS N
. . N

This DT N
study NN N
demonstrated VBD N
the DT N
safety NN N
and CC N
enhanced JJ N
immunogenicity NN o
of IN N
the DT N
candidate NN N
meningococcal JJ N
conjugate NN N
vaccine NN N
as IN N
compared VBN N
with IN N
the DT N
licensed JJ N
polysaccharide NN N
vaccine NN N
in IN N
adolescents NNS p
. . p

-DOCSTART- -X- O O

Clinical JJ N
impact NN N
of IN N
leak JJ N
compensation NN N
during IN N
non-invasive JJ N
ventilation NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
leak JJ N
compensation NN N
capabilities NNS N
during IN N
pressure- JJ i
and CC i
volume-limited JJ i
non-invasive JJ i
positive-pressure NN i
ventilation NN i
( ( i
NPPV NNP i
) ) i
in IN N
COPD NNP N
patients NNS N
. . N

METHODS NNP N
Fourteen NNP p
patients NNS p
with IN p
stable JJ p
hypercapnic JJ p
COPD NN p
who WP p
were VBD p
receiving VBG p
long-term JJ p
NPPV NNP p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

For IN N
both DT N
modes NNS N
of IN N
NPPV NNP N
, , N
a DT N
full JJ i
face NN i
mask NN i
and CC i
an DT i
artificial JJ i
leak NN i
in IN i
the DT i
ventilatory NN i
circuit NN i
were VBD N
used VBN N
at IN N
three CD N
different JJ N
settings NNS N
, , N
and CC N
applied VBD N
during IN N
daytime JJ N
NPPV NNP N
, , N
either RB i
without IN i
leakage NN i
( ( i
setting VBG i
I PRP i
) ) i
, , i
with IN i
leakage NN i
during IN i
inspiration NN i
only RB i
( ( i
setting VBG i
II NNP i
) ) i
, , i
and CC i
with IN i
leakage NN i
during IN i
inspiration NN i
and CC i
expiration NN i
( ( i
setting VBG i
III NNP i
) ) i
. . i

Ventilation NNP o
pattern NN o
was VBD N
pneumotachy-graphically RB N
recorded VBN N
. . N

RESULTS NNP N
NPPV NNP N
was VBD N
feasible JJ N
with IN N
negligible JJ N
leak NN o
volumes NNS o
, , N
indicating VBG N
optimal JJ N
mask NN N
fitting VBG N
during IN N
the DT N
daytime NN N
( ( N
setting VBG N
I PRP N
) ) N
. . N

In IN N
the DT N
presence NN N
of IN N
leakage NN o
( ( N
settings NNS N
II NNP N
and CC N
III NNP N
) ) N
, , N
the DT N
attempt NN N
to TO N
compensate VB N
for IN N
leak NN N
was VBD N
only RB N
evident JJ N
during IN N
pressure-limited JJ N
NPPV NNP N
, , N
since IN N
inspiratory NN o
volumes NNS o
delivered VBN o
by IN o
the DT o
ventilator NN o
increased VBD N
from IN N
726+/-129 NNP N
( ( N
setting VBG N
I PRP N
) ) N
to TO N
1104+/-164 JJ N
( ( N
setting VBG N
II NNP N
) ) N
, , N
and CC N
to TO N
1257+/-166 JJ N
( ( N
setting VBG N
III NNP N
) ) N
ml NN N
during IN N
pressure-limited JJ N
NPPV NNP N
, , N
respectively RB N
( ( N
all DT N
p VBP N
< $ N
0.001 CD N
) ) N
; : N
however RB N
, , N
they PRP N
remained VBD N
stable JJ N
during IN N
volume-limited JJ N
NPPV NNP N
. . N

Leak NNP N
compensation NN N
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
leakage-induced JJ o
dyspnea NN o
. . o

However RB N
, , N
83 CD N
% NN N
/87 CD N
% NN N
( ( N
setting VBG N
II/III NNP N
) ) N
of IN N
the DT N
additionally-delivered JJ N
inspiratory NN N
volume NN N
during IN N
pressure-limited JJ N
NPPV NNP N
was VBD N
also RB N
lost VBN N
via IN N
leakage NN N
. . N

Expiratory JJ o
volume NN o
was VBD N
higher RBR N
in IN N
setting VBG N
II NNP N
compared VBN N
to TO N
setting VBG N
III NNP N
( ( N
both DT N
p VBP N
< $ N
0.001 CD N
) ) N
, , N
indicating VBG N
the DT N
presence NN N
of IN N
significant JJ N
expiratory JJ N
leakage NN N
. . N

CONCLUSIONS VB N
The DT N
attempt NN N
at IN N
leak JJ N
compensation NN N
largely RB N
feeds VBZ N
the DT N
leakage NN N
itself PRP N
and CC N
only RB N
results NNS N
in IN N
a DT N
marginal JJ N
increase NN N
of IN N
tidal JJ N
volume NN N
. . N

However RB N
, , N
pressure-limited JJ N
-- : N
but CC N
not RB N
volume-limited JJ N
-- : N
NPPV JJ N
results NNS N
in IN N
a DT N
clinically-important JJ N
leak JJ N
compensation NN N
in IN N
vivo NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
www.uniklinik-freiburg.de/zks/live/uklregister/Oeffentlich.html JJ N
Identifier NNP N
: : N
UKF001272 NN N
. . N

-DOCSTART- -X- O O

The DT N
benefit NN N
of IN N
low-dose JJ N
dopamine NN i
during IN N
vigorous JJ N
diuresis NN N
for IN N
congestive JJ p
heart NN p
failure NN p
associated VBN p
with IN p
renal JJ p
insufficiency NN p
: : p
does VBZ N
it PRP N
protect VB N
renal JJ N
function NN N
? . N
BACKGROUND NNP N
Low-dose NNP N
dopamine NN i
, , N
a DT N
renal JJ N
vasodilator NN N
, , N
has VBZ N
been VBN N
used VBN N
empirically RB N
to TO N
improve VB N
renal JJ N
function NN N
or CC N
outcome NN N
in IN N
critically RB p
ill JJ p
patients NNS p
with IN p
oliguria NNS p
or CC p
acute JJ p
renal JJ p
failure NN p
. . p

HYPOTHESIS NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
low-dose JJ N
dopamine NN i
( ( N
2 CD N
micrograms/kg/min NN N
) ) N
as IN N
a DT N
renal-protective JJ N
agent NN N
during IN N
vigorous JJ N
diuresis NN N
for IN N
congestive JJ N
heart NN N
failure NN N
( ( N
CHF NNP N
) ) N
associated VBN N
with IN N
mild NN N
or CC N
moderate JJ N
renal JJ N
insufficiency NN N
. . N

METHODS NNP N
Of IN N
20 CD p
study NN p
patients NNS p
( ( p
mean JJ p
age NN p
74.3 CD p
+/- JJ p
15 CD p
years NNS p
) ) p
with IN p
severe JJ p
CHF NNP p
, , p
10 CD p
( ( p
Group NNP p
A NNP p
) ) p
were VBD N
randomized VBN N
to TO N
a DT N
treatment NN N
strategy NN N
of IN N
intravenous JJ N
bumetanide NN i
( ( N
1 CD N
mg NN N
b.i.d NN N
. . N

) ) N
alone RB N
and CC N
another DT N
10 CD N
( ( N
Group NNP N
B NNP N
) ) N
to TO N
low-dose JJ N
dopamine NN i
and CC N
a DT N
similar JJ N
diuretic JJ N
regimen NNS N
for IN N
a DT N
duration NN N
of IN N
5 CD N
days NNS N
or CC N
less JJR N
if IN N
clinical JJ N
edema NN N
remitted VBN N
. . N

RESULTS NNP N
Group NNP N
B NNP N
patients NNS N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
renal JJ o
function NN o
and CC o
urinary JJ o
output NN o
: : o
serum NN o
blood NN o
urea JJ o
nitrogen RB o
48.9 CD N
+/- JJ N
10.3 CD N
to TO N
32.1 CD N
+/- JJ N
14.4 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
serum JJ o
creatinine NN o
1.97 CD N
+/- JJ N
0.24 CD N
to TO N
1.49 CD N
+/- JJ N
0.39 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
creatinine JJ o
clearance NN o
35.6 CD N
+/- JJ N
11.6 CD N
to TO N
48.8 CD N
+/- JJ N
12.3 CD N
ml/min NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
and CC N
indexed JJ o
urinary JJ o
output NN o
0.56 CD N
+/- JJ N
0.16 CD N
to TO N
2.02 CD N
+/- JJ N
0.72 CD N
ml/kg/h NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Group NNP N
A NNP N
patients NNS N
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
urinary JJ o
output NN o
but CC o
nonsignificant JJ o
renal JJ o
functional JJ o
deterioration NN o
. . o

CONCLUSION VB N
The DT N
renal-protective JJ N
effect NN N
of IN N
low-dose JJ N
dopamine NN i
in IN N
the DT N
setting NN N
of IN N
CHF NNP N
and CC N
vigorous JJ N
diuresis NN N
is VBZ N
supported VBN N
by IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O

REVIVE JJ N
Trial NN N
: : N
Retrograde JJ N
Delivery NNP N
of IN N
Autologous NNP N
Bone NNP N
Marrow NNP N
in IN N
Patients NNP p
With IN p
Heart NNP p
Failure NNP p
. . p

UNLABELLED NNP N
Cell NNP i
therapy NN i
is VBZ N
an DT N
evolving VBG N
option NN N
for IN N
patients NNS p
with IN p
end-stage JJ p
heart NN p
failure NN p
and CC p
ongoing NN p
symptoms NNS p
despite IN p
optimal JJ p
medical JJ p
therapy NN p
. . p

Our PRP$ N
goal NN N
was VBD N
to TO N
evaluate VB N
retrograde VB N
bone NN N
marrow NN N
cell NN N
delivery NN N
in IN N
patients NNS p
with IN p
either DT p
ischemic JJ p
heart NN p
failure NN p
( ( p
IHF NNP p
) ) p
or CC p
nonischemic JJ p
heart NN p
failure NN p
( ( p
NIHF NNP p
) ) p
. . p

This DT N
was VBD N
a DT N
prospective JJ N
randomized NN N
, , N
multicenter NN N
, , N
open-label JJ N
study NN N
of IN N
the DT N
safety NN N
and CC N
feasibility NN N
of IN N
bone NN i
marrow NN i
aspirate NN i
concentrate NN i
( ( N
BMAC NNP N
) ) N
infused VBD N
retrograde NN i
into IN N
the DT N
coronary JJ N
sinus NN N
. . N

Sixty JJ p
patients NNS p
were VBD p
stratified VBN p
by IN p
IHF NNP p
and CC p
NIHF NNP p
and CC N
randomized VBN N
to TO N
receive VB N
either DT N
BMAC NNP i
infusion NN i
or CC N
control NN i
( ( N
standard JJ N
heart NN N
failure NN N
care NN N
) ) N
in IN N
a DT N
4:1 CD N
ratio NN N
. . N

Accordingly RB N
, , N
24 CD N
subjects NNS N
were VBD N
randomized VBN N
to TO N
the DT N
ischemic JJ N
BMAC NNP N
group NN N
and CC N
6 CD N
to TO N
the DT N
ischemic JJ N
control NN N
group NN N
. . N

Similarly RB N
, , N
24 CD N
subjects NNS N
were VBD N
randomized VBN N
to TO N
the DT N
nonischemic JJ N
BMAC NNP N
group NN N
and CC N
6 CD N
to TO N
the DT N
nonischemic JJ N
control NN N
group NN N
. . N

All DT p
60 CD p
patients NNS p
were VBD p
successfully RB p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

The DT N
treatment NN N
groups NNS N
received VBD N
BMAC NNP i
infusion NN i
without IN N
complications NNS N
. . N

The DT N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
in IN N
the DT N
patients NNS N
receiving VBG N
BMAC NNP N
demonstrated VBD N
significant JJ o
improvement NN o
compared VBN N
with IN N
baseline NN N
, , N
from IN N
25.1 CD N
% NN N
at IN N
screening VBG N
to TO N
31.1 CD N
% NN N
at IN N
12 CD N
months NNS N
( ( N
p=.007 NN N
) ) N
in IN N
the DT N
NIHF NNP N
group NN N
and CC N
from IN N
26.3 CD N
% NN N
to TO N
31.1 CD N
% NN N
in IN N
the DT N
IHF NNP N
group NN N
( ( N
p=.035 NN N
) ) N
. . N

The DT N
end-systolic JJ o
diameter NN o
decreased VBN o
significantly RB o
in IN N
the DT N
nonischemic JJ N
BMAC NNP i
group NN N
from IN N
55.6 CD N
to TO N
50.9 CD N
mm NN N
( ( N
p=.020 NN N
) ) N
. . N

Retrograde NNP N
BMAC NNP N
delivery NN o
is VBZ o
safe JJ o
. . o

All DT N
patients NNS N
receiving VBG N
BMAC NNP N
experienced VBD o
improvements NNS o
in IN N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
, , N
but CC N
only RB N
those DT N
with IN N
NIHF NNP N
showed VBD N
improvements NNS o
in IN N
left JJ o
ventricular JJ o
end-systolic JJ o
diameter NN o
and CC o
B-type NNP o
natriuretic JJ o
peptide NN o
. . o

These DT N
results NNS N
provide VBP N
the DT N
basis NN N
for IN N
a DT N
larger JJR N
clinical JJ N
trial NN N
in IN N
HF NNP N
patients NNS N
. . N

SIGNIFICANCE VB N
This DT N
work NN N
is VBZ N
the DT N
first JJ N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
using VBG N
high-dose JJ N
cell NN N
therapy NN N
delivered VBN N
via IN N
a DT N
retrograde JJ N
coronary JJ N
sinus NN N
infusion NN N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
. . p

This DT N
was VBD N
a DT N
multinational JJ N
, , N
multicenter NN N
study NN N
, , N
and CC N
it PRP N
is VBZ N
novel JJ N
, , N
translatable JJ N
, , N
and CC N
scalable JJ N
. . N

On IN N
the DT N
basis NN N
of IN N
this DT N
trial NN N
and CC N
the DT N
safety NN N
of IN N
retrograde JJ N
coronary JJ N
sinus NN N
infusion NN N
, , N
there EX N
are VBP N
three CD N
other JJ N
trials NNS N
under IN N
way NN N
using VBG N
this DT N
route NN N
of IN N
delivery NN N
. . N

-DOCSTART- -X- O O

Placebo-controlled JJ i
acute JJ N
dosage NN N
naltrexone NN i
study NN N
in IN N
young JJ p
autistic JJ p
children NNS p
. . p

In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
trial NN N
23 CD p
autistic JJ p
children NNS p
were VBD N
treated VBN N
with IN N
a DT N
single JJ N
40-mg JJ N
dose NN N
of IN N
the DT N
opiate JJ N
antagonist NN N
naltrexone NN i
. . i

Drug JJ N
effects NNS o
were VBD N
monitored VBN N
by IN N
detailed JJ N
playroom NN N
observations NNS N
, , N
actometers NNS N
, , N
and CC N
parents NNS N
' POS N
checklist NN N
ratings NNS N
( ( o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
, , o
social JJ o
items NNS o
and CC o
target NN o
behaviors NNS o
) ) o
. . o

Naltrexone CD i
treatment NN N
failed VBD N
to TO N
produce VB N
significant JJ o
changes NNS o
in IN N
social JJ o
behavior NN o
, , N
but CC N
it PRP N
did VBD N
reduce VB o
irritability NN o
and CC o
target NN o
scores NNS o
on IN o
behavior JJ o
checklists NNS o
. . o

The DT N
playroom NN N
data NNS N
indicated VBD N
that IN N
naltrexone NN i
significantly RB o
affected VBD o
indices NNS N
of IN N
activity NN o
and CC o
attention NN o
. . o

-DOCSTART- -X- O O

Oral NNP N
ondansetron NN i
in IN N
the DT N
prevention NN o
of IN o
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
. . o

The DT N
effect NN N
of IN N
three CD N
times NNS N
daily JJ N
oral JJ N
ondansetron NN N
in IN N
preventing VBG N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
was VBD N
investigated VBN N
in IN N
two CD N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
multi-centre JJ N
studies NNS N
. . N

The DT N
first JJ N
study NN N
compared VBN N
ondansetron RB i
1 CD i
, , i
8 CD i
and CC i
16 CD i
mg NN i
to TO N
placebo VB i
, , N
and CC N
the DT N
second JJ N
study NN N
compared VBN N
8 CD i
mg JJ i
ondansetron NN i
to TO i
placebo VB i
. . i

Both DT N
studies NNS N
included VBD N
ASA NNP p
Class NNP p
I-III NNP p
female JJ p
patients NNS p
about IN p
to TO p
undergo VB p
major JJ p
abdominal JJ p
gynaecological JJ p
surgery NN p
or CC p
vaginal JJ p
hysterectomy NN p
. . p

In IN N
the DT N
first JJ N
study NN N
, , N
the DT N
8 CD i
and CC i
16 CD i
mg NN i
ondansetron NN i
groups NNS i
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN o
of IN o
nausea NN o
and CC o
vomiting NN o
in IN N
the DT N
0-24 JJ N
h JJ N
period NN N
following VBG N
recovery NN N
from IN N
anaesthesia NN N
than IN N
the DT N
placebo NN i
group NN N
. . N

Ondansetron NNP i
8 CD N
mg NN N
three CD N
times NNS N
daily RB N
was VBD N
also RB N
significantly RB N
better JJR N
than IN N
placebo NN N
in IN N
the DT N
second JJ N
study NN N
. . N

Side-effects NNS o
mainly RB N
consisted VBD N
of IN N
constipation NN o
, , o
headache NN o
, , o
and CC o
asymptomatic JJ o
elevation NN o
of IN o
liver NN o
enzymes NNS o
. . o

The DT N
incidence NN N
of IN N
side-effects NNS o
was VBD N
similar JJ N
in IN N
ondansetron- JJ N
and CC N
placebo-treated JJ N
patients NNS N
. . N

There EX N
appeared VBD N
to TO N
be VB N
no DT N
clinically RB o
important JJ o
benefit NN o
of IN N
the DT N
16 CD N
mg NN N
three CD N
times NNS N
daily JJ N
ondansetron VBP i
regimen NNS N
over IN N
the DT N
8 CD N
mg NN N
three CD N
times NNS N
daily RB N
dose VBP N
, , N
therefore RB N
8 CD N
mg NN N
three CD N
times NNS N
daily RB N
is VBZ N
recommended VBN N
as IN N
the DT N
optimal JJ o
oral JJ o
dose NN o
in IN N
the DT N
prevention NN N
of IN N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
. . o

-DOCSTART- -X- O O

Heat-exercise JJ p
performance NN p
of IN p
pyridostigmine-treated JJ i
subjects NNS p
wearing VBG p
chemical NN p
protective JJ p
clothing NN p
. . p

Pyridostigmine NNP i
bromide NN i
is VBZ N
currently RB N
the DT N
pretreatment NN N
of IN N
choice NN N
for IN N
operation NN N
in IN N
a DT N
chemical NN N
warfare NN N
( ( N
CW NNP N
) ) N
environment NN N
. . N

Under IN N
CW NNP N
conditions NNS N
, , N
subjects NNS N
are VBP N
exposed VBN N
to TO N
thermal VB p
stress NN p
caused VBN p
by IN p
CW NNP p
protective JJ p
clothing NN p
. . p

This DT N
investigation NN N
was VBD N
conducted VBN N
to TO N
determine VB N
if IN N
pyridostigmine JJ i
affects VBZ N
various JJ N
physiological JJ N
and CC N
biophysical JJ N
parameters NNS N
of IN N
human JJ N
temperature NN N
regulation NN N
in IN N
subjects NNS N
wearing VBG N
CW NNP N
protective JJ N
clothing NN N
. . N

Pyridostigmine NNP i
was VBD i
administered VBN i
orally RB i
in IN N
a DT N
randomized JJ N
double-blind JJ N
cross-over NN N
study NN N
in IN N
four CD N
doses NNS N
of IN N
30 CD N
mg NN N
every DT N
8 CD N
h. NN N
An DT N
average NN N
of IN N
33 CD N
% NN N
whole JJ N
blood NN N
cholinesterase NN N
inhibition NN N
was VBD N
induced VBN N
in IN N
the DT N
pyridostigmine NN i
treated VBD N
group NN N
4 CD N
h NN N
after IN N
ingestion NN N
of IN N
last JJ N
tablet NN N
. . N

The DT N
subjects NNS N
were VBD N
exposed VBN N
to TO N
170 CD N
min NNS N
exercise-heat JJ N
stress NN N
( ( N
Tdb NNP N
= VBZ N
33 CD N
degrees NNS N
C NNP N
; : N
rh VBZ N
= $ N
60 CD N
% NN N
) ) N
consisting NN N
of IN N
60 CD N
min NNS N
in IN N
a DT N
sitting JJ N
position NN N
and CC N
two CD N
50-min JJ N
walks NNS N
( ( N
1.39 CD N
m.s-1 NN N
, , N
5 CD N
% NN N
grade NN N
) ) N
separated VBN N
by IN N
10 CD N
min NN N
of IN N
rest NN N
. . N

Non-evaporative NNP o
heat NN o
exchange NN o
was VBD N
significantly RB N
higher JJR N
, , N
-14.0 JJ N
and CC N
-10.6 JJ N
W.m-2 NNP N
( ( N
p NN N
less JJR N
than IN N
0.03 CD N
) ) N
, , N
for IN N
the DT N
pyridostigmine-treated JJ i
subjects NNS N
. . N

No DT N
additional JJ N
differences NNS N
were VBD N
found VBN N
between IN N
treatments NNS N
in IN N
the DT N
physiological JJ N
responses NNS N
and CC N
heat NN N
balance NN N
parameters NNS N
at IN N
the DT N
end NN N
of IN N
exposure NN N
: : N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
was VBD N
( ( N
mean JJ N
+/- JJ N
S.D NNP N
. . N

) ) N
154 CD N
+/- JJ N
16 CD N
and CC N
151 CD N
+/- JJ N
24 CD N
bpm NN N
, , N
rectal JJ N
temperature NN N
( ( N
Tre NNP N
) ) N
was VBD N
39.0 CD N
+/- JJ N
0.4 CD N
and CC N
38.9 CD N
+/- JJ N
0.2 CD N
degrees NNS N
C NNP N
, , N
heat NN N
storage NN N
over IN N
the DT N
2 CD N
h NN N
of IN N
exercise NN N
was VBD N
62 CD N
+/- JJ N
15 CD N
and CC N
70 CD N
+/- JJ N
15 CD N
W.m-2 JJ N
, , N
and CC N
sweat NN N
rate NN N
was VBD N
832 CD N
+/- JJ N
185 CD N
and CC N
748 CD N
+/- JJ N
52 CD N
g.h-1 NN N
, , N
in IN N
the DT N
pyridostigmine NN N
and CC N
placebo NN N
treatments NNS N
, , N
respectively RB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Bisphosphonate JJ i
infusions NNS i
: : i
patient NN o
preference NN o
, , o
safety NN o
and CC o
clinic JJ o
use NN o
. . o

GOALS NNP N
OF NNP N
WORK NNP N
We PRP N
set VBD N
out RP N
to TO N
assess VB N
the DT N
preference NN N
of IN N
patients NNS p
with IN p
common JJ p
cancers NNS p
involving VBG p
bone NN p
receiving VBG p
intravenous JJ p
bisphosphonate NN i
therapy NN i
for IN N
either DT N
pamidronate NN i
( ( i
P NNP i
) ) i
or CC i
zoledronic JJ i
acid NN i
( ( i
Z NNP i
) ) i
and CC N
their PRP$ N
preference NN N
for IN N
the DT N
location NN N
of IN N
the DT N
infusion NN N
( ( N
clinic JJ N
or CC N
home NN N
) ) N
. . N

We PRP N
also RB N
aimed VBD N
to TO N
monitor VB N
these DT N
patients NNS N
' POS N
renal JJ o
safety NN o
, , N
and CC N
to TO N
compare VB N
their PRP$ N
time NN N
in IN N
clinic NN N
to TO N
receive VB N
P NNP i
and CC i
Z NNP i
infusions NNS i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Enrolled NNP p
in IN p
the DT p
study NN p
were VBD p
184 CD p
patients NNS p
, , N
and CC N
all DT N
received VBD N
initial JJ N
infusions NNS i
of IN i
Z NNP i
( ( N
so RB N
any DT N
first JJ N
infusion NN N
reactions NNS N
did VBD N
not RB N
confound VB N
preferences NNS N
for IN N
P NNP N
) ) N
. . N

For IN N
their PRP$ N
second JJ N
and CC N
third JJ N
infusions NNS N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
Z NNP i
then RB i
P NNP i
or CC i
P NNP i
then RB i
Z NNP i
, , N
and CC N
questioned VBD N
on IN N
their PRP$ N
preferences NNS N
. . N

For IN N
up IN N
to TO N
1 CD N
year NN N
they PRP N
continued VBD N
on IN N
Z NNP i
infusions NNS i
every DT N
3-4 JJ N
weeks NNS N
, , N
while IN N
their PRP$ N
renal JJ N
safety NN N
was VBD N
monitored VBN N
. . N

Where NNP N
practical JJ N
, , N
later JJ N
infusions NNS N
were VBD N
given VBN N
at IN N
home NN N
( ( N
rather RB N
than IN N
in IN N
the DT N
clinic NN N
) ) N
and CC N
patients NNS N
questioned VBN N
on IN N
their PRP$ N
preferred JJ N
infusion NN N
location NN N
. . N

In IN N
a DT N
convenience NN N
subset NN N
of IN N
43 CD N
patients NNS N
, , N
clinic JJ N
use NN N
for IN N
Z NNP i
and CC i
P NNP i
infusions NNS i
was VBD N
also RB N
measured VBN N
by IN N
timing VBG N
infusions NNS N
and CC N
other JJ N
procedures NNS N
. . N

MAIN NNP N
RESULTS NNP N
Of IN N
144 CD N
patients NNS N
who WP N
received VBD N
a DT N
third JJ N
infusion NN N
, , N
138 CD N
responded VBD N
to TO N
questions NNS N
on IN N
bisphosphonate NN N
preference NN N
, , N
and CC N
of IN N
these DT N
138 CD N
, , N
92 CD N
% NN N
( ( N
127 CD N
) ) N
preferred VBD N
Z NNP i
to TO i
P VB i
, , N
because IN N
shorter JJR N
infusions NNS N
caused VBD N
less JJR N
disruption NN o
to TO o
their PRP$ o
day NN o
. . o

Only RB N
12 CD p
% NN p
of IN p
eligible JJ p
patients NNS p
( ( p
16/138 CD p
) ) p
received VBD N
home NN N
infusions NNS N
, , N
but CC N
13/14 CD N
questioned VBD N
preferred VBN N
this DT N
location NN N
. . N

Among IN N
184 CD N
patients NNS N
, , N
19 CD N
episodes NNS N
of IN N
renal JJ o
impairment NN o
were VBD N
noted VBN N
, , N
mostly RB N
owing VBG N
to TO N
disease VB o
progression NN o
( ( N
e.g JJ N
. . N

obstructive JJ N
uropathy JJ N
) ) N
, , N
with IN N
none NN N
linked VBN N
to TO N
Z NNP N
therapy NN N
. . N

The DT N
mean JJ o
clinic JJ o
time NN o
taken VBN o
to TO o
receive VB o
Z NNP o
and CC o
any DT o
concomitant JJ o
therapy NN o
was VBD N
about IN N
half PDT N
that DT N
for IN N
P NNP N
( ( N
78 CD N
vs RB N
161 CD N
min NN N
) ) N
. . N

CONCLUSIONS NNP N
Cancer NNP p
patients NNS p
prefer VBP N
shorter JJR N
bisphosphonate JJ o
infusions-and NN o
at IN N
home NN N
, , N
where WRB N
practical JJ N
. . N

Regular JJ N
Z NNP i
4 CD i
mg NN i
infusions NNS i
appear VBP N
to TO N
be VB N
safe JJ o
in IN N
these DT N
patients NNS N
, , N
with IN N
routine JJ N
monitoring NN N
of IN N
serum JJ N
creatinine NN N
. . N

Using VBG N
Z NNP i
rather RB i
than IN i
P NNP i
could MD N
save VB N
busy JJ N
cancer NN N
centres NNS N
time NN N
and CC N
improve VB N
patient JJ o
satisfaction NN o
. . o

-DOCSTART- -X- O O

Cariprazine NN i
in IN N
the DT N
treatment NN N
of IN N
acute NN N
mania NN N
in IN N
bipolar JJ N
I PRP N
disorder VBP N
: : N
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
phase JJ N
III NNP N
trial NN N
. . N

BACKGROUND VB N
This DT N
Phase NNP N
III NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
investigated VBD N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
flexibly-dosed JJ N
cariprazine NN i
in IN N
patients NNS p
with IN p
acute JJ p
manic NN p
or CC p
mixed JJ p
episodes NNS p
associated VBN p
with IN p
bipolar JJ p
I PRP p
disorder VBP p
. . p

METHODS NNP N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
3 CD N
weeks NNS N
of IN N
double-blind JJ N
treatment NN p
with IN p
cariprazine JJ i
3-12mg/day JJ p
( ( p
n=158 JJ p
) ) p
or CC i
placebo NN i
( ( p
n=154 JJ p
) ) p
. . p

The DT N
primary JJ N
efficacy NN N
parameter NN N
was VBD N
change NN N
from IN N
baseline NN N
to TO N
Week VB N
3 CD N
in IN N
Young NNP o
Mania NNP o
Rating NNP o
Scale NNP o
( ( o
YMRS NNP o
) ) o
total NN o
score NN o
. . o

The DT N
secondary JJ N
efficacy NN N
parameter NN N
was VBD N
change NN N
from IN N
baseline NN N
to TO N
Week VB N
3 CD N
in IN N
Clinical JJ o
Global NNP o
Impressions-Severity NNP o
( ( o
CGI-S NNP o
) ) o
score NN o
. . o

RESULTS JJ N
Mean JJ N
change NN N
from IN N
baseline NN N
to TO N
Week VB N
3 CD N
in IN N
YMRS NNP N
total JJ N
score NN N
was VBD N
significantly RB N
greater JJR N
for IN N
patients NNS N
receiving VBG N
cariprazine JJ i
3-12mg/day JJ N
versus NN N
placebo NN N
( ( N
P=0.0004 NNP N
) ) N
. . N

Significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
YMRS NNP o
total JJ o
score NN o
mean JJ N
change NN N
were VBD N
observed VBN N
by IN N
Day NNP N
4 CD N
( ( N
first JJ N
postbaseline NN N
assessment NN N
) ) N
and CC N
maintained VBN N
throughout IN N
double-blind JJ N
treatment NN N
( ( N
all DT N
assessments NNS N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Cariprazine NNP i
also RB N
demonstrated VBD N
statistically RB N
significant JJ N
superiority NN N
over IN N
placebo NN N
on IN N
YMRS NNP o
response NN o
( ( N
?50 CD N
% NN N
improvement NN i
: : i
cariprazine NN i
, , i
58.9 CD i
% NN i
; : i
placebo NN i
, , i
44.1 CD N
% NN N
; : N
P=0.0097 NNP N
) ) N
and CC o
remission NN o
( ( o
YMRS NNP N
total JJ N
score?12 NN N
: : N
cariprazine NN N
, , N
51.9 CD N
% NN N
; : N
placebo NN N
, , N
34.9 CD N
% NN N
; : N
P=0.0025 NNP N
) ) N
and CC N
mean JJ N
change NN N
in IN N
CGI-S NNP N
( ( N
P=0.0027 NNP N
) ) N
score NN N
and CC N
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scale NNP o
( ( o
PANSS NNP o
) ) o
( ( o
P=0.0035 NNP o
) ) N
total NN N
score NN N
. . N

The DT N
most RBS N
common JJ i
cariprazine-related JJ i
( ( i
?10 CD i
% NN i
and CC i
twice RB i
placebo NN i
) ) i
treatment NN i
emergent JJ N
adverse JJ N
events NNS N
( ( N
TEAEs NNP N
) ) o
were VBD o
akathisia JJ o
, , o
extrapyramidal JJ o
disorder NN o
, , o
tremor NN o
, , o
dyspepsia NN o
, , o
and CC o
vomiting VBG o
. . o

Mean JJ o
change NN N
from IN N
baseline NN o
in IN o
metabolic JJ o
parameters NNS o
were VBD o
generally RB N
small JJ N
and CC N
similar JJ N
between IN N
groups NNS N
. . N

LIMITATIONS NNP N
Lack NNP N
of IN N
active JJ N
comparator NN N
arm NN N
; : N
short JJ N
duration NN N
of IN N
study NN N
. . N

CONCLUSION NNP N
In IN N
this DT N
study NN N
, , N
cariprazine VB i
3-12mg/day JJ i
was VBD N
effective JJ N
and CC N
generally RB N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
manic NN N
and CC N
mixed JJ N
episodes NNS N
associated VBN N
with IN N
bipolar JJ N
I PRP N
disorder VBP N
. . N

-DOCSTART- -X- O O

Onset/offset NNP o
characteristics NNS o
and CC o
intubating VBG o
conditions NNS o
of IN N
rapacuronium NN N
: : N
a DT N
comparison NN N
with IN N
rocuronium NN N
. . N

We PRP N
compared VBN N
onset PRP o
and CC o
offset VB o
of IN o
action NN o
and CC o
tracheal JJ o
intubating NN o
conditions NNS o
after IN N
rapacuronium NN i
and CC i
rocuronium NN i
in IN N
60 CD p
patients NNS p
in IN N
a DT N
randomized JJ N
, , N
assessor-blinded JJ N
study NN N
. . N

Following VBG N
induction NN N
of IN N
anaesthesia NN i
with IN i
propofol JJ i
2.5 CD i
mg JJ i
kg-1 NN i
, , i
either CC i
rapacuronium NN i
1.5 CD i
mg NN i
kg-1 NN i
( ( i
n JJ i
= NNP i
30 CD i
) ) i
or CC i
rocuronium $ i
0.6 CD i
mg JJ i
kg-1 NN i
( ( i
n JJ i
= NNP i
30 CD i
) ) i
was VBD i
administered VBN i
to TO i
facilitate VB i
tracheal JJ i
intubation NN i
. . i

Anaesthesia NNP i
was VBD i
maintained VBN i
with IN i
either CC i
a DT i
propofol JJ i
infusion NN i
( ( i
100 CD i
micrograms NNS i
kg-1 JJ i
min-1 JJ i
) ) i
or CC i
sevoflurane NN i
( ( i
1 CD i
% NN i
end-tidal JJ i
) ) i
with IN i
66 CD i
% NN i
nitrous JJ i
oxide NN i
( ( i
N2O NNP i
) ) i
, , i
n JJ i
= VBP i
15 CD i
in IN i
each DT i
subgroup NN i
. . i

Neuromuscular JJ o
monitoring NN o
was VBD i
performed VBN i
using VBG i
an DT i
electromyographic JJ i
( ( i
EMG NNP i
) ) i
device NN i
( ( i
Datex NNP i
Relaxograph NNP i
) ) i
. . i

The DT N
lag NN o
times NNS o
( ( N
mean JJ N
42 CD N
( ( N
SD NNP N
11 CD N
) ) N
s NN N
and CC N
44 CD N
( ( N
16 CD N
) ) N
s NN N
) ) N
, , N
maximum JJ o
block NN o
( ( N
99 CD N
( ( N
2 CD N
) ) N
% NN N
and CC N
98 CD N
( ( N
3 CD N
) ) N
% NN N
) ) N
and CC N
intubating JJ o
conditions NNS o
at IN o
60 CD o
s NN o
( ( N
good-to-excellent JJ N
in IN N
86 CD N
% NN N
and CC N
84 CD N
% NN N
of IN N
patients NNS N
) ) N
were VBD N
similar JJ N
for IN N
rapacuronium NN N
and CC N
rocuronium NN N
, , N
respectively RB N
. . N

The DT N
onset JJ o
time NN o
of IN N
rapacuronium NN N
was VBD N
shorter JJR N
than IN N
rocuronium NN N
( ( N
87 CD N
( ( N
20 CD N
) ) N
vs NN N
141 CD N
( ( N
65 CD N
) ) N
s NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
degree NN o
of IN o
block NN o
at IN o
60 CD o
s NN o
was VBD N
greater JJR N
( ( N
69 CD N
( ( N
26 CD N
) ) N
vs NN N
50 CD N
( ( N
27 CD N
) ) N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Twenty-five JJ N
per IN N
cent NN N
recovery NN o
was VBD N
shorter JJR N
with IN N
rapacuronium NN N
than IN N
rocuronium NN N
during IN N
propofol NN N
( ( N
15.0 CD N
( ( N
3.2 CD N
) ) N
vs NN N
39.1 CD N
( ( N
14.2 CD N
) ) N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
sevoflurane NN N
( ( N
15.1 CD N
( ( N
4.2 CD N
) ) N
vs NN N
47.8 CD N
( ( N
19.0 CD N
) ) N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
anaesthesia NN N
. . N

We PRP N
conclude VBP N
that IN N
rapacuronium NN N
1.5 CD N
mg NN N
kg-1 NN N
had VBD N
a DT N
more RBR N
rapid JJ N
onset NN o
, , N
similar JJ N
intubating NN o
conditions NNS o
, , N
and CC N
shorter JJR N
recovery NN o
times NNS o
than IN N
rocuronium NN N
0.6 CD N
mg JJ N
kg-1 NN N
. . N

-DOCSTART- -X- O O

Can MD N
simvastatin VB i
improve VB N
erectile JJ o
function NN o
and CC N
health-related JJ o
quality NN o
of IN o
life NN o
in IN N
men NNS p
aged VBN p
?40 CD p
years NNS p
with IN p
erectile JJ p
dysfunction NN p
? . p
Results NNS N
of IN N
the DT N
Erectile NNP N
Dysfunction NNP N
and CC N
Statins NNP N
Trial NNP N
[ NNP N
ISRCTN66772971 NNP N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT o
effectiveness NN o
and CC o
cost-effectiveness NN o
of IN o
simvastatin NN i
on IN i
erectile JJ o
function NN o
and CC o
health-related JJ o
quality NN o
of IN o
life NN o
in IN o
men NNS p
aged VBN p
?40 CD p
years NNS p
with IN p
erectile JJ p
dysfunction NN p
( ( p
ED NNP p
) ) p
. . p

PATIENTS NNP p
AND CC N
METHODS NNP N
ED NNP N
is VBZ N
common JJ N
in IN N
men NNS N
aged VBN N
?40 CD N
years NNS N
and CC N
impacts NNS N
upon VBP N
their PRP$ N
overall JJ N
health-related JJ N
quality NN N
of IN N
life NN N
and CC N
that IN N
of IN N
their PRP$ N
partners NNS p
. . p

Men NNP p
aged VBD p
?40 CD p
years NNS p
who WP p
were VBD p
not RB p
receiving VBG p
lipid JJ p
lowering NN p
or CC p
anti-hypertensive JJ p
medication NN p
and CC p
not RB p
at IN p
high JJ p
cardiovascular JJ p
risk NN p
were VBD p
recruited VBN p
from IN p
10 CD p
general JJ p
practices NNS p
in IN p
the DT p
East NNP p
of IN p
England NNP p
. . N

In IN N
total JJ N
, , p
173 CD p
eligible JJ p
men NNS p
with IN p
untreated JJ p
ED NNP p
were VBD p
randomized VBN p
to TO p
double-blind VB p
treatment NN i
with IN i
40 CD i
mg NNS i
of IN i
simvastatin NN i
or CC i
placebo NN i
once RB N
daily JJ N
for IN N
6 CD N
months NNS N
. . N

Data NNS N
were VBD N
collected VBN N
at IN N
three CD N
points NNS N
over IN N
30 CD N
weeks NNS N
. . N

The DT N
main JJ N
outcome NN N
was VBD o
erectile JJ o
function NN o
( ( o
International NNP o
Index NNP o
of IN o
Erectile NNP o
Function-5 NNP o
score NN o
) ) o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
male JJ o
ED-specific JJ o
quality NN o
of IN o
life NN o
( ( o
MED-QoL NNP o
) ) o
, , o
quality-adjusted JJ o
life NN o
years NNS o
( ( o
QALYs NNP o
) ) o
using VBG o
the DT o
generic JJ o
Euroqol NNP o
measure NN o
( ( o
EQ-5D NNP o
) ) o
, , o
endothelial JJ o
function NN o
, , o
cardiovascular JJ o
risk NN o
, , o
cholesterol NN o
and CC o
health NN o
service NN o
costs NNS o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN o
in IN o
erectile JJ o
function NN o
between IN o
the DT i
simvastatin NN i
and CC i
placebo NN i
groups NNS N
( ( N
mean JJ N
change NN N
, , N
1.28 CD N
vs NN N
0.07 CD N
, , N
z NN N
= VBD N
1.1 CD N
, , N
p NN N
= NNP N
0.27 CD N
) ) N
, , N
although IN N
a DT N
significant JJ N
improvement NN o
in IN o
MED-QoL NNP o
was VBD N
observed VBN N
( ( N
5 CD N
% NN N
vs JJ N
2 CD N
% NN N
, , N
z NN N
= VBD N
2.09 CD N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
. . N

Both DT o
10-year JJ o
cardiovascular NN o
risk NN o
and CC o
low-density NN o
lipoprotein NN o
were VBD o
reduced VBN o
( ( N
cardiovascular JJ N
risk NN N
, , N
z NN N
= NNP N
-3.67 NNP N
, , N
p NN N
< VBD N
0.001 CD N
; : N
low-density JJ N
lipoprotein NN N
, , N
z NN N
= NNP N
-5.46 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
with IN N
no DT N
consistent JJ N
change NN N
in IN o
endothelial JJ o
function NN o
. . o

The DT o
frequency NN o
of IN o
sexual JJ o
encounters NNS o
is VBZ o
correlated VBN o
with IN o
improved JJ o
erectile JJ o
function NN o
. . o

The DT o
joint JJ o
distribution NN o
of IN o
costs NNS o
and CC o
QALY NNP o
benefits NNS o
indicates VBZ o
that IN N
the DT N
probability NN N
of IN N
simvastatin NN o
being VBG o
cost-effective JJ o
for IN o
willingness-to-pay JJ o
thresholds NNS N
of IN N
?20,000 NN N
and CC N
?30,000 NN N
is VBZ N
86 CD N
% NN N
and CC N
83 CD N
% NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Identifying VBG p
men NNS p
with IN p
ED NNP p
provides VBZ p
an DT N
opportunity NN N
to TO N
modify VB N
future JJ N
cardiovascular JJ N
risk NN N
and CC N
to TO N
improve VB N
MED-QoL NNP N
by IN N
treating VBG N
them PRP N
with IN N
40 CD N
mg NNS N
of IN i
simvastatin NN i
. . i

The DT i
joint JJ i
analysis NN N
of IN o
costs NNS o
and CC N
QALY NNP o
benefits NNS o
suggests VBZ N
that IN N
there EX N
is VBZ N
high JJ N
probability NN N
that IN N
simvastatin NN N
is VBZ N
a DT N
cost-effective JJ N
strategy NN N
in IN N
men NNS N
with IN N
ED NNP N
. . N

The DT N
findings NNS N
could MD N
influence VB N
urological JJ N
and CC N
primary JJ N
care NN N
practice NN N
by IN N
including VBG N
questions NNS N
on IN N
ED NNP N
during IN N
routine JJ N
consultations NNS N
and CC N
relevant JJ N
clinical JJ N
protocols NNS N
. . N

This DT N
provides VBZ N
an DT N
opportunity NN N
to TO N
impart VB N
lifestyle JJ N
advice NN N
. . N

-DOCSTART- -X- O O

Pharmacokinetics NNS N
of IN N
cefuroxime NN i
in IN N
healthy JJ o
volunteers NNS o
: : o
an DT N
update NN N
. . N

-DOCSTART- -X- O O

Immunologic NNP N
and CC N
hemodynamic JJ N
effects NNS N
of IN N
low-dose JJ i
hydrocortisone NN i
in IN N
septic JJ p
shock NN p
: : p
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

Within IN N
the DT N
last JJ N
few JJ N
years NNS N
, , N
increasing VBG N
evidence NN N
of IN N
relative JJ N
adrenal JJ p
insufficiency NN p
in IN p
septic JJ p
shock NN p
evoked VBD N
a DT N
reassessment NN N
of IN N
hydrocortisone NN i
therapy NN i
. . i

To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
hydrocortisone NN i
on IN N
the DT N
balance NN N
between IN N
proinflammatory NN N
and CC N
antiinflammation NN N
, , N
40 CD p
patients NNS p
with IN p
septic JJ p
shock NN p
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
crossover NN N
study NN N
to TO N
receive VB N
either CC N
the DT N
first JJ N
100 CD N
mg NN N
of IN N
hydrocortisone NN i
as IN N
a DT N
loading NN N
dose NN N
and CC N
10 CD N
mg NNS N
per IN N
hour NN N
until IN N
Day NNP N
3 CD N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
20 CD N
) ) N
, , N
followed VBN N
by IN N
the DT N
opposite JJ N
medication NN N
until IN N
Day NNP N
6 CD N
. . N

Hydrocortisone CD i
infusion NN N
induced VBD N
an DT N
increase NN N
of IN N
mean JJ o
arterial JJ o
pressure NN o
, , o
systemic JJ o
vascular NN o
resistance NN o
, , N
and CC N
a DT N
decline NN N
of IN N
heart NN o
rate NN o
, , o
cardiac JJ o
index NN o
, , o
and CC o
norepinephrine JJ o
requirement NN o
. . o

A DT N
reduction NN N
of IN N
plasma NN o
nitrite/nitrate NN o
indicated VBD N
inhibition NN N
of IN N
nitric JJ o
oxide JJ o
formation NN o
and CC N
correlated VBN N
with IN N
a DT N
reduction NN o
of IN o
vasopressor NN o
support NN o
. . o

The DT N
inflammatory JJ o
response NN o
( ( o
interleukin-6 JJ o
and CC o
interleukin-8 JJ o
) ) o
, , o
endothelial JJ o
( ( o
soluble JJ o
E-selectin NN o
) ) o
and CC o
neutrophil JJ o
activation NN o
( ( o
expression NN o
of IN o
CD11b NNP o
, , o
CD64 NNP o
) ) o
, , o
and CC o
antiinflammatory JJ o
response NN o
( ( o
soluble JJ o
tumor NN o
necrosis NN o
factor NN o
receptors NNS o
I PRP o
and CC o
II NNP o
and CC o
interleukin-10 JJ o
) ) o
were VBD N
attenuated VBN N
. . N

In IN N
peripheral JJ N
blood NN N
monocytes NNS N
, , N
human JJ o
leukocyte VBD o
antigen-DR JJ o
expression NN o
was VBD N
only RB N
slightly RB N
depressed VBN N
, , N
whereas NNS N
in IN o
vitro JJ o
phagocytosis NN o
and CC o
the DT o
monocyte-activating JJ o
cytokine JJ o
interleukin-12 NN o
increased VBD N
. . N

Hydrocortisone NNP i
withdrawal NN N
induced VBD N
hemodynamic JJ o
and CC o
immunologic JJ o
rebound NN o
effects NNS o
. . o

In IN N
conclusion NN N
, , N
hydrocortisone NN i
therapy NN i
restored VBD N
hemodynamic JJ o
stability NN o
and CC N
differentially RB N
modulated VBD N
the DT N
immunologic JJ o
response NN o
to TO o
stress VB o
in IN N
a DT N
way NN N
of IN N
antiinflammation NN N
rather RB N
than IN N
immunosuppression NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
menopausal NN N
symptoms NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
adjuvant JJ N
therapy NN N
with IN N
either DT N
exemestane NN i
or CC i
tamoxifen NN i
in IN N
early JJ p
breast NN p
cancer NN p
: : p
report NN N
of IN N
a DT N
Tamoxifen NNP N
Exemestane NNP N
Adjuvant NNP N
Multicenter NNP N
trial NN N
substudy NN N
. . N

PURPOSE NNP N
Hormonal NNP N
breast NN N
cancer NN N
treatment NN N
increases NNS N
menopausal VBP o
symptoms NNS o
in IN N
women NNS p
. . p

This DT N
study NN N
investigated VBD N
differences NNS N
between IN N
the DT N
symptoms NNS N
associated VBN N
with IN N
either DT N
adjuvant JJ i
tamoxifen NN i
or CC i
exemestane NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Ten NNP N
common JJ N
symptoms NNS N
were VBD N
assessed VBN N
by IN N
self-report JJ N
questionnaire NN N
administered VBD N
to TO N
1,614 CD p
consecutive JJ p
patients NNS p
at IN N
baseline NN N
and CC N
every DT N
3 CD N
months NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
a DT N
double-blind NN N
, , N
randomized VBN N
trial NN N
of IN N
postmenopausal JJ p
women NNS p
with IN p
early JJ p
hormone NN p
receptor-positive JJ p
breast NN p
cancer NN p
. . p

Symptoms NNS N
were VBD N
categorized VBN N
as IN N
none NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
or CC N
severe RB N
. . N

A DT N
hot JJ o
flash NN o
score NN o
was VBD N
calculated VBN N
at IN N
each DT N
time NN N
point NN N
. . N

Symptoms NNS N
were VBD N
analyzed VBN N
by IN N
repeated-measures NNS N
analysis NN N
of IN N
variance NN N
. . N

Each DT N
time NN N
period NN N
was VBD N
tested VBN N
repeatedly RB N
against IN N
the DT N
baseline NN N
; : N
an DT N
overall JJ N
P NNP N
value NN N
was VBD N
assigned VBN N
for IN N
each DT N
reported VBN N
symptom NN N
. . N

RESULTS NNP N
Compliance NNP N
was VBD N
excellent JJ N
, , N
with IN N
7,286 CD N
questionnaires NNS N
analyzed VBN N
. . N

Baseline NNP o
symptom JJ o
prevalence NN N
ranged VBD N
from IN N
2 CD N
% NN N
( ( N
vaginal JJ N
bleeding NN N
) ) N
to TO N
60 CD N
% NN N
to TO N
70 CD N
% NN N
( ( o
bone/muscle NN o
aches NNS o
and CC o
low JJ o
energy NN o
) ) o
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
vaginal JJ o
bleeding NN o
, , o
mood NN o
alteration NN o
, , o
or CC o
low JJ o
energy NN o
. . o

Patients NNS p
receiving VBG p
tamoxifen NN p
had VBD N
significantly RB N
more RBR N
vaginal JJ o
discharge NN o
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

Exemestane NN N
patients NNS N
reported VBD N
more RBR N
bone/muscle NN o
aches NNS o
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
vaginal JJ o
dryness NN o
( ( N
P NNP N
= NNP N
.0004 NNP N
) ) N
, , N
and CC N
difficulty NN o
sleeping NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
hot JJ o
flash NN o
score NN o
peaked VBD N
at IN N
3 CD N
months NNS N
and CC N
decreased JJ N
thereafter NN N
. . N

At IN N
12 CD N
months NNS N
, , N
patients NNS N
receiving VBG N
tamoxifen NN N
had VBD N
a DT N
significantly RB N
higher JJR N
mean JJ o
hot JJ o
flash NN o
score NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
, , N
with IN N
daily JJ N
hot JJ o
flashes NNS o
increasing VBG N
from IN N
baseline NN N
by IN N
33 CD N
% NN N
compared VBN N
with IN N
a DT N
7 CD N
% NN N
increase NN N
from IN N
baseline NN N
with IN N
exemestane NN N
. . N

CONCLUSION NNP N
At IN N
12 CD N
months NNS N
, , N
exemestane NN N
was VBD N
associated VBN N
with IN N
fewer JJR N
hot JJ o
flashes NNS o
and CC N
less JJR N
vaginal JJ o
discharge NN o
than IN N
tamoxifen NN N
, , N
but CC N
with IN N
more JJR N
vaginal JJ o
dryness NN o
, , o
bone/muscle NN o
aches NNS o
, , o
and CC o
difficulty NN o
sleeping NN o
. . o

Symptoms NNS N
were VBD N
common JJ N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -X- O O

The DT N
treatment NN N
of IN N
localized JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
in IN p
children NNS p
: : p
a DT N
report NN N
from IN N
the DT N
Children NNP N
's POS N
Cancer NNP N
Study NNP N
Group NNP N
. . N

Investigators NNS N
of IN N
the DT N
Children NNP N
's POS N
Cancer NNP N
Study NNP N
Group NNP N
entered VBD N
73 CD p
children NNS p
with IN p
previously RB p
untreated VBN p
localized JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
on IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
systemic JJ N
treatment NN N
with IN N
either DT N
a DT N
four-drug JJ N
program NN N
( ( i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
methotrexate NN i
, , i
prednisone NN i
[ NNP i
COMP NNP i
] NNP i
) ) i
or CC N
a DT N
10-drug JJ i
( ( i
LSA2-L2 NNP i
modified VBN i
) ) i
program NN N
of IN N
18 CD N
months NNS N
duration NN N
. . N

All DT N
patients NNS N
received VBD N
central JJ i
nervous JJ i
system NN i
prophylaxis NN i
with IN i
intrathecal JJ i
methotrexate NN i
and CC N
most JJS N
received JJ N
local JJ i
or CC i
regional JJ i
radiation NN i
treatment NN i
. . i

The DT N
three-year JJ o
relapse-free JJ o
survival NN o
rate NN o
for IN N
all DT N
patients NNS N
( ( N
N NNP N
= NNP N
73 CD N
) ) N
was VBD N
84 CD N
% NN N
; : N
for IN N
COMP NNP N
( ( N
N NNP N
= NNP N
42 CD N
) ) N
was VBD N
85 CD N
% NN N
, , N
and CC N
for IN N
LSA2-L2 NNP N
( ( N
N NNP N
= NNP N
31 CD N
) ) N
was VBD N
84 CD N
% NN N
. . N

Of IN N
the DT N
12 CD N
patients NNS N
who WP N
suffered VBD N
adverse JJ o
events NNS o
eight CD N
relapsed VBN o
and CC N
four CD N
died NN o
of IN o
toxicity NN o
. . o

Histopathology NNP N
was VBD N
reviewed VBN N
centrally RB N
. . N

Of IN N
32 CD N
patients NNS N
with IN N
nonlymphoblastic JJ N
disease NN N
treated VBD N
with IN N
COMP NNP i
only RB N
one CD N
relapsed VBD o
. . o

Of IN N
26 CD N
patients NNS N
treated VBN N
with IN N
LSA2-L2 NNP i
, , N
four CD N
relapsed VBN o
. . o

Patients NNS N
with IN N
localized JJ o
lymphoblastic JJ o
disease NN o
were VBD N
uncommon JJ N
. . N

None NN N
of IN N
three CD N
patients NNS N
treated VBN N
with IN N
LSA2-L2 NNP i
relapsed VBD N
compared VBN N
with IN N
three CD N
of IN N
nine CD N
treated VBN N
with IN N
COMP NNP N
. . N

COMP NNP i
is VBZ N
an DT N
excellent JJ N
treatment NN N
for IN N
patients NNS N
with IN N
localized JJ N
disease NN N
of IN N
nonlymphoblastic JJ N
type NN N
, , N
but CC N
the DT N
relative JJ N
value NN N
of IN N
the DT N
two CD N
regimens NNS N
for IN N
patients NNS N
with IN N
localized JJ N
lymphoblastic JJ N
disease NN N
is VBZ N
uncertain JJ N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
fenoterol NN i
on IN N
inspiratory JJ N
effort NN N
sensation NN N
and CC N
fatigue NN N
during IN N
inspiratory JJ N
threshold JJ N
loading NN N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
fenoterol NN i
on IN N
the DT N
relationship NN N
between IN N
inspiratory NN N
effort NN N
sensation NN N
( ( N
IES NNP N
) ) N
and CC N
inspiratory JJ N
muscle NN N
fatigue NN N
induced VBN N
by IN N
inspiratory NN N
threshold NN N
loading NN N
in IN N
healthy JJ p
subjects NNS p
. . p

The DT N
magnitude NN N
of IN N
the DT N
threshold NN N
was VBD N
60 CD N
% NN N
of IN N
maximal JJ N
static JJ N
inspiratory NN N
mouth NN N
pressure NN N
( ( N
PI NNP N
, , N
mmax NN N
) ) N
at IN N
functional JJ N
residual JJ N
capacity NN N
, , N
and CC N
the DT N
duty NN N
cycle NN N
was VBD N
0.5 CD N
. . N

Subjects NNS p
continued VBD N
the DT N
threshold NN N
loaded VBD N
breathing NN N
until IN N
the DT N
target NN N
mouth NN N
pressure NN N
could MD N
no RB N
longer RB N
be VB N
maintained VBN N
( ( N
endurance JJ N
time NN N
) ) N
. . N

The DT N
intensity NN N
of IN N
the DT N
IES NNP N
was VBD N
scored VBN N
with IN N
a DT N
modified JJ N
Borg NNP N
scale NN N
. . N

Either CC N
fenoterol NN i
( ( i
5 CD i
mg NN i
) ) i
or CC i
a DT i
placebo NN i
was VBD N
given VBN N
orally RB N
2 CD N
h NN N
before IN N
loading VBG N
in IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
protocol NN N
. . N

The DT N
endurance NN o
time NN o
with IN N
fenoterol NN N
( ( N
34.4 CD N
+/- JJ N
8.6 CD N
min NN N
) ) N
was VBD N
longer JJR N
than IN N
that DT N
with IN N
the DT N
placebo NN N
( ( N
22.2 CD N
+/- JJ N
7.1 CD N
min NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
ratio NN o
of IN o
high- JJ o
to TO o
low-frequency JJ o
power NN o
of IN o
the DT o
diaphragmatic JJ o
electromyogram NN o
( ( o
EMGdi NNP o
) ) o
decreased VBD N
during IN N
loading NN N
; : N
the DT N
decrease NN N
was VBD N
less RBR N
with IN N
fenoterol NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
EMGdi NNP o
also RB N
decreased VBD N
with IN N
loading NN N
; : N
the DT N
decrease NN N
was VBD N
greater JJR N
on IN N
fenoterol NN N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
PI NNP o
, , o
mmax NN o
and CC o
maximal JJ o
transdiaphragmatic JJ o
pressure NN o
( ( o
Pdi NNP o
) ) o
were VBD N
similarly RB N
decreased VBN N
after IN N
loading VBG N
on IN N
either DT N
treatment NN N
. . N

The DT N
intensity NN o
of IN o
the DT o
IES NNP o
rose VBD o
with IN o
time NN o
during IN N
loading VBG N
in IN N
both DT N
groups NNS N
but CC N
was VBD N
lower JJR N
with IN N
fenoterol NN i
than IN N
with IN N
the DT N
placebo NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
ratio NN o
of IN o
Pdi NNP o
to TO N
integrated JJ N
activity NN N
of IN N
the DT N
EMGdi NNP N
increased VBD N
with IN N
fenoterol NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Fenoterol NNP N
treatment NN N
increased VBD N
both DT N
superimposed VBN o
Pdi NNP o
twitch NN o
and CC o
Pdi NNP o
twitch NN o
of IN o
relaxed JJ o
diaphragm NN o
and CC N
decreased VBD N
the DT N
value NN o
of IN o
( ( o
1-superimposed JJ o
Pdi NNP o
twitch/Pdi NN o
twitch NN o
of IN o
relaxed JJ o
diaphragm NN o
) ) o
. . o

Thus IN N
we PRP N
conclude VBP N
that IN N
in IN N
normal JJ p
subjects NNS p
fenoterol JJ N
reduces NNS N
diaphragmatic JJ N
fatigue NN N
and CC N
decreases VBZ N
the DT N
motor NN N
command NN N
to TO N
the DT N
diaphragm NN N
, , N
resulting VBG N
in IN N
a DT N
decrease NN N
in IN N
IES NNP N
during IN N
inspiratory JJ N
threshold JJ N
loading NN N
and CC N
a DT N
prolongation NN N
of IN N
endurance NN N
. . N

-DOCSTART- -X- O O

A DT N
Randomized NNP N
Clinical NNP N
Trial NNP N
Comparison NNP N
Between NNP N
Pivotal NNP i
Response NNP i
Treatment NNP i
( ( i
PRT NNP i
) ) i
and CC i
Adult-Driven NNP i
Applied NNP i
Behavior NNP i
Analysis NNP i
( ( i
ABA NNP i
) ) i
Intervention NN i
on IN N
Disruptive JJ o
Behaviors NNS o
in IN p
Public NNP p
School NNP p
Children NNP p
with IN p
Autism NNP p
. . p

Children NNP p
with IN p
autism NN p
often RB N
demonstrate JJ N
disruptive JJ o
behaviors NNS o
during IN N
demanding VBG N
teaching VBG N
tasks NNS N
. . N

Language VB N
intervention NN N
can MD N
be VB N
particularly RB N
difficult JJ N
as IN N
it PRP N
involves VBZ N
social JJ N
and CC N
communicative JJ N
areas NNS N
, , N
which WDT N
are VBP N
challenging VBG N
for IN N
this DT N
population NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
two CD N
intervention NN N
conditions NNS N
, , N
a DT i
naturalistic JJ i
approach NN i
, , i
Pivotal NNP i
Response NNP i
Treatment NNP i
( ( i
PRT NNP i
) ) i
with IN i
an DT i
adult-directed JJ i
ABA NNP i
approach NN i
on IN i
disruptive JJ o
behavior NN o
during IN i
language NN i
intervention NN i
in IN N
the DT N
public JJ N
schools NNS N
. . N

A DT N
randomized JJ N
clinical JJ N
trial NN N
design NN N
was VBD N
used VBN N
with IN N
two CD p
groups NNS p
of IN p
children NNS p
, , p
matched VBD p
according VBG p
to TO p
age NN p
, , p
sex NN p
and CC p
mean JJ p
length NN p
of IN p
utterance NN p
. . p

The DT N
data NN N
showed VBD N
that IN N
the DT N
children NNS N
demonstrated VBD N
significantly RB N
lower JJR N
levels NNS N
of IN N
disruptive JJ o
behavior NN o
during IN N
the DT N
PRT NNP N
condition NN N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
with IN N
respect NN N
to TO N
antecedent VB N
manipulations NNS N
that WDT N
may MD N
be VB N
helpful JJ N
in IN N
reducing VBG N
disruptive JJ o
behavior NN o
. . o

-DOCSTART- -X- O O

Metformin NNP i
does VBZ N
not RB N
enhance VB N
ovulation NN N
induction NN N
in IN N
clomiphene NN p
resistant JJ p
polycystic JJ p
ovary JJ p
syndrome NN p
in IN N
clinical JJ N
practice NN N
. . N

AIMS NNP N
To TO N
determine VB N
whether IN N
metformin NN i
pretreatment NN i
has VBZ N
beneficial JJ o
effects NNS o
in IN N
clomiphene NN p
resistant JJ p
infertile JJ p
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
in IN p
an DT p
infertility NN p
clinic NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
placebo NN N
controlled VBD N
double-blind NN N
crossover NN N
study NN N
of IN N
3 CD N
months NNS N
metformin RB i
( ( N
1500 CD N
mg IN N
day-1 NN i
) ) i
/placebo NN i
, , N
followed VBN N
by IN N
3 CD N
months NNS N
metformin/placebo VBN i
together RB i
with IN i
clomiphene NN i
( ( N
50-100 JJ N
mg NN N
for IN N
5 CD N
days NNS N
) ) N
for IN N
three CD N
cycles NNS N
in IN N
clomiphene NN p
resistant JJ p
women NNS p
with IN p
PCOS NNP p
. . p

The DT N
primary JJ N
outcomes NNS N
were VBD N
restoration NN o
of IN o
spontaneous JJ o
menses NNS o
, , o
ovulation NN o
induction NN o
( ( o
spontaneous JJ o
or CC o
clomiphene NN o
induced VBN o
) ) o
and CC o
pregnancy NN o
. . o

Secondary JJ o
endpoints NNS o
were VBD N
changes NNS N
in IN N
biochemical JJ N
parameters NNS N
related VBN N
to TO N
androgens NNS N
and CC N
insulin NN N
. . N

RESULTS NNP N
Twelve NNP p
women NNS p
completed VBD p
the DT p
metformin NN i
arm NN p
and CC p
14 CD p
the DT p
placebo NN i
arm NN p
. . p

Spontaneous JJ o
menstruation NN o
resumed VBD N
in IN N
five CD N
metformin NNS i
treated VBD N
patients NNS N
and CC N
in IN N
six CD N
placebo NN i
treated VBN N
women NNS N
, , N
P=0.63 NNP N
. . N

No NNP N
women NNS N
given VBN N
metformin NNS N
spontaneously RB o
ovulated VBD o
, , N
although IN N
one CD N
patient NN N
given VBN N
placebo NN i
did VBD N
, , N
P=0.30 NNP N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
efficacy NN o
of IN o
clomiphene NN o
between IN N
the DT N
two CD N
groups NNS N
with IN N
ovulation NN o
being VBG o
induced VBN o
in IN N
five CD N
( ( N
out IN N
of IN N
12 CD N
) ) N
metformin NN i
treated VBN N
women NNS N
and CC N
four CD N
( ( N
out IN N
of IN N
14 CD N
) ) N
placebo NN i
treated VBN N
women NNS N
, , N
P=0.63 NNP N
. . N

Pregnancy NN o
occurred VBD N
in IN N
three CD N
( ( N
out IN N
of IN N
12 CD N
) ) N
women NNS N
given VBN N
metformin NNS i
and CC N
two CD N
( ( N
out IN N
of IN N
14 CD N
) ) N
women NNS N
given VBN N
placebo NNS i
, , N
P=0.59 NNP N
. . N

CONCLUSIONS NNP N
Metformin NNP i
is VBZ N
not RB N
always RB N
beneficial JJ N
when WRB N
given VBN N
to TO N
clomiphene VB p
resistant JJ p
infertile JJ p
women NNS p
with IN p
PCOS NNP p
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
music NN i
therapy NN i
group NN i
intervention NN i
on IN N
enhancing VBG N
social JJ o
skills NNS o
in IN N
children NNS p
with IN p
autism NN p
. . p

BACKGROUND NNP N
Research NNP N
indicates VBZ N
that IN N
music NN i
therapy NN i
can MD N
improve VB N
social JJ N
behaviors NNS N
and CC N
joint JJ N
attention NN N
in IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
( ( p
ASD NNP p
) ) p
; : p
however RB N
, , N
more JJR N
research NN N
on IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
interventions NNS N
for IN N
social JJ o
skills NNS o
is VBZ N
needed VBN N
to TO N
determine VB N
the DT N
impact NN N
of IN N
group NN N
music NN N
therapy NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
a DT N
music NN i
therapy NN i
group NN N
intervention NN N
on IN N
eye NN o
gaze NN o
, , o
joint JJ o
attention NN o
, , o
and CC o
communication NN o
in IN N
children NNS p
with IN p
ASD NNP p
. . p

METHOD NNP N
Seventeen NNP p
children NNS p
, , p
ages VBZ p
6 CD p
to TO p
9 CD p
, , p
with IN p
a DT p
diagnosis NN p
of IN p
ASD NNP p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
music NN i
therapy NN i
group NN i
( ( i
MTG NNP i
) ) i
or CC p
the DT p
no-music JJ i
social JJ i
skills NNS i
group NN i
( ( i
SSG NNP i
) ) i
. . i

Children NNP N
participated VBD N
in IN N
ten JJ N
50-minute JJ N
group NN N
sessions NNS N
over IN N
a DT N
period NN N
of IN N
5 CD N
weeks NNS N
. . N

All DT N
group NN N
sessions NNS N
were VBD N
designed VBN N
to TO N
target VB N
social JJ N
skills NNS N
. . N

The DT N
Social NNP o
Responsiveness NNP o
Scale NNP o
( ( o
SRS NNP o
) ) o
, , o
the DT o
Autism NNP o
Treatment NNP o
Evaluation NNP o
Checklist NNP o
( ( o
ATEC NNP o
) ) o
, , o
and CC o
video JJ o
analysis NN o
of IN o
sessions NNS o
were VBD N
used VBN N
to TO N
evaluate VB N
changes NNS N
in IN N
social JJ N
behavior NN N
. . N

RESULTS CC N
There EX N
were VBD N
significant JJ N
between-group JJ N
differences NNS N
for IN N
joint JJ o
attention NN o
with IN o
peers NNS o
and CC o
eye NN o
gaze NN o
towards NNS o
persons NNS o
, , N
with IN N
participants NNS N
in IN N
the DT N
MTG NNP N
demonstrating NN N
greater JJR N
gains NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
between-group NN N
differences NNS N
for IN N
initiation NN o
of IN o
communication NN o
, , o
response NN o
to TO o
communication NN o
, , o
or CC o
social JJ o
withdraw/behaviors NNS o
. . o

There EX N
was VBD N
a DT N
significant JJ N
interaction NN N
between IN N
time NN N
and CC N
group NN N
for IN N
SRS NNP o
scores NNS o
, , N
with IN N
improvements NNS N
for IN N
the DT N
MTG NNP N
but CC N
not RB N
the DT N
SSG NNP N
. . N

Scores NNS o
on IN o
the DT o
ATEC NNP o
did VBD N
not RB N
differ VB N
over IN N
time NN N
between IN N
the DT N
MTG NNP i
and CC N
SSG NNP N
. . N

CONCLUSIONS NNP N
The DT N
results NNS N
of IN N
this DT N
study NN N
support VB N
further JJ N
research NN N
on IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
group NN N
interventions NNS N
for IN N
social JJ o
skills NNS o
in IN N
children NNS p
with IN p
ASD NNP p
. . p

Statistical JJ N
results NNS N
demonstrate VBP N
initial JJ N
support NN N
for IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
social JJ N
groups NNS N
to TO N
develop VB N
joint JJ o
attention NN o
. . o

-DOCSTART- -X- O O

Personalized VBN N
smoking NN N
cessation NN N
: : N
interactions NNS N
between IN N
nicotine NN N
dose NN N
, , N
dependence NN N
and CC N
quit-success JJ N
genotype NN N
score NN N
. . N

Improving NNP N
and CC N
targeting VBG N
nicotine JJ i
replacement NN i
therapy NN i
( ( i
NRT NNP i
) ) i
are VBP N
cost-effective JJ N
strategies NNS N
for IN N
reducing VBG N
adverse JJ N
health NN N
consequences NNS N
for IN N
smokers NNS p
. . p

Treatment NNP N
studies NNS N
document VBP N
the DT N
efficacy NN N
of IN N
precessation NN N
NRT NNP i
and CC N
support NN N
important JJ N
roles NNS N
for IN N
level NN N
of IN N
nicotine JJ N
dependence NN N
and CC N
precessation NN N
smoking NN N
reduction NN N
in IN N
successful JJ N
quitting NN N
. . N

However RB N
, , N
prior JJ N
work NN N
has VBZ N
not RB N
identified VBN N
the DT N
optimal JJ N
precessation NN N
dose NN N
or CC N
means NNS N
for IN N
personalizing VBG N
NRT NNP i
. . i

Genome-wide NNP N
association NN N
has VBZ N
identified VBN N
groups NNS N
of IN N
genomic JJ N
markers NNS N
associated VBN N
with IN N
successful JJ N
quitting NN N
, , N
allowing VBG N
us PRP N
to TO N
develop VB N
a DT N
v1.0 JJ N
quit-success JJ N
genotype NN N
score NN N
. . N

We PRP N
now RB N
report VBP N
influences NNS N
of IN N
v1.0 JJ o
quit-success JJ o
genotype NN o
score NN o
, , o
level NN o
of IN o
dependence NN o
and CC o
precessation NN o
smoking NN o
reduction NN o
in IN N
a DT N
smoking NN N
cessation NN N
trial NN N
that WDT N
examined VBD N
effects NNS N
of IN N
21 CD N
versus NN N
42 CD N
mg/24 NN N
h NN N
precessation NN N
NRT NNP i
. . i

Four CD p
hundred VBD p
seventy-nine JJ p
smokers NNS p
were VBD N
randomized VBN N
to TO N
21 CD N
or CC N
42 CD N
mg NN N
NRT NNP i
, , N
initiated VBD N
2 CD N
wks NN N
prior RB N
to TO N
target VB N
quit NN N
dates NNS N
. . N

We PRP N
monitored VBD N
self-reported JJ o
abstinence NN o
and CC o
end-expired JJ o
air NN o
carbon NN o
monoxide NN o
( ( o
CO NNP o
) ) o
. . o

Genotyping VBG p
used VBN p
Affymetrix NNP o
arrays NNS o
( ( p
Santa NNP p
Clara NNP p
, , p
CA NNP p
, , p
USA NNP p
) ) p
. . p

The DT N
primary JJ N
outcome NN N
was VBD N
10-wk JJ o
continuous JJ o
smoking NN o
abstinence NN o
. . o

NRT NNP o
dose NN o
, , o
level NN o
of IN o
nicotine JJ o
dependence NN o
and CC o
genotype NN o
scores NNS o
displayed VBD N
significant JJ o
interactive JJ o
effects NNS o
on IN N
successful JJ N
quitting NN N
. . N

Successful JJ o
abstinence NN o
also RB N
was VBD N
predicted VBN N
by IN N
CO NNP o
reductions NNS o
during IN N
precessation NN N
NRT NNP i
. . i

These DT N
results NNS N
document VBP N
ways NNS N
in IN N
which WDT N
smoking VBG N
cessation NN N
strategies NNS N
can MD N
be VB N
personalized VBN N
based VBN N
on IN N
levels NNS o
of IN o
nicotine JJ o
dependence NN o
, , o
genotype NN o
scores NNS o
and CC o
CO NNP o
monitoring NN o
. . o

These DT N
assessments NNS N
, , N
taken VBN N
together RB N
, , N
can MD N
help VB N
match VB N
most JJS N
smokers NNS p
with IN N
optimal JJ N
NRT NNP i
doses NNS N
and CC N
help VB N
rapidly RB N
identify VB N
some DT N
who WP N
may MD N
be VB N
better RB N
treated VBN N
using VBG N
other JJ N
methods NNS N
. . N

-DOCSTART- -X- O O

[ IN N
The DT N
comparison NN N
of IN N
the DT N
effect NN N
of IN N
enalapril NN i
and CC i
indapamide NN i
on IN N
the DT N
peripheral JJ o
blood NN o
pressure NN o
and CC o
central JJ o
blood NN o
pressure NN o
through IN N
pulse JJ N
wave NN N
analysis NN N
] NNP N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS o
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitor NN i
enalapril NN i
and CC i
diuretic JJ i
indapamide NN i
on IN N
the DT N
peripheral JJ o
blood NN o
pressure NN o
and CC o
the DT o
central JJ o
blood NN o
pressure NN o
in IN N
Chinese JJ p
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
double JJ N
blind NN N
, , N
randomized VBN N
study NN N
. . N

Informed VBN N
consent NN N
were VBD N
given VBN N
by IN N
all DT N
patients NNS N
. . N

After IN N
2 CD N
weeks NNS N
of IN N
placebo JJ i
run-in JJ N
period NN N
, , N
105 CD p
patients NNS p
with IN p
mild JJ p
or CC p
moderate JJ p
essential JJ p
hypertension NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
enalapril NN i
( ( N
10 CD N
mg NNS N
per IN N
day NN N
) ) N
or CC i
indapamide NN i
( ( N
2.5 CD N
mg NNS N
per IN N
day NN N
) ) N
for IN N
8 CD N
weeks NNS N
. . N

Radial JJ N
pulse JJ N
wave NN N
recordings NNS N
were VBD N
performed VBN N
in IN N
all PDT N
the DT N
patients NNS N
before IN N
the DT N
active JJ N
treatments NNS N
were VBD N
given VBN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

Only RB p
those DT p
patients NNS p
who WP p
have VBP p
finished VBN p
8 CD p
weeks NNS p
of IN p
active JJ p
treatment NN p
in IN p
both DT p
groups NNS p
were VBD p
included VBN p
into IN p
the DT p
final JJ p
analysis NN p
. . p

RESULTS NNP N
One CD p
hundred VBD p
one CD p
patients NNS p
( ( p
51 CD p
in IN p
enalapril NN i
group NN p
and CC p
50 CD p
in IN p
indapamide JJ i
group NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

No DT N
significant JJ N
difference NN N
( ( N
all DT N
P NNP N
values NNS N
> VBP N
0.05 CD N
) ) N
was VBD N
found VBN N
in IN N
baseline NN N
data NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

After IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
, , N
all PDT N
the DT N
parameters NNS o
of IN o
pulse JJ o
wave NN o
( ( N
except IN N
heart NN N
rates NNS N
in IN N
both DT N
groups NNS N
and CC N
augmentation NN N
index NN N
in IN N
indapamide JJ i
group NN N
) ) N
decreased VBD N
significantly RB N
. . N

Comparison NNP N
of IN N
the DT N
2 CD N
groups NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
( ( N
all DT N
P NNP N
values NNS N
> VBP N
0.05 CD N
) ) N
in IN N
all PDT N
the DT N
parameters NNS N
of IN N
pulse JJ N
wave NN N
except IN N
that IN N
the DT N
central JJ o
systolic JJ o
blood NN o
pressure NN o
, , o
augmentation NN o
and CC o
augmentation NN o
index NN o
were VBD N
significantly RB N
lower JJR N
in IN N
enalapril NN i
group NN N
than IN N
in IN N
indapamide JJ i
group NN N
. . N

In IN N
enalapril JJ i
group NN N
, , N
the DT N
reduced JJ N
values NNS N
of IN N
systolic JJ o
blood NN o
pressure NN o
and CC o
pulse JJ o
pressure NN o
in IN o
central JJ o
aorta NNS o
were VBD N
significantly RB N
larger JJR N
than IN N
those DT N
in IN N
brachial JJ N
artery NN N
. . N

However RB N
, , N
the DT N
difference NN o
was VBD N
not RB N
observed VBN N
in IN N
indapamide JJ i
group NN N
. . N

CONCLUSIONS NNP N
Enalapril NNP i
and CC i
indapamide NN i
are VBP N
both DT N
similarly RB N
effective JJ N
in IN N
reducing VBG N
peripheral JJ o
arterial JJ o
blood NN o
pressure NN o
. . o

Moreover RB N
, , N
enalapril NN i
is VBZ N
more RBR N
effective JJ N
in IN N
reducing VBG N
central JJ o
systolic JJ o
pressure NN o
and CC o
augmentation NN o
index NN o
than IN N
indapamide NN i
. . i

The DT N
difference NN N
is VBZ N
probably RB N
due JJ N
to TO N
the DT N
reduction NN N
of IN N
wave NN o
reflection NN o
caused VBN N
by IN N
enalapril NN i
. . i

-DOCSTART- -X- O O

Effect NN N
of IN N
nitric-oxide-generating JJ i
system NN i
on IN N
microcirculatory NN o
blood NN o
flow NN o
in IN N
skin NN N
of IN N
patients NNS p
with IN p
severe JJ p
Raynaud NNP p
's POS p
syndrome NN p
: : p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Patients NNPS p
with IN p
Raynaud NNP p
's POS p
syndrome NN p
have VBP N
abnormal JJ N
digital JJ N
vasoconstriction NN N
, , N
which WDT N
may MD N
be VB N
secondary JJ N
to TO N
impaired JJ N
synthesis NN N
of IN N
, , N
or CC N
impaired JJ N
sensitivity NN N
to TO N
, , N
nitric JJ N
oxide NN N
. . N

We PRP N
studied VBD N
the DT N
effect NN N
on IN N
microcirculation NN N
of IN N
a DT N
nitric-oxide-generating JJ i
system NN i
applied VBN N
topically RB N
to TO N
the DT N
finger NN N
and CC N
forearm NN N
of IN N
healthy JJ p
volunteers NNS p
and CC p
patients NNS p
with IN p
primary JJ p
Raynaud NNP p
's POS p
syndrome NN p
. . p

METHODS NNP N
We PRP N
did VBD N
a DT N
single-blind NN N
, , N
randomised VBN N
, , N
placebo NN N
controlled VBD N
, , N
cross-over NN N
study NN N
of IN N
the DT N
microcirculatory NN o
response NN o
to TO N
topical JJ N
application NN N
of IN N
a DT N
nitric-oxidegenerating JJ i
gel NN i
in IN N
20 CD p
patients NNS p
with IN p
severe JJ p
Raynaud NNP p
's POS p
syndrome NN p
, , p
and CC p
ten RB p
healthy JJ p
volunteers NNS p
. . p

We PRP i
prepared VBD i
the DT i
nitric-oxide-generating JJ i
system NN i
by IN i
mixing VBG i
a DT i
solution NN i
of IN i
KY NNP i
jelly RB i
and CC i
sodium JJ i
nitrite NN i
( ( i
5 CD i
% NN i
weight/volume NN i
) ) i
, , i
with IN i
a DT i
solution NN i
of IN i
KY NNP i
jelly RB i
and CC i
ascorbic JJ i
acid NN i
( ( i
5 CD i
% NN i
weight/volume NN i
) ) i
. . N

About IN i
0.5 CD i
mL NNS i
of IN i
each DT i
solution NN i
was VBD i
separately RB i
applied VBN i
to TO i
the DT i
skin NN i
of IN i
the DT i
forearm NN i
( ( i
3 CD i
cm2 NN i
) ) i
, , i
and CC i
then RB i
mixed JJ i
with IN i
a DT i
sterile JJ i
cotton NN i
bud NN i
. . i

A DT i
similar JJ i
procedure NN i
was VBD i
done VBN i
simultaneously RB i
on IN i
the DT i
other JJ i
arm NN i
with IN i
KY NNP i
jelly RB i
only RB i
( ( i
placebo NN i
) ) i
. . N

The DT N
procedure NN N
was VBD N
then RB N
repeated VBN N
on IN N
the DT N
finger NN N
pulps VBZ N
. . N

Changes NNS o
in IN o
skin JJ o
microcirculatory NN o
volume NN o
and CC o
flux NN o
were VBD N
measured VBN N
bilaterally RB N
by IN N
infrared JJ N
photoplethysmography NN N
and CC N
laser NN N
doppler NN N
fluxmetry NN N
, , N
respectively RB N
. . N

FINDINGS NNP N
In IN N
the DT N
forearm NN N
, , N
blood NN o
flow NN o
increased VBD N
significantly RB N
after IN N
application NN N
of IN N
the DT N
active JJ N
gel NN N
both DT N
in IN N
patients NNS N
with IN N
Raynaud NNP N
's POS N
syndrome NN N
( ( N
microcirculatory JJ N
volume NN N
from IN N
mean JJ N
area NN N
under IN N
the DT N
curve NN N
98 CD N
[ NNP N
SE NNP N
14 CD N
] NN N
to TO N
1024 CD N
[ NN N
130 CD N
] NN N
; : N
microcirculatory JJ N
flux NN N
from IN N
5060 CD N
[ $ N
462 CD N
] NN N
to TO N
74,800 CD N
[ NN N
3940 CD N
] NN N
) ) N
and CC N
in IN N
healthy JJ N
controls NNS N
( ( N
volume NN N
from IN N
85 CD N
[ $ N
19 CD N
] NN N
to TO N
1020 CD N
[ NN N
60 CD N
] NN N
; : N
flux NN N
from IN N
4420 CD N
[ $ N
435 CD N
] NN N
to TO N
84,500 CD N
[ NN N
7000 CD N
] NN N
) ) N
. . N

In IN N
the DT N
fingers NNS N
, , N
although IN N
baseline NN o
blood NN o
flow NN o
was VBD N
lower JJR N
in IN N
patients NNS N
than IN N
in IN N
controls NNS N
, , N
both DT N
groups NNS N
showed VBD N
increases NNS N
with IN N
application NN N
of IN N
active JJ N
gel NN N
( ( N
volume NN N
from IN N
1100 CD N
[ $ N
194 CD N
] NN N
to TO N
3280 CD N
[ NN N
672 CD N
] NN N
and CC N
2380 CD N
[ NN N
441 CD N
] NN N
to TO N
6160 CD N
[ NN N
1160 CD N
] NN N
, , N
respectively RB N
; : N
flux NN o
from IN N
33,400 CD N
[ JJ N
4200 CD N
] NN N
to TO N
108,000 CD N
[ NNS N
13,600 CD N
] NNS N
and CC N
52,000 CD N
[ NN N
8950 CD N
] NN N
to TO N
185,000 CD N
[ NNS N
19,500 CD N
] NN N
) ) N
. . N

Increases VBZ N
in IN N
blood NN o
flow NN o
with IN N
placebo JJ N
gel NNS N
were VBD N
not RB N
significant JJ N
. . N

No DT N
adverse JJ N
effects NNS N
were VBD N
reported VBN N
. . N

INTERPRETATION NNP N
In IN N
primary JJ p
Raynaud NNP p
's POS p
syndrome NN p
, , N
topical JJ N
application NN N
of IN N
a DT N
nitric-oxide-generating JJ i
system NN i
can MD N
stimulate VB N
an DT N
increase NN N
in IN N
both DT N
microcirculatory JJ o
volume NN o
and CC o
flux NN o
. . o

-DOCSTART- -X- O O

Chloroprocaine NNP i
and CC i
lidocaine JJ i
decrease NN N
hospital NN N
stay NN N
and CC N
admission NN N
rate NN N
after IN N
outpatient JJ p
epidural JJ p
anesthesia NN p
. . p

Lumbar NNP i
epidural JJ i
anesthesia NN i
with IN i
20 CD i
ml NN i
of IN i
either DT i
3 CD i
% NN i
2-chloroprocaine JJ i
( ( i
C NNP i
) ) i
, , i
1.5 CD i
% NN i
lidocaine NN i
( ( i
L NNP i
) ) i
, , i
or CC i
1.5 CD i
% NN i
mepivacaine NN i
( ( i
M NNP i
) ) i
with IN i
epinephrine NN i
was VBD N
studied VBN N
in IN N
84 CD p
outpatients NNS p
undergoing JJ p
surgery NN p
( ( p
extracorporeal JJ p
shock NN p
wave NN p
lithotripsy NN p
( ( p
ESWL NNP p
] NNP p
. . p

The DT N
average JJ o
duration NN o
of IN o
the DT o
procedure NN o
was VBD N
31.9 CD N
minutes NNS N
. . N

The DT N
total JJ o
duration NN o
of IN o
sensory JJ o
anesthesia NN o
was VBD N
133 CD N
+/- JJ N
28 CD N
minutes NNS N
( ( N
C NNP N
) ) N
, , N
182 CD N
+/- JJ N
38 CD N
( ( N
L NNP N
) ) N
, , N
and CC N
247 CD N
+/- JJ N
42 CD N
( ( N
M NNP N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Times NNS o
to TO o
discharge VB o
were VBD N
269 CD N
+/- JJ N
62 CD N
minutes NNS N
( ( N
C NNP N
) ) N
, , N
284 CD N
+/- JJ N
62 CD N
( ( N
L NNP N
) ) N
, , N
and CC N
357 CD N
+/- JJ N
71 CD N
( ( N
M NNP N
) ) N
. . N

The DT N
time NN o
to TO o
discharge VB o
with IN N
M NNP N
, , N
almost RB N
six CD N
hours NNS N
, , N
was VBD N
significantly RB N
longer JJR N
than IN N
with IN N
C NNP N
or CC N
L. NNP N
There EX N
was VBD N
a DT N
trend NN N
to TO N
an DT N
increasing VBG N
rate NN N
of IN N
unplanned JJ o
overnight JJ o
hospital NN o
admission NN o
with IN N
increasing VBG N
duration NN N
of IN N
the DT N
local JJ N
anesthetic JJ N
drug NN N
employed VBN N
. . N

Continuous JJ N
epidural JJ N
anesthesia NN N
with IN N
C NNP N
, , N
L NNP N
or CC N
M NNP N
appears VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
outpatient JJ N
surgical JJ N
procedures NNS N
such JJ N
as IN N
ESWL NNP N
. . N

In IN N
contrast NN N
to TO N
previous JJ N
understanding NN N
, , N
mepivacaine NN N
produces VBZ N
significantly RB N
longer JJR N
anesthesia NN N
and CC N
recovery NN N
times NNS N
and CC N
may MD N
not RB N
be VB N
optimal JJ N
for IN N
outpatient JJ N
epidural JJ N
use NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
sclerotherapy NN i
with IN N
staple JJ i
transection NN i
of IN i
the DT i
esophagus NN i
for IN N
the DT N
emergency NN N
control NN o
of IN o
bleeding VBG o
from IN p
esophageal JJ p
varices NNS p
. . p

We PRP N
compared VBN N
two CD N
procedures NNS N
for IN N
the DT N
emergency NN N
treatment NN N
of IN N
bleeding VBG o
esophageal JJ p
varices NNS p
in IN p
patients NNS p
who WP p
did VBD p
not RB p
respond VB p
to TO p
blood VB p
transfusion NN p
and CC p
vasoactive JJ p
drugs NNS p
. . p

We PRP N
randomly VBP N
assigned VBD N
101 CD p
patients NNS p
with IN p
cirrhosis NN p
of IN p
the DT p
liver NN p
and CC p
bleeding VBG p
esophageal JJ p
varices NNS p
to TO N
undergo VB i
either DT i
emergency NN i
sclerotherapy NN i
( ( i
n JJ i
= NNP i
50 CD i
) ) i
or CC i
staple JJ i
transection NN i
of IN i
the DT i
esophagus NN i
( ( i
n JJ i
= NNP i
51 CD i
) ) i
. . N

Four CD N
patients NNS N
assigned VBN N
to TO N
sclerotherapy VB i
and CC N
12 CD N
assigned VBN N
to TO N
staple VB N
transection NN N
did VBD N
not RB N
actually RB N
undergo VBP N
those DT N
procedures NNS N
, , N
but CC N
all DT N
analyses NNS N
were VBD N
made VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

Total JJ o
mortality NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
; : N
the DT N
relative JJ o
risk NN o
of IN o
death NN o
for IN N
staple JJ N
transection NN N
as IN N
compared VBN N
with IN N
sclerotherapy NN N
was VBD N
0.88 CD N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.51 CD N
to TO N
1.54 CD N
) ) N
. . N

Mortality NN o
at IN N
six CD N
weeks NNS N
was VBD N
44 CD N
percent NN N
among IN N
those DT N
assigned VBN N
to TO N
sclerotherapy VB i
and CC N
35 CD N
percent NN N
among IN N
those DT N
assigned VBN N
to TO N
staple VB N
transection NN N
. . N

Complication NN o
rates NNS o
were VBD N
similar JJ N
for IN N
the DT N
two CD N
groups NNS N
. . N

An DT N
interval NN o
of IN o
five CD o
days NNS o
without IN o
bleeding NN o
was VBD N
achieved VBN N
in IN N
88 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
staple VB N
transection NN N
and CC N
in IN N
62 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
sclerotherapy VB i
after IN N
a DT N
single JJ N
injection NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
82 CD N
percent NN N
after IN N
three CD N
injections NNS N
. . N

In IN N
only RB N
2 CD N
of IN N
the DT N
11 CD N
patients NNS N
who WP N
received VBD N
a DT N
third JJ N
sclerotherapy NN i
injection NN N
was VBD N
bleeding VBG o
controlled VBN o
for IN N
more JJR N
than IN N
five CD N
days NNS N
, , N
and CC N
9 CD N
died VBD N
. . N

We PRP N
conclude VBP N
that IN N
staple JJ N
transection NN N
of IN N
the DT N
esophagus NN N
is VBZ N
as RB o
safe JJ o
as IN o
sclerotherapy NN o
for IN N
the DT N
emergency NN o
treatment NN o
of IN o
bleeding VBG o
esophageal JJ N
varices NNS N
and CC N
that IN N
it PRP N
is VBZ N
more RBR N
effective JJ N
than IN N
a DT N
single JJ N
sclerotherapy NN i
procedure NN N
. . N

We PRP N
currently RB N
recommend VBP N
surgery NN N
after IN N
two CD N
injection NN N
treatments NNS N
have VBP N
failed VBN N
. . N

-DOCSTART- -X- O O

Monotherapy NNP N
of IN N
mild JJ p
hypertension NN o
with IN N
nifedipine NN i
. . i

The DT N
effectiveness NN o
of IN N
nifedipine JJ i
as IN N
first-line JJ N
monotherapy NN N
for IN N
mild JJ p
diastolic JJ o
hypertension NN o
( ( p
range NN p
: : p
95 CD p
to TO p
105 CD p
mm NNS p
Hg NNP p
) ) p
was VBD N
tested VBN N
in IN N
this DT N
placebo-controlled JJ i
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
. . N

Fifty-six JJ p
patients NNS p
were VBD p
enrolled VBN p
and CC N
, , N
after IN N
titration NN N
of IN N
the DT N
placebo NN i
or CC N
active JJ i
drug NN i
, , N
they PRP N
were VBD N
followed VBN N
for IN N
12 CD N
weeks NNS N
. . N

Significant JJ N
declines NNS N
in IN N
the DT N
sitting VBG N
systolic JJ o
and CC o
diastolic JJ o
pressures NNS o
of IN N
-19 JJ N
+/- JJ N
4 CD N
mm NN N
Hg NNP N
( ( N
standard JJ N
error NN N
) ) N
and CC N
-13 $ N
+/- JJ N
2 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
, , N
were VBD N
observed VBN N
during IN N
this DT N
follow-up JJ N
period NN N
. . N

Overall JJ N
, , N
75 CD N
percent NN N
of IN N
patients NNS N
receiving VBG N
active JJ i
drug NN i
had VBD N
diastolic JJ o
pressures NNS o
less RBR N
than IN N
or CC N
equal JJ N
to TO N
90 CD N
mm NNS N
Hg NNP N
at IN N
the DT N
last JJ N
treatment NN N
visit NN N
. . N

Heart NNP o
rate NN o
was VBD N
not RB N
significantly RB N
changed VBN N
in IN N
the DT N
sitting VBG N
position NN N
during IN N
the DT N
treatment NN N
period NN N
, , N
and CC N
the DT N
majority NN N
of IN N
patients NNS N
( ( N
75 CD N
percent NN N
) ) N
showed VBD N
a DT N
response NN N
to TO N
nifedipine JJ i
doses NNS N
of IN N
10 CD N
or CC N
20 CD N
mg NNS N
orally RB N
three CD N
times NNS N
daily RB N
in IN N
the DT N
capsule NN N
form NN N
. . N

The DT N
levels NNS N
of IN N
the DT N
systolic NN o
and CC o
diastolic JJ o
pressures NNS o
at IN N
entry NN N
were VBD N
not RB N
predictive JJ N
of IN N
the DT N
dose NN N
of IN N
nifedipine NN i
required VBN N
for IN N
effective JJ o
blood NN o
pressure NN o
control NN N
. . N

-DOCSTART- -X- O O

Commentary NNP N
on IN N
cytoreduction NN i
nephrectomy NN i
in IN p
metastatic JJ p
renal JJ p
cancer NN p
: : p
the DT N
results NNS N
of IN N
Southwest NNP p
Oncology NNP p
Group NNP p
Trial NNP p
8949 CD p
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
hyperinsulinaemia NN N
in IN N
polycystic JJ N
ovary JJ N
syndrome NN N
? . N
-DOCSTART- -X- O O

The DT N
clinical JJ N
effectiveness NN N
and CC N
cost-effectiveness NN N
of IN N
telephone NN i
triage NN i
for IN N
managing VBG N
same-day JJ N
consultation NN N
requests NNS N
in IN N
general JJ N
practice NN N
: : N
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
comparing VBG N
general JJ i
practitioner-led JJ i
and CC i
nurse-led JJ i
management NN i
systems NNS i
with IN N
usual JJ N
care NN N
( ( N
the DT N
ESTEEM NNP N
trial NN N
) ) N
. . N

BACKGROUND NNP N
Telephone NNP i
triage NN i
is VBZ N
proposed VBN N
as IN N
a DT N
method NN N
of IN N
managing VBG N
increasing VBG N
demand NN N
for IN N
primary JJ N
care NN N
. . N

Previous JJ N
studies NNS N
have VBP N
involved VBN N
small JJ N
samples NNS N
in IN N
limited JJ N
settings NNS N
, , N
and CC N
focused VBD N
on IN N
nurse JJ N
roles NNS N
. . N

Evidence NN N
is VBZ N
limited JJ N
regarding VBG N
the DT N
impact NN N
on IN N
primary JJ N
care NN N
workload NN N
, , N
costs NNS N
, , N
and CC N
patient JJ N
safety NN N
and CC N
experience NN N
when WRB N
triage NN i
is VBZ N
used VBN N
to TO N
manage VB N
patients NNS p
requesting VBG p
same-day JJ p
consultations NNS p
in IN p
general JJ p
practice NN p
. . p

OBJECTIVES NNP N
In IN N
comparison NN N
with IN N
usual JJ i
care NN i
( ( i
UC NNP i
) ) i
, , N
to TO N
assess VB N
the DT N
impact NN N
of IN N
GP-led NNP i
telephone NN i
triage NN i
( ( i
GPT NNP i
) ) i
and CC i
nurse-led JJ i
computer-supported JJ i
telephone NN i
triage NN i
( ( i
NT NNP i
) ) i
on IN N
primary JJ N
care NN N
workload NN N
and CC N
cost NN N
, , N
patient JJ N
experience NN N
of IN N
care NN N
, , N
and CC N
patient JJ N
safety NN N
and CC N
health NN N
status NN N
for IN N
patients NNS N
requesting VBG N
same-day JJ N
consultations NNS N
in IN N
general JJ N
practice NN N
. . N

DESIGN NNP N
Pragmatic NNP N
cluster NN N
randomised VBD N
controlled VBN N
trial NN N
, , N
incorporating VBG N
economic JJ N
evaluation NN N
and CC N
qualitative JJ N
process NN N
evaluation NN N
. . N

SETTING NNP N
General NNP p
practices NNS p
( ( p
n JJ p
= NNP p
42 CD p
) ) p
in IN p
four CD p
regions NNS p
of IN p
England NNP p
, , p
UK NNP p
( ( N
Devon NNP N
, , N
Bristol/Somerset NNP N
, , N
Warwickshire/Coventry NNP N
, , N
Norfolk/Suffolk NNP N
) ) N
. . N

PARTICIPANTS JJ p
Patients NNPS p
requesting VBG p
same-day JJ p
consultations NNS p
. . p

INTERVENTIONS NNP p
Practices NNPS N
were VBD N
randomised VBN i
to TO i
GPT NNP i
, , i
NT NNP i
or CC i
UC NNP i
. . i

Data NNP N
collection NN N
was VBD N
not RB N
blinded VBN N
; : N
however RB N
, , N
analysis NN N
was VBD N
conducted VBN N
by IN N
a DT N
statistician NN N
blinded VBD N
to TO N
practice NN N
allocation NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP o
- : o
primary JJ o
care NN o
contacts NNS o
[ NNP o
general JJ o
practice NN o
, , o
out-of-hours JJ o
primary NN o
care NN o
, , o
accident NN o
and CC o
emergency NN o
( ( o
A NNP o
& CC o
E NNP N
) ) N
and CC N
walk-in JJ N
centre NN N
attendances NNS N
] VBP N
in IN N
the DT N
28 CD N
days NNS N
following VBG N
the DT N
index NN N
consultation NN N
request NN N
. . N

Secondary JJ o
- : o
resource NN o
use NN o
and CC o
costs NNS o
, , o
patient JJ o
safety NN o
( ( o
deaths NNS o
and CC o
emergency NN o
hospital NN o
admissions NNS o
within IN o
7 CD N
days NNS N
of IN N
index NN N
request NN N
, , N
and CC N
A NNP N
& CC N
E NNP N
attendance NN N
within IN N
28 CD N
days NNS N
) ) N
, , N
health NN N
status NN N
and CC N
experience NN N
of IN N
care NN N
. . N

RESULTS NNP p
Of IN p
20,990 CD p
eligible JJ p
randomised VBN p
patients NNS p
( ( p
UC NNP p
n RB p
= JJ p
7283 CD p
; : p
GPT NNP p
n IN p
= JJ p
6695 CD p
; : p
NT NNP p
n IN p
= NNP p
7012 CD p
) ) p
, , p
primary JJ p
outcome NN p
data NNS p
were VBD p
analysed VBN p
for IN p
16,211 CD p
patients NNS p
( ( N
UC NNP N
n RB N
= JJ N
5572 CD N
; : N
GPT NNP N
n IN N
= JJ N
5171 CD N
; : N
NT NNP N
n IN N
= NNP N
5468 CD N
) ) N
. . N

Compared VBN N
with IN N
UC NNP N
, , N
GPT NNP N
and CC N
NT NNP N
increased VBD o
primary JJ o
outcome NN o
contacts NNS o
( ( o
over IN o
28-day JJ N
follow-up NN N
) ) N
by IN N
33 CD N
% NN N
[ JJ N
rate NN N
ratio NN N
( ( N
RR NNP N
) ) N
1.33 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
1.30 CD N
to TO N
1.36 CD N
] NNS N
and CC N
48 CD N
% NN N
( ( N
RR NNP N
1.48 CD N
, , N
95 CD N
% NN N
CI NNP N
1.44 CD N
to TO N
1.52 CD N
) ) N
, , N
respectively RB N
. . N

Compared VBN N
with IN N
GPT NNP N
, , N
NT NNP N
was VBD N
associated VBN N
with IN N
a DT N
marginal JJ N
increase NN N
in IN N
primary JJ o
outcome NN o
contacts NNS o
by IN N
4 CD N
% NN N
( ( N
RR NNP N
1.04 CD N
, , N
95 CD N
% NN N
CI NNP N
1.01 CD N
to TO N
1.08 CD N
) ) N
. . N

Triage NN N
was VBD N
associated VBN N
with IN N
a DT N
redistribution NN N
of IN N
primary JJ N
care NN N
contacts NNS N
. . N

Although IN N
GPT NNP N
, , N
compared VBN N
with IN N
UC NNP N
, , N
increased VBD N
the DT o
rate NN o
of IN o
overall JJ o
GP NNP o
contacts NNS o
( ( N
face NN N
to TO N
face NN N
and CC N
telephone NN N
) ) N
over IN N
the DT N
28 CD N
days NNS N
by IN N
38 CD N
% NN N
( ( N
RR NNP N
1.38 CD N
, , N
95 CD N
% NN N
CI NNP N
1.28 CD N
to TO N
1.50 CD N
) ) N
, , N
GP NNP N
face-to-face NN N
contacts NNS N
were VBD N
reduced VBN N
by IN N
39 CD N
% NN N
( ( N
RR NNP N
0.61 CD N
, , N
95 CD N
% NN N
CI NNP N
0.54 CD N
to TO N
0.69 CD N
) ) N
. . N

NT NNP N
reduced VBD N
the DT N
rate NN N
of IN o
overall JJ o
GP NNP o
contacts NNS o
by IN N
16 CD N
% NN N
( ( N
RR NNP N
0.84 CD N
, , N
95 CD N
% NN N
CI NNP N
0.78 CD N
to TO N
0.91 CD N
) ) N
and CC N
GP NNP N
face-to-face NN N
contacts NNS N
by IN N
20 CD N
% NN N
( ( N
RR NNP N
0.80 CD N
, , N
95 CD N
% NN N
CI NNP N
0.71 CD N
to TO N
0.90 CD N
) ) N
, , N
whereas JJ N
nurse JJ N
contacts NNS N
increased VBN N
. . N

The DT N
increased JJ o
rate NN o
of IN o
primary JJ o
care NN o
contacts NNS o
in IN o
triage NN N
arms NNS N
is VBZ N
largely RB N
attributable JJ N
to TO N
increased VB N
telephone NN N
contacts NNS N
. . o

Estimated VBN o
overall JJ o
patient-clinician JJ o
contact NN o
time NN o
on IN o
the DT o
index NN o
day NN o
increased VBD o
in IN N
triage NN N
( ( N
GPT NNP N
= VBZ N
10.3 CD N
minutes NNS N
; : N
NT NNP N
= VBD N
14.8 CD N
minutes NNS N
; : N
UC NNP N
= VBD N
9.6 CD N
minutes NNS N
) ) N
, , N
although IN N
patterns NNS N
of IN N
clinician JJ N
use NN N
varied VBD N
between IN N
arms NNS N
. . N

Taking VBG N
account NN N
of IN N
both DT N
the DT N
pattern NN N
and CC N
duration NN N
of IN o
primary JJ o
outcome NN o
contacts NNS o
, , o
overall JJ o
costs NNS o
over IN N
the DT N
28-day JJ N
follow-up NN N
were VBD N
similar JJ N
in IN N
all DT N
three CD N
arms NNS N
( ( N
approximately RB N
?75 VBN N
per IN N
patient NN N
) ) N
. . N

Triage NN N
appeared VBD o
safe JJ o
, , o
and CC N
no DT N
differences NNS N
in IN N
patient JJ N
health NN N
status NN N
were VBD N
observed VBN N
. . N

NT NNP N
was VBD N
somewhat RB N
less RBR N
acceptable JJ N
to TO N
patients NNS N
than IN N
GPT NNP i
or CC i
UC NNP i
. . i

The DT i
process NN N
evaluation NN N
identified VBD N
the DT N
complexity NN N
associated VBN N
with IN N
introducing JJ N
triage NN N
but CC N
found VBD N
no DT N
consistency NN N
across IN N
practices NNS N
about IN N
what WP N
works VBZ N
and CC N
what WP N
does VBZ N
not RB N
work VB N
when WRB N
implementing VBG N
it PRP N
. . N

CONCLUSIONS NNP N
Introducing NNP N
GPT NNP N
or CC N
NT NNP N
was VBD N
associated VBN N
with IN N
a DT N
redistribution NN N
of IN N
primary JJ N
care NN N
workload NN N
for IN N
patients NNS N
requesting VBG N
same-day JJ N
consultations NNS N
, , N
and CC N
at IN N
similar JJ N
cost NN N
to TO N
UC NNP N
. . N

Although IN N
triage NN N
seemed VBD N
to TO N
be VB N
safe JJ N
, , N
investigation NN N
of IN N
the DT N
circumstances NNS N
of IN N
a DT N
larger JJR N
number NN N
of IN N
deaths NNS N
or CC N
admissions NNS N
after IN N
triage NN N
might MD N
be VB N
warranted VBN N
, , N
and CC N
monitoring NN N
of IN N
these DT N
events NNS N
is VBZ N
necessary JJ N
as IN N
triage NN N
is VBZ N
implemented VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ISRCTN20687662 NNP N
. . N

FUNDING NN N
This DT N
project NN N
was VBD N
funded VBN N
by IN N
the DT N
NIHR NNP N
Health NNP N
Technology NNP N
Assessment NNP N
programme NN N
and CC N
will MD N
be VB N
published VBN N
in IN N
full JJ N
in IN N
Health NNP N
Technology NNP N
Assessment NNP N
; : N
Vol NNP N
. . N

19 CD N
, , N
No NNP N
. . N

13 CD N
. . N

See VB N
the DT N
NIHR NNP N
Journals NNP N
Library NNP N
website NN N
for IN N
further JJ N
project NN N
information NN N
. . N

-DOCSTART- -X- O O

Galantamine NN i
may MD N
be VB N
effective JJ N
in IN N
treating VBG N
autistic JJ p
disorder NN p
. . p

-DOCSTART- -X- O O

Metformin NNP i
therapy NN i
improves VBZ N
ovulatory JJ o
rates NNS o
, , o
cervical JJ o
scores NNS o
, , o
and CC o
pregnancy NN o
rates NNS o
in IN N
clomiphene JJ p
citrate-resistant JJ p
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
metformin NN i
therapy NN i
on IN N
hyperandrogenism NN N
, , N
insulin NN N
resistance NN N
, , N
cervical JJ N
scores NNS N
, , N
ovulation NN N
, , N
and CC N
pregnancy NN N
rates NNS N
in IN N
clomiphene JJ p
citrate-resistant JJ p
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

SETTING NNP N
Infertility NNP p
clinic NN p
of IN p
a DT p
tertiary JJ p
referral NN p
center NN p
. . p

PATIENT NNP N
( ( N
S NNP N
) ) N
Fifty-six NNP p
women NNS p
with IN p
clomiphene JJ p
citrate-resistant JJ p
PCOS NNP p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Two CD N
cycles NNS N
of IN N
oral JJ i
metformin NN i
therapy NN i
( ( N
850 CD N
mg NN N
, , N
twice RB N
daily RB N
) ) N
in IN N
group NN N
I PRP N
and CC N
placebo VB i
therapy NN i
( ( N
twice JJ N
daily RB N
) ) N
in IN N
group NN N
II NNP N
. . N

Clomiphene NNP i
citrate NN i
( ( N
100 CD N
mg/day NN N
) ) N
on IN N
cycle NN N
days NNS N
3-7 CD N
of IN N
the DT N
second JJ N
cycle NN N
in IN N
both DT N
groups NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Insulin NNP o
, , o
T NNP o
, , o
DHEAS NNP o
, , o
FSH NNP o
, , o
LH NNP o
, , o
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
, , o
waist-to-hip JJ o
ratio NN o
, , o
endometrial JJ o
thickness NN o
, , o
cervical JJ o
score NN o
, , o
ovulation NN o
, , o
and CC o
pregnancy NN o
rates NNS o
in IN N
clomiphene-induced JJ N
cycles NNS N
after IN N
metformin JJ i
therapy NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Metformin NNP i
therapy NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
total JJ o
T NNP o
, , o
LH NNP o
level NN o
, , o
LH/FSH NNP o
ratio NN o
, , o
insulin NN o
resistance NN o
, , o
and CC o
mean JJ o
BMI NNP o
. . o

No DT N
difference NN N
in IN N
waist-to-hip JJ o
ratio NN o
, , o
DHEAS NNP o
level NN o
, , o
and CC o
fasting VBG o
insulin JJ o
level NN o
was VBD N
observed VBN N
. . N

Clomiphene NNP N
citrate JJ N
induction NN N
resulted VBD N
in IN N
higher JJR N
ovulation NN o
rates NNS o
and CC o
thicker NN o
endometrium NN o
in IN N
the DT N
metformin NN i
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
. . N

There EX N
was VBD N
higher JJR N
cumulative JJ o
pregnancy NN o
rate NN o
in IN N
the DT N
metformin NN N
group NN N
; : N
however RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
pregnancy NN o
rate NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Metformin NNP i
therapy NN N
not RB N
only RB N
decreases VBZ N
hyperandrogenism NN o
and CC o
insulin NN o
resistance NN o
but CC N
also RB N
improves VBZ N
ovulation NN o
rates NNS o
, , o
cervical JJ o
scores NNS o
, , o
and CC o
pregnancy NN o
rates NNS o
in IN N
clomiphene JJ p
citrate-resistant JJ p
women NNS p
with IN p
PCOS NNP p
. . p

-DOCSTART- -X- O O

Esmolol NNP i
blunts VBZ N
the DT N
cerebral JJ o
blood NN o
flow NN o
velocity NN o
increase NN o
during IN N
emergence NN N
from IN N
anesthesia NN N
in IN N
neurosurgical JJ p
patients NNS p
. . p

UNLABELLED JJ N
Cerebral NNP o
hyperemia NN o
has VBZ N
been VBN N
demonstrated VBN N
during IN N
emergence NN N
from IN N
anesthesia NN N
in IN N
neurosurgical JJ p
patients NNS p
, , N
but CC N
its PRP$ N
mechanism NN N
is VBZ N
speculative JJ N
. . N

We PRP N
performed VBD N
this DT N
study NN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
this DT N
could MD N
be VB N
attributed VBN N
to TO N
sympathetic JJ N
overactivity NN N
. . N

Thirty NNP p
neurosurgical JJ p
patients NNS p
were VBD N
included VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blinded JJ N
study NN N
comparing VBG N
esmolol NN i
, , N
a DT N
short-acting JJ N
beta-blocker NN N
, , N
and CC N
a DT N
placebo NN i
. . i

Esmolol NNP i
( ( N
0.3 CD N
mg. NN N
kg NN N
( ( N
-1 NNP N
) ) N
. . N

min NN N
( ( N
-1 NNP N
) ) N
) ) N
was VBD N
infused VBN N
from IN N
the DT N
end NN N
of IN N
anesthesia NN i
to TO N
15 CD N
min NNS N
after IN N
extubation NN i
. . i

Cerebral JJ o
blood NN o
flow NN o
velocity NN o
( ( o
CBFV NNP o
) ) o
, , o
mean JJ o
arterial JJ o
blood NN o
pressure NN o
, , o
and CC o
heart NN o
rate NN o
were VBD N
recorded VBN N
before IN N
anesthesia NN N
, , N
during IN N
anesthesia NN N
after IN N
surgery NN N
, , N
at IN N
extubation NN N
, , N
and CC N
5-60 JJ N
min NN N
after IN N
extubation NN N
. . N

Cardiac NNP o
output NN o
( ( o
COe NNP o
) ) o
was VBD N
estimated VBN N
by IN N
using VBG N
an DT N
esophageal JJ N
Doppler NN N
from IN N
anesthesia NN N
to TO N
60 CD N
min NNS N
after IN N
extubation NN N
. . N

CBFV NNP o
, , o
COe NNP o
, , o
and CC o
heart NN o
rate NN o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
esmolol NN N
group NN N
. . N

Mean NNP o
arterial JJ o
blood NN o
pressure NN o
was VBD N
comparable JJ N
between IN N
the DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
correlation NN N
between IN N
CBFV NNP o
and CC o
COe NNP o
at IN N
any DT N
time NN N
point NN N
during IN N
the DT N
study NN N
. . N

In IN N
conclusion NN N
, , N
esmolol RB N
blunted VBD N
the DT N
CBFV NNP o
increase NN o
during IN N
emergence NN N
, , N
confirming VBG N
that IN N
sympathetic JJ N
overactivity NN N
contributes NNS N
to TO N
cerebral JJ o
hyperemia NN o
during IN N
neurosurgical JJ N
recovery NN N
. . N

IMPLICATIONS NNP N
Esmolol NNP N
blunted VBD N
the DT N
postoperative JJ N
increase NN N
in IN N
cerebral JJ o
blood NN o
flow NN o
velocity NN o
in IN N
neurosurgical JJ p
patients NNS p
. . p

The DT N
origin NN N
of IN N
sympathetic JJ N
hyperactivity NN N
and CC N
its PRP$ N
potential JJ N
deleterious JJ N
consequences NNS N
require VBP N
further JJ N
study NN N
. . N

-DOCSTART- -X- O O

Physician-pharmacist JJ i
cooperation NN i
program NN i
for IN N
blood NN o
pressure NN o
control NN o
in IN N
patients NNS p
with IN p
hypertension NN p
: : p
a DT N
randomized-controlled JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
aim NN N
of IN N
the DT N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
program NN N
of IN N
cooperation NN i
between IN i
physician NN i
and CC i
pharmacist NN i
to TO N
reduce VB N
cardiovascular JJ p
risk NN p
factors NNS p
in IN p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
by IN N
promoting VBG N
better JJR N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
control NN N
, , N
appropriate JJ N
changes NNS N
in IN N
antihypertensive JJ N
medications NNS N
, , N
and CC N
beneficial JJ N
changes NNS N
in IN N
lifestyle NN N
. . N

METHODS NNP N
The DT p
132 CD p
subjects NNS p
in IN p
this DT p
randomized VBN p
, , p
controlled VBN p
trial NN p
were VBD p
in IN p
the DT p
age NN p
range NN p
of IN p
40-79 JJ p
years NNS p
. . p

The DT p
inclusion NN p
criteria NNS p
were VBD p
: : p
systolic JJ o
BP NNP o
( ( o
SBP NNP o
) ) o
ranging VBG p
from IN p
140-179 JJ p
mm NN p
Hg NNP p
and/or VBZ p
diastolic JJ o
BP NNP o
( ( o
DBP NNP o
) ) o
ranging VBG p
from IN p
90-99 CD p
mm NNS p
Hg NNP p
and CC p
treatment-naive JJ p
( ( p
untreated JJ p
for IN p
hypertension NN p
) ) p
; : p
or CC p
on IN p
a DT p
regimen NN p
of IN p
medication NN p
for IN p
hypertension NN p
. . p

Of IN p
these DT p
132 CD p
subjects NNS p
, , p
124 CD p
( ( p
94 CD p
% NN p
) ) p
were VBD p
already RB p
receiving VBG p
treatment NN p
with IN p
antihypertensive JJ p
medications NNS p
. . p

Equal JJ N
numbers NNS N
of IN N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
: : N
a DT N
physician-pharmacist JJ i
intervention NN i
group NN i
( ( N
n JJ N
= NNP N
66 CD N
) ) N
and CC N
a DT N
control NN i
group NN i
( ( N
n JJ N
= NNP N
66 CD N
) ) N
. . N

RESULTS VB N
The DT N
6-month JJ N
follow-up JJ N
rate NN N
was VBD N
97 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
mean JJ N
decrease NN N
in IN N
SBP/DBP NNP o
, , N
as IN N
measured VBN N
at IN N
home NN N
in IN N
the DT N
morning NN N
, , N
was VBD N
2.9/3.3 CD N
mm NN N
Hg NNP N
in IN N
the DT N
intervention NN N
group NN N
relative VBP N
to TO N
baseline VB N
( ( N
P NNP N
= NNP N
0.02 CD N
and CC N
P NNP N
< NNP N
0.0001 CD N
for IN N
SBP NNP N
and CC N
DBP NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
mean JJ N
decrease NN N
in IN N
home NN o
morning NN o
SBP NNP o
in IN N
the DT N
intervention NN N
group NN N
was VBD N
not RB N
significantly RB N
greater JJR N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
the DT N
DBP NNP o
decline NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
intervention NN N
than IN N
control NN N
groups NNS N
, , N
which WDT N
showed VBD N
a DT N
mean JJ N
decrease NN N
of IN N
2.8 CD N
mm NNS N
Hg NNP N
( ( N
confidence NN N
interval NN N
: : N
-5.5 NN N
to TO N
-0.1 VB N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
percentage NN N
of IN N
patients NNS N
in IN N
whom WP N
control NN N
of IN N
home NN o
morning NN o
BP NNP o
was VBD N
achieved VBN N
was VBD N
53 CD N
% NN N
in IN N
the DT N
intervention NN N
group NN N
and CC N
47 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.40 CD N
) ) N
. . N

A DT N
higher JJR N
percentage NN N
of IN N
patients NNS N
in IN N
the DT N
intervention NN N
group NN N
, , N
relative VBP N
to TO N
the DT N
control NN N
group NN N
, , N
were VBD N
able JJ N
to TO N
reduce VB N
the DT N
use NN o
of IN o
antihypertensive JJ o
medications NNS o
( ( N
31 CD N
vs. FW N
8 CD N
% NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
fewer JJR N
patients NNS N
in IN N
this DT N
group NN N
required VBD N
additional JJ o
medications NNS o
or CC N
increases NNS N
in IN N
dosage NN N
relative NN N
to TO N
the DT N
controls NNS N
( ( N
11 CD N
vs. FW N
28 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Patients NNS N
of IN N
the DT N
intervention NN N
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
show VB N
reduction NN N
in IN N
body NN o
mass NN o
index NN o
and CC o
sodium NN o
intake NN o
and CC o
to TO o
stop VB o
smoking NN o
, , N
as IN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS VB N
A DT N
program NN N
of IN N
cooperation NN N
between IN N
physician NN N
and CC N
pharmacist NN N
was VBD N
successful JJ N
in IN N
reducing VBG N
cardiovascular JJ N
risk NN N
factors NNS N
in IN N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
by IN N
promoting VBG N
better JJR N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
control NN N
, , N
appropriate JJ N
changes NNS N
in IN N
antihypertensive JJ N
medications NNS N
, , N
and CC N
beneficial JJ N
changes NNS N
in IN N
lifestyle NN N
. . N

-DOCSTART- -X- O O

The DT N
impact NN N
of IN N
emotional JJ i
distress NN i
on IN N
HIV NNP o
risk NN o
reduction NN o
among IN p
women NNS p
. . p

This DT N
study NN N
evaluated VBD N
whether IN N
333 CD p
seronegative JJ p
African JJ p
American JJ p
female JJ p
drug NN p
users NNS p
( ( p
aged VBN p
18-59 CD p
years NNS p
) ) p
participating VBG p
in IN p
an DT p
HIV NNP i
intervention NN i
and CC p
with IN p
higher JJR p
levels NNS p
of IN p
emotional JJ p
distress NN p
, , p
specifically RB p
symptoms NNS p
of IN p
depression NN p
and CC p
anxiety NN p
, , N
reduced VBD N
HIV NNP N
risk NN N
behaviors NNS N
to TO N
a DT N
lesser JJR N
extent NN N
than IN N
those DT N
with IN N
lower JJR N
levels NNS N
of IN N
emotional JJ N
distress NN N
. . N

Participants NNS p
were VBD N
recruited VBN p
between IN p
June NNP p
1998 CD p
and CC p
January NNP p
2001 CD p
from IN p
inner-city NN p
Atlanta NNP p
( ( p
Georgia NNP p
, , p
U.S. NNP p
) ) p
neighborhoods NNS p
and CC N
were VBD N
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
two CD p
enhanced JJ i
gender-specific JJ i
and CC i
culturally RB i
specific JJ i
HIV NNP i
intervention NN i
conditions NNS p
or CC N
to TO N
the DT N
NIDA NNP N
standard JJ N
condition NN N
. . N

Participants NNS N
were VBD N
interviewed VBN N
at IN N
baseline NN N
, , N
post-intervention NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
with IN N
a DT N
structured JJ i
questionnaire NN i
including VBG N
information NN N
on IN N
sociodemographics NNS N
, , N
sexual JJ N
and CC N
drug-using JJ N
behavior NN N
, , N
and CC N
psychosocial JJ N
characteristics NNS N
. . N

Despite IN N
a DT N
significant JJ N
decline NN N
in IN N
symptoms NNS N
of IN N
emotional JJ N
distress NN N
during IN N
the DT N
study NN N
period NN N
, , N
the DT N
women NNS N
in IN N
this DT N
sample NN N
reported VBD N
high JJ N
levels NNS N
of IN N
depressive NN o
and CC o
anxiety NN o
symptoms NNS o
at IN N
baseline NN N
and CC N
6-month JJ N
follow-up NN N
. . N

Higher JJR o
levels NNS o
of IN o
emotional JJ o
distress NN o
were VBD N
positively RB N
associated VBN N
with IN N
post-intervention NN o
sexual JJ o
and CC o
drug-taking JJ o
risk NN o
. . o

Women NNS N
in IN N
both DT N
enhanced JJ i
intervention NN i
conditions NNS i
reduced VBD N
their PRP$ N
sexual JJ o
and CC o
drug-taking JJ o
risks NNS o
more RBR N
than IN N
women NNS N
in IN N
the DT N
standard JJ i
intervention NN i
. . i

Those DT N
in IN N
the DT N
motivation NN i
intervention NN i
arm NN N
experienced VBD N
a DT N
greater JJR N
reduction NN N
in IN N
depressive JJ o
symptoms NNS o
, , N
accompanied VBN N
by IN N
a DT N
greater JJR N
reduction NN N
in IN N
sexual JJ o
risk NN o
behavior NN o
. . o

Findings NNS N
suggest VBP N
the DT N
need NN N
for IN N
effective JJ N
interventions NNS N
and CC N
mental JJ N
health NN N
resources NNS N
among IN N
subgroups NNS N
of IN N
high-risk JJ p
women NNS p
who WP p
may MD p
be VB p
most RBS p
resistant JJ p
to TO p
behavioral JJ p
change NN p
. . p

-DOCSTART- -X- O O

Effects NNS N
of IN N
temafloxacin NN i
and CC N
ciprofloxacin NN i
on IN N
the DT N
pharmacokinetics NNS N
of IN N
caffeine NN N
. . N

A DT N
number NN N
of IN N
quinolone JJ N
antibacterial JJ N
agents NNS N
, , N
particularly RB N
enoxacin NN N
, , N
pefloxacin NN N
, , N
pipemidic JJ N
acid NN N
and CC N
ciprofloxacin NN i
, , N
are VBP N
known VBN N
to TO N
decrease VB N
the DT N
clearance NN N
of IN N
methylxanthines NNS N
. . N

The DT N
effects NNS N
of IN N
temafloxacin NN i
and CC i
ciprofloxacin NN i
on IN N
the DT N
pharmacokinetics NNS N
of IN N
caffeine NN N
were VBD N
therefore RB N
compared VBN N
in IN N
a DT N
3-way JJ N
crossover NN N
study NN N
in IN N
12 CD p
healthy JJ p
young JJ p
volunteers NNS p
. . p

Each DT N
volunteer NN N
received VBD N
183mg CD i
once-daily JJ i
doses NNS i
of IN i
caffeine NN i
in IN N
conjunction NN N
with IN N
twice-daily JJ N
placebo NN i
, , i
temafloxacin CC i
600mg CD i
and CC i
ciprofloxacin VB i
750mg CD i
in IN N
3 CD N
separate JJ N
phases NNS N
according VBG N
to TO N
a DT N
randomised JJ N
sequence NN N
. . N

A DT N
doubling NN N
of IN N
the DT N
area NN o
under IN o
the DT o
plasma JJ o
concentration-time JJ o
curve NN o
( ( N
77.8 CD N
vs RB N
31.8 CD N
mg/L.h NN N
) ) N
and CC N
terminal-phase JJ o
half-life NN o
( ( N
9.7 CD N
vs RB N
4.5h CD N
) ) N
of IN N
caffeine NN i
were VBD N
observed VBN N
in IN N
the DT N
presence NN N
of IN N
ciprofloxacin NN N
. . N

The DT N
magnitude NN o
of IN o
the DT o
reduction NN o
in IN o
the DT o
intrinsic JJ o
clearance NN o
of IN o
caffeine NN o
produced VBN N
by IN N
ciprofloxacin NN i
was VBD N
greater JJR N
than IN N
that DT N
described VBN N
in IN N
the DT N
literature NN N
for IN N
ciprofloxacin NN i
and CC i
theophylline NN i
. . i

This DT N
may MD N
partly RB N
be VB N
explained VBN N
by IN N
intertrial JJ N
differences NNS N
in IN N
dosage NN N
and CC N
study NN N
design NN N
. . N

Coadministration NN N
of IN N
temafloxacin NN i
did VBD N
not RB N
have VB N
any DT N
effect NN N
on IN N
the DT N
pharmacokinetics NNS o
of IN o
caffeine NN o
, , N
confirming VBG N
results NNS N
of IN N
other JJ N
studies NNS N
suggesting VBG N
that IN N
this DT N
agent NN N
does VBZ N
not RB N
affect VB N
methylxanthine JJ o
clearance NN o
. . o

Accordingly RB N
, , N
it PRP N
appears VBZ N
that IN N
restriction NN N
of IN N
caffeine JJ N
intake NN N
during IN N
temafloxacin JJ i
therapy NN N
is VBZ N
not RB N
necessary JJ N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
comparative JJ N
study NN N
of IN N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
artesunate JJ i
plus CC i
amodiaquine JJ i
, , N
administered VBN N
as IN N
a DT N
single JJ N
daily JJ N
intake VB N
versus JJ N
two CD N
daily JJ N
intakes NNS N
in IN N
the DT N
treatment NN N
of IN N
uncomplicated JJ p
falciparum NN p
malaria NN p
. . p

BACKGROUND NNP N
Artesunate NNP i
plus CC i
amodiaquine NN i
is VBZ N
a DT N
coblistered JJ N
ACT NNP N
, , N
given VBN N
as IN N
a DT N
single JJ N
daily JJ N
intake NN N
. . N

It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
, , N
in IN N
view NN N
of IN N
the DT N
number NN N
of IN N
tablets NNS N
to TO N
be VB N
taken VBN N
( ( N
particularly RB N
in IN N
adults NNS N
) ) N
, , N
it PRP N
may MD N
be VB N
possible JJ N
to TO N
improve VB N
compliance NN o
by IN N
allowing VBG N
patients NNS N
to TO N
divide VB N
the DT N
daily JJ N
dose NN N
. . N

The DT N
objectives NNS N
of IN N
this DT N
randomized VBN N
, , N
comparative JJ N
, , N
open-label JJ N
, , N
multicentre JJ p
study NN p
, , p
conducted VBN p
in IN p
Senegal NNP p
and CC p
in IN p
Cameroon NNP p
in IN p
2005 CD p
, , N
was VBD N
to TO N
demonstrate VB N
the DT N
non-inferiority NN o
and CC N
to TO N
compare VB N
the DT N
safety NN o
of IN o
artesunate JJ o
plus CC o
amodiaquine JJ o
, , N
as IN N
a DT N
single JJ N
daily JJ N
intake VB N
versus JJ N
two CD N
daily JJ N
intakes NNS N
. . N

METHODS VB N
A DT N
three-day JJ N
treatment NN N
period NN N
and CC N
14-day JJ N
follow-up JJ N
period NN N
was VBD N
performed VBN N
in IN N
any DT p
subject JJ p
weighting NN p
more JJR p
than IN p
10 CD p
kg NNS p
, , p
presenting VBG p
with IN p
a DT p
malaria NN p
paroxysm NN p
confirmed VBN p
by IN p
parasitaemia NN p
> NN p
or CC p
= $ p
1,000/microl CD p
, , p
after IN p
informed JJ p
consent NN p
. . p

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
into IN N
one CD N
of IN N
the DT N
two CD N
regimens NNS N
, , N
with IN N
dosage NN N
according VBG N
to TO N
bodyweight JJ N
range NN N
. . N

All DT N
products NNS N
were VBD N
administered VBN N
by IN N
an DT N
authorized JJ N
person NN N
, , N
blinded VBN N
to TO N
both DT N
the DT N
investigating NN N
physician NN N
and CC N
the DT N
biologist NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
an DT N
adequate JJ o
response NN o
to TO o
treatment NN o
on IN o
D14 NNP o
( ( N
WHO NNP N
definition NN N
) ) N
. . N

The DT N
two-sided JJ N
90 CD N
% NN N
confidence NN N
interval NN N
of IN N
the DT N
difference NN N
was VBD N
calculated VBN N
on IN N
intent NN N
to TO N
treat VB N
( ( N
ITT NNP N
) ) N
population NN N
; : N
the DT N
acceptance NN N
limit NN N
for IN N
non-inferiority NN N
was VBD N
3 CD N
% NN N
. . N

The DT N
safety NN o
was VBD N
evaluated VBN N
by IN N
incidence NN o
of IN o
adverse JJ o
events NNS o
. . o

RESULTS NNP N
Three-hundred JJ p
and CC p
sixteen JJ p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

The DT N
two CD N
patient NN N
groups NNS N
were VBD N
strictly RB N
comparable JJ N
on IN N
D0 NNP N
. . N

The DT N
adequate JJ o
responses NNS o
to TO o
treatment NN o
were VBD N
similar JJ N
for IN N
the DT N
two CD N
treatment NN N
regimens NNS N
on IN N
D14 NNP N
, , N
PCR-corrected NNP N
( ( N
99,4 CD N
% NN N
in IN N
the DT N
one-daily JJ N
intake NN N
group NN N
versus VBD N
99,3 CD N
% NN N
in IN N
the DT N
comparative JJ N
group NN N
) ) N
. . N

The DT N
statistical JJ N
analyses NNS N
demonstrated VBD N
the DT N
non-inferiority NN o
of IN N
administering VBG N
artesunate/amodiaquine NN N
as IN N
two CD N
intakes NNS N
. . N

The DT N
drug NN N
was VBD N
well RB o
tolerated VBN o
. . o

The DT N
main JJ N
adverse JJ N
events NNS N
were VBD N
gastrointestinal JJ o
disorders NNS o
( ( N
2.5 CD N
% NN N
) ) N
and CC N
pruritus NN o
( ( N
2.5 CD N
% NN N
) ) N
; : N
safety NN o
profiles NNS o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
This DT N
pilot NN N
study NN N
confirms VBZ N
the DT N
efficacy NN o
and CC N
good JJ o
tolerability NN o
of IN N
artesunate JJ N
plus CC N
amodiaquine JJ i
, , N
administrated VBD N
either CC N
in IN N
one CD N
or CC N
in IN N
two CD N
daily JJ N
intakes NNS N
. . N

-DOCSTART- -X- O O

Pharmacodynamic JJ N
effects NNS N
on IN N
biochemical JJ o
markers NNS o
of IN o
bone NN o
turnover NN o
and CC o
pharmacokinetics NNS o
of IN N
the DT N
cathepsin NN i
K NNP i
inhibitor NN i
, , i
ONO-5334 NNP i
, , N
in IN N
an DT N
ascending VBG N
multiple-dose NN N
, , N
phase NN N
1 CD N
study NN N
. . N

Selective JJ N
inhibitors NNS N
of IN N
cathepsin NN N
K NNP N
, , N
which WDT N
has VBZ N
a DT N
major JJ N
role NN N
in IN N
the DT N
degradation NN N
of IN N
bone NN N
collagen NN N
, , N
are VBP N
potential JJ N
new JJ N
treatments NNS N
for IN N
osteoporosis NN N
. . N

The DT N
pharmacokinetics NNS o
and CC o
the DT o
pharmacodynamic JJ o
effects NNS o
on IN o
biochemical JJ o
markers NNS o
of IN o
bone NN o
turnover NN o
of IN N
the DT N
new JJ N
cathepsin NN i
K NNP i
inhibitor NN i
, , i
ONO-5334 NNP i
, , N
were VBD N
investigated VBN N
in IN N
a DT N
multiple JJ N
ascending NN N
dose NN N
, , N
phase NN N
1 CD N
study NN N
. . N

A DT p
total NN p
of IN p
120 CD p
healthy JJ p
postmenopausal NN p
women NNS p
were VBD p
enrolled VBN p
, , p
and CC p
doses NNS i
of IN i
10 CD i
to TO i
600 CD i
mg NNS i
once RB i
daily JJ i
and CC i
50 CD i
and CC i
300 CD i
mg NN i
twice RB i
daily RB i
were VBD i
evaluated VBN i
in IN i
15- JJ i
and CC i
28-day JJ i
multiple-dosing JJ i
cohorts NNS i
. . i

Plasma NNP N
ONO-5334 NNP N
concentration NN N
reached VBD N
steady JJ N
state NN N
within IN N
2 CD N
days NNS N
. . N

Twenty-four CD N
hours NNS N
after IN N
the DT N
last JJ N
dose NN N
in IN N
the DT N
15-day JJ N
multiple-dose JJ N
cohort NN N
, , N
100 CD N
, , N
300 CD N
, , N
and CC N
600 CD N
mg NN N
once RB N
daily RB N
reduced VBN N
urinary JJ o
C-terminal JJ o
telopeptide NN o
of IN o
type NN o
I PRP o
collagen VBP o
by IN N
a DT N
mean NN N
( ( N
? . N
standard JJ N
deviation NN N
) ) N
44.9 CD N
% NN N
? . N
13.6 CD N
% NN N
, , N
84.5 CD N
% NN N
? . N
4.4 CD N
% NN N
, , N
and CC N
92.5 CD N
% NN N
? . N
1.3 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
28-day JJ N
cohort NN N
showed VBD N
similar JJ N
effects NNS N
. . N

There EX N
were VBD N
far RB N
smaller JJR N
effects NNS o
on IN o
bone-specific JJ o
alkaline JJ o
phosphatase NN o
( ( o
B-ALP NNP o
) ) o
, , o
tartrate-resistant JJ o
acid NN o
phosphatase NN o
5b CD o
( ( o
TRAP5b NNP o
) ) o
, , o
or CC o
osteocalcin NN o
( ( o
OC NNP o
) ) o
( ( o
measured VBN o
after IN N
28 CD N
days NNS N
) ) i
. . i

ONO-5334 NN i
was VBD i
well RB N
tolerated VBN N
up RP N
to TO N
600 CD N
mg/d NNS N
and CC N
for IN N
up RB N
to TO N
28 CD N
days NNS N
of IN N
multiple JJ N
dosing NN N
. . N

Multiple JJ N
dosing VBG N
with IN N
ONO-5334 NNP i
100 CD i
mg NN N
resulted VBD N
in IN N
considerable JJ N
suppression NN o
of IN o
bone NN o
resorption NN o
markers NNS o
with IN o
no DT N
appreciable JJ N
effects NNS o
on IN o
bone NN o
formation NN o
markers NNS o
( ( o
B-ALP NNP o
, , o
OC NNP o
) ) o
or CC o
osteoclast JJ o
number NN o
( ( o
TRAP5b NNP o
) ) o
. . o

-DOCSTART- -X- O O

Cytokine NNP i
and CC N
clinical JJ N
response NN N
to TO N
Saccharomyces NNP i
boulardii NN i
therapy NN i
in IN N
diarrhea-dominant JJ N
irritable JJ N
bowel NN N
syndrome NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

INTRODUCTION NNP N
This DT N
preliminary JJ N
study NN N
aimed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
the DT N
probiotic JJ i
Saccharomyces NNP i
boulardii NN i
on IN N
proinflammatory NN N
and CC N
anti-inflammatory JJ N
cytokines NNS N
in IN N
patients NNS p
with IN p
diarrhea-dominant JJ p
irritable JJ p
bowel NN p
syndrome NN p
( ( p
IBS-D NNP p
) ) p
. . p

The DT N
other JJ N
objectives NNS N
were VBD N
to TO N
document VB N
any DT N
clinical JJ N
improvement NN N
as IN N
judged VBN N
by IN N
symptoms NNS N
, , N
quality NN N
of IN N
life NN N
, , N
and CC N
histology NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ i
trial NN N
in IN N
which WDT N
S. NNP i
boulardii NN i
, , i
750 CD i
mg/day NN i
, , i
or CC i
placebo NN i
was VBD i
administered VBN i
for IN i
6 CD i
weeks NNS i
in IN i
IBS-D NNP i
patients NNS i
, , i
in IN i
addition NN i
to TO i
ispaghula VB i
husk JJ i
standard NN i
treatment NN i
. . i

RESULTS NNP N
Thirty-seven JJ p
patients NNS p
received VBD p
S. NNP i
boulardii NNS i
and CC p
35 CD p
patients NNS p
received VBD p
the DT p
placebo NN i
. . i

As IN N
compared VBN N
with IN N
placebo NN i
, , N
the DT N
S. NNP i
boulardii NN i
group NN N
showed VBD N
a DT N
significant JJ N
decrease NN o
in IN o
blood NN o
and CC o
tissue NN o
levels NNS o
of IN o
proinflammatory NN o
cytokines NNS o
interleukin-8 JJ o
( ( o
IL-8 NNP o
) ) o
and CC o
tumor JJ o
necrosis NN o
factor-? NN o
( ( o
P NNP o
< NNP o
0.001 CD o
) ) o
and CC o
an DT o
increase NN o
in IN o
anti-inflammatory JJ o
IL-10 JJ o
levels NNS o
, , o
as RB o
well RB o
as IN o
an DT o
increase NN o
in IN o
the DT o
tissue NN o
IL-10/IL-12 NNP o
ratio NN o
( ( o
P NNP o
< NNP o
0.001 CD o
) ) o
. . o

No DT o
significant JJ o
change NN o
in IN o
the DT o
blood NN o
and CC o
tissue NN o
levels NNS o
of IN o
cytokines NNS o
was VBD N
found VBN N
in IN N
the DT N
placebo NN N
group NN N
. . N

Bowel-related JJ o
IBS-D JJ o
symptoms NNS o
reported VBN N
in IN N
the DT N
patients NNS o
' POS o
daily JJ o
diary NNS o
improved VBN o
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
overall JJ o
improvement NN o
in IN o
the DT o
quality NN o
of IN o
life NN o
was VBD N
more RBR N
marked JJ N
in IN N
the DT i
S. NNP i
boulardii NN i
group NN N
. . N

Although IN N
baseline JJ N
histological JJ N
findings NNS N
were VBD o
mild JJ o
, , o
an DT o
improvement NN o
was VBD N
observed VBN N
in IN N
the DT N
probiotic JJ N
group NN N
in IN N
the DT o
lymphocyte NN o
and CC o
neutrophil JJ o
infiltrates NNS o
( ( N
P=0.017 NNP N
and CC N
0.018 CD N
) ) N
, , N
epithelial JJ o
mitosis NN o
( ( N
P=0.003 NNP N
) ) N
, , N
and CC o
intraepithelial JJ o
lymphocytes NNS o
( ( N
P=0.024 NNP N
) ) N
. . N

No DT N
serious JJ N
adverse JJ N
events NNS N
were VBD N
found VBN N
in IN N
either DT N
group NN N
. . N

CONCLUSION NNP N
S. NNP i
boulardii NN i
with IN N
ispaghula JJ N
husk NN N
was VBD N
superior JJ N
to TO N
placebo VB N
with IN N
ispaghula JJ N
husk NN N
in IN N
improving VBG N
the DT N
cytokine NN N
profile NN N
, , N
histology NN N
, , N
and CC N
quality NN N
of IN N
life NN N
of IN p
patients NNS p
with IN p
IBS-D NNP p
. . p

These DT N
preliminary JJ N
results NNS N
need VBP N
to TO N
be VB N
confirmed VBN N
in IN N
a DT N
well-powered JJ N
trial NN N
. . N

-DOCSTART- -X- O O

Breast NNP i
reduction NN i
alleviates VBZ N
depression NN o
and CC o
anxiety NN o
and CC N
restores VBZ N
self-esteem NNS o
: : o
a DT N
prospective JJ N
randomised JJ N
clinical JJ N
trial NN N
. . N

Of IN N
women NNS p
who WP p
seek VBP p
reduction NN p
mammaplasty NN p
, , N
up RB N
to TO N
a DT N
third JJ N
have VBP p
pathological JJ p
degrees NNS p
of IN p
anxiety NN o
or CC o
depression NN o
, , p
or CC p
both DT p
. . p

The DT N
psychological JJ o
aspect NN o
of IN N
reduction NN i
mammaplasty NN i
is VBZ N
therefore RB N
an DT N
important JJ N
consideration NN N
. . N

We PRP N
did VBD N
a DT N
prospective NN N
randomised VBN N
clinical JJ N
trial NN N
to TO N
see VB N
how WRB N
reduction NN i
mammaplasty RB i
affected VBD N
macromastia JJ N
patients NNS N
' POS N
depression NN o
, , o
anxiety NN o
, , o
and CC o
self-esteem JJ o
. . o

Eighty-two JJ p
patients NNS p
were VBD p
randomised VBN p
, , p
40 CD p
to TO p
have VB p
the DT p
operation NN p
, , p
and CC p
42 CD p
patients NNS p
to TO p
conservative JJ p
treatment NN p
. . p

Both DT N
groups NNS N
were VBD N
followed VBN N
for IN N
six CD N
months NNS N
. . N

The DT N
patients NNS N
completed VBD N
the DT N
RBDI NNP o
questionnaire NN o
( ( o
Raitasalo NNP o
's POS o
modification NN o
of IN o
the DT o
short JJ o
form NN o
of IN o
the DT o
Beck NNP o
Depression NNP o
Inventory NNP o
) ) o
. . o

Twenty-nine JJ p
patients NNS p
in IN p
the DT p
operated JJ p
group NN p
and CC p
35 CD p
patients NNS p
in IN p
the DT p
conservative JJ p
group NN p
completed VBD N
the DT N
study NN N
. . N

At IN N
the DT N
second JJ N
examination NN N
, , N
the DT N
patients NNS N
who WP N
had VBD N
been VBN N
operated VBN N
on IN N
, , N
had VBD N
significantly RB N
less JJR N
depression NN o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
better JJR o
self-esteem NN o
( ( N
p=0.03 NN N
) ) N
than IN N
the DT N
conservative JJ N
group NN N
. . N

The DT N
proportions NNS o
of IN N
depressed JJ o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
anxious JJ o
( ( N
p=0.04 NN N
) ) N
patients NNS N
were VBD N
also RB N
smaller JJR N
in IN N
the DT N
group NN N
who WP N
were VBD N
operated VBN N
on IN N
. . N

There EX N
is VBZ N
significantly RB N
less JJR N
depression NN o
and CC o
anxiety NN o
after IN N
reduction NN N
mammaplasty NN i
, , N
and CC N
patients NNS N
' POS N
self-esteem NN o
is VBZ N
restored VBN N
. . N

-DOCSTART- -X- O O

A DT p
limited JJ p
sampling NN p
method NN p
for IN p
the DT p
estimation NN o
of IN o
flunarizine JJ o
area NN o
under IN o
the DT o
curve NN o
( ( o
AUC NNP o
) ) o
and CC o
maximum JJ o
plasma JJ o
concentration NN o
( ( o
Cmax NNP o
) ) o
. . o

A DT N
limited JJ N
sampling NN N
model NN N
has VBZ N
been VBN N
developed VBN N
for IN N
flunarizine NN N
following VBG N
a DT N
30 CD N
mg JJ N
oral JJ N
dose NN N
in IN N
epileptic JJ p
patients NNS p
who WP p
were VBD i
receiving VBG i
phenytoin NN i
or CC i
carbamazepine NN i
or CC i
both DT i
, , i
to TO i
estimate VB o
the DT o
area NN o
under IN o
the DT o
curve NN o
( ( o
AUC NNP o
) ) o
and CC o
maximum JJ o
plasma JJ o
concentration NN o
( ( o
Cmax NNP o
) ) o
. . o

The DT N
model NN N
was VBD N
developed VBN N
using VBG N
training VBG N
data NNS N
sets NNS N
from IN N
30 CD p
, , p
20 CD p
, , p
15 CD p
, , p
or CC p
10 CD p
patients NNS p
at IN p
one CD p
or CC p
two CD p
time NN p
points NNS p
. . p

The DT N
equations NNS N
describing VBG N
the DT N
models NNS N
for IN N
AUC NNP N
using VBG N
two CD N
time NN N
points NNS N
( ( N
3 CD N
and CC N
24h CD N
) ) N
and CC N
Cmax NNP N
for IN N
the DT N
training NN N
data NNS N
set NN N
of IN N
30 CD N
subjects NNS N
were VBD N
AUCpredicted NNP N
= NNP N
11.1 CD N
C3h NNP N
+ VBD N
121.4 CD N
C24h NNP N
- : N
157 CD N
( ( N
r NN N
= RB N
0.80 CD N
) ) N
Cmax NNP N
( ( N
predicted VBN N
) ) N
= $ N
0.036 CD N
AUC NNP N
+ $ N
42.9 CD N
( ( N
r NN N
= RB N
0.74 CD N
) ) N
The DT N
model NN N
was VBD N
validated VBN N
on IN N
64 CD p
patients NNS p
who WP N
received VBD N
flunarizine JJ N
orally RB N
. . N

The DT N
model NN N
provided VBD N
reasonably RB N
good JJ N
estimates NNS o
for IN o
both DT o
AUC NNP o
and CC o
Cmax NNP o
. . o

The DT N
mean NN o
predicted VBD o
AUC NNP o
of IN o
flunarizine NN o
was VBD N
1230 CD N
+/- JJ N
717 CD N
ng JJ N
h NN N
mL-1 NN N
, , N
whereas IN N
the DT N
observed JJ o
AUC NNP o
was VBD N
1203 CD N
+/- JJ N
900 CD N
ng JJ N
h JJ N
mL-1 NN N
. . N

The DT N
bias NN o
of IN o
the DT o
prediction NN o
was VBD N
2 CD N
% NN N
and CC N
precision NN N
was VBD N
28 CD N
% NN N
. . N

The DT N
mean NN N
predicted VBD o
Cmax NNP o
of IN o
flunarizine NN o
was VBD N
86 CD N
+/- JJ N
32 CD N
ng JJ N
mL-1 NN N
as IN N
compared VBN N
to TO N
an DT N
observed JJ o
mean NN o
Cmax NNP o
of IN N
90 CD N
+/- JJ N
42 CD N
ng JJ N
mL-1 NN N
. . N

The DT N
bias NN o
and CC o
precision NN o
of IN o
the DT o
prediction NN o
were VBD N
4 CD N
% NN N
and CC N
24 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
method NN N
described VBD N
here RB N
may MD N
be VB N
used VBN N
to TO N
estimate VB N
AUC NNP N
and CC N
Cmax NNP N
for IN N
flunarizine NN N
without IN N
detailed JJ N
pharmacokinetic JJ N
studies NNS N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
, , N
randomized VBD N
controlled VBN N
trial NN N
of IN N
single-incision NN i
laparoscopic NN i
vs JJ i
conventional JJ i
3-port JJ i
laparoscopic NN i
appendectomy NN i
for IN N
treatment NN N
of IN N
acute JJ N
appendicitis NN N
. . N

BACKGROUND NNP N
Proponents NNPS N
of IN N
single-incision NN i
laparoscopic NN i
surgery NN i
( ( i
SILS NNP i
) ) i
claim NN N
patients NNS N
have VBP N
less JJR N
pain NN N
, , N
faster JJR N
recovery NN N
, , N
and CC N
better JJR N
long-term JJ N
cosmetic JJ N
results NNS N
than IN N
patients NNS N
who WP N
undergo VBP N
multiport NN i
laparoscopy NN i
. . i

However RB N
, , N
randomized JJ N
comparisons NNS N
are VBP N
lacking VBG N
. . N

This DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
SILS NNP i
or CC N
3-port JJ i
laparoscopic NN i
appendectomy NN i
. . i

STUDY NNP N
DESIGN NNP N
Adults NNP p
with IN p
uncomplicated JJ p
acute NN p
appendicitis NN p
were VBD N
randomized VBN N
1:1 CD N
to TO N
either DT N
SILS NNP i
or CC i
3-port JJ i
laparoscopic NN i
appendectomy NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
early JJ o
postoperative JJ o
pain NN o
( ( N
measured VBN N
by IN N
opiate JJ N
usage NN N
and CC N
pain NN N
score NN N
in IN N
the DT N
first JJ N
12 CD N
hours NNS N
) ) N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
operative JJ o
time NN o
, , o
complication NN o
rate NN o
( ( o
including VBG o
conversions NNS o
) ) o
, , o
and CC o
recovery NN o
time NN o
( ( o
days NNS o
of IN o
oral JJ o
opiate JJ o
usage NN o
and CC o
return NN o
to TO o
work VB o
) ) o
. . N

After IN N
6 CD N
months NNS N
, , N
body NN o
image NN o
and CC N
cosmetic JJ o
appearance NN o
were VBD N
assessed VBN N
using VBG N
a DT N
validated JJ N
survey NN N
. . N

RESULTS VB N
The DT p
trial NN p
was VBD p
planned VBN p
for IN p
150 CD p
patients NNS p
, , p
but CC p
was VBD p
halted VBN p
after IN p
75 CD p
patients NNS p
when WRB p
planned VBN p
interim NN p
analysis NN p
showed VBD p
that IN p
SILS NNP i
patients NNS p
had VBD p
more RBR p
postoperative JJ o
pain NN o
( ( N
pain NN N
score NN N
: : N
4.4 CD N
? . N
1.6 CD N
vs NN N
3.5 CD N
? . N
1.5 CD N
; : N
p NN N
= VBZ N
0.01 CD N
) ) N
and CC N
higher JJR o
inpatient NN o
opiate NN o
usage NN o
( ( o
hydromorphone NN N
use NN N
: : N
3.9 CD N
? . N
1.9 CD N
mg NN N
vs NN N
2.8 CD N
? . N
1.7 CD N
mg NN N
; : N
p CC N
= VB N
0.01 CD N
) ) N
than IN N
3-port JJ N
laparoscopy NN o
. . o

Operative JJ o
time NN o
for IN o
SILS NNP i
averaged VBD i
40 CD N
% NN N
longer JJR N
( ( N
54 CD N
? . N
17 CD N
minutes NNS N
vs RB N
38 CD N
? . N
11 CD N
minutes NNS N
; : N
p VB N
< $ N
0.01 CD N
) ) N
. . N

Only RB N
1 CD N
SILS NNP o
case NN o
was VBD N
converted VBN i
to TO i
3-port JJ i
. . i

There EX i
were VBD N
no DT N
significant JJ N
differences NNS o
in IN o
length NN o
of IN o
stay NN o
, , o
complications NNS o
, , o
oral JJ o
pain NN o
medication NN o
usage NN o
after IN o
discharge NN o
, , o
or CC o
return VB o
to TO o
work VB o
. . o

After IN N
6 CD N
months NNS N
, , N
body NN N
image NN N
and CC N
cosmetic JJ N
appearance NN N
were VBD N
excellent JJ N
for IN N
both DT N
groups NNS N
and CC N
indistinguishable JJ N
by IN N
most JJS N
measures NNS N
. . N

However RB i
, , i
3-port JJ i
patients NNS i
reported VBD N
better RBR N
physical JJ o
attractiveness NN o
( ( o
4.0 CD o
? . N
0.4 CD N
vs NN N
3.8 CD N
? . N
0.4 CD N
; : N
p NN N
= VBZ N
0.04 CD N
) ) N
and CC i
SILS NNP i
patients NNS i
reported VBD N
better JJR o
scars NNS o
( ( o
score VB N
18.4 CD N
? . N
2.7 CD N
vs NN N
16.4 CD N
? . N
3.0 CD N
; : N
p NN N
< VBZ N
0.01 CD N
) ) N
. . N

Results NNS N
are VBP N
reported VBN N
as IN N
mean NN N
? . N
SD NNP N
. . N

CONCLUSIONS NNP N
Single-incision NNP i
laparoscopic NN i
surgery NN i
appendectomy NN i
resulted VBD i
in IN i
more RBR o
pain NN o
and CC N
longer RB N
operative JJ o
times NNS o
without IN o
improving VBG N
short-term JJ N
recovery NN N
or CC N
complications NNS N
. . N

Long-term JJ N
body NN N
image NN N
and CC N
cosmetic JJ N
appearance NN N
were VBD N
excellent JJ N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -X- O O

Esomeprazole NNP i
resolves VBZ N
chronic JJ o
heartburn NN o
in IN N
patients NNS p
without IN p
erosive JJ p
oesophagitis NN p
. . p

BACKGROUND NNP N
Patients NNPS p
with IN p
chronic JJ o
heartburn NN o
but CC p
with IN p
no DT p
endoscopic JJ p
evidence NN p
of IN p
erosive JJ p
oesophagitis NN p
require NN p
gastric JJ p
acid JJ p
suppression NN p
to TO p
relieve VB o
symptoms NNS o
. . o

AIM NNP N
To TO N
assess VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
esomeprazole NN i
in IN N
patients NNS p
with IN p
frequent JJ o
heartburn NN o
for IN p
> NN p
or CC p
= $ p
6 CD p
months NNS p
and CC p
no DT p
evidence NN p
of IN p
erosive JJ p
oesophagitis NN p
on IN p
endoscopy NN p
. . p

METHODS NNP N
Two CD N
randomized VBD N
, , N
double-blind JJ N
, , N
4-week JJ N
, , N
multi-centre JJ N
trials NNS N
with IN N
identical JJ N
methodology NN N
compared VBN N
once-daily RB N
esomeprazole JJ i
, , N
40 CD p
mg NN p
( ( p
n JJ p
= NNP p
241 CD p
) ) p
or CC p
20 CD p
mg NN p
( ( p
n JJ p
= NNP p
234 CD p
) ) p
, , p
with IN p
placebo NN i
( ( p
n JJ p
= NNP p
242 CD p
) ) p
for IN N
the DT N
rigorous JJ N
end-point NN N
of IN N
complete JJ o
resolution NN o
of IN o
heartburn NN o
. . o

Secondary JJ N
end-points NNS N
included VBD N
the DT N
percentage NN o
of IN o
heartburn-free JJ o
days NNS o
and CC o
the DT o
time NN o
to TO o
first RB o
and CC o
sustained JJ o
resolution NN o
of IN o
heartburn NN o
. . o

RESULTS JJ N
Patients NNS N
treated VBN N
with IN N
either DT N
dose NN N
of IN N
esomeprazole JJ i
were VBD N
two CD N
to TO N
three CD N
times NNS N
more RBR N
likely JJ N
to TO N
achieve VB N
complete JJ o
resolution NN o
of IN o
heartburn NN o
than IN N
patients NNS N
treated VBN N
with IN N
placebo NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
percentage NN o
of IN o
heartburn-free JJ o
days NNS o
was VBD N
significantly RB N
higher JJR N
with IN N
esomeprazole JJ i
40 CD N
mg NN N
( ( N
63 CD N
% NN N
, , N
66 CD N
% NN N
) ) N
or CC N
20 CD N
mg NN N
( ( N
63 CD N
% NN N
, , N
68 CD N
% NN N
) ) N
than IN N
with IN N
placebo NN i
( ( N
46 CD N
% NN N
, , N
36 CD N
% NN N
; : N
P NNP N
< NNP N
or CC N
= VB N
0.001 CD N
) ) N
in IN N
each DT N
of IN N
the DT N
two CD N
studies NNS N
. . N

Esomeprazole NNP i
was VBD N
associated VBN N
with IN N
a DT N
significantly RB N
shorter JJR N
mean JJ N
time NN N
to TO N
first VB N
( ( N
6-7 JJ N
days NNS N
) ) N
and CC N
sustained VBN N
( ( N
12-17 JJ N
days NNS N
) ) N
resolution NN o
of IN o
heartburn NN o
compared VBN N
with IN N
placebo NN i
( ( N
first JJ N
, , N
10-12 JJ N
days NNS N
; : N
sustained VBN N
, , N
21-22 JJ N
days NNS N
; : N
P NNP N
< NNP N
or CC N
= VB N
0.008 CD N
) ) N
. . N

The DT N
spectrum NN o
and CC o
frequency NN o
of IN o
adverse JJ o
events NNS o
with IN N
esomeprazole NN i
were VBD N
similar JJ N
to TO N
those DT N
with IN N
placebo NN i
. . i

CONCLUSIONS NNP N
Esomeprazole NNP i
, , N
at IN N
daily JJ N
doses NNS N
of IN N
40 CD N
mg NNS N
or CC N
20 CD N
mg NN N
, , N
is VBZ N
effective JJ o
and CC o
safe JJ o
for IN N
the DT N
treatment NN N
of IN N
chronic JJ o
heartburn NN o
in IN N
patients NNS p
without IN p
erosive JJ p
oesophagitis NN p
. . p

-DOCSTART- -X- O O

Altered NNP N
growth NN o
hormone NN o
response NN o
after IN N
growth NN i
hormone NN i
releasing VBG i
hormone CD i
administration NN i
in IN N
chronic JJ N
renal JJ N
failure NN N
. . N

Eleven NNP p
chronic JJ p
renal JJ p
failure NN p
patients NNS p
and CC p
11 CD p
matched JJ p
controls NNS p
, , N
received VBD N
growth NN i
hormone NN i
GHRH NNP i
( ( i
1 CD i
microgram/kg RB i
iv NN i
) ) i
or CC i
TRH NNP i
( ( i
400 CD i
microgram RB i
iv NN i
) ) i
on IN N
separate JJ N
occasions NNS N
, , N
immediately RB N
before IN N
undergoing JJ N
hemodialysis NN N
. . N

GHRH-induced JJ i
GH NNP N
peak NN N
in IN N
uremics NNS N
( ( N
22.7 CD N
+/- JJ N
5.2 CD N
micrograms/l NN N
) ) N
was VBD N
not RB N
different JJ N
from IN N
that DT N
obtained VBN N
in IN N
control NN N
subjects NNS N
( ( N
16.0 CD N
+/- JJ N
4.3 CD N
micrograms/l NN N
) ) N
. . N

However RB N
, , N
the DT p
uremic JJ p
patients NNS p
did VBD N
not RB N
show VB N
the DT N
habitual JJ N
post-peak JJ N
fall NN N
, , N
remaining VBG N
GH NNP o
levels NNS o
over IN N
10 CD N
micrograms/l NNS N
till IN N
the DT N
end NN N
of IN N
the DT N
test NN N
. . N

Differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Uremic JJ p
patients NNS p
showed VBD N
PRL NNP o
values VBZ o
higher JJR N
than IN N
in IN N
controls NNS N
, , N
however RB N
their PRP$ N
TRH-induced JJ o
PRL NNP o
peak NN o
( ( N
20.6 CD N
+/- JJ N
6.6 CD N
micrograms/l NN N
) ) N
was VBD N
not RB N
different JJ N
from IN N
that DT N
of IN N
controls NNS N
( ( N
26.5 CD N
+/- JJ N
3.0 CD N
micrograms/l NN N
) ) N
. . N

Again NNP N
chronic JJ p
renal JJ p
failure NN p
patients NNS p
showed VBD N
PRL NNP o
plasma NN o
values NNS o
abnormally RB N
elevated VBD N
till IN N
the DT N
end NN N
of IN N
the DT N
test NN N
. . N

Differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Administration NN N
of IN N
placebo NN i
to TO N
a DT N
different JJ p
group NN p
of IN p
seven CD p
uremic JJ p
patients NNS p
did VBD N
not RB N
alter VB N
GH NNP o
and CC o
PRL NNP o
plasma NN o
levels NNS o
. . o

This DT N
sustained JJ N
secretion NN N
of IN N
both DT N
GH NNP o
and CC o
PRL NNP o
in IN N
uremia NN N
could MD N
be VB N
attributed VBN N
to TO N
reduced VB N
kidney NN N
clearance NN N
. . N

However RB N
, , N
when WRB N
subjects NNS N
were VBD N
examined VBN N
individually RB N
both DT N
the DT N
GHRH- NNP o
and CC o
the DT o
TRH-induced NNP o
hormonal JJ o
peaks NNS o
and CC o
the DT o
subsequent JJ o
fall NN o
were VBD N
not RB N
different JJ N
in IN N
both DT N
groups NNS N
. . N

Unlike IN N
with IN N
controls NNS N
, , N
in IN N
uremic JJ p
patients NNS p
GHRH-stimulated JJ i
GH NNP N
and CC N
TRH-stimulated NNP i
PRL/GH NNP o
peaks NNS o
were VBD N
dispersed VBN N
throughout IN N
the DT N
120 CD N
min JJ N
period NN N
. . N

In IN N
controls NNS N
GH NNP o
and CC o
PRL NNP o
peaks NNS N
clustered VBD N
around IN N
15-30 JJ N
min NN N
. . N

The DT N
peak JJ N
dispersion NN N
created VBD N
a DT N
false JJ N
impression NN N
of IN N
flattened JJ N
curves NNS N
or CC N
sustained VBN N
hypersecretion NN N
in IN N
uremia NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Growth NNP o
hormone NN o
( ( o
GH NNP o
) ) o
responses VBZ o
to TO N
GH-releasing NNP i
hormone NN i
alone RB i
or CC N
combined VBN i
with IN i
arginine NN i
in IN N
patients NNS p
with IN p
adrenal JJ p
incidentaloma NN p
: : p
evidence NN N
for IN N
enhanced JJ N
somatostatinergic JJ N
tone NN N
. . N

Spontaneous JJ N
and CC N
stimulated VBD N
GH NNP N
secretion NN N
is VBZ N
blunted VBN N
in IN N
hypercortisolemic JJ N
states NNS N
due JJ N
to TO N
increased VBN N
hypothalamic JJ N
somatostatinergic NN N
tone NN N
. . N

However RB N
, , N
no DT N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
characteristics NNS N
of IN N
GH NNP N
secretion NN N
in IN N
patients NNS p
with IN p
incidentally RB p
discovered VBN p
adrenal JJ p
adenomas NN p
. . p

They PRP N
represent VBP N
an DT N
interesting JJ N
model NN N
for IN N
studying VBG N
GH NNP N
secretion NN N
, , N
as IN N
a DT N
slight JJ N
degree NN N
of IN N
cortisol NN N
excess NN N
may MD N
frequently RB N
be VB N
observed VBN N
in IN N
such JJ N
patients NNS p
who WP p
do VBP p
not RB p
present VB p
with IN p
any DT p
clear JJ p
Cushingoid NNP p
sign NN p
. . p

In IN N
the DT N
present JJ N
study NN N
, , N
10 CD p
patients NNS p
( ( p
3 CD p
men NNS p
and CC p
7 CD p
women NNS p
, , p
aged VBD p
48-63 JJ p
yr NN p
) ) p
with IN p
an DT p
adrenal JJ p
mass NN p
discovered VBD p
serendipitously RB p
underwent JJ N
, , N
on IN N
separate JJ N
occasions NNS N
, , N
a DT N
GHRH NNP i
injection NN i
alone RB i
or CC N
combined VBN i
with IN i
an DT i
infusion NN i
of IN i
the DT i
functional JJ i
somatostatin NN i
antagonist NN i
, , i
arginine NN i
. . i

Thirteen JJ p
age-matched JJ p
healthy JJ p
volunteers NNS p
served VBD p
as IN p
controls NNS i
. . i

Briefly NNP N
, , N
arginine NN i
( ( i
30 CD i
g NN i
) ) i
was VBD i
infused VBN i
from IN i
-30 NN i
to TO i
0 CD i
min NN i
, , i
and CC i
GHRH NNP i
( ( i
100 CD i
microg NN i
) ) i
was VBD i
injected VBN i
as IN i
a DT i
bolus NN i
at IN i
0 CD i
min NNS i
, , N
with IN N
measurement NN N
of IN N
serum NN i
GH NNP i
[ NNP i
immunoradiometric JJ i
assay NN i
( ( i
IRMA NNP i
) ) i
] VBP i
every DT N
15 CD N
min NN N
for IN N
150 CD N
min NN N
. . N

Plasma NNP i
IGF-I NNP i
( ( i
RIA NNP i
after IN i
acid-ethanol JJ i
extraction NN i
) ) i
was VBD N
measured VBN N
in IN N
a DT N
morning NN N
sample NN N
. . N

The DT N
diagnosis NN N
of IN N
cortical JJ N
adenoma NN N
was VBD N
based VBN N
on IN N
computed JJ N
tomography NN N
features NNS N
and CC N
pattern NN N
of IN N
uptake NN N
on IN N
adrenal JJ N
scintigraphy NN N
. . N

Patients NNS p
with IN p
obesity NN p
and/or NN p
diabetes NNS p
were VBD p
excluded VBN p
. . p

The DT N
study NN N
design NN N
included VBD N
also RB N
an DT N
endocrine JJ N
work-up NN N
aimed VBN N
to TO N
study VB N
the DT N
hypothalamic-pituitary-adrenal JJ o
axis NN o
[ NNP o
urinary JJ o
free JJ o
cortisol NN o
( ( o
UFC NNP o
) ) o
excretion NN o
, , o
serum NN o
cortisol NN o
at IN o
0800 CD o
h NN o
, , o
plasma JJ o
ACTH NNP o
at IN o
0800 CD o
h NN o
, , o
morning NN o
cortisol NN o
after IN o
overnight JJ o
1 CD o
mg NN o
dexamethasone NN o
] NN o
. . o

Five CD N
of IN N
10 CD N
patients NNS N
showed VBD N
abnormalities NNS o
of IN o
the DT o
hypothalamic-pituitary-adrenal JJ o
axis NN o
, , N
including VBG N
borderline NN o
or CC o
increased VBN o
UFC JJ o
excretion NN o
in IN N
4 CD N
of IN N
them PRP N
accompanied VBN N
by IN N
blunted JJ N
ACTH NNP N
in IN N
2 CD N
cases NNS N
and CC N
failure NN N
of IN N
cortisol NN N
to TO N
suppress VB N
after IN N
dexamethasone NN N
in IN N
1 CD N
; : N
the DT N
fifth JJ N
patient NN N
displayed VBD N
low JJ N
ACTH NNP N
and CC N
resistance NN N
to TO N
dexamethasone VB N
suppression NN N
. . N

However RB N
, , N
all DT N
patients NNS N
had VBD N
a DT N
unilateral JJ N
uptake NN N
of IN N
the DT N
tracer NN N
on IN N
the DT N
side NN N
of IN N
the DT N
mass NN N
with IN N
suppression NN N
of IN N
the DT N
contralateral JJ N
normal JJ N
adrenal JJ N
gland NN N
. . N

As IN N
a DT N
group NN N
, , N
the DT N
patients NNS N
displayed VBD N
greater JJR N
UFC NNP o
excretion NN o
and CC o
lower JJR o
ACTH NNP o
concentrations NNS o
than IN N
the DT N
controls NNS N
. . N

GH NNP o
release NN o
after IN o
GHRH NNP o
treatment NN o
was VBD N
blunted VBN N
in IN N
patients NNS p
bearing VBG p
adrenal JJ p
incidentaloma NNS p
compared VBN N
with IN N
controls NNS N
( ( N
GH NNP N
peak NN N
, , N
5.7 CD N
+/- JJ N
5.2 CD N
vs. FW N
18.0 CD N
+/- JJ N
7.0 CD N
microg/L NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
whereas JJ N
GHRH NNP i
plus CC i
arginine NN i
was VBD N
able JJ N
to TO N
elicit VB N
a DT N
comparable JJ N
response NN N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
GH NNP N
peak NN N
, , N
33.5 CD N
+/- JJ N
20.3 CD N
vs. FW N
33.7 CD N
+/- JJ N
17.5 CD N
microg/L NN N
; : N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

The DT N
ratio NN N
between IN N
GH NNP o
peaks NNS o
after IN o
GHRH NNP o
plus CC o
arginine NN o
and CC o
after IN o
GHRH NNP o
plus CC o
saline NN o
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS N
than IN N
in IN N
controls NNS N
( ( N
751 CD N
+/- JJ N
531 CD N
% NN N
vs. FW N
81 CD N
+/- JJ N
45 CD N
% NN N
; : N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

Similar JJ N
data NNS N
were VBD N
obtained VBN N
when WRB N
comparing VBG N
GH NNP N
area NN N
under IN N
the DT N
curve NN N
after IN N
GHRH NNP N
plus CC N
saline NN N
or CC N
GHRH NNP N
plus CC N
arginine NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
summary JJ N
, , N
the DT N
present JJ N
data NNS N
suggest VBP N
that IN N
in IN N
patients NNS p
with IN p
incidental JJ p
adrenal JJ p
adenomas IN p
the DT N
GH NNP o
response NN o
to TO N
GHRH NNP N
is VBZ N
blunted VBN N
due JJ N
to TO N
increased VBN N
somatostatinergic NN o
tone NN o
, , N
as IN N
it PRP N
can MD N
be VB N
restored VBN N
to TO N
normal JJ N
by IN N
pretreatment NN N
with IN N
the DT N
functional JJ N
somatostatin NN N
antagonist JJ N
arginine NN N
. . N

The DT N
blunted JJ N
GH NNP N
release NN N
to TO N
GHRH NNP N
may MD N
be VB N
an DT N
early JJ N
and CC N
long JJ N
lasting JJ N
sign NN N
of IN N
autonomous JJ N
cortisol NNS N
secretion NN N
by IN N
the DT N
adrenal JJ N
adenoma NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
phenylephrine NN i
on IN N
the DT N
haemodynamic JJ o
state NN o
and CC o
cerebral JJ o
oxygen NN o
saturation NN o
during IN N
anaesthesia NN N
in IN N
the DT N
upright JJ N
position NN N
. . N

BACKGROUND IN N
The DT N
upright JJ N
sitting NN N
or CC N
beachchair NN N
position NN N
is VBZ N
associated VBN N
with IN N
hypotension NN o
, , o
risk NN o
of IN o
cerebral JJ o
hypoperfusion NN o
, , o
and CC o
cerebral JJ o
injury NN o
. . o

We PRP N
hypothesized VBD N
that IN N
by IN N
increasing VBG N
arterial JJ N
pressure NN N
with IN N
phenylephrine JJ i
administration NN N
, , N
cerebral JJ o
perfusion NN o
, , N
and CC N
postoperative JJ o
recovery NN o
would MD N
be VB N
improved VBN N
. . N

METHODS NNP N
Thirty-four JJ p
patients NNS p
undergoing VBG p
elective JJ p
shoulder NN p
surgery NN p
were VBD p
randomized VBN p
to TO N
receive VB N
either DT N
saline NN i
or CC i
phenylephrine NN i
infusion NN i
( ( i
PE NNP i
) ) i
5 CD N
min NN N
before IN N
being VBG N
placed VBN N
in IN N
the DT N
upright JJ N
position NN N
. . N

Simultaneous JJ N
measurements NNS N
of IN N
mean JJ o
arterial JJ o
pressure NN o
, , o
cerebral JJ o
oxygen NN o
saturation NN o
, , o
middle JJ o
cerebral JJ o
artery NN o
velocity NN o
, , o
and CC o
cardiac JJ o
function NN o
using VBG o
transthoracic JJ o
echocardiography NN o
were VBD N
made VBN N
. . N

Postoperative JJ N
neurocognitive JJ o
function NN o
was VBD N
assessed VBN N
. . N

RESULTS NNP N
At IN N
the DT N
commencement NN N
of IN N
PE NNP N
, , N
mean NN o
( ( o
SD NNP o
) ) o
cerebral JJ o
oxygen NN o
saturation NN o
significantly RB N
decreased VBN N
from IN N
77 CD N
( ( N
10 CD N
) ) N
to TO N
67 CD N
( ( N
13 CD N
) ) N
% NN N
( ( N
P=0.02 NNP N
) ) N
, , N
and CC N
further RB N
to TO N
59 CD N
( ( N
11 CD N
) ) N
% NN N
on IN N
upright JJ N
positioning NN N
. . N

The DT N
level NN o
of IN o
cerebral JJ o
saturation NN o
upright NN o
was VBD N
not RB N
significantly RB N
different JJ N
to TO N
patients NNS N
receiving VBG N
saline NN N
( ( N
P=0.07 NNP N
) ) N
, , N
with IN N
values NNS N
remaining VBG N
at IN N
room-air JJ N
levels NNS N
. . N

Middle NNP o
cerebral JJ o
artery RB o
blood NN o
velocity NN o
increased VBN N
by IN N
20 CD N
% NN N
( ( N
P=0.04 NNP N
) ) N
. . N

Phenylephrine NNP N
prevented VBD N
hypotension NN o
in IN N
the DT N
upright JJ N
position NN N
primarily RB N
by IN N
maintaining VBG N
preload NN N
and CC N
increasing VBG N
systemic JJ o
vascular NN o
resistance NN o
( ( N
P=0.01 NNP N
) ) N
, , N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
cardiac JJ o
output NN o
. . o

No DT N
postoperative JJ o
neurocognitive JJ o
dysfunction NN o
was VBD N
identified VBN N
. . N

CONCLUSIONS NNP N
Despite IN N
maintaining VBG N
arterial JJ N
pressure NN N
with IN N
phenylephrine NN i
, , N
cerebral JJ o
desaturation NN o
occurred VBD N
with IN N
upright JJ N
positioning VBG N
. . N

Cerebral NNP o
oxygen IN o
saturation NN o
can MD N
provide VB N
a DT N
valuable JJ N
endpoint NN N
when WRB N
evaluating VBG N
the DT N
effect NN N
of IN N
vasopressor NN N
therapy NN N
on IN N
cerebral JJ N
perfusion NN N
. . N

-DOCSTART- -X- O O

Topical JJ N
treatment NN N
of IN N
tinea NN p
pedis NNS p
using VBG N
6 CD N
% NN N
coriander NN i
oil NN i
in IN i
unguentum NN N
leniens NNS N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
comparative JJ N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
The DT N
antifungal JJ N
activity NN N
of IN N
coriander NN i
oil NN i
has VBZ N
already RB N
been VBN N
demonstrated VBN N
in IN N
vitro NN N
. . N

OBJECTIVE NNP N
Evaluation NN N
of IN N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
6 CD i
% NN i
coriander NN i
oil NN i
in IN N
unguentum NN N
leniens NNS N
in IN N
the DT N
treatment NN N
of IN N
interdigital JJ p
tinea NN p
pedis NN p
. . p

METHODS NNP N
Half-side NNP p
comparative NN p
pilot NN N
study NN p
on IN p
subjects NNS p
with IN p
symmetric JJ p
, , p
bilateral JJ p
interdigital JJ p
tinea NN p
pedis NN p
. . p

Active JJ N
drug NN N
and CC N
placebo NN i
control NN N
were VBD N
applied VBN N
twice RB N
daily RB N
on IN N
the DT N
affected JJ N
areas NNS N
, , N
and CC N
follow-up JJ N
visits NNS N
were VBD N
performed VBN N
on IN N
days NNS N
14 CD N
and CC N
28 CD N
. . N

RESULTS VB N
40 CD p
participants NNS p
( ( p
mean JJ p
age NN p
52.5 CD p
years NNS p
, , p
60 CD p
% NN p
male NN p
) ) p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

For IN N
6 CD N
% NN N
coriander NN i
oil NN i
in IN N
unguentum NN N
leniens NNS N
, , N
a DT N
highly RB N
significant JJ N
improvement NN N
of IN N
the DT N
clinical JJ o
signs NNS o
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
was VBD N
observed VBN N
during IN N
the DT N
entire JJ N
observation NN N
period NN N
; : N
the DT N
number NN o
of IN o
positive JJ o
fungal NN o
cultures NNS o
also RB N
tended VBD N
to TO N
decrease VB N
( ( N
p JJ N
= NNP N
0.0654 CD N
) ) N
. . N

The DT N
tolerability NN o
of IN N
the DT N
tested JJ N
substances NNS N
was VBD N
good JJ N
. . N

CONCLUSION NNP N
Coriander NNP i
oil NN i
is VBZ N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
interdigital JJ N
tinea NN N
pedis NN N
. . N

-DOCSTART- -X- O O

Perceptual JJ o
learning NN o
of IN o
speech NN o
under IN N
optimal JJ N
and CC N
adverse JJ N
conditions NNS N
. . N

Humans NNS p
have VBP N
a DT N
remarkable JJ N
ability NN N
to TO N
understand VB N
spoken JJ N
language NN N
despite IN N
the DT N
large JJ N
amount NN N
of IN N
variability NN N
in IN N
speech NN N
. . N

Previous JJ N
research NN N
has VBZ N
shown VBN N
that IN N
listeners NNS N
can MD N
use VB N
lexical JJ i
information NN i
to TO N
guide VB N
their PRP$ N
interpretation NN N
of IN N
atypical JJ N
sounds NNS N
in IN N
speech NN N
( ( N
Norris NNP N
, , N
McQueen NNP N
, , N
& CC N
Cutler NNP N
, , N
2003 CD N
) ) N
. . N

This DT N
kind NN N
of IN N
lexically RB i
induced VBN i
perceptual JJ o
learning NN o
enables NNS N
people NNS p
to TO N
adjust VB N
to TO N
the DT N
variations NNS N
in IN N
utterances NNS N
due JJ N
to TO N
talker-specific JJ N
characteristics NNS N
, , N
such JJ N
as IN N
individual JJ N
identity NN N
and CC N
dialect NN N
. . N

The DT N
current JJ N
study NN N
investigated VBD N
perceptual JJ o
learning NN o
in IN N
two CD N
optimal JJ N
conditions NNS N
: : N
conversational JJ i
speech NN i
( ( i
Experiment NNP i
1 CD N
) ) N
versus NN N
clear JJ i
speech NN i
( ( N
Experiment NNP N
2 CD N
) ) N
, , N
and CC N
three CD N
adverse JJ N
conditions NNS N
: : N
noise NN i
( ( N
Experiment NNP N
3a CD N
) ) N
versus NN N
two CD i
cognitive JJ i
loads NNS i
( ( N
Experiments NNS N
4a CD N
and CC N
4b CD N
) ) N
. . N

Perceptual JJ o
learning NN o
occurred VBD N
in IN N
the DT N
two CD N
optimal JJ i
conditions NNS i
and CC N
in IN N
the DT N
two CD N
cognitive JJ i
load NN i
conditions NNS i
, , N
but CC N
not RB N
in IN N
the DT N
noise NN i
condition NN i
. . i

Furthermore NNP N
, , N
perceptual JJ o
learning NN o
occurred VBD N
only RB N
in IN N
the DT N
first JJ N
of IN N
two CD N
sessions NNS N
for IN N
each DT N
participant NN N
, , N
and CC N
only RB N
for IN N
atypical JJ N
/s/ NNP N
sounds NNS N
and CC N
not RB N
for IN N
atypical JJ N
/f/ NNP N
sounds VBZ N
. . N

This DT N
pattern NN N
of IN N
learning NN N
and CC N
nonlearning NN N
reflects VBZ N
a DT N
balance NN N
between IN N
flexibility NN N
and CC N
stability NN N
that IN N
the DT N
speech NN N
system NN N
must MD N
have VB N
to TO N
deal VB N
with IN N
speech NN N
variability NN N
in IN N
the DT N
diverse JJ N
conditions NNS N
that IN N
speech NN N
is VBZ N
encountered VBN N
. . N

-DOCSTART- -X- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
hydrocodone/acetaminophen NN N
versus NN N
codeine/acetaminophen NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ p
extremity NN p
pain NN p
after IN p
emergency NN p
department NN p
discharge NN p
. . p

OBJECTIVES CC N
The DT N
objective NN N
was VBD N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
hydrocodone/acetaminophen NN i
( ( N
Vicodin NNP N
[ VBZ N
5/500 CD N
] NN N
) ) N
provides VBZ N
more RBR N
efficacious JJ N
analgesia NN N
than IN N
codeine/acetaminophen NN i
( ( N
Tylenol NNP N
# # N
3 CD N
[ $ N
30/300 CD N
] NN N
) ) N
in IN N
patients NNS p
discharged VBN p
from IN p
the DT p
emergency NN p
department NN p
( ( p
ED NNP p
) ) p
. . p

Both DT N
are VBP N
currently RB N
Drug NNP N
Enforcement NNP N
Administration NNP N
( ( N
DEA NNP N
) ) N
Schedule NNP N
III NNP N
narcotics NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
clinical JJ N
trial NN N
of IN N
patients NNS p
with IN p
acute JJ p
extremity NN p
pain NN p
who WP p
were VBD p
discharged VBN p
home NN p
from IN p
the DT p
ED NNP p
, , N
comparing VBG N
a DT N
3-day JJ N
supply NN N
of IN N
oral JJ i
hydrocodone/acetaminophen NN i
( ( i
5 CD i
mg/500 RB i
mg NN i
) ) i
to TO i
oral JJ i
codeine/acetaminophen NN i
( ( i
30 CD i
mg/300 RB i
mg NN i
) ) i
. . i

Pain NN o
was VBD N
measured VBN N
on IN N
a DT N
valid JJ N
and CC N
reproducible JJ N
verbal JJ N
numeric NN N
rating NN N
scale NN N
( ( N
NRS NNP N
) ) N
ranging VBG N
from IN N
0 CD N
to TO N
10 CD N
, , N
and CC N
patients NNS N
were VBD N
contacted VBN N
by IN N
telephone NN N
approximately RB N
24 CD N
hours NNS N
after IN N
being VBG N
discharged VBN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
between-group JJ N
difference NN N
in IN N
improvement NN N
in IN N
pain NN o
at IN N
2 CD N
hours NNS N
following VBG N
the DT N
most RBS N
recent JJ N
ingestion NN N
of IN N
the DT N
study NN N
drug NN N
, , N
relative JJ N
to TO N
the DT N
time NN N
of IN N
phone NN N
contact NN N
after IN N
ED NNP N
discharge NN N
. . N

Secondary JJ N
outcomes NNS N
compared VBN N
side-effect JJ o
profiles NNS o
and CC o
patient JJ o
satisfaction NN o
. . o

RESULTS VB N
The DT N
median JJ o
time NN o
from IN o
ED NNP o
discharge NN N
to TO N
follow-up NN N
was VBD N
26 CD N
hours NNS N
( ( N
interquartile JJ N
range NN N
[ NNP N
IQR NNP N
] NNP N
= VBD N
24 CD N
to TO N
39 CD N
hours NNS N
) ) N
. . N

The DT N
mean JJ o
NRS NNP o
pain NN o
score NN o
before IN N
the DT N
most RBS N
recent JJ N
dose NN N
of IN N
pain NN N
medication NN N
after IN N
ED NNP N
discharge NN N
was VBD N
7.6 CD N
NRS NNP N
units NNS N
for IN N
both DT N
groups NNS N
. . N

The DT N
mean JJ o
decrease NN o
in IN o
pain NN o
scores NNS o
2 CD N
hours NNS N
after IN N
pain NN o
medications NNS N
were VBD N
taken VBN N
were VBD N
3.9 CD N
NRS NNP N
units NNS N
in IN N
the DT N
hydrocodone/acetaminophen NN i
group NN N
versus VBD N
3.5 CD N
NRS NNP N
units NNS N
in IN N
the DT N
codeine/acetaminophen NN i
group NN N
, , N
for IN N
a DT N
difference NN N
of IN N
0.4 CD N
NRS NNP N
units NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= NNP N
-0.3 NNP N
to TO N
1.2 CD N
NRS NNP N
units NNS N
) ) N
. . N

No UH o
differences NNS o
were VBD N
found VBN N
in IN N
side JJ o
effects NNS o
or CC o
patient JJ o
satisfaction NN o
. . o

CONCLUSIONS NNP N
Both NNP N
medications NNS N
decreased VBD o
NRS NNP o
pain NN o
scores NNS o
by IN N
approximately RB N
50 CD N
% NN N
. . N

However RB N
, , N
the DT N
oral JJ N
hydrocodone/acetaminophen NN N
failed VBD N
to TO N
provide VB N
clinically RB N
or CC N
statistically RB N
superior JJ o
pain NN o
relief NN o
compared VBN N
to TO N
oral VB N
codeine/acetaminophen NN i
when WRB N
prescribed VBN N
to TO N
patients NNS N
discharged VBN N
from IN N
the DT N
ED NNP N
with IN N
acute JJ N
extremity NN N
pain NN N
. . N

Similarly RB N
, , N
there EX N
were VBD N
no DT N
clinically RB N
or CC N
statistically RB N
important JJ N
differences NNS N
in IN N
side-effect JJ N
profiles NNS N
or CC N
patient JJ N
satisfaction NN N
. . N

If IN N
the DT N
DEA NNP N
reclassifies VBZ N
hydrocodone NN N
as IN N
a DT N
Schedule NNP N
II NNP N
narcotic JJ N
, , N
as IN N
recently RB N
recommended VBN N
by IN N
its PRP$ N
advisory JJ N
board NN N
, , N
our PRP$ N
data NNS N
suggest VBP N
that IN N
the DT N
codeine/acetaminophen NN i
may MD N
be VB N
a DT N
clinically RB N
reasonable JJ N
Schedule NNP N
III NNP N
substitute NN N
for IN N
hydrocodone/acetaminophen NN N
at IN N
ED NNP N
discharge NN N
. . N

These DT N
findings NNS N
should MD N
be VB N
regarded VBN N
as IN N
tentative JJ N
and CC N
require JJ N
independent JJ N
validation NN N
in IN N
similar JJ N
and CC N
other JJ N
acute NN N
pain NN N
models NNS N
. . N

-DOCSTART- -X- O O

Effects NNS o
of IN N
nutritional JJ i
supplementation NN i
on IN N
IQ NNP o
and CC N
certain JJ N
other JJ N
variables NNS N
associated VBN N
with IN N
Down NNP p
syndrome NN p
. . p

In IN N
a DT N
double-blind NN N
study NN N
, , N
24 CD p
Down NNP p
syndrome NN p
children NNS p
, , p
ages VBZ p
6 CD p
to TO p
17 CD p
years NNS p
living VBG p
at IN p
home NN p
, , p
were VBD p
given VBN p
a DT p
megadose JJ i
multi-vitamin/mineral JJ i
supplement NN i
for IN p
4 CD p
months NNS p
. . p

A DT N
matched JJ N
group NN N
of IN N
23 CD p
children NNS p
received VBD p
a DT p
placebo NN i
in IN p
identical JJ p
form NN p
. . p

The DT o
children NNS o
's POS o
IQ NNP o
, , o
vision NN o
, , o
and CC o
visual-motor JJ o
integration NN o
were VBD N
tested VBN N
before IN N
and CC N
after IN N
supplementation NN N
, , N
and CC N
weekly JJ N
checks NNS N
were VBD N
made VBN N
to TO N
monitor VB N
behavioral JJ N
changes NNS N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
on IN N
any DT N
measures NNS N
as IN N
a DT N
result NN N
of IN N
supplementation NN N
. . N

-DOCSTART- -X- O O

Minimally RB N
invasive JJ N
treatment NN N
combined VBN N
with IN N
cytokine-induced JJ i
killer NN i
cells NNS i
therapy VBP i
lower JJR N
the DT N
short-term JJ N
recurrence NN N
rates NNS N
of IN N
hepatocellular JJ p
carcinomas NN p
. . p

The DT N
recurrence NN N
of IN N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
after IN N
minimally RB N
invasive JJ N
therapy NN N
is VBZ N
frequent JJ N
. . N

Adoptive JJ i
immunotherapy NN i
is VBZ N
thought VBN N
to TO N
be VB N
an DT N
effective JJ N
method NN N
to TO N
lower JJR N
recurrence NN N
and CC N
metastasis NN N
rates NNS N
of IN N
malignant JJ N
tumors NNS N
. . N

Therefore RB N
, , N
85 CD p
HCC NNP p
patients NNS p
after IN p
transcatheter JJ i
arterial JJ i
chemoembolization NN i
and CC p
radiofrequency NN i
ablation NN i
therapy NN i
were VBD p
randomized VBN p
to TO p
immunotherapy VB i
group NN p
and CC p
no DT i
adjuvant JJ i
therapy NN i
group NN p
. . p

Autologous JJ i
cytokine-induced JJ i
killer NN i
( ( i
CIK NNP i
) ) i
cells NNS i
were VBD i
transfused VBN i
via IN N
hepatic JJ N
artery NN N
to TO N
the DT N
patients NNS N
. . N

The DT N
alteration NN N
of IN N
levels NNS N
of IN N
lymphocyte JJ N
subsets NNS N
in IN N
peripheral JJ N
blood NN N
of IN N
patients NNS N
was VBD N
examined VBN N
by IN N
flow JJ N
cytometry NN N
. . N

All DT p
patients NNS p
were VBD p
screened VBN p
by IN p
computed JJ p
tomography NN p
every DT p
2 CD p
months NNS p
to TO p
observe VB p
the DT p
tumor NN p
recurrent NN p
conditions NNS p
. . p

After IN N
CIK NNP i
cell NN i
infusions NNS N
, , N
the DT N
percentages NNS o
of IN o
CD3+ NNP o
, , o
CD4+ NNP o
, , o
CD56+ NNP o
, , o
CD3+CD56+ NNP o
cells NNS o
, , o
and CC o
CD4+/CD8+ NNP o
ratio VBP o
increased VBN N
from IN N
68.6+/-11.0 CD N
% NN N
, , N
31.1+/-9.0 CD N
% NN N
, , N
15.6+/-7.9 CD N
% NN N
, , N
5.2+/-3.1 CD N
% NN N
, , N
and CC N
1.1+/-0.5 JJ N
to TO N
70.7+/-10.1 CD N
% NN N
, , N
33.5+/-8.0 CD N
% NN N
, , N
18.4+/-9.4 CD N
% NN N
, , N
5.9+/-2.8 CD N
% NN N
, , N
and CC N
1.3+/-0.7 JJ N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
whereas IN N
the DT N
percentage NN o
of IN o
CD8 NNP o
cells NNS o
decreased VBN N
from IN N
31.1+/-7.8 CD N
% NN N
to TO N
28.6+/-8.3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
1-year JJ o
and CC o
18-month JJ o
recurrence NN o
rates NNS o
of IN o
the DT o
study NN o
group NN o
were VBD N
8.9 CD N
% NN N
and CC N
15.6 CD N
% NN N
, , N
compared VBN N
with IN N
30.0 CD N
% NN N
and CC N
40.0 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
both DT N
P NNP N
value NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
data NN N
suggest NN N
that IN N
CIK NNP i
cell NN i
transfusion NN i
is VBZ N
an DT N
effective JJ N
treatment NN N
. . N

It PRP N
can MD N
boost VB N
the DT N
immunologic JJ N
function NN N
in IN N
HCC NNP p
patients NNS p
and CC N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
reducing VBG N
the DT N
recurrence NN N
rate NN N
of IN N
HCC NNP N
. . N

-DOCSTART- -X- O O

Evaluating VBG N
the DT N
efficacy NN o
of IN N
thoracoscopy NN i
and CC i
talc JJ i
poudrage NN i
versus NN i
pleurodesis NN i
using VBG i
talc JJ i
slurry NN i
( ( N
TAPPS NNP N
trial NN N
) ) N
: : N
protocol NN N
of IN N
an DT N
open-label NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

INTRODUCTION VB N
The DT N
management NN N
of IN N
recurrent NN N
malignant JJ N
pleural JJ N
effusions NNS N
( ( N
MPE NNP N
) ) N
can MD N
be VB N
challenging VBG N
. . N

Various JJ N
options NNS N
are VBP N
available JJ N
, , N
with IN N
the DT N
most RBS N
efficacious JJ N
and CC N
widely RB N
used VBD N
being VBG N
talc JJ i
pleurodesis NN i
. . i

Talc NNP i
can MD N
either RB N
be VB N
applied VBN N
via IN N
a DT N
chest NN N
drain NN N
in IN N
the DT N
form NN N
of IN N
slurry NN N
, , N
or CC N
at IN N
medical JJ i
thoracoscopy NN i
using VBG i
poudrage NN i
. . i

Current JJ N
evidence NN N
regarding VBG N
which WDT N
method NN N
is VBZ N
most RBS N
effective JJ N
is VBZ N
conflicting VBG N
and CC N
often RB N
methodologically RB N
flawed VBN N
. . N

The DT N
TAPPS NNP N
trial NN N
is VBZ N
a DT N
suitably RB N
powered VBN N
, , N
multicentre FW N
, , N
open-label JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
designed VBN N
to TO N
compare VB N
the DT N
pleurodesis NN N
success NN N
rate NN N
of IN N
medical JJ i
thoracoscopy NN i
and CC i
talc JJ i
poudrage NN i
with IN i
chest NN i
drain NN i
insertion NN i
and CC i
talc NN i
slurry NN i
. . i

METHODS NNP N
AND CC N
ANALYSIS NNP N
330 CD p
patients NNS p
with IN p
a DT p
confirmed JJ p
MPE NNP p
requiring VBG p
intervention NN p
will MD p
be VB p
recruited VBN p
from IN p
UK NNP p
hospitals NNS p
. . p

Patients NNS N
will MD N
be VB N
randomised VBN N
( ( N
1:1 CD N
) ) N
to TO N
undergo VB N
either RB N
small JJ i
bore NN i
( ( i
< JJ i
14 CD i
Fr NNP i
) ) i
Seldinger NNP i
chest JJS i
drain NN i
insertion NN i
followed VBN i
by IN i
instillation NN i
of IN i
sterile JJ i
talc NN i
( ( i
4 CD N
g NN N
) ) N
, , N
or CC N
to TO i
undergo VB i
medical JJ i
thoracoscopy NN i
and CC i
simultaneous JJ i
poudrage NN i
( ( i
4 CD i
g NN N
) ) N
. . N

The DT N
allocated JJ N
procedure NN N
will MD N
be VB N
performed VBN N
as IN N
an DT N
inpatient NN N
within IN N
3 CD N
days NNS N
of IN N
randomisation NN N
taking VBG N
place NN N
. . N

Following VBG N
discharge NN N
, , N
patients NNS N
will MD N
be VB N
followed VBN N
up RP N
at IN N
regular JJ N
intervals NNS N
for IN N
6 CD N
months NNS N
. . N

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
pleurodesis JJ o
failure NN o
rates NNS o
at IN o
3 CD N
months NNS N
. . N

Pleurodesis NNP o
failure NN o
is VBZ o
defined VBN N
as IN N
the DT N
need NN N
for IN N
further JJ N
pleural JJ N
intervention NN N
for IN N
fluid JJ N
management NN N
on IN N
the DT N
side NN N
of IN N
the DT N
trial NN N
intervention NN N
. . N

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
The DT N
trial NN N
has VBZ N
received VBN N
ethical JJ N
approval NN N
from IN N
the DT N
National NNP N
Research NNP N
Ethics NNP N
Service NNP N
Committee NNP N
North NNP N
West-Preston NNP N
( ( N
12/NW/0467 CD N
) ) N
. . N

There EX N
is VBZ N
a DT N
trial NN N
steering VBG N
committee NN N
which WDT N
includes VBZ N
independent JJ N
members NNS N
and CC N
a DT N
patient NN N
and CC N
public JJ N
representative NN N
. . N

The DT N
trial NN N
results NNS N
will MD N
be VB N
published VBN N
in IN N
a DT N
peer-reviewed JJ N
journal NN N
and CC N
presented VBD N
at IN N
international JJ N
conferences NNS N
, , N
as RB N
well RB N
as IN N
being VBG N
disseminated VBN N
via IN N
local JJ N
and CC N
national JJ N
charities NNS N
and CC N
patient JJ N
groups NNS N
. . N

All DT N
participants NNS N
who WP N
wish VBP N
to TO N
know VB N
the DT N
study NN N
results NNS N
will MD N
also RB N
be VB N
contacted VBN N
directly RB N
on IN N
their PRP$ N
publication NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN47845793 NNP N
. . N

-DOCSTART- -X- O O

The DT N
interaction NN N
between IN N
propofol NN i
and CC i
clonidine NN i
for IN N
loss NN N
of IN N
consciousness NN N
. . N

UNLABELLED NNP N
Clonidine NNP i
premedication NN N
reduces VBZ N
the DT N
intraoperative JJ N
requirement NN N
for IN N
opioids NNS N
and CC N
volatile JJ N
anesthetics NNS N
. . N

Clonidine NNP i
also RB N
reduces VBZ N
the DT N
induction NN N
dose NN N
of IN N
IV NNP N
anesthetics NNS N
. . N

There EX N
is VBZ N
no DT N
information NN N
, , N
however RB N
, , N
regarding VBG N
the DT N
effect NN N
of IN N
oral JJ N
clonidine NN i
premedication NN N
on IN N
the DT N
propofol NN i
blood NN N
concentrations NNS N
required VBD N
for IN N
loss NN N
of IN N
consciousness NN N
, , N
and CC N
the DT N
interaction NN N
between IN N
propofol NN i
and CC i
clonidine NN i
. . i

We PRP N
randomly RB N
administered VBD N
target NN N
effect-site JJ N
concentrations NNS N
of IN N
propofol NN i
ranging VBG N
from IN N
0.5 CD N
to TO N
5 CD N
. . N

0 CD N
microg/mL NN N
by IN N
using VBG N
computer-assisted JJ N
target-controlled JJ N
infusion NN N
to TO N
3 CD p
groups NNS p
of IN p
healthy JJ p
male JJ p
patients NNS p
: : p
Control NNP i
( ( i
n JJ i
= NNP i
35 CD i
) ) i
, , i
2.5 CD i
microg/kg NN i
Clonidine NNP i
( ( i
n JJ i
= NNP i
36 CD i
) ) i
, , i
and CC i
5.0 CD i
microg/kg NNS i
Clonidine NNP i
( ( i
n JJ i
= NNP i
36 CD i
) ) i
groups NNS i
. . i

Nothing NN i
was VBD i
administered VBN i
to TO i
the DT i
Control NNP i
group NN i
. . i

Clonidine NNP i
( ( N
2.5 CD N
or CC N
5.0 CD N
microg/kg NN N
) ) N
was VBD N
administered VBN N
orally RB N
90 CD N
min NN N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
in IN N
the DT N
Clonidine NNP i
groups NNS N
. . N

After IN N
equilibration NN N
between IN N
the DT N
blood NN N
and CC N
effect-site NN N
for IN N
15 CD N
min NN N
, , N
a DT N
verbal JJ N
command NN N
to TO N
open VB N
their PRP$ N
eyes NNS N
was VBD N
given VBN N
two CD N
times NNS N
to TO N
the DT N
patients NNS N
. . N

Arterial JJ o
blood NN o
samples NNS o
for IN N
analysis NN N
of IN N
the DT N
serum NN N
propofol NN i
and CC i
clonidine NN i
concentrations NNS N
were VBD N
taken VBN N
immediately RB N
before IN N
verbal JJ N
commands NNS N
were VBD N
given VBN N
. . N

Measured NNP N
serum VBD o
propofol JJ o
concentrations NNS o
in IN o
equilibrium NN o
with IN N
the DT N
effect-site NN N
at IN N
which WDT N
50 CD N
% NN N
of IN N
the DT N
patients NNS N
did VBD N
not RB N
respond VB N
to TO N
verbal VB N
commands NNS N
( ( N
EC50 NNP N
for IN N
loss NN N
of IN N
consciousness NN N
) ) N
were VBD N
determined VBN N
by IN N
logistic JJ N
regression NN N
. . N

The DT N
EC50 NNP o
+/- JJ o
SE NNP o
values NNS o
in IN N
the DT N
Control NNP N
, , N
2.5 CD N
microg/kg NN N
Clonidine NNP i
, , N
and CC N
5.0 CD N
microg/kg NNS N
Clonidine NNP i
groups NNS N
were VBD N
2.67 CD N
+/- JJ N
0.18 CD N
, , N
1.31 CD N
+/- JJ N
0.12 CD N
, , N
and CC N
0.91 CD N
+/- JJ N
0.13 CD N
microg/mL NN N
, , N
respectively RB N
. . N

The DT N
EC50 NNP o
in IN N
the DT N
2.5 CD N
and CC N
5.0 CD N
microg/kg NNS N
clonidine JJ N
groups NNS N
was VBD N
significantly RB N
smaller JJR N
than IN N
that DT N
in IN N
the DT N
Control NNP N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
use NN N
of IN N
a DT N
response NN N
surface NN N
modeling VBG N
analysis NN N
indicated VBD N
that IN N
there EX N
was VBD N
an DT N
additive JJ o
interaction NN o
between IN N
measured VBN N
arterial JJ N
propofol NN i
and CC i
clonidine NN i
concentrations NNS N
in IN N
relation NN N
to TO N
loss NN o
of IN o
consciousness NN o
. . o

These DT N
results NNS N
indicate VBP N
that IN N
propofol NN N
and CC N
clonidine NN N
act NN N
additively RB N
for IN N
loss NN o
of IN o
consciousness NN o
. . o

IMPLICATIONS NNP N
Oral NNP N
clonidine NN i
2.5 CD N
and CC N
5.0 CD N
microg/kg NN N
premedication NN N
decreases VBZ N
the DT N
propofol JJ i
concentration NN N
required VBN N
for IN N
loss NN N
of IN N
consciousness NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
creatine JJ i
supplementation NN i
on IN N
repetitive JJ N
sprint NN N
performance NN N
and CC N
body NN N
composition NN N
in IN N
competitive JJ p
swimmers NNS p
. . p

In IN N
a DT N
double-blind NN N
and CC N
randomized JJ N
manner NN N
, , N
18 CD p
male NN p
and CC p
female JJ p
junior JJ p
competitive JJ p
swimmers NNS p
supplemented VBD N
their PRP$ N
diets NNS N
with IN N
21 CD N
g.day-1 NN N
of IN N
creatine NN i
monohydrate NN i
( ( i
Cr NNP i
) ) i
or CC N
a DT N
maltodextrin JJ i
placebo NN i
( ( i
P NNP i
) ) i
for IN N
9 CD p
days NNS p
during IN p
training NN p
. . p

Prior NNP N
to TO N
and CC N
following VBG N
supplementation NN N
, , N
subjects NNS N
performed VBD N
three CD N
100-m JJ N
freestyle JJ N
sprint NN N
swims NNS N
( ( N
long JJ N
course NN N
) ) N
with IN N
60 CD N
s JJ N
rest/recovery NN N
between IN N
heats NNS N
. . N

In IN N
addition NN N
, , N
subjects NNS N
performed VBD N
three CD N
20-s JJ N
arm NN N
ergometer NN N
maximal-effort JJ N
sprint NN N
tests NNS N
in IN N
the DT N
prone NN N
position NN N
with IN N
60 CD N
s JJ N
rest/recovery NN N
between IN N
sprint NN N
tests NNS N
. . N

Significant JJ N
differences NNS N
were VBD N
observed VBN N
among IN N
swim JJ o
times NNS o
, , N
with IN N
Cr NNP N
subjects NNS N
swimming VBG N
significantly RB N
faster RBR N
than IN N
P NNP N
subjects NNS N
following VBG N
supplementation NN N
in IN N
Heat NNP N
1 CD N
and CC N
significantly RB N
decreasing VBG N
swim JJ o
time NN o
in IN N
the DT N
second JJ N
100-m JJ N
sprint NN N
. . N

There EX N
was VBD N
also RB N
some DT N
evidence NN N
that IN N
cumulative JJ o
time NN o
to TO o
perform VB o
the DT o
three CD o
100-m JJ o
swims NNS o
was VBD N
decreased VBN N
in IN N
the DT N
Cr NNP N
group NN N
. . N

Results NNP N
indicate VBP N
that IN N
9 CD N
days NNS N
of IN N
Cr NNP i
supplementation NN N
during IN N
swim JJ N
training NN N
may MD N
provide VB N
some DT N
ergogenic JJ N
value NN N
to TO N
competitive JJ N
junior JJ N
swimmers NNS N
during IN N
repetitive JJ N
sprint NN N
performance NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Observation NNP N
on IN N
therapeutic JJ N
effect NN N
of IN N
electroacupuncture NN i
plus CC i
blood-letting JJ i
puncture NN i
and CC i
cupping NN i
combined VBN i
with IN i
diet JJ i
intervention NN i
for IN N
treatment NN N
of IN N
acute JJ p
gouty NN p
arthritis NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
explore VB N
a DT N
more RBR N
effective JJ N
therapy NN N
for IN N
acute JJ p
gouty NN p
arthritis NN p
. . p

METHODS NNP N
Sixty NNP p
cases NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
observation NN N
group NN N
and CC N
a DT N
control NN N
group NN N
, , N
30 CD N
cases NNS N
in IN N
eachgroup NN N
. . N

On IN N
the DT N
basis NN N
of IN N
diet JJ i
intervention NN i
, , N
the DT N
observation NN N
group NN N
was VBD N
treated VBN N
with IN N
electroacupuncture NN i
at IN i
local JJ i
points NNS i
combined VBN i
with IN i
blood-letting JJ i
puncture NN i
and CC i
cupping NN i
, , N
and CC N
the DT N
control NN N
group NN N
with IN N
oral JJ N
administration NN N
of IN N
Probenecid NNP i
. . i

Their PRP$ N
therapeutic JJ N
effects NNS N
were VBD N
ob JJ N
served VBN N
. . N

RESULTS VB N
The DT N
effective JJ N
rate NN N
was VBD N
96.7 CD N
% NN N
in IN N
the DT N
observation NN N
group NN N
which WDT N
was VBD N
better JJR N
than IN N
86.7 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
blood NN o
uric JJ o
acid NN o
decreased VBN N
significantly RB N
in IN N
the DT N
two CD N
groups NNS N
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
the DT N
observed JJ N
group NN N
being VBG N
lower JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NN N
On IN N
the DT N
basis NN N
of IN N
diet JJ i
intervention NN i
, , i
electroacupuncture JJ i
plus CC i
blood-letting JJ i
puncture NN i
and CC i
cupping NN i
is VBZ N
a DT N
better JJR N
therapy NN N
for IN N
acute JJ N
gouty NN N
arthritis NN N
. . N

-DOCSTART- -X- O O

Language NN N
, , N
speech NN N
sound NN N
production NN N
, , N
and CC N
cognition NN N
in IN N
three-year-old JJ p
children NNS p
in IN p
relation NN p
to TO p
otitis VB p
media NNS p
in IN p
their PRP$ p
first JJ p
three CD p
years NNS p
of IN p
life NN p
. . p

OBJECTIVE CC N
As IN N
part NN N
of IN N
a DT N
prospective JJ N
study NN N
of IN N
possible JJ N
effects NNS N
of IN N
early-life JJ N
otitis NN N
media NNS N
on IN N
speech NN N
, , N
language NN N
, , N
cognitive JJ N
, , N
and CC N
psychosocial JJ N
development NN N
, , N
we PRP N
tested VBD N
relationships NNS N
between IN N
children NNS N
's POS N
cumulative JJ N
duration NN N
of IN N
middle JJ N
ear JJ N
effusion NN N
( ( N
MEE NNP N
) ) N
in IN N
their PRP$ N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
and CC N
their PRP$ N
scores NNS N
on IN N
measures NNS o
of IN o
language NN o
, , o
speech NN o
sound NN o
production NN o
, , o
and CC o
cognition NN o
at IN N
3 CD N
years NNS N
of IN N
age NN N
. . N

METHODS NNP N
We PRP p
enrolled VBD p
6350 CD p
healthy JJ p
infants NNS p
by IN p
2 CD p
months NNS p
of IN p
age NN p
who WP p
presented VBD p
for IN p
primary JJ p
care NN p
at IN p
1 CD p
of IN p
2 CD p
urban JJ p
hospitals NNS p
or CC p
1 CD p
of IN p
2 CD p
small JJ p
town/rural JJ p
and CC p
4 CD p
suburban JJ p
private JJ p
pediatric JJ p
practices NNS p
. . p

We PRP N
intensively RB N
monitored VBD N
the DT N
children NNS N
's POS N
middle JJ N
ear NN N
status NN N
by IN N
pneumatic JJ i
otoscopy NN i
, , i
supplemented VBN i
by IN i
tympanometry NN i
, , N
throughout IN N
their PRP$ N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
; : N
we PRP N
monitored VBD N
the DT N
validity NN N
of IN N
the DT N
otoscopic JJ N
observations NNS N
on IN N
an DT N
ongoing JJ N
basis NN N
; : N
and CC N
we PRP i
treated VBD i
children NNS i
for IN i
otitis NN i
media NNS i
according VBG i
to TO i
specified VBN i
guidelines NNS i
. . i

Children NNP p
who WP p
met VBD p
specified VBN p
minimum JJ p
criteria NNS p
regarding VBG p
the DT p
persistence NN p
of IN p
MEE NNP p
became VBD p
eligible JJ p
for IN p
a DT p
clinical JJ p
trial NN p
in IN N
which WDT N
they PRP N
were VBD N
assigned VBN N
randomly RB N
to TO N
undergo VB N
tympanostomy JJ i
tube NN i
placement NN i
either CC N
promptly RB N
or CC N
after IN N
a DT N
defined JJ N
extended JJ N
period NN N
if IN N
MEE NNP N
remained VBD N
present JJ N
. . N

From IN p
among IN p
those DT p
remaining VBG p
, , p
we PRP p
selected VBD p
randomly RB p
, , p
within IN p
sociodemographic JJ p
strata NNS p
, , p
a DT p
sample NN p
of IN p
241 CD p
children NNS p
who WP p
represented VBD p
a DT p
spectrum NN p
of IN p
MEE NNP p
experience NN p
from IN p
having VBG p
no DT p
MEE NNP p
to TO p
having VBG p
MEE NNP p
whose WP$ p
cumulative JJ p
duration NN p
fell VBD p
just RB p
short RB p
of IN p
meeting VBG p
randomization NN p
criteria NNS p
. . p

In IN p
subjects NNS p
so RB p
selected VBN p
, , p
the DT p
estimated JJ p
duration NN p
of IN p
MEE NNP p
ranged VBD p
from IN p
none NN p
to TO p
65.6 CD p
% NN p
of IN p
the DT p
first JJ p
year NN p
of IN p
life NN p
and CC p
44.8 CD p
% NN p
of IN p
the DT p
first JJ p
3 CD p
years NNS p
of IN p
life NN p
. . p

In IN N
these DT N
241 CD p
children NNS p
we PRP N
assessed VBD N
language NN o
development NN o
, , o
speech NN o
sound NN o
production NN o
, , o
and CC o
cognition NN o
at IN N
3 CD N
years NNS N
of IN N
age NN N
, , N
using VBG N
both DT N
formal JJ N
tests NNS N
and CC N
conversational JJ N
samples NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
weak JJ N
to TO N
moderate VB N
, , N
statistically RB N
significant JJ N
negative JJ N
correlations NNS N
between IN N
children NNS N
's POS N
cumulative JJ N
durations NNS N
of IN N
MEE NNP N
in IN N
their PRP$ N
first JJ N
year NN N
of IN N
life NN N
or CC N
in IN N
age NN N
periods NNS N
that WDT N
included VBD N
their PRP$ N
first JJ N
year NN N
of IN N
life NN N
, , N
and CC N
their PRP$ N
scores NNS o
on IN o
formal JJ o
tests NNS o
of IN o
receptive JJ o
vocabulary NN o
and CC o
verbal JJ o
aspects NNS o
of IN o
cognition NN o
at IN N
3 CD N
years NNS N
of IN N
age NN N
. . N

However RB N
, , N
the DT N
percent NN N
of IN N
variance NN N
in IN N
these DT N
scores NNS N
explained VBN N
by IN N
time NN N
with IN N
MEE NNP N
in IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
beyond IN N
that DT N
explained VBN N
by IN N
sociodemographic JJ N
variables NNS N
ranged VBD N
only RB N
from IN N
1.2 CD N
% NN N
to TO N
2.9 CD N
% NN N
, , N
and CC N
the DT N
negative JJ N
correlations NNS N
were VBD N
concentrated VBN N
in IN N
the DT N
subgroup NN N
of IN N
children NNS N
whose WP$ N
families NNS N
had VBD N
private JJ N
health NN N
insurance NN N
( ( N
rather RB N
than IN N
Medicaid NNP N
) ) N
. . N

We PRP N
found VBD N
no DT N
significant JJ N
correlations NNS N
in IN N
the DT N
study NN N
population NN N
as IN N
a DT N
whole NN N
or CC N
in IN N
any DT N
subgroup NN N
between IN N
time NN N
with IN N
MEE NNP N
during IN N
antecedent JJ N
periods NNS N
and CC N
children NNS N
's POS N
scores NNS N
on IN N
measures NNS N
of IN N
spontaneous JJ o
expressive JJ o
language NN o
, , o
speech NN o
sound NN o
production NN o
, , o
or CC o
other JJ o
measured JJ o
aspects NNS o
of IN o
cognition NN o
. . o

In IN N
contrast NN N
, , N
by IN N
wide JJ N
margins NNS N
, , N
scores NNS o
on IN o
all DT o
measures NNS o
were VBD N
consistently RB N
highest JJS N
among IN N
the DT N
most RBS N
socioeconomically RB N
advantaged JJ N
children NNS N
and CC N
lowest JJS N
among IN N
the DT N
most RBS N
socioeconomically RB N
disadvantaged JJ N
children NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
either RB N
that DT N
persistent JJ p
early-life JJ p
MEE NNP p
actually RB N
causes VBZ N
later RB N
small JJ N
, , N
circumscribed JJ N
impairments NNS N
of IN N
receptive JJ N
language NN N
and CC N
verbal JJ N
aspects NNS N
of IN N
cognition NN N
in IN N
certain JJ N
groups NNS N
of IN N
children NNS N
or CC N
that DT N
unidentified JJ N
, , N
confounding VBG N
factors NNS N
predispose JJ N
children NNS N
both DT N
to TO N
early-life NN N
otitis NN N
media NNS N
and CC N
to TO N
certain JJ N
types NNS N
of IN N
developmental JJ o
impairment NN o
. . o

Findings NNS N
in IN N
the DT N
randomized JJ N
clinical JJ N
trial NN N
component NN N
of IN N
the DT N
larger JJR N
study NN N
should MD N
help VB N
distinguish VB N
between IN N
causality NN N
and CC N
confounding NN N
as IN N
explanations NNS N
for IN N
our PRP$ N
findings.language NN o
, , o
speech NN o
, , o
cognition NN o
, , N
development NN N
, , N
otitis NN N
media NNS N
, , N
middle JJ N
ear JJ N
effusion NN N
. . N

-DOCSTART- -X- O O

Determinants NNS N
of IN N
serum JJ N
creatinine NN N
trajectory NN N
in IN N
acute JJ p
contrast NN p
nephropathy NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
describe VB N
the DT N
trajectory NN N
of IN N
creatinine NN o
( ( o
Cr NNP o
) ) o
rise NN o
and CC N
its PRP$ N
determinants NNS N
after IN p
exposure NN p
to TO p
radiocontrast VB p
media NNS p
. . p

Included VBN N
were VBD N
98 CD p
subjects NNS p
who WP p
underwent VBP p
cardiac JJ p
catheterization NN p
and CC N
were VBD N
randomized VBN N
to TO N
forced VBN N
diuresis NN i
with IN i
i.v NN i
. . i

crystalloid NN i
, , i
furosemide RB i
, , i
mannitol NN i
( ( i
if IN i
pulmonary JJ i
capillary JJ i
wedge NN i
pressure NN i
was VBD i
< JJ i
20 CD i
mmHg NN i
) ) i
, , i
and CC i
low JJ i
dose JJ i
dopamine NN i
versus NN i
intravenous JJ i
crystalloid NN i
and CC i
matching VBG i
placebos NNS i
. . i

Baseline NNP N
and CC N
postcatheterization NN N
serum NN o
Cr NNP o
levels NNS o
were VBD N
analyzed VBN N
in IN N
a DT N
longitudinal JJ N
fashion NN N
, , N
allowing VBG N
for IN N
differences NNS N
in IN N
the DT N
time NN N
between IN N
blood NN N
draws NNS N
, , N
to TO N
determine VB N
the DT N
different JJ N
critical JJ N
trajectories NNS N
of IN N
serum NN N
Cr NNP N
. . N

The DT p
mean JJ o
age NN o
, , o
baseline NN o
serum NN o
Cr NNP o
, , o
and CC o
Cr NNP o
clearance NN o
( ( o
CrCl NNP o
) ) o
were VBD p
69.3 CD p
+/- JJ p
10.8 CD p
years NNS p
, , p
2.5 CD p
+/- JJ p
0.9 CD p
mg/dL NN p
, , p
and CC p
31.4 CD p
+/- JJ p
12.1 CD p
mL/min NN p
, , p
respectively RB p
. . p

The DT N
clinically RB o
driven JJ o
postprocedural JJ o
observation NN o
time NN o
was VBD N
5.5 CD N
+/- JJ N
5.1 CD N
days NNS N
( ( N
range VB N
19 CD N
hours NNS N
and CC N
one CD N
Cr NNP N
value NN N
to TO N
25.7 CD N
days NNS N
and CC N
18 CD N
values NNS N
) ) N
. . N

The DT N
mean JJ o
maximum NN o
Cr NNP o
was VBD N
3.3 CD N
+/- JJ N
1.4 CD N
, , N
range NN N
1.7-8.7 JJ N
mg/dL NN N
) ) N
. . N

Longitudinal JJ N
models NNS N
support VBP N
baseline JJ N
Cr NNP o
clearance NN o
predictions NNS N
for IN N
the DT N
change NN N
in IN N
Cr NNP N
at IN N
24 CD N
hours NNS N
, , N
time NN N
as IN N
the DT N
determinant NN N
of IN N
Cr NNP N
trajectory NN N
, , N
and CC N
requisite JJ N
monitoring NN N
. . N

For IN N
any DT N
given VBN N
individual NN N
, , N
a DT N
rise NN N
in IN N
Cr NNP o
of IN N
< NNP N
or CC N
= $ N
0.5 CD N
mg/dL NN N
in IN N
the DT N
first JJ N
24 CD N
hours NNS N
after IN N
contrast NN N
exposure NN N
predicted VBD N
a DT N
favorable JJ N
outcome NN N
. . N

Baseline NNP o
renal JJ o
function NN o
is VBZ N
the DT N
major JJ N
determinant NN N
of IN N
the DT N
rate NN N
of IN N
rise NN N
, , N
height NN N
, , N
and CC N
duration NN N
of IN N
Cr NNP N
trajectory NN N
after IN N
contrast NN N
exposure NN N
. . N

Length NNP N
of IN N
observation NN N
and CC N
frequency NN N
of IN N
laboratory NN N
measures NNS N
can MD N
be VB N
anticipated VBN N
from IN N
these DT N
models NNS N
. . N

-DOCSTART- -X- O O

Dark-phase NNP N
light JJ N
contamination NN N
disrupts NNS N
circadian JJ N
rhythms NN N
in IN N
plasma JJ o
measures NNS N
of IN N
endocrine NN p
physiology NN o
and CC p
metabolism NN o
in IN p
rats NNS p
. . p

Dark-phase NNP i
light JJ i
contamination NN i
can MD N
significantly RB N
disrupt VB N
chronobiologic JJ o
rhythms NN o
, , N
thereby RB N
potentially RB N
altering VBG N
the DT N
endocrine NN N
physiology NN N
and CC N
metabolism NN N
of IN N
experimental JJ p
animals NNS p
and CC N
influencing VBG N
the DT N
outcome NN N
of IN N
scientific JJ N
investigations NNS N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
whether IN N
exposure NN N
to TO N
low-level JJ N
light JJ N
contamination NN N
during IN N
the DT N
dark JJ N
phase NN N
influenced VBD N
the DT N
normally RB N
entrained JJ N
circadian JJ N
rhythms NN N
of IN N
various JJ N
substances NNS N
in IN N
plasma NN N
. . N

Male JJ p
Sprague-Dawley JJ p
rats NNS p
( ( p
n JJ p
= $ p
6 CD p
per IN p
group NN p
) ) p
were VBD N
housed VBN N
in IN N
photobiologic JJ i
light-exposure JJ i
chambers NNS i
configured VBD N
to TO N
create VB N
1 CD N
) ) N
a DT N
12:12-h JJ N
light NN i
: : i
dark JJ i
cycle NN i
without IN i
dark-phase JJ i
light JJ i
contamination NN i
( ( N
control JJ N
condition NN N
; : N
123 CD N
?W/cm NN N
( ( N
2 CD N
) ) N
, , N
lights NNS N
on IN N
at IN N
0600 CD N
) ) N
, , N
2 CD N
) ) N
experimental NN N
exposure NN N
to TO N
a DT N
low JJ i
level NN i
of IN i
light NN i
during IN N
the DT N
12-h JJ N
dark NN N
phase NN N
( ( N
with IN N
0.02 CD N
, , N
0.05 CD N
, , N
0.06 CD N
, , N
or CC N
0.08 CD N
?W/cm NNS N
( ( N
2 CD N
) ) N
light NN N
at IN N
night NN N
) ) N
, , N
or CC N
3 CD N
) ) N
constant JJ i
bright JJ i
light NN i
( ( i
123 CD N
?W/cm NNP N
( ( N
2 CD N
) ) N
) ) N
. . N

Dietary NNP N
and CC N
water NN N
intakes NNS N
were VBD N
recorded VBN N
daily RB N
. . N

After IN N
2 CD N
wk NN N
, , N
rats VB N
underwent JJ N
6 CD N
low-volume JJ N
blood NN N
draws NNS N
at IN N
4-h JJ N
intervals NNS N
( ( N
beginning VBG N
at IN N
0400 CD N
) ) N
during IN N
both DT N
the DT N
light NN N
and CC N
dark JJ N
phases NNS o
. . o

Circadian JJ o
rhythms NN o
in IN o
dietary JJ o
and CC o
water NN o
intake NN o
and CC o
levels NNS o
of IN o
plasma NN o
total JJ o
fatty JJ o
acids NNS o
and CC o
lipid JJ o
fractions NNS o
remained VBD o
entrained JJ N
during IN N
exposure NN N
to TO N
either DT N
control NN N
conditions NNS N
or CC N
low-intensity NN N
light NN N
during IN N
the DT N
dark JJ N
phase NN N
. . N

However RB N
, , N
these DT N
patterns NNS N
were VBD N
disrupted VBN N
in IN N
rats NNS N
exposed VBN N
to TO N
constant VB i
bright JJ i
light NN o
. . o

Circadian JJ o
patterns NNS o
of IN o
plasma NN o
melatonin NN o
, , o
glucose NN o
, , o
lactic JJ o
acid NN o
, , o
and CC o
corticosterone NN o
were VBD o
maintained VBN N
in IN N
all DT N
rats NNS N
except IN N
those DT N
exposed VBN N
to TO N
constant VB i
bright JJ i
light NN i
or CC i
the DT N
highest JJS N
level NN N
of IN N
light NN N
during IN N
the DT N
dark JJ N
phase NN N
. . N

Therefore RB N
even RB N
minimal JJ N
light JJ N
contamination NN N
during IN N
the DT N
dark JJ N
phase NN N
can MD N
disrupt VB N
normal JJ o
circadian JJ o
rhythms NN o
of IN o
endocrine JJ N
metabolism NN N
and CC N
physiology NN N
and CC N
may MD N
alter VB N
the DT N
outcome NN N
of IN N
scientific JJ N
investigations NNS N
. . N

-DOCSTART- -X- O O

A DT N
step-by-step JJ N
introduction NN N
to TO N
vegetables NNS i
at IN N
the DT N
beginning NN N
of IN N
complementary JJ N
feeding NN N
. . N

The DT N
effects NNS N
of IN N
early JJ N
and CC N
repeated JJ N
exposure NN N
. . N

Breastfeeding NNP p
( ( p
BF NNP p
) ) p
is VBZ N
associated VBN N
with IN N
willingness NN N
to TO N
accept VB N
vegetables NNS N
. . N

This DT N
may MD N
be VB N
due JJ N
to TO N
the DT N
variety NN N
of IN N
flavours NNS N
delivered VBN N
via IN N
breast NN N
milk NN N
. . N

Some DT N
mothers NNS p
add VBP N
vegetables NNS N
to TO N
milk VB N
during IN N
complementary JJ N
feeding NN N
( ( N
CF NNP N
) ) N
to TO N
enhance VB N
acceptance NN N
. . N

The DT N
present JJ N
study NN N
tested VBD N
a DT N
step-by-step JJ N
exposure NN N
to TO N
vegetables NNS i
in IN i
milk NN i
then RB i
rice NN i
during IN N
CF NNP N
, , N
on IN N
intake NN N
and CC N
liking NN N
of IN N
vegetables NNS N
. . N

Just NNP N
before IN N
CF NNP N
, , N
enrolled VBD p
mothers NNS p
were VBD p
randomised VBN p
to TO p
an DT p
intervention NN p
( ( p
IG NNP p
, , p
n JJ p
= VBP p
18 CD p
; : p
6 CD p
BF NNP p
) ) p
or CC p
control VB p
group NN p
( ( p
CG NNP p
, , p
n JJ p
= VBP p
18 CD p
; : p
6 CD p
BF NNP p
) ) p
. . p

IG JJ p
infants NNS p
received VBD N
12 CD N
daily JJ N
exposures NNS i
to TO i
vegetable JJ i
puree NN i
added VBD i
to TO i
milk VB i
( ( N
days NNS N
1-12 RB N
) ) N
, , N
then RB N
12 CD N
? . N
2 CD N
daily JJ N
exposures NNS N
to TO N
vegetable JJ i
puree NN i
added VBD i
to TO i
rice VB i
at IN i
home NN i
( ( N
days NNS N
13-24 RB N
) ) N
. . N

Plain NNP i
milk NN i
and CC i
rice NN i
were VBD i
given VBN N
to TO N
CG NNP N
. . N

Then RB N
both DT N
received VBD N
11 CD N
daily JJ N
exposures NNS N
to TO N
vegetable JJ i
puree NN i
. . i

Intake NNP i
was VBD N
weighed VBN N
and CC N
liking VBG N
rated VBN N
on IN N
days NNS N
25-26 JJ N
and CC N
33-35 JJ N
after IN N
the DT N
start NN N
of IN N
CF NNP N
in IN N
the DT N
laboratory NN N
, , N
supplemented VBN N
by IN N
the DT N
same JJ N
data NN N
recorded VBD N
at IN N
home NN N
. . N

Vegetables NNS N
were VBD N
rotated VBN N
daily RB N
( ( N
carrots NNS N
, , N
green JJ N
beans NNS N
, , N
spinach NN N
, , N
broccoli NN o
) ) o
. . o

Intake NNP o
, , o
liking VBG o
and CC o
pace NN o
of IN o
eating VBG o
were VBD o
greater JJR N
for IN N
IG NNP N
than IN N
CG NNP N
infants NNS o
. . o

Intake NNP o
and CC o
liking NN o
of IN o
carrots NNS o
were VBD o
greater JJR N
than IN N
green JJ N
beans NNS N
. . N

However RB N
, , N
at IN N
6m CD N
then RB N
18m CD N
follow VBP N
up RB N
, , N
vegetable JJ N
( ( N
carrot JJ N
> NN N
green JJ N
beans NNS N
) ) N
but CC N
not RB N
group NN N
differences NNS N
were VBD N
observed VBN p
. . p

Mothers NNS p
reported VBD p
appreciation NN N
of IN N
the DT N
structure NN N
and CC N
guidance NN N
of IN N
this DT N
systematic JJ N
approach NN N
. . N

Early JJ N
exposure NN N
to TO N
vegetables NNS i
in IN i
a DT N
step-by-step JJ N
method NN N
could MD N
be VB N
included VBN N
in IN N
CF NNP N
guidelines NNS N
and CC N
longer JJR N
term NN N
benefits NNS N
assessed VBN N
by IN N
extending VBG N
the DT N
exposure NN N
period NN N
. . N

-DOCSTART- -X- O O

Rapid JJ N
efficacy NN N
of IN N
the DT N
highly RB N
selective JJ N
alpha1A-adrenoceptor NN N
antagonist NN N
silodosin NN i
in IN N
men NNS p
with IN p
signs NNS p
and CC p
symptoms NNS p
of IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
: : p
pooled JJ N
results NNS N
of IN N
2 CD N
phase NN N
3 CD N
studies NNS N
. . N

PURPOSE NNP N
We PRP N
evaluated VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
silodosin NN i
for IN N
treatment NN N
of IN N
benign JJ N
prostatic JJ N
hyperplasia NN N
symptoms NNS N
in IN N
2 CD N
randomized NNS N
, , N
placebo NN i
controlled VBD i
, , N
phase NN N
3 CD N
studies NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Men NNP p
50 CD p
years NNS p
or CC p
older JJR p
with IN p
an DT p
International NNP p
Prostate NNP p
Symptom NNP p
Score NNP p
of IN p
13 CD p
or CC p
greater JJR p
and CC p
peak JJ p
urinary JJ p
flow NN p
rate NN p
of IN p
4 CD p
to TO p
15 CD p
ml NNS p
per IN p
second JJ p
received VBN p
placebo NN i
or CC i
8 CD p
mg NNS p
silodosin JJ i
daily JJ p
with IN p
breakfast NN p
for IN p
12 CD p
weeks NNS p
. . p

The DT N
primary JJ N
end NN N
point NN N
was VBD N
International NNP o
Prostate NNP o
Symptom NNP o
Score NNP o
change NN N
from IN N
baseline NN N
to TO N
last JJ N
observation NN N
. . N

Change NN N
in IN N
peak NN o
urinary JJ o
flow NN o
rate NN o
was VBD N
a DT N
secondary JJ N
end NN N
point NN N
. . N

Differences NNS o
in IN o
treatment NN o
efficacy NN o
were VBD N
assessed VBN N
by IN N
ANCOVA NNP N
. . N

RESULTS NNP N
Of IN N
923 CD p
patients NNS p
( ( p
mean JJ p
age NN p
65 CD p
years NNS p
) ) p
466 CD p
received VBN p
silodosin NN p
and CC p
457 CD p
placebo NN p
. . p

After IN N
0.5 CD N
week NN N
( ( N
range VBP N
3 CD N
to TO N
4 CD N
days NNS N
) ) N
of IN N
treatment NN N
patients NNS N
receiving VBG N
silodosin NN i
vs NN N
placebo NN N
achieved VBD N
significant JJ N
improvement NN N
in IN N
total JJ o
International NNP o
Prostate NNP o
Symptom NNP o
Score NNP o
( ( N
difference NN N
-1.9 NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
and CC N
irritative JJ o
( ( N
-0.5 JJ N
, , N
p JJ N
= NNP N
0.0002 CD N
) ) N
and CC N
obstructive JJ o
( ( N
-1.4 JJ N
, , N
p JJ N
< NNP N
0.0001 CD N
) ) N
subscores NNS N
. . N

The DT N
mean JJ N
+/- JJ N
SD NNP N
change NN N
from IN N
baseline NN N
in IN N
total JJ N
International NNP o
Prostate NNP o
Symptom NNP o
Score NNP o
was VBD N
-4.2 JJ N
+/- JJ N
5.3 CD N
for IN N
silodosin NN N
vs NN N
-2.3 VBD N
+/- JJ N
4.4 CD N
for IN N
placebo NN N
. . N

Differences NNS N
( ( N
silodosin JJ N
vs NN N
placebo NN N
) ) N
in IN N
International NNP o
Prostate NNP o
Symptom NNP o
Score NNP o
and CC N
subscores NNS N
increased VBN N
by IN N
week NN N
12 CD N
( ( N
p NN N
< RB N
0.0001 CD N
) ) N
. . N

Mean JJ N
change NN N
from IN N
baseline NN N
in IN N
peak JJ o
urinary JJ o
flow NN o
rate NN o
( ( N
ml FW N
per IN N
second NN N
) ) N
2 CD N
to TO N
6 CD N
hours NNS N
after IN N
initial JJ N
dose NN N
was VBD N
greater JJR N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
with IN N
silodosin NN N
( ( N
2.8 CD N
+/- JJ N
3.4 CD N
) ) N
than IN N
placebo NN N
( ( N
1.5 CD N
+/- JJ N
3.8 CD N
) ) N
. . N

Differences NNS N
remained VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
through IN N
week NN N
12 CD N
. . N

The DT N
most RBS N
common JJ N
treatment NN N
emergent JJ N
adverse JJ o
event NN o
was VBD N
( ( N
mostly RB N
mild VBN N
) ) N
retrograde NN o
ejaculation NN o
( ( N
silodosin JJ N
28.1 CD N
% NN N
of IN N
patients NNS N
, , N
placebo RB N
0.9 CD N
% NN N
) ) N
. . N

Few JJ N
patients NNS N
receiving VBG N
silodosin NN i
( ( N
2.8 CD N
% NN N
) ) N
discontinued VBN N
because IN N
of IN N
retrograde JJ o
ejaculation NN o
. . o

Proportions NNS N
of IN N
patients NNS N
with IN N
treatment NN N
emergent JJ N
orthostatic JJ o
hypotension NN o
were VBD N
similar JJ N
for IN N
silodosin NN N
( ( N
2.6 CD N
% NN N
) ) N
and CC N
placebo NN N
( ( N
1.5 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
silodosin NN N
produced VBN N
rapid JJ N
improvement NN N
in IN N
urinary JJ o
symptoms NNS o
that WDT N
was VBD N
sustained VBN N
for IN N
12 CD N
weeks NNS N
. . N

Silodosin NNP N
was VBD N
well RB N
tolerated VBN N
with IN N
a DT N
low JJ N
incidence NN N
of IN N
orthostatic JJ o
hypotension NN o
. . o

-DOCSTART- -X- O O

Comparison NNP N
of IN N
increasing VBG N
doses NNS N
of IN N
olmesartan JJ N
medoxomil NN N
, , N
losartan JJ N
potassium NN N
, , N
and CC N
valsartan NN N
in IN N
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

This DT N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
forced-titration NN N
study NN N
compared VBN N
the DT N
efficacy NN N
of IN N
3 CD N
angiotensin NNS N
receptor NN N
blockers NNS N
. . N

Patients NNS i
received VBD i
olmesartan JJ i
medoxomil NN i
20 CD i
mg NN i
, , i
losartan JJ i
potassium NN i
50 CD i
mg NN i
, , i
valsartan JJ i
80 CD i
mg NN i
, , i
or CC i
placebo NN i
once RB i
daily JJ i
. . i

At IN i
week NN i
4 CD i
, , i
doses NNS i
were VBD i
titrated VBN i
to TO i
40 CD i
, , i
100 CD i
, , i
and CC i
160 CD i
mg NN i
once RB i
daily JJ i
for IN i
olmesartan NN i
, , i
losartan NN i
, , i
and CC i
valsartan NN i
, , i
respectively RB i
. . i

At IN i
week NN i
8 CD i
, , i
losartan NN i
was VBD i
increased VBN i
to TO i
50 CD i
mg NNS i
twice RB i
daily RB i
and CC i
valsartan NNS i
increased VBD i
to TO i
320 CD i
mg NNS i
once RB i
daily JJ i
( ( i
olmesartan JJ i
remained VBN i
at IN i
40 CD i
mg NNS i
once RB i
daily RB i
) ) i
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
seated VBN o
diastolic JJ o
blood NN o
pressure NN o
( ( o
SeDBP NNP o
) ) o
at IN N
week NN N
8 CD N
. . N

All DT N
3 CD N
medications NNS N
significantly RB N
reduced VBN N
mean JJ o
SeDBP NNP o
from IN N
baseline NN N
compared VBN N
with IN N
placebo NN i
at IN N
weeks NNS N
4 CD N
, , N
8 CD N
, , N
and CC N
12 CD N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

At IN N
week NN N
8 CD N
, , N
olmesartan RB N
reduced VBN N
mean JJ N
SeDBP NNP o
more JJR N
than IN N
losartan NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
; : N
more JJR N
patients NNS N
in IN N
the DT N
olmesartan JJ N
medoxomil NN N
group NN N
achieved VBD N
a DT N
blood NN o
pressure NN o
goal NN N
of IN N
< $ N
140/90 CD N
mm NN N
Hg NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Olmesartan NNP N
did VBD N
not RB N
reduce VB N
mean NN o
SeDBP NNP o
significantly RB N
compared VBN N
with IN N
valsartan NN N
, , N
although IN N
more JJR N
patients NNS N
attained VBD N
blood JJ o
pressure NN o
goal NN N
with IN N
olmesartan NN N
( ( N
P=.031 NNP N
) ) N
. . N

At IN N
week NN N
12 CD N
, , N
all DT N
agents NNS N
lowered VBD N
blood NN o
pressure NN o
equivalently RB N
. . N

-DOCSTART- -X- O O

Oxytocin NNP i
promotes VBZ N
facial JJ o
emotion NN o
recognition NN o
and CC o
amygdala JJ o
reactivity NN o
in IN N
adults NNS p
with IN p
asperger JJ p
syndrome NN p
. . p

The DT N
neuropeptide JJ i
oxytocin NN i
has VBZ N
recently RB N
been VBN N
shown VBN N
to TO N
enhance VB N
eye NN o
gaze NN o
and CC o
emotion NN o
recognition NN o
in IN N
healthy JJ p
men NNS p
. . p

Here RB N
, , N
we PRP N
report VBP N
a DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
that WDT N
examined VBD N
the DT N
neural JJ N
and CC N
behavioral JJ N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
intranasal JJ i
oxytocin NN i
on IN N
emotion NN N
recognition NN N
in IN N
individuals NNS p
with IN p
Asperger NNP p
syndrome NN p
( ( p
AS IN p
) ) p
, , N
a DT N
clinical JJ N
condition NN N
characterized VBN N
by IN N
impaired JJ N
eye NN N
gaze NN N
and CC N
facial JJ N
emotion NN N
recognition NN N
. . N

Using VBG N
functional JJ i
magnetic JJ i
resonance NN i
imaging NN i
, , N
we PRP N
examined VBD N
whether IN N
oxytocin NN i
would MD N
enhance VB N
emotion NN o
recognition NN o
from IN N
facial JJ N
sections NNS N
of IN N
the DT N
eye NN N
vs VBZ N
the DT N
mouth JJ N
region NN N
and CC N
modulate JJ o
regional JJ o
activity NN o
in IN o
brain NN o
areas NNS o
associated VBN o
with IN o
face NN o
perception NN o
in IN N
both DT N
adults NNS p
with IN p
AS NNP p
, , N
and CC N
a DT N
neurotypical JJ i
control NN i
group NN N
. . N

Intranasal NNP N
administration NN N
of IN N
the DT N
neuropeptide JJ i
oxytocin NN i
improved VBD N
performance NN o
in IN o
a DT o
facial JJ o
emotion NN o
recognition NN o
task NN o
in IN N
individuals NNS p
with IN p
AS NNP p
. . p

This DT N
was VBD N
linked VBN N
to TO N
increased VBN o
left JJ o
amygdala NN o
reactivity NN o
in IN N
response NN N
to TO N
facial JJ N
stimuli NNS N
and CC N
increased JJ o
activity NN o
in IN N
the DT N
neural JJ o
network NN o
involved VBN N
in IN N
social JJ N
cognition NN N
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
the DT N
amygdala NN N
, , N
together RB N
with IN N
functionally RB N
associated VBN N
cortical JJ N
areas NNS N
mediate VBP N
the DT N
positive JJ N
effect NN N
of IN N
oxytocin NN i
on IN N
social JJ o
cognitive JJ o
functioning NN o
in IN N
AS NNP N
. . N

-DOCSTART- -X- O O

[ NN N
Treating VBG N
rheumatoid JJ p
arthritis NN p
patients NNS p
of IN p
Shen NNP p
deficiency NN p
and CC p
cold JJ p
invading NN p
syndrome NN p
by IN p
bushen NN i
quhan NN i
zhiwang CD i
decoction NN i
combined VBN i
methotrexate NN i
: : i
an DT N
evaluation NN N
of IN N
clinical JJ N
efficacy NN N
and CC N
safety NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
safety NN N
of IN N
bushen NN i
quhan NN i
zhiwang CD i
decoction NN i
( ( i
BQZD NNP i
) ) i
combined VBN i
methotrexate NN i
( ( i
MTX NNP i
) ) i
in IN N
treating VBG N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

METHODS CC N
A DT N
prospective JJ N
, , N
randomized VBN N
controlled VBD N
study NN N
was VBD N
carried VBN N
out RP N
. . N

RA NNP p
patients NNS p
of IN p
Shen NNP p
deficiency NN p
and CC p
cold JJ p
invading NN p
syndrome NN p
in IN p
the DT p
treatment NN p
group NN p
( ( p
120 CD p
cases NNS p
) ) p
were VBD p
treated VBN p
with IN p
BQZD NNP i
and CC i
MTX NNP i
( ( i
10 CD i
mg/week NN i
) ) i
, , N
while IN N
those DT N
in IN N
the DT N
control NN p
group NN p
( ( p
120 CD p
cases NNS p
) ) p
were VBD p
treated VBN i
with IN i
MTX NNP i
( ( i
10 CD i
mg/week NN i
) ) i
alone RB i
. . i

The DT N
therapeutic JJ N
course NN N
for IN N
all DT N
was VBD N
24 CD N
weeks NNS N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
indices NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
baseline NN N
and CC N
24 CD N
weeks NNS N
after IN N
treatment NN N
, , N
including VBG N
clinical JJ o
signs NNS o
and CC o
symptoms NNS o
, , o
condition NN o
assessment NN o
, , o
Health NNP o
Assessment NNP o
Questionnaire NNP o
( ( o
HAQ NNP o
) ) o
, , o
disease NN o
activity NN o
index NN o
28 CD o
( ( o
DAS28 NNP o
) ) o
, , o
laboratory JJ o
parameters NNS o
of IN o
erythrocyte JJ o
sedimentation NN o
rate NN o
( ( o
ESR NNP o
) ) o
and CC o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
safety NN o
indicators NNS o
, , o
and CC o
Chinese NNP o
medical JJ o
syndrome NN o
integrals NNS o
. . o

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
was VBD N
80 CD N
. . N

0 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
, , N
better JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
( ( N
66.7 CD N
% NN N
) ) N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
the DT N
two CD N
groups NNS N
significant JJ N
improvement NN N
of IN N
clinical JJ o
signs NNS o
and CC o
symptoms NNS o
, , o
ESR NNP o
, , o
CRP NNP o
, , o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
by IN N
both DT N
physicians NNS N
and CC N
patients NNS N
, , N
HAQ NNP o
, , o
DAS28 NNP o
, , N
and CC N
Chinese NNP N
medical JJ N
syndrome NN N
integrals NNS N
after IN N
treatment NN N
were VBD N
shown VBN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Better JJR N
effects NNS N
were VBD N
obtained VBN N
in IN N
the DT N
treatment NN N
group NN N
in IN N
lessening VBG N
tender NN o
joint NN o
numbers NNS o
and CC o
swollen JJ o
joint NN o
numbers NNS o
, , N
VAS NNP N
by IN N
both DT N
physicians NNS N
and CC N
patients NNS N
, , N
DAS28 NNP N
, , N
and CC N
Chinese NNP N
medical JJ N
syndrome NN N
integrals NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Besides NNP N
, , N
adverse JJ N
reactions NNS N
occurred VBD N
less RBR N
in IN N
the DT N
treatment NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
BQZD NNP i
had VBD N
roles NNS N
in IN N
relieving VBG N
symptoms NNS N
, , N
improving VBG N
joint JJ N
functions NNS N
, , N
signs NNS N
, , N
ESR NNP N
, , N
and CC N
CRP NNP N
. . N

It PRP N
was VBD N
an DT N
effective JJ N
herb NN N
for IN N
RA NNP p
patients NNS p
of IN p
Shen NNP p
deficiency NN p
and CC p
cold JJ p
invading NN p
syndrome NN p
. . p

It PRP N
could MD N
enhance VB N
the DT N
efficacy NN N
and CC N
reduce VB N
adverse JJ N
reactions NNS N
of IN N
MTX NNP N
through IN N
synergistic JJ N
effects NNS N
with IN N
MTX NNP N
. . N

-DOCSTART- -X- O O

A DT N
home NN i
visiting NN i
asthma JJ i
education NN i
program NN i
: : i
challenges NNS N
to TO N
program NN N
implementation NN N
. . N

This DT N
study NN N
describes VBZ N
the DT N
implementation NN N
of IN N
a DT N
nurse JJ i
home NN i
visiting NN i
asthma JJ i
education NN i
program NN i
for IN N
low-income JJ p
African JJ p
American JJ p
families NNS p
of IN p
young JJ p
children NNS p
with IN p
asthma NN p
. . p

Of IN p
55 CD p
families NNS p
, , p
71 CD p
% NN p
completed VBD p
the DT p
program NN p
consisting NN N
of IN N
eight CD N
lessons NNS N
. . N

The DT N
achievement NN o
of IN o
learning VBG o
objectives NNS o
was VBD N
predicted VBN N
by IN N
caregiver NN o
factors NNS o
, , o
such JJ o
as IN o
education NN o
, , o
presence NN o
of IN o
father NN o
or CC o
surrogate VB o
father NN o
in IN o
the DT o
household NN o
, , o
and CC o
safety NN o
of IN o
the DT o
neighborhood NN o
, , N
but CC N
not RB N
by IN N
child JJ o
factors NNS o
, , o
such JJ o
as IN o
age NN o
or CC o
severity NN o
of IN o
asthma NN o
as IN N
implied VBN N
by IN N
the DT N
prescribed JJ N
asthma JJ N
medication NN N
regimen NNS N
. . N

Incompatibility NN N
between IN N
the DT N
scheduling VBG N
needs NNS N
of IN N
the DT N
families NNS N
and CC N
the DT N
nurse JJ N
home NN N
visitors NNS N
was VBD N
a DT N
major JJ N
obstacle NN N
in IN N
delivering VBG N
the DT N
program NN N
on IN N
time NN N
, , N
despite IN N
the DT N
flexibility NN N
of IN N
the DT N
nurse JJ N
home NN N
visitors NNS N
. . N

The DT N
authors NNS N
suggest VBP N
that IN N
future JJ N
home-based JJ i
asthma NN i
education NN i
programs NNS i
contain VBP N
a DT N
more RBR N
limited JJ N
number NN o
of IN o
home NN o
visits NNS o
but CC N
add VBP N
telephone NN N
follow-ups NNS N
and CC N
address VB N
the DT N
broader JJR N
needs NNS N
of IN N
low-income JJ p
families NNS p
that IN N
most JJS N
likely JJ N
function NN N
as IN N
barriers NNS N
to TO N
program NN N
success NN N
. . N

-DOCSTART- -X- O O

Inhibition NN N
of IN N
spontaneous JJ N
platelet NN o
aggregation NN o
and CC o
adhesion NN o
by IN N
indobufen NN i
( ( i
K NNP i
3920 CD i
) ) i
. . i

A DT N
randomized JJ N
, , N
double-blind JJ N
crossover NN N
study NN N
on IN N
platelet NN N
, , N
coagulation NN N
and CC N
fibrinolysis NN N
function NN N
tests NNS N
. . N

In IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
study NN N
in IN p
12 CD p
patients NNS p
with IN p
atherosclerotic JJ p
disease NN p
, , N
the DT N
effect NN N
of IN N
2 CD N
dosages NNS N
( ( N
100 CD N
and CC N
200 CD N
mg NN N
twice RB N
daily RB N
) ) N
of IN N
indobufen NN i
, , N
a DT N
new JJ N
synthetic JJ N
inhibition NN N
of IN N
platelet NN N
aggregation NN N
, , N
on IN N
some DT N
platelet NN o
functions NNS o
, , o
coagulation NN o
and CC o
fibrinolysis NN o
tests NNS o
was VBD N
investigated VBN N
. . N

Regardless NNP N
of IN N
the DT N
dosage NN N
used VBN N
, , N
indobufen NN i
was VBD N
shown VBN N
to TO N
induce VB N
a DT N
prompt JJ N
normalization NN N
of IN N
the DT N
enhanced JJ o
platelet NN o
aggregation NN o
of IN N
these DT N
patients NNS N
. . N

The DT N
effect NN N
lasted VBD N
for IN N
the DT N
entire JJ N
period NN N
of IN N
drug NN N
administration NN N
and CC N
in IN N
50 CD N
% NN N
of IN N
patients NNS N
a DT N
normal JJ N
platelet NN N
aggregation NN N
was VBD N
maintained VBN N
until IN N
the DT N
fourth JJ N
day NN N
after IN N
discontinuation NN N
of IN N
the DT N
drug NN N
. . N

Indobufen NNP i
was VBD N
also RB N
able JJ N
to TO N
reduce VB N
platelet NN o
adhesiveness NN o
and CC N
to TO N
lengthen VB N
bleeding NN o
time NN o
, , N
especially RB N
when WRB N
the DT N
higher JJR N
dosage NN N
was VBD N
used VBN N
. . N

-DOCSTART- -X- O O

Therapy NN N
for IN N
progressive JJ p
supranuclear JJ p
palsy NN p
: : p
past NN N
and CC N
future NN N
. . N

Dysfunction NN N
of IN N
multiple JJ N
brain NN N
systems NNS N
in IN N
progressive JJ p
supranuclear JJ p
palsy NN p
( ( p
PSP NNP p
) ) p
has VBZ N
complicated VBN N
attempts NNS N
to TO N
treat VB N
the DT N
disease NN N
. . N

Neurotransmitter NNP i
replacement NN i
strategies NNS i
targeting VBG N
the DT N
dopaminergic NN N
, , N
cholinergic NN N
, , N
and CC N
serotonergic JJ N
systems NNS N
have VBP N
been VBN N
unsuccessful JJ N
. . N

In IN N
order NN N
to TO N
bypass VB N
the DT N
degenerated JJ N
cortico-striato-pallidal JJ N
loop NN N
, , N
we PRP N
administered VBD N
the DT N
adrenergic JJ i
agonist NN i
idazoxan NN i
( ( i
IDA NNP i
) ) i
to TO N
treat VB N
PSP NNP N
in IN N
two CD N
randomized JJ N
double-blind NN N
, , N
placebo NN i
controlled VBD N
, , N
crossover NN N
studies NNS N
. . N

Approximately RB N
one CD N
half NN N
of IN N
patients NNS p
enrolled VBN p
in IN p
these DT p
studies NNS p
showed VBD N
statistically RB o
significant JJ o
improvement NN o
in IN o
balance NN o
and CC o
manual JJ o
dexterity NN o
while IN N
taking VBG N
IDA NNP N
compared VBN N
to TO N
placebo VB i
. . i

These DT N
results NNS N
suggest VBP N
that IN N
new JJ N
therapies NNS i
that WDT N
target VBP N
structures NNS N
outside IN N
of IN N
the DT N
basal NN N
ganglia NN N
may MD N
be VB N
useful JJ N
for IN N
symptomatic JJ o
treatment NN o
of IN o
PSP NNP o
. . o

Applying VBG N
this DT N
strategy NN N
and CC N
developing VBG N
treatments NNS N
that WDT N
arrest VBP N
or CC N
reverse VB N
clinical JJ N
deterioration NN N
in IN N
PSP NNP N
will MD N
require VB N
improved JJ N
understanding NN N
of IN N
the DT N
process NN N
underlying VBG N
the DT N
illness NN N
. . N

-DOCSTART- -X- O O

Tofacitinib NN i
with IN i
methotrexate NN i
in IN N
third-line JJ N
treatment NN N
of IN N
patients NNS p
with IN p
active JJ p
rheumatoid NN p
arthritis NN p
: : p
patient-reported JJ N
outcomes NNS N
from IN N
a DT N
phase NN N
III NNP N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
patient-reported JJ N
outcomes NNS N
( ( N
PROs NNP N
) ) N
for IN N
tofacitinib NN N
, , N
an DT N
oral JJ N
JAK NNP N
inhibitor NN N
for IN N
the DT N
treatment NN N
of IN N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
, , N
in IN N
a DT N
6-month JJ N
, , N
phase JJ N
III NNP N
, , N
randomized VBD N
controlled VBN N
trial NN N
. . N

METHODS NNP N
Patients NNPS p
ages VBZ p
?18 CD p
years NNS p
with IN p
active JJ p
RA NNP p
with IN p
an DT p
inadequate JJ p
response NN p
to TO p
?1 VB p
tumor NN p
necrosis NN p
factor NN p
inhibitor NN p
( ( p
TNFi NNP p
) ) p
and CC p
receiving VBG p
stable JJ p
background NN p
methotrexate NN p
were VBD p
randomized VBN p
2:2:1:1 CD i
to TO i
tofacitinib VB i
5 CD i
mg NN i
or CC i
10 CD i
mg JJ i
twice RB i
daily RB i
, , i
or CC i
placebo NN i
advanced VBD i
to TO i
tofacitinib VB i
5 CD i
mg NN i
or CC i
10 CD i
mg JJ i
twice RB i
daily RB i
at IN i
month NN i
3 CD i
. . i

PROs NNS N
measured VBD N
at IN N
month NN N
3 CD N
included VBD o
patient NN o
global JJ o
assessment NN o
of IN o
disease NN o
activity NN o
( ( o
PtGA NNP o
) ) o
, , o
pain VBP o
, , o
Health NNP o
Assessment NNP o
Questionnaire NNP o
( ( o
HAQ NNP o
) ) o
disability NN o
index NN o
( ( o
DI NNP o
) ) o
, , o
Medical NNP o
Outcomes NNP o
Study NNP o
( ( o
MOS NNP o
) ) o
Short NNP o
Form NNP o
36 CD o
Health NNP o
Survey NNP o
version NN o
2 CD o
( ( o
SF-36v2 NNP o
; : o
acute NN o
) ) o
, , o
Functional NNP o
Assessment NNP o
of IN o
Chronic NNP o
Illness NNP o
Therapy-Fatigue NNP o
( ( o
FACIT-F NNP o
) ) o
, , o
and CC o
MOS NNP o
Sleep NNP o
Scale NNP o
. . o

RESULTS NNP o
Patients NNPS N
received VBD N
tofacitinib JJ N
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
133 CD N
) ) N
or CC N
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
134 CD N
) ) N
or CC N
placebo NN N
advanced VBD N
to TO N
tofacitinib VB N
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
66 CD N
) ) N
or CC N
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
66 CD N
) ) N
. . N

HAQ NNP o
DI NNP o
( ( o
reported VBD o
previously RB o
) ) o
, , o
PtGA NNP o
( ( o
P NNP o
< NNP o
0.0001 CD o
) ) o
, , o
and CC o
SF-36v2 NNP o
physical JJ o
and CC o
mental JJ o
component NN o
summary NN o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) o
scores NNS o
were VBD o
improved VBN o
for IN o
both DT N
tofacitinib JJ N
doses NNS N
versus VBP N
placebo NN N
. . N

Furthermore NNP N
, , N
improvements NNS N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
the DT N
minimum NN N
clinically RB N
important JJ N
difference NN N
were VBD N
more RBR N
frequently RB N
reported VBN N
by IN N
tofacitinib-treated JJ N
patients NNS N
versus VBP N
placebo NN N
for IN N
PtGA NNP o
( ( o
P NNP o
< NNP N
0.05 CD N
) ) o
, , o
pain NN o
( ( o
P NNP o
< NNP N
0.0001 CD o
) ) o
, , o
HAQ NNP o
DI NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) o
, , o
SF-36v2 NNP o
physical JJ o
and CC o
mental JJ o
component NN o
summary JJ o
scores NNS o
( ( o
P NNP o
< NNP N
0.05 CD N
) ) N
, , N
and CC N
FACIT-F NNP o
( ( o
P NNP o
< VBZ N
0.001 CD N
for IN N
5 CD N
mg JJ N
twice RB N
daily RB o
) ) o
. . o

No DT o
statistical JJ o
differences NNS o
were VBD o
observed VBN N
in IN N
the DT N
MOS NNP o
Sleep NNP o
Scale NNP o
. . o

CONCLUSION NNP o
Tofacitinib NNP N
treatment NN N
resulted VBD N
in IN N
significant JJ N
, , N
clinically RB N
meaningful JJ N
improvements NNS N
in IN N
multiple JJ N
PROs NNP N
versus NN N
placebo NN N
over IN N
3 CD N
months NNS N
of IN N
treatment NN p
in IN p
patients NNS p
with IN p
active JJ p
RA NNP p
and CC p
a DT p
previous JJ p
inadequate JJ p
response NN p
to TO p
TNFi NNP p
. . p

-DOCSTART- -X- O O

Comparison NNP N
of IN N
tidal JJ N
volumes NNS N
obtained VBN N
by IN N
one-handed JJ i
and CC i
two-handed JJ i
ventilation NN i
techniques NNS i
. . i

OBJECTIVES NNP N
To TO N
compare VB N
tidal JJ N
volumes NNS N
delivered VBN N
by IN N
one- JJ i
vs JJ i
two-handed JJ i
compressions NNS i
of IN i
a DT i
manual JJ i
resuscitation NN i
bag NN i
and CC N
assess VB N
the DT N
effects NNS N
of IN N
subject JJ N
characteristics NNS N
on IN N
those DT N
tidal JJ N
volumes NNS N
. . N

DESIGN NNP N
Subjects NNP p
( ( p
108 CD p
healthcare NN p
providers NNS p
from IN p
a DT p
500-bed JJ p
teaching NN p
hospital NN p
) ) p
were VBD N
assigned VBN N
randomly RB N
to TO N
one CD N
of IN N
two CD N
procedures NNS N
: : N
one- JJ i
followed VBN i
by IN i
two-handed JJ i
compression NN i
or CC i
two- NN i
followed VBN i
by IN i
one-handed JJ i
compression NN i
. . i

A DT N
1-liter JJ N
resuscitation NN N
bag NN N
, , N
lung NN N
performance NN N
analyzer NN N
and CC N
Wright NNP N
spirometer NN N
were VBD N
used VBN N
to TO N
measure VB N
tidal JJ N
volume NN N
. . N

Data NNP N
collection NN N
occurred VBD N
in IN N
a DT p
simulated JJ p
situation NN p
. . p

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
tidal JJ o
volume NN o
delivered VBN N
by IN N
one-handed JJ i
( ( N
mean JJ N
= VBP N
694 CD N
mL NN N
, , N
SD NNP N
= NNP N
111 CD N
) ) N
vs NN N
two-handed JJ i
compressions NNS i
( ( N
mean JJ N
= VBP N
827 CD N
mL NN N
, , N
SD NNP N
= NNP N
113 CD N
) ) N
. . N

Hand NNP N
size NN N
, , N
grip NN N
strength NN N
, , N
height NN N
and CC N
weight NN N
were VBD N
correlated VBN N
with IN N
tidal JJ o
volumes NNS o
generated VBN N
by IN N
one-handed JJ i
and CC N
two-handed JJ i
procedures NNS N
. . N

No DT N
other JJ N
subject JJ N
characteristics NNS N
were VBD N
correlated VBN N
with IN N
tidal JJ o
volumes NNS o
. . o

CONCLUSIONS NNP N
Tidal NNP o
volumes NNS o
delivered VBN N
by IN N
healthcare NN N
providers NNS N
using VBG N
one- JJ i
vs JJ i
two-handed JJ i
compressions NNS i
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
different JJ N
, , N
with IN N
those DT N
delivered VBN N
by IN N
two CD i
hands NNS i
significantly RB N
greater JJR N
than IN N
those DT N
delivered VBN N
by IN N
one CD i
hand NN i
. . i

Strength NN N
of IN N
hand NN N
grip NN N
was VBD N
the DT N
best JJS N
predictor NN N
of IN N
volume NN N
delivered VBN N
and CC N
was VBD N
more RBR N
strongly RB N
correlated VBN N
with IN N
volumes NNS N
delivered VBN N
by IN N
one CD i
rather RB N
than IN N
two CD i
hands NNS i
. . i

-DOCSTART- -X- O O

Assessment NN N
of IN N
paravalvular JJ N
aortic JJ N
regurgitation NN N
after IN N
transcatheter NN i
aortic JJ i
valve NN i
replacement NN i
: : i
intra-core JJ N
laboratory NN N
variability NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
significant JJ N
disparity NN N
in IN N
the DT N
reported JJ N
incidence NN N
of IN N
moderate JJ p
and CC p
severe JJ p
paravalvular JJ o
aortic JJ o
regurgitation NN o
( ( o
PAR NNP o
) ) o
between IN N
the DT N
Placement NNP p
of IN p
Aortic NNP p
Transcatheter NNP p
Valves NNP p
( ( p
PARTNER NNP p
) ) p
I PRP p
and CC p
PARTNER NNP p
II NNP p
trials NNS p
, , N
which WDT N
may MD N
be VB N
related VBN N
to TO N
the DT N
echocardiographic JJ N
methodologies NNS N
used VBN N
by IN N
separate JJ N
core NN N
laboratories NNS N
. . N

To TO N
further RBR N
explore VB N
the DT N
variability NN N
in IN N
echocardiographic JJ N
interpretation NN N
of IN N
PAR NNP N
, , N
agreement NN N
between IN N
the DT N
grading NN N
of IN N
PAR NNP N
by IN N
the DT N
core NN N
laboratory NN N
of IN N
PARTNER NNP N
IIB NNP N
was VBD N
compared VBN N
with IN N
that DT N
by IN N
a DT N
consortium NN N
of IN N
echocardiography NN N
core NN N
laboratory NN N
directors NNS N
. . N

METHODS NNP N
The DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
reevaluated VBD N
patients NNS N
using VBG N
primarily RB N
the DT N
circumferential JJ N
extent NN N
of IN N
the DT N
regurgitant NN N
jet NN N
for IN N
PAR NNP o
. . o

A NNP N
consortium NN p
of IN p
echocardiography NN p
core NN p
laboratory NN p
directors NNS p
was VBD N
formed VBN N
to TO N
evaluate VB N
the DT N
echocardiographic JJ i
images NNS i
and CC N
to TO N
grade VB N
PAR NNP o
and CC N
central JJ N
and CC N
total JJ N
aortic JJ N
regurgitation NN N
in IN N
a DT N
randomly JJ p
chosen NN p
subset NN p
of IN p
the DT p
randomized JJ p
patients NNS p
in IN p
the DT p
PARTNER NNP p
IIB NNP p
trial NN p
using VBG p
a DT p
multiwindow NN p
, , p
multiparametric JJ p
approach NN p
. . p

Both CC N
a DT N
four-class JJ N
scale NN N
( ( N
none NN N
or CC N
trace NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
and CC N
severe RB N
) ) N
and CC N
a DT N
seven-class NN N
( ( N
none NN N
, , N
trace NN N
, , N
mild NN N
, , N
mild NN N
to TO N
moderate VB N
, , N
moderate VB N
, , N
moderate VB N
to TO N
severe VB N
, , N
and CC N
severe RB N
) ) N
scale NN N
were VBD N
used VBN N
. . N

Levels NNP N
of IN N
grading VBG N
agreement NN N
between IN N
the DT N
consortium NN N
and CC N
original JJ N
core NN N
laboratory NN N
in IN N
both DT N
scales NNS N
were VBD N
determined VBN N
using VBG N
weighted VBN N
? . N
statistics NNS N
. . N

RESULTS NNP p
Only RB p
87 CD p
patients NNS p
assessed VBN p
for IN o
PAR NNP o
by IN p
the DT p
consortium NN p
could MD p
be VB p
paired VBN p
with IN p
readings NNS p
by IN p
the DT p
PARTNER NNP p
IIB NNP p
core NN p
laboratory NN p
. . p

Using VBG N
the DT N
four-class NN N
grading VBG N
scheme NN N
the DT o
weighted VBN o
? . o
statistic JJ o
for IN o
PAR NNP o
was VBD o
0.481 CD N
( ( N
95 CD N
% NN N
confidence NN N
limits NNS N
, , N
0.367 CD N
, , N
0.595 CD N
) ) N
. . N

Using VBG N
the DT N
seven-class JJ N
scale NN N
, , N
the DT o
weighted VBN o
? . o
statistic JJ o
for IN o
PAR NNP o
was VBD o
0.517 CD N
( ( N
95 CD N
% NN N
confidence NN N
limits NNS N
, , N
0.431 CD N
, , N
0.607 CD N
) ) N
. . N

For IN N
either DT N
grading VBG N
scheme NN N
, , N
15.9 CD N
% NN N
of IN N
patients NNS N
graded VBN N
by IN N
the DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
as IN N
having VBG N
moderate JJ o
PAR NNP o
would MD o
have VB N
been VBN N
graded VBN N
as IN N
having VBG N
mild JJ o
PAR NNP o
using VBG o
the DT N
multiparametric JJ N
approach NN N
. . N

Similar JJ N
results NNS N
were VBD N
seen VBN N
for IN N
central JJ o
and CC o
total JJ o
aortic JJ o
regurgitation NN o
assessments NNS o
. . N

CONCLUSIONS NNP N
Using NNP N
primarily RB N
the DT N
circumferential JJ N
extent NN N
criteria NNS N
, , N
the DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
overestimated VBD N
the DT N
severity NN N
of IN N
PAR NNP o
compared VBN o
to TO N
the DT N
consortium NN N
using VBG N
a DT N
multi-parametric JJ N
approach NN N
. . N

Although IN N
a DT N
more RBR N
granular JJ N
classification NN N
scheme NN N
for IN N
PAR NNP N
may MD N
slightly RB N
improve VB N
concordance NN N
between IN N
core NN N
laboratories NNS N
, , N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
moderate JJ N
or CC N
severe JJ o
PAR NN o
are VBP o
likely JJ N
related VBN N
to TO N
differences NNS N
in IN N
grading VBG N
methodology NN N
. . N

A DT N
multiparametric JJ N
approach NN N
is VBZ N
advocated VBN N
, , N
and CC N
other JJ N
echocardiographic JJ N
methods NNS N
for IN N
assessing VBG N
PAR NNP N
deserve VB N
further RB N
study NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
treatment NN N
of IN N
non-nephrotic JJ p
syndrome JJ p
IgA NNP p
nephropathy NN p
with IN N
Shenyanning NNP i
] NNP i
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
curative JJ o
effect NN o
of IN N
Shenyanning NNP i
( ( i
SYN NNP i
) ) i
on IN N
non-nephrotic JJ p
syndrome NN p
IgA NNP p
nephropathy NN p
( ( p
IgAN NNP p
) ) p
. . p

METHODS NNP N
Seventy NNP p
primary JJ p
IgAN NNP p
patients NNS p
were VBD N
equally RB N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
treatment NN N
group NN N
and CC N
the DT N
control NN N
group NN N
, , N
they PRP N
were VBD N
orally RB N
treated VBN N
with IN N
SYN NNP i
Decoction NNP i
( ( N
one CD N
dose NN N
per IN N
day NN N
) ) N
and CC N
Losartan NNP i
( ( N
50 CD N
mg NNS N
per IN N
day NN N
) ) N
respectively RB N
for IN N
1 CD N
year NN N
. . N

Efficacy NNP o
of IN o
treatment NN o
, , o
Chinese JJ o
medicine JJ o
syndrome NN o
scores NNS o
, , o
end-point JJ o
events NNS o
occurrence NN o
as RB N
well RB N
as IN N
changes NNS N
of IN N
related JJ N
laboratory NN o
indices NNS o
were VBD N
observed VBN N
. . N

RESULTS VB N
The DT N
total JJ o
effective JJ o
rate NN o
in IN N
the DT N
treatment NN N
group NN N
was VBD N
obviously RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
77.1 CD N
% NN N
vs. FW N
54.3 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
the DT N
Chinese JJ o
medicine JJ o
syndrome NN o
scores NNS o
, , o
urinary JJ o
protein NN o
and CC o
urinary JJ o
red-cell NN o
count NN o
reduced VBD N
significantly RB N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
showed VBD N
significant JJ N
difference NN N
as IN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
while IN N
the DT N
endogenous JJ o
creatinine NN o
clearance NN o
was VBD N
changed VBN N
insignificantly RB N
in IN N
both DT N
groups NNS N
. . N

Beside NNP N
, , N
the DT N
occurrence NN N
of IN N
end-point JJ o
events NNS o
in IN N
the DT N
treatment NN N
group NN N
was VBD N
slightly RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
, , N
though IN N
showed VBN N
no DT N
statistical JJ N
difference NN N
between IN N
them PRP N
. . N

CONCLUSION VB N
The DT N
curative JJ N
effect NN N
of IN N
SYN NNP i
in IN N
treating VBG N
IgAN NNP N
was VBD N
obviously RB N
better JJR N
than IN N
that DT N
of IN N
simple JJ N
Western JJ N
medicine NN N
. . N

-DOCSTART- -X- O O

Multitomographic JJ N
evaluation NN N
of IN N
the DT N
dental JJ o
effects NNS o
of IN N
two CD N
different JJ N
rapid JJ i
palatal JJ i
expansion NN i
appliances NNS i
. . i

Rapid NNP i
palatal JJ i
expansion NN i
( ( i
RPE NNP i
) ) i
is VBZ N
widely RB N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
transverse JJ p
maxillary JJ p
deficiencies NNS p
. . p

Generally RB N
, , N
there EX N
are VBP N
two CD N
types NNS N
of IN N
RPE NNP i
appliances NNS i
: : i
banded VBN i
and CC i
bonded VBN i
expanders NNS i
. . i

The DT N
purpose NN N
of IN N
this DT N
prospective JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
dental JJ o
effects NNS o
of IN N
banded JJ i
and CC i
bonded VBD i
appliances NNS i
. . i

The DT N
study NN N
consisted VBD N
of IN N
23 CD p
patients NNS p
( ( p
13 CD p
females NNS p
and CC p
10 CD p
males NNS p
) ) p
with IN p
a DT p
bilateral JJ p
maxillary JJ p
deficiency NN p
. . p

Twelve CD p
patients NNS p
( ( p
seven CD p
females NNS p
and CC p
five CD p
males NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
14.8 CD p
+/- JJ p
0.3 CD p
years NNS p
were VBD N
treated VBN N
with IN N
banded JJ i
RPE NNP i
and CC N
11 CD p
patients NNS p
( ( p
six CD p
females NNS p
and CC p
five CD p
males NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
15.1 CD p
+/- JJ p
0.7 CD p
years NNS p
with IN N
bonded JJ i
RPE NNP i
. . i

Multitomographic NNP N
radiographs NN N
were VBD N
taken VBN N
before RB N
( ( N
T0 NNP N
) ) N
and CC N
at IN N
the DT N
end NN N
( ( N
T1 NNP N
) ) N
of IN N
expansion NN N
while IN N
the DT N
patients NNS N
were VBD N
wearing VBG N
an DT N
acrylic JJ N
mandibular JJ N
appliance NN N
in IN N
which WDT N
ball JJ N
bearings NNS N
and CC N
bars NNS N
were VBD N
embedded VBN N
. . N

Statistical JJ N
analyses NNS N
of IN N
the DT N
measurements NNS N
at IN N
T0 NNP N
and CC N
T1 NNP N
were VBD N
undertaken VBN N
with IN N
a DT N
paired JJ N
t-test NN N
, , N
and CC N
the DT N
difference NN N
between IN N
the DT N
groups NNS N
assesed VBD N
with IN N
a DT N
Student NN N
's POS N
t-test NN N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
angle NN o
between IN o
the DT o
radiographic JJ o
image NN o
of IN o
the DT o
bar NN o
and CC o
the DT o
axial JJ o
inclination NN o
of IN o
the DT o
upper JJ o
first JJ o
premolar NN o
and CC o
molar JJ o
teeth NN o
was VBD N
( ( N
5.34 CD N
and CC N
2.73 CD N
degrees NNS N
for IN N
the DT N
right JJ N
premolars NNS N
, , N
5.17 CD N
and CC N
2.28 CD N
degrees NNS N
for IN N
the DT N
left NN N
premolars VBZ N
, , N
11.83 CD N
and CC N
3.73 CD N
degrees NNS N
for IN N
the DT N
right JJ N
molars NNS N
, , N
and CC N
9.75 CD N
and CC N
5.64 CD N
degrees NNS N
for IN N
the DT N
left JJ N
molars NNS N
in IN N
the DT N
banded JJ N
and CC N
bonded VBD N
groups NNS N
, , N
respectively RB N
. . N

The DT N
distance NN o
from IN o
the DT o
vestibular JJ o
cortical JJ o
plate NN o
to TO o
the DT o
palatal JJ o
root NN o
of IN o
these DT o
teeth NNS o
( ( N
1.17 CD N
and CC N
1.23 CD N
mm NN N
for IN N
the DT N
right JJ N
premolars NNS N
, , N
2.46 CD N
and CC N
1.09 CD N
mm NN N
for IN N
the DT N
left NN N
premolars VBZ N
, , N
2.75 CD N
and CC N
0.64 CD N
mm NN N
for IN N
the DT N
right JJ N
molars NNS N
, , N
2.23 CD N
and CC N
0.96 CD N
mm NN N
for IN N
the DT N
left JJ N
molars NNS N
in IN N
the DT N
banded JJ N
and CC N
bonded VBD N
groups NNS N
, , N
respectively RB N
) ) N
increased VBN N
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

These DT N
increases NNS N
indicated VBD N
buccal JJ o
tipping NN o
of IN N
the DT N
teeth NNS N
. . N

Comparison NNP N
of IN N
the DT N
two CD N
groups NNS N
showed VBD N
that IN N
tipping NN o
of IN o
the DT o
first JJ o
molar NN o
and CC o
premolar JJ o
teeth NNS o
in IN N
the DT N
banded JJ N
group NN N
was VBD N
significantly RB N
more JJR N
than IN N
in IN N
the DT N
bonded VBN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
and CC N
P NNP N
< NNP N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

-DOCSTART- -X- O O

Similar JJ N
effects NNS N
of IN N
rofecoxib NN i
and CC N
indomethacin NN i
on IN N
the DT N
incidence NN N
of IN N
heterotopic NN N
ossification NN N
after IN p
hip NN p
arthroplasty NN p
. . p

BACKGROUND NNP N
Although IN N
indomethacin NN i
is VBZ N
effective JJ N
in IN N
preventing VBG N
heterotopic NN o
ossification NN o
( ( o
HO NNP o
) ) o
after IN N
primary JJ p
total JJ p
hip NN p
arthroplasty NN p
, , N
side NN o
effects NNS o
are VBP N
frequently RB N
observed VBN N
. . N

In IN N
the DT N
last JJ N
decade NN N
a DT N
new JJ N
class NN N
of IN N
drugs NNS N
-- : N
the DT N
COX-2 NNP i
selective JJ i
nonsteroidal JJ i
anti-inflammatory JJ i
drugs NNS i
-- : i
has VBZ i
been VBN N
developed VBN N
. . N

To TO N
investigate VB N
the DT N
effect NN N
of IN N
these DT N
COX-2 NNP i
selective NN i
NSAIDs NNP o
on IN o
heterotopic NN o
ossification NN o
( ( o
HO NNP o
) ) o
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty NN N
( ( N
THA NNP N
) ) N
, , N
we PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
using VBG N
either CC N
indomethacin NN i
or CC N
rofecoxib NN i
for IN N
7 CD N
days NNS N
. . N

METHODS NNP N
186 CD p
patients NNS p
received VBD p
either RB p
indomethacin JJ i
3 CD p
times NNS p
daily RB p
, , p
or CC p
rofecoxib VB i
twice RB p
, , p
and CC p
1 CD p
placebo NN i
, , p
daily RB p
for IN p
7 CD p
days NNS p
. . p

HO NNP o
was VBD o
graded VBN o
according VBG N
to TO N
the DT N
1-year JJ N
postoperative NN N
radiographs NN N
according VBG N
to TO N
the DT N
Brooker NNP N
classification NN N
. . N

RESULTS NNP N
12 CD p
of IN p
the DT p
186 CD p
patients NNS p
included VBD p
discontinued VBN o
their PRP$ p
medication NN p
before IN p
the DT p
end NN p
of IN p
the DT p
trial NN p
due JJ p
to TO p
side VB o
effects NNS o
. . o

The DT p
remaining VBG p
174 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
analysis NN p
. . p

In IN p
the DT p
indomethacin NN i
group NN p
( ( p
n JJ p
= NNP p
89 CD p
) ) p
, , p
77 CD p
patients NNS p
( ( p
87 CD p
% NN p
) ) p
showed VBD o
no DT o
HO NNP o
, , p
9 CD p
showed VBD o
HO NNP o
of IN o
grade NN o
1 CD o
and CC p
3 CD p
showed VBD o
HO NNP o
of IN o
grade NN o
2 CD o
according VBG p
to TO p
the DT p
Brooker NNP p
classification NN p
. . p

In IN p
the DT p
rofecoxib NN i
group NN p
( ( p
n JJ p
= NNP p
85 CD p
) ) p
73 CD p
patients NNS p
( ( p
86 CD p
% NN p
) ) p
showed VBD o
no DT o
ossification NN o
, , p
9 CD p
showed VBD o
grade NN o
1 CD o
, , p
and CC p
3 CD p
showed VBD o
grade JJ o
2 CD o
. . o

INTERPRETATION VB N
The DT N
prophylactic JJ N
effect NN N
of IN N
rofecoxib NN i
for IN N
7 CD N
days NNS N
in IN N
preventing VBG N
heterotopic NN N
ossification NN N
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty NN N
is VBZ N
comparable JJ N
to TO N
the DT N
effect NN N
of IN N
indomethacin NN i
given VBN N
for IN N
7 CD N
days NNS N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
development NN N
of IN N
HO NNP N
follows VBZ N
a DT N
COX-2 JJ N
pathway NN N
. . N

-DOCSTART- -X- O O

Investigation NN p
of IN p
maxillary JJ o
tooth NN o
sizes NNS o
in IN p
patients NNS p
with IN p
palatal JJ p
canine NN p
displacement NN p
. . p

AIM IN N
The DT N
aim NN N
of IN N
this DT N
retrospective JJ N
trial NN N
was VBD N
to TO N
investigate VB N
differences NNS N
in IN N
mesiodistal JJ N
and CC N
vestibulo-oral JJ N
crown NN N
sizes NNS N
of IN N
naturally RB N
, , N
fully-erupted JJ N
permanent JJ N
maxillary JJ N
teeth NNS N
between IN N
patients NNS p
with IN p
and CC p
without IN p
palatal JJ p
canine NN p
displacement NN p
. . p

PATIENTS NNP N
AND CC N
METHOD NNP N
115 CD p
patients NNS p
( ( p
mean JJ p
age NN p
: : p
14 CD p
years NNS p
10 CD p
months NNS p
; : p
females NNS p
: : p
77 CD p
males NNS p
: : p
38 CD p
) ) p
treated VBN p
in IN p
the DT p
Department NNP p
of IN p
Orthodontics NNP p
, , p
University NNP p
of IN p
Munich NNP p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

65 CD p
of IN p
the DT p
patients NNS p
showed VBD p
at IN p
least JJS p
one CD p
palatally-displaced JJ p
canine NN p
. . p

Diagnosis NN p
and CC p
the DT p
location NN p
of IN p
the DT p
displacement NN p
were VBD p
determined VBN p
on IN p
the DT p
basis NN p
of IN p
standardized JJ i
radiographs NN i
and CC p
confirmed VBN p
by IN p
surgical JJ p
documentation NN p
. . p

Each DT p
maxillary JJ p
tooth NN p
's POS p
mesiodistal JJ p
and CC p
vestibulo-oral JJ p
width NN p
was VBD p
measured VBN p
using VBG p
a DT p
dial JJ i
caliper NN i
on IN p
each DT p
dental JJ p
cast NN p
. . p

Excluded VBN p
were VBD p
partially-erupted JJ p
teeth NNS p
and CC p
surfaces NNS p
with IN p
caries NNS p
or CC p
restorations NNS p
that WDT p
had VBD p
to TO p
be VB p
measured VBN p
. . p

An DT N
analysis NN N
of IN N
available JJ N
space NN N
was VBD N
made VBN N
by IN N
evaluating VBG N
the DT N
pre-treatment JJ N
dental JJ N
casts NNS N
of IN N
all DT N
patients NNS N
included VBN N
in IN N
the DT N
study NN N
. . N

RESULTS NNP N
Comparing VBG N
the DT N
tooth JJ o
widths NNS o
of IN N
patients NNS N
with IN N
unilateral JJ N
canine NN N
displacement NN N
with IN N
the DT N
corresponding JJ N
contralateral JJ N
quadrants NNS N
, , N
we PRP N
noted VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
, , N
namely RB N
that IN N
the DT N
central JJ N
and CC N
lateral JJ N
incisors NNS N
and CC N
the DT N
canines NNS N
of IN N
the DT N
affected JJ N
side NN N
were VBD N
narrower JJR N
than IN N
those DT N
of IN N
the DT N
non-affected JJ N
side NN N
in IN N
the DT N
same JJ N
patient NN N
. . N

Moreover RB N
, , N
the DT N
displaced JJ N
upper JJ N
canines NNS N
showed VBD N
an DT N
increase NN N
in IN N
vestibulo-oral JJ o
dimension NN o
. . o

Overall JJ o
tooth JJ o
width NN o
( ( N
including VBG N
all DT N
tooth DT N
groups NNS N
) ) N
in IN N
patients NNS N
with IN N
palatally-displaced JJ N
canines NNS N
was VBD N
significantly RB N
less JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
when WRB N
comparing VBG N
the DT N
crown JJ o
diameters NNS o
of IN N
unilaterally- JJ N
and CC N
bilaterally-affected JJ N
patients NNS N
, , N
no DT N
differences NNS N
in IN N
tooth-size NN o
were VBD N
observed VBN N
. . N

The DT N
space-analysis NN N
showed VBD N
excessive JJ N
dental-arch JJ o
space NN o
in IN N
patients NNS N
with IN N
a DT N
palatally-displaced JJ N
canine NN N
. . N

CONCLUSION NNP N
Patients NNPS N
affected VBN N
by IN N
palatal JJ N
canine NN N
displacement NN N
showed VBD N
significantly RB N
smaller JJR N
maxillary JJ N
tooth DT N
size NN N
. . N

-DOCSTART- -X- O O

Aerobic NNP i
versus NN i
resistance NN i
training NN i
effects NNS N
on IN N
health-related JJ o
quality NN o
of IN o
life NN o
, , o
body NN o
composition NN o
, , o
and CC o
function NN o
of IN o
older JJR o
adults NNS o
. . o

This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
training VBG N
on IN N
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
HRQoL NNP o
) ) o
, , o
body NN o
composition NN o
, , o
and CC o
function NN o
in IN p
older JJR p
adults NNS p
. . p

Fifty JJ p
participants NNS p
were VBD p
randomized VBN p
into IN N
aerobic JJ i
training NN i
( ( N
AT NNP N
-- : N
70 CD N
% NN N
-80 CD N
% NN N
HR NNP N
reserve NN N
) ) N
, , N
resistance NN i
training NN i
( ( N
RT NNP N
-- : N
80 CD N
% NN N
1RM CD N
) ) N
, , N
or CC N
controls NNS i
. . i

They PRP N
had VBD N
HRQoL NNP o
, , o
body NN o
composition NN o
, , o
and CC o
function NN o
assessed VBN N
before IN N
and CC N
after IN N
8 CD N
months NNS N
. . N

Training VBG N
groups NNS N
reduced VBD o
body NN o
fat JJ o
, , o
increased JJ o
performance NN o
in IN o
the DT o
stair NN o
ascent NN o
, , o
8-ft JJ o
up-and-go JJ o
and CC o
sit-to-stand JJ o
five-times JJ o
tests NNS o
, , N
and CC N
improved VBD o
their PRP$ o
physical JJ o
component NN o
score NN o
( ( N
PCS NNP N
; : N
p NN N
? . N
.03 NN N
) ) N
. . N

AT NNP N
increased VBD o
performance NN o
in IN o
the DT N
6MWT CD N
test NN N
, , N
and CC o
improved VBN o
general JJ o
and CC o
mental JJ o
health NN o
( ( o
MH NNP o
) ) o
domains VBZ o
when WRB N
compared VBN N
to TO N
controls NNS N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
. . N

Finally RB N
, , N
changes NNS N
in IN N
stair NN N
ascent NN N
were VBD N
associated VBN N
with IN o
changes NNS o
in IN o
bodily RB o
pain NN o
, , o
MH NNP o
, , o
and CC o
mental JJ o
component NN o
score NN o
( ( o
p VB N
? . N
.04 NN N
) ) N
, , N
while IN N
changes NNS o
in IN o
handgrip NN o
strength NN o
were VBD o
associated VBN N
with IN N
changes NNS o
in IN o
physical JJ o
role NN o
and CC o
MH NNP o
( ( N
p JJ N
= NNP N
.03 NNP N
) ) N
. . i

AT NNP i
and CC N
RT NNP i
were VBD N
effective JJ N
interventions NNS N
for IN N
decreasing VBG o
body NN o
fat JJ o
and CC N
improving VBG o
functionality NN o
and CC o
the DT N
PCS NNP o
in IN o
older JJR o
adults NNS o
. . o

-DOCSTART- -X- O O

Creon NNP i
10,000 CD i
Minimicrospheres NNP i
vs. FW i
Creon NNP i
8,000 CD i
microspheres NNS i
-- : i
an DT i
open JJ N
randomised VBN N
crossover NN N
preference NN N
study NN N
. . N

Creon NNP i
10,000 CD i
Minimicrospherestrade NNP i
mark NN i
( ( i
Creon NNP i
) ) i
10,000 CD i
MMS NNP i
) ) i
is VBZ N
a DT N
pancreatic JJ N
enzyme NN N
formulation NN N
that IN N
contains VBZ N
smaller JJR N
spheres NNS N
of IN N
pancreatin NN N
in IN N
a DT N
50 CD N
% NN N
smaller JJR N
capsule NN N
than IN N
conventional JJ N
microspheres NNS i
( ( i
Creon NNP i
) ) i
8,000 CD i
) ) i
. . i

This DT N
three-centre JJ p
study NN p
investigated VBD p
the DT p
preference NN o
of IN p
cystic JJ p
fibrosis NN p
( ( p
CF NNP p
) ) p
patients NNS p
for IN N
these DT N
products NNS N
. . N

In IN N
one CD N
centre NN N
, , N
72 CD N
h NN N
stool NN o
fat JJ o
excretion NN o
and CC o
coefficient NN o
of IN o
fat JJ o
absorption NN o
( ( o
CFA NNP o
) ) o
were VBD N
also RB N
compared VBN N
. . N

Fifty-nine JJ p
patients NNS p
with IN p
a DT p
mean JJ p
age NN p
10 CD p
years NNS p
( ( p
range VB p
3-17 NNP p
) ) p
took VBD N
Creon NNP N
8,000 CD N
ms NN N
for IN N
14 CD N
days NNS N
and CC N
were VBD N
then RB N
randomised VBN N
to TO N
28 CD i
days NNS i
of IN i
Creon NNP i
8,000 CD i
ms NN i
followed VBN i
by IN i
28 CD i
days NNS i
of IN i
Creon NNP i
10,000 CD i
MMS NNP i
, , i
or CC i
vice NN i
versa NN i
. . i

Dosing NNP N
was VBD N
lipase NN N
for IN N
lipase NN N
according VBG N
to TO N
the DT N
labelled VBN N
declaration NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
second JJ N
treatment NN N
period NN N
, , N
51 CD p
of IN p
54 CD p
patients NNS p
who WP p
completed VBD p
the DT p
study NN p
expressed VBD N
a DT N
preference NN N
, , N
with IN N
a DT N
statistically RB o
significant JJ o
preference NN o
in IN N
favour NN N
of IN N
Creon NNP N
10,000 CD N
MMS NNP N
( ( N
47/51 CD N
; : N
87 CD N
% NN N
) ) N
vs. FW N
Creon NNP N
8,000 CD N
ms NN N
( ( N
4/51 CD N
; : N
7.4 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Stool NNP o
fat NN o
( ( o
g/day NN o
) ) o
and CC o
CFA NNP o
( ( o
% NN o
) ) o
were VBD N
measured VBN N
in IN N
24 CD N
patients NNS N
at IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
: : N
the DT N
products NNS N
were VBD N
therapeutically RB N
equivalent JJ N
( ( i
Creon JJ i
10,000 CD N
: : N
8.4 CD N
g/day NN N
, , N
91.3 CD N
% NN N
CFA NNP N
; : N
Creon NNP N
8,000 CD N
: : N
6.7 CD N
g/day NN N
, , N
93.5 CD N
% NN N
CFA NNP N
) ) N
. . N

Both DT N
products NNS N
were VBD N
well RB N
tolerated VBN N
. . N

In IN N
conclusion NN N
, , N
in IN N
CF NNP p
children NNS p
we PRP N
found VBD N
a DT N
clear JJ N
preference NN N
for IN N
Creon NNP N
10,000 CD N
MMS NNP N
compared VBN N
with IN N
Creon NNP N
8,000 CD N
ms NN N
with IN N
no DT N
difference NN N
in IN N
fat JJ o
absorption NN o
between IN N
the DT N
two CD N
products NNS N
. . N

Creon NNP i
10,000s CD N
smaller JJR N
capsules NNS N
are VBP N
easier JJR N
to TO N
take VB N
and CC N
should MD N
aid VB N
patient NN N
compliance NN N
. . N

-DOCSTART- -X- O O

Intensive JJ i
case NN i
management NN i
before IN N
and CC N
after IN N
prison NN N
release NN N
is VBZ N
no DT N
more RBR N
effective JJ N
than IN N
comprehensive JJ i
pre-release JJ i
discharge NN i
planning NN i
in IN N
linking VBG N
HIV-infected JJ p
prisoners NNS p
to TO N
care VB N
: : N
a DT N
randomized JJ N
trial NN N
. . N

Imprisonment NNP N
provides VBZ N
opportunities NNS N
for IN N
the DT N
diagnosis NN N
and CC N
successful JJ N
treatment NN N
of IN N
HIV NNP N
, , N
however RB N
, , N
the DT N
benefits NNS N
of IN N
antiretroviral JJ i
therapy NN i
are VBP N
frequently RB N
lost VBN N
following VBG N
release NN N
due JJ N
to TO N
suboptimal JJ N
access NN N
and CC N
utilization NN N
of IN N
health NN N
care NN N
and CC N
services NNS N
. . N

In IN N
response NN N
, , N
some DT N
have VBP N
advocated VBN N
for IN N
development NN N
of IN N
intensive JJ N
case-management JJ N
interventions NNS N
spanning VBG N
incarceration NN N
and CC N
release NN N
to TO N
support VB N
treatment NN N
adherence NN N
and CC N
community NN N
re-entry NN N
for IN N
HIV-infected JJ p
releasees NNS p
. . p

We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
motivational JJ i
Strengths NNP i
Model NNP i
bridging VBG i
case NN i
management NN i
intervention NN i
( ( i
BCM NNP i
) ) i
beginning VBG N
approximately RB N
3 CD N
months NNS N
prior RB N
to TO N
and CC N
continuing VBG N
6 CD N
months NNS N
after IN N
release NN N
versus IN N
a DT N
standard NN i
of IN i
care NN i
prison-administered JJ i
discharge NN i
planning VBG i
program NN i
( ( i
SOC NNP i
) ) i
for IN i
HIV-infected JJ p
state NN p
prison NN p
inmates NNS p
. . p

The DT N
primary JJ N
outcome NN N
variable NN N
was VBD o
self-reported JJ o
access NN o
to TO o
post-release VB o
medical JJ o
care NN o
. . o

Of IN N
the DT p
104 CD p
inmates NNS p
enrolled VBD p
, , p
89 CD p
had VBD p
at IN p
least JJS p
1 CD p
post-release JJ p
study NN p
visit NN p
. . p

Of IN N
these DT N
, , N
65.1 CD N
% NN N
of IN N
BCM NNP N
and CC N
54.4 CD N
% NN N
of IN N
SOC NNP i
assigned VBD i
participants NNS N
attended VBD N
a DT N
routine JJ o
medical JJ o
appointment NN o
within IN o
4 CD N
weeks NNS N
of IN N
release NN N
( ( N
P NNP N
> NNP N
0.3 CD N
) ) N
. . N

By IN N
week NN N
12 CD N
post-release NN N
, , N
88.4 CD N
% NN N
of IN N
the DT i
BCM NNP i
arm NN N
and CC N
78.3 CD N
% NN N
of IN N
the DT N
SOC NNP N
arm NN N
had VBD N
at IN N
attended VBN N
at IN N
least JJS N
one CD o
medical JJ o
appointment NN o
( ( o
P NNP o
= NNP o
0.2 CD N
) ) N
, , N
increasing VBG N
in IN N
both DT N
arms NNS N
at IN N
week NN N
24-90.7 CD N
% NN N
with IN N
BCM NNP N
and CC N
89.1 CD N
% NN N
with IN N
SOC NNP N
( ( N
P NNP N
> NNP N
0.5 CD N
) ) N
. . N

No DT N
participant NN N
without IN N
a DT N
routine JJ N
medical JJ N
visit NN N
by IN N
week NN N
24 CD N
attended VBD N
an DT o
appointment NN o
from IN o
weeks NNS o
24 CD N
to TO N
48 CD N
. . N

The DT o
mean JJ o
number NN o
of IN o
clinic JJ o
visits NNS o
during IN o
the DT N
48 CD N
weeks NNS N
post NN N
release NN N
was VBD N
5.23 CD N
( ( N
SD NNP N
= NNP N
3.14 CD N
) ) N
for IN N
BCM NNP N
and CC N
4.07 CD N
( ( N
SD NNP N
= NNP N
3.20 CD N
) ) N
for IN N
SOC NNP N
( ( N
P NNP N
> NNP N
0.5 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
arms NNS N
in IN N
social JJ o
service NN o
utilization NN o
and CC o
re-incarceration NN o
rates NNS o
were VBD o
also RB o
similar JJ N
. . N

We PRP N
found VBD N
that IN N
a DT N
case NN i
management NN i
intervention NN i
bridging VBG i
incarceration NN i
and CC i
release NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
a DT N
less RBR N
intensive JJ N
pre-release JJ i
discharge NN i
planning VBG i
program NN i
in IN i
supporting VBG i
health NN N
and CC N
social JJ N
service NN N
utilization NN N
for IN N
HIV-infected JJ p
individuals NNS p
released VBN p
from IN p
prison NN p
. . p

-DOCSTART- -X- O O

A DT N
controlled VBN N
study NN N
comparing VBG N
patients NNS p
with IN p
and CC p
without IN p
polycystic JJ p
ovaries NNS p
undergoing VBG p
in-vitro JJ o
fertilization NN o
. . o

The DT N
outcome NN N
of IN N
in-vitro JJ i
fertilization NN i
and CC i
embryo NN i
transfer NN i
( ( i
IVF-ET NNP i
) ) i
was VBD N
compared VBN N
in IN N
76 CD p
patients NNS p
with IN p
polycystic JJ p
ovaries NNS p
( ( p
PCO NNP p
) ) p
diagnosed VBD p
on IN p
pre-treatment JJ p
ultrasound JJ p
scan NN p
, , p
and CC p
76 CD p
control NN p
patients NNS p
who WP p
had VBD p
normal JJ p
ovaries NNS p
and CC p
were VBD p
matched VBN p
for IN p
age NN p
, , p
cause NN p
of IN p
infertility NN p
and CC p
stimulation NN p
regimen NNS p
. . p

Despite IN N
receiving VBG N
significantly RB N
less JJR N
human JJ i
menopausal NN i
gonadotrophin NN i
( ( i
HMG NNP i
) ) i
, , N
patients NNS p
with IN p
PCO NNP p
, , N
as IN N
compared VBN N
with IN N
controls NNS N
, , N
had VBD N
significantly RB N
higher JJR N
serum NN o
oestradiol NN o
levels NNS o
on IN N
the DT N
day NN N
of IN N
human JJ N
chorionic NN i
gonadotrophin NN i
administration NN N
( ( N
5940 CD N
+/- NN N
255 CD N
versus NN N
4370 CD N
+/- JJ N
240 CD N
pmol/l NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
developed VBD N
more JJR N
follicles NNS o
( ( N
14.9 CD N
+/- JJ N
0.7 CD N
versus NN N
9.8 CD N
+/- JJ N
0.6 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
produced VBD N
more JJR N
oocytes NNS o
( ( N
9.3 CD N
+/- JJ N
0.6 CD N
versus NN N
6.8 CD N
+/- JJ N
0.5 CD N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

However RB N
, , N
fertilization NN o
rates NNS o
were VBD N
reduced VBN N
in IN N
the DT N
PCO NNP N
patients NNS N
( ( N
52.8 CD N
+/- JJ N
3.4 CD N
% NN N
versus NN N
66.1 CD N
+/- JJ N
3.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.007 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
cleavage NN o
rates NNS o
. . o

The DT N
pregnancy NN o
rate/embryo NN o
transfer NN o
was VBD N
25.4 CD N
% NN N
in IN N
the DT N
PCO NNP p
group NN p
and CC N
23.0 CD N
% NN N
in IN N
the DT N
group NN p
with IN p
normal JJ p
ovaries NNS p
. . p

There EX N
were VBD N
three CD N
high JJ N
order NN N
multiple JJ N
pregnancies NNS N
in IN N
the DT N
PCO NNP N
group NN N
compared VBN N
with IN N
none NN N
in IN N
the DT N
group NN N
with IN N
normal JJ N
ovaries NNS N
. . N

Of IN N
the DT N
PCO NNP N
patients NNS N
, , N
10.5 CD N
% NN N
developed VBD N
moderate/severe RB N
ovarian JJ o
hyperstimulation NN o
syndrome NN o
( ( o
OHSS NNP o
) ) o
compared VBN N
with IN N
none NN N
of IN N
the DT N
controls NNS N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
. . N

Patients NNS p
with IN p
and CC p
without IN p
PCO NNP p
undergoing VBG p
IVF NNP p
have VBP N
comparable JJ N
pregnancy NN o
and CC o
livebirth JJ o
rates NNS o
. . o

However RB N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
diagnose VB N
PCO NNP N
before IN N
ovarian JJ N
stimulation NN N
is VBZ N
initiated VBN N
as IN N
these DT N
patients NNS N
are VBP N
more RBR N
likely JJ N
to TO N
develop VB N
moderate JJ N
or CC N
severe JJ N
OHSS NNP N
following VBG N
IVF-ET NNP N
. . N

-DOCSTART- -X- O O

Once-daily RB N
MMX NNP i
( ( i
? . i
) ) i
mesalamine NN i
for IN N
endoscopic JJ N
maintenance NN N
of IN N
remission NN N
of IN p
ulcerative JJ p
colitis NN p
. . p

OBJECTIVES NNP N
Treatment NNP N
with IN i
mesalamine NN i
to TO N
maintain VB N
endoscopic JJ N
remission NN N
( ( N
mucosal JJ N
healing VBG N
) ) N
of IN N
ulcerative JJ N
colitis NN N
( ( N
UC NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
relapse NN N
and CC N
is VBZ N
the DT N
recommended JJ N
first-line JJ N
maintenance NN N
therapy NN N
. . N

To TO N
improve VB N
treatment NN N
adherence NN N
, , N
a DT N
mesalamine NN N
formulation NN N
that WDT N
can MD N
be VB N
administered VBN N
once-daily RB N
, , N
MMX NNP i
( ( i
? . i
) ) i
mesalamine NN i
( ( i
Lialda NNP i
; : i
Shire NNP i
Pharmaceuticals NNP i
LLC NNP i
, , i
Wayne NNP i
, , i
PA NNP i
) ) i
, , i
was VBD N
developed VBN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ i
MMX NNP i
mesalamine NN i
compared VBN i
with IN N
twice-daily JJ i
delayed-release JJ i
mesalamine NN i
( ( i
Asacol NNP i
; : i
Warner NNP i
Chilcott NNP i
, , i
Dublin NNP i
, , i
Ireland NNP i
) ) i
for IN i
maintaining VBG N
endoscopic JJ N
remission NN N
in IN N
patients NNS N
with IN N
UC NNP N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
6-month JJ N
, , N
active-control JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
non-inferiority NN N
of IN N
once-daily JJ i
MMX NNP i
mesalamine NN i
2.4 CD i
g/day NN N
compared VBN N
with IN i
twice-daily JJ i
delayed-release JJ i
mesalamine NN i
at IN i
a DT i
total JJ i
daily JJ i
dose NN i
of IN i
1.6 CD i
g/day NN i
in IN i
patients NNS N
with IN N
UC NNP N
in IN N
endoscopic JJ N
remission NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD o
maintenance NN o
of IN o
endoscopic JJ o
remission NN o
at IN o
month NN o
6 CD o
in IN o
the DT o
per-protocol NN o
( ( o
PP NNP o
) ) o
population NN o
. . o

RESULTS NNP N
Overall NNP p
, , p
826 CD p
patients NNS p
were VBD p
randomized VBN p
and CC p
dosed VBN p
. . p

The DT N
primary JJ N
objective JJ N
( ( N
non-inferiority NN N
) ) N
was VBD N
met VBN N
. . N

At IN N
month NN N
6 CD N
, , N
83.7 CD N
and CC N
77.8 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
MMX NNP N
mesalamine NN N
in IN N
the DT N
PP NNP N
and CC N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
populations NNS N
, , N
respectively RB N
, , N
had VBD N
maintained VBN o
endoscopic JJ o
remission NN o
compared VBN o
with IN N
81.5 CD N
% NN N
( ( N
PP NNP N
) ) N
and CC N
76.9 CD N
% NN N
( ( N
ITT NNP N
) ) N
of IN N
patients NNS N
receiving VBG N
delayed-release JJ N
mesalamine NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
difference NN N
: : N
-3.9 CD N
% NN N
, , N
8.1 CD N
% NN N
( ( N
PP NNP N
) ) N
; : N
-5.0 CD N
% NN N
, , N
6.9 CD N
% NN N
( ( N
ITT NNP o
) ) o
) ) o
. . o

Time NN o
to TO o
relapse VB o
was VBD o
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
( ( N
log-rank JJ N
test NN N
, , N
P=0.5116 NNP N
( ( N
PP NNP N
) ) N
; : N
P=0.5455 NNP N
( ( N
ITT NNP N
) ) N
) ) N
. . N

The DT o
proportion NN o
of IN o
patients NNS o
with IN o
adverse JJ o
events NNS o
was VBD o
37.1 CD N
and CC N
36.0 CD N
% NN N
in IN N
patients NNS N
receiving VBG N
MMX NNP N
mesalamine NN N
and CC N
delayed-release JJ N
mesalamine NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Once-daily JJ N
dosing NN N
of IN N
MMX NNP N
mesalamine NN N
2.4 CD N
g/day NN N
was VBD N
shown VBN N
to TO N
be VB N
well RB N
tolerated VBN N
and CC N
non-inferior JJ N
to TO N
twice-daily JJ N
dosing VBG N
with IN N
delayed-release JJ N
mesalamine NN N
1.6 CD N
g/day NN N
for IN N
maintenance NN N
of IN N
endoscopic JJ N
remission NN N
in IN N
patients NNS N
with IN N
UC NNP N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
antiresorptive JJ N
activities NNS N
of IN N
ipriflavone NN i
, , N
an DT N
isoflavone NN i
derivative NN i
, , N
and CC N
elcatonin NN i
, , N
an DT N
eel NN i
carbocalcitonin NN i
. . i

Thirty NNP p
postmenopausal JJ p
women NNS p
with IN p
reduced JJ p
bone NN p
mineral JJ p
density NN p
were VBD p
divided VBN p
randomly RB p
into IN p
two CD p
groups NNS p
based VBN p
on IN p
the DT p
chronological JJ p
sequence NN p
of IN p
their PRP$ p
first JJ p
visit NN p
to TO p
the DT p
Osteoporosis NNP p
Clinic NNP p
of IN p
Katsuragi NNP p
Hospital NNP p
. . p

Group NNP N
I PRP N
was VBD N
given VBN N
600 CD N
mg JJ N
ipriflavone NN i
orally RB N
daily JJ N
and CC N
group NN N
II NNP N
was VBD N
weekly RB N
injected VBN N
intramuscularly RB N
with IN N
20 CD N
units NNS N
elcatonin RB i
, , i
Asu1-7 NNP i
eel NN i
calcitonin NN i
( ( i
carbocalcitonin NN i
) ) i
. . i

Lumbar NNP o
spine NN o
BMD NNP o
was VBD N
measured VBN N
by IN N
dual-energy JJ i
X-ray JJ i
absorptiometry NN i
, , N
and CC N
trabecular JJ o
bone NN o
mineral JJ o
density NN o
at IN N
the DT N
distal JJ N
radius NN N
, , N
cortical JJ o
bone NN o
density NN o
, , N
and CC N
relative JJ o
cortical JJ o
volume NN o
at IN N
the DT N
radial JJ N
diaphysis NN N
by IN N
peripheral JJ N
computed VBN N
tomography NN N
before IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
and CC N
at IN N
the DT N
4th CD N
, , N
8th CD N
, , N
and CC N
12th CD N
month NN N
. . N

Markers NNS o
of IN o
bone NN o
metabolism NN o
-- : o
serum JJ o
total JJ o
alkaline NN o
phosphatase NN o
, , o
bone-specific JJ o
alkaline NN o
phosphatase NN o
, , o
tartrate-resistant JJ o
acid NN o
phosphatase NN o
, , o
osteocalcin NN o
, , o
intact JJ o
osteocalcin NN o
, , o
PICP NNP o
and CC o
ICTP NNP o
, , o
and CC o
urinary JJ o
pyridinoline NN o
, , o
deoxypyridinoline NN o
, , o
and CC o
calcium/creatinine NN o
( ( o
Ca/Cr NNP o
) ) o
-- : o
were VBD o
also RB N
measured VBN N
at IN N
the DT N
same JJ N
interval NN N
. . N

Plasma NNP o
parathyroid JJ o
hormone NN o
( ( o
PTH NNP o
) ) o
and CC o
calcitonin NN o
( ( o
CT NNP o
) ) o
were VBD N
measured VBN N
at IN N
the DT N
same JJ N
time NN N
. . N

Radial JJ o
trabecular JJ o
bone NN o
density NN o
showed VBD N
a DT N
significantly RB N
higher JJR N
rate NN N
of IN N
increase NN N
in IN N
group NN N
I PRP N
( ( i
ipriflavone VB i
group NN N
) ) N
than IN N
in IN N
group NN N
II NNP N
( ( N
elcatonin JJ N
group NN N
) ) N
at IN N
the DT N
4th CD N
month NN N
, , N
whereas JJ N
lumbar NN o
spine NN o
BMD NNP o
showed VBD N
more RBR N
pronounced JJ N
increase NN N
in IN N
the DT N
elcatonin NN N
group NN N
than IN N
in IN N
the DT N
ipriflavone NN i
group NN N
throughout IN N
the DT N
study NN N
period NN N
. . N

Bone NNP o
metabolism NN o
markers NNS o
tended VBD N
to TO N
decline VB N
in IN N
both DT N
groups NNS N
. . N

Total JJ o
and CC o
intact JJ o
osteocalcin NN o
showed VBD N
a DT N
significant JJ N
fall NN N
from IN N
the DT N
baseline NN N
throughout IN N
the DT N
study NN N
period NN N
only RB N
in IN N
the DT N
ipriflavone NN N
group NN N
. . N

Urine NNP o
pyridinoline NN o
and CC o
deoxypyridinoline NN o
showed VBD N
a DT N
significant JJ N
fall NN N
from IN N
the DT N
baseline NN N
at IN N
the DT N
12th CD N
month NN N
only RB N
in IN N
the DT N
ipriflavone NN N
group NN N
. . N

On IN N
comparing VBG N
bone NN N
gainers NNS N
with IN N
increase NN N
of IN N
lumbar JJ o
spine NN o
BMD NNP o
by IN N
2 CD N
% NN N
or CC N
more JJR N
with IN N
bone NN N
losers NNS N
with IN N
a DT N
decrease NN N
by IN N
2 CD N
% NN N
or CC N
more JJR N
, , N
only RB N
urine JJ o
Ca/Cr NNP o
was VBD N
significantly RB N
different JJ N
, , N
lower RBR N
in IN N
the DT N
former JJ N
than IN N
in IN N
the DT N
latter NN N
, , N
despite IN N
the DT N
general JJ N
tendency NN N
for IN N
bone NN N
resorption NN N
markers NNS N
to TO N
decrease VB N
in IN N
bone NN N
gainers NNS N
and CC N
to TO N
increase VB N
in IN N
bone JJ N
losers NNS N
. . N

-DOCSTART- -X- O O

Intravenous JJ N
platelet NN N
blockade NN N
with IN N
cangrelor NN i
during IN N
PCI NNP p
. . p

BACKGROUND NNP N
Intravenous NNP N
cangrelor NN i
, , N
a DT N
rapid-acting NN N
, , N
reversible JJ N
adenosine NN N
diphosphate NN N
( ( N
ADP NNP N
) ) N
receptor NN N
antagonist NN N
, , N
might MD N
reduce VB N
ischemic JJ N
events NNS N
during IN N
percutaneous JJ p
coronary JJ p
intervention NN p
( ( p
PCI NNP p
) ) p
. . p

METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
, , N
we PRP N
randomly VBP N
assigned JJ N
5362 CD p
patients NNS p
who WP p
had VBD p
not RB p
been VBN p
treated VBN p
with IN p
clopidogrel NN p
to TO p
receive VB p
either DT p
cangrelor NN i
or CC i
placebo NN i
at IN p
the DT p
time NN p
of IN p
PCI NNP p
, , p
followed VBN p
by IN p
600 CD i
mg NNS i
of IN i
clopidogrel NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
a DT N
composite JJ o
of IN o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
or CC o
ischemia-driven JJ o
revascularization NN o
at IN o
48 CD o
hours NNS o
. . o

Enrollment NN N
was VBD N
stopped VBN N
when WRB N
an DT N
interim JJ N
analysis NN N
concluded VBD N
that IN N
the DT N
trial NN N
would MD N
be VB N
unlikely JJ N
to TO N
show VB N
superiority NN N
for IN N
the DT N
primary JJ N
end NN N
point NN N
. . N

RESULTS VB N
The DT N
primary JJ o
end NN o
point NN o
occurred VBD p
in IN p
185 CD p
of IN p
2654 CD p
patients NNS p
receiving VBG p
cangrelor NN i
( ( p
7.0 CD p
% NN p
) ) p
and CC p
in IN p
210 CD p
of IN p
2641 CD p
patients NNS p
receiving VBG p
placebo NN i
( ( p
8.0 CD p
% NN p
) ) p
( ( N
odds NNS N
ratio NN N
in IN N
the DT N
cangrelor NN N
group NN N
, , N
0.87 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.71 CD N
to TO N
1.07 CD N
; : N
P=0.17 NNP N
) ) N
( ( N
modified VBN N
intention-to-treat NN N
population NN N
adjusted VBN N
for IN N
missing VBG N
data NNS N
) ) N
. . N

In IN N
the DT N
cangrelor NN i
group NN N
, , N
as IN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
, , N
two CD N
prespecified VBD N
secondary JJ N
end NN N
points NNS N
were VBD N
significantly RB N
reduced VBN N
at IN N
48 CD N
hours NNS N
: : N
the DT N
rate NN o
of IN o
stent JJ o
thrombosis NN o
, , N
from IN N
0.6 CD N
% NN N
to TO N
0.2 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
0.31 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.11 CD N
to TO N
0.85 CD N
; : N
P=0.02 NNP N
) ) N
, , N
and CC N
the DT N
rate NN o
of IN o
death NN o
from IN o
any DT o
cause NN o
, , N
from IN N
0.7 CD N
% NN N
to TO N
0.2 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
0.33 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.13 CD N
to TO N
0.83 CD N
; : N
P=0.02 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
blood NN o
transfusion NN o
( ( N
1.0 CD N
% NN N
in IN N
the DT N
cangrelor NN i
group NN N
and CC N
0.6 CD N
% NN N
in IN N
the DT N
placebo NN i
group NN N
, , N
P=0.13 NNP N
) ) N
, , N
though IN N
major JJ o
bleeding VBG o
on IN N
one CD N
scale NN N
was VBD N
increased VBN N
in IN N
the DT N
cangrelor NN N
group NN N
, , N
from IN N
3.5 CD N
% NN N
to TO N
5.5 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
because IN N
of IN N
more JJR N
groin JJ o
hematomas NN o
. . o

CONCLUSIONS VB N
The DT N
use NN N
of IN N
periprocedural JJ N
cangrelor NN i
during IN N
PCI NNP N
was VBD N
not RB N
superior JJ N
to TO N
placebo VB N
in IN N
reducing VBG N
the DT N
primary JJ N
end NN N
point NN N
. . N

The DT N
prespecified JJ N
secondary JJ N
end NN N
points NNS N
of IN N
stent JJ N
thrombosis NN N
and CC N
death NN N
were VBD N
lower JJR N
in IN N
the DT N
cangrelor NN i
group NN N
, , N
with IN N
no DT N
significant JJ N
increase NN N
in IN N
the DT N
rate NN N
of IN N
transfusion NN N
. . N

Further NNP N
study NN N
of IN N
intravenous JJ N
ADP NNP i
blockade NN i
with IN i
cangrelor NN i
may MD N
be VB N
warranted VBN N
. . N

( ( N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00385138 NNP N
. . N

) ) N
-DOCSTART- -X- O O

Impact NN N
of IN N
a DT N
16-community JJ p
trial NN p
to TO p
promote VB p
judicious JJ p
antibiotic JJ p
use NN p
in IN p
Massachusetts NNP p
. . p

OBJECTIVES NNP N
Reducing VBG N
unnecessary JJ N
antibiotic JJ N
use NN N
, , N
particularly RB N
among IN N
children NNS N
, , N
continues VBZ N
to TO N
be VB N
a DT N
public JJ N
health NN N
priority NN N
. . N

Previous JJ N
intervention NN N
studies NNS N
have VBP N
been VBN N
limited VBN N
by IN N
size NN N
or CC N
design NN N
and CC N
have VBP N
shown VBN N
mixed JJ N
results NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
a DT N
multifaceted VBN i
, , i
community-wide JJ i
intervention NN i
on IN i
overall JJ i
antibiotic JJ i
use NN i
for IN N
young JJ p
children NNS p
and CC N
on IN N
use NN N
of IN N
broad-spectrum JJ N
agents NNS N
. . N

In IN N
addition NN N
, , N
we PRP N
sought VBD N
to TO N
compare VB N
the DT N
intervention NN N
's POS N
impact NN N
on IN N
commercially RB p
and CC p
Medicaid-insured JJ p
children NNS p
. . p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
controlled VBN N
, , N
community-level JJ p
, , p
cluster-randomized JJ p
trial NN p
in IN p
16 CD p
nonoverlapping VBG p
Massachusetts NNP p
communities NNS p
, , p
studied VBN p
from IN p
1998 CD p
to TO p
2003 CD p
. . p

During IN N
3 CD N
years NNS N
, , N
we PRP N
implemented VBD N
a DT N
physician JJ i
behavior-change NN i
strategy NN i
that WDT i
included VBD i
guideline JJ i
dissemination NN i
, , i
small-group JJ i
education NN i
, , i
frequent JJ i
updates NNS i
and CC i
educational JJ i
materials NNS i
, , i
and CC i
prescribing VBG i
feedback NN i
. . i

Parents NNS i
received VBD i
educational JJ i
materials NNS i
by IN i
mail NN i
and CC i
in IN i
primary JJ i
care NN i
practices NNS i
, , i
pharmacies NNS i
, , i
and CC i
child NN i
care NN i
settings NNS i
. . i

Using VBG N
health-plan JJ i
data NNS i
, , N
we PRP N
measured VBD N
changes NNS N
in IN N
antibiotics NNS N
dispensed VBN N
per IN N
person-year NN N
of IN N
observation NN N
among IN N
children NNS p
who WP p
were VBD p
aged VBN p
3 CD p
to TO p
< VB p
72 CD p
months NNS p
, , p
resided VBN p
in IN p
study NN p
communities NNS p
, , p
and CC p
were VBD p
insured VBN p
by IN p
a DT p
participating VBG p
commercial JJ p
health NN p
plan NN p
or CC p
Medicaid NNP p
. . p

RESULTS VB N
The DT N
data NNS N
include VBP N
223,135 CD p
person-years NNS p
of IN p
observation NN p
. . p

Antibiotic-use JJ o
rates NNS o
at IN N
baseline NN N
were VBD N
2.8 CD N
, , N
1.7 CD N
, , N
and CC N
1.4 CD N
antibiotics NNS N
per IN N
person-year NN N
among IN N
those DT N
aged VBN N
3 CD N
to TO N
< VB N
24 CD N
, , N
24 CD N
to TO N
< VB N
48 CD N
, , N
and CC N
48 CD N
to TO N
< VB N
72 CD N
months NNS N
, , N
respectively RB N
. . N

We PRP N
observed VBD N
a DT N
substantial JJ N
downward JJ N
trend NN N
in IN N
antibiotic JJ o
prescribing NN o
, , N
even RB N
in IN N
the DT N
absence NN N
of IN N
intervention NN N
. . N

The DT N
intervention NN N
had VBD N
no DT N
additional JJ N
effect NN N
among IN N
children NNS N
aged VBD N
3 CD N
to TO N
< VB N
24 CD N
months NNS N
but CC N
was VBD N
responsible JJ N
for IN N
a DT N
4.2 CD N
% NN N
decrease NN N
among IN N
those DT N
aged VBN N
24 CD N
to TO N
< VB N
48 CD N
months NNS N
and CC N
a DT N
6.7 CD N
% NN N
decrease NN N
among IN N
those DT N
aged VBN N
48 CD N
to TO N
< VB N
72 CD N
months NNS N
. . N

The DT N
intervention NN N
effect NN N
was VBD N
greater JJR N
among IN N
Medicaid-insured JJ N
children NNS N
and CC N
for IN N
broad-spectrum JJ N
agents NNS N
. . N

CONCLUSIONS VB N
A DT N
sustained JJ N
, , N
multifaceted VBN N
, , N
community-level JJ N
intervention NN N
was VBD N
only RB N
modestly RB N
successful JJ N
at IN N
decreasing VBG N
overall JJ o
antibiotic JJ o
use NN o
beyond IN N
substantial JJ N
secular JJ N
trends NNS N
. . N

The DT N
more RBR N
robust JJ N
impact NN N
among IN N
Medicaid-insured JJ p
children NNS p
and CC N
for IN N
specific JJ N
medication NN N
classes NNS N
provides VBZ N
an DT N
argument NN N
for IN N
specific JJ N
targeting NN N
of IN N
resources NNS N
for IN N
patient NN N
and CC N
physician JJ N
behavior NN N
change NN N
. . N

-DOCSTART- -X- O O

Left NNP i
thoracoabdominal JJ i
approach NN i
versus IN N
abdominal-transhiatal JJ i
approach NN i
for IN N
gastric JJ p
cancer NN p
of IN p
the DT p
cardia NN p
or CC p
subcardia NN p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Because IN N
of IN N
the DT N
inaccessibility NN N
of IN N
mediastinal JJ N
nodal JJ N
metastases NNS N
, , N
the DT N
left JJ i
thoracoabdominal JJ i
approach NN i
( ( i
LTA NNP i
) ) i
has VBZ N
often RB N
been VBN N
used VBN N
to TO N
treat VB N
gastric JJ p
cancer NN p
of IN p
the DT p
cardia NN p
or CC p
subcardia NN p
. . p

In IN N
a DT N
randomised JJ N
phase NN N
III NNP N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
compare VB o
LTA NNP i
with IN i
the DT i
abdominal-transhiatal JJ i
approach NN i
( ( i
TH NNP i
) ) i
in IN i
the DT i
treatment NN i
of IN N
these DT N
tumours NNS N
. . N

METHODS NNP N
Between NNP p
July NNP p
, , p
1995 CD p
, , p
and CC p
December NNP p
, , p
2003 CD p
, , p
167 CD p
patients NNS p
were VBD p
enrolled VBN p
from IN p
27 CD p
Japanese JJ p
hospitals NNS p
and CC N
randomly RB N
assigned VBN N
to TO N
TH NNP N
( ( N
n=82 NN N
) ) N
or CC N
LTA NNP N
( ( N
n=85 NN N
) ) N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
overall JJ o
survival NN o
, , N
and CC N
secondary JJ N
endpoints NNS N
were VBD N
disease-free JJ o
survival NN o
, , o
postoperative JJ o
morbidity NN o
and CC o
hospital NN o
mortality NN o
, , o
and CC o
postoperative JJ o
symptoms NNS o
and CC o
change NN o
of IN o
respiratory NN o
function NN o
. . o

The DT p
projected JJ p
sample NN p
size NN p
was VBD p
302 CD p
. . p

After IN p
the DT p
first JJ p
interim JJ p
analysis NN p
, , p
the DT p
predicted JJ p
probability NN p
of IN p
LTA NNP p
having VBG p
a DT p
significantly RB p
better RBR p
overall JJ p
survival NN p
than IN p
TH NNP p
at IN p
the DT p
final JJ p
analysis NN p
was VBD p
only RB p
3.65 CD p
% NN p
, , p
and CC p
the DT p
trial NN p
was VBD p
closed VBN p
immediately RB p
. . p

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
, , N
number NN N
NCT00149266 NNP N
. . N

FINDINGS NNP N
5-year JJ o
overall JJ o
survival NN o
was VBD N
52.3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
40.4-64.1 CD N
) ) N
in IN N
the DT N
TH NNP N
group NN N
and CC N
37.9 CD N
% NN N
( ( N
26.1-49.6 JJ N
) ) N
in IN N
the DT N
LTA NNP N
group NN N
. . N

The DT N
hazard NN o
ratio NN o
of IN o
death NN o
for IN o
LTA NNP o
compared VBN N
with IN N
TH NNP N
was VBD N
1.36 CD N
( ( N
0.89-2.08 CD N
, , N
p=0.92 NN N
) ) N
. . N

Three CD N
patients NNS N
died VBD o
in IN N
hospital NN N
after IN N
LTA NNP N
but CC N
none NN N
after IN N
TH NNP N
. . N

Morbidity NNP o
was VBD N
worse JJR N
after IN N
LTA NNP N
than IN N
after IN N
TH NNP N
. . N

INTERPRETATION NNP N
Because IN N
LTA NNP N
does VBZ N
not RB N
improve VB N
survival NN N
after IN N
TH NNP N
and CC N
leads VBZ N
to TO N
increased VBN N
morbidity NN N
in IN N
patients NNS p
with IN p
cancer NN p
of IN p
the DT p
cardia NN p
or CC p
subcardia NN p
, , N
LTA NNP N
can MD N
not RB N
be VB N
justified VBN N
to TO N
treat VB N
these DT N
tumours NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Value NNP N
of IN N
combining VBG N
64 CD i
multi-slice JJ i
spiral JJ i
computer NN i
tomography NN i
and CC i
serum NN i
amyloid VBP i
A DT i
protein NN i
in IN N
surgical JJ N
decision-making NN N
in IN N
rectal JJ p
cancer NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
determine VB N
the DT N
accuracy NN N
and CC N
clinical JJ N
value NN N
of IN N
combining VBG N
64 CD i
multi-slice JJ i
spiral JJ i
computer NN i
tomography NN i
( ( i
MSCT NNP i
) ) i
and CC i
serum $ i
amyloid VB i
A NNP i
protein NN i
( ( i
SAA NNP i
) ) i
in IN N
the DT N
preoperative JJ p
staging NN p
of IN p
rectal JJ p
cancer NN p
. . p

METHODS NNP N
Prospectively RB N
enrolled VBD N
patients NNS p
with IN p
rectal JJ p
cancer NN p
from IN p
October NNP p
2007 CD p
to TO p
October NNP p
2008 CD p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
into IN N
two CD N
groups NNS N
: : N
MSCT NNP i
and CC i
SAA NNP i
combined VBD N
group NN N
: : N
both DT N
MSCT NNP i
and CC i
SAA NNP i
combinative JJ N
assessment NN N
were VBD N
performed VBN N
for IN N
preoperative JJ N
evaluation NN N
; : N
MSCT NNP i
group NN i
: : i
only RB i
MSCT NNP i
was VBD N
performed VBN N
preoperatively RB N
for IN N
tumor NN N
staging NN N
. . N

The DT N
accuracy NN N
of IN N
the DT N
preoperative JJ N
T NNP N
, , N
N NNP N
, , N
M NNP N
, , N
and CC N
TNM NNP N
staging NN N
and CC N
the DT N
concordance NN N
rate NN N
of IN N
predictive JJ N
operative JJ N
strategy NN N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Total NNP p
of IN p
225 CD p
cases NNS p
with IN p
rectal JJ p
cancer NN p
were VBD p
enrolled VBN p
in IN p
this DT p
study NN p
. . p

There EX N
were VBD N
110 CD p
cases NNS p
in IN p
MSCT NNP i
and CC i
SAA NNP i
combined VBD i
group NN p
and CC p
115 CD p
cases NNS p
in IN p
MSCT NNP i
group NN p
. . p

The DT N
baseline NN N
characteristics NNS N
was VBD N
comparable JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

For IN N
MSCT NNP i
and CC i
SAA NNP i
combined VBD i
group NN N
, , N
the DT N
accuracies NNS o
of IN o
preoperative JJ o
staging NN o
of IN o
T NNP o
, , o
N NNP o
, , o
M NNP o
and CC o
TNM NNP o
was VBD N
87.3 CD N
% NN N
, , N
85.2 CD N
% NN N
, , N
100 CD N
% NN N
and CC N
86.4 CD N
% NN N
, , N
respectively RB N
; : N
and CC N
for IN N
MSCT NNP N
group NN N
, , N
the DT N
corresponding JJ N
rates NNS N
was VBD N
85.2 CD N
% NN N
, , N
67.0 CD N
% NN N
, , N
100 CD N
% NN N
and CC N
66.1 CD N
% NN N
, , N
respectively RB N
. . N

Statistical JJ N
differences NNS N
was VBD N
found VBN N
in IN N
the DT N
accuracy NN o
of IN o
preoperative JJ o
N NNP o
and CC o
TNM NNP o
staging VBG o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.009 CD N
and CC N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
statistical JJ N
difference NN N
in IN N
the DT N
accuracy NN o
of IN o
prediction NN o
to TO o
operative VB o
procedures NNS o
between IN N
the DT N
two CD N
groups NNS N
( ( N
94.7 CD N
% NN N
vs. FW N
81.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

CONCLUSION NNP N
Combinative NNP N
assessment NN N
of IN N
MSCT NNP i
and CC i
SAA NNP i
could MD N
improve VB N
the DT N
accuracy NN N
of IN N
preoperative JJ N
staging NN N
, , N
and CC N
thus RB N
provide VB N
higher JJR N
predictive JJ N
coincidence NN N
rate NN N
of IN N
operative JJ N
procedures NNS N
. . N

-DOCSTART- -X- O O

A DT N
Randomized NNP N
, , N
Placebo-Controlled JJ i
Trial NNP N
Evaluating NNP N
Safety NNP N
and CC N
Immunogenicity NNP N
of IN N
the DT N
Killed NNP N
, , N
Bivalent NNP N
, , N
Whole-Cell NNP i
Oral NNP i
Cholera NNP i
Vaccine NNP i
in IN p
Ethiopia NNP p
. . p

Killed VBN i
whole-cell JJ i
oral JJ i
cholera NN i
vaccine NN i
( ( i
OCV NNP i
) ) i
has VBZ N
been VBN N
a DT N
key JJ N
component NN N
of IN N
a DT N
comprehensive JJ N
package NN N
including VBG N
water NN N
and CC N
sanitation NN N
measures NNS N
for IN N
recent JJ N
cholera NN N
epidemics NNS N
. . N

The DT N
vaccine NN i
, , N
given VBN N
in IN N
a DT N
two-dose JJ N
regimen NN N
, , N
has VBZ N
been VBN N
evaluated VBN N
in IN N
a DT p
large JJ p
number NN p
of IN p
human JJ p
volunteers NNS p
in IN p
India NNP p
, , p
Vietnam NNP p
, , p
and CC p
Bangladesh NNP p
, , N
where WRB N
it PRP N
has VBZ N
demonstrated VBN N
safety NN N
, , N
immunogenicity NN N
, , N
and CC N
clinical JJ N
efficacy NN N
. . N

We PRP N
conducted VBD N
a DT N
double-blind JJ N
randomized JJ N
placebo-controlled JJ i
trial NN N
in IN p
Ethiopia NNP p
, , N
where WRB N
we PRP N
evaluated VBD p
the DT p
safety NN o
and CC o
immunogenicity NN o
of IN p
the DT p
vaccine NN i
in IN p
216 CD p
healthy JJ p
adults NNS p
and CC p
children NNS p
. . p

OCV NNP i
was VBD N
found VBN N
to TO N
be VB N
safe JJ o
and CC o
elicited VBD o
a DT o
robust JJ o
immunological JJ o
response NN o
against IN o
Vibrio NNP o
cholerae NN o
O1 NNP o
, , N
with IN N
81 CD N
% NN N
adults NNS N
and CC N
77 CD N
% NN N
children NNS N
demonstrating VBG N
seroconversion NN o
14 CD N
days NNS N
after IN N
the DT N
second JJ N
dose NN N
of IN N
vaccine NN N
. . N

This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
evaluate VB N
safety NN N
and CC N
immunogenicity NN N
of IN N
the DT N
vaccine NN i
in IN N
a DT N
population NN p
outside IN p
Asia NNP p
using VBG N
a DT N
placebo-controlled JJ i
, , N
double-blind JJ N
, , N
randomized JJ N
study NN N
design NN N
. . N

-DOCSTART- -X- O O

Lung NNP N
function NN N
measurement NN N
in IN N
general JJ N
practice NN N
: : N
a DT N
comparison NN N
of IN N
the DT N
Escort NNP i
spirometer NN i
with IN N
the DT N
Micromed NNP i
turbine NN i
spirometer NN i
and CC N
the DT N
mini-Wright JJ i
peak NN i
flow NN i
meter NN i
. . i

It PRP N
is VBZ N
important JJ N
that IN N
new JJ N
types NNS N
of IN N
spirometer NN i
for IN N
widespread JJ N
clinical JJ N
use NN N
are VBP N
pragmatically RB N
evaluated VBN N
in IN N
primary JJ N
care NN N
. . N

This DT N
study NN N
compared VBN N
measurements NNS N
taken VBN N
by IN N
a DT N
new JJ i
portable JJ i
Fleisch NNP i
pneumotachograph NN i
spirometer NN i
( ( i
known VBN i
as IN i
the DT i
Escort NNP i
) ) i
with IN N
those DT N
of IN N
the DT N
commonly NN N
used VBN N
mini-Wright JJ i
peak NN i
flow NN i
meter NN i
and CC N
the DT N
Micromed NNP i
Pocket NNP i
turbine NN i
spirometer NN i
. . i

A NNP N
pragmatic JJ N
study NN N
was VBD N
conducted VBN N
in IN N
two CD N
phases NNS N
during IN p
routine JJ p
surgeries NNS p
at IN N
Aldermoor NNP N
Health NNP N
Centre NNP N
, , N
Southampton NNP N
. . N

Phase NNP N
I PRP N
compared VBN N
the DT N
new JJ i
spirometer NN i
with IN N
the DT N
mini-Wright JJ i
peak NN i
flow NN i
meter NN i
and CC N
Phase NNP N
2 CD N
compared VBN N
the DT N
new JJ i
spirometer NN i
and CC N
the DT N
turbine NN i
spirometer NN i
. . i

One CD p
hundred VBD p
patients NNS p
aged VBN p
5-88 CD p
years NNS p
( ( p
56 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
chronic JJ p
respiratory NN p
complaints NNS p
and CC p
44 CD p
patients NNS p
without IN p
) ) p
entered VBD p
Phase NNP p
1 CD p
, , p
and CC p
100 CD p
patients NNS p
aged VBN p
6-82 JJ p
years NNS p
( ( p
62 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
chronic JJ p
respiratory NN p
complaints NNS p
and CC p
38 CD p
patients NNS p
without IN p
) ) p
entered VBD p
Phase NNP p
2 CD p
. . p

Each DT N
patient NN N
contributed VBD N
only RB N
once RB N
to TO N
each DT N
phase NN N
, , N
but CC N
some DT N
entered VBD N
both DT N
phases NNS N
on IN N
separate JJ N
occasions NNS N
. . N

Ninety-five JJ N
percent NN N
limits NNS N
of IN N
agreement NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
were VBD N
wide JJ N
for IN N
all DT N
comparisons NNS N
. . N

Graphical JJ o
plots NNS o
revealed VBD N
trends NNS N
towards IN N
higher JJR N
Escort NN o
values NNS o
as IN N
mean NN N
values NNS N
rose VBD N
compared VBN N
with IN N
both DT N
mini-Wright JJ i
and CC N
turbine JJ i
readings NNS N
for IN N
peak JJ o
expiratory JJ o
flow NN o
rate NN o
and CC o
forced VBD o
expiratory JJ o
volume NN o
in IN o
one CD o
second NN o
. . o

Possible JJ N
over-reading NN N
of IN N
peak JJ o
expiratory JJ o
flow NN o
rate NN o
with IN N
the DT N
mini-Wright JJ i
meter NN i
at IN N
low JJ N
mean NN N
values NNS N
was VBD N
also RB N
seen VBN N
. . N

Readings NNS N
taken VBN N
with IN N
these DT N
different JJ N
types NNS N
of IN N
meter NN N
can MD N
not RB N
be VB N
interchanged VBN N
with IN N
confidence NN N
in IN N
clinical JJ N
practice NN N
. . N

The DT N
clinical JJ N
significance NN N
of IN N
the DT N
theoretically RB N
more RBR N
accurate JJ N
measures NNS o
of IN o
lung NN o
function NN o
produced VBN N
with IN N
the DT N
new JJ i
meter NN i
, , N
and CC N
indeed RB N
of IN N
spirometry NN N
itself PRP N
, , N
needs VBZ N
further JJ N
investigation NN N
. . N

-DOCSTART- -X- O O

Transcranial NNP i
Magnetic NNP i
Stimulation NNP i
to TO N
Address NNP N
Mild NNP p
Cognitive NNP p
Impairment NNP p
in IN p
the DT p
Elderly JJ p
: : p
A DT N
Randomized NNP N
Controlled NNP N
Study NNP N
. . N

Transcranial NNP i
magnetic JJ i
stimulation NN i
( ( i
TMS NNP i
) ) i
is VBZ N
a DT N
noninvasive JJ N
brain NN N
stimulation NN N
technique NN N
with IN N
potential JJ N
to TO N
improve VB N
memory NN N
. . N

Mild NNP p
cognitive JJ p
impairment NN p
( ( p
MCI NNP p
) ) p
, , N
which WDT N
still RB N
lacks VBZ N
a DT N
specific JJ N
therapy NN N
, , N
is VBZ N
a DT N
clinical JJ N
syndrome NN N
associated VBN N
with IN N
increased JJ N
risk NN N
of IN N
dementia NN N
. . N

This DT N
study NN N
aims VBZ N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
high-frequency NN i
repetitive JJ i
TMS NNP i
( ( i
HF NNP i
rTMS NN i
) ) i
on IN N
everyday JJ N
memory NN N
of IN N
the DT p
elderly JJ p
with IN p
MCI NNP p
. . p

We PRP N
conducted VBD N
a DT N
double-blinded JJ N
randomized JJ N
sham-controlled JJ N
trial NN N
using VBG N
rTMS NN i
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal NN N
cortex NN N
( ( N
DLPFC NNP N
) ) N
. . N

Thirty-four CD p
elderly JJ p
outpatients NNS p
meeting VBG p
Petersen NNP p
's POS p
MCI NNP p
criteria NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB i
10 CD i
sessions NNS i
of IN i
either DT i
active JJ i
TMS NNP i
or CC i
sham NN i
, , i
10 CD i
Hz NNP i
rTMS NN i
at IN i
110 CD i
% NN i
of IN i
motor NN i
threshold NN i
, , i
2,000 CD i
pulses NNS i
per IN i
session NN i
. . i

Neuropsychological JJ i
assessment NN i
at IN i
baseline NN i
, , i
after IN i
the DT i
last JJ i
session NN i
( ( i
10th CD i
) ) i
and CC i
at IN i
one-month JJ i
follow-up NN i
, , i
was VBD i
applied VBN i
. . i

ANOVA NNP N
on IN N
the DT N
primary JJ N
efficacy NN N
measure NN N
, , N
the DT o
Rivermead NNP o
Behavioural NNP o
Memory NNP o
Test NNP o
, , o
revealed VBD N
a DT N
significant JJ N
group-by-time JJ N
interaction NN N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
, , N
favoring VBG N
the DT N
active JJ N
group NN N
. . N

The DT N
improvement NN N
was VBD N
kept VBN N
after IN N
one CD N
month NN N
. . N

Other JJ N
neuropsychological JJ N
tests NNS N
were VBD o
heterogeneous JJ o
. . o

rTMS NN o
at IN o
10 CD o
Hz NNP o
enhanced VBD o
everyday JJ o
memory NN o
in IN o
elderly JJ p
with IN p
MCI NNP p
after IN N
10 CD N
sessions NNS N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
rTMS NN i
might MD i
be VB N
effective JJ N
as IN N
a DT N
therapy NN N
for IN N
MCI NNP N
and CC N
probably RB N
a DT N
tool NN N
to TO N
delay VB N
deterioration NN N
. . N

-DOCSTART- -X- O O

Clinical JJ N
evaluation NN N
of IN N
imidapril NN i
in IN N
congestive JJ p
heart NN p
failure NN p
in IN p
dogs NNS p
: : p
results NNS N
of IN N
the DT N
EFFIC NNP N
study NN N
. . N

OBJECTIVES CC N
The DT N
clinical JJ N
efficacy NN o
and CC o
safety NN o
of IN N
imidapril NN i
were VBD N
evaluated VBN N
in IN N
dogs NNS p
that WDT p
presented VBD p
with IN p
mild NN p
to TO p
severe VB p
congestive JJ p
heart NN p
failure NN p
( ( p
New NNP p
York NNP p
Heart NNP p
Association NNP p
stage NN p
II NNP p
to TO p
IV NNP p
) ) p
by IN N
comparing VBG N
the DT N
success NN N
rate NN N
of IN N
imidapril NN i
with IN N
a DT N
positive JJ N
control NN N
by IN N
a DT N
non-inferiority JJ N
approach NN N
. . N

METHODS NNP N
This DT N
good JJ N
, , N
clinical JJ N
practice NN N
compliant NN N
, , N
multicentre NN N
study NN N
( ( N
EFFIC NNP N
study NN N
) ) N
enrolled VBD p
142 CD p
client-owned JJ p
dogs NNS p
and CC p
was VBD p
conducted VBN p
in IN p
20 CD p
locations NNS p
in IN p
France NNP p
, , p
Belgium NNP p
and CC p
Germany NNP p
. . p

Dogs NNP p
of IN p
various JJ p
breed NN p
, , p
age NN p
and CC p
weight NN p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

These DT N
dogs NNS N
were VBD N
randomised VBN N
into IN N
two CD N
groups NNS N
that WDT N
were VBD N
treated VBN N
for IN N
84 CD N
days NNS N
with IN N
either DT N
the DT N
test NN N
product NN N
, , N
imidapril NN i
, , N
or CC N
the DT N
positive JJ N
control NN N
, , N
benazepril NN i
, , N
and CC N
followed VBD N
up RP N
in IN N
parallel NN N
over IN N
this DT N
period NN N
. . N

Both DT N
treatments NNS N
were VBD N
administered VBN N
at IN N
a DT N
dose NN N
of IN N
0.25 CD N
mg/kg NN N
once RB N
a DT N
day NN N
with IN N
the DT N
possibility NN N
of IN N
doubling VBG N
this DT N
dose NN N
to TO N
0.5 CD N
mg/kg NN N
if IN N
considered VBN N
necessary JJ N
from IN N
a DT N
clinical JJ N
point NN N
of IN N
view NN N
. . N

In IN N
addition NN N
, , N
concomitant JJ N
treatment NN N
was VBD N
given VBN N
to TO N
dogs NNS p
presenting VBG N
with IN N
pulmonary JJ N
oedema NN N
and/or NN N
ascites NNS N
, , N
supraventricular JJ N
tachyarrhythmia NN N
and/or NN N
dilated VBD N
cardiomyopathy NN N
. . N

The DT N
evolution NN o
of IN o
the DT o
New NNP o
York NNP o
Heart NNP o
Association NNP o
stage NN o
and CC N
the DT N
functional JJ o
signs NNS o
score NN o
were VBD N
evaluated VBN N
as IN N
primary JJ N
efficacy NN N
criteria NNS N
. . N

RESULTS VB N
The DT N
success NN o
rate NN o
in IN N
the DT N
imidapril NN i
group NN N
was VBD N
66 CD N
compared VBN N
with IN N
68 CD N
per IN N
cent NN N
in IN N
the DT N
benazepril NN i
group NN N
. . N

Regarding VBG N
safety NN N
, , N
35 CD N
dogs NNS N
in IN N
each DT N
group NN N
experienced VBD N
at IN N
least JJS N
one CD N
adverse JJ o
event NN o
. . o

Nine NNP N
dogs NNS N
in IN N
each DT N
group NN N
experienced VBD N
at IN N
least JJS N
one CD N
serious JJ o
adverse JJ o
event NN N
. . N

The DT N
difference NN N
between IN N
these DT N
results NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

CLINICAL JJ N
SIGNIFICANCE NNP N
Imidapril NNP i
is VBZ N
as RB N
efficacious JJ o
and CC o
safe JJ o
as IN N
the DT N
reference NN N
product NN N
, , N
benazepril NN i
. . i

-DOCSTART- -X- O O

Women NNP p
's POS p
responses NNS p
to TO p
information NN p
on IN p
mammographic JJ p
breast NN p
density NN p
. . p

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
negative JJ N
and CC N
positive JJ N
outcomes NNS N
of IN N
providing VBG N
mammographic JJ N
breast NN N
density NN N
( ( N
MBD NNP N
) ) N
information NN N
to TO N
participants NNS p
of IN p
a DT p
screening JJ i
program NN i
. . i

A DT N
randomized JJ N
experiment NN N
was VBD N
conducted VBN N
with IN N
a DT N
sample NN p
of IN p
618 CD p
women NNS p
50 CD p
years NNS p
or CC p
older JJR p
with IN p
MBD NNP p
greater JJR p
than IN p
50 CD p
% NN p
of IN p
breast NN p
volume NN p
. . p

The DT N
intervention NN N
consisted VBD N
of IN N
reporting VBG i
the DT i
presence NN i
of IN i
MBD NNP i
in IN i
the DT i
screening NN i
mammography NN i
results NNS i
letter NN i
that WDT i
was VBD i
sent VBN i
along IN i
with IN i
an DT i
information NN i
pamphlet NN i
. . i

Compared VBN N
to TO N
the DT N
controls NNS i
, , N
more JJR N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
described VBD N
the DT N
term NN N
breast NN o
density NN o
correctly RB N
and CC N
recognized VBD N
it PRP N
as IN N
a DT N
risk NN N
factor NN N
for IN N
breast NN N
cancer NN N
. . N

Although IN N
at IN N
the DT N
4-week JJ N
follow-up NN N
the DT N
intervention NN N
group NN N
indicated VBD N
that IN N
they PRP N
were VBD N
very RB N
likely JJ N
to TO N
have VB N
an DT N
annual JJ i
clinical JJ i
breast NN i
examination NN i
more RBR N
frequently RB N
than IN N
controls NNS N
, , N
no DT N
differences NNS N
were VBD N
detected VBN N
at IN N
6 CD N
months NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
on IN N
other JJ N
behavioural JJ o
or CC o
psychological JJ o
measures NNS o
, , N
although IN N
at IN N
the DT N
4-week JJ N
follow-up JJ N
the DT N
control NN N
group NN N
perceived VBD N
their PRP$ N
risk NN N
for IN N
breast NN N
cancer NN N
, , N
relative VBP N
to TO N
other JJ N
women NNS N
their PRP$ N
age NN N
, , N
as IN N
a DT N
lot NN N
lower JJR N
than IN N
did VBD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

The DT N
results NNS N
demonstrate VBP N
a DT N
feasible JJ N
and CC N
non-threatening JJ N
way NN N
to TO N
provide VB N
women NNS N
with IN N
important JJ N
personalized VBN N
information NN N
about IN N
breast NN o
cancer NN o
risk NN o
. . o

-DOCSTART- -X- O O

Prospective JJ N
randomized VBN N
controlled VBN N
trial NN N
to TO N
evaluate VB N
fast-track JJ i
elective JJ i
open JJ i
infrarenal JJ i
aneurysm NN i
repair NN i
. . i

BACKGROUND NNP N
AND CC N
AIMS NNP N
Fast-track NNP N
programs NNS N
have VBP N
been VBN N
introduced VBN N
in IN N
many JJ N
surgical JJ N
fields NNS N
to TO N
minimize VB N
postoperative JJ o
morbidity NN o
and CC o
mortality NN o
. . o

Morbidity NN o
after IN N
elective JJ p
open JJ p
infrarenal JJ p
aneurysm NN p
repair NN p
is VBZ N
as RB N
high JJ N
as IN N
30 CD N
% NN N
; : N
mortality NN o
ranges VBZ N
up IN N
to TO N
10 CD N
% NN N
. . N

In IN N
terms NNS N
of IN N
open JJ p
infrarenal JJ p
aneurysm NN p
repair NN p
, , N
no DT N
randomized VBN N
controlled VBN N
trials NNS N
exist VBP N
to TO N
introduce VB N
and CC N
evaluate VB N
such JJ N
patient JJ N
care NN N
programs NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
study NN N
involved VBD N
prospective JJ N
randomization NN N
of IN N
82 CD p
patients NNS p
in IN p
a DT p
traditional JJ p
and CC p
a DT p
fast-track JJ i
treatment NN p
arm NN p
. . p

Main NNP N
differences NNS N
consisted VBD N
in IN N
preoperative JJ i
bowel NN i
washout NN i
( ( N
none NN N
vs. FW N
3 CD N
l NN N
cleaning VBG N
solution NN N
) ) N
and CC N
analgesia $ N
( ( N
patient NN N
controlled VBN N
analgesia JJ N
vs. FW N
patient NN N
controlled VBD N
epidural JJ N
analgesia NN N
) ) N
. . N

Study NN N
endpoints NNS N
were VBD N
morbidity NN o
and CC o
mortality NN o
, , o
need VBP o
for IN o
postoperative JJ o
mechanical JJ o
ventilation NN o
, , o
and CC o
length NN o
of IN o
stay NN o
( ( o
LOS NNP o
) ) o
on IN o
intensive JJ o
care NN o
unit NN o
( ( o
ICU NNP o
) ) o
. . o

RESULTS VB N
The DT N
need NN N
for IN N
assisted JJ o
postoperative JJ o
ventilation NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
traditional JJ N
group NN N
( ( N
33.3 CD N
% NN N
vs. FW N
5.4 CD N
% NN N
; : N
p CC N
= VB N
0.011 CD N
) ) N
. . N

Median JJ o
LOS NNP o
on IN o
ICU NNP o
was VBD N
shorter RBR N
in IN N
the DT N
fast-track JJ N
group NN N
, , N
41 CD N
vs. FW N
20 CD N
h. PDT N
The DT N
rate NN o
of IN o
postoperative JJ o
medical JJ o
complications NNS o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
fast-track JJ N
group NN N
, , N
16.2 CD N
% NN N
vs. FW N
35.7 CD N
% NN N
( ( N
p JJ N
= NNP N
0.045 CD N
) ) N
. . N

CONCLUSION NN N
We PRP N
introduced VBD N
and CC N
evaluated VBD N
an DT N
optimized JJ N
patient NN i
care NN i
program NN i
for IN N
patients NNS p
undergoing VBG p
open JJ p
infrarenal JJ p
aortic JJ p
aneurysm NN p
repair NN p
which WDT N
showed VBD N
a DT N
significant JJ N
advantage NN N
for IN N
fast-track JJ N
patients NNS N
in IN N
terms NNS N
of IN N
postoperative JJ o
morbidity NN o
. . o

-DOCSTART- -X- O O

An DT N
Exploratory NNP N
, , N
Open-Label NNP N
, , N
Randomized NNP N
Trial NNP N
Comparing NNP N
Risperidone NNP i
Long-Acting NNP i
Injectable NNP i
with IN N
Oral NNP i
Antipsychotic NNP i
Medication NNP i
in IN N
the DT N
Treatment NNP N
of IN N
Early NNP p
Psychosis NNP p
. . p

Few JJ N
studies NNS N
have VBP N
examined VBN N
effectiveness NN N
and CC N
tolerability NN N
of IN N
risperidone NN i
long-acting JJ i
injections NNS i
( ( i
RLAI NNP i
) ) i
in IN N
the DT N
early JJ p
phase NN p
of IN p
a DT p
schizophrenia NN p
spectrum NN p
( ( p
SS NNP p
) ) p
disorder NN p
using VBG N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
design NN N
. . N

Eighty-five JJ p
patients NNS p
in IN p
early JJ p
phase NN p
of IN p
an DT p
SS NNP p
disorder NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ i
second-generation NN i
antipsychotics NNS i
( ( i
SGAs NNP i
; : i
n=41 CC N
) ) N
or CC N
RLAI NNP i
( ( N
n=44 NN N
) ) N
over IN N
two CD N
years NNS N
. . N

Analyses NNS N
were VBD N
conducted VBN N
on IN N
eligible JJ p
participants NNS p
( ( p
n=77 NN p
) ) p
for IN N
the DT N
stabilization NN N
( ( N
maximum JJ N
18 CD N
weeks NNS N
) ) N
and CC N
maintenance NN N
phases NNS N
( ( N
up RB N
to TO N
Week NNP N
104 CD N
) ) N
on IN N
primary JJ N
outcome JJ N
measures NNS N
of IN N
time NN o
to TO o
stabilization NN o
and CC N
relapse NN o
, , o
change NN o
in IN o
symptoms NNS o
and CC o
safety NN o
, , N
and CC N
comparisons NNS o
made VBN N
across IN N
the DT N
two CD N
groups NNS N
. . N

Both DT N
groups NNS N
showed VBD N
improvement NN N
on IN N
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scale NNP o
( ( o
PANSS NNP o
) ) o
scores NNS o
and CC o
Clinical NNP o
Global NNP o
Impression-Severity NNP o
( ( o
CGI-S NNP o
) ) o
scores VBZ o
. . o

There EX N
were VBD N
no DT N
time NN N
X NNP N
group NN N
interactions NNS N
on IN N
any DT N
of IN N
the DT N
primary JJ N
outcome NN N
measures NNS N
. . N

Post NNP N
hoc JJ N
examination NN N
revealed VBD N
that IN N
the DT N
RLAI NNP N
group NN N
showed VBD N
greater JJR N
change NN N
on IN N
CGI-S NNP o
and CC o
PANSS NNP o
negative JJ o
symptom NN o
scores NNS o
during IN N
the DT N
stabilization NN N
phase NN N
, , N
while IN N
the DT N
oral JJ N
group NN N
reached VBD N
the DT N
same JJ N
level NN N
of IN N
improvement NN N
during IN N
the DT N
maintenance NN N
phase NN N
. . N

The DT N
current JJ N
exploratory NN N
study NN N
suggests VBZ N
that-within VBP N
an DT N
RCT NNP N
design-RLAI NN N
and CC N
oral JJ N
SGAs NNP N
are VBP N
equally RB N
effective JJ o
and CC N
have VBP N
similar JJ o
safety NN o
profiles NNS o
in IN N
patients NNS p
in IN N
the DT N
early JJ N
phase NN N
of IN N
SS NNP N
disorders NNS N
. . N

Thus RB N
, , N
RLAI NNP N
offers VBZ N
no DT N
advantage NN N
to TO N
patients NNS N
in IN N
early JJ N
phase NN N
of IN N
SS NNP N
disorders NNS N
, , N
but CC N
is VBZ N
likely JJ N
to TO N
be VB N
effective JJ o
and CC N
safe JJ o
for IN N
those DT N
who WP N
may MD N
have VB N
problems NNS N
with IN N
adherence NN N
and CC N
may MD N
either RB N
choose VB N
to TO N
take VB N
it PRP N
or CC N
be VB N
prescribed VBN N
under IN N
conditions NNS N
of IN N
external JJ N
control NN N
such JJ N
as IN N
community NN N
treatment NN N
orders NNS N
. . N

-DOCSTART- -X- O O

Barriers NNS N
to TO N
hypertension NN N
care NN N
and CC N
control NN N
in IN N
young JJ p
urban JJ p
black JJ p
men NNS p
. . p

Barriers NNS N
to TO N
high JJ o
blood NN o
pressure NN o
( ( N
HBP NNP N
) ) N
care NN N
and CC N
control NN N
have VBP N
been VBN N
reported VBN N
in IN N
the DT N
literature NN N
for IN N
> $ N
30 CD N
years NNS N
. . N

Few JJ N
reports NNS N
on IN N
barriers NNS N
, , N
however RB N
, , N
have VBP N
focused VBN N
on IN N
the DT N
young JJ p
black JJ p
man NN p
with IN p
HBP NNP p
, , N
the DT N
age/sex/race NN N
group NN N
with IN N
the DT N
highest JJS N
rates NNS N
of IN N
early JJ N
severe JJ N
and CC N
complicated JJ N
HBP NNP N
and CC N
the DT N
lowest JJS N
rates NNS N
of IN N
awareness NN N
, , N
treatment NN N
, , N
and CC N
control NN N
. . N

In IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
comprehensive JJ N
care NN N
for IN N
hypertensive JJ p
young JJ p
urban JJ p
black JJ p
men NNS p
, , N
factors NNS N
potentially RB N
associated VBN N
with IN N
care NN N
and CC N
control NN N
were VBD N
assessed VBN N
at IN N
baseline NN N
for IN N
the DT N
309 CD p
enrolled VBD p
men NNS p
. . p

A DT p
majority NN p
of IN p
the DT p
men NNS p
encountered VBD p
a DT p
variety NN p
of IN p
barriers NNS p
including VBG p
economic JJ p
, , p
social JJ p
, , p
and CC p
lifestyle JJ p
obstacles NNS p
to TO p
adequate VB p
BP NNP p
care NN p
and CC p
control NN p
, , p
including VBG p
no DT o
current JJ o
HBP NNP o
care NN o
( ( p
49 CD p
% NN p
) ) p
, , p
risk NN o
of IN o
alcoholism NN o
( ( p
62 CD p
% NN p
) ) p
, , p
use NN o
of IN o
illicit NN o
drugs NNS o
( ( p
45 CD p
% NN p
) ) p
, , p
social JJ o
isolation NN o
( ( p
47 CD p
% NN p
) ) p
, , p
unemployment NN o
( ( p
40 CD p
% NN p
) ) p
, , p
and CC p
lack NN o
of IN o
health NN o
insurance NN o
( ( p
51 CD p
% NN p
) ) p
. . p

Having VBG o
health NN o
insurance NN o
( ( N
odds NNS N
ratio VBP N
= JJ N
7.20 CD N
, , N
P NNP N
= NNP N
.00 NNP N
) ) N
and CC N
a DT N
negative JJ o
urine JJ o
drug NN o
screen NN o
( ( N
odds NNS N
ratio VBP N
= JJ N
.56 NNP N
, , N
P NNP N
= NNP N
.04 NNP N
) ) N
were VBD N
significant JJ N
predictors NNS N
of IN N
being VBG N
in IN N
HBP NNP N
care NN N
. . N

Low JJ o
alcoholism NN o
risk NN o
and CC o
employment NN o
were VBD N
identified VBN N
as IN N
significant JJ N
predictors NNS N
of IN N
compliance NN N
with IN N
HBP NNP N
medication-taking JJ N
behavior NN N
. . N

Men NNP p
currently RB p
using VBG o
illicit JJ o
drugs NNS o
were VBD N
2.64 CD N
times NNS N
less RBR N
likely JJ N
to TO N
have VB N
controlled VBN o
BP NNP o
compared VBN N
with IN N
their PRP$ N
counterparts NNS p
who WP p
did VBD p
not RB p
use VB p
illicit JJ p
drugs NNS p
, , N
and CC N
men NNS p
currently RB p
taking VBG o
HBP NNP o
medication NN o
were VBD N
63 CD N
times NNS N
more RBR N
likely JJ N
have VBP N
controlled VBN o
BP NNP o
compared VBN N
with IN N
men NNS p
not RB p
taking VBG p
HBP NNP p
medication NN p
. . p

Comprehensive JJ i
interventions NNS i
are VBP N
needed VBN N
to TO N
address VB N
socioeconomic JJ N
and CC N
lifestyle JJ N
issues NNS N
as RB N
well RB N
as IN N
other JJ N
barriers NNS N
to TO N
care VB N
and CC N
treatment NN N
, , N
if IN N
HBP NNP N
care NN N
is VBZ N
to TO N
be VB N
salient JJ N
and CC N
effective JJ N
in IN N
this DT N
high JJ p
risk NN p
group NN p
. . p

-DOCSTART- -X- O O

Early RB N
clinical JJ N
outcomes NNS N
and CC N
toxicity NN N
of IN N
intensity NN N
modulated VBN N
versus IN N
conventional JJ N
pelvic JJ N
radiation NN N
therapy NN N
for IN N
locally RB p
advanced JJ p
cervix NN p
carcinoma NN p
: : p
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
toxicity NN o
and CC o
clinical JJ o
outcome NN o
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
cervical JJ p
cancer NN p
( ( p
LACC NNP p
) ) p
treated VBD N
with IN N
whole JJ i
pelvic JJ i
conventional JJ i
radiation NN i
therapy NN i
( ( N
WP-CRT NNP N
) ) N
versus NN N
intensity NN i
modulated VBN i
radiation NN i
therapy NN i
( ( N
WP-IMRT NNP N
) ) N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP p
January NNP p
2010 CD p
and CC p
January NNP p
2012 CD p
, , p
44 CD p
patients NNS p
with IN p
International NNP p
Federation NNP p
of IN p
Gynecology NNP p
and CC p
Obstetrics NNP p
( ( p
FIGO NNP p
2009 CD p
) ) p
stage NN p
IIB-IIIB NNP p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
cervix NN p
were VBD p
randomized VBN i
to TO i
receive VB i
50.4 CD i
Gy NNP i
in IN i
28 CD i
fractions NNS i
delivered VBN i
via IN i
either DT i
WP-CRT JJ i
or CC i
WP-IMRT JJ i
with IN i
concurrent JJ i
weekly JJ i
cisplatin NN i
40 CD i
mg/m NN i
( ( i
2 CD i
) ) i
. . i

Acute NNP o
toxicity NN o
was VBD i
graded VBN i
according VBG i
to TO i
the DT i
Common NNP o
Terminology NNP o
Criteria NNP o
for IN o
Adverse NNP o
Events NNP o
, , o
version NN o
3.0 CD o
, , o
and CC o
late JJ o
toxicity NN o
was VBD o
graded VBN o
according VBG o
to TO o
the DT o
Radiation NNP o
Therapy NNP o
Oncology NNP o
Group NNP o
system NN o
. . o

The DT N
primary JJ N
and CC N
secondary JJ N
endpoints NNS N
were VBD N
acute JJ o
gastrointestinal JJ o
toxicity NN o
and CC N
disease-free JJ o
survival NN o
, , N
respectively RB N
. . N

RESULTS NNP N
Of IN N
44 CD N
patients NNS N
, , N
22 CD N
patients NNS N
received VBD N
WP-CRT NNP i
and CC N
22 CD N
received VBD N
WP-IMRT NNP i
. . i

In IN N
the DT N
WP-CRT JJ i
arm NN N
, , N
13 CD N
patients NNS N
had VBD N
stage NN N
IIB NNP N
disease NN N
and CC N
9 CD N
had VBD N
stage NN N
IIIB NNP N
disease NN N
; : N
in IN N
the DT N
IMRT NNP i
arm NN N
, , N
12 CD N
patients NNS N
had VBD N
stage NN N
IIB NNP N
disease NN N
and CC N
10 CD N
had VBD N
stage NN N
IIIB NNP N
disease NN N
. . N

The DT N
median JJ N
follow-up JJ N
time NN N
in IN N
the DT N
WP-CRT JJ N
arm NN N
was VBD N
21.7 CD N
months NNS N
( ( N
range NN N
, , N
10.7-37.4 JJ N
months NNS N
) ) N
, , N
and CC N
in IN N
the DT N
WP-IMRT JJ N
arm NN N
it PRP N
was VBD N
21.6 CD N
months NNS N
( ( N
range NN N
, , N
7.7-34.4 JJ N
months NNS N
) ) N
. . N

At IN N
27 CD N
months NNS N
, , N
disease-free JJ o
survival NN o
was VBD N
79.4 CD N
% NN N
in IN N
the DT N
WP-CRT NNP i
group NN N
versus VBD N
60 CD N
% NN N
in IN N
the DT N
WP-IMRT NNP i
group NN N
( ( N
P=.651 NNP N
) ) N
, , N
and CC N
overall JJ o
survival NN o
was VBD N
76 CD N
% NN N
in IN N
the DT N
WP-CRT NNP N
group NN N
versus VBD N
85.7 CD N
% NN N
in IN N
the DT N
WP-IMRT NNP N
group NN N
( ( N
P=.645 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
WP-IMRT JJ N
arm NN N
experienced VBD N
significantly RB N
fewer JJR N
grade NN o
?2 NNP o
acute VBZ o
gastrointestinal JJ o
toxicities NNS o
( ( o
31.8 CD N
% NN N
vs JJ N
63.6 CD N
% NN N
, , N
P=.034 NNP N
) ) N
and CC N
grade JJ N
?3 NNP N
gastrointestinal JJ o
toxicities NNS o
( ( o
4.5 CD o
% NN N
vs JJ N
27.3 CD N
% NN N
, , N
P=.047 NNP N
) ) N
than IN N
did VBD N
patients NNS N
receiving VBG N
WP-CRT NNP N
and CC N
had VBD N
less JJR N
chronic JJ o
gastrointestinal JJ o
toxicity NN o
( ( o
13.6 CD o
% NN N
vs JJ N
50 CD N
% NN N
, , N
P=.011 NNP N
) ) N
. . N

CONCLUSION NNP i
WP-IMRT NNP i
is VBZ i
associated VBN N
with IN N
significantly RB o
less JJR o
toxicity NN o
compared VBN o
with IN N
WP-CRT NNP i
and CC i
has VBZ N
a DT N
comparable JJ o
clinical JJ o
outcome NN o
. . o

Further JJ o
studies NNS N
with IN N
larger JJR N
sample NN N
sizes NNS N
and CC N
longer JJR N
follow-up JJ N
times NNS N
are VBP N
warranted VBN N
to TO N
justify VB N
its PRP$ N
use NN N
in IN N
routine JJ N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

Tubeless NNP i
percutaneous JJ i
nephrolithotomy NN i
: : i
safe JJ N
even RB N
in IN N
supracostal JJ N
access NN N
. . N

PURPOSE VB N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
outcome NN o
and CC o
safety NN o
of IN N
tubeless NN i
percutaneous JJ i
nephrolithotomy NN i
( ( i
PCNL NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
renal JJ p
calculi NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP p
November NNP p
2005 CD p
and CC p
March NNP p
2006 CD p
, , p
48 CD p
patients NNS p
were VBD p
randomized VBN p
to TO p
either DT p
an DT p
18F CD i
Re-entry JJ i
nephrostomy NN i
tube NN i
( ( p
group NN p
1 CD p
) ) p
or CC i
a DT i
6F CD i
Double-J JJ i
stent NN i
( ( p
group NN p
2 CD p
) ) p
. . p

The DT N
two CD N
groups NNS N
were VBD N
well RB N
matched VBN N
for IN N
age NN N
, , N
sex NN N
, , N
stone NN N
size NN N
, , N
stone NN N
laterality NN N
, , N
and CC N
number NN N
of IN N
previous JJ N
renal JJ N
procedures NNS N
. . N

All DT N
PCNL NNP N
procedures NNS N
were VBD N
performed VBN N
by IN N
the DT N
same JJ N
surgeon NN N
. . N

Postoperative JJ o
visual JJ o
analog NN o
pain NN o
scale NN o
( ( o
VAS NNP o
) ) o
scores VBZ o
at IN N
8 CD N
and CC N
24 CD N
hours NNS N
and CC N
14 CD N
days NNS N
after IN N
surgery NN N
, , N
in-hospital JJ o
analgesic JJ o
use NN o
, , o
length NN o
of IN o
hospital NN o
stay NN o
, , o
success NN o
rate NN o
, , o
blood NN o
transfusion NN o
rate NN o
, , o
and CC o
postoperative JJ o
complications NNS o
were VBD N
compared VBN N
for IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS VB N
The DT N
mean JJ o
hospital NN o
stays NNS o
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
were VBD N
3.1 CD N
and CC N
1.6 CD N
days NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

The DT N
mean JJ o
VAS NNP o
scores VBZ o
8 CD N
and CC N
24 CD N
hours NNS N
after IN N
surgery NN N
were VBD N
significantly RB N
lower JJR N
in IN N
group NN N
2 CD N
than IN N
in IN N
group NN N
1 CD N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
postoperative JJ o
analgesic JJ o
requirement NN o
( ( i
diclofenac JJ i
sodium NN i
) ) i
was VBD N
significantly RB N
higher JJR N
in IN N
group NN N
1 CD N
( ( N
263 CD N
mg NN N
) ) N
than IN N
in IN N
group NN N
2 CD N
( ( N
120 CD N
mg NN N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
rate NN o
of IN o
blood NN o
transfusion NN o
in IN N
the DT N
two CD N
groups NNS N
was VBD N
similar JJ N
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
VAS NNP o
scores NNS o
on IN N
postoperative JJ N
day NN N
14 CD N
. . N

The DT N
number NN o
of IN o
supracostal JJ o
accesses NNS o
was VBD N
significantly RB N
higher JJR N
in IN N
group NN N
2 CD N
than IN N
in IN N
group NN N
1 CD N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
stone-free JJ o
rates NNS o
and CC o
the DT o
numbers NNS o
of IN o
patients NNS o
with IN N
insignificant JJ o
residual JJ o
fragments NNS o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
no DT o
urine JJ o
leakage NN o
or CC o
formation NN o
of IN o
urinoma NN o
in IN N
patients NNS N
with IN N
Double-J NNP N
stents NNS N
. . N

CONCLUSION NNP N
Tubeless NNP i
PCNL NNP i
is VBZ N
safe JJ N
and CC N
effective JJ N
even RB N
after IN N
supracostal JJ N
access NN N
and CC N
is VBZ N
associated VBN N
with IN N
less RBR N
postoperative JJ o
pain NN o
and CC N
a DT o
shorter JJR o
hospital NN o
stay NN o
. . o

-DOCSTART- -X- O O

Evaluation NN N
of IN N
the DT N
topical JJ N
hemostatic JJ N
efficacy NN o
and CC o
safety NN o
of IN N
TISSEEL NNP i
VH NNP i
S/D NNP i
fibrin NN i
sealant NN i
compared VBN N
with IN N
currently RB i
licensed VBN i
TISSEEL NNP i
VH NNP i
in IN N
patients NNS p
undergoing JJ p
cardiac JJ p
surgery NN p
: : p
a DT N
phase NN N
3 CD N
, , N
randomized VBN N
, , N
double-blind JJ N
clinical JJ N
study NN N
. . N

AIM NNP N
TISSEEL NNP N
VH NNP N
is VBZ N
the DT N
only JJ N
commercially RB N
available JJ N
fibrin NN N
sealant NN N
indicated VBD N
as IN N
an DT N
adjunct NN N
to TO N
conventional JJ N
methods NNS N
of IN N
hemostasis NN N
during IN N
cardiac JJ N
surgery NN N
. . N

A DT N
next JJ N
generation NN N
fibrin NN i
sealant NN i
( ( i
TISSEEL NNP i
VH NNP i
S/D NNP i
) ) i
has VBZ N
been VBN N
developed VBN N
in IN N
frozen JJ N
, , N
ready-to-use JJ N
form NN N
with IN N
an DT N
added JJ N
virus NN N
inactivation NN N
step NN N
( ( N
solvent/detergent JJ N
[ NNP N
S/D NNP N
] NNP N
treatment NN N
) ) N
to TO N
provide VB N
added JJ N
safety NN N
and CC N
convenience NN N
to TO N
the DT N
currently RB N
licensed VBN N
product NN N
. . N

This DT N
study NN N
was VBD N
performed VBN N
to TO N
compare VB N
efficacy NN o
and CC o
safety NN o
of IN N
the DT N
two CD N
products NNS N
. . N

METHODS NNP N
Phase NNP N
3 CD N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
multicenter NN N
study NN N
to TO N
compare VB N
TISSEEL NNP i
VH NNP i
S/D NNP i
to TO i
TISSEEL NNP i
VH NNP i
during IN N
cardiac JJ N
surgery NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
the DT N
proportion NN o
of IN o
patients NNS o
who WP o
achieved VBD o
hemostasis NN o
at IN p
the DT p
primary JJ p
treatment NN p
site NN p
within IN p
5 CD p
min NN p
, , p
and CC p
maintained VBD p
hemostasis NN p
until IN p
surgical JJ p
closure NN p
. . p

RESULTS VB N
The DT N
proportion NN o
of IN o
patients NNS o
who WP o
achieved VBD o
hemostasis NN o
at IN N
the DT N
primary JJ N
treatment NN N
site NN N
within IN N
5 CD N
min NN N
, , N
and CC N
maintained VBD o
hemostasis NN o
until IN N
surgical JJ N
closure NN N
was VBD N
88.2 CD N
% NN N
for IN N
TISSEEL NNP N
VH NNP N
S/D NNP N
and CC N
89.6 CD N
% NN N
for IN N
TISSEEL NNP N
VH NNP N
in IN N
the DT N
intent-to-treat JJ N
population NN N
. . N

The DT N
difference NN N
in IN N
proportions NNS N
, , N
TISSEEL NNP N
VH NNP N
S/D NNP N
minus CC N
TISSEEL NNP N
VH NNP N
, , N
was VBD N
1.4 CD N
% NN N
with IN N
a DT N
standard JJ N
error NN N
of IN N
3.70 CD N
% NN N
. . N

The DT N
lower JJR N
97.5 CD N
% NN N
confidence NN N
bound NN N
of IN N
this DT N
difference NN N
was VBD N
8.6 CD N
% NN N
, , N
which WDT N
is VBZ N
above IN N
the DT N
predefined JJ N
noninferiority NN N
margin NN N
of IN N
15 CD N
% NN N
. . N

Therefore RB N
, , N
TISSEEL NNP N
VH NNP N
S/D NNP N
is VBZ N
at IN N
least JJS N
as RB N
efficacious JJ N
as IN N
TISSEEL NNP N
VH NNP N
. . N

The DT N
safety NN N
profile NN N
of IN N
TISSEEL NNP N
VH NNP N
S/D NNP N
was VBD N
very RB N
similar JJ N
to TO N
that DT N
of IN N
currently RB N
licensed VBN N
TISSEEL NNP N
VH NNP N
as IN N
assessed VBN N
by IN N
the DT N
safety NN N
endpoints NNS N
. . N

CONCLUSION NNP N
TISSEEL NNP N
VH NNP N
S/D NNP N
is VBZ N
safe JJ o
and CC N
effective JJ o
for IN N
use NN N
as IN N
an DT N
adjunct NN N
to TO N
hemostasis VB N
in IN N
patients NNS p
undergoing JJ p
cardiac JJ p
surgery NN p
. . p

-DOCSTART- -X- O O

Observer NNP N
variation NN N
in IN N
the DT N
assessment NN o
of IN o
outcome NN o
in IN N
traumatic JJ N
brain NN N
injury NN N
: : N
experience NN N
from IN N
a DT N
multicenter NN N
, , N
international JJ N
randomized VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE NNP N
Accurate NNP N
and CC N
consistent JJ N
outcome NN o
assessment NN o
is VBZ N
essential JJ N
to TO N
randomized VB N
clinical JJ N
trials NNS N
. . N

We PRP N
aimed VBD N
to TO N
explore VB N
observer JJ N
variation NN N
in IN N
the DT N
assessment NN o
of IN o
outcome NN o
in IN N
a DT N
recently RB N
completed VBN N
trial NN N
of IN N
dexanabinol NN i
in IN N
head JJ p
injury NN p
and CC N
to TO N
consider VB N
steps NNS N
to TO N
reduce VB N
such JJ N
variation NN N
. . N

METHODS NNP N
Eight NNP p
hundred VBD p
sixty-one JJ p
patients NNS p
with IN p
severe JJ p
traumatic JJ p
brain NN p
injury NN p
who WP p
were VBD p
admitted VBN p
to TO p
86 CD p
centers NNS p
were VBD N
included VBN N
in IN N
a DT N
multicenter NN N
, , N
placebo-controlled JJ i
, , N
Phase NNP N
III NNP N
trial NN N
. . N

Outcome NNP N
was VBD N
assessed VBN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
postinjury NN N
using VBG N
the DT N
extended JJ o
Glasgow NNP o
Outcome NNP o
Scale NNP o
; : o
standardized VBD N
assessment NN N
was VBD N
facilitated VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
structured JJ N
interview NN N
. . N

Before IN N
initiation NN N
of IN N
trial NN N
centers NNS N
, , N
outcome JJ o
ratings NNS o
were VBD N
obtained VBN N
for IN N
sample JJ N
cases NNS N
to TO N
establish VB N
initial JJ N
levels NNS N
of IN N
agreement NN N
. . N

Training NN N
sessions NNS N
in IN N
outcome JJ N
assessment NN N
were VBD N
held VBN N
, , N
and CC N
problems NNS N
in IN N
assigning VBG N
outcome NN N
were VBD N
investigated VBN N
. . N

During IN N
the DT N
trial NN N
, , N
a DT N
process NN N
of IN N
central JJ N
review NN N
was VBD N
established VBN N
to TO N
monitor VB N
performance NN N
. . N

Interobserver NNP N
variation NN N
was VBD N
analyzed VBN N
using VBG N
the DT N
kappa NN N
statistic JJ N
. . N

RESULTS NNP N
Substantial NNP o
observer JJ o
variation NN o
was VBD N
found VBN N
in IN N
the DT N
rating NN N
of IN N
sample JJ N
cases NNS N
( ( N
weighted JJ N
kappa NN N
, , N
0.72 CD N
; : N
confidence NN N
interval NN N
, , N
0.68-0.75 JJ N
) ) N
and CC N
in IN N
assigning VBG N
outcome NN o
based VBN N
on IN N
completed VBN N
structured JJ N
interviews NNS N
( ( N
weighted JJ N
kappa NN N
, , N
0.61 CD N
; : N
confidence NN N
interval NN N
, , N
0.57-0.64 JJ N
) ) N
. . N

In IN N
the DT N
early JJ N
stages NNS N
of IN N
the DT N
trial NN N
, , N
a DT N
relatively RB N
large JJ N
number NN N
of IN N
discrepancies NNS o
( ( N
29-37 CD N
% NN N
) ) N
were VBD N
identified VBN N
on IN N
central JJ N
review NN N
. . N

This DT N
number NN N
declined VBD N
as IN N
the DT N
trial NN N
progressed VBD N
and CC N
coincided VBD N
with IN N
investigator NN N
training NN N
and CC N
feedback NN N
from IN N
central JJ N
review NN N
. . N

Centers NNS N
with IN N
higher JJR N
enrollment NN N
rates NNS N
showed VBD N
better JJR N
performance NN N
. . N

CONCLUSION NNP N
Observer NNP o
variation NN o
in IN N
outcome JJ o
assessment NN o
is VBZ N
a DT N
significant JJ N
problem NN N
for IN N
head NN N
injury NN N
trials NNS N
. . N

Consistency NN o
can MD N
be VB N
improved VBN N
by IN N
standardizing VBG N
procedures NNS N
, , N
training VBG N
assessors NNS N
, , N
and CC N
monitoring VBG N
the DT N
quality NN N
of IN N
assessments NNS N
and CC N
providing VBG N
feedback NN N
to TO N
interviewers NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Antiinflammatory NNP N
potential NN N
of IN N
seven CD i
plant NN i
extracts NNS i
in IN N
the DT N
ultraviolet NN N
erythema JJ N
test NN N
. . N

A DT N
randomized JJ N
, , N
placebo-controlled JJ i
study NN N
] NNP N
. . N

BACKGROUND NNP N
Phytotherapeutics NNPS N
are VBP N
widely RB N
used VBN N
in IN N
medicine NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
the DT N
evaluation NN N
of IN N
the DT N
antiinflammatory JJ N
potential NN N
of IN N
seven CD i
medical JJ i
plant NN i
extracts NNS i
using VBG N
the DT N
ultraviolet- JJ N
( ( N
UV NNP N
) ) N
-erythema VBP N
test NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Randomized NNP N
, , N
placebo-controlled JJ i
study NN N
on IN N
40 CD p
healthy JJ p
subjects NNS p
. . p

Test NNP N
areas NNS N
on IN N
the DT N
upper JJ N
back NN N
were VBD N
irradiated VBN N
with IN N
the DT N
1.5 CD i
fold JJ i
UV-B NNP i
minimal NN i
erythema NN i
dose NN i
( ( N
MED NNP N
) ) N
. . N

Formulations NNS N
of IN N
Aloe NNP i
vera NN i
, , i
Chamomilla NNP i
recutita NN i
, , i
Hamamelis NNP i
virginiana NN i
, , i
Melissa NNP i
officinalis NN i
, , i
Mentha NNP i
arvensis NN i
, , i
Melaleuca NNP i
alternifolia NN i
, , i
Coriandrum NNP i
sativum NN i
as RB i
well RB i
as IN i
1 CD i
% NN i
hydrocortisone NN i
acetate NN i
and CC i
0.1 CD i
% NN i
betamethasone NN i
valerate NN i
as IN N
positive JJ N
controls NNS N
and CC N
unguentum JJ i
leniens NNS i
as IN N
vehicle NN N
control NN N
were VBD N
applied VBN N
under IN N
occlusion NN N
on IN N
the DT N
irradiated JJ N
areas NNS N
and CC N
on IN N
non-irradiated JJ N
area NN N
on IN N
the DT N
contralateral JJ N
side NN N
. . N

Photometric NNP N
assessment NN N
of IN N
the DT N
erythema NN N
was VBD N
performed VBN N
before IN N
the DT N
application NN N
of IN N
the DT N
substances NNS N
( ( N
t0 NN N
) ) N
, , N
at IN N
24 CD N
h NN N
( ( N
t1 NN N
) ) N
and CC N
at IN N
48 CD N
h NN N
( ( N
t2 NN N
) ) N
. . N

RESULTS NNP i
Aloe NNP i
vera NN i
, , i
Chamomilla NNP i
recutita NN i
, , i
Melissa NNP i
officinalis NN i
, , i
Melaleuca NNP i
alternifolia NN i
and CC i
Coriandrum NNP i
sativum NN i
showed VBD i
an DT N
antiinflammatory JJ o
effect NN o
compared VBN o
to TO N
UV-control NNP N
and CC N
unguentum JJ N
leniens NNS N
. . N

However RB N
, , N
the DT N
results NNS N
were VBD N
only RB N
statistically RB N
significant JJ N
for IN N
Aloe NNP N
vera NN N
. . N

All DT N
tested VBD N
plant NN N
extracts NNS N
were VBD N
well RB o
tolerated VBN o
. . o

CONCLUSION NNP i
Aloe NNP i
vera NN i
possesses VBZ i
an DT N
antiinflammatory JJ N
effect NN N
on IN N
UV-induced NNP N
erythemas NN N
. . N

-DOCSTART- -X- O O

Early JJ N
reperfusion NN i
and CC N
late JJ N
clinical JJ N
outcomes NNS N
in IN N
patients NNS p
presenting VBG p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
randomly RB N
assigned VBN N
to TO N
primary VB i
percutaneous JJ i
coronary JJ i
intervention NN i
or CC N
streptokinase NN i
. . i

BACKGROUND NNP N
Primary NNP i
percutaneous JJ i
coronary JJ i
intervention NN i
( ( i
PCI NNP i
) ) i
has VBZ N
become VBN N
an DT N
alternative JJ N
to TO N
thrombolytic JJ i
therapy NN i
as IN N
a DT N
reperfusion NN N
strategy NN N
for IN N
ST-elevation NNP p
acute JJ p
myocardial JJ p
infarction NN p
( ( p
AMI NNP p
) ) p
. . p

METHODS PDT N
The DT N
main JJ N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
PCI NNP i
and CC N
thrombolytic JJ i
therapy NN i
achieve VBP N
comparable JJ N
reperfusion NN N
rates NNS N
, , N
as IN N
evidenced VBN N
by IN N
ST-segment JJ N
resolution NN N
. . N

Secondary JJ N
end NN N
points NNS N
included VBD N
infarct JJ o
vessel NN o
patency NN o
rates NNS o
before IN N
hospital JJ N
discharge NN N
and CC N
short- JJ o
and CC o
long-term JJ o
outcomes NNS o
. . o

Patients NNS p
with IN p
ischemic JJ p
chest NN p
pain NN p
with IN p
duration NN p
< NN p
or CC p
=12 NN p
hours NNS p
and CC p
no DT p
contraindication NN p
for IN p
thrombolytic JJ p
therapy NN p
were VBD p
included VBN p
. . p

RESULTS NNP N
Between NNP p
October NNP p
1993 CD p
and CC p
August NNP p
1995 CD p
, , p
58 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
streptokinase VB i
( ( i
SK NNP i
) ) i
and CC p
54 CD p
patients NNS p
to TO p
primary JJ i
PCI NNP i
. . i

Baseline NNP N
clinical JJ N
characteristics NNS N
and CC N
infarct JJ N
location NN N
were VBD N
well RB N
balanced VBN N
in IN N
both DT N
groups NNS N
. . N

Median JJ p
age NN p
( ( p
interquartile JJ p
range NN p
) ) p
was VBD p
68 CD p
( ( p
58 CD p
, , p
75 CD p
) ) p
years NNS p
, , p
29 CD p
% NN p
were VBD p
women NNS p
, , p
and CC p
78 CD p
% NN p
of IN p
the DT p
patients NNS p
met VBD p
at IN p
least JJS p
one CD p
criterion NN p
for IN p
not RB p
low JJ p
risk NN p
AMI NNP p
( ( p
anterior JJ p
location NN p
, , p
age NN p
> VBD p
70 CD p
years NNS p
old JJ p
, , p
previous JJ p
MI NNP p
, , p
systolic JJ p
blood NN o
pressure NN o
< VBZ p
100 CD p
mm NN p
Hg NNP p
, , p
and/or JJ p
heart NN p
rate NN p
> VBD p
100 CD p
bpm NN p
) ) p
. . p

The DT N
median JJ o
time NN o
from IN o
symptom JJ o
onset VBN o
to TO N
random VB N
assignment NN N
was VBD N
217 CD N
( ( N
139 CD N
, , N
335 CD N
) ) N
minutes NNS N
in IN N
the DT N
PCI NNP i
group NN N
and CC N
210 CD N
( ( N
145 CD N
, , N
334 CD N
) ) N
minutes NNS N
in IN N
the DT N
SK NNP i
group NN N
. . N

Median JJ N
random JJ N
assignment NN N
to TO N
balloon VB o
time NN o
was VBD N
82 CD N
( ( N
55 CD N
, , N
100 CD N
) ) N
minutes NNS N
, , N
and CC N
median JJ N
random NN N
assignment NN N
to TO N
needle JJ o
time NN o
was VBD N
15 CD N
( ( N
10 CD N
, , N
26 CD N
) ) N
minutes NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

TIMI NNP o
grade VBD o
3 CD o
flow NN o
after IN N
primary JJ N
PCI NNP N
was VBD N
obtained VBN N
in IN N
85 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
with IN N
ST-segment JJ o
resolution NN o
> NN N
or CC N
=50 VB N
% NN N
at IN N
120 CD N
minutes NNS N
was VBD N
80 CD N
% NN N
in IN N
the DT N
PCI NNP N
group NN N
and CC N
50 CD N
% NN N
in IN N
the DT N
SK NNP N
group NN N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

The DT N
predischarge NN N
angiogram NN N
showed VBD N
the DT N
presence NN o
of IN o
TIMI NNP o
3 CD o
flow NN o
in IN N
96 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
PCI NNP N
and CC N
65 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
SK NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

A DT N
composite JJ N
of IN N
in-hospital JJ o
death NN o
, , o
reinfarction NN o
, , o
severe JJ o
heart NN o
failure NN o
, , o
stroke NN o
, , o
and CC o
major JJ o
bleeding NN o
occurred VBD N
in IN N
15 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
PCI NNP N
and CC N
21 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
SK NNP N
( ( N
P NNP N
=.4 NNP N
) ) N
. . N

At IN N
3 CD N
years NNS N
, , N
freedom NN N
from IN N
the DT N
composite JJ o
end NN o
point NN o
of IN o
AMI NNP o
, , o
postdischarge NN o
revascularization NN o
, , o
and CC o
death NN o
was VBD N
61 CD N
% NN N
in IN N
the DT N
PCI NNP N
group NN N
and CC N
40 CD N
% NN N
in IN N
the DT N
SK NNP N
group NN N
( ( N
P NNP N
=.025 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
shows VBZ N
that IN N
primary JJ N
PCI NNP N
, , N
as IN N
compared VBN N
with IN N
SK NNP N
, , N
is VBZ N
associated VBN N
with IN N
more RBR N
effective JJ N
ST-segment JJ o
resolution NN o
, , N
higher JJR N
patency NN o
rates NNS o
in IN N
the DT N
infarct JJ N
vessel NN N
at IN N
7 CD N
days NNS N
, , N
and CC N
more RBR N
favorable JJ N
clinical JJ N
outcomes NNS N
at IN N
3 CD N
years NNS N
of IN N
follow-up NN N
. . N

-DOCSTART- -X- O O

Angiotensin NNP N
converting VBG N
enzyme JJ N
inhibition NN N
does VBZ N
not RB N
affect VB N
the DT N
response NN N
to TO N
exogenous JJ N
angiotensin NN N
II NNP N
in IN N
the DT N
human JJ p
forearm NN p
. . p

Suppression NN N
of IN N
endogenous JJ N
levels NNS N
of IN N
angiotensin NN N
II NNP N
by IN N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibition NN N
, , N
may MD N
result VB N
in IN N
up-regulation NN N
of IN N
vascular JJ N
AT1 NNP N
receptors NNS N
. . N

We PRP N
have VBP N
evaluated VBN N
the DT N
effects NNS N
of IN N
orally RB N
administered VBN N
enalapril NN i
on IN N
angiotensin NN N
II NNP N
induced VBD N
vasoconstriction NN N
in IN N
the DT N
human JJ p
forearm NN p
. . p

Subjects VBZ p
received VBN N
in IN N
random JJ N
order NN N
, , N
enalapril NN i
( ( N
20 CD N
mg NN N
) ) N
or CC i
matched VBN i
placebo JJ i
daily JJ N
for IN N
2 CD N
weeks NNS N
. . N

Forearm NNP o
blood NN o
flow NN o
response NN N
to TO N
increasing VBG N
doses NNS N
of IN N
angiotensin NN N
II NNP N
was VBD N
measured VBN N
using VBG N
venous JJ N
occlusion NN N
plethysmography NN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
and CC N
at IN N
the DT N
end NN N
of IN N
each DT N
2 CD N
week NN N
treatment NN N
period NN N
. . N

Treatment NN N
with IN N
enalapril NN N
significantly RB N
reduced VBN N
plasma NN o
angiotensin NN o
II NNP o
levels NNS o
and CC o
supine VB o
blood NN o
pressure NN o
compared VBN N
with IN N
placebo NN N
. . N

The DT N
percentage NN N
reductions NNS o
in IN o
forearm NN o
blood NN o
flow NN o
in IN N
the DT N
infused JJ N
arm NN N
, , N
in IN N
response NN N
to TO N
the DT N
maximum JJ N
dose NN N
of IN N
angiotensin NN N
II NNP N
( ( N
50,000 CD N
fmol RB N
min-1 NN N
) ) N
were VBD N
48.1 CD N
+/- JJ N
3.6 CD N
% NN N
at IN N
baseline NN N
, , N
57.5 CD N
+/- JJ N
3.6 CD N
% NN N
on IN N
placebo NN N
and CC N
54.5 CD N
+/- JJ N
4.2 CD N
% NN N
on IN N
enalapril NN N
. . N

The DT N
differences NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

This DT N
demonstrates VBZ N
that IN N
suppression NN N
of IN N
plasma NN N
angiotensin NN N
II NNP N
for IN N
a DT N
14 CD N
day NN N
period NN N
does VBZ N
not RB N
enhance VB N
the DT N
response NN N
to TO N
exogenous JJ N
intra-arterial JJ N
angiotensin NN N
II NNP N
in IN N
the DT N
human JJ p
forearm NN p
of IN p
healthy JJ p
salt NN p
replete JJ p
subjects NNS p
. . p

-DOCSTART- -X- O O

Coenzyme NNP i
Q10 NNP i
and CC N
exercise NN N
training NN N
in IN N
chronic JJ p
heart NN p
failure NN p
. . p

AIMS NNP N
There EX N
is VBZ N
evidence NN N
that IN N
plasma NN N
coenzyme NN o
Q NNP o
( ( o
10 CD o
) ) o
( ( o
CoQ NNP o
( ( o
10 CD o
) ) o
) ) o
levels NNS o
decrease NN N
in IN N
patients NNS p
with IN p
advanced JJ p
chronic JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
. . p

However RB N
, , N
it PRP N
is VBZ N
not RB N
known VBN N
whether IN N
oral JJ N
CoQ NNP i
( ( i
10 CD i
) ) i
supplementation NN N
may MD N
improve VB N
cardiocirculatory NN o
efficiency NN o
and CC o
endothelial JJ o
function NN o
in IN N
patients NNS p
with IN p
CHF NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
studied VBD N
23 CD p
patients NNS p
in IN p
NYHA NNP p
class NN p
II NNP p
and CC p
III NNP p
( ( p
20 CD p
men NNS p
, , p
three CD p
women NNS p
, , p
mean JJ p
age NN p
59+/-9 CD p
years NNS p
) ) p
with IN p
stable JJ p
CHF NNP p
secondary JJ p
to TO p
ischaemic VB p
heart NN p
disease NN p
[ NNP p
ejection NN p
fraction NN p
37+/-7 CD p
% NN p
] NN p
, , N
using VBG N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
cross-over NN N
design NN N
. . N

Patients NNS p
were VBD N
assigned VBN N
to TO N
each DT N
of IN N
the DT N
following JJ N
treatments NNS N
: : N
oral JJ i
CoQ NNP i
( ( i
10 CD i
) ) i
( ( i
100 CD i
mg RB i
tid NN i
) ) i
, , i
CoQ NNP i
( ( i
10 CD i
) ) i
plus CC i
supervised JJ i
exercise NN i
training NN i
( ( i
ET NNP i
) ) i
( ( N
60 CD N
% NN N
of IN N
peak NN N
VO NNP N
( ( N
2 CD N
) ) N
, , N
five CD N
times NNS N
a DT N
week NN N
) ) N
, , N
placebo NN i
, , i
and CC i
placebo NN i
plus CC i
ET NNP i
. . i

Each DT N
phase NN N
lasted VBD N
4 CD N
weeks NNS N
. . N

Both DT N
peak JJ o
VO NNP o
( ( o
2 CD o
) ) o
and CC o
endothelium-dependent JJ o
dilation NN o
of IN o
the DT o
brachial JJ o
artery NN o
( ( o
EDDBA NNP o
) ) o
improved VBD N
significantly RB N
after IN N
CoQ NNP i
( ( i
10 CD i
) ) i
and CC N
after IN N
ET NNP i
as IN N
compared VBN N
with IN N
placebo NN i
. . i

CoQ NNP i
( ( i
10 CD i
) ) i
main JJ N
effect NN N
was VBD N
: : N
peak NN o
VO NNP o
( ( o
2 CD o
) ) o
+9 CD o
% NN o
, , o
EDDBA NNP o
+38 NNP N
% NN N
, , N
systolic JJ o
wall NN o
thickening VBG o
score NN o
index NN o
( ( o
SWTI NNP o
) ) o
-12 CD N
% NN N
; : N
ET NNP i
produced VBD N
comparable JJ N
effects NNS N
. . N

CoQ NNP i
( ( i
10 CD i
) ) i
supplementation NN N
resulted VBD N
in IN N
a DT N
four-fold JJ N
increase NN N
in IN N
plasma JJ o
CoQ NNP o
( ( o
10 CD o
) ) o
level NN o
, , N
whereas IN N
the DT N
combination NN N
with IN N
ET NNP i
further RB N
increased VBD N
it PRP N
. . N

No DT N
side NN N
effects NNS N
were VBD N
reported VBN N
with IN N
CoQ NNP i
( ( i
10 CD i
) ) i
. . i

CONCLUSIONS NNP N
Oral NNP i
CoQ NNP i
( ( i
10 CD i
) ) i
improves VBZ N
functional JJ o
capacity NN o
, , o
endothelial JJ o
function NN o
, , o
and CC o
LV NNP o
contractility NN o
in IN N
CHF NNP N
without IN N
any DT N
side NN o
effects NNS o
. . o

The DT N
combination NN N
of IN N
CoQ NNP i
( ( i
10 CD i
) ) i
and CC N
ET NNP i
resulted VBD N
in IN N
higher JJR N
plasma NN o
CoQ NNP o
( ( o
10 CD o
) ) o
levels NNS o
and CC N
more JJR N
pronounced JJ N
effects NNS N
on IN N
all PDT N
the DT N
abovementioned JJ N
parameters NNS N
. . N

However RB N
, , N
significant JJ N
synergistic JJ N
effect NN N
of IN N
CoQ NNP i
( ( i
10 CD i
) ) i
with IN N
ET NNP i
was VBD N
observed VBN N
only RB N
for IN N
peak NN N
SWTI NNP o
suggesting VBG N
that IN N
ET NNP i
amplifies VBZ N
the DT N
already RB N
described JJ N
effect NN N
of IN N
CoQ NNP i
( ( i
10 CD i
) ) i
on IN N
contractility NN o
of IN o
dysfunctional JJ o
myocardium NN o
. . o

-DOCSTART- -X- O O

Aftermath NN N
of IN N
a DT N
clinical JJ N
trial NN N
: : N
evaluating VBG N
the DT N
sustainability NN N
of IN N
a DT N
medical JJ i
device NN i
intervention NN i
in IN p
Ghana NNP p
. . p

A NNP N
randomized VBD N
controlled VBN N
trial NN N
recently RB N
demonstrated VBD N
that IN N
continuous JJ i
positive JJ i
airway NN i
pressure NN i
( ( p
CPAP NNP p
) ) p
effectively RB p
decreases VBZ p
respiratory JJ o
rate NN o
in IN p
children NNS p
presenting VBG p
to TO p
Ghanaian NNP p
district NN p
hospitals NNS p
with IN p
respiratory NN p
distress NN p
. . p

A DT N
follow-up JJ N
study NN N
16 CD N
months NNS N
later RB N
evaluated VBD N
the DT N
extent NN N
to TO N
which WDT N
the DT N
skills NNS N
and CC N
equipment NN N
necessary JJ N
for IN N
CPAP NNP N
use NN N
have VBP N
been VBN N
maintained VBN N
. . N

Seven NNP N
of IN N
eight CD N
CPAP NNP N
machines NNS N
were VBD N
functional JJ N
, , N
but CC N
five CD N
of IN N
eight CD N
oxygen NN N
concentrators NNS N
and CC N
three CD N
of IN N
four CD N
electric JJ N
generators NNS N
were VBD N
non-functional JJ N
. . N

Nurses NNS p
trained VBN p
by IN p
US NNP p
study NN p
personnel NNS p
( ( p
first-generation NN p
) ) p
and CC p
nurses NNS p
trained VBN p
by IN p
Ghanaian JJ p
nurses NNS p
after IN p
the DT p
study NN p
( ( p
second-generation NN p
) ) p
were VBD p
evaluated VBN p
on IN p
CPAP NNP p
knowledge NN p
and CC p
skills NNS p
. . p

Twenty-eight JJ p
nurses NNS p
participated VBN p
in IN p
the DT p
study NN p
, , p
9 CD p
first-generation NN p
and CC p
19 CD p
second-generation NN p
. . p

First-generation NN N
trainees NNS N
scored VBD N
significantly RB N
higher JJR N
than IN N
second-generation NN N
trainees NNS N
on IN N
both DT N
skills NNS o
and CC o
knowledge NN o
assessments NNS o
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

Appropriate NNP N
technical JJ N
support NN N
and CC N
training NN N
must MD N
be VB N
ensured VBN N
to TO N
address VB N
equipment NN N
maintenance NN N
. . N

Protocolization NN N
of IN N
the DT N
training NN N
program NN N
, , N
in IN N
conjunction NN N
with IN N
skills NNS o
and CC o
knowledge NN o
assessment NN N
, , N
may MD N
improve VB N
acquisition NN o
and CC o
retention NN o
among IN N
second- JJ N
and CC N
future-generation JJ N
trainees NNS N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
body NN N
positioning VBG N
upon IN N
maximal JJ i
oxygenation NN i
of IN N
patients NNS p
with IN p
unilateral JJ p
lung NN p
pathology NN p
. . p

A DT N
quasi-experimental JJ N
, , N
repeated-measures JJ N
cross-over NN N
design NN N
study NN N
on IN N
the DT N
effect NN N
of IN N
body NN N
position NN N
on IN N
oxygenation NN i
( ( i
SaO2 NNP i
) ) i
blood NN N
pressure NN N
, , N
respiration NN N
and CC N
pulse NN N
in IN N
patients NNS p
with IN p
unilateral JJ p
lung NN p
pathology NN p
was VBD N
conducted VBN N
. . N

Previous JJ N
research NN N
strongly RB N
suggests VBZ N
that IN N
positioning VBG N
with IN N
the DT N
healthy JJ N
( ( N
unaffected JJ N
) ) N
lung NN N
in IN N
the DT N
dependent JJ N
lateral NN N
( ( N
down RP N
) ) N
position NN N
is VBZ N
related VBN N
to TO N
improved VBN N
oxygenation NN N
, , N
but CC N
knowledge VBP N
about IN N
whether IN N
this DT N
effect NN N
is VBZ N
maintained VBN N
over IN N
time NN N
is VBZ N
lacking VBG N
. . N

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
determine VB N
: : N
( ( N
1 CD N
) ) N
Is VBZ N
positioning VBG N
with IN N
the DT N
unaffected JJ N
lung NN N
in IN N
the DT N
dependent JJ N
lateral JJ N
position NN N
related VBN N
to TO N
increased VBN N
arterial JJ N
blood NN N
saturation NN N
levels NNS N
and CC N
decreased VBD N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
? . N
( ( N
2 CD N
) ) N
What WP N
is VBZ N
the DT N
relationship NN N
between IN N
the DT N
dependent JJ N
variables NNS N
-- : N
oxygenation NN N
saturation NN N
levels NNS N
, , N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
-- : N
and CC N
the DT N
independent JJ N
variables NNS N
-- : N
body NN N
position NN N
and CC N
time NN N
in IN N
the DT N
position NN N
? . N
Thirty-nine JJ p
patients NNS p
with IN p
unilateral JJ p
lung NN p
pathology NN p
were VBD N
positioned VBN i
on IN i
their PRP$ i
sides NNS i
with IN i
the DT i
unaffected JJ i
lung NN i
down RP i
, , i
on IN i
their PRP$ i
sides NNS i
with IN i
the DT i
affected JJ i
lung NN i
down RB i
, , i
and CC i
also RB i
in IN i
semi-Fowler NN i
's POS i
position NN i
. . i

Arterial NNP o
( ( o
SaO2 NNP o
) ) o
blood NN o
saturation NN o
and CC o
vital JJ o
signs NNS o
were VBD N
measured VBN N
at IN N
baseline NN N
0 CD N
, , N
15 CD N
and CC N
30 CD N
minutes NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
relationship NN N
between IN N
oxygenation NN o
level NN o
or CC o
systolic JJ o
blood NN o
pressure NN o
. . o

Diastolic NNP o
blood NN o
pressure NN o
, , o
respiration NN o
and CC o
pulse NN o
did VBD N
vary JJ N
significantly RB N
with IN N
position NN N
. . N

-DOCSTART- -X- O O

Making VBG N
the DT N
connection NN N
: : N
randomized VBN N
controlled VBD N
trial NN N
of IN N
social JJ N
skills NNS N
at IN N
school NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

BACKGROUND NNP N
This DT N
study NN N
compared VBN N
two CD N
interventions NNS N
for IN N
improving VBG N
the DT N
social JJ o
skills NNS o
of IN N
high JJ p
functioning VBG p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
in IN p
general JJ p
education NN p
classrooms NNS p
. . p

One CD N
intervention NN N
involved VBN N
a DT N
peer-mediated JJ i
approach NN i
( ( i
PEER NNP i
) ) i
and CC N
the DT N
other JJ N
involved VBD N
a DT N
child-assisted JJ i
approach NN i
( ( i
CHILD NNP i
) ) i
. . i

METHOD PDT N
The DT N
two CD N
interventions NNS N
were VBD N
crossed VBN N
in IN N
a DT N
2 CD N
? . N
2 CD N
factorial JJ N
design NN N
yielding VBG N
control NN i
, , i
PEER NNP i
, , i
CHILD NNP i
, , i
and CC i
both DT N
PEER NNP i
and CC i
CHILD NNP i
conditions NNS i
. . p

Sixty NNP p
children NNS p
participated VBD p
from IN p
56 CD p
classrooms NNS p
in IN p
30 CD p
schools NNS p
. . p

Interventions NNS p
involved VBD N
12 CD N
sessions NNS N
over IN N
6 CD N
weeks NNS N
, , N
with IN N
a DT N
3-month JJ N
follow-up NN N
. . N

Outcome NNP N
measures NNS N
included VBD o
self NN o
, , o
peer NN o
and CC o
teacher JJR o
reports NNS o
of IN o
social JJ o
skills NNS o
and CC o
independent JJ o
weekly JJ o
observations NNS o
of IN o
children NNS o
on IN o
their PRP$ o
school NN o
playground NN o
over IN o
the DT o
course NN o
of IN o
the DT o
intervention NN o
. . o

RESULTS NNP o
Significant JJ N
improvements NNS N
were VBD N
found VBN N
in IN o
social JJ o
network NN o
salience NN o
, , o
number NN o
of IN o
friendship JJ o
nominations NNS o
, , o
teacher JJ o
report NN o
of IN o
social JJ o
skills NNS o
in IN o
the DT o
classroom NN o
, , o
and CC o
decreased JJ o
isolation NN o
on IN o
the DT o
playground NN o
for IN o
children NNS N
who WP N
received VBD i
PEER NNP i
interventions NNS N
. . N

Changes NNS N
obtained VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
persisted VBD N
to TO N
the DT N
3-month JJ N
follow-up NN N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
significant JJ N
improvements NNS N
can MD N
be VB N
made VBN N
in IN o
peer JJ o
social JJ o
connections NNS o
for IN o
children NNS N
with IN N
autism NN p
spectrum NN p
disorders NNS p
in IN p
general JJ p
education NN N
classrooms NNS N
with IN N
a DT N
brief JJ N
intervention NN N
, , N
and CC N
that IN N
these DT N
gains NNS N
persist VBP N
over IN N
time NN N
. . N

-DOCSTART- -X- O O

Goodstart NN N
: : N
a DT N
cluster NN N
randomised VBD N
effectiveness JJ o
trial NN N
of IN N
an DT N
integrated VBN i
, , i
community-based JJ i
package NN i
for IN i
maternal JJ i
and CC i
newborn JJ i
care NN i
, , i
with IN i
prevention NN i
of IN i
mother-to-child JJ i
transmission NN i
of IN i
HIV NNP i
in IN p
a DT p
South JJ p
African JJ p
township NN p
. . p

BACKGROUND NNP N
Progress NNP N
towards NNS N
MDG4 NNP N
for IN N
child NN N
survival NN N
in IN N
South NNP N
Africa NNP N
requires VBZ N
effective JJ N
prevention NN N
of IN N
mother-to-child JJ N
transmission NN N
( ( N
PMTCT NNP N
) ) N
of IN N
HIV NNP N
including VBG N
increasing VBG N
exclusive JJ N
breastfeeding NN N
, , N
as RB N
well RB N
as IN N
a DT N
new JJ N
focus NN N
on IN N
reducing VBG N
neonatal JJ N
deaths NNS N
. . N

This DT N
necessitates VBZ N
increased JJ N
focus NN N
on IN N
the DT N
pregnancy NN N
and CC N
early JJ N
post-natal JJ N
periods NNS N
, , N
developing VBG N
and CC N
scaling VBG N
up RP N
appropriate JJ N
models NNS N
of IN N
community-based JJ N
care NN N
, , N
especially RB N
to TO N
reach VB N
the DT N
peri-urban JJ p
poor JJ p
. . p

METHODS NNP N
We PRP N
used VBD N
a DT N
randomised JJ N
controlled VBN N
trial NN N
with IN N
30 CD p
clusters NNS p
( ( p
15 CD p
in IN p
each DT p
arm NN p
) ) p
to TO p
evaluate VB p
an DT p
integrated VBN i
, , i
scalable JJ i
package NN i
providing VBG i
two CD i
pregnancy NN i
visits NNS i
and CC i
five CD i
post-natal JJ i
home NN i
visits NNS i
delivered VBN i
by IN i
community NN i
health NN i
workers NNS i
in IN p
Umlazi NNP p
, , p
Durban NNP p
, , p
South NNP p
Africa NNP p
. . p

Primary NNP N
outcomes NNS N
were VBD N
exclusive JJ o
and CC o
appropriate JJ o
infant NN o
feeding NN o
at IN o
12 CD o
weeks NNS o
post-natally RB o
and CC o
HIV-free JJ o
infant NN o
survival NN o
. . o

RESULTS NNP N
At IN N
12 CD p
weeks NNS p
of IN p
infant JJ p
age NN p
, , N
the DT N
intervention NN N
was VBD N
effective JJ N
in IN N
almost RB N
doubling VBG N
the DT N
rate NN o
of IN o
exclusive JJ o
breastfeeding NN o
( ( N
risk NN N
ratio VBP N
1.92 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.59-2.33 JJ N
) ) N
and CC N
increasing VBG N
infant JJ o
weight NN o
and CC o
length-for-age JJ o
z-scores NNS o
( ( N
weight JJ N
difference NN N
0.09 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.00-0.18 JJ N
, , N
length JJ N
difference NN N
0.11 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.03-0.19 NN N
) ) N
. . N

No DT N
difference NN N
was VBD N
seen VBN N
between IN N
study NN N
arms NNS N
in IN N
HIV-free JJ o
survival NN o
. . o

Women NNS N
in IN N
the DT N
intervention NN N
arm NN N
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
take VB o
their PRP$ o
infant NN o
to TO o
the DT o
clinic NN o
within IN o
the DT o
first JJ o
week NN o
of IN o
life NN o
( ( N
risk NN N
ratio VBP N
1.10 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.04-1.18 JJ N
) ) N
. . N

CONCLUSIONS VB N
The DT N
trial NN N
coincided VBD N
with IN N
national JJ N
scale NN N
up IN N
of IN N
ARVs NNP N
for IN N
PMTCT NNP N
, , N
and CC N
this DT N
could MD N
have VB N
diluted VBN N
the DT N
effect NN N
of IN N
the DT N
intervention NN N
on IN N
HIV-free NNP o
survival NN o
. . o

We PRP N
have VBP N
demonstrated VBN N
that IN N
implementation NN N
of IN N
a DT N
pro-poor JJ N
integrated JJ N
PMTCT NNP N
and CC N
maternal JJ N
, , N
neonatal JJ N
and CC N
child JJ N
health NN N
home NN N
visiting VBG N
model NN N
is VBZ N
feasible JJ N
and CC N
effective JJ N
. . N

This DT N
trial NN N
could MD N
inform VB N
national JJ N
primary NN N
healthcare NN N
reengineering VBG N
strategies NNS N
in IN N
favour NN N
of IN N
home NN N
visits NNS N
. . N

The DT N
dose JJ N
effect NN N
on IN N
exclusive JJ N
breastfeeding NN N
is VBZ N
notable JJ N
as IN N
improving VBG N
exclusive JJ N
breastfeeding NN N
has VBZ N
been VBN N
resistant JJ N
to TO N
change VB N
in IN N
other JJ N
studies NNS N
targeting VBG N
urban JJ N
poor JJ N
families NNS N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
adult NN p
asthma NN p
: : p
controlled VBN N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
oxitropium NN i
bromide NN i
. . i

Sixteen NNP p
young JJ p
adult NN p
sufferers NNS p
from IN p
extrinsic JJ p
paroxysmal JJ p
asthma NN p
with IN p
pollen JJ p
hypersensitivity NN p
took VBD p
part NN p
in IN p
a DT p
therapeutic JJ p
trial NN p
of IN p
the DT p
synthetic JJ i
anticholinergic NN i
agent NN i
oxitropium NN i
bromide NN i
administered VBN p
by IN p
a DT p
metered VBN p
dose NN p
inhaler NN p
. . p

The DT N
study NN N
comprised VBD N
three CD N
3-week JJ N
periods NNS N
. . N

The DT N
first JJ N
, , N
run-in JJ N
period NN N
was VBD N
carried VBN N
out IN N
to TO N
confirm VB N
the DT N
ability NN N
of IN N
the DT N
patients NNS N
to TO N
maintain VB N
a DT N
daily JJ N
record NN N
of IN N
symptoms NNS N
. . N

During IN N
the DT N
second JJ N
and CC N
third JJ N
periods NNS N
, , N
the DT N
patient NN N
received VBD N
3 CD N
X NNP N
2 CD N
inhalations NNS N
of IN N
drug NN N
or CC N
placebo NN i
in IN N
a DT N
cross-over JJ N
design NN N
. . N

The DT N
medical JJ N
staff NN N
was VBD N
blind NN N
to TO N
the DT N
nature NN N
of IN N
the DT N
aerosol NN N
( ( i
drug NN i
or CC N
placebo NN i
) ) i
, , N
which WDT N
was VBD N
given VBN N
in IN N
random JJ N
order NN N
. . N

The DT N
run-in JJ N
clinical JJ N
score NN N
was VBD N
high JJ N
. . N

Asymptomatic JJ o
days NNS o
were VBD N
relatively RB N
infrequent JJ N
and CC N
daily JJ o
drug NN o
consumption NN o
was VBD N
high JJ N
. . N

Functional JJ N
studies NNS N
between IN N
the DT N
cross-over NN N
periods NNS N
showed VBD N
flow-rate JJ o
values NNS o
close RB N
to TO N
normal JJ N
, , N
with IN N
an DT N
increase NN N
in IN N
residual JJ o
volume NN o
and CC o
functional JJ o
residual JJ o
capacity NN o
. . o

During IN N
treatment NN N
either CC N
with IN N
placebo NN i
or CC N
oxitropium NN i
, , N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
decrease NN o
in IN N
clinical JJ o
scores NNS o
. . o

Results NNS N
for IN N
oxitropium JJ i
bromide NN i
treatment NN i
were VBD N
significantly RB o
better JJR o
than IN N
the DT N
run-in JJ o
values NNS o
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
and CC N
the DT N
placebo NN i
period NN N
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
change NN N
in IN N
non-trial JJ o
drug NN o
consumption NN o
. . o

Functional NNP N
values NNS N
showed VBD N
no DT N
difference NN N
in IN N
terms NNS N
of IN N
flow NN o
rate NN o
, , N
although IN N
oxitropium NN N
did VBD N
cause VB N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
RV/TLC NNP o
ratio NN o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

No DT N
adverse JJ o
reactions NNS o
were VBD N
reported VBN N
. . N

-DOCSTART- -X- O O

Dietary NNP i
lignan NN i
and CC i
proanthocyanidin NN i
consumption NN i
and CC N
colorectal JJ o
adenoma NN o
recurrence NN o
in IN N
the DT N
Polyp NNP N
Prevention NNP N
Trial NNP N
. . N

Lignans NNPS N
and CC N
proanthocyanidins NNS N
are VBP N
plant NN N
polyphenols NNS i
that WDT N
have VBP N
shown VBN N
protective JJ N
properties NNS N
against IN N
colorectal JJ o
neoplasms NNS o
in IN p
some DT p
human JJ p
studies NNS p
. . p

Using VBG N
logistic JJ N
regression NN N
, , N
we PRP N
estimated VBD N
odds NNS N
ratios NNS N
( ( N
ORs NNP N
) ) N
and CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
to TO N
prospectively RB N
evaluate VB N
the DT N
association NN N
between IN N
lignan NN i
and CC i
proanthocyanidin JJ i
intake NN i
, , N
estimated VBN N
from IN N
databases NNS N
linked VBN N
to TO N
a DT N
food NN N
frequency NN N
questionnaire NN N
, , N
and CC N
adenoma JJ o
recurrence NN o
in IN N
1,859 CD p
participants NNS p
of IN p
the DT p
Polyp NNP p
Prevention NNP p
Trial NNP p
. . p

Overall NNP N
, , N
individual NN N
or CC N
total JJ N
lignans NNS N
or CC N
proanthocyanidins NNS N
were VBD N
not RB N
associated VBN N
with IN N
colorectal JJ o
adenoma NN o
recurrence NN o
. . o

However RB N
, , N
in IN N
sex-specific JJ N
analyses NNS N
, , N
total JJ N
lignan JJ N
intake NN N
was VBD N
positively RB N
associated VBN N
with IN N
any DT N
adenoma JJ o
recurrence NN o
in IN N
women NNS N
( ( N
highest JJS N
vs. NN N
lowest JJS N
lignan JJ N
intake NN N
quartile NN N
OR NNP N
= VBZ N
2.07 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.22-3.52 JJ N
, , N
p JJ N
trend NN N
= VBZ N
0.004 CD N
) ) N
but CC N
not RB N
in IN N
men NNS N
( ( N
p JJ N
interaction NN N
= NNP N
0.04 CD N
) ) N
. . N

To TO N
conclude VB N
, , N
dietary JJ N
lignan NN N
and CC N
proanthocyanidin NN N
consumption NN N
were VBD N
not RB N
generally RB N
related VBN N
to TO N
colorectal JJ o
adenoma JJ o
recurrence NN o
; : o
however RB N
, , N
high JJ N
lignan NNS N
intake VBP N
may MD N
increase VB N
the DT N
risk NN o
of IN o
adenoma JJ o
recurrence NN o
in IN p
women NNS p
. . p

-DOCSTART- -X- O O

Randomized VBN N
placebo NN i
controlled VBN N
human JJ p
volunteer NN p
trial NN p
of IN N
a DT N
live JJ i
oral JJ i
cholera NN i
vaccine NN i
VA1.3 NNP i
for IN N
safety NN o
and CC N
immune JJ N
response NN N
. . N

A DT N
live JJ i
oral JJ i
cholera NN i
vaccine NN i
developed VBN i
from IN i
a DT i
non-toxigenic JJ i
Vibrio NNP i
cholerae NN i
O1 NNP i
El NNP i
Tor NNP i
strain NN i
VA1.3 NNP i
was VBD N
tested VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
placebo NN i
controlled VBD N
study NN N
for IN N
safety NN N
and CC N
immunogenicity NN N
in IN N
304 CD p
men NNS p
aged VBN p
between IN p
16 CD p
and CC p
50 CD p
years NNS p
from IN p
Kolkata NNP p
, , p
India NNP p
. . p

A NNP N
dose NN N
of IN N
5 CD N
x NNS N
10 CD N
( ( N
9 CD N
) ) N
CFU NNP N
( ( N
n=186 NN N
) ) N
or CC N
a DT N
placebo NN i
( ( N
n=116 JJ N
) ) N
containing VBG N
the DT N
diluent NN N
buffer NN N
was VBD N
administered VBN N
. . N

The DT N
vaccine NN N
did VBD N
not RB N
elicit JJ N
adverse JJ o
events NNS o
except IN N
in IN N
two CD N
vaccine NN N
recipients NNS N
with IN N
mild JJ o
diarrhoea NN o
and CC o
vomiting NN o
. . o

None NN o
excreted VBD o
the DT N
vaccine NN N
strain NN N
. . N

Vibriocidal NNP o
antibody NN o
response NN o
developed VBD N
in IN N
105/186 CD N
( ( N
57 CD N
% NN N
) ) N
and CC N
5/116 CD N
( ( N
4 CD N
% NN N
) ) N
in IN N
vaccine NN N
and CC N
placebo NN N
recipients NNS N
, , N
respectively RB N
. . N

In IN N
a DT N
subgroup NN N
, , N
anti-CT JJ o
antibody NN o
rose VBD o
( ( N
> JJ N
or CC N
=2-folds NNS N
) ) N
in IN N
23/30 CD N
( ( N
77 CD N
% NN N
) ) N
and CC N
6/19 CD N
( ( N
32 CD N
% NN N
) ) N
in IN N
vaccine NN N
and CC N
placebo NN N
recipients NNS N
, , N
respectively RB N
. . N

These DT N
studies NNS N
demonstrate VBP N
that IN N
VA1.3 NNP i
at IN N
a DT N
dose NN N
of IN N
5 CD N
x NNS N
10 CD N
( ( N
9 CD N
) ) N
is VBZ N
safe JJ o
and CC o
immunogenic JJ o
in IN N
adults NNS p
from IN p
a DT p
cholera NN p
endemic JJ p
region NN p
. . p

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
a DT N
decision NN N
aid NN N
for IN N
individuals NNS p
considering VBG p
genetic JJ p
testing NN p
for IN p
hereditary JJ p
nonpolyposis NN p
colorectal NN p
cancer NN p
risk NN p
. . p

BACKGROUND NNP N
Despite IN N
the DT N
potential JJ N
benefits NNS N
of IN N
genetic JJ N
testing VBG N
for IN N
hereditary JJ N
nonpolyposis NN N
colorectal NN N
cancer NN N
( ( N
HNPCC NNP N
) ) N
risk NN N
, , N
individuals NNS N
can MD N
find VB N
the DT N
genetic JJ N
testing VBG N
decision-making JJ N
process NN N
complicated VBN N
and CC N
challenging VBG N
. . N

The DT N
goal NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
measure VB N
the DT N
effectiveness NN o
of IN o
a DT o
tailored JJ o
decision NN o
aid NN o
designed VBN N
specifically RB N
to TO N
assist VB N
individuals NNS N
to TO N
make VB N
informed JJ N
decisions NNS N
regarding VBG N
genetic JJ N
testing NN N
for IN N
HNPCC NNP N
risk NN N
. . N

METHODS NNP N
In IN N
all DT N
, , N
153 CD p
individuals NNS p
were VBD N
randomized VBN N
to TO N
receive VB i
the DT i
decision NN i
aid NN i
or CC i
a DT i
control JJ i
pamphlet NN i
at IN i
the DT i
end NN i
of IN i
their PRP$ i
first JJ i
genetic JJ i
counseling NN i
consultation NN i
. . i

Of IN N
these DT N
, , N
109 CD N
( ( N
71.2 CD N
% NN N
) ) N
completed VBD N
the DT N
first JJ N
questionnaire NN o
1 CD N
week NN N
after IN N
consultation NN N
, , N
whereas IN N
95 CD N
( ( N
62.1 CD N
% NN N
) ) N
completed VBD N
the DT N
6-month JJ N
follow-up JJ o
questionnaire NN o
. . o

RESULTS CC N
Although IN N
the DT N
decision NN N
aid NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
postdecisional JJ N
regret NN N
or CC N
actual JJ N
genetic JJ N
testing VBG N
decision NN N
, , N
the DT N
trial NN N
results NNS N
demonstrated VBD N
that IN N
participants NNS N
who WP N
received VBD N
the DT N
decision NN i
aid NN i
had VBD N
significantly RB N
lower JJR N
levels NNS N
of IN N
decisional JJ o
conflict NN o
( ( o
ie JJ o
, , o
uncertainty NN o
) ) o
regarding VBG N
genetic JJ o
testing NN o
( ( N
chi-square JJ N
( ( N
1 CD N
) ) N
= NN N
8.97 CD N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
classified VBN N
as IN N
having VBG N
made VBN N
an DT N
informed JJ o
choice NN o
concerning VBG N
genetic JJ N
testing NN N
( ( N
chi-square JJ N
( ( N
1 CD N
) ) N
= NN N
4.37 CD N
; : N
P NNP N
= NNP N
.037 NNP N
) ) N
than IN N
participants NNS N
who WP N
received VBD N
a DT N
control NN i
pamphlet NN i
. . i

Also RB N
, , N
men NNS N
who WP N
received VBD N
the DT N
decision NN i
aid NN i
had VBD N
significantly RB N
higher JJR o
knowledge NN o
levels NNS o
regarding VBG N
genetic JJ N
testing NN N
compared VBN N
with IN N
men NNS p
who WP N
received VBD N
the DT N
control NN i
pamphlet NN i
, , N
whereas JJ N
no DT N
such JJ N
differences NNS N
were VBD N
found VBN N
for IN N
women NNS p
( ( N
chi-square NN N
( ( N
2 CD N
) ) N
= NN N
6.76 CD N
; : N
P NNP N
= NNP N
.034 NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
decision NN i
aid NN i
for IN N
individuals NNS N
considering VBG N
genetic JJ N
testing NN N
for IN N
HNPCC NNP N
is VBZ N
an DT N
effective JJ N
intervention NN N
to TO N
reduce VB N
uncertainty NN N
and CC N
assist JJ N
individuals NNS N
to TO N
make VB N
an DT N
informed JJ N
choice NN N
regarding VBG N
genetic JJ N
testing NN N
for IN N
HNPCC NNP N
after IN N
genetic JJ N
counseling NN N
. . N

-DOCSTART- -X- O O

Naltrexone NN i
in IN N
young JJ p
autistic JJ p
children NNS p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
. . N

OBJECTIVE NNP N
This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
naltrexone NN i
, , N
an DT N
opiate NN N
blocker NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
autism NN p
. . p

METHOD NNP N
Thirteen NNP p
children NNS p
with IN p
autistic JJ p
disorder NN p
, , p
aged VBD p
3.4 CD p
to TO p
8.3 CD p
years NNS p
( ( p
mean VB p
5.4 CD p
) ) p
, , p
were VBD p
studied VBN p
in IN p
home NN p
, , p
school NN p
, , p
and CC p
outpatient JJ p
laboratory NN p
. . p

Naltrexone NNP i
, , i
1.0 CD i
mg/kg NN i
, , i
was VBD i
given VBN i
daily RB i
in IN i
a DT i
randomized JJ i
, , i
double-blind JJ i
, , i
placebo-controlled JJ i
crossover NN i
design NN i
. . i

Dependent JJ i
measures NNS i
included VBD i
parent NN i
and CC i
teacher RB i
Clinical JJ o
Global NNP o
Impressions NNP o
( ( o
CGI NNP o
) ) o
, , o
Conners NNPS o
Rating NNP o
Scales NNP o
, , o
and CC o
Naltrexone NNP o
Side-Effects NNP o
( ( o
SE NNP o
) ) o
Rating NNP o
Scale NNP o
; : o
laboratory NN o
CGI NNP o
, , o
movement NN o
actometer NN o
readings NNS o
, , o
and CC o
a DT o
10-second JJ o
interval NN o
recording VBG o
system NN o
analysis NN o
of IN o
on-task NN o
, , o
communication NN o
initiations NNS o
, , o
disruptive JJ o
behavior NN o
, , o
and CC o
self-stimulation NN o
. . o

RESULTS NNP N
Eight NNP N
of IN N
13 CD N
subjects NNS N
improved VBN N
in IN N
two CD N
or CC N
more JJR N
settings NNS N
. . N

Changes NNS N
in IN N
parent NN o
measures NNS o
( ( o
CGI NNP o
, , o
Conners NNP o
Impulsivity-Hyperactivity NNP o
Factor NNP o
, , o
and CC o
SE-Restlessness NNP o
) ) o
and CC o
Teacher NNP o
CGI NNP o
achieved VBD N
statistical JJ N
significance NN N
. . N

Teacher CC o
SE-Restlessness JJ o
and CC o
initiation NN o
of IN o
communication NN o
in IN N
the DT N
clinic NN N
showed VBD N
a DT N
trend NN N
toward IN N
improvement NN N
. . N

Actometer NNP o
readings NNS o
improved VBN N
in IN N
two CD N
children NNS N
who WP N
were VBD N
very RB N
active JJ N
at IN N
baseline NN N
. . N

Adverse JJ o
side NN o
effects NNS o
were VBD N
behavioral JJ N
, , N
mild JJ N
, , N
and CC N
transient NN N
. . N

Administering VBG N
the DT N
bitter JJ N
tablet NN N
was VBD N
a DT N
challenge NN N
. . N

CONCLUSIONS NNP N
Naltrexone NNP i
offers VBZ N
promise RB N
as IN N
an DT N
agent NN N
for IN N
modest JJ N
improvement NN N
of IN N
behavior NN o
and CC N
social JJ o
communication NN o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

Parent NN N
and CC N
teacher NN N
measures NNS N
can MD N
be VB N
useful JJ N
in IN N
outpatient JJ N
trials NNS N
to TO N
evaluate VB N
change NN N
. . N

-DOCSTART- -X- O O

Efficacy NN o
, , o
safety NN o
, , o
and CC o
steady-state JJ o
pharmacokinetics NNS o
of IN N
once-a-day JJ N
controlled-release JJ N
morphine NN i
( ( N
MS NNP N
Contin NNP N
XL NNP N
) ) N
in IN N
cancer NN p
pain NN p
. . p

The DT N
efficacy NN o
, , o
safety NN o
, , o
and CC o
pharmacokinetics NNS o
of IN N
a DT N
novel JJ N
once-daily JJ N
morphine NN i
formulation NN i
( ( i
OAD NNP i
morphine NN i
) ) i
and CC N
a DT N
12-hourly JJ N
formulation NN N
( ( N
twice-daily JJ N
CR NNP N
morphine NN i
) ) i
were VBD N
compared VBN N
in IN N
a DT N
double-blind JJ N
, , N
multi-centered JJ N
crossover NN N
study NN N
. . N

Chronic NNP p
cancer NN p
pain NN p
patients NNS p
( ( p
n=25 JJ p
) ) p
were VBD p
randomized VBN p
to TO p
OAD NNP i
morphine NN i
( ( p
mean JJ p
238 CD p
+/- JJ p
319 CD p
mg NN p
q24h NN p
) ) p
or CC p
twice-daily JJ i
CR NNP i
morphine NN i
( ( N
mean JJ N
119 CD N
+/- JJ N
159 CD N
mg NN N
q12h NN N
) ) N
for IN N
one CD N
week NN N
. . N

They PRP N
then RB N
crossed VBD N
over IN N
to TO N
the DT N
alternate JJ N
drug NN N
, , N
which WDT N
also RB N
was VBD N
taken VBN N
for IN N
one CD N
week NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
treatments NNS N
for IN N
evaluations NNS N
of IN N
overall JJ o
pain NN o
intensity NN o
, , o
analgesic JJ o
efficacy NN o
, , o
or CC o
adverse JJ o
events NNS o
. . o

However RB N
, , N
whereas JJ N
pain NN o
scores NNS o
increased VBD N
during IN N
the DT N
day NN N
on IN N
twice-daily JJ N
CR NNP N
morphine NN i
( ( N
P=0.0108 NNP N
) ) N
, , N
they PRP N
remained VBD N
stable JJ N
on IN N
OAD NNP N
morphine NN N
. . N

Most JJS N
patients NNS N
( ( N
68 CD N
% NN N
) ) N
chose VBD N
once-daily JJ N
dosing NN N
for IN N
continuing VBG N
pain JJ o
management NN o
( ( N
P=0.015 NNP N
) ) N
. . N

The DT N
AUC NNP o
ratio NN o
was VBD N
100.3 CD N
% NN N
, , N
indicating VBG N
equivalent JJ N
absorption NN N
. . N

Fluctuation NN o
indices NNS o
were VBD N
93.5 CD N
+/- JJ N
28.8 CD N
% NN N
and CC N
179.3 CD N
+/- JJ N
41.3 CD N
% NN N
( ( N
P=0.0001 NNP N
) ) N
for IN N
OAD NNP N
morphine NN i
and CC N
twice-daily JJ N
CR NNP i
morphine NN i
, , N
respectively RB N
. . N

OAD NNP N
morphine NN i
provides VBZ N
analgesia RB o
similar JJ N
to TO N
twice-daily JJ N
CR NNP N
morphine NN N
with IN N
reduced JJ N
fluctuation NN o
in IN o
plasma JJ o
morphine NN o
concentration NN o
and CC N
more RBR N
stable JJ N
pain NN o
control NN o
. . o

-DOCSTART- -X- O O

Lead-time NN N
in IN N
the DT N
European NNP N
Randomised VBD N
Study NNP N
of IN N
Screening NNP N
for IN N
Prostate NNP p
Cancer NNP p
. . p

BACKGROUND NNP N
Lead-time NNP N
is VBZ N
defined VBN N
as IN N
the DT N
time NN N
by IN N
which WDT N
screening VBG N
advances VBZ N
the DT N
diagnosis NN N
compared VBN N
with IN N
absence NN N
of IN N
screening VBG N
. . N

A DT N
sufficiently RB N
long JJ N
lead-time JJ N
needs NNS N
to TO N
be VB N
achieved VBN N
so RB N
that IN N
cancer NN N
can MD N
be VB N
detected VBN N
while IN N
still RB N
curable JJ N
. . N

A DT N
very RB N
short JJ N
lead-time NN N
may MD N
indicate VB N
poor JJ N
sensitivity NN N
of IN N
the DT N
screening JJ N
test NN N
, , N
while IN N
a DT N
very RB N
long JJ N
lead-time JJ N
suggests NNS N
overdiagnosis NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
In IN N
the DT N
first JJ N
screening NN N
round NN N
, , N
a DT p
total NN p
of IN p
56,294 CD p
men NNS p
aged VBN p
55-74 CD p
years NNS p
were VBD p
screened VBN p
with IN p
serum NN i
prostate NN i
specific JJ i
antigen NN i
( ( i
PSA NNP i
) ) i
in IN p
five CD p
countries NNS p
of IN p
the DT p
European NNP p
Randomised VBD p
Study NNP p
of IN p
Screening NNP p
for IN p
Prostate NNP p
Cancer NNP p
( ( p
ERSPC NNP p
) ) p
with IN p
an DT p
overall JJ p
detection NN p
rate NN p
( ( p
prevalence NN p
) ) p
of IN p
2.8 CD p
% NN p
( ( p
1972 CD p
prostate NN p
cancers NNS p
) ) p
. . p

Prostate NNP p
cancer NN p
incidence NN p
among IN p
92,142 CD p
men NNS p
randomly RB p
allocated VBN p
to TO p
the DT p
control NN p
arm NN p
of IN p
the DT p
trial NN p
was VBD p
also RB p
assessed VBN p
. . p

Lead-time NNP o
was VBD N
estimated VBN N
as IN N
the DT N
time NN N
required VBN N
to TO N
accumulate VB N
a DT N
similar JJ N
cumulative JJ N
risk NN N
of IN N
prostate NN N
cancer NN N
in IN N
the DT N
control NN N
arm NN N
to TO N
the DT N
detection NN N
rate NN N
in IN N
the DT N
intervention NN N
arm NN N
, , N
i.e NN N
. . N

from IN N
the DT N
ratio NN N
of IN N
detection NN N
rate NN N
( ( N
prevalence NN N
of IN N
screen-detected JJ N
cases NNS N
) ) N
and CC N
expected VBN N
incidence NN N
( ( N
cumulative JJ N
risk NN N
) ) N
. . N

RESULTS NNP N
Using VBG N
a DT N
serum JJ N
PSA NNP N
cut-off NN N
of IN N
4 CD N
ng/ml NNS N
, , N
the DT N
mean JJ o
lead-time NN o
in IN N
the DT N
whole NN N
study NN N
population NN N
was VBD N
estimated VBN N
as IN N
6.8 CD N
years NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
7.9-8.4 NN N
) ) N
. . N

It PRP N
was VBD N
8 CD N
years NNS N
in IN N
The DT N
Netherlands NNP p
, , N
6 CD N
in IN N
Sweden NNP p
and CC p
Finland NNP p
, , N
5 CD N
in IN N
Italy NNP p
and CC N
4 CD N
in IN N
Belgium NNP p
. . p

The DT N
mean JJ o
lead-time NN o
was VBD N
similar JJ N
, , N
6-7 JJ N
years NNS N
, , N
at IN N
ages NNS N
50-64 CD N
years NNS N
, , N
but CC N
close RB N
to TO N
8 CD N
years NNS N
among IN N
men NNS N
aged VBN N
65-74 CD N
years NNS N
. . N

A DT N
lower JJR N
PSA NNP o
cut-off JJ o
level NN o
of IN N
3 CD N
ng/ml NNS N
used VBN N
in IN N
Sweden NNP N
and CC N
The DT N
Netherlands NNP N
prolonged VBD N
the DT N
mean JJ N
lead-time JJ N
by IN N
approximately RB N
1 CD N
year NN N
. . N

Lead-time NNP o
based VBN o
on IN o
advanced JJ o
prostate NN o
cancer NN o
only RB N
was VBD N
slightly RB N
shorter JJR N
, , N
mean JJ N
5.3 CD N
years NNS N
( ( N
95 CD N
% NN N
CI NNP N
4.6-6.0 CD N
) ) N
. . N

The DT N
lead-time NN o
for IN o
the DT o
second JJ o
screening NN o
round NN o
was VBD N
slightly RB N
shorter JJR N
than IN N
that DT N
for IN N
the DT N
first JJ N
( ( N
5.9 CD N
, , N
95 CD N
% NN N
CI NNP N
5.4-6.4 CD N
) ) N
, , N
reflecting VBG N
a DT N
similar JJ N
relation NN N
between IN N
detection NN N
rate NN N
and CC N
control NN N
group NN N
incidence NN N
. . N

CONCLUSION VB N
The DT N
lead-time NN N
for IN N
prostate NN N
cancer NN N
found VBD N
in IN N
ERSPC NNP N
substantially RB N
exceeded VBD N
that IN N
found NN N
for IN N
breast NN N
, , N
cervical JJ N
and CC N
colorectal JJ N
cancer NN N
screening NN N
. . N

One CD N
round NN N
of IN N
prostate NN N
cancer NN N
screening VBG N
can MD N
advance VB N
clinical JJ N
diagnosis NN N
by IN N
4-8 JJ N
years NNS N
. . N

Overdiagnosis NN N
or CC N
detection NN N
of IN N
non-progressive JJ N
tumours NNS N
may MD N
contribute VB N
substantially RB N
to TO N
the DT N
lead-time NN o
. . o

-DOCSTART- -X- O O

Shorter NNP N
treatment NN N
for IN N
vaginal JJ p
candidosis NN p
: : p
comparison NN N
between IN N
single-dose JJ N
oral JJ N
fluconazole NN i
and CC N
three-day JJ N
treatment NN N
with IN N
local JJ N
miconazole NN i
. . i

Fluconazole NNP i
is VBZ N
an DT N
effective JJ N
, , N
simple JJ N
and CC N
safe JJ N
, , N
although IN N
slightly RB N
expensive JJ N
, , N
agent NN N
for IN N
the DT N
treatment NN N
of IN N
vaginal JJ p
candidosis NN p
. . p

Single-dose JJ i
fluconazole NN i
( ( i
150 CD i
mg NN i
) ) i
administered VBD i
orally RB i
in IN i
capsule NN i
form NN i
was VBD i
compared VBN i
with IN i
three-day JJ i
local JJ i
treatment NN i
with IN i
miconazole JJ i
pessaries NNS i
in IN i
the DT i
treatment NN i
of IN i
vaginal JJ i
candidosis NN i
in IN i
a DT i
randomized JJ i
study NN i
in IN i
Finland NNP i
. . i

Cure NN o
rates NNS o
were VBD N
good JJ N
( ( N
> JJ N
80 CD N
% NN N
) ) N
in IN N
randomized VBN N
patient NN N
groups NNS N
assessed VBD N
both DT N
clinically RB N
and CC N
by IN N
the DT N
results NNS N
of IN N
yeast JJ N
cultures NNS N
. . N

Oral JJ N
administration NN N
was VBD N
preferred VBN N
to TO N
local JJ N
therapy NN N
by IN N
patients NNS N
in IN N
both DT N
the DT N
miconazole NN i
and CC N
fluconazole JJ i
groups NNS N
. . N

For IN N
the DT N
time NN N
being VBG N
, , N
fluconazole NN i
is VBZ N
not RB N
recommended VBN N
for IN N
use NN N
during IN N
pregnancy NN N
or CC N
lactation NN N
. . N

-DOCSTART- -X- O O

Best JJS N
evidence NN N
in IN N
critical JJ N
care NN N
medicine NN N
. . N

Steroids NNS i
to TO N
prevent VB N
post-extubation NN o
airway JJ o
obstruction NN o
in IN N
adult NN p
critically RB p
ill JJ p
patients NNS p
. . p

-DOCSTART- -X- O O

[ RB N
Clinical NNP N
study NN N
of IN N
feiyanqing VBG i
rectum NN i
condensed VBD i
liquid NN i
in IN N
treating VBG N
36 CD N
cases NNS N
of IN N
children NNS N
syncytial JJ N
viral JJ N
pneumonia NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
mechanism NN N
of IN N
Feiyangqin NNP i
Rectum NNP i
Condensed VBD i
Liquid NNP i
( ( i
FRCL NNP i
) ) i
in IN N
treating VBG N
children NNS p
syncytial JJ p
viral JJ p
pneumonia NN p
. . p

Methods NNS N
Seventy-two JJ p
patients NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
two CD p
groups NNS p
, , p
the DT p
36 CD p
patients NNS p
in IN p
the DT p
treated JJ p
group NN p
were VBD p
treated VBN p
with IN p
FRCL NNP i
, , p
and CC p
the DT p
other JJ p
36 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
simply RB p
treated VBD p
with IN p
Western JJ i
medicine NN i
. . i

Efficacy NN o
of IN N
treatment NN N
on IN N
clinical JJ N
condition NN N
and CC N
some DT N
immune JJ o
function NN o
( ( o
IgA NNP o
, , o
IgG NNP o
, , o
CD3 NNP o
, , o
CD4 NNP o
) ) o
were VBD N
observed VBN N
. . N

RESULTS NNP N
In IN N
the DT N
treated JJ N
group NN N
, , N
28 CD N
patients NNS N
were VBD N
cured VBN o
( ( N
77.8 CD N
% NN N
) ) N
, , N
treatment NN N
was VBD N
markedly RB N
effective JJ N
in IN N
4 CD N
patients NNS N
( ( N
11.1 CD N
% NN N
) ) N
, , N
effective JJ N
in IN N
2 CD N
( ( N
5.5 CD N
% NN N
) ) N
and CC N
ineffective JJ N
in IN N
2 CD N
( ( N
5.6 CD N
% NN N
) ) N
, , N
with IN N
the DT N
total JJ o
effective JJ o
rate NN o
of IN N
94.4 CD N
% NN N
. . N

The DT N
corresponding JJ N
number NN N
in IN N
the DT N
control NN N
group NN N
was VBD N
20 CD N
( ( N
55.6 CD N
% NN N
) ) N
, , N
7 CD N
( ( N
19.4 CD N
% NN N
) ) N
, , N
6 CD N
( ( N
16.7 CD N
% NN N
) ) N
, , N
3 CD N
( ( N
8.3 CD N
% NN N
) ) N
and CC N
91.7 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
cure NN o
rate NN o
in IN N
the DT N
treated JJ N
group NN N
was VBD N
obviously RB N
superior JJ N
to TO N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

FRCL NNP i
could MD N
improve VB N
serum NN o
IgA NNP o
, , o
IgG NNP o
, , o
CD3 NNP o
, , o
CD4 NNP o
, , o
and CC o
CD4/CD8 NNP o
, , o
lower JJR o
serum NN o
IgE NNP o
, , N
these DT N
indexes NNS N
in IN N
the DT N
treated JJ N
group NN N
were VBD N
significantly RB N
different JJ N
to TO N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
FRCL NNP i
had VBD N
the DT N
action NN N
in IN N
treating VBG N
children NNS N
syncytial JJ N
viral JJ N
pneumonia NN N
without IN N
any DT N
adverse JJ N
reaction NN N
, , N
one CD N
of IN N
its PRP$ N
mechanisms NNS N
might MD N
be VB N
related VBN N
to TO N
its PRP$ N
regulation NN N
on IN N
immune JJ N
function NN N
. . N

-DOCSTART- -X- O O

Femoral NNP N
vein NN N
delivery NN N
of IN N
contrast NN N
medium NN N
enhances VBZ N
transthoracic JJ o
echocardiographic JJ o
detection NN o
of IN N
patent NN o
foramen NNS o
ovale VBP o
. . o

OBJECTIVES IN N
We PRP N
postulated VBD N
that IN N
femoral JJ N
vein JJ N
delivery NN N
of IN N
contrast NN N
medium NN N
because IN N
of IN N
streaming NN N
, , N
might MD N
enhance VB N
precordial JJ o
echocardiographic JJ o
detection NN o
of IN N
patent NN N
foramen NNS N
ovale VBP N
. . N

BACKGROUND NNP N
Although IN N
precordial JJ N
contrast NN N
echocardiography NN N
is VBZ N
widely RB N
used VBN N
to TO N
diagnose VB N
patent JJ N
foramen NNS N
ovale RB N
, , N
this DT N
method NN N
is VBZ N
limited VBN N
by IN N
poor JJ N
sensitivity NN N
. . N

Previous JJ N
investigators NNS N
have VBP N
demonstrated VBN N
enhanced JJ N
detection NN N
of IN N
atrial JJ o
defects NNS o
by IN N
the DT N
dye-dilution NN N
technique NN N
after IN N
delivery NN N
of IN N
contrast NN N
medium NN N
into IN N
the DT N
inferior NN N
rather RB N
than IN N
the DT N
superior JJ N
vena NN N
cava NN N
. . N

METHODS NNP N
Transthoracic NNP i
contrast NN i
examinations NNS i
were VBD N
performed VBN N
in IN N
a DT N
randomly RB N
selected VBN N
group NN N
of IN N
70 CD p
patients NNS p
( ( p
without IN p
previous JJ p
history NN p
of IN p
cerebral JJ p
or CC p
systemic JJ p
embolus NN p
) ) p
undergoing VBG p
cardiac JJ p
catheterization NN p
. . p

Paired VBN N
contrast NN i
agent NN i
injections NNS i
( ( i
10 CD i
ml NN i
dextrose NN i
in IN i
water/0.25 NN i
ml NNP i
air NN i
) ) i
were VBD N
administered VBN N
from IN N
an DT N
upper JJ N
extremity NN N
vein NN N
and CC N
femoral JJ N
vein NN N
in IN N
each DT N
patient NN N
during IN N
spontaneous JJ N
respiration NN N
, , N
cough NN N
and CC N
Valsalva NNP N
maneuvers NNS N
. . N

Studies NNS N
were VBD N
interpreted VBN N
by IN N
an DT N
experienced JJ N
echocardiographer NN N
unaware NN N
of IN N
the DT N
sequence NN N
and CC N
site NN N
of IN N
injections NNS N
. . N

Positive JJ N
studies NNS N
were VBD N
semiquantitatively RB N
graded VBN N
from IN N
+1 NNP N
( ( N
minimal JJ N
left VBD N
ventricular JJ N
opacification NN N
) ) N
to TO N
+4 VB N
( ( N
intense JJ N
left VBD N
ventricular JJ N
opacification NN N
) ) N
. . N

Catheterization NN o
and CC o
echocardiographic JJ o
assessment NN o
of IN o
patent NN o
foramen NNS o
ovale VBP o
were VBD N
compared VBN N
in IN N
21 CD N
subjects NNS N
. . N

RESULTS NNP N
Patent NNP o
foramen NNS o
ovale NN o
was VBD N
detected VBN N
significantly RB N
more RBR N
often RB N
during IN N
femoral JJ N
vein NNS N
versus VBP N
upper JJ N
extremity NN N
contrast NN N
delivery NN N
( ( N
23 CD N
of IN N
70 CD N
patients NNS N
[ JJ N
prevalence RB N
33 CD N
% NN N
] NNP N
vs. IN N
9 CD N
of IN N
70 CD N
patients NNS N
[ JJ N
prevalence RB N
13 CD N
% NN N
] NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
intensity NN o
of IN o
left JJ o
ventricular JJ o
opacification NN o
was VBD N
also RB N
greater JJR N
during IN N
femoral JJ N
vein NNS N
contrast NN N
injection NN N
. . N

Precordial JJ N
echocardiography NN N
combined VBN N
with IN N
femoral JJ N
contrast NN N
delivery NN N
was VBD N
significantly RB N
more RBR N
sensitive JJ o
than IN N
cardiac JJ N
catheterization NN N
for IN N
assessment NN o
of IN o
patent NN o
foramen NNS o
ovale VBP o
( ( N
8 CD N
of IN N
21 CD N
patients NNS N
vs. FW N
2 CD N
of IN N
21 CD N
patients NNS N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Femoral NNP i
vein NNP i
contrast NN i
delivery NN i
significantly RB N
enhances VBZ N
the DT N
ability NN o
of IN o
precordial JJ o
contrast NN o
echocardiography NN o
to TO o
diagnose VB o
patent JJ o
foramen NNS o
ovale VBP o
. . o

Physiologic NNP N
patency NN N
of IN N
the DT N
foramen NNS N
ovale VBP N
is VBZ N
more RBR N
common JJ N
( ( N
prevalence JJ N
33 CD N
% NN N
) ) N
than IN N
previously RB N
documented VBN N
. . N

-DOCSTART- -X- O O

A DT N
comparative JJ N
study NN N
of IN N
methyldopa NN i
and CC N
labetalol NN i
in IN N
the DT N
treatment NN N
of IN N
hypertension NN o
. . o

1 CD N
Twenty CD p
patients NNS p
with IN p
essential JJ p
hypertension NN p
completed VBD N
a DT N
double-blind JJ N
, , N
dose-tritrated JJ N
, , N
cross-over JJ N
comparison NN N
of IN N
methyldopa NN i
and CC i
labetalol NN i
. . i

2 CD N
Average JJ o
lying VBG o
BPs NNP o
( ( o
systolic/diastolic JJ o
) ) o
were VBD N
reduced VBN N
by IN N
28/15 CD N
mmHg NNS N
with IN N
methyldopa NN i
and CC N
by IN N
23/15 CD N
mmHg NNS N
with IN N
labetalol NN i
. . i

3 CD N
Average JJ o
standing VBG o
BPs NNP o
( ( o
systolic/diastolic JJ o
) ) o
were VBD N
reduced VBN N
by IN N
29/14 CD N
mmHg NNS N
with IN N
methyldopa NN i
and CC N
by IN N
29/15 CD N
mmHg NNS N
with IN N
labetalol NN i
. . i

4 CD N
Both DT N
lying NN o
and CC o
standing VBG o
heart NN o
rates NNS o
were VBD N
reduced VBN N
with IN N
labetalol NN i
. . i

5 CD N
It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
antihypertensive JJ o
properties NNS o
of IN N
labetalol NN i
and CC N
methyldopa NN i
are VBP N
similar JJ N
but CC N
that IN N
larger JJR N
patient NN N
populations NNS N
are VBP N
needed VBN N
to TO N
study VB N
the DT N
relative JJ N
incidence NN N
of IN N
subjective JJ N
adverse JJ N
effects NNS N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
partial JJ i
vs. FW N
stepwise NN i
caries NNS p
removal NN N
: : N
3-year JJ N
follow-up NN N
. . N

This DT N
randomized JJ N
, , N
multicenter RB N
clinical JJ N
trial NN N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
2 CD N
treatments NNS N
for IN N
deep JJ p
caries NNS p
lesions NNS p
- : N
partial JJ i
caries NNS i
removal NN i
( ( i
PCR NNP i
) ) i
and CC i
stepwise JJ i
excavation NN i
( ( i
SW NNP i
) ) i
- : N
with IN N
respect NN N
to TO N
the DT N
primary JJ N
outcome NN N
of IN N
pulp NN N
vitality NN N
for IN N
a DT N
3-year JJ N
follow-up JJ N
period NN N
. . N

Inclusion NN p
criteria NNS p
were VBD p
as IN p
follows VBZ p
: : p
patients NNS p
with IN p
permanent JJ p
molars NNS p
presenting VBG p
deep JJ p
caries NNS p
lesions NNS p
( ( p
lesion NN p
affecting VBG p
? . p
1/2 CD p
of IN p
the DT p
dentin NN p
on IN p
radiographic JJ p
examination NN p
) ) p
, , p
positive JJ p
response NN p
to TO p
a DT p
cold JJ p
test NN p
, , p
absence NN p
of IN p
spontaneous JJ p
pain NN p
, , p
negative JJ p
sensitivity NN p
to TO p
percussion NN p
, , p
and CC p
absence NN p
of IN p
periapical JJ p
lesions NNS p
( ( p
radiographic JJ p
examination NN p
) ) p
. . p

Teeth NNP N
randomly RB N
assigned VBD N
to TO N
PCR NNP N
( ( N
test NN N
) ) N
received VBD N
incomplete JJ N
caries NNS N
removal NN N
and CC N
filling NN N
in IN N
a DT N
single JJ N
session NN N
. . N

Outcome NNP N
success NN N
was VBD N
evaluated VBN N
by IN N
assessment NN N
of IN N
pulp NN o
vitality NN o
, , o
determined VBN N
by IN N
pulp NN N
sensitivity NN N
to TO N
a DT N
cold JJ N
test NN N
and CC N
the DT N
absence NN N
of IN N
periapical JJ N
lesions NNS N
. . N

Data NNS N
were VBD N
analyzed VBN N
by IN N
a DT N
Weibull NNP N
regression NN N
model NN N
with IN N
shared VBN N
frailty NN N
term NN N
( ( N
survival JJ N
analysis NN N
) ) N
. . N

At IN N
baseline NN p
, , p
299 CD p
treatments NNS p
were VBD p
executed VBN p
: : p
PCR NNP p
, , N
152 CD N
and CC N
SW NNP N
, , N
147 CD p
. . p

By IN N
the DT N
end NN N
of IN N
the DT N
3-year JJ N
follow-up JJ N
period NN p
, , p
213 CD p
teeth NNS p
had VBD p
been VBN p
evaluated VBN o
. . o

Adjusted VBN o
survival JJ o
rates NNS o
were VBD o
91 CD N
% NN N
for IN N
PCR NNP N
and CC N
69 CD N
% NN N
for IN N
SW NNP N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
there EX N
is VBZ N
no DT N
need NN N
to TO N
re-open VB N
a DT N
cavity NN N
and CC N
perform VB N
a DT N
second JJ N
excavation NN N
for IN o
pulp NN o
vitality NN o
to TO o
be VB N
preserved VBN N
( ( N
Clinical JJ N
trials NNS N
registration VBP N
NCT00887952 NNP N
) ) N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
electroacununcture NN i
on IN N
sex NN N
hormone NN N
levels NNS N
in IN N
patients NNS p
with IN p
Sj?gren NNP p
's POS p
syndrome JJ p
] NN p
. . p

OBJECTIVE UH N
To TO N
observe VB N
the DT N
effect NN N
of IN i
electroacupuncture NN i
( ( i
EA NNP i
) ) i
on IN o
serum NN o
testosterone NN o
( ( o
T NNP o
) ) o
, , o
estradiol FW o
( ( o
F2 NNP o
) ) o
, , o
luteotropic VBZ o
hormone NN o
( ( o
LH NNP o
) ) o
, , o
follicle-stimulating JJ o
hormone NN o
( ( o
FSH NNP o
) ) o
, , o
progesterone NN o
( ( o
P NNP o
) ) o
, , o
and CC o
prolactin NN o
( ( o
PRL NNP o
) ) o
in IN p
patients NNS p
with IN p
Sj?gren NNP p
's POS p
Syndrome NNP p
( ( p
SS NNP p
) ) p
in IN p
order NN N
to TO N
analyze VB N
the DT N
correlation NN N
between IN N
the DT N
adjustment NN N
effect NN N
of IN N
EA NNP i
and CC i
changes NNS N
of IN N
hormone NN N
levels NNS N
. . N

METHODS NNP p
Fifty-seven JJ p
middle-aged JJ p
and CC p
old JJ p
women NNS p
with IN p
SS NNP p
were VBD p
divided VBN N
into IN i
medication NN i
group NN i
( ( N
n=27 CC N
) ) N
and CC i
acupuncture NN i
group NN i
( ( N
n=30 RB N
) ) N
. . N

Patients NNS N
in IN N
acupuncture NN i
group NN i
were VBD i
treated VBN i
with IN i
EA NNP i
( ( i
80 CD i
Hz NNP i
, , i
2.5 CD i
mA NN i
) ) i
of IN i
Shenshu NNP i
( ( i
BL NNP i
23 CD i
) ) i
, , i
Taixi NNP i
( ( i
KI NNP i
3 CD i
) ) i
, , i
Hegu NNP i
( ( i
LI NNP i
4 CD i
) ) i
, , i
etc FW i
. . i

for IN i
30 CD i
min NN i
, , i
once RB i
every DT i
other JJ i
day NN i
, , i
and CC i
those DT i
of IN i
medication NN i
group NN i
were VBD i
treated VBN i
with IN i
oral JJ i
administration NN i
of IN i
hydroxyl-chloroquine JJ i
( ( i
6 CD i
mg/kg NNS i
per IN i
day NN i
) ) i
, , i
oral JJ i
transfer NN i
agent NN i
liquid NN i
, , i
Vit NNP i
B1 NNP i
, , i
Vit NNP i
B2 NNP i
, , i
Vit NNP i
C NNP i
, , i
fish-liver JJ i
oil NN i
, , i
one CD i
tablet/time NN i
, , i
t.i.d. NN i
, , i
and CC i
pilocarpine NN i
( ( i
20 CD i
mg/d NN i
) ) i
, , i
continuously RB i
for IN i
2 CD i
months NNS i
. . i

Venous JJ N
blood NN N
samples NNS N
were VBD N
collected VBN N
before IN N
and CC N
after IN N
the DT N
treatment NN N
to TO N
examine VB N
contents NNS N
of IN N
the DT N
abovementioned JJ N
sex NN N
hormones NNS N
by IN N
using VBG i
electro-chemiluminescent JJ i
immunoassay NN i
( ( i
CLIA NNP i
) ) i
. . i

RESULTS NNP N
( ( N
1 CD N
) ) N
Before IN N
the DT N
treatment NN N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
two CD N
groups NNS N
in IN N
the DT o
levels NNS o
of IN o
serum NN o
T NNP o
, , o
E2 NNP o
, , o
LH NNP o
, , o
FSH NNP o
, , o
P NNP o
and CC o
PRL NNP o
( ( o
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

After IN N
the DT N
treatment NN N
, , N
self-comparison NN N
of IN N
each DT N
group NN N
showed VBD N
that IN o
serum NN o
EF NNP o
and CC o
T NNP o
contents NNS o
in IN o
acupuncture NN N
group NN N
increased VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC o
serum JJ o
LH NNP o
content NN o
decreased VBN o
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
while IN N
in IN N
medication NN N
group NN N
, , N
only RB o
serum JJ o
LH NNP o
decreased VBD o
markedly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
comparison NN N
with IN N
its PRP$ N
basic JJ N
value NN N
of IN N
pretreatment NN N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
serum NN o
P NNP o
, , o
FSH NNP o
and CC o
PRL NNP o
levels NNS o
in IN o
both DT N
groups NNS N
after IN N
the DT N
treatment NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
results NNS N
suggested VBD N
that IN N
the DT N
therapeutic JJ N
effect NN N
of IN N
acupuncture NN N
group NN N
was VBD N
better JJR N
than IN N
that DT N
of IN N
medication NN N
group NN N
in IN N
regulating VBG o
multiple JJ o
sex NN o
hormones NNS o
. . o

CONCLUSION NNP i
EA NNP i
can MD i
effectively RB N
adjust VB N
E2 NNP N
, , N
T NNP N
and CC N
LH NNP N
levels NNS N
in IN N
Sj?gren NNP p
's POS p
Syndrome NNP p
patients NNS p
and CC p
improve VB N
most JJS N
patients NNS N
' POS N
clinical JJ N
symptoms NNS N
, , N
and CC N
the DT N
therapeutic JJ N
effect NN N
of IN N
EA NNP i
is VBZ N
better JJR N
than IN N
that DT N
of IN N
medication NN i
. . i

-DOCSTART- -X- O O

Transdermal NNP i
scopolamine NN i
patch NN i
in IN N
addition NN N
to TO N
ondansetron VB i
for IN N
postoperative JJ N
nausea NN N
and CC N
vomiting VBG N
prophylaxis NN N
in IN N
patients NNS p
undergoing VBG p
ambulatory JJ p
cosmetic JJ p
surgery NN p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
transdermal JJ i
scopolamine NN i
in IN N
addition NN N
to TO N
ondansetron VB i
in IN N
decreasing VBG N
the DT N
incidence NN N
of IN N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
( ( p
PONV NNP p
) ) p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NN N
Academic NNP p
hospital NN p
. . p

PATIENTS CC N
126 CD p
ASA NNP p
physical JJ p
status NN p
I PRP p
and CC p
II NNP p
patients NNS p
undergoing VBG p
outpatient JJ p
plastic NN p
surgery NN p
with IN p
three CD p
or CC p
more JJR p
risk NN p
factors NNS p
for IN p
PONV NNP p
. . p

INTERVENTIONS NNP N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
to TO N
receive VB N
( ( N
Group NNP N
1 CD N
) ) N
a DT N
transdermal JJ i
scopolamine NN i
( ( i
TDS NNP i
) ) i
patch NN i
or CC N
( ( N
Group NNP N
2 CD N
) ) N
, , N
a DT i
placebo JJ i
patch NN i
two CD N
hours NNS N
before IN N
surgery NN N
. . N

MEASUREMENTS NNP N
Occurrence NNP o
of IN o
vomiting VBG o
, , o
severity NN o
of IN o
nausea NN o
using VBG o
a DT o
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
, , o
rescue JJ o
medication NN o
, , o
pain VBP o
intensity NN o
and CC o
pain NN o
medications NNS o
, , o
and CC o
side JJ o
effects NNS o
were VBD N
recorded VBN N
every DT N
hour NN N
until IN N
discharge NN N
from IN N
hospital NN N
, , N
then RB N
every DT N
4 CD N
hours NNS N
thereafter RB N
for IN N
a DT N
total NN N
of IN N
24 CD N
hours NNS N
. . N

MAIN NNP N
RESULTS NNP N
A NNP N
statistically RB N
significant JJ N
reduction NN N
in IN N
postoperative JJ o
nausea NN o
between IN N
8 CD N
and CC N
24 CD N
hours NNS N
in IN N
patients NNS N
receiving VBG N
TDS NNP N
was VBD N
noted VBN N
. . N

CONCLUSIONS NNP N
Transdermal NNP N
scopolamine NN i
in IN N
addition NN N
to TO N
ondansetron VB N
benefits NNS N
patients NNS p
at IN p
high JJ p
risk NN p
for IN p
PONV NNP p
undergoing JJ p
outpatient NN p
plastic NN p
surgery NN p
for IN N
up IN N
to TO N
20 CD N
hours NNS N
after IN N
surgery NN N
. . N

-DOCSTART- -X- O O

Uterine JJ N
incision NN N
closure NN N
at IN N
caesarean JJ N
section NN N
: : N
a DT N
randomised JJ N
comparative NN N
study NN N
of IN N
intraperitoneal JJ i
closure NN i
and CC i
closure NN i
after IN i
temporary JJ i
exteriorisation NN i
. . i

BACKGROUND IN N
The DT N
safety NN N
of IN N
the DT N
technique NN i
of IN i
uterine JJ i
exteriorization NN i
at IN i
caesarean JJ i
section NN i
though IN N
popular JJ N
among IN N
obstetricians NNS N
, , N
remains VBZ N
controversial JJ N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
influence NN N
of IN N
exteriorization NN N
of IN N
uterus NN N
during IN N
uterine JJ N
repair NN N
on IN N
caesarean JJ N
morbidity NN N
. . N

METHODS NNP N
A NNP N
randomized VBD N
comparative JJ N
study NN N
of IN N
136 CD p
women NNS p
undergoing VBG p
primary JJ p
caesarean JJ p
delivery NN p
at IN p
Havana NNP p
Specialist NNP p
Hospital NNP p
Lagos NNP p
Nigeria NNP p
. . p

Data NNP N
on IN N
operation NN N
time NN N
, , N
estimated VBN N
blood NN N
loss NN N
, , N
postoperative JJ N
morbidities NNS N
were VBD N
collected VBN N
and CC N
analysed VBN N
with IN N
comparison NN N
between IN N
the DT N
two CD N
groups NNS N
using VBG N
chi JJ N
square NN N
, , N
Fischer NNP N
's POS N
exact JJ N
test NN N
and CC N
t-test NN N
as IN N
appropriate JJ N
. . N

RESULTS VB N
The DT N
mean JJ o
operative JJ o
time NN o
, , o
estimated VBN o
blood NN o
loss NN o
, , o
transfusion NN o
rate NN o
and CC o
postoperative JJ o
anemia NN o
rate NN o
were VBD N
significantly RB N
less RBR N
in IN N
the DT N
exteriorized JJ N
group NN N
than IN N
the DT N
intraperitoneal JJ N
group NN N
( ( N
p JJ N
= NN N
0.000 CD N
, , N
0.009,0.048 CD N
0.038 CD N
and CC N
0.028 CD N
respectively RB N
) ) N
, , N
but CC N
not RB N
in IN N
other JJ N
outcome JJ N
measures NNS N
. . N

CONCLUSION NNP N
With IN N
shorter JJR N
operative JJ N
time NN N
, , N
less JJR N
blood NN N
loss NN N
and CC N
similar JJ N
morbidity NN N
profile NN N
exteriorization NN N
of IN N
uterus NN N
during IN N
caesarean JJ N
section NN N
seems VBZ N
to TO N
be VB N
preferred VBN N
except IN N
where WRB N
it PRP N
is VBZ N
not RB N
possible JJ N
because IN N
of IN N
adhesions NNS N
and CC N
surgeons NNS N
inexperience NN N
. . N

-DOCSTART- -X- O O

Pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
six CD N
epoetin JJ i
alfa NN i
dosing VBG N
regimens NNS N
in IN N
anemic JJ p
critically RB p
ill JJ p
patients NNS p
without IN p
acute JJ p
blood NN p
loss NN p
. . p

OBJECTIVE UH N
To TO N
describe VB N
the DT N
pharmacokinetic JJ N
profiles NNS N
of IN N
six CD N
different JJ N
dosing VBG N
regimens NNS N
for IN N
epoetin NN i
alfa NN i
, , N
and CC N
whether IN N
more JJR N
rapid JJ N
and CC N
robust JJ N
reticulocytosis NN N
can MD N
be VB N
elicited VBN N
with IN N
more RBR N
frequent JJ N
administration NN N
of IN N
epoetin JJ i
alfa NN i
in IN N
anemic JJ p
critically RB p
ill JJ p
patients NNS p
. . p

DESIGN NNP N
Randomized NNP N
, , N
open-label NN N
, , N
multicenter NN N
, , N
28-day JJ N
clinical JJ N
trial NN N
. . N

SETTING NN N
Ten CD p
centers NNS p
in IN p
the DT p
United NNP p
States NNPS p
. . p

PATIENTS VB N
Adult NNP p
( ( p
age NN p
> VBN p
or=18 CD p
years NNS p
) ) p
critically RB p
ill JJ p
patients NNS p
with IN p
hemoglobin JJ p
< NNP p
or=12 NN p
g/dL NN p
, , p
expected VBN p
hospitalization NN p
of IN p
> NNP p
or=7 NNP p
days NNS p
, , p
with IN p
no DT p
ongoing VBG p
acute RB p
blood NN p
loss NN p
. . p

INTERVENTIONS NNP N
One CD N
of IN N
six CD i
dosing VBG i
epoetin NN i
alfa NN i
regimens VBZ i
for IN N
15 CD N
days NNS N
, , N
as IN N
follows VBZ N
: : N
40,000 CD i
IU NNP i
once RB i
weekly RB i
, , N
subcutaneously RB N
( ( N
group NN N
A NNP N
) ) N
or CC N
intravenously RB N
( ( N
IV NNP N
) ) N
( ( N
group NN N
B NNP N
) ) N
; : N
15,000 CD i
IU NNP i
every DT i
other JJ i
day NN i
, , i
subcutaneously RB i
( ( N
group NN N
C NNP N
) ) N
or CC N
IV NNP N
( ( N
group NN N
D NNP N
) ) N
; : N
or CC N
40,000 CD i
IU NNP i
day NN i
1 CD N
and CC N
3 CD N
, , N
subcutaneously RB i
( ( N
group NN N
E NNP N
) ) N
or CC N
IV NNP N
( ( N
group NN N
F NNP N
) ) N
, , N
followed VBN N
by IN N
15,000 CD N
IU NNP N
once RB N
every DT N
other JJ N
day NN N
on IN N
[ NN N
corrected VBN N
] JJ N
days NNS N
5-15 JJ N
[ NNP N
corrected VBD N
] NN N
MEASUREMENTS NNP N
Serum NNP o
erythropoietin NN o
concentration NN o
, , o
absolute JJ o
reticulocyte NN o
count NN o
, , o
and CC o
adverse JJ o
events NNS o
. . o

MAIN NNP N
RESULTS NNP N
Of IN N
the DT N
60 CD N
patients NNS N
who WP N
were VBD N
enrolled VBN N
( ( N
60 CD N
% NN N
men NNS N
, , N
mean JJ N
age NN N
53 CD N
years NNS N
, , N
mean VBP N
Acute NNP N
Physiology NNP N
and CC N
Chronic NNP N
Health NNP N
Evaluation NNP N
II NNP N
score NN N
, , N
19.5 CD N
) ) N
, , N
30 CD N
were VBD N
evaluable JJ N
for IN N
both DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
( ( N
50 CD N
% NN N
) ) N
. . N

Erythropoietin NNP o
exposure NN o
was VBD N
approximately RB N
ten JJ N
times NNS N
greater JJR N
for IN N
IV NNP N
dosing VBG N
than IN N
for IN N
subcutaneous JJ i
dosing NN i
. . i

Mean NNP o
absolute JJ o
reticulocyte NN o
count NN o
peaked VBD N
at IN N
day NN N
11 CD N
or CC N
15 CD N
in IN N
each DT N
group NN N
and CC N
appeared VBD N
to TO N
be VB N
greater JJR N
for IN N
subcutaneous JJ N
dosing NN i
( ( N
mean JJ N
peak NN N
response NN N
149-169 JJ N
x NN N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
) ) N
compared VBN N
with IN N
IV NNP N
dosing VBG i
( ( N
mean JJ N
peak NN N
response NN N
138-147 JJ N
x NN N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
) ) N
at IN N
most JJS N
visits NNS N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
adverse JJ o
events NNS o
were VBD N
pyrexia NNS o
( ( N
18 CD N
% NN N
) ) N
, , N
hypokalemia NN o
( ( N
15 CD N
% NN N
) ) N
, , N
and CC N
hypophosphatemia NN o
( ( N
15 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
of IN N
anemic JJ N
critically NN N
ill JJ N
patients NNS N
treated VBN N
with IN N
epoetin JJ i
alfa NN i
, , N
all DT N
dosing VBG N
regimens NNS N
were VBD N
well RB N
tolerated VBN o
and CC N
appeared VBN N
to TO N
effect NN N
reticulocytosis NN o
, , N
with IN N
a DT N
peak NN N
at IN N
day NN N
11 CD N
or CC N
15 CD N
in IN N
most JJS N
patients NNS N
. . N

The DT N
pharmacokinetics NNS N
of IN N
epoetin JJ i
alfa NN i
did VBD N
not RB N
predict VB N
pharmacodynamic JJ o
response NN o
in IN N
anemic JJ N
critically RB N
ill JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

Virtual JJ i
reality NN i
for IN N
acute NN N
pain NN N
reduction NN N
in IN N
adolescents NNS p
undergoing VBG p
burn NN p
wound NN p
care NN p
: : p
a DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
Effective NNP N
pain NN i
management NN i
remains VBZ N
a DT N
challenge NN N
for IN N
adolescents NNS p
during IN p
conscious JJ p
burn NN p
wound NN p
care NN p
procedures NNS p
. . p

Virtual JJ i
reality NN i
( ( i
VR NNP i
) ) i
shows VBZ N
promise NN N
as IN N
a DT N
non-pharmacological JJ N
adjunct NN N
in IN N
reducing VBG N
pain NN N
. . N

AIMS VB N
This DT N
study NN N
assessed VBD N
off-the-shelf JJ i
VR NNP i
for IN N
( ( N
1 CD N
) ) N
its PRP$ N
effect NN N
on IN N
reducing VBG N
acute JJ N
pain NN N
intensity NN N
during IN N
adolescent JJ N
burn NN N
wound NN N
care NN N
, , N
and CC N
( ( N
2 CD N
) ) N
its PRP$ N
clinical JJ N
utility NN N
in IN N
a DT N
busy JJ N
hospital NN N
setting NN N
. . N

METHODS NNP N
Forty-one CD p
adolescents NNS p
( ( p
11-17 CD p
years NNS p
) ) p
participated VBD N
in IN N
this DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

Acute NNP N
pain NN N
outcomes NNS N
including VBG N
adolescent JJ N
self-report NN N
, , N
nursing VBG N
staff NN N
behavioral JJ N
observation NN N
, , N
caregiver NN N
observation NN N
and CC N
physiological JJ N
measures NNS N
were VBD N
collected VBN N
. . N

Length NNP N
of IN N
procedure NN N
times NNS N
and CC N
adolescent JJ N
reactions NNS N
were VBD N
also RB N
recorded VBN N
to TO N
inform VB N
clinical JJ N
utility NN N
. . N

RESULTS NNP N
Nursing JJ N
staff NN N
reported VBD N
a DT N
statistically RB N
significant JJ N
reduction NN N
in IN N
pain NN o
scores NNS o
during IN N
dressing VBG N
removal NN N
, , N
and CC N
significantly RB N
less JJR N
rescue JJ o
doses NNS o
of IN o
Entonox NNP o
given VBN N
to TO N
those DT N
receiving VBG N
VR NNP i
, , N
compared VBN N
to TO N
those DT N
receiving VBG N
standard JJ N
distraction NN N
. . N

For IN N
all DT N
other JJ N
pain NN N
outcomes NNS N
and CC N
length NN N
of IN N
treatment NN N
, , N
there EX N
was VBD N
a DT N
trend NN N
for IN N
lower JJR N
pain NN o
scores NNS o
and CC o
treatment NN o
times NNS o
for IN N
those DT N
receiving VBG N
VR NNP i
, , N
but CC N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

CONCLUSION NNP N
Despite IN N
only RB N
minimal JJ N
pain NN N
reduction NN N
achieved VBD N
using VBG N
off-the-shelf JJ N
VR NNP i
, , N
other JJ N
results NNS N
from IN N
this DT N
trial NN N
and CC N
previous JJ N
research NN N
on IN N
younger JJR N
children NNS N
with IN N
burns NNS N
suggest VBP N
a DT N
customized JJ N
, , N
adolescent JJ N
and CC N
hospital JJ N
friendly JJ N
device NN N
may MD N
be VB N
more RBR N
effective JJ N
in IN N
pain NN N
reduction NN N
. . N

-DOCSTART- -X- O O

Breast NNP p
cancer NN p
screening VBG i
in IN N
Sweden NNP p
. . p

The DT N
single JJ N
modality NN N
approach NN N
. . N

Four CD p
population-based JJ p
breast NN p
cancer NN p
screening VBG p
projects NNS p
are VBP p
in IN p
progress NN p
in IN p
Sweden NNP p
, , N
three CD N
of IN N
which WDT N
are VBP N
randomized VBN N
studies NNS N
. . N

Mammography NNP i
is VBZ N
the DT N
only JJ N
screening NN N
method NN N
. . N

51 CD N
% NN N
of IN N
all DT N
carcinomas NN N
detected VBN N
at IN N
the DT N
first JJ N
screening NN N
were VBD N
either RB N
in IN N
situ NN N
or CC N
invasive JJ N
with IN N
a DT N
diameter NN N
of IN N
10 CD N
mm NN N
or CC N
less JJR N
. . N

Axillary JJ o
metastases NNS o
were VBD N
found VBN N
in IN N
16 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

Sensitivity NNP o
was VBD N
over RB N
90 CD N
% NN N
in IN N
all DT N
projects NNS N
. . N

The DT o
ultimate JJ o
aim NN o
of IN o
the DT o
randomized JJ o
projects NNS o
is VBZ o
to TO o
demonstrate VB o
the DT o
effect NN o
of IN o
screening VBG o
on IN o
breast NN o
cancer NN o
mortality NN o
. . o

It PRP N
is VBZ N
estimated VBN N
that IN N
mortality NN o
statistics NNS o
will MD N
reach VB N
significant JJ N
levels NNS N
in IN N
1983. CD N
, , N
-DOCSTART- -X- O O

Mandibular JJ i
advancement NN i
splint NN i
improves VBZ N
indices NNS N
of IN N
obstructive JJ p
sleep NN p
apnoea NN p
and CC p
snoring VBG p
but CC N
side JJ N
effects NNS N
are VBP N
common JJ N
. . N

AIM NNP N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
a DT N
mandibular JJ i
advancement NN i
splint NN i
( ( i
MAS NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
obstructive JJ o
sleep JJ o
apnoea NN o
syndrome NN o
( ( o
OSAS NNP o
) ) o
. . o

METHODS NNP N
Nineteen NNP p
patients NNS p
using VBG p
a DT p
MAS NNP i
for IN p
symptomatic JJ p
OSAS NNP p
underwent NN p
polysomnography NN i
, , p
with IN p
MAS NNP i
use NN p
randomised VBD p
to TO p
one CD p
half NN p
of IN p
the DT p
night NN p
. . p

Indices NNS o
of IN o
snoring VBG o
and CC o
OSAS NNP o
were VBD N
compared VBN N
. . N

Side NNP o
effects NNS o
, , o
compliance NN o
and CC o
treatment NN o
response NN o
were VBD N
evaluated VBN N
by IN N
questionnaire NN N
. . N

RESULTS NNP N
Use NNP N
of IN N
the DT N
MAS NNP i
improved VBD N
total JJ o
respiratory NN o
disturbance NN o
index NN o
( ( o
RDI NNP o
) ) o
from IN N
22.2 CD N
+/- JJ N
19.8 CD N
( ( N
SD NNP N
) ) N
events NNS o
per IN o
hour NN o
to TO N
16.5 CD N
+/- JJ N
21.4/hr CD N
( ( N
p NN N
= RB N
0.03 CD N
) ) N
, , N
supine JJ o
RDI NNP o
( ( N
30.8 CD N
+/- JJ N
23.8/hr CD N
to TO N
18.8 CD N
+/- JJ N
22.1/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
arousal JJ o
index NN o
( ( N
25.2 CD N
+/- JJ N
18.9/hr CD N
to TO N
19.3 CD N
+/- JJ N
14.2/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
and CC N
snoring VBG o
intensity NN o
( ( N
52.7 CD N
+/- JJ N
4.1 CD N
to TO N
50.7 CD N
+/- JJ N
2.7 CD N
dB NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
but CC N
not RB N
total JJ o
snore NN o
frequency NN o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Using VBG N
polysomnographic JJ N
criteria NNS N
, , N
MAS NNP i
treatment NN N
was VBD N
completely RB o
successful JJ o
in IN N
four CD N
( ( N
21 CD N
% NN N
) ) N
patients NNS N
, , N
partially RB o
successful JJ o
in IN N
ten NN N
( ( N
52.6 CD N
% NN N
) ) N
and CC N
a DT N
failure NN o
in IN N
five CD N
( ( N
26.3 CD N
% NN N
) ) N
. . N

Treatment NN N
over IN N
a DT N
median NN N
of IN N
6.5 CD N
weeks NNS N
( ( N
range VB N
2-48 CD N
) ) N
was VBD N
perceived VBN N
as IN N
beneficial JJ N
by IN N
ten NN N
of IN N
eleven JJ N
partners NNS N
. . N

Fifteen JJ p
patients NNS p
( ( p
79 CD p
% NN p
) ) p
reported VBD N
side JJ o
effects NNS o
, , N
9 CD N
( ( N
46 CD N
% NN N
) ) N
did VBD N
not RB N
use VB N
the DT N
device NN N
every DT N
night NN N
and CC N
four CD N
( ( N
21 CD N
% NN N
) ) N
used VBD N
the DT N
device NN N
less JJR N
than IN N
three CD N
nights NNS N
per IN N
week NN N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
the DT N
MAS NNP i
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
indices NNS N
of IN N
OSAS NNP o
and CC o
snoring VBG o
. . o

However RB N
, , N
a DT N
significant JJ N
number NN N
of IN N
patients NNS N
had VBD N
difficulty NN N
tolerating NN N
and CC N
regularly RB N
using VBG N
the DT N
device NN N
. . N

-DOCSTART- -X- O O

[ RB N
Clinical NNP N
study NN N
on IN N
retarding VBG o
aging VBG o
effect NN o
of IN N
tongbu NN N
recipe NN N
to TO N
traditional JJ N
Chinese JJ N
medicine NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
mechanism NN N
of IN N
Tongbu NNP i
No NNP i
. . i

1 CD i
( ( i
TB1 NNP i
, , i
a DT i
prescription NN i
for IN i
reinforcing VBG i
Kidney NNP i
and CC i
Spleen NNP i
, , i
clearing VBG i
up RP i
the DT i
bowel NN i
viscera NN i
to TO i
send VB i
Turbid NNP i
downward NN i
and CC i
regulating NN i
Qi NNP i
and CC i
blood NN i
) ) i
in IN o
retarding VBG o
aging VBG o
. . o

METHODS NNP N
A NNP N
controlled VBD N
, , N
multiple NN N
indexes NNS N
study NN N
was VBD N
conducted VBN N
in IN N
56 CD p
old JJ p
subjects NNS p
randomized VBN p
into IN p
3 CD p
groups NNS p
. . p

RESULTS NNP N
TB1 NNP N
( ( N
containing VBG N
ginseng NN N
leaf NN N
, , N
cistanche NN N
, , N
fleeceflower JJR N
root NN N
, , N
immature NN N
bitter JJ N
orange NN N
, , N
rhubarb NN N
, , N
etc FW N
) ) N
could MD N
improve VB N
various JJ N
symptoms NNS o
of IN o
aging VBG o
, , N
and CC N
had VBD N
the DT N
effect NN N
in IN N
regulating VBG o
immune NN o
and CC o
endocrinal JJ o
function NN o
, , o
scavenging VBG o
free JJ o
radicals NNS o
and CC o
adjusting VBG o
coli JJ o
flora NNS o
. . o

The DT N
effects NNS N
of IN N
TB1 NNP N
and CC N
TB2 NNP N
( ( N
containing VBG N
ginseng NN N
leaf NN N
, , N
cistanche NN N
and CC N
fleeceflower JJR N
root NN N
) ) N
were VBD N
different JJ N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
TB1 NNP N
has VBZ N
a DT N
good JJ N
comprehensive JJ N
effect NN N
in IN N
retarding VBG o
aging NN o
. . o

-DOCSTART- -X- O O

An DT N
evaluation NN N
of IN N
an DT N
adaptive JJ i
automation NN i
system NN i
using VBG N
a DT N
cognitive JJ i
vigilance NN i
task NN i
. . i

The DT N
performance NN N
of IN N
an DT N
adaptive JJ i
automation NN i
system NN i
was VBD N
evaluated VBN N
using VBG N
a DT N
cognitive JJ N
vigilance NN N
task NN N
. . N

Participants NNS p
responded VBD N
to TO N
the DT N
presence NN N
of IN N
a DT N
green JJ i
K NNP i
in IN i
an DT i
array NN i
of IN i
two CD i
, , i
five CD i
, , i
or CC i
nine CD i
distractor NN i
stimuli NNS i
during IN i
a DT i
40-min JJ i
vigil NN i
. . i

The DT N
array NN N
with IN N
the DT N
target NN N
stimulus NN N
was VBD N
presented VBN N
once RB N
each DT N
minute NN N
. . N

Participants NNS p
EEG NNP i
was VBD N
recorded VBN N
and CC N
an DT N
engagement JJ o
index NN o
( ( N
EI NNP N
= VBZ N
20 CD N
x NN N
beta/ NN N
( ( N
alpha JJ N
+ NNP N
theta NN N
) ) N
) ) N
was VBD N
derived VBN N
. . N

In IN N
the DT N
negative JJ N
feedback NN N
condition NN N
, , N
increases VBZ N
in IN N
the DT N
EI NNP o
caused VBD o
the DT o
number NN o
of IN o
stimuli NNS o
in IN o
the DT o
array NN o
to TO o
decrease VB o
while IN N
decreases NNS o
in IN o
the DT o
EI NNP o
caused VBD o
the DT o
number NN o
of IN o
stimuli NNS o
to TO o
increase VB o
. . o

For IN N
the DT N
positive JJ N
feedback NN N
condition NN N
, , N
increases VBZ o
in IN o
the DT o
index NN o
caused VBD o
an DT o
increase NN o
in IN o
the DT o
array NN o
size NN o
( ( o
AS IN o
) ) o
while IN N
decreases NNS o
caused VBD o
a DT o
decrease NN o
in IN o
the DT o
array NN o
size NN o
. . o

Each DT N
experimental JJ N
participant NN p
had VBD p
a DT p
yoked VBN p
control NN p
partner NN p
who WP N
received VBD N
the DT N
same JJ N
pattern NN N
of IN N
changes NNS N
in IN N
array JJ N
irrespective NN N
of IN N
their PRP$ N
engagement JJ N
index NN N
. . N

A DT N
vigilance NN N
decrement NN N
was VBD N
seen VBN N
only RB N
for IN N
the DT N
positive JJ N
feedback NN N
, , N
experimental JJ p
group NN p
. . p

-DOCSTART- -X- O O

Randomized VBN N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
of IN N
methylphenidate NN i
for IN N
attention-deficit/hyperactivity NN N
disorder NN N
symptoms NNS N
in IN p
preschoolers NNS p
with IN p
developmental JJ p
disorders NNS p
. . p

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
short-term JJ N
efficacy NN o
and CC N
safety NN N
of IN N
methylphenidate NN i
( ( i
MPH NNP i
) ) i
to TO N
treat VB N
attention-deficit/hyperactivity JJ N
disorder NN N
( ( N
ADHD NNP N
) ) N
symptoms NNS N
in IN N
an DT N
understudied JJ p
population NN p
of IN p
preschoolers NNS p
with IN p
pervasive JJ p
developmental JJ p
disorder NN p
( ( p
PDD NNP p
) ) p
or CC p
intellectual JJ p
disability NN p
( ( p
ID NNP p
) ) p
. . p

METHODS NNP N
Fourteen NNP p
preschoolers NNS p
with IN p
developmental JJ p
disorders NNS p
( ( p
DD NNP p
, , p
n JJ p
= VBP p
14 CD p
; : p
PDD NNP p
, , p
n JJ p
= VBP p
12 CD p
; : p
ID NNP p
, , p
n JJ p
= NNP p
2 CD p
) ) p
underwent NN N
MPH NNP i
titration NN i
in IN N
a DT N
single-blind JJ N
manner NN N
followed VBN N
by IN N
a DT N
4-week JJ N
double-blind NN N
crossover NN N
phase NN N
. . N

Each DT N
child NN N
was VBD N
administered VBN N
placebo NN i
for IN N
2 CD N
weeks NNS N
and CC N
optimal JJ i
dose NN i
for IN N
2 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Diagnostic NNP o
and CC o
Statistical NNP o
Manual NNP o
of IN o
Mental NNP o
Disorders NNP o
, , o
4 CD o
( ( o
th NN o
) ) o
edition NN o
( ( o
DSM-IV NNP o
) ) o
ADHD NNP o
subscale NN o
of IN o
the DT o
Conners NNP o
' POS o
Parent NN o
Rating VBG o
Scale-Revised JJ o
( ( N
CPRS-R-DSM-IV-ADHD NNP N
) ) N
. . N

RESULTS NNP N
MPH NNP i
improved VBD N
parent-rated JJ o
ADHD NNP o
symptoms NNS o
of IN N
the DT N
preschoolers NNS N
; : N
50 CD N
% NN N
were VBD N
rated VBN N
as IN N
responders NNS N
. . N

The DT N
CPRS-R-DSM-IV-ADHD JJ o
subscale NN o
was VBD N
significant JJ N
for IN N
the DT N
PDD NNP p
subgroup NN p
( ( N
p JJ N
= NN N
0.005 CD N
, , N
Cohen NNP N
d VBZ N
= NNP N
0.97 CD N
) ) N
and CC N
marginally RB N
significant JJ N
for IN N
the DT N
entire JJ N
DD NNP N
sample NN N
( ( N
p JJ N
= NN N
0.08 CD N
, , N
Cohen NNP N
d VBZ N
= NNP N
0.50 CD N
) ) N
. . N

Half NN N
of IN N
the DT N
preschoolers NNS p
experienced VBD N
side JJ o
effects NNS o
with IN N
MPH NNP i
, , N
including VBG N
reports NNS N
of IN N
increased VBN N
stereotypic NN o
behavior NN o
, , o
upset JJ o
stomach NN o
, , o
sleep-related JJ o
difficulties NNS o
, , o
and CC o
emotional JJ o
lability NN o
. . o

One CD N
child NN N
discontinued VBN N
during IN N
titration NN N
due JJ N
to TO N
side VB N
effects NNS N
. . N

CONCLUSION VB N
The DT N
predominant JJ N
direction NN N
of IN N
response NN N
in IN N
these DT N
preschoolers NNS p
with IN p
both DT p
ADHD NNP p
and CC p
PDD/ID NNP p
favored VBD N
MPH NNP i
, , N
even RB N
though IN N
the DT N
response NN N
was VBD N
more RBR N
subtle JJ N
and CC N
variable JJ N
than IN N
in IN N
older JJR N
and CC N
typically RB N
developing VBG N
children NNS N
. . N

Due NNP N
to TO N
high JJ N
rates NNS N
of IN N
adverse JJ N
effects NNS N
, , N
preschoolers NNS N
should MD N
be VB N
monitored VBN N
closely RB N
. . N

-DOCSTART- -X- O O

A DT N
clinical JJ N
trial NN N
of IN N
glutathione NN N
supplementation NN N
in IN N
autism NN p
spectrum NN p
disorders NNS p
. . p

BACKGROUND NNP N
Recent NNP N
evidence NN N
shows VBZ N
that IN N
subjects NNS p
diagnosed VBN p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
have VBP N
significantly RB N
lower JJR N
levels NNS N
of IN N
glutathione NN N
than IN N
typically RB N
developing VBG N
children NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
use NN N
of IN N
two CD N
commonly NNS N
used VBD N
glutathione NN N
supplements NNS N
in IN N
subjects NNS p
diagnosed VBN p
with IN p
an DT p
ASD NNP p
to TO N
determine VB N
their PRP$ N
efficacy NN N
in IN N
increasing VBG N
blood NN o
glutathione NN o
levels NNS o
in IN N
subjects NNS p
diagnosed VBN p
with IN p
an DT p
ASD NNP p
. . p

MATERIAL/METHODS NNP N
The DT N
study NN N
was VBD N
an DT N
eight-week JJ N
, , N
open-label JJ N
trial NN p
using VBG p
oral JJ i
lipoceutical JJ i
glutathione NN i
( ( i
n=13 JJ i
) ) i
or CC i
transdermal JJ i
glutathione NN i
( ( i
n=13 JJ i
) ) i
in IN p
children NNS p
, , p
3-13 CD p
years NNS p
of IN p
age NN p
, , p
with IN p
a DT p
diagnosis NN p
of IN p
an DT p
ASD NNP p
. . p

Subjects NNPS p
underwent JJ p
pre- JJ p
and CC p
post-treatment JJ p
lab NN p
testing VBG p
to TO N
evaluate VB N
plasma NN o
reduced VBN o
glutathione NN o
, , o
oxidized VBD o
glutathione NN o
, , o
cysteine NN o
, , o
taurine NN o
, , o
free JJ o
and CC o
total JJ o
sulfate NN o
, , o
and CC o
whole-blood JJ o
glutathione NN o
levels NNS o
. . o

RESULTS VB N
The DT N
oral JJ N
treatment NN N
group NN N
showed VBD N
significant JJ N
increases NNS N
in IN N
plasma NN o
reduced VBD o
glutathione NN o
, , o
but CC o
not RB o
whole-blood JJ o
glutathione NN o
levels NNS o
following VBG N
supplementation NN N
. . N

Both CC N
the DT N
oral JJ p
and CC p
transdermal JJ p
treatment NN p
groups NNS p
showed VBD N
significant JJ N
increases NNS N
in IN N
plasma NN o
sulfate NN o
, , o
cysteine NN o
, , o
and CC o
taurine NN o
following VBG N
supplementation NN N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
suggest VBP N
that IN N
oral JJ N
and CC N
transdermal JJ N
glutathione NN N
supplementation NN N
may MD N
have VB N
some DT N
benefit NN N
in IN N
improving VBG N
some DT N
of IN N
the DT N
transsulfuration NN N
metabolites VBZ N
. . N

Future JJ N
studies NNS N
among IN N
subjects NNS p
diagnosed VBN p
with IN p
an DT p
ASD NNP p
should MD N
further RB N
explore VB N
the DT N
pharmacokinetics NNS N
of IN N
glutathione NN N
supplementation NN N
and CC N
evaluate VB N
the DT N
potential JJ N
effects NNS N
of IN N
glutathione NN N
supplementation NN N
upon IN N
clinical JJ N
symptoms NNS N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
topical JJ N
pimecrolimus NN i
for IN N
cetuximab-associated JJ p
acnelike JJ p
eruption NN p
. . p

BACKGROUND NNP N
Clinical NNP N
trials NNS N
addressing VBG N
the DT N
acneiform NN N
rash NN N
associated VBN N
with IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
inhibitors NNS N
are VBP N
lacking VBG N
. . N

OBJECTIVE IN N
We PRP N
evaluated VBD N
the DT N
ability NN N
of IN N
topical JJ N
pimecrolimus NN i
to TO N
reduce VB N
the DT N
severity NN N
of IN N
cetuximab-related JJ p
facial JJ p
rash NN p
. . p

METHODS NNP N
In IN p
all DT p
, , p
24 CD p
patients NNS p
with IN p
metastatic JJ p
colorectal JJ p
cancer NN p
with IN p
cetuximab JJ p
facial JJ p
rash NN p
received VBD N
twice RB N
daily JJ N
pimecrolimus NNS i
application NN N
for IN N
5 CD N
weeks NNS N
to TO N
half NN N
of IN N
the DT N
face NN N
. . N

At IN N
baseline NN N
, , N
week NN N
2 CD N
, , N
and CC N
week NN N
5 CD N
, , N
a DT N
dermatologist NN N
performed VBN N
facial JJ N
lesion NN N
counts NNS N
, , N
patients NNS N
reported VBD N
perceived JJ N
severity NN N
of IN N
rash-related JJ N
symptoms NNS N
, , N
and CC N
standardized VBD N
facial JJ N
photographs NN N
were VBD N
obtained VBN N
for IN N
blinded JJ N
evaluation NN N
of IN N
global JJ N
rash NN N
severity NN N
. . N

RESULTS NNP N
Treatment NNP N
sides NNS N
had VBD N
greater JJR N
decrease NN N
in IN N
lesion NN o
counts NNS o
than IN N
observation NN N
sides NNS N
of IN N
face NN N
at IN N
weeks NNS N
2 CD N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
5 CD N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
patients NNS N
' POS N
assessment NN N
of IN N
symptoms NNS N
and CC N
in IN N
review NN N
of IN N
facial JJ N
photographs NN N
for IN N
rash NN o
severity NN o
between IN N
treatment NN N
and CC N
observation NN N
sides NNS N
. . N

LIMITATIONS VB N
This DT N
study NN N
was VBD N
not RB N
placebo JJ N
controlled VBN N
. . N

CONCLUSIONS NNP N
Pimecrolimus NNP i
application NN N
did VBD N
not RB N
translate VB N
into IN N
clinically RB N
meaningful JJ N
benefit NN N
for IN N
patients NNS p
with IN p
cetuximab-related JJ p
facial JJ p
rash NN p
. . p

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
effects NNS N
of IN N
terazosin NN i
and CC N
enalapril NN i
on IN N
laboratory NN N
stress NN N
testing VBG N
blood NN N
pressure NN N
in IN N
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

It PRP N
is VBZ N
the DT N
current JJ N
opinion NN N
that IN N
an DT N
ideal JJ N
antihypertensive JJ i
drug NN i
should MD N
reduce VB N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
not RB N
only RB N
at IN N
rest NN N
but CC N
also RB N
during IN N
stressful JJ N
situations NNS N
. . N

The DT N
current JJ N
study NN N
was VBD N
aimed VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
selective JJ i
alpha NN i
1-adrenergic JJ i
blocker NN i
terazosin NN i
( ( N
5 CD N
mg NN N
once RB N
daily JJ N
) ) N
and CC N
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
enalapril NN i
( ( N
20 CD N
mg NN N
once RB N
daily RB N
) ) N
on IN N
cardiovascular JJ N
response NN N
to TO N
a DT N
set NN N
of IN N
standardized JJ N
laboratory NN N
stressors NNS N
, , N
such JJ N
as IN N
mental JJ N
arithmetic JJ N
, , N
handgrip JJ N
test NN N
and CC N
cycle NN N
ergometry NN N
, , N
in IN N
a DT N
group NN p
of IN p
16 CD p
essential JJ p
hypertensive JJ p
patients NNS p
. . p

The DT N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
trial NN N
preceded VBN N
by IN N
a DT N
placebo JJ i
run-in JJ N
period NN N
. . N

Terazosin NNP i
and CC i
enalapril VB i
had VBD N
a DT N
comparable JJ N
effect NN N
on IN N
resting VBG o
BP NNP o
, , o
reducing VBG o
systolic JJ o
( ( o
SBP NNP o
) ) o
and CC o
diastolic JJ o
( ( o
DBP NNP o
) ) o
blood NN o
pressure NN o
from IN N
159.5 CD N
+/- JJ N
13.9/101.6 CD N
+/- JJ N
8.8 CD N
mm NN N
Hg NNP N
during IN N
placebo NN N
by IN N
7.8 CD N
% NN N
/6.7 CC N
% NN N
and CC N
by IN N
11.3 CD N
% NN N
/10.2 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
response NN o
rate NN o
to TO N
the DT N
two CD N
treatments NNS N
was VBD N
approximately RB N
the DT N
same JJ N
, , N
being VBG N
69 CD N
% NN N
and CC N
75 CD N
% NN N
after IN N
terazosin NN i
and CC N
enalapril NN i
, , N
respectively RB N
. . N

During IN N
mental JJ N
arithmetic JJ N
, , N
from IN N
an DT N
average NN N
of IN N
181.6 CD N
+/- JJ N
17.8/118.6 CD N
+/- JJ N
11.5 CD N
mm NN N
Hg NNP N
during IN N
placebo NN i
, , N
BP NNP o
was VBD N
reduced VBN N
by IN N
11.5 CD N
% NN N
/7.9 CD N
% NN N
after IN N
terazosin NN i
and CC N
by IN N
13.6 CD N
% NN N
/8.5 CD N
% NN N
after IN N
enalapril NN i
; : i
during IN N
handgrip NN N
test NN N
, , N
BP NNP o
decreased VBD N
from IN N
207.2 CD N
+/- JJ N
22.2/142.2 CD N
+/- JJ N
13.6 CD N
mm NN N
Hg NNP N
by IN N
7.3 CD N
% NN N
/8.4 CD N
% NN N
after IN N
terazosin NN i
and CC N
by IN N
7.7 CD N
% NN N
/7.1 CD N
% NN N
after IN N
enalapril NN i
; : i
finally RB N
, , N
during IN N
cycle NN N
ergometry NN N
, , N
terazosin NN N
and CC N
enalapril NN N
lowered VBN N
BP NNP o
by IN N
5.4 CD N
% NN N
/6.7 CC N
% NN N
and CC N
7 CD N
% NN N
/3.1 CD N
% NN N
, , N
respectively RB N
, , N
from IN N
a DT N
placebo NN i
value NN N
of IN N
215.5 CD N
+/- JJ N
17.3/127.6 CD N
+/- JJ N
11.2 CD N
. . N

No DT N
significant JJ N
difference NN N
in IN N
antihypertensive JJ N
efficacy NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
drugs NNS N
, , N
either RB N
at IN N
rest NN N
and CC N
during IN N
stress JJ N
testing VBG N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Early RB N
versus NN N
late JJ N
hCG NN i
administration NN i
to TO N
trigger VB N
ovulation NN N
in IN N
mild NN N
stimulated VBN N
IUI NNP N
cycles NNS N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
verify VB N
non-inferiority NN N
of IN N
the DT N
clinical JJ N
pregnancy NN N
rate NN N
of IN N
Early NNP i
hCG NN i
administration NN i
( ( N
leading VBG N
follicle NN N
sizes NNS N
within IN N
16.0-16.9 JJ N
mm NN N
in IN N
diameter NN N
) ) N
compared VBN N
to TO N
Late NNP i
hCG NN i
administration NN i
( ( N
leading VBG N
follicle NN N
sizes NNS N
within IN N
18.0-18.9 JJ N
mm NN N
in IN N
diameter NN N
) ) N
. . N

STUDY NNP N
DESIGN NNP N
Prospective NNP N
randomized VBD N
trial NN N
. . N

Six CD p
hundred CD p
and CC p
twelve VB p
infertile JJ p
women NNS p
candidates NNS p
for IN p
intrauterine JJ p
insemination NN p
( ( p
IUI NNP p
) ) p
received VBD N
HP-hMG JJ i
75 CD N
IU/day NNP N
SC NNP N
from IN N
cycle NN N
days NNS N
4 CD N
to TO N
8 CD N
and CC N
then RB N
as IN N
per IN N
ovarian JJ N
response NN N
. . N

Ovulation NN N
was VBD N
randomly RB N
triggered VBN N
( ( N
hCG JJ N
5000 CD N
IU NNP N
, , N
IM NNP N
) ) N
when WRB N
the DT N
leading VBG N
follicle NN N
diameter NN N
ranged VBD N
between IN N
either CC N
16.0 CD N
and CC N
16.9 CD N
mm NN N
( ( N
Early JJ N
hCG NN i
group NN N
, , N
n=227 RB N
) ) N
or CC N
18.0 CD N
and CC N
18.9 CD N
mm NNS N
( ( N
Late JJ N
hCG NN N
group NN N
, , N
n=207 NN N
) ) N
and CC N
IUI NNP N
was VBD N
performed VBN N
approximately RB N
36 CD N
h NN N
later RB N
. . N

RESULTS NNP N
Whereas NNP N
population NN o
and CC o
sperm JJ o
characteristics NNS o
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
, , N
the DT N
number NN o
of IN o
follicles NNS o
? . N
14 CD N
mm NN N
in IN N
diameter NN N
( ( N
P NNP N
< NNP N
0.007 CD N
) ) N
and CC o
serum JJ o
estradiol NN o
levels NNS o
( ( o
P NNP N
< NNP N
0.001 CD N
) ) N
on IN N
the DT N
day NN N
of IN N
hCG NN i
were VBD i
lower JJR N
in IN N
the DT N
Early JJ N
versus NN N
the DT N
Late NNP i
hCG NN i
groups NNS i
. . N

Clinical NNP N
( ( N
11.9 CD N
% NN N
versus IN N
12.1 CD N
% NN N
) ) N
and CC N
ongoing VBG N
( ( N
11.0 CD N
% NN N
versus IN N
8.6 CD o
% NN o
) ) o
pregnancy NN o
rates NNS o
per IN o
randomized VBN p
women NNS p
were VBD p
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
and CC N
statistical JJ N
non-inferiority NN N
of IN N
clinical JJ o
and CC o
ongoing JJ o
pregnancy NN o
rates NNS o
was VBD N
demonstrated VBN N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN i
hCG NN i
administered VBD i
when WRB N
the DT N
largest JJS N
follicle NN N
size NN N
reaches VBZ N
16.0-16.9 JJ N
mm NN N
leads VBZ N
to TO N
similar JJ N
clinical JJ N
and CC N
ongoing JJ N
pregnancy NN N
rates NNS N
as IN N
when WRB N
it PRP N
reaches VBZ N
18.0-18.9 JJ N
mm NN N
in IN N
IUI NNP N
cycles NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
of IN N
continuous JJ N
subcutaneous JJ N
insulin NN i
infusion NN N
and CC N
intensive JJ N
injection NN N
therapy NN N
in IN N
type NN p
1 CD p
diabetes NNS p
for IN p
patients NNS p
with IN p
long-standing JJ p
poor JJ p
glycemic JJ p
control NN p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
in IN N
a DT N
randomized JJ N
crossover NN N
trial NN N
the DT N
efficacy NN N
of IN N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
in IN N
improving VBG N
glycemic JJ o
control NN o
and CC o
health-related JJ o
quality NN o
of IN o
life NN o
in IN N
type JJ p
1 CD p
diabetic JJ p
patients NNS p
with IN p
long-standing JJ p
poor JJ p
glycemic JJ p
control NN p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
79 CD p
patients NNS p
in IN p
11 CD p
Dutch NN p
centers NNS p
were VBD N
randomized VBN N
to TO N
16 CD N
weeks NNS N
of IN N
continuous JJ i
subcutaneous JJ i
insulin NN i
infusion NN i
followed VBN i
by IN i
16 CD i
weeks NNS i
intensive JJ i
injection NN i
therapy NN i
or CC i
the DT i
reverse JJ i
order NN i
. . i

Glycemic NNP N
control NN N
was VBD N
assessed VBN N
by IN N
HbA NNP N
( ( N
1c CD N
) ) N
, , N
self-reported JJ N
hypoglycemic JJ N
events NNS N
, , N
and CC N
blood NN N
glucose JJ N
memory NN N
meter NN N
read VBD N
outs NNS N
. . N

Changes NNS N
in IN N
quality NN o
of IN o
life NN o
were VBD N
assessed VBN N
by IN N
self-report JJ N
questionnaires NNS N
administered VBN N
at IN N
baseline NN N
and CC N
16 CD N
weeks NNS N
. . N

RESULTS NNP N
As IN N
the DT N
drop-out NN N
rate NN N
after IN N
crossover NN N
was VBD N
high JJ N
( ( N
17 CD N
of IN N
79 CD N
patients NNS N
[ JJ N
22 CD N
% NN N
] NN N
) ) N
, , N
we PRP N
analyzed VBD N
the DT N
trial NN N
as IN N
a DT N
parallel JJ N
clinical JJ N
trial NN N
, , N
using VBG N
data NNS N
of IN N
the DT N
first JJ N
half NN N
of IN N
the DT N
crossover NN N
phase NN N
only RB N
. . N

At IN N
16 CD N
weeks NNS N
, , N
mean JJ o
HbA NNP o
( ( o
1c CD o
) ) o
was VBD N
0.84 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-1.31 NNP N
to TO N
-0.36 VB N
) ) N
lower JJR N
in IN N
the DT N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
group NN N
compared VBN N
with IN N
the DT N
insulin NN i
injection NN N
group NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Stability NN o
of IN o
blood NN o
glucose JJ o
self-measurement JJ o
values NNS o
, , N
expressed VBD N
as IN N
SD NNP N
of IN N
the DT N
nine-point JJ N
blood NN N
glucose NN N
profiles NNS N
, , N
improved VBN N
in IN N
the DT N
insulin NN N
pump NN N
group NN N
by IN N
29.3 CD N
+/- JJ N
41.1 CD N
vs. FW N
8.2 CD N
+/- JJ N
36.5 CD N
% NN N
in IN N
the DT N
injection NN N
group NN N
( ( N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

The DT N
number NN o
of IN o
mild JJ o
hypoglycemic JJ o
episodes NNS o
per IN N
patient-week NN N
was VBD N
0.99 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.11-1.87 NN N
) ) N
higher JJR N
in IN N
the DT N
insulin NN N
pump NN N
group NN N
( ( N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

Weight NNP o
gain NN o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Scores NNS o
on IN o
the DT o
Short-Form JJ o
36-Item JJ o
subscales NNS o
'general POS o
health NN o
' '' o
and CC o
'mental JJ o
health NN o
' '' o
improved VBN N
in IN N
the DT N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
group NN N
, , N
compared VBN N
with IN N
stable JJ N
values NNS N
in IN N
the DT N
injection NN N
group NN N
( ( N
P NNP N
= NNP N
0.048 CD N
and CC N
0.050 CD N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Continuous NNP N
subcutaneous JJ N
insulin NN i
infusion NN N
improves VBZ N
glycemic JJ N
control NN N
and CC N
some DT N
aspects NNS N
of IN N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
patients NNS p
with IN p
a DT p
history NN p
of IN p
long-term JJ p
poor JJ p
glycemic JJ p
control NN p
. . p

-DOCSTART- -X- O O

Naltrexone NNP i
plasma NN N
levels NNS N
, , N
clinical JJ N
response NN N
and CC N
effect NN N
on IN N
weight NN N
in IN N
autistic JJ p
children NNS p
. . p

This DT N
research NN N
measured VBD N
naltrexone NN i
levels NNS N
in IN N
plasma NN N
, , N
to TO N
assess VB N
the DT N
relationship NN N
between IN N
behavioral JJ N
response NN N
to TO N
naltrexone CD i
and CC N
plasma NN N
levels NNS N
, , N
and CC N
the DT N
effects NNS N
of IN N
naltrexone NN i
on IN N
weight NN N
in IN N
hospitalized VBN p
autistic JJ p
children NNS p
( ( p
n JJ p
= NNP p
41 CD p
) ) p
. . p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
parallel JJ N
groups NNS N
design NN N
with IN i
fixed JJ i
dose NN i
was VBD i
used VBN i
, , i
with IN i
random JJ i
assignment NN i
to TO i
naltrexone CD i
or CC i
placebo VB i
. . i

Drug NNP o
plasma NN o
levels NNS o
were VBD N
analyzed VBN N
by IN N
gas NN i
chromatography/mass NN i
spectrometry NN i
, , i
and CC i
weights NNS i
were VBD i
obtained VBN i
weekly RB i
. . i

Naltrexone NN i
levels NNS N
measured VBN N
in IN N
17 CD p
children NNS p
ranged VBD N
from IN N
0.12 CD N
to TO N
5.60 CD N
ng/mL NNS N
( ( N
mean JJ N
= NN N
0.71 CD N
, , N
standard JJ N
error NN N
of IN N
the DT N
mean JJ N
= NNP N
0.32 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
relationship NN N
between IN N
plasma NN N
levels NNS N
and CC N
age NN N
, , N
level NN N
of IN N
intellectual JJ N
functioning NN N
, , N
scores NNS N
on IN N
the DT N
14 CD p
selected VBD p
Children NNP o
's POS o
Psychiatric NNP o
Rating NNP o
Scale NNP o
( ( o
CPRS NNP o
) ) o
items NNS o
, , o
Clinical NNP o
Global NNP o
Impressions NNP o
, , o
Global NNP o
Clinical NNP o
Consensus NNP o
, , o
and CC o
the DT o
CPRS NNP o
hyperactivity NN o
factor NN o
. . o

There EX N
was VBD N
a DT N
trend NN N
( ( N
p JJ N
= NNP N
.06 NNP N
) ) N
for IN N
children NNS N
receiving VBG N
naltrexone NN N
in IN N
the DT N
highest JJS N
weight NN N
percentile NN N
( ( N
> CD N
or CC N
= VB N
90th CD N
) ) N
to TO N
lose VB N
weight NN N
( ( N
mean JJ N
= NNP N
-0.42 NNP N
kg NN N
) ) N
but CC N
this DT N
was VBD N
not RB N
the DT N
case NN N
for IN N
those DT N
in IN N
the DT N
lower JJR N
weight NN N
percentiles NNS N
( ( N
mean JJ N
= NNP N
+0.03 NNP N
kg NN N
) ) N
. . N

-DOCSTART- -X- O O

Predictors NNS N
of IN N
response NN N
to TO N
ziprasidone NN i
: : i
results NNS N
from IN N
a DT N
6-week JJ N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
for IN N
acute JJ p
depressive JJ p
mixed JJ p
state NN p
. . p

INTRODUCTION NNP N
The DT N
present JJ N
study NN N
is VBZ N
aimed VBN N
at IN N
investigating VBG N
possible JJ N
predictors NNS N
of IN N
response NN N
to TO N
ziprasidone NN N
in IN N
a DT N
sample NN N
of IN N
patients NNS p
with IN p
mixed JJ p
depressive JJ p
state NN p
. . p

METHODS NNP N
72 CD p
patients NNS p
were VBD p
randomized VBN p
to TO N
either DT N
ziprasidone NN i
or CC i
placebo NN i
and CC N
treated VBD N
prospectively RB N
for IN N
6 CD N
weeks NNS N
. . N

The DT N
clinical JJ N
response NN N
and CC N
remission NN N
were VBD N
defined VBN N
with IN N
various JJ N
clinical JJ N
variables NNS N
including VBG N
Montgomery NNP o
Asberg NNP o
Depression NNP o
Rating NNP o
Scale NNP o
. . o

Further NNP N
outcome NN N
measures NNS N
included VBD N
predictors NNS N
of IN N
remission NN o
and CC N
other JJ N
clinical JJ N
variables NNS N
over IN N
time NN N
. . N

RESULTS NNP N
None NN N
of IN N
the DT N
variables NNS N
under IN N
investigation NN N
were VBD N
significantly RB N
associated VBN N
with IN N
response NN o
or CC o
remission NN o
at IN N
6 CD N
weeks NNS N
( ( N
all DT N
p-values NNS N
> VBP N
0.003 CD N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Further NNP N
investigations NNS N
are VBP N
warranted VBN N
due JJ N
to TO N
clear JJ N
limitations NNS N
, , N
mostly RB N
small JJ N
sample NN N
size NN N
and CC N
use NN N
of IN N
concomitant JJ N
medications NNS N
. . N

-DOCSTART- -X- O O

Reaching VBG N
out RP N
, , N
inviting VBG N
back RB N
: : N
using VBG N
Interactive NNP i
voice NN i
response NN i
( ( i
IVR NNP i
) ) i
technology NN i
to TO N
recycle VB N
relapsed JJ p
smokers NNS p
back RB N
to TO N
Quitline NNP i
treatment NN i
-- : i
a DT i
randomized JJ N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Tobacco NNP N
dependence NN N
is VBZ N
a DT N
chronic JJ N
, , N
relapsing VBG N
condition NN N
that WDT N
typically RB N
requires VBZ N
multiple JJ N
quit NN N
attempts NNS N
and CC N
extended VBD N
treatment NN N
. . N

When WRB N
offered VBD N
the DT N
opportunity NN N
, , N
relapsed VBN N
smokers NNS N
are VBP N
interested JJ N
in IN N
recycling VBG N
back RB N
into IN N
treatment NN N
for IN N
a DT N
new JJ N
, , N
assisted VBN N
quit NN N
attempt NN N
. . N

This DT N
manuscript NN N
presents VBZ N
the DT N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
testing VBG N
the DT N
efficacy NN N
of IN N
interactive JJ i
voice NN i
response NN i
( ( i
IVR NNP i
) ) i
in IN N
recycling VBG N
low JJ p
income NN p
smokers NNS p
who WP p
had VBD p
previously RB p
used VBN p
quitline NN i
( ( i
QL NNP i
) ) i
support NN i
back RB N
to TO N
QL NNP N
support NN N
for IN N
a DT N
new JJ N
quit NN N
attempt NN N
. . N

METHODS NNP N
A NNP p
sample NN p
of IN p
2985 CD p
previous JJ p
QL NNP p
callers NNS p
were VBD N
randomized VBN N
to TO N
either DT N
receive JJ N
IVR NNP i
screening NN i
for IN i
current JJ i
smoking NN i
( ( i
control VB i
group NN i
) ) i
or CC N
IVR NNP i
screening VBG i
plus CC i
an DT i
IVR NNP i
intervention NN i
. . i

The DT N
IVR NNP i
intervention NN i
consists VBZ N
of IN N
automated JJ N
questions NNS N
to TO N
identify VB N
and CC N
address VB N
barriers NNS N
to TO N
re-cycling NN N
in IN N
QL NNP N
support NN N
, , N
followed VBN N
by IN N
an DT N
offer NN N
to TO N
be VB N
transferred VBN N
to TO N
the DT N
QL NNP N
and CC N
reinitiate VB N
treatment NN N
. . N

Re-enrollment JJ N
in IN N
QL NNP N
services NNS N
for IN N
both DT N
groups NNS N
was VBD N
documented VBN N
. . N

RESULTS VB N
The DT N
IVR NNP i
system NN i
successfully RB o
reached VBD o
715 CD N
( ( N
23.9 CD N
% NN N
) ) N
former JJ N
QL NNP N
participants NNS N
. . N

Of IN N
those DT N
, , N
27 CD N
% NN N
( ( N
194/715 CD N
) ) N
reported VBD N
to TO N
the DT N
IVR NNP i
system NN i
that IN N
they PRP N
had VBD N
quit NN o
smoking NN o
and CC N
were VBD N
therefore RB N
excluded VBN N
from IN N
the DT N
study NN N
and CC N
analysis NN N
. . N

The DT N
trial NN N
's POS N
final JJ N
sample NN N
was VBD N
composed VBN N
of IN N
521 CD N
current JJ N
smokers NNS N
. . N

The DT N
re-enrollment JJ o
rate NN o
was VBD N
3.3 CD N
% NN N
for IN N
the DT N
control NN N
group NN N
and CC N
28.2 CD N
% NN N
for IN N
the DT N
intervention NN N
group NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Logistic JJ N
regression NN N
results NNS N
indicated VBD N
an DT N
11.2 CD N
times NNS N
higher JJR N
odds NNS N
for IN N
re-enrollment NN N
of IN N
the DT N
intervention NN N
group NN N
than IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Results NNS o
did VBD o
not RB o
vary JJ o
by IN o
gender NN o
, , o
race NN o
, , o
ethnicity NN o
, , o
or CC o
level NN o
of IN o
education NN o
, , N
however RB N
recycled JJ o
smokers NNS o
were VBD o
older JJR o
( ( N
Mean NNP N
= NNP N
45.2 CD N
; : N
SD NNP N
= NNP N
11.7 CD N
) ) N
than IN N
smokers NNS N
who WP N
declined VBD N
a DT N
new JJ N
treatment NN N
cycle NN N
( ( N
Mean NNP N
= NNP N
41.8 CD N
; : N
SD NNP N
= NNP N
13.2 CD N
) ) N
; : N
( ( N
p VB N
= RB N
0.013 CD N
) ) N
. . N

The DT N
main JJ N
barriers NNS N
reported VBD N
for IN N
not RB N
engaging VBG N
in IN N
a DT N
new JJ N
treatment NN N
cycle NN N
were VBD N
low JJ N
self-efficacy NN o
and CC o
lack NN o
of IN o
interest NN o
in IN N
quitting VBG N
. . N

After IN N
delivering VBG N
IVR NNP i
messages NNS i
targeting VBG N
these DT N
reported VBN N
barriers NNS N
, , N
32 CD N
% NN N
of IN N
the DT N
smokers NNS N
reporting VBG N
low JJ o
self-efficacy NN o
and CC N
4.8 CD N
% NN N
of IN N
those DT N
reporting VBG N
lack NN N
of IN N
interest NN N
in IN N
quitting VBG N
re-engaged JJ N
in IN N
a DT N
new JJ N
QL NNP N
treatment NN N
cycle NN N
. . N

CONCLUSION NNP N
Proactive NNP i
IVR NNP i
outreach NN i
is VBZ N
a DT N
promising JJ N
tool NN N
to TO N
engage VB N
low JJ N
income NN N
, , N
relapsed VBD N
smokers NNS N
back RB N
into IN N
a DT N
new JJ N
cycle NN N
of IN N
treatment NN N
. . N

Integration NN N
of IN N
IVR NNP i
intervention NN N
for IN N
recycling VBG N
smokers NNS p
with IN p
previous JJ p
QL NNP p
treatment NN p
has VBZ N
the DT N
potential JJ N
to TO N
decrease VB N
tobacco-related JJ N
disparities NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
Identifier NNP N
: : N
NCT01260597 NN N
. . N

-DOCSTART- -X- O O

Predictors NNS N
of IN N
local JJ N
adverse JJ N
effects NNS N
caused VBN N
by IN N
topical JJ N
tretinoin NN i
cream NN N
0?1 CD N
% NN N
in IN N
the DT p
Veterans NNP p
Affairs NNP p
Topical NNP p
Tretinoin NNP p
Chemoprevention NNP p
trial NN p
. . p

BACKGROUND NNP N
Topical NNP i
tretinoin NN i
is VBZ N
commonly RB N
prescribed VBN N
, , N
but CC N
its PRP$ N
frequent JJ N
adverse JJ N
effects NNS N
are VBP N
barriers NNS N
to TO N
use VB N
. . N

Predictors NNS N
of IN N
resistance NN N
or CC N
susceptibility NN N
to TO N
retinoid VB N
irritation NN N
are VBP N
not RB N
known VBN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
baseline JJ N
patient NN N
characteristics NNS N
associated VBN N
with IN N
adverse JJ N
effects NNS N
of IN N
topical JJ N
tretinoin NN N
. . N

METHODS NNP p
This DT p
cohort NN p
study NN p
used VBN p
data NNS p
collected VBD p
from IN p
324 CD p
participants NNS p
in IN p
the DT p
Veterans NNP p
Affairs NNP p
Topical NNP p
Tretinoin NNP p
Chemoprevention NNP p
trial NN p
who WP p
were VBD p
randomized VBN p
to TO p
apply VB i
tretinoin JJ i
cream NN i
on IN i
the DT i
face NN i
and CC i
ears NNS i
. . i

Univariate NNP N
and CC N
multivariate VB N
logistic JJ N
regression NN N
models NNS N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
associations NNS N
between IN N
baseline NN N
characteristics NNS N
and CC N
local JJ N
adverse JJ N
effects NNS N
. . N

RESULTS NNP N
One CD N
hundred CD N
and CC N
ninety-seven JJ N
patients NNS N
( ( N
61 CD N
% NN N
of IN N
those DT N
randomized VBN N
to TO N
tretinoin VB N
) ) N
reported VBD o
local JJ o
adverse JJ o
effects NNS o
within IN N
6 CD N
months NNS N
. . N

Clinical JJ N
signs NNS N
of IN o
severe JJ o
photodamage NN o
at IN N
baseline NN N
[ NNP N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
0?15 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0?04-0?54 NN N
] NN N
and CC N
history NN o
of IN o
acne NN o
( ( o
OR CC o
0?46 CD N
, , N
95 CD N
% NN N
CI NNP N
0?27-0?77 NN N
) ) N
were VBD N
associated VBN N
with IN N
a DT N
decreased JJ N
risk NN N
of IN N
adverse JJ o
effects NNS o
to TO o
tretinoin VB o
. . N

The DT N
use NN N
of IN N
other JJ N
topical JJ N
medications NNS N
at IN N
enrolment NN N
( ( N
OR CC N
1?88 CD N
, , N
95 CD N
% NN N
CI NNP N
1?15-3?08 CD N
) ) N
predicted VBD N
an DT N
increase NN N
in IN o
adverse JJ o
effects NNS o
. . o

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
population NN N
, , N
the DT N
common JJ N
indications NNS N
of IN N
topical JJ N
tretinoin NN N
treatment NN N
were VBD N
associated VBN N
with IN N
lower JJR N
risks NNS o
of IN o
adverse JJ o
effects NNS o
. . o

The DT N
concurrent NN N
use NN N
of IN N
other JJ N
topical JJ N
medications NNS N
may MD N
worsen VB N
irritation NN N
caused VBN N
by IN N
tretinoin NN N
. . N

-DOCSTART- -X- O O

The DT N
experience NN N
of IN N
pleasure NN N
before IN N
and CC N
after IN N
hearing VBG i
rehabilitation NN i
. . i

Hearing NNP p
loss NN p
may MD N
lead VB N
to TO N
major JJ N
changes NNS N
in IN N
the DT N
social JJ N
and CC N
emotional JJ N
aspects NNS N
of IN N
daily JJ N
life NN N
. . N

This DT N
follow-up JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
hearing-aid NN i
use NN N
on IN N
emotional JJ N
experience NN N
in IN N
adults NNS p
with IN p
hearing VBG p
impairment NN p
. . p

Thirteen JJ p
individuals NNS p
with IN p
impaired JJ p
hearing NN p
were VBD p
tested VBN p
before IN p
and CC p
after IN p
6 CD p
months NNS p
of IN p
hearing-aid JJ i
use NN i
, , N
and CC N
were VBD N
compared VBN N
with IN N
19 CD p
individuals NNS p
who WP p
had VBD p
worn VBN p
hearing NN p
aids NNS p
for IN p
many JJ p
years NNS p
. . p

The DT N
participants NNS N
reported VBD N
their PRP$ N
daily JJ o
emotional JJ o
experiences NNS o
, , N
by IN N
completing VBG N
questionnaires NNS o
relating VBG o
to TO o
sensory JJ o
and CC o
social JJ o
pleasure NN o
. . o

After IN N
6 CD N
months NNS N
of IN N
hearing-aid JJ i
use NN N
, , N
individuals NNS N
experienced VBD N
more JJR N
physical JJ o
and CC o
social JJ o
pleasure NN o
, , N
whereas JJ N
individuals NNS N
using VBG N
hearing NN N
aids NNS N
for IN N
long JJ N
periods NNS N
of IN N
time NN N
reported VBD N
similar JJ N
levels NNS N
of IN N
pleasure NN N
at IN N
the DT N
beginning NN N
and CC N
at IN N
the DT N
end NN N
of IN N
a DT N
6-month JJ N
interval NN N
. . N

The DT N
participants NNS N
also RB N
performed VBD N
a DT N
visual JJ N
task NN N
, , N
in IN N
which WDT N
they PRP N
rated VBD N
the DT N
intensity NN o
of IN o
pleasure NN o
they PRP o
experienced VBD o
in IN o
response NN o
to TO o
emotionally RB o
positive JJ o
and CC o
neutral JJ o
pictures NNS o
differing VBG o
in IN o
luminance NN o
contrast NN o
. . o

In IN N
this DT N
task NN N
, , N
pleasure NN N
typically RB N
decreases VBZ N
with IN N
decreasing VBG N
contrast NN N
of IN N
the DT N
positive JJ N
images NNS N
displayed VBN N
. . N

Once IN N
they PRP N
had VBD N
been VBN N
fitted VBN N
with IN N
hearing NN N
aids NNS N
, , N
the DT N
participants NNS N
reported VBD N
lower JJR N
levels NNS o
of IN o
pleasure NN o
, , N
especially RB N
at IN N
low JJ N
contrast NN N
. . N

These DT N
findings NNS N
highlight VBD N
that IN N
the DT N
anhedonia NN o
scales VBZ o
provide VBP N
a DT N
measure NN N
sensitive JJ N
to TO N
emotional JJ N
improvements NNS N
that WDT N
accompany VBP N
the DT N
partial JJ N
restoration NN N
of IN N
hearing VBG N
function NN N
, , N
although IN N
these DT N
scales NNS N
were VBD N
not RB N
specifically RB N
designed VBN N
for IN N
hearing-impaired JJ N
populations NNS N
. . N

In IN N
contrast NN N
, , N
the DT N
surprising JJ N
decrease NN N
in IN N
pleasure NN N
ratings NNS N
for IN N
pictures NNS N
after IN N
the DT N
introduction NN N
of IN N
hearing-aid JJ i
use NN N
may MD N
be VB N
because IN N
of IN N
the DT N
compensation NN N
of IN N
hearing VBG N
loss NN N
by IN N
changes NNS N
in IN N
visual JJ N
attention NN N
functions NNS N
. . N

-DOCSTART- -X- O O

Perioperative JJ i
blood NN i
transfusions NNS i
, , i
with IN i
or CC i
without IN i
allogeneic JJ i
leucocytes NNS i
, , N
relate NN N
to TO N
survival VB o
, , N
not RB N
to TO N
cancer NN o
recurrence NN o
. . o

BACKGROUND NNP N
Perioperative NNP i
blood NN i
transfusions NNS i
are VBP N
reported VBN N
to TO N
be VB N
related VBN N
to TO N
cancer NN o
recurrence NN o
and CC N
reduced JJ o
survival NN o
. . o

Different NNP N
underlying VBG N
mechanisms NNS N
have VBP N
been VBN N
proposed VBN N
, , N
and CC N
allogeneic JJ N
leucocytes NNS N
in IN N
transfused JJ N
blood NN N
have VBP N
been VBN N
suggested VBN N
to TO N
contribute VB N
to TO N
this DT N
phenomenon NN N
. . N

METHODS NNP N
Packed VBD i
red JJ i
cells NNS i
without IN i
buffy NN i
coat NN i
( ( i
PC NNP i
group NN i
) ) i
were VBD i
compared VBN i
with IN i
filtered JJ i
, , i
leucoreduced VBD i
, , i
red JJ i
cells NNS i
( ( i
LD NNP i
group NN i
) ) i
in IN N
a DT N
randomized JJ N
trial NN p
of IN p
697 CD p
patients NNS p
with IN p
colorectal JJ p
carcinoma NN p
. . p

Five-year JJ o
survival NN o
and CC o
cancer NN o
recurrence NN o
rates NNS o
were VBD N
determined VBN N
, , N
with IN N
special JJ N
emphasis NN N
on IN N
the DT N
location NN o
of IN o
recurrence NN o
. . o

RESULTS VB N
The DT N
intention-to-treat JJ N
analysis NN N
showed VBD N
a DT N
survival JJ o
rate NN o
of IN N
63.6 CD N
per IN N
cent NN N
in IN N
the DT N
PC NN N
group NN N
and CC N
65.3 CD N
per IN N
cent NN N
in IN N
the DT N
LD NNP N
group NN N
( ( N
P NNP N
= NNP N
0.69 CD N
) ) N
, , N
with IN N
recurrence NN o
rates NNS o
of IN N
27.8 CD N
and CC N
27.9 CD N
per IN N
cent NN N
respectively RB N
. . N

The DT N
observational JJ N
analysis NN N
showed VBD N
a DT N
significant JJ N
difference NN o
in IN o
survival NN o
between IN N
transfused VBN N
and CC N
non-transfused JJ N
patients NNS N
( ( N
59.6 CD N
versus NN N
72.9 CD N
per IN N
cent NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
difference NN o
in IN o
cancer NN o
recurrence NN o
rate NN o
between IN N
transfused VBN N
and CC N
non-transfused JJ N
patients NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
29.8 CD N
versus NN N
24.3 CD N
per IN N
cent NN N
; : N
P NNP N
= NNP N
0.13 CD N
) ) N
. . N

Local JJ o
recurrences NNS o
were VBD N
more RBR N
frequent JJ N
in IN N
transfused JJ N
than IN N
non-transfused JJ N
patients NNS N
( ( N
11.9 CD N
versus NN N
7.6 CD N
per IN N
cent NN N
; : N
P NNP N
= NNP N
0.09 CD N
) ) N
. . N

CONCLUSION NNP N
Leucocyte NNP N
depletion NN N
of IN N
perioperative NN i
transfused VBN i
blood NN i
has VBZ N
no DT N
effect NN N
on IN N
long-term JJ o
survival NN o
and/or NN o
cancer NN o
recurrence NN o
. . o

Perioperative JJ N
blood NN N
transfusions NNS N
are VBP N
associated VBN N
with IN N
impaired JJ N
survival NN N
, , N
but CC N
not RB N
with IN N
cancer NN N
recurrence NN N
. . N

The DT N
slight JJ N
increase NN N
in IN N
local JJ N
recurrence NN o
rate NN o
in IN N
transfused JJ p
patients NNS p
appears VBZ N
to TO N
be VB N
related VBN N
to TO N
complicated VBN N
, , N
in IN N
particular JJ N
rectal NN N
, , N
surgery NN N
. . N

-DOCSTART- -X- O O

Do VB N
physicians NNS p
' POS p
implicit JJ N
views NNS N
of IN N
African JJ N
Americans NNPS N
affect VBP N
clinical JJ N
decision NN N
making NN N
? . N
BACKGROUND NNP N
Total NNP i
knee FW i
replacement NN i
( ( i
TKR NNP i
) ) i
is VBZ N
a DT N
cost-effective JJ N
treatment NN N
option NN N
for IN N
severe JJ N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
. . N

While IN N
prevalence NN N
of IN N
OA NNP p
is VBZ p
higher JJR p
among IN p
blacks NNS p
than IN p
whites NNS p
, , N
TKR NNP i
rates NNS N
are VBP N
lower JJR N
among IN N
blacks NNS N
. . N

Physicians NNPS N
' POS N
implicit JJ N
preferences NNS N
might MD N
explain VB N
racial JJ N
differences NNS N
in IN N
TKR NNP i
recommendation NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
the DT N
magnitude NN N
of IN N
implicit JJ N
racial JJ N
bias NN N
predicts VBZ N
physician JJ N
recommendation NN N
of IN N
TKR NNP N
for IN N
black JJ N
and CC N
white JJ N
patients NNS N
with IN N
OA NNP N
and CC N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
a DT N
web-based JJ N
instrument NN N
as IN N
an DT N
intervention NN N
to TO N
decrease VB N
the DT N
effect NN N
of IN N
implicit JJ N
racial JJ N
bias NN N
on IN N
physician JJ N
recommendation NN N
of IN N
TKR NNP i
. . i

METHODS NNP N
In IN N
this DT N
web-based JJ i
study NN i
, , N
543 CD p
family NN p
and CC p
internal JJ p
medicine NN p
physicians NNS p
were VBD N
given VBN N
a DT N
scenario NN i
describing VBG i
either CC i
a DT i
black JJ i
or CC i
white JJ i
patient NN i
with IN i
severe JJ i
OA NNP i
refractory NN i
to TO i
medical JJ i
treatment NN i
. . i

Questionnaires VBZ i
evaluating VBG i
the DT i
likelihood NN i
of IN i
recommending VBG i
TKR NNP i
, , i
perceived VBD i
medical JJ i
cooperativeness NN i
, , i
and CC i
measures NNS i
of IN i
implicit JJ i
racial JJ i
bias NN i
were VBD i
administered VBN i
. . i

The DT N
main JJ N
outcome NN N
measures NNS N
included VBD N
TKR NNP i
recommendation NN N
, , N
implicit JJ N
racial JJ N
preference NN N
, , N
and CC N
medical JJ N
cooperativeness NN N
stereotypes NNS N
measured VBN N
with IN N
implicit JJ N
association NN N
tests NNS N
. . N

RESULTS NNP N
Subjects NNPS N
displayed VBD N
a DT N
strong JJ N
implicit JJ N
preference NN N
for IN N
whites NNS N
over IN N
blacks NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
and CC N
associated VBN N
medically RB o
cooperative JJ o
with IN N
whites NNS N
over IN N
blacks NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

Physicians NNPS N
reported VBD N
significantly RB N
greater JJR N
liking VBG o
for IN N
whites NNS N
over IN N
blacks NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
and CC N
reported VBD N
believing VBG N
whites NNS N
were VBD N
more RBR N
medically RB o
cooperative JJ o
than IN N
blacks NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

Participants NNS N
reported VBD N
providing VBG N
similar JJ N
care NN o
for IN N
white JJ N
and CC N
black JJ N
patients NNS N
( ( N
P NNP N
= NNP N
.10 NNP N
) ) N
but CC N
agreed VBD N
that IN N
subconscious JJ N
biases NNS N
could MD N
influence VB N
their PRP$ N
treatment NN N
decisions NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
recommendation NN o
for IN o
TKR NNP o
when WRB N
the DT N
patient NN N
was VBD N
black JJ N
( ( N
47 CD N
% NN N
) ) N
versus NN N
white JJ N
( ( N
38 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
.439 NNP N
) ) N
, , N
and CC N
neither DT N
implicit JJ N
nor CC N
explicit JJ N
racial JJ N
biases NNS N
predicted VBD N
differential JJ N
treatment NN N
recommendations NNS N
by IN N
race NN N
( ( N
all DT N
P NNP N
> NNP N
.06 NNP N
) ) N
. . N

Although IN N
participants NNS N
were VBD N
more RBR N
likely JJ N
to TO N
recommend VB o
TKR NNP o
when WRB N
completing VBG N
the DT N
implicit JJ N
association NN N
test NN N
before IN N
the DT N
decision NN N
, , N
patient JJ N
race NN N
was VBD N
not RB N
significant JJ N
in IN N
the DT N
association NN N
( ( N
P NNP N
= NNP N
.960 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Physicians NNPS p
possessed VBD N
explicit NN N
and CC N
implicit JJ N
racial JJ N
biases NNS N
, , N
but CC N
those DT N
biases NNS N
did VBD N
not RB N
predict VB N
treatment NN N
recommendations NNS N
. . N

Clinicians NNPS p
' POS p
biases NNS N
about IN N
the DT N
medical JJ N
cooperativeness NN N
of IN N
blacks NNS N
versus VBP N
whites NNS N
, , N
however RB N
, , N
may MD N
have VB N
influenced VBN N
treatment NN N
decisions NNS N
. . N

-DOCSTART- -X- O O

Tailored NNP i
, , i
iterative JJ i
, , i
printed JJ i
dietary JJ i
feedback NN i
is VBZ N
as RB N
effective JJ N
as IN N
group NN N
education NN N
in IN N
improving VBG N
dietary JJ N
behaviours NNS N
: : N
results NNS N
from IN N
a DT N
randomised VBN N
control NN N
trial NN N
in IN N
middle-aged JJ p
adults NNS p
with IN p
cardiovascular JJ p
risk NN p
factors NNS p
. . p

BACKGROUND NNP N
Tailored NNP N
nutrition NN N
interventions NNS N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
non-tailored JJ N
materials NNS N
in IN N
changing VBG N
dietary JJ N
behaviours NNS N
, , N
particularly RB N
fat JJ N
intake NN N
and CC N
fruit NN N
and CC N
vegetable JJ N
intake NN N
. . N

But CC N
further JJ N
research NN N
examining VBG N
efficacy NN N
of IN N
tailored JJ N
nutrition NN N
education NN N
in IN N
comparison NN N
to TO N
other JJ N
nutrition JJ N
education NN N
methods NNS N
and CC N
across IN N
a DT N
wider NN N
range NN N
of IN N
dietary JJ N
behaviours NNS N
is VBZ N
needed VBN N
. . N

The DT p
Stages NNPS p
to TO p
Healthy NNP p
Eating NNP p
Patterns NNP p
Study NNP p
( ( p
STEPs NNP p
) ) p
was VBD N
an DT N
intervention NN N
study NN N
, , N
in IN N
middle-aged JJ p
adults NNS p
with IN p
cardiovascular JJ p
risk NN p
factors NNS p
, , N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
delivered VBN N
by IN N
mail NN N
in IN N
improving VBG N
short-term JJ N
dietary JJ N
behaviour NN N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ N
fat NN N
, , N
fruit NN N
, , N
vegetable JJ N
and CC N
grain NN N
and CC N
cereal NN N
intake NN N
. . N

METHODS NNP N
STEPs NNP N
was VBD N
a DT N
3-month JJ N
randomised VBN N
controlled VBN N
trial NN N
with IN N
a DT N
pre NN N
and CC N
post-test JJ N
design NN N
. . N

There EX N
were VBD N
three CD N
experimental JJ N
conditions NNS N
: : N
1 CD N
) ) N
tailored VBN i
, , i
iterative JJ i
, , i
printed JJ i
dietary JJ i
feedback NN i
( ( i
TF NNP i
) ) i
with IN N
three CD N
instalments NNS N
mail-delivered JJ N
over IN N
a DT N
3-month JJ N
period NN N
that WDT N
were VBD N
re-tailored VBN N
to TO N
most RBS N
recent JJ N
assessment NN N
of IN N
dietary JJ N
intake NN N
, , N
intention NN N
to TO N
change VB N
and CC N
assessment NN N
of IN N
self-adequacy NN N
of IN N
dietary JJ N
intake NN N
. . N

Tailoring VBG N
for IN N
dietary JJ N
intake NN N
was VBD N
performed VBN N
on IN N
data NNS N
from IN N
a DT N
validated JJ N
63-item JJ N
combination NN N
FFQ NNP N
designed VBN N
for IN N
the DT N
purpose JJ N
2 CD N
) ) N
small JJ N
group NN N
nutrition NN i
education NN i
sessions NNS i
( ( N
GE NNP N
) ) N
: : N
consisting NN N
of IN N
two CD N
90-minute JJ N
dietitian-led JJ N
small JJ N
group NN N
nutrition NN N
education NN N
sessions NNS N
and CC N
3 CD N
) ) N
and CC N
a DT N
wait-listed JJ N
control NN N
( ( N
C NNP N
) ) N
group NN N
who WP N
completed VBD N
the DT N
dietary JJ i
measures NNS i
and CC i
socio-demographic JJ i
questionnaires NNS i
at IN N
baseline NN N
and CC N
3-months JJ N
later NN N
. . N

Dietary NNP N
outcome NN N
measures NNS N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ o
fat JJ o
intake NN o
( ( o
g NN o
) ) o
, , N
and CC N
the DT N
intake NN o
of IN o
fruit NN o
( ( o
serves NNS o
) ) o
, , o
vegetables NNS o
( ( o
serves NNS o
) ) o
, , o
grain NN o
and CC o
cereals NNS o
as IN N
total JJ o
and CC o
wholegrain NN o
( ( o
serves NNS o
) ) o
were VBD N
collected VBN N
using VBG N
7-day JJ N
estimated VBN N
dietary JJ N
records NNS N
. . N

Descriptive JJ N
statistics NNS N
, , N
paired VBD N
t-tests NNS N
and CC N
general JJ N
linear JJ N
models NNS N
adjusted VBN N
for IN N
baseline NN N
dietary JJ N
intake NN N
, , N
age NN N
and CC N
gender NN N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
different JJ N
nutrition NN N
interventions NNS N
. . N

RESULTS VB N
The DT N
TF NNP i
group NN N
reported VBD N
a DT N
significantly RB N
greater JJR N
increase NN N
in IN N
fruit JJ o
intake NN o
( ( N
0.3 CD N
serves/d NN N
P NNP N
= NNP N
0.031 CD N
) ) N
in IN N
comparison NN N
to TO N
GE NNP N
and CC N
the DT N
C NNP N
group NN N
. . N

All DT N
three CD N
intervention NN N
groups NNS N
showed VBD N
a DT N
reduction NN N
in IN N
total JJ o
saturated JJ o
fat JJ o
intake NN o
. . o

GE NNP N
also RB N
had VBD N
a DT N
within-group JJ N
increase NN N
in IN N
mean JJ o
vegetable JJ o
intake NN o
after IN N
3 CD N
months NNS N
, , N
but CC N
this DT N
increase NN N
was VBD N
not RB N
different JJ N
from IN N
changes NNS N
in IN N
the DT N
other JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
was VBD N
more RBR N
effective JJ N
than IN N
small JJ N
group NN N
nutrition NN N
education NN N
in IN N
improving VBG N
the DT N
short-term JJ N
fruit NN N
intake VB N
behaviour NN N
, , N
and CC N
as IN N
effective JJ N
in IN N
improving VBG N
saturated VBN N
fat JJ N
intake NN N
of IN N
middle-aged JJ p
adults NNS p
with IN p
cardiovascular JJ p
risk NN p
factors NNS p
. . p

This DT N
showed VBD N
that IN N
a DT N
low-level JJ N
dietary JJ N
intervention NN N
could MD N
achieve VB N
modest JJ N
dietary JJ N
behaviour NN N
changes NNS N
that WDT N
are VBP N
of IN N
public JJ N
health NN N
significance NN N
. . N

-DOCSTART- -X- O O

T NNP N
lymphocyte JJ N
subsets NNS N
and CC N
NK NNP N
cell VBP N
cytotoxicity NN N
in IN N
chronic JJ p
hemodialysis NN p
patients NNS p
. . p

The DT N
effect NN N
of IN N
recombinant JJ i
human JJ i
erythropoietin NN i
( ( i
rHu-EPO JJ i
) ) i
treatment NN i
. . i

We PRP N
investigated VBD N
subpopulations NNS N
of IN N
T NNP o
lymphocytes NNS o
, , o
NK NNP o
cell NN o
number NN o
and CC o
cytotoxic JJ o
activity NN o
in IN N
14 CD p
chronic JJ p
uremic JJ p
patients NNS p
on IN p
regular JJ i
hemodialysis NN i
treatment NN i
. . i

We PRP N
observed VBD N
a DT N
significantly RB N
decreased VBN N
absolute NN o
lymphocyte NN o
number NN o
and CC o
percentage NN o
of IN o
CD3 NNP o
cells NNS o
. . o

Relative JJ N
numbers NNS N
of IN N
CD16 NNP o
cells NNS o
were VBD N
significantly RB N
elevated VBN N
, , N
but CC N
NK NNP o
cell VBP o
cytotoxic JJ o
activity NN o
was VBD N
within IN N
a DT N
normal JJ N
range NN N
. . N

Nine JJ p
patients NNS p
with IN p
chronic JJ p
renal JJ p
anemia NN p
on IN p
maintenance NN p
hemodialysis NN p
were VBD N
enrolled VBN N
in IN N
rHu-EPO JJ i
treatment NN N
trial NN N
. . N

The DT N
treatment NN N
was VBD N
continued VBN N
till IN N
the DT N
hematocrit NN o
level NN o
reached VBD N
30 CD N
% NN N
. . N

Each DT N
of IN N
the DT N
patients NNS p
had VBD p
corrected VBN N
anemia NN o
and CC N
well-being NN N
. . N

After IN N
12 CD N
weeks NNS N
of IN N
the DT N
treatment NN N
we PRP N
observed VBD N
in IN N
these DT N
patients NNS N
decreases NNS N
in IN N
CD3 NNP o
, , o
CD4 NNP o
, , o
CD8 NNP o
and CC o
CD16 NNP o
cell NN o
numbers NNS o
and CC N
elevation NN N
of IN N
CD4/CD8 NNP o
ratio NN o
. . o

Cytotoxic NNP o
activity NN o
of IN o
NK NNP o
cells NNS o
did VBD N
not RB N
change VB N
significantly RB N
. . N

Presented VBN N
results NNS N
indicate VBP N
that IN N
chronic JJ p
hemodialysis NN p
patients NNS p
have VBP N
significantly RB N
diminished VBN N
lymphocyte JJ o
number NN o
. . o

rHu JJ i
EPO NNP i
treatment NN N
affects VBZ N
the DT N
T NNP N
lymphocyte NN N
subsets NNS N
inducing VBG N
a DT N
deep JJ N
decrease NN N
of IN N
CD8 NNP o
and CC o
CD16 NNP o
cell NN o
percentage NN o
leading VBG N
to TO N
normalisation NN N
of IN N
the DT N
CD4/CD8 NNP o
ratio NN o
. . o

-DOCSTART- -X- O O

Quality NN o
of IN o
life NN o
and CC o
fatigue NN o
of IN N
patients NNS p
with IN p
spinal JJ p
bone NN p
metastases NNS p
under IN p
combined VBN p
treatment NN p
with IN p
resistance NN i
training NN i
and CC i
radiation NN i
therapy- NN i
a DT N
randomized VBN N
pilot NN N
trial NN N
. . N

BACKGROUND VB N
The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
resistance NN i
training NN i
versus IN i
passive JJ i
physical JJ i
therapy NN i
on IN N
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
, , o
fatigue NN o
, , o
and CC o
emotional JJ o
distress NN o
outcomes NNS N
during IN N
radiation NN N
therapy NN N
in IN N
patients NNS p
with IN p
spinal JJ p
bone NN p
metastases NNS p
under IN p
radiotherapy NN i
( ( i
RT NNP i
) ) i
. . i

METHODS NNP N
In IN N
this DT N
randomized JJ N
trial NN N
, , N
60 CD p
patients NNS p
were VBD p
treated VBN p
from IN p
September NNP p
2011 CD p
until IN p
March NNP p
2013 CD p
into IN N
one CD N
of IN N
the DT N
two CD N
groups NNS N
: : N
isometric JJ i
resistance NN i
training NN i
or CC i
physical JJ i
therapy NN i
with IN N
thirty JJ N
patients NNS N
in IN N
each DT N
group NN N
during IN N
RT NNP i
. . i

EORTC NNP o
QLQ-BM22 NNP o
, , o
EORTC NNP o
QLQ-FA13 NNP o
, , N
and CC N
FBK-R10 NNP o
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
three CD N
months NNS N
, , N
and CC N
six CD N
months NNS N
after IN N
RT NNP i
. . i

RESULTS NNP N
Psychosocial JJ N
aspects NNS N
in IN N
resistance NN i
training NN i
group NN N
( ( N
Arm NNP N
A NNP N
) ) N
were VBD N
significantly RB N
improved VBN N
after IN N
three CD N
( ( N
p VB N
= RB N
0.001 CD N
) ) N
and CC N
six CD N
months NNS N
( ( N
p JJ N
= NNP N
0.010 CD N
) ) N
. . N

Other JJ N
rated JJ N
items NNS N
of IN N
the DT o
QLQ-BM22 NNP o
painful JJ o
site NN o
, , o
and CC o
pain NN N
characteristics NNS o
were VBD o
without IN o
significant JJ N
differences NNS o
. . o

Functional JJ o
interference NN N
showed VBD N
a DT N
positive JJ N
trend NN N
after IN N
six CD N
months NNS N
( ( N
p JJ N
= NNP N
0.081 CD N
) ) N
. . N

After IN N
six CD N
months NNS N
, , N
physical JJ o
fatigue NN o
( ( o
p JJ o
= NNP N
0.013 CD N
) ) N
, , N
and CC o
interference NN o
with IN o
daily JJ o
life NN o
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
according VBG N
to TO N
the DT N
QLQ-FA13 NNP N
assessment NN N
improved VBN N
in IN N
Arm NNP N
A NNP N
significantly RB N
. . N

Emotional JJ o
distress NN o
was VBD N
in IN N
Arm NNP N
A NNP N
lower JJR N
after IN N
six CD N
months NNS N
( ( N
p JJ N
= NNP N
0.016 CD N
) ) N
. . N

The DT N
Cohen NNP N
's POS N
effect NN N
size NN N
confirmed VBD N
the DT N
clinically NN N
significant JJ N
improvement NN N
of IN N
these DT N
findings NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
group NN p
of IN p
patients NNS p
we PRP N
were VBD N
able JJ N
to TO N
show VB N
that DT i
guided VBD i
isometric JJ i
resistance NN i
training NN i
of IN i
the DT i
paravertebral JJ i
muscles NNS i
can MD o
improve VB o
functional JJ o
capacity NN o
, , o
reduce VB o
fatigue NN o
and CC o
thereby NN o
enhance NN o
QoL NNP o
over IN N
a DT N
6-months JJ N
period NN N
in IN N
patients NNS N
with IN N
stable JJ N
spinal JJ N
metastases NNS N
. . N

The DT N
results NNS N
offer VBP N
a DT N
rationale NN N
for IN N
future JJ N
large JJ N
controlled VBN N
investigations NNS N
to TO N
confirm VB N
these DT N
findings NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
trial NN N
identifier NN N
NCT01409720 NNP N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
vitamin JJ i
A-fortified NNP i
coconut NN i
cooking VBG i
oil NN i
on IN N
the DT N
serum NN o
retinol JJ o
concentration NN o
of IN p
Filipino NNP p
children NNS p
4-7 CD p
years NNS p
old JJ p
. . p

A DT N
6-month JJ N
intervention NN N
trial NN N
was VBD N
conducted VBN N
among IN N
542 CD p
Filipino NNP p
children NNS p
aged VBD p
4 CD p
to TO p
7 CD p
years NNS p
to TO N
determine VB N
the DT N
effect NN N
of IN N
vitamin JJ i
A-fortified NNP i
coconut NN i
cooking VBG i
oil NN i
intake NN N
on IN N
their PRP$ N
vitamin NN N
A DT N
status NN N
and CC N
to TO N
identify VB N
factors NNS N
that WDT N
influence NN N
this DT N
. . N

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
Experimental NNP N
group NN N
, , N
with IN N
vitamin JJ i
A-fortified JJ i
cooking NN i
oil NN i
ration NN N
; : N
to TO N
Control-1 NNP N
group NN N
with IN N
unfortified JJ i
cooking NN i
oil NN i
ration NN i
; : i
and CC N
to TO N
Control-2 NNP N
group NN N
without IN i
cooking VBG i
oil NN i
ration NN i
. . i

In IN N
all DT N
groups NNS N
, , N
children NNS N
's POS N
serum NN N
retinol NN o
concentration NN o
improved VBN N
. . N

Relative JJ N
change NN N
in IN N
serum NN o
retinol NN o
concentration NN o
was VBD N
significantly RB N
higher JJR N
among IN N
the DT N
Experimental NNP N
group NN N
, , N
with IN N
one-third NN N
of IN N
total JJ N
vitamin FW N
A DT N
intake NN N
coming VBG N
from IN N
vitamin JJ i
A-fortified JJ i
cooking NN i
oil NN i
intake NN N
, , N
than IN N
in IN N
the DT N
Control NNP N
groups NNS N
, , N
with IN N
more JJR N
than IN N
half NN N
of IN N
intake NN N
from IN N
other JJ N
vitamin JJ N
A-rich JJ N
foods NNS N
. . N

Determinants NNS N
of IN N
post-intervention NN N
serum NN N
retinol NN N
concentration NN N
included VBD N
baseline JJ N
serum NN N
retinol NN N
concentration NN N
, , N
caregiver NN N
's POS N
education NN N
, , N
receipt NN N
of IN N
high-dose JJ N
vitamin NN N
A NNP N
capsule NN N
, , N
interaction NN N
between IN N
consumption NN N
of IN N
vitamin JJ N
A-fortified JJ N
cooking NN N
oil NN N
and CC N
of IN N
other JJ N
vitamin JJ N
A-rich NNP N
foods NNS N
, , N
and CC N
between IN N
households NNS N
purchasing VBG N
cooking JJ N
oil NN N
and CC N
food NN N
expenditure NN N
. . N

Intake NNP N
of IN N
vitamin JJ i
A-fortified JJ i
cooking NN i
oil NN i
combined VBN N
with IN N
vitamin JJ N
A-rich NNP N
foods NNS N
was VBD N
necessary JJ N
to TO N
increase VB N
serum NN o
retinol JJ o
concentration NN o
. . o

It PRP N
is VBZ N
recommended VBN N
to TO N
vigorously RB N
promote VB N
the DT N
consumption NN N
of IN N
vitamin JJ i
A-fortified JJ i
cooking NN i
oil NN i
together RB N
with IN N
other JJ N
vitamin JJ N
A-rich JJ N
sources NNS N
to TO N
sustain VB N
the DT N
prevention NN o
and CC N
control NN o
of IN N
vitamin FW N
A DT N
deficiency NN o
. . o

-DOCSTART- -X- O O

Anxiety NN p
sensitivity NN p
as IN N
an DT N
incremental JJ N
predictor NN N
of IN N
later JJ p
anxiety NN p
symptoms NNS p
and CC p
syndromes NNS p
. . p

Although IN N
anxiety NN p
sensitivity NN p
( ( p
AS NNP p
) ) p
has VBZ N
been VBN N
shown VBN N
to TO N
predict VB N
anxiety NN p
symptoms NNS p
and CC p
panic NN p
, , N
this DT N
literature NN N
is VBZ N
limited VBN N
in IN N
regard NN N
to TO N
evaluating VBG N
AS NNP N
as IN N
an DT N
incremental JJ N
predictor NN N
of IN N
anxiety NN i
psychopathology NN i
relative VBP N
to TO N
other JJ N
established VBN N
risk NN N
factors NNS N
including VBG N
sex NN N
and CC N
negative JJ N
affect NN N
. . N

The DT N
present JJ N
report NN N
prospectively RB N
evaluated VBD N
whether IN N
AS NNP N
was VBD N
predictive NN N
of IN N
later JJ N
changes NNS N
in IN N
anxiety NN o
symptoms NNS o
after IN N
controlling VBG i
for IN i
potential JJ i
confounding NN i
factors NNS i
. . i

Consistent JJ N
with IN N
hypothesis NN N
, , N
AS NNP N
was VBD N
found VBN N
to TO N
be VB N
a DT N
significant JJ N
, , N
incremental JJ N
predictor NN N
of IN N
anxiety NN o
symptoms NNS o
over IN N
time NN N
, , N
even RB N
after IN N
controlling VBG N
for IN N
sex NN N
and CC N
negative JJ N
affectivity NN N
. . N

These DT N
data NNS N
provide VBP N
novel JJ N
evidence NN N
for IN N
the DT N
unique JJ N
association NN N
between IN N
AS NNP N
of IN N
the DT N
development NN N
of IN N
anxiety NN p
symptoms NNS p
. . p

-DOCSTART- -X- O O

Assessment NN N
of IN N
radiotherapy NN i
combined VBN i
with IN i
adjuvant JJ i
chemotherapy NN i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
advanced JJ p
nasopharyngeal JJ p
carcinoma NN p
: : p
a DT N
prospective JJ N
study NN N
. . N

PURPOSE NNP N
To TO N
explore VB N
the DT N
clinical JJ N
efficacy NN o
of IN N
radiotherapy NN i
combined VBN i
with IN i
concurrent JJ i
combination NN i
chemotherapy NN i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
advanced JJ p
nasopharyngeal JJ p
carcinoma NN p
( ( p
NPC NNP p
) ) p
. . p

METHODS NNP N
Two CD p
hundred VBD p
patients NNS p
with IN p
stage NN p
III/IV NNP p
NPC NNP p
were VBD p
randomly RB p
allocated VBN p
into IN N
the DT N
treatment NN p
group NN p
( ( p
N=100 NNP p
) ) p
and CC p
the DT p
control NN p
group NN p
( ( p
N=100 NNP p
) ) p
. . p

Patients NNS N
in IN N
the DT N
control NN N
group NN N
received VBD N
conventional JJ i
fractionated JJ i
radiotherapy NN i
, , N
while IN N
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
received VBD N
conventional JJ i
fractionated JJ i
radiotherapy NN i
combined VBN i
with IN i
concurrent JJ i
combination NN i
chemotherapy NN i
with IN i
cisplatin NN i
and CC i
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
. . i

Short-term JJ o
efficacy NN o
, , o
radiotherapy NN o
toxicity NN o
, , o
shortand VB o
long-term JJ o
survival NN o
were VBD N
compared VBN N
. . N

RESULTS VB N
The DT N
short-term JJ o
response NN o
rate NN o
of IN N
the DT N
treatment NN N
group NN N
was VBD N
96 CD N
% NN N
, , N
which WDT N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
( ( N
87 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
local JJ o
radiation NN o
toxicity NN o
of IN N
the DT N
treatment NN N
group NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
the DT N
control NN N
group NN N
p VBD N
> NNP N
0.05 CD N
) ) N
, , N
but CC N
the DT N
hematological JJ o
and CC o
gastrointestinal JJ o
toxicities NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
treatment NN N
group NN N
p VBD N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
1- JJ N
, , N
3- JJ N
and CC N
5-year JJ N
overall JJ o
survival NN o
rates NNS o
were VBD N
87 CD N
, , N
80 CD N
, , N
and CC N
76 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
treatment NN N
group NN N
and CC N
74 CD N
, , N
64 CD N
, , N
and CC N
51 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
control NN N
group NN N
, , N
significantly RB N
favoring VBG N
the DT N
treatment NN N
group NN N
p VBD N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Radiotherapy NNP i
with IN i
concurrent JJ i
combination NN i
chemotherapy NN i
can MD N
improve VB N
the DT N
prognosis NN o
of IN N
patients NNS p
with IN p
advanced JJ p
NPC NNP p
but CC N
at IN N
the DT N
cost NN N
of IN N
significant JJ N
toxicity NN o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
gemfibrozil NN i
on IN N
change NN N
in IN N
renal JJ N
function NN N
in IN N
men NNS p
with IN p
moderate JJ p
chronic JJ p
renal JJ p
insufficiency NN p
and CC p
coronary JJ p
disease NN p
. . p

BACKGROUND NNP N
Limited NNP N
data NN N
suggest NN N
that IN N
low JJ N
levels NNS N
of IN N
serum JJ N
high-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
HDL-C NNP N
) ) N
and CC N
high JJ N
levels NNS N
of IN N
triglyceride-rich JJ N
lipoproteins NNS N
may MD N
be VB N
associated VBN N
with IN N
more RBR N
rapid JJ N
rates NNS N
of IN N
kidney NN N
function NN N
loss NN N
in IN N
individuals NNS p
with IN p
chronic JJ p
renal JJ p
insufficiency NN p
( ( p
CRI NNP p
) ) p
. . p

Although IN N
fibric JJ N
acid NN N
derivatives NNS N
increase VBP N
serum JJ N
HDL-C NNP N
levels NNS N
and CC N
decrease VB N
triglyceride NN N
levels NNS N
, , N
their PRP$ N
effects NNS N
on IN N
renal JJ N
function NN N
are VBP N
largely RB N
unknown JJ N
. . N

We PRP N
conducted VBD N
this DT N
study NN N
to TO N
determine VB N
whether IN N
gemfibrozil NN i
reduced VBN N
rates NNS N
of IN N
renal JJ N
function NN N
loss NN N
in IN N
people NNS p
with IN p
moderate JJ p
CRI NNP p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
post NN N
hoc NN N
subgroup NN N
analysis NN N
in IN N
the DT N
Veterans NNP N
Affairs NNPS N
High-Density NNP N
Lipoprotein NNP N
Intervention NNP N
Trial NNP N
, , N
a DT N
randomized JJ N
double-blind JJ N
trial NN N
of IN N
gemfibrozil JJ i
versus NN i
placebo NN i
in IN N
2,531 CD p
men NNS p
with IN p
coronary JJ p
disease NN p
, , p
HDL-C NNP p
levels NNS p
of IN p
40 CD p
mg/dL NN p
or CC p
less JJR p
( ( p
< NN p
or CC p
=1.0 VB p
mmol/L NN p
) ) p
, , p
low-density JJ p
lipoprotein NN p
cholesterol NN p
levels NNS p
of IN p
140 CD p
mg/dL NN p
or CC p
less JJR p
( ( p
< NN p
or CC p
=3.6 VB p
mmol/L NN p
) ) p
, , p
and CC p
a DT p
range NN p
of IN p
triglyceride NN p
values NNS p
. . p

Moderate NNP N
CRI NNP N
is VBZ N
defined VBN N
as IN N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
( ( N
GFR NNP N
) ) N
of IN N
30 CD N
to TO N
59.9 CD N
mL/min/1.73 NNS N
m2 NN N
at IN N
baseline NN N
. . N

Multivariate NNP N
regression NN N
was VBD N
used VBN N
to TO N
calculate VB N
rates NNS N
of IN N
decline NN N
in IN N
estimated VBN N
GFR NNP N
for IN N
individuals NNS N
administered VBN N
gemfibrozil NN i
or CC i
placebo NN i
, , N
controlling VBG N
for IN N
prospectively RB N
determined VBN N
potential JJ N
confounders NNS N
. . N

RESULTS NNP N
Change NNP o
in IN o
renal JJ o
function NN o
could MD N
be VB N
calculated VBN N
in IN N
1,981 CD p
individuals NNS p
, , p
of IN p
whom WP p
399 CD p
individuals NNS p
( ( p
20.2 CD p
% NN p
) ) p
were VBD p
eligible JJ p
for IN p
inclusion NN p
. . p

Among IN N
399 CD p
study NN p
subjects NNS p
, , N
the DT N
rate NN o
of IN o
change NN o
in IN o
renal JJ o
function NN o
in IN N
the DT N
gemfibrozil NN i
group NN N
during IN N
a DT N
median NN N
of IN N
61 CD N
months NNS N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
in IN N
the DT N
placebo NN i
group NN N
( ( N
0.49 CD N
mL/min/1.73 NN N
m2/y NN N
faster RBR N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.09 CD N
slower JJR N
to TO N
1.09 CD N
faster NN N
; : N
P NNP N
= NNP N
0.10 CD N
) ) N
. . N

No UH N
clinically RB N
relevant JJ N
effect NN N
of IN N
gemfibrozil NN i
on IN N
renal JJ o
function NN o
was VBD N
observed VBN N
in IN N
groups NNS N
defined VBN N
by IN N
baseline NN o
lipid NN o
levels NNS o
, , o
kidney NN o
function NN o
, , o
diabetic JJ o
status NN o
, , o
or CC o
other JJ o
components NNS o
of IN o
the DT o
metabolic JJ o
syndrome NN o
. . o

The DT N
incidence NN N
of IN N
transient NN N
( ( N
10 CD N
% NN N
versus IN N
4 CD N
% NN N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
but CC N
not RB N
sustained VBN N
( ( N
9 CD N
% NN N
versus IN N
4 CD N
% NN N
; : N
P NNP N
= NNP N
0.07 CD N
) ) N
, , N
increases VBZ N
in IN N
serum JJ o
creatinine NN o
levels NNS o
of IN N
0.5 CD N
mg/dL NN N
or CC N
greater JJR N
( ( N
> CD N
or CC N
=44 VB N
micromol/L NN N
) ) N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
gemfibrozil NN i
group NN N
. . N

However RB N
, , N
in IN N
5 CD N
subjects NNS N
with IN N
acute JJ N
increases NNS N
in IN N
serum JJ o
creatinine NN o
levels NNS o
, , o
serum NN o
creatine NN o
kinase NN o
levels NNS o
were VBD N
significantly RB N
elevated VBN N
as RB N
well RB N
, , N
suggesting VBG N
that IN N
myocyte JJ N
toxicity NN N
may MD N
have VB N
been VBN N
responsible JJ N
. . N

Even RB N
when WRB N
these DT N
individuals NNS N
were VBD N
excluded VBN N
, , N
no DT N
clinically RB N
significant JJ N
effect NN N
of IN N
gemfibrozil NN i
on IN N
kidney NN o
function NN o
was VBD N
observed VBN N
. . N

CONCLUSION NNP N
Gemfibrozil NNP i
does VBZ N
not RB N
appear VB N
to TO N
exert VB N
a DT N
clinically RB N
relevant JJ N
effect NN N
on IN N
rates NNS N
of IN N
kidney NN o
function NN o
loss NN N
in IN N
individuals NNS p
with IN p
moderate JJ p
CRI NNP p
, , p
low JJ p
HDL-C NNP p
levels NNS p
, , p
and CC p
concomitant JJ p
coronary JJ p
disease NN p
. . p

-DOCSTART- -X- O O

A DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
amoxycillin NN i
and CC i
omeprazole NN i
with IN N
and CC N
without IN N
metronidazole NN i
in IN N
the DT N
eradication NN N
treatment NN p
of IN p
Helicobacter NNP p
pylori NN p
. . p

A DT N
combination NN N
of IN i
amoxycillin NN i
and CC i
omeprazole NN i
is VBZ N
often RB N
used VBN N
to TO N
treat VB N
Helicobacter NNP p
pylori JJ p
infection NN p
. . p

A DT N
three-drug JJ N
regimen NN N
comprising VBG N
metronidazole NN i
, , i
amoxycillin NN i
and CC i
omeprazole NN i
has VBZ N
been VBN N
proposed VBN N
as IN N
an DT N
alternative JJ N
therapy NN N
. . N

In IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
comparative JJ N
study NN N
, , N
we PRP N
evaluated VBD N
these DT N
two CD N
regimens NNS N
with IN N
respect NN N
to TO N
safety NN N
and CC N
efficacy NN N
in IN N
patients NNS p
with IN p
H. NNP p
pylori JJ p
infection NN p
. . p

Sixty JJ p
patients NNS p
with IN p
peptic JJ p
ulcer NN p
( ( p
gastric JJ p
, , p
32 CD p
patients NNS p
; : p
duodenal JJ p
, , p
28 CD p
patients NNS p
) ) p
who WP p
had VBD p
a DT p
history NN p
of IN p
ulcer JJ p
recurrence NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
dual JJ N
therapy NN N
with IN N
amoxycillin NN i
( ( N
500 CD N
mg NN N
three CD N
times NNS N
daily RB N
for IN N
2 CD N
weeks NNS N
) ) N
and CC N
omeprazole JJ i
( ( N
20 CD N
mg NN N
once RB N
daily JJ N
for IN N
8 CD N
weeks NNS N
) ) N
or CC N
to TO N
triple VB N
therapy NN N
with IN N
metronidazole NN i
( ( N
500 CD N
mg NN N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
) ) N
plus CC i
amoxycillin JJ i
and CC i
omeprazole JJ i
, , N
given VBN N
in IN N
the DT N
same JJ N
dosages NNS N
as IN N
dual JJ N
therapy NN N
. . N

Forty-eight JJ p
patients NNS p
completed VBD p
the DT p
protocol NN p
; : p
treatment NN N
was VBD N
discontinued VBN N
because IN N
of IN N
side NN N
effects NNS N
in IN N
nine CD N
patients NNS N
, , N
and CC N
three CD N
patients NNS N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
. . N

On IN N
the DT N
basis NN N
of IN N
all DT N
patients NNS N
treated VBN N
, , N
the DT o
rate NN o
of IN o
H. NNP o
pylori FW o
eradication NN o
was VBD o
significantly RB o
higher JJR o
for IN o
triple JJ o
therapy NN o
20/23 CD o
cases NNS o
, , o
87.0 CD o
% NN o
; : o
95 CD o
% NN o
confidence NN o
interval NN o
( ( o
CI NNP o
) ) o
, , o
0.664-0.972 JJ o
) ) o
than IN o
for IN o
dual JJ o
therapy NN o
13/25 CD N
, , N
52.0 CD N
% NN N
; : N
0.313-0.722 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

On IN N
an DT N
intention-to-treat JJ N
basis NN N
, , N
the DT o
difference NN o
between IN o
the DT o
groups NNS o
in IN o
the DT o
rate NN o
of IN o
H. NNP o
pylori FW o
eradication NN o
was VBD o
marginally RB o
significant JJ o
( ( N
P NNP N
= VBZ N
0.06 CD N
[ JJ N
0.028-0.512 JJ N
] NN N
) ) N
. . N

Side JJ o
effects NNS o
were VBD o
reported VBN o
by IN o
five CD o
patients NNS o
receiving VBG o
triple JJ o
therapy NN o
( ( o
skin JJ o
rash NN o
, , N
one CD N
; : N
nausea NN o
, , N
two CD N
; : N
headache NN o
, , N
one CD N
; : N
abdominal JJ o
pain NN o
, , N
one CD N
) ) N
, , N
and CC N
four CD o
patients NNS o
receiving VBG o
dual JJ o
therapy NN o
( ( o
skin JJ o
rash NN o
, , N
two CD N
; : N
abdominal JJ o
pain NN o
, , N
one CD N
; : N
diarrhoea NN o
, , N
one CD N
) ) N
. . N

All DT o
side NN o
effects NNS o
resolved VBD o
spontaneously RB o
after IN o
termination NN o
of IN o
treatment NN o
. . o

There EX o
was VBD o
no DT o
significant JJ o
difference NN o
in IN o
safety NN o
between IN o
the DT o
two CD o
regimens NNS o
. . o

Triple JJ o
therapy NN o
with IN o
metronidazole NN o
, , o
amoxycillin NN o
, , o
and CC o
omeprazole NN o
was VBD o
significantly RB o
more RBR o
effective JJ o
for IN o
the DT o
eradication NN o
of IN o
H. NNP o
pylori FW o
than IN o
dual JJ o
therapy NN o
with IN o
amoxycillin NN o
and CC o
omeprazole JJ o
alone RB o
. . o

The DT N
safety NN N
of IN N
these DT N
regimens NNS N
was VBD N
similar JJ N
, , N
and CC N
triple JJ N
therapy NN N
was VBD N
found VBN N
to TO N
be VB N
clinically RB N
acceptable JJ N
. . N

-DOCSTART- -X- O O

Are NNP N
oral JJ N
cathartics NNS N
of IN N
value NN N
in IN N
optimizing VBG N
the DT N
gallium NN N
scan JJ N
? . N
Concise NNP N
communication NN N
. . N

The DT N
normal JJ N
intestinal JJ N
secretion NN N
of IN N
9-15 CD N
% NN N
of IN N
an DT N
administered VBN N
dose NN N
of IN N
gallium-67 NN i
may MD N
prevent VB N
early JJ N
detection NN N
of IN N
intra-abdominal JJ N
disease NN N
. . N

We PRP p
randomized VBD p
50 CD p
patients NNS p
to TO N
receive VB N
either DT N
no DT i
bowel NN i
preparation NN i
or CC i
30 CD i
cc NN i
of IN i
milk NN i
of IN i
magnesia JJ i
plus CC i
5 CD i
cc NN i
of IN i
cascara NN i
. . i

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
frequency NN o
with IN o
which WDT o
gallium NN o
interfered VBD o
with IN o
readings NNS o
or CC o
time NN o
to TO o
complete VB o
the DT o
study NN o
. . o

-DOCSTART- -X- O O

Human JJ N
achaete-scute JJ N
homologue NN N
( ( N
hASH1 NN N
) ) N
mRNA NN N
level NN N
as IN N
a DT N
diagnostic JJ N
marker NN N
to TO N
distinguish VB N
esthesioneuroblastoma NN p
from IN N
poorly RB p
differentiated VBN p
tumors NNS p
arising VBG p
in IN p
the DT p
sinonasal NN p
tract NN p
. . p

Distinction NN N
of IN N
high-grade JJ p
esthesioneuroblastomas NN p
from IN N
other JJ p
poorly RB p
differentiated VBN p
tumors NNS p
arising VBG p
in IN p
the DT p
nasal JJ p
cavity NN p
is VBZ N
an DT N
important JJ N
diagnostic JJ N
challenge NN N
because IN N
it PRP N
determines VBZ N
patient JJ N
management NN N
and CC N
prognosis NN N
. . N

The DT N
human JJ N
achaete-scute JJ N
homologue NN N
( ( N
hASH1 NN N
) ) N
gene NN N
is VBZ N
critical JJ N
in IN N
olfactory JJ N
neuronal JJ N
differentiation NN N
and CC N
is VBZ N
expressed VBN N
in IN N
immature NN N
olfactory NN N
cells NNS N
; : N
therefore RB N
, , N
it PRP N
could MD N
have VB N
potential JJ N
use NN N
as IN N
a DT N
diagnostic JJ N
marker NN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
value NN N
of IN N
hASH1 JJ N
messenger NN N
RNA NNP N
( ( N
mRNA NN N
) ) N
levels NNS N
in IN N
differentiating VBG N
esthesioneuroblastoma NN N
from IN N
other JJ N
poorly RB N
differentiated VBN N
tumors NNS N
. . N

A DT N
real-time JJ i
polymerase NN i
chain NN i
reaction NN i
assay NN i
was VBD N
developed VBN N
, , N
permitting VBG N
the DT N
comparative JJ N
determination NN N
of IN N
hASH1 NN o
mRNA NN o
levels NNS o
in IN N
triplicate NN N
in IN N
a DT N
double-blind JJ N
pilot NN N
study NN N
including VBG N
24 CD p
frozen JJ p
cases NNS p
of IN p
esthesioneuroblastoma NN p
and CC p
poorly RB p
differentiated VBN p
tumors NNS p
. . p

All DT N
4 CD N
positive JJ N
cases NNS N
were VBD N
esthesioneuroblastomas JJ o
, , N
and CC N
all DT N
19 CD N
poorly RB N
differentiated VBN N
tumors NNS N
were VBD N
negative JJ N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
an DT N
inverse JJ N
association NN N
between IN N
the DT N
grade NN o
of IN o
esthesioneuroblastomas NN o
and CC N
hASH1 NN N
mRNA NN N
levels NNS N
. . N

The DT N
hASH1 NN N
mRNA FW N
level NN N
might MD N
represent VB N
a DT N
useful JJ N
tool NN N
for IN N
distinguishing VBG N
esthesioneuroblastoma NN N
from IN N
poorly RB p
differentiated VBN p
tumors NNS p
of IN p
the DT p
sinonasal JJ p
region NN p
. . p

-DOCSTART- -X- O O

Impact NN N
of IN N
angiotensin-converting JJ N
enzyme JJ N
gene NN N
polymorphism NN N
on IN N
neurohormonal JJ o
responses NNS o
to TO N
high- JJ N
versus NN N
low-dose JJ N
enalapril NN N
in IN N
advanced JJ p
heart NN p
failure NN p
. . p

BACKGROUND CC N
The DT N
impact NN N
of IN N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
gene NN N
polymorphism NN N
on IN N
neurohormonal JJ N
dose JJ N
response NN N
to TO N
ACE NNP i
inhibitor NN N
therapy NN N
is VBZ N
unclear JJ N
. . N

METHODS NNP N
ACE NNP N
Insertion NNP N
( ( N
I PRP N
) ) N
or CC N
Deletion NNP N
( ( N
D NNP N
) ) N
genotype NN N
was VBD N
determined VBN N
in IN N
74 CD p
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
who WP N
were VBD N
randomly RB i
assigned VBN i
to TO i
receive VB i
either DT i
high-dose JJ i
or CC i
low-dose JJ i
enalapril NN i
over IN i
a DT i
period NN i
of IN i
6 CD i
months NNS i
. . i

Monthly JJ i
pre-enalapril JJ o
and CC o
post-enalapril JJ o
neurohormone NN o
levels NNS o
( ( o
serum JJ o
ACE NNP o
activity NN o
( ( o
sACE NN o
) ) o
, , o
plasma JJ o
angiotensin NN o
II NNP o
( ( o
A-II NNP o
) ) o
, , o
plasma JJ o
renin NN o
activity NN o
( ( o
PRA NNP o
) ) o
, , o
and CC o
serum VB o
aldosterone NN o
( ( o
ALDO NNP o
) ) o
were VBD N
compared VBN N
between IN N
genotype NN N
subgroups NNS N
and CC N
between IN N
patients NNS N
who WP N
received VBD N
high- JJ N
or CC N
low-dose JJ N
enalapril NN i
within IN N
each DT N
genotype NN N
subgroup NN N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
predose/postdose JJ o
sACE NN o
and CC o
postdose JJ o
PRA NNP o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
DD NNP p
genotype NN p
. . p

At IN N
6-month JJ N
follow-up NN N
, , N
postdose JJ o
sACE NN o
was VBD N
reduced VBN N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
in IN N
all DT N
three CD N
genotypes NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

However RB N
, , N
predose JJ o
and CC o
postdose JJ o
ALDO NNP o
and CC o
A-II NNP o
levels NNS o
did VBD N
not RB N
differ VB N
between IN N
each DT N
genotype NN N
subgroup NN N
at IN N
baseline NN N
or CC N
by IN N
enalapril JJ N
dose NN N
within IN N
each DT N
genotype NN N
subgroup NN N
. . N

ALDO NNP o
escape NN o
and CC o
A-II JJ o
reactivation NN o
were VBD N
not RB N
affected VBN N
by IN N
ACE NNP p
genotype NN p
or CC N
enalapril JJ N
dosage NN N
. . N

CONCLUSIONS NNP N
Predose NNP o
sACE NN o
were VBD N
consistently RB N
higher JJR N
in IN N
the DT N
DD NNP N
genotype NN N
when WRB N
compared VBN N
with IN N
ID NNP p
or CC p
II NNP p
subgroups NNS p
. . p

Despite IN N
a DT N
dose-dependent JJ N
suppression NN o
of IN o
sACE NN o
, , N
there EX N
were VBD N
no DT N
observed VBN N
statistically RB N
significant JJ N
differences NNS N
in IN N
ALDO NNP o
and CC o
A-II NNP o
suppression NN o
or CC N
escape NN N
with IN N
escalating VBG N
doses NNS N
of IN N
enalapril NN N
within IN N
each DT N
subgroup NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
m-chlorophenylpiperazine NN i
on IN N
plasma NN o
homovanillic JJ o
acid NN o
concentrations NNS o
in IN N
healthy JJ p
subjects NNS p
. . p

In IN N
view NN N
of IN N
the DT N
abundant JJ N
anatomical JJ N
and CC N
functional JJ N
interactions NNS N
between IN N
serotonin NN N
and CC N
dopamine NN N
systems NNS N
, , N
this DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
the DT N
serotonin JJ N
agonist NN N
, , N
m-chlorophenylpiperazine NN i
( ( i
mCPP NN i
) ) i
on IN N
plasma NN o
concentrations NNS o
of IN o
the DT o
dopamine NN o
metabolite NN o
, , o
homovanillic JJ o
acid NN o
. . o

Plasma NNP N
prolactin NN N
levels NNS N
, , N
body NN N
temperature NN N
, , N
and CC N
mCPP RB o
blood NN N
level NN N
were VBD N
also RB N
measured VBN N
. . N

mCPP NN i
( ( N
0.35 CD N
mg/kg NN N
) ) N
and CC N
placebo $ i
were VBD N
administered VBN N
orally RB N
to TO N
10 CD p
healthy JJ p
men NNS p
in IN N
a DT N
randomized JJ N
double-blind NN N
design NN N
. . N

Variables NNS N
were VBD N
measured VBN N
for IN N
210 CD N
min NNS N
after IN N
administration NN N
of IN N
capsules NNS N
. . N

mCPP NNS o
raised VBD o
prolactin NN o
and CC o
temperature NN o
as IN o
compared VBN o
to TO o
placebo VB o
, , N
but CC N
did VBD N
not RB N
affect VB N
plasma NN o
homovanillic JJ o
acid JJ o
concentrations NNS o
. . o

Results VB N
suggest JJS N
that IN N
mCPP NN o
does VBZ o
not RB o
alter VB o
dopamine NN o
function NN o
. . o

-DOCSTART- -X- O O

Temporal JJ N
variation NN N
in IN N
the DT N
effects NNS o
of IN N
ophthalmic JJ i
timolol NN i
on IN N
cardiovascular NN o
and CC o
respiratory JJ o
functions NNS o
in IN N
healthy JJ p
men NNS p
. . p

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
ophthalmic JJ i
timolol NN i
and CC N
time NN N
of IN N
administration NN N
on IN N
cardiovascular JJ o
and CC o
respiratory JJ o
functions NNS o
in IN N
healthy JJ p
young JJ p
male NN p
volunteers NNS p
. . p

Eight CD p
participants NNS p
( ( p
mean JJ p
age NN p
+/- JJ p
standard NN p
deviation NN p
, , p
22 CD p
+/- JJ p
0.9 CD p
years NNS p
) ) p
received VBD N
either CC N
50 CD N
microL NN N
of IN N
0.5 CD N
% NN N
timolol NN i
or CC N
placebo NN i
in IN N
the DT N
lower JJR N
conjunctival NN N
sacs NN N
of IN N
both DT N
eyes NNS N
in IN N
the DT N
morning NN N
or CC N
evening NN N
. . N

Intraocular JJ o
pressure NN o
, , o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
and CC o
respiratory JJ o
functions NNS o
, , o
including VBG o
percent NN o
forced VBD o
expiratory JJ o
volume NN o
in IN o
1 CD o
second JJ o
and CC o
peak JJ o
expiratory NN o
flow NN o
rate NN o
, , N
were VBD N
then RB N
measured VBN N
for IN N
3 CD N
hours NNS N
after IN N
drug NN N
administration NN N
. . N

Timolol NNP i
reduced VBD N
intraocular JJ o
pressure NN o
and CC o
cardiovascular JJ o
function NN o
at IN N
both DT N
administration NN N
times NNS N
. . N

However RB N
, , N
a DT N
timolol-induced JJ i
reduction NN N
in IN N
respiratory NN o
function NN o
was VBD N
observed VBN N
only RB N
in IN N
the DT N
evening NN N
: : N
percent NN o
forced VBD o
expiratory JJ o
volume NN o
in IN o
1 CD o
second JJ o
, , o
peak JJ o
expiratory NN o
flow NN o
rate NN o
, , o
and CC o
expiratory JJ o
flow NN o
rate NN o
at IN o
75 CD o
% NN o
vital JJ o
capacity NN o
were VBD N
reduced VBN N
by IN N
3 CD N
% NN N
, , N
7 CD N
% NN N
, , N
and CC N
12 CD N
% NN N
, , N
respectively RB N
, , N
3 CD N
hours NNS N
after IN N
administration NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
ophthalmic JJ i
timolol NN i
reduces NNS N
cardiovascular JJ o
and CC o
respiratory JJ o
functions NNS o
in IN N
healthy JJ p
young JJ p
male JJ p
subjects NNS p
and CC N
that DT N
bronchial JJ o
sensitivity NN o
to TO N
timolol VB N
differs NNS N
between IN N
morning NN N
and CC N
evening NN N
. . N

-DOCSTART- -X- O O

[ JJ i
Mitomycin NNP i
C NNP i
plus CC i
HCFU NNP i
adjuvant VBP N
chemotherapy NN N
for IN N
noncuratively RB N
resected VBN N
cases NNS N
of IN N
colorectal JJ N
carcinoma NN N
. . N

( ( N
Second JJ N
report NN N
) ) N
: : N
5-year JJ N
survival NN N
rate NN N
. . N

Cooperative NNP N
Study NNP N
Group NNP N
of IN N
Kyushu NNP N
and CC N
Chugoku NNP N
for IN N
HCFU NNP N
Adjuvant NNP N
Chemotherapy NNP N
] NNP N
. . N

In IN N
order NN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
adjuvant JJ i
chemotherapy NN i
employing VBG N
mitomycin JJ i
C NNP i
( ( i
MMC NNP i
) ) i
and CC i
carmofur NN i
( ( i
HCFU NNP i
) ) i
for IN p
patients NNS p
with IN p
noncuratively RB p
resected VBN p
colorectal JJ p
carcinoma NN p
, , N
a DT N
cooperative JJ N
study NN N
was VBD N
performed VBN N
by IN N
54 CD p
institutions NNS p
in IN p
the DT p
Kyushu NNP p
and CC p
Chugoku NNP p
areas NNS p
of IN p
Japan NNP p
. . p

The DT p
criteria NNS p
for IN p
patient JJ p
selection NN p
were VBD p
as IN p
follows VBZ p
: : p
1 CD p
) ) p
Age NNP p
of IN p
75 CD p
years NNS p
or CC p
less JJR p
and CC p
not RB p
accompanied VBN p
by IN p
any DT p
serious JJ p
disease NN p
. . p

2 CD p
) ) p
Macroscopic NNP p
diagnosis NN p
as IN p
being VBG p
noncuratively RB p
resected VBN p
on IN p
completion NN p
of IN p
the DT p
surgical JJ p
procedure NN p
. . p

3 CD p
) ) p
Definitive JJ p
diagnosis NN p
of IN p
colorectal JJ p
carcinomas NN p
, , p
histologically RB p
. . p

4 CD p
) ) p
No DT p
synchronous JJ p
or CC p
metachronous JJ p
double JJ p
cancer NN p
. . p

The DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
consisted VBN N
of IN N
two CD N
groups NNS N
. . N

In IN N
Group NNP N
A NNP N
, , N
the DT N
MMC NNP i
group NN p
received VBD N
bolus RB N
intravenous JJ N
injections NNS N
of IN N
20 CD N
mg NNS N
MMC NNP i
on IN N
the DT N
day NN N
of IN N
operation NN N
and CC N
10 CD N
mg NN N
the DT N
next JJ N
day NN N
, , N
followed VBN N
by IN N
10 CD N
mg NNS N
every DT N
4 CD N
weeks NNS N
until IN N
a DT N
total NN N
of IN N
100 CD N
mg NNS N
had VBD N
been VBN N
administered VBN N
. . N

In IN N
Group NNP N
B NNP N
, , N
the DT N
MMC NNP i
+ NNP i
HCFU NNP i
group NN i
received VBD N
the DT N
same JJ N
treatment NN N
in IN N
Group NNP N
A NNP N
, , N
but CC N
with IN N
the DT N
addition NN N
of IN N
600 CD N
mg/day NN N
of IN N
HCFU NNP i
from IN N
the DT N
second JJ N
week NN N
, , N
orally RB N
for IN N
at IN N
least JJS N
one CD N
year NN N
. . N

Concerning VBG N
the DT N
69-month JJ o
survival NN o
rate NN o
, , N
a DT N
better JJR N
result NN N
was VBD N
observed VBN N
in IN N
the DT N
MMC NNP i
+ NNP i
HCFU NNP i
group NN N
than IN N
in IN N
the DT N
MMC NNP i
only RB i
group NN N
( ( N
generalized VBN N
Wilcoxon NNP N
test NN N
: : N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Significantly RB N
better JJR N
survival NN o
rates NNS o
were VBD N
obtained VBN N
in IN N
those DT N
cases NNS N
with IN N
disseminating VBG N
peritoneal JJ N
metastasis NN N
, , N
hepatic JJ N
metastasis NN N
and CC N
stage NN N
V NNP N
cancer NN N
in IN N
the DT N
MMC NNP i
+ NNP i
HCFU NNP i
group NN N
as IN N
when WRB N
compared VBN N
with IN N
the DT N
MMC NNP i
only RB N
group NN N
. . N

No DT o
significant JJ o
side NN o
effects NNS o
due JJ N
to TO N
the DT N
combined JJ N
administration NN N
of IN N
HCFU NNP i
were VBD N
recognized VBN N
. . N

The DT N
combined JJ N
administration NN N
of IN N
MMC NNP i
and CC N
HCFU NNP i
was VBD N
suggested VBN N
to TO N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
adjuvant NN N
chemotherapy NN N
for IN N
noncuratively RB N
resected VBN N
cases NNS N
of IN N
colorectal JJ N
carcinoma NN N
. . N

-DOCSTART- -X- O O

[ JJ i
Radiotherapy NNP i
for IN N
choroidal JJ N
neovascularization NN N
in IN N
age-related JJ N
macular JJ N
degeneration NN N
. . N

A DT N
pilot NN N
study NN N
using VBG N
low- JJ i
versus NN i
high-dose JJ i
photon NN i
bean NN i
radiation NN i
] NN i
. . N

PURPOSE NNP N
Several JJ N
pilot NN N
studies NNS N
have VBP N
indicated VBN N
that IN N
low-dose JJ i
radiation NN i
therapy NN i
might MD N
have VB N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
course NN N
of IN N
choroidal JJ N
neovascularization NN N
( ( N
CNV NNP N
) ) N
in IN N
age-related JJ p
macular JJ p
degeneration NN p
( ( p
AMD NNP p
) ) p
. . p

This DT N
study NN N
aimed VBD N
to TO N
ascertain VB N
whether IN N
such JJ N
treatment NN N
might MD N
halt VB N
the DT N
progression NN N
of IN N
neovascular JJ N
AMD NNP N
and CC N
whether IN N
a DT N
low JJ N
or CC N
a DT N
high JJ N
radiation NN N
dose NN N
should MD N
be VB N
applied VBN N
. . N

PATIENTS VB N
The DT N
patients NNS p
comprised VBD p
some DT p
randomized VBN p
to TO p
0 CD i
vs NNS i
10 CD i
vs NNS i
36 CD i
Gy NNP i
of IN i
radiation NN i
and CC p
( ( p
after IN p
a DT p
change NN p
of IN p
the DT p
study NN p
protocol NN p
became VBD p
necessary JJ p
) ) p
others NNS p
who WP p
participated VBD p
in IN p
a DT p
prospective JJ p
, , p
controlled VBD p
non-randomized JJ p
pilot NN p
study NN p
. . p

Enclosed VBN N
were VBD N
eyes NNS p
with IN p
visual JJ p
acuity NN p
of IN p
> NN p
or CC p
= VB p
0.1 CD p
and CC p
< NNP p
or CC p
= $ p
0.6 CD p
revealing VBG p
a DT p
juxta-subfoveal JJ p
CNV NNP p
either NN p
of IN p
the DT p
occult NN p
type NN p
( ( p
type JJ p
1 CD p
) ) p
or CC p
the DT p
classic JJ p
type NN p
( ( p
isolated JJ p
or CC p
as IN p
part NN p
of IN p
a DT p
predominantly RB p
occult JJ p
lesion NN p
) ) p
. . p

RESULTS NNP N
Eyes NNP N
treated VBD N
with IN N
10 CD i
Gy NNP i
for IN N
occult NN N
CNV NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
were VBD N
subject JJ N
to TO N
severe JJ o
visual JJ o
loss NN o
in IN N
41.6 CD N
% NN N
of IN N
the DT N
cases NNS N
compared VBN N
to TO N
38.5 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
at IN N
12 CD N
months NNS N
of IN N
follow-up NN N
. . N

For IN N
eyes NNS N
treated VBN N
with IN N
10 CD i
Gy NNP i
because IN N
of IN N
classic JJ N
CNV NNP N
, , N
the DT N
corresponding JJ N
figures NNS N
were VBD N
33 CD N
% NN N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
and CC N
57 CD N
% NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
respectively RB N
. . N

At IN N
18 CD N
months NNS N
of IN N
follow-up NN N
, , N
the DT N
percentages NNS N
were VBD N
63 CD N
% NN N
and CC N
75 CD N
% NN N
respectively RB N
. . N

Fluorescein NNP o
angiographic JJ o
growth NN o
of IN o
classic JJ o
and CC o
occult NN o
CNV NNP o
could MD N
not RB N
be VB N
halted VBN N
by IN N
10 CD N
Gy NNP N
, , N
while IN N
a DT N
temporary JJ o
growth NN o
retardation NN o
was VBD N
observed VBN N
in IN N
cases NNS N
irradiated VBN N
with IN N
36 CD i
Gy NNP i
. . i

CONCLUSION NNP N
In IN N
the DT N
study NN N
presented VBD N
, , N
the DT N
natural JJ N
course NN N
of IN N
occult NN N
CNV NNP N
could MD N
not RB N
be VB N
improved VBN N
by IN N
irradiation NN N
with IN N
10 CD i
or CC i
36 CD i
Gy NNP i
. . i

In IN N
cases NNS N
of IN N
classic JJ N
CNV NNP N
, , N
low-dose JJ N
irradiation NN N
with IN N
10 CD i
Gy NNP i
postponed VBD N
severe JJ o
visual JJ o
loss NN o
by IN N
a DT N
maximum NN N
of IN N
18 CD N
months NNS N
. . N

A DT N
positive JJ N
treatment NN N
effect NN N
was VBD N
also RB N
observed VBN N
in IN N
cases NNS N
irradiated VBN N
with IN N
36 CD i
Gy NNP i
; : i
however RB N
, , N
a DT N
25 CD N
% NN N
incidence NN N
of IN N
radiation NN N
retinopathy NN N
seems VBZ N
unacceptable JJ N
. . N

-DOCSTART- -X- O O

Pharmacokinetic JJ N
interaction NN N
between IN N
proton NN i
pump NN i
inhibitors NNS i
and CC i
roxithromycin NN i
in IN N
volunteers NNS p
. . p

BACKGROUND NNP N
Triple NNP N
therapy NN N
including VBG N
two CD N
antibiotics NNS N
and CC N
a DT N
proton NN N
pump NN N
inhibitor NN N
is VBZ N
a DT N
rational JJ N
approach NN N
to TO N
the DT N
treatment NN N
of IN N
Helicobacter NNP N
pylori NN N
induced VBD N
peptic JJ N
ulcer JJ N
disease NN N
. . N

The DT N
interaction NN N
of IN N
antimicrobial JJ N
therapy NN N
and CC N
acid JJ N
suppression NN N
is VBZ N
not RB N
yet RB N
well RB N
elucidated VBN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
proton NN i
pump NN i
inhibitors NNS i
on IN N
roxithromycin NN i
levels NNS N
in IN N
plasma NN N
and CC N
gastric JJ N
tissue NN N
under IN N
steady-state JJ p
conditions NNS p
in IN p
volunteers NNS p
. . p

METHODS NNP N
In IN N
two CD N
crossover NN N
studies NNS N
omeprazole VBP i
20 CD i
mg NN i
b.d. NN i
, , N
lansoprazole JJ i
30 CD i
mg NN i
b.d. NN i
, , N
roxithromycin VBZ i
300 CD i
mg NN i
b.d. NN i
, , N
and CC i
the DT i
combination NN i
of IN i
roxithromycin NN i
with IN i
either DT i
omeprazole NN i
or CC i
lansoprazole NN i
were VBD N
administered VBN N
to TO N
12 CD p
healthy JJ p
volunteers NNS p
over IN p
6 CD p
days NNS p
. . p

Blood NNP o
plasma NN o
levels NNS o
of IN N
the DT N
drugs NNS N
were VBD N
measured VBN N
. . N

In IN N
addition NN N
, , N
roxithromycin JJ o
concentrations NNS o
were VBD N
also RB N
determined VBN N
in IN N
gastric JJ N
juice NN N
and CC N
gastric JJ N
tissue NN N
obtained VBN N
during IN N
endoscopy NN N
. . N

RESULTS VB N
The DT N
proton NN i
pump NN i
inhibitors NNS i
and CC i
roxithromycin NN i
did VBD N
not RB N
alter VB N
the DT N
blood NN o
plasma NN o
pharmacokinetics NNS o
of IN N
each DT N
other JJ N
. . N

When WRB N
compared VBN N
to TO N
roxithromycin VB i
administered JJ N
alone RB N
, , N
its PRP$ N
combination NN N
with IN N
a DT N
proton NN i
pump NN i
inhibitor NN i
significantly RB N
increased VBD N
the DT N
roxithromycin NN o
concentrations NNS o
in IN o
gastric JJ o
juice NN o
( ( N
3.0-5.0 JJ N
microg/mL NN N
vs. IN N
0.3-0.4 NNP N
microg/mL NN N
) ) N
and CC N
gastric JJ o
tissue NN o
( ( N
antrum NN N
: : N
3.8-4.0 JJ N
vs. FW N
2.8 CD N
microg/g NN N
, , N
fundus NN N
: : N
5.9-7.4 JJ N
vs. IN N
4.2-4.4 JJ N
microg/g NN N
) ) N
. . N

CONCLUSIONS NNP N
Proton NNP i
pump NN i
inhibitors NNS i
and CC N
roxithromycin VB i
do VBP N
not RB N
alter VB N
the DT N
systemic JJ N
bioavailability NN N
of IN N
each DT N
other JJ N
. . N

However RB N
, , N
proton VBP i
pump NN i
inhibitors NNS i
increase VBP N
the DT N
local JJ N
concentration NN o
of IN o
roxithromycin NN o
in IN N
the DT N
stomach NN N
which WDT N
may MD N
contribute VB N
to TO N
the DT N
clinically RB N
proven JJ N
synergic JJ N
beneficial JJ N
action NN N
in IN N
eradication NN N
therapy NN N
of IN N
H. NNP N
pylori NN N
. . N

-DOCSTART- -X- O O

Testing VBG N
the DT N
efficacy NN N
of IN N
an DT N
HIV NNP o
stigma NN o
reduction NN o
intervention NN i
with IN N
medical JJ p
students NNS p
in IN p
Puerto NNP p
Rico NNP p
: : p
the DT N
SPACES NNP N
project NN N
. . N

INTRODUCTION NNP N
Stigma NNP o
associated VBD N
with IN N
HIV NNP N
has VBZ N
been VBN N
documented VBN N
as IN N
a DT N
barrier NN N
for IN N
accessing VBG N
quality NN N
health-related JJ N
services NNS N
. . N

When WRB N
the DT N
stigma NN N
manifests NNS N
in IN N
the DT N
health NN N
care NN N
setting VBG N
, , N
people NNS N
living VBG N
with IN N
HIV NNP N
receive VBP N
substandard NN N
services NNS N
or CC N
even RB N
be VB N
denied VBN N
care NN N
altogether RB N
. . N

Although IN N
the DT N
consequences NNS N
of IN N
HIV NNP o
stigma NN o
have VBP N
been VBN N
documented VBN N
extensively RB N
, , N
efforts NNS N
to TO N
reduce VB N
these DT N
negative JJ N
attitudes NNS N
have VBP N
been VBN N
scarce JJ N
. . N

Interventions NNS i
to TO i
reduce VB i
HIV NNP o
stigma NN o
should MD N
be VB N
implemented VBN N
as IN N
part NN N
of IN N
the DT N
formal JJ N
training NN N
of IN N
future JJ N
health NN N
care NN N
professionals NNS N
. . N

The DT N
interventions NNS N
that WDT N
have VBP N
been VBN N
tested VBN N
with IN N
health NN p
care NN p
professionals NNS p
and CC N
published VBN N
have VBP N
several JJ N
limitations NNS N
that WDT N
must MD N
be VB N
surpassed VBN N
( ( N
i.e NN N
. . N

lack NN N
of IN N
comparison NN N
groups NNS N
in IN N
research NN N
designs NNS N
and CC N
longitudinal JJ N
follow-up JJ N
data NNS N
) ) N
. . N

Furthermore UH N
, , N
Latino NNP p
health NN p
care NN p
professionals NNS p
have VBP N
been VBN N
absent JJ N
from IN N
these DT N
intervention NN N
efforts NNS N
even RB N
though IN N
the DT N
epidemic NN N
has VBZ N
affected VBN N
this DT N
population NN N
disproportionately RB N
. . N

METHODS NNP N
In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
an DT N
intervention NN i
developed VBD i
to TO i
reduce VB i
HIV NNP o
stigma NN o
among IN i
medical JJ i
students NNS i
in IN i
Puerto NNP i
Rico NNP i
. . i

A NNP N
total NN N
of IN N
507 CD p
medical JJ p
students NNS p
were VBD N
randomly RB N
introduced VBN N
into IN N
our PRP$ N
intervention NN i
and CC i
control NN i
conditions NNS i
. . i

RESULTS VB N
The DT N
results NNS N
show VBP N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
intervention NN i
and CC N
control NN i
groups NNS N
; : N
intervention NN N
group NN N
participants NNS N
had VBD N
lower JJR o
HIV NNP o
stigma NN o
levels NNS o
than IN N
control NN N
participants NNS N
after IN N
the DT N
intervention NN N
. . N

In IN N
addition NN N
, , N
differences NNS N
in IN N
HIV NNP o
stigma NN o
levels NNS o
between IN N
the DT N
groups NNS N
were VBD N
sustained VBN N
for IN N
a DT N
12-month JJ N
period NN N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
our PRP$ N
study NN N
demonstrate VB N
the DT N
efficacy NN N
of IN N
the DT N
modes NNS N
of IN N
intervention NN N
developed VBN N
by IN N
us PRP N
and CC N
serve VB N
as IN N
a DT N
new JJ N
training NN N
tool NN N
for IN N
future JJ p
health NN p
care NN p
professionals NNS p
with IN N
regard NN N
to TO N
stigma VB o
reduction NN o
. . o

-DOCSTART- -X- O O

Short-term NNP i
intravenous JJ i
antibiotic JJ i
treatment NN i
of IN N
acute JJ p
hematogenous JJ p
bone NN p
and CC p
joint JJ p
infection NN p
in IN p
children NNS p
: : p
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

Thirty-three JJ p
cases NNS p
of IN p
acute JJ p
hematogenous JJ p
bone NN p
or CC p
joint JJ p
infection NN p
in IN p
children NNS p
were VBD N
randomly RB N
treated VBN N
with IN N
short-term JJ i
( ( N
7 CD N
days NNS N
for IN N
joint JJ N
infection NN N
, , N
10 CD N
days NNS N
for IN N
bone JJ N
infection NN N
) ) N
or CC N
long-term JJ i
( ( N
14 CD N
days NNS N
and CC N
21 CD N
days NNS N
, , N
respectively RB N
) ) N
intravenous JJ i
antibiotics NNS i
after IN N
surgical JJ i
drainage NN i
. . i

The DT N
treatment NN N
outcome NN N
was VBD N
measured VBN N
through IN N
a DT N
detailed JJ o
scoring NN o
system NN o
that WDT o
included VBD o
the DT o
ability NN o
to TO o
eradicate VB o
infection NN o
, , o
the DT o
functional JJ o
status NN o
of IN o
the DT o
limb NN o
, , o
and CC o
the DT o
radiographic JJ o
appearance NN o
of IN o
the DT o
bone NN o
and CC o
joint NN o
. . o

The DT N
results NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
showing VBG N
the DT N
added JJ N
benefit NN N
of IN N
a DT N
shorter JJR N
hospital NN N
stay NN N
for IN N
children NNS p
with IN p
blood-borne JJ p
musculoskeletal JJ p
infection NN p
. . p

The DT N
use NN N
of IN N
this DT N
scoring VBG N
system NN N
in IN N
choosing VBG N
the DT N
route NN N
of IN N
antibiotic JJ i
administration NN N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -X- O O

A DT N
short-term JJ i
cognitive JJ i
group NN i
treatment NN i
program NN i
gives VBZ N
substantial JJ N
weight NN o
reduction NN o
up RB N
to TO N
18 CD N
months NNS N
from IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

A DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
describe VB N
and CC N
evaluate VB N
long-term JJ N
efficacy NN N
( ( N
18 CD N
months NNS N
from IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
of IN N
a DT N
new JJ N
cognitive JJ i
short-term JJ i
weight NN i
reducing VBG i
treatment NN i
program NN i
for IN N
obese JJ p
patients NNS p
. . p

SUBJECTS NNP N
One CD p
hundred CD p
and CC p
five CD p
obese JJ p
[ NN p
Body NNP p
Mass NNP p
Index NNP p
( ( p
BMI NNP p
) ) p
> VBD p
or CC p
= $ p
30 CD p
] JJ p
patients NNS p
participated VBN p
in IN p
the DT p
study NN p
. . p

Of IN N
these DT N
, , N
62 CD p
took VBD p
part NN p
in IN p
the DT p
treatment NN p
program NN p
and CC p
43 CD p
served VBD p
as IN p
controls NNS p
. . p

METHOD NNP N
From IN N
an DT N
obesity NN p
unit NN p
's POS p
waiting VBG p
list NN p
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
treatment NN N
group NN N
or CC N
remained VBN N
in IN N
the DT N
waiting VBG N
list NN N
to TO N
serve VB N
as IN N
a DT N
control NN i
group NN N
. . N

The DT N
treatment NN N
group NN N
participated VBD N
in IN N
a DT N
10-week JJ i
( ( i
30 CD i
hours NNS i
) ) i
cognitive VBP i
group NN i
treatment NN i
program NN i
. . i

All DT N
participants NNS N
were VBD N
weighed VBN N
at IN N
the DT N
outset NN N
of IN N
the DT N
study NN N
, , N
directly RB N
after IN N
treatment NN N
and CC N
at IN N
a DT N
6- JJ N
, , N
12- JJ N
and CC N
18-month JJ N
post-treatment JJ i
follow-up NN N
without IN N
any DT N
booster NN N
treatment NN i
after IN N
the DT N
10-week JJ N
program NN N
. . N

RESULTS NNP N
Fifty-seven NNP p
( ( p
92 CD p
% NN p
) ) p
patients NNS p
completed VBN p
treatment NN i
. . i

For IN N
the DT N
34 CD N
( ( N
60 CD N
% NN N
) ) N
patients NNS N
who WP N
participated VBD N
in IN N
the DT N
study NN N
18 CD N
months NNS N
after IN N
treatment NN N
was VBD N
terminated VBN N
, , N
the DT N
mean JJ o
weight NN o
loss NN o
at IN N
treatment NN N
's POS N
end NN N
was VBD N
8.5 CD N
kg NN N
( ( N
SD=16.1 NNP N
) ) N
. . N

Eighteen JJ N
months NNS N
later RB N
their PRP$ N
mean JJ o
weight NN o
loss NN o
was VBD N
10.4 CD N
kg NN N
( ( N
SD=10.8 NNP N
) ) N
. . N

The DT N
control NN N
patients NNS N
( ( N
n=31.72 JJ N
% NN N
) ) N
that WDT N
participated VBD N
in IN N
the DT N
study NN N
during IN N
the DT N
same JJ N
period NN N
increased VBD N
in IN N
weight NN o
by IN N
2.3 CD N
kg NNS N
( ( N
SD=7.0 NNP N
) ) N
. . N

The DT N
weight NN o
difference NN o
between IN N
the DT N
treatment NN N
and CC N
control NN N
group NN N
at IN N
the DT N
18-month JJ N
follow-up NN N
was VBD N
highly RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
cognitive JJ i
group NN i
treatment NN i
program NN i
was VBD N
highly RB N
acceptable JJ N
among IN N
the DT N
participants NNS N
and CC N
was VBD N
completed VBN N
by IN N
nearly RB N
all PDT N
the DT N
patients NNS N
. . N

The DT N
10-week JJ N
treatment NN N
program NN N
resulted VBD N
in IN N
satisfactory JJ N
weight JJ o
loss NN o
. . o

The DT N
weight NN N
difference NN N
between IN N
the DT N
treatment NN i
group NN N
and CC N
controls NNS i
was VBD N
nearly RB N
the DT N
same JJ N
at IN N
18 CD N
months NNS N
after IN N
end NN N
of IN N
treatment NN N
as IN N
at IN N
six CD N
months NNS N
. . N

The DT N
study NN N
, , N
therefore RB N
, , N
does VBZ N
not RB N
provide VB N
support NN N
for IN N
the DT N
contention NN N
that IN N
a DT N
lengthy JJ N
therapy NN N
for IN N
obesity NN N
is VBZ N
necessary JJ N
if IN N
treatment NN N
results NNS N
are VBP N
lasting VBG N
. . N

-DOCSTART- -X- O O

Nitroglycerin NNP i
, , i
nitroprusside RB i
, , N
or CC N
both DT N
, , N
in IN N
preventing VBG N
radial JJ o
artery NN o
spasm NN o
during IN N
transradial JJ p
artery NN p
catheterization NN p
. . p

OBJECTIVE NNP N
Radial JJ N
artery NN N
spasm NN N
remains VBZ N
a DT N
major JJ N
complication NN N
of IN N
transradial JJ N
coronary JJ N
interventions NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
three CD N
different JJ N
intra-arterial JJ N
vasodilating NN i
cocktails NNS i
in IN N
reducing VBG N
the DT N
incidence NN N
of IN N
radial JJ o
artery NN o
spasm NN o
in IN N
patients NNS p
undergoing VBG p
transradial JJ p
coronary JJ p
angiography NN p
. . p

The DT N
secondary JJ N
goal NN N
was VBD N
to TO N
assess VB N
the DT N
predictors NNS o
of IN o
arterial JJ o
spasm NN o
in IN N
this DT N
large JJ N
group NN N
of IN N
patients NNS N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
379 CD p
patients NNS p
undergoing VBG p
the DT p
procedure NN p
were VBD p
randomly RB p
enrolled VBN p
in IN N
1 CD N
of IN N
3 CD N
groups NNS N
. . N

Every DT N
patient NN N
in IN N
each DT N
of IN N
the DT N
3 CD N
groups NNS N
received VBD N
intra-arterial JJ N
heparin NN i
, , i
lidocaine NN i
and CC N
diltiazem NN i
. . i

Along IN N
with IN N
that DT N
, , N
patients NNS N
in IN N
Group NNP N
A NNP N
received VBD N
nitroglycerin JJ i
; : i
patients NNS N
in IN N
Group NNP N
B NNP N
received VBD N
nitroprusside JJ i
instead RB N
of IN N
nitroglycerin NN i
; : i
and CC N
patients NNS N
in IN N
Group NNP N
C NNP N
received VBD N
both DT N
nitroglycerin NNS i
and CC i
nitroprusside RB i
. . i

A DT N
single JJ N
experienced NN N
operator NN N
, , N
blinded VBD N
to TO N
the DT N
study NN N
drug NN N
, , N
subjectively RB N
determined VBD N
the DT N
presence NN N
of IN N
spasm NN o
. . o

RESULTS NNP N
Of IN N
379 CD N
patients NNS N
, , N
a DT N
total NN N
of IN N
44 CD N
patients NNS N
( ( N
11.6 CD N
% NN N
) ) N
experienced VBD N
spasm NN N
. . N

The DT N
occurrence NN N
of IN N
spasm NN o
was VBD N
similar JJ N
, , N
independent JJ N
of IN N
the DT N
vasodilator NN N
cocktail NN N
used VBN N
( ( N
Group NNP N
A NNP N
: : N
12.2 CD N
% NN N
, , N
Group NNP N
B NNP N
: : N
13.4 CD N
% NN N
, , N
Group NNP N
C NNP N
: : N
9.5 CD N
% NN N
; : N
p CC N
= VB N
0.597 CD N
) ) N
. . N

After IN N
multivariate JJ N
analysis NN N
, , N
the DT N
following JJ N
variables NNS N
were VBD N
found VBN N
to TO N
be VB N
independent JJ N
predictors NNS N
of IN N
spasm NN N
: : N
radial JJ N
artery NN N
diameter NN N
( ( N
RD NNP N
) ) N
/height VBD N
index NN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
, , N
RD/BSA NNP N
index NN N
( ( N
p JJ N
= NNP N
0.012 CD N
) ) N
, , N
and CC N
sheath NN N
outer NN N
diameter NN N
( ( N
OD NNP N
) ) N
/RD NNP N
index NN N
( ( N
p JJ N
= NNP N
0.024 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
this DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
, , N
the DT N
addition NN N
of IN N
a DT N
direct JJ i
nitric JJ i
oxide NN i
donor NN i
to TO N
nitroglycerin VB i
in IN N
an DT N
antispastic JJ N
cocktail NN N
did VBD N
not RB N
reduce VB o
the DT o
risk NN o
of IN o
spasm NN o
, , N
and CC N
the DT N
use NN N
of IN N
nitroglycerin NN i
was VBD N
found VBN N
to TO N
be VB N
as RB o
effective JJ o
as IN o
nitroprusside NN i
. . i

Also RB N
, , N
morphometric JJ N
and CC N
mechanical JJ N
factors NNS N
play VBP N
a DT N
significant JJ N
role NN N
in IN N
predicting VBG o
the DT o
occurrence NN o
of IN o
radial JJ o
spasm NN o
. . o

The DT N
sex NN N
of IN N
the DT N
patient NN N
, , N
presence NN N
of IN N
diabetes NNS N
, , N
body NN N
surface JJ N
area NN N
and CC N
smoking VBG N
history NN N
appeared VBD N
to TO N
play VB N
no DT N
role NN N
in IN N
predicting VBG o
the DT o
occurrence NN o
of IN o
radial JJ o
spasm NN o
. . o

-DOCSTART- -X- O O

A DT N
double-blind JJ N
comparison NN N
of IN N
clomipramine NN i
, , i
desipramine NN i
, , i
and CC i
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ p
disorder NN p
. . p

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
clomipramine NN i
hydrochloride NN i
, , N
a DT N
serotonin JJ N
reuptake NN N
blocker NN N
with IN N
unique JJ N
anti-obsessional JJ N
properties NNS N
, , N
is VBZ N
differentially RB N
effective JJ N
for IN N
obsessive-compulsive JJ N
and CC N
stereotyped VBD N
motor NN N
behaviors NNS N
in IN N
autistic JJ N
disorder NN N
compared VBN N
with IN N
placebo NN i
and CC N
with IN N
the DT N
noradrenergic JJ i
tricyclic JJ i
antidepressant NN i
agent NN i
, , i
desipramine JJ i
hydrochloride NN i
. . i

DESIGN NNP N
Following VBG N
a DT N
2-week JJ N
, , N
single-blind JJ N
placebo NN i
washout IN N
phase NN N
, , N
12 CD p
autistic JJ p
subjects NNS p
completed VBD N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
comparison NN N
of IN N
clomipramine NN i
and CC i
placebo NN i
, , N
and CC N
12 CD p
different JJ p
subjects NNS p
completed VBD N
a DT N
similar JJ N
comparison NN N
of IN N
clomipramine NN i
and CC N
desipramine NN i
. . i

SETTING CC N
Outpatient JJ N
clinic NN N
. . N

PATIENTS VB N
A DT p
referral JJ p
sample NN p
of IN p
30 CD p
male NN p
and CC p
female JJ p
autistic JJ p
patients NNS p
were VBD p
enrolled VBN p
, , p
and CC p
24 CD p
completed VBD p
the DT p
study NN p
. . p

MEASURES NNP N
Key NNP N
outcome NN N
measures NNS N
were VBD N
the DT N
Autism NNP o
Relevant NNP o
Subscale NNP o
of IN o
the DT o
Children NNP o
's POS o
Psychiatric NNP o
Rating NNP o
Scale NNP o
, , o
the DT o
Modified NNP o
Comprehensive NNP o
Psychopathological NNP o
Rating NNP o
Scale-Obsessive-Compulsive JJ o
Disorder NNP o
Subscale NNP o
, , o
and CC o
the DT o
Clinical NNP o
Global NNP o
Impressions NNP o
Scale NNP o
. . o

RESULTS NNP N
Clomipramine NNP i
was VBD N
superior JJ N
to TO N
both DT N
placebo NN N
and CC N
desipramine NN N
on IN N
ratings NNS N
of IN N
autistic JJ o
symptoms NNS o
( ( o
including VBG o
stereotypies NNS o
) ) o
, , o
anger NN o
, , o
and CC o
compulsive JJ o
, , o
ritualized JJ o
behaviors NNS o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
with IN N
no DT N
differences NNS N
between IN N
desipramine NN i
and CC N
placebo NN i
. . i

Clomipramine NNP i
was VBD N
equal JJ N
to TO N
desipramine VB i
and CC N
both DT N
tricyclic JJ N
agents NNS N
were VBD N
superior JJ N
to TO N
placebo VB N
for IN N
amelioration NN N
of IN N
hyperactivity NN o
. . o

CONCLUSION NNP N
Biological NNP N
links NNS N
between IN N
compulsions NNS N
and CC N
stereotyped VBD N
, , N
repetitive JJ N
behaviors NNS N
in IN N
autistic JJ p
disorder NN p
should MD N
be VB N
explored VBN N
. . N

-DOCSTART- -X- O O

Carbenicillin-trimethoprim/sulfamethoxazole JJ i
versus NN i
carbenicillin-gentamicin NN i
as IN N
empiric JJ N
therapy NN N
of IN N
infection NN N
in IN N
granulocytopenic JJ p
patients NNS p
. . p

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
. . N

The DT N
results NNS N
of IN N
therapy NN N
with IN N
carbenicillin JJ i
plus CC i
trimethoprim-sulfamethoxazole JJ i
( ( i
C-T/S NNP i
) ) i
were VBD i
compared VBN i
to TO i
those DT i
obtained VBN i
with IN i
carbenicillin JJ i
plus CC i
gentamicin JJ i
( ( i
C-G NNP i
) ) i
in IN N
a DT N
prospective JJ N
double-blind NN N
study NN N
of IN N
empiric JJ N
antibiotic JJ N
therapy NN N
in IN N
granulocytopenic JJ p
patients NNS p
. . p

Patients NNS p
were VBD p
stratified VBN p
into IN p
two CD p
groups NNS p
: : p
favorable-prognosis NN p
, , p
group NN p
1 CD p
( ( p
carcinoma NN p
, , p
lymphoma NN p
, , p
multiple JJ p
myeloma NN p
) ) p
, , p
or CC p
unfavorable-prognosis NN p
, , p
group NN p
2 CD p
( ( p
acute JJ p
leukemia NN p
, , p
bone NN p
marrow NN p
transplantation NN p
) ) p
, , p
based VBN p
on IN p
anticipated JJ p
duration NN p
of IN p
granulocytopenia NN p
. . p

Over-all NN N
, , N
empiric JJ N
antibiotic JJ N
trials NNS N
were VBD N
more RBR N
often RB N
successful JJ o
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
in IN N
group NN N
1 CD N
( ( N
55 CD N
of IN N
62 CD N
patients NNS N
or CC N
89 CD N
per IN N
cent NN N
) ) N
than IN N
in IN N
group NN N
2 CD N
( ( N
42 CD N
of IN N
64 CD N
patients NNS N
, , N
66 CD N
per IN N
cent NN N
) ) N
mwithin NN N
group NN N
1 CD N
, , N
there EX N
was VBD N
a DT N
favorable JJ o
outcome NN o
in IN N
30 CD N
of IN N
32 CD N
( ( N
94 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
and CC N
in IN N
25 CD N
of IN N
30 CD N
( ( N
83 CD N
per IN N
cent NN N
) ) N
C-G NN N
trials NNS N
( ( N
P NNP N
= NNP N
0.25 CD N
) ) N
; : N
within IN N
group NN N
2 CD N
, , N
there EX N
was VBD N
a DT N
favorable JJ N
outcome NN N
in IN N
23 CD N
of IN N
30 CD N
( ( N
77 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
and CC N
in IN N
19 CD N
of IN N
34 CD N
( ( N
56 CD N
per IN N
cent NN N
) ) N
C-G NN N
trials NNS N
( ( N
P NNP N
= NNP N
0.14 CD N
) ) N
, , N
Combined VBN N
results NNS N
in IN N
both DT N
groups NNS N
indicated VBD N
a DT N
higher JJR N
proportion NN N
of IN N
favorable JJ o
outcome NN o
in IN N
C-T/S NNP N
trials NNS N
( ( N
53 CD N
of IN N
62 CD N
, , N
85 CD N
per IN N
cent NN N
) ) N
than IN N
in IN N
C-G JJ N
trials NNS N
( ( N
44 CD N
of IN N
64 CD N
, , N
69 CD N
per IN N
cent NN N
) ) N
. . N

Further JJ N
analysis NN o
( ( o
Manetl-Naenszel NNP o
test NN o
) ) o
showed VBD N
the DT N
over-all JJ N
difference NN N
in IN N
outcome NN N
to TO N
be VB N
significant JJ N
( ( N
P NNP N
= NNP N
0.049 CD N
) ) N
, , N
but CC N
the DT N
general JJ N
applicability NN N
of IN N
this DT N
result NN N
may MD N
be VB N
limited VBN N
by IN N
the DT N
rather RB N
low JJ N
incidence NN N
of IN N
gram-negative JJ N
bacterial JJ N
infections NNS N
in IN N
this DT N
study NN N
. . N

There EX N
was VBD N
no DT o
difference NN o
between IN N
the DT N
treatment NN N
regimens VBZ N
in IN N
antibiotic JJ o
toxicity NN o
, , N
and CC N
serious JJ o
superinfection NN o
occurred VBD N
only RB N
in IN N
group NN N
2 CD N
patients NNS N
( ( N
21 CD N
per IN N
cent NN N
of IN N
trials NNS N
) ) N
, , N
equally RB N
divided VBD N
between IN N
treatment NN N
arms NNS N
. . N

Initial JJ N
protocol NN N
dosing VBG N
achieved VBN N
target NN N
plasma NN N
levels NNS N
of IN N
trimethoprim NN N
( ( N
3 CD N
to TO N
8 CD N
micrograms/ml NN N
) ) N
or CC N
gentamicin NN N
( ( N
4 CD N
to TO N
10 CD N
micrograms/ml NN N
) ) N
in IN N
57 CD N
of IN N
68 CD N
( ( N
84 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
compared VBN N
to TO N
21 CD N
of IN N
60 CD N
( ( N
35 CD N
per IN N
cent NN N
) ) N
C-G NNP N
trials NNS N
. . N

-DOCSTART- -X- O O

Greater NNP N
knowledge NN o
gain NN o
with IN N
structured VBN i
than IN N
student-directed JJ i
learning NN i
in IN N
Child NNP p
Health NNP p
: : p
cluster NN N
randomized VBD N
trial NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
detect VB N
a DT N
difference NN N
in IN N
knowledge NN o
gain NN o
between IN N
students NNS p
receiving VBG p
structured JJ i
versus NN i
student-directed JJ i
learning NN i
for IN p
the DT p
two-week JJ p
Child NNP p
Health NNP p
outpatient NN p
module NN p
. . p

A DT p
total NN p
of IN p
138 CD p
phase NN p
3 CD p
( ( p
year NN p
4 CD p
) ) p
medical JJ p
students NNS p
in IN p
10 CD p
two-week JJ p
paediatric JJ p
outpatient NN p
blocks NNS p
at IN p
the DT p
Department NNP p
of IN p
Child NNP p
Health NNP p
, , p
University NNP p
of IN p
Dundee NNP p
, , p
Scotland NNP p
, , N
were VBD N
randomized VBN N
to TO N
student-directed JJ i
or CC i
structured VBN i
learning NN i
between IN N
January NNP N
and CC N
December NNP N
2002 CD N
. . N

Pre- JJ o
and CC o
post-course JJ o
tests NNS o
were VBD N
administered VBN N
at IN N
the DT N
start NN N
and CC N
the DT N
end NN N
of IN N
the DT N
attachment NN N
; : N
129 CD p
students NNS p
sat VBD p
both DT p
tests NNS p
. . p

Results NNS N
are VBP N
presented VBN N
as IN N
mean JJ N
scores NNS N
with IN N
standard JJ N
deviations NNS N
or CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CI NNP N
) ) N
in IN N
parentheses NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
gain NN o
in IN o
knowledge NN o
of IN N
the DT N
Child NNP N
Health NNP N
core NN N
curriculum NN N
that WDT N
is VBZ N
covered VBN N
in IN N
the DT N
outpatient JJ N
setting NN N
. . N

Although IN N
pre-course JJ o
scores NNS o
were VBD N
similar JJ N
( ( N
student-directed JJ N
25.3 CD N
( ( N
7.3 CD N
) ) N
; : N
structured VBN N
24.8 CD N
( ( N
7.5 CD N
) ) N
) ) N
the DT N
structured JJ N
approach NN N
resulted VBD N
in IN N
higher JJR N
post-course NN o
scores NNS o
in IN N
comparison NN N
with IN N
the DT N
student-directed JJ N
approach NN N
( ( N
student-directed JJ N
41.8 CD N
( ( N
9.4 CD N
) ) N
; : N
structured VBN N
53.8 CD N
( ( N
8.8 CD N
) ) N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

Knowledge NNP o
gain NN o
showed VBD N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
learning NN N
approaches NNS N
( ( N
student-directed JJ N
16.5 CD N
( ( N
3.7 CD N
) ) N
; : N
structured VBN N
29.1 CD N
( ( N
3.8 CD N
) ) N
, , N
difference NN N
= VBD N
12.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
11.3 CD N
to TO N
13.9 CD N
) ) N
) ) N
. . N

Low JJ N
pre-course JJ o
scores NNS o
or CC N
gender VB N
did VBD N
not RB N
affect VB N
knowledge NN o
gain NN o
. . o

In IN N
the DT N
Child NNP N
Health NNP N
outpatient NN N
setting NN N
, , N
the DT N
'traditional NNP N
' POS N
structured JJ N
approach NN N
led VBD N
to TO N
significantly RB N
greater JJR N
knowledge NN o
gain NN o
in IN N
comparison NN N
with IN N
the DT N
'novel NNP N
' POS N
student-directed JJ N
approach NN N
. . N

The DT N
findings NNS N
emphasize VBP N
the DT N
importance NN N
of IN N
careful JJ N
evaluation NN N
of IN N
novel JJ N
medical JJ N
education NN N
strategies NNS N
before IN N
their PRP$ N
implementation NN N
in IN N
medical JJ N
schools NNS N
, , N
and CC N
the DT N
need NN N
for IN N
further JJ N
research NN N
to TO N
define VB N
the DT N
effective JJ N
methods NNS N
for IN N
delivering VBG N
medical JJ N
education NN N
in IN N
Child NNP N
Health NNP N
. . N

-DOCSTART- -X- O O

Qingre NNP N
quyu NN N
granule NN N
stabilizes VBZ N
plaques NNS N
through IN N
inhibiting VBG N
the DT N
expression NN N
of IN N
tenascin-C NN N
in IN N
patients NNS p
with IN p
severe JJ p
carotid NN p
stenosis NN p
. . p

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
therapeutic JJ o
effects NNS o
of IN N
Qingre NNP i
Quyu NNP i
Granule NNP i
( ( i
QQG NNP i
) ) i
on IN N
the DT N
patients NNS p
with IN p
severe JJ p
carotid NN p
stenosis NN p
, , N
and CC N
to TO N
explore VB N
the DT N
mechanism NN N
of IN N
it PRP N
. . N

METHODS NNP N
Ninety-six JJ p
patients NNS p
with IN p
severe JJ p
carotid NN p
stenosis NN p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
and CC N
were VBD N
classified VBN N
into IN N
a DT N
QQG NNP i
group NN N
( ( N
n=48 CC N
) ) N
and CC N
a DT N
control NN i
group NN i
( ( N
n=48 RB N
) ) N
randomly RB N
using VBG N
consecutively RB N
numbered JJ N
envelopes NNS N
. . N

The DT N
patients NNS N
in IN N
the DT N
QQG NNP i
group NN N
were VBD N
given VBN N
QQG NNP i
and CC N
Western NNP i
medicine NN i
, , N
those DT N
in IN N
the DT N
control NN N
group NN N
were VBD N
given VBN N
Western JJ i
medicine NN i
merely RB N
, , N
the DT N
course NN N
of IN N
treatment NN N
was VBD N
16 CD N
weeks NNS N
. . N

All DT N
patients NNS N
went VBD N
through IN N
endarterectomy NN N
after IN N
treatment NN N
. . N

Plaques NNS N
were VBD N
subjected VBN N
to TO N
the DT N
analysis NN N
of IN N
CD3 NNP N
, , N
CD68 NNP N
, , N
soluble JJ N
intercellular JJ N
adhesion NN N
molecule NN N
1 CD N
( ( N
ICAM-1 NNP N
) ) N
, , N
matrix JJ N
metalloprotease-9 NN N
( ( N
MMP-9 NNP N
) ) N
, , N
CD40L NNP N
, , N
tenascin-C NN N
, , N
and CC N
collagen NN N
content NN N
lipid JJ N
content NN N
by IN N
immunohistochemistry NN N
or CC N
polarized VBN N
light JJ N
analysis NN N
. . N

RESULTS VBN N
By IN N
the DT N
end NN N
of IN N
experiment NN N
, , N
the DT N
expressions NNS o
of IN o
CD3 NNP o
, , o
CD68 NNP o
, , o
ICAM-1 NNP o
, , o
MMP9 NNP o
, , o
CD40L NNP o
and CC o
tenascin-C NN o
on IN N
the DT N
plaques NNS N
were VBD N
statistically RB N
significant JJ N
lower JJR N
in IN N
the DT N
QQG NNP N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
lipid JJ o
content NN o
of IN o
the DT o
plaque NN o
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
QQG NNP i
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
interstitial JJ N
collagen NN N
in IN N
the DT N
tissue NN N
sections NNS N
of IN N
the DT N
plaques NNS N
was VBD N
also RB N
significantly RB N
higher RBR N
in IN N
the DT N
QQG NNP i
group NN N
in IN N
comparison NN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
QQG NNP i
could MD N
stabilize VB N
carotid JJ N
artery NN N
plaques NNS N
through IN N
inhibiting VBG N
pro-inflammation NN N
factors NNS N
and CC N
restraining VBG N
the DT N
tenascin-C NN N
and CC N
MMP9 NNP N
pathway NN N
. . N

-DOCSTART- -X- O O

Parent NN p
and CC p
family NN p
outcomes NNS p
of IN p
PEERS NNS i
: : i
a DT p
social JJ i
skills NNS i
intervention NN i
for IN p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Raising VBG N
a DT N
child NN p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
is VBZ N
associated VBN N
with IN N
increased VBN N
family NN p
chaos NN N
and CC N
parent NN p
distress NN N
. . N

Successful JJ N
long-term JJ N
treatment NN N
outcomes NNS N
are VBP N
dependent JJ N
on IN N
healthy JJ N
systemic JJ N
functioning NN N
, , N
but CC N
the DT N
family NN o
impact NN o
of IN o
treatment NN o
is VBZ N
rarely RB N
evaluated VBN N
. . N

The DT i
Program NNP i
for IN i
the DT i
Education NNP i
and CC i
Enrichment NNP i
of IN i
Relational NNP i
Skills NNP i
( ( i
PEERS NNP i
) ) i
is VBZ N
a DT N
social JJ N
skills NNS N
intervention NN N
designed VBN N
for IN N
adolescents NNS p
with IN p
high-functioning JJ p
ASD NNP p
. . p

This DT N
study NN N
assessed VBD N
the DT N
impact NN N
of IN N
PEERS NNS o
on IN N
family NN o
chaos NN o
, , o
parenting VBG o
stress NN o
, , o
and CC o
parenting VBG o
self-efficacy NN o
via IN N
a DT N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

Results NNP N
suggested VBD N
beneficial JJ N
effects NNS N
for IN N
the DT N
experimental JJ N
group NN N
in IN N
the DT N
domain NN N
of IN N
family NN o
chaos NN o
compared VBN N
to TO N
the DT N
waitlist NN N
control NN N
, , N
while IN N
parents NNS p
in IN p
the DT p
PEERS NNP i
experimental JJ p
group NN p
also RB N
demonstrated VBD N
increased JJ N
parenting VBG o
self-efficacy NN o
. . o

These DT N
findings NNS N
highlight VBD N
adjunctive JJ N
family NN N
system NN N
benefits NNS N
of IN N
PEERS NNP i
intervention NN i
and CC N
suggest VBP N
the DT N
need NN N
for IN N
overall JJ N
better JJR N
understanding NN N
of IN N
parent NN N
and CC N
family NN N
outcomes NNS N
of IN N
ASD NNP N
interventions NNS N
. . N

-DOCSTART- -X- O O

Calcium NN i
acetate NN i
versus NN N
calcium NN i
carbonate NN i
as IN N
phosphate NN N
binders NNS N
in IN N
hemodialysis NN p
patients NNS p
. . p

We PRP N
conducted VBD N
a DT N
randomized VBN N
unblinded JJ N
parallel RB N
clinical JJ N
trial NN N
to TO N
compare VB N
the DT N
effectiveness NN o
, , o
side NN o
effects NNS o
and CC o
tolerance NN o
between IN o
calcium NN o
acetate NN o
( ( o
CA NNP o
) ) o
and CC o
calcium NN o
carbonate NN o
( ( o
CC NNP o
) ) o
in IN N
80 CD p
stable JJ p
chronic JJ p
hemodialysis NN p
patients NNS p
selected VBN p
on IN p
the DT p
basis NN p
of IN p
their PRP$ p
acceptable JJ p
control NN p
of IN p
serum NN p
phosphorus NN p
( ( p
P NNP p
) ) p
levels NNS p
with IN p
aluminum NN p
hydroxide NN p
( ( p
AH NNP p
) ) p
. . p

All DT N
patients NNS p
were VBD p
dialyzed VBN p
against IN p
the DT p
same JJ p
calcium NN i
dialyzate NN i
( ( N
1.62 CD N
mmol/l NN N
) ) N
. . N

The DT N
serum JJ N
analytical JJ N
tests NNS N
included VBD N
: : N
calcium NN o
corrected VBD o
to TO o
total JJ o
protein NN o
, , o
P NNP o
, , o
PTH NNP o
( ( o
intact JJ o
molecule NN o
) ) o
and CC o
bicarbonate NN o
. . o

The DT N
study NN N
was VBD N
divided VBN N
into IN N
the DT N
following JJ N
periods NNS N
: : N
P0 NN N
: : N
baseline NN N
measurements NNS N
; : N
P1 NNP N
: : N
washout NN N
( ( N
withdrawal NN N
of IN N
AH NNP N
for IN N
15 CD N
days NNS N
) ) N
; : N
P2 NNP N
: : N
random NN N
allocation NN N
to TO N
CA NNP i
and CC N
CC NNP i
treatment NN N
at IN N
doses NNS N
equivalent JJ N
to TO N
75 CD N
mEq NN N
of IN N
elemental JJ N
calcium NN N
, , N
stratified VBD N
according VBG N
to TO N
previous JJ N
doses NNS N
of IN N
AH NNP N
( ( N
2 CD N
months NNS N
) ) N
; : N
P3 NNP N
: : N
adjustment NN N
of IN N
doses NNS N
until IN N
control NN N
P NNP N
( ( N
2 CD N
months NNS N
) ) N
. . N

CA NNP o
was VBD o
poorly RB o
tolerated VBN o
in IN N
7 CD N
patients NNS N
and CC N
CC NNP N
in IN N
2 CD N
( ( N
NS NNP N
) ) N
. . N

The DT N
changes NNS o
in IN o
serum NN o
P NNP o
levels NNS o
between IN N
P0 NNP N
and CC N
P2 NNP N
periods NNS N
were VBD N
lower JJR N
in IN N
the DT N
CA NNP N
group NN N
( ( N
1.73 CD N
+/- JJ N
0.25 CD N
vs. FW N
1.80 CD N
+/- JJ N
0.50 CD N
mmol/l NN N
; : N
p CC N
= VB N
0.26 CD N
) ) N
than IN N
in IN N
the DT N
CC NNP N
group NN N
( ( N
1.77 CD N
+/- JJ N
0.35 CD N
vs. FW N
1.93 CD N
+/- JJ N
0.48 CD N
mmol/l NN N
; : N
p CC N
= $ N
0.03 CD N
, , N
paired VBD N
t JJ N
test NN N
) ) N
. . N

Serum NNP o
calcium NN o
was VBD N
hardly RB N
modified VBN N
by IN N
CA NNP N
( ( N
2.42 CD N
+/- JJ N
0.20 CD N
vs. FW N
2.47 CD N
+/- JJ N
0.17 CD N
mmol/l NN N
; : N
NS NNP N
) ) N
while IN N
in IN N
the DT N
CC NNP N
group NN N
, , N
it PRP N
rose VBD N
significantly RB N
( ( N
2.40 CD N
+/- JJ N
0.12 CD N
vs. FW N
2.55 CD N
+/- JJ N
0.22 CD N
mmol/l NN N
; : N
p CC N
= VB N
0.0004 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
control NN N
of IN N
PTH NNP N
or CC N
bicarbonate NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Acamprosate NNP i
appears VBZ N
to TO N
decrease VB o
alcohol JJ o
intake NN o
in IN N
weaned JJ p
alcoholics NNS p
. . p

Five CD p
hundred JJ p
and CC p
sixty-nine JJ p
alcoholics NNS p
were VBD N
included VBN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ i
randomized VBN N
multicenter NN N
study NN N
of IN N
the DT N
effects NNS N
of IN N
Acamprosate NNP i
( ( i
calcium NN i
acetylhomotaurinate NN i
( ( i
CA NNP i
) ) i
, , i
1.3 CD i
g/day NN i
) ) i
on IN N
indicators NNS N
of IN N
alcoholic JJ N
relapse NN N
after IN N
withdrawal NN N
. . N

One CD p
hundred CD p
and CC p
eighty-one JJ p
patients NNS p
in IN p
the DT p
CA NNP i
group NN p
versus VBD p
175 CD p
in IN p
the DT p
placebo NN i
group NN p
completed VBD p
the DT p
three-month JJ p
study NN p
. . p

The DT N
major JJ N
efficacy NN N
criterion NN N
was VBD N
plasma JJ N
gamma-glutamyl JJ N
transpeptidase NN N
( ( N
GGT NNP N
) ) N
, , N
as IN N
an DT N
indicator NN N
of IN N
recent JJ N
alcohol NN N
ingestion NN N
. . N

This DT N
analysis NN N
was VBD N
completed VBN N
by IN N
criteria NNS N
concordance NN N
analysis NN N
on IN N
a DT N
number NN N
of IN N
indicators NNS N
of IN N
alcohol NN N
intake NN N
. . N

Patients NNS N
in IN N
both DT N
groups NNS N
were VBD N
similar JJ N
initially RB N
. . N

After IN N
3 CD N
months NNS N
of IN N
treatment NN N
, , N
the DT N
patients NNS N
in IN N
the DT N
CA NNP i
group NN N
had VBD N
significantly RB N
lower JJR o
GGT NNP o
( ( N
1.4 CD N
+/- JJ N
1.56 CD N
versus NN N
2.0 CD N
+/- JJ N
3.19 CD N
times NNS N
normal JJ N
, , N
P NNP N
= NNP N
0.016 CD N
) ) N
. . N

All DT N
significant JJ N
differences NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
or CC N
trends NNS N
( ( N
0.10 CD N
greater JJR N
than IN N
P NNP N
greater JJR N
than IN N
0.05 CD N
) ) N
were VBD N
in IN N
favor NN N
of IN N
a DT N
superior JJ N
effect NN N
of IN N
CA NNP i
over IN N
placebo NN i
. . i

The DT N
major JJ N
side-effect NN N
of IN N
CA NNP i
was VBD N
diarrhea VBN o
( ( N
present JJ N
in IN N
13 CD N
% NN N
of IN N
CA NNP N
patients NNS N
versus VBP N
7 CD N
% NN N
of IN N
placebo NN i
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

CA NNP i
proved VBD N
superior JJ N
to TO N
placebo VB i
on IN N
the DT N
evolution NN N
of IN N
markers NNS N
of IN N
alcohol NN N
ingestion NN N
at IN N
three CD N
months NNS N
, , N
in IN N
this DT N
large-scale JJ N
multicenter NN N
study NN N
. . N

It PRP N
could MD N
be VB N
a DT N
new JJ N
modality NN N
in IN N
the DT N
drug NN N
therapy NN N
of IN N
alcoholism NN N
, , N
not RB N
involving VBG N
an DT N
antabuse NN N
effect NN N
, , N
an DT N
antidepressant JJ N
action NN N
, , N
or CC N
conditioning NN N
. . N

-DOCSTART- -X- O O

DESFLURANE NNP N
COMPARED NNP N
TO NNP N
SEVOFLURANE NNP N
FOR NNP N
CIRRHOTIC NNP p
PATIENTS NNP p
UNDERGOING NNP p
MAJOR NNP p
LIVER NNP p
RESECTION NNP p
. . p

A NNP N
RANDOMIZED NNP N
CONTROL NNP N
STUDY NNP N
. . N

BACKGROUND NNP N
Major NNP N
liver NN N
resection NN N
is VBZ N
associated VBN N
with IN N
haemodynamic JJ N
, , N
hepatic JJ N
and CC N
renal JJ N
changes NNS N
as IN N
a DT N
result NN N
of IN N
the DT N
procedure NN N
. . N

AIM NNP N
To TO N
compare VB N
Desflurane NNP i
( ( i
D NNP i
) ) i
versus NN i
Sevoflurane NNP i
( ( i
S NNP i
) ) i
on IN N
hepatic JJ o
, , o
renal JJ o
functions NNS o
, , o
haemodynamics NNS o
and CC o
perioperative JJ o
course NN o
for IN N
cirrhotic JJ p
patients NNS p
undergoing VBG p
major JJ p
liver NN p
resection NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
control NN N
study NN N
with IN N
50 CD p
patients NNS p
( ( p
Child NNP p
A NNP p
) ) p
( ( N
D NNP N
, , N
n JJ N
= NN N
25 CD N
and CC N
S NNP N
, , N
n JJ N
= NNP N
25 CD N
) ) N
. . N

End NN o
tidal JJ o
D NNP o
or CC o
S NNP o
adjusted VBN o
with IN o
Entropy NNP o
( ( N
40-60 JJ N
) ) N
. . N

Haemodynamics NNS o
monitored VBD o
with IN o
invasive JJ o
blood NN o
pressure NN o
and CC o
trans-oesophageal JJ o
Doppler NNP o
( ( o
TED NNP o
) ) o
. . o

Liver NNP o
and CC o
kidney VB o
function NN o
tests NNS o
, , o
blood NN o
Glutathione-S-transferase NNP o
( ( o
GST NNP o
) ) o
, , o
urinary JJ o
microalbuminuria NN o
( ( o
Microalb NNP o
) ) o
were VBD o
assayed VBN o
. . o

Extubation NN o
time NN o
and CC o
anaesthetic JJ o
consumption NN o
were VBD o
recorded VBN o
. . o

RESULTS NNP N
Systemic NNP o
vascular JJ o
resistance NN o
( ( o
SVR NNP o
) ) o
post-resection NN o
and CC o
stroke NN o
volume NN o
of IN N
D NNP N
vs FW N
S NNP N
were VBD N
835.04 CD N
? . N
12.02 CD N
vs NN N
778.16 CD N
? . N
11.97 CD N
dyn.sec.cm NN N
( ( N
-5 NNP N
) ) N
, , N
P NNP N
< NNP N
0.01 CD N
, , N
and CC N
85.72 CD N
? . N
2.95 CD N
vs NN N
76.16 CD N
? . N
6.52 CD N
ml NN N
, , N
P NNP N
< VBZ N
0.01 CD N
respectively RB o
. . o

Doppler NNP o
corrected VBD o
flow JJ o
time NN o
( ( o
FTc NNP o
) ) o
between IN o
groups NNS N
were VBD N
comparable JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

No DT N
difference NN N
post-operatively RB N
regarding VBG o
hepatic JJ o
and CC o
renal JJ o
functions NNS o
, , o
and CC o
urine JJ o
Microalb NNP o
( ( o
14.76 CD o
? . N
3.95 CD N
vs NN N
l4.24 NN N
? . N
8.65 CD N
?g/ml NN N
, , N
P NNP N
= NNP N
0.78 CD N
) ) N
, , N
but CC N
a DT N
statistically RB N
difference NN N
was VBD N
found VBN N
with IN o
GST NNP o
( ( o
0.046 CD o
? . N
[ JJ N
symbols NNS N
: : N
see VB N
text JJ N
] NNP N
, , N
vs VBD N
0.043 CD N
? . N
[ JJ N
symbols NNS N
: : N
see VB N
text JJ N
] NNP N
IU/ml NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Despite IN N
a DT N
higher JJR N
D NNP o
consumption NN o
( ( o
73 CD o
? . o
17 CD o
vs NN N
64 CD N
? . N
22 CD N
ml NN N
, , N
P NNP N
= NNP N
0.102 CD N
) ) N
, , N
cost NN o
in IN o
Egyptian JJ o
pounds NNS o
( ( o
LE NNP o
) ) N
was VBD N
lower JJR N
with IN N
D NNP N
( ( N
141.14 CD N
? . N
32.90 CD N
vs NN N
320.60 CD N
? . N
114.01 CD N
, , N
LE NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . o

Extubation NN o
time NN o
and CC o
ICU NNP o
stay VBP o
with IN N
D NNP N
vS NN N
( ( N
4.52 CD N
? . N
2 CD N
vs NN N
7.72 CD N
? . N
2 CD N
min NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
( ( N
1.40 CD N
0.50 CD N
vs NN N
1.64 CD N
? . N
0.48 CD N
, , N
days NNS N
P NNP N
= VBP N
0.09 CD N
) ) N
respectively RB N
. . N

CONCLUSION NNP N
Neither NNP N
D NNP N
nor CC N
S NNP N
were VBD N
clinically RB N
superior JJ N
to TO N
the DT N
other JJ N
with IN N
respect NN N
to TO N
liver VB o
and CC o
kidneys VB o
functions NNS o
, , o
but CC o
D NNP N
was VBD N
found VBN N
to TO N
preserve VB N
better JJR N
the DT o
haemodynamic JJ o
parameters NNS o
and CC o
enhance VB o
recovery NN o
at IN o
a DT o
lower JJR o
cost NN N
. . N

-DOCSTART- -X- O O

Body NNP N
Mass NNP N
Index NNP N
and CC N
Adverse NNP N
Outcomes NNP N
in IN N
Elderly JJ p
Patients NNS p
With IN p
Atrial JJ p
Fibrillation NN p
: : p
The DT N
AMADEUS NNP N
Trial NNP N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Obesity NNP N
has VBZ N
been VBN N
associated VBN N
with IN N
increased JJ N
cardiovascular NN N
risk NN N
in IN N
atrial JJ N
fibrillation NN N
, , N
but CC N
little JJ N
is VBZ N
known VBN N
in IN N
elderly JJ p
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
. . p

METHODS NNP N
Post NNP N
hoc NN N
analysis NN N
of IN N
data NNS N
from IN N
the DT N
AMADEUS NNP N
( ( N
Evaluating VBG N
the DT N
Use NNP N
of IN N
SR34006 NNP N
Compared NNP N
to TO N
Warfarin NNP i
or CC i
Acenocoumarol NNP i
in IN N
Patients NNP p
With IN p
Atrial NNP p
Fibrillation NNP p
) ) p
trial NN N
. . N

RESULTS NNP N
We PRP N
studied VBD N
1588 CD p
elderly JJ p
patients NNS p
, , p
who WP p
were VBD p
categorized VBN p
as IN p
normal JJ p
body NN p
mass NN p
index NN p
( ( p
BMI NNP p
, , p
18.5-25 JJ p
kg/m NN p
( ( p
2 CD p
) ) p
; : p
n=515 CC p
[ VB p
32.4 CD p
% NN p
] NN p
) ) p
, , p
overweight JJ p
( ( p
BMI NNP p
, , p
25-30 JJ p
kg/m NN p
( ( p
2 CD p
) ) p
; : p
n=711 CC p
[ VB p
44.8 CD p
% NN p
] NN p
) ) p
, , p
and CC p
obese JJ p
( ( p
BMI?30 NNP p
kg/m NNP p
( ( p
2 CD p
) ) p
; : p
n=362 CC p
[ VB p
22.8 CD p
% NN p
] NN p
) ) p
. . p

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
composite JJ N
outcome NN N
of IN N
cardiovascular JJ o
death NN o
and CC o
stroke/systemic JJ o
embolism NN o
with IN o
increasing VBG N
BMI NNP N
category NN N
, , N
being VBG N
5.0 CD N
% NN N
, , N
3.2 CD N
% NN N
, , N
and CC N
1.5 CD N
% NN N
per IN N
100 CD N
patient-years NNS N
, , N
respectively RB N
( ( N
P NNP N
for IN N
trend=0.01 NN N
) ) N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
analysis NN N
found VBD N
obesity NN N
to TO N
be VB N
associated VBN N
with IN N
a DT N
lower JJR N
risk NN N
of IN N
the DT N
primary JJ N
composite JJ N
outcome NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.29 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.11-0.77 JJ N
; : N
P=0.01 NNP N
) ) N
. . N

In IN N
the DT i
warfarin NN i
arm NN i
( ( N
n=814 NN N
) ) N
, , N
multivariate JJ N
logistic JJ N
regression NN N
analysis NN N
demonstrated VBD N
that IN N
obesity NN N
was VBD N
independently RB N
related VBN N
to TO N
higher JJR N
odds NNS N
of IN N
time NN N
in IN N
therapeutic JJ N
range NN N
?60 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
1.84 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.21-2.80 JJ N
; : N
P=0.004 NNP N
) ) N
. . N

CONCLUSION NNP N
Obesity NNP N
was VBD N
associated VBN N
with IN N
a DT o
lower JJR o
stroke NN o
and CC o
mortality NN o
rate NN o
in IN o
elderly JJ p
anticoagulated VBN p
atrial JJ p
fibrillation NN p
patients NNS p
. . p

Obesity NNP p
was VBD N
related VBN N
to TO N
good JJ N
quality NN N
anticoagulation NN N
control NN N
. . N

-DOCSTART- -X- O O

Efficacy NN o
of IN N
chlorhexidine NN i
gluconate NN i
use NN N
in IN N
the DT N
prevention NN N
of IN N
perirectal JJ N
infections NNS N
in IN N
patients NNS p
with IN p
acute JJ p
leukemia NN p
. . p

The DT N
frequency NN N
of IN N
rectal JJ o
infections NNS o
is VBZ N
increased VBN N
in IN N
patients NNS p
with IN p
acute JJ p
leukemia NN p
. . p

Complications NNS N
associated VBN N
with IN N
rectal JJ N
lesions NNS N
may MD N
be VB N
severe JJ N
enough RB N
to TO N
cause VB N
life-threatening JJ N
septicemia NN N
. . N

Clinical JJ N
research NN N
evaluating VBG N
the DT N
effects NNS N
of IN N
preventive JJ N
perirectal NN N
skin NN N
care NN N
is VBZ N
scarce JJ N
. . N

This DT N
study NN N
's POS N
purpose NN N
was VBD N
to TO N
determine VB N
whether IN N
using VBG N
chlorhexidine JJ i
gluconate NN i
( ( i
CHG NNP i
) ) i
in IN N
a DT N
prophylactic JJ N
perirectal JJ N
skin-care JJ N
regimen NNS N
decreases VBZ N
perirectal JJ N
infections NNS N
and CC N
whether IN N
it PRP N
produces VBZ N
more JJR N
skin JJ N
irritation NN N
than IN N
a DT N
nonmedicated JJ N
skin NN N
cleanser NN N
. . N

The DT N
sample NN p
consisted VBD p
of IN p
40 CD p
patients NNS p
, , N
16 CD N
of IN N
whom WP N
were VBD N
randomized VBN N
to TO N
use VB N
chlorhexidine NN i
and CC N
24 CD N
of IN N
whom WP N
were VBD N
randomized VBN N
to TO N
use VB N
nonmedicated JJ i
skin NN i
cleanser NN i
. . i

Chi-square JJ N
and CC N
t-tests NNS N
were VBD N
used VBN N
to TO N
analyze VB N
the DT N
incidence NN N
of IN N
skin JJ o
breakdown NN o
and CC N
rectal JJ o
infections NNS o
; : o
the DT N
correlation NN N
between IN N
the DT N
two CD N
factors NNS N
; : N
a DT N
positive JJ N
history NN N
of IN N
rectal JJ N
infections NNS N
, , N
fissures NNS N
, , N
or CC N
hemorrhoids NNS N
; : N
presence NN N
of IN N
hemorrhoids NNS N
; : N
severity NN N
of IN N
diarrhea NN N
; : N
and CC N
duration NN N
and CC N
severity NN N
of IN N
granulocytopenia NN N
. . N

A DT N
positive JJ N
relationship NN N
was VBD N
found VBN N
between IN N
the DT N
severity NN o
of IN o
granulocytopenia NN o
and CC N
the DT N
incidence NN o
of IN o
rectal JJ o
infections NNS o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
seen VBN N
in IN N
the DT N
occurrence NN o
of IN o
perirectal JJ o
infections NNS o
( ( N
p JJ N
= NNP N
0.35 CD N
) ) N
or CC N
skin JJ o
breakdown NN o
( ( N
p JJ N
= NNP N
0.18 CD N
) ) N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
data NN N
suggest NN N
that IN N
CHG NNP N
does VBZ N
not RB N
offer VB N
increased JJ N
protection NN N
against IN N
perirectal JJ N
infections NNS N
in IN N
patients NNS N
undergoing VBG N
intensive JJ N
chemotherapy NN N
, , N
nor CC N
is VBZ N
it PRP N
more RBR N
irritating JJ N
than IN N
a DT N
nonmedicated JJ N
skin NN N
cleanser NN N
. . N

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
hygienic JJ N
measures NNS N
such JJ N
as IN N
using VBG N
skin JJ N
disinfectants NNS N
to TO N
prevent VB N
infections NNS N
in IN N
patients NNS N
who WP N
are VBP N
immunocompromised VBN N
. . N

-DOCSTART- -X- O O

Clinical JJ N
evaluation NN N
of IN N
the DT N
speed NN o
and CC o
effectiveness NN o
of IN o
subgingival JJ o
calculus NN o
removal NN o
on IN N
single-rooted JJ N
teeth NNS N
with IN N
diamond-coated JJ i
ultrasonic JJ i
tips NNS i
. . i

Several JJ N
studies NNS N
have VBP N
found VBN N
incomplete JJ N
calculus NN o
removal NN o
during IN N
periodontal JJ N
treatment NN N
with IN N
traditional JJ N
hand NN N
curets NNS N
, , N
sonic JJ N
, , N
and CC N
ultrasonic JJ N
instruments NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
speed NN o
and CC o
effectiveness NN o
of IN o
subgingival JJ o
calculus NN o
removal NN o
with IN N
new JJ i
diamond-coated JJ i
ultrasonic JJ i
tips NNS i
on IN N
single-rooted JJ N
teeth NNS N
. . N

Single NNP N
session NN N
subgingival NN N
scaling NN N
and CC N
root NN N
planing NN N
was VBD N
performed VBN N
on IN N
80 CD p
teeth NNS p
with IN p
5 CD p
to TO p
12 CD p
mm NNS p
probing VBG p
depths NNS p
in IN p
15 CD p
patients NNS p
. . p

Each DT N
patient NN N
provided VBD N
groups NNS p
of IN p
4 CD p
teeth NNS p
that WDT N
were VBD N
randomly RB N
treated VBN N
with IN N
either DT N
hand NN i
curets NNS i
( ( i
HAND NNP i
) ) i
; : i
standard JJ i
smooth CC i
ultrasonic JJ i
tip NN i
( ( i
US NNP i
) ) i
; : i
or CC i
fine VB i
grit NN i
( ( i
FINDIAM NNP i
) ) i
or CC i
medium NN i
grit NN i
( ( i
MEDDIAM NNP i
) ) i
diamond-coated VBD i
ultrasonic JJ i
tips NNS i
. . i

The DT N
time NN o
taken VBN o
to TO o
reach VB o
the DT o
therapeutic JJ o
endpoint NN o
of IN o
a DT o
clean JJ o
, , o
smooth JJ o
root NN o
surface NN o
in IN o
a DT o
defined JJ o
region NN o
on IN o
each DT o
tooth NN o
with IN N
each DT N
instrument NN N
by IN N
the DT N
3 CD N
therapists NNS N
with IN N
differing VBG N
experience NN N
levels NNS N
was VBD N
recorded VBN N
. . N

The DT N
teeth NNS N
were VBD N
then RB N
atraumatically RB N
extracted VBN N
, , N
stored VBN N
in IN N
a DT N
surfactant NN N
, , N
photographed VBN N
at IN N
10X CD N
, , N
and CC N
the DT N
percent NN N
of IN N
calculus JJ N
present NN N
in IN N
the DT N
area NN N
of IN N
the DT N
pocket NN N
or CC N
on IN N
a DT N
comparable JJ N
control NN N
surface NN N
calculated VBN N
by IN N
histometric JJ N
point NN N
counting NN N
. . N

ANOVA NNP N
and CC N
paired VBD N
t NN N
tests NNS N
showed VBD N
that IN N
mean JJ o
percent NN o
remaining VBG o
calculus NN o
on IN N
treated JJ N
versus NN N
control NN N
surfaces NNS N
was VBD N
HAND $ N
4.6 CD N
+/- JJ N
5.3 CD N
versus NN N
57.5 CD N
+/- JJ N
28.2 CD N
, , N
US PRP N
4.7 CD N
+/- JJ N
6.4 CD N
versus NN N
54.4 CD N
+/- JJ N
25.9 CD N
, , N
FINDIAM NNP N
4.3 CD N
+/- JJ N
5.2 CD N
versus NN N
37.5 CD N
+/- JJ N
22.1 CD N
, , N
and CC N
MEDDIAM NNP N
3.4 CD N
+/- JJ N
4.2 CD N
versus NN N
50.7 CD N
+/- JJ N
20.1 CD N
, , N
respectively RB N
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
mean JJ o
time NN o
in IN o
seconds NNS o
to TO o
reach VB o
the DT o
clinical JJ o
endpoint NN o
ranged VBD N
from IN N
HAND NNP N
289 CD N
+/- JJ N
193 CD N
, , N
US PRP N
194 CD N
+/- JJ N
67 CD N
, , N
FINDIAM NNP N
167 CD N
+/- JJ N
71 CD N
, , N
to TO N
MEDDIAM NNP N
147 CD N
+/- JJ N
92 CD N
. . N

All DT N
powered JJ N
instruments NNS N
were VBD N
significantly RB N
faster JJR N
than IN N
HAND NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
did VBD N
not RB N
differ VB N
from IN N
each DT N
other JJ N
. . N

On IN N
a DT N
0 CD N
= NN N
smooth NN N
to TO N
3 CD N
= NNS N
rough JJ N
scale NN N
, , N
most RBS N
often RB N
HAND NNP N
resulted VBD N
in IN N
smooth JJ o
surfaces NNS o
( ( N
10/20 CD N
) ) N
, , N
the DT N
powered JJ N
tips NNS N
of IN N
all DT N
types NNS N
slight VBD o
surface NN o
roughness NN o
( ( N
10/20 CD N
each DT N
) ) N
, , N
and CC N
US PRP N
the DT N
most RBS N
moderate JJ o
roughness NN o
( ( N
7/20 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
percent JJ o
calculus NN o
remaining VBG o
, , o
surface NN o
roughness NN o
, , o
or CC o
time NN o
spent VBN o
among IN o
the DT o
3 CD o
treating NN o
clinicians NNS o
despite IN N
their PRP$ N
varying JJ N
experience NN N
levels NNS N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
showed VBD N
that IN N
percent NN o
calculus NN o
remaining VBG o
was VBD N
< JJ N
5 CD N
% NN N
with IN N
all PDT N
the DT N
instruments NNS N
given VBN N
time NN N
ad NN N
libitum NN N
on IN N
a DT N
given VBN N
root NN N
surface NN N
. . N

Root NNP o
roughness NN o
was VBD N
generally RB N
slightly RB N
greater JJR N
with IN N
all DT N
3 CD N
powered VBN N
tips NNS N
. . N

All DT N
of IN N
the DT N
powered JJ N
instruments NNS N
took VBD N
significantly RB N
less JJR N
time NN o
than IN N
the DT N
HAND NNP N
. . N

Both DT N
DIAM NNP N
tips NNS N
took VBD N
less JJR N
time NN o
than IN N
US NNP i
. . i

Diamond-coated NNP i
ultrasonic JJ i
tips NNS i
appeared VBD N
to TO N
be VB N
much RB N
more RBR N
efficient JJ N
than IN N
HAND NNP N
or CC N
US NNP N
in IN N
removing VBG N
calculus NN N
in IN N
moderate-deep JJ N
probing VBG N
depths NNS N
on IN N
single-rooted JJ N
teeth NNS N
in IN N
vivo NN N
. . N

-DOCSTART- -X- O O

Response NN N
of IN N
pre-core NN p
mutant NN p
chronic JJ p
hepatitis NN p
B NNP p
infection NN p
to TO N
lamivudine VB i
. . i

The DT N
proportion NN N
of IN N
chronic JJ N
liver NN N
disease NN N
associated VBN N
with IN N
the DT N
pre-core JJ p
mutant NN p
of IN p
hepatitis NN p
B NNP p
virus NN p
( ( p
HBV NNP p
) ) p
infection NN p
is VBZ N
increasing VBG N
, , N
particularly RB N
in IN N
Mediterranean NNP p
Europe NNP p
and CC p
in IN p
Asia NNP p
. . p

The DT N
pre-core JJ p
mutant NN p
HBV NNP p
is VBZ N
unable JJ N
to TO N
produce VB N
hepatitis NN N
B NNP N
e NN N
antigen NN N
( ( N
HBeAg NNP N
) ) N
, , N
so RB N
that IN N
patients NNS p
with IN p
this DT p
variant NN p
do VBP N
not RB N
present VB N
with IN N
HBV NNP N
characterised VBN N
by IN N
HBeAg NNP o
in IN o
the DT o
serum NN o
. . o

Pre-core NN N
mutant JJ N
chronic JJ N
hepatitis NN N
B NNP N
infection NN N
usually RB N
proceeds VBZ N
to TO N
serious JJ N
liver JJ N
disease NN N
. . N

Wild-type JJ N
HBV NNP N
infection NN N
may MD N
be VB N
mild JJ N
and CC N
respond NN N
relatively RB N
well RB N
to TO N
interferon VB N
( ( N
IFN NNP N
) ) N
alpha NN N
therapy NN N
, , N
but CC N
IFN NNP N
alpha NN N
is VBZ N
not RB N
an DT N
effective JJ N
therapeutic JJ N
option NN N
in IN N
pre-core NN N
mutant NN N
hepatitis NN N
B NNP N
infection NN N
and CC N
new JJ N
therapeutic JJ N
options NNS N
are VBP N
needed VBN N
. . N

Clinical JJ N
data NNS N
show VBP N
that IN N
lamivudine NN i
is VBZ N
an DT N
effective JJ o
treatment NN N
for IN N
patients NNS p
with IN p
pre-core JJ p
mutant NN p
hepatitis NN p
B NNP p
. . p

There EX N
is VBZ N
profound JJ N
suppression NN N
of IN N
HBV NNP o
replication NN o
and CC N
improvement NN N
in IN N
indicators NNS o
of IN o
liver JJ o
disease NN o
in IN N
most JJS N
patients NNS N
. . N

In IN N
conclusion NN N
, , N
lamivudine NN i
is VBZ N
suitable JJ N
for IN N
treatment NN N
of IN N
a DT N
wide JJ N
range NN N
of IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
B NNP p
, , p
including VBG p
those DT p
with IN p
pre-core JJ p
mutant JJ p
HBV NNP p
infection NN p
. . p

-DOCSTART- -X- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
radiofrequency NN i
ablation NN i
or CC N
conventional JJ i
high JJ i
ligation NN i
and CC N
stripping VBG N
for IN N
great JJ p
saphenous JJ p
varicose NN p
veins NNS p
. . p

BACKGROUND NNP N
This DT N
randomized VBD N
clinical JJ N
trial NN N
compared VBN N
early JJ N
outcomes NNS N
after IN N
radiofrequency NN i
ablation NN i
( ( i
RFA NNP i
) ) i
and CC N
conventional JJ N
surgery NN N
for IN N
varicose JJ N
veins NNS N
. . N

METHODS NNP N
Consecutive JJ p
patients NNS p
with IN p
symptomatic JJ p
varicose NN p
veins NNS p
due JJ p
to TO p
isolated JJ p
great JJ p
saphenous JJ p
vein NN p
( ( p
GSV NNP p
) ) p
incompetence NN p
and CC p
suitable JJ p
for IN p
RFA NNP p
were VBD N
randomized VBN N
to TO N
either DT N
RFA NNP i
or CC N
conventional JJ N
surgery NN N
( ( N
saphenofemoral JJ N
disconnection NN N
and CC N
stripping NN N
) ) N
. . N

Clinical JJ o
, , o
radiological JJ o
and CC o
patient-based JJ o
outcomes NNS o
were VBD N
recorded VBN N
at IN N
1 CD N
and CC N
5 CD N
weeks NNS N
after IN N
intervention NN N
. . N

RESULTS NNP N
RFA NNP i
resulted VBD N
in IN N
successful JJ N
obliteration NN N
of IN N
the DT N
GSV NNP p
in IN p
all DT p
47 CD p
patients NNS p
. . p

Complete JJ o
above-knee JJ o
stripping NN o
was VBD N
unsuccessful JJ N
in IN N
seven CD N
of IN N
41 CD N
patients NNS N
. . N

RFA NNP N
took VBD N
longer JJR N
than IN N
conventional JJ N
surgery NN N
: : N
median JJ N
interquartile NN N
range NN N
76 CD N
( ( N
67-84 JJ N
) ) N
versus NN N
48 CD N
( ( N
39-54 CD N
) ) N
min NN N
; : N
P NNP N
< VBD N
0.001 CD N
. . N

Patients NNS N
returned VBD o
to TO o
their PRP$ o
normal JJ o
activities NNS o
significantly RB N
earlier RBR N
after IN N
RFA NNP i
( ( N
median JJ N
3 CD N
( ( N
2-5 CD N
) ) N
versus NN N
12.5 CD N
( ( N
4-21 JJ N
) ) N
days NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Postoperative JJ o
pain NN o
was VBD N
significantly RB N
less JJR N
after IN N
RFA NNP i
( ( N
median JJ N
score NN N
on IN N
visual JJ N
analogue NN N
scale NN N
1.70 CD N
( ( N
0.50-4.30 NN N
) ) N
versus NN N
4.0 CD N
( ( N
2.35-6.05 JJ N
) ) N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

Patient JJ o
satisfaction NN o
, , o
quality NN o
of IN o
life NN o
improvement NN o
and CC o
analgesic JJ o
requirements NNS o
significantly RB N
favoured VBD N
RFA NNP i
. . i

CONCLUSION NNP N
RFA NNP N
took VBD N
longer JJR N
to TO N
perform VB N
but CC N
resulted VBD N
in IN N
a DT N
significantly RB o
better RBR o
early RB o
outcome NN o
than IN N
conventional JJ N
surgery NN N
in IN N
suitable JJ N
patients NNS p
with IN p
great JJ p
saphenous JJ p
varicose NN p
veins NNS p
. . p

-DOCSTART- -X- O O

Chronology NN N
of IN N
panic NN N
and CC N
avoidance NN N
, , N
age NN p
of IN p
onset NN p
in IN p
panic JJ p
disorder NN p
, , N
and CC N
prediction NN N
of IN N
treatment NN N
response NN N
. . N

A DT N
report NN N
from IN N
the DT N
Cross-National JJ N
Collaborative NNP N
Panic NNP N
Study NNP N
. . N

The DT N
relevance NN N
of IN N
the DT N
chronology NN N
between IN N
panic JJ N
disorder NN N
and CC N
avoidance NN N
behavior NN N
and CC N
of IN N
an DT N
early JJ N
, , N
medium NN N
or CC N
late JJ N
onset NN N
of IN N
panic JJ N
disorder NN N
was VBD N
tested VBN N
. . N

Groups NNP p
from IN N
the DT p
sample NN p
of IN p
the DT p
cross-national JJ i
collaborative NN i
panic NN i
study NN i
( ( p
CNCPS NNP p
) ) p
were VBD N
compared VBN N
for IN N
differences NNS N
in IN N
basic JJ N
characteristics NNS N
and CC N
for IN N
the DT N
ability NN N
to TO N
predict VB N
treatment NN N
response NN N
. . N

Patients NNS p
who WP p
developed VBD p
avoidance NN o
behavior NN o
before IN p
the DT p
full JJ p
syndrome NN p
of IN p
panic JJ o
disorder NN o
had VBD N
less RBR N
often RB N
a DT N
full JJ N
agoraphobia NN o
but CC N
were VBD N
not RB N
different JJ N
in IN N
their PRP$ N
response NN N
to TO N
treatment NN i
. . i

Patients NNS p
with IN N
an DT N
early JJ o
onset NN o
of IN o
panic JJ o
disorder NN o
suffered VBD N
more RBR N
often RB N
from IN N
agoraphobia NNS o
. . o

The DT N
treatment NN o
response NN o
was VBD N
similar JJ o
in IN N
the DT N
groups NNS N
with IN N
early JJ o
, , o
medium NN o
or CC o
late JJ o
onset NN o
of IN o
panic JJ o
disorder NN o
. . o

Neither CC N
the DT N
chronology NN N
between IN N
panic JJ o
disorder NN o
and CC o
avoidance NN o
behavior NN o
nor CC N
the DT N
age NN o
of IN o
onset NN o
of IN o
panic JJ o
disorder NN o
predicted VBD N
outcome NN N
in IN N
short-term JJ i
treatment NN i
with IN i
alprazolam NN i
or CC i
imipramine NN i
. . i

-DOCSTART- -X- O O

Effect NN N
of IN N
total JJ i
androgen NN i
ablation NN i
on IN N
pathologic JJ o
stage NN o
and CC o
resection NN o
limit NN o
status NN o
of IN o
prostate NN o
cancer NN o
. . o

Initial JJ N
results NNS N
of IN N
the DT N
Italian JJ p
PROSIT NNP p
study NN p
. . p

The DT N
likelihood NN N
of IN N
finding VBG N
organ-confined JJ N
untreated JJ N
prostate NN N
cancer NN N
( ( N
PCa NNP N
) ) N
by IN N
pathological JJ N
examination NN N
at IN N
the DT N
time NN N
of IN N
radical JJ i
prostatectomy NN i
( ( i
RP NNP i
) ) i
is VBZ N
only RB N
50 CD N
% NN N
in IN N
patients NNS N
with IN N
clinically RB N
organ-confined JJ N
disease NN N
. . N

In IN N
addition NN N
, , N
tumour NN N
is VBZ N
present JJ N
at IN N
the DT N
resection NN N
margin NN N
in IN N
approximately RB N
30 CD N
% NN N
of IN N
clinical JJ N
T2 NNP N
( ( N
clinical JJ N
stage NN N
B NNP N
) ) N
cases NNS N
. . N

The DT N
issue NN N
of IN N
clinical JJ N
understaging NN N
and CC N
of IN N
resection NN N
limit NN N
positivity NN N
have VBP N
led VBN N
to TO N
the DT N
development NN N
of IN N
novel JJ N
management NN N
practices NNS N
, , N
including VBG N
neoadjuvant JJ i
hormonal JJ i
therapy NN i
( ( i
NHT NNP i
) ) i
. . i

The DT N
optimal JJ N
duration NN N
of IN N
NHT NNP N
is VBZ N
unknown JJ N
. . N

We PRP N
undertook VBD N
the DT N
present JJ N
analysis NN N
to TO N
evaluate VB N
the DT N
effect NN o
of IN o
NHT NNP o
on IN o
pathologic JJ o
stage NN o
of IN o
PCa NNP o
and CC o
resection NN o
limit NN o
status NN o
in IN N
patients NNS p
with IN p
prostate JJ p
cancer NN p
and CC p
treated VBN p
with IN p
total JJ i
androgen NN i
ablation NN i
either DT p
for IN p
three CD p
or CC p
six CD p
months NNS p
before IN p
RP NNP p
. . p

Between NNP p
January NNP p
1996 CD p
and CC p
February NNP p
1998 CD p
, , p
259 CD p
men NNS p
with IN p
prostate NN p
cancer NN p
underwent JJ p
radical JJ i
retropubic NN i
prostatectomy NN i
and CC i
bilateral JJ i
pelvic JJ i
node NN i
dissection NN i
in IN p
the DT p
26 CD p
centres NNS p
participating VBG p
in IN p
the DT p
Italian JJ p
randomised VBD p
prospective JJ p
PROSIT NNP p
study NN p
. . p

Whole NNP N
mount NN N
sectioning NN N
of IN N
the DT N
complete JJ N
RP NNP N
specimens NNS N
was VBD N
adopted VBN N
in IN N
each DT N
centre NN N
for IN N
accurately RB N
evaluating VBG N
the DT N
pathologic JJ o
stage NN o
and CC o
resection NN o
limit NN o
status NN o
. . o

By IN N
February NNP N
1998 CD N
, , N
haematoxylin NN N
and CC N
eosin NN N
stained VBD N
sections NNS N
from IN N
155 CD N
RP NNP N
specimens NNS N
had VBD N
been VBN N
received VBN N
and CC N
evaluated VBN N
by IN N
the DT N
reviewing VBG N
pathologist NN N
( ( N
RM NNP N
) ) N
. . N

64 CD N
cases NNS N
had VBD N
not RB N
been VBN N
treated VBN N
with IN N
total JJ i
androgen NN i
ablation NN i
( ( N
e.g JJ N
. . N

NHT NNP i
) ) i
before IN N
RP NNP N
was VBD N
performed VBN N
, , N
whereas JJ N
58 CD N
and CC N
33 CD N
had VBD N
been VBN N
treated VBN N
for IN N
three CD N
and CC N
six CD N
months NNS N
, , N
respectively RB N
. . N

114 CD p
patients NNS p
were VBD N
clinical JJ N
stage NN N
B NNP N
whereas IN N
41 CD N
were VBD N
clinical JJ N
stage NN N
C. NNP N
After IN N
three CD N
months NNS N
of IN N
total JJ i
androgen NN i
ablation NN i
, , N
pathological JJ o
stage NN o
B NNP o
was VBD N
more RBR N
prevalent JJ N
among IN N
patients NNS N
with IN N
clinical JJ N
B NNP N
tumours NN N
, , N
compared VBN N
with IN N
untreated JJ N
patients NNS N
( ( N
57 CD N
% NN N
in IN N
treated JJ N
patients NNS N
vs. FW N
36 CD N
% NN N
in IN N
untreated JJ N
) ) N
. . N

The DT N
percentage NN o
of IN o
cancers NNS o
with IN o
negative JJ o
margins NNS o
was VBD N
statistically RB N
significantly RB N
greater JJR N
in IN N
patients NNS N
treated VBN N
with IN N
neoadjuvant JJ i
therapy NN i
than IN N
those DT N
treated VBN N
with IN N
immediate JJ i
surgery NN i
alone RB i
( ( N
69 CD N
% NN N
vs. FW N
42 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

After IN N
six CD N
months NNS N
of IN N
NHT NNP N
therapy VBP N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
pathological JJ o
stage NN o
B NNP o
( ( N
67 CD N
% NN N
vs. FW N
36 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
negative JJ o
margins NNS o
was VBD N
greater JJR N
than IN N
after IN N
3 CD N
months NNS N
( ( N
92 CD N
% NN N
vs. FW N
42 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

For IN N
clinical JJ N
C NNP N
tumours NN N
, , N
the DT N
prevalence NN N
of IN N
pathological JJ o
stage NN o
B NNP o
and CC o
negative JJ o
margins NNS o
in IN N
the DT N
patients NNS N
treated VBD N
for IN N
either DT N
3 CD N
or CC N
6 CD N
months NNS N
was VBD N
not RB N
as RB N
high JJ N
as IN N
in IN N
the DT N
clinical JJ N
B NNP N
tumours NN N
, , N
when WRB N
compared VBN N
with IN N
the DT N
untreated JJ N
group NN N
( ( N
pathological JJ N
stage NN N
B NNP N
: : N
31 CD N
% NN N
and CC N
33 CD N
% NN N
vs. FW N
6 CD N
% NN N
in IN N
the DT N
clinical JJ N
C NNP N
cases NNS N
, , N
respectively RB N
. . N

Negative JJ N
margins NNS N
: : N
56 CD N
% NN N
and CC N
67 CD N
% NN N
vs. FW N
31 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

The DT N
initial JJ N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
total JJ i
androgen NN i
ablation NN i
before IN i
RP NNP i
is VBZ N
beneficial JJ N
in IN N
men NNS N
with IN N
clinical JJ N
stage NN N
B NNP N
because IN N
of IN N
the DT N
significant JJ N
pathological JJ o
downstaging NN o
and CC N
decrease NN N
in IN N
the DT N
number NN N
of IN N
positive JJ o
margins NNS o
in IN o
the DT o
RP NNP o
specimens NNS o
. . o

These DT N
two CD N
effects NNS N
are VBP N
more RBR N
pronounced JJ N
after IN N
six CD N
months NNS N
of IN N
NHT NNP i
than IN N
after IN N
three CD N
months NNS N
of IN N
therapy NN N
. . N

The DT N
same JJ N
degree NN N
of IN N
beneficial JJ o
effects NNS o
are VBP N
not RB N
observed VBN N
in IN N
clinical JJ N
C NNP N
tumours NN N
. . N

-DOCSTART- -X- O O

Radiotherapy NNP i
and CC N
CCNU NNP i
in IN N
the DT N
treatment NN N
of IN N
high-grade JJ N
supratentorial JJ N
astrocytomas NN N
. . N

Forty-one CD p
consecutive JJ p
patients NNS p
with IN p
supratentorial JJ p
primary JJ p
brain NN p
tumors NNS p
( ( p
38 CD p
Grade NNP p
III NNP p
and CC p
IV NNP p
astrocytomas RB p
, , p
one CD p
giant-cell NN p
astrocytoma NN p
, , p
and CC p
two CD p
cases NNS p
with IN p
insufficient JJ p
tissue NN p
for IN p
diagnosis NN p
) ) p
were VBD N
randomly RB N
allocated VBN N
within IN p
2 CD p
weeks NNS p
of IN p
surgery NN p
to TO N
one CD N
of IN N
three CD N
therapeutic JJ N
groups NNS N
. . N

Group NNP N
1 CD N
( ( N
15 CD N
patients NNS N
) ) N
received VBD N
radiation NN i
therapy NN i
totaling VBG N
4000 CD N
to TO N
4500 CD N
rads NNS N
in IN N
4 CD N
to TO N
5 CD N
weeks NNS N
. . N

Group NNP N
2 CD N
( ( N
13 CD N
patients NNS N
) ) N
received VBD N
1- JJ i
( ( i
2-chloroethyl JJ i
) ) i
-3-cyclohexyl-1-nitrosourea FW i
CCNU NNP i
) ) i
130 CD N
mg/sq JJ N
m NNS N
orally RB N
every DT N
6 CD N
weeks NNS N
. . N

Group NNP N
3 CD N
( ( N
13 CD N
patients NNS N
) ) N
received VBD N
radiation NN i
therapy NN i
plus CC i
CCNU NNP i
as IN N
for IN N
Groups NNP N
1 CD N
and CC N
2 CD N
. . N

When WRB N
the DT N
disease NN N
progressed VBD N
, , N
patients NNS N
in IN N
Groups NNP N
1 CD N
and CC N
2 CD N
were VBD N
crossed VBN N
over IN N
to TO N
receive VB N
CCNU NNP i
and CC N
irradiation NN N
respectively RB N
. . N

The DT N
median JJ o
survival NN o
time NN o
in IN N
these DT N
groups NNS N
was VBD N
188 CD N
, , N
259 CD N
, , N
and CC N
252 CD N
days NNS N
, , N
and CC N
the DT N
mean JJ N
survival NN o
263 CD N
, , N
262 CD N
, , N
and CC N
329 CD N
days NNS N
. . N

The DT N
median JJ o
time NN o
from IN o
diagnosis NN o
to TO o
crossover VB o
( ( o
Groups NNP o
1 CD o
and CC o
2 CD o
) ) o
or CC o
to TO o
progression NN o
( ( N
Group NNP N
3 CD N
) ) N
was VBD N
163 CD N
, , N
99 CD N
, , N
and CC N
220 CD N
days NNS N
, , N
and CC N
the DT N
mean JJ N
time NN N
was VBD N
172 CD N
, , N
108 CD N
, , N
and CC N
231 CD N
days NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
means NNS o
or CC o
medians NNS o
in IN N
any DT N
of IN N
these DT N
situations NNS N
. . N

-DOCSTART- -X- O O

Clinical JJ N
benefits NNS N
of IN N
concurrent JJ N
capecitabine NN i
and CC i
cisplatin NN i
versus NN N
concurrent NN i
cisplatin NN i
and CC i
5-flurouracil JJ i
in IN N
locally RB p
advanced JJ p
squamous JJ p
cell NN p
head NN p
and CC p
neck NN p
cancer NN p
. . p

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
concurrent JJ N
capecitabine NN i
and CC i
cisplatin NN i
over IN N
concurrent JJ i
cisplatin NN i
and CC i
5-flurouracil JJ i
( ( i
5-FU JJ i
) ) i
in IN N
locally RB p
advanced JJ p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
. . p

One CD p
hundred CD p
and CC p
fifty-three JJ p
patients NNS p
( ( p
all DT p
of IN p
whom WP p
had VBD p
stage NN p
III NNP p
or CC p
IV NNP p
unresectable JJ p
disease NN p
with IN p
no DT p
distant JJ p
metastases NNS p
and CC p
who WP p
had VBD p
received VBN p
two CD p
cycles NNS p
of IN p
taxol NN i
and CC i
cisplatin NN i
chemotherapy NN i
) ) i
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
concurrent NN i
cisplatin NN i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
in IN N
day NN N
1 CD N
and CC N
2 CD N
) ) N
and CC i
5-FU JJ i
( ( N
750 CD N
mg/m NN N
( ( N
2 CD N
) ) N
in IN N
day NN N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
) ) N
from IN N
the DT N
first JJ N
day NN N
of IN N
radiotherapy NN N
at IN N
an DT N
interval NN N
of IN N
3 CD N
weeks NNS N
( ( N
Arm NNP N
I PRP N
) ) N
or CC N
cisplatin NN i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
in IN N
day NN N
1 CD N
and CC N
2 CD N
) ) N
and CC N
capecitabine NN i
( ( N
750 CD N
mg/m NN N
( ( N
2 CD N
) ) N
in IN N
two CD N
divided JJ N
doses NNS N
from IN N
day NN N
1-14 CD N
) ) N
from IN N
the DT N
first JJ N
day NN N
of IN N
radiotherapy NN N
at IN N
a DT N
3-week JJ N
interval NN N
( ( N
Arm NNP N
II NNP N
) ) N
. . N

Results CC N
showed VBD N
that IN N
patients NNS N
in IN N
Arm NNP N
II NNP N
had VBD N
a DT N
significantly RB N
better RBR o
rate NN o
of IN o
complete JJ o
response NN o
, , o
fewer JJR o
nodes NNS o
, , o
and CC o
better JJR o
overall JJ o
response NN o
compared VBN N
to TO N
those DT N
in IN N
Arm NNP N
I PRP N
. . N

The DT N
two CD N
groups NNS N
had VBD N
a DT N
similar JJ N
3-year JJ o
disease-free JJ o
survival NN o
, , o
progression NN o
free JJ o
survival NN o
, , o
and CC o
overall JJ o
survival NN o
, , N
i.e NN N
. . N

they PRP N
did VBD N
not RB N
differ VB N
significantly RB N
. . N

Variables NNS N
indicating VBG N
the DT N
quality NN o
of IN o
life NN o
of IN N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
. . N

Patients NNS N
in IN N
Arm NNP N
II NNP N
had VBD N
a DT N
significantly RB N
higher JJR N
quality NN o
of IN o
life NN o
compared VBN N
to TO N
those DT N
in IN N
Arm NNP N
I PRP N
. . N

The DT N
two CD N
groups NNS N
had VBD N
similar JJ N
treatment-related JJ N
acute NN o
and CC o
late JJ o
toxicity NN o
, , N
i.e NN N
. . N

they PRP N
did VBD N
not RB N
differ VB N
significantly RB N
. . N

These DT N
results NNS N
have VBP N
thoroughly RB N
substantiated VBN N
the DT N
contention NN N
that WDT N
concurrent JJ N
chemoradiation NN N
with IN N
capecitabine NN i
and CC i
cisplatin NN i
may MD N
be VB N
regarded VBN N
as IN N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
regimen NNS N
in IN N
the DT N
treatment NN N
of IN N
the DT N
patients NNS p
with IN p
locally RB p
advanced VBN p
head NN p
and CC p
neck NN p
cancer NN p
. . p

-DOCSTART- -X- O O

A DT N
Randomized NNP N
Controlled NNP N
Trial NNP N
to TO N
Improve VB N
Social NNP N
Skills NNP N
in IN N
Young NNP p
Adults NNP p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
: : p
The DT N
UCLA NNP i
PEERS NNP i
( ( i
? . i
) ) i
Program NNP i
. . i

Research NNP N
suggests VBZ N
that IN N
impaired JJ N
social JJ N
skills NNS N
are VBP N
often RB N
the DT N
most RBS N
significant JJ N
challenge NN N
for IN N
those DT N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
yet RB N
few JJ N
evidence-based JJ o
social JJ o
skills NNS o
interventions NNS N
exist VBP N
for IN p
adults NNS p
on IN p
the DT p
spectrum NN p
. . p

This DT N
replication NN N
trial NN N
tested VBD N
the DT o
effectiveness NN o
of IN i
PEERS NNP i
, , i
a DT i
caregiver-assisted JJ i
social JJ i
skills NNS i
program NN i
for IN p
high-functioning JJ p
young JJ p
adults NNS p
with IN p
ASD NNP p
. . p

Using VBG N
a DT N
randomized VBN p
controlled JJ p
design NN p
, , p
22 CD p
young JJ p
adults NNS p
18-24 JJ p
years NNS p
of IN p
age NN p
were VBD p
randomly RB p
assigned VBN p
to TO N
a DT N
treatment NN i
( ( N
n JJ N
= NNP N
12 CD N
) ) N
or CC i
delayed VBN i
treatment NN i
control NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
group NN N
. . N

Results NNP N
revealed VBD N
that IN N
the DT N
treatment NN N
group NN N
improved VBD N
significantly RB N
in IN o
overall JJ o
social JJ o
skills NNS o
, , o
frequency NN o
of IN o
social JJ o
engagement NN o
, , o
and CC o
social JJ o
skills NNS o
knowledge NN o
, , o
and CC N
significantly RB N
reduced VBN o
ASD NNP o
symptoms NNS o
related VBN o
to TO o
social JJ o
responsiveness NN o
following VBG o
PEERS NNP o
. . o

Most JJS N
treatment NN N
gains NNS N
were VBD N
maintained VBN N
at IN N
a DT N
16-week JJ N
follow-up JJ N
assessment NN N
with IN N
new JJ N
improvements NNS N
observed VBN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
efficacy NN N
of IN N
fluoxetine NN i
alone RB i
vs. FW i
fluoxetine JJ i
plus CC i
local JJ i
lidocaine NN i
ointment NN i
in IN N
the DT N
treatment NN N
of IN N
premature JJ p
ejaculation NN p
. . p

OBJECTIVE CC N
The DT N
present JJ N
study NN N
compares VBZ N
the DT N
efficacy NN N
and CC N
side JJ N
effects NNS N
of IN N
fluoxetine NN i
alone RB i
vs. FW i
fluoxetine JJ i
plus CC i
local JJ i
lidocaine NN i
ointment NN i
in IN N
the DT N
treatment NN N
of IN N
premature JJ p
ejaculation NN p
. . p

METHODS NNP N
Forty-three JJ p
patients NNS p
suffering VBG p
from IN p
premature JJ p
ejaculation NN p
were VBD N
studied VBN N
. . N

The DT p
exclusion NN p
criteria NNS p
were VBD p
erectile JJ p
dysfunction NN p
, , p
loss NN p
of IN p
libido NN p
, , p
alcohol NN p
and CC p
substance NN p
abuse NN p
, , p
mental JJ p
retardation NN p
, , p
diabetes VBZ p
mellitus NN p
, , p
thyroid JJ p
disease NN p
, , p
hypotension NN p
, , p
previous JJ p
use NN p
of IN p
these DT p
drugs NNS p
and CC p
urogenital JJ p
infections NNS p
. . p

The DT p
patients NNS p
' POS p
ages NNS p
ranged VBD p
from IN p
19 CD p
to TO p
48 CD p
years NNS p
( ( p
mean JJ p
age NN p
28 CD p
+/- JJ p
1.6 CD p
) ) p
. . p

They PRP p
had VBD p
regular JJ p
sexual JJ p
lives NNS p
. . p

They PRP p
had VBD p
normal JJ p
psychiatric JJ p
consultation NN p
and CC p
the DT p
Glombock NNP o
Rast NNP o
Sexual NNP o
Satisfactory NNP o
Test NNP o
( ( o
GRISS NNP o
) ) o
psychiatric JJ o
test NN o
were VBD p
in IN p
accordance NN p
with IN p
premature JJ p
ejaculation NN p
. . p

RESULTS VB N
The DT N
patients NNS N
were VBD N
assigned VBN N
to TO N
two CD N
groups NNS N
. . N

Twenty-six JJ N
patients NNS N
, , N
aged VBD N
21 CD N
to TO N
36 CD N
years NNS N
( ( N
mean JJ N
age NN N
27 CD N
) ) N
, , N
received VBD N
only RB N
fluoxetine JJ i
20 CD N
mg/day NN N
( ( N
1 CD N
capsule NN N
) ) N
for IN N
a DT N
week NN N
which WDT N
was VBD N
later RBR N
increased VBN N
to TO N
40 CD N
mg/day NN N
( ( N
2 CD N
capsules NNS N
) ) N
. . N

Seventeen JJ N
patients NNS N
, , N
aged VBD N
19 CD N
to TO N
48 CD N
years NNS N
( ( N
mean JJ N
age NN N
31 CD N
) ) N
, , N
were VBD N
given VBN N
fluoxetine JJ i
20 CD N
mg/day JJ N
plus CC N
local JJ N
application NN N
of IN N
lidocaine JJ i
ointment NN i
. . i

The DT N
patients NNS N
and CC N
partners NNS N
were VBD N
re-evaluated JJ N
8 CD N
weeks NNS N
after IN N
the DT N
treatment NN N
. . N

The DT N
results NNS N
were VBD N
classified VBN N
as IN N
unsuccessful JJ o
, , o
improvement NN o
and CC o
cure NN o
. . o

The DT N
chi-square JJ o
test NN o
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

In IN N
the DT N
fluoxetine NN N
group NN N
, , N
8 CD N
( ( N
30.8 CD N
% NN N
) ) N
patients NNS N
cured VBD o
, , N
11 CD N
( ( N
42.2 CD N
% NN N
) ) N
showed VBD N
improvement NN o
and CC N
there EX N
were VBD N
7 CD N
failures NNS o
( ( N
26.9 CD N
% NN N
) ) N
. . N

In IN N
the DT N
combination NN N
treatment NN N
group NN N
, , N
9 CD N
( ( N
52.9 CD N
% NN N
) ) N
patients NNS N
cured VBN N
, , N
improvement NN o
was VBD N
observed VBN N
in IN N
5 CD N
( ( N
29.4 CD N
% NN N
) ) N
and CC N
failure NN N
in IN N
3 CD N
( ( N
17.6 CD N
% NN N
) ) N
. . N

Side JJ N
effects NNS N
in IN N
group NN N
I PRP N
were VBD N
observed VBN N
in IN N
6 CD N
patients NNS N
( ( N
23 CD N
% NN N
) ) N
and CC N
in IN N
5 CD N
( ( N
29.4 CD N
% NN N
) ) N
in IN N
group NN N
II NNP N
. . N

There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
according VBG N
to TO N
the DT N
side NN N
effects NNS N
( ( N
p JJ N
> NNP N
0.01 CD N
) ) N
. . N

No UH p
patients NNS p
were VBD p
excluded VBN p
from IN p
the DT p
study NN p
due JJ p
to TO p
side VB p
effects NNS p
. . p

CONCLUSION VB N
The DT N
combination NN N
of IN N
fluoxetine JJ i
plus CC N
local JJ N
application NN N
of IN N
lidocaine JJ i
ointment NN N
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
fluoxetine VB i
alone RB N
in IN N
the DT N
treatment NN N
of IN N
premature JJ p
ejaculation NN p
. . p

However RB N
, , N
the DT N
results NNS N
should MD N
be VB N
confirmed VBN N
in IN N
further JJ N
studies NNS N
with IN N
a DT N
placebo NN N
group NN N
to TO N
rule VB N
out IN N
the DT N
placebo NN N
effect NN N
. . N

-DOCSTART- -X- O O

Arthroscopic NNP i
rotator NN i
cuff NN i
repair NN i
with IN i
and CC i
without IN i
acromioplasty NN i
in IN N
the DT N
treatment NN N
of IN N
full-thickness JJ p
rotator NN p
cuff NN p
tears NNS p
: : p
a DT N
multicenter NN N
, , N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
was VBD N
to TO N
compare VB N
functional JJ o
and CC o
quality-of-life JJ o
indices NNS o
and CC N
rates NNS o
of IN o
revision NN o
surgery NN o
in IN N
arthroscopic NN i
rotator NN i
cuff NN i
repair NN i
with IN i
and CC i
without IN i
acromioplasty JJ i
. . i

METHODS NNP N
Eighty-six JJ p
patients NNS p
consented VBN N
and CC N
were VBD N
randomly RB N
assigned VBN N
intraoperatively RB N
to TO N
one CD N
of IN N
two CD N
study NN N
groups NNS N
, , N
and CC N
sixty-eight NN p
of IN p
them PRP p
completed VBD p
the DT p
study NN p
. . p

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
Western JJ o
Ontario NNP o
Rotator NNP o
Cuff NNP o
( ( o
WORC NNP o
) ) o
index NN o
. . o

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
the DT N
American JJ o
Shoulder NNP o
and CC o
Elbow NNP o
Surgeons NNP o
( ( o
ASES NNP o
) ) o
shoulder NN o
assessment JJ o
form NN o
and CC o
a DT o
count NN o
of IN o
revisions NNS o
required VBN N
in IN N
each DT N
group NN N
. . N

Outcome NNP N
measures NNS N
were VBD N
completed VBN N
preoperatively RB N
and CC N
at IN N
three CD N
, , N
six CD N
, , N
twelve NN N
, , N
eighteen NN N
, , N
and CC N
twenty-four JJ N
months NNS N
after IN N
surgery NN N
. . N

RESULTS NNP N
WORC NNP o
and CC o
ASES NNP o
scores VBZ o
improved VBN N
significantly RB N
in IN N
each DT N
group NN N
over IN N
time NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
WORC NNP o
or CC o
ASES NNP o
scores NNS o
between IN N
the DT N
groups NNS N
that WDT N
had VBD N
arthroscopic VBN i
cuff JJ i
repair NN i
with IN i
or CC i
without IN i
acromioplasty JJ i
at IN N
any DT N
time NN N
point NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
scores NNS N
on IN N
the DT N
basis NN N
of IN N
acromion NN N
type NN N
, , N
nor CC N
were VBD N
any DT N
interaction NN N
effects NNS N
identified VBN N
between IN N
group NN N
and CC N
acromion NN N
type NN N
. . N

Four CD p
participants NNS p
( ( p
9 CD p
% NN p
) ) p
in IN p
the DT p
group NN p
that WDT p
had VBD p
arthroscopic VBN i
cuff JJ i
repair NN o
alone RB p
, , p
one CD p
with IN p
a DT p
Type-2 JJ p
and CC p
three CD p
with IN p
a DT p
Type-3 JJ p
acromion NN p
, , p
required VBN p
additional JJ o
surgery NN o
by IN N
the DT N
twenty-four-month JJ N
time NN N
point NN N
. . N

The DT N
number NN o
of IN o
patients NNS o
who WP o
required VBD o
additional JJ o
surgery NN o
was VBD N
greater JJR N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
alone RB N
than IN N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
and CC N
acromioplasty NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
are VBP N
consistent JJ N
with IN N
previous JJ N
research NN N
reports NNS N
in IN N
which WDT N
there EX N
was VBD N
no DT N
difference NN N
in IN N
functional JJ o
and CC o
quality-of-life JJ o
indices NNS o
for IN N
patients NNS p
who WP p
had VBD p
rotator NN p
cuff NN p
repair NN p
with IN p
or CC p
without IN p
acromioplasty JJ p
. . p

The DT N
higher JJR o
reoperation NN o
rate NN o
was VBD N
found VBN N
in IN N
the DT N
group NN p
without IN N
acromioplasty NN N
. . N

Further CC N
study NN N
that WDT N
includes VBZ N
follow-up JJ N
imaging NN N
and CC N
patient-reported JJ N
outcomes NNS N
over IN N
a DT N
greater JJR N
follow-up JJ N
period NN N
is VBZ N
needed VBN N
. . N

-DOCSTART- -X- O O

Health NNP N
promotion NN N
and CC N
disease NN N
prevention NN N
for IN N
older JJR p
adults NNS p
: : p
opportunity NN N
for IN N
change NN N
or CC N
preaching NN N
to TO N
the DT N
converted VBN N
? . N
Health NNP N
promotion NN N
and CC N
disease NN N
prevention NN N
for IN N
the DT p
elderly JJ p
offer NN N
the DT N
potential NN N
for IN N
improving VBG N
the DT N
quality NN N
of IN N
life NN N
for IN N
the DT N
growing VBG N
population NN N
of IN N
older JJR p
adults NNS p
, , N
while IN N
reducing VBG N
the DT N
economic JJ N
burden NN N
on IN N
the DT N
health NN N
system NN N
. . N

Whether CC N
this DT N
potential JJ N
can MD N
be VB N
realized VBN N
depends NNS N
, , N
in IN N
part NN N
, , N
on IN N
whether IN N
those DT N
older JJR p
adults NNS p
whose WP$ p
health NN p
behaviors NNS p
put VBD p
them PRP p
at IN p
risk NN p
actually RB N
use VBP N
preventive JJ i
services NNS i
when WRB N
offered VBD N
the DT N
opportunity NN N
. . N

In IN N
1988 CD p
the DT p
Health NNP p
Care NNP p
Financing NNP p
Administration NNP p
began VBD N
a DT N
series NN N
of IN N
health NN i
promotion NN i
demonstrations NNS i
to TO N
address VB N
health NN N
issues NNS N
related VBN N
to TO N
older JJR p
adults NNS p
. . p

This DT N
article NN N
reports VBZ N
on IN N
program NN N
participation NN N
at IN N
one CD p
of IN p
the DT p
five CD p
demonstration NN p
sites NNS p
. . p

Over IN p
1,900 CD p
community-dwelling JJ p
Medicare NNP p
beneficiaries NNS p
who WP p
receive VBP p
their PRP$ p
health NN p
care NN p
through IN p
fee-for-service JJ p
providers NNS p
were VBD p
enrolled VBN p
in IN p
the DT p
demonstration NN p
. . p

These DT N
enrollees NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
control VB i
and CC N
experimental JJ N
groups NNS N
, , N
with IN N
the DT N
latter JJ N
offered VBN N
health NN i
screening NN i
and CC i
promotion NN i
services NNS i
. . i

Nine NNP p
hundred-seventy-three NN p
of IN p
the DT p
experimental JJ p
subjects NNS p
and CC p
938 CD p
of IN p
the DT p
control NN p
subjects VBZ p
completed VBN p
a DT p
lengthy JJ p
telephone NN p
interview NN p
, , p
which WDT p
determined VBD p
each DT p
person NN p
's POS p
use NN p
of IN p
preventive JJ p
services NNS p
and CC p
practices NNS p
. . p

Although IN p
all DT p
973 CD p
experimental JJ p
subjects NNS p
were VBD p
invited VBN p
by IN p
letter NN p
and CC p
follow-up JJ p
telephone NN p
calls VBZ p
to TO p
attend VB p
these DT p
free-of-charge JJ p
, , p
Medicare-provided JJ p
sessions NNS p
, , p
not RB p
everyone NN p
attended VBD p
. . N

We PRP N
analyzed VBD N
17 CD N
health NN N
behaviors NNS N
of IN N
those DT N
who WP N
attended VBD N
the DT N
first JJ N
session NN N
and CC N
those DT N
who WP N
did VBD N
not RB N
. . N

Those DT N
engaging VBG N
in IN N
these DT N
preventive JJ N
behaviors NNS N
were VBD N
neither RB N
more JJR N
nor CC N
less RBR N
likely JJ N
to TO N
attend VB N
the DT N
screening NN N
services NNS N
. . N

Thus RB N
, , N
we PRP N
found VBD N
neither CC N
favorable JJ N
nor CC N
unfavorable JJ N
selection NN N
bias NN N
in IN N
the DT N
use NN N
of IN N
these DT N
preventive JJ N
services NNS N
. . N

-DOCSTART- -X- O O

Calcium NNP i
channel NN i
blocker NN i
inhibition NN i
of IN i
AGE NNP i
and CC i
RAGE NNP i
axis VBP N
limits NNS N
renal JJ o
injury NN o
in IN N
nondiabetic JJ p
patients NNS p
with IN p
stage NN p
I PRP p
or CC p
II NNP p
chronic JJ p
kidney NN p
disease NN p
. . p

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
growing VBG N
body NN N
of IN N
evidence NN N
that IN N
advanced VBD N
glycation JJ N
end NN N
products NNS N
( ( N
AGE NNP N
) ) N
and CC N
their PRP$ N
receptor NN N
( ( N
RAGE NNP N
) ) N
system NN N
are VBP N
implicated VBN N
in IN N
chronic JJ N
kidney NN N
disease NN N
( ( N
CKD NNP N
) ) N
. . N

We PRP N
have VBP N
previously RB N
found VBN N
that IN N
a DT N
long-acting JJ N
calcium NN i
channel NN i
blocker NN i
, , i
azelnidipine NN i
, , i
but CC i
not RB i
amlodipine VB i
, , N
improves VBZ N
renal JJ o
injury NN o
in IN N
CKD NNP N
patients NNS N
. . N

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effect NN N
of IN N
azelnidipine NN i
on IN N
the DT N
AGE-RAGE NNP o
axis NN o
in IN N
humans NNS N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
examined VBD N
whether IN N
azelnidipine JJ i
addition NN N
could MD N
have VB N
renoprotective JJ o
properties NNS o
in IN N
hypertensive JJ N
CKD NNP N
patients NNS N
by IN N
reducing VBG N
serum NN o
levels NNS o
of IN o
AGE NNP o
and CC o
soluble JJ o
form NN o
of IN o
RAGE NNP o
( ( o
sRAGE NN o
) ) o
. . o

Thirty NNP p
nondiabetic JJ p
stage NN p
I PRP p
or CC p
II NNP p
CKD NNP p
patients NNS p
who WP p
had VBD p
already RB p
been VBN p
treated VBN p
with IN p
angiotensin NN p
II NNP p
receptor NN p
blockers NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
study NN N
. . N

HYPOTHESIS NNP N
We PRP N
hypothesized VBD N
that IN N
azelnidipine NN i
treatment NN N
could MD N
limit VB N
renal JJ N
injury NN N
partly RB N
by IN N
blocking VBG N
the DT N
AGE-RAGE NNP o
axis NN o
. . o

METHODS JJ N
Patients NNPS p
were VBD N
randomly RB N
divided VBN N
into IN N
2 CD p
groups NNS p
; : p
one CD N
group NN N
was VBD N
treated VBN N
with IN N
16 CD N
mg NNS N
azelnidipine NN i
and CC N
the DT N
other JJ N
with IN N
5 CD N
mg NNS N
amlodipine JJ i
once RB N
daily JJ N
. . N

They PRP N
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
Proteinuria NNP o
was VBD N
positively RB N
correlated VBN N
with IN N
circulating VBG o
AGE NNP o
and CC o
sRAGE NN o
levels NNS o
in IN N
our PRP$ N
subjects NNS N
. . N

Both DT N
drugs NNS N
exhibited VBN N
comparable JJ N
and CC N
significant JJ N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
-lowering VBG o
effects NNS o
. . o

Although IN N
neither DT N
of IN N
them PRP N
affected VBD N
glucose NN o
, , o
glycated VBD o
hemoglobin NN o
, , o
lipid JJ o
levels NNS o
, , o
and CC o
estimated VBD o
glomerular JJ o
filtration NN o
rate NN o
, , o
treatment NN o
with IN o
azelnidipine NN o
, , N
but CC N
not RB N
amlodipine VB i
, , N
decreased VBN N
circulating NN o
AGE NNP o
, , o
sRAGE NN o
, , o
proteinuria NN o
, , o
and CC o
urinary JJ o
levels NNS o
of IN o
liver-type JJ o
fatty JJ o
acid NN o
binding VBG o
protein NN o
, , N
a DT N
marker NN N
of IN N
tubular JJ N
injury NN N
, , N
in IN N
a DT N
BP-lowering-independent JJ N
manner NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
present JJ N
results NNS N
suggest VBP N
that IN N
azelnidipine NN i
may MD N
exert VB N
renoprotective JJ o
properties NNS o
in IN N
nondiabetic JJ p
hypertensive JJ p
CKD NNP p
patients NNS p
via IN N
its PRP$ N
unique JJ N
inhibitory JJ N
effects NNS N
on IN N
the DT N
AGE-RAGE NNP N
axis NN N
. . N

-DOCSTART- -X- O O

Superior JJ N
survival NN o
with IN N
capecitabine JJ i
plus CC i
docetaxel JJ i
combination NN i
therapy NN i
in IN N
anthracycline-pretreated JJ p
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
: : p
phase NN N
III NNP N
trial NN N
results NNS N
. . N

PURPOSE NNP N
Docetaxel NNP i
and CC i
capecitabine NN i
, , N
a DT N
tumor-activated JJ N
oral JJ N
fluoropyrimidine NN N
, , N
show VBP N
high JJ N
single-agent JJ N
efficacy NN N
in IN N
metastatic JJ p
breast NN p
cancer NN p
( ( N
MBC NNP N
) ) N
and CC N
synergy NN N
in IN N
preclinical JJ N
studies NNS N
. . N

This DT N
international JJ N
phase NN N
III NNP N
trial NN N
compared VBN N
efficacy NN o
and CC o
tolerability NN o
of IN N
capecitabine/docetaxel JJ i
therapy NN i
with IN N
single-agent JJ i
docetaxel NN i
in IN N
anthracycline-pretreated JJ p
patients NNS p
with IN p
MBC NNP p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
21-day JJ N
cycles NNS N
of IN N
oral JJ N
capecitabine NN i
1,250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
twice RB N
daily RB N
on IN N
days NNS N
1 CD N
to TO N
14 CD N
plus CC N
docetaxel JJ i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
1 CD N
( ( N
n JJ N
= NNP N
255 CD N
) ) N
or CC N
to TO N
docetaxel VB i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
1 CD N
( ( N
n JJ N
= NNP N
256 CD N
) ) N
. . N

RESULTS NNP N
Capecitabine/docetaxel NNP i
resulted VBD N
in IN N
significantly RB N
superior JJ N
efficacy NN o
in IN N
time NN o
to TO o
disease VB o
progression NN o
( ( o
TTP NNP o
) ) o
( ( N
hazard JJ N
ratio NN N
, , N
0.652 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.545 CD N
to TO N
0.780 CD N
; : N
P NNP N
=.0001 NNP N
; : N
median JJ N
, , N
6.1 CD N
v NN N
4.2 CD N
months NNS N
) ) N
, , N
overall JJ o
survival NN o
( ( N
hazard JJ N
ratio NN N
, , N
0.775 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.634 CD N
to TO N
0.947 CD N
; : N
P NNP N
=.0126 NNP N
; : N
median JJ N
, , N
14.5 CD N
v NN N
11.5 CD N
months NNS N
) ) N
, , N
and CC N
objective JJ o
tumor NN o
response NN o
rate NN o
( ( N
42 CD N
% NN N
v JJ N
30 CD N
% NN N
, , N
P NNP N
=.006 NNP N
) ) N
compared VBN N
with IN N
docetaxel NN i
. . i

Gastrointestinal JJ o
side NN o
effects NNS o
and CC o
hand-foot JJ o
syndrome NN o
were VBD N
more JJR N
common JJ N
with IN N
combination NN i
therapy NN i
, , N
whereas JJ N
myalgia NN o
, , o
arthralgia NN o
, , N
and CC N
neutropenic JJ o
fever/sepsis NN o
were VBD N
more JJR N
common JJ N
with IN N
single-agent JJ i
docetaxel NN i
. . i

More JJR N
grade JJ o
3 CD o
adverse JJ o
events NNS o
occurred VBD N
with IN N
combination NN i
therapy NN i
( ( N
71 CD N
% NN N
v JJ N
49 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
whereas JJ N
grade VBP o
4 CD o
events NNS o
were VBD N
slightly RB N
more RBR N
common JJ N
with IN N
docetaxel NN i
( ( N
31 CD N
% NN N
v JJ N
25 CD N
% NN N
with IN N
combination NN N
) ) N
. . N

CONCLUSION VB N
The DT N
significantly RB N
superior JJ N
TTP NNP o
and CC o
survival NN o
achieved VBN N
with IN N
the DT N
addition NN i
of IN i
capecitabine NN i
to TO i
docetaxel VB i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
with IN N
the DT N
manageable JJ N
toxicity NN o
profile NN o
, , N
indicate VBP N
that IN N
this DT N
combination NN i
provides VBZ N
clear JJ N
benefits NNS N
over IN N
single-agent JJ i
docetaxel NN i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
. . N

Docetaxel/capecitabine NNP i
therapy NN i
is VBZ N
an DT N
important JJ N
treatment NN N
option NN N
for IN N
women NNS p
with IN p
anthracycline-pretreated JJ p
MBC NNP p
. . p

-DOCSTART- -X- O O

Treatment NN N
of IN N
Wilms NNP p
' POS p
tumor NN p
. . p

Results NNS N
of IN N
the DT N
Third NNP N
National NNP p
Wilms NNP p
' POS p
Tumor NNP p
Study NNP N
. . N

The DT N
Third NNP N
National NNP p
Wilms NNP p
' POS p
Tumor NNP p
Study NNP N
sought VBD N
to TO N
reduce VB N
treatment NN N
for IN N
low-risk JJ p
patients NNS p
and CC N
find VB N
better JJR N
chemotherapy NN i
for IN N
those DT p
at IN p
high JJ p
risk NN p
for IN p
relapse NN p
. . p

Eligible JJ p
patients NNS p
( ( p
1439 CD p
) ) p
were VBD N
randomized VBN N
according VBG N
to TO N
stage NN p
( ( p
I-IV NNP p
) ) p
and CC p
histology NN p
( ( p
favorable JJ p
[ NN p
FH NNP p
] NNP p
or CC p
unfavorable JJ p
[ JJ p
UH NNP p
] NNP p
) ) p
, , p
and CC p
contributed VBD p
data NNS p
to TO p
survival VB p
and CC p
relapse-free JJ p
survival NN p
( ( p
RFS NNP p
) ) p
analyses VBZ p
. . p

Four-year JJ p
( ( p
postnephrectomy NN p
) ) p
survival NN p
percentages NNS p
and CC N
randomized VBN N
treatment NN N
regimens NNS N
for IN N
low-risk JJ N
patients NNS N
were VBD N
96.5 CD N
% NN N
for IN N
607 CD N
Stage NNP N
I/FH NNP N
patients NNS N
who WP N
received VBD N
dactinomycin NN i
( ( i
Actinomycin NNP i
D NNP i
[ NNP i
AMD NNP i
] NNP i
, , N
Merck NNP N
Sharp NNP N
& CC N
Dohme NNP N
, , N
West NNP N
Point NNP N
, , N
PA NNP N
) ) N
and CC N
vincristine NN i
( ( i
VCR NNP i
) ) i
for IN N
10 CD N
weeks NNS N
versus RB N
6 CD N
months NNS N
; : N
92.2 CD N
% NN N
for IN N
278 CD N
Stage NNP N
II/FH NNP N
patients NNS N
; : N
and CC N
86.9 CD N
% NN N
for IN N
275 CD N
Stage NNP N
III/FH NNP N
patients NNS N
who WP N
received VBD N
AMD NNP i
+ NNP i
VCR NNP i
+/- JJ i
Adriamycin NNP i
( ( i
ADR NNP i
, , N
Adria NNP N
Laboratories NNPS N
, , N
Columbus NNP N
, , N
OH NNP N
) ) N
for IN N
15 CD N
months NNS N
. . N

Stage NNP N
II/FH NNP N
patients NNS N
also RB N
had VBD N
either CC N
zero CD N
or CC N
2000 CD N
cGy NN N
irradiation NN N
( ( N
RT NNP N
) ) N
postoperatively RB N
and CC N
Stage NNP N
III/FH NNP N
patients NNS N
either RB N
1000 CD N
or CC N
2000 CD N
cGy NN N
. . N

Four-year JJ o
survival NN o
was VBD N
73.0 CD N
% NN N
for IN N
279 CD N
high-risk JJ p
patients NNS p
( ( N
any DT N
Stage NNP N
IV NNP N
, , N
all DT N
UH NNP N
) ) N
who WP N
received VBD N
postoperative JJ i
radiation NN i
therapy NN i
( ( i
RT NNP i
) ) i
and CC N
AMD NNP i
+ NNP i
VCR NNP i
+ NNP i
ADR NNP i
+/- JJ i
cyclophosphamide NN i
( ( i
CPM NNP i
) ) i
. . i

Statistical JJ N
analysis NN N
of IN N
survival NN o
and CC o
RFS NNP o
experience NN o
shows VBZ o
that IN N
the DT N
less RBR N
intensive JJ N
therapy NN N
does VBZ N
not RB N
worsen VB N
results NNS N
for IN N
low-risk JJ N
patients NNS N
and CC N
CPM NNP i
does VBZ N
not RB N
benefit VB N
those DT N
at IN N
high JJ N
risk NN N
. . N

-DOCSTART- -X- O O

Increased VBN N
5?-reductase JJ o
type NN o
2 CD o
expression NN o
in IN p
human JJ p
breast NN p
carcinoma NN p
following VBG i
aromatase NN i
inhibitor NN i
therapy NN i
: : i
the DT N
correlation NN N
with IN o
decreased JJ o
tumor NN o
cell NN o
proliferation NN o
. . o

Tumor NNP o
cell NN o
proliferation NN o
and CC o
progression NN o
of IN o
breast NN o
cancer NN o
are VBP N
influenced VBN N
by IN N
female JJ N
sex NN N
steroids NNS N
. . N

However RB N
, , N
not RB N
all DT N
breast NN N
cancer NN N
patients NNS N
respond VBP N
to TO i
aromatase VB i
inhibitors NNS i
( ( i
AI NNP i
) ) i
, , i
and CC N
many JJ N
patients NNS N
become VBP N
unresponsive JJ N
or CC N
relapse NN N
. . N

Recent JJ N
studies NNS N
demonstrate VBP N
that IN N
not RB N
only RB N
estrogens VBZ N
but CC N
also RB N
androgens VBZ N
may MD N
serve VB N
as IN N
regulators NNS N
of IN N
estrogen-responsive JJ N
as RB N
well RB N
as IN N
estrogen-unresponsive JJ N
human JJ N
breast NN N
cancers NNS N
. . N

However RB N
, , N
the DT N
mechanism NN N
underlying VBG N
these DT N
androgenic JJ N
actions NNS N
has VBZ N
remained VBN N
relatively RB N
unknown JJ N
. . N

Therefore RB N
, , N
in IN N
this DT N
study NN N
, , N
we PRP N
evaluated VBD N
the DT o
effects NNS o
of IN N
AI NNP N
upon IN N
the DT o
expression NN o
of IN o
enzymes NNS o
involved VBN o
in IN o
intratumoral JJ o
androgen NN o
production NN o
including VBG o
17?-hydroxysteroid JJ o
dehydrogenase NN o
type NN o
5 CD o
( ( o
17?HSD5 CD o
) ) o
, , o
5?-reductase JJ o
types NNS o
1 CD o
and CC o
2 CD o
( ( o
5?Red1 CD o
and CC o
5?Red2 CD o
) ) o
as RB o
well RB o
as IN o
androgen NN o
receptor NN o
( ( o
AR NNP o
) ) o
levels NNS o
and CC o
correlated VBD o
the DT N
findings NNS o
with IN o
therapeutic JJ o
responses NNS o
including VBG o
Ki67 NNP o
labeling VBG o
index NN o
( ( o
Ki67 NNP o
) ) o
. . o

Eighty-two JJ o
postmenopausal NN p
invasive JJ p
ductal JJ p
carcinoma NN p
patients NNS p
were VBD p
enrolled VBN p
in IN p
CAAN NNP p
study NN p
from IN p
November NNP p
2001 CD p
to TO p
April NNP p
2004 CD p
. . p

Pre- JJ N
and CC N
post-treatment JJ N
specimens NNS N
of IN N
29 CD N
cases NNS N
were VBD N
available JJ N
for IN N
this DT N
study NN N
. . N

The DT N
status NN N
of IN o
17?HSD5 CD o
, , o
5?Red1 CD o
, , o
5?Red2 CD o
, , o
and CC o
Ki67 NNP o
in IN N
pre- JJ N
and CC N
post-treatment JJ N
specimens NNS N
were VBD N
evaluated VBN N
. . N

The DT N
significant JJ N
increments NNS o
of IN o
5?Red2 CD o
as RB o
well RB o
as IN o
AR NNP o
were VBD o
detected VBN N
in IN N
biological JJ N
response NN N
group NN N
whose WP$ o
Ki67 NNP o
LI NNP o
decreased VBN o
by IN N
more JJR N
than IN N
40 CD N
% NN N
of IN N
the DT N
pre-treatment JJ N
level NN N
. . N

This DT N
is VBZ N
the DT N
first JJ N
study NN N
demonstrating VBG N
an DT N
increment NN N
of IN o
5?Red2 CD o
and CC o
AR NNP o
in IN o
the DT N
group NN N
of IN N
the DT N
patients NNS N
associated VBN N
with IN o
Ki67 NNP o
decrement NN N
following VBG N
AI NNP N
treatment NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
increased VBD o
5?Red2 CD o
and CC o
AR NNP o
following VBG o
AI NNP N
treatment NN N
may MD N
partly RB N
contribute VB N
to TO N
reduce VB N
the DT N
tumor NN N
cell NN N
proliferation NN N
through IN N
increasing VBG N
intratumoral JJ N
androgen NN N
concentrations NNS N
and CC N
its PRP$ N
receptor NN N
. . N

-DOCSTART- -X- O O

Increasing VBG p
the DT p
reach NN p
of IN p
health NN o
sponsorship NN p
: : p
using VBG p
a DT p
sponsorship JJ i
kit NN i
to TO p
promote VB p
health NN p
. . p

In IN N
Australia NNP p
, , N
a DT N
tobacco NN N
tax NN N
provides VBZ N
funding NN N
for IN N
Healthway NNP N
, , N
the DT N
Western NNP N
Australian NNP N
Health NNP N
Promotion NNP N
Foundation NNP N
. . N

Healthway NNP N
provides VBZ N
sponsorships NNS N
for IN N
the DT N
arts NNS N
and CC N
racing NN N
and CC N
sporting VBG N
events NNS N
to TO N
replace VB N
funds NNS N
previously RB N
provided VBN N
by IN N
tobacco NN N
companies NNS N
. . N

These DT N
sponsorships NNS N
provide VBP N
visibility NN N
for IN N
Healthway NNP N
and CC N
positive JJ N
health NN N
messages NNS N
. . N

Normally RB N
, , N
Healthway NNP N
staff NN N
attends VBZ N
these DT N
events NNS N
to TO N
help VB N
promote VB N
health NN N
messages NNS N
. . N

To TO N
reduce VB N
Healthway NNP p
staff NN p
time NN N
spent VBN N
helping VBG N
event NN N
organizers NNS N
promote VBP N
health NN N
messages NNS N
, , N
Healthway NNP N
developed VBD N
a DT N
sponsor JJ i
kit NN i
of IN i
promotional JJ i
materials NNS i
which WDT N
communicate VBP N
health NN N
messages NNS N
without IN N
requiring VBG N
Healthway NNP p
staff NN p
to TO N
attend VB N
events NNS N
. . N

Recognition NNP o
, , o
awareness NN o
, , o
comprehension NN o
, , o
and CC o
acceptance NN o
of IN o
health NN o
messages NNS o
was VBD N
comparable JJ N
at IN N
events NNS N
that WDT N
featured VBD N
Healthway NNP N
staff NN N
versus IN N
the DT N
sponsor NN N
kits NNS N
, , N
but CC N
the DT N
average JJ N
cost NN N
of IN N
the DT N
sponsorship NN i
kits NNS i
was VBD N
only RB N
40 CD N
% NN N
of IN N
the DT N
cost NN N
when WRB N
Healthway NNP N
staff NN N
was VBD N
featured VBN N
. . N

-DOCSTART- -X- O O

[ JJ N
Efficacy NNP N
of IN N
combination NN N
with IN N
granisetron NN i
and CC i
methylprednisolone NN i
for IN N
nausea NN o
, , o
vomiting VBG o
and CC o
appetite JJ o
loss NN o
in IN p
remission NN p
induction NN p
chemotherapy NN p
of IN p
acute JJ p
myeloid NN p
leukemia NN p
-- : p
a DT p
randomized JJ N
comparative JJ N
trial NN N
between IN N
granisetron NN i
alone RB i
and CC i
granisetron JJ i
plus CC i
methylprednisolone JJ i
] NN i
. . N

The DT N
prevention NN N
of IN N
nausea NN o
, , o
vomiting VBG o
and CC o
appetite JJ o
loss NN o
induced VBN N
by IN N
remission NN N
induction NN N
chemotherapy NN N
for IN N
acute JJ p
myeloid NN p
leukemia NN p
was VBD N
compared VBN N
by IN N
randomization NN N
between IN N
granisetron NN i
alone RB i
and CC p
combination NN p
with IN p
granisetron NN i
plus CC i
methylprednisolone NN i
. . i

Granisetron NNP i
was VBD N
administered VBN N
at IN N
40 CD i
micrograms/kg NN i
during IN i
chemotherapy NN i
, , i
and CC i
methylprednisolone NN i
was VBD N
administered VBN N
concomitantly RB N
at IN N
125 CD N
mg/body NN N
for IN N
3 CD N
days NNS N
or CC N
more JJR N
in IN N
the DT N
combination NN p
group NN p
. . p

The DT p
single JJ p
and CC p
combination NN p
groups NNS p
comprised VBD p
14 CD p
and CC p
13 CD p
patients NNS p
, , p
respectively RB p
, , p
and CC p
there EX p
was VBD p
no DT p
significant JJ p
difference NN p
between IN p
the DT p
background NN p
of IN p
both DT p
groups NNS p
. . p

To TO N
evaluate VB N
the DT N
effect NN N
they PRP N
were VBD N
scored VBN N
according VBG N
to TO N
4 CD N
grades NNS N
, , N
and CC N
evaluated VBD N
every DT N
24 CD N
hours NNS N
from IN N
the DT N
start NN N
of IN N
chemotherapy NN N
to TO N
5 CD N
days NNS N
after IN N
its PRP$ N
completion NN N
. . N

The DT N
complete JJ o
inhibition NN o
rate NN o
of IN o
vomiting VBG o
was VBD N
as RB N
high JJ N
as IN N
71.4 CD N
% NN N
and CC N
92.3 CD N
% NN N
in IN N
the DT N
single JJ N
and CC N
combination NN N
groups NNS N
, , N
respectively RB N
, , N
showing VBG N
no DT N
significant JJ N
difference NN N
. . N

The DT N
grade NN o
of IN o
vomiting VBG o
was VBD N
mild VBN N
in IN N
both DT N
groups NNS N
. . N

Nausea NN o
was VBD N
noted VBN N
in IN N
71.4 CD N
% NN N
and CC N
46.2 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
inhibitory JJ N
effect NN N
tended VBD N
to TO N
be VB N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

Appetite NNP o
loss NN o
developed VBD N
in IN N
92.9 CD N
% NN N
and CC N
41.7 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
prevention NN N
effect NN N
was VBD N
clearly RB N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

The DT N
prevention NN N
effects NNS N
on IN N
nausea NN o
7 CD N
, , N
8 CD N
and CC N
10 CD N
days NNS N
after IN N
the DT N
start NN N
of IN N
chemotherapy NN N
, , N
on IN o
appetite JJ o
loss NN o
2-10 JJ N
days NNS N
after IN N
it PRP N
, , N
and CC N
2-5 JJ N
days NNS N
after IN N
its PRP$ N
completion NN N
, , N
were VBD N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

Granisetron NNP i
revealed VBD N
an DT N
excellent JJ N
inhibitory NN o
effect NN o
on IN o
vomiting VBG o
induced VBN N
by IN N
remission NN N
induction NN N
chemotherapy NN N
for IN N
acute JJ N
myeloid NN N
leukemia NN N
, , N
but CC N
combination NN N
with IN N
granisetron NN i
and CC i
methylprednisolone NN i
was VBD N
considered VBN N
useful JJ N
for IN N
nausea NN o
in IN N
the DT N
latter JJ N
half NN N
of IN N
the DT N
treatment NN N
period NN N
and CC N
for IN N
appetite JJ o
loss NN o
during IN N
the DT N
whole JJ N
period NN N
. . N

-DOCSTART- -X- O O

Supportive-expressive JJ i
group NN i
therapy NN i
for IN N
primary JJ p
breast NN o
cancer NN o
patients NNS p
: : p
a DT N
randomized JJ N
prospective JJ N
multicenter NN N
trial NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
is VBZ N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
manualized JJ i
12-week JJ i
supportive-expressive JJ i
group NN i
therapy NN i
program NN i
among IN N
primary JJ p
breast NN o
cancer NN o
patients NNS p
treated VBN p
in IN p
community NN p
settings NNS p
, , N
to TO N
determine VB N
whether IN N
highly RB p
distressed JJ p
patients NNS p
were VBD N
most RBS N
likely JJ N
to TO N
benefit VB N
and CC N
whether IN N
therapist NN N
's POS N
training NN N
or CC N
experience NN N
was VBD N
related VBN N
to TO N
outcome VB N
. . N

METHOD NNP N
Three CD p
hundred VBD p
and CC p
fifty-three JJ p
women NNS p
within IN p
one CD p
year NN p
of IN p
diagnosis NN p
with IN p
primary JJ p
breast NN p
cancer NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
supportive-expressive JJ i
group NN i
therapy NN i
or CC i
to TO i
an DT i
education NN i
control NN i
condition NN i
. . i

Participants NNS p
were VBD p
recruited VBN p
from IN p
two CD p
academic JJ p
centers NNS p
and CC p
nine CD p
oncology NN p
practices NNS p
, , p
which WDT p
were VBD p
members NNS p
of IN p
NCI NNP p
's POS p
Community NNP p
Clinical NNP p
Oncology NNP p
Program NNP p
( ( p
CCOP NNP p
) ) p
and CC p
were VBD p
followed VBN p
over IN p
2 CD p
years NNS p
. . p

RESULTS VB N
A DT N
2x2x19 CD N
analysis NN N
of IN N
variance NN N
was VBD N
conducted VBN N
with IN N
main JJ N
effects NNS o
of IN o
treatment NN o
condition NN o
, , o
cohort NN o
, , o
and CC o
baseline NN o
distress NN o
and CC o
their PRP$ o
interactions NNS o
. . o

There EX N
was VBD N
no DT N
main JJ N
effect NN N
for IN N
treatment NN o
condition NN o
after IN N
removing VBG N
one CD N
subject NN N
with IN N
an DT N
extreme JJ N
score NN N
. . N

Highly NNP p
distressed JJ o
women NNS p
did VBD N
not RB N
derive VB N
a DT N
greater JJR o
benefit NN o
from IN N
treatment NN N
. . N

Therapist VB N
training NN N
and CC N
psychotherapy NN N
experience NN N
were VBD N
not RB N
associated VBN N
with IN N
a DT N
treatment NN N
effect NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
no DT N
evidence NN N
of IN N
reduction NN N
in IN N
distress NN o
as IN N
the DT N
result NN N
of IN N
a DT N
brief JJ i
supportive-expressive JJ i
intervention NN i
for IN N
women NNS p
with IN p
primary JJ p
breast NN o
cancer NN o
. . o

Future NNP N
studies NNS N
might MD N
productively RB N
focus VB N
on IN N
women NNS p
with IN p
higher JJR p
initial JJ p
levels NNS p
of IN p
distress NN o
. . o

-DOCSTART- -X- O O

Influence NN N
of IN N
Aloe NNP i
arborescens NNS i
Mill NNP i
. . i

extract NN i
on IN N
selected VBN N
parameters NNS o
of IN N
pro-oxidant-antioxidant JJ o
equilibrium NN o
and CC N
cytokine JJ o
synthesis NN o
in IN N
rowers NNS p
. . p

This DT N
investigation NN N
examined VBD N
the DT N
effect NN N
of IN N
supplementation NN i
with IN i
Biostimine NNP i
, , i
extract NN i
from IN i
Aloe NNP i
arborescens NNS i
Mill NNP i
. . i

leaves NNS i
, , N
on IN N
the DT N
levels NNS N
of IN N
pro-oxidant-antioxidant JJ o
equilibrium NN o
markers NNS o
and CC N
anti- JJ N
and CC N
proinflammatory JJ o
cytokines NNS o
in IN N
rowers NNS p
subjected VBN p
to TO p
exhaustive VB p
exercise NN p
. . p

This DT N
double-blind NN N
study NN p
included VBD p
18 CD p
members NNS p
of IN p
the DT p
Polish JJ p
Rowing NNP p
Team NNP p
. . p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
supplemented VBN N
group NN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
, , N
which WDT N
received VBD N
one CD N
ampoule NN N
of IN N
Biostimine NNP i
once RB N
daily RB N
for IN N
4 CD N
weeks NNS N
, , N
or CC N
to TO N
the DT N
placebo NN i
group NN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
. . N

Subjects NNS N
performed VBD N
a DT N
2,000-meter-maximum JJ N
test NN N
on IN N
a DT N
rowing NN N
ergometer NN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
preparatory NN N
camp NN N
. . N

Blood NN N
samples NNS N
were VBD N
obtained VBN N
from IN N
the DT N
antecubital JJ N
vein NN N
before IN N
each DT N
exercise NN N
test NN N
, , N
1 CD N
min NN N
after IN N
completing VBG N
the DT N
test NN N
and CC N
after IN N
a DT N
24-hr JJ N
recovery NN N
period NN N
. . N

Superoxide NNP o
dismutase NN o
and CC o
glutathione NN o
peroxidase NN o
activity NN o
as RB N
well RB N
as IN N
the DT o
concentration NN o
of IN o
thiobarbituric JJ o
acid NN o
reactive JJ o
substances NNS o
( ( o
TBARS NNP o
) ) o
were VBD N
assessed VBN N
in IN N
erythrocytes NNS N
. . N

In IN N
addition NN N
, , N
total JJ o
antioxidant JJ o
capacity NN o
( ( o
TAC NNP o
) ) o
and CC o
creatine JJ o
kinase NN o
activity NN o
were VBD N
measured VBN N
in IN N
plasma NN N
samples NNS N
, , N
and CC N
cytokine NN o
( ( o
IL-6 NNP o
, , o
IL-10 NNP o
) ) o
concentrations NNS o
were VBD N
determined VBN N
in IN N
the DT N
serum NN N
. . N

Before IN N
and CC N
after IN N
Biostimine NNP i
supplementation NN i
, , N
exercise VBP N
significantly RB N
increased VBN N
the DT N
values NNS o
of IN o
SOD NNP o
, , o
IL-6 NNP o
, , o
IL-10 NNP o
, , o
and CC o
TBARS NNP o
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
postexercise NN N
and CC N
recovery NN N
levels NNS N
of IN N
TBARS NNP o
were VBD N
significantly RB N
lower JJR N
in IN N
athletes NNS N
receiving VBG N
Biostimine NNP i
than IN N
in IN N
controls NNS N
. . N

After IN N
supplementation NN N
, , N
TAC NNP o
was VBD N
the DT N
only JJ N
variable NN N
with IN N
the DT N
level NN N
being VBG N
significantly RB N
higher RBR N
in IN N
the DT N
supplemented JJ N
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
. . N

Consequently RB N
, , N
we PRP N
can MD N
conclude VB N
that DT N
Biostimine NNP i
supplementation NN i
reduces VBZ N
the DT N
postexercise NN N
level NN N
of IN N
TBARS NNP o
by IN N
increasing VBG N
the DT N
antioxidant JJ o
activity NN o
of IN o
plasma NN o
but CC N
has VBZ N
no DT N
effect NN N
on IN N
inflammatory NN o
markers NNS o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
weight JJ N
loss NN N
on IN N
inflammation NN N
in IN N
patients NNS p
with IN p
mild JJ p
obstructive JJ p
sleep NN p
apnea NN p
. . p

BACKGROUND NNP N
AND CC N
AIMS NNP N
Inflammation NNP N
may MD N
be VB N
one CD N
mediating VBG N
mechanism NN N
for IN N
cardiovascular JJ p
diseases NNS p
in IN p
obstructive JJ p
sleep NN p
apnea NN p
( ( p
OSA NNP p
) ) p
. . N

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
subclinical JJ N
inflammation NN N
or CC N
the DT N
effect NN N
of IN N
lifestyle JJ N
intervention NN N
on IN N
inflammation NN N
in IN N
early JJ N
stages NNS N
of IN N
OSA NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
substudy NN N
of IN N
an DT N
existing VBG N
randomized NN N
controlled VBD N
trial NN N
, , N
with IN N
post NN N
hoc NN N
analyses NNS N
, , N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
lifestyle JJ N
changes NNS N
aimed VBN N
at IN N
weight JJ N
reduction NN N
on IN N
inflammatory NN N
biomarkers NNS N
in IN N
overweight JJ p
patients NNS p
with IN p
mild JJ p
OSA NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNPS p
were VBD p
randomized VBN p
to TO p
supervised VBN i
intensive JJ i
lifestyle JJ i
intervention NN i
group NN i
( ( p
N=28 NNP p
) ) p
or CC p
to TO p
control VB i
group NN i
( ( p
N=31 NNP p
) ) p
, , p
which WDT p
received VBD p
routine JJ i
lifestyle JJ i
advices NNS i
. . i

Circulating VBG N
concentrations NNS N
of IN N
pro- JJ N
and CC N
anti-inflammatory JJ N
mediators NNS N
were VBD N
measured VBN N
before IN N
and CC N
after IN N
the DT N
1-year JJ N
intervention NN N
. . N

The DT N
concentrations NNS N
of IN N
two CD N
pro-inflammatory JJ N
mediators NNS N
, , N
high-sensitivity JJ o
C-reactive JJ o
protein NN o
( ( o
hsCRP NN o
) ) o
and CC o
interleukin JJ o
( ( o
IL NNP o
) ) o
-6 NN o
, , o
decreased VBN o
significantly RB N
in IN N
both DT N
groups NNS N
. . N

Although IN N
the DT N
changes NNS N
in IN N
inflammatory JJ o
biomarkers NNS o
favored VBD o
the DT N
supervised JJ N
lifestyle NN i
intervention NN i
, , N
the DT N
only JJ N
significant JJ N
reduction NN N
observed VBD N
between IN N
the DT N
groups NNS N
was VBD N
for IN N
the DT N
anti-inflammatory JJ N
IL-1 NNP N
receptor NN N
antagonist NN N
( ( N
IL-1RA NNP N
) ) N
. . N

The DT N
change NN o
in IN o
hsCRP NN o
was VBD N
associated VBN N
with IN N
apnea-hypopnea JJ o
index NN o
, , N
and CC N
improving VBG o
night-time JJ o
oxygen NN o
saturation NN o
was VBD N
related VBN N
to TO N
tumor VB N
necrosis JJ N
factor NN N
alpha NN N
. . N

IL-1RA JJ N
and CC N
IL-6 NNP N
were VBD N
associated VBN N
with IN N
insulin NN N
metabolism NN N
. . N

CONCLUSION NNP N
Weight NNP o
loss NN o
resulted VBD N
in IN N
reductions NNS N
in IN N
concentrations NNS N
of IN N
some DT N
pro- JJ N
and CC N
anti-inflammatory JJ N
mediators NNS N
in IN N
overweight JJ p
patients NNS p
with IN p
mild JJ p
OSA NNP p
, , N
overall JJ N
favoring VBG N
the DT N
supervised JJ N
lifestyle JJ i
intervention NN i
. . i

These DT N
findings NNS N
suggest VBP N
that IN N
more RBR N
intensive JJ N
treatment NN N
of IN N
obesity NN N
in IN N
OSA NNP p
patients NNS p
might MD N
be VB N
well-justified JJ N
. . N

-DOCSTART- -X- O O

Marginal NNP N
biotin NN N
deficiency NN N
during IN N
normal JJ p
pregnancy NN p
. . p

BACKGROUND NNP N
Biotin NNP N
deficiency NN N
is VBZ N
teratogenic JJ N
in IN N
several JJ p
mammalian JJ p
species NNS p
. . p

Approximately RB N
50 CD N
% NN N
of IN N
pregnant JJ p
women NNS p
have VBP N
an DT N
abnormally RB N
increased JJ N
urinary JJ N
excretion NN N
of IN N
3-hydroxyisovaleric JJ o
acid NN o
( ( o
3-HIA JJ o
) ) o
, , N
which WDT N
probably RB N
reflects VBZ N
decreased JJ N
activity NN N
of IN N
the DT N
biotin-dependent JJ N
enzyme JJ N
methylcrotonyl-CoA JJ N
carboxylase NN N
. . N

However RB N
, , N
increased VBD N
3-HIA JJ N
excretion NN N
could MD N
result VB N
from IN N
pregnancy NN N
per IN N
se NN N
( ( N
eg JJ N
, , N
from IN N
an DT N
effect NN N
of IN N
pregnancy NN N
on IN N
renal JJ N
handling NN N
of IN N
organic JJ N
acids NNS N
) ) N
. . N

OBJECTIVE IN N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
biotin VBZ N
supplementation NN N
significantly RB N
decreases VBZ N
3-HIA JJ N
excretion NN N
in IN N
pregnant JJ p
women NNS p
with IN p
abnormally RB p
increased VBN p
3-HIA JJ p
excretion NN p
. . p

DESIGN NNP N
Twenty-six NNP p
pregnant JJ p
women NNS p
with IN p
increased JJ p
3-HIA JJ p
excretion NN p
were VBD p
studied VBN p
in IN p
a DT p
randomized JJ p
, , p
placebo-controlled JJ i
trial NN p
; : p
10 CD N
women NNS N
were VBD N
studied VBN N
during IN N
early JJ N
pregnancy NN N
( ( N
6-17 JJ N
wk NN N
gestation NN N
) ) N
and CC N
16 CD N
women NNS N
during IN N
late JJ N
pregnancy NN N
( ( N
21-37 JJ N
wk NN N
gestation NN N
) ) N
. . N

Urine JJ o
samples NNS o
were VBD N
collected VBN N
before IN N
and CC N
after IN N
14 CD N
d NN N
of IN N
supplementation NN N
with IN N
300 CD i
microg NNS i
( ( i
1.2 CD i
micromol NN i
) ) i
biotin/d NN i
or CC i
placebo NN i
. . i

RESULTS NNP N
In IN N
the DT N
early-pregnancy NN N
group NN N
, , N
3-HIA JJ o
excretion NN o
decreased VBN N
( ( N
P NNP N
< NNP N
0.006 CD N
) ) N
by IN N
11.7 CD N
+/- JJ N
3.6 CD N
mmol/mol NN N
creatinine NN N
( ( N
mean JJ N
+/- NNP N
SEM NNP N
) ) N
in IN N
the DT N
5 CD N
women NNS N
who WP N
received VBD N
biotin NN N
supplements NNS N
, , N
whereas IN N
3-HIA JJ o
excretion NN o
increased VBN N
by IN N
1.6 CD N
+/- JJ N
0.6 CD N
mmol/mol JJ N
creatinine NN N
in IN N
the DT N
5 CD N
women NNS N
who WP N
received VBD N
placebo NN N
. . N

In IN N
the DT N
late-pregnancy NN N
group NN N
, , N
3-HIA JJ o
excretion NN o
decreased VBN N
( ( N
P NNP N
< NNP N
0.002 CD N
) ) N
by IN N
7.1 CD N
+/- JJ N
1.2 CD N
mmol/mol JJ N
creatinine NN N
in IN N
the DT N
8 CD N
women NNS N
who WP N
received VBD N
biotin NN N
supplements NNS N
, , N
whereas IN N
3-HIA JJ o
excretion NN o
increased VBN N
by IN N
0.9 CD N
+/- JJ N
1.8 CD N
mmol/mol JJ N
creatinine NN N
in IN N
the DT N
8 CD N
women NNS N
who WP N
received VBD N
placebo NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
evidence NN N
that IN N
the DT N
increased JJ N
excretion NN o
of IN o
3-HIA JJ o
seen VBN N
frequently RB N
in IN N
normal JJ p
pregnancy NN p
reflects VBZ N
reduced VBN N
biotin JJ o
status NN o
. . o

The DT N
conclusion NN N
that IN N
marginal JJ N
biotin NN N
deficiency NN N
occurs VBZ N
frequently RB N
in IN N
the DT N
first JJ N
trimester NN N
further RBR N
raises NNS N
concern NN N
about IN N
potential JJ N
human JJ N
teratogenicity NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
a DT N
total JJ i
occlusive JJ i
ionic JJ i
silver-containing NN i
dressing VBG i
combination NN i
in IN N
decreasing VBG N
risk NN o
of IN o
surgical JJ o
site NN o
infection NN o
: : o
an DT N
RCT NNP N
. . N

OBJECTIVE NNP N
To TO N
perform VB N
a DT N
comparative JJ N
assessment NN N
of IN N
the DT N
efficacy NN N
of IN N
total JJ i
occlusive JJ i
ionic JJ i
silver-containing NN i
dressing NN i
( ( i
TOISD NNP i
) ) i
combination NN i
vs IN i
no DT i
dressing NN i
after IN N
colorectal JJ p
surgery NN p
. . p

METHOD NNP N
The DT N
surgical JJ N
sites NNS N
from IN N
both DT N
groups NNS N
were VBD N
swabbed VBN N
and CC N
sent VBN N
for IN N
culture NN N
and CC N
sensitivity NN N
upon IN N
wound JJ N
closure NN N
( ( N
superficial JJ N
incisional JJ N
skin NN N
surface NN N
) ) N
in IN N
the DT N
operating NN N
theatre NN N
, , N
as IN N
a DT N
baseline NN N
for IN N
bacterial JJ N
colonisation NN N
. . N

The DT p
patients NNS p
' POS p
surgical JJ p
wounds NNS p
in IN N
the DT N
study NN N
group NN N
were VBD N
dressed VBN N
with IN N
TOISD NNP i
combination NN N
and CC N
the DT N
patient NN N
's POS N
surgical JJ N
wounds NNS N
in IN N
the DT N
control NN N
group NN N
received VBD N
the DT N
conventional JJ N
method NN N
of IN N
no DT N
dressing NN N
. . N

A DT N
second JJ N
swab NN N
was VBD N
taken VBN N
from IN N
the DT N
superficial JJ N
incisional JJ N
skin NN N
surface NN N
for IN N
culture NN N
and CC N
sensitivity NN N
investigation NN N
between IN N
the DT N
fifth NN N
to TO N
seventh VB N
postoperative JJ N
day NN N
for IN N
comparison NN N
of IN N
the DT N
bacterial JJ N
colonisation NN N
in IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
One-hundred JJ p
and CC p
sixty-six JJ p
patients NNS p
were VBD p
recruited VBN p
. . p

Six CD p
patients NNS p
dropped VBD p
out RP p
before IN N
the DT N
fifth JJ N
postoperative JJ N
day NN N
, , N
leaving VBG N
79 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
and CC N
81 CD p
patients NNS p
in IN p
the DT p
study NN p
group NN p
. . p

Microbial NNP N
swab NN N
cultures NNS N
revealed VBD N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
mean=1.43?0.63 NN N
) ) N
in IN o
bacterial JJ o
colonisation NN o
. . o

The DT o
odds NNS o
ratio NN o
( ( o
OR NNP o
) ) o
of IN N
patients NNS N
with IN N
wounds NNS N
in IN N
the DT N
control NN N
group NN N
was VBD N
4.1 CD N
( ( N
95 CD N
% NN N
CI NNP N
is VBZ N
1.884 CD N
, , N
8.964 CD N
) ) N
more RBR N
likely JJ N
to TO N
be VB N
contaminated VBN N
with IN N
bacteria NNS N
compared VBN N
with IN N
wounds NNS N
covered VBN N
with IN N
occlusive JJ N
ionic JJ N
silver-containing NN N
dressing NN N
. . N

CONCLUSION NNP N
TOISD NNP N
was VBD N
found VBN N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG o
bacterial JJ o
colonisation NN o
on IN N
the DT N
surgical JJ N
site NN N
compared VBN N
with IN N
no DT N
dressing NN N
. . N

However RB N
, , N
it PRP N
properties NNS N
were VBD N
unable JJ N
to TO N
be VB N
put VBN N
into IN N
use NN N
if IN N
there EX N
were VBD N
the DT N
surgical JJ N
sites NNS N
were VBD N
not RB N
infested VBN N
with IN N
bacterial JJ N
. . N

Although IN N
TOISD NNP N
might MD N
not RB N
be VB N
necessarily RB N
on IN N
surgical JJ N
incisional JJ N
site NN N
not RB N
infested VBN N
with IN N
bacteria NNS N
for IN N
the DT N
initial JJ N
post-operation NN N
days NNS N
, , N
it PRP N
is VBZ N
helpful JJ N
in IN N
preventing VBG N
further JJ N
transcription NN N
and CC N
division NN N
for IN N
opportunistic JJ N
bacteria NNS N
, , N
thus RB N
might MD N
reduce VB N
the DT o
risk NN o
of IN o
superficial JJ o
incisional JJ o
SSI NNP o
. . o

The DT N
use NN N
of IN N
TOSID NNP N
though IN N
statistically RB N
insignificant JJ N
compared VBN N
to TO N
no DT N
dressing NN N
, , N
could MD N
also RB N
be VB N
possible JJ N
in IN N
reducing VBG N
the DT o
risk NN o
and CC o
exaceration NN o
of IN o
deep JJ o
incisional JJ o
SSI NNP o
. . o

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
diagnosis NN N
of IN N
deep JJ N
venous JJ N
thrombosis NN N
after IN N
hip NN N
replacement NN N
surgery NN N
] NN N
. . N

Hip NNP N
replacement NN N
surgery NN N
is VBZ N
associated VBN N
with IN N
a DT N
high JJ N
frequency NN N
of IN N
postoperative JJ N
deep JJ N
vein NN N
thrombosis NN N
. . N

This DT N
prospective JJ N
study NN N
was VBD N
performed VBN N
in IN N
order NN N
to TO N
investigate VB N
if IN N
routine JJ i
bedside NN i
questioning VBG i
and CC i
examination NN i
by IN i
the DT i
visiting NN i
doctor NN i
could MD N
reveal VB N
deep JJ N
vein NN N
thrombosis NN N
in IN N
the DT N
legs NN N
of IN N
patients NNS p
who WP p
had VBD p
received VBN p
a DT p
hip NN p
replacement NN p
. . p

258 CD p
patients NNS p
were VBD p
evaluated VBN p
. . p

Thromboprophylaxis NNP i
( ( i
dextran-70 JJ i
, , i
low JJ i
molecular JJ i
weight NN i
heparin NN i
and CC i
graded VBD i
elastic JJ i
stockings NNS i
) ) i
was VBD N
given VBN N
during IN N
the DT N
first JJ N
week NN N
after IN N
operation NN N
. . N

Bilateral NNP i
venography NN i
was VBD N
performed VBN N
in IN N
all DT N
patients NNS N
on IN N
day NN N
seven CD N
after IN N
operation NN N
, , N
and CC N
showed VBD N
an DT N
overall JJ N
deep JJ N
vein NN N
thrombosis NN N
incidence NN N
of IN N
16 CD N
% NN N
. . N

The DT N
visiting NN N
doctors NNS N
had VBD N
not RB N
suspected VBN N
deep JJ N
vein NN N
thrombosis NN N
in IN N
any DT N
of IN N
the DT N
patients NNS N
. . N

This DT N
may MD N
have VB N
been VBN N
because RB N
postoperative JJ o
painful NN o
and CC o
swollen JJ o
legs NNS o
effectively RB N
masked VBD N
any DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
deep JJ N
vein NN N
thrombosis NN N
. . N

Our PRP$ N
results NNS N
show VBP N
that IN N
deep JJ o
vein NN o
thrombosis NN o
during IN N
the DT N
first JJ N
week NN N
after IN N
hip NN N
replacement NN N
surgery NN N
can MD N
not RB N
be VB N
discovered VBN N
by IN N
clinical JJ N
diagnostics NNS N
. . N

The DT N
high JJ N
subclinical JJ N
frequency NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
indicates VBZ N
the DT N
importance NN N
of IN N
improving VBG N
thromboprophylaxis NN N
in IN N
order NN N
to TO N
further RBR N
minimise VB N
the DT N
occurrence NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
and CC N
the DT N
risk NN N
of IN N
thromboembolic JJ N
complications NNS N
. . N

-DOCSTART- -X- O O

Humoral NNP p
immunity NN p
after IN p
kidney NN p
transplantation NN p
: : p
impact NN N
of IN N
two CD N
randomized JJ N
immunosuppressive JJ N
protocols NNS N
. . N

BACKGROUND NNP N
Controlling NNP N
alloimmune JJ N
humoral JJ N
response NN N
is VBZ N
a DT N
challenge NN N
in IN N
transplantation NN N
. . N

Few JJ N
studies NNS N
have VBP N
evaluated VBN N
the DT N
impact NN N
of IN N
maintenance NN N
immunosuppression NN N
on IN N
blood NN N
humoral JJ N
parameters NNS N
. . N

MATERIAL/METHODS NNP N
We PRP N
performed VBD N
a DT N
post-hoc JJ N
analysis NN N
on IN N
307 CD p
kidney NN p
transplant NN p
recipients NNS p
included VBD p
in IN p
a DT p
prospective JJ p
randomized VBN p
trial NN p
comparing VBG p
tacrolimus/mycophenolate NN i
mofetil NN i
( ( i
Tac/MMF NNP i
) ) i
vs. FW i
cyclosporine/azathioprine NN i
( ( i
CsA/AZA NNP i
) ) i
, , N
both DT N
used VBN N
with IN N
antithymocyte JJ i
globulin NN i
induction NN i
and CC N
steroids NNS i
. . i

Humoral JJ N
parameters NNS N
were VBD N
analyzed VBN N
at IN N
D0 NNP N
, , N
D15 NNP N
, , N
and CC N
M12 NNP N
. . N

RESULTS NNP N
IgG NNP o
, , o
IgA NNP o
, , o
and CC o
IgM NNP o
levels NNS o
decreased VBN N
significantly RB N
as RB N
soon RB N
as IN N
D15 NNP N
in IN N
both DT N
groups NNS N
( ( N
?35 CD N
% NN N
, , N
?26 CD N
% NN N
, , N
and CC N
?35 CD N
% NN N
respectively RB N
, , N
vs. FW N
D0 NNP N
) ) N
. . N

At IN N
M12 NNP N
, , N
although IN o
peripheral JJ o
B-cell NNP o
counts NNS o
did VBD o
not RB o
differ VB N
between IN N
the DT N
groups NNS N
, , N
Tac/MMF NNP N
regimen NN N
was VBD N
associated VBN N
with IN N
lower JJR N
IgG NNP N
, , N
IgA NNP N
, , N
and CC N
IgM NNP N
levels NNS N
than IN N
CsA/AZA NNP N
( ( N
?5.9 CD N
% NN N
, , N
?14.6 CD N
% NN N
, , N
and CC N
?34 NNP N
% NN N
, , N
respectively RB N
) ) o
. . o

Hypogammaglobulinemia NNP o
at IN o
D15 NNP o
was VBD o
not RB N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN o
of IN o
infections NNS o
during IN N
the DT N
first JJ N
year NN N
. . N

The DT o
proportion NN o
of IN o
HLA-sensitized JJ o
patients NNS o
decreased VBN o
in IN N
the DT N
Tac/MMF NNP N
group NN N
( ( N
15.9 CD N
% NN N
at IN N
D0 NNP N
and CC N
6.7 CD N
% NN N
at IN N
M12 NNP N
, , N
p=0.02 NN N
) ) N
and CC N
remained VBD N
stable JJ N
in IN N
the DT N
CsA/AZA NNP N
group NN N
( ( N
10.3 CD N
% NN N
at IN N
D0 NNP N
and CC N
8.9 CD N
% NN N
at IN N
M12 NNP N
, , N
p=0.5 NN N
) ) N
. . N

More JJR N
patients NNS N
sensitized VBN N
at IN N
baseline NN N
became VBD N
non-sensitized JJ N
at IN N
M12 NNP N
with IN N
Tac/MMF NNP N
than IN N
with IN N
CsA/AZA NNP N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
humoral JJ N
immunosuppression NN N
is VBZ N
better RBR N
with IN N
Tac/MMF NNP N
than IN N
with IN N
CsA/AZA NNP N
during IN N
the DT N
first JJ N
year NN N
of IN N
kidney NN N
transplantation NN N
. . N

-DOCSTART- -X- O O

Intensive JJ i
insulin NN i
therapy NN i
on IN N
infection NN N
rate NN N
, , N
days NNS N
in IN N
NICU NNP N
, , N
in-hospital JJ o
mortality NN o
and CC o
neurological JJ o
outcome NN o
in IN N
severe JJ p
traumatic JJ p
brain NN p
injury NN p
patients NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVES NNP N
Evaluate NNP N
the DT N
impact NN N
of IN N
an DT N
intensive JJ i
insulin NN i
therapy NN i
and CC N
conventional JJ i
glucose NN i
control NN i
protocol NN i
during IN N
staying VBG N
in IN N
neurological JJ N
intensive JJ N
care NN N
unit NN N
( ( N
NICU NNP N
) ) N
on IN N
infection NN o
rate NN o
, , o
days NNS o
in IN o
NICU NNP o
, , o
in-hospital JJ o
mortality NN o
and CC o
long-term JJ o
neurological JJ o
outcome NN o
in IN N
severe JJ p
traumatic JJ p
brain NN p
injury NN p
( ( p
TBI NNP p
) ) p
patients NNS p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
240 CD p
patients NNS p
with IN p
severe JJ p
TBI NNP p
( ( p
GCS NNP p
score RB p
3-8 JJ p
) ) p
admitted VBD p
to TO p
NICU NNP p
were VBD N
prospectively RB N
enrolled VBN N
and CC N
randomly RB N
assigned VBD N
either DT N
to TO N
conventional JJ i
insulin NN i
therapy NN i
or CC N
to TO N
intensive JJ i
insulin NN i
therapy NN i
. . i

Patients NNS N
in IN N
intensive JJ i
glucose NNS i
control NN i
group NN i
( ( N
n=121 NN N
) ) N
received VBD N
continuous JJ i
insulin NN i
infusion NN i
to TO N
maintain VB N
glucose JJ N
levels NNS N
between IN N
4.4 CD N
m NNS N
mol/l NN N
( ( N
80 CD N
mg/dl NN N
) ) N
and CC N
6.1 CD N
m NN N
mol/l NN N
( ( N
110 CD N
mg/dl NN N
) ) N
. . N

Patients NNS N
in IN N
the DT N
conventional JJ i
treatment NN i
group NN i
( ( N
n=119 RB N
) ) N
were VBD N
not RB N
given VBN N
insulin NN i
unless IN N
glucose JJ o
levels NNS o
were VBD N
greater JJR N
than IN N
11.1 CD N
m JJ N
mol/l NN N
( ( N
200mg/dl CD N
) ) N
. . N

Both DT N
groups NNS N
were VBD N
treated VBN N
with IN N
insulin JJ i
infusion NN N
to TO N
maintain VB N
normoglycemia RB N
after IN N
leaving VBG N
NICU NNP N
. . N

Comparison NNP N
was VBD N
made VBN N
against IN N
conventional JJ i
insulin NN i
therapy NN i
using VBG N
a DT N
randomized JJ N
trial NN N
design NN N
. . N

The DT N
primary JJ N
outcomes NNS N
is VBZ N
the DT N
mortality NN o
rate NN o
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

The DT N
second JJ N
outcomes NNS N
including VBG N
ICU NNP o
infection NN o
rate NN o
, , o
duration NN o
of IN o
ICU NNP o
stay NN o
, , o
in-hospital JJ o
mortality NN o
rate NN o
and CC o
neurologic JJ o
outcome NN o
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
gender NN p
( ( p
66 CD p
% NN p
vs. FW p
67 CD p
% NN p
male NN p
) ) p
, , p
age NN p
( ( p
46+/-11 CD p
years NNS p
vs. IN p
45+/-10 CD p
years NNS p
) ) p
, , p
APACHE NNP p
II NNP p
score NN p
( ( p
30 CD p
vs. FW p
29 CD p
) ) p
, , p
TISS-28 NNP o
score NN o
( ( p
47 CD p
vs. FW p
46 CD p
) ) p
, , p
and CC p
Glasgow NNP o
Coma NNP o
Score NNP o
( ( p
GCS NNP p
, , p
5.3 CD p
vs. FW p
5.3 CD p
) ) p
between IN N
the DT N
two CD N
groups NNS N
. . N

Overall JJ o
mortality NN o
rates NNS o
at IN N
6 CD N
months NNS N
follow-up JJ N
were VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
61 CD N
of IN N
117 CD N
, , N
52.1 CD N
% NN N
vs. FW N
62 CD N
of IN N
116 CD N
, , N
53.4 CD N
% NN N
; : N
P=0.8 NNP N
) ) N
. . N

The DT N
infection NN o
rate NN o
during IN N
the DT N
study NN N
was VBD N
significantly RB N
higher JJR N
in IN N
patients NNS N
who WP N
received VBD N
conventional JJ i
insulin NN i
therapy NN i
than IN N
that DT N
in IN N
patients NNS N
who WP N
received VBD N
intensive JJ i
insulin NN i
therapy NN i
( ( N
46.2 CD N
% NN N
vs. FW N
31.4 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
days NNS o
stay VBP o
in IN o
NICU NNP o
was VBD N
shorter RBR N
in IN N
intensive JJ i
insulin NN i
control NN i
group NN i
than IN N
that DT N
in IN N
conventional JJ i
therapy NN i
group NN i
[ VBD N
4.2 CD N
days NNS N
vs. FW N
5.6 CD N
days NNS N
( ( N
medians NNS N
) ) N
P NNP N
< $ N
0.05 CD N
] NNP N
. . N

The DT N
in-hospital JJ o
mortality NN o
during IN N
the DT N
study NN N
was VBD N
similar JJ N
in IN N
conventional JJ i
and CC i
intensive JJ i
therapy NN i
groups NNS i
( ( N
34 CD N
of IN N
119 CD N
, , N
28.6 CD N
% NN N
vs. FW N
35 CD N
of IN N
121 CD N
, , N
28.9 CD N
% NN N
in IN N
the DT N
conventional JJ i
and CC i
intensive JJ i
insulin NN i
therapy NN i
groups NNS N
; : N
P=0.85 NNP N
) ) N
. . N

The DT N
neurologic JJ o
outcome NN o
according VBG N
to TO N
Glasgow NNP o
Outcome NNP o
Score NNP o
( ( o
GOS NNP o
) ) o
at IN N
6 CD N
months NNS N
( ( N
GOS NNP N
5 CD N
and CC N
4 CD N
) ) N
was VBD N
better RBR N
in IN N
the DT N
intensive JJ i
insulin NN i
therapy NN i
group NN N
( ( N
34 CD N
of IN N
117 CD N
, , N
29.1 CD N
% NN N
) ) N
than IN N
that DT N
in IN N
the DT N
conventional JJ i
therapy NN i
group NN N
( ( N
26 CD N
of IN N
116 CD N
, , N
22.4 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Mortality NNP o
rates NNS o
at IN N
6 CD N
months NNS N
follow-up NNS N
are VBP N
not RB N
affected VBN N
by IN N
intensive JJ N
glucose NNS N
control NN N
in IN N
patients NNS p
with IN p
severe JJ p
TBI NNP p
. . p

Intensive JJ i
insulin NN i
therapy NN i
decreases VBZ N
infection NN o
rate NN o
and CC o
days NNS o
in IN o
NICU NNP o
and CC N
improves VBZ o
the DT o
neurological JJ o
outcome NN o
at IN N
6 CD N
months NNS N
follow-up RB N
, , N
while IN N
has VBZ N
no DT N
obvious JJ N
influence NN N
on IN N
in-hospital JJ o
mortality NN o
of IN N
severe JJ p
TBI NNP p
patients NNS p
. . p

-DOCSTART- -X- O O

The DT N
implications NNS o
of IN N
introducing VBG N
the DT N
symphyseal-fundal JJ i
height-measurement NN i
. . i

A DT N
prospective JJ p
randomized NN N
controlled VBD N
trial NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
stellate NN i
ganglionic JJ i
block NN i
on IN N
hemodynamic JJ o
changes NNS o
and CC o
intrapulmonary JJ o
shunt NN o
in IN N
perioperative JJ p
patients NNS p
with IN p
esophageal JJ p
cancer NN p
. . p

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
observe VB N
the DT N
effects NNS N
of IN i
stellate JJ i
ganglion NN i
block NN i
( ( i
SGB NNP i
) ) i
on IN o
hemodynamic JJ o
changes NNS o
and CC o
intrapulmonary JJ o
shunt NN o
during IN N
one-lung JJ N
ventilation NN N
( ( N
OLV NNP N
) ) N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP p
Thirty NNP p
ASA NNP p
class NN p
I-II NNP p
patients NNS p
undergoing VBG p
elective JJ p
esophageal NN p
surgery NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS i
: : i
general JJ i
anesthesia NN i
group NN i
( ( i
group NN i
N NNP i
, , i
n=15 NN i
) ) i
and CC i
general JJ i
anesthesia NN i
combined VBD i
SGB NNP i
group NN i
( ( i
group NN i
S NNP i
, , i
n=15 NN i
) ) i
, , i
patients NNS i
in IN i
group NN i
S NNP i
were VBD i
received VBN i
left JJ i
SGB NNP i
before IN i
induction NN i
. . i

Radial JJ i
artery NN i
was VBD i
cannulated VBN i
for IN o
arterial JJ o
blood NN o
pressure NN o
( ( o
ABP NNP o
) ) o
monitoring NN o
and CC o
blood NN o
sampling NN i
and CC i
Swan-Ganz NNP i
catheter NN i
was VBD i
position NN i
in IN i
the DT i
pulmonary JJ i
artery NN i
via IN i
right JJ i
internal JJ i
jugular NN i
vein NN i
under IN i
local JJ i
anesthesia NN i
. . i

ECG NNP o
, , o
MAP NNP o
, , o
HR NNP o
, , o
CVP NNP o
, , o
continuous JJ o
cardiac NN o
output NN o
( ( o
CCO NNP o
) ) o
index NN o
and CC o
BIS NNP o
were VBD N
continuously RB N
monitored VBN N
during IN N
anesthesia NN N
. . N

General NNP N
anesthesia NN N
was VBD N
induced VBN N
with IN N
propofol JJ N
1.5-2.0 JJ N
mg/kg NN N
, , N
sufentanil VBD N
0.4 CD N
?g/kg NN N
, , N
and CC N
Rocuronium NNP N
0.6-0.9 JJ N
mg/kg NN N
. . N

Endobronchial JJ N
occluder NN N
was VBD N
placed VBN N
blindly RB N
after IN N
tracheal JJ N
indubation NN N
and CC N
the DT N
correct JJ N
position NN N
was VBD N
verified VBN N
by IN N
auscultation NN N
and CC N
fiberoptic JJ N
bronchoscopy NN N
. . N

The DT N
patients NNS N
were VBD N
mechanically RB N
ventilated VBN N
. . N

The DT N
ventilation NN N
conditions NNS N
were VBD N
Fio2=100 NNP N
% NN N
, , N
VT NNP N
= NNP N
8-10 JJ N
ml/kg NN N
, , N
I PRP N
: : N
E NN N
= VBZ N
1:2 CD N
and CC N
respiratory JJ N
rate NN N
was VBD N
adjusted VBN N
to TO N
maintained VBN N
PETCO2 NNP N
at IN N
35-45 JJ N
mmHg NN N
during IN N
both DT N
two-lung JJ N
ventilation NN N
( ( N
TLV NNP N
) ) N
and CC N
OLV NNP N
. . N

Anesthesia NNP N
was VBD N
maintained VBN N
with IN N
continuous JJ N
infusion NN N
of IN N
propofol JJ N
4-10 JJ N
mg/kg?h NN N
, , N
sufentanil VBD N
0.2 CD N
?g/kg?h NN N
, , N
vecuronium NN N
o.1 NN N
mg/kg?h NN N
, , N
BIS NNP N
was VBD N
maintained VBN N
at IN N
45-55 JJ N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
from IN N
radial JJ N
artery NN N
and CC N
S-G NNP N
catheter NN N
for IN N
blood NN N
gas NN N
analysis NN N
at IN N
following VBG N
intervals NNS N
: : N
during IN N
spontaneous JJ N
breathing VBG N
when WRB N
the DT N
patient NN N
was VBD N
awake JJ N
( ( N
T0 NNP N
) ) N
, , N
1 CD N
min NN N
after IN N
tracheal JJ N
indubation NN N
( ( N
T1 NNP N
) ) N
, , N
1 CD N
min NN N
after IN N
patient NN N
was VBD N
placed VBN N
in IN N
lateral JJ N
position NN N
( ( N
T2 NNP N
) ) N
and CC N
15 CD N
min NN N
after IN N
it PRP N
( ( N
T3 NNP N
) ) N
, , N
1 CD N
min NN N
after IN N
ribs NN N
was VBD N
braced VBN N
( ( N
T4 NNP N
) ) N
, , N
30 CD N
, , N
60 CD N
, , N
120 CD N
min NN N
during IN N
the DT N
course NN N
of IN N
OLV NNP N
( ( N
T5 NNP N
, , N
T6 NNP N
, , N
T7 NNP N
) ) N
, , N
the DT N
two CD N
lungs NNS N
were VBD N
ventilated VBN N
again RB N
for IN N
30 CD N
min NN N
( ( N
T8 NNP N
) ) N
and CC o
Qs/Qt NNP o
was VBD N
calculated VBN N
. . N

RESULTS NNP o
SVRI NNP o
, , o
MAP NNP o
, , o
HR NNP o
in IN o
group NN o
N NNP o
increased VBD o
significantly RB N
at IN N
T1 NNP N
, , N
T2 NNP N
, , N
T4 NNP N
compared VBN N
with IN N
group NN N
S NNP N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Qs/Qt NNP o
was VBD N
significantly RB N
increased VBN N
after IN N
patient NN N
was VBD N
placed VBN N
in IN N
lateral JJ N
position NN N
and CC N
increased VBD N
further RBR N
during IN N
OLV NNP N
; : N
the DT N
calculated JJ o
Qs/Qt NNP o
values NNS N
were VBD N
highest JJS N
at IN N
T5? NNP N
PaO2 NNP o
was VBD o
significantly RB N
lower JJR N
after IN N
OLV NNP N
was VBD N
started VBN N
and CC N
reached VBN N
the DT N
lowest JJS N
level NN N
at IN N
T6 NNP N
then RB N
was VBD N
gradually RB N
increasing VBG N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN o
in IN o
Qs/Qt NNP o
and CC o
PaO2 NNP o
at IN o
all DT N
time NN N
points NNS N
between IN N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP i
SGB NNP i
before IN i
induction NN N
effectively RB N
suppress VBD N
the DT N
stress NN N
response NN N
work NN N
as IN N
stable JJ N
blood NN N
dynamics NNS N
and CC N
does VBZ N
not RB N
affect VB N
Qs/Qt NNP o
and CC N
arterial JJ N
oxygenation NN N
during IN N
OLV NNP N
, , N
SGB NNP N
is VBZ N
a DT N
safe JJ N
technique NN N
of IN N
anesthesia NN N
for IN N
general JJ N
thoracic NN N
surgery NN N
. . N

-DOCSTART- -X- O O

Comparative JJ N
clinical JJ N
and CC N
microbiological JJ N
effects NNS N
of IN N
subgingival JJ N
metronidazole JJ i
application NN N
in IN N
adult NN p
periodontitis NN p
; : p
12-months JJ N
results NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
clinical JJ N
and CC N
microbiological JJ N
effects NNS N
of IN N
subgingival JJ N
application NN N
of IN N
25 CD N
% NN N
metronidazole JJ i
dental JJ i
gel NN i
as IN N
an DT N
adjunct NN N
to TO N
scaling NN i
and CC i
root NN i
planing NN i
( ( i
SRP NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
adult NN p
periodontitis NN p
. . p

Eighty NNP p
teeth VBZ p
in IN p
18 CD p
patients NNS p
were VBD N
evaluated VBN N
using VBG N
a DT N
split NN N
mouth NN N
design NN N
. . N

The DT N
test NN N
teeth NN N
received VBD N
SRP NNP i
and CC N
a DT N
25 CD N
% NN N
metronidazole JJ i
gel NN i
applied VBN N
subgingivally RB N
on IN N
days NNS N
0 CD N
and CC N
7 CD N
. . N

The DT N
control NN N
teeth VBZ N
received VBN N
SRP NNP i
only RB i
. . i

Clinical JJ N
and CC N
microbiological JJ N
examinations NNS N
were VBD N
carried VBN N
out RP N
before IN N
treatment NN N
and CC N
on IN N
weeks NNS N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
13 CD N
, , N
26 CD N
, , N
38 CD N
and CC N
52 CD N
of IN N
the DT N
experimental JJ N
period NN N
. . N

Colony NNP N
forming VBG N
units NNS N
of IN N
Porphyromonas NNP N
gingivalis NN N
and CC N
Prevotella NNP N
intermedia VBP N
/ NNP N
Prevotella NNP N
nigrescens NNS N
were VBD N
determined VBN N
. . N

Both DT N
treatments NNS N
provided VBD N
significant JJ N
improvements NNS N
in IN N
all PDT N
the DT N
clinical JJ o
and CC o
microbiological JJ o
parameters NNS o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
none NN N
of IN N
the DT N
differences NNS N
between IN N
the DT N
study NN N
groups NNS N
were VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

As IN N
a DT N
conclusion NN N
, , N
the DT N
present JJ N
study NN N
does VBZ o
not RB o
provide VB o
evidence NN o
in IN o
favour NN o
of IN o
the DT o
routine JJ o
use NN o
of IN o
adjunctive JJ o
metronidazole JJ o
dental NN o
gel NN o
in IN N
the DT N
treatment NN N
of IN N
adult NN o
periodontitis NN o
. . o

-DOCSTART- -X- O O

Milk NN o
intolerance NN o
in IN N
children NNS p
with IN p
persistent JJ p
sleeplessness NN p
: : p
a DT N
prospective JJ N
double-blind NN N
crossover NN N
evaluation NN N
. . N

From IN N
July NNP N
1986 CD N
to TO N
July NNP N
1988 CD N
, , N
146 CD p
children NNS p
less JJR p
than IN p
5 CD p
years NNS p
of IN p
age NN p
were VBD p
referred VBN p
by IN p
their PRP$ p
physicians NNS p
to TO p
our PRP$ p
university NN p
sleep NN p
clinic NN p
for IN p
continual JJ p
waking NN p
and CC p
crying VBG p
during IN p
sleep JJ p
hours NNS p
. . p

For IN N
85 CD p
children NNS p
( ( N
58.2 CD N
% NN N
) ) N
, , N
the DT N
sleeplessness NN N
was VBD N
attributed VBN N
to TO N
inappropriate VB N
sleep JJ N
habits NNS N
. . N

For IN N
17 CD p
children NNS p
( ( N
11.6 CD N
% NN N
) ) N
, , N
no DT N
explanation NN N
was VBD N
found VBN N
for IN N
the DT N
sleep JJ N
difficulties NNS N
in IN N
spite NN N
of IN N
an DT N
extensive JJ N
workup NN N
. . N

Their PRP$ N
median JJ p
age NN p
at IN p
referral NN p
was VBD p
13.5 CD p
months NNS p
( ( p
range VB p
2.5 CD p
to TO p
29 CD p
months NNS p
) ) p
. . N

Their PRP$ N
persistent JJ N
sleeplessness NN N
was VBD N
tentatively RB N
attributed VBN N
to TO N
an DT N
undiagnosed JJ N
intolerance NN N
to TO N
cow VB N
's POS N
milk NN N
. . N

Cow NNP i
's POS i
milk NN i
was VBD i
excluded VBN i
from IN i
their PRP$ i
diet NN i
. . i

In IN N
15 CD N
children NNS N
sleep JJ N
normalized VBN N
after IN N
5 CD N
weeks NNS N
( ( N
range VB N
4 CD N
to TO N
6 CD N
weeks NNS N
) ) N
. . N

As IN N
seen VBN N
from IN N
the DT N
parents NNS N
' POS N
logs NNS N
, , N
the DT N
median JJ o
time NN o
needed VBN o
by IN o
the DT o
children NNS o
to TO o
fall VB o
asleep RB o
decreased VBN N
from IN N
15 CD N
minutes NNS N
( ( N
range VB N
15 CD N
to TO N
60 CD N
minutes NNS N
) ) N
to TO N
10 CD N
minutes NNS N
( ( N
range VB N
10 CD N
to TO N
15 CD N
minutes NNS N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

The DT N
number NN o
of IN o
complete JJ o
arousals NNS o
decreased VBD N
from IN N
5 CD N
( ( N
range NN N
1 CD N
to TO N
12 CD N
) ) N
to TO N
less JJR N
than IN N
1 CD N
per IN N
night NN N
( ( N
range VB N
0 CD N
to TO N
2 CD N
) ) N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Total JJ o
sleep JJ o
time NN o
per IN o
24 CD o
hours NNS o
increased VBD N
from IN N
5.5 CD N
hours NNS N
( ( N
range VB N
3 CD N
to TO N
8.5 CD N
hours NNS N
) ) N
to TO N
13.0 CD N
hours NNS N
( ( N
range VB N
10 CD N
to TO N
14.5 CD N
hours NNS N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Sleep JJ o
normalized VBN N
in IN N
one CD N
child NN N
who WP N
continued VBD N
to TO N
receive VB N
no DT N
cow NN N
's POS N
milk NN N
only RB N
after IN N
the DT N
hydrolyzed JJ N
hypoallergenic JJ N
diet NN N
was VBD N
discontinued VBN N
. . N

In IN N
every DT N
child NN N
, , N
a DT N
double-blind JJ N
crossover NN N
challenge NN N
was VBD N
conducted VBN N
involving VBG N
a DT N
control NN i
diet JJ i
containing VBG i
no DT i
cow NN i
's POS i
milk NN i
and CC i
a DT i
diet JJ i
containing VBG i
cow NN i
's POS i
milk NN i
. . i

The DT N
challenge NN N
induced VBD N
the DT N
reappearance NN o
of IN o
insomnia NN o
and CC o
agitated VBD o
behavior NN o
in IN N
all DT N
except IN N
one CD N
child NN N
. . N

The DT N
child NN N
's POS N
initial JJ N
sleep JJ N
difficulties NNS N
were VBD N
retrospectively RB N
attributed VBN N
to TO N
inappropriate VB N
sleep JJ N
habits NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Depressive JJ N
mood NN N
symptoms NNS N
associated VBN N
with IN N
ovarian JJ N
suppression NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
if IN N
sertraline NN i
is VBZ N
helpful JJ N
in IN N
the DT N
management NN N
of IN N
depressive NN N
symptoms NNS N
associated VBN N
with IN N
ovarian JJ N
suppression NN N
during IN N
GnRH NNP i
agonist JJ i
therapy NN i
as IN N
compared VBN N
with IN N
a DT N
placebo-controlled JJ i
group NN N
. . N

DESIGN NNP N
Double-blind JJ N
placebo-controlled JJ i
prospective JJ N
study NN N
design NN N
. . N

SETTING NN N
An DT N
obstetrics/gynecological JJ N
office NN N
specializing VBG N
in IN N
infertility NN N
in IN N
an DT N
academic JJ N
environment NN N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
Premenstrual NNP p
women NNS p
with IN p
laparoscopically RB p
diagnosed VBN p
endometriosis NN p
who WP p
required VBD p
GnRH NNP i
agonist JJ i
therapy NN i
for IN p
treatment NN p
and CC p
did VBD p
not RB p
have VB p
significant JJ p
depressive JJ p
or CC p
premenstrual JJ p
mood NN p
symptoms NNS p
at IN p
baseline NN p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Participants NNPS p
were VBD p
randomly RB p
assigned VBN p
to TO p
either CC p
the DT p
sertraline JJ i
treatment NN i
group NN p
or CC p
to TO p
the DT p
placebo NN i
group NN p
for IN p
the DT p
3-month JJ p
duration NN p
of IN p
the DT p
GnRH NNP i
agonist NN i
therapy NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
The DT o
21-item JJ o
Hamilton NNP o
Rating NNP o
Scale NNP o
for IN o
Depression NNP o
( ( o
HRSD NNP o
) ) o
, , N
which WDT N
is VBZ N
an DT N
instrument NN N
designed VBN N
to TO N
assess VB N
depressive JJ N
symptomatology NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
A NNP N
Hotellings NNP N
T NNP N
( ( N
2 CD N
) ) N
test NN N
for IN N
repeated VBN N
measure NN N
analysis NN N
indicated VBD N
a DT N
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
between-group NN N
difference NN N
across IN N
time NN N
for IN N
the DT N
HRSD NNP o
( ( N
T NNP N
( ( N
2 CD N
) ) N
= NN N
13.3 CD N
; : N
F NNP N
[ VBZ N
3 CD N
, , N
28 CD N
] NN N
= NN N
4.1 CD N
; : N
P=.02 NNP N
) ) N
with IN N
the DT N
sertraline NN i
treatment NN N
group NN N
manifesting VBG N
significantly RB N
fewer JJR N
depressive NN o
symptoms NNS o
than IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
The DT N
results NNS N
indicate VBP N
that DT N
sertraline NN i
is VBZ N
an DT N
effective JJ N
option NN N
in IN N
the DT N
management NN N
of IN N
depressive JJ N
mood NN N
symptoms NNS N
associated VBN N
with IN N
ovarian JJ N
suppression NN N
during IN N
GnRH NNP i
agonist JJ i
therapy NN i
. . i

-DOCSTART- -X- O O

Atrophy NNP N
and CC N
intestinal JJ p
metaplasia NN p
one CD N
year NN N
after IN N
cure NN N
of IN N
H. NNP p
pylori FW p
infection NN p
: : p
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
Helicobacter NNP N
pylori-infected JJ N
gastric JJ N
mucosa NN N
evolves VBZ N
through IN N
stages NNS N
of IN N
chronic JJ N
gastritis NN N
, , N
intestinal JJ N
metaplasia NN N
( ( N
IM NNP N
) ) N
, , N
glandular JJ N
atrophy NN N
( ( N
GA NNP N
) ) N
, , N
and CC N
dysplasia NN N
before IN N
carcinoma NN N
develops NNS N
. . N

We PRP N
studied VBD N
if IN N
H. NNP N
pylori FW N
eradication NN N
would MD N
alter VB N
the DT N
course NN N
of IN N
premalignant JJ N
histologic NN N
changes NNS N
in IN N
the DT N
stomach NN N
. . N

METHODS NNP N
Volunteers NNPS p
from IN p
the DT p
Yantai NNP p
County NNP p
in IN p
China NNP p
underwent JJ p
upper JJ i
endoscopy NN i
with IN i
biopsy NN i
specimens NNS p
obtained VBN p
from IN p
the DT p
antrum NN p
and CC p
corpus NN p
. . p

H. NNP p
pylori-infected JJ p
subjects NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
a DT N
1-week JJ i
course NN i
of IN i
omeprazole JJ i
, , i
amoxicillin NN i
, , i
and CC i
clarithromycin NN i
( ( i
OAC NNP i
) ) i
or CC i
placebo NN i
. . i

At IN N
1 CD N
year NN N
, , N
endoscopies NNS N
with IN N
biopsies NNS N
were VBD N
repeated VBN N
. . N

RESULTS VB N
A DT N
total NN p
of IN p
587 CD p
H. NNP p
pylori-infected JJ p
subjects NNS p
were VBD p
randomized VBN p
to TO p
OAC NNP i
( ( N
n JJ N
= NNP N
295 CD N
) ) N
and CC N
placebo NN N
( ( N
n JJ N
= NNP N
292 CD N
) ) N
. . N

At IN N
1 CD N
year NN N
, , N
H. NNP N
pylori NN N
was VBD N
eradicated VBN N
in IN N
226 CD N
subjects NNS N
assigned VBN N
to TO N
OAC NNP i
. . N

In IN N
the DT N
placebo NN i
group NN N
, , N
245 CD p
patients NNS p
remained VBD p
H. NNP p
pylori NN p
infected VBD p
. . p

Analysis NN N
of IN N
paired JJ N
samples NNS N
obtained VBN N
from IN N
the DT N
same JJ N
patients NNS N
showed VBD N
that IN N
acute NN o
and CC o
chronic JJ o
gastritis NN o
decreased VBN N
in IN N
both DT N
the DT N
antrum NN N
and CC N
corpus NN N
after IN N
H. NNP N
pylori FW N
eradication NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
activity NN o
of IN o
IM NNP o
decreased VBD N
in IN N
antrum NN N
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

In IN N
the DT N
H. NNP N
pylori-infected JJ N
group NN N
, , N
antral JJ N
biopsy NN N
specimens NNS N
had VBD N
more RBR N
pronounced JJ N
acute NN o
gastritis NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
whereas JJ N
corpus NN N
specimens NNS N
showed VBD N
increased VBN N
acute NN o
and CC o
chronic JJ o
gastritis NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
marginal JJ N
increase NN N
in IN N
GA NNP o
( ( N
P NNP N
= NNP N
0.052 CD N
) ) N
. . N

When WRB N
histologic JJ N
changes NNS N
were VBD N
compared VBN N
between IN N
the DT N
2 CD N
groups NNS N
, , N
decrease NN N
in IN N
acute NN o
and CC o
chronic JJ o
gastritis NN o
was VBD N
more RBR N
frequent JJ N
after IN N
H. NNP N
pylori FW N
eradication NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
but CC N
changes NNS N
in IN N
IM NNP o
were VBD N
similar JJ N
. . N

In IN N
the DT N
H. NNP N
pylori-infected JJ N
group NN N
, , N
increase NN N
in IN N
GA NNP o
was VBD N
seen VBN N
in IN N
the DT N
corpus NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
At IN N
1 CD N
year NN N
, , N
H. NNP N
pylori FW N
eradication NN N
is VBZ N
beneficial JJ N
in IN N
preventing VBG N
progression NN N
of IN N
pathologic JJ o
changes NNS o
of IN N
the DT N
gastric JJ N
mucosa NN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
25-gauge JJ i
Quincke NNP i
and CC i
24-gauge JJ i
Gertie NNP i
Marx NNP i
needles NNS N
for IN N
spinal JJ p
anaesthesia NN p
for IN p
caesarean JJ p
section NN p
. . p

OBJECTIVE UH N
To TO N
compare VB N
the DT N
insertion NN N
characteristics NNS N
and CC N
rate NN N
of IN N
complications NNS N
between IN N
25-gauge JJ i
Quincke NNP i
and CC i
24-gauge JJ i
Gertie NNP i
Marx NNP i
needles NNS i
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
study NN N
. . N

SETTING NNP N
University NNP N
of IN N
Benin NNP N
Teaching NNP N
Hospital NNP N
; : N
a DT N
university-affiliated JJ N
tertiary JJ N
centre NN N
. . N

SUBJECTS JJ N
Parturients NNPS p
( ( p
ASA NNP p
1 CD p
and CC p
2 CD p
) ) p
scheduled VBN p
for IN p
elective JJ p
caesarean JJ p
section NN p
. . p

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
spinal JJ i
anaesthesia NN i
with IN i
either DT i
25-gauge JJ i
Quincke NNP i
needle NN i
or CC i
24-gauge JJ i
Gertie NNP i
Marx NNP i
needle NN i
. . i

The DT p
patients NNS p
with IN p
abnormal JJ p
spaces NNS p
, , p
coagulopathy NN p
, , p
infection NN p
, , p
pre-eclampsia/eclampsia NN p
or CC p
obesity NN p
were VBD p
excluded VBN p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
number NN o
of IN o
attempts NNS o
at IN o
successful JJ o
identification NN o
of IN o
the DT o
spinal JJ o
space NN o
, , o
intraoperative JJ o
complications NNS o
, , o
incidence NN o
of IN o
postdural JJ o
puncture NN o
headache NN o
( ( o
PDPH NNP o
) ) o
, , o
non-postdural JJ o
puncture NN o
headache NN o
( ( o
NPDPH NNP o
) ) o
and CC o
backache NN o
. . o

RESULTS NNP N
Sixty NNP p
women NNS p
were VBD p
studied VBN p
. . p

The DT N
24-gauge JJ N
Gertie NNP N
Marx NNP N
needle RB N
resulted VBD N
in IN N
more RBR N
successful JJ o
location NN o
of IN o
the DT o
spinal JJ o
space NN o
on IN N
the DT N
second JJ N
attempt NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Non-postdural JJ o
puncture NN o
headache NN o
was VBD N
seen VBN N
in IN N
43 CD N
% NN N
of IN N
the DT N
study NN N
population NN N
. . N

PDPH NNP o
was VBD N
seen VBN N
in IN N
10 CD N
% NN N
of IN N
the DT N
Quincke NNP N
group NN N
and CC N
none NN N
in IN N
the DT N
Gertie NNP N
Marx NNP N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
backache NN o
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
ease NN N
of IN N
insertion NN N
and CC N
low JJ N
incidence NN N
of IN N
PDPH NNP o
with IN N
the DT N
Gertie NNP N
Marx NNP N
needle NN N
may MD N
encourage VB N
trainee NN N
anaesthetists NNS N
to TO N
use VB N
this DT N
needle NN N
for IN N
caesarean JJ N
section NN N
. . N

-DOCSTART- -X- O O

Ganitumab NNP i
with IN N
either DT N
exemestane NN i
or CC N
fulvestrant NN i
for IN N
postmenopausal JJ p
women NNS p
with IN p
advanced JJ p
, , p
hormone-receptor-positive JJ p
breast NN p
cancer NN p
: : p
a DT N
randomised JJ N
, , N
controlled VBN N
, , N
double-blind NN N
, , N
phase NN N
2 CD N
trial NN N
. . N

BACKGROUND NNP N
Insulin-like JJ N
growth NN N
factors NNS N
( ( N
IGF-1 JJ N
and CC N
IGF-2 NNP N
) ) N
bind NN N
to TO N
the DT N
IGF-1 NNP N
receptor NN N
( ( N
IGF-1R NNP N
) ) N
, , N
increasing VBG N
cell NN o
proliferation NN o
and CC N
survival NN o
. . o

Ganitumab NNP i
is VBZ N
a DT N
monoclonal JJ N
IgG1 NNP N
antibody NN N
that WDT N
blocks VBZ N
IGF-1R NNP N
. . N

We PRP N
tested VBD N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
adding VBG N
ganitumab NN N
to TO N
endocrine VB N
treatment NN N
for IN N
patients NNS p
with IN p
hormone-receptor-positive JJ p
breast NN p
cancer NN p
. . p

METHODS NNP N
We PRP N
did VBD N
this DT N
phase NN N
2 CD N
trial NN N
in IN N
outpatient JJ p
clinics NNS p
and CC p
hospitals NNS p
. . p

We PRP p
enrolled VBD p
postmenopausal JJ p
women NNS p
with IN p
hormone-receptor-positive JJ p
, , p
locally RB p
advanced VBD p
or CC p
metastatic JJ p
breast NN p
cancer NN p
previously RB p
treated VBN p
with IN p
endocrine JJ p
treatment NN p
. . p

They PRP N
were VBD N
randomly RB N
assigned VBN N
( ( N
2:1 CD N
) ) N
with IN N
a DT N
central JJ N
randomisation NN N
schedule NN N
to TO N
receive VB N
intravenous JJ i
ganitumab NNS i
12 CD i
mg NNS i
per IN i
kg NN i
bodyweight NN i
or CC i
placebo NN i
in IN i
combination NN i
with IN i
open-label JJ i
intramuscular JJ i
fulvestrant NN i
( ( i
500 CD i
mg NN i
on IN i
day NN i
1 CD i
, , i
then RB i
250 CD i
mg NNS i
on IN i
days NNS i
15 CD i
, , i
29 CD i
, , i
and CC i
every DT i
28 CD i
days NNS i
) ) i
or CC i
oral JJ i
exemestane NN i
( ( i
25 CD i
mg NN i
once RB i
daily RB i
) ) i
on IN i
a DT i
28-day JJ i
cycle NN i
. . i

Patients NNS N
, , N
investigators NNS N
, , N
study NN N
monitors NNS N
, , N
and CC N
the DT N
sponsor JJ N
staff NN N
were VBD N
masked VBN N
to TO N
treatment NN N
allocation NN N
. . N

Response NNP i
was VBD i
assessed VBN i
every DT i
8 CD i
weeks NNS i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
median JJ o
progression-free JJ o
survival NN o
in IN N
the DT N
intention-to-treat JJ N
population NN N
. . N

We PRP N
analysed VBD N
overall JJ o
survival NN o
as IN N
one CD N
of IN N
our PRP$ N
secondary JJ N
endpoints NNS N
. . N

The DT N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00626106 NNP N
. . N

FINDINGS NNP N
We PRP p
screened VBD p
189 CD p
patients NNS p
and CC p
enrolled VBD p
156 CD p
( ( p
106 CD p
in IN p
the DT p
ganitumab NN i
group NN p
and CC p
50 CD p
in IN p
the DT p
placebo NN p
group NN p
) ) p
. . p

Median JJ o
progression-free JJ o
survival NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
ganitumab NN i
and CC N
placebo NN N
groups NNS N
( ( N
3?9 CD N
months NNS N
, , N
80 CD N
% NN N
CI NNP N
3?6-5?3 CD N
vs NN N
5?7 CD N
months NNS N
, , N
4?4-7?4 JJ N
; : N
hazard PRP$ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
1?17 CD N
, , N
80 CD N
% NN N
CI NNP N
0?91-1?50 CD N
; : N
p=0?44 NN N
) ) N
. . N

However RB N
, , N
overall JJ o
survival NN o
was VBD N
worse RBR N
in IN N
the DT N
the DT N
ganitumab NN i
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
HR NNP N
1?78 CD N
, , N
80 CD N
% NN N
CI NNP N
1?27-2?50 CD N
; : N
p=0?025 NN N
) ) N
. . N

With IN N
the DT N
exception NN N
of IN N
hyperglycaemia NN N
, , N
adverse JJ N
events NNS N
were VBD N
generally RB N
similar JJ N
between IN N
groups NNS N
. . N

The DT N
most RBS N
common JJ N
grade NN N
3 CD N
or CC N
higher JJR o
adverse JJ o
event NN o
was VBD o
neutropenia-reported JJ o
by IN N
six CD N
of IN N
106 CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT i
ganitumab NN i
group NN N
and CC N
one CD N
of IN N
49 CD N
( ( N
2 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

Hyperglycaemia NNP o
was VBD o
reported VBN o
by IN N
12 CD N
of IN N
106 CD N
( ( N
11 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
ganitumab NN N
group NN N
( ( N
with IN N
six CD N
patients NNS N
having VBG N
grade JJ N
3 CD N
or CC N
4 CD N
hyperglycaemia NN N
) ) N
and CC N
none NN N
of IN N
49 CD N
in IN N
the DT N
placebo NN N
group NN N
. . N

Serious JJ o
adverse JJ o
events NNS o
were VBD o
reported VBN o
by IN N
27 CD N
of IN N
106 CD N
( ( N
25 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
ganitumab NN N
group NN N
and CC N
nine CD N
of IN N
49 CD N
( ( N
18 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

INTERPRETATION NNP N
Addition NNP i
of IN i
ganitumab NN i
to TO N
endocrine VB N
treatment NN p
in IN p
women NNS p
with IN p
previously RB p
treated VBN p
hormone-receptor-positive JJ p
locally RB p
advanced VBD p
or CC p
metastatic JJ p
breast NN p
cancer NN p
did VBD N
not RB N
improve VB o
outcomes RB o
. . o

Our PRP$ o
results NNS N
do VBP N
not RB N
support VB N
further RBR N
study NN N
of IN N
ganitumab NN N
in IN N
this DT N
subgroup NN N
of IN N
patients NNS N
. . N

FUNDING NN N
Amgen NNP N
. . N

-DOCSTART- -X- O O

Practice NNP N
makes VBZ N
improvement NN N
: : N
how WRB N
adults NNS p
with IN p
autism NN p
out-perform JJ N
others NNS N
in IN N
a DT N
naturalistic JJ N
visual JJ N
search NN N
task NN N
. . N

People NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
often RB N
exhibit JJ N
superior JJ N
performance NN N
in IN N
visual JJ N
search NN N
compared VBN N
to TO N
others NNS N
. . N

However RB N
, , N
most JJS N
studies NNS N
demonstrating VBG N
this DT N
advantage NN N
have VBP N
employed VBN N
simple JJ N
, , N
uncluttered JJ N
images NNS N
with IN N
fully RB N
visible JJ N
targets NNS N
. . N

We PRP N
compare VBP N
the DT N
performance NN N
of IN N
high-functioning JJ p
adults NNS p
with IN p
ASD NNP p
and CC N
matched VBN p
controls NNS p
on IN N
a DT N
naturalistic JJ i
luggage NN i
screening VBG i
task NN i
. . i

Although IN N
the DT N
two CD N
groups NNS N
were VBD N
equally RB N
accurate JJ N
in IN N
detecting VBG N
targets NNS N
, , N
the DT N
ASD NNP p
adults NNS p
improve VBP N
in IN N
their PRP$ N
correct JJ o
elimination NN o
of IN o
target-absent NN o
bags NNS N
faster RBR N
than IN N
controls NNS N
. . N

This DT N
feature NN N
of IN N
their PRP$ N
behavior NN N
is VBZ N
extremely RB N
important JJ N
for IN N
many JJ N
real-world JJ N
monitoring NN N
tasks NNS N
that WDT N
require VBP N
sustained JJ N
attention NN N
for IN N
long JJ N
time NN N
periods NNS N
. . N

Further JJ N
analyses NNS N
suggest VBP N
that IN N
this DT N
improvement NN N
is VBZ N
attributable JJ N
neither RB N
to TO N
the DT N
motor NN N
speed NN N
nor CC N
to TO N
the DT N
level NN N
of IN N
intelligence NN N
of IN N
the DT N
adults NNS p
with IN p
ASD NNP p
. . p

These DT N
findings NNS N
may MD N
have VB N
possible JJ N
implications NNS N
for IN N
employment NN N
opportunities NNS N
of IN N
adult NN p
individuals NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -X- O O

The DT N
low-dose JJ i
monoethylglycinexylidide JJ i
test NN i
: : i
assessment NN o
of IN N
liver NN p
function NN p
with IN p
fewer JJR p
side NN p
effects NNS p
. . p

The DT N
hepatic JJ N
metabolism NN N
of IN N
lidocaine NN i
( ( N
1 CD N
mg/kg RB N
intravenously RB N
) ) N
to TO N
its PRP$ N
metabolite JJ N
monoethylglycinexylidide NN i
( ( i
MEG-X NNP i
) ) i
is VBZ N
the DT N
basis NN N
of IN N
the DT N
standard JJ N
MEG-X NNP i
test NN N
. . N

To TO N
reduce VB N
the DT N
lidocaine-induced JJ i
side NN N
effects NNS N
, , N
we PRP N
evaluated VBD N
the DT N
MEG-X NNP i
formation NN N
after IN N
0.5 CD N
and CC N
1 CD N
mg/kg NNS N
lidocaine JJ i
intravenously RB N
in IN N
subjects NNS p
with IN p
normal JJ p
( ( p
n JJ p
= NNP p
5 CD p
) ) p
and CC p
severely RB p
impaired JJ p
liver NN p
function NN p
( ( p
n JJ p
= NNP p
7 CD p
) ) p
( ( p
study NN p
I PRP p
) ) p
. . p

From IN N
this DT N
study NN N
, , N
a DT N
low-dose JJ N
test NN N
( ( i
MEG-X NNP i
concentration NN N
30 CD N
minutes NNS N
after IN N
50 CD N
mg JJ N
lidocaine NN i
intravenously RB N
[ JJ i
MEG-X30min NNP i
] NNP i
normalized VBD N
to TO N
standard VB N
MEG-X NNP i
test NN N
results NNS N
) ) N
was VBD N
developed VBN N
. . N

Sensory JJ N
side NN N
effects NNS N
from IN N
this DT N
low JJ N
dose NN N
and CC N
from IN N
the DT N
standard JJ N
MEG-X NNP i
test NN N
were VBD N
compared VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
cross-over JJ N
study NN N
( ( N
study VB N
II NNP N
) ) N
comprising VBG N
15 CD p
individuals NNS p
with IN p
normal JJ p
liver NN p
function NN p
and CC p
45 CD p
patients NNS p
with IN p
cirrhosis NN p
( ( p
15 CD p
Child NNP p
A NNP p
, , p
15 CD p
Child NNP p
B NNP p
, , p
and CC p
15 CD p
Child NNP p
C NNP p
) ) p
. . p

In IN N
study NN N
I PRP N
, , N
MEG-X JJ o
formation NN o
rate NN o
was VBD N
dose-independent JJ N
in IN N
patients NNS N
with IN N
severely RB N
impaired JJ N
liver NN N
function NN N
. . N

In IN N
study NN N
II NNP N
, , N
normalized VBD N
MEG-X JJ i
test NN N
results NNS N
( ( N
ranging VBG N
from IN N
< NN N
or CC N
= $ N
4 CD N
to TO N
120 CD N
microg/L NNS N
) ) N
were VBD N
virtually RB N
identical JJ N
to TO N
the DT N
standard JJ N
test NN N
results NNS N
( ( N
mean JJ N
difference NN N
: : N
-1.9 JJ N
microg/L NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
-5.3 NN N
; : N
1.5 CD N
microg/L NN N
) ) N
. . N

Fewer JJR N
individuals NNS N
experienced VBD N
side NN o
effects NNS o
( ( N
30 CD N
% NN N
vs. FW N
53 CD N
% NN N
) ) N
with IN N
the DT N
low-dose JJ N
test NN N
( ( N
P NNP N
= NNP N
.0013 NNP N
) ) N
. . N

In IN N
a DT N
multivariate NN N
analysis NN N
, , N
the DT N
Child-Pugh NNP o
score NN o
was VBD N
inversely RB N
related VBN N
to TO N
the DT N
occurrence NN N
of IN N
side NN o
effects NNS o
. . o

The DT N
low-dose JJ N
MEG-X JJ i
test NN N
gives VBZ N
almost RB N
identical JJ N
results NNS N
to TO N
the DT N
standard JJ N
MEG-X NNP i
test NN N
and CC N
is VBZ N
associated VBN N
with IN N
fewer JJR o
side NN o
effects NNS o
, , N
which WDT N
occur VBP N
less RBR N
often RB N
in IN N
individuals NNS N
with IN N
more RBR N
severely RB N
compromised VBN N
liver NN N
function NN N
. . N

-DOCSTART- -X- O O

Long-term JJ N
decrease NN N
in IN N
bladder NN o
cancer NN o
recurrence NN o
with IN N
hexaminolevulinate NN i
enabled VBN i
fluorescence NN i
cystoscopy NN i
. . i

PURPOSE NNP N
We PRP N
assessed VBD N
the DT N
impact NN N
of IN N
hexaminolevulinate NN i
fluorescence NN i
cystoscopic NN i
detection NN i
of IN N
papillary JJ N
, , N
nonmuscle JJ N
invasive JJ N
bladder NN N
cancer NN N
on IN N
the DT N
long-term JJ o
recurrence NN o
rate NN o
. . o

MATERIALS NNP N
AND CC N
METHODS NNP N
Long-term NNP p
followup NN p
was VBD p
assessed VBN p
in IN p
551 CD p
participants NNS p
enrolled VBN p
in IN p
a DT p
prospective JJ p
, , p
randomized JJ p
study NN p
of IN p
fluorescence NN i
cystoscopy NN i
for IN i
Ta NNP i
or CC i
T1 NNP i
urothelial JJ i
bladder NN i
cancer NN i
. . i

In IN N
the DT N
original JJ N
study NN N
280 CD p
patients NNS p
in IN p
the DT p
white JJ i
light JJ i
cystoscopy NN i
group NN p
and CC N
271 CD p
in IN p
the DT p
fluorescence NN i
cystoscopy NN i
group NN p
were VBD p
followed VBN p
with IN p
cystoscopy NN i
for IN N
3 CD N
, , N
6 CD N
and CC N
9 CD N
months NNS N
after IN N
initial JJ N
resection NN N
or CC N
until IN N
recurrence NN N
. . N

A DT N
study NN N
extension NN N
protocol NN N
was VBD N
done VBN N
for IN N
long-term JJ N
followup NN N
of IN N
these DT N
patients NNS N
. . N

RESULTS NNP N
Followup NNP N
information NN p
was VBD p
obtained VBN p
for IN p
261 CD p
of IN p
the DT p
280 CD p
patients NNS p
( ( p
93 CD p
% NN p
) ) p
in IN p
the DT p
white JJ i
light NN i
group NN p
and CC N
255 CD p
of IN p
the DT p
271 CD p
( ( p
94 CD p
% NN p
) ) p
in IN p
the DT p
fluorescence NN i
group NN p
. . p

Median JJ N
followup NN N
in IN N
the DT N
white JJ i
light NN i
and CC N
fluorescence NN i
groups NNS N
was VBD N
53.0 CD N
and CC N
55.1 CD N
months NNS N
, , N
and CC N
83 CD N
( ( N
31.8 CD N
% NN N
) ) N
and CC N
97 CD N
patients NNS N
( ( N
38 CD N
% NN N
) ) N
remained VBD N
tumor JJ N
free JJ N
, , N
respectively RB N
. . N

Median JJ o
time NN o
to TO o
recurrence VB o
was VBD N
9.4 CD N
months NNS N
in IN N
the DT N
white JJ i
light NN i
group NN N
and CC N
16.4 CD N
months NNS N
in IN N
the DT N
fluorescence NN i
group NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
intravesical JJ o
therapy NN o
rate NN o
was VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
46 CD N
% NN N
and CC N
45 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Cystectomy NNP i
was VBD N
done VBN N
in IN N
22 CD N
of IN N
280 CD N
cases NNS N
( ( N
7.9 CD N
% NN N
) ) N
in IN N
the DT N
white JJ i
light NN i
group NN N
and CC N
in IN N
13 CD N
of IN N
the DT N
271 CD N
( ( N
4.8 CD N
% NN N
) ) N
in IN N
the DT N
fluorescence NN i
group NN N
( ( N
p JJ N
= NNP N
0.16 CD N
) ) N
. . N

CONCLUSIONS NNP N
Hexaminolevulinate NNP i
fluorescence NN i
cystoscopy NN i
significantly RB N
improves VBZ N
long-term JJ o
bladder NN o
cancer NN o
time NN o
to TO o
recurrence VB o
with IN N
a DT N
trend NN N
toward IN N
improved JJ N
bladder NN N
preservation NN N
. . N

-DOCSTART- -X- O O

Family RB i
education NN i
for IN N
people NNS p
with IN p
schizophrenia NN p
in IN p
Beijing NNP p
, , p
China NNP p
: : p
randomised VBD N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Much NNP N
of IN N
China NNP N
lacks VBZ N
well-developed JJ N
services NNS N
for IN N
people NNS p
with IN p
schizophrenia NN p
and CC p
their PRP$ p
families NNS p
, , N
and CC N
most JJS N
of IN N
the DT N
existing VBG N
services NNS N
focus NN N
on IN N
hospitals NNS N
. . N

There EX N
is VBZ N
a DT N
need NN N
for IN N
culturally RB N
sensitive JJ N
family NN i
treatments NNS i
offered VBN N
by IN N
nurses NNS N
. . N

AIMS NNP N
To TO N
conduct VB N
a DT N
longitudinal JJ N
experimental NN N
study NN N
examining VBG N
the DT N
effect NN N
of IN N
patient NN i
and CC i
family NN i
education NN i
in IN N
a DT N
sample NN p
of IN p
Chinese JJ p
people NNS p
with IN p
schizophrenia NN p
. . p

METHOD NNP N
A NNP N
randomised VBD N
controlled VBN N
trial NN N
was VBD N
conducted VBN N
in IN N
a DT N
large JJ N
hospital NN N
with IN N
a DT N
was VBD N
conducted VBN N
in IN N
a DT N
large JJ p
hospital NN p
with IN p
a DT p
sample NN p
of IN p
101 CD p
patients NNS p
with IN p
schizophrenia NN p
and CC p
their PRP$ p
families NNS p
. . p

Data NNS N
were VBD N
collected VBN N
at IN N
admission NN N
and CC N
at IN N
discharge NN N
, , N
and CC N
then RB N
at IN N
3 CD N
and CC N
9 CD N
months NNS N
after IN N
discharge NN N
. . N

The DT N
intervention NN N
group NN N
received VBD N
family NN i
education NN i
, , N
and CC N
data NNS N
on IN N
their PRP$ N
knowledge NN o
about IN o
schizophrenia NN o
, , o
symptoms NNS o
, , o
functioning VBG o
, , o
psychosocial JJ o
behaviour NN o
, , o
relapse NN o
and CC o
medication NN o
adherence NN o
were VBD N
collected VBN N
and CC N
compared VBN N
with IN N
the DT N
control NN i
group NN i
. . i

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ o
improvement NN o
in IN o
knowledge NN o
about IN o
schizophrenia NN o
in IN N
the DT N
experimental JJ N
group NN N
and CC N
a DT N
significant JJ o
difference NN o
in IN o
symptom JJ o
scores NNS o
and CC o
functioning VBG o
at IN N
9 CD N
months NNS N
after IN N
discharge NN N
. . N

Patients NNS N
who WP N
were VBD N
nonadherent JJ N
to TO N
medication NN N
regimens NNS N
were VBD N
more RBR N
likely JJ N
to TO N
relapse VB o
. . o

CONCLUSIONS NNP N
Family NNP i
education NN i
on IN N
schizophrenia NN N
by IN N
nurses NNS N
in IN N
China NNP N
was VBD N
effective JJ N
in IN N
improving VBG N
knowledge NN N
and CC N
promoting VBG N
improvement NN N
in IN N
patients NNS N
' POS N
symptoms NNS N
. . N

-DOCSTART- -X- O O

Sodium NN i
bicarbonate NN i
, , i
N-acetylcysteine NNP i
, , i
and CC i
saline NN i
for IN N
prevention NN N
of IN N
radiocontrast-induced JJ o
nephropathy NN o
. . o

A DT N
comparison NN N
of IN N
3 CD N
regimens NNS N
for IN N
protecting VBG N
contrast-induced JJ N
nephropathy JJ N
in IN N
patients NNS p
undergoing VBG p
coronary JJ i
procedures NNS i
. . i

A DT N
single-center JJ p
prospective NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Several NNP N
protective JJ N
therapies NNS N
have VBP N
been VBN N
developed VBN N
to TO N
prevent VB N
contrast-induced JJ o
nephropathy JJ o
( ( o
CIN NNP o
) ) o
. . o

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
sodium NN i
bicarbonate NN i
by IN N
comparing VBG N
2 CD N
other JJ N
regimens NNS N
, , N
including VBG N
combination NN i
of IN i
N-acetylcysteine NNP i
( ( i
NAC NNP i
) ) i
plus CC i
sodium JJ i
chloride NN i
and CC i
sodium NN i
chloride NN i
alone RB i
, , N
to TO N
prevent VB N
CIN NNP N
in IN N
patients NNS p
undergoing VBG p
cardiovascular JJ p
procedures NNS p
. . p

METHODS NNP N
We PRP p
prospectively RB p
enrolled VBD p
264 CD p
patients NNS p
who WP p
were VBD p
scheduled VBN p
for IN p
cardiovascular JJ p
procedures NNS p
and CC p
had VBD p
a DT p
baseline JJ p
creatinine NN p
level NN p
> VBD p
1.2 CD p
mg/dL NN p
. . p

The DT N
patients NNS N
were VBD N
assigned VBN N
1 CD N
of IN N
3 CD N
prophylactic JJ N
regimens NNS N
: : N
infusion NN i
of IN i
sodium NN i
bicarbonate NN i
, , i
sodium NN i
chloride NN i
, , i
sodium NN i
chloride NN i
plus CC i
oral JJ i
NAC NNP i
( ( N
600 CD N
mg RB N
bid NN N
) ) N
. . N

Contrast-induced JJ o
nephropathy NN o
was VBD N
defined VBN N
as IN N
an DT N
increase NN o
in IN o
serum JJ o
creatinine NN o
level NN o
> VBD o
25 CD o
% NN o
or CC N
0.5 CD N
mg/dL NNS N
after IN N
48 CD N
hours NNS N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
groups NNS N
regarding VBG N
baseline NN N
demographic JJ o
properties NNS o
and CC N
nephropathy JJ o
risk NN o
factors NNS o
. . o

The DT N
change NN o
in IN o
creatinine JJ o
clearance NN o
was VBD N
significantly RB N
better RBR N
in IN N
the DT N
sodium NN i
bicarbonate NN i
group NN N
than IN N
other JJ N
2 CD N
groups NNS N
( ( N
P NNP N
= NNP N
.007 NNP N
) ) N
. . N

The DT N
incidence NN o
of IN o
CIN NNP o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
sodium NN i
bicarbonate NN i
group NN N
( ( N
4.5 CD N
% NN N
) ) N
compared VBN N
with IN N
sodium JJ i
chloride NN i
alone RB i
( ( N
13.6 CD N
% NN N
, , N
P NNP N
= NNP N
.036 NNP N
) ) N
and CC N
tended VBD N
to TO N
be VB N
lower JJR N
than IN N
in IN N
the DT N
combination NN i
group NN N
( ( N
12.5 CD N
% NN N
, , N
P NNP N
= NNP N
.059 NNP N
) ) N
. . N

After IN N
adjusting VBG N
the DT N
Mehran NNP o
nephropathy NN o
risk NN o
score NN o
, , N
the DT N
risk NN o
of IN o
CIN NNP o
significantly RB N
reduced VBD N
with IN N
sodium NN i
bicarbonate NN i
compared VBN N
with IN N
sodium JJ i
chloride NN i
alone RB N
( ( N
adjusted VBN N
risk NN N
ratio NN N
0.29 CD N
, , N
P NNP N
= NNP N
.043 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Hydration NNP N
with IN N
sodium JJ i
bicarbonate NN i
provides VBZ N
better JJR N
protection NN o
against IN N
CIN NNP o
than IN N
the DT N
sodium NN i
chloride JJ i
infusion NN i
does VBZ N
alone RB N
. . N

Combination NNP i
therapy NN i
of IN i
NAC NNP i
plus CC i
sodium JJ i
chloride NN i
did VBD N
not RB N
offer VB N
additional JJ N
benefit NN N
over IN N
hydration NN N
with IN N
sodium JJ i
chloride NN i
alone RB i
. . i

-DOCSTART- -X- O O

On IN N
the DT N
benign JJ N
qualities NNS N
of IN N
behavioral JJ i
disinhibition NN i
: : i
because IN N
of IN N
the DT N
prosocial JJ p
nature NN p
of IN p
people NNS p
, , N
behavioral JJ N
disinhibition NN N
can MD N
weaken VB N
pleasure NN N
with IN N
getting VBG N
more JJR N
than IN N
you PRP N
deserve VBP N
. . N

This DT N
article NN N
focuses VBZ N
on IN N
social JJ N
situations NNS N
in IN N
which WDT N
people NNS N
are VBP N
surprised VBN N
about IN N
what WP N
is VBZ N
happening VBG N
and CC N
inhibited VBN N
about IN N
how WRB N
to TO N
respond VB N
to TO N
the DT N
situation NN N
at IN N
hand NN N
. . N

We PRP N
study VBP N
these DT N
situations NNS N
by IN N
examining VBG N
a DT N
classic JJ N
topic NN N
in IN N
social JJ N
psychology NN N
: : N
how WRB N
people NNS p
respond VBP p
to TO p
receiving VBG p
better JJR p
outcomes NNS p
than IN p
are VBP p
deserved VBN p
. . p

In IN N
these DT N
situations NNS N
, , N
the DT N
actions NNS N
of IN N
an DT N
authority NN N
or CC N
a DT N
coworker NN N
push NN N
in IN N
the DT N
direction NN N
of IN N
accepting VBG N
and CC N
enjoying VBG N
the DT N
unfair JJ N
outcome NN N
, , N
whereas JJ N
personal JJ N
values NNS N
for IN N
most JJS N
people NNS N
push VBP N
in IN N
the DT N
direction NN N
of IN N
rejecting VBG N
or CC N
being VBG N
displeased VBN N
with IN N
the DT N
outcome NN N
. . N

This DT N
conflict NN N
may MD N
inhibit VB N
people NNS p
's POS p
response NN N
to TO N
the DT N
advantageous JJ N
but CC N
unfair JJ N
outcomes NNS N
. . N

If IN N
people NNS p
are VBP N
indeed RB N
inhibited VBN N
about IN N
how WRB N
to TO N
respond VB N
to TO N
these DT N
kinds NNS N
of IN N
outcomes NNS N
, , N
then RB N
lowering VBG N
behavioral JJ N
inhibition NN N
by IN N
reminding VBG N
people NNS N
of IN N
having VBG N
acted VBN N
in IN N
the DT N
past NN N
without IN N
inhibitions NNS N
( ( N
in IN N
a DT N
manner NN N
that WDT N
is VBZ N
unrelated JJ N
to TO N
the DT N
outcomes NNS N
participants NNS N
subsequently RB N
receive VBP N
) ) N
should MD N
affect VB N
reactions NNS N
to TO N
the DT N
outcomes NNS N
. . N

Specifically RB N
, , N
we PRP N
hypothesize VBP N
that IN N
because IN N
many JJ N
people NNS p
are VBP N
prosocial JJ N
and CC N
want VBP N
to TO N
adhere VB N
to TO N
principles NNS N
of IN N
fairness NN N
, , N
reminders NNS N
of IN N
behavioral JJ i
disinhibition NN i
will MD N
lead VB N
to TO N
less JJR N
pleasure NN N
with IN N
the DT N
unfairly RB N
obtained VBN N
outcomes RB N
. . N

The DT N
results NNS N
of IN N
8 CD N
experiments NNS i
( ( N
conducted VBN N
both DT N
inside IN i
and CC i
outside IN i
the DT i
psychology NN i
laboratory NN i
) ) i
revealed VBD N
evidence NN N
for IN N
this DT N
benign JJ N
disinhibition NN N
effect NN N
on IN N
various JJ N
reactions NNS N
to TO N
outcomes NNS N
that WDT N
are VBP N
better JJR N
than IN N
deserved VBN N
. . N

In IN N
further JJ N
accordance NN N
with IN N
our PRP$ N
line NN N
of IN N
reasoning NN N
, , N
the DT N
effect NN N
is VBZ N
particularly RB N
pronounced VBN N
among IN N
those DT N
who WP N
adhere VBP N
to TO N
a DT N
prosocial JJ N
orientation NN N
or CC N
who WP N
have VBP N
adopted VBN N
a DT N
prosocial JJ N
mindset NN N
and CC N
is VBZ N
not RB N
observed VBN N
among IN N
those DT N
with IN N
proself JJ N
orientations NNS N
or CC N
mindsets NNS N
. . N

-DOCSTART- -X- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
education NN N
and CC N
feedback NN N
for IN N
implementation NN N
of IN N
guidelines NNS N
for IN N
acute NN N
low JJ N
back RB N
pain NN N
. . N

OBJECTIVE CC N
The DT N
effect NN N
of IN N
clinical JJ N
guidelines NNS N
on IN N
resource NN N
utilization NN N
for IN N
complex JJ N
conditions NNS N
with IN N
substantial JJ N
barriers NNS N
to TO N
clinician JJ N
behavior NN N
change NN N
has VBZ N
not RB N
been VBN N
well RB N
studied VBN N
. . N

We PRP N
report VBP N
the DT N
impact NN N
of IN N
a DT N
multifaceted JJ i
guideline NN i
implementation NN i
intervention NN i
on IN N
primary JJ p
care NN p
clinician JJ p
utilization NN N
of IN N
radiologic NN N
and CC N
specialty NN N
services NNS N
for IN N
the DT N
care NN N
of IN N
acute NN N
low JJ N
back RB N
pain NN N
. . N

DESIGN NNP N
Physician JJ p
groups NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
guideline JJ i
education NN i
and CC i
individual JJ i
feedback NN i
, , i
supporting VBG i
patient JJ i
education NN i
materials NNS i
, , i
both DT i
, , N
or CC N
neither RB i
. . i

The DT N
impact NN N
on IN N
guideline NN N
adherence NN N
and CC N
resource NN N
utilization NN N
was VBD N
evaluated VBN N
during IN N
the DT N
12-month JJ N
period NN N
before IN N
and CC N
after IN N
implementation NN N
. . N

PARTICIPANTS NNP N
Fourteen NNP p
physician JJ p
groups NNS p
with IN p
120 CD p
primary JJ p
care NN p
physician NN p
and CC p
associate JJ p
practitioners NNS p
from IN p
2 CD p
group NN p
model NN p
HMO NNP p
practices NNS p
. . p

INTERVENTIONS NNP N
Guideline NNP i
implementation NN i
utilized VBD N
an DT N
education/audit/feedback NN N
model NN N
with IN N
local JJ N
peer NN N
opinion NN N
leaders NNS N
. . N

The DT N
patient JJ i
education NN i
component NN i
included VBD i
written VBN i
and CC i
videotaped VBN i
materials NNS i
on IN i
the DT i
care NN i
of IN i
low JJ i
back RB i
pain NN i
. . i

MAIN NNP N
RESULTS NNP N
The DT N
clinician JJ i
intervention NN i
was VBD N
associated VBN N
with IN N
an DT N
absolute JJ N
increase NN N
in IN N
guideline-consistent JJ o
behavior NN o
of IN N
5.4 CD N
% NN N
in IN N
the DT N
intervention NN N
group NN N
versus VBD N
a DT N
decline NN N
of IN N
2.7 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
=.04 NNP N
) ) N
. . N

The DT N
patient JJ N
education NN N
intervention NN N
produced VBD N
no DT N
significant JJ N
change NN N
in IN N
guideline-consistent JJ o
behavior NN o
, , N
but CC N
was VBD N
poorly RB N
adopted VBN N
. . N

Patient JJ N
characteristics NNS N
including VBG N
duration NN o
of IN o
pain NN o
, , o
prior JJ o
history NN o
of IN o
low JJ o
back RB o
pain NN o
, , o
and CC o
number NN o
of IN o
visits NNS o
during IN N
the DT N
illness JJ N
episode NN N
were VBD N
strong JJ N
predictors NNS N
of IN N
service NN N
utilization NN N
and CC N
guideline-consistent JJ N
behavior NN N
. . N

CONCLUSIONS NNP N
Implementation NNP N
of IN N
an DT N
education NN N
and CC N
feedback-supported JJ N
acute NN N
low JJ N
back RB N
pain NN N
care NN N
guideline NN N
for IN N
primary JJ p
care NN p
clinicians NNS p
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
guideline-consistent JJ N
behavior NN N
. . N

Patient JJ N
education NN N
materials NNS N
did VBD N
not RB N
enhance VB N
guideline NN N
effectiveness NN N
. . N

Implementation NNP N
barriers NNS N
could MD N
limit VB N
the DT N
utility NN N
of IN N
this DT N
approach NN N
in IN N
usual JJ p
care NN p
settings NNS p
. . p

-DOCSTART- -X- O O

Effects NNS N
of IN N
fatty NN i
and CC i
lean JJ i
fish JJ i
intake NN i
on IN N
blood NN o
pressure NN o
in IN N
subjects NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
using VBG p
multiple JJ p
medications NNS p
. . p

BACKGROUND NNP N
Intake NNP N
of IN N
fish JJ N
and CC N
long-chain JJ N
n-3 JJ N
fatty NN N
acids NNS N
has VBZ N
been VBN N
of IN N
wide JJ N
interest NN N
due JJ N
to TO N
their PRP$ N
beneficial JJ N
effects NNS N
on IN N
cardiovascular JJ N
risk NN N
factors NNS N
and CC N
lower JJR N
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
risk NN N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
The DT N
aim NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
fatty JJ i
fish NN i
and CC N
lean JJ i
( ( i
white JJ i
) ) i
fish NN i
on IN N
fatty JJ o
acid JJ o
composition NN o
of IN o
serum NN o
lipids NNS o
and CC N
cardiovascular JJ o
risk NN o
factors NNS o
in IN N
subjects NNS p
with IN p
CHD NNP p
using VBG p
multiple JJ p
drugs NNS p
for IN p
this DT p
condition NN p
. . p

METHODS NNP N
The DT N
study NN N
was VBD N
an DT N
8-week JJ N
controlled NN N
, , N
parallel JJ N
intervention NN N
. . N

Inclusion NNP p
criteria NNS p
were VBD p
myocardial JJ p
infarction NN p
or CC p
unstable JJ p
ischemic JJ p
attack NN p
, , p
age NN p
under IN p
70 CD p
years NNS p
, , p
use NN p
of IN p
betablockers NNS p
and CC p
presence NN p
of IN p
sinus NN p
rhythm NN p
. . p

The DT N
subjects NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
groups NNS N
: : N
4 CD i
meals/week NN i
fatty JJ i
fish NN i
( ( i
n JJ i
= NNP i
11 CD i
) ) i
, , i
4 CD i
meals/week JJ i
lean JJ i
fish NN i
( ( i
n JJ i
= NNP i
12 CD i
) ) i
and CC i
control VB i
diet JJ i
including VBG i
lean JJ i
meat NN i
( ( i
n JJ i
= NNP i
10 CD i
) ) i
. . i

RESULTS VB N
The DT N
mean JJ N
( ( N
+/-SD JJ N
) ) N
of IN N
reported VBN N
fish JJ N
meals NNS N
per IN N
week NN N
was VBD N
4.3 CD N
+/- JJ N
0.4 CD N
, , N
4.7 CD N
+/- JJ N
1.1 CD N
and CC N
0.6 CD N
+/- JJ N
0.4 CD N
in IN N
the DT N
groups NNS N
, , N
respectively RB N
. . N

The DT N
proportions NNS o
of IN o
eicosapentaenoic NN o
and CC o
docosahexaenoic JJ o
acids NNS o
in IN o
serum JJ o
lipids NNS o
increased VBD N
in IN N
the DT N
fatty JJ N
fish NN N
group NN N
only RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Systolic NNP o
and CC o
diastolic JJ o
blood NN o
pressure NN o
levels NNS N
decreased VBN N
in IN N
the DT N
lean JJ N
fish NN N
group NN N
( ( N
0 CD N
vs. FW N
8 CD N
week NN N
: : N
3.5 CD N
+/- JJ N
3.2 CD N
and CC N
4.6 CD N
+/- JJ N
3.6 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Serum NNP o
total JJ o
triglyceride JJ o
concentration NN o
did VBD N
not RB N
significantly RB N
change VBP N
. . N

HDL NNP o
cholesterol NN o
concentration NN o
change NN N
differed VBD N
among IN N
groups NNS N
but CC N
without IN N
significant JJ N
post NN N
hoc NN N
differences NNS N
. . N

Apolipoprotein NNP o
A-1 JJ o
concentration NN o
decreased VBN N
in IN N
the DT N
control NN N
group NN N
( ( N
0 CD N
vs. FW N
8 CD N
week NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Coagulation NN o
factors NNS o
, , o
25-hydroxy JJ o
vitamin NN o
D NNP o
, , o
and CC o
heart NN o
rate NN o
variability NN o
( ( o
24 CD o
h RB o
Holter NNP o
) ) o
did VBD N
not RB N
change VB N
among IN N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
intake NN N
of IN N
lean JJ i
fish NN i
at IN N
least JJS N
four CD N
times NNS N
per IN N
week NN N
could MD N
reduce VB N
blood NN N
pressure NN N
levels NNS N
in IN N
CHD NNP p
patients NNS p
. . p

-DOCSTART- -X- O O

Heparin NNP i
plus CC i
dipyridamole NN i
in IN N
childhood NN p
hemolytic-uremic JJ p
syndrome NN p
: : p
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

From IN N
1976 CD p
to TO p
1985 CD p
, , p
a DT p
total NN p
of IN p
58 CD p
infants NNS p
and CC p
children NNS p
with IN p
the DT p
hemolytic-uremic JJ p
syndrome NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
either RB N
with IN N
heparin NN i
and CC i
dipyridamole NN i
or CC i
with IN i
supportive JJ i
management NN i
only RB i
. . i

In IN N
the DT N
treatment NN N
group NN N
, , N
two CD N
patients NNS N
died VBD N
in IN N
the DT N
early JJ N
weeks NNS N
of IN N
the DT N
disease NN N
. . N

Analysis NN N
of IN N
clinical JJ N
and CC N
laboratory NN N
data NNS N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
either DT N
group NN N
of IN N
patients NNS N
as IN N
to TO N
the DT N
evolution NN N
of IN N
their PRP$ N
illness NN N
except IN N
for IN N
a DT N
significantly RB N
higher JJR N
incidence NN o
of IN o
anuria NNS o
and CC N
a DT N
significantly RB N
faster RBR o
recovery NN o
from IN o
hypertension NN o
in IN N
the DT N
treated JJ N
group NN N
. . N

Renal NNP N
biopsy NN N
studies NNS N
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
incidence NN o
and CC o
severity NN o
of IN o
the DT o
histologic JJ o
lesions NNS o
. . o

The DT N
long-term JJ N
data NNS N
on IN N
blood NN o
pressure NN o
and CC o
creatinine JJ o
clearance NN o
values NNS o
in IN N
the DT N
survivors NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

This DT N
study NN N
indicates VBZ N
that IN N
treatment NN i
with IN i
heparin NN o
and CC o
dipyridamole NN o
has VBZ N
no DT N
benefit NN o
over IN o
symptomatic JJ o
therapy NN o
alone RB N
in IN N
the DT N
typical JJ N
form NN N
of IN N
childhood NN p
hemolytic-uremic JJ p
syndrome NN p
. . p

-DOCSTART- -X- O O

N-acetylcysteine NNP i
as IN N
an DT N
adjunctive JJ i
therapy NN i
to TO N
risperidone VB i
for IN N
treatment NN N
of IN N
irritability NN N
in IN p
autism NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
efficacy NN N
and CC N
safety NN N
. . N

OBJECTIVES NNP N
According VBG N
to TO N
the DT N
proposed VBN N
interference NN N
of IN N
N-acetylcysteine NNP i
( ( i
NAC NNP i
) ) i
with IN N
pathophysiologic JJ N
processes NNS N
of IN N
autistic JJ N
disorders NNS N
( ( N
ADs NNP N
) ) N
, , N
we PRP N
aimed VBD N
to TO N
assess VB N
the DT o
effectiveness NN o
and CC o
safety NN o
of IN N
NAC NNP i
as IN N
an DT N
adjunct NN N
to TO N
risperidone VB i
in IN N
the DT N
treatment NN N
of IN N
ADs NNP N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
clinical JJ N
trial NN N
. . N

METHODS NNP N
The DT N
participants NNS p
were VBD p
referred VBN p
outpatients NNS p
between IN p
4 CD p
and CC p
12 CD p
years NNS p
of IN p
age NN p
with IN p
the DT p
diagnosis NN p
of IN p
ADs NNP p
and CC p
a DT p
score NN p
of IN p
more JJR p
than IN p
12 CD p
on IN p
Aberrant JJ o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
Irritability NNP o
subscale NN o
score NN o
. . o

The DT N
participants NNS N
were VBD N
randomized VBN N
into IN N
2 CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
risperidone JJ i
plus CC i
NAC NNP i
, , N
and CC N
the DT N
other JJ N
group NN N
received VBD N
risperidone JJ i
plus CC i
placebo NN i
. . i

The DT N
dose NN N
of IN N
risperidone NN i
was VBD N
titrated VBN N
between IN N
1 CD N
and CC N
2.0 CD N
mg/d NN N
, , N
and CC N
the DT N
dose NN N
of IN N
NAC NNP i
was VBD N
600 CD N
to TO N
900 CD N
mg/d NN N
. . N

The DT N
main JJ N
outcome NN N
was VBD N
mean JJ o
decrease NN o
in IN o
the DT o
ABC-C NNP o
irritability NN o
subscale NN o
score NN o
from IN N
baseline NN N
at IN N
5 CD N
and CC N
10 CD N
weeks NNS N
. . N

Changes NNS o
in IN o
other JJ o
subscales NNS o
were VBD N
considered VBN N
as IN N
secondary JJ N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
Forty NNP p
patients NNS p
completed VBD p
the DT p
10-week JJ p
trial NN p
. . p

Baseline NNP N
characteristics NNS N
including VBG N
age NN o
, , o
sex NN o
and CC o
body NN o
weight NN o
, , N
as RB N
well RB N
as IN N
baseline NN o
scores NNS o
in IN N
5 CD N
subscales NNS o
did VBD N
not RB N
demonstrate VB N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Repeated-measures NNS N
analysis NN N
showed VBD N
significant JJ N
effect NN o
for IN N
time NN N
? . N
treatment NN N
interaction NN N
in IN o
irritability NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
and CC o
hyperactivity/noncompliance NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
subscales NNS N
. . N

By IN N
week NN N
10 CD N
, , N
the DT i
NAC NNP i
group NN N
showed VBD N
significantly RB N
more JJR o
reduction NN o
in IN o
irritability NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC o
hyperactivity/noncompliance NN o
( ( N
P NNP N
= NNP N
0.01 CD o
) ) o
subscales NNS o
scores NNS o
. . o

CONCLUSIONS NNP i
N-acetylcysteine JJ i
can MD N
be VB N
considered VBN N
as IN N
an DT N
adjuvant JJ N
therapy NN N
for IN N
ADs NNP N
with IN N
beneficial JJ o
therapeutic JJ o
outcomes NNS o
. . o

-DOCSTART- -X- O O

Clinical JJ o
pharmacology NN o
of IN N
methadone NN i
in IN N
dogs NNS p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
pharmacokinetics NNS o
and CC o
effects NNS o
of IN N
methadone NN i
on IN N
behaviour NN o
and CC N
plasma JJ o
concentrations NNS o
of IN o
cortisol NN o
and CC o
vasopressin NN o
in IN N
healthy JJ p
dogs NNS p
. . p

STUDY NNP N
DESIGN NNP N
Randomized NNP N
, , N
cross-over NN N
, , N
experimental JJ N
trial NN N
. . N

ANIMALS NNP N
Nine NNP p
adult NN p
dogs NNS p
( ( p
beagle NN p
and CC p
beagle NN p
cross NN p
breeds NNS p
) ) p
, , p
four CD p
males NNS p
and CC p
five CD p
females NNS p
. . p

METHODS NNP N
Methadone NNP i
hydrochloride NN i
, , N
0.4 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
was VBD N
administered VBN N
intravenously RB N
( ( N
IV NNP N
) ) N
and CC N
subcutaneously RB N
( ( N
SC NNP N
) ) N
with IN N
a DT N
crossover NN N
design NN N
. . N

Drug NNP o
and CC o
hormone NN o
analyses NNS o
in IN o
plasma NN o
were VBD N
performed VBN N
using VBG N
Liquid NNP i
Chromatography-Electrospray NNP i
Ionization-Tandem NNP i
Mass NNP i
Spectrometry NNP i
and CC i
radioimmunoassay VB i
respectively RB N
. . N

Behavioural NNP o
data NNS o
were VBD N
collected VBN N
using VBG N
a DT N
standardized JJ N
protocol NN N
. . N

RESULTS NNP N
After IN N
IV NNP N
administration NN N
, , N
the DT N
plasma JJ o
concentration NN o
of IN o
methadone NN o
at IN N
10 CD N
minutes NNS N
was VBD N
82.1 CD N
+/- JJ N
9.2 CD N
ng JJ N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
, , N
the DT N
terminal JJ o
half-life NN o
was VBD N
3.9 CD N
+/- JJ N
1.0 CD N
hours NNS N
, , N
the DT N
volume NN o
of IN o
distribution NN o
9.2 CD N
+/- JJ N
3.3 CD N
L NNP N
kg NN N
( ( N
-1 NNP N
) ) N
and CC N
plasma JJ o
clearance NN o
27.9 CD N
+/- JJ N
7.6 CD N
mL NNS N
minute NN N
( ( N
-1 NNP N
) ) N
kg NN N
( ( N
-1 NNP N
) ) N
. . N

After IN N
SC NNP N
administration NN N
, , N
time NN o
to TO o
maximal VB o
plasma JJ o
concentration NN o
was VBD N
1.26 CD N
+/- JJ N
1.04 CD N
hours NNS N
and CC N
maximal JJ o
plasma NN o
concentration NN o
of IN o
methadone NN o
was VBD N
23.9 CD N
+/- JJ N
14.4 CD N
ng JJ N
mL NN N
( ( N
-1 NNP N
) ) N
, , N
the DT N
terminal JJ o
half-life NN o
was VBD N
10.7 CD N
+/- JJ N
4.3 CD N
hours NNS N
and CC N
bioavailability NN o
was VBD N
79 CD N
+/- JJ N
22 CD N
% NN N
. . N

Concentrations NNS o
of IN o
both DT o
cortisol NNS o
and CC o
vasopressin NN o
were VBD N
increased VBN N
for IN N
an DT N
hour NN N
following VBG N
IV NNP N
methadone NN i
. . i

The DT N
observed JJ o
behavioural JJ o
effects NNS o
of IN N
methadone NN N
were VBD N
decreased VBN N
licking NN o
and CC o
swallowing NN o
and CC N
an DT N
increase NN N
in IN N
whining VBG o
after IN N
SC NNP N
administration NN N
. . N

The DT N
latter JJ N
finding NN N
is VBZ N
notable JJ N
as IN N
it PRP N
can MD N
be VB N
misinterpreted VBN N
as IN N
pain NN o
when WRB N
methadone NN i
is VBZ N
used VBN N
as IN N
an DT N
analgesic JJ N
. . N

CONCLUSION NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
When WRB N
methadone NN i
was VBD N
administered VBN N
by IN N
the DT N
SC NNP N
route NN N
, , N
the DT N
half-life NN o
was VBD N
longer RBR N
, , N
but CC N
the DT N
individual JJ N
variation NN o
in IN o
plasma JJ o
concentrations NNS o
was VBD N
greater JJR N
compared VBN N
with IN N
IV NNP N
administration NN N
. . N

Increased VBD N
frequency NN o
of IN o
whining VBG o
occurred VBN N
after IN N
administration NN N
of IN N
methadone NN i
and CC N
may MD N
be VB N
a DT N
drug NN N
effect NN N
and CC N
not RB N
a DT N
sign NN N
of IN N
pain NN N
. . N

Cortisol NNP o
and CC o
vasopressin JJ o
concentrations NNS o
in IN o
plasma NN o
may MD N
not RB N
be VB N
suitable JJ N
for IN N
evaluating VBG N
analgesia NN o
after IN N
methadone NN i
treatment NN N
. . N

-DOCSTART- -X- O O

Adjvant NNP i
treatment NN i
of IN N
tongue NN p
and CC p
floor NN p
of IN p
the DT p
mouth NN p
cancers NNS p
. . p

Since IN p
January NNP p
1974 CD p
, , p
95 CD p
patients NNS p
with IN p
anterior JJ p
tongue NN p
and CC p
floor NN p
of IN p
the DT p
mouth NN p
cancers NNS p
were VBD N
included VBN N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

After IN N
stratification NN N
according VBG N
to TO N
staging VBG N
and CC N
initial JJ N
treatment NN N
, , N
one-third NN p
of IN p
the DT p
patients NNS p
received VBD p
chemotherapy NN i
for IN i
2 CD i
years NNS i
( ( i
methotrexate VB i
400 CD i
mg NN i
followed VBN i
by IN i
citrovorum NN i
factor NN i
100 CD i
mg NN i
+ NNP i
bleomycin VBZ i
60 CD i
mg/week NN i
, , i
during IN i
the DT i
first JJ i
15 CD i
weeks NNS i
) ) i
, , i
one-third JJ i
of IN i
the DT i
patients NNS i
received VBD i
immunotherapy JJ i
with IN i
weekly JJ i
C. NNP i
parvum NN i
injections NNS i
during IN i
2 CD i
years NNS i
, , i
while IN i
the DT i
remaining VBG i
third NN i
did VBD i
not RB i
receive VB i
any DT i
treatment NN i
. . i

If IN N
adjuvant JJ N
treatment NN N
seems VBZ N
to TO N
delay VB o
recurrence NN o
it PRP N
did VBD N
not RB N
significantly RB N
decrease VB N
the DT N
recurrence NN o
rate NN o
. . o

Survival NN o
is VBZ N
also RB N
not RB N
signigicantly RB N
modified VBN N
by IN N
adjuvant JJ i
treatment NN N
and CC N
was VBD N
better JJR N
for IN N
patients NNS N
with IN N
small JJ N
tumors NNS N
. . N

Patients NNS p
who WP p
previously RB p
received VBD p
radiotherapy NN i
did VBD N
not RB N
benefit VB N
from IN N
adjuvant JJ i
therapy NN i
. . i

-DOCSTART- -X- O O

Tacrolimus/sirolimus NNP i
vs NN i
tacrolimus/methotrexate NN i
as IN N
GVHD NNP N
prophylaxis NN N
after IN p
matched VBN p
, , N
related VBN N
donor NN p
allogeneic NN p
HCT NNP p
. . p

Grades NNP N
2-4 JJ N
acute JJ N
graft-versus-host JJ N
disease NN N
( ( N
GVHD NNP N
) ) N
occurs VBZ N
in IN N
approximately RB N
35 CD N
% NN N
of IN N
matched VBN p
, , p
related VBN p
donor NN p
( ( p
MRD NNP p
) ) p
allogeneic VBZ p
hematopoietic JJ p
cell NN p
transplantation NN p
( ( p
HCT NNP p
) ) p
recipients NNS p
. . p

We PRP N
sought VBD N
to TO N
determine VB N
if IN N
the DT N
combination NN N
of IN N
tacrolimus NN i
and CC i
sirolimus NN i
( ( i
Tac/Sir NNP i
) ) i
was VBD N
more RBR N
effective JJ N
than IN N
tacrolimus NN i
and CC i
methotrexate NN i
( ( i
Tac/Mtx NNP i
) ) i
in IN N
preventing VBG N
acute JJ N
GVHD NNP N
and CC N
early JJ N
mortality NN N
after IN N
allogeneic JJ N
MRD NNP N
HCT NNP N
in IN N
a DT N
phase NN N
3 CD N
, , N
multicenter JJR N
trial NN N
. . N

The DT N
primary JJ o
end NN o
point NN o
of IN N
the DT N
trial NN N
was VBD N
to TO N
compare VB N
114-day JJ o
grades NNS o
2-4 JJ o
acute JJ o
GVHD-free NNP o
survival NN o
using VBG N
an DT N
intention-to-treat JJ N
analysis NN N
of IN N
304 CD p
randomized JJ p
subjects NNS p
. . p

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
probability NN N
of IN N
day NN N
114 CD N
grades NNS N
2-4 JJ N
acute JJ N
GVHD-free JJ N
survival NN N
( ( N
67 CD N
% NN N
vs JJ N
62 CD N
% NN N
, , N
P NNP N
= NNP N
.38 NNP N
) ) N
. . N

Grades NNP o
2-4 JJ o
GVHD NNP o
was VBD N
similar JJ N
in IN N
the DT N
Tac/Sir NNP N
and CC N
Tac/Mtx NNP N
arms NNS N
( ( N
26 CD N
% NN N
vs JJ N
34 CD N
% NN N
, , N
P NNP N
= NNP N
.48 NNP N
) ) N
. . N

Neutrophil NNP o
and CC o
platelet VB o
engraftment NN o
were VBD N
more RBR N
rapid JJ N
in IN N
the DT N
Tac/Sir NNP N
arm NN N
( ( N
14 CD N
vs RB N
16 CD N
days NNS N
, , N
P NNP N
< NNP N
.001 NNP N
; : N
16 CD N
vs IN N
19 CD N
days NNS N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Oropharyngeal NNP o
mucositis NN o
was VBD N
less RBR N
severe JJ N
in IN N
the DT N
Tac/Sir NNP N
arm NN N
( ( N
peak JJ N
Oral NNP o
Mucositis NNP o
Assessment NNP o
Scale NNP o
score VBD o
0.70 CD N
vs NN N
0.96 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
but CC N
otherwise RB N
toxicity NN o
was VBD N
similar JJ N
. . N

Chronic NNP o
GVHD NNP o
, , o
relapse-free JJ o
survival NN o
, , o
and CC o
overall JJ o
survival NN o
at IN o
2 CD o
years NNS o
were VBD N
no DT N
different JJ N
between IN N
study NN N
arms NNS N
( ( N
53 CD N
% NN N
vs JJ N
45 CD N
% NN N
, , N
P NNP N
= NNP N
.06 NNP N
; : N
53 CD N
% NN N
vs JJ N
54 CD N
% NN N
, , N
P NNP N
= NNP N
.77 NNP N
; : N
and CC N
59 CD N
% NN N
vs JJ N
63 CD N
% NN N
, , N
P NNP N
= NNP N
.36 NNP N
) ) N
. . N

Based VBN N
on IN N
similar JJ N
long-term JJ N
outcomes NNS N
, , N
more RBR N
rapid JJ N
engraftment NN N
, , N
and CC N
less JJR N
oropharyngeal JJ N
mucositis NN N
, , N
the DT N
combination NN N
of IN N
Tac/Sir NNP N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
to TO N
Tac/Mtx NNP N
after IN p
MRD NNP p
HCT NNP p
. . p

This DT N
study NN N
was VBD N
funded VBN N
by IN N
the DT N
National NNP N
Heart NNP N
, , N
Lung NNP N
, , N
and CC N
Blood NNP N
Institute NNP N
and CC N
the DT N
National NNP N
Cancer NNP N
Institute NNP N
; : N
and CC N
the DT N
trial NN N
was VBD N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00406393 NNP N
. . N

-DOCSTART- -X- O O

Environmental JJ i
enrichment NN i
as IN N
a DT N
therapy NN N
for IN N
autism NN p
: : p
A DT N
clinical JJ N
trial NN N
replication NN N
and CC N
extension NN N
. . N

Based VBN N
on IN N
work NN N
done VBN N
in IN N
animal NN N
models NNS N
showing VBG N
that IN N
autism-like JJ N
symptoms NNS N
are VBP N
ameliorated VBN N
following JJ N
exposure NN N
to TO N
an DT N
enriched JJ i
sensorimotor NN i
environment NN i
, , N
we PRP N
attempted VBD N
to TO N
develop VB N
a DT N
comparable JJ N
therapy NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

In IN N
an DT N
initial JJ N
randomized NN N
controlled VBD N
trial NN N
, , N
children NNS p
with IN p
autism NN p
who WP p
received VBD p
sensorimotor NN i
enrichment NN i
at IN i
home NN i
for IN p
6 CD p
months NNS p
had VBD p
significant JJ p
improvements NNS p
in IN p
both DT p
their PRP$ p
cognitive NN p
ability NN p
and CC p
the DT p
severity NN p
of IN p
their PRP$ p
autism NN p
symptoms NNS p
( ( N
Woo NNP N
& CC N
Leon NNP N
, , N
2013 CD N
) ) N
. . N

We PRP N
now RB N
report VBP N
the DT N
outcomes NNS N
of IN N
a DT N
similar JJ N
randomized NN N
controlled VBD N
trial NN N
in IN N
which WDT N
children NNS p
with IN p
autism NN p
, , p
3 CD p
to TO p
6 CD p
years NNS p
old JJ p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO N
groups NNS i
that WDT i
received VBD i
either DT i
daily JJ i
sensorimotor NN i
enrichment NN i
, , i
administered VBN i
by IN i
their PRP$ i
parents NNS i
, , i
along IN i
with IN i
standard JJ i
care NN i
, , i
or CC i
they PRP i
received VBD i
standard JJ i
care NN i
alone RB i
. . i

After IN N
6 CD N
months NNS N
, , N
enriched VBD N
children NNS N
showed VBD N
statistically RB N
significant JJ N
gains NNS N
in IN N
their PRP$ N
IQ NNP o
scores NNS o
, , N
a DT N
decline NN N
in IN N
their PRP$ N
atypical JJ o
sensory NN o
responses NNS o
, , N
and CC N
an DT N
improvement NN N
in IN N
their PRP$ N
receptive JJ o
language NN o
performance NN o
, , N
compared VBN N
to TO N
controls NNS N
. . N

Furthermore NNP N
, , N
after IN N
6 CD N
months NNS N
of IN N
enrichment JJ N
therapy NN N
, , N
21 CD N
% NN N
of IN N
the DT N
children NNS N
who WP N
initially RB N
had VBD N
been VBN N
given VBN N
an DT N
autism NN N
classification NN N
, , N
using VBG N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
, , N
improved VBN N
to TO N
the DT N
point NN N
that IN N
, , N
although IN N
they PRP N
remained VBD N
on IN N
the DT N
autism NN N
spectrum NN N
, , N
they PRP N
no RB N
longer RBR N
met VBD N
the DT N
criteria NNS N
for IN N
classic JJ N
autism NN N
. . N

None NN N
of IN N
the DT N
standard NN N
care NN N
controls VBZ N
reached VBD N
an DT N
equivalent JJ N
level NN N
of IN N
improvement NN N
. . N

Finally RB N
, , N
the DT N
outcome NN o
measures NNS o
for IN N
children NNS N
who WP N
received VBD N
only RB N
a DT N
subset NN N
of IN N
sensory JJ N
stimuli NNS N
were VBD N
similar JJ N
to TO N
those DT N
receiving VBG N
the DT N
full JJ N
complement NN N
of IN N
enrichment NN N
exercises NNS N
. . N

Sensorimotor NNP N
enrichment JJ N
therapy NN N
therefore RB N
appears VBZ N
to TO N
be VB N
a DT N
cost-effective JJ o
means NNS N
of IN N
treating VBG N
a DT N
range NN N
of IN N
symptoms NNS N
for IN N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O

Osteoporosis NN i
and CC N
gait NN N
and CC N
balance NN N
disturbances NNS N
in IN N
older JJR p
sarcopenic JJ p
obese JJ p
New NNP p
Zealanders NNP p
. . p

UNLABELLED NNP N
Bone NNP N
, , N
muscle NN N
, , N
and CC N
fat NN N
may MD N
affect VB N
gait NN N
and CC N
balance NN N
in IN N
older JJR p
adults NNS p
. . p

Osteoporosis NN p
was VBD p
prevalent JJ p
in IN p
low JJ p
muscle NN p
mass NN p
participants NNS p
and CC p
related VBN p
to TO p
gait VB p
and CC p
balance VB p
deficits NNS p
. . p

Low JJ N
muscle NN N
combined VBN N
with IN N
high JJ N
fat JJ N
mass NN N
had VBD N
more RBR N
functional JJ N
deficits NNS N
and CC N
poorer JJR N
bone NN N
health NN N
, , N
which WDT N
has VBZ N
implications NNS N
for IN N
falls NNS N
risk NN N
and CC N
fractures NNS N
. . N

INTRODUCTION NNP N
Decreasing VBG N
bone NN N
density NN N
and CC N
muscle NN N
mass NN N
and CC N
increasing VBG N
fat JJ N
mass NN N
may MD N
act VB N
synergistically RB N
to TO N
affect VB N
gait NN N
and CC N
balance NN N
in IN N
older JJR N
adults NNS N
. . N

METHODS NNP N
One CD p
hundred VBD p
eighty-three JJ p
older NN p
adults NNS p
( ( p
age NN p
72.7 CD p
+/- JJ p
6 CD p
years NNS p
, , p
range VBP p
56-93 JJ p
; : p
body NN p
mass NN p
index NN p
28.2 CD p
+/- JJ p
4.9 CD p
, , p
range VBP p
16.6-46.0 JJ p
) ) p
were VBD p
recruited VBN p
from IN p
a DT p
New NNP p
Zealand NNP p
falls VBZ p
prevention NN p
intervention NN p
trial NN p
. . p

Total JJ o
and CC o
appendicular JJ o
skeletal JJ o
muscle NN o
mass NN o
( ( o
ASM NNP o
) ) o
, , o
percent JJ o
fat NN o
, , o
and CC o
bone NN o
mineralization NN o
were VBD p
assessed VBN p
by IN p
dual JJ i
energy NN i
X-ray JJ i
absorptiometry NN i
and CC p
used VBD p
to TO p
characterize VB p
normal JJ p
lean JJ p
( ( p
NL NNP p
, , p
n JJ p
= NNP p
51 CD p
) ) p
, , p
sarcopenic JJ p
( ( p
SS NNP p
, , p
n JJ p
= NNP p
18 CD p
) ) p
, , p
sarcopenic JJ p
obese NN p
( ( p
SO NNP p
, , p
n JJ p
= NNP p
29 CD p
) ) p
, , p
and CC p
obese JJ p
( ( p
OO NNP p
, , p
n JJ p
= NNP p
85 CD p
) ) p
phenotypes NNS p
. . p

Functional JJ N
performance NN N
was VBD N
assessed VBN N
using VBG N
timed VBN i
up RP i
and CC i
go VB i
, , i
chair NN i
stand NN i
, , i
single JJ i
leg NN i
stand NN i
, , N
and CC N
step VB i
test NN i
. . i

Regression NN N
models NNS N
were VBD N
adjusted VBN N
for IN N
age NN N
, , N
sex NN N
, , N
medications NNS N
, , N
and CC N
physical JJ N
activity NN N
. . N

RESULTS NNP N
Femoral NNP o
neck NN o
osteoporosis NN o
was VBD N
present JJ N
in IN N
22 CD N
% NN N
SS NNP N
, , N
17 CD N
% NN N
SO NNP N
, , N
12 CD N
% NN N
NL NNP N
, , N
and CC N
7 CD N
% NN N
OO NNP N
. . N

Femoral NNP N
neck NN N
osteoporosis NN N
with IN N
low JJ N
ASM NNP o
predicted VBD N
poor JJ N
chair NN o
stand VBP o
performance NN o
( ( N
beta JJ N
-3.3 NNP N
, , N
standard JJ N
error NN N
1.6 CD N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
. . N

SO RB N
scored JJ N
lowest NN N
on IN N
the DT N
chair NN N
stand NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
step JJ N
test NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

Higher JJR o
ASM NNP o
predicted VBD N
faster RBR N
timed VBN N
up RP N
and CC N
go VB N
performance NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Osteoporosis NNP N
was VBD N
prevalent VBN N
in IN N
low JJ p
ASM NNP p
groups NNS p
( ( N
SS NNP N
and CC N
SO NNP N
) ) N
and CC N
related VBN N
to TO N
gait VB N
and CC N
balance VB N
deficits NNS N
, , N
particularly RB N
in IN N
the DT N
SO NNP N
. . N

This DT N
has VBZ N
implications NNS N
for IN N
falls NNS N
risk NN N
, , N
fractures NNS N
, , N
and CC N
interventions NNS N
. . N

-DOCSTART- -X- O O

Deep JJ o
vein NN o
thrombosis NN o
after IN p
major JJ p
reconstructive JJ p
spinal NN p
surgery NN p
. . p

STUDY NNP N
DESIGN NNP N
A NNP N
prospective JJ N
study NN N
was VBD N
performed VBN N
. . N

OBJECTIVES IN N
The DT N
goals NNS N
of IN N
the DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
incidence NN N
of IN N
deep JJ o
vein NN o
thrombosis NN o
after IN p
major JJ p
adult NN p
spinal JJ p
surgery NN p
and CC N
the DT N
optimal JJ N
mode NN N
of IN N
prophylaxis NN N
in IN N
this DT N
surgical JJ N
population NN N
. . N

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
Few NNP N
studies NNS N
have VBP N
evaluated VBN N
deep JJ o
vein NN o
thrombosis NN o
incidence NN N
and CC N
prophylaxis NN o
after IN N
major JJ p
adult NN p
spinal JJ p
surgery NN p
. . p

Incidence NN N
rates NNS N
have VBP N
ranged VBN N
from IN N
0.9-14 CD N
% NN N
. . N

METHODS NNP N
Three CD p
hundred VBD p
twenty-nine JJ p
patients NNS p
were VBD N
evaluated VBN N
. . N

One CD p
hundred VBD p
ten JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
3 CD N
different JJ N
deep JJ o
vein NN o
thrombosis NN o
prophylaxis NN o
groups NNS N
. . N

These DT N
patients NNS N
had VBD N
duplex JJ o
doppler NN o
scans NNS o
between IN N
the DT N
fifth NN N
and CC N
seventh JJ N
postoperative JJ N
days NNS N
. . N

The DT N
remaining VBG N
219 CD N
patients NNS N
formed VBD N
a DT N
nonrandomized JJ N
group NN N
and CC N
received VBD N
either CC N
thrombosis JJ i
embolic JJ i
deterrent NN i
stockings NNS i
alone RB i
or CC i
thrombosis VB i
embolic JJ i
deterrent NN i
stockings NNS i
and CC i
pneumatic JJ i
compression NN i
boots NNS i
for IN N
deep JJ N
vein NN N
thrombosis NN N
prophylaxis NN N
. . N

The DT N
type NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
prophylaxis NN N
in IN N
this DT N
group NN N
was VBD N
based VBN N
on IN N
surgeon NN N
preference NN N
. . N

All DT N
329 CD N
patients NNS N
were VBD N
followed VBN N
for IN N
clinical JJ o
signs NNS o
and CC o
symptoms NNS o
of IN o
thromboembolic JJ o
disease NN o
. . o

Patients NNS N
were VBD N
followed VBN N
clinically RB N
for IN N
a DT N
minimum NN N
of IN N
1 CD N
year NN N
. . N

RESULTS NNP N
All DT N
110 CD N
prophylaxis NNS N
study NN N
group NN N
patients NNS N
were VBD N
clinically RB N
asymptomatic JJ o
and CC N
109 CD N
duplex JJ o
scans NNS o
were VBD N
normal JJ N
. . N

One CD N
scan NN N
was VBD N
indeterminate JJ N
and CC N
a DT N
follow-up JJ N
venogram NN o
was VBD N
negative JJ N
. . N

Two CD N
patients NNS N
in IN N
the DT N
coumadin NN N
group NN N
( ( N
5.7 CD N
% NN N
) ) N
experienced VBD N
excessive JJ o
blood NN o
loss NN o
. . o

One CD N
of IN N
the DT N
219 CD N
patients NNS N
from IN N
the DT N
nonrandomized VBN N
group NN N
developed VBD N
a DT N
clinically RB o
detectable JJ o
proximal JJ o
deep JJ o
vein NN o
thrombosis NN o
which WDT N
was VBD N
confirmed VBN N
by IN N
duplex JJ o
ultra-sonography NN o
. . o

The DT N
overall JJ N
clinical JJ o
incidence NN o
of IN N
deep JJ o
vein NN o
thrombosis NN o
was VBD N
0.3 CD N
% NN N
( ( N
1 CD N
in IN N
329 CD N
patients NNS N
) ) N
. . N

CONCLUSIONS VB N
This DT N
low JJ N
0.3 CD N
% NN N
rate NN N
is VBZ N
in IN N
agreement NN N
with IN N
recent JJ N
studies NNS N
that WDT N
focus VBP N
on IN N
thromboembolic JJ o
disease NN o
. . o

Given VBN N
the DT N
low JJ N
incidence NN N
, , N
routine JJ N
screening NN N
for IN N
asymptomatic JJ N
thrombi NN N
appears VBZ N
unwarranted JJ N
. . N

In IN N
addition NN N
, , N
mechanical JJ N
prophylaxis NN N
with IN N
graduated JJ N
compression NN N
stockings NNS N
and CC N
pneumatic JJ N
compression NN N
boots NNS N
is VBZ N
preferable JJ N
to TO N
anticoagulation VB N
therapy NN N
. . N

-DOCSTART- -X- O O

Continuous JJ i
event NN i
recorders NNS i
did VBD N
not RB N
affect VB N
anxiety NN o
or CC N
quality NN o
of IN o
life NN o
in IN N
patients NNS p
with IN p
palpitations NNS p
. . p

OBJECTIVES NNP N
Palpitations NNPS N
can MD N
generate VB N
feelings NNS N
of IN N
anxiety NN o
and CC N
decrease NN N
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
due JJ N
to TO N
fear VB N
of IN N
a DT N
cardiac JJ N
abnormality NN N
. . N

Continuous JJ i
event NN i
recorders NNS i
( ( i
CERs NNP i
) ) i
have VBP N
proven VBN N
to TO N
be VB N
successful JJ N
in IN N
diagnosing VBG N
causes NNS N
of IN N
palpitations NNS N
but CC N
may MD N
affect VB N
patient NN N
QoL NNP o
and CC N
anxiety NN o
. . o

The DT N
aim NN N
is VBZ N
to TO N
determine VB N
anxiety NN o
and CC N
health-related JJ o
( ( o
HR NNP o
) ) o
-QoL NN o
and CC N
evaluate VB N
the DT N
burden NN N
of IN N
carrying VBG N
a DT N
CER NNP i
in IN N
general JJ N
practice NN N
populations NNS N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
Patients NNP p
( ( p
n=244 JJ p
) ) p
participated VBD N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

One CD N
group NN N
( ( N
n=127 RB N
) ) N
carried VBD N
a DT N
CER NNP i
during IN N
4 CD N
weeks NNS N
. . N

One CD p
hundred CD p
and CC p
seventeen JJ p
patients NNS p
formed VBD N
the DT N
usual JJ i
care NN i
( ( i
UC NNP i
) ) i
group NN N
. . N

State-Trait NNP o
Anxiety NNP o
Inventory NNP o
( ( o
STAI NNP o
) ) o
and CC o
the DT o
Short NNP o
Form-36 NNP o
( ( o
SF-36 NNP o
) ) o
were VBD N
administered VBN N
at IN N
study NN N
inclusion NN N
, , N
after IN N
1 CD N
, , N
6 CD N
months NNS N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
patients NNS N
reported VBD N
greater JJR N
anxiety NN o
and CC N
lower JJR o
QoL NNP o
than IN N
healthy JJ N
populations NNS N
. . N

The DT N
CER NNP i
group NN N
had VBD N
three CD N
times NNS N
more RBR N
cardiac JJ o
diagnoses NNS o
than IN N
the DT N
UC NNP i
group NN N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
CER NNP i
group NN N
and CC N
UC NNP i
group NN N
at IN N
6 CD N
weeks NNS N
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
UC NNP i
group NN N
showed VBD N
QoL NNP o
improvement NN o
and CC N
less JJR N
anxiety NN o
compared VBN N
to TO N
the DT N
CER NNP i
group NN N
. . N

Type NN o
of IN o
diagnosis NN o
had VBD N
influence NN N
, , N
but CC N
did VBD N
not RB N
fully RB N
explain VB N
these DT N
differences NNS N
. . N

CONCLUSION VB N
A DT N
CER NNP i
does VBZ N
not RB N
negatively RB N
influence JJ N
anxiety NN o
or CC N
QoL NNP o
. . o

Better NNP N
outcomes VBZ N
in IN N
the DT N
UC NNP i
group NN N
might MD N
be VB N
attributed VBN N
to TO N
less JJR N
cardiac JJ o
diagnosis NN o
and CC N
more JJR N
emphasis NN N
on IN N
psychological JJ o
well-being NN o
. . o

-DOCSTART- -X- O O

Treatment NN N
of IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
to TO N
evaluate VB N
a DT N
caregiver-based JJ i
intervention NN i
program NN i
in IN N
community NN p
day-care NN p
centers NNS p
. . p

This DT N
study NN N
reports VBZ N
on IN N
the DT N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
that WDT N
evaluated VBD N
a DT N
caregiver-based JJ i
intervention NN i
program NN i
for IN N
children NNS p
with IN p
autism NN p
in IN p
community NN p
day-care NN p
centers NNS p
. . p

Thirty-five JJ p
preschool NN p
children NNS p
with IN p
a DT p
DSM NNP p
III-R NNP p
diagnosis NN p
of IN p
autism NN p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
were VBD N
randomized VBN N
to TO N
an DT N
experimental JJ N
or CC N
control NN N
group NN N
. . N

Children NNP N
in IN N
the DT N
experimental JJ N
group NN N
were VBD N
enrolled VBN N
in IN N
day NN N
care NN N
and CC N
their PRP$ N
parents NNS i
and CC i
child NN i
care NN i
workers NNS i
received VBD i
a DT i
12-week JJ i
intervention NN i
consisting NN i
of IN i
lectures NNS i
and CC i
on-site JJ i
consultations NNS i
to TO i
day-care JJ i
centers NNS i
. . i

In IN N
addition NN N
, , N
supportive JJ N
work NN N
was VBD N
undertaken VBN N
with IN N
families NNS N
. . N

Control NNP N
subjects VBZ N
received VBN N
day NN i
care VB i
alone RB i
. . i

In IN N
the DT N
experimental JJ N
group NN N
, , N
there EX N
were VBD N
greater JJR N
gains NNS N
in IN N
language NN o
abilities NNS o
, , N
significant JJ N
increases NNS N
in IN N
caregivers NNS o
' POS o
knowledge NN o
about IN o
autism NN o
, , N
greater JJR N
perception NN o
of IN o
control NN o
on IN o
the DT o
part NN o
of IN o
mothers NNS o
, , N
and CC N
greater JJR N
parent NN o
satisfaction NN o
. . o

We PRP N
conclude VBP N
that IN N
this DT N
research NN N
design NN N
demonstrated VBD N
that IN N
the DT N
intervention NN N
was VBD N
significantly RB N
superior JJ N
to TO N
day NN N
care VB N
alone RB N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
early JJ i
developmental JJ i
intervention NN i
on IN N
outcomes NNS N
in IN N
children NNS p
after IN p
birth NN o
asphyxia NN o
in IN N
developing VBG N
countries NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
if IN N
early JJ i
developmental NN i
intervention NN i
( ( N
EDI NNP N
) ) N
improves VBZ N
developmental JJ N
abilities NNS N
in IN N
resuscitated JJ p
children NNS p
. . p

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
parallel JJ p
group NN p
, , N
randomized VBD N
controlled VBN N
trial NN N
of IN N
infants NNS p
unresponsive JJ p
to TO p
stimulation NN p
who WP p
received VBD p
bag NN i
and CC i
mask NN i
ventilation NN i
as IN p
part NN p
of IN p
their PRP$ p
resuscitation NN p
at IN p
birth NN p
and CC p
infants NNS p
who WP p
did VBD p
not RB p
require VB p
any DT p
resuscitation NN p
born VBN p
in IN p
rural JJ p
communities NNS p
in IN p
India NNP p
, , p
Pakistan NNP p
, , p
and CC p
Zambia NNP p
. . p

Intervention NN p
infants NNS p
received VBD N
a DT N
parent-implemented JJ i
EDI NNP i
delivered VBN N
with IN N
home NN N
visits NNS N
by IN N
parent NN N
trainers NNS N
every DT N
other JJ N
week NN N
for IN N
3 CD N
years NNS N
starting VBG N
the DT N
first JJ N
month NN N
after IN N
birth NN N
. . N

Parents NNS N
in IN N
both DT N
intervention NN N
and CC N
control NN N
groups NNS N
received VBD N
health NN i
and CC i
safety NN i
counseling NN i
during IN N
home NN N
visits NNS N
on IN N
the DT N
same JJ N
schedule NN N
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Mental NNP o
Development NNP o
Index NNP o
( ( o
MDI NNP o
) ) o
of IN N
the DT N
Bayley NNP N
Scales NNP N
of IN N
Infant NNP N
Development NNP N
, , N
2nd CD N
edition NN N
, , N
assessed VBN N
at IN N
36 CD N
months NNS N
by IN N
evaluators NNS N
unaware JJ N
of IN N
treatment NN N
group NN N
and CC N
resuscitation NN N
history NN N
. . N

RESULTS NNP N
MDI NNP o
was VBD N
higher RBR N
in IN N
the DT N
EDI NNP N
( ( N
102.6 CD N
? . N
9.8 CD N
) ) N
compared VBN N
with IN N
the DT N
control NN N
resuscitated VBD N
children NNS N
( ( N
98.0 CD N
? . N
14.6 CD N
, , N
1-sided JJ N
P NNP N
= NNP N
.0202 NNP N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
nonresuscitated JJ N
children NNS N
( ( N
100.1 CD N
? . N
10.7 CD N
vs NN N
97.7 CD N
? . N
10.4 CD N
, , N
P NNP N
= NNP N
.1392 NNP N
) ) N
. . N

The DT o
Psychomotor NNP o
Development NNP o
Index NNP o
was VBD o
higher RBR o
in IN N
the DT N
EDI NNP N
group NN N
for IN N
both DT N
the DT N
resuscitated VBN N
( ( N
P NNP N
= NNP N
.0430 NNP N
) ) N
and CC N
nonresuscitated JJ N
children NNS N
( ( N
P NNP N
= NNP N
.0164 NNP N
) ) N
. . N

CONCLUSIONS VB N
This DT N
trial NN N
of IN N
home-based JJ N
, , N
parent NN N
provided VBD N
EDI NNP N
in IN p
children NNS p
resuscitated VBN p
at IN p
birth NN p
provides VBZ p
evidence NN p
of IN N
treatment NN N
benefits NNS o
on IN o
cognitive NN o
and CC o
psychomotor NN o
outcomes NNS o
. . o

MDI NNP o
and CC o
Psychomotor NNP o
Development NNP o
Index NNP o
scores NNS o
of IN o
both DT o
nonresuscitated JJ N
and CC p
resuscitated JJ p
infants NNS p
were VBD N
within IN N
normal JJ N
range NN N
, , N
independent JJ N
of IN N
early JJ N
intervention NN N
. . N

-DOCSTART- -X- O O

Enhancing VBG N
the DT N
application NN N
and CC N
evaluation NN N
of IN N
a DT N
discrete JJ i
trial NN i
intervention NN i
package NN i
for IN N
eliciting VBG N
first JJ N
words NNS N
in IN N
preverbal JJ p
preschoolers NNS p
with IN p
ASD NNP p
. . p

This DT N
study NN N
evaluates VBZ N
the DT N
effectiveness NN N
of IN N
an DT N
intervention NN N
package NN N
including VBG N
a DT N
discrete JJ i
trial NN i
program NN i
( ( i
Rapid NNP i
Motor NNP i
Imitation NNP i
Antecedent NNP i
Training NNP i
( ( N
Tsiouri NNP N
and CC N
Greer NNP N
, , N
J NNP N
Behav NNP N
Educat NNP N
12:185-206 CD N
, , N
2003 CD N
) ) N
combined VBN i
with IN i
parent NN i
education NN i
for IN i
eliciting VBG N
first JJ N
words NNS N
in IN N
children NNS p
with IN p
ASD NNP p
who WP p
had VBD p
little JJ p
or CC p
no DT p
spoken JJ p
language NN p
. . p

Evaluation NN N
of IN N
the DT N
approach NN N
includes VBZ N
specific JJ N
intervention NN N
targets NNS N
and CC N
functional JJ o
spoken JJ o
language NN o
outcomes NNS o
( ( o
Tager-Flusberg NNP o
et FW o
al. NN o
, , N
J NNP o
Speech NNP o
Lang NNP o
Hear NNP o
Res NNP o
52:643-652 CD o
, , o
2009 CD o
) ) o
. . o

Results VB N
suggest JJS N
that IN N
RMIA NNP N
, , N
with IN N
parent NN N
training NN N
, , N
catalyzes VBZ N
development NN N
of IN N
verbal JJ o
imitation NN o
and CC o
production NN o
for IN N
some DT N
children NNS N
. . N

Three CD p
of IN p
five CD p
participants NNS p
acquired VBD N
word NN o
production NN o
within IN N
the DT N
DTT NNP N
framework NN N
and CC N
achieved VBD N
milestones NNS N
of IN N
early JJ o
functional JJ o
spoken NN o
language NN o
use NN o
( ( N
Tager-Flusberg NNP N
et FW N
al. NN N
, , N
J NNP N
Speech NNP N
Lang NNP N
Hear NNP N
Res NNP N
52:643-652 CD N
, , N
2009 CD N
) ) N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
for IN N
understanding VBG N
the DT N
role NN N
of IN N
discrete JJ N
trial NN N
approaches NNS N
to TO N
language NN N
intervention NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Feasibility NNP N
study NN N
of IN N
the DT N
effects NNS o
of IN N
art NN N
as IN N
a DT N
creative JJ N
engagement NN N
intervention NN N
during IN N
stroke NN N
rehabilitation NN N
on IN N
improvement NN N
of IN N
psychosocial JJ o
outcomes NNS o
: : o
study NN N
protocol NN N
for IN N
a DT N
single JJ N
blind NN N
randomized VBD N
controlled VBN N
trial NN N
: : N
the DT N
ACES NNP N
study NN N
. . N

BACKGROUND NNP N
Benefits NNP N
of IN N
art NN N
participation NN N
after IN N
stroke NN N
are VBP N
becoming VBG N
increasingly RB N
recognized VBN N
. . N

Qualitative JJ N
studies NNS N
suggest VBP N
that IN N
participation NN N
in IN N
visual JJ N
arts NNS N
creative JJ N
engagement JJ N
interventions NNS N
( ( N
CEIs NNP N
) ) N
during IN N
rehabilitation NN N
after IN N
stroke NN N
may MD N
improve VB N
mood NN o
, , o
self-esteem JJ o
, , o
hope NN o
and CC N
some DT N
aspects NNS N
of IN N
physical JJ N
recovery NN N
. . N

This DT N
study NN N
examines VBZ N
the DT N
feasibility NN N
of IN N
undertaking VBG N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
CEI NNP N
delivered VBN N
by IN N
artists NNS N
within IN N
in-patient JJ N
stroke NN N
rehabilitation NN N
to TO N
test VB N
effectiveness NN N
. . N

METHODS/DESIGN NNP N
This DT N
trial NN N
is VBZ N
a DT N
two CD N
arm NN N
, , N
single-blind NN N
, , N
randomized VBN N
controlled VBN N
feasibility NN N
trial NN N
within IN N
in-patient JJ N
stroke NN N
rehabilitation NN N
. . N

We PRP N
will MD N
recruit VB N
80 CD p
patients NNS p
receiving VBG i
stroke NN i
rehabilitation NN i
in IN i
two CD i
stroke VBD i
units NNS i
in IN i
a DT i
health NN i
board NN i
area NN i
of IN i
Scotland NNP i
( ( i
40 CD i
patients NNS i
in IN i
each DT i
arm NN i
) ) i
. . i

Intervention NNP i
arm NN i
participants NNS i
will MD i
receive VB i
a DT i
visual-arts NNS i
based VBN i
CEI NNP i
facilitated VBN i
by IN i
experienced JJ i
artists NNS i
. . i

Artists NNS i
will MD i
follow VB i
an DT i
intervention NN i
protocol NN i
with IN i
specific JJ i
components NNS i
that WDT i
enable VBP i
participants NNS i
to TO i
set VB i
, , i
achieve VB i
and CC i
review VB i
artistic JJ i
goals NNS i
. . i

Participants NNS i
will MD i
receive VB i
up RP i
to TO i
eight CD i
intervention NN i
sessions NNS i
, , i
four CD i
within IN i
a DT i
group NN i
and CC i
four CD i
one-to-one NN i
with IN i
the DT i
artist NN i
. . i

Control NNP N
group NN N
participants NNS N
will MD N
receive VB N
usual JJ N
care NN N
only.Data JJ N
collection NN N
will MD N
occur VB N
at IN N
baseline NN N
, , N
post-intervention NN N
and CC N
three-month JJ N
follow-up NN N
. . N

Stroke-related JJ o
health NN o
status NN o
is VBZ N
the DT N
primary JJ N
outcome NN N
; : N
mood NN o
, , o
self-esteem JJ o
, , o
self-efficacy JJ o
, , o
perceived JJ o
recovery NN o
control NN o
and CC o
hope NN o
are VBP o
secondary JJ o
outcomes NNS N
. . N

Semi-structured JJ N
interviews NNS N
will MD N
be VB N
conducted VBN N
with IN N
purposively RB N
selected VBN N
patients NNS N
, , N
artists NNS N
and CC N
healthcare JJ N
staff NN N
to TO N
elicit VB o
views NNS o
and CC o
experiences NNS o
of IN N
the DT N
intervention NN N
and CC N
feasibility NN o
and CC o
acceptability NN o
of IN N
trial NN N
processes NNS N
. . N

Recruitment JJ o
rates NNS o
, , o
retention NN o
rates NNS o
and CC o
patient JJ o
preference NN o
for IN o
art JJ o
participation NN o
will MD N
also RB N
be VB N
collected VBN N
. . N

Data NNP N
will MD N
indicate VB N
, , N
with IN N
confidence NN N
intervals NNS N
, , N
the DT N
proportion NN N
of IN N
patients NNS N
choosing VBG N
or CC N
refusing VBG N
participation NN N
in IN N
the DT N
CEI NNP N
and CC N
will MD N
allow VB N
calculation NN N
of IN N
recruitment NN o
rates NNS o
for IN N
a DT N
future JJ N
definitive JJ N
trial NN N
. . N

Summary NNP N
data NNS N
will MD N
indicate VB N
potential JJ N
variability NN N
, , N
magnitude NN N
and CC N
direction NN N
of IN N
difference NN N
between IN N
groups NNS N
. . N

Findings NNS N
will MD N
inform VB N
sample JJ N
size NN N
calculations NNS N
for IN N
a DT N
definitive JJ N
trial NN N
. . N

Thematic JJ N
analysis NN N
of IN N
qualitative JJ N
data NNS N
will MD N
be VB N
managed VBN N
using VBG N
the DT N
Framework NNP N
Approach NNP N
. . N

Framework NNP N
is VBZ N
an DT N
analytical JJ N
approach NN N
for IN N
qualitative JJ N
data NNS N
, , N
commonly RB N
used VBN N
in IN N
policy NN N
and CC N
medical JJ N
research NN N
. . N

DISCUSSION NNP N
If IN N
shown VBN N
to TO N
demonstrate VB N
effects NNS N
, , N
this DT N
intervention NN N
has VBZ N
the DT N
potential JJ N
to TO N
address VB N
aspects NNS N
of IN N
stroke NN N
recovery NN N
previously RB N
. . N

Not RB N
routinely RB N
addressed VBN N
in IN N
rehabilitation NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Registered NNP N
with IN N
Clinical NNP N
Trials.Gov NNP N
: : N
NCT02085226 NN N
on IN N
6th CD N
March NNP N
2014 CD N
. . N

-DOCSTART- -X- O O

Pharmacodynamic JJ N
analysis NN N
of IN N
intravenous JJ i
recombinant JJ i
urate JJ i
oxidase NN i
using VBG N
an DT N
indirect JJ p
pharmacological JJ p
response NN p
model NN p
in IN p
healthy JJ p
subjects NNS p
. . p

AIM NNP N
Pharmacodynamic NNP N
analysis NN N
of IN N
intravenous JJ i
recombinant JJ i
urate JJ i
oxidase NN i
produced VBN N
by IN N
Escherichia NNP N
coli NN N
was VBD N
performed VBN N
in IN p
healthy JJ p
subjects NNS p
using VBG p
a DT p
pharmacokinetic/pharmacodynamic JJ p
( ( p
PK/PD NNP p
) ) p
model NN p
. . p

METHODS CC N
A DT N
randomized JJ N
, , N
single-blind JJ N
, , N
placebo-controlled JJ i
study NN N
was VBD N
performed VBN N
in IN p
40 CD p
healthy JJ p
Chinese JJ p
subjects NNS p
( ( p
4 CD p
groups NNS p
of IN p
10 CD p
subjects NNS p
each DT p
, , p
placebo VBZ p
4:1 CD p
ratio NN p
) ) p
who WP p
received VBD p
infusions NNS p
of IN p
uricase NN i
( ( p
single JJ p
doses NNS p
of IN p
0.1 CD p
, , p
0.2 CD p
, , p
and CC p
0.3 CD p
mg/kg NN p
; : p
multiple JJ p
doses NNS p
of IN p
0.2 CD p
mg?kg NN p
( ( p
-1 NNP p
) ) p
?d NN p
( ( p
-1 NNP p
) ) p
for IN p
7 CD p
d NN p
) ) p
. . p

PK JJ N
profiles NNS N
were VBD N
determined VBN N
through IN o
plasma JJ o
uricase JJ o
activity NN o
, , o
and CC N
PD NNP N
profiles NNS N
were VBD N
established VBN N
using VBG o
uric JJ o
acid NN o
levels NNS o
in IN o
plasma NN o
and CC o
urine NN o
. . o

The DT N
plasma NN N
PD NNP N
parameter NN N
was VBD N
estimated VBN N
as IN N
changes NNS N
in IN N
plasma NN o
uric JJ o
acid NN o
levels NNS o
as IN o
the DT N
effect NN N
in IN N
the DT N
indirect JJ N
response NN N
model NN o
. . o

Adverse JJ o
events NNS o
were VBD o
also RB N
monitored VBN N
. . N

RESULTS VB N
A DT N
two-compartment JJ N
PK NNP N
model NN N
with IN N
constant JJ N
iv NN N
input NN N
and CC N
first-order NN N
output NN N
was VBD N
used VBN N
to TO N
describe VB N
the DT N
kinetic JJ N
process NN N
of IN N
plasma JJ N
uricase NN N
. . N

The DT N
low JJ N
value NN N
( ( N
2.8 CD N
U/L NNP N
) ) N
of IN N
drug NN N
concentration NN N
that WDT N
achieved VBD N
50 CD N
% NN N
of IN N
maximum JJ N
effect NN N
( ( N
EC50 NNP N
) ) N
indicated VBD N
that IN N
low JJ N
plasma NN N
uricase NN N
concentrations NNS N
were VBD N
sufficient JJ N
to TO N
produce VB o
pharmacological JJ o
effects NNS o
. . o

A DT N
strong JJ N
relationship NN N
( ( N
r NN N
( ( N
2 CD N
) ) N
=0.9991 NN N
) ) N
between IN N
the DT o
mean JJ o
uric JJ o
acid NN o
concentration NN o
in IN o
blood NN o
and CC o
the DT o
mean JJ o
uric JJ o
acid JJ o
excretion NN o
rate NN o
in IN o
urine NN o
in IN o
the DT N
range NN N
of IN N
11 CD N
to TO N
30 CD N
h NN N
after IN N
single JJ N
dosing NN N
was VBD N
found VBN N
. . N

Infusions NNS p
of IN p
uricase NN i
were VBD i
well RB p
tolerated VBN p
in IN p
all DT p
subjects NNS p
. . p

CONCLUSION VB N
The DT N
PK/PD NNP N
model NN N
predicted VBD N
the DT p
effective JJ p
dose NN p
to TO p
be VB p
0.1 CD p
mg/kg NN p
in IN p
healthy JJ p
subjects NNS p
. . p

The DT N
excretion NN N
rate NN N
of IN N
uric JJ N
acid NN N
in IN N
urine NN N
may MD N
be VB N
used VBN N
as IN N
a DT N
new JJ N
index NN N
for IN N
pharmacological JJ N
effects NNS N
in IN N
further JJ N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
olanzapine JJ i
long-acting JJ i
injection NN i
and CC i
oral JJ i
olanzapine NN i
: : i
a DT N
2-year JJ N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
in IN N
outpatients NNS p
with IN p
schizophrenia NN o
. . o

We PRP N
compared VBN N
long-term JJ N
treatment NN N
effectiveness NN N
of IN N
monthly JJ N
olanzapine JJ i
long-acting JJ i
injection NN i
( ( i
LAI NNP i
) ) i
with IN N
that DT N
of IN N
oral JJ i
olanzapine NN i
. . i

Outpatients NNS p
with IN p
2 CD p
or CC p
more JJR p
episodes NNS p
of IN p
psychotic JJ p
worsening NN p
in IN p
the DT p
past JJ p
24 CD p
months NNS p
with IN p
Positive NNP p
and CC p
Negative NNP p
Syndrome NNP p
Scale NNP p
total JJ p
score NN p
of IN p
lower JJR p
than IN p
70 CD p
were VBD p
randomized VBN p
to TO N
405 CD N
mg/4 JJ N
weeks NNS N
of IN N
olanzapine JJ i
LAI NNP i
( ( N
n JJ N
= NNP N
264 CD N
) ) N
or CC N
10 CD N
mg/d NN N
of IN N
oral JJ i
olanzapine NN i
( ( N
n JJ N
= NNP N
260 CD N
) ) N
for IN N
2 CD N
years NNS N
of IN N
open-label JJ N
treatment NN N
. . N

Dosing VBG N
thereafter RB N
was VBD N
flexible JJ N
( ( N
150-405 JJ N
mg/4 NN N
weeks NNS N
of IN N
LAI NNP i
vs FW N
5-20 JJ N
mg/d NN N
of IN N
oral JJ N
) ) N
. . N

Primary JJ N
outcome NN N
was VBD N
time NN o
to TO o
all-cause JJ o
discontinuation NN o
. . o

At IN N
baseline NN N
, , N
patients NNS N
were VBD N
clinically RB N
stable JJ N
( ( N
mean JJ N
Positive NNP N
and CC N
Negative NNP N
Syndrome NNP N
Scale NNP N
total JJ N
score NN N
of IN N
57 CD N
) ) N
. . N

Seventeen JJ N
percent NN N
of IN N
patients NNS N
had VBD N
been VBN N
psychiatrically RB N
hospitalized VBN N
in IN N
the DT N
previous JJ N
6 CD N
months NNS N
, , N
and CC N
4.6 CD N
% NN N
were VBD N
rated VBN N
nonadherent JJ N
in IN N
the DT N
month NN N
before IN N
study NN N
entry NN N
. . N

The DT N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
median JJ N
time NN N
to TO N
all-cause JJ N
discontinuation NN N
( ( N
645 CD N
days NNS N
for IN N
LAI NNP N
, , N
678 CD N
days NNS N
for IN N
oral JJ N
; : N
P NNP N
= NNP N
0.61 CD N
) ) N
, , N
discontinuation NN N
rate NN N
( ( N
53.8 CD N
% NN N
for IN N
LAI NNP N
, , N
51.2 CD N
% NN N
for IN N
oral JJ N
; : N
P NNP N
= NNP N
0.60 CD N
) ) N
, , N
or CC N
relapse NN N
rate NN N
( ( N
20.1 CD N
% NN N
for IN N
LAI NNP i
, , N
18.5 CD N
% NN N
for IN N
oral JJ N
; : N
P NNP N
= NNP N
0.66 CD N
) ) N
. . N

Postbaseline NNP N
psychiatric JJ o
hospitalization NN N
rate NN N
was VBD N
low JJ N
for IN N
both DT N
groups NNS N
( ( N
7.6 CD N
% NN N
for IN N
LAI NNP i
, , N
9.2 CD N
% NN N
for IN N
oral JJ N
) ) N
, , N
but CC N
mean JJ N
hospitalization NN N
duration NN N
was VBD N
significantly RB N
longer JJR N
for IN N
oral JJ N
patients NNS N
( ( N
1.80 CD N
days NNS N
[ VBP N
20 CD N
for IN N
those DT N
hospitalized VBN N
] VBP N
vs JJ N
0.43 CD N
days NNS N
[ VBP N
6 CD N
for IN N
those DT N
hospitalized JJ N
] NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
clinically RB N
significant JJ N
group NN N
differences NNS N
in IN N
adverse JJ N
events NNS N
or CC N
safety NN N
measures NNS N
. . N

No DT N
post-injection JJ N
delirium/sedation NN o
syndrome NN o
events NNS N
occurred VBD N
. . N

In IN N
conclusion NN N
, , N
olanzapine JJ o
LAI NNP o
and CC N
oral JJ N
olanzapine NN o
were VBD N
similarly RB N
effective JJ o
and CC N
well RB N
tolerated VBN o
for IN N
up RB N
to TO N
2 CD N
years NNS N
of IN N
treatment NN N
in IN N
patients NNS p
with IN p
schizophrenia NN o
. . o

Treatment NNP o
discontinuation NN o
for IN N
olanzapine JJ i
LAI NNP i
was VBD N
similar JJ N
to TO N
that DT N
of IN N
oral JJ N
olanzapine NN i
, , N
despite IN N
the DT N
3-hour JJ N
post-injection NN N
observation NN N
period NN N
and CC N
other JJ N
precautionary JJ N
procedures NNS N
related VBN N
to TO N
risk NN N
of IN N
post-injection JJ N
delirium/sedation NN N
syndrome NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
amantadine NN i
and CC i
desipramine NN i
combined VBN N
with IN N
psychotherapy NN i
for IN N
treatment NN N
of IN N
cocaine NN p
dependence NN p
. . p

We PRP N
conducted VBD N
a DT N
single-blind NN N
, , N
random JJ N
assignment NN N
, , N
placebo-controlled JJ i
, , N
12-week JJ N
comparison NN N
of IN N
desipramine JJ i
hydrochloride NN i
and CC i
amantadine JJ i
hydrochloride NN i
as IN N
adjunctive JJ N
treatments NNS N
to TO N
counseling VBG N
for IN N
cocaine NN N
dependence NN N
. . N

Subjects NNS p
were VBD p
54 CD p
outpatients NNS p
who WP p
met VBD p
DSM NNP p
III-R NNP p
criteria NNS p
for IN p
active JJ p
cocaine NN p
dependence NN p
and CC p
who WP p
completed VBD p
a DT p
minimum NN p
of IN p
2 CD p
weeks NNS p
of IN p
treatment NN p
. . p

Subjects NNS N
treated VBD N
with IN N
fixed JJ N
doses NNS N
of IN N
200 CD N
mg/day JJ N
desipramine NN i
( ( N
N NNP N
= NNP N
17 CD N
) ) N
, , N
400 CD N
mg/day JJ N
amantadine-placebo JJ i
( ( N
N NNP N
= NNP N
16 CD N
) ) N
, , N
and CC N
placebo NN i
( ( N
N NNP N
= NNP N
21 CD N
) ) N
did VBD p
not RB p
differ VB p
for IN p
lifetime NN p
cocaine NN p
use NN p
, , p
lifetime JJ p
histories NNS p
of IN p
psychopathology NN p
, , p
admission NN p
scores NNS p
on IN p
psychometric JJ p
assessments NNS p
, , p
and CC p
sociodemographics NNS p
. . p

All DT N
treatment NN N
groups NNS N
demonstrated VBD N
dramatic JJ o
and CC o
persistent JJ o
decreases NNS o
in IN N
cocaine NN o
use NN o
, , o
craving VBG o
for IN o
cocaine NN o
, , o
and CC o
psychiatric JJ o
symptoms NNS o
consequent NN N
to TO N
treatment NN N
. . N

Although IN N
there EX N
was VBD N
a DT N
trend NN N
for IN N
more JJR N
dropouts NNS o
by IN N
subjects NNS N
taking VBG N
desipramine NN i
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
treatment NN N
groups NNS N
regarding VBG N
retention NN o
in IN o
treatment NN o
, , o
craving VBG o
for IN o
cocaine NN o
, , o
and CC o
decreased VBD o
cocaine NN o
use NN o
confirmed VBN N
by IN N
urine JJ o
toxicology NN o
. . o

There EX N
was VBD N
a DT N
trend NN N
for IN N
subjects NNS N
treated VBN N
with IN N
desipramine NN i
to TO N
maintain VB N
longer JJR N
periods NNS N
of IN N
cocaine NN o
abstinence NN o
. . o

Mean NNP o
plasma JJ o
concentration NN o
of IN o
desipramine NN o
in IN N
a DT N
subsample NN N
of IN N
our PRP$ N
subjects NNS N
was VBD N
less JJR N
than IN N
that DT N
recommended VBD N
for IN N
treatment NN N
of IN N
depression NN N
, , N
thus RB N
the DT N
dosage NN N
of IN N
desipramine NN i
may MD N
have VB N
been VBN N
subtherapeutic JJ N
. . N

-DOCSTART- -X- O O

Sequential JJ i
therapy NN i
versus IN i
standard JJ i
triple-drug JJ i
therapy NN i
for IN N
Helicobacter NNP N
pylori JJ N
eradication NN N
: : N
a DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
Antimicrobial NNP N
resistance NN N
has VBZ N
decreased VBN N
eradication NN N
rates NNS N
for IN N
Helicobacter NNP p
pylori JJ p
infection NN p
worldwide NN N
. . N

A DT N
sequential JJ N
treatment NN N
schedule NN N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
, , N
but CC N
studies NNS N
published VBN N
to TO N
date NN N
were VBD N
performed VBN N
in IN N
Italy NNP N
. . N

We PRP N
undertook VBD N
this DT N
study NN N
to TO N
determine VB N
whether IN N
these DT N
results NNS N
could MD N
be VB N
replicated VBN N
in IN p
India NNP p
. . p

METHODS NNP N
A NNP N
randomized JJ N
, , N
open-labeled JJ N
, , N
prospective JJ N
controlled VBN N
trial NN N
comparing VBG N
sequential JJ i
vs. FW i
standard JJ i
triple-drug JJ i
therapy NN i
was VBD N
carried VBN N
out RP N
at IN p
Lokmanya NNP p
Tilak NNP p
Municipal NNP p
General NNP p
Hospital NNP p
, , p
Mumbai NNP p
. . p

Two CD p
hundred CD p
and CC p
thirty-one JJ p
patients NNS p
with IN p
dyspepsia NNS p
were VBD N
randomized VBN N
to TO N
a DT N
10-day JJ i
sequential JJ i
regimen NNS i
( ( i
40 CD i
mg NN i
of IN i
pantoprazole NN i
, , i
1 CD i
g NN i
of IN i
amoxicillin NN i
, , i
each DT i
administered VBN i
twice RB i
daily RB i
for IN i
the DT i
first JJ i
5 CD i
days NNS i
, , i
followed VBN i
by IN i
40 CD i
mg NNS i
of IN i
pantoprazole NN i
, , i
500 CD i
mg NN i
of IN i
clarithromycin NN i
, , i
and CC i
500 CD i
mg NN i
of IN i
tinidazole NN i
, , i
each DT i
administered VBN i
twice RB i
daily RB i
for IN i
the DT i
remaining VBG i
5 CD i
days NNS i
) ) i
or CC i
to TO i
standard VB i
14-day JJ i
therapy NN i
( ( i
40 CD i
mg NN i
of IN i
pantoprazole NN i
, , i
500 CD i
mg NN i
of IN i
clarithromycin NN i
, , i
and CC i
1 CD i
g NN i
of IN i
amoxicillin NN i
, , i
each DT i
administered VBN i
twice RB i
daily RB i
) ) i
. . i

RESULTS VB N
The DT N
eradication NN o
rate NN o
achieved VBN N
with IN N
the DT N
sequential JJ i
regimen NN i
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
obtained VBN N
with IN N
the DT N
triple JJ i
therapy NN i
. . i

Per-protocol JJ o
eradication NN o
rate NN o
of IN N
sequential JJ i
therapy NN i
was VBD N
92.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
85.8-96.1 CD N
% NN N
) ) N
vs. FW N
81.8 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
73.9-87.8 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.027 CD N
) ) N
for IN N
standard JJ i
drug NN i
therapy NN o
. . o

Intention-to-treat JJ o
eradication NN o
rates NNS o
were VBD o
88.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
80.9-93.0 CD N
% NN N
) ) N
vs. FW N
79.1 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
71.1-85.4 CD N
% NN N
) ) N
, , N
p JJ N
= NN N
0.029 CD N
, , N
respectively RB o
. . o

The DT o
incidence NN o
of IN o
major JJ o
and CC o
minor JJ o
side NN o
effects NNS o
between IN N
therapy NN N
groups NNS N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
14.6 CD N
% NN N
in IN N
the DT N
triple JJ N
therapy NN N
group NN N
vs. FW N
23.5 CD N
% NN N
in IN N
sequential JJ N
group NN N
, , N
p VBP N
= RB N
0.12 CD N
) ) N
. . N

Follow NNP N
up RP N
was VBD N
incomplete JJ N
in IN N
3.3 CD N
% NN N
and CC N
4.7 CD N
% NN N
patients NNS N
in IN N
standard JJ i
and CC i
sequential JJ i
therapy NN i
groups NNS i
, , N
respectively RB N
. . i

Sequential JJ i
therapy NN i
includes VBZ i
one CD N
additional JJ N
antibiotic NN N
( ( N
tinidazole NN i
) ) N
that WDT N
is VBZ N
not RB N
contained VBN N
in IN N
standard JJ i
therapy NN i
. . i

CONCLUSIONS NNP i
Sequential NNP i
therapy NN i
was VBD i
significantly RB N
better JJR N
than IN N
standard JJ i
therapy NN i
for IN i
eradicating VBG o
H. NNP o
pylori JJ o
infection NN o
. . o

-DOCSTART- -X- O O

Risperidone NNP i
versus NN i
haloperidol NN i
in IN p
children NNS p
and CC p
adolescents NNS p
with IN p
AD NNP p
: : N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
double-blind JJ N
trial NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
safety NN o
, , o
efficacy NN o
and CC o
tolerability NN o
of IN N
risperidone NN i
with IN i
haloperidol NN i
in IN N
the DT N
treatment NN N
of IN N
Autistic JJ p
Disorder NNP p
( ( p
AD NNP p
) ) p
. . N

METHOD NNP N
This DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
double-blind NN N
, , N
prospective JJ N
, , N
for IN N
a DT N
12-week JJ N
period NN N
. . N

A DT p
total NN p
of IN p
30 CD p
subjects NNS p
, , p
between IN p
the DT p
ages NNS p
of IN p
8 CD p
and CC p
18 CD p
with IN p
AD NNP p
based VBN p
on IN p
DSM NNP p
IV NNP p
criteria NNS p
, , p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Behavioral NNP o
Rating VBG o
Scales NNS o
were VBD N
performed VBN N
by IN N
the DT N
investigators NNS N
and CC N
the DT N
parents NNS N
. . N

Safety NNP o
assessment NN o
included VBD N
vital JJ o
signs NNS o
, , o
electrocardiogram NN o
, , o
electroencephalogram NN o
, , o
adverse JJ o
events NNS o
, , o
laboratory NN o
tests NNS o
, , o
extrapyramidal NN o
symptoms NNS o
and CC o
the DT o
side NN o
effects NNS o
. . o

Both DT N
treatments NNS N
were VBD N
applied VBN N
in IN N
a DT N
once RB N
daily JJ N
dosage NN N
regimen NNS N
of IN N
0.01-0.08 JJ N
mg/kg/day NN N
. . N

RESULTS VB N
The DT N
reduction NN N
from IN N
baseline NN N
in IN N
Ritvo-Freeman NNP o
Real NNP o
Life NNP o
Rating NNP o
Scale NNP o
( ( o
RF-RLRS NNP o
) ) o
, , o
sensory JJ o
motor NN o
( ( o
subscale JJ o
I PRP o
) ) o
and CC o
language NN o
( ( o
subscale JJ o
V NNP o
) ) o
scores NNS o
were VBD N
significant JJ N
in IN N
risperidone NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Compared VBN N
to TO N
haloperidol VB N
, , N
risperidone NN N
led VBD N
to TO N
a DT N
significantly RB N
greater JJR N
reduction NN N
in IN N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
and CC o
Turgay NNP o
DSM-IV NNP o
Pervasive NNP o
Developmental NNP o
Disorder NNP o
( ( o
PDD NNP o
) ) o
scale NN o
scores NNS o
( ( N
P NNP N
< NNP N
0.05 CD N
and CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
greater JJR N
increase NN N
of IN N
prolactin NN o
in IN N
the DT N
risperidone NN N
group NN N
, , N
while IN N
alanine JJ o
amino NN o
transferase NN o
( ( o
ALT NNP o
) ) o
had VBD N
further RBR N
increased VBN N
in IN N
the DT N
haloperidol NN N
group NN N
. . N

Sensory NNP o
motor NN o
behaviors NNS o
( ( o
subscale JJ o
I PRP o
) ) o
and CC N
language NN o
at IN N
the DT N
end NN N
of IN N
the DT N
12th CD N
week NN N
, , N
RF-RLRS NNP o
sensory NN o
motor NN o
and CC o
language NN o
subscale JJ o
scores NNS o
decreased VBN N
in IN N
the DT N
risperidone NN N
group NN N
further RBR N
than IN N
the DT N
other JJ N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Risperidone NNP N
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
haloperidol NN N
in IN N
the DT N
treatment NN N
of IN N
behavioral JJ o
symptoms NNS o
, , o
impulsivity NN o
, , o
language NN o
skills NNS o
, , N
and CC N
impaired JJ o
social JJ o
relations NNS o
in IN N
children NNS p
with IN p
AD NNP p
. . p

These DT N
results NNS N
demonstrated VBD N
that IN N
both DT N
drugs NNS N
were VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
AD NNP N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
a DT N
5 CD N
day NN N
regimen NNS N
of IN N
cefdinir NN i
with IN N
a DT N
10 CD N
day NN N
regimen NNS N
of IN N
cefprozil NN i
for IN N
treatment NN N
of IN N
acute JJ o
exacerbations NNS o
of IN o
chronic JJ o
bronchitis NN o
. . o

Patients NNS p
with IN p
acute JJ p
exacerbations NNS p
of IN p
chronic JJ p
bronchitis NN p
were VBD N
treated VBN N
with IN N
cefdinir NN i
300 CD N
mg NN N
bd NN N
for IN N
5 CD N
days NNS N
or CC N
cefprozil JJ i
500 CD N
mg NN N
bd NN N
for IN N
10 CD N
days NNS N
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
multicentre JJ N
study NN N
. . N

Of IN N
the DT N
548 CD p
patients NNS p
enrolled VBD p
, , p
281 CD p
( ( p
51 CD p
% NN p
) ) p
were VBD p
evaluable JJ p
. . p

The DT N
clinical JJ o
cure NN o
rates NNS o
at IN N
the DT N
test-of-cure JJ N
visit NN N
were VBD N
80 CD N
% NN N
( ( N
114/142 CD N
) ) N
and CC N
72 CD N
% NN N
( ( N
100/139 CD N
) ) N
for IN N
the DT N
evaluable JJ p
patients NNS p
treated VBN p
with IN p
cefdinir NN i
and CC i
cefprozil NN i
, , N
respectively RB N
. . N

Respiratory NNP o
tract JJ o
pathogens NNS o
were VBD N
isolated VBN N
from IN N
409 CD N
( ( N
75 CD N
% NN N
) ) N
of IN N
548 CD N
admission NN N
sputum NN N
specimens NNS N
, , N
with IN N
the DT N
predominant NN N
pathogens VBZ N
being VBG N
Haemophilus NNP N
parainfluenzae NN N
, , N
Haemophilus NNP N
influenzae NN N
, , N
Staphylococcus NNP N
aureus NN N
and CC N
Moraxella NNP N
catarrhalis NN N
. . N

The DT N
microbiological JJ o
eradication NN o
rates NNS o
at IN N
the DT N
test-of-cure JJ N
visit NN N
were VBD N
81 CD N
% NN N
( ( N
157 CD N
of IN N
193 CD N
pathogens NNS N
) ) N
and CC N
84 CD N
% NN N
( ( N
166 CD N
of IN N
198 CD N
pathogens NNS N
) ) N
for IN N
the DT N
evaluable JJ N
patients NNS N
treated VBN N
with IN N
cefdinir NN i
and CC N
cefprozil NN i
, , N
respectively RB N
. . N

Adverse JJ o
event NN o
rates NNS o
while IN N
on IN N
treatment NN N
were VBD N
equivalent JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

The DT N
incidence NN o
of IN o
diarrhoea NN o
during IN N
therapy NN N
was VBD N
higher JJR N
for IN N
patients NNS p
treated VBN p
with IN p
cefdinir NN i
( ( p
17 CD p
% NN p
) ) p
than IN p
for IN p
patients NNS p
treated VBN p
with IN p
cefprozil NN i
( ( p
6 CD p
% NN p
) ) p
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
most JJS N
cases NNS N
were VBD N
mild JJ N
and CC N
did VBD N
not RB N
lead VB N
to TO N
discontinuation NN N
of IN N
treatment NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
a DT N
5 CD N
day NN N
regimen NNS N
of IN N
cefdinir NN i
is VBZ N
as IN N
effective JJ o
and CC o
safe JJ o
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN N
acute JJ o
exacerbations NNS o
of IN o
chronic JJ o
bronchitis NN o
as IN N
a DT N
10 CD N
day NN N
regimen NNS N
of IN N
cefprozil NN i
. . i

-DOCSTART- -X- O O

Randomised VBN N
trial NN N
comparing VBG N
the DT N
recording VBG N
ability NN N
of IN N
a DT N
novel NN i
, , i
electronic JJ i
emergency NN i
documentation NN i
system NN i
with IN N
the DT N
AHA NNP i
paper NN i
cardiac NN i
arrest NN i
record NN i
. . i

OBJECTIVE UH N
To TO N
evaluate VB o
the DT o
ability NN o
of IN N
an DT N
electronic JJ i
system NN i
created VBD N
at IN N
the DT N
University NNP N
of IN N
Washington NNP N
to TO N
accurately RB N
document VB N
prerecorded JJ N
VF NNP N
and CC N
pulseless JJ N
electrical JJ N
activity NN N
( ( N
PEA NNP N
) ) N
cardiac VBP N
arrest JJS N
scenarios NNS N
compared VBN N
with IN N
the DT N
American NNP N
Heart NNP N
Association NNP N
paper NN N
cardiac NN N
arrest NN N
record NN N
. . N

METHODS NNP N
16 CD p
anaesthesiology NN p
residents NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
view VB N
one CD N
of IN N
two CD N
prerecorded VBD N
, , N
simulated VBD i
VF NNP i
and CC i
PEA NNP i
scenarios NNS i
and CC N
asked VBD N
to TO N
document VB N
the DT N
event NN N
with IN N
either CC N
the DT N
paper NN i
or CC i
electronic JJ i
system NN i
. . i

Each DT N
subject NN N
then RB N
repeated VBD N
the DT N
process NN N
with IN N
the DT N
other JJ N
video NN N
and CC N
documentation NN N
method NN N
. . N

Five CD N
types NNS N
of IN N
documentation NN N
errors NNS N
were VBD N
defined VBN N
: : N
( ( o
1 CD o
) ) o
omission NN o
, , o
( ( o
2 CD o
) ) o
specification NN o
, , o
( ( o
3 CD o
) ) o
timing NN o
, , o
( ( o
4 CD o
) ) o
commission NN o
and CC o
( ( o
5 CD o
) ) o
noise NN o
. . o

The DT N
mean JJ N
difference NN N
in IN N
errors NNS N
between IN N
the DT N
paper NN o
and CC o
electronic JJ o
methods NNS o
was VBD o
analysed VBN o
using VBG N
a DT N
single JJ N
factor NN N
repeated VBD o
measures NNS o
ANOVA NNP o
model NN o
. . N

RESULTS NNP N
Compared VBD N
with IN N
paper NN N
records NNS N
, , N
the DT N
electronic JJ N
system NN N
omitted VBD N
6.3 CD N
fewer JJR N
events NNS N
( ( N
95 CD N
% NN N
CI NNP N
-10.1 NNP N
to TO N
-2.5 VB N
, , N
p=0.003 NN N
) ) N
, , N
which WDT N
represents VBZ N
a DT N
28 CD N
% NN N
reduction NN N
in IN N
omission NN N
errors NNS N
. . N

Users NNS N
recorded VBD N
2.9 CD N
fewer JJR N
noise NN N
items NNS N
( ( N
95 CD N
% NN N
CI NNP N
-5.3 NNP N
to TO N
-0.6 VB N
, , N
p=0.003 NN N
) ) N
when WRB N
compared VBN N
with IN N
paper NN i
, , N
representing VBG N
a DT N
36 CD N
% NN N
decrease NN N
in IN N
redundant NN N
or CC N
irrelevant JJ N
information NN N
. . N

The DT N
rate NN o
of IN o
timing NN o
( ( N
?=-3.2 JJ N
, , N
95 CD N
% NN N
CI NNP N
-9.3 NNP N
to TO N
3.0 CD N
, , N
p=0.286 NN N
) ) N
and CC o
commission NN o
( ( N
?=-4.4 JJ N
, , N
95 CD N
% NN N
CI NNP N
-9.4 NNP N
to TO N
0.5 CD N
, , N
p=0.075 NN N
) ) N
errors NNS N
were VBD N
similar JJ N
between IN N
the DT i
electronic JJ i
system NN i
and CC i
paper NN i
, , i
while IN N
the DT N
rate NN N
of IN N
specification NN N
errors NNS N
were VBD N
about IN N
a DT N
third JJ N
lower JJR N
for IN N
the DT N
electronic JJ N
system NN N
when WRB N
compared VBN N
with IN N
the DT N
paper NN N
record NN N
( ( N
?=-3.2 JJ N
, , N
95 CD N
% NN N
CI NNP N
-6.3 NNP N
to TO N
-0.2 VB N
, , N
p=0.037 NN N
) ) N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN i
paper NN i
documentation NN i
, , i
documentation NN i
with IN i
the DT i
electronic JJ i
system NN i
captured VBD i
24 CD N
% NN N
more JJR N
critical JJ N
information NN N
during IN N
a DT N
simulated JJ N
medical JJ N
emergency NN N
without IN N
loss NN N
in IN N
data NNS N
quality NN N
. . N

-DOCSTART- -X- O O

Two CD N
different JJ N
methods NNS N
for IN N
donor JJ p
hepatic JJ p
transection NN p
: : p
cavitron NN i
ultrasonic JJ i
surgical JJ i
aspirator NN i
with IN i
bipolar JJ i
cautery NN i
versus NN N
cavitron NN i
ultrasonic JJ i
surgical JJ i
aspirator NN i
with IN i
radiofrequency NN i
coagulator-A JJ i
randomized VBN N
controlled JJ N
trial NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
Cavitron NNP i
ultrasonic JJ i
surgical JJ i
aspirator NN i
( ( i
CUSA NNP i
) ) i
with IN i
bipolar JJ i
cautery NN i
( ( i
BP NNP i
) ) i
to TO i
CUSA NNP i
with IN i
a DT i
radiofrequency NN i
coagulator NN i
[ NN N
TissueLink NNP N
( ( N
TL NNP N
) ) N
] VBP N
in IN N
terms NNS N
of IN N
efficacy NN N
and CC N
safety NN N
for IN N
hepatic JJ N
transection NN N
in IN N
living VBG N
donor NN N
liver JJ N
transplantation NN N
. . N

Twenty-four CD p
living NN p
liver NN p
donors NNS p
( ( p
n JJ p
= VBP p
12 CD p
for IN p
each DT p
group NN p
) ) p
were VBD N
randomized VBN N
to TO N
undergo VB N
hepatic JJ N
transection NN N
using VBG N
CUSA NNP i
with IN i
BP NNP i
or CC N
CUSA NNP i
with IN i
TL NNP i
. . i

Blood NNP o
loss NN o
during IN o
parenchymal JJ o
transection NN o
and CC o
speed NN o
of IN o
transection NN o
were VBD N
the DT N
primary JJ N
endpoints NNS N
, , N
whereas IN N
the DT N
degree NN o
of IN o
postoperative JJ o
liver JJ o
injury NN o
and CC o
morbidity NN o
were VBD N
secondary JJ N
endpoints NNS N
. . N

Median JJ o
blood NN o
loss NN o
during IN o
liver JJ o
transection NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
TL NNP N
group NN N
than IN N
in IN N
the DT N
BP NNP N
group NN N
( ( N
195.2 CD N
+/- JJ N
84.5 CD N
versus NN N
343.3 CD N
+/- JJ N
198.4 CD N
mL NN N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
, , N
and CC N
liver JJS o
transection NN o
was VBD N
significantly RB N
faster RBR N
in IN N
the DT N
TL NNP N
group NN N
than IN N
in IN N
the DT N
BP NNP N
group NN N
( ( N
0.7 CD N
+/- JJ N
0.2 CD N
versus NN N
0.5 CD N
+/- JJ N
0.2 CD N
cm NN N
( ( N
2 CD N
) ) N
/minute NN N
; : N
P NNP N
= NNP N
0.048 CD N
) ) N
. . N

Significantly RB N
fewer JJR o
ties NNS o
were VBD N
required VBN N
during IN N
liver JJ N
transection NN N
in IN N
the DT N
TL NNP N
group NN N
than IN N
in IN N
the DT N
BP NNP N
group NN N
( ( N
15.8 CD N
+/- JJ N
4.8 CD N
versus NN N
22.8 CD N
+/- JJ N
7.9 CD N
ties NNS N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
. . N

The DT N
morbidity NN o
rates NNS o
were VBD N
similar JJ N
for IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
CUSA NNP N
with IN N
TL NNP N
is VBZ N
superior JJ N
to TO N
CUSA NNP N
with IN N
BP NNP N
for IN N
donor JJ N
hepatectomy NN N
in IN N
terms NNS N
of IN N
blood NN o
loss NN o
and CC o
speed NN o
of IN o
transection NN o
with IN o
no DT o
increase NN o
in IN o
morbidity NN o
. . o

-DOCSTART- -X- O O

Effect NNP N
of IN N
four CD i
intermediate JJ i
layer NN i
treatments NNS i
on IN N
microleakage NN p
of IN p
Class NNP p
II NNP p
composite JJ p
restorations NNS p
. . p

This DT N
in IN N
vitro NN N
study NN N
examines VBZ N
the DT N
marginal JJ N
sealing NN N
ability NN N
of IN N
four CD i
different JJ i
intermediate JJ i
materials NNS i
applied VBN N
before IN N
placement NN N
of IN N
a DT N
condensable JJ i
composite NN i
. . i

Class NNP p
II NNP p
preparations NNS p
were VBD N
made VBN N
with IN N
gingival JJ N
margins NNS N
placed VBD N
1.0 CD N
mm JJ N
apical JJ N
to TO N
the DT N
cementoenamel JJ N
junction NN N
of IN N
60 CD p
extracted JJ p
teeth NNS p
, , N
randomly RB N
assigned VBN N
to TO N
five CD p
groups NNS p
of IN p
12 CD p
. . p

Following VBG N
restoration NN N
, , N
teeth EX N
were VBD N
thermocycled VBN N
, , N
soaked VBN N
in IN N
0.5 CD N
% NN N
basic JJ N
fuchsin NN i
, , N
and CC N
sectioned VBD N
longitudinally RB N
. . N

The DT N
resin-modified JJ i
glass NN i
ionomer NN i
cement NN i
demonstrated VBD N
significantly RB N
less JJR o
microleakage NN o
than IN N
the DT N
use NN N
of IN N
a DT N
dentin NN i
bonding NN i
agent NN i
alone RB i
or CC N
in IN N
combination NN i
with IN i
flowable JJ i
composite JJ i
, , N
flowable JJ N
compomer NN N
, , N
or CC N
autoploymerizing VBG N
composite JJ N
( ( N
p JJ N
< NN N
0.05 CD N
, , N
Dunn NNP N
's POS N
test NN N
) ) N
. . N

This DT N
study NN N
supports VBZ N
the DT N
use NN N
of IN N
the DT N
glass NN i
ionomer NN i
open JJ i
sandwich NN i
technique NN i
in IN N
deep JJ p
Class NNP p
II NNP p
direct JJ p
composite JJ p
restorations NNS p
. . p

-DOCSTART- -X- O O

Comparison NNP N
of IN N
single- JJ i
and CC i
dual-coil JJ i
active JJ i
pectoral JJ i
defibrillation NN i
lead NN i
systems NNS i
. . i

OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
defibrillation NN N
thresholds NNS N
with IN N
lead JJ N
systems NNS N
consisting VBG N
of IN N
an DT N
active JJ N
left JJ N
pectoral JJ N
electrode NN N
and CC N
either DT N
single JJ i
or CC N
dual JJ i
transvenous JJ i
coils NNS i
. . i

BACKGROUND NNP N
Lead NNP N
systems NNS N
that WDT N
include VBP N
an DT N
active JJ N
pectoral JJ N
pulse NN N
generator NN N
reduce VB N
defibrillation NN N
thresholds NNS N
and CC N
permit VBP N
transvenous JJ N
defibrillation NN N
in IN N
nearly RB N
all DT N
patients NNS N
. . N

A DT N
further JJ N
improvement NN N
in IN N
defibrillation NN o
efficacy NN o
is VBZ N
desirable JJ N
to TO N
allow VB N
for IN N
smaller JJR N
pulse NN N
generators NNS N
with IN N
a DT N
reduced VBN N
maximal NN N
output NN N
. . N

METHODS NNP N
This DT N
prospective JJ N
study NN N
was VBD N
performed VBN N
in IN N
50 CD p
consecutive JJ p
patients NNS p
. . p

Each DT p
patient NN p
was VBD N
evaluated VBN N
with IN N
two CD N
lead JJ i
configurations NNS i
with IN N
the DT N
order NN N
of IN N
testing VBG N
randomized VBN N
. . N

Shocks NNS N
were VBD N
delivered VBN N
between IN N
the DT N
right JJ N
ventricular NN N
coil NN N
and CC N
either DT N
an DT N
active JJ N
can MD N
alone RB N
( ( i
single JJ i
coil NN i
) ) i
or CC N
an DT N
active JJ N
can MD N
with IN N
the DT N
proximal JJ N
atrial JJ N
coil NN N
( ( i
dual JJ i
coil NN i
) ) i
. . N

The DT N
right JJ N
ventricular NN N
coil NN N
was VBD N
the DT N
cathode NN N
for IN N
the DT N
first JJ N
phase NN N
of IN N
the DT N
biphasic JJ N
defibrillation NN N
waveform NN N
. . N

RESULTS NNP N
Delivered NNP o
energy NN o
at IN N
the DT N
defibrillation NN o
threshold NN o
was VBD N
10.1+/-5.0 JJ N
J NNP N
for IN N
the DT N
single-coil JJ i
configuration NN N
and CC N
8.7+/-4.0 JJ N
J NNP N
for IN N
the DT N
dual-coil JJ i
configuration NN N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

Moreover RB N
, , N
98 CD p
% NN p
of IN p
patients NNS p
had VBD p
low JJ p
( ( p
< JJ p
15 CD p
J NNP p
) ) p
thresholds VBZ o
with IN N
the DT N
dual-coil JJ i
lead NN p
system NN p
, , N
compared VBN N
with IN N
88 CD p
% NN p
of IN p
patients NNS p
with IN p
the DT p
single-coil JJ i
configuration NN p
( ( N
p=0.05 NN N
) ) N
. . N

Leading VBG o
edge NN o
voltage NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
shock NN o
impedance NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
were VBD N
also RB N
decreased VBN N
with IN N
the DT N
dual-coil NN i
configuration NN N
, , N
although IN N
peak JJ o
current JJ o
was VBD N
increased VBN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS VB N
A DT N
dual-coil NN i
, , N
active JJ N
pectoral JJ N
lead NN N
system NN N
reduces VBZ N
defibrillation NN o
energy NN o
requirements NNS o
compared VBN N
with IN N
a DT N
single-coil NN i
, , N
unipolar JJ N
configuration NN N
. . N

-DOCSTART- -X- O O

Does VBZ N
an DT N
in-season JJ i
detraining NN i
period NN N
affect VBP N
the DT N
shoulder NN N
rotator NN N
cuff NN N
strength NN N
and CC N
balance NN N
of IN N
young JJ p
swimmers NNS p
? . N
Imbalance NN N
in IN N
shoulder NN N
rotator NN N
muscles NNS N
is VBZ N
a DT N
well-documented JJ N
problem NN N
in IN N
swimmers NNS p
, , N
and CC N
it PRP N
is VBZ N
important JJ N
to TO N
implement VB N
land-based JJ N
strength NN N
training NN N
programs NNS N
. . N

Meanwhile RB N
, , N
the DT N
effects NNS N
of IN N
a DT N
detraining JJ N
period NN N
on IN N
swimmers NNS N
' POS N
shoulder NN N
rotator NN N
muscles NNS N
are VBP N
unknown JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyze VB N
the DT N
effects NNS N
of IN N
a DT N
strength NN i
training NN i
program NN i
and CC i
detraining VBG i
on IN N
the DT N
strength NN N
and CC N
balance NN N
of IN N
shoulder NN N
rotator NN N
cuff NN N
muscles NNS N
in IN N
young JJ p
swimmers NNS p
, , N
despite IN N
the DT N
continuity NN N
of IN N
usual JJ N
water NN N
training NN N
. . N

An DT p
experimental JJ p
group NN p
( ( p
n JJ p
= NNP p
20 CD p
) ) p
and CC p
a DT p
control NN p
group NN p
( ( p
n JJ p
= NNP p
20 CD p
) ) p
of IN p
young JJ p
male NN p
swimmers NNS p
with IN p
the DT p
same JJ p
characteristics NNS p
( ( p
age NN p
, , p
body NN p
mass NN p
, , p
height NN p
, , p
training NN p
volume NN p
, , p
and CC p
maturational JJ p
state NN p
) ) p
were VBD p
evaluated VBN p
. . p

In IN N
both DT N
groups NNS N
, , N
the DT N
peak NN o
torques NNS o
of IN o
shoulder NN o
internal JJ o
( ( o
IR NNP o
) ) o
and CC o
external JJ o
( ( o
ER NNP o
) ) o
rotators NNS o
were VBD N
assessed VBN N
during IN N
preseason NN N
, , N
midseason NN N
( ( N
16 CD N
weeks NNS N
) ) N
, , N
and CC N
postseason NN N
( ( N
32 CD N
weeks NNS N
) ) N
. . N

The DT N
experimental JJ N
group NN N
underwent VBD N
a DT N
strength NN i
training VBG i
regimen NNS i
from IN N
baseline NN N
to TO N
16 CD N
weeks NNS N
and CC N
a DT N
detraining JJ i
period NN N
from IN N
16 CD N
to TO N
32 CD N
weeks NNS N
. . N

Concentric JJ N
action NN N
at IN N
60??s-1 JJ N
and CC N
180??s-1 JJ N
was VBD N
measured VBN N
using VBG N
an DT N
isokinetic JJ N
dynamometer NN N
. . N

The DT N
ER/IR NNP o
strength NN o
ratios NNS o
were VBD o
obtained VBN N
. . N

At IN N
60??s-1 JJ N
, , N
there EX N
were VBD N
significant JJ o
increments NNS o
in IN o
IR NNP o
strength NN o
and CC o
the DT o
ER/IR NNP o
ratio NN o
in IN N
both DT N
shoulders NNS N
. . N

This DT N
trend NN N
was VBD N
the DT N
same JJ N
throughout IN N
the DT N
competitive JJ N
season NN N
. . N

The DT N
tendency NN N
was VBD N
the DT N
same JJ N
at IN N
180??s-1 JJ N
because IN N
training VBG N
effects NNS N
were VBD N
noted VBN N
primarily RB o
in IN o
IR NNP o
and CC o
ER/IR NNP o
ratios NNS o
. . o

Moreover RB N
, , N
the DT N
absence NN N
of IN N
land-based JJ N
strength NN N
training NN N
, , N
from IN N
16 CD N
to TO N
32 CD N
weeks NNS N
, , N
revealed VBD N
a DT o
reduction NN o
in IN o
the DT o
ER/IR NNP o
ratio NN o
values NNS o
in IN N
both DT N
shoulders NNS N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
young JJ N
swimmers NNS N
' POS N
coaches NNS N
should MD N
use VB i
dry-land JJ i
strength NN i
training NN i
protocols NNS i
, , i
and CC i
that IN i
it PRP N
is VBZ N
recommended VBN N
that IN N
these DT N
should MD N
be VB N
conducted VBN N
on IN N
a DT N
regular JJ N
basis NN N
( ( N
during IN N
the DT N
whole JJ N
season NN N
) ) N
. . N

-DOCSTART- -X- O O

A DT N
single JJ N
infusion NN N
of IN N
intravenous JJ N
ketamine NN i
improves VBZ N
pain VBP N
relief NN N
in IN N
patients NNS p
with IN p
critical JJ p
limb NN p
ischaemia NN p
: : p
results NNS N
of IN N
a DT N
double JJ N
blind NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

We PRP N
report VBP N
the DT N
first JJ N
double JJ N
blind NN N
randomised VBD N
controlled JJ N
trial NN N
of IN N
regular JJ N
opioids NNS i
and CC N
an DT N
infusion NN N
of IN N
low JJ N
dose NN N
( ( N
0.6 CD N
mg/kg NN N
) ) N
intravenous JJ N
ketamine NN i
compared VBN N
with IN N
opioids NNS i
and CC N
placebo NN i
in IN N
patients NNS p
with IN p
allodynia NN p
, , p
hyperalgesia NN p
and CC p
hyperpathia NN p
secondary JJ p
to TO p
critical JJ p
limb NN p
ischaemia NN p
. . p

Thirty-five JJ p
patients NNS p
completed VBD p
the DT p
study NN p
, , p
18 CD p
received VBD N
regular JJ N
opioids NNS i
plus CC i
ketamine NN i
, , N
while IN N
17 CD p
received VBD N
regular JJ i
opioids NNS i
plus CC i
placebo NN i
. . i

Using VBG N
the DT N
Brief NNP o
Pain NNP o
Inventory NNP o
, , o
the DT o
% NN o
pain NN o
relief NN o
that IN N
the DT N
patients NNS N
in IN N
the DT N
ketamine NN N
group NN N
attributed VBD N
to TO N
their PRP$ N
medication NN N
improved VBN N
significantly RB N
from IN N
50 CD N
% NN N
immediately RB N
pre-infusion NN N
to TO N
65 CD N
% NN N
24 CD N
h JJ N
post-infusion NN N
and CC N
69 CD N
% NN N
5 CD N
days NNS N
post VBN N
infusion NN N
. . N

Over IN N
the DT N
same JJ N
period NN N
, , N
the DT N
pain NN o
relief NN o
achieved VBN o
by IN N
the DT N
placebo NN N
group NN N
rose VBD N
from IN N
58 CD N
% NN N
pre-infusion NN N
to TO N
56 CD N
% NN N
24 CD N
h NN N
post NN N
infusion NN N
and CC N
then RB N
50 CD N
% NN N
relief NN N
5 CD N
days NNS N
later RB N
. . N

This DT N
was VBD N
statistically RB o
significant JJ o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
using VBG N
both DT N
the DT N
t-test NN o
and CC o
the DT o
Wilcoxon NNP o
Rank NNP o
Sum NNP o
test NN o
. . o

The DT N
ketamine NN N
group NN N
also RB N
showed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
24 CD N
h NN N
post NN N
infusion NN N
of IN N
the DT N
effect NN N
of IN N
pain NN o
on IN N
their PRP$ N
general JJ N
activity NN N
( ( N
P=0.03 NNP N
) ) N
and CC N
on IN N
their PRP$ N
enjoyment NN N
of IN N
life NN N
( ( N
P=0.004 NNP N
) ) N
. . N

This DT N
study NN N
shows VBZ N
that IN N
combining VBG N
a DT N
single JJ N
infusion NN N
of IN N
low JJ N
dose JJ N
ketamine NN N
with IN N
regular JJ N
opioid JJ i
analgesia NN i
can MD N
result VB N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
pain NN o
relief NN o
for IN N
this DT N
patient NN N
group NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
human JJ N
papillomavirus NN N
testing NN N
of IN N
clinician-collected JJ i
and CC i
self-collected JJ i
samples NNS i
during IN N
follow-up JJ N
after IN N
screen-and-treat NN N
. . N

Screen-and-treat JJ N
cervical JJ N
cancer NN N
prevention NN N
programs NNS N
based VBN N
on IN N
high-risk JJ N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
testing NN N
and CC N
cryotherapy NN N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
resource-limited JJ N
settings NNS N
. . N

However RB N
, , N
because IN N
cryotherapy NN N
is VBZ N
not RB N
100 CD N
% NN N
effective JJ N
, , N
follow-up JJ N
is VBZ N
needed VBN N
after IN N
treatment NN N
to TO N
detect VB N
post-treatment JJ N
failures NNS N
. . N

We PRP N
compared VBN N
the DT N
test NN N
performances NNS N
of IN N
high-risk JJ N
HPV NNP N
testing NN N
( ( N
Hybrid JJ N
Capture NNP N
2 CD N
) ) N
using VBG N
self-collected JJ i
and CC i
clinician-collected JJ i
samples NNS i
as RB N
well RB N
as IN N
cervical JJ i
cytology NN i
for IN N
identifying VBG N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
grades NNS N
2 CD N
or CC N
3 CD N
or CC N
invasive JJ N
cervical JJ N
cancer NN N
( ( N
CIN2+ NNP N
) ) N
among IN p
women NNS p
who WP p
did VBD p
( ( p
n=812 NN p
) ) p
and CC p
did VBD p
not RB p
( ( p
n=1858 JJ p
) ) p
undergo VBP p
cryotherapy NN p
in IN p
a DT p
South JJ p
African JJ p
screen-and-treat JJ p
trial NN p
. . p

At IN N
6 CD N
months NNS N
after IN N
enrolment NN N
( ( N
and CC N
after IN N
cryotherapy NN i
, , N
if IN N
performed VBN N
) ) N
, , N
women NNS N
were VBD N
tested VBN N
using VBG N
all DT N
three CD N
screening VBG N
methods NNS N
and CC N
then RB N
underwent JJ N
colposcopy/biopsy NN i
. . N

A DT N
predefined JJ N
subset NN N
of IN N
women NNS N
( ( N
n=1,455 NN N
) ) N
had VBD N
extended VBN N
follow-up NN N
with IN N
colposcopy/biopsy NN i
at IN N
12 CD N
months NNS N
. . N

A DT N
total NN N
of IN N
33 CD N
and CC N
91 CD N
cases NNS N
of IN N
CIN2+ NNP N
were VBD N
detected VBN N
among IN N
treated JJ N
and CC N
untreated JJ N
women NNS N
, , N
respectively RB N
. . N

The DT N
sensitivity NN o
of IN o
HPV NNP o
testing VBG o
using VBG N
clinician-collected JJ i
samples NNS i
and CC N
cervical JJ N
cytology NN N
did VBD N
not RB N
differ VB N
by IN N
treatment NN N
status NN N
. . N

HPV NNP N
testing VBG N
of IN N
clinician-collected JJ i
samples NNS i
detected VBN N
the DT N
most RBS N
cases NNS N
of IN N
CIN2+ NNP o
among IN N
both DT N
treated VBN N
( ( N
85 CD N
% NN N
) ) N
and CC N
untreated JJ N
( ( N
91 CD N
% NN N
) ) N
women NNS N
( ( N
p=0.31 NN N
) ) N
. . N

Cytology NNP o
( ( N
at IN N
a DT N
cutoff NN N
of IN N
atypical JJ N
squamous JJ N
cells NNS N
of IN N
undetermined JJ N
significance NN N
or CC N
greater JJR N
) ) N
detected VBD N
76 CD N
% NN N
of IN N
cases NNS N
among IN N
both DT N
treated VBN N
and CC N
untreated JJ N
women NNS N
. . N

However RB N
, , N
the DT N
sensitivity NN o
of IN o
HPV NNP o
testing VBG o
using VBG N
self-collected JJ i
samples NNS i
was VBD N
significantly RB N
lower JJR N
among IN N
treated JJ N
versus NN N
untreated JJ N
women NNS N
( ( N
55 CD N
% NN N
vs. FW N
78 CD N
% NN N
, , N
p=0.01 NN N
) ) N
. . N

HPV NNP N
testing VBG N
using VBG N
self-collected JJ i
vaginal JJ i
specimens NNS i
may MD N
be VB N
useful JJ N
in IN N
primary JJ N
screening NN N
but CC N
performs NNS N
poorly RB N
for IN N
detecting VBG N
post-treatment JJ o
failures NNS o
. . o

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
Cys NNP i
LT1 NNP i
receptor NN i
blockade NN i
on IN N
airway NN p
responses NNS p
to TO p
allergen VB p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
potent JJ N
experimental JJ N
leukotriene NN i
receptor NN i
antagonist NN i
, , i
MK-571 NNP i
, , N
on IN N
airway NN p
responses NNS p
to TO p
inhaled VB p
allergen NN p
. . p

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
crossover JJ N
trial NN N
. . N

SETTING NNP N
Clinical NNP N
research NN N
center NN N
. . N

SUBJECTS NNP N
Eight NNP p
male NN p
volunteers NNS p
with IN p
allergic JJ p
asthma NN p
. . p

INTERVENTIONS NNP N
An DT N
intravenous JJ N
loading NN N
dose NN N
was VBD N
followed VBN N
by IN N
an DT N
8-hour JJ i
infusion NN i
of IN i
MK-571 NNP i
or CC i
placebo NN i
, , N
with IN N
a DT N
7- JJ N
to TO N
14-day JJ N
washout NN N
between IN N
treatments NNS N
. . N

Allergen NNP N
challenge NN N
was VBD N
performed VBN N
after IN N
the DT N
loading NN N
dose NN N
and CC N
a DT N
histamine NN i
challenge NN N
was VBD N
performed VBN N
before IN N
and CC N
24 CD N
hours NNS N
after IN N
allergen NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Forced NNP o
expiratory JJ o
volume NN o
in IN N
1 CD N
second NN N
was VBD N
measured VBN N
serially RB N
. . N

MK-571 NNP i
provided VBD N
about IN N
50 CD N
% NN N
protection NN N
during IN N
maximum JJ N
early JJ N
and CC N
late JJ N
responses NNS N
compared VBN N
with IN N
placebo NN i
( ( N
p=0.005 NN N
) ) N
, , N
but CC N
airway RB o
obstruction NN o
persisted VBD N
8-24 CD N
hours NNS N
after IN N
allergen NN N
on IN N
both DT N
treatment NN N
days NNS N
. . N

Airway NNP o
responsiveness NN o
to TO o
histamine VB o
was VBD N
not RB N
significantly RB N
attenuated VBN N
at IN N
24 CD N
hours NNS N
. . N

CONCLUSION NNP N
Blocking NNP N
Cys NNP N
LT1 NNP N
receptors NNS N
for IN N
8 CD N
hours NNS N
attenuated VBD N
the DT N
early JJ N
and CC N
late JJ N
responses NNS N
but CC N
did VBD N
not RB N
interrupt VB N
the DT N
cascade NN N
of IN N
events NNS N
leading VBG N
to TO N
subsequent JJ N
allergen-induced JJ N
airway NN N
obstruction NN N
and CC N
hyperreactivity NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
and CC N
safety NN N
of IN N
a DT N
high JJ i
protein NN i
, , i
low JJ i
carbohydrate NN i
diet NN i
for IN N
weight JJ N
loss NN N
in IN N
severely JJ p
obese JJ p
adolescents NNS p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
a DT N
carbohydrate NN i
restricted VBN i
versus IN i
a DT i
low JJ i
fat NN i
diet NN i
on IN N
weight JJ o
loss NN o
, , o
metabolic JJ o
markers NNS o
, , o
body NN o
composition NN o
, , N
and CC N
cardiac JJ o
function NN o
tests NNS o
in IN N
severely RB p
obese JJ p
adolescents NNS p
. . p

STUDY NNP N
DESIGN NNP N
Subjects NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
diets NNS i
: : i
a DT i
high JJ i
protein NN i
, , i
low JJ i
carbohydrate NN i
( ( i
20 CD i
g/d NN i
) ) i
diet NN i
( ( i
high JJ i
protein NN i
, , i
low JJ i
carbohydrate NN i
, , i
HPLC NNP i
) ) i
or CC i
low JJ i
fat NN i
( ( i
30 CD i
% NN i
of IN i
calories NNS i
) ) i
regimen VBP i
for IN i
13 CD i
weeks NNS i
; : i
close JJ N
monitoring NN N
was VBD N
maintained VBN N
to TO N
evaluate VB N
safety NN N
. . N

After IN N
the DT N
intervention NN N
, , N
no DT N
clinical JJ N
contact NN N
was VBD N
made VBN N
until IN N
follow-up JJ N
measurements NNS N
were VBD N
obtained VBN N
at IN N
24 CD N
and CC N
36 CD N
weeks NNS N
from IN N
baseline NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
change NN o
in IN o
body NN o
mass NN o
index NN o
Z-score NNP o
for IN N
age NN N
and CC N
sex NN N
( ( o
BMI-Z NNP o
) ) o
at IN N
13 CD N
, , N
24 CD N
, , N
and CC N
36 CD N
weeks NNS N
. . N

RESULTS NNP N
Forty-six JJ p
subjects NNS p
( ( p
24 CD p
HPLC NNP p
, , p
22 CD p
in IN p
low JJ p
fat NN p
) ) p
initiated VBD p
and CC p
33 CD p
subjects NNS p
completed VBD p
the DT p
intervention NN p
; : p
follow-up JJ N
data NNS N
were VBD N
available JJ N
on IN N
approximately RB N
half NN N
of IN N
the DT N
subjects NNS N
. . N

Significant JJ N
reduction NN N
in IN N
( ( o
BMI-Z NNP o
) ) o
was VBD N
achieved VBN N
in IN N
both DT N
groups NNS N
during IN N
intervention NN N
and CC N
was VBD N
significantly RB N
greater JJR N
for IN N
the DT N
HPLC NNP N
group NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Both DT N
groups NNS N
maintained VBD N
significant JJ N
BMI-Z JJ o
reduction NN o
at IN N
follow-up NN N
; : N
changes NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
. . N

Loss NNP N
of IN N
lean JJ o
body NN o
mass NN o
was VBD N
not RB N
spared VBN N
in IN N
the DT N
HPLC NNP N
group NN N
. . N

No DT N
serious JJ o
adverse JJ o
effects NNS o
were VBD N
observed VBN N
related VBN N
to TO N
metabolic JJ o
profiles NNS o
, , o
cardiac JJ o
function NN o
, , N
or CC N
subjective JJ o
complaints NNS o
. . o

CONCLUSIONS VB N
The DT N
HPLC NNP i
diet NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
option NN N
for IN N
medically RB N
supervised VBN N
weight JJ N
loss NN N
in IN N
severely JJ p
obese JJ p
adolescents NNS p
. . p

-DOCSTART- -X- O O

Effects NNS N
of IN N
phosphorus-restricted JJ i
diet JJ i
and CC i
phosphate-binding JJ i
therapy NN i
on IN N
outcomes NNS N
in IN N
patients NNS p
with IN p
chronic JJ p
kidney NN p
disease NN p
. . p

BACKGROUND NNP N
Phosphorus NNP N
is VBZ N
associated VBN N
with IN N
mortality NN N
in IN N
patients NNS p
with IN p
chronic JJ p
kidney NN p
disease NN p
( ( p
CKD NNP p
) ) p
not RB p
on IN p
dialysis NN p
, , N
possibly RB N
through IN N
phosphorus-dependent JJ N
vascular JJ N
calcification NN N
. . N

Although IN N
a DT N
phosphorus-restricted JJ i
diet JJ i
reduces NNS N
serum VBP N
phosphorus NN N
, , N
it PRP N
is VBZ N
unlikely JJ N
that IN N
it PRP N
reduces VBZ N
vascular JJ N
calcification NN N
progression NN N
in IN N
CKD NNP N
. . N

This DT N
study NN N
evaluated VBD N
whether IN N
a DT N
combined JJ i
strategy NN i
of IN i
phosphorus-restricted JJ i
diet JJ i
and CC i
phosphate-binding JJ i
therapy NN i
can MD N
reduce VB N
the DT N
risk NN o
of IN o
all-cause JJ o
mortality NN o
and/or JJ o
dialysis NN o
initiation NN o
by IN N
attenuating VBG N
coronary JJ o
artery NN o
calcification NN o
( ( o
CAC NNP o
) ) o
progression NN o
in IN N
non-dialysis JJ p
CKD NNP p
patients NNS p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
post NN N
hoc NN N
analysis NN N
of IN N
a DT N
subgroup NN p
of IN p
patients NNS p
from IN p
a DT p
study NN p
that WDT p
evaluated VBD p
the DT p
impact NN p
of IN p
two CD p
phosphorus NN p
binder NN p
regimens NNS p
on IN p
hard JJ p
outcomes NNS p
in IN p
CKD NNP p
. . p

Patients NNS p
( ( p
n JJ p
= NNP p
113 CD p
) ) p
with IN p
stage NN p
3-4 JJ p
CKD NNP p
and CC p
evidence NN p
of IN p
CAC NNP p
on IN p
a DT p
phosphorus-restricted JJ i
diet NN i
were VBD i
randomized VBN N
to TO N
receive VB N
either DT i
calcium NN i
carbonate NN i
or CC i
sevelamer NN i
added VBN i
to TO N
their PRP$ i
phosphorus-restricted JJ i
diet NN i
. . i

End-points NNS N
were VBD o
death NN o
for IN o
any DT o
cause NN o
and CC o
initiation NN o
of IN o
dialysis NN o
. . o

Patients NNS N
were VBD N
monitored VBN N
to TO N
the DT N
first JJ N
event NN N
or CC N
to TO N
conclusion NN N
of IN N
the DT N
36-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Overall NNP N
, , N
treatment NN N
with IN i
calcium NN i
carbonate NN i
was VBD i
associated VBN N
with IN o
increased JJ o
CAC NNP o
progression NN o
and CC o
occurrence NN o
of IN o
all-cause JJ o
mortality NN o
, , o
dialysis NN o
initiation NN o
, , o
and CC o
the DT o
composite JJ o
end-point NN o
. . o

After IN N
adjustment NN N
for IN N
confounders NNS i
, , i
sevelamer NN i
use NN i
was VBD N
the DT N
only JJ N
independent JJ N
predictive JJ N
factor NN N
of IN N
reduced JJ o
risk NN o
of IN o
each DT o
endpoint NN o
but CC o
only RB N
if IN N
CAC NNP o
progression NN o
was VBD o
either CC N
absent JJ N
or CC N
moderate JJ o
. . o

Accelerated VBN o
progression NN o
( ( o
annual JJ N
CAC NNP N
increase NN N
> VBD N
75th CD N
percentile NN N
of IN N
the DT N
study NN N
cohort NN N
) ) N
increased VBD N
the DT o
risk NN o
of IN o
all-cause JJ o
mortality NN o
and CC o
composite JJ o
end-point NN o
( ( o
p JJ N
= NNP N
0.01 CD N
) ) N
independently RB N
of IN N
the DT N
use NN N
of IN N
sevelamer NN N
. . N

CONCLUSIONS VB N
A DT N
significant JJ N
reduction NN o
in IN o
all-cause JJ o
mortality NN o
, , o
dialysis NN o
initiation NN o
, , o
and CC o
composite JJ o
end-point NN o
risk NN o
was VBD o
achieved VBN N
by IN N
combining VBG i
phosphorus-restricted JJ i
diet JJ i
and CC i
sevelamer JJ i
in IN i
non-dialysis JJ N
CKD NNP N
patients NNS p
with IN p
absent NN N
or CC N
moderate VB N
but CC N
not RB N
accelerated JJ o
CAC NNP o
progression NN o
. . o

Future JJ o
studies NNS N
should MD N
investigate VB N
the DT N
role NN N
of IN N
serum NN N
phosphorus NN N
, , N
the DT N
usefulness NN N
of IN N
a DT N
phosphorus-restricted JJ N
diet NN N
, , N
and CC N
the DT N
appropriateness NN N
of IN N
current JJ N
normal JJ N
ranges NNS N
of IN N
serum NN N
phosphorus NN N
concentration NN N
in IN N
relation NN N
to TO N
events NNS N
in IN N
non-dialyzed JJ N
CKD NNP N
patients NNS N
. . N

-DOCSTART- -X- O O

Conservative JJ N
surgery NN N
with IN N
and CC N
without IN N
radiotherapy NN N
in IN N
elderly JJ p
patients NNS p
with IN p
early-stage JJ p
breast NN p
cancer NN p
: : p
a DT N
prospective JJ N
randomised VBN N
multicentre JJ N
trial NN N
. . N

Breast NNP i
conserving VBG i
therapy NN i
( ( i
BCT NNP i
) ) i
including VBG N
postoperative JJ N
irradiation NN N
of IN N
the DT N
remaining VBG N
breast NN N
tissue NN N
is VBZ N
generally RB N
accepted VBN N
as IN N
the DT N
best JJS N
treatment NN N
for IN N
the DT N
majority NN N
of IN N
patients NNS p
with IN p
early-stage JJ p
breast NN p
cancer NN p
. . p

The DT N
question NN N
is VBZ N
whether IN N
there EX N
is VBZ N
a DT N
necessity NN N
for IN N
irradiating VBG N
all DT N
patients NNS N
. . N

Between JJ p
2001 CD p
and CC p
2005 CD p
, , p
749 CD p
women NNS p
aged VBN p
55-75 JJ p
years NNS p
with IN p
infiltrating VBG p
breast NN p
carcinoma NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
breast VB i
conservative JJ i
surgery NN i
, , i
with IN i
or CC i
without IN i
radiotherapy NN i
( ( N
RT NNP N
) ) N
, , N
to TO N
evaluate VB N
the DT N
incidence NN o
of IN o
in-breast JJ o
recurrence NN o
( ( o
IBR NNP o
) ) o
. . o

After IN N
5 CD N
years NNS N
of IN N
median JJ N
follow-up NN N
, , N
the DT N
cumulative JJ o
incidence NN o
of IN o
IBR NNP o
was VBD N
2.5 CD N
% NN N
in IN N
the DT N
surgery-only JJ N
arm NN N
and CC N
0.7 CD N
% NN N
in IN N
the DT N
surgery NN N
plus CC N
RT NNP N
arm NN N
. . N

There EX N
are VBP N
no DT o
differences NNS o
in IN N
terms NNS N
of IN N
overall JJ o
survival NN o
and CC o
distant JJ o
disease-free JJ o
survival NN o
. . o

The DT N
preliminary JJ N
evaluation NN N
suggests VBZ N
that IN N
breast NN N
irradiation NN N
after IN N
conservative JJ N
surgery NN N
can MD N
be VB N
avoided VBN N
without IN N
exposing VBG N
these DT N
patients NNS N
to TO N
an DT N
increased VBN N
risk NN o
of IN o
distant-disease JJ o
recurrence NN o
. . o

Prolonged VBN N
follow-up NN N
will MD N
further RBR N
clarify VB N
the DT N
possible JJ N
risks NNS N
and CC N
late JJ N
sequelae NN N
potentially RB N
induced VBN N
by IN N
breast NN N
RT NNP N
. . N

-DOCSTART- -X- O O

Efficacy NN o
and CC o
cost-effectiveness NN o
of IN N
an DT N
experimental JJ N
short-term JJ N
inpatient JJ i
Dialectical NNP i
Behavior NNP i
Therapy NNP i
( ( i
DBT NNP i
) ) i
program NN N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Borderline NNP p
Personality NNP p
Disorder NNP p
( ( p
BPD NNP p
) ) p
is VBZ N
a DT N
serious JJ N
psychiatric JJ N
condition NN N
associated VBN N
with IN N
substantial JJ N
mortality NN N
, , N
burden NN N
and CC N
public JJ N
health NN N
costs NNS N
. . N

DBT NNP N
is VBZ N
the DT N
treatment NN N
model NN N
with IN N
the DT N
largest JJS N
number NN N
of IN N
published VBN N
research NN N
articles VBZ N
showing VBG N
effectiveness NN N
. . N

However RB N
, , N
some DT N
patients NNS N
are VBP N
not RB N
sufficiently RB N
engaged VBN N
in IN N
outpatient JJ N
treatment NN N
while IN N
presenting VBG N
severe JJ N
parasuicidal JJ N
behavior NN N
, , N
making VBG N
hospitalization NN N
necessary JJ N
. . N

The DT N
Center NNP N
for IN N
Personality NNP N
Disorders NNP N
Jelgersma NNP N
developed VBD N
an DT N
intensive JJ N
12-week JJ N
inpatient NN N
DBT NNP N
program NN N
that IN N
( ( N
i NN N
) ) N
rapidly RB N
reduces VBZ N
core NN N
borderline NN N
symptoms NNS N
like IN N
suicidal JJ N
behavior NN N
, , N
( ( N
ii NN N
) ) N
minimizes VBZ N
the DT N
negative JJ N
effects NNS N
of IN N
an DT N
inpatient NN N
setting NN N
, , N
and CC N
( ( N
iii NN N
) ) N
enhances VBZ N
compliance NN N
with IN N
outpatient JJ N
treatment NN N
. . N

We PRP N
evaluate VBP N
the DT N
( ( o
cost- NN o
) ) o
effectiveness NN o
of IN N
this DT N
experimental JJ N
program NN N
. . N

METHODS/DESIGN NNP N
Seventy NNP p
patients NNS p
, , p
aged VBD p
18 CD p
to TO p
45 CD p
years NNS p
with IN p
a DT p
primary JJ p
diagnosis NN p
of IN p
BPD NNP p
, , p
showing VBG p
a DT p
chronic JJ p
pattern NN p
of IN p
parasuicidal JJ p
gestures NNS p
and/or IN p
reporting VBG p
high JJ p
degrees NNS p
of IN p
severity NN p
of IN p
other JJ p
borderline NN p
symptoms NNS p
, , p
are VBP p
randomly RB p
allocated VBN p
to TO p
the DT p
control NN p
and CC p
intervention NN p
groups NNS p
. . p

Subjects NNS p
in IN p
the DT p
control NN p
group NN p
receive VBP p
standard JJ i
outpatient NN i
DBT NNP i
, , i
provided VBD p
in IN p
one CD p
of IN p
three CD p
regular JJ p
mental JJ p
health NN p
settings NNS p
in IN p
GGZ NNP p
Rivierduinen NNP p
. . p

Subjects NNS p
in IN p
the DT p
intervention NN p
group NN p
receive VBP i
12 CD i
weeks NNS i
of IN i
intensified JJ i
inpatient NN i
DBT NNP i
plus CC i
six CD i
months NNS i
of IN i
standard JJ i
DBT NNP i
, , i
provided VBN p
in IN p
the DT p
Center NNP p
for IN p
Personality NNP p
Disorders NNP p
Jelgersma NNP p
. . p

The DT N
primary JJ N
outcome NN N
is VBZ N
the DT o
number NN o
of IN o
suicide JJ o
attempts/self-harming JJ o
acts NNS o
. . o

Secondary JJ N
outcomes NNS N
are VBP o
severity NN o
of IN o
other JJ o
borderline NN o
complaints NNS o
, , o
quality NN o
of IN o
life NN o
, , o
general JJ o
psychopathological NN o
symptoms NNS o
and CC o
health NN o
care NN o
utilization NN o
and CC o
productivity NN o
costs NNS o
. . o

Data NNS N
are VBP N
gathered VBN N
using VBG N
a DT N
prospective JJ N
, , N
two CD N
( ( N
group NN N
: : N
intervention NN N
and CC N
control NN N
) ) N
by IN N
five CD N
( ( N
time NN N
of IN N
measurement NN N
) ) N
repeated VBD N
measures NNS N
factorial JJ N
design.Participants NNS N
will MD N
complete VB N
three-monthly JJ N
outcome NN N
assessments NNS N
in IN N
the DT N
course NN N
of IN N
therapy NN N
: : N
at IN N
baseline NN N
, , N
and CC N
12 CD N
, , N
24 CD N
, , N
36 CD N
and CC N
52 CD N
weeks NNS N
after IN N
the DT N
start NN N
of IN N
the DT N
treatment NN N
. . N

The DT N
period NN N
of IN N
recruitment NN N
started VBN N
in IN N
March NNP N
2012 CD N
and CC N
the DT N
study NN N
will MD N
end VB N
in IN N
December NNP N
2014 CD N
. . N

DISCUSSION NNP p
Highly NNP p
suicidal JJ p
outpatient NN p
patients NNS p
can MD p
pose VB N
a DT N
dilemma NN N
for IN N
mental JJ N
health NN N
care NN N
professionals NNS N
. . N

Although IN N
hospitalization NN N
seems VBZ N
inevitable JJ N
under IN N
some DT N
circumstances NNS N
, , N
it PRP N
has VBZ N
proven VBN N
to TO N
be VB N
harmful JJ N
in IN N
its PRP$ N
own JJ N
right NN N
. . N

This DT N
paper NN N
outlines VBZ N
the DT N
background NN N
and CC N
methods NNS N
of IN N
a DT N
randomized JJ N
trial NN N
evaluating VBG N
the DT N
possible JJ N
surplus NN N
value NN N
of IN N
a DT N
short-term JJ N
inpatient NN N
DBT NNP N
program NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
crossover NN N
study NN N
investigating VBG N
the DT N
influence NN N
of IN N
ranitidine NN i
or CC i
omeprazole NN i
on IN N
the DT N
pharmacokinetics NNS o
of IN o
cephalexin NN o
monohydrate NN o
. . o

Limited VBN N
data NNS N
characterize RBR N
pharmacokinetic JJ N
interactions NNS N
between IN N
cephalexin NN N
and CC N
ranitidine NN N
, , N
and CC N
no DT N
data NNS N
exist VBP N
for IN N
an DT N
interaction NN N
with IN N
proton NN N
pump NN N
inhibitors NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
ranitidine NN i
or CC N
omeprazole JJ i
administration NN N
on IN N
the DT N
pharmacokinetics NNS o
and CC o
pharmacodynamics NNS o
of IN o
cephalexin NN o
. . o

A DT N
randomized JJ N
single- NN N
and CC N
multiple-dose JJ N
crossover NN N
study NN N
was VBD N
conducted VBN N
in IN N
healthy JJ p
subjects NNS p
ingesting VBG p
cephalexin NN i
before IN p
and CC p
after IN p
steady-state JJ p
administration NN p
of IN p
ranitidine NN i
or CC i
omeprazole NN i
. . i

Time-concentration NN o
profiles NNS N
were VBD N
determined VBN N
and CC N
pharmacokinetic JJ o
parameters NNS o
were VBD N
characterized VBN N
using VBG N
noncompartmental JJ N
methods NNS N
. . N

Pharmacokinetic JJ N
data NNS N
were VBD N
analyzed VBN N
in IN N
accordance NN N
with IN N
the DT N
two CD N
1-sided JJ N
test NN N
for IN N
bioequivalence NN N
. . N

The DT N
percentage NN o
of IN o
time NN o
that IN o
serum JJ o
concentrations NNS o
remain VBP o
above IN o
the DT o
MIC NNP o
( ( o
90 CD o
) ) o
during IN o
the DT o
dosing VBG o
interval NN o
( ( o
T NNP o
> NNP o
MIC NNP o
( ( o
90 CD o
) ) o
) ) o
for IN o
Streptococcus NNP o
pyogenes NNS o
and CC o
Staphylococcus NNP o
aureus RB o
associated VBD o
with IN o
the DT o
pharmacokinetic JJ o
profiles NNS o
was VBD o
calculated VBN o
. . o

The DT N
coadministration NN N
of IN N
cephalexin NN N
with IN N
ranitidine NN N
or CC N
omeprazole NN N
resulted VBD N
in IN N
relatively RB N
minor JJ N
changes NNS N
in IN N
C NNP o
( ( o
max NN o
) ) o
, , o
AUC NNP o
( ( o
infinity NN o
) ) o
, , o
t EX o
( ( o
1/2 CD o
) ) o
, , o
or CC o
CL/F NNP o
. . o

t NN o
( ( o
max NN o
) ) o
was VBD N
significantly RB N
prolonged VBN N
when WRB N
cephalexin NN N
was VBD N
administered VBN N
with IN N
ranitidine NN N
or CC N
omeprazole NN N
. . N

Suboptimal NNP o
T NNP o
> NNP o
MIC NNP o
( ( o
90 CD o
) ) o
was VBD N
observed VBN N
for IN N
cephalexin NN N
irrespective NN N
of IN N
acid JJ N
suppression NN N
. . N

Delay NNP N
in IN N
absorption NN N
of IN N
cephalexin NN N
resulted VBN N
in IN N
a DT N
decrease NN N
in IN N
the DT N
percentage NN N
of IN N
T NNP o
> NNP o
MIC NNP o
( ( o
90 CD o
) ) o
for IN N
certain JJ N
acid-suppressive JJ N
regimens NNS N
and CC N
pathogen NN N
combinations NNS N
. . N

With IN N
the DT N
exception NN N
of IN N
an DT N
increase NN N
in IN N
t NN o
( ( o
max NN o
) ) o
, , N
there EX N
were VBD N
no DT N
significant JJ N
pharmacokinetic JJ N
interactions NNS N
between IN N
cephalexin NN N
and CC N
ranitidine NN N
or CC N
omeprazole NN N
. . N

Delayed VBN N
t NN o
( ( o
max NN o
) ) o
associated VBN N
with IN N
acid JJ N
suppression NN N
may MD N
result VB N
in IN N
a DT N
diminished JJ N
T NNP N
> NNP N
MIC NNP N
( ( N
90 CD N
) ) N
. . N

-DOCSTART- -X- O O

Circadian JJ N
changes NNS N
in IN N
the DT N
pharmacokinetics NNS o
of IN N
oral JJ p
ketoprofen NN i
. . i

Several JJ N
investigations NNS N
which WDT N
have VBP N
taken VBN N
treatment NN N
time NN N
into IN N
account NN N
have VBP N
shown VBN N
that IN N
the DT N
pharmacokinetic JJ N
parameters NNS N
, , N
the DT N
therapeutic JJ o
efficacy NN o
and CC N
even RB N
the DT N
toxicity NN o
of IN N
a DT N
large JJ N
number NN N
of IN N
products NNS N
may MD N
vary VB N
according VBG N
to TO N
the DT N
administration NN N
schedule NN N
. . N

The DT N
present JJ N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
order NN N
to TO N
evaluate VB N
any DT N
circadian JJ N
changes NNS N
in IN N
pharmacokinetic JJ N
parameters NNS N
of IN N
ketoprofen NN i
, , N
a DT N
new JJ N
non-steroidal JJ N
anti-inflammatory JJ N
drug NN N
( ( N
NSAID NNP N
) ) N
. . N

This DT N
randomised VBD N
crossover NN N
study NN N
consisted VBD N
of IN N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
ketoprofen $ i
100mg CD N
administered VBN N
to TO N
8 CD p
healthy JJ p
male NN p
volunteers NNS p
, , p
mean JJ p
age NN p
27.2 CD p
years NNS p
, , N
at IN N
07.00 CD N
hours NNS N
, , N
13.00 CD N
hours NNS N
, , N
19.00 CD N
hours NNS N
or CC N
01.00 CD N
hours NNS N
in IN N
4 CD N
study NN N
periods NNS N
during IN N
the DT N
first JJ N
3 CD N
months NNS N
of IN N
the DT N
year NN N
. . N

The DT N
order NN N
of IN N
administration NN N
was VBD N
randomised VBN N
, , N
with IN N
each DT N
subject NN N
acting VBG N
as IN N
his PRP$ N
own JJ N
control NN N
. . N

A DT N
total NN N
of IN N
14 CD p
blood NN p
and CC p
4 CD p
urine JJ p
samples NNS p
were VBD N
taken VBN N
over RP N
a DT N
12-hour JJ N
period NN N
. . N

The DT N
peak JJ o
plasma NN o
concentration NN o
was VBD N
twice RB N
as RB N
high JJ N
after IN N
drug NN N
administration NN N
at IN N
07.00 CD N
hours NNS N
( ( N
13.4 CD N
+/- JJ N
1 CD N
mg/L NN N
) ) N
than IN N
after IN N
other JJ N
administration NN N
times NNS N
( ( N
13.00 CD N
hours NNS N
: : N
6.9 CD N
+/- JJ N
1 CD N
; : N
19.00 CD N
hours NNS N
: : N
7.2 CD N
+/- JJ N
0.7 CD N
; : N
01.00 CD N
hours NNS N
: : N
6.3 CD N
+/- JJ N
0.5 CD N
mg/L NN N
) ) N
[ VBZ N
p NN N
less JJR N
than IN N
0.001 CD N
] NN N
. . N

The DT N
time NN o
to TO o
reach VB o
peak JJ o
concentration NN o
was VBD N
much RB N
longer JJR N
after IN N
drug NN N
administration NN N
at IN N
01.00 CD N
hours NNS N
( ( N
135 CD N
+/- JJ N
16.7 CD N
min NN N
) ) N
than IN N
at IN N
07.00 CD N
( ( N
73.1 CD N
+/- JJ N
14.1 CD N
min NN N
) ) N
, , N
13.00 CD N
( ( N
75 CD N
+/- JJ N
16.5 CD N
min NN N
) ) N
or CC N
19.00 CD N
hours NNS N
( ( N
82.5 CD N
+/- JJ N
12.7 CD N
min NN N
) ) N
[ VBZ N
p NN N
less JJR N
than IN N
0.05 CD N
] NN N
. . N

The DT N
lag NN o
time NN o
was VBD N
significantly RB N
longer JJR N
at IN N
01.00 CD N
hours NNS N
than IN N
at IN N
13.00 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
absorption NN o
rate NN o
constant JJ N
after IN N
treatment NN N
at IN N
01.00 CD N
hours NNS N
was VBD N
less JJR N
than IN N
at IN N
the DT N
other JJ N
times NNS N
of IN N
administration NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
bodyweight-corrected JJ o
area NN o
under IN o
the DT o
curve NN o
( ( o
AUC0-12 NNP o
) ) o
was VBD N
greater JJR N
after IN N
07.00 CD N
hours NNS N
than IN N
after IN N
13.00 CD N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
or CC N
19.00 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
greater JJR N
after IN N
01.00 CD N
hours NNS N
than IN N
after IN N
13.00 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
elimination NN o
half-life NN o
was VBD N
significantly RB N
longer RBR N
after IN N
administration NN N
at IN N
01.00 CD N
hours NNS N
than IN N
after IN N
19.00 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
while IN N
the DT N
total JJ o
clearance NN o
was VBD N
lowest VBN N
at IN N
07.00 CD N
hours NNS N
. . N

Cosinor NNP N
analysis NN N
demonstrated VBD N
statistically RB N
significant JJ N
circadian JJ o
rhythms NN o
for IN N
all DT N
pharmacokinetic JJ N
parameters NNS N
described VBN N
above IN N
. . N

The DT N
amount NN N
of IN N
ketoprofen NN i
eliminated VBN N
in IN N
the DT N
urine NN N
was VBD N
delayed VBN N
, , N
and CC N
was VBD N
significantly RB N
greater JJR N
after IN N
the DT N
administration NN N
at IN N
01.00 CD N
hours NNS N
than IN N
07.00 CD N
hours NNS N
or CC N
19.00 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
relationship NN N
between IN N
absorption NN N
, , N
diffusion NN N
and/or NN N
elimination NN N
mechanisms NNS N
of IN N
the DT N
drug NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Autism NNP N
Spectrum NNP N
Social NNP N
Stories NNP N
In IN N
Schools NNP N
Trial NNP N
( ( N
ASSSIST NNP N
) ) N
: : N
study NN N
protocol NN N
for IN N
a DT N
feasibility NN N
randomised VBN N
controlled VBN N
trial NN N
analysing VBG N
clinical JJ o
and CC o
cost-effectiveness NN o
of IN o
Social NNP o
Stories NNP o
in IN N
mainstream JJ N
schools NNS N
. . N

INTRODUCTION NNP N
Current NNP N
evidence NN N
suggests VBZ N
that IN N
Social NNP i
Stories NNPS i
can MD N
be VB N
effective JJ N
in IN N
tackling VBG N
problem NN o
behaviours NNS o
exhibited VBN N
by IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Exploring VBG N
the DT N
meaning NN N
of IN N
behaviour NN N
from IN N
a DT N
child NN N
's POS N
perspective JJ N
allows NNS N
stories NNS N
to TO N
provide VB N
social JJ N
information NN N
that WDT N
is VBZ N
tailored VBN N
to TO N
their PRP$ N
needs NNS N
. . N

Case NNP N
reports VBZ N
in IN N
children NNS p
with IN p
autism NN p
have VBP N
suggested VBN N
that IN N
these DT N
stories NNS N
can MD N
lead VB N
to TO N
a DT N
number NN N
of IN N
benefits NNS N
including VBG N
improvements NNS N
in IN N
social JJ o
interactions NNS o
and CC o
choice NN o
making NN o
in IN N
educational JJ N
settings NNS N
. . N

METHODS NNP N
AND CC N
ANALYSIS NNP N
The DT N
feasibility NN o
of IN o
clinical JJ o
and CC o
cost-effectiveness NN o
of IN N
a DT N
Social NNP i
Stories NNP i
toolkit NN N
will MD N
be VB N
assessed VBN N
using VBG N
a DT N
randomised VBN N
control NN N
framework NN N
. . N

Participants NNS p
( ( p
n=50 NN p
) ) p
will MD p
be VB p
randomised VBN p
to TO p
either CC p
the DT p
Social NNP i
Stories NNPS i
intervention NN i
or CC i
a DT i
comparator NN i
group NN i
where WRB p
they PRP p
will MD p
be VB p
read VBN p
standard JJ p
stories NNS p
for IN p
an DT p
equivalent JJ p
amount NN p
of IN p
time NN p
. . p

Statistics NNS N
will MD N
be VB N
calculated VBN N
for IN N
recruitment NN o
rates NNS o
, , o
follow-up JJ o
rates NNS o
and CC o
attrition NN o
. . o

Economic JJ N
analysis NN N
will MD N
determine VB N
appropriate JJ N
measures NNS o
of IN o
generic JJ o
health NN o
and CC o
resource NN o
use NN o
categories NNS o
for IN o
cost-effectiveness JJ o
analysis NN o
. . o

Qualitative JJ N
analysis NN N
will MD N
ascertain VB N
information NN N
on IN N
perceptions NNS N
about IN N
the DT N
feasibility NN o
and CC o
acceptability NN o
of IN N
the DT N
intervention NN N
. . N

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
National NNP N
Health NNP N
Service NNP N
Ethics NNP N
Approval NNP N
( ( N
NHS NNP N
; : N
ref VBZ N
11/YH/0340 CD N
) ) N
for IN N
the DT N
trial NN N
protocol NN N
has VBZ N
been VBN N
obtained VBN N
along IN N
with IN N
NHS NNP N
Research NNP N
and CC N
Development NNP N
permission NN N
from IN N
Leeds NNP N
and CC N
York NNP N
Partnership NNP N
NHS NNP N
Foundation NNP N
Trust NNP N
. . N

All DT N
adverse JJ o
events NNS o
will MD N
be VB N
closely RB N
monitored VBN N
, , N
documented VBN N
and CC N
reported VBN N
to TO N
the DT N
study NN N
Data NNP N
Monitoring NNP N
Ethics NNP N
Committee NNP N
. . N

At IN N
least JJS N
one CD N
article NN N
in IN N
a DT N
peer NN N
reviewed VBN N
journal NN N
will MD N
be VB N
published VBN N
and CC N
research NN N
findings NNS N
presented VBN N
at IN N
relevant JJ N
conferences NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN96286707 NNP N
. . N

-DOCSTART- -X- O O

Valsartan NNP N
alone RB N
or CC N
with IN N
a DT N
diuretic JJ N
or CC N
ACE NNP N
inhibitor NN i
as IN N
treatment NN N
for IN N
African JJ p
American JJ p
hypertensives NNS p
: : p
relation NN N
to TO N
salt VB N
intake NN N
. . N

Previous JJ N
clinical JJ N
trials NNS N
have VBP N
demonstrated VBN N
the DT N
important JJ N
influence NN N
of IN N
ethnicity NN N
and CC N
dietary JJ N
salt NN N
on IN N
the DT N
antihypertensive JJ N
efficacy NN N
of IN N
drugs NNS N
that WDT N
block VBP N
the DT N
renin NN N
angiotensin NN N
system NN N
. . N

Angiotensin NNP N
II NNP N
receptor NN N
blockers NNS N
are VBP N
a DT N
new JJ N
therapeutic JJ N
entity NN N
that WDT N
have VBP N
not RB N
been VBN N
widely RB N
studied VBN N
in IN N
African JJ N
American JJ N
hypertensives NNS N
, , N
either RB N
alone RB N
, , N
or CC N
in IN N
combination NN N
with IN N
other JJ N
therapies NNS N
such JJ N
as IN N
diuretics NNS N
or CC N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitors NNS N
. . N

We PRP N
performed VBD N
a DT N
pilot NN N
, , N
prospective JJ N
, , N
open JJ N
label NN N
, , N
randomized VBN N
design NN N
clinical JJ N
trial NN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
the DT N
angiotensin NN i
II NNP i
receptor NN i
blocker NN i
valsartan NN i
( ( N
160 CD N
mg NN N
once RB N
a DT N
day NN N
) ) N
on IN N
systolic NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
in IN N
hypertensive JJ p
African JJ p
Americans NNPS p
( ( p
n JJ p
= NNP p
88 CD p
) ) p
on IN p
a DT p
low JJ i
salt NN i
( ( i
100 CD i
mEq NNS i
Na+/day NNP i
) ) i
for IN i
2 CD i
weeks NNS i
and CC i
the DT i
same JJ i
diet NN i
supplemented VBN i
by IN i
100 CD i
mEq NNS i
Na+ NNP i
for IN i
4 CD i
weeks NNS i
. . i

After IN N
this DT N
evaluation NN N
, , N
while IN N
continuing VBG N
the DT N
Na+ NNP N
supplementation NN N
, , N
patients NNS N
were VBD N
randomized VBN i
to TO i
valsartan VB i
320 CD i
mg/day NN i
( ( i
n JJ i
= NNP i
28 CD i
) ) i
, , i
or CC i
the DT i
addition NN i
of IN i
hydrochlorothiazide NN i
( ( i
HCTZ NNP i
) ) i
12.5 CD i
mg/day NN i
( ( i
n JJ i
= NNP i
30 CD i
) ) i
, , i
or CC i
benazepril VB i
20 CD i
mg/day NN i
to TO i
the DT i
valsartan NN i
160 CD i
mg/day NN i
for IN i
an DT i
additional JJ i
6 CD i
weeks NNS i
. . i

Valsartan NNP N
( ( N
160 CD N
mg/day NN N
) ) N
lowered VBD N
blood NN o
pressure NN o
significantly RB N
in IN N
African JJ N
American JJ N
patients NNS N
on IN N
both DT N
low JJ N
salt NN N
( ( N
-6.4/-4.8 JJ N
mm NN N
Hg NNP N
: : N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
a DT N
high JJ N
salt NN N
diet NN N
( ( N
-4.9/-3.8 JJ N
mm NN N
Hg NNP N
: : N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

The DT N
high JJ N
salt NN N
diet NN N
attenuated VBD N
the DT N
antihypertensive JJ o
effect NN o
slightly RB N
( ( N
1.6/1.3 CD N
mm NN N
Hg NNP N
, , N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

When WRB N
comparing VBG N
the DT N
efficacy NN N
of IN N
the DT N
three CD N
randomized VBN N
therapeutic JJ N
regimens NNS N
while IN N
on IN N
the DT N
Na+ NNP N
supplement NN N
, , N
the DT N
valsartan NN N
160 CD N
mg/HCTZ NN N
12.5 CD N
mg NN N
was VBD N
the DT N
most RBS N
effective JJ N
therapy NN N
with IN N
an DT N
incremental JJ N
reduction NN N
in IN N
blood NN o
pressure NN o
of IN N
-10.5/-6.9 NNP N
mm FW N
Hg NNP N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
compared VBN N
to TO N
valsartan VB N
160 CD N
mg/day JJ N
alone RB N
. . N

Doubling VBG N
the DT N
dose NN N
of IN N
valsartan NN N
to TO N
320 CD N
mg NNS N
incrementally RB N
lowered VBD N
blood NN o
pressure NN o
by IN N
-3.8/-3.3 NNP N
mm NN N
Hg NNP N
( ( N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

The DT N
least JJS N
effective JJ N
approach NN N
was VBD N
adding VBG N
benazepril RB N
20 CD N
mg/day NN N
to TO N
valsartan VB N
160 CD N
mg/day NN N
with IN N
no DT N
incremental JJ N
reduction NN N
in IN N
systolic JJ o
blood NN o
pressure NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
reduction NN N
of IN N
only RB N
1.7 CD N
mm NNS N
Hg NNP N
( ( N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
in IN N
our PRP$ N
open JJ N
label NN N
pilot NN N
study NN N
, , N
the DT N
antihypertensive JJ N
activity NN N
of IN N
valsartan NN N
is VBZ N
not RB N
significantly RB N
attenuated VBN N
by IN N
supplemented JJ N
salt NN N
diet NN N
in IN N
hypertensive JJ p
African JJ p
Americans NNPS p
. . p

Moreover RB N
, , N
adding VBG N
a DT N
low JJ N
dose NN N
of IN N
HCTZ NNP N
appears VBZ N
to TO N
be VB N
the DT N
most RBS N
effective JJ N
strategy NN N
in IN N
enhancing VBG N
the DT N
antihypertensive JJ N
activity NN N
of IN N
this DT N
angiotensin NN N
II NNP N
receptor NN N
blocker NN N
in IN N
contrast NN N
to TO N
either DT N
doubling VBG N
the DT N
dose NN N
or CC N
adding VBG N
an DT N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitor NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
cognitive JJ i
behavioral JJ i
therapy NN i
on IN N
daily JJ o
living NN o
skills NNS o
in IN p
children NNS p
with IN p
high-functioning JJ p
autism NN p
and CC p
concurrent JJ p
anxiety NN p
disorders NNS p
. . p

CBT NNP i
is VBZ N
a DT N
promising JJ N
treatment NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
and CC N
focuses VBZ N
, , N
in IN N
part NN N
, , N
on IN N
children NNS N
's POS N
independence NN o
and CC o
self-help JJ o
skills NNS o
. . o

In IN N
a DT N
trial NN N
of IN N
CBT NNP i
for IN N
anxiety NN N
in IN N
ASD NNP N
( ( N
Wood NNP N
et RB N
al RB N
. . N

in IN N
J NNP N
Child NNP N
Psychol NNP N
Psychiatry NNP N
50:224-234 CD N
, , N
2009 CD N
) ) N
, , N
children NNS N
's POS N
daily JJ N
living NN N
skills NNS N
and CC N
related JJ N
parental JJ o
intrusiveness NN o
were VBD N
assessed VBN N
. . N

Forty NNP p
children NNS p
with IN p
ASD NNP p
( ( p
7-11 CD p
years NNS p
) ) p
and CC p
their PRP$ p
primary JJ p
caregiver NN p
were VBD N
randomly RB i
assigned VBN i
to TO i
an DT i
immediate JJ i
treatment NN i
( ( i
IT NNP i
; : i
n JJ i
= NNP i
17 CD i
) ) i
or CC i
3-month JJ i
waitlist NN i
( ( i
WL NNP i
; : i
n CC i
= VB i
23 CD i
) ) i
condition NN i
. . i

In IN N
comparison NN N
to TO N
WL NNP N
, , N
IT NNP N
parents VBZ N
reported VBN N
increases NNS N
in IN N
children NNS N
's POS N
total NN o
and CC o
personal JJ o
daily JJ o
living NN o
skills NNS o
, , N
and CC N
reduced JJ N
involvement NN o
in IN o
their PRP$ o
children NNS o
's POS o
private JJ o
daily JJ o
routines NNS o
. . o

Reductions NNS N
correlated VBD N
with IN N
reduced JJ N
anxiety NN N
severity NN o
. . o

These DT N
results NNS N
provide VBP N
preliminary JJ N
evidence NN N
that IN N
CBT NNP N
may MD N
yield VB N
increased JJ N
independence NN o
and CC o
daily JJ o
living NN o
skills NNS o
among IN N
children NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -X- O O

Prognostic JJ N
value NN N
of IN N
clinical JJ N
, , N
laboratory NN N
, , N
and CC N
histological JJ N
characteristics NNS N
in IN N
multiple JJ N
myeloma NN N
: : N
improved JJ N
definition NN N
of IN N
risk NN N
groups NNS N
. . N

Follow-up NNP N
data NN N
of IN N
320 CD p
multiple JJ p
myeloma NN p
( ( p
MM NNP p
) ) p
patients NNS p
entering VBG p
the DT i
German JJ i
Myeloma NNP i
Treatment NNP i
Group NNP i
( ( i
GMTG NNP i
) ) i
trial NN p
MM01 NNP p
were VBD N
analysed VBN N
for IN N
factors NNS N
predicting VBG N
overall JJ o
( ( o
OAS NNP o
) ) o
and CC o
tumour $ o
related VBN o
survival NN o
( ( o
TRS NNP o
) ) o
. . N

Response NN N
to TO N
primary JJ i
induction NN i
chemotherapy NN i
was VBD N
relevant JJ N
for IN N
prognosis NN N
if IN N
a DT N
limit NN N
of IN N
25 CD N
% NN N
tumour NN N
cell NN N
mass NN N
( ( N
TCM NNP N
) ) N
reduction NN N
was VBD N
used VBN N
to TO N
separate JJ N
responders NNS N
from IN N
non-responders NNS N
. . N

Furthermore NNP N
, , N
TCM NNP o
, , o
histological JJ o
grading NN o
of IN o
myeloma NN o
cells NNS o
, , o
degree NN o
of IN o
bone NN o
marrow NN o
infiltration NN o
, , o
haemoglobin NN o
, , o
platelet NN o
counts NNS o
, , o
calcium NN o
, , o
creatinine NN o
, , o
albumin NN o
, , o
beta NN o
2M CD o
, , o
and CC o
Bence NNP o
Jones NNP o
proteinuria NNS o
correlated VBD N
to TO N
both DT N
OAS NNP N
and CC N
TRS NNP N
. . N

Age NNP N
was VBD N
relevant JJ N
for IN N
OAS NNP N
only RB N
. . N

The DT N
multivariate NN N
analysis NN N
revealed VBD N
histological JJ o
grading NN o
, , o
TCM NNP o
and CC o
platelets NNS o
as IN N
the DT N
most RBS N
reliable JJ N
prognostic JJ N
factors NNS N
. . N

Based VBN N
on IN N
these DT N
data NNS N
the DT N
Durie/Salmon NNP N
classification NN N
could MD N
be VB N
improved VBN N
by IN N
defining VBG N
poor JJ i
prognosis NN i
patients NNS p
( ( p
50 CD p
% NN p
TRS NNP p
: : p
16 CD p
months NNS p
) ) p
characterised VBN p
by IN p
pretreatment JJ p
platelets NNS p
of IN p
< NN p
or CC p
= $ p
150,000 CD p
and/or JJ N
poorly RB N
differentiated VBN N
myeloma NN N
cell NN N
morphology NN N
. . N

Patients NNS p
lacking VBG p
both DT p
risk NN p
factors NNS p
displayed VBD N
50 CD N
% NN N
survival JJ o
times NNS o
of IN N
46 CD N
months NNS N
in IN N
stage NN N
III NNP N
and CC N
88 CD N
months NNS N
in IN N
stage NN N
II NNP N
. . N

-DOCSTART- -X- O O

Pars NNS i
plana VBP i
vitrectomy NN i
for IN N
diabetic JJ N
macular JJ N
edema NN N
. . N

Internal NNP i
limiting VBG i
membrane NN i
delamination NN i
vs FW N
posterior JJ i
hyaloid NN i
removal NN i
. . i

A DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Diabetes VBZ N
mellitus RB N
, , N
as RB N
well RB N
as IN N
subsequent JJ N
ocular JJ N
complications NNS N
such JJ N
as IN N
cystoid JJ N
macular JJ N
edema NN N
( ( N
CME NNP N
) ) N
, , N
are VBP N
of IN N
fundametal JJ N
socio-economic JJ N
relevance NN N
. . N

Therefore RB N
, , N
we PRP N
evaluated VBD N
the DT N
influence NN N
of IN N
internal JJ i
limiting VBG i
membrane NN i
( ( i
ILM NNP i
) ) i
removal NN i
on IN N
longterm JJ N
morphological JJ N
and CC N
functional JJ N
outcome NN N
in IN N
patients NNS p
with IN p
diabetes NNS p
mellitus NNS p
( ( p
DM NNP p
) ) p
type NN p
2 CD p
and CC p
chronic JJ p
CME NNP p
without IN p
evident JJ p
vitreomacular JJ p
traction NN p
. . p

METHOD NNP N
Forty NNP p
eyes NNS p
with IN p
attached JJ p
posterior JJ p
hyaloid NN p
were VBD N
included VBN N
in IN N
this DT N
prospective JJ N
trial NN N
and CC N
randomized VBN N
intraoperatively RB N
. . N

Prior NNP N
focal JJ N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
or CC N
panretinal JJ N
( ( N
n JJ N
= NNP N
25 CD i
) ) i
laser JJR i
coagulation NN i
was VBD i
permitted VBN i
. . N

Group NNP N
I PRP N
( ( N
n JJ N
= $ N
19 CD N
patients NNS N
) ) N
underwent JJ i
surgical JJ i
induction NN i
of IN i
posterior JJ i
vitreous JJ i
detachment NN i
( ( i
PVD NNP i
) ) i
, , i
group NN i
II NNP N
( ( N
n JJ N
= $ N
20 CD N
patients NNS i
) ) i
PVD NNP i
and CC i
removal NN i
of IN i
the DT i
ILM NNP i
. . i

Eleven NNP i
patients NNS N
with IN N
detached JJ N
posterior JJ N
hyaloid NN N
( ( N
group NN N
III NNP N
) ) N
were VBD N
not RB N
randomized VBN N
, , N
and CC N
ILM NNP i
removal NN i
was VBD N
performed VBN N
. . N

One CD N
eye NN N
had VBD N
to TO N
be VB N
excluded VBN N
from IN N
further JJ N
analysis NN N
. . N

Examinations NNS N
included VBD o
ETDRS NNP o
best-corrected JJ o
visual JJ o
acuity NN o
( ( o
BCVA NNP o
) ) o
, , o
fluorescein JJ o
angiography NN o
( ( o
FLA NNP o
) ) o
and CC o
OCT NNP o
at IN o
baseline NN N
, , N
3 CD N
and CC N
6 CD N
months NNS N
postoperatively RB N
. . N

Main NNP N
outcome JJ N
measure NN N
was VBD o
BCVA NNP o
at IN N
6 CD N
months NNS N
, , N
secondary JJ o
was VBD o
foveal JJ o
thickness NN o
. . o

RESULTS NNP N
Mean NNP o
BCVA NNP o
over IN N
6 CD N
months NNS N
remained VBD N
unchanged JJ N
in IN N
85 CD N
% NN N
of IN N
patients NNS N
of IN N
group NN N
II NNP N
, , N
and CC N
decreased VBD N
in IN N
53 CD N
% NN N
of IN N
patients NNS N
of IN N
group NN N
I PRP N
. . N

Results NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
different JJ N
[ NNP N
group NN N
I PRP N
: : N
mean JJ N
decrease NN N
log NN N
MAR NNP N
95 CD N
% NN N
CI NNP N
( ( N
0.06 CD N
; : N
0.32 CD N
) ) N
, , N
group NN N
II NNP N
: : N
( ( N
-0.02 VBP N
; : N
0.11 CD N
) ) N
] NN N
. . N

OCT NNP N
revealed VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
of IN o
foveal JJ o
thickness NN o
following VBG o
PVD NNP N
with IN N
ILM NNP N
removal NN N
[ NNP N
group NN N
I PRP N
: : N
mean JJ N
change NN N
: : N
95 CD N
% NN N
CI NNP N
( ( N
-208.95 NNP N
?m NNP N
; : N
-78.05 NNP N
?m NNP N
) ) N
, , N
group NN N
II NNP N
: : N
( ( N
-80.90 JJ N
?m NN N
: : N
+59.17 JJ N
?m NN N
) ) N
] NN N
. . i

CONCLUSION NNP i
Vitrectomy NNP i
, , i
PVD NNP i
with IN i
or CC i
without IN i
ILM NNP i
removal NN i
does VBZ i
not RB N
improve VB N
vision NN N
in IN N
patients NNS p
with IN p
DM NNP p
type NN p
2 CD p
and CC p
cystoid JJ p
diabetic JJ p
macular NN p
edema NN p
without IN p
evident JJ p
vitreoretinal JJ p
traction NN p
. . p

ILM NNP p
delamination NN N
shows VBZ N
improved JJ N
morphological JJ N
results NNS N
, , N
and CC N
appears VBZ N
to TO N
be VB N
beneficial JJ N
in IN N
eyes NNS p
with IN p
preexisting VBG p
PVD NNP p
. . p

-DOCSTART- -X- O O

Efficacy NN N
of IN N
bepotastine NN i
besilate NN i
ophthalmic JJ i
solution NN i
1.5 CD N
% NN N
for IN N
seasonal JJ o
allergic JJ o
conjunctivitis NN o
: : o
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
natural JJ N
exposure NN N
, , N
clinical JJ N
trial NN N
. . N

Allergic NNP N
conjunctivitis NN N
( ( N
AC NNP N
) ) N
affects VBZ N
an DT N
estimated JJ N
20 CD N
% NN N
of IN N
the DT N
population NN N
in IN N
the DT N
Western JJ N
world NN N
, , N
with IN N
a DT N
large JJ N
fraction NN N
suffering VBG N
due JJ N
to TO N
seasonal JJ N
or CC N
perennial JJ N
allergen NN N
exposures NNS N
. . N

Bepotastine NNP i
besilate NN i
ophthalmic JJ i
solution NN i
( ( i
BBOS NNP i
) ) i
1.5 CD N
% NN N
, , N
a DT N
dual-acting JJ i
histamine NN i
( ( N
H NNP N
( ( N
1 CD N
) ) N
) ) N
receptor NN N
antagonist NN N
and CC N
mast NN N
cell NN N
stabilizer NN N
, , N
is VBZ N
indicated VBN N
for IN N
itching VBG N
associated VBN N
with IN N
AC NNP N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
BBOS NNP N
1.5 CD N
% NN N
for IN N
reducing VBG N
ocular JJ p
itching NN p
associated VBN p
with IN p
AC NNP p
in IN p
subjects NNS p
enrolled VBN p
in IN p
a DT p
natural JJ p
exposure NN p
trial NN p
. . p

Eligible JJ p
subjects NNS p
in IN N
a DT N
multicenter NN N
, , N
double-masked JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ i
, , N
natural JJ N
exposure NN N
clinical JJ N
trial NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
BBOS NNP i
1.5 CD N
% NN N
or CC i
placebo NN i
eyedrops NNS i
on IN N
a DT N
1:1 CD N
basis NN N
and CC N
instilled VBD N
1 CD N
drop NN N
of IN N
the DT N
test NN N
agent NN N
into IN N
both DT N
eyes NNS N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
instantaneous JJ N
and CC N
reflective JJ o
ocular JJ o
itching NN o
scores NNS o
at IN N
the DT N
end NN N
of IN N
2 CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
evaluated VBN N
based VBN N
on IN N
subject-assessed JJ N
severity NN N
of IN N
instantaneous JJ N
and CC N
reflective JJ N
itching NN N
. . N

Subject-reported JJ o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
were VBD N
also RB N
recorded VBN N
for IN N
safety NN N
. . N

Treatment NN N
with IN N
BBOS NNP N
1.5 CD N
% NN N
significantly RB N
reduced VBN N
instantaneous JJ o
and CC o
reflective JJ o
ocular JJ o
itching NN o
scores NNS o
from IN N
baseline NN N
compared VBN N
with IN N
placebo NN N
over IN N
the DT N
2-week JJ N
study NN N
period NN N
( ( N
p JJ N
= NN N
0.007 CD N
and CC N
p VB N
= JJ N
0.005 CD N
, , N
respectively RB N
) ) N
. . N

BBOS $ N
1.5 CD N
% NN N
was VBD N
well RB N
tolerated VBN o
, , o
and CC o
AEs NNP o
were VBD N
generally RB N
transient JJ N
and CC N
mild JJ N
. . N

This DT N
clinical JJ N
study NN N
indicates VBZ N
BBOS NNP N
1.5 CD N
% NN N
effectively RB o
and CC o
safely RB o
treated VBD o
ocular JJ o
itching NN o
in IN N
a DT N
natural JJ N
exposure NN N
allergy NN N
study NN N
and CC N
is VBZ N
a DT N
useful JJ N
treatment NN N
option NN N
for IN N
the DT N
management NN N
of IN N
ocular JJ N
itching NN N
associated VBN N
with IN N
AC NNP N
. . N

( ( N
ClinicalTrials.gov NNP N
identifier VBZ N
number NN N
: : N
NCT01174823 NNP N
. . N

) ) N
-DOCSTART- -X- O O

Intensive JJ i
behavioral JJ i
treatment NN i
for IN N
children NNS p
with IN p
autism NN o
: : o
four-year JJ N
outcome NN N
and CC N
predictors NNS N
. . N

Twenty-four JJ p
children NNS p
with IN p
autism NN p
were VBD N
randomly RB N
assigned VBN p
to TO p
a DT p
clinic-directed JJ i
group NN i
, , N
replicating VBG N
the DT N
parameters NNS N
of IN N
the DT N
early JJ i
intensive JJ i
behavioral JJ i
treatment NN i
developed VBD i
at IN i
UCLA NNP i
, , i
or CC i
to TO i
a DT i
parent-directed JJ i
group NN i
that WDT i
received VBD i
intensive JJ i
hours NNS i
but CC i
less JJR i
supervision NN i
by IN i
equally RB i
well-trained JJ i
supervisors NNS i
. . i

Outcome NNP N
after IN N
4 CD N
years NNS N
of IN N
treatment NN N
, , N
including VBG N
cognitive JJ o
, , o
language NN o
, , o
adaptive JJ o
, , o
social JJ o
, , o
and CC o
academic JJ o
measures NNS o
, , N
was VBD N
similar JJ N
for IN N
both DT N
groups NNS N
. . N

After IN N
combining VBG N
groups NNS N
, , N
we PRP N
found VBD N
that IN N
48 CD N
% NN N
of IN N
all DT N
children NNS N
showed VBD N
rapid JJ o
learning NN o
, , N
achieved VBN N
average JJ o
posttreatment JJ o
scores NNS o
, , N
and CC N
at IN N
age NN N
7 CD N
, , N
were VBD N
succeeding VBG N
in IN N
regular JJ N
education NN N
classrooms NNS N
. . N

Treatment NNP N
outcome NN N
was VBD N
best RB N
predicted VBN N
by IN N
pretreatment JJ o
imitation NN o
, , o
language NN o
, , o
and CC o
social JJ o
responsiveness NN o
. . o

These DT N
results NNS N
are VBP N
consistent JJ N
with IN N
those DT N
reported VBN N
by IN N
Lovaas NNP N
and CC N
colleagues NNS N
( ( N
Lovaas NNP N
, , N
1987 CD N
; : N
McEachin NNP N
, , N
Smith NNP N
, , N
& CC N
Lovaas NNP N
, , N
1993 CD N
) ) N
. . N

-DOCSTART- -X- O O

High JJ p
general JJ p
anger NN o
: : o
correlates NNS i
and CC N
treatment NN i
. . i

-DOCSTART- -X- O O

The DT N
unconscious JJ N
thought NN N
effect NN N
in IN N
clinical JJ N
decision NN N
making NN N
: : N
an DT N
example NN N
in IN N
diagnosis NN N
. . N

The DT N
unconscious JJ N
thought NN N
effect NN N
refers NNS N
to TO N
improved JJ N
judgments NNS N
and CC N
decisions NNS N
after IN N
a DT N
period NN N
of IN N
distraction NN N
. . N

The DT N
authors NNS N
studied VBD N
the DT N
unconscious JJ N
thought NN N
effect NN N
in IN N
a DT N
complex JJ N
and CC N
error-prone JJ N
part NN N
of IN N
clinical JJ N
decision NN N
making NN N
: : N
diagnosis NN N
. . N

Their PRP$ N
aim NN N
was VBD N
to TO N
test VB N
whether IN N
conscious JJ N
versus FW N
unconscious JJ N
processing NN N
influenced JJ N
diagnosis NN N
of IN N
psychiatric JJ N
cases NNS N
. . N

They PRP N
used VBD N
case NN N
descriptions NNS N
from IN N
the DT N
DSM-IV NNP N
casebook NN N
. . N

Half NN p
of IN p
the DT p
participants NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
conscious-processing-condition NN i
( ( p
i.e. FW p
, , N
consciously RB p
thinking VBG p
about IN p
the DT p
information NN p
they PRP p
read VBP p
in IN p
the DT p
case NN p
description NN p
) ) p
, , p
the DT p
other JJ p
half NN p
to TO p
the DT p
unconscious-processing JJ i
condition NN i
( ( p
i.e. FW p
, , N
performing VBG p
an DT p
unrelated JJ p
distracter NN p
task NN p
) ) p
. . p

The DT N
main JJ N
dependent JJ N
measure NN N
was VBD N
the DT N
total JJ o
number NN o
of IN o
correct JJ o
classifications NNS o
. . o

Compared VBN N
to TO N
conscious JJ N
processing NN N
, , N
unconscious JJ N
processing VBG N
significantly RB N
increased VBN N
the DT N
number NN o
of IN o
correct JJ o
classifications NNS o
. . o

The DT N
results NNS N
show VBP N
the DT N
potential JJ N
merits NNS N
of IN N
unconscious JJ N
processing NN N
in IN N
diagnostic JJ o
decision NN o
making NN o
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
nimodipine JJ i
upon IN N
electroencephalographic JJ o
vigilance NN o
in IN N
elderly JJ p
persons NNS p
with IN p
minor JJ p
impairment NN p
of IN p
brain NN p
functions NNS p
. . p

10 CD p
volunteers NNS p
( ( p
61-78 CD p
years NNS p
) ) p
with IN p
minor JJ p
impairment NN p
of IN p
brain NN p
function NN p
were VBD N
given VBN N
placebo NNS i
, , N
40 CD N
mg NN N
and CC N
60 CD N
mg NNS N
nimodipine JJ i
( ( i
Nimotop NNP i
) ) i
in IN N
single JJ N
doses NNS N
with IN N
intervals NNS N
of IN N
3 CD N
medication-free JJ N
days NNS N
between IN N
medications NNS N
under IN N
double-blind JJ N
conditions NNS N
. . N

Consecutive JJ N
2-s JJ N
epochs NN N
of IN N
a DT N
10-min JJ i
EEG NN i
record NN N
( ( N
resting VBG N
conditions NNS N
) ) N
of IN N
F3/C3-F4/C4-P3/01-P4/02 NNP N
were VBD N
subjected VBN N
to TO N
FFT NNP N
( ( N
Fast NNP N
Fourier NNP N
Transform NNP N
) ) N
. . N

Using VBG N
the DT N
information NN N
given VBN N
by IN N
the DT N
4 CD N
leads NNS N
for IN N
each DT N
minute NN N
of IN N
recording VBG N
the DT N
number NN o
of IN o
epochs NN o
which WDT N
correspond NN N
to TO N
a DT N
stage NN N
A DT N
or CC N
non-A JJ N
were VBD N
determined VBN N
. . N

In IN N
order NN N
to TO N
evaluate VB N
subtle JJ N
effects NNS N
on IN N
electroencephalographic JJ N
vigilance NN N
within IN N
stage NN N
A NNP N
, , N
also RB N
the DT N
anterior-posterior JJ o
and CC o
left-right JJ o
relations NNS o
of IN o
absolute JJ o
alpha-power NN o
were VBD N
calculated VBN N
. . N

Since IN N
previous JJ N
findings NNS N
suggested VBD N
that IN N
a DT N
nimodipine JJ N
effect NN N
can MD N
only RB N
be VB N
demonstrated VBN N
when WRB N
individual JJ N
differences NNS N
in IN N
the DT N
baseline-EEG NN o
are VBP N
considered VBN N
, , N
the DT N
subjects NNS N
were VBD N
subdivided VBN N
in IN N
equal JJ N
subgroups NNS N
according VBG N
to TO N
the DT N
number NN N
of IN N
non-A JJ N
epochs NN N
under IN N
placebo NN N
. . N

The DT N
rationale NN N
for IN N
this DT N
is VBZ N
the DT N
finding NN N
that IN N
in IN N
geriatric JJ p
patients NNS p
two CD N
electroencephalographically RB N
distinguishable JJ N
forms NNS o
of IN N
dissolution NN N
can MD N
be VB N
observed VBN N
. . N

Under IN N
both DT N
40 CD N
mg NN N
and CC N
60 CD N
mg NNS N
nimodipine VBP i
the DT N
subgroup NN N
with IN N
a DT N
prevalence NN N
of IN N
non-A JJ o
epochs NN o
( ( N
poor JJ N
alpha-activity NN o
) ) o
showed VBD N
a DT N
decrease NN N
of IN N
non-A JJ o
epochs NN o
; : o
the DT N
subgroup NN N
with IN N
a DT N
prevalence NN o
of IN o
A-epochs NNP o
( ( o
abundant JJ o
alpha-activity NN o
) ) o
, , N
an DT N
increase NN N
. . N

Opposite JJ N
results NNS N
for IN N
the DT N
two CD N
subgroups NNS N
were VBD N
also RB N
obtained VBN N
for IN N
the DT N
left-right JJ o
relations NNS o
of IN o
alpha-power NN o
over IN N
the DT N
anterior JJ N
regions NNS N
. . N

Under IN N
40 CD N
mg NNS N
nimodipine VBP i
the DT N
subgroup NN N
with IN N
poor JJ N
alpha-activity NN o
showed VBD N
a DT N
shift NN o
to TO o
the DT o
left NN o
; : o
the DT N
subgroup NN N
with IN N
abundant JJ N
alpha-activity NN o
to TO o
the DT o
right NN o
. . o

Under IN N
60 CD N
mg NN N
nimodipine JJ i
both DT N
subgroups NNS N
showed VBD N
a DT N
shift NN o
to TO o
the DT o
left NN o
. . o

The DT N
results NNS N
confirm VBP N
findings NNS N
that WDT N
nimodipine VBP N
stabilizes VBZ N
electroencephalographic JJ o
vigilance NN o
at IN N
a DT N
medium NN N
level NN N
. . N

Moreover RB N
they PRP N
suggest VBP N
a DT N
dose JJ N
dependence NN N
of IN N
the DT N
effect NN N
, , N
i.e. FW N
, , N
at IN N
higher JJR N
doses NNS N
nimodipine VBP i
seems VBZ N
to TO N
act VB N
as IN N
a DT N
sedative NN N
. . N

-DOCSTART- -X- O O

PDE5 NNP i
inhibition NN i
with IN N
sildenafil JJ i
improves NNS N
left VBD N
ventricular JJ N
diastolic JJ N
function NN N
, , N
cardiac JJ N
geometry NN N
, , N
and CC N
clinical JJ N
status NN N
in IN N
patients NNS p
with IN p
stable JJ p
systolic JJ p
heart NN p
failure NN p
: : p
results NNS N
of IN N
a DT N
1-year JJ N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
. . N

BACKGROUND NNP N
In IN N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
, , N
a DT N
defective JJ N
nitric JJ N
oxide IN N
signaling VBG N
is VBZ N
involved VBN N
in IN N
left JJ N
ventricular NN N
( ( N
LV NNP N
) ) N
diastolic NN N
abnormalities NNS N
and CC N
remodeling VBG N
. . N

PDE5 NNP N
inhibition NN N
, , N
by IN N
blocking VBG N
degradation NN N
of IN N
nitric JJ N
oxide IN N
second-messenger JJ N
cyclic JJ N
guanosine NN N
monophosphate NN N
, , N
might MD N
be VB N
beneficial JJ N
. . N

In IN N
a DT N
cohort NN N
of IN N
systolic JJ p
HF NNP p
patients NNS p
, , N
we PRP N
tested VBD N
the DT N
effects NNS N
of IN N
PDE5 NNP N
inhibition NN N
( ( i
sildenafil NN i
) ) i
on IN N
LV NNP N
ejection NN N
fraction NN N
, , N
diastolic JJ N
function NN N
, , N
cardiac JJ N
geometry NN N
, , N
and CC N
clinical JJ N
status NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Forty-five JJ p
HF NNP p
patients NNS p
( ( p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
II-III NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB i
or CC i
sildenafil VB i
( ( N
50 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
) ) N
for IN N
1 CD N
year NN N
, , N
with IN N
assessment NN N
( ( N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
) ) N
of IN N
LV NNP o
ejection NN o
fraction NN o
, , o
diastolic JJ o
function NN o
, , o
geometry NN o
, , o
cardiopulmonary JJ o
exercise NN o
performance NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

In IN N
the DT N
sildenafil NN N
group NN N
only RB N
, , N
at IN N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
, , N
LV NNP o
ejection NN o
fraction NN o
, , o
early JJ o
diastolic JJ o
tissue NN o
Doppler NNP o
velocities NNS o
( ( o
E NNP o
' POS o
) ) o
at IN o
the DT o
mitral JJ o
lateral JJ o
( ( N
from IN N
4.62 CD N
to TO N
5.20 CD N
and CC N
5.19 CD N
m/s NN N
) ) N
and CC N
septal JJ o
( ( N
from IN N
4.71 CD N
to TO N
5.23 CD N
and CC N
5.24 CD N
m/s NN N
) ) N
annuli VBZ o
significantly RB o
increased VBN N
, , N
whereas IN N
the DT N
ratio NN N
of IN N
early JJ N
transmitral NN N
( ( N
E NNP N
) ) N
to TO N
E NNP N
' POS N
lateral JJ N
decreased VBN N
( ( N
from IN N
13.1 CD N
to TO N
9.8 CD N
to TO N
9.4 CD N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Changes NNS N
were VBD N
accompanied VBN N
by IN N
a DT N
reverse NN o
remodeling NN o
of IN o
left JJ o
atrial JJ o
volume NN o
index NN o
( ( N
from IN N
32.0 CD N
to TO N
29.0 CD N
and CC N
29.1 CD N
mL/m NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
LV NNP o
mass NNP o
index NN o
( ( N
from IN N
148.0 CD N
to TO N
130.0 CD N
and CC N
128.0 CD N
g/m NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Furthermore UH N
, , N
sildenafil JJ i
improved VBN N
exercise NN o
performance NN o
( ( o
peak JJ o
Vo NNP o
( ( o
2 CD o
) ) o
) ) o
, , o
ventilation NN o
efficiency NN o
( ( o
ventilation NN o
to TO o
CO NNP o
( ( o
2 CD o
) ) o
production NN o
slope NN o
) ) o
, , o
and CC o
quality NN o
of IN o
life NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Minor JJ N
adverse JJ N
effects NNS N
were VBD N
noted VBN N
: : N
flushing NN o
in IN N
4 CD N
and CC N
headache NN o
in IN N
2 CD N
treated JJ N
patients NNS N
. . N

CONCLUSIONS NNP N
Findings NNP N
confirm NN N
that IN N
in IN N
HF NNP N
, , N
sildenafil NN i
improves VBZ N
functional JJ o
capacity NN o
and CC o
clinical JJ o
status NN o
and CC N
provide VB N
the DT N
first JJ N
human JJ N
evidence NN N
that IN N
LV NNP o
diastolic JJ o
function NN o
and CC N
cardiac JJ o
geometry NN o
are VBP N
additional JJ N
targets NNS N
of IN N
benefits NNS N
related VBN N
to TO N
chronic JJ N
PDE5 NNP N
inhibition NN N
. . N

-DOCSTART- -X- O O

Infant NNP N
distress NN N
and CC N
development NN N
of IN N
functional JJ N
gastrointestinal JJ N
disorders NNS N
in IN N
childhood NN N
: : N
is VBZ N
there EX N
a DT N
connection NN N
? . N
-DOCSTART- -X- O O

Hypoxic NNP i
exercise NN i
training NN i
reduces NNS N
senescent JJ o
T-lymphocyte JJ o
subsets NNS o
in IN o
blood NN o
. . o

The DT N
integration NN N
and CC N
control NN N
of IN N
systemic JJ N
immune JJ N
responses NNS N
depends VBZ N
on IN N
the DT N
regulated JJ N
trafficking NN N
of IN N
T-lymphocytes NNP N
. . N

This DT N
study NN N
elucidates VBZ N
how WRB N
various JJ N
exercises NNS N
regimens VBZ N
with/without IN N
hypoxia NN N
affect VBP N
phenotypic NN o
characteristics NNS o
of IN o
T-lymphocyte NNP o
subsets NNS o
in IN o
blood NN o
. . o

Fifty NNP p
sedentary JJ p
males NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
five CD N
groups NNS N
. . N

Each DT N
group NN N
( ( N
n=10 NN N
) ) N
received VBD N
one CD N
of IN N
five CD N
interventions NNS N
: : N
normoxic NN i
( ( i
21 CD i
% NN i
O? NNP i
) ) i
resting NN i
( ( i
N-C NNP i
) ) i
, , i
hypoxic NN i
( ( i
15 CD i
% NN i
O? NNP i
) ) i
resting NN i
( ( i
H-C NNP i
) ) i
, , i
normoxic JJ i
exercise NN i
( ( i
50 CD i
% NN i
W NNP i
( ( i
max NN i
) ) i
under IN i
21 CD i
% NN i
O? NNP i
, , i
N-T NNP i
) ) i
, , i
hypoxic-relative JJ i
exercise NN i
( ( i
50 CD i
% NN i
maximal JJ i
heart NN i
rate NN i
reserve NN i
under IN i
15 CD i
% NN i
O? NNP i
, , i
H-RT NNP i
) ) i
, , i
or CC i
hypoxic-absolute JJ i
exercise NN i
( ( i
50 CD i
% NN i
W NNP i
( ( i
max NN i
) ) i
under IN i
15 CD i
% NN i
O? NNP i
, , i
H-AT NNP i
) ) i
for IN i
30 CD N
min/day NN N
, , N
5 CD N
days/week NN N
for IN N
4 CD N
weeks NNS N
. . N

Before IN N
the DT N
intervention NN N
, , N
strenuous JJ N
exercise NN N
up RB N
to TO N
exhaustion NN N
increased VBD N
the DT o
mobilization NN o
of IN o
CD3 NNP o
, , o
CD4 NNP o
, , o
CD8 NNP o
, , o
or CC o
CD8 NNP o
( ( o
bright VBN o
) ) o
lymphocytes VBZ o
expressing VBG o
activated VBN o
( ( o
CD11a NNP o
) ) o
or CC o
senescent NN o
( ( o
KLRG1 NNP o
) ) o
molecules VBZ o
into IN o
the DT o
peripheral JJ o
blood NN o
compartment NN o
. . o

The DT o
H-AT NNP o
for IN N
4 CD N
weeks NNS N
up-regulated JJ o
co-stimulatory JJ o
molecule NN o
CD28 NNP o
expression NN o
and CC o
was VBD o
accompanied VBN o
by IN N
depressed JJ N
KLRG1 NNP o
level NN o
on IN o
CD3 NNP o
, , o
CD4 NNP o
, , o
CD8 NNP o
, , o
or CC o
CD8 NNP o
( ( o
bright VBN o
) ) o
lymphocytes VBZ o
at IN o
rest NN o
or CC o
following VBG N
exercise NN N
. . N

Simultaneously RB i
, , i
this DT i
intervention NN i
increased VBD i
interferon-? JJ o
( ( o
IFN-? NNP o
) ) o
level NN o
and CC o
unchanged JJ o
interleukin-4 JJ o
level NN o
, , o
as RB o
well RB o
as IN N
, , N
decreased VBD o
myeloperoxidase NN o
( ( o
MPO NNP o
) ) o
and CC o
interleukin-6 JJ o
levels NNS o
in IN o
plasma NN o
. . o

However RB N
, , N
no DT N
significant JJ N
changes NNS N
in IN N
resting VBG N
and CC N
exercise-induced JJ o
mobilizations NNS o
of IN o
various JJ o
T-lymphocyte JJ o
subsets NNS o
and CC o
productions NNS o
of IN o
cytokines NNS o
and CC o
MPO NNP o
occurred VBD o
following VBG N
the DT i
N-C NNP i
, , i
H-C NNP i
, , i
N-T NNP i
, , i
and CC i
H-RT NNP i
interventions NNS i
. . i

Therefore RB i
, , i
we PRP N
conclude VBP N
that IN N
4-week JJ N
H-AT NNP i
intervention NN i
reduced VBD o
senescent JJ o
T-lymphocyte JJ o
subsets NNS o
with IN o
increasing VBG o
IFN-? NNP o
level NN o
in IN o
blood NN o
, , o
which WDT o
responses NNS N
are VBP N
accompanied VBN N
by IN o
depressed JJ o
oxidative JJ o
stress NN o
and CC o
pro-inflammatory JJ o
cytokine NN o
production NN o
. . o

These DT N
findings NNS N
can MD N
help VB N
to TO N
determine VB N
an DT N
effective JJ N
hypoxic NN i
exercise NN i
regimen NNS i
to TO N
minimize VB o
immune JJ o
dysfunction NN o
by IN N
retarding VBG N
T-lymphocyte JJ o
senescence NN o
. . o

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
different JJ N
acupuncture NN i
and CC i
moxibustion NN i
therapies NNS i
for IN N
treatment NN N
of IN N
postsurgical JJ p
gastroparesis NN p
syndrome NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
optimize VB N
therapy NN N
of IN N
acupuncture NN i
and CC i
moxibustion NN i
for IN N
postsurgical JJ p
gastroparesis NN p
syndrome NN p
( ( p
PGS NNP p
) ) p
. . p

METHODS NNP N
Forty-one JJ p
cases NNS p
of IN p
PGS NNP p
were VBD p
randomly RB p
divided VBN p
into IN p
3 CD p
groups NNS p
in IN p
order NN p
of IN p
visiting VBG p
. . p

Group NNP N
A NNP N
( ( p
n JJ p
= NNP p
17 CD p
) ) p
were VBD N
treated VBN N
by IN N
warming VBG i
needle JJ i
moxibustion NN i
, , N
group NN N
B NNP N
( ( p
n JJ p
= NNP p
12 CD p
) ) p
by IN N
acupuncture NN i
plus CC i
auricular JJ i
point NN i
sticking NN i
, , N
and CC N
group NN N
C NNP N
( ( p
n JJ p
= NNP p
12 CD p
) ) p
by IN N
routine JJ i
acupuncture NN i
. . i

Changes NNS N
of IN N
gastric JJ o
drainage NN o
volume NN o
, , o
therapeutic JJ o
times NNS o
and CC o
cured JJ o
rate NN o
were VBD N
investigated VBN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

RESULTS NNP N
All PDT N
the DT N
3 CD N
therapeutic JJ N
methods NNS N
could MD N
significantly RB N
decrease VB N
gastric JJ o
drainage NN o
volume NN o
. . o

The DT N
cured JJ o
rate NN o
was VBD N
100.0 CD N
% NN N
and CC N
the DT N
therapeutic JJ o
times NNS o
was VBD N
( ( N
7.24 CD N
+/- JJ N
3.87 CD N
) ) N
in IN N
the DT N
group NN N
A NNP N
, , N
66.7 CD N
% NN N
, , N
( ( N
9.83 CD N
+/- JJ N
4.60 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
B NNP N
and CC N
75.0 CD N
% NN N
, , N
( ( N
15.25 CD N
+/- JJ N
3.81 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
C NNP N
, , N
with IN N
significant JJ N
differences NNS N
in IN N
the DT N
cured JJ o
rate NN o
and CC o
the DT o
therapeutic JJ o
times NNS o
among IN N
the DT N
3 CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
The DT N
warming VBG i
needle JJ i
moxibustion NN i
is VBZ N
the DT N
best JJS N
method NN N
for IN N
PGS NNP p
, , N
with IN N
less RBR N
therapeutic JJ o
times NNS o
, , N
high JJ N
cured VBN o
rate NN o
and CC N
rapid JJ N
effect NN o
. . o

-DOCSTART- -X- O O

Comparison NNP N
of IN N
high JJ N
and CC N
low JJ N
dose NN N
of IN N
the DT N
inhaled JJ i
steroid NN i
, , i
budesonide RB i
, , N
as IN N
an DT N
initial JJ N
treatment NN N
in IN N
newly RB p
detected VBN p
asthma NN p
. . p

The DT N
importance NN N
of IN N
early JJ N
initiation NN N
of IN N
inhaled JJ i
steroids NNS i
even RB N
in IN N
mild JJ N
asthma NN N
has VBZ N
been VBN N
documented VBN N
in IN N
several JJ N
studies NNS N
. . N

It PRP N
is VBZ N
not RB N
, , N
however RB N
, , N
clear JJ N
whether IN N
the DT N
treatment NN N
should MD N
be VB N
started VBN N
with IN N
a DT N
high JJ N
or CC N
a DT N
low JJ N
dose NN N
of IN N
the DT N
inhaled JJ N
steroid NN N
. . N

We PRP N
have VBP N
compared VBN N
the DT N
effects NNS N
of IN N
high JJ i
and CC i
low JJ i
dose NN i
inhaled VBN i
steroid NN i
, , i
budesonide NN i
, , N
in IN N
patients NNS p
with IN p
newly RB p
detected VBN p
asthma NN p
. . p

We PRP N
studied VBD N
101 CD p
adult NN p
patients NNS p
with IN p
newly RB p
detected VBN p
bronchial JJ p
asthma NN p
who WP p
were VBD p
without IN p
inhaled VBN p
steroid NN p
or CC p
any DT p
regular JJ p
pharmacological JJ p
treatment NN p
for IN p
their PRP$ p
asthma NN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
treatment NN N
groups NNS N
: : N
one CD N
to TO N
receive VB N
800 CD i
microg NN i
inhaled VBD i
budesonide JJ i
per IN N
day NN N
and CC N
the DT N
other JJ N
to TO N
receive VB N
200 CD i
microg NN i
inhaled VBD i
budesonide JJ i
per IN N
day NN N
. . N

The DT N
drugs NNS N
were VBD N
given VBN N
with IN N
a DT N
Turbuhaler NNP i
dry JJ i
powder NN i
inhaler NN i
. . i

During IN N
the DT N
3-month JJ N
treatment NN N
period NN N
, , N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
were VBD N
noted VBN N
in IN N
morning NN o
or CC o
evening NN o
PEF NNP o
values VBZ o
, , N
in IN N
spirometric JJ N
parameters NNS N
, , N
in IN N
asthmatic JJ N
symptoms NNS N
or CC N
in IN N
the DT N
use NN N
of IN N
rescue NN N
beta2-agonists NNS N
. . N

The DT N
decrease NN o
in IN o
bronchial JJ o
hyperresponsiveness NN o
was VBD N
, , N
however RB N
, , N
more JJR o
marked VBN o
in IN N
the DT N
high JJ N
dose JJ N
budesonide NN i
group NN N
, , N
reaching VBG N
a DT N
borderline NN N
significance NN N
( ( N
P=0.10 NNP N
high RB N
vs. FW N
low JJ N
dose JJ N
budesonide NN N
) ) N
. . N

In IN N
addition NN N
, , N
in IN N
serum JJ o
markers NNS o
of IN o
asthmatic JJ o
inflammation NN o
significant JJ N
differences NNS N
were VBD N
shown VBN N
between IN N
the DT N
treatment NN N
groups NNS N
. . N

The DT N
decrease NN o
in IN o
the DT o
number NN o
of IN o
blood NN o
eosinophils NNS o
during IN N
the DT N
treatment NN N
was VBD N
more RBR o
marked JJ o
in IN N
the DT N
high JJ N
dose JJ N
budesonide NN i
group NN N
( ( N
P=0.02 NNP N
; : N
high JJ N
vs. FW N
low JJ N
dose JJ N
budesonide NN N
) ) N
. . N

In IN N
serum JJ o
ECP NNP o
no DT N
change NN N
was VBD N
observed VBN N
in IN N
the DT N
low JJ N
dose JJ N
budesonide NN N
group NN N
, , N
but CC N
a DT N
marked JJ N
decrease NN N
in IN N
the DT N
high-dose JJ N
budesonide NN N
group NN N
( ( N
P=0.008 NNP N
; : N
high JJ N
vs. FW N
low JJ N
dose JJ N
budesonide NN N
) ) N
. . N

The DT N
change NN N
was VBD N
even RB N
more JJR N
marked JJ o
with IN N
regard NN o
to TO o
serum VB o
EPX NNP o
( ( N
P=0.005 NNP N
; : N
high JJ N
vs. FW N
low JJ N
dose JJ N
budesonide NN N
) ) N
. . N

Our PRP$ N
results NNS N
support VB N
the DT N
view NN N
that IN N
the DT N
treatment NN N
of IN N
newly RB N
detected VBN N
asthma NN N
should MD N
be VB N
started VBN N
with IN N
a DT N
high JJ N
dose NN N
of IN N
inhaled JJ N
steroid NN N
. . N

The DT N
low JJ N
dose NN N
may MD N
not RB N
be VB N
enough RB N
to TO N
suppress VB N
asthmatic JJ N
inflammation NN N
despite IN N
good JJ o
clinical JJ o
primary JJ o
response NN o
. . o

-DOCSTART- -X- O O

Comparative JJ N
trial NN N
of IN N
carbenicillin NN i
and CC N
ampicillin NN i
therapy NN N
for IN N
purulent NN p
meningitis NN p
. . p

A DT N
randomized JJ N
therapeutic JJ N
trial NN N
of IN N
carbenicillin NN i
( ( i
CB NNP i
) ) i
or CC i
ampicillin NN i
( ( i
AMP NNP i
) ) i
in IN N
purulent NN N
meningitis NN N
was VBD N
performed VBN N
in IN N
86 CD p
pediatric JJ p
and CC p
adult NN p
patients NNS p
( ( p
41 CD p
Haemophilus NNP p
influenzae NN p
, , p
22 CD p
Streptococcus NNP p
pneumoniae NN p
, , p
13 CD p
Neisseria NNP p
meningitidis NN p
, , p
and CC p
10 CD p
of IN p
unknown JJ p
etiology NN p
) ) p
. . p

All DT N
isolates NNS N
, , N
incuding VBG N
H. NNP N
influenzae NN N
, , N
were VBD N
susceptible JJ N
to TO N
CB NNP N
and CC N
AMP NNP N
. . N

Median JJ N
cerebrospinal JJ o
fluid NN o
( ( o
CSF NNP o
) ) o
antibiotic JJ o
concentrations NNS o
were VBD N
0.85 CD N
and CC N
1.60 CD N
mug/ml NN N
for IN N
CB NNP N
and CC N
AMP NNP N
, , N
respectively RB N
, , N
during IN N
administration NN N
of IN N
daily JJ N
doses NNS N
of IN N
400 CD N
mg/kg NNS N
and CC N
0.65 CD N
and CC N
0.45 CD N
mug/ml NN N
, , N
respectively RB N
, , N
on IN N
daily JJ N
doses NNS N
of IN N
200 CD N
mg/kg NN N
. . N

Higher JJR o
CSF NNP o
concentrations NNS o
, , N
up RB N
to TO N
a DT N
median JJ N
concentration NN N
of IN N
4.5 CD N
mug/ml NNS N
, , N
were VBD N
observed VBN N
in IN N
patients NNS N
with IN N
CSF NNP N
protein NN N
concentrations NNS N
> VBP N
/=75 JJ N
mg/100 NN N
ml NN N
. . N

Clinical JJ o
responses NNS o
were VBD N
equivalent JJ N
on IN N
either CC N
antibiotic JJ N
regimen NNS N
. . N

Among IN N
AMP JJ i
patients NNS N
( ( N
45 CD N
) ) N
, , N
8 CD N
had VBD o
significant JJ o
residua NN o
and CC N
3 CD N
died VBD o
; : o
among IN N
CB NNP i
patients NNS N
( ( N
41 CD N
) ) N
, , N
5 CD N
had VBD o
residua NN o
and CC N
none NN o
died VBD o
. . o

However RB N
, , N
38 CD N
% NN N
of IN N
H. NNP p
influenzae NN p
patients NNS p
treated VBN N
with IN N
CB NNP i
had VBD N
positive JJ o
CSF NNP o
cultures NNS o
on IN N
day NN N
1 CD N
follow-up JJ N
lumbar NN N
punctures NNS N
, , N
compared VBN N
with IN N
only RB N
5.8 CD N
% NN N
of IN N
AMP NNP N
patients NNS p
with IN p
H. NNP p
influenzae NN p
. . p

The DT N
significance NN N
of IN N
a DT N
delay NN o
of IN o
CSF NNP o
sterilization NN o
among IN N
CB-treated JJ N
patients NNS N
is VBZ N
unknown JJ N
, , N
since IN N
there EX N
was VBD N
no DT N
correlation NN N
between IN N
persistence NN N
of IN N
hemophilus JJ N
organisms NNS N
and CC N
the DT N
frequency NN N
of IN N
adverse JJ N
outcome NN N
. . N

AMP NNP i
and CC N
CB NNP i
are VBP N
equivalent JJ N
for IN N
the DT N
treatment NN N
of IN N
bacterial JJ N
meningitis NN N
due JJ N
to TO N
susceptible JJ N
organisms NNS N
. . N

-DOCSTART- -X- O O

Pulsatile NNP o
insulin NN o
delivery NN o
is VBZ N
more RBR N
efficient JJ N
than IN N
continuous JJ i
infusion NN i
in IN N
modulating VBG N
islet NN N
cell NN N
function NN N
in IN N
normal JJ p
subjects NNS p
and CC p
patients NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
. . p

The DT N
respective JJ N
modulating NN N
effects NNS N
of IN N
continuous JJ i
and CC i
intermittent JJ i
insulin NN i
delivery NN i
on IN N
pancreatic JJ N
islet NN N
cell NN N
function NN N
were VBD N
studied VBN N
in IN N
seven CD p
normal JJ p
men NNS p
and CC p
nine CD p
insulin-dependent NN p
( ( p
type JJ p
1 CD p
) ) p
diabetic JJ p
patients NNS p
. . p

In IN N
the DT N
normal JJ p
men NNS p
, , N
saline NN i
or CC i
continuous JJ i
( ( N
0.8 CD N
mU RB N
kg-1 JJ N
min-1 NN N
) ) N
or CC i
pulsatile NN i
( ( N
5.2 CD N
mU RB N
kg-1 JJ N
min-1 NNS N
, , N
with IN N
a DT N
switching VBG N
on/off RP N
length NN N
of IN N
2/11 CD N
min NN N
) ) N
human JJ i
insulin NN i
were VBD N
delivered VBN N
on IN N
different JJ N
days NNS N
and CC N
in IN N
random JJ N
order NN N
. . N

Despite IN N
hyperinsulinemia NN N
, , N
blood NN N
glucose NN N
was VBD N
kept VBN N
close RB N
to TO N
its PRP$ N
basal NN N
value NN N
by IN N
the DT N
glucose JJ N
clamp NN N
technique NN N
. . N

The DT N
diabetic JJ p
patients NNS p
also RB N
were VBD N
infused VBN N
in IN N
random JJ N
order NN N
and CC N
on IN N
different JJ N
days NNS N
with IN N
either DT N
saline NN i
or CC N
a DT N
smaller JJR i
amount NN i
of IN i
insulin NN i
delivered VBN i
continuously RB i
( ( N
0.15 CD N
mU RB N
kg-1 JJ N
min-1 NN N
) ) N
or CC i
in IN i
a DT i
pulsatile JJ i
manner NN i
( ( N
0.97 CD N
mU RB N
kg-1 JJ N
min-1 NN N
for IN N
2 CD N
min NN N
, , N
followed VBN N
by IN N
11 CD N
min NNS N
during IN N
which WDT N
no DT N
insulin NN N
was VBD N
infused VBN N
) ) N
. . N

In IN N
all DT N
experiments NNS N
, , N
5 CD N
g NN N
arginine NN i
were VBD N
given VBN N
iv NNS N
as IN N
a DT N
bolus NN N
dose JJ N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
and CC N
plasma VB o
C-peptide NNP o
and CC o
glucagon NN o
levels NNS o
were VBD N
determined VBN N
to TO N
assess VB N
islet NN N
cell NN N
function NN N
. . N

In IN N
the DT N
normal JJ p
men NNS p
, , N
insulin NN N
administration NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decline NN N
of IN N
basal NN o
plasma NN o
glucagon NN o
and CC o
C-peptide JJ o
levels NNS o
and CC N
in IN N
a DT N
clear-cut JJ N
decrease NN N
in IN N
the DT N
arginine-induced JJ o
glucagon NN o
response NN o
. . o

These DT N
effects NNS N
of IN N
insulin NN N
were VBD N
significantly RB N
more RBR N
marked JJ N
when WRB N
insulin NN N
was VBD N
delivered VBN N
in IN N
a DT N
pulsatile NN N
rather RB N
than IN N
a DT N
continuous JJ N
manner NN N
. . N

In IN N
the DT N
insulin-dependent JJ p
diabetic JJ p
patients NNS p
, , N
the DT N
lower JJR N
dose NN N
of IN N
insulin NN N
infused VBN N
continuously RB N
did VBD N
not RB N
alter VB N
the DT N
basal NN o
or CC o
arginine-stimulated JJ o
glucagon NN o
response NN o
. . o

In IN N
contrast NN N
, , N
when WRB N
the DT N
same JJ N
amount NN N
of IN N
insulin NN N
was VBD N
delivered VBN N
intermittently RB N
, , N
arginine-induced JJ o
glucagon NN o
release NN o
was VBD N
greatly RB N
reduced VBN N
. . N

Thus RB N
, , N
these DT N
data NNS N
support NN N
the DT N
concept NN N
that WDT N
insulin VBZ N
per IN N
se NN N
is VBZ N
a DT N
potent JJ N
physiological JJ o
modulator NN o
of IN o
islet NN o
A- NNP o
and CC o
B-cell NNP o
function NN o
. . o

Furthermore RB N
, , N
they PRP N
suggest VBP N
that IN N
these DT N
effects NNS N
of IN N
insulin NN N
are VBP N
reinforced VBN N
when WRB N
the DT N
hormone NN N
is VBZ N
administered VBN N
in IN N
an DT N
intermittent JJ N
manner NN N
in IN N
an DT N
attempt NN N
to TO N
reproduce VB N
the DT N
pulsatile NN o
physiological JJ o
release NN o
of IN o
insulin NN o
. . o

-DOCSTART- -X- O O

Brain NNP o
activity NN o
correlates VBZ p
differentially RB p
with IN p
increasing VBG p
temporal JJ p
complexity NN p
of IN p
rhythms NN p
during IN p
initialisation NN p
, , p
synchronisation NN p
, , p
and CC p
continuation NN p
phases NNS p
of IN p
paced JJ i
finger NN i
tapping VBG i
. . i

Activity NN o
in IN o
parts NNS o
of IN o
the DT o
human JJ o
motor NN o
system NN o
has VBZ N
been VBN N
shown VBN N
to TO N
correlate VB N
with IN N
the DT N
complexity NN N
of IN N
performed JJ N
motor NN N
sequences NNS N
in IN N
terms NNS N
of IN N
the DT N
number NN N
of IN N
limbs NNS N
moved VBN N
, , N
number NN N
of IN N
movements NNS N
, , N
and CC N
number NN N
of IN N
trajectories NNS N
. . N

Here RB N
, , N
we PRP N
searched VBD N
for IN N
activity NN N
correlating VBG N
with IN N
temporal JJ N
complexity NN N
, , N
in IN N
terms NNS N
of IN N
the DT N
number NN N
of IN N
different JJ N
intervals NNS N
produced VBN N
in IN N
the DT N
sequence NN N
, , N
using VBG N
an DT N
overlearned JJ N
tapping NN N
task NN N
. . N

Our PRP$ N
task NN N
was VBD N
divided VBN N
into IN N
three CD N
phases NNS N
: : N
movement NN i
selection NN i
and CC i
initiation NN i
( ( i
initiate NN i
) ) i
, , i
synchronisation NN i
of IN i
finger NN i
tapping VBG i
with IN i
an DT i
external JJ i
auditory NN i
cue NN i
( ( i
synchronise NN i
) ) i
, , N
and CC N
continued VBD i
tapping VBG i
in IN i
absence NN i
of IN i
the DT i
auditory JJ i
pacer NN i
( ( N
continue NN N
) ) N
. . N

Comparisons NNS N
between IN N
synchronisation NN N
and CC N
continuation NN N
showed VBD N
a DT N
pattern NN N
in IN N
keeping VBG N
with IN N
prior JJ N
neuroimaging VBG N
studies NNS N
of IN N
paced JJ N
finger NN N
tapping VBG N
. . N

Thus RB N
, , N
activation NN o
of IN o
bilateral JJ o
SMA NNP o
and CC o
basal NN o
ganglia NN o
was VBD N
greater JJR N
in IN N
continuation NN i
tapping VBG N
than IN N
in IN N
synchronisation NN i
tapping NN N
. . N

Parametric JJ N
analysis NN N
revealed VBD N
activity NN o
correlating VBG o
with IN o
temporal JJ o
complexity NN o
during IN o
initiate NN o
in IN o
bilateral JJ o
supplementary JJ o
and CC o
pre-supplementary JJ o
motor NN o
cortex NN o
( ( o
SMA NNP o
and CC o
preSMA NN o
) ) o
, , o
rostral JJ o
dorsal NN o
premotor NN o
cortex NN o
( ( o
PMC NNP o
) ) o
, , o
basal JJ o
ganglia NN o
, , o
and CC o
dorsolateral JJ o
prefrontal NN o
cortex NN o
( ( o
DLPFC NNP o
) ) o
, , o
among IN o
other JJ o
areas NNS o
. . o

During IN N
synchronise NN N
, , N
correlated VBD o
activity NN o
was VBD N
observed VBN N
in IN N
bilateral JJ N
SMA NNP N
, , N
more RBR N
caudal JJ N
dorsal NN N
and CC N
ventral JJ N
PMC NNP N
, , N
right JJ N
DLPFC NNP N
and CC N
right JJ N
primary NN N
motor NN N
cortex NN N
. . N

No DT N
correlated JJ N
activity NN N
was VBD N
observed VBN N
during IN N
continue NN N
at IN N
P NNP N
< $ N
0.01 CD N
( ( N
corrected VBN N
, , N
cluster JJR N
level NN N
) ) N
, , N
though RB N
left VBD N
angular JJ N
gyrus NN N
was VBD N
active JJ N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

We PRP N
suggest VBP N
that IN N
the DT N
preSMA NN o
and CC o
rostral JJ o
dorsal NN o
PMC NNP o
activities NNS o
during IN N
initiate NN N
may MD N
be VB N
associated VBN N
with IN N
selection NN o
of IN o
timing VBG o
parameters NNS o
, , N
while IN N
activation NN N
in IN N
centromedial JJ N
prefrontal JJ N
cortex NN N
during IN N
both DT N
initiate JJ N
and CC N
synchronise NN N
may MD N
be VB N
associated VBN N
with IN N
temporal JJ o
error NN o
monitoring NN o
or CC o
correction NN o
. . o

The DT N
absence NN N
of IN N
activity NN o
significantly RB o
correlated VBN o
with IN o
temporal JJ o
complexity NN o
during IN N
continue JJ N
suggests NNS N
that IN N
, , N
once RB N
an DT N
overlearned VBN N
timed JJ N
movement NN N
sequence NN N
has VBZ N
been VBN N
selected VBN N
and CC N
initiated VBN N
, , N
there EX N
is VBZ N
no DT N
further JJ N
adjustment NN N
of IN N
the DT N
timing NN N
control NN N
processes VBZ N
related VBN N
to TO N
its PRP$ N
continued JJ N
production NN N
in IN N
absence NN N
of IN N
external JJ N
cues NNS N
. . N

-DOCSTART- -X- O O

Theophylline NNP o
concentrations NNS o
in IN N
serum NN N
and CC N
saliva NN N
after IN N
oral JJ N
microcrystalline NN i
and CC N
sustained-release JJ i
preparations NNS i
in IN N
asthmatics NNS p
. . p

Theophylline NNP o
concentrations NNS o
in IN N
saliva NN N
have VBP N
been VBN N
compared VBN N
with IN N
those DT N
in IN N
serum NN N
in IN N
13 CD p
asthmatic JJ p
patients NNS p
after IN p
single JJ p
and CC p
multiple JJ p
oral JJ p
dosage NN p
of IN p
a DT p
microcrystalline JJ i
theophylline NN i
tablet NN i
( ( p
Nuelin NNP p
) ) p
and CC p
a DT p
sustained-release JJ i
preparation NN i
( ( p
Nuelin NNP p
Retard NNP p
) ) p
. . N

There EX N
was VBD N
wide JJ N
individual JJ N
variation NN N
in IN N
the DT N
ratio NN o
of IN o
serum NN o
to TO o
saliva VB o
concentrations NNS o
indicating VBG N
that IN N
, , N
even RB N
when WRB N
individual JJ N
serum NN N
to TO N
saliva VB N
ratios NNS N
have VBP N
been VBN N
established VBN N
, , N
the DT N
use NN N
of IN N
saliva JJ N
theophylline NN i
measurements NNS N
alone RB N
is VBZ N
unreliable JJ N
for IN N
the DT N
routine JJ N
monitoring NN N
of IN N
theophylline JJ i
therapy NN i
. . i

Both DT N
preparations NNS N
produced VBD N
mean JJ o
serum NN o
theophylline NN o
concentrations NNS o
within IN N
the DT N
10 CD N
-- : N
20 CD N
mcg/ml NN N
range NN N
, , N
the DT N
sustained-release JJ N
tablet NN N
giving VBG N
higher JJR N
monitoring NN N
through IN N
values NNS N
and CC N
smaller JJR N
through IN N
to TO N
peak VB o
variation NN o
. . o

The DT N
preparations NNS N
were VBD N
equally RB N
and CC N
highly RB N
bioavailable JJ N
. . N

Side JJ o
effects NNS o
were VBD N
reported VBN N
by IN N
three CD N
patients NNS N
, , N
which WDT N
were VBD N
the DT N
patients NNS N
with IN N
the DT N
highest JJS N
AUC NN N
. . N

The DT N
Nuelin NNP i
Retard NNP i
preparation NN N
appears VBZ N
to TO N
provide VB N
smooth RB N
, , N
sustained VBD N
serum JJ o
theophylline NN o
concentrations NNS o
within IN N
the DT N
therapeutic JJ N
range NN N
and CC N
the DT N
simple JJ N
, , N
twice-daily JJ N
dosage NN N
should MD N
result VB N
in IN N
improved JJ N
patient NN N
compliance NN N
. . N

-DOCSTART- -X- O O

[ NN p
Evaluating VBG p
an DT p
interactive JJ i
, , i
multi-media JJ i
learning NN i
system NN i
for IN p
the DT p
study NN p
of IN p
primary JJ p
open JJ p
angle NN p
glaucoma NN p
] NNP p
. . N

Using VBG N
the DT N
interactive JJ i
multimedia NN i
learning NN i
system NN i
for IN N
studying VBG N
open-angle JJ p
glaucoma NN p
[ $ N
3 CD N
] CC N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
case-controlled JJ N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
determine VB N
the DT N
value NN N
of IN N
this DT N
new JJ N
form NN N
of IN N
learning VBG N
in IN N
terms NNS N
of IN N
acceptance NN o
and CC o
the DT o
imparting NN o
of IN o
knowledge NN o
. . o

This DT N
article NN N
describes VBZ N
details NNS N
of IN N
the DT N
study NN N
and CC N
presents NNS N
their PRP$ N
results NNS N
. . N

Results NNS N
were VBD N
established VBN N
on IN N
the DT N
basis NN N
of IN N
targeted JJ N
questions NNS N
asked VBD N
prior JJ N
to TO N
and CC N
after IN N
the DT N
learning NN N
phase NN N
, , N
followed VBN N
by IN N
an DT N
analysis NN N
of IN N
frequencies NNS N
and CC N
significance NN N
testing NN N
by IN N
the DT N
Chi NNP N
squared VBD N
method NN N
. . N

It PRP N
was VBD N
shown VBN N
that IN N
the DT N
imparting NN o
of IN o
knowledge NN o
is VBZ N
significantly RB N
improved VBN N
when WRB N
this DT N
learning NN i
system NN i
is VBZ N
employed VBN N
. . N

In IN N
addition NN N
, , N
after IN N
its PRP$ N
first JJ N
use NN N
, , N
acceptance NN o
of IN o
this DT o
new JJ o
medium NN o
rose VBD N
dramatically RB N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
prostaglandin NN i
E1 NNP i
for IN N
prevention NN N
of IN N
respiratory JJ N
failure NN N
in IN N
high JJ p
risk NN p
trauma NN p
patients NNS p
: : p
a DT N
prospective JJ N
clinical JJ N
trial NN N
and CC N
correlation NN N
with IN N
plasma JJ N
suppressive JJ N
factors NNS N
for IN N
neutrophil DT N
activation NN N
. . N

A DT p
group NN p
of IN p
48 CD p
critically RB p
injured JJ p
patients NNS p
were VBD N
entered VBN N
into IN N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
early JJ i
infusion NN i
of IN i
PGE1 NNP i
for IN N
reducing VBG N
the DT N
incidence NN o
of IN o
severe JJ o
respiratory JJ o
failure NN o
and CC o
mortality NN o
. . o

Secondary JJ N
assessments NNS N
examined VBD N
the DT N
effects NNS N
of IN N
the DT N
PGE1 NNP N
infusion NN N
on IN N
plasma NN N
mediated VBN N
suppression NN N
of IN N
PMN NNP N
superoxide JJ N
production NN N
and CC N
loss NN N
of IN N
PMN NNP N
granule NN N
enzyme NN N
content NN N
. . N

The DT N
incidence NN N
of IN N
severe JJ o
respiratory JJ o
failure NN o
was VBD N
lower JJR N
in IN N
the DT N
PGE1 NNP N
group NN N
-- : N
13 CD N
% NN N
versus IN N
32 CD N
% NN N
, , N
but CC N
this DT N
did VBD N
not RB N
reach VB N
significance NN N
. . N

The DT N
overall JJ N
morality NN N
was VBD N
equivalent JJ N
between IN N
the DT N
two CD N
groups NNS N
-- : N
26 CD N
% NN N
( ( i
PGE1 NNP i
) ) i
versus VBP N
28 CD N
% NN N
( ( i
placebo NN i
) ) i
. . N

The DT N
suppressive JJ N
activity NN N
of IN N
the DT N
patient NN N
plasma NN N
was VBD N
assayed VBN N
by IN N
measurement NN N
of IN N
normal JJ N
PMN NNP N
superoxide NN N
production NN N
relative JJ N
to TO N
normal JJ N
control NN N
plasma NN N
( ( N
ratio JJ N
P NNP N
: : N
C NNP N
) ) N
. . N

The DT N
baseline NN N
ratio NN N
P NNP N
: : N
C NNP N
was VBD N
62 CD N
+/- JJ N
5 CD N
% NN N
in IN N
the DT N
PGE1 NNP N
group NN N
versus VBD N
60 CD N
+/- JJ N
5 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
day NN N
1 CD N
plasma NN N
samples NNS N
showed VBD N
significant JJ N
reversal NN N
of IN N
plasma JJ o
suppressive JJ o
activity NN o
in IN N
the DT N
PGE1 NNP N
group NN N
-- : N
ratio JJ N
P NN N
: : N
C $ N
88 CD N
+/- JJ N
5 CD N
% NN N
versus NN N
67 CD N
+/- JJ N
5 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

In IN N
patients NNS N
who WP N
received VBD N
the DT N
full JJ N
7 CD N
days NNS N
of IN N
infusion NN N
, , N
the DT N
plasma JJ o
suppressive JJ o
activity NN o
remained VBD N
significantly RB N
diminished VBN N
in IN N
the DT N
PGE1 NNP N
group NN N
-- : N
ratio JJ N
P NN N
: : N
C $ N
77 CD N
+/- JJ N
4 CD N
% NN N
versus NN N
61 CD N
+/- JJ N
5 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.04 CD N
) ) N
. . N

The DT N
baseline NN N
lysozyme NN N
content NN N
of IN N
patient JJ N
PMN NNP N
's POS N
relative NN N
to TO N
that DT N
of IN N
normal JJ N
control NN N
PMNs NNP N
( ( N
ratio JJ N
P NNP N
: : N
C NNP N
) ) N
was VBD N
119 CD N
+/- JJ N
14 CD N
% NN N
in IN N
the DT N
PGE1 NNP N
group NN N
. . N

A DT N
significant JJ N
loss NN N
of IN N
lysozyme JJ N
content NN N
was VBD N
observed VBN N
in IN N
the DT N
PGE1 NNP N
group NN N
on IN N
day NN N
1 CD N
of IN N
the DT N
infusion NN N
-- : N
ratio JJ N
P NN N
: : N
C $ N
79 CD N
+/- JJ N
8 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.03 CD N
) ) N
, , N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
plasma JJ N
suppressive JJ N
activity NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Double-blind NNP N
, , N
placebo-controlled JJ i
trial NN N
of IN N
risperidone NN i
plus CC i
amantadine NN i
in IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
10-week JJ N
randomized NN N
study NN N
. . N

OBJECTIVE NNP N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
adding VBG N
amantadine NN i
to TO i
risperidone VB i
for IN N
treatment NN N
of IN N
autism NN N
. . N

METHODS NNP N
Forty NNP p
outpatients NNS p
aged VBD p
4 CD p
to12 NN p
years NNS p
, , p
who WP p
were VBD p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
based VBN p
on IN p
the DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Fourth NNP p
Edition NNP p
, , p
Text NNP p
Revision NNP p
criteria NNS p
, , N
were VBD N
assigned VBN N
to TO N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
. . N

The DT N
subjects NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
risperidone JJ i
plus CC i
amantadine JJ i
, , i
and CC i
the DT i
other JJ i
group NN i
received VBD i
risperidone JJ i
plus CC i
placebo NN i
. . i

The DT N
dose NN N
of IN N
risperidone NN N
was VBD N
titrated VBN N
between IN N
1 CD N
and CC N
2.0 CD N
mg/d NN N
, , N
and CC N
the DT N
dose NN N
of IN N
amantadine NN i
was VBD N
100 CD N
or CC N
150 CD N
mg/d NNS N
for IN N
patients NNS N
less JJR N
than IN N
30 CD N
kg NN N
or CC N
more JJR N
than IN N
30 CD N
kg NNS N
, , N
respectively RB N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
using VBG N
the DT N
Aberrant NNP o
Behavioral NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
and CC o
adverse JJ o
effects NNS o
checklist NN o
as RB N
well RB N
as IN N
clinical JJ o
global JJ o
impression-improvement NN o
( ( o
CGI-I NNP o
) ) o
at2 VBZ N
checkpoints NNS N
of IN N
5-week JJ N
intervals NNS N
after IN N
the DT N
baseline NN N
. . N

Informed NNP N
consentwas NN N
obtained VBN N
from IN N
the DT N
parents NNS N
of IN N
each DT N
participant NN N
. . N

RESULTS NNP N
Among IN N
ABC-C NNP o
subscales NNS o
, , o
Hyperactivity NNP o
and CC o
Irritability NNP o
showed VBD N
significantly RB N
greater JJR N
reduction NN N
in IN N
the DT N
amantadine NN N
group NN N
than IN N
the DT N
placebo NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
adverse JJ o
effects NNS o
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
CGI-I JJ o
scores NNS o
show VBP N
significant JJ N
improvement NN N
in IN N
the DT N
amantadine NN i
group NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
. . N

CONCLUSIONS VB N
The DT N
present JJ N
study NN N
suggests VBZ N
that IN N
amantadine NN i
may MD N
be VB N
a DT N
potential JJ N
adjunctive JJ N
treatment NN N
strategy NN N
for IN N
autism NN N
and CC N
it PRP N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

-DOCSTART- -X- O O

Single-dose JJ N
tranexamic JJ i
acid NN i
reduces NNS N
postoperative VBP o
bleeding NN o
after IN N
coronary JJ i
surgery NN i
in IN N
patients NNS p
treated VBN p
with IN p
aspirin NN i
until IN p
surgery NN p
. . p

UNLABELLED NNP N
Tranexamic NNP i
acid NN i
reduces NNS N
postoperative VBP N
bleeding NN N
after IN N
coronary JJ i
artery NN i
bypass NN i
grafting VBG i
. . i

We PRP N
evaluated VBD N
the DT N
effects NNS o
of IN N
a DT N
single JJ N
dose NN N
of IN N
tranexamic JJ i
acid NN i
given VBN N
immediately RB N
before IN N
cardiopulmonary JJ i
bypass NN i
( ( i
CPB NNP i
) ) i
in IN p
patients NNS p
treated VBN p
with IN p
aspirin NN i
until IN p
the DT p
day NN p
before IN p
surgery NN p
. . p

The DT N
study NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ i
, , N
parallel-group JJ N
trial NN N
. . N

Eighty JJ p
patients NNS p
were VBD p
included VBN p
and CC p
divided VBN p
into IN p
two CD p
groups NNS p
: : p
one CD p
group NN p
received VBD p
tranexamic JJ i
acid NN i
30 CD i
mg/kg NN i
, , i
and CC i
one CD i
group NN i
received VBD i
placebo NN i
( ( i
0.9 CD i
% NN i
NaCl NNP i
) ) i
as IN i
a DT i
bolus JJ i
injection NN i
before IN i
CPB NNP i
. . i

Postoperative NNP o
blood NN o
loss NN o
was VBD N
recorded VBN N
for IN N
16 CD N
h. JJ N
Transfusions NNS o
of IN o
blood NN o
products NNS o
were VBD N
recorded VBN N
for IN N
the DT N
whole JJ N
hospital NN N
stay NN N
. . N

Transfusions NNS N
of IN N
packed JJ N
red JJ N
cells NNS N
were VBD N
given VBN N
when WRB N
the DT N
hematocrit NN o
value NN o
was VBD N
less JJR N
than IN N
20 CD N
% NN N
during IN N
CPB NNP N
and CC N
less JJR N
than IN N
25 CD N
% NN N
after IN N
surgery NN N
. . N

The DT p
patients NNS p
in IN p
the DT p
tranexamic JJ i
acid NN i
group NN p
had VBD N
significantly RB N
less RBR N
postoperative JJ o
bleeding NN o
compared VBN N
with IN N
the DT p
patients NNS p
in IN p
the DT p
placebo NN i
group NN p
( ( N
mean JJ N
[ NNP N
SD NNP N
] NNP N
) ) N
( ( N
475 CD N
[ RB N
274 CD N
] JJ N
mL NN N
versus NN N
713 CD N
[ NN N
243 CD N
] NNP N
mL NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

An DT N
effective JJ N
inhibition NN o
of IN o
fibrinolysis NN o
was VBD N
found VBN N
in IN N
patients NNS p
receiving VBG p
tranexamic JJ i
acid NN i
. . i

Tranexamic NNP i
acid NN i
reduces NNS N
postoperative VBP o
bleeding NN o
in IN N
coronary JJ i
artery NN i
bypass NN i
grafting VBG i
patients NNS N
treated VBN N
with IN N
aspirin NN N
until IN N
the DT N
day NN N
before IN N
surgery NN N
. . N

IMPLICATIONS NNP N
Continuation NNP N
of IN N
aspirin JJ i
medication NN N
until IN N
the DT N
day NN N
before IN N
coronary JJ i
artery NN i
bypass NN i
grafting NN i
may MD N
increase VB N
postoperative JJ o
bleeding NN o
. . o

The DT N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
tranexamic JJ i
acid NN i
( ( N
30 CD N
mg/kg NN N
) ) N
immediately RB N
before IN N
cardiopulmonary JJ N
bypass NN N
significantly RB N
reduced VBD N
postoperative JJ o
bleeding NN o
and CC N
inhibited JJ N
fibrinolysis NN o
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

Paclitaxel NNP i
( ( N
175 CD N
mg/m2 NN N
) ) N
plus CC i
carboplatin NN i
( ( N
6 CD N
AUC NNP N
) ) N
versus NN i
paclitaxel NN i
( ( N
225 CD N
mg/m2 NN N
) ) N
plus CC i
carboplatin NN i
( ( N
6 CD N
AUC NNP N
) ) N
in IN N
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
: : p
a DT N
multicenter NN N
randomized VBN N
trial NN N
. . N

Hellenic NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
( ( N
HeCOG NNP N
) ) N
. . N

PURPOSE VB N
The DT N
combination NN N
of IN N
paclitaxel NN i
and CC i
carboplatin NN i
has VBZ N
become VBN N
a DT N
widely RB N
used VBN N
regimen NNS N
in IN N
NSCLC NNP N
due JJ N
to TO N
phase VB N
II NNP N
reports NNS N
of IN N
moderate JJ N
toxicity NN N
, , N
reasonable JJ N
activity NN N
and CC N
easy JJ N
outpatient JJ N
administration NN N
. . N

Purpose NNP N
of IN N
our PRP$ N
present JJ N
prospective JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
dose JJ o
response NN o
relationship NN N
of IN N
paclitaxel NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Since IN p
July NNP p
1996 CD p
, , p
198 CD p
patients NNS p
with IN p
non-operable JJ p
NSCLC NNP p
and CC p
measurable JJ p
disease NN p
without IN p
previous JJ p
chemotherapy NN i
entered VBD p
the DT p
trial NN p
. . p

Ninety NNP p
nine CD p
patients NNS p
( ( p
group NN p
A DT p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
paclitaxel NN i
175 CD N
mg/m2 NN N
in IN N
three-hour JJ N
infusion NN N
plus CC i
carboplatin NN i
dosed VBD N
to TO N
an DT N
area NN N
under IN N
the DT N
concentration-time JJ N
curve NN N
of IN N
6 CD N
every DT N
3 CD N
weeks NNS N
and CC N
99 CD N
( ( N
group NN N
B NNP N
) ) N
to TO N
receive VB N
the DT N
same JJ N
regimen NN N
with IN N
paclitaxel NN i
increased VBN N
to TO N
225 CD N
mg/m2 NN N
. . N

Eligibility NNP N
criteria NNS N
included VBD N
WHO NNP N
performance NN N
status NN N
0-2 CD N
, , N
documented VBN N
inoperable JJ N
stage NN N
IIIA NNP N
and CC N
IIIB NNP N
, , N
IV NNP N
, , N
no DT N
brain NN N
metastasis NN N
, , N
no DT N
prior JJ N
chemotherapy NN i
and CC N
adequate JJ N
renal NN N
and CC N
hepatic JJ N
function NN N
. . N

Patients NNS N
in IN N
both DT N
groups NNS N
were VBD N
well-matched JJ N
with IN N
baseline JJ N
disease NN N
characteristics NNS N
. . N

RESULTS NNP N
In IN N
group NN N
A NNP N
with IN N
90 CD N
evaluable JJ N
patients NNS N
, , N
the DT N
response NN o
rate NN o
was VBD N
25.6 CD N
% NN N
( ( N
6 CD N
CR NNP N
, , N
17 CD N
PR NNP N
) ) N
whereas VBP N
in IN N
group NN N
B NNP N
with IN N
88 CD N
evaluable JJ N
patients NNS N
, , N
the DT N
response NN o
rate NN o
was VBD N
31.8 CD N
% NN N
( ( N
3 CD N
CR NNP N
, , N
25 CD N
PR NNP N
) ) N
, , N
P NNP N
= VBZ N
0.733 CD N
. . N

Median JJ o
time NN o
to TO o
progression NN o
favored VBD N
the DT N
high-dose JJ N
paclitaxel NN N
( ( N
4.3 CD N
vs. FW N
6.4 CD N
months NNS N
, , N
P NNP N
= NNP N
0.044 CD N
) ) N
. . N

The DT N
median JJ o
survival NN o
was VBD N
9.5 CD N
months NNS N
for IN N
group NN N
A NNP N
versus NN N
11.4 CD N
months NNS N
for IN N
group NN N
B NNP N
( ( N
P NNP N
= NNP N
0.16 CD N
) ) N
. . N

The DT N
one-year JJ o
survival NN o
was VBD N
37 CD N
% NN N
for IN N
group NN N
A NNP N
and CC N
44 CD N
% NN N
for IN N
group NN N
B NNP N
( ( N
P NNP N
= NNP N
0.35 CD N
) ) N
. . N

The DT N
best JJS N
prognostic JJ N
factor NN N
for IN N
one-year JJ o
survival NN o
was VBD N
the DT N
response NN o
rate NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

With IN N
a DT N
relative JJ N
dose JJ N
intensity NN N
of IN N
paclitaxel NN i
0.94 CD N
in IN N
both DT N
groups NNS N
, , N
neurotoxicity NN o
( ( N
P NNP N
= NNP N
0.025 CD N
) ) N
and CC N
leucopenia $ o
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
were VBD N
more RBR N
pronounced JJ N
in IN N
group NN N
B NNP N
patients NNS N
. . N

No DT N
toxic JJ o
death NN o
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Higher NNP N
dose VBD N
paclitaxel JJ i
prolongs NNS N
the DT N
median JJ N
time NN N
to TO N
progression NN N
but CC N
causes VBZ N
more JJR N
neurotoxicity NN N
and CC N
leucopenia NN N
. . N

The DT N
better JJR N
response NN N
rate NN N
, , N
the DT N
longer JJR N
overall JJ N
and CC N
better JJR N
one-year JJ N
survival NN N
seen VBN N
with IN N
the DT N
higher JJR N
dose NN N
of IN N
paclitaxel NNS i
are VBP N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -X- O O

Gefitinib NNP i
plus CC i
best JJS i
supportive JJ i
care NN i
in IN N
previously RB p
treated VBN p
patients NNS p
with IN p
refractory JJ p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
: : p
results NNS N
from IN N
a DT N
randomised VBN N
, , N
placebo-controlled JJ N
, , N
multicentre JJ N
study NN N
( ( N
Iressa NNP N
Survival NNP N
Evaluation NNP N
in IN N
Lung NNP N
Cancer NNP N
) ) N
. . N

BACKGROUND VB N
This DT N
placebo-controlled JJ i
phase NN N
III NNP N
study NN N
investigated VBD N
the DT N
effect NN o
on IN o
survival NN o
of IN N
gefitinib NN i
as IN N
second-line JJ N
or CC N
third-line JJ N
treatment NN N
for IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
or CC p
metastatic JJ p
non-small-cell JJ p
lung NN p
cancer NN p
. . p

METHODS NNP N
1692 CD p
patients NNS p
who WP p
were VBD p
refractory JJ p
to TO p
or CC p
intolerant VB p
of IN p
their PRP$ p
latest JJS p
chemotherapy NN i
regimen NNS p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
ratio NN N
of IN N
two CD N
to TO N
one CD N
either DT N
gefitinib NN i
( ( i
250 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
, , i
plus CC i
best JJS i
supportive JJ i
care NN i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
survival VBN o
in IN N
the DT N
overall JJ N
population NN N
of IN N
patients NNS N
and CC N
those DT N
with IN N
adenocarcinoma NN N
. . N

The DT N
primary JJ N
analysis NN N
of IN N
the DT N
population NN N
for IN N
survival NN o
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
has VBZ N
been VBN N
submitted VBN N
for IN N
registration NN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
1839IL/709 CD N
. . N

FINDINGS JJ N
1129 CD p
patients NNS p
were VBD p
assigned VBN p
gefitinib NNS p
and CC p
563 CD p
placebo NN p
. . p

At IN N
median JJ N
follow-up NN N
of IN N
7.2 CD N
months NNS N
, , N
median JJ o
survival NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
in IN N
the DT N
overall JJ N
population NN N
( ( N
5.6 CD N
months NNS N
for IN N
gefitinib NN N
and CC N
5.1 CD N
months NNS N
for IN N
placebo NN N
; : N
hazard CC N
ratio VB N
0.89 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
0.77-1.02 CD N
] NNP N
, , N
p=0.087 NN N
) ) N
or CC N
among IN N
the DT N
812 CD p
patients NNS p
with IN p
adenocarcinoma NN p
( ( N
6.3 CD N
months NNS N
vs RB N
5.4 CD N
months NNS N
; : N
0.84 CD N
[ IN N
0.68-1.03 JJ N
] NN N
, , N
p=0.089 NN N
) ) N
. . N

Preplanned VBN N
subgroup NN N
analyses VBZ N
showed VBN N
significantly RB N
longer RBR N
survival NN o
in IN N
the DT N
gefitinib NN N
group NN N
than IN N
the DT N
placebo NN N
group NN N
for IN N
never-smokers NNS p
( ( N
n=375 NN N
; : N
0.67 CD N
[ IN N
0.49-0.92 JJ N
] NN N
, , N
p=0.012 NN N
; : N
median JJ o
survival NN o
8.9 CD N
vs NN N
6.1 CD N
months NNS N
) ) N
and CC N
patients NNS N
of IN N
Asian JJ p
origin NN p
( ( N
n=342 JJ N
; : N
0.66 CD N
[ IN N
0.48-0.91 JJ N
] NN N
, , N
p=0.01 NN N
; : N
median JJ o
survival NN o
9.5 CD N
vs NN N
5.5 CD N
months NNS N
) ) N
. . N

Gefitinib NNP N
was VBD N
well RB N
tolerated VBN o
, , N
as IN N
in IN N
previous JJ N
studies NNS N
. . N

INTERPRETATION NNP N
Treatment NNP N
with IN N
gefitinib NN i
was VBD N
not RB N
associated VBN N
with IN N
significant JJ N
improvement NN N
in IN N
survival NN o
in IN N
either DT N
coprimary JJ N
population NN N
. . N

There EX N
was VBD N
pronounced JJ N
heterogeneity NN N
in IN N
survival JJ o
outcomes NNS N
between IN N
groups NNS N
of IN N
patients NNS N
, , N
with IN N
some DT N
evidence NN N
of IN N
benefit NN N
among IN N
never-smokers NNS p
and CC p
patients NNS p
of IN p
Asian JJ p
origin NN p
. . p

-DOCSTART- -X- O O

Pharmacokinetics NNS o
and CC o
tolerance NN o
of IN N
single- JJ N
and CC N
multiple-dose JJ N
oral JJ N
or CC N
intravenous JJ N
linezolid NNS i
, , N
an DT N
oxazolidinone NN N
antibiotic JJ N
, , N
in IN N
healthy JJ p
volunteers NNS p
. . p

AIMS NNP N
To TO N
determine VB N
the DT N
pharmacokinetics NNS N
and CC N
tolerance NN o
of IN N
oral JJ N
and CC N
intravenous JJ N
linezolid NN i
, , N
an DT N
oxazolidinone NN N
antibiotic JJ N
, , N
in IN N
healthy JJ p
volunteers NNS p
following VBG N
single- JJ N
and CC N
multiple-dose JJ N
administration NN N
. . N

METHODS NNP N
In IN N
two CD N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
dose-escalating JJ N
trials NNS N
, , N
subjects NNS p
were VBD N
exposed VBN N
either RB N
to TO N
oral JJ N
( ( N
375 CD N
, , N
500 CD N
or CC N
625 CD N
mg NN N
) ) N
or CC N
intravenous JJ N
( ( N
500 CD N
or CC N
625 CD N
mg NN N
) ) N
linezolid VBD i
or CC i
placebo VB i
twice JJ N
daily RB N
. . N

Serial JJ o
blood NN o
and CC o
urine JJ o
samples NNS o
were VBD N
obtained VBN N
after IN N
the DT N
first- JJ N
and CC N
multiple-dose JJ N
administrations NNS N
for IN N
up IN N
to TO N
18 CD N
days NNS N
. . N

Non-compartmental JJ N
pharmacokinetic JJ o
analyses NNS o
were VBD N
used VBN N
to TO N
describe VB N
the DT N
disposition NN N
of IN N
linezolid JJ i
. . i

RESULTS NNP N
Plasma NNP o
linezolid JJ o
concentrations NNS o
and CC o
area NN o
under IN o
the DT o
concentration-time JJ o
curves NNS o
increased VBD N
proportionally RB N
with IN N
dose JJ N
irrespective NN N
of IN N
the DT N
route NN N
of IN N
administration NN N
. . N

Plasma NNP o
linezolid JJ o
concentrations NNS o
remained VBN N
above IN N
the DT N
MIC90 NNP N
for IN N
susceptible JJ N
target NN N
pathogens NNS N
( ( N
4.0 CD N
mg/L NN N
) ) N
for IN N
the DT N
majority NN N
of IN N
the DT N
12 CD N
h NN N
dosing VBG N
interval NN N
. . N

Mean JJ o
clearance NN o
, , o
half-life JJ o
and CC o
volume NN o
of IN o
distribution NN o
were VBD N
similar JJ N
irrespective NN N
of IN N
dose NN N
for IN N
both DT N
the DT N
oral JJ N
and CC N
intravenous JJ N
routes NNS N
. . N

Linezolid NNP i
was VBD N
well RB N
tolerated VBN o
and CC N
the DT N
frequency NN o
of IN o
drug-related JJ o
adverse JJ o
events NNS o
was VBD N
similar JJ N
between IN N
the DT N
linezolid JJ i
and CC N
placebo JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
Oral NNP N
and CC N
intravenous JJ N
linezolid JJ i
exhibit NN N
linear JJ o
pharmacokinetics NNS o
, , N
with IN N
concentrations NNS N
remaining VBG N
above IN N
the DT N
target NN o
MIC90 NNP o
for IN N
most JJS N
of IN N
the DT N
dosing NN N
interval NN N
. . N

These DT N
results NNS N
support VBD N
a DT N
twice-daily JJ N
schedule NN N
for IN N
linezolid JJ N
and CC N
demonstrate VB N
the DT N
feasibility NN N
of IN N
converting VBG N
from IN N
intravenous JJ N
to TO N
oral JJ N
dosing NN N
without IN N
a DT N
dose JJ N
adjustment NN N
. . N

-DOCSTART- -X- O O

Peritonsillar JJ N
infiltration NN N
with IN N
levobupivacaine NN i
for IN N
posttonsillectomy NN p
pain NN o
relief NN o
: : o
does VBZ N
concentration NN N
have VB N
any DT N
effect NN N
? . N
A DT N
double-blind JJ N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
. . N

OBJECTIVE NNP N
Post-tonsillectomy JJ p
pain NN p
is VBZ N
believed VBN N
to TO N
be VB N
mediated VBN N
by IN N
noxious JJ N
stimulation NN N
of IN N
C-fiber NNP N
afferents NNS N
located VBN N
in IN N
the DT N
peritonsillary JJ N
space NN N
, , N
and CC N
local JJ N
anesthetic JJ N
infiltration NN N
to TO N
this DT N
area NN N
may MD N
decrease VB N
pain NN N
by IN N
blocking VBG N
the DT N
sensory JJ N
pathways NNS N
and CC N
thus RB N
preventing VBG N
the DT N
nociceptive JJ N
impulses NNS N
. . N

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
different JJ N
concentrations NNS N
of IN N
preincisional JJ N
peritonsillar JJ i
levobupivacaine NN i
( ( N
0.25 CD N
% NN N
and CC N
0.5 CD N
% NN N
) ) N
infiltration NN N
on IN N
postoperative JJ o
pain NN o
and CC o
bleeding NN o
in IN N
a DT N
placebo-controlled JJ i
design NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
After IN N
obtaining VBG N
Institutional NNP N
Ethics NNP N
Committee NNP N
approval NN N
, , N
72 CD p
ASA NNP p
I-II JJ p
patients NNS p
between IN p
3 CD p
and CC p
12 CD p
years NNS p
of IN p
age NN p
, , p
scheduled VBN p
to TO p
undergo VB p
tonsillectomy NN p
were VBD p
enrolled VBN p
and CC N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
three CD N
groups NNS N
using VBG N
the DT N
sealed VBN N
envelope NN N
technique NN N
, , N
as IN N
Group NNP N
I PRP N
( ( i
Control NNP i
group NN i
) ) i
, , N
Group NNP N
II NNP N
, , N
and CC N
Group NNP N
III NNP N
receiving VBG N
preincisional JJ i
bilateral JJ i
peritonsillar JJ i
infiltration NN i
with IN i
saline NN i
, , i
0.25 CD i
% NN i
levobupivacaine NN i
and CC i
0.5 CD i
% NN i
levobupivacaine NN i
, , N
respectively RB N
( ( N
3 CD N
mL NN N
to TO N
each DT N
tonsil NN N
) ) N
. . N

Pain NNP o
, , o
fever NN o
, , o
dysphagia NN o
; : o
nausea-vomiting JJ o
and CC o
hemorrhage NN o
were VBD N
evaluated VBN N
at IN N
postoperative JJ N
0 CD N
, , N
30 CD N
, , N
and CC N
60 CD N
minutes NNS N
and CC N
2 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
hours NNS N
. . N

Oral NNP i
paracetamol NN i
was VBD N
administered VBN N
at IN N
a DT N
dose NN N
of IN N
15 CD N
mg/kg NN N
when WRB N
FLACC NNP N
score NN N
was VBD N
> JJ N
4 CD N
. . N

The DT N
number NN o
of IN o
paracetamol JJ o
administrations NNS o
within IN N
the DT N
first JJ N
24 CD N
hours NNS N
were VBD N
recorded VBN N
. . N

RESULTS VB N
The DT N
patients NNS N
in IN N
Groups NNP N
I PRP N
, , N
II NNP N
and CC N
III NNP N
defined VBD N
pain NN o
( ( N
FLACC NNP N
> NNP N
4 CD N
) ) N
at IN N
a DT N
rate NN N
of IN N
87 CD N
% NN N
, , N
60.9 CD N
% NN N
, , N
and CC N
54.2 CD N
% NN N
within IN N
the DT N
postoperative JJ N
first JJ N
24 CD N
hours NNS N
, , N
respectively RB N
. . N

The DT N
total JJ N
number NN N
of IN N
additional JJ o
analgesic JJ o
requirements NNS o
was VBD N
significantly RB N
low JJ N
in IN N
Group NNP N
II NNP N
and CC N
III NNP N
when WRB N
compared VBN N
with IN N
Group NNP N
I PRP N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
groups NNS N
in IN N
terms NNS N
of IN N
fever NN o
, , o
dysphagia NN o
, , o
nausea-vomiting JJ o
, , o
hemorrhage NN o
. . o

CONCLUSIONS NNP N
Both NNP N
concentrations NNS N
( ( N
0.50 CD N
% NN N
and CC N
0.25 CD N
% NN N
) ) N
of IN N
levobupivacaine NN i
were VBD N
found VBN N
to TO N
be VB N
equally RB N
safe JJ o
and CC o
effective JJ o
during IN N
preincisional JJ N
peritonsillar JJ N
infiltration NN N
in IN N
children NNS p
. . p

NCT NNP N
number NN N
: : N
02322346 CD N
. . N

-DOCSTART- -X- O O

Immunogenicity NN o
and CC o
reactogenicity NN o
of IN N
two CD N
regimens NNS N
of IN N
diphtheria-tetanus-acellular JJ N
pertussis-hepatitis JJ N
B-inactivated JJ N
polio NN N
and CC N
Haemophilus NNP N
influenzae VBP N
type NN i
b NN i
vaccines NNS i
administered VBN i
to TO N
infants NNS p
primed VBN p
at IN p
birth NN p
with IN p
hepatitis NN p
B NNP p
vaccine NN p
. . p

An DT N
open JJ N
, , N
randomized VBN N
study NN N
evaluated VBD N
the DT N
immune JJ o
response NN o
and CC o
safety NN o
of IN N
two CD N
different JJ N
regimens NNS N
of IN N
diphtheria-tetanus-acellular JJ o
pertussis-hepatitis JJ o
B-inactivated JJ o
poliovirus-Haemophilus JJ o
influenzae NN o
type NN o
b NN o
( ( o
DTPa-HBV-IPV-Hib NNP o
) ) o
immunization NN N
in IN N
infants NNS p
primed VBN p
at IN p
birth NN p
with IN p
hepatitis NN p
B NNP p
vaccine NN p
. . p

One-half NN N
of IN N
the DT N
150 CD p
healthy JJ p
, , p
full-term JJ p
infants NNS p
received VBD i
a DT i
DTPa NNP i
HBV-IPV-Hib NNP i
vaccine NN i
at IN i
1 CD i
1/2 CD i
, , i
3 CD i
and CC i
5 CD i
months NNS i
of IN i
age NN i
; : i
the DT i
other JJ i
received VBD i
a DT i
DTPa-IPV-Hib JJ i
vaccine NN i
at IN i
1 CD i
1/2 CD i
, , i
3 CD i
and CC i
5 CD i
months NNS i
of IN i
age NN i
with IN i
separate JJ i
HBV NNP i
vaccine NN i
at IN i
1 CD i
and CC i
5 CD i
months NNS i
of IN i
age NN i
. . i

Immune NNP N
response NN N
was VBD N
similar JJ N
following VBG N
the DT N
two CD N
regimens NNS N
with IN N
100 CD N
% NN N
of IN N
the DT N
vaccinees NNS N
seroprotected VBD N
for IN N
HBV NNP N
, , N
diphtheria NN N
, , N
tetanus NN N
, , N
Hib NNP N
and CC N
poliovirus VB N
types NNS N
2 CD N
and CC N
3 CD N
diseases NNS N
after IN N
the DT N
full JJ N
vaccination NN N
course NN N
. . N

One CD N
vaccinee NN N
in IN N
the DT N
DTPa NNP N
HBV-HPV- NNP N
Hib NNP N
group NN N
failed VBD N
to TO N
respond VB N
to TO N
the DT N
poliovirus NN N
type NN N
1 CD N
antigen NN N
. . N

Response NN o
to TO N
the DT N
three CD N
pertussis NN N
antigens NNS N
ranged VBD N
from IN N
92-97 CD N
% NN N
in IN N
the DT N
DTPa-IPV-Hib NNP N
plus CC N
separate JJ N
HBV NNP N
group NN N
and CC N
100 CD N
% NN N
in IN N
the DT N
DTPa NNP N
HBV-IPV-Hib NNP N
group NN N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
post-vaccination NN N
symptoms NNS N
were VBD N
irritability NN o
in IN N
the DT N
DTPa-IPV-Hib NNP N
plus CC N
separate JJ N
HBV NNP N
group NN N
( ( N
49 CD N
% NN N
of IN N
vaccinees NNS N
) ) N
and CC N
fever NN o
, , N
defined VBD N
as IN N
axillary JJ N
temperature NN N
> NN N
or CC N
=37.5 NN N
degrees NNS N
C NNP N
, , N
in IN N
the DT N
DTPa NNP N
HBV- NNP N
IPV-Hib NNP N
group NN N
( ( N
50 CD N
% NN N
of IN N
vaccinees NNS N
) ) N
. . N

-DOCSTART- -X- O O

A DT N
placebo-controlled JJ i
, , N
fixed-dose JJ N
study NN N
of IN N
aripiprazole NN i
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
irritability NN p
associated VBN p
with IN p
autistic JJ p
disorder NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
short-term JJ N
efficacy NN o
and CC N
safety NN o
of IN N
aripiprazole NN i
in IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
. . p

METHOD NNP N
Two CD p
hundred VBD p
eighteen JJ p
children NNS p
and CC p
adolescents NNS p
( ( p
aged VBN p
6-17 CD p
years NNS p
) ) p
with IN p
a DT p
diagnosis NN p
of IN p
autistic JJ p
disorder NN p
, , p
and CC p
with IN p
behaviors NNS p
such JJ p
as IN p
tantrums NNS p
, , p
aggression NN p
, , p
self-injurious JJ p
behavior NN p
, , p
or CC p
a DT p
combination NN p
of IN p
these DT p
symptoms NNS p
, , N
were VBD N
randomized VBN N
1:1:1:1 CD N
to TO N
aripiprazole VB i
( ( i
5 CD i
, , i
10 CD i
, , i
or CC i
15 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
in IN N
this DT N
8-week JJ N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
study NN N
. . N

Efficacy NNP o
was VBD N
evaluated VBN N
using VBG N
the DT N
caregiver-rated JJ N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Irritability NNP o
subscale NN o
( ( o
primary JJ o
efficacy NN o
measure NN o
) ) o
and CC o
the DT o
clinician-rated JJ o
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
score NN o
. . o

Safety NNP o
and CC o
tolerability NN o
were VBD N
also RB N
assessed VBN N
. . N

RESULTS NNP N
At IN N
week NN N
8 CD N
, , N
all DT N
aripiprazole JJ i
doses NNS N
produced VBN N
significantly RB N
greater JJR N
improvement NN o
than IN N
placebo NN N
in IN N
mean JJ N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Irritability NNP o
subscale NN o
scores NNS o
( ( N
5 CD N
mg/day NN N
, , N
-12.4 NNP N
; : N
10 CD N
mg/day NN N
, , N
-13.2 NNP N
; : N
15 CD N
mg/day NN N
, , N
-14.4 NNP N
; : N
versus NN N
placebo NN N
, , N
-8.4 NNP N
; : N
all DT N
p VBP N
< NNP N
.05 NNP N
) ) N
. . N

All DT N
aripiprazole JJ i
doses NNS N
demonstrated VBN N
significantly RB N
greater JJR N
improvements NNS o
in IN o
mean JJ o
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
score NN o
than IN N
placebo NN i
at IN N
week NN N
8 CD N
. . N

Discontinuation NN N
rates NNS N
due JJ N
to TO N
adverse JJ o
events NNS o
were VBD N
as IN N
follows VBZ N
: : N
placebo VB N
7.7 CD N
% NN N
, , N
aripiprazole JJ N
5 CD N
mg/day JJ N
9.4 CD N
% NN N
, , N
10 CD N
mg/day JJ N
13.6 CD N
% NN N
, , N
and CC N
15 CD N
mg/day JJ N
7.4 CD N
% NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ o
event NN o
leading VBG N
to TO N
discontinuation NN N
was VBD N
sedation NN o
. . o

There EX N
were VBD N
two CD N
serious JJ o
adverse JJ o
events NNS o
: : o
presyncope NN o
( ( N
5 CD N
mg/day NN N
) ) N
and CC N
aggression NN o
( ( N
10 CD N
mg/day NN N
) ) N
. . N

At IN N
week NN N
8 CD N
, , N
mean JJ N
weight NN o
change NN o
( ( N
last JJ N
observation NN N
carried VBD N
forward RB N
) ) N
was VBD N
as IN N
follows VBZ N
: : N
placebo NN N
+0.3 NNP N
kg NN N
, , N
aripiprazole JJ i
5 CD N
mg/day JJ N
+1.3 NNP N
kg NN N
, , N
10 CD N
mg/day NN N
+1.3 NNP N
kg NN N
, , N
and CC N
15 CD N
mg/day NN N
+1.5 NNP N
kg NN N
; : N
all DT N
p VBP N
< JJ N
.05 NNP N
versus NN N
placebo NN i
. . i

CONCLUSIONS NNP N
Aripiprazole NNP i
was VBD N
efficacious JJ o
and CC N
generally RB N
safe JJ o
and CC N
well RB o
tolerated VBN o
in IN N
the DT N
treatment NN N
of IN N
children NNS p
and CC p
adolescents NNS p
with IN p
irritability NN p
associated VBN p
with IN p
autistic JJ p
disorder NN p
. . p

-DOCSTART- -X- O O

Increased VBN N
blood NN o
pressure NN o
and CC o
neural JJ o
tone NN o
in IN N
the DT N
silent JJ N
ischemia NN N
of IN N
hypertension NN N
: : N
disparate JJ N
effects NNS N
of IN N
immediate JJ N
release NN N
nifedipine NN i
. . i

OBJECTIVES CC N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
1 CD N
) ) N
to TO N
evaluate VB N
the DT N
role NN N
of IN N
blood NN o
pressure NN o
and CC N
associated JJ N
neural JJ o
tonicity NN o
in IN N
ambient JJ N
ischemia NN N
of IN N
a DT N
group NN N
of IN N
hypertensive JJ p
patients NNS p
with IN p
stable JJ p
angina NN p
, , N
and CC N
2 CD N
) ) N
to TO N
determine VB N
the DT N
efficacy NN o
of IN N
immediate JJ N
release NN N
nifedipine JJ i
therapy NN N
in IN N
controlling VBG N
the DT N
total JJ N
ischemic JJ N
burden NN N
in IN N
both DT N
office-measured JJ N
and CC N
ambulatory JJ N
blood NN N
pressure NN N
. . N

BACKGROUND NNP N
Low NNP N
heart NN N
rate NN N
ischemia NN N
, , N
as IN N
detected VBN N
by IN N
Holter NNP N
ambulatory JJ N
electrocardiographic JJ N
monitoring NN N
, , N
suggests VBZ N
that IN N
reduced VBD N
coronary JJ N
flow NN N
is VBZ N
the DT N
major JJ N
factor NN N
leading VBG N
to TO N
ischemia VB N
. . N

We PRP N
previously RB N
found VBD N
that IN N
91 CD N
% NN N
of IN N
the DT N
ischemic JJ N
episodes NNS N
in IN N
our PRP$ N
hypertensive JJ p
patients NNS p
with IN p
stable JJ p
angina NNS p
were VBD N
silent JJ N
. . N

METHODS NNP N
We PRP N
measured VBD N
plasma JJ N
norepinephrine JJ N
content NN N
during IN N
ischemic JJ N
events NNS N
from IN N
blood NN N
obtained VBN N
from IN N
automatic JJ N
pump NN N
withdrawal NN N
with IN N
the DT N
assistance NN N
of IN N
a DT N
real-time JJ i
ST NNP i
segment NN i
depression NN i
monitor NN i
. . i

We PRP N
then RB N
related VBD N
the DT N
norepinephrine JJ N
content NN N
to TO N
ischemic VB N
episodes NNS N
assessed VBN N
by IN N
48-h JJ N
Holter NNP N
recording NN N
, , N
blood NN N
pressure NN N
reading NN N
by IN N
ambulatory JJ N
blood NN N
pressure NN N
monitoring NN N
and CC N
patients NNS N
' POS N
diaries NNS N
. . N

Measurements NNS N
were VBD N
taken VBN N
during IN N
the DT N
placebo NN i
period NN N
and CC N
immediate-release JJ N
nifedipine NN i
therapy NN i
in IN N
30 CD p
hypertensive JJ p
patients NNS p
( ( p
20 CD p
with IN p
and CC p
10 CD p
without IN p
stable JJ p
angina NN p
) ) p
. . p

RESULTS NNP N
More JJR N
than IN N
half NN N
of IN N
the DT N
patients NNS N
had VBD N
ischemic JJ o
episodes NNS o
; : o
95 CD N
% NN N
of IN N
these DT N
were VBD N
silent JJ N
. . N

Ischemic NNP o
episodes VBZ o
peaked VBN N
in IN N
the DT N
early JJ N
morning NN N
, , N
and CC N
55 CD N
% NN N
occurred VBD N
during IN N
routine JJ N
sedentary JJ N
activities NNS N
. . N

There EX N
was VBD N
a DT N
10 CD N
% NN N
to TO N
15 CD N
% NN N
increase NN N
in IN N
heart NN o
rate NN o
at IN N
the DT N
onset NN N
of IN N
ischemia NN N
associated VBN N
with IN N
a DT N
30 CD N
% NN N
higher JJR N
plasma JJ o
norepinephrine JJ o
level NN o
. . o

Seventy-five JJ N
percent NN N
of IN N
patients NNS N
had VBD N
increased VBN N
norepinephrine NN o
after IN N
nifedipine JJ i
therapy NN N
. . N

Nifedipine NNP N
therapy NN N
controlled VBD N
measured VBN N
blood NN o
pressure NN o
but CC N
not RB N
24-h JJ o
ambulatory NN o
blood NN o
pressure NN o
. . o

Ischemic NNP o
episodes NNS o
were VBD N
reduced VBN N
only RB N
in IN N
patients NNS N
whose WP$ N
ambulatory JJ N
blood NN N
pressure NN N
was VBD N
controlled VBN N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
suggest VBP N
that IN N
increased VBD N
neural JJ o
tone NN o
at IN N
the DT N
time NN N
of IN N
the DT N
ischemic JJ N
event NN N
may MD N
play VB N
a DT N
role NN N
in IN N
reducing VBG N
coronary JJ N
perfusion NN N
leading VBG N
to TO N
silent JJ N
ischemia NN N
. . N

Nifedipine NNP i
therapy NN i
( ( i
immediate JJ i
release NN i
) ) i
was VBD N
effective JJ N
in IN N
control NN o
of IN o
ischemia NN o
only RB N
when WRB N
both DT N
ambulatory NN N
and CC N
office-measured JJ N
blood NN o
pressure NN o
were VBD N
controlled VBN N
. . N

-DOCSTART- -X- O O

Analgesic JJ N
effect NN N
of IN N
expressed VBN N
breast NN N
milk NN N
in IN N
procedural JJ N
pain NN N
in IN N
term NN p
neonates NNS p
: : p
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
trial NN N
. . N

AIM NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
expressed VBN i
breast NN i
milk NN i
( ( N
EBM NNP N
) ) N
in IN N
reducing VBG N
pain NN o
due JJ N
to TO N
venepuncture NN N
, , N
in IN N
term NN N
neonates NNS N
, , N
as IN N
measured VBN N
by IN N
behavioural JJ o
and CC o
physiological JJ o
observations NNS o
. . o

METHODS NNP N
This DT N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
trial NN N
involved VBD N
81 CD p
full-term JJ p
neonates NNS p
, , p
up RB p
to TO p
4 CD p
wk NN p
of IN p
postnatal JJ p
age NN p
, , p
who WP p
needed VBD p
venepuncture NN p
for IN p
blood NN p
investigations NNS p
. . p

Two CD N
minutes NNS N
before IN N
the DT N
venepuncture NN i
, , N
in IN N
the DT N
intervention NN N
arm NN N
, , N
40 CD N
babies NNS N
received VBD N
5 CD N
ml NN N
of IN N
EBM NNP N
, , N
while IN N
41 CD N
babies NNS N
in IN N
control NN N
group NN N
received VBD N
5 CD i
ml NN i
of IN i
distilled JJ i
water NN i
( ( i
DW NNP i
) ) i
as IN i
placebo NN i
. . i

Two CD N
observers NNS N
who WP N
were VBD N
blinded VBN N
to TO N
the DT N
intervention NN N
recorded VBD N
the DT N
physiological JJ o
( ( o
heart NN o
rate NN o
and CC o
oxygen NN o
saturation NN o
) ) o
and CC o
behavioural JJ o
parameters NNS o
[ POS o
duration NN o
of IN o
crying VBG o
and CC o
modified VBN o
Neonatal NNP o
Facial NNP o
Coding NNP o
Scores NNP o
( ( o
NFCS NNP o
) ) o
] NN o
after IN N
the DT N
venepuncture NN i
. . i

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
baseline NN N
characteristics NNS N
of IN N
the DT N
neonates NNS N
in IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
duration NN o
of IN o
crying NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
babies NNS N
fed VBP N
EBM NNP N
[ NNP N
median JJ N
38.5 CD N
s NN N
, , N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
9.5-57.5 CD N
s NN N
] NN N
than IN N
in IN N
those DT N
fed VBN N
DW NNP N
( ( N
median JJ N
90 CD N
s NN N
, , N
IQR NNP N
28-210 CD N
s NN N
) ) N
. . N

The DT N
mean JJ o
duration NN o
of IN o
crying VBG o
in IN N
EBM NNP i
group NN N
was VBD N
shorter JJR N
by IN N
70.7 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
36.6-104.9 JJ N
) ) N
s. VBZ N
The DT N
modified JJ o
NFCS NNP o
at IN N
0 CD N
, , N
1 CD N
and CC N
3 CD N
min NN N
was VBD N
significantly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
in IN N
the DT N
EBM NNP i
than IN N
in IN N
the DT N
DW NNP N
group NN N
. . N

The DT N
change NN o
in IN o
heart NN o
rate NN o
and CC o
oxygen NN o
saturation NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
EBM NNP i
group NN N
and CC N
returned VBN N
to TO N
baseline VB N
values NNS N
sooner JJR N
than IN N
in IN N
the DT N
DW NNP N
group NN N
. . N

CONCLUSION NNP N
Feeding VBG N
5 CD N
ml NN N
of IN N
EBM NNP i
before IN N
venepuncture NN i
is VBZ N
effective JJ N
in IN N
reducing VBG N
symptoms NNS o
due JJ N
to TO N
pain VB p
in IN p
term NN p
neonates NNS p
. . p

-DOCSTART- -X- O O

Continuous JJ N
glucose JJ N
monitoring NN N
in IN N
acute JJ p
coronary JJ p
syndrome NN p
. . p

BACKGROUND NNP N
Diabetes NNP p
mellitus NN p
is VBZ N
an DT N
independent JJ N
risk NN N
factor NN N
for IN N
cardiovascular JJ p
disease NN p
. . p

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN o
of IN o
devices NNS o
for IN N
continuous JJ N
glucose JJ N
monitoring NN N
and CC N
capillary JJ N
glucose NN N
monitoring NN N
in IN N
hospitalized JJ p
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndrome NN p
using VBG N
the DT N
following JJ N
parameters NNS N
: : N
time NN o
to TO o
achieve VB o
normoglycemia NN o
, , o
period NN o
of IN o
time NN o
in IN o
normoglycemia NN o
, , o
and CC o
episodes NNS o
of IN o
hypoglycemia NN o
. . o

METHODS NNP N
We PRP N
performed VBD N
a DT N
pilot NN N
, , N
non-randomized JJ N
, , N
unblinded JJ N
clinical JJ N
trial NN N
that WDT N
included VBD N
16 CD p
patients NNS p
with IN p
acute JJ p
coronary JJ p
artery NN p
syndrome NN p
, , p
a DT p
capillary JJ p
or CC p
venous JJ p
blood NN p
glucose NN p
? . p
140 CD p
mg/dl NN p
, , p
and CC p
treatment NN p
with IN p
a DT p
continuous JJ p
infusion NN p
of IN p
fast JJ p
acting VBG p
human JJ i
insulin NN i
. . i

These DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
2 CD N
groups NNS N
: : N
a DT N
conventional JJ N
group NN N
, , N
in IN N
which WDT i
capillary JJ i
measurement NN i
and CC i
recording NN i
as RB i
well RB i
as IN i
insulin NN i
adjustment NN i
were VBD i
made VBN N
every DT N
4h CD N
, , N
and CC N
an DT N
intervention NN N
group NN N
, , N
in IN N
which WDT i
measurement NN i
and CC i
recording NN i
as RB i
well RB i
as IN i
insulin NN i
adjustment NN i
were VBD i
made VBN i
every DT i
hour NN i
with IN i
a DT i
subcutaneous JJ i
continuous JJ i
monitoring NN i
system NN o
. . o

Student NN o
's POS o
t-test NN o
was VBD o
applied VBN N
for IN N
mean JJ N
differences NNS N
and CC N
the DT o
X NNP o
( ( o
2 CD o
) ) o
test NN o
for IN o
qualitative JJ N
variables NNS N
. . N

RESULTS NNP N
We PRP N
observed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT o
mean JJ o
time NN o
for IN o
achieving VBG o
normoglycemia NN o
, , o
favoring VBG N
the DT N
conventional JJ N
group NN N
with IN N
a DT N
P NNP N
= NN N
0.02 CD N
. . N

CONCLUSION NNP N
Continuous NNP N
monitoring VBG N
systems NNS N
are VBP N
as RB N
useful JJ N
as IN N
capillary JJ N
monitoring NN N
for IN N
achieving VBG N
normoglycemia NN N
. . N

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
sensory JJ i
integration NN i
interventions NNS i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
pilot NN N
study NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
establish VB N
a DT N
model NN N
for IN N
randomized VBN N
controlled JJ N
trial NN N
research NN N
, , N
identify VB N
appropriate JJ N
outcome NN N
measures NNS N
, , N
and CC N
address VB N
the DT N
effectiveness NN N
of IN N
sensory JJ i
integration NN i
( ( i
SI NNP i
) ) i
interventions NNS N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

Children NNP p
ages VBZ p
6-12 NN p
with IN p
ASD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
fine JJ i
motor NN i
or CC N
SI NNP i
treatment NN i
group NN N
. . N

Pretests NNS N
and CC N
posttests NNS N
measured VBD N
social JJ o
responsiveness NN o
, , o
sensory JJ o
processing NN o
, , o
functional JJ o
motor NN o
skills NNS o
, , o
and CC o
social-emotional JJ o
factors NNS o
. . o

Results NNS N
identified VBD N
significant JJ N
positive JJ N
changes NNS N
in IN N
Goal NNP o
Attainment NNP o
Scaling NNP o
scores NNS o
for IN N
both DT N
groups NNS N
; : N
more RBR N
significant JJ N
changes NNS N
occurred VBD N
in IN N
the DT N
SI NNP N
group NN N
, , N
and CC N
a DT N
significant JJ N
decrease NN N
in IN N
autistic JJ o
mannerisms NNS o
occurred VBD N
in IN N
the DT N
SI NNP N
group NN N
. . N

No DT N
other JJ N
results NNS N
were VBD N
significant JJ N
. . N

The DT N
study NN N
discusses VBZ N
considerations NNS N
for IN N
designing VBG N
future JJ N
outcome NN N
studies NNS N
for IN N
children NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -X- O O

Thrombus NNP N
aspiration NN N
reduces NNS N
microvascular JJ o
obstruction NN o
after IN N
primary JJ p
coronary JJ p
intervention NN p
: : p
a DT N
myocardial JJ N
contrast NN N
echocardiography NN N
substudy NN N
of IN N
the DT N
REMEDIA NNP N
Trial NNP N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
clarify VB N
the DT N
role NN N
of IN N
microembolization NN N
in IN N
the DT N
genesis NN N
of IN N
microvascular JJ o
obstruction NN o
( ( o
MO NNP o
) ) o
after IN N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

BACKGROUND NNP N
Fifty NNP p
consecutive JJ p
patients NNS p
entered VBD p
the DT p
myocardial JJ p
contrast NN p
echocardiography NN p
( ( p
MCE NNP p
) ) p
substudy NN p
of IN p
the DT p
REMEDIA NNP p
( ( p
Randomized NNP p
Evaluation NNP p
of IN p
the DT p
Effect NNP p
of IN p
Mechanical NNP p
Reduction NNP p
of IN p
Distal NNP p
Embolization NNP p
by IN p
Thrombus NNP p
Aspiration NNP p
in IN p
Primary NNP p
and CC p
Rescue NNP p
Angioplasty NNP p
) ) p
trial NN p
, , N
which WDT N
defined VBD N
the DT N
role NN N
of IN N
a DT N
new JJ N
thrombus-aspirating JJ N
device NN N
in IN N
preventing VBG N
distal JJ N
microembolization NN o
after IN N
PCI NNP N
. . N

METHODS NNP N
A NNP N
total NN p
of IN p
25 CD p
patients NNS p
were VBD p
randomized VBN p
to TO p
be VB p
pretreated VBN p
with IN p
thrombus JJ i
aspiration NN i
before IN i
PCI NNP i
of IN i
the DT i
culprit NN i
lesion NN i
and CC i
25 CD p
received JJ p
standard JJ i
PCI NNP i
. . i

At IN N
24 CD N
h NN N
, , N
1 CD N
week NN N
, , N
and CC N
6 CD N
months NNS N
after IN N
PCI NNP N
, , N
MCE NNP N
was VBD N
performed VBN N
by IN N
Sonovue NNP N
, , N
and CC N
real-time JJ N
imaging NN N
was VBD N
performed VBN N
by IN N
contrast NN N
pulse JJ N
sequencing VBG N
technology NN N
. . N

Regional NNP o
wall NN o
motion NN o
score NN o
index NN o
( ( o
WMSI NNP o
) ) o
, , o
contrast RB o
score NN o
index NN o
( ( o
CSI NNP o
) ) o
, , o
endocardial JJ o
length NN o
of IN o
wall NN o
motion NN o
abnormality NN o
( ( o
WML NNP o
) ) o
and CC o
contrast NN o
defect NN o
( ( o
CDL NNP o
) ) o
, , o
end-diastolic JJ o
and CC o
end-systolic JJ o
left NN o
ventricular NN o
( ( o
LV NNP o
) ) o
volumes NNS o
, , o
and CC o
ejection NN o
fraction NN o
were VBD N
calculated VBN N
. . N

RESULTS NNP N
At IN N
each DT N
time NN N
point NN N
, , N
in IN N
patients NNS N
treated VBN N
with IN N
a DT N
thrombus-aspiration NN N
filter NN N
device NN N
, , N
WMSI NNP o
, , o
CSI NNP o
, , o
WML NNP o
, , o
and CC o
CDL NNP o
were VBD N
significantly RB N
lower JJR N
and CC N
ejection NN o
fraction NN o
higher JJR N
( ( N
p JJ N
< $ N
0.05 CD N
vs. FW N
control NN N
patients NNS N
) ) N
, , N
whereas JJ N
LV NNP o
volumes NNS o
were VBD N
slightly RB N
but CC N
not RB N
significantly RB N
smaller JJR N
compared VBN N
with IN N
control NN N
patients NNS N
. . N

In IN N
the DT N
overall JJ N
study NN N
population NN N
, , N
the DT N
extent NN o
of IN o
MO NNP o
significantly RB N
correlated VBD N
with IN N
temporal JJ N
changes NNS N
in IN N
LV NNP o
volumes NNS o
. . o

CONCLUSIONS NNP N
Thrombus NNP N
aspiration NN N
used VBN N
at IN N
the DT N
time NN N
of IN N
PCI NNP N
significantly RB N
reduces VBZ N
the DT N
extent NN o
of IN o
MO NNP o
and CC N
myocardial JJ o
dysfunction NN o
, , N
although IN N
it PRP N
does VBZ N
not RB N
have VB N
a DT N
significant JJ N
favorable JJ N
effect NN N
in IN N
preventing VBG N
LV NNP o
remodeling VBG o
. . o

Thus RB N
, , N
the DT N
beneficial JJ N
effect NN N
of IN N
thrombus NN N
aspiration NN N
occurs VBZ N
at IN N
the DT N
microvascular JJ N
level NN N
, , N
but CC N
additional JJ N
mechanisms NN N
may MD N
play VB N
a DT N
role NN N
in IN N
influencing VBG N
the DT N
final JJ N
extent NN N
of IN N
MO NNP o
, , N
which WDT N
strictly RB N
correlates VBZ N
with IN N
post-infarct JJ N
LV NNP o
remodeling NN o
. . o

-DOCSTART- -X- O O

Motion NNP i
style NN i
acupuncture NN i
treatment NN i
( ( i
MSAT NNP i
) ) i
for IN N
acute NN p
low JJ p
back RB p
pain NN p
with IN p
severe JJ p
disability NN p
: : p
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
protocol NN N
. . N

BACKGROUND NNP N
Acupuncture NNP N
is VBZ N
widely-used JJ N
to TO N
treat VB N
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
, , N
despite IN N
insufficient JJ N
evidence NN N
of IN N
the DT N
technique NN N
's POS N
efficacy NN N
for IN N
acute NN N
back RB N
pain NN N
. . N

Motion NNP i
style NN i
acupuncture NN i
treatment NN i
( ( i
MSAT NNP i
) ) i
is VBZ N
a DT N
non-traditional JJ N
acupuncture NN N
treatment NN N
requiring VBG N
a DT N
patient NN N
to TO N
exercise VB N
while IN N
receiving VBG N
acupuncture NN N
. . N

In IN p
Korea NNP p
, , N
MSAT NNP N
is VBZ N
used VBN N
to TO N
reduce VB N
musculoskeletal JJ N
pain NN N
and CC N
improve VB N
functional JJ N
status NN N
. . N

The DT N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
MSAT NNP N
on IN N
acute NN N
low JJ N
back RB N
pain NN N
with IN N
severe JJ N
disability NN N
. . N

METHODS/DESIGN NNP N
This DT N
study NN N
is VBZ N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
active-controlled JJ N
trial NN N
with IN N
two CD N
parallel JJ N
arms NNS N
. . N

Participants NNS p
with IN p
acute NN p
low JJ p
back RB p
pain NN p
and CC p
severe JJ p
functional JJ p
disability NN p
, , p
defined VBD p
as IN p
an DT p
Oswestry NNP p
Disability NNP p
Index NNP p
( ( p
ODI NNP p
) ) p
value NN p
> $ p
60 CD p
% NN p
, , N
will MD N
be VB N
randomly RB N
allocated VBN N
to TO N
the DT N
acupuncture NN i
group NN i
and CC i
the DT i
nonsteroidal JJ i
anti-inflammatory JJ i
drug NN i
( ( i
NSAID NNP i
) ) i
injection NN i
group NN i
. . i

The DT N
acupuncture NN N
group NN N
will MD N
receive VB N
MSAT NNP i
and CC i
the DT i
NSAID NNP i
injection NN i
group NN i
will MD N
receive VB N
an DT N
intramuscular JJ N
injection NN N
of IN N
diclofenac NN i
. . i

All DT N
procedures NNS N
will MD N
be VB N
limited VBN N
to TO N
one CD N
session NN N
and CC N
the DT N
symptoms NNS N
before IN N
and CC N
after IN N
treatment NN N
will MD N
be VB N
measured VBN N
by IN N
assessors NNS N
blinded VBD N
to TO N
treatment NN N
allocation NN N
. . N

The DT N
primary JJ N
outcome NN N
will MD N
be VB N
measured VBN N
at IN N
30 CD N
minutes NNS N
after IN N
treatment NN N
using VBG N
the DT N
numerical JJ o
rating NN o
scale NN o
( ( o
NRS NNP o
) ) o
of IN o
low JJ o
back RB o
pain NN o
while IN o
the DT o
patient NN o
is VBZ o
moving VBG o
. . o

Secondary JJ N
outcomes NNS N
will MD N
be VB N
measured VBN N
at IN N
30 CD N
minutes NNS N
after IN N
treatment NN N
using VBG N
the DT N
NRS NNP o
of IN o
leg NN o
pain NN o
, , o
ODI NNP o
, , o
patient NN o
global JJ o
impression NN o
of IN o
change NN o
, , o
range NN o
of IN o
motion NN o
( ( o
ROM NNP o
) ) o
of IN o
the DT o
lumbar NN o
spine NN o
, , o
and CC o
degrees NNS o
of IN o
straight JJ o
leg NN o
raising VBG o
( ( o
SLR NNP o
) ) o
. . o

Post-treatment JJ N
follow-up NN N
will MD N
be VB N
performed VBN N
to TO N
measure VB N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
with IN N
the DT N
exception NN N
of IN N
ROM NNP o
and CC o
SLR NNP o
at IN N
2 CD N
, , N
4 CD N
, , N
and CC N
24 CD N
weeks NNS N
after IN N
treatment NN N
. . N

DISCUSSION NNP N
The DT N
results NNS N
of IN N
this DT N
trial NN N
will MD N
be VB N
discussed VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrial.gov NNP N
NCT01315561 NNP N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
esomeprazole JJ i
triple JJ i
therapy NN i
on IN N
eradication NN o
rates NNS o
of IN o
Helicobacter NNP o
pylori NN o
, , o
gastric JJ o
ulcer NN o
healing NN o
and CC o
prevention NN o
of IN o
relapse NN o
in IN N
gastric JJ p
ulcer JJ p
patients NNS p
. . p

OBJECTIVES NNP N
To TO N
compare VB N
esomeprazole-based JJ i
triple JJ N
therapy NN N
with IN N
esomeprazole JJ N
alone NN N
for IN N
the DT N
eradication NN o
of IN o
Helicobacter NNP o
pylori FW o
( ( o
H. NNP o
pylori NN o
) ) o
, , o
healing VBG o
of IN o
ulcer NN o
and CC o
prevention NN o
of IN o
relapse NN o
in IN N
H. NNP N
pylori-related JJ N
gastric JJ N
ulcer NN N
( ( N
GU NNP N
) ) N
diseases VBZ N
. . N

METHODS NNP N
In IN N
this DT N
double-blind NN N
study NN N
, , N
401 CD p
H. NNP p
pylori-positive JJ p
patients NNS p
with IN p
more JJR p
than IN p
or CC p
equal JJ p
to TO p
two CD p
GUs NNP p
were VBD N
randomized VBN N
to TO N
: : N
esomeprazole NN i
( ( N
20 CD N
mg NN N
) ) N
twice RB N
daily RB N
( ( N
bid NN N
) ) N
and CC N
amoxicillin NN i
( ( N
1000 CD N
mg NN N
) ) N
bid NN N
and CC N
clarithromycin NN i
( ( N
500 CD N
mg NN N
) ) N
bid NN N
( ( N
EAC NNP N
) ) N
for IN N
1 CD N
week NN N
, , N
followed VBN N
by IN N
placebo NN i
for IN N
3 CD N
weeks NNS N
( ( N
EAC NNP N
and CC N
placebo NN N
) ) N
; : N
EAC NNP N
for IN N
1 CD N
week NN N
, , N
followed VBN N
by IN N
esomeprazole NN i
( ( N
20 CD N
mg NN N
) ) N
once RB N
daily JJ N
( ( N
E20 NNP N
) ) N
for IN N
3 CD N
weeks NNS N
( ( N
EAC NNP N
and CC N
E20 NNP N
) ) N
; : N
or CC N
esomeprazole VB i
( ( N
20 CD N
mg NN N
) ) N
bid NN N
and CC N
placebo NN i
antimicrobials NNS i
for IN N
1 CD N
week NN N
, , N
followed VBN N
by IN N
E20 NNP N
for IN N
3 CD N
weeks NNS N
( ( N
E20 NNP N
bid NN N
and CC N
E20 NNP N
) ) N
. . N

Patients NNS p
with IN p
unhealed JJ p
GUs NNP p
at IN p
4 CD p
weeks NNS p
received VBD N
E20 NNP N
for IN N
an DT N
additional JJ N
4 CD N
weeks NNS N
. . N

Healed VBN p
patients NNS p
were VBD N
followed VBN N
up RP N
for IN N
12 CD N
months NNS N
. . N

RESULTS NNP N
Eradication NNP o
rates NNS o
at IN N
4 CD N
weeks NNS N
or CC N
8 CD N
weeks NNS N
were VBD N
82 CD N
% NN N
for IN N
EAC NNP N
and CC N
E20 NNP N
, , N
77 CD N
% NN N
for IN N
EAC NNP N
and CC N
placebo NN N
and CC N
9.5 CD N
% NN N
for IN N
E20 NNP N
bid NN N
and CC N
E20 NNP N
( ( N
intention-to-treat JJ N
analysis NN N
) ) N
. . N

Significantly RB N
more RBR N
patients NNS N
receiving VBG N
EAC NNP N
than IN N
those DT N
receiving JJ N
esomeprazole JJ N
alone RB N
remained VBD o
free JJ o
of IN o
GUs NNP o
during IN N
follow-up JJ N
[ NNP N
EAC NNP N
and CC N
E20 NNP N
, , N
90 CD N
% NN N
; : N
EAC NNP N
and CC N
placebo NN N
, , N
87 CD N
% NN N
; : N
P=0.0005 NNP N
for IN N
combined VBN N
group NN N
vs. FW N
esomeprazole FW N
alone RB N
[ JJ N
E20 NNP N
bid NN N
and CC N
E20 NNP N
( ( N
74 CD N
% NN N
) ) N
] NN N
. . N

All DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN o
. . o

CONCLUSION NNP N
Esomeprazole-based JJ i
triple JJ N
therapy NN N
is VBZ N
effective JJ o
for IN N
the DT N
eradication NN o
of IN o
H. NNP o
pylori NN o
, , o
healing NN o
of IN o
GU NNP o
and CC o
prevention NN o
of IN o
relapse NN o
. . o

Esomeprazole NNP N
monotherapy NN N
for IN N
3 CD N
weeks NNS N
after IN N
triple JJ N
therapy NN N
may MD N
be VB N
beneficial JJ o
in IN N
terms NNS N
of IN N
healing NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
Behavioral NNP i
Family NNP i
Systems NNP i
Therapy NNP i
for IN N
Diabetes NNPS p
: : p
maintenance NN N
and CC N
generalization NN N
of IN N
effects NNS N
on IN N
parent-adolescent JJ N
communication NN N
. . N

We PRP N
report VBP N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
revised JJ N
Behavioral NNP i
Family NNP i
Systems NNP i
Therapy NNP i
for IN i
Diabetes NNP i
( ( i
BFST-D NNP i
) ) i
intervention NN i
. . N

Families NNS p
of IN p
104 CD p
adolescents NNS p
with IN p
diabetes NNS p
were VBD p
randomized VBN p
to TO N
standard VB i
care NN i
( ( i
SC NNP i
) ) i
or CC i
to TO i
6 CD i
months NNS i
of IN i
an DT i
educational JJ i
support NN i
group NN i
( ( i
ES NNP i
) ) i
or CC i
BFST-D. JJ i
Family NNP o
communication NN o
and CC o
problem-solving JJ o
skills NNS o
were VBD N
assessed VBN N
at IN N
0 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
months NNS N
by IN N
independent JJ N
rating NN N
of IN N
videotaped JJ N
family NN N
problem-solving JJ N
discussions NNS N
. . N

BFST-D NNP i
improved VBD N
individual JJ N
communication NN o
of IN o
adolescents NNS o
and CC o
mothers NNS o
, , o
but CC o
not RB o
fathers NNS o
. . o

BFST-D NNP i
significantly RB N
improved VBD N
quality NN o
of IN o
family NN o
interaction NN o
compared VBN N
to TO N
SC NNP N
( ( N
10 CD N
of IN N
12 CD N
comparisons NNS N
) ) N
and CC N
ES NNP N
( ( N
6 CD N
of IN N
12 CD N
comparisons NNS N
) ) N
. . N

Changes NNS N
in IN N
family NN N
communication NN N
were VBD N
differentially RB N
associated VBN N
with IN N
changes NNS N
in IN N
glycemic JJ o
control NN o
, , o
adherence NN o
, , o
and CC o
family NN o
conflict NN o
. . o

BFST-D NNP i
improved VBD N
family NN o
communication NN o
and CC o
problem NN o
solving VBG o
relative JJ N
to TO N
SC NNP N
and CC N
modestly RB N
relative JJ N
to TO N
ES NNP N
. . N

-DOCSTART- -X- O O

Six-month JJ N
trial NN N
of IN N
on-demand JJ N
rabeprazole NN i
10 CD N
mg NN N
maintains NNS N
symptom JJ o
relief NN o
in IN N
patients NNS p
with IN p
non-erosive JJ p
reflux NN o
disease NN o
. . o

BACKGROUND NNP N
Compliance NNP N
studies NNS N
have VBP N
shown VBN N
that IN N
patients NNS p
with IN p
reflux NN p
symptoms NNS p
generally RB N
take VBP N
their PRP$ N
medication NN N
only RB N
when WRB N
experiencing VBG N
these DT N
symptoms NNS N
. . N

AIM NNP N
To TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
on-demand JJ N
rabeprazole JJ i
maintenance NN N
therapy NN N
in IN N
patients NNS p
with IN p
non-erosive JJ p
reflux NN p
disease NN p
. . p

METHODS NNP N
This DT N
multicentre NN p
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
withdrawal NN N
study NN N
compared VBN N
6 CD N
months NNS N
of IN N
on-demand JJ N
treatment NN N
with IN N
rabeprazole JJ i
10 CD N
mg NN N
vs. FW N
placebo NN i
. . i

Adults NNS p
with IN p
a DT p
history NN p
of IN p
reflux NN p
symptoms NNS p
, , p
a DT p
negative JJ p
endoscopy NN p
, , p
and CC p
> NNP p
or CC p
= VB p
3 CD p
days NNS p
of IN p
moderate JJ p
to TO p
very RB p
severe JJ p
heartburn NN p
in IN p
the DT p
7 CD p
days NNS p
before IN p
enrollment NN p
( ( p
N NNP p
= NNP p
535 CD p
) ) p
entered VBD N
4 CD N
weeks NNS N
of IN N
open-label NN N
, , N
acute JJ N
treatment NN N
with IN N
rabeprazole JJ i
10 CD N
mg NN N
once RB N
daily JJ N
. . N

Patients NNS p
with IN p
complete JJ p
symptom NN o
relief NN o
then RB p
entered VBD p
the DT p
on-demand JJ p
phase NN p
. . p

The DT N
primary JJ N
end-point NN N
was VBD N
discontinuation NN o
due JJ o
to TO o
lack VB o
of IN o
heartburn NN o
control NN o
during IN o
the DT o
on-demand JJ o
phase NN o
. . o

RESULTS NNP N
Eighty-three JJ N
percent NN N
( ( N
432 CD N
of IN N
523 CD N
) ) N
of IN N
patients NNS N
reported VBD N
complete JJ N
symptom NN o
relief NN o
at IN N
the DT N
end NN N
of IN N
the DT N
acute JJ N
phase NN N
. . N

During IN N
on-demand JJ N
treatment NN N
, , N
rates NNS o
of IN o
discontinuation NN o
because IN o
of IN o
inadequate JJ o
heartburn NN o
control NN o
were VBD N
20 CD N
% NN N
( ( N
28 CD N
of IN N
139 CD N
) ) N
for IN N
placebo NN i
vs. FW N
6 CD N
% NN N
( ( N
16 CD N
of IN N
279 CD N
) ) N
for IN N
rabeprazole NN i
( ( N
P NNP N
< NNP N
0.00001 CD N
) ) N
. . N

Antacid NNP o
use NN o
was VBD N
twofold JJ N
higher JJR N
in IN N
the DT N
placebo NN i
group NN N
vs. FW N
the DT N
rabeprazole NN i
group NN N
( ( N
P NNP N
= NNP N
0.0009 CD N
) ) N
. . N

CONCLUSIONS NNP N
Rabeprazole NNP i
10 CD N
mg NN N
once RB N
daily JJ N
is VBZ N
highly RB N
effective JJ o
in IN N
acute JJ o
symptom NN o
relief NN o
and CC N
as IN N
on-demand JJ N
long-term JJ N
maintenance NN N
therapy NN N
in IN N
non-erosive JJ p
reflux NN p
disease NN p
patients NNS p
. . p

-DOCSTART- -X- O O

Final NNP o
height NN o
in IN o
girls NNS o
with IN p
turner NN p
syndrome NN p
after IN N
long-term JJ N
growth NN i
hormone NN i
treatment NN i
in IN N
three CD N
dosages NNS N
and CC N
low JJ N
dose NN N
estrogens NNS i
. . i

Although IN N
GH NNP i
treatment NN i
for IN N
short JJ N
stature NN N
in IN N
Turner NNP N
syndrome NN N
is VBZ N
an DT N
accepted JJ N
treatment NN N
in IN N
many JJ N
countries NNS N
, , N
which WDT N
GH NNP N
dosage NN N
to TO N
use VB N
and CC N
which WDT N
age NN N
to TO N
start VB N
puberty JJ N
induction NN N
are VBP N
issues NNS N
of IN N
debate NN N
. . N

This DT N
study NN N
shows VBZ N
final JJ o
height NN o
( ( o
FH NNP o
) ) o
in IN N
60 CD p
girls NNS p
with IN p
Turner NNP p
syndrome NN p
treated VBD p
in IN p
a DT p
randomized JJ p
dose-response JJ p
trial NN p
, , N
combining VBG i
GH NNP i
treatment NN i
with IN i
low JJ i
dose NN i
estrogens NNS i
at IN N
a DT N
relatively RB N
young JJ N
age NN N
. . N

Girls NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
group NN N
A NNP N
( ( N
4 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
; : N
approximately RB N
0.045 CD N
mg/kg/d NN N
) ) N
, , N
group NN N
B NNP N
( ( N
first JJ N
year NN N
, , N
4 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
; : N
thereafter RB N
6 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
) ) N
, , N
or CC N
group NN N
C NNP N
( ( N
first JJ N
year NN N
, , N
4 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
; : N
second JJ N
year NN N
, , N
6 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
; : N
thereafter RB N
, , N
8 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
) ) N
. . N

After IN N
a DT N
minimum NN N
of IN N
4 CD N
yr NN N
of IN N
GH NNP i
treatment NN i
, , N
at IN N
a DT N
mean JJ N
age NN N
of IN N
12.7 CD N
+/- JJ N
0.7 CD N
yr NNS N
, , N
low JJ N
dose RB N
micronized VBN i
17beta-estradiol CD i
was VBD N
given VBN N
orally RB N
. . N

After IN N
a DT N
mean JJ N
duration NN o
of IN o
GH NNP o
treatment NN o
of IN N
8.6 CD N
+/- JJ N
1.9 CD N
yr NN N
, , N
FH NNP N
was VBD N
reached VBN N
at IN N
a DT N
mean JJ N
age NN N
of IN N
15.8 CD N
+/- JJ N
0.9 CD N
yr. NN N
FH NNP o
, , N
expressed VBD N
in IN N
centimeters NNS N
or CC N
SD NNP N
score NN N
, , N
was VBD N
157.6 CD N
+/- JJ N
6.5 CD N
or CC N
-1.6 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
A NNP N
, , N
162.9 CD N
+/- JJ N
6.1 CD N
or CC N
-0.7 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
B NNP N
, , N
and CC N
163.6 CD N
+/- JJ N
6.0 CD N
or CC N
-0.6 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
C. NNP N
The DT N
difference NN N
in IN N
FH NNP o
in IN o
centimeters NNS o
, , N
corrected VBN N
for IN N
height NN N
SD NNP N
score NN N
and CC N
age NN N
at IN N
start NN N
of IN N
treatment NN N
, , N
was VBD N
significant JJ N
between IN N
groups NNS N
A NNP N
and CC N
B NNP N
[ NNP N
regression NN N
coefficient NN N
, , N
4.1 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.4 CD N
, , N
6.9 CD N
; : N
P NNP N
< VBD N
0.01 CD N
] NN N
, , N
and CC N
groups NNS N
A NNP N
and CC N
C NNP N
( ( N
coefficient NN N
, , N
5.0 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
2.3 CD N
, , N
7.7 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
between IN N
groups NNS N
B NNP N
and CC N
C NNP N
( ( N
coefficient NN N
, , N
0.9 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
-1.8 NNP N
, , N
3.6 CD N
) ) N
. . N

Fifty NNP p
of IN p
the DT p
60 CD p
girls NNS p
( ( p
83 CD p
% NN p
) ) p
had VBD p
reached VBN p
a DT p
normal JJ o
FH NNP o
( ( p
FH NNP p
SD NNP p
score NN p
, , p
more JJR p
than IN p
-2 NN p
) ) p
. . N

After IN N
starting VBG N
estrogen NN i
treatment NN N
, , N
the DT N
decrease NN o
in IN o
height JJ o
velocity NN o
( ( o
HV NNP o
) ) o
changed VBD o
significantly RB o
to TO o
a DT o
stable JJ o
HV NNP o
, , N
without IN N
affecting VBG N
bone NN o
maturation NN o
( ( N
change NN N
in IN N
bone NN N
age/change NN N
in IN N
chronological JJ N
age NN N
) ) N
. . N

The DT N
following JJ N
variables NNS N
contributed VBD N
significantly RB N
to TO N
predicting VBG N
FH NNP o
SD NNP o
score NN o
: : o
GH NNP o
dose NN o
, , o
height VBD o
SD NNP o
score NN o
( ( N
ref JJ N
. . N

normal JJ N
girls NNS N
) ) N
, , N
chronological JJ o
age NN o
at IN o
start NN o
of IN o
treatment NN o
, , N
and CC N
HV NNP o
in IN N
the DT N
first JJ N
year NN N
of IN N
GH NNP N
treatment NN N
. . N

GH NNP i
treatment NN N
was VBD N
well RB o
tolerated VBN o
. . o

In IN N
conclusion NN N
, , N
GH NNP i
treatment NN N
leads VBZ N
to TO N
a DT N
normalization NN N
of IN N
FH NNP o
in IN N
most JJS N
girls NNS N
, , N
even RB N
when WRB N
puberty NN N
is VBZ N
induced VBN N
at IN N
a DT N
normal JJ N
pubertal JJ N
age NN N
. . N

The DT N
optimal JJ N
GH NNP i
dosage NN N
depends VBZ N
on IN N
height NN N
and CC N
age NN N
at IN N
the DT N
start NN N
of IN N
treatment NN N
and CC N
first JJ N
year NN N
HV NNP N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
metformin NN i
and CC i
insulin NN i
on IN N
sympathetic JJ N
nerve NN N
activity NN N
, , N
norepinephrine JJ N
spillover NN N
and CC N
blood NN N
pressure NN N
in IN N
obese JJ p
, , p
insulin JJ p
resistant NN p
, , p
normoglycemic JJ p
, , p
hypertensive JJ p
men NNS p
. . p

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
metformin NN i
on IN N
insulin NN N
sensitivity NN N
and CC N
to TO N
further RBR N
examine VB N
the DT N
relationship NN N
between IN N
insulin NN N
resistance NN N
, , N
sympathetic JJ N
nerve NN N
activity NN N
and CC N
blood NN N
pressure NN N
, , N
6 CD p
obese JJ p
insulin NN p
resistant NN p
, , p
normoglycemic JJ p
hypertensive JJ p
men NNS p
were VBD p
investigated VBN p
( ( p
age NN p
49 CD p
+/- JJ p
2 CD p
years NNS p
, , p
BMI NNP p
27.6 CD p
+/- JJ p
1.2 CD p
, , p
mean JJ p
+/- JJ p
SEM NNP p
) ) p
. . p

The DT N
study NN N
had VBD N
a DT N
placebo NN i
controlled VBN N
, , N
double JJ N
blind NN N
, , N
cross NN N
over IN N
design NN N
with IN N
6 CD N
weeks NNS N
' POS N
metformin NN i
treatment NN i
( ( i
850 CD i
mg RB i
b.i.d NN i
) ) i
vs NN i
placebo NN i
. . i

Blood NNP o
pressure NN o
was VBD N
measured VBN N
weekly RB N
. . N

At IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
, , N
glucose JJ o
infusion NN o
rate NN o
( ( o
GIR NNP o
) ) o
, , o
muscle FW o
sympathetic JJ o
nerve NN o
activity NN o
( ( o
MSA NNP o
) ) o
and CC o
renal JJ o
and CC o
total JJ o
body NN o
norepinephrine NN o
( ( o
NE NNP o
) ) o
kinetics NNS o
( ( o
radioisotope VB o
dilution NN o
) ) o
were VBD N
examined VBN N
during IN N
euglycemic JJ N
hyperinsulinemic JJ N
clamp NN N
. . N

Fasting VBG o
insulin NN o
was VBD N
13 CD N
+/- JJ N
3 CD N
and CC N
10 CD N
+/- JJ N
2 CD N
mU/l NN N
and CC N
fasting VBG N
glucose JJ N
5.3 CD N
+/- JJ N
0.2 CD N
and CC N
5.1 CD N
+/- JJ N
0.1 CD N
mmol/l NN N
after IN N
placebo NN N
and CC N
metformin NN N
treatment NN N
, , N
respectively RB N
( ( N
ns JJ N
) ) N
. . N

GIR NNP N
during IN N
the DT N
last JJ N
hour NN N
of IN N
the DT N
insulin NN N
clamp NN N
was VBD N
3.7 CD N
+/- JJ N
0.6 CD N
vs JJ N
3.6 CD N
+/- JJ N
0.6 CD N
mg/kg NN N
x NN N
min NN N
( ( N
ns JJ N
) ) N
. . N

Resting VBG o
MSA NNP o
, , o
total JJ o
body NN o
and CC o
right JJ o
renal NN o
NE NNP o
spillover NN o
did VBD N
not RB N
differ VB N
significantly RB N
after IN N
placebo NN i
and CC N
metformin NN i
treatment NN N
. . N

Systolic NNP o
and CC o
diastolic JJ o
blood NN o
pressures NNS o
were VBD N
151 CD N
+/- JJ N
10/95 CD N
+/- JJ N
5 CD N
mmHg NN N
after IN N
placebo NN N
and CC N
146 CD N
+/- JJ N
5/94 CD N
+/- JJ N
5 CD N
mmHg NN N
after IN N
metformin NN N
treatment NN N
( ( N
ns JJ N
) ) N
. . N

Thus NNP N
metformin NN i
treatment NN N
did VBD N
not RB N
have VB N
any DT N
significant JJ N
effect NN N
on IN N
insulin NN N
sensitivity NN N
, , N
blood NN o
pressure NN o
or CC o
sympathetic JJ o
activity NN o
in IN N
this DT N
small JJ N
group NN N
of IN N
patients NNS N
. . N

Renal JJ N
plasma NN N
flow NN N
and CC N
MSA NNP N
increased VBD N
significantly RB N
during IN N
the DT N
insulin NN N
clamp NN N
, , N
whereas JJ N
renal JJ N
NE NNP N
and CC N
total JJ N
body NN N
NE NNP N
spillover NN N
remained VBD N
unchanged JJ N
, , N
suggesting VBG N
nonuniform JJ N
regional JJ N
sympathetic JJ N
nerve NN N
responses NNS N
to TO N
acute VB N
hyperinsulinemia NN N
. . N

-DOCSTART- -X- O O

Safety NN N
and CC N
benefit NN N
of IN N
discontinuing VBG N
statin JJ i
therapy NN i
in IN N
the DT N
setting NN N
of IN N
advanced JJ p
, , p
life-limiting JJ p
illness NN p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
For IN N
patients NNS p
with IN p
limited JJ p
prognosis NN p
, , N
some DT N
medication NN N
risks NNS N
may MD N
outweigh VB N
the DT N
benefits NNS N
, , N
particularly RB N
when WRB N
benefits NNS N
take VBP N
years NNS N
to TO N
accrue VB N
; : N
statins NNS N
are VBP N
one CD N
example NN N
. . N

Data NNS N
are VBP N
lacking VBG N
regarding VBG N
the DT N
risks NNS N
and CC N
benefits NNS N
of IN N
discontinuing VBG N
statin JJ N
therapy NN N
for IN N
patients NNS p
with IN p
limited JJ p
life NN p
expectancy NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
safety NN N
, , N
clinical JJ N
, , N
and CC N
cost NN N
impact NN N
of IN N
discontinuing VBG N
statin JJ i
medications NNS N
for IN N
patients NNS p
in IN p
the DT p
palliative JJ p
care NN p
setting VBG p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
parallel-group NN N
, , N
unblinded JJ N
, , N
pragmatic JJ N
clinical JJ N
trial NN N
. . N

Eligibility NNP p
included VBD p
adults NNS p
with IN p
an DT p
estimated JJ p
life NN p
expectancy NN p
of IN p
between IN p
1 CD p
month NN p
and CC p
1 CD p
year NN p
, , p
statin NN p
therapy NN p
for IN p
3 CD p
months NNS p
or CC p
more JJR p
for IN p
primary JJ p
or CC p
secondary JJ p
prevention NN p
of IN p
cardiovascular JJ p
disease NN p
, , p
recent JJ p
deterioration NN p
in IN p
functional JJ p
status NN p
, , p
and CC p
no DT p
recent JJ p
active JJ p
cardiovascular JJ p
disease NN p
. . p

Participants NNS N
were VBD N
randomized VBN N
to TO N
either DT N
discontinue NN i
or CC i
continue VB i
statin JJ i
therapy NN i
and CC N
were VBD N
monitored VBN N
monthly RB N
for IN N
up IN N
to TO N
1 CD N
year NN N
. . N

The DT N
study NN N
was VBD N
conducted VBN p
from IN p
June NNP p
3 CD p
, , p
2011 CD p
, , p
to TO p
May NNP p
2 CD p
, , p
2013 CD p
. . p

All DT N
analyses NNS N
were VBD N
performed VBN N
using VBG N
an DT N
intent-to-treat JJ N
approach NN N
. . N

INTERVENTIONS NNP N
Statin NNP i
therapy NN i
was VBD N
withdrawn VBN N
from IN N
eligible JJ N
patients NNS N
who WP N
were VBD N
randomized VBN N
to TO N
the DT N
discontinuation NN N
group NN N
. . N

Patients NNS N
in IN N
the DT N
continuation NN N
group NN N
continued VBD N
to TO N
receive VB i
statins NNS i
. . i

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Outcomes NNP N
included VBD N
death NN o
within IN o
60 CD o
days NNS o
( ( o
primary JJ o
outcome NN o
) ) o
, , o
survival JJ o
, , o
cardiovascular JJ o
events NNS o
, , o
performance NN o
status NN o
, , o
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
, , o
symptoms NNS o
, , o
number NN o
of IN o
nonstatin JJ o
medications NNS o
, , o
and CC o
cost NN o
savings NNS o
. . o

RESULTS VB N
A DT p
total NN p
of IN p
381 CD p
patients NNS p
were VBD p
enrolled VBN p
; : p
189 CD N
of IN N
these DT N
were VBD N
randomized VBN N
to TO N
discontinue VB N
statins NNS i
, , N
and CC N
192 CD N
were VBD N
randomized VBN N
to TO N
continue VB N
therapy NN N
. . N

Mean NNP o
( ( o
SD NNP o
) ) o
age NN o
was VBD p
74.1 CD p
( ( p
11.6 CD p
) ) p
years NNS p
, , p
22.0 CD p
% NN p
of IN p
the DT p
participants NNS p
were VBD p
cognitively RB p
impaired VBN p
, , p
and CC p
48.8 CD p
% NN p
had VBD p
cancer NN p
. . p

The DT N
proportion NN N
of IN N
participants NNS N
in IN N
the DT N
discontinuation NN N
vs NN N
continuation NN N
groups NNS N
who WP N
died VBD N
within IN N
60 CD N
days NNS N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
23.8 CD N
% NN N
vs JJ N
20.3 CD N
% NN N
; : N
90 CD N
% NN N
CI NNP N
, , N
-3.5 NNP N
% NN N
to TO N
10.5 CD N
% NN N
; : N
P=.36 NNP N
) ) N
and CC N
did VBD N
not RB N
meet VB N
the DT N
noninferiority JJ N
end NN N
point NN N
. . N

Total JJ o
QOL NNP o
was VBD N
better RBR N
for IN N
the DT N
group NN N
discontinuing VBG N
statin JJ N
therapy NN N
( ( N
mean JJ N
McGill NNP N
QOL NNP N
score NN N
, , N
7.11 CD N
vs NN N
6.85 CD N
; : N
P=.04 NNP N
) ) N
. . N

Few JJ N
participants NNS N
experienced VBD N
cardiovascular JJ o
events NNS o
( ( N
13 CD N
in IN N
the DT N
discontinuation NN N
group NN N
vs VBD N
11 CD N
in IN N
the DT N
continuation NN N
group NN N
) ) N
. . N

Mean JJ o
cost NN o
savings NNS o
were VBD N
$ $ N
3.37 CD N
per IN N
day NN N
and CC N
$ $ N
716 CD N
per IN N
patient NN N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
This DT N
pragmatic JJ N
trial NN N
suggests VBZ N
that IN N
stopping VBG N
statin JJ N
medication NN N
therapy NN N
is VBZ N
safe JJ N
and CC N
may MD N
be VB N
associated VBN N
with IN N
benefits NNS N
including VBG N
improved JJ o
QOL NNP o
, , o
use NN o
of IN o
fewer JJR o
nonstatin NN o
medications NNS o
, , o
and CC o
a DT o
corresponding JJ o
reduction NN o
in IN o
medication NN o
costs NNS o
. . o

Thoughtful JJ N
patient-provider JJ N
discussions NNS N
regarding VBG N
the DT N
uncertain JJ N
benefit NN N
and CC N
potential JJ N
decrement NN N
in IN N
QOL NNP N
associated VBD N
with IN N
statin JJ N
continuation NN N
in IN N
this DT N
setting NN N
are VBP N
warranted VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT01415934 NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
cognitive-behavioral JJ i
therapy NN i
on IN N
anxiety NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

We PRP N
compared VBN N
the DT N
effects NNS N
of IN N
a DT N
16-week JJ N
Cognitive-Behavioral JJ i
Therapy NNP i
( ( i
CBT NNP i
) ) i
program NN i
and CC i
a DT i
Social NNP i
Recreational NNP i
( ( i
SR NNP i
) ) i
program NN i
on IN N
anxiety NN N
in IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

Seventy JJ p
children NNS p
( ( p
9-16 CD p
years NNS p
old JJ p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
of IN N
the DT N
programs NNS N
( ( N
n FW N
( ( i
CBT NNP i
) ) i
= VBZ N
36 CD N
; : N
n NNS N
( ( N
SR NNP N
) ) N
= VBP N
34 CD N
) ) N
. . N

Measures NNS N
on IN N
child NN N
's POS N
anxiety NN N
using VBG N
the DT N
Spence NNP o
Child NNP o
Anxiety NNP o
Scale NNP o
-- : o
Child NNP o
( ( o
SCAS-C NNP o
) ) o
and CC N
the DT N
Clinical JJ o
Global NNP o
Impression-Severity NNP o
scale NN o
( ( o
CGI NNP o
-- : o
S NNP o
) ) o
were VBD N
administered VBN N
at IN N
pre- JJ N
, , N
post-treatment JJ N
, , N
and CC N
follow-ups NNS N
( ( N
3- CD N
and CC N
6-month JJ N
) ) N
. . N

Children NNP N
in IN N
both DT N
programs NNS N
showed VBD N
significantly RB N
lower JJR N
levels NNS N
of IN N
generalized VBN o
anxiety NN o
and CC o
total JJ o
anxiety NN o
symptoms NNS o
at IN N
6-month JJ N
follow-up NN N
on IN N
SCAS-C. NNP N
Clinician NNP N
ratings NNS N
on IN N
the DT N
CGI-S NNP o
demonstrated VBD N
an DT N
increase NN N
in IN N
the DT N
percentage NN N
of IN N
participants NNS N
rated VBN N
as IN N
Normal NNP N
and CC N
Borderline NNP N
for IN N
both DT N
programs NNS N
. . N

Findings NNS N
from IN N
the DT N
present JJ N
study NN N
suggest JJS N
factors NNS N
such JJ N
as IN N
regular JJ i
sessions NNS i
in IN i
a DT i
structured JJ i
setting NN i
, , i
consistent JJ i
therapists NNS i
, , i
social JJ i
exposure NN i
and CC N
the DT N
use NN N
of IN N
autism-friendly JJ i
strategies NNS i
are VBP N
important JJ N
components NNS N
of IN N
an DT N
effective JJ N
framework NN N
in IN N
the DT N
management NN N
of IN N
anxiety NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -X- O O

Inhibition NN N
of IN N
epidural JJ o
morphine-induced JJ o
pruritus NN o
by IN N
intravenous JJ N
droperidol NN i
. . i

The DT N
effect NN N
of IN N
increasing VBG N
the DT N
doses NNS N
of IN N
morphine NN i
and CC N
of IN N
droperidol NN i
. . i

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
Because IN N
the DT N
mechanism NN N
of IN N
inhibition NN N
of IN N
epidural JJ N
morphine-induced JJ N
pruritus NN N
by IN N
droperidol NN N
is VBZ N
not RB N
clear JJ N
, , N
this DT N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
larger JJR N
doses NNS N
of IN N
droperidol NN i
or CC i
morphine NN i
, , N
or CC N
both DT N
. . N

METHODS VB N
A DT N
double-blind NN N
study NN N
was VBD N
performed VBN N
in IN N
210 CD p
ASA NNP p
I PRP p
or CC p
II NNP p
patients NNS p
undergoing VBG p
cesarean JJ p
delivery NN p
, , p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
six CD p
groups NNS p
. . p

All DT N
patients NNS N
received VBD N
epidural JJ i
anesthesia NN i
with IN i
0.5 CD i
% NN i
bupivacaine NN i
containing VBG i
1:200,000 CD i
epinephrine NN i
, , i
to TO i
which WDT i
2 CD i
mg NN i
( ( N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
) ) N
or CC N
4 CD N
mg NN N
( ( N
groups NNS N
4 CD N
, , N
5 CD N
, , N
and CC N
6 CD N
) ) N
morphine NN i
sulfate NN i
was VBD N
added VBN N
. . N

Just RB N
after IN N
delivery NN N
, , N
2.5 CD N
mg NN N
droperidol NN i
was VBD N
given VBN N
intravenously RB N
to TO N
groups NNS N
2 CD N
and CC N
5 CD N
, , N
and CC N
5 CD N
mg NN N
was VBD N
given VBN N
to TO N
groups NNS N
3 CD N
and CC N
6 CD N
. . N

During IN N
the DT N
postoperative JJ N
period NN N
, , N
the DT N
patients NNS N
were VBD N
assessed VBN N
for IN N
the DT N
occurrence NN o
and CC o
severity NN o
of IN o
pruritus NN o
( ( N
classified VBN N
as IN N
absent NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
or CC N
severe RB N
) ) N
or CC N
other JJ o
untoward JJ o
symptoms NNS o
. . o

The DT N
groups NNS N
were VBD N
compared VBN N
for IN N
the DT N
incidence NN o
of IN o
pruritus NN o
by IN N
the DT N
Mann-Whitney NNP N
nonparametric JJ N
test NN N
. . N

RESULTS VB N
The DT N
incidence NN o
of IN o
pruritus NN o
was VBD N
significantly RB N
reduced VBN N
only RB N
when WRB N
the DT N
control NN N
group NN N
. . N

( ( N
no DT N
droperidol NN i
) ) i
was VBD N
compared VBN N
with IN N
the DT N
group NN N
that WDT N
received VBD N
2.5 CD N
mg NN N
droperidol NN i
, , N
both DT N
when WRB N
2 CD N
mg NN N
and CC N
when WRB N
4 CD N
mg NN N
morphine NN i
was VBD N
used VBN N
. . N

A DT N
5-mg JJ N
dose NN N
of IN N
droperidol NN N
had VBD N
no DT N
inhibitory JJ o
effect NN o
. . o

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
incidence NN o
of IN o
pruritus NN o
between IN N
use NN N
of IN N
2 CD N
mg NNS N
and CC N
4 CD N
mg NN N
morphine NN i
. . i

Other JJ N
untoward JJ o
effects NNS o
of IN N
morphine NN i
either DT N
could MD N
not RB N
be VB N
observed VBN N
or CC N
occurred VBN N
with IN N
an DT N
incidence NN N
unaffected VBN N
by IN N
either DT N
dose NN N
of IN N
droperidol NN i
. . i

CONCLUSION NNP N
Pruritus NNP o
caused VBN N
by IN N
epidural JJ N
use NN N
of IN N
2 CD N
or CC N
4 CD N
mg NN N
of IN N
morphine NN i
is VBZ N
inhibited VBN N
by IN N
the DT N
intravenous JJ N
use NN N
of IN N
2.5 CD N
mg NNS N
droperidol RB i
but CC N
not RB N
by IN N
a DT N
larger JJR N
dose NN N
. . N

-DOCSTART- -X- O O

Chemoradiotherapy NN N
with IN N
concurrent JJ i
gemcitabine NN i
and CC i
cisplatin NN i
with IN i
or CC i
without IN i
sequential JJ i
chemotherapy NN i
with IN i
gemcitabine/cisplatin JJ i
vs NNS N
chemoradiotherapy NN i
with IN i
concurrent JJ i
5-fluorouracil JJ i
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
pancreatic JJ p
cancer NN p
-- : p
a DT p
multi-centre JJ p
randomised JJ N
phase NN N
II NNP N
study NN N
. . N

BACKGROUND NNP N
No NNP N
standard NN N
treatment NN N
for IN N
locally RB p
advanced JJ p
pancreatic JJ p
cancer NN p
( ( p
LAPC NNP p
) ) p
is VBZ N
defined VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Within NNP N
a DT N
multi-centre JJ N
, , N
randomised JJ N
phase NN N
II NNP N
trial NN N
, , N
95 CD p
patients NNS p
with IN p
LAPC NNP p
were VBD N
assigned VBN N
to TO N
three CD N
different JJ N
chemoradiotherapy NN N
( ( N
CRT NNP N
) ) N
regimens VBZ N
: : N
patients NNS N
received VBD N
conventionally RB N
fractionated VBN N
radiotherapy NN i
of IN N
50 CD N
Gy NNP N
and CC N
were VBD N
randomised VBN N
to TO N
concurrent VB N
5-fluorouracil NNP i
( ( N
350 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
per IN N
day NN N
on IN N
each DT N
day NN N
of IN N
radiotherapy NN i
, , N
RT-5-FU NNP N
arm NN N
) ) N
, , N
concurrent JJ i
gemcitabine NN i
( ( N
300 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
, , N
and CC N
cisplatin NN i
( ( N
30 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
on IN N
days NNS N
1 CD N
, , N
8 CD N
, , N
22 CD N
, , N
and CC N
29 CD N
( ( N
RT-GC NNP N
arm NN N
) ) N
, , N
or CC N
the DT N
same JJ i
concurrent NN i
treatment NN i
followed VBN i
by IN i
sequential JJ i
full-dose JJ i
gemcitabine NN i
( ( N
1000 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
and CC N
cisplatin NN i
( ( N
50 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
every DT N
2 CD N
weeks NNS N
( ( N
RT-GC+GC NNP N
arm NN N
) ) N
. . N

Primary JJ N
end NN N
point NN N
was VBD N
the DT N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
rate NN o
after IN o
9 CD o
months NNS o
. . o

RESULTS VB N
The DT N
9-month JJ o
OS NNP o
rate NN o
was VBD N
58 CD N
% NN N
in IN N
the DT N
RT-5-FU NNP N
arm NN N
, , N
52 CD N
% NN N
in IN N
the DT N
RT-GC NNP N
arm NN N
, , N
and CC N
45 CD N
% NN N
in IN N
the DT N
RT-GC+GC JJ N
arm NN N
. . N

Corresponding VBG N
median JJ o
survival NN o
times NNS o
were VBD N
9.6 CD N
, , N
9.3 CD N
, , N
and CC N
7.3 CD N
months NNS N
( ( N
P=0.61 NNP N
) ) N
respectively RB N
. . N

The DT N
intent-to-treat JJ o
response NN o
rate NN o
was VBD N
19 CD N
, , N
22 CD N
, , N
and CC N
13 CD N
% NN N
respectively RB N
. . N

Median JJ o
progression-free JJ o
survival NN o
was VBD N
estimated VBN N
with IN N
4.0 CD N
, , N
5.6 CD N
, , N
and CC N
6.0 CD N
months NNS N
( ( N
P=0.21 NNP N
) ) N
. . N

Grade $ o
3/4 CD o
haematological JJ o
toxicities NNS o
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
two CD N
GC-containing JJ N
arms NNS N
, , N
no DT N
grade NN o
3/4 CD o
febrile NN o
neutropaenia NN o
was VBD N
observed VBN N
. . N

CONCLUSION NNP N
None NN N
of IN N
the DT N
three CD N
CRT NNP N
regimens NNS N
tested VBD N
met VBD N
the DT N
investigators NNS N
' POS N
definition NN N
for IN N
efficacy NN N
; : N
the DT N
median JJ N
OS NNP N
was VBD N
similar JJ N
to TO N
those DT N
previously RB N
reported VBN N
with IN N
gemcitabine NN N
alone RB N
in IN N
LAPC NNP N
. . N

-DOCSTART- -X- O O

NHS NNP i
Direct NNP N
and CC N
older JJR p
people NNS p
. . p

-DOCSTART- -X- O O

Effects NNS N
of IN N
pyridostigmine NN i
and CC N
naloxone NN i
on IN N
the DT N
abnormal JJ o
TSH NNP o
response NN o
to TO o
TRH NNP o
during IN o
starvation NN o
in IN p
humans NNS p
. . p

BACKGROUND NNP N
Starvation NNP N
is VBZ N
associated VBN N
with IN N
a DT N
blunted JJ o
TSH NNP o
response NN o
to TO N
thyrotropin-releasing JJ o
hormone NN o
( ( o
TRH NNP o
) ) o
( ( N
peak JJ N
minus NN N
baseline NN N
< $ N
5 CD N
mIU/L NN N
) ) N
, , N
despite IN N
basal JJ N
TSH NNP N
and CC N
thyroid VB N
hormone NN N
levels NNS N
within IN N
the DT N
normal JJ N
range NN N
. . N

In IN N
light NN N
of IN N
the DT N
inhibitory JJ N
effect NN N
of IN N
somatostatin NN N
on IN N
TSH NNP N
secretion NN N
, , N
we PRP N
examined VBD N
whether IN N
this DT N
condition NN N
is VBZ N
caused VBN N
by IN N
an DT N
increased VBN N
hypothalamic NN o
somatostatinergic NN o
tone NN o
in IN N
starving VBG p
subjects NNS p
. . p

The DT N
possible JJ N
involvement NN o
of IN o
endogenous JJ o
opioids NNS o
in IN o
the DT o
mechanism NN o
underlying VBG o
the DT o
abnormal JJ o
TSH NNP o
response NN o
to TO o
TRH NNP o
was VBD N
also RB N
evaluated VBN N
. . N

METHODS NNP N
The DT N
TSH NNP o
response NN o
to TO o
TRH NNP o
( ( o
25 CD o
micrograms NNS o
in IN o
an DT o
intravenous JJ o
bolus NN o
) ) o
, , o
serum JJ o
total NN o
and CC o
free JJ o
T4 NNP o
and CC o
T3 NNP o
levels NNS o
, , o
and CC o
24-hour JJ o
urinary-free JJ o
cortisol NN o
levels NNS o
were VBD N
measured VBN N
in IN N
28 CD p
normal JJ p
men NNS p
( ( p
age NN p
27-35 CD p
years NNS p
) ) p
within IN p
10 CD p
% NN p
of IN p
their PRP$ p
ideal NN p
body NN p
weight NN p
. . p

They PRP p
were VBD p
randomly RB p
divided VBN p
into IN p
4 CD p
groups NNS p
of IN p
7 CD p
. . p

In IN N
21 CD N
subjects NNS N
( ( N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
) ) N
, , N
TRH NNP i
tests NNS i
were VBD i
performed VBN i
after IN i
an DT i
overnight NN i
( ( i
8 CD i
hours NNS i
) ) i
fast RB i
, , i
placebo JJ i
administrations NNS i
( ( i
control VB i
test NN i
) ) i
, , i
and CC i
after IN i
prolonged VBN i
( ( i
56 CD i
hours NNS i
) ) i
starvation NN i
. . i

TRH NNP o
tests NNS o
after IN o
prolonged JJ o
starvation NN o
were VBD i
performed VBN i
either RB i
after IN i
placebos NN i
( ( i
in IN i
all DT i
subjects NNS i
) ) i
or CC i
the DT i
administration NN i
of IN i
pyridostigmine NN i
( ( i
180 CD i
mg NNS i
orally RB i
) ) i
( ( i
in IN i
7 CD i
subjects NNS i
, , i
group NN i
1 CD i
) ) i
; : i
naloxone NN i
( ( i
0.8 CD i
mg NN i
in IN i
an DT i
i.v NN i
. . i

bolus CC i
injection NN i
) ) i
( ( i
in IN i
7 CD i
subjects NNS i
, , i
group NN i
2 CD i
) ) i
; : i
or CC i
the DT i
combination NN i
of IN i
pyridostigmine NN i
and CC i
naloxone NN i
( ( i
in IN i
7 CD i
subjects NNS i
, , i
group NN i
3 CD i
) ) i
. . i

The DT N
remaining VBG N
7 CD N
subjects NNS N
( ( N
group NN N
4 CD N
) ) N
were VBD N
tested VBN N
at IN N
weekly JJ N
intervals NNS N
with IN N
TRH NNP i
plus CC i
placebo NN i
, , i
TRH NNP i
plus CC i
naloxone NN i
, , i
TRH NNP i
plus CC i
pyridostigmine NN i
, , i
and CC i
TRH NNP i
plus CC i
naloxone JJ i
plus CC i
pyridostigmine NN i
after IN N
a DT N
fasting JJ N
period NN N
of IN N
8 CD N
hours NNS N
. . N

RESULTS NNP N
In IN N
all DT N
subjects NNS N
of IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
TRH-induced NNP o
TSH NNP o
rise NN o
was VBD N
significantly RB N
lower JJR N
after IN N
prolonged JJ N
starvation NN N
than IN N
after IN N
overnight JJ N
fast NN N
. . N

Neither CC N
pyridostigmine JJ i
nor CC N
naloxone JJ i
, , N
given VBN N
alone RB N
, , N
changed VBD N
the DT N
basal NN o
levels NNS o
of IN o
TSH NNP o
and CC N
the DT N
TSH NNP o
response NN o
to TO o
TRH NNP o
after IN o
prolonged JJ o
starvation NN o
. . o

In IN N
contrast NN N
, , N
the DT N
concomitant JJ N
administration NN N
of IN N
naloxone NN N
and CC N
pyridostigmine NN N
significantly RB N
enhanced VBD N
the DT N
TRH-induced NNP N
TSH NNP N
rise NN N
. . N

After IN N
overnight JJ N
fasting NN N
, , N
naloxone JJ N
administration NN N
in IN N
group NN N
4 CD N
subjects NNS N
did VBD N
not RB N
change VB N
the DT N
TSH NNP N
response NN N
to TO N
TRH NNP N
, , N
whereas JJ N
pyridostigmine VBP N
significantly RB N
enhanced VBN N
the DT N
TSH NNP N
response NN N
to TO N
TRH NNP N
. . N

When WRB N
naloxone NN N
was VBD N
given VBN N
together RB N
with IN N
pyridostigmine NN i
and CC N
TRH NNP i
the DT N
TSH NNP N
response NN N
was VBD N
similar JJ N
to TO N
that DT N
observed VBN N
in IN N
the DT N
TRH NNP N
plus CC N
pyridostigmine JJ N
test NN N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
indicate VBP N
that IN N
naloxone-sensitive JJ N
endogenous JJ N
opioids NNS N
exert VBP N
an DT N
inhibitory JJ N
effect NN N
on IN N
the DT N
cholinergic JJ o
stimulatory NN o
control NN o
of IN o
TSH NNP o
secretion NN o
during IN N
prolonged JJ N
starvation NN N
. . N

This DT N
suggests VBZ N
that IN N
an DT N
enhanced JJ N
hypothalamic JJ N
somatostatinergic NN N
activity NN N
is VBZ N
involved VBN N
in IN N
the DT N
mechanism NN N
underlying VBG N
the DT N
reduced VBN N
TSH NNP N
response NN N
to TO N
TRH NNP N
. . N

-DOCSTART- -X- O O

The DT N
effect NN o
of IN N
iron NN i
in IN N
formula NN N
milk NN N
after IN N
6 CD N
months NNS N
of IN N
age NN N
. . N

Ninety NNP p
two CD p
normal JJ p
birthweight JJ p
infants NNS p
aged VBD p
6 CD p
months NNS p
entered VBD N
a DT N
double JJ N
blind NN N
controlled VBD N
trial NN N
which WDT N
compared VBN N
a DT N
follow NN N
on IN N
formula NN i
milk NN i
with IN i
no DT i
added JJ i
iron NN i
against IN i
the DT i
same JJ i
formula NN i
milk NN i
containing VBG i
1.2 CD i
mg NN i
of IN i
iron NN i
per IN i
100 CD i
ml NN i
. . i

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
social JJ N
class NN N
or CC N
demographic JJ N
characteristics NNS N
of IN N
the DT N
two CD N
treatment NN N
groups NNS N
or CC N
in IN N
the DT N
proportion NN N
of IN N
each DT N
group NN N
completing VBG N
the DT N
trial NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
quantity NN o
of IN o
milk NN o
taken VBN o
but CC N
the DT N
amounts NNS N
taken VBN N
lessened VBD N
between IN N
6 CD N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
mean VB o
haemoglobin NN o
and CC o
median JJ o
serum NN o
ferritin NN o
at IN N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
15 CD N
, , N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

Very RB N
few JJ N
infants NNS N
developed VBD N
iron NN o
deficiency NN o
anaemia NN o
in IN N
either CC N
group NN N
but CC N
there EX N
was VBD N
a DT N
tendency NN N
for IN N
serum NN o
ferritin NN o
levels NNS o
to TO N
fall VB N
between IN N
6 CD N
and CC N
18 CD N
months NNS N
of IN N
age NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
iron NN i
added VBD N
to TO N
follow VB N
on IN N
milk NN N
was VBD N
not RB N
an DT N
important JJ N
source NN N
of IN N
dietary JJ N
iron NN i
in IN N
the DT N
infants NNS N
studied VBN N
. . N

-DOCSTART- -X- O O

Addressing VBG N
dental JJ p
fear NN p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
using VBG N
electronic JJ i
screen JJ i
media NNS i
. . i

BACKGROUND NNP N
Dental NNP N
care NN N
is VBZ N
a DT N
significant JJ N
unmet JJ N
health NN N
care NN N
need NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

Many JJ N
children NNS N
with IN N
ASD NNP N
do VBP N
not RB N
receive VB N
dental NN N
care NN N
because IN N
of IN N
fear NN N
associated VBN N
with IN N
dental JJ N
procedures NNS N
; : N
oftentimes VBZ N
they PRP N
require VBP N
general JJ N
anesthesia NN N
for IN N
regular JJ N
dental NN N
procedures NNS N
, , N
placing VBG N
them PRP N
at IN N
risk NN N
of IN N
associated JJ N
complications NNS N
. . N

Many JJ N
children NNS p
with IN p
ASD NNP p
have VBP N
a DT N
strong JJ N
preference NN N
for IN N
visual JJ N
stimuli NNS N
, , N
particularly RB N
electronic JJ N
screen NN N
media NNS N
. . N

The DT N
use NN N
of IN N
visual JJ N
teaching NN N
materials NNS N
is VBZ N
a DT N
fundamental JJ N
principle NN N
in IN N
designing VBG N
educational JJ N
programs NNS N
for IN N
children NNS p
with IN p
ASD NNP p
. . p

PURPOSE NNP N
To TO N
determine VB N
if IN N
an DT N
innovative JJ N
strategy NN N
using VBG N
2 CD N
types NNS N
of IN N
electronic JJ i
screen JJ i
media NNS i
was VBD N
feasible JJ N
and CC N
beneficial JJ N
in IN N
reducing VBG N
fear NN N
and CC N
uncooperative JJ N
behaviors NNS N
in IN N
children NNS p
with IN p
ASD NNP p
undergoing VBG p
dental JJ p
visits NNS p
. . p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
at IN N
Boston NNP p
Children NNP p
's POS p
Hospital NNP p
dental NN p
clinic NN p
. . p

Eighty NNP p
( ( p
80 CD p
) ) p
children NNS p
aged VBD p
7 CD p
to TO p
17 CD p
years NNS p
with IN p
a DT p
known JJ p
diagnosis NN p
of IN p
ASD NNP p
and CC p
history NN p
of IN p
dental JJ p
fear NN p
were VBD p
enrolled VBN p
in IN N
the DT N
study NN N
. . N

Each DT N
child NN N
completed VBD N
2 CD N
preventive JJ N
dental JJ N
visits NNS N
that WDT N
were VBD N
scheduled VBN N
6 CD N
months NNS N
apart RB N
( ( N
visit NN N
1 CD N
and CC N
visit VB N
2 CD N
) ) N
. . N

After IN N
visit NN N
1 CD N
, , N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
group NN N
A NNP N
, , N
control NN i
( ( i
usual JJ i
care NN i
) ) i
; : i
( ( N
2 CD N
) ) N
group NN N
B NNP N
, , N
treatment NN i
( ( i
video JJ i
peer NN i
modeling NN i
that WDT i
involved VBD i
watching VBG i
a DT i
DVD NNP i
recording NN i
of IN i
a DT i
typically RB i
developing VBG i
child NN i
undergoing VBG i
a DT i
dental JJ i
visit NN i
) ) i
; : i
( ( N
3 CD N
) ) N
group NN N
C NNP N
, , N
treatment NN N
( ( i
video JJ i
goggles NNS i
that WDT i
involved VBD i
watching VBG i
a DT i
favorite JJ i
movie NN i
during IN i
the DT i
dental JJ i
visit NN i
using VBG i
sunglass-style JJ i
video NN i
eyewear NN i
) ) i
; : i
and CC N
( ( N
4 CD N
) ) N
group NN N
D NNP N
, , N
treatment NN N
( ( i
video JJ i
peer NN i
modeling VBG i
plus CC i
video JJ i
goggles NNS i
) ) i
. . N

Subjects NNS N
who WP N
refused VBD N
or CC N
were VBD N
unable JJ N
to TO N
wear VB N
the DT N
goggles NNS N
watched VBD N
the DT N
movie NN N
using VBG N
a DT N
handheld NN N
portable JJ N
DVD NNP N
player NN N
. . N

During IN N
both DT N
visits NNS N
, , N
the DT N
subject NN N
's POS N
level NN N
of IN N
anxiety NN N
and CC N
behavior NN N
were VBD N
measured VBN N
using VBG N
the DT N
Venham NNP N
Anxiety NNP N
and CC N
Behavior NNP N
Scales NNP N
. . N

Analyses NNS N
of IN N
variance NN N
and CC N
Fisher NNP N
's POS N
exact NN N
tests NNS N
compared VBN N
baseline JJ N
characteristics NNS N
across IN N
groups NNS N
. . N

Using VBG N
intention NN N
to TO N
treat VB N
approach NN N
, , N
repeated VBD N
measures NNS N
analyses NNS N
were VBD N
employed VBN N
to TO N
test VB N
whether IN N
the DT N
outcomes NNS N
differed VBD N
significantly RB N
: : N
( ( N
1 CD N
) ) N
between IN N
visits NNS N
1 CD N
and CC N
2 CD N
within IN N
each DT N
group NN N
and CC N
( ( N
2 CD N
) ) N
between IN N
each DT N
intervention NN N
group NN N
and CC N
the DT N
control NN N
group NN N
over IN N
time NN N
( ( N
an DT N
interaction NN N
) ) N
. . N

RESULTS NNP N
Between NNP N
visits VBZ N
1 CD N
and CC N
2 CD N
, , N
mean JJ o
anxiety NN o
and CC o
behavior NN o
scores NNS o
decreased VBN N
significantly RB N
by IN N
0.8 CD N
points NNS N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
for IN N
subjects NNS N
within IN N
groups NNS N
C NNP N
and CC N
D. NNP N
Significant NNP N
changes NNS N
were VBD N
not RB N
observed VBN N
within IN N
groups NNS N
A NNP N
and CC N
B NNP N
. . N

Mean NNP o
anxiety NN o
and CC o
behavior JJ o
scores NNS o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
groups NNS N
over IN N
time NN N
, , N
although IN N
group NN N
A NNP N
versus NN N
C NNP N
pairwise NN N
comparisons NNS N
showed VBD N
a DT N
trend NN N
toward IN N
significance NN N
( ( N
P NNP N
= NNP N
.06 NNP N
) ) N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
certain JJ N
electronic JJ N
screen NN N
media NNS N
technologies NNS N
may MD N
be VB N
useful JJ N
tools NNS N
for IN N
reducing VBG o
fear NN o
and CC o
uncooperative JJ o
behaviors NNS o
among IN N
children NNS p
with IN p
ASD NNP p
undergoing VBG N
dental JJ N
visits NNS N
. . N

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
these DT N
strategies NNS N
using VBG N
larger JJR N
sample NN N
sizes NNS N
. . N

Findings NNS N
from IN N
future JJ N
studies NNS N
could MD N
be VB N
relevant JJ N
for IN N
nondental JJ N
providers NNS N
who WP N
care VBP N
for IN N
children NNS p
with IN p
ASD NNP p
in IN N
other JJ N
medical JJ N
settings NNS N
. . N

-DOCSTART- -X- O O

Relationships NNS N
of IN N
PROP NNP N
Taste NNP N
Phenotype NNP N
, , N
Taste NNP N
Receptor NNP N
Genotype NNP N
, , N
and CC N
Oral NNP N
Nicotine NNP N
Replacement NNP N
Use NNP N
. . N

INTRODUCTION NNP N
Recommended VBD N
dosage NN N
of IN N
oral JJ N
nicotine JJ N
replacement NN N
therapy NN N
( ( N
NRT NNP N
) ) N
product NN N
is VBZ N
often RB N
not RB N
achieved VBN N
in IN N
smoking VBG N
cessation NN N
attempts NNS N
. . N

n-6-propylthiouracil NN N
( ( N
PROP NNP N
) ) N
bitter NN N
taste NN N
phenotype NN N
may MD N
be VB N
a DT N
potential JJ N
risk NN N
factor NN N
for IN N
non-adherence NN N
to TO N
oral JJ N
NRT NNP N
products NNS N
due JJ N
to TO N
their PRP$ N
bitter JJ N
taste NN N
. . N

There EX N
is VBZ N
limited JJ N
literature NN N
on IN N
this DT N
phenotype NN N
in IN N
the DT N
context NN N
of IN N
smoking NN N
and CC N
none NN N
in IN N
relation NN N
to TO N
oral JJ N
NRT NNP N
pharmacotherapy NN N
. . N

METHODS NNP N
The DT N
association NN N
of IN N
PROP NNP N
taste NN N
phenotype NN N
with IN N
NRT NNP N
usage NN N
and CC N
sensory JJ N
response NN N
to TO N
products NNS N
was VBD N
examined VBN N
. . N

In IN N
a DT N
cross-over JJ N
experimental JJ N
design NN N
, , N
120 CD p
participants NNS p
received VBD p
a DT p
1 CD i
week NN i
supply NN i
of IN i
nicotine JJ i
inhalers NNS i
and CC i
1 CD i
week NN i
of IN i
nicotine JJ i
lozenges NNS i
with IN N
random JJ N
assignment NN N
to TO N
order NN N
. . N

Mixed JJ N
effects NNS N
linear JJ N
model NN N
analyses NNS N
were VBD N
conducted VBN N
. . N

RESULTS NNP N
PROP NNP N
taste NN N
phenotype NN N
and CC N
taste NN N
receptor NN N
genotype NN N
were VBD N
not RB N
associated VBN N
with IN N
NRT NNP N
usage NN N
or CC N
sensory JJ N
response NN N
to TO N
NRT NNP N
, , N
after IN N
adjusting VBG N
for IN N
other JJ N
factors NNS N
. . N

However RB N
, , N
PROP NNP N
non-tasters NNS N
used VBD N
a DT N
higher JJR N
number NN o
of IN o
lozenges NNS o
per IN o
day NN o
( ( N
continuous JJ N
exposure NN N
) ) N
than IN N
nicotine JJ N
cartridges NNS N
( ( N
intermittent JJ N
exposure NN N
) ) N
. . N

Unexpectedly RB N
, , N
half NN N
of IN N
baseline JJ N
PROP NNP N
non-tasters NNS N
shifted VBD N
to TO N
taster VB N
phenotype JJ N
2 CD N
weeks NNS N
after IN N
smoking VBG N
cessation NN N
or CC N
reduction NN N
. . N

Menthol NNP p
cigarette NN p
smokers NNS p
identified VBD N
higher JJR o
NRT NNP o
strength NN o
of IN o
sensation NN o
scores NNS o
than IN N
nonmenthol JJ p
smokers NNS p
. . p

Taste NNP N
receptor NN N
genotype NN N
was VBD N
related VBN N
to TO N
PROP NNP N
taste NN N
phenotype NN N
( ( N
Kendall NNP N
? . N
= NNP N
.591 NNP N
, , N
p NN N
= NNP N
.0001 NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
nonsignificant JJ N
relationship NN N
of IN N
PROP NNP N
phenotype NN N
and CC N
NRT NNP N
usage NN N
may MD N
be VB N
associated VBN N
with IN N
NRT NNP N
under-dosing JJ N
and CC N
limited JJ N
variance NN N
in IN N
the DT N
outcome NN N
variable NN N
. . N

PROP NNP N
non-tasters NNS N
' POS N
greater JJR N
use NN N
of IN N
lozenges NNS N
is VBZ N
consistent JJ N
with IN N
nicotine JJ N
exposure NN N
being VBG N
less RBR N
aversive JJ N
to TO N
non-tasters NNS N
. . N

Further NNP N
research NN N
of IN N
this DT N
and CC N
other JJ N
factors NNS N
impacting VBG N
NRT NNP N
usage NN N
are VBP N
warranted VBN N
to TO N
effectively RB N
inform VB N
smoking VBG N
cessation NN N
pharmacotherapy NN N
. . N

-DOCSTART- -X- O O

A DT N
randomised JJ N
double-blind NN N
control NN N
study NN N
of IN N
early JJ N
intracoronary JJ i
autologous JJ i
bone NN i
marrow NN i
cell NN i
infusion NN i
in IN N
acute JJ p
myocardial JJ p
infarction NN p
( ( N
REGENERATE-AMI NNP N
) ) N
. . N

INTRODUCTION NNP N
Acute NNP N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
remains VBZ N
a DT N
major JJ N
cause NN N
of IN N
mortality NN N
and CC N
morbidity NN N
worldwide VBP N
despite IN N
the DT N
latest JJS N
therapeutic JJ N
advances NNS N
designed VBN N
to TO N
decrease VB N
myocardial JJ N
injury NN N
. . N

Preclinical NNP N
and CC N
emerging VBG N
clinical JJ N
evidence NN N
show NN N
that IN N
the DT N
intracoronary JJ N
injection NN N
of IN N
autologous JJ i
bone NN i
marrow NN i
mononuclear JJ i
cells NNS i
( ( N
BMCs NNP N
) ) N
following VBG N
AMI NNP N
leads VBZ N
to TO N
improvement NN N
in IN N
left JJ N
ventricular JJ N
ejection NN N
function NN N
( ( N
LVEF NNP N
) ) N
. . N

In IN N
this DT N
clinical JJ N
trial NN N
we PRP N
will MD N
for IN N
the DT N
first JJ N
time NN N
assess VB N
the DT N
effect NN o
of IN N
early JJ N
( ( N
< JJ N
24 CD N
h NN N
) ) N
infusion NN N
of IN N
autologous JJ N
BMCs NNP N
following VBG N
AMI NNP N
on IN N
cardiac JJ N
function NN N
. . N

METHODS NNP N
AND CC N
ANALYSIS NNP N
REGENERATE-AMI NNP N
is VBZ N
a DT N
double-blind JJ N
, , N
randomised VBN N
, , N
multicentre FW p
, , N
placebo-controlled JJ i
trial NN N
to TO N
determine VB N
whether IN N
early JJ N
( ( N
< JJ N
24 CD N
h NN N
) ) N
intracoronary JJ N
infusion NN N
of IN N
BMCs NNP N
improves NNS N
LVEF NNP N
after IN N
AMI NNP N
. . N

The DT N
study NN N
will MD N
enrol VB p
100 CD p
patients NNS p
presenting VBG p
with IN p
an DT p
anterior JJ p
AMI NNP p
demonstrating VBG p
anterior JJ p
regional JJ p
wall NN p
motion NN p
abnormality NN p
. . p

Patients NNS N
will MD N
be VB N
randomised VBN N
to TO N
receive VB N
intracoronary JJ i
infusion NN i
of IN i
BMCs NNP i
or CC N
placebo NN i
( ( N
0.9 CD N
% NN N
saline NN i
) ) i
. . N

Primary JJ N
endpoint NN N
will MD N
be VB N
change NN o
in IN o
LVEF NNP o
at IN o
1 CD o
year NN o
compared VBN o
to TO o
baseline VB o
, , o
measured VBN o
by IN o
cardiac JJ o
MRI NNP o
. . o

Secondary JJ N
endpoints NNS N
at IN N
6 CD N
months NNS N
include VBP N
the DT N
change NN o
in IN o
global JJ o
LVEF NNP o
relative NN o
to TO o
baseline VB o
measured VBN o
by IN o
quantitative JJ o
left NN o
ventriculography NN o
and CC o
echocardiography NN o
, , o
as RB o
well RB o
as IN o
major JJ o
adverse JJ o
cardiac NN o
events NNS o
which WDT N
is VBZ N
also RB N
measured VBN N
at IN N
1 CD N
year NN N
. . N

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
The DT N
study NN N
will MD N
be VB N
performed VBN N
in IN N
agreement NN N
with IN N
the DT N
Declaration NNP N
of IN N
Helsinki NNP N
and CC N
is VBZ N
approved VBN N
by IN N
local JJ N
ethics NNS N
committee NN N
( ( N
NRES NNP N
Committee NNP N
London NNP N
West NNP N
London NNP N
: : N
07/Q0603/76 CD N
) ) N
. . N

TRIAL NNP N
REGISTRATION NNP N
http NN N
: : N
//clincialtrials.gov NN N
( ( N
NCT00765453 NNP N
) ) N
. . N

The DT N
results NNS N
of IN N
the DT N
trial NN N
will MD N
be VB N
published VBN N
according VBG N
to TO N
the DT N
CONSORT NNP N
statement NN N
and CC N
will MD N
be VB N
presented VBN N
at IN N
conferences NNS N
and CC N
reported VBD N
in IN N
peer-reviewed JJ N
journals NNS N
. . N

-DOCSTART- -X- O O

An DT N
oxytocin-induced JJ N
facilitation NN N
of IN N
neural JJ o
and CC o
emotional JJ o
responses NNS o
to TO o
social JJ o
touch NN o
correlates NNS N
inversely RB N
with IN N
autism NN p
traits NNS p
. . p

Social JJ N
communication NN N
through IN N
touch NN N
and CC N
mutual JJ N
grooming NN N
can MD N
convey VB N
highly RB N
salient JJ N
socio-emotional JJ N
signals NNS N
and CC N
has VBZ N
been VBN N
shown VBN N
to TO N
involve VB N
the DT N
neuropeptide JJ N
oxytocin NN i
( ( N
OXT NNP N
) ) N
in IN N
several JJ N
species NNS N
. . N

Less NNP N
is VBZ N
known VBN N
about IN N
the DT N
modulatory JJ N
influence NN N
of IN N
OXT NNP N
on IN N
the DT N
neural JJ N
and CC N
emotional JJ N
responses NNS N
to TO N
human JJ N
interpersonal JJ N
touch NN N
. . N

The DT N
present JJ N
randomized VBN N
placebo NN i
( ( N
PLC NNP N
) ) N
-controlled VBD N
within-subject JJ N
pharmaco-functional JJ N
magnetic JJ i
resonance NN i
imaging NN i
( ( i
fMRI NN i
) ) i
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
a DT N
single JJ i
intranasal NN i
dose NN i
of IN i
synthetic JJ i
OXT NNP i
( ( N
24 CD N
IU NNP N
) ) N
would MD N
facilitate VB N
both DT N
neural JJ N
and CC N
emotional JJ N
responses NNS N
to TO N
interpersonal VB N
touch NN N
in IN N
a DT N
context- NN N
( ( N
female JJ N
vs NN N
male NN N
touch NN N
) ) N
and CC N
trait- JJ N
( ( N
autistic JJ N
trait NN N
load NN N
) ) N
specific JJ N
manner NN N
. . N

Specifically RB N
, , N
the DT N
experimental JJ N
rationale NN N
was VBD N
to TO N
manipulate VB N
the DT N
reward NN N
value NN N
of IN N
interpersonal JJ N
touch JJ N
independent JJ N
of IN N
the DT N
intensity NN N
and CC N
type NN N
of IN N
actual JJ N
cutaneous JJ N
stimulation NN N
administered VBN N
. . N

Thus NNP p
, , p
40 CD p
heterosexual JJ p
males NNS p
believed VBN p
that IN p
they PRP p
were VBD p
touched VBN p
by IN p
either CC p
a DT p
man NN p
or CC p
a DT p
woman NN p
, , p
although IN p
in IN p
fact NN p
an DT p
identical JJ p
pattern NN p
of IN p
touch NN p
was VBD p
always RB p
given VBN p
by IN p
the DT p
same JJ p
female JJ p
experimenter NN p
blind NN p
to TO p
condition NN p
type NN p
. . p

Our PRP$ N
results NNS N
show VBP N
that IN N
OXT NNP N
increased VBD N
the DT o
perceived JJ o
pleasantness NN o
of IN o
female JJ N
, , N
but CC N
not RB o
male JJ o
touch NN o
, , o
and CC o
associated VBD o
neural JJ o
responses NNS o
in IN o
insula NN o
, , o
precuneus NN o
, , o
orbitofrontal JJ o
, , o
and CC o
pregenual JJ o
anterior JJ o
cingulate NN o
cortex NN o
. . o

Moreover RB N
, , N
the DT o
behavioral JJ o
and CC o
neural JJ o
effects NNS o
of IN o
OXT NNP o
were VBD o
negatively RB N
correlated VBN N
with IN N
autistic-like JJ N
traits NNS N
. . N

Taken VB N
together RB N
, , N
this DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
show VB N
that IN N
the DT N
perceived VBN N
hedonic JJ N
value NN N
of IN N
human JJ N
heterosexual JJ N
interpersonal JJ N
touch NN N
is VBZ N
facilitated VBN N
by IN N
OXT NNP N
in IN N
men NNS N
, , N
but CC N
that IN N
its PRP$ o
behavioral JJ o
and CC o
neural JJ o
effects NNS o
in IN o
this DT N
context NN N
are VBP N
blunted VBN N
in IN N
individuals NNS p
with IN p
autistic JJ p
traits NNS p
. . p

-DOCSTART- -X- O O

A DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
of IN N
5-fluorouracil JJ i
, , N
with IN N
or CC N
without IN N
human JJ i
interferon-beta NN i
, , N
for IN N
advanced JJ p
colorectal JJ p
cancer NN p
. . p

This DT N
study NN N
compared VBN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
monotherapy NN i
to TO N
that DT N
of IN N
5-FU JJ i
combined VBN i
with IN i
natural JJ i
human JJ i
interferon-beta NN i
( ( i
IFN-beta NNP i
) ) i
in IN N
patients NNS p
with IN p
unresectable JJ p
, , p
advanced JJ p
colorectal JJ p
carcinoma NN p
. . p

Forty-nine JJ p
chemotherapy-naive JJ p
patients NNS p
were VBD p
randomized VBN p
to TO N
5-FU JJ N
alone RB N
or CC N
to TO N
the DT N
combination NN N
. . N

All DT N
patients NNS N
received VBD N
750 CD N
mg NNS N
m NN N
( ( N
-2 JJ N
) ) N
day NN N
( ( N
-1 JJ N
) ) N
5-FU NN N
for IN N
5 CD N
days NNS N
by IN N
continuous JJ N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
infusion NN N
, , N
followed VBD N
after IN N
day NN N
15 CD N
by IN N
a DT N
weekly JJ N
i.v NN N
. . N

bolus NN N
of IN N
750 CD N
mg NNS N
m NN N
( ( N
-2 NNP N
) ) N
. . N

IFN-beta NNP i
was VBD N
injected VBN N
intramuscularly RB N
three CD N
times NNS N
weekly RB N
at IN N
9 CD N
M NNP N
IU NNP N
. . N

Treatment NNP N
continued VBD N
for IN N
52 CD N
weeks NNS N
, , N
or CC N
until IN N
disease JJ o
progression NN o
or CC N
intolerable JJ o
toxicity NN o
. . o

Clinical JJ N
endpoints NNS N
were VBD N
tumor JJ o
response NN o
, , o
time NN o
to TO o
progression NN o
, , o
survival NN o
and CC o
toxicity NN o
. . o

The DT N
addition NN N
of IN N
IFN-3 NNP i
to TO i
5-FU CD i
significantly RB N
improved VBN o
response NN o
rate NN o
( ( N
33.3 CD N
% NN N
vs JJ N
4.5 CD N
% NN N
for IN N
evaluable JJ N
patients NNS N
; : N
P NNP N
= NNP N
0.021 CD N
) ) N
, , N
time NN o
to TO o
progression NN o
( ( N
median JJ N
7.2 CD N
vs JJ N
4.2 CD N
months NNS N
; : N
P NNP N
= NNP N
0.0435 CD N
) ) N
, , N
and CC N
survival JJ o
time NN o
( ( N
median JJ N
15.9 CD N
vs JJ N
7.2 CD N
months NNS N
; : N
P NNP N
= NNP N
0.038 CD N
) ) N
without IN N
significantly RB N
increasing VBG N
toxicity NN o
compared VBN N
to TO N
5-FU JJ N
alone RB N
. . N

Cumulative JJ o
5-FU JJ o
dose NN o
was VBD N
higher JJR N
with IN N
combined JJ N
therapy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
: : N
more JJR N
patients NNS N
receiving VBG N
monotherapy JJ N
discontinued VBN N
treatment NN N
because IN N
of IN N
disease NN o
progression NN o
. . o

Fever NNP o
was VBD N
more RBR N
frequent JJ N
with IN N
combined JJ N
therapy NN N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
; : N
there EX N
were VBD N
no DT N
other JJ N
differences NNS N
in IN N
toxicity NN o
. . o

The DT N
only JJ N
grade NN o
IV NNP o
toxicity NN o
observed VBD N
was VBD N
neutropenia JJ N
( ( N
two CD N
patients NNS N
per IN N
group NN N
) ) N
. . N

A DT N
randomized JJ N
phase NN N
III NNP N
trial NN N
has VBZ N
been VBN N
initiated VBN N
to TO N
confirm VB N
the DT N
synergy NN N
between IN N
5-FU JJ i
and CC N
IFN-beta NNP i
. . i

-DOCSTART- -X- O O

Robotic JJ i
therapy NN i
: : i
a DT N
novel JJ N
approach NN N
in IN N
upper-limb JJ o
neurorehabilitation NN o
after IN N
stroke NN p
. . p

-DOCSTART- -X- O O

Randomized VBN N
controlled VBD N
study NN N
of IN N
customized JJ N
preventive JJ N
medicine NN N
reminder NN N
letters NNS N
in IN N
a DT N
community NN N
practice NN N
. . N

OBJECTIVE UH N
To TO N
test VB N
the DT N
effectiveness NN o
of IN N
customized JJ N
, , N
family-oriented JJ N
reminder NN N
letters NNS N
in IN N
activating VBG N
patients NNS p
to TO N
seek VB N
appropriate JJ N
preventive JJ N
services NNS N
. . N

DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
. . N

One CD i
group NN i
received VBD i
computer-generated JJ i
, , i
customized JJ i
letters NNS i
explaining VBG i
recommended VBD i
preventive JJ i
procedures NNS i
for IN i
each DT i
family NN i
member NN i
. . i

A DT i
second JJ i
group NN i
received VBD i
a DT i
form JJ i
letter NN i
listing NN i
recommendations NNS i
for IN i
all DT i
preventive JJ i
procedures NNS i
for IN i
all DT i
age NN i
and CC i
sex NN i
groups NNS i
. . i

A DT i
third JJ i
group NN i
( ( i
control VB i
group NN i
) ) i
received VBD i
no DT i
letters NNS i
. . i

SETTING VBG N
A DT p
private JJ p
medical JJ p
centre NN p
, , p
without IN p
university NN p
affiliation NN p
, , p
in IN p
rural JJ p
Quebec NNP p
. . p

PARTICIPANTS NN N
From IN p
8770 CD p
patients NNS p
who WP p
met VBD p
study NN p
criteria NNS p
, , p
719 CD p
families NNS p
were VBD p
randomly RB p
selected VBN p
. . p

Data NNS p
were VBD p
available JJ p
for IN p
1971 CD p
of IN p
1998 CD p
patients NNS p
in IN p
these DT p
families NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT o
Family NNP o
Received NNP o
Index NNP o
is VBZ N
the DT N
proportion NN N
of IN N
all DT N
procedures NNS N
for IN N
which WDT N
a DT N
family NN N
was VBD N
overdue JJ N
that IN N
they PRP N
received VBD N
. . N

The DT N
Family JJ o
End-of-study NNP o
Up-to-date NNP o
Index NNP o
is VBZ N
the DT N
proportion NN N
of IN N
procedures NNS N
for IN N
which WDT N
the DT N
family NN N
was VBD N
eligible JJ N
and CC N
for IN N
which WDT N
they PRP N
were VBD N
up-to-date JJ N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS VB N
The DT N
Family NNP o
Received NNP o
Index NNP o
for IN N
families NNS N
mailed VBN N
customized JJ i
letters NNS i
was VBD N
more RBR N
than IN N
double RB N
the DT N
index NN N
for IN N
patients NNS N
not RB N
mailed VBN N
letters NNS N
( ( N
Kruskal-Wallis NNP N
P NNP N
= NNP N
.0139 NNP N
) ) N
. . N

Comparison NNP N
of IN N
the DT N
Family NNP o
End-of-study NNP o
Up-to-date NNP o
indices NNS o
also RB N
demonstrated VBD N
that IN N
families NNS N
of IN N
patients NNS N
sent JJ N
customized JJ i
letters NNS i
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
up-to-date JJ N
than IN N
families NNS N
not RB N
sent VBD N
letters NNS N
( ( N
Kruskal-Wallis NNP N
P NNP N
= NNP N
.0054 NNP N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
difference NN N
appeared VBD N
between IN N
the DT N
number NN N
of IN N
preventive JJ N
measures NNS N
received VBN N
by IN N
the DT N
control NN i
group NN N
and CC N
the DT N
form-letter JJ i
group NN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
demonstrates VBZ N
a DT N
clinically RB N
small JJ N
but CC N
statistically RB N
significant JJ N
value NN N
to TO N
customizing VBG i
reminder NN i
letters NNS i
. . i

-DOCSTART- -X- O O

Learning VBG N
the DT N
'traceback NN i
' POS i
approach NN i
for IN N
interscalene JJ p
block NN p
. . p

-DOCSTART- -X- O O

Different NNP i
aprotinin NN i
applications NNS i
influencing VBG N
hemostatic JJ N
changes NNS N
in IN N
orthotopic NN p
liver NN p
transplantation NN p
. . p

The DT N
effect NN N
of IN N
different JJ N
aprotinin NN i
applications NNS i
on IN N
hemostatic JJ N
changes NNS N
and CC N
blood NN N
product NN N
requirements NNS N
in IN N
orthotopic JJ p
liver NN p
transplantation NN p
was VBD N
investigated VBN N
in IN N
a DT N
prospective JJ N
, , N
open JJ N
, , N
and CC N
randomized VBD N
study NN N
. . N

From IN p
November NNP p
1989 CD p
to TO p
June NNP p
1990 CD p
, , p
13 CD p
patients NNS p
received VBD N
aprotinin RB i
as IN N
a DT N
bolus NN i
of IN i
0.5 CD i
Mill NNP i
. . i

Kallikrein NNP N
inactivator JJ N
units NNS N
( ( N
KIU NNP N
) ) N
on IN N
three CD N
occasions NNS N
in IN N
the DT N
course NN N
of IN N
an DT N
OLT NNP N
, , N
whereas RB N
10 CD N
other JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
continuous JJ i
aprotinin JJ i
infusion NN i
of IN i
0.1-0.4 JJ i
Mill NNP i
. . i

KIU/hr NNP N
. . N

Before IN N
and CC N
after IN N
reperfusion NN N
of IN N
the DT N
graft NN o
liver NN o
, , o
signs NNS o
of IN o
hyperfibrinolysis NN o
, , N
measured VBN N
by IN N
thrombelastography NN N
, , N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
infusion NN N
group NN N
. . N

Tissue-type JJ o
plasminogen NN o
activator NN o
( ( o
t-PA JJ o
) ) o
activity NN o
increased VBD N
during IN N
the DT N
anhepatic JJ N
phase NN N
but CC N
to TO N
a DT N
significantly RB N
lesser JJR N
extent NN N
in IN N
the DT N
infusion NN N
group NN N
. . N

Blood NNP o
product NN o
requirements NNS o
during IN N
OLT NNP N
were VBD N
tendentiously RB N
higher JJR N
in IN N
the DT N
bolus NN N
group NN N
but CC N
not RB N
significantly RB N
so RB N
. . N

However RB N
, , N
the DT N
use NN N
of IN N
packed JJ o
red JJ o
blood NN o
cells NNS o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
postoperative JJ N
period NN N
, , N
whereas IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
fresh JJ N
frozen NN N
plasma NN o
requirements NNS o
between IN N
the DT N
two CD N
groups NNS N
. . N

All DT N
23 CD p
patients NNS p
have VBP N
survived VBN o
, , N
and CC N
only RB N
one CD N
woman NN N
of IN N
each DT N
group NN N
required VBN N
retransplantation NN o
due JJ N
to TO N
severe VB N
host-versus-graft JJ o
reactions NNS o
. . o

Furthermore RB N
, , N
we PRP N
investigated VBD N
the DT N
perfusate NN N
of IN N
the DT N
graft NN N
liver NN N
in IN N
both DT N
groups NNS N
and CC N
detected JJ N
signs NNS N
of IN N
a DT N
decreased JJ N
t-PA JJ o
release NN o
in IN N
the DT N
infusion NN N
group NN N
. . N

Our PRP$ N
results NNS N
demonstrate VBP N
an DT N
advantage NN N
of IN N
aprotinin NN i
given VBN N
as IN N
continuous JJ N
infusion NN N
over IN N
bolus JJ N
application NN N
in IN N
OLT NNP N
. . N

-DOCSTART- -X- O O

Chemotherapy NN N
of IN N
large JJ p
bowel NN p
carcinoma NN i
-- : i
fluorouracil NN i
( ( i
FU NNP i
) ) i
+ VBP i
hydroxyurea NN i
( ( i
HU NNP i
) ) i
vs. FW i
methyl-CCNU NN i
, , i
oncovin NN i
, , i
fluorouracil NN i
, , i
and CC i
streptozotocin NN i
( ( i
MOF-Strep NNP i
) ) i
. . i

An DT N
Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

In IN N
this DT N
prospective JJ N
randomized NN N
study NN N
of IN N
initial JJ N
chemotherapy NN N
for IN N
advanced JJ p
measurable JJ p
metastatic JJ p
large JJ p
bowel NN o
carcinoma NN o
, , N
the DT N
response NN o
rate NN o
was VBD N
6/32 CD p
( ( p
19 CD p
% NN p
) ) p
for IN p
FU NNP p
+ NNP p
HU NNP p
and CC p
5/32 CD p
( ( p
16 CD p
% NN p
) ) p
for IN p
MOF-Strep NNP p
; : p
the DT N
estimated JJ N
median JJ o
survival NN o
is VBZ N
43 CD N
weeks NNS N
for IN N
both DT N
treatments NNS N
. . N

Patients NNS N
who WP N
received VBD N
MOF-Strep NNP N
experienced VBD N
substantially RB N
greater JJR N
vomiting VBG o
and CC o
hematologic JJ o
toxicity NN o
than IN N
patients NNS p
who WP p
received VBD p
FU NNP N
+ NNP N
HU NNP N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

-DOCSTART- -X- O O

Supplementation NN i
effect NN o
with IN i
slow-release JJ i
urea NN i
in IN N
feed NN N
blocks NNS N
for IN N
Thai NNP p
beef NN p
cattle NNS p
-- : p
nitrogen DT p
utilization NN p
, , p
blood NN p
biochemistry NN p
, , p
and CC p
hematology NN p
. . p

Four CD p
Thai NNP p
male NN p
native JJ p
beef NN p
cattle NNS p
, , p
initial JJ p
body NN p
weight NN p
( ( p
BW NNP p
) ) p
of IN p
100 CD p
? . p
3.0 CD p
kg NN p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
4 CD N
? . N
4 CD N
Latin NNP N
square JJ N
design NN N
to TO N
receive VB N
four CD i
dietary JJ i
treatments NNS i
with IN i
inclusion NN i
of IN i
urea JJ i
calcium NN i
sulphate NN i
mixture NN i
( ( i
U-cas NNP i
) ) i
in IN i
feed NN i
block NN i
( ( i
FB NNP N
) ) N
at IN N
0 CD N
, , N
120 CD N
, , N
150 CD N
, , N
and CC N
180 CD N
g/kg NN N
dry JJ N
matter NN N
( ( N
DM NNP N
) ) N
. . N

Total JJ N
intakes NNS N
were VBD N
increased VBN N
with IN N
the DT N
increasing VBG N
level NN N
of IN N
U-cas JJ i
supplementation NN i
in IN i
FB NNP N
and CC N
the DT N
result NN N
obtained VBD N
the DT N
highest JJS N
when WRB N
supplementation NN N
of IN N
U-cas NNP i
in IN i
FB NNP N
at IN N
180 CD N
, , N
followed VBN N
by IN N
150 CD N
, , N
120 CD N
, , N
and CC N
0 CD N
g/kg NN N
DM NNP N
, , N
respectively RB N
. . N

Moreover RB i
, , i
supplementation NN i
of IN i
U-cas NNP i
in IN i
FB NNP N
at IN N
180 CD N
g/kg NNS N
DM NNP N
could MD N
reduce VB o
total JJ o
N NNP o
excretion NN o
( ( o
4.1 CD N
g/day NN N
) ) N
, , N
as IN N
compared VBN N
to TO N
others NNS N
treatments NNS N
, , N
while IN N
N NNP N
retention NN N
and CC N
proportion NN N
of IN N
N NNP N
retention NN N
to TO N
N NNP o
intake VB o
were VBD o
increased VBN N
up RB N
to TO N
6.9 CD N
g/day NN N
and CC N
14.9 CD N
% NN N
, , N
respectively RB N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT o
blood NN o
biochemistry NN o
and CC o
hematological JJ o
parameters NNS o
were VBD o
not RB N
different JJ N
among IN N
treatments NNS N
except IN o
concentration NN o
of IN o
plasma JJ o
urea JJ o
N NNP o
, , o
plasma NN o
glucose NN o
, , o
and CC o
total JJ o
blood NN o
protein NN o
were VBD o
improved VBN N
especially RB N
with IN i
U-cas JJ i
supplementation NN i
at IN i
180 CD N
g/kg NN N
DM NNP N
in IN N
FB NNP N
. . N

In IN N
conclusion NN i
, , i
supplementation NN i
of IN i
U-cas NNP i
at IN i
180 CD N
g/kg NN N
in IN N
FB NNP N
improved VBD o
feed JJ o
intake NN o
, , o
N NNP o
utilization NN o
, , o
and CC o
blood NN o
biochemistry NN o
in IN o
Thai NNP p
native JJ p
beef NN p
cattle NNS p
fed VBP p
on IN p
rice NN p
straw NN p
. . p

-DOCSTART- -X- O O

Skin NNP o
concentrations NNS o
of IN N
thromboxane NN N
synthetase NN N
inhibitor NN N
after IN N
topical JJ N
application NN N
with IN N
bioelastic JJ N
membrane NN N
. . N

Elevated VBN N
thromboxane NN N
levels NNS N
are VBP N
associated VBN N
with IN N
a DT N
number NN N
of IN N
disease NN N
states NNS N
, , N
including VBG N
dermal JJ N
pressure NN N
ulcers NNS N
. . N

When WRB N
dazmegrel NN i
was VBD i
orally RB i
administered VBN i
to TO i
greyhound VB i
dogs NNS i
wearing VBG i
leg NN i
casts NNS i
, , N
it PRP N
resulted VBD N
in IN N
a DT N
sparring JJ N
effect NN N
on IN N
the DT N
skin JJ N
areas NNS N
of IN N
potential JJ N
pressure NN N
ulcer NN N
development NN N
. . N

The DT N
objective NN N
of IN N
this DT N
research NN N
was VBD N
to TO N
determine VB N
if IN N
bioelastic JJ N
matrices NNS N
could MD N
provide VB N
controlled VBD o
release NN o
of IN N
thromboxane NN N
A2 NNP N
synthetase NN N
inhibitor NN N
( ( N
dazmegrel NN N
) ) N
at IN N
tissue NN N
concentrations NNS N
sufficient NN N
for IN N
inhibition NN N
of IN N
thromboxane NN N
synthesis NN N
. . N

The DT p
animal NN p
used VBN p
for IN p
these DT p
studies NNS p
was VBD p
the DT p
greyhound NN p
, , p
which WDT p
has VBZ p
thin JJ p
skin NN p
, , p
angular JJ p
conformation NN p
, , p
limited JJ p
body NN p
fat JJ p
and CC p
is VBZ p
predisposed VBN p
to TO p
pressure VB p
ulcers NNS p
similar JJ p
to TO p
those DT p
occurring VBG p
in IN p
humans NNS p
. . p

In IN N
vivo JJ N
skin JJ N
penetration NN N
studies NNS N
showed VBD N
that IN N
epidermal JJ N
exposure NN N
to TO N
bioelastic JJ N
thromboxane NN N
synthetase NN N
inhibitor NN N
( ( N
TSI NNP N
) ) N
matrix NN N
resulted VBD N
in IN N
local JJ o
tissue NN o
concentrations NNS o
of IN o
TSI NNP o
sufficient NN N
for IN N
thromboxane NN N
synthetase NN N
inhibition NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
dazmegrel NN N
in IN N
the DT N
skin NN N
layers NNS N
( ( N
epidermis NN N
, , N
dermis NN N
and CC N
subcutaneous JJ N
layers NNS N
) ) N
on IN N
1 CD N
, , N
7 CD N
and CC N
14-day JJ N
exposures NNS N
. . N

-DOCSTART- -X- O O

Value NNP N
of IN N
an DT N
anal JJ i
dilator NN i
after IN N
anal JJ N
stretch NN N
for IN N
haemorrhoids NNS o
. . o

A DT N
prospective JJ N
randomized VBN N
trial NN N
compared VBN N
anal JJ i
stretch NN i
with IN i
or CC i
without IN i
continued JJ i
dilatation NN i
for IN N
three CD N
months NNS N
in IN N
89 CD p
consecutive JJ p
patients NNS p
with IN p
haemorrhoids NNS p
. . p

Complications NNS o
of IN o
therapy NN o
occurred VBD N
in IN N
only RB N
4 CD N
patients NNS N
, , N
3 CD N
of IN N
whom WP N
had VBD N
transient JJ N
incontinence NN o
of IN N
flatus NN N
. . N

When WRB N
patients NNS N
were VBD N
reviewed VBN N
four CD N
months NNS N
after IN N
treatment NN N
, , N
only RB N
4 CD N
of IN N
44 CD N
patients NNS N
( ( N
9 CD N
% NN N
) ) N
who WP N
used VBD N
a DT N
dilator NN N
had VBD N
not RB N
been VBN N
improved VBN N
and CC N
required VBN N
additional JJ N
therapy NN N
, , N
compared VBN N
with IN N
15 CD N
of IN N
42 CD N
patients NNS N
( ( N
36 CD N
% NN N
) ) N
who WP N
had VBD N
anal JJ i
stretch NN i
alone RB N
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
use NN N
of IN N
an DT N
anal JJ N
dilator NN N
improves VBZ N
the DT N
results NNS N
of IN N
anal JJ o
stretch NN o
. . o

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
via IN N
perioperative JJ i
nutrition NN i
on IN N
postoperative JJ o
ileus NN o
and CC o
anastomotic JJ o
leakage NN o
following VBG N
colorectal JJ N
surgery NN N
( ( N
SANICS NNP N
II NNP N
trial NN N
) ) N
: : N
a DT N
study NN N
protocol NN N
for IN N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
Postoperative NNP N
ileus NN N
and CC N
anastomotic JJ N
leakage NN N
are VBP N
important JJ N
complications NNS N
following VBG N
colorectal JJ N
surgery NN N
associated VBN N
with IN N
short-term JJ N
morbidity NN N
and CC N
mortality NN N
. . N

Previous JJ N
experimental JJ N
and CC N
preclinical JJ N
studies NNS N
have VBP N
shown VBN N
that IN N
a DT N
short JJ N
intervention NN N
with IN N
enriched JJ N
enteral JJ N
nutrition NN N
dampens VBZ N
inflammation NN N
via IN N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
and CC N
thereby RB N
reduces NNS N
postoperative JJ N
ileus NN N
. . N

Furthermore RB N
, , N
early JJ N
administration NN N
of IN N
enteral JJ N
nutrition NN N
reduced VBD N
anastomotic JJ o
leakage NN o
. . o

This DT N
study NN N
will MD N
investigate VB N
the DT N
effect NN N
of IN N
nutritional JJ N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
just RB N
before RB N
, , N
during IN N
and CC N
early RB N
after IN N
colorectal JJ N
surgery NN N
on IN N
inflammation NN N
, , N
postoperative JJ N
ileus NN N
and CC N
anastomotic JJ N
leakage NN N
. . N

METHODS/DESIGN NNP N
This DT N
multicenter NN N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
will MD N
include VB N
280 CD p
patients NNS p
undergoing JJ p
colorectal JJ p
surgery NN p
. . p

All DT N
patients NNS p
will MD N
receive VB N
a DT N
selfmigrating JJ i
nasojejunal JJ i
tube NN i
that WDT N
will MD N
be VB N
connected VBN N
to TO N
a DT N
specially RB N
designed VBN N
blinded VBN N
tubing NN N
system NN N
. . N

Patients NNS p
will MD N
be VB N
allocated VBN N
either DT N
to TO N
the DT N
intervention NN N
group NN N
, , N
receiving VBG i
perioperative JJ i
nutrition NN i
, , N
or CC N
to TO N
the DT N
control NN N
group NN N
, , N
receiving VBG i
no DT i
nutrition NN i
. . i

The DT N
primary JJ N
endpoint NN N
is VBZ N
postoperative JJ o
ileus NN o
. . o

Secondary JJ N
endpoints NNS N
include VBP N
anastomotic JJ o
leakage NN o
, , o
local JJ o
and CC o
systemic JJ o
inflammation NN o
, , o
( ( o
aspiration NN o
) ) o
pneumonia NN o
, , o
surgical JJ o
complications NNS o
classified VBD o
according VBG o
to TO o
Clavien-Dindo NNP o
, , o
quality NN o
of IN o
life NN o
, , o
gut FW o
barrier JJR o
integrity NN o
and CC o
time NN o
until IN o
functional JJ o
recovery NN o
. . o

Furthermore NNP N
, , N
a DT N
cost-effectiveness JJ N
analysis NN N
will MD N
be VB N
performed VBN N
. . N

DISCUSSION NNP N
Activation NNP N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
via IN N
perioperative JJ N
enteral JJ N
feeding NN N
is VBZ N
expected VBN N
to TO N
dampen VB N
the DT N
local JJ o
and CC o
systemic JJ o
inflammatory NN o
response NN o
. . o

Consequently RB N
, , N
postoperative JJ o
ileus NN o
will MD N
be VB N
reduced VBN N
as RB N
well RB N
as IN N
anastomotic JJ o
leakage NN o
. . o

The DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
enriched JJ N
nutrition NN N
given VBN N
shortly RB N
before RB N
, , N
during IN N
and CC N
after IN N
surgery NN N
in IN N
a DT N
clinical JJ N
setting NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT02175979 NNP N
- : N
date NN N
of IN N
registration NN N
: : N
25 CD N
June NNP N
2014 CD N
. . N

Dutch VB N
Trial JJ N
Registry NN N
: : N
NTR4670 NNP N
- : N
date NN N
of IN N
registration NN N
: : N
1 CD N
August NNP N
2014 CD N
. . N

-DOCSTART- -X- O O

Clonidine NNP i
premedication NN N
improves VBZ N
metabolic JJ o
control NN o
in IN o
type NN o
2 CD o
diabetic JJ o
patients NNS o
during IN p
ophthalmic JJ p
surgery NN p
. . p

BACKGROUND NNP N
In IN N
stressful JJ N
conditions NNS N
, , N
increasing VBG N
blood NN N
glucose NN N
concentrations NNS N
are VBP N
closely RB N
related VBN N
to TO N
an DT N
increase NN N
in IN N
catecholamines NNS N
and CC N
cortisol NN N
release NN N
. . N

Clonidine NNP N
, , N
a DT N
centrally RB N
acting VBG N
alpha NN N
( ( N
2 CD N
) ) N
-adrenoceptor NN N
agonist NN N
, , N
has VBZ N
neuroendocrine JJ N
effects NNS N
, , N
including VBG N
inhibition NN N
of IN N
sympathoadrenal JJ N
activity NN N
. . N

We PRP N
therefore RB N
evaluated VBD N
the DT N
effect NN N
of IN N
clonidine NN i
on IN N
blood NN o
glucose NN o
control NN o
and CC N
insulin NN o
requirements NNS o
during IN N
ophthalmic JJ N
surgery NN N
when WRB N
given VBN N
as IN N
premedication NN N
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
. . p

METHODS NNP N
After IN N
randomization NN N
, , N
patients NNS N
were VBD N
premedicated VBN N
with IN N
clonidine NN i
or CC i
flunitrazepam NN i
( ( N
control NN N
) ) N
. . N

Patients NNPS N
were VBD N
given VBN N
insulin NN i
by IN N
continuous JJ N
i.v NN N
. . N

infusion NN N
to TO N
maintain VB N
blood NN N
glucose NN N
in IN N
the DT N
range NN N
5.5-11.1 JJ N
mmol NN N
litre NN N
( ( N
-1 NNP N
) ) N
. . N

Blood NNP o
glucose JJ o
concentrations NNS o
were VBD N
measured VBN N
every DT N
15 CD N
min NN N
during IN N
surgery NN N
, , N
and CC N
hourly RB N
for IN N
6 CD N
h NN N
after IN N
surgery NN N
. . N

Plasma NNP o
C-peptide JJ o
and CC o
counter-regulatory JJ o
hormones NNS o
were VBD N
also RB N
measured VBN N
. . N

RESULTS NNP N
Glycaemia NNP o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
clonidine NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
the DT N
median JJ o
amount NN o
of IN o
insulin NN o
administered VBN o
was VBD N
significantly RB N
reduced VBN N
: : N
clonidine NN N
group NN N
9.0 CD N
( ( N
interquartile JJ N
range NN N
5.1 CD N
) ) N
units NNS N
; : N
control VB N
18.6 CD N
( ( N
10.2 CD N
) ) N
units NNS N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Plasma NNP o
catecholamine JJ o
concentrations NNS o
were VBD N
lower JJR N
in IN N
patients NNS N
given VBN N
clonidine NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
but CC N
there EX N
was VBD N
no DT N
difference NN N
in IN N
cortisol JJ o
concentrations NNS o
. . o

CONCLUSION NNP N
Premedication NNP N
of IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN N
clonidine JJ i
90 CD N
min NN N
before IN N
surgery NN N
improves VBZ N
blood NN o
glucose VB o
control NN o
and CC N
decreases VBZ N
insulin NN o
requirements NNS o
during IN N
ophthalmic JJ N
surgery NN N
. . N

-DOCSTART- -X- O O

Anti-angiogenic JJ N
effect NN N
of IN N
tamoxifen NN i
combined VBN i
with IN i
epirubicin NN i
in IN N
breast NN p
cancer NN p
patients NNS p
. . p

Vascular JJ N
endothelial JJ N
growth NN N
factor NN N
A NNP N
( ( N
VEGF-A NNP N
) ) N
and CC N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
receptor NN N
2 CD N
( ( N
VEGFR2 NNP N
) ) N
are VBP N
the DT N
key JJ N
factors NNS N
mediating VBG N
neo-vascularization NN N
. . N

They PRP N
are VBP N
often RB N
coexpressed VBN N
in IN N
breast NN N
cancer NN N
. . N

Sex NNP N
steroids NNS N
may MD N
stimulate VB N
angiogenesis NN N
via IN N
the DT N
estrogen NN N
receptor NN N
( ( N
ER NNP N
) ) N
pathway RB N
. . N

We PRP N
investigated VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
addition NN N
of IN N
tamoxifen NN i
to TO i
epirubicin VB i
versus NN i
epirubicin FW i
alone RB i
on IN N
VEGF NNP N
and CC N
VEGFR2 NNP N
expression NN N
in IN N
breast NN N
cancer NN N
patients NNS N
. . N

The DT N
expression NN N
of IN N
VEGF NNP o
and CC o
VEGFR2 NNP o
was VBD N
assessed VBN N
on IN N
tissue NN N
microarray NN N
by IN N
immunohistochemistry NN N
at IN N
baseline JJ N
conditions NNS N
and CC N
after IN N
treatments NNS N
in IN N
the DT N
case NN N
of IN N
191 CD p
patients NNS p
with IN p
T2-4 NNP p
N0-1 NNP p
breast NN p
cancer NN p
enrolled VBN p
in IN p
a DT p
randomized JJ p
trial NN p
comparing VBG N
four CD N
cycles NNS N
of IN N
single JJ N
agent NN N
epirubicin NN N
versus NN N
epirubicin NN N
plus CC N
tamoxifen NN N
as IN N
primary JJ N
systemic JJ N
treatment NN N
. . N

Epirubicin NNP N
alone RB N
failed VBD N
to TO N
induce VB N
changes NNS o
in IN o
VEGF NNP o
expression NN o
( ( N
P NNP N
= NNP N
0.54 CD N
) ) N
, , N
while IN N
the DT N
addition NN N
of IN N
tamoxifen NN i
to TO i
epirubicin VB i
resulted VBN N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
VEGF NNP o
expression NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

As IN N
a DT N
consequence NN N
, , N
baseline NN o
VEGF NNP o
had VBD N
a DT N
negative JJ N
prognostic JJ N
role NN N
in IN N
patients NNS N
who WP N
received VBD N
epirubicin JJ N
alone RB N
but CC N
not RB N
in IN N
patients NNS N
receiving VBG N
epirubicin JJ i
plus CC i
tamoxifen JJ i
( ( N
interaction JJ N
test NN N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

VEGFR2 NNP o
expression NN o
increased VBD N
at IN N
residual JJ N
tumor NN N
histology NN N
in IN N
both DT N
treatment NN N
arms NNS N
, , N
with IN N
a DT N
lesser JJR N
extent NN N
in IN N
patients NNS N
receiving VBG N
tamoxifen JJ i
plus CC i
epirubicin JJ i
. . i

Decrease NNP N
in IN N
VEGFR2 NNP o
expression NN o
was VBD N
significantly RB N
associated VBN N
with IN N
response NN o
rate NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
addition NN i
of IN i
tamoxifen NN i
to TO i
epirubicin VB i
resulted VBN N
in IN N
a DT N
suppression NN o
of IN o
a DT o
key JJ o
angiogenic JJ o
pathway NN o
. . o

These DT N
data NNS N
suggest VBP N
a DT N
potential JJ N
synergism NN N
of IN N
these DT N
two CD N
drugs NNS N
. . N

-DOCSTART- -X- O O

Virtual JJ i
reality NN i
job NN i
interview NN i
training NN i
in IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

The DT N
feasibility NN N
and CC N
efficacy NN N
of IN N
virtual JJ i
reality NN i
job NN i
interview NN i
training NN i
( ( i
VR-JIT NNP i
) ) i
was VBD N
assessed VBN N
in IN N
a DT N
single-blinded JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

Adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
were VBD p
randomized VBN p
to TO p
VR-JIT NNP i
( ( p
n JJ p
= NNP p
16 CD p
) ) p
or CC p
treatment-as-usual JJ i
( ( i
TAU NNP i
) ) i
( ( p
n JJ p
= NNP p
10 CD p
) ) p
groups NNS p
. . p

VR-JIT NNP i
consisted VBD i
of IN i
simulated JJ i
job NN i
interviews NNS i
with IN i
a DT i
virtual JJ i
character NN i
and CC i
didactic JJ i
training NN i
. . i

Participants NNS N
attended VBD N
90 CD N
% NN N
of IN N
laboratory-based JJ N
training NN N
sessions NNS N
, , N
found VBD N
VR-JIT NNP i
easy JJ o
to TO o
use VB o
and CC N
enjoyable JJ o
, , N
and CC N
they PRP N
felt VBD N
prepared VBN o
for IN o
future JJ o
interviews NNS o
. . o

VR-JIT JJ i
participants NNS p
had VBD N
greater JJR o
improvement NN o
during IN o
live JJ o
standardized JJ o
job NN o
interview NN o
role-play NN o
performances NNS o
than IN N
TAU NNP i
participants NNS p
( ( N
p JJ N
= NNP N
0.046 CD N
) ) N
. . N

A DT N
similar JJ N
pattern NN N
was VBD N
observed VBN N
for IN N
self-reported JJ o
self-confidence NN o
at IN N
a DT N
trend NN N
level NN N
( ( N
p JJ N
= NNP N
0.060 CD N
) ) N
. . N

VR-JIT JJ o
simulation NN o
performance NN o
scores NNS o
increased VBD N
over IN N
time NN N
( ( N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.83 CD N
) ) N
. . N

Results JJ N
indicate JJ N
preliminary JJ N
support NN N
for IN N
the DT N
feasibility NN o
and CC N
efficacy NN o
of IN N
VR-JIT NNP i
, , N
which WDT N
can MD N
be VB N
administered VBN N
using VBG N
computer NN N
software NN N
or CC N
via IN N
the DT N
internet NN N
. . N

-DOCSTART- -X- O O

Transthoracic NNP i
versus NN i
transesophageal NN i
cardioversion NN i
of IN i
atrial JJ i
fibrillation NN i
under IN i
light JJ i
sedation NN i
: : i
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Electrical JJ p
cardioversion NN p
( ( p
ECV NNP p
) ) p
of IN p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
is VBZ N
limited VBN N
by IN N
a DT N
5-10 JJ N
% NN N
failure NN N
rate NN N
and CC N
by IN N
the DT N
expense NN N
arising VBG N
from IN N
a DT N
perceived JJ N
need NN N
for IN N
general JJ N
anesthesia NN N
. . N

A DT N
transesophageal JJ N
approach NN N
using VBG N
light JJ N
sedation NN N
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
means NN N
of IN N
augmenting VBG N
the DT N
success NN N
rate NN N
and CC N
avoiding VBG N
the DT N
need NN N
for IN N
general JJ N
anesthesia NN N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
high JJ N
rate NN N
of IN N
success NN N
and CC N
the DT N
lower JJR N
energy NN N
requirement NN N
associated VBN N
with IN N
biphasic JJ N
cardioversion NN N
might MD N
eliminate VB N
any DT N
advantage NN N
of IN N
the DT N
transesophageal JJ N
approach NN N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
60 CD p
patients NNS p
attending VBG p
for IN p
ECV NNP i
of IN i
persistent JJ i
AF NNP i
to TO i
a DT i
transesophageal NN i
or CC i
a DT i
transthoracic JJ i
approach NN i
. . i

Sedation NN N
of IN N
moderate JJ N
depth NN N
was VBD N
achieved VBN N
with IN N
intravenous JJ i
midazolam NNS i
. . i

The DT N
dose NN N
of IN N
midazolam NN N
was VBD N
titrated VBN N
in IN N
the DT N
same JJ N
manner NN N
in IN N
both DT N
groups NNS N
. . N

RESULTS NNP N
Sinus NNP o
rhythm NN o
was VBD N
restored VBN N
in IN N
29/30 CD N
patients NNS N
( ( N
97 CD N
% NN N
) ) N
in IN N
each DT N
group NN N
using VBG N
a DT N
similar JJ N
number NN N
of IN N
shocks NNS N
for IN N
both DT N
groups NNS N
( ( N
1.3 CD N
+/- JJ N
0.6 CD N
transesophageal NN N
vs NN N
1.4 CD N
+/- JJ N
0.7 CD N
transthoracic NN N
, , N
P NNP N
= NNP N
NS NNP N
) ) N
with IN N
a DT N
similar JJ N
procedure NN N
duration NN N
( ( N
14.1 CD N
+/- JJ N
8.2 CD N
minutes NNS N
vs JJ N
13.8 CD N
+/- JJ N
7.5 CD N
minutes NNS N
, , N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

Both DT N
groups NNS N
received VBD N
similar JJ N
doses NNS N
of IN N
midazolam NN N
( ( N
4.2 CD N
+/- JJ N
2.7 CD N
mg NN N
vs NN N
4.4 CD N
+/- JJ N
2.8 CD N
mg NN N
, , N
P NNP N
= NNP N
NS NNP N
) ) N
and CC N
both DT N
reported VBD N
a DT N
similar JJ N
discomfort NN o
score NN o
in IN N
( ( N
0.9 CD N
+/- JJ N
1.3 CD N
vs JJ N
1.1 CD N
+/- JJ N
1.8 CD N
, , N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

No DT N
complication NN o
occurred VBD N
in IN N
either DT N
group NN N
. . N

CONCLUSION NNP N
AF NNP N
may MD N
be VB N
cardioverted VBN N
safely RB o
and CC o
effectively RB o
by IN N
either CC N
a DT N
transthoracic NN N
or CC N
a DT N
transesophageal JJ N
approach NN N
. . N

The DT N
use NN N
of IN N
sedation NN N
of IN N
moderate JJ N
depth NN N
renders NNS N
cardioversion NN N
by IN N
either DT N
approach NN N
acceptable JJ N
. . N

As IN N
transesophageal NN N
ECV NNP N
shows VBZ N
no DT N
clear JJ N
advantage NN N
, , N
transthoracic JJ N
cardioversion NN N
should MD N
remain VB N
the DT N
approach NN N
of IN N
first JJ N
choice NN N
. . N

-DOCSTART- -X- O O

Preventive JJ N
treatment NN N
of IN N
serotonin-migraine JJ p
with IN N
1,3,4,14b-tetrahydro-2,7-dimethyl-2H-dibenzo JJ i
( ( i
b NN i
, , i
f NN i
) ) i
pyrazino- NN i
( ( i
1,2 CD i
-- : i
d NN i
) ) i
- : i
( ( i
1,4 CD i
) ) i
-oxazepine NN i
hydrogen NN i
maleate NN i
( ( i
Org NNP i
GC NNP i
94 CD i
) ) i
. . i

A DT N
double-blind JJ N
study NN N
. . N

1,3,4,14b-Tetrahydro-2,7-dimethyl-2H-dibenzo JJ i
( ( i
b NN i
, , i
f NN i
) ) i
pyrazino- NN i
( ( i
1,2-d CD i
) ) i
- : i
( ( i
1,4 CD i
) ) i
-oxazepine NN i
hydrogen NN i
maleate NN i
( ( i
Org NNP i
GC NNP i
94 CD i
) ) i
is VBZ N
an DT N
oral JJ N
antamine NN N
preparation NN N
with IN N
anti-serotoninergic JJ N
and CC N
anti-histaminic JJ N
effects NNS N
. . N

Its PRP$ N
lack NN N
of IN N
unpleasant JJ N
side-effects NNS N
permits NNS N
protracted VBN N
use NN N
for IN N
the DT N
preventive JJ N
treatment NN N
of IN N
serotonin-migraine NN N
. . N

Its PRP$ N
chemical NN N
structure NN N
-- : N
tetracyclic JJ N
ring NN N
, , N
C-beta NNP N
, , N
C-alpha NNP N
, , N
amine NN N
in IN N
a DT N
secondary JJ N
position NN N
-- : N
allows VBZ N
block NN N
of IN N
the DT N
receptors NNS N
for IN N
serotonin NN N
and CC N
histamine NN N
. . N

Preventive JJ N
treatment NN N
with IN N
3 CD N
x NNS N
5 CD N
mg/day NN N
of IN N
Org NNP i
GC NNP i
94 CD i
for IN N
a DT N
period NN N
of IN N
3 CD N
months NNS N
can MD N
almost RB N
completely RB N
eliminate JJ N
migraine NN o
attacks NNS N
. . N

21 CD N
out IN N
of IN N
30 CD p
patients NNS p
( ( N
70 CD N
% NN N
) ) N
profited VBN N
from IN N
such JJ N
a DT N
treatment NN N
, , N
showing VBG N
a DT N
drop NN N
from IN N
5 CD N
-- : N
30 CD N
attacks NNS N
to TO N
0 CD N
-- : N
1 CD N
attack NN o
per IN o
month NN o
and CC o
normalization NN o
of IN o
high JJ o
urinary JJ o
serotonin NN o
, , o
5-HIAA JJ o
or CC o
histamine JJ o
levels NNS o
. . o

However RB N
, , N
30 CD p
patients NNS p
receiving VBG p
3 CD p
x JJ p
0.5 CD p
mg NN p
or CC p
placebo JJ i
daily RB p
reacted VBD N
only RB N
rarely RB N
. . N

The DT N
typical JJ N
side-effects NNS N
of IN N
anti-serotonin JJ o
drugs NNS o
, , N
especially RB N
sedation NN o
or CC o
dizziness NN o
and CC o
hyperorexia NN o
were VBD N
hardly RB N
observed VBN N
. . N

Randomization NN N
of IN N
the DT N
serotonin-migraine JJ N
cases NNS N
and CC N
double-blind JJ N
methodology NN N
were VBD N
applied VBN N
throughout IN N
the DT N
trial NN N
. . N

-DOCSTART- -X- O O

Social NNP i
skills NNS i
training VBG i
for IN N
young JJ p
adults NNS p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

Despite IN N
the DT N
psychosocial JJ N
difficulties NNS N
common JJ N
among IN N
young JJ p
adults NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
, , N
little JJ N
to TO N
no DT N
evidence-based JJ N
social JJ i
skills NNS i
interventions NNS i
exist VBP N
for IN N
this DT N
population NN N
. . N

Using VBG N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
design NN N
, , N
the DT N
current JJ N
study NN N
tested VBD N
the DT N
effectiveness NN N
of IN N
an DT i
evidence-based JJ i
, , i
caregiver-assisted JJ i
social JJ i
skills NNS i
intervention NN i
known VBN i
as IN i
PEERS NNP i
for IN i
Young NNP i
Adults NNP i
with IN N
high-functioning JJ p
young JJ p
adults NNS p
with IN p
ASD NNP p
( ( p
ages VBZ p
18-23 CD p
) ) p
using VBG N
self- JJ o
and CC o
caregiver-report JJ o
measures NNS o
. . o

Results NNS N
revealed VBD N
that IN N
treated JJ N
young JJ p
adults NNS p
reported VBD N
significantly RB N
less JJR N
loneliness JJ o
and CC N
improved VBN o
social JJ o
skills NNS o
knowledge VBP o
, , N
while IN N
caregivers NNS N
reported VBD N
significant JJ N
improvements NNS N
in IN N
young JJ p
adults NNS p
' POS p
overall JJ o
social JJ o
skills NNS o
, , o
social JJ o
responsiveness NN o
, , o
empathy NN o
, , o
and CC o
frequency NN o
of IN o
get-togethers NNS o
. . o

Results NNS N
support VBD N
the DT N
effectiveness NN N
of IN N
using VBG N
this DT N
caregiver-assisted JJ i
, , i
manualized VBN i
intervention NN i
for IN N
young JJ p
adults NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -X- O O

Pimecrolimus NNP i
cream VBZ i
1 CD N
% NN N
vs. FW N
betamethasone CD i
17-valerate JJ i
0.1 CD N
% NN N
cream NN N
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

A DT N
randomized JJ N
open-label JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Seborrhoeic NNP N
dermatitis NN N
is VBZ N
a DT N
chronic JJ N
inflammatory NN N
disease NN N
with IN N
remissions NNS N
and CC N
exacerbations NNS N
, , N
characterized VBN N
by IN N
erythema NN N
, , N
scaling VBG N
and CC N
pruritus JJ N
primarily RB N
on IN N
the DT N
face NN N
, , N
scalp NN N
and CC N
chest NN N
. . N

Corticosteroids NNP N
and CC N
antifungals NNS N
are VBP N
the DT N
mainstay NN N
of IN N
therapy NN N
. . N

However RB N
, , N
chronic JJ N
use NN N
of IN N
corticosteroids NNS N
is VBZ N
associated VBN N
with IN N
side-effects NNS N
such JJ N
as IN N
skin JJ N
atrophy NN N
and CC N
telangiectasia NN N
. . N

Pimecrolimus NNP i
, , N
an DT N
inhibitor NN N
of IN N
calcineurin NN N
, , N
has VBZ N
been VBN N
used VBN N
successfully RB N
in IN N
one CD N
patient NN N
with IN N
seborrhoeic JJ N
dermatitis NN N
. . N

OBJECTIVES CC N
The DT N
objective NN N
of IN N
this DT N
randomized VBN N
open-label JJ N
clinical JJ N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
pimecrolimus NN i
in IN N
comparison NN N
with IN N
a DT N
potent NN N
corticosteroid NN i
( ( i
betamethasone CD i
17-valerate NN i
) ) i
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

METHODS NNP N
Twenty NNP p
patients NNS p
with IN p
seborrhoeic JJ p
dermatitis NN p
were VBD p
included VBN p
in IN p
this DT p
study NN p
, , p
11 CD p
patients NNS p
in IN p
the DT p
pimecrolimus JJ i
1 CD i
% NN i
cream NN i
group NN i
and CC p
nine CD p
patients NNS p
in IN p
the DT p
betamethasone NN i
17-valerate JJ i
0.1 CD i
% NN i
cream NN i
group NN i
. . i

Patients NNS N
were VBD N
instructed VBN N
to TO N
use VB N
a DT N
thin JJ N
layer NN N
of IN N
the DT N
study NN N
products NNS N
twice RB N
daily RB N
at IN N
the DT N
lesional JJ N
area NN N
and CC N
to TO N
discontinue VB N
treatment NN N
as RB N
soon RB N
as IN N
symptoms NNS N
were VBD N
absent JJ N
. . N

Clinical JJ N
measures NNS N
assessed VBN N
were VBD N
erythema RB o
, , o
scaling VBG o
and CC o
pruritus NN o
which WDT N
were VBD N
evaluated VBN N
using VBG N
a DT N
four-point JJ N
scale NN N
( ( N
0-3 JJ N
) ) N
. . N

RESULTS NNP N
Both NNP N
pimecrolimus FW i
and CC N
betamethasone NN i
were VBD N
highly RB N
effective JJ o
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

Betamethasone NNP i
reduced VBD N
all DT N
three CD N
parameters NNS N
, , N
erythema NN o
, , o
scaling VBG o
and CC o
pruritus NN o
, , N
faster JJR N
than IN N
pimecrolimus NN i
, , N
but CC N
the DT N
differences NNS N
in IN N
reduction NN N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Relapses NNS o
were VBD N
observed VBN N
more RBR N
frequently RB N
and CC N
were VBD N
more JJR N
severe JJ N
with IN N
betamethasone NN i
than IN N
with IN N
pimecrolimus NN i
. . i

Moreover RB N
, , N
pruritus NN o
was VBD N
not RB N
observed VBN N
after IN N
discontinuation NN N
of IN N
treatment NN N
from IN N
day NN N
15 CD N
and CC N
beyond IN N
in IN N
the DT N
pimecrolimus NN i
group NN N
, , N
whereas IN N
it PRP N
was VBD N
reported VBN N
in IN N
most JJS N
patients NNS N
of IN N
the DT N
betamethasone NN i
group NN N
. . N

This DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

CONCLUSIONS VB N
It PRP N
appears VBZ N
that IN N
pimecrolimus NN i
, , N
a DT N
nonsteroidal JJ N
topical JJ N
treatment NN N
, , N
may MD N
be VB N
an DT N
excellent JJ N
alternative JJ N
therapeutic JJ N
modality NN N
for IN N
treating VBG N
seborrhoeic JJ N
dermatitis NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
Sandostatin NNP i
prophylaxis NN i
for IN p
preservation NN o
injury NN o
after IN p
pancreas JJ p
transplantation NN p
. . p

-DOCSTART- -X- O O

An DT N
emergency NN N
clinical JJ N
pathway NN N
for IN N
stroke NN p
patients NNS p
-- : p
results NNS p
of IN N
a DT N
cluster NN N
randomised VBN N
trial NN N
( ( N
isrctn41456865 NN N
) ) N
. . N

BACKGROUND NNP N
Emergency NNP i
Clinical NNP i
Pathways NNP i
( ( i
ECP NNP i
) ) i
for IN N
stroke NN N
have VBP N
never RB N
been VBN N
tested VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN o
of IN N
an DT N
ECP NNP i
for IN N
stroke NN p
patients NNS p
in IN p
Latium NNP p
( ( p
Italy NNP p
) ) p
emergency NN p
system NN p
. . p

METHODS NNP N
cluster-RCT NN i
designed VBN N
to TO N
compare VB N
stroke JJ p
patient JJ p
referrals NNS p
by IN p
Emergency NNP i
Medical NNP i
Service NNP i
( ( i
EMS NNP i
) ) i
and CC p
Emergency NNP p
Room NNP p
( ( p
ER NNP p
) ) p
health NN p
professionals NNS p
trained VBN p
in IN p
the DT p
ECP NNP i
, , p
with IN p
those DT p
of IN p
non-trained JJ p
EMS NNP p
and CC p
ER NNP p
controls NNS p
. . p

Primary NNP N
outcome JJ N
measure NN N
was VBD N
the DT N
proportion NN o
of IN o
eligible JJ o
( ( o
aged VBN o
< NNP o
/= $ o
80 CD o
and CC o
symptom JJ o
onset NN o
< NNP o
/= VBZ o
6 CD o
hours NNS o
) ) o
stroke VBD o
patients NNS o
referred VBN o
to TO o
a DT o
stroke NN o
unit NN o
( ( o
SU NNP o
) ) o
. . o

Intention NN o
to TO o
treat VB o
( ( o
ITT NNP o
) ) o
and CC o
per-protocol JJ o
( ( o
PP NNP o
) ) o
analyses NNS o
were VBD N
performed VBN N
, , N
and CC N
risk NN o
ratios NNS o
( ( o
RR NNP o
) ) o
adjusted VBN N
by IN N
age NN N
, , N
gender NN N
and CC N
area NN N
, , N
were VBD N
calculated VBN N
. . N

RESULTS JJ N
2656 CD p
patients NNS p
in IN p
the DT p
intervention NN p
arm NN p
and CC p
2239 CD p
in IN p
the DT p
control NN p
arm NN p
required VBN N
assistance NN o
; : o
78.3 CD N
% NN N
of IN N
the DT N
former JJ N
and CC N
80.6 CD N
% NN N
of IN N
the DT N
latter NN N
were VBD N
admitted VBN o
to TO o
hospitals NNS o
, , N
and CC N
respectively RB N
74.8 CD N
% NN N
and CC N
78.3 CD N
% NN N
were VBD N
confirmed VBN o
strokes NNS o
. . o

Of IN N
the DT N
eligible JJ N
confirmed JJ o
strokes NNS o
, , N
106/434 CD N
( ( N
24.4 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
43/328 CD N
( ( N
13.1 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
arm NN N
were VBD N
referred VBN N
to TO N
the DT N
SU NNP o
in IN N
the DT N
ITT NNP N
analysis NN N
( ( N
RR NNP N
= NNP N
2.01 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.79-4.00 NN N
) ) N
, , N
and CC N
respectively RB N
105/243 CD N
( ( N
43.2 CD N
% NN N
) ) N
and CC N
43/311 CD N
( ( N
13.8 CD N
% NN N
) ) N
in IN N
the DT N
PP NNP N
analysis NN N
( ( N
RR NNP N
= NNP N
3.21 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.62-4.98 JJ N
) ) N
. . N

Of IN N
patients NNS N
suitable JJ N
for IN N
i.v NN N
. . N

thrombolysis NN N
, , N
15/175 CD N
( ( N
8.6 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
2/115 CD N
( ( N
1.7 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
arm NN N
received VBN N
thrombolysis NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
in IN N
the DT N
ITT NNP N
analysis NN N
, , N
and CC N
respectively RB N
15/99 CD N
( ( N
15.1 CD N
% NN N
) ) N
and CC N
2/107 CD N
( ( N
1.9 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
in IN N
the DT N
PP NNP N
analysis NN N
. . N

CONCLUSION NNP N
Our PRP$ N
data NNS N
suggest VBP N
potenti JJ N
efficiency NN o
and CC o
feasibility NN o
of IN N
an DT N
ECP NNP N
. . N

The DT N
integration NN N
of IN N
EMS NNP N
and CC N
ERs NNP N
with IN N
SU NNP N
networks NNS N
for IN N
organised JJ N
acute NN N
stroke NN N
care NN N
is VBZ N
feasible JJ N
and CC N
may MD N
ameliorate VB N
the DT N
quality NN o
of IN o
care NN o
for IN N
stroke NN p
patients NNS p
. . p

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
( ( N
ISRCTN41456865 NNP N
) ) N
. . N

-DOCSTART- -X- O O

Rosiglitazone NN i
and CC N
cognitive JJ N
function NN N
in IN N
clozapine-treated JJ i
patients NNS p
with IN p
schizophrenia NN p
: : p
a DT N
pilot NN N
study NN N
. . N

Studies NNS N
have VBP N
shown VBN N
that IN N
insulin NN N
resistance NN N
is VBZ N
associated VBN N
with IN N
cognitive JJ N
impairment NN N
. . N

Peroxisome VB i
proliferator-activated JJ i
receptor-? NN i
( ( i
PPAR-? NNP i
) ) i
agonists VBZ i
improve JJ N
insulin NN N
sensitivity NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT o
effect NN o
of IN o
rosiglitazone NN o
, , o
a DT N
PPAR-? JJ N
agonist NN N
, , N
on IN N
cognition NN N
in IN N
clozapine-treated JJ p
patients NNS p
with IN p
schizophrenia NN p
. . p

In IN p
an DT N
eight-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
pilot NN N
trial NN p
, , p
clozapine-treated JJ p
patients NNS p
with IN p
schizophrenia NN p
were VBD p
randomized VBN N
to TO N
receive VB i
rosiglitazone NN i
( ( i
4mg/day CD i
) ) i
or CC i
placebo NN i
. . i

A DT i
neuropsychological JJ N
battery NN N
including VBG o
the DT o
Digit NNP o
Span NNP o
subtest JJS o
from IN o
the DT o
Wechsler NNP o
Adult NNP o
Intelligence NNP o
Scale-III NNP o
( ( o
WAIS-III NNP o
) ) o
, , o
the DT o
verbal JJ o
fluency NN o
test NN o
, , o
the DT o
Hopkins NNP o
Verbal NNP o
Learning NNP o
Test NNP o
( ( o
HVLT NNP o
) ) o
, , o
the DT o
Trail-Making JJ o
Test NNP o
( ( o
TMT NNP o
) ) o
and CC o
the DT o
Wisconsin NNP o
Card NNP o
Sorting NNP o
Test NNP o
( ( o
WCST NNP o
) ) o
was VBD o
administered VBN N
at IN N
baseline NN N
and CC N
week NN N
eight CD p
. . p

Nineteen JJ p
patients NNS p
completed VBD p
the DT p
study NN p
. . p

There EX p
were VBD N
no DT N
significant JJ N
differences NNS N
on IN N
any DT N
demographic JJ o
or CC o
general JJ o
clinical JJ o
variables NNS o
between IN o
the DT N
rosiglitazone NN i
group NN i
( ( p
n=9 CC p
) ) p
and CC p
the DT p
placebo NN i
group NN i
( ( p
n=10 RB p
) ) p
. . p

When WRB p
baseline NN N
scores NNS N
were VBD N
controlled VBN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
change NN N
scores NNS N
of IN N
cognitive JJ o
performance NN o
over IN o
eight CD N
weeks NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
this DT N
pilot NN N
study NN i
, , i
rosiglitazone NN i
had VBD i
no DT N
cognitive JJ o
benefit NN o
in IN o
clozapine-treated JJ p
patients NNS p
with IN p
schizophrenia NN p
. . p

Future JJ p
studies NNS N
with IN N
longer JJR N
treatment NN N
duration NN N
and CC N
larger JJR N
sample NN N
size NN N
are VBP N
needed VBN N
to TO N
further RBR N
explore VB N
the DT N
potential JJ N
role NN N
of IN N
rosiglitazone NN i
in IN i
improving VBG N
cognitive JJ N
function NN N
in IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
multiphasic JJ i
oral JJ i
contraceptives NNS i
containing VBG i
norgestimate NN i
or CC i
desogestrel NN i
in IN N
acne JJ o
treatment NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE VB N
This DT N
study NN N
aimed VBD N
to TO N
compare VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
triphasic JJ i
combined JJ i
oral JJ i
contraceptives NNS i
( ( i
OCs NNP i
) ) i
containing VBG i
ethinyl JJ i
estradiol NN i
( ( i
EE NNP i
) ) i
and CC i
norgestimate JJ i
( ( i
NGM NNP i
) ) i
and CC N
biphasic JJ i
combined VBN i
OCs NNP i
containing VBG i
EE NNP i
and CC i
desogestrel NN i
( ( i
DSG NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
mild NN p
to TO p
moderate VB p
acne NN p
. . p

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
an DT N
investigator-blinded JJ N
, , N
randomized VBN N
, , N
parallel JJ N
group NN N
trial NN N
conducted VBD N
at IN N
3 CD p
centers NNS p
in IN p
Thailand NNP p
. . p

Female NNP p
subjects VBZ p
18-45 CD p
years NNS p
old JJ p
were VBD N
assigned VBN N
to TO N
one CD N
or CC N
the DT N
other JJ N
OCs NNP N
and CC N
evaluated VBN N
for IN N
efficacy NN N
and CC N
safety NN N
parameters NNS N
at IN N
the DT N
baseline NN N
visit NN N
and CC N
after IN N
1 CD N
, , N
3 CD N
and CC N
6 CD N
months NNS N
of IN N
treatment NN N
. . N

RESULTS NNP N
Among IN N
201 CD p
randomized JJ p
subjects NNS p
, , N
data NNS N
from IN N
93 CD N
subjects NNS N
in IN N
the DT N
EE/NGM NNP i
group NN N
and CC N
95 CD N
subjects NNS N
in IN N
the DT N
EE/DSG NNP i
group NN N
were VBD N
analyzed VBN N
. . N

After IN N
6 CD N
months NNS N
of IN N
treatment NN N
with IN N
EE/NGM NNP i
and CC i
EE/DSG NNP i
, , N
no DT N
differences NNS N
between IN N
formulations NNS N
were VBD N
found VBN N
for IN N
the DT N
decrease NN o
in IN o
total JJ o
acne JJ o
lesion NN o
counts NNS o
( ( N
74.4 CD N
% NN N
vs. FW N
65.1 CD N
% NN N
, , N
respectively RB N
, , N
p=.070 NN N
) ) N
or CC N
facial JJ o
improvement NN o
score NN o
. . o

More JJR N
women NNS N
using VBG N
EE/NGM NNP i
showed VBD N
a DT N
decrease NN N
in IN N
severity NN o
of IN o
facial JJ o
seborrhea NN o
than IN N
those DT N
using VBG N
EE/DSG NNP i
( ( N
p=.005 NN N
) ) N
. . N

No DT N
changes NNS o
in IN o
weight NN o
were VBD N
noted VBN N
in IN N
either DT N
group NN N
as IN N
compared VBN N
to TO N
baseline VB N
. . N

CONCLUSION NNP N
Multiphasic NNP N
OCs NNP i
containing VBG N
EE/NGM NNP i
and CC i
EE/DSG NNP i
provided VBD N
comparable JJ N
efficacy NN o
and CC o
tolerability NN o
in IN N
the DT N
treatment NN N
of IN N
acne NN N
. . N

However RB N
, , N
EE/NGM NNP i
had VBD N
a DT N
more RBR N
beneficial JJ N
effect NN N
on IN N
facial JJ o
seborrhea NN o
reduction NN N
than IN N
EE/DSG NNP i
. . i

IMPLICATIONS NNP N
EE/NGM NNP i
and CC i
EE/DSG NNP i
are VBP N
multiphasic JJ i
OCs NNP i
, , N
which WDT N
were VBD N
shown VBN N
to TO N
be VB N
clinically RB N
equally RB N
effective JJ N
for IN N
mild NN N
to TO N
moderate VB N
facial JJ N
acne NN N
, , N
and CC N
the DT N
multiphasic JJ N
combined JJ N
OC NNP N
with IN N
NGM NNP N
was VBD N
more RBR N
effective JJ N
for IN N
women NNS N
with IN N
facial JJ N
seborrhea NN N
. . N

Clinicians NNPS N
may MD N
apply VB N
the DT N
results NNS N
of IN N
this DT N
study NN N
when WRB N
considering VBG N
treatment NN N
options NNS N
for IN N
facial JJ p
acne NN p
and CC p
seborrhea NN p
. . p

-DOCSTART- -X- O O

Polydioxanone NNP i
sternal JJ i
sutures NNS i
for IN N
prevention NN N
of IN N
sternal JJ N
dehiscence NN N
. . N

BACKGROUND NNP N
Sternal NNP o
dehiscence NN o
and CC o
wound NN o
instability NN o
are VBP N
troublesome JJ N
complications NNS N
following VBG N
median JJ N
sternotomy NN N
. . N

Classic JJ N
sternal JJ N
approximation NN N
with IN N
stainless JJ N
steel NN N
wires NNS N
may MD N
not RB N
be VB N
the DT N
ideal JJ N
approach NN N
in IN N
patients NNS N
predisposed VBN N
to TO N
these DT N
complications NNS N
. . N

We PRP N
tested VBD N
the DT N
efficacy NN o
of IN N
polydioxanone NN i
( ( i
PDS NNP i
) ) i
suture NN i
in IN N
sternal JJ o
closure NN o
and CC N
in IN N
prevention NN N
of IN N
complications NNS o
in IN N
comparison NN N
to TO N
steel NN N
wires NNS N
in IN N
high-risk JJ p
individuals NNS p
. . p

METHODS NNP N
Three CD p
hundred VBD p
sixty-six JJ p
patients NNS p
undergoing VBG p
elective JJ p
cardiac JJ p
surgery NN p
with IN p
full JJ p
median JJ p
sternotomy NN p
and CC p
having VBG p
body NN p
surface JJ p
area NN p
( ( p
BSA NNP p
) ) p
less JJR p
than IN p
1.5 CD p
m NN p
( ( p
2 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
PDS NNP i
( ( N
n JJ N
= NNP N
181 CD N
) ) N
or CC N
stainless JJ i
steel NN i
( ( N
SS NNP N
, , N
n JJ N
= NNP N
185 CD N
) ) N
sternal JJ N
approximation NN N
. . N

The DT N
study NN N
was VBD N
focused VBN N
on IN N
aseptic JJ N
sternal JJ N
complications NNS N
, , N
namely RB N
bone JJ o
dehiscence NN o
and CC o
superficial JJ o
wound NN o
instability NN o
. . o

RESULTS NNP N
Both NNP N
bone VBD o
dehiscence NN o
and CC o
superficial JJ o
wound NN o
instability NN o
were VBD N
less JJR N
frequent JJ N
in IN N
the DT N
PDS NNP i
Group NNP N
( ( N
4 CD N
and CC N
3 CD N
cases NNS N
in IN N
the DT N
SS NNP N
Group NNP N
, , N
respectively RB N
, , N
vs. IN N
no DT N
cases NNS N
in IN N
the DT N
PDS NNP N
Group NNP N
) ) N
. . N

Cox NNP o
proportional JJ o
hazards NNS o
regression NN o
model NN N
in IN N
the DT N
whole NN N
study NN N
population NN N
identified VBN N
female JJ o
sex NN o
, , o
chronic JJ o
renal JJ o
insufficiency NN o
, , o
diabetes VBZ o
, , o
advanced JJ o
age NN o
, , o
lower JJR o
sternal JJ o
thickness NN o
, , o
osteoporosis NN o
, , o
corticosteroid JJ o
therapy NN o
, , o
and CC o
prolonged VBD o
CPB NNP o
or CC o
ventilation NN o
times NNS o
as IN N
predisposing VBG N
factors NNS N
to TO N
any DT N
of IN N
the DT N
two CD N
studied VBD N
sternal JJ N
complications NNS N
. . N

DISCUSSION NNP N
Data NNP N
suggest NN N
that IN N
PDS NNP i
suture NN N
can MD N
protect VB N
against IN N
development NN N
of IN N
aseptic JJ o
sternal JJ o
complications NNS o
following VBG p
median JJ p
sternotomy NN p
in IN p
high-risk JJ p
patients NNS p
with IN p
little JJ p
body NN p
mass NN p
. . p

The DT N
adoption NN N
of IN N
PDS NNP i
in IN N
other JJ N
subsets NNS N
of IN N
patients NNS N
, , N
i.e. FW N
, , N
obese JJ N
individuals NNS N
, , N
is VBZ N
to TO N
be VB N
questioned VBN N
. . N

-DOCSTART- -X- O O

N-butyl JJ N
cyanoacrylate NN N
embolization NN N
of IN N
cerebral JJ N
arteriovenous JJ N
malformations NNS N
: : N
results NNS N
of IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multi-center JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Liquid NNP N
N-butyl NNP N
cyanoacrylate NN N
( ( N
n-BCA JJ N
) ) N
use NN N
for IN N
the DT N
treatment NN N
of IN N
arteriovenous JJ N
malformations NNS N
( ( N
AVM NNP N
) ) N
in IN N
the DT N
brain NN N
has VBZ N
become VBN N
part NN N
of IN N
medical JJ N
practice NN N
. . N

However RB N
, , N
no DT N
study NN N
has VBZ N
led VBN N
to TO N
the DT N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
's POS N
approval NN N
of IN N
n-BCA JJ N
for IN N
intravascular JJ N
use NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
verify VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
an DT N
n-BCA/Tantalum JJ N
Powder/Ethiodized NNP N
Oil NNP N
mixture NN N
, , N
compared VBN N
with IN N
conventional JJ N
treatment NN N
( ( N
Trufill NNP N
polyvinyl VBZ N
alcohol NN N
[ NNP N
PVA NNP N
] NNP N
) ) N
for IN N
preoperative JJ N
embolization NN N
of IN N
cerebral JJ N
AVM NNP N
. . N

METHODS NNP N
Between NNP p
October NNP p
15 CD p
, , p
1996 CD p
, , p
and CC p
March NNP p
24 CD p
, , p
1999 CD p
, , p
104 CD p
patients NNS p
at IN p
13 CD p
centers NNS p
were VBD p
prospectively RB p
randomized VBN p
to TO N
undergo VB N
embolization NN i
using VBG i
an DT i
n-BCA/Tantalum JJ i
Powder/Ethiodol NNP i
mixture NN i
or CC i
Trufill NNP i
PVA NNP i
. . i

The DT N
pre-embolization NN N
therapy NN N
goals NNS N
were VBD N
determined VBN N
in IN N
terms NNS N
of IN N
the DT N
number NN N
of IN N
pedicles NNS N
to TO N
be VB N
embolized VBN N
and CC N
the DT N
percent NN N
of IN N
nidus JJ N
reduction NN N
expected VBN N
. . N

Embolization NN N
results NNS N
were VBD N
evaluated VBN N
by IN N
a DT N
central JJ N
laboratory NN N
. . N

Subsequent JJ N
surgical JJ N
resection NN N
data NNS N
were VBD N
recorded VBN N
. . N

Safety NNP N
evaluation NN N
data NNS N
included VBD N
recording VBG N
device NN o
complications NNS o
, , o
procedure NN o
complications NNS o
, , o
and CC o
intracranial JJ o
events/overall NN o
neurologic JJ o
outcomes NNS o
, , N
which WDT N
could MD N
be VB N
either CC N
device-related JJ N
, , N
procedure-related JJ N
, , N
or CC N
both DT N
. . N

RESULTS VB N
The DT N
reduction NN N
of IN N
AVM NNP o
dimensions NNS o
( ( N
79.4 CD N
% NN N
in IN N
the DT N
n-BCA JJ N
group NN N
and CC N
86.9 CD N
% NN N
in IN N
the DT N
PVA NNP N
group NN N
) ) N
and CC N
the DT N
mean JJ o
number NN o
of IN o
vessels NNS o
embolized VBN o
( ( N
2.2 CD N
in IN N
the DT N
n-BCA JJ N
group NN N
and CC N
2.1 CD N
in IN N
the DT N
PVA NNP N
group NN N
) ) N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Coils NNS N
were VBD N
used VBN N
more RBR N
commonly RB N
with IN N
PVA NNP N
embolization NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

No UH N
differences NNS N
were VBD N
detected VBN N
in IN N
surgical JJ o
resection NN o
time NN o
, , o
number NN o
of IN o
patients NNS o
who WP o
required VBD o
transfusion NN o
, , o
volume NN o
and CC o
number NN o
of IN o
transfusion NN o
units NNS o
, , o
or CC o
type NN o
and CC o
volume NN o
of IN o
fluid JJ o
replacement NN o
. . o

Glasgow NNP o
Outcome NNP o
Scale NNP o
scores NNS o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
before IN N
treatment NN N
, , N
after IN N
embolization NN N
, , N
or CC N
after IN N
resection NN N
. . N

Two CD N
of IN N
42 CD N
patients NNS N
who WP N
underwent JJ N
resection NN N
and CC N
had VBD N
been VBN N
treated VBN N
with IN N
n-BCA JJ N
experienced JJ N
post-resection NN o
hematoma NN o
, , N
compared VBN N
with IN N
eight CD N
of IN N
45 CD N
patients NNS N
who WP N
underwent JJ N
resection NN N
and CC N
had VBD N
been VBN N
treated VBN N
with IN N
PVA NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION VB N
This DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
showed VBD N
that IN N
n-BCA JJ N
is VBZ N
equivalent JJ N
to TO N
PVA NNP N
as IN N
a DT N
preoperative JJ N
embolic JJ N
agent NN N
for IN N
treatment NN N
of IN N
cerebral JJ p
AVM NNP p
as IN N
determined VBN N
by IN N
percent NN N
of IN N
nidus JJ N
reduction NN N
and CC N
number NN N
of IN N
feeding VBG N
pedicles NNS N
embolized VBN N
. . N

-DOCSTART- -X- O O

The DT N
problem NN N
of IN N
measurement NN N
error NN N
in IN N
multisite JJ p
clinical JJ p
trials NNS p
. . p

The DT N
implementation NN N
of IN N
a DT N
multisite NN p
, , N
randomized VBN N
, , N
clinical JJ N
psychopharmacologic JJ N
trial NN N
involves VBZ N
a DT N
substantial JJ N
investment NN N
of IN N
time NN N
and CC N
effort NN N
on IN N
the DT N
part NN N
of IN N
all DT N
participants NNS N
. . N

Because IN N
of IN N
their PRP$ N
complexity NN N
, , N
such JJ N
clinical JJ N
trials NNS N
present JJ N
unique JJ N
methodological JJ N
and CC N
design NN N
challenges NNS N
. . N

Indeed RB N
, , N
it PRP N
is VBZ N
not RB N
uncommon JJ N
for IN N
such JJ N
studies NNS N
to TO N
conclude VB N
with IN N
uninterpretable JJ N
results NNS N
, , N
due JJ N
in IN N
part NN N
to TO N
such JJ N
methodological JJ N
pitfalls NNS N
. . N

It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
clarification NN N
of IN N
such JJ N
methodologic JJ N
dilemmas NN N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
important JJ N
challenges NNS N
facing VBG N
the DT N
future NN N
of IN N
industry-sponsored JJ N
psychopharmacologic JJ N
drug NN N
development NN N
. . N

Among IN N
the DT N
many JJ N
factors NNS N
that WDT N
may MD N
contribute VB N
to TO N
problematic JJ N
clinical JJ p
trial NN p
results NNS p
, , N
error NN N
in IN N
measuring VBG N
the DT N
phenomena NN N
being VBG N
studied VBN N
is VBZ N
of IN N
particular JJ N
concern NN N
. . N

In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
the DT N
outcome NN N
of IN N
an DT N
intensive JJ i
series NN i
of IN i
interrater JJ i
reliability NN i
training NN i
sessions NNS i
for IN N
the DT N
17-item JJ i
Hamilton NNP o
Depression NNP o
Rating NNP o
Scale NNP o
conducted VBD N
at IN N
the DT N
start NN N
of IN N
a DT N
Phase NNP p
II NNP p
multisite RB p
clinical JJ p
drug NN p
trial NN p
. . p

The DT N
data NN N
underscore IN N
the DT N
magnitude NN o
of IN o
error NN o
present NN o
in IN N
such JJ N
a DT N
test NN N
setting NN N
and CC N
provide VB N
preliminary JJ N
evidence NN N
for IN N
the DT N
potential JJ N
effect NN N
of IN N
this DT N
problem NN N
on IN N
the DT N
detection NN N
of IN N
clinical JJ N
change NN N
. . N

-DOCSTART- -X- O O

Injection NNP i
sclerotherapy NN i
versus NN i
electrocoagulation NN i
in IN N
the DT N
management NN N
outcome NN N
of IN N
early JJ p
haemorrhoids NNS p
. . p

OBJECTIVE NNP N
To TO N
study VB N
the DT N
symptomatology NN N
of IN N
early JJ p
hemorrhoids NNS p
and CC N
to TO N
compare VB N
injection NN i
sclerotherapy NN i
( ( i
IS NNP i
) ) i
with IN i
electrocoagulation NN i
( ( i
EC NNP i
) ) i
in IN N
the DT N
management NN N
outcome NN N
of IN N
early JJ N
haemorrhoids NNS N
with IN N
respect NN N
to TO N
pain VB o
during IN o
the DT o
procedure NN o
, , o
reduction NN o
in IN o
bleeding VBG o
per IN o
rectum NN o
, , N
and CC N
overall JJ o
patient NN o
satisfaction NN o
score NN o
. . o

METHODS NNP N
A NNP N
total NN N
of IN N
102 CD p
patients NNS p
were VBD p
included VBN p
in IN N
this DT N
experimental JJ N
study NN N
at IN p
the DT p
POF NNP p
Hospital NNP p
, , p
Wah NNP p
Cantt NNP p
from IN p
October NNP p
2004 CD p
to TO p
June NNP p
2005 CD p
. . p

A DT N
detailed JJ N
history NN N
was VBD N
taken VBN N
and CC N
proctoscopic JJ N
examination NN N
was VBD N
performed VBN N
. . N

Patients NNS N
were VBD N
then RB N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
( ( N
Lottery NNP N
method NN N
) ) N
. . N

One CD N
group NN N
was VBD N
subjected VBN N
to TO N
EC NNP N
and CC N
the DT N
other JJ N
to TO N
IS NNP N
. . N

In IN N
the DT N
EC NNP N
, , N
using VBG N
the DT N
EC NNP N
machine NN N
( ( N
Wieda NNP N
, , N
China NNP N
) ) N
, , N
direct JJ N
current JJ N
of IN N
10-20 JJ N
mA NN N
was VBD N
applied VBN N
in IN N
the DT N
submucosal JJ N
plane NN N
of IN N
each DT N
pile NN N
core NN N
for IN N
5-7 JJ N
minutes NNS N
. . N

In IN N
the DT N
IS NNP N
1-2 JJ N
ml NN N
of IN N
5 CD N
% NN N
phenol NN i
in IN i
almond NN i
oil NN i
was VBD N
injected VBN N
in IN N
the DT N
same JJ N
plane NN N
in IN N
each DT N
pile NN N
core NN N
. . N

Pain NN o
during IN o
the DT o
procedure NN o
, , o
reduction NN o
in IN o
bleeding VBG o
per IN o
rectum NN o
and CC o
overall JJ o
patient NN o
satisfaction NN o
, , N
were VBD N
studied VBN N
as IN N
outcome JJ N
measures NNS N
. . N

RESULTS VB N
The DT p
mean JJ p
age NN p
of IN p
the DT p
patients NNS p
was VBD p
44 CD p
years NNS p
, , p
86 CD p
were VBD p
males NNS p
and CC p
16 CD p
were VBD p
females NNS p
. . p

Two CD N
thirds NNS N
of IN N
the DT N
patients NNS N
were VBD N
having VBG N
symptoms NNS N
for IN N
more JJR N
than IN N
6 CD N
months NNS N
. . N

A DT N
third JJ N
of IN N
patients NNS N
had VBD N
associated VBN N
local JJ o
pain NN o
while IN N
another DT N
third JJ N
had VBD N
associated VBN N
mucous JJ o
discharge NN o
. . o

Chronic JJ o
constipation NN o
was VBD N
present JJ N
in IN N
81 CD N
% NN N
patients NNS N
. . N

Only RB N
24.5 CD p
% NN p
of IN p
the DT p
patients NNS p
had VBD p
a DT p
positive JJ p
family NN p
history NN p
of IN p
haemorrhoids NNS p
. . p

Patients NNS N
in IN N
the DT N
electrocoagulation NN N
( ( N
EC NNP N
) ) N
group NN N
experienced VBD N
more JJR N
pain NN o
during IN o
the DT o
procedure NN o
than IN N
the DT N
injection NN N
sclerotherapy NN i
( ( i
IS NNP i
) ) i
group NN N
( ( N
P NNP N
< NNP N
0.000 CD N
) ) N
, , N
but CC N
EC NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
IS NNP N
in IN N
terms NNS N
of IN N
reducing VBG N
the DT N
bleeding NN o
per IN o
rectum NN o
( ( N
P NNP N
= NNP N
0.039 CD N
) ) N
, , N
and CC N
also RB N
significantly RB N
higher JJR N
number NN N
of IN N
patients NNS N
were VBD N
fully RB o
satisfied VBN o
with IN N
EC NNP N
than IN N
with IN N
IS NNP N
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
. . N

CONCLUSION NNP N
EC NNP N
, , N
although IN N
more RBR N
painful JJ o
, , N
is VBZ N
a DT N
safe JJ o
, , N
more RBR N
effective JJ o
and CC N
a DT N
highly RB o
satisfying JJ o
procedure NN N
for IN N
treating VBG N
early JJ N
hemorrhoids NNS N
. . N

-DOCSTART- -X- O O

Randomized VBN N
study NN N
of IN N
six CD p
umbilical JJ i
cord NN i
care NN i
regimens VBZ i
. . i

Comparing VBG N
length NN N
of IN N
attachment NN N
, , N
microbial JJ N
control NN N
, , N
and CC N
satisfaction NN N
. . N

Two CD p
hundred VBD p
and CC p
seventy VB p
one CD p
infants NNS p
were VBD p
enrolled VBN p
in IN p
a DT p
study NN p
to TO p
compare VB p
six CD p
different JJ p
methods NNS p
of IN p
treating VBG p
the DT p
umbilical JJ p
cord NN p
. . p

Antimicrobial NNP N
control NN N
was VBD N
equal JJ N
for IN N
all DT N
methods NNS N
. . N

Repeated VBN N
triple JJ i
dye NN i
application NN i
was VBD N
considered VBN N
least JJS o
acceptable JJ o
by IN N
staff NN N
and CC N
parents NNS N
and CC N
had VBD N
the DT N
longest JJS o
attachment JJ o
time NN o
. . o

Povidone-iodine NN i
was VBD N
associated VBN N
with IN N
the DT N
shortest JJS N
attachment JJ o
time NN o
and CC N
was VBD N
most RBS N
liked JJ N
. . N

If IN N
there EX N
is VBZ N
no DT N
special JJ N
need NN N
to TO N
treat VB N
a DT N
specific JJ o
nosocomial JJ o
outbreak NN o
, , o
duration NN o
of IN o
cord NN o
attachment NN o
and CC o
satisfaction NN o
of IN o
staff NN o
and CC o
parents NNS o
can MD N
help VB N
clinicians NNS N
decide VB N
on IN N
a DT N
cord NN N
care NN N
regimen NNS N
. . N

-DOCSTART- -X- O O

Ambient JJ i
temperature NN i
and CC i
biomarkers NNS i
of IN N
heart NN N
failure NN N
: : N
a DT N
repeated JJ N
measures NNS N
analysis NN N
. . N

BACKGROUND NNP N
Extreme NNP N
temperatures NNS N
have VBP N
been VBN N
associated VBN N
with IN N
hospitalization NN N
and CC N
death NN N
among IN p
individuals NNS p
with IN p
heart NN p
failure NN p
, , N
but CC N
few JJ N
studies NNS N
have VBP N
explored VBN N
the DT N
underlying JJ N
mechanisms NN N
. . N

OBJECTIVES IN N
We PRP N
hypothesized VBD N
that IN N
outdoor JJ N
temperature NN N
in IN N
the DT N
Boston NNP p
, , p
Massachusetts NNP p
, , N
area NN N
( ( N
1- JJ N
to TO N
4-day JJ N
moving NN N
averages NNS N
) ) N
would MD N
be VB N
associated VBN N
with IN N
higher JJR o
levels NNS o
of IN o
biomarkers NNS o
of IN o
inflammation NN o
and CC N
myocyte JJ o
injury NN o
in IN N
a DT N
repeated-measures JJ N
study NN N
of IN N
individuals NNS p
with IN p
stable JJ p
heart NN p
failure NN p
. . p

METHODS NNP N
We PRP N
analyzed VBD N
data NNS N
from IN N
a DT N
completed VBN N
clinical JJ N
trial NN N
that WDT N
randomized VBD N
100 CD p
patients NNS p
to TO N
12 CD i
weeks NNS i
of IN i
tai NN i
chi NN i
classes NNS i
or CC i
to TO i
time-matched JJ i
education NN i
control NN i
. . i

B-type NNP o
natriuretic JJ o
peptide NN o
( ( o
BNP NNP o
) ) o
, , o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
and CC o
tumor NN o
necrosis NN o
factor NN o
( ( o
TNF NNP o
) ) o
were VBD N
measured VBN N
at IN N
baseline NN N
, , N
6 CD N
weeks NNS N
, , N
and CC N
12 CD N
weeks NNS N
. . N

Endothelin-1 NNP o
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
12 CD N
weeks NNS N
. . N

We PRP N
used VBD N
fixed VBN N
effects NNS N
models NNS N
to TO N
evaluate VB N
associations NNS N
with IN N
measures NNS N
of IN N
temperature NN N
that WDT N
were VBD N
adjusted VBN N
for IN N
time-varying JJ N
covariates NNS N
. . N

RESULTS NNP N
Higher NNP N
apparent JJ N
temperature NN N
was VBD N
associated VBN N
with IN N
higher JJR N
levels NNS N
of IN N
BNP NNP o
beginning VBG N
with IN N
2-day JJ N
moving VBG N
averages NNS N
and CC N
reached VBD N
statistical JJ N
significance NN N
for IN N
3- JJ N
and CC N
4-day JJ N
moving NN N
averages NNS N
. . N

CRP NNP o
results NNS N
followed VBD N
a DT N
similar JJ N
pattern NN N
but CC N
were VBD N
delayed VBN N
by IN N
1 CD N
day NN N
. . N

A DT N
5?C CD N
change NN N
in IN N
3- JJ N
and CC N
4-day JJ N
moving NN N
averages NNS N
of IN N
apparent JJ o
temperature NN o
was VBD N
associated VBN N
with IN N
11.3 CD N
% NN N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
1.1 CD N
, , N
22.5 CD N
; : N
p NN N
= VBZ N
0.03 CD N
) ) N
and CC N
11.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
1.2 CD N
, , N
22.5 CD N
; : N
p NN N
= VBZ N
0.03 CD N
) ) N
higher JJR o
BNP NNP o
. . o

A DT N
5?C CD N
change NN N
in IN N
the DT N
4-day JJ N
moving JJ N
average NN N
of IN N
apparent JJ o
temperature NN o
was VBD o
associated VBN N
with IN N
21.6 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
2.5 CD N
, , N
44.2 CD N
; : N
p NN N
= VBZ N
0.03 CD N
) ) N
higher JJR N
CRP NNP o
. . o

No DT N
clear JJ N
associations NNS N
with IN o
TNF NNP o
or CC o
endothelin-1 JJ o
were VBD o
observed VBN N
. . N

CONCLUSIONS NNP N
Among IN p
patients NNS p
undergoing VBG p
treatment NN p
for IN p
heart NN p
failure NN p
, , p
we PRP N
observed VBD N
positive JJ N
associations NNS N
between IN o
temperature NN o
and CC o
both DT o
BNP NNP o
and CC o
CRP-predictors NNS o
of IN o
heart NN o
failure NN o
prognosis NN o
and CC o
severity NN o
. . o

-DOCSTART- -X- O O

Effects NNS N
of IN N
ursodeoxycholic JJ i
acid NN i
on IN N
serum NN o
liver NN o
enzymes NNS o
in IN N
patients NNS p
with IN p
hepatitis JJ p
C NNP p
virus-related JJ p
chronic JJ p
liver NN p
disease NN p
. . p

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
ursodeoxycholic JJ i
acid NN i
( ( i
UDCA NNP i
) ) i
on IN N
serum NN o
liver NN o
enzyme NN o
levels NNS o
[ VBP o
alanine JJ o
aminotransferase NN o
( ( o
ALT NNP o
) ) o
and CC o
gamma-glutamyl JJ o
transferase NN o
( ( o
GGT NNP o
) ) o
] VBP o
in IN N
101 CD p
patients NNS p
with IN p
hepatitis JJ p
C NNP p
virus-related JJ p
chronic JJ p
liver NN p
disease NN p
. . p

METHODS NNP N
Forty-nine JJ p
patients NNS p
were VBD p
assigned VBN p
to TO p
receive VB p
UDCA NNP i
( ( p
450 CD p
mg/day NN p
) ) p
over IN p
a DT p
period NN p
of IN p
6 CD p
months NNS p
and CC p
52 CD p
to TO p
receive VB p
no DT i
treatment NN i
. . i

RESULTS NNP N
In IN N
the DT N
UDCA NNP i
group NN N
, , N
serum NN o
ALT NNP o
and CC o
GGT NNP o
levels NNS o
significantly RB N
improved VBN N
. . N

ALT NNP o
values NNS o
decreased VBN N
from IN N
pre-treatment JJ N
levels NNS N
of IN N
157.0 CD N
+/- JJ N
62.6 CD N
IU/l NNP N
to TO N
82.5 CD N
+/- JJ N
46.4 CD N
IU/l NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
GGT NNP N
fell VBD N
from IN N
141.3 CD N
+/- JJ N
86.2 CD N
IU/l NNP N
to TO N
66.0 CD N
+/- JJ N
49.5 CD N
IU/l NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
change NN N
occurred VBD N
in IN N
the DT N
mean JJ o
ALT NNP o
and CC o
GGT NNP o
levels NNS o
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
Although IN N
our PRP$ N
encouraging JJ N
preliminary JJ N
results NNS N
must MD N
be VB N
validated VBN N
by IN N
double-blind JJ N
histological JJ N
trials NNS N
, , N
UDCA NNP i
may MD N
be VB N
an DT N
alternative JJ N
treatment NN N
for IN N
patients NNS p
who WP p
fail VBP p
to TO p
respond VB p
to TO p
interferon VB i
therapy NN i
. . i

-DOCSTART- -X- O O

Randomized VBN N
, , N
placebo-controlled JJ N
, , N
phase JJ N
III NNP N
trial NN N
of IN N
sunitinib JJ N
plus CC N
prednisone JJ N
versus NN N
prednisone NN N
alone RB N
in IN N
progressive JJ p
, , p
metastatic JJ p
, , p
castration-resistant JJ p
prostate NN p
cancer NN p
. . p

PURPOSE NNP N
We PRP N
evaluated VBD N
angiogenesis-targeted JJ o
sunitinib NN o
therapy NN o
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
of IN N
metastatic JJ p
castration-resistant JJ p
prostate NN p
cancer NN p
( ( p
mCRPC NN p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Men NNP p
with IN p
progressive JJ p
mCRPC NN p
after IN p
docetaxel-based JJ p
chemotherapy NN p
were VBD N
randomly RB N
assigned VBN N
2:1 CD N
to TO N
receive VB N
sunitinib NN i
37.5 CD i
mg/d NN i
continuously RB i
or CC i
placebo VB i
. . i

Patients NNS N
also RB N
received VBD N
oral JJ i
prednisone NN i
5 CD i
mg NN i
twice RB i
daily RB i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ o
survival NN o
( ( N
OS NNP N
) ) N
; : N
secondary JJ N
end NN N
points NNS N
included VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . N

Two CD N
interim JJ N
analyses NNS N
were VBD N
planned VBN N
. . N

RESULTS NNP N
Overall NNP N
, , N
873 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
receive VB N
sunitinib NN N
( ( N
n JJ N
= NNP N
584 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
289 CD N
) ) N
. . N

The DT N
independent JJ N
data NNS N
monitoring VBG N
committee NN N
stopped VBD N
the DT N
study NN N
for IN N
futility NN N
after IN N
the DT N
second JJ N
interim JJ N
analysis NN N
. . N

After IN N
a DT N
median JJ N
overall JJ N
follow-up NN N
of IN N
8.7 CD N
months NNS N
, , N
median JJ o
OS NNP o
was VBD N
13.1 CD N
months NNS N
and CC N
11.8 CD N
months NNS N
for IN N
sunitinib NN N
and CC N
placebo NN N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.914 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.762 CD N
to TO N
1.097 CD N
; : N
stratified VBN N
log-rank JJ N
test NN N
, , N
P NNP N
= NNP N
.168 NNP N
) ) N
. . N

PFS NNP o
was VBD N
significantly RB N
improved VBN N
in IN N
the DT N
sunitinib NN N
arm NN N
( ( N
median JJ N
5.6 CD N
v JJ N
4.1 CD N
months NNS N
; : N
HR NNP N
, , N
0.725 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.591 CD N
to TO N
0.890 CD N
; : N
stratified VBN N
log-rank JJ N
test NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Toxicity NN o
and CC o
rates NNS o
of IN o
discontinuations NNS o
because IN o
of IN o
adverse JJ o
events NNS o
( ( N
AEs NNP N
; : N
27 CD N
% NN N
v JJ N
7 CD N
% NN N
) ) N
were VBD N
greater JJR N
with IN N
sunitinib JJR N
than IN N
placebo NN N
. . N

The DT N
most RBS N
common JJ N
treatment-related JJ N
grade NN N
3/4 CD N
AEs NNP N
were VBD N
fatigue JJ o
( ( N
9 CD N
% NN N
v JJ N
1 CD N
% NN N
) ) N
, , N
asthenia RB o
( ( N
8 CD N
% NN N
v JJ N
2 CD N
% NN N
) ) N
, , N
and CC N
hand-foot JJ o
syndrome NN o
( ( N
7 CD N
% NN N
v JJ N
0 CD N
% NN N
) ) N
. . N

Frequent JJ N
treatment-emergent JJ N
grade NN N
3/4 CD N
hematologic JJ o
abnormalities NNS o
were VBD N
lymphopenia JJ o
( ( N
20 CD N
% NN N
v JJ N
11 CD N
% NN N
) ) N
, , N
anemia NN o
( ( N
9 CD N
% NN N
v JJ N
8 CD N
% NN N
) ) N
, , N
and CC N
neutropenia NN o
( ( N
6 CD N
% NN N
v NN N
< CD N
1 CD N
% NN N
) ) N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
sunitinib NN N
to TO N
prednisone VB N
did VBD N
not RB N
improve VB N
OS NNP o
compared VBN N
with IN N
placebo NN N
in IN N
docetaxel-refractory JJ N
mCRPC NN N
. . N

The DT N
role NN N
of IN N
antiangiogenic JJ N
therapy NN N
in IN N
mCRPC NN N
remains VBZ N
investigational JJ N
. . N

-DOCSTART- -X- O O

The DT N
peroxisome JJ N
proliferator-activated JJ N
receptor-gamma JJ N
agonist NN N
pioglitazone NN i
increases VBZ N
number NN o
and CC o
function NN o
of IN o
endothelial JJ o
progenitor NN o
cells NNS o
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
and CC p
normal JJ p
glucose JJ p
tolerance NN p
. . p

OBJECTIVE CC N
Peroxisome JJ N
proliferator-activated JJ N
receptor-gamma NN N
( ( N
PPAR NNP N
gamma NN N
) ) N
agonists VBZ N
( ( i
thiazolidinediones NNS i
[ NNP i
TZDs NNP i
] NNP i
) ) i
are VBP N
used VBN N
for IN N
the DT N
treatment NN N
of IN N
diabetes NNS N
. . N

Bone CD N
marrow-derived JJ N
endothelial JJ N
progenitor NN N
cells NNS N
( ( N
EPCs NNP N
) ) N
improve VB N
vascular JJ o
function NN o
and CC N
predict NN N
cardiovascular NN o
risk NN o
. . o

The DT N
effect NN N
of IN N
pioglitazone NN i
therapy NN N
on IN N
EPCs NNP N
was VBD N
examined VBN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
AND NNP N
RESULTS NNP N
We PRP N
performed VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
on IN N
patients NNS p
with IN p
documented JJ p
stable JJ p
coronary JJ p
artery NN p
disease NN p
and CC p
normal JJ p
glucose JJ p
tolerance NN p
. . p

Of IN N
54 CD p
patients NNS p
with IN p
normal JJ p
fasting VBG p
glucose JJ p
levels NNS p
, , p
18 CD p
showed VBD p
impaired JJ p
glucose JJ p
tolerance NN p
and CC p
36 CD p
patients NNS p
with IN p
normal JJ p
glucose JJ p
tolerance NN p
were VBD p
randomized VBN p
to TO N
30-day JJ N
treatment NN N
with IN N
pioglitazone NN i
( ( N
45 CD N
mg NN N
) ) N
or CC i
placebo NN i
in IN i
addition NN i
to TO i
optimal VB i
medical JJ i
therapy NN i
. . i

All DT N
patients NNS N
in IN N
the DT N
TZD NNP i
group NN N
showed VBD N
an DT N
increase NN N
of IN N
adiponectin JJ o
levels NNS o
as IN N
an DT N
indicator NN N
of IN N
compliance NN N
( ( N
11.4 CD N
+/- JJ N
1.1 CD N
to TO N
36.8 CD N
+/- JJ N
2.1 CD N
microg/ml NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

TZD NNP i
, , N
but CC N
not RB N
placebo VB i
, , N
decreased VBN N
mean JJ o
high-sensitivity NN o
C-reactive JJ o
protein NN o
to TO N
43 CD N
+/- JJ N
19 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Pioglitazone NN N
increased VBD N
CD34 NNP o
( ( o
+ NNP o
) ) o
/kinase NN o
insert JJ o
domain NN o
receptor NN o
( ( o
+ NNP o
) ) o
EPCs NNP o
to TO N
142 CD N
+/- JJ N
9 CD N
% NN N
and CC N
cultured VBD o
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled JJ o
acetylated JJ o
LDL NNP o
( ( o
+ NNP o
) ) o
/lectin NN o
( ( o
+ NNP o
) ) o
EPCs NNP o
to TO N
180 CD N
+/- JJ N
3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

EPC JJ o
numbers NNS o
were VBD N
not RB N
changed VBN N
in IN N
the DT N
placebo NN N
group NN N
. . N

TZD NNP N
increased VBD N
the DT N
SDF-1-induced NNP o
migratory NN o
capacity NN o
to TO N
146 CD N
+/- JJ N
9 CD N
% NN N
per IN N
EPC NNP N
number NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
upregulated VBD N
the DT N
clonogenic JJ o
potential NN o
of IN o
EPCs NNP o
, , N
increasing VBG N
the DT o
colony-forming JJ o
units NNS o
to TO N
172 CD N
+/- JJ N
12 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
cultured JJ N
human JJ N
EPCs NNP N
, , N
TZD NNP i
increased VBD N
EPC NNP o
numbers NNS o
and CC o
migration NN o
and CC o
reduced JJ o
NADPH-oxidase NNP o
activity NN o
. . o

The DT N
TZD NNP i
effect NN N
was VBD N
reversed VBN N
by IN N
the DT N
PPAR NNP N
gamma NN N
antagonist NN N
GW9662 NNP N
and CC N
mimicked VBN N
by IN N
treatment NN N
with IN N
adiponectin NN N
. . N

CONCLUSIONS VB N
The DT N
PPAR NNP N
gamma NN N
agonist NN N
pioglitazone NN i
increases VBZ N
the DT N
number NN o
and CC o
function NN o
of IN o
EPCs NNP o
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

The DT N
effect NN N
represents VBZ N
a DT N
potential JJ N
regenerative NN N
mechanism NN N
in IN N
atherosclerosis NN N
and CC N
is VBZ N
observed VBN N
in IN N
normoglycemic JJ p
individuals NNS p
with IN p
stable JJ p
coronary JJ p
artery NN p
disease NN p
. . p

-DOCSTART- -X- O O

Spatial JJ i
orientation NN i
adjustments NNS i
in IN N
children NNS p
with IN p
autism NN p
in IN p
Hong NNP p
Kong NNP p
. . p

Abnormal NNP N
spatial JJ o
orientation NN o
and CC o
body NN o
postures NNS o
in IN N
children NNS p
with IN p
autism NN p
often RB N
interfere RB N
with IN N
visual JJ N
abilities NNS N
to TO N
attend VB N
tasks NNS N
and CC N
social JJ N
interactions NNS N
. . N

Twenty-four JJ p
children NNS p
diagnosed VBN p
with IN p
autism NN p
from IN p
Kowloon NNP p
, , p
Hong NNP p
Kong NNP p
were VBD N
assessed VBN N
for IN N
spatial JJ o
orientation NN o
and CC N
spatial JJ o
management NN o
abilities NNS N
. . N

Positive JJ o
changes NNS o
in IN N
spatial JJ o
orientation NN o
were VBD N
evident JJ N
when WRB N
the DT N
children NNS N
wore VBD i
ambient JJ i
prism NN i
lenses NNS i
and CC N
included VBD N
changes NNS o
in IN o
posture NN o
from IN N
slanted VBN N
to TO N
erect VB N
. . N

Adjustments NNS N
in IN N
spatial JJ o
management NN o
were VBD N
evident JJ N
in IN N
improved JJ N
ball NN N
catching VBG o
ability NN o
, , N
a DT N
task NN N
requiring VBG N
visual JJ N
tracking NN N
and CC N
eye-hand JJ N
coordination NN N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
alterations NNS i
to TO i
the DT i
sensory JJ i
systems NNS i
may MD N
lead VB N
to TO N
behavioral JJ N
change NN N
in IN N
some DT N
children NNS N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
imidapril NN i
on IN N
plasma NN N
plasminogen NN N
activator NN N
inhibitor NN N
activity NN N
in IN N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
. . p

This DT N
study NN N
sought VBD N
to TO N
determine VB N
whether IN N
early JJ N
treatment NN N
with IN N
angiotensin-converting JJ i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitors NNS i
in IN N
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
is VBZ N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ o
function NN o
, , N
as RB N
well RB N
as IN N
left VBN o
ventricular JJ o
function NN o
. . o

This DT N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
levels NNS N
of IN N
plasma NN o
plasminogen NN o
activator NN o
inhibitor NN o
( ( o
PAI NNP o
) ) o
activity NN o
and CC N
serum JJ o
ACE NNP o
activity NN o
during IN N
the DT N
course NN N
of IN N
2 CD N
weeks NNS N
in IN N
40 CD p
patients NNS p
with IN p
AMI NNP p
within IN p
12 CD p
hours NNS p
after IN p
the DT p
onset NN p
of IN p
the DT p
symptom NN p
and CC p
who WP p
randomly VBP p
received VBN p
early JJ p
treatment NN p
with IN p
either CC p
the DT p
ACE NNP i
inhibitor NN i
imidapril NN i
or CC i
a DT i
placebo NN i
( ( p
20 CD p
patients NNS p
in IN p
the DT p
imidapril NN p
group NN p
and CC p
20 CD p
in IN p
the DT p
placebo NN p
group NN p
) ) p
. . p

The DT N
levels NNS o
of IN o
serum JJ o
ACE NNP o
activity NN o
in IN N
the DT N
imidapril NN i
group NN N
decreased VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
8 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN i
, , N
and CC N
the DT N
levels NNS N
24 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
( ( N
3.6 CD N
+/- JJ N
0.6 CD N
IU/L NNP N
vs VBD N
7.4 CD N
+/- JJ N
0.8 CD N
IU/L NNP N
; : N
p VBZ N
< $ N
0.001 CD N
) ) N
. . N

The DT N
plasma JJ o
PAI NNP o
activity NN o
increased VBD N
gradually RB N
to TO N
peak VB N
levels NNS N
16 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN N
and CC N
placebo NN N
. . N

The DT N
levels NNS N
in IN N
the DT N
placebo NN N
group NN N
decreased VBD N
gradually RB N
but CC N
remained VBD N
high JJ N
during IN N
the DT N
study NN N
period NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
levels NNS o
of IN o
PAI NNP o
activity NN o
in IN N
the DT N
imidapril NN i
group NN N
decreased VBD N
rapidly RB N
and CC N
those DT N
48 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
( ( N
7.9 CD N
+/- JJ N
1.9 CD N
IU/ml NNP N
vs VBD N
18.4 CD N
+/- JJ N
3.5 CD N
IU/ml NNP N
; : N
p VBZ N
< $ N
0.01 CD N
) ) N
. . N

The DT N
levels NNS o
of IN o
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
about IN N
2 CD N
weeks NNS N
after IN N
admission NN N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
imidapril NN N
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
65.9 CD N
% NN N
+/- JJ N
2.5 CD N
% NN N
vs JJ N
49.1 CD N
% NN N
+/- JJ N
4.4 CD N
% NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

This DT N
study NN N
showed VBD N
that IN N
imidapril NN i
, , N
an DT N
ACE NNP N
inhibitor NN N
, , N
might MD N
be VB N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ o
function NN o
and CC N
left VBD o
ventricular JJ o
function NN o
in IN N
the DT N
acute JJ N
phase NN N
of IN N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- O O

Roles NNS o
of IN o
adapalene NN o
in IN N
the DT N
treatment NN N
of IN N
pityriasis NN p
versicolor NN p
. . p

BACKGROUND NNP N
Ketoconazole NNP i
is VBZ N
a DT N
typical JJ N
treatment NN N
available JJ N
for IN N
pityriasis NN p
versicolor NN p
; : p
tretinoin CC i
cream NN i
is VBZ N
effective JJ N
, , N
too RB N
. . N

Adapalene NNP i
gel NN i
is VBZ N
a DT N
tretinoin JJ N
derivative NN N
and CC N
has VBZ N
a DT N
lower JJR N
incidence NN N
of IN N
irritation NN o
compared VBN N
with IN N
other JJ N
topical JJ N
retinoid NN N
products NNS N
. . N

However RB N
, , N
there EX N
are VBP N
no DT N
reports NNS N
on IN N
adapalene NN i
gel NN i
for IN N
the DT N
treatment NN N
of IN N
pityriasis NN p
versicolor NN p
. . p

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
adapalene NN i
gel NN i
comparing VBG N
the DT N
treatment NN N
with IN N
adapalene JJ i
gel NNS i
and CC i
2 CD i
% NN i
ketoconazole JJ i
cream NN i
in IN N
pityriasis NN p
versicolor NN p
. . p

METHODS NNP N
Eighty NNP p
patients NNS p
suffering VBG p
from IN p
pityriasis NN p
versicolor NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
; : N
one CD N
group NN N
were VBD N
treated VBN N
with IN N
2 CD i
% NN i
ketoconazole JJ i
cream NN i
topically RB N
twice JJ N
daily RB N
for IN N
2 CD N
weeks NNS N
, , N
adapalene JJ i
gel NN i
was VBD N
used VBN N
for IN N
the DT N
other JJ N
group NN N
in IN N
a DT N
similar JJ N
fashion NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
efficacy NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

No DT N
major JJ N
side NN o
effects NNS o
were VBD N
noted VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
either CC N
. . N

CONCLUSION NNP N
Adapalene NNP i
was VBD N
the DT N
favorable JJ N
option NN N
in IN N
the DT N
treatment NN N
of IN N
pityriasis NN p
versicolor NN p
. . p

The DT N
probable JJ N
therapeutic JJ N
mechanism NN N
of IN N
adapalene NN i
is VBZ N
also RB N
discussed VBN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
evaluation NN N
of IN N
octreotide JJ i
vs FW N
prochlorperazine NN i
for IN N
ED NNP N
treatment NN N
of IN N
migraine NN o
headache NN o
. . o

UNLABELLED JJ N
Patients NNS p
with IN p
headaches NNS p
account VBP N
for IN N
approximately RB N
2 CD N
% NN N
of IN N
all DT N
ED NNP N
visits NNS N
, , N
with IN N
migraines NNS N
being VBG N
the DT N
most RBS N
common JJ N
defined VBD N
primary JJ N
headache NN N
syndrome NN N
. . N

Our PRP$ N
goals NNS N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
intravenous JJ N
octreotide NN i
( ( i
OC NNP i
) ) i
for IN N
the DT N
treatment NN N
of IN N
migraines NNS N
, , N
when WRB N
compared VBN N
to TO N
standard VB N
therapy NN N
with IN N
prochlorperazine NN i
. . i

METHODS NNP N
The DT N
study NN N
was VBD N
conducted VBN N
as IN N
a DT N
double-blinded JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
. . N

Each DT N
subject NN N
received VBD N
either CC N
100 CD i
microg NN i
of IN i
octreotide NN i
or CC i
10 CD i
mg NN i
of IN i
prochlorperazine NN i
intravenously RB i
for IN N
a DT N
2-minute JJ N
period NN N
. . N

RESULTS NNP N
Comparison NNP N
of IN N
the DT N
change NN N
in IN N
median JJ o
visual JJ o
analog NN o
scale NN o
scores NNS o
for IN N
60 CD N
minutes NNS N
demonstrated VBD N
that IN N
octreotide NN i
was VBD N
less RBR N
effective JJ N
at IN N
reducing VBG N
pain NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC N
producing VBG N
clinical JJ N
success NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Restlessness JJ o
consistent JJ o
with IN o
akathisia NN o
was VBD N
noted VBN N
by IN N
35 CD N
% NN N
of IN N
the DT N
PC NN N
group NN N
and CC N
8 CD N
% NN N
of IN N
the DT N
OC NNP N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

At IN N
60 CD N
minutes NNS N
, , N
rescue NN o
medication NN o
was VBD N
required VBN N
by IN N
48 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
OC NNP N
group NN N
, , N
whereas RB N
10 CD N
% NN N
of IN N
the DT N
PC NNP N
group NN N
required VBD N
such JJ N
therapy NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

All DT p
44 CD p
patients NNS p
were VBD N
contacted VBN N
for IN N
follow-up NN N
at IN N
48 CD N
to TO N
72 CD N
hours NNS N
after IN N
enrollment NN N
. . N

At IN N
that DT N
time NN N
, , N
10 CD N
% NN N
of IN N
the DT N
prochlorperazine NN i
and CC N
25 CD N
% NN N
of IN N
the DT N
octreotide JJ i
patients NNS N
had VBD N
experienced VBN N
some DT N
headache NN o
recurrence NN o
( ( N
P NNP N
= NNP N
.1 NNP N
) ) N
. . N

CONCLUSION NNP N
Prochlorperazine NNP N
was VBD N
statistically RB N
superior JJ N
to TO N
octreotide VB N
in IN N
clinical JJ o
success NN o
rate NN o
and CC N
decrease NN N
in IN N
pain NN o
in IN N
migraine NN p
patients NNS p
but CC N
caused VBD N
more JJR N
restlessness NN o
and CC N
sedation NN o
. . o

-DOCSTART- -X- O O

Patient-reported JJ N
outcomes NNS o
after IN N
inguinal JJ i
herniorrhaphy NN i
. . i

BACKGROUND NNP N
Patient-reported JJ N
outcomes NNS o
( ( N
PRO NNP N
) ) N
reflect VBP N
the DT N
functional JJ N
outcomes NNS N
of IN N
inguinal JJ i
herniorrhaphy NN i
. . i

We PRP N
studied VBD N
the DT N
effect NN N
of IN N
hernia NN p
recurrence NN p
and CC p
complications NNS p
on IN p
PRO NNP p
for IN p
participants NNS p
in IN p
the DT p
Veterans NNP p
Affairs NNPS p
trial NN p
of IN p
Open NNP p
or CC p
Laparoscopic NNP p
Repair NNP p
of IN p
Inguinal NNP p
Hernia NNP p
. . p

METHODS NNP N
Analyzed NNP N
PRO NNP N
included VBD N
( ( N
1 CD N
) ) N
the DT N
Medical NNP N
Outcomes NNP N
Study NNP N
Short NNP N
Form NNP N
36 CD N
, , N
version NN N
2 CD N
, , N
( ( N
2 CD N
) ) N
the DT N
Surgical NNP N
Pain NNP N
Scale NNP N
, , N
( ( N
3 CD N
) ) N
the DT N
Activities NNPS N
Assessment NNP N
Scale NNP N
, , N
and CC N
( ( N
4 CD N
) ) N
patient NN N
satisfaction NN N
. . N

Recurrences NNS N
and CC N
complications NNS N
were VBD N
recorded VBN N
at IN N
follow-up JJ N
visits NNS N
. . N

Complications NNS N
were VBD N
categorized VBN N
by IN N
( ( N
1 CD N
) ) N
hematoma/seroma NN o
, , N
( ( N
2 CD N
) ) N
orchitis NN o
, , N
( ( N
3 CD N
) ) N
neuralgia NN o
, , N
and CC N
( ( N
4 CD N
) ) N
other JJ N
. . N

Univariate NNP N
and CC N
multivariable JJ N
regression NN N
analyses NNS N
identified VBD N
variables NNS N
significantly RB N
associated VBN N
with IN N
postoperative JJ N
PRO NNP N
. . N

RESULTS NNP N
Of IN N
the DT N
1603 CD p
patients NNS p
with IN p
PRO NNP p
data NNS p
, , p
105 CD p
had VBD p
a DT p
recurrence NN o
and CC p
342 CD p
had VBD p
a DT p
complication NN p
at IN p
2 CD p
years NNS p
. . p

Multivariable JJ N
analyses NNS N
showed VBD N
neuralgia JJ o
( ( N
P NNP N
< NNP N
.0005 NNP N
) ) N
adversely RB N
affected VBD N
all DT N
PRO NNP N
, , N
and CC N
recurrence NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
affected VBD N
patient-reported JJ o
pain NN o
, , o
activity NN o
, , o
and CC o
satisfaction NN o
, , N
but CC N
not RB N
the DT N
score NN N
for IN N
the DT N
Medical NNP o
Outcomes NNP o
Study NNP o
Short NNP o
Form NNP o
3 CD o
. . o

Patients NNS N
with IN N
a DT N
recurrence NN N
after IN N
open JJ N
repair NN N
had VBD N
more RBR N
pain NN o
than IN N
those DT N
with IN N
a DT N
recurrence NN N
after IN N
laparoscopic JJ N
repair NN N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
. . N

Patients NNS N
with IN N
other JJ N
complications NNS N
after IN N
laparoscopic NN N
repair NN N
reported VBD N
more JJR N
pain NN o
and CC o
less JJR o
activity NN o
than IN N
those DT N
with IN N
other JJ N
complications NNS N
after IN N
open JJ N
repair NN N
( ( N
P NNP N
= NNP N
.003 NNP N
and CC N
P NNP N
= NNP N
.009 NNP N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS VB N
The DT N
effectiveness NN N
of IN N
inguinal JJ N
herniorrhaphy NN N
should MD N
be VB N
measured VBN N
by IN N
the DT N
rate NN N
of IN N
recurrence NN o
and CC o
neuralgia NN o
. . o

Postoperative JJ N
neuralgias NNS N
have VBP N
a DT N
deleterious JJ N
effect NN N
on IN N
all DT N
patient-reported JJ N
outcomes NNS N
. . N

-DOCSTART- -X- O O

Application NN N
of IN N
ambulatory JJ N
blood NN N
pressure NN N
monitoring NN N
to TO N
clinical JJ N
therapeutic JJ N
decisions NNS N
in IN N
hypertension NN p
. . p

The DT N
antihypertensive JJ o
efficacies NNS N
of IN N
lisinopril NN i
and CC N
captopril NN i
were VBD N
compared VBN N
using VBG N
office NN N
sphygmomanometry NN N
and CC N
24-h JJ N
ambulatory NN N
blood NN N
pressure NN N
monitoring NN N
. . N

In IN N
a DT N
double-blind NN N
, , N
prospective JJ N
, , N
randomly RB N
allocated VBN N
trial NN N
, , N
the DT p
patients NNS p
were VBD N
given VBN N
increasing VBG N
doses NNS N
of IN N
captopril NN i
at IN N
25-100 JJ N
mg NN N
twice RB N
a DT N
day NN N
or CC N
lisinopril NN i
at IN N
10-40 JJ N
mg NN N
once IN N
a DT N
day NN N
until IN N
a DT N
clinical JJ o
response NN o
was VBD N
achieved VBN N
or CC N
the DT N
highest JJS N
dose NN N
was VBD N
reached VBN N
. . N

A DT N
response NN N
was VBD N
defined VBN N
as IN N
a DT N
reduction NN o
in IN o
diastolic JJ o
pressure NN o
below IN o
90 CD o
mmHg NN o
or CC o
a DT o
fall NN o
of IN o
at IN o
least JJS o
10 CD o
mmHg NN o
from IN o
baseline NN o
. . o

The DT N
ambulatory NN N
monitoring NN N
showed VBD N
that IN N
lisinopril NN N
reduced VBD N
blood NN o
pressure NN o
from IN N
baseline NN N
to TO N
the DT N
final JJ N
value NN N
and CC N
maintained VBD o
the DT o
reduction NN o
to TO N
a DT N
greater JJR N
degree NN N
than IN N
captopril NN i
throughout IN N
24-h JJ N
periods NNS N
of IN N
observation NN N
. . N

The DT N
office NN o
measurements NNS o
showed VBD N
a DT N
similar JJ N
trend NN N
, , N
but CC N
the DT N
intertreatment JJ N
differences NNS N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

No DT N
first-dose JJ o
side NN o
effects NNS N
were VBD N
observed VBN N
with IN N
either DT N
drug NN N
. . N

Once IN N
a DT N
day NN N
lisinopril NN i
appeared VBD N
to TO N
be VB N
a DT N
more RBR N
effective JJ o
antihypertensive JJ i
regimen NNS i
than IN N
twice RB N
a DT N
day NN N
captopril NN N
. . N

-DOCSTART- -X- O O

Pathology NN N
parameters NNS N
and CC N
adjuvant JJ o
tamoxifen NN o
response NN o
in IN N
a DT N
randomised JJ N
premenopausal NN p
breast NN p
cancer NN p
trial NN N
. . N

BACKGROUND NNP N
Subgroups NNP N
of IN N
breast NN N
cancer NN N
that WDT N
have VBP N
an DT N
impaired JJ N
response NN N
to TO N
endocrine VB N
treatment NN N
, , N
despite IN N
hormone NN N
receptor NN N
positivity NN N
, , N
are VBP N
still RB N
poorly RB N
defined VBN N
. . N

Breast NNP N
cancer NN N
can MD N
be VB N
subdivided VBN N
according VBG N
to TO N
standard JJ N
pathological JJ N
parameters NNS N
including VBG N
histological JJ N
type NN N
, , N
grade NN N
, , N
and CC N
assessment NN N
of IN N
proliferation NN N
. . N

These DT N
parameters NNS N
are VBP N
the DT N
net JJ N
result NN N
of IN N
combinations NNS N
of IN N
genetic JJ N
alterations NNS N
effecting VBG N
tumour JJ N
behaviour NN N
and CC N
could MD N
potentially RB N
reflect VB N
subtypes NNS N
that IN N
respond NN N
differently RB N
to TO N
endocrine VB N
treatment NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
usefulness NN N
of IN N
these DT N
parameters NNS N
as IN N
predictors NNS N
of IN N
the DT N
response NN N
to TO N
tamoxifen VB i
in IN N
premenopausal JJ p
women NNS p
with IN p
breast NN p
cancer NN p
. . p

MATERIALS/METHODS NNP N
Clinically NNP N
established VBD N
pathological JJ N
parameters NNS N
were VBD N
assessed VBN N
and CC N
related VBN N
to TO N
the DT N
tamoxifen NN i
response NN N
in IN N
500 CD p
available JJ p
tumour NN p
specimens NNS p
from IN p
564 CD p
premenopausal NN p
patients NNS p
with IN p
breast JJ p
cancer NN p
randomised VBD N
to TO N
either DT N
two CD N
years NNS N
of IN N
tamoxifen NN i
or CC N
no DT i
treatment NN i
with IN N
14 CD N
years NNS N
of IN N
follow NN N
up RB N
. . N

Proliferation NN N
was VBD N
further RB N
evaluated VBN N
by IN N
immunohistochemical JJ N
Ki-67 NNP N
expression NN N
. . N

RESULTS NNP N
Oestrogen NNP o
receptor NN o
positive JJ o
ductal JJ o
carcinomas NN o
responded VBD N
as IN N
expected VBN N
to TO N
tamoxifen VB i
, , N
whereas IN N
the DT N
difference NN N
in IN N
recurrence NN o
free JJ o
survival NN o
between IN N
control NN i
and CC N
tamoxifen NN i
treated VBD N
patients NNS N
was VBD N
less RBR N
apparent JJ N
in IN N
the DT N
relatively RB N
few JJ N
lobular JJ N
carcinomas NN N
. . N

For IN N
histological JJ N
grade NN N
, , N
there EX N
was VBD N
no DT N
obvious JJ N
difference NN N
in IN N
treatment NN N
response NN N
between IN N
the DT N
groups NNS N
. . N

The DT N
relation NN N
between IN N
proliferation NN N
and CC N
tamoxifen NN i
response NN N
seemed VBD N
to TO N
be VB N
more RBR o
complex JJ o
, , o
with IN o
a DT o
clear JJ o
response NN o
in IN o
tumours NN o
with IN o
high JJ o
and CC o
low JJ o
proliferation NN o
, , N
whereas JJ N
tumours NN N
with IN N
intermediate JJ N
proliferation NN N
defined VBN N
by IN N
Ki-67 NNP N
responded VBD N
more RBR N
poorly RB o
. . o

CONCLUSIONS NNP N
Clinically NNP N
established VBD N
pathology NN N
parameters NNS N
seem VBP N
to TO N
mirror VB N
the DT N
endocrine NN N
treatment NN N
response NN N
and CC N
could MD N
potentially RB N
be VB N
valuable JJ N
in IN N
future JJ N
treatment NN N
decisions NNS N
for IN N
patients NNS p
with IN p
breast JJ p
cancer NN p
. . p

-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled VBN N
trial NN N
for IN N
reducing VBG N
risks NNS o
for IN o
sexually RB o
transmitted VBN o
infections NNS o
through IN N
enhanced JJ i
patient-based JJ i
partner NN i
notification NN i
. . i

OBJECTIVES IN N
We PRP N
sought VBD N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
approaches NNS N
targeting VBG N
improved VBN N
sexually RB N
transmitted VBN N
infection NN N
( ( N
STI NNP N
) ) N
sexual JJ N
partner NN N
notification NN N
through IN N
patient JJ N
referral JJ N
. . N

METHODS NN N
From IN p
January NNP p
2002 CD p
through IN p
December NNP p
2004 CD p
, , p
600 CD p
patients NNS p
with IN p
Neisseria NNP p
gonorrhoeae NN p
or CC p
Chlamydia NNP p
trachomatis NN p
were VBD p
recruited VBN p
from IN p
STI NNP p
clinics NNS p
and CC N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
standard-of-care JJ i
group NN i
or CC N
a DT i
group NN i
that WDT i
was VBD i
counseled VBN i
at IN i
the DT i
time NN i
of IN i
diagnosis NN i
and CC i
given VBN i
additional JJ i
follow-up JJ i
contact NN i
. . i

Participants NNS N
completed VBD N
an DT N
interview NN N
at IN N
baseline NN N
, , N
1 CD N
month NN N
, , N
and CC N
6 CD N
months NNS N
and CC N
were VBD N
checked VBN N
at IN N
6 CD N
months NNS N
for IN N
gonorrhea NN N
or CC N
chlamydial JJ N
infection NN N
via IN N
nucleic JJ N
acid JJ N
amplification NN N
testing NN N
of IN N
urine NN N
. . N

RESULTS NNP N
Program NNP N
participants NNS N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
sexual JJ N
partner NN N
notification NN N
at IN N
1 CD N
month NN N
( ( N
86 CD N
% NN N
control NN N
, , N
92 CD N
% NN N
intervention NN N
; : N
adjusted VBN N
odds NNS N
ratio VBP N
[ JJ N
AOR NNP N
] NNP N
= NNP N
1.8 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= NNP N
1.02 CD N
, , N
3.0 CD N
) ) N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
no DT N
unprotected JJ o
sexual JJ o
intercourse NN o
at IN N
6 CD N
months NNS N
( ( N
38 CD N
% NN N
control NN N
, , N
48 CD N
% NN N
intervention NN N
; : N
AOR NNP N
= VBZ N
1.5 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.1 CD N
, , N
2.1 CD N
) ) N
. . N

Gonorrhea NNP o
or CC o
chlamydial JJ o
infection NN o
was VBD N
detected VBN N
in IN N
6 CD N
% NN N
of IN N
intervention NN N
and CC N
11 CD N
% NN N
of IN N
control NN N
participants NNS N
at IN N
follow-up NN N
( ( N
AOR NNP N
= NNP N
2.2 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.1 CD N
, , N
4.1 CD N
) ) N
, , N
with IN N
greatest JJS N
benefits NNS N
seen VBN N
among IN N
men NNS N
( ( N
for IN N
gender NN N
interaction NN N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

CONCLUSIONS VB N
This DT N
patient-based JJ N
sexual JJ N
partner NN N
notification NN N
program NN N
can MD N
help VB N
reduce VB N
risks NNS N
for IN N
subsequent JJ N
STIs NNP N
among IN N
urban JJ p
, , p
minority NN p
patients NNS p
presenting VBG N
for IN N
care NN N
at IN N
STI NNP N
clinics NNS N
. . N

-DOCSTART- -X- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
a DT N
bladder NN i
neck NN i
plication NN i
stitch NN i
during IN N
robot-assisted JJ p
radical JJ p
prostatectomy NN p
. . p

Urinary JJ N
incontinence NN N
after IN N
robot-assisted JJ p
radical JJ p
prostatectomy NN p
( ( p
RARP NNP p
) ) p
is VBZ N
one CD N
of IN N
the DT N
most RBS N
bothersome JJ N
complications NNS N
affecting VBG N
patients NNS N
' POS N
daily JJ N
lives NNS N
. . N

The DT N
efficacy NN N
of IN N
the DT N
bladder NN i
neck NN i
plication NN i
stitch NN i
technique NN i
in IN N
promoting VBG N
an DT N
earlier JJR N
return NN N
of IN N
continence NN N
was VBD N
prospectively RB N
evaluated VBN N
in IN N
158 CD p
patients NNS p
who WP p
underwent VBP p
RARP NNP p
for IN p
clinically RB p
localized VBN p
prostate NN p
cancer NN p
by IN p
a DT p
single JJ p
surgeon NN p
at IN p
our PRP$ p
institute NN p
from IN p
March NNP p
2012 CD p
to TO p
January NNP p
2013 CD p
. . p

Patients NNS N
were VBD N
randomized VBN N
1:1 CD N
to TO N
undergo VB N
surgery NN N
with IN i
( ( p
n JJ p
= NNP p
79 CD p
) ) p
or CC i
without IN i
( ( p
n JJ p
= NNP p
79 CD p
) ) p
the DT i
bladder NN i
neck NN i
plication NN i
stitch NN i
, , N
and CC N
their PRP$ N
time NN N
to TO N
recovery NN N
from IN N
incontinence NN N
, , N
defined VBD N
as IN N
being VBG N
pad JJ N
free JJ N
, , N
was VBD N
compared VBN N
. . N

Recovery NN o
from IN o
incontinence NN o
at IN N
1 CD N
, , N
3 CD N
, , N
and CC N
6 CD N
months NNS N
were VBD N
observed VBN N
in IN N
22 CD N
( ( N
27.8 CD N
% NN N
) ) N
, , N
42 CD N
( ( N
53.2 CD N
% NN N
) ) N
, , N
and CC N
57 CD N
( ( N
72.2 CD N
% NN N
) ) N
patients NNS N
, , N
respectively RB N
, , N
treated VBD N
with IN N
, , N
and CC N
23 CD N
( ( N
29.1 CD N
% NN N
) ) N
, , N
47 CD N
( ( N
59.5 CD N
% NN N
) ) N
, , N
and CC N
59 CD N
( ( N
74.7 CD N
% NN N
) ) N
patients NNS N
, , N
respectively RB N
, , N
treated VBD N
without IN N
the DT N
bladder NN i
neck NN i
plication NN i
stitch NN i
, , N
with IN N
no DT N
significant JJ N
difference NN N
in IN N
time NN N
to TO N
recovery NN N
from IN N
incontinence NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

Multivariate NNP N
analysis NN N
showed VBD N
that IN N
age NN o
, , o
membranous JJ o
urethral JJ o
length NN o
and CC o
shape NN o
of IN o
the DT o
prostatic JJ o
apex NN o
on IN o
magnetic JJ o
resonance NN o
imaging NN o
were VBD N
independent JJ N
predictors NNS N
of IN N
early JJ N
recovery NN N
from IN N
urinary JJ N
incontinence NN N
after IN N
RARP NNP N
. . N

The DT N
bladder NN i
neck NN i
plication NN i
stitch NN i
had VBD N
no DT N
effect NN N
on IN N
time NN o
to TO o
recovery NN o
from IN N
postoperative JJ N
urinary JJ N
incontinence NN N
following VBG N
RARP NNP N
. . N

-DOCSTART- -X- O O

A DT N
pharmacy NN i
discharge NN i
plan NN i
for IN N
hospitalized JJ p
elderly JJ p
patients NNS p
-- : p
a DT p
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVES UH N
to TO N
investigate VB N
the DT N
effectiveness NN o
of IN o
a DT o
pharmacy NN o
discharge NN o
plan NN o
in IN N
elderly JJ p
hospitalized JJ p
patients NNS p
. . p

DESIGN NNP N
randomized VBD N
controlled VBN N
trial NN N
. . N

SUBJECTS NNP N
AND CC N
SETTINGS NNP N
we PRP N
randomized VBD N
patients NNS p
aged VBN p
75 CD p
years NNS p
and CC p
older JJR p
on IN p
four CD p
or CC p
more JJR p
medicines NNS p
who WP p
had VBD p
been VBN p
discharged VBN p
from IN p
three CD p
acute JJ p
general JJ p
and CC p
one CD p
long-stay JJ p
hospital NN p
to TO p
a DT p
pharmacy NN p
intervention NN p
or CC p
usual JJ p
care NN p
. . p

INTERVENTIONS VBZ N
the DT N
hospital NN i
pharmacist NN i
developed VBD i
discharge NN i
plans NNS i
which WDT N
gave VBD N
details NNS N
of IN N
medication NN N
and CC N
support NN N
required VBN N
by IN N
the DT N
patient NN N
. . N

A DT N
copy NN N
was VBD N
given VBN N
to TO N
the DT N
patient NN N
and CC N
to TO N
all DT N
relevant JJ N
professionals NNS N
and CC N
carers NNS N
. . N

This DT N
was VBD N
followed VBN N
by IN N
a DT N
domiciliary JJ N
assessment NN N
by IN N
a DT N
community NN N
pharmacist NN N
. . N

In IN N
the DT N
control NN N
group NN N
, , N
patients NNS N
were VBD N
discharged VBN i
from IN i
hospital NN i
following VBG i
standard JJ i
procedures NNS i
that WDT N
included VBD N
a DT N
discharge NN N
letter NN N
to TO N
the DT N
general JJ N
practitioner NN N
listing VBG N
current JJ N
medications NNS N
. . N

OUTCOMES IN N
the DT N
primary JJ N
outcome NN N
was VBD N
re-admission NN o
to TO o
hospital VB o
within IN o
6 CD o
months NNS o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
the DT N
number NN o
of IN o
deaths NNS o
, , o
attendance NN o
at IN o
hospital JJ o
outpatient NN o
clinics NNS o
and CC o
general JJ o
practice NN o
and CC o
proportion NN o
of IN o
days NNS o
in IN o
hospital NN o
over IN o
the DT o
follow-up JJ o
period NN o
, , o
together RB o
with IN o
patients NNS o
' POS o
general JJ o
well-being NN o
, , o
satisfaction NN o
with IN o
the DT o
service NN o
and CC o
knowledge NN o
of IN o
and CC o
adherence NN o
to TO o
prescribed VB o
medication NN o
. . o

RESULTS NNP N
we PRP p
recruited VBD p
362 CD p
patients NNS p
, , p
of IN p
whom WP p
181 CD p
were VBD p
randomized VBN p
to TO p
each DT p
group NN p
. . p

We PRP p
collected VBD p
hospital NN p
and CC p
general JJ p
practice NN p
data NNS p
on IN p
at IN p
least JJS p
91 CD p
and CC p
72 CD p
% NN p
of IN p
patients NNS p
respectively RB p
at IN p
each DT p
follow-up JJ p
point NN p
and CC p
interviewed VBD p
between IN p
43 CD p
and CC p
90 CD p
% NN p
of IN p
the DT p
study NN p
subjects NNS p
. . p

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
the DT N
proportion NN o
of IN o
patients NNS o
re-admitted JJ o
to TO o
hospital VB o
between IN N
baseline NN N
and CC N
3 CD N
months NNS N
or CC N
3 CD N
and CC N
6 CD N
months NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
any DT N
of IN N
the DT N
secondary JJ N
outcomes NNS N
. . N

CONCLUSIONS NNP N
we PRP N
found VBD N
no DT N
evidence NN N
to TO N
suggest VB N
that IN N
the DT N
co-ordinated JJ N
hospital NN N
and CC N
community NN i
pharmacy NN i
care NN i
discharge NN i
plans NNS i
in IN N
elderly JJ N
patients NNS N
in IN N
this DT N
study NN N
influence NN N
outcomes NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
acustimulation NN N
and CC N
ondansetron NN N
for IN N
the DT N
treatment NN N
of IN N
established VBN p
postoperative JJ p
nausea NN p
and CC p
vomiting NN p
. . p

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
transcutaneous JJ N
electrical JJ N
acupoint NN N
stimulation NN N
( ( N
acustimulation NN N
) ) N
using VBG N
the DT N
ReliefBand NNP N
compared VBN N
with IN N
ondansetron NN N
for IN N
the DT N
treatment NN p
of IN p
established VBN p
postoperative JJ p
nausea NN p
and CC p
vomiting NN p
( ( p
PONV NNP p
) ) p
after IN p
outpatient NN p
laparoscopic NN p
surgery NN p
. . p

METHODS NNP N
After IN N
the DT N
authors NNS N
obtained VBD N
institutional JJ N
review NN N
board NN N
approval NN N
and CC N
written VBN N
informed JJ N
consent NN N
, , N
268 CD p
outpatients NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo- JJ N
and CC N
sham-controlled JJ N
study NN N
. . N

All DT N
patients NNS N
received VBN N
antiemetic JJ N
prophylaxis NN N
with IN N
metoclopramide NN N
, , N
10 CD N
mg NN N
intravenously RB N
, , N
or CC N
droperidol NN N
, , N
0.625 CD N
mg NN N
intravenously RB N
, , N
after IN N
induction NN N
of IN N
anesthesia NN N
. . N

A DT N
total NN N
of IN N
90 CD p
patients NNS p
developed VBD p
PONV NNP p
in IN N
the DT N
recovery NN N
units NNS N
and CC N
were VBD N
randomized VBN N
to TO N
one CD i
of IN i
three CD i
treatment NN i
groups NNS i
: : i
( ( i
1 CD i
) ) i
the DT i
ondansetron NN i
group NN i
received VBD i
4 CD i
mg NNS i
intravenous JJ i
ondansetron NN i
and CC i
a DT i
sham JJ i
ReliefBand NNP i
; : i
( ( i
2 CD i
) ) i
the DT i
acustimulation NN i
group NN i
received VBD i
2 CD i
ml NNS i
intravenous JJ i
saline NN i
and CC i
a DT i
ReliefBand NNP i
; : i
and CC i
( ( i
3 CD i
) ) i
the DT i
combination NN i
group NN i
received VBD i
4 CD i
mg NNS i
intravenous JJ i
ondansetron NN i
and CC i
a DT i
ReliefBand NNP i
. . i

A NNP i
rescue NN i
antiemetic NN i
( ( i
10 CD i
mg RB i
intravenous JJ i
metoclopramide NN i
) ) i
was VBD i
administered VBN i
only RB i
if IN i
the DT i
PONV NNP i
symptoms NNS i
persisted VBD i
for IN i
15 CD i
min NN i
or CC i
longer JJR i
after IN i
initiating VBG i
the DT i
treatment NN i
. . i

A DT N
blinded JJ N
observer NN N
recorded VBD N
the DT N
recovery NN o
times NNS o
, , o
emetic JJ o
symptoms NNS o
, , o
rescue NN o
antiemetics NNS o
, , o
maximum JJ o
nausea NN o
scores NNS o
, , o
complete JJ o
response NN o
to TO o
study VB o
treatment NN o
, , o
and CC o
time NN o
to TO o
achieve VB o
discharge NN o
criteria NNS o
. . o

Postdischarge NNP N
side JJ N
effects NNS N
, , N
as RB N
well RB N
as IN N
patient JJ N
satisfaction NN N
and CC N
quality NN N
of IN N
recovery NN N
scores NNS N
, , N
were VBD N
assessed VBN N
at IN N
24 CD N
and CC N
72 CD N
h NN N
after IN N
surgery NN N
. . N

RESULTS VB N
The DT N
combination NN N
group NN N
had VBD N
a DT N
significantly RB N
higher JJR N
complete JJ o
response NN o
rate NN N
than IN N
the DT N
acustimulation NN N
group NN N
( ( N
73 CD N
% NN N
vs.40 NN N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
addition NN N
, , N
fewer JJR N
patients NNS N
( ( N
8 CD N
vs. FW N
18 CD N
) ) N
in IN N
the DT N
combination NN N
( ( N
vs. IN N
acustimulation NN N
) ) N
group NN N
experienced VBD N
subsequent JJ o
emetic JJ o
events NNS o
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
three CD N
groups NNS N
with IN N
respect NN N
to TO N
patient JJ o
satisfaction NN o
and CC o
quality NN o
of IN o
recovery NN o
scores NNS o
. . o

CONCLUSIONS NNP N
Acustimulation NNP N
with IN N
the DT N
ReliefBand NNP N
can MD N
be VB N
used VBN N
as IN N
an DT N
alternative NN N
to TO N
ondansetron VB N
for IN N
the DT N
treatment NN N
of IN N
established VBN p
PONV NNP p
. . p

However RB N
, , N
the DT N
use NN N
of IN N
ondansetron NN N
( ( N
4 CD N
mg RB N
intravenously RB N
) ) N
in IN N
combination NN N
with IN N
the DT N
ReliefBand NNP N
device NN N
improved VBD N
the DT N
complete JJ N
response NN N
rate NN N
to TO N
the DT N
acustimulation NN N
therapy NN N
. . N

-DOCSTART- -X- O O

Speech NN i
following VBG i
sign JJ i
language NN i
training NN i
in IN N
autistic JJ p
children NNS p
with IN p
minimal JJ p
verbal JJ p
language NN p
. . p

This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
test VB N
the DT N
main JJ o
and CC o
interaction JJ o
effects NNS o
of IN N
training VBG N
condition NN N
and CC N
pretreatment-elicited JJ N
verbal JJ N
imitation NN N
ability NN N
when WRB N
predicting VBG N
spoken JJ N
language NN N
use NN N
during IN N
language NN i
training NN i
of IN N
60 CD p
minimally RB p
verbal JJ p
autistic JJ p
children NNS p
. . p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
Speech NNP o
Alone NNP o
, , o
Sign NNP o
Alone NNP o
, , o
Simultaneous NNP o
Presentation NNP o
of IN o
Sign NNP o
and CC o
Speech NNP o
, , o
and CC o
Alternating NNP o
Presentation NNP o
of IN o
Sign NNP o
and CC o
Speech NNP o
training NN o
conditions NNS o
. . o

Speech NNP o
Alone RB o
, , o
Simultaneous JJ o
Presentation NNP o
, , o
and CC o
Alternating NNP o
Presentation NNP o
condition NN o
facilitated VBD N
more RBR N
child-initiated JJ N
speech NN N
during IN N
treatment NN N
than IN N
did VBD N
the DT N
Sign NNP i
Alone NNP i
condition NN N
. . N

Regardless NNP N
of IN N
training VBG N
condition NN N
, , N
pretreatment NN N
verbal JJ N
imitation NN N
ability NN N
positively RB N
predicted VBD N
the DT N
size NN o
of IN o
child-initiated JJ o
spoken JJ o
vocabulary JJ o
observed VBD N
during IN N
training NN N
. . N

Exploratory JJ N
analyses NNS N
indicated VBD N
that IN N
, , N
in IN N
addition NN N
to TO N
verbal JJ N
imitation NN N
, , N
pretreatment JJ N
age NN N
and CC N
IQ NNP N
may MD N
also RB N
predict VB N
spoken JJ N
language NN N
developed VBD N
during IN N
training NN N
. . N

-DOCSTART- -X- O O

Study NN N
of IN N
the DT N
therapeutic JJ N
effects NNS N
of IN N
a DT N
hippotherapy NN i
simulator NN i
in IN N
children NNS p
with IN p
cerebral JJ p
palsy NN p
: : p
a DT N
stratified JJ N
single-blind NN N
randomized VBD N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
hippotherapy NN i
( ( i
when WRB i
applied VBN i
by IN i
a DT i
simulator NN i
) ) i
improves VBZ N
postural JJ N
control NN N
and CC N
balance NN N
in IN N
children NNS p
with IN p
cerebral JJ p
palsy NN p
. . p

DESIGN NNP N
Stratified VBD N
single-blind JJ N
randomized NN N
controlled VBD N
trial NN N
with IN N
an DT N
independent JJ N
assessor NN N
. . N

Stratification NN N
was VBD N
made VBN N
by IN N
gross JJ N
motor NN N
function NN N
classification NN N
system NN N
levels NNS N
, , N
and CC N
allocation NN N
was VBD N
concealed VBN N
. . N

SUBJECTS NNP N
Children NNP p
between IN p
4 CD p
and CC p
18 CD p
years NNS p
old JJ p
with IN p
cerebral JJ p
palsy NN p
. . p

INTERVENTIONS JJ N
Participants NNS N
were VBD N
randomized VBN N
to TO N
an DT N
intervention NN i
( ( i
simulator NN i
ON NNP i
) ) i
or CC i
control NN i
( ( i
simulator VB i
OFF NNP i
) ) i
group NN N
after IN N
getting VBG N
informed JJ N
consent NN N
. . N

Treatment NNP N
was VBD N
provided VBN N
once RB N
a DT N
week NN N
( ( N
15 CD N
minutes NNS N
) ) N
for IN N
10 CD N
weeks NNS N
. . N

MAIN NNP N
MEASURES NNP N
Gross NNP o
Motor NNP o
Function NNP o
Measure NNP o
( ( o
dimension NN o
B NNP o
for IN o
balance NN o
and CC o
the DT o
Total NNP o
Score NNP o
) ) o
and CC o
Sitting VBG o
Assessment NNP o
Scale NNP o
were VBD N
carried VBN N
out RP N
at IN N
baseline NN N
( ( N
prior JJ N
to TO N
randomization NN N
) ) N
, , N
end NN N
of IN N
intervention NN N
and CC N
12 CD N
weeks NNS N
after IN N
completing VBG N
the DT N
intervention NN N
. . N

RESULTS NNP N
Thirty-eight JJ p
children NNS p
participated VBN p
. . p

The DT N
groups NNS N
were VBD N
balanced VBN N
at IN N
baseline NN N
. . N

Sitting VBG o
balance NN o
( ( N
measured VBN N
by IN N
dimension NN N
B NNP N
of IN N
the DT N
Gross NNP N
Motor NNP N
Function NNP N
Measure NNP N
) ) N
improved VBD N
significantly RB N
in IN N
the DT N
treatment NN N
group NN N
( ( N
effect NN N
size NN N
= $ N
0.36 CD N
; : N
95 CD N
% NN N
CI NNP N
0.01-0.71 NN N
) ) N
and CC N
the DT N
effect NN o
size NN o
was VBD N
greater JJR N
in IN N
the DT N
severely RB N
disabled JJ N
group NN N
( ( N
effect NN N
size NN N
= $ N
0.80 CD N
; : N
95 CD N
% NN N
CI NNP N
0.13-1.47 NN N
) ) N
. . N

The DT N
improvements NNS o
in IN o
sitting VBG o
balance NN o
were VBD N
not RB N
maintained VBN N
over IN N
the DT N
follow-up JJ N
period NN N
. . N

Changes NNS N
in IN N
the DT N
total JJ o
score NN o
of IN o
the DT o
Gross NNP o
Motor NNP o
Function NNP o
Measure NNP o
and CC o
the DT o
Sitting NNP o
Assessment NNP o
Scale NNP o
were VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Hippotherapy NNP i
with IN N
a DT N
simulator NN N
can MD N
improve VB N
sitting VBG o
balance NN o
in IN N
cerebral JJ p
palsy NN p
children NNS p
who WP N
have VBP N
higher JJR N
levels NNS N
of IN N
disability NN N
. . N

However RB N
, , N
this DT N
did VBD N
not RB N
lead VB N
to TO N
a DT N
change NN N
in IN N
the DT N
overall JJ N
function NN N
of IN N
these DT N
children NNS N
( ( N
Gross NNP N
Motor NNP N
Function NNP N
Classification NNP N
System NNP N
level JJ N
V NNP N
) ) N
. . N

-DOCSTART- -X- O O

Comparison NNP N
on IN N
therapeutic JJ N
effect NN o
of IN N
plasma JJ i
exchange NN i
and CC i
intravenous JJ i
immunoglobulin NN i
for IN N
Guillian-Barre NNP p
syndrome NN p
. . p

OBJECTIVES NNP N
To TO N
observe VB N
and CC N
compare VB N
the DT N
clinical JJ o
curative JJ o
effect NN o
of IN N
the DT N
plasma JJ i
exchange NN i
( ( i
PE NNP i
) ) i
and CC p
intravenous JJ i
immunoglobulin NN i
( ( i
IVIg NNP i
) ) i
for IN p
Guillian-Barre NNP p
Syndrome NNP p
( ( p
GBS NNP p
) ) p
. . p

METHODS NNP N
Overall NNP N
, , N
64 CD p
adult NN p
patients NNS p
with IN p
GBS NNP p
for IN p
PE NNP i
and CC p
IVIg NNP i
treatment NN p
, , p
respectively RB p
, , p
and CC p
nerve NN o
function NN o
were VBD N
observed VBN N
pre-treatment JJ N
and CC N
at IN N
1 CD N
week/2 NN N
weeks NNS N
after IN N
completion NN N
of IN N
treatment NN N
; : N
the DT N
blood NN N
immunoglobulin NN N
, , N
complement NN N
, , N
fibrinogen NN N
( ( N
Fib NNP N
) ) N
and CC N
monocyte JJ N
percentage NN N
( ( N
MON NNP N
% NN N
) ) N
were VBD N
detected VBN N
simultaneously RB N
. . N

RESULTS NNP N
After IN i
PE NNP i
treatment NN o
, , o
nerve NN o
function NN o
defect NN o
appeared VBD o
to TO N
improve VB N
better JJR N
than IN N
the DT N
IVIg NNP i
group NN i
and CC N
clinical JJ N
effect NN N
was VBD N
better JJR N
than IN N
the DT N
IVIg NNP i
group NN i
. . N

Treatment NNP o
effective JJ o
rates NNS o
of IN o
the DT N
two CD N
groups NNS N
after IN N
2 CD N
weeks NNS N
, , N
respectively RB N
, , N
are VBP N
96 CD N
and CC N
79 CD N
% NN i
. . i

PE NNP i
and CC i
IVIg NNP i
can MD N
significantly RB N
reduce VB N
the DT o
GBS NNP o
patients NNS o
' POS o
blood NN o
immunoglobulin NN o
IgG NNP o
, , o
IgA NNP o
, , o
IgM NNP o
, , o
C3 NNP o
and CC o
C4 NNP o
, , o
but CC o
these DT N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
PE NNP i
group NN i
than IN N
in IN N
the DT N
IVIg NNP i
group NN N
. . N

Fib NNP o
and CC o
MON NNP o
% NN o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
PE NNP i
group NN i
than IN N
in IN N
the DT N
IVIg NNP i
group NN N
. . N

CONCLUSION NNP i
Both NNP i
PE NNP i
and CC i
IVIg NNP i
have VBP N
a DT N
high JJ N
response NN N
as IN N
therapy NN N
and CC N
are VBP N
reasonable JJ N
therapeutic JJ N
options NNS N
for IN N
GBS NNP N
. . N

However RB i
, , i
PE NNP i
treatment NN i
has VBZ N
a DT N
more RBR N
significantly RB N
curative JJ N
effect NN N
, , N
as IN N
it PRP N
can MD N
effectively RB N
improve VB N
symptoms NNS N
and CC N
be VB N
helpful VBN N
in IN N
the DT N
early JJ N
rehabilitation NN p
of IN p
patients NNS p
. . p

-DOCSTART- -X- O O

Comparison NNP N
between IN N
obtained VBN N
mydriasis NN p
in IN p
type NN p
2 CD p
diabetics NNS p
and CC p
non-diabetic JJ p
patients NNS p
. . p

BACKGROUND/AIMS NNP N
To TO N
evaluate VB N
and CC N
compare VB N
obtained VBN N
mydriasis NN N
with IN N
phenylephrine JJ i
10 CD N
% NN N
associated VBN N
with IN N
tropicamide JJ i
1 CD N
% NN N
in IN N
type NN p
2 CD p
diabetics NNS p
and CC p
non-diabetic JJ p
patients NNS p
. . p

METHODS NNP N
A NNP p
total NN p
of IN p
50 CD p
patients NNS p
( ( p
100 CD p
eyes NNS p
) ) p
scheduled VBD p
for IN p
fundoscopy NN p
were VBD p
dilated VBN p
with IN p
phenylephrine JJ i
10 CD i
% NN i
and CC i
yropicamide RB i
1 CD i
% NN i
( ( N
group NN N
0 CD N
: : N
n JJ N
= $ N
20 CD N
type NN N
2 CD N
diabetic JJ N
patients NNS N
, , N
40 CD N
eyes NNS N
, , N
and CC N
group NN N
1 CD N
: : N
n JJ N
= $ N
30 CD N
non-diabetic JJ N
patients NNS N
, , N
60 CD N
eyes NNS N
) ) N
. . N

Only RB N
one CD N
drop NN N
per IN N
eye NN N
of IN N
each DT N
drug NN N
was VBD N
administered VBN N
. . N

In IN N
both DT N
groups NNS N
, , N
pupil VBP o
diameter NN o
was VBD N
measured VBN N
after IN N
40 CD N
minutes NNS N
of IN N
eye NN N
drops NNS N
instillation NN N
. . N

RESULTS NNP N
Both DT N
groups NNS N
were VBD N
similar JJ N
regarding VBG N
age NN N
( ( N
p JJ N
= NN N
0.06 CD N
, , N
Mann-Whitney NNP N
test NN N
) ) N
. . N

Mean NNP o
pupil NN o
diameter NN o
in IN N
group NN N
0 CD N
was VBD N
8.57 CD N
and CC N
8.73 CD N
in IN N
group NN N
1 CD N
. . N

There EX N
was VBD N
no DT N
statistic JJ o
difference NN o
between IN N
both DT N
groups NNS N
( ( N
p JJ N
= NNP N
0.44 CD N
) ) N
. . N

Pupil NNP o
diameter NN o
was VBD N
greater JJR N
than IN N
7 CD N
mm NNS N
in IN N
all DT N
patients NNS N
( ( N
100 CD N
% NN N
) ) N
. . N

CONCLUSION NN N
When WRB N
an DT N
appropriate JJ N
drug NN N
combination NN N
is VBZ N
used VBN N
, , N
diabetic JJ N
patients NNS N
can MD N
achieve VB N
mydriasis NN o
as RB N
satisfactory JJ N
as IN N
non-diabetic JJ N
patients NNS N
, , N
allowing VBG N
adequate JJ N
fundus NN N
examination NN N
and/or IN N
retinopathy JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Topical JJ i
treatment NN i
of IN N
alopecia NN N
areata NN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
previously RB N
that IN N
alopecia JJ N
areata NNS N
can MD N
be VB N
treated VBN N
with IN N
dinitrochlorobenzene NN i
( ( i
DNCB NNP i
) ) i
and CC N
other JJ N
contact NN i
allergens NNS i
. . i

Whether IN N
these DT N
agents NNS N
work NN N
by IN N
inducing VBG N
immunologic JJ N
stimulation NN N
or CC N
simply RB N
a DT N
nonspecific JJ N
inflammatory NN N
reaction NN N
has VBZ N
not RB N
been VBN N
definitively RB N
demonstrated VBN N
. . N

To TO N
test VB N
the DT N
relative JJ N
importance NN N
of IN N
these DT N
two CD N
mechanisms NNS N
, , N
we PRP N
have VBP N
randomly RB N
studied VBN N
22 CD p
patients NNS p
with IN p
alopecia JJ p
areata NNS p
to TO p
whom WP p
either DT p
DNCB NNP i
or CC i
croton VB i
oil NN i
was VBD p
applied VBN p
topically RB p
. . p

Sixty-three JJ N
percent NN N
of IN N
patients NNS N
without IN N
spontaneous JJ N
regrowth NN o
of IN o
hair NN o
regrew NNS o
hair NN o
after IN N
DNCB NNP N
application NN N
. . N

None NN o
of IN N
those DT N
treated VBN N
with IN N
croton NN i
oil NN i
regrew VBD o
hair NN o
when WRB N
treated VBN N
later RB N
with IN N
DNCB NNP i
. . i

Therefore NNP N
, , N
a DT N
proved JJ N
contact NN N
allergen NN N
was VBD N
shown VBN N
to TO N
be VB N
required VBN N
for IN N
therapeutic JJ N
success NN N
. . N

Patient JJ o
acceptance NN o
of IN N
the DT N
induced JJ N
contact NN N
dermatitis NN N
was VBD N
excellent JJ N
. . N

In IN N
light NN N
of IN N
recent JJ N
data NNS N
on IN N
the DT N
mutagenicity NN N
of IN N
DNCB NNP i
to TO N
bacteria NNS N
, , N
other JJ N
contact NN N
allergens NNS N
for IN N
topical JJ N
immunotherapy NN N
are VBP N
being VBG N
sought VBN N
. . N

-DOCSTART- -X- O O

Changes NNS N
in IN N
spinal JJ N
inhibitory NN N
networks NNS N
induced VBN N
by IN N
furosemide NN i
in IN N
humans NNS N
. . N

During IN N
neural JJ N
development NN N
in IN N
animals NNS N
, , N
GABAergic NNP N
and CC N
glycinergic JJ N
neurons NNS N
are VBP N
first JJ N
excitatory NN N
, , N
and CC N
then RB N
become VB N
inhibitory NN N
in IN N
the DT N
mature NN N
state NN N
. . N

This DT N
developmental JJ N
shift NN N
is VBZ N
due JJ N
mainly RB N
to TO N
strong JJ N
expression NN N
of IN N
the DT N
cation-chloride JJ N
K-Cl NNP N
cotransporter NN N
2 CD N
( ( N
KCC2 NNP N
) ) N
and CC N
down-regulation NN N
of IN N
Na-K-Cl NNP N
cotransporter NN N
1 CD N
( ( N
NKCC1 NNP N
) ) N
during IN N
maturation NN N
. . N

The DT N
down-regulation NN N
of IN N
co-transporter NN N
KCC2 NNP N
after IN N
spinal JJ N
cord NN N
transection NN N
in IN N
animals NNS N
leads NNS N
to TO N
the DT N
depolarising NN N
( ( N
excitatory NN N
) ) N
action NN N
of IN N
GABA NNP N
and CC N
glycine NN N
and CC N
thus RB N
results NNS N
in IN N
a DT N
reduction NN N
of IN N
inhibitory JJ N
synaptic JJ N
efficiency NN N
. . N

Furosemide NNP i
, , N
a DT N
loop NN N
diuretic NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
selectively RB N
and CC N
reversibly RB N
block VB N
inhibitory NN N
postsynaptic JJ N
potentials NNS N
without IN N
affecting VBG N
excitatory JJ N
postsynaptic JJ N
potentials NNS N
in IN N
animal JJ N
spinal JJ N
neurons NNS N
. . N

Moreover RB N
, , N
this DT N
diuretic NN N
has VBZ N
been VBN N
also RB N
demonstrated VBN N
to TO N
block VB N
the DT N
cation-chloride JJ N
co-transporters NNS N
. . N

Here RB N
, , N
we PRP N
used VBD N
furosemide RB i
to TO N
demonstrate VB N
changes NNS p
in IN p
spinal JJ p
inhibitory NN p
networks NNS p
in IN p
healthy JJ p
human JJ p
subjects NNS p
. . p

Non-invasive JJ N
electrophysiological JJ N
techniques NNS N
were VBD N
used VBN N
to TO N
assess VB N
presynaptic JJ N
inhibition NN N
, , N
postsynaptic JJ N
inhibition NN N
and CC N
the DT N
efficacy NN N
of IN N
synaptic JJ N
transmission NN N
between IN N
muscle NN N
afferent NN N
terminals NNS N
and CC N
soleus JJ N
motoneurons NNS N
in IN N
the DT N
spinal JJ N
cord NN N
. . N

Orally RB i
administered VBN i
furosemide NN i
, , i
at IN i
doses NNS i
commonly RB i
used VBN i
in IN i
the DT i
clinic NN i
( ( i
40 CD i
mg NN i
) ) i
, , N
significantly RB N
reduced VBN N
spinal JJ o
inhibitory JJ o
interneuronal JJ o
activity NN o
for IN N
at IN N
least JJS N
70 CD N
min NN N
from IN N
intake NN N
compared VBN N
to TO N
control VB N
experiments NNS N
in IN N
the DT N
same JJ N
subjects NNS N
while IN N
no DT N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
efficacy NN N
of IN N
synaptic JJ N
transmission NN N
between IN N
muscle NN N
afferent NN N
terminals NNS N
and CC N
soleus JJ N
motoneurons NNS N
. . N

The DT N
reduction NN o
of IN o
inhibition NN o
was VBD N
dose-dependent JJ N
. . N

Our PRP$ N
results NNS N
provide VBP N
indirect JJ N
evidence NN N
that IN N
reversible JJ N
changes NNS N
in IN N
the DT N
cation-chloride JJ N
transport NN N
system NN N
induce JJ N
modulations NNS N
of IN N
inhibitory JJ N
neuronal JJ N
activity NN N
at IN N
spinal JJ N
cord NN N
level NN N
in IN N
humans NNS N
. . N

-DOCSTART- -X- O O

The DT N
pharmacokinetics NNS o
of IN N
metronidazole NN i
and CC i
tinidazole NN i
in IN N
patients NNS p
with IN p
mixed JJ p
aerobic NNS p
-- : p
anaerobic JJ p
infections NNS p
. . p

-DOCSTART- -X- O O

Memory NN o
monitoring NN N
by IN N
animals NNS p
and CC p
humans NNS p
. . p

The DT N
authors NNS N
asked VBD N
whether IN N
animals NNS p
and CC p
humans NNS p
would MD N
use VB N
similarly RB N
an DT N
uncertain JJ N
response NN o
to TO N
escape VB N
indeterminate JJ N
memories NNS N
. . N

Monkeys NNS p
and CC p
humans NNS p
performed VBD p
serial JJ i
probe NN i
recognition NN i
tasks NNS i
that WDT N
produced VBD N
differential JJ N
memory NN N
difficulty NN N
across IN N
serial JJ N
positions NNS N
( ( N
e.g. NN N
, , N
primacy NN N
and CC N
recency NN N
effects NNS N
) ) N
. . N

Participants NNS p
were VBD N
given VBN N
an DT N
escape NN N
option NN N
that WDT N
let VBD N
them PRP N
avoid VB N
any DT N
trials NNS N
they PRP N
wished VBD N
and CC N
receive VB N
a DT N
hint NN N
to TO N
the DT N
trial NN N
's POS N
answer NN N
. . N

Across IN N
species NNS N
, , N
across IN N
tasks NNS N
, , N
and CC N
even RB N
across IN N
conspecifics NNS N
with IN N
sharper NN N
or CC N
duller NN N
memories NNS N
, , N
monkeys NNS p
and CC p
humans NNS p
used VBD o
the DT o
escape NN o
option NN o
selectively RB N
when WRB N
more RBR N
indeterminate JJ N
memory NN N
traces NNS N
were VBD N
probed VBN N
. . N

Their PRP$ N
pattern NN N
of IN N
escaping VBG N
always RB N
mirrored VBN N
the DT N
pattern NN N
of IN N
their PRP$ N
primary JJ N
memory NN N
performance NN N
across IN N
serial JJ N
positions NNS N
. . N

Signal-detection NN o
analyses NNS o
confirm VBP N
the DT N
similarity NN N
of IN N
the DT N
animals NNS N
' POS N
and CC N
humans NNS N
' POS N
performances NNS N
. . N

Optimality NNP o
analyses VBZ o
assess VB N
their PRP$ N
efficiency NN o
. . o

Several JJ N
aspects NNS N
of IN N
monkeys NNS N
' POS N
performance NN N
suggest VBP N
the DT N
cognitive JJ N
sophistication NN N
of IN N
their PRP$ N
decisions NNS N
to TO N
escape VB N
. . N

-DOCSTART- -X- O O

Should MD N
we PRP N
debrief VB N
and CC N
counsel NN N
people NNS N
who WP N
have VBP N
had VBN N
psychological JJ N
shock NN N
? . N
-DOCSTART- -X- O O

A DT N
double-blind JJ N
comparative NN N
study NN N
of IN N
ofloxacin JJ i
otic JJ i
drops NNS i
versus IN N
neomycin-polymyxin JJ i
B-hydrocortisone NNP i
otic JJ i
drops NNS i
in IN N
the DT N
medical JJ N
treatment NN N
of IN N
chronic JJ p
suppurative JJ p
otitis NN p
media NNS p
. . p

Active NNP p
chronic JJ p
suppurative NN p
otitis NN p
media NNS p
poses VBZ N
a DT N
management NN N
problem NN N
when WRB N
patients NNS p
are VBP p
being VBG p
considered VBN p
for IN p
surgical JJ p
treatment NN p
. . p

Topical JJ N
antibiotics NNS N
have VBP N
demonstrated VBN N
varying VBG N
degrees NNS N
of IN N
success NN N
in IN N
the DT N
management NN N
of IN N
discharging VBG p
ears NNS p
. . p

The DT N
introduction NN N
of IN N
quinolones NNS N
has VBZ N
revived VBN N
interest NN N
in IN N
these DT N
topical JJ N
agents NNS N
. . N

This DT N
double-blind NN N
study NN N
compares VBZ N
two CD N
antibiotics NNS i
, , N
namely RB N
ofloxacin JJ i
and CC i
neomycin-polymyxin JJ i
B NNP i
, , N
with IN N
similar JJ N
in IN N
vitro JJ N
sensitivities NNS N
to TO N
Gram NNP N
positive JJ N
and CC N
Gram NNP N
negative JJ N
organisms NNS N
. . N

Fifty-two JJ p
patients NNS p
were VBD p
selected VBN p
randomly RB N
and CC N
the DT N
results NNS N
show VBP N
that IN N
ofloxacin NN i
eardrops NNS i
have VBP N
marginal JJ N
benefits NNS N
in IN N
symptomatic JJ o
improvement NN o
( ( N
89 CD N
per IN N
cent NN N
versus NN N
79 CD N
per IN N
cent NN N
, , N
p VBP N
= RB N
0.27 CD N
) ) N
and CC N
bacterial JJ o
eradication NN o
( ( N
81 CD N
per IN N
cent NN N
versus NN N
75 CD N
per IN N
cent NN N
, , N
p VBP N
= RB N
0.81 CD N
) ) N
in IN N
active JJ o
chronic JJ o
suppurative NN o
otitis NN o
media NNS o
. . o

Significantly RB N
fewer JJR N
patients NNS N
( ( N
seven CD N
per IN N
cent NN N
versus NN N
29 CD N
per IN N
cent NN N
, , N
p VBP N
= RB N
0.04 CD N
) ) N
in IN N
the DT N
ofloxacin NN N
group NN N
had VBD o
active JJ o
disease NN o
at IN N
the DT N
end NN N
of IN N
the DT N
two-week JJ N
treatment NN N
. . N

We PRP N
recommend VBP N
the DT N
use NN N
of IN N
ofloxacin JJ i
eardrops NNS i
in IN N
managing VBG N
active JJ p
chronic JJ p
suppurative NN p
otitis NN p
media NNS p
since IN N
it PRP N
has VBZ N
high JJ N
clinical JJ o
efficacy NN o
, , N
contains VBZ N
no DT N
steroid JJ N
component NN N
and CC N
has VBZ N
no DT N
demonstrated VBN N
risk NN o
of IN o
ototoxicity NN o
. . o

-DOCSTART- -X- O O

Effects NNS N
of IN N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
in IN N
performing VBG N
eye-hand JJ N
integration NN N
tasks NNS N
: : N
four CD N
preliminary JJ N
studies NNS N
with IN N
children NNS p
showing VBG p
low-functioning JJ p
autism NN p
. . p

This DT N
report NN N
, , N
based VBN N
on IN N
four CD N
studies NNS N
with IN N
children NNS p
with IN p
low-functioning JJ p
autism NN p
, , N
aimed VBN N
at IN N
evaluating VBG N
the DT N
effects NNS N
of IN N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
delivered VBN N
on IN N
the DT N
left NN N
and CC N
right JJ N
premotor NN N
cortices NNS N
on IN N
eye-hand JJ N
integration NN N
tasks NNS N
; : N
defining VBG N
the DT N
long-lasting JJ N
effects NNS N
of IN N
high-frequency NN i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
; : i
and CC N
investigating VBG N
the DT N
real JJ N
efficacy NN N
of IN N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
by IN N
comparing VBG N
three CD N
kinds NNS N
of IN N
treatments NNS N
( ( N
high-frequency JJ N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
, , N
a DT N
traditional JJ N
eye-hand JJ N
integration NN N
training NN N
, , N
and CC N
both DT N
treatments NNS N
combined VBN N
) ) N
. . N

Results $ N
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
eye-hand JJ o
performances NNS o
only RB N
when WRB N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
was VBD N
delivered VBN N
on IN N
the DT N
left JJ N
premotor NN N
cortex NN N
; : N
a DT N
persistent NN N
improvement NN N
up IN N
to TO N
1 CD N
h NN N
after IN N
the DT N
end NN N
of IN N
the DT N
stimulation NN N
; : N
better JJR N
outcomes NNS N
in IN N
the DT N
treatment NN N
combining VBG N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
and CC N
eye-hand JJ N
integration NN N
training NN N
. . N

Based VBN N
on IN N
these DT N
preliminary JJ N
findings NNS N
, , N
further JJ N
evaluations NNS N
on IN N
the DT N
usefulness NN N
of IN N
high-frequency NN i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
in IN N
rehabilitation NN N
of IN N
children NNS o
with IN o
autism NN o
are VBP N
strongly RB N
recommended VBN N
. . N

-DOCSTART- -X- O O

Monitoring NN N
of IN N
CA19-9 NNP N
and CC N
SPan-1 NNP N
can MD N
facilitate VB N
the DT N
earlier JJR N
confirmation NN N
of IN N
progressing VBG N
pancreatic JJ N
cancer NN N
during IN N
chemotherapy NN N
. . N

BACKGROUND NNP N
Measurement NNP N
of IN N
objective JJ o
response NN o
to TO o
chemotherapy VB o
using VBG o
imaging VBG o
modalities NNS o
is VBZ N
sometimes RB N
difficult JJ N
in IN N
pancreatic JJ p
cancer NN p
( ( p
PC NN p
) ) p
. . p

We PRP N
aimed VBD N
to TO N
verify VB N
whether IN N
monitoring NN N
of IN N
serum JJ o
tumor NN o
markers NNS o
( ( o
TMs NNP o
) ) o
, , o
namely RB o
carcinoembryonic JJ o
antigen NN o
, , o
CA19-9 NNP o
, , o
DUPAN-2 NNP o
, , o
SPan-1 NNP o
, , N
can MD N
facilitate VB N
earlier JJR N
confirmation NN N
of IN N
treatment NN N
failure NN N
. . N

METHODS NNP N
Monitoring NNP o
of IN o
serum NN o
TMs NNP o
and CC o
computed VBN o
tomography NN o
were VBD i
performed VBN i
every DT i
4 CD i
weeks NNS i
until IN i
progression NN i
of IN i
disease NN i
in IN N
90 CD p
patients NNS p
with IN p
PC NNP p
undergoing VBG p
gemcitabine JJ p
therapy NN p
. . p

In IN N
Group NNP N
A NNP N
( ( N
January NNP N
2006-October NNP N
2007 CD N
) ) N
, , N
we PRP i
analyzed VBD i
the DT i
fluctuation NN o
rates NNS o
of IN o
TMs NNP o
with IN i
high JJ i
pretreatment NN i
positive JJ i
rates NNS i
, , i
and CC i
defined VBD i
the DT i
criteria NNS i
of IN i
progressive JJ i
disease NN i
under IN i
TM NNP i
monitoring NN i
( ( i
TM-PD NNP i
) ) i
. . i

In IN N
Group NNP N
B NNP N
( ( N
November NNP N
2007-October JJ N
2008 CD N
) ) N
, , N
we PRP i
calculated VBD i
the DT i
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
under IN i
this DT i
TM-PD NNP i
criteria NNS i
, , i
which WDT i
was VBD i
compared VBN i
with IN i
the DT i
TTP NNP i
under IN i
the DT i
RECIST NNP i
criteria NNS i
. . i

RESULTS NNP N
CA19-9 JJ N
and CC N
SPan-1 NNP N
had VBD N
the DT N
highest JJS N
pretreatment JJ N
positive JJ N
rates NNS N
: : N
83 CD N
% NN N
and CC N
90 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
Group NNP N
A NNP N
( ( N
CA19-9 NNP N
, , N
n JJ N
= VBP N
38 CD N
; : N
SPan-1 NNP N
, , N
n JJ N
= NNP N
36 CD N
) ) N
, , N
TM-PD JJ N
criteria NNS N
were VBD N
defined VBN N
as IN N
follows VBZ o
: : o
fluctuation NN o
rates NNS o
were VBD o
?25 CD N
% NN N
for IN N
a DT N
month NN N
or CC N
?10 CD N
% NN N
for IN N
2 CD N
consecutive JJ N
months NNS N
in IN N
CA19-9 NNP N
, , N
and CC N
?10 CD N
% NN N
for IN N
a DT N
month NN N
in IN N
SPan-1 NNP N
. . N

In IN N
Group NNP N
B NNP N
( ( N
CA19-9 NNP N
, , N
n JJ N
= VBP N
18 CD N
; : N
SPan-1 NNP N
, , N
n JJ N
= NNP N
17 CD N
) ) N
, , N
under IN N
these DT N
criteria NNS N
, , N
one-month JJ N
earlier JJR o
confirmation NN o
of IN o
treatment NN o
failure NN o
was VBD o
feasible JJ o
in IN N
61 CD N
% NN N
by IN N
CA19-9 NNP N
and CC N
59 CD N
% NN N
by IN N
SPan-1 NNP N
. . N

Furthermore NNP N
, , N
the DT N
combination NN N
could MD N
facilitate VB N
this DT N
determination NN N
in IN N
72 CD N
% NN N
( ( N
35/49 CD N
) ) N
, , N
significantly RB N
better JJR N
than IN N
CA19-9 NNP N
alone RB N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

CONCLUSION NNP N
Monitoring NNP N
of IN N
serum JJ N
CA19-9 NNP N
and CC N
SPan-1 NNP N
is VBZ N
helpful JJ N
for IN N
earlier JJR N
confirmation NN N
of IN N
treatment NN N
failure NN N
during IN N
gemcitabine JJ N
therapy NN N
in IN N
PC NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
topical JJ N
rh-TGF-beta JJ i
1 CD i
on IN N
second JJ o
intention NN o
wound IN o
healing VBG o
in IN p
horses NNS p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
on IN N
wound IN N
healing NN N
of IN N
transforming VBG N
growth NN i
factor-beta JJ i
1 CD i
as IN N
a DT N
topical JJ N
treatment NN N
to TO N
full-thickness NN N
, , N
excisional JJ N
wounds NNS N
of IN N
the DT N
distal JJ N
limb NN N
of IN N
horses NNS p
. . p

DESIGN VB N
A DT N
randomised JJ N
block NN N
study NN N
using VBG N
four CD p
horses NNS p
, , p
each DT p
with IN p
wounds NNS p
assigned VBN N
to TO N
four CD N
treatment NN N
groups NNS N
. . N

ANIMALS NNP N
Four CD p
adult NN p
Standardbred NNP p
geldings NNS p
. . p

PROCEDURE NNP N
Four NNP N
, , N
4 CD N
cm2 NN N
, , N
full-thickness JJ N
wounds NNS N
were VBD N
created VBN N
on IN N
the DT N
dorsomedial JJ N
and CC N
dorsolateral JJ N
aspect NN N
of IN N
the DT N
metacarpus NN N
or CC N
metatarsus NN N
of IN N
each DT N
limb NN N
of IN N
four CD p
horses NNS p
, , p
giving VBG p
a DT p
total NN p
of IN p
64 CD p
wounds NNS p
. . p

For IN N
each DT N
limb NN N
, , N
wounds NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
treatment NN N
groups NNS N
: : N
no DT i
treatment NN i
( ( i
control NN i
) ) i
, , i
carrier NN i
( ( i
Methyl NNP i
Cellulose NNP i
gel NN i
) ) i
, , i
50 CD i
ng/wound IN i
rhTGF-beta JJ i
1 CD i
in IN i
carrier NN i
, , i
and CC i
500 CD i
ng/wound JJ i
rhTGF-beta JJ i
1 CD i
in IN i
carrier NN i
. . i

Wounds NNS N
were VBD N
treated VBN N
on IN N
day NN N
0 CD N
and CC N
day NN N
8 CD N
. . N

Effects NNS N
of IN N
treatment NN N
were VBD N
evaluated VBN N
on IN N
the DT N
basis NN N
of IN N
the DT N
presence NN o
of IN o
exuberant JJ o
granulation NN o
tissue NN o
requiring VBG o
excision NN o
, , o
number NN o
of IN o
times NNS o
excision NN o
was VBD o
required VBN o
, , o
total JJ o
wound JJ o
area NN o
, , o
area NN o
of IN o
epithelialisation NN o
, , o
area NN o
of IN o
granulation NN o
, , o
and CC o
histological JJ o
evaluation NN o
of IN o
biopsy NN o
samples NNS o
of IN o
wounds NNS o
on IN N
day NN N
8 CD N
and CC N
excised VBD N
wounds NNS N
on IN N
day NN N
21 CD N
. . N

RESULTS NNP N
Topical JJ N
application NN N
of IN N
TGF-beta NNP N
1 CD N
at IN N
the DT N
two CD N
concentrations NNS N
studied VBN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
the DT N
total JJ o
area NN o
of IN o
wounds NNS o
( ( N
P NNP N
= NNP N
0.7 CD N
) ) N
, , N
the DT o
area NN o
of IN o
granulation NN o
tissue NN o
( ( N
P NNP N
= NNP N
0.78 CD N
) ) N
, , N
the DT o
area NN o
of IN o
epithelialisation NN o
( ( N
P NNP N
= NNP N
0.92 CD N
) ) N
, , N
histological JJ N
assessment NN N
or CC N
subjective JJ o
clinical JJ o
assessment NN o
of IN o
wounds NNS o
. . o

CONCLUSION NNP N
TGF-beta NNP i
1 CD i
had VBD N
no DT N
beneficial JJ N
effects NNS N
on IN N
wound NN o
healing NN o
. . o

Additional JJ N
trials NNS N
are VBP N
needed VBN N
to TO N
test VB N
if IN N
it PRP N
has VBZ N
value NN N
for IN N
wound NN N
treatment NN N
in IN N
horses NNS p
. . p

-DOCSTART- -X- O O

The DT N
UKEP NNP N
study NN N
: : N
multicentre JJ N
clinical JJ N
trial NN N
on IN N
two CD N
local JJ N
regimens NNS N
of IN N
urokinase NN i
in IN N
massive JJ N
pulmonary JJ N
embolism NN N
. . N

The DT N
UKEP NNP N
Study NNP N
Research NNP N
Group NNP N
. . N

A NNP i
multicentre JJ i
trial NN i
( ( i
10 CD i
centres NNS i
) ) i
of IN i
urokinase NN i
( ( i
UK NNP i
) ) i
was VBD N
performed VBN N
in IN N
patients NNS p
with IN p
acute NN p
severe JJ p
pulmonary JJ p
embolism NN p
( ( p
PE NNP p
) ) p
. . p

The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
, , N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
two CD i
doses NNS i
of IN i
UK NNP i
administered VBD i
via IN i
a DT i
catheter NN i
in IN i
the DT i
pulmonary JJ i
artery NN i
: : i
2000 CD i
IU NNP i
kg-1 JJ i
h-1 NN i
for IN i
24 CD i
hours NNS i
( ( i
UK IN i
2000 CD i
) ) i
in IN i
conjunction NN i
with IN i
heparin NN i
versus NN i
4400 CD i
IU NNP i
kg-1 JJ i
h-1 JJ i
UK NNP i
alone RB i
for IN i
12 CD i
hours NNS i
( ( i
UK IN i
4400 CD i
) ) i
followed VBN i
by IN i
heparin NN i
. . i

PE NNP p
was VBD p
less JJR p
than IN p
5 CD p
days NNS p
old JJ p
and CC N
the DT N
clinical JJ N
diagnosis NN N
was VBD N
confirmed VBN N
by IN N
pulmonary JJ N
angiograms NNS N
demonstrating VBG N
a DT N
vascular JJ N
obstruction NN N
of IN N
more JJR N
than IN N
30 CD N
% NN N
( ( N
Miller NNP N
's POS N
index NN N
greater JJR N
than IN N
11 CD N
) ) N
. . N

The DT N
efficacy NN N
of IN N
treatment NN N
was VBD N
evaluated VBN N
by IN N
the DT N
degree NN o
of IN o
early JJ o
revascularization NN o
( ( N
pulmonary JJ N
angiograms NNS N
were VBD N
performed VBN N
30 CD N
to TO N
48 CD N
hours NNS N
after IN N
initiation NN N
of IN N
thrombolytic JJ i
treatment NN i
and CC N
analysed VBN N
blindly RB N
by IN N
four CD N
independent JJ N
vascular JJ N
radiologists NNS N
) ) N
. . N

133 CD p
patients NNS p
were VBD N
included VBN N
in IN N
this DT N
trial NN N
: : N
two CD p
patients NNS p
died VBD o
before IN p
treatment NN p
and CC p
two CD p
were VBD p
excluded VBN p
retrospectively RB p
, , p
leaving VBG p
129 CD p
patients NNS p
for IN p
final JJ p
analysis NN p
( ( N
67 CD N
: : N
UK NN N
2000 CD N
+ NNP N
heparin NN N
; : N
62 CD N
: : N
UK JJ N
4400 CD N
) ) N
. . N

The DT N
two CD N
groups NNS N
had VBD N
similar JJ N
pretreatment NN N
clinical JJ N
, , N
haemodynamic JJ N
and CC N
angiographic JJ N
characteristics NNS N
: : N
the DT N
Miller NNP o
angiographic JJ o
index NN o
of IN N
severity NN N
averaged VBD N
22.6 CD N
+/- JJ N
3.7 CD N
for IN N
patients NNS N
in IN N
the DT N
UK NNP N
2000 CD N
group NN N
, , N
and CC N
22.6 CD N
+/- JJ N
3.4 CD N
for IN N
patients NNS N
in IN N
the DT N
UK NNP N
4400 CD N
group NN N
( ( N
average JJ N
filling VBG N
defect NN N
of IN N
66 CD N
% NN N
on IN N
pulmonary JJ N
angiograms NNS N
) ) N
. . N

There EX N
was VBD N
a DT N
similar JJ N
and CC N
significant JJ o
degree NN o
of IN o
resolution NN o
in IN N
the DT N
two CD N
groups NNS N
: : N
26 CD N
% NN N
and CC N
20 CD N
% NN N
, , N
respectively RB N
. . N

Minor NNP o
and CC o
major JJ o
bleeding NN o
problems NNS o
were VBD N
observed VBN N
with IN N
equal JJ N
frequency NN N
in IN N
the DT N
two CD p
groups NNS p
( ( N
24 CD N
% NN N
and CC N
29 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

These DT N
bleeding VBG N
complications NNS N
were VBD N
severe RB N
in IN N
only RB N
4.5 CD N
% NN N
and CC N
3 CD N
% NN N
, , N
respectively RB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Effects NNS N
of IN N
low JJ N
and CC N
high JJ N
protein NN o
: : o
carbohydrate JJ o
ratios NNS o
in IN N
the DT N
diet NN N
of IN N
pregnant JJ p
gilts NNS p
on IN N
maternal JJ o
cortisol NN o
concentrations NNS o
and CC N
the DT N
adrenocortical JJ o
and CC o
sympathoadrenal JJ o
reactivity NN o
in IN p
their PRP$ p
offspring NN p
. . p

Inadequate NNP N
maternal JJ N
nutrition NN N
during IN N
gestation NN N
may MD N
cause VB N
an DT N
adverse JJ N
environment NN N
for IN N
the DT N
fetus NN N
leading VBG N
to TO N
alterations NNS N
of IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
( ( N
HPA NNP N
) ) N
and CC N
sympatho-adrenomedullary JJ N
( ( N
SAM NNP N
) ) N
systems NNS N
later RBR N
in IN N
life NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
diets NNS i
with IN i
low JJ i
and CC i
high JJ i
protein NN i
: : i
carbohydrate JJ i
ratios NNS N
on IN N
cortisol JJ o
concentrations NNS o
of IN N
pregnant JJ p
gilts NNS p
as RB N
well RB N
as IN N
the DT N
long-term JJ N
effects NNS N
on IN N
the DT N
function NN N
of IN N
the DT N
HPA NNP o
and CC o
SAM NNP o
axes NNS o
in IN p
their PRP$ p
offspring NN p
. . p

Throughout IN N
gestation NN N
, , N
33 CD p
German JJ p
Landrace NNP p
gilts NNS p
were VBD N
fed VBN N
high JJ i
( ( i
HP NNP i
, , i
30 CD i
% NN i
) ) i
, , i
low JJ i
( ( i
LP NNP i
, , i
6.5 CD i
% NN i
) ) i
, , i
or CC i
adequate NN i
( ( i
AP NNP i
, , i
12.1 CD i
% NN i
) ) i
protein NN i
diets NNS i
, , N
which WDT N
were VBD N
made VBN N
isocaloric JJ N
by IN N
adjusting VBG N
the DT N
carbohydrate NN N
content NN N
. . N

The DT N
salivary JJ N
cortisol NN N
concentrations NNS N
of IN p
the DT p
sows NNS p
were VBD N
measured VBN N
in IN N
the DT N
course NN N
of IN N
the DT N
gestation NN N
period NN N
. . N

The DT p
offspring VBG p
were VBD p
cross-fostered JJ p
, , N
and CC N
the DT N
plasma NN o
cortisol NN o
and CC o
catecholamine JJ o
concentrations NNS o
of IN N
the DT N
offspring NN p
were VBD N
determined VBN N
on IN N
postnatal JJ N
d NN N
( ( N
PND NNP N
) ) N
1 CD N
and CC N
27 CD N
and CC N
under IN N
specific JJ N
challenging JJ N
conditions NNS N
: : N
after IN N
weaning VBG N
( ( N
PND NNP N
29 CD N
) ) N
and CC N
after IN N
ACTH NNP N
and CC N
insulin NN N
challenges NNS N
( ( N
PND NNP N
68 CD N
and CC N
70 CD N
, , N
respectively RB N
) ) N
. . N

Glucocorticoid NNP o
receptor NN o
( ( o
GR NNP o
) ) o
binding NN o
and CC o
neurotransmitter JJ o
concentrations NNS o
were VBD N
measured VBN N
in IN N
stress-related JJ N
brain NN N
regions NNS N
, , N
and CC N
histological JJ N
analyses NNS N
of IN N
the DT N
adrenal JJ N
were VBD N
performed VBN N
. . N

Maternal NNP o
salivary JJ o
cortisol NN o
concentrations NNS o
increased VBD N
throughout IN N
gestation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
LP NNP N
gilts NNS N
had VBD N
greater JJR N
salivary JJ o
cortisol NNS o
compared VBN N
with IN N
the DT N
AP NNP N
and CC N
HP NNP N
gilts NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No UH N
differences NNS N
between IN N
diets NNS N
were VBD N
found VBN N
for IN N
cortisol NN N
, , N
corticosteroid-binding JJ N
globulin NN N
, , N
and CC N
catecholamine JJ N
concentrations NNS N
in IN N
plasma NN N
and CC N
for IN N
GR NNP N
binding NN N
in IN N
hippocampus NN N
and CC N
hypothalamus NN N
in IN N
piglets NNS p
at IN N
PND NNP N
1 CD N
and CC N
27 CD N
. . N

However RB N
, , N
the DT N
cortisol NN o
response NN o
to TO o
weaning NN o
was VBD N
increased VBN N
in IN N
LP NNP N
piglets NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
in IN N
HP NNP N
offspring VBG N
the DT N
basal NN o
plasma VBZ o
noradrenaline JJ o
concentrations NNS o
were VBD N
increased VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
cortisol NN o
response NN o
to TO o
the DT o
ACTH NNP o
and CC o
the DT o
insulin NN o
challenge NN o
did VBD N
not RB N
differ VB N
between IN N
diets NNS N
. . N

On IN N
PND NNP N
81 CD N
, , N
an DT N
increased VBN N
adrenal JJ o
medulla NN o
area NN o
was VBD N
observed VBN N
in IN N
LP NNP N
offspring VBG N
compared VBN N
with IN N
the DT N
AP NNP N
offspring NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Our PRP$ N
results NNS N
show VBP N
that IN N
maternal JJ i
diets NNS i
with IN i
aberrant JJ o
protein NN o
: : o
carbohydrate JJ o
ratios NNS o
during IN i
gestation NN i
have VBP N
moderate VBN N
long-term JJ N
effects NNS N
on IN N
the DT N
function NN o
of IN o
the DT o
HPA NNP o
and CC o
SAM NNP o
system NN o
in IN N
the DT N
offspring NN N
, , N
which WDT N
indicates VBZ N
that IN N
pigs NNS p
show VBP N
a DT N
considerable JJ N
plasticity NN N
to TO N
cope VB N
with IN N
maternal JJ N
malnutrition NN N
. . N

-DOCSTART- -X- O O

Hepatic JJ N
cytoprotective JJ N
effect NN N
of IN N
ischemic JJ i
and CC i
anesthetic JJ i
preconditioning NN i
before IN N
liver JJ N
resection NN N
when WRB N
using VBG N
intermittent JJ N
vascular JJ N
inflow JJ N
occlusion NN N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Ischemic NNP i
preconditioning NN i
( ( i
IPC NNP i
) ) i
and CC N
anesthetic JJ i
preconditioning NN i
( ( i
APC NNP i
) ) i
have VBP N
been VBN N
reported VBN N
to TO N
attenuate VB N
ischemia-reperfusion NN N
( ( N
IR NNP N
) ) N
injury NN N
after IN N
liver JJ N
resection NN N
under IN N
continuous JJ N
inflow JJ N
occlusion NN N
. . N

This DT N
study NN N
evaluates VBZ N
whether IN N
these DT N
strategies NNS N
enhance VBP N
hepatic JJ N
protection NN N
of IN N
remnant JJ N
liver NN N
against IN N
IR NNP N
after IN N
liver JJ p
resection NN p
with IN p
intermittent JJ i
clamping NN i
( ( i
INT NNP i
) ) i
. . i

METHODS CC N
A DT p
total NN p
of IN p
106 CD p
patients NNS p
without IN p
underlying VBG p
liver NN p
disease NN p
and CC p
submitted VBN p
to TO p
liver VB p
resection NN p
using VBG p
INT NNP p
were VBD N
randomized VBN N
into IN N
3 CD N
groups NNS N
: : N
IPC NNP i
( ( i
10 CD i
minutes NNS i
of IN i
inflow JJ i
occlusion NN i
followed VBN i
by IN i
10 CD i
minutes NNS i
of IN i
reperfusion NN i
before IN i
liver JJ i
transection NN i
) ) i
, , i
APC NNP i
( ( i
sevoflurane JJ i
administration NN i
for IN i
20 CD i
minutes NNS i
before IN i
liver JJ i
transection NN i
) ) i
, , i
and CC i
INT NNP i
( ( i
no DT i
preconditioning NN i
) ) i
. . i

Patients NNS N
were VBD N
also RB N
stratified VBN N
according VBG N
to TO N
the DT N
extent NN N
of IN N
the DT N
hepatectomy NN N
. . N

Cytoprotection NN o
was VBD N
evaluated VBN N
by IN N
comparing VBG o
hepatocyte NN o
and CC o
endothelial JJ o
dysfunction NN o
markers NNS o
, , o
apoptosis NN o
, , o
histologic JJ o
lesions NNS o
, , o
and CC o
postoperative JJ o
outcome NN o
. . o

RESULTS NNP N
No NNP N
differences NNS N
were VBD N
observed VBN N
in IN N
preoperative JJ o
chemotherapy NN o
and CC o
steatosis NN o
, , o
total JJ o
warm JJ o
ischemia NN o
time NN o
, , o
operative JJ o
time NN o
, , o
or CC o
blood NN o
loss NN o
. . o

Kinetics NNS o
of IN o
transaminases NNS o
( ( N
aspartate JJ N
aminotransferase NN N
, , N
P NNP N
= NNP N
.137 NNP N
; : N
alanine JJ N
aminotransferase NN N
, , N
P NNP N
= NNP N
.616 NNP N
) ) N
, , N
bilirubin FW o
( ( N
P NNP N
= NNP N
.980 NNP N
) ) N
, , N
and CC N
hyaluronic JJ o
acid NN o
increase NN N
( ( N
P NNP N
= NNP N
.514 NNP N
) ) N
revealed VBD N
no DT N
differences NNS N
. . N

Significant JJ o
apoptosis NN o
was VBD N
present JJ N
in IN N
40 CD N
% NN N
of IN N
patients NNS N
, , N
mild-to-moderate JJ o
leukocyte NN o
infiltration NN o
and CC o
steatosis NN o
in IN N
45 CD N
% NN N
and CC N
55 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
mild VB o
sinusoidal JJ o
congestion NN o
in IN N
65 CD N
% NN N
, , N
with IN N
a DT N
similar JJ N
distribution NN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

When WRB N
patients NNS N
were VBD N
stratified VBN N
by IN N
major JJ N
versus NN N
minor JJ N
resections NNS N
, , N
no DT N
differences NNS N
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
variables NNS N
studied VBN N
. . N

Postoperative JJ N
clinical JJ N
outcomes NNS N
were VBD N
also RB N
similar JJ N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
these DT N
protocols NNS i
of IN i
IPC NNP i
and CC i
APC NNP i
used VBD N
in IN N
this DT N
study NN N
do VBP N
not RB N
provide VB N
better JJR N
cytoprotection NN N
from IN N
IR NNP N
when WRB N
INT NNP i
is VBZ N
used VBN N
. . N

-DOCSTART- -X- O O

Netilmicin NNP i
versus NN i
tobramycin NN i
in IN N
multi-centre JJ p
studies NNS p
. . p

In IN N
two CD N
prospective JJ N
, , N
randomized JJ N
studies NNS N
conducted VBN N
in IN N
West NNP p
Germany NNP p
and CC p
involving VBG p
80 CD p
patients NNS p
, , N
netilmicin-ticarcillin NN i
was VBD N
compared VBN N
to TO N
tobramycin-ticarcillin NN i
in IN N
the DT N
treatment NN N
of IN N
serious JJ p
systemic JJ p
infections NNS p
. . p

Both DT N
regimens NNS N
were VBD N
essentially RB N
identical JJ N
with IN N
respect NN N
to TO N
the DT N
clinical JJ N
and CC N
bacteriological JJ N
results NNS N
they PRP N
produced VBD N
. . N

The DT N
netilmicin JJ N
group NN N
developed VBD N
significantly RB N
less JJR N
nephrotoxicity NN o
than IN N
the DT N
tobramycin NN N
group NN N
( ( N
0 CD N
% NN N
versus IN N
15 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Ototoxicity NNP o
also RB N
occurred VBD N
less RBR N
frequently RB N
in IN N
the DT N
netilmicin-treated JJ N
patients NNS N
( ( N
3 CD N
% NN N
versus IN N
10 CD N
% NN N
, , N
P NNP N
= NNP N
0.4 CD N
) ) N
. . N

In IN N
a DT N
large JJ p
collaborative NN p
study NN p
involving VBG p
15 CD p
centres NNS p
, , p
254 CD p
patients NNS p
were VBD p
enrolled VBN p
. . p

Clinical JJ o
and CC o
bacteriological JJ o
responses NNS o
were VBD N
excellent JJ N
, , N
with IN N
netilmicin JJ N
and CC N
tobramycin JJ N
equally RB N
effective JJ o
, , N
but CC N
the DT N
incidences NNS N
of IN N
nephrotoxicity NN o
and CC o
ototoxicity NN o
were VBD N
lower JJR N
in IN N
patients NNS N
treated VBN N
with IN N
netilmicin NN N
than IN N
those DT N
receiving VBG N
tobramycin NN N
. . N

-DOCSTART- -X- O O

Midazolam NNP i
vs NN i
ondansetron NN i
for IN N
preventing VBG N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
: : o
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

We PRP N
compared VBN N
the DT N
prophylactic JJ N
anti-emetic JJ N
efficacy NN N
of IN N
midazolam NN i
and CC N
ondansetron NN i
in IN N
90 CD p
patients NNS p
scheduled VBN p
for IN p
minor JJ p
gynaecological JJ p
( ( p
hysteroscopy NN p
) ) p
or CC p
urological JJ p
( ( p
ureteroscopy JJ p
) ) p
procedures NNS p
planned VBN p
to TO p
last JJ p
1-2 JJ p
h NN p
under IN p
sevoflurane NN p
anaesthesia NN p
with IN p
spontaneous JJ p
ventilation NN p
of IN p
the DT p
lungs NNS p
via IN p
a DT p
laryngeal JJ p
mask NN p
airway NN p
. . p

Midazolam NNP i
2 CD i
mg NN i
or CC i
ondansetron $ i
4 CD i
mg NN i
were VBD N
administered VBN N
intravenously RB N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

The DT N
proportions NNS N
of IN N
patients NNS p
who WP p
experienced VBD p
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
in IN p
the DT p
first JJ p
24 CD p
h NN p
( ( p
30 CD p
% NN p
and CC p
27 CD p
% NN p
for IN p
the DT p
midazolam NN i
and CC p
ondansetron NN i
groups NNS p
, , p
respectively RB p
) ) p
were VBD p
similar JJ o
in IN p
the DT p
two CD p
groups NNS p
. . p

The DT N
incidence NN N
of IN N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
was VBD N
significantly RB N
smaller JJR o
in IN N
both DT N
groups NNS N
than IN N
predicted VBN N
according VBG N
to TO N
the DT N
patients NNS p
' POS p
underlying JJ p
risks NNS p
( ( i
midazolam JJ i
group NN p
: : p
p NN p
= VBZ p
0.018 CD p
; : p
ondansetron VBN i
group NN p
: : p
p NN p
= VBZ p
0.017 CD p
) ) p
. . p

There EX N
were VBD N
no DT o
significant JJ o
differences NNS o
in IN N
average JJ o
sedation NN o
scores NNS o
or CC o
pain NN o
scores NNS o
. . o

Treatment NNP N
using VBG N
ondansetron NN i
for IN N
anti-emetic JJ N
prophylaxis NN N
did VBD N
not RB N
provide VB N
a DT N
superior JJ N
benefit NN N
compared VBN N
to TO N
midazolam VB i
in IN N
the DT N
present JJ N
study NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
acebutolol NN i
on IN N
left JJ N
ventricular JJ N
performance NN N
. . N

The DT N
effect NN N
of IN N
acebutolol NN i
on IN N
left JJ N
ventricular JJ N
performance NN N
was VBD N
examined VBN N
by IN N
various JJ N
noninvasive JJ N
means NNS N
in IN N
three CD N
studies NNS N
. . N

M-mode NNP N
echocardiographic JJ N
measurements NNS N
were VBD N
made VBN N
in IN N
21 CD p
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
who WP p
were VBD p
receiving VBG p
placebo NN i
, , i
acebutolol NN i
, , p
and CC p
propranolol NN i
in IN p
a DT p
double-blind NN p
, , N
randomized VBN N
, , N
crossover NN N
study NN N
. . N

In IN N
these DT N
patients NNS N
with IN N
normal JJ N
or CC N
near-normal JJ N
resting NN N
left VBD N
ventricular JJ N
function NN N
, , N
neither CC N
drug NN N
induced JJ N
depression NN N
of IN N
left JJ N
ventricular JJ N
function NN N
. . N

In IN N
26 CD p
patients NNS p
with IN p
chronic JJ p
angina NNS p
pectoris VBP p
receiving VBG N
acebutolol NN i
under IN N
double-blind NN N
, , N
placebo-controlled JJ i
conditions NNS N
, , N
gated VBN N
( ( N
equilibrium NN N
) ) N
myocardial NN N
blood NN N
pool NN N
imaging VBG N
using VBG N
red JJ N
blood NN N
cells NNS N
labeled VBN N
with IN N
technetium NN N
99m CD N
showed VBD N
acebutolol NN i
to TO N
have VB N
no DT N
clinically RB N
significant JJ N
negative JJ N
effect NN N
on IN N
left JJ N
ventricular JJ N
performance NN N
at IN N
rest NN N
or CC N
during IN N
supine JJ N
bicycle NN N
exercise NN N
. . N

Acebutolol NNP i
at IN N
effective JJ N
antianginal JJ N
doses NNS N
modestly RB N
improved VBN N
resting NN o
global JJ o
and CC o
regional JJ o
myocardial JJ o
function NN o
. . o

In IN N
13 CD p
patients NNS p
with IN p
stable JJ p
angina NNS p
pectoris VBP p
, , N
single-pass JJ N
studies NNS N
of IN N
left JJ N
ventricular JJ N
function NN N
with IN N
indium NN N
113 CD N
under IN N
double-blind NN N
, , N
placebo-controlled JJ N
conditions NNS N
similarly RB N
showed VBD N
acebutolol NN i
to TO N
have VB N
no DT N
clinically RB N
significant JJ N
negative JJ N
inotropic NN N
effects NNS N
. . N

In IN N
conclusion NN N
, , N
acebutolol NN i
is VBZ N
safe JJ N
for IN N
use NN N
in IN N
patients NNS p
with IN p
coronary JJ p
disease NN p
and CC p
a DT p
wide JJ p
range NN p
of IN p
ejection NN p
fractions NNS p
but CC N
, , N
as IN N
with IN N
all DT N
beta NN N
blockers NNS N
, , N
should MD N
be VB N
used VBN N
cautiously RB N
in IN N
patients NNS N
with IN N
markedly RB N
reduced VBN p
resting NN p
left VBD p
ventricular JJ p
function NN p
. . p

-DOCSTART- -X- O O

Granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
( ( i
GM-CSF NNP i
) ) i
allows VBZ N
acceleration NN N
and CC N
dose JJ N
intensity NN N
increase NN N
of IN N
CEF NNP i
chemotherapy NN i
: : i
a DT N
randomised JJ N
study NN N
in IN N
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
. . p

A DT N
randomised JJ N
study NN N
was VBD N
conducted VBN N
in IN N
62 CD p
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
to TO N
assess VB N
whether IN N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( i
GM-CSF NNP i
) ) i
would MD N
yield VB N
an DT N
increase NN N
in IN N
the DT N
dose JJ N
intensity NN N
of IN N
a DT N
standard-dose JJ i
CEF NNP i
regimen NNS i
through IN N
an DT N
acceleration NN N
of IN N
chemotherapy JJ i
administration NN N
. . N

Patients NNS N
received VBD N
CEF NNP i
( ( i
cyclophosphamide VB i
600 CD i
mg JJ i
m-2 NN i
, , i
epidoxorubicin VBZ i
60 CD i
mg NN i
m-2 NN i
and CC i
fluorouracil NN i
600 CD i
mg JJ i
m-2 NN i
) ) i
i.v NN N
. . N

on IN N
day NN N
1 CD N
or CC N
the DT N
same JJ N
chemotherapy NN i
, , N
plus CC N
GM-CSF NNP i
10 CD N
micrograms NNS N
kg-1 JJ N
s.c. NNS N
starting VBG N
from IN N
day NN N
4 CD N
, , N
repeated VBN N
as RB N
soon RB N
as IN N
haematopoietic JJ N
recovery NN N
from IN N
nadir NN N
occurred VBD N
. . N

Patients NNS N
in IN N
the DT N
CEF NNP i
+ NNP i
GM-CSF NNP i
group NN N
received VBD N
chemotherapy NN N
at IN N
a DT N
median JJ N
interval NN N
of IN N
16 CD N
days NNS N
compared VBN N
with IN N
20 CD N
days NNS N
in IN N
the DT N
control NN N
group NN N
. . N

This DT N
led VBD N
to TO N
a DT N
significant JJ N
increase NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
in IN N
the DT N
dose JJ N
intensity NN N
actually RB N
administered VBN N
in IN N
the DT N
third JJ N
, , N
fourth JJ N
and CC N
sixth JJ N
cycles NNS N
: : N
+28 CD N
% NN N
, , N
+25 CD N
% NN N
, , N
+20 CD N
% NN N
respectively RB N
. . N

Non-haematological JJ o
toxicity NN o
was VBD N
mild JJ N
. . N

GM-CSF NNP i
had VBD N
to TO N
be VB N
reduced VBN N
or CC N
suspended VBN N
in IN N
50 CD N
% NN N
of IN N
patients NNS N
because IN N
of IN N
toxicity NN o
. . o

Haematological JJ o
toxicity NN o
, , N
mainly RB N
cumulative JJ o
anaemia NN o
and CC o
thrombocytopenia NN o
, , N
was VBD N
manageable JJ N
. . N

An DT N
increase NN N
in IN N
response NN o
rate NN o
for IN N
patients NNS N
with IN N
measurable JJ o
disease NN o
, , N
of IN N
borderline JJ N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
0.088 CD N
, , N
P NNP N
for IN N
trend NN N
= NNP N
0.018 CD N
) ) N
, , N
from IN N
42 CD N
% NN N
in IN N
the DT N
CEF NNP i
group NN N
to TO N
69 CD N
% NN N
in IN N
the DT N
CEF NNP i
+ NNP i
GM-CSF NNP i
group NN N
, , N
was VBD N
observed VBN N
. . N

This DT N
randomised JJ N
trial NN N
indicates VBZ N
that IN N
GM-CSF NNP i
is VBZ N
useful JJ N
for IN N
chemotherapy NN N
acceleration NN N
. . N

Accelerated NNP N
CEF NNP i
+ NNP i
GM-CSF NNP i
is VBZ N
a DT N
moderately RB N
dose-intensive JJ N
regimen NNS N
that WDT N
can MD N
be VB N
administered VBN N
in IN N
an DT N
outpatient NN N
clinic NN N
and CC N
is VBZ N
associated VBN N
with IN N
a DT N
high JJ N
objective JJ N
response NN N
. . N

-DOCSTART- -X- O O

Herpesvirus-like JJ N
particles NNS N
in IN N
the DT N
skin NN N
of IN N
a DT N
saltwater NN p
crocodile NN p
( ( p
Crocodylus NNP p
porosus NN p
) ) p
. . p

-DOCSTART- -X- O O

Dexamethasone NN i
for IN N
the DT N
treatment NN N
of IN N
depression NN N
: : N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

OBJECTIVE CC N
The DT N
authors NNS N
' POS N
goal NN N
was VBD N
to TO N
assess VB N
dexamethasone NN i
for IN N
the DT N
treatment NN N
of IN N
depression NN N
. . N

METHOD NNP N
Thirty-seven JJ p
outpatients NNS p
( ( p
11 CD p
men NNS p
and CC p
26 CD p
women NNS p
) ) p
meeting VBG p
DSM-III-R JJ p
criteria NNS p
for IN p
major JJ p
depressive JJ p
disorder NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
placebo NN i
or CC i
4 CD i
mg/day NN i
of IN i
oral JJ i
dexamethasone NN i
for IN i
4 CD i
days NNS i
. . i

Baseline NNP N
Hamilton NNP o
depression NN o
scale NN o
scores NNS o
were VBD N
compared VBN N
with IN N
scores NNS N
obtained VBN N
14 CD N
days NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
study NN N
medication NN N
. . N

Data NNS N
were VBD N
analyzed VBN N
by IN N
using VBG N
two-sample JJ N
t NN N
tests NNS N
, , N
chi-square JJ N
methods NNS N
, , N
and CC N
Fisher NNP N
's POS N
exact JJ N
test NN N
. . N

RESULTS VB N
Seven NNP N
( ( N
37 CD N
% NN N
) ) N
of IN N
the DT N
19 CD N
patients NNS N
given VBN N
dexamethasone NN N
but CC N
only RB N
one CD N
( ( N
6 CD N
% NN N
) ) N
of IN N
the DT N
18 CD N
patients NNS N
given VBN N
placebo NNS N
responded VBD N
positively RB N
. . N

No UH N
adverse JJ o
events NNS o
or CC o
side NN o
effects NNS o
were VBD N
reported VBN N
, , N
and CC N
all DT N
patients NNS N
who WP N
entered VBD N
the DT N
study NN N
completed VBD N
it PRP N
. . N

CONCLUSIONS VB N
A DT N
brief JJ N
course NN N
of IN N
oral JJ N
dexamethasone NN i
( ( N
4 CD N
days NNS N
) ) N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
placebo NN i
within IN N
14 CD N
days NNS N
for IN N
the DT N
treatment NN N
of IN N
depression NN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
of IN N
depressed JJ N
outpatients NNS N
. . N

-DOCSTART- -X- O O

Children NNP p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

II NN N
: : N
parents NNS p
are VBP N
unable JJ N
to TO N
distinguish VB N
secretin NN N
from IN N
placebo NN N
under IN N
double-blind JJ N
conditions NNS N
. . N

BACKGROUND NNP N
Standardised VBD o
measures NNS o
of IN o
behaviour NNS o
have VBP N
failed VBN N
to TO N
detect VB N
short JJ o
term NN o
improvement NN o
in IN N
children NNS p
with IN p
autism NN p
following VBG N
treatment NN N
with IN N
secretin NN i
. . i

However RB N
, , N
it PRP N
is VBZ N
possible JJ N
that IN N
standardised JJ N
measures NNS N
are VBP N
insensitive JJ N
to TO N
dimensions NNS N
of IN N
child NN N
behaviour NN N
that WDT N
are VBP N
nonetheless RB N
detectable JJ N
by IN N
parents NNS N
. . N

AIM NNP N
To TO N
determine VB N
the DT N
ability NN o
of IN o
parents NNS o
of IN o
children NNS o
with IN o
autism NN o
to TO N
guess VB N
, , N
under IN N
double JJ N
blind NN N
conditions NNS N
, , N
whether IN N
their PRP$ N
child NN N
had VBD N
received VBN N
secretin NN i
or CC N
placebo NN i
. . i

METHODS NNP N
2x2 CD N
crossover NN N
randomised VBD N
blinded VBN N
study NN N
, , N
comparing VBG N
the DT N
effect NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
2 CD N
U/kg NNP N
to TO N
placebo VB i
( ( i
saline NN i
) ) i
. . i

Sixty CD p
two CD p
children NNS p
with IN p
autism NN p
( ( p
aged VBN p
43-103 CD p
months NNS p
) ) p
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
group NN N
1 CD N
received VBD N
placebo NN i
, , i
followed VBD i
six CD i
weeks NNS i
later RB i
by IN i
secretin NN i
, , N
and CC N
group NN N
2 CD N
received VBD N
secretin NN i
followed VBN i
by IN i
placebo NN i
. . i

At IN N
the DT N
conclusion NN N
of IN N
the DT N
study NN N
, , N
parents NNS p
were VBD N
asked VBN N
to TO N
guess VB N
their PRP$ N
child NN N
's POS N
group NN N
assignment NN N
. . N

RESULTS NNP N
Twenty NNP p
seven CD p
families NNS p
guessed VBD N
their PRP$ N
child NN N
's POS N
group NN N
assignment NN N
correctly RB N
and CC N
27 CD p
guessed VBN p
incorrectly RB p
. . p

In IN N
48 CD N
instances NNS N
, , N
parents NNS N
based VBN N
their PRP$ N
guess NN N
on IN N
perceived JJ N
improvement NN o
; : o
in IN N
six CD N
cases NNS N
, , N
parents NNS N
based VBN N
their PRP$ N
guess NN N
on IN N
perceived JJ N
deterioration NN o
. . o

Six NNP p
families NNS p
saw VBD N
no DT N
difference NN N
after IN N
either DT N
infusion NN N
, , N
and CC N
offered VBD N
no DT N
guess NN N
. . N

One CD N
family NN N
dropped VBD N
out RP N
after IN N
the DT N
first JJ N
infusion NN N
, , N
and CC N
one CD N
family NN N
was VBD N
lost VBN N
to TO N
follow VB N
up RP N
after IN N
the DT N
second JJ N
infusion NN N
. . N

CONCLUSION NNP N
In IN N
a DT N
controlled JJ N
setting NN N
, , N
parents NNS p
of IN p
young JJ p
children NNS p
with IN p
autism NN p
are VBP N
unable JJ N
to TO N
distinguish VB N
the DT N
short JJ o
term NN o
behavioural JJ o
effects NNS o
of IN N
secretin NN i
from IN N
placebo NN i
. . i

-DOCSTART- -X- O O

Treatment NN o
of IN o
human JJ o
tungiasis NN o
with IN N
niridazole JJ i
( ( i
Ambilhar NNP i
) ) i
a DT N
double-blind JJ N
placebo-controlled JJ N
trial NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
a DT N
specific JJ N
preparation NN N
of IN N
Chinese JJ i
herbs NNS i
( ( N
clear JJ N
the DT N
way NN N
) ) N
on IN N
duration NN o
and CC o
severity NN o
of IN o
the DT o
common JJ o
cold NN o
. . o

-DOCSTART- -X- O O

Penetration NN o
and CC o
accumulation NN o
of IN N
moxifloxacin NN i
in IN N
uterine JJ N
tissue NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
moxifloxacin NN i
penetrates VBZ N
the DT N
uterine JJ N
tissue NN N
and CC N
accumulates NNS N
at IN N
levels NNS N
sufficient JJ N
to TO N
eradicate VB o
the DT o
major JJ o
pathogens NNS o
causing VBG N
pelvic JJ p
inflammatory JJ p
disease NN p
( ( p
PID NNP p
) ) p
. . p

METHOD NNP N
In IN N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
open-label JJ N
, , N
parallel-group JJ N
study NN N
we PRP N
determined VBD N
the DT N
concentration NN N
of IN N
moxifloxacin NN N
in IN N
plasma NN N
and CC N
uterine JJ N
tissue NN N
after IN N
a DT N
single JJ N
, , N
400-mg JJ i
intravenous JJ i
dose NN i
of IN i
moxifloxacin NN i
. . i

Study NN N
participants NNS N
were VBD N
randomized VBN N
for IN N
time NN N
of IN N
tissue NN N
sampling NN N
, , N
which WDT N
was VBD N
performed VBN N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
7 CD N
, , N
or CC N
24 CD N
hours NNS N
following VBG N
the DT N
moxifloxacin JJ i
infusion NN N
. . N

RESULTS NNP N
Of IN N
43 CD p
participants NNS p
, , p
40 CD p
were VBD p
randomized VBN p
to TO p
tissue VB p
sampling VBG p
. . p

Moxifloxacin NNP o
accumulated VBD o
in IN o
uterine JJ o
tissue NN o
and CC o
concentrations NNS o
were VBD N
highest JJS N
1 CD N
hour NN N
after IN N
infusion NN N
in IN N
both DT N
plasma NN N
and CC N
tissue NN N
. . N

Tissue NN o
to TO o
plasma VB o
ratios NNS o
remained VBD N
between IN N
1.7 CD N
and CC N
2.1 CD N
for IN N
24 CD N
hours NNS N
. . N

Moxifloxacin NNP N
was VBD N
found VBN N
to TO N
be VB N
safe JJ o
and CC o
well RB o
tolerated VBN o
. . o

CONCLUSION NNP N
Based VBD N
on IN N
known VBN N
minimum JJ N
inhibitory JJ N
concentration NN N
data NNS N
, , N
the DT N
uterine JJ o
tissue NN o
concentrations NNS o
of IN N
moxifloxacin NN N
achieved VBN N
over IN N
24 CD N
hours NNS N
would MD N
be VB N
sufficient JJ N
to TO N
eradicate VB N
the DT N
range NN N
of IN N
bacterial JJ N
pathogens NNS N
responsible JJ N
for IN N
PID NNP p
. . p

-DOCSTART- -X- O O

Effects NNS N
of IN N
therapeutic JJ i
horse NN i
riding VBG i
on IN N
gait NN o
cycle NN o
parameters NNS o
and CC N
some DT N
aspects NNS o
of IN o
behavior NN o
of IN N
children NNS p
with IN p
autism NN p
. . p

We PRP N
studied VBD N
effects NNS N
of IN N
therapeutic JJ i
riding VBG i
on IN N
the DT N
development NN N
of IN N
children NNS p
with IN p
autism NN p
. . p

Experiments NNS N
in IN N
walking NN N
is VBZ N
appropriate JJ N
for IN N
assessing VBG N
the DT N
coordination NN N
of IN N
movement NN N
and CC N
for IN N
following VBG N
the DT N
changes NNS N
. . N

We PRP N
found VBD N
that IN N
therapeutic JJ i
riding NN i
should MD N
be VB N
considered VBN N
as IN N
a DT N
new JJ N
form NN N
of IN N
rehabilitation NN N
. . N

Twenty-six JJ p
pupils NNS p
( ( p
12 CD p
boys NNS p
and CC p
14 CD p
girls NNS p
) ) p
of IN p
a DT p
special JJ p
needs JJ p
school NN p
participated VBD p
in IN N
therapeutic JJ i
riding NN i
. . i

We PRP N
analyzed VBD N
walking VBG N
twice RB N
during IN N
a DT N
school-term JJ N
: : N
full JJ i
body NN i
analyses VBZ i
each DT N
time NN N
before IN N
and CC N
after IN N
one-month JJ i
therapy NN i
. . i

The DT N
research NN N
included VBD N
a DT N
non-riding JJ i
control NN i
group NN i
. . i

All DT N
together RB N
104 CD p
analyses NNS p
were VBD N
performed VBN N
. . N

We PRP N
measured VBD N
mental JJ N
skills NNS N
using VBG N
Pedagogical JJ o
Analysis NN o
and CC o
Curriculum NNP o
( ( o
PAC NNP o
) ) o
test NN o
consisting VBG N
of IN N
four CD N
parts NNS N
being VBG N
communication NN o
, , o
self PRP o
care NN o
, , o
motor NN o
skills NNS o
and CC N
socialization NN o
. . o

The DT N
Gait NNP N
Cycle NNP N
Analysis NNP N
consists VBZ N
of IN N
the DT N
time-series NNS N
analysis NN N
, , N
the DT N
analysis NN N
of IN N
part NN N
of IN N
the DT N
gait NN N
cycle NN N
and CC N
the DT N
measurement NN N
of IN N
joint JJ N
angles NNS N
in IN N
each DT N
plane NN N
. . N

We PRP N
found VBD N
significant JJ N
differences NNS N
between IN N
before IN N
and CC N
after IN N
the DT N
therapy NN N
in IN N
the DT N
length NN o
of IN o
the DT o
gait NN o
cycle NN o
that WDT N
became VBD N
more RBR N
stable JJ N
in IN N
the DT N
sagital JJ N
plane NN N
and CC N
concluded VBD N
that IN N
our PRP$ N
results NNS N
proved VBD N
that IN N
horse NN N
therapy NN N
may MD N
be VB N
successfully RB N
used VBN N
as IN N
an DT N
additional JJ N
therapy NN N
for IN N
children NNS p
with IN p
autism NN p
, , N
and CC N
it PRP N
may MD N
be VB N
a DT N
form NN N
of IN N
rehabilitation NN N
in IN N
cases NNS N
when WRB N
other JJ N
therapies NNS N
are VBP N
not RB N
successful JJ N
. . N

-DOCSTART- -X- O O

A DT N
randomised JJ N
trial NN N
of IN N
radiotherapy NN i
compared VBN N
with IN N
cisplatin JJ i
chemo-radiotherapy NN i
in IN N
patients NNS p
with IN p
unresectable JJ p
squamous JJ p
cell NN p
cancer NN p
of IN p
the DT p
esophagus NN p
. . p

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Following NNP N
our PRP$ N
phase NN N
II NNP N
experience NN N
, , N
a DT N
randomised JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
adding VBG i
chemotherapy NN i
to TO i
radiotherapy VB i
in IN i
patients NNS p
with IN p
unresectable JJ p
squamous JJ p
cell NN p
cancer NN p
of IN p
the DT p
esophagus NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNS N
randomised VBD N
to TO N
the DT N
RT NNP i
group NN i
received VBD i
50 CD i
Gy/25 NNP i
fx/5 JJ i
weeks NNS i
of IN i
teletherapy NN i
followed VBD i
1-2 JJ i
weeks NNS i
later RB i
with IN i
12 CD i
Gy/2 NNP i
fx NN i
of IN i
high-dose-rate JJ i
intra-lumenal JJ i
brachytherapy NN i
spaced VBD i
a DT i
week NN i
apart RB i
. . i

Following VBG N
the DT N
first JJ N
3 CD N
years NNS N
of IN N
recruitment NN N
, , N
due JJ N
to TO N
unexpected JJ N
late JJ N
morbidity NN N
, , N
brachytherapy NN i
was VBD N
excluded VBN N
and CC N
the DT N
protocol NN N
modified VBD N
to TO N
66 CD N
Gy/33 NNP N
fx/6.5 JJ N
weeks NNS N
. . N

The DT N
CRT NNP N
group NN N
received VBD i
identical JJ i
radiotherapy NN i
with IN i
concurrent JJ i
weekly JJ i
cisplatin NN i
at IN i
35 CD i
mg/m NN i
( ( i
2 CD i
) ) i
for IN i
6-7 JJ i
cycles NNS i
. . i

RESULTS NNP N
Between NNP p
April NNP p
1999 CD p
and CC p
December NNP p
2005 CD p
, , p
125 CD p
patients NNS p
were VBD p
randomised VBN p
to TO N
a DT N
RT NNP N
( ( N
n=60 NN N
) ) N
or CC N
CRT NNP N
group NN N
( ( N
n=65 RB N
) ) N
. . N

Radiotherapy NNP N
treatment NN N
was VBD N
completed VBN N
in IN N
78 CD N
% NN N
( ( N
47/60 CD N
) ) N
of IN N
the DT N
RT NNP N
group NN N
and CC N
89 CD N
% NN N
( ( N
58/65 CD N
) ) N
of IN N
the DT N
CRT NNP N
group NN N
( ( N
P=0.10 NNP N
) ) N
. . N

Six CD N
or CC N
more JJR N
cycles NNS N
of IN N
cisplatin NN N
could MD N
be VB N
delivered VBN N
in IN N
63 CD N
% NN N
( ( N
41/65 CD N
) ) N
, , N
which WDT N
resulted VBD N
in IN N
RTOG NNP o
grade VBD o
3 CD o
neutropenia NN o
of IN N
3 CD N
% NN N
. . N

Late JJ o
morbidity NN o
in IN o
the DT o
form NN o
of IN o
ulcers NNS o
( ( N
5 CD N
% NN N
vs. FW N
15 CD N
% NN N
odds NNS N
ratio VBP N
0.29 CD N
, , N
95 CD N
% NN N
CI NNP N
0.08-1.11 CD N
, , N
P=0.08 NNP N
) ) N
and CC N
strictures NNS o
( ( N
13 CD N
% NN N
vs. FW N
28 CD N
% NN N
, , N
odds NNS N
ratio VBP N
0.40 CD N
, , N
95 CD N
% NN N
CI NNP N
0.16-1.01 CD N
, , N
P=0.05 NNP N
) ) N
was VBD N
observed VBN N
in IN N
the DT N
RT NNP N
and CC N
CRT NNP N
groups NNS N
, , N
respectively RB N
. . N

At IN N
a DT N
median NN N
follow VBP N
up IN N
of IN N
23 CD N
months NNS N
of IN N
all DT N
patients NNS N
alive JJ N
( ( N
range JJ N
6-82 JJ N
months NNS N
) ) N
and CC N
with IN N
95/125 CD N
events NNS N
, , N
the DT N
median NN N
, , N
1 CD N
, , N
2 CD N
and CC N
5 CD N
year NN N
projected VBD N
survival NN o
was VBD N
7.1 CD N
months NNS N
, , N
32.3 CD N
% NN N
, , N
22.8 CD N
% NN N
and CC N
13.7 CD N
% NN N
vs. FW N
13.4 CD N
months NNS N
, , N
57.6 CD N
% NN N
, , N
38.9 CD N
% NN N
and CC N
24.8 CD N
% NN N
for IN N
the DT N
RT NNP N
and CC N
CRT NNP N
groups NNS N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
0.65 CD N
, , N
95 CD N
% NN N
CI NNP N
0.44-0.98 CD N
, , N
P=0.038 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
concurrent NN N
cisplatin NN i
to TO N
radiotherapy VB i
resulted VBN N
in IN N
a DT N
modest JJ o
improvement NN o
in IN o
survival NN o
and CC N
was VBD N
associated VBN N
with IN N
manageable JJ o
additional JJ o
acute NN o
and CC o
late JJ o
morbidity NN o
. . o

-DOCSTART- -X- O O

Intra-operative JJ N
antibiotic JJ i
prophylaxis NN N
in IN N
neurosurgery NN p
. . p

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
on IN N
cefotiam NN i
. . i

In IN N
this DT N
prospective JJ N
, , N
randomized VBN N
and CC N
controlled VBN N
study VB N
the DT N
effect NN N
of IN N
cefotiam NN i
for IN N
the DT N
prevention NN N
of IN N
wound JJ N
infections NNS N
following VBG N
trepanations NNS p
was VBD N
investigated VBN N
. . N

The DT N
main JJ N
interest NN N
was VBD N
centered VBN N
on IN N
the DT N
rate NN N
of IN N
post-operative JJ N
bone NN N
flap NN N
infections NNS N
requiring VBG N
operative JJ N
revision NN N
. . N

Administration NNP N
of IN N
cefotiam NN i
was VBD N
randomized VBN N
for IN N
patients NNS p
undergoing VBG p
major JJ p
craniotomies NNS p
. . p

The DT N
antibiotic NN i
was VBD N
administered VBN N
intravenously RB N
in IN N
a DT N
single JJ N
dose NN N
of IN N
2 CD N
g NN N
with IN N
induction NN N
of IN N
anaesthesia NN i
. . i

Only JJ p
clean JJ p
or CC p
clean JJ p
contaminated VBN p
cases NNS p
were VBD p
included VBN p
. . p

Excluded VBN p
were VBD p
contaminated VBN p
cases NNS p
, , p
operations NNS p
with IN p
a DT p
transnasal-transsphenoidal JJ p
approach NN p
, , p
shunt-operations NNS p
and CC p
patients NNS p
with IN p
any DT p
other JJ p
preoperative JJ p
infection NN p
or CC p
antibiotic JJ i
therapy NN i
. . i

Outpatients NNS p
were VBD p
excluded VBN p
due JJ p
to TO p
difficulties NNS p
in IN p
obtaining VBG p
sufficient JJ p
clinical JJ p
information NN p
. . p

From NNP p
originally RB p
918 CD p
consecutive JJ p
patients NNS p
operated VBN p
on IN p
711 CD p
fulfilled VBD p
the DT p
entry NN p
criteria NNS p
. . p

With IN p
regard NN p
to TO p
age NN p
, , p
sex NN p
, , p
diagnosis NN p
and CC p
the DT p
site NN p
of IN p
te JJ p
trepanation NN p
, , p
control NN i
patients NNS i
( ( p
n JJ p
= NNP p
355 CD p
) ) p
and CC p
cefotiam $ p
treated VBN p
patients NNS p
( ( p
n JJ p
= NNP p
356 CD p
) ) p
were VBD p
shown VBN p
to TO p
be VB p
comparable JJ p
. . p

In IN N
the DT N
various JJ N
subgroups NNS N
formed VBN N
for IN N
different JJ p
primary JJ p
diagnoses NNS p
, , p
concomitant JJ i
steroidal NN i
therapy NN i
and CC N
concomitant NN p
severe JJ p
internal JJ p
medical JJ p
diseases NNS p
cefotiam VBP N
treated VBN N
patients NNS N
and CC N
controls NNS N
were VBD N
comparable JJ N
as RB N
well RB N
. . N

A DT N
highly RB N
significant JJ N
difference NN N
for IN N
bone NN o
flap NN o
infection NN o
could MD N
be VB N
shown VBN N
with IN N
0.3 CD N
% NN N
in IN N
the DT N
cefotiam NN N
group NN N
versus VBD N
5.1 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
overall JJ o
rate NN o
of IN o
post-operative JJ o
deep JJ o
wound NN o
infections NNS o
including VBG o
meningitis NN o
and CC o
abscesses NNS o
was VBD N
also RB N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
different JJ o
with IN N
3.1 CD N
% NN N
in IN N
the DT N
cefotiam NN i
versus IN N
9.0 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
. . N

Thus VB N
it PRP N
was VBD N
concluded VBN N
that IN N
a DT N
single JJ N
dose NN N
of IN N
cefotiam NN N
significantly RB N
reduces VBZ N
post-operative JJ o
deep JJ o
wound NN o
infection NN o
. . o

-DOCSTART- -X- O O

Principal JJ N
findings NNS N
from IN N
a DT N
multicenter NN p
trial NN p
investigating VBG N
the DT N
safety NN N
of IN N
follicular-fluid JJ i
meiosis-activating JJ i
sterol NN i
for IN N
in IN N
vitro JJ N
maturation NN N
of IN N
human JJ N
cumulus-enclosed JJ N
oocytes NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
safety NN N
of IN N
applying VBG N
follicular-fluid JJ i
meiosis-activating JJ i
sterol NN i
( ( i
FF-MAS NNP i
) ) i
in IN N
vitro NN N
to TO N
immature VB N
human JJ N
oocytes NNS N
. . N

DESIGN NNP N
Phase NNP N
I PRP N
bicenter VBP N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
controlled VBN N
, , N
partially RB N
blinded VBN N
trial NN N
. . N

SETTING CC N
Third-level JJ p
referral JJ p
academic JJ p
centers NNS p
, , N
including VBG N
reproductive JJ N
biology NN N
and CC N
genetics NNS N
laboratories NNS N
. . N

PATIENTS NNP N
Endocrinologically NNP p
normal JJ p
women NNS p
with IN p
a DT p
medical JJ p
indication NN p
for IN p
IVF NNP p
or CC p
intracytoplasmic JJ p
sperm JJ p
injection NN p
, , p
or CC p
healthy JJ p
volunteers NNS p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Subjects NNPS N
were VBD N
randomized VBN N
at IN N
a DT N
ratio NN N
1 CD N
to TO N
6 CD N
into IN N
either DT i
conventional JJ i
GnRH-agonist JJ i
and CC i
recombinant JJ i
FSH NNP i
stimulation NN i
( ( i
IVO NNP i
) ) i
for IN i
oocyte NN i
retrieval NN i
, , i
or CC i
minimally RB i
stimulated VBN i
in IN i
vitro JJ i
maturation NN i
( ( i
IVM NNP i
) ) i
with IN i
the DT i
use NN i
of IN i
recombinant JJ i
FSH NNP i
. . i

Retrieved VBN N
immature NN N
oocyte NN N
cumulus NN N
complexes NNS N
were VBD N
cultured VBN N
for IN N
30 CD N
or CC N
36 CD N
hours NNS N
in IN N
one CD N
of IN N
six CD N
IVM NNP i
culture NN i
conditions NNS i
containing VBG i
FF-MAS NNP i
( ( N
range NN N
, , N
0.1-20 JJ N
microM NN N
) ) N
. . N

Polar JJ N
body-extruded JJ N
oocytes NNS N
from IN N
the DT N
IVO NNP N
and CC N
IVM NNP N
groups NNS N
were VBD N
processed VBN N
for IN N
chromosomal JJ N
analysis NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
incidence NN o
of IN o
metaphase NN o
II NNP o
stage NN o
oocytes NNS o
with IN o
numeric JJ o
chromosomal JJ o
abnormalities NNS o
, , N
using VBG N
full JJ N
( ( N
spectral JJ N
karyotyping NN N
) ) N
or CC N
partial JJ N
( ( N
fluorescent JJ N
in IN N
situ JJ N
hybridization NN N
with IN N
seven CD N
probes NNS N
) ) N
karyotyping VBG N
or CC N
Giemsa NNP N
count NN N
. . N

A DT N
secondary JJ N
objective NN N
was VBD N
to TO N
document VB N
the DT N
frequency NN o
of IN o
metaphase NN o
II NNP o
oocytes VBZ o
after IN N
IVM NNP N
with IN N
FF-MAS NNP N
supplements NNS N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Oocyte NNP N
cumulus NN N
complexes NNS N
obtained VBN N
from IN N
the DT N
IVO NNP N
( ( N
mean NN N
, , N
8.9 CD N
) ) N
and CC N
IVM NNP N
( ( N
mean NN N
, , N
6.2 CD N
) ) N
groups NNS N
had VBD N
equal JJ o
maturation NN o
rates NNS o
. . o

Compared VBN N
to TO N
IVO NNP N
, , N
exposure NN N
of IN N
germinal-vesicle NN N
oocytes NNS N
for IN N
a DT N
maturation NN N
period NN N
of IN N
30 CD N
hours NNS N
did VBD N
not RB N
increase VB N
aneuploidy NN o
. . o

An DT N
exposure JJ N
period NN N
of IN N
36 CD N
hours NNS N
doubled VBD N
the DT N
aneuploidy NN o
rate NN o
, , N
but CC N
this DT N
was VBD N
significant JJ N
only RB N
for IN N
the DT N
20-muM JJ N
dose NN N
of IN N
FF-MAS NNP i
. . i

CONCLUSION NNP N
Inclusion NNP N
of IN N
1-10 JJ N
microM JJ i
FF-MAS NNP i
in IN N
a DT N
30-hour JJ N
IVM NNP N
protocol NN N
is VBZ N
safe JJ N
. . N

-DOCSTART- -X- O O

Transdermal NNP i
nitroglycerin NN i
in IN N
angina JJ p
pectoris NN p
: : p
efficacy NN N
of IN N
intermittent JJ N
application NN N
. . N

Continuous JJ N
application NN N
of IN N
transdermal JJ i
nitroglycerin JJ i
appears VBZ N
to TO N
result VB N
in IN N
tolerance NN o
to TO o
the DT o
antianginal JJ o
effect NN o
. . o

In IN N
a DT N
double-blind NN N
study NN N
the DT N
effects NNS N
of IN N
continuous JJ N
( ( N
24 CD N
h/day NN N
) ) N
and CC N
intermittent NN N
( ( N
16 CD N
h/day NN N
) ) N
application NN N
of IN N
transdermal JJ i
nitroglycerin NN i
in IN i
a DT N
dosage NN N
of IN N
10 CD N
mg/day NN N
were VBD N
compared VBN N
with IN N
the DT N
effects NNS N
of IN N
placebo NN i
in IN N
12 CD p
patients NNS p
with IN p
chronic JJ p
stable JJ p
angina NN p
receiving VBG p
treatment NN p
with IN p
beta-adrenergic JJ i
blocking NN i
or CC i
calcium NN i
channel NNS i
blocking VBG i
agents NNS i
. . i

Exercise NN o
performance NN o
was VBD N
assessed VBN N
2 CD N
to TO N
4 CD N
hours NNS N
after IN N
initial JJ N
application NN N
and CC N
after IN N
1 CD N
week NN N
of IN N
each DT N
treatment NN N
given VBN N
in IN N
random JJ N
order NN N
with IN N
a DT N
3 CD N
day NN N
interval NN N
between IN N
treatments NNS N
. . N

Exercise NN o
time NN o
to TO o
onset VB o
of IN o
angina NN o
, , o
total JJ o
exercise NN o
duration NN o
and CC o
time NN o
to TO o
1 CD o
mm NNS o
ST NNP o
segment NN o
depression NN o
were VBD N
all DT N
significantly RB N
increased VBN N
after IN N
initial JJ N
application NN N
during IN N
the DT N
continuous JJ N
and CC N
intermittent JJ N
treatment NN N
periods NNS N
. . N

These DT N
increases NNS N
were VBD N
maintained VBN N
after IN N
1 CD N
week NN N
of IN N
intermittent NN N
but CC N
not RB N
continuous JJ N
treatment NN N
. . N

Thus VB N
the DT N
benefit NN N
of IN N
initial JJ N
application NN N
of IN N
transdermal JJ i
nitroglycerin NN i
is VBZ N
maintained VBN N
with IN N
intermittent JJ N
treatment NN N
and CC N
a DT N
daily JJ N
nitrate-free JJ N
interval NN N
, , N
whereas JJ N
tolerance NN o
to TO o
antianginal JJ o
effect NN o
occurs VBZ N
with IN N
continuous JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Body NN N
size NN N
indexes NNS N
for IN N
optimizing VBG N
iodine NN i
dose NN N
for IN N
aortic JJ p
and CC p
hepatic JJ p
enhancement NN p
at IN p
multidetector NN p
CT NNP p
: : p
comparison NN N
of IN N
total JJ N
body NN N
weight NN N
, , N
lean JJ N
body NN N
weight NN N
, , N
and CC N
blood NN N
volume NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
and CC N
compare VB N
total JJ o
body NN o
weight NN o
( ( o
TBW NNP o
) ) o
, , o
lean JJ o
body NN o
weight NN o
( ( o
LBW NNP o
) ) o
, , o
and CC o
estimated VBD o
blood NN o
volume NN o
( ( o
BV NNP o
) ) o
for IN N
the DT N
adjustment NN N
of IN N
the DT N
iodine NN i
dose NN i
required VBN N
for IN N
contrast NN N
material-enhanced JJ N
multidetector NN N
computed VBD N
tomography NN N
( ( N
CT NNP N
) ) N
of IN N
the DT N
aorta NN N
and CC N
liver NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Institutional NNP N
review NN N
committee NN N
approval NN N
and CC N
written VBN N
informed JJ N
consent NN N
were VBD N
obtained VBN N
. . N

One CD p
hundred VBD p
twenty NN p
patients NNS p
( ( p
54 CD p
men NNS p
, , p
66 CD p
women NNS p
; : p
mean JJ p
age NN p
, , p
64.1 CD p
years NNS p
; : p
range NN p
, , p
19-88 CD p
years NNS p
) ) p
who WP p
underwent JJ p
multidetector NN i
CT NNP i
of IN p
the DT p
upper JJ p
abdomen NNS p
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
of IN N
40 CD N
patients NNS N
each DT N
: : N
( ( N
a DT N
) ) N
TBW NNP N
group NN N
( ( N
0.6 CD N
g NN N
of IN N
iodine NN i
per IN N
kilogram NN N
of IN N
TBW NNP N
) ) N
, , N
( ( N
b NN N
) ) N
LBW NNP N
group NN N
( ( N
0.821 CD N
g NN N
of IN N
iodine NN i
per IN N
kilogram NN N
of IN N
LBW NNP N
) ) N
, , N
and CC N
( ( N
c NN N
) ) N
BV NNP N
group NN N
( ( N
men NNS N
, , N
8.6 CD N
g NN N
of IN N
iodine NN i
per IN N
liter NN N
of IN N
BV NNP N
; : N
women NNS N
, , N
9.9 CD N
g NN N
of IN N
iodine NN N
per IN N
liter NN N
of IN N
BV NNP N
) ) N
. . N

Change NN N
in IN N
CT NNP N
number NN N
between IN N
unenhanced JJ N
and CC N
contrast-enhanced JJ N
images NNS N
per IN N
gram NN N
of IN N
iodine NN N
and CC N
maximum JJ N
hepatic JJ N
enhancement NN N
( ( N
MHE NNP N
) ) N
adjusted VBD N
for IN N
iodine NN i
dose NN N
were VBD N
examined VBN N
for IN N
correlation NN N
with IN N
TBW NNP N
, , N
LBW NNP N
, , N
and CC N
BV NNP N
by IN N
using VBG N
linear JJ N
regression NN N
analysis NN N
. . N

RESULTS NNP N
In IN N
the DT N
portal JJ N
venous JJ N
phase NN N
, , N
correlation NN o
coefficients NNS o
for IN N
the DT N
correlation NN o
of IN o
change NN o
in IN o
CT NNP o
number NN o
per IN o
gram NN o
of IN N
iodine NN i
with IN N
TBW NNP o
for IN N
the DT N
aorta NN N
and CC N
liver NN N
were VBD N
-0.71 NNP N
and CC N
-0.79 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
TBW NNP N
group NN N
; : N
-0.80 CC N
and CC N
-0.86 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
LBW NNP N
group NN N
; : N
and CC N
-0.68 VB N
and CC N
-0.66 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
BV NNP N
group NN N
. . N

In IN N
the DT N
liver NN N
, , N
they PRP N
were VBD N
marginally RB N
higher JJR N
in IN N
the DT N
LBW NNP N
group NN N
than IN N
in IN N
the DT N
BV NNP N
group NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Adjusted VBN o
MHE NNP o
remained VBD N
constant JJ N
at IN N
77.9 CD N
HU NNP N
+/- JJ N
10.2 CD N
( ( N
standard JJ N
deviation NN N
) ) N
in IN N
the DT N
LBW NNP o
group NN N
with IN N
respect NN N
to TO N
TBW NNP o
, , N
but CC N
it PRP N
increased VBD N
in IN N
the DT N
TBW NNP o
( ( N
r VB N
= RB N
0.80 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
BV NNP o
( ( N
r VB N
= RB N
0.70 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
groups NNS N
as IN N
TBW NNP o
increased VBD N
. . N

CONCLUSION NN N
When WRB o
LBW NNP o
, , o
rather RB o
than IN o
TBW NNP o
or CC o
BV NNP o
, , o
is VBZ o
used VBN o
, , N
the DT N
iodine NN i
dose NN N
required VBN N
to TO N
achieve VB N
consistent JJ N
hepatic JJ N
enhancement NN N
may MD N
be VB N
estimated VBN N
more RBR N
precisely RB N
and CC N
with IN N
reduced JJ N
patient-to-patient JJ N
variability NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN o
of IN N
posture NN i
on IN N
Cheyne-Stokes NNP N
respirations NNS N
and CC N
hemodynamics NNS N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
. . p

STUDY NNP N
OBJECTIVES NNP N
Cheyne-Stokes NNP N
respirations NNS N
occur VBP N
in IN N
40 CD N
% NN N
of IN N
patients NNS p
with IN p
heart NN p
failure NN p
. . p

Orthopnea NNP N
is VBZ N
a DT N
cardinal JJ N
symptom NN N
of IN N
heart NN N
failure NN N
and CC N
may MD N
affect VB N
the DT N
patient NN N
's POS N
sleeping VBG N
angle NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB o
the DT o
respiratory NN o
and CC o
hemodynamic JJ o
response NN o
to TO N
sleeping VBG i
angle NN i
in IN N
a DT N
group NN p
of IN p
subjects NNS p
with IN p
stable JJ p
heart NN p
failure NN p
. . p

DESIGN NNP N
Twenty-five JJ p
patients NNS p
underwent JJ N
overnight JJ N
polysomnography NN N
with IN N
simultaneous JJ N
and CC N
continuous JJ N
impedance NN N
cardiographic JJ N
monitoring NN N
. . N

Sleeping VBG o
polysomnographic JJ o
and CC o
impedance JJ o
cardiographic JJ o
data NNS o
were VBD N
recorded VBN N
. . N

SETTING VBG N
The DT N
study NN N
was VBD N
conducted VBN N
in IN N
a DT N
sleep JJ N
center NN N
. . N

PATIENTS VB N
All DT p
25 CD p
patients NNS p
had VBD p
clinically RB p
stable JJ p
heart NN p
failure NN p
and CC p
left VBD p
ventricular JJ p
ejection NN p
fractions NNS p
< VBP p
40 CD p
% NN p
. . p

INTERVENTIONS NNP N
The DT N
patients NNS N
slept VBD i
at IN i
0 CD i
degrees NNS i
, , i
15 CD i
degrees NNS i
, , i
30 CD i
degrees NNS i
, , i
and CC i
45 CD i
degrees NNS i
in IN i
random JJ i
order NN i
. . i

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
Seventeen NNP N
patients NNS N
had VBD N
Cheyne-Stokes NNP o
apneas NNS o
( ( N
index NN N
> RB N
5/h CD N
) ) N
and CC N
23 CD N
patients NNS N
had VBD N
hypopneas NNS o
( ( N
index NN N
> RB N
5/h CD N
) ) N
. . N

The DT N
hypopnea NN o
index NN o
showed VBD N
no DT N
response NN N
to TO N
sleeping VBG N
angle NN N
. . N

The DT N
Cheyne-Stokes NNP o
apnea NN o
index NN o
decreased VBD N
with IN N
increasing VBG N
sleeping VBG N
angle NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

This DT N
effect NN N
was VBD N
seen VBN N
only RB N
during IN N
supine JJ N
sleep NN N
and CC N
non-rapid JJ N
eye NN N
movement NN N
sleep NN N
and CC N
was VBD N
absent VBN N
in IN N
non-supine JJ N
sleep NN N
, , N
rapid JJ N
eye NN N
movement NN N
sleep NN N
, , N
and CC N
during IN N
periods NNS N
of IN N
wakefulness NN N
. . N

Thoracic NNP o
fluid NN o
content NN o
index NN o
and CC o
left VBD o
ventricular JJ o
hemodynamics NNS o
measured VBN N
by IN N
impedance NN N
cardiography NN N
showed VBD N
no DT N
response NN N
to TO N
sleeping VBG N
angle NN N
. . N

CONCLUSIONS NNP N
Changing VBG N
the DT N
heart NN N
failure NN N
patient NN N
's POS N
sleeping VBG N
angle NN N
from IN N
0 CD N
degrees NNS N
to TO N
45 CD N
degrees NNS N
results NNS N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
Cheyne-Stokes NNP N
apneas NN N
. . N

This DT N
decrease NN N
occurs VBZ N
on IN N
a DT N
constant JJ N
base NN N
of IN N
hypopneas NNS N
. . N

The DT N
changes NNS N
in IN N
Cheyne-Stokes NNP N
apneas NNS N
are VBP N
not RB N
related VBN N
to TO N
changes NNS N
in IN N
lung NN N
congestion NN N
and CC N
left VBD N
ventricular JJ N
hemodynamics NNS N
. . N

-DOCSTART- -X- O O

Abstinence NN i
or CC i
controlled VBN i
drinking NN i
in IN N
clinical JJ N
practice NN N
: : N
indications NNS N
at IN N
initial JJ N
assessment NN N
. . N

Previous JJ N
research NN N
has VBZ N
suggested VBN N
two CD N
leading JJ N
hypotheses NNS N
concerning VBG N
which WDT N
excessive JJ p
drinkers NNS p
can MD N
re-establish VB N
control NN N
: : N
one CD N
based VBN N
upon IN N
level NN N
of IN N
dependence NN N
, , N
the DT N
other JJ N
upon IN N
the DT N
client NN N
's POS N
personal JJ N
persuasion NN N
. . N

Using VBG N
initial JJ N
assessment NN N
data NNS N
from IN N
46 CD p
clients NNS p
of IN p
a DT p
clinical JJ p
psychology NN p
alcohol NN p
problems NNS p
service NN p
( ( p
30 CD p
men NNS p
, , p
16 CD p
women NNS p
) ) p
, , N
an DT N
attempt NN N
was VBD N
made VBN N
to TO N
operationalize VB N
the DT N
concepts NNS N
of IN N
dependence NN i
and CC N
personal JJ i
persuasion NN i
using VBG N
a DT N
variety NN N
of IN N
indicators NNS N
of IN N
each DT N
. . N

Although IN N
SADQ NNP o
scores NNS o
and CC o
Rand NNP o
definite VBP o
alcoholism NN o
were VBD N
in IN N
general JJ N
agreement NN N
, , N
there EX N
were VBD N
a DT N
number NN N
of IN N
borderline JJ N
instances NNS N
and CC N
cases NNS N
of IN N
disagreement NN N
, , N
and CC N
neither DT N
was VBD N
in IN N
good JJ N
agreement NN N
with IN N
estimates NNS N
of IN N
problem NN N
duration NN N
, , N
nor CC N
with IN N
reports NNS N
of IN N
recent JJ N
or CC N
earlier RBR N
attainment NN N
of IN N
abstinence NN i
or CC N
control NN i
. . i

Indicators NNS N
of IN N
personal JJ o
persuasion NN o
were VBD N
more RBR N
consistent JJ N
. . N

Those DT p
with IN p
dependence NN i
indicators NNS o
for IN o
abstinence NN o
tended VBD N
to TO N
prefer VB N
abstinence NN i
as IN N
a DT N
goal NN N
, , N
but CC N
there EX N
were VBD N
many JJ N
departures NNS N
from IN N
this DT N
pattern NN N
particularly RB N
for IN N
women NNS N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
in IN N
clinical JJ N
practice NN N
it PRP N
will MD N
be VB N
very RB N
difficult JJ N
to TO N
make VB N
a DT N
clear JJ N
cut NN N
recommendation NN N
about IN N
treatment NN N
goal NN N
at IN N
initial JJ N
assessment NN N
except IN N
in IN N
a DT N
few JJ N
cases NNS N
. . N

-DOCSTART- -X- O O

The DT N
therapeutic JJ o
efficacy NN o
and CC o
cost-effectiveness NN o
of IN N
aggressive JJ N
tocolysis NN N
for IN N
premature JJ p
labor NN p
associated VBN p
with IN p
premature JJ p
rupture NN p
of IN p
the DT p
membranes NNS p
. . p

We PRP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
comparing VBG N
bed VBD i
rest NN i
with IN i
tocolysis NN i
to TO N
determine VB N
the DT N
therapeutic JJ o
efficacy NN o
, , o
safety NN o
, , o
and CC o
cost-effectiveness NN o
of IN N
tocolysis NN i
for IN N
the DT N
treatment NN N
of IN N
preterm JJ p
labor NN p
after IN p
membrane JJ p
rupture NN p
. . p

One CD p
hundred VBD p
nine CD p
women NNS p
participated VBD p
over IN p
a DT p
26-month JJ p
interval NN p
. . p

Treatment NNP N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
terms NNS N
of IN N
gestational JJ o
age NN o
at IN o
membrane NN o
rupture NN o
, , o
gestational JJ o
age NN o
at IN o
delivery NN o
, , o
birth NN o
weight NN o
, , o
maternal JJ o
or CC o
fetal JJ o
infectious JJ o
morbidity NN o
, , o
respiratory JJ o
distress NN o
syndrome NN o
, , o
necrotizing VBG o
enterocolitis NN o
, , o
or CC o
perinatal JJ o
mortality NN o
. . o

Prolongation NN N
of IN N
intrauterine JJ N
time NN N
after IN N
the DT N
onset NN N
of IN N
uterine JJ N
contractions NNS N
was VBD N
seen VBN N
in IN N
women NNS N
receiving VBG N
tocolysis NN i
( ( N
105.2 CD N
+/- JJ N
157 CD N
hours NNS N
versus JJ N
62.1 CD N
+/- JJ N
77 CD N
hours NNS N
, , N
p VBP N
= RB N
0.06 CD N
) ) N
. . N

This DT N
prolongation NN N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
total JJ o
cost NN o
per IN N
surviving VBG N
infant NN N
( ( N
tocolysis NN N
, , N
$ $ N
38,593 CD N
+/- JJ N
$ $ N
40,887 CD N
versus NN N
bed NN N
rest NN N
, , N
$ $ N
43,158 CD N
+/- JJ N
$ $ N
37,116 CD N
; : N
p NN N
= VBZ N
0.445 CD N
) ) N
. . N

The DT N
cost NN o
difference NN o
was VBD N
artifactual JJ N
. . N

The DT N
number NN N
of IN N
very RB o
premature JJ o
infants NNS o
born VBN o
( ( N
less JJR N
than IN N
28 CD N
weeks NNS N
' POS N
gestation NN N
) ) N
was VBD N
unequal JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
12 CD N
in IN N
the DT N
bed NN N
rest NN N
group NN N
and CC N
5 CD N
in IN N
the DT N
tocolysis NN N
group NN N
) ) N
and CC N
skewed VBD N
the DT N
results NNS N
. . N

Before IN N
28 CD N
weeks NNS N
' POS N
gestation NN N
tocolysis NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN o
in IN o
intrauterine JJ o
time NN o
after IN N
the DT N
onset NN N
of IN N
regular JJ o
contractions NNS o
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
identifiable JJ N
perinatal JJ N
benefit NN N
garnered VBD N
from IN N
the DT N
additional JJ N
5 CD N
days NNS N
. . N

After IN N
28 CD N
weeks NNS N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
in IN N
terms NNS N
of IN N
intrauterine NN o
time NN o
after IN N
the DT N
onset NN N
of IN N
regular JJ o
contractions NNS o
and CC N
total JJ o
cost NN o
per IN N
surviving VBG N
infant NN N
. . N

Because IN N
tocolysis NN i
does VBZ N
not RB N
improve VB N
perinatal JJ N
outcome NN N
and CC N
can MD N
itself PRP N
be VB N
associated VBN N
with IN N
major JJ N
maternal JJ N
morbidity NN N
, , N
it PRP N
should MD N
be VB N
avoided VBN N
after IN N
28 CD N
weeks NNS N
' POS N
gestation NN N
. . N

Before IN N
28 CD N
weeks NNS N
' POS N
gestation NN N
tocolysis NN i
may MD N
greatly RB N
increase VB N
intrauterine JJ N
time NN N
, , N
but CC N
the DT N
benefit NN N
of IN N
this DT N
prolongation NN N
is VBZ N
not RB N
clear JJ N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
stable JJ p
angina NN p
of IN p
effort NN p
with IN N
verapamil NN i
: : i
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
randomized VBN N
crossover NN N
study NN N
. . N

The DT N
effects NNS N
of IN N
verapamil NN i
were VBD N
assessed VBN N
in IN N
26 CD p
patients NNS p
with IN p
stable JJ p
exertional JJ p
angina NN p
pectoris NN p
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized VBN N
crossover NN N
protocol NN N
using VBG N
serial JJ N
treadmill NN N
tests NNS N
. . N

Verapamil NNP i
, , N
480 CD N
mg/day NN N
, , N
reduced VBD N
anginal JJ o
frequency NN o
from IN N
5.6 CD N
+/- JJ N
7.3 CD N
to TO N
2.2 CD N
+/- JJ N
3.9 CD N
attacks NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
nitroglycerin JJ o
consumption NN o
from IN N
3.4 CD N
+/- JJ N
4.9 CD N
to TO N
1.2 CD N
+/- JJ N
2.5 CD N
tablets NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
compared VBN N
with IN N
placebo NN i
. . i

Treadmill NNP o
time NN o
increased VBD N
from IN N
6.4 CD N
+/- JJ N
2.1 CD N
minutes NNS N
during IN N
the DT N
placebo NN i
phase NN N
to TO N
7.5 CD N
+/- JJ N
1.8 CD N
minutes NNS N
during IN N
the DT N
verapamil JJ i
phase NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP i
's POS i
beneficial JJ N
effect NN N
appeared VBD N
to TO N
be VB N
related VBN N
, , N
in IN N
part NN N
, , N
to TO N
a DT N
10 CD N
% NN N
reduction NN N
of IN N
the DT N
rate-pressure JJ o
product NN o
at IN N
rest NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
a DT N
12 CD N
% NN N
reduction NN N
during IN N
submaximal JJ N
exercise NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP i
also RB N
caused VBD N
less JJR N
marked JJ N
ST-segment JJ o
depressions NNS o
at IN o
peak NN o
exercise NN o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
at IN N
a DT N
similar JJ N
rate-pressure NN N
product NN N
, , N
suggesting VBG N
a DT N
favorable JJ N
redistribution NN N
of IN N
coronary JJ o
blood NN o
flow NN o
to TO N
the DT N
ischemic JJ N
zone NN N
. . N

Side JJ N
effects NNS N
from IN N
verapamil NN i
were VBD N
minimal JJ N
, , N
consisting VBG N
mainly RB N
of IN N
constipation NN o
( ( N
six CD N
patients NNS N
) ) N
. . N

Verapamil NNP i
appears VBZ N
to TO N
be VB N
a DT N
safe JJ o
and CC o
effective JJ o
drug NN N
for IN N
treating VBG N
angina NN p
of IN N
effort NN N
. . N

-DOCSTART- -X- O O

An DT N
evaluation NN N
method NN N
providing VBG N
confidence NN N
intervals NNS N
applied VBD N
to TO N
radioimmunoassay VB i
. . i

A DT N
method NN N
for IN N
evaluation NN i
of IN i
radioimmunoassay NN i
results NNS N
is VBZ N
described VBN N
. . N

The DT N
order NN N
of IN N
the DT N
single JJ i
tubes NNS i
in IN N
each DT N
assay NN N
run NN N
is VBZ N
randomized VBN N
. . N

A DT N
polynomial NN N
is VBZ N
fitted VBN N
to TO N
untransformed JJ N
data NNS N
( ( N
y JJ N
= NN N
counts NNS N
per IN N
minute NN N
; : N
x CC N
= JJ N
concentration NN N
of IN N
curve.A JJ N
confidence NN N
interval NN N
is VBZ N
calculated VBN N
for IN N
each DT N
sample NN N
, , N
taking VBG N
into IN N
account NN N
the DT N
variance NN N
of IN N
the DT N
standard JJ N
curve NN N
and CC N
that IN N
of IN N
the DT N
actual JJ N
duplicate NN N
assay NN N
jointly RB N
. . N

-DOCSTART- -X- O O

Position NN N
of IN N
anterior JJ N
capsulorhexis NN N
and CC N
posterior JJ N
capsule NN N
opacification NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
whether IN N
the DT N
position NN N
of IN N
the DT N
anterior JJ N
continuous JJ N
curvilinear NN N
capsulorhexis NN N
influences VBZ N
the DT N
rate NN o
of IN o
posterior JJ o
capsule NN o
opacification NN o
( ( o
PCO NNP o
) ) o
. . o

METHODS CC N
A DT p
total NN p
of IN p
119 CD p
patients NNS p
, , p
aged VBN p
61-86 CD p
years NNS p
, , p
underwent JJ p
cataract NN p
surgery NN p
with IN p
phacoemulsification NN p
performed VBN p
by IN p
a DT p
single JJ p
surgeon NN p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
implantation NN N
with IN N
either CC N
a DT N
silicone NN i
intraocular NN i
lens NNS i
( ( i
IOL NNP i
) ) i
( ( i
SI40NB NNP i
, , i
Allergan NNP i
) ) i
or CC i
an DT i
AcrySof NNP i
IOL NNP i
( ( N
MA60BM NNP N
, , N
Alcon NNP N
) ) N
. . N

Three CD N
years NNS N
after IN N
surgery NN N
, , N
the DT N
rate NN o
of IN o
PCO NNP o
was VBD N
analysed VBN N
using VBG N
the DT N
evaluation NN N
of IN N
posterior JJ N
capsule NN N
opacification NN N
computer NN N
software NN N
( ( N
EPCO NNP N
) ) N
. . N

The DT N
results NNS N
were VBD N
related VBN N
to TO N
the DT N
capsulorhexis NN N
position NN N
, , N
which WDT N
was VBD N
assessed VBN N
with IN N
a DT N
retroillumination NN N
photograph NN N
. . N

RESULTS VB N
If IN N
the DT N
capsulorhexis NN o
was VBD N
located VBN N
partially RB N
or CC N
completely RB N
off IN N
the DT N
optics NNS o
of IN o
the DT o
IOL NNP o
, , N
compared VBN N
to TO N
totally RB o
on IN o
the DT o
IOL NNP o
, , N
significantly RB N
more JJR N
PCO NNP o
was VBD N
found VBN N
( ( N
p JJ N
= NNP N
0.0014 CD N
) ) N
. . N

When WRB N
comparing VBG N
within IN N
each DT N
IOL NNP N
type NN N
, , N
patients NNS N
with IN N
AcrySof NNP N
IOLs NNP N
were VBD N
found VBN N
to TO N
have VB N
significantly RB N
less JJR N
PCO NNP o
when WRB N
the DT N
capsulorhexis NN N
was VBD N
totally RB N
on IN N
the DT N
optic JJ N
( ( N
p JJ N
= NNP N
0.0048 CD N
) ) N
. . N

This DT N
difference NN N
was VBD N
also RB N
significant JJ N
in IN N
the DT N
silicone NN N
group NN N
( ( N
p JJ N
= NNP N
0.041 CD N
) ) N
. . N

CONCLUSION VB N
A NNP N
relatively RB N
small JJ N
and CC N
central JJ N
capsulorhexis NN N
allowing VBG N
for IN N
the DT N
complete JJ N
covering NN N
of IN N
the DT N
IOL NNP i
optics NNS i
by IN N
the DT N
rhexis NN N
edges VBZ N
seems VBZ N
to TO N
protect VB N
against IN N
PCO NNP o
in IN N
cataract NN N
surgery NN N
, , N
with IN N
both DT N
round-edged JJ N
silicone NN N
IOLs NNP N
and CC N
sharp-edged JJ N
hydrophobic JJ N
acrylic JJ i
IOLs NNP i
. . i

-DOCSTART- -X- O O

Comparison NNP N
of IN N
coronary JJ i
bypass NN i
surgery NN i
with IN N
angioplasty NN i
in IN N
patients NNS p
with IN p
multivessel JJ p
disease NN p
. . p

The DT N
Bypass NNP N
Angioplasty NNP N
Revascularization NNP N
Investigation NNP N
( ( N
BARI NNP N
) ) N
Investigators NNPS N
. . N

BACKGROUND NNP N
Coronary-artery JJ i
bypass NN i
grafting NN i
( ( i
CABG NNP i
) ) i
and CC N
percutaneous JJ i
transluminal JJ i
coronary NN i
angioplasty NN i
( ( i
PTCA NNP i
) ) i
are VBP N
alternative JJ N
methods NNS N
of IN N
revascularization NN N
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

We PRP N
tested VBD N
the DT N
hypothesis NN N
that IN N
in IN N
selected JJ N
patients NNS p
with IN p
multivessel JJ p
disease NN p
suitable JJ p
for IN p
treatment NN p
with IN p
either DT p
procedure NN p
, , N
an DT N
initial JJ N
strategy NN N
of IN N
PTCA NNP N
does VBZ N
not RB N
result VB N
in IN N
a DT N
poorer JJR N
five-year JJ N
clinical JJ o
outcome NN o
than IN N
CABG NNP N
. . N

METHODS NNP N
Patients NNPS p
with IN p
multivessel JJ p
disease NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
an DT p
initial JJ p
treatment NN p
strategy NN p
of IN p
CABG NNP p
( ( p
n JJ p
= NNP p
914 CD p
) ) p
or CC p
PTCA NNP p
( ( p
n JJ p
= NNP p
915 CD p
) ) p
and CC N
were VBD N
followed VBN N
for IN N
an DT N
average NN N
of IN N
5.4 CD N
years NNS N
. . N

Analysis NN N
of IN N
outcome JJ N
events NNS N
was VBD N
performed VBN N
according VBG N
to TO N
the DT N
intention NN N
to TO N
treat VB N
. . N

RESULTS VB N
The DT N
respective JJ N
in-hospital JJ N
event NN N
rates NNS N
for IN N
CABG NNP N
and CC N
PTCA NNP N
were VBD N
1.3 CD N
percent NN N
and CC N
1.1 CD N
percent NN N
for IN N
mortality NN o
, , N
4.6 CD N
percent NN N
and CC N
2.1 CD N
percent NN N
for IN N
Q-wave NNP o
myocardial JJ o
infarction NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
0.8 CD N
percent NN N
and CC N
0.2 CD N
percent NN N
for IN N
stroke NN o
. . o

The DT N
five-year JJ o
survival NN o
rate NN o
was VBD N
89.3 CD N
percent NN N
for IN N
those DT N
assigned VBN N
to TO N
CABG NNP N
and CC N
86.3 CD N
percent NN N
for IN N
those DT N
assigned VBN N
to TO N
PTCA NNP N
( ( N
P NNP N
= NNP N
0.19 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
of IN N
the DT N
difference NN N
in IN N
survival NN N
, , N
-0.2 JJ N
percent NN N
to TO N
6.0 CD N
percent NN N
) ) N
. . N

The DT N
respective JJ o
five-year JJ o
survival NN o
rates NNS o
free VBP o
from IN o
Q-wave NNP o
myocardial JJ o
infarction NN o
were VBD N
80.4 CD N
percent NN N
and CC N
78.7 CD N
percent NN N
. . N

By IN N
five CD N
years NNS N
after IN N
study NN N
entry NN N
, , N
8 CD N
percent NN N
of IN N
the DT N
patients NNS N
assigned VBD N
to TO N
CABG NNP N
had VBD N
undergone JJ N
additional JJ N
revascularization NN o
procedures NNS o
, , N
as IN N
compared VBN N
with IN N
54 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
PTCA NNP N
; : N
69 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
PTCA NNP N
did VBD N
not RB N
subsequently RB N
undergo JJ N
CABG NNP N
. . N

Among IN p
diabetic JJ p
patients NNS p
who WP p
were VBD p
being VBG p
treated VBN p
with IN p
insulin NN p
or CC p
oral JJ p
hypoglycemic JJ p
agents NNS p
at IN p
base NN p
line NN p
, , N
a DT N
subgroup NN N
not RB N
specified VBN N
by IN N
the DT N
protocol NN N
, , N
five-year JJ o
survival NN o
was VBD N
80.6 CD N
percent NN N
for IN N
the DT N
CABG NNP N
group NN N
as IN N
compared VBN N
with IN N
65.5 CD N
percent NN N
for IN N
the DT N
PTCA NNP N
group NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

CONCLUSIONS NNP N
As IN N
compared VBN N
with IN N
CABG NNP i
, , N
an DT N
initial JJ N
strategy NN N
of IN N
PTCA NNP i
did VBD N
not RB N
significantly RB N
compromise VB N
five-year JJ o
survival NN o
in IN N
patients NNS p
with IN p
multivessel JJ p
disease NN p
, , N
although IN N
subsequent JJ o
revascularization NN o
was VBD N
required VBN N
more RBR N
often RB N
with IN N
this DT N
strategy NN N
. . N

For IN N
treated JJ p
diabetics NNS p
, , N
five-year JJ o
survival NN o
was VBD N
significantly RB N
better JJR N
after IN N
CABG NNP i
than IN N
after IN N
PTCA NNP i
. . i

-DOCSTART- -X- O O

Reducing VBG N
polycystic JJ o
liver NN o
volume NN o
in IN p
ADPKD NNP p
: : p
effects NNS N
of IN N
somatostatin NN i
analogue NN i
octreotide NN i
. . i

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
No NNP N
medical JJ N
treatment NN N
is VBZ N
available JJ N
for IN N
polycystic JJ N
liver NN N
disease NN N
, , N
a DT N
frequent JJ N
manifestation NN N
of IN N
autosomal-dominant JJ p
polycystic JJ p
kidney NN p
disease NN p
( ( p
ADPKD NNP p
) ) p
. . p

In IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
crossover NN N
study NN N
, , N
6 CD N
months NNS N
of IN N
octreotide NN i
( ( N
40 CD N
mg NN N
every DT N
28 CD N
days NNS N
) ) N
therapy NN N
limited JJ N
kidney NN N
volume NN N
growth NN N
more RBR N
effectively RB N
than IN N
placebo NN i
in IN N
12 CD p
patients NNS p
with IN p
ADPKD NNP p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
In IN N
this DT N
secondary JJ N
, , N
post NN N
hoc NN N
analysis NN N
of IN N
the DT N
above NN N
study NN N
, , N
octreotide-induced JJ i
changes NNS N
in IN N
liver NN o
volumes NNS o
compared VBN N
with IN N
placebo NN i
and CC N
the DT N
relationship NN N
between IN N
concomitant NN N
changes NNS N
in IN N
liver NN N
and CC N
kidney NN N
volumes NNS N
were VBD N
evaluated VBN N
. . N

Those DT N
analyzing VBG N
liver NN o
and CC o
kidney NN o
volumes NNS o
were VBD N
blinded VBN N
to TO N
treatment NN N
. . N

RESULTS NNP N
Liver NNP o
volumes VBZ o
significantly RB o
decreased VBN o
from IN N
1595 CD N
+/- JJ N
478 CD N
ml NN N
to TO N
1524 CD N
+/- JJ N
453 CD N
ml NN N
with IN N
octreotide JJ N
whereas IN N
they PRP N
did VBD N
not RB N
appreciably RB N
change NN N
with IN N
placebo NN i
. . i

Changes NNS o
in IN o
liver NN o
volumes NNS o
were VBD N
significantly RB o
different JJ o
between IN N
the DT N
two CD N
treatment NN N
periods NNS N
( ( N
-71 JJ N
+/- JJ N
57 CD N
ml NN N
versus NN N
+14 VBD N
+/- JJ N
85 CD N
ml NN N
) ) N
. . N

Octreotide-induced JJ o
liver NN o
volume NN o
reduction NN o
was VBD N
fully RB N
explained VBN N
by IN N
a DT N
reduction NN N
in IN N
parenchyma JJ o
volume NN o
from IN N
1506 CD N
+/- JJ N
431 CD N
ml NN N
to TO N
1432 CD N
+/- JJ N
403 CD N
ml NN N
. . N

Changes NNS o
in IN o
liver NN o
volumes NNS o
were VBD N
significantly RB N
correlated VBN N
with IN N
concomitant JJ N
changes NNS N
in IN N
kidney NN o
volumes NNS o
( ( N
r VB N
= RB N
0.67 CD N
) ) N
during IN N
octreotide NN N
but CC N
not RB N
during IN N
placebo JJ N
treatment NN N
. . N

Liver NNP o
and CC o
kidney NN o
volume NN o
changes NNS o
significantly RB N
differed VBN o
with IN N
both DT N
treatments NNS N
( ( i
octreotide IN i
: : i
-71 JJ N
+/- JJ N
57 CD N
ml NN N
versus NN N
+71 VBD N
+/- JJ N
107 CD N
; : N
placebo NN i
: : i
+14 JJ N
+/- JJ N
85 CD N
ml NN N
versus NN N
+162 VBD N
+/- JJ N
114 CD N
) ) N
, , N
but CC N
net JJ o
reductions NNS o
in IN o
liver NN o
( ( N
-85 JJ N
+/- JJ N
103 CD N
ml NN N
) ) N
and CC N
kidney NN o
( ( N
-91 JJ N
+/- JJ N
125 CD N
ml NN N
) ) N
volume NN o
growth NN o
on IN N
octreotide IN i
versus NN N
placebo NN i
were VBD N
similar JJ o
. . o

CONCLUSIONS NNP N
Octreotide NNP i
therapy NN i
reduces NNS N
liver RB o
volumes NNS o
in IN N
patients NNS N
with IN N
ADPKD NNP N
and CC N
is VBZ N
safe JJ N
. . N

-DOCSTART- -X- O O

[ RB N
Preventive NNP N
use NN N
of IN N
Pentaglobin NNP i
in IN N
intensive JJ N
care NN N
treatment NN N
of IN N
trauma NN p
patients NNS p
] VBP p
. . N

Basing VBG N
on IN N
50 CD p
posttraumatic JJ p
intensive-care JJ p
patients NNS p
with IN p
medium NN p
grade NN p
lesions NNS p
( ( p
ISS NNP p
criteria NNS p
) ) p
, , p
the DT p
prophylactic JJ N
effect NN N
of IN N
an DT N
intravenously RB N
applicable JJ N
IgM NNP N
preparation NN N
( ( i
Pentaglobin NNP i
) ) i
against IN N
nosocomial JJ N
infections NNS o
was VBD N
investigated VBN N
. . N

The DT N
prophylaxis NN N
group NN N
received VBD N
on IN N
the DT N
3rd CD N
, , N
4th CD N
and CC N
5th CD N
day NN N
a DT N
daily JJ N
dose NN N
of IN N
10 CD N
g NNS N
each DT N
. . N

At IN N
the DT N
same JJ N
times VBZ N
the DT N
controls NNS N
were VBD N
given VBN N
12.5 CD i
g JJ i
human JJ i
albumin NN i
each DT N
. . N

Whereas IN N
no DT N
difference NN N
was VBD N
seen VBN N
between IN N
both DT N
groups NNS N
regarding VBG N
the DT N
definitive JJ N
outcome NN N
of IN N
the DT N
treatment NN N
, , N
the DT N
prophylaxis NN N
group NN N
clearly RB N
showed VBD N
fewer JJR N
infection NN o
pointers NNS o
during IN N
the DT N
clinical JJ N
course NN N
. . N

In IN N
particular JJ N
, , N
the DT N
incidence NN o
and CC o
magnitude NN o
of IN o
febrile JJ o
temperatures NNS o
were VBD N
significantly RB N
lower JJR N
between IN N
the DT N
4th CD N
and CC N
8th CD N
days NNS N
of IN N
treatment NN N
. . N

Our PRP$ N
results NNS N
indicate VBP N
, , N
however RB N
, , N
that IN N
the DT N
prophylactic JJ N
use NN N
those DT N
patients NNS p
who WP p
are VBP p
at IN p
particularly RB p
high JJ p
infection NN p
exposure NN p
risk NN p
, , p
e.g NN p
. . p

through IN p
reintervention NN o
surgery NN o
, , o
haemorrhage NN o
complications NNS o
or CC o
extensive JJ o
diagnostic JJ o
interventions NNS o
. . o

-DOCSTART- -X- O O

Internet-based JJ N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
for IN N
hyperactivity NN o
in IN p
autism NN p
. . p

OBJECTIVE NNP N
Preliminary NNP N
evidence NN N
suggests VBZ N
that IN N
omega-3 JJ i
fatty JJ i
acids NNS i
may MD N
reduce VB N
hyperactivity NN o
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

We PRP N
sought VBD N
to TO N
examine VB N
the DT N
feasibility NN N
of IN N
a DT N
novel NN N
, , N
Internet-based JJ N
clinical JJ N
trial NN N
design NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
this DT N
supplement NN N
. . N

METHOD NNP N
E-mail JJ i
invitations NNS i
were VBD N
sent VBN N
to TO N
parents NNS p
of IN p
children NNS p
aged VBN p
5 CD p
to TO p
8 CD p
years NNS p
enrolled VBN p
in IN p
the DT p
Interactive NNP p
Autism NNP p
Network NNP p
. . p

All DT N
study NN i
procedures NNS i
, , i
including VBG i
screening NN i
, , i
informed JJ i
consent NN i
, , i
and CC i
collection NN i
of IN i
outcome NN i
measures NNS i
took VBD i
place NN i
over IN i
the DT i
Internet NNP i
. . i

The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
parent- JJ o
and CC o
teacher-rated JJ o
changes NNS o
in IN o
hyperactivity NN o
on IN o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC-H NNP o
) ) o
. . o

RESULTS NNP N
During IN N
the DT N
6-week JJ N
recruitment NN N
period NN N
, , N
57 CD p
children NNS p
from IN p
28 CD p
states NNS p
satisfied VBD p
all DT p
eligibility NN p
criteria NNS p
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
1.3 CD N
grams NNS N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
or CC i
an DT i
identical JJ i
placebo NN i
daily RB N
for IN N
6 CD N
weeks NNS N
. . N

Outcome JJ N
assessments NNS N
were VBD N
obtained VBN N
from IN N
all DT N
57 CD N
participants NNS N
and CC N
57 CD N
teachers NNS N
, , N
and CC N
the DT N
study NN N
was VBD N
completed VBN N
in IN N
3 CD N
months NNS N
. . N

Children NNP N
in IN N
the DT N
omega-3 JJ i
fatty JJ i
acid NN i
group NN N
had VBD N
a DT N
greater JJR N
reduction NN N
in IN N
hyperactivity NN o
( ( N
-5.3 JJ N
points NNS N
) ) N
compared VBN N
to TO N
the DT N
placebo NN i
group NN N
( ( N
-2.6 CD N
points NNS N
) ) N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
1.9-point JJ N
greater JJR N
improvement NN N
in IN N
the DT N
omega-3 JJ i
group NN i
, , N
95 CD N
% NN N
CI NNP N
= NNP N
-2.2 NNP N
to TO N
5.2 CD N
) ) N
. . N

Adverse JJ o
events NNS o
were VBD N
rare JJ N
and CC N
not RB N
associated VBN N
with IN N
omega-3 JJ i
fatty JJ i
acids NNS i
. . i

Participant NNP N
feedback NN o
was VBD N
positive JJ N
. . N

CONCLUSION NNP N
Internet-based JJ N
, , N
randomized VBN N
controlled JJ N
trials NNS N
of IN N
therapies NNS N
in IN N
children NNS p
with IN p
ASD NNP p
are VBP N
feasible JJ N
and CC N
may MD N
lead VB N
to TO N
marked JJ N
reductions NNS N
in IN N
the DT N
time NN N
and CC N
cost NN N
of IN N
completing VBG N
trials NNS N
. . N

A NNP N
larger JJR N
sample NN N
size NN N
is VBZ N
required VBN N
to TO N
definitively RB N
determine VB N
the DT N
efficacy NN o
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
. . i

Clinical JJ N
trial NN N
registration NN N
information-Omega-3 JJ i
Fatty NNP i
Acids NNP i
for IN N
Hyperactivity NNP N
Treatment NNP N
in IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
; : N
http NN N
: : N
//clinicaltrials.gov NN N
; : N
NCT01694667 NNP N
. . N

-DOCSTART- -X- O O

Dofequidar NNP i
fumarate NN i
( ( N
MS-209 NNP N
) ) N
in IN N
combination NN N
with IN N
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
fluorouracil NN i
for IN N
patients NNS p
with IN p
advanced JJ p
or CC p
recurrent JJ p
breast NN p
cancer NN p
. . p

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
dofequidar NN i
plus CC i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
fluorouracil NN i
( ( i
CAF NNP i
) ) i
therapy NN i
in IN N
comparison NN N
with IN N
CAF NNP i
alone RB i
, , N
in IN N
patients NNS p
with IN p
advanced JJ p
or CC p
recurrent JJ p
breast NN p
cancer NN p
. . p

Dofequidar NNP N
is VBZ N
a DT N
novel NN N
, , N
orally RB N
active JJ N
quinoline NN N
derivative NN N
that WDT N
reverses VBZ N
multidrug JJ N
resistance NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
, , N
patients NNS N
were VBD N
treated VBN N
with IN N
six CD N
cycles NNS N
of IN N
CAF NNP i
therapy NN i
: : i
28 CD N
days/cycle NN i
, , i
with IN i
doxorubicin NN i
( ( i
25 CD i
mg/m2 NN i
) ) i
and CC i
fluorouracil NN i
( ( i
500 CD i
mg/m2 NN i
) ) i
administered VBN i
on IN i
days NNS i
1 CD i
and CC i
8 CD i
and CC i
cyclophosphamide NN i
( ( i
100 CD i
mg NN i
orally RB i
[ NNP i
PO NNP i
] NNP i
) ) i
administered VBD i
on IN i
day NN i
1 CD i
through IN i
14 CD i
. . i

Patients NNS N
received VBD N
dofequidar NN i
( ( i
900 CD i
mg RB i
PO NNP i
) ) i
30 CD N
minutes NNS N
before IN N
each DT N
dose NN N
of IN N
doxorubicin NN i
. . i

Primary JJ N
end NN N
point NN N
was VBD N
overall JJ o
response NN o
rate NN o
( ( o
ORR NNP o
; : o
partial JJ o
or CC o
complete JJ o
response NN o
) ) o
. . o

In IN N
total JJ N
, , N
221 CD p
patients NNS p
were VBD p
assessable JJ p
. . p

RESULTS NNP N
ORR NNP o
was VBD N
42.6 CD N
% NN N
for IN N
CAF NNP i
compared VBN N
with IN N
53.1 CD N
% NN N
for IN N
dofequidar NN i
+ NNP i
CAF NNP i
, , N
a DT N
24.6 CD N
% NN N
relative JJ N
improvement NN N
and CC N
10.5 CD N
% NN N
absolute JJ N
increase NN N
( ( N
P NNP N
= NNP N
.077 NNP N
) ) N
. . N

There EX N
was VBD N
a DT N
trend NN N
for IN N
prolonged JJ o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
; : o
median JJ N
241 CD N
days NNS N
for IN N
CAF NNP N
v $ N
366 CD N
days NNS N
for IN N
dofequidar NN N
+ NNP N
CAF NNP N
; : N
P NNP N
= NNP N
.145 NNP N
) ) N
. . N

In IN N
retrospectively RB N
defined VBN N
subgroups NNS N
, , N
significant JJ N
improvement NN N
in IN N
PFS NNP o
in IN N
favor NN N
of IN N
dofequidar NN N
was VBD N
observed VBN N
in IN N
patients NNS p
who WP p
were VBD p
premenopausal NN p
, , p
had VBD p
no DT p
prior JJ p
therapy NN p
, , p
and CC p
were VBD p
stage NN p
IV NNP p
at IN p
diagnosis NN p
with IN p
an DT p
intact JJ p
primary JJ p
tumor NN p
. . p

Except IN N
for IN N
neutropenia NN o
and CC o
leukopenia NN o
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
excess NN N
of IN N
grade NN N
3/4 CD N
adverse JJ N
events NNS N
compared VBN N
with IN N
CAF NNP N
. . N

Treatment NN N
with IN N
dofequidar NN i
did VBD N
not RB N
affect VB N
the DT N
plasma JJ o
concentration NN o
of IN o
doxorubicin NN o
. . o

CONCLUSION NNP N
Dofequidar NNP i
+ NNP i
CAF NNP i
was VBD N
well RB N
tolerated VBN N
and CC N
is VBZ N
suggested VBN N
to TO N
have VB N
efficacy NN N
in IN N
patients NNS p
who WP p
had VBD p
not RB p
received VBN p
prior JJ p
therapy NN p
. . p

-DOCSTART- -X- O O

Effect NN o
of IN o
cooling VBG o
proparacaine JJ i
0.5 CD i
% NN i
eye NN i
drops NNS i
on IN p
patient NN o
's POS o
comfort NN o
during IN p
instillation NN p
. . p

-DOCSTART- -X- O O

Intravesical JJ i
seeding NN i
of IN i
upper JJ i
urinary JJ i
tract NN i
urothelial JJ i
carcinoma NN i
cells NNS i
during IN N
nephroureterectomy NN i
: : i
an DT N
exploratory JJ N
analysis NN N
from IN N
the DT N
THPMG NNP N
trial NN N
. . N

OBJECTIVE CC N
The DT N
Pirarubicin NNP N
Monotherapy NNP N
Study NNP N
Group NNP N
trial NN N
was VBD N
a DT N
randomized JJ N
Phase NNP N
II NNP N
study NN N
that WDT N
evaluated VBD N
the DT N
efficacy NN N
of IN N
intravesical JJ N
instillation NN N
of IN N
pirarubicin NN i
in IN N
the DT N
prevention NN N
of IN N
bladder NN N
recurrence NN N
after IN N
nephroureterectomy NN p
for IN p
upper JJ p
urinary JJ p
tract NN p
urothelial JJ p
carcinoma NN p
. . p

This DT N
study NN N
conducted VBD N
further JJ N
analysis NN N
of IN N
the DT N
Pirarubicin NNP N
Monotherapy NNP N
Study NNP N
Group NNP N
cohort NN N
, , N
focusing VBG N
on IN N
intravesical JJ i
seeding NN i
of IN i
cancer NN i
cells NNS i
. . i

METHODS NNP N
Using VBG N
the DT N
data NN p
from IN p
the DT p
Pirarubicin NNP p
Monotherapy NNP p
Study NNP p
Group NNP p
trial NN p
, , N
bladder VB o
recurrence-free JJ o
survival NN o
rates NNS o
and CC o
factors NNS o
associated VBN o
with IN o
bladder NN o
recurrence NN o
in IN N
the DT N
control NN N
group NN N
were VBD N
analyzed VBN N
. . N

RESULTS NNP N
Of IN N
36 CD p
patients NNS p
in IN p
the DT p
control NN i
group NN p
, , p
14 CD p
with IN p
positive JJ o
urine JJ o
cytology NN o
had VBD N
more RBR N
frequent JJ N
recurrence NN o
when WRB N
compared VBN N
with IN N
the DT N
22 CD p
patients NNS p
with IN p
negative JJ p
cytology NN p
( ( p
P NNP p
= NNP p
0.004 CD p
) ) p
. . p

Based VBN N
on IN N
the DT N
multivariate NN N
analysis NN N
in IN N
the DT N
control NN N
group NN N
, , N
voided VBD N
urine JJ N
cytology NN N
was VBD N
an DT N
independent JJ N
predictive JJ N
factor NN N
of IN N
bladder NN N
recurrence NN N
( ( N
hazard JJ N
ratio NN N
, , N
5.54 CD N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
1.12-27.5 JJ N
; : N
P NNP N
= NNP N
0.036 CD N
) ) N
. . N

Of IN N
72 CD p
patients NNS p
in IN p
the DT p
Pirarubicin NNP p
Monotherapy NNP p
Study NNP p
Group NNP p
trial NN p
, , N
31 CD N
had VBD N
positive JJ N
urine JJ o
cytology NN o
. . o

Among IN p
the DT p
31 CD p
patients NNS p
, , p
17 CD p
patients NNS p
who WP p
received VBD p
pirarubicin JJ i
instillation NN i
had VBD N
fewer JJR N
recurrences NNS o
when WRB N
compared VBN N
with IN N
14 CD p
patients NNS p
who WP p
received VBD p
control NN i
treatment NN p
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

On IN N
multivariate NN N
analysis NN N
, , N
pirarubicin JJ i
instillation NN i
was VBD N
an DT N
independent JJ N
predictor NN N
of IN N
better JJR N
recurrence-free JJ o
survival NN o
rates NNS o
in IN N
the DT N
patients NNS N
with IN N
positive JJ N
urine JJ N
cytology NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.02 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.00-0.53 JJ N
; : N
P NNP N
= NNP N
0.018 CD N
) ) N
. . N

Of IN N
21 CD N
patients NNS N
with IN N
bladder NN N
recurrence NN N
, , N
17 CD N
had VBD N
recurrent JJ o
tumor NN o
around IN o
cystotomy NN o
or CC o
in IN o
the DT o
bladder NN o
neck NN o
compromised VBN N
by IN N
the DT N
urethral JJ N
catheter NN N
, , N
supporting VBG N
the DT N
notion NN N
that IN N
tumor NN N
cells NNS N
seeded VBN N
in IN N
the DT N
injured JJ N
urothelium NN N
. . N

CONCLUSIONS NNP N
Intravesical NNP i
instillation NN i
of IN i
pirarubicin NN i
immediately RB N
after IN N
nephroureterectomy NN i
significantly RB N
reduced VBD N
the DT N
bladder NN o
recurrence NN o
rate NN o
in IN N
patients NNS N
with IN N
positive JJ N
voided JJ N
urine JJ N
cytology NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
intravesical JJ N
seeding NN N
of IN N
upper JJ N
urinary JJ N
tract NN N
urothelial JJ N
carcinoma NN N
occurs VBZ N
during IN N
nephroureterectomy NN N
. . N

-DOCSTART- -X- O O

Comparative NNP N
study NN N
of IN N
actinic JJ p
keratosis NN p
treatment NN N
with IN N
3 CD i
% NN i
diclofenac JJ i
sodium NN i
and CC i
5 CD i
% NN i
5-fluorouracil JJ i
. . i

BACKGROUND NNP N
Actinic NNP p
keratosis NN p
is VBZ N
a DT N
frequent JJ N
lesion NN N
which WDT N
occurs VBZ N
in IN N
sunlight NN N
exposed VBN N
areas NNS N
. . N

Diclofenac NNP i
sodium NN i
and CC i
5-Fluorouracil JJ i
are VBP N
effective JJ N
, , N
non-invasive JJ N
and CC N
easy-to-apply JJ N
topical JJ N
treatment NN N
options NNS N
. . N

OBJECTIVES NNP N
To TO N
assess VB o
and CC o
compare VB o
the DT o
effectiveness NN o
of IN N
3 CD i
% NN i
diclofenac JJ i
sodium NN i
associated VBN N
with IN N
2.5 CD i
% NN i
hyaluronic JJ i
acid NN i
and CC i
of IN i
5 CD i
% NN i
5-Fluorouracil JJ i
for IN N
the DT N
treatment NN N
of IN N
actinic JJ N
keratosis NN N
, , N
as RB N
well RB N
as IN N
the DT N
patient NN N
's POS N
degree NN N
of IN N
satisfaction NN N
and CC N
tolerability NN N
. . N

METHODS NNP N
28 CD p
patients NNS p
with IN p
a DT p
clinical JJ p
diagnosis NN p
of IN p
actinic JJ p
keratosis NN p
were VBD N
randomized VBN N
to TO N
receive VB N
diclofenac JJ i
sodium NN i
or CC i
5-Fluorouracil JJ i
and CC N
were VBD N
clinically RB N
assessed VBN N
before IN N
and CC N
after IN N
treatment NN N
as RB N
well RB N
as IN N
8 CD N
weeks NNS N
after IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

Modified NNP o
versions NNS o
of IN o
the DT o
Investigator NNP o
and CC o
Patient NNP o
Global NNP o
Improvement NNP o
Scores NNP o
were VBD N
used VBN N
. . N

RESULTS VB N
The DT N
average JJ o
number NN o
of IN o
lesions NNS o
in IN o
the DT o
diclofenac NN o
sodium NN o
group NN o
before IN o
and CC o
after IN o
treatment NN o
was VBD N
13.6 CD N
and CC N
6.6 CD N
( ( N
p NN N
< RB N
0,001 CD N
) ) N
, , N
respectively RB N
, , N
while IN N
it PRP N
was VBD N
17.4 CD N
and CC N
3.15 CD N
( ( N
p NN N
< RB N
0.001 CD N
) ) N
in IN N
the DT N
5-Fluorouracil JJ i
group NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN o
of IN o
lesions NNS o
in IN o
the DT o
5-Fluorouracil JJ o
group NN o
in IN N
relation NN N
to TO N
the DT N
diclofenac NN i
sodium NN N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

To TO N
the DT N
non-blinded JJ N
physician NN N
, , N
there EX N
was VBD N
a DT N
higher JJR N
satisfactory JJ N
therapeutic JJ o
response NN o
in IN N
the DT N
5-Fluorouracil JJ i
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
; : N
to TO N
the DT N
blinded JJ N
physician NN N
, , N
there EX N
was VBD N
a DT N
higher JJR N
satisfactory JJ N
response NN N
in IN N
this DT N
same JJ N
group NN N
, , N
although IN N
not RB N
statistically RB N
significant JJ N
( ( N
p=0.09 NN N
) ) N
. . N

There EX N
was VBD N
a DT N
high JJ N
degree NN N
of IN N
satisfaction NN N
in IN N
both DT N
groups NNS N
( ( N
73 CD N
% NN N
in IN N
the DT N
diclofenac NN i
sodium NN N
group NN N
and CC N
77 CD N
% NN N
in IN N
the DT N
5-Fluorouracil JJ i
group NN N
; : N
p=0.827 NN N
) ) N
. . N

Regarding VBG N
adverse JJ o
effects NNS o
, , N
the DT N
diclofenac NN i
sodium NN i
group NN N
presented VBD N
a DT N
higher JJR N
degree NN N
of IN N
satisfaction NN N
( ( N
93.3 CD N
% NN N
vs JJ N
38.4 CD N
% NN N
; : N
p=0.008 NN N
) ) N
. . N

Erythema NNP o
, , o
edema NN o
, , o
crusts NNS o
and CC o
itching VBG o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
5-Fluorouracil JJ i
group NN N
. . N

CONCLUSION NNP N
We PRP N
concluded VBD N
that IN N
5-Fluorouracil NN i
was VBD N
more RBR N
effective JJ N
; : N
however RB N
, , N
it PRP N
showed VBD N
lower JJR N
tolerability NN N
than IN N
diclofenac JJ i
sodium NN i
. . i

-DOCSTART- -X- O O

[ JJ N
Observation NNP N
on IN N
therapeutic JJ N
effect NN N
of IN N
acupuncture NN i
on IN N
early JJ p
peripheral JJ p
facial JJ p
paralysis NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
observe VB N
therapeutic JJ N
effects NNS N
of IN N
acupuncture NN i
at IN N
different JJ N
opportunities NNS N
on IN N
peripheral JJ p
facial JJ p
paralysis NN p
. . p

METHODS NNP N
Fifty-two JJ p
cases NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
treatment NN N
group NN N
( ( N
n=28 CC N
) ) N
and CC N
a DT N
control NN N
group NN N
( ( N
n=24 RB N
) ) N
. . N

The DT N
treatment NN N
group NN N
at IN N
the DT N
acute JJ N
stage NN N
( ( N
1-10 JJ N
days NNS N
) ) N
were VBD N
treated VBN N
with IN N
acupuncture NN i
at IN i
Dicang NNP i
( ( i
ST NNP i
4 CD i
) ) i
, , i
Jiache NNP i
( ( i
ST NNP i
6 CD i
) ) i
, , i
Yangbai NNP i
( ( i
GB NNP i
14 CD i
) ) i
, , i
etc. FW i
, , N
with IN i
less JJR i
than IN i
4 CD i
points NNS i
selected VBN i
on IN i
the DT i
face NN i
and CC i
with IN i
shallow JJ i
puncture NN i
, , i
and CC i
10 CD i
days NNS i
later RB i
electroacupuncture VBP i
were VBD i
added VBN i
at IN i
acupoints NNS i
selected VBN i
routinely RB i
; : i
the DT i
control NN i
group NN i
were VBD i
treated VBN i
with IN i
the DT i
same JJ i
methods NNS i
as IN i
the DT i
treatment NN i
group NN i
but CC i
acupuncture NN i
was VBD i
not RB i
given VBN i
at IN i
the DT i
acute JJ i
stage NN i
. . i

RESULTS VB N
The DT N
cured JJ o
rate NN o
of IN N
78.6 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
50.0 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Early JJ N
acupuncture NN i
is VBZ N
a DT N
key NN N
for IN N
achieving VBG N
the DT N
best JJS N
therapeutic JJ N
effect NN N
on IN N
facial JJ p
paralysis NN p
. . p

-DOCSTART- -X- O O

Long JJ N
term NN N
response NN N
to TO N
therapy NN N
of IN N
chronic JJ p
anti-HBe-positive JJ p
hepatitis NN p
B NNP p
is VBZ N
poor JJ N
independent JJ N
of IN N
type NN N
and CC N
schedule NN N
of IN N
interferon NN N
. . N

OBJECTIVE CC N
The DT N
response NN o
rate NN o
to TO o
alpha VB o
interferon NN o
( ( o
IFN NNP o
) ) o
of IN N
chronic JJ N
anti-HBe-positive JJ N
hepatitis NN N
B NNP N
is VBZ N
variable JJ N
. . N

We PRP N
studied VBD N
whether IN N
type NN N
, , N
dose NN N
, , N
and CC N
schedule NN N
of IN N
IFN NNP i
, , N
and CC N
type NN N
and CC N
frequency NN N
of IN N
posttreatment NN N
monitoring NN N
, , N
influence VB N
the DT N
response NN N
rate NN N
. . N

METHODS NNP N
Seventy-two JJ p
consecutive JJ p
anti-HBe-positive JJ p
chronic NN p
hepatitis NN p
B NNP p
patients NNS p
( ( p
59 CD p
male NN p
and CC p
13 CD p
female NN p
, , p
median JJ p
age NN p
41 CD p
yr NN p
) ) p
stratified VBN p
by IN p
sex NN p
and CC p
histology NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
three CD N
treatment NN N
arms NNS N
. . N

Twenty-seven JJ N
patients NNS N
( ( N
A DT N
) ) N
received VBD N
10 CD N
million CD N
units NNS N
alpha-N1 JJ i
IFN NNP i
i.m NN i
. . i

t.w NN N
. . N

for IN N
24 CD N
wk NN N
( ( N
total JJ N
dose NN N
: : N
720 CD N
million CD N
units NNS N
) ) N
; : N
21 CD N
( ( N
B NNP N
) ) N
received VBD N
9 CD N
million CD N
units NNS N
alpha-2a JJ i
IFN NNP i
i.m NN i
. . i

t.w NN N
. . N

for IN N
4 CD N
wk NN N
, , N
followed VBN N
by IN N
18 CD N
million CD N
units NNS N
for IN N
12 CD N
wk NN N
and CC N
9 CD N
million CD N
units NNS N
for IN N
8 CD N
wk NN N
( ( N
972 CD N
million CD N
units NNS N
) ) N
; : N
24 CD N
( ( N
C NNP N
) ) N
received VBD N
2 CD i
alpha-2a JJ i
IFN NNP i
courses NNS i
( ( N
9 CD N
million CD N
units NNS N
i.m RB N
. . N

t.w NN N
. . N

for IN N
16 CD N
and CC N
12 CD N
wk NN N
separated VBN N
by IN N
a DT N
6-month JJ N
interval NN N
[ $ N
756 CD N
million CD N
units NNS N
] NNP N
) ) N
. . N

Primary JJ N
response NN N
was VBD N
defined VBN N
by IN N
normal JJ o
ALT NNP o
and CC o
serum VB o
HBV-DNA NNP o
levels NNS o
below IN N
10 CD N
pg/ml NN N
at IN N
the DT N
end NN N
of IN N
therapy NN N
and CC N
sustained VBN N
response NN N
by IN N
normal JJ o
ALT NNP o
( ( N
tested VBN N
monthly RB N
) ) N
, , N
undetectable JJ o
HBV-DNA NN o
and CC N
IgM NNP N
anti-HBc NN N
( ( N
< JJ N
7 CD N
I.U NNP N
. . N

Paul NNP N
Ehrlich NNP N
Institute NNP N
) ) N
( ( N
tested VBN N
every DT N
3 CD N
months NNS N
) ) N
during IN N
the DT N
posttreatment JJ N
follow-up NN N
. . N

RESULTS NNP N
At IN N
the DT N
end NN N
of IN N
treatment NN N
, , N
12 CD N
, , N
8 CD N
, , N
and CC N
13 CD N
patients NNS N
from IN N
groups NNS N
A NNP N
, , N
B NNP N
, , N
and CC N
C NNP N
, , N
respectively RB N
, , N
were VBD N
responders NNS N
. . N

At IN N
the DT N
18-month JJ N
follow-up JJ N
, , N
two CD N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
only RB N
one CD N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
maintained VBD N
the DT N
response NN o
. . o

Overall NNP N
, , N
after IN N
34 CD N
months NNS N
( ( N
median JJ N
posttreatment NN N
follow-up NN N
) ) N
, , N
three CD N
patients NNS N
were VBD N
long JJ N
term NN N
responders NNS N
, , N
whereas NNS N
three CD N
showed VBD N
a DT N
sustained VBN N
remission NN o
after IN N
relapse NN N
. . N

CONCLUSIONS VB N
The DT N
rate NN o
of IN o
long JJ o
term NN o
response NN o
to TO N
interferon VB N
of IN N
anti-HBe-positive JJ N
chronic JJ N
hepatitis NN N
B NNP N
is VBZ N
poor JJ N
, , N
independent JJ N
of IN N
IFN NNP N
type NN N
, , N
dose VB N
, , N
or CC N
schedule NN N
; : N
the DT N
more RBR N
stringent JJ N
the DT N
monitoring NN N
, , N
the DT N
higher JJR N
the DT N
relapse NN N
rate NN N
. . N

-DOCSTART- -X- O O

Antibiotic JJ i
prophylaxis NN i
in IN N
high-risk JJ p
head NN p
and CC p
neck NN p
surgery NN p
: : p
one-day JJ i
vs. IN N
five-day JJ i
therapy NN i
. . i

Patients NNS p
who WP p
undergo VBP p
major JJ p
contaminated VBN p
surgery NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
benefit NN N
from IN N
perioperative JJ N
antibiotic JJ i
prophylaxis NN i
. . i

This DT N
study NN N
was VBD N
developed VBN N
to TO N
determine VB N
if IN N
5 CD N
days NNS N
of IN N
antibiotic JJ o
administration NN o
would MD N
be VB N
more RBR N
effective JJ N
than IN N
1 CD N
day NN N
. . N

A DT N
multi-institutional JJ N
prospective JJ N
randomized VBN N
double-blind NN N
study NN N
was VBD N
designed VBN N
. . N

Patients NNS p
who WP p
were VBD p
identified VBN p
as IN p
requiring VBG p
pedicled VBD p
flap JJ p
reconstruction NN p
were VBD p
potential JJ p
candidates NNS p
for IN p
the DT p
study NN p
. . p

Later NNP N
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
cefoperazone NN i
sodium NN i
for IN N
either DT N
24 CD i
hours NNS i
or CC i
120 CD i
hours NNS i
. . i

In IN N
each DT N
case NN N
, , N
the DT N
drug NN N
was VBD N
administered VBN N
intravenously RB N
, , N
beginning VBG N
1 CD N
to TO N
2 CD N
hours NNS N
preoperatively RB N
and CC N
continued VBD N
for IN N
the DT N
prescribed JJ N
period NN N
. . N

One CD p
hundred VBD p
nine CD p
patients NNS p
were VBD p
evaluable JJ p
. . p

Fifty-three JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
1 CD N
day NN N
of IN N
perioperative JJ N
prophylaxis NN N
. . N

Wound NNP o
infection NN o
developed VBD N
in IN N
ten JJ N
patients NNS N
( ( N
18.9 CD N
% NN N
) ) N
. . N

Fifty-six JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
5 CD N
days NNS N
of IN N
perioperative JJ i
antibiotic JJ i
prophylaxis NN i
. . i

Wound NNP o
infection NN o
developed VBD N
in IN N
14 CD N
( ( N
25 CD N
% NN N
) ) N
of IN N
these DT N
patients NNS N
( ( N
P NNP N
greater JJR N
than IN N
.05 NN N
) ) N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
no DT N
beneficial JJ N
effect NN N
from IN N
administration NN N
of IN N
antibiotics NNS i
for IN N
longer JJR N
than IN N
24 CD N
hours NNS N
postoperatively RB N
can MD N
be VB N
achieved VBN N
in IN N
patients NNS N
who WP N
undergo VBP N
myocutaneous JJ N
flap JJ N
reconstruction NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
developmental JJ i
speech NN i
and CC i
language NN i
training NN i
through IN i
music NN i
on IN N
speech NN o
production NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

The DT N
study NN N
compared VBN N
the DT N
effect NN N
of IN N
music NN i
training NN i
, , i
speech NN i
training NN i
and CC N
no-training NN i
on IN N
the DT N
verbal JJ N
production NN N
of IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

Participants NNS p
were VBD p
50 CD p
children NNS p
with IN p
ASD NNP p
, , p
age NN p
range NN p
3 CD p
to TO p
5 CD p
years NNS p
, , p
who WP p
had VBD p
previously RB p
been VBN p
evaluated VBN p
on IN p
standard JJ p
tests NNS p
of IN p
language NN p
and CC p
level NN p
of IN p
functioning VBG p
. . p

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
3-day JJ N
conditions NNS N
. . N

Participants NNS N
in IN N
music NN i
training NN i
( ( N
n JJ N
= NNP N
18 CD N
) ) N
watched VBD N
a DT N
music NN i
video NN i
containing VBG i
6 CD i
songs NNS i
and CC i
pictures NNS i
of IN i
the DT i
36 CD i
target NN i
words NNS i
; : i
those DT N
in IN N
speech JJ i
training NN i
( ( N
n JJ N
= NNP N
18 CD N
) ) N
watched VBD N
a DT N
speech NN i
video NN i
containing VBG i
6 CD i
stories NNS i
and CC i
pictures NNS i
, , N
and CC N
those DT N
in IN N
the DT N
control NN i
condition NN i
( ( N
n JJ N
= NNP N
14 CD N
) ) N
received VBD N
no DT i
treatment NN i
. . i

Participants NNS N
' POS N
verbal JJ N
production NN N
including VBG N
semantics NNS N
, , N
phonology NN N
, , N
pragmatics NNS N
, , N
and CC N
prosody NN N
was VBD N
measured VBN N
by IN N
an DT N
experimenter NN N
designed VBN N
verbal JJ N
production NN N
evaluation NN N
scale NN N
. . N

Results NNS N
showed VBD N
that IN N
participants NNS N
in IN N
both DT N
music NN i
and CC N
speech NN i
training NN i
significantly RB N
increased VBD N
their PRP$ N
pre NN o
to TO o
posttest VB o
verbal JJ o
production NN o
. . o

Results NNP N
also RB N
indicated VBD N
that IN N
both DT N
high JJ N
and CC N
low JJ N
functioning NN N
participants NNS N
improved VBD N
their PRP$ N
speech NN o
production NN o
after IN N
receiving VBG N
either CC N
music NN N
or CC N
speech NN N
training NN N
; : N
however RB N
, , N
low JJ N
functioning NN N
participants NNS N
showed VBD N
a DT N
greater JJR o
improvement NN o
after IN N
the DT N
music NN i
training NN i
than IN N
the DT N
speech NN N
training NN N
. . N

Children NNP p
with IN p
ASD NNP p
perceive JJ N
important JJ N
linguistic JJ N
information NN N
embedded VBN N
in IN N
music NN N
stimuli NNS N
organized VBN N
by IN N
principles NNS N
of IN N
pattern JJ N
perception NN N
, , N
and CC N
produce VBP N
the DT N
functional JJ N
speech NN N
. . N

-DOCSTART- -X- O O

The DT N
Impact NNP N
of IN N
Partial NNP i
Vascular NNP i
Occlusion NNP i
on IN N
Oxidative NNP N
Stress NNP N
Markers NNP N
during IN N
Resistance NNP i
Exercise NNP i
. . i

This DT N
study NN N
sought VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
partial JJ i
vascular JJ i
occlusion NN i
( ( i
PVO NNP i
) ) i
on IN N
oxidative JJ N
stress NN N
markers NNS N
in IN N
response NN N
to TO N
resistance VB i
exercise NN i
and CC N
at IN N
rest NN N
in IN N
young JJ p
resistance-trained JJ p
males NNS p
. . p

12 CD p
resistance-trained JJ p
males NNS p
performed VBD p
6 CD p
conditions NNS p
in IN p
random NN p
counterbalanced VBN p
order NN p
: : p
rest NN i
( ( i
R NNP i
) ) i
, , i
low-intensity NN i
( ( i
LIRE NNP i
: : i
30 CD p
% NN p
1RM CD p
) ) p
and CC p
moderate-intensity NN i
( ( i
MIRE NNP i
: : i
70 CD p
% NN p
1RM CD p
) ) p
resistance NN i
exercise NN i
with IN i
or CC i
without IN i
PVO NNP i
. . i

Blood NN o
samples NNS o
were VBD N
obtained VBN N
before IN N
and CC N
immediately RB N
after IN N
each DT N
condition NN N
and CC N
plasma NN o
protein NN o
carbonyls NN o
( ( o
PC NN o
) ) o
, , o
glutathione NN o
ratio NN o
, , o
oxygen RB o
radical JJ o
absorbance NN o
capacity NN o
( ( o
ORAC NNP o
) ) o
, , o
and CC o
xanthine JJ o
oxidase NN o
( ( o
XO NNP o
) ) o
were VBD N
evaluated VBN N
. . N

The DT N
addition NN N
of IN N
PVO NNP i
resulted VBD N
in IN N
significantly RB N
greater JJR N
plasma JJ o
PC NN o
and CC o
glutathione NN o
ratio NN o
in IN N
the DT N
rest NN N
condition NN N
. . N

During IN N
LIRE NNP i
the DT N
addition NN N
of IN N
PVO NNP i
significantly RB N
attenuated VBD N
plasma JJ N
PC NN N
. . N

The DT N
MIRE NNP N
condition NN N
, , N
independent JJ N
of IN N
PVO NNP i
, , N
resulted VBD N
in IN N
significantly RB N
higher JJR o
PC NN o
concentration NN o
and CC o
glutathione NN o
ratio NN o
compared VBN N
to TO N
the DT N
rest NN N
and CC N
LIRE NNP N
conditions NNS N
. . N

The DT N
addition NN i
of IN N
PVO NNP i
during IN i
MIRE NNP i
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
PC NNP o
. . o

Thus RB N
, , N
this DT N
study NN N
revealed VBD N
that IN N
PVO NNP i
increased VBD N
oxidative JJ o
stress NN o
at IN N
rest NN N
and CC N
enhanced VBD N
the DT N
oxidative JJ N
stress NN N
response NN N
to TO N
MIRE NNP i
, , N
but CC N
when WRB N
combined VBN N
with IN N
LIRE NNP i
oxidative JJ N
stress NN N
was VBD N
attenuated VBN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
utilization NN N
of IN N
PVO NNP i
during IN N
LIRE NNP i
may MD N
alter VB N
ROS-induced NNP N
accumulation NN N
in IN N
the DT N
blood NN N
which WDT N
may MD N
influence VB N
cellular JJ N
signaling NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
acupuncture NN i
on IN N
rehabilitation NN N
training NN N
of IN N
child NN p
's POS p
autism NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
effect NN N
of IN N
acupuncture NN i
on IN N
rehabilitation NN N
training NN N
for IN N
children NNS p
's POS p
autism NN p
. . p

METHODS NNP N
Forty NNP p
autistic JJ p
children NNS p
receiving VBG p
rehabilitation NN p
training NN p
were VBD N
divided VBN N
into IN N
a DT N
control NN N
group NN N
and CC N
a DT N
treatment NN N
group NN N
, , N
20 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

The DT N
control NN N
group NN N
received VBD N
rehabilitation NN i
training NN i
including VBG i
ABA NNP i
training NN i
, , i
the DT i
Conductive NNP i
Education NNP i
Approach NNP i
and CC i
the DT i
training NN i
of IN i
sensory JJ i
integration NN i
, , N
about RB N
90 CD N
sessions NNS N
for IN N
each DT N
training NN N
; : N
the DT N
treatment NN N
group NN N
received VBD N
acupuncture JJ i
treatment NN i
for IN N
60-90 JJ N
sessions NNS N
after IN i
the DT i
rehabilitation NN i
training NN i
. . i

Their PRP$ N
results NNS N
were VBD N
detected VBN N
by IN N
the DT N
revised VBN o
Chinese JJ o
version NN o
of IN o
Psycho-Educational NNP o
Profile NNP o
for IN o
autistic JJ o
and CC o
developmentally RB o
disabled JJ o
children NNS o
( ( o
C-PEP NNP o
) ) o
. . o

RESULTS VB N
The DT N
markedly RB N
effective JJ o
rate NN o
was VBD N
55.0 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
and CC N
15.0 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
with IN N
a DT N
very RB N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
the DT N
differences NNS N
before IN N
and CC N
after IN N
training NN N
in IN N
some DT N
projects NNS N
such JJ N
as IN N
the DT N
total JJ o
score NN o
of IN o
development NN o
, , o
imitation NN o
, , o
oral JJ o
cognition NN o
in IN N
the DT N
treatment NN N
group NN N
were VBD N
very RB N
significantly RB N
different JJ N
from IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Acupuncture NNP i
combined VBN N
with IN N
scientific JJ i
and CC i
effective JJ i
rehabilitation NN i
training NN i
has VBZ N
a DT N
better RBR N
therapeutic JJ o
effect NN o
than IN N
that DT N
of IN N
the DT N
simple JJ i
rehabilitation NN i
training NN i
for IN N
child NN p
's POS p
autism NN p
. . p

-DOCSTART- -X- O O

Efficacy NN o
, , o
tolerability NN o
and CC o
pharmacokinetics NNS o
of IN N
two CD N
nelfinavir-based JJ i
regimens NNS N
in IN N
human JJ p
immunodeficiency NN p
virus-infected JJ p
children NNS p
and CC p
adolescents NNS p
: : p
pediatric JJ N
AIDS NNP N
clinical JJ N
trials NNS N
group NN N
protocol VBZ N
403 CD N
. . N

INTRODUCTION NNP N
Few JJ N
combinations NNS N
of IN N
highly RB N
active JJ N
antiretrovirals NNS i
have VBP N
been VBN N
studied VBN N
in IN N
nucleoside JJ p
reverse NN p
transcription NN p
inhibitor NN p
( ( p
NRTI NNP p
) ) p
-experienced VBD p
, , p
human JJ p
immunodeficiency NN p
virus NN p
( ( p
HIV NNP p
) ) p
-infected VBD p
children NNS p
. . p

We PRP N
tested VBD N
the DT N
efficacy NN N
, , N
tolerability NN N
and CC N
pharmacokinetics NNS N
of IN N
2 CD N
combination NN N
therapies NNS N
containing VBG N
an DT N
NRTI NNP i
, , i
protease NN i
inhibitors NNS i
+/- VBP i
a DT i
nonnucleoside JJ i
reverse NN i
transcription NN i
inhibitor NN i
( ( i
NNRTI NNP i
) ) i
. . i

METHODS NNP N
This DT N
was VBD N
a DT N
phase NN N
II NNP N
, , N
randomized VBD N
, , N
multicenter NN N
study NN N
. . N

Forty-one CD p
children NNS p
and CC p
youths NNS p
between IN p
5 CD p
months NNS p
and CC p
21 CD p
years NNS p
with IN p
prior JJ p
NRTI NNP p
and CC p
no DT p
prior JJ p
NNRTI NNP p
or CC p
protease VB p
inhibitor NN p
experience NN p
received VBD N
either CC N
nelfinavir JJ i
( ( i
NFV NNP i
) ) i
30 CD i
mg/kg JJ i
twice RB i
daily RB i
( ( i
bid NN i
) ) i
, , i
ritonavir FW i
( ( i
RTV NNP i
) ) i
400 CD i
mg/m JJ i
bid NN i
and CC i
buffered VBN i
didanosine NN i
( ( i
ddI NN i
) ) i
240 CD i
mg/m JJ i
daily JJ i
( ( i
arm IN i
A NNP i
) ) i
or CC N
NFV NNP i
50-55 JJ i
mg/kg NN i
bid NN i
, , i
nevirapine NN i
( ( i
NVP NNP i
) ) i
120 CD i
mg/m JJ i
bid NN i
and CC i
stavudine NN i
( ( i
d4T NN i
) ) i
1 CD i
mg/kg JJ i
bid NN i
( ( i
arm NN i
B NNP i
) ) i
. . N

Patients NNS N
were VBD N
evaluated VBN N
clinically RB N
for IN N
48 CD N
weeks NNS N
after IN N
initiation NN N
of IN N
therapy NN N
. . N

Intensive JJ N
pharmacokinetic JJ N
sampling NN N
occurred VBD N
after IN N
4 CD N
weeks NNS N
of IN N
therapy NN N
. . N

RESULTS NN N
: : N
The DT N
proportion NN N
of IN N
children NNS N
with IN N
HIV-1 NNP N
RNA NNP N
< NNP N
or CC N
=400 NNP N
copies/mL NN N
and CC N
on IN N
randomized JJ N
treatment NN N
at IN N
48 CD N
weeks NNS N
was VBD N
65 CD N
% NN N
among IN N
children NNS N
assigned VBN N
NFV NNP N
+ NNP N
RTV NNP N
+ NNP N
ddI VBD N
versus JJ N
28 CD N
% NN N
among IN N
those DT N
assigned VBN N
NFV NNP N
+ NNP N
NVP NNP N
+ NNP N
d4T NN N
( ( N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
in IN N
median JJ o
CD4 NNP o
% NN o
change NN o
from IN N
baseline NN N
to TO N
week NN N
48 CD N
was VBD N
found VBN N
( ( N
3 CD N
% NN N
versus IN N
1 CD N
% NN N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
safety NN o
or CC o
tolerability NN o
between IN N
children NNS N
randomized VBN N
to TO N
NFV NNP i
+ NNP i
RTV NNP i
+ NNP i
ddI VBZ i
versus NN N
NFV NNP i
+ NNP i
NVP NNP i
+ NNP i
d4T NN i
were VBD N
identified VBN N
. . N

However RB N
, , N
a DT N
trend NN N
toward IN N
a DT N
higher JJR N
rate NN N
of IN N
permanent JJ o
discontinuation NN o
of IN o
study NN o
treatment NN o
was VBD N
noted VBN N
among IN N
children NNS N
assigned VBN N
to TO N
NFV NNP N
+ NNP N
NVP NNP N
+ NNP N
d4T NN N
compared VBN N
with IN N
NFV NNP N
+ NNP N
RTV NNP N
+ NNP N
ddI VBD N
[ JJ N
7 CD N
of IN N
20 CD N
( ( N
35 CD N
% NN N
) ) N
versus NN N
2 CD N
of IN N
21 CD N
( ( N
10 CD N
% NN N
) ) N
; : N
P NNP N
= VBD N
0.12 CD N
] NN N
. . N

NFV NNP o
pharmacokinetic JJ o
measurements NNS o
were VBD N
not RB N
statistically RB N
different JJ N
between IN N
the DT N
treatment NN N
groups NNS N
, , N
yet RB N
exposure NN N
to TO N
the DT N
NFV NNP N
metabolite NN N
, , N
M8 NNP N
, , N
was VBD N
significantly RB N
higher JJR N
in IN N
subjects NNS N
receiving VBG N
RTV NNP N
. . N

The DT N
pharmacokinetics NNS o
for IN o
NVP NNP o
, , o
RTV NNP o
and CC o
d4T NN o
were VBD N
similar JJ N
to TO N
those DT N
of IN N
previously RB N
reported VBN N
data NN N
. . N

CONCLUSION NN N
: : N
Combination NN N
therapy NN N
containing VBG N
NFV NNP N
+ NNP N
RTV NNP N
+ NNP N
ddI NN N
appears VBZ N
more RBR N
efficacious JJ N
in IN N
NRTI-experienced NNP N
children NNS N
than IN N
a DT N
regimen JJ N
containing VBG N
NFV NNP N
+ NNP N
NVP NNP N
+ NNP N
d4T NN N
. . N

Differences NNS N
in IN N
tolerability NN o
between IN N
the DT N
2 CD N
treatment NN N
groups NNS N
were VBD N
not RB N
identified VBN N
. . N

Systemic JJ N
exposure NN N
of IN N
these DT N
drugs NNS N
was VBD N
similar JJ N
to TO N
that DT N
reported VBN N
in IN N
other JJ N
HIV-infected JJ p
children NNS p
and CC p
adults NNS p
. . p

-DOCSTART- -X- O O

Evaluation NN N
of IN N
an DT N
intervention NN N
to TO N
change VB N
benzodiazepine-prescribing JJ i
behavior NN N
in IN N
a DT N
prepaid NN N
group NN N
practice NN N
setting VBG N
. . N

To TO N
determine VB N
the DT N
effect NN N
of IN N
two CD N
levels NNS N
of IN N
educational JJ i
intervention NN i
on IN i
benzodiazepine-prescribing JJ i
behavior NN i
in IN N
an DT N
elderly JJ p
population NN p
in IN N
a DT N
controlled JJ N
prepaid NN N
group NN N
practice NN N
( ( N
PPGP NNP N
) ) N
setting NN N
, , N
we PRP N
designed VBD N
a DT N
prospective JJ N
controlled VBN N
trial NN N
, , N
with IN N
six-month JJ N
follow-up NN N
. . N

Our PRP$ N
setting NN p
was VBD p
a DT p
270,000 CD p
member NN p
group-model JJ p
PPGP NNP p
in IN p
Colorado NNP p
, , p
from IN p
1990 CD p
to TO p
1991 CD p
. . p

Participants NNS p
included VBD p
91 CD p
physicians NNS p
, , p
62 CD p
men NNS p
and CC p
29 CD p
women NNS p
; : p
median JJ p
age NN p
was VBD p
38.7 CD p
years NNS p
. . p

Group NNP N
1 CD N
received VBD N
a DT N
one-on-one JJ i
educational JJ i
presentation NN i
by IN i
a DT i
clinical JJ i
pharmacist NN i
, , i
written VBN i
educational JJ i
materials NNS i
, , i
a DT i
brief JJ i
follow-up JJ i
visit NN i
, , i
and CC i
feedback NN i
with IN i
recommendations NNS i
. . i

Group NNP N
2 CD N
received VBD N
only RB N
a DT N
face-to-face JJ i
presentation NN i
, , i
given VBN i
to TO i
departmental VB i
groups NNS i
, , i
as RB i
well RB i
as IN i
the DT i
same JJ i
written VBN i
educational JJ i
materials NNS i
used VBN i
in IN i
group NN i
1 CD i
. . i

Controls NNP N
received VBD N
no DT i
intervention NN i
. . i

Our PRP$ N
primary JJ N
outcome JJ N
measure NN N
was VBD N
the DT N
benzodiazepine NN o
on/off NN o
status NN o
of IN o
the DT o
elderly JJ o
PPGP NNP o
members NNS o
. . o

The DT N
secondary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
median JJ o
change NN o
( ( o
preintervention NN o
minus IN o
postintervention NN o
) ) o
in IN o
a DT o
standardized JJ o
amount NN o
of IN o
benzodiazepines NNS o
prescribed VBN o
per IN o
physician NN o
. . o

Logistic JJ N
regression NN N
analysis NN N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
effect NN N
on IN N
postintervention NN N
benzodiazepine NN o
on/off NN o
status NN o
between IN N
study NN N
groups NNS N
, , N
when WRB N
controlling VBG N
for IN N
preintervention NN N
on/off NN N
status NN N
, , N
PPGP-member NNP N
age NN N
, , N
PPGP-member NNP N
gender NN N
, , N
and CC N
all DT N
possible JJ N
interactions NNS N
. . N

Analysis NN N
of IN N
variance NN N
failed VBD N
to TO N
demonstrate VB N
an DT N
effect NN N
of IN N
either DT N
intervention NN N
on IN N
the DT N
median JJ o
change NN o
in IN o
standardized JJ o
amount NN o
of IN o
benzodiazepines NNS o
prescribed VBN N
per IN N
physician NN N
, , N
with IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
controls NNS N
yielding VBG N
values NNS N
of IN N
-278 NN N
( ( N
range NN N
: : N
-4,137 NN N
, , N
2,844 CD N
) ) N
, , N
-330 NNP N
( ( N
-1,531 NNP N
, , N
1,358 CD N
) ) N
, , N
and CC N
-541 NNP N
( ( N
range NN N
: : N
-3,716 NN N
, , N
2,185 CD N
) ) N
, , N
respectively RB N
. . N

We PRP N
conclude VBP N
that IN N
strategies NNS N
effective JJ N
in IN N
changing VBG N
physician JJ N
prescribing VBG N
behavior NN N
in IN N
other JJ N
settings NNS N
may MD N
not RB N
be VB N
effective JJ N
in IN N
a DT N
PPGP NNP N
setting VBG N
with IN N
benzodiazepines NNS i
in IN N
the DT N
elderly JJ N
as IN N
the DT N
target NN N
for IN N
change NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
light-cured JJ N
filled VBN N
sealant NN N
on IN N
shear JJ N
bond NN N
strength NN N
of IN N
metal NN N
and CC N
ceramic JJ N
brackets NNS N
bonded VBN N
with IN N
a DT N
resin-modified JJ N
glass NN N
ionomer NN N
cement NN N
. . N

INTRODUCTION NNP N
Our PRP$ N
objective NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
highly RB N
filled VBN N
light-cured JJ i
sealant NN i
( ( i
HFLCS NNP i
) ) i
on IN N
the DT N
shear JJ N
bond NN N
strength NN N
and CC N
bond NN N
failure NN N
site NN N
of IN N
metal NN N
and CC N
ceramic JJ N
brackets NNS N
bonded VBN N
with IN N
resin-modified JJ N
glass NN N
ionomer NN N
cement NN N
( ( N
RMGIC NNP N
) ) N
. . N

METHODS NNP N
Eighty NNP p
freshly RB p
extracted VBD p
maxillary JJ p
premolars NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
4 CD p
groups NNS p
( ( p
20 CD p
in IN p
each DT p
group NN p
) ) p
. . p

In IN N
all DT N
groups NNS N
, , N
the DT N
teeth NNS p
were VBD N
etched VBN N
with IN N
37 CD i
% NN i
phosphoric JJ i
acid NN i
for IN i
20 CD i
seconds NNS i
, , i
and CC i
RMGIC NNP i
( ( i
Fuji NNP i
Ortho NNP i
LC NNP i
, , i
GC NNP i
Europe NNP i
, , i
Leuven NNP i
, , i
Belgium NNP i
) ) i
was VBD N
used VBN N
for IN N
bracket NN N
bonding NN N
. . N

In IN N
groups NNS N
1 CD N
and CC N
3 CD N
, , N
the DT N
brackets NNS N
were VBD N
bonded VBN N
directly RB N
to TO N
etched VB N
enamel JJ N
surfaces NNS N
; : N
in IN N
groups NNS N
2 CD N
and CC N
4 CD N
, , N
the DT N
etched JJ N
enamel NN N
was VBD N
covered VBN N
with IN N
HFLCS NNP i
( ( i
Pro NNP i
Seal NNP i
, , i
Reliance NNP i
Orthodontic NNP i
Products NNP i
, , i
Itasca NNP i
, , i
Ill NNP i
) ) i
. . i

Groups $ N
1 CD N
and CC N
2 CD N
received VBD N
metal JJ i
brackets NNS i
, , N
and CC N
groups NNS N
3 CD N
and CC N
4 CD N
had VBD N
ceramic JJ i
brackets NNS i
. . i

The DT N
specimens NNS N
were VBD N
stored VBN N
in IN N
distilled JJ N
water NN N
at IN N
room NN N
temperature NN N
for IN N
24 CD N
hours NNS N
and CC N
subsequently RB N
tested VBN N
in IN N
shear JJ N
mode NN N
with IN N
a DT N
universal JJ N
testing NN N
machine NN N
. . N

After IN N
debonding VBG N
, , N
the DT N
teeth NNS N
and CC N
the DT N
brackets NNS N
were VBD N
examined VBN N
under IN N
a DT N
stereomicroscope NN N
( ( N
model JJ N
SMZ-1B NNP N
, , N
Nikon NNP N
, , N
Osaka NNP N
, , N
Japan NNP N
) ) N
at IN N
20-times JJ N
magnification NN N
to TO N
assess VB N
the DT N
residual JJ N
adhesive NN N
on IN N
the DT N
tooth NN N
surfaces NNS N
. . N

RESULTS NNP N
Interaction NNP N
between IN N
HFLCS NNP N
and CC N
bracket NN N
type NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.15 CD N
) ) N
. . N

Pretreatment NN N
with IN N
HFLCS NNP o
did VBD o
not RB o
cause VB o
a DT o
statistically RB o
significant JJ o
change NN o
in IN o
the DT o
shear JJ o
bond NN o
values NNS o
of IN o
either DT o
metal NN o
or CC o
ceramic JJ o
brackets NNS o
( ( N
P NNP N
= NNP N
0.38 CD N
) ) N
. . N

Shear JJ o
bond NN o
values NNS o
of IN o
the DT o
ceramic JJ o
brackets NNS o
were VBD N
higher JJR N
than IN N
those DT N
of IN N
the DT N
metal JJ N
brackets NNS N
independent JJ N
of IN N
HFLCS NNP N
application NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
bond NN o
failure NN o
modes VBZ o
in IN N
the DT N
4 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
HFLCS NNP N
application NN N
on IN N
enamel NN N
etched VBN N
with IN N
37 CD N
% NN N
phosphoric JJ N
acid NN N
did VBD N
not RB N
affect VB N
the DT N
bond NN o
strength NN o
values NNS o
and CC N
the DT N
bond NN o
failure NN o
modes NNS o
of IN N
metal NN N
and CC N
ceramic JJ N
brackets NNS N
bonded VBN N
with IN N
RMGIC NNP N
. . N

RESULTS NNP N
Interaction NNP N
between IN N
HFLCS NNP N
and CC N
bracket NN N
type NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.15 CD N
) ) N
. . N

Pretreatment NN N
with IN N
HFLCS NNP N
did VBD N
not RB N
cause VB N
a DT N
statistically RB N
significant JJ N
change NN N
in IN N
the DT N
shear JJ o
bond NN o
values NNS o
of IN o
either DT o
metal NN o
or CC o
ceramic JJ o
brackets NNS o
( ( N
P NNP N
= NNP N
0.38 CD N
) ) N
. . N

Shear JJ o
bond NN o
values NNS o
of IN o
the DT o
ceramic JJ o
brackets NNS o
were VBD N
higher JJR N
than IN N
those DT N
of IN N
the DT N
metal JJ N
brackets NNS N
independent JJ N
of IN N
HFLCS NNP N
application NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
bond NN N
failure NN N
modes VBZ N
in IN N
the DT N
4 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
HFLCS NNP N
application NN N
on IN N
enamel NN N
etched VBN N
with IN N
37 CD N
% NN N
phosphoric JJ N
acid NN N
did VBD N
not RB N
affect VB N
the DT N
bond NN N
strength NN N
values NNS N
and CC N
the DT N
bond NN N
failure NN N
modes NNS N
of IN N
metal NN N
and CC N
ceramic JJ N
brackets NNS N
bonded VBN N
with IN N
RMGIC NNP N
. . N

-DOCSTART- -X- O O

Adequacy NNP N
of IN N
hot JJ N
biopsy NN N
for IN N
the DT N
treatment NN N
of IN N
diminutive JJ N
polyps NNS N
: : N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

Patients NNS p
with IN p
diminutive JJ p
polyps NNS p
in IN p
the DT p
rectum NN p
or CC p
sigmoid JJ p
colon NN p
were VBD N
randomized VBN i
to TO i
hot JJ i
biopsy NN i
treatment NN i
for IN i
either DT i
1 CD i
) ) i
electrocautery NN i
for IN i
2 CD i
s NNS i
( ( i
fixed VBN i
duration NN i
cautery NN i
) ) i
or CC i
2 CD i
) ) i
cautery NN i
until IN i
visible JJ i
necrosis NN i
of IN i
the DT i
polyp NN i
base NN i
was VBD i
evident JJ i
( ( i
variable JJ i
duration NN i
cautery NN i
) ) i
. . i

Sigmoidoscopy NNP i
was VBD i
performed VBN i
4 CD i
wk NN i
after IN i
treatment NN i
to TO i
determine VB i
the DT i
adequacy NN i
of IN i
polyp JJ i
eradication NN i
. . i

In IN N
the DT N
fixed JJ N
duration NN N
cautery NN N
group NN N
, , N
11 CD N
of IN N
21 CD N
polyps NNS N
( ( N
52 CD N
% NN N
) ) N
were VBD N
eradicated VBN o
, , N
compared VBN N
with IN N
12 CD N
of IN N
14 CD N
polyps NNS N
( ( N
86 CD N
% NN N
) ) N
in IN N
the DT N
variable JJ N
duration NN N
cautery NN N
group NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
. . N

When WRB N
analyzed JJ N
according VBG N
to TO N
whether IN N
or CC N
not RB N
visible JJ o
necrosis NN o
was VBD N
achieved VBN N
( ( N
some DT N
of IN N
the DT N
polyps NNS N
in IN N
the DT N
fixed JJ N
duration NN N
cautery NN N
group NN N
showed VBD N
necrosis NN N
with IN N
2 CD N
s JJ N
cautery NN N
) ) N
, , N
19 CD N
of IN N
23 CD N
polyps NNS N
( ( N
83 CD N
% NN N
) ) N
were VBD N
eradicated VBN o
when WRB N
necrosis NN N
was VBD N
evident JJ N
, , N
compared VBN N
to TO N
5 CD N
of IN N
12 CD N
( ( N
42 CD N
% NN N
) ) N
without IN N
necrosis NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
hot JJ N
biopsy NN N
treatment NN N
for IN N
diminutive JJ N
polyps NNS N
is VBZ N
significantly RB N
more RBR N
effective JJ N
when WRB N
visible JJ N
necrosis NN N
is VBZ N
achieved VBN N
during IN N
cautery NN N
. . N

Furthermore NNP N
, , N
even RB N
with IN N
visible JJ N
necrosis NN N
, , N
there EX N
is VBZ N
a DT N
17 CD N
% NN N
failure NN N
rate NN N
of IN N
polyp NN N
eradication NN N
. . N

-DOCSTART- -X- O O

An DT N
in IN N
vitro NN N
comparative JJ N
analysis NN N
: : N
scanning NN N
electron NN N
microscopy NN N
of IN N
dentin/restoration NN N
interfaces NNS N
. . N

One CD p
hundred VBD p
maxillary JJ p
premolar JJ p
teeth NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
ten VB p
groups NNS p
. . p

Each DT p
group NN p
was VBD N
restored VBN N
with IN N
one CD N
of IN N
ten JJ i
different JJ i
restorative NN i
techniques NNS i
. . i

The DT N
teeth NNS N
were VBD N
stored VBN N
in IN N
deionized JJ i
water NN i
for IN i
7d CD i
prior JJ i
to TO i
longitudinal JJ i
sectioning NN i
in IN i
a DT i
mesio-distal JJ i
plane NN i
. . i

Following VBG N
sectioning NN N
, , N
ten JJ N
specimens NNS N
from IN N
each DT N
group NN N
were VBD N
chosen VBN N
at IN N
random NN N
from IN N
the DT N
20 CD N
available JJ N
sections NNS N
. . N

The DT N
sectioned JJ N
surfaces NNS N
were VBD N
polished VBN i
using VBG i
600-grit JJ i
SiC NNP i
abrasive JJ i
paper NN i
and CC i
etched VBD i
for IN i
10 CD i
s NN i
with IN i
50 CD i
% NN i
phosphoric JJ i
acid NN i
to TO N
remove VB N
the DT N
smear JJ N
layer NN N
produced VBN N
by IN N
sectioning VBG N
. . N

Five CD N
tooth JJ N
sections NNS N
from IN N
the DT N
dentin NN N
bonding VBG N
resin NN N
groups NNS N
were VBD N
allowed VBN N
to TO N
dry VB N
at IN N
20 CD N
degrees NNS N
C NNP N
for IN N
24h CD N
. . N

The DT N
glass NN N
ionomer-based JJ N
groups NNS N
were VBD N
reimmersed VBN N
in IN N
deionized JJ N
water NN N
during IN N
this DT N
period NN N
. . N

The DT N
remaining VBG N
five CD N
sections NNS N
from IN N
each DT N
group NN N
were VBD N
replicated VBN N
using VBG N
an DT N
addition-cure JJ i
vinyl NN i
polysiloxane NN i
impression NN i
material NN i
and CC i
an DT i
epoxy JJ i
resin NN i
. . i

A DT N
comparison NN N
was VBD N
made VBN N
of IN N
the DT N
sections NNS N
and CC N
the DT N
replicas NN N
. . N

All DT N
tooth JJ N
specimens NNS N
were VBD N
sputter-coated JJ i
with IN i
gold NN i
for IN N
4 CD N
min NNS N
and CC N
examined VBD N
using VBG N
a DT N
scanning VBG N
electron NN N
microscope NN N
. . N

Replicas NNPS N
were VBD N
gold-coated JJ N
for IN N
3 CD N
min NN N
. . N

Different JJ N
tooth/restoration NN N
interfaces NNS N
, , N
associated VBN N
with IN N
different JJ N
materials NNS N
, , N
were VBD N
observed VBN N
. . N

A DT N
marked JJ N
difference NN o
between IN N
the DT N
replicas NN N
and CC N
tooth JJ N
sections NNS N
was VBD N
observed VBN N
for IN N
glass NN i
ionomer-based JJ i
restorations NNS i
but CC N
not RB N
for IN N
resin-based JJ i
bonding NN i
systems NNS N
. . N

Representative JJ N
samples NNS N
of IN N
replicas NN N
and CC N
specimens NNS N
are VBP N
shown VBN N
, , N
and CC N
the DT N
significance NN N
of IN N
the DT N
observed JJ N
differences NNS N
is VBZ N
discussed VBN N
. . N

-DOCSTART- -X- O O

Determination NN N
of IN N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
DIG NNP N
trial NN N
. . N

The DT N
Digitalis NNP N
Investigation NNP N
Group NNP N
( ( N
DIG NNP N
) ) N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
placebo-controlled JJ i
trial NN N
whose WP$ N
primary JJ N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
digoxin NN i
had VBD N
beneficial JJ N
, , N
harmful JJ N
, , N
or CC N
no DT N
effect NN N
on IN N
total JJ N
mortality NN N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
who WP p
were VBD p
in IN p
sinus NN p
rhythm NN p
and CC p
whose WP$ p
ejection NN p
fraction NN p
was VBD p
< JJ p
/=0.45 NNP p
. . p

The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
large JJ N
simple JJ N
trial NN N
with IN N
a DT p
large JJ p
number NN p
of IN p
centers NNS p
( ( p
302 CD p
) ) p
in IN p
the DT p
United NNP p
States NNPS p
and CC p
Canada NNP p
, , p
many JJ p
of IN p
which WDT p
were VBD p
inexperienced VBN p
in IN p
research NN p
. . p

To TO N
ensure VB N
that IN N
the DT N
results NNS N
of IN N
the DT N
trial NN N
would MD N
be VB N
reported VBN N
accurately RB N
without IN N
possible JJ N
bias NN N
due JJ N
to TO N
missing VBG N
data NNS N
, , N
the DT N
study NN N
leadership NN N
decided VBD N
that IN N
no DT N
outcome NN N
results NNS N
would MD N
be VB N
reported VBN N
until IN N
the DT N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
known VBN N
for IN N
at IN N
least JJS N
97 CD N
% NN N
of IN N
the DT N
study NN N
participants NNS N
. . N

Planning VBG N
for IN N
closeout NN N
of IN N
the DT N
study NN N
began VBD N
a DT N
year NN N
prior RB N
to TO N
the DT N
common JJ N
end NN N
date NN N
of IN N
December NNP N
31 CD N
, , N
1995 CD N
and CC N
included VBD N
plans NNS N
for IN N
obtaining VBG N
vital JJ N
status NN N
on IN N
December NNP N
31 CD N
, , N
1995 CD N
. . N

Participants NNS N
were VBD N
given VBN i
postcards NNS i
at IN i
their PRP$ i
final JJ i
study NN i
visit NN i
to TO i
be VB i
completed VBN i
and CC i
mailed VBN i
on IN i
or CC i
after IN i
January NNP i
1 CD i
, , i
1996 CD i
. . i

Of IN p
5602 CD p
postcards NNS p
distributed VBN p
, , p
5070 CD p
( ( p
90.5 CD p
% NN p
) ) p
were VBD p
completed VBN p
and CC p
returned VBN p
. . p

A DT N
contract NN N
search NN N
agency NN N
was VBD N
hired VBN N
to TO N
locate VB N
the DT N
remaining VBG N
participants NNS N
. . N

Of IN p
the DT p
total JJ p
7788 CD p
participants NNS p
entered VBD p
into IN p
the DT p
DIG NNP p
trial NN p
, , p
only RB p
97 CD p
participants NNS p
( ( p
1.2 CD p
% NN p
) ) p
could MD p
not RB p
have VB p
their PRP$ p
vital JJ o
status NN o
as IN p
of IN p
December NNP p
31 CD p
, , p
1995 CD p
determined VBD p
. . p

It PRP N
is VBZ N
recommended VBN N
that IN N
investigators NNS N
having VBG N
an DT N
outcome NN N
measure NN N
with IN N
a DT N
common JJ N
end NN N
date NN N
include VBP N
plans NNS N
in IN N
their PRP$ N
protocols NNS N
for IN N
obtaining VBG N
their PRP$ N
measures NNS N
and CC N
activate VBP N
those DT N
plans NNS N
as RB N
early RB N
as IN N
possible JJ N
during IN N
the DT N
course NN N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN o
of IN N
oral JJ N
sodium NN i
acetate JJ i
administration NN N
on IN N
plasma JJ o
acetate JJ o
concentration NN o
and CC N
acid-base JJ o
state NN o
in IN N
horses NNS p
. . p

AIM NNP N
Sodium NNP i
acetate NN i
( ( i
NaAcetate NNP i
) ) i
has VBZ N
received VBN N
some DT N
attention NN N
as IN N
an DT N
alkalinizing NN N
agent NN N
and CC N
possible JJ N
alternative JJ N
energy NN N
source NN N
for IN N
the DT N
horse NN N
, , N
however RB N
the DT N
effects NNS N
of IN N
oral JJ N
administration NN N
remain VBP N
largely RB N
unknown JJ N
. . N

The DT N
present JJ N
study NN N
used VBD N
the DT N
physicochemical JJ N
approach NN N
to TO N
characterize VB N
the DT N
changes NNS N
in IN N
acid-base NN o
status NN o
occurring VBG N
after IN N
oral JJ N
NaAcetate/acetic NNP N
acid NN N
( ( N
NAA NNP N
) ) N
administration NN N
in IN N
horses NNS N
. . N

METHODS NNP N
Jugular NNP o
venous JJ o
blood NN o
was VBD N
sampled VBN N
from IN N
9 CD p
exercise-conditioned JJ p
horses NNS p
on IN p
2 CD p
separate JJ p
occasions NNS p
, , N
at IN N
rest NN N
and CC N
for IN N
24 CD N
h NN N
following VBG N
a DT N
competition NN i
exercise NN i
test NN i
( ( N
CET NNP N
) ) N
designed VBN N
to TO N
simulate VB N
the DT N
speed NN N
and CC N
endurance NN N
test NN N
of IN N
3-day JJ N
event NN N
. . N

Immediately RB N
after IN N
the DT N
CETs NNP N
horses NNS N
were VBD N
allowed VBN N
water NN N
ad NN N
libitum NN N
and CC N
either DT N
: : N
1 CD N
) ) N
8 CD N
L NNP N
of IN N
a DT N
hypertonic JJ i
NaAcetate/acetic NNP i
acid NN i
solution NN i
via IN N
nasogastric JJ N
tube NN N
followed VBN N
by IN N
a DT N
typical JJ i
hay/grain NN i
meal NN i
( ( N
NAA NNP N
trial NN N
) ) N
; : N
or CC N
2 CD N
) ) N
a DT i
hay/grain JJ i
meal NN i
alone RB i
( ( N
Control NNP N
trial NN N
) ) N
. . N

RESULTS NNP N
Oral NNP N
NAA NNP N
resulted VBD N
in IN N
a DT N
profound NN o
plasma NN o
alkalosis NN o
marked VBN N
by IN N
decreased JJ N
plasma NN o
[ NNP o
H+ NNP o
] NNP o
and CC N
increased VBD N
plasma NN o
[ NN o
TCO2 NNP o
] NNP o
and CC o
[ NNP o
HCO3- NNP o
] NNP o
compared VBN N
to TO N
Control NNP N
. . N

The DT N
primary JJ N
contributor NN N
to TO N
the DT N
plasma NN o
alkalosis NN o
was VBD N
an DT N
increased VBN N
[ NN o
SID NNP o
] NNP o
, , N
as IN N
a DT N
result NN N
of IN N
increased VBN N
plasma NN N
[ NN N
Na+ NNP N
] NNP N
and CC N
decreased VBD N
plasma NNS N
[ JJ N
Cl- NNP N
] NNP N
. . N

An DT N
increased JJ N
[ NN o
Atot NNP o
] NNP o
, , N
due JJ N
to TO N
increased VBN N
[ NNP o
PP NNP o
] NNP o
and CC N
a DT N
sustained JJ N
increase NN N
in IN N
plasma JJ o
[ JJ o
acetate NN o
] NN o
, , N
contributed VBD N
a DT N
minor JJ N
acidifying NN o
effect NN o
. . N

CONCLUSION VB N
It PRP N
is VBZ N
concluded VBN N
that IN N
oral JJ N
NaAcetate NNP N
could MD N
be VB N
used VBN N
as IN N
both DT N
an DT N
alkalinizing NN N
agent NN N
and CC N
an DT N
alternative JJ N
energy NN N
source NN N
in IN N
the DT N
horse NN p
. . p

-DOCSTART- -X- O O

Effects NNS N
of IN N
irrigation NN N
fluid NN N
temperature NN N
on IN N
core NN N
body NN N
temperature NN N
during IN N
transurethral JJ i
resection NN i
of IN N
the DT N
prostate NN N
. . N

OBJECTIVES UH N
To TO N
determine VB N
the DT N
effect NN N
irrigation NN N
fluid NN N
temperature NN N
has VBZ N
on IN N
core NN N
body NN N
temperature NN N
changes NNS N
in IN N
patients NNS p
undergoing JJ p
transurethral JJ i
resection NN i
of IN i
the DT i
prostate NN i
( ( i
TURP NNP i
) ) i
. . p

METHODS NNP N
Fifty-six NNP p
male NN p
patients NNS p
( ( p
mean JJ p
age NN p
71.2 CD p
+/- JJ p
8.2 CD p
years NNS p
) ) p
scheduled VBD p
for IN p
TURP NNP p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Group NNP N
1 CD N
consisted VBD N
of IN N
27 CD p
patients NNS p
who WP N
received VBD N
room NN i
temperature NN i
irrigation NN i
fluid NN i
( ( i
70 CD i
degrees NNS i
F NNP i
) ) i
throughout IN i
TURP NNP i
; : i
group NN N
2 CD N
consisted VBD N
of IN N
29 CD p
patients NNS p
whose WP$ N
procedure NN N
was VBD N
performed VBN N
with IN N
warmed JJ i
irrigation NN i
fluid NN i
( ( N
91.5 CD N
degrees NNS N
F NNP N
) ) N
. . N

The DT N
irrigation NN N
fluid NN N
used VBN N
for IN N
both DT N
groups NNS N
was VBD N
glycine NN N
. . N

The DT N
baseline NN N
temperature NN N
, , N
final JJ N
temperature NN N
, , N
total JJ N
time NN N
in IN N
the DT N
operating NN N
room NN N
, , N
and CC N
amount NN N
of IN N
irrigation NN N
fluid NN N
used VBN N
during IN N
the DT N
procedure NN N
were VBD N
recorded VBN N
for IN N
each DT N
patient NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
in IN N
the DT N
average JJ o
time NN o
spent VBN o
in IN o
the DT o
operating NN o
room NN o
or CC o
in IN o
the DT o
total JJ o
irrigation NN o
fluid NN o
used VBN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
observed VBN N
. . N

Of IN N
the DT N
27 CD N
patients NNS N
who WP N
received VBD N
room NN o
temperature NN o
irrigation NN o
fluid NN o
, , N
15 CD N
( ( N
55.6 CD N
% NN N
) ) N
had VBD N
a DT N
decrease NN N
in IN N
body NN o
temperature NN o
. . o

A DT N
decrease NN N
in IN N
temperature NN o
was VBD N
observed VBN N
in IN N
21 CD N
( ( N
72.4 CD N
% NN N
) ) N
of IN N
the DT N
29 CD N
patients NNS N
who WP N
received VBD N
warm JJ i
irrigation NN o
fluid NN o
. . o

Groups NNP N
1 CD N
and CC N
2 CD N
had VBD N
12 CD N
( ( N
44.4 CD N
% NN N
) ) N
of IN N
27 CD N
and CC N
8 CD N
( ( N
27.6 CD N
% NN N
) ) N
of IN N
29 CD N
patients NNS N
, , N
respectively RB N
, , N
who WP N
demonstrated VBD N
an DT N
elevation NN o
in IN N
their PRP$ N
core NN o
body NN o
temperature NN o
. . o

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
our PRP$ N
study NN N
suggest VBP N
that IN N
irrigation NN N
fluid NN N
temperature NN N
is VBZ N
not RB N
a DT N
factor NN N
responsible JJ N
for IN N
altering VBG N
the DT N
core NN N
body NN o
temperature NN o
in IN N
patients NNS N
undergoing JJ N
TURP NNP N
. . N

-DOCSTART- -X- O O

West NNP N
vs. FW N
West NNP N
like IN N
East NNP N
vs. FW N
West NNP N
? . N
A NNP N
comparison NN N
between IN N
Italian JJ p
and CC p
US JJ p
American JJ p
context NN p
sensitivity NN p
and CC p
Fear NNP p
of IN p
Isolation NNP p
. . p

Easterners NNS p
tend VBP N
to TO N
process VB N
information NN N
more RBR N
holistically RB N
than IN N
Westerners NNS p
. . p

Kim NNP N
and CC N
Markman NNP N
( ( N
J NNP N
Exp NNP N
Soc NNP N
Psychol NNP N
42 CD N
( ( N
3 CD N
) ) N
:350-364 NN N
, , N
2006 CD N
) ) N
suggest VBP N
that IN N
these DT N
differences NNS N
are VBP N
rooted VBN N
in IN N
higher JJR N
chronic NN o
levels NNS N
of IN N
Fear NNP N
of IN N
Isolation NNP N
( ( N
FOI NNP N
) ) N
for IN N
those DT N
cultures NNS N
that WDT N
process VBP N
information NN N
more RBR N
holistically RB N
. . N

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
these DT N
differences NNS o
and CC N
their PRP$ N
suggested VBN N
cause NN N
could MD N
be VB N
found VBN N
with IN N
two CD p
different JJ p
Western JJ p
cultures NNS p
. . p

Testing VBG p
Italian JJ p
( ( p
IT NNP p
) ) p
and CC p
US JJ p
American NNP p
( ( p
US NNP p
) ) p
adults NNS p
, , N
we PRP N
found VBD N
that IN N
IT NNP N
participants VBZ N
processed VBN N
information NN o
more RBR o
holistically RB o
and CC o
had VBD o
a DT o
higher JJR o
chronic JJ o
level NN o
of IN o
FOI NNP o
than IN N
US NNP N
participants NNS N
; : N
furthermore RB N
, , N
the DT N
manipulation NN N
of IN N
FOI NNP o
affected VBD o
context JJ o
sensitivity NN o
more RBR N
for IN N
IT NNP N
than IN N
for IN N
US JJ p
participants NNS p
. . p

The DT N
results NNS N
demonstrate VBP N
that IN N
IT NNP N
participants NNS N
were VBD N
more JJR N
similar JJ N
to TO N
previous JJ N
research NN N
with IN N
Eastern NNP p
populations NNS p
than IN N
with IN N
Western JJ N
populations NNS N
( ( N
Kim NNP N
and CC N
Markman NNP N
in IN N
J NNP N
Exp NNP N
Soc NNP N
Psychol NNP N
42 CD N
( ( N
3 CD N
) ) N
:350-364 NN N
, , N
2006 CD N
) ) N
and CC N
indicate VB N
a DT N
within-Western JJ N
culture NN N
difference NN N
for IN N
reasoning VBG N
styles NNS N
and CC N
support VB N
the DT N
hypothesis NN N
that IN N
this DT o
difference NN o
is VBZ o
due JJ o
to TO o
different JJ o
chronic JJ o
levels NNS o
of IN o
FOI NNP o
. . o

-DOCSTART- -X- O O

Baseline NNP N
distribution NN N
of IN N
participants NNS p
with IN p
depression NN p
and CC p
impaired JJ p
quality NN p
of IN p
life NN p
in IN N
the DT N
Treatment NNP N
of IN N
Preserved NNP N
Cardiac NNP N
Function NNP N
Heart NNP N
Failure NNP N
with IN N
an DT N
Aldosterone NNP N
Antagonist NNP N
Trial NNP N
. . N

BACKGROUND NNP N
Previous NNP N
studies NNS N
have VBP N
demonstrated VBN N
the DT N
psychosocial JJ N
effect NN N
of IN N
heart NN N
failure NN N
in IN N
patients NNS p
with IN p
reduced JJ p
ejection NN p
fraction NN p
. . p

However RB N
, , N
the DT N
effects NNS N
on IN N
patients NNS N
with IN N
preserved JJ N
ejection NN N
fraction NN N
have VBP N
not RB N
yet RB N
been VBN N
elucidated VBN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
determine VB N
the DT N
baseline NN N
characteristics NNS N
of IN N
participants NNS p
with IN p
heart NN p
failure NN p
with IN p
preserved JJ p
ejection NN p
fraction NN p
as IN N
it PRP N
relates VBZ N
to TO N
impaired JJ N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
and CC N
depression NN N
, , N
identify JJ N
predictors NNS N
of IN N
poor JJ N
QOL NNP N
and CC N
depression NN N
, , N
and CC N
determine VB N
the DT N
correlation NN N
between IN N
QOL NNP N
and CC N
depression NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Among IN N
patients NNS p
enrolled VBN p
in IN p
the DT p
Treatment NNP p
of IN p
Preserved NNP p
Cardiac NNP p
Function NNP p
Heart NNP p
Failure NNP p
With IN p
an DT p
Aldosterone NNP i
Antagonist NNP i
Trial NNP i
( ( i
TOPCAT NNP i
) ) i
, , p
3400 CD p
patients NNS p
completed VBD p
the DT p
Kansas NNP o
City NNP o
Cardiomyopathy NNP o
Questionnaire NNP o
, , p
3395 CD p
patients NNS p
completed VBN p
European JJ o
QOL NNP o
5D CD o
Visual NNP o
Analog NNP o
Scale NNP o
, , p
and CC p
1431 CD p
patients NNS p
in IN p
United NNP p
States NNPS p
and CC p
Canada NNP p
completed VBD p
the DT p
Patient NNP o
Health NNP o
Questionnaire-9 NNP o
. . o

The DT N
mean JJ N
summary JJ N
score NN N
on IN N
the DT N
Kansas NNP o
City NNP o
Cardiomyopathy NNP o
Questionnaire NNP o
was VBD N
54.8 CD N
, , N
and CC N
on IN N
European JJ o
QOL NNP o
5D CD o
Visual NNP o
Analog NNP o
Scale NNP o
, , N
it PRP N
was VBD N
60.3 CD N
; : N
27 CD N
% NN N
of IN N
patients NNS N
had VBD N
moderate JJ N
to TO N
severe JJ N
depression NN N
. . N

Factors NNS N
associated VBD N
with IN N
better JJR N
Kansas NNP o
City NNP o
Cardiomyopathy NNP o
Questionnaire NNP o
and CC o
European NNP o
QOL NNP o
5D CD o
Visual NNP o
Analog NNP o
Scale NNP o
via IN N
multiple JJ N
logistic JJ N
regression NN N
analysis NN N
were VBD N
American JJ N
region NN N
, , N
older JJR N
age NN N
, , N
no DT N
history NN N
of IN N
angina JJ N
pectoris NN N
or CC N
asthma NN N
, , N
no DT N
use NN N
of IN N
hypoglycemic JJ N
agent NN N
, , N
more JJR N
activity NN N
level NN N
, , N
and CC N
lower JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
. . N

Factors NNS N
associated VBD N
with IN N
depression NN N
via IN N
multiple JJ N
logistic JJ N
regression NN N
analysis NN N
included VBD N
younger JJR N
age NN N
, , N
female JJ N
sex NN N
, , N
comorbid NN N
angina NN N
, , N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
, , N
use NN N
of IN N
a DT N
hypoglycemic JJ N
agent NN N
, , N
lower JJR N
activity NN N
level NN N
, , N
higher JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
, , N
and CC N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
use NN N
. . N

There EX N
were VBD N
significant JJ N
correlations NNS N
between IN N
each DT N
of IN N
the DT N
QOL NNP o
scores NNS o
and CC o
depression NN o
. . o

CONCLUSIONS JJ N
Patients NNS p
with IN p
heart NN p
failure NN p
with IN p
preserved JJ p
ejection NN p
fraction NN p
, , p
who WP p
were VBD p
younger JJR p
had VBD p
higher JJR p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
or CC p
comorbid NN p
angina NNS p
pectoris NN p
, , p
had VBD p
lower JJR p
activity NN p
levels NNS p
, , p
lived VBD p
in IN p
Eastern NNP p
Europe NNP p
or CC p
were VBD p
taking VBG p
hypoglycemic JJ p
agents NNS p
, , N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
impaired VBN p
QOL NNP p
and CC p
depression NN p
. . p

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique NNP N
identifier NN N
: : N
NCT00094302 NNP N
. . N

-DOCSTART- -X- O O

Osteosarcoma NN N
: : N
the DT N
addition NN N
of IN N
muramyl NN i
tripeptide NN i
to TO N
chemotherapy VB N
improves NNS N
overall JJ o
survival NN o
-- : o
a DT o
report NN N
from IN N
the DT N
Children NNP p
's POS p
Oncology NNP p
Group NNP p
. . p

PURPOSE NNP N
To TO N
compare VB N
three-drug JJ N
chemotherapy NN N
with IN N
cisplatin NN i
, , i
doxorubicin NN i
, , i
and CC i
methotrexate NN i
with IN N
four-drug JJ i
chemotherapy NN i
with IN i
cisplatin NN i
, , i
doxorubicin NN i
, , i
methotrexate NN i
, , i
and CC i
ifosfamide NN i
for IN N
the DT N
treatment NN N
of IN N
osteosarcoma NN N
. . N

To TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
muramyl NN i
tripeptide NN i
( ( i
MTP NNP i
) ) i
to TO N
chemotherapy VB N
enhances NNS N
event-free JJ o
survival NN o
( ( o
EFS NNP o
) ) o
and CC o
overall JJ o
survival NN o
in IN N
newly RB N
diagnosed VBN N
patients NNS N
with IN N
osteosarcoma NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Six NNP p
hundred VBD p
sixty-two JJ p
patients NNS p
with IN p
osteosarcoma NN p
without IN p
clinically RB p
detectable JJ p
metastatic JJ p
disease NN p
and CC p
whose WP$ p
disease NN p
was VBD p
considered VBN p
resectable JJ p
received VBD p
one CD p
of IN p
four CD p
prospectively RB p
randomized JJ p
treatments NNS p
. . p

All DT N
patients NNS N
received VBD N
identical JJ N
cumulative JJ N
doses NNS N
of IN N
cisplatin NN i
, , i
doxorubicin NN i
, , i
and CC i
methotrexate NN i
and CC N
underwent JJ N
definitive JJ N
surgical JJ N
resection NN N
of IN N
primary JJ N
tumor NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
or CC N
not RB N
to TO N
receive VB i
ifosfamide JJ i
and/or NN i
MTP NNP i
in IN N
a DT N
2 CD N
x NN N
2 CD N
factorial JJ N
design NN N
. . N

The DT N
primary JJ N
end NN N
points NNS N
for IN N
analysis NN N
were VBD N
EFS NNP o
and CC o
overall JJ o
survival NN o
. . o

RESULTS NNP N
In IN N
the DT N
current JJ N
analysis NN N
, , N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
interaction NN N
, , N
and CC N
we PRP N
were VBD N
able JJ N
to TO N
examine VB N
each DT N
intervention NN N
separately RB N
. . N

The DT N
chemotherapy NN N
regimens VBZ N
resulted VBN N
in IN N
similar JJ N
EFS NNP o
and CC o
overall JJ o
survival NN o
. . o

There EX N
was VBD N
a DT N
trend NN N
toward IN N
better JJR N
EFS NN o
with IN N
the DT N
addition NN N
of IN N
MTP NNP N
( ( N
P NNP N
= NNP N
.08 NNP N
) ) N
. . N

The DT N
addition NN N
of IN N
MTP NNP N
to TO N
chemotherapy VB N
improved JJ N
6-year JJ o
overall JJ o
survival NN o
from IN N
70 CD N
% NN N
to TO N
78 CD N
% NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

The DT N
hazard NN o
ratio NN o
for IN o
overall JJ o
survival NN o
with IN N
the DT N
addition NN N
of IN N
MTP NNP N
was VBD N
0.71 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.52 CD N
to TO N
0.96 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
ifosfamide NN N
to TO N
cisplatin VB N
, , N
doxorubicin NN N
, , N
and CC N
methotrexate NN N
did VBD N
not RB N
enhance VB N
EFS NNP o
or CC N
overall JJ o
survival NN o
for IN N
patients NNS N
with IN N
osteosarcoma NN N
. . N

The DT N
addition NN N
of IN N
MTP NNP N
to TO N
chemotherapy VB N
resulted VBN N
in IN N
a DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
overall JJ o
survival NN o
and CC N
a DT N
trend NN N
toward IN N
better JJR N
EFS NNP o
. . o

-DOCSTART- -X- O O

B-type JJ i
natriuretic JJ i
peptide NN i
in IN N
the DT N
evaluation NN N
and CC N
management NN N
of IN N
dyspnoea NN p
in IN p
primary JJ p
care NN p
. . p

OBJECTIVES IN N
The DT N
rapid JJ N
and CC N
accurate JJ N
diagnosis NN N
of IN N
heart NN p
failure NN p
in IN p
primary JJ p
care NN p
is VBZ N
a DT N
major JJ N
unmet JJ N
clinical JJ N
need NN N
. . N

We PRP N
evaluated VBD N
the DT N
additional JJ N
use NN N
of IN N
B-type NNP o
natriuretic JJ o
peptide NN o
( ( o
BNP NNP o
) ) o
levels NNS o
. . o

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

SETTING CC N
Twenty-nine JJ p
primary JJ p
care NN p
physicians NNS p
in IN p
Switzerland NNP p
and CC p
Germany NNP p
coordinated VBN p
by IN p
the DT p
University NNP p
Hospital NNP p
Basel NNP p
, , p
Switzerland NNP p
. . p

SUBJECTS NNP N
A NNP N
total NN p
of IN p
323 CD p
consecutive JJ p
patients NNS p
presenting VBG p
with IN p
dyspnoea NN p
. . p

INTERVENTIONS NNP N
Assignment NNP N
in IN N
a DT N
1 CD N
: : N
1 CD N
ratio NN N
to TO N
a DT N
diagnostic JJ i
strategy NN i
including VBG i
point-of-care JJ i
measurement NN i
of IN i
BNP NNP i
( ( N
n JJ N
= NNP N
163 CD N
) ) N
or CC N
standard JJ i
assessment NN i
without IN i
BNP NNP i
( ( N
n JJ N
= NNP N
160 CD N
) ) N
. . N

The DT N
total JJ o
medical JJ o
cost NN o
at IN o
3 CD o
months NNS o
was VBD N
the DT N
primary JJ N
end-point NN N
. . N

Secondary JJ N
end-points NNS N
were VBD N
diagnostic JJ o
certainty NN o
, , o
time NN o
to TO o
appropriate VB o
therapy NN o
, , o
functional JJ o
capacity NN o
, , o
hospitalization NN o
and CC o
mortality NN o
. . o

The DT N
final JJ N
diagnosis NN N
was VBD N
adjudicated VBN N
by IN N
a DT N
physician NN N
blinded VBN N
to TO N
the DT N
BNP NNP N
levels NNS N
. . N

RESULTS NNP N
Heart NNP o
failure NN o
was VBD N
the DT N
final JJ N
diagnosis NN N
in IN N
34 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
number NN o
of IN o
hospitalizations NNS o
, , o
functional JJ o
status NN o
and CC o
total JJ o
medical JJ o
cost NN o
at IN o
3 CD o
months NNS o
[ JJ N
median JJ N
$ $ N
1655 CD N
, , N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
, , N
850-3331 JJ N
vs. IN N
$ $ N
1541 CD N
, , N
IQR NNP N
859-2827 CD N
; : N
P NNP N
= VBD N
0.68 CD N
] NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

BNP NNP o
increased VBD N
diagnostic JJ o
certainty NN o
as IN N
defined VBN N
by IN N
the DT N
need NN N
for IN N
further JJ N
diagnostic JJ N
work-up NN N
( ( N
33 CD N
% NN N
vs. FW N
45 CD N
% NN N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
accelerated VBD N
the DT N
initiation NN N
of IN N
the DT N
appropriate JJ N
treatment NN N
( ( N
13 CD N
days NNS N
vs. FW N
25 CD N
days NNS N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

The DT N
area NN N
under IN N
the DT N
receiver-operating JJ N
characteristics NNS N
curve NN N
for IN N
BNP NNP N
to TO N
identify VB N
heart NN N
failure NN N
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.81-0.93 JJ N
) ) N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
BNP NNP i
levels NNS i
in IN N
primary JJ N
care NN N
did VBD N
not RB N
reduce VB N
total JJ N
medical JJ N
cost NN N
, , N
but CC N
improved VBD N
some DT N
of IN N
the DT N
secondary JJ N
end-points NNS N
including VBG N
diagnostic JJ N
certainty NN N
and CC N
time NN N
to TO N
initiation NN N
of IN N
appropriate JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
iron NN i
supplements NNS i
and CC N
perinatal JJ N
factors NNS N
on IN N
fetal JJ N
hemoglobin NN N
disappearance NN N
in IN N
LBW NNP p
infants NNS p
. . p

BACKGROUND IN N
The DT N
homeostatic JJ N
mechanisms NN N
of IN N
iron NN N
metabolism NN N
and CC N
erythropoiesis NN N
in IN N
infants NNS N
are VBP N
unclear JJ N
. . N

Infants NNS N
synthesize VB N
both DT N
fetal JJ N
hemoglobin NN N
( ( N
HbF NNP N
) ) N
and CC N
adult NN N
hemoglobin NN N
( ( N
HbA NNP N
) ) N
, , N
and CC N
it PRP N
is VBZ N
not RB N
known VBN N
how WRB N
the DT N
hemoglobin NN N
switch NN N
is VBZ N
regulated VBN N
. . N

We PRP N
hypothesized VBD N
that IN N
iron NN N
supplements NNS N
to TO N
infants NNS N
affect VB N
the DT N
disappearance NN N
of IN N
HbF NNP N
. . N

METHODS NNP N
We PRP N
randomized VBD N
285 CD p
low-birth-weight JJ p
infants NNS p
( ( p
2,000-2,500 JJ p
g NN p
) ) p
into IN p
three CD N
intervention NN N
groups NNS i
receiving VBG i
0 CD i
, , i
1 CD i
, , i
or CC i
2 CD i
mg/kg/d NN i
of IN i
iron NN i
supplements NNS i
from IN i
6 CD i
wk NN i
to TO i
6 CD i
mo NN i
of IN i
age NN i
. . i

In IN N
the DT N
present JJ N
secondary JJ N
analysis NN i
, , i
we PRP i
analyzed VBD o
iron NN o
status NN o
, , o
total JJ o
hemoglobin NN o
( ( o
Hb NNP o
) ) o
, , o
and CC o
HbF NNP o
fraction NN o
at IN i
6 CD i
wk NN N
, , N
12 CD N
wk NN N
, , N
and CC N
at IN N
6 CD N
mo NN N
and CC N
calculated VBD N
absolute JJ N
levels NNS N
of IN N
HbF NNP N
. . N

RESULTS NNP N
We PRP N
observed VBD N
dose-dependent JJ N
increased JJ N
levels NNS N
of IN N
Hb NNP o
in IN o
iron-supplemented JJ N
groups NNS N
at IN N
6 CD N
mo NN N
of IN N
age NN N
. . N

However RB N
, , N
for IN o
absolute JJ o
HbF NNP o
concentration NN o
, , o
there EX o
was VBD o
no DT N
similar JJ N
effect NN N
of IN N
intervention NN o
. . o

Mean NNP o
( ( o
SD NNP o
) ) o
HbF NNP o
was VBD N
81.2 CD N
( ( N
16.8 CD N
) ) N
, , N
37.0 CD N
( ( N
13.8 CD N
) ) N
, , N
and CC N
8.1 CD N
( ( N
5.6 CD N
) ) N
g/l NN N
at IN N
6 CD N
wk NN N
, , N
12 CD N
wk NN N
, , N
and CC N
6 CD N
mo NN N
, , N
respectively RB N
, , N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

In IN N
linear JJ N
regression NN N
analyses NNS N
, , N
postconceptional JJ N
age NN N
turned VBD N
out RP N
as IN N
the DT N
major JJ N
predictor NN N
of IN N
HbF NNP N
, , N
independent JJ N
of IN N
gestational JJ N
age NN N
at IN N
birth NN N
. . N

CONCLUSION NNP N
Our PRP$ N
hypothesis NN N
was VBD N
rejected VBN N
. . N

Instead RB N
, , N
we PRP N
confirmed VBD N
a DT N
close JJ N
correlation NN N
to TO N
postconceptional JJ N
age NN N
, , N
supporting VBG N
a DT N
genetically RB N
programmed VBN N
switch NN N
, , N
insensitive JJ N
to TO N
most JJS N
environmental JJ N
factors NNS N
including VBG N
birth NN N
. . N

-DOCSTART- -X- O O

Relaxing VBG i
retinotomy NN i
with IN i
silicone JJ i
oil NN i
or CC i
long-acting NN i
gas NN i
in IN N
eyes NNS p
with IN p
severe JJ p
proliferative JJ p
vitreoretinopathy NN p
. . p

Silicone NNP N
Study NNP N
Report NNP N
5 CD N
. . N

The DT N
Silicone NNP N
Study NNP N
Group NNP N
. . N

In IN N
the DT N
Silicone NNP N
Study NNP N
, , N
117 CD p
of IN p
404 CD p
eyes NNS p
( ( p
29 CD p
% NN p
) ) p
with IN p
severe JJ p
proliferative JJ p
vitreoretinopathy NN p
( ( p
> CD p
or CC p
= VB p
C-3 NNP p
, , p
full-thickness JJ p
retinal JJ p
folds NNS p
in IN p
three CD p
or CC p
more JJR p
quadrants NNS p
) ) p
enrolled VBD N
in IN N
the DT N
study NN N
were VBD N
treated VBN N
with IN N
vitrectomy NN i
, , N
underwent VBD N
a DT N
relaxing VBG i
retinotomy NN i
, , N
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN i
with IN i
long-acting JJ i
gas NN i
or CC i
silicone NN i
oil NN i
. . i

Forty-six JJ p
eyes NNS p
( ( N
20 CD N
% NN N
) ) N
had VBD N
undergone JJ N
no DT N
previous JJ N
vitrectomy NN N
( ( N
group NN N
1 CD N
) ) N
; : N
71 CD N
eyes NNS N
( ( N
42 CD N
% NN N
) ) N
had VBD N
undergone JJ N
previous JJ N
vitrectomy NN N
( ( N
group NN N
2 CD N
) ) N
with IN N
intraocular JJ N
gas NN N
tamponade NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Group NNP N
1 CD N
eyes NNS N
not RB N
undergoing VBG N
retinotomy NN N
had VBD N
better JJR o
anatomic JJ o
( ( o
six CD o
months NNS o
) ) o
and CC o
visual JJ o
( ( o
six CD o
and CC o
24 CD o
months NNS o
) ) o
outcomes NNS o
and CC o
less JJR o
hypotony NN o
( ( N
six CD N
months NNS N
) ) N
than IN N
eyes NNS N
that WDT N
did VBD N
regardless RB N
of IN N
tamponade NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

For IN N
eyes NNS N
undergoing VBG N
retinotomy NN N
, , N
silicone NN N
oil NN N
decreased VBD o
the DT o
likelihood NN o
of IN o
hypotony NN o
( ( N
six CD N
months NNS N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

These DT N
differences NNS N
were VBD N
not RB N
found VBN N
in IN N
group NN N
2 CD N
eyes NNS N
. . N

We PRP N
conclude VBP N
that IN N
eyes NNS N
undergoing VBG N
a DT N
vitreous JJ N
operation NN N
for IN N
the DT N
first JJ N
time NN N
for IN N
the DT N
treatment NN N
of IN N
proliferative JJ o
vitreoretinopathy NN o
can MD N
in IN N
most JJS N
instances NNS N
be VB N
successfully RB N
treated VBN N
by IN N
conventional JJ N
techniques NNS N
without IN N
the DT N
need NN N
for IN N
relaxing VBG N
retinotomy NN N
. . N

Retinotomy NNP N
may MD N
be VB N
required VBN N
more RBR N
often RB N
in IN N
patients NNS N
undergoing VBG N
repeat NN N
vitreous JJ N
surgery NN N
for IN N
proliferative JJ N
vitreoretinopathy NN N
, , N
in IN N
which WDT N
case NN N
both DT N
silicone NN N
oil NN N
and CC N
long-acting NN N
perflouropropane NN i
gas NN N
appear VBP N
to TO N
be VB N
equally RB o
effective JJ o
. . o

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
angiotensin JJ i
II-receptor NNP i
blocker NN i
vs. FW N
dihydropiridine NN i
calcium NN i
channel NN i
blocker NN i
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ p
atrial JJ p
fibrillation NN p
with IN p
hypertension NN p
( ( N
J-RHYTHM NNP N
II NNP N
study NN N
) ) N
. . N

AIMS NNP N
Atrial NNP N
fibrillation NN N
( ( N
AF NNP N
) ) N
is VBZ N
a DT N
common JJ N
arrhythmia NN N
frequently RB N
associated VBN N
with IN N
hypertension NN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
lowering VBG N
blood NN N
pressure NN N
by IN N
angiotensin JJ i
II-receptor NNP i
blockers NNS i
( ( i
ARB NNP i
) ) i
has VBZ N
more JJR N
beneficial JJ N
effects NNS N
than IN N
by IN N
conventional JJ i
calcium NN i
channel NN i
blockers NNS i
( ( i
CCB NNP i
) ) i
on IN N
the DT N
frequency NN N
of IN N
paroxysmal JJ N
AF NNP N
with IN N
hypertension NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
Japanese JJ p
Rhythm NNP p
Management NNP p
Trial NNP p
II NNP p
for IN p
Atrial NNP p
Fibrillation NNP p
( ( p
J-RHYTHM NNP p
II NNP p
study NN p
) ) p
is VBZ N
an DT N
open-label JJ N
randomized JJ N
comparison NN N
between IN N
an DT N
ARB NNP i
( ( i
candesartan NN i
) ) i
and CC N
a DT N
CCB NNP i
( ( i
amlodipine NN i
) ) i
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ N
AF NNP N
associated VBN N
with IN N
hypertension NN N
. . N

Using VBG N
daily JJ N
transtelephonic JJ i
monitoring NN i
, , N
we PRP N
examined VBD N
asymptomatic JJ N
and CC N
symptomatic JJ N
paroxysmal NN o
AF NNP o
episodes VBZ N
during IN N
a DT N
maximum JJ N
1 CD N
year NN N
treatment NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
difference NN o
in IN o
AF NNP o
frequency NN o
between IN N
the DT N
pre-treatment JJ N
period NN N
and CC N
the DT N
final JJ N
month NN N
of IN N
the DT N
follow-up NN N
. . N

The DT N
secondary JJ N
endpoints NNS N
included VBD N
cardiovascular JJ o
events NNS o
, , o
development NN o
of IN o
persistent JJ o
AF NNP o
, , o
left VBD o
atrial JJ o
dimension NN o
, , o
and CC o
quality-of-life NN o
( ( o
QOL NNP o
) ) o
. . o

The DT p
study NN p
enrolled VBD p
318 CD p
patients NNS p
( ( p
66 CD p
years NNS p
, , p
male/female JJ p
219/99 CD p
, , p
158 CD p
in IN p
the DT p
ARB NNP i
group NN p
and CC p
160 CD p
in IN p
the DT p
CCB NNP i
group NN p
) ) p
treated VBD p
at IN p
48 CD p
sites NNS p
throughout IN p
Japan NNP p
. . p

At IN p
baseline NN p
, , p
the DT p
frequency NN o
of IN o
AF NNP o
episodes NNS o
( ( p
days/month NN p
) ) p
was VBD p
3.8 CD p
? . p
5.0 CD p
in IN p
the DT p
ARB NNP p
group NN p
vs. FW p
4.8 CD p
? . p
6.3 CD p
in IN p
the DT p
CCB NNP p
group NN p
( ( p
not RB N
significant JJ N
) ) N
. . N

During IN N
the DT N
follow-up JJ o
, , o
blood NN o
pressure NN o
was VBD o
significantly RB N
lower JJR N
in IN N
the DT N
CCB NNP N
group NN N
than IN N
in IN N
the DT N
ARB NNP N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT o
AF NNP o
frequency NN o
decreased VBD o
similarly RB N
in IN N
both DT N
groups NNS N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
primary JJ N
endpoint NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT o
development NN o
of IN o
persistent JJ o
AF NNP o
, , o
changes NNS o
in IN o
left JJ o
atrial JJ o
dimension NN o
, , o
occurrence NN o
of IN o
cardiovascular JJ o
events NNS o
, , o
or CC o
changes NNS o
in IN o
QOL NNP o
. . o

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
paroxysmal JJ p
AF NNP p
and CC p
hypertension NN p
, , p
treatment NN N
of IN N
hypertension NN N
by IN N
candesartan NN i
did VBD i
not RB N
have VB N
an DT N
advantage NN N
over RP i
amlodipine NN i
in IN i
the DT N
reduction NN N
in IN N
the DT N
frequency NN N
of IN N
paroxysmal JJ N
AF NNP N
( ( N
umin JJ N
CTR NNP N
C000000427 NNP N
) ) N
. . N

-DOCSTART- -X- O O

Combined VBN N
use NN N
of IN N
vasopressin NN i
and CC N
synthetic JJ i
hypothalamic JJ i
releasing NN i
factors NNS i
as IN N
a DT N
new JJ N
test NN N
of IN N
anterior JJ N
pituitary JJ N
function NN N
. . N

Nine NNP p
normal JJ p
volunteers NNS p
and CC p
15 CD p
patients NNS p
with IN p
pituitary JJ p
disorders NNS p
were VBD N
given VBN N
a DT N
combined JJ N
test NN N
of IN N
anterior JJ N
pituitary JJ N
function NN N
using VBG N
four CD N
hypothalamic JJ N
releasing VBG N
factors NNS N
and CC N
arginine JJ i
vasopressin NN i
. . i

Rapid JJ N
sequential JJ N
intravenous JJ N
infusions NNS N
of IN N
human JJ i
corticotrophin NN i
releasing VBG N
factor NN N
100 CD N
micrograms NNS N
, , N
growth NN i
hormone NN i
releasing VBG N
factor NN N
100 CD N
micrograms NNS N
, , N
luteinising VBG i
hormone NN i
releasing VBG N
hormone NN N
100 CD N
micrograms NNS N
, , N
and CC N
thyrotrophin IN i
releasing VBG N
hormone NN N
200 CD N
micrograms NNS N
were VBD N
administered VBN N
. . N

Arginine NNP i
vasopressin NN i
( ( N
10 CD N
pressor NN N
units NNS N
) ) N
was VBD N
given VBN N
intramuscularly RB N
at IN N
the DT N
same JJ N
time NN N
. . N

Plasma NNP N
or CC N
serum NN N
samples NNS N
were VBD N
assayed VBN N
for IN N
concentrations NNS N
of IN N
cortisol NN N
, , N
growth NN N
hormone NN N
, , N
luteinising VBG N
hormone NN N
, , N
follicle NN N
stimulating VBG N
hormone NN N
, , N
prolactin NN N
, , N
and CC N
thyroid JJ N
stimulating VBG N
hormone NN N
at IN N
multiple JJ N
times NNS N
for IN N
120 CD N
minutes NNS N
. . N

No DT N
troublesome JJ N
side NN o
effects NNS o
occurred VBD N
. . N

The DT N
results NNS N
of IN N
the DT N
releasing VBG N
factor NN N
combined VBD N
test NN N
with IN N
arginine JJ N
vasopressin NN N
were VBD N
compared VBN N
in IN N
the DT N
same JJ N
subjects NNS N
with IN N
a DT N
conventional JJ N
combined JJ N
test NN N
using VBG N
insulin NN N
together RB N
with IN N
thyrotrophin JJ N
releasing VBG N
hormone NN N
and CC N
luteinising VBG N
hormone NN N
releasing VBG N
hormone NN N
. . N

No DT N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
basal NN o
and CC o
peak JJ o
concentrations NNS o
of IN o
luteinising VBG o
hormone NN o
, , o
follicle NN o
stimulating VBG o
hormone NN o
, , o
thyroid JJ o
stimulating VBG o
hormone NN o
, , o
and CC o
prolactin NN o
. . o

Both DT N
cortisol NN o
and CC o
growth NN o
hormone NN o
responses VBZ o
to TO N
the DT N
releasing VBG N
factors NNS N
with IN N
arginine JJ N
vasopressin NN N
were VBD N
much RB N
greater JJR N
than IN N
those DT N
seen VBN N
with IN N
insulin NN N
induced VBN N
hypoglycaemia NN N
or CC N
the DT N
combined JJ N
releasing NN N
factors NNS N
without IN N
arginine JJ N
vasopressin NN N
. . N

Patients NNS N
with IN N
pituitary JJ o
hypo-function NN o
were VBD N
similarly RB N
recognised VBN N
in IN N
both DT N
studies NNS N
. . N

There EX N
was VBD N
a DT N
rapid JJ N
increase NN N
in IN N
all DT N
hormone NN o
values NNS o
with IN N
a DT N
peak NN N
usually RB N
by IN N
60 CD N
minutes NNS N
. . N

In IN N
most JJS N
people NNS N
adequate VBP N
assessment NN N
of IN N
individual JJ N
hormone NN N
reserves NNS N
may MD N
be VB N
achieved VBN N
using VBG N
basal NN N
, , N
30 CD N
minute NN N
, , N
and CC N
60 CD N
minute NN N
samples NNS N
. . N

This DT N
new JJ N
combined JJ N
releasing NN N
factor NN N
test NN N
appears VBZ N
to TO N
be VB N
a DT N
safe JJ N
, , N
rapid JJ N
, , N
and CC N
useful JJ N
test NN N
of IN N
anterior JJ N
pituitary JJ N
function NN N
. . N

-DOCSTART- -X- O O

A DT N
crossover NN N
study NN N
of IN N
risperidone NN i
in IN N
children NNS p
, , p
adolescents NNS p
and CC p
adults NNS p
with IN p
mental JJ p
retardation NN p
. . p

Risperidone NN i
has VBZ N
shown VBN N
safety NN o
and CC o
efficacy NN o
for IN N
aggressive JJ N
and CC N
destructive JJ p
behaviors NNS N
in IN N
short-term JJ N
studies NNS N
. . N

This DT N
longer-duration NN N
study NN N
includes VBZ N
a DT N
broad JJ N
sample NN N
. . N

Forty NNP p
subjects NNS p
, , p
aged VBN p
8-56 CD p
years NNS p
( ( p
mean=22 NN p
) ) p
, , p
all DT p
with IN p
mental JJ p
retardation NN p
and CC p
36 CD p
with IN p
autism NN p
spectrum NN p
disorders NNS p
participated VBD p
in IN N
this DT N
22-week JJ N
crossover NN N
study NN N
, , N
with IN N
24 CD N
weeks NNS N
of IN N
open JJ N
maintenance NN N
thereafter RB N
. . N

Of IN N
40 CD N
subjects NNS N
, , N
23 CD N
( ( N
57.5 CD N
% NN N
) ) N
responded VBD N
fully RB N
( ( N
50 CD N
% NN N
decrease NN o
in IN o
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
Irritability NNP o
subscale NNP o
score NN o
) ) o
, , N
while IN N
35 CD N
subjects NNS N
( ( N
87.5 CD N
% NN N
) ) N
showed VBD N
a DT N
25 CD N
% NN N
decrease NN o
. . o

Gender NNP N
, , N
mood NN N
disorder NN N
, , N
and CC N
antiseizure NN N
medications NNS N
did VBD N
not RB N
alter VB N
response NN N
. . N

Increased VBN o
appetite NN o
and CC o
weight JJ o
gain NN o
were VBD N
common JJ N
. . N

Low JJ N
dose JJ N
risperidone NN N
was VBD N
effective JJ o
for IN o
aggressive JJ o
behavior NN o
in IN N
persons NNS N
with IN N
MR. NNP N
More NNP N
long-term JJ N
studies NNS N
are VBP N
needed VBN N
, , N
incorporating VBG N
weight NN N
control NN N
interventions NNS N
. . N

-DOCSTART- -X- O O

Pulse NNP i
versus NN i
continuous JJ i
terbinafine NN i
for IN N
onychomycosis NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Effective NNP N
treatments NNS N
for IN N
onychomycosis NN N
are VBP N
expensive JJ N
. . N

Previous JJ N
studies NNS N
suggest VBP N
that IN N
less JJR N
costly JJ N
, , N
pulsed JJ N
doses NNS N
of IN N
antifungal JJ i
medications NNS i
may MD N
be VB N
as RB N
effective JJ N
as IN N
standard NN N
, , N
continuous JJ N
doses NNS N
. . N

Terbinafine NNP N
is VBZ N
the DT N
current JJ N
treatment NN N
of IN N
choice NN N
for IN N
toenail JJ N
onychomycosis NN N
. . N

OBJECTIVE CC N
Our PRP$ N
purpose NN N
was VBD N
to TO N
determine VB N
whether IN N
pulse-dose JJ i
terbinafine NN i
is VBZ N
as RB N
effective JJ N
as IN N
standard JJ i
continuous-dose JJ i
terbinafine NN i
for IN N
treatment NN N
of IN N
toenail JJ N
onychomycosis NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
noninferiority NN N
, , N
clinical JJ N
intervention NN N
trial NN N
in IN N
the DT N
Minneapolis NNP p
Veterans NNP p
Affairs NNP p
Medical NNP p
Center NNP p
. . p

The DT p
main JJ p
inclusion NN p
criteria NNS p
for IN p
participants NNS p
were VBD p
a DT p
positive JJ p
dermatophyte NN p
culture NN p
and CC p
at IN p
least JJS p
25 CD p
% NN p
distal JJ p
subungual JJ p
clinical JJ p
involvement NN p
. . p

Six CD p
hundred VBD p
eighteen JJ p
volunteers NNS p
were VBD p
screened VBN p
; : p
306 CD p
were VBD p
randomized VBN p
. . p

Terbinafine NNP i
, , N
250 CD N
mg NNS N
daily RB N
for IN N
3 CD N
months NNS N
( ( N
continuous JJ N
) ) N
or CC N
terbinafine NN i
, , N
500 CD N
mg NNS N
daily RB N
for IN N
1 CD N
week NN N
per IN N
month NN N
for IN N
3 CD N
months NNS N
( ( N
pulse NN N
) ) N
was VBD N
administered VBN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
mycological JJ o
cure NN o
of IN o
the DT o
target NN o
toenail NN o
at IN o
18 CD o
months NNS o
. . o

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
clinical JJ o
cure NN o
and CC o
complete JJ o
( ( o
clinical JJ o
plus CC o
mycological JJ o
) ) o
cure NN o
of IN o
the DT o
target NN o
toenail NN o
and CC o
complete JJ o
cure NN o
of IN o
all DT o
10 CD o
toenails NNS o
. . o

RESULTS NNP N
Results NNP N
of IN N
an DT N
intent-to-treat JJ N
analysis NN N
did VBD N
not RB N
meet VB N
the DT N
prespecified JJ N
criterion NN N
for IN N
noninferiority NN N
but CC N
did VBD N
demonstrate VB N
the DT N
superiority NN N
of IN N
continuous-dose JJ i
terbinafine NN i
for IN N
: : N
mycological JJ o
cure NN o
of IN N
the DT N
target NN N
toenail NN N
( ( N
70.9 CD N
% NN N
[ CC N
105/148 CD N
] JJ N
vs RB N
58.7 CD N
% NN N
[ CC N
84/143 CD N
] NN N
; : N
P NNP N
=.03 NNP N
, , N
relative JJ o
risk NN o
[ NNP N
RR NNP N
] NNP N
of IN N
1.21 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.02-1.43 JJ N
] NN N
) ) N
; : N
clinical JJ o
cure NN o
of IN N
the DT N
target NN N
toenail NN N
( ( N
44.6 CD N
% NN N
[ CC N
66/148 CD N
] JJ N
vs RB N
29.3 CD N
% NN N
[ CC N
42/143 CD N
] NN N
; : N
P NNP N
=.007 NNP N
, , N
RR NNP N
=1.52 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.11-2.07 JJ N
) ) N
; : N
complete JJ o
cure NN o
of IN N
the DT N
target NN N
toenail NN N
( ( N
40.5 CD N
% NN N
[ CC N
60/148 CD N
] JJ N
vs RB N
28.0 CD N
% NN N
[ CC N
40/143 CD N
] NN N
; : N
P NNP N
=.02 NNP N
, , N
RR=1.45 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.04-2.01 JJ N
) ) N
; : N
and CC N
complete JJ o
cure NN o
of IN N
all DT N
10 CD N
toenails NNS N
( ( N
25.2 CD N
% NN N
[ CC N
36/143 CD N
] JJ N
vs RB N
14.7 CD N
% NN N
[ CC N
21/143 CD N
] NN N
; : N
P NNP N
=.03 NNP N
, , N
RR NNP N
=1.71 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.05-2.79 JJ N
) ) N
. . N

Tolerability NN o
of IN N
the DT N
regimens NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
( ( N
chi2 JJ N
=1.63 NN N
; : N
P NNP N
=.65 NNP N
) ) N
. . N

LIMITATIONS VB N
The DT p
study NN p
population NN p
primarily RB p
consisted VBN p
of IN p
older JJR p
men NNS p
with IN p
severe JJ p
onychomycosis NN p
. . p

CONCLUSIONS VB N
This DT N
study NN N
demonstrated VBD N
the DT N
superiority NN N
of IN N
continuous- NN N
over IN N
pulse-dose JJ i
terbinafine NN i
. . i

We PRP N
also RB N
found VBD N
this DT N
expensive JJ N
therapy NN N
to TO N
be VB N
much RB N
less RBR N
effective JJ o
than IN N
previously RB N
believed VBN N
, , N
particularly RB N
for IN N
achieving VBG N
complete JJ N
cure NN N
of IN N
all DT N
10 CD N
toenails NNS N
. . N

-DOCSTART- -X- O O

Early JJ N
behavioral JJ N
intervention NN N
is VBZ N
associated VBN N
with IN N
normalized JJ N
brain NN o
activity NN o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

OBJECTIVE CC N
A DT N
previously RB N
published VBN N
randomized JJ N
clinical JJ N
trial NN N
indicated VBD N
that IN N
a DT N
developmental JJ N
behavioral JJ i
intervention NN i
, , N
the DT N
Early JJ N
Start NNP N
Denver NNP N
Model NNP N
( ( N
ESDM NNP N
) ) N
, , N
resulted VBD N
in IN N
gains NNS N
in IN N
IQ NNP N
, , N
language NN N
, , N
and CC N
adaptive JJ N
behavior NN N
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

This DT N
report NN N
describes VBZ N
a DT N
secondary JJ N
outcome NN N
measurement NN N
from IN N
this DT N
trial NN N
, , N
EEG NNP o
activity NN o
. . o

METHOD NNP N
Forty-eight JJ p
18- JJ p
to TO p
30-month-old JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
were VBD N
randomized VBN N
to TO N
receive VB i
the DT i
ESDM NNP i
or CC i
referral JJ i
to TO i
community NN i
intervention NN i
for IN i
2 CD i
years NNS i
. . i

After IN N
the DT N
intervention NN N
( ( N
age NN N
48 CD N
to TO N
77 CD N
months NNS N
) ) N
, , N
EEG NNP o
activity NN o
( ( o
event-related JJ o
potentials NNS o
and CC o
spectral JJ o
power NN o
) ) o
was VBD i
measured VBN i
during IN i
the DT i
presentation NN i
of IN i
faces VBZ i
versus JJ i
objects NNS i
. . i

Age-matched JJ p
typical JJ p
children NNS p
were VBD N
also RB N
assessed VBN N
. . N

RESULTS VB N
The DT N
ESDM NNP i
group NN N
exhibited VBD N
greater JJR N
improvements NNS N
in IN N
autism NN o
symptoms NNS o
, , o
IQ NNP o
, , o
language NN o
, , o
and CC o
adaptive JJ o
and CC o
social JJ o
behaviors NNS o
than IN N
the DT N
community NN N
intervention NN N
group NN N
. . N

The DT N
ESDM NNP N
group NN N
and CC N
typical JJ N
children NNS N
showed VBD N
a DT N
shorter NN o
Nc NNP o
latency NN o
and CC o
increased VBD o
cortical JJ o
activation NN o
( ( o
decreased VBN o
? . o
power NN o
and CC o
increased VBD o
? . o
power NN o
) ) o
when WRB o
viewing VBG N
faces VBZ N
, , N
whereas IN N
the DT N
community NN N
intervention NN N
group NN N
showed VBD N
the DT N
opposite JJ N
pattern NN N
( ( N
shorter JJ o
latency NN o
event-related JJ o
potential JJ o
[ NN o
ERP NNP o
] NNP o
and CC o
greater JJR o
cortical JJ o
activation NN o
when WRB o
viewing VBG N
objects NNS o
) ) o
. . o

Greater NNP o
cortical JJ o
activation NN o
while IN o
viewing VBG N
faces VBZ N
was VBD N
associated VBN N
with IN o
improved VBN o
social JJ o
behavior NN o
. . o

CONCLUSIONS VB N
This DT N
was VBD N
the DT N
first JJ N
trial NN N
to TO N
demonstrate VB N
that DT N
early JJ N
behavioral JJ N
intervention NN N
is VBZ N
associated VBN N
with IN o
normalized JJ o
patterns NNS o
of IN o
brain NN o
activity NN o
, , o
which WDT N
is VBZ N
associated VBN N
with IN o
improvements NNS o
in IN o
social JJ o
behavior NN o
, , o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

-DOCSTART- -X- O O

Effect NN N
of IN N
intravenous JJ N
dezocine NN i
on IN N
fentanyl-induced JJ p
cough NN o
during IN p
general JJ p
anesthesia JJ p
induction NN p
: : p
a DT N
double-blinded JJ N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
suppressive JJ N
effect NN N
of IN N
intravenous JJ N
dezocine NN i
on IN N
fentanyl-induced JJ N
cough NN o
during IN N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
. . N

METHODS NNP N
A NNP N
total NN p
of IN p
120 CD p
patients NNS p
, , p
American NNP p
Society NNP p
of IN p
Anesthesiologists NNP p
( ( p
ASA NNP p
) ) p
physical JJ p
status NN p
I-II NNP p
, , p
were VBD p
randomized VBN p
into IN p
two CD p
equally RB p
sized JJ p
groups NNS p
( ( p
n JJ p
= NNP p
60 CD p
) ) p
. . p

These DT N
two CD N
groups NNS N
were VBD N
given VBN N
either RB N
intravenous JJ i
dezocine NN i
0.1 CD N
mg/kg NN N
or CC i
a DT i
matching JJ i
placebo NN i
( ( N
equal JJ N
volume NN N
of IN N
0.9 CD N
% NN N
saline NN N
) ) N
10 CD N
min NN N
before IN N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
. . N

Patients NNS N
were VBD N
induced VBN N
with IN N
midazolam JJ i
0.1 CD i
mg/kg NN i
, , i
fentanyl VBP i
5 CD i
?g/kg NN i
, , i
propofol JJ i
1-1.5 JJ i
mg/kg NN i
, , i
and CC i
suxamethonium NN i
1.5 CD N
mg/kg NN N
. . N

The DT N
injection NN N
time NN N
of IN N
fentanyl NN N
was VBD N
less JJR N
than IN N
2 CD N
s NNS N
in IN N
all DT N
patients NNS N
. . N

The DT N
occurrence NN N
of IN o
cough NN o
was VBD N
recorded VBN N
2 CD N
min NN N
after IN N
fentanyl JJ N
bolus NN N
. . N

RESULTS NNP p
No NNP p
patient NN p
in IN p
the DT p
dezocine NN p
group NN p
had VBD o
cough VBN o
, , o
and CC p
42 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
had VBD o
cough NN o
. . o

This DT N
difference NN N
was VBD N
statistically RB N
different JJ N
between IN N
these DT N
two CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.000 CD N
) ) N
. . N

CONCLUSION NNP N
These DT N
results NNS N
demonstrate VBP N
that IN N
intravenous JJ i
dezocine NN i
0.1 CD N
mg/kg NN N
10 CD N
min NN N
prior RB N
to TO N
induction NN N
was VBD N
effective JJ N
in IN N
suppressing VBG p
fentanyl-induced JJ o
cough NN o
in IN p
our PRP$ p
patients NNS p
. . p

-DOCSTART- -X- O O

ApoA-I JJ i
induction NN N
as IN N
a DT N
potential JJ N
cardioprotective JJ N
strategy NN N
: : N
rationale NN N
for IN N
the DT N
SUSTAIN NNP N
and CC N
ASSURE NNP N
studies NNS N
. . N

BACKGROUND NNP N
Considerable JJ N
interest NN N
has VBZ N
focused VBN N
on IN N
the DT N
development NN N
of IN N
therapies NNS N
that WDT N
target VBP N
the DT N
functionality NN N
of IN N
high-density NN N
lipoproteins NNS N
( ( N
HDL NNP N
) ) N
. . N

Upregulation NN N
of IN N
endogenous JJ N
synthesis NN N
of IN N
the DT N
major JJ N
protein NN N
on IN N
HDL NNP N
particles NNS N
, , N
apolipoprotein RB i
A-I NNP i
( ( N
apoA-I NN N
) ) N
, , N
represents VBZ N
a DT N
novel JJ N
approach NN N
to TO N
generation NN N
of IN N
new JJ N
HDL NNP N
particles NNS N
. . N

The DT N
Study NNP N
of IN N
Quantitative NNP N
Serial NNP N
Trends NNP N
in IN N
Lipids NNP N
with IN N
Apolipoprotein NNP i
A-I NNP i
Stimulation NNP i
( ( N
SUSTAIN NNP N
, , N
NCT01423188 NNP N
) ) N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
lipid JJ o
efficacy NN o
, , o
safety NN o
and CC N
tolerability NN o
of IN N
an DT N
apoA-I JJ i
inducer NN i
( ( i
RVX-208 NNP i
) ) i
. . N

The DT N
ApoA-I JJ N
Synthesis NNP N
Stimulation NNP N
and CC N
Intravascular NNP i
Ultrasound NNP i
for IN N
Coronary NNP N
Atheroma NNP N
Regression NNP N
Evaluation NNP N
( ( N
ASSURE NNP N
, , N
NCT01067820 NNP N
) ) N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
RVX-208 NNP N
on IN N
plaque NN N
burden NN N
. . N

METHODS NNP N
In IN p
SUSTAIN NNP p
, , p
172 CD p
patients NNS p
with IN p
low JJ p
levels NNS p
of IN p
HDL-C NNP p
will MD p
be VB p
randomized VBN p
to TO N
receive VB N
RVX-208 NNP i
100 CD N
mg NN N
bid NN N
or CC N
placebo NN i
for IN N
24 CD N
weeks NNS N
. . N

The DT N
primary JJ N
efficacy NN N
parameter NN N
will MD N
be VB N
the DT N
percentage NN o
change NN o
in IN o
HDL-C NNP o
levels NNS o
. . o

In IN p
ASSURE NNP p
, , p
310 CD p
patients NNS p
with IN p
angiographic JJ p
coronary JJ p
artery NN p
disease NN p
and CC p
low JJ p
HDL-C NNP p
levels NNS p
will MD p
be VB p
randomized VBN p
to TO N
receive VB N
RVX-208 NNP i
100 CD N
mg NN N
bid NN N
or CC N
placebo NN i
for IN N
26 CD N
weeks NNS N
. . N

The DT N
primary JJ N
efficacy NN N
parameter NN N
will MD N
be VB N
the DT N
nominal JJ N
change NN N
in IN N
percent NN o
atheroma NN o
volume NN o
( ( o
PAV NNP o
) ) o
, , N
determined VBN N
by IN N
analysis NN N
of IN N
intravascular JJ N
ultrasound NN N
( ( N
IVUS NNP N
) ) N
images NNS N
of IN N
matched JJ N
coronary JJ N
artery NN N
segments NNS N
acquired VBD N
at IN N
baseline NN N
and CC N
at IN N
26-week JJ N
follow-up NN N
. . N

The DT N
effect NN N
of IN N
RVX-208 NNP i
on IN N
other JJ N
lipid JJ o
and CC o
inflammatory JJ o
markers NNS o
, , o
safety NN o
and CC o
tolerability NN o
will MD N
also RB N
be VB N
assessed VBN N
in IN N
both DT N
studies NNS N
. . N

CONCLUSION NNP N
ApoA-I NNP i
induction NN N
represents VBZ N
a DT N
potential JJ N
novel NN N
strategy NN N
to TO N
reduce VB N
cardiovascular JJ o
risk NN o
, , N
by IN N
generating VBG N
nascent JJ N
HDL NNP N
particles NNS N
. . N

These DT N
studies NNS N
will MD N
provide VB N
early JJ N
evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
RVX-208 NNP i
on IN N
lipids NNS N
and CC N
atherosclerotic JJ N
plaque NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
enamel JJ i
pretreatment NN i
on IN N
shear JJ o
bond NN o
strength NN o
of IN N
brackets NNS p
bonded VBN p
with IN p
resin-modified JJ p
glass-ionomer JJ p
cement NN p
. . p

AIM NNP N
To TO N
evaluate VB N
the DT N
shear JJ o
bond NN o
strength NN o
of IN N
brackets NNS N
bonded VBN N
with IN N
resin-modified JJ i
glass-ionomer JJ i
cement NN i
( ( i
RMGIC NNP i
) ) i
using VBG N
various JJ N
methods NNS N
of IN N
enamel JJ i
conditioning NN N
. . N

METHODS NNP N
Forty-five JJ p
human JJ p
premolars NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
five CD p
groups NNS p
. . p

The DT N
roots NNS N
of IN N
these DT N
teeth NNS N
were VBD N
fixed VBN N
in IN N
acrylic JJ N
resin NN N
cylinders NNS N
, , N
and CC N
brackets NNS N
were VBD N
bonded VBN N
to TO N
the DT N
teeth NN N
's POS N
crowns NNS N
using VBG N
the DT N
following JJ N
material NN N
combinations NNS N
: : N
RMGIC NNP i
only RB N
; : N
RMGIC NNP N
and CC N
corresponding VBG N
primer NN i
; : i
RMGIC NNP N
, , N
acid NN i
etching NN i
, , N
and CC N
Scotchbond NNP i
Multipurpose NNP N
; : N
RMGIC NNP N
and CC N
two-step JJ N
self-etching JJ N
primer NN N
; : N
and CC N
RMGIC NNP i
and CC N
one-step JJ N
primer NN N
. . N

All DT N
specimens NNS N
were VBD N
submitted VBN N
to TO N
pH VB N
cycling NN N
for IN N
14 CD N
days NNS N
before IN N
shear JJ N
bond NN o
strength NN o
was VBD N
assessed VBN N
in IN N
a DT N
universal JJ N
test NN N
machine NN N
. . N

RESULTS VB N
The DT N
medians NNS N
and CC N
standard JJ N
deviations NNS N
( ( N
in IN N
MPa NNP N
) ) N
were VBD N
RMGIC NNP i
only RB N
= VBZ N
8.34 CD N
? . N
1.11 CD N
; : N
RMGIC NNP N
and CC N
corresponding VBG N
primer NN N
= $ N
7.05 CD N
? . N
2.24 CD N
; : N
RMGIC NNP N
, , N
acid NN N
etching NN N
, , N
and CC N
Scotchbond NNP N
Multipurpose NNP N
= VBD N
7.00 CD N
? . N
4.79 CD N
; : N
RMGIC NNP N
and CC N
two-step JJ N
self-etching JJ N
primer NN N
= NN N
0.54 CD N
? . N
0.30 CD N
; : N
and CC N
RMGIC NNP N
and CC N
one-step JJ N
primer NN N
= NN N
10.61 CD N
? . N
4.58 CD N
. . N

The DT N
value NN o
for IN o
RMGIC NNP i
and CC i
two-step JJ N
self-etching JJ N
primer NN o
was VBD o
significantly RB N
lower JJR N
than IN N
all DT N
other JJ N
values NNS N
. . N

CONCLUSION VB N
It PRP N
can MD N
be VB N
concluded VBN N
that IN N
the DT N
tested JJ N
RMGIC NNP N
is VBZ N
suitable JJ N
for IN N
bonding VBG N
orthodontic JJ N
brackets NNS N
, , N
even RB N
when WRB N
used VBN N
by IN N
itself PRP N
. . N

Different NNP N
enamel JJ N
preparations NNS N
do VBP N
not RB N
improve VB N
its PRP$ N
performance NN N
. . N

However RB N
, , N
they PRP N
can MD N
worsen VB N
its PRP$ N
bonding VBG N
capacity NN N
as IN N
the DT N
combination NN N
with IN N
the DT N
two-step JJ N
primer NN N
system NN N
clearly RB N
shows VBZ N
. . N

-DOCSTART- -X- O O

[ JJ N
Trial NNP N
of IN N
a DT N
calcium NN i
antagonist NN i
in IN N
dysmenorrhea NN o
] NN o
. . N

-DOCSTART- -X- O O

Public NNP N
and CC N
private JJ N
heart NN N
rate NN N
feedback NN N
in IN N
social JJ i
phobia NN i
: : i
a DT N
manipulation NN N
of IN N
anxiety NN o
visibility NN o
. . o

According VBG N
to TO N
cognitive JJ N
behavioural JJ N
models NNS N
of IN N
social JJ i
phobia NN i
, , N
bodily RB o
symptoms NNS o
are VBP N
the DT N
main JJ N
source NN N
of IN N
information NN N
concerning VBG N
social JJ o
evaluation NN o
for IN N
social JJ i
phobics NNS i
. . i

Experience NN N
and CC N
perception NN N
of IN N
bodily RB N
symptoms NNS N
therefore RB N
play VBP N
an DT N
important JJ N
role NN N
in IN N
social JJ N
anxiety NN N
. . N

In IN N
this DT N
study NN N
we PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
anxiety NN o
visibility NN o
on IN N
patients NNS p
and CC p
controls NNS p
using VBG N
feedback NN N
of IN N
veridical JJ N
heart NN N
sounds VBZ N
. . N

A DT p
total NN p
of IN p
32 CD p
social JJ i
phobics NNS i
and CC p
32 CD p
controls NNS p
were VBD N
asked VBN N
twice RB N
to TO N
sit VB N
in IN N
a DT N
chair NN N
and CC N
appear VB N
relaxed VBN N
while IN N
being VBG N
evaluated VBN N
. . N

Half NN N
of IN N
the DT N
participants NNS i
heard VBP i
their PRP$ i
heart NN i
sounds VBZ i
first JJ i
via IN i
headphones NNS i
and CC i
then RB i
via IN i
loudspeakers NNS i
which WDT i
were VBD i
also RB i
audible JJ i
to TO i
observers NNS i
. . i

The DT N
presentation NN N
order NN N
of IN N
the DT N
heart NN o
sound NN o
was VBD N
reversed VBN N
for IN N
the DT N
other JJ N
half NN N
of IN N
the DT N
subjects NNS N
. . N

Social NNP i
phobics NNS i
reported VBD N
substantially RB N
more JJR N
anxiety NN o
than IN N
controls NNS N
. . N

Both DT N
groups NNS N
showed VBD N
habituation NN o
in IN o
heart NN o
rate NN o
from IN N
the DT N
first JJ N
to TO N
the DT N
second JJ N
presentation NN N
, , N
and CC N
both DT N
groups NNS N
reported VBD N
perception NN N
of IN N
a DT N
higher JJR o
heart NN o
rate NN o
, , N
but CC N
only RB N
social JJ N
phobics NNS N
reported VBD N
significantly RB N
more JJR N
anxiety NN o
and CC N
were VBD N
more JJR N
worried JJ o
about IN o
their PRP$ o
heart NN o
rates NNS o
in IN N
the DT N
public NN N
than IN N
in IN N
the DT N
private JJ N
condition NN N
. . N

These DT N
effects NNS N
were VBD N
in IN N
excess NN N
of IN N
actual JJ o
heart NN o
rate NN o
differences NNS o
. . o

In IN N
conclusion NN N
, , N
social JJ i
phobics NNS i
worried VBD o
about IN N
the DT N
broadcast NN N
of IN N
a DT N
bodily JJ o
anxiety NN o
symptom NN o
, , N
whereas JJ N
controls NNS i
did VBD N
not RB N
. . N

Information NN N
about IN N
arousal NN N
made VBN N
public NN N
has VBZ N
a DT N
strong JJ N
potential NN N
to TO N
increase VB N
anxiety NN o
levels NNS o
in IN N
social JJ N
phobics NNS N
. . N

-DOCSTART- -X- O O

Delayed VBN o
alloimmunization NN o
using VBG N
random JJ i
single JJ i
donor NN i
platelet NN i
transfusions NNS i
: : i
a DT N
prospective JJ N
study NN N
in IN N
thrombocytopenic JJ p
patients NNS p
with IN p
acute JJ p
leukemia NN p
. . p

A DT N
randomized JJ N
study NN N
was VBD N
performed VBN N
in IN N
54 CD p
thrombocytopenic JJ p
patients NNS p
with IN p
acute JJ p
leukemia NN p
. . p

Alloimmunization NN N
of IN N
recipients NNS N
of IN N
random JJ N
multiple-donor JJ i
platelet NN i
concentrates NNS i
( ( N
MD NNP N
group NN N
) ) N
was VBD N
compared VBN N
to TO N
that DT N
of IN N
patients NNS N
receiving VBG N
random JJ i
single-donor JJ i
platelets NNS i
( ( N
SD NNP N
group NN N
) ) N
. . N

In IN N
the DT N
SD NNP N
patients NNS N
, , N
formation NN o
of IN o
alloantibodies NNS o
( ( o
mostly RB o
anti-HLA RB o
) ) o
occurred VBD N
less RBR N
frequently RB N
( ( N
p NN N
less JJR N
than IN N
0.002 CD N
) ) N
, , N
after IN N
a DT N
longer JJR N
time NN N
period NN N
( ( N
p NN N
less JJR N
than IN N
0.002 CD N
) ) N
, , N
and CC N
after IN N
a DT N
higher JJR N
number NN N
of IN N
transfusions NNS N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
as IN N
compared VBN N
to TO N
MD NNP N
patients NNS N
. . N

SD NNP N
patients NNS N
also RB N
became VBD N
refractory JJ N
to TO N
random VB N
platelets NNS N
less RBR N
frequently RB N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
, , N
after IN N
a DT N
longer JJR N
time NN N
period NN N
, , N
and CC N
after IN N
a DT N
higher JJR o
number NN o
of IN o
transfusions NNS o
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

In IN N
SD NNP N
patients NNS N
, , N
the DT N
increments NNS o
after IN N
the DT N
first JJ o
and CC o
the DT o
last JJ o
transfusion NN o
were VBD N
in IN N
the DT N
same JJ N
range NN N
, , N
whereas NNS N
in IN N
MD NNP N
patients NNS N
, , N
the DT N
1-hr JJ N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
the DT N
24-hr JJ N
( ( N
p NN N
less JJR N
than IN N
0.025 CD N
) ) N
increments NNS o
decreased VBN N
from IN N
the DT N
first JJ N
to TO N
the DT N
last JJ N
transfusion NN N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
random NN i
SD NNP i
platelet NN i
transfusions NNS i
postponed VBD N
alloimmunization NN N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
familial JJ N
hypercholesterolemia NN N
with IN N
a DT N
combination NN i
of IN i
bezafibrate NN i
and CC i
guar NN i
. . i

The DT N
effect NN o
of IN N
guar NN i
( ( N
15.6 CD N
g/day NN N
) ) N
, , N
a DT i
dietary JJ i
fibre NN i
, , N
and CC N
simultaneous JJ N
administration NN N
of IN N
bezafibrate NN i
( ( N
600 CD N
mg/day NN N
) ) N
during IN N
dietetic JJ N
treatment NN N
on IN N
the DT N
plasma NN N
lipoproteins NNS N
and CC N
apolipoproteins NNS N
was VBD N
investigated VBN N
in IN N
12 CD p
patients NNS p
with IN p
familial JJ p
hypercholesterolemia NN p
( ( p
corresponding VBG p
to TO p
the DT p
HLP NNP p
type NN p
IIa NNP p
pattern NN p
) ) p
. . p

Either CC i
bezafibrate VB i
alone RB i
or CC i
bezafibrate VB i
in IN i
combination NN i
with IN i
guar NN i
was VBD i
administered VBN i
in IN i
a DT i
cross-over NN i
study NN i
for IN i
3 CD i
months NNS i
. . i

Guar NNP i
led VBD N
to TO N
an DT N
additional JJ N
lowering NN N
of IN N
the DT N
total JJ o
cholesterol NN o
in IN N
the DT N
plasma NN N
by IN N
7 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.05 CD N
) ) N
associated VBN N
with IN N
a DT N
fall NN N
of IN N
the DT N
low JJ o
density NN o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-cholesterol NNP o
( ( N
LDL-cholesterol NNP N
) ) N
by IN N
13 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.01 CD N
) ) N
without IN N
any DT N
changes NNS N
in IN N
the DT N
very RB N
low JJ N
density NN N
lipoprotein NN N
( ( N
VLDL NNP N
) ) N
and CC N
high JJ N
density NN N
lipoprotein NN N
( ( N
HDL NNP N
) ) N
cholesterols NNS N
. . N

In IN N
parallel NN N
with IN N
the DT N
decrease NN N
in IN N
LDL-cholesterol NNP o
, , N
the DT N
apoprotein NN o
B NNP o
also RB N
was VBD N
diminished VBN N
by IN N
20 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.05 CD N
) ) N
. . N

The DT N
plasma JJ o
triglyceride NN o
level NN o
and CC o
the DT o
triglyceride JJ o
distribution NN o
within IN N
the DT N
individual JJ N
lipoprotein NN N
fractions NNS N
were VBD N
not RB N
altered VBN N
in IN N
any DT N
consistent JJ N
manner NN N
by IN N
the DT N
addition NN N
of IN N
guar NN i
. . i

Neither CC N
the DT N
fasting NN o
plasma NN o
glucose JJ o
level NN o
nor CC o
the DT o
body NN o
weight WDT o
were VBD N
affected VBN N
. . N

The DT N
side-effects NNS N
due JJ N
to TO N
guar VB i
treatment NN i
consisted VBN N
of IN N
slight JJ o
nausea NN o
, , o
meteorism NN o
and CC o
constipation NN o
, , N
but CC N
this DT N
did VBD N
not RB N
in IN N
any DT N
of IN N
the DT N
cases NNS N
lead VBP N
to TO N
early JJ N
termination NN N
of IN N
the DT N
study NN N
. . N

These DT N
results NNS N
demonstrate VBP N
that IN N
guar NN i
exerts VBZ N
its PRP$ N
cholesterol-lowering JJ N
effect NN N
in IN N
addition NN N
to TO N
that DT N
of IN N
bezafibrate NN i
. . i

-DOCSTART- -X- O O

Social NNP i
competence NN i
and CC i
social JJ i
skills NNS i
training VBG i
and CC i
intervention NN i
for IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
. . p

This DT N
study NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
30 CD N
week NN N
social JJ i
competence NN i
and CC i
social JJ i
skills NNS i
group NN i
intervention NN i
program NN i
with IN N
children NNS p
, , p
ages VBZ p
7-11 CD p
, , p
diagnosed VBN p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

Eighteen JJ p
children NNS p
with IN p
ASD NNP p
were VBD N
assessed VBN N
with IN N
pretreatment NN N
and CC N
posttreatment NN N
measures NNS N
on IN N
the DT N
Walker-McConnell NNP o
Scale NNP o
( ( o
WMS NNP o
) ) o
and CC o
the DT o
MGH NNP o
YouthCare NNP o
Social NNP o
Competence NNP o
Development NNP o
Scale NNP o
. . o

Each DT N
received VBD N
the DT N
30-week JJ N
intervention NN N
program NN N
. . N

For IN N
comparison NN N
, , N
a DT N
matched JJ N
sample NN N
of IN N
ten JJ p
non-ASD JJ p
children NNS p
was VBD N
also RB N
assessed VBN N
, , N
but CC N
received VBD N
no DT N
treatment NN N
. . N

The DT N
findings NNS N
indicated VBD N
that IN N
each DT N
ASD NNP N
intervention NN N
group NN N
demonstrated VBD N
significant JJ N
gains NNS N
on IN N
the DT N
WMS NNP o
and CC N
significant JJ N
improvement NN N
in IN N
the DT N
areas NNS N
of IN N
anxiety NN o
management NN o
, , o
joint JJ o
attention NN o
, , o
and CC o
flexibility/transitions NNS o
. . o

Results VB N
suggest JJS N
that IN N
this DT N
approach NN N
can MD N
be VB N
effective JJ N
in IN N
improving VBG N
core NN N
social JJ o
deficits NNS o
in IN N
individuals NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -X- O O

Active NNP i
specific JJ i
immunotherapy NN i
for IN N
stage NN p
II NNP p
and CC p
stage NN p
III NNP p
human JJ p
colon NN p
cancer NN p
: : p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Colon NNP N
cancer NN N
is VBZ N
curable JJ N
by IN N
surgery NN N
, , N
but CC N
cure NN N
rate NN N
depends VBZ N
on IN N
the DT N
extent NN N
of IN N
disease NN N
. . N

We PRP N
investigated VBD N
whether IN N
adjuvant JJ N
active JJ i
specific JJ i
immunotherapy NN i
( ( N
ASI NNP N
) ) N
with IN N
an DT N
autologous JJ N
tumour JJ N
cell-BCG JJ N
vaccine NN N
with IN N
surgical JJ N
resection NN N
was VBD N
more RBR N
beneficial JJ N
than IN N
resection NN N
alone RB N
in IN N
stage NN N
II NNP N
and CC N
III NNP N
colon NN N
cancer NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomised VBN N
trial NN N
, , N
254 CD p
patients NNS p
with IN p
colon NN p
cancer NN p
were VBD p
randomly RB p
assigned VBN p
postoperative JJ i
ASI NNP i
or CC i
no DT i
adjuvant JJ i
treatment NN i
. . i

ASI NNP N
was VBD N
three CD N
weekly JJ N
vaccinations NNS N
starting VBG N
4 CD N
weeks NNS N
after IN N
surgery NN N
, , N
with IN N
a DT N
booster NN N
vaccination NN N
at IN N
6 CD N
months NNS N
with IN N
10 CD N
( ( N
7 CD N
) ) N
irradiated VBN N
autologous JJ i
tumour NN i
cells NNS i
. . i

The DT N
first JJ N
vaccinations NNS N
contained VBN N
10 CD N
( ( N
7 CD N
) ) N
BCG NNP N
organisms UH N
. . N

We PRP N
followed VBD N
up RP N
patients NNS N
for IN N
time NN N
to TO N
recurrence VB N
, , N
and CC N
recurrence-free JJ N
and CC N
overall JJ N
survival NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

FINDINGS NNP N
The DT N
5.3 CD N
year NN N
median JJ N
follow-up NN N
( ( N
range VB N
8 CD N
months NNS N
to TO N
8 CD N
years NNS N
11 CD N
months NNS N
) ) N
showed VBD N
44 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
7-66 CD N
) ) N
risk NN N
reduction NN N
for IN N
recurrence NN N
in IN N
the DT N
recurrence-free JJ N
period NN N
in IN N
all DT N
patients NNS N
receiving VBG N
ASI NNP i
( ( N
p=0.023 NN N
) ) N
. . N

Overall JJ N
, , N
there EX N
were VBD N
40 CD N
recurrences NNS N
in IN N
the DT N
control NN N
group NN N
and CC N
25 CD N
in IN N
the DT N
ASI NNP N
group NN N
. . N

Analysis NN N
by IN N
stage NN N
showed VBD N
no DT N
significant JJ N
benefit NN N
of IN N
ASI NNP o
in IN N
stage NN N
III NNP N
disease NN N
. . N

The DT N
major JJ N
impact NN N
of IN N
ASI NNP N
was VBD N
seen VBN N
in IN N
patients NNS p
with IN p
stage NN p
II NNP p
disease NN p
, , N
with IN N
a DT N
significantly RB N
longer RBR N
recurrence-free JJ o
period NN o
( ( N
p=0.011 NN N
) ) N
and CC N
61 CD N
% NN N
( ( N
18-81 JJ N
) ) N
risk NN o
reduction NN o
for IN o
recurrences NNS o
. . o

Recurrence-free JJ o
survival NN o
was VBD N
significantly RB N
longer RBR N
with IN N
ASI NNP N
( ( N
42 CD N
% NN N
risk NN N
reduction NN N
for IN N
recurrence NN N
or CC N
death NN N
[ JJ N
0-68 JJ N
] NN N
, , N
p=0.032 NN N
) ) N
and CC N
there EX N
was VBD N
a DT N
trend NN N
towards VBZ N
improved VBN N
overall JJ o
survival NN o
. . o

INTERPRETATION NNP N
ASI NNP N
gave VBD N
significant JJ N
clinical JJ N
benefit NN N
in IN N
surgically RB N
resected VBN N
patients NNS N
with IN N
stage NN p
II NNP p
colon NN p
cancer NN p
. . p

ASI NNP N
has VBZ N
minimal JJ N
adverse JJ N
reactions NNS N
and CC N
should MD N
be VB N
considered VBN N
in IN N
the DT N
management NN N
of IN N
stage NN N
II NNP N
colon NN N
cancer NN N
. . N

-DOCSTART- -X- O O

A DT N
multicenter NN N
, , N
open-label JJ N
study NN N
of IN N
vernakalant NN N
for IN N
the DT N
conversion NN N
of IN N
atrial JJ p
fibrillation NN p
to TO N
sinus VB N
rhythm NN N
. . N

BACKGROUND IN N
The DT N
efficacy NN o
and CC o
safety NN o
of IN N
vernakalant NN N
, , N
a DT N
relatively RB N
atrial-selective JJ N
antiarrhythmic JJ N
agent NN N
, , N
in IN N
converting VBG N
atrial JJ o
fibrillation NN o
( ( o
AF NNP o
) ) o
to TO N
sinus VB o
rhythm NN o
( ( o
SR NNP o
) ) o
were VBD N
evaluated VBN N
in IN N
this DT N
multicenter NN p
, , p
open-label JJ p
study NN p
of IN p
patients NNS p
with IN p
AF NNP p
lasting VBG p
> RB p
3 CD p
hours NNS p
and CC p
< NNP p
or CC p
=45 JJ p
days NNS p
( ( N
RCT NNP N
no DT N
. . N

NCT00281554 NNP N
) ) N
. . N

METHODS NNP N
Adult NNP p
patients NNS p
with IN p
AF NNP p
and CC p
an DT p
indication NN p
for IN p
conversion NN p
to TO p
SR NNP o
received VBD i
a DT i
10-minute JJ i
intravenous JJ i
infusion NN i
of IN i
vernakalant NN i
( ( i
3 CD i
mg/kg NN i
) ) i
. . i

If IN i
after IN i
a DT i
15-minute JJ i
observation NN i
period NN i
AF NNP i
was VBD i
present JJ i
, , i
a DT i
second JJ i
10-minute JJ i
infusion NN i
of IN i
intravenous JJ i
vernakalant NN i
( ( i
2 CD i
mg/kg NN i
) ) i
was VBD i
given VBN i
. . i

The DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS i
with IN i
recent-onset JJ i
AF NNP o
( ( i
AF NNP i
lasting VBG i
> RB i
3 CD i
hours NNS i
to TO i
< VB i
or CC i
=7 VB i
days NNS i
) ) i
who WP i
converted VBD i
to TO i
SR NNP i
within IN i
90 CD i
minutes NNS i
of IN i
the DT i
start NN i
of IN i
the DT i
first JJ i
infusion NN i
. . i

Safety NNP i
evaluations NNS i
included VBD i
vital JJ o
signs NNS o
, , o
telemetry NN o
and CC o
Holter NNP o
monitoring NN o
, , o
12-lead JJ o
electrocardiography NN o
, , o
clinical JJ o
laboratory NN o
tests NNS o
, , o
physical JJ o
examinations NNS o
, , o
and CC o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
. . o

RESULTS VB N
A DT N
total NN N
of IN N
236 CD p
hemodynamically RB p
stable JJ p
patients NNS p
with IN p
AF NNP p
received VBD N
intravenous JJ N
vernakalant NN N
. . N

Among IN N
them PRP N
, , N
167 CD p
( ( p
71 CD p
% NN p
) ) p
had VBD p
recent-onset VBN o
AF NNP o
and CC N
were VBD N
eligible JJ N
for IN N
the DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
. . N

Vernakalant NNP N
rapidly RB N
converted VBD N
recent-onset JJ o
AF NNP o
to TO o
SR NNP o
in IN N
50.9 CD N
% NN N
of IN N
patients NNS N
, , N
with IN N
a DT N
median JJ N
time NN N
to TO N
conversion NN N
of IN N
14 CD N
minutes NNS N
among IN N
responders NNS N
. . N

The DT N
most RBS N
common JJ N
AEs NNP N
were VBD N
dysgeusia NNS o
, , o
sneezing VBG o
, , o
and CC o
paresthesia NN o
. . o

These DT N
occurred VBD N
at IN N
the DT N
time NN N
of IN N
vernakalant JJ N
infusion NN N
, , N
were VBD N
transient JJ N
, , N
and CC N
resolved VBD N
spontaneously RB N
. . N

Ten CD N
patients NNS N
( ( N
4.2 CD N
% NN N
) ) N
discontinued VBN N
vernakalant JJ N
treatment NN N
because IN N
of IN N
AEs NNP N
, , N
most JJS N
commonly RB N
( ( N
in IN N
4 CD N
of IN N
10 CD N
) ) N
hypotension NN o
. . o

There EX N
were VBD N
no DT N
episodes NNS N
of IN N
torsades NNS o
de FW o
pointes NNS o
, , o
ventricular JJ o
fibrillation NN o
, , o
or CC o
sustained VBD o
ventricular JJ o
tachycardia NN o
. . o

CONCLUSIONS NNP N
Vernakalant NNP N
rapidly RB N
converted VBD N
recent-onset JJ N
AF NNP N
to TO N
SR NNP N
, , N
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
may MD N
be VB N
a DT N
valuable JJ N
therapeutic JJ N
alternative NN N
for IN N
reestablishing VBG N
SR NNP N
in IN N
patients NNS p
with IN p
recent-onset JJ p
AF NNP p
. . p

-DOCSTART- -X- O O

[ JJ N
Effects NNS N
of IN N
dujieqing VBG i
oral JJ i
liquid NN i
on IN N
the DT N
promoter NN N
methylation NN N
of IN N
the DT N
MGMT NNP N
gene NN N
in IN N
middle-and-late JJ p
stage NN p
tumor NN p
patients NNS p
receiving VBG p
chemotherapy NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
effects NNS N
of IN N
Dujieqing VBG i
Oral NNP i
Liquid NNP i
( ( i
DJQ NNP i
) ) i
on IN N
the DT N
promoter NN N
methylation NN N
of IN N
the DT N
O6-methylguanine-DNA JJ N
methyltransferase NN N
( ( N
MGMT NNP N
) ) N
gene NN N
in IN N
the DT N
plasma NN N
DNA NNP N
samples NNS N
from IN N
middle-and-late JJ p
stage NN p
tumor NN p
patients NNS p
receiving VBG p
chemotherapy NN p
. . p

METHODS NNP N
Recruited VBD p
60 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
the DT N
treatment NN i
group NN i
( ( i
treated VBN i
by IN i
conventional JJ i
chemotherapy NN i
combined VBN i
DJQ NNP i
, , N
20 CD N
mL NN N
each DT N
time NN N
, , N
three CD N
times NNS N
daily RB N
) ) N
and CC N
the DT N
control NN i
group NN i
( ( i
treated VBN i
by IN i
chemotherapy NN i
alone RB i
) ) i
, , N
30 CD N
in IN N
each DT N
group NN N
. . N

The DT N
therapeutic JJ N
course NN N
was VBD N
8 CD N
weeks NNS N
. . N

The DT N
promoter NN N
methylation NN N
of IN N
the DT N
MGMT NNP N
gene NN N
in IN N
the DT N
plasma NN N
DNA NNP N
samples VBZ N
form VB N
middle-and-late JJ p
stage NN p
tumor NN p
patients NNS p
receiving VBG p
chemotherapy NN p
was VBD N
detected VBN N
before IN N
and CC N
after IN N
treatment NN N
using VBG N
nested JJ N
methylation-specific JJ N
polymerase NN N
chain NN N
reaction NN N
( ( N
MSP NNP N
) ) N
. . N

Meanwhile RB N
, , N
the DT N
peripheral JJ N
hemogram NN N
was VBD N
detected VBN N
. . N

The DT N
clinical JJ o
efficacy NN o
and CC o
toxic/adverse JJ o
reactions NNS o
were VBD N
assessed VBN N
using VBG N
Karnofsky NNP N
performance NN N
scale NN N
( ( N
KPS NNP N
) ) N
. . N

RESULTS JJ N
Results NNP N
of IN N
the DT N
promoter NN N
methylation NN N
of IN N
MGMT NNP N
genes NNS N
showed VBD N
that IN N
methylation NN N
rate NN N
was VBD N
20.00 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
and CC N
46.67 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Compared VBN N
with IN N
before RB N
treatment NN N
, , N
the DT N
KPS NNP o
was VBD N
significantly RB N
improved VBN N
in IN N
the DT N
treatment NN N
group NN N
after IN N
treatment NN N
, , N
while IN N
it PRP N
significantly RB N
decreased VBD N
in IN N
the DT N
control NN N
group NN N
after IN N
treatment NN N
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
statistical JJ N
difference NN N
in IN N
the DT N
KPS NNP o
between IN N
the DT N
two CD N
groups NNS N
after IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
toxic/adverse JJ o
reactions NNS o
were VBD N
milder VBN N
in IN N
the DT N
treatment NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
DJQ NNP i
showed VBD N
efficiency NN N
synergism NN N
and CC N
toxicity NN N
reducing NN N
effects NNS N
, , N
but CC N
with IN N
no DT N
effect NN N
on IN N
the DT N
hematopoietic JJ N
function NN N
of IN N
the DT N
bone NN N
marrow NN N
. . N

MGMT NNP N
gene NN N
was VBD N
indicated VBN N
as IN N
DJQ NNP i
's POS i
target NN N
point NN N
for IN N
efficiency NN N
synergism NN N
and CC N
toxicity NN N
reducing NN N
. . N

The DT N
efficiency NN N
synergism NN N
and CC N
toxicity NN N
reducing VBG N
effects NNS N
were VBD N
achieved VBN N
by IN N
regulating VBG N
the DT N
activities NNS N
of IN N
MGMT NNP N
gene NN N
. . N

-DOCSTART- -X- O O

Psychological JJ N
well-being NN N
correlates NNS N
with IN N
free JJ N
thyroxine NN N
but CC N
not RB N
free JJ N
3,5,3'-triiodothyronine JJ N
levels NNS N
in IN N
patients NNS p
on IN p
thyroid JJ p
hormone NN p
replacement NN p
. . p

CONTEXT NNP N
AND NNP N
OBJECTIVE NNP N
An DT N
association NN N
between IN N
mood NN N
disorders NNS N
and CC N
overt JJ N
thyroid JJ N
dysfunction NN N
is VBZ N
well RB N
established VBN N
, , N
but CC N
there EX N
are VBP N
few JJ N
data NNS N
on IN N
the DT N
potential NN N
for IN N
thyroid JJ N
hormone NN N
levels NNS N
closer RBR N
to TO N
the DT N
reference NN N
range NN N
to TO N
correlate VB N
with IN N
psychological JJ N
well-being NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
We PRP N
analyzed VBD N
the DT N
relationship NN N
between IN N
psychological JJ N
well-being NN N
and CC N
free JJ N
T NNP N
( ( N
4 CD N
) ) N
( ( N
fT4 NN N
) ) N
, , N
free JJ N
T NNP N
( ( N
3 CD N
) ) N
( ( N
fT3 NN N
) ) N
, , N
TSH NNP N
, , N
and CC N
total JJ N
rT NN N
( ( N
3 CD N
) ) N
in IN N
697 CD p
patients NNS p
on IN p
thyroid JJ i
hormone NN i
replacement NN i
therapy NN i
at IN p
entry NN p
to TO p
a DT p
randomized VBN p
, , p
controlled VBD p
trial NN p
of IN p
combined JJ i
T NNP i
( ( i
4 CD i
) ) i
and CC i
T NNP i
( ( i
3 CD i
) ) i
replacement NN i
therapy NN i
. . i

All DT p
patients NNS p
were VBD p
on IN p
100 CD p
mug NN p
or CC p
more JJR p
T NNP p
( ( p
4 CD p
) ) p
. . p

INTERVENTIONS NNP N
AND CC N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Psychological NNP o
well-being NN o
was VBD o
assessed VBN o
with IN o
General NNP o
Health NNP o
Questionnaire-12 NNP o
( ( o
GHQ-12 NNP o
) ) o
, , o
Thyroid NNP o
Symptom NNP o
Questionnaire NNP o
, , o
and CC o
Hospital NNP o
Anxiety NNP o
and CC o
Depression NNP o
Scale NNP o
. . o

RESULTS NNP N
fT NN N
( ( N
4 CD N
) ) N
and CC N
TSH NNP N
showed VBD N
a DT N
strong JJ N
correlation NN N
with IN N
GHQ-12 NNP o
scores NNS o
( ( N
fT4 SYM N
- : N
b NN N
: : N
-0.16 NN N
, , N
P NNP N
= NNP N
0.005 CD N
; : N
TSH NNP N
- : N
b NN N
: : N
0.663 CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

No UH N
correlations NNS N
were VBD N
seen VBN N
between IN N
the DT N
GHQ NNP o
scores NNS o
and CC o
fT3 NN o
( ( N
b NN N
: : N
0.318 CD N
, , N
P NNP N
= NNP N
0.275 CD N
) ) N
, , N
rT NN N
( ( N
3 CD N
) ) N
( ( N
b NN N
: : N
0.095 CD N
, , N
P NNP N
= NNP N
0.95 CD N
) ) N
, , N
rT NN N
( ( N
3 CD N
) ) N
to TO N
fT4 VB N
ratio NN N
( ( N
b NN N
: : N
71.83 CD N
, , N
P NNP N
= NNP N
0.09 CD N
) ) N
or CC N
fT3 VBN N
to TO N
rT VB N
( ( N
3 CD N
) ) N
ratio NN N
( ( N
b NN N
: : N
0.05 CD N
, , N
P NNP N
= NNP N
0.32 CD N
) ) N
. . N

The DT N
correlations NNS N
remained VBD N
when WRB N
the DT N
data NN N
set NN N
was VBD N
limited VBN N
to TO N
patients NNS N
with IN N
TSH NNP N
in IN N
the DT N
range NN N
0.3-4.0 JJ N
mIU/liter NN N
. . N

Similar JJ N
correlations NNS N
were VBD N
seen VBN N
with IN N
the DT N
Thyroid NNP o
Symptom NNP o
Questionnaire NNP o
, , N
although IN N
not RB N
with IN N
the DT N
Hospital NNP o
Anxiety NNP o
and CC o
Depression NNP o
Scale NNP o
scores NNS o
. . o

CONCLUSIONS NNP N
Differences NNPS N
in IN N
fT4 NN N
and CC N
TSH NNP N
concentration NN N
, , N
even RB N
within IN N
the DT N
reference NN N
range NN N
, , N
may MD N
be VB N
a DT N
determinant NN N
of IN N
psychological JJ N
well-being NN N
in IN N
treated JJ p
hypothyroid NN p
patients NNS p
although IN N
not RB N
necessarily RB N
with IN N
symptoms NNS N
typical JJ N
of IN N
anxiety NN N
or CC N
depression NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
preoperative JJ N
skull NN N
block NN N
on IN N
pediatric JJ p
moyamoya NN p
disease NN p
. . p

OBJECT NNP N
Stable JJ N
hemodynamics NNS N
, , N
normocapnia NN N
, , N
and CC N
adequate JJ N
pain NN N
relief NN N
are VBP N
considered VBN N
important JJ N
factors NNS N
in IN N
the DT N
reduction NN N
of IN N
neurological JJ N
complications NNS N
in IN N
pediatric JJ p
patients NNS p
undergoing JJ p
encephaloduroarteriomyosynangiosis NN i
( ( i
EDAMS NNP i
) ) i
operations NNS p
for IN p
the DT p
treatment NN p
of IN p
moyamoya JJ p
disease NN p
. . p

A DT N
preoperative JJ N
skull NN N
block NN N
may MD N
reduce VB N
hemodynamic JJ o
fluctuations NNS o
and CC o
hypo- NN o
or CC o
hyperventilation NN o
due JJ N
to TO N
emergence VB N
delirium NN N
or CC N
oversedation NN N
and CC N
provide VB N
adequate JJ N
pain NN N
relief NN N
, , N
thereby RB N
reducing VBG N
postoperative JJ o
morbidity NN o
. . o

METHODS NNP N
Pediatric NNP p
patients NNS p
( ( p
age NN p
3-13 CD p
years NNS p
) ) p
undergoing VBG p
EDAMS NNP i
surgery NN i
for IN p
moyamoya JJ p
disease NN p
were VBD p
randomly RB p
divided VBN p
into IN p
a DT p
nerve NN p
block NN p
( ( p
NB NNP p
) ) p
group NN p
( ( p
18 CD p
cases NNS p
) ) p
or CC p
control VB p
group NN p
( ( p
21 CD p
cases NNS p
) ) p
. . N

The DT N
treatment NN N
group NN N
patients NNS N
received VBD N
a DT N
preoperative JJ N
NB NNP i
( ( N
0.25 CD N
% NN N
5-8 JJ N
ml NN N
bupivacaine NN i
mixed JJ N
with IN N
20-40 JJ N
mg NNS N
methylprednisolone NN i
) ) i
targeting VBG N
the DT N
supraorbital NN N
, , N
supratrochlear JJ N
, , N
auriculotemporal JJ N
, , N
and CC N
posterior JJ N
auricular JJ N
nerves NNS N
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
did VBD N
not RB N
receive VB N
NB NNP N
. . N

General NNP N
anesthesia NN N
with IN N
sevoflurane NN i
was VBD N
induced VBN N
in IN N
both DT N
groups NNS N
. . N

RESULTS NNP N
In IN N
the DT N
NB NNP N
group NN N
, , N
stable JJ o
hemodynamic JJ o
parameters NNS o
were VBD N
obtained VBN N
with IN N
a DT N
lower JJR N
sevoflurane NN N
concentration NN N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

For IN N
delirious JJ o
awakening NN o
, , N
the DT N
odds NNS N
ratio NN N
in IN N
the DT N
control NN N
group NN N
was VBD N
4.9 CD N
compared VBN N
with IN N
the DT N
NB NNP N
group NN N
. . N

Pain NNP o
and CC o
analgesic JJ o
requirement NN o
were VBD N
higher JJR N
in IN N
the DT N
control NN N
patients NNS N
than IN N
in IN N
the DT N
NB-treated JJ N
patients NNS N
during IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
stay NN N
. . N

However RB N
, , N
the DT N
arterial JJ o
CO NNP o
( ( o
2 CD o
) ) o
tension NN o
in IN o
the DT o
postanesthesia NN o
care NN o
unit NN o
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
odds NNS o
ratio NN o
in IN N
the DT N
control NN N
group NN N
for IN N
the DT N
rate NN o
of IN o
morbidity NN o
( ( o
cerebral JJ o
infarction NN o
and CC o
reversible JJ o
ischemic JJ o
neurological JJ o
deficits NNS o
) ) o
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
following VBG N
the DT N
operation NN N
was VBD N
3.2 CD N
compared VBN N
with IN N
the DT N
NB NNP N
group NN N
. . N

CONCLUSIONS NNP N
The DT N
use NN N
of IN N
skull JJ N
block NN N
during IN N
EDAMS NNP N
surgery NN N
provided VBD N
easy JJ N
hemodynamic JJ o
control NN o
, , o
calm JJ o
awakening NN o
, , o
and CC o
better JJR o
pain NN o
relief NN o
and CC N
may MD N
be VB N
related VBN N
to TO N
the DT N
reduced VBN N
postoperative JJ o
morbidity NN o
. . o

-DOCSTART- -X- O O

Prospective JJ N
randomized VBN N
multicenter RBR N
trial NN N
of IN N
sevelamer NN i
hydrochloride NN i
and CC i
calcium NN i
carbonate NN i
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN o
in IN p
hemodialysis NN p
patients NNS p
in IN p
Japan NNP p
. . p

A NNP N
prospective JJ N
, , N
randomized JJ N
open-label JJ N
trial NN N
of IN N
sevelamer JJ i
hydrochloride NN i
with IN i
or CC i
without IN i
calcium JJ i
carbonate NN i
( ( i
CC NNP i
) ) i
involved VBD N
86 CD p
hemodialysis NN p
patients NNS p
in IN p
Japan NNP p
. . p

The DT N
dosage NN N
of IN N
CC NNP N
was VBD N
fixed VBN N
at IN N
3.0 CD N
g/day NN N
for IN N
the DT N
12-week JJ N
study NN N
. . N

After IN N
the DT N
first JJ N
4 CD N
weeks NNS N
all DT N
subjects NNS N
were VBD N
changed VBN N
from IN N
CC NNP i
to TO i
sevelamer VB i
3.0 CD N
g/day NN N
for IN N
another DT N
4 CD N
weeks NNS N
, , N
then RB N
allocated VBD N
randomly RB N
to TO N
three CD N
groups NNS N
for IN N
the DT N
final JJ N
4 CD N
weeks NNS N
: : N
group NN i
A NNP i
, , i
sevelamer NN i
6.0 CD i
g/day NN i
; : i
group NN i
B NNP i
, , i
sevelamer VBD i
3.0 CD i
g/day NN i
and CC i
CC NNP i
3.0 CD i
g/day NN i
; : i
group NN i
C NNP i
, , i
CC NNP i
3.0 CD i
g/day NN i
. . i

The DT N
target NN o
serum NN o
phosphorous JJ o
concentration NN o
( ( N
P NNP N
) ) N
=5.5 VBP N
mg/dL NN N
and CC N
the DT N
corrected JJ o
calcium NN o
concentration NN o
( ( o
Ca NNP o
) ) o
was VBD N
9.0-10.0 JJ N
mg/dL NN N
. . N

Of IN p
the DT p
86 CD p
patients NNS p
, , p
62 CD p
finished VBD p
the DT p
study NN p
without IN p
a DT p
change NN p
of IN p
dosage NN p
and CC p
their PRP$ p
data NNS p
were VBD p
analyzed VBN p
( ( p
group NN p
A NNP p
, , p
N=16 NNP p
; : p
group NN p
B NNP p
, , p
N=26 NNP p
; : p
group NN p
C NNP p
, , p
N=20 NNP p
) ) p
. . p

At IN N
week NN N
8 CD N
compared VBN N
with IN N
week NN N
4 CD N
, , N
the DT N
concentration NN o
of IN o
P NNP o
increased VBD N
from IN N
5.7+/-1.4 JJ N
to TO N
6.4+/-1.7 JJ N
mg/dL NN N
in IN N
group NN N
A NNP N
, , N
and CC N
decreased VBD N
significantly RB N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
, , N
and CC N
in IN N
group NN N
B NNP N
compared VBN N
with IN N
groups NNS N
A NNP N
and CC N
C NNP N
; : N
groups NNS N
A DT N
and CC N
C NNP N
had VBD N
similar JJ N
concentrations NNS N
at IN N
week NN N
8 CD N
. . N

The DT N
Ca NNP o
concentration NN o
decreased VBD N
significantly RB N
from IN N
9.7+/-1.0 CD N
to TO N
9.1+/-0.7 CD N
mg/dL NNS N
after IN N
the DT N
change NN N
to TO N
sevelamer VB i
. . i

At IN N
week NN N
8 CD N
Ca NNP o
was VBD N
not RB N
significantly RB N
changed VBN N
in IN N
group NN N
A NNP N
, , N
whereas IN N
a DT N
significant JJ N
increase NN N
occurred VBD N
in IN N
groups NNS N
B NNP N
and CC N
C. NNP N
Side-effects NNP o
with IN N
sevelamer JJ i
administration NN N
occurred VBD N
in IN N
34 CD N
of IN N
the DT N
86 CD N
patients NNS N
and CC N
24 CD N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
, , N
with IN N
a DT N
high JJ N
frequency NN N
in IN N
group NN N
A NNP N
( ( N
13/29 CD N
; : N
44.8 CD N
% NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
there EX N
was VBD N
an DT N
additive JJ o
effect NN o
of IN N
sevelamer NN N
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN N
with IN N
CC NNP N
. . N

The DT N
combination NN N
therapy NN N
was VBD N
better RBR N
tolerated VBN o
and CC N
showed VBD N
higher JJR N
patient NN o
compliance NN o
than IN N
CC NNP N
or CC N
sevelamer JJR N
monotherapy NN N
. . N

-DOCSTART- -X- O O

A DT N
proof NN N
of IN N
concept NN N
study NN N
to TO N
evaluate VB N
putative JJ o
benefits NNS o
of IN N
montelukast NN i
in IN N
moderate JJ p
persistent NN p
asthmatics NNS p
. . p

AIMS NNP N
Whether NNP N
chronic JJ N
dosing VBG N
with IN N
montelukast JJ i
confers NNS N
benefit VBP N
in IN N
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
asthma NN p
remains VBZ N
to TO N
be VB N
fully RB N
established VBN N
. . N

A DT N
proof NN N
of IN N
concept NN N
study NN N
was VBD N
performed VBN N
evaluating VBG N
putative JJ N
benefits NNS N
with IN N
montelukast NN i
in IN N
moderate JJ p
persistent JJ p
asthmatics NNS p
who WP N
were VBD N
taken VBN N
off RP N
inhaled JJ i
corticosteroids NNS i
( ( i
ICS NNP i
) ) i
and CC N
switched VBN N
to TO N
salmeterol VB i
. . i

The DT N
latter NN N
was VBD N
done VBN N
to TO N
dissociate VB N
the DT N
effects NNS N
of IN N
montelukast NN i
from IN N
ICS NNP N
. . N

METHODS NNP N
Twenty NNP p
moderate NN p
to TO p
severe VB p
persistent JJ p
asthmatics NNS p
completed VBD N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
study NN N
. . N

Subjects NNS N
received VBD N
montelukast RB i
10 CD i
mg JJ i
daily JJ i
or CC i
placebo NN i
for IN N
2 CD N
weeks NNS N
each DT N
. . N

This DT N
was VBD N
preceded VBN N
by IN N
a DT N
2-week JJ N
run-in NN N
when WRB N
ICS NNP i
were VBD N
discontinued VBN N
and CC N
salmeterol NN i
started VBD N
, , N
and CC N
used VBD N
on IN N
a DT N
regular JJ N
basis NN N
throughout IN N
the DT N
study NN N
. . N

Measurements NNS N
were VBD N
made VBN N
after IN N
run-in NN N
and CC N
after IN N
both DT N
randomized JJ N
treatments NNS N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
sequence NN o
effects NNS o
for IN N
responses NNS N
as IN N
to TO N
whether IN N
placebo NN i
or CC N
montelukast NN i
were VBD N
given VBN N
first RB N
or CC N
second JJ N
. . N

Methacholine NNP o
PD20 NNP o
values NNS o
after IN N
run-in NN N
, , N
first JJ N
and CC N
second JJ N
placebo NN i
were VBD N
63 CD N
micro NN N
g NN N
, , N
60 CD N
micro NN N
g NN N
and CC N
64 CD N
micro NN N
g NN N
, , N
respectively RB N
( ( N
corresponding VBG N
to TO N
2 CD N
, , N
4 CD N
and CC N
6 CD N
weeks NNS N
of IN N
ICS NNP N
washout NN N
, , N
respectively RB N
) ) N
. . N

Lung NNP o
function NN o
deteriorated VBD o
pre JJ N
vs NN N
post NN N
run-in NN N
, , N
which WDT N
was VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
for IN N
FEF25-75 NNP N
% NN N
predicted VBD N
. . N

Montelukast NNP N
conferred VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
improvements NNS N
as IN N
change NN N
from IN N
post NN N
run-in NN N
compared VBN N
with IN N
placebo NN i
in IN N
methacholine NN N
PD20 NNP N
, , N
FEV1 NNP o
% NN N
predicted VBD N
, , N
FEF25-75 NNP o
% NN N
predicted VBD N
, , N
diurnal JJ o
peak NN o
expiratory NN o
flow NN o
, , o
symptoms NNS o
and CC N
salbutamol NN o
use NN o
. . o

For IN N
the DT N
primary JJ N
outcome NN N
of IN N
methacholine NN N
PD20 NNP N
, , N
this DT N
amounted VBD N
to TO N
a DT N
1.6-fold JJ N
difference NN N
( ( N
95 CD N
% NN N
CI NNP N
1.1 CD N
, , N
2.5 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
moderate JJ N
persistent NN N
asthmatics NNS N
switched VBD N
from IN N
taking VBG N
ICS NNP N
to TO N
salmeterol VB i
alone RB N
, , N
adding VBG N
montelukast NN i
conferred VBD N
significant JJ N
benefits NNS N
on IN N
all DT N
parameters NNS N
of IN N
asthma NN N
control NN N
. . N

Further JJ N
studies NNS N
are VBP N
indicated VBN N
to TO N
evaluate VB N
whether IN N
montelukast NN i
exhibits NNS N
additive JJ N
effects NNS N
to TO N
ICS/long-acting JJ i
beta2-adrenoceptor JJ i
agonist NN i
combination NN N
inhalers NNS N
upon IN N
clinically RB N
important JJ o
outcomes NNS o
. . o

-DOCSTART- -X- O O

Time NN N
intervals NNS N
production NN N
in IN N
tapping VBG p
and CC N
oscillatory JJ p
motion NN p
. . p

We PRP N
applied VBD N
spectral JJ i
analysis NN i
on IN N
series NN N
of IN N
time NN N
intervals NNS N
produced VBN N
in IN N
a DT N
synchronization-continuation JJ N
experiment NN N
. . N

In IN N
the DT N
first JJ N
condition NN N
intervals NNS N
were VBD N
produced VBN N
by IN N
finger NN p
tapping NN p
, , N
and CC N
in IN N
the DT N
second JJ N
by IN N
an DT N
oscillatory JJ p
motion NN p
of IN p
the DT p
hand NN p
. . p

Results NNS N
obtained VBD N
in IN N
tapping VBG p
were VBD N
consistent JJ N
with IN N
a DT N
discrete JJ N
, , N
event-based JJ N
timing NN N
model NN N
. . N

In IN N
the DT N
oscillatory JJ p
condition NN p
, , N
the DT N
spectra NN N
suggested VBD N
a DT N
continuous JJ N
, , N
dynamic JJ N
timing NN N
mechanism NN N
, , N
based VBN N
on IN N
the DT N
regulation NN N
of IN N
effector NN N
stiffness NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
oscillatory JJ p
character NN p
of IN N
movement NN N
can MD N
offer VB N
an DT N
important JJ N
resource NN N
for IN N
timing VBG N
control NN N
. . N

The DT N
use NN N
of IN N
an DT N
event-based JJ N
timing NN N
control NN N
such JJ N
as IN N
postulated VBN N
in IN N
the DT N
Wing-Kristoffersson NNP N
model NN N
could MD N
be VB N
restricted VBN N
to TO N
a DT N
quite RB N
limited JJ N
class NN N
of IN N
rhythmic JJ N
tasks NNS N
, , N
characterized VBN N
by IN N
the DT N
concatenation NN N
of IN N
discrete JJ N
events NNS N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
a DT N
single JJ i
dose NN i
of IN i
oxytocin NN i
on IN N
working VBG o
memory NN o
in IN N
schizophrenia NN p
. . p

-DOCSTART- -X- O O

Diet-Related JJ N
Colorectal NNP N
Cancer NNP N
Prevention NNP N
Beliefs NNP N
and CC N
Dietary NNP i
Intakes NNP i
in IN N
an DT N
Urban JJ p
Minority NNP p
Population NNP p
. . p

In IN N
the DT N
United NNP p
States NNPS p
, , N
colorectal JJ N
cancer NN N
( ( N
CRC NNP N
) ) N
is VBZ N
the DT N
third JJ N
leading JJ N
cause NN N
of IN N
cancer-related JJ N
death NN N
and CC N
third JJ N
most RBS N
commonly RB N
diagnosed JJ N
cancer NN N
among IN N
adults NNS N
. . N

This DT N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
diet-related JJ o
beliefs NNS o
for IN o
colorectal JJ o
cancer NN o
prevention NN o
and CC o
dietary JJ o
intake NN o
among IN N
an DT N
urban JJ p
, , p
predominantly RB p
Black NNP p
population NN p
( ( p
n JJ p
= NNP p
169 CD p
) ) p
. . p

More JJR N
than IN N
two-thirds NNS N
reported VBN N
diet-related JJ N
CRC NNP N
prevention NN N
beliefs NN N
. . N

Those DT N
with IN N
diet-related JJ i
CRC NNP N
prevention NN N
beliefs NNS N
had VBD N
healthier JJR N
intakes NNS o
for IN o
dietary JJ o
fiber NN o
( ( N
p JJ N
= NNP N
.005 NNP N
) ) N
, , N
fruit NN o
, , o
vegetable NN o
, , o
bean NN o
( ( N
p JJ N
= NNP N
.027 NNP N
) ) N
, , N
red JJ o
meat NN o
( ( N
p JJ N
= NNP N
.032 NNP N
) ) N
, , N
vitamin FW o
C NNP o
( ( N
p JJ N
= NNP N
.039 NNP N
) ) N
, , N
and CC N
cholesterol NN o
( ( N
p JJ N
= NNP N
.045 NNP N
) ) N
. . N

Most JJS N
people NNS N
may MD N
already RB N
have VB N
diet-related JJ i
CRC NNP i
prevention NN i
beliefs NN i
and CC N
having VBG N
them PRP N
is VBZ N
associated VBN N
with IN N
a DT N
more RBR N
healthful JJ o
dietary JJ o
intake NN o
. . o

-DOCSTART- -X- O O

Failure NN N
of IN N
pyridoxine NN N
to TO N
suppress VB N
raised VBN o
serum NN o
prolactin NN o
levels NNS o
. . o

Pyridoxine NNP N
has VBZ N
been VBN N
reported VBN N
as IN N
having VBG N
an DT N
antilactogenic JJ N
effect NN N
, , N
presumably RB N
by IN N
suppressing VBG N
prolactin JJ o
secretion NN o
. . o

We PRP N
have VBP N
measured VBN N
serum JJ o
prolactin NN o
levels NNS o
during IN N
pyridoxine JJ i
administration NN i
in IN N
two CD p
groups NNS p
of IN p
hyperprolactinaemic JJ i
subjects NNS i
. . i

In IN N
normal JJ p
postpartum JJ p
women NNS p
, , N
the DT N
postdelivery NN N
fall NN N
in IN N
serum NN o
prolactin NN o
levels NNS o
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
treated JJ N
and CC N
control JJ N
subjects NNS N
. . N

In IN N
patients NNS p
with IN p
chlorpromazine-induced JJ p
hyperprolactinaemia NN p
and CC p
galactorrhoea NN p
, , N
pyridoxine NN N
did VBD N
not RB N
reduce VB N
the DT N
elevated JJ N
levels NNS N
. . N

In IN p
neither DT p
group NN p
was VBD p
milk VBN o
production NN o
suppressed VBN p
. . p

-DOCSTART- -X- O O

Multidose NNP N
, , N
live VBP N
attenuated VBN N
, , N
cold-recombinant JJ N
, , N
trivalent JJ N
influenza NN i
vaccine NN i
in IN N
infants NNS p
and CC p
young JJ p
children NNS p
. . p

Twenty-two NNP p
healthy JJ p
infants NNS p
and CC p
children NNS p
received VBD N
either DT N
cold-recombinant JJ i
, , i
trivalent JJ i
influenza NN i
vaccine NN i
or CC N
placebo NN i
in IN N
a DT N
three-dose JJ N
vaccine NN N
trial NN N
. . N

Most JJS N
( ( N
82 CD N
% NN N
) ) N
who WP N
received VBD N
vaccine NN N
were VBD N
seronegative JJ N
to TO N
all DT N
three CD i
vaccine NN i
strains NNS i
( ( i
10 CD i
( ( i
6 CD i
) ) i
TCID50/dose NNP i
each DT i
) ) i
: : i
A/Kawasaki/9/86 NNP i
( ( i
H1N1 NNP i
) ) i
, , i
A/Los NNP i
Angeles/2/87 NNP i
( ( i
H3N2 NNP i
) ) i
, , i
and CC i
B/Yamagata/16/88 NNP i
. . i

Vaccine NNP N
was VBD N
administered VBN N
intranasally RB N
at IN N
time NN N
0 CD N
and CC N
2 CD N
and CC N
4 CD N
months NNS N
later RB N
. . N

The DT N
vaccine NN N
was VBD N
well RB o
tolerated VBN o
and CC o
immunogenic JJ o
when WRB N
administered VBN N
in IN N
a DT N
multidose JJ N
regimen NNS N
. . N

The DT N
first JJ N
dose NN N
stimulated VBN N
antibody NN N
to TO N
H1 NNP N
, , N
H3 NNP N
, , N
and CC N
B NNP N
in IN N
59 CD N
% NN N
, , N
94 CD N
% NN N
, , N
and CC N
35 CD N
% NN N
of IN N
vaccinees NNS N
, , N
respectively RB N
, , N
by IN N
hemagglutination NN N
inhibition NN N
( ( N
HAI NNP N
) ) N
or CC N
ELISA NNP N
. . N

After IN N
two CD N
doses NNS N
of IN N
vaccine NN N
, , N
93 CD N
% NN N
, , N
93 CD N
% NN N
, , N
and CC N
80 CD N
% NN N
had VBD N
antibody VBN N
by IN N
HAI NNP N
or CC N
ELISA NNP N
to TO N
H1 NNP o
, , o
H3 NNP o
, , o
and CC o
B NNP o
, , N
respectively RB N
. . N

Most JJS N
vaccinees NNS N
( ( N
67 CD N
% NN N
) ) N
responded VBD N
to TO N
all DT N
three CD N
viruses NNS N
after IN N
two CD N
doses NNS N
of IN N
vaccine NN N
. . N

The DT N
third JJ N
dose NN N
contributed VBD N
little JJ N
to TO N
the DT N
vaccine NN o
's POS o
immunogenicity NN o
. . o

Multidose NNP N
trivalent JJ N
influenza NN N
vaccine NN N
is VBZ N
safe JJ N
and CC N
induces VBZ N
an DT N
immune JJ o
response NN o
in IN N
most JJS N
vaccinees NNS N
after IN N
two CD N
doses NNS N
. . N

-DOCSTART- -X- O O

Self-management JJ N
education NN N
for IN N
adults NNS p
with IN p
poorly RB p
controlled VBN p
epilepsy NN p
( ( p
SMILE NNP p
( ( p
UK NNP p
) ) p
) ) p
: : p
statistical JJ N
, , N
economic JJ N
and CC N
qualitative JJ N
analysis NN N
plan NN N
for IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
need NN N
to TO N
test VB N
the DT o
effectiveness NN o
of IN o
new JJ o
educational JJ o
interventions NNS o
for IN N
people NNS N
with IN N
poorly RB N
controlled VBN N
epilepsy NN N
. . N

The DT N
SMILE NNP p
( ( p
self-management JJ p
education NN p
for IN p
adults NNS p
with IN p
poorly RB p
controlled VBN p
epilepsy NN p
) ) p
trial NN p
evaluates VBZ N
a DT N
complex JJ N
service NN N
intervention NN N
that WDT N
involves VBZ N
a DT N
2-day JJ N
self-management JJ N
course NN N
with IN N
the DT N
aim NN N
of IN N
improving VBG o
quality NN o
of IN o
life NN o
and CC o
clinical JJ o
outcomes NNS o
. . o

This DT N
article NN N
describes VBZ N
the DT N
statistical JJ N
, , N
economic JJ N
, , N
and CC N
qualitative JJ N
analysis NN N
plan NN N
for IN N
the DT N
trial NN N
. . N

METHODS NNP N
AND CC N
DESIGN NNP N
SMILE NNP p
is VBZ p
a DT p
pragmatic JJ p
, , p
parallel JJ p
design NN p
, , p
two-arm JJ p
, , p
multi-centre JJ p
randomised VBD p
controlled JJ p
superiority NN p
trial NN p
of IN p
a DT i
group-based JJ i
interactive JJ i
course NN i
compared VBN i
with IN i
treatment NN i
as IN i
usual JJ i
for IN p
people NNS p
who WP p
have VBP p
experienced VBN p
two CD p
or CC p
more JJR p
seizures NNS p
in IN p
the DT p
past JJ p
12 CD p
months NNS p
. . p

RESULTS VB N
A DT N
summary NN N
of IN N
the DT N
objectives NNS N
and CC N
design NN N
of IN N
the DT N
trial NN N
are VBP N
reported VBN N
as RB N
well RB N
as IN N
the DT N
manner NN N
in IN N
which WDT N
the DT N
data NN N
will MD N
be VB N
summarised VBN N
and CC N
inferentially RB N
analysed VBN N
. . N

This DT N
includes VBZ N
the DT N
type NN N
of IN N
modelling VBG N
that DT N
will MD N
be VB N
employed VBN N
for IN N
each DT N
of IN N
the DT N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
and CC N
the DT N
methods NNS N
by IN N
which WDT N
the DT N
assumptions NNS N
of IN N
these DT N
models NNS N
will MD N
be VB N
checked VBN N
. . N

Strategies NNS N
are VBP N
described VBN N
for IN N
handling VBG N
clustering NN N
of IN N
outcome NN N
data NNS N
, , N
missing VBG N
observations NNS N
, , N
and CC N
treatment NN N
non-compliance NN N
. . N

CONCLUSION VB N
This DT N
update NN N
to TO N
the DT N
previously RB N
published VBN N
trial NN N
protocol NN N
provides VBZ N
a DT N
description NN N
of IN N
the DT N
trial NN N
analysis NN N
which WDT N
is VBZ N
transparent JJ N
and CC N
specified VBN N
before IN N
any DT N
outcome NN N
data NNS N
are VBP N
available JJ N
. . N

It PRP N
also RB N
provides VBZ N
guidance NN N
to TO N
those DT N
planning VBG N
the DT N
analysis NN N
of IN N
similar JJ N
trials NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ISRCTN57937389 NNP N
; : N
date NN N
assigned VBD N
: : N
27 CD N
March NNP N
2013 CD N
. . N

-DOCSTART- -X- O O

Beta-adrenoceptor NNP N
blockade NN N
and CC N
cardiovascular JJ o
response NN o
to TO N
the DT N
cold JJ N
pressor NN N
test NN N
. . N

Seven NNP p
healthy JJ p
subjects NNS p
immersed VBD N
a DT N
hand NN N
in IN N
random NN N
order NN N
in IN N
either CC N
warm JJ N
water NN N
or CC N
in IN N
cold JJ N
water NN N
at IN N
5 CD N
degrees NNS N
C NNP N
for IN N
2 CD N
min NNS N
, , N
after IN N
taking VBG N
orally RB N
a DT N
single JJ N
dose NN N
of IN N
120 CD N
mg NN N
of IN N
propranolol NN i
or CC i
a DT i
placebo NN i
in IN N
a DT N
double JJ N
blind NN N
fashion NN N
. . N

The DT N
cold JJ N
stress NN N
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
blood NN o
pressure NN o
and CC N
the DT N
rate NN o
pressure NN o
product NN o
without IN N
a DT N
change NN N
in IN N
heart NN o
rate NN o
. . o

Beta-adrenoceptor NNP N
blockade NN N
did VBD N
not RB N
affect VB N
the DT N
pressor NN o
response NN o
the DT o
cold NN o
. . o

The DT N
changes NNS N
induced VBN N
by IN N
the DT N
cold JJ N
stress NN N
in IN N
the DT N
cardiovascular JJ o
variables NNS o
in IN N
the DT N
placebo NN N
and CC N
propranolol NN N
experiments NNS N
were VBD N
not RB N
statistically RB N
different JJ N
. . N

The DT N
highest JJS N
rate NN o
pressure NN o
product NN o
during IN N
the DT N
cold JJ N
pressor NN N
test NN N
was VBD N
about IN N
109 CD N
units NNS N
. . N

This DT N
was VBD N
well RB N
below IN N
the DT N
pain NN o
threshold JJ o
value NN N
of IN N
about IN N
200 CD N
found NN N
during IN N
exercise NN N
in IN N
patients NNS p
with IN p
ischaemic JJ p
heart NN p
disease NN p
. . p

In IN N
the DT N
recovery NN N
phase NN N
, , N
the DT N
cardiovascular JJ o
variables NNS o
reverted VBN N
to TO N
pre-immersion NN N
values NNS N
within IN N
1 CD N
min JJ N
inspite NN N
of IN N
continued JJ N
low JJ N
hand NN N
skin NN N
temperature NN N
. . N

-DOCSTART- -X- O O

Metabolic NNP N
and CC N
ventilatory JJ N
responses NNS N
during IN N
very RB i
low JJ i
level NN i
exercise NN i
. . i

1 CD N
. . N

Nine NNP p
male NN p
and CC p
six CD p
female JJ p
healthy JJ p
subjects NNS p
were VBD p
studied VBN p
during IN p
supine JJ i
bicycle NN i
exercise NN i
at IN p
workloads NNS p
of IN p
12 CD p
and CC p
37 CD p
W NNP p
; : p
pedalling VBG p
rates NNS p
varied VBD p
between IN p
30 CD p
and CC p
50 CD p
cycles/min NN p
at IN p
each DT p
workload NN p
. . p

Measurements NNS N
were VBD N
made VBN N
of IN N
oxygen NN o
consumption NN o
( ( o
VO2 NNP o
) ) o
, , o
carbon NN o
dioxide NN o
production NN o
( ( o
VCO2 NNP o
) ) o
, , o
minute JJ o
ventilation NN o
( ( o
VE NNP o
) ) o
, , o
tidal JJ o
volume NN o
( ( o
VT NNP o
) ) o
, , o
respiratory JJ o
frequency NN o
( ( o
fR NN o
) ) o
, , o
inspiratory JJ o
and CC o
expiratory JJ o
time NN o
( ( o
TI NNP o
, , o
TE NNP o
) ) o
and CC o
mean JJ o
inspiratory NN o
flow NN o
( ( o
VT/TI NNP o
) ) o
using VBG N
a DT N
non-invasive JJ N
canopy-computer-spirometer NN N
system NN N
. . N

2 CD N
. . N

At IN N
rest NN N
, , N
males NNS N
had VBD N
greater JJR N
values NNS N
of IN N
VE NNP o
, , o
VT NNP o
, , o
TI NNP o
, , o
inspiratory JJ o
duty NN o
cycle NN o
( ( o
TI/TTOT NNP o
) ) o
, , o
VCO2 NNP o
and CC o
VO2 NNP o
, , o
and CC o
a DT o
lower JJR o
fR NN o
, , N
than IN N
females NNS N
. . N

3 CD N
. . N

At IN N
the DT N
lower JJR N
workload NN N
, , N
VO2 NNP o
, , o
VCO2 NNP o
, , o
VE NNP o
, , o
VT NNP o
and CC o
VT/TI NNP o
increased VBD N
linearly RB N
with IN N
increasing VBG N
pedalling VBG N
rate NN N
, , N
whereas WP N
at IN N
the DT N
higher JJR N
workload NN N
there EX N
was VBD N
a DT N
decrease NN N
in IN N
VO2 NNP o
and CC N
little JJ N
or CC N
no DT N
change NN N
in IN N
ventilatory NN o
parameters NNS o
from IN N
30 CD N
to TO N
50 CD N
cycles/min NN N
except IN N
for IN N
an DT N
increase NN N
in IN N
fR NN o
in IN N
females NNS N
. . N

4 CD N
. . N

While IN N
performing VBG N
supine JJ i
exercise NN i
, , N
there EX N
was VBD N
an DT N
effect NN N
of IN N
pedalling VBG o
rate NN o
on IN o
ventilatory NN o
and CC o
metabolic JJ o
parameters NNS o
at IN N
the DT N
low JJ N
workload NN N
( ( N
12 CD N
W NNP N
) ) N
which WDT N
diminished VBD N
at IN N
the DT N
higher JJR N
workload NN N
( ( N
37 CD N
W NNP N
) ) N
. . N

An DT N
increase NN N
in IN N
pedalling VBG o
rate NN o
appears VBZ N
to TO N
enhance VB N
efficiency NN N
at IN N
these DT N
low JJ N
workloads NNS N
. . N

5 CD N
. . N

Differences NNS N
between IN N
the DT N
sexes NNS N
during IN N
exercise NN N
generally RB N
include VBP N
: : N
( ( N
a DT N
) ) N
a DT N
higher JJR o
breathing NN o
frequency NN o
, , o
( ( o
b NN o
) ) o
a DT o
greater JJR o
mechanical JJ o
efficiency NN o
, , o
and CC o
( ( o
c NN o
) ) o
lower JJR o
ventilatory NN o
equivalents NNS o
of IN o
O2 NNP o
and CC o
CO2 NNP o
( ( o
VE/VO2 NNP o
and CC o
VE/VCO2 NNP o
) ) o
during IN N
the DT N
higher JJR N
workload NN N
in IN N
females NNS N
than IN N
males NNS N
. . N

-DOCSTART- -X- O O

Matched-pair JJ N
analysis NN i
of IN N
all-polyethylene JJ i
versus NN i
metal-backed JJ i
tibial JJ i
components NNS i
. . i

Forty-eight NNP p
matched VBD p
pairs NNS p
of IN p
osteoarthritic JJ p
knees NNS p
from IN p
patients NNS p
who WP p
underwent VBP p
primary JJ p
total JJ p
knee NN p
arthroplasty NN p
with IN p
a DT p
round-on-round NN p
, , p
Apollo NNP p
Knee NNP p
System NNP p
were VBD N
studied VBN N
to TO N
evaluate VB N
the DT N
outcome NN N
between IN N
all-polyethylene JJ i
and CC i
metal-backed JJ i
tibial JJ i
components NNS i
. . i

Patients NNS p
were VBD p
matched VBN p
for IN p
patient JJ p
factors NNS p
, , p
preoperative JJ p
deformities NNS p
, , p
cruciate JJ p
salvage NN p
or CC p
sacrifice NN p
, , p
and CC p
surgical JJ p
technique NN p
. . p

At IN N
the DT N
last JJ N
follow-up JJ N
( ( N
average JJ N
, , N
38.4 CD N
months NNS N
) ) N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
knee NN o
scores NNS o
, , o
patient JJ o
self-assessment NN o
, , o
and CC o
radiographic JJ o
outcomes NNS o
. . o

No DT N
component NN N
required VBN N
revision NN N
, , N
and CC N
no DT N
revisions NNS N
were VBD N
pending VBG N
. . N

Maintenance NN N
of IN N
these DT N
results NNS N
over IN N
time NN N
would MD N
project VB N
into IN N
better JJR N
long-term JJ N
success NN N
for IN N
all-polyethylene JJ i
tibial JJ i
components NNS i
because IN N
of IN N
the DT N
amount NN N
of IN N
wear NN N
and CC N
osteolysis NN N
with IN N
current JJ N
modular JJ N
metal-backed JJ i
tibial JJ i
components NNS i
. . i

We PRP N
advocate VBP N
the DT N
use NN N
of IN N
a DT N
more RBR N
cost-effective JJ N
all-polyethylene JJ i
tibial JJ i
component NN i
in IN N
elderly JJ p
patients NNS p
( ( p
> JJ p
70 CD p
years NNS p
old JJ p
) ) p
who WP N
are VBP N
not RB N
likely JJ N
to TO N
need VB N
the DT N
versatility NN N
of IN N
exchange NN N
of IN N
a DT N
modular JJ N
polyethylene NN N
insert NN N
because IN N
of IN N
wear NN N
. . N

-DOCSTART- -X- O O

Parent NNP i
management NN i
training NN i
and CC p
Asperger NNP p
syndrome NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
to TO N
evaluate VB N
a DT N
parent NN o
based VBN o
intervention NN o
. . o

This DT N
controlled JJ N
trial NN N
of IN N
a DT N
parent NN i
management NN i
intervention NN i
aimed VBN N
to TO N
increase VB N
parental JJ N
competence NN N
in IN N
management NN N
of IN N
problem NN N
behaviours NNS N
associated VBN N
with IN N
Asperger NNP p
syndrome NN p
. . p

The DT N
intervention NN N
compared VBN N
two CD N
formats NNS N
, , N
a DT N
1 CD i
day NN i
workshop NN i
and CC i
six CD i
individual JJ i
sessions NNS i
. . i

Measures NNS N
were VBD N
taken VBN N
on IN N
three CD N
occasions NNS N
: : N
pre-intervention NN N
, , N
at IN N
4 CD N
weeks NNS N
, , N
and CC N
at IN N
3 CD N
month NN N
follow-up NN N
. . N

Variables NNS N
of IN N
interest NN N
were VBD N
number NN o
and CC o
intensity NN o
of IN o
problem NN o
behaviours NN o
, , o
and CC o
parent JJ o
evaluation NN o
of IN o
social JJ o
interaction NN o
skills NNS o
. . o

Results NNS N
showed VBD N
parents NNS N
reporting VBG N
fewer JJR N
and CC N
lower JJR N
intensity NN o
of IN o
problem NN o
behaviours NNS o
and CC N
increased VBD o
social JJ o
interactions NNS o
at IN N
4 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
. . N

Results NNS N
held VBD N
across IN N
formats NNS N
and CC N
suggest VBP N
that IN N
parent NN N
management NN N
training NN N
can MD N
provide VB N
an DT N
effective JJ o
intervention NN o
for IN o
parents NNS o
of IN o
a DT o
child NN o
with IN o
Asperger NNP o
syndrome NN o
. . o

Group NNP N
differences VBZ N
on IN N
outcome NN N
measures NNS N
and CC N
in IN N
the DT N
use NN N
of IN N
strategies NNS N
are VBP N
discussed VBN N
along IN N
with IN N
limitations NNS N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O

Long-term JJ N
effects NNS N
of IN N
choline NN i
on IN N
productive JJ o
performance NN o
and CC o
egg NN o
quality NN o
of IN N
brown-egg NN p
laying NN p
hens NNS p
. . p

A DT N
total NN p
of IN p
five CD p
hundred JJ p
forty NN p
19-wk-old JJ p
HyLine NNP p
Brown NNP p
hens NNS p
were VBD p
used VBN p
to TO p
study VB p
the DT N
long-term JJ N
effects NNS N
of IN N
increasing VBG N
choline NN i
with IN i
0 CD i
( ( i
control NN i
) ) i
, , i
425 CD i
, , i
850 CD i
, , i
1,700 CD i
, , i
3,400 CD i
, , N
and CC N
6,800 CD i
mg/kg NN i
of IN i
corn-soybean JJ i
meal-based JJ i
diets NNS i
on IN N
productive JJ o
performance NN o
and CC o
egg NN o
quality NN o
. . o

Phase VB N
1 CD N
was VBD N
from IN N
19 CD N
to TO N
58 CD N
wk NN N
, , N
and CC N
phase NN N
2 CD N
was VBD N
from IN N
59 CD N
to TO N
68 CD N
wk NN N
. . N

During IN N
the DT N
whole JJ N
experimental JJ N
period NN N
, , N
dietary JJ N
choline NN N
had VBD N
no DT N
significant JJ N
effects NNS N
on IN N
feed NN o
intake NN o
, , o
egg NN o
weight NN o
, , o
and CC o
egg NN o
mass NN o
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

During IN N
phase NN N
1 CD N
, , N
egg NN o
production NN o
decreased VBD N
linearly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
feed JJ o
conversion NN o
ratio NN o
( ( o
FCR NNP o
) ) o
tended VBD N
to TO N
increase VB N
linearly RB N
( ( N
P NNP N
= NNP N
0.057 CD N
) ) N
with IN N
increasing VBG N
choline JJ N
level NN N
in IN N
the DT N
diet NN N
. . N

Moreover RB N
, , N
BW NNP o
decreased VBD N
both DT N
linearly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
quadratically RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
as IN N
choline NN N
increased VBN N
from IN N
0 CD N
to TO N
6,800 CD N
mg/kg NNS N
. . N

No DT N
significant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
for IN N
shell NN o
thickness NN o
and CC o
shell NN o
strength NN o
of IN N
eggs NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
albumen NNS o
height VBD o
and CC o
Haugh NNP o
units NNS o
increased VBD N
linearly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
and CC N
P NNP N
< NNP N
0.05 CD N
, , N
respectively RB N
) ) N
as IN N
choline NN N
increased VBD N
during IN N
phase NN N
2 CD N
. . N

Compared VBN N
with IN N
the DT N
control NN N
group NN N
, , N
diets NNS N
supplemented VBD N
with IN N
425 CD N
or CC N
850 CD N
mg NN N
of IN N
choline/kg NN N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
improved VBN N
yolk JJ o
color NN o
during IN N
phase NN N
1 CD N
. . N

This DT N
study NN N
indicates VBZ N
that IN N
a DT N
dietary JJ N
choline NN N
level NN N
of IN N
no DT N
more JJR N
than IN N
700 CD N
mg/kg NN N
is VBZ N
sufficient JJ N
to TO N
maintain VB N
egg NN N
production NN N
. . N

The DT N
effect NN N
of IN N
choline NN N
on IN N
egg NN o
quality NN o
was VBD N
minimal JJ N
when WRB N
hens NNS N
were VBD N
fed VBN N
a DT N
corn-soybean JJ i
meal-based JJ i
diet NN i
from IN N
19 CD N
to TO N
68 CD N
wk NN N
of IN N
age NN N
. . N

-DOCSTART- -X- O O

Retroinfusion-supported JJ i
stenting NN i
in IN N
high-risk JJ p
patients NNS p
for IN p
percutaneous JJ p
intervention NN p
and CC p
bypass NN i
surgery NN i
: : i
results NNS N
of IN N
the DT N
prospective JJ N
randomized NN N
myoprotect NN N
I PRP N
study VBP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
event-free JJ o
survival NN o
and CC o
total JJ o
treatment NN o
costs NNS o
of IN N
retroinfusion-supported JJ i
stenting NN i
in IN N
high-risk JJ p
patients NNS p
compared VBN N
to TO N
bypass VB i
surgery NN i
. . i

An DT N
increasing VBG N
number NN N
of IN N
patients NNS p
with IN p
main-stem JJ p
and CC p
main-stem-equivalent JJ p
stenosis NN p
are VBP N
treated VBN N
by IN N
stent JJ i
implantation NN i
, , N
which WDT N
appears VBZ N
to TO N
be VB N
safe JJ N
in IN N
the DT N
short-term JJ N
follow-up NN N
. . N

However RB N
, , N
there EX N
is VBZ N
a DT N
lack NN N
of IN N
randomized JJ N
studies NNS N
comparing VBG N
conventional JJ i
bypass NN i
surgery NN i
with IN N
stent JJ i
implantation NN i
, , N
particularly RB N
in IN N
patients NNS p
with IN p
high JJ p
risk NN p
for IN p
both DT p
treatments NNS p
. . p

We PRP N
here RB N
report VBP N
on IN N
the DT N
1-year JJ N
results NNS N
of IN N
a DT N
prospective JJ N
randomized VBN N
single-center NN N
study NN N
in IN N
patients NNS p
with IN p
symptomatic JJ p
main-stem NN p
and CC p
main-stem-equivalent JJ p
lesions NNS p
with IN p
substantially RB p
increased VBN p
risk NN p
for IN p
bypass NN i
surgery NN i
. . i

Patients NNS N
where WRB N
randomized VBN N
to TO N
undergo VB N
either RB N
percutaneous JJ i
transluminal JJ i
coronary JJ i
angioplasty/stent NN i
procedure NN i
( ( p
n JJ p
= NNP p
23 CD p
) ) p
or CC N
bypass NN i
surgery NN i
( ( p
n JJ p
= NNP p
21 CD p
) ) p
. . p

Patients NNS N
randomized VBD N
to TO N
stent VB i
implantation NN i
were VBD N
supported VBN N
by IN N
selective JJ i
pressure-regulated JJ i
retroinfusion NN i
of IN N
the DT N
anterior JJ N
cardiac JJ N
vein NN N
during IN N
ischemia NN N
. . N

Patients NNS p
of IN p
the DT p
stent NN i
group NN p
and CC p
the DT p
bypass NN i
group NN p
did VBD p
not RB p
differ VB p
in IN p
baseline NN p
characteristics NNS p
, , p
including VBG p
Parsonnet NNP o
score NN o
and CC o
quality-of-life JJ o
score NN o
. . o

Twenty-eight-day JJ o
mortality NN o
and CC o
1-year JJ o
mortality NN o
rate NN o
as RB N
well RB N
as IN N
quality-of-life JJ o
scores NNS o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Event-free JJ o
survival NN o
after IN N
1 CD N
year NN N
was VBD N
higher RBR N
in IN N
the DT N
bypass NN N
group NN N
( ( N
71.4 CD N
% NN N
vs. FW N
52.3 CD N
% NN N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
due JJ N
to TO N
a DT N
lower JJR N
target NN N
lesion NN N
revascularization NN N
rate NN N
. . N

With IN N
regard NN N
to TO N
total JJ o
treatment NN o
costs NNS o
, , N
however RB N
, , N
the DT N
stent NN N
group NN N
compared VBN N
favorably RB N
to TO N
the DT N
bypass NN N
group NN N
( ( N
9,346 CD N
+/- JJ N
807 CD N
vs. FW N
26,874 CD N
+/- JJ N
3,985 CD N
euro NN N
) ) N
, , N
predominantly RB N
as IN N
a DT N
result NN N
of IN N
a DT N
shorter NN N
intensive JJ N
care NN N
and CC N
hospital NN N
stay NN N
. . N

In IN N
this DT N
first JJ N
randomized VBN N
study NN N
in IN N
high-risk JJ p
patients NNS p
for IN p
stent JJ i
implantation NN i
and CC p
bypass NN i
surgery NN i
, , N
patients NNS N
with IN N
retroinfusion-supported JJ i
stent NN i
implantation NN i
had VBD N
a DT N
similar JJ N
1-year JJ o
outcome NN o
and CC o
quality NN o
of IN o
life NN o
compared VBN N
to TO N
patients NNS N
with IN N
bypass NN i
surgery NN i
. . i

Though IN N
in IN N
the DT N
stent JJ N
group NN N
event-free JJ o
survival NN o
was VBD N
lower JJR N
and CC N
target VB N
lesion JJ N
revascularization NN o
rate NN o
was VBD N
higher JJR N
, , N
retroinfusion-supported JJ i
stent NN i
implantation NN i
was VBD N
associated VBN N
with IN N
substantially RB N
lower JJR o
costs NNS o
and CC N
might MD N
be VB N
considered VBN N
as IN N
an DT N
alternative JJ N
treatment NN N
option NN N
in IN N
this DT N
selected VBN N
group NN N
of IN N
high-risk JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

Using VBG N
a DT N
choice NN i
assessment NN i
to TO N
predict VB N
reinforcer NN N
effectiveness NN N
. . N

A DT i
choice NN i
assessment NN i
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
a DT N
more RBR N
accurate JJ N
method NN N
of IN N
identifying VBG N
preferences NNS N
than IN N
is VBZ N
single-item JJ N
presentation NN N
. . N

However RB N
, , N
it PRP N
is VBZ N
not RB N
clear JJ N
whether IN N
the DT N
effectiveness NN N
of IN N
reinforcement NN N
varies NNS N
positively RB N
with IN N
the DT N
degree NN N
of IN N
preference NN N
( ( N
i.e. FW N
, , N
whether IN N
the DT N
relative JJ N
preference NN N
based VBN N
on IN N
the DT N
results NNS N
of IN N
a DT N
choice NN N
assessment NN N
predicts VBZ N
relative JJ N
reinforcer NN N
effectiveness NN N
) ) N
. . N

In IN N
the DT N
current JJ N
study NN N
, , N
we PRP N
attempted VBD N
to TO N
address VB N
this DT N
question NN N
by IN N
categorizing VBG N
stimuli NNS N
as RB N
high JJ N
, , N
middle JJ N
, , N
and CC N
low JJ N
preference NN N
based VBN N
on IN N
the DT N
results NNS N
of IN N
a DT N
choice NN i
assessment NN i
, , N
and CC N
then RB N
comparing VBG N
the DT N
reinforcing VBG N
effectiveness NN N
of IN N
these DT N
stimuli NNS N
using VBG N
a DT N
concurrent NN i
operants VBZ i
paradigm JJ i
. . i

High-preference NN N
stimuli NNS N
consistently RB N
functioned VBN N
as IN N
reinforcers NNS N
for IN N
all DT N
4 CD p
clients NNS p
. . p

Middle-preference NN N
stimuli NN N
functioned VBD N
as IN N
reinforcers NNS N
for IN N
2 CD p
clients NNS p
, , N
but CC N
only RB N
when WRB N
compared VBN N
with IN N
low-preference NN N
stimuli NNS N
. . N

Low-preference NNP N
stimuli NN N
did VBD N
not RB N
function NN N
as IN N
reinforcers NNS N
when WRB N
compared VBN N
to TO N
high- JJ N
and CC N
middle-preference JJ N
stimuli NNS N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
a DT N
choice NN i
assessment NN i
can MD N
be VB N
used VBN N
to TO N
predict VB N
the DT N
relative JJ N
reinforcing VBG N
value NN N
of IN N
various JJ N
stimuli NNS o
, , N
which WDT N
, , N
in IN N
turn NN N
, , N
may MD N
help VB N
to TO N
improve VB N
programs NNS N
for IN N
clients NNS p
with IN p
severe JJ p
to TO p
profound VB p
disabilities NNS p
. . p

-DOCSTART- -X- O O

Effects NNS o
of IN N
Combined NNP i
Resistive NNP i
Underwater NNP i
Exercises NNP i
and CC i
Interferential NNP i
Current NNP i
Therapy NNP i
in IN N
Patients NNP p
with IN p
Juvenile NNP p
Idiopathic NNP p
Arthritis NNP p
: : p
A DT p
Randomized NNP p
Controlled NNP p
Trial NNP p
. . p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
verify VB N
the DT N
effects NNS o
of IN N
combined JJ i
resistive JJ i
underwater NN i
exercises NNS i
and CC i
interferential JJ i
current JJ i
on IN N
the DT N
peak JJ N
torque NN N
of IN N
the DT N
quadriceps NNS N
and CC N
hamstrings NNS N
and CC N
pain NN N
levels NNS N
in IN N
patients NNS p
with IN p
juvenile JJ p
idiopathic JJ p
arthritis NN p
. . p

DESIGN NNP N
This DT N
is VBZ N
a DT N
randomized JJ N
controlled VBN N
study NN N
; : N
30 CD p
children NNS p
with IN p
polyarticular JJ p
juvenile NN p
idiopathic JJ p
arthritis NN p
were VBD N
randomly RB N
distributed VBN N
into IN N
two CD N
groups NNS N
: : N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
received VBD N
the DT N
traditional JJ i
physical JJ i
therapy NN i
program NN i
and CC N
the DT N
study NN N
group NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
received VBD N
resistive JJ i
underwater NN i
exercises NNS i
and CC i
interferential JJ i
current JJ i
therapy NN i
. . i

Peak NNP o
torque NN o
of IN o
the DT o
quadriceps NNS o
and CC o
hamstrings NNS o
and CC o
pain NN o
levels NNS o
were VBD N
evaluated VBN N
before IN N
treatment NN N
, , N
1 CD N
mo NN N
later RB N
, , N
and CC N
after IN N
3 CD N
mos NNS N
using VBG N
the DT N
HUMAC NNP N
NORM NNP N
, , N
CSMI NNP N
Testing NNP N
and CC N
Rehabilitation NNP N
Isokinetic NNP N
System NNP N
and CC N
visual JJ N
analog NN N
scale NN N
, , N
respectively RB N
. . N

RESULTS NNP N
In IN N
the DT N
control NN N
group NN N
, , N
all DT N
measures NNS o
showed VBD N
significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
after IN N
1 CD N
mo NN N
except IN N
peak JJ o
torque NN o
of IN o
left JJ o
quadriceps NNS o
and CC o
pain NN o
levels NNS o
, , N
and CC N
significant JJ N
differences NNS N
were VBD N
found VBN N
after IN N
3 CD N
mos NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
all DT N
. . N

In IN N
the DT N
study NN N
group NN N
, , N
all DT N
measures NNS N
showed VBD N
significant JJ N
differences NNS N
after IN N
1 CD N
and CC N
3 CD N
mos NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
there EX N
were VBD N
significant JJ N
differences NNS N
between IN N
groups NNS N
after IN N
1 CD N
and CC N
3 CD N
mos NNS N
in IN N
favor NN N
of IN N
the DT N
study NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT i
combination NN i
of IN i
resistive JJ i
underwater NN i
exercises NNS i
and CC i
interferential JJ i
current JJ i
therapy NN i
is VBZ N
a DT N
potentially RB N
valuable JJ N
treatment NN N
for IN N
patients NNS p
with IN p
juvenile JJ p
idiopathic JJ p
arthritis NN p
. . p

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
type NN i
of IN i
incision NN i
on IN N
the DT N
success NN N
rate NN N
of IN N
implant JJ p
integration NN p
at IN p
stage NN p
II NNP p
uncovering NN p
surgery NN i
. . i

In IN N
1991 CD N
, , N
the DT N
Dental NNP N
Implant NNP N
Clinical NNP N
Research NNP N
Group NNP N
comprising VBG N
30 CD p
Department NNP p
of IN p
Veterans NNP p
Affairs NNP p
medical JJ p
centers NNS p
and CC p
two CD p
dental JJ p
schools NNS p
initiated VBD p
a DT p
long-term JJ p
clinical JJ p
study NN p
to TO p
investigate VB p
the DT p
clinical JJ p
performance NN p
of IN p
implants NNS i
within IN p
the DT p
Spectra-System NNP p
( ( p
Core-Vent JJ p
Corporation NNP p
, , p
Las NNP p
Vegas NNP p
, , p
NV NNP p
) ) p
. . p

This DT N
article NN N
focuses VBZ N
on IN N
a DT N
portion NN N
of IN N
the DT N
study NN N
database NN N
related VBN N
to TO N
incision NN N
type NN N
, , N
implant JJ N
success NN N
rates NNS N
, , N
and CC N
response NN N
of IN N
crestal NN N
bone NN N
up RB N
to TO N
the DT N
time NN N
of IN N
surgical JJ i
uncovering NN i
. . i

The DT N
crestal JJ i
incision NN i
was VBD p
used VBN p
for IN p
1,705 CD p
implants NNS p
( ( p
381 CD p
patients NNS p
) ) p
and CC p
the DT p
remote JJ i
incision NN i
for IN p
593 CD p
implants NNS p
( ( p
141 CD p
patients NNS p
) ) p
. . p

No DT N
statistically RB N
significant JJ N
difference NN N
( ( N
P NNP N
= NNP N
.092 NNP N
chi-square JJ N
statistic NN N
) ) N
was VBD N
found VBN N
in IN N
implant JJ o
integration NN o
or CC N
the DT N
response NN o
of IN o
crestal JJ o
bone NN o
. . o

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
a DT N
theory-based JJ i
intervention NN i
to TO N
increase VB N
colorectal JJ o
cancer NN o
screening VBG o
among IN p
Iranian JJ p
health NN p
club NN p
members NNS p
: : p
a DT N
randomized JJ N
trial NN N
. . N

Colorectal JJ N
cancer NN N
is VBZ N
the DT N
third JJ N
most RBS N
commonly RB N
diagnosed JJ N
cancer NN N
and CC N
the DT N
fourth JJ N
leading VBG N
cause NN N
of IN N
death NN N
in IN N
the DT N
world NN N
. . N

There EX N
are VBP N
few JJ N
published VBN N
studies NNS N
that WDT N
have VBP N
used VBN N
theory-based JJ i
interventions NNS i
designed VBN N
to TO N
increase VB N
colorectal JJ N
cancer NN N
screening VBG N
in IN N
community NN N
lay VBP N
health NN N
organizations NNS N
. . N

The DT N
present JJ N
study NN N
was VBD N
guided VBN N
by IN N
the DT N
theoretical JJ N
concepts NNS N
of IN N
the DT N
preventive JJ N
health NN N
model NN N
. . N

Twelve NNP p
health NN p
clubs NNS p
of IN p
a DT p
municipal JJ p
district NN p
in IN p
Tehran NNP p
were VBD p
randomized VBN p
to TO N
two CD N
study NN N
groups NNS N
with IN N
equal JJ N
ratio NN N
. . N

The DT N
control NN N
group NN N
received VBD i
usual JJ i
services NNS i
throughout IN i
the DT i
study NN i
while IN N
the DT N
intervention NN N
group NN N
also RB N
received VBD i
a DT i
theory-based JJ i
educational JJ i
program NN i
on IN i
colorectal JJ i
cancer NN i
screening VBG i
plus CC i
a DT i
reminder NN i
call NN i
. . i

Screening VBG o
behavior NN o
, , N
the DT N
main JJ N
outcome NN N
, , N
was VBD N
assessed VBN N
4 CD N
months NNS N
after IN N
randomization NN N
. . N

A DT p
total NN p
of IN p
360 CD p
members NNS p
aged VBN p
50 CD p
and CC p
older JJR p
from IN p
12 CD p
health NN p
clubs NNS p
completed VBD p
a DT p
baseline NN p
survey NN p
. . p

Participants NNS N
in IN N
the DT N
intervention NN N
group NN N
reported VBD N
increased JJ o
knowledge NN o
of IN o
colorectal JJ o
cancer NN o
and CC o
screening NN o
tests NNS o
at IN N
4 CD N
months NNS N
follow-up JJ N
( ( N
p NN N
's POS N
< NNP N
.001 NNP N
) ) N
. . N

Moreover RB N
, , N
exposure NN N
to TO N
the DT N
theory-based JJ i
intervention NN i
significantly RB N
improved VBN o
self-efficacy NN o
, , o
perceived VBN o
susceptibility NN o
, , o
efficacy NN o
of IN o
screening NN o
, , o
social JJ o
support NN o
, , o
and CC o
intention NN o
to TO o
be VB o
screened VBN o
for IN o
colorectal JJ o
cancer NN o
, , N
from IN N
baseline NN N
to TO N
4 CD N
months NNS N
follow-up JJ N
( ( N
p NN N
's POS N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
screening NN o
rate NN o
for IN o
colorectal JJ o
cancer NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
( ( N
odds NNS N
ratio VBP N
= JJ N
15.93 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
5.57 CD N
, , N
45.53 CD N
) ) N
. . N

Our PRP$ N
theory-based JJ N
intervention NN N
was VBD N
found VBN N
to TO N
have VB N
a DT N
significant JJ N
effect NN N
on IN N
colorectal JJ o
cancer NN o
screening VBG o
use NN N
as IN N
measured VBN N
by IN N
self-report NN N
. . N

The DT N
findings NNS N
could MD N
have VB N
implications NNS N
for IN N
colorectal JJ N
cancer NN N
screening VBG N
program NN N
development NN N
and CC N
implementation NN N
in IN N
primary JJ N
health NN N
care NN N
settings NNS N
and CC N
through IN N
other JJ N
community NN N
organizations NNS N
. . N

-DOCSTART- -X- O O

Laparoscopic NNP i
vs NN N
open JJ i
appendectomy NN i
in IN N
overweight JJ p
patients NNS p
. . p

BACKGROUND NNP N
Laparoscopic NNP i
appendectomy NN i
( ( i
LA NNP i
) ) i
has VBZ N
been VBN N
associated VBN N
with IN N
a DT N
faster JJ N
recovery NN N
and CC N
less RBR N
postoperative JJ N
pain NN N
than IN N
the DT N
open JJ N
technique NN N
. . N

However RB N
, , N
few JJ N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
clinical JJ N
outcome NN N
of IN N
LA NNP i
in IN N
overweight JJ p
patients NNS p
. . p

METHODS NNP N
A NNP p
group NN p
of IN p
106 CD p
patients NNS p
with IN p
a DT p
body NN p
mass NN p
index NN p
( ( p
BMI NNP p
) ) p
> VBD p
26.4 CD p
, , p
representing VBG p
the DT p
upper JJ p
quintile NN p
of IN p
500 CD p
prospectively RB p
randomized JJ p
patients NNS p
, , N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

They PRP N
were VBD N
randomized VBN N
to TO N
undergo VB N
either DT N
laparoscopic NN i
or CC i
open JJ i
appendectomy NN i
( ( i
OA NNP i
) ) i
. . i

Operating NN o
and CC o
anesthesia NN o
times NNS o
, , o
postoperative JJ o
pain NN o
, , o
complications NNS o
, , o
hospital NN o
stay NN o
, , o
functional JJ o
index NN o
( ( N
1 CD N
week NN N
postoperatively RB N
) ) N
, , N
sick JJ o
leave VBP o
, , o
and CC o
time NN o
to TO o
full JJ o
recovery NN o
were VBD N
documented VBN N
. . N

RESULTS NNP N
In IN N
OA NNP i
, , N
the DT N
operating NN o
time NN o
for IN N
overweight JJ o
patients NNS p
was VBD N
significantly RB N
longer JJR N
than IN N
that DT N
for IN N
patients NNS N
in IN N
the DT N
normal JJ N
weight NN N
range NN N
( ( N
40 CD N
vs RB N
35 CD N
min NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
LA NNP i
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
operating NN o
time NN o
between IN N
the DT N
normal JJ N
and CC N
overweight JJ N
patients NNS N
. . N

Overweight JJ N
patients NNS N
who WP N
underwent JJ N
LA NNP i
had VBD N
longer RBR N
operating NN o
and CC o
anesthesia NN o
times NNS o
than IN N
their PRP$ N
OA NNP i
counterparts NNS N
( ( N
55 CD N
vs RB N
40 CD N
min NN N
, , N
p NN N
< VBD N
0.001 CD N
; : N
and CC N
125 CD N
vs NN N
100 CD N
min NN N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

Postoperative JJ o
pain NN o
was VBD N
significantly RB N
greater JJR N
in IN N
overweight JJ N
patients NNS N
who WP N
underwent VBP N
OA NNP i
than IN N
in IN N
those DT N
treated VBN N
with IN N
the DT N
laparoscopic NN i
technique NN i
. . i

Postoperative JJ o
pain NN o
was VBD N
also RB N
significantly RB N
greater JJR N
in IN N
overweight JJ N
patients NNS N
subjected VBN N
to TO N
OA NNP i
than IN N
in IN N
patients NNS N
of IN N
normal JJ N
weight NN N
after IN N
4 CD N
weeks NNS N
; : N
the DT N
clinical JJ N
significance NN N
may MD N
, , N
however RB N
, , N
be VB N
of IN N
less JJR N
importance NN N
since IN N
the DT N
values NNS N
are VBP N
low JJ N
( ( N
0.26 CD N
vs NN N
0.09 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
operating VBG N
techniques NNS N
in IN N
terms NNS N
of IN N
complications NNS N
. . N

Hospital NNP o
stay NN o
was VBD N
longer JJR N
for IN N
overweight NN N
patients NNS N
than IN N
for IN N
normal-weight JJ N
patients NNS N
undergoing VBG N
OA NNP i
( ( N
3.0 CD N
vs NN N
2.0 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
functional JJ N
index NN N
did VBD N
not RB N
differ VB N
between IN N
any DT N
group NN N
of IN N
patients NNS N
. . N

Sick NNP o
leave NN o
was VBD N
longer JJR N
for IN N
overweight JJ N
patients NNS N
who WP N
underwent VBP N
OA NNP i
than IN N
for IN N
normal-weight JJ N
patients NNS N
treated VBN N
with IN N
the DT N
same JJ N
technique NN N
( ( N
17 CD N
vs RB N
13 CD N
days NNS N
, , N
p VBP N
< RB N
0.01 CD N
) ) N
. . N

In IN N
the DT N
laparoscopic NN i
group NN N
, , N
however RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
overweight NN p
and CC p
normal-weight JJ p
patients NNS p
. . p

Time NN o
to TO o
full JJ o
recovery NN o
was VBD N
greater JJR N
in IN N
overweight JJ N
patients NNS N
subjected VBN N
to TO N
OA NNP i
than IN N
in IN N
the DT N
overweight JJ N
patients NNS N
in IN N
the DT N
LA NNP i
group NN N
( ( N
22 CD N
vs RB N
15 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
this DT N
study NN N
, , N
overweight JJ N
patients NNS N
who WP N
were VBD N
submitted VBN N
to TO N
LA NNP i
had VBD N
less RBR N
postoperative JJ o
pain NN o
and CC N
a DT N
faster RBR N
postoperative JJ o
recovery NN o
than IN N
overweight JJ N
patients NNS N
who WP N
had VBD N
OA NNP i
. . i

LA NNP i
also RB N
abolished VBD N
some DT N
of IN N
the DT N
negative JJ N
effects NNS N
that WDT N
overweight VBD N
had VBD N
on IN N
operating NN o
time NN o
, , o
hospital NN o
stay NN o
, , o
and CC o
sick JJ o
leave NN o
with IN N
the DT N
open JJ N
technique NN N
. . N

However RB N
, , N
anesthesia NN N
and CC N
operating NN N
times NNS N
were VBD N
significantly RB N
longer RBR N
in IN N
LA NNP i
for IN N
both DT N
overweight JJ N
patients NNS N
and CC N
those DT N
with IN N
a DT N
normal JJ N
BMI NNP N
. . N

-DOCSTART- -X- O O

Carvedilol NNP i
increases VBZ N
plasma JJ o
vascular JJ o
endothelial JJ o
growth NN o
factor NN o
( ( o
VEGF NNP o
) ) o
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
. . p

-DOCSTART- -X- O O

Getting VBG N
a DT N
high JJ N
response NN N
rate NN N
of IN N
sexual JJ N
behavior JJ N
survey NN N
among IN N
the DT N
general JJ p
population NN p
in IN p
Japan NNP p
: : p
three CD N
different JJ N
methods NNS N
of IN N
survey NN N
on IN N
sexual JJ N
behavior NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
specify VB N
the DT N
most RBS N
accurate JJ N
, , N
reliable JJ N
and CC N
valid JJ N
technique NN N
for IN N
a DT N
general JJ p
sexual JJ p
behavioral JJ p
survey NN p
in IN p
Japan NNP p
. . p

This DT N
pilot NN N
study NN N
was VBD N
conducted VBN N
to TO N
assure VB N
a DT N
high JJ N
response NN N
rate NN N
and CC N
to TO N
keep VB N
respondents NNS N
' POS N
privacy NN N
confidential NN N
by IN N
using VBG N
an DT N
anonymous JJ N
questionnaire NN N
survey NN N
technique NN N
. . N

The DT p
sample NN p
( ( p
360 CD p
potential JJ p
respondents NNS p
) ) p
was VBD p
selected VBN p
randomly RB p
from IN p
basic JJ p
resident NN p
registers NNS p
in IN N
two CD p
geographically RB p
different JJ p
areas NNS p
. . p

From IN N
the DT N
registries NNS N
, , N
90 CD p
residents NNS p
, , p
aged VBD p
20 CD p
to TO p
49 CD p
years NNS p
old JJ p
, , N
were VBD N
randomly RB N
selected VBN N
to TO N
represent VB N
each DT N
sex NN N
from IN N
each DT N
area NN N
. . N

The DT N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
groups NNS N
each DT N
having VBG N
a DT N
different JJ N
procedure NN N
of IN N
requesting VBG N
the DT N
completion NN N
of IN N
the DT N
survey NN N
and CC N
providing VBG N
the DT N
questionnaires NNS N
: : N
( ( N
1 CD N
) ) N
Postal NNP i
Group NNP i
, , i
( ( i
2 CD i
) ) i
Telephone CD i
Group NNP i
, , i
and CC i
( ( i
3 CD i
) ) i
Face-to-face NN i
Group NNP i
. . i

The DT N
survey NN N
was VBD N
carried VBN N
out RP N
from IN N
October NNP p
1995 CD p
to TO p
February NNP p
1996 CD p
. . p

Effective JJ o
response NN o
rates NNS o
for IN N
the DT N
above NN N
mentioned VBD N
three CD N
groups NNS N
were VBD N
69.2 CD N
% NN N
, , N
69.2 CD N
% NN N
and CC N
55.8 CD N
% NN N
, , N
respectively RB N
. . N

It PRP N
is VBZ N
difficult JJ N
to TO N
determine VB N
the DT N
best JJS N
method NN N
when WRB N
only RB N
considering VBG N
the DT N
effective JJ o
response NN o
rates NNS o
. . o

However RB N
, , N
judging VBG N
from IN N
our PRP$ N
effort NN N
and CC N
expense NN N
, , N
the DT N
mail NN i
survey NN i
is VBZ N
the DT N
best JJS N
possible JJ N
procedure NN N
and CC N
would MD N
be VB N
a DT N
reasonable JJ N
method NN N
for IN N
a DT N
national JJ N
sexual JJ N
behavior NN N
survey NN N
. . N

-DOCSTART- -X- O O

Improved VBN o
intraoperative JJ o
management NN o
of IN N
anastomotic JJ o
bleeding NN o
during IN p
aortic JJ p
reconstruction NN p
: : p
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
the DT N
effectiveness NN o
of IN N
a DT N
polymeric JJ i
surgical JJ i
sealant NN i
( ( i
CoSeal NNP i
) ) i
was VBD N
compared VBN i
to TO i
Gelfoam/thrombin NNP i
for IN i
managing VBG i
anastomotic JJ o
bleeding NN o
after IN i
implantation NN i
of IN i
Dacron NNP i
grafts NNS i
during IN i
aortic JJ i
reconstruction NN i
for IN i
nonruptured JJ i
aneurysms NNS i
. . i

Each DT i
treatment NN i
was VBD i
directly RB i
applied VBN i
to TO i
the DT i
suture NN i
line NN i
after IN i
confirmation NN i
of IN i
anastomotic JJ i
bleeding NN i
. . i

The DT N
proportion NN N
of IN N
suture NN N
line NN N
sites VBZ N
that IN N
achieved VBD N
immediate JJ o
sealing NN o
and CC N
the DT N
proportion NN N
sealed VBD N
within IN N
5 CD N
minutes NNS N
were VBD N
determined VBN N
among IN N
37 CD p
experimental JJ p
( ( p
59 CD p
sites NNS p
) ) p
and CC p
17 CD p
control NN p
subjects NNS p
( ( p
27 CD p
sites NNS p
) ) p
. . p

A DT N
significantly RB N
greater JJR N
proportion NN N
of IN N
bleeding VBG N
suture NN N
line NN N
sites NNS N
treated VBD N
with IN N
the DT N
polymeric JJ i
sealant NN i
achieved VBN N
immediate JJ o
sealing NN o
following VBG N
reestablishment NN N
of IN N
blood NN N
flow NN N
compared VBN N
with IN N
control-treated JJ N
sites NNS N
[ VBP N
48 CD N
of IN N
59 CD N
( ( N
81 CD N
% NN N
) ) N
vs VBZ N
10 CD N
of IN N
27 CD N
( ( N
37 CD N
% NN N
) ) N
; : N
P NNP N
= VBD N
0.002 CD N
] NN N
. . N

The DT N
difference NN N
between IN N
treatment NN N
groups NNS N
was VBD N
maintained VBN N
after IN N
5 CD N
minutes NNS N
with IN N
approximately RB N
85 CD N
per IN N
cent NN N
( ( N
50 CD N
of IN N
59 CD N
) ) N
of IN N
CoSeal NNP i
sites NNS N
compared VBN N
to TO N
just RB N
over IN N
one-half JJ N
( ( N
14 CD N
of IN N
27 CD N
) ) N
of IN N
control NN N
sites VBZ N
demonstrating VBG N
ultimate JJ o
sealing NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
adverse JJ N
events NNS N
related VBN N
to TO N
the DT N
use NN N
of IN N
the DT N
polymeric JJ i
sealant NN i
in IN N
this DT N
study NN N
. . N

These DT N
results NNS N
support VBP N
the DT N
use NN N
of IN N
this DT N
novel JJ N
sealant NN N
for IN N
the DT N
intraoperative JJ p
management NN p
of IN p
anastomotic JJ p
bleeding NN p
during IN p
aortic JJ p
reconstruction NN p
procedures NNS p
. . p

-DOCSTART- -X- O O

Prospective JJ N
randomised VBD p
multicentre JJ p
trial NN p
with IN p
the DT p
birth NN i
trainer NN i
EPI-NO NNP i
for IN N
the DT N
prevention NN N
of IN N
perineal JJ o
trauma NN o
. . o

BACKGROUND NNP N
In IN N
several JJ N
non-randomised JJ N
trials NNS N
training VBG N
with IN N
EPI-NO NNP i
increased VBD N
the DT N
rate NN N
of IN N
intact JJ N
perineum NN N
and CC N
decreased JJ N
episiotomy NN N
rates NNS N
, , N
shortened VBD N
the DT N
second JJ N
stage NN N
of IN N
labour NN N
and CC N
lowered VBN N
use NN N
of IN N
pain NN N
killers NNS N
. . N

AIMS NNP N
To TO N
verify VB N
the DT N
preliminary JJ N
results NNS N
with IN N
EPI-NO NNP i
in IN N
a DT N
prospective JJ N
randomised VBN N
trial NN N
. . N

METHODS NNP N
Randomised VBD p
, , p
single-blind JJ p
multicentre NN p
trial NN p
in IN p
four CD p
university NN p
hospitals NNS p
in IN p
Germany NNP p
including VBG p
276 CD p
primigravidae NN p
. . p

RESULTS NNP N
After IN N
training VBG N
with IN N
EPI-NO NNP i
we PRP N
observed VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
incidence NN o
of IN o
intact JJ o
perineum NN o
( ( N
37.4 CD N
% NN N
vs JJ N
25.7 CD N
% NN N
; : N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
a DT N
tendency NN N
towards NNS N
lower JJR o
episiotomy NN o
rates NNS o
( ( N
41.9 CD N
% NN N
vs JJ N
50.5 CD N
% NN N
; : N
P NNP N
= NNP N
0.11 CD N
) ) N
. . N

We PRP N
found VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD p
groups NNS p
regarding VBG N
incidence NN o
of IN o
perineal NN o
tears NNS o
, , o
duration NN o
of IN o
second JJ o
stage NN o
of IN o
labour NN o
, , o
use NN o
of IN o
pain NN o
relief NN o
and CC o
rate NN o
of IN o
vaginal JJ o
infection NN o
. . o

CONCLUSIONS NNP N
Training VBG N
with IN N
EPI-NO NNP i
increases NNS N
significantly RB N
the DT N
likelihood NN N
of IN N
having VBG o
an DT o
intact JJ o
perineum NN o
and CC o
reduces VBZ o
the DT o
episiotomy NN o
rate NN o
. . o

-DOCSTART- -X- O O

Gabexate NNP i
mesilate NN i
and CC N
antithrombin NN i
III NNP i
for IN N
intraoperative JJ N
anticoagulation NN N
in IN N
heparin NN p
pretreated VBN p
patients NNS p
. . p

Thirty NNP p
patients NNS p
scheduled VBN p
for IN p
elective JJ p
myocardial JJ p
revascularization NN p
and CC p
having VBG p
undergone JJ p
preoperative JJ p
heparin NN p
treatment NN p
have VBP N
been VBN N
admitted VBN N
to TO N
this DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
test VB N
two CD N
different JJ N
strategies NNS N
for IN N
preserving VBG N
circulating VBG o
antithrombin JJ o
III NNP o
( ( o
AT-III NNP o
) ) o
during IN N
cardiopulmonary JJ N
bypass NN N
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
group NN N
C NNP N
, , N
n JJ N
= NNP N
10 CD N
) ) N
were VBD N
treated VBN N
with IN N
a DT N
standard JJ i
heparinization NN i
( ( N
300 CD N
IU/kg NNP N
) ) N
. . N

Patients NNS N
in IN N
group NN N
A NNP N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
received VBD N
the DT N
same JJ N
management NN N
plus CC N
two CD i
doses NNS i
of IN i
purified JJ i
antithrombin NN i
III NNP i
( ( N
1000 CD N
IU NNP N
each DT N
) ) N
. . N

Patients NNS N
in IN N
group NN N
GA NNP N
received VBD N
200 CD i
IU/kg NNP i
heparin NN i
and CC i
a DT i
continuous JJ i
infusion NN i
of IN i
heparin NN i
( ( i
100 CD i
IU/kg/h NNP i
) ) i
and CC i
gabexate JJ i
mesilate NN i
( ( N
2 CD N
mg/kg/h NN N
) ) N
plus CC N
the DT N
same JJ N
dose NN N
of IN N
antithrombin JJ i
III NNP i
as IN N
group NN N
A NNP N
. . N

Both NNP N
group NN N
A NNP N
and CC N
group NN N
GA NNP N
demonstrated VBD N
a DT N
preservation NN o
of IN o
circulating VBG o
AT-III NNP o
when WRB N
compared VBN N
to TO N
group NN N
C NNP N
; : N
this DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
group NN N
GA NNP N
. . N

The DT N
total JJ o
heparin NN o
dosage NN o
was VBD N
less RBR N
in IN N
group NN N
GA NNP N
than IN N
in IN N
groups NNS N
A NNP N
and CC N
C. NNP N
Purified NNP N
AT-III NNP N
administration NN N
is VBZ N
recommended VBN N
in IN N
heparin NN p
pretreated JJ p
patients NNS p
; : p
the DT N
addition NN N
of IN N
gabexate NN N
mesilate NN N
to TO N
this DT N
protocol NN N
decreases VBZ N
the DT N
heparin NN o
requirement NN o
and CC N
increases VBZ N
the DT N
AT-III JJ o
preservation NN o
. . o

-DOCSTART- -X- O O

Treatment NN N
of IN N
anal JJ p
fissures NNS p
using VBG N
a DT N
combination NN N
of IN N
minoxidil NN i
and CC N
lignocaine NN i
: : i
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
. . N

AIM NNP N
Anal NNP N
fissures NNS N
are VBP N
associated VBN N
with IN N
hypertonia NN N
of IN N
the DT N
internal JJ N
anal JJ N
sphincter NN N
and CC N
pain NN N
. . N

We PRP N
evaluated VBD N
the DT N
efficacy NN N
of IN N
local JJ N
application NN N
of IN N
a DT N
combination NN N
of IN N
minoxidil NN i
and CC N
lignocaine NN i
in IN N
healing VBG N
anal JJ N
fissures NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
, , N
90 CD p
patients NNS p
with IN p
anal JJ p
fissure NN p
were VBD p
recruited VBN p
. . p

Patients NNS N
received VBD N
local JJ i
applications NNS i
of IN i
ointments NNS i
containing VBG i
5 CD i
% NN i
lignocaine NN i
( ( i
n=28 JJ i
) ) i
, , i
0.5 CD i
% NN i
minoxidil NN i
( ( N
n=36 JJ N
) ) N
, , N
or CC i
both DT i
( ( N
n=26 NN N
) ) N
. . N

Healing VBG o
of IN o
anal JJ o
fissure NN o
at IN N
6 CD N
weeks NNS N
was VBD N
used VBN N
as IN N
the DT N
primary JJ N
end-point NN N
. . N

RESULTS NNP N
Rates NNPS o
of IN o
complete JJ o
healing NN o
of IN o
fissure NN o
were VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
( ( i
lignocaine VB i
alone RB N
8/27 CD N
, , N
minoxidil VBD i
alone RB N
10/34 CD N
, , N
combination NN N
7/22 CD N
; : N
p=ns NN N
) ) N
. . N

Mean NNP o
( ( o
SD NNP o
) ) o
time NN o
taken VBN o
for IN o
complete JJ o
healing VBG o
with IN o
combination NN o
treatment NN o
[ VBZ N
1.9 CD N
( ( N
0.6 CD N
) ) N
weeks NNS N
] NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
that DT N
with IN N
minoxidil NN i
alone RB N
( ( N
3.1 CD N
[ RB N
1.7 CD N
] JJ N
weeks NNS N
; : N
p=0.001 NN N
) ) N
or CC N
with IN N
lignocaine JJ i
alone NN N
( ( N
3.3 CD N
[ RB N
0.8 CD N
] JJ N
weeks NNS N
; : N
p=0.002 NN N
) ) N
. . N

Rates NNS o
of IN o
pain NN o
relief NN o
were VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

Stoppage NN o
of IN o
bleeding VBG o
occurred VBD N
more RBR N
often RB N
with IN N
combination NN N
treatment NN N
than IN N
with IN N
lignocaine JJ i
alone RB N
. . N

No DT N
patient NN N
had VBD N
systemic JJ o
or CC o
local JJ o
side NN o
effects NNS o
. . o

CONCLUSION NNP N
Combination NNP N
treatment NN N
with IN N
minoxidil NN i
and CC N
lignocaine NN i
helps VBZ N
in IN N
faster RBR N
healing NN N
of IN N
anal JJ N
fissures NNS N
and CC N
provides VBZ N
better RBR N
symptomatic JJ N
relief NN N
than IN N
either DT N
drug NN N
alone RB N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
cognitive JJ i
behavioural JJ i
intervention NN i
for IN N
anger JJ N
management NN N
in IN N
children NNS p
diagnosed VBN p
with IN p
Asperger NNP p
syndrome NN p
. . p

The DT N
purpose NN N
of IN N
the DT N
study NN N
described VBD N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
cognitive JJ N
behavioural JJ N
intervention NN N
for IN N
anger JJ N
management NN N
with IN N
children NNS p
diagnosed VBN p
with IN p
Asperger NNP p
syndrome NN p
. . p

Forty-five JJ p
children NNS p
and CC p
their PRP$ p
parents NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
intervention NN i
or CC N
wait-list JJ i
control NN i
conditions NNS i
. . i

Children NNP N
in IN N
the DT N
intervention NN N
participated VBD N
in IN N
six CD i
2-h JJ i
weekly JJ i
sessions NNS i
while IN N
parents NNS N
participated VBN N
in IN N
a DT N
larger JJR N
parent NN N
group NN N
. . N

Parent NN N
reports NNS N
indicated VBD N
a DT N
significant JJ N
decrease NN N
in IN N
episodes NNS o
of IN o
anger NN o
following VBG N
intervention NN N
and CC N
a DT N
significant JJ N
increase NN N
in IN N
their PRP$ N
own JJ N
confidence NN o
in IN N
managing VBG o
anger NN o
in IN o
their PRP$ o
child NN o
. . o

Qualitative JJ N
information NN N
gathered VBN N
from IN N
parents NNS N
and CC N
teachers NNS N
indicated VBD N
some DT N
generalization NN N
of IN N
strategies NNS N
learned VBN N
in IN N
the DT N
clinic JJ N
setting NN N
to TO N
both DT N
home NN N
and CC N
school NN N
settings NNS N
. . N

Limitations NNS N
of IN N
the DT N
study NN N
and CC N
suggestions NNS N
for IN N
future JJ N
research NN N
are VBP N
also RB N
discussed VBN N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
delay NN N
in IN N
standard JJ N
treatment NN N
due JJ N
to TO N
induction VB N
chemotherapy NN N
in IN N
two CD N
randomized JJ N
prospective JJ N
studies NNS N
. . N

It PRP N
is VBZ N
often RB N
suggested VBN N
that IN N
tumors NNS N
will MD N
respond VB N
to TO N
induction VB i
chemotherapy NN i
and CC N
result NN N
in IN N
improved JJ N
survival NN o
for IN N
patients NNS p
with IN p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
. . p

Two CD N
regimens NNS N
of IN N
induction NN N
chemotherapy NN N
were VBD N
studied VBN N
in IN N
separate JJ N
randomized VBN N
, , N
prospective JJ N
trials NNS N
over IN N
the DT N
last JJ N
6 CD N
years NNS N
. . N

Eighty-three JJ p
patients NNS p
with IN p
advanced JJ p
disease NN p
were VBD p
entered VBN p
into IN p
the DT p
first JJ p
study NN p
( ( p
43/chemotherapy CD p
; : p
40/control CD p
) ) p
, , p
and CC p
60 CD p
into IN p
the DT p
second JJ p
( ( N
27/chemotherapy CD N
; : N
33/control CD N
) ) N
. . N

Patient JJ p
randomization NN p
was VBD p
stratified VBN p
by IN p
stage NN p
( ( p
III/IV NNP p
) ) p
and CC p
site NN p
( ( N
oral JJ N
cavity NN N
, , N
oropharynx NN N
, , N
nasopharynx RB N
, , N
hypopharynx NN N
, , N
larynx NN N
, , N
paranasal NN N
sinuses NNS N
) ) N
. . N

The DT N
first JJ N
study NN N
utilized JJ i
bleomycin NN i
, , i
Cytoxan NNP i
, , i
methotrexate NN i
and CC i
5-fluorouracil JJ i
in IN i
two CD i
cycles NNS i
( ( i
one CD i
cycle NN i
if IN i
no DT i
tumor NN i
response NN i
) ) i
, , i
followed VBN i
by IN i
standard NN i
treatment NN i
which WDT i
consisted VBD i
of IN i
combined JJ i
irradiation NN i
and CC i
surgery NN i
or CC i
, , i
in IN i
some DT i
instances NNS i
, , i
primary JJ i
irradiation NN i
alone RB i
. . i

The DT i
second JJ i
study NN i
utilized VBD i
cisplatin NN i
and CC i
5-fluorouracil NN i
in IN i
three CD i
cycles NNS i
prior RB i
to TO i
standard VB i
treatment NN i
. . i

An DT N
objective JJ o
tumor NN o
response NN o
to TO N
chemotherapy NN N
was VBD N
observed VBN N
in IN N
68 CD N
% NN N
in IN N
the DT N
first JJ N
study NN N
and CC N
85 CD N
% NN N
in IN N
the DT N
second JJ N
. . N

The DT N
patient NN o
survival NN o
in IN N
both DT N
studies NNS N
( ( N
at IN N
24 CD N
months NNS N
in IN N
the DT N
first JJ N
; : N
at IN N
19 CD N
in IN N
the DT N
second JJ N
) ) N
was VBD N
better RBR N
in IN N
the DT N
control NN N
than IN N
that DT N
in IN N
the DT N
experimental JJ N
groups NNS N
( ( N
43 CD N
% NN N
to TO N
31 CD N
% NN N
; : N
69 CD N
% NN N
to TO N
46 CD N
% NN N
) ) N
. . N

In IN N
the DT N
second JJ N
study NN N
, , N
the DT N
average JJ o
length NN o
of IN o
delay NN o
of IN o
standard JJ o
treatment NN o
was VBD N
longer JJR N
than IN N
in IN N
the DT N
first JJ N
study NN N
( ( N
95 CD N
days NNS N
vs. FW N
66 CD N
days NNS N
; : N
P NNP N
less JJR N
than IN N
.02 NN N
) ) N
. . N

Results CC N
combining VBG N
the DT N
P-values NNS N
of IN N
both DT N
studies NNS N
indicate VBP N
that IN N
the DT N
relative JJ N
risk NN N
of IN N
having VBG N
persistent JJ N
disease NN N
was VBD N
2.9 CD N
times NNS N
greater JJR N
for IN N
patients NNS N
who WP N
received VBD N
chemotherapy NN N
. . N

While IN N
toxicity NN o
to TO o
chemotherapy VB o
was VBD N
not RB N
a DT N
factor NN N
in IN N
survival NN N
, , N
the DT N
number NN N
of IN N
patients NNS N
who WP N
withdrew VBP N
from IN N
the DT N
studies NNS N
and CC N
those DT N
who WP N
did VBD N
not RB N
comply VB N
with IN N
treatment NN N
were VBD N
greater JJR N
in IN N
the DT N
chemotherapy NN N
groups NNS N
. . N

Except IN N
for IN N
new JJ N
drug NN N
regimens NNS N
of IN N
exceptional JJ N
promise NN N
, , N
it PRP N
is VBZ N
recommended VBN N
that IN N
future JJ N
studies NNS N
be VB N
designed VBN N
so RB N
that IN N
chemotherapy NN N
is VBZ N
given VBN N
concurrent NN N
with IN N
, , N
or CC N
following VBG N
the DT N
completion NN N
of IN N
standard JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Does VBZ N
short-term JJ N
treatment NN N
with IN N
proton NN i
pump NN i
inhibitors NNS i
cause VBP N
rebound JJ N
aggravation NN N
of IN N
symptoms NNS N
? . N
BACKGROUND NNP N
Rebound NNP N
acid VBZ N
hypersecretion NN N
might MD N
occur VB N
after IN N
treatment NN N
with IN N
proton NN i
pump NN i
inhibitors NNS i
. . i

This DT N
study NN N
looks VBZ N
for IN N
a DT N
rebound JJ N
aggravation NN N
of IN N
symptoms NNS N
after IN N
short-term JJ N
treatment NN N
with IN N
lansoprazole NN i
. . i

STUDY NNP N
Sixty-two JJ p
patients NNS p
( ( p
19 CD p
men NNS p
and CC p
43 CD p
women NNS p
; : p
mean JJ p
age NN p
, , p
54 CD p
years NNS p
; : p
range NN p
, , p
32-77 CD p
years NNS p
) ) p
with IN p
heartburn NN p
and CC p
regurgitation NN p
and CC p
normal JJ p
upper JJ p
endoscopy NN p
findings NNS p
were VBD N
studied VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
with IN N
a DT N
crossover NN N
design NN N
. . N

There EX N
were VBD N
two CD N
5-day JJ N
treatment NN N
periods NNS N
with IN N
lansoprazole JJ i
60 CD i
mg NN i
once RB i
daily JJ i
or CC i
placebo NN i
in IN N
random JJ N
order NN N
, , N
separated VBN N
by IN N
a DT N
9-day JJ N
washout NN N
period NN N
. . N

Reflux NNP o
, , o
total JJ o
, , o
and CC o
antacid JJ o
scores NNS o
were VBD N
calculated VBN N
for IN N
each DT N
of IN N
the DT N
treatment NN N
periods NNS N
. . N

Higher JJR N
scores NNS N
during IN N
the DT N
placebo JJ i
period NN N
in IN N
the DT N
group NN N
given VBN N
lansoprazole VBZ i
first RB N
than IN N
in IN N
the DT N
group NN N
given VBN N
placebo VBP N
first RB N
indicated VBN N
a DT N
rebound NN N
aggravation NN N
of IN N
symptoms NNS N
. . N

RESULTS VB N
The DT N
mean JJ N
symptom NN o
scores NNS o
during IN N
the DT N
placebo JJ i
period NN N
in IN N
the DT N
groups NNS N
given VBN N
lansoprazole VBP N
first JJ N
and CC N
placebo NN N
first RB N
were VBD N
as IN N
follows VBZ N
: : N
reflux NN o
score NN o
, , N
21.5 CD N
and CC N
17.6 CD N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
; : N
total JJ o
score NN o
, , N
11.2 CD N
and CC N
10.3 CD N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
; : N
and CC N
antacid VB o
score NN o
, , N
8.2 CD N
and CC N
7.2 CD N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
no DT N
indication NN N
of IN N
a DT N
rebound JJ N
aggravation NN N
of IN N
symptoms NNS N
12 CD N
to TO N
14 CD N
days NNS N
after IN N
a DT N
5-day JJ N
treatment NN N
with IN N
lansoprazole JJ i
60 CD N
mg NN N
once RB N
daily JJ N
in IN N
patients NNS p
with IN p
reflux NN p
symptoms NNS p
. . p

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
comet NN N
assay NN N
and CC N
the DT N
oxygen NN N
microelectrode NN N
for IN N
measuring VBG N
tumor NN o
oxygenation NN o
in IN N
head-and-neck JJ p
cancer NN p
patients NNS p
. . p

PURPOSE NNP N
To TO N
compare VB N
the DT N
Eppendorf NNP i
PO2 NNP i
histograph NN i
and CC N
the DT N
alkaline NN i
comet NN i
assay VBP i
as IN N
methods NNS N
of IN N
measuring VBG N
tumor NN o
hypoxia NN o
in IN N
patients NNS p
with IN p
head-and-neck JJ p
squamous JJ p
cell NN p
carcinomas NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
As IN N
part NN N
of IN N
a DT N
larger JJR N
clinical JJ N
trial NN N
, , N
65 CD p
patients NNS p
with IN p
head-and-neck JJ p
squamous JJ p
cell NN p
carcinoma NN p
nodal JJ p
metastasis NN p
underwent JJ N
tumor NN o
oxygenation NN o
measurements NNS o
with IN o
Eppendorf NNP o
PO2 NNP o
histographs NN o
and CC o
comet NN o
assays NNS o
, , i
performed VBN i
on IN i
fine-needle JJ i
aspirates NNS i
at IN i
1 CD i
and CC i
2 CD i
min NN i
after IN i
5 CD i
Gy NNP i
. . i

Fifty-four CD p
patients NNS p
had VBD p
sufficient JJ p
tumor NN p
cells NNS p
for IN p
comet JJ p
analysis NN p
at IN N
1 CD N
min NN N
and CC N
26 CD N
at IN N
both DT N
1 CD N
and CC N
2 CD N
min NN N
. . N

Individual JJ N
cells NNS N
were VBD N
examined VBN i
for IN i
DNA NNP i
single-strand NN i
breaks NNS i
by IN i
alkaline JJ i
gel NN i
electrophoresis NN i
, , i
and CC i
the DT i
distribution NN i
of IN i
values NNS i
was VBD i
quantified VBN i
using VBG i
median JJ i
tail NN i
moment NN i
( ( i
MTM NNP i
) ) i
. . N

Nonirradiated VBN N
tumor NN N
cells NNS N
from IN N
pretreatment JJ N
fine-needle JJ N
aspirates NNS N
received VBD N
5 CD i
Gy NNP i
in IN i
vitro NN i
to TO N
establish VB N
the DT N
oxygenated JJ N
response NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
correlation NN N
between IN N
the DT N
1- JJ N
and CC N
2-min JJ N
MTM NNP N
( ( N
slope VBP N
= RB N
0.77 CD N
+/- JJ N
0.03 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
relationship NN N
between IN N
DNA NNP o
damage NN o
in IN o
tumor NN o
cells NNS o
irradiated VBN N
in IN N
vitro NN N
and CC N
in IN N
vivo NN N
. . N

No DT N
correlation NN N
was VBD N
found VBN N
between IN N
Eppendorf NNP o
PO2 NNP o
measurements NNS o
and CC o
comet VBD o
MTM NNP o
. . o

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
correlation NN N
between IN N
the DT N
treatment NN N
response NN N
in IN N
the DT N
node NN N
studied VBD N
and CC N
comet VBD N
MTMs NNP N
, , N
whereas VBZ N
no DT N
correlation NN N
was VBD N
observed VBN N
between IN N
treatment NN N
response NN N
and CC N
Eppendorf NNP N
measurements NNS N
. . N

CONCLUSIONS NNP N
Comet NNP N
assays NNS N
are VBP N
reproducible JJ N
, , N
as IN N
shown VBN N
by IN N
biopsies NNS N
at IN N
1 CD N
and CC N
2 CD N
min NN N
. . N

Intertumor NNP N
variation NN N
in IN N
the DT N
MTM NNP N
is VBZ N
not RB N
a DT N
result NN N
of IN N
intrinsic JJ N
radiosensitivity NN N
but CC N
of IN N
tumor NN N
hypoxia NN N
. . N

There EX N
was VBD N
no DT N
correlation NN N
between IN N
Eppendorf NNP N
PO2 NNP N
measurements NNS N
and CC N
comet VBD N
MTM NNP N
. . N

Comet NNP N
assays NNS N
were VBD N
better JJR N
than IN N
Eppendorf NNP N
in IN N
predicting VBG N
treatment NN N
response NN N
as IN N
an DT N
end NN N
point NN N
for IN N
short-term JJ N
outcome NN N
. . N

Longer JJR N
follow-up NN N
is VBZ N
needed VBN N
to TO N
determine VB N
the DT N
role NN N
of IN N
the DT N
comet NN N
assay NN N
as IN N
a DT N
predictor NN N
for IN N
locoregional JJ N
tumor NN N
control NN N
and CC N
survivals NNS N
. . N

-DOCSTART- -X- O O

Deleterious JJ N
effects NNS N
of IN N
low-dose JJ i
oestrogen NN i
therapy NN i
on IN N
coronary JJ N
status NN N
in IN N
patients NNS p
with IN p
prostatic JJ p
cancer NN p
. . p

The DT N
effects NNS N
of IN N
oestrogen NN i
therapy NN i
and CC N
of IN N
orchidectomy NN i
on IN N
coronary JJ N
status NN N
, , N
as IN N
reflected VBN N
by IN N
exercise NN N
ECG-testing NN N
before IN N
and CC N
after IN N
one CD N
year NN N
of IN N
treatment NN N
, , N
were VBD N
assessed VBN N
in IN N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS p
( ( p
N NNP p
= NNP p
100 CD p
) ) p
with IN p
prostatic JJ p
cancer NN p
. . p

Oestrogen NNP i
was VBD N
given VBN N
as IN N
polyestradiol NN i
phosphate NN i
80 CD N
mg NN N
i.m NN N
. . N

per IN N
month NN N
in IN N
combination NN N
with IN N
150 CD i
micrograms NNS i
ethinylestradiol JJ i
p.o NN N
. . N

per IN N
day NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
inter-group JJ N
differences NNS N
in IN N
conventional JJ N
risk NN N
factors NNS N
or CC N
in IN N
pre-treatment JJ N
exercise NN N
test NN N
results NNS N
. . N

Twelve NNP N
months NNS N
after IN N
the DT N
start NN N
of IN N
therapy NN N
the DT N
oestrogen NN N
group NN N
showed VBD N
a DT N
significantly RB N
greater JJR N
depression NN N
of IN N
the DT N
ST-segment NNP N
during IN N
maximal JJ N
exercise NN N
in IN N
leads NNS N
CH2 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.0005 CD N
) ) N
and CC N
CH5 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
compared VBN N
with IN N
the DT N
pre-treatment JJ N
depression NN N
. . N

Twenty-five JJ N
per IN N
cent NN N
( ( N
N NNP N
= NNP N
13 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
oestrogen NN N
group NN N
suffered VBD N
cardiovascular JJ o
complications NNS o
during IN N
the DT N
year NN N
of IN N
therapy NN N
, , N
whereas JJ N
no DT N
such JJ N
complications NNS N
were VBD N
observed VBN N
in IN N
the DT N
orchidectomy NN N
group NN N
. . N

However RB N
, , N
even RB N
the DT N
patients NNS N
in IN N
the DT N
oestrogen NN N
group NN N
who WP N
had VBD N
not RB N
suffered VBN N
cardiovascular JJ o
complications NNS o
had VBD N
significantly RB N
greater JJR N
depressions NNS o
of IN o
the DT o
ST-segment NNP o
during IN N
exercise NN N
both DT N
in IN N
lead NN N
CH2 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.0005 CD N
) ) N
and CC N
in IN N
CH5 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
change NN N
in IN N
the DT N
ST-segment JJ o
level NN o
in IN N
the DT N
orchidectomy NN N
group NN N
twelve VBD N
months NNS N
after IN N
surgery NN N
. . N

In IN N
summary JJ N
, , N
we PRP N
found VBD N
evidence NN N
of IN N
an DT N
induction NN N
of IN N
myocardial JJ o
ischaemia NN o
during IN N
treatment NN N
with IN N
exogenous JJ i
oestrogens NNS i
at IN N
low JJ N
dosage NN N
in IN N
patients NNS p
with IN p
prostatic JJ p
cancer NN p
. . p

This DT N
deleterious JJ N
effect NN N
of IN N
oestrogen NN i
on IN N
the DT N
coronary JJ N
status NN N
argues NNS N
against IN N
oestrogen NN N
therapy NN N
, , N
since IN N
oestrogen NN i
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
more RBR N
beneficial JJ N
than IN N
orchidectomy NN N
against IN N
prostatic JJ N
carcinoma NN N
. . N

-DOCSTART- -X- O O

FDA NNP N
review NN N
of IN N
a DT N
panitumumab NN i
( ( i
Vectibix NNP i
) ) i
clinical JJ N
trial NN N
for IN N
first-line JJ N
treatment NN N
of IN N
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

On IN N
September NNP N
27 CD N
, , N
2006 CD N
, , N
the DT N
U.S. NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
granted VBD N
accelerated VBD N
approval NN N
to TO N
panitumumab VB i
( ( i
Vectibix NNP i
; : i
Amgen NNP N
, , N
Inc. NNP N
, , N
Thousand NNP N
Oaks NNP N
, , N
CA NNP N
) ) N
for IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
epidermal JJ p
growth NN p
factor NN p
receptor-expressing NN p
, , p
metastatic JJ p
colorectal NN p
carcinoma NN p
with IN p
disease JJ p
progression NN p
on IN p
or CC p
following VBG p
fluoropyrimidine- JJ i
, , i
oxaliplatin- JJ i
, , i
and CC i
irinotecan-containing JJ i
chemotherapy NN i
regimens NNS i
. . i

Accelerated NNP N
approval NN N
was VBD N
based VBN N
on IN N
demonstration NN N
of IN N
a DT N
beneficial JJ N
effect NN N
on IN N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
. . N

The DT N
present JJ N
submission NN N
summarizes VBZ N
a DT N
second JJ N
clinical JJ N
trial NN N
, , N
to TO N
be VB N
included VBN N
in IN N
the DT N
panitumumab JJ i
package NN N
insert NN N
in IN N
June NNP N
2008 CD N
, , N
of IN N
chemotherapy NN i
and CC i
bevacizumab NN i
with IN i
and CC i
without IN i
panitumumab NN i
in IN N
the DT N
first-line JJ N
treatment NN N
of IN N
patients NNS p
with IN p
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

The DT N
study NN N
was VBD N
closed VBN N
when WRB N
inferior JJ N
PFS NNP N
and CC N
greater JJR N
toxicity NN N
were VBD N
demonstrated VBN N
at IN N
the DT N
time NN N
of IN N
the DT N
planned VBN N
interim NN N
efficacy NN N
analysis NN N
. . N

Patients NNS p
receiving VBG p
panitumumab NN i
in IN N
combination NN N
with IN N
bevacizumab NN i
and CC i
chemotherapy NN i
experienced VBD N
a DT N
higher JJR N
incidence NN N
of IN N
death NN o
( ( N
9 CD N
% NN N
versus IN N
4 CD N
% NN N
) ) N
and CC N
a DT N
higher JJR N
risk NN N
for IN N
grade NN o
3 CD o
and CC o
4 CD o
toxicities NNS o
than IN N
patients NNS p
receiving VBG p
bevacizumab NN i
and CC i
chemotherapy NN i
alone RB i
. . i

The DT N
incidences NNS o
of IN o
any DT o
Common NNP o
Terminology NNP o
Criteria NNP o
for IN o
Adverse NNP o
Events NNP o
grade VBD o
3 CD o
and CC o
4 CD o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
were VBD N
87 CD N
% NN N
and CC N
72 CD N
% NN N
in IN N
the DT N
panitumumab NN i
and CC N
control NN N
groups NNS N
, , N
respectively RB N
. . N

Grade VB o
3 CD o
and CC o
4 CD o
AEs NNP o
occurring VBG N
more JJR N
commonly RB N
in IN N
panitumumab-treated JJ i
patients NNS N
included VBD N
rash/acneiform NN o
dermatitis NN o
, , o
diarrhea NN o
, , o
dehydration NN o
, , o
primarily RB o
resulting VBG o
from IN o
diarrhea NN o
, , o
hypokalemia NN o
, , o
stomatitis/mucositis NN o
, , o
and CC o
pulmonary JJ o
embolism NN o
. . o

The DT N
addition NN N
of IN N
panitumumab NN i
to TO i
bevacizumab VB i
and CC i
chemotherapy VB i
for IN N
the DT N
first-line JJ N
treatment NN N
of IN N
metastatic JJ p
colorectal NN p
cancer NN p
was VBD N
harmful JJ N
when WRB N
compared VBN N
with IN N
bevacizumab NN i
and CC i
chemotherapy NN i
alone RB i
. . i

The DT N
use NN N
of IN N
panitumumab NN i
in IN N
this DT N
setting NN N
can MD N
not RB N
be VB N
recommended VBN N
. . N

-DOCSTART- -X- O O

Changes NNS N
in IN N
calcanean JJ N
bone NN N
mineral NN N
occurring VBG N
spontaneously RB N
and CC N
during IN N
hormone JJ i
replacement NN i
therapy NN i
in IN N
early JJ p
post-menopausal JJ p
women NNS p
. . p

The DT N
spontaneous JJ p
calcanean JJ p
bone NN p
loss NN p
occurring VBG p
in IN p
healthy JJ p
early JJ p
post-menopausal JJ p
women NNS p
and CC N
the DT N
effect NN N
of IN N
two CD i
hormone NN i
replacement NN i
therapies NNS i
( ( i
HRT NNP i
's POS i
) ) i
were VBD N
investigated VBN N
in IN N
a DT N
longitudinal JJ N
study NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
right NN N
and CC N
left VBD N
calcanean JJ N
BMC NNP N
or CC N
BMD NNP N
( ( N
p JJ N
> NNP N
0.15 CD N
) ) N
. . N

The DT N
spontaneous JJ N
bone NN N
loss NN N
was VBD N
similar JJ N
at IN N
all PDT N
the DT N
skeletal JJ N
sites NNS N
measured VBD N
, , N
with IN N
a DT N
mean JJ N
spontaneous JJ N
loss NN N
in IN N
calcanean JJ N
BMD NNP N
of IN N
1.6 CD N
% NN N
over IN N
one CD N
year NN N
. . N

Both DT N
HRT NNP N
's POS N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
prevented VBD N
the DT N
bone NN o
loss NN o
from IN N
all DT N
skeletal JJ N
sites NNS N
irrespective VBP N
of IN N
the DT N
weight-bearing NN N
or CC N
content NN N
of IN N
trabecular JJ N
bone NN N
, , N
and CC N
( ( N
for IN N
the DT N
weight-bearing JJ N
bones NNS N
) ) N
there EX N
was VBD N
even RB N
a DT N
gain NN N
in IN N
calcanean JJ o
BMC NNP o
and CC o
BMD NNP o
and CC o
spinal JJ o
BMD NNP o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Bone NNP N
mineral NN N
of IN N
the DT N
calcaneus NN N
and CC N
the DT N
spine NN N
correlated VBN N
equally RB N
to TO N
body NN N
weight NN N
( ( N
r VB N
approximately RB N
0.4 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
whereas WP N
bone RB N
mineral NN N
in IN N
the DT N
forearm NN N
was VBD N
not RB N
correlated VBN N
to TO N
body VB N
weight NN N
. . N

The DT N
correlations NNS N
between IN N
the DT N
changes NNS N
in IN N
bone NN N
mineral NN N
at IN N
the DT N
sites NNS N
measured VBN N
were VBD N
all DT N
significant JJ N
( ( N
r VB N
approximately RB N
0.2-0.4 JJ N
) ) N
. . N

-DOCSTART- -X- O O

Parents NNS p
' POS p
state NN N
and CC N
trait NN N
anxiety NN N
: : N
relationships NNS N
with IN N
anxiety NN o
severity NN o
and CC N
treatment NN N
response NN N
in IN N
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Comorbid NNP N
anxiety NN N
is VBZ N
common JJ N
among IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
( ( p
ASD NNP p
) ) p
, , p
and CC p
parents NNS p
of IN p
children NNS p
with IN p
ASD NNP p
are VBP p
more RBR p
likely JJ p
to TO p
have VB p
anxiety NN p
disorders NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
relationship NN N
between IN N
parents NNS i
' POS i
state NN o
and CC o
trait NN o
anxiety NN o
and CC p
parent-reported JJ i
internalizing NN i
and CC i
externalizing VBG i
symptoms NNS i
among IN i
adolescents NNS i
( ( p
n JJ p
= NNP p
30 CD p
) ) p
with IN p
ASD NNP p
, , p
as RB p
well RB p
as IN p
the DT p
relationship NN p
of IN p
parents NNS o
' POS o
anxiety NN o
symptoms NNS o
and CC o
adolescent JJ o
treatment NN o
response NN o
in IN o
the DT N
context NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN o
. . o

Parental JJ o
state NN o
anxiety NN o
correlated VBD o
with IN o
severity NN o
of IN o
adolescent JJ o
anxiety NN o
, , o
and CC o
trait NN o
anxiety NN o
in IN o
parents NNS N
correlated VBN N
with IN o
parent-reported JJ o
adolescent NN o
internalizing NN o
and CC o
externalizing NN o
symptoms NNS o
. . o

Also RB N
, , N
parents NNS N
of IN N
adolescent JJ N
treatment NN N
responders NNS N
experienced VBD N
a DT N
decrease NN o
in IN o
their PRP$ o
own JJ o
trait NN o
anxiety NN o
. . o

Findings NNS N
highlight VBD N
the DT N
importance NN N
of IN N
considering VBG o
parental JJ o
anxiety NN o
when WRB o
targeting VBG o
anxiety NN o
among IN o
youth NN N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O

A DT N
play NN i
and CC i
joint JJ i
attention NN i
intervention NN i
for IN N
teachers NNS p
of IN p
young JJ p
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
pilot VB N
test VB N
a DT N
classroom-based JJ N
intervention NN N
focused VBD N
on IN N
facilitating VBG N
play NN N
and CC N
joint JJ N
attention NN N
for IN N
young JJ p
children NNS p
with IN p
autism NN p
in IN p
self-contained JJ p
special JJ p
education NN p
classrooms NNS p
. . p

Thirty-three JJ p
children NNS p
with IN p
autism NN p
between IN p
the DT p
ages NNS p
of IN p
3 CD p
and CC p
6 CD p
years NNS p
participated VBN p
in IN p
the DT p
study NN p
with IN p
their PRP$ p
classroom NN p
teachers NNS p
( ( p
n JJ p
= NNP p
14 CD p
) ) p
. . p

The DT N
14 CD p
preschool NN p
special JJ p
education NN p
teachers NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
symbolic NN i
play NN i
then RB i
joint JJ i
attention NN i
intervention NN i
, , N
( ( N
2 CD N
) ) N
joint NN i
attention NN i
then RB i
symbolic JJ i
intervention NN i
, , N
and CC N
( ( N
3 CD N
) ) N
wait-list NN i
control NN i
period NN i
then RB i
further RB i
randomized VBN i
to TO i
either DT i
group NN i
1 CD i
or CC i
group NN i
2 CD i
. . i

In IN N
the DT N
intervention NN N
, , N
teachers NNS N
participated VBD N
in IN N
eight CD N
weekly JJ N
individualized VBN N
1-h JJ N
sessions NNS N
with IN N
a DT N
researcher NN N
that WDT N
emphasized VBD N
embedding VBG N
strategies NNS N
targeting VBG N
symbolic JJ N
play NN N
and CC N
joint JJ N
attention NN N
into IN N
their PRP$ N
everyday JJ N
classroom NN N
routines NNS N
and CC N
activities NNS N
. . N

The DT N
main JJ N
child NN N
outcome NN N
variables NNS N
of IN N
interest NN N
were VBD N
collected VBN N
through IN N
direct JJ N
classroom NN N
observations NNS N
. . N

Findings NNS N
indicate VBP N
that IN N
teachers NNS N
can MD N
implement VB N
an DT N
intervention NN o
to TO o
significantly RB o
improve VB o
joint JJ o
engagement NN o
of IN N
young JJ p
children NNS p
with IN p
autism NN p
in IN p
their PRP$ p
classrooms NNS p
. . p

Furthermore RB N
, , N
multilevel NN N
analyses NNS N
showed VBD N
significant JJ o
increases NNS o
in IN o
joint JJ o
attention NN o
and CC o
symbolic JJ o
play NN o
skills NNS o
. . o

Thus RB N
, , N
these DT N
pilot NN N
data NNS N
emphasize VBP N
the DT N
need NN N
for IN N
further JJ N
research NN N
and CC N
implementation NN N
of IN N
classroom-based JJ N
interventions NNS N
targeting VBG N
play NN o
and CC o
joint JJ o
attention NN o
skills NNS o
for IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

-DOCSTART- -X- O O

Studies NNS N
on IN N
section NN o
2D1 CD o
monoclonal JJ o
antibodies NNS o
. . o

Monoclonal JJ N
antibodies NNS N
in IN N
Other JJ N
Blood NNP N
Groups NNP N
were VBD N
tested VBN N
with IN N
random JJ i
blood NN i
samples NNS i
collected VBN N
from IN N
the DT N
various JJ p
ethnic JJ p
groups NNS p
in IN p
KwaZulu-Natal NNP p
, , p
South NNP p
Africa NNP p
, , p
and CC p
with IN p
samples NNS p
of IN p
selected VBN p
red JJ p
cell NN p
phenotypes NNS p
. . p

Standard NNP i
red VBD i
cell NN i
serological JJ i
techniques NNS i
were VBD N
used VBN N
. . N

-DOCSTART- -X- O O

Primary JJ N
glaucoma NN N
triple JJ N
procedure NN N
in IN N
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
: : p
the DT N
effect NN o
of IN N
mitomycin NN i
C NNP i
in IN N
patients NNS N
with IN N
and CC N
without IN N
prognostic JJ N
factors NNS N
for IN N
filtration NN N
failure NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
the DT N
effect NN o
of IN N
adjunctive JJ i
mitomycin NN i
C NNP i
on IN N
primary JJ p
glaucoma NN p
triple JJ p
procedure NN p
in IN p
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
with IN p
and CC p
without IN p
one CD p
or CC p
more JJR p
of IN p
the DT p
prognostic JJ p
factors NNS p
for IN p
filtration NN p
failure NN p
of IN p
primary JJ p
glaucoma NN p
triple JJ p
procedure NN p
. . p

Those DT N
factors NNS N
include VBP N
being VBG N
of IN N
African-American JJ p
race NN p
, , N
having VBG N
a DT N
preoperative JJ N
intraocular JJ N
pressure NN N
of IN N
20 CD N
mm NNS N
Hg NNP N
or CC N
more JJR N
on IN N
maximum NN N
tolerated JJ N
medications NNS N
, , N
and CC N
being VBG N
on IN N
two CD N
or CC N
more JJR N
medications NNS N
preoperatively RB N
. . N

METHODS NNP N
Study NNP N
patients NNS N
consisted VBD N
of IN N
197 CD p
consecutive JJ p
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
who WP N
were VBD N
randomly RB i
assigned VBN i
to TO i
receive VB i
either DT i
no DT i
adjunctive JJ i
mitomycin NN i
C NNP i
( ( i
101 CD i
eyes NNS i
of IN i
101 CD i
patients NNS i
) ) i
or CC i
to TO i
receive VB i
adjunctive JJ i
subconjunctival NN i
mitomycin NN i
C NNP i
( ( i
96 CD i
eyes NNS i
of IN i
96 CD i
patients NNS i
) ) i
during IN i
the DT i
primary JJ i
glaucoma NN i
triple JJ i
procedure NN i
. . i

Kaplan-Meier NNP o
survival JJ o
analysis NN o
comparisons NNS o
were VBD N
made VBN N
between IN N
respective JJ N
subgroups NNS N
with IN N
and CC N
without IN N
prognostic JJ N
indicators NNS N
for IN N
filtration NN N
failures NNS N
using VBG N
a DT N
relatively RB N
stringent JJ N
set NN N
of IN N
criteria NNS N
for IN N
filtration NN N
success NN N
of IN N
primary JJ N
glaucoma NN N
triple JJ N
procedure NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.117 NNP N
) ) N
difference NN N
in IN N
filtration NN o
success NN o
of IN N
primary JJ N
glaucoma NN N
triple JJ N
procedure NN N
between IN N
the DT N
control NN i
and CC N
mitomycin NN i
C NNP i
groups NNS N
. . N

Adjunctive NNP i
mitomycin NN i
C NNP i
significantly RB N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
improved VBD N
the DT N
filtration NN o
outcome NN N
of IN N
the DT N
primary JJ N
glaucoma NN N
triple JJ N
procedure NN N
in IN N
the DT N
subgroups NNS N
with IN N
each DT N
of IN N
the DT N
three CD N
prognostic JJ N
factors NNS N
for IN N
filtration NN N
failure NN N
of IN N
primary JJ N
glaucoma NN N
triple JJ N
procedure NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
in IN N
the DT N
subgroups NNS N
without IN N
the DT N
prognostic JJ N
factors NNS N
, , N
adjunctive JJ i
mitomycin NN i
C NNP i
did VBD N
not RB N
significantly RB N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
change VBP N
the DT N
filtration NN o
outcome NN o
of IN N
the DT N
primary JJ N
glaucoma NN N
triple JJ N
procedure NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
establish VB N
the DT N
basis NN N
for IN N
selective JJ N
use NN N
of IN N
mitomycin NN i
C NNP i
in IN N
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
undergoing VBG p
primary JJ p
glaucoma NN p
triple JJ p
procedure NN p
. . p

-DOCSTART- -X- O O

Residual JJ N
platelet NN N
reactivity NN N
, , N
bleedings NNS N
, , N
and CC N
adherence NN N
to TO N
treatment NN N
in IN N
patients NNS p
having VBG p
coronary JJ p
stent JJ p
implantation NN p
treated VBN p
with IN p
prasugrel NN i
. . i

Recent JJ N
guidelines NNS N
have VBP N
recommended VBN N
the DT N
use NN N
of IN N
aspirin NN N
and CC N
prasugrel NN i
in IN N
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndromes NNS p
undergoing VBG p
percutaneous JJ p
coronary JJ p
intervention NN p
. . p

However RB N
, , N
prasugrel NN i
use NN N
has VBZ N
been VBN N
evaluated VBN N
only RB N
in IN N
randomized JJ N
trials NNS N
. . N

This DT N
study NN N
sought VBD N
to TO N
evaluate VB N
bleeding NN o
rates NNS o
and CC N
adherence NN N
to TO N
treatment NN N
in IN N
real-world JJ N
patients NNS N
treated VBN N
with IN N
prasugrel NN i
. . i

In IN N
total JJ p
298 CD p
consecutive JJ p
patients NNS p
68 CD p
? . p
10 CD p
years NNS p
old JJ p
( ( p
31 CD p
% NN p
> JJ p
75 CD p
years NNS p
old JJ p
) ) p
underwent JJ i
stent JJ i
implantation NN i
and CC i
received VBD i
prasugrel JJ i
therapy NN i
. . i

Indications NNS N
to TO N
prasugrel VB N
therapy NN N
were VBD N
( ( N
1 CD N
) ) N
ST-elevation NNP N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
41 CD N
% NN N
) ) N
, , N
( ( N
2 CD N
) ) N
drug-eluting NN N
stent JJ N
implantation NN N
in IN N
diabetics NNS N
( ( N
24 CD N
% NN N
) ) N
, , N
( ( N
3 CD N
) ) N
stent NN N
thrombosis NN N
( ( N
3 CD N
% NN N
) ) N
, , N
( ( N
4 CD N
) ) N
left VBD N
main JJ N
coronary JJ N
artery NN N
drug-eluting JJ N
stent NN N
implantation NN N
( ( N
6 CD N
% NN N
) ) N
, , N
and CC N
( ( N
5 CD N
) ) N
percutaneous JJ N
coronary JJ N
intervention NN N
in IN N
patients NNS N
with IN N
high JJ N
residual JJ N
platelet NN N
reactivity NN N
on IN N
clopidogrel NN N
therapy NN N
( ( N
26 CD N
% NN N
) ) N
. . N

All DT N
patients NNS N
received VBD N
a DT N
loading NN N
of IN i
prasugrel NN i
60 CD N
mg NN N
. . N

Patients NNS p
?75 CD p
years NNS p
old JJ p
and CC p
with IN p
body NN p
weight JJ p
?60 NNP p
kg NN p
received VBD p
a DT N
maintenance NN N
dose NN N
of IN N
5 CD N
mg/day NN N
( ( N
10 CD N
mg/day NN N
for IN N
all PDT N
the DT N
other JJ N
patients NNS N
) ) N
. . N

Follow-up NNP N
data NNS N
including VBG o
adherence NN o
to TO o
prasugrel VB o
therapy NN o
were VBD o
collected VBN N
by IN N
telephone NN N
interviews NNS N
or CC N
outpatient JJ N
visits NNS N
. . N

Minimal JJ N
follow-up JJ N
length NN N
was VBD N
6 CD N
months NNS N
( ( N
mean VB N
9 CD N
? . N
3 CD N
) ) N
. . N

Major NNP o
, , N
minor NN o
, , o
and CC o
minimal JJ o
bleedings NNS o
( ( o
Thrombolysis NNP o
In IN N
Myocardial NNP N
Infarction NNP N
criteria NNS N
) ) N
occurred VBD N
in IN N
2.7 CD N
% NN N
, , N
4.7 CD N
% NN N
, , N
and CC N
15.1 CD N
% NN N
of IN N
enrolled JJ N
patients NNS o
. . o

Low JJ o
residual JJ o
platelet NN o
reactivity NN o
( ( o
p JJ o
= NNP o
0.001 CD N
) ) N
and CC N
female JJ N
gender NN N
( ( N
p JJ N
= NNP N
0.29 CD N
) ) N
were VBD N
independent JJ N
predictors NNS N
of IN N
bleeding VBG N
events NNS N
. . N

The DT N
most RBS N
frequent JJ N
minimal JJ N
bleeding VBG N
event NN N
was VBD o
epistaxis RB o
. . o

Only RB o
8 CD N
patients NNS N
( ( N
2.7 CD N
% NN N
) ) N
permanently RB N
discontinued VBN N
prasugrel NN N
therapy NN N
because IN o
of IN o
bleeding VBG o
events NNS o
( ( o
n JJ o
= NNP o
4 CD N
) ) N
, , N
possible JJ o
side NN o
effects NNS o
( ( o
n JJ o
= NNP o
2 CD N
) ) N
, , N
or CC N
medical JJ o
decisions NNS o
not RB o
associated VBN o
with IN o
bleeding NN o
or CC o
side NN o
effects NNS o
( ( o
n JJ o
= NNP o
2 CD N
) ) N
. . N

Fourteen JJ N
patients NNS N
( ( N
4.7 CD N
% NN N
) ) N
temporarily RB o
discontinued VBN o
prasugrel NN o
( ( N
average JJ N
6.5 CD N
days NNS N
) ) N
mainly RB N
because IN N
of IN N
surgical JJ N
procedures NNS N
. . N

No DT N
definite NN o
or CC o
probable JJ o
stent JJ o
thrombosis NN o
occurred VBD o
, , N
although IN N
3 CD N
patients NNS N
develop VB o
de FW o
novo FW o
myocardial JJ o
infarction NN o
and CC o
1 CD o
an DT o
ischemic JJ o
stroke NN o
. . o

There EX o
were VBD N
11 CD o
deaths NNS o
because IN o
of IN o
heart NN o
failure NN o
or CC o
refractory NN o
cardiogenic JJ o
shock NN o
in IN N
9 CD N
, , N
pulmonary JJ o
embolism NN o
in IN o
1 CD o
, , o
and CC N
cancer NN o
in IN o
1 CD o
. . o

In IN N
conclusion NN N
, , N
in IN N
clinical JJ N
practice NN o
, , o
major JJ o
and CC o
minor JJ o
bleeding NN o
event NN o
rates NNS o
associated VBN N
with IN N
prasugrel NN N
therapy NN N
are VBP N
comparable JJ N
to TO N
those DT N
reported VBN N
in IN N
controlled JJ N
randomized JJ N
trials NNS N
. . o

The DT o
minimal JJ o
bleeding JJ o
event NN o
rate NN o
is VBZ N
higher JJR N
than IN N
reported VBN N
but CC N
does VBZ N
not RB N
seem VB N
to TO N
affect VB N
adherence NN N
to TO N
treatment NN N
. . N

-DOCSTART- -X- O O

A DT N
single JJ i
nasal NN i
allergen NN i
challenge NN i
increases NNS N
induced VBD N
sputum JJ o
inflammatory JJ o
markers NNS o
in IN N
non-asthmatic JJ p
subjects NNS p
with IN p
seasonal JJ p
allergic JJ p
rhinitis NN p
: : p
correlation NN N
with IN N
plasma JJ N
interleukin-5 JJ N
. . N

BACKGROUND NNP N
Seasonal NNP N
allergic JJ N
rhinitis NN N
( ( N
SAR NNP N
) ) N
is VBZ N
a DT N
risk NN p
factor NN p
for IN p
asthma NN p
in IN p
affected JJ p
individuals NNS p
. . p

Nasal NNP N
allergic JJ N
inflammation NN N
enhances VBZ N
bone-marrow JJ N
eosinophil NN N
production NN N
, , N
mainly RB N
via IN N
IL-5 NNP N
, , N
and CC N
rhinitis NN N
patients NNS N
have VBP N
increased VBN N
airway JJ N
inflammation NN N
during IN N
the DT N
pollen NN N
season NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
impact NN N
of IN N
nasal NN N
allergy NN N
on IN N
sputum NN o
inflammatory NN o
markers NNS o
. . o

METHODS NNP N
In IN N
an DT N
open-labelled JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
cross-over NN N
study NN N
with IN N
16 CD p
non-asthmatic JJ p
SAR NNP p
patients NNS p
( ( p
median JJ p
age NN p
25 CD p
years NNS p
, , p
56 CD p
% NN p
males NNS p
) ) p
, , N
the DT N
effect NN N
of IN N
a DT N
single JJ i
nasal NN i
allergen NN i
challenge NN i
performed VBD N
out IN N
of IN N
season NN N
on IN N
induced JJ N
sputum NN o
inflammatory NN o
parameters NNS N
was VBD N
evaluated VBN N
. . N

SAR JJ p
patients NNS p
were VBD p
identified VBN p
by IN p
history NN p
, , p
skin-prick JJ p
test NN p
and CC p
specific JJ p
IgE NNP p
. . p

All DT p
patients NNS p
had VBD p
normal JJ p
lung JJ p
function/bronchial JJ p
hyper-responsiveness NN p
out IN p
of IN p
season NN p
and CC p
a DT p
negative JJ p
asthma/wheezing NN p
history NN p
. . p

Sputum NNP o
cells NNS o
and CC o
supernatant JJ o
levels NNS o
of IN o
ECP NNP o
, , o
sICAM NN o
, , o
IL-5 NNP o
and CC o
IL-10 NNP o
, , o
and CC o
plasma NN o
levels NNS o
of IN o
IL-5 NNP o
and CC o
ECP NNP o
, , i
were VBD i
measured VBN i
before IN i
and CC i
24 CD i
h NN i
after IN i
nasal JJ i
allergen NN i
challenge NN i
. . i

After IN i
a DT i
washout JJ i
period NN i
of IN i
at IN i
least JJS i
4 CD i
weeks NNS i
, , i
the DT i
procedure NN i
was VBD i
repeated VBN i
with IN i
placebo NN i
challenge NN i
( ( i
diluent NN i
) ) i
. . i

RESULTS NNP N
Nasal NNP N
allergen VBZ N
challenge NN N
led VBD N
to TO N
an DT N
increase NN N
in IN N
sputum JJ o
ECP NNP o
( ( N
pre JJ N
= $ N
60 CD N
+/- JJ N
12 CD N
, , N
post NN N
= VBD N
212 CD N
+/- JJ N
63 CD N
micro NN N
g/L NN N
, , N
P NNP N
= VBZ N
0.02 CD N
vs. FW N
placebo NN N
) ) N
, , N
and CC N
sICAM NN o
( ( N
4.8 CD N
+/- JJ N
2.7 CD N
to TO N
6.5 CD N
+/- JJ N
2.9 CD N
ng/mL NN N
, , N
P NNP N
= VBZ N
0.02 CD N
vs. FW N
placebo NN N
) ) N
, , N
whereas JJ N
IL-10 NNP o
decreased VBD N
after IN N
provocation NN N
( ( N
44 CD N
+/- JJ N
11 CD N
to TO N
29 CD N
+/- JJ N
6 CD N
pg/mL NN N
, , N
P NNP N
= VBZ N
0.06 CD N
vs. FW N
placebo NN N
) ) N
. . N

Sputum NNP o
IL-5 NNP o
was VBD N
undetectable JJ N
in IN N
all DT N
patients NNS N
. . N

The DT N
absolute JJ N
number NN N
of IN N
blood NN o
and CC o
sputum NN o
eosinophils NNS o
did VBD N
not RB N
change VB N
significantly RB N
after IN N
allergen NN N
or CC N
placebo NN N
challenge NN N
( ( N
P NNP N
> NNP N
0.07 CD N
, , N
both DT N
comparisons NNS N
) ) N
. . N

Plasma NNP o
levels NNS o
of IN o
IL-5 NNP o
increased VBD N
after IN N
allergen NN N
challenge NN N
( ( N
8.7 CD N
+/- JJ N
2.9 CD N
to TO N
14.5 CD N
+/- JJ N
3.9 CD N
pg/mL NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
increase NN N
in IN N
plasma JJ N
IL-5 NNP N
was VBD N
positively RB N
correlated VBN N
with IN N
the DT N
rise NN N
in IN N
sputum NN o
ECP NNP o
in IN N
a DT N
subgroup NN N
of IN N
'responders NNS N
' POS N
( ( N
n JJ N
= NN N
12 CD N
, , N
r NN N
= VBD N
0.71 CD N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS VB N
A DT N
single JJ i
nasal NN i
allergen NN i
challenge NN i
in IN N
SAR NNP p
patients NNS p
increased VBD N
markers NNS N
of IN N
allergic JJ o
inflammation NN o
in IN N
the DT N
lower JJR N
respiratory NN N
tract NN N
, , N
possibly RB N
via IN N
pronounced JJ N
activation NN N
of IN N
inflammatory NN N
cells NNS N
through IN N
circulating VBG N
immediate-type JJ N
reaction NN N
cytokines NNS N
like IN N
IL-5 NNP N
. . N

These DT N
findings NNS N
may MD N
provide VB N
additional JJ N
explanatory NN N
data NNS N
for IN N
the DT N
high JJ N
susceptibility NN N
of IN N
SAR NNP p
patients NNS p
to TO N
incident VB N
asthma NN N
. . N

-DOCSTART- -X- O O

Acid NNP o
resistance NN o
of IN N
enamel JJ p
subsurface NN p
lesions NNS p
remineralized VBN p
by IN p
a DT p
sugar-free JJ i
chewing NN i
gum NN i
containing VBG p
casein JJ p
phosphopeptide-amorphous JJ p
calcium NN p
phosphate NN p
. . p

The DT N
aim NN N
of IN N
this DT N
clinical JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
acid JJ o
resistance NN o
of IN N
enamel JJ p
lesions NNS p
remineralized VBN p
in IN p
situ NN p
by IN p
a DT p
sugar-free JJ i
chewing NN i
gum NN i
containing VBG p
casein JJ p
phosphopeptide-amorphous JJ p
calcium NN p
phosphate NN p
nanocomplexes NNS p
( ( p
CPP-ACP JJ p
: : p
Recaldent NN p
) ) p
. . p

The DT N
study NN N
utilized VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover VB N
design NN N
with IN N
two CD N
treatments NNS N
: : N
( ( N
i NN N
) ) N
sugar-free JJ i
gum NN i
containing VBG N
18.8 CD N
mg NN N
of IN N
CPP-ACP NNP i
, , N
and CC N
( ( N
ii NN N
) ) N
sugar-free JJ i
gum NN i
not RB i
containing VBG i
CPP-ACP NNP i
as IN N
control NN N
. . N

Subjects NNS p
wore RBR p
removable JJ p
palatal JJ p
appliances NNS p
with IN p
insets NNS p
of IN p
human JJ p
enamel NN p
containing VBG p
demineralized JJ p
subsurface NN p
lesions NNS p
and CC p
chewed VBD p
the DT p
gum NN i
for IN i
20 CD p
min NN p
4 CD p
times NNS p
per IN p
day NN p
for IN p
14 CD p
days NNS p
. . p

After IN N
each DT N
treatment NN N
the DT N
enamel NN N
slabs NN N
were VBD N
removed VBN N
and CC N
half NN N
of IN N
each DT N
lesion NN N
challenged VBD o
with IN o
acid NN o
in IN o
vitro NN o
for IN N
8 CD N
or CC N
16 CD N
h. VBP N
The DT N
level NN o
of IN o
remineralization NN o
was VBD N
determined VBN N
using VBG N
microradiography NN o
. . o

The DT N
gum NN i
containing VBG i
CPP-ACP NNP i
produced VBD N
approximately RB N
twice JJ N
the DT N
level NN o
of IN o
remineralization NN o
as IN N
the DT N
control NN N
sugar-free JJ N
gum NN N
. . N

The DT N
8- JJ N
and CC N
16-hour JJ N
acid NN N
challenge NN N
of IN N
the DT N
lesions NNS o
remineralized VBN o
with IN N
the DT N
control NN i
gum NN i
resulted VBD N
in IN N
65.4 CD N
and CC N
88.0 CD N
% NN N
reductions NNS N
, , N
respectively RB N
, , N
of IN N
deposited JJ N
mineral NN N
, , N
while IN N
for IN N
the DT N
CPP-ACP-remineralized JJ N
lesions NNS N
the DT N
corresponding JJ N
reductions NNS N
were VBD N
30.5 CD N
and CC N
41.8 CD N
% NN N
. . N

The DT N
acid NN N
challenge NN N
after IN N
in IN N
situ JJ N
remineralization NN N
for IN N
both DT N
control NN N
and CC N
CPP-ACP-treated JJ N
lesions NNS N
resulted VBD N
in IN N
demineralization NN o
underneath IN N
the DT N
remineralized JJ N
zone NN N
, , N
indicating VBG N
that IN N
the DT N
remineralized JJ N
mineral NN N
was VBD N
more RBR N
resistant JJ N
to TO N
subsequent JJ N
acid NN N
challenge NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
sugar-free JJ i
gum NN i
containing VBG i
CPP-ACP NNP i
is VBZ N
superior JJ o
to TO N
an DT N
equivalent JJ N
gum NN i
not RB N
containing VBG N
CPP-ACP NNP N
in IN N
remineralization NN N
of IN N
enamel JJ N
subsurface NN N
lesions NNS N
in IN N
situ NN N
with IN N
mineral NN N
that WDT N
is VBZ N
more RBR o
resistant JJ o
to TO N
subsequent JJ N
acid NN N
challenge NN N
. . N

-DOCSTART- -X- O O

Buprenorphine NNP i
alone RB N
and CC N
in IN N
combination NN N
with IN N
naloxone NN i
in IN N
non-dependent JJ p
humans NNS p
. . p

This DT N
study NN N
evaluated VBD N
the DT N
effects NNS N
of IN N
concurrent NN N
naloxone NN i
on IN N
the DT N
opioid JJ o
agonist JJ o
effects NNS o
of IN N
buprenorphine NN i
, , N
a DT N
mixed JJ N
agonist-antagonist JJ N
marketed VBN N
as IN N
an DT N
analgesic JJ N
and CC N
under IN N
development NN N
as IN N
a DT N
treatment NN N
for IN N
drug NN N
abuse NN N
. . N

In IN N
a DT N
residential JJ N
laboratory NN N
seven CD p
non-physically-dependent JJ p
opioid JJ p
abuser NN p
volunteers NNS p
received VBD N
intramuscular JJ N
buprenorphine NN i
( ( N
0.4 CD N
mg NN N
or CC N
0.8 CD N
mg/70 NNS N
kg NN N
) ) N
alone RB N
and CC N
in IN N
combination NN N
with IN N
naloxone NN i
( ( N
0.4 CD N
mg NN N
or CC N
0.8 CD N
mg/70 NNS N
kg NN N
) ) N
versus NN N
placebo NN i
. . i

Buprenorphine NNP i
produced VBD N
dose-related JJ N
opioid JJ N
agonist NN N
effects NNS N
on IN N
physiological JJ o
and CC o
subjective JJ o
measures NNS o
. . o

Concurrent NNP N
naloxone RB i
attenuated VBD N
the DT o
opioid JJ o
agonist JJ o
effects NNS o
of IN N
buprenorphine NN i
. . i

Thus RB N
, , N
a DT N
combination NN N
product NN N
of IN N
buprenorphine NN i
and CC N
naloxone NN N
may MD N
have VB N
lower JJR N
abuse NN o
liability NN o
than IN N
buprenorphine VB i
alone JJ N
. . N

-DOCSTART- -X- O O

JobTIPS NN i
: : i
a DT N
transition NN N
to TO N
employment NN N
program NN N
for IN N
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
evaluated VBD N
the DT N
effectiveness NN o
of IN N
an DT N
internet NN o
accessed VBD o
training VBG o
program NN o
that WDT N
included VBD N
Theory NNP N
of IN N
Mind-based JJ N
guidance NN N
, , N
video NN N
models NNS N
, , N
visual JJ N
supports NNS N
, , N
and CC N
virtual JJ N
reality NN N
practice NN N
sessions NNS N
in IN N
teaching VBG N
appropriate JJ N
job NN N
interview NN N
skills NNS N
to TO N
individuals NNS p
with IN p
high JJ p
functioning VBG p
Autism NNP p
Spectrum NNP p
Disorders NNP p
. . p

In IN N
a DT N
randomized JJ N
study NN N
, , N
twenty-two JJ p
youth NN p
, , p
ages VBZ p
16-19 JJ p
, , p
were VBD p
evaluated VBN p
during IN p
two CD p
employment NN p
interviews NNS p
. . p

Half NNP N
received VBD N
a DT N
training NN N
intervention NN N
following VBG N
the DT N
initial JJ N
interview NN N
and CC N
the DT N
half NN N
who WP N
served VBD N
as IN N
a DT N
contrast NN N
group NN N
did VBD N
not RB N
. . N

Their PRP$ N
performance NN N
pre NN N
and CC N
post NN N
intervention NN N
was VBD N
assessed VBN N
by IN N
four CD N
independent JJ N
raters NNS N
using VBG N
a DT N
scale NN N
that WDT N
included VBD N
evaluation NN N
of IN N
both DT N
Content NNP o
and CC o
Delivery NNP o
. . o

Results NNP N
suggest VBP N
that IN N
youth NN N
who WP N
completed VBD N
the DT N
JobTIPS NNP i
employment NN i
program NN i
demonstrated VBD N
significantly RB o
more RBR o
effective JJ o
verbal JJ o
content NN o
skills NNS o
than IN N
those DT N
who WP N
did VBD N
not RB N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
prelinguistic JJ i
milieu NN i
teaching NN i
and CC i
parent NN i
responsivity NN i
education NN i
on IN N
dyads NNS o
involving VBG o
children NNS o
with IN o
intellectual JJ o
disabilities NNS o
. . o

This DT N
study NN N
tested VBD N
the DT N
effect NN N
of IN N
a DT N
method NN N
of IN N
facilitating VBG i
prelinguistic JJ i
communication NN i
on IN N
parents NNS o
' POS o
responsivity NN o
and CC o
children NNS o
's POS o
communication NN o
and CC o
productive JJ o
language NN o
development NN o
. . o

The DT N
method NN N
involved VBN N
Responsivity NNP i
education NN i
for IN i
the DT i
parents NNS i
and CC p
Prelinguistic NNP i
Milieu NNP i
Teaching NNP i
for IN i
the DT i
children NNS i
( ( i
RPMT NNP i
) ) i
. . i

Thirty-nine JJ p
prelinguistic JJ p
toddlers NNS p
with IN p
intellectual JJ p
disabilities NNS p
and CC p
their PRP$ p
primary JJ p
caregivers NNS p
participated VBD p
in IN p
this DT p
study NN p
. . p

Parent-child JJ N
pairs NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
RPMT NNP i
group NN N
or CC N
a DT N
control NN i
group NN i
. . i

Communication NNP o
and CC o
language NN o
were VBD N
assessed VBN N
at IN N
study NN N
entry NN N
and CC N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
later RB N
. . N

RPMT NNP i
facilitated VBD N
parental JJ o
responsivity NN o
in IN N
the DT N
posttreatment JJ N
period NN N
. . N

The DT N
effect NN N
of IN N
RPMT NNP i
on IN N
growth NN o
rate NN o
of IN o
child-initiated JJ o
comments NNS o
( ( N
i.e. NN N
, , N
the DT N
most RBS N
common JJ N
type NN N
of IN N
initiating VBG N
joint JJ N
attention NN N
) ) N
varied VBN N
by IN N
pretreatment JJ N
measures NNS N
of IN N
that DT N
variable JJ N
. . N

The DT N
effect NN N
of IN N
RPMT NNP i
on IN N
growth NN o
rate NN o
of IN o
child-initiated JJ o
requests NNS o
( ( N
i.e. NN N
, , N
the DT N
most RBS N
common JJ N
type NN N
of IN N
initiating VBG N
behavior JJ N
regulation NN N
) ) N
varied VBN N
by IN N
presence NN N
or CC N
absence NN N
of IN N
Down NNP N
syndrome NN N
. . N

Finally RB N
, , N
the DT N
effect NN N
of IN N
RPMT NNP i
on IN N
growth NN o
of IN o
productive JJ o
language NN o
varied VBN N
by IN N
pretreatment JJ N
frequency NN N
of IN N
canonical JJ N
vocal JJ N
communication NN N
. . N

Recommended VBN N
alterations NNS N
in IN N
PMT NNP i
and CC N
implications NNS N
for IN N
defining VBG N
which WDT N
nonspeaking VBG N
children NNS N
are VBP N
appropriate JJ N
for IN N
prelinguistic JJ N
goals NNS N
and CC N
treatment NN N
were VBD N
discussed VBN N
. . N

-DOCSTART- -X- O O

Two CD N
to TO N
ten CD N
years NNS N
: : N
developmental JJ N
trajectories NNS N
of IN N
joint JJ N
attention NN N
in IN N
children NNS p
with IN p
ASD NNP p
who WP p
received VBD p
targeted VBN i
social JJ i
communication NN i
interventions NNS i
. . i

This DT N
study NN N
follows VBZ N
40 CD p
children NNS p
who WP p
were VBD p
participants NNS p
in IN p
a DT p
randomized NN p
controlled VBD p
early JJ p
intervention NN p
trial NN p
( ( p
Kasari NNP p
et RB p
al RB p
. . p

) ) p
from IN p
early JJ p
childhood NN p
( ( p
2-5 CD p
years NNS p
of IN p
age NN p
) ) p
to TO p
elementary JJ p
school NN p
age NN p
( ( p
8-10 CD p
years NNS p
) ) p
. . p

To TO N
fully RB N
utilize VB N
the DT N
available JJ N
longitudinal JJ N
data NNS N
, , N
the DT N
general JJ N
linear NN N
mixed JJ N
model NN N
was VBD N
the DT N
primary JJ N
analytical JJ N
approach NN N
. . N

The DT N
growth NN N
trajectories NNS N
of IN N
joint JJ o
attention NN o
skills NNS o
( ( o
pointing VBG o
, , o
coordinated VBD o
joint JJ o
looking VBG o
, , o
and CC o
showing VBG o
) ) o
and CC o
expressive JJ o
language NN o
outcomes NNS o
in IN o
these DT N
children NNS N
were VBD N
estimated VBN N
based VBN N
on IN N
five CD N
time NN N
points NNS N
during IN N
the DT N
measurement JJ N
period NN N
. . N

The DT N
children NNS N
were VBD N
grouped VBN N
by IN N
diagnosis NN N
at IN N
the DT N
last JJ N
follow-up JJ N
( ( N
autism NN N
, , N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
no DT N
diagnosis NN N
) ) N
and CC N
by IN N
their PRP$ N
original JJ N
treatment NN N
group NN N
assignment NN i
( ( i
joint JJ i
attention NN i
, , i
symbolic JJ i
play NN i
, , i
control NN i
) ) i
, , i
and CC N
differences NNS N
between IN N
these DT N
groups NNS N
were VBD N
evaluated VBN N
. . N

Results NNS N
showed VBD N
that IN o
joint JJ o
attention NN o
skills NNS o
of IN o
coordinated VBN o
joint NN o
looking VBG o
and CC o
showing VBG o
increased VBN o
over IN N
time NN N
, , N
and CC o
pointing VBG o
to TO o
share NN o
interest NN o
increased VBN o
over IN N
the DT N
first JJ N
year NN N
measured VBN N
and CC N
decreased VBN N
thereafter RB N
. . N

These DT o
trajectories NNS o
were VBD o
influenced VBN N
by IN N
both DT N
original JJ N
treatment NN N
assignment NN N
and CC N
diagnostic JJ N
status NN N
at IN N
follow-up NN N
. . N

In IN N
addition NN N
, , N
a DT N
cross-lagged JJ N
panel NN N
analysis NN N
revealed VBD N
a DT N
causal NN N
relationship NN N
between IN o
early JJ o
pointing NN o
and CC o
later RB o
language NN o
development NN o
. . o

This DT N
study NN N
highlights VBZ N
the DT N
longitudinal JJ N
and CC N
developmental JJ N
importance NN N
of IN N
measures NNS N
of IN N
early JJ o
core NN o
deficits NNS o
in IN o
autism NN o
, , o
and CC N
suggests VBZ N
that IN N
both DT N
treatment NN N
and CC N
ASD NNP N
symptomatology NN o
may MD o
influence VB N
growth NN N
in IN N
these DT N
skills NNS N
over IN N
time NN N
. . N

-DOCSTART- -X- O O

Comparison NNP p
of IN p
nasal JJ o
deposition NN o
and CC o
clearance NN o
of IN o
aerosol NN o
generated VBN N
by IN N
nebulizer NN i
and CC i
an DT i
aqueous JJ i
spray NN i
pump NN i
. . i

-DOCSTART- -X- O O

12-week JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
add-on JJ N
riluzole NN i
in IN N
the DT N
treatment NN N
of IN N
childhood-onset JJ p
obsessive-compulsive JJ p
disorder NN p
. . p

Many JJ N
children NNS p
with IN p
childhood-onset JJ p
obsessive-compulsive JJ p
disorder NN p
( ( p
OCD NNP p
) ) p
fail VBP N
to TO N
respond VB N
adequately RB N
to TO N
standard VB N
therapies NNS N
. . N

Evidence NN N
from IN N
preclinical JJ N
and CC N
clinical JJ N
studies NNS N
suggests VBZ N
that IN N
the DT N
glutamatergic NN N
neurotransmitter NN N
system NN N
might MD N
be VB N
an DT N
alternative JJ N
treatment NN N
target NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
efficacy NN N
of IN N
riluzole NN i
, , N
a DT N
glutamatergic JJ N
modulator NN N
, , N
as IN N
an DT N
adjunctive JJ N
therapy NN N
for IN N
children NNS p
with IN p
treatment-resistant JJ p
OCD NNP p
. . p

In IN N
a DT N
12-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
, , N
60 CD p
treatment-resistant JJ p
children NNS p
and CC p
adolescents NNS p
( ( p
mean VB p
age=14.5 RB p
? . p
2.4 CD p
years NNS p
) ) p
, , p
with IN p
moderate JJ p
to TO p
severe VB p
OCD NNP p
( ( p
mean JJ p
Children NNP p
's POS p
Yale-Brown JJ p
Obsessive-Compulsive JJ p
Scale NNP p
( ( p
CY-BOCS NNP p
) ) p
=28.2 NN p
? . p
3.7 CD p
) ) p
, , p
17 CD p
of IN p
whom WP p
also RB p
had VBD p
concomitant JJ p
autism NN p
spectrum NN p
disorder NN p
, , p
were VBD N
randomized VBN N
to TO N
receive VB i
riluzole NN i
( ( i
final JJ i
dose NN i
of IN i
100 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
in IN i
addition NN N
to TO N
the DT N
existing VBG N
treatment NN N
regimen NNS p
. . p

Fifty-nine JJ p
subjects NNS p
completed VBD p
the DT p
randomized JJ N
trial NN N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
changes NNS N
on IN N
the DT o
CY-BOCS NNP o
, , o
the DT o
Clinical NNP o
Global NNP o
Impressions NNP o
Scale NNP o
, , o
and CC o
the DT o
Children NNP o
's POS o
Global NNP o
Assessment NNP o
Scale NNP o
. . o

Riluzole NNP N
was VBD N
fairly RB N
well RB o
tolerated VBN o
, , o
although IN N
it PRP N
was VBD N
associated VBN N
with IN N
one CD N
case NN N
of IN N
pancreatitis NN o
and CC o
five CD N
instances NNS N
of IN N
slight JJ N
increases NNS N
in IN N
transaminases NNS o
. . o

All DT N
subjects NNS N
showed VBD N
significant JJ N
reductions NNS N
in IN N
CY-BOCS NNP o
scores NNS o
during IN o
treatment NN N
; : N
however RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
placebo NN N
and CC N
riluzole NN N
on IN N
any DT N
of IN N
the DT N
primary JJ N
or CC N
secondary JJ N
outcome NN N
measures NNS N
. . N

The DT N
study NN N
failed VBD N
to TO N
demonstrate VB N
superiority NN N
of IN N
riluzole NN N
over RB N
placebo RB N
as IN N
an DT N
adjunctive JJ N
treatment NN N
for IN p
children NNS p
with IN p
childhood-onset JJ p
OCD NNP p
. . p

However RB N
, , N
future JJ N
studies NNS N
may MD N
show VB N
benefits NNS N
for IN N
less JJR N
treatment-refractory JJ p
children NNS p
with IN p
fewer JJR p
concomitant NN p
medications NNS p
. . p

-DOCSTART- -X- O O

Prevention NN N
of IN N
a DT N
first JJ N
stroke NN N
by IN N
transfusions NNS N
in IN N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
and CC p
abnormal JJ p
results NNS p
on IN p
transcranial JJ p
Doppler NNP p
ultrasonography NN p
. . p

BACKGROUND NNP N
Blood NNP i
transfusions NNS i
prevent VBP N
recurrent JJ N
stroke NN N
in IN N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
, , N
but CC N
the DT N
value NN N
of IN N
transfusions NNS N
in IN N
preventing VBG N
a DT N
first JJ N
stroke NN N
is VBZ N
unknown JJ N
. . N

We PRP N
used VBD N
transcranial JJ N
Doppler NNP N
ultrasonography NN N
to TO N
identify VB N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
who WP p
were VBD p
at IN p
high JJ p
risk NN p
for IN p
stroke NN p
and CC N
then RB N
randomly RB N
assigned VBN N
them PRP N
to TO N
receive VB N
standard JJ N
care NN N
or CC N
transfusions NNS N
to TO N
prevent VB N
a DT N
first JJ N
stroke NN N
. . N

METHODS NNP N
To TO N
enter VB N
the DT N
study NN N
, , N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
and CC p
no DT p
history NN p
of IN p
stroke NN p
had VBD p
to TO p
have VB p
undergone JJ p
two CD p
transcranial JJ p
Doppler NNP p
studies NNS p
that WDT p
showed VBD p
that IN p
the DT p
time-averaged JJ p
mean JJ p
blood-flow JJ p
velocity NN p
in IN p
the DT p
internal JJ p
carotid NN p
or CC p
middle JJ p
cerebral JJ p
artery NN p
was VBD p
200 CD p
cm JJ p
per IN p
second NN p
or CC p
higher JJR p
. . p

The DT N
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
standard JJ i
care NN i
or CC i
transfusions NNS i
to TO N
reduce VB N
the DT N
hemoglobin NN N
S NNP N
concentration NN N
to TO N
less JJR N
than IN N
30 CD N
percent NN N
of IN N
the DT N
total JJ N
hemoglobin NN N
concentration NN N
. . N

The DT N
incidence NN N
of IN N
stroke NN N
( ( N
cerebral JJ N
infarction NN N
or CC N
intracranial JJ N
hemorrhage NN N
) ) N
was VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
130 CD p
children NNS p
( ( p
mean JJ p
[ NNP p
+/-SD NN p
] NNP p
age NN p
, , p
8.3+/-3.3 CD p
years NNS p
) ) p
were VBD p
enrolled VBN p
; : p
63 CD p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
transfusions NNS N
and CC N
67 CD N
to TO N
receive VB N
standard NN N
care NN N
. . N

At IN N
base NN N
line NN N
, , N
the DT N
transfusion NN N
group NN N
had VBD N
a DT N
slightly RB N
lower JJR N
mean NN o
hemoglobin NN o
concentration NN o
( ( N
7.2 CD N
vs. FW N
7.6 CD N
g NN N
per IN N
deciliter NN N
, , N
P=0.001 NNP N
) ) N
and CC N
hematocrit NN o
( ( N
20.4 CD N
vs. FW N
21.7 CD N
percent NN N
, , N
P=0.002 NNP N
) ) N
. . N

Ten CD N
patients NNS N
dropped VBD N
out IN N
of IN N
the DT N
transfusion NN N
group NN N
, , N
and CC N
two CD N
patients NNS N
crossed VBD N
over IN N
from IN N
the DT N
standard-care JJ N
group NN N
to TO N
the DT N
transfusion NN N
group NN N
. . N

There EX N
were VBD N
10 CD N
cerebral JJ o
infarctions NNS o
and CC N
1 CD N
intracerebral JJ o
hematoma NN o
in IN N
the DT N
standard-care JJ N
group NN N
, , N
as IN N
compared VBN N
with IN N
1 CD N
infarction NN o
in IN N
the DT N
transfusion NN N
group NN N
-- : N
a DT N
92 CD N
percent NN N
difference NN N
in IN N
the DT N
risk NN N
of IN N
stroke NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

This DT N
result NN N
led VBD N
to TO N
the DT N
early JJ N
termination NN N
of IN N
the DT N
trial NN N
. . N

CONCLUSIONS NNP N
Transfusion NNP i
greatly RB N
reduces VBZ N
the DT N
risk NN o
of IN o
a DT o
first JJ o
stroke NN o
in IN N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
who WP p
have VBP p
abnormal JJ p
results NNS p
on IN p
transcranial JJ p
Doppler NNP p
ultrasonography NN p
. . p

-DOCSTART- -X- O O

Effects NNS o
of IN o
surfactant NN o
on IN N
biofilm NN N
formation NN N
on IN N
silicone NN i
nasal NN i
splints NNS i
. . i

Biofilms NNS i
are VBP N
sessile JJ N
communities NNS N
of IN N
bacteria NNS N
embedded VBN N
in IN N
self-produced JJ N
extracellular JJ N
polysaccharide NN N
matrix NN N
and CC N
are VBP N
considered VBN N
to TO N
be VB N
responsible JJ N
for IN N
bacterial JJ N
infections NNS N
in IN N
humans NNS p
. . p

Topical NNP N
surfactant NN N
use NN N
on IN N
silicone NN N
nasal JJ N
splints NNS N
may MD N
have VB N
a DT N
preventive JJ N
effect NN N
on IN N
biofilm NN o
formation NN o
. . o

The DT N
objective NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
surfactant-containing JJ N
nasal JJ N
solutions NNS N
on IN N
biofilm NN o
formation NN o
over IN N
the DT N
surface NN N
of IN N
silicone NN o
nasal JJ o
splints NNS o
. . o

Forty CD p
patients NNS p
were VBD p
randomized VBN p
after IN p
septoplasty NN i
to TO N
receive VB N
surfactant-containing JJ i
saline JJ i
solution NN i
( ( i
group NN i
1 CD N
) ) N
or CC N
saline VB i
without IN i
surfactant JJ i
( ( N
group NN N
2 CD N
) ) N
. . N

At IN N
the DT N
postoperative JJ N
48th CD N
, , N
72th CD N
and CC N
96th CD N
hours NNS N
, , N
pieces NNS N
of IN N
splint NN N
samples NNS N
were VBD N
taken VBN N
and CC N
prepared VBN N
for IN N
scanning VBG o
electron NN o
microscopic NN o
evaluation NN o
. . o

Biofilm NNP o
formation NN o
was VBD N
observed VBN N
in IN N
3 CD N
, , N
6 CD N
and CC N
14 CD N
of IN N
20 CD N
samples NNS N
in IN N
group NN N
1 CD N
( ( N
surfactant NN N
used VBN N
) ) N
and CC N
3 CD N
, , N
14 CD N
and CC N
20 CD N
of IN N
20 CD N
samples NNS N
in IN N
group NN N
2 CD N
( ( N
control NN N
) ) N
at IN N
48th CD N
, , N
72th CD N
and CC N
96th CD N
hours NNS N
, , N
respectively RB N
. . N

Biofilm NNP o
formation NN o
incidences NNS N
of IN N
groups NNS N
at IN N
48th CD N
hour NN N
were VBD N
similar JJ N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
, , N
whereas IN N
it PRP N
was VBD N
significantly RB N
lower JJR N
at IN N
group NN N
1 CD N
regarding VBG N
72th CD N
and CC N
96th CD N
hours NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Surfactant-containing JJ i
nasal JJ i
solutions NNS i
have VBP N
an DT N
inhibitory JJ N
effect NN N
on IN N
biofilm NN o
formation NN o
over IN N
the DT N
surface NN N
of IN N
silicone NN N
nasal JJ N
splints NNS N
especially RB N
after IN N
48 CD N
h. JJ N
Surfactant-containing JJ i
nasal JJ i
solutions NNS i
may MD N
have VB N
an DT N
important JJ N
role NN N
in IN N
nasal JJ o
septal JJ o
dressing NN o
in IN N
the DT N
future NN N
. . N

-DOCSTART- -X- O O

Role NNP N
of IN N
memory NN N
B-cell NNP N
responses NNS N
in IN N
serum NN N
and CC N
mucosal JJ N
fluids NNS N
of IN N
swine NN N
for IN N
protective JJ N
immunity NN N
against IN N
pseudorabies NNS N
virus VBP N
. . N

We PRP N
examined VBD N
primary JJ N
and CC N
memory JJ N
isotype-specific JJ N
antibody NN N
responses NNS N
directed VBN N
against IN N
pseudorabies NNS N
virus VBP N
in IN N
serum NN N
and CC N
mucosal JJ N
fluids NNS N
of IN N
pigs NNS p
with IN p
and CC p
without IN p
passively RB p
acquired VBN p
maternal JJ p
antibody NN p
, , N
and CC N
we PRP N
studied VBD N
the DT N
relationship NN N
between IN N
these DT N
responses NNS N
and CC N
protection NN N
against IN N
virus NN N
challenge NN N
. . N

Pigs NNS p
were VBD N
inoculated VBN N
intranasally RB N
with IN N
the DT N
virulent JJ i
NIA-3 NNP i
strain NN i
or CC i
the DT i
avirulent JJ i
Bartha NNP i
strain NN i
, , i
or CC i
they PRP i
were VBD i
inoculated VBN i
IM NNP i
with IN i
an DT i
inactivated JJ i
vaccine NN i
containing VBG i
the DT i
Phylaxia NNP i
strain NN i
. . i

Ten CD N
weeks NNS N
later RB N
, , N
all DT N
pigs NNS N
were VBD N
challenge-exposed JJ i
intranasally RB i
with IN i
strain JJ i
NIA-3 NNP i
. . i

Only RB N
pigs VBZ N
that IN N
were VBD N
without IN N
passively RB N
acquired VBN N
antibody NN N
at IN N
the DT N
time NN N
they PRP N
were VBD N
inoculated VBN N
with IN N
virulent JJ N
virus NN N
appeared VBD N
to TO N
have VB N
complete JJ o
protective JJ o
immunity NN o
against IN N
challenge NN N
exposure NN N
, , N
as IN N
evidenced VBN N
by IN N
lack NN N
of IN N
clinical JJ o
signs NNS o
of IN o
pseudorabies NNS o
and CC N
lack NN N
of IN N
virus NN o
excretion NN o
. . o

In IN N
contrast NN N
, , N
pigs NNS p
inoculated VBD p
with IN p
strain NN p
Bartha NNP p
or CC p
with IN p
the DT p
inactivated JJ p
vaccine NN p
developed VBD N
fever NN o
, , N
had VBD N
a DT N
period NN o
of IN o
growth NN o
arrest NN o
, , N
and CC N
excreted VBD o
virus NN o
after IN N
challenge NN N
exposure NN N
. . N

In IN N
pigs NNS N
without IN N
passively RB N
acquired VBN N
antibody NN N
, , N
intranasal JJ N
inoculation NN N
with IN N
strains NNS N
NIA-3 NNP N
or CC N
Bartha NNP N
was VBD N
followed VBN N
by IN N
primary JJ N
IgM NNP o
and CC o
IgA NNP o
responses NNS o
in IN N
serum NN o
and CC N
in IN N
oropharyngeal JJ o
fluid NN o
as RB N
well RB N
as IN N
primary JJ N
IgG1 NNP N
and CC N
IgG2 NNP N
responses NNS N
in IN N
serum NN N
. . N

Intramuscular JJ N
inoculation NN N
with IN N
the DT N
inactivated JJ N
vaccine NN N
induced VBD N
primary JJ o
serum NN o
IgM NNP o
, , o
IgG1 NNP o
, , o
and CC o
IgG2 NNP o
responses NNS o
, , N
but CC N
no DT N
mucosal NN o
responses VBZ o
. . o

Challenge NNP N
exposure NN N
of IN N
pigs NNS N
that WDT N
had VBD N
been VBN N
inoculated VBN N
with IN N
the DT N
Bartha NNP N
strain NN N
or CC N
the DT N
inactivated JJ N
vaccine NN N
was VBD N
followed VBN N
by IN N
clear JJ N
memory NN o
responses NNS o
in IN o
serum NN o
and CC o
in IN o
oropharyngeal JJ o
fluid NN o
. . o

In IN N
contrast NN N
, , N
challenge VBP N
exposure NN N
of IN N
pigs NNS N
that WDT N
had VBD N
been VBN N
inoculated VBN N
by IN N
the DT N
virulent JJ N
NIA-3 NNP N
strain NN N
was VBD N
not RB N
followed VBN N
by IN N
memory NN N
responses NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

MSL-109 NNP i
adjuvant JJ i
therapy NN i
for IN N
cytomegalovirus NN p
retinitis NN p
in IN p
patients NNS p
with IN p
acquired JJ p
immunodeficiency NN p
syndrome NN p
: : p
the DT N
Monoclonal NNP N
Antibody NNP N
Cytomegalovirus NNP N
Retinitis NNP N
Trial NNP N
. . N

The DT p
Studies NNPS p
of IN p
Ocular JJ p
Complications NNS p
of IN p
AIDS NNP p
Research NNP p
Group NNP p
. . p

AIDS NNP p
Clinical JJ p
Trials NNP p
Group NNP p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
an DT N
intravenous JJ N
human JJ N
monoclonal NN N
antibody NN N
to TO N
cytomegalovirus VB N
( ( N
CMV NNP N
) ) N
, , N
MSL-109 NNP i
, , N
as IN N
adjuvant JJ N
treatment NN N
for IN N
CMV NNP N
retinitis NN N
. . N

METHODS NNP N
Two CD p
hundred VBD p
nine CD p
patients NNS p
with IN p
acquired JJ p
immunodeficiency NN p
syndrome NN p
and CC p
active JJ p
CMV NNP p
retinitis NN p
were VBD p
enrolled VBN p
in IN p
a DT p
multicenter NN p
, , p
phase NN p
2/3 CD p
, , p
randomized VBN p
, , p
placebo-controlled JJ i
clinical JJ p
trial NN p
. . p

Patients NNS N
received VBD N
adjuvant JJ N
treatment NN N
with IN N
MSL-109 NNP i
, , N
60 CD N
mg NN N
intravenously RB N
every DT N
2 CD N
weeks NNS N
, , N
or CC N
placebo NN i
. . i

Randomization NN N
was VBD N
stratified VBN N
on IN N
the DT N
basis NN N
of IN N
whether IN N
patients NNS N
had VBD N
untreated VBN N
or CC N
relapsed VBN N
retinitis NN N
. . N

Primary JJ i
drug NN i
therapy NN i
for IN N
CMV NNP N
retinitis NN N
was VBD N
determined VBN N
by IN N
the DT N
treating NN N
physician NN N
. . N

RESULTS VB N
The DT N
rates NNS o
of IN o
retinitis NN o
progression NN o
, , N
as IN N
evaluated VBN N
in IN N
a DT N
masked JJ N
fashion NN N
, , N
were VBD N
3.04/person-year JJ N
in IN N
the DT N
MSL-109-treated NNP i
group NN N
and CC N
3.05/person-year JJ N
in IN N
the DT N
placebo-treated JJ i
group NN N
( ( N
P=.98 NNP N
; : N
Wald NNP N
test NN N
) ) N
; : N
the DT N
median JJ N
times NNS N
to TO N
progression NN N
were VBD N
67 CD N
days NNS N
in IN N
the DT N
MSL-109-treated NNP i
group NN N
and CC N
65 CD N
days NNS N
in IN N
the DT N
placebo-treated JJ N
group NN N
. . N

No DT N
differences NNS N
between IN N
the DT N
2 CD N
groups NNS N
were VBD N
noted VBN N
in IN N
the DT N
rates NNS o
of IN o
increase NN o
in IN o
retinal JJ o
area NN o
involved VBN o
by IN o
CMV NNP o
, , o
visual JJ o
field NN o
loss NN o
, , o
or CC o
visual JJ o
acuity NN o
outcomes NNS o
. . o

The DT N
mortality NN o
rate NN o
in IN N
the DT N
MSL-109-treated NNP i
group NN N
was VBD N
0.68/person-year JJ N
, , N
and CC N
in IN N
the DT N
placebo-treated JJ i
group NN N
, , N
0.31/person-year JJ N
( ( N
P=.01 NNP N
) ) N
. . N

The DT N
mortality NN o
difference NN N
was VBD N
not RB N
explained VBN N
by IN N
differences NNS N
in IN N
baseline NN N
variables NNS N
or CC N
in IN N
concurrent JJ N
antiretroviral JJ N
therapy NN N
. . N

Among IN p
patients NNS p
with IN p
newly RB p
diagnosed VBN p
retinitis NN p
, , N
mortality NN o
rates NNS o
were VBD N
similar JJ N
( ( N
MSL-109 NNP N
, , N
0.41/person-year JJ N
; : N
placebo NN N
, , N
0.42/person-year JJ N
; : N
P=.95 NNP N
) ) N
, , N
whereas JJ N
among IN N
patients NNS N
with IN N
relapsed JJ N
retinitis NN N
the DT N
MSL-109-treated NNP i
group NN N
had VBD N
a DT N
greater JJR N
mortality NN o
rate NN o
( ( i
MSL-109 NNP i
, , N
0.83/person-year JJ N
; : N
placebo NN i
, , N
0.24/person-year JJ N
; : N
P=.003 NNP N
) ) N
. . N

However RB N
, , N
the DT N
mortality NN o
rate NN o
in IN N
the DT N
placebo-treated JJ i
patients NNS N
with IN N
relapsed JJ N
CMV NNP N
retinitis NN N
was VBD N
lower JJR N
than IN N
that DT N
in IN N
the DT N
placebo-treated JJ N
patients NNS N
with IN N
newly RB N
diagnosed VBN N
CMV NNP N
retinitis NN N
and CC N
lower JJR N
than IN N
that DT N
in IN N
other JJ N
trials NNS N
of IN N
patients NNS N
with IN N
relapsed JJ N
CMV NNP N
retinitis NN N
. . N

CONCLUSIONS NNP N
Intravenous NNP N
MSL-109 NNP i
, , N
60 CD N
mg NN N
every DT N
2 CD N
weeks NNS N
, , N
appeared VBD N
to TO N
be VB N
ineffective JJ o
adjuvant JJ N
therapy NN N
for IN N
CMV NNP N
retinitis NN N
. . N

The DT N
mortality NN o
rate NN o
was VBD N
higher RBR N
in IN N
the DT N
MSL-109-treated NNP i
group NN N
, , N
but CC N
the DT N
reasons NNS N
for IN N
this DT N
difference NN N
remain NN N
uncertain JJ N
. . N

-DOCSTART- -X- O O

Ropinirole NNP i
as IN N
a DT N
treatment NN N
of IN N
restless JJ p
legs JJ p
syndrome NN p
in IN p
patients NNS p
on IN p
chronic JJ p
hemodialysis NN p
: : p
an DT N
open JJ N
randomized VBN N
crossover NN N
trial NN N
versus NN N
levodopa NN i
sustained VBD i
release NN i
. . i

OBJECTIVE NNP N
Restless NNP N
legs VBZ N
syndrome NN N
( ( N
RLS NNP N
) ) N
is VBZ N
a DT N
common JJ N
neurologic JJ N
condition NN N
characterized VBN N
by IN N
uncomfortable JJ N
and CC N
unpleasant JJ N
sensations NNS N
in IN N
the DT N
legs NN N
, , N
occurring VBG N
primarily RB N
at IN N
rest NN N
, , N
which WDT N
are VBP N
usually RB N
worse JJR N
in IN N
the DT N
evening NN N
and CC N
are VBP N
alleviated VBN N
by IN N
movement NN N
. . N

RLS NNP N
is VBZ N
present JJ N
in IN N
20-40 JJ N
% NN N
of IN N
patients NNS p
with IN p
renal JJ p
failure NN p
. . p

This DT N
study NN N
was VBD N
a DT N
14-week JJ N
open JJ N
, , N
randomized VBN N
, , N
crossover JJ N
trial NN N
of IN N
ropinirole NN i
vs. FW i
levodopa NN i
sustained VBN i
release NN i
( ( i
SR NNP i
) ) i
in IN N
11 CD p
patients NNS p
with IN p
RLS NNP p
on IN p
chronic JJ p
hemodialysis NN p
. . p

METHODS NNP N
Eleven NNP p
patients NNS p
( ( p
7 CD p
men NNS p
, , p
4 CD p
women NNS p
) ) p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

They PRP N
received VBD N
either CC N
levodopa JJ i
SR NNP i
or CC i
ropinirole VB i
for IN N
6 CD N
weeks NNS N
, , N
followed VBN N
by IN N
a DT N
washout NN N
week NN N
, , N
then RB i
the DT i
alternate NN i
treatment NN i
for IN N
6 CD N
weeks NNS N
. . N

Patients NNS N
rated VBD N
the DT N
severity NN o
of IN o
RLS NNP o
by IN N
means NNS N
of IN N
a DT N
6-item JJ N
questionnaire NN N
developed VBN N
by IN N
the DT N
International NNP N
Restless NNP N
Legs NNP N
Study NNP N
Group NNP N
( ( N
6-item JJ N
IRLS NNP N
) ) N
, , N
by IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
( ( N
CGI NNP N
) ) N
scale NN N
, , N
and CC N
by IN N
sleep JJ N
diaries NNS N
. . N

RESULTS NNP N
Under IN N
treatment NN N
with IN N
levodopa JJ N
SR NNP N
, , N
1 CD N
patient NN N
presented VBN N
severe JJ o
vomiting NN o
, , N
leading VBG N
to TO N
study VB N
discontinuation NN N
. . N

The DT p
10 CD p
patients NNS p
who WP p
completed VBD p
the DT p
study NN p
reported VBD N
a DT N
33.5 CD N
% NN N
improvement NN N
( ( N
from IN N
16.7 CD N
+/- JJ N
3.2 CD N
to TO N
11.1 CD N
+/- JJ N
4 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
of IN N
the DT N
6-item JJ N
IRLS NNP N
scores NNS N
during IN N
levodopa JJ N
SR NNP N
treatment NN N
and CC N
a DT N
73.5 CD N
% NN N
improvement NN N
( ( N
from IN N
16.6 CD N
+/- JJ N
2.8 CD N
to TO N
4.4 CD N
+/- JJ N
3.8 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
during IN N
ropinirole JJ N
treatment NN N
. . N

By IN N
the DT N
end NN N
of IN N
the DT N
study NN N
the DT N
mean JJ N
levodopa NN N
SR NNP N
dosage NN N
was VBD N
190 CD N
mg/d NN N
and CC N
the DT N
mean JJ N
ropinirole NN N
dosage NN N
was VBD N
1.45 CD N
mg/d NN N
. . N

Ropinirole NNP i
was VBD N
superior JJ N
to TO N
levodopa VB i
SR NNP i
in IN N
reducing VBG N
6-item JJ N
IRLS NNP N
scores NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
in IN N
increasing VBG N
sleep JJ o
time NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
patient NN N
CGI NNP o
scale NN o
showed VBD N
a DT N
significant JJ N
difference NN N
favoring VBG N
ropinirole NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
carryover NN o
or CC o
period NN o
effect NN o
for IN N
any DT N
outcome JJ N
measure NN N
. . N

Four CD N
patients NNS N
reported VBD N
a DT N
complete JJ N
reversion NN N
of IN N
RLS NNP o
symptoms NNS o
during IN N
ropinirole JJ N
treatment NN N
at IN N
doses NNS N
ranging VBG N
from IN N
0.25-2 JJ N
mg/d NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
ropinirole NN N
is VBZ N
more RBR N
effective JJ N
than IN N
levodopa JJS N
SR NNP N
in IN N
the DT N
treatment NN N
of IN N
RLS NNP N
in IN N
patients NNS p
on IN p
chronic JJ p
hemodialysis NN p
. . p

-DOCSTART- -X- O O

Clinical JJ N
and CC N
radiographic JJ N
evaluation NN N
of IN N
guided JJ N
tissue NN N
regeneration NN N
in IN N
the DT N
treatment NN N
of IN N
class NN p
II NNP p
furcation NN p
defects NNS p
. . p

A DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
treatment NN N
outcomes RB o
after IN N
guided VBN i
tissue NN i
regeneration NN i
( ( i
GTR NNP i
) ) i
with IN N
a DT N
bioabsorbable JJ N
membrane NN N
in IN N
Class NNP p
II NNP p
furcation NN p
defects NNS p
in IN N
mandibular JJ N
molars NNS N
. . N

The DT N
open JJ N
flap NN N
debridement NN N
( ( N
OFD NNP N
) ) N
was VBD N
used VBN N
as IN N
the DT N
control NN N
. . N

METHODS NNP N
Nine NNP p
patients NNS p
, , p
with IN p
two CD p
comparable JJ p
Class NNP p
II NNP p
furcation NN p
defects NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

After IN N
initial JJ N
preparation NN N
, , N
the DT N
defects NNS N
were VBD N
randomly RB N
assigned VBN N
in IN N
each DT N
patient NN N
to TO N
either DT N
GTR-group NNP i
or CC p
OFD-group NNP i
. . p

Clinical JJ N
parameters NNS N
and CC N
standardized JJ N
radiographs NN N
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
after IN N
the DT N
surgeries NNS N
. . N

The DT N
radiographs NN i
were VBD N
analyzed VBN N
by IN N
subtraction NN N
radiography NN N
. . N

RESULTS NNP N
Comparing NNP N
baseline NN N
to TO N
6-month JJ N
results NNS N
, , N
both DT N
groups NNS N
showed VBD N
statistically RB N
significant JJ N
probing VBG o
depth NN o
reduction NN o
( ( o
PD NNP o
) ) o
, , o
horizontal JJ o
clinical JJ o
attachment NN o
level NN o
( ( o
CAL-h NNP o
) ) o
gain NN o
, , o
and CC o
increase VB o
in IN o
gingival JJ o
recession NN o
( ( o
GR NNP o
) ) o
. . o

The DT N
vertical JJ o
clinical JJ o
attachment NN o
level NN o
( ( o
CAL-v NNP o
) ) o
gain NN o
was VBD N
statistically RB N
significant JJ N
only RB N
for IN N
the DT N
OFD-group NNP N
. . N

Comparing VBG N
the DT N
two CD N
treatments NNS N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
PD NNP o
reduction NN o
( ( N
GTR NNP N
: : N
1.67 CD N
mm NN N
; : N
OFD NNP N
: : N
2.51 CD N
mm NN N
, , N
P NNP N
= NNP N
0.26 CD N
) ) N
, , N
CAL-v JJ o
gain NN o
( ( N
GTR NNP N
: : N
0.62 CD N
mm NN N
; : N
OFD NNP N
: : N
1.16 CD N
mm NN N
, , N
P= NNP N
0.37 CD N
) ) N
, , N
and CC N
GR NNP o
increase NN o
( ( N
GTR NNP N
: : N
1.04 CD N
mm NN N
; : N
OFD NNP N
: : N
1.24 CD N
mm NN N
, , N
P NNP N
= NNP N
0.31 CD N
) ) N
. . N

GTR NNP i
provided VBD N
complete JJ N
closure NN o
of IN o
the DT o
furcation NN o
defect NN o
in IN N
two CD N
sites NNS N
and CC N
superior JJ o
horizontal JJ o
clinical JJ o
attachment NN o
level NN o
gain NN o
( ( N
GTR NNP N
: : N
2.27 CD N
mm NN N
; : N
OFD NNP N
: : N
1.01 CD N
mm NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

Subtraction NN N
radiography NN N
showed VBD N
significant JJ N
difference NN N
in IN N
bone NN N
height NN N
change NN N
between IN N
GTR-group NNP N
and CC N
OFD-group NNP N
( ( N
-0.14 NNP N
mm NN N
and CC N
0.86 CD N
mm NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.028 CD N
) ) N
at IN N
6 CD N
months NNS N
. . N

-DOCSTART- -X- O O

Promoting VBG N
health NN N
in IN p
schools NNS p
through IN N
a DT N
board NN i
game NN i
. . i

Primary JJ N
prevention NN N
and CC N
health NN N
promotion NN N
have VBP N
become VBN N
salient JJ N
topics NNS N
in IN N
Canadian JJ N
society NN N
and CC N
in IN N
nursing NN N
during IN N
the DT N
past JJ N
two CD N
decades NNS N
. . N

The DT N
noncommunicable JJ N
chronic NN N
diseases NNS N
, , N
such JJ N
as IN N
heart NN N
disease NN N
and CC N
cancer NN N
, , N
have VBP N
been VBN N
linked VBN N
to TO N
specific JJ N
lifestyle JJ o
behaviors NNS o
or CC N
habits NNS N
, , N
which WDT N
often RB N
develop VBP N
early JJ N
in IN N
life NN N
. . N

The DT N
success NN N
of IN N
public JJ N
health NN N
efforts NNS N
to TO N
improve VB N
the DT N
health NN N
status NN N
of IN N
all DT N
Canadians NNPS N
depends VBZ N
substantially RB N
on IN N
the DT N
success NN N
of IN N
educational JJ N
programs NNS N
directed VBD N
toward IN N
children NNS p
. . p

Effective JJ N
teaching NN N
strategies NNS N
that WDT N
seek VBP N
to TO N
promote VB N
health NN N
and CC N
wellness NN N
in IN p
children NNS p
need VBP N
to TO N
be VB N
developed VBN N
and CC N
empirically RB N
evaluated VBN N
. . N

Educational JJ N
games NNS N
may MD N
provide VB N
an DT N
efficient JJ N
vehicle NN N
for IN N
carrying VBG N
out RP N
developmentally RB N
specific JJ N
nursing NN N
interventions NNS N
in IN p
school NN p
settings NNS p
. . p

This DT N
article NN N
begins VBZ N
with IN N
a DT N
brief JJ N
overview NN N
of IN N
the DT N
historical JJ N
origins NNS N
of IN N
games NNS N
, , N
along IN N
with IN N
their PRP$ N
advantages NNS N
and CC N
disadvantages NNS N
as IN N
educational JJ N
strategies NNS N
. . N

The DT N
results NNS N
of IN N
a DT N
pretest-posttest JJ N
control NN N
group NN N
design NN N
study NN N
that WDT N
evaluated VBD N
the DT N
effectiveness NN i
of IN i
a DT i
board NN i
game NN i
as IN i
a DT i
primary JJ i
prevention NN i
teaching VBG i
strategy NN i
with IN N
23 CD p
sixth NNS p
grade JJ p
children NNS p
in IN p
Winnipeg NNP p
, , p
Manitoba NNP p
are VBP N
presented VBN N
. . N

The DT N
experimental JJ N
group NN N
had VBD N
significant JJ N
gains NNS N
in IN N
knowledge NN o
related VBN o
to TO o
anatomy VB o
and CC o
physiology VB o
, , o
diet JJ o
, , o
and CC o
lifestyle JJ o
risk NN o
factors NNS o
associated VBN o
with IN o
the DT o
development NN o
of IN o
heart NN o
disease NN o
and CC o
cancer NN o
. . o

-DOCSTART- -X- O O

Prospective JJ N
study NN N
of IN N
Clostridium NNP o
difficile JJ o
intestinal JJ N
colonization NN N
and CC N
disease NN N
following VBG N
single-dose JJ i
antibiotic JJ i
prophylaxis NN i
in IN N
surgery NN N
. . N

A DT N
total NN N
of IN N
108 CD p
volunteers NNS p
undergoing VBG p
an DT p
elective JJ p
surgical JJ p
procedure NN p
were VBD N
randomly RB N
given VBN N
a DT N
single JJ N
2-g JJ N
intravenous JJ i
prophylactic JJ i
dose NN i
of IN i
either CC i
a DT i
cephalosporin NN i
or CC i
mezlocillin NN i
. . i

Stool NNP N
samples NNS N
were VBD N
cultured VBN N
for IN N
Clostridium NNP N
difficile VBP N
the DT N
day NN N
before IN N
the DT N
operation NN N
and CC N
later RB N
on IN N
postoperative JJ N
days NNS N
4 CD N
, , N
7 CD N
, , N
and CC N
14 CD N
. . N

C. NNP o
difficile NN o
was VBD N
detected VBN N
in IN N
23.0 CD N
% NN N
of IN N
patients NNS p
who WP N
received VBD N
a DT N
cephalosporin NN i
( ( i
cefoxitin NN i
, , i
8.3 CD i
% NN i
; : i
cefazolin NN i
, , i
14.3 CD i
% NN i
; : i
cefotetan NN i
, , i
20.0 CD i
% NN i
; : i
ceftriaxone NN i
, , i
25.0 CD i
% NN i
; : i
cefoperazone NN i
, , i
43.7 CD i
% NN i
) ) i
, , N
in IN N
3.3 CD N
% NN N
of IN N
patients NNS p
given VBN N
mezlocillin NNS i
, , N
and CC N
in IN N
none NN N
of IN N
15 CD p
control NN p
volunteers NNS p
given VBN N
no DT i
antimicrobial JJ i
agent NN i
. . i

No DT N
patient NN N
experienced VBD N
diarrhea NN o
. . o

-DOCSTART- -X- O O

PRL-8-53 NN i
: : i
enhanced VBN N
learning NN o
and CC N
subsequent JJ N
retention NN o
in IN N
humans NNS p
as IN N
a DT N
result NN N
of IN N
low JJ N
oral JJ N
doses NNS N
of IN N
new JJ N
psychotropic NN i
agent NN N
. . N

The DT N
effect NN N
of IN N
3- JJ i
( ( i
2-benzylmethylaminoethyl JJ i
) ) i
benzoic NN i
acid JJ i
methyl NN i
ester NN i
hydrochloride NN i
( ( i
PRL-8-53 NNP i
) ) i
on IN N
learning NN o
and CC N
on IN N
retention NN o
of IN o
verbal JJ o
information NN o
in IN N
human JJ p
subjects NNS p
was VBD N
investigated VBN N
. . N

Using VBG N
the DT N
serial JJ N
anticipation NN N
method NN N
under IN N
double-blind JJ N
conditions NNS N
it PRP N
was VBD N
found VBN N
that IN N
PRL-8-53 NNP i
causes NNS N
slight JJ N
improvement NN N
of IN N
acquisition NN o
. . o

Retinetion NN o
of IN o
verbal JJ o
information NN o
was VBD N
found VBN N
improved VBN N
to TO N
a DT N
statistically RB N
significant JJ N
degree NN N
( ( N
most RBS N
P NNP N
values NNS N
better RBR N
than IN N
0.01 CD N
, , N
some DT N
better JJR N
than IN N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
for IN N
either DT N
visual JJ o
reaction NN o
time NN o
or CC o
motor NN o
control NN o
after IN N
drug NN N
when WRB N
compared VBN N
with IN N
placebo NN i
values NNS N
. . N

-DOCSTART- -X- O O

A DT N
study NN N
on IN N
the DT N
effect NN N
of IN N
the DT N
duration NN N
of IN N
subcutaneous JJ i
heparin NN i
injection NN i
on IN p
bruising NN p
and CC p
pain NN p
. . p

AIM NNP N
This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
injection NN N
duration NN N
on IN N
bruising NN N
and CC N
pain NN N
following VBG N
the DT N
administration NN N
of IN N
the DT N
subcutaneous JJ N
injection NN N
of IN N
heparin NN i
. . i

BACKGROUND NNP N
Although IN N
different JJ N
methods NNS N
to TO N
prevent VB N
bruising NN N
and CC N
pain NN N
following VBG N
the DT N
subcutaneous JJ N
injection NN N
of IN N
heparin NNS i
have VBP N
been VBN N
widely RB N
studied VBN N
and CC N
described VBN N
, , N
the DT N
effect NN N
of IN N
injection NN N
duration NN N
on IN N
the DT N
occurrence NN N
of IN N
bruising NN N
and CC N
pain NN N
is VBZ N
little RB N
documented JJ N
. . N

DESIGN VB N
This DT N
study NN N
was VBD N
designed VBN N
as IN N
within-subject JJ N
, , N
quasi-experimental JJ N
research NN N
. . N

METHOD NNP N
The DT N
sample NN N
for IN N
the DT N
study NN N
consisted VBD N
of IN N
50 CD p
patients NNS p
to TO p
whom WP p
subcutaneous JJ p
heparin NN i
was VBD p
administered VBN p
. . p

Heparin NNP i
was VBD N
injected VBN N
over IN N
10 CD N
seconds NNS N
on IN N
the DT N
right JJ N
abdominal JJ N
site NN N
and CC N
30 CD N
seconds NNS N
on IN N
the DT N
left JJ N
abdominal JJ N
site NN N
. . N

Injections NNS N
areas NNS N
were VBD N
assessed VBN N
for IN N
the DT N
presence NN N
of IN N
bruising VBG o
at IN N
48 CD N
and CC N
72 CD N
hours NNS N
after IN N
each DT N
injection NN N
. . N

Dimensions NNS N
of IN N
the DT N
bruising NN N
on IN N
the DT N
heparin NN N
applied VBN N
areas NNS N
were VBD N
measured VBN N
using VBG N
transparent JJ N
millimetric JJ N
measuring VBG N
paper NN N
. . N

The DT N
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
was VBD N
used VBN N
to TO N
measure VB N
pain NN N
intensity NN N
and CC N
a DT N
stop-watch NN N
was VBD N
used VBN N
to TO N
time NN N
the DT N
pain NN N
period NN N
. . N

Data NNS N
were VBD N
analysed VBN N
using VBG N
chi-square JJ N
test NN N
, , N
Mann-Whitney NNP N
U NNP N
, , N
Wilcoxon NNP N
signed VBD N
ranks NNS N
tests NNS N
and CC N
correlation NN N
. . N

RESULTS VB N
The DT N
percentage NN o
of IN o
bruising VBG o
occurrence NN o
was VBD N
64 CD N
% NN N
with IN N
the DT N
injection NN N
of IN N
10 CD N
seconds NNS N
duration NN N
and CC N
42 CD N
% NN N
in IN N
the DT N
30-second JJ N
injection NN N
. . N

It PRP N
was VBD N
determined VBN N
that IN N
the DT N
size NN o
of IN o
the DT o
bruising NN o
was VBD N
smaller JJR N
in IN N
the DT N
30-second JJ N
injection NN N
. . N

Pain NNP o
intensity NN o
and CC o
pain NN o
period NN o
were VBD N
statistically RB N
significantly RB N
lower JJR N
for IN N
the DT N
30-second JJ N
injection NN N
than IN N
for IN N
the DT N
10-second JJ N
injection NN N
. . N

CONCLUSIONS VB N
It PRP N
was VBD N
determined VBN N
that IN N
injection NN N
duration NN N
had VBD N
an DT N
effect NN N
on IN N
bruising NN N
and CC N
pain NN N
following VBG N
the DT N
subcutaneous JJ N
administration NN N
of IN N
heparin NN i
. . i

This DT N
study NN N
should MD N
be VB N
repeated VBN N
on IN N
a DT N
larger JJR N
sample NN N
. . N

RELEVANCE NNP N
TO NNP N
CLINICAL NNP N
PRACTICE NNP N
When WRB N
administering VBG N
subcutaneous JJ N
heparin NN i
injections NNS N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
extend VB N
the DT N
duration NN N
of IN N
the DT N
injection NN N
. . N

-DOCSTART- -X- O O

Clinical JJ N
effects NNS N
of IN N
nanocrystalline JJ i
hydroxyapatite JJ i
paste NN i
in IN N
the DT N
treatment NN N
of IN N
intrabony JJ N
periodontal JJ N
defects NNS N
: : N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
clinical JJ N
outcomes NNS N
of IN N
papilla NN N
preservation NN N
flap NN N
surgery NN N
with IN N
or CC N
without IN N
the DT N
application NN N
of IN N
a DT N
novel JJ N
nanocrystalline NN i
hydroxyapatite NN i
( ( i
nano-HA JJ i
) ) i
bone NN i
graft NN i
substitute NN i
. . i

Fourteen JJ p
patients NNS p
with IN p
paired JJ p
intrabony NN p
periodontal JJ p
defects NNS p
of IN p
? . p
4 CD p
mm NN p
participated VBN p
in IN p
this DT N
split-mouth JJ N
design NN N
study NN N
. . N

The DT N
defects NNS N
in IN N
each DT N
subject NN N
were VBD i
randomly RB i
selected VBN i
to TO i
receive VB i
nano-HA JJ i
paste NN i
in IN i
conjunction NN i
with IN i
papilla NN i
preservation NN i
flaps NNS i
or CC i
papilla NN i
preservation NN i
flaps NNS i
alone RB o
. . o

Probing VBG o
bone NN o
levels NNS o
( ( o
PBL NNP o
) ) o
from IN o
a DT i
customized JJ i
acrylic JJ i
stent NN i
and CC o
probing VBG o
pocket NN o
depths NNS o
( ( o
PPD NNP o
) ) o
were VBD o
measured VBN i
at IN i
baseline NN i
and CC i
again RB i
6 CD i
months NNS i
following VBG i
surgery NN i
. . i

No DT N
differences NNS N
in IN N
any DT N
of IN N
the DT N
investigated JJ N
parameters NNS N
were VBD N
observed VBN N
at IN N
baseline NN N
between IN N
the DT N
two CD N
groups NNS o
. . o

Healing NNP o
was VBD o
uneventful JJ N
in IN N
all DT N
patients NNS N
. . N

Both DT N
treatments NNS N
resulted VBD N
in IN N
significant JJ N
improvements NNS N
between IN N
baseline NN N
and CC N
6 CD N
months NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
6 CD N
months NNS N
after IN N
therapy NN N
, , N
the DT N
sites NNS N
treated VBD N
with IN i
nano-HA JJ i
paste NN i
showed VBD i
a DT N
reduction NN N
in IN N
mean JJ o
PPD NNP o
from IN o
8.3 CD N
? . N
1.2 CD N
to TO N
4.0 CD N
? . N
1.1 CD N
mm NN N
and CC N
a DT N
gain NN N
in IN o
PBL NNP o
of IN N
4.3 CD N
? . N
1.4 CD N
mm NN N
, , N
whereas NNS N
in IN N
the DT N
control NN N
group NN N
, , N
the DT N
mean NN N
PPD NNP o
changed VBD N
from IN N
7.9 CD N
? . N
1.2 CD N
mm NN N
to TO N
5.0 CD N
? . N
1.2 CD N
mm NN N
and CC N
PBL NNP o
gain NN o
was VBD N
2.6 CD N
? . N
1.4 CD N
mm NN N
. . N

Results NNP N
demonstrated VBD N
statistically RB N
greater JJR N
PPD NNP o
reduction NN o
and CC o
PBL NNP o
gain NN o
( ( o
p JJ o
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
test NN N
group NN N
as IN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

In IN N
conclusion NN N
, , N
after IN N
6 CD N
months NNS N
, , N
the DT N
treatment NN N
of IN N
intrabony JJ N
periodontal JJ N
defects NNS N
with IN N
a DT N
nano-HA JJ N
paste NN N
leads VBZ N
to TO N
significantly RB N
improved VBN N
clinical JJ N
outcomes NNS N
when WRB N
compared VBN N
with IN i
papilla NN i
preservation NN i
flap NN i
surgery NN i
alone RB N
. . N

-DOCSTART- -X- O O

A DT N
double-blind JJ N
placebo-controlled JJ i
study NN N
to TO N
evaluate VB N
valacyclovir NN i
alone RB i
and CC N
with IN N
aspirin NN i
for IN N
asymptomatic JJ N
HSV-1 NNP N
DNA NNP N
shedding VBG N
in IN N
human JJ p
tears NNS p
and CC p
saliva NN p
. . p

PURPOSE NNP N
To TO N
test VB N
the DT N
effect NN N
of IN N
valacyclovir NN i
alone RB i
and CC N
with IN N
aspirin NN i
on IN N
the DT N
asymptomatic JJ N
shedding NN N
of IN N
HSV-1 NNP N
DNA NNP N
in IN N
tears NNS p
and CC p
saliva NN p
of IN p
healthy JJ p
individuals NNS p
. . p

METHOD NNP N
. . N

The DT p
subjects NNS p
( ( p
n JJ p
= NNP p
45 CD p
) ) p
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
without IN N
regard NN N
to TO N
age NN N
, , N
sex NN N
, , N
or CC N
race NN N
. . N

Group NNP N
1 CD N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
received VBD N
the DT N
placebo NN i
, , N
group NN N
2 CD N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
received VBD N
a DT N
dose NN N
of IN N
500 CD i
mg NNS i
valacyclovir JJ i
once RB i
daily JJ i
, , N
and CC N
group NN N
3 CD N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
received VBD N
a DT N
dose NN N
of IN N
500 CD i
mg NNS i
valacyclovir JJ i
once RB i
daily JJ i
and CC i
350 CD i
mg NN i
aspirin JJ i
twice RB N
daily RB N
for IN N
30 CD N
days NNS N
. . N

Ocular JJ N
and CC N
oral JJ N
swabs NNS N
were VBD N
collected VBN N
twice RB N
daily RB N
for IN N
30 CD N
days NNS N
. . N

DNA NN N
was VBD N
extracted VBN N
from IN N
all DT N
swabs NNS N
and CC N
HSV-1 NNP N
DNA NNP N
copy NN N
numbers NNS N
were VBD N
determined VBN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
to TO N
compare VB N
the DT N
DNA NNP N
copy NN N
numbers NNS N
of IN N
the DT N
three CD N
groups NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
HSV-1 NNP o
DNA NNP o
copy NN o
numbers NNS o
in IN o
the DT o
tears NNS o
or CC o
saliva NN o
among IN N
any DT N
of IN N
the DT N
three CD N
treatment NN i
groups NNS N
. . N

The DT N
mean JJ o
copy NN o
numbers NNS o
+/- JJ o
SE NNP o
of IN o
mean NN o
( ( o
SEM NNP o
) ) o
of IN o
HSV-1 NNP o
DNA NNP o
in IN N
tears NNS N
were VBD N
340 CD N
+/- JJ N
35 CD N
, , N
1074 CD N
+/- JJ N
320 CD N
, , N
and CC N
630 CD N
+/- JJ N
51 CD N
for IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
and CC N
in IN N
saliva NN N
were VBD N
238 CD N
+/- JJ N
35 CD N
, , N
963 CD N
+/- JJ N
462 CD N
, , N
and CC N
493 CD N
+/- JJ N
25 CD N
, , N
respectively RB N
, , N
for IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
. . N

CONCLUSIONS NNP N
No NNP N
correlation NN N
was VBD N
found VBN N
between IN N
HSV-1 NNP o
shedding VBG o
and CC N
valacyclovir NNS i
and CC N
valacyclovir NN i
with IN i
aspirin JJ i
treatment NN N
. . N

The DT N
HSV-1 NNP N
DNA NNP N
copy NN N
number NN N
was VBD N
not RB N
reduced VBN N
by IN N
treatment NN N
with IN N
500 CD N
mg NNS N
of IN N
valacyclovir JJ i
daily JJ N
or CC N
with IN N
a DT N
combination NN N
of IN N
daily JJ N
valacyclovir NN i
( ( N
500 CD N
mg NN N
) ) N
plus CC N
twice-daily JJ N
doses NNS N
of IN N
aspirin NN i
( ( N
350 CD N
mg NN N
) ) N
over IN N
30 CD N
days NNS N
. . N

-DOCSTART- -X- O O

Desmopressin NNP i
in IN N
the DT N
treatment NN N
of IN N
nocturia NNS p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

OBJECTIVES NNP N
To TO N
investigate VB N
efficacy NN o
, , o
safety NN o
, , N
and CC N
impact NN N
on IN N
quality NN o
of IN o
sleep NN o
of IN N
desmopressin NN i
in IN N
the DT N
treatment NN N
of IN N
nocturia NNS N
. . N

METHODS NNP N
Adults NNP p
aged VBD p
> NNP p
or CC p
=18 NNP p
yr NN p
with IN p
nocturia NNS p
( ( p
> CD p
or CC p
=2 VB p
voids/night NN p
) ) p
received VBD N
desmopressin JJ i
tablets NNS N
( ( N
0.1 CD N
, , N
0.2 CD N
, , N
or CC N
0.4 CD N
mg NN N
) ) N
during IN N
a DT N
3-wk JJ N
dose-titration NN N
period NN N
. . N

Patients NNS N
should MD N
show VB N
sufficient JJ N
response NN N
during IN N
the DT N
dose-titration JJ N
period NN N
( ( N
> CD N
or CC N
=20 CD N
% NN N
reduction NN N
in IN N
nocturnal JJ N
diuresis NN N
) ) N
and CC N
a DT N
return NN N
of IN N
nocturnal JJ N
diuresis NN N
to TO N
> VB N
or CC N
=80 VB N
% NN N
of IN N
baseline NN N
levels NNS N
during IN N
washout NN N
. . N

Eligible JJ N
patients NNS N
then RB N
entered VBD N
a DT N
3-wk JJ N
double-blind JJ N
treatment NN N
period NN N
and CC N
received VBD N
either CC N
desmopressin NN i
or CC N
placebo NN i
. . i

RESULTS CC N
127 CD p
patients NNS p
were VBD p
randomised VBN p
to TO N
either DT N
desmopressin NN i
( ( N
n=61 JJ N
) ) N
or CC N
placebo NN i
( ( N
n=66 JJ N
) ) N
. . N

Twenty NNP N
( ( N
33 CD N
% NN N
) ) N
desmopressin-treated JJ i
patients NNS N
compared VBN N
with IN N
seven CD N
( ( N
11 CD N
% NN N
) ) N
placebo-treated JJ i
patients NNS N
showed VBD N
a DT N
clinical JJ N
response NN N
, , N
defined VBD N
as IN N
a DT N
> NN N
or CC N
=50 CD N
% NN N
reduction NN N
in IN N
the DT N
number NN o
of IN o
nocturnal JJ o
voids NNS o
compared VBN N
with IN N
baseline NN N
( ( N
p=0.0014 NN N
) ) N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
desmopressin NN i
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
mean JJ o
number NN o
of IN o
nocturnal JJ o
voids NNS o
( ( N
39 CD N
% NN N
reduction NN N
with IN N
desmopressin NN i
vs. FW N
15 CD N
% NN N
with IN N
placebo NN i
; : i
absolute JJ N
difference NN N
-0.84 NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
and CC N
duration NN o
of IN o
the DT o
first JJ o
sleep JJ o
period NN o
( ( N
prolonged VBN N
by IN N
108 CD N
min NNS N
with IN N
desmopressin NN i
vs. FW N
41 CD N
min NN N
with IN N
placebo NN i
; : i
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Quality NN o
of IN o
sleep NN o
was VBD N
also RB N
improved VBN N
with IN N
desmopressin NN i
versus NN N
placebo NN i
( ( N
statistically RB N
significant JJ N
for IN N
one CD N
of IN N
the DT N
two CD N
parameters NNS N
evaluated VBD N
) ) N
. . N

Adverse JJ o
events NNS o
were VBD N
mainly RB N
mild JJ N
. . N

CONCLUSIONS NNP N
Oral NNP N
desmopressin NN i
tablets NNS N
provide VBP N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
treatment NN o
for IN N
nocturia NN N
. . N

Compared VBN N
with IN N
placebo NN i
, , N
nocturnal JJ o
voiding NN o
frequency NN o
is VBZ N
reduced VBN N
, , N
duration NN N
of IN N
the DT N
first JJ N
sleep JJ N
period NN N
is VBZ N
increased VBN N
, , N
and CC N
sleep JJ o
quality NN o
may MD N
be VB N
improved VBN N
. . N

-DOCSTART- -X- O O

Determinants NNS N
of IN N
total JJ N
and CC N
specific JJ N
IgE NNP N
in IN N
infants NNS p
with IN p
atopic JJ p
dermatitis NN p
. . p

ETAC NNP N
Study NNP N
Group NNP N
. . N

Early NNP N
Treatment NNP N
of IN N
the DT N
Atopic NNP p
Child NNP p
. . p

ETAC NNP p
( ( p
Early JJ p
Treatment NN p
of IN p
the DT p
Atopic NNP p
Child NNP p
) ) p
, , p
a DT p
multi-centre JJ p
predominantly RB p
European JJ p
study NN p
to TO p
investigate VB p
the DT p
potential NN p
for IN p
cetirizine NN i
to TO p
prevent VB p
the DT p
development NN p
of IN p
asthma NN p
in IN p
infants NNS p
with IN p
atopic NN p
dermatitis NN p
has VBZ N
completed VBN N
enrollment NN N
: : N
817 CD p
children NNS p
have VBP N
been VBN N
randomised VBN N
to TO N
18 CD N
months NNS N
' POS N
treatment NN N
with IN N
either DT N
active JJ i
or CC N
placebo NN i
and CC N
a DT N
subsequent JJ N
18 CD N
months NNS N
of IN N
post-treatment JJ N
follow-up NN N
. . N

Results NNS N
of IN N
the DT N
therapeutic JJ N
effects NNS N
will MD N
not RB N
be VB N
available JJ N
for IN N
some DT N
time NN N
, , N
but CC N
the DT N
study NN N
has VBZ N
provided VBN N
an DT N
opportunity NN N
to TO N
investigate VB N
influences NNS N
on IN N
sensitization NN o
to TO o
allergens NNS o
in IN N
a DT N
large JJ p
cohort NN p
of IN p
1-2 JJ p
years NNS p
olds VBZ p
with IN p
already RB p
established VBN p
atopic NN p
dermatitis NN p
, , p
resident NN p
in IN p
different JJ p
countries NNS p
and CC p
in IN p
different JJ p
environments NNS p
. . p

The DT N
study NN N
shows VBZ N
that IN N
in IN N
infants NNS p
with IN p
atopic NN p
dermatitis NN p
, , N
raised VBD N
serum JJ o
total NN o
IgE NNP o
has VBZ N
significantly RB N
different JJ N
determinants NNS N
from IN N
that IN N
a DT N
specific JJ o
allergen NN o
sensitization NN o
. . o

In IN N
infancy NN N
, , N
increased VBD N
total JJ o
IgE NNP o
is VBZ N
more RBR N
affected JJ N
by IN N
factors NNS N
increasing VBG N
risk NN N
of IN N
intercurrent JJ N
infection NN N
and CC N
non-specific JJ N
airway NN N
inflammation NN N
, , N
such JJ N
as IN N
environmental JJ N
tobacco NN N
smoke NN N
exposure NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
use NN N
of IN N
gas NN N
cookers NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

Specific JJ N
allergen NN o
sensitization NN o
as IN N
represented VBN N
by IN N
detectable JJ N
IgE NNP o
antibodies NNS o
is VBZ N
influenced VBN N
primarily RB N
by IN N
allergen NN N
exposure NN N
. . N

In IN N
Sweden NNP N
, , N
low JJ N
level NN N
exposure NN N
to TO N
allergens NNS N
is VBZ N
associated VBN N
with IN N
reduced VBN N
specific JJ o
allergen NN o
sensitization NN o
rates NNS N
even RB N
though IN N
the DT N
infants NNS p
already RB N
have VBP N
atopic VBN N
dermatitis NN N
. . N

-DOCSTART- -X- O O

Implementing VBG N
a DT N
simplified JJ i
neonatal JJ i
resuscitation NN i
protocol-helping JJ i
babies NNS p
breathe VBP p
at IN p
birth NN p
( ( N
HBB NNP N
) ) N
- : N
at IN N
a DT N
tertiary JJ N
level NN N
hospital NN N
in IN N
Nepal NNP p
for IN N
an DT N
increased JJ N
perinatal NN o
survival NN o
. . o

BACKGROUND NNP N
Reducing NNP N
neonatal JJ o
death NN o
has VBZ N
been VBN N
an DT N
emerging VBG N
challenge NN N
in IN N
low JJ p
and CC p
middle JJ p
income NN p
countries NNS p
in IN N
the DT N
past JJ N
decade NN N
. . N

The DT N
development NN N
of IN N
the DT N
low JJ N
cost NN N
interventions NNS N
and CC N
their PRP$ N
effective JJ N
delivery NN N
are VBP N
needed VBN N
to TO N
reduce VB N
deaths NNS o
from IN N
birth NN N
asphyxia NN N
. . N

This DT N
study NN N
will MD N
assess VB N
the DT N
impact NN N
of IN N
a DT N
simplified JJ i
neonatal JJ i
resuscitation NN i
protocol NN i
provided VBN N
by IN N
Helping VBG N
Babies NNS N
Breathe NNP N
( ( N
HBB NNP N
) ) N
at IN N
a DT N
tertiary JJ p
hospital NN p
in IN p
Nepal NNP p
. . p

Perinatal NNP N
outcomes NNS N
and CC N
performance NN N
of IN N
skilled JJ p
birth NN p
attendants NNS p
on IN N
management NN o
of IN o
intrapartum-related JJ o
neonatal JJ o
hypoxia NN o
will MD N
be VB N
the DT N
main JJ N
measurements NNS N
. . N

METHODS/DESIGN NNP N
The DT N
study NN N
will MD N
be VB N
carried VBN N
out RP N
at IN N
a DT N
tertiary JJ p
level NN p
maternity NN p
hospital NN p
in IN p
Nepal NNP p
. . p

A DT N
prospective JJ N
cohort-study NN N
will MD N
include VB N
a DT N
six-month JJ N
baseline NN N
a DT N
six CD N
month NN N
intervention NN N
period NN N
and CC N
a DT N
three-month JJ N
post NN N
intervention NN N
period NN N
. . N

A DT N
quality NN N
improvement NN N
process NN N
cycle NN N
will MD N
introduce VB N
the DT N
neonatal JJ N
resuscitation NN N
protocol NN N
. . N

A DT N
surveillance NN N
system NN N
, , N
including VBG N
CCD NNP i
cameras NNS i
and CC i
pulse JJ i
oximeters NNS i
, , N
will MD N
be VB N
set VBN N
up RP N
to TO N
evaluate VB N
the DT N
intervention NN N
. . N

DISCUSSION NNP N
Along IN N
with IN N
a DT N
technique NN N
to TO N
improve VB N
health NN o
workers NNS o
performance NN o
on IN N
the DT N
protocol NN N
, , N
the DT N
study NN N
will MD N
generate VB N
evidence NN N
on IN N
the DT N
research NN N
gap NN N
on IN N
the DT N
effectiveness NN N
of IN N
the DT N
simplified JJ N
neonatal JJ N
resuscitation NN N
protocol NN N
on IN N
intrapartum NN o
outcome NN o
and CC o
early JJ o
neonatal JJ o
survival NN o
. . o

This DT N
will MD N
generate VB N
a DT N
global JJ N
interest NN N
and CC N
inform NN N
policymaking NN N
in IN N
relation NN N
to TO N
delivery NN N
care NN N
in IN N
all DT N
income NN N
settings NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN97846009 NNP N
. . N

-DOCSTART- -X- O O

A DT N
controlled JJ N
trial NN N
of IN N
'Senokot NNP i
' POS i
in IN N
faecal JJ N
soiling NN N
treated VBN N
by IN N
behavioural JJ N
methods NNS N
. . N

A DT N
double-blind JJ N
randomly NN N
controlled VBD N
trial NN N
of IN N
one CD N
particular JJ N
laxative NN N
, , N
Senokot NNP i
, , N
used VBD N
in IN N
moderate JJ N
dosage NN N
, , N
was VBD N
carried VBN N
out RP N
on IN N
a DT N
group NN N
of IN N
40 CD p
children NNS p
with IN p
severe JJ p
and CC p
persistent JJ p
soiling NN p
and CC p
often RB p
with IN p
a DT p
history NN p
of IN p
faecal JJ p
retention NN p
. . p

Significant JJ o
improvement NN o
occurred VBD N
following VBG N
three CD N
months NNS N
of IN N
outpatient JJ N
treatment NN N
using VBG N
a DT N
behavioural JJ i
approach NN i
and CC i
either DT i
Senokot NNP i
, , i
placebo NN i
or CC i
no DT i
medication NN i
. . i

However RB N
, , N
there EX N
was VBD N
no DT N
evidence NN N
either RB N
during IN N
the DT N
trial NN N
or CC N
subsequently RB N
when WRB N
Senokot NNP N
was VBD N
employed VBN N
to TO N
supplement VB N
behavioural JJ N
treatment NN N
in IN N
every DT N
child NN N
who WP N
continued VBD N
with IN N
therapy NN N
that IN N
this DT N
laxative NN N
contributed VBD N
in IN N
any DT N
way NN N
to TO N
relieving VBG o
the DT o
problem NN o
in IN N
this DT N
group NN N
of IN N
cases NNS N
. . N

-DOCSTART- -X- O O

Long JJ N
term NN N
follow VBP N
up IN N
of IN N
patients NNS p
treated VBN p
for IN p
Helicobacter NNP o
pylori JJ o
infection NN o
. . o

BACKGROUND NNP N
Helicobacter NNP N
pylori POS N
infection NN N
induces NNS N
progressive JJ N
inflammatory JJ o
changes NNS o
in IN N
the DT N
gastric JJ N
mucosa NN N
that WDT N
may MD N
lead VB N
to TO N
gastric JJ N
cancer NN N
. . N

Understanding VBG N
long JJ N
term NN N
effects NNS N
resulting VBG N
from IN N
the DT N
cure NN N
of IN N
this DT N
infection NN N
is VBZ N
needed VBN N
to TO N
design VB N
cancer NN N
prevention NN N
strategies NNS N
. . N

METHODS NNP N
A NNP N
cohort NN N
of IN N
795 CD p
adults NNS p
with IN p
preneoplastic JJ p
gastric JJ p
lesions NNS p
was VBD p
randomised VBN p
to TO p
receive VB i
anti-H JJ i
pylori NN i
treatment NN i
and/or JJ i
antioxidants NNS i
. . i

At IN N
the DT N
end NN N
of IN N
six CD N
years NNS N
of IN N
intervention NN N
, , N
those DT N
who WP N
did VBD N
not RB N
receive VB N
anti-H JJ N
pylori NN N
treatment NN N
were VBD N
offered VBN N
it PRP N
. . N

Gastric JJ N
biopsies NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
and CC N
at IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
years NNS N
. . N

A DT N
histopathology NN o
score NN o
was VBD N
utilised VBN N
to TO N
document VB N
changes NNS N
in IN N
gastric JJ o
lesions NNS o
. . o

Non-linear JJ N
mixed JJ N
models NNS N
were VBD N
used VBN N
to TO N
estimate VB N
the DT N
cumulative JJ N
effect NN N
of IN N
H NNP N
pylori JJ N
clearance NN N
on IN N
histopathology NN o
scores NNS o
adjusted VBN N
for IN N
follow VB N
up RP N
time NN N
, , N
interventions NNS N
, , N
and CC N
confounders NNS N
. . N

RESULTS NNP N
Ninety NNP p
seven CD p
per IN p
cent NN p
of IN p
subjects NNS p
were VBD p
H NNP o
pylori JJ o
positive JJ p
at IN p
baseline NN p
, , p
and CC p
53 CD p
% NN p
were VBD p
positive JJ p
at IN p
12 CD p
years NNS p
. . p

Subjects NNS N
accumulated JJ N
1703 CD N
person NN N
years NNS N
free JJ o
of IN o
infection NN o
. . o

A DT N
multivariate NN N
model NN N
showed VBD N
a DT N
significant JJ N
regression NN o
in IN o
histopathology NN o
score NN o
as IN N
a DT N
function NN N
of IN N
the DT N
square NN N
of IN N
H NNP o
pylori FW o
negative JJ o
time NN o
. . o

Subjects NNS N
who WP N
were VBD N
H NNP o
pylori JJ o
negative JJ N
had VBD N
14.8 CD N
% NN N
more JJR N
regression NN o
and CC N
13.7 CD N
% NN N
less JJR N
progression NN o
than IN N
patients NNS N
who WP N
were VBD N
positive JJ N
at IN N
12 CD N
years NNS N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
rate NN o
of IN o
healing NN o
of IN o
gastric JJ o
lesions NNS o
occurred VBD N
more RBR N
rapidly RB N
as IN N
years NNS o
free JJ o
of IN o
infection NN o
accumulated VBN N
, , N
and CC N
was VBD N
more RBR N
pronounced JJ N
in IN N
less RBR N
advanced JJ N
lesions NNS N
. . N

CONCLUSIONS NNP N
Preneoplastic NNP o
gastric JJ o
lesions NNS o
regress NN N
at IN N
a DT N
rate NN N
equal JJ N
to TO N
the DT N
square NN N
of IN N
time NN N
in IN N
patients NNS N
rendered JJ N
free JJ N
of IN N
H NNP N
pylori JJ N
infection NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
patients NNS p
with IN p
preneoplastic JJ p
gastric JJ p
lesions NNS p
should MD N
be VB N
treated VBN N
and CC N
cured VBN N
of IN N
their PRP$ N
H NNP o
pylori NN o
infection NN o
. . o

-DOCSTART- -X- O O

The DT N
prevalence NN N
of IN N
IgE NNP N
sensitization NN N
to TO N
formaldehyde VB N
in IN N
asthmatic JJ p
children NNS p
. . p

BACKGROUND NNP N
Formaldehyde NNP i
( ( N
FA NNP N
) ) N
is VBZ N
well RB N
documented VBN N
as IN N
a DT N
cause NN N
of IN N
occupational JJ o
asthma NN o
. . o

Recently RB N
, , N
attention NN N
has VBZ N
been VBN N
paid VBN N
to TO N
FA NNP N
as IN N
an DT N
allergen NN N
and CC N
a DT N
pollutant NN N
that WDT N
enhances VBZ o
allergic JJ o
sensitization NN o
. . o

We PRP N
have VBP N
investigated VBN N
the DT N
prevalence NN N
of IN N
FA-specific NNP N
IgE NNP N
in IN N
asthmatic JJ p
children NNS p
and CC N
the DT N
correlation NN N
between IN N
IgE NNP N
sensitization NN N
to TO N
FA NNP N
and CC N
the DT N
severity NN o
of IN o
asthma NN o
. . o

METHODS NNP N
One CD p
hundred CD p
and CC p
fifty-five JJ p
children NNS p
were VBD p
investigated VBN p
, , p
122 CD p
of IN p
them PRP p
asthmatic JJ p
and CC p
33 CD p
nonallergic NN p
. . p

Specific JJ o
IgE NNP o
against IN o
FA NNP o
was VBD N
measured VBN N
by IN N
CAP NNP i
RAST NNP i
. . i

In IN N
addition NN N
, , N
the DT N
patients NNS N
answered VBD N
a DT N
questionnaire NN o
, , N
containing VBG N
questions NNS N
on IN N
clinical JJ o
features NNS o
of IN o
their PRP$ o
asthma NN o
, , o
their PRP$ o
living NN o
conditions NNS o
, , o
and CC o
symptoms NNS o
of IN o
mucosal JJ o
irritation NN o
. . o

RESULTS NNP N
Of IN N
all PDT N
the DT N
subjects NNS N
assessed VBN N
, , N
FA-specific NNP o
IgE NNP o
was VBD N
detected VBN N
in IN N
only RB N
two CD N
asthmatics NNS N
, , N
and CC N
their PRP$ N
IgE NNP N
levels NNS N
of IN N
FA NNP N
were VBD N
low JJ N
( ( N
0.42 CD N
and CC N
0.46 CD N
UA/ml NNP N
) ) N
. . N

One CD N
of IN N
the DT N
two CD N
patients NNS N
with IN N
FA-specific NNP N
IgE NNP N
had VBD N
severe JJ o
asthma NN o
and CC o
frequent JJ o
symptoms NNS o
of IN o
mucosal JJ o
irritation NN o
, , N
but CC N
the DT N
other JJ N
had VBD N
mild VBN o
asthma NNS o
and CC o
only RB o
rare JJ o
symptoms NNS o
of IN o
mucosal JJ o
irritation NN o
. . o

CONCLUSIONS VB N
The DT N
prevalence NN N
of IN N
IgE NNP o
sensitization NN o
to TO N
FA NNP N
appears VBZ N
very RB N
low JJ N
in IN N
Japanese JJ p
children NNS p
, , N
whether IN N
or CC N
not RB N
they PRP N
have VBP N
asthma VBN N
. . N

Therefore RB N
, , N
it PRP N
appears VBZ N
likely JJ N
that IN N
FA NNP N
is VBZ N
not RB N
one CD N
of IN N
the DT N
major JJ N
allergens NNS N
causing VBG N
childhood NN p
asthma NN p
. . N

-DOCSTART- -X- O O

Is VBZ N
altered JJ N
central JJ N
pain NN N
processing NN N
related VBN N
to TO N
disease VB N
stage NN N
in IN N
chronic JJ p
pancreatitis NN p
patients NNS p
with IN p
pain NN p
? . N
An DT N
exploratory NN N
study NN N
. . N

BACKGROUND NNP N
The DT N
most RBS N
dominant JJ N
feature NN N
in IN N
chronic JJ N
pancreatitis NN N
is VBZ N
intense JJ N
abdominal JJ N
pain NN N
. . N

Changes NNS N
in IN N
spinal JJ N
and/or JJ N
supraspinal JJ N
central JJ N
nervous JJ N
system NN N
pain NN N
processing NN N
due JJ N
to TO N
visceral JJ N
nociceptive JJ N
input NN N
play VBP N
an DT N
important JJ N
role NN N
in IN N
this DT N
pain NN N
. . N

How WRB N
altered JJ i
pain NN i
processing NN i
is VBZ N
related VBN N
to TO N
disease VB N
stage NN N
still RB N
needs VBZ N
study NN N
. . N

METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
Sixty NNP p
chronic JJ p
pancreatitis NN p
patients NNS p
were VBD p
compared VBN p
to TO p
15 CD p
healthy JJ p
controls NNS p
. . p

Two CD N
subgroups NNS N
of IN N
pancreatitis NN N
patients NNS N
were VBD N
defined VBN N
based VBN N
on IN N
the DT N
M-ANNHEIM NNP N
severity NN N
index NN N
of IN N
chronic JJ N
pancreatitis NN N
; : N
i.e NN N
. . N

moderate JJ N
and CC N
severe JJ N
. . N

Pain VB o
detection NN o
and CC o
tolerance NN o
thresholds NNS o
for IN o
pressure NN o
and CC o
electric JJ o
stimuli NNS o
were VBD N
measured VBN N
in IN N
six CD N
selected VBN N
dermatomes NNS N
( ( N
C5 NNP N
, , N
T4 NNP N
, , N
T10 NNP N
, , N
L1 NNP N
, , N
L4 NNP N
and CC N
T10BACK NNP N
) ) N
. . N

In IN N
addition NN N
, , N
the DT N
conditioned VBN N
pain NN i
modulation NN i
response NN i
to TO N
cold VB i
pressor NN i
task NN i
was VBD N
determined VBN N
. . N

These DT N
measures NNS N
were VBD N
compared VBN N
between IN N
the DT N
healthy JJ N
controls NNS N
and CC N
chronic JJ N
pancreatitis NN N
patients NNS N
. . N

Severe NNP N
pancreatitis NN N
patients NNS N
showed VBD N
lower JJR N
pain NN o
thresholds NNS o
than IN N
moderate JJ N
pancreatitis NN N
patients NNS p
or CC N
healthy JJ N
volunteers NNS N
. . N

Healthy NNP N
controls VBZ N
showed VBD N
a DT N
significantly RB N
larger JJR N
conditioned VBN N
pain NN o
modulation NN o
response NN N
compared VBN N
to TO N
all DT N
chronic JJ N
pancreatitis NN N
patients NNS p
taken VBN N
together RB N
. . N

CONCLUSIONS/SIGNIFICANCE VB N
The DT N
present JJ N
study NN N
confirms VBZ N
that IN N
chronic JJ N
pancreatitis NN N
patients NNS N
show VBP N
signs NNS N
of IN N
altered JJ i
central JJ i
processing NN i
of IN N
nociception NN N
compared VBN N
to TO N
healthy JJ N
controls NNS N
. . N

The DT N
study NN N
further JJ N
suggests VBZ N
that IN N
these DT N
changes NNS N
, , N
i.e NN N
. . N

central JJ N
sensitization NN N
, , N
may MD N
be VB N
influenced VBN N
by IN N
disease NN N
stage NN N
. . N

These DT N
findings NNS N
underline VBP N
the DT N
need NN N
to TO N
take VB N
altered JJ N
central JJ N
pain NN N
processing NN N
into IN N
account NN N
when WRB N
managing VBG N
the DT N
pain NN N
of IN N
chronic JJ N
pancreatitis NN N
. . N

-DOCSTART- -X- O O

The DT N
Effects NNPS N
of IN N
Naltrexone NNP i
on IN N
Subjective NNP N
Response NNP N
to TO N
Methamphetamine NNP i
in IN N
a DT N
Clinical JJ p
Sample NN p
: : p
a DT N
Double-Blind NNP N
, , N
Placebo-Controlled NNP N
Laboratory NNP N
Study NNP N
. . N

Methamphetamine NNP i
( ( p
MA NNP p
) ) p
use NN p
disorder NN p
is VBZ N
a DT N
serious JJ N
psychiatric JJ N
condition NN N
for IN N
which WDT N
there EX N
are VBP N
no DT N
FDA-approved JJ N
medications NNS N
. . N

Naltrexone NNP i
( ( N
NTX NNP N
) ) N
is VBZ N
an DT N
opioid JJ N
receptor NN N
antagonist NN N
with IN N
demonstrated JJ N
efficacy NN N
, , N
albeit IN N
moderate JJ N
, , N
for IN N
the DT N
treatment NN N
of IN N
alcoholism NN N
and CC N
opioid JJ N
dependence NN N
. . N

Preclinical NNP N
and CC N
clinical JJ N
studies NNS N
suggest VBP N
that IN N
NTX NNP N
may MD N
be VB N
useful JJ N
for IN N
the DT N
treatment NN N
of IN N
MA NNP N
use NN N
disorder NN N
. . N

To TO N
inform VB N
treatment NN N
development NN N
, , N
we PRP N
conducted VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
, , N
placebo-controlled JJ N
human JJ N
laboratory NN N
study NN N
of IN N
NTX NNP N
. . N

Non-treatment-seeking JJ p
individuals NNS p
meeting VBG p
DSM-IV NNP p
criteria NNS p
for IN p
MA NNP p
abuse NN p
or CC p
dependence NN p
( ( p
n=30 NN p
) ) p
completed VBD p
two CD p
separate JJ p
5-day JJ p
inpatient NN p
stays NNS p
. . p

During IN N
each DT N
admission NN N
, , N
participants NNS N
completed VBD N
testing VBG N
sessions NNS N
comprised VBN N
of IN N
MA NNP i
cue-reactivity NN N
and CC N
intravenous JJ i
MA NNP i
administration NN i
( ( i
30 CD i
mg NN i
) ) i
after IN i
receiving VBG i
oral JJ i
NTX NNP i
( ( i
50 CD i
mg NN i
) ) i
or CC i
placebo NN i
for IN i
4 CD N
days NNS N
. . N

This DT N
study NN N
tested VBD N
the DT N
hypotheses NNS N
that WDT N
NTX NNP N
would MD N
( ( N
a DT N
) ) N
attenuate NN N
cue-induced JJ N
MA NNP N
craving NN N
, , N
and CC N
( ( N
b NN N
) ) N
reduce VB N
subjective JJ N
responses NNS N
to TO N
MA NNP N
administration NN N
. . N

Results NNP N
largely RB N
supported VBD N
the DT N
study NN N
hypotheses NNS N
such JJ N
that IN N
( ( N
a DT N
) ) N
NTX NNP N
significantly RB N
blunted VBD N
cue-induced JJ N
craving NN N
for IN N
MA NNP N
and CC N
( ( N
b NN N
) ) N
attenuated VBD N
several JJ N
of IN N
the DT N
hedonic JJ N
subjective JJ N
effects NNS N
of IN N
MA NNP N
, , N
including VBG N
craving NN N
, , N
during IN N
controlled VBN N
MA NNP N
administration NN N
and CC N
as IN N
compared VBN N
with IN N
placebo NN i
. . i

NTX NNP i
decreased VBD N
overall JJ o
subjective JJ o
ratings NNS o
of IN o
'crave JJ o
drug NN o
, , o
' '' o
'stimulated VBN o
, , o
' '' o
and CC o
'would MD o
like VB o
drug NN o
access NN o
, , o
' '' o
decreased VBD o
the DT N
the DT N
post-MA JJ N
administration NN N
timecourse NN o
of IN o
'anxious JJ o
' POS o
and CC o
increased VBD o
ratings NNS o
of IN o
'bad JJ o
drug NN o
effects NNS o
, , o
' '' o
as IN o
compared VBN N
with IN N
placebo NN i
. . i

These DT i
findings NNS N
support VBP N
a DT N
potential JJ N
mechanism NN N
of IN N
action NN N
by IN N
showing VBG N
that IN N
NTX NNP N
reduced VBD o
cue-induced JJ o
craving NN o
and CC o
subjective JJ o
responses NNS o
to TO o
MA NNP o
. . o

This DT N
is VBZ N
consistent JJ N
with IN N
positive JJ N
treatment NN N
studies NNS i
of IN i
NTX NNP i
for IN N
amphetamine JJ i
dependence NN i
, , N
as RB N
well RB N
as IN N
ongoing VBG N
clinical JJ N
trials NNS N
for IN N
MA NNP N
. . N

-DOCSTART- -X- O O

Treatment NN N
with IN N
the DT N
dipeptidyl JJ i
peptidase-4 JJ i
inhibitor NN i
vildagliptin NN i
improves VBZ N
fasting VBG N
islet-cell JJ N
function NN N
in IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

CONTEXT NNP N
Dipeptidyl NNP i
peptidase NN i
4 CD i
( ( i
DPP-4 NNP i
) ) i
inhibitors NNS i
are VBP N
proposed VBN N
to TO N
lower VB N
blood NN N
glucose NN N
in IN N
type NN p
2 CD p
diabetes NNS p
mellitus FW p
( ( p
T2DM NNP p
) ) p
by IN N
prolonging VBG N
the DT N
activity NN N
of IN N
the DT N
circulating NN N
incretins NNS N
, , N
glucose-dependent JJ N
insulinotropic NN N
polypeptide NN N
( ( N
GIP NNP N
) ) N
and CC N
glucagon-like JJ N
peptide NN N
1 CD N
( ( N
GLP-1 NNP N
) ) N
. . N

Consistent JJ N
with IN N
this DT N
mechanism NN N
of IN N
action NN N
, , N
DPP-4 NNP i
inhibitors NNS i
improve VBP N
glucose JJ N
tolerance NN N
after IN N
meals NNS N
by IN N
increasing VBG N
insulin NN N
and CC N
reducing VBG N
glucagon NN N
levels NNS N
in IN N
the DT N
plasma NN N
. . N

However RB N
, , N
DPP-4 NNP i
inhibitors NNS i
also RB N
reduce VB N
fasting VBG N
blood NN N
glucose NN N
, , N
an DT N
unexpected JJ N
effect NN N
because IN N
circulating VBG N
levels NNS N
of IN N
active JJ N
GIP NNP N
and CC N
GLP-1 NNP N
are VBP N
low JJ N
in IN N
the DT N
postabsorptive JJ N
state NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS o
of IN o
DPP-4 NNP o
inhibition NN o
on IN o
fasting VBG o
islet NN o
function NN o
. . o

DESIGN NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

SETTING VB N
The DT N
study NN N
was VBD N
performed VBN N
in IN N
General NNP p
Clinical NNP p
Research NNP p
Centers NNPS p
at IN p
two CD p
University NNP p
Hospitals NNP p
. . p

SUBJECTS NNP N
Forty-one JJ p
subjects NNS p
with IN p
T2DM NNP p
were VBD N
treated VBN N
with IN N
metformin NN i
or CC N
diet NN i
, , N
having VBG N
good JJ N
glycemic NNS N
control NN N
with IN N
glycosylated JJ N
hemoglobin NN N
values NNS N
of IN N
6.2-7.5 JJ N
% NN N
. . N

INTERVENTION JJ N
Subjects NNPS N
were VBD N
treated VBN N
with IN N
vildagliptin NN i
( ( N
50 CD N
mg NN N
twice RB N
daily RB N
) ) N
or CC N
placebo NN i
for IN N
3 CD N
months NNS N
, , N
followed VBN N
by IN N
a DT N
2-wk JJ N
washout NN N
. . N

Major JJ N
Outcome JJ N
Measure NN N
: : N
We PRP N
measured VBD N
insulin JJ o
secretion NN o
in IN o
response NN o
to TO o
iv VB o
glucose JJ o
and CC o
arginine JJ o
before NN N
and CC N
after IN N
treatment NN N
and CC N
after IN N
drug NN N
washout NN N
. . N

RESULTS CC N
There EX N
were VBD N
small JJ N
and CC N
comparable JJ N
reductions NNS N
in IN N
glycosylated JJ o
hemoglobin NN o
in IN N
both DT N
groups NNS N
over IN N
3 CD N
months NNS N
. . N

Vildagliptin NNP N
increased VBD N
fasting VBG N
GLP-1 NNP o
levels NNS N
in IN N
subjects NNS N
taking VBG N
metformin NN i
, , N
but CC N
not RB N
those DT N
managed VBN N
with IN N
diet JJ i
, , N
and CC N
raised VBD N
active JJ N
GIP NNP N
levels NNS N
slightly RB N
. . N

DPP-4 JJ i
inhibitor NN i
treatment NN N
improved VBD N
the DT N
acute JJ o
insulin NN o
and CC o
C-peptide JJ o
responses NNS o
to TO N
glucose VB N
( ( N
50 CD N
and CC N
100 CD N
% NN N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
increased VBD N
the DT N
slope NN N
of IN N
the DT N
C-peptide NNP o
response NN o
to TO N
glucose VB N
( ( N
33 CD N
% NN N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
. . N

CONCLUSION NNP N
Vildagliptin NNP i
improves VBZ N
islet JJ N
function NN N
in IN N
T2DM NNP N
under IN N
fasting VBG N
conditions NNS N
. . N

This DT N
suggests VBZ N
that IN N
DPP-4 NNP N
inhibition NN N
has VBZ N
metabolic JJ N
benefits NNS N
in IN N
addition NN N
to TO N
enhancing VBG N
meal-induced JJ N
GLP-1 NNP N
and CC N
GIP NNP N
activity NN N
. . N

-DOCSTART- -X- O O

Face NNP i
composite JJ i
effects NNS N
reveal VBP N
abnormal JJ N
face NN N
processing NN N
in IN N
Autism NNP p
spectrum NN p
disorders NNS p
. . p

Although IN N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
individuals NNS p
with IN p
an DT p
Autism NNP p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
process NN N
faces VBZ N
less RBR N
holistically RB N
than IN N
typically RB N
developing VBG N
controls NNS N
, , N
there EX N
are VBP N
few JJ N
direct JJ N
investigations NNS N
of IN N
this DT N
hypothesis NN N
. . N

This DT N
question NN N
was VBD N
addressed VBN N
before IN N
using VBG N
the DT N
composite JJ N
paradigm NN N
( ( N
Teunisse NNP N
, , N
J. NNP N
P. NNP N
, , N
& CC N
de FW N
Gelder NNP N
, , N
B NNP N
. . N

( ( N
2003 CD N
) ) N
. . N

Face NN N
processing NN N
in IN N
adolescents NNS N
with IN N
autistic JJ N
disorder NN N
: : N
The DT N
inversion NN N
and CC N
composite JJ N
effects NNS N
. . N

Brain NNP N
Cognition NNP N
, , N
52 CD N
( ( N
3 CD N
) ) N
, , N
285-294. JJ N
) ) N
. . N

The DT N
results NNS N
had VBD N
revealed VBN N
that IN N
adolescents NNS p
with IN p
ASDs NNP p
were VBD N
less RBR N
sensitive JJ N
than IN N
controls NNS N
to TO N
the DT N
misalignment NN N
of IN N
face NN N
parts NNS N
and CC N
it PRP N
was VBD N
concluded VBN N
their PRP$ N
face NN N
processing NN N
was VBD N
less RBR N
holistic JJ N
. . N

However RB N
, , N
because IN N
of IN N
shortcomings NNS N
of IN N
the DT N
design NN N
, , N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
distinguish VB N
whether IN N
individuals NNS p
with IN p
Autism NNP p
processed VBD N
both DT N
aligned VBN N
and CC N
misaligned VBN N
composites NNS N
in IN N
a DT N
part-based JJ N
fashion NN N
, , N
or CC N
both DT N
in IN N
a DT N
holistic JJ N
fashion NN N
. . N

We PRP N
compared VBN N
adolescents NNS i
with IN i
ASDs NNP i
to TO p
controls VB i
matched VBN p
on IN p
sex NN p
, , p
age NN p
and CC p
IQ NNP p
on IN N
a DT N
more RBR N
complete JJ N
version NN N
of IN N
the DT N
composite JJ i
paradigm NN i
. . i

The DT o
results NNS o
indicate VBP o
that IN o
individuals NNS o
with IN o
ASDs NNP o
, , o
like IN o
controls NNS o
, , o
experience NN o
interference NN o
from IN o
facial JJ o
features NNS o
that IN o
they PRP o
are VBP o
told VBN o
to TO o
ignore VB o
. . o

However RB o
, , o
while IN o
such JJ o
interference NN o
is VBZ o
released VBN o
for IN o
controls NNS o
if IN o
parts NNS o
of IN o
face NN o
composites NNS o
are VBP o
misaligned VBN o
, , o
individuals NNS o
with IN o
ASDs NNP o
show VBP o
comparable JJ o
interference NN o
from IN o
irrelevant JJ o
parts NNS o
regardless RB o
of IN o
alignment NN o
. . o

Two CD o
different JJ o
interpretations NNS o
are VBP o
discussed VBN o
, , o
both DT o
compatible JJ o
with IN o
the DT o
idea NN o
that WDT o
perceptual JJ o
and CC o
or CC o
attentional JJ o
abnormalities NNS o
in IN o
ASDs NNP o
result NN o
in IN o
a DT o
diminished JJ o
level NN o
of IN o
expertise NN o
for IN o
faces VBZ o
. . o

-DOCSTART- -X- O O

Norfloxacin NNP i
modulates VBZ p
the DT p
inflammatory JJ p
response NN p
and CC p
directly RB p
affects VBZ p
neutrophils NNS p
in IN p
patients NNS p
with IN p
decompensated JJ p
cirrhosis NN p
. . p

BACKGROUND NNP N
& CC N
AIMS NNP N
Patients NNPS p
with IN p
cirrhosis NN p
undergoing VBG p
selective JJ p
intestinal JJ p
decontamination NN p
with IN p
norfloxacin JJ i
show NN N
a DT N
reduction NN N
in IN N
serum JJ N
cytokine NN N
levels NNS N
, , N
probably RB N
because IN N
of IN N
a DT N
combined JJ N
effect NN N
of IN N
norfloxacin NN i
on IN N
bowel NN N
flora NNS N
and CC N
neutrophils NNS N
. . N

METHODS NNP N
Thirty-one CD p
patients NNS p
with IN p
cirrhosis NN p
receiving VBG p
norfloxacin NN i
( ( p
400 CD p
mg/day NN p
) ) p
were VBD p
included VBN p
. . p

Blood NNP N
samples NNS N
were VBD N
collected VBN N
at IN N
0.5-4 JJ N
hours NNS N
( ( N
peak JJ N
samples NNS N
group NN N
, , N
n RB N
= VBZ N
47 CD N
) ) N
and CC N
at IN N
22-24 JJ N
hours NNS N
( ( N
trough IN N
samples NNS N
group NN N
, , N
n RB N
= VBZ N
84 CD N
) ) N
after IN N
dose NN N
. . N

Fifty-nine JJ p
ascitic JJ p
fluid NN p
samples NNS p
were VBD N
obtained VBN N
. . N

Single NNP N
doses NNS N
of IN N
norfloxacin NN i
and CC i
trimethoprim/sulfamethoxazole NN i
were VBD N
administered VBN N
to TO N
13 CD N
and CC N
5 CD N
patients NNS N
, , N
respectively RB N
, , N
( ( N
temporal JJ N
profile NN N
group NN N
) ) N
and CC N
samples NNS N
were VBD N
collected VBN N
at IN N
0 CD N
, , N
0.5 CD N
, , N
1 CD N
, , N
1.5 CD N
, , N
2 CD N
, , N
4 CD N
, , N
and CC N
24 CD N
hours NNS N
. . N

Norfloxacin NNP i
, , i
trimethoprim/sulfamethoxazole NN i
, , i
cytokines NNS i
, , i
nitric JJ i
oxide NN i
, , N
expression NN N
levels NNS N
of IN N
nuclear JJ N
factor NN N
( ( N
NF NNP N
) ) N
-kappaB NN N
and CC N
inhibitor NN N
of IN N
NF-kappaB NNP N
( ( N
IkB-alpha NNP N
) ) N
, , N
neutrophil JJ N
oxidative JJ N
burst NN N
, , N
and CC N
rate NN N
of IN N
apoptotic JJ N
events NNS N
were VBD N
determined VBN N
. . N

RESULTS NNP N
All NNP N
samples NNS N
were VBD N
bacterial JJ N
DNA NNP N
negative NN N
and CC N
had VBD N
no DT N
significant JJ N
levels NNS N
of IN N
lipopolysaccharide NN N
. . N

Serum NNP o
and CC o
ascitic JJ o
levels NNS o
of IN o
tumor NN o
necrosis NN o
factor-alpha JJ o
, , o
interferon-gamma JJ o
, , o
interleukin-12 JJ o
, , o
and CC o
nitric JJ o
oxide NN o
were VBD N
significantly RB N
lower JJR N
in IN N
peak NN N
than IN N
in IN N
trough JJ N
samples NNS N
. . N

A DT N
correlation NN N
was VBD N
present JJ N
between IN N
serum NN o
norfloxacins NNS o
concentrations NNS o
and CC o
tumor NN o
necrosis NN o
factor-alpha NN o
( ( N
r JJ N
= NNP N
-0.68 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
interferon-gamma JJ o
( ( N
r JJ N
= NNP N
-0.66 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
interleukin-12 JJ o
( ( N
r JJ N
= NNP N
-0.66 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
nitric JJ o
oxide NN o
( ( N
r JJ N
= NNP N
-0.68 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Serum NNP o
norfloxacin NN o
's POS o
highest JJS o
concentrations NNS o
( ( N
1 CD N
+/- JJ N
0.5 CD N
microg/mL NN N
) ) N
were VBD N
achieved VBN N
at IN N
1-2 JJ N
hours NNS N
and CC N
concurred VBN N
in IN N
time NN N
with IN N
the DT N
lower JJR N
levels NNS N
of IN N
cytokines NNS o
and CC o
nitric JJ o
oxide NN o
. . o

Intracellular NNP o
norfloxacin NN o
's POS o
highest JJS o
levels NNS o
( ( N
2 CD N
+/- JJ N
1 CD N
microg/mL/10 NN N
( ( N
7 CD N
) ) N
cells NNS N
) ) N
were VBD N
observed VBN N
at IN N
2 CD N
hours NNS N
and CC N
concurred VBN N
with IN N
a DT N
lower JJR N
NF-kappaB JJ N
expression NN N
, , N
a DT N
reduced JJ N
anion NN N
superoxide NN N
generation NN N
, , N
and CC N
apoptotic JJ N
rate NN N
in IN N
response NN N
to TO N
phorbol VB N
myristate JJ N
acetate NN N
. . N

Trimethoprim/sulfamethoxazole NNP i
did VBD N
not RB N
significantly RB N
modulate VB N
cytokine JJ o
expression NN o
. . o

CONCLUSIONS NNP N
Norfloxacin NNP i
but CC N
not RB N
trimethoprim/sulfamethoxazole JJ i
modulates NNS N
inflammatory JJ N
response NN N
and CC N
directly RB N
affects VBZ N
neutrophils NNS N
in IN N
patients NNS p
with IN p
cirrhosis NN p
. . p

-DOCSTART- -X- O O

Treatment NN N
of IN N
men NNS p
with IN p
flat JJ p
( ( p
FC NNP p
) ) p
or CC p
acuminata NN p
( ( p
CA NNP p
) ) p
condylomata NN p
with IN p
interferon JJ i
alpha-2a NN i
. . i

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
CO2 NNP i
laser NN i
vaporization NN i
, , i
5-fluorouracil JJ i
5 CD i
% NN i
( ( i
5-FU JJ i
) ) i
topical JJ i
application NN i
and CC i
Interferon NNP i
alpha-2a NN i
( ( i
IFA NNP i
alpha-2a NN i
) ) i
in IN N
the DT N
treatment NN N
of IN N
C.A NNP p
. . p

or CC p
F.C NNP p
. . p

of IN p
the DT p
male JJ p
genital JJ p
tract NN p
. . p

From IN p
March NNP p
1986 CD p
to TO p
September NNP p
1991 CD p
, , p
1372 CD p
men NNS p
, , p
sexual JJ p
partners NNS p
of IN p
women NNS p
with IN p
F.C NNP p
. . p

or CC p
C.A NNP p
. . p

or CC p
cervical JJ p
intraepithelial JJ p
neoplasia NN p
, , p
were VBD p
submitted VBN p
to TO p
peoscopy VB i
. . i

One CD p
thousand NN p
and CC p
nineteen JJ p
( ( p
74.27 CD p
% NN p
) ) p
men NNS p
presented VBN p
with IN p
various JJ p
penile JJ p
lesions NNS p
caused VBN p
by IN p
HPV NNP p
( ( p
histologically RB p
confirmed VBN p
) ) p
; : p
of IN N
these DT N
505 CD p
were VBD p
treated VBN p
for IN p
C.A NNP p
. . p

or CC p
F.C NNP p
. . p

or CC p
a DT p
combination NN p
of IN p
F.C NNP p
. . p

and CC p
C.A NNP p
. . p

The DT N
best JJS N
treatment NN N
modalities NNS N
, , N
irrespective NN N
of IN N
the DT N
kind NN N
of IN N
lesion NN N
, , N
were VBD N
found VBN N
to TO N
be VB N
the DT N
combination NN N
of IN N
5-FU JJ i
plus JJ i
IFN NNP i
alpha-2a NN i
( ( N
high JJ N
dose NN N
) ) N
( ( N
98.27 CD N
% NN N
) ) N
, , N
the DT N
combination NN N
of IN N
CO2 NNP i
laser NN i
vaporization NN i
plus CC i
5-FU JJ i
plus JJ i
IFN NNP i
alpha-2a NN i
( ( i
high JJ i
dose NN i
) ) i
( ( i
93.93 CD i
% NN i
) ) i
and CC N
the DT N
combination NN i
of IN i
CO2 NNP i
laser NN i
vaporization NN i
plus CC i
5-FU JJ i
( ( N
87.23 CD N
% NN N
) ) N
. . N

In IN N
conclusion NN N
we PRP N
believe VBP N
that IN N
IFN NNP i
alpha-2a NN i
can MD N
be VB N
used VBN N
with IN N
excellent JJ N
results NNS N
as IN N
first JJ N
line NN N
treatment NN N
in IN N
combination NN N
with IN N
CO2 NNP i
laser NN i
vaporization NN i
or/plus IN i
5-FU JJ i
in IN N
patients NNS N
with IN N
C.A NNP p
. . p

or CC p
F.C NNP p
. . p

or CC p
combined VBN p
condylomata NNS p
. . N

-DOCSTART- -X- O O

Positive JJ N
impact NN N
of IN N
crisis NN i
resource NN i
management NN i
training NN i
on IN N
no-flow JJ N
time NN N
and CC N
team NN N
member NN N
verbalisations NNS N
during IN N
simulated JJ i
cardiopulmonary JJ i
resuscitation NN i
: : i
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

OBJECTIVES UH N
To TO N
evaluate VB N
the DT N
impact NN N
of IN N
video-based JJ i
interactive JJ i
crisis NN i
resource NN i
management NN i
( ( i
CRM NNP i
) ) i
training VBG i
on IN N
no-flow JJ o
time NN o
( ( o
NFT NNP o
) ) o
and CC N
on IN N
proportions NNS N
of IN N
team NN o
member NN o
verbalisations NNS o
( ( o
TMV NNP o
) ) o
during IN N
simulated VBN i
cardiopulmonary JJ i
resuscitation NN i
( ( i
CPR NNP i
) ) i
. . N

Further UH N
, , N
to TO N
investigate VB N
the DT N
link NN N
between IN N
team NN N
leader NN N
verbalisation NN N
accuracy NN N
and CC N
NFT NNP N
. . N

METHODS NNP N
The DT N
randomised VBN N
controlled VBD N
study NN N
was VBD N
embedded VBN N
in IN N
the DT N
obligatory NN N
advanced VBD N
life NN N
support NN N
( ( N
ALS NNP N
) ) N
course NN N
for IN N
final-year JJ p
medical JJ p
students NNS p
. . p

Students NNS p
( ( p
176 CD p
; : p
25.35?1.03 CD p
years NNS p
, , p
63 CD p
% NN p
female NN p
) ) p
were VBD N
alphabetically RB N
assigned VBN N
to TO p
44 CD p
four-person JJ p
teams NNS p
that WDT N
were VBD N
then RB N
randomly RB N
( ( N
computer-generated JJ N
) ) N
assigned VBN N
to TO N
either DT i
CRM NNP i
intervention NN i
( ( N
n=26 JJ N
) ) N
, , N
receiving VBG i
interactive JJ i
video-based JJ i
CRM-training NN i
, , i
or CC i
to TO i
control VB i
intervention NN i
( ( i
n=18 JJ i
) ) i
, , i
receiving VBG i
an DT i
additional JJ i
ALS-training NN i
. . i

Primary JJ N
outcomes NNS N
were VBD o
NFT NNP o
and CC o
proportions NNS o
of IN o
TMV NNP o
, , o
which WDT N
were VBD N
subdivided VBN N
into IN N
eight CD N
categories NNS N
: : N
four CD N
team NN N
leader NN N
verbalisations NNS N
( ( N
TLV NNP N
) ) N
with IN N
different JJ N
accuracy NN N
levels NNS N
and CC N
four CD N
follower JJR N
verbalisation NN N
categories NNS N
( ( N
FV NNP N
) ) N
. . N

Measurements NNS N
were VBD N
made VBN N
of IN p
all DT p
groups NNS p
administering VBG p
simulated JJ p
adult NN p
CPR NNP p
. . p

RESULTS NNP o
NFT NNP o
rates NNS o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
CRM-training NNP N
group NN N
( ( N
31.4?6.1 CD N
% NN N
vs. FW N
36.3?6.6 CD N
% NN N
, , N
p=0.014 NN N
) ) N
. . N

Proportions NNS N
of IN N
all DT N
TLV NNP o
categories NNS o
were VBD N
higher JJR N
in IN N
the DT N
CRM-training NNP N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Differences NNS N
in IN N
FV NNP N
were VBD N
only RB N
found VBN N
for IN N
one CD N
category NN N
( ( N
unsolicited JJ N
information NN N
) ) N
( ( N
p=0.012 NN N
) ) N
. . N

The DT N
highest JJS o
correlation NN o
with IN o
NFT NNP o
was VBD o
found VBN N
for IN N
high JJ o
accuracy NN o
TLV NNP o
( ( o
direct JJ o
orders NNS N
) ) N
( ( N
p=0.06 NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
inclusion NN N
of IN N
CRM NNP i
training NN i
in IN i
undergraduate JJ N
medical JJ N
education NN N
reduces NNS N
NFT NNP N
in IN N
simulated JJ i
CPR NNP i
and CC i
improves VBZ N
TLV NNP N
proportions NNS N
during IN i
simulated JJ i
CPR NNP i
. . i

Further NNP i
research NN N
will MD N
test VB N
how WRB N
these DT N
results NNS N
translate VBP N
into IN N
clinical JJ N
performance NN N
and CC N
patient JJ N
outcome NN N
. . N

-DOCSTART- -X- O O

Determinants NNS N
of IN N
improvement NN N
in IN N
walking VBG o
capacity NN o
among IN N
individuals NNS p
with IN p
chronic JJ p
stroke NN p
following VBG N
a DT N
multi-dimensional JJ i
exercise NN i
program NN i
. . i

OBJECTIVE NNP N
To TO N
identify VB N
the DT N
determinants NNS N
of IN N
improvement NN N
in IN N
walking VBG o
capacity NN o
following VBG N
therapeutic JJ i
exercise NN i
in IN N
chronic JJ p
stroke NN p
survivors NNS p
. . p

DESIGN VB N
A DT N
secondary JJ N
analysis NN N
of IN N
data NNS N
obtained VBN N
from IN N
a DT N
prospective JJ N
, , N
single-blind JJ N
, , N
randomized VBN N
controlled VBN N
intervention NN N
trial NN N
. . N

SUBJECTS JJ N
Sixty-three JJ p
community-dwelling JJ p
individuals NNS p
( ( p
mean JJ p
age NN p
= VBD p
65 CD p
years NNS p
, , p
age NN p
range NN p
= NNP p
50-87 CD p
years NNS p
) ) p
with IN p
a DT p
chronic JJ p
stroke NN p
( ( p
post-stroke JJ p
duration NN p
: : p
mean JJ p
= VBP p
5.5 CD p
years NNS p
, , p
range NN p
= NNP p
1-28 CD p
years NNS p
) ) p
. . p

METHODS JJ N
Subjects NNPS N
were VBD N
randomized VBN N
into IN N
a DT N
leg JJ i
exercise NN i
group NN N
( ( N
n JJ N
= NNP N
32 CD N
) ) N
or CC N
an DT N
arm JJ i
exercise NN i
group NN N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
. . N

Subjects NNS N
in IN N
each DT N
group NN N
underwent VBD N
3 CD N
1-hour JJ N
exercise NN i
sessions NNS i
per IN N
week NN N
for IN N
19 CD N
weeks NNS N
. . N

Walking VBG o
capacity NN o
, , o
cardiorespiratory NN o
fitness NN o
, , o
isometric JJ o
knee NN o
extensor NN o
muscle NN o
strength NN o
, , o
balance NN o
ability NN o
, , o
and CC o
balance NN o
confidence NN o
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
the DT N
interventions NNS N
. . N

Multiple JJ N
regression NN N
analysis NN N
was VBD N
performed VBN N
to TO N
identify VB N
the DT N
determinants NNS N
of IN N
improvement NN N
in IN N
walking VBG N
capacity NN N
. . N

RESULTS VB N
After IN N
controlling VBG N
for IN N
age NN N
, , N
gender NN N
, , N
post-stroke JJ N
duration NN N
, , N
and CC N
baseline NN N
walking NN o
capacity NN o
, , o
gain NN o
in IN o
paretic JJ o
leg NN o
muscle NN o
strength NN o
and CC o
peak NN o
oxygen NN o
consumption NN o
remained VBD o
independently RB o
associated VBN N
with IN N
gain NN o
in IN o
walking VBG o
capacity NN o
( ( N
R2 NNP N
= NNP N
0.229 CD N
) ) N
. . N

CONCLUSION NNP N
Enhancement NNP N
of IN N
cardiorespiratory NN N
fitness NN N
and CC N
paretic JJ N
leg NN N
muscle NN N
strength NN N
are VBP N
both DT N
significant JJ N
determinants NNS N
in IN N
improving VBG N
walking JJ N
capacity NN N
among IN N
chronic JJ N
stroke NN N
survivors NNS N
. . N

However RB N
, , N
the DT N
rather RB N
weak JJ N
relationship NN N
( ( N
R2 NNP N
= NNP N
0.229 CD N
) ) N
indicates VBZ N
that IN N
other JJ N
factors NNS N
not RB N
measured VBN N
in IN N
this DT N
study NN N
may MD N
also RB N
contribute VB N
to TO N
the DT N
improvement NN N
in IN N
walking VBG N
capacity NN N
. . N

-DOCSTART- -X- O O

Calcitriol NNP i
for IN N
bone NN N
disease NN N
in IN N
patients NNS p
with IN p
cirrhosis NN p
of IN p
the DT p
liver NN p
. . p

BACKGROUND NNP N
Osteoporosis NNP N
is VBZ N
associated VBN N
with IN N
cirrhosis NN N
of IN N
the DT N
liver NN N
, , N
but CC N
the DT N
effects NNS N
of IN N
therapy NN N
for IN N
osteoporosis NN o
associated VBN N
with IN N
cirrhosis NN N
are VBP N
still RB N
controversial JJ N
. . N

METHODS NNP N
We PRP N
evaluated VBD N
the DT N
effects NNS o
of IN N
calcitriol NN i
( ( i
1alpha,25-dihydroxyvitamin JJ i
D3 NNP i
) ) i
on IN N
bone NN o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
in IN N
76 CD p
patients NNS p
( ( p
26 CD p
men NNS p
and CC p
50 CD p
women NNS p
) ) p
with IN p
cirrhosis NN p
who WP N
were VBD N
assigned VBN N
randomly RB i
to TO i
receive VB i
calcitriol NN i
( ( i
0.5 CD i
mg NN i
twice RB i
per IN i
day NN i
) ) i
or CC i
not RB i
. . i

The DT N
BMD NNP o
of IN o
the DT o
lumbar NN o
vertebrae NN o
was VBD N
measured VBN i
by IN i
dual-energy JJ o
X-ray JJ o
absorptiometry NN o
at IN i
least JJS i
twice RB i
, , i
12-57 JJ i
months NNS i
apart RB i
. . i

RESULTS VB N
For IN p
men NNS p
, , p
the DT p
mean JJ p
annual JJ p
change NN o
in IN o
BMD NNP o
was VBD p
1.1 CD p
% NN p
in IN p
the DT p
treated JJ p
group NN p
and CC p
-0.4 CD p
% NN p
in IN p
the DT p
control NN p
group NN p
. . p

The DT N
median JJ N
( ( N
25th CD N
and CC N
75th CD N
percentiles NNS N
) ) N
annual JJ o
change NN o
in IN o
BMD NNP o
was VBD N
0.6 CD N
( ( N
-0.1 NN N
, , N
2.1 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
group NN N
and CC N
-1.4 NNP N
( ( N
-1.9 NNP N
, , N
1.6 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
difference NN N
in IN N
the DT N
median JJ N
annual JJ N
change NN N
between IN N
the DT N
two CD p
groups NNS p
was VBD N
significant JJ N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
. . N

For IN p
women NNS p
, , p
the DT p
mean JJ p
annual JJ p
change NN o
in IN o
BMD NNP o
was VBD p
-0.5 JJ p
% NN p
in IN p
the DT p
treated JJ p
group NN p
and CC p
-2.3 CD p
% NN p
in IN p
the DT p
control NN p
group NN p
. . p

The DT N
median JJ N
( ( N
25th CD N
and CC N
75th CD N
percentiles NNS N
) ) N
annual JJ N
change NN N
in IN N
BMD NNP o
was VBD N
-0.5 NNP N
( ( N
-1.8 NNP N
, , N
1.3 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
group NN N
and CC N
-1.5 NNP N
( ( N
-3.8 NNP N
, , N
-0.7 NNP N
% NN N
) ) N
in IN N
the DT N
control NN p
group NN p
. . p

This DT N
difference NN N
was VBD N
significant JJ N
( ( N
P NNP N
= NNP N
0.011 CD N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
calcitriol NN N
can MD N
prevent VB N
bone JJ o
loss NN o
and CC N
, , N
therefore RB N
, , N
may MD N
be VB N
useful JJ N
for IN N
the DT N
treatment NN N
of IN N
bone NN N
disease NN N
in IN N
patients NNS p
with IN p
cirrhosis NN p
of IN p
the DT p
liver NN p
. . p

-DOCSTART- -X- O O

Carbon NNP i
dioxide NN i
insufflation NN i
in IN N
open-chamber JJ N
cardiac JJ N
surgery NN N
: : N
a DT N
double-blind NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
of IN N
neurocognitive JJ N
effects NNS N
. . N

OBJECTIVE IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
first RB N
to TO N
analyze VB N
neurocognitive JJ o
outcomes NNS o
of IN N
patients NNS p
after IN p
open-chamber JJ p
cardiac JJ p
surgery NN p
to TO N
determine VB N
whether IN N
carbon NN i
dioxide NN i
pericardial JJ i
insufflation NN i
reduces NNS N
incidence NN N
of IN N
neurocognitive JJ o
decline NN o
( ( N
primary JJ N
end NN N
point NN N
) ) N
as IN N
measured VBN N
6 CD N
weeks NNS N
postoperatively RB N
and CC N
second JJ N
to TO N
assess VB N
the DT N
utility NN N
of IN N
carbon NN i
dioxide NN i
insufflation NN i
in IN N
cardiac JJ N
chamber NN N
deairing NN N
as IN N
assessed VBN N
by IN N
transesophageal JJ N
echocardiography NN N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
compared VBN N
neurocognitive JJ N
outcomes NNS N
in IN N
patients NNS p
undergoing VBG p
open-chamber JJ p
( ( p
left-sided JJ p
) ) p
cardiac NN p
surgery NN p
who WP p
were VBD p
assigned VBN p
carbon NN i
dioxide NN i
insufflation NN i
or CC i
placebo NN i
( ( p
control VB p
group NN p
) ) p
in IN p
addition NN p
to TO p
standardized VB p
mechanical JJ p
deairing VBG p
maneuvers NNS p
. . p

RESULTS NNP N
One CD p
hundred VBD p
twenty-five JJ p
patients NNS p
underwent JJ p
surgery NN p
and CC N
were VBD N
randomly RB N
allocated VBN N
. . N

Neurocognitive JJ N
testing NN N
showed VBD N
no DT N
clinically RB N
significant JJ N
differences NNS N
in IN N
z NN o
scores NNS o
between IN N
preoperative JJ N
and CC N
postoperative JJ N
testing NN N
. . N

Linear JJ N
regression NN N
was VBD N
used VBN N
to TO N
identify VB N
factors NNS N
associated VBN N
with IN N
neurocognitive JJ N
decline NN N
. . N

Factors NNS p
most RBS p
strongly RB p
associated VBN p
with IN p
neurocognitive JJ p
decline NN p
were VBD p
hypercholesterolemia JJ o
, , o
aortic JJ o
atheroma NN o
grade NN o
, , o
and CC o
coronary JJ o
artery NN o
disease NN o
. . o

There EX N
was VBD N
significantly RB N
more JJR N
intracardiac JJ o
gas NN o
noted VBD N
on IN N
intraoperative JJ N
transesophageal NN N
echocardiography NN N
in IN N
all DT N
cardiac JJ N
chambers NNS N
( ( N
left JJ N
atrium NN N
, , N
left VBD N
ventricle NN N
, , N
and CC N
aorta NN N
) ) N
at IN N
all DT N
measured VBN N
times NNS N
( ( N
after IN N
crossclamp NN N
removal NN N
, , N
during IN N
weaning VBG N
from IN N
cardiopulmonary JJ N
bypass NN N
, , N
and CC N
at IN N
declaration NN N
of IN N
adequate JJ N
deairing NN N
by IN N
the DT N
anesthetist NN N
) ) N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
carbon NN N
dioxide NN N
group NN N
( ( N
P NNP N
< NNP N
.04 NNP N
) ) N
. . N

Deairing VBG o
time NN o
was VBD N
also RB N
significantly RB N
longer RBR N
in IN N
the DT N
control NN N
group NN N
( ( N
12 CD N
minutes NNS N
[ VBP N
interquartile JJ N
range NN N
, , N
9-18 CD N
] NNP N
versus NN N
9 CD N
minutes NNS N
[ VBP N
interquartile JJ N
range NN N
, , N
7-14 JJ N
minutes NNS N
] VBP N
; : N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Carbon NNP i
dioxide IN i
pericardial JJ N
insufflation NN N
in IN N
open-chamber JJ N
cardiac JJ N
surgery NN N
does VBZ N
not RB N
affect VB N
postoperative JJ N
neurocognitive JJ o
decline NN o
. . o

The DT p
most RBS p
important JJ p
factor NN p
is VBZ p
atheromatous JJ p
vascular JJ p
disease NN p
. . p

-DOCSTART- -X- O O

Predicting VBG N
the DT N
effect NN N
of IN N
anthelmintic JJ i
treatment NN i
on IN N
milk NN o
production NN o
of IN o
dairy NN o
cattle NNS o
in IN p
Canada NNP p
using VBG N
an DT N
Ostertagia NNP N
ostertagi NN N
ELISA NNP N
from IN N
individual JJ N
milk NN N
samples NNS N
. . N

Gastrointestinal NNP p
nematodes NNS p
, , p
such JJ p
as IN p
Ostertagia NNP p
ostertagi NN p
and CC p
several JJ p
species NNS p
of IN p
Cooperia NNP p
, , p
are VBP p
ubiquitous JJ p
in IN p
temperate NN p
climates NNS p
and CC p
have VBP p
been VBN p
shown VBN p
to TO p
have VB p
detrimental JJ p
effects NNS p
on IN p
production NN p
in IN p
adult NN p
dairy NN p
cattle NNS p
. . p

A DT N
published VBN N
meta-analysis NN N
demonstrated VBD N
that IN N
overall JJ N
, , N
producers NNS N
lose VBP p
approximately RB p
0.35 CD p
kg NNS p
of IN p
milk NN p
per IN p
parasitized VBN p
cow NN p
per IN p
day NN p
. . p

Enzyme-linked JJ i
immunosorbent NN i
assays NNS i
( ( N
ELISAs NNP N
) ) N
have VBP N
the DT N
ability NN N
to TO N
quantify VB N
nematode JJ N
infections NNS N
in IN N
cattle NNS N
, , N
and CC N
thus RB N
, , N
could MD N
be VB N
used VBN N
to TO N
estimate VB N
the DT N
amount NN N
of IN N
milk NN N
production NN N
loss NN N
due JJ N
to TO N
differing VBG N
levels NNS N
of IN N
parasitism NN N
at IN N
the DT N
individual JJ N
cow NN N
level NN N
. . N

ELISA JJ p
results NNS p
from IN p
individual JJ p
cow NN p
milk NN p
samples NNS p
were VBD p
used VBN p
to TO p
predict VB p
milk NN p
production NN p
response NN p
following VBG N
a DT N
randomized JJ N
anthelmintic JJ N
treatment NN N
in IN N
a DT N
large JJ N
field NN N
trial NN N
. . N

To TO N
increase VB N
statistical JJ N
power NN N
, , N
the DT N
data NNS N
collected VBN N
from IN N
this DT N
field NN N
trial NN N
was VBD N
pooled VBN N
with IN N
data NNS N
from IN N
two CD N
other JJ N
published VBN N
field NN N
trials NNS N
to TO N
form VB N
an DT N
individual JJ N
patient NN N
data NNS N
meta-analysis NN N
( ( N
IPDMA NNP N
) ) N
. . N

The DT N
ability NN N
to TO N
predict VB N
the DT N
effect NN N
of IN N
anthelmintic JJ N
treatment NN N
on IN N
milk NN N
production NN N
depends VBZ N
on IN N
the DT N
level NN N
of IN N
parasitism NN N
quantified VBN N
by IN N
an DT N
ELISA NNP N
measuring NN N
milk NN o
antibodies NNS o
against IN N
O. NNP N
ostertagi NN N
, , N
and CC N
reported VBD N
as IN N
optical JJ o
density NN o
ratios NNS o
( ( o
ODRs NNP o
) ) o
. . N

Therefore RB N
, , N
the DT N
estimates NNS N
from IN N
the DT N
interaction NN N
between IN N
ODR NNP N
and CC N
treatment NN N
on IN N
milk NN N
production NN N
were VBD N
used VBN N
to TO N
determine VB N
how WRB N
well RB N
the DT N
ODR NNP N
predicted VBD N
the DT N
response NN N
of IN N
the DT N
treatment NN N
. . N

It PRP N
was VBD N
anticipated VBN N
that IN N
the DT N
relationship NN N
between IN N
milk NN o
production NN o
and CC N
ODR NNP o
was VBD N
unlikely JJ N
to TO N
be VB N
linear JJ N
, , N
so IN N
fractional JJ N
polynomials NNS N
were VBD N
applied VBN N
to TO N
the DT N
continuous JJ N
ODR NNP o
values NNS o
. . o

The DT N
interaction NN N
in IN N
the DT N
field NN N
trial NN N
showed VBD N
a DT N
trend NN N
( ( N
p=0.138 NN N
) ) N
toward IN N
a DT N
beneficial JJ N
treatment NN N
effect NN N
when WRB N
the DT N
individual JJ N
ODR NNP o
values NNS o
, , N
measured VBN N
in IN N
late JJ N
lactation NN N
and CC N
using VBG N
Svanovir NNP N
( ( N
? . N
) ) N
, , N
were VBD N
greater JJR N
than IN N
0.12 CD N
. . N

When WRB N
individual JJ N
data NNS N
from IN N
two CD N
other JJ N
similar JJ N
studies NNS N
were VBD N
included VBN N
in IN N
an DT N
IPDMA NNP N
, , N
the DT N
interaction NN N
terms NNS N
became VBD N
statistically RB N
significant JJ N
( ( N
p=0.009 NN N
) ) N
indicating NN N
that IN N
there EX N
is VBZ N
a DT N
beneficial JJ N
treatment NN N
effect NN N
when WRB o
ODR NNP o
values NNS o
are VBP N
slightly RB N
elevated VBN N
. . N

A DT N
graph NN N
was VBD N
used VBN N
to TO N
demonstrate VB N
the DT N
treatment NN N
effect NN N
( ( N
the DT N
estimated VBN N
difference NN N
of IN N
kg/cow/day NN N
of IN N
milk NN N
yield NN N
between IN N
the DT N
treated VBN N
and CC N
placebo JJ N
cows NNS N
) ) N
, , N
with IN N
95 CD N
% NN N
confidence NN N
intervals NNS N
, , N
as IN N
the DT o
ODR NNP o
values NNS o
increase NN N
. . N

It PRP N
is VBZ N
important JJ N
to TO N
note VB N
that IN N
the DT N
methods NNS N
of IN N
quantifying VBG N
the DT N
ODR NNP N
values NNS N
differed VBD N
between IN N
the DT N
three CD N
studies NNS N
in IN N
the DT N
IPDMA NNP N
, , N
therefore RB N
some DT N
caution NN N
should MD N
be VB N
used VBN N
when WRB N
using VBG N
these DT N
final JJ N
estimated VBN N
values NNS N
. . N

However RB N
, , N
the DT N
shape NN N
and CC N
magnitude NN N
of IN N
the DT N
treatment NN N
effects NNS N
, , N
as RB N
well RB N
as IN N
the DT N
other JJ N
fixed JJ N
model NN N
estimates NNS N
, , N
were VBD N
very RB N
similar JJ N
between IN N
the DT N
field NN N
trial NN N
and CC N
the DT N
IPDMA NNP N
suggesting VBG N
that IN N
any DT N
bias NN N
would MD N
likely RB N
be VB N
minimal JJ N
. . N

-DOCSTART- -X- O O

Engagement NN i
with IN i
electronic JJ i
screen JJ i
media NNS i
among IN N
students NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
relative JJ N
engagement JJ N
potential NN N
of IN N
four CD N
types NNS N
of IN N
electronic JJ i
screen JJ i
media NNS i
( ( i
ESM NNP i
) ) i
: : i
animated VBN i
video NN i
, , i
video NN i
of IN i
self NN i
, , i
video NN i
of IN i
a DT i
familiar JJ i
person NN i
engaged VBD i
with IN i
an DT i
immersive JJ i
virtual JJ i
reality NN i
( ( i
VR NNP i
) ) i
game NN i
, , i
and CC i
immersion NN i
of IN i
self NN i
in IN i
the DT i
VR NNP i
game NN i
. . i

Forty-two JJ p
students NNS p
with IN p
autism NN p
, , p
varying VBG p
in IN p
age NN p
and CC p
expressive JJ p
communication NN p
ability NN p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
experimental JJ p
conditions NNS p
. . p

Gaze NNP o
duration NN o
and CC o
vocalization NN o
served VBD N
as IN N
dependent JJ N
measures NNS N
of IN N
engagement NN N
. . N

The DT N
results NNS N
reveal VBP N
differential JJ N
responding NN N
across IN N
ESM NNP o
, , N
with IN N
some DT N
variation NN N
related VBN N
to TO N
the DT N
engagement NN N
metric JJ N
employed VBN N
. . N

Preferences NNS N
for IN N
seeing VBG o
themselves PRP o
on IN o
the DT o
screen NN o
, , o
as RB o
well RB o
as IN o
for IN o
viewing VBG o
the DT o
VR NNP o
scenarios NNS o
, , N
emerged VBD N
from IN N
the DT N
data NNS N
. . N

While IN N
the DT N
study NN N
did VBD N
not RB N
yield VB N
definitive JJ N
data NNS N
about IN N
the DT N
relative JJ N
engagement JJ N
potential NN N
of IN N
ESM NNP i
alternatives NNS N
, , N
it PRP N
does VBZ N
provide VB N
a DT N
foundation NN N
for IN N
future JJ N
research NN N
, , N
including VBG N
guidance NN N
related VBN N
to TO N
participant JJ N
profiles NNS N
, , N
stimulus NN N
characteristics NNS N
, , N
and CC N
data NNS N
coding NN N
challenges NNS N
. . N

-DOCSTART- -X- O O

Hemiarthroplasty NNP i
compared VBN N
to TO N
internal JJ i
fixation NN i
with IN i
percutaneous JJ i
cannulated VBN i
screws NNS i
as IN N
treatment NN N
of IN N
displaced JJ p
femoral JJ p
neck NN p
fractures NNS p
in IN p
the DT p
elderly JJ p
: : p
cost-utility NN N
analysis NN N
performed VBD N
alongside IN N
a DT N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

UNLABELLED IN N
We PRP N
estimated VBD N
the DT N
cost-effectiveness NN o
of IN N
hemiarthroplasty NN i
compared VBN N
to TO N
internal JJ i
fixation NN i
for IN N
elderly JJ p
patients NNS p
with IN p
displaced JJ p
femoral JJ p
neck NN p
fractures NNS p
. . p

Over IN N
2 CD N
years NNS N
, , N
patients NNS N
treated VBD N
with IN N
hemiarthroplasty NN i
gained VBN N
more RBR N
quality-adjusted JJ o
life NN o
years NNS o
than IN N
patients NNS N
treated VBN N
with IN N
internal JJ i
fixation NN i
. . i

In IN N
addition NN N
, , N
costs NNS N
for IN N
hemiarthroplasty NN i
were VBD N
lower JJR N
. . N

Hemiarthroplasty NNP i
was VBD N
thus RB N
cost VBN N
effective JJ N
. . N

INTRODUCTION NNP N
Estimating VBG N
the DT N
cost NN N
utility NN N
of IN N
hemiarthroplasty NN i
compared VBN N
to TO N
internal JJ i
fixation NN i
in IN N
the DT N
treatment NN N
of IN N
displaced JJ N
femoral JJ N
neck NN N
fractures NNS N
in IN N
the DT N
elderly JJ N
. . N

METHODS VB N
A DT N
cost-utility NN N
analysis NN N
( ( N
CUA NNP N
) ) N
was VBD N
conducted VBN N
alongside IN N
a DT N
clinical JJ N
randomized NN N
controlled VBD N
trial NN N
at IN p
a DT p
university NN p
hospital NN p
in IN p
Norway NNP p
; : p
166 CD p
patients NNS p
, , p
124 CD p
( ( p
75 CD p
% NN p
) ) p
women NNS p
with IN p
a DT p
mean JJ p
age NN p
of IN p
82 CD p
years NNS p
were VBD N
randomized VBN N
to TO N
either DT N
internal JJ i
fixation NN i
( ( i
n JJ i
= NNP i
86 CD i
) ) i
or CC i
hemiarthroplasty JJ i
( ( i
n JJ i
= NNP N
80 CD N
) ) N
. . N

Patients NNS N
were VBD N
followed VBN N
up RP N
at IN N
4 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
months NNS N
. . N

Health-related JJ N
quality NN N
of IN N
life NN N
was VBD N
assessed VBN N
with IN N
the DT N
EQ-5D NNP N
, , N
and CC N
in IN N
combination NN N
with IN N
time NN N
used VBN N
to TO N
calculate VB N
patients NNS N
' POS o
quality-adjusted JJ o
life NN o
years NNS o
( ( o
QALYs NNP o
) ) o
. . N

Resource NNP N
use NN N
was VBD N
identified VBN N
, , N
quantified VBN N
, , N
and CC N
valued VBN N
for IN N
direct JJ N
and CC N
indirect JJ N
hospital NN N
costs NNS N
and CC N
for IN N
societal JJ N
costs NNS N
. . N

Results NNS N
were VBD N
expressed VBN N
in IN N
incremental JJ N
cost-effectiveness JJ N
ratios NNS N
. . N

RESULTS NNP N
Over IN N
the DT N
2-year JJ N
period NN N
, , N
patients NNS N
treated VBD N
with IN i
hemiarthroplasty NN o
gained VBN o
0.15-0.20 CD o
more JJR o
QALYs NNP o
than IN o
patients NNS N
treated VBN N
with IN i
internal JJ i
fixation NN i
. . i

For IN i
the DT i
hemiarthroplasty NN i
group NN i
, , i
the DT o
direct JJ o
hospital NN o
costs NNS o
, , o
total JJ o
hospital NN o
costs NNS o
, , o
and CC o
total JJ o
costs NNS o
were VBD o
non-significantly RB o
less RBR o
costly JJ o
compared VBN N
with IN N
the DT N
internal JJ i
fixation NN i
group NN i
, , i
with IN N
an DT N
incremental JJ N
cost NN N
of IN N
?2,731 NNP N
( ( N
p JJ N
= NNP N
0.81 CD N
) ) N
, , N
?2,474 NNP N
( ( N
p JJ N
= NNP N
0.80 CD N
) ) N
, , N
and CC N
?14,160 NNP N
( ( N
p JJ N
= NNP N
0.07 CD N
) ) N
, , N
respectively RB i
. . i

Thus RB i
, , i
hemiarthroplasty NN i
was VBD i
the DT N
dominant JJ N
treatment NN N
. . N

Sensitivity NN N
analyses NNS N
by IN N
bootstrapping VBG N
supported VBN N
these DT N
findings NNS N
. . N

CONCLUSION NNP N
Hemiarthroplasty NNP o
was VBD o
a DT o
cost-effective JJ o
treatment NN o
. . o

Trial JJ N
registration NN N
, , N
NCT00464230 NNP N
. . N

-DOCSTART- -X- O O

Toxicity NN o
and CC o
efficacy NN o
of IN N
6-thioguanine JJ i
versus NN i
6-mercaptopurine JJ i
in IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
: : p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
6-mercaptopurine JJ i
has VBZ N
been VBN N
a DT N
standard JJ N
component NN N
of IN N
long-term JJ N
continuing VBG N
treatment NN N
for IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
, , N
whereas JJ N
6-thioguanine NN i
has VBZ N
been VBN N
mainly RB N
used VBN N
for IN N
intensification NN N
courses NNS N
. . N

Since IN N
preliminary JJ N
data NNS N
have VBP N
shown VBN N
that IN N
6-thioguanine JJ i
is VBZ N
more RBR N
effective JJ N
than IN N
6-mercaptopurine JJ i
, , N
we PRP N
compared VBN N
the DT N
efficacy NN o
and CC o
toxicity NN o
of IN N
the DT N
two CD N
drugs NNS N
for IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
. . p

METHODS NNP N
Consecutive JJ p
children NNS p
with IN p
lymphoblastic JJ p
leukaemia NN p
diagnosed VBN p
in IN p
the DT p
UK NNP p
and CC p
Ireland NNP p
between IN p
April NNP p
, , p
1997 CD p
, , p
and CC p
June NNP p
, , p
2002 CD p
, , N
were VBD N
randomly RB N
assigned VBN N
either CC N
6-thioguanine JJ i
( ( i
750 CD i
patients NNS N
) ) N
or CC N
6-mercaptopurine JJ i
( ( N
748 CD N
patients NNS N
) ) N
during IN N
interim JJ N
maintenance NN N
and CC N
continuing VBG N
therapy NN N
. . N

All DT N
patients NNS N
received VBD N
6-thioguanine JJ i
during IN N
intensification NN N
courses NNS N
. . N

We PRP N
analysed VBD N
event-free JJ o
and CC o
overall JJ o
survival NN o
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

We PRP N
obtained VBD N
toxicity NN o
data NNS N
using VBG N
an DT N
adverse-event JJ N
reporting NN N
system NN N
, , N
with IN N
follow-up JJ N
questionnaires NNS N
to TO N
seek VB N
detailed JJ N
information NN N
for IN N
specific JJ N
toxicities NNS N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
the DT N
International NNP N
Standard NNP N
Randomised VBD N
Controlled NNP N
Number NNP N
26727615 CD N
with IN N
the DT N
name NN N
ALL97 NNP N
. . N

FINDINGS NNP N
After IN N
a DT N
median JJ N
follow NN N
up IN N
of IN N
6 CD N
years NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
event-free JJ o
or CC o
overall JJ o
survival NN o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Although IN N
6-thioguanine JJ i
conferred VBD N
a DT N
significantly RB N
lower JJR N
risk NN N
of IN N
isolated JJ N
CNS NNP o
relapse NN o
than IN N
did VBD N
6-mercaptopurine JJ i
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
0.53 CD N
, , N
95 CD N
% NN N
CI NNP N
0.30-0.92 CD N
, , N
p=0.02 NN N
) ) N
, , N
the DT N
benefit NN N
was VBD N
offset VBN N
by IN N
an DT N
increased VBN N
risk NN o
of IN o
death NN o
in IN N
remission NN N
( ( N
2.22 CD N
, , N
1.20-4.14 CD N
, , N
p=0.01 NN N
) ) N
, , N
mainly RB N
due JJ N
to TO N
infections NNS N
during IN N
continuing VBG N
therapy NN N
. . N

Additionally RB N
, , N
95 CD N
patients NNS N
developed VBD N
veno-occlusive JJ o
disease NN o
of IN o
the DT o
liver NN o
. . o

Of IN N
these DT N
, , N
82 CD N
were VBD N
randomly RB N
assigned VBN N
6-thioguanine JJ i
, , N
representing VBG N
11 CD N
% NN N
of IN N
all DT N
6-thioguanine JJ i
recipients NNS N
. . N

On IN N
long-term JJ N
follow-up NN N
, , N
about RB N
5 CD N
% NN N
of IN N
6-thioguanine JJ i
recipients NNS N
have VBP N
evidence NN N
of IN N
non-cirrhotic JJ o
portal JJ o
hypertension NN o
due JJ N
to TO N
periportal JJ N
liver JJ N
fibrosis NN N
or CC N
nodular JJ N
regenerative JJ N
hyperplasia NN N
. . N

INTERPRETATION NNP N
Compared VBD N
with IN N
6-mercaptopurine JJ i
, , i
6-thioguanine JJ i
causes NNS N
excess JJ N
toxicity NN o
without IN N
an DT N
overall JJ o
benefit NN o
. . o

6-mercaptopurine JJ i
should MD N
remain VB N
the DT N
thiopurine NN N
of IN N
choice NN N
for IN N
continuing VBG N
therapy NN N
of IN N
childhood NN N
lymphoblastic JJ N
leukaemia NN N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
surgical JJ i
staging NN i
in IN N
evaluating VBG N
the DT N
radiotherapeutic JJ N
outcome NN N
in IN N
RTOG NNP N
# # N
77-06 NNP N
, , N
a DT N
phase NN N
III NNP N
study NN N
for IN N
T1BN0M0 NNP N
( ( N
A2 NNP N
) ) N
and CC N
T2N0M0 NNP N
( ( N
B NNP N
) ) N
prostate NN N
carcinoma NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
survival NN N
and CC N
time NN N
to TO N
metastatic JJ N
disease NN N
in IN N
patients NNS p
treated VBN p
for IN p
localized JJ p
prostatic JJ p
carcinoma NN p
in IN p
a DT p
Phase NNP i
III NNP i
radiotherapy NN i
( ( p
RT NNP p
) ) p
protocol NN p
, , p
Radiation NNP i
Therapy NNP i
Oncology NNP i
Group NNP i
( ( p
RTOG NNP p
) ) p
77-06 NN p
. . p

Patients NNS p
with IN p
T18N0M0 NNP p
( ( p
A2 NNP p
) ) p
or CC p
T2N0M0 NNP p
( ( p
B NNP p
) ) p
disease NN p
after IN p
lymphangiogram NN p
( ( p
LAG NNP p
) ) p
or CC p
staging VBG p
laparotomy NN p
( ( p
SL NNP p
) ) p
were VBD p
randomized VBN p
between IN p
prophylactic JJ p
radiation NN p
to TO p
the DT p
pelvic JJ p
lymph NN p
nodes NNS p
and CC p
prostatic JJ p
bed NN p
vs. FW p
prostatic JJ p
bed NN p
alone RB p
. . p

The DT N
outcome NN N
of IN N
both DT N
treatment NN N
arms NNS N
, , N
as RB N
well RB N
as IN N
a DT N
comparison NN N
of IN N
the DT N
LAG NNP N
group NN N
, , N
to TO N
that DT N
of IN N
the DT N
SL NNP N
group NN N
, , N
are VBP N
updated VBN N
. . N

METHODS NNP N
AND NNP N
MATERIALS NNP N
A NNP p
total NN p
of IN p
449 CD p
eligible JJ p
males NNS p
were VBD p
entered VBN p
into IN p
RTOG NNP p
protocol NN p
7706 CD p
between IN p
1978 CD p
and CC p
1983 CD p
. . p

Lymph NNP N
node IN N
staging VBG N
was VBD N
mandatory JJ N
but CC N
at IN N
the DT N
physician NN N
's POS N
discretion NN N
; : N
117 CD p
( ( p
26 CD p
% NN p
) ) p
patients NNS p
had VBD p
SL NNP p
, , p
while IN p
332 CD p
( ( p
74 CD p
% NN p
) ) p
had VBD p
LAG NNP p
. . p

Follow-up NNP N
was VBD N
a DT N
median NN N
of IN N
12 CD N
years NNS N
and CC N
a DT N
maximum NN N
of IN N
16 CD N
years NNS N
. . N

For IN N
those DT N
randomized VBN N
to TO N
receive VB N
prophylactic JJ N
pelvic NNS N
lymph VBP N
nodal JJ N
irradiation NN N
, , N
45 CD N
Gy NNP N
of IN N
megavoltage NN N
RT NNP N
was VBD N
delivered VBN N
via IN N
multiple JJ N
portals NNS N
in IN N
4.5-5 JJ N
weeks NNS N
, , N
while IN N
all DT N
patients NNS N
received VBD N
65 CD N
Gy NNP N
in IN N
6.5-8 JJ N
weeks NNS N
to TO N
the DT N
prostatic JJ N
bed NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
survival JJ o
whether IN N
treatment NN N
was VBD N
administered VBN N
to TO N
the DT N
prostate NN N
or CC N
prostate NN N
and CC N
pelvic JJ N
lymph NN N
nodes NNS N
. . N

The DT N
SL NNP N
group NN N
had VBD N
greater JJR N
12-year JJ o
survival NN o
than IN N
the DT N
LAG NNP N
group NN N
( ( N
48 CD N
% NN N
vs. FW N
38 CD N
% NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

Disease-free JJ o
survival NN o
was VBD N
statistically RB N
significant JJ N
, , N
with IN N
38 CD N
% NN N
for IN N
the DT N
SL NNP N
group NN N
vs. FW N
26 CD N
% NN N
for IN N
the DT N
LAG NNP N
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

Bone NNP o
metastasis NN o
was VBD N
less JJR N
common JJ N
in IN N
the DT N
SL NNP N
group NN N
( ( N
14 CD N
% NN N
) ) N
than IN N
the DT N
LAG NNP N
group NN N
( ( N
27 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

CONCLUSION NN N
At IN N
12-year JJ N
median JJ N
follow-up NN N
, , N
there EX N
still RB N
was VBD N
no DT N
survival JJ N
difference NN N
in IN N
those DT N
patients NNS N
treated VBD N
prophylactically RB N
to TO N
the DT N
pelvic JJ N
nodes NNS N
and CC N
prostatic JJ N
bed NN N
vs. IN N
the DT N
prostatic JJ N
bed NN N
alone RB N
. . N

Those DT N
patients NNS N
not RB N
surgically RB N
staged VBN N
with IN N
only RB N
LAG NNP N
for IN N
lymph JJ N
node JJ N
evaluation NN N
were VBD N
less RBR N
accurately RB N
staged VBN N
, , N
as IN N
reflected VBN N
by IN N
a DT N
statistically RB N
significant JJ N
reduced VBN N
survival NN N
and CC N
earlier JJR N
metastases NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
the DT N
Quest NNP i
to TO i
Lava NNP i
Mountain NNP i
Computer NNP i
Game NNP i
on IN N
Dietary NNP o
and CC o
Physical NNP o
Activity NNP o
Behaviors NNP o
of IN N
Elementary NNP p
School NNP p
Children NNP p
: : p
A DT N
Pilot NNP N
Group-Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

BACKGROUND NNP N
Computer-based JJ i
educational JJ i
games NNS i
present VBP N
an DT N
opportunity NN N
for IN N
health NN N
education NN N
in IN N
school NN N
; : N
however RB N
, , N
their PRP$ N
feasibility NN N
in IN N
school NN N
settings NNS N
and CC N
effectiveness NN N
in IN N
changing VBG N
behavior NN N
are VBP N
poorly RB N
understood JJ N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
feasibility NN N
, , N
acceptability NN N
, , N
and CC N
effects NNS N
of IN N
the DT N
Quest NNP i
to TO i
Lava NNP i
Mountain NNP i
( ( i
QTLM NNP i
) ) i
computer NN i
game NN i
on IN N
dietary JJ o
behaviors NNS o
, , o
physical JJ o
activity NN o
behaviors NNS o
, , o
and CC o
psychosocial JJ o
factors NNS o
among IN N
ethnically RB p
diverse JJ p
children NNS p
in IN p
Texas NNP p
. . p

DESIGN NNP N
Quasi-experimental JJ N
group-randomized JJ N
controlled VBN N
trial NN N
conducted VBN N
during IN N
the DT N
2012-2013 JJ p
school NN p
year NN p
. . p

PARTICIPANTS/SETTING CC N
A DT p
total NN p
of IN p
107 CD p
children NNS p
in IN p
fourth JJ p
and CC p
fifth JJ p
grade NN p
consented VBN p
. . p

There EX p
was VBD p
an DT p
attrition NN p
rate NN p
of IN p
8.8 CD p
% NN p
with IN p
a DT p
final JJ p
sample NN p
size NN p
of IN p
44 CD p
children NNS p
in IN p
three CD p
intervention NN p
schools NNS p
, , p
and CC p
a DT p
sample NN p
of IN p
50 CD p
children NNS p
in IN p
three CD p
comparison NN p
schools NNS p
. . p

Dietary NNP N
intake NN N
was VBD N
measured VBN N
using VBG N
two CD N
random JJ N
24-hour JJ N
recalls NNS N
, , N
whereas JJ N
child NN N
self-report JJ N
surveys NNS N
measured VBN N
diet JJ o
, , o
physical JJ o
activity NN o
, , o
and CC o
psychosocial JJ o
factors NNS o
before IN N
and CC N
after IN N
the DT N
intervention NN N
. . N

Process NNP N
data NN N
on IN N
QTLM NNP i
usability NN N
and CC N
back-end JJ N
server NN N
data NNS N
on IN N
QTLM NNP N
exposure NN N
and CC N
progress NN N
achieved VBN N
were VBD N
collected VBN N
. . N

INTERVENTION NNP N
QTLM NNP i
was VBD N
implemented VBN N
as IN N
part NN N
of IN N
the DT N
in-school NN p
or CC p
afterschool JJ p
program NN p
. . p

Recommended JJ N
game NN N
exposure NN N
duration NN N
was VBD N
90 CD N
min/wk NN N
for IN N
6 CD N
weeks NNS N
. . N

STATISTICAL JJ N
ANALYSIS NNP N
Analysis NNP N
of IN N
covariance NN N
or CC N
logistic JJ N
regression NN N
models NNS N
evaluated VBN N
effects NNS N
of IN N
QTLM NNP i
on IN N
diet JJ o
, , o
physical JJ o
activity NN o
, , o
and CC o
psychosocial JJ o
factors NNS o
. . o

Post NNP N
hoc JJ N
exploratory NN N
analysis NN N
examined VBD N
the DT N
changes NNS N
before IN N
and CC N
after IN N
the DT N
intervention NN N
in IN N
outcome JJ N
variables NNS N
among IN N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

Significance NN N
was VBD N
set VBN N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

RESULTS NNP N
Children NNP N
played VBD N
an DT N
average NN N
of IN N
274?110 CD N
minutes NNS N
( ( N
approximately RB N
4.6 CD N
hours NNS N
) ) N
of IN i
QTLM NNP i
during IN N
the DT N
6 CD N
weeks NNS N
( ( N
51 CD N
% NN N
of IN N
recommended JJ N
dosage NN N
) ) N
. . N

Compared VBN N
with IN N
the DT N
comparison NN N
group NN N
, , N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
reported VBD o
decreased JJ o
sugar NN o
consumption NN o
( ( N
P=0.021 NNP N
) ) N
and CC o
higher JJR o
nutrition/physical JJ o
activity NN o
attitudes NNS o
( ( N
P=0.041 NNP N
) ) N
pre- NN N
to TO N
postintervention NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
effects NNS N
of IN N
QTLM NNP N
on IN o
physical JJ o
activity NN o
. . o

However RB N
, , N
post NN N
hoc NN N
analysis NN N
showed VBD N
that IN N
higher JJR i
QTLM NNP i
exposure NN N
and CC N
gaming VBG N
progress NN N
was VBD N
associated VBN N
with IN N
increased JJ o
frequency NN o
of IN o
physical JJ o
activity NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP i
QTLM NNP i
has VBZ N
some DT N
promising JJ N
acceptability NN N
and CC N
initial JJ N
effects NNS N
on IN o
diet JJ o
and CC o
physical JJ o
activity NN o
behaviors NNS o
among IN p
children NNS p
in IN p
elementary JJ p
school NN p
. . p

-DOCSTART- -X- O O

Oral NNP N
and CC N
parenteral JJ N
glutamine NN i
in IN N
bone NN N
marrow NN N
transplantation NN N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
. . N

BACKGROUND NNP N
Total NNP i
parenteral JJ i
nutrition NN i
( ( i
TPN NNP i
) ) i
supplemented VBD i
with IN i
glutamine NN i
( ( i
GLN NNP i
) ) i
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
for IN N
patients NNS p
with IN p
bone NN p
marrow NN p
transplantation NN p
( ( p
BMT NNP p
) ) p
. . p

Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
enteral JJ N
and CC N
parenteral JJ N
glutamine NN N
in IN N
patients NNS p
undergoing JJ p
BMT NNP p
. . p

METHODS NNP N
For IN N
evaluation NN N
of IN N
GLN NNP N
in IN N
BMT NNP N
, , N
66 CD p
patients NNS p
with IN p
43 CD p
hematologic NNS p
and CC p
23 CD p
solid JJ p
malignancies NNS p
( ( p
21 CD p
breast NN p
carcinomas NN p
) ) p
, , N
were VBD N
randomized VBN N
, , N
double-blinded JJ N
, , N
to TO N
either DT N
oral JJ i
GLN NNP i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
or CC N
glycine-control NN i
( ( N
GLY NNP N
) ) N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
, , N
10 CD N
g NN N
three CD N
times NNS N
daily RB N
. . N

When WRB N
TPN NNP i
became VBD N
necessary JJ N
, , N
patients NNS N
who WP N
received VBD N
GLN NNP i
orally RB N
were VBD N
given VBN N
TPN NNP i
with IN i
GLN NNP i
( ( N
0.57 CD N
g/kg NN N
) ) N
. . N

Those DT N
who WP N
received VBD N
GLY NNP N
received VBD N
standard JJ N
TPN NNP i
, , N
isocaloric JJ N
and CC N
isonitrogenous JJ N
. . N

Patients NNS p
with IN p
hematologic JJ p
malignancies NNS p
received VBD N
high-dose JJ i
chemotherapy NN i
, , i
total JJ i
body NN i
irradiation NN i
, , i
and CC i
either DT i
allogeneic NN i
( ( i
ALLO NNP i
) ) i
BMT NNP i
( ( N
n JJ N
= NNP N
18 CD N
) ) N
or CC N
autologous JJ i
( ( i
AUTO NNP i
) ) i
stem NN i
cell NN i
transplantation NN i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
. . N

Patients NNS p
with IN p
solid JJ p
malignancies NNS p
( ( p
n JJ p
= NNP p
23 CD p
) ) p
received VBD N
AUTO NNP i
. . i

RESULTS NNP N
There EX N
were VBD N
14 CD p
in-hospital JJ p
deaths NNS p
without IN p
relationship NN p
to TO p
GLN NNP p
administration NN p
. . p

For IN N
respective JJ N
comparisons NNS N
of IN N
ALLO NNP N
and CC N
AUTO NNP N
transplants NNS N
in IN N
the DT N
GLN NNP N
and CC N
GLY NNP N
hematologic VBP N
groups NNS N
and CC N
AUTO NNP N
in IN N
the DT N
solid JJ N
tumor NN N
groups NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
hospital NN o
stay NN o
, , o
duration NN o
of IN o
stay NN o
after IN o
BMT NNP o
, , o
TPN NNP o
days NNS o
, , o
neutrophil JJ o
recovery NN o
> NN o
500/mm3 CD o
, , o
incidence NN o
of IN o
positive JJ o
blood NN o
cultures NNS o
, , o
sepsis NN o
, , o
mucositis NN o
, , o
and CC o
diarrhea NN o
. . o

Acute NNP o
graft VBD o
us PRP o
host VB o
disease NN o
occurred VBD N
in IN N
1 CD p
of IN p
10 CD p
hematologic JJ p
patients NNS p
receiving VBG p
GLN NNP p
and CC N
in IN N
3 CD N
of IN N
8 CD N
patients NNS N
receiving VBG N
GLY NNP N
placebo NN N
( ( N
p JJ N
> NNP N
.05 NNP N
) ) N
. . N

Possible JJ N
reduction NN o
in IN o
need NN o
for IN o
TPN NNP o
and CC N
a DT N
suggestion NN N
of IN N
improved JJ o
long-term JJ o
survival NN o
were VBD N
associated VBN N
with IN N
GLN NNP N
. . N

CONCLUSIONS NNP N
Oral NNP N
and CC N
parenteral JJ N
GLN NNP i
seemed VBD N
to TO N
be VB N
of IN N
limited JJ N
benefit NN N
for IN N
patients NNS N
having VBG N
AUTO NNP N
or CC N
ALLO NNP N
BMT NNP N
for IN N
hematologic NN N
or CC N
solid JJ N
malignancies NNS N
. . N

Further NNP N
study NN N
of IN N
long-term JJ N
effects NNS N
of IN N
GLN NNP N
in IN N
BMT NNP N
seems VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Noninfiltrative JJ i
anesthesia NN i
for IN N
transrectal JJ i
prostate NN i
biopsy NN i
: : i
a DT N
randomized JJ N
prospective JJ N
study NN N
comparing VBG N
lidocaine-prilocaine JJ i
cream NN i
and CC N
lidocaine-ketorolac JJ i
gel NN i
. . i

OBJECTIVES NNP N
Periprostatic NNP N
nerve NN N
block NN N
( ( N
PPNB NNP N
) ) N
is VBZ N
the DT N
standard JJ N
anesthesia NN i
for IN N
ultrasound NN N
( ( N
US NNP N
) ) N
guided VBD N
transrectal JJ p
prostate NN p
biopsy NN p
( ( p
TPB NNP p
) ) p
, , N
but CC N
periprostatic JJ N
infiltration NN N
itself PRP N
constitutes VBZ N
a DT N
major JJ N
, , N
though RB N
often RB N
neglected VBN N
, , N
source NN N
of IN N
discomfort NN N
even RB N
in IN N
patients NNS p
receiving VBG p
perianal-intrarectal JJ i
lidocaine-prilocaine NN i
( ( i
PILP NNP i
) ) i
cream NN i
before IN p
PPNB NNP p
. . p

Noninfiltrative NNP i
anesthesia NN i
therefore NN N
represents VBZ N
an DT N
attractive JJ N
alternative NN N
to TO N
periprostatic JJ N
infiltration NN N
. . N

With IN N
this DT N
in IN N
mind NN N
, , N
we PRP N
aimed VBD N
to TO N
determine VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
perianal-intrarectal JJ i
( ( i
PI NNP i
) ) i
lidocaine NN i
gel NN i
, , i
lidocaine-ketorolac JJ i
gel NN i
, , N
and CC N
lidocaine-prilocaine JJ i
cream NN i
in IN N
relieving VBG o
pain NN o
during IN N
TPB NNP N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Three NNP p
hundred VBD p
consecutive JJ p
patients NNS p
scheduled VBN p
for IN p
US-guided JJ p
TPB NNP p
were VBD N
randomized VBN N
1:1:1 CD N
to TO N
receive VB N
PI NNP i
administration NN N
of IN N
5 CD N
g JJ N
2.5 CD N
% NN N
lidocaine JJ i
gel NN i
10 CD N
minutes NNS N
before IN N
TPB NNP N
( ( N
Group NNP N
1 CD N
) ) N
, , N
or CC N
a DT N
mixture NN N
of IN N
5 CD i
g JJ i
2.5 CD i
% NN i
lidocaine JJ i
gel NN i
and CC i
0.3 CD i
% NN i
ketorolac NN i
tromethamine JJ i
solution NN i
1 CD i
hour NN i
before IN i
TPB NNP i
( ( N
Group NNP N
2 CD N
) ) N
, , N
or CC N
5 CD i
g JJ i
2.5 CD i
% NN i
lidocaine NN i
and CC i
2.5 CD i
% NN i
prilocaine NN i
cream NN i
20 CD i
minutes NNS i
before IN i
TPB NNP i
( ( N
Group NNP N
3 CD N
) ) N
. . N

The DT N
0-to-10 JJ o
points NNS o
visual JJ o
analogue JJ o
scale NN o
( ( o
VAS NNP o
) ) o
was VBD N
used VBN N
for IN N
assessing VBG N
pain NN N
at IN N
probe NN N
insertion NN N
and CC N
movements NNS N
( ( N
VAS-1 NNP N
) ) N
, , N
at IN N
prostate NN N
sampling NN N
( ( N
VAS-2 NNP N
) ) N
, , N
and CC N
maximal JJ N
procedural JJ N
pain NN N
( ( N
MPP NNP N
) ) N
. . N

Complications NNS N
occurring VBG N
up RB N
to TO N
20 CD N
days NNS N
after IN N
the DT N
procedure NN N
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
Four NNP N
( ( N
1.3 CD N
% NN N
) ) N
patients NNS N
were VBD N
excluded VBN N
because IN N
of IN N
unbearable JJ o
pain NN o
during IN N
the DT N
procedure NN N
, , N
leaving VBG N
Group NNP N
1 CD N
with IN N
98 CD N
patients NNS N
, , N
Group NNP N
2 CD N
with IN N
99 CD N
, , N
and CC N
Group NNP N
3 CD N
with IN N
99 CD N
; : N
the DT N
3 CD N
groups NNS N
were VBD N
comparable JJ N
for IN N
patients NNS N
' POS N
age NN N
, , N
serum NN o
PSA NNP o
, , o
prostate NN o
volume NN o
, , o
and CC o
cancer NN o
detection NN o
rate NN o
. . o

The DT N
addition NN N
of IN N
either DT N
ketorolac NN i
or CC N
prilocaine NN i
to TO i
lidocaine VB i
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
reduced VBD N
probe-related JJ N
, , N
sampling-related JJ N
, , N
and CC N
maximal JJ N
procedural JJ o
pain NN o
. . o

Compared VBN N
with IN N
lidocaine-prilocaine JJ i
, , i
lidocaine-ketorolac JJ i
was VBD N
less RBR N
effective JJ N
in IN N
relieving VBG N
probe-related JJ o
pain NN o
( ( N
mean JJ N
VAS-1 NNP N
: : N
1.47 CD N
? . N
1.30 CD N
vs. IN N
0.39 CD N
? . N
0.65 CD N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
but CC N
more RBR N
effective JJ N
in IN N
relieving VBG o
sampling-related JJ o
pain NN o
( ( o
mean JJ N
VAS-2 NNP N
: : N
0.76 CD N
? . N
0.94 CD N
vs. IN N
1.54 CD N
? . N
1.02 CD N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
; : N
there EX N
was VBD N
no DT N
difference NN N
in IN N
MPP NNP N
( ( N
mean VB N
1.82 CD N
? . N
1.21 CD N
vs. IN N
1.67 CD N
? . N
0.95 CD N
) ) N
, , N
probably RB N
due JJ N
to TO N
such JJ N
different JJ N
efficacy NN N
on IN N
the DT N
two CD o
pain NN o
sources NNS o
. . o

Complications NNS o
were VBD N
similar JJ N
in IN N
the DT N
3 CD N
groups NNS N
. . N

CONCLUSIONS NNP i
Lidocaine-prilocaine JJ i
cream NN i
was VBD N
most RBS N
effective JJ N
on IN N
probe-related JJ o
pain NN o
, , o
whereas IN i
lidocaine-ketorolac JJ i
gel NN i
was VBD i
most RBS N
effective JJ N
on IN N
sampling-related JJ N
pain NN N
. . N

These DT N
noninfiltrative JJ N
anesthetics NNS N
were VBD N
safe JJ N
, , N
easy JJ N
to TO N
administer VB N
, , N
and CC N
well RB N
accepted VBN N
by IN N
patients NNS N
; : N
the DT N
possibility NN N
to TO N
combine VB N
them PRP N
to TO N
further JJ N
improve VB o
pain NN o
control NN o
during IN o
TPB NNP N
deserves VBZ N
further JJ N
well-designed JJ N
studies NNS N
. . N

-DOCSTART- -X- O O

Efficacy NN N
and CC N
safety NN N
of IN N
zoledronic JJ i
acid NN i
in IN N
patients NNS p
with IN p
breast JJ p
cancer NN p
metastatic NN p
to TO p
bone NN p
: : p
a DT N
multicenter NN N
clinical JJ N
trial NN N
. . N

PURPOSE VB N
This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
zoledronic JJ i
acid NN i
in IN N
breast NN p
cancer NN p
patients NNS p
with IN p
newly RB p
diagnosed VBN p
bone NN p
metastases NNS p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Patients NNS p
diagnosed VBD p
with IN p
bone NN p
metastases NNS p
< VBP p
or CC p
= VBP p
6 CD p
weeks NNS p
prior RB p
to TO p
first JJ p
visit NN p
were VBD N
enrolled VBN N
. . N

Zoledronic JJ i
acid NN i
( ( N
4 CD N
mg NN N
) ) N
was VBD N
administered VBN N
via IN N
a DT N
15-minute JJ N
infusion NN N
every DT N
3 CD N
or CC N
4 CD N
weeks NNS N
for IN N
12 CD N
infusions NNS N
. . N

Skeletal-related JJ o
events NNS o
( ( o
SREs NNP o
) ) o
were VBD N
defined VBN N
as IN N
pathologic JJ N
bone NN N
fractures NNS N
, , N
spinal JJ N
cord NN N
compression NN N
, , N
surgery NN N
to TO N
bone VB N
, , N
radiation NN N
therapy NN N
to TO N
bone VB N
, , N
and CC N
hypercalcemia NN N
of IN N
malignancy NN N
. . N

Primary NNP N
efficacy JJ N
end NN N
points NNS N
were VBD N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
at IN N
least JJS N
one CD N
SRE NNP N
and CC N
the DT N
time NN N
to TO N
first JJ N
SRE NNP N
. . N

Secondary JJ N
end NN N
points NNS N
included VBD N
pain NN o
, , o
analgesic JJ o
use NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

RESULTS NNP N
Among IN N
312 CD p
patients NNS p
enrolled VBD p
, , N
30 CD N
% NN N
experienced VBN N
at IN N
least JJS N
one CD N
SRE NNP o
during IN N
the DT N
12-month JJ N
study NN N
, , N
and CC N
22 CD N
% NN N
experienced VBD N
only RB N
one CD N
SRE NNP o
. . o

The DT N
median JJ N
time NN N
to TO N
first VB N
SRE NNP o
was VBD N
not RB N
reached VBN N
in IN N
the DT N
intent-to-treat JJ N
population NN N
. . N

Mean NNP o
pain NN o
and CC o
analgesic JJ o
scores NNS o
declined VBD o
from IN N
baseline NN N
, , N
and CC N
quality-of-life JJ o
scores NNS o
remained VBD o
stable JJ o
to TO N
study VB N
end NN N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
adverse JJ N
events NNS N
, , N
regardless RB N
of IN N
relationship NN N
to TO N
study VB N
drug NN N
, , N
were VBD N
pyrexia VBN o
( ( N
22 CD N
% NN N
) ) N
and CC N
bone NN o
pain NN o
( ( N
10 CD N
% NN N
) ) N
. . N

Serum NNP o
creatinine NN o
levels NNS o
did VBD o
not RB o
significantly RB o
increase VB o
from IN N
baseline NN N
throughout IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
Breast NNP p
cancer NN p
patients NNS p
with IN p
newly RB p
diagnosed VBN p
bone NN p
metastases NNS p
who WP N
were VBD N
treated VBN N
with IN N
zoledronic JJ i
acid NN i
had VBD N
a DT N
low JJ N
incidence NN N
of IN N
SREs NNP o
compared VBN N
with IN N
patients NNS N
who WP N
received VBD N
placebo NN i
in IN N
randomized JJ N
phase NN N
III NNP N
trials NNS N
, , N
and CC N
pain NN N
was VBD N
decreased VBN N
from IN N
baseline NN N
. . N

This DT N
study NN N
demonstrated VBD N
the DT N
favorable JJ N
risk NN N
: : N
benefit NN N
ratio NN N
of IN N
zoledronic JJ i
acid NN i
for IN N
the DT N
prevention NN N
of IN N
skeletal JJ N
complications NNS N
. . N

-DOCSTART- -X- O O

Nutrient JJ N
retention NN N
in IN N
preterm JJ p
infants NNS p
fed VBN p
standard JJ p
infant NN p
formulas NN p
. . p

Our PRP$ N
purpose NN N
was VBD N
to TO N
compare VB o
nitrogen NN o
, , o
mineral NN o
, , o
and CC o
zinc NN o
balance NN o
in IN N
preterm JJ p
infants NNS p
fed VBN p
standard JJ i
infant NN i
formulas NNS i
, , i
Similac NNP i
With IN i
Iron NNP i
and CC i
Similac NNP i
With IN i
Whey NNP i
+ NNP i
Iron NNP i
. . i

Nitrogen NNP o
and CC o
magnesium NN o
balances NNS o
were VBD N
similar JJ N
during IN N
both DT N
feeds NNS N
, , N
and CC N
met VBD N
estimated VBN N
fetal JJ N
requirements NNS N
. . N

Infants NNS N
absorbed VBD N
and CC N
retained VBD N
( ( N
milligrams FW N
per IN N
kilogram FW N
per IN N
day NN N
) ) N
more JJR N
calcium NN o
, , o
phosphorus NN o
, , o
and CC o
zinc NN o
when WRB N
fed VBN N
Similac NNP i
With IN i
Iron NNP i
. . i

However RB N
, , N
retention NN o
of IN o
calcium NN o
, , o
phosphorus NN o
( ( o
both DT o
formulas NN o
) ) o
, , o
and CC o
zinc NN o
( ( N
Similac NNP N
With IN N
Whey NNP N
+ NNP N
Iron NNP N
) ) N
was VBD N
inadequate JJ N
to TO N
meet VB N
estimated JJ N
fetal JJ N
requirements NNS N
. . N

These DT N
findings NNS N
are VBP N
important JJ N
in IN N
the DT N
rapidly RB p
growing VBG p
preterm JJ p
infant NN p
, , N
who WP N
is VBZ N
already RB N
at IN N
risk NN N
for IN N
the DT N
development NN N
of IN N
rickets NNS N
and CC N
zinc NN N
deficiency NN N
and CC N
may MD N
be VB N
fed VBN N
either DT N
formula NN N
on IN N
discharge NN N
from IN N
the DT N
newborn JJ N
nursery NN N
. . N

-DOCSTART- -X- O O

Group NNP i
therapy NN i
for IN N
anxiety NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

AIM NNP N
To TO N
investigate VB N
the DT N
acceptability NN N
and CC N
feasibility NN N
of IN N
adapted VBN i
group NN i
therapy NN i
for IN N
anxiety NN N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
in IN N
a DT N
pilot NN N
randomised VBN N
controlled VBN N
trial NN N
. . N

METHOD VB N
A DT p
total NN p
of IN p
32 CD p
children NNS p
aged VBN p
9-13 CD p
years NNS p
were VBD N
randomised VBN N
to TO N
immediate VB i
or CC i
delayed VBN i
therapy NN i
using VBG N
the DT N
'Exploring VBG i
Feelings NNP i
' POS i
manual JJ N
( ( N
Attwood NNP N
, , N
2004 CD N
) ) N
. . N

Child NN p
and CC p
parent NN p
groups NNS p
were VBD N
run VBN N
in IN N
parallel NN N
, , N
for IN N
seven CD N
weekly JJ N
sessions NNS N
, , N
under IN N
the DT N
supervision NN N
of IN N
experienced JJ N
psychologists NNS N
. . N

The DT N
primary JJ N
blinded VBD N
outcome JJ N
measures NNS N
addressed VBD N
change NN N
in IN N
overall JJ o
functioning NN o
and CC N
in IN N
severity NN o
of IN o
the DT o
primary JJ o
anxiety NN o
diagnosis NN o
after IN N
3 CD N
months NNS N
. . N

RESULTS NNP N
Children NNP p
met VBD p
diagnostic JJ p
criteria NNS p
for IN p
1-6 JJ p
anxiety NN p
disorders NNS p
( ( p
median JJ p
3 CD p
) ) p
. . p

At IN N
end NN N
point NN N
, , N
both DT N
parents NNS N
and CC N
children NNS N
in IN N
the DT N
immediate JJ i
therapy NN i
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
a DT N
reduction NN o
in IN o
anxiety NN o
symptoms NNS o
. . o

Fidelity NNP o
of IN o
delivery NN o
of IN N
the DT N
group NN i
therapy NN i
was VBD N
high JJ o
, , N
and CC N
attendance NN o
was VBD N
91 CD N
% NN N
. . N

CONCLUSIONS NNP N
This DT N
pilot NN N
trial NN N
established VBD N
that IN N
children NNS N
and CC N
families NNS N
were VBD N
willing JJ N
to TO N
be VB N
recruited VBN N
and CC N
randomised VBN N
, , N
the DT N
outcome NN N
measures NNS N
were VBD N
acceptable JJ N
, , N
the DT N
format NN N
and CC N
content NN N
of IN N
the DT N
groups NNS N
were VBD N
feasible JJ N
within IN N
UK NNP p
child NN p
and CC p
adolescent JJ p
mental NN p
health NN p
services NNS p
, , N
the DT N
intervention NN N
was VBD N
appreciated VBN N
by IN N
families NNS N
and CC N
attrition NN N
was VBD N
very RB N
small JJ N
. . N

-DOCSTART- -X- O O

Treatment NN p
of IN p
renal JJ o
failure NN o
associated VBN p
with IN p
multiple JJ p
myeloma NN p
. . p

Plasmapheresis NN N
, , N
hemodialysis NN N
, , N
and CC N
chemotherapy NN N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
the DT N
efficacy NN N
of IN N
plasmapheresis NN N
in IN N
preventing VBG N
irreversible JJ o
renal JJ o
failure NN o
in IN N
patients NNS p
with IN p
multiple JJ p
myeloma NN p
and CC N
to TO N
study VB N
the DT N
renal JJ N
biopsy NN N
tissues NNS N
from IN N
such JJ N
patients NNS N
. . N

Twenty-one CD p
patients NNS p
with IN p
active JJ p
myeloma NN p
and CC p
progressive JJ p
renal JJ p
failure NN p
were VBD N
randomized VBN i
to TO i
one CD i
of IN i
two CD i
groups NNS i
: : i
group NN i
1 CD i
, , i
forced VBN i
diuresis NN i
and CC i
chemotherapy NN i
( ( i
10 CD i
patients NNS i
) ) i
, , i
and CC i
group NN i
2 CD i
, , i
forced VBN i
diuresis NN i
, , i
chemotherapy NN i
, , i
and CC i
plasmapheresis NN i
( ( i
11 CD i
patients NNS i
) ) i
. . i

Plasmapheresis NN N
and CC N
chemotherapy NN N
lowered VBD N
the DT N
serum NN o
myeloma NN o
protein IN o
value NN o
much RB N
more RBR N
rapidly RB N
than IN N
chemotherapy VB N
alone JJ N
. . N

Of IN p
5 CD p
patients NNS p
who WP p
were VBD p
oliguric JJ p
and CC p
undergoing JJ p
dialysis NN p
at IN p
presentation NN p
, , N
only RB N
3 CD N
who WP N
were VBD N
treated VBN N
by IN N
plasmapheresis NN N
recovered VBN N
. . N

Of IN p
16 CD p
polyuric JJ p
patients NNS p
, , N
5 CD N
in IN N
group NN N
1 CD N
and CC N
7 CD N
in IN N
group NN N
2 CD N
showed VBD N
improvement NN N
in IN N
renal JJ o
function NN o
. . o

The DT N
main JJ N
factor NN N
that WDT N
determined VBD N
irreversibility NN N
of IN N
renal JJ N
failure NN N
was VBD N
the DT N
severity NN N
of IN N
myeloma NN N
cast NN N
formation NN N
. . N

-DOCSTART- -X- O O

Pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
the DT N
monoamine NN i
oxidase NN i
B NNP i
inhibitor NN i
mofegiline NN i
assessed VBN N
during IN N
a DT N
phase NN N
I PRP N
dose VBP N
tolerance JJ N
trial NN N
. . N

The DT N
safety NN N
, , N
pharmacokinetics NNS i
, , i
and CC i
pharmacodynamics NNS i
of IN i
single JJ i
oral JJ i
doses NNS i
of IN i
up IN i
to TO i
48 CD i
mg NNS i
and CC i
daily JJ i
( ( i
for IN i
28 CD i
days NNS i
) ) i
doses NNS i
of IN i
up IN i
24 CD i
mg NNS i
mofegiline NN i
were VBD N
investigated VBN N
in IN N
healthy JJ p
male NN p
volunteers NNS p
. . p

Plasma NNP N
pharmacokinetics NNS N
indicated VBD N
rapid JJ N
absorption NN N
and CC N
elimination NN N
: : N
time NN N
to TO N
reach VB N
maximum JJ N
concentration NN N
occurred VBD N
at IN N
about IN N
1 CD N
hour NN N
; : N
half-life JJ N
ranged VBD N
from IN N
1 CD N
to TO N
3 CD N
hours NNS N
. . N

Maximal NNP o
plasma JJ o
concentration NN o
and CC o
area NN o
under IN o
the DT o
plasma JJ o
concentration-time JJ o
curve NN o
increased VBD N
and CC N
oral JJ N
clearance NN N
decreased VBD N
disproportionately RB N
with IN N
dose JJ N
. . N

Mofegiline NNP o
rapidly RB o
and CC o
markedly RB o
inhibited JJ o
platelet NN o
monoamine NN o
oxidase NN o
B NNP o
( ( o
MAOB NNP o
) ) o
activity NN o
, , N
which WDT N
returned VBD N
to TO N
baseline VB N
within IN N
14 CD N
days NNS N
. . N

Urinary JJ o
excretion NN o
of IN o
phenylethylamine NN o
increased VBN N
proportionately RB N
with IN N
doses NNS N
up RB N
to TO N
24 CD N
mg. NN N
No NNP N
changes NNS N
in IN N
urinary JJ o
elimination NN o
of IN o
catecholamines NNS o
, , o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
or CC o
ECG NNP o
were VBD N
observed VBN N
. . N

A DT N
classic JJ N
maximum NN o
tolerated VBD o
dose NN o
was VBD N
not RB N
achieved VBN N
in IN N
these DT N
studies NNS N
. . N

However RB N
, , N
the DT N
48 CD N
mg NN N
single JJ N
dose NN N
and CC N
the DT N
24 CD N
mg NN N
multiple JJ N
daily JJ N
dose NN N
far RB N
exceeded VBD N
the DT N
dose NN N
( ( N
1 CD N
mg NN N
) ) N
that WDT N
was VBD N
associated VBN N
with IN N
> JJ N
90 CD N
% NN N
platelet NN N
MAOB NNP N
inhibition NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
monotherapy NN i
and CC i
combination NN i
therapy NN i
on IN N
blood NN N
pressure NN N
control NN N
and CC N
target NN N
organ JJ N
damage NN N
: : N
a DT N
randomized JJ N
prospective JJ N
intervention NN N
study NN N
in IN N
a DT N
large JJ p
population NN p
of IN p
hypertensive JJ p
patients NNS p
. . p

This DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
evaluated VBD N
the DT N
effect NN N
of IN N
monotherapy NN i
and CC i
different JJ i
combination NN i
therapies NNS i
on IN N
cardiovascular JJ p
target NN p
organ JJ p
damage NN p
and CC p
metabolic JJ p
profile NN p
in IN p
520 CD p
hypertensive JJ p
patients NNS p
. . p

Patients NNS N
were VBD N
allocated VBN N
to TO N
a DT N
single JJ N
agent NN N
: : N
carvedilol NN i
25 CD i
mg NN i
, , i
amlodipine VBP i
10 CD i
mg NN i
, , i
enalapril VBZ i
20 CD i
mg NN i
, , i
or CC i
losartan VBZ i
50 CD i
mg NN i
( ( N
groups NNS N
C NNP N
, , N
A NNP N
, , N
E NNP N
, , N
and CC N
L NNP N
, , N
respectively RB N
) ) N
. . N

After IN N
2 CD N
months NNS N
( ( N
level JJ N
2 CD N
) ) N
, , N
nonresponders NNS N
received VBD N
a DT N
low-dose JJ i
thiazide NN i
diuretic NN i
, , N
and CC N
after IN N
4 CD N
months NNS N
( ( N
level JJ N
3 CD N
) ) N
, , N
amlodipine JJ i
( ( N
groups NNS N
E NNP N
, , N
C NNP N
, , N
and CC N
L NNP N
) ) N
and CC N
carvedilol NN i
( ( N
group NN N
A DT N
) ) N
. . N

Twenty-four-hour JJ o
blood NN o
pressure NN o
was VBD N
significantly RB N
lowered VBN N
in IN N
all DT N
treatment NN N
groups NNS N
. . N

Blood NNP o
pressure NN o
control NN o
was VBD N
more RBR N
pronounced JJ N
in IN N
patients NNS p
receiving VBG N
two CD N
or CC N
three CD N
drugs NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
the DT N
carotid JJ o
intima-media JJ o
thickness NN o
decreased VBN N
in IN N
group NN N
L NNP N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
left VBD o
ventricular JJ o
mass NN o
index NN o
in IN N
groups NNS N
E NNP N
and CC N
L NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
and CC N
P NNP N
< NNP N
.001 NNP N
, , N
respectively RB N
) ) N
, , N
with IN N
a DT N
concomitant JJ N
reduction NN N
in IN N
cholesterol NN o
in IN N
group NN N
L NNP N
( ( N
P NNP N
< NNP N
.03 NNP N
) ) N
. . N

Diastolic NNP o
function NN o
improved VBD N
significantly RB N
in IN N
group NN N
L NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

This DT N
study NN N
describes VBZ N
the DT N
need NN N
to TO N
control VB N
blood NN o
pressure NN o
with IN N
two CD N
or CC N
more JJR N
drugs NNS N
in IN N
most JJS N
hypertensive JJ p
patients NNS p
and CC N
illustrates NNS N
good JJ N
clinical JJ N
outcomes NNS N
, , N
independent JJ N
of IN N
blood NN N
pressure NN N
lowering NN N
, , N
using VBG N
combination NN N
therapy NN N
with IN N
losartan JJ i
, , i
low-dose JJ i
thiazide NN i
, , i
and CC i
amlodipine NN i
. . i

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
calcium NN i
supplementation NN i
on IN N
bone NN N
density NN N
in IN N
premenarcheal JJ p
females NNS p
: : p
a DT N
co-twin JJ p
approach NN N
. . N

The DT N
age NN N
and CC N
developmental JJ N
stage NN N
at IN N
which WDT N
calcium NN i
supplementation NN i
produces VBZ N
the DT N
greatest JJS N
bone NN N
effects NNS N
remain VBP N
controversial JJ N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
calcium NN i
supplementation NN i
may MD N
improve VB N
bone NN o
accrual JJ o
in IN N
premenarcheal JJ p
females NNS p
. . p

Fifty-one CD p
pairs NNS p
of IN p
premenarcheal JJ p
female NN p
twins NNS p
( ( p
27 CD p
monozygotic NN p
and CC p
24 CD p
dizygotic JJ p
; : p
mean JJ p
+/- JJ p
sd NN p
age NN p
, , p
10.3 CD p
+/- JJ p
1.5 CD p
yr NN p
) ) p
participated VBD N
in IN N
a DT N
randomized JJ N
, , N
single-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
with IN N
one CD N
twin NN N
of IN N
each DT N
pair NN N
receiving VBG i
a DT i
1200-mg JJ i
calcium NN i
carbonate NN i
( ( i
Caltrate NNP i
) ) i
supplement NN i
. . i

Areal NNP o
bone JJ o
mineral NN o
density NN o
( ( o
aBMD NN o
) ) o
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
6 CD N
, , N
12 CD N
, , N
18 CD N
and CC N
24 CD N
months NNS N
. . N

There EX N
were VBD N
no DT N
within-pair JJ p
differences NNS p
in IN p
height NN p
, , p
weight NN p
, , p
or CC p
calcium NN p
intake NN p
at IN p
baseline NN p
. . p

Calcium NNP N
supplementation NN N
was VBD N
associated VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
increased VBN N
aBMD NNS o
compared VBN N
with IN N
placebo NN N
, , N
adjusted VBN N
for IN N
age NN N
, , N
height NN N
, , N
and CC N
weight NN N
at IN N
the DT N
following JJ N
time NN N
points NNS N
from IN N
baseline NN N
: : N
total JJ N
hip NN N
, , N
6 CD N
months NNS N
( ( N
1.9 CD N
% NN N
) ) N
, , N
12 CD N
months NNS N
( ( N
1.6 CD N
% NN N
) ) N
, , N
and CC N
18 CD N
months NNS N
( ( N
2.4 CD N
% NN N
) ) N
; : N
lumbar CC N
spine NN N
, , N
12 CD N
months NNS N
( ( N
1.0 CD N
% NN N
) ) N
; : N
femoral JJ N
neck NN N
, , N
6 CD N
months NNS N
( ( N
1.9 CD N
% NN N
) ) N
. . N

Adjusted VBN o
total JJ o
body NN o
bone JJ o
mineral JJ o
content NN o
was VBD N
higher RBR N
in IN N
the DT N
calcium NN N
group NN N
at IN N
6 CD N
months NNS N
( ( N
2.0 CD N
% NN N
) ) N
, , N
12 CD N
months NNS N
( ( N
2.5 CD N
% NN N
) ) N
, , N
18 CD N
months NNS N
( ( N
4.6 CD N
% NN N
) ) N
, , N
and CC N
24 CD N
months NNS N
( ( N
3.7 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Calcium NNP i
supplementation NN i
was VBD N
effective JJ N
in IN N
increasing VBG N
aBMD NN o
at IN N
regional JJ N
sites NNS N
over IN N
the DT N
first JJ N
12-18 JJ N
months NNS N
, , N
but CC N
these DT N
gains NNS N
were VBD N
not RB N
maintained VBN N
to TO N
24 CD N
months NNS N
. . N

-DOCSTART- -X- O O

Vitamin NNP i
C NNP i
and CC N
acute JJ N
illness NN N
in IN N
Navajo NNP p
school NN p
children NNS p
. . p

To TO N
evaluate VB N
earlier JJR N
observations NNS N
, , N
including VBG N
our PRP$ N
own JJ N
, , N
showing VBG N
usefulness NN N
of IN N
vitamin NN i
C NNP i
for IN N
managing VBG N
the DT N
common JJ N
cold NN N
, , N
we PRP N
performed VBD N
a DT N
double-blind JJ N
trial NN N
of IN N
vitamin NN i
C NNP i
versus NN i
placebo NN i
in IN N
868 CD p
children NNS p
. . p

There EX N
was VBD N
no DT N
difference NN N
in IN N
number NN o
becoming VBG o
ill JJ o
( ( N
133 CD N
versus IN N
129 CD N
) ) N
, , N
number NN o
of IN o
episodes NNS o
( ( N
166 CD N
versus IN N
159 CD N
) ) N
or CC N
mean JJ o
illness JJ o
duration NN o
( ( N
5.5 CD N
versus NN N
5.8 CD N
days NNS N
) ) N
between IN N
the DT N
groups NNS N
. . N

Children NNP p
receiving VBG p
vitamin NN p
C NNP p
had VBD N
fewer JJR N
throat NN o
cultures NNS o
yielding VBG N
beta-hemolytic JJ o
streptococcus NN o
( ( N
six CD N
versus NN N
13 CD N
, , N
P NNP N
less JJR N
than IN N
0.10 CD N
) ) N
, , N
but CC N
no DT N
difference NN N
in IN N
overall JJ o
complicated JJ o
illness NN o
rate NN o
( ( N
24 CD N
versus IN N
25 CD N
) ) N
. . N

Plasma NNP o
ascorbic JJ o
acid NN o
levels NNS o
were VBD N
higher JJR N
in IN N
the DT N
vitamin NN p
group NN p
24 CD N
to TO N
26 CD N
hours NNS N
after IN N
supplementation NN N
( ( N
1.28 CD N
versus NN N
1.04 CD N
mg NN N
per IN N
100 CD N
ml NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Children NNP p
with IN p
high JJ p
plasma NN p
ascorbic JJ p
acid JJ p
concentrations NNS N
had VBD N
longer RBR N
mean JJ o
illness NN o
( ( N
6.8 CD N
versus NN N
4.0 CD N
days NNS N
, , N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
than IN N
those DT N
with IN N
low JJ N
levels NNS N
. . N

Vitamin NNP i
C NNP i
does VBZ N
not RB N
seem VB N
to TO N
be VB N
an DT N
effective JJ N
prophylactic NN N
or CC N
therapeutic JJ N
agent NN N
for IN N
upper JJ N
respiratory NN N
illness NN N
. . N

-DOCSTART- -X- O O

Local JJ o
contextual JJ o
processing NN o
in IN N
major JJ N
depressive JJ N
disorder NN N
. . N

OBJECTIVE CC N
The DT N
study NN N
investigated VBD N
local JJ o
contextual JJ o
processing NN o
in IN N
patients NNS p
with IN p
major JJ p
depressive JJ p
disorder NN p
( ( p
MDD NNP p
) ) p
. . p

This DT N
was VBD N
defined VBN N
as IN N
the DT N
ability NN N
to TO N
utilize VB N
predictive JJ N
contextual JJ N
information NN N
to TO N
facilitate VB N
detection NN N
of IN N
predictable JJ N
versus NN N
random JJ N
targets NNS N
. . N

METHOD NNP N
We PRP N
recorded VBD N
EEG NNP i
in IN N
15 CD p
MDD NNP p
patients NNS p
and CC p
14 CD p
age-matched JJ p
controls NNS p
. . p

Recording VBG i
blocks NNS i
consisted VBN i
of IN i
targets NNS i
preceded VBN i
by IN i
randomized JJ i
sequences NNS i
of IN i
standards NNS i
and CC i
by IN i
sequences NNS i
of IN i
standards NNS i
that WDT i
included VBD i
a DT i
predictive JJ i
sequence NN i
signaling VBG i
the DT i
occurrence NN i
of IN i
a DT i
subsequent JJ i
target NN i
event NN i
. . i

RESULTS NNP N
Both NNP N
MDD NNP p
patients NNS p
and CC p
age-matched JJ p
controls NNS p
demonstrated VBD N
a DT N
significant JJ o
reaction NN o
time NN o
( ( o
RT NNP o
) ) o
and CC o
P3b NNP o
latency NN o
differences NNS o
between IN N
predicted VBN N
and CC N
random JJ N
targets NNS N
. . N

However RB N
, , N
patients NNS N
demonstrated VBD N
a DT N
specific JJ o
prolongation NN o
of IN N
these DT N
measures NNS N
during IN N
processing NN N
of IN N
predicted JJ N
targets NNS N
, , N
as RB N
well RB N
as IN N
an DT N
attenuation NN o
of IN o
P3b NNP o
amplitudes NNS o
for IN N
the DT N
predictive JJ N
sequence NN N
. . N

In IN N
addition NN N
, , N
patients NNS N
target VBP N
N1 NNP o
amplitudes NNS o
were VBD o
attenuated VBN o
compared VBN N
with IN N
controls NNS i
. . i

CONCLUSION NNP N
MDD NNP p
patients NNS p
were VBD N
able JJ N
to TO N
utilize VB o
predictive JJ o
context NN o
in IN N
order NN N
to TO N
facilitate VB N
processing NN N
of IN N
deterministic JJ N
targets NNS N
, , N
however RB N
, , N
this DT N
ability NN o
was VBD o
limited VBN o
compared VBN N
to TO N
controls NNS N
, , N
as IN N
demonstrated VBN N
by IN N
context-dependent JJ N
P3b NNP N
deficits NNS N
. . N

SIGNIFICANCE NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
patients NNS N
with IN N
major JJ N
depression NN N
have VBP N
altered VBN o
processing NN o
of IN o
local JJ o
contextual JJ o
processing NN o
. . o

-DOCSTART- -X- O O

Removal NN i
of IN i
hypertrophied JJ i
anal JJ i
papillae NN i
and CC i
fibrous JJ i
anal JJ i
polyps NN i
increases NNS N
patient JJ o
satisfaction NN o
after IN p
anal JJ p
fissure NN p
surgery NN p
. . p

BACKGROUND NNP N
Hypertrophied NNP N
anal JJ N
papillae NN N
and CC N
fibrous JJ N
anal JJ N
polyps NNS N
are VBP N
frequently RB N
found VBN N
in IN N
association NN N
with IN N
chronic JJ N
fissure NN N
in IN N
ano NN N
. . N

Usually RB N
, , N
no DT N
specific JJ N
attention NN N
is VBZ N
given VBN N
to TO N
them PRP N
and CC N
they PRP N
are VBP N
considered VBN N
normal JJ N
findings NNS N
. . N

The DT N
present JJ N
prospective JJ N
study NN N
was VBD N
aimed VBN N
at IN N
determining VBG N
whether IN N
removal NN i
of IN i
hypertrophied JJ i
anal JJ i
papillae NN i
and CC i
fibrous JJ i
anal JJ i
polyps NNS i
while IN N
dealing VBG N
with IN N
chronic JJ N
fissure NN N
in IN N
ano JJ N
confers NNS N
long-term JJ o
benefit NN o
to TO N
patients NNS p
. . p

METHODS NNP N
Between NNP p
July NNP p
1999 CD p
and CC p
December NNP p
2000 CD p
, , p
140 CD p
patients NNS p
undergoing JJ p
anal JJ p
sphincterotomy NN p
were VBD N
randomized VBN i
into IN i
two CD i
groups NNS i
to TO i
have VB i
their PRP$ i
fibrous JJ i
polyps NNS i
and CC i
hypertrophied VBD i
anal JJ i
papillae NN i
either DT i
removed VBN i
by IN i
radiofrequency NN i
surgery NN i
or CC i
left VBN i
intact JJ i
. . i

After IN N
two CD N
years NNS N
, , N
they PRP N
underwent VBP N
a DT N
detailed JJ N
interview NN o
by IN o
an DT o
independent JJ o
, , o
masked JJ o
investigator NN o
. . o

RESULTS NNP N
Overall JJ N
84 CD N
% NN N
of IN N
patients NNS p
who WP p
had VBD p
polyp NN p
and CC p
papilla NN p
removal NN p
rated VBD N
the DT N
outcome NN o
of IN o
their PRP$ o
surgery NN o
as IN N
excellent NN N
or CC N
good JJ N
in IN N
comparison NN N
to TO N
58 CD N
% NN N
of IN N
controls NNS N
. . N

The DT N
mean JJ N
satisfaction NN N
grading NN N
was VBD N
9.2 CD N
on IN N
a DT N
visual JJ o
analogue NN o
scale NN o
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
8.1 CD N
in IN N
controls NNS N
( ( N
p=0.004 NN N
) ) N
. . N

CONCLUSION NNP N
Removal NNP i
of IN i
hypertrophied JJ i
anal JJ i
papillae NN i
and CC i
fibrous JJ i
anal JJ i
polyps NNS i
should MD N
be VB N
an DT N
essential JJ N
part NN N
of IN N
treatment NN N
of IN N
chronic JJ N
fissure NN N
in IN N
ano NN N
. . N

Persistence NN N
of IN N
these DT N
structures NNS N
leaves VBZ N
behind IN N
a DT N
sense NN N
of IN N
incomplete JJ N
treatment NN N
, , N
reducing VBG N
the DT N
overall JJ o
satisfaction NN o
on IN N
the DT N
part NN N
of IN N
the DT N
patient NN N
. . N

Radiofrequency NNP i
procedure NN i
is VBZ N
useful JJ N
in IN N
eradication NN N
of IN N
these DT N
concomitant JJ N
pathologies NNS N
. . N

-DOCSTART- -X- O O

Preliminary JJ N
evaluation NN N
of IN N
psychoeducational JJ i
support NN i
interventions NNS i
on IN N
quality NN o
of IN o
life NN o
in IN N
rural JJ p
breast NN p
cancer NN p
survivors NNS p
after IN p
primary JJ p
treatment NN p
. . p

Although IN N
most JJS N
cancer NN p
survivors NNS p
are VBP N
at IN N
risk NN N
for IN N
being VBG N
lost VBN N
in IN N
the DT N
transition NN N
from IN N
treatment NN N
to TO N
survivorship VB N
, , N
rural JJ p
breast NN p
cancer NN p
survivors NNS p
face VBP N
special JJ N
challenges NNS N
that WDT N
might MD N
place VB N
them PRP N
at IN N
particular JJ N
risk NN N
. . N

This DT N
small-scale JJ N
preliminary JJ N
study NN N
had VBD N
2 CD N
specific JJ N
aims NNS N
: : N
( ( N
aim IN N
1 CD N
) ) N
establish VB N
the DT N
feasibility NN N
of IN N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
participation VBP N
in IN N
a DT N
longitudinal JJ i
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
intervention NN i
trial NN N
and CC N
( ( N
aim VB N
2 CD N
) ) N
determine VB N
the DT N
effects NNS N
of IN N
the DT N
Breast NNP i
Cancer NNP i
Education NNP i
Intervention NNP i
( ( i
BCEI NNP i
) ) i
on IN N
overall JJ o
QOL NNP o
. . o

Fifty-three JJ p
rural JJ p
breast NN p
cancer NN p
survivors NNS p
were VBD N
randomized VBN N
to TO N
either DT N
an DT N
experimental JJ N
( ( N
n JJ N
= NNP N
27 CD N
) ) N
or CC N
a DT N
wait-control JJ N
arm NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
. . N

Participants NNS N
in IN N
the DT N
experimental JJ N
arm NN N
received VBD N
the DT N
BCEI NNP N
consisting NN N
of IN N
3 CD i
face-to-face JJ i
education NN i
and CC i
support NN i
sessions NNS i
and CC N
2 CD N
face-to-face NN N
and CC N
3 CD N
telephone NN i
follow-up JJ i
sessions NNS i
, , N
along IN N
with IN N
supplemental JJ N
written VBN N
and CC N
audiotape JJ N
materials NNS N
over IN N
a DT N
6-month JJ N
period NN N
. . N

Breast NNP i
Cancer NNP i
Education NNP i
Intervention NNP i
modules NNS i
and CC i
interventions NNS i
are VBP N
organized VBN N
within IN N
a DT N
QOL NNP N
framework NN N
. . N

To TO N
address VB N
the DT N
possible JJ N
effects NNS N
of IN N
attention NN N
, , N
wait-control JJ N
participants NNS N
received VBD N
3 CD N
face-to-face JJ N
sessions NNS N
and CC N
3 CD N
telephone NN N
sessions NNS N
during IN N
the DT N
first JJ N
6 CD N
months NNS N
of IN N
participation NN N
in IN N
the DT N
study NN N
, , N
but CC N
not RB N
the DT N
BCEI NNP i
intervention NN i
. . i

Research NNP N
questions NNS N
addressing VBG N
aim NN N
1 CD N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
a DT N
) ) N
can MD N
rural VB N
breast NN N
cancer NN N
survivors NNS N
be VB N
recruited VBN N
into IN N
a DT N
longitudinal JJ N
intervention NN N
trial NN N
, , N
and CC N
( ( N
b NN N
) ) N
can MD N
their PRP$ N
participation NN N
be VB N
retained VBN N
. . N

Research NNP N
questions NNS N
for IN N
aim NN N
2 CD N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
a DT N
) ) N
do VBP N
participants NNS N
who WP N
received VBD N
the DT N
BCEI NNP N
show NN N
improvement NN N
in IN N
overall JJ o
QOL NNP o
, , N
and CC N
( ( N
b NN N
) ) N
is VBZ N
the DT N
QOL NNP o
improvement NN o
sustained VBD N
over IN N
time NN N
. . N

Data NNS N
were VBD N
analyzed VBN N
using VBG N
repeated-measures JJ N
general JJ N
linear NN N
mixed JJ N
models NNS N
. . N

Results NNS N
demonstrated VBD N
the DT N
ability NN N
to TO N
recruit VB N
and CC N
retain VB N
53 CD N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
, , N
that IN N
the DT N
experimental JJ N
arm NN N
showed VBD N
improvement NN N
in IN N
overall JJ o
QOL NNP o
( ( N
P NNP N
= NNP N
.013 NNP N
) ) N
, , N
and CC N
that IN N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
overall JJ o
QOL NNP o
between IN N
the DT N
experimental JJ N
and CC N
wait-control JJ N
groups NNS N
at IN N
both DT N
months NNS N
3 CD N
and CC N
6 CD N
. . N

Thus RB N
, , N
it PRP N
appears VBZ N
that IN N
at IN N
least JJS N
some DT N
rural JJ p
breast NN p
cancer NN p
survivors NNS p
can MD N
and CC N
will MD N
participate VB N
in IN N
a DT N
larger JJR N
trial NN N
and CC N
will MD N
maintain VB N
their PRP$ N
participation NN N
and CC N
that IN N
those DT N
that WDT N
do VBP N
participate VB N
experience NN N
significant JJ N
QOL NNP o
benefit NN N
. . N

-DOCSTART- -X- O O

Single-use NNP N
plaque NN N
removal NN N
efficacy NN o
of IN N
three CD p
power NN i
toothbrushes NNS i
. . i

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
safety NN o
and CC o
plaque NN o
removal NN o
efficacy NN o
of IN N
two CD i
oscillating/rotating/pulsating VBG i
toothbrushes NNS i
( ( i
Oral-B NNP i
ProfessionalCare NNP i
7000 CD i
[ NNP i
PC NN i
7000 CD i
] NN i
and CC i
Oral-B JJ i
3D CD i
Excel NNP i
[ VBD i
3DE CD i
] NN i
) ) i
and CC i
a DT i
high-frequency NN i
toothbrush NN i
( ( i
Sonicare NNP i
Advance NNP i
, , i
Philips NNP i
Oral NNP i
Healthcare NNP i
; : i
SA NNP i
) ) i
in IN N
a DT N
single-use NN N
, , N
examiner-blind NN N
, , N
three CD N
period NN N
crossover NN N
study NN N
. . N

METHODS NNP N
After IN p
refraining VBG p
from IN p
all DT p
oral JJ p
hygiene NN p
procedures NNS p
for IN p
23-25 JJ p
hours NNS p
, , p
subjects NNS p
received VBD p
an DT p
oral JJ p
tissue NN p
examination NN p
and CC N
those DT N
with IN N
pre-brushing JJ N
whole JJ N
mouth NN N
mean JJ N
plaque NN N
scores NNS N
> VBP N
or CC N
= VBP N
0.6 CD N
based VBN N
on IN N
the DT N
Rustogi NNP N
et CC N
al NN N
. . N

Modified NNP N
Navy NNP N
Plaque NNP N
Index NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
sequence NN N
. . N

After IN N
brushing VBG N
with IN N
the DT N
assigned JJ N
toothbrush NN N
and CC N
a DT N
commercially RB N
available JJ N
dentifrice NN N
for IN N
2 CD N
minutes NNS N
, , N
oral JJ o
tissues NNS o
were VBD o
then RB o
re-examined JJ o
and CC o
post-brushing JJ o
plaque NN o
scores NNS o
recorded VBN o
. . o

Following VBG N
a DT N
brief JJ N
washout JJ N
period NN N
between IN N
two CD N
additional JJ N
visits NNS N
, , N
the DT N
above NN N
procedures NNS N
were VBD N
repeated VBN N
with IN N
the DT N
two CD N
alternate NN N
toothbrushes NNS N
. . N

One CD N
examiner NN N
, , N
blinded VBD N
to TO N
the DT N
treatment NN N
sequence NN N
, , N
performed VBD N
all DT N
clinical JJ N
measurements NNS N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
79 CD p
subjects NNS p
( ( p
28 CD p
males NNS p
and CC p
51 CD p
females NNS p
) ) p
were VBD p
enrolled VBN p
and CC p
completed VBN p
the DT p
study NN p
. . p

Each DT N
toothbrush NN N
was VBD N
found VBN N
to TO N
be VB N
safe JJ o
and CC N
significantly RB N
reduced VBN N
plaque NN o
levels NNS o
after IN N
a DT N
single JJ N
brushing NN N
. . N

The DT N
PC NN N
7000 CD N
and CC N
3DE CD N
were VBD N
equally RB N
more RBR N
effective JJ N
in IN N
plaque NN o
removal NN o
than IN N
the DT N
SA NNP N
, , N
at IN N
all DT N
tooth DT N
areas NNS N
, , N
reducing VBG N
plaque NN o
by IN N
59.0 CD N
% NN N
, , N
59.7 CD N
% NN N
and CC N
51.8 CD N
% NN N
, , N
respectively RB N
on IN N
whole JJ N
mouth NN N
surfaces NNS N
, , N
and CC N
by IN N
67.5 CD N
% NN N
, , N
67.8 CD N
% NN N
and CC N
59.4 CD N
% NN N
, , N
respectively RB N
on IN N
approximal JJ N
surfaces NNS N
. . N

CONCLUSIONS VB N
The DT N
action NN N
of IN N
the DT N
oscillating/rotating/pulsating NN N
toothbrushes NNS N
( ( N
Oral-B NNP N
ProfessionalCare NNP N
7000 CD N
and CC N
Oral-B NNP N
3D CD N
Excel NNP N
) ) N
was VBD N
more RBR N
effective JJ N
in IN N
plaque NN N
removal NN N
than IN N
the DT N
high-frequency NN N
toothbrush NN N
( ( N
Sonicare NNP N
Advance NNP N
) ) N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
omega JJ i
3 CD i
fatty JJ i
acids NNS i
and CC i
vitamin NN i
E NNP i
supplements NNS i
on IN N
lipid JJ o
peroxidation NN o
measured VBN N
by IN N
breath NN i
ethane NN i
and CC N
pentane NN i
output NN i
: : i
a DT p
randomized NN p
controlled VBN p
trial NN p
. . p

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
cisapride NN i
on IN N
delayed JJ N
colonic JJ o
transit NN o
time NN o
in IN N
patients NNS p
with IN p
idiopathic JJ p
Parkinson NNP p
's POS p
disease NN p
. . p

Disorders NNS p
of IN p
autonomic JJ p
regulation NN p
are VBP N
common JJ N
in IN N
patients NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
( ( p
PD NNP p
) ) p
. . p

Patients NNS N
most RBS N
frequently RB N
complain VBP N
of IN N
dysphagia NN N
and CC N
therapy NN N
resistant JJ N
constipation NN N
, , N
as RB N
far RB N
as IN N
the DT N
gastrointestinal JJ N
tract NN N
is VBZ N
concerned VBN N
. . N

These DT N
symptoms NNS N
have VBP N
to TO N
be VB N
attributed VBN N
to TO N
a DT N
neuronal JJ N
degeneration NN N
. . N

In IN N
a DT N
pilot NN N
study NN N
we PRP N
therefore RB N
investigated VBD N
the DT N
effect NN N
of IN N
stimulation NN N
of IN N
the DT N
myenteric JJ N
plexus NN N
by IN N
cisapride NN i
. . i

11 CD p
women NNS p
and CC p
13 CD p
men NNS p
were VBD p
examined VBN p
, , p
the DT p
average JJ p
age NN p
was VBD p
67.3 CD p
years NNS p
, , p
the DT p
Webster NNP p
rating NN p
17 CD p
points NNS p
. . p

In IN N
2 CD N
out IN N
of IN N
24 CD N
patients NNS N
, , N
colonic JJ o
transit NN o
was VBD N
prolonged VBN N
up RB N
to TO N
the DT N
limit NN N
, , N
both DT N
with IN N
and CC N
without IN N
therapy NN N
. . N

The DT N
other JJ N
22 CD N
patients NNS N
showed VBD N
an DT N
acceleration NN o
in IN o
transit NN o
on IN N
response NN N
to TO N
cisapride VB i
. . i

On IN N
average JJ N
the DT N
colonic JJ o
transit NN o
of IN N
130 CD N
hours NNS N
was VBD N
reduced VBN N
to TO N
79 CD N
hours NNS N
. . N

This DT N
objective JJ N
improvement NN N
was VBD N
associated VBN N
with IN N
a DT N
subjective JJ N
improvement NN N
. . N

Central JJ N
side NN N
effects NNS N
or CC N
a DT N
worsening NN o
of IN o
Parkinsonian JJ o
symptoms NNS o
were VBD N
not RB N
found VBN N
. . N

We PRP N
conclude VBP N
that DT N
cisapride NN i
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
constipation NN p
in IN p
idiopathic JJ p
PD NNP p
. . p

-DOCSTART- -X- O O

Prior JJ p
experience NN p
with IN p
a DT p
pain NN p
stimulus NN p
as IN N
a DT N
predictor NN N
of IN N
placebo NN N
analgesia NN o
. . o

Placebo NNP i
effects NNS N
are VBP N
important JJ N
in IN N
pain NN o
reduction NN o
, , N
but CC N
the DT N
effects NNS N
are VBP N
inconsistent JJ N
. . N

Prior JJ N
experience NN N
with IN N
a DT N
pain NN N
stimulus NN N
may MD N
moderate VB N
placebo NN N
analgesia NN o
. . o

The DT N
current JJ N
study NN N
tests VBZ N
the DT N
effect NN N
of IN N
prior JJ N
experience NN N
with IN N
a DT N
pain NN N
stimulus NN N
on IN N
placebo NN o
analgesia NN o
during IN N
a DT N
laboratory NN N
pain NN N
task NN N
. . N

Healthy NNP p
normotensive JJ p
undergraduates NNS p
( ( p
66 CD p
women NNS p
, , p
68 CD p
men NNS p
) ) p
who WP p
either DT p
did VBD p
or CC p
did VBD p
not RB p
report VB p
prior JJ p
experience NN p
with IN p
pain NN o
from IN p
submerging VBG p
a DT p
limb NN p
in IN p
cold JJ p
water NN p
were VBD p
enrolled VBN p
. . p

In IN N
the DT N
laboratory NN N
, , N
an DT N
experimenter NN N
applied VBD N
an DT N
inert NN N
, , N
medicinal-smelling JJ i
cream NN i
to TO N
participants NNS N
' POS N
non-dominant JJ N
hand NN N
. . N

Participants NNS N
randomized VBD N
to TO N
the DT N
no-expectation JJ N
group NN N
were VBD N
told VBN N
that IN N
the DT N
cream NN i
was VBD i
a DT i
hand NN i
cleanser NN i
. . i

Participants NNS N
randomized VBD N
to TO N
the DT N
placebo NN i
expectation NN N
group NN N
were VBD N
told VBN N
that IN N
the DT N
cream NN i
would MD N
reduce VB N
the DT N
pain NN o
associated VBN N
with IN N
the DT N
cold JJ i
pressor NN i
task NN i
. . i

Participants NNS N
then RB N
completed VBD N
the DT N
cold JJ i
pressor NN i
task NN i
and CC N
reported VBD N
their PRP$ N
pain NN o
on IN N
the DT N
short JJ N
form NN N
of IN N
the DT N
McGill NNP o
Pain NNP o
Questionnaire NNP o
. . o

Analysis NN N
of IN N
variance NN N
revealed VBD N
a DT N
main JJ N
effect NN N
of IN N
expectation NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
, , N
such JJ N
that IN N
participants NNS N
in IN N
the DT N
placebo NN N
expectation NN N
group NN N
reported VBD N
less JJR o
pain NN o
. . o

An DT N
interaction NN N
was VBD N
also RB N
found VBN N
between IN N
expectation NN N
and CC N
prior JJ N
experience NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
, , N
such JJ N
that IN N
participants NNS N
with IN N
prior JJ N
experience NN N
with IN N
pain NN o
from IN o
cold JJ N
water NN N
immersion NN N
showed VBD N
no DT N
difference NN o
in IN o
pain NN o
reports NNS o
between IN o
expectation NN N
groups NNS N
. . N

In IN N
a DT N
pain NN N
context NN p
, , p
prior JJ p
experience NN p
with IN p
the DT p
pain NN p
stimulus NN p
may MD p
prevent VB i
a DT i
placebo JJ i
expectation NN i
from IN N
reducing VBG N
the DT N
experience NN o
of IN o
pain NN o
. . o

-DOCSTART- -X- O O

Cost-effectiveness NN o
of IN N
cognitive-behavioral JJ i
group NN i
therapy NN i
for IN N
dysfunctional JJ N
fear NN N
of IN N
progression NN N
in IN N
cancer NN p
patients NNS p
. . p

Anxiety NNP o
and CC o
fear NN o
are VBP N
often RB N
associated VBN N
with IN N
chronic JJ N
conditions NNS N
such JJ N
as IN N
cancer NN N
. . N

This DT N
paper NN N
targets VBZ N
the DT N
cost-effectiveness JJ o
analysis NN o
of IN N
a DT N
cognitive-behavioral JJ i
group NN i
therapy NN i
( ( i
CBT NNP i
) ) i
in IN N
comparison NN N
to TO N
a DT N
client-centered JJ i
, , i
supportive-experiential JJ i
group NN i
therapy NN i
( ( i
SET NNP i
) ) i
in IN N
cancer NN p
patients NNS p
with IN p
dysfunctional JJ p
fear NN p
of IN p
progression NN p
. . p

An DT N
incremental JJ N
cost-effectiveness JJ o
analysis NN o
was VBD N
performed VBN N
using VBG N
data NNS N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
among IN N
cancer NN p
patients NNS p
receiving VBG p
inpatient JJ p
rehabilitation NN p
. . p

The DT N
means NNPS o
, , o
95 CD o
% NN o
confidence NN o
intervals NNS o
[ VBP o
95 CD o
% NN o
CI NNP o
] NNP o
, , o
incremental JJ o
cost-effectiveness JJ o
graphic NN o
and CC o
acceptability NN o
curve NN o
were VBD N
obtained VBN N
from IN N
1,000 CD N
bootstrap NN N
replications NNS N
. . N

A DT p
total NN p
of IN p
174 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
economic JJ p
evaluation NN p
. . p

The DT N
estimated JJ o
means VBZ o
[ JJ N
95 CD N
% NN N
CI NNP N
] NNP N
of IN o
direct JJ o
costs NNS o
and CC o
reduction NN o
of IN o
fear NN o
of IN o
progression NN o
were VBD N
< JJ N
euro JJ N
> NN N
9,045.03 CD N
[ JJ N
6,359.07 CD N
; : N
12,091.87 CD N
] NN N
and CC N
1.41 CD N
[ JJ N
0.93 CD N
; : N
1.92 CD N
] NN N
for IN N
patients NNS N
in IN N
the DT N
SET NNP N
and CC N
< NNP N
euro VBP N
> $ N
6,682.78 CD N
[ JJ N
4,998.09 CD N
; : N
8,440.95 CD N
] NN N
and CC N
1.44 CD N
[ JJ N
1.02 CD N
; : N
1.09 CD N
] NN N
for IN N
patients NNS N
in IN N
the DT N
CBT NNP i
. . i

The DT N
incremental JJ o
cost-effectiveness JJ o
ratio NN o
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
amounts NNS N
to TO N
minus NNS N
< NNP N
euro VBP N
> $ N
78,741.66 CD N
[ NNP N
-154,987.20 NNP N
; : N
110,486.32 CD N
] NN N
for IN N
an DT N
additional JJ N
unit NN N
of IN N
effect NN N
. . N

Given VBN N
the DT N
acceptability NN o
curve NN o
, , N
there EX N
is VBZ N
a DT N
92.4 CD N
% NN N
chance NN N
that IN N
the DT N
CBT NNP i
, , N
compared VBN N
with IN N
the DT N
SET NNP i
, , N
is VBZ N
cost-effective JJ o
without IN N
the DT N
need NN N
of IN N
additional JJ N
costs NNS N
to TO N
payers NNS N
. . N

Our PRP$ N
main JJ N
result NN N
is VBZ N
the DT N
superior JJ N
cost-effectiveness NN o
of IN N
the DT N
cognitive-behavioral JJ i
intervention NN i
program NN N
in IN N
comparison NN N
to TO N
the DT N
non-directive JJ N
encounter NN N
group NN N
for IN N
our PRP$ N
sample NN N
of IN N
cancer NN p
patients NNS p
with IN p
high JJ p
levels NNS p
of IN p
anxiety NN o
. . o

-DOCSTART- -X- O O

Effects NNS N
of IN N
topical JJ i
boswellic JJ i
acid NN i
on IN N
photo NN p
and CC p
age-damaged JJ p
skin NN p
: : p
clinical JJ o
, , o
biophysical JJ o
, , o
and CC o
echographic JJ o
evaluations NNS o
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
split-face JJ N
study NN N
. . N

Boswellic NNP i
acids NNS i
( ( i
BAs NNP i
) ) i
are VBP N
pentacyclic JJ N
triterpenes NNS N
with IN N
strong JJ N
anti-inflammatory JJ N
activity NN N
; : N
their PRP$ N
most RBS N
important JJ N
source NN N
is VBZ N
the DT N
extract NN N
of IN N
the DT N
gum NN N
resin NN N
of IN N
Boswellia NNP N
serrata NN N
, , N
a DT N
tropical JJ N
tree NN N
that WDT N
grows VBZ N
in IN N
India NNP N
and CC N
Africa NNP N
. . N

In IN N
the DT N
present JJ N
randomized VBN N
, , N
double-blind JJ N
, , N
split-face JJ N
, , N
comparative JJ N
study NN N
we PRP N
have VBP N
assessed VBN N
efficacy NN o
, , o
tolerability NN o
, , o
and CC o
safety NN o
of IN N
a DT N
base NN i
cream NN i
containing VBG i
0.5 CD i
% NN i
BAs NNP i
as IN N
compared VBN N
to TO N
the DT i
same JJ i
cream NN i
without IN i
these DT i
active JJ i
ingredients NNS i
in IN N
the DT N
treatment NN N
of IN N
clinical JJ N
manifestations NNS N
of IN N
photoaging NN p
of IN p
facial JJ p
skin NN p
. . p

Fifteen NNP p
female JJ p
volunteers NNS p
were VBD p
enrolled VBN p
; : p
they PRP N
applied VBD N
creams NNS N
once RB N
daily RB N
for IN N
30 CD N
days NNS N
. . N

At IN N
baseline NN N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
, , N
and CC N
after IN N
a DT N
2-month JJ N
follow-up NN N
, , N
clinical JJ N
findings NNS N
were VBD N
assessed VBN N
according VBG N
to TO N
the DT N
Dover NNP o
classification NN o
scale NN o
for IN o
photoaging VBG o
and CC N
by IN N
biophysical JJ o
and CC o
ecographic JJ o
measurements NNS o
. . o

We PRP N
registered VBD N
a DT N
significant JJ N
improvement NN N
of IN N
tactile JJ o
roughness NN o
and CC o
fine JJ o
lines NNS o
in IN N
the DT N
half JJ N
side NN N
of IN N
the DT N
face NN N
treated VBD N
with IN N
BAs NNP i
; : i
noninvasive JJ N
instrumental JJ N
diagnostic JJ N
investigations NNS N
showed VBD N
an DT N
improvement NN N
of IN N
elasticity NN o
, , N
a DT N
decrease NN N
of IN N
sebum JJ o
excretion NN o
, , N
and CC N
a DT N
change NN N
of IN N
echographic JJ o
parameters NNS o
suggesting VBG N
a DT N
reshaping NN o
of IN o
dermal JJ o
tissue NN o
. . o

The DT N
treatment NN N
was VBD N
always RB N
well RB N
tolerated VBN o
without IN N
adverse JJ o
effects NNS o
. . o

The DT N
present JJ N
findings NNS N
seem VBP N
to TO N
indicate VB N
that IN N
the DT N
topical JJ N
application NN N
of IN N
BAs NNP i
may MD N
represent VB N
a DT N
suitable JJ N
treatment NN N
option NN N
for IN N
selected VBN N
features NNS N
of IN N
skin NN p
photoaging NN p
. . p

-DOCSTART- -X- O O

The DT N
role NN N
of IN N
choice NN N
in IN N
health NN p
education NN p
intervention NN p
trials NNS p
: : p
a DT N
review NN N
and CC N
case NN N
study NN N
. . N

Although IN N
the DT N
randomized VBN N
, , N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
is VBZ N
considered VBN N
the DT N
gold JJ N
standard NN N
in IN N
research NN N
for IN N
determining VBG N
the DT N
efficacy NN N
of IN N
health NN N
education NN N
interventions NNS N
, , N
such JJ N
trials NNS N
may MD N
be VB N
vulnerable JJ N
to TO N
preference VB N
effects NNS N
; : N
that DT N
is VBZ N
, , N
differential JJ N
outcomes NNS N
depending VBG N
on IN N
whether IN N
an DT N
individual NN N
is VBZ N
randomized VBN N
to TO N
his PRP$ N
or CC N
her PRP$ N
preferred JJ N
treatment NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
review VBP N
theoretical JJ N
and CC N
empirical JJ N
literature NN N
regarding VBG N
designs NNS N
that WDT N
account VBP N
for IN N
such JJ N
effects NNS N
in IN N
medical JJ N
research NN N
, , N
and CC N
consider VB N
the DT N
appropriateness NN N
of IN N
these DT N
designs NNS N
to TO N
health NN p
education NN p
research NN p
. . p

To TO N
illustrate VB N
the DT N
application NN N
of IN N
a DT N
preference NN N
design NN N
to TO N
health NN N
education NN N
research NN N
, , N
we PRP N
present VBP N
analyses NNS N
using VBG N
process NN N
data NNS N
from IN N
a DT N
mixed JJ p
RCT/preference NNP p
trial NN p
comparing VBG p
two CD p
formats NNS p
( ( i
Group NNP i
or CC N
Self-Directed NNP i
) ) i
of IN N
the DT N
Women NNP p
take VB p
PRIDE NNP p
heart NN p
disease NN p
management NN p
program NN p
. . p

Results NNP N
indicate VBP N
that IN N
being VBG N
able JJ N
to TO N
choose VB N
one CD N
's POS N
program NN N
format NN N
did VBD N
not RB N
significantly RB N
affect VB N
the DT N
decision NN o
to TO o
participate VB o
in IN N
the DT N
study NN N
. . N

However RB N
, , N
women NNS p
who WP N
chose VBD i
the DT i
Group NNP i
format WDT i
were VBD N
over RB N
4 CD N
times NNS N
as RB N
likely JJ N
to TO N
attend VB N
at IN N
least JJS N
one CD N
class NN N
and CC N
were VBD N
twice RB N
as RB N
likely JJ N
to TO N
attend VB N
a DT N
greater JJR N
number NN N
of IN N
classes NNS N
than IN N
those DT N
who WP N
were VBD N
randomized VBN i
to TO i
the DT i
Group NNP i
format NN i
. . i

Several JJ N
predictors NNS N
of IN N
format JJ N
preference NN N
were VBD N
also RB N
identified VBN N
, , N
with IN N
important JJ N
implications NNS N
for IN N
targeting VBG N
disease-management JJ N
education NN N
to TO N
this DT N
population NN N
. . N

-DOCSTART- -X- O O

Variability NN N
of IN N
thrombolytic JJ i
coronary JJ i
reperfusion NN i
: : i
an DT N
angiographic JJ N
study NN N
of IN N
streptokinase NN i
and CC N
anistreplase NN i
. . i

A DT N
total NN N
of IN N
1,615 CD p
angiographic JJ p
readings NNS p
in IN p
240 CD p
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
were VBD N
analyzed VBN N
from IN N
a DT N
randomized JJ N
trial NN N
of IN N
intravenous JJ i
anistreplase NN i
( ( i
Eminase NNP i
) ) i
, , i
also RB i
known VBN i
as IN i
anisoylated JJ i
plasminogen NN i
streptokinase JJ i
activator NN i
complex NN i
( ( i
APSAC NNP i
) ) i
, , N
versus FW N
intracoronary JJ N
streptokinase NN i
. . i

Coronary JJ N
arteriography NN N
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
15 CD N
, , N
30 CD N
, , N
45 CD N
, , N
60 CD N
, , N
75 CD N
, , N
and CC N
90 CD N
minutes NNS N
after IN N
drug NN N
infusion NN N
. . N

Coronary NNP N
flow NN N
in IN N
the DT N
infarct-related JJ N
artery NN N
was VBD N
defined VBN N
using VBG N
the DT N
TIMI NNP N
criteria NNS N
. . N

Some DT N
serial JJ o
change NN o
in IN o
perfusion NN o
was VBD N
noted VBN N
in IN N
25 CD N
% NN N
of IN N
the DT N
total JJ N
patient JJ N
population NN N
and CC N
in IN N
49 CD N
% NN N
of IN N
all DT N
reperfusion NN N
patients NNS N
. . N

Complete JJ o
loss NN o
of IN o
perfusion NN o
( ( N
grade JJ N
2 CD N
or CC N
3 CD N
to TO N
grade VB N
0 CD N
or CC N
1 CD N
) ) N
occurred VBD N
in IN N
35 CD N
% NN N
of IN N
all DT N
reperfused JJ N
patients NNS N
. . N

Half NNP p
of IN p
these DT p
patients NNS p
ultimately RB N
developed VBD N
complete JJ N
loss NN o
of IN o
perfusion NN o
at IN N
the DT N
study NN N
endpoint NN N
. . N

All DT N
of IN N
these DT N
changes NNS N
in IN N
flow NN N
were VBD N
statistically RB N
more JJR N
common JJ N
for IN N
the DT N
circumflex JJ N
coronary JJ N
artery NN N
and CC N
early JJ N
treatment NN N
( ( N
less JJR N
than IN N
4 CD N
h NN N
) ) N
, , N
but CC N
did VBD N
not RB N
differ VB N
for IN N
anistreplase NN i
or CC N
streptokinase NN i
. . i

We PRP N
conclude VBP N
that DT N
frequent JJ N
alterations NNS o
in IN o
coronary JJ o
blood NN o
flow NN o
occur VBD N
early JJ N
during IN N
reperfusion NN i
therapy NN i
and CC N
that IN N
these DT N
findings NNS N
may MD N
explain VB N
reports NNS N
with IN N
varying VBG N
results NNS N
of IN N
thrombolytic JJ i
therapy NN i
. . i

Any DT N
angiographic JJ N
assessment NN N
of IN N
thrombolytic JJ i
drug NN i
efficacy NN N
should MD N
take VB N
these DT N
variations NNS N
as RB N
well RB N
as IN N
interobserver NN N
variability NN N
into IN N
account NN N
. . N

-DOCSTART- -X- O O

Lofexidine NNP i
in IN N
hyperactive JJ p
and CC p
impulsive JJ p
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

-DOCSTART- -X- O O

Fadrozole NNP i
HCL NNP i
( ( i
CGS-16949A NNP i
) ) i
versus NN N
megestrol NN i
acetate VBP i
treatment NN N
of IN N
postmenopausal NN p
patients NNS p
with IN p
metastatic JJ p
breast NN p
carcinoma NN p
: : p
results NNS N
of IN N
two CD N
randomized JJ N
double JJ N
blind NN N
controlled VBD N
multiinstitutional JJ N
trials NNS N
. . N

BACKGROUND NNP N
Breast NNP p
cancer NN p
patients NNS p
with IN p
prior JJ p
response NN p
to TO p
endocrine VB p
therapy NN p
achieve VB N
subsequent JJ N
benefit NN N
from IN N
additional JJ N
endocrine NN N
therapies NNS N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
an DT N
aromatase NN N
inhibitor NN N
, , N
fadrozole JJ i
HCL NNP i
, , N
were VBD N
compared VBN N
with IN N
megestrol NN N
acetate NN N
in IN N
post NN p
menopausal NN p
patients NNS p
who WP p
had VBD p
disease NN p
progression NN p
after IN p
receiving VBG p
antiestrogen NN p
therapy NN p
either DT p
for IN p
metastatic JJ p
disease NN p
or CC p
as IN p
adjuvant JJ p
therapy NN p
. . p

METHODS NNP N
In IN p
2 CD p
multiinstitutional JJ p
prospective JJ p
trials NNS p
, , p
683 CD p
postmenopausal NN p
patients NNS p
were VBD N
randomized VBN i
to TO i
receive VB i
either DT i
fadrozole JJ i
HCL NNP i
, , i
1 CD i
mg NN i
twice RB i
daily RB i
, , i
or CC i
megestrol NN i
acetate NN i
, , i
40 CD i
mg NN i
4 CD i
times NNS i
daily RB i
, , i
in IN i
a DT i
double JJ i
blind NN i
fashion NN i
after IN i
progression NN i
on IN i
first-line JJ i
hormonal JJ i
therapy NN i
. . i

Objective JJ o
response NN o
rates NNS o
, , o
time NN o
to TO o
progression NN o
, , o
survival NN o
and CC o
safety NN o
of IN N
the DT N
two CD N
regimens NNS N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Results NNP N
of IN N
intent-to-treat JJ N
analyses NNS N
are VBP N
presented VBN N
in IN N
this DT N
study NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
detected VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
time NN o
to TO o
progression NN o
, , o
objective JJ o
response NN o
rates NNS o
, , o
duration NN o
of IN o
response NN o
, , o
and CC o
survival NN o
in IN N
either DT N
trial NN N
. . N

There EX N
were VBD N
no DT N
clinically RB N
meaningful JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
in IN N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ o
experiences NNS o
, , N
except IN N
that DT N
weight NN o
gain NN o
, , o
fluid JJ o
retention NN o
, , o
and CC o
dyspnea NN o
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS N
in IN N
the DT N
megestrol NN N
acetate NN N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
fadrozole JJ N
HCL NNP N
, , N
whereas JJ N
nausea NN o
and CC o
vomiting NN o
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS N
in IN N
the DT N
fadrozole JJ N
HCL NNP N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
megestrol NN N
acetate NN N
. . N

CONCLUSIONS NNP N
Fadrozole NNP i
HCL NNP i
was VBD N
as RB N
efficacious JJ o
as IN N
megestrol NN N
acetate NN N
in IN N
postmenopausal NN p
patients NNS p
with IN p
metastatic JJ p
breast NN p
carcinoma NN p
after IN N
one CD N
hormonal JJ N
therapy NN N
. . N

Adverse JJ N
experiences NNS N
were VBD N
mild JJ N
with IN N
both DT N
therapies NNS N
, , N
but CC N
megestrol NN N
acetate NN N
was VBD N
associated VBN N
wiht PDT N
a DT N
higher JJR N
frequency NN N
of IN N
weight NN o
gain NN o
, , o
fluid JJ o
retention NN o
and CC o
dyspnea NN o
, , N
whereas JJ N
fadrozole NN i
HCL NNP i
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
frequency NN N
of IN N
nausea NN o
and CC o
vomiting NN o
. . o

-DOCSTART- -X- O O

Sociopsychological JJ N
tailoring VBG N
to TO N
address VB N
colorectal JJ N
cancer NN N
screening VBG N
disparities NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
Interventions NNP i
tailored VBD i
to TO i
sociopsychological JJ i
factors NNS i
associated VBN i
with IN i
health NN i
behaviors NNS i
have VBP N
promise NN N
for IN N
reducing VBG N
colorectal JJ N
cancer NN N
screening VBG N
disparities NNS N
, , N
but CC N
limited VBD N
research NN N
has VBZ N
assessed VBN N
their PRP$ N
impact NN N
in IN N
multiethnic JJ N
populations NNS N
. . N

We PRP N
examined VBD N
whether IN N
an DT N
interactive JJ i
multimedia NN i
computer NN i
program NN i
( ( i
IMCP NNP i
) ) i
tailored VBD N
to TO N
expanded VB N
health NN N
belief NN N
model NN N
sociopsychological JJ N
factors NNS N
could MD N
promote VB N
colorectal JJ N
cancer NN N
screening NN N
in IN N
a DT N
multiethnic JJ p
sample NN p
. . p

METHODS NNP N
We PRP N
undertook VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
, , N
comparing VBG N
an DT N
IMCP NNP i
tailored VBD i
to TO i
colorectal JJ i
cancer NN i
screening VBG i
self-efficacy NN i
, , i
knowledge NN i
, , i
barriers NNS i
, , i
readiness NN i
, , i
test NN i
preference NN i
, , i
and CC i
experiences NNS i
with IN i
a DT i
nontailored JJ i
informational JJ i
program NN i
, , N
both DT N
delivered VBN N
before IN N
office NN N
visits NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
record-documented JJ o
colorectal JJ o
cancer NN o
screening VBG o
during IN o
a DT o
12-month JJ o
follow-up JJ o
period NN o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
postvisit JJ o
sociopsychological JJ o
factor NN o
status NN o
and CC o
discussion NN o
, , o
as RB o
well RB o
as IN o
clinician JJ o
recommendation NN o
of IN o
screening VBG o
during IN o
office NN o
visits NNS o
. . o

We PRP N
enrolled VBD p
1,164 CD p
patients NNS p
stratified VBN p
by IN p
ethnicity NN p
and CC p
language NN p
( ( p
49.3 CD p
% NN p
non-Hispanic JJ p
, , p
27.2 CD p
% NN p
Hispanic/English NNP p
, , p
23.4 CD p
% NN p
Hispanic/Spanish NNP p
) ) p
from IN p
26 CD p
offices NNS p
around IN p
5 CD p
centers NNS p
( ( p
Sacramento NNP p
, , p
California NNP p
; : p
Rochester NNP p
and CC p
the DT p
Bronx NNP p
, , p
New NNP p
York NNP p
; : p
Denver NNP p
, , p
Colorado NNP p
; : p
and CC p
San NNP p
Antonio NNP p
, , p
Texas NNP p
) ) p
. . p

RESULTS NNP N
Adjusting NNP N
for IN N
ethnicity/language NN N
, , N
study NN N
center NN N
, , N
and CC N
the DT N
previsit NN N
value NN N
of IN N
the DT N
dependent NN N
variable NN N
, , N
compared VBN N
with IN N
control NN N
patients NNS N
, , N
the DT N
IMCP NNP N
led VBD N
to TO N
significantly RB N
greater JJR N
colorectal JJ o
cancer NN o
screening VBG o
knowledge NN o
, , o
self-efficacy NN o
, , o
readiness NN o
, , o
test NN o
preference NN o
specificity NN o
, , o
discussion NN o
, , o
and CC o
recommendation NN o
. . o

During IN N
the DT N
followup JJ N
period NN N
, , N
132 CD N
( ( N
23 CD N
% NN N
) ) N
IMCP NNP N
and CC N
123 CD N
( ( N
22 CD N
% NN N
) ) N
control NN N
patients NNS N
received VBD N
screening VBG o
( ( N
adjusted VBN N
difference NN N
= $ N
0.5 CD N
percentage NN N
points NNS N
, , N
95 CD N
% NN N
CI NNP N
-4.3 NNP N
to TO N
5.3 CD N
) ) N
. . N

IMCP NNP o
effects NNS N
did VBD N
not RB N
differ VB N
significantly RB N
by IN N
ethnicity/language NN N
. . N

CONCLUSIONS NNP N
Sociopsychological NNP N
factor NN N
tailoring NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
nontailored JJ N
information NN N
in IN N
encouraging VBG N
colorectal JJ N
cancer NN N
screening NN N
in IN N
a DT N
multiethnic JJ p
sample NN p
, , N
despite IN N
enhancing VBG N
sociopsychological JJ N
factors NNS N
and CC N
visit NN N
behaviors NNS N
associated VBN N
with IN N
screening NN N
. . N

The DT N
utility NN N
of IN N
sociopsychological JJ N
tailoring NN N
in IN N
addressing VBG N
screening VBG N
disparities NNS N
remains VBZ N
uncertain JJ N
. . N

-DOCSTART- -X- O O

Development NNP N
, , N
description NN N
, , N
and CC N
acceptability NN N
of IN N
a DT N
small-group NN i
, , i
behavioral JJ i
intervention NN i
to TO N
prevent VB N
HIV NNP N
and CC N
hepatitis NN N
C NNP N
virus NN N
infections NNS N
among IN N
young JJ p
adult NN p
injection JJ p
drug NN p
users NNS p
. . p

Young NNP p
injection NN p
drug NN p
users NNS p
( ( p
IDUs NNP p
) ) p
who WP p
are VBP p
not RB p
infected VBN p
with IN p
HIV NNP p
or CC p
hepatitis NN p
C NNP p
virus NN p
are VBP N
at IN N
great JJ N
risk NN N
of IN N
acquiring VBG N
one CD N
or CC N
both DT N
of IN N
these DT N
infections NNS N
through IN N
their PRP$ N
sexual JJ N
or CC N
injection NN N
behaviors NNS N
. . N

We PRP N
describe VBP N
the DT N
development NN N
of IN N
a DT N
behavioral JJ N
intervention NN N
designed VBN N
to TO N
decrease VB N
sexual JJ o
and CC o
injection NN o
risk NN o
behaviors NNS o
among IN N
young JJ p
IDUs NNP p
. . p

The DT N
intervention NN N
was VBD N
developed VBN N
through IN N
a DT N
dynamic JJ N
and CC N
iterative JJ N
process NN N
that WDT N
involved VBD N
extensive JJ N
development NN N
activities NNS N
, , N
focus NN N
groups NNS N
with IN N
the DT N
target NN N
population NN N
to TO N
pilot VB N
individual JJ N
activities NNS N
and CC N
intervention NN N
sessions NNS N
, , N
and CC N
later RB N
, , N
pilot NN N
testing NN N
of IN N
the DT N
entire JJ N
intervention NN N
. . N

The DT N
six-session NN N
intervention NN N
that WDT N
emerged VBD N
from IN N
the DT N
development NN N
process NN N
relied VBN N
on IN N
both DT N
social-cognitive JJ i
theories NNS i
and CC i
peer VB i
influence NN i
models NNS i
. . i

We PRP N
also RB N
designed VBD N
a DT N
control NN N
intervention NN N
, , N
trained VBD N
facilitators NNS N
to TO N
deliver VB N
the DT N
interventions NNS N
, , N
and CC N
conducted VBD N
quality NN N
assurance NN N
of IN N
intervention NN N
delivery NN N
. . N

To TO N
better JJR N
understand VB N
intervention NN N
trial NN N
findings NNS N
, , N
we PRP N
asked VBD N
participants NNS N
about IN N
their PRP$ N
intervention NN N
experiences NNS N
and CC N
examined VBD N
potential JJ N
contamination NN N
across IN N
arms NNS N
. . N

Both DT N
interventions NNS N
were VBD N
delivered VBN N
with IN N
high JJ N
fidelity NN N
and CC N
participants NNS N
in IN N
both DT N
groups NNS N
reported VBD N
positive JJ N
experiences NNS N
. . N

More JJR N
perceived JJ o
impact NN o
was VBD N
reported VBN N
for IN N
injection NN o
risk NN o
behaviors NNS o
than IN N
for IN N
sexual JJ o
risk NN o
behaviors NNS o
among IN N
participants NNS N
in IN N
the DT N
intervention NN N
arm NN N
. . N

Minimal JJ N
evidence NN N
of IN N
contamination NN o
was VBD N
found VBN N
. . N

Lessons NNS N
learned VBD N
can MD N
help VB N
future VB N
researchers NNS N
to TO N
develop VB N
stronger JJR N
interventions NNS N
for IN N
this DT N
high-need JJ N
population NN N
. . N

-DOCSTART- -X- O O

Serum NNP o
bactericidal NN o
activities NNS o
and CC o
comparative JJ o
pharmacokinetics NNS o
of IN N
meropenem NN N
and CC N
imipenem-cilastatin NN N
. . N

The DT N
pharmacokinetics NNS o
and CC o
serum NN o
bactericidal NN o
activities NNS o
( ( o
SBAs NNP o
) ) o
of IN N
imipenem NN i
and CC N
meropenem NN i
were VBD N
investigated VBN N
in IN N
a DT N
randomized VBN N
crossover NN N
study NN N
. . N

Twelve NNP p
healthy JJ p
male NN p
volunteers NNS p
received VBD N
a DT N
constant JJ i
30-min JJ i
infusion NN i
of IN i
either CC i
1 CD i
g NN i
of IN i
imipenem JJ i
plus CC i
1 CD i
g NN i
of IN i
cilastatin NN i
or CC i
1 CD i
g NN i
of IN i
meropenem NN i
. . i

The DT N
concentrations NNS o
of IN o
the DT o
drugs NNS o
in IN o
serum NN o
and CC o
urine NN o
were VBD N
determined VBN i
by IN i
bioassay NN o
and CC o
high-pressure NN o
liquid NN o
chromatography NN o
. . o

Pharmacokinetic JJ N
parameters NNS N
were VBD N
based VBN N
on IN N
an DT N
open JJ N
two-compartment JJ i
model NN i
and CC i
a DT i
noncompartmental JJ i
technique NN i
. . i

At IN N
the DT N
end NN N
of IN N
infusion NN N
, , N
the DT N
mean JJ o
concentrations NNS o
of IN o
imipenem NN o
and CC o
meropenem NN o
measured VBN o
in IN o
serum NN o
were VBD N
61.2 CD N
+/- JJ N
9.8 CD N
and CC N
51.6 CD N
+/- JJ N
6.5 CD N
mg/liter NN N
, , N
respectively RB N
; : N
urinary JJ o
recoveries NNS o
were VBD N
48.6 CD N
% NN N
+/- JJ N
8.2 CD N
% NN N
and CC N
60.0 CD N
% NN N
+/- JJ N
6.5 CD N
% NN N
of IN N
the DT N
dose NN N
in IN N
12 CD N
h NN N
, , N
respectively RB N
; : N
and CC N
the DT N
areas NNS o
under IN o
the DT o
concentration-time JJ o
curve NN o
from IN N
time NN N
zero CD N
to TO N
infinity NN N
were VBD N
96.1 CD N
+/- JJ N
14.4 CD N
and CC N
70.5 CD N
+/- JJ N
10.3 CD N
mg.h/liter NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.02 CD N
) ) N
. . N

Imipenem NNP N
had VBD N
a DT N
mean JJ N
half-life NN N
of IN N
66.7 CD N
+/- JJ N
10.4 CD N
min NN N
; : N
that IN N
of IN N
meropenem NN N
was VBD N
64.4 CD N
+/- JJ N
6.9 CD N
min NN N
. . N

The DT N
volumes NNS N
of IN N
distribution NN N
at IN N
steady JJ N
state NN N
of IN N
imipenem NN N
and CC N
meropenem NN N
were VBD N
15.3 CD N
+/- JJ N
3.3 CD N
and CC N
18.6 CD N
+/- JJ N
3.0 CD N
liters/70 NN N
kg NN N
, , N
respectively RB N
, , N
and CC N
the DT N
mean JJ N
renal JJ N
clearances NNS N
per IN N
1.73 CD N
m2 NNS N
were VBD N
85.6 CD N
+/- JJ N
17.6 CD N
and CC N
144.6 CD N
+/- JJ N
26.0 CD N
ml/min NN N
, , N
respectively RB N
. . N

Both DT p
antibiotics NNS p
were VBD p
well RB p
tolerated VBN p
in IN p
this DT p
single-dose JJ p
administration NN p
study NN p
. . p

The DT N
SBAs NNP o
were VBD N
measured VBN N
by IN N
the DT N
microdilution NN o
method NN o
of IN o
Reller NNP o
and CC o
Stratton NNP o
( ( N
L. NNP N
B. NNP N
Reller NNP N
and CC N
C. NNP N
W. NNP N
Stratton NNP N
, , N
J. NNP N
Infect NNP N
. . N

Dis NNP N
. . N

136:196-204 CD N
, , N
1977 CD N
) ) N
against IN N
40 CD N
clinically RB N
isolated JJ N
strains NNS N
. . N

Mean NNP o
reciprocal JJ o
bactericidal NN o
titers NNS o
were VBD N
measured VBN N
1 CD N
and CC N
6 CD N
h NN N
after IN N
administration NN N
. . N

After IN N
1 CD N
and CC N
6 CD N
h NN N
the DT N
median JJ N
SBAs NNP o
for IN N
imipenem NN N
and CC N
meropenem NN N
, , N
were VBD N
409 CD N
and CC N
34.9 CD N
and CC N
97.9 CD N
and CC N
5.8 CD N
, , N
respectively RB N
, , N
against IN N
Staphylococcus NNP N
aureus NN N
, , N
19.9 CD N
and CC N
4.4 CD N
and CC N
19.4 CD N
and CC N
4.8 CD N
, , N
respectively RB N
, , N
against IN N
Pseudomonas NNP N
aeruginosa NN N
, , N
34.3 CD N
and CC N
2.2 CD N
and CC N
232 CD N
and CC N
15.5 CD N
, , N
respectively RB N
, , N
against IN N
Enterobacter NNP N
cloacae NN N
, , N
and CC N
13.4 CD N
and CC N
2.25 CD N
and CC N
90.7 CD N
and CC N
7.9 CD N
, , N
respectively RB N
, , N
against IN N
Proteus NNP N
mirabilis NN N
. . N

Both DT p
drugs NNS p
had VBD p
rather RB p
short JJ p
biological JJ p
elimination NN p
half-lives NNS o
and CC p
a DT p
predominantly RB p
renal JJ p
route NN p
of IN p
elimination NN p
. . p

Both DT N
carbapenems NNS N
revealed VBD N
high JJ N
SBAs NNP o
against IN o
clinically RB o
important JJ o
pathogens NNS o
at IN N
1 CD N
h NN N
; : N
meropenem NN N
had VBD N
a DT N
higher JJR N
SBA NNP o
against IN N
E. NNP N
cloacae NN N
and CC N
P. NNP N
mirabilis NN N
, , N
and CC N
the DT N
SBA NNP o
of IN N
imipenem NN N
against IN N
S. NNP N
aureus NN N
was VBD N
greater JJR N
than IN N
the DT N
SBA NNP N
of IN N
meropenem NN N
. . N

-DOCSTART- -X- O O

Parent-based JJ i
sleep JJ i
education NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
provided VBD N
sleep JJ i
education NN i
to TO i
parents NNS i
of IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
to TO N
determine VB N
whether IN N
an DT N
individual NN i
or CC N
group NN i
format NN i
was VBD N
more RBR N
effective JJ N
in IN N
improving VBG N
sleep NN o
and CC N
aspects NNS N
of IN N
daytime JJ o
behavior NN o
and CC N
family NN o
functioning NN o
. . o

Eighty NNP p
children NNS p
, , p
ages VBZ p
2-10 CD p
years NNS p
, , p
with IN p
ASD NNP p
and CC p
sleep JJ p
onset NN p
delay NN p
completed VBD p
the DT p
study NN p
. . p

Actigraphy NN N
and CC N
parent NN N
questionnaires NNS N
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
1 CD N
month NN N
after IN N
treatment NN N
. . N

Mode NNP N
of IN N
education NN N
did VBD N
not RB N
affect VB N
outcomes NNS o
. . o

Sleep NNP o
latency NN o
, , o
insomnia NN o
subscales NNS o
on IN o
the DT o
Children NNP o
's POS o
Sleep NNP o
Habits NNP o
Questionnaire NNP o
, , o
and CC N
other JJ o
outcomes NNS o
related VBN o
to TO o
child VB o
and CC o
family NN o
functioning VBG o
improved VBN o
with IN N
treatment NN N
. . N

Parent-based JJ N
sleep JJ N
education NN N
, , N
delivered VBN N
in IN N
relatively RB N
few JJ N
sessions NNS N
, , N
was VBD N
associated VBN N
with IN N
improved JJ o
sleep JJ o
onset NN o
delay NN o
in IN o
children NNS N
with IN N
ASD NNP p
. . p

Group NNP N
versus VBD N
individualized JJ N
education NN N
did VBD N
not RB N
affect VB N
outcome NN N
. . N

-DOCSTART- -X- O O

Postoperative JJ p
magnesium NN i
sulphate NN i
infusion NN i
reduces NNS N
analgesic JJ N
requirements NNS N
in IN N
spinal JJ N
anaesthesia NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Magnesium NNP i
sulphate NN i
infusion NN N
during IN N
general JJ N
anaesthesia NN N
reduces NNS N
anaesthetic JJ o
consumption NN o
and CC N
analgesic JJ o
requirements NNS o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
postoperative JJ N
magnesium NN i
infusion NN N
on IN N
duration NN o
of IN o
block NN o
, , o
sedation NN o
and CC o
analgesic JJ o
consumption NN o
after IN N
spinal JJ N
anaesthesia NN N
. . N

METHODS NNP N
Fifty NNP p
ASA NNP p
I-II JJ p
patients NNS p
were VBD N
included VBN N
in IN N
the DT N
randomized JJ N
double JJ N
blind NN N
study NN N
. . N

Spinal NNP i
anaesthesia NN i
was VBD i
performed VBN i
at IN i
L3-4 NNP i
or CC i
L4-5 NNP i
interspace NN i
with IN i
12.5 CD i
mg NNS i
0.5 CD i
% NN i
heavy JJ i
bupivacaine NN i
, , i
using VBG i
a DT i
25 CD i
G NNP i
Quincke NNP i
needle NN i
. . i

Patients NNS i
received VBD i
a DT i
5 CD i
mg NN i
kg NN i
( ( i
-1 NNP i
) ) i
bolus NN i
of IN i
magnesium NN i
sulphate NN i
followed VBN i
by IN i
a DT i
500 CD i
mg NN i
h NN i
( ( i
-1 NNP i
) ) i
infusion NN i
or CC i
saline NN i
in IN N
the DT N
same JJ N
volumes NNS N
for IN N
24 CD N
h. JJ N
Time NNP o
to TO o
first VB o
pain NN o
, , o
analgesic JJ o
request NN o
, , o
return NN o
of IN o
motor NN o
function NN o
, , o
visual JJ o
analogue NN o
pain NN o
and CC o
sedation NN o
scores NNS o
were VBD N
evaluated VBN N
every DT N
4 CD N
h NN N
during IN N
the DT N
24 CD N
h JJ N
postoperative JJ N
period NN N
. . N

The DT N
t- JJ N
and CC N
U-tests NNS N
were VBD N
used VBN N
for IN N
statistical JJ N
analyses NNS N
. . N

Data NNS N
were VBD N
expressed VBN N
as IN N
mean JJ N
+/- JJ N
SD NNP N
, , N
with IN N
P NNP N
< $ N
0.05 CD N
being VBG N
considered VBN N
significant JJ N
. . N

RESULTS NNP N
Vital JJ o
signs NNS o
were VBD N
stable JJ N
during IN N
spinal JJ N
anaesthesia NN N
and CC N
postoperative JJ N
period NN N
. . N

When WRB N
compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
time NN o
to TO o
analgesic VB o
need NN o
was VBD N
increased VBN N
and CC N
total JJ o
analgesic JJ o
consumption NN o
was VBD N
reduced VBN N
in IN N
the DT N
magnesium NN N
group NN N
( ( N
meperidine JJ N
consumption NN N
60.0 CD N
+/- JJ N
73.1 CD N
mg NNS N
control NN N
group NN N
, , N
31.8 CD N
+/- JJ N
30.7 CD N
mg JJ N
magnesium NN N
group NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS NNP N
Magnesium NNP i
sulphate JJ i
infusion NN N
may MD N
be VB N
used VBN N
as IN N
an DT N
adjunct NN N
for IN N
reducing VBG N
analgesic JJ o
consumption NN o
after IN p
spinal JJ p
anaesthesia NN p
. . p

-DOCSTART- -X- O O

Pharmacogenetic JJ N
interaction NN N
analysis NN N
for IN N
the DT N
efficacy NN N
of IN N
systemic JJ N
treatment NN N
in IN N
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

BACKGROUND NNP N
Pharmacogenetic NNP N
markers NNS N
related VBN N
to TO N
drug NN N
metabolism NN N
and CC N
mechanisms NNS N
of IN N
action NN N
could MD N
help VB N
to TO N
better VB N
select JJ N
patients NNS p
with IN p
metastatic JJ p
colorectal NN p
cancer NN p
( ( p
mCRC NN p
) ) p
for IN N
treatment NN N
. . N

Genetic JJ N
interaction NN N
analysis NN N
is VBZ N
used VBN N
as IN N
a DT N
rational JJ N
tool NN N
to TO N
study VB N
the DT N
contribution NN N
of IN N
polygenic JJ N
variation NN N
in IN N
relation NN N
to TO N
drug NN N
response NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
selection NN N
of IN N
17 CD p
polymorphisms NNS p
in IN p
genes NNS p
encoding VBG p
drug NN p
targets NNS p
, , p
pathway NN o
molecules NNS o
and CC o
detoxification NN o
enzymes NNS o
was VBD p
analyzed VBN p
in IN p
279 CD p
previously RB p
untreated JJ p
mCRC NN p
patients NNS p
treated VBN p
with IN p
capecitabine NN i
, , i
oxaliplatin NN i
and CC i
bevacizumab NN i
( ( i
CAPOX-B NNP i
) ) i
. . i

Multifactor NNP N
dimensionality NN N
reduction NN N
analysis NN N
was VBD N
used VBN N
to TO N
identify VB N
a DT N
genetic JJ o
interaction NN o
profile NN o
for IN o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . o

RESULTS NNP N
Median JJ N
PFS NNP o
was VBD N
10.9 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
9.4-12.4 CD N
] JJ N
months NNS N
. . N

A NNP N
genetic JJ o
interaction NN o
profile NN o
consisting VBG N
of IN N
the DT N
TYMS NNP N
enhancer NN N
region NN N
and CC N
VEGF NNP N
+405G NNP N
> NNP N
C NNP N
polymorphisms NN N
was VBD N
significantly RB N
associated VBN N
with IN N
PFS NNP N
. . N

Median JJ o
PFS NNP o
was VBD N
13.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
11.4-15.3 CD N
) ) N
and CC N
9.7 CD N
( ( N
95 CD N
% NN N
CI NNP N
7.6-11.8 CD N
) ) N
months NNS N
for IN N
the DT N
beneficial JJ N
and CC N
unfavorable JJ N
genetic JJ o
profiles NNS o
, , N
respectively RB N
, , N
corresponding VBG N
to TO N
a DT N
hazards NNS N
ratio NN N
for IN N
PFS NNP o
of IN N
1.58 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.14-2.19 CD N
) ) N
. . N

None NN N
of IN N
the DT N
studied JJ N
polymorphisms NNS N
were VBD N
individually RB N
associated VBN N
with IN N
PFS NNP N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
support VB N
a DT N
genetic JJ o
interaction NN o
between IN N
the DT N
TYMS NNP N
enhancer NN N
region NN N
and CC N
VEGF NNP N
+405G NNP N
> NNP N
C NNP N
polymorphisms NN N
as IN N
a DT N
predictor NN N
of IN N
the DT N
efficacy NN N
of IN N
CAPOX-B NNP N
in IN N
mCRC NN p
patients NNS p
. . p

-DOCSTART- -X- O O

Conjugated VBN N
equine JJ N
estrogen NN N
influence NN N
on IN N
mammographic JJ o
density NN o
in IN N
postmenopausal JJ p
women NNS p
in IN p
a DT p
substudy NN p
of IN p
the DT p
women NNS p
's POS p
health NN p
initiative NN p
randomized VBN p
trial NN p
. . p

PURPOSE NNP N
Increased VBD N
mammographic JJ o
density NN o
is VBZ N
associated VBN N
with IN N
increased JJ N
breast NN N
cancer NN N
risk NN N
and CC N
reduced JJ N
sensitivity NN N
of IN N
screening VBG N
mammography NN N
and CC N
is VBZ N
related VBN N
to TO N
hormone VB N
exposure NN N
. . N

However RB N
, , N
the DT N
effects NNS N
of IN N
conjugated JJ i
equine NN i
estrogens NNS i
( ( i
CEEs NNP i
) ) i
alone RB N
on IN N
mammographic JJ o
density NN o
in IN N
diverse JJ p
racial/ethnic JJ p
populations NNS p
are VBP N
not RB N
established VBN N
. . N

We PRP N
examined VBD N
the DT N
effect NN N
of IN N
CEE NNP N
alone RB N
on IN N
mammographic JJ o
density NN o
in IN N
a DT N
subsample NN p
of IN p
the DT p
Women NNP p
's POS p
Health NNP p
Initiative NNP p
( ( p
WHI NNP p
) ) p
clinical JJ p
trial NN p
participants NNS p
. . p

PATIENTS NNS N
AND CC N
METHODS NNP N
In IN N
the DT N
WHI NNP N
trial NN N
, , N
women NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
daily VB i
CEE NNP i
0.625 CD i
mg NN i
or CC i
placebo NN i
. . i

The DT N
effect NN N
of IN N
CEE NNP N
on IN N
mammographic JJ o
percent NN o
density NN o
was VBD N
determined VBN N
over IN N
1 CD N
and CC N
2 CD N
years NNS N
in IN N
a DT N
stratified JJ N
random JJ p
sample NN p
of IN p
435 CD p
racially RB p
and CC p
ethnically RB p
diverse JJ p
participants NNS p
from IN p
15 CD p
of IN p
40 CD p
WHI NNP p
clinics NNS p
. . p

RESULTS NNP N
Use NNP N
of IN N
CEE NNP N
resulted VBD N
in IN N
mean JJ N
increase NN N
in IN N
mammographic JJ o
percent NN o
density NN o
of IN N
1.6 CD N
percentage NN N
points NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.8 CD N
to TO N
2.4 CD N
) ) N
at IN N
year NN N
1 CD N
compared VBN N
with IN N
a DT N
mean JJ N
decrease NN N
of IN N
1.0 CD N
percentage NN N
point NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-1.7 NNP N
to TO N
-0.4 VB N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
effect NN N
persisted VBD N
for IN N
2 CD N
years NNS N
, , N
with IN N
a DT N
mean JJ N
increase NN N
of IN N
1.7 CD N
percentage NN N
points NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.7 CD N
to TO N
2.7 CD N
) ) N
versus NN N
a DT N
mean JJ N
decrease NN N
of IN N
1.2 CD N
percentage NN N
points NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-1.8 NNP N
to TO N
-0.5 VB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
hormone NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
. . N

These DT N
effects NNS N
were VBD N
greater JJR N
in IN N
women NNS p
age NN p
60 CD p
to TO p
79 CD p
years NNS p
( ( N
P NNP N
= NNP N
.03 NNP N
for IN N
interaction NN N
across IN N
age NN N
) ) N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
CEE NNP N
results NNS N
in IN N
a DT N
modest JJ N
but CC N
statistically RB N
significant JJ N
increase NN N
in IN N
mammographic JJ o
density NN o
that WDT N
is VBZ N
sustained VBN N
over IN N
at IN N
least JJS N
a DT N
2-year JJ N
period NN N
. . N

The DT N
clinical JJ N
significance NN N
of IN N
the DT N
CEE NNP N
effect NN N
on IN N
mammographic JJ o
density NN o
remains VBZ N
to TO N
be VB N
determined VBN N
. . N

-DOCSTART- -X- O O

Long-term JJ N
effects NNS N
of IN N
ezetimibe-plus-statin JJ i
therapy NN i
on IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
levels NNS o
as IN N
compared VBN N
with IN N
double-dose JJ i
statin NN i
therapy NN i
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

OBJECTIVE UH N
To TO N
assess VB N
the DT N
mechanism NN N
of IN N
long-term JJ N
LDL-C-lowering JJ N
effect NN N
of IN N
ezetimibe-plus-statin NN i
. . i

METHODS NNP N
Coronary NNP p
artery NN p
disease NN p
patients NNS p
whose WP$ p
LDL-C NNP p
? . p
70 CD p
mg/dL NN p
after IN p
treatment NN p
with IN i
atorvastatin JJ i
10 CD i
mg/day NN i
or CC i
rosuvastatin VB i
2.5 CD i
mg/day NN i
were VBD i
randomly RB N
assigned VBN N
to TO N
receive VB i
ezetimibe NN i
10 CD i
mg/day NN i
+ NNP i
statin NN i
( ( i
n JJ N
= NNP N
78 CD N
) ) N
or CC N
double-dose JJ i
statin NN i
( ( i
n JJ N
= NNP N
72 CD N
) ) N
for IN N
52 CD N
weeks NNS N
. . N

RESULTS NNP N
Greater NNP o
LDL-C NNP o
reduction NN o
was VBD o
observed VBN N
and CC N
maintained VBN N
until IN N
52 CD N
weeks NNS N
in IN N
ezetimibe-plus-statin JJ i
, , i
while IN o
LDL-C JJ o
levels NNS o
re-increased VBN o
after IN N
12 CD N
weeks NNS N
in IN N
double-dose JJ N
statin NN N
. . N

Although IN o
lathosterol/TC NN o
increased VBD o
, , o
campesterol/TC NN o
decreased VBD o
more RBR N
in IN N
ezetimibe-plus-statin NN i
. . i

In IN N
contrast NN o
, , o
lathosterol/TC CC o
unchanged JJ o
and CC o
campesterol/TC NN o
increased VBD o
, , N
increasing VBG o
campesterol/lathosterol NN o
ratio NN o
for IN o
52 CD N
weeks NNS N
in IN N
double-dose JJ i
statin NN o
. . o

Plasma NNP o
PCSK9 NNP o
levels NNS o
were VBD o
higher JJR N
in IN N
double-dose JJ i
statin NN i
than IN i
in IN N
ezetimibe-plus-statin NN i
at IN i
12 CD N
weeks NNS N
, , N
but CC N
similar JJ N
at IN N
52 CD N
weeks NNS N
. . N

CONCLUSION NNP N
Although IN N
the DT N
difference NN N
in IN N
PCSK9 NNP N
between IN N
2 CD N
groups NNS N
was VBD N
transient JJ N
, , N
that IN N
in IN N
both DT N
campesterol NN N
and CC N
lathosterol NN N
persisted VBN N
until IN N
52 CD N
weeks NNS N
. . N

These DT N
results NNS N
demonstrated VBD N
simultaneous JJ N
inhibition NN N
of IN N
cholesterol NN N
absorption NN N
and CC N
synthesis NN N
provides VBZ N
stable JJ N
and CC N
greater JJR N
decrease NN N
in IN N
LDL-C NNP o
levels NNS o
. . o

-DOCSTART- -X- O O

Double JJ N
contrast NN i
arthrography NN i
of IN p
the DT p
knee NN p
. . p

Comparison NNP N
between IN N
three CD N
contrast NN N
media NNS N
. . N

Meglumine NNP i
iothalamate NN i
( ( i
Conray NNP i
Meglumin NNP i
) ) i
, , i
sodium-calcium-meglumine JJ i
metrizoate NN i
( ( i
Isopaque NNP i
Cerebral NNP i
) ) i
and CC i
dimeglumine JJ i
iocarmate NN i
( ( i
Dimerex NNP i
) ) i
, , N
each DT N
containing VBG N
about IN N
280 CD N
mg NNS N
I/ml NNP N
, , N
were VBD N
compared VBN N
in IN N
two CD N
series NN N
of IN N
double JJ p
contrast NN p
knee NN p
arthrography NN p
, , p
190 CD p
and CC p
184 CD p
patients NNS p
each DT p
. . p

With IN N
Dimerex NNP N
the DT N
mixing NN N
of IN N
the DT N
contrast NN N
medium NN N
with IN N
the DT N
synovial JJ o
fluid NN o
was VBD N
slower JJR N
than IN N
with IN N
Conray NNP i
Meglumin NNP i
, , N
and CC N
a DT N
good JJ N
or CC N
fair JJ N
image NN o
quality NN o
, , N
as IN N
evaluated VBN N
subjectively RB N
, , N
lasted VBD N
longer RBR N
. . N

No DT N
difference NN N
was VBD N
observed VBN N
between IN N
Isopaque NNP i
Cerebral NNP i
and CC i
Conray NNP i
Meglumin NNP i
, , N
regardless RB N
of IN N
dosage NN N
. . N

-DOCSTART- -X- O O

Offering VBG N
personalized VBN i
health NN i
behavior NN i
feedback NN i
did VBD N
not RB N
increase VB N
response NN o
rate NN o
: : o
a DT N
randomized NN p
controlled VBN N
trial NN N
. . N

-DOCSTART- -X- O O

A DT N
randomised JJ N
comparison NN N
of IN N
three CD N
drainage NN N
systems NNS N
following VBG p
cholecystectomy NN p
. . p

The DT N
efficacy NN o
of IN N
low JJ i
pressure NN i
, , i
high JJ i
pressure NN i
and CC i
passive JJ i
drainage NN i
systems NNS i
have VBP N
been VBN N
compared VBN N
after IN p
cholecystectomy NN p
. . p

Symptoms NNS o
of IN o
pain NN o
, , o
discomfort NN o
and CC o
nausea NN o
were VBD N
compared VBN N
using VBG N
linear JJ N
analogue NN N
scales NNS N
and CC N
spirometry NN N
was VBD N
used VBN N
to TO N
examine VB N
pre-operative JJ N
and CC N
postoperative JJ N
respiratory NN o
function NN o
. . o

The DT N
low JJ i
pressure NN i
suction NN i
drain NN i
removed VBD N
an DT N
intraperitoneal NN o
marker NN o
, , o
gentamicin NN o
, , N
more RBR N
effectively RB N
than IN N
the DT N
high JJ i
pressure NN i
suction NN i
drain NN i
, , N
but CC N
not RB N
more RBR N
effectively RB N
than IN N
the DT N
passive JJ i
drain NN i
. . i

There EX N
were VBD N
no DT N
differences NNS N
in IN N
postoperative JJ o
respiratory NN o
function NN o
nor CC N
in IN N
the DT N
amount NN o
of IN o
pain NN o
or CC o
discomfort NN o
between IN N
the DT N
groups NNS N
. . N

The DT N
passive JJ N
drain NN N
group NN N
reported VBD N
less JJR N
nausea NN o
than IN N
the DT N
suction NN N
drain NN N
groups NNS N
. . N

If IN N
a DT N
negative JJ N
pressure NN N
drainage NN N
system NN N
is VBZ N
to TO N
be VB N
used VBN N
, , N
a DT N
low JJ N
pressure NN N
suction NN N
drain NN N
should MD N
be VB N
used VBN N
in IN N
preference NN N
to TO N
a DT N
high JJ N
pressure NN N
system NN N
. . N

-DOCSTART- -X- O O

Combination NN i
peel NN i
with IN i
incorporated JJ i
fractional JJ i
prickle NN i
coral JJ i
calcium NN i
for IN N
the DT N
treatment NN N
of IN N
keratosis NN p
pilaris NN p
: : p
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Keratosis NNP p
pilaris NN p
( ( N
KP NNP N
) ) N
is VBZ N
a DT N
common JJ N
condition NN N
of IN N
follicular JJ N
plugging VBG N
with IN N
variable JJ N
erythema NN N
. . N

There EX N
is VBZ N
a DT N
lack NN N
of IN N
reliable JJ N
response NN N
to TO N
the DT N
treatment NN N
of IN N
KP NNP N
. . N

OBJECTIVE NNP N
We PRP N
evaluated VBD N
the DT N
effect NN N
and CC N
safety NN N
of IN N
combination NN N
peel NN N
with IN N
fractional JJ i
prickle JJ i
coral JJ i
calcium NN i
( ( i
FCR? NNP i
) ) i
in IN i
the DT N
treatment NN N
of IN N
KP NNP N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP p
Sixteen NNP p
Korean JJ p
patients NNS p
were VBD p
treated VBN p
with IN p
FCR? NNP p
on IN p
both DT p
upper JJ p
arms NNS p
for IN p
five CD p
sessions NNS p
at IN p
2-week JJ p
intervals NNS o
. . o

Clinical JJ o
evaluations NNS o
, , o
mexameter NN o
measurements NNS o
, , o
and CC o
assessment NN o
of IN o
patients NNS o
' POS o
satisfaction NN o
and CC o
adverse JJ o
events NNS o
were VBD o
performed VBN N
at IN N
baseline NN N
and CC N
every DT N
visit NN N
. . N

RESULTS NNP N
After IN N
treatments NNS N
, , N
statistically RB N
significant JJ N
improvements NNS N
in IN N
the DT N
baseline NN o
KP NNP o
were VBD N
observed VBN N
in IN N
erythema NN N
and CC N
melanin NN N
index NN N
of IN N
mexameter NN N
on IN N
treated JJ N
upper JJ N
arms NNS N
. . N

Both CC N
the DT N
physicians NNS N
' POS N
and CC N
patients NNS N
' POS N
assessments NNS N
correlate VBP N
with IN N
the DT N
results NNS N
of IN N
mexameter NN N
scores NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
suggest VBP N
FCR? NNP N
should MD N
be VB N
considered VBN N
as IN N
an DT N
effective JJ o
and CC o
safe JJ o
treatment NN N
option NN N
for IN N
the DT N
patients NNS p
with IN p
KP NNP p
. . p

-DOCSTART- -X- O O

Long-term JJ N
follow-up NN N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
fludarabine-mitoxantrone NN i
, , N
compared VBN N
with IN N
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vindesine NN i
, , i
prednisone NN i
( ( i
CHVP NNP i
) ) i
, , N
as IN N
first-line JJ N
treatment NN N
of IN N
elderly JJ p
patients NNS p
with IN p
advanced JJ p
, , p
low-grade JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
before IN p
the DT p
era NN p
of IN p
monoclonal JJ p
antibodies NNS p
. . p

BACKGROUND NNP N
This DT N
randomized VBN N
study NN N
compared VBN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
fludarabine-mitoxantrone NN i
( ( i
FM NNP i
) ) i
with IN i
mini-CHVP NN i
( ( i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vindesine NN i
, , i
prednisone NN i
) ) i
in IN N
elderly JJ p
patients NNS p
with IN p
advanced JJ p
, , p
low-grade JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
End NNP N
points NNS N
were VBD N
remission JJ o
rates NNS o
[ VBP o
overall JJ o
response NN o
( ( o
OR NNP o
) ) o
and CC o
complete JJ o
response NN o
( ( o
CR NNP o
) ) o
] NN o
, , o
failure-free JJ o
survival NN o
( ( o
FFS NNP o
) ) o
, , o
survival JJ o
and CC o
toxicity NN o
. . o

One CD p
hundred CD p
and CC p
fifty-five JJ p
patients NNS p
were VBD p
randomized VBN p
, , p
144 CD p
were VBD p
evaluable JJ p
for IN p
safety NN p
and CC p
142 CD p
for IN p
response NN p
. . p

Each DT N
treatment NN N
arm NN N
was VBD N
given VBN N
as IN N
six CD N
monthly JJ N
cycles NNS N
, , N
followed VBN N
by IN N
three CD N
bimonthly JJ N
cycles NNS N
. . N

FM NNP N
comprised VBD N
fludarabine NN i
( ( N
20 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

) ) N
, , N
days NNS N
1-5 CD N
, , N
plus CC N
mitoxantrone NN i
( ( N
10 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

) ) N
, , N
day NN N
1 CD N
. . N

CHVP NNP N
cycles NNS N
comprised VBD N
cyclophosphamide NN i
( ( N
750 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

infusion NN N
) ) N
, , N
doxorubicin NN i
( ( N
25 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

) ) N
and CC N
vindesine NN i
( ( N
3 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

) ) N
on IN N
day NN N
1 CD N
, , N
and CC N
prednisone NN i
( ( N
50 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
on IN N
days NNS N
1-5 JJ N
. . N

RESULTS NNP N
FM NNP i
therapy NN N
resulted VBD N
in IN N
superior JJ N
remission NN o
rates NNS o
( ( N
OR CC N
81 CD N
% NN N
versus IN N
64 CD N
% NN N
, , N
CR NNP N
49 CD N
% NN N
versus IN N
17 CD N
% NN N
; : N
P NNP N
= NNP N
0.0004 CD N
) ) N
. . N

Median JJ o
FFS NNP o
for IN N
FM NNP i
patients NNS N
was VBD N
36 CD N
months NNS N
, , N
compared VBN N
with IN N
19 CD N
months NNS N
for IN N
CHVP NNP N
patients NNS N
, , N
and CC N
has VBZ N
not RB N
yet RB N
been VBN N
reached VBN N
for IN N
early JJ N
CR NNP N
patients NNS N
at IN N
53 CD N
months NNS N
. . N

Treatment NNP N
arm NN N
was VBD N
the DT N
major JJ N
risk NN N
factor NN N
influencing VBG N
survival NN o
. . o

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN o
, , N
with IN N
only RB N
few JJ N
infectious JJ o
complications NNS o
. . o

CONCLUSION NNP N
FM NNP i
was VBD N
more RBR N
effective JJ o
than IN N
CHVP NNP N
in IN N
achieving VBG N
OR NNP o
and CC o
CR NNP o
, , N
and CC N
favorably RB N
affected VBD N
the DT N
outcome NN N
. . N

-DOCSTART- -X- O O

Ganciclovir NNP i
use NN N
during IN N
mild JJ p
renal JJ o
failure NN o
in IN p
heart NN i
transplantation NN i
. . i

-DOCSTART- -X- O O

The DT N
cardiovascular JJ N
effects NNS N
of IN N
sevoflurane NN i
and CC i
isoflurane NN i
after IN N
premedication NN N
of IN N
healthy JJ p
dogs NNS p
undergoing VBG p
elective JJ p
surgery NN p
. . p

Sevoflurane NNP i
and CC i
isoflurane NN i
are VBP N
commonly RB N
used VBN N
in IN N
veterinary JJ N
anesthesia NN N
. . N

The DT N
objective NN N
of IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
clinical JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
cardiovascular JJ N
effects NNS N
of IN N
sevoflurane NN i
and CC i
isoflurane NN i
via IN N
direct JJ N
arterial JJ N
blood NN N
pressure NN N
measurements NNS N
and CC N
the DT N
lithium NN N
dilution NN N
cardiac NN N
output NN N
( ( N
LDCO NNP N
) ) N
on IN N
premedicated VBN p
healthy JJ p
dogs NNS p
undergoing VBG p
elective JJ p
tibial JJ p
plateau NN p
leveling VBG p
osteotomy NN p
( ( p
TPLO NNP p
) ) p
. . p

Nineteen JJ p
client-owned JJ p
dogs NNS p
were VBD N
included VBN N
. . N

All DT N
dogs NNS N
were VBD N
premedicated VBN N
with IN N
hydromorphone NN i
( ( N
0.05 CD N
mg/kg NN N
IV NNP N
and CC N
glycopyrrolate VB i
0.01 CD N
mg/kg NNS N
subcutaneously RB N
) ) N
. . N

Ten CD p
dogs NNS p
were VBD p
anesthetized VBN p
with IN p
sevoflurane NN i
and CC p
nine CD p
dogs NNS p
were VBD p
anesthetized VBN p
with IN p
isoflurane NN i
. . i

Eighteen JJ N
dogs NNS N
were VBD N
instrumented VBN N
with IN N
a DT N
dorsal NN N
pedal JJ N
arterial JJ N
catheter NN N
, , N
and CC N
one CD N
dog NN N
had VBD N
a DT N
femoral JJ N
arterial JJ N
catheter NN N
. . N

All DT N
dogs NNS N
had VBD N
continuous JJ N
, , N
direct JJ o
systolic NN o
( ( o
SAP NNP o
) ) o
, , o
diastolic JJ o
( ( o
DAP NNP o
) ) o
, , o
and CC o
mean JJ o
arterial NN o
( ( o
MAP NNP o
) ) o
blood NN o
pressure NN o
readings NNS o
as RB N
well RB N
as IN N
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
, , o
cardiac JJ o
output NN o
( ( o
CO NNP o
) ) o
, , o
cardiac JJ o
index NN o
( ( o
CI NNP o
) ) o
, , o
systemic JJ o
vascular NN o
resistance NN o
( ( o
SVR NNP o
) ) o
, , o
systemic JJ o
vascular NN o
resistance NN o
index NN o
( ( o
SVRI NNP o
) ) o
, , o
stroke VBD o
volume NN o
variation NN o
( ( o
SVV NNP o
) ) o
, , o
and CC o
pulse JJ o
pressure NN o
variation NN o
( ( o
PPV NNP o
) ) o
recorded VBD N
q $ N
5 CD N
min NN N
during IN N
the DT N
surgical JJ N
procedure NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
statistical JJ N
difference NN N
in IN N
all DT N
parameters NNS N
between IN N
the DT N
sevoflurane NN i
and CC N
isoflurane NN i
treatment NN N
groups NNS N
. . N

Both DT N
sevoflurane NN i
and CC N
isoflurane NN i
inhalant JJ N
anesthetics NNS N
appear VBP N
to TO N
have VB N
similar JJ N
hemodynamic JJ N
effects NNS N
when WRB N
used VBN N
as IN N
part NN N
of IN N
a DT N
multimodal JJ N
anesthetic JJ N
protocol NN N
in IN N
premedicated VBN p
healthy JJ p
dogs NNS p
undergoing VBG p
an DT p
elective JJ p
surgical JJ p
procedure NN p
. . p

-DOCSTART- -X- O O

[ JJ N
Long-term NNP N
treatment NN N
of IN N
cerebrovascular JJ N
changes NNS N
in IN N
the DT N
elderly JJ p
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

A DT N
prospective JJ N
study NN N
over IN N
15 CD N
months NNS N
in IN N
100 CD p
elderly JJ p
patients NNS p
with IN p
signs NNS p
of IN p
cerebro-vascular JJ p
impairment NN p
demonstrated VBN p
by IN p
psychometric JJ p
testing VBG p
that IN N
Hydergine NNP i
( ( N
an DT N
ergot NN N
alkaloid JJ N
preparation NN N
: : N
4.5 CD N
mg NNS N
daily RB N
) ) N
compensated VBD N
the DT N
signs NNS N
of IN N
dementia NN N
, , N
present NN N
in IN N
the DT N
placebo NN i
group NN N
, , N
and CC N
in IN N
some DT N
patients NNS N
actually RB N
brought VBD N
about IN N
a DT N
significant JJ N
improvement NN o
in IN o
mental JJ o
activity NN o
. . o

Similar JJ N
compensatory NN o
effect NN o
was VBD N
also RB N
demonstrable JJ N
in IN N
cerebral JJ o
haemodynamics NNS o
: : o
in IN N
the DT N
placebo NN i
group NN N
there EX N
was VBD N
a DT N
progressive JJ o
increase NN o
in IN o
cerebral JJ o
circulation NN o
time NN o
, , N
an DT N
expression NN o
of IN o
decreased JJ o
cerebral JJ o
blood NN o
flow NN o
, , N
while IN N
with IN N
Hydergine NNP i
cerebral JJ N
circulation NN N
time NN N
was VBD N
shortened VBN N
and CC N
stabilized VBN N
. . N

Serial JJ N
EEGs NNP N
, , N
obtained VBN N
in IN N
parallel JJ N
with IN N
psychometric JJ N
and CC N
circulation NN N
time NN N
tests NNS N
, , N
demonstrated VBD N
a DT N
marked JJ N
increase NN N
in IN N
the DT N
8-10 JJ o
Hz NNP o
pattern NN o
which WDT N
corresponds VBZ N
to TO N
the DT N
physiological JJ N
alpha NN N
activity NN N
in IN N
this DT N
age NN N
group NN N
. . N

Furthermore RB N
, , N
there EX N
was VBD N
a DT N
diminished JJ N
variability NN N
in IN N
performance NN o
in IN N
the DT N
tested JJ N
frequency NN N
bands NNS N
with IN N
Hydergine NNP i
, , N
the DT N
opposite JJ N
tendency NN N
being VBG N
obtained VBN N
in IN N
the DT N
placebo NN i
group NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
combination NN N
of IN N
evening VBG i
primrose JJ i
oil NN i
( ( i
gamma NN i
linolenic RB i
acid NN i
) ) i
and CC i
fish JJ i
oil NN i
( ( i
eicosapentaenoic JJ i
+ NNP i
docahexaenoic NN i
acid NN i
) ) i
versus NN i
magnesium NN i
, , i
and CC i
versus NN i
placebo NN i
in IN N
preventing VBG N
pre-eclampsia NN o
. . o

In IN N
a DT N
placebo NN i
controlled VBN N
, , N
partially RB N
double-blinded JJ N
, , N
clinical JJ N
trial NN N
, , N
a DT N
combination NN i
of IN i
evening VBG i
primrose JJ i
oil NN i
and CC i
fish JJ i
oil NN i
was VBD i
compared VBN i
to TO i
Magnesium NNP i
Oxide NNP i
, , i
and CC i
to TO i
a DT i
Placebo NNP i
in IN N
preventing VBG N
Pre-Eclampsia NNP o
of IN o
Pregnancy NNP o
. . o

All DT N
were VBD N
given VBN N
as IN N
nutritional JJ N
supplements NNS N
for IN N
six CD N
months NNS N
to TO N
a DT N
group NN p
of IN p
primiparous JJ p
and CC p
multiparous JJ p
pregnant JJ p
women NNS p
. . p

Some DT p
of IN p
these DT p
women NNS p
had VBD p
personal JJ p
or CC p
family NN p
histories NNS p
of IN p
hypertension NN p
( ( p
21 CD p
% NN p
) ) p
. . p

Only RB p
those DT p
patients NNS p
who WP p
received VBD p
prenatal JJ p
care NN p
at IN p
the DT p
Central NNP p
Maternity NNP p
Hospital NNP p
for IN p
Luanda NNP p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Compared VBN N
to TO N
the DT N
Placebo NNP i
group NN N
( ( N
29 CD N
% NN N
) ) N
, , N
the DT N
group NN N
receiving VBG N
the DT N
mixture NN N
of IN N
evening VBG i
primrose JJ i
oil NN i
and CC N
fish JJ i
oil NN i
containing VBG N
Gamma-linolenic JJ i
acid NN i
( ( i
GLA NNP i
) ) i
, , i
Eicosapentaenoic NNP i
acid NN i
( ( i
EPA NNP i
) ) i
, , N
and CC N
Docosahexaenoic NNP i
acid NN i
( ( i
DHA NNP i
) ) i
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN o
of IN o
edema NN o
( ( N
13 CD N
% NN N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
group NN N
receiving VBG N
Magnesium NNP i
Oxide NNP i
had VBD N
statistically RB N
significant JJ N
fewer JJR N
subjects NNS N
who WP N
developed VBD N
hypertension NN o
of IN o
pregnancy NN o
. . o

There EX N
were VBD N
3 CD N
cases NNS N
of IN N
eclampsia NN o
, , N
all DT N
in IN N
the DT N
Placebo NNP i
group NN N
. . N

-DOCSTART- -X- O O

Association NNP N
between IN N
platelet NN N
activation NN N
and CC N
fibrinolysis NN N
in IN N
acute JJ p
stroke NN p
patients NNS p
. . p

We PRP N
aimed VBD N
to TO N
evaluate VB N
platelet NN N
activation NN N
and CC N
fibrinolyis NN N
in IN N
acute JJ p
atherosclerotic JJ p
ischemic JJ p
stroke NN p
patients NNS p
to TO N
clarify VB N
the DT N
relationship NN N
between IN N
them PRP N
. . N

Plasma VB o
P-selectin NNP o
antigen NN o
, , o
tissue NN o
plasminogen NN o
activator NN o
( ( o
tPA NN o
) ) o
antigen NN o
and CC o
activity NN o
, , o
and CC o
plasminogen NN o
activator NN o
inhibitor-1 JJ o
( ( o
PAI-1 NNP o
) ) o
activity NN o
were VBD N
determined VBN N
in IN N
60 CD p
acute JJ p
atherosclerotic JJ p
stroke NN p
patients NNS p
and CC p
matched VBN p
control NN p
subjects NNS p
. . p

All DT p
patients NNS p
were VBD p
examined VBN p
within IN p
72 CD p
h NN p
after IN p
stroke NN p
onset NN p
. . p

The DT N
levels NNS o
of IN o
P-selectin NNP o
, , o
tPA NN o
antigen NN o
, , o
and CC o
PAI-1 JJ o
activity NN o
were VBD N
all DT N
significantly RB o
higher JJR o
in IN N
stroke NN N
patients NNS N
compared VBN N
with IN N
controls NNS N
( ( N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
; : N
the DT N
level NN o
of IN o
tPA JJ o
activity NN o
was VBD N
significantly RB N
lower JJR N
in IN N
patients NNS N
than IN N
that DT N
in IN N
controls NNS N
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
. . N

These DT N
markers NNS N
did VBD N
not RB N
change VB N
much RB N
at IN N
different JJ N
time NN N
points NNS N
within IN N
72 CD N
h. NN N
In IN N
stroke NN N
group NN N
, , N
P-selectin NNP o
concentration NN o
was VBD N
highly RB N
correlated VBN N
to TO N
PAI-1 NNP o
activity NN o
( ( N
r NN N
= VBZ N
0.8433 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
to TO N
tPA VB o
antigen NN o
( ( N
r JJ N
= NNP N
-0.1752 NNP N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
, , N
and CC N
tPA NN o
activity NN o
( ( N
r NN N
= VBZ N
0.2465 CD N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
, , N
which WDT N
was VBD N
further RBR N
confirmed VBN N
in IN N
the DT N
multiple JJ N
linear JJ N
regression NN N
analysis NN N
( ( N
F NNP N
= NNP N
47.052 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Our PRP$ N
results NNS N
indicate VBP N
increased JJ o
platelet NN o
activation NN o
and CC N
decreased JJ o
fibrinolysis NN o
in IN N
patients NNS p
with IN p
acute JJ p
atherosclerotic JJ p
ischemic JJ p
stroke NN p
. . p

Increased VBN N
platelet NN o
activation NN o
may MD N
be VB N
correlated VBN N
with IN N
decreased JJ N
fibrinolysis NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
pindolol NN i
and CC i
clopamide NN i
on IN N
blood NN o
lipids NNS o
in IN N
arterial JJ p
hypertensive JJ p
patients NNS p
. . p

The DT N
effects NNS N
of IN N
clopamide NN i
, , i
pindolol NN i
and CC i
its PRP$ i
combination NN i
on IN i
plasma JJ i
lipids NNS i
in IN N
49 CD p
hypertensive JJ p
patients NNS p
( ( p
WHO NNP p
I-II NNP p
) ) p
, , p
divided VBD p
into IN p
three CD p
parallel JJ p
randomized VBN p
groups NNS p
, , p
were VBD p
studied VBN p
over IN p
a DT p
6 CD p
months NNS p
period NN p
. . p

Total JJ o
cholesterol NN o
, , o
triglycerides NNS o
, , o
HDL NNP o
and CC o
LDL NNP o
cholesterol NN o
fractions NNS o
were VBD N
determined VBN N
twice RB N
during IN N
an DT N
initial JJ N
4-week JJ N
washout NN N
phase NN N
, , N
and CC N
after IN N
a DT N
1- JJ N
, , N
3- JJ N
and CC N
6-month JJ N
active JJ N
hypotensive JJ N
drug NN N
phase NN N
. . N

Patients NNS N
were VBD N
instructed VBN N
to TO N
maintain VB N
their PRP$ N
usual JJ N
dietary JJ N
habits NNS N
. . N

Daily JJ N
drug NN N
doses NNS N
were VBD N
adjusted VBN N
progressively RB N
to TO N
attain VB N
optimal JJ N
hypotensive JJ N
effects NNS N
. . N

In IN N
the DT N
clopamide NN N
monotherapy NN N
group NN N
, , N
total JJ o
cholesterol NN o
increased VBD N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
; : N
triglycerides NNS o
and CC N
LDL NNP o
showed VBD N
a DT N
tendency NN N
to TO N
increase VB N
while IN N
for IN N
HDL NNP o
a DT N
tendency NN N
to TO N
decrease VB N
was VBD N
observed VBN N
. . N

In IN N
the DT N
pindolol NN N
monotherapy NN N
group NN N
, , N
a DT N
significant JJ N
reduction NN N
of IN N
triglycerides NNS o
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
a DT N
significant JJ N
increase NN N
of IN N
HDL NNP o
cholesterol NN o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
were VBD N
recorded VBN N
. . N

No DT N
significant JJ N
changes NNS N
in IN N
total JJ o
cholesterol NN o
or CC o
LDL NNP o
fraction NN o
were VBD N
observed VBN N
. . N

Combined VBN N
pindolol-clopamide JJ N
therapy NN N
decreased VBD N
total JJ o
triglycerides NNS o
( ( o
NS NNP o
) ) o
, , N
increased VBD N
HDL NNP o
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
did VBD N
not RB N
influence VB N
total JJ o
cholesterol NN o
and CC o
LDL NNP o
fraction NN o
. . o

It PRP N
is VBZ N
concluded VBN N
that IN N
pindolol NN N
does VBZ N
not RB N
negatively RB N
influence VB N
blood NN o
lipids NNS o
as IN N
the DT N
thiazide-type JJ N
diuretic JJ N
clopamide NN N
does VBZ N
, , N
and CC N
that IN N
when WRB N
both DT N
drugs NNS N
are VBP N
used VBN N
together RB N
, , N
the DT N
beta-blocker NN N
can MD N
probably RB N
counterbalance VB N
the DT N
diuretic-induced JJ N
negative JJ N
effects NNS N
on IN N
blood NN o
lipids NNS o
. . o

Accordingly RB N
, , N
it PRP N
is VBZ N
suggested VBN N
that IN N
pindolol NN N
could MD N
be VB N
a DT N
more RBR N
favorable JJ N
beta-blocker JJ N
drug NN N
to TO N
be VB N
used VBN N
on IN N
hypertensive JJ p
subjects NNS p
with IN p
metabolic JJ p
coronary JJ p
risk NN p
factors NNS p
. . p

-DOCSTART- -X- O O

Use NNP N
of IN N
an DT N
inspiratory JJ i
impedance NN i
threshold JJ i
device NN i
on IN i
a DT i
facemask NN i
and CC i
endotracheal VB i
tube NN i
to TO N
reduce VB N
intrathoracic JJ o
pressures NNS o
during IN N
the DT N
decompression NN N
phase NN N
of IN N
active JJ p
compression-decompression NN o
cardiopulmonary JJ o
resuscitation NN o
. . o

INTRODUCTION NNP N
Use NNP N
of IN N
an DT N
inspiratory JJ i
impedance NN i
threshold NN i
device NN i
( ( i
ITD NNP i
) ) i
significantly RB N
increases VBZ N
coronary JJ N
perfusion NN N
pressures NNS N
and CC N
survival NN N
in IN N
patients NNS p
ventilated VBN p
with IN p
an DT p
endotracheal JJ i
tube NN i
( ( i
ETT NNP i
) ) i
during IN p
active JJ i
compression-decompression NN i
cardiopulmonary JJ i
resuscitation NN i
. . i

We PRP N
tested VBD N
the DT N
hypothesis NN N
that IN N
the DT N
ITD NNP i
could MD N
lower VB N
intratracheal NN N
pressures NNS N
when WRB N
attached VBN N
to TO N
either VB N
a DT N
facemask NN i
or CC i
ETT NNP i
. . i

METHODS NNP N
An DT i
active JJ i
and CC i
sham JJ i
ITD NNP i
were VBD N
randomly RB N
applied VBN N
first RB N
to TO N
a DT N
facemask NN i
and CC N
then RB N
to TO N
an DT N
ETT NNP i
during IN N
active JJ i
compression-decompression NN i
cardiopulmonary JJ i
resuscitation NN i
in IN p
13 CD p
out-of-hospital JJ p
cardiac JJ p
arrest NN p
patients NNS p
in IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
prospective JJ N
clinical JJ N
trial NN N
. . N

The DT N
compression-to-bag-valve JJ N
ventilation NN N
ratio NN N
was VBD N
15:2 CD N
. . N

Airway NN N
pressures NNS N
( ( N
surrogate NN N
for IN N
intrathoracic JJ N
pressure NN N
) ) N
were VBD N
measured VBN N
with IN N
a DT N
pressure NN N
transducer NN N
. . N

A DT i
sham NN i
and CC i
an DT i
active JJ i
ITD NNP i
were VBD N
used VBN N
for IN N
1 CD N
min NNS N
each DT N
in IN N
a DT N
randomized JJ N
order NN N
, , N
first RB N
on IN N
a DT N
facemask NN i
and CC N
then RB N
on IN N
an DT N
ETT NNP i
. . i

Statistical JJ N
analyses NNS N
were VBD N
made VBN N
using VBG N
Friedman NNP N
's POS N
and CC N
Wilcoxon NNP N
's POS N
rank-sum JJ N
tests NNS N
. . N

RESULTS NNP N
For IN N
the DT N
primary JJ N
end NN N
point NN N
, , N
mean JJ o
+/- JJ o
sd NN o
maximum JJ o
negative JJ o
intrathoracic NN o
pressures NNS o
( ( N
mm VB N
Hg NNP N
) ) N
during IN N
the DT N
decompression NN o
phase NN o
of IN o
cardiopulmonary JJ o
resuscitation NN o
were VBD N
-1.0 JJ N
+/- JJ N
0.73 CD N
mm NN N
Hg NNP N
with IN N
a DT N
sham NN i
vs. FW N
-4.6 NNP N
+/- JJ N
3.7 CD N
mm NN N
Hg NNP N
with IN N
an DT N
active JJ i
ITD NN i
on IN N
the DT N
facemask NN N
( ( N
p JJ N
= NNP N
.003 NNP N
) ) N
and CC N
-1.3 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
with IN N
a DT N
sham NN N
ITD NNP N
vs. IN N
-7.3 NNP N
+/- JJ N
4.5 CD N
mm NN N
Hg NNP N
with IN N
an DT N
active JJ N
ITD NNP N
on IN N
an DT N
ETT NNP N
( ( N
p JJ N
= NNP N
.0009 NNP N
) ) N
. . N

Decompression NNP o
phase NN o
airway NN o
pressures NNS o
with IN N
the DT N
facemask NN i
and CC i
ETT NNP i
were VBD N
not RB N
statistically RB N
different JJ N
. . N

CONCLUSIONS NNP N
Use NNP N
of IN N
an DT N
active JJ i
ITD NNP i
attached VBD i
to TO i
a DT i
facemask NN i
or CC i
an DT i
ETT NNP i
resulted VBD N
in IN N
a DT N
significantly RB N
lower JJR N
negative JJ o
intratracheal JJ o
pressure NN o
during IN N
the DT N
decompression NN N
phase NN N
of IN N
active JJ N
compression-decompression NN N
cardiopulmonary JJ N
resuscitation NN N
when WRB N
compared VBN N
with IN N
controls NNS N
. . N

Airway NNP N
pressures VBZ N
with IN N
an DT N
ITD NNP i
on IN N
either CC N
a DT i
facemask NN i
or CC N
ETT NNP i
were VBD N
similar JJ N
. . N

The DT N
ITD-facemask JJ i
combination NN i
was VBD N
practical JJ N
and CC N
enables VBZ N
rapid JJ N
deployment NN N
of IN N
this DT N
life-saving JJ N
technology NN N
. . N

-DOCSTART- -X- O O

Treatment NN o
of IN o
gastrointestinal JJ o
cancer NN o
: : o
the DT N
Southeastern NNP p
Cancer NNP p
Study NNP p
Group NNP p
experience NN p
, , p
1979 CD p
to TO p
1983 CD p
. . p

The DT N
treatment NN N
of IN N
gastrointestinal JJ o
cancer NN o
was VBD N
studied VBN N
in IN N
20 CD N
phase NN N
I PRP N
, , N
II NNP N
, , N
and CC N
III NNP N
clinical JJ N
trials NNS N
from IN p
1979 CD p
to TO p
1983 CD p
at IN p
30 CD p
member NN p
institutions NNS p
of IN p
the DT p
Southeastern NNP p
Cancer NNP p
Study NNP p
Group NNP p
( ( p
SECSG NNP p
) ) p
. . p

These DT N
studies NNS N
used VBD N
both DT N
new JJ i
and CC i
commercially RB i
available JJ i
drugs NNS i
, , N
as RB N
well RB N
as IN N
surgery NN i
and/or NN i
radiation NN i
therapy NN i
in IN N
1,087 CD p
patients NNS p
. . p

No DT N
significant JJ N
benefit NN N
was VBD N
seen VBN N
from IN N
18 CD i
agents NNS i
, , N
and CC N
one CD N
agent NN N
is VBZ N
still RB N
under IN N
evaluation NN N
. . N

Unfortunately RB N
, , N
no DT N
recommendations NNS N
can MD N
be VB N
drawn VBN N
from IN N
these DT N
studies NNS N
that WDT N
would MD N
alter VB N
presently RB N
accepted VBN N
methods NNS N
of IN N
management NN N
. . N

Adenocarcinoma NNP N
of IN N
the DT N
gastrointestinal JJ N
tract NN N
remains VBZ N
a DT N
major JJ N
challenge NN N
to TO N
tumor VB N
biologists NNS N
and CC N
clinical JJ N
oncologists NNS N
because IN N
it PRP N
is VBZ N
generally RB N
resistant JJ N
to TO N
chemotherapy VB i
and CC N
radiation NN i
therapy NN i
, , N
yet RB N
common JJ N
enough RB N
to TO N
represent VB N
a DT N
vital JJ N
public JJ N
health NN N
concern NN N
in IN N
America NNP p
. . p

-DOCSTART- -X- O O

[ JJ N
Triple NNP N
therapy NN N
regimens VBZ N
involving VBG N
H2 NNP i
blockaders NNS i
for IN N
therapy NN N
of IN N
Helicobacter NNP o
pylori FW o
infections NNS o
] VBP o
. . N

Comparison NNP o
of IN N
ranitidine NN i
and CC N
lansoprazole NN i
in IN N
short-term JJ N
low-dose JJ N
triple NN N
therapy NN N
for IN N
Helicobacter NNP N
pylori JJ N
infection NN N
. . N

To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
two CD N
1-week JJ N
low-dose JJ N
triple-therapy JJ N
drug NN N
regimens NNS N
involving VBG N
antisecretory NN i
drugs NNS i
for IN N
Helicobacter NNP N
pylori JJ N
infection NN N
, , N
99 CD p
patients NNS p
with IN p
H. NNP p
pylori FW p
infection NN p
were VBD p
treated VBN N
with IN N
either DT N
lansoprazole NN i
( ( N
LPZ NNP N
) ) N
or CC N
ranitidine NN i
( ( N
RNT NNP N
) ) N
used VBD N
together RB N
with IN N
clarithromycin NN i
( ( i
CAM NNP i
) ) i
and CC N
metrinidazole $ i
( ( i
MTZ NNP i
) ) i
. . N

The DT N
drug NN N
combination NN N
and CC N
administration NN N
periods NNS N
in IN N
the DT N
PPI NNP N
group NN N
were VBD N
LPZ NNP i
30 CD N
mg NN N
, , N
CAM NNP i
400 CD N
mg NN N
, , N
MTZ NNP i
500 CD N
mg NN N
( ( N
LCM NNP N
group NN N
) ) N
. . N

The DT N
ranitidine NN i
group NN N
received VBD N
RNT NNP i
300 CD N
mg NN N
, , N
CAM NNP i
400 CD N
mg NN N
, , N
MTZ NNP i
500 CD N
mg NN N
( ( N
RCM NNP N
group NN N
) ) N
. . N

The DT N
cure NN o
rate NN o
of IN o
H. NNP o
pylori FW o
infection NN o
was VBD N
88 CD N
% NN N
in IN N
the DT N
LCM NNP i
group NN N
; : N
95 CD N
% NN N
CI NNP N
79-97 CD N
and CC N
92 CD N
% NN N
in IN N
the DT N
RCM NNP i
group NN N
; : N
95 CD N
% NN N
CI NNP N
84-99 CD N
. . N

-DOCSTART- -X- O O

Children NNP p
's POS p
attitudes NNS o
and CC o
behavioral JJ o
intentions NNS o
toward IN p
a DT p
peer NN p
with IN p
autistic JJ o
behaviors NNS o
: : o
does VBZ N
a DT N
brief JJ N
educational JJ i
intervention NN i
have VBP N
an DT N
effect NN N
? . N
This DT N
study NN N
examined VBD N
children NNS p
's POS p
ratings NNS p
of IN p
attitudes NNS o
and CC o
behavioral JJ o
intentions NNS o
toward IN p
a DT p
peer NN p
presented VBN p
with IN p
or CC p
without IN p
autistic JJ o
behaviors NNS o
. . o

The DT N
impact NN N
of IN N
information NN N
about IN N
autism NN N
on IN N
these DT N
ratings NNS N
was VBD N
investigated VBN N
as RB N
well RB N
as IN N
age NN N
and CC N
gender NN N
effects NNS N
. . N

Third- CD p
and CC p
sixth-grade JJ p
children NNS p
( ( p
N NNP p
= NNP p
233 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
view VB i
a DT i
video NN i
of IN i
the DT i
same JJ i
boy NN i
in IN i
one CD i
of IN i
three CD i
conditions NNS i
: : i
No DT i
Autism NNP i
, , i
Autism NNP i
, , i
or CC i
Autism/Information NNP i
. . i

Children NNP N
at IN N
both DT N
grade NN N
levels NNS N
showed VBD N
less RBR o
positive JJ o
attitudes NNS o
toward IN N
the DT N
child NN N
in IN N
the DT N
two CD N
autism NN N
conditions NNS N
. . N

In IN N
rating NN N
their PRP$ N
own JJ N
behavioral JJ o
intentions NNS o
, , N
children NNS N
showed VBD N
no DT N
differences NNS N
between IN N
conditions NNS N
. . N

However RB N
, , N
in IN N
attributing VBG N
intentions NNS N
to TO N
their PRP$ N
classmates NNS N
, , N
older JJR N
children NNS N
and CC N
girls NNS N
gave VBD N
lower JJR o
ratings NNS o
to TO N
the DT N
child NN N
in IN N
the DT N
autism NN N
conditions NNS N
. . N

Information NN N
about IN N
autism NN N
did VBD N
not RB N
affect JJ N
ratings NNS N
of IN N
either DT N
attitudes NNS o
or CC o
behavioral JJ o
intentions NNS o
as IN N
ascribed NN N
to TO N
self VB N
or CC N
others NNS N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
electrofunctional JJ N
data NNS N
following VBG N
argon-laser NN i
trabeculoplasty NN i
in IN N
primary JJ N
open-angle JJ N
glaucoma NN N
. . N

To TO N
establish VB N
whether IN N
or CC N
not RB N
glaucomatous JJ o
damage NN o
is VBZ N
reversible JJ N
, , N
we PRP N
obtained VBD N
pattern-reversal JJ o
electroretinograms NNS o
( ( o
PERGs NNP o
) ) o
and CC o
visual JJ o
evoked VBN o
potentials NNS o
( ( o
VEPs NNP o
) ) o
in IN N
25 CD p
eyes NNS p
of IN p
25 CD p
patients NNS p
suffering VBG p
from IN p
bilateral JJ p
primary JJ p
open-angle JJ p
glaucoma NN p
( ( p
POAG NNP p
) ) p
before IN p
and CC p
after IN p
argon-laser JJ i
trabeculoplasty NN i
. . i

The DT N
laser NN N
treatment NN N
was VBD N
carried VBN N
out RP N
in IN N
only RB N
one CD N
eye NN N
chosen VBN N
at IN N
random NN N
, , N
and CC N
the DT N
fellow JJ N
eye NN N
was VBD N
used VBN N
as IN N
a DT N
control NN N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
intended VBD N
to TO N
verify VB N
the DT N
possibility NN N
of IN N
using VBG N
electrofunctional JJ N
techniques NNS N
to TO N
determine VB N
the DT N
two CD N
distinct NN N
and CC N
, , N
probably RB N
, , N
consecutive JJ N
glaucomatous JJ o
alterations NNS o
occurring VBG o
in IN o
ganglion NN o
cells NNS o
: : o
functional JJ o
( ( o
reversible JJ o
) ) o
and CC o
anatomical JJ o
( ( o
irreversible JJ o
) ) o
. . o

The DT N
results NNS N
obtained VBD N
indicate VBP N
that IN N
glaucomatous JJ o
damage NN o
is VBZ N
irreversible JJ N
. . N

We PRP N
propose VBP N
that IN N
such JJ N
alterations NNS N
differ VBP N
very RB N
slightly RB N
and CC N
that IN N
the DT N
current JJ N
electrofunctional JJ N
techniques NNS N
may MD N
not RB N
be VB N
sufficiently RB N
sophisticated JJ N
to TO N
distinguish VB N
between IN N
them PRP N
. . N

-DOCSTART- -X- O O

Double-blind NNP N
placebo-controlled JJ i
administration NN N
of IN N
fluoxetine NN i
in IN N
restricting- JJ p
and CC p
restricting-purging-type JJ p
anorexia NN p
nervosa NN p
. . p

BACKGROUND NNP N
Anorexia NNP N
nervosa NN N
is VBZ N
an DT N
often RB N
chronic JJ N
disorder NN N
with IN N
high JJ N
morbidity NN N
and CC N
mortality NN N
. . N

Many JJ N
people NNS N
relapse VBP N
after IN N
weight JJ N
restoration NN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
whether IN N
a DT N
selective JJ i
serotonin NN i
reuptake NN i
inhibitor NN i
would MD N
improve VB N
outcome NN N
and CC N
reduce VB N
relapse NN N
after IN N
weight JJ o
restoration NN o
by IN o
contributing VBG o
to TO o
maintenance NN o
of IN o
a DT o
healthy JJ o
normal JJ o
weight NN o
and CC o
a DT o
reduction NN o
of IN o
symptoms NNS o
. . o

METHODS NNP N
We PRP N
administered VBD N
a DT N
double-blind JJ N
placebo-controlled JJ i
trial NN N
of IN N
fluoxetine NN i
to TO N
35 CD p
patients NNS p
with IN p
restricting-type JJ p
anorexia NN p
nervosa NN p
. . p

Anorexics NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
fluoxetine VB i
( ( i
n JJ i
= NNP i
16 CD i
) ) i
or CC i
a DT i
placebo NN i
( ( i
n JJ i
= NNP i
19 CD i
) ) i
after IN N
inpatient NN N
weight NN N
gain NN N
and CC N
then RB N
were VBD N
observed VBN N
as IN N
outpatients NNS N
for IN N
1 CD N
year NN N
. . N

RESULTS NNP N
Ten CD N
of IN N
16 CD N
( ( N
63 CD N
% NN N
) ) N
subjects NNS N
remained VBN N
on IN N
fluoxetine NN i
for IN N
a DT N
year NN N
, , N
whereas IN N
only RB N
three CD N
of IN N
19 CD N
( ( N
16 CD N
% NN N
) ) N
remained VBD N
on IN N
the DT N
placebo NN i
for IN N
a DT N
year NN N
( ( N
p IN N
=.006 NN N
) ) N
. . N

Those DT N
subjects NNS N
remaining VBG N
on IN N
fluoxetine NN i
for IN N
a DT N
year NN N
had VBD N
reduced VBN o
relapse NN o
as IN N
determined VBN N
by IN N
a DT N
significant JJ o
increase NN o
in IN o
weight NN o
and CC o
reduction NN o
in IN o
symptoms NNS o
. . o

CONCLUSIONS VB N
This DT N
study NN N
offers VBZ N
preliminary JJ N
evidence NN N
that IN N
fluoxetine NN i
may MD N
be VB N
useful JJ N
in IN N
improving VBG N
outcome NN N
and CC N
preventing VBG N
relapse NN o
of IN N
patients NNS p
with IN p
anorexia JJ p
nervosa NN p
after IN N
weight JJ N
restoration NN N
. . N

-DOCSTART- -X- O O

Depiction NN o
of IN o
hypervascular JJ o
hepatocellular JJ o
carcinoma NN o
with IN N
64-MDCT JJ o
: : o
comparison NN N
of IN N
moderate- JJ i
and CC i
high-concentration JJ i
contrast NN i
material NN i
with IN i
and CC i
without IN i
saline JJ i
flush NN i
. . i

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
prospectively RB N
the DT N
depiction NN o
of IN o
hypervascular JJ o
hepatocellular JJ o
carcinoma NN o
on IN N
64-MDCT JJ N
scans NNS N
obtained VBN N
with IN N
contrast NN i
agents NNS i
of IN N
varying VBG N
iodine JJ i
concentrations NNS i
administered VBN N
with IN N
and CC N
without IN N
saline JJ i
flush NN i
. . i

SUBJECTS NNP N
AND CC N
METHODS NNP N
The DT p
study NN p
included VBD p
149 CD p
patients NNS p
, , p
among IN p
whom WP p
36 CD p
patients NNS p
with IN p
hypervascular JJ p
hepatocellular JJ p
carcinoma NN p
were VBD p
identified VBN p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
protocols NNS N
: : N
A DT N
, , N
contrast JJ i
material NN i
of IN i
300 CD i
mg NNS i
I/mL NNP i
; : i
B NNP i
, , i
370 CD i
mg NN i
I/mL NNP i
; : i
C NNP i
, , i
370 CD i
mg NN i
I/mL NNP i
plus CC i
saline JJ i
flush NN i
. . i

In IN N
all DT N
protocols NNS N
, , N
the DT N
same JJ i
iodine NN i
load NN i
per IN i
kilogram NN i
of IN i
body NN i
weight NN i
( ( N
516 CD N
mg/kg NN N
) ) N
was VBD N
administered VBN N
for IN N
the DT N
same JJ N
injection NN N
duration NN N
( ( N
30 CD N
seconds NNS N
) ) N
. . N

Enhancement JJ o
values NNS o
in IN o
the DT o
aorta NN o
, , o
liver NN o
, , o
and CC o
portal JJ o
vein NN o
and CC o
tumor-liver JJ o
contrast NN o
were VBD N
measured VBN N
at IN N
multiphase NN N
CT NNP N
. . N

RESULTS NNP N
Aortic JJ o
enhancement NN o
was VBD N
significantly RB N
different JJ N
between IN N
protocols NNS N
A NNP N
and CC N
B NNP N
( ( N
p JJ N
= NN N
0.04 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
and CC N
protocols VBZ N
B NNP N
and CC N
C NNP N
( ( N
p JJ N
= NN N
0.02 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
in IN N
the DT N
first JJ N
and CC N
second JJ N
phases NNS N
. . N

Portal NNP o
venous JJ o
enhancement NN o
was VBD N
significantly RB N
different JJ N
between IN N
protocols NNS N
B NNP N
and CC N
C NNP N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
in IN N
the DT N
first JJ N
phase NN N
and CC N
between IN N
protocols NNS N
B NNP N
and CC N
C NNP N
and CC N
protocols VBZ N
A DT N
and CC N
C NNP N
( ( N
p JJ N
< NN N
0.01 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
in IN N
the DT N
second JJ N
phase NN N
. . N

Tumor-liver JJ o
contrast NN o
was VBD N
significantly RB N
different JJ N
between IN N
protocols NNS N
A NNP N
and CC N
B NNP N
( ( N
p JJ N
= NN N
0.03 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
and CC N
protocols VBZ N
B NNP N
and CC N
C NNP N
( ( N
p JJ N
= NN N
0.03 CD N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
first JJ N
and CC N
second JJ N
phases NNS N
but CC N
not RB N
between IN N
protocols NNS N
A NNP N
and CC N
C. NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
hepatic JJ o
enhancement NN o
among IN N
the DT N
three CD N
protocols NNS N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
moderate JJ N
concentration NN N
was VBD N
more RBR N
effective JJ N
than IN N
use NN N
of IN N
a DT N
high JJ N
concentration NN N
of IN N
contrast NN N
material NN N
for IN N
depiction NN N
of IN N
hepatocellular JJ N
carcinoma NN N
. . N

Adding VBG N
a DT N
saline NN N
flush NN N
to TO N
the DT N
high-concentration NN i
protocol NN i
eliminated VBD N
the DT N
difference NN N
in IN N
depiction NN o
of IN o
hepatocellular JJ o
carcinoma NN o
between IN N
the DT N
moderate- JJ N
and CC N
high-concentration NN N
protocols NNS N
. . N

-DOCSTART- -X- O O

Is VBZ N
psychotherapy VBN i
more RBR N
effective JJ N
when WRB N
therapists NNS p
disclose VB N
information NN N
about IN N
themselves PRP N
? . N
Theorists NNS N
have VBP N
long RB N
debated VBN N
the DT N
wisdom NN N
of IN N
therapists NNS p
disclosing VBG o
personal JJ o
information NN o
during IN p
psychotherapy NN i
. . i

Some DT N
observers NNS N
have VBP N
argued VBN N
that IN N
such JJ N
therapist JJ N
self-disclosure NN N
impedes NNS N
treatment NN N
, , N
whereas IN N
others NNS N
have VBP N
suggested VBN N
that IN N
it PRP N
enhances VBZ N
the DT N
effectiveness NN o
of IN o
therapy NN o
. . o

To TO N
test VB N
these DT N
competing VBG N
positions NNS N
, , N
therapists NNS p
at IN p
a DT p
university NN p
counseling NN p
center NN p
were VBD N
instructed VBN N
to TO N
increase VB i
the DT i
number NN i
of IN i
self-disclosures NNS i
they PRP N
made VBD N
during IN N
treatment NN i
of IN N
one CD p
client NN p
and CC N
refrain NN i
from IN i
making VBG i
self-disclosures NNS i
during IN i
treatment NN i
of IN N
another DT p
client NN p
. . p

Analyses NNS N
revealed VBD N
that IN N
clients NNS N
receiving VBG N
psychotherapy NN i
under IN N
conditions NNS N
of IN N
heightened VBN N
therapist NN i
disclosure NN i
not RB N
only RB N
reported VBD N
lower JJR o
levels NNS o
of IN o
symptom NN o
distress NN o
but CC N
also RB N
liked VBD o
their PRP$ o
therapist NN o
more RBR o
. . o

Such JJ N
findings NNS N
suggest VBP N
that IN N
self-disclosure NN N
by IN N
the DT N
therapist NN N
may MD N
improve VB N
both PDT N
the DT N
quality NN o
of IN o
the DT o
therapeutic JJ o
relationship NN o
and CC o
the DT o
outcome NN o
of IN o
treatment NN o
. . o

-DOCSTART- -X- O O

Coping VBG N
strategies NNS N
as IN N
mediators NNS N
of IN N
the DT N
effect NN N
of IN N
the DT N
START NNP i
( ( i
strategies NNS i
for IN i
RelaTives NNP i
) ) i
intervention NN i
on IN N
psychological JJ o
morbidity NN o
for IN o
family NN o
carers NNS o
of IN o
people NNS o
with IN o
dementia NN o
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Family NNP p
carers NNS p
of IN p
people NNS p
with IN p
dementia NN p
frequently RB N
become VBN N
depressed JJ N
or CC N
anxious JJ N
. . N

In IN N
observational JJ N
studies NNS N
, , N
more JJR N
emotion-focused JJ N
and CC N
less RBR N
dysfunctional JJ N
coping VBG N
predict NN N
fewer JJR N
psychological JJ N
symptoms NNS N
, , N
but CC N
no DT N
randomised VBD N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
has VBZ N
directly RB N
investigated VBN N
emotion-focused JJ N
coping NN N
as IN N
mediator NN N
of IN N
effectiveness NN N
of IN N
a DT N
successful JJ N
psychological JJ N
intervention NN N
. . N

We PRP N
hypothesised VBD N
that IN N
emotion-focused JJ N
coping VBG N
would MD N
mediate VB N
the DT N
START NNP i
psychological JJ i
intervention?s NN i
effects NNS N
in IN N
an DT N
RCT NNP N
. . N

We PRP N
tested VBD N
whether IN N
mediated JJ N
effects NNS N
were VBD N
moderated VBN N
by IN N
severity NN N
of IN N
baseline NN N
symptoms NNS N
. . N

METHODS NNP p
260 CD p
family NN p
carers NNS p
from IN p
NHS NNP p
dementia NN p
services NNS p
were VBD N
randomised VBN N
to TO i
START NNP i
( ( i
manualised VBN i
coping VBG i
skills NNS i
intervention NN i
) ) i
, , i
or CC i
treatment-as-usual JJ i
( ( i
TAU NNP i
) ) i
. . i

Blinded VBN N
raters NNS N
administered VBD N
the DT o
Hospital NNP o
Anxiety NNP o
and CC o
Depression NNP o
Scale NNP o
( ( o
HADS-T NNP o
) ) o
and CC o
Brief NNP o
COPE NNP o
inventory NN o
at IN N
baseline NN N
, , N
4 CD N
and CC N
8 CD N
months NNS N
. . N

HADS-T NNP N
improved VBD N
in IN N
the DT N
intervention NN N
group NN N
when WRB N
compared VBN N
to TO i
TAU VB i
at IN N
all DT N
levels NNS N
of IN N
psychological JJ N
distress NN N
. . N

We PRP N
tested VBD N
whether IN N
coping NN N
was VBD N
a DT N
mediator NN N
and CC N
for IN N
moderated JJ N
mediation NN N
, , N
and CC N
( ( N
post-hoc NN N
) ) N
subgroup NN N
treatment NN N
effects NNS N
on IN N
coping VBG N
. . N

RESULTS NNP p
Data NNP p
were VBD p
available JJ p
for IN p
187 CD p
carers NNS p
( ( p
71.9 CD p
% NN p
) ) p
for IN N
the DT N
mediation NN N
analysis NN N
. . N

The DT N
reduced JJ o
HADS-T NNP o
score NN o
in IN N
the DT N
intervention NN N
group NN N
was VBD N
mediated VBN N
by IN N
increased JJ o
emotion-focused JJ o
coping VBG o
only RB N
among IN N
carers NNS N
with IN N
higher JJR N
( ( N
16+ CD N
) ) N
baseline NN o
HADS-T JJ o
scores NNS o
( ( N
mediated VBN N
effect=-0.63 RB N
[ JJ N
-1.11 NNP N
, , N
-0.15 NNP N
] NNP N
; : N
proportion NN N
of IN N
overall JJ N
effect=33 NN N
% NN N
[ JJ N
3 CD N
% NN N
, , N
64 CD N
% NN N
] NN N
) ) N
. . N

LIMITATIONS IN N
We PRP N
did VBD N
not RB N
measure NN N
plausible JJ N
psychosocial JJ N
treatment NN N
mechanisms VBZ N
other JJ N
than IN N
coping VBG N
. . N

CONCLUSIONS NNP i
START NNP i
benefited VBD N
family NN N
carers NNS N
both DT N
in IN N
preventing NN N
and CC N
treating VBG N
psychological JJ N
morbidity NN N
, , N
through IN N
different JJ N
mechanisms NNS N
of IN N
action NN N
. . N

The DT N
most RBS N
psychologically RB N
distressed JJ N
carers NNS N
increased VBD N
their PRP$ N
emotion-focused JJ N
coping NN N
and CC N
did VBD N
not RB N
decrease VB N
their PRP$ o
dysfunctional JJ o
coping NN o
, , o
while IN N
others NNS N
benefited VBD N
but CC N
not RB N
through IN N
this DT N
mechanism NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
skin-to-skin JJ i
contact NN i
on IN N
autonomic JJ o
pain NN o
responses NNS o
in IN N
preterm JJ p
infants NNS p
. . p

UNLABELLED IN N
The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
crossover NN N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
on IN N
autonomic JJ N
responses NNS N
in IN N
preterm JJ p
infants NNS p
of IN p
longer JJR p
Kangaroo NNP i
Care NNP i
( ( p
30 CD p
minutes NNS p
, , p
KC30 NNP i
) ) i
and CC p
shorter JJR p
KC NNP i
( ( p
15 CD p
minutes NNS p
, , p
KC15 NNP i
) ) i
before IN p
and CC p
throughout IN p
heel NN p
stick NNS p
compared VBN p
with IN p
incubator NN i
care NN i
( ( i
IC NNP i
) ) i
. . p

Beat-to-beat JJ N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
and CC N
spectral JJ N
power NN N
analysis NN N
of IN N
heart NN N
rate NN N
variability NN N
, , N
low JJ N
frequency NN N
power NN N
( ( N
LF NNP N
) ) N
, , N
high JJ N
frequency NN N
power NN N
( ( N
HF NNP N
) ) N
, , N
and CC N
LF/HF NNP N
ratio NN N
were VBD N
measured VBN N
in IN N
26 CD p
infants NNS p
. . p

HR NNP o
changes NNS N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
were VBD N
significantly RB N
less RBR N
in IN N
KC30 NNP N
and CC N
KC15 NNP N
than IN N
in IN N
IC NNP N
, , N
and CC N
more JJR N
infants NNS N
had VBD N
HR NNP o
decrease NN N
in IN N
IC NNP N
than IN N
in IN N
2 CD N
KC NNP N
conditions NNS N
. . N

In IN N
IC NNP N
, , N
LF NNP o
and CC o
HF NNP o
significantly RB N
increased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
dropped VBD N
from IN N
Heel NNP N
Stick NNP N
to TO N
Recovery NNP N
; : N
in IN N
2 CD N
KC NNP N
conditions NNS N
, , N
no DT N
changes NNS N
across IN N
study NN N
phases NNS N
were VBD N
found VBN N
. . N

During IN N
Heel NNP N
Stick NNP N
, , N
LF NNP o
and CC N
HF NNP o
were VBD N
significantly RB N
higher JJR N
in IN N
IC NNP N
than IN N
in IN N
KC30 NNP i
. . i

In IN N
all DT N
3 CD N
conditions NNS N
, , N
LF/HF NNP o
ratio NN o
decreased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
increased VBD N
to TO N
Recovery NNP N
; : N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
IC NNP i
and CC N
two CD N
KC NNP i
conditions NNS N
. . N

Both NNP N
longer JJR N
and CC N
shorter JJR N
KC NNP i
before IN N
and CC N
throughout IN N
heel NN N
stick NN N
can MD N
stabilize VB N
HR NNP o
response NN o
in IN N
preterm JJ N
infants NNS N
, , N
and CC N
longer JJR N
KC NNP i
significantly RB N
affected VBD N
infants NNS N
' POS N
sympathetic JJ N
and CC N
parasympathetic JJ N
responses NNS N
during IN N
heel NN N
stick NNS N
compared VBN N
with IN N
incubator NN i
care NN i
. . i

PERSPECTIVE VB N
This DT N
study NN N
showed VBD N
that IN N
KC NNP i
has VBZ N
a DT N
significant JJ N
effect NN N
on IN N
reducing VBG N
autonomic JJ N
pain NN N
responses NNS N
in IN N
preterm JJ p
infants NNS p
. . p

The DT N
findings NNS N
support NN N
that IN N
KC NNP i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
pain NN N
intervention NN N
in IN N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
. . N

-DOCSTART- -X- O O

A DT N
feasibility NN N
study NN N
for IN N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
treatment NN N
withdrawal NN N
in IN N
psoriatic JJ p
arthritis NN p
( ( N
REmoval NNP N
of IN N
treatment NN N
for IN N
patients NNS p
in IN N
REmission NNP N
in IN N
psoriatic JJ N
ArThritis NNP N
( ( N
RETREAT NNP N
( ( N
F NNP N
) ) N
) ) N
. . N

TNF NNP N
therapy NN N
is VBZ N
effective JJ N
for IN N
all DT N
aspects NNS N
of IN N
psoriatic JJ N
disease NN N
, , N
but CC N
these DT N
drugs NNS N
are VBP N
costly JJ N
and CC N
the DT N
long-term JJ N
effects NNS N
are VBP N
unknown JJ N
. . N

Further NNP N
, , N
methotrexate NN N
causes NNS N
concern NN N
with IN N
long-term JJ N
adverse JJ N
events NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
test VB o
the DT o
feasibility NN o
of IN N
drug NN i
withdrawal NN i
from IN N
patients NNS p
with IN p
psoriatic JJ p
arthritis NN p
, , p
in IN p
stable JJ p
low JJ p
disease NN p
state NN p
. . p

We PRP N
examined VBD N
the DT N
availability NN o
of IN o
patients NNS o
, , o
their PRP$ o
willingness NN o
to TO o
participate VB o
, , o
study NN o
procedures NNS o
, , o
and CC o
the DT o
proportion NN o
of IN o
patients NNS o
in IN o
the DT o
withdrawal NN o
arm NN o
who WP o
relapsed VBD o
during IN N
the DT N
study NN N
. . N

Low JJ N
disease NN N
state NN N
was VBD N
defined VBN N
by IN N
minimal JJ N
disease NN N
activity NN N
criteria NNS N
( ( N
MDA NNP N
) ) N
, , N
and CC N
relapse NN N
by IN N
failure NN N
to TO N
achieve VB N
these DT N
criteria NNS N
. . N

Patients NNS N
in IN N
the DT N
withdrawal NN N
group NN N
underwent VBD N
a DT N
phased JJ i
withdrawal NN i
of IN i
medication NN i
where WRB N
the DT N
last JJ N
treatment NN N
added VBD N
was VBD N
the DT N
first JJ N
withdrawn NN i
. . i

Assessments NNS o
were VBD N
monthly RB N
for IN N
3 CD N
months NNS N
before IN N
study NN N
exit NN N
. . N

Seventy-two JJ p
patients NNS p
were VBD p
invited VBN p
to TO p
participate VB p
, , p
of IN p
which WDT p
57 CD p
were VBD p
found VBN p
to TO p
be VB p
eligible JJ p
. . p

Twenty-six NNP N
( ( N
36.1 CD N
% NN N
) ) N
subsequently RB N
attended VBD N
the DT N
screening JJ N
visit NN N
but CC N
9 CD N
failed VBD N
eligibility NN N
criteria NNS N
so RB N
that IN N
17 CD N
patients NNS N
( ( N
29.8 CD N
% NN N
of IN N
the DT N
57 CD N
eligible JJ N
patients NNS N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
18.4 CD N
, , N
43.4 CD N
% NN N
) ) N
were VBD N
randomised VBN N
at IN N
a DT N
ratio NN N
of IN N
2:1 CD N
in IN N
favour NN N
of IN N
the DT N
withdrawal NN i
arm NN i
( ( N
11 CD N
withdrawals NNS N
, , N
6 CD N
standard NN N
care NN N
) ) N
. . N

Six CD N
patients NNS N
experienced VBD N
a DT N
flare NN o
, , N
all DT N
of IN N
whom WP N
were VBD N
in IN N
the DT N
withdrawal NN i
arm NN i
( ( N
relapse JJ N
rate NN N
54.6 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
23.4 CD N
, , N
83.3 CD N
% NN N
) ) N
. . N

Four CD N
of IN N
the DT N
flares NNS N
were VBD N
apparent JJ N
from IN N
visit NN N
3 CD N
( ( N
8 CD N
weeks NNS N
after IN N
starting VBG N
withdrawal NN i
) ) i
. . N

Given VBN N
the DT N
high JJ N
relapse NN o
rate NN o
, , N
an DT N
alternative JJ N
trial NN N
design NN N
of IN N
partial JJ N
treatment NN N
withdrawal NN N
, , N
possibly RB N
including VBG N
a DT N
patient JJ N
preference NN N
arm NN N
, , N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -X- O O

Types NNS N
of IN N
parent NN i
verbal JJ i
responsiveness NN i
that WDT N
predict VBP N
language NN N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

PURPOSE VB N
This DT N
study NN N
examined VBD N
short-term JJ N
predictive JJ N
associations NNS N
between IN N
5 CD N
different JJ N
types NNS N
of IN N
parent NN i
verbal JJ i
responsiveness NN i
and CC N
later RB N
spoken JJ N
vocabulary NN N
for IN N
32 CD p
young JJ p
children NNS p
with IN p
a DT p
confirmed JJ p
diagnosis NN p
of IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

METHOD NNP N
Parent NNP i
verbal JJ i
utterances NNS i
were VBD N
coded VBN N
from IN N
videotapes NNS i
of IN i
naturalistic JJ i
parent-child JJ i
play NN i
sessions NNS i
using VBG N
interval JJ i
and CC N
event-based JJ i
coding NN i
. . i

A DT N
vocabulary JJ o
difference NN o
score NN o
, , N
calculated VBD N
using VBG N
the DT N
MacArthur NNP N
Communicative NNP N
Development NNP N
Inventories NNP N
( ( N
L. NNP N
Fenson NNP N
et FW N
al. NN N
, , N
1993 CD N
) ) N
, , N
was VBD N
used VBN N
as IN N
the DT N
outcome NN N
measure NN N
of IN N
spoken JJ N
vocabulary JJ N
6 CD N
months NNS N
later RB N
. . N

RESULTS VB N
Parent JJ N
follow-in JJ N
comments NNS N
and CC N
follow-in JJ N
directives NNS N
predicted VBD N
spoken JJ N
vocabulary JJ N
after IN N
controlling VBG N
for IN N
child JJ N
engagement NN N
. . N

Parent NNP o
expansions NNS o
of IN o
child NN o
verbal JJ o
utterances NNS o
predicted VBD N
spoken JJ o
vocabulary JJ o
after IN N
controlling VBG N
for IN N
child NN N
talkativeness NN N
. . N

When WRB N
entered VBN N
together RB N
into IN N
a DT N
regression NN N
analysis NN N
, , N
metrics NNS N
that IN N
represented VBD N
( ( N
a DT N
) ) N
the DT o
number NN o
of IN o
parent NN o
utterances NNS o
following VBG o
into IN o
the DT o
child NN o
's POS o
focus NN o
of IN o
attention NN o
and CC N
( ( N
b NN N
) ) N
the DT o
number NN o
of IN o
parent NN o
utterances NNS o
responding VBG o
to TO o
child VB o
verbal JJ o
communication NN o
acts NNS N
both DT N
accounted VBD N
for IN N
unique JJ N
variance NN N
in IN N
predicting VBG N
change NN N
in IN N
spoken JJ o
vocabulary NN o
from IN N
Time NNP N
1 CD N
to TO N
Time NNP N
2 CD N
. . N

CONCLUSION NNP N
Parent NNP i
verbal JJ i
utterances NNS i
that WDT N
follow VBP N
into IN N
the DT N
child NN N
's POS N
current JJ N
focus NN N
of IN N
attention NN N
or CC N
respond NN N
to TO N
child VB N
verbal JJ N
communication NN N
acts NNS N
may MD N
facilitate VB N
the DT N
process NN N
of IN N
early JJ N
vocabulary JJ N
acquisition NN N
by IN N
mitigating VBG N
the DT N
need NN N
for IN N
children NNS p
with IN p
ASD NNP p
to TO N
use VB N
attention-following JJ N
as IN N
a DT N
word-learning JJ N
strategy NN N
. . N

-DOCSTART- -X- O O

Intraperitoneal NNP i
cisplatin NN i
versus NN N
no DT N
further JJ N
treatment NN N
: : N
8-year JJ N
results NNS N
of IN N
EORTC NNP N
55875 CD N
, , N
a DT N
randomized JJ N
phase NN N
III NNP N
study NN N
in IN N
ovarian JJ p
cancer NN p
patients NNS p
with IN p
a DT p
pathologically RB p
complete JJ p
remission NN p
after IN p
platinum-based JJ i
intravenous JJ i
chemotherapy NN i
. . i

First-line NNP i
intravenous JJ i
chemotherapy NN i
( ( N
CT NNP N
) ) N
following VBG N
debulking VBG N
surgery NN N
is VBZ N
associated VBN N
with IN N
prolonged JJ o
survival NN o
, , N
in IN N
particular JJ N
in IN N
patients NNS p
who WP p
achieve VBP p
a DT p
pathological JJ p
complete JJ p
remission NN p
( ( p
pCR NN p
) ) p
at IN p
second-look NN p
surgery NN p
but CC p
in IN p
whom WP p
a DT p
high JJ p
rate NN p
of IN p
relapses NNS p
still RB p
occurs VBZ p
. . p

Between JJ p
1988 CD p
and CC p
1997 CD p
, , p
153 CD p
patients NNS p
in IN p
pCR JJ p
following VBG p
platinum-based JJ i
intravenous JJ i
CT NNP i
were VBD N
randomized VBN N
between IN N
four CD i
courses NNS i
of IN i
intraperitoneal NN i
cisplatin NN i
( ( i
P NNP i
) ) i
( ( i
90 CD i
mg/m2 NN i
every DT i
3 CD i
weeks NNS i
) ) i
or CC i
observation NN i
. . i

Overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
was VBD N
the DT N
primary JJ N
endpoint NN N
, , N
while IN N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
was VBD N
a DT N
secondary JJ N
endpoint NN N
. . N

This DT N
intent-to-treat JJ N
analysis NN N
includes VBZ p
16 CD p
patients NNS p
who WP p
were VBD p
not RB p
eligible JJ p
and CC p
17 CD p
patients NNS p
who WP p
had VBD p
protocol NN p
violations NNS p
. . p

The DT N
two CD p
groups NNS p
were VBD p
well RB p
balanced VBN p
in IN p
terms NNS p
of IN p
age NN p
( ( p
median JJ p
= VBZ p
55 CD p
years NNS p
) ) p
, , p
performance NN p
status NN p
( ( p
78 CD p
% NN p
P.S NNP p
. . p

O NNP p
) ) p
, , p
FIGO NNP p
stage NN p
( ( p
96 CD p
% NN p
stage NN p
III NNP p
) ) p
, , p
histology NN p
( ( p
serous JJ p
in IN p
66 CD p
% NN p
) ) p
, , p
grade VBD p
( ( p
2 CD p
or CC p
3 CD p
in IN p
80 CD p
% NN p
) ) p
, , p
and CC p
residuum NN p
before RB p
intravenous JJ p
CT NNP p
( ( p
> $ p
1 CD p
cm NN p
in IN p
40 CD p
% NN p
) ) p
. . p

Intraperitoneal NNP i
CT NNP i
was VBD N
delivered VBN N
mainly RB N
through IN N
intraperitoneal JJ N
catheters NNS N
( ( N
Port-a-Cath JJ N
61 CD N
% NN N
and CC N
Tenckhoff NNP N
25 CD N
% NN N
) ) N
. . N

Side JJ N
effects NNS N
of IN N
intraperitoneal NN i
cisplatin NN i
included VBD N
vomiting VBG o
[ NNP N
> NNP N
or CC N
=grade VB N
2 CD N
( ( N
82 CD N
% NN N
) ) N
] NN N
, , N
rise NN o
in IN o
serum JJ o
creatinine NN o
[ NNP N
> NNP N
or CC N
=grade VB N
2 CD N
( ( N
14 CD N
% NN N
) ) N
] NN N
, , N
abdominal JJ o
pain NN o
[ JJ N
grade NN N
1-2 JJ N
( ( N
38 CD N
% NN N
) ) N
] NN N
, , N
and CC N
neurotoxicity NN o
[ NNP N
grade VBD N
2-3 CD N
( ( N
15 CD N
% NN N
) ) N
] NN N
. . N

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
8 CD N
years NNS N
, , N
80 CD N
patients NNS N
( ( N
52 CD N
% NN N
) ) N
have VBP N
progressed VBN N
with IN N
no DT N
difference NN N
in IN N
the DT N
pattern NN o
of IN o
relapse NN o
between IN N
the DT N
two CD N
groups NNS N
and CC N
75 CD N
patients NNS N
( ( N
49 CD N
% NN N
) ) N
have VBP N
died VBN o
; : o
the DT N
respective JJ N
hazard NN N
ratios NNS N
for IN N
PFS NNP N
and CC N
OS NNP N
with IN N
95 CD N
% NN N
CI NNP N
are VBP N
0.89 CD N
( ( N
0.59-1.33 NN N
) ) N
and CC N
0.82 CD N
( ( N
0.52-1.29 NN N
) ) N
. . N

These DT N
results NNS N
are VBP N
suggestive JJ N
of IN N
a DT N
treatment NN N
benefit NN N
but CC N
do VBP N
not RB N
support VB N
a DT N
change NN N
in IN N
clinical JJ N
practice NN N
. . N

Other JJ N
randomized JJ N
clinical JJ N
trials NNS N
of IN N
intraperitoneal JJ i
CT NNP i
are VBP N
reviewed VBN N
and CC N
briefly NN N
discussed VBN N
. . N

-DOCSTART- -X- O O

Weight NNP o
and CC o
leptin JJ o
changes NNS o
among IN N
risperidone-treated JJ i
youths NNS p
with IN p
autism NN p
: : p
6-month JJ N
prospective JJ N
data NNS N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
examined VBD N
the DT N
developmental JJ N
impact NN N
and CC N
temporal JJ N
characteristics NNS N
of IN N
risperidone-associated JJ i
weight NN o
change NN o
. . o

METHOD NNP N
Weight NNP o
change NN o
was VBD N
measured VBN N
for IN N
63 CD p
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
treated VBN p
with IN p
risperidone NN i
for IN p
6 CD p
months NNS p
. . p

Change NNP o
in IN o
serum NN o
leptin NN o
levels NNS o
after IN N
2 CD N
months NNS N
was VBD N
examined VBN N
as IN N
a DT N
predictor NN N
of IN N
final JJ o
weight NN o
gain NN o
in IN N
mixed JJ N
regression NN N
models NNS N
that WDT N
controlled VBD N
for IN N
site NN N
, , N
gender NN N
, , N
age NN N
, , N
and CC N
risperidone NN i
dose NN N
. . N

RESULTS NNP N
Age- JJ N
and CC N
gender-standardized JJ N
weight NN o
increased VBD o
after IN N
6 CD N
months NNS N
of IN N
treatment NN N
( ( N
gross JJ N
: : N
mean=5.6 NN N
kg NN N
[ NNP N
SD=3.9 NNP N
] NNP N
; : N
standardized VBN N
: : N
mean=0.6 NN N
z NN N
[ NNP N
SD=0.5 NNP N
] NNP N
) ) N
and CC N
was VBD N
positively RB N
correlated VBN N
with IN N
weight NN o
gained VBN o
after IN N
1 CD N
month NN N
. . N

Change NN o
in IN o
leptin NN o
levels NNS o
after IN N
2 CD N
months NNS N
of IN N
treatment NN N
( ( N
mean=-0.3 JJ N
ng/ml NN N
, , N
SD=6.2 NNP N
) ) N
( ( N
N=48 NNP N
) ) N
did VBD N
not RB N
predict JJ N
final JJ o
weight NN o
gain NN o
. . o

CONCLUSIONS NNP N
Chronic NNP N
risperidone NN i
exposure NN N
in IN N
children NNS N
with IN N
autism NN N
causes NNS N
weight VBD o
gain NN o
in IN N
excess NN N
of IN N
developmentally RB N
expected VBN N
norms NNS N
that WDT N
follows VBZ N
a DT N
curvilinear JJ N
trajectory NN N
and CC N
decelerates VBZ N
over IN N
time NN N
. . N

Serum NNP o
leptin JJ o
change NN o
does VBZ N
not RB N
reliably VB N
predict JJ N
risperidone-associated JJ N
weight NN o
gain NN o
. . o

-DOCSTART- -X- O O

Efficacy NN o
of IN N
a DT N
barrier NN i
cream NN i
and CC i
its PRP$ i
vehicle NN i
as IN N
protective JJ N
measures NNS N
against IN N
occupational JJ o
irritant JJ o
contact NN o
dermatitis NN o
. . o

The DT N
actual JJ N
advantage NN N
of IN N
barrier NN i
creams NNS i
over IN N
bland NN N
emollients NNS N
for IN N
skin NN N
protection NN N
is VBZ N
still RB N
hotly RB N
debated VBN N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
study NN N
, , N
a DT N
newly-introduced JJ N
barrier NN i
cream NN i
and CC N
its PRP$ N
moisturizing NN i
vehicle NN i
were VBD N
compared VBN N
regarding VBG N
their PRP$ N
skin NN o
compatibility NN o
, , o
efficacy NN o
and CC o
resulting VBG o
acceptance NN o
. . o

Thus NNP N
, , N
2 CD p
panels NNS p
of IN p
25 CD p
hospital NN p
nurses NNS p
with IN p
mild JJ p
signs NNS p
of IN p
skin JJ p
irritation NN p
were VBD N
asked VBN N
to TO N
use VB N
1 CD N
of IN N
the DT N
test NN N
products NNS N
provided VBN N
( ( i
verum NN i
or CC i
vehicle NN i
) ) i
over IN i
a DT i
period NN i
of IN i
4 CD i
weeks NNS i
. . i

Effects NNS N
of IN N
both DT N
types NNS N
of IN N
preparations NNS N
were VBD N
studied VBN N
weekly JJ N
by IN N
clinical JJ N
examination NN N
and CC N
the DT N
instrumental JJ N
assessment NN N
of IN N
bioengineering VBG N
parameters NNS N
. . N

Results NNS N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
barrier NN i
cream NN i
and CC N
vehicle NN i
. . i

In IN N
both DT N
groups NNS N
, , N
clinical JJ o
skin NN o
status NN o
improved VBN N
and CC N
stratum JJ o
corneum NN o
hydration NN o
increased VBD N
significantly RB N
during IN N
the DT N
study NN N
period NN N
. . N

Both DT N
preparations NNS N
were VBD N
tolerated VBN o
and CC o
accepted VBN o
well RB o
, , N
thus RB N
showing VBG N
both DT N
skin JJ o
protection NN o
and CC o
skin NN o
care NN o
. . o

These DT N
results NNS N
contribute VBP N
to TO N
the DT N
debate NN N
as IN N
to TO N
whether IN N
a DT N
strict JJ N
distinction NN N
between IN N
skin NN N
care NN N
and CC N
skin NN N
protection NN N
products NNS N
is VBZ N
justified JJ N
. . N

The DT N
vehicle NN i
alone RB N
is VBZ N
capable JJ N
of IN N
positively RB N
influencing VBG N
skin NN N
status NN N
. . N

Emphasis NN N
must MD N
be VB N
laid VBN N
on IN N
regular JJ N
, , N
frequent JJ N
, , N
and CC N
correct JJ N
application NN N
of IN N
a DT N
product NN N
for IN N
it PRP N
to TO N
be VB N
effective JJ N
. . N

-DOCSTART- -X- O O

Treatment NN p
of IN p
bladder NN p
cancer NN p
with IN p
intravesical JJ p
instillation NN p
of IN p
adriamycin NN i
. . i

Intravesical JJ N
treatment NN N
with IN N
adriamycin NN i
has VBZ N
been VBN N
extensively RB N
employed VBN N
in IN N
the DT N
last JJ N
decade NN N
. . N

In IN N
the DT N
treatment NN N
of IN N
carcinoma NN N
in IN N
situ JJ N
complete JJ N
responses NNS N
have VBP N
been VBN N
reported VBN N
in IN N
about RB N
60 CD N
% NN N
of IN N
cases NNS N
. . N

Its PRP$ N
efficacy NN o
is VBZ N
probably RB N
lower RBR N
in IN N
the DT N
therapy NN N
of IN N
multiple JJ N
or CC N
diffuse NN N
low JJ N
stage NN N
transitional JJ N
cell NN N
carcinoma NN N
that WDT N
is VBZ N
too RB N
extensive JJ N
to TO N
be VB N
completely RB N
resected VBN N
by IN N
conventional JJ N
transurethral JJ N
surgery NN N
. . N

In IN N
such JJ N
circumstances NNS N
, , N
including VBG N
cancer NN N
in IN N
situ NN N
, , N
adriamycin JJ i
compares VBZ N
favorably RB N
with IN N
other JJ N
local JJ N
forms NNS N
of IN N
treatment NN N
. . N

The DT N
prophylactic JJ N
use NN N
of IN N
intravesical JJ N
instillation NN N
of IN N
Adriamycin NNP i
has VBZ N
been VBN N
studied VBN N
more RBR N
extensively RB N
. . N

Preliminary JJ N
results NNS N
of IN N
controlled JJ N
randomized JJ N
trials NNS N
implemented VBN N
from IN N
the DT N
EORTC NNP N
Urological NNP N
Group NNP N
show VBP N
that IN N
adriamycin JJ i
instillations NNS N
significantly RB N
reduce VB N
recurrence NN o
rate NN o
after IN o
TUR NNP o
. . o

The DT N
treatment NN N
is VBZ N
well RB N
tolerated VBN o
. . o

Systemic JJ o
absorption NN o
is VBZ N
virtually RB N
absent JJ N
, , N
and CC N
no DT o
severe JJ o
drug-related JJ o
side NN o
effects NNS o
have VBP N
ever RB N
been VBN N
reported VBN N
. . N

Chemical NNP o
cystitis NN o
is VBZ N
occasionally RB N
observed VBN N
, , N
especially RB N
if IN N
multiple JJ N
instillations NNS N
are VBP N
started VBN N
immediately RB N
after IN N
TUR NNP N
, , N
or CC N
in IN N
the DT N
presence NN N
of IN N
additional JJ N
inflammatory NN N
conditions NNS N
, , N
such JJ N
as IN N
previous JJ N
irradiation NN N
or CC N
bacterial JJ N
cystitis NN N
. . N

-DOCSTART- -X- O O

Competitive JJ N
employment NN N
for IN N
youth NN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
early JJ N
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

For IN N
most JJS N
youth NN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
, , N
employment NN N
upon IN N
graduation NN N
from IN N
high JJ N
school NN N
or CC N
college NN N
is VBZ N
elusive JJ N
. . N

Employment JJ N
rates NNS N
are VBP N
reported VBN N
in IN N
many JJ N
studies NNS N
to TO N
be VB N
very RB N
low JJ N
despite IN N
many JJ N
years NNS N
of IN N
intensive JJ N
special JJ N
education NN N
services NNS N
. . N

This DT N
paper NN N
presented VBD N
the DT N
preliminary JJ N
results NNS N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
Project NNP i
SEARCH NNP i
plus CC i
ASD NNP i
Supports NNP i
on IN N
the DT N
employment NN N
outcomes NNS N
for IN N
youth NN p
with IN p
ASD NNP p
between IN p
the DT p
ages NNS p
of IN p
18-21 JJ p
years NNS p
of IN p
age NN p
. . p

This DT o
model NN o
provides VBZ o
very RB o
promising JJ o
results NNS o
in IN o
that DT o
the DT o
employment NN o
outcomes NNS o
for IN o
youth NN o
in IN o
the DT o
treatment NN o
group NN o
were VBD o
much RB o
higher JJR o
in IN o
non-traditional JJ o
jobs NNS o
with IN o
higher JJR o
than IN o
minimum JJ o
wage NN o
incomes NNS o
than IN o
for IN o
youth NN o
in IN o
the DT o
control NN o
condition NN o
. . o

Specifically RB o
, , o
21 CD o
out IN o
of IN o
24 CD o
( ( o
87.5 CD o
% NN o
) ) o
treatment NN o
group NN o
participants NNS o
acquired VBD o
employment NN o
while IN o
1 CD o
of IN o
16 CD o
( ( o
6.25 CD o
% NN o
) ) o
of IN o
control NN o
group NN o
participants NNS o
acquired VBD o
employment NN o
. . o

-DOCSTART- -X- O O

Bioavailability NN o
of IN N
omega-3 JJ i
essential JJ i
fatty JJ i
acids NNS i
from IN p
perilla NN i
seed NN i
oil NN i
. . i

Increased VBD N
dietary JJ N
intake NN N
of IN N
fish JJ i
oil NN i
omega-3 JJ i
fatty NN i
acids NNS i
, , N
eicosapentanoic JJ N
acid NN N
and CC N
docosohexanoic NN N
acid NN N
, , N
and CC N
their PRP$ N
precursor NN N
, , N
alpha-linolenic JJ i
acid NN i
( ( N
ALA NNP N
) ) N
, , N
is VBZ N
associated VBN N
with IN N
various JJ N
health NN N
benefits NNS N
. . N

Enteric-coating NNP N
( ( N
Entrox NNP N
) ) N
, , N
which WDT N
improves VBZ N
stability NN N
of IN N
omega-3 JJ N
capsules NNS N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
facilitate VB N
fish JJ N
oil NN N
absorption NN N
after IN N
chronic JJ N
treatment NN N
. . N

To TO N
assess VB N
the DT N
effect NN N
of IN N
Entrox NNP N
coating VBG N
on IN N
the DT N
short-term JJ N
bioavailability NN N
of IN N
ALA NNP i
administered VBD N
in IN N
the DT N
form NN N
of IN N
ALA-rich NNP N
Perilla NNP N
seed NN N
oil NN N
, , N
12 CD p
healthy JJ p
subjects NNS p
( ( p
6 CD p
males NNS p
and CC p
6 CD p
females NNS p
) ) p
received VBN N
in IN N
a DT N
random JJ N
order NN N
Entrox-coated JJ i
and CC i
non-coated JJ i
ALA NNP i
formulations NNS i
, , N
each DT N
as IN N
a DT N
single JJ N
6g CD N
dose NN N
separated VBN N
by IN N
a DT N
3-week JJ N
washout NN N
period NN N
. . N

Measurements NNS N
of IN N
plasma NN o
ALA NNP o
concentrations NNS o
from IN N
0 CD N
to TO N
24h CD N
showed VBD N
no DT N
difference NN N
in IN N
ALA NNP N
pharmacokinetics NNS N
between IN N
the DT N
two CD N
formulations NNS N
. . N

However RB N
, , N
significantly RB N
greater JJR N
increases NNS N
in IN N
plasma JJ o
ALA NNP o
levels NNS o
from IN N
baseline NN N
to TO N
24h CD N
were VBD N
observed VBN N
after IN N
ingestion NN N
of IN N
Entrox NNP N
vs. IN N
non-coated JJ N
product NN N
, , N
suggesting VBG N
a DT N
possible JJ N
benefit NN N
of IN N
Entrox NNP N
with IN N
long-term JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Strategies NNS N
for IN N
dietary JJ N
and CC N
anti-smoking JJ N
advice NN N
. . N

Practical JJ N
experiences NNS N
from IN N
the DT N
Oslo NNP N
Study NNP N
. . N

One CD N
of IN N
the DT N
2 CD N
controlled VBD N
preventive JJ N
trials NNS N
within IN N
the DT N
Oslo NNP N
Study NNP N
was VBD N
a DT N
non-drug JJ N
trial NN N
on IN N
the DT N
effect NN o
of IN o
diet NN o
and CC o
smoking VBG o
intervention NN o
on IN N
coronary JJ N
heart NN N
disease NN N
in IN N
1232 CD p
middleaged VBD p
, , p
normotensive JJ p
, , p
healthy JJ p
men NNS p
. . p

All DT N
had VBD N
elevated VBN N
serum NN N
cholesterol NN N
and CC N
4 CD N
out IN N
of IN N
5 CD N
smoked JJ N
every DT N
day NN N
. . N

The DT N
participants NNS N
in IN N
the DT N
intervention NN N
group NN N
met VBD N
every DT N
6 CD N
months NNS N
during IN N
the DT N
5-year JJ N
study NN N
for IN N
clinical JJ N
examination NN N
and CC N
for IN N
dietary JJ o
and CC o
smoking VBG o
counselling NN o
. . o

The DT N
effect NN o
on IN o
serum NN o
cholesterol NN o
was VBD N
a DT N
13 CD N
% NN N
lowering NN N
( ( N
i.e NN N
. . N

10 CD N
% NN N
net JJ N
reduction NN N
compared VBN N
with IN N
control NN N
group NN N
) ) N
, , N
and CC N
about IN N
a DT N
50 CD N
% NN N
reduction NN N
in IN N
cigarette NN o
consumption NN o
. . o

The DT N
effect NN o
on IN o
coronary JJ o
heart NN o
disease NN o
( ( o
fatal JJ o
and CC o
non-fatal JJ o
myocardial JJ o
infarction NN o
or CC o
sudden JJ o
death NN o
) ) o
was VBD N
a DT N
47 CD N
% NN N
lowering NN N
of IN N
the DT N
5-year JJ N
incidence NN N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NN N
0.02 CD N
, , N
2-sided JJ N
) ) N
. . N

The DT N
main JJ N
intervention NN N
strategies NNS N
were VBD N
: : N
information NN N
about IN N
the DT N
risk NN N
factor NN N
concept NN N
to TO N
participant VB N
and CC N
spouse VB N
( ( N
in IN N
groups NNS N
) ) N
individual VBP i
diet JJ i
and CC i
anti-smoking JJ i
counselling NN i
after IN N
finishing VBG N
an DT N
extensive JJ N
clinical JJ N
and CC N
electrocardiographic JJ N
examination NN N
, , N
including VBG N
exercise-ECG JJ N
basis NN N
and CC N
background NN N
for IN N
the DT N
counselling NN N
strategy NN N
: : N
the DT N
total JJ N
situation NN N
of IN N
the DT N
participant NN N
. . N

Some DT N
of IN N
the DT N
most RBS N
important JJ N
items NNS N
: : N
personality NN N
, , N
motivation NN N
, , N
diet JJ N
history NN N
, , N
bodyweight NN N
, , N
blood NN N
lipids NNS N
and CC N
blood NN N
sugar NN N
anti-smoking JJ N
advice NN N
given VBN N
individually RB N
to TO N
all DT N
smokers NNS N
in IN N
the DT N
intervention NN N
group NN N
advice NN N
that IN N
smoking VBG N
cessation NN N
was VBD N
expected VBN N
to TO N
be VB N
of IN N
special JJ N
importance NN N
for IN N
those DT N
with IN N
elevated JJ N
blood NN N
lipids NNS N
. . N

-DOCSTART- -X- O O

Patient JJ o
satisfaction NN o
with IN N
nutrition NN N
services NNS N
amongst JJ N
cancer NN p
patients NNS p
treated VBN p
with IN p
autologous JJ p
stem NN p
cell NN p
transplantation NN p
: : p
a DT N
comparison NN N
of IN N
usual JJ i
and CC N
extended JJ i
care NN i
. . i

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
determine VB N
patient JJ N
satisfaction NN N
with IN N
clinical JJ N
nutrition NN i
services NNS i
delivered VBN N
by IN N
an DT N
accredited JJ N
practicing NN N
dietitian JJ N
amongst NN N
cancer NN p
patients NNS p
treated VBN p
with IN p
autologous JJ p
stem NN p
cell NN p
transplantation NN p
that WDT N
was VBD N
provided VBN N
with IN N
usual JJ i
and CC N
extended VBD i
care NN i
at IN N
100 CD N
days NNS N
post-transplantation NN N
. . N

METHODS JJ N
Patients NNPS N
were VBD N
randomised VBN N
to TO N
receive VB i
usual JJ i
nutrition NN i
care NN i
or CC i
extended VBN i
nutrition NN i
care NN i
during IN N
the DT N
course NN N
of IN N
their PRP$ N
stem NN N
cell NN N
transplantation NN N
. . N

After IN N
hospital JJ N
discharge NN N
, , N
usual JJ i
care NN i
patients NNS i
received VBD i
no DT i
further JJ i
nutrition NN i
support NN i
, , i
whereas RB i
extended VBN i
care NN i
patients NNS i
received VBD i
telephone NN i
dietary JJ i
counselling NN i
from IN i
the DT i
same JJ i
dietitian NN i
for IN i
up IN i
to TO i
100 CD i
days NNS i
post-transplantation NN i
. . i

The DT N
patient JJ N
satisfaction NN N
with IN N
clinical JJ N
nutrition NN N
service NN N
questionnaire NN N
was VBD N
completed VBN N
anonymously RB N
at IN N
100 CD N
days NNS N
post-transplantation NN N
. . N

Group NNP N
comparisons NNS N
were VBD N
made VBN N
using VBG N
independent JJ N
t-tests NNS N
. . N

RESULTS NNP p
Thirty-seven JJ p
patients NNS p
consented VBN p
to TO p
participate VB p
in IN p
the DT p
study NN p
( ( p
54 CD p
% NN p
male NN p
; : p
mean JJ p
age NN p
58.7 CD p
? . p
9.5 CD p
years NNS p
; : p
median JJ p
body NN p
mass NN p
index NN p
26.8 CD p
kg NN p
m NN p
( ( p
-2 NNP p
) ) p
, , p
range VBP p
16.4-47.6 JJ p
kg NN p
m NN p
( ( p
-2 NNP p
) ) p
) ) p
; : p
33 CD p
patients NNS p
completed VBD p
the DT p
study NN p
and CC p
28 CD p
patients NNS p
returned VBD p
the DT p
questionnaire NN p
( ( p
response NN p
rate NN p
= VBD p
85 CD p
% NN p
) ) p
. . o

All DT o
components NNS o
of IN o
the DT o
questionnaire NN o
were VBD o
rated VBN o
highly RB o
by IN N
both DT N
groups NNS N
; : N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Although IN N
not RB N
statistically RB N
significant JJ N
, , N
extended VBD N
care NN N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
three CD N
telephone NN N
calls VBZ N
rated VBN o
a DT o
higher JJR N
overall JJ N
satisfaction NN o
compared VBN o
to TO N
those DT N
who WP N
received VBD N
less JJR N
calls NNS N
; : N
this DT N
difference NN N
was VBD N
clinically RB N
important JJ N
( ( N
score JJ N
difference NN N
= NNP N
0.56 CD p
) ) p
. . p

CONCLUSIONS NNP p
Cancer NNP p
patients NNS p
treated VBD p
with IN p
autologous JJ p
stem NN p
cell NN p
transplantation NN p
were VBD N
satisfied VBN N
with IN i
usual JJ i
and CC i
extended JJ i
nutrition NN i
care NN i
. . i

Extended NNP i
care NN i
patients NNS i
who WP p
received VBD N
at IN N
least JJS N
three CD N
telephone NN N
calls VBZ N
after IN N
hospital NN N
discharge NN N
were VBD N
more JJR N
satisfied JJ N
than IN N
those DT N
with IN N
less JJR N
frequent JJ N
intervention NN N
. . N

Further JJ N
exploration NN N
regarding VBG N
the DT N
frequency NN N
and CC N
intensity NN N
of IN N
nutrition NN N
service NN N
is VBZ N
required VBN N
. . N

-DOCSTART- -X- O O

Sulfasalazine NNP i
decreases VBZ N
acute JJ N
gastrointestinal JJ N
complications NNS N
due JJ N
to TO N
pelvic JJ N
radiotherapy NN N
. . N

BACKGROUND NNP N
Radiation-induced NNP N
gastrointestinal JJ N
toxicity NN N
is VBZ N
a DT N
significant JJ N
concern NN N
for IN N
patients NNS p
who WP p
are VBP p
treated VBN p
with IN p
this DT p
modality NN p
for IN p
pelvic JJ p
malignancies NNS p
. . p

Eicosanoids NNS N
and CC N
free JJ N
radicals NNS N
are VBP N
thought VBN N
to TO N
be VB N
among IN N
the DT N
reasons NNS N
for IN N
this DT N
effect NN N
. . N

Sulfasalazine NNP i
is VBZ N
an DT N
inhibitor NN N
of IN N
their PRP$ N
synthesis NN N
in IN N
the DT N
mucosa NN N
. . N

OBJECTlVE NN N
: : N
To TO N
determine VB N
whether IN N
sulfasalazine NN i
can MD N
reduce VB N
the DT N
radiation-induced JJ N
acute JJ N
gastrointestinal JJ N
complications NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
double-blind JJ N
study NN N
, , N
31 CD p
patients NNS p
receiving VBG p
pelvic JJ p
radiotherapy NN p
were VBD N
randomized VBN N
to TO N
receive VB N
two CD N
sulfasalazine JJ i
500-mg JJ i
tablets NNS i
twice JJ i
daily RB i
or CC i
placebo VB i
, , N
administered VBN N
orally RB N
from IN N
the DT N
first JJ N
day NN N
of IN N
irradiation NN N
. . N

Patients NNS N
were VBD N
evaluated JJ N
weekly JJ N
, , N
and CC N
gastrointestinal JJ o
toxicities NNS o
were VBD N
graded VBN N
according VBG N
to TO N
the DT N
Late JJ o
Effect NNP o
of IN o
Normal NNP o
Tissue-Subjective NNP o
Objective NNP o
Management NNP o
Analytic NNP o
( ( o
LENT-SOMA NNP o
) ) o
toxicity NN o
table NN o
during IN N
pelvic JJ N
radiotherapy NN N
. . N

On IN N
the DT N
last JJ N
day NN N
of IN N
week NN N
5 CD N
, , N
the DT N
subjects NNS N
were VBD N
graded VBN N
endoscopically RB N
, , N
and CC N
biopsies NNS N
taken VBN N
from IN N
the DT N
rectum NN N
were VBD N
classified VBN N
histopathologically RB N
. . N

RESULTS NNP N
Groups NNP p
did VBD p
not RB p
differ VB p
in IN p
age NN p
, , p
gender NN p
, , p
tumor NN p
site NN p
, , p
or CC p
irradiation NN p
procedure NN p
. . p

During IN N
radiotherapy NN N
, , N
grade VBD o
2 CD o
or CC o
higher JJR o
gastrointestinal JJ o
toxicity NN o
occurred VBD N
in IN N
20 CD N
% NN N
( ( N
3/15 CD N
) ) N
and CC N
63 CD N
% NN N
( ( N
10/16 CD N
) ) N
of IN N
the DT N
sulfasalazine NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
. . N

This DT N
difference NN o
was VBD N
significant JJ N
( ( N
p JJ N
= NNP N
0.017 CD N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
endoscopic NN N
and CC N
histopathologic JJ N
evaluations NNS N
. . N

CONCLUSIONS NNP N
Sulfasalazine NNP N
is VBZ N
effective JJ N
in IN N
decreasing VBG N
clinically RB N
acute JJ N
gastrointestinal JJ N
toxicities NNS N
. . N

Long-term JJ N
follow-up JJ N
with IN N
the DT p
subjects NNS p
will MD N
help VB N
to TO N
determine VB N
the DT N
net JJ N
effect NN N
of IN N
sulfasalazine NN N
on IN N
the DT N
radiation-induced JJ p
gastrointestinal JJ p
injuries NNS p
. . p

-DOCSTART- -X- O O

Comparison NNP N
of IN N
three CD N
methods NNS N
to TO N
increase VB N
knowledge NN o
about IN N
breast NN N
cancer NN N
and CC N
breast NN N
cancer NN N
screening VBG N
in IN N
screening VBG p
mammography NN p
patients NNS p
. . p

RATIONALE NNP N
AND CC N
OBJECTIVES NNP N
The DT N
specific JJ N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
which WDT N
of IN N
several JJ N
cost-effective JJ N
interventions NNS N
is VBZ N
best RBS N
able JJ N
to TO N
improve VB N
the DT N
breast NN o
cancer NN o
knowledge NN o
of IN N
women NNS p
who WP p
present VBP p
for IN p
screening VBG p
mammography NN p
. . p

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
198 CD p
English-speaking JJ p
women NNS p
, , p
with IN p
no DT p
personal JJ p
or CC p
family NN p
history NN p
of IN p
breast NN p
cancer NN p
, , p
were VBD p
recruited VBN p
and CC p
randomized VBN p
to TO p
four CD p
groups NNS p
when WRB p
they PRP p
presented VBD p
to TO p
the DT p
clinic NN p
for IN p
a DT p
screening NN p
mammogram NN p
. . p

All DT N
women NNS N
filled VBN N
in IN N
a DT N
demographic JJ N
data NN N
form NN N
and CC N
answered VBD N
a DT N
questionnaire NN N
containing VBG N
nine CD N
questions NNS N
about IN N
breast NN N
cancer NN N
, , N
risk NN N
, , N
and CC N
screening VBG N
to TO N
assess VB N
their PRP$ N
knowledge NN N
and CC N
perception NN N
. . N

Three CD N
educational JJ i
interventions NNS i
were VBD N
tested VBN N
in IN N
this DT N
study NN N
. . N

The DT N
first JJ N
consisted VBN N
of IN N
a DT N
brochure NN i
, , i
which WDT i
provided VBD i
answers NNS i
to TO i
the DT i
questionnaire NN i
items NNS i
and CC i
addressed VBD i
the DT i
issues NNS i
in IN i
more JJR i
depth NN i
. . i

The DT N
second JJ N
intervention NN N
was VBD N
an DT N
educational JJ i
conversation NN i
with IN i
a DT i
specially RB i
trained JJ i
mammography NN i
technologist NN i
. . i

She PRP N
reviewed VBD N
the DT N
subject NN N
's POS N
answers NNS N
to TO N
the DT N
questionnaire NN N
items NNS N
correcting VBG N
and/or NN N
clarifying VBG N
them PRP N
. . N

The DT N
third JJ N
intervention NN N
consisted VBD N
of IN N
the DT N
brochure NN i
together RB i
with IN i
the DT i
conversation NN i
with IN i
a DT i
trained JJ i
technologist NN i
. . i

There EX N
was VBD N
also RB N
a DT N
control NN N
group NN N
that WDT N
just RB N
filled VBN N
in IN N
the DT N
study NN N
questionnaire NN N
but CC i
did VBD i
not RB i
receive VB i
an DT i
educational JJ i
intervention NN i
. . i

The DT N
same JJ N
questionnaire NN N
was VBD N
administered VBN N
by IN N
telephone NN N
4 CD N
to TO N
6 CD N
weeks NNS N
after IN N
the DT N
screening NN N
experience NN N
to TO N
all DT N
study NN N
subjects NNS N
. . N

Changes NNS N
in IN N
their PRP$ N
knowledge NN o
and CC o
perceptions NNS o
of IN o
breast NN o
cancer NN o
were VBD N
measured VBN N
and CC N
compared VBN N
. . N

RESULTS VB N
A NNP N
statistically RB N
significant JJ N
increase NN N
in IN N
knowledge NN o
was VBD N
found VBN N
in IN N
all DT N
of IN N
the DT N
three CD N
investigated VBD N
groups NNS N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
amount NN N
of IN N
increase NN N
between IN N
women NNS N
who WP N
underwent VBP N
different JJ N
interventions NNS N
. . N

CONCLUSIONS NNP N
All NNP N
three CD N
interventions NNS N
resulted VBD N
in IN N
increased VBN N
knowledge NN o
about IN N
breast NN N
cancer NN N
and CC N
screening NN N
. . N

No DT N
differences NNS N
in IN N
the DT N
amount NN N
of IN N
knowledge NN o
increase NN N
were VBD N
found VBN N
between IN N
three CD N
interventions NNS N
tested VBN N
. . N

The DT N
educational JJ N
brochure NN N
seems VBZ N
to TO N
represent VB N
the DT N
most RBS N
convenient JJ N
and CC N
least JJS N
costly JJ N
method NN N
to TO N
increase VB N
knowledge NN o
about IN N
breast NN N
cancer NN N
and CC N
screening VBG N
among IN N
women NNS N
who WP N
present VBP N
for IN N
screening VBG N
mammography NN N
. . N

-DOCSTART- -X- O O

Comparison NNP o
of IN N
autologous JJ N
bone NN N
marrow NN N
transplantation NN N
with IN N
sequential JJ N
chemotherapy NN N
for IN N
intermediate-grade JJ p
and CC p
high-grade JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
in IN p
first JJ p
complete JJ o
remission NN o
: : o
a DT p
study NN p
of IN p
464 CD p
patients NNS p
. . p

Groupe NNP N
d'Etude NN N
des NNS N
Lymphomes NNP N
de IN N
l'Adulte FW N
. . N

PURPOSE NNP N
Intensive NNP N
chemotherapy NN N
followed VBN N
by IN N
autotransplantation NN N
has VBZ N
given VBN N
promising VBG N
results NNS N
in IN N
partially RB N
responding VBG N
or CC N
sensitive JJ N
relapsed JJ N
patients NNS p
with IN p
aggressive JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
. . p

In IN N
1987 CD N
, , N
we PRP N
designed VBD N
a DT N
randomized VBN N
study NN N
to TO N
evaluate VB N
the DT N
potential JJ N
benefit NN o
of IN N
a DT N
high-dose JJ i
regimen NN i
containing VBG i
cyclophosphamide NN i
, , i
carmustine NN i
, , i
and CC i
etoposide RB i
( ( i
CBV NNP i
) ) i
followed VBN i
by IN i
autotransplantation NN i
over IN i
a DT i
consolidative JJ i
sequential JJ i
chemotherapy NN i
( ( i
ifosfamide JJ i
, , i
etoposide RB i
, , i
asparaginase NN i
, , i
and CC i
cytarabine NN i
) ) i
in IN N
patients NNS N
in IN N
first JJ N
complete JJ N
remission NN N
with IN N
intermediate- JJ p
and CC p
high-grade JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
were VBD p
younger JJR p
than IN p
55 CD p
years NNS p
and CC p
had VBD p
at IN p
least JJS p
one CD p
adverse JJ p
prognostic JJ p
factor NN p
. . p

Induction NNP N
treatment NN N
was VBD N
that IN N
of IN N
the DT N
LNH84 NNP N
protocol NN N
with IN N
an DT N
open JJ N
randomization NN N
on IN N
the DT N
anthracycline NN i
. . i

Patients NNS N
in IN N
complete JJ o
remission NN o
were VBD N
further JJ N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
consolidation NN N
procedure NN N
. . N

RESULTS NNP N
After IN N
induction NN N
treatment NN N
, , N
464 CD p
patients NNS p
were VBD N
assessable JJ N
for IN N
the DT N
consolidation NN N
phase NN N
. . N

With IN N
a DT N
median JJ N
follow-up JJ N
duration NN N
of IN N
28 CD N
months NNS N
, , N
the DT N
3-year JJ o
disease-free JJ o
survival NN o
rate NN o
was VBD N
52 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
45 CD N
% NN N
to TO N
59 CD N
% NN N
) ) N
in IN N
the DT N
sequential JJ N
chemotherapy NN N
arm NN N
and CC N
59 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
52 CD N
% NN N
to TO N
66 CD N
% NN N
) ) N
in IN N
the DT N
autologous JJ N
transplant NN N
arm NN N
( ( N
P NNP N
= NNP N
.46 NNP N
, , N
relative JJ N
risk NN N
= NNP N
0.90 CD N
) ) N
. . N

The DT N
3-year JJ o
survival NN o
rate NN o
did VBD N
not RB N
differ VB N
between IN N
sequential JJ N
chemotherapy NN N
and CC N
autotransplantation NN N
, , N
at IN N
71 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
64 CD N
% NN N
to TO N
78 CD N
% NN N
) ) N
and CC N
69 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
62 CD N
% NN N
to TO N
76 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.60 NNP N
, , N
relative JJ N
risk NN N
= NNP N
1.11 CD N
) ) N
. . N

CONCLUSION NNP N
For IN N
such JJ N
a DT N
subset NN N
of IN N
patients NNS N
, , N
consolidation NN N
with IN N
the DT N
CBV NNP N
regimen NNS N
followed VBN N
by IN N
autologous JJ N
bone NN N
marrow NN N
transplantation NN N
is VBZ N
not RB N
superior JJ o
to TO N
sequential JJ N
chemotherapy NN N
. . N

-DOCSTART- -X- O O

High JJ N
Platelet NNP N
Reactivity NNP N
in IN N
Patients NNP p
with IN p
Acute NNP p
Coronary NNP p
Syndromes NNP p
Undergoing NNP p
Percutaneous NNP p
Coronary NNP p
Intervention NN p
: : p
Randomised VBN N
Controlled NNP N
Trial NNP N
Comparing NNP N
Prasugrel NNP N
and CC N
Clopidogrel NNP N
. . N

BACKGROUND NNP N
Prasugrel NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
clopidogrel NN N
in IN N
reducing VBG N
platelet NN N
aggregation NN N
in IN N
acute JJ p
coronary JJ p
syndromes NNS p
. . p

Data NNP N
available JJ N
on IN N
prasugrel NN N
reloading NN N
in IN N
clopidogrel NN N
treated VBD N
patients NNS N
with IN N
high JJ N
residual JJ N
platelet NN N
reactivity NN N
( ( N
HRPR NNP N
) ) N
i.e NN N
. . N

poor JJ N
responders NNS N
, , N
is VBZ N
limited VBN N
. . N

OBJECTIVES UH N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
prasugrel NN i
loading VBG N
on IN N
platelet NN N
function NN N
in IN N
patients NNS p
on IN p
clopidogrel NN i
and CC p
high JJ p
platelet NN p
reactivity NN p
undergoing VBG p
percutaneous JJ i
coronary JJ i
intervention NN i
for IN p
acute JJ p
coronary JJ p
syndrome NN p
( ( p
ACS NNP p
) ) p
. . p

PATIENTS JJ N
Patients NNS p
with IN p
ACS NNP p
on IN N
clopidogrel NN i
who WP N
were VBD N
scheduled VBN N
for IN N
PCI NNP i
found VBD N
to TO N
have VB N
a DT N
platelet NN N
reactivity NN N
?40 NNP N
AUC NNP N
with IN N
the DT N
Multiplate NNP N
Analyzer NNP N
, , N
i.e NN N
. . N

poor JJ N
responders NNS N
were VBD N
randomised VBN N
to TO N
prasugrel VB i
( ( i
60 CD N
mg NN N
loading NN N
and CC N
10 CD N
mg JJ N
maintenance NN N
dose NN N
) ) N
or CC N
clopidogrel NN i
( ( i
600 CD N
mg NN N
reloading NN N
and CC N
150 CD N
mg JJ N
maintenance NN N
dose NN N
) ) N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD o
proportion NN o
of IN o
patients NNS o
with IN o
platelet JJ o
reactivity NN o
< VBP o
40 CD o
AUC NNP o
4 CD N
hours NNS N
after IN N
loading VBG N
with IN N
study NN N
medication NN N
, , N
and CC N
also RB N
at IN N
one CD N
hour NN N
( ( N
secondary JJ N
outcome NN p
) ) p
. . p

44 CD p
patients NNS p
were VBD p
enrolled VBN p
and CC p
the DT N
study NN N
was VBD N
terminated VBN N
early RB N
as IN N
clopidogrel NN N
use NN N
decreased VBD N
sharply RB N
due JJ N
to TO N
introduction NN N
of IN N
newer JJR N
P2Y12 NNP N
inhibitors NNS N
. . N

RESULTS NNP N
At IN N
4 CD N
hours NNS N
after IN N
study NN N
medication NN N
100 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
prasugrel NN N
compared VBN N
to TO N
91 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
clopidogrel NN N
had VBD o
platelet VBN o
reactivity NN o
< VBZ o
40 CD o
AUC NNP o
( ( o
p JJ N
= NNP N
0.49 CD N
) ) N
, , N
while IN N
at IN N
1 CD N
hour NN N
the DT N
proportions NNS N
were VBD N
95 CD N
% NN N
and CC N
64 CD N
% NN N
respectively RB N
( ( N
p JJ N
= NNP N
0.02 CD o
) ) o
. . o

Mean JJ o
platelet NN o
reactivity NN o
at IN o
4 CD N
and CC N
1 CD N
hours NNS N
after IN N
study NN N
medication NN N
in IN N
prasugrel NN N
and CC N
clopidogrel NN N
groups NNS N
respectively RB N
were VBD N
12 CD N
versus NN N
22 CD N
( ( N
p NN N
= RB N
0.005 CD N
) ) N
and CC N
19 CD N
versus NN N
34 CD N
( ( N
p NN N
= RB N
0.01 CD N
) ) N
respectively RB N
. . N

CONCLUSIONS NNP N
Routine NNP N
platelet NN N
function NN N
testing VBG N
identifies NNS N
patients NNS N
with IN N
high JJ o
residual JJ o
platelet NN o
reactivity NN o
( ( o
poor JJ N
responders NNS N
) ) N
on IN N
clopidogrel NN N
. . N

A DT N
strategy NN N
of IN N
prasugrel NN N
rather RB N
than IN N
clopidogrel VB N
reloading VBG N
results NNS N
in IN N
earlier JJR N
and CC N
more RBR N
sustained JJ N
suppression NN N
of IN N
platelet NN N
reactivity NN N
. . N

Future JJ N
trials NNS N
need VBP N
to TO N
identify VB N
if IN N
this DT N
translates VBZ N
into IN N
clinical JJ N
benefit NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT01339026 NNP N
. . N

-DOCSTART- -X- O O

Response NNP N
prediction NN N
in IN N
metastasised JJ N
colorectal NN N
cancer NN N
using VBG N
intratumoural JJ N
thymidylate JJ N
synthase NN N
: : N
results NNS N
of IN N
a DT N
randomised JJ N
multicentre NN N
trial NN N
. . N

BACKGROUND NNP N
Molecular NNP N
markers NNS N
to TO N
predict VB N
response NN N
to TO N
5-fluorouracil JJ i
( ( i
FU NNP i
) ) i
-based VBD i
treatment NN N
of IN N
recurrent NN p
or CC p
metastasised VBN p
colorectal JJ p
cancer NN p
( ( p
mCRC NN p
) ) p
are VBP N
not RB N
established VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
value NN N
of IN N
thymidylate JJ N
synthase NN N
( ( N
TS NNP N
) ) N
, , N
a DT N
key JJ N
enzyme NN N
of IN N
DNA NNP N
synthesis NN N
and CC N
target NN N
of IN N
5-FU JJ N
, , N
to TO N
predict VB o
response NN o
to TO N
chemotherapy NN N
of IN N
mCRC NN N
. . N

METHODS NNP N
Tumour NNP p
tissue NN p
was VBD p
obtained VBN p
from IN p
168 CD p
patients NNS p
with IN p
mCRC NN p
for IN p
relative JJ p
thymidylate NN o
synthase NN o
( ( o
TS NNP o
) ) o
mRNA NN p
quantitation NN p
. . p

Patients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
5-FU/folinic JJ i
acid NN i
( ( i
FA NNP i
, , i
FUFA NNP i
) ) i
alone RB i
or CC i
in IN i
combination NN i
with IN i
irinotecan JJ i
5-fluorouracil/folinic JJ i
acid NN i
and CC i
irinotecan JJ i
( ( i
FOLFIRI NNP i
) ) i
stratified VBN i
by IN i
TS NNP i
( ( i
low JJ i
versus RB i
high JJ i
) ) i
. . N

Primary JJ N
end-point NN N
was VBD N
overall JJ o
response NN o
to TO o
first-line JJ o
treatment NN o
among IN N
TS NNP N
high JJ N
patients NNS N
. . N

All DT N
parties NNS N
, , N
except IN N
for IN N
the DT N
randomisation NN N
centre NN N
, , N
were VBD N
blinded VBN N
for IN N
TS NNP N
status NN N
. . N

RESULTS NNP N
Biopsies NNP N
( ( N
n=168 RB N
) ) N
were VBD N
taken VBN N
without IN N
complications NNS N
. . N

TS NN o
levels NNS o
were VBD N
available JJ N
for IN N
147 CD N
patients NNS N
( ( N
87.5 CD N
% NN N
) ) N
. . N

Analysing VBG N
response NN o
to TO o
FUFA NNP o
and CC o
FOLFIRI NNP o
in IN N
the DT N
per NN N
protocol NN N
set VBN N
( ( N
n=119 NN N
) ) N
after IN N
un-blinding JJ N
TS NNP N
in IN N
the DT N
data NN N
base NN N
revealed VBD N
a DT N
trend NN N
to TO N
better JJR N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
( ( N
9/19 CD N
, , N
47 CD N
% NN N
) ) N
in IN N
TS NNP N
high JJ N
compared VBN N
to TO N
FUFA NNP N
( ( N
5/23 CD N
, , N
22 CD N
% NN N
, , N
p=0.077 NN N
) ) N
. . N

In IN N
patients NNS N
with IN N
biopsies NNS N
taken VBN N
from IN N
liver JJ N
lesions NNS N
( ( N
n=91 NN N
) ) N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
and CC N
FUFA NNP N
in IN N
TS NNP N
high NN N
was VBD N
53 CD N
% NN N
( ( N
9/17 CD N
) ) N
and CC N
18 CD N
% NN N
( ( N
3/17 CD N
) ) N
, , N
respectively RB N
( ( N
p=0.035 NN N
) ) N
. . N

In IN N
patients NNS N
with IN N
low JJ N
TS NNP N
, , N
no DT N
remarkable JJ N
difference NN N
in IN N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
and CC N
FUFA NNP N
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Taking VBG N
a DT N
pre-treatment JJ N
biopsy NN N
is VBZ N
a DT N
safe JJ N
and CC N
feasible JJ N
procedure NN N
in IN N
mCRC NN N
. . N

After IN N
validation NN N
of IN N
our PRP$ N
data NNS N
in IN N
a DT N
larger JJR N
group NN N
TS NNP N
determination NN N
may MD N
have VB N
the DT N
potential NN N
to TO N
better JJR N
help NN N
direct VB N
systemic JJ N
treatment NN N
in IN N
patients NNS p
with IN p
primarily RB p
non-resectable JJ p
mCRC NN p
. . p

-DOCSTART- -X- O O

Population NNP N
pharmacokinetic/pharmacodynamic JJ N
analysis NN N
of IN N
the DT N
DPP-4 NNP i
inhibitor NN i
linagliptin NN i
in IN N
Japanese JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus RB p
. . p

OBJECTIVES NNP N
Linagliptin NNP i
is VBZ N
a DT N
novel JJ N
, , N
highly RB N
selective JJ N
and CC N
long JJ N
acting VBG N
DPP-4 NNP N
inhibitor NN N
for IN N
the DT N
treatment NN N
of IN N
type NN N
2 CD N
diabetes NNS N
mellitus FW N
( ( N
T2DM NNP N
) ) N
. . N

Linagliptin JJ i
exhibits VBZ N
non-linear JJ N
pharmacokinetics NNS N
( ( N
PK NNP N
) ) N
due JJ N
to TO N
saturable JJ N
binding NN N
to TO N
plasma VB N
and CC N
tissue VB N
DPP-4 NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
characterize VB N
the DT N
PK NNP N
and CC N
PK/DPP-4 NNP N
inhibition NN N
relationship NN N
of IN N
linagliptin NN i
in IN N
Japanese JJ p
patients NNS p
with IN p
T2DM NNP p
using VBG N
a DT N
population NN N
PK/DPP-4 NNP N
model NN N
and CC N
to TO N
support VB N
the DT N
rationale NN N
for IN N
the DT N
therapeutic JJ N
dose NN N
in IN N
Japanese JJ N
patients NNS N
by IN N
simulation NN N
. . N

METHODS NNP N
Linagliptin NNP i
plasma NN N
concentration NN N
and CC N
DPP-4 NNP N
inhibition NN N
measurements NNS N
from IN N
a DT N
placebo-controlled JJ i
, , N
parallel JJ N
group NN N
multiple NN N
( ( N
28 CD N
days NNS N
) ) N
dose VBP N
trial NN N
that WDT N
included VBD N
36 CD p
T2DM NNP p
patients NNS p
( ( p
18 CD p
patients NNS p
each DT p
in IN p
2.5 CD p
mg NN p
and CC p
10 CD p
mg NNS p
dose JJ p
group NN p
) ) p
were VBD N
used VBN N
for IN N
analysis NN N
. . N

Modeling NNP N
was VBD N
performed VBN N
using VBG N
FOCE NNP N
INTERACTION NNP N
estimation NN N
method NN N
implemented VBN N
in IN N
NONMEM NNP N
V. NNP N
The DT N
linagliptin JJ N
plasma JJ N
concentration- NN N
and CC N
DPP-4 NNP N
inhibition- JJ N
time NN N
profiles NNS N
were VBD N
simulated VBN N
for IN N
Japanese JJ N
patients NNS N
receiving VBG N
5 CD N
mg JJ N
linagliptin NN i
once RB N
daily JJ N
by IN N
the DT N
model NN N
established VBN N
. . N

RESULTS NNP N
Nonlinear NNP N
PK NNP N
of IN N
linagliptin NN N
in IN N
T2DM NNP N
patients NNS N
were VBD N
well RB N
described VBN N
by IN N
a DT N
2-compartment JJ N
model NN N
assuming VBG N
concentration-dependent JJ N
binding NN N
to TO N
DPP-4 NNP N
in IN N
the DT N
central JJ N
and CC N
peripheral JJ N
compartment NN N
. . N

Plasma NNP o
DPP-4 NNP o
inhibition NN o
was VBD N
integrated VBN N
in IN N
the DT N
model NN N
by IN N
relating VBG N
the DT N
model-predicted JJ N
DPP-4 NNP N
occupancy NN N
with IN N
linagliptin JJ i
linearly JJ N
to TO N
DPP-4 JJ N
inhibition NN N
. . N

The DT N
simulation NN N
predicted VBD N
that IN N
for IN N
the DT N
5 CD N
mg NN N
dose NN N
group NN N
the DT N
trough JJ N
DPP-4 JJ o
inhibition NN o
at IN N
steady-state NN N
was VBD N
84.2 CD N
% NN N
, , N
which WDT N
is VBZ N
higher JJR N
than IN N
the DT N
target NN N
inhibition NN N
( ( N
?80 CD N
% NN N
) ) N
for IN N
an DT N
effective JJ N
dose NN N
of IN N
DPP-4 NNP N
inhibitor NN N
. . N

In IN N
2.5 CD N
mg NNS N
dose JJ N
group NN o
, , o
steady-state JJ o
DPP-4 NNP o
inhibition NN o
of IN o
> $ N
80 CD N
% NN N
was VBD N
not RB N
maintained VBN N
over IN N
24 CD N
hours NNS N
( ( N
observed VBN N
and CC N
simulated VBN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
nonlinear JJ N
PK NNP N
of IN N
linagliptin NN i
and CC i
its PRP$ N
plasma JJ N
DPP-4 JJ N
inhibition NN N
in IN N
patients NNS N
were VBD N
well RB N
characterized VBN N
by IN N
a DT N
target-mediated JJ N
drug NN N
disposition NN N
model NN N
relating VBG N
DPP-4 NNP N
occupancy NN N
with IN N
linagliptin NN N
to TO N
DPP-4 NNP N
inhibition NN N
. . N

Simulations NNS N
of IN N
plasma JJ N
DPP-4 NNP N
inhibition NN N
suggest VBP N
that IN N
5 CD N
mg NNS N
linagliptin JJ i
once RB i
daily JJ N
is VBZ N
an DT N
appropriate JJ N
therapeutic JJ N
dose NN N
for IN N
Japanese JJ N
patients NNS N
with IN N
T2DM NNP N
. . N

-DOCSTART- -X- O O

Should MD N
snacks NNS i
be VB N
recommended VBN N
in IN N
obesity NN p
treatment NN p
? . N
A DT N
1-year JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
to TO N
recommend VB N
no DT i
snacks NNS i
vs VBP i
three CD i
snacks NNS i
per IN N
day NN N
on IN N
1-year JJ N
weight JJ N
loss NN N
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
it PRP N
is VBZ N
easier JJR N
to TO N
control VB N
energy NN N
intake NN N
and CC N
lose VB N
weight NN N
if IN N
snacks NNS N
in IN N
between IN N
meals NNS N
are VBP N
omitted VBN N
. . N

SUBJECTS/METHOD NNP N
In IN N
total JJ N
140 CD p
patients NNS p
( ( p
36 CD p
men NNS p
, , p
104 CD p
women NNS p
) ) p
, , p
aged VBN p
18-60 CD p
years NNS p
and CC p
body NN p
mass NN p
index NN p
> VBD p
30 CD p
kg/m NN p
( ( p
2 CD p
) ) p
were VBD p
randomized VBN p
and CC p
93 CD p
patients NNS p
( ( p
27 CD p
men NNS p
, , p
66 CD p
women NNS p
) ) p
completed VBD p
the DT p
study NN p
. . p

A DT N
1-year JJ N
randomized JJ N
intervention NN N
trial NN N
was VBD N
conducted VBN N
with IN N
two CD N
treatment NN N
arms NNS N
with IN N
different JJ N
eating VBG N
frequencies NNS N
; : N
3 CD i
meals/day NN i
( ( i
3M CD i
) ) i
or CC N
3 CD i
meals NNS i
and CC i
3 CD i
snacks/day NN i
( ( N
3+3M CD N
) ) N
. . N

The DT N
patients NNS N
received VBD N
regular JJ N
and CC N
individualized JJ N
counseling NN N
by IN N
dieticians NNS N
. . N

Information NN o
on IN o
eating NN o
patterns NNS o
, , o
dietary JJ o
intake NN o
, , o
weight NN o
and CC o
metabolic JJ o
variables NNS o
was VBD N
collected VBN N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
year NN N
. . N

RESULTS NNP N
Over IN N
1 CD N
year NN N
the DT N
3M CD i
group NN N
reported VBD N
a DT N
decrease NN N
in IN N
the DT N
number NN o
of IN o
snacks NNS o
whereas VBP N
the DT N
3+3M CD i
group NN N
reported VBD N
an DT N
increase NN N
( ( N
-1.1 JJ N
vs NN N
+0.4 NN N
snacks/day NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Both DT N
groups NNS N
decreased VBD N
energy NN o
intake NN o
and CC N
E NNP o
% NN o
( ( o
energy NN o
percent NN o
) ) o
fat NN o
and CC N
increased VBD N
E NNP o
% NN o
protein NN o
and CC o
fiber VB o
intake NN o
but CC N
there EX N
was VBD N
no DT N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

Both DT N
groups NNS N
lost VBD o
weight NN o
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
weight JJ o
loss NN o
after IN N
1 CD N
year NN N
of IN N
treatment NN N
( ( i
3M CD i
vs RB N
3+3M=-4.1+/-6.1 JJ i
vs NN N
-5.9+/-9.4 NNP N
kg NN N
; : N
P=0.31 NNP N
) ) N
. . N

Changes NNS N
in IN N
metabolic JJ o
variables NNS o
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
, , N
except IN N
for IN N
high-density NN o
lipoprotein NN o
that WDT N
increased VBD N
in IN N
the DT N
3M CD i
group NN N
but CC N
not RB N
in IN N
3+3M CD i
group NN N
( ( N
P NNP N
< VBZ N
0.033 CD N
for IN N
group NN N
difference NN N
) ) N
. . N

CONCLUSION NNP N
Recommending VBG N
snacks NNS N
or CC N
not RB N
between IN N
meals NNS N
does VBZ N
not RB N
influence VB N
1-year JJ o
weight NN o
loss NN o
. . o

-DOCSTART- -X- O O

Surgery NN N
of IN N
aphakic JJ p
retinal JJ p
detachment NN p
. . p

In IN N
a DT N
prospective JJ N
study NN N
84 CD p
patients NNS p
with IN p
aphakic JJ p
retinal JJ p
detachment NN p
were VBD p
treated VBN p
either RB p
by IN p
local JJ i
scleral JJ i
buckling VBG i
alone RB i
or CC i
combined VBN i
with IN i
an DT i
encirclement NN i
. . i

The DT N
rate NN o
of IN o
surgical JJ o
reattachment NN o
of IN o
the DT o
retina NN o
was VBD N
found VBN N
to TO N
be VB N
similar JJ N
with IN N
either DT N
technique NN N
over IN N
a DT N
minimum JJ N
follow-up JJ N
period NN N
of IN N
one CD N
year NN N
. . N

Simplicity NNP N
and CC N
a DT N
low JJ N
incidence NN N
of IN N
serious JJ N
complications NNS N
of IN N
the DT N
local JJ N
procedure NN N
merit NN N
its PRP$ N
application NN N
as IN N
the DT N
initial JJ N
method NN N
of IN N
repairing VBG N
aphakic JJ N
detachments NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
acupuncture NN i
combined VBN N
with IN N
Yizhi NNP i
Jiannao NNP i
granules NNS i
for IN N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
clinical JJ N
therapeutic JJ o
effect NN o
of IN N
acupuncture NN i
combined VBN N
with IN N
Yizhi NNP i
Jiannao NNP i
Granules NNP i
for IN N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
and CC N
its PRP$ N
effects NNS N
on IN N
intelligence NN o
, , o
daily JJ o
life NN o
and CC o
social JJ o
activity NN o
ability NN o
. . o

METHODS NNP N
Eighty-four JJ p
cases NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
3 CD p
groups NNS p
, , p
28 CD p
cases NNS p
in IN p
each DT p
group NN p
. . p

The DT N
combined JJ N
acupuncture NN i
and CC N
medication NN N
group NN N
was VBD N
treated VBN N
with IN N
acupuncture NN i
at IN N
Baihui NNP N
( ( N
GV NNP N
20 CD N
) ) N
, , N
Sishencong NNP N
( ( N
EX-HN NNP N
1 CD N
) ) N
, , N
Dazhui NNP N
( ( N
GV NNP N
14 CD N
) ) N
, , N
Guanyuan NNP N
( ( N
CV NNP N
4 CD N
) ) N
, , N
etc FW N
. . N

and CC N
oral JJ N
administration NN N
of IN N
Yizhi NNP i
Jiannao NNP i
Granules NNP i
; : i
the DT N
Chinese NNP N
herb NN N
group NN N
was VBD N
treated VBN N
with IN N
Yizhi NNP i
Jiannao NNP i
Granules NNP i
, , N
and CC N
the DT N
western JJ i
medicine NN i
group NN i
with IN N
oral JJ N
administration NN N
of IN N
Aricept NNP i
. . i

The DT N
scores NNS o
for IN o
the DT o
Mini-Mental JJ o
State NNP o
Examination NNP o
( ( o
MMSE NNP o
) ) o
, , o
Ability NNP o
of IN o
Daily NNP o
Life NNP o
( ( o
ADL NNP o
) ) o
and CC o
the DT o
therapeutic JJ o
effects NNS o
were VBD N
assessed VBN N
and CC N
compared VBN N
before IN N
treatment NN N
and CC N
after IN N
treatment NN N
for IN N
12 CD N
weeks NNS N
among IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
scores NNS N
for IN N
MMSE NNP o
and CC o
ADL NNP o
were VBD N
improved VBN N
in IN N
the DT N
combined JJ i
acupuncture NN i
and CC i
medication NN i
group NN N
, , N
the DT N
Chinese JJ i
herb NN i
group NN N
and CC N
the DT N
western JJ i
medicine NN i
group NN N
, , N
which WDT N
were VBD N
better RBR N
in IN N
the DT N
combined JJ N
acupuncture NN i
and CC i
medication NN i
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
total JJ o
effective JJ o
rate NN o
of IN N
85.7 CD N
% NN N
in IN N
the DT N
combined JJ i
acupuncture NN i
and CC i
medication NN i
group NN N
was VBD N
better JJR N
than IN N
71.4 CD N
% NN N
in IN N
the DT N
Chinese JJ N
herb NN N
group NN N
and CC N
67.9 CD N
% NN N
in IN N
the DT N
western JJ N
medicine NN N
group NN N
. . N

CONCLUSION NNP N
Acupuncture NNP i
combined VBN i
with IN i
Yizhi NNP i
Jiannao NNP i
Granules NNP i
has VBZ N
a DT N
significant JJ N
therapeutic JJ o
effect NN o
on IN N
Alzheimer NNP N
's POS N
disease NN N
, , N
which WDT N
is VBZ N
better JJR N
than IN N
that DT N
of IN N
Yizhi NNP i
Jiannao NNP i
Granules NNP i
or CC N
Aricept NNP i
. . i

-DOCSTART- -X- O O

Influence NN N
of IN N
special-effect JJ i
contact NN i
lenses NNS i
( ( i
Crazy NNP i
Lenses NNP i
) ) i
on IN N
visual JJ o
function NN o
. . o

PURPOSE NNP N
Special-effect JJ i
contact NN i
lenses NNS i
( ( N
opaque NN N
, , N
tinted VBD N
soft JJ N
contact NN N
lenses VBZ N
that IN N
incorporate JJ N
decorative JJ N
images NNS N
such JJ N
as IN N
cateyes NNS N
, , N
stars NNS N
, , N
or CC N
hearts NNS N
to TO N
alter VB N
eye NN N
color NN N
and CC N
structure NN N
) ) N
have VBP N
become VBN N
increasingly RB N
popular JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
such JJ N
lenses NNS N
impair VBP N
visual JJ o
function NN o
. . o

METHODS NNP N
A DT i
clear JJ i
soft JJ i
contact NN i
lens NNS i
and CC i
a DT i
special-effect JJ i
soft JJ i
contact NN i
lens NNS i
( ( i
Crazy NNP i
lens VBZ i
, , i
) ) i
were VBD N
fit JJ N
in IN N
changing VBG N
sequence NN N
in IN N
nine CD p
healthy JJ p
subjects NNS p
. . p

The DT N
parameters NNS N
studied VBD N
included VBN N
: : N
visual JJ o
acuity NN o
, , o
contrast NN o
sensitivity NN o
( ( o
with IN o
and CC o
without IN o
glare NN o
) ) o
, , o
visual JJ o
field NN o
, , o
and CC o
mesopic NN o
vision NN o
( ( o
with IN o
and CC o
without IN o
glare NN o
) ) o
. . o

RESULTS VB N
The DT N
following JJ N
parameters NNS N
displayed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Visual JJ o
acuity NN o
was VBD N
decreased VBN N
to TO N
0.9 CD N
+/- JJ N
0.23 CD N
in IN N
the DT N
Crazy NNP N
lens VBZ N
group NN N
as IN N
compared VBN N
with IN N
1.2 CD N
+/- JJ N
0.13 CD N
in IN N
the DT N
clear JJ i
lens NNS i
group NN N
. . N

Goldmann NNP o
visual JJ o
field NN o
displayed VBD N
a DT N
significant JJ N
constriction NN o
of IN o
the DT o
isopters NNS o
: : o
III/4 NNP N
, , N
I/4 NNP N
, , N
and CC N
I/3 NNP N
. . N

Mesopic NNP o
vision NN o
without IN o
glare NN o
was VBD N
reduced VBN N
from IN N
1:2.5 CD N
to TO N
1:7.4 CD N
. . N

Contrast NNP o
sensitivity NN o
was VBD N
significantly RB N
reduced VBN N
in IN N
a DT N
photopic JJ N
condition NN N
with IN N
and CC N
without IN N
glare NN N
and CC N
in IN N
a DT N
scotopic JJ N
condition NN N
without IN N
glare NN N
. . N

Furthermore RB N
, , N
the DT N
special-effect JJ i
lenses NNS i
were VBD N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
lens NNS o
wearing VBG o
comfort NN o
. . o

CONCLUSIONS NNP N
Special-effect JJ i
contact NN i
lenses NNS i
were VBD N
associated VBN N
with IN N
a DT N
reduction NN N
of IN N
many JJ N
visual JJ o
functions NNS o
, , N
including VBG N
visual JJ o
acuity NN o
and CC o
contrast NN o
sensitivity NN o
. . o

For IN N
some DT N
wearers NNS p
this DT N
may MD N
interfere VB N
with IN N
activities NNS N
where WRB N
excellent JJ N
vision NN N
is VBZ N
crucial JJ N
, , N
such JJ N
as IN N
driving VBG N
a DT N
car NN N
. . N

-DOCSTART- -X- O O

Domperidone NN i
, , i
metoclopramide NN i
, , i
and CC i
placebo NN i
. . i

All DT N
give JJ N
symptomatic JJ o
improvement NN o
in IN o
gastroesophageal JJ o
reflux NN o
. . o

A DT N
double-blind JJ N
crossover NN N
study NN N
was VBD N
conducted VBN N
of IN N
two CD N
gastric JJ i
prokinetic JJ i
drugs NNS i
in IN N
23 CD p
patients NNS p
with IN p
gastroesophageal JJ p
reflux NN p
. . p

Patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
on IN N
the DT N
basis NN N
of IN N
a DT N
dual-isotope JJ N
mixed-meal JJ N
study NN N
of IN N
their PRP$ N
gastric JJ N
emptying NN N
( ( N
GE NNP N
) ) N
. . N

Group NNP p
I PRP p
had VBD N
normal JJ N
GE NNP N
and CC N
group NN N
II NNP N
delayed VBD N
GE NNP N
. . N

Nine NNP N
gastrointestinal JJ N
symptoms NNS N
were VBD N
assessed VBN N
for IN N
frequency NN N
and CC N
severity NN N
before IN N
treatment NN N
. . N

The DT N
trial NN N
had VBD N
three CD N
1-month JJ N
treatment NN N
periods NNS N
using VBG N
metoclopramide RB i
10 CD N
mg NN N
q.i.d. NN N
, , N
domperidone NN i
20 CD N
mg NN N
q.i.d. NN N
, , N
or CC i
placebo NN i
on IN N
a DT N
random JJ N
basis NN N
. . N

Symptoms NNS N
were VBD N
reassessed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
month NN N
. . N

Taken NNP N
as IN N
a DT N
whole NN N
, , N
the DT N
group NN N
showed VBD N
a DT N
significant JJ N
symptomatic JJ o
response NN o
in IN N
all DT N
three CD N
treatment NN N
periods NNS N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
, , N
but CC N
patients NNS p
with IN p
delayed JJ p
or CC p
normal JJ p
GE NNP p
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
their PRP$ N
symptomatic JJ N
response NN N
. . N

Eleven JJ N
patients NNS N
complained VBD N
of IN N
side NN o
effects NNS o
with IN N
metoclopramide NN i
and CC N
three CD N
stopped VBD N
therapy NN N
before IN N
the DT N
1-month JJ N
course NN N
was VBD N
completed VBN N
. . N

Two CD N
patients NNS N
described JJ N
side JJ N
effects NNS N
with IN N
domperidone NN i
, , N
including VBG N
one CD N
woman NN N
with IN N
galactorrhea NN o
after IN N
36 CD N
h NN N
of IN N
treatment NN N
. . N

Three CD N
patients NNS N
on IN N
placebo NN i
also RB N
complained VBD N
of IN N
important JJ o
side NN o
effects NNS o
. . o

We PRP N
conclude VBP N
that IN N
a DT N
significant JJ N
placebo NN N
effect NN N
is VBZ N
present JJ N
in IN N
the DT N
treatment NN N
of IN N
gastroesophageal JJ N
reflux NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
demonstrated VBN N
in IN N
symptomatic JJ o
improvement NN o
between IN N
placebo NN i
, , i
domperidone NN i
, , N
and CC N
metoclopramide RB i
in IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O

Sustained VBN N
augmentation NN N
of IN N
parasympathetic JJ N
tone NN N
with IN N
angiotensin-converting JJ i
enzyme JJ i
inhibition NN i
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
. . p

OBJECTIVES CC N
The DT N
objective NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
evaluate VB N
the DT N
changes NNS N
in IN N
parasympathetic JJ N
tone NN N
associated VBN N
with IN N
long-term JJ N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
therapy NN i
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
. . p

BACKGROUND NNP N
Angiotensin-converting NNP N
enzyme NN N
inhibitors NNS N
provide VBP N
hemodynamic JJ N
and CC N
symptomatic JJ N
benefit NN N
and CC N
are VBP N
associated VBN N
with IN N
improved JJ N
survival NN N
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
. . p

Angiotensin NNP N
II NNP N
, , N
whose WP$ N
production NN N
is VBZ N
ultimately RB N
inhibited VBN N
by IN N
these DT N
agents NNS N
, , N
exerts NNS N
significant JJ N
regulatory JJ N
influence NN N
on IN N
a DT N
variety NN N
of IN N
target NN N
organs NNS N
including VBG N
the DT N
central JJ N
and CC N
peripheral JJ N
nervous JJ N
systems NNS N
. . N

Accordingly RB N
, , N
it PRP N
would MD N
be VB N
anticipated VBN N
that IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
would MD N
significantly RB N
alter VB N
the DT N
autonomic JJ N
imbalance NN N
characteristic NN N
of IN N
patients NNS N
with IN N
congestive JJ N
heart NN N
failure NN N
and CC N
that IN N
this DT N
influence NN N
over IN N
neural JJ N
mechanisms NNS N
of IN N
cardiovascular JJ N
control NN N
may MD N
significantly RB N
contribute VB N
to TO N
the DT N
hemodynamic JJ N
benefit NN N
and CC N
improved VBN N
survival NN N
associated VBN N
with IN N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
therapy NN N
. . N

METHODS NNP N
In IN N
the DT N
current JJ N
investigation NN N
, , N
changes NNS N
in IN N
autonomic JJ N
tone NN N
associated VBN N
with IN N
long-term JJ N
administration NN N
of IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
were VBD N
measured VBN N
using VBG N
spectral JJ N
analysis NN N
of IN N
heart NN N
rate NN N
variability NN N
in IN N
13 CD p
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
who WP N
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
placebo-controlled JJ i
trial NN N
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
zofenopril NN i
. . i

Both DT N
placebo NN i
and CC N
treatment NN N
groups NNS N
were VBD N
balanced VBN N
at IN N
baseline NN N
study NN N
in IN N
terms NNS N
of IN N
functional JJ N
class NN N
, , N
ventricular JJ N
performance NN N
and CC N
autonomic JJ N
tone NN N
. . N

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
of IN N
therapy NN N
with IN N
placebo NN i
, , N
there EX N
was VBD N
no DT N
change NN N
in IN N
total JJ o
heart NN o
rate NN o
variability NN o
, , o
parasympathetically RB o
governed VBN o
high JJ o
frequency NN o
heart NN o
rate NN o
variability NN o
or CC o
sympathetically RB o
influenced JJ o
low JJ o
frequency NN o
heart NN o
rate NN o
variability NN o
. . o

In IN N
contrast NN N
, , N
therapy NN N
with IN N
zofenopril NN i
was VBD N
associated VBN N
with IN N
a DT N
50 CD N
% NN N
increase NN o
in IN o
total JJ o
heart NN o
rate NN o
variability NN o
( ( N
p JJ N
= NNP N
0.09 CD N
) ) N
and CC N
a DT N
significant JJ N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
twofold NN N
increase NN o
in IN o
high JJ o
frequency NN o
heart NN o
rate NN o
variability NN o
, , N
indicating VBG N
a DT N
significant JJ N
augmentation NN N
of IN N
parasympathetic JJ N
tone NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
demonstrate VBP N
that IN N
long-term JJ p
treatment NN p
of IN p
patients NNS p
having VBG p
congestive JJ p
heart NN p
failure NN p
with IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
is VBZ N
associated VBN N
with IN N
a DT N
restoration NN N
of IN N
autonomic JJ N
balance NN N
, , N
which WDT N
derives VBZ N
in IN N
part NN N
from IN N
a DT N
sustained JJ N
augmentation NN N
of IN N
parasympathetic JJ N
tone NN N
. . N

Such JJ N
augmentation NN N
of IN N
vagal JJ N
tone NN N
is VBZ N
known VBN N
to TO N
be VB N
protective JJ N
against IN N
malignant JJ N
ventricular JJ N
arrhythmias NNS N
in IN N
patients NNS p
with IN p
ischemic JJ p
heart NN p
disease NN p
and CC N
therefore NN N
may MD N
have VB N
similar JJ N
benefit NN N
in IN N
the DT N
setting NN N
of IN N
ventricular JJ N
failure NN N
, , N
thus RB N
contributing VBG N
to TO N
the DT N
improved JJ N
survival NN N
associated VBN N
with IN N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
therapy NN N
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
. . p

-DOCSTART- -X- O O

Hodgkin NNP p
's POS p
disease NN p
in IN p
childhood NN p
and CC p
adolescence NN p
: : p
results NNS N
of IN N
chemotherapy-radiotherapy NN N
in IN N
clinical JJ N
stages NNS N
IA-IIB NNP N
. . N

From IN N
April NNP N
1972 CD N
to TO N
May NNP N
1980 CD N
, , N
72 CD p
children NNS p
and CC p
adolescents NNS p
( ( p
aged VBN p
5 CD p
to TO p
19 CD p
years NNS p
old JJ p
, , p
median JJ p
16 CD p
) ) p
with IN p
Hodgkin NNP p
's POS p
disease NN p
, , p
clinical JJ p
stages NNS p
IA-IIB NNP p
( ( p
IA NNP p
, , p
18 CD p
; : p
II2A NNP p
, , p
two CD p
areas NNS p
involved VBN p
on IN p
the DT p
same JJ p
side NN p
of IN p
the DT p
diaphragm NN p
, , p
23 CD p
; : p
II3+A NNP p
, , p
three CD p
areas NNS p
or CC p
more JJR p
, , p
16 CD p
; : p
IIB NNP p
, , p
15 CD p
) ) p
were VBD N
prospectively RB N
treated VBN N
in IN N
two CD N
successive JJ N
clinical JJ N
trials NNS N
( ( N
H NNP N
72 CD N
and CC N
H NNP N
77 CD N
) ) N
. . N

Clinical JJ N
stages NNS N
IA NNP N
and CC N
II2A NNP N
received VBD N
three CD N
courses NNS N
of IN N
mechlorethamine NN i
, , i
Oncovin NNP i
, , i
procarbazine NN i
, , i
and CC i
prednisone NN i
( ( i
MOPP NNP i
) ) i
and CC i
supradiaphragmatic JJ i
radiotherapy NN i
( ( i
40 CD i
Gy NNP i
) ) i
, , i
and CC i
no DT i
laparotomy NN i
was VBD N
performed VBN N
. . N

Clinical JJ N
stages NNS N
II3+A NNP N
and CC N
IIB NNP N
received VBD N
either DT N
six CD N
cycles NNS N
of IN N
MOPP NNP i
( ( N
H NNP N
72 CD N
) ) N
, , N
three CD N
cycles NNS N
of IN N
MOPP NNP N
, , N
or CC N
three CD N
cycles NNS N
of IN N
CCNU NNP i
, , i
vinblastine NN i
, , i
procarbazine NN i
, , N
and CC N
prednisone NN i
( ( N
CVPP NNP N
) ) N
( ( N
H $ N
77 CD N
) ) N
and CC N
subsequently RB N
had VBD N
a DT N
laparotomy NN i
followed VBN N
by IN N
supradiaphragmatic JJ i
radiotherapy NN i
and CC N
a DT N
lumboaortic JJ N
field NN N
if IN N
results NNS N
of IN N
laparotomy NN N
were VBD N
positive JJ N
. . N

Patients NNS p
without IN p
evidence NN p
of IN p
mediastinal JJ p
involvement NN p
did VBD N
not RB N
have VB N
mediastinal JJ N
radiotherapy NN N
. . N

At IN N
the DT N
completion NN N
of IN N
therapy NN N
, , N
the DT N
disease NN N
in IN N
70 CD N
of IN N
72 CD N
patients NNS N
was VBD N
in IN N
complete JJ N
remission NN N
( ( N
one CD N
failure NN o
, , N
one CD N
death NN o
during IN N
treatment NN N
) ) N
. . N

Eight CD N
patients NNS N
relapsed VBN o
( ( N
in IN N
situ NN N
, , N
1 CD N
; : N
marginal JJ N
, , N
1 CD N
; : N
nonirradiated VBN N
subdiaphragmatic JJ N
area NN N
, , N
6 CD N
) ) N
after IN N
three CD N
to TO N
57 CD N
months NNS N
of IN N
complete JJ N
remission NN N
( ( N
median JJ N
20 CD N
months NNS N
) ) N
; : N
one CD N
patient NN N
died VBD N
after IN N
relapse NN N
. . N

There EX N
were VBD N
three CD N
deaths NNS o
after IN N
complete JJ N
remission NN N
of IN N
the DT N
disease NN N
( ( N
infection NN N
, , N
two CD N
; : N
acute CC N
nonlymphocytic JJ o
leukemia NN o
[ NNP N
ANLL NNP N
] NNP N
, , N
one CD N
) ) N
. . N

As IN N
of IN N
June NNP N
1984 CD N
the DT N
median JJ N
follow-up NN N
was VBD N
82 CD N
months NNS N
( ( N
range NN N
, , N
49 CD N
to TO N
145 CD N
months NNS N
) ) N
, , N
the DT o
actuarial JJ o
probabilities NNS o
for IN o
survival NN o
and CC o
freedom NN o
from IN o
relapse NN o
for IN N
all DT N
patients NNS N
being VBG N
91.6 CD N
% NN N
and CC N
87.6 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
according VBG N
to TO N
clinical JJ N
stage NN N
, , N
age NN N
( ( N
greater JJR N
than IN N
15 CD N
or CC N
less JJR N
than IN N
15 CD N
years NNS N
) ) N
, , N
sex NN N
, , N
or CC N
number NN o
of IN o
cycles NNS o
of IN o
chemotherapy NN o
( ( N
six CD N
or CC N
three CD N
) ) N
. . N

Bone NNP o
growth NN o
defects NNS o
related VBN o
to TO o
radiotherapy VB o
were VBD N
reduced VBN N
particularly RB N
in IN N
the DT N
29 CD N
patients NNS N
who WP N
did VBD N
not RB N
receive VB N
mediastinal JJ N
radiotherapy NN N
. . N

None NN N
of IN N
these DT N
patients NNS N
had VBD N
a DT N
mediastinal JJ o
relapse NN o
. . o

Azoospermia NNP o
was VBD N
the DT N
rule NN N
for IN N
the DT N
male NN N
patients NNS N
studied VBN N
, , N
but CC N
young JJ N
girls NNS N
and CC N
young JJ N
women NNS N
retained VBD N
reproductive JJ N
integrity NN N
. . N

-DOCSTART- -X- O O

An DT N
analysis NN N
of IN N
the DT N
radiation NN N
related VBN N
morbidity NN o
observed VBN N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
neutron NN i
therapy NN i
for IN N
bladder NN p
cancer NN p
. . p

This DT N
report NN N
is VBZ N
an DT N
analysis NN N
of IN N
the DT N
morbidity NN o
in IN p
the DT p
bladder NN p
and CC N
bowel NN N
observed VBN N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
d NN i
( ( i
15 CD i
) ) i
+Be NN i
neutrons NNS i
versus VBP N
megavoltage NN i
photons NNS i
in IN N
the DT N
treatment NN N
of IN N
bladder NN N
cancer NN N
. . N

Acute JJ o
reactions NNS o
in IN N
the DT N
bladder NN N
and CC N
bowel NN N
were VBD N
significantly RB N
worse JJR N
after IN N
photon NN i
therapy NN i
. . i

Of IN N
the DT N
patients NNS p
treated VBN p
with IN p
photons NNS i
45.7 CD N
% NN N
had VBD N
severe JJ N
reactions NNS o
in IN o
the DT o
bladder NN o
compared VBN N
with IN N
10.6 CD N
% NN N
after IN N
neutron JJ i
therapy NN i
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Severe NNP o
acute JJ o
bowel NN o
reactions NNS o
were VBD N
observed VBN N
in IN N
8.5 CD N
% NN N
of IN N
the DT N
patients NNS N
after IN N
photon NN i
therapy NN i
compared VBN N
with IN N
3.8 CD N
% NN N
after IN N
neutron JJ i
therapy NN i
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Late JJ o
reactions NNS o
were VBD N
significantly RB N
worse JJR N
after IN N
neutrons NNS i
. . i

Severe NNP o
late JJ o
reactions NNS o
in IN o
the DT o
bladder NN o
were VBD N
seen VBN N
in IN N
58.5 CD N
% NN N
of IN N
patients NNS N
after IN N
neutron JJ i
therapy NN i
and CC N
in IN N
40.5 CD N
% NN N
after IN N
photon NN i
therapy NN i
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

In IN N
the DT N
bowel NN N
they PRP N
were VBD N
observed VBN N
in IN N
53.3 CD N
% NN N
of IN N
patients NNS N
after IN N
neutron JJ i
therapy NN i
compared VBN N
with IN N
8 CD N
% NN N
after IN N
photon NN i
therapy NN i
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
disparity NN o
in IN o
the DT o
degree NN o
of IN o
early JJ o
and CC o
late JJ o
complications NNS o
makes VBZ N
assessment NN N
of IN N
RBE NNP o
values NNS o
difficult JJ N
. . N

It PRP N
is VBZ N
estimated VBN N
that IN N
for IN N
bladder NN o
morbidity NN o
the DT N
RBE NNP o
value NN o
, , N
for IN N
photon NN N
dose JJ N
fractions NNS N
of IN N
2.75 CD N
Gy NNP N
, , N
is VBZ N
less JJR N
than IN N
3.3 CD N
for IN N
early JJ N
reactions NNS N
and CC N
equal JJ N
to TO N
3.4 CD N
for IN N
late JJ N
effects NNS N
. . N

The DT N
respective JJ N
RBE NNP o
values NNS o
for IN N
early RB N
and CC N
late JJ N
effects NNS N
in IN N
the DT N
bowel NN N
are VBP N
less JJR N
than IN N
3.4 CD N
and CC N
3.8 CD N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
an DT N
aquatics NNS i
programme NN i
on IN N
fitness NN o
parameters NNS o
of IN N
individuals NNS p
with IN p
a DT p
brain NN p
injury NN p
. . p

The DT N
primary JJ N
objective NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
an DT N
aquatic JJ i
exercise NN i
programme NN i
on IN N
the DT N
physical JJ o
fitness NN o
of IN N
people NNS p
with IN p
a DT p
brain NN p
injury NN p
. . p

A DT N
pre-test-post-test JJ N
randomized-groups JJ N
design NN N
was VBD N
conducted VBN N
. . N

Sixteen JJ p
outpatients NNS p
with IN p
a DT p
brain NN p
injury NN p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Eight CD N
participants NNS N
were VBD N
assigned VBN N
to TO N
an DT N
aquatic JJ i
exercise NN i
group NN i
and CC i
eight CD i
to TO i
a DT i
control NN i
group NN i
. . i

The DT N
components NNS N
of IN N
physical JJ N
fitness NN N
measured VBD N
included VBD N
cardiovascular JJ o
endurance NN o
, , o
body NN o
composition NN o
, , o
muscular JJ o
strength NN o
and CC o
endurance NN o
and CC o
flexibility NN o
. . o

Measurements NNS N
were VBD N
taken VBN N
pre- JJ N
and CC N
post-programme JJ N
. . N

Results NNP N
indicated VBD N
an DT N
increase NN N
in IN N
components NNS o
of IN o
physical JJ o
fitness NN o
for IN N
the DT N
experimental JJ N
group NN N
but CC N
not RB N
the DT N
control NN N
group NN N
. . N

Increases VBZ N
in IN N
fitness NN N
were VBD N
reported VBN N
as IN N
having VBG N
a DT N
positive JJ N
impact NN N
on IN N
the DT N
functional JJ o
capacity NN o
of IN N
individuals NNS N
in IN N
the DT N
exercise NN N
group NN N
as RB N
well RB N
as IN N
enhancing VBG N
the DT N
individual NN N
's POS N
ability NN o
to TO o
complete VB o
activities NNS o
of IN o
daily JJ o
living VBG o
successfully RB N
. . N

Results VB N
indicate JJ N
that IN N
aquatic JJ N
exercise NN N
may MD N
positively RB N
impact VB N
the DT N
primary JJ o
and CC o
secondary JJ o
physical JJ o
injuries NNS o
caused VBN N
by IN N
a DT N
brain NN N
injury NN N
. . N

-DOCSTART- -X- O O

A DT N
Double-Blind JJ N
Placebo-Controlled JJ i
Study NNP N
of IN N
the DT N
Effects NNS N
of IN N
Olprinone NNP i
, , N
a DT N
Specific JJ i
Phosphodiesterase NNP i
III NNP i
Inhibitor NNP i
, , N
for IN N
Preventing VBG N
Postoperative NNP N
Atrial NNP N
Fibrillation NNP N
in IN N
Patients NNP p
Undergoing NNP p
Pulmonary NNP p
Resection NNP p
for IN p
Lung NNP p
Cancer NNP p
. . p

BACKGROUND NNP N
We PRP N
previously RB N
reported VBD N
that IN N
patients NNS N
with IN N
elevated JJ p
preoperative JJ p
B-type NNP p
natriuretic JJ p
peptide NN p
( ( p
BNP NNP p
) ) p
levels NNS p
have VBP N
an DT N
increased VBN N
risk NN N
for IN N
postoperative JJ N
atrial JJ N
fibrillation NN N
following VBG N
lung NN N
cancer NN N
surgery NN N
. . N

The DT N
present JJ N
study NN N
evaluated VBD N
whether IN N
the DT N
specific JJ i
phosphodiesterase NN i
III NNP i
inhibitor NN i
olprinone NN i
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
postoperative JJ N
atrial JJ N
fibrillation NN N
in IN N
patients NNS N
with IN N
elevated JJ N
BNP NNP N
levels NNS N
undergoing VBG N
pulmonary JJ N
resection NN N
for IN N
lung NN N
cancer NN N
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
with IN N
40 CD p
patients NNS p
who WP p
had VBD p
elevated VBN p
preoperative JJ p
BNP NNP p
levels NNS p
( ( p
? . p
30 CD p
pg/mL NN p
) ) p
and CC p
underwent JJ p
scheduled VBN p
lung NN p
cancer NN p
surgery NN p
. . p

All DT p
patients NNS p
were VBD p
in IN p
sinus JJ p
rhythm NN p
at IN p
surgery NN i
. . i

Low-dose JJ i
olprinone NN i
or CC i
placebo NN i
was VBD i
continuously RB N
infused VBN N
for IN N
24 CD N
h NN N
and CC N
started VBD N
just RB N
before RB N
anesthesia JJ N
induction NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT o
incidence NN o
of IN o
postoperative JJ o
atrial JJ o
fibrillation NN o
. . o

The DT N
secondary JJ N
end NN N
points NNS N
were VBD o
perioperative JJ o
hemodynamics NNS o
and CC o
levels NNS o
of IN o
BNP NNP o
, , o
WBC NNP o
counts VBZ o
, , o
and CC o
C-reactive JJ o
protein NN o
. . o

RESULTS VB N
The DT o
incidence NN o
of IN o
postoperative JJ o
atrial JJ o
fibrillation NN o
was VBD o
significantly RB N
lower JJR N
in IN N
the DT i
olprinone NN i
group NN i
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
10 CD N
% NN N
vs JJ N
60 CD N
% NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT i
olprinone NN i
group NN i
showed VBD N
significantly RB o
lower JJR o
BNP NNP o
, , o
WBC NNP o
counts VBZ o
, , o
and CC o
C-reactive JJ o
protein NN o
levels NNS o
after IN o
surgery NN N
. . N

CONCLUSIONS NNP N
Continuous NNP N
infusion NN N
of IN N
olprinone NN N
during IN N
lung NN N
cancer NN N
surgery NN N
was VBD o
safe JJ o
and CC o
reduced VBD N
the DT o
incidence NN o
of IN o
postoperative JJ o
atrial JJ o
fibrillation NN o
following VBG o
pulmonary JJ N
resection NN N
in IN N
patients NNS N
with IN N
elevated JJ N
preoperative JJ N
BNP NNP N
levels NNS N
. . N

TRIAL NNP N
REGISTRY NNP N
Japan NNP N
Primary NNP N
Registries NNP N
Network NNP N
; : N
No NNP N
. . N

: : N
JPRN-UMIN2404 JJ N
; : N
URL NNP N
: : N
http NN N
: : N
//www.umin.ac.jp/ctr/ NN N
. . N

-DOCSTART- -X- O O

Why WRB N
the DT N
prone NN i
position NN i
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
sudden JJ N
infant NN N
death NN N
syndrome NN N
. . N

INTRODUCTION NNP N
The DT N
laryngeal NN N
chemoreflex NN N
may MD N
explain VB N
why WRB N
prone NN N
sleeping NN N
increases VBZ N
the DT N
risk NN N
of IN N
sudden JJ N
infant NN N
death NN N
syndrome NN N
( ( N
SIDS NNP N
) ) N
. . N

Swallowing VBG N
and CC N
arousal NN N
are VBP N
crucial JJ N
to TO N
prevent VB N
laryngeal JJ N
chemoreflex JJ N
stimulation NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
examine VB N
these DT N
reflexes NNS o
and CC o
breathing VBG o
responses NNS o
in IN N
healthy JJ p
neonates NNS p
after IN N
pharyngeal JJ N
infusion NN N
of IN N
water NN N
in IN N
the DT N
supine NN N
versus IN N
the DT N
prone NN N
position NN N
, , N
controlling VBG N
for IN N
sleep JJ N
state NN N
. . N

METHODS CC N
A DT N
total NN N
of IN N
10 CD p
term NN p
infants NNS p
were VBD N
recruited VBN N
after IN N
parental JJ N
consent NN N
and CC N
ethics NNS N
approval NN N
. . N

Polygraphic JJ N
recordings NNS N
included VBD N
sleep JJ o
state NN o
( ( o
active JJ o
and CC o
quiet JJ o
sleep NN o
by IN o
electroencephalogram NN o
, , o
eye NN o
movements NNS o
, , o
breathing NN o
, , o
and CC o
behavior NN o
) ) o
, , o
cardiorespiratory JJ o
measurements NNS o
( ( o
nasal JJ o
airflow NN o
, , o
chest VBP o
wall NN o
movements NNS o
, , o
heart NN o
rate NN o
, , o
and CC o
oxygen PRP o
saturation NN o
) ) o
, , o
swallowing VBG o
, , o
and CC o
esophageal JJ o
activity NN o
( ( o
solid JJ o
state NN o
pressure NN o
catheter NN o
) ) o
. . o

Initial JJ i
sleeping VBG i
position NN i
was VBD i
assigned VBN i
randomly RB i
. . i

Measurements NNS N
were VBD N
made VBN N
for IN N
1 CD i
minute NN i
before IN i
and CC i
after IN i
0.4 CD i
mL NN i
of IN i
water NN i
was VBD i
instilled VBN i
into IN i
the DT i
oropharynx NN i
. . i

To TO N
detect VB N
a DT N
30 CD N
% NN N
decrease NN N
in IN N
swallowing NN o
, , N
power NN N
analysis NN N
indicated VBD N
that IN N
> NNP N
/=10 NNP N
babies NNS N
were VBD N
required VBN N
. . N

Analysis NN N
, , N
blinded VBD N
to TO N
position NN N
, , N
was VBD N
made VBN N
using VBG N
nonparametric JJ N
statistics NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
164 CD N
infusions NNS N
, , N
the DT N
most RBS N
commonly RB N
evoked VBD N
airway RB N
protective JJ N
responses NNS N
to TO N
pharyngeal VB N
infusion NN N
were VBD N
swallowing VBG o
( ( N
95 CD N
% NN N
) ) N
and CC N
arousal NN o
( ( N
54 CD N
% NN N
) ) N
. . N

After IN N
infusion NN N
in IN N
active JJ N
sleep NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
swallowing VBG o
and CC o
breathing VBG o
when WRB N
the DT N
prone NN N
position NN N
was VBD N
compared VBN N
with IN N
the DT N
supine JJ N
position NN N
( ( N
prone NN N
: : N
21.3 CD N
[ $ N
1.0 CD N
] NNP N
swallows/min NN o
and CC N
-9.6 NNP N
[ NNP N
2.1 CD N
] NNP N
breaths/min NN o
; : o
and CC N
supine VB N
: : N
32 CD N
( ( N
2.2 CD N
) ) N
and CC N
-2 NNP N
. . N

9 CD N
( ( N
1.5 CD N
) ) N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
occurrence NN N
of IN N
arousal NN o
after IN N
water NN N
infusion NN N
. . N

CONCLUSION NNP N
These DT N
data NNS N
suggest VBP N
that IN N
airway NN N
protection NN N
is VBZ N
compromised VBN N
in IN N
the DT N
prone NN N
sleeping VBG N
position NN N
during IN N
active JJ N
sleep NN N
, , N
even RB N
in IN N
healthy JJ N
infants NNS N
exposed VBN N
to TO N
minute VB N
pharyngeal JJ N
fluid JJ N
volumes NNS N
of IN N
0.4 CD N
mL NN N
. . N

This DT N
is VBZ N
because IN N
swallowing VBG o
rate NN o
is VBZ N
reduced VBN N
significantly RB N
, , N
and CC N
there EX N
is VBZ N
no DT N
compensatory JJ N
increase NN N
in IN N
arousal NN o
. . o

The DT N
reduction NN N
in IN N
airway RB o
protective JJ o
reflexes NNS o
when WRB N
in IN N
the DT N
prone NN N
position NN N
and CC N
in IN N
active JJ N
sleep NN N
may MD N
be VB N
the DT N
mechanism NN N
for IN N
the DT N
increased VBN N
risk NN N
of IN N
SIDS NNP N
in IN N
the DT N
prone NN N
position NN N
. . N

-DOCSTART- -X- O O

Small-diameter JJ i
hysteroscopy NN i
with IN i
Versapoint NNP i
versus NN N
resectoscopy NN i
with IN i
a DT i
unipolar JJ i
knife NN i
for IN N
the DT N
treatment NN N
of IN N
septate JJ p
uterus NN p
: : p
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
compare VB N
2 CD N
procedures NNS N
for IN N
metroplasty NN N
: : N
resectoscopy NN i
with IN i
monopolar JJ i
knife NNS i
versus IN N
small-diameter JJ i
hysteroscopy NN i
fitted VBN i
with IN i
a DT i
Versapoint NNP i
device NN i
. . i

DESIGN NNP N
Prospective NNP N
randomized VBN N
study NN N
( ( N
Canadian JJ N
Task NNP N
Force NNP N
classification NN N
I PRP N
) ) N
. . N

SETTING NN N
Endoscopic NNP p
gynecology NN p
units NNS p
at IN p
tertiary JJ p
care NN p
university NN p
hospitals NNS p
. . p

PATIENTS VB N
One CD p
hundred-sixty JJ p
patients NNS p
with IN p
septate JJ p
uterus NNS p
and CC p
a DT p
history NN p
of IN p
recurrent JJ p
abortion NN p
or CC p
primary JJ p
infertility NN p
undergoing VBG p
hysteroscopic NN p
metroplasty NN p
from IN p
2001 CD p
to TO p
2005 CD p
. . p

INTERVENTIONS NNP N
Hysteroscopic NNP i
resection NN N
of IN N
the DT N
uterine JJ N
septum NN N
performed VBN N
with IN N
either CC N
a DT N
26F CD i
resectoscope NN i
with IN i
unipolar JJ i
knife NN i
( ( N
80 CD N
women NNS N
, , N
group NN N
A NNP N
) ) N
or CC N
a DT N
5-mm JJ i
diameter NN i
hysteroscope NN i
with IN i
Versapoint NNP i
device NN i
( ( N
80 CD N
women NNS N
, , N
group NN N
B NNP N
) ) N
. . N

All DT N
patients NNS N
were VBD N
managed VBN N
expectantly RB N
, , N
with IN N
follow-up JJ N
lasting VBG N
1 CD N
year NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Operative NNP N
parameters NNS N
( ( o
operative JJ o
time NN o
, , o
fluid JJ o
absorption NN o
, , o
complications NNS o
, , o
need VBP o
for IN o
second JJ o
intervention NN o
) ) o
and CC N
reproductive JJ N
outcome NN N
parameters NNS N
( ( o
pregnancy NN o
, , o
abortion NN o
, , o
term NN o
and CC o
preterm JJ o
delivery NN o
, , o
modality NN o
of IN o
delivery NN o
, , o
cervical JJ o
cerclage NN o
) ) o
were VBD N
measured VBN N
. . N

Operative JJ o
time NN o
and CC o
fluid JJ o
absorption NN o
were VBD N
significantly RB N
greater JJR N
in IN N
group NN N
A NNP N
than IN N
in IN N
group NN N
B NNP N
( ( N
23.4 CD N
+/- JJ N
5.7 CD N
vs JJ N
16.9 CD N
+/- JJ N
4.7 CD N
minutes NNS N
and CC N
486.4 CD N
+/- JJ N
170.0 CD N
vs JJ N
222.1 CD N
+/- JJ N
104.9 CD N
mL NN N
, , N
respectively RB N
) ) N
. . N

The DT N
cumulative JJ o
complication NN o
rate NN o
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
B NNP N
than IN N
in IN N
group NN N
A NNP N
. . N

No DT N
difference NN N
in IN N
any DT N
of IN N
the DT N
reproductive JJ o
parameters NNS o
was VBD N
observed VBN N
between IN N
the DT N
2 CD N
groups NNS N
: : N
pregnancy NN o
and CC o
delivery NN o
rates NNS o
were VBD N
70 CD N
% NN N
and CC N
81.6 CD N
% NN N
in IN N
group NN N
A NNP N
vs RB N
76.9 CD N
% NN N
and CC N
84 CD N
% NN N
in IN N
group NN N
B NNP N
. . N

Nine NNP N
women NNS N
( ( N
18.4 CD N
% NN N
) ) N
from IN N
group NN N
B NNP N
and CC N
8 CD N
women NNS N
( ( N
16 CD N
% NN N
) ) N
from IN N
group NN N
B NNP N
experienced VBD N
spontaneous JJ o
abortions NNS o
. . o

Most JJS N
patients NNS N
( ( N
54/82 CD N
) ) N
delivered VBN N
by IN N
cesarean JJ o
section NN o
without IN o
differences NNS o
according VBG N
to TO N
the DT N
hysteroscopic NN N
technique NN N
used VBN N
for IN N
metroplasty NN N
( ( N
65 CD N
% NN N
in IN N
group NN N
A NNP N
vs RB N
67.7 CD N
% NN N
in IN N
group NN N
B NNP N
) ) N
or CC N
to TO N
the DT N
gestational JJ N
age NN N
( ( N
65.1 CD N
% NN N
of IN N
term NN N
and CC N
68.7 CD N
% NN N
of IN N
preterm JJ N
deliveries NNS N
) ) N
. . N

CONCLUSIONS NNP N
Small-diameter NNP N
hysteroscopy NN i
with IN N
bipolar JJ N
electrode NN N
for IN N
the DT N
incision NN N
of IN N
uterine JJ N
septum NN N
is VBZ N
as RB N
effective JJ N
as IN N
resectoscopy NN i
with IN N
unipolar JJ N
electrode NN N
regarding VBG N
reproductive JJ N
outcome NN N
and CC N
is VBZ N
associated VBN N
with IN N
shorter JJR N
operating NN o
time NN o
and CC N
lower JJR N
complication NN o
rate NN o
. . o

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
rectal JJ i
distension NN i
on IN N
bladder NN N
function NN N
in IN N
patients NNS p
with IN p
overactive JJ p
bladder NN p
. . p

AIMS NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
rectal JJ i
distension NN i
on IN N
bladder NN o
sensation NN o
volumes NNS o
and CC o
the DT o
number NN o
of IN o
detrusor NN o
contractions NNS o
in IN N
patients NNS p
with IN p
overactive JJ p
bladder NN p
( ( p
OAB NNP p
) ) p
symptoms NNS p
. . p

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
study NN N
included VBD N
patients NNS p
with IN p
OAB NNP p
symptoms NNS p
. . p

Multichannel NNP N
urodynamic JJ N
studies NNS N
were VBD N
completed VBN N
with IN i
and CC i
without IN i
rectal JJ i
balloon NN i
distension NN i
. . i

Bladder NNP N
sensation NN N
volumes NNS N
and CC N
detrusor NN N
contractions NNS N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Twenty-six JJ p
patients NNS p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

The DT p
mean JJ p
age NN p
was VBD p
67 CD p
years NNS p
and CC p
mean JJ p
BMI NNP p
was VBD p
28.3 CD p
kg/m NN p
( ( p
2 CD p
) ) p
. . p

Bladder NNP o
sensation NN o
volumes NNS o
were VBD o
lower JJR N
with IN i
rectal JJ i
distention NN i
as IN i
follows VBZ N
: : N
normal JJ N
desire NN N
to TO N
void VB N
( ( N
139 CD N
ml NN N
SD NNP N
, , N
?114 NNP N
vs. FW N
197 CD N
ml NN N
SD NNP N
?150 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
strong JJ N
desire NN N
to TO N
void VB N
( ( N
260 CD N
ml NN N
SD NNP N
?171 NNP N
vs. IN N
330 CD N
ml NNS N
SD NNP N
?172 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
maximum JJ N
cystometric JJ N
capacity NN N
( ( N
326 CD N
ml NN N
SD NNP N
?183 NNP N
vs. IN N
403 CD N
ml NNS N
SD NNP N
?180 NNP N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
number NN o
of IN o
detrusor JJ o
contractions NNS o
or CC o
the DT o
bladder NN o
volume NN o
at IN o
which WDT o
the DT o
first JJ o
detrusor NN o
contraction NN o
had VBD o
occurred VBN o
with IN o
and CC o
without IN N
rectal JJ N
distension NN N
. . N

CONCLUSION NNP i
Rectal NNP i
distention NN i
in IN i
patients NNS p
with IN p
OAB NNP p
symptoms NNS N
significantly RB N
lowered VBD o
bladder JJR o
sensation NN o
volumes NNS o
( ( o
normal JJ o
desire NN N
, , N
strong JJ N
desire NN N
, , N
and CC N
maximal JJ N
capacity NN N
) ) N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
effect NN N
of IN N
gonadotropin-releasing NN i
hormone NN i
analog NN i
( ( i
Diphereline NNP i
) ) i
and CC N
Cabergoline NNP i
( ( i
Dostinex NNP i
) ) i
treatment NN N
on IN N
uterine JJ p
myoma NN p
regression NN p
. . p

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
cabergoline NN i
( ( i
Dostinex NNP i
, , i
a DT i
dopamine JJ i
agonist NN i
) ) i
on IN N
the DT N
myoma NN N
growth NN N
compared VBN N
to TO N
Diphereline NNP i
( ( i
a DT i
gonadotropin-releasing NN i
hormone NN i
agonist NN i
) ) i
. . i

METHODS NNP N
This DT p
study NN p
took VBD p
place NN p
in IN p
the DT p
Department NNP p
of IN p
Obstetrics NNP p
and CC p
Gynecology NNP p
of IN p
Tabriz NNP p
University NNP p
of IN p
Medical NNP p
Sciences NNPS p
, , p
Tabriz NNP p
, , p
Iran NNP p
from IN p
July NNP p
2004 CD p
to TO p
December NNP p
2005 CD p
. . p

Fifty NNP p
women NNS p
with IN p
uterine JJ p
myoma NN p
, , p
who WP p
met VBD p
the DT p
criteria NNS p
of IN p
the DT p
study NN p
thoroughly RB p
, , N
were VBD N
randomly RB N
allocated VBN N
into IN N
2 CD N
equal JJ N
groups NNS N
to TO N
take VB N
either DT N
Diphereline NNP i
or CC N
Cabergoline NNP i
. . i

The DT N
first JJ N
Group NNP N
took VBD N
3.75 CD N
mg NN N
of IN N
Diphereline NNP i
4 CD N
times NNS N
every DT N
28 CD N
days NNS N
and CC N
the DT N
second JJ N
group NN N
took VBD N
0.5 CD N
mg NN N
of IN N
Cabergoline NNP i
once RB N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
. . N

RESULTS VB N
The DT N
Cabergoline NNP i
was VBD N
well RB o
tolerated VBN o
and CC N
fewer JJR o
adverse JJ o
effects NNS o
were VBD N
noted VBN N
. . N

The DT N
tumor NN o
regressed VBD o
significantly RB o
and CC N
volume NN o
reduction NN o
rate NN o
of IN o
individual JJ o
tumor NN o
nodule NN o
varied VBD N
from IN N
46-53 CD N
% NN N
. . N

The DT N
gonadotropin NN i
releasing VBG i
hormone JJ i
agonist NN i
group NN N
all DT N
responded VBD N
to TO N
the DT N
treatment NN N
, , N
and CC N
volume NN o
reduction NN o
rate NN o
of IN N
the DT N
individual JJ N
tumor NN N
nodule NN N
varied VBD N
from IN N
21-97 CD N
% NN N
. . N

The DT N
extent NN N
of IN N
tumor NN o
shrinkage NN o
was VBD N
positively RB N
correlated VBN N
to TO N
the DT N
number NN o
of IN o
nodules NNS o
( ( N
p=0.881 NN N
, , N
p NN N
< VBD N
0.005 CD N
and CC N
0.701 CD N
, , N
p NN N
< NNP N
0.005 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
light NN N
of IN N
therapeutic JJ N
efficacy NN N
and CC N
few JJ N
adverse JJ N
effects NNS N
, , N
the DT N
dopamine NN i
agonists NNS i
may MD N
hold VB N
promise NN N
as IN N
novel JJ N
treatment NN N
modalities NNS N
for IN N
leiomyoma NN N
. . N

Further JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
optimal JJ N
strategy NN N
for IN N
the DT N
treatment NN N
of IN N
leiomyoma NN N
through IN N
these DT N
agents NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
study NN N
comparing VBG N
glucagon NN i
and CC i
hyoscine VB i
N-butyl NNP i
bromide NN i
before IN p
endoscopic NN i
retrograde NN i
cholangiopancreatography NN i
. . i

BACKGROUND NNP N
This DT N
study NN N
tried VBD N
to TO N
resolve VB N
whether IN N
glucagon NN i
is VBZ N
a DT N
better JJR N
premedication NN N
for IN N
endoscopic NN o
retrograde NN o
cholangiopancreatography NN o
( ( o
ERCP NNP o
) ) o
. . o

METHODS NNP N
We PRP N
first RB N
measured VBD N
the DT N
basal NN o
blood NN o
sugar NN o
and CC o
amylase NN o
levels NNS o
. . o

Then RB N
an DT N
endoscope NN N
was VBD N
placed VBN N
in IN N
the DT N
duodenum NN N
without IN N
premedication NN N
, , N
and CC N
basal NN o
pulse NN o
and CC o
duodenal JJ o
peristaltic JJ o
rates NNS o
were VBD N
measured VBN N
. . N

ERCP NNP N
began VBD N
after IN N
studied JJ p
subjects NNS p
were VBD N
randomly RB N
premedicated VBN N
with IN N
either DT N
1 CD i
mg NN i
glucagon NN i
( ( p
n JJ p
= NNP p
38 CD p
) ) p
or CC p
40 CD i
mg JJ i
hyoscine NN i
N-butyl NNP i
bromide NN i
( ( p
n JJ p
= NNP p
36 CD p
) ) p
intravenously RB N
. . N

Ten CD N
minutes NNS N
later RB N
the DT N
variables NNS o
were VBD N
measured VBN N
again RB N
. . N

RESULTS NNP N
Glucagon NNP i
elicited VBD N
hyperglycemia NN o
whereas NNS N
hyoscine VBP i
N-butyl NNP i
bromide NN i
manifested VBD N
an DT N
anticholinergic JJ o
effect NN o
. . o

No DT N
difference NN N
was VBD N
found VBN N
between IN N
these DT N
two CD N
groups NNS N
with IN N
regard NN N
to TO N
the DT N
necessary JJ o
interval NN o
for IN o
ERCP NNP o
( ( N
20.6 CD N
+/- JJ N
14.1 CD N
min NN N
versus NN N
21.4 CD N
+/- JJ N
14.7 CD N
min NN N
; : N
NS NNP N
) ) N
or CC N
the DT N
success NN o
rate NN o
for IN o
cholangiopancreatography NN o
( ( N
92.1 CD N
% NN N
versus IN N
91.7 CD N
% NN N
; : N
NS NNP N
) ) N
. . N

Neither CC N
hyperamylasemia JJ o
nor CC o
pancreatitis NN o
was VBD N
preventable JJ N
when WRB N
glucagon NN i
was VBD N
used VBN N
. . N

CONCLUSIONS VB N
The DT N
two CD N
premedications NNS N
appear VBP N
equally RB N
effective JJ N
in IN N
the DT N
performance NN o
of IN o
ERCP NNP o
. . o

-DOCSTART- -X- O O

Recombinant JJ i
human JJ i
erythropoietin NN i
. . i

-DOCSTART- -X- O O

A DT N
randomized JJ N
double-blind NN N
study NN N
of IN N
atomoxetine JJ i
versus NN N
placebo NN i
for IN N
attention-deficit/hyperactivity NN p
disorder NN p
symptoms NNS p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

OBJECTIVE CC N
The DT N
efficacy NN N
of IN N
atomoxetine NN i
as IN N
treatment NN N
of IN N
symptoms NNS N
of IN N
attention-deficit/hyperactivity NN p
disorder NN p
( ( p
ADHD NNP p
) ) p
in IN p
patients NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
has VBZ N
not RB N
been VBN N
established VBN N
. . N

METHOD NNP N
In IN N
this DT N
study NN N
, , N
97 CD p
patients NNS p
aged VBD p
6 CD p
to TO p
17 CD p
years NNS p
with IN p
ADHD NNP p
and CC p
ASD NNP p
were VBD p
randomly RB p
assigned VBN p
to TO N
double-blind VB N
treatment NN N
with IN N
1.2 CD N
mg/kg/day JJ N
atomoxetine NN i
or CC i
placebo NN i
for IN N
8 CD N
weeks NNS N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
ADHD NNP o
Rating NNP o
Scale NNP o
( ( o
ADHD-RS NNP o
) ) o
score NN o
; : o
secondary JJ o
endpoints NNS o
were VBD o
the DT o
Clinical JJ o
Global NNP o
Impression NNP o
of IN o
ADHD-Improvement NNP o
( ( o
CGI-I NNP o
) ) o
and CC o
the DT o
Conners NNP o
Teacher NNP o
Rating VBG o
Scale-Revised JJ o
: : o
Short JJ o
Form NNP o
( ( o
CTRS-R JJ o
: : o
S NN o
) ) o
score NN o
. . o

RESULTS NNP N
Baseline NNP N
mean JJ N
ADHD-RS NNP o
scores NNS N
for IN N
atomoxetine JJ i
versus NN N
placebo NN i
were VBD N
40.7 CD N
and CC N
38.6 CD N
; : N
after IN N
8 CD N
weeks NNS N
, , N
mixed-effect JJ N
model NN N
repeated-measure NN N
means NNS N
were VBD N
31.6 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
29.2-33.9 JJ N
) ) N
and CC N
38.3 CD N
( ( N
36.0-40.6 CD N
) ) N
, , N
respectively RB N
, , N
with IN N
a DT N
difference NN N
in IN N
least JJS N
square JJ N
means NNS N
of IN N
-6.7 NNP N
( ( N
-10.0 UH N
to TO N
-3.4 VB N
; : N
p CC N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
CTRS-R JJ o
: : o
S NNP o
Hyperactivity NNP N
subscore NN N
also RB N
improved VBN N
significantly RB N
for IN N
atomoxetine NN i
compared VBN N
with IN N
placebo NN i
, , N
but CC N
not RB N
the DT N
other JJ N
CTRS-R JJ o
: : o
S JJ o
subscores NNS N
. . N

However RB N
, , N
there EX N
were VBD N
not RB N
significantly RB N
more RBR N
patients NNS N
on IN N
atomoxetine NN i
( ( N
20.9 CD N
% NN N
) ) N
who WP N
improved VBD N
much RB N
, , N
or CC N
very RB N
much JJ N
according VBG N
to TO N
the DT N
CGI-I NNP N
, , N
than IN N
on IN N
placebo NN i
( ( N
8.7 CD N
% NN N
; : N
p CC N
= VB N
0.14 CD N
) ) N
. . N

Adverse JJ N
events NNS N
( ( N
mostly RB N
nausea RB o
, , N
decrease NN N
in IN N
appetite NN o
, , o
fatigue NN o
, , o
and CC o
early JJ o
morning NN o
awakening VBG o
) ) o
were VBD N
reported VBN N
in IN N
81.3 CD N
% NN N
of IN N
atomoxetine JJ i
patients NNS N
and CC N
65.3 CD N
% NN N
of IN N
placebo NN i
patients NNS N
( ( N
p JJ N
> NNP N
.1 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ o
events NNS o
. . o

CONCLUSIONS NNP N
Atomoxetine NNP i
moderately RB N
improved VBD N
ADHD NNP N
symptoms NNS N
in IN N
patients NNS N
with IN N
ASD NNP N
and CC N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

Adverse JJ N
events NNS N
in IN N
this DT N
study NN N
were VBD N
similar JJ N
to TO N
those DT N
in IN N
other JJ N
studies NNS N
with IN N
ADHD NNP p
patients NNS p
without IN p
ASD NNP p
. . p

Clinical JJ N
trial NN N
registration NN N
information-A JJ N
Randomized NNP N
Double-Blind NNP N
Study NNP N
of IN N
Atomoxetine NNP i
Versus NNP N
Placebo NNP i
for IN N
ADHD NNP N
Symptoms NNP N
in IN N
Children NNP p
with IN p
ASD NNP p
; : p
www.clinicaltrials.gov NN N
; : N
NCT00380692 NNP N
. . N

-DOCSTART- -X- O O

Growth NNP N
hormone NN N
effects NNS N
on IN N
cortical JJ o
bone NN o
dimensions NNS o
in IN N
young JJ p
adults NNS p
with IN p
childhood-onset JJ p
growth NN p
hormone NN p
deficiency NN p
. . p

UNLABELLED JJ N
Growth NNP i
hormone NN i
( ( i
GH NNP i
) ) i
treatment NN i
in IN N
young JJ p
adults NNS p
with IN p
childhood-onset JJ p
GH NNP p
deficiency NN p
has VBZ N
beneficial JJ N
effects NNS N
on IN N
bone NN o
mass NN o
. . o

The DT N
present JJ N
study NN N
shows VBZ N
that IN N
cortical JJ N
bone NN N
dimensions NNS N
also RB N
benefit VBP N
from IN N
GH NNP N
treatment NN N
, , N
with IN N
endosteal JJ N
expansion NN N
and CC N
increased VBD N
cortical JJ N
thickness NN N
leading VBG N
to TO N
improved VBN o
bone NN o
strength NN o
. . o

INTRODUCTION NNP N
In IN p
young JJ p
adults NNS p
with IN p
childhood-onset JJ p
growth NN p
hormone NN p
deficiency NN p
( ( p
CO NNP p
GHD NNP p
) ) p
, , N
GH NNP N
treatment NN N
after IN N
final JJ N
height NN N
is VBZ N
reached VBN N
has VBZ N
been VBN N
shown VBN N
to TO N
have VB N
beneficial JJ N
effects NNS N
on IN N
spine NN N
and CC N
hip NN N
bone NN N
mineral JJ N
density NN N
. . N

The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
influence NN N
of IN N
GH NNP o
on IN o
cortical JJ o
bone NN o
dimensions NNS o
. . o

METHODS NNP N
Patients NNPS p
( ( p
n JJ p
= VBZ p
160 CD p
; : p
mean JJ p
age NN p
, , p
21.2 CD p
years NNS p
; : p
63 CD p
% NN p
males NNS p
) ) p
with IN p
CO NNP p
GHD NNP p
were VBD N
randomised VBN N
2:1 CD N
to TO i
GH NNP i
or CC i
no DT i
treatment NN i
for IN i
24 CD N
months NNS o
. . o

Cortical NNP o
bone NN o
dimensions NNS o
were VBD o
evaluated VBN o
by IN o
digital JJ o
x-ray JJ o
radiogrammetry NN o
of IN o
the DT o
metacarpal JJ N
bones NNS N
every DT N
6 CD N
months NNS N
. . N

RESULTS NNP N
After IN N
24 CD N
months NNS o
, , o
cortical JJ o
thickness NN o
was VBD o
increased VBN o
compared VBN N
with IN N
the DT N
controls NNS N
( ( N
6.43 CD N
% NN N
, , N
CI NNP N
3.34 CD N
to TO N
9.61 CD N
% NN N
; : N
p CC N
= VB N
0.0001 CD o
) ) o
and CC o
metacarpal JJ o
index NN o
( ( o
MCI NNP o
) ) o
( ( N
6.14 CD N
% NN N
, , N
CI NNP N
3.95 CD N
to TO N
8.38 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
, , N
while IN o
the DT o
endosteal JJ o
diameter NN o
decreased VBN o
( ( o
-4.64 CD o
% NN N
, , N
CI NNP N
-7.15 NNP N
to TO N
-2.05 VB N
; : N
p VB N
< $ N
0.001 CD N
) ) o
. . o

Total JJ o
bone NN o
width NN o
did VBD o
not RB N
change VB N
significantly RB N
( ( N
0.68 CD N
% NN N
, , N
CI NNP N
-1.17 NNP N
to TO N
2.57 CD N
% NN N
; : N
not RB N
significant JJ N
( ( N
NS NNP N
) ) N
) ) N
. . N

A DT N
gender NN N
effect NN N
was VBD N
seen VBN o
on IN o
bone NN o
width NN o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
endosteal JJ o
diameter NN o
( ( o
p JJ o
< NNP N
0.01 CD N
) ) N
and CC N
cortical JJ o
thickness NN o
( ( o
p JJ o
< NNP o
0.01 CD N
) ) N
, , N
but CC N
not RB N
with IN N
MCI NNP N
( ( N
NS NNP N
) ) N
. . N

CONCLUSIONS NNP N
Cortical NNP N
bone NN N
reacts VBZ N
promptly RB N
to TO N
reinstitution NN N
of IN N
GH NNP N
beyond IN N
the DT N
attainment NN N
of IN N
final JJ N
height NN N
by IN N
increasing VBG N
the DT o
cortical JJ o
thickness NN o
through IN o
endosteal JJ N
bone NN N
growth NN N
. . N

This DT N
leads VBZ o
to TO o
a DT o
higher JJR o
peak NN o
bone NN o
mass NN o
and CC o
may MD N
reduce VB o
the DT o
risk NN o
of IN o
cortical JJ o
bone NN o
fragility NN o
later RB N
in IN N
life NN N
. . N

-DOCSTART- -X- O O

Sinemet NNP i
CR NNP i
in IN p
Parkinson NNP p
's POS p
disease NN p
. . p

Sinemet NNP i
CR NNP i
, , N
a DT N
controlled JJ N
release NN N
carbidopa/levodopa NN i
preparation NN i
, , N
was VBD N
compared VBN N
to TO N
conventional JJ N
carbidopa/levodopa NN i
in IN N
a DT N
double JJ N
blind NN N
, , N
placebo-controlled JJ i
trial NN N
. . N

Comparable JJ o
clinical JJ o
benefits NNS o
and CC o
adverse JJ o
effects NNS o
were VBD N
noted VBN N
with IN N
the DT N
two CD N
medications NNS N
. . N

However RB N
significantly RB N
less RBR N
frequent JJ N
dosing NN N
was VBD N
necessary JJ N
with IN N
Sinemet NNP N
CR NNP N
. . N

-DOCSTART- -X- O O

Pharmacokinetic JJ o
and CC o
safety NN o
assessments NNS o
of IN N
concurrent JJ p
administration NN p
of IN p
risperidone NN i
and CC p
donepezil NN i
. . i

Treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
sometimes RB N
uses VBZ N
combinations NNS N
of IN N
drugs NNS N
because IN N
dementia NN N
is VBZ N
frequently RB N
associated VBN N
with IN N
behavioral JJ N
symptoms NNS N
. . N

Risperidone NN i
and CC N
donepezil NN i
are VBP N
both DT N
metabolized VBN N
through IN N
cytochrome NN N
P450 NNP N
2D6 CD N
and CC N
3A4 CD N
, , N
raising VBG N
the DT N
possibility NN N
of IN N
drug NN N
interactions NNS N
with IN N
combination NN N
therapy NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
significant JJ N
drug NN o
interactions NNS o
occur VBP N
with IN N
concomitant JJ N
administration NN N
of IN N
donepezil NN i
and CC N
risperidone NN i
. . i

In IN N
an DT N
open-label JJ N
, , N
three-way JJ N
crossover NN N
study NN N
, , N
24 CD p
healthy JJ p
men NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
0.5 CD N
mg NN N
of IN N
risperidone NN i
twice JJ N
daily RB N
, , N
5 CD N
mg NN N
of IN N
donepezil NN i
once RB N
daily JJ N
, , N
or CC N
both DT i
drugs NNS i
for IN N
14 CD N
consecutive JJ N
days NNS N
, , N
followed VBN N
by IN N
a DT N
21-day JJ N
washout NN N
period NN N
. . N

The DT N
treatment NN N
ratios NNS o
of IN o
AUC NNP o
and CC N
associated VBD N
90 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
for IN N
risperidone NN N
active JJ N
moiety NN N
, , N
defined VBD N
as IN N
risperidone NN N
plus CC N
9-hydroxyrisperidone CD N
( ( N
ratio VB N
= RB N
110.2 CD N
% NN N
; : N
90 CD N
% NN N
CI NNP N
= NNP N
103.7-117.2 JJ N
) ) N
, , N
and CC N
for IN N
donepezil NN N
( ( N
ratio JJ N
= RB N
97.1 CD N
% NN N
; : N
90 CD N
% NN N
CI NNP N
= NNP N
90.0-103.6 CD N
) ) N
were VBD N
within IN N
the DT N
80 CD N
% NN N
to TO N
125 CD N
% NN N
of IN N
bioequivalence NN N
range NN N
. . N

The DT N
treatment NN o
ratios NNS o
of IN o
Cmax NNP o
and CC o
associated VBD o
90 CD o
% NN o
CIs NNP o
for IN N
risperidone NN N
active JJ N
moiety NN N
( ( N
ratio JJ N
= RB N
114.6 CD N
% NN N
; : N
90 CD N
% NN N
CI NNP N
= NNP N
107.0-122.8 JJ N
) ) N
and CC N
for IN N
donepezil NN N
( ( N
ratio JJ N
= RB N
96.1 CD N
% NN N
; : N
90 CD N
% NN N
CI NNP N
= NNP N
90.0-102.6 CD N
) ) N
were VBD N
also RB N
within IN N
the DT N
bioequivalence NN N
range NN N
. . N

Therefore NNP N
, , N
no DT N
significant JJ N
pharmacokinetic JJ o
differences NNS N
occurred VBD N
in IN N
either CC N
risperidone VB N
active JJ N
moiety NN N
or CC N
donepezil NN N
when WRB N
given VBN N
alone RB N
or CC N
in IN N
combination NN N
. . N

Adverse JJ o
events NNS o
( ( o
predominantly RB o
headache NN o
, , o
nervousness NN o
, , o
and CC o
somnolence NN o
) ) o
were VBD N
minor JJ N
and CC N
comparable JJ N
for IN N
all DT N
treatment NN N
groups NNS N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
no DT N
clinically RB o
meaningful JJ o
drug NN o
interactions NNS o
occurred VBD N
between IN N
risperidone NN N
1 CD N
mg JJ N
daily JJ N
and CC N
donepezil JJ N
5 CD N
mg JJ N
daily RB N
at IN N
steady JJ N
state NN N
, , N
and CC N
therefore RB N
no DT N
dosage NN N
adjustment NN N
is VBZ N
required VBN N
when WRB N
both DT N
drugs NNS N
are VBP N
combined VBN N
with IN N
the DT N
dosage NN N
regimen NNS N
studied VBN N
. . N

Additional JJ N
investigations NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
potential NN N
for IN N
interactions NNS N
in IN N
elderly JJ N
patients NNS N
with IN N
dementia NNS N
who WP N
may MD N
eliminate VB N
risperidone NN N
and CC N
donepezil VB N
more JJR N
slowly RB N
and CC N
thus RB N
be VB N
more RBR N
vulnerable JJ N
to TO N
clinical JJ N
drug NN N
interactions NNS N
than IN N
the DT N
young JJ p
healthy JJ p
subjects NNS p
examined VBN N
in IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O

Prolonged JJ N
effects NNS N
of IN N
a DT N
home-based JJ i
intervention NN i
in IN N
patients NNS p
with IN p
chronic JJ p
illness NN p
. . p

BACKGROUND NNP N
Data NNP N
on IN N
the DT N
long-term JJ N
benefits NNS N
of IN N
nonspecific JJ N
disease NN N
management NN N
programs NNS N
are VBP N
limited JJ N
. . N

We PRP N
performed VBD N
a DT N
long-term JJ N
follow-up NN N
of IN N
a DT N
previously RB N
published VBN N
randomized VBN N
trial NN N
. . N

METHODS NNP N
We PRP N
compared VBN N
all-cause JJ o
mortality NN o
and CC o
recurrent JJ o
hospitalization NN o
during IN N
median JJ N
follow-up NN N
of IN N
7.5 CD N
years NNS N
in IN N
a DT N
heterogeneous JJ p
cohort NN p
of IN p
patients NNS p
with IN p
chronic JJ p
illness NN p
initially RB p
exposed VBD p
to TO p
a DT p
multidisciplinary JJ i
, , i
home-based JJ i
intervention NN i
( ( i
HBI NNP i
) ) i
( ( p
n JJ p
= NNP p
260 CD p
) ) p
or CC p
to TO p
usual JJ i
postdischarge NN i
care NN i
( ( p
n JJ p
= NNP p
268 CD p
) ) p
. . p

RESULTS NNP N
During IN N
follow-up JJ N
, , N
HBI NNP i
had VBD N
no DT N
impact NN N
on IN N
all-cause JJ o
mortality NN o
( ( N
relative JJ N
risk NN N
, , N
1.04 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.80-1.35 JJ N
) ) N
or CC N
event-free JJ o
survival NN o
from IN o
death NN o
or CC o
unplanned JJ o
hospitalization NN o
( ( N
relative JJ N
risk NN N
, , N
1.03 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.86-1.24 JJ N
) ) N
. . N

Initial JJ N
analysis NN N
suggested VBD N
that IN N
HBI NNP i
had VBD N
only RB N
a DT N
marginal JJ N
impact NN N
in IN N
reducing VBG N
unplanned JJ o
hospitalization NN o
, , N
with IN N
677 CD N
readmissions NNS N
vs VBP N
824 CD N
for IN N
the DT N
usual JJ N
care NN N
group NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
rate NN N
, , N
0.72 CD N
+/- JJ N
0.96 CD N
vs JJ N
0.84 CD N
+/- JJ N
1.20 CD N
readmissions/patient NN N
per IN N
year NN N
; : N
P NNP N
= NNP N
.08 NNP N
) ) N
. . N

When WRB N
accounting VBG N
for IN N
increased JJ N
hospital NN o
activity NN o
in IN N
HBI NNP N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
during IN N
follow-up NN N
for IN N
2 CD N
years NNS N
, , N
post NN N
hoc NN N
analyses VBZ N
showed VBD N
that IN N
HBI NNP i
reduced VBD N
readmissions NNS o
by IN N
14 CD N
% NN N
within IN N
2 CD N
years NNS N
in IN N
patients NNS N
without IN N
this DT N
condition NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
rate NN N
, , N
0.54 CD N
+/- JJ N
0.72 CD N
vs JJ N
0.63 CD N
+/- JJ N
0.88 CD N
readmission/patient NN N
per IN N
year NN N
; : N
P NNP N
= NNP N
.04 NNP N
) ) N
and CC N
by IN N
21 CD N
% NN N
in IN N
all DT N
surviving VBG N
patients NNS N
within IN N
3 CD N
to TO N
8 CD N
years NNS N
( ( N
mean JJ N
+/- JJ N
SD NNP N
rate NN N
, , N
0.64 CD N
+/- JJ N
1.26 CD N
vs JJ N
0.81 CD N
+/- JJ N
1.61 CD N
readmissions/patient NN N
per IN N
year NN N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Overall JJ N
, , N
recurrent JJ o
hospital NN o
costs NNS o
were VBD N
significantly RB N
lower JJR N
( ( N
14 CD N
% NN N
) ) N
in IN N
the DT N
HBI NNP i
group NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
823 CD N
dollars NNS N
+/- JJ N
1642 CD N
dollars NNS N
vs JJ N
960 CD N
dollars NNS N
+/- JJ N
1376 CD N
dollars NNS N
per IN N
patient NN N
per IN N
year NN N
; : N
P NNP N
= NNP N
.045 NNP N
) ) N
. . N

CONCLUSION VB N
This DT N
unique JJ N
study NN N
suggests VBZ N
that IN N
a DT N
nonspecific JJ N
HBI NNP i
provides VBZ N
long-term JJ N
cost NN N
benefits NNS N
in IN N
a DT N
range NN N
of IN N
chronic JJ N
illnesses NNS N
, , N
except IN N
for IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
. . N

-DOCSTART- -X- O O

Matching VBG N
doses NNS N
of IN N
distraction NN N
with IN N
child NN p
risk NN p
for IN p
distress NN p
during IN N
a DT N
medical JJ N
procedure NN N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Parents NNPS N
often RB N
want VBP N
to TO N
provide VB N
support NN N
to TO N
their PRP$ N
children NNS N
during IN N
medical JJ N
procedures NNS N
, , N
but CC N
not RB N
all DT N
parents NNS N
are VBP N
effective JJ N
in IN N
providing VBG N
distraction NN N
after IN N
brief JJ N
training NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
three CD N
doses NNS i
of IN i
distraction NN i
intervention NN i
for IN N
children NNS p
at IN p
high JJ p
and CC p
medium NN p
risk NN p
for IN p
procedure-related JJ p
distress NN p
. . p

METHODS NNP N
Children NNP p
undergoing VBG p
scheduled VBN p
intravenous JJ p
insertions NNS p
for IN p
diagnostic JJ p
or CC p
treatment NN p
purposes NNS p
and CC p
their PRP$ p
parents NNS p
participated VBN p
. . p

A DT N
computerized JJ N
application NN N
, , N
Children NNP N
, , N
Parents NNP N
and CC N
Distraction NNP N
, , N
was VBD N
used VBN N
to TO N
predict VB N
distress NN N
risk NN N
. . N

Doses NNS i
of IN i
intervention NN i
were VBD N
basic JJ N
( ( i
parents NNS i
trained VBN i
on IN i
providing VBG i
distraction NN i
) ) i
, , N
enhanced VBN N
( ( i
basic JJ i
training NN i
plus CC i
tailored JJ i
instructions NNS i
, , i
environmental JJ i
modifications NNS i
, , i
and CC i
support NN i
and CC i
guidance NN i
from IN i
the DT i
research NN i
assistant NN i
) ) i
, , N
and CC N
professional JJ N
( ( i
a DT i
trained VBN i
research NN i
assistant NN i
provided VBD i
distraction NN i
) ) i
. . N

Outcome JJ N
measures NNS N
were VBD N
Observational NNP o
Scale NNP o
of IN o
Behavioral NNP o
Distress-Revised JJ o
for IN o
behavioral JJ o
distress NN o
, , o
Oucher NNP o
for IN o
self-reported JJ o
pain NN o
, , o
parent JJ o
report NN o
of IN o
child JJ o
distress NN o
, , o
and CC o
salivary JJ o
cortisol NN o
for IN o
physiological JJ o
distress NN o
. . o

RESULTS VB N
A DT p
total NN p
of IN p
574 CD p
children NNS p
, , p
ages VBZ p
4-10 JJ p
, , p
and CC p
their PRP$ p
parents NNS p
participated VBN p
. . p

The DT N
Children NNP N
, , N
Parents NNP N
and CC N
Distraction NNP N
predicted VBD N
that IN N
the DT N
risk NN o
for IN o
distress NN o
was VBD N
high JJ N
for IN N
156 CD N
children NNS N
, , N
medium NN N
for IN N
372 CD N
, , N
and CC N
low JJ N
for IN N
46 CD N
. . N

Children NNP N
predicted VBD N
to TO N
have VB N
higher JJR N
risk NN N
for IN N
distress NN N
displayed VBD N
more RBR N
behavioral JJ o
distress NN o
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
. . N

Children NNP N
in IN N
the DT N
medium-risk JJ N
group NN N
who WP N
had VBD N
the DT N
professional JJ N
intervention NN N
displayed VBD N
significantly RB N
less RBR N
behavioral JJ o
distress NN o
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Children NNP N
in IN N
the DT N
high-risk JJ N
group NN N
tended VBD N
to TO N
have VB N
less JJR N
behavioral JJ N
distress NN N
when WRB N
receiving VBG N
the DT N
professional JJ N
intervention NN N
( ( N
p JJ N
= NNP N
.07 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
group NN N
differences NNS N
for IN N
self-report NN o
of IN o
pain NN o
, , o
parent JJ o
report NN o
of IN o
distress NN o
, , o
or CC o
cortisol NN o
levels NNS o
. . o

DISCUSSION NNP N
Some DT N
parents NNS N
may MD N
need VB N
additional JJ N
training NN N
in IN N
providing VBG N
distraction NN N
to TO N
their PRP$ N
children NNS N
during IN N
procedures NNS N
, , N
and CC N
some DT N
children NNS p
at IN p
medium NN p
and CC p
high JJ p
risk NN p
for IN p
distress NN p
may MD N
need VB N
professional JJ N
support NN N
. . N

Parents NNS N
should MD N
be VB N
asked VBN N
about IN N
their PRP$ N
preferences NNS N
in IN N
acting VBG N
as IN N
the DT N
distraction NN N
coach NN N
and CC N
, , N
if IN N
willing JJ N
, , N
be VB N
provided VBN N
as IN N
much JJ N
training NN N
and CC N
support NN N
as IN N
possible JJ N
in IN N
the DT N
clinical JJ N
situation NN N
. . N

-DOCSTART- -X- O O

Intensive JJ i
induction NN i
chemotherapy NN i
for IN N
small JJ N
cell NN N
anaplastic JJ N
carcinoma NN N
of IN N
the DT N
lung NN N
. . N

The DT N
role NN N
of IN N
intensive JJ i
induction NN i
chemotherapy NN i
in IN N
small JJ N
cell NN N
cancer NN N
of IN N
the DT N
lung NN N
remains VBZ N
unclear JJ N
. . N

Twenty-eight JJ p
newly RB p
diagnosed VBN p
patients NNS p
with IN p
small JJ p
cell NN p
lung NN p
cancer NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
high-dose JJ i
or CC i
standard-dose JJ i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
and CC i
semustine NN i
in IN N
a DT N
trial NN N
where WRB N
the DT N
dose NN N
of IN N
induction NN N
chemotherapy NN N
was VBD N
the DT N
sole JJ N
treatment NN N
variable JJ N
. . N

Complete JJ o
responses NNS o
( ( o
CR NNP o
) ) o
were VBD N
achieved VBN N
in IN N
57 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
high-dose JJ N
therapy NN N
as IN N
compared VBN N
to TO N
21 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
standard-dose JJ N
therapy NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
higher JJR N
rate NN N
of IN N
severe JJ o
toxicity NN o
in IN N
the DT N
high-dose JJ N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
overall JJ o
median JJ o
survival NN o
was VBD N
not RB N
improved VBN N
( ( N
36 CD N
weeks NNS N
for IN N
the DT N
high-dose JJ N
group NN N
vs VBD N
43 CD N
weeks NNS N
for IN N
the DT N
standard-dose JJ N
group NN N
) ) N
; : N
however RB N
, , N
the DT N
median JJ o
survival NN o
in IN N
patients NNS N
achieving VBG N
CR NNP N
was VBD N
prolonged VBN N
( ( N
92 CD N
weeks NNS N
for IN N
the DT N
high-dose JJ N
group NN N
vs VBD N
50 CD N
weeks NNS N
for IN N
the DT N
standard-dose JJ N
group NN N
) ) N
. . N

These DT N
effects NNS N
were VBD N
most RBS N
pronounced VBN N
in IN N
patients NNS p
with IN p
extensive JJ p
disease NN p
; : p
a DT N
CR NNP o
after IN N
induction NN N
was VBD N
achieved VBN N
in IN N
five CD N
of IN N
nine CD N
patients NNS N
treated VBN N
with IN N
high JJ N
doses NNS N
but CC N
not RB N
in IN N
any DT N
of IN N
those DT N
treated VBN N
with IN N
standard JJ N
doses NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

A NNP N
small JJ N
group NN N
of IN N
patients NNS N
appear VBP N
to TO N
benefit VB N
by IN N
achieving VBG N
a DT N
long-term JJ N
remission NN N
with IN N
intensive JJ N
induction NN N
chemotherapy NN N
, , N
but CC N
this DT N
effect NN N
may MD N
be VB N
offset VBN N
by IN N
increased JJ N
morbidity NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
hypnotherapy NN i
with IN N
systematic JJ i
relaxation NN i
in IN N
the DT N
treatment NN N
of IN N
cigarette NN N
habituation NN N
. . N

Because IN N
of IN N
the DT N
methodological JJ N
deficiencies NNS N
in IN N
this DT N
area NN N
of IN N
research NN N
, , N
it PRP N
is VBZ N
impossible JJ N
to TO N
make VB N
any DT N
valid JJ N
conclusions NNS N
about IN N
whether IN N
hypnosis NN N
itself PRP N
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
cigarette NN N
habituation NN N
. . N

In IN N
this DT N
study NN N
, , N
87 CD p
volunteers NNS p
who WP p
wanted VBD p
to TO p
quit VB p
cigarette NN p
smoking NN p
were VBD N
assigned VBN N
randomly RB N
to TO N
the DT N
experimental JJ i
hypnosis NN i
group NN i
, , i
the DT i
comparison NN i
relaxation NN i
group NN i
, , i
and CC i
the DT i
waiting VBG i
list NN i
control NN i
group NN i
. . i

Ss NNP N
in IN N
the DT N
treatment NN N
groups NNS N
had VBD N
four CD N
weekly JJ N
50-minute NN N
, , N
individual JJ N
sessions NNS N
. . N

Four CD N
months NNS N
after IN N
the DT N
completion NN N
of IN N
treatment NN N
, , N
Ss NNP N
were VBD N
administered VBN N
a DT N
questionnaire NN o
and CC o
a DT o
hypnotic JJ o
susceptibility NN o
scale NN o
. . o

Ss NNP N
in IN N
the DT N
hypnosis NN i
group NN N
who WP N
were VBD N
in IN N
the DT N
upper JJ N
two-thirds NNS N
of IN N
the DT N
group NN N
in IN N
terms NNS N
of IN N
hypnotic JJ N
susceptibility NN N
reduced VBD N
their PRP$ N
cigarette NN o
consumption NN o
substantially RB N
more JJR N
than IN N
Ss NNP N
in IN N
the DT N
relaxation NN N
group NN N
who WP N
were VBD N
in IN N
the DT N
upper JJ N
two-thirds NNS N
of IN N
the DT N
group NN N
in IN N
terms NNS N
of IN N
hypnotic JJ o
susceptibility NN o
. . o

Therefore RB N
, , N
the DT N
hypnotic JJ N
state NN N
appears VBZ N
to TO N
be VB N
therapeutic JJ N
for IN N
individuals NNS p
who WP N
can MD N
enter VB N
medium NN N
or CC N
deep JJ N
states NNS N
of IN N
hypnosis NN N
. . N

-DOCSTART- -X- O O

Acupuncture NNP i
versus NN i
venlafaxine NN i
for IN N
the DT N
management NN N
of IN N
vasomotor NN o
symptoms NNS o
in IN N
patients NNS p
with IN p
hormone JJ p
receptor-positive JJ p
breast NN p
cancer NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
Vasomotor NNP o
symptoms NNS o
are VBP N
common JJ N
adverse JJ N
effects NNS N
of IN N
antiestrogen NN i
hormone NN i
treatment NN i
in IN N
conventional JJ N
breast NN N
cancer NN N
care NN N
. . N

Hormone CD i
replacement NN i
therapy NN i
is VBZ N
contraindicated VBN N
in IN N
patients NNS p
with IN p
breast JJ p
cancer NN p
. . p

Venlafaxine NNP i
( ( i
Effexor NNP i
) ) i
, , N
the DT N
therapy NN N
of IN N
choice NN N
for IN N
these DT N
symptoms NNS N
, , N
has VBZ N
numerous JJ N
adverse JJ N
effects NNS N
. . N

Recent JJ N
studies NNS N
suggest VBP N
acupuncture NN i
may MD N
be VB N
effective JJ N
in IN N
reducing VBG N
vasomotor NN o
symptoms NNS o
in IN N
menopausal JJ p
women NNS p
. . p

This DT N
randomized VBD N
controlled JJ N
trial NN N
tested VBD N
whether IN N
acupuncture NN i
reduces NNS N
vasomotor NN o
symptoms NNS o
and CC N
produces VBZ N
fewer JJR N
adverse JJ N
effects NNS N
than IN N
venlafaxine NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Fifty NNP p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
12 CD N
weeks NNS N
of IN N
acupuncture NN i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
or CC N
venlafaxine NN i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
treatment NN N
. . N

Health NNP o
outcomes NNS o
were VBD N
measured VBN N
for IN N
up RB N
to TO N
1 CD N
year NN N
post-treatment NN N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
exhibited VBD N
significant JJ N
decreases NNS N
in IN N
hot JJ o
flashes NNS o
, , o
depressive NN o
symptoms NNS o
, , o
and CC o
other JJ o
quality-of-life NN o
symptoms NNS o
, , N
including VBG N
significant JJ o
improvements NNS o
in IN o
mental JJ o
health NN o
from IN N
pre- JJ N
to TO N
post-treatment JJ N
. . N

These DT N
changes NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
indicating VBG N
that IN N
acupuncture NN i
was VBD N
as RB N
effective JJ N
as IN N
venlafaxine NN i
. . i

By IN N
2 CD N
weeks NNS N
post-treatment JJ N
, , N
the DT N
venlafaxine NN i
group NN N
experienced VBD N
significant JJ N
increases NNS N
in IN N
hot JJ o
flashes NNS o
, , N
whereas NNS N
hot JJ N
flashes NNS N
in IN N
the DT N
acupuncture NN i
group NN N
remained VBD N
at IN N
low JJ N
levels NNS N
. . N

The DT N
venlafaxine NN i
group NN N
experienced VBD N
18 CD N
incidences NNS N
of IN N
adverse JJ N
effects NNS N
( ( N
eg NN N
, , N
nausea NN o
, , o
dry JJ o
mouth NN o
, , o
dizziness NN o
, , o
anxiety NN o
) ) o
, , N
whereas IN N
the DT N
acupuncture NN i
group NN N
experienced VBD N
no DT N
negative JJ N
adverse JJ N
effects NNS N
. . N

Acupuncture NN i
had VBD N
the DT N
additional JJ N
benefit NN N
of IN N
increased JJ N
sex NN o
drive NN o
in IN N
some DT N
women NNS N
, , N
and CC N
most JJS N
reported VBD N
an DT N
improvement NN N
in IN N
their PRP$ N
energy NN o
, , o
clarity NN o
of IN o
thought NN o
, , o
and CC o
sense NN o
of IN o
well-being NN o
. . o

CONCLUSION NNP N
Acupuncture NNP i
appears VBZ N
to TO N
be VB N
equivalent JJ N
to TO N
drug NN N
therapy NN N
in IN N
these DT N
patients NNS N
. . N

It PRP N
is VBZ N
a DT N
safe JJ N
, , N
effective JJ N
and CC N
durable JJ N
treatment NN N
for IN N
vasomotor NN N
symptoms NNS N
secondary JJ N
to TO N
long-term JJ N
antiestrogen NN i
hormone NN i
use NN N
in IN N
patients NNS p
with IN p
breast JJ p
cancer NN p
. . p

-DOCSTART- -X- O O

Effects NNS N
of IN N
four CD N
traditional JJ i
Chinese NNP i
medicines NNS i
on IN N
the DT N
pharmacokinetics NNS p
of IN p
simvastatin NN i
. . i

1 CD i
. . i

Concomitant JJ i
traditional JJ i
Chinese JJ i
medicines NNS i
( ( i
TCMs NNP i
) ) i
could MD i
be VB N
the DT N
reason NN N
for IN N
relative JJ N
poor JJ N
efficacy NN N
of IN N
statins NNS p
in IN p
dyslipidemia NN p
patients NNS p
in IN p
China NNP p
. . p

2 CD N
. . N

An DT N
open-label JJ N
, , N
randomized VBN N
, , N
5-period JJ N
crossover NN N
study NN p
in IN p
healthy JJ p
Chinese NNP p
was VBD p
designed VBN N
to TO N
evaluate VB N
the DT N
pharmacokinetic JJ o
interaction NN o
and CC o
tolerability NN o
of IN o
multiple JJ N
doses NNS i
of IN i
certain JJ i
TCMs NNP i
on IN i
a DT N
single JJ N
dose NN N
of IN i
simvastatin NN i
. . i

In IN i
each DT N
period NN N
, , N
subjects VBZ N
received VBN N
one CD N
of IN N
five CD N
treatments NNS N
. . N

In IN N
Treatment NNP N
A NNP N
, , N
subjects VBZ N
received VBN N
a DT N
single JJ N
dose NN N
of IN N
20 CD N
mg NN i
simvastatin NN i
. . i

In IN i
Treatment NNP i
B NNP N
, , N
C NNP N
, , N
D NNP N
or CC N
E NNP N
, , N
subjects VBZ N
received VBN i
Tong NNP i
Xin NNP i
Luo NNP i
, , i
Nao NNP i
Xin NNP i
Tong NNP i
, , i
Guan NNP i
Mai NNP i
Ning NNP i
or CC i
Yin NNP i
Xing NNP i
Ye NNP i
for IN i
7 CD N
days NNS N
and CC N
a DT N
single JJ N
dose NN N
of IN N
20 CD N
mg NNS N
simvastatin NN i
on IN i
Day NNP i
7 CD N
. . N

The DT N
washout NN N
period NN N
was VBD N
7 CD N
days NNS N
. . N

3 CD N
. . N

The DT N
97.5 CD N
% NN N
confidence NN N
interval NN N
of IN o
the DT o
AUC0-48 NNP o
h NN o
geometric JJ o
mean JJ o
ratio NN o
of IN i
simvastatin NN i
acid NN i
and CC i
simvastatin NN i
for IN i
simvastatin NN i
given VBN N
after IN N
multiple JJ N
oral JJ N
doses NNS N
of IN N
one CD N
of IN N
the DT i
TCMs NNP i
versus NN i
simvastatin NN i
given VBN i
alone RB i
were VBD N
fully RB N
contained VBN N
within IN N
the DT N
prespecified JJ N
bounds NNS N
of IN N
( ( N
0.50 CD N
, , N
2.00 CD N
) ) N
. . o

4 CD o
. . o

Exposures NNS o
to TO o
simvastatin VB o
acid NN o
and CC o
simvastatin NN o
following VBG o
a DT N
single JJ N
dose NN N
of IN N
simvastatin NN i
alone RB i
were VBD N
similar JJ N
to TO N
those DT N
following JJ N
coadministration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
simvastatin NN i
with IN i
multiple JJ N
doses NNS N
of IN N
each DT N
of IN N
the DT N
TCM NNP i
preparations NNS i
tested VBD i
. . i

Simvastatin NNP i
and CC i
these DT i
TCMs NNP i
were VBD o
well RB o
tolerated VBN o
. . o

-DOCSTART- -X- O O

Impact NN o
of IN N
early JJ i
mobilization NN i
on IN N
glycemic JJ o
control NN o
and CC N
ICU-acquired NNP o
weakness NN o
in IN N
critically RB p
ill JJ p
patients NNS p
who WP p
are VBP p
mechanically RB p
ventilated VBN p
. . p

BACKGROUND NNP N
ICU-acquired JJ o
weakness NN o
( ( o
ICU-AW NNP o
) ) o
has VBZ N
immediate JJ N
and CC N
long-term JJ N
consequences NNS N
for IN N
critically RB p
ill JJ p
patients NNS p
. . p

Strategies NNS N
for IN N
the DT N
prevention NN N
of IN N
weakness NN N
include VBP N
modification NN N
of IN N
known VBN N
risk NN N
factors NNS N
, , N
such JJ N
as IN N
hyperglycemia NN N
and CC N
immobility NN N
. . N

Intensive JJ i
insulin NN i
therapy NN i
( ( N
IIT NNP N
) ) N
has VBZ N
been VBN N
proposed VBN N
to TO N
prevent VB N
critical JJ N
illness NN N
polyneuropathy NN N
. . N

However RB N
, , N
the DT N
effect NN N
of IN N
insulin NN N
and CC N
early JJ N
mobilization NN N
on IN N
clinically RB N
apparent JJ N
weakness NN N
is VBZ N
not RB N
well RB N
known VBN N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
secondary JJ N
analysis NN N
of IN N
all DT p
patients NNS p
with IN p
mechanical JJ p
ventilation NN p
( ( p
N NNP p
= NNP p
104 CD p
) ) p
previously RB p
enrolled VBN p
in IN p
a DT p
randomized NN p
controlled VBN p
trial NN p
of IN p
early JJ p
occupational JJ p
and CC p
physical JJ p
therapy NN p
vs JJ p
conventional JJ p
therapy NN p
, , p
which WDT p
evaluated VBD p
the DT p
end NN p
point NN p
of IN p
functional JJ o
independence NN o
. . o

Every NNP p
patient NN p
had VBD p
IIT NNP p
and CC p
blinded VBD p
muscle NN p
strength NN p
testing VBG p
on IN p
hospital NN p
discharge NN p
to TO N
determine VB N
the DT N
incidence NN N
of IN N
clinically RB o
apparent JJ o
weakness NN o
. . o

The DT N
effects NNS o
of IN o
insulin NN o
dose NN o
and CC N
early JJ o
mobilization NN o
on IN N
the DT N
incidence NN o
of IN o
ICU-AW NNP o
were VBD N
assessed VBN N
. . N

RESULTS VB N
On IN N
logistic JJ N
regression NN N
analyses NNS N
, , N
early JJ N
mobilization NN N
and CC N
increasing VBG N
insulin NN N
dose NN N
prevented VBD N
the DT N
incidence NN o
of IN o
ICU-AW NNP o
( ( N
OR NNP N
, , N
0.18 CD N
, , N
P NNP N
= NNP N
.001 NNP N
; : N
OR NNP N
, , N
0.001 CD N
, , N
P NNP N
= NNP N
.011 NNP N
; : N
respectively RB N
) ) N
independent JJ N
of IN N
known VBN N
risk NN N
factors NNS N
for IN N
weakness NN N
. . N

Early JJ N
mobilization NN N
also RB N
significantly RB N
reduced VBN N
insulin NN o
requirements NNS o
to TO N
achieve VB o
similar JJ o
glycemic JJ o
goals NNS o
as IN N
compared VBN N
with IN N
control NN N
patients NNS N
( ( N
0.07 CD N
units/kg/d RB N
vs JJ N
0.2 CD N
units/kg/d NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
duel NN N
effect NN N
of IN N
early JJ N
mobilization NN N
in IN N
reducing VBG N
clinically RB o
relevant JJ o
ICU-AW NNP o
and CC N
promoting VBG o
euglycemia JJ o
suggests VBZ N
its PRP$ N
potential JJ N
usefulness NN N
as IN N
an DT N
alternative NN N
to TO N
IIT NNP N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
risedronate NN i
on IN N
vertebral JJ o
fractures NNS o
in IN N
women NNS p
with IN p
established VBN p
postmenopausal NN p
osteoporosis NN p
. . p

Vertebral JJ N
Efficacy NN N
with IN N
Risedronate NNP N
Therapy NNP N
( ( N
VERT NNP N
) ) N
Study NNP N
Group NNP N
. . N

The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
, , N
double-masked JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN o
risedronate NN o
in IN N
the DT N
prevention NN N
of IN N
vertebral JJ N
fractures NNS N
in IN N
postmenopausal JJ p
women NNS p
with IN p
established VBN p
osteoporosis NN p
. . p

The DT N
study NN N
was VBD N
conducted VBN N
at IN N
80 CD p
study NN p
centers NNS p
in IN p
Europe NNP p
and CC p
Australia NNP p
. . p

Postmenopausal NNP p
women NNS p
( ( p
n JJ p
= NN p
1226 CD p
) ) p
with IN p
two CD p
or CC p
more JJR p
prevalent JJ p
vertebral JJ o
fractures NNS o
received VBD i
risedronate JJ i
2.5 CD i
or CC i
5 CD i
mg/day NN i
or CC i
placebo NN i
; : i
all DT i
subjects NNS i
also RB i
received VBD i
elemental JJ i
calcium NN i
1000 CD i
mg/day NN i
, , i
and CC i
up RB i
to TO i
500 CD i
IU/day NNP i
vitamin FW i
D NNP i
if IN i
baseline NN i
levels NNS i
were VBD i
low JJ i
. . i

The DT N
study NN N
duration NN N
was VBD N
3 CD N
years NNS N
; : N
however RB N
, , N
the DT i
2.5 CD i
mg NN i
group NN i
was VBD i
discontinued VBN i
by IN i
protocol NN i
amendment NN i
after IN i
2 CD i
years NNS i
. . i

Lateral JJ N
spinal JJ N
radiographs NN N
were VBD N
taken VBN N
annually RB N
for IN N
assessment NN N
of IN N
vertebral JJ o
fractures NNS o
, , o
and CC o
bone RB o
mineral JJ o
density NN o
was VBD N
measured VBN N
by IN N
dual-energy JJ N
X-ray JJ N
absorptiometry NN N
at IN N
6-month JJ N
intervals NNS N
. . N

Risedronate VB N
5 CD N
mg NN N
reduced VBD N
the DT N
risk NN N
of IN N
new JJ o
vertebral JJ o
fractures NNS o
by IN N
49 CD N
% NN N
over IN N
3 CD N
years NNS N
compared VBN N
with IN N
control NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
significant JJ N
reduction NN N
of IN N
61 CD N
% NN N
was VBD N
seen VBN N
within IN N
the DT N
first JJ N
year NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
fracture NN o
reduction NN o
with IN N
risedronate NN N
2.5 CD N
mg NN N
was VBD N
similar JJ N
to TO N
that DT N
in IN N
the DT N
5 CD N
mg NN N
group NN N
over IN N
2 CD N
years NNS N
. . N

The DT N
risk NN N
of IN N
nonvertebral JJ o
fractures NNS o
was VBD N
reduced VBN N
by IN N
33 CD N
% NN N
compared VBN N
with IN N
control NN N
over IN N
3 CD N
years NNS N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

Risedronate NNP N
significantly RB N
increased VBD N
bone JJ o
mineral JJ o
density NN o
at IN N
the DT N
spine NN N
and CC N
hip NN N
within IN N
6 CD N
months NNS N
. . N

The DT N
adverse-event JJ N
profile NN N
of IN N
risedronate NN N
, , N
including VBG N
gastrointestinal JJ o
adverse JJ o
events NNS o
, , N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
control NN N
. . N

Risedronate NNP N
5 CD N
mg NN N
provides VBZ N
effective JJ N
and CC N
well-tolerated JJ N
therapy NN N
for IN N
severe JJ p
postmenopausal NN p
osteoporosis NN p
, , N
reducing VBG N
the DT N
incidence NN N
of IN N
vertebral JJ N
fractures NNS N
and CC N
improving VBG N
bone NN N
density NN N
in IN N
women NNS p
with IN p
established VBN p
disease NN p
. . p

-DOCSTART- -X- O O

Disopyramide NNP i
in IN N
the DT N
treatment NN N
and CC N
prevention NN N
of IN N
arrhythmias NN o
following VBG p
myocardial JJ p
infarction NN p
. . p

-DOCSTART- -X- O O

Cyproheptadine NN i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ p
disorder NN p
: : p
a DT N
double-blind JJ N
placebo-controlled JJ i
trial NN N
. . N

OBJECTIVE CC N
Autism NNP N
is VBZ N
a DT N
childhood-onset JJ N
disorder NN N
of IN N
unknown JJ N
, , N
possibly RB N
of IN N
multiple JJ N
aetiologies NNS N
. . N

The DT N
core NN N
symptoms NNS N
of IN N
autism NN N
are VBP N
abnormalities NNS N
in IN N
social JJ N
interaction NN N
, , N
communication NN N
and CC N
behaviour NN N
. . N

The DT N
involvement NN N
of IN N
neurotransmitters NNS N
such JJ N
as IN N
5-HT JJ N
has VBZ N
been VBN N
suggested VBN N
in IN N
neuropsychiatric JJ N
disorders NNS N
and CC N
particularly RB N
in IN N
autistic JJ N
disorder NN N
. . N

Increased VBN N
platelet NN N
5-HT JJ N
levels NNS N
were VBD N
found VBN N
in IN N
40 CD N
% NN N
of IN N
the DT N
autistic JJ N
population NN N
, , N
suggesting VBG N
that IN N
hyperserotonaemia NN N
may MD N
be VB N
a DT N
pathologic JJ N
factor NN N
in IN N
infantile JJ p
autism NN p
. . p

Therefore RB N
, , N
it PRP N
is VBZ N
of IN N
interest NN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
cyproheptadine NN i
, , i
a DT i
5-HT2 JJ i
antagonist NN i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ N
disorder NN N
. . N

In IN N
this DT N
8-week JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
, , N
we PRP N
assessed VBD N
the DT N
effects NNS N
of IN N
cyproheptadine NN i
plus CC i
haloperidol NN i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ N
disorder NN N
. . N

METHODS NNP N
Children NNP p
between IN p
the DT p
ages NNS p
3 CD p
and CC p
11 CD p
years NNS p
( ( p
inclusive JJ p
) ) p
with IN p
a DT p
DSM NNP p
IV NNP p
clinical JJ p
diagnosis NN p
of IN p
autism NN p
and CC p
who WP p
were VBD p
outpatients NNS p
from IN p
a DT p
specialty NN p
clinic NN p
for IN p
children NNS p
at IN p
Roozbeh NNP p
Psychiatric NNP p
Teaching NNP p
Hospital NNP p
were VBD p
recruited VBN p
. . p

The DT N
children NNS p
presented VBN p
with IN p
a DT p
chief JJ p
complaint NN p
of IN p
severely RB p
disruptive JJ p
symptoms NNS p
related VBN p
to TO p
autistic JJ p
disorder NN p
. . p

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
cyproheptadine VB i
+ NNP i
haloperidol NN i
( ( N
Group NNP N
A NNP N
) ) N
or CC N
haloperidol JJ i
+ JJ i
placebo NN i
( ( N
Group NNP N
B NNP N
) ) N
for IN N
an DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
haloperidol NN i
and CC i
cyproheptadine NN i
was VBD N
titrated VBN N
up RB N
to TO N
0.05 CD N
and CC N
0.2 CD N
mg/kg/day NN N
respectively RB N
. . N

Patients NNS N
were VBD N
assessed VBN N
by IN N
a DT N
third-year JJ N
resident NN N
of IN N
psychiatry NN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
and CC N
8 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
. . N

The DT N
primary JJ N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP o
Behaviour NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
and CC N
the DT N
secondary JJ N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
relating VBG o
to TO o
people NNS o
and CC o
verbal JJ o
communication NN o
) ) o
. . N

Side JJ N
effects NNS N
and CC N
extrapyramidal NN N
symptoms NNS N
were VBD N
systematically RB N
recorded VBN N
throughout IN N
the DT N
study NN N
and CC N
were VBD N
assessed VBN N
using VBG N
a DT N
checklist NN N
and CC N
the DT N
Extrapyramidal NNP N
Symptoms NNP N
Rating NNP N
Scale NNP N
, , N
administered VBN N
by IN N
a DT N
resident NN N
of IN N
psychiatry NN N
during IN N
weeks NNS N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
6 CD N
and CC N
8 CD N
. . N

RESULTS VB N
The DT N
ABC-C NNP o
and CC o
the DT o
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
scores VBZ o
improved VBN N
with IN N
cyproheptadine NN i
. . i

The DT N
behaviour NN o
of IN N
the DT N
two CD N
treatments NNS N
was VBD N
not RB N
homogeneous JJ N
across IN N
time NN N
( ( N
groups-by-time JJ N
interaction NN N
, , N
Greenhouse-Geisser NNP N
correction NN N
; : N
F NNP N
= VBZ N
7.30 CD N
, , N
d.f NN N
. . N

= CC N
1.68 CD N
, , N
P NNP N
= NNP N
0.002 CD N
; : N
F NNP N
= VBZ N
8.21 CD N
, , N
d.f NN N
. . N

= CC N
1.19 CD N
, , N
P NNP N
= VBZ N
0.004 CD N
respectively RB N
) ) N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
treatments NNS N
was VBD N
significant JJ N
as IN N
indicated VBN N
by IN N
the DT N
effect NN N
of IN N
group NN N
, , N
and CC N
the DT N
between-subjects NNS N
factor NN N
( ( N
F NNP N
= NNP N
4.17 CD N
, , N
d.f NN N
. . N

= CC N
1 CD N
, , N
P NNP N
= NNP N
0.048 CD N
; : N
F NNP N
= VBZ N
4.29 CD N
, , N
d.f NN N
. . N

= CC N
1 CD N
, , N
P NNP N
= VBZ N
0.045 CD N
respectively RB N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
extrapyramidal NN o
symptoms NNS o
( ( N
P NNP N
= NNP N
0.23 CD N
) ) N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
frequency NN o
of IN o
side NN o
effects NNS o
was VBD N
not RB N
significant JJ N
. . N

CONCLUSION VB N
The DT N
results NNS N
suggest VBP N
that IN N
the DT N
combination NN N
of IN N
cyproheptadine NN i
with IN i
a DT i
conventional JJ i
antipsychotic JJ i
may MD N
be VB N
superior JJ N
to TO N
conventional JJ i
antipsychotic JJ i
alone NN i
for IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

However RB N
the DT N
results NNS N
need VBP N
confirmation NN N
by IN N
a DT N
larger JJR N
randomized VBN N
controlled VBN N
trial NN N
. . N

-DOCSTART- -X- O O

Influence NN N
of IN N
SNPs NNP N
in IN N
nutrient-sensitive JJ o
candidate NN N
genes NNS o
and CC N
gene-diet JJ o
interactions NNS o
on IN o
blood NN o
lipids NNS o
: : o
the DT N
DiOGenes NNP p
study NN p
. . p

Blood NNP o
lipid JJ o
response NN N
to TO N
a DT N
given VBN i
dietary JJ i
intervention NN i
could MD N
be VB N
determined VBN N
by IN N
the DT N
effect NN N
of IN N
diet NN N
, , N
gene NN N
variants NNS N
or CC N
gene-diet JJ N
interactions NNS N
. . N

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
variants NNS N
in IN N
presumed JJ N
nutrient-sensitive JJ o
genes NNS o
involved VBN o
in IN o
lipid JJ o
metabolism NN o
modified VBD N
lipid JJ o
profile NN o
after IN N
weight JJ N
loss NN N
and CC N
in IN N
response NN N
to TO N
a DT N
given VBN i
diet JJ i
, , N
among IN N
overweight JJ p
European JJ p
adults NNS p
participating VBG p
in IN p
the DT p
Diet NNP p
Obesity NNP p
and CC p
Genes NNP p
study NN p
. . p

By IN N
multiple JJ N
linear JJ N
regressions NNS N
, , N
240 CD N
SNPs NNP N
in IN N
twenty-four JJ p
candidate NN p
genes NNS p
were VBD p
investigated VBN p
for IN N
SNP NNP N
main JJ N
and CC N
SNP-diet JJ N
interaction NN N
effects NNS N
on IN N
total JJ o
cholesterol NN o
, , o
LDL-cholesterol NNP o
, , o
HDL-cholesterol NNP o
and CC o
TAG NNP o
after IN N
an DT i
8-week JJ i
low-energy JJ i
diet NN i
( ( N
only RB N
main JJ N
effect NN N
) ) N
, , N
and CC N
a DT N
6-month JJ i
ad NN i
libitum NN i
weight VBD i
maintenance NN i
diet NN i
, , N
with IN N
different JJ N
contents NNS N
of IN N
dietary JJ i
protein NN i
or CC N
glycaemic JJ i
index NN i
. . i

After IN N
adjusting VBG N
for IN N
multiple JJ N
testing NN N
, , N
a DT N
SNP-dietary JJ o
protein NN o
interaction NN o
effect NN o
on IN o
TAG NNP o
was VBD N
identified VBN N
for IN N
lipin NN N
1 CD N
( ( N
LPIN1 NNP N
) ) N
rs4315495 NN N
, , N
with IN N
a DT N
decrease NN o
in IN o
TAG NNP o
of IN N
20.26 CD N
mmol/l NNS N
per IN N
A-allele/protein NNP N
unit NN N
( ( N
95 CD N
% NN N
CI NNP N
20.38 CD N
, , N
20.14 CD N
, , N
P=0.000043 NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
we PRP N
investigated VBD N
SNP-diet JJ o
interactions NNS o
for IN o
blood NN o
lipid JJ o
profiles NNS o
for IN N
240 CD N
SNPs NNP N
in IN N
twenty-four JJ N
candidate NN N
genes NNS N
, , N
selected VBN N
for IN N
their PRP$ N
involvement NN N
in IN N
lipid JJ N
metabolism NN N
pathways NNS N
, , N
and CC N
identified VBD N
one CD N
significant JJ N
interaction NN o
between IN o
LPIN1 NNP o
rs4315495 NN o
and CC o
dietary JJ o
protein NN o
for IN o
TAG NNP o
concentration NN o
. . o

-DOCSTART- -X- O O

Clonidine JJ o
clearance NN o
matures NNS N
rapidly RB N
during IN N
the DT N
early JJ N
postnatal JJ N
period NN N
: : N
a DT N
population NN N
pharmacokinetic JJ N
analysis NN N
in IN N
newborns NNS p
with IN p
neonatal JJ p
abstinence NN p
syndrome NN p
. . p

The DT N
population NN N
pharmacokinetic NN o
( ( o
PK NNP o
) ) o
profile NN o
of IN N
oral JJ i
clonidine NN i
was VBD N
characterized VBN N
in IN N
newborns NNS p
with IN p
neonatal JJ p
abstinence NN p
syndrome NN p
, , N
and CC N
significant JJ N
covariates NNS N
affecting VBG N
its PRP$ N
PK NNP N
parameters NNS N
were VBD N
identified VBN N
. . N

Plasma NNP o
clonidine JJ o
concentration NN o
data NNS o
were VBD N
obtained VBN N
from IN N
a DT N
clinical JJ N
trial NN N
in IN N
which WDT N
36 CD p
newborns NNS p
, , p
aged VBD p
1 CD p
to TO p
25 CD p
days NNS p
( ( p
postnatal JJ p
age NN p
, , p
PNA NNP p
) ) p
and CC p
weighing VBG p
2.1 CD p
to TO p
3.9 CD p
kg NNS p
, , N
were VBD N
enrolled VBN N
to TO N
take VB N
multiple JJ N
oral JJ N
doses NNS N
of IN N
clonidine NN N
. . N

The DT N
population NN N
PK NNP o
model NN o
of IN o
clonidine NN o
was VBD N
developed VBN N
by IN N
NONMEM NNP N
, , N
and CC N
significant JJ N
covariates NNS N
were VBD N
identified VBN N
, , N
followed VBN N
by IN N
nonparametric JJ N
bootstraps NNS N
( ( N
2000 CD N
replicates NNS N
) ) N
and CC N
simulation NN N
experiments NNS N
. . N

A DT N
1-compartment JJ N
open JJ N
linear NN N
PK NNP N
model NN N
was VBD N
chosen VBN N
to TO N
describe VB N
plasma JJ o
concentrations NNS o
of IN o
clonidine NN o
, , N
and CC N
body NN o
weight NN o
and CC o
PNA NNP o
were VBD N
significant JJ N
covariates NNS N
for IN N
apparent JJ o
clearance NN o
( ( N
CL/F NNP N
) ) N
as IN N
follows VBZ N
: : N
CL/F NNP N
( ( N
L/h NNP N
) ) N
= VBD N
15.2 CD N
? . N
[ VB N
body NN N
weight NN N
( ( N
kg NN N
) ) N
/70 NN N
] NNP N
( ( N
0.75 CD N
) ) N
? . N
[ JJ N
PNA NNP N
( ( N
day NN N
) ) N
( ( N
0.441 CD N
) ) N
/ NN N
( ( N
4.06 CD N
( ( N
0.441 CD N
) ) N
+ NN N
PNA NNP N
( ( N
day NN N
) ) N
( ( N
0.441 CD N
) ) N
) ) N
] NN N
. . N

Furthermore NNP o
, , o
CL/F NNP o
of IN o
clonidine NN o
increased VBN o
rapidly RB N
with IN N
PNA NNP N
during IN N
the DT N
first JJ N
month NN N
of IN N
life NN N
after IN N
body NN N
weight NN N
was VBD N
adjusted VBN N
. . N

Any DT N
optimal JJ N
dosage NN N
regimen NNS N
for IN i
clonidine NN i
in IN i
term NN N
neonates NNS N
should MD N
be VB N
based VBN N
on IN N
infant NN N
's POS N
age NN N
and CC N
body NN N
weight NN N
, , N
and CC N
1.5 CD N
?g/kg NN N
every DT N
4 CD N
hours NNS N
is VBZ N
proposed VBN N
starting VBG N
the DT N
second JJ N
week NN N
of IN N
life NN N
based VBN N
on IN N
the DT N
simulation NN N
results NNS N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
comparing VBG N
induction NN i
chemotherapy NN i
versus NN N
induction NN i
chemotherapy NN i
followed VBN i
by IN i
maintenance NN i
chemotherapy NN i
in IN N
small-cell JJ p
lung NN p
cancer NN p
. . p

European JJ N
Lung NNP N
Cancer NNP N
Working NNP N
Party NNP N
. . N

PURPOSE NNP N
AND CC N
METHODS NNP N
The DT N
European NNP N
Lung NNP N
Cancer NNP N
Working NNP N
Party NNP N
( ( N
ELCWP NNP N
) ) N
performed VBD N
a DT N
randomized JJ N
trial NN N
with IN N
the DT N
primary JJ N
end NN N
point NN N
to TO N
determine VB N
if IN N
maintenance NN N
chemotherapy NN N
with IN N
12 CD N
courses NNS N
of IN N
etoposide NN i
( ( N
120 CD N
mg/m2 NN N
on IN N
days NNS N
1 CD N
and CC N
3 CD N
) ) N
and CC N
vindesine NN i
( ( N
3 CD N
mg/m2 NN N
on IN N
day NN N
3 CD N
) ) N
could MD N
improve VB N
progression-free JJ o
survival NN o
in IN N
small-cell JJ p
lung NN p
cancer NN p
( ( p
SCLC NNP p
) ) p
patients NNS p
who WP p
responded VBD p
to TO p
six CD p
courses NNS p
of IN p
induction NN i
chemotherapy NN i
with IN i
ifosfamide NN i
, , i
etoposide RB i
, , i
and CC i
an DT i
anthracycline NN i
( ( i
doxorubicin NN i
or CC i
epirubicin NN i
) ) i
. . i

RESULTS NNP N
Among IN p
235 CD p
eligible JJ p
patients NNS p
initially RB p
registered VBD p
, , p
91 CD p
were VBD p
randomized VBN p
to TO p
receive VB p
maintenance NN p
therapy NN p
, , p
including VBG p
seven CD p
patients NNS p
who WP p
were VBD p
no RB p
longer RBR p
responding VBG p
. . p

Among IN N
84 CD N
randomized JJ N
responders NNS N
, , N
progression-free JJ o
survival NN o
was VBD N
significantly RB N
improved VBN N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
by IN N
maintenance NN N
therapy NN N
, , N
with IN N
median JJ N
durations NNS N
( ( N
maintenance NN N
v IN N
follow-up JJ N
) ) N
of IN N
25 CD N
versus NNS N
12 CD N
weeks NNS N
after IN N
the DT N
second JJ N
randomization NN N
, , N
but CC N
survival NN o
was VBD N
not RB N
significantly RB N
increased VBN N
( ( N
P NNP N
= NNP N
.10 NNP N
) ) N
, , N
with IN N
median JJ N
durations NNS N
of IN N
48 CD N
and CC N
38 CD N
weeks NNS N
. . N

However RB N
, , N
in IN N
a DT N
multi-variate JJ N
analysis NN N
that WDT N
took VBD N
into IN N
account NN o
disease NN o
extent NN o
, , o
maintenance NN o
therapy NN o
, , o
Karnofsky NNP o
performance NN o
status NN o
( ( o
PS NNP o
) ) o
, , o
and CC o
absolute JJ o
dose-intensity NN o
( ( o
ADI NNP o
) ) o
of IN o
anthracycline NN o
given VBN N
during IN N
induction NN N
, , N
limited JJ o
disease NN o
( ( o
LD NNP o
) ) o
and CC o
maintenance NN o
were VBD N
found VBN N
to TO N
be VB N
independent JJ N
positive JJ N
predictors NNS N
of IN N
survival NN o
. . o

CONCLUSION NNP N
We PRP N
conclude VBP N
that DT N
maintenance NN N
chemotherapy NN N
in IN N
responding VBG N
patients NNS N
is VBZ N
beneficial JJ N
in IN N
SCLC NNP N
. . N

-DOCSTART- -X- O O

Amoxicillin/metronidazole/omeprazole/clarithromycin NN N
: : N
a DT N
new JJ N
, , N
short JJ N
quadruple NN N
therapy NN p
for IN p
Helicobacter NNP o
pylori JJ o
eradication NN o
. . o

BACKGROUND NNP N
Triple NNP N
therapy NN N
regimens VBZ N
including VBG N
two CD N
antibiotics NNS N
plus CC N
acid JJ N
suppression NN N
have VBP N
become VBN N
the DT N
new JJ N
standard NN N
therapy NN N
in IN N
Helicobacter NNP N
pylori FW N
eradication NN N
because IN N
of IN N
success NN N
rates NNS N
of IN N
about RB N
90 CD N
% NN N
. . N

However RB N
, , N
these DT N
regimens NNS N
are VBP N
still RB N
costly JJ N
, , N
duration NN N
is VBZ N
about IN N
one CD N
week NN N
or CC N
less JJR N
, , N
and CC N
side-effects NNS N
are VBP N
not RB N
negligible JJ N
. . N

We PRP N
therefore RB N
evaluated VBD N
a DT N
new JJ N
quadruple NN N
therapy NN N
, , N
because IN N
theoretically RB N
a DT N
shorter JJR N
duration NN N
of IN N
treatment NN N
may MD N
result VB N
in IN N
reduced JJ N
costs NNS N
, , N
fewer JJR N
side-effects NNS N
, , N
and CC N
possibly RB N
in IN N
a DT N
lower JJR N
potential NN N
for IN N
antibiotic JJ N
resistances NNS N
. . N

METHODS NNP N
Controlled NNP N
, , N
prospective JJ N
pilot NN N
study NN N
including VBG N
H. NNP p
pylori-positive JJ p
patients NNS p
with IN p
gastric JJ p
or CC p
duodenal JJ p
ulcers NNS p
or CC p
erosive JJ p
gastritis NN p
, , p
treated VBN p
after IN p
failure NN p
of IN p
dual JJ p
therapy NN p
( ( p
proton-pump-inhibitors NNS p
or CC p
ranitidine VB p
plus CC p
amoxicillin VB p
) ) p
or CC p
for IN p
the DT p
first JJ p
time NN p
. . p

They PRP N
were VBD N
assigned VBN N
to TO N
a DT N
one CD i
week NN i
triple JJ i
standard NN i
therapy NN i
, , i
consisting VBG i
of IN i
metronidazole JJ i
400 CD i
mg JJ i
bid NN i
+ NNP i
omeprazole VBZ i
20 CD i
mg NN i
bid NN i
+ NNP i
clarithromycin VBZ i
250 CD i
mg NN i
bid NN i
, , i
or CC i
a DT i
newly RB i
created VBN i
quadruple-regimen NNS i
, , i
which WDT i
adds VBZ i
amoxicillin NN i
( ( i
1 CD i
g RB i
bid NN i
) ) i
to TO i
the DT i
above JJ i
triple NN i
regimen NNS i
. . i

Each DT N
of IN N
the DT N
four CD N
drugs NNS N
was VBD N
given VBN N
for IN N
5 CD N
days NNS N
. . N

H. NNP N
pylori NN N
status NN N
was VBD N
checked VBN N
by IN N
13C CD o
urea JJ o
breath NN o
test NN o
before IN N
and CC N
after IN N
four CD N
weeks NNS N
of IN N
therapy NN N
. . N

RESULTS VB N
A DT N
total NN p
of IN p
71 CD p
patients NNS p
were VBD p
treated VBN p
by IN p
quadruple JJ p
therapy NN p
, , p
and CC p
42 CD p
patients NNS p
were VBD p
treated VBN p
by IN p
triple JJ p
therapy NN p
. . p

The DT N
eradication NN o
rate NN o
of IN N
H. NNP N
pylori NN N
for IN N
patients NNS N
under IN N
quadruple JJ N
treatment NN N
, , N
without IN N
vs. FW N
with IN N
previous JJ N
dual JJ N
therapy NN N
, , N
were VBD N
96 CD N
% NN N
vs. FW N
92 CD N
% NN N
( ( N
42/44 CD N
vs. FW N
22/24 CD N
) ) N
by IN N
per IN N
protocol NN N
and CC N
91 CD N
% NN N
vs. FW N
88 CD N
% NN N
( ( N
42/46 CD N
vs. FW N
22/25 CD N
) ) N
by IN N
intention NN N
to TO N
treat VB N
analysis NN N
( ( N
comparisons NNS N
not RB N
significant JJ N
) ) N
. . N

No DT N
major JJ N
side-effects NNS N
were VBD N
reported VBN N
. . N

CONCLUSIONS NNP N
Five-day JJ N
quadruple NN N
therapy NN N
( ( N
with IN N
omeprazole NN N
, , N
metronidazole NN N
, , N
clarithromycin NN N
and CC N
amoxicillin NN N
) ) N
represents VBZ N
an DT N
effective JJ N
and CC N
safe JJ N
new JJ N
regimen NNS N
for IN N
H. NNP N
pylori JJ N
eradication NN N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
hormone NN i
replacement NN i
therapy NN i
on IN N
hemostatic JJ N
variables NNS N
in IN N
women NNS p
with IN p
angiographically RB p
verified VBN p
coronary JJ p
artery NN p
disease NN p
: : p
results NNS N
from IN N
the DT N
estrogen NN N
in IN N
women NNS p
with IN p
atherosclerosis NN p
study NN p
. . p

Data NNP N
on IN N
the DT N
effect NN N
of IN N
hormone NN i
replacement NN i
therapy NN i
on IN N
hemostasis NN N
are VBP N
inconsistent JJ N
, , N
and CC N
there EX N
are VBP N
few JJ N
data NNS N
in IN N
women NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

In IN N
a DT N
single-center NN N
, , N
open JJ N
, , N
randomized VBN N
study NN N
, , N
118 CD p
postmenopausal JJ p
women NNS p
with IN p
angiographically RB p
verified VBN p
coronary JJ p
artery NN p
disease NN p
were VBD N
randomized VBN N
to TO N
hormone VB N
replacement NN N
therapy NN N
, , N
given VBN N
as IN N
long-cycle JJ i
transdermal JJ i
17-beta-estradiol JJ i
( ( N
50 CD N
microg/24 RB N
hour NN N
) ) N
for IN N
3 CD N
months NNS N
with IN N
sequential JJ i
medroxy-progesterone NN i
acetate NN i
for IN N
14 CD N
days NNS N
, , N
or CC N
to TO N
a DT N
control NN i
group NN N
receiving VBG i
no DT i
therapy NN i
. . i

Hemostatic JJ N
parameters NNS N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
3 CD N
and CC N
12 CD N
months NNS N
of IN N
therapy NN N
. . N

The DT N
coagulation NN o
inhibitors NNS o
antithrombin VBP o
, , o
protein JJ o
C NNP o
, , o
and CC o
protein NN o
S NNP o
, , N
but CC N
not RB N
tissue VB o
factor NN o
pathway NN o
inhibitor NN o
, , N
decreased VBN N
significantly RB N
from IN N
baseline NN N
in IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
at IN N
both DT N
3 CD N
and CC N
12 CD N
months NNS N
as IN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

The DT N
absolute NN N
decreases VBZ N
within IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
were VBD N
3 CD N
to TO N
10 CD N
% NN N
. . N

No DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
were VBD N
observed VBN N
for IN N
the DT N
coagulation NN o
products NNS o
prothrombin VBP o
fragment JJ o
1+2 CD o
or CC o
thrombin-antithrombin JJ o
complex NN o
or CC o
for IN o
D-dimer NNP o
, , N
although IN N
there EX N
were VBD N
significant JJ N
decreases NNS N
in IN N
the DT N
levels NNS N
within IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
. . N

Levels NNP o
of IN o
fibrinogen NN o
, , o
activated VBD o
factor NN o
VII NNP o
, , o
and CC o
factor NN o
VII NNP o
antigen NN o
were VBD N
not RB N
significantly RB N
influenced VBN N
by IN N
hormone NN N
replacement NN N
therapy NN N
treatment NN N
. . N

Similarly RB N
, , N
nonsignificant JJ N
changes NNS N
were VBD N
detected VBN N
for IN N
the DT N
fibrinolytic JJ o
parameters NNS o
tissue VBP o
plasminogen JJ o
activator NN o
activity NN o
, , o
tissue NN o
plasminogen NN o
activator NN o
antigen NN o
, , o
and CC o
global JJ o
fibrinolytic JJ o
activity NN o
, , o
but CC o
plasminogen NN o
activator NN o
inhibitor NN o
type VBD o
1 CD o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
due JJ N
to TO N
a DT N
questionable JJ N
increase NN N
in IN N
the DT N
levels NNS N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
conclusion NN N
, , N
treatment NN N
with IN N
transdermal JJ i
estradiol NNS i
combined VBN i
with IN i
long-cycle NN i
progestins NNS i
was VBD N
associated VBN N
with IN N
no DT N
net JJ N
activation NN o
of IN o
coagulation NN o
despite IN N
reduced JJ N
levels NNS N
of IN N
coagulation NN o
inhibitors NNS o
. . o

-DOCSTART- -X- O O

Comparison NNP o
of IN N
outcome NN N
of IN N
labetalol NN i
or CC p
hydralazine JJ i
therapy NN p
during IN p
hypertension NN p
in IN p
pregnancy NN p
in IN p
very RB p
low JJ p
birth NN p
weight NN p
infants NNS p
. . p

Ninety-seven JJ p
women NNS p
with IN p
moderate JJ p
to TO p
severe VB p
preeclampsia NN p
( ( p
PE NNP p
) ) p
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
labetalol VB i
or CC i
hydralazine VB i
treatment NN N
. . N

Of IN N
these DT N
, , N
22 CD p
women NNS p
with IN p
severe JJ p
PE NNP p
gave VBD p
birth NN p
to TO p
neonates NNS p
with IN p
VLBW NNP p
( ( p
very RB p
low JJ p
birth NN p
weight NN p
< NN p
or CC p
= JJ p
1500 CD p
g NN p
) ) p
. . p

Seven VBN p
were VBD p
allocated VBN p
to TO p
labetalol VB i
treatment NN i
( ( i
Group NNP i
A NNP i
) ) i
, , p
eight CD p
to TO p
hydralazine VB i
treatment NN i
( ( i
Group NNP i
B NNP i
) ) i
and CC i
seven CD p
women NNS p
received VBD i
both DT i
drugs NNS i
due JJ i
to TO i
poor JJ i
blood NN i
pressure NN i
control NN i
with IN i
a DT i
single JJ i
drug NN i
therapy NN i
( ( N
Group NNP N
C NNP N
) ) N
. . N

No DT N
difference NN N
in IN N
cesarean JJ o
section NN o
rate NN o
or CC o
in IN o
the DT o
indication NN o
for IN o
operative JJ o
delivery NN o
could MD N
be VB N
seen VBN N
. . N

Gestational JJ o
age NN o
was VBD p
29.9 CD p
weeks NNS p
( ( p
25.4-32.5 JJ p
) ) p
in IN N
Group NNP N
A NNP N
, , N
28.6 CD p
weeks NNS p
( ( p
26.6-33.4 JJ p
) ) p
in IN N
Group NNP N
B NNP N
and CC N
27.3 CD p
weeks NNS p
( ( p
26.7-31.1 JJ p
) ) p
in IN N
Group NNP N
C NNP N
( ( N
median JJ N
and CC N
range NN N
) ) N
. . N

Birth NNP o
weight VBD o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
and CC N
13 CD p
of IN p
the DT p
22 CD p
infants NNS p
weighed VBN p
below IN p
1000 CD p
g. NN p
There EX N
was VBD N
a DT N
tendency NN N
to TO N
lower VB o
Apgar NNP o
scores NNS o
at IN N
five CD N
minutes NNS N
in IN N
the DT N
hydralazine NN N
group NN N
. . N

Time NNP o
spent NN o
in IN o
the DT o
neonatal JJ o
intensive JJ o
care NN o
unit NN o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

Five CD N
of IN N
the DT N
11 CD N
neonates NNS p
with IN N
gestational JJ N
age NN N
( ( N
GA NNP N
) ) N
< VBD N
or CC N
= $ N
28 CD N
weeks NNS N
and CC N
three CD N
of IN N
the DT N
seven CD N
neonates NNS p
in IN N
GA NNP N
29-30 JJ N
weeks NNS N
died VBD o
. . o

Neither CC N
the DT N
number NN o
of IN o
infants NNS o
requiring VBG o
intermittent JJ o
positive JJ o
pressure NN o
ventilation NN o
or CC o
duration NN o
of IN o
O2- NNP o
treatment NN o
, , o
nor CC o
number NN o
of IN o
infants NNS o
with IN o
respiratory JJ o
distress JJ o
syndrome NN o
differed VBD N
between IN N
groups NNS N
. . N

We PRP N
did VBD N
not RB N
find VB N
any DT N
difference NN N
in IN N
the DT N
outcome NN N
of IN N
the DT N
VLBW NNP p
infants NNS p
when WRB p
the DT p
hypertensive NN p
mother NN p
had VBD p
been VBN p
treated VBN p
with IN p
either DT p
hydralazine NN i
or CC p
labetalol NN i
. . i

-DOCSTART- -X- O O

Effect NN N
of IN N
exercise NN i
, , i
training NN i
, , N
and CC N
glycogen NN i
availability NN i
on IN N
IL-6 NNP N
receptor NN N
expression NN N
in IN N
human JJ p
skeletal JJ p
muscle NN p
. . p

The DT N
cytokine JJ N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
exerts VBZ N
it PRP N
actions NNS N
via IN N
the DT N
IL-6 NNP N
receptor NN N
( ( N
IL-6R NNP N
) ) N
in IN N
conjunction NN N
with IN N
the DT N
ubiquitously RB N
expressed VBN N
gp130 NN N
receptor NN N
. . N

IL-6 NNP N
is VBZ N
tightly RB N
regulated VBN N
in IN N
response NN N
to TO N
exercise NN i
, , N
being VBG N
affected VBN N
by IN N
factors NNS N
such JJ N
as IN N
exercise NN N
intensity NN N
and CC N
duration NN N
, , N
as RB N
well RB N
as IN N
energy NN N
availability NN N
. . N

Although IN N
the DT N
IL-6 NNP N
response NN N
to TO N
exercise NN N
has VBZ N
been VBN N
extensively RB N
studied VBN N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
regulation NN N
of IN N
the DT N
IL-6R NNP N
response NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
exercise NN i
, , i
training NN i
, , i
and CC i
glycogen NN i
availability NN i
, , N
factors NNS N
known VBN N
to TO N
affect VB N
IL-6 NNP N
, , N
on IN N
the DT N
regulation NN N
of IN N
gene NN N
expression NN N
of IN N
the DT N
IL-6R NNP N
in IN N
human JJ N
skeletal JJ N
muscle NN N
. . N

Human NNP p
subjects VBZ p
performed VBD N
either CC N
10 CD i
wk NN i
of IN i
training VBG i
with IN i
an DT i
acute JJ i
exercise NN i
bout NN i
before IN i
and CC i
after IN i
the DT i
training NN i
period NN i
, , i
or CC i
a DT i
low-glycogen JJ i
vs. NN i
normal-glycogen JJ i
acute NN i
exercise NN i
trial NN i
. . i

The DT N
IL-6R JJ o
mRNA NN o
response NN o
was VBD N
evaluated VBN N
in IN N
both DT N
trials NNS N
. . N

In IN N
response NN N
to TO N
acute VB N
exercise NN N
, , N
an DT N
increase NN N
in IN N
IL-6R NNP o
mRNA NN o
levels NNS o
was VBD N
observed VBN N
. . N

Neither CC N
training VBG N
nor CC N
intramuscular JJ N
glycogen NN N
levels NNS N
had VBD N
an DT N
effect NN N
on IN N
the DT N
IL-6R NNP o
mRNA NN o
response NN o
to TO N
exercise NN N
. . N

However RB N
, , N
after IN N
10 CD N
wk NN N
of IN N
training NN N
, , N
the DT N
skeletal JJ N
muscle NN N
expressed VBD N
a DT N
higher JJR N
mRNA JJ o
level NN o
of IN o
IL-6R NNP o
compared VBN N
with IN N
before RB N
training VBG N
. . N

The DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
the DT N
IL-6R NNP o
gene NN o
expression NN o
levels NNS o
in IN N
skeletal JJ N
muscle NN N
are VBP N
increased VBN N
in IN N
response NN N
to TO N
acute VB N
exercise NN N
, , N
a DT N
response NN N
that WDT N
is VBZ N
very RB N
well RB N
conserved VBN N
, , N
being VBG N
affected VBN N
by IN N
neither DT N
training NN o
status NN o
nor CC N
intramuscular JJ o
glycogen NN o
levels NNS o
, , N
as IN N
opposed VBN N
to TO N
IL-6 NNP N
. . N

However RB N
, , N
after IN N
the DT N
training NN N
period NN N
, , N
IL-6R JJ o
mRNA NN o
production NN o
was VBD N
increased VBN N
in IN N
skeletal JJ N
muscle NN N
, , N
suggesting VBG N
a DT N
sensitization NN N
of IN N
skeletal JJ N
muscle NN N
to TO N
IL-6 NNP N
at IN N
rest NN N
. . N

-DOCSTART- -X- O O

A DT N
simplified JJ N
approach NN N
to TO N
virtual JJ i
colonoscopy NN i
using VBG i
different JJ i
intestinal JJ i
preparations NNS i
: : i
preliminary JJ N
experience NN N
with IN N
regard NN N
to TO N
quality NN N
, , N
accuracy NN N
and CC N
patient JJ N
acceptability NN N
. . N

PURPOSE VB N
The DT N
authors NNS N
assessed VBD N
the DT N
quality NN N
, , N
diagnostic JJ N
accuracy NN N
and CC N
patient JJ N
acceptability NN N
of IN N
computed VBN i
tomography NN i
( ( i
CT NNP i
) ) i
colonography NN i
performed VBD N
using VBG N
a DT N
simplified JJ N
bowel NN N
preparation NN N
and CC N
software NN N
for IN N
post-processing JJ N
digital JJ N
elimination NN N
of IN N
stool NN N
and CC N
fluid NN N
data NNS N
from IN N
images NNS N
compared VBN N
with IN N
the DT N
examination NN N
obtained VBN N
with IN N
conventional JJ N
preparation NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Two CD p
groups NNS p
of IN p
40 CD p
consecutive JJ p
asymptomatic JJ p
patients NNS p
aged VBN p
between IN p
48 CD p
and CC p
72 CD p
years NNS p
underwent JJ p
CT NNP i
colonography NN i
. . i

In IN N
group NN N
A NNP N
, , N
the DT N
CT NNP i
scan NN i
was VBD i
performed VBN i
with IN i
conventional JJ i
bowel NN i
preparation NN i
( ( N
a DT N
full JJ N
cathartic NN N
dose NN N
and CC N
oral JJ N
contrast NN N
medium NN N
to TO N
tag VB N
any DT N
residue NN N
in IN N
the DT N
3 CD N
days NNS N
preceding VBG N
the DT N
study NN N
) ) N
. . N

In IN N
the DT N
second JJ N
group NN N
, , N
CT NNP i
colonography NN i
was VBD i
performed VBN i
after IN i
a DT i
reduced JJ i
bowel NN i
preparation NN i
, , N
with IN N
the DT N
oral JJ N
contrast NN N
medium NN N
for IN N
residue JJ N
tagging VBG N
being VBG N
administered VBN N
only RB N
on IN N
the DT N
day NN N
of IN N
the DT N
investigation NN N
. . N

Examination NNP o
quality NN o
, , o
diagnostic JJ o
performance NN o
and CC o
patient JJ o
acceptability NN o
( ( o
rated VBN o
with IN o
a DT o
self-completed JJ o
questionnaire NN o
) ) o
in IN N
the DT N
two CD N
groups NNS N
of IN N
patients NNS N
were VBD N
compared VBN N
by IN N
using VBG N
the DT N
McNemar NNP N
test NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
was VBD N
obtained VBN N
with IN N
regard NN N
to TO N
examination NN o
quality NN o
( ( N
180 CD N
vs. FW N
165 CD N
segments NNS N
free JJ N
from IN N
stools NNS N
and CC N
fluid NN N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
and CC N
overall JJ o
diagnostic JJ o
accuracy NN o
( ( N
16/17 CD N
colonic JJ N
polyps NNS N
detected VBN N
in IN N
group NN N
A NNP N
and CC N
12/13 CD N
in IN N
group NN N
B NNP N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
questionnaires NNS N
revealed VBD N
a DT N
greater JJR N
acceptability NN N
of IN N
the DT N
reduced JJ i
bowel NN o
preparation NN o
compared VBN N
with IN N
the DT N
standard JJ i
procedure NN i
( ( N
p=0.01 NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
asymptomatic JJ N
patients NNS N
, , N
the DT N
use NN N
of IN N
software NN N
for IN N
post-processing JJ N
digital JJ N
elimination NN N
of IN N
residue NN N
from IN N
images NNS N
in IN N
conjunction NN N
with IN N
reduced JJ i
bowel NN i
preparation NN i
does VBZ N
not RB N
reduce VB N
examination NN o
quality NN o
or CC N
diagnostic JJ o
performance NN o
when WRB N
compared VBN N
with IN N
the DT N
conventional JJ i
CT NNP i
colonography NN i
technique NN i
and CC N
is VBZ N
more RBR N
acceptable JJ o
to TO N
and CC N
better RB N
tolerated VBN o
by IN N
the DT N
patient NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
food NN i
on IN N
the DT N
antiviral JJ o
activity NN o
of IN N
didanosine JJ i
enteric-coated JJ i
capsules NNS i
: : i
a DT N
pilot NN N
comparative NN N
study NN N
. . N

OBJECTIVES NNP N
To TO N
determine VB N
the DT N
effect NN N
of IN N
food NN i
on IN N
the DT N
antiviral JJ N
activity NN N
of IN N
enteric-coated JJ i
( ( i
EC NNP i
) ) i
capsules NNS i
of IN i
didanosine NN i
( ( i
ddI NN i
) ) i
. . i

METHODS NNP N
We PRP N
conducted VBD N
a DT N
pilot NN N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
of IN N
28-day JJ N
ddI-EC JJ i
capsules NNS i
monotherapy-administered VBN i
in IN N
a DT N
fasted JJ i
state NN i
( ( p
group NN p
1 CD p
, , p
n=11 NN p
) ) p
or CC p
with IN i
food NN i
( ( p
group NN p
2 CD p
, , p
n=10 RB p
) ) p
to TO p
treatment-na?ve JJ p
chronically RB p
HIV-1-infected JJ p
individuals NNS p
. . p

To TO N
assess VB N
the DT o
antiviral JJ o
efficacy NN o
, , o
HIV-1 NNP o
RNA NNP o
was VBD N
determined VBN N
at IN N
baseline NN N
, , N
day NN N
3 CD N
, , N
day NN N
7 CD N
and CC N
weekly JJ N
thereafter NN N
. . N

The DT N
area NN N
under IN N
the DT N
HIV-1 NNP N
RNA NNP N
curve NN N
minus NN N
baseline NN N
weighted VBN N
by IN N
time NN o
( ( o
AUCMB/day NNP o
) ) o
was VBD N
calculated VBN N
. . N

RESULTS JJ o
Mean JJ o
baseline JJ o
HIV-1 NNP o
RNA NNP o
was VBD N
4.2 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
in IN N
group NN N
1 CD N
and CC N
3.8 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
in IN N
group NN N
2 CD N
. . N

After IN N
28 CD N
days NNS N
, , N
the DT o
mean JJ o
HIV-1 NNP o
RNA NNP o
reduction NN o
was VBD N
0.99 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
[ $ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0.45-1.53 CD N
] NN N
for IN N
group NN N
1 CD N
and CC N
0.89 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
0.38-1.40 NN N
) ) N
for IN N
group NN N
2 CD N
. . N

AUCMB/day JJ o
values NNS o
were VBD N
0.775 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
0.33-1.22 NN N
) ) N
and CC N
0.774 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
0.48-1.07 NN N
) ) N
, , N
respectively RB N
, , N
showing VBG N
no DT N
difference NN N
in IN N
the DT N
rate NN N
of IN N
decrease NN N
of IN o
HIV-1 NNP o
RNA NNP o
( ( N
P=0.995 NNP N
) ) N
. . N

Mean NNP o
ddI JJ o
plasma NN o
levels NNS o
at IN N
day NN N
28 CD N
were VBD N
0.0234 CD N
mg/L NN N
for IN N
group NN N
1 CD N
and CC N
0.0227 CD N
mg/L NN N
for IN N
group NN N
2 CD N
( ( N
P=0.96 NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
pilot NN N
study NN N
, , N
the DT N
administration NN N
of IN i
food NN i
did VBD N
not RB N
have VB N
any DT N
significant JJ N
effect NN N
on IN N
the DT o
antiviral JJ o
activity NN o
of IN o
ddI-EC JJ o
capsules NNS o
. . o

-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled VBN N
trial NN N
investigating VBG N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
aripiprazole NN i
in IN N
the DT N
long-term JJ N
maintenance NN N
treatment NN N
of IN N
pediatric JJ p
patients NNS p
with IN p
irritability NN p
associated VBN p
with IN p
autistic JJ p
disorder NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
aripiprazole JJ i
versus NN N
placebo NN i
in IN N
preventing VBG N
relapse NN N
of IN N
irritability NN o
symptoms NNS o
associated VBN N
with IN N
autistic JJ p
disorder NN p
in IN p
pediatric JJ p
patients NNS p
. . p

METHOD NNP N
This DT N
multicenter NN N
, , N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
relapse-prevention JJ N
trial NN N
enrolled VBD N
patients NNS p
( ( p
6-17 CD p
years NNS p
) ) p
who WP p
met VBD p
the DT p
current JJ p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Fourth NNP p
Edition NNP p
, , p
Text NNP p
Revision NNP p
( ( p
DMS-IV-TR NNP p
) ) p
criteria NN p
for IN p
autistic JJ p
disorder NN p
and CC p
who WP p
also RB p
had VBD p
serious JJ p
behavioral JJ p
problems NNS p
( ( p
ie VB p
, , p
tantrums NNS p
, , p
aggression NN p
, , p
self-injurious JJ p
behavior NN p
, , p
or CC p
a DT p
combination NN p
of IN p
these DT p
behavioral JJ p
problems NNS p
) ) p
between IN p
March NNP p
2011 CD p
and CC p
June NNP p
2012 CD p
. . p

In IN N
phase NN N
1 CD N
, , N
single-blind JJ N
aripiprazole NN i
was VBD N
flexibly RB N
dosed VBN N
( ( N
2-15 JJ N
mg/d NN N
) ) N
for IN N
13-26 JJ N
weeks NNS N
. . N

Patients NNS p
with IN p
a DT p
stable JJ p
response NN p
( ( p
? . p
25 CD p
% NN p
decrease NN p
in IN p
Aberrant NNP o
Behavior NNP o
Checklist-irritability NNP o
subscale NN o
score NN o
and CC o
a DT p
rating NN p
of IN p
much JJ p
improved VBN p
or CC p
very RB p
much JJ p
improved VBN p
on IN p
the DT o
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
scale NN o
) ) o
for IN o
12 CD p
consecutive JJ p
weeks NNS p
were VBD p
randomized VBN N
into IN N
phase NN N
2 CD N
to TO N
continue VB i
aripiprazole NN i
or CC i
switch VB i
to TO i
placebo VB i
. . i

Treatment NN N
was VBD N
continued VBN N
until IN N
relapse NN N
or CC N
up RB N
to TO N
16 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
time NN N
from IN N
randomization NN N
to TO N
relapse VB N
. . N

RESULTS NNP p
Eighty-five JJ p
patients NNS p
were VBD p
randomized VBN p
in IN p
phase NN p
2 CD p
. . N

The DT N
difference NN N
in IN N
time NN o
to TO o
relapse VB o
between IN o
aripiprazole NN i
and CC i
placebo NN i
was VBD i
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.097 NNP o
) ) o
. . o

Kaplan-Meier NNP o
relapse NN o
rates NNS o
at IN o
week NN N
16 CD N
were VBD N
35 CD N
% NN N
for IN N
aripiprazole NN N
and CC N
52 CD N
% NN N
for IN i
placebo NN i
( ( i
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
= NNP N
0.57 CD N
; : N
number NN N
needed VBN N
to TO N
treat VB N
[ JJ N
NNT NNP N
] NNP N
= NNP N
6 CD N
) ) N
. . N

The DT N
most RBS N
common JJ o
adverse JJ o
events NNS o
during IN o
phase NN N
1 CD N
were VBD o
weight JJ o
increase NN o
( ( o
25.2 CD o
% NN o
) ) o
, , o
somnolence NN o
( ( o
14.8 CD N
% NN N
) ) N
, , N
and CC o
vomiting VBG o
( ( o
14.2 CD N
% NN N
) ) N
; : N
and CC N
, , N
during IN N
phase NN N
2 CD N
( ( N
aripiprazole JJ N
vs NN N
placebo NN N
) ) N
, , N
they PRP N
were VBD o
upper JJ o
respiratory NN o
tract NN o
infection NN o
( ( o
10.3 CD N
% NN N
vs JJ N
2.3 CD o
% NN o
) ) o
, , o
constipation NN o
( ( o
5.1 CD N
% NN N
vs JJ N
0 CD N
% NN N
) ) N
, , N
and CC o
movement NN o
disorder NN o
( ( o
5.1 CD N
% NN N
vs JJ N
0 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN i
aripiprazole NN i
and CC i
placebo NN i
in IN i
time NN o
to TO o
relapse VB o
during IN o
maintenance NN N
therapy NN N
. . N

However RB N
, , N
the DT N
HR NNP N
and CC N
NNT NNP N
suggest VBP N
some DT N
patients NNS N
will MD N
benefit VB N
from IN N
maintenance NN N
treatment NN N
. . N

Patients NNS N
receiving VBG N
aripiprazole NN N
should MD N
be VB N
periodically RB N
reassessed VBN N
to TO N
determine VB N
the DT N
continued JJ N
need NN N
for IN N
treatment NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT01227668 NNP N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
type NN p
2 CD p
( ( p
non-insulin-dependent JJ p
) ) p
diabetes VBZ p
mellitus VBN p
by IN N
diet JJ N
and CC N
physical JJ N
exercise NN N
. . N

The DT N
6-year JJ N
Malm? NNP N
feasibility NN N
study NN N
. . N

From IN N
a DT N
previously RB N
reported VBN N
5-year JJ N
screening VBG N
programme NN N
of IN p
6,956 CD p
47-49-year-old JJ p
Malm? NNP p
males NNS p
, , p
a DT p
series NN p
of IN p
41 CD p
subjects NNS p
with IN p
early-stage JJ p
Type NNP p
2 CD p
( ( p
non-insulin-dependent JJ p
) ) p
diabetes VBZ p
mellitus JJ p
and CC p
181 CD p
subjects NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
were VBD p
selected VBN N
for IN N
prospective JJ N
study NN N
and CC N
to TO N
test VB N
the DT N
feasibility NN N
aspect NN N
of IN N
long-term JJ N
intervention NN N
with IN N
an DT N
emphasis NN N
on IN N
life-style JJ i
changes NNS i
. . i

A DT N
5-year JJ N
protocol NN N
, , N
including VBG N
an DT N
initial JJ N
6-months JJ N
( ( N
randomised VBN N
) ) N
pilot NN N
study NN i
, , i
consisting VBG i
of IN i
dietary JJ i
treatment NN i
and/or JJ i
increase NN i
of IN i
physical JJ i
activity NN i
or CC i
training NN i
with IN i
annual JJ i
check-ups NNS i
, , i
was VBD N
completed VBN N
by IN N
90 CD N
% NN N
of IN N
subjects NNS o
. . o

Body NNP o
weight NN o
was VBD o
reduced VBN N
by IN N
2.3-3.7 JJ N
% NN N
among IN N
participants NNS N
, , N
whereas JJ N
values NNS N
increased VBN N
by IN N
0.5-1.7 CD N
% NN N
in IN N
non-intervened JJ N
subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
and CC N
in IN N
normal JJ N
control NN N
subjects NNS N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD o
) ) o
; : o
maximal JJ o
oxygen NN o
uptake NN o
( ( o
ml.min-1.kg-1 JJ N
) ) N
was VBD N
increased VBN N
by IN N
10-14 CD N
% NN N
vs NN N
decreased VBN N
by IN N
5-9 JJ N
% NN N
, , N
respectively RB N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD o
) ) o
. . o

Glucose JJ o
tolerance NN o
was VBD o
normalized VBN N
in IN N
greater JJR N
than IN N
50 CD N
% NN N
of IN N
subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
, , N
the DT N
accumulated JJ o
incidence NN o
of IN o
diabetes NNS o
was VBD o
10.6 CD N
% NN N
, , N
and CC N
more JJR N
than IN N
50 CD N
% NN N
of IN N
the DT N
diabetic JJ N
patients NNS N
were VBD N
in IN N
remission NN o
after IN o
a DT N
mean JJ N
follow-up NN N
of IN N
6 CD N
years NNS o
. . o

Blood NNP o
pressure NN o
, , o
lipids NNS o
, , o
and CC o
hyperinsulinaemia NN o
were VBD o
reduced VBN N
and CC o
early JJ o
insulin NN o
responsiveness NN o
to TO o
glucose VB o
loading VBG o
preserved VBN N
. . N

Improvement NN N
in IN N
glucose JJ o
tolerance NN o
was VBD o
correlated VBN N
to TO N
weight VB o
reduction NN o
( ( o
r JJ N
= NN N
0.19 CD N
, , N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
and CC o
increased JJ o
fitness NN o
( ( o
r JJ N
= NN N
0.22 CD N
, , N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

Treatment NN N
was VBD N
safe JJ N
, , N
and CC N
mortality NN N
was VBD N
low JJ N
( ( N
in IN N
fact NN N
33 CD N
% NN N
lower JJR N
than IN N
in IN N
the DT N
remainder NN N
of IN N
the DT N
cohort NN N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Lengthening VBG N
the DT N
moment NN N
arm NN N
of IN N
the DT N
patella NN N
confers NNS N
enhanced VBD N
extensor NN o
mechanism NN o
power NN o
following VBG p
total JJ p
knee JJ p
arthroplasty NN p
. . p

We PRP N
investigated VBD N
whether IN N
a DT N
postulated JJ N
biomechanical JJ N
advantage NN N
conferred VBD N
to TO N
the DT N
extensor NN N
mechanism NN N
by IN N
a DT N
change NN N
in IN N
knee NN N
implant JJ N
design NN N
was VBD N
detectable JJ N
in IN N
patients NNS p
by IN p
direct JJ p
physical JJ p
testing NN p
. . p

212 CD p
TKA JJ p
patients NNS p
were VBD N
enrolled VBN N
in IN N
a DT N
double JJ N
blind NN N
randomized VBD N
controlled VBN N
trial NN N
to TO N
receive VB N
either CC N
a DT N
traditional JJ i
implant NN i
or CC i
one CD i
which WDT i
incorporated VBD i
new JJ i
design NN i
features NNS i
. . i

Extensor NNP o
mechanism NN o
power NN o
output NN o
and CC o
physical JJ o
performance NN o
on IN o
a DT o
battery NN o
of IN o
timed JJ o
functional JJ o
activities NNS o
was VBD N
assessed VBN N
pre-operatively RB N
and CC N
then RB N
at IN N
6 CD N
, , N
26 CD N
, , N
and CC N
52 CD N
weeks NNS N
post-operatively RB N
. . N

Significantly RB N
enhanced JJ N
power NN o
output NN o
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
post-arthroplasty VBP N
; : N
however RB N
, , N
the DT N
new JJ i
design NN i
implant JJ i
group NN N
demonstrated VBD N
a DT N
greater JJR N
change NN o
in IN o
power NN o
output NN o
than IN N
the DT N
traditional JJ i
implant NN i
group NN N
. . N

Posthoc NNP o
testing VBG o
of IN N
between IN N
group NN N
differences NNS N
highlighted VBD N
greater JJR N
improvement NN N
at IN N
all DT o
post-operative JJ o
assessments NNS o
. . o

At IN N
52 CD N
weeks NNS N
, , N
patients NNS N
receiving VBG N
the DT N
implant NN N
with IN N
the DT N
postulated JJ N
biomechanical JJ N
advantage NN N
achieved VBD N
116 CD N
% NN N
of IN N
the DT N
power NN o
output NN o
of IN o
their PRP$ o
contralateral JJ o
limb NN o
, , N
whereas JJ N
patients NNS N
with IN N
the DT N
traditional JJ N
design NN N
achieved VBD N
90 CD N
% NN N
. . N

No DT N
between IN N
group NN N
difference NN N
was VBD N
detected VBN N
in IN N
the DT N
patient NN N
's POS N
time NN N
to TO N
complete VB N
functional JJ N
tasks NNS N
. . N

Thus RB N
, , N
patients NNS N
receiving VBG N
a DT N
knee NN i
implant NN i
of IN i
a DT i
modern JJ i
design NN i
( ( N
theoretically RB N
able JJ N
to TO N
confer VB N
a DT N
mechanical JJ N
advantage NN N
to TO N
the DT N
extensor NN N
mechanism NN N
) ) N
were VBD N
found VBN N
to TO N
generate VB N
significantly RB N
greater JJR N
extensor NN o
power NN o
than IN N
those DT N
receiving VBG N
a DT N
traditional JJ i
implant NN i
without IN N
the DT N
postulated JJ N
mechanical JJ N
advantage NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
comfort NN o
and CC o
local JJ o
complications NNS o
after IN N
cardiac JJ i
catheterization NN i
. . i

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
4 CD N
hours NNS N
of IN N
bed NN i
rest NN i
versus NN N
6 CD N
hours NNS N
of IN N
bed NN i
rest NN i
on IN N
patients NNS N
' POS N
safety NN o
, , o
comfort NN o
, , o
and CC o
satisfaction NN o
levels NNS o
. . o

Using VBG N
a DT N
quasi-experimental JJ N
design NN N
, , N
the DT N
authors NNS N
studied VBD N
118 CD p
left-heart JJ i
catheterization NN i
patients NNS p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
4 CD p
hours NNS p
or CC p
6 CD p
hours NNS p
of IN p
bed NN p
rest NN p
. . p

Among IN N
the DT N
study NN N
participants NNS N
, , N
only RB N
1 CD N
in IN N
the DT N
6-hour JJ N
group NN N
had VBD N
significant JJ o
bleeding NN o
. . o

There EX N
were VBD N
no DT N
complications NNS o
in IN N
the DT N
4-hour JJ N
group NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
on IN N
any DT N
of IN N
the DT N
other JJ N
study NN N
variables NNS N
. . N

Given VBN N
the DT N
lack NN N
of IN N
significant JJ N
complications NNS N
for IN N
the DT N
4-hour JJ N
group NN N
and CC N
similar JJ N
comfort NN o
levels NNS o
for IN N
both DT N
study NN N
groups NNS N
, , N
these DT N
findings NNS N
suggest VBP N
the DT N
feasibility NN N
of IN N
reducing VBG N
the DT N
standard JJ N
period NN N
of IN N
postcatheterization NN N
bed VBN N
rest NN N
from IN N
6 CD N
hours NNS N
to TO N
4 CD N
hours NNS N
, , N
thereby RB N
possibly RB N
lowering VBG N
the DT N
cost NN o
of IN o
the DT o
outpatient JJ o
procedure NN o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
parent NN i
training NN i
vs NN i
parent NN i
education NN i
on IN N
behavioral JJ p
problems NNS p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
Disruptive NNP N
behavior NN N
is VBZ N
common JJ N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Behavioral JJ N
interventions NNS N
are VBP N
used VBN N
to TO N
treat VB N
disruptive JJ N
behavior NN N
but CC N
have VBP N
not RB N
been VBN N
evaluated VBN N
in IN N
large-scale JJ N
randomized JJ N
trials NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
parent NN i
training NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
and CC p
disruptive JJ p
behavior NN p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
This DT N
24-week JJ N
randomized JJ N
trial NN N
compared VBN N
parent NN i
training NN i
( ( i
n JJ i
= NNP i
89 CD i
) ) i
to TO i
parent VB i
education NN i
( ( i
n JJ i
= NNP p
91 CD p
) ) p
at IN p
6 CD p
centers NNS p
( ( p
Emory NNP p
University NNP p
, , p
Indiana NNP p
University NNP p
, , p
Ohio NNP p
State NNP p
University NNP p
, , p
University NNP p
of IN p
Pittsburgh NNP p
, , p
University NNP p
of IN p
Rochester NNP p
, , p
Yale NNP p
University NNP p
) ) p
. . p

We PRP p
screened VBD p
267 CD p
children NNS p
; : p
180 CD p
children NNS p
( ( p
aged VBN p
3-7 CD p
years NNS p
) ) p
with IN p
autism NN p
spectrum NN p
disorder NN p
and CC p
disruptive JJ p
behaviors NNS p
were VBD p
randomly RB p
assigned VBN p
( ( p
86 CD p
% NN p
white JJ p
, , p
88 CD p
% NN p
male NN p
) ) p
between IN p
September NNP p
2010 CD p
and CC p
February NNP p
2014 CD p
. . p

INTERVENTIONS NNP i
Parent NNP i
training NN i
( ( i
11 CD i
core NN i
, , i
2 CD i
optional JJ i
sessions NNS i
; : i
2 CD i
telephone NN i
boosters NNS i
; : i
2 CD i
home NN i
visits NNS i
) ) i
provided VBD N
specific JJ N
strategies NNS N
to TO N
manage VB N
disruptive JJ N
behavior NN N
. . i

Parent NN i
education NN i
( ( i
12 CD i
core NN i
sessions NNS i
, , i
1 CD i
home NN i
visit NN i
) ) i
provided VBN N
information NN N
about IN N
autism NN N
but CC N
no DT N
behavior JJ N
management NN N
strategies NNS N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Parents NNP o
rated VBD o
disruptive JJ o
behavior NN o
and CC o
noncompliance NN o
on IN o
co-primary JJ o
outcomes NNS o
: : o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist-Irritability NNP o
subscale NN o
( ( o
range NN o
, , o
0-45 NN o
) ) o
and CC o
the DT o
Home NNP o
Situations NNP o
Questionnaire-Autism NNP o
Spectrum NNP o
Disorder NNP o
( ( o
range NN o
, , o
0-9 JJ o
) ) o
. . o

On IN N
both DT N
measures NNS N
, , N
higher JJR N
scores NNS N
indicate VBP N
greater JJR N
severity NN N
and CC N
a DT N
25 CD N
% NN N
reduction NN N
indicates VBZ N
clinical JJ N
improvement NN N
. . N

A DT N
clinician JJ N
blind NN N
to TO N
treatment NN N
assignment NN N
rated VBD N
the DT N
Improvement NNP N
scale NN N
of IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
( ( N
range NN N
, , N
1-7 JJ N
) ) N
, , N
a DT N
secondary JJ N
outcome NN N
, , N
with IN N
a DT N
positive JJ N
response NN N
less JJR N
than IN N
3 CD N
. . N

RESULTS NN N
At IN N
week NN N
24 CD N
, , N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist-Irritability NNP o
subscale NN o
declined VBD o
47.7 CD N
% NN N
in IN N
parent NN i
training NN i
( ( i
from IN i
23.7 CD i
to TO N
12.4 CD N
) ) N
compared VBN N
with IN N
31.8 CD N
% NN N
for IN i
parent NN i
education NN i
( ( i
23.9 CD i
to TO i
16.3 CD N
) ) N
( ( N
treatment NN N
effect NN N
, , N
-3.9 NNP N
; : N
95 CD N
% NN N
CI NNP N
, , N
-6.2 NNP N
to TO N
-1.7 VB N
; : N
P NNP N
< NNP N
.001 NNP N
, , N
standardized VBD N
effect NN N
size NN N
= NNP N
0.62 CD N
) ) N
. . o

The DT o
Home NNP o
Situations NNP o
Questionnaire-Autism NNP o
Spectrum NNP o
Disorder NNP o
declined VBD o
55 CD N
% NN N
( ( N
from IN N
4.0 CD N
to TO N
1.8 CD N
) ) N
compared VBN N
with IN N
34.2 CD N
% NN N
in IN N
parent NN N
education NN N
( ( N
3.8 CD N
to TO N
2.5 CD N
) ) N
( ( N
treatment NN N
effect NN N
, , N
-0.7 NNP N
; : N
95 CD N
% NN N
CI NNP N
, , N
-1.1 NNP N
to TO N
-0.3 VB N
; : N
P NNP N
< NNP N
.001 NNP N
, , N
standardized VBD N
effect NN N
size NN N
= NNP N
0.45 CD N
) ) N
. . N

Neither CC N
measure NN N
met VBD N
the DT N
prespecified VBN N
minimal JJ N
clinically RB N
important JJ N
difference NN N
. . N

The DT N
proportions NNS N
with IN N
a DT N
positive JJ N
response NN N
on IN N
the DT N
Clinical JJ o
Global NNP o
Impression-Improvement NNP o
scale NN o
were VBD o
68.5 CD o
% NN o
for IN o
parent NN o
training NN N
vs JJ N
39.6 CD N
% NN N
for IN N
parent NN N
education NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
For IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
, , p
a DT p
24-week JJ N
parent NN N
training NN N
program NN N
was VBD N
superior JJ i
to TO i
parent VB i
education NN i
for IN i
reducing VBG i
disruptive JJ N
behavior NN N
on IN N
parent-reported JJ N
outcomes NNS N
, , N
although IN N
the DT N
clinical JJ N
significance NN N
of IN N
the DT N
improvement NN N
is VBZ N
unclear JJ N
. . N

The DT N
rate NN N
of IN N
positive JJ N
response NN N
judged VBN N
by IN N
a DT N
blinded JJ N
clinician NN N
was VBD N
greater JJR i
for IN i
parent NN i
training NN i
vs NN i
parent NN i
education NN i
. . i

TRIAL NNP i
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT01233414 NN N
. . N

-DOCSTART- -X- O O

Comparative JJ N
efficacy NN N
of IN N
LEAP NNP i
, , i
TEACCH NNP i
and CC N
non-model-specific JJ i
special JJ i
education NN i
programs NNS i
for IN N
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

LEAP NNP i
and CC i
TEACCH NNP i
represent VBP N
two CD N
comprehensive JJ N
treatment NN N
models NNS N
( ( N
CTMs NNP N
) ) N
that WDT N
have VBP N
been VBN N
widely RB N
used VBN N
across IN N
several JJ N
decades NNS N
to TO N
educate VB N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
quasi-experimental JJ N
study NN N
was VBD N
to TO N
compare VB N
high JJ i
fidelity NN i
LEAP NNP i
( ( N
n JJ N
= NNP N
22 CD N
) ) N
and CC i
TEACCH NNP i
( ( i
n JJ N
= NNP N
25 CD N
) ) N
classrooms NNS N
to TO N
each DT N
other JJ N
and CC N
a DT N
control NN N
condition NN N
( ( N
n JJ N
= NNP N
28 CD N
) ) N
, , N
in IN N
which WDT N
teachers NNS p
in IN p
high JJ p
quality NN p
special JJ p
education NN p
programs NNS p
used VBD p
non-model-specific JJ N
practices NNS N
. . N

A DT N
total NN N
of IN p
198 CD p
children NNS p
were VBD p
included VBN N
in IN N
data NNS N
analysis NN N
. . N

Across IN N
conditions NNS o
, , o
children NNS o
's POS o
performances NNS o
improved VBN o
over IN N
time NN N
. . N

This DT N
study NN N
raises VBZ N
issues NNS N
of IN N
the DT N
replication NN N
of IN N
effects NNS N
for IN N
CTMs NNP N
, , N
and CC N
whether IN N
having VBG N
access NN N
to TO N
a DT N
high JJ N
quality NN i
special JJ i
education NN i
program NN i
is VBZ i
as RB i
beneficial JJ N
as IN N
access NN N
to TO N
a DT N
specific JJ N
CTM NNP N
. . N

-DOCSTART- -X- O O

Brief JJ N
report NN N
: : N
case NN N
reports NNS N
on IN N
naltrexone NN i
use NN N
in IN N
children NNS p
with IN p
autism NN p
: : p
controlled VBN N
observations NNS N
regarding VBG N
benefits NNS o
and CC N
practical JJ o
issues NNS o
of IN N
medication NN N
management NN N
. . N

-DOCSTART- -X- O O

Acute NNP o
hemodynamic JJ o
effects NNS o
of IN N
conivaptan NN i
, , N
a DT N
dual JJ N
V NNP N
( ( N
1A CD N
) ) N
and CC N
V NNP N
( ( N
2 CD N
) ) N
vasopressin NN N
receptor NN N
antagonist NN N
, , N
in IN N
patients NNS p
with IN p
advanced JJ p
heart NN p
failure NN p
. . p

BACKGROUND NNP N
Arginine NNP N
vasopressin NN N
may MD N
contribute VB N
to TO N
abnormalities NNS o
in IN o
hemodynamics NNS o
and CC o
fluid JJ o
balance NN o
in IN N
heart NN N
failure NN N
through IN N
its PRP$ N
actions NNS N
on IN N
V NNP o
( ( o
1A CD o
) ) o
( ( o
vascular JJ o
and CC o
myocardial JJ o
effects NNS o
) ) o
and CC o
V NNP o
( ( o
2 CD o
) ) o
receptors NNS o
( ( o
renal JJ o
effects NNS o
) ) o
. . o

Inhibiting VBG N
the DT N
action NN N
of IN N
vasopressin NN N
may MD N
be VB N
beneficial JJ N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
. . p

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
142 CD p
patients NNS p
with IN p
symptomatic JJ p
heart NN p
failure NN p
( ( p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
III NNP p
and CC p
IV NNP p
) ) p
were VBD N
randomized VBN N
to TO N
double-blind VB N
, , N
short-term JJ N
treatment NN N
with IN N
conivaptan NN i
, , N
a DT N
dual JJ N
V NNP N
( ( N
1a CD N
) ) N
/V NN N
( ( N
2 CD N
) ) N
vasopressin NN i
receptor NN N
antagonist NN N
, , N
at IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
( ( N
10 CD N
, , N
20 CD N
, , N
or CC N
40 CD N
mg NN N
) ) N
or CC N
placebo NN i
. . i

Compared VBN N
with IN N
placebo NN N
, , N
conivaptan NN N
at IN N
20 CD N
and CC N
40 CD N
mg NN N
significantly RB N
reduced VBD N
pulmonary JJ o
capillary JJ o
wedge NN o
pressure NN o
( ( N
-2.6+/-0.7 UH N
, , N
-5.4+/-0.7 NNP N
, , N
and CC N
-4.6+/-0.7 NNP N
mm VBP N
Hg NNP N
for IN N
placebo NN N
and CC N
20 CD N
and CC N
40 CD N
mg NN N
groups NNS N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
right JJ o
atrial JJ o
pressure NN o
( ( N
-2.0+/-0.4 UH N
, , N
-3.7+/-0.4 NNP N
, , N
and CC N
-3.5+/-0.4 NNP N
mm VBP N
Hg NNP N
for IN N
placebo NN N
and CC N
20 CD N
and CC N
40 CD N
mg NN N
groups NNS N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
during IN N
the DT N
3- JJ N
to TO N
6-hour JJ N
interval NN N
after IN N
intravenous JJ N
administration NN N
. . N

Conivaptan NNP i
significantly RB N
increased VBD N
urine JJ o
output NN o
in IN N
a DT N
dose-dependent JJ N
manner NN N
( ( N
-11+/-17 JJ N
, , N
68+/-17 JJ N
, , N
152+/-19 JJ N
, , N
and CC N
176+/-18 JJ N
mL/hour NN N
for IN N
placebo NN N
and CC N
10 CD N
, , N
20 CD N
, , N
and CC N
40 CD N
mg NN N
groups NNS N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
during IN N
the DT N
first JJ N
4 CD N
hours NNS N
after IN N
the DT N
dose NN N
. . N

Changes NNS N
in IN N
cardiac JJ o
index NN o
, , o
systemic JJ o
and CC o
pulmonary JJ o
vascular NN o
resistance NN o
, , o
blood NN o
pressure NN o
, , o
and CC o
heart NN o
rate NN o
did VBD N
not RB N
significantly RB N
differ VBP N
from IN N
placebo NN N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
advanced JJ p
heart NN p
failure NN p
, , N
vasopressin NN N
receptor NN N
antagonism NN N
with IN N
conivaptan NN i
resulted VBN N
in IN N
favorable JJ N
changes NNS N
in IN N
hemodynamics NNS o
and CC o
urine JJ o
output NN o
without IN N
affecting VBG N
blood NN o
pressure NN o
or CC o
heart NN o
rate NN o
. . o

These DT N
data NNS N
suggest VBP N
that IN N
vasopressin NN N
is VBZ N
functionally RB N
significant JJ N
in IN N
advanced JJ N
heart NN N
failure NN N
and CC N
that IN N
further JJ N
investigations NNS N
are VBP N
warranted VBN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
conivaptan NN N
on IN N
symptom JJ N
relief NN N
and CC N
natural JJ N
history NN N
in IN N
such JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
enamel JJ i
preparation NN i
method NN i
on IN N
in IN N
vitro JJ N
marginal JJ o
microleakage NN o
of IN N
a DT N
flowable JJ N
composite NN N
used VBN N
as IN N
pit NN N
and CC N
fissure NN N
sealant NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
in IN N
vitro NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
microleakage NN o
in IN o
occlusal JJ o
surfaces NNS o
, , N
after IN N
preparation NN N
with IN N
Er NNP i
: : i
YAG NNP i
laser NN i
and CC N
compared VBN N
to TO N
the DT N
diamond-bur JJ i
conventional JJ i
technique NN i
. . i

METHODS NNP N
Thirty NNP p
premolars NNS p
were VBD N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
I PRP N
- : N
high-speed JJ i
handpiece NN i
+ VBD i
37 CD i
% NN i
phosphoric JJ i
acid NN i
; : i
II NNP N
- : N
Er NN i
: : i
YAG NNP i
laser NN i
( ( i
350 CD i
mJ NN i
, , i
4 CD i
Hz NNP i
and CC i
112 CD i
J/cm NNP i
( ( i
2 CD i
) ) i
) ) i
+ $ i
37 CD i
% NN i
phosphoric JJ i
acid NN i
; : i
and CC N
III NNP N
- : N
Er NN i
: : i
YAG NNP i
laser NN i
( ( i
350 CD i
mJ NN i
, , i
4 CD i
Hz NNP i
and CC i
112 CD i
J/cm NNP i
( ( i
2 CD i
) ) i
) ) i
+ FW i
Er NNP i
: : i
YAG NNP i
laser NN i
( ( i
80 CD i
mJ NN i
, , i
4 CD i
Hz NNP i
, , i
and CC i
25 CD i
mJ/cm NN i
( ( i
2 CD i
) ) i
) ) i
. . N

All DT N
cavities NNS p
received VBD N
the DT N
same JJ N
adhesive JJ N
system NN N
and CC N
were VBD N
restored VBN N
with IN N
flowable JJ N
composite JJ N
according VBG N
to TO N
manufacturer NN N
's POS N
instructions NNS N
. . N

Teeth NNP N
were VBD N
submitted VBN N
to TO N
thermal VB i
cycling NN i
and CC N
immersed VBN N
in IN N
50 CD N
% NN N
silver NN i
nitrate JJ i
solutions NNS i
for IN N
8 CD N
h NN N
in IN N
total JJ N
darkness NN N
. . N

Specimens NNS N
were VBD N
sectioned VBN N
longitudinally RB N
in IN N
the DT N
bucco-lingual JJ N
direction NN N
, , N
in IN N
slices NNS N
of IN N
1 CD N
mm NNS N
thick JJ N
. . N

Each DT N
slice NN N
was VBD N
immersed VBN N
into IN N
photo NN N
developing VBG N
solution NN N
and CC N
was VBD N
photographed VBN N
, , N
and CC N
microleakage NN o
was VBD o
scored VBN o
from IN o
0 CD o
to TO o
7 CD o
, , N
by IN N
three CD N
calibrated JJ N
examiners NNS N
. . N

RESULTS VB N
A NNP N
statistically RB N
significant JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
was VBD N
observed VBN N
between IN N
Er NNP N
: : N
YAG NNP N
laser NN N
prepared VBD N
and CC N
etched VBD N
specimens NNS N
and CC N
those DT N
in IN N
the DT N
other JJ N
groups NNS N
. . N

CONCLUSIONS VB N
It PRP N
can MD N
be VB N
concluded VBN N
that IN N
no DT N
significant JJ N
difference NN N
was VBD N
noted VBN N
between IN N
the DT N
two CD N
types NNS N
of IN N
enamel NN i
preparation NN i
when WRB N
etching NN N
was VBD N
performed VBN N
. . N

Preparing VBG N
and CC N
treating VBG N
the DT N
enamel JJ N
surface NN N
exclusively RB N
by IN N
Er NNP i
: : i
YAG NNP i
laser NN i
resulted VBD N
in IN N
the DT N
highest JJS N
degree NN o
of IN o
leakage NN o
. . o

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
comparison NN N
of IN N
the DT N
analgesic JJ o
efficacy NN o
, , o
onset NN o
of IN o
action NN o
, , N
and CC N
tolerability NN o
of IN N
ibuprofen JJ i
arginate NN i
and CC N
ibuprofen NN i
in IN N
postoperative JJ p
dental NN p
pain NN p
. . p

BACKGROUND NNP N
Because IN N
of IN N
its PRP$ N
enhanced JJ N
pharmacokinetic JJ o
characteristics NNS o
, , N
ibuprofen JJ i
arginate NN i
might MD N
be VB N
expected VBN N
to TO N
provide VB N
faster JJR N
pain NN o
relief NN o
than IN N
standard JJ i
ibuprofen JJ i
formulations NNS N
in IN N
patients NNS p
experiencing VBG p
acute JJ p
pain NN p
. . p

OBJECTIVE CC N
This DT N
study NN N
assessed VBD N
the DT N
analgesic JJ o
efficacy NN o
, , o
speed NN o
of IN o
onset NN o
, , o
and CC o
tolerability NN o
of IN N
ibuprofen JJ N
arginate NN N
compared VBN N
with IN N
a DT N
commercially RB N
available JJ N
form NN N
of IN N
ibuprofen NN N
in IN N
patients NNS p
with IN p
postoperative JJ p
dental NN p
pain NN p
. . p

METHODS NNP N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
receive VB N
ibuprofen JJ i
arginate NN i
200 CD i
or CC i
400 CD i
mg NN i
, , i
ibuprofen JJ i
200 CD i
or CC i
400 CD i
mg NN i
, , i
or CC i
placebo NN i
in IN N
this DT N
multicenter NN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
parallel-group JJ N
trial NN N
. . N

Patients NNS N
were VBD N
observed VBN N
for IN N
6 CD N
hours NNS N
after IN N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
study NN N
medication NN N
. . N

A DT N
repeated-dose JJ N
, , N
open-label JJ N
phase NN N
followed VBD N
. . N

Pain NNP o
intensity NN o
and CC o
pain NN o
relief NN o
were VBD N
measured VBN N
using VBG N
traditional JJ N
verbal JJ o
descriptor NN o
scales NNS o
; : o
onset VBN o
of IN o
analgesia NN o
was VBD N
assessed VBN N
using VBG N
2 CD N
stopwatches NNS N
to TO N
measure VB N
the DT N
time NN o
to TO o
achievement NN o
of IN o
specific JJ o
pain NN o
relief NN o
criteria NNS N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
498 CD p
patients NNS p
( ( p
219 CD p
men NNS p
, , p
279 CD p
women NNS p
; : p
mean JJ p
age NN p
, , p
21.5 CD p
years NNS p
) ) p
participated VBD p
in IN p
this DT p
study NN p
. . p

Baseline NNP o
pain NN o
was VBD N
moderate JJ N
in IN N
388 CD N
patients NNS N
( ( N
78 CD N
% NN N
) ) N
and CC N
severe JJ N
in IN N
110 CD N
patients NNS N
( ( N
22 CD N
% NN N
) ) N
. . N

Meaningful JJ N
pain NN o
relief NN o
was VBD N
reached VBN N
after IN N
a DT N
median NN N
of IN N
29 CD N
and CC N
28 CD N
minutes NNS N
with IN N
ibuprofen JJ i
arginate NN i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
and CC N
after IN N
52 CD N
and CC N
44 CD N
minutes NNS N
with IN N
ibuprofen JJ i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
( ( N
all DT N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
percentages NNS N
of IN N
patients NNS N
who WP N
achieved VBD N
meaningful JJ N
pain NN o
relief NN o
within IN N
the DT N
first JJ N
hour NN N
after IN N
treatment NN N
were VBD N
77.6 CD N
% NN N
and CC N
83.7 CD N
% NN N
for IN N
ibuprofen JJ i
arginate NN i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
61.0 CD N
% NN N
and CC N
63.0 CD N
% NN N
for IN N
ibuprofen JJ i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
and CC N
39.8 CD N
% NN N
for IN N
placebo NN N
. . N

The DT N
differences NNS N
between IN N
ibuprofen JJ N
arginate NN N
and CC N
ibuprofen NN N
were VBD N
statistically RB N
significant JJ N
( ( N
both DT N
doses NNS N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Significantly RB N
greater JJR N
numbers NNS N
of IN N
patients NNS N
achieved VBN N
meaningful JJ N
pain NN o
relief NN o
with IN N
ibuprofen JJ i
arginate NN i
400 CD N
mg NN N
compared VBN N
with IN N
placebo NN i
from IN N
20 CD N
minutes NNS N
through IN N
6 CD N
hours NNS N
and CC N
with IN N
ibuprofen JJ N
arginate NN N
200 CD N
mg NN N
from IN N
30 CD N
minutes NNS N
through IN N
6 CD N
hours NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
a DT N
greater JJR N
number NN N
of IN N
patients NNS N
achieved VBN N
meaningful JJ N
pain NN o
relief NN o
with IN N
ibuprofen JJ i
400 CD N
mg NN N
from IN N
45 CD N
minutes NNS N
through IN N
6 CD N
hours NNS N
; : N
with IN N
ibuprofen NN N
200 CD N
mg. NN N
the DT N
corresponding JJ N
interval NN N
was VBD N
from IN N
I PRP N
through IN N
6 CD N
hours NNS N
. . N

After IN N
the DT N
first JJ N
hour NN N
, , N
pain NN o
reduction NN o
was VBD N
similar JJ N
for IN N
the DT N
similar JJ N
doses NNS N
of IN N
the DT N
2 CD N
ibuprofen JJ i
preparations NNS N
. . N

Median JJ o
remedication NN o
times NNS o
with IN N
both DT N
doses NNS N
of IN N
ibuprofen JJ i
arginate NN i
were VBD N
similar JJ N
to TO N
those DT N
with IN N
both DT N
doses NNS N
of IN N
ibuprofen NN N
, , N
ranging VBG N
from IN N
4.0 CD N
to TO N
5.2 CD N
hours NNS N
. . N

Adverse-event JJ o
profiles NNS o
were VBD N
similar JJ N
between IN N
the DT N
2 CD N
active JJ N
medications NNS N
. . N

CONCLUSIONS NNP N
Ibuprofen NNP i
arginate NN i
was VBD N
effective JJ N
in IN N
this DT N
population NN N
of IN N
patients NNS N
experiencing VBG N
moderate JJ N
to TO N
severe VB N
pain NN N
after IN N
surgical JJ N
extraction NN N
of IN N
> NN N
or CC N
= $ N
1 CD N
impacted JJ N
third JJ N
molar NN N
, , N
with IN N
16 CD N
to TO N
24 CD N
minutes NNS N
' POS N
faster NN N
time NN N
to TO N
meaningful VB N
pain NN o
relief NN o
than IN N
with IN N
ibuprofen NN N
. . N

The DT N
2 CD N
formulations NNS N
had VBD N
similar JJ N
tolerability NN o
profiles NNS o
. . o

-DOCSTART- -X- O O

Beverage NNP i
vs. FW i
solid JJ i
fruits NNS i
and CC i
vegetables NNS i
: : i
effects NNS N
on IN N
energy NN N
intake NN N
and CC N
body NN o
weight NN o
. . o

Beverage NN N
consumption NN N
has VBZ N
been VBN N
implicated VBN N
in IN N
weight NN N
gain NN N
, , N
but CC N
questions NNS N
remain VBP N
about IN N
the DT N
veracity NN N
of IN N
the DT N
association NN N
, , N
whether IN N
the DT N
relationship NN N
is VBZ N
causal JJ N
and CC N
what WP N
property NN N
of IN N
beverages NNS N
is VBZ N
responsible JJ N
. . N

It PRP N
was VBD N
hypothesized VBN N
that IN N
food NN N
form NN N
is VBZ N
the DT N
most RBS N
salient JJ N
attribute NN N
. . N

Thus RB N
, , N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
food NN N
form NN N
was VBD N
conducted VBN N
. . N

Energy-matched JJ i
beverage NN i
or CC i
solid JJ i
forms NNS i
of IN i
fruits NNS i
and CC i
vegetables NNS i
were VBD N
provided VBN N
to TO N
34 CD p
, , p
lean JJ p
or CC p
overweight/obese JJ p
adults NNS p
for IN N
two CD N
8-week JJ N
periods NNS N
with IN N
a DT N
3-week JJ N
washout NN N
interspersed VBN N
. . N

Dietary JJ o
compensation NN o
was VBD N
incomplete JJ N
( ( N
beverage VB N
53 CD N
% NN N
; : N
solid JJ N
78 CD N
% NN N
) ) N
and CC N
body JJ o
weight NN o
increased VBD N
after IN N
the DT N
beverage NN N
( ( N
1.95 CD N
? . N
0.33 CD N
kg NN N
) ) N
( ( N
77 CD N
% NN N
fat JJ N
mass NN N
) ) N
and CC N
solid JJ N
( ( N
1.36 CD N
? . N
0.30 CD N
kg NN N
) ) N
( ( N
85 CD N
% NN N
fat JJ N
mass NN N
) ) N
treatments NNS N
( ( N
both DT N
P NNP N
< NNP N
0.0005 CD N
) ) N
. . N

Differences NNS N
between IN N
food NN N
forms NNS N
were VBD N
not RB N
significant JJ N
. . N

The DT N
lean JJ N
group NN N
had VBD N
the DT N
highest JJS o
dietary JJ o
compensation NN o
( ( o
119 CD N
% NN N
) ) N
and CC N
no DT N
significant JJ o
weight NN o
change NN o
( ( o
0.84 CD N
? . N
0.53 CD N
kg NN N
) ) N
after IN N
consuming VBG N
the DT N
solid JJ N
fruits NNS N
and CC N
vegetables NNS N
whereas VBP N
the DT N
overweight/obese JJ N
group NN N
had VBD N
lower JJR o
compensation NN o
and CC o
significant JJ o
weight JJ o
gain NN o
during IN o
the DT N
solid JJ N
arm NN N
( ( N
46 CD N
% NN N
, , N
1.77 CD N
? . N
0.32 CD N
kg NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
incomplete JJ o
dietary JJ o
compensation NN o
and CC o
weight JJ o
gain NN o
occurred VBD o
in IN N
both CC N
the DT N
lean NN N
( ( N
43 CD N
% NN N
, , N
1.61 CD N
? . N
0.44 CD N
kg NN N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
and CC N
overweight/obese JJ N
( ( N
61 CD N
% NN N
, , N
2.22 CD N
? . N
0.47 CD N
kg NN N
, , N
P NNP N
< NNP N
0.0005 CD N
) ) N
groups NNS N
during IN N
the DT N
beverage NN N
arm NN N
. . N

Secondary JJ N
analyses NNS N
revealed VBD p
the DT p
obese JJ p
group NN p
gained VBD N
more JJR N
weight NN N
than IN N
the DT p
lean JJ p
and CC p
overweight JJ p
groups NNS p
during IN N
the DT N
beverage NN N
intervention NN N
( ( N
P NNP N
= NNP N
0.024 CD N
) ) N
. . N

These DT N
data NNS N
demonstrate VBP N
energy NN N
consumed VBN N
as IN N
beverages NNS N
may MD N
be VB N
especially RB N
problematic JJ o
for IN o
weight JJ o
gain NN o
. . o

They PRP N
also RB N
indicate VBP N
that IN N
advice NN N
to TO N
increase VB N
fruit NN N
and CC N
vegetable JJ N
consumption NN N
should MD N
emphasize VB N
total JJ N
energy NN N
intake NN N
because IN N
the DT N
additional JJ N
energy NN N
contributed VBD N
may MD N
promote VB o
weight NN o
gain NN o
, , o
especially RB N
among IN N
overweight JJ p
and CC p
obese JJ p
individuals NNS p
. . p

-DOCSTART- -X- O O

Effect NN N
of IN N
ozone NN i
application NN i
on IN N
the DT N
resin-dentin JJ o
microtensile NN o
bond NN o
strength NN o
. . o

When WRB N
ozone NN N
is VBZ N
used VBN N
during IN N
caries NNS N
treatment NN N
, , N
bond NN N
strength NN N
can MD N
be VB N
compromised VBN N
by IN N
the DT N
release NN N
of IN N
oxygen NN N
. . N

The DT N
use NN N
of IN N
antioxidant JJ N
agents NNS N
neutralizes VBZ N
the DT N
free JJ N
oxygen NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
ozone NN i
and CC i
sodium NN i
ascorbate NN i
on IN N
resin-dentin JJ o
microtensile NN o
bond NN o
strength NN o
( ( o
?TBS NN o
) ) o
. . o

Forty NNP p
human JJ p
third JJ p
molars NNS p
were VBD N
divided VBN N
into IN N
four CD N
groups NNS N
: : N
Group NNP N
1 CD N
, , N
not RB i
treated VBN i
with IN i
ozone NN i
; : i
Group NNP N
2 CD N
, , N
ozone NN i
application NN i
followed VBN i
by IN i
acid NN i
etching NN i
; : i
Group NNP N
3 CD N
, , N
acid NN i
etching VBG i
followed VBN i
by IN i
ozone NN i
application NN i
; : i
and CC N
Group NNP N
4 CD N
, , N
ozone NN i
and CC i
application NN i
of IN i
sodium NN i
ascorbate NN i
. . i

Bonded VBN N
beams NN N
( ( N
1.0 CD N
mm NN N
( ( N
2 CD N
) ) N
) ) N
were VBD N
tested VBN N
under IN N
tension NN N
( ( N
0.5 CD N
mm NN N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

The DT o
?TBS JJ o
values NNS o
were VBD N
analyzed VBN N
using VBG N
one-way JJ N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
and CC N
the DT N
Tukey NNP N
test NN N
( ( N
p=0.05 NN N
) ) N
. . N

All DT N
beams NNS N
that WDT N
fractured VBD N
were VBD N
analyzed VBN N
under IN N
stereomicroscopy NN N
( ( N
40? CD N
) ) N
. . N

Group NNP N
1 CD N
had VBD N
significantly RB N
higher JJR o
?TBS NN o
values NNS o
than IN o
Group NNP N
2 CD N
or CC N
3 CD N
. . N

The DT N
?TBS JJ o
values NNS o
of IN o
Groups NNP o
1 CD N
and CC N
4 CD N
were VBD N
similar JJ N
and CC N
higher JJR N
than IN N
those DT N
of IN N
Group NNP N
2 CD N
. . N

The DT N
use NN N
of IN N
ozone NN N
in IN N
Group NNP N
2 CD N
resulted VBD N
in IN N
lower JJR N
values NNS o
of IN o
?TBS NN o
in IN N
all DT N
conditions NNS N
evaluated VBN N
. . N

The DT N
predominant JJ o
failure NN o
mode NN o
was VBD N
adhesive JJ N
. . N

The DT N
application NN N
of IN N
ozone NN N
decreased VBD o
the DT o
?TBS NN o
of IN o
the DT o
dentin-composite JJ o
resin NN o
interface NN o
. . o

These DT o
values NNS N
were VBD N
reversed VBN N
when WRB N
compared VBN N
with IN N
Groups NNP N
1 CD N
and CC N
2 CD N
when WRB N
sodium NN N
ascorbate NN N
was VBD N
used VBN N
. . N

-DOCSTART- -X- O O

A DT N
pilot NN N
randomised VBN N
controlled JJ N
trial NN N
of IN N
cognitive JJ i
behavioural JJ i
therapy NN i
for IN N
antenatal JJ p
depression NN p
. . p

BACKGROUND NNP N
Few JJ N
trials NNS N
have VBP N
evaluated VBN N
the DT N
effectiveness NN N
of IN N
psychological JJ N
treatment NN N
in IN N
improving VBG N
depression NN N
by IN N
the DT N
end NN N
of IN N
pregnancy NN p
. . p

This DT N
is VBZ N
the DT N
first JJ N
pilot NN N
randomised VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
of IN N
individual JJ i
cognitive JJ i
behavioural JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
looking VBG N
at IN N
treating VBG N
depression NN N
by IN N
the DT N
end NN N
of IN N
pregnancy NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
assess VB N
the DT N
feasibility NN N
of IN N
delivering VBG N
a DT N
CBT NNP i
intervention NN i
modified VBD N
for IN N
antenatal JJ N
depression NN N
during IN N
pregnancy NN N
. . N

METHODS NNP N
Women NNP p
in IN p
North NNP p
Bristol NNP p
, , p
UK NNP p
between IN p
8-18 JJ p
weeks NNS p
pregnant JJ p
were VBD p
recruited VBN p
through IN p
routine JJ p
contact NN p
with IN p
midwives NNS p
and CC N
randomised VBN N
to TO N
receive VB N
up RP N
to TO N
12 CD N
sessions NNS N
of IN i
individual JJ i
CBT NNP i
in IN i
addition NN i
to TO i
usual JJ i
care NN i
or CC N
to TO N
continue VB N
with IN i
usual JJ i
care NN i
only RB i
. . i

Women NNS p
were VBD p
eligible JJ p
for IN p
randomisation NN p
if IN N
they PRP N
screened VBD N
positive JJ N
on IN N
a DT N
3-question JJ N
depression NN N
screen NN N
used VBN N
routinely RB N
by IN p
midwives NNS p
and CC p
met VBD p
ICD-10 NNP p
criteria NNS p
for IN p
depression NN p
assessed VBN p
using VBG p
the DT p
clinical JJ p
interview NN p
schedule NN p
- : p
revised VBN p
version NN p
( ( p
CIS-R NNP p
) ) p
. . p

Two CD i
CBT NNP i
therapists NNS N
delivered VBD N
the DT N
intervention NN N
. . N

Follow-up NN N
was VBD N
at IN N
15 CD N
and CC N
33 CD N
weeks NNS N
post-randomisation NN N
when WRB N
assessments NNS N
of IN N
mental JJ o
health NN o
were VBD o
made VBN N
using VBG N
measures NNS N
which WDT N
included VBD N
the DT N
CIS-R NNP N
. . N

RESULTS NNP p
Of IN p
the DT p
50 CD p
women NNS p
assessed VBD p
for IN p
the DT p
trial NN p
, , p
36 CD p
met VBD p
ICD-10 NNP p
depression NN p
criteria NNS p
and CC p
were VBD p
randomised VBN p
: : p
18 CD p
to TO p
the DT p
intervention NN p
and CC p
18 CD p
to TO p
usual JJ p
care NN p
. . p

Thirteen NNP p
of IN p
the DT p
18 CD p
( ( p
72 CD p
% NN p
) ) p
women NNS p
who WP p
were VBD N
allocated VBN N
to TO N
receive VB N
the DT N
intervention NN N
completed VBD N
9 CD N
or CC N
more JJR N
sessions NNS N
of IN N
CBT NNP i
before IN i
the DT N
end NN N
of IN N
pregnancy NN N
. . N

Follow-up JJ N
rates NNS N
at IN N
15 CD N
and CC N
33 CD N
weeks NNS N
post-randomisation NN N
were VBD N
higher JJR N
in IN N
the DT N
group NN N
who WP N
received VBD N
the DT N
intervention NN N
( ( N
89 CD N
% NN N
vs. FW N
72 CD N
% NN N
at IN N
15 CD N
weeks NNS N
and CC N
89 CD N
% NN N
vs. FW N
61 CD N
% NN N
at IN N
33 CD N
weeks NNS N
post-randomisation NN N
) ) N
. . N

At IN N
15 CD N
weeks NNS N
post-randomisation NN N
( ( N
the DT N
end NN N
of IN N
pregnancy NN N
) ) N
, , N
there EX N
were VBD N
more JJR N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
( ( N
11/16 CD N
; : N
68.7 CD N
% NN N
) ) N
who WP N
recovered VBD N
( ( N
i.e NN N
. . N

no RB N
longer RBR N
met VBD N
ICD-10 NNP N
criteria NNS o
for IN o
depression NN o
) ) o
, , o
than IN o
those DT N
receiving VBG N
only RB N
usual JJ N
care NN N
( ( N
5/13 CD N
; : N
38.5 CD N
% NN N
) ) N
. . N

CONCLUSIONS VB N
This DT N
pilot NN N
trial NN N
shows VBZ N
the DT N
feasibility NN N
of IN N
conducting VBG N
a DT N
large JJ N
RCT NNP N
to TO N
assess VB N
the DT N
effectiveness NN i
of IN i
CBT NNP i
for IN i
treating VBG N
antenatal JJ N
depression NN N
before IN N
the DT N
end NN N
of IN N
pregnancy NN N
. . N

The DT N
intervention NN N
could MD N
be VB N
delivered VBN N
during IN N
the DT N
antenatal JJ N
period NN N
and CC N
there EX N
was VBD N
some DT N
evidence NN N
to TO N
suggest VB N
that IN N
it PRP N
could MD N
be VB N
effective JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN44902048 NNP N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
recombinant JJ N
human JJ N
thyrotropin NN N
and CC N
thyroid VB N
hormone NN N
withdrawal NN N
for IN N
the DT N
detection NN N
of IN N
thyroid JJ N
remnant NN N
or CC N
cancer NN N
. . N

Recombinant NNP i
human JJ i
TSH NNP i
has VBZ N
been VBN N
developed VBN N
to TO N
facilitate VB N
monitoring NN N
for IN N
thyroid JJ N
carcinoma NN N
recurrence NN N
or CC N
persistence NN N
without IN N
the DT N
attendant JJ N
morbidity NN N
of IN N
hypothyroidism NN N
seen VBN N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
administered VBN i
recombinant JJ i
human JJ i
TSH NN i
with IN N
thyroid JJ N
hormone NN N
withdrawal NN N
on IN N
the DT N
results NNS N
of IN N
radioiodine JJ N
whole JJ N
body NN N
scanning VBG N
( ( N
WBS NNP N
) ) N
and CC N
serum JJ N
thyroglobulin NN N
( ( N
Tg NNP N
) ) N
levels NNS N
. . N

Two CD p
hundred CD p
and CC p
twenty-nine JJ p
adult NN p
patients NNS p
with IN p
differentiated JJ p
thyroid NN p
cancer NN p
requiring VBG p
radioiodine NN p
WBS NNP p
were VBD p
studied VBN p
. . p

Radioiodine NNP i
WBS NNP i
and CC N
serum VB N
Tg NNP N
measurements NNS N
were VBD N
performed VBN N
after IN N
administration NN N
of IN N
recombinant JJ i
human JJ i
TSH NNP i
and CC N
again RB N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
in IN N
each DT N
patient NN N
. . N

Radioiodine NNP N
whole JJ N
body NN N
scans NNS N
were VBD N
concordant JJ N
between IN N
the DT N
recombinant JJ o
TSH-stimulated JJ o
and CC o
thyroid JJ o
hormone NN o
withdrawal NN o
phases NNS o
in IN N
195 CD N
of IN N
220 CD N
( ( N
89 CD N
% NN N
) ) N
patients NNS N
. . N

Of IN N
the DT N
discordant NN N
scans NNS N
, , N
8 CD N
( ( N
4 CD N
% NN N
) ) N
had VBD N
superior JJ N
scans NNS N
after IN N
recombinant JJ i
human JJ i
TSH NNP i
administration NN i
, , N
and CC N
17 CD N
( ( N
8 CD N
% NN N
) ) N
had VBD N
superior JJ N
scans NNS N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
( ( N
P NNP N
= NNP N
0.108 CD N
) ) N
. . N

Based VBN N
on IN N
a DT N
serum NN o
Tg NNP o
level NN o
of IN N
2 CD N
ng/mL NNS N
or CC N
more JJR N
, , N
thyroid JJ N
tissue NN N
or CC N
cancer NN N
was VBD N
detected VBN N
during IN N
thyroid JJ i
hormone NN i
therapy NN i
in IN N
22 CD N
% NN N
, , N
after IN N
recombinant JJ i
human JJ i
TSH NNP i
stimulation NN N
in IN N
52 CD N
% NN N
, , N
and CC N
after IN N
thyroid JJ i
hormone NN i
withdrawal NN i
in IN N
56 CD N
% NN N
of IN N
patients NNS p
with IN p
disease NN p
or CC p
tissue NN p
limited VBN p
to TO p
the DT p
thyroid NN p
bed NN p
and CC N
in IN N
80 CD N
% NN N
, , N
100 CD N
% NN N
, , N
and CC N
100 CD p
% NN p
of IN p
patients NNS p
, , p
respectively RB p
, , p
with IN p
metastatic JJ p
disease NN p
. . p

A DT N
combination NN N
of IN N
radioiodine NN N
WBS NNP N
and CC N
serum NN N
Tg NNP N
after IN N
recombinant JJ N
human JJ N
TSH NNP N
stimulation NN N
detected VBD N
thyroid JJ o
tissue NN o
or CC o
cancer NN o
in IN N
93 CD N
% NN N
of IN N
patients NNS p
with IN p
disease NN p
or CC p
tissue NN p
limited VBN p
to TO p
the DT p
thyroid NN p
bed NN p
and CC N
100 CD N
% NN N
of IN N
patients NNS p
with IN p
metastatic JJ p
disease NN p
. . p

In IN N
conclusion NN N
, , N
recombinant JJ i
human JJ i
TSH NNP i
administration NN i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
means NNS N
of IN N
stimulating VBG N
radioiodine JJ N
uptake NN N
and CC N
serum NN N
Tg NNP N
levels NNS N
in IN N
patients NNS p
undergoing JJ p
evaluation NN p
for IN p
thyroid JJ p
cancer NN p
persistence NN p
and CC p
recurrence NN p
. . p

-DOCSTART- -X- O O

Ketorolac NNP i
versus NN i
fentanyl NN i
for IN N
gynaecological JJ p
day-case NN p
surgery NN p
. . p

The DT N
effectiveness NN N
of IN N
fentanyl NN i
and CC N
ketorolac NN i
in IN N
providing VBG N
analgesia NN N
for IN N
day-case JJ p
gynaecological JJ p
procedures NNS p
was VBD p
evaluated VBN p
in IN p
55 CD p
healthy JJ p
volunteers NNS p
in IN p
a DT p
single JJ p
blinded JJ p
fashion NN p
. . p

Fentanyl NNP i
( ( N
1 CD N
mcg/kg RB N
iv NN N
) ) N
and CC N
ketorolac NN i
( ( N
30 CD N
mg RB N
im NN N
) ) N
were VBD N
administered VBN N
immediately RB N
following VBG N
induction NN N
of IN N
anaesthesia NN N
. . N

Anaesthesia NNP N
was VBD N
standardized VBN N
with IN N
propofol NN i
, , i
nitrous JJ i
oxide NN i
and CC i
enflurane NN i
. . i

Outcome NNP N
variables NNS N
assessed VBN N
were VBD N
pain RB o
, , o
additional JJ o
analgesic NN o
requirements NNS o
, , o
and CC o
incidence NN o
of IN o
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
. . o

All DT N
variables NNS N
were VBD N
recorded VBN N
at IN N
15 CD N
minutes NNS N
, , N
2 CD N
hours NNS N
and CC N
24 CD N
hours NNS N
postoperatively RB N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
with IN N
respect NN N
to TO N
any DT N
of IN N
the DT N
measured JJ N
variables NNS N
. . N

Both DT N
drugs NNS N
were VBD N
ineffective JJ o
as IN N
sole JJ o
analgesic JJ o
agents NNS o
in IN N
half NN N
of IN N
their PRP$ N
respective JJ N
groups NNS N
. . N

It PRP N
may MD N
be VB N
that IN N
a DT N
combination NN N
of IN N
these DT N
drugs NNS N
, , N
providing VBG N
a DT N
multireceptor NN N
approach NN N
to TO N
analgesia VB N
, , N
will MD N
prove VB N
to TO N
be VB N
more RBR N
effective JJ N
. . N

-DOCSTART- -X- O O

Selective JJ N
insulin NN N
resistance NN N
in IN N
homeostatic JJ N
and CC N
cognitive JJ N
control NN N
brain NN N
areas NNS N
in IN N
overweight NN p
and CC p
obese JJ p
adults NNS p
. . p

OBJECTIVE NNP N
Impaired NNP N
brain NN N
insulin NN N
action NN N
has VBZ N
been VBN N
linked VBN N
to TO N
obesity NN N
, , N
type NN N
2 CD N
diabetes NNS N
, , N
and CC N
neurodegenerative JJ N
diseases NNS N
. . N

To TO N
date NN N
, , N
the DT N
central JJ N
nervous JJ N
effects NNS N
of IN N
insulin NN N
in IN N
obese JJ N
humans NNS N
still RB N
remain VBP N
ill JJ N
defined VBN N
, , N
and CC N
no DT N
study NN N
thus RB N
far RB N
has VBZ N
evaluated VBN N
the DT N
specific JJ N
brain NN N
areas NNS N
affected VBN N
by IN N
insulin NN N
resistance NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
25 CD p
healthy JJ p
lean NN p
and CC p
23 CD p
overweight/obese JJ p
participants NNS p
, , N
we PRP N
performed VBD N
magnetic JJ i
resonance NN i
imaging NN i
to TO N
measure VB N
cerebral JJ o
blood NN o
flow NN o
( ( o
CBF NNP o
) ) o
before IN N
and CC N
15 CD N
and CC N
30 CD N
min NN N
after IN N
application NN N
of IN N
intranasal JJ i
insulin NN i
or CC i
placebo NN i
. . i

Additionally RB N
, , N
participants NNS N
explicitly RB N
rated VBN N
pictures NNS N
of IN N
high-caloric JJ N
savory NN N
and CC N
sweet VB N
food NN N
60 CD N
min NN N
after IN N
the DT N
spray NN N
for IN N
wanting VBG N
and CC N
liking VBG N
. . N

RESULTS NNP N
In IN N
response NN N
to TO N
insulin VB i
compared VBN N
with IN N
placebo NN i
, , N
we PRP N
found VBD N
a DT N
significant JJ N
CBF NNP o
decrease NN N
in IN N
the DT N
hypothalamus NN N
in IN N
both DT N
lean JJ o
and CC o
overweight/obese JJ o
participants NNS N
. . N

The DT N
magnitude NN N
of IN N
this DT N
response NN N
correlated VBD N
with IN N
visceral JJ N
adipose JJ N
tissue NN N
independent JJ N
of IN N
other JJ N
fat JJ N
compartments NNS N
. . N

Furthermore RB N
, , N
we PRP N
observed VBD N
a DT N
differential JJ N
response NN N
in IN N
the DT N
lean JJ N
compared VBN N
with IN N
the DT N
overweight/obese JJ N
group NN N
in IN N
the DT N
prefrontal JJ N
cortex NN N
, , N
resulting VBG N
in IN N
an DT N
insulin-induced JJ o
CBF NNP o
reduction NN o
in IN N
lean JJ N
participants NNS N
only RB N
. . N

This DT N
prefrontal JJ N
cortex NN N
response NN N
significantly RB N
correlated VBN N
with IN N
peripheral JJ o
insulin NN o
sensitivity NN o
and CC o
eating VBG o
behavior JJ o
measures NNS N
such JJ N
as IN N
disinhibition NN N
and CC N
food NN N
craving NN N
. . N

Behaviorally NNP N
, , N
we PRP N
were VBD N
able JJ N
to TO N
observe VB N
a DT N
significant JJ N
reduction NN N
for IN N
the DT N
wanting NN o
of IN o
sweet JJ o
foods NNS o
after IN N
insulin JJ N
application NN N
in IN N
lean JJ N
men NNS N
only RB N
. . N

CONCLUSIONS NNP N
Brain NNP N
insulin NN N
action NN N
was VBD N
selectively RB N
impaired VBN N
in IN N
the DT N
prefrontal JJ N
cortex NN N
in IN N
overweight NN N
and CC N
obese JJ N
adults NNS N
and CC N
in IN N
the DT N
hypothalamus NN N
in IN N
participants NNS N
with IN N
high JJ N
visceral JJ N
adipose JJ N
tissue NN N
, , N
potentially RB N
promoting VBG N
an DT N
altered JJ N
homeostatic JJ N
set NN N
point NN N
and CC N
reduced JJ N
inhibitory NN N
control NN N
contributing VBG N
to TO N
overeating VBG N
behavior NN N
. . N

-DOCSTART- -X- O O

Physical JJ i
exercise NN i
at IN i
the DT i
workplace NN i
reduces VBZ N
perceived JJ N
physical JJ N
exertion NN N
during IN N
healthcare JJ N
work NN N
: : N
cluster NN N
randomized VBD N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
High NNP i
physical JJ i
exertion NN i
during IN N
work NN N
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
musculoskeletal JJ N
pain NN N
and CC N
long-term JJ N
sickness NN N
absence NN N
. . N

Physical JJ N
exertion NN N
( ( N
RPE NNP N
) ) N
reflects VBZ N
the DT N
balance NN N
between IN N
physical JJ N
work NN N
demands NNS N
and CC N
physical JJ N
capacity NN N
of IN N
the DT N
individual NN N
. . N

Thus RB N
, , N
increasing VBG N
the DT N
physical JJ N
capacity NN N
through IN N
physical JJ N
exercise NN N
may MD N
decrease VB N
physical JJ N
exertion NN N
during IN N
work NN N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
effect NN o
of IN N
workplace-based JJ N
versus NN N
home-based JJ N
physical JJ N
exercise NN N
on IN N
physical JJ N
exertion NN N
during IN N
work NN N
( ( N
WRPE NNP N
) ) N
among IN N
healthcare JJ p
workers NNS p
. . p

METHODS NNP N
200 CD p
female NN p
healthcare NN p
workers NNS p
( ( p
age NN p
: : p
42.0 CD p
, , p
body NN p
mass NN p
index NN p
: : p
24.1 CD p
, , p
average JJ p
pain NN p
intensity NN p
: : p
3.1 CD p
on IN p
a DT p
scale NN p
of IN p
0 CD p
to TO p
10 CD p
, , p
average JJ p
WRPE NNP p
: : p
3.6 CD p
on IN p
a DT p
scale NN p
of IN p
0 CD p
to TO p
10 CD p
) ) p
from IN p
18 CD p
departments NNS p
at IN p
three CD p
participating VBG p
hospitals NNS p
. . p

Participants NNS p
were VBD p
randomly RB p
allocated VBN p
at IN p
the DT p
cluster NN p
level NN p
to TO N
10 CD N
weeks NNS N
of IN N
: : N
( ( i
1 CD i
) ) i
workplace NN i
physical JJ i
exercise NN i
( ( i
WORK NNP i
) ) i
performed VBD i
in IN i
groups NNS i
during IN i
working VBG i
hours NNS i
for IN i
5?10 CD i
minutes NNS i
per IN i
week NN i
and CC i
up RB i
to TO i
five CD i
group-based JJ i
coaching NN i
sessions NNS i
on IN i
motivation NN i
for IN i
regular JJ i
physical JJ i
exercise NN i
, , i
or CC i
( ( i
2 CD i
) ) i
home-based JJ i
physical JJ i
exercise NN i
( ( i
HOME NNP i
) ) i
performed VBD i
during IN i
leisure NN i
time NN i
for IN i
5?10 CD i
minutes NNS i
per IN i
week NN o
. . o

Physical JJ o
exertion NN o
was VBD o
assessed VBN N
at IN N
baseline NN N
and CC N
at IN N
10-week JJ N
follow-up NN N
. . N

RESULTS VB N
2.2 CD N
( ( N
SD NNP N
: : N
1.1 CD N
) ) N
and CC N
1.0 CD N
( ( N
SD NNP N
: : N
1.2 CD N
) ) N
training NN N
sessions NNS N
were VBD N
performed VBN N
per IN N
week NN N
in IN N
WORK NNP N
and CC N
HOME NNP N
, , N
respectively RB o
. . o

Physical JJ o
exertion NN o
was VBD o
reduced VBN o
more RBR o
in IN N
WORK NNP N
than IN N
HOME NNP N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Between-group JJ N
differences NNS N
in IN N
physical JJ o
exertion NN o
at IN o
follow-up NN N
( ( N
WORK NNP N
vs. NNP N
HOME NNP N
) ) N
was VBD N
-0.5 JJ N
points NNS N
( ( N
95 CD N
% NN N
CI NNP N
-0.8 NNP N
to TO N
-0.2 VB N
) ) N
. . N

Within-group JJ o
effect NN o
size NN o
( ( o
Cohen NNP o
's POS o
d NN o
) ) o
in IN o
WORK NNP N
and CC N
HOME NNP N
was VBD N
0.43 CD N
and CC N
0.13 CD N
, , N
respectively RB N
. . N

CONCLUSIONS NNP i
Physical NNP i
exercise NN i
performed VBN i
at IN N
the DT N
workplace NN N
appears VBZ N
more RBR N
effective JJ N
than IN i
home-based JJ i
exercise NN i
in IN i
reducing VBG N
physical JJ N
exertion NN N
during IN N
daily JJ N
work NN N
tasks NNS N
in IN N
healthcare JJ p
workers NNS p
. . p

-DOCSTART- -X- O O

Virtual JJ i
patients NNS i
design NN i
and CC N
its PRP$ N
effect NN N
on IN N
clinical JJ o
reasoning NN o
and CC N
student NN o
experience NN o
: : o
a DT N
protocol NN N
for IN N
a DT N
randomised JJ N
factorial JJ N
multi-centre NN N
study NN N
. . N

BACKGROUND NNP N
Virtual JJ i
Patients NNP i
( ( i
VPs NNP i
) ) i
are VBP N
web-based JJ N
representations NNS N
of IN N
realistic JJ N
clinical JJ N
cases NNS N
. . N

They PRP N
are VBP N
proposed VBN N
as IN N
being VBG N
an DT N
optimal JJ N
method NN N
for IN N
teaching VBG N
clinical JJ N
reasoning NN N
skills NNS N
. . N

International NNP N
standards NNS N
exist VBP N
which WDT N
define VBP N
precisely RB N
what WP N
constitutes VBZ N
a DT N
VP NNP i
. . i

There EX N
are VBP N
multiple JJ N
design NN N
possibilities NNS N
for IN N
VPs NNP N
, , N
however RB N
there EX N
is VBZ N
little JJ N
formal JJ N
evidence NN N
to TO N
support VB N
individual JJ N
design NN N
features NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
trial NN N
is VBZ N
to TO N
explore VB N
the DT N
effect NN N
of IN N
two CD N
different JJ N
potentially RB N
important JJ N
design NN N
features NNS N
on IN N
clinical JJ o
reasoning NN o
skills NNS o
and CC o
the DT o
student NN o
experience NN o
. . o

These DT N
are VBP N
the DT N
branching VBG N
case NN N
pathways NNS N
( ( N
present JJ N
or CC N
absent NN N
) ) N
and CC N
structured JJ N
clinical JJ N
reasoning VBG N
feedback NN N
( ( N
present JJ N
or CC N
absent NN N
) ) N
. . N

METHODS/DESIGN NNP N
This DT N
is VBZ N
a DT N
multi-centre JJ N
randomised JJ N
2 CD N
x JJ N
2 CD N
factorial JJ N
design NN N
study NN N
evaluating VBG N
two CD N
independent JJ N
variables NNS N
of IN N
VP NNP i
design NN i
, , i
branching NN i
( ( i
present JJ i
or CC i
absent NN i
) ) i
, , N
and CC N
structured VBD i
clinical JJ i
reasoning NN i
feedback NN i
( ( i
present JJ i
or CC i
absent NN i
) ) i
.The NN i
study NN N
will MD N
be VB N
carried VBN N
out RP N
in IN N
medical JJ p
student NN p
volunteers NNS p
in IN p
one CD p
year NN p
group NN p
from IN p
three CD p
university NN p
medical JJ p
schools NNS p
in IN p
the DT p
United NNP p
Kingdom NNP p
, , p
Warwick NNP p
, , p
Keele NNP p
and CC p
Birmingham NNP p
. . p

There EX N
are VBP N
four CD N
core NN N
musculoskeletal NN N
topics NNS N
. . N

Each DT N
case NN N
can MD N
be VB N
designed VBN N
in IN N
four CD N
different JJ N
ways NNS N
, , N
equating VBG N
to TO N
16 CD N
VPs NNP N
required VBN N
for IN N
the DT N
research NN N
. . N

Students NNS p
will MD N
be VB N
randomised VBN N
to TO N
four CD N
groups NNS N
, , N
completing VBG N
the DT N
four CD N
VP NNP i
topics NNS N
in IN N
the DT N
same JJ N
order NN N
, , N
but CC N
with IN N
each DT N
group NN N
exposed VBD N
to TO N
a DT N
different JJ N
VP NNP i
design NN N
sequentially RB N
. . N

All DT N
students NNS p
will MD N
be VB N
exposed VBN N
to TO N
the DT N
four CD N
designs NNS N
. . N

Primary JJ N
outcomes NNS N
are VBP N
performance NN o
for IN o
each DT o
case NN o
design NN o
in IN o
a DT o
standardized JJ o
fifteen JJ o
item NN o
clinical JJ o
reasoning NN o
assessment NN o
, , o
integrated VBN o
into IN o
each DT o
VP NNP o
, , o
which WDT o
is VBZ o
identical JJ o
for IN o
each DT o
topic NN o
. . o

Additionally RB N
a DT N
15-item JJ o
self-reported JJ o
evaluation NN o
is VBZ N
completed VBN N
for IN N
each DT N
VP NNP i
, , N
based VBN N
on IN N
a DT N
widely RB N
used VBN N
EViP NNP N
tool NN N
. . N

Student NN p
patterns NNS N
of IN N
use NN N
of IN N
the DT N
VPs NNP N
will MD N
be VB N
recorded.In JJ N
one CD N
centre NN N
, , N
formative JJ N
clinical JJ N
and CC N
examination NN N
performance NN N
will MD N
be VB N
recorded VBN N
, , N
along IN N
with IN N
a DT N
self NN N
reported VBN N
pre JJ N
and CC N
post-intervention NN N
reasoning NN N
score NN N
, , N
the DT N
DTI NNP N
. . N

Our PRP$ N
power NN N
calculations NNS N
indicate VBP N
a DT p
sample JJ p
size NN p
of IN p
112 CD p
is VBZ p
required VBN p
for IN N
both DT N
primary JJ N
outcomes NNS N
. . N

DISCUSSION NNP N
This DT N
trial NN N
will MD N
provide VB N
robust JJ N
evidence NN N
to TO N
support VB N
the DT N
effectiveness NN N
of IN N
different JJ N
designs NNS N
of IN N
virtual JJ N
patients NNS N
, , N
based VBN N
on IN N
student NN o
performance NN o
and CC o
evaluation NN o
. . o

The DT N
cases NNS N
and CC N
all DT N
learning JJ N
materials NNS N
will MD N
be VB N
open JJ N
access NN N
and CC N
available JJ N
on IN N
a DT N
Creative JJ N
Commons NNP N
Attribution-Share-Alike NNP N
license NN N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double JJ N
dummy NN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
oral JJ N
cefditoren NNS i
pivoxil VBP i
400mg CD N
once RB N
daily JJ N
as IN N
switch NN N
therapy NN N
after IN N
intravenous JJ N
ceftriaxone NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
pyelonephritis NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
clinical JJ N
and CC N
bacteriological JJ o
effectiveness NN o
of IN N
intravenous JJ N
( ( N
IV NNP N
) ) N
ceftriaxone NN i
followed VBN N
by IN N
oral JJ N
cefditoren NNS i
pivoxil VBP i
or CC N
IV NNP i
ceftriaxone NN i
for IN N
acute JJ N
pyelonephritis NN N
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
controlled JJ N
trial NN N
of IN N
patients NNS p
with IN p
a DT p
presumptive JJ p
diagnosis NN p
of IN p
acute JJ p
pyelonephritis NN p
was VBD N
performed VBN N
. . N

Daily JJ N
2g CD i
IV NNP i
ceftriaxone NN i
was VBD N
initially RB N
given VBN N
to TO N
all DT N
patients NNS p
. . p

After IN N
day NN N
3 CD N
, , N
patients NNS p
who WP p
satisfied VBD p
the DT p
criteria NNS p
for IN p
switch NN p
therapy NN p
were VBD N
randomized VBN N
to TO N
either DT N
group NN p
A NNP p
( ( i
IV NNP i
ceftriaxone NN i
) ) i
or CC N
group NN i
B NNP i
( ( i
oral JJ i
cefditoren NNS i
pivoxil VBP i
400mg CD i
once RB N
daily JJ N
) ) N
. . N

RESULTS JJ N
Eighty-two JJ p
patients NNS p
were VBD p
enrolled VBN p
; : p
41 CD p
( ( p
50 CD p
% NN p
) ) p
patients NNS p
in IN p
group NN p
A NNP p
and CC p
41 CD p
( ( p
50 CD p
% NN p
) ) p
patients NNS p
in IN p
group NN p
B NNP p
were VBD p
evaluated VBN p
. . p

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
baseline NN o
characteristics NNS o
between IN N
the DT N
two CD N
groups NNS N
. . N

Clinical JJ o
cure NN o
was VBD N
observed VBN N
in IN N
39 CD N
of IN N
41 CD N
( ( N
95.1 CD N
% NN N
) ) N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
41 CD N
of IN N
41 CD N
( ( N
100 CD N
% NN N
) ) N
patients NNS N
in IN N
group NN N
B NNP N
( ( N
p=0.15 NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
-0.12 VBP N
to TO N
0.02 CD N
) ) N
. . N

Urine NNP o
bacteriological JJ o
eradication NN o
was VBD N
found VBN N
in IN N
63.4 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
60 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p=0.75 NN N
, , N
95 CD N
% NN N
CI NNP N
-0.18 NNP N
to TO N
0.25 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
adverse JJ o
effects NNS o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
These DT N
data NNS N
suggest VBP N
that IN N
IV NNP N
ceftriaxone NN i
followed VBN N
by IN N
oral JJ N
cefditoren NNS i
pivoxil NN i
is VBZ N
highly RB N
effective JJ o
and CC N
well-tolerated JJ o
for IN N
the DT N
treatment NN N
of IN N
acute JJ N
pyelonephritis NN N
, , N
even RB N
for IN N
uropathogens NNS N
with IN N
a DT N
high JJ N
proportion NN N
of IN N
quinolone-resistant JJ N
strains NNS N
. . N

-DOCSTART- -X- O O

Visual JJ i
Assessment NNP i
of IN i
Relative NNP i
Apical NNP i
Sparing NNP i
Pattern NNP i
Is VBZ N
More RBR N
Useful JJ N
Than NNP N
Quantitative NNP N
Assessment NNP N
for IN N
Diagnosing NNP N
Cardiac NNP N
Amyloidosis NNP N
in IN N
Borderline NNP p
or CC p
Mildly RB p
Increased VBD p
Left NNP p
Ventricular NNP p
Wall NNP p
Thickness NNP p
. . p

BACKGROUND NNP N
Relative NNP i
apical JJ i
sparing VBG i
pattern NN i
of IN i
longitudinal JJ i
strain NN i
( ( i
RapSP-LS NNP i
) ) i
was VBD N
suggested VBN N
in IN N
advanced JJ N
cardiac JJ N
amyloidosis NN N
( ( N
CA NNP N
) ) N
. . N

It PRP N
is VBZ N
unclear JJ N
whether IN N
it PRP N
is VBZ N
present JJ N
in IN N
less RBR N
advanced JJ p
CA NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNP p
with IN p
presumptive JJ p
diagnosis NN p
of IN p
CA NNP p
and CC p
mean VB p
left JJR p
ventricular NN p
wall NN p
thickness NN p
( ( p
LVWT NNP p
) ) p
?14 VBP p
mm NNS p
were VBD p
recruited VBN p
. . p

Apart RB N
from IN i
RapSP-LS NNP i
visually RB i
identified VBD i
, , i
relative JJ i
apical JJ i
longitudinal NN i
strain NN i
index NN i
( ( i
RapLSI NNP i
) ) i
was VBD i
defined VBN N
as IN N
[ JJ N
average JJ N
apical JJ N
LS/ NNP N
( ( N
average JJ N
basal NN N
LS+average NNP N
mid-ventricle NN N
LS NNP N
) ) p
] NN p
. . p

Among IN p
119 CD p
patients NNS p
included VBD p
, , p
47 CD p
were VBD p
finally RB p
diagnosed VBN p
with IN p
CA NNP p
. . o

RapLSI NNP o
was VBD o
higher RBR N
in IN N
the DT N
CA NNP N
group NN N
compared VBN N
to TO N
other JJ N
causes NNS N
of IN N
increased JJ o
mean NN o
LVWT NNP o
( ( o
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
with IN N
a DT N
significant JJ N
range NN N
of IN N
overlap NN N
noted VBN N
. . N

In IN N
contrast NN i
, , i
RapSP-LS NNP i
visually RB i
assessed VBD N
was VBD N
noted VBN N
in IN N
most JJS N
CA JJ N
patients NNS N
( ( N
31/47 CD N
, , N
66.0 CD N
% NN N
) ) N
except IN N
in IN N
those DT N
with IN N
preserved JJ N
LV NNP N
ejection NN N
fraction NN N
, , N
normal JJ N
LVWT NNP N
, , N
and CC N
mildly RB N
decreased VBD N
global JJ N
LS NNP N
, , N
suggesting VBG N
least JJS N
advanced JJ N
CA NNP N
. . N

On IN N
multivariate JJ N
analysis NN N
of IN N
the DT N
added JJ N
diagnostic JJ N
role NN N
of IN N
RapSP-LS NNP i
or CC i
RapLSI NNP i
on IN i
top NN N
of IN N
clinical JJ N
, , N
electrocardiographic JJ N
, , N
and CC N
conventional JJ N
echocardiographic JJ N
parameters NNS N
, , N
addition NN N
of IN N
RapLSI NNP i
produced VBD i
only RB N
borderline JJ N
increase NN N
in IN N
area NN N
under IN N
the DT N
curve NN N
of IN N
the DT N
multivariate NN N
model NN N
( ( N
P=0.05 NNP N
) ) N
, , N
whereas JJ N
addition NN N
of IN N
RapSP-LS NNP i
significantly RB i
increased VBD N
it PRP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Visual NNP N
identification NN N
of IN N
RapSP-LS NNP i
is VBZ i
useful JJ N
in IN N
terms NNS N
of IN N
added VBN o
diagnostic JJ o
value NN o
compared VBN o
with IN N
quantitative JJ N
calculation NN N
of IN N
RapLSI NNP i
. . i

Its PRP$ N
clinical JJ N
application NN N
, , N
however RB N
, , N
should MD N
be VB N
used VBN N
with IN N
caution NN N
in IN N
patients NNS p
with IN p
less JJR p
advanced JJ p
CA NNP p
. . p

-DOCSTART- -X- O O

The DT N
tolerability NN N
of IN N
lactated JJ i
Ringer NNP i
's POS i
solution NN i
and CC N
BSS NNP i
plus CC i
for IN N
ocular JJ N
irrigation NN N
with IN N
and CC N
without IN N
the DT N
Morgan NNP N
therapeutic JJ N
lens NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
two CD N
solutions NNS N
, , N
lactated VBD i
Ringer NNP i
's POS i
( ( i
LR NNP i
) ) i
and CC i
a DT i
balanced JJ i
salt NN i
solution NN i
( ( N
BSS NNP N
Plus NNP N
, , N
Alcon NNP N
Laboratories NNPS N
, , N
Ft. NNP N
Worth NNP N
, , N
TX NNP N
) ) N
, , N
compared VBN N
with IN N
normal JJ N
saline JJ i
solution NN i
( ( i
NSS NNP i
) ) i
, , N
for IN N
ocular JJ N
irrigation NN N
in IN N
healthy JJ p
adult NN p
volunteers NNS p
with IN p
and CC p
without IN p
the DT p
Morgan NNP p
therapeutic JJ p
lens NNS p
( ( p
MTL NNP p
) ) p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
study NN N
of IN N
healthy JJ p
volunteers NNS p
who WP p
were VBD p
at IN p
least JJS p
18 CD p
years NNS p
of IN p
age NN p
. . p

Exclusion NN N
criteria NNS N
included VBD N
the DT N
use NN N
of IN N
analgesics NNS N
within IN N
four CD N
hours NNS N
of IN N
the DT N
study NN N
. . N

A NNP N
complete JJ N
ophthalmologic JJ N
examination NN N
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
the DT N
completion NN N
of IN N
the DT N
study NN N
. . N

Following VBG N
randomization NN N
and CC N
prior RB N
to TO N
any DT N
intervention NN N
, , N
baseline JJ N
discomfort NN o
scores NNS o
were VBD N
obtained VBN N
by IN N
means NNS N
of IN N
a DT N
verbally RB N
administered VBN N
, , N
horizontal JJ N
, , N
100-mm JJ N
, , N
unnumbered JJ N
analog NN N
discomfort NN N
scale NN N
. . N

Both DT p
eyes NNS i
of IN i
each DT i
volunteer NN i
were VBD i
irrigated VBN i
simultaneously RB i
for IN i
15 CD i
minutes NNS i
, , N
with IN N
additional JJ N
discomfort NN o
scores NNS o
being VBG N
recorded VBN N
every DT N
5 CD N
minutes NNS N
using VBG N
the DT N
same JJ N
100-mm JJ N
, , N
unnumbered JJ o
analog NN o
discomfort NN o
scale NN o
. . o

A DT N
global JJ N
evaluation NN N
to TO N
assess VB N
the DT N
method NN N
of IN N
irrigation NN N
and CC N
the DT N
solutions NNS N
used VBN N
for IN N
irrigation NN N
was VBD N
completed VBN N
by IN N
both DT N
the DT N
physician NN N
blinded VBD N
to TO N
the DT N
treatment NN p
groups NNS p
and CC p
the DT p
volunteers NNS p
. . p

The DT p
volunteers NNS p
were VBD N
continuously RB N
monitored VBN N
for IN N
any DT N
adverse JJ o
effects NNS o
resulting VBG N
from IN N
the DT N
irrigation NN N
solutions NNS N
or CC N
MTL NNP N
. . N

RESULTS NNP N
Sixty-three JJ p
volunteers NNS p
were VBD p
recruited VBN p
into IN p
the DT p
study NN p
, , p
with IN p
61 CD p
entered VBN p
in IN p
the DT p
final JJ p
analysis NN p
. . p

Age NNP N
and CC N
gender NN N
were VBD N
balanced VBN N
within IN N
each DT N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
discomfort NN o
scores NNS o
between IN N
the DT N
two CD N
groups NNS N
; : N
however RB N
, , N
all DT N
discomfort NN o
scores NNS o
decreased VBN N
over IN N
time NN N
( ( N
p JJ N
= NNP N
0.008 CD N
) ) N
. . N

A DT N
lens-solution JJ N
interaction NN N
was VBD N
identified VBN N
, , N
with IN N
LR NNP N
being VBG N
the DT N
most RBS N
tolerated JJ o
when WRB N
administered VBN N
with IN N
the DT N
MTL NNP N
. . N

A NNP N
statistically RB N
higher JJR N
ocular JJ o
pH NN o
difference NN o
was VBD N
seen VBN N
between IN N
the DT N
pre- NN N
and CC N
postirrigation NN N
readings NNS N
for IN N
the DT N
control NN N
eye NN N
in IN N
volunteers NNS N
irrigated VBN N
with IN N
MTL NNP N
( ( N
p JJ N
= NNP N
0.046 CD N
) ) N
. . N

Analysis NN N
of IN N
the DT N
global JJ N
evaluations NNS N
for IN N
each DT N
group NN N
revealed VBD N
no DT N
difference NN N
in IN N
the DT N
distributions NNS N
of IN N
physician JJ o
and CC o
volunteer JJ o
scores NNS o
. . o

No DT N
adverse JJ o
event NN o
was VBD N
reported VBN N
in IN N
either DT N
group NN N
. . N

CONCLUSION NNP N
There EX N
does VBZ N
not RB N
appear VB N
to TO N
be VB N
any DT N
difference NN N
in IN N
discomfort NN o
scores NNS o
between IN N
the DT N
ocular JJ N
irrigation NN N
fluids NNS N
when WRB N
used VBN N
without IN N
the DT N
MTL NNP N
. . N

Overall NNP N
, , N
the DT N
use NN N
of IN N
the DT N
MTL NNP N
appears VBZ N
well RB N
tolerated VBN N
by IN N
healthy JJ N
, , N
adult JJ N
volunteers NNS N
. . N

However RB N
, , N
there EX N
does VBZ N
appear VB N
to TO N
be VB N
a DT N
significant JJ N
lens-solution JJ o
effect NN o
on IN N
volunteers NNS N
' POS N
discomfort NN N
scores NNS N
, , N
with IN N
LR NNP N
having VBG N
significantly RB N
lower JJR N
discomfort NN N
scores NNS N
when WRB N
used VBN N
for IN N
ocular JJ N
irrigation NN N
with IN N
the DT N
MTL NNP N
. . N

The DT N
authors NNS N
conclude VBP N
that IN N
the DT N
use NN N
of IN N
the DT N
MTL NNP N
for IN N
ocular JJ N
irrigation NN N
is VBZ N
well RB N
tolerated VBN N
and CC N
recommend VB N
using VBG N
LR NNP N
as IN N
the DT N
irrigation NN N
solution NN N
for IN N
maximal JJ N
patient NN N
comfort NN N
. . N

-DOCSTART- -X- O O

Sustained VBN N
ventricular JJ N
arrhythmias NNS N
and CC N
mortality NN N
among IN N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
: : p
results NNS N
from IN N
the DT N
GUSTO-III NNP N
trial NN N
. . N

BACKGROUND NNP N
In IN N
many JJ N
patients NNS N
, , N
ventricular JJ N
arrhythmias NN N
will MD N
develop VB N
early JJ N
after IN N
acute JJ p
myocardial JJ p
infarction NN p
. . p

We PRP N
studied VBD N
the DT N
incidence NN N
, , N
timing NN N
, , N
and CC N
outcomes NNS N
of IN N
such JJ N
arrhythmias NNS N
in IN N
the DT N
international JJ N
Global NNP N
Utilization NNP N
of IN N
Streptokinase NNP N
and CC N
TPA NNP N
( ( N
alteplase NN N
) ) N
for IN N
Occluded NNP N
Coronary NNP N
Arteries NNP N
( ( N
GUSTO NNP N
) ) N
-III VBP N
trial NN N
. . N

METHODS NNP N
We PRP i
identified VBD i
independent JJ i
predictors NNS i
of IN i
inhospital JJ i
ventricular JJ i
fibrillation NN i
( ( i
VF NNP i
) ) i
and CC i
ventricular JJ i
tachycardia NN i
( ( i
VT NNP i
) ) i
and CC i
compared VBN i
30-day JJ i
and CC i
1-year JJ i
mortality NN i
rates NNS i
of IN i
patients NNS i
who WP i
did VBD i
( ( i
n VB i
= NNP i
1121 CD i
) ) i
and CC i
did VBD i
not RB i
( ( i
n JJ i
= NNP i
13,921 CD i
) ) i
have VBP i
these DT i
arrhythmias NNS i
during IN i
the DT i
index NN i
hospitalization NN i
. . i

RESULTS NNP N
Significant NNP N
independent JJ N
predictors NNS N
of IN N
inhospital JJ N
VF NNP N
were VBD N
higher JJR N
Killip NNP o
class NN o
, , o
lower JJR o
baseline NN o
systolic JJ o
pressure NN o
, , o
intravenous JJ o
preenrollment NN o
lidocaine NN o
use NN o
, , N
shorter JJR N
time NN N
to TO N
thrombolysis VB o
, , N
and CC N
beta-blocker NN i
use NN i
< VBZ N
2 CD N
weeks NNS N
before IN N
enrollment NN N
; : N
independent JJ N
predictors NNS N
of IN N
inhospital JJ N
VT NNP N
were VBD N
lower JJR N
baseline NN o
systolic JJ o
pressure NN o
, , o
intravenous JJ o
lidocaine NN o
use NN N
before IN N
enrollment NN N
, , N
higher JJR N
Killip NNP N
class NN N
, , N
faster JJR N
baseline JJ o
heart NN o
rate NN o
, , N
and CC N
advanced JJ N
age NN N
. . N

The DT N
30-day JJ o
mortality NN o
rate NN o
was VBD N
31 CD N
% NN N
in IN N
patients NNS N
with IN N
VF NNP N
, , N
24 CD N
% NN N
in IN N
those DT N
with IN N
VT NNP N
, , N
44 CD N
% NN N
in IN N
those DT N
with IN N
both DT N
, , N
and CC N
6 CD N
% NN N
in IN N
those DT N
with IN N
neither DT N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

The DT N
corresponding JJ N
1-year JJ o
mortality NN o
rates NNS o
were VBD N
34 CD N
% NN N
, , N
29 CD N
% NN N
, , N
49 CD N
% NN N
, , N
and CC N
9 CD N
% NN N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

The DT N
30-day JJ o
and CC o
1-year JJ o
mortality NN o
rates NNS o
were VBD N
higher JJR N
for IN N
patients NNS N
with IN N
late JJ N
( ( N
> JJ N
48 CD N
hours NNS N
after IN N
enrollment NN N
) ) N
versus FW N
early JJ N
arrhythmias NN N
( ( N
< CD N
or CC N
=48 VB N
hours NNS N
after IN N
enrollment NN N
) ) N
. . N

CONCLUSIONS NNP N
Despite IN N
thrombolysis NN N
, , N
inhospital JJ N
ventricular NN N
arrhythmias NNS N
are VBP N
associated VBN N
with IN N
higher JJR N
30-day JJ N
and CC N
1-year JJ N
mortality NN o
rates NNS o
after IN N
acute JJ p
myocardial JJ p
infarction NN p
, , N
particularly RB N
when WRB N
occurring VBG N
later RB N
during IN N
the DT N
initial JJ N
hospitalization NN N
. . N

Better JJR N
therapies NNS N
are VBP N
needed VBN N
to TO N
improve VB N
outcomes NNS N
of IN N
these DT N
arrhythmias NNS N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
umbilical JJ i
cord NN i
serum NN i
therapy NN i
for IN N
persistent JJ p
corneal JJ p
epithelial JJ p
defects NNS p
. . p

AIMS NNP N
To TO N
evaluate VB N
umbilical JJ i
cord NN i
serum NN i
therapy NN i
as IN N
a DT N
means NN N
of IN N
promoting VBG N
the DT N
healing NN N
of IN N
persistent JJ o
corneal JJ o
epithelial JJ o
defects NNS o
. . o

METHODS NNP N
Umbilical NNP i
cord NN i
serum NN i
or CC i
autologous JJ i
serum NN i
drops NNS i
were VBD N
used VBN N
to TO N
promote VB N
the DT N
healing NN N
of IN N
persistent JJ o
epithelial JJ o
defects NNS o
. . o

The DT N
study NN N
design NN N
was VBD N
a DT N
prospective JJ N
randomised VBN N
controlled VBD N
clinical JJ N
trial NN N
. . N

60 CD p
eyes NNS p
of IN p
59 CD p
patients NNS p
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
31 CD N
in IN N
the DT N
cord NN i
serum NN i
group NN N
and CC N
29 CD N
in IN N
the DT N
autologous JJ i
serum NN i
control NN i
group NN i
. . i

Epithelial JJ N
defects NNS N
measuring VBG N
at IN N
least JJS N
2 CD N
mm NN N
in IN N
linear JJ N
dimension NN N
resistant NN N
to TO N
conventional JJ N
medical JJ N
management NN N
were VBD N
included VBN N
. . N

Serial JJ N
measurements NNS N
of IN N
the DT N
size NN N
of IN N
the DT N
epithelial JJ N
defects-namely RB N
, , N
two CD N
maximum JJ N
linear JJ N
dimensions NNS N
perpendicular VBP N
to TO N
each DT N
other JJ N
, , N
and CC N
the DT N
area NN N
and CC N
perimeter NN N
was VBD N
done VBN N
at IN N
start NN N
of IN N
therapy NN N
and CC N
follow VB N
up RP N
days NNS N
3 CD N
, , N
7 CD N
, , N
14 CD N
, , N
21 CD N
. . N

Rate NN o
of IN o
healing NN o
of IN o
the DT o
epithelial JJ o
defects NNS o
were VBD N
measured VBN N
as IN N
percentage NN N
decrease NN N
from IN N
the DT N
baseline NN N
parameter NN N
at IN N
each DT N
subsequent NN N
follow VBP N
up RB N
. . N

The DT N
data NNS N
were VBD N
analysed VBN N
by IN N
the DT N
non-parametric JJ N
Wilcoxon NNP N
rank NN N
sum NN N
test NN N
using VBG N
STATA NNP N
7.0 CD N
. . N

RESULTS VB N
The DT N
median JJ N
percentage NN N
decrease NN o
in IN o
the DT o
size NN o
of IN o
the DT o
epithelial JJ o
defect NN o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
cord NN i
serum NN i
group NN N
at IN N
days NNS N
7 CD N
, , N
14 CD N
and CC N
21 CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
when WRB N
measured VBN N
in IN N
terms NNS N
of IN N
the DT N
area NN N
and CC N
perimeter NN N
. . N

A DT N
greater JJR N
number NN N
of IN N
patients NNS N
showed VBD N
complete JJ o
re-epithelialisation NN o
with IN N
umbilical JJ N
cord NN i
serum NN i
( ( N
n JJ N
= NNP N
18 CD N
) ) N
than IN N
with IN N
autologous JJ N
serum NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
( ( N
Pearson NNP N
chi VBZ N
= NNP N
0.19 CD N
) ) N
. . N

None NN N
of IN N
the DT N
patients NNS N
reported VBD N
any DT N
side NN N
effects NNS N
or CC N
discomfort NN N
with IN N
either DT N
treatment NN N
. . N

CONCLUSIONS NNP N
Umbilical NNP i
cord NN i
serum NN i
leads VBZ N
to TO N
faster RBR o
healing NN o
of IN o
the DT o
persistent JJ o
corneal NN o
epithelial JJ o
defects NNS o
refractory NN N
to TO N
all DT N
medical JJ N
management NN N
compared VBN N
to TO N
autologous JJ i
serum NN i
. . i

-DOCSTART- -X- O O

Biochemical NNP N
and CC N
functional JJ N
effects NNS N
of IN N
creatine NN i
phosphate NN i
in IN N
cardioplegic JJ N
solution NN N
during IN N
aortic JJ p
valve NN p
surgery NN p
-- : p
a DT p
clinical JJ N
study NN N
. . N

During IN N
myocardial JJ N
ischemia NN N
there EX N
is VBZ N
a DT N
drop NN o
in IN o
high-energy JJ o
phosphates NNS o
in IN N
the DT N
myocardium NN N
. . N

Cold NNP N
potassium NN N
cardioplegia NN N
decreases NNS N
but CC N
does VBZ N
not RB N
altogether RB N
prevent VB N
this DT N
reduction NN N
. . N

Supplementation NN N
of IN N
cardioplegic JJ N
solutions NNS N
with IN N
the DT N
high-energy JJ N
compound NN N
creatine NN i
phosphate NN i
( ( N
10 CD N
mmol/L NN N
) ) N
compared VBN N
to TO N
plain VB i
cardioplegic JJ i
solutions NNS i
was VBD N
investigated VBN N
in IN N
this DT N
study NN N
. . N

Thirty NNP p
patients NNS p
scheduled VBN p
for IN p
aortic JJ p
valve NNS p
replacement NN p
were VBD p
included VBN p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
group NN N
I PRP N
( ( i
creatine VB i
phosphate NN i
) ) i
or CC N
group NN N
II NNP N
( ( i
control NN i
) ) i
. . N

Postoperative JJ N
hemodynamic JJ o
evaluation NN o
revealed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

However RB N
, , N
group NN N
I PRP N
exhibited VBD N
a DT N
tendency NN N
toward IN N
a DT N
better JJR N
stroke-work NN o
index NN o
( ( N
135 CD N
+/- JJ N
18 CD N
% NN N
vs. FW N
102 CD N
+/- JJ N
5 CD N
% NN N
recovery NN N
15 CD N
minutes NNS N
after IN N
bypass NN N
and CC N
145 CD N
+/- JJ N
16 CD N
% NN N
vs. FW N
119 CD N
+/- JJ N
11 CD N
% NN N
recovery NN N
105 CD N
min NN N
after IN N
bypass NN N
) ) N
. . N

There EX N
were VBD N
fewer JJR N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
5/15 CD N
) ) N
needing VBG o
inotropic JJ o
support NN o
compared VBN N
to TO N
group NN N
II NNP N
( ( N
9/14 CD N
) ) N
. . N

The DT N
myocardial JJ o
content NN o
of IN o
ATP NNP o
and CC o
creatine NN o
phosphate NN o
showed VBD N
no DT N
significant JJ N
differences NNS N
during IN N
ischemia NN N
and CC N
reperfusion NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
myocardial JJ N
protection NN N
during IN N
ischemia NN N
was VBD N
sufficient JJ N
to TO N
prevent VB N
significant JJ N
reductions NNS N
of IN N
myocardial JJ o
ATP NNP o
and CC o
creatine VB o
phosphate JJ o
irrespective NN N
of IN N
supplementation NN N
with IN N
CP NNP N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
entacapone NN i
, , N
a DT N
peripherally RB N
acting VBG N
catechol-O-methyltransferase NN N
inhibitor NN N
, , N
on IN N
the DT N
motor NN o
response NN o
to TO o
acute VB o
treatment NN o
with IN o
levodopa NN o
in IN N
patients NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
. . p

Catechol-O-methyltransferase NNP N
( ( N
COMT NNP N
) ) N
inhibitors NNS N
may MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
Parkinson NNP N
's POS N
disease NN N
by IN N
improving VBG N
the DT N
bioavailability NN o
of IN N
levodopa NN N
and CC N
by IN N
prolonging VBG N
its PRP$ N
effects NNS N
. . N

Entacapone NNP i
( ( i
OR-611 NNP i
) ) i
, , i
a DT i
novel JJ i
COMT NNP i
inhibitor NN i
, , N
which WDT N
does VBZ N
not RB N
cross VB N
the DT N
blood NN N
brain NN N
barrier NN N
, , N
was VBD N
assessed VBN N
in IN N
12 CD p
patients NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
and CC p
motor NN p
fluctuations NNS p
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
, , N
single JJ N
dose NN N
study NN N
. . N

The DT N
magnitude NN N
and CC N
duration NN N
of IN N
the DT N
therapeutic JJ N
response NN N
to TO N
a DT N
single JJ N
dose NN N
of IN N
200 CD N
mg NNS N
levodopa/50 JJ i
mg FW N
carbidopa NN i
was VBD N
evaluated VBN N
after IN N
concomitant JJ N
placebo NN i
, , N
or CC N
200 CD N
or CC N
800 CD N
mg NN N
entacapone NN i
. . i

A DT N
significant JJ N
increase NN N
in IN N
the DT N
duration NN o
of IN o
the DT o
motor NN o
response NN o
to TO o
levodopa NN o
was VBD N
seen VBN N
when WRB N
200 CD N
mg NN N
entacapone NN N
was VBD N
given VBN N
with IN N
levodopa/carbidopa NN N
. . N

Plasma NNP o
levodopa JJ o
concentrations NNS o
were VBD N
increased VBN N
with IN N
both DT N
doses NNS N
of IN N
the DT N
COMT NNP N
inhibitor NN N
. . N

The DT N
latency NN o
to TO o
onset VB o
of IN o
motor NN o
response NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
active JJ N
drug NN N
and CC N
placebo NN N
. . N

Entacapone NN N
may MD N
prove VB N
useful JJ N
in IN N
prolonging VBG o
the DT o
duration NN o
of IN o
the DT o
benefit NN o
obtained VBN N
from IN N
individual JJ N
doses NNS N
of IN N
levodopa NN N
. . N

-DOCSTART- -X- O O

Peritoneovenous JJ i
shunting VBG i
as IN N
compared VBN N
with IN N
medical JJ i
treatment NN i
in IN N
patients NNS p
with IN p
alcoholic JJ p
cirrhosis NN p
and CC p
massive JJ p
ascites NNS p
. . p

Veterans NNPS N
Administration NNP N
Cooperative NNP N
Study NNP N
on IN N
Treatment NNP N
of IN N
Alcoholic NNP N
Cirrhosis NNP N
with IN N
Ascites NNP N
. . N

The DT N
optimal JJ N
management NN N
of IN N
severe JJ N
ascites NNS N
in IN N
patients NNS p
with IN p
alcoholic JJ p
cirrhosis NN p
has VBZ N
not RB N
been VBN N
defined VBN N
. . N

in IN N
a DT N
5 CD N
1/2-year JJ N
study NN N
, , N
we PRP N
randomly VBP N
assigned VBN N
299 CD p
men NNS p
with IN p
alcoholic JJ p
cirrhosis NN p
, , p
who WP p
had VBD p
persistent NN p
or CC p
recurrent NN p
severe JJ p
ascites VBZ p
despite IN p
a DT p
standard JJ p
medical JJ p
regimen NNS p
, , p
to TO p
receive VB p
either RB p
intensive JJ i
medical JJ i
treatment NN i
or CC i
peritoneovenous JJ i
( ( i
LeVeen NNP i
) ) i
shunting VBG i
. . i

We PRP N
identified VBD N
three CD N
risk NN N
groups NNS N
: : N
Group NNP p
1 CD p
had VBD p
normal JJ p
or CC p
mildly RB p
abnormal JJ p
results NNS p
on IN p
liver-function NN p
tests NNS p
, , p
Group NNP p
2 CD p
had VBD p
more RBR p
severe JJ p
liver NN p
dysfunction NN p
or CC p
previous JJ p
complications NNS p
, , p
and CC p
Group NNP p
3 CD p
had VBD p
severe JJ p
prerenal JJ p
azotemia NN p
without IN p
kidney NN p
disease NN p
. . p

For IN N
the DT N
patients NNS N
who WP N
received VBD N
the DT N
medical JJ N
treatment NN N
and CC N
those DT N
who WP N
received VBD N
the DT N
surgical JJ N
treatment NN N
combined VBN N
, , N
the DT N
median JJ N
survival NN N
times NNS N
were VBD N
1093 CD N
days NNS N
in IN N
Group NNP N
1 CD N
, , N
222 CD N
days NNS N
in IN N
Group NNP N
2 CD N
, , N
and CC N
37 CD N
days NNS N
in IN N
Group NNP N
3 CD N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.01 CD N
) ) N
for IN N
all DT N
comparisons NNS N
) ) N
. . N

For IN N
all PDT N
the DT N
groups NNS N
combined VBN N
, , N
the DT N
median JJ N
time NN N
to TO N
the DT N
resolution NN N
of IN N
ascites NNS N
was VBD N
5.4 CD N
weeks NNS N
for IN N
medical JJ N
patients NNS N
and CC N
3.0 CD N
weeks NNS N
for IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Within IN N
each DT N
risk NN N
group NN N
, , N
mortality NN o
during IN N
the DT N
initial JJ N
hospitalization NN N
and CC N
median JJ o
long-term JJ o
survival NN o
were VBD N
similar JJ N
among IN N
patients NNS N
receiving VBG N
either DT N
treatment NN N
. . N

However RB N
, , N
the DT N
median JJ N
time NN N
to TO N
the DT N
recurrence NN o
of IN o
ascites NNS o
in IN N
Group NNP N
1 CD N
was VBD N
4 CD N
months NNS N
in IN N
medical JJ N
patients NNS N
, , N
as IN N
compared VBN N
with IN N
18 CD N
months NNS N
in IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
; : N
in IN N
Group NNP N
2 CD N
it PRP N
was VBD N
3 CD N
months NNS N
in IN N
medical JJ N
patients NNS N
as IN N
compared VBN N
with IN N
12 CD N
months NNS N
in IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
median JJ o
duration NN o
of IN o
hospitalization NN o
was VBD N
longer RBR N
in IN N
medical JJ p
patients NNS p
than IN N
in IN N
surgical JJ p
patients NNS p
( ( N
6.1 CD N
vs. RB N
2.4 CD N
weeks NNS N
in IN N
Group NNP N
1 CD N
[ NNP N
P NNP N
less JJR N
than IN N
0.001 CD N
] NNS N
and CC N
5.0 CD N
vs. FW N
3.1 CD N
weeks NNS N
in IN N
Group NNP N
2 CD N
[ NNP N
P NNP N
less JJR N
than IN N
0.01 CD N
] NN N
) ) N
. . N

Group NNP N
3 CD N
was VBD N
too RB N
small JJ N
to TO N
permit VB N
a DT N
meaningful JJ N
comparison NN N
. . N

During IN N
the DT N
initial JJ N
hospitalization NN N
, , N
the DT N
incidence NN o
of IN o
infections NNS o
, , o
gastrointestinal JJ o
bleeding NN o
, , o
and CC o
encephalopathy NN o
was VBD N
similar JJ N
among IN N
the DT N
medical JJ p
and CC p
surgical JJ p
patients NNS p
. . p

We PRP N
conclude VBP N
that DT N
peritoneovenous JJ N
shunting NN N
alleviated VBD N
disabling VBG o
ascites NNS o
more RBR N
rapidly RB N
than IN N
medical JJ N
management NN N
. . N

However RB N
, , N
survival NN o
was VBD N
closely RB N
related VBN N
to TO N
the DT N
severity NN N
of IN N
the DT N
illness NN N
at IN N
the DT N
time NN N
of IN N
randomization NN N
and CC N
was VBD N
not RB N
altered VBN N
by IN N
shunting VBG N
. . N

-DOCSTART- -X- O O

Corticosteroids NNP i
plus CC i
pulse JJ i
cyclophosphamide NN i
and CC i
plasma NN i
exchanges NNS i
versus VBP N
corticosteroids NNS i
plus CC i
pulse JJ i
cyclophosphamide NN i
alone RB i
in IN N
the DT N
treatment NN N
of IN N
polyarteritis NN p
nodosa NN p
and CC p
Churg-Strauss NNP p
syndrome NN p
patients NNS p
with IN p
factors NNS p
predicting VBG p
poor JJ p
prognosis NN p
. . p

A DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
in IN N
sixty-two JJ p
patients NNS p
. . p

OBJECTIVE NNP N
To TO N
define VB N
the DT N
most RBS N
effective JJ N
treatment NN N
for IN N
severe JJ p
polyarteritis NN p
nodosa NN p
( ( p
PAN NNP p
) ) p
and CC p
Churg-Strauss JJ p
syndrome NN p
( ( p
CSS NNP p
) ) p
and CC N
to TO N
investigate VB N
the DT N
indication NN N
for IN N
plasma JJ N
exchange NN N
treatment NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
in IN N
which WDT N
62 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
either DT p
prednisone NN i
plus CC i
cyclophosphamide NN i
( ( i
intravenous JJ i
bolus NN i
) ) i
( ( i
group NN i
A NNP i
; : i
n JJ i
= NNP i
28 CD i
) ) i
or CC i
prednisone JJ i
plus CC i
cyclophosphamide JJ i
( ( i
intravenous JJ i
bolus NN i
) ) i
plus CC i
plasma JJ i
exchanges NNS i
( ( p
group NN p
B NNP p
; : p
n CC p
= VB p
34 CD p
) ) p
as IN p
first-line JJ p
treatment NN p
for IN p
severe JJ p
PAN NNP p
or CC p
CSS NNP p
. . p

Factors NNS N
predicting VBG N
poor JJ N
prognosis NN N
were VBD N
renal JJ N
symptoms NNS N
, , N
gastrointestinal JJ N
tract NN N
involvement NN N
, , N
cardiomyopathy NN N
, , N
central JJ N
nervous JJ N
system NN N
involvement NN N
, , N
weight JJ N
loss NN N
> VBZ N
10 CD N
% NN N
of IN N
body NN N
weight NN N
, , N
and CC N
age NN N
> VBP N
50 CD N
years NNS N
old JJ N
. . N

Patients NNS N
with IN N
hepatitis NN N
B NNP N
virus-related JJ N
PAN NNP N
were VBD N
not RB N
included VBN N
in IN N
this DT N
study NN N
. . N

The DT N
end NN N
point NN N
of IN N
the DT N
study NN N
was VBD N
control NN N
of IN N
the DT N
disease NN N
( ( N
recovery NN N
or CC N
remission NN N
) ) N
or CC N
death NN N
. . N

RESULTS NNP N
Clinical NNP N
symptoms NNS N
and CC N
laboratory JJ N
findings NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
the DT N
2 CD N
groups NNS N
. . N

Initial NNP N
control NN N
of IN N
the DT N
disease NN N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Relapse NNP o
after IN N
initial JJ N
control NN N
of IN N
the DT N
disease NN N
was VBD N
observed VBN N
in IN N
7 CD N
patients NNS N
( ( N
4 CD N
in IN N
group NN N
A NNP N
and CC N
3 CD N
in IN N
group NN N
B NNP N
) ) N
. . N

The DT N
mean JJ o
+/- JJ o
SD NNP o
followup NN o
period NN N
was VBD N
31.1 CD N
+/- JJ N
20 CD N
months NNS N
for IN N
group NN N
A NNP N
and CC N
35.9 CD N
+/- JJ N
16.8 CD N
months NNS N
for IN N
group NN N
B NNP N
. . N

At IN N
5 CD N
years NNS N
of IN N
followup NN N
, , N
38 CD N
patients NNS N
( ( N
61.3 CD N
% NN N
) ) N
were VBD N
cured VBN o
( ( N
16 CD N
in IN N
group NN N
A NNP N
and CC N
22 CD N
in IN N
group NN N
B NNP N
) ) N
, , N
and CC N
5 CD N
( ( N
8.1 CD N
% NN N
) ) N
were VBD N
in IN N
remission NN N
without IN N
treatment NN N
but CC N
had VBD N
not RB N
yet RB N
completed VBN N
the DT N
cure-defining JJ N
period NN N
of IN N
18 CD N
months NNS N
( ( N
3 CD N
in IN N
group NN N
A NNP N
and CC N
2 CD N
in IN N
group NN N
B NNP N
) ) N
. . N

Eight NNP N
( ( N
12.9 CD N
% NN N
) ) N
( ( N
2 CD N
in IN N
group NN N
A NNP N
and CC N
2 CD N
in IN N
group NN N
B NNP N
) ) N
were VBD N
considered VBN N
to TO N
be VB N
in IN N
clinical JJ o
remission NN o
and CC N
required VBD N
a DT N
maintenance NN o
regimen NN o
of IN o
low-dose JJ o
corticosteroids NNS o
. . o

Eleven JJ N
patients NNS N
died VBD o
during IN N
the DT N
study NN N
period NN N
( ( N
7 CD N
in IN N
group NN N
A NNP N
[ RB N
25 CD N
% NN N
] NN N
, , N
4 CD N
in IN N
group NN N
B NNP N
[ VBZ N
11.8 CD N
% NN N
] NN N
) ) N
. . N

Uncontrolled VBN N
vasculitis NN N
was VBD N
responsible JJ N
for IN N
4 CD N
deaths NNS o
( ( N
2 CD N
in IN N
each DT N
group NN N
) ) N
, , N
and CC N
treatment NN o
side NN o
effects NNS o
caused VBD N
the DT N
death NN o
of IN N
1 CD N
patient NN N
in IN N
group NN N
A NNP N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
5-year JJ o
cumulative JJ o
survival NN o
rates NNS o
of IN N
the DT N
2 CD N
groups NNS N
( ( N
75 CD N
% NN N
and CC N
88 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
our PRP$ N
data NNS N
, , N
combined VBN N
treatment NN N
with IN N
prednisone NN i
, , i
cyclophosphamide NN i
, , N
and CC N
plasma NN i
exchanges NNS i
is VBZ N
not RB N
superior JJ N
to TO N
treatment NN N
with IN N
prednisone NN i
and CC N
cyclophosphamide VB i
alone RB N
, , N
and CC N
plasma JJ N
exchanges NNS N
should MD N
not RB N
be VB N
systematically RB N
proposed VBN N
for IN N
initial JJ N
treatment NN N
of IN N
severe JJ N
PAN NNP N
or CC N
CSS NNP N
. . N

-DOCSTART- -X- O O

Conservative JJ i
treatment NN i
of IN N
plantar NN p
fasciitis NN p
. . p

A DT N
prospective JJ N
study NN N
. . N

A DT N
randomized JJ N
, , N
prospective JJ N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
individual JJ o
effectiveness NN o
of IN N
three CD N
types NNS N
of IN N
conservative JJ i
therapy NN i
in IN N
the DT N
treatment NN N
of IN N
plantar NN N
fasciitis NN N
. . N

One CD p
hundred VBD p
three CD p
subjects NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
three CD p
treatment NN p
categories NNS p
: : p
anti-inflammatory NN i
, , i
accommodative JJ i
, , i
or CC i
mechanical JJ i
. . i

Subjects NNS p
were VBD N
treated VBN N
for IN N
3 CD N
months NNS N
, , N
with IN N
follow-up JJ N
visits NNS N
at IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
weeks NNS N
. . N

For IN N
the DT N
85 CD p
patients NNS p
who WP p
completed VBD p
the DT p
study NN p
, , N
a DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
noted VBN N
between IN N
groups NNS N
, , N
with IN N
mechanical JJ i
treatment NN i
with IN i
taping VBG i
and CC i
orthoses NNS i
proving VBG N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
either DT N
anti-inflammatory JJ i
or CC N
accommodative JJ i
modalities NNS i
. . i

-DOCSTART- -X- O O

Glucosamine NNP o
in IN o
serum NN o
of IN N
patients NNS p
after IN p
myocardial JJ p
infarction NN p
subjected VBN N
to TO N
rehabilitation VB i
training NN i
. . i

This DT N
paper NN N
presents VBZ N
results NNS N
of IN N
3 CD N
weeks NNS N
physical JJ i
training NN i
on IN N
glucosamine JJ o
level NN o
in IN o
serum NN o
of IN N
male NN p
patients NNS p
after IN p
myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
aged VBD p
between IN p
38 CD p
and CC p
61 CD p
. . p

Patients NNS N
were VBD N
randomised VBN N
in IN N
two CD N
groups NNS N
: : N
the DT p
training NN i
group NN i
( ( p
n JJ p
= NNP p
21 CD p
) ) p
, , p
staying VBG p
in IN p
Cardiac NNP p
Rehabilitation NNP p
Department NNP p
and CC p
the DT p
control NN i
group NN i
( ( i
n JJ i
= NNP i
11 CD i
) ) i
, , i
discharged VBD i
home NN i
for IN N
3 CD N
weeks NNS N
. . N

Each DT N
group NN N
received VBD N
identical JJ N
dietary JJ N
instructions NNS N
. . N

The DT p
training NN p
group NN p
performed VBD N
exercises NNS i
every DT i
day NN i
: : i
on IN i
bicycle NN i
ergometer NN i
during IN i
30 CD i
minutes NNS i
( ( i
5 CD i
times NNS i
a DT i
week NN i
) ) i
, , i
overall-conditioning JJ i
exercises NNS i
for IN i
30 CD i
minutes NNS i
daily RB i
and CC i
30 CD i
to TO i
60 CD i
minutes NNS i
of IN i
walking VBG i
each DT i
day NN i
. . i

Before IN i
administering VBG i
of IN i
the DT i
therapy NN i
and CC i
3 CD i
weeks NNS i
later RB i
all DT i
MI NNP i
patients NNS i
performed VBD i
the DT i
bicycle NN i
ergometer NN i
exercise NN i
test NN i
until IN i
the DT i
ventilatory NN o
threshold NN o
was VBD i
reached VBN i
. . i

Before IN i
that DT i
test NN i
and CC i
3 CD i
minutes NNS i
after IN i
its PRP$ i
termination NN i
capillary NN i
and CC i
venous JJ i
blood NN i
samples NNS i
were VBD i
drawn VBN i
. . i

In IN i
the DT i
capillary JJ i
blood NN i
samples NNS i
indices NNS o
of IN o
acid-base JJ o
balance NN o
, , o
lactate JJ o
level NN o
, , o
and CC o
glucose JJ o
level NN o
were VBD i
determined VBN i
. . i

In IN N
venous JJ N
blood NN N
samples NNS N
the DT N
serum NN o
levels NNS o
of IN o
immunoreactive JJ o
insulin NN o
, , o
C-peptide NNP o
and CC o
glucosamine NN o
were VBD N
determined VBN N
as RB N
well RB N
as IN N
binding NN o
of IN o
125I-insulin JJ o
to TO o
erythrocyte VB o
receptors NNS o
. . o

Obtained VBN N
results NNS N
show VBP N
that IN N
administered JJ N
therapy NN N
increased VBD N
physical JJ o
fitness NN o
and CC N
decreased VBN N
of IN N
glucosamine NN o
concentration NN o
, , o
insulinaemia NN o
and CC o
insulin NN o
resistance NN o
. . o

-DOCSTART- -X- O O

A DT N
Randomized NNP N
Double NNP N
Blind NNP N
Clinical NNP N
Trial NNP N
on IN N
a DT N
Sabgh NNP i
Formulation NNP i
for IN N
Patients NNPS p
With IN p
Vitiligo NNP p
. . p

BACKGROUND NNP N
The DT N
cosmetic JJ N
problem NN N
that WDT N
vitiligo VBZ i
produces VBZ N
affects NNS p
patients NNS p
psychologically RB p
. . p

Many JJ N
patients NNS p
with IN p
vitiligo NNS p
are VBP N
suggested VBN N
to TO N
cover VB N
their PRP$ N
white JJ N
skin NN N
patches NNS N
with IN N
cosmetic JJ N
products NNS N
. . N

There EX N
are VBP N
formulations NNS N
in IN N
traditional JJ N
Iranian JJ N
pharmacy NN N
to TO N
color VB N
these DT N
white JJ N
skin NN N
patches NNS N
. . N

In IN N
this DT N
study NN N
, , N
one CD N
of IN N
these DT N
formulations NNS i
was VBD N
compared VBN N
with IN N
a DT N
cosmetic JJ i
formulation NN i
. . i

METHODS NNP N
Two CD p
groups NNS p
of IN p
patients NNS p
were VBD p
selected VBN p
. . p

One CD N
group NN N
used VBD N
a DT N
marketed JJ i
formulation NN i
and CC N
other JJ N
group NN N
used VBD N
a DT N
traditional JJ i
Iranian JJ i
Pharmacy NNP i
formulation NN i
. . i

The DT N
quality NN o
of IN o
life NN o
of IN N
the DT N
patients NNS N
was VBD N
compared VBN N
based VBN N
on IN N
the DT N
Dermatology NNP N
Life NNP N
Quality NNP N
Index NNP N
Questionnaire NNP N
. . N

RESULTS NNP N
Both NNP N
interventions NNS N
were VBD N
associated VBN N
with IN N
statistically RB N
improved VBN N
Dermatology NNP o
Life NNP o
Quality NNP o
Index NNP o
scores VBZ o
over IN N
the DT N
8-week JJ N
intervention NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
although IN N
the DT N
difference NN N
between IN N
the DT N
2 CD N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.436 NNP N
) ) N
. . N

CONCLUSION NNP N
Traditional NNP i
Iranian JJ i
Pharmacy NNP i
formulation NN N
is VBZ N
effective JJ N
in IN N
increasing VBG N
the DT N
quality NN o
of IN o
life NN o
in IN N
vitiligo JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

[ JJ i
Intra-arterial JJ i
( ( i
5-FU/FA JJ i
and CC i
FUDR NNP i
) ) i
versus VBP i
systemic JJ i
chemotherapy NN i
( ( i
5-FU/FA JJ i
) ) i
of IN N
non-resectable JJ o
colorectal JJ o
liver NN o
metastases NNS o
] VBP o
. . N

The DT N
relative JJ o
efficacy NN o
of IN N
HAI NNP i
FUDR NNP i
, , i
HAI NNP i
5-FU/FA CD i
, , i
and CC i
i.v NN i
. . i

5-FU/FA JJ i
chemotherapy NN i
for IN N
the DT N
treatment NN N
of IN N
unresectable JJ p
colorectal JJ p
liver NN p
metastases NNS p
was VBD N
compared VBN N
in IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
. . N

The DT N
response NN o
rate NN o
after IN N
HAI NNP i
treatment NN N
was VBD N
significantly RB N
higher JJR N
as IN N
compared VBN N
to TO N
i.v VB N
. . N

treatment NN N
with IN N
no DT N
statistical JJ N
benefit NN N
regarding VBG N
survival NN o
and CC o
time NN o
to TO o
progression NN o
. . o

HAI NNP i
FUDR NNP i
treatment NN N
was VBD N
inferior JJ o
as IN N
compared VBN N
to TO N
HAI NNP i
or CC N
i.v NN N
. . N

5-FU/FA JJ i
. . i

i.v NN N
. . N

5-FU/FA-therapy NN i
is VBZ N
therefore IN N
the DT N
method NN N
of IN N
choice NN N
outside IN N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
of IN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
2 CD N
doses NNS N
of IN N
vortioxetine NN i
in IN N
adults NNS p
with IN p
major JJ p
depressive JJ p
disorder NN p
. . p

BACKGROUND VB N
This DT N
8-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
, , N
conducted VBN N
August NNP N
2010-May JJ N
2012 CD N
in IN N
the DT N
United NNP N
States NNPS N
, , N
evaluated VBD N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
vortioxetine NN i
10 CD N
mg NN N
and CC N
15 CD N
mg NNS N
in IN N
patients NNS p
with IN p
major JJ p
depressive JJ p
disorder NN p
( ( p
MDD NNP p
) ) p
. . p

The DT N
mechanism NN N
of IN N
action NN N
of IN N
vortioxetine NN i
is VBZ N
thought VBN N
to TO N
be VB N
related VBN N
to TO N
direct JJ N
modulation NN N
of IN N
serotonin NN o
( ( o
5-HT JJ o
) ) o
receptor NN o
activity NN o
and CC N
inhibition NN N
of IN N
the DT N
serotonin NN o
transporter NN o
. . o

METHOD NNP N
Adults NNP p
aged VBD p
18-75 CD p
years NNS p
with IN p
MDD NNP p
( ( p
DSM-IV-TR NNP p
) ) p
and CC p
Montgomery-Asberg NNP p
Depression NNP p
Rating NNP p
Scale NNP p
( ( p
MADRS NNP p
) ) p
total NN p
score NN p
? . p
26 CD p
were VBD p
randomized VBN p
( ( p
1:1:1 CD p
) ) p
to TO p
receive VB i
vortioxetine NN i
10 CD i
mg NN N
or CC N
15 CD N
mg NN N
or CC N
placebo NN i
once RB i
daily JJ N
, , N
with IN N
the DT o
primary JJ o
efficacy JJ o
end NN o
point NN o
being VBG o
change NN o
from IN o
baseline NN o
at IN o
week NN o
8 CD o
in IN o
MADRS NNP o
analyzed VBN o
by IN N
mixed JJ N
model NN N
for IN N
repeated JJ N
measures NNS o
. . o

Adverse JJ o
events NNS o
were VBD o
recorded VBN N
during IN N
the DT N
study NN o
, , o
suicidal JJ o
ideation NN o
and CC o
behavior NN o
were VBD o
assessed VBN o
using VBG o
the DT o
Columbia-Suicide JJ o
Severity NNP o
Rating NNP o
Scale NNP o
( ( o
C-SSRS NNP o
) ) o
, , o
and CC o
sexual JJ o
dysfunction NN o
was VBD o
assessed VBN o
using VBG o
the DT o
Arizona NNP o
Sexual NNP o
Experience NNP o
( ( o
ASEX NNP o
) ) o
scale NN o
. . o

RESULTS NNP p
Of IN p
the DT p
1,111 CD p
subjects NNS p
screened VBN p
, , p
469 CD p
subjects NNS p
were VBD p
randomized VBN p
: : p
160 CD p
to TO p
placebo VB i
, , i
157 CD p
to TO p
vortioxetine VB i
10 CD i
mg NN p
, , p
and CC p
152 CD p
to TO p
vortioxetine VB i
15 CD i
mg NN p
. . p

Differences NNS N
from IN i
placebo NN i
in IN i
the DT o
primary JJ o
efficacy JJ o
end NN o
point NN o
were VBD o
not RB N
statistically RB N
significant JJ N
for IN i
vortioxetine NN i
10 CD i
mg NN N
or CC N
vortioxetine NN N
15 CD N
mg. NN o
Nausea NNP o
, , o
headache NN o
, , o
dry JJ o
mouth NN o
, , o
constipation NN o
, , o
diarrhea NN o
, , o
vomiting VBG o
, , o
dizziness NN o
, , o
and CC o
flatulence NN o
were VBD o
reported VBN N
in IN N
? . N
5 CD N
% NN N
of IN N
subjects NNS N
receiving VBG N
vortioxetine NN N
. . N

Discontinuation NN N
due JJ N
to TO o
adverse JJ o
events NNS o
occurred VBD o
in IN N
7 CD N
subjects NNS N
( ( N
4.4 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN i
group NN i
, , N
8 CD N
( ( N
5.2 CD N
% NN N
) ) N
in IN N
the DT N
vortioxetine NN i
10 CD i
mg NN N
group NN N
, , N
and CC N
12 CD N
( ( N
7.9 CD N
% NN N
) ) N
in IN N
the DT N
vortioxetine NN i
15 CD i
mg NN N
group NN N
. . N

ASEX NNP N
total JJ N
scores NNS N
were VBD N
similar JJ N
across IN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
clinically RB N
significant JJ N
trends NNS N
within IN N
or CC N
between IN N
treatment NN N
groups NNS N
on IN N
the DT N
C-SSRS NNP o
, , o
laboratory NN o
values NNS o
, , o
electrocardiogram NN o
, , o
or CC o
vital JJ o
sign NN o
parameters NNS o
. . o

CONCLUSIONS NNP o
In IN N
this DT N
study NN i
, , i
vortioxetine NN i
did VBD i
not RB N
differ VB N
significantly RB N
from IN N
placebo NN i
on IN i
MADRS NNP N
total NN N
score NN N
after IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
in IN N
MDD NNP N
subjects NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT01179516 NNP N
. . N

-DOCSTART- -X- O O

Para-anaesthetic JJ i
headache NN i
in IN p
female JJ p
patients NNS p
. . p

-DOCSTART- -X- O O

Intraperitoneal NNP N
application NN N
of IN N
bupivacaine NN i
plus CC N
morphine NN i
for IN N
pain NN o
relief NN o
after IN N
laparoscopic JJ p
cholecystectomy NN p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Intraperitoneal NNP N
administration NN N
of IN N
a DT N
local JJ N
anaesthetic NN N
in IN N
combination NN N
with IN N
an DT N
opioid NN i
, , N
for IN N
the DT N
relief NN N
of IN N
postoperative JJ o
pain NN o
, , N
has VBZ N
already RB N
been VBN N
reported VBN N
except IN N
after IN N
laparoscopic JJ p
cholecystectomy NN p
. . p

This DT N
study NN N
was VBD N
aimed VBN N
at IN N
assessing VBG N
the DT N
analgesic JJ N
effect NN N
of IN N
the DT N
intraperitoneal JJ N
administration NN N
of IN N
bupivacaine NN i
and CC i
morphine NN i
in IN N
patients NNS p
undergoing VBG p
laparoscopic JJ p
cholecystectomy NN p
. . p

METHODS NNP N
At IN N
the DT N
end NN N
of IN N
laparoscopic JJ N
cholecystectomy NN N
, , N
in IN N
a DT N
double-blind NN N
, , N
randomized JJ N
manner NN N
, , N
one CD N
of IN N
the DT N
following JJ N
injections NNS N
was VBD N
given VBN N
intraperitoneally RB N
. . N

There EX N
were VBD N
30 CD p
patients NNS p
in IN p
each DT p
group NN p
: : p
Group NNP N
1 CD N
, , N
physiological JJ i
saline NN i
30 CD N
mL NN N
; : N
Group NNP N
2 CD N
, , N
bupivacaine VBP i
0.25 CD N
% NN N
30 CD N
mL NN N
; : N
Group NNP N
3 CD N
, , N
bupivacaine VBP i
0.25 CD N
% NN N
30 CD N
mL NN N
plus CC i
morphine JJ i
2 CD N
mg NN N
. . N

In IN N
addition NN N
, , N
Group NNP N
2 CD N
received VBD N
2 CD N
mg NNS N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
morphine NN i
in IN N
2 CD N
mL NNS N
saline NN i
, , N
and CC N
Groups NNP N
1 CD N
and CC N
3 CD N
, , N
2 CD N
mL NN N
saline NN i
intravenously RB N
. . N

Patients NNS N
' POS N
postoperative JJ o
pain NN o
was VBD N
evaluated VBN N
using VBG N
a DT N
visual JJ o
analogue NN o
scale NN o
and CC N
a DT N
verbal JJ o
rating NN o
score NN o
. . o

The DT N
postoperative JJ N
analgesic JJ N
requirement NN N
was VBD N
assessed VBN N
by IN N
the DT N
total JJ N
dose NN N
of IN N
metamizol NN o
administered VBN N
by IN N
an DT N
i.v NN N
. . N

patient-controlled JJ o
analgesia NN o
( ( o
PCA NNP o
) ) o
device NN N
. . N

Pain NNP o
, , o
vital JJ o
signs NNS o
, , o
supplemental JJ o
analgesic JJ o
consumption NN o
and CC o
side-effects NNS o
were VBD N
recorded VBN N
for IN N
all DT N
patients NNS N
for IN N
24 CD N
h. JJ N
RESULTS NNP N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
three CD N
groups NNS N
regarding VBG N
pain NN o
scores NNS o
( ( N
at IN N
rest NN N
and CC N
coughing VBG N
) ) N
during IN N
the DT N
study NN N
except IN N
in IN N
the DT N
first JJ N
2 CD N
h NN N
, , N
when WRB N
scores NNS N
were VBD N
lower JJR N
for IN N
patients NNS N
receiving VBG N
intraperitoneal JJ N
bupivacaine NN i
plus CC N
i.v NN N
. . N

morphine NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Supplemental JJ o
consumption NN o
of IN o
metamizol NN o
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
Group NNP N
3 CD N
than IN N
in IN N
Group NNP N
1 CD N
during IN N
the DT N
first JJ N
6 CD N
h NN N
after IN N
surgery NN N
. . N

However RB N
, , N
the DT N
cumulative JJ o
doses NNS o
of IN N
metamizol NN N
were VBD N
also RB N
lower JJR N
in IN N
Group NNP N
2 CD N
than IN N
in IN N
Groups NNP N
1 CD N
and CC N
3 CD N
over IN N
the DT N
entire JJ N
study NN N
( ( N
2025 CD N
+/- NN N
1044 CD N
mg NN N
vs. FW N
4925 CD N
+/- JJ N
1238 CD N
and CC N
4125 CD N
+/- JJ N
1276mg CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
undergoing VBG p
laparoscopic JJ p
cholecystectomy NN p
, , N
the DT N
intraperitoneal JJ N
administration NN N
of IN N
morphine JJ i
plus CC N
bupivacaine JJ i
0.25 CD N
% NN N
reduced VBD N
the DT N
analgesic JJ o
requirements NNS o
during IN N
the DT N
first JJ N
6 CD N
postoperative JJ N
hours NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
the DT N
combination NN N
of IN N
intraperitoneal JJ N
bupivacaine JJ i
0.25 CD N
% NN N
and CC N
i.v NN N
. . N

morphine NN i
was VBD N
more RBR N
effective JJ N
for IN N
treatment NN N
of IN N
pain NN o
after IN N
laparoscopic JJ p
cholecystectomy NN p
. . p

-DOCSTART- -X- O O

[ NN N
Study NNP N
of IN N
setting VBG i
of IN i
ventilator NN o
volume NN i
tidal NN i
and CC i
airway JJ i
pressure NN i
alarm NN i
threshold NN i
with IN N
continuous JJ i
extra-sternum JJ i
heart NN i
compression NN i
in IN N
cardiopulmonary JJ p
resuscitation NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
setting NN N
of IN N
ventilator NN i
volume NN i
tidal NN i
( ( i
VT NNP i
) ) i
and CC i
airway JJ i
pressure NN i
alarm NN i
threshold NN i
during IN N
cardiopulmonary JJ i
resuscitation NN i
( ( i
CPR NNP i
) ) i
by IN N
continuous JJ i
extra-sternum JJ i
heart NN i
compression NN i
. . i

METHODS NNP N
Forty NNP p
cases NNS p
with IN p
respiration NN p
and CC p
cardiac JJ p
arrest NN p
in IN p
the DT p
department NN p
of IN p
critical JJ p
care NN p
medicine NN p
were VBD p
randomly RB p
divided VBN p
into IN N
low JJ i
VT NNP i
ventilation NN i
group NN i
and CC i
conventional JJ i
VT NNP i
group NN i
. . i

Both DT N
groups NNS N
were VBD N
given VBN N
the DT N
volume NN N
control NN N
mode NN N
. . N

In IN N
the DT N
low JJ i
VT NNP i
ventilation NN i
group NN N
, , N
VT NNP N
was VBD N
set VBN N
on IN N
6 CD N
- : N
7 CD N
ml/kg NN N
, , N
and CC N
high JJ N
pressure NN N
alarm NN N
threshold NN N
was VBD N
adjusted VBN N
to TO N
60 CD N
cm NNS N
H2O NNP N
by IN N
the DT N
conventional JJ i
40 CD N
cm NN N
H2O NNP N
during IN N
CPR NNP N
. . N

In IN N
the DT N
conventional JJ i
VT NNP i
group NN i
, , N
VT NNP N
and CC N
high JJ N
pressure NN N
alarm NN N
threshold NN N
were VBD N
set VBN N
at IN N
8 CD N
- : N
12 CD N
ml/kg NN N
and CC N
40 CD N
cm NN N
H2O NNP N
, , N
respectively RB N
. . N

Real-time JJ o
actual JJ o
VT NNP o
, , o
peak JJ o
inspiratory JJ o
pressure NN o
( ( o
PIP NNP o
) ) o
, , o
and CC o
arterial JJ o
blood NN o
gas NN o
test NN o
, , o
blood NN o
lactic JJ o
acid NN o
at IN o
10 CD o
minutes NNS o
and CC o
30 CD o
minutes NNS o
after IN o
CPR NNP o
were VBD N
observed VBN N
. . N

RESULTS NNP N
At IN N
10 CD N
minutes NNS N
after IN N
CPR NNP N
, , N
in IN N
the DT N
low JJ i
VT NNP i
ventilation NN i
group NN N
, , N
arterial JJ o
blood NN o
pH NN o
, , o
arterial JJ o
partial JJ o
pressure NN o
of IN o
oxygen NN o
( ( o
PaO2 NNP o
) ) o
, , o
arterial JJ o
partial JJ o
pressure NN o
of IN o
carbon NN o
dioxide NN o
( ( o
PaCO2 NNP o
) ) o
, , o
HCO3 NNP o
( ( o
- : o
) ) o
, , o
arterial JJ o
oxygen NN o
saturation NN o
( ( o
SaO2 NNP o
) ) o
and CC o
blood NN o
lactic JJ o
acid NN o
were VBD N
better RB N
as IN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
conventional JJ i
VT NNP i
ventilation NN i
group NN N
( ( N
pH NN N
: : N
7.21?0.09 CD N
vs. IN N
7.13?0.07 CD N
, , N
PaO2 NNP N
: : N
45.35?5.92 CD N
mm NN N
Hg NNP N
vs. IN N
40.70?4.70 CD N
mm NN N
Hg NNP N
, , N
PaCO2 NNP N
: : N
57.10?7.59 CD N
mm NN N
Hg NNP N
vs. IN N
61.60?5.47 CD N
mm NN N
Hg NNP N
, , N
HCO3 NNP N
( ( N
- : N
) ) N
: : N
18.50?3.50 CD N
mmol/L NN N
vs. FW N
14.75?2.65 CD N
mmol/L NN N
, , N
SaO2 NNP N
: : N
0.796?0.069 CD N
vs. IN N
0.699?0.066 CD N
, , N
blood NN N
lactic JJ N
acid NN N
: : N
7.07?1.60 CD N
mmol/L NN N
vs. FW N
8.13?1.56 CD N
mmol/L NN N
, , N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
success NN o
rate NN o
of IN o
resuscitation NN o
in IN o
the DT o
low JJ o
VT NNP i
ventilation NN i
group NN N
was VBD N
higher JJR N
than IN N
that DT N
of IN N
the DT N
conventional JJ i
VT NNP i
ventilation NN i
group NN N
( ( N
45 CD N
% NN N
vs. FW N
15 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
PIP NNP N
( ( N
cm JJ N
H2O NNP N
) ) N
of IN N
low JJ i
VT NNP i
ventilation NN i
group NN N
was VBD N
lower JJR N
than IN N
that DT N
of IN N
the DT N
conventional JJ i
VT NNP i
group NN i
( ( i
37.25?7.99 CD i
cm NN N
H2O NNP N
vs. IN N
42.70?7.40 CD N
cm NN N
H2O NNP N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
all PDT N
the DT N
patients NNS N
in IN N
both DT N
groups NNS N
barotrauma VBP o
did VBD o
not RB N
occur VB N
. . N

CONCLUSION VB N
The DT N
strategy NN N
of IN i
low JJ i
ventilator NN i
VT NNP o
( ( N
6 CD N
- : N
7 CD N
ml/kg NN N
) ) N
with IN N
appropriate JJ o
elevation NN o
of IN o
airway JJ o
pressure NN o
alarm NN o
threshold NN o
was VBD o
better JJR N
than IN N
that DT i
of IN i
conventional JJ i
ventilation NN i
setting NN i
, , N
with IN N
no DT N
increase NN N
in IN N
incidence NN o
of IN o
barotraumas NN o
during IN o
CPR NNP N
. . N

-DOCSTART- -X- O O

MRI NNP o
signal JJ o
hyperintensities NNS o
and CC o
failure NN o
to TO o
remit VB o
following VBG N
antidepressant JJ i
treatment NN i
. . i

BACKGROUND NNP N
MRI NNP N
signal JJ N
hyperintensities NNS N
predict VBP N
poor JJ N
remission NN o
to TO N
antidepressant VB i
treatment NN i
. . i

Previous JJ N
studies NNS N
using VBG N
volumetrics NNS N
in IN N
outpatient NN N
samples NNS N
have VBP N
relied VBN N
on IN N
total JJ o
lesion NN o
volume NN o
. . o

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
whether IN N
remission NN N
from IN N
geriatric JJ p
depression NN p
depends VBZ N
on IN N
lesion NN o
volume NN o
by IN o
region NN o
of IN o
interest NN o
( ( o
ROI NNP o
) ) o
. . o

METHOD NNP N
Thirty-eight JJ p
patients NNS p
received VBD N
baseline JJ i
MRIs NNP i
as IN N
part NN N
of IN N
a DT N
larger JJR N
12-week JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
comparing VBG N
sertraline NN i
and CC i
nortriptyline NN i
in IN i
the DT i
treatment NN i
of IN i
late-life JJ i
depression NN i
. . i

MRIcro NNP N
was VBD N
used VBN N
to TO N
quantify VB N
MRI-hyperintensity NNP N
volume NN N
into IN N
total JJ N
hyperintensity NN N
, , N
deep JJ N
white JJ N
matter NN N
hyperintensity NN N
( ( N
DWMH NNP N
) ) N
, , N
and CC N
periventricular JJ N
hyperintensity NN N
( ( N
PVH NNP N
) ) N
volumes NNS N
. . N

High NNP N
versus NN N
low JJ N
total NN N
, , N
DWMH NNP o
, , o
and CC o
PVH NNP o
volumes NNS o
were VBD N
defined VBN N
based VBN N
on IN N
the DT N
highest JJS N
quartile NN N
of IN N
their PRP$ N
respective JJ N
distributions NNS N
. . N

Remission NN o
from IN o
depression NN o
was VBD N
defined VBN N
as IN N
a DT N
24-item JJ N
Hamilton NNP o
Rating NNP o
Scale NNP o
for IN o
Depression NNP o
score NN o
? . N
7 CD N
for IN N
two CD N
consecutive JJ N
weeks NNS N
. . N

RESULTS JJ N
Patients NNS N
classified VBD N
as IN N
having VBG N
high JJ N
DWMH NNP N
were VBD N
7.14 CD N
times NNS N
more RBR N
likely JJ N
not RB N
to TO N
remit VB o
following VBG o
antidepressant JJ i
treatment NN i
compared VBN i
to TO N
patients NNS N
classified VBN N
as IN N
having VBG N
low JJ N
DWMH NNP N
( ( N
p=0.02 NN N
) ) N
. . N

Similar JJ N
odds NNS N
ratios NNS N
were VBD N
obtained VBN N
for IN N
PVH NNP N
( ( N
OR=4.17 NNP N
, , N
p=0.16 NN N
) ) N
and CC N
total JJ N
volumes NNS N
( ( N
OR=5.00 NNP N
, , N
p=0.05 NN N
) ) N
. . N

Importantly RB N
, , N
adjusting VBG N
for IN N
age NN N
did VBD N
not RB N
change VB N
the DT N
magnitude NN N
of IN N
these DT N
effects NNS N
. . N

LIMITATIONS VB N
A NNP N
small JJ p
and CC p
predominantly RB p
White NNP p
sample NN p
. . p

CONCLUSIONS VB N
This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
test VB N
whether IN o
remission NN o
from IN o
geriatric JJ o
depression NN o
depends VBZ o
on IN N
lesion NN o
volume NN o
by IN o
ROI NNP o
in IN o
an DT N
outpatient JJ N
sample NN N
. . N

The DT N
pattern NN N
of IN N
remission NN N
rates NNS N
and CC N
odds JJ N
ratios NNS N
was VBD N
similar JJ N
when WRB N
patients NNS N
were VBD N
classified VBN N
as IN N
having VBG N
high JJ N
DWMH NNP N
, , N
PVH NNP N
or CC N
total JJ N
volume NN N
suggesting VBG N
that IN o
lesion NN o
location NN o
may MD o
not RB N
be VB N
critical JJ N
. . N

-DOCSTART- -X- O O

Safety NN o
and CC o
efficacy NN o
of IN N
oral JJ N
DMSA NNP i
therapy NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
Part VB N
A DT N
-- : N
medical JJ N
results NNS N
. . N

BACKGROUND NNP N
This DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
oral JJ i
dimercapto NN i
succinic JJ i
acid NN i
( ( i
DMSA NNP i
) ) i
therapy NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
ages VBZ p
3-8 CD p
years NNS p
. . p

METHODS NNP N
Phase NNP p
1 CD p
involved VBD p
65 CD p
children NNS p
who WP p
received VBD p
one CD p
round NN p
of IN p
DMSA NNP i
( ( p
3 CD p
days NNS p
) ) p
. . p

Participants NNS p
who WP p
had VBD p
high JJ p
urinary JJ p
excretion NN p
of IN p
toxic JJ p
metals NNS p
were VBD N
selected VBN N
to TO N
continue VB N
on IN N
to TO N
phase VB N
2 CD N
. . N

In IN N
phase NN p
2 CD p
, , p
49 CD p
participants NNS p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
double-blind JJ N
design NN N
to TO N
receive VB N
an DT N
additional JJ N
6 CD N
rounds NNS N
of IN N
either DT N
DMSA NNP i
or CC i
placebo NN i
. . i

RESULTS NNP N
DMSA NNP N
greatly RB N
increased VBD N
the DT N
excretion NN o
of IN o
lead NN o
, , N
substantially RB N
increased VBN N
excretion NN o
of IN o
tin NN o
and CC o
bismuth NN o
, , N
and CC N
somewhat RB N
increased VBD N
the DT N
excretion NN o
of IN o
thallium NN o
, , o
mercury NN o
, , o
antimony NN o
, , o
and CC o
tungsten RB o
. . o

There EX N
was VBD N
some DT N
increase NN N
in IN N
urinary JJ o
excretion NN o
of IN o
essential JJ o
minerals NNS o
, , N
especially RB N
potassium JJ N
and CC N
chromium NN N
. . N

The DT N
Phase NNP N
1 CD N
single JJ N
round NN N
of IN N
DMSA NNP i
led VBD N
to TO N
a DT N
dramatic JJ N
normalization NN o
of IN o
RBC NNP o
glutathione NN o
in IN N
almost RB N
all DT N
cases NNS N
, , N
and CC N
greatly RB N
improved VBN N
abnormal JJ o
platelet NN o
counts NNS o
, , N
suggesting VBG N
a DT N
significant JJ N
decrease NN N
in IN N
inflammation NN o
. . o

CONCLUSION NNP N
Overall NNP N
, , N
DMSA NNP i
therapy NN N
seems VBZ N
to TO N
be VB N
reasonably RB N
safe JJ o
, , o
effective JJ o
in IN N
removing VBG N
several JJ N
toxic JJ o
metals NNS o
( ( N
especially RB N
lead VBP N
) ) N
, , N
dramatically RB N
effective JJ N
in IN N
normalizing VBG o
RBC NNP o
glutathione NN o
, , N
and CC N
effective JJ N
in IN N
normalizing VBG o
platelet NN o
counts NNS o
. . o

Only RB N
1 CD N
round NN N
( ( N
3 CD N
days NNS N
) ) N
was VBD N
sufficient JJ N
to TO N
improve VB N
glutathione NN o
and CC o
platelets NNS o
. . o

Additional JJ N
rounds NNS N
increased VBD N
excretion NN o
of IN o
toxic JJ o
metals NNS o
. . o

-DOCSTART- -X- O O

Randomised VBN N
, , N
parallel-group JJ N
, , N
multicentre NN N
, , N
multinational JJ N
phase NN N
2 CD N
study NN N
comparing VBG N
edoxaban NN i
, , N
an DT N
oral JJ N
factor NN i
Xa NNP i
inhibitor NN i
, , N
with IN N
warfarin NN i
for IN N
stroke NN p
prevention NN p
in IN p
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
. . p

The DT N
primary JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
safety NN N
of IN N
four CD N
fixed-dose JJ N
regimens NNS N
of IN N
edoxaban NN i
with IN i
warfarin NN i
in IN N
patients NNS p
with IN p
non-valvular JJ p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
. . p

In IN N
this DT N
12-week JJ N
, , N
parallel-group JJ N
, , N
multicentre NN p
, , p
multinational JJ p
study NN p
, , p
1,146 CD p
patients NNS p
with IN p
AF NNP p
and CC p
risk NN p
of IN p
stroke NN p
were VBD N
randomised VBN N
to TO N
edoxaban VB i
30 CD N
mg NN N
qd NN N
, , N
30 CD N
mg NN N
bid NN N
, , N
60 CD N
mg NN N
qd NN N
, , N
or CC N
60 CD N
mg JJ N
bid NN N
or CC i
warfarin VB i
dose-adjusted JJ N
to TO N
a DT N
target NN N
international JJ N
normalised JJ N
ratio NN N
of IN N
2.0-3.0 JJ N
. . N

The DT N
study NN N
was VBD N
double-blind JJ N
to TO N
edoxaban VB i
dose JJ N
, , N
but CC N
open-label JJ N
to TO N
warfarin VB i
. . i

Primary JJ N
outcomes NNS N
were VBD N
occurrence NN N
of IN N
major JJ o
and/or NNS o
clinically RB o
relevant JJ o
non-major JJ o
bleeding NN o
and CC o
elevated VBD o
hepatic JJ o
enzymes NNS o
and/or VBP o
bilirubin NN o
. . o

Mean NNP p
age NN p
was VBD p
65 CD p
+/- JJ p
8.7 CD p
years NNS p
and CC p
64.4 CD p
% NN p
were VBD p
warfarin-na?ve JJ i
. . i

Whereas IN N
major JJ N
plus CC N
clinically JJ N
relevant JJ o
non-major JJ o
bleeding NN o
occurred VBD N
in IN N
3.2 CD N
% NN N
of IN N
patients NNS N
randomised VBN N
to TO i
warfarin VB i
, , i
the DT o
incidence NN o
of IN o
bleeding NN o
was VBD N
significantly RB N
higher JJR N
with IN N
the DT i
edoxaban NN i
60 CD N
mg NN N
bid NN N
( ( N
10.6 CD N
% NN N
; : N
p=0.002 CC N
) ) N
and CC N
30 CD N
mg NNS N
bid NN N
regimens VBZ N
( ( N
7.8 CD N
% NN N
; : N
p=0.029 NN N
) ) N
, , N
but CC N
not RB N
with IN N
the DT i
edoxaban NN i
60 CD N
mg NN N
qd NN N
( ( N
3.8 CD N
% NN N
) ) N
or CC N
30 CD N
mg NNS N
qd JJ N
regimens NNS N
( ( N
3.0 CD N
% NN N
) ) N
. . N

For IN N
the DT N
same JJ N
total JJ N
daily JJ N
dose NN N
of IN N
60 CD N
mg NN N
, , N
both DT o
bleeding VBG o
frequency NN o
and CC o
trough JJ o
edoxaban NN o
concentrations NNS o
were VBD N
higher JJR N
in IN N
the DT N
30-mg JJ N
bid NN N
group NN N
than IN N
in IN N
the DT N
60-mg JJ N
qd NN N
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN o
hepatic JJ o
enzyme NN o
elevations NNS o
or CC o
bilirubin JJ o
values NNS o
among IN N
the DT N
groups NNS N
. . N

The DT N
safety NN N
profiles NNS N
of IN i
edoxaban JJ i
30 CD N
and CC N
60 CD N
mg NN N
qd NN N
in IN N
patients NNS N
with IN N
AF NNP N
were VBD N
similar JJ N
to TO i
warfarin VB i
. . i

In IN N
contrast NN N
, , N
the DT i
edoxaban JJ i
bid NN N
regimens NNS N
were VBD N
associated VBN N
with IN N
more RBR o
bleeding NN o
than IN i
warfarin NN i
. . i

These DT N
results NNS N
suggest VBP N
that IN N
in IN N
this DT N
three-month JJ N
study NN N
, , N
edoxaban VBP i
30 CD N
or CC N
60 CD N
mg NNS N
qd NNS N
are VBP o
safe JJ o
and CC o
well-tolerated JJ o
. . o

-DOCSTART- -X- O O

Zolmitriptan NNP i
( ( i
311C90 CD i
) ) i
does VBZ N
not RB N
interact VB N
with IN N
fluoxetine NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

Zolmitriptan NNP i
( ( i
Zomig NNP i
, , i
formerly RB i
311C90 CD i
) ) i
is VBZ N
a DT N
selective JJ i
5-hydroxytryptamine JJ i
( ( i
5-HT JJ i
) ) i
1B/1D-receptor JJ i
agonist NN i
with IN N
central JJ N
and CC N
peripheral JJ N
activity NN N
for IN N
the DT N
acute JJ N
treatment NN N
of IN N
migraine NN N
. . N

This DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
fluoxetine JJ i
administration NN N
on IN N
the DT N
pharmacokinetics NNS o
and CC o
pharmacodynamics NNS o
of IN o
zolmitriptan NN o
. . o

Twenty CD p
volunteers NNS p
were VBD p
given VBN p
single JJ p
doses NNS p
of IN p
fluoxetine JJ i
20 CD i
mg NN i
or CC p
an DT p
identical JJ p
placebo NN i
daily RB p
for IN p
28 CD p
days NNS p
prior RB p
to TO p
receiving VBG p
a DT p
single JJ p
10 CD p
mg JJ p
oral JJ p
dose NN p
of IN p
zolmitriptan NN i
. . i

Sixteen JJ p
volunteers NNS p
completed VBD p
the DT p
two CD p
treatment NN p
phases NNS p
. . p

The DT N
pharmacokinetic JJ o
parameters NNS o
of IN o
zolmitriptan NN o
and CC o
its PRP$ o
metabolites NNS o
were VBD N
not RB N
significantly RB N
affected VBN N
by IN N
fluoxetine JJ i
pretreatment NN N
. . N

The DT N
pharmacodynamic JJ o
effects NNS o
of IN o
zolmitriptan NN o
were VBD N
also RB N
unaffected VBN N
by IN N
fluoxetine JJ i
pretreatment NN N
. . N

There EX N
were VBD N
small JJ N
, , N
clinically RB N
insignificant JJ N
increases NNS N
in IN N
blood NN o
pressure NN o
following VBG N
zolmitriptan NN i
which WDT N
were VBD N
unaltered VBN N
by IN N
fluoxetine NN i
. . i

Zolmitriptan NNP i
was VBD N
well RB o
tolerated VBN o
when WRB N
given VBN N
alone RB N
or CC N
concomitantly RB N
with IN N
fluoxetine NN i
. . i

These DT N
results NNS N
indicate VBP N
that IN N
there EX N
is VBZ N
no DT N
contraindication NN o
to TO N
the DT N
use NN N
of IN N
zolmitriptan NN i
in IN N
patients NNS p
treated VBN p
concurrently RB p
with IN p
selective JJ i
serotonin NNS i
reuptake VBP i
inhibitors NNS i
and CC N
that IN N
no DT N
adjustment NN N
of IN N
the DT N
zolmitriptan NN i
dose NN N
is VBZ N
required VBN N
in IN N
these DT N
circumstances NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
bumetanide NN i
in IN N
the DT N
treatment NN N
of IN N
autism NN p
in IN p
children NNS p
. . p

Gamma NNP N
aminobutyric JJ N
acid NN N
( ( N
GABA NNP N
) ) N
-mediated VBD N
synapses NNS N
and CC N
the DT N
oscillations NNS N
they PRP N
orchestrate VBP N
are VBP N
altered VBN N
in IN N
autism NN N
. . N

GABA-acting JJ N
benzodiazepines NNS i
exert NN N
in IN N
some DT N
patients NNS N
with IN N
autism NN N
paradoxical JJ N
effects NNS o
, , N
raising VBG N
the DT N
possibility NN N
that IN N
like IN N
in IN N
epilepsies NNS N
, , N
GABA NNP N
excites VBZ N
neurons NNS N
because IN N
of IN N
elevated JJ N
intracellular JJ N
concentrations NNS N
of IN N
chloride NN N
. . N

Following VBG N
a DT N
successful JJ N
pilot NN N
study NN N
, , N
( ( N
1 CD N
) ) N
we PRP N
have VBP N
now RB N
performed VBN N
a DT N
double-blind JJ N
clinical JJ N
trial NN N
using VBG N
the DT N
diuretic JJ N
, , N
chloride-importer JJ N
antagonist NN N
bumetanide IN i
that DT N
reduces VBZ N
intracellular JJ N
chloride NN N
reinforcing VBG N
GABAergic NNP N
inhibition NN N
. . N

Sixty NNP p
children NNS p
with IN p
autism NN p
or CC p
Asperger NNP p
syndrome VBP p
( ( p
3-11 CD p
years NNS p
old JJ p
) ) p
received VBD N
for IN N
3 CD N
months NNS N
placebo NN i
or CC N
bumetanide NN i
( ( N
1 CD N
mg NNS N
daily RB N
) ) N
, , N
followed VBN N
by IN N
1-month JJ N
wash NN N
out IN N
. . N

Determination NN N
of IN N
the DT N
severity NN N
of IN N
autism NN N
was VBD N
made VBN N
with IN N
video JJ N
films NNS N
at IN N
day NN N
0 CD N
( ( N
D0 NNP N
) ) N
and CC N
D90 NNP N
by IN N
blind NN N
, , N
independent JJ N
evaluators NNS N
. . N

Bumetanide NNP i
reduced VBD N
significantly RB N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
CARS NNP o
) ) o
( ( N
D90-D0 NNP N
; : N
P NNP N
< VBD N
0.004 CD N
treated JJ N
vs NN N
placebo NN i
) ) i
, , N
Clinical JJ o
Global NNP o
Impressions NNP o
( ( N
P NNP N
< VBZ N
0.017 CD N
treated JJ N
vs NN N
placebo NN i
) ) i
and CC N
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
values NNS o
when WRB N
the DT N
most RBS N
severe JJ N
cases NNS N
( ( N
CARS NNPS N
values NNS N
above IN N
the DT N
mean NN N
? . N
s.d NN N
. . N

; : N
n=9 CC N
) ) N
were VBD N
removed VBN N
( ( N
Wilcoxon JJ N
test NN N
: : N
P-value=0.031 NN N
; : N
Student NNP N
's POS N
t-test NN N
: : N
P-value=0.017 NN N
) ) N
. . N

Side JJ o
effects NNS o
were VBD N
restricted VBN N
to TO N
an DT N
occasional JJ o
mild NN o
hypokalaemia NN o
( ( N
3.0-3.5 JJ N
mM NN N
l NN N
( ( N
-1 NNP N
) ) N
K NNP N
( ( N
+ NNP N
) ) N
) ) N
that WDT N
was VBD N
treated VBN N
with IN N
supplemental JJ N
potassium NN N
. . N

In IN N
a DT N
companion NN N
study NN N
, , N
chronic JJ N
bumetanide NN N
treatment NN N
significantly RB N
improved VBN o
accuracy NN o
in IN o
facial JJ o
emotional JJ o
labelling NN o
, , o
and CC o
increased VBD o
brain NN o
activation NN o
in IN o
areas NNS o
involved VBN o
in IN o
social JJ o
and CC o
emotional JJ o
perception NN o
( ( o
Hadjikhani NNP o
et RB N
al. RB N
, , N
submitted VBN N
) ) N
. . N

Therefore RB i
, , i
bumetanide NN i
is VBZ i
a DT N
promising JJ N
novel NN N
therapeutic JJ N
agent NN N
to TO N
treat VB N
autism NN N
. . N

Larger JJR N
trials NNS N
are VBP N
warranted VBN N
to TO N
better RBR N
determine VB N
the DT N
population NN N
best RB N
suited VBN N
for IN N
this DT N
treatment NN N
. . N

-DOCSTART- -X- O O

Direct JJ N
and CC N
indirect JJ N
effects NNS N
of IN N
interdental JJ i
hygiene NN i
in IN N
a DT N
clinical JJ N
trial NN N
. . N

Many JJ N
randomized VBD N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
in IN N
dental JJ N
research NN N
test NN N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
more JJR N
than IN N
one CD N
outcome NN N
variable NN N
. . N

Univariate NNP N
methods NNS N
, , N
such JJ N
as IN N
the DT N
t JJ N
test NN N
or CC N
analysis NN N
of IN N
covariance NN N
, , N
can MD N
not RB N
evaluate VB N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
multiple JJ N
outcomes NNS N
simultaneously RB N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
use VB N
structural JJ i
equation NN i
modeling NN i
( ( N
SEM NNP N
) ) N
to TO N
re-analyze VB N
a DT N
RCT NNP N
, , N
comparing VBG N
the DT N
effects NNS N
of IN N
pre-curved JJ i
interdental JJ i
brushes NNS i
and CC i
flossing VBG i
on IN N
probing VBG N
pocket NN N
depth NN N
( ( N
PPD NNP N
) ) N
, , N
plaque JJ N
indices NNS N
, , N
and CC N
bleeding VBG N
on IN N
probing VBG N
( ( N
BOP NNP N
) ) N
measured VBD N
at IN N
baseline NN N
, , N
intermediate NN N
, , N
and CC N
final JJ N
examinations NNS N
. . N

Results NNS N
of IN N
SEM NNP N
showed VBD N
that IN N
the DT N
observed JJ N
greater JJR o
reduction NN o
in IN o
PPD NNP o
and CC o
BOP NNP o
in IN N
persons NNS p
using VBG p
interdental JJ p
brushing NN p
than IN p
in IN p
those DT p
flossing NN p
is VBZ N
due JJ N
mainly RB N
to TO N
the DT N
greater JJR N
efficiency NN o
in IN o
plaque NN o
removal NN o
with IN N
the DT N
interdental JJ N
brushes NNS N
( ( N
indirect JJ N
effect NN N
) ) N
rather RB N
than IN N
to TO N
the DT N
compression NN N
of IN N
the DT N
interdental JJ N
papillae NN N
( ( N
direct JJ N
effect NN N
) ) N
. . N

In IN N
contrast NN N
, , N
smokers NNS p
showed VBD N
less JJR N
BOP NNP o
at IN N
baseline NN N
but CC N
also RB N
less RBR N
improvement NN N
in IN N
BOP NNP o
through IN N
direct JJ N
effects NNS N
. . N

-DOCSTART- -X- O O

Serum NNP o
C-peptide NNP o
after IN N
6 CD N
months NNS N
on IN N
glibenclamide NN i
remains VBZ N
higher JJR N
than IN N
during IN N
insulin JJ N
treatment NN N
. . N

Serum NNP o
C-peptide NNP o
was VBD N
measured VBN N
fasting NN N
and CC N
6 CD i
minutes NNS i
after IN i
glucagon NN i
( ( i
1 CD i
mg NN i
given VBN i
intravenously RB i
) ) i
in IN N
49 CD p
patients NNS p
with IN p
non-insulin-dependent JJ p
diabetes NNS p
mellitus NNS p
, , N
after IN i
4 CD i
and CC i
6 CD i
months NNS i
of IN i
successive JJ i
periods NNS i
of IN i
treatment NN i
with IN i
insulin NN i
and CC i
oral JJ i
hypoglycaemics NNS i
( ( i
glibenclamide NN i
and CC i
metformin NN i
) ) i
, , N
given VBN N
in IN N
random JJ N
order NN N
. . N

Glycaemic NNP o
control NN o
was VBD N
not RB N
significantly RB N
different JJ N
on IN N
the DT N
two CD N
treatments NNS N
, , N
but CC N
C-peptide NNP o
was VBD N
much RB N
higher JJR N
while IN N
the DT N
patients NNS N
were VBD N
on IN N
glibenclamide NN N
. . N

We PRP N
conclude VBP N
that IN N
glibenclamide NN i
stimulates VBZ N
pancreatic JJ N
insulin NN N
production NN N
even RB N
after IN N
6 CD N
months NNS N
treatment NN N
. . N

-DOCSTART- -X- O O

Desmopressin NNP i
has VBZ N
no DT N
beneficial JJ N
effect NN N
on IN N
excessive JJ N
postoperative JJ o
bleeding NN o
or CC p
blood NN p
product NN p
requirements NNS p
associated VBN p
with IN p
cardiopulmonary JJ p
bypass NN p
. . p

Cardiopulmonary JJ N
bypass NN N
during IN N
open-heart JJ N
surgery NN N
is VBZ N
sometimes RB N
associated VBN N
with IN N
excessive JJ N
perioperative JJ o
bleeding NN o
. . o

Following VBG N
a DT N
non-randomized JJ N
study NN N
suggesting VBG N
that IN N
desmopressin NN i
acetate NN i
( ( i
desmopressin NN i
) ) i
reduced VBD N
blood NN N
product NN N
requirements NNS N
in IN N
these DT N
patients NNS N
, , N
we PRP N
conducted VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
randomized JJ N
trial NN N
of IN N
desmopressin NN i
( ( N
0.3 CD N
micrograms/kg NN N
, , N
i. JJ N
v. NN N
) ) N
in IN N
92 CD p
patients NNS p
with IN p
overt JJ p
bleeding NN p
and CC p
a DT p
prolonged JJ p
bleeding NN p
time NN p
. . p

Mean JJ N
blood NN o
loss NN o
during IN N
the DT N
first JJ N
24 CD N
h JJ N
post-treatment NN N
was VBD N
similar JJ N
in IN N
the DT N
desmopressin NN i
and CC i
placebo NN i
groups NNS i
( ( N
582 CD N
vs RB N
465 CD N
ml NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.15 CD N
) ) N
. . N

Red-cell NNP N
( ( N
p JJ N
= NNP N
0.76 CD N
) ) N
, , N
fresh JJ N
frozen JJ N
plasma NN N
( ( N
r JJ N
= NNP N
0.66 CD N
) ) N
and CC N
platelet JJ N
unit NN N
( ( N
p JJ N
= NNP N
0.74 CD N
) ) N
requirements NNS N
were VBD N
also RB N
similar JJ N
. . N

The DT N
haemostatic JJ N
effect NN N
of IN N
desmopressin NN N
has VBZ N
been VBN N
attributed VBN N
to TO N
the DT N
release NN N
of IN N
von JJ N
Willebrand NNP N
factor NN N
( ( N
vWF NN N
) ) N
and CC N
a DT N
reduced JJ N
bleeding NN o
time NN o
. . o

In IN N
our PRP$ N
study NN N
, , N
vWF NN o
and CC o
factor NN o
VIII NNP o
: : o
C NNP o
levels NNS o
increased VBN N
while IN N
the DT N
bleeding NN o
time NN o
decreased VBN N
significantly RB N
at IN N
90 CD N
min NN N
and CC N
24 CD N
h NN N
in IN N
both DT N
groups NNS N
and CC N
, , N
although IN N
vWF NN o
and CC o
factor NN o
VIII NNP o
: : o
C NN o
levels NNS o
were VBD N
slightly RB N
higher JJR N
in IN N
desmopressin-treated JJ N
patients NNS N
at IN N
90 CD N
min NN N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

Thrombin-antithrombin JJ o
III NNP o
complex NN o
, , o
fibrinogen NN o
degradation NN o
product NN o
and CC o
tissue NN o
plasminogen NN o
activator NN o
levels NNS o
, , N
reflecting VBG N
activation NN o
of IN o
the DT o
coagulation NN o
and CC o
fibrinolytic JJ o
systems NNS o
, , N
respectively RB N
, , N
decreased VBD N
uniformly RB N
in IN N
both DT N
groups NNS N
. . N

We PRP N
conclude VBP N
that DT N
desmopressin NN N
is VBZ N
not RB N
useful JJ N
in IN N
reducing VBG N
blood NN o
loss NN o
or CC o
blood NN o
product NN o
requirements NNS o
in IN N
patients NNS p
with IN p
excessive JJ p
immediate JJ p
postoperative JJ p
bleeding NN p
. . p

-DOCSTART- -X- O O

Continuous JJ i
thoracic JJ i
epidural JJ i
analgesia NN i
for IN N
postoperative JJ o
pain NN o
relief NN o
following VBG p
thoracotomy NN i
: : i
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
eltanolone NN i
and CC N
thiopental NN i
in IN N
anaesthesia NN o
for IN N
termination NN p
of IN p
pregnancy NN p
. . p

Eltanolone NNP i
, , N
a DT N
new JJ N
steroid JJ N
hypnotic NN N
, , N
was VBD N
compared VBN N
to TO N
thiopental VB N
in IN N
short JJ N
anaesthesia NN N
. . N

Sixty NNP p
unpremedicated VBD p
, , p
Asa NNP p
1-2 JJ p
women NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
eltanolone NN i
0.6 CD i
( ( N
group NN N
E1 NNP N
) ) N
or CC N
0.8 CD N
mg.kg-1 JJ N
( ( N
group NN N
E2 NNP N
) ) N
or CC N
thiopental JJ i
4 CD N
mg.kg-1 NN N
( ( N
group NN N
T NNP N
) ) N
for IN N
induction NN N
of IN N
anaesthesia NN N
. . N

One CD N
minute NN N
before IN N
induction NN N
glycopyrrolate NN i
0.2 CD i
mg NN i
and CC i
alfentanil JJ i
15 CD i
micrograms.kg-1 JJ i
i.v NN N
. . N

were VBD N
administered VBN N
. . N

If IN N
induction NN N
failed VBD N
, , N
additional JJ N
boluses NNS N
of IN N
the DT N
test NN N
drug NN N
were VBD N
given VBN N
. . N

Anaesthesia NNP N
was VBD N
maintained VBN N
with IN N
67 CD N
% NN N
nitrous JJ i
oxide NN i
in IN i
oxygen NN i
, , N
and CC N
additional JJ N
bolus NN N
doses NNS N
of IN N
the DT N
test NN N
drug NN N
were VBD N
given VBN N
in IN N
a DT N
standardized JJ N
fashion NN N
, , N
if IN N
needed VBN N
. . N

Recovery NN o
was VBD N
assessed VBN N
by IN N
a DT N
research NN N
nurse NN N
blinded VBD N
to TO N
the DT N
agent NN N
used VBN N
. . N

Mean JJ o
+/- JJ o
s.d NN o
. . o

induction NN o
doss NN o
were VBD N
0.7 CD N
+/- JJ N
0.1 CD N
mg.kg-1 NN N
( ( N
group NN N
E1 NNP N
) ) N
, , N
0.8 CD N
+/- JJ N
0.1 CD N
mg.kg-1 NN N
( ( N
group NN N
E2 NNP N
) ) N
and CC N
4.0 CD N
+/- JJ N
0.0 CD N
mg.kg-1 NN N
( ( N
group NN N
T NNP N
) ) N
. . N

Induction NN o
time NN o
was VBD N
prolonged VBN N
in IN N
the DT N
group NN N
E1 NNP N
compared VBN N
to TO N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Side JJ o
effects NNS o
were VBD N
few JJ N
in IN N
all DT N
groups NNS N
, , N
but CC N
involuntary JJ o
muscle NN o
movements NNS o
or CC o
hypertonus NN o
occurred VBD N
in IN N
23 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
eltanolone NN N
and CC N
in IN N
3 CD N
% NN N
in IN N
the DT N
thiopental JJ N
groups NNS N
( ( N
n.s NN N
) ) N
. . N

Early JJ o
recovery NN o
( ( o
eye NN o
opening NN o
, , o
orientation NN o
and CC o
sitting VBG o
) ) o
was VBD N
slower VBN N
in IN N
both DT N
eltanolone NN N
groups NNS N
compared VBN N
to TO N
the DT N
thiopental JJ N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

No UH N
differences NNS N
between IN N
the DT N
groups NNS N
were VBD N
found VBN N
in IN N
toleration NN N
of IN N
oral JJ N
fluids NNS N
, , N
walking VBG N
, , N
voiding VBG N
, , N
postoperative JJ N
analgesic JJ N
requirements NNS N
or CC N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Sodium-potassium JJ i
pump NN i
activity NN i
in IN N
white JJ N
blood NN N
cells NNS N
from IN N
children NNS p
with IN p
an DT p
increased VBN p
risk NN p
of IN p
developing VBG p
hypertension NN p
-- : p
The DT p
Odense NNP N
Schoolchild NNP N
Study NNP N
. . N

We PRP N
have VBP N
measured VBN N
the DT N
capacity NN N
of IN N
the DT N
sodium-potassium JJ i
pump NN i
, , N
as IN N
assessed VBN N
by IN N
86rubidium CD N
uptake NN N
and CC N
the DT N
number NN N
of IN N
[ $ N
3H CD N
] NNP N
-ouabain NN N
binding VBG N
sites NNS N
on IN N
white JJ N
blood NN N
cells NNS N
, , N
in IN N
children NNS p
aged VBN p
9-11 CD p
years NNS p
, , p
partly RB p
cross-sectionally RB p
and CC p
partly RB p
longitudinally RB p
after IN p
a DT p
physical JJ i
training NN i
programme NN i
. . i

Children NNP p
from IN p
a DT p
hypertensive JJ p
subgroup NN p
comprising VBG p
the DT p
upper JJ p
5 CD p
% NN p
of IN p
the DT p
blood NN p
pressure NN p
distribution NN p
and CC p
children NNS p
from IN p
a DT p
randomly RB p
selected VBN p
normotensive JJ p
subgroup NN p
were VBD p
eligible JJ p
for IN p
the DT p
study NN p
. . p

In IN p
the DT p
cross-sectional JJ p
study NN p
40 CD p
children NNS p
from IN p
the DT p
hypertensive JJ p
subgroup NN p
and CC p
40 CD p
children NNS p
from IN p
the DT p
normotensive JJ p
subgroup NN p
were VBD p
evaluated VBN p
. . p

A DT N
significant JJ N
increase NN N
in IN N
86rubidium CD o
uptake NN o
was VBD N
present JJ N
in IN N
boys NN N
as IN N
compared VBN N
to TO N
girls NNS N
. . N

After IN N
adjustment NN N
for IN N
differences NNS N
in IN N
sexual JJ N
maturation NN N
the DT N
observed JJ N
significant JJ N
difference NN N
disappeared VBD N
. . N

Important NNP N
correlates NNS N
of IN N
pump NN i
activity NN i
were VBD N
height VBN N
, , N
plasma FW N
glucose NN N
, , N
and CC N
physical JJ N
fitness NN N
. . N

In IN N
the DT N
training NN N
study NN N
10 CD p
boys NNS p
from IN p
the DT p
hypertensive JJ p
subgroup NN p
and CC p
10 CD p
boys NNS p
from IN p
the DT p
normotensive JJ p
subgroup NN p
were VBD N
also RB N
evaluated VBN N
after IN N
eight CD N
months NNS N
of IN N
physical JJ N
training NN N
. . N

A DT N
significant JJ N
fall NN N
in IN N
86rubidium CD o
uptake NN o
was VBD N
observed VBN N
. . N

No DT N
control NN N
group NN N
was VBD N
examined VBN N
and CC N
probably RB N
the DT N
changes NNS N
reflect VBP N
some DT N
effects NNS N
of IN N
sexual JJ o
maturation NN o
on IN o
cation NN o
handling NN o
of IN o
cells NNS o
. . o

These DT N
results NNS N
indicate VBP N
a DT N
significant JJ N
effect NN N
of IN N
sexual JJ o
maturation NN o
in IN o
capacity NN o
of IN o
sodium-potassium JJ o
pump NN o
in IN N
children NNS p
. . p

-DOCSTART- -X- O O

Randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
oral JJ N
phytonadione NN i
for IN N
excessive JJ o
anticoagulation NN o
. . o

STUDY NNP N
OBJECTIVE NNP N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
managing VBG N
excessive JJ N
anticoagulation NN N
in IN N
the DT N
absence NN N
of IN N
bleeding NN N
by IN N
either DT N
omitting VBG N
warfarin JJ N
therapy NN N
alone RB N
or CC N
administering VBG N
oral JJ N
phytonadione NN i
in IN N
addition NN N
to TO N
omitting VBG N
warfarin JJ N
therapy NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

SETTING NNP N
Clinical JJ N
pharmacy NN N
anticoagulation NN N
service NN N
in IN N
a DT N
group NN N
model NN N
health NN N
maintenance NN N
organization NN N
. . N

SUBJECTS NNP N
Thirty NNP p
nonbleeding VBG p
patients NNS p
with IN p
international JJ p
normalized JJ p
ratios NNS p
( ( p
INRs NNP p
) ) p
ranging VBG p
from IN p
6.0-10.0 JJ p
. . p

INTERVENTIONS JJ N
Patients NNPS p
were VBD p
randomized VBN p
to TO p
receive VB p
either CC p
a DT p
single JJ i
oral JJ i
dose NN i
of IN i
phytonadione NN i
2.5 CD i
mg NN i
or CC i
placebo NN i
. . i

Both DT N
groups NNS N
omitted VBD i
warfarin JJ i
doses NNS i
until IN i
the DT i
INR NNP i
became VBD i
less RBR i
than IN i
or CC i
equal JJ i
to TO i
4.0 CD i
. . i

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
The DT N
mean NN o
calculated VBD o
time NN o
to TO o
reach VB o
an DT o
INR NNP o
of IN o
4.0 CD o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
placebo NN N
than IN N
the DT N
phytonadione NN N
group NN N
( ( N
2.6 CD N
vs RB N
1.4 CD N
days NNS N
, , N
p=0.006 NN N
) ) N
. . N

Overcorrection NN o
of IN o
anticoagulation NN o
was VBD N
significantly RB N
more JJR N
common JJ N
in IN N
patients NNS N
receiving VBG N
phytonadione NN N
. . N

Overt NNP o
warfarin VBD o
resistance NN o
was VBD N
not RB N
observed VBN N
in IN N
either DT N
group NN N
after IN N
reinitiating VBG N
warfarin JJ N
therapy NN N
. . N

No DT N
major JJ o
bleeding NN o
or CC o
thromboembolic JJ o
complications NNS o
occurred VBD N
, , N
and CC N
minor JJ N
bleeding NN o
episodes NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
addition NN N
of IN N
oral JJ N
phytonadione NN N
2.5 CD N
mg NN N
reduced VBD N
the DT N
time NN N
to TO N
achieve VB N
an DT N
INR NNP N
of IN N
4.0 CD N
by IN N
approximately RB N
1 CD N
day NN N
compared VBN N
with IN N
omitting VBG N
warfarin JJ N
therapy NN N
alone RB N
. . N

Adverse JJ N
events NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
. . N

Both DT N
strategies NNS N
were VBD N
effective JJ N
in IN N
managing VBG N
asymptomatic JJ p
patients NNS p
with IN p
INRs NNP p
of IN p
6.0-10.0 NNP p
. . p

Oral NNP N
phytonadione NN N
may MD N
be VB N
most RBS N
appropriate JJ N
for IN N
patients NNS p
at IN p
high JJ p
risk NN p
for IN p
bleeding VBG p
in IN p
whom WP p
the DT p
benefit NN p
of IN p
prompt JJ p
INR NNP o
reduction NN o
would MD p
outweigh VB p
the DT p
thromboembolic JJ p
risk NN p
associated VBN p
with IN p
INR NNP o
overcorrection NN o
. . o

-DOCSTART- -X- O O

Does VBZ N
the DT N
result NN N
of IN N
completion NN i
axillary JJ i
lymph NN i
node NN i
dissection NN i
influence NN N
the DT N
recommendation NN N
for IN N
adjuvant JJ i
treatment NN i
in IN N
sentinel JJ p
lymph JJ p
node-positive JJ p
patients NNS p
? . N
OBJECTIVE IN N
The DT N
Hungarian NNP N
National NNP N
Institute NNP N
of IN N
Oncology NNP N
has VBZ N
just RB N
closed VBN N
a DT N
single-center JJ N
randomized JJ N
clinical JJ N
study NN N
. . N

The DT N
Optimal NNP N
Treatment NNP N
of IN N
the DT N
Axilla-Surgery NNP N
or CC N
Radiotherapy NNP N
( ( N
OTOASOR NNP N
) ) N
trial NN N
compares VBZ N
completion NN i
axillary JJ i
lymph NN i
node NN i
dissection NN i
( ( i
cALND NN i
) ) i
with IN N
regional JJ i
nodal JJ i
irradiation NN i
( ( i
RNI NNP i
) ) i
in IN N
patients NNS p
with IN p
sentinel JJ p
lymph JJ p
node-positive JJ p
( ( p
SLN+ NNP p
) ) p
primary VBP p
invasive JJ p
breast NN p
cancer NN p
. . p

In IN N
the DT N
investigational JJ N
treatment NN N
arm NN N
, , N
patients NNS N
received VBD N
50 CD N
Gy NNP N
RNI NNP i
instead RB N
of IN N
cALND NN i
. . i

In IN N
these DT N
patients NNS N
we PRP N
had VBD N
information NN N
only RB N
about IN N
the DT N
sentinel NN N
lymph NN N
node NN N
( ( N
SLN NNP N
) ) N
status NN N
, , N
but CC N
the DT N
further JJ N
axillary JJ N
nodal JJ N
involvement NN N
remained VBD N
unknown JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
result NN N
of IN N
cALND NN i
influenced VBD N
the DT N
recommendation NN N
for IN N
adjuvant JJ N
treatment NN N
in IN N
patients NNS p
with IN p
SLN+ NNP p
breast NN p
cancer NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
SLN+ NNP p
primary JJ p
breast NN p
cancer NN p
were VBD N
randomized VBN N
for IN N
cALND NN i
( ( N
arm NN N
A NNP N
, , N
standard JJ N
treatment NN N
) ) N
or CC N
RNI NNP N
( ( N
arm NN N
B NNP N
, , N
investigational JJ N
treatment NN N
) ) N
. . N

Adjuvant JJ N
systemic JJ N
treatments NNS N
were VBD N
given VBN N
according VBG N
to TO N
the DT N
standard JJ N
institutional JJ N
protocol NN N
, , N
and CC N
patients NNS N
were VBD N
followed VBN N
according VBG N
to TO N
the DT N
actual JJ N
institutional JJ N
guidelines NNS N
. . N

RESULTS NNP N
Between NNP N
August NNP N
2002 CD N
and CC N
June NNP N
2009 CD N
, , N
474 CD p
SLN+ NN p
patients NNS p
were VBD N
randomized VBN N
to TO N
cALND VB i
( ( N
arm NN N
A NNP N
, , N
standard JJ N
treatment NN N
= JJ N
244 CD N
patients NNS N
) ) N
or CC N
RNI NNP i
( ( N
arm NN N
B NNP N
, , N
investigational JJ N
treatment NN N
= VBD N
230 CD N
patients NNS N
) ) N
. . N

The DT N
2 CD N
arms NNS N
were VBD N
well RB N
balanced VBN N
according VBG N
to TO N
the DT N
majority NN N
of IN N
main JJ N
prognostic JJ N
factors NNS N
. . N

However RB N
, , N
more JJR N
patients NNS p
were VBD p
premenopausal JJ p
( ( p
34 CD p
% NN p
vs. FW p
27 CD p
% NN p
; : p
P NNP p
= NNP p
.095 NNP p
) ) p
and CC p
had VBD p
pT2-3 NN p
tumors NNS p
( ( N
57 CD N
% NN N
vs. FW N
40 CD N
% NN N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
in IN N
the DT N
completion NN N
axillary JJ N
lymph NN N
node NN N
dissection NN N
( ( N
ALND NNP N
) ) N
arm NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
there EX N
were VBD N
more JJR N
patients NNS p
with IN p
known JJ p
human JJ p
epidermal JJ p
growth NN p
factor NN p
receptor NN p
type VBD p
2 CD p
positive JJ p
tumor NN p
( ( p
12 CD p
% NN p
vs. FW p
17 CD p
% NN p
, , p
P NNP p
= NNP p
.066 NNP p
) ) p
in IN N
the DT N
RNI NNP N
arm NN N
. . N

In IN N
the DT N
ALND NNP i
and CC N
RNI NNP i
arms NNS N
, , N
78 CD N
% NN N
( ( N
190/244 CD N
) ) N
and CC N
69 CD N
% NN N
( ( N
159/230 CD N
) ) N
, , N
respectively RB N
, , N
received VBD N
chemotherapy NN i
( ( N
P NNP N
= NNP N
.020 NNP N
) ) N
. . N

Endocrine NNP i
therapy NN i
was VBD N
administered VBN N
in IN N
87 CD N
% NN N
( ( N
213/244 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
ALND NNP N
arm NN N
and CC N
89 CD N
% NN N
( ( N
204/230 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
RNI NNP N
arm NN N
( ( N
P NNP N
= NNP N
.372 NNP N
) ) N
. . N

Six CD N
patients NNS N
( ( N
2.5 CD N
% NN N
) ) N
on IN N
arm NN N
A NN N
and CC N
13 CD N
patients NNS N
( ( N
5.7 CD N
% NN N
) ) N
on IN N
arm NN N
B NNP N
received VBD N
adjuvant JJ N
trastuzumab NN N
treatment NN N
( ( N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

Subgroup NNP N
analyses VBZ N
explored VBD N
that IN N
more RBR N
frequent JJ N
administration NN N
of IN N
adjuvant JJ i
chemotherapy NN i
in IN N
arm NN N
A NN N
was VBD N
associated VBN N
with IN N
the DT N
higher JJR N
percentage NN N
of IN N
premenopausal NN p
patients NNS p
and CC p
patients NNS p
with IN p
larger JJR p
( ( p
pT2-3 NN p
) ) p
tumors NNS p
. . p

CONCLUSIONS VB N
The DT N
result NN N
of IN N
cALND NN i
after IN N
positive JJ N
SLN NNP N
biopsy NN N
seems VBZ N
to TO N
have VB N
no DT N
major JJ N
impact NN N
on IN N
the DT N
administration NN N
of IN N
adjuvant JJ i
systemic JJ i
therapy NN i
. . i

-DOCSTART- -X- O O

Thoracoscopic NNP i
talc NN i
insufflation NN i
versus IN N
talc NN i
slurry NN i
for IN N
symptomatic JJ p
malignant JJ p
pleural JJ p
effusion NN p
. . p

BACKGROUND NNP N
Talc NNP N
has VBZ N
been VBN N
generally RB N
accepted VBN N
to TO N
be VB N
the DT N
most RBS N
effective JJ N
sclerosant NN N
for IN N
chemical NN N
pleurodesis NN N
, , N
although IN N
the DT N
optimal JJ N
route NN N
of IN N
administration NN N
remains VBZ N
unclear JJ N
. . N

METHODS NNP N
We PRP N
designed VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
to TO N
compare VB N
video-assisted JJ i
thoracoscopic NN i
talc NN i
insufflation NN i
with IN i
bedside JJ i
talc NN i
slurry NN i
in IN i
the DT N
treatment NN N
of IN N
malignant JJ p
pleural JJ p
effusion NN p
. . p

From IN p
September NNP p
1993 CD p
to TO p
November NNP p
1995 CD p
, , p
57 CD p
patients NNS p
were VBD N
recruited VBN N
and CC N
randomized VBN N
to TO N
either DT N
video-assisted JJ i
thoracoscopic NN i
talc NN i
insufflation NN i
under IN N
general JJ i
anesthesia NN i
( ( N
n JJ N
= NNP N
28 CD N
) ) N
or CC N
talc JJ N
slurry NN N
by IN N
the DT N
bedside NN N
( ( N
n JJ N
= NNP N
29 CD N
) ) N
. . N

Patients NNS p
with IN p
poor JJ p
general JJ p
condition NN p
( ( p
Karnofsky NNP p
score RB p
less JJR p
than IN p
30 CD p
% NN p
) ) p
, , p
poor JJ p
pulmonary JJ p
function NN p
( ( p
forced JJ p
expiratory NN p
volume NN p
in IN p
1 CD p
second NN p
less JJR p
than IN p
0.5 CD p
L NNP p
) ) p
, , p
or CC p
trapped VBN p
lungs NNS p
were VBD p
excluded VBN p
from IN p
this DT p
study NN p
. . p

Five CD N
grams NNS N
of IN N
purified JJ N
talc NN N
was VBD N
used VBN N
for IN N
either DT N
video-assisted JJ N
thoracoscopic NN N
talc NN N
insufflation NN N
or CC N
talc NN N
slurry NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ o
difference NN o
between IN o
the DT o
two CD o
groups NNS o
of IN o
patients NNS o
with IN o
respect NN o
to TO o
age NN o
, , o
sex NN o
ratio NN o
, , o
chest JJS o
drainage NN o
duration NN o
, , o
postprocedural JJ o
hospital NN o
stay NN o
, , o
parenteral JJ o
narcotics NNS o
requirement NN o
, , o
complications NNS o
, , o
or CC o
procedure NN o
failure NN o
( ( o
ie NN o
, , o
recurrence NN o
) ) o
. . o

CONCLUSIONS NNP N
Video-assisted JJ N
thoracoscopic NN N
talc NN N
insufflation NN N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
a DT N
superior JJ N
approach NN N
compared VBN N
with IN N
talc NN N
slurry NN N
in IN N
our PRP$ N
study NN N
. . N

Because IN N
the DT N
former JJ N
demands NNS N
more RBR N
resources NNS N
, , N
we PRP N
advocate VBP N
that IN N
talc NN N
slurry NN N
should MD N
be VB N
considered VBN N
as IN N
the DT N
procedure NN N
of IN N
choice NN N
in IN N
the DT N
treatment NN N
of IN N
symptomatic JJ N
malignant JJ N
pleural JJ N
effusion NN N
in IN N
patients NNS p
who WP p
do VBP p
not RB p
have VB p
trapped VBN p
lungs NNS p
. . p

-DOCSTART- -X- O O

Targeting VBG N
alpha-7 JJ i
nicotinic JJ i
neurotransmission NN i
in IN N
schizophrenia NN p
: : p
a DT N
novel JJ N
agonist NN N
strategy NN N
. . N

Alpha7 NNP i
nicotinic JJ i
acetylcholine NN i
receptor NN i
( ( i
?7 NNP i
nAChR RB i
) ) i
agonists NNS i
may MD N
be VB N
valuable JJ N
treatments NNS N
for IN N
negative JJ N
symptoms NNS N
and CC N
cognitive JJ N
impairment NN N
in IN p
schizophrenia NN p
. . p

Unfortunately RB N
, , N
chronic JJ N
exposure NN N
to TO N
an DT N
agonist NN N
may MD N
reduce VB N
the DT N
receptor NN N
's POS N
sensitivity NN N
. . N

Therefore RB N
, , N
we PRP N
combined VBD i
CDP-choline NNP i
, , i
a DT N
dietary JJ N
source NN N
of IN N
the DT N
direct JJ N
agonist NN N
choline NN N
, , N
with IN i
galantamine NN i
, , i
a DT i
positive JJ i
allosteric JJ i
modulator NN i
( ( i
PAM NNP i
) ) i
of IN i
nicotinic JJ i
acetylcholine NN i
receptors NNS i
, , i
to TO N
improve VB N
the DT N
efficiency NN N
of IN N
transducing VBG N
the DT N
choline JJ N
signal NN N
and CC N
, , N
possibly RB N
, , N
preserve VB N
the DT N
receptor NN N
in IN N
a DT N
sensitive JJ N
state NN N
. . N

We PRP N
conducted VBD N
a DT N
single-site JJ N
, , N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
comparing VBG i
galantamine/CDP-choline NN i
to TO i
placebos VB i
in IN p
schizophrenia NN p
patients NNS p
with IN p
negative JJ p
symptoms NNS p
who WP p
were VBD p
receiving VBG p
second JJ p
generation NN p
antipsychotics NNS p
. . p

Forty-three JJ p
subjects NNS p
received VBN i
galantamine JJ i
and CC i
CDP-choline JJ i
or CC N
matching JJ i
placebos NNS i
for IN N
16weeks CD N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT o
5-item JJ o
Marder NNP o
negative-symptoms JJ o
factor NN o
of IN o
the DT o
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scale NNP o
( ( o
PANSS NNP o
) ) o
. . o

Cognition NN o
and CC o
functioning NN o
were VBD N
also RB N
assessed VBN N
. . N

Trial JJ N
completion NN N
was VBD N
high JJ N
; : N
79 CD N
% NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
treatment NN N
effect NN N
on IN o
negative JJ o
symptoms NNS o
, , o
other JJ o
PANSS NNP o
symptom NN o
factors NNS o
, , o
or CC o
the DT o
MATRICS NNP o
Cognitive NNP o
Consensus NNP o
Battery NNP o
. . o

There EX N
were VBD N
significant JJ N
treatment NN N
effects NNS N
in IN o
overall JJ o
functioning NN o
and CC o
a DT o
test NN o
of IN o
free JJ o
verbal JJ o
recall NN o
. . o

Three CD N
subjects NNS N
discontinued VBN N
treatment NN N
in IN N
the DT N
active JJ N
treatment NN N
group NN N
for IN N
gastro-intestinal JJ N
adverse JJ N
events NNS N
( ( N
AE NNP N
) ) N
. . N

The DT N
most RBS N
common JJ N
AE NNP N
for IN i
galantamine/CDP-choline NN i
was VBD o
abdominal JJ o
pain NN o
; : o
for IN i
placebo NN i
it PRP N
was VBD o
headache NN o
and CC o
sweating NN o
. . o

Although IN N
there EX N
was VBD N
no DT N
significant JJ N
treatment NN N
effect NN N
on IN N
negative JJ N
symptoms NNS N
, , N
the DT N
direction NN N
of IN N
effect NN N
mirrored VBD N
the DT N
effects NNS N
on IN N
a DT N
cognitive JJ N
measure NN N
and CC N
overall JJ N
functioning NN N
. . N

Further NNP N
study NN N
of IN i
?7 NNP i
nAChR JJ i
agonist/PAMs NN i
is VBZ i
warranted VBN N
in IN N
larger JJR N
studies NNS N
that WDT N
will MD N
have VB N
greater JJR N
power NN N
. . N

-DOCSTART- -X- O O

Effectiveness NN o
and CC o
Safety NNP o
of IN N
Tapentadol NNP i
Prolonged NNP N
Release NNP N
( ( N
PR NNP N
) ) N
Versus NNP N
a DT N
Combination NNP i
of IN i
Tapentadol NNP i
PR NNP i
and CC i
Pregabalin NNP i
for IN N
the DT N
Management NNP N
of IN N
Severe NNP p
, , p
Chronic NNP p
Low NNP p
Back NNP p
Pain NNP p
With IN p
a DT p
Neuropathic JJ p
Component NN p
: : p
A DT N
Randomized NNP N
, , N
Double-blind NNP N
, , N
Phase NNP N
3b CD N
Study NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN o
and CC o
tolerability NN o
of IN N
tapentadol NN i
PR NNP i
monotherapy NN N
versus NN N
tapentadol NN i
PR/pregabalin NNP i
combination NN N
therapy NN N
for IN N
severe JJ p
, , p
chronic JJ p
low JJ p
back RB p
pain NN p
with IN p
a DT p
neuropathic JJ p
component NN p
. . p

METHODS NNP N
Eligible JJ p
patients NNS p
had VBD p
painDETECT VBN p
unclear JJ p
or CC p
positive JJ p
ratings NNS p
and CC p
average JJ p
pain NN p
intensity NN p
? . p
6 CD p
( ( p
11-point JJ p
NRS-3 NNP p
[ NNP p
average JJ p
3-day JJ p
pain NN p
intensity NN p
] NN p
) ) p
at IN p
baseline NN i
. . i

Patients NNS i
were VBD i
titrated VBN i
to TO i
tapentadol VB i
PR NNP i
300 CD i
mg/day NN i
over IN i
3 CD i
weeks NNS i
. . i

Patients NNS i
with IN N
? . N
1-point JJ N
decrease NN N
in IN o
pain NN o
intensity NN o
and CC o
average JJ o
pain NN o
intensity NN o
? . o
4 CD o
were VBD o
randomized VBN N
to TO i
tapentadol VB i
PR NNP i
( ( i
500 CD i
mg/day NN i
) ) i
or CC i
tapentadol JJ i
PR NNP i
( ( i
300 CD i
mg/day NN i
) ) i
/pregabalin NN i
( ( i
300 CD i
mg/day NN i
) ) i
during IN N
an DT N
8-week JJ N
comparative JJ N
period NN N
. . N

RESULTS NNP N
In IN N
the DT N
per-protocol JJ N
population NN N
( ( N
n JJ N
= NNP N
288 CD N
) ) N
, , N
the DT N
effectiveness NN o
of IN o
tapentadol NN i
PR NNP i
was VBD i
clinically RB N
and CC N
statistically RB N
comparable JJ i
to TO i
tapentadol VB i
PR/pregabalin NNP i
based VBN i
on IN N
the DT N
change NN N
in IN N
pain NN o
intensity NN o
from IN N
randomization NN N
to TO N
final JJ N
evaluation NN N
( ( N
LOCF NNP N
; : N
LSMD NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
, , N
-0.066 NNP N
[ NNP N
-0.57 NNP N
, , N
0.43 CD N
] NN N
; : N
P NNP N
< VBZ N
0.0001 CD N
for IN N
noninferiority NN N
) ) o
. . o

Neuropathic JJ o
pain NN o
and CC o
quality-of-life JJ o
measures NNS o
improved VBN o
significantly RB N
in IN N
both DT o
groups NNS o
. . o

Tolerability NNP o
was VBD o
good JJ N
in IN N
both DT N
groups NNS N
, , N
in IN N
line NN N
with IN N
prior JJ N
trials NNS N
in IN N
the DT N
high JJ N
dose NN N
range NN N
of IN N
500 CD N
mg/day NN N
for IN N
tapentadol NN i
PR NNP i
monotherapy NN N
, , N
and CC N
favorable JJ N
compared VBN N
with IN N
historical JJ N
combination NN N
trials NNS N
of IN N
strong JJ N
opioids NNS N
and CC N
anticonvulsants NNS N
for IN N
combination NN N
therapy NN N
. . N

The DT N
incidence NN N
of IN N
the DT N
composite NN N
of IN N
dizziness NN o
and/or NN o
somnolence NN o
was VBD N
significantly RB N
lower JJR N
with IN i
tapentadol JJ i
PR NNP i
( ( N
16.9 CD N
% NN i
) ) i
than IN i
tapentadol NN i
PR/pregabalin NNP i
( ( i
27.0 CD i
% NN N
; : N
P NNP N
= NNP N
0.0302 CD N
) ) N
. . N

CONCLUSIONS NNP i
Tapentadol NNP i
PR NNP i
500 CD i
mg NN i
is VBZ N
associated VBN N
with IN N
comparable JJ o
improvements NNS o
in IN o
pain NN o
intensity NN o
and CC o
quality-of-life JJ o
measures NNS o
to TO o
tapentadol VB o
PR NNP i
300 CD i
mg/pregabalin NN N
300 CD N
mg NN o
, , o
with IN o
improved JJ o
central JJ o
nervous JJ o
system NN o
tolerability NN o
, , o
suggesting VBG o
that IN N
tapentadol NN N
PR NNP N
monotherapy NN N
may MD N
offer VB N
a DT N
favorable JJ N
treatment NN N
option NN p
for IN p
severe JJ p
low JJ p
back RB p
pain NN p
with IN p
a DT p
neuropathic JJ p
component NN p
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
static JJ i
stretching VBG i
on IN N
repeated VBN o
sprint NN o
and CC o
change NN o
of IN o
direction NN o
performance NN o
. . o

PURPOSE NNP N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
static JJ i
stretching VBG i
during IN N
the DT N
recovery NN N
periods NNS N
of IN N
field-based JJ N
team NN N
sports NNS N
on IN N
subsequent NN N
repeated VBN o
sprint JJ o
ability NN o
( ( o
RSA NNP o
) ) o
and CC o
change NN o
of IN o
direction NN o
speed NN o
( ( o
CODS NNP o
) ) o
performance NN o
. . o

METHODS NNP N
On IN N
four CD N
separate JJ N
occasions NNS N
, , N
12 CD p
male JJ p
team-sport NN p
players NNS p
performed VBD N
a DT N
standardized JJ N
warm-up NN N
, , N
followed VBN N
by IN N
a DT N
test NN N
of IN N
either DT N
RSA NNP o
or CC N
CODS NNP i
( ( N
on IN N
two CD N
occasions NNS N
each DT N
) ) N
in IN N
a DT N
counterbalanced JJ N
design NN N
. . N

Both DT N
tests NNS N
involved VBD N
three CD N
sets NNS N
of IN N
six CD i
maximal JJ i
sprint NN i
repetitions NNS i
, , i
with IN i
a DT i
4-min JJ i
recovery NN i
between IN i
sets NNS i
. . i

During IN N
the DT N
break NN N
between IN N
sets NNS N
, , N
the DT N
participants NNS p
either CC N
rested VBN i
( ( i
control VB i
[ NNP i
CON NNP i
] NNP i
) ) i
or CC N
completed VBN N
a DT N
static JJ i
stretching NN i
protocol NN i
( ( i
static JJ i
stretch NN i
[ NNP i
SS NNP i
] NNP i
) ) i
. . N

The DT N
RSA NNP i
test NN N
involved VBN N
straight-line JJ i
sprints NNS i
, , N
whereas IN N
the DT N
CODS NNP i
test NN N
required VBD N
a DT N
change NN N
of IN N
direction NN N
( ( N
100 CD N
degrees NNS N
) ) N
every DT N
4 CD N
m NN N
( ( N
total JJ N
of IN N
four CD N
) ) N
. . N

Mean NNP o
, , o
total NN o
( ( o
sum NN o
of IN o
six CD o
sprints NNS o
) ) o
, , o
first RB o
, , o
and CC o
best JJS o
sprint NN o
times NNS o
( ( o
MST NNP o
, , o
TST NNP o
, , o
FST NNP o
, , o
and CC o
BST NNP o
, , o
respectively RB o
) ) o
were VBD N
recorded VBN N
for IN N
each DT N
set NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
consistent JJ N
tendency NN N
for IN N
RSA NNP o
times NNS o
to TO N
be VB N
slower JJR N
after IN N
the DT N
static JJ i
stretching NN i
intervention NN i
, , N
which WDT N
was VBD N
supported VBN N
by IN N
statistical JJ N
significance NN N
for IN N
three CD N
performance NN N
variables NNS N
( ( N
MST NNP N
0-5 NNP N
m NN N
set NN N
2 CD N
, , N
MST NNP N
0-20 NNP N
m NN N
set NN N
2 CD N
, , N
and CC N
TST NNP N
set VBD N
2 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

This DT N
tendency NN N
was VBD N
also RB N
supported VBN N
by IN N
moderate JJ N
effect NN N
sizes NNS N
and CC N
qualitative JJ N
indications NNS N
of IN N
likely JJ N
harmful NN N
or CC N
detrimental JJ N
effects NNS N
associated VBN N
with IN N
RSA-SS NNP i
. . i

Further NNP N
, , N
sprint NN o
times NNS o
again RB N
tended VBD N
to TO N
be VB N
slower JJR N
in IN N
the DT N
CODS-SS NNP i
trial NN N
compared VBN N
with IN N
the DT N
CODS-CON NNP i
across IN N
all DT N
sprint NN N
variables NNS N
, , N
with IN N
a DT N
significantly RB N
slower JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
BST NNP N
recorded VBD N
for IN N
set NN N
3 CD N
after IN N
static JJ N
stretching NN N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
an DT N
acute NN N
bout NN N
( ( N
4 CD N
min NN N
) ) N
of IN N
static JJ i
stretching NN i
of IN N
the DT N
lower JJR N
limbs NN N
during IN N
recovery NN N
periods NNS N
between IN N
efforts NNS N
may MD N
compromise VB N
RSA NNP o
performance NN o
but CC N
has VBZ N
less JJR N
effect NN N
on IN N
CODS NNP o
performance NN o
. . o

-DOCSTART- -X- O O

Efficacy NN o
and CC N
safety NN o
of IN N
zidovudine NN i
and CC i
zalcitabine NN i
combined VBN N
with IN N
a DT N
combination NN N
of IN N
herbs NN N
in IN N
the DT N
treatment NN N
of IN N
HIV-infected NNP p
Thai NNP p
patients NNS p
. . p

A DT N
randomized JJ N
double JJ N
blind NN N
placebo NN i
controlled VBD N
trial NN N
to TO N
determine VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
combined-herbs JJ N
( ( N
SH NNP N
) ) N
given VBN N
with IN N
zidovudine NN i
( ( N
ZDV NNP N
) ) N
and CC N
zalcitabine NN i
( ( N
ddC NN N
) ) N
for IN N
the DT N
treatment NN N
of IN N
HIV NNP p
infection NN p
in IN p
Thai NNP p
adults NNS p
was VBD p
conducted VBN p
in IN p
3 CD p
hospitals NNS p
in IN p
northern JJ p
Thailand NNP p
during IN p
2002 CD p
to TO p
2003 CD p
. . p

The DT N
eligible JJ N
subjects NNS N
were VBD N
HIV-infected JJ p
Thai NNP p
adults NNS p
who WP p
had VBD p
never RB p
received VBN p
anti-retrovirals NNS i
, , p
had VBD p
a DT p
Karnofski NNP p
Performance NNP p
Score NNP p
( ( p
KPS NNP p
) ) p
of IN p
> NN p
or CC p
= $ p
70 CD p
, , p
and CC p
had VBD p
no DT p
opportunistic JJ p
infections NNS p
. . p

The DT N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
a DT N
combination NN N
of IN N
ZDV NNP i
200 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
, , N
ddC VB i
0.75 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
, , N
and CC N
SH NNP i
2.5 CD N
g NN N
three CD N
times NNS N
per IN N
day NN N
or CC N
a DT i
combination NN i
of IN i
ZDV NNP i
200 CD i
mg NN i
three CD i
times NNS i
per IN i
day NN i
, , i
ddC VB i
0.75 CD i
mg NN i
three CD i
times NNS i
per IN i
day NN i
, , i
and CC i
placebo VBZ i
2.5 CD N
g NN N
three CD N
times NNS N
per IN N
day NN N
for IN N
24 CD N
weeks NNS N
. . N

The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
HIV-RNA NNP o
, , o
CD4 NNP o
cells NNS o
, , o
and CC o
blood NN o
chemistry NN o
profiles VBZ o
prior RB N
to TO N
the DT N
treatment NN N
and CC N
then RB N
every DT N
4 CD N
weeks NNS N
for IN N
24 CD N
weeks NNS N
. . N

The DT N
baseline NN N
characteristics NNS N
of IN N
60 CD p
evaluable JJ p
subjects NNS p
, , p
40 CD p
in IN p
the DT p
SH NNP i
group NN p
and CC p
20 CD p
in IN p
the DT p
placebo NN i
group NN p
, , N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

HIV NNP o
RNA NNP o
at IN N
week NN N
4 CD N
and CC N
thereafter RB N
was VBD N
significantly RB N
decreased VBN N
from IN N
the DT N
baseline NN N
value NN N
in IN N
both DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

However RB N
, , N
the DT N
decline NN N
in IN N
HIV NNP o
RNA NNP o
in IN N
the DT N
SH NNP i
group NN N
was VBD N
significantly RB N
more JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
CD4 NNP o
cells NNS o
in IN N
the DT N
SH NNP N
group NN N
at IN N
week NN N
12 CD N
and CC N
thereafter RB N
were VBD N
significantly RB N
increased VBN N
from IN N
the DT N
baseline NN N
value NN N
. . N

Serious JJ o
adverse JJ o
events NNS o
in IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
observed VBN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
an DT N
addition NN N
of IN N
SH NNP N
herbs NNS N
to TO N
two CD N
nucleoside JJ N
reverse NN N
transcriptase NN N
inhibitors NNS N
has VBZ N
greater JJR N
antiviral JJ o
activity NN o
than IN N
antiretrovirals NNS N
only RB N
. . N

The DT N
SH NNP i
herbs NN N
may MD N
be VB N
an DT N
alternative NN N
for IN N
the DT N
third JJ N
anti-retroviral JJ N
agent NN N
in IN N
the DT N
triple JJ N
drug NN N
regimen NNS N
for IN N
the DT N
treatment NN N
of IN N
HIV NNP N
infected VBD N
patients NNS N
in IN N
countries NNS N
with IN N
limited JJ N
resources NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
congestive JJ N
heart NN N
failure NN N
on IN N
plasma NN o
von NN o
Willebrand NNP o
factor NN o
and CC N
soluble JJ o
P-selectin JJ o
concentrations NNS o
in IN N
patients NNS p
with IN p
non-valvar JJ p
atrial JJ p
fibrillation NN p
. . p

OBJECTIVE UH N
To TO N
examine VB N
further RB N
the DT N
relations NNS N
of IN N
plasma NN o
von NN o
Willebrand NNP o
factor NN o
( ( o
vWf NN o
, , o
an DT o
index NN o
of IN o
endothelial JJ o
damage NN o
and CC o
dysfunction NN o
) ) o
and CC N
soluble JJ o
P-selectin NNP o
( ( o
sP-sel NN o
, , o
an DT o
index NN o
of IN o
platelet NN o
activation NN o
) ) o
concentrations NNS N
to TO N
the DT N
presence NN N
and CC N
onset NN N
of IN N
clinical JJ N
congestive JJ N
heart NN N
failure NN N
( ( N
CHF NNP N
) ) N
and CC N
the DT N
degree NN N
of IN N
left NN N
ventricular NN N
( ( N
LV NNP N
) ) N
dysfunction NN N
in IN N
patients NNS p
taking VBG p
part NN p
in IN p
the DT p
SPAF NNP p
( ( p
stroke JJ p
prevention NN p
in IN p
atrial JJ p
fibrillation NN p
) ) p
study NN p
. . p

METHODS NNP N
Plasma NNP o
concentrations NNS o
of IN o
vWf NN o
and CC o
sP-sel NN o
were VBD N
measured VBN N
by IN N
enzyme NN N
linked VBN N
immunosorbent JJ N
assay NN N
( ( N
ELISA NNP N
) ) N
in IN N
1321 CD p
participants NNS p
in IN p
the DT p
SPAF NNP p
III NNP p
study NN p
and CC N
related VBN N
to TO N
the DT N
presence NN N
and CC N
onset NN N
of IN N
clinical JJ N
CHF NNP N
, , N
as RB N
well RB N
as IN N
echocardiographic JJ N
findings NNS N
. . N

Of IN N
the DT N
1321 CD p
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
, , p
331 CD p
( ( p
25 CD p
% NN p
) ) p
had VBD p
a DT p
documented JJ p
history NN p
of IN p
clinical JJ p
heart NN p
failure NN p
, , p
of IN p
which WDT p
168 CD p
cases NNS p
were VBD p
related VBN p
to TO p
a DT p
new JJ p
or CC p
recurrent JJ p
episode NN p
of IN p
acute NN p
decompensated VBN p
heart NN p
failure NN p
occurring VBG p
within IN p
the DT p
preceding VBG p
three CD p
months NNS p
. . p

RESULTS NNP N
Mean NNP o
plasma NN o
vWf NN o
was VBD N
higher JJR N
among IN N
patients NNS N
with IN N
AF NNP N
and CC N
CHF NNP N
( ( N
154 CD N
( ( N
29 CD N
) ) N
v NN N
144 CD N
( ( N
31 CD N
) ) N
IU/dl NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
particularly RB N
those DT N
with IN N
acute NN N
or CC N
recent JJ N
decompensated VBN N
symptoms NNS N
. . N

Patients NNS p
with IN p
severe JJ o
LV NNP o
dysfunction NN o
on IN p
two CD p
dimensional JJ p
echocardiography NN p
and CC p
low JJ p
fractional JJ p
shortening NN p
also RB N
had VBD N
significantly RB N
higher JJR N
vWf NN o
concentrations NNS o
than IN N
those DT N
with IN N
no DT N
LV NNP N
dysfunction NN N
. . N

CHF NNP N
patients NNS N
with IN N
clinical JJ N
features NNS N
-- : N
with IN N
( ( N
156 CD N
( ( N
28 CD N
) ) N
IU/dl NNP N
) ) N
and CC N
without IN N
( ( N
152 CD N
( ( N
31 CD N
) ) N
IU/dl NNP N
) ) N
LV NNP N
dysfunction NN N
-- : N
also RB N
had VBD N
higher JJR N
mean JJ o
vWf NN o
concentrations NNS o
than IN N
patients NNS N
with IN N
asymptomatic JJ N
LV NNP N
dysfunction NN N
( ( N
146 CD N
( ( N
31 CD N
) ) N
IU/dl NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
presence NN N
of IN N
mitral JJ o
regurgitation NN o
in IN o
CHF NNP o
was VBD N
associated VBN N
with IN N
lower JJR N
vWf NN N
concentrations NNS N
. . N

Plasma NNP o
sP-sel JJ o
concentrations NNS o
were VBD N
not RB N
affected VBN N
by IN N
presence NN N
, , N
onset NN N
, , N
or CC N
severity NN N
of IN N
heart NN N
failure NN N
. . N

CONCLUSIONS NNP N
CHF NNP N
may MD N
contribute VB N
to TO N
hypercoagulability NN N
and CC N
thrombotic JJ N
risk NN N
in IN N
AF NNP N
through IN N
increased VBN N
endothelial JJ o
damage NN o
and CC o
dysfunction NN o
. . o

Patients NNS p
with IN p
acute NN p
or CC p
recent JJ p
decompensated VBN p
features NNS p
have VBP N
the DT N
highest JJS N
degree NN N
of IN N
endothelial JJ o
damage NN o
and CC o
dysfunction NN o
. . o

The DT N
presence NN N
of IN N
CHF NNP N
clinical JJ N
features NNS N
was VBD N
an DT N
important JJ N
determinant NN N
of IN N
plasma NN N
vWf NN N
concentrations NNS N
. . N

-DOCSTART- -X- O O

Field NNP N
trials NNS N
of IN N
a DT N
vaccine NN i
against IN N
bovine NN N
mastitis NN N
. . N

1 CD N
. . N

Evaluation NN N
in IN N
heifers NNS p
. . p

A DT N
vaccine NN i
was VBD N
developed VBN N
against IN N
bovine NN N
mastitis NN N
based VBN N
on IN N
inactivated JJ N
, , N
highly RB N
encapsulated JJ N
Staphylococcus NNP N
aureus NN N
cells NNS N
; : N
a DT N
crude NN N
extract NN N
of IN N
Staph NNP N
. . N

aureus NN N
exopolysaccharides NNS N
; : N
and CC N
inactivated VBD N
, , N
unencapsulated JJ N
Staph NNP N
, , N
aureus NN N
and CC N
Streptococcus NNP N
spp NN N
. . N

cells NNS N
. . N

This DT N
vaccine NN i
was VBD N
tested VBN N
on IN N
30 CD p
heifers NNS p
during IN N
a DT N
7-mo JJ N
period NN N
. . N

The DT N
30 CD p
heifers NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
groups NNS N
of IN N
10 CD N
heifers NNS N
each DT N
. . N

The DT N
prepartum NN N
group NN N
received VBD N
two CD N
injections NNS N
of IN N
the DT N
vaccine NN i
at IN N
8 CD N
and CC N
4 CD N
wk NN N
before IN N
calving NN N
, , N
and CC N
the DT N
postpartum NN N
group NN N
received VBD N
two CD N
injections NNS N
at IN N
1 CD N
and CC N
5 CD N
wk NN N
after IN N
calving VBG N
. . N

The DT N
control NN N
group NN N
received VBD N
two CD N
injections NNS N
of IN N
a DT N
placebo NN N
at IN N
8 CD N
and CC N
4 CD N
wk NN N
before IN N
calving VBG N
. . N

The DT N
vaccine NN i
or CC N
the DT N
placebo NN i
was VBD N
administered VBN N
subcutaneously RB N
in IN N
the DT N
brachiocephalicus NN N
muscle NN N
of IN N
the DT N
neck NN N
. . N

The DT N
frequencies NNS o
of IN o
intramammary JJ o
infections NNS o
caused VBN o
by IN o
Staph NNP o
. . o

aureus NN o
were VBD N
reduced VBN N
from IN N
18.8 CD N
% NN N
for IN N
heifers NNS N
in IN N
the DT N
control NN N
group NN N
to TO N
6.7 CD N
and CC N
6.0 CD N
% NN N
for IN N
heifers NNS N
in IN N
the DT N
prepartum NN N
and CC N
postpartum NN N
groups NNS N
, , N
respectively RB N
. . N

This DT N
protective JJ o
effect NN o
was VBD N
maintained VBN N
for IN N
at IN N
least JJS N
6 CD N
mo NN N
. . N

The DT N
relative JJ o
risk NN o
of IN o
mastitis NN o
caused VBN o
by IN o
Staph NNP o
. . o

aureus NN o
was VBD N
0.31 CD N
and CC N
0.28 CD N
for IN N
heifers NNS N
in IN N
the DT N
prepartum NN N
and CC N
postpartum NN N
groups NNS N
, , N
respectively RB N
, , N
compared VBN N
with IN N
that DT N
for IN N
heifers NNS N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
results NNS o
of IN o
the DT o
trial NN o
indicated VBD o
the DT o
effectiveness NN o
of IN o
the DT o
vaccine NN o
in IN N
decreasing VBG N
the DT N
incidence NN N
of IN N
intrammammary JJ N
infections NNS N
caused VBN N
by IN N
Staph NNP N
. . N

aureus NN N
. . N

A DT N
slight JJ N
but CC N
nonsignificant JJ N
increase NN N
occurred VBD N
in IN N
fat JJ o
production NN o
in IN N
the DT N
milk NN N
of IN N
vaccinated JJ N
cows NNS N
. . N

The DT N
vaccine NN N
had VBD N
no DT N
observable JJ N
effect NN N
on IN N
somatic JJ N
cell NN N
count NN N
or CC N
streptococcal JJ N
infections NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
weight JJ i
loss NN i
and CC N
exercise NN i
on IN N
insulin NN p
resistance NN p
, , N
and CC N
intramyocellular JJ N
triacylglycerol NN N
, , N
diacylglycerol NN N
and CC N
ceramide NN N
. . N

AIMS/HYPOTHESIS NNP N
Intramyocellular NNP N
lipids NNS N
, , N
including VBG N
diacylglycerol NN N
( ( N
DAG NNP N
) ) N
and CC N
ceramides NNS N
, , N
have VBP N
been VBN N
linked VBN N
to TO N
insulin VB N
resistance NN N
. . N

This DT N
randomised VBD N
repeated-measures NNS N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
diet-induced JJ i
weight JJ i
loss NN i
( ( i
DIWL NNP i
) ) i
and CC i
aerobic JJ i
exercise NN i
( ( i
EX NNP i
) ) i
on IN N
insulin NN N
sensitivity NN N
and CC N
intramyocellular JJ N
triacylglycerol NN N
( ( N
IMTG NNP N
) ) N
, , N
DAG NNP N
and CC N
ceramide NN N
. . N

METHODS NNP N
Sixteen NNP p
overweight MD p
to TO p
obese VB p
adults NNS p
( ( p
BMI NNP p
30.6 CD p
? . p
0.8 CD p
; : p
67.2 CD p
? . p
4.0 CD p
years NNS p
of IN p
age NN p
) ) p
with IN p
either DT p
impaired JJ p
fasting NN p
glucose NN p
, , p
or CC p
impaired VBD p
glucose JJ p
tolerance NN p
completed VBD p
one CD p
of IN p
two CD p
lifestyle JJ p
interventions NNS p
: : p
DIWL NNP p
( ( p
n JJ p
= NNP p
8 CD p
) ) p
or CC p
EX NNP p
( ( p
n JJ p
= NNP p
8 CD p
) ) p
. . N

Insulin NNP N
sensitivity NN N
was VBD N
determined VBN N
using VBG N
hyperinsulinaemic-euglycaemic JJ N
clamps NNS N
. . N

Intramyocellular JJ N
lipids NNS N
were VBD N
measured VBN N
in IN N
muscle NN N
biopsies NNS N
using VBG N
histochemistry NN N
and CC N
tandem JJ N
mass NN N
spectrometry NN N
. . N

RESULTS NNP o
Insulin NNP o
sensitivity NN o
was VBD o
improved VBN o
with IN N
DIWL NNP N
( ( N
20.6 CD N
? . N
4.7 CD N
% NN N
) ) N
and CC N
EX NNP N
( ( N
19.2 CD N
? . N
12.9 CD N
% NN N
) ) N
. . N

Body NNP o
weight VBD o
and CC o
body NN o
fat NNS o
were VBD o
decreased VBN N
by IN N
both DT N
interventions NNS N
, , N
with IN N
greater JJR N
decreases NNS N
in IN N
DIWL NNP N
compared VBN N
with IN o
EX NNP o
. . o

Muscle NNP o
glycogen NN o
, , o
IMTG NNP o
content NN o
and CC o
oxidative JJ o
capacity NN o
were VBD o
all DT N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
decreased VBN N
with IN N
DIWL NNP N
and CC N
increased VBD N
with IN N
EX NNP N
. . N

There EX N
were VBD N
decreases NNS N
in IN N
DAG NNP o
with IN N
DIWL NNP N
( ( N
-12.4 NNP N
? . N
14.6 CD N
% NN N
) ) N
and CC N
EX NNP N
( ( N
-40.9 NNP N
? . N
12.0 CD o
% NN o
) ) o
. . o

Ceramide NNP o
decreased VBD o
with IN N
EX NNP N
( ( N
-33.7 NNP N
? . N
11.2 CD N
% NN N
) ) N
, , N
but CC N
not RB N
with IN N
DIWL NNP N
. . o

Dihydroceramide NNP o
was VBD o
decreased VBN o
with IN N
both DT N
interventions NNS o
. . o

Sphingosine NNP o
was VBD N
decreased VBN N
only RB N
with IN o
EX NNP o
. . o

Changes NNS o
in IN o
total JJ o
DAG NNP o
, , o
total JJ o
ceramides NNS o
and CC o
other JJ o
sphingolipids NNS o
did VBD o
not RB N
correlate VB N
with IN N
changes NNS N
in IN N
glucose NN N
disposal NN N
. . N

Stearoyl-coenzyme VB o
A DT o
desaturase NN o
1 CD o
( ( o
SCD1 NNP o
) ) o
content NN o
was VBD o
decreased VBN o
with IN o
DIWL NNP N
( ( N
-19.5 NNP N
? . N
8.5 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
increased VBD N
with IN N
EX NNP N
( ( N
19.6 CD N
? . N
7.4 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD o
) ) o
. . o

Diacylglycerol NNP o
acyltransferase VBD o
1 CD o
( ( o
DGAT1 NNP o
) ) o
was VBD o
unchanged JJ o
with IN N
the DT N
interventions NNS N
. . N

CONCLUSIONS/INTERPRETATION NNP N
Diet-induced NNP N
weight NN N
loss NN N
and CC N
exercise NN N
training NN N
both DT N
improved JJ N
insulin NN N
resistance NN N
and CC N
decreased VBD N
DAG NNP N
, , N
while IN N
only RB N
exercise NN N
decreased VBD N
ceramides NNS N
, , N
despite IN N
the DT N
interventions NNS N
having VBG N
different JJ N
effects NNS N
on IN N
IMTG NNP N
. . N

These DT N
alterations NNS N
may MD N
be VB N
mediated VBN N
through IN N
differential JJ N
changes NNS N
in IN N
skeletal JJ N
muscle NN N
capacity NN N
for IN N
oxidation NN N
and CC N
triacylglycerol NN N
synthesis NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00766298 NNP N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
telephone NN i
call NN i
interventions NNS i
on IN N
patients NNS p
' POS p
well-being NN p
in IN p
a DT p
radiation NN p
therapy NN p
department NN p
. . p

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
telephone NN i
call NN i
interventions NNS i
by IN N
a DT N
collaborative JJ N
team NN N
on IN N
patients NNS p
' POS p
well-being JJ p
. . p

Fifty-five JJ p
subjects NNS p
undergoing VBG p
radiation NN p
therapy NN p
for IN p
cure NN p
and CC p
who WP p
were VBD p
able JJ p
to TO p
communicate VB p
by IN p
telephone NN p
comprised VBD p
the DT p
sample NN p
. . p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
control NN i
group NN i
, , i
who WP i
received VBD i
the DT i
usual JJ i
care NN i
or CC i
to TO i
an DT i
experimental JJ i
group NN i
, , i
who WP i
received VBD i
a DT i
weekly JJ i
telephone NN i
call NN i
intervention NN i
in IN i
addition NN i
to TO i
the DT i
usual JJ i
care NN i
. . i

Speilberger NNP o
's POS o
State NNP o
Trait NNP o
Inventory NNP o
, , o
the DT o
Side NNP o
Effects NNP o
Profile NNP o
, , o
and CC o
the DT o
Coping NNP o
Strategies NNP o
Profile NNP o
were VBD N
used VBN N
along IN N
with IN N
a DT N
telephone NN N
survey NN N
to TO N
collect VB N
data NNS N
. . N

Analysis NN N
of IN N
the DT N
data NN N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
anxiety NN o
, , o
severity NN o
of IN o
side NN o
effects NNS o
, , o
helpfulness NN o
of IN o
self-care JJ o
strategies NNS o
, , o
and CC o
coping VBG o
strategies NNS o
. . o

However RB N
, , N
the DT N
survey NN N
indicated VBD N
that IN N
the DT N
telephone NN N
calls VBZ N
were VBD N
clinically RB o
significant JJ o
and CC N
provided VBD N
a DT N
mechanism NN N
for IN N
demonstrating VBG N
that IN N
the DT N
health NN N
care NN N
professionals NNS N
cared VBD N
about IN N
their PRP$ N
patients NNS N
and CC N
provided VBD N
an DT N
opportunity NN N
for IN N
patients NNS N
to TO N
talk VB N
about IN N
their PRP$ N
concerns NNS N
. . N

The DT N
investigators NNS N
believe VBP N
that IN N
collaboration NN N
, , N
caring NN N
, , N
and CC N
communication NN N
are VBP N
the DT N
essence NN N
of IN N
exemplary JJ N
health NN N
care NN N
. . N

-DOCSTART- -X- O O

Genetic JJ N
polymorphisms NNS N
of IN N
human JJ N
flavin JJ N
monooxygenase NN N
3 CD N
in IN N
sulindac-mediated JJ i
primary JJ N
chemoprevention NN N
of IN N
familial JJ p
adenomatous JJ p
polyposis NN p
. . p

PURPOSE NNP N
Sulindac NNP i
is VBZ N
a DT N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
( ( N
NSAID NNP N
) ) N
effective JJ N
in IN N
regressing VBG N
adenomas NN N
in IN N
patients NNS p
with IN p
familial JJ p
adenomatous JJ p
polyposis NN p
( ( p
FAP NNP p
) ) p
. . p

However RB N
, , N
a DT N
recent JJ N
randomized JJ N
trial NN N
showed VBD N
that IN N
sulindac NN i
, , N
when WRB N
compared VBN N
with IN N
placebo NN i
, , N
failed VBD N
to TO N
prevent VB N
the DT N
development NN N
of IN N
adenomatous JJ N
polyps NNS N
in IN N
genotypically RB N
positive JJ N
but CC N
phenotypically RB N
negative JJ N
FAP NNP N
patients NNS N
. . N

The DT N
present JJ N
study NN N
determined VBD N
whether IN N
polymorphisms NNS N
in IN N
the DT N
gene NN N
encoding VBG N
flavin JJ N
monooxygenase NN N
3 CD N
( ( N
FMO3 NNP N
) ) N
, , N
a DT N
hepatic JJ N
microsomal NN N
enzyme NN N
that WDT N
inactivates VBZ N
sulindac RB i
, , N
played VBD N
a DT N
role NN N
in IN N
determining VBG N
the DT N
efficacy NN N
of IN N
sulindac NN i
in IN N
preventing VBG N
polyposis NN N
in IN N
this DT N
cohort NN N
of IN N
FAP NNP p
patients NNS p
. . p

EXPERIMENTAL NNP N
DESIGN NNP N
Genotyping NNP N
was VBD N
performed VBN N
on IN N
seven CD N
established VBD N
FMO3 NNP N
polymorphisms NNS N
previously RB N
shown VBN N
to TO N
have VB N
functional JJ N
relevance-M66I NN p
, , p
P153L NNP p
, , p
E158K NNP p
, , p
V257M NNP p
, , p
E305X NNP p
, , p
E308G NNP p
, , p
and CC p
R492W-in NNP p
21 CD p
and CC p
20 CD p
FAP NNP p
patients NNS p
, , p
who WP p
received VBD p
sulindac NN i
and CC i
placebo NN i
, , p
respectively RB p
. . p

RESULTS NNP N
None NN N
of IN N
the DT N
41 CD p
patients NNS p
exhibited VBN N
heterozygous JJ o
or CC o
homozygous JJ o
M66I NNP o
and CC o
R492W NNP o
variant NN o
alleles NNS o
, , o
or CC o
homozygous JJ o
P153L NNP o
, , o
V257M NNP o
, , o
and CC o
E305X NNP o
variant JJ o
alleles NNS o
. . o

Among IN N
sulindac-treated JJ i
patients NNS p
who WP N
did VBD N
not RB N
develop VB N
adenomas NN N
( ( N
responders NNS N
) ) N
, , N
4 CD N
( ( N
33 CD N
% NN N
) ) N
were VBD N
homozygous JJ o
for IN o
E158K NNP o
and CC N
2 CD N
( ( N
17 CD N
% NN N
) ) N
were VBD N
homozygous JJ o
for IN o
E308G NNP o
variant JJ o
alleles NNS o
. . o

In IN N
contrast NN N
, , N
none NN N
of IN N
the DT N
patients NNS p
on IN p
sulindac NN p
who WP N
developed VBD N
adenomas NN N
( ( N
nonresponders NNS N
) ) N
exhibited VBD N
homozygosity NN o
for IN N
either DT N
of IN N
the DT N
two CD N
variant JJ N
alleles NNS N
. . N

In IN N
addition NN N
, , N
polymorphisms NN N
in IN N
the DT N
E158K NNP N
or CC N
E308G NNP N
allele NNS N
were VBD N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
mucosal NN o
prostanoid NN o
levels NNS o
in IN N
patients NNS N
treated VBN N
with IN N
sulindac NN i
. . i

CONCLUSIONS NNP N
Polymorphisms NNP N
in IN N
FMO3 NNP N
, , N
particularly RB N
at IN N
the DT N
E158K NNP N
and CC N
E308G NNP N
loci NN N
, , N
may MD N
reduce VB N
activity NN N
in IN N
catabolizing VBG N
sulindac NN i
and CC N
result NN N
in IN N
an DT N
increased JJ N
efficacy NN N
to TO N
prevent VB N
polyposis NN N
in IN N
FAP NNP N
. . N

-DOCSTART- -X- O O

The DT N
Relaxation NNP N
Inventory NN N
: : N
self-report JJ N
scales NNS N
of IN N
relaxation NN i
training NN i
effects NNS i
. . i

The DT N
development NN N
of IN N
a DT N
self-report JJ N
measure NN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
relaxation NN N
training NN N
was VBD N
examined VBN N
. . N

A DT N
rigorous JJ N
statistical JJ N
method NN N
of IN N
scale JJ N
construction NN N
consisting NN N
of IN N
a DT N
modification NN N
of IN N
the DT N
scale JJ N
discrimination NN N
technique NN N
was VBD N
employed VBN N
, , N
resulting VBG N
in IN N
a DT N
45-item JJ i
questionnaire NN i
representing VBG N
three CD N
orthogonally RB N
derived VBN N
scales NNS N
. . N

The DT N
three CD N
scales NNS N
, , N
Physiological NNP N
Tension NNP N
, , N
Physical NNP N
Assessment NNP N
, , N
and CC N
Cognitive NNP N
Tension NNP N
, , N
demonstrated VBD N
adequate JJ N
internal JJ N
consistency NN N
with IN N
KR20 NNP N
reliability NN N
coefficients NNS N
of IN N
.89 NNP N
, , N
.95 NNP N
, , N
and CC N
.81 NNP N
, , N
respectively RB N
. . N

In IN N
a DT N
second JJ N
study NN N
of IN N
predictive JJ N
validity NN N
, , N
40 CD p
individuals NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
one CD N
of IN N
four CD N
conditions NNS N
: : N
relaxation NN i
training NN i
, , i
tension NN i
inducement NN i
, , i
pre-postcontrol NN i
, , i
or CC i
postcontrol NN i
. . i

Univariate NNP N
analysis NN N
of IN N
variance NN N
indicated VBN N
significant JJ N
findings NNS N
for IN N
each DT N
of IN N
the DT N
three CD N
dimensions NNS N
of IN N
the DT N
inventory NN N
. . N

The DT N
Physiological JJ N
Tension NNP N
Scale NNP N
detected VBD N
significant JJ N
increases NNS N
in IN N
tension NN o
following VBG N
tension NN N
inducement NN N
, , N
whereas IN N
the DT N
Physical NNP N
Assessment NNP N
Scale NNP N
and CC N
Cognitive NNP N
Tension NNP N
Scale NNP N
detected VBD N
increases NNS N
in IN N
relaxation NN o
following VBG N
relaxation NN i
training NN i
. . i

Recommendations NNS N
were VBD N
made VBN N
for IN N
future JJ N
research NN N
on IN N
the DT N
inventory NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
acupressure NN i
at IN N
the DT N
extra JJ N
1 CD N
point NN N
on IN N
subjective JJ N
and CC N
autonomic JJ o
responses NNS o
to TO N
needle VB N
insertion NN N
. . N

BACKGROUND NNP N
Premedication NNP i
with IN i
sedatives NNS i
can MD N
decrease VB N
the DT N
discomfort NN o
associated VBN N
with IN N
invasive JJ N
anesthetic JJ N
procedures NNS N
. . N

Some DT N
researchers NNS N
have VBP N
shown VBN N
that IN N
acupressure NN N
on IN N
the DT N
acupuncture NN N
extra JJ N
1 CD N
point NN N
is VBZ N
effective JJ N
for IN N
sedation NN N
. . N

We PRP N
investigated VBD N
whether IN N
acupressure NN N
on IN N
the DT N
extra JJ N
1 CD N
point NN N
could MD N
alleviate VB N
the DT N
pain NN o
of IN N
needle JJ N
insertion NN N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
acupressure NN i
at IN N
the DT N
extra JJ N
1 CD N
point NN N
or CC N
a DT N
sham JJ N
point NN N
on IN N
needle JJ N
insertion NN N
using VBG N
verbal JJ o
rating NN o
scale NN o
( ( o
VRS NNP o
) ) o
pain NN o
scores NNS o
and CC N
heart NN o
rate NN o
variability NN o
( ( o
HRV NNP o
) ) o
. . o

Twenty-two NNP p
healthy JJ p
female NN p
volunteers NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
the DT N
extra JJ i
1 CD i
group NN i
received VBD N
acupressure NN i
at IN i
the DT i
extra JJ i
1 CD i
point NN i
, , N
and CC N
the DT N
sham NN i
group NN i
received VBD N
acupressure NN i
at IN i
a DT i
sham JJ i
point NN i
. . i

After IN N
starting VBG N
the DT N
electrocardiogram NN i
record NN N
, , N
a DT N
27-gauge JJ N
needle NN N
was VBD N
inserted VBN N
into IN N
the DT N
skin NN N
of IN N
a DT N
forearm NN N
. . N

Thereafter NNP N
, , N
another DT N
needle NN N
was VBD N
inserted VBN N
into IN N
the DT N
skin NN N
of IN N
the DT N
other JJ N
forearm NN N
during IN N
acupressure NN N
. . N

RESULTS JJ N
Acupressure NN i
at IN N
the DT N
extra JJ N
1 CD N
point NN N
significantly RB N
reduced VBD N
the DT N
VRS NNP o
, , N
but CC N
acupressure NN i
at IN N
the DT N
sham NN N
increased VBD N
the DT N
VRS NNP o
. . o

Acupressure NN i
at IN N
the DT N
extra JJ N
1 CD N
significantly RB N
reduced VBD N
the DT N
low JJ o
frequency/high JJ o
frequency NN o
ratio NN o
of IN o
HRV NNP o
responding VBG o
to TO o
needle DT o
insertion NN o
. . o

CONCLUSIONS JJ N
Acupressure NN i
at IN N
the DT N
extra JJ N
1 CD N
point NN N
significantly RB N
reduced VBD N
needle JJ o
insertion NN o
pain NN o
compared VBN N
with IN N
acupressure NN i
at IN N
the DT N
sham NN N
point NN N
. . N

Also RB N
, , N
acupressure NN i
at IN N
the DT N
extra JJ N
1 CD N
point NN N
significantly RB N
reduced VBD N
the DT N
low JJ o
frequency/high JJ o
frequency NN o
ratio NN o
of IN o
HRV NNP o
responding VBG N
to TO N
needle VB N
insertion NN N
, , N
which WDT N
implies VBZ N
a DT N
reduction NN o
in IN N
sympathetic JJ o
nervous JJ o
system NN o
activity NN o
. . o

-DOCSTART- -X- O O

Effects NNS N
of IN N
two CD N
combined JJ N
oral JJ i
contraceptives NNS i
containing VBG N
ethinyl NN i
estradiol $ i
20 CD N
microg NN N
combined VBN N
with IN N
either DT N
drospirenone NN i
or CC i
desogestrel NN i
on IN N
lipids NNS N
, , N
hemostatic JJ N
parameters NNS N
and CC N
carbohydrate JJ N
metabolism NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
ethinyl NN i
estradiol NN i
20 CD i
microg/drospirenone NN i
3 CD i
mg NN i
( ( N
EE NNP N
20 CD N
microg/DRSP NN N
3 CD N
mg NN N
) ) N
administered VBD N
according VBG N
to TO N
a DT N
24/4 JJ N
regimen NN N
with IN N
ethinyl JJ i
estradiol NN i
20 CD i
microg/desogestrel NN i
150 CD N
microg NN N
( ( N
EE NNP N
20 CD N
microg/DSG NN N
150 CD N
microg NN N
) ) N
administered VBD N
according VBG N
to TO N
the DT N
conventional JJ N
21/7 CD N
regimen NNS N
on IN N
lipid JJ N
, , N
carbohydrate NN N
and CC N
hemostatic JJ N
parameters NNS N
. . N

STUDY NNP N
DESIGN NNP N
In IN N
this DT N
open-label JJ N
study NN N
, , N
healthy JJ p
women NNS p
were VBD p
randomized VBN p
to TO p
EE VB p
20 CD p
microg/DRSP NN p
3 CD p
mg NN p
or CC p
EE NNP p
20 CD p
microg/DSG NN p
150 CD p
microg NN p
for IN p
seven CD p
cycles NNS p
. . p

Mean JJ N
differences NNS N
in IN N
high-density NN o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
- : o
and CC o
low-density JJ o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
-cholesterol NN o
levels NNS o
at IN N
cycle NN N
7 CD N
compared VBN N
to TO N
baseline VB N
were VBD N
assessed VBN N
. . N

Secondary JJ N
variables NNS N
included VBD N
changes NNS N
in IN N
other JJ o
lipid JJ o
, , o
hemostatic JJ o
and CC o
carbohydrate JJ o
parameters NNS o
. . o

RESULTS NNP N
Both NNP N
treatments NNS N
increased VBD N
HDL-cholesterol NNP o
, , N
but CC N
decreased VBD N
LDL-cholesterol NNP o
by IN N
a DT N
comparable JJ N
extent NN N
. . N

Although IN N
slightly RB N
elevated VBN N
in IN N
both DT N
groups NNS N
, , N
blood NN o
glucose NN o
and CC o
C-peptide JJ o
levels NNS o
measured VBN N
during IN N
oral JJ N
glucose JJ N
tolerance NN N
tests NNS N
were VBD N
within IN N
normal JJ N
reference NN N
ranges VBZ N
at IN N
cycle NN N
7 CD N
. . N

Overall JJ N
, , N
the DT N
differences NNS N
in IN N
lipid JJ o
, , o
hemostatic JJ o
or CC o
carbohydrate JJ o
parameters NNS o
were VBD N
not RB N
significant JJ N
between IN N
the DT N
two CD N
treatments NNS N
. . N

CONCLUSION NNP N
EE NNP N
20 CD N
microg/DRSP NN N
3 CD N
mg NN N
has VBZ N
a DT N
good JJ N
safety NN N
profile NN N
comparable JJ N
with IN N
EE NNP N
20 CD N
microg/DSG NN N
150 CD N
microg NN N
. . N

-DOCSTART- -X- O O

Postoperative JJ N
analgesia NN N
with IN N
preoperative JJ N
oral JJ N
ibuprofen NN i
or CC N
acetaminophen NN i
in IN N
children NNS p
undergoing VBG p
myringotomy NN p
. . p

Previous JJ N
studies NNS N
have VBP N
shown VBN N
over IN N
70 CD p
% NN p
of IN p
children NNS p
require VBP N
analgesics NNS i
following VBG N
bilateral JJ p
myringotomy NNS p
and CC p
tube VB p
placement NN p
( ( p
BM NNP p
& CC p
T NNP p
) ) p
. . p

This DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
compared VBN N
the DT N
postoperative JJ N
analgesic JJ N
effects NNS N
of IN N
preoperatively RB N
administered VBN N
oral JJ N
acetaminophen NN i
or CC i
ibuprofen NN i
. . i

Forty NNP p
three CD p
ASA NNP p
I PRP p
or CC p
II NNP p
children NNS p
age NN p
six CD p
months NNS p
or CC p
older JJR p
scheduled VBN p
for IN p
elective JJ p
BM NNP p
& CC p
T NNP p
were VBD N
randomized VBN N
to TO N
receive VB N
acetaminophen NN i
( ( i
paracetamol NN i
) ) i
15 CD i
mg.kg-1 JJ i
, , i
ibuprofen JJ i
10 CD i
mg.kg-1 NN i
, , i
or CC i
placebo NN i
. . i

Postoperative JJ N
pain NN N
was VBD N
assessed VBN N
using VBG N
the DT N
Children NNP o
's POS o
Hospital NNP o
of IN o
Eastern NNP o
Ontario NNP o
Pain NNP o
Scale NNP o
( ( o
CHEOPS NNP o
) ) o
upon IN N
arrival NN N
to TO N
the DT N
PACU NNP N
and CC N
at IN N
5 CD N
, , N
10 CD N
, , N
15 CD N
, , N
30 CD N
, , N
45 CD N
, , N
and CC N
60 CD N
min NN N
. . N

CHEOP NNP N
scores NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
at IN N
any DT N
time NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
number NN N
of IN N
children NNS p
receiving VBG p
rescue NN o
analgesia NN o
. . o

This DT N
study NN N
showed VBD N
no DT N
benefit NN N
of IN N
preoperatively RB N
administered VBN N
oral JJ N
ibuprofen NN i
10 CD N
mg.kg-1 NN N
or CC N
acetaminophen VB i
15 CD N
mg.kg-1 NN N
over IN N
placebo NN N
for IN N
the DT N
relief NN N
of IN N
postoperative JJ N
pain NN N
in IN N
children NNS p
undergoing VBG p
BM NNP p
& CC p
T NNP p
. . p

-DOCSTART- -X- O O

[ JJ N
Advantages NNP N
of IN N
video NN i
assisted VBN i
thoracic NN i
surgery NN i
in IN N
the DT N
treatment NN N
of IN N
spontaneous JJ p
pneumothorax NN p
] NNP p
. . N

Spontaneous JJ p
pneumothorax NN p
( ( p
SP NNP p
) ) p
is VBZ N
a DT N
disabling VBG N
condition NN N
mostly RB N
affecting VBG N
young JJ p
, , p
thin JJ p
and CC p
otherwise RB p
healthy JJ p
males NNS p
. . p

It PRP N
is VBZ N
usually RB N
caused VBN N
by IN N
ruptured JJ N
pleural JJ N
blebs NN N
. . N

The DT N
first JJ N
treatment NN N
is VBZ N
the DT N
insertion NN i
of IN i
a DT i
chest NN i
tube NN i
( ( i
ICT NNP i
) ) i
but CC N
in IN N
a DT N
great JJ N
number NN N
of IN N
patients NNS N
there EX N
is VBZ N
recurrence NN N
of IN N
the DT N
disease NN N
. . N

We PRP N
believe VBP N
that IN N
the DT N
video NN i
assisted VBN i
thoracoscopy NN i
( ( i
VATS NNP i
) ) i
is VBZ N
the DT N
best JJS N
treatment NN N
possible JJ N
because IN N
it PRP N
allows VBZ N
us PRP N
to TO N
treat VB N
the DT N
ruptured JJ N
bleb NN N
radically RB N
avoiding VBG N
any DT N
recurrence NN N
. . N

In IN N
order NN N
to TO N
prove VB N
it PRP N
, , N
40 CD p
patients NNS p
admitted VBN p
in IN p
a DT p
five-year JJ p
period NN p
, , p
with IN p
a DT p
SP NNP p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
be VB N
treated VBN N
by IN N
ICT NNP i
or CC i
VATS NNP i
. . i

The DT N
ICT JJ i
patients NNS N
were VBD N
in IN N
the DT N
hospital NN N
a DT N
mean JJ o
time NN o
of IN N
7.5 CD N
( ( N
4 CD N
to TO N
15 CD N
) ) N
days NNS N
and CC N
the DT N
VATS NNP i
patients NNS N
, , N
5.3 CD N
( ( N
2 CD N
to TO N
7 CD N
) ) N
days NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

ICT JJ i
patients NNS N
required VBN N
analgesic JJ o
drugs NNS o
during IN N
76.8 CD N
+/- JJ N
31 CD N
hours NNS N
and CC N
VATS NNP i
patients NNS N
38.4 CD N
+/- JJ N
13 CD N
hours NNS N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
. . N

From IN N
the DT N
ICT NNP i
group NN N
, , N
8 CD N
( ( N
53 CD N
% NN N
) ) N
patients NNS N
had VBD N
recurrence NN o
of IN o
the DT o
disease NN o
and CC N
6 CD N
( ( N
40 CD N
% NN N
) ) N
had VBD N
a DT N
prolonged JJ N
air NN o
leak NN o
, , N
while IN N
none NN N
of IN N
the DT N
patients NNS N
of IN N
the DT N
VATS NNP i
group NN N
had VBD N
any DT N
complication NN o
( ( N
< NNP N
.001 NNP N
) ) N
. . N

Cost NN o
of IN o
ICT NNP o
and CC o
VATS NNP o
were VBD N
$ $ N
850 CD N
and CC N
$ $ N
1730 CD N
, , N
respectively RB N
. . N

According VBG N
to TO N
these DT N
results NNS N
, , N
VATS NNP i
should MD N
be VB N
the DT N
treatment NN N
of IN N
choice NN N
in IN N
SP NNP N
patients NNS N
. . N

It PRP N
treats VBZ N
the DT N
cause NN N
of IN N
the DT N
disease NN N
. . N

It PRP N
also RB N
reduces VBZ N
the DT N
hospitalization NN o
time NN o
, , N
the DT N
use NN N
of IN N
analgesic JJ N
drugs NNS N
post NN N
surgery NN N
, , N
decreases VBZ N
recurrence NN o
of IN o
the DT o
disease NN o
and CC o
the DT o
cost NN o
of IN o
the DT o
treatment NN o
. . o

Moreover RB N
, , N
the DT N
patients NNS N
were VBD N
back RB N
to TO N
work VB N
in IN N
less JJR N
than IN N
10 CD N
days NNS N
. . N

-DOCSTART- -X- O O

Helicobacter NNP N
pylori NN N
and CC N
gastric JJ N
cancer NN N
: : N
current JJ N
status NN N
of IN N
the DT N
Austrain NNP p
Czech JJ p
German NNP p
gastric NN p
cancer NN p
prevention NN N
trial NN N
( ( N
PRISMA NNP N
Study NNP N
) ) N
. . N

AIM UH N
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
Helicobacter NNP N
pylori VBZ N
eradication NN N
alone RB N
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
gastric JJ o
cancer NN o
in IN N
a DT N
subgroup NN p
of IN p
individuals NNS p
with IN p
an DT p
increased VBN p
risk NN p
for IN p
this DT p
fatal JJ p
disease NN p
. . p

METHODS NNP N
It PRP N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
multinational JJ N
multicenter NN N
trial NN N
. . N

Men NN p
between IN p
55 CD p
and CC p
65 CD p
years NNS p
of IN p
age NN p
with IN p
a DT p
gastric JJ p
cancer NN p
phenotype NN p
of IN p
Helicobacter NNP p
pylori FW p
gastritis NN p
are VBP p
randomized VBN p
to TO N
receive VB N
a DT N
7 CD N
day NN N
course NN N
of IN N
omeprazole JJ i
2 CD i
X NN i
20mg CD i
, , i
clarithromycin VBD i
2 CD i
X NNP i
500mg CD i
, , i
and CC i
amoxicillin RB i
2 CD i
X NNS i
1g CD i
for IN i
7 CD i
days NNS i
, , i
or CC i
omeprazole JJ i
2 CD i
X NN i
20mg CD i
plus CC i
placebo NN i
. . i

Follow-up JJ N
endoscopy NN N
is VBZ N
scheduled VBN N
3 CD N
months NNS N
after IN N
therapy NN N
, , N
and CC N
thereafter RB N
in IN N
one-year JJ N
intervals NNS N
. . N

Predefined VBN N
study NN N
endpoints NNS N
are VBP N
gastric JJ o
cancer NN o
, , o
precancerous JJ o
lesions NNS o
( ( o
dysplasia NN o
, , o
adenoma NN o
) ) o
, , o
other JJ o
cancers NNS o
, , o
and CC o
death NN o
. . o

RESULTS NNP N
Since IN p
March NNP p
1998 CD p
, , p
1524 CD p
target NN p
patients NNS p
have VBP p
been VBN p
screened VBN p
, , p
279 CD p
patients NNS p
( ( p
18.3 CD p
% NN p
) ) p
had VBD p
a DT p
corpus NN p
dominant JJ p
type NN p
of IN p
H. NNP p
pylori FW p
gastritis NN p
, , p
and CC p
167 CD p
of IN p
those DT p
were VBD p
randomized VBN p
( ( N
58.8 CD N
% NN N
) ) N
. . N

In IN N
the DT N
active JJ N
treatment NN N
group NN N
( ( N
r NN N
= RB N
86 CD N
) ) N
, , N
H. NNP N
pylori VBZ N
infection NN N
infection NN N
was VBD N
cured VBN o
in IN N
88.9 CD N
% NN N
of IN N
patients NNS N
. . N

Currently RB N
, , N
the DT N
cumulative JJ N
follow-up JJ N
time NN N
is VBZ N
3046 CD N
months NNS N
( ( N
253.38 CD N
patient NN N
years NNS N
, , N
median NN N
follow VBP N
up RB N
16 CD N
months NNS N
) ) N
. . N

So RB N
far RB N
, , N
none NN N
of IN N
the DT N
patients NNS N
developed VBD N
gastric JJ o
cancer NN o
or CC o
any DT o
precancerous JJ o
lesion NN o
. . o

Three NNP N
( ( N
1.8 CD N
% NN N
) ) N
patients NNS N
reached VBD N
study NN o
endpoints NNS o
other JJ o
than IN o
gastric JJ o
cancer NN o
. . o

CONCLUSION NNP N
Among IN N
men NNS N
between IN N
55 CD N
and CC N
65 CD N
years NNS N
of IN N
age NN N
, , N
the DT N
gastric JJ N
cancer NN N
phenotype NN N
of IN N
H. NNP N
pylori FW N
gastritis NN N
appears VBZ N
to TO N
be VB N
more JJR N
common JJ N
than IN N
expected VBN N
. . N

Further RBR N
follow VB N
up RB N
and CC N
continuing VBG N
recruitment NN N
are VBP N
necessary JJ N
to TO N
fulfil VB N
the DT N
main JJ N
aim NN N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O

D-dimer JJ N
predicts NNS N
outcome VBP N
after IN N
aneurysmal JJ N
subarachnoid JJ p
hemorrhage NN p
: : p
no DT N
effect NN N
of IN N
thromboprophylaxis NN N
on IN N
coagulation NN o
activity NN o
. . o

OBJECTIVE NNP N
Approximately RB N
one-third NN N
of IN N
all DT N
patients NNS p
with IN p
acute JJ p
nontraumatic JJ p
subarachnoid NN p
hemorrhage NN p
( ( p
SAH NNP p
) ) p
experience NN N
complications NNS N
owing VBG N
to TO N
delayed VB N
ischemic JJ N
deficit NN N
. . N

We PRP N
reported VBD N
recently RB N
that IN N
enoxaparin VBZ i
40 CD N
mg NN N
once RB N
daily JJ N
for IN N
10 CD N
days NNS N
seems VBZ N
safe JJ N
and CC N
demonstrates VBZ N
thromboprophylactic JJ o
efficacy NN o
, , N
but CC N
it PRP N
failed VBD N
to TO N
improve VB N
outcome NN N
in IN N
a DT N
randomized JJ N
SAH NNP N
trial NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
assessed VBD N
hemostatic JJ o
variables NNS o
associated VBN N
with IN N
clinical JJ N
status NN N
and CC N
outcome NN N
of IN N
SAH NNP N
. . N

We PRP N
also RB N
monitored VBD N
the DT N
effect NN N
of IN N
enoxaparin NN i
on IN N
activation NN o
of IN o
coagulation NN o
and CC o
fibrinolysis NN o
after IN N
closure NN N
of IN N
the DT N
ruptured JJ N
aneurysm NN N
. . N

METHODS NNP N
Blood NNP o
samples NNS o
to TO N
measure VB N
activation NN o
of IN o
coagulation NN o
and CC o
fibrinolysis NN o
were VBD N
collected VBN N
from IN N
42 CD p
patients NNS p
participating VBG p
in IN p
the DT p
enoxaparin JJ i
trial NN p
for IN p
acute NN p
aneurysmal JJ p
SAH NNP p
at IN p
four CD p
time NN p
points NNS p
: : p
1 CD p
) ) p
at IN p
hospital JJ p
admission NN p
; : p
2 CD p
) ) p
12 CD p
to TO p
24 CD p
hours NNS p
after IN p
aneurysm JJ p
surgery NN p
but CC p
before IN p
initiation NN p
of IN p
enoxaparin JJ i
therapy NN p
; : p
3 CD p
) ) p
3 CD p
hours NNS p
after IN p
the DT p
first JJ p
dose NN p
; : p
and CC p
4 CD p
) ) p
at IN p
the DT p
conclusion NN p
of IN p
treatment NN p
. . p

RESULTS NNP N
At IN N
admission NN N
, , N
several JJ N
variables NNS o
of IN o
coagulation NN o
and CC o
fibrinolysis NN o
were VBD N
elevated VBN N
and CC N
correlated VBN N
well RB N
with IN N
clinical JJ N
status NN N
. . N

Specifically RB N
, , N
D-dimer NNP o
levels NNS o
at IN N
all DT N
four CD N
time NN N
points NNS N
correlated VBN N
with IN N
patients NNS N
' POS N
long-term JJ N
outcomes NNS N
. . N

A DT N
single JJ N
dose NN N
of IN N
enoxaparin NN i
suppressed VBD N
early JJ o
coagulation NN o
activity NN o
, , N
but CC N
thrombin JJ o
generation NN o
was VBD N
not RB o
inhibited VBN o
during IN N
thromboprophylaxis NN N
. . N

However RB N
, , N
PAI-1 NNP o
activity NN o
was VBD N
suppressed VBN N
. . N

CONCLUSION NNP N
D-dimer NNP N
offers VBZ N
a DT N
useful JJ N
laboratory NN N
tool NN N
for IN N
assessing VBG N
early JJ N
and CC N
late JJ N
clinical JJ N
severity NN o
of IN o
SAH NNP o
. . o

A NNP N
thromboprophylactic JJ N
dose NN N
of IN N
enoxaparin NN i
inhibited VBN N
PAI-1 JJ o
activity NN o
but CC N
failed VBD N
to TO N
down-regulate JJ N
coagulation NN o
activity NN o
and CC o
D-dimer NNP o
. . o

These DT N
findings NNS N
are VBP N
compatible JJ N
with IN N
the DT N
lack NN N
of IN N
efficacy NN N
of IN N
enoxaparin NN i
in IN N
reducing VBG N
ischemic JJ N
deficit NN N
after IN N
SAH NNP N
. . N

-DOCSTART- -X- O O

[ IN p
The DT p
use NN p
of IN p
cephalosporins NNS i
in IN p
hospital NN p
practice NN p
] NN p
. . N

-DOCSTART- -X- O O

Phase NN N
I PRP N
pharmacokinetic JJ N
, , N
food NN N
effect NN N
, , N
and CC N
pharmacogenetic JJ N
study NN N
of IN N
oral JJ N
irinotecan JJ i
given VBN N
as IN N
semisolid JJ N
matrix NN N
capsules NNS N
in IN N
patients NNS p
with IN p
solid JJ p
tumors NNS p
. . p

PURPOSE NNP N
To TO N
characterize VB N
the DT N
maximum-tolerated JJ N
dose NN N
, , N
recommended VBD N
dose NN N
, , N
dose-limiting JJ N
toxicities NNS N
( ( N
DLT NNP N
) ) N
, , N
pharmacokinetic JJ N
profile NN N
, , N
and CC N
food NN N
effect NN N
of IN N
orally RB N
administered VBN N
irinotecan JJ i
formulated VBN N
as IN N
new JJ N
semisolid JJ N
matrix NN N
capsules NNS N
. . N

EXPERIMENTAL NNP N
DESIGN NNP N
Irinotecan NNP i
was VBD N
given VBN N
orally RB N
in IN N
fasted JJ p
patients NNS p
once RB N
daily JJ N
for IN N
5 CD N
consecutive JJ N
days NNS N
and CC N
repeated VBD N
every DT N
3 CD N
weeks NNS N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
take VB N
the DT N
drug NN N
along IN N
with IN N
a DT N
high-fat JJ i
, , i
high-calorie JJ i
breakfast NN i
for IN N
the DT N
administration NN N
at IN N
day NN N
1 CD N
of IN N
the DT N
first JJ N
or CC N
second JJ N
cycle NN N
. . N

Dosages NNS N
tested VBN N
were VBD N
70 CD N
and CC N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
. . N

RESULTS NNP N
Twenty-five JJ p
patients NNS p
received VBD N
101 CD N
cycles NNS N
of IN N
therapy NN N
( ( N
median JJ N
two CD N
cycles NNS N
, , N
range VB N
1-15 JJ N
) ) N
. . N

During IN N
the DT N
first JJ N
cycle NN N
, , N
grade VBD o
3 CD o
delayed VBN o
diarrhea NN o
and CC o
grade VBD o
3 CD o
fever NN o
were VBD N
the DT N
DLTs NNP N
at IN N
the DT N
dosage NN N
of IN N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
in IN N
three CD N
out IN N
of IN N
five CD N
patients NNS N
. . N

Hematologic NNP o
and CC o
nonhematologic JJ o
toxicities NNS o
were VBD N
mild JJ N
to TO N
moderate VB N
. . N

Exposure NN o
to TO o
the DT o
active JJ o
metabolite JJ o
SN-38 NN o
was VBD N
relatively RB N
high JJ N
compared VBN N
with IN N
i.v NN N
. . N

infusion NN N
, , N
but CC N
no DT N
relevant JJ N
accumulation NN N
was VBD N
observed VBN N
. . N

Food NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
irinotecan JJ i
pharmacokinetics NNS N
. . N

One CD N
confirmed VBD N
partial JJ o
remission NN o
and CC N
10 CD N
disease NN o
stabilizations NNS o
were VBD N
observed VBN N
in IN N
previously RB N
treated VBN N
patients NNS N
. . N

No DT N
association NN N
was VBD N
found VBN N
between IN N
the DT N
UGT1A1*28 NNP N
genotype NN N
and CC N
the DT N
risk NN N
of IN N
severe JJ o
irinotecan-induced JJ o
toxicity NN o
. . o

CONCLUSIONS NNP N
For IN N
oral JJ N
irinotecan JJ i
, , N
a DT N
dose NN N
of IN N
70 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
every DT N
3 CD N
weeks NNS N
is VBZ N
recommended VBN N
for IN N
further JJ N
studies NNS N
. . N

Delayed NNP N
diarrhea NN N
was VBD N
the DT N
main JJ N
DLT NNP N
, , N
similar JJ N
to TO N
that DT N
observed VBN N
with IN N
intravenously RB N
administered VBN N
irinotecan JJ N
. . N

This DT N
study NN N
confirms VBZ N
that IN N
oral JJ N
administration NN N
of IN N
irinotecan JJ i
is VBZ N
feasible JJ N
and CC N
may MD N
have VB N
favorable JJ N
pharmacokinetic JJ N
characteristics NNS N
. . N

-DOCSTART- -X- O O

Wrist JJ N
Rehabilitation NNP N
Assisted NNP N
by IN N
an DT N
Electromyography-Driven JJ i
Neuromuscular JJ i
Electrical JJ i
Stimulation NNP i
Robot NNP i
After IN N
Stroke NNP p
. . p

BACKGROUND NNP N
Augmented NNP i
physical JJ i
training NN i
with IN i
assistance NN i
from IN i
robot NN i
and CC i
neuromuscular JJ i
electrical JJ i
stimulation NN i
( ( i
NMES NNP i
) ) i
may MD N
introduce VB N
intensive JJ N
motor NN N
improvement NN N
in IN N
chronic JJ N
stroke NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
rehabilitation NN N
effectiveness NN N
achieved VBN N
by IN N
NMES NNP i
robot-assisted JJ i
wrist NN i
training NN i
and CC N
that IN N
by IN N
robot-assisted JJ i
training NN i
. . i

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
single-blinded JJ N
randomized NN N
controlled VBD N
trial NN N
with IN N
a DT N
3-month JJ N
follow-up NN N
. . N

Twenty-six JJ p
hemiplegic JJ p
subjects NNS p
with IN p
chronic JJ p
stroke NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
20-session JJ i
wrist NN i
training NN i
with IN i
an DT i
electromyography NN i
( ( i
EMG NNP i
) ) i
-driven RB i
NMES NNP i
robot NN i
( ( N
NMES NNP N
robot NNP N
group NN N
, , N
n RB N
= VBZ N
11 CD N
) ) N
and CC N
with IN N
an DT N
EMG-driven JJ i
robot NN i
( ( N
robot JJ N
group NN N
, , N
n RB N
= VBZ N
15 CD N
) ) N
, , N
completed VBD N
within IN N
7 CD N
consecutive JJ N
weeks NNS N
. . N

Clinical JJ o
scores NNS o
, , o
Fugl-Meyer NNP o
Assessment NNP o
( ( o
FMA NNP o
) ) o
, , o
Modified NNP o
Ashworth NNP o
Score NNP o
( ( o
MAS NNP o
) ) o
, , o
and CC o
Action NNP o
Research NNP o
Arm NNP o
Test NNP o
( ( o
ARAT NNP o
) ) o
were VBD N
used VBN N
to TO N
evaluate VB N
the DT N
training NN N
effects NNS N
before IN N
and CC N
after IN N
the DT N
training NN N
, , N
as RB N
well RB N
as IN N
3 CD N
months NNS N
later RB N
. . N

An DT N
EMG NNP N
parameter NN N
, , N
muscle NN N
co-contraction NN N
index NN N
, , N
was VBD N
also RB N
applied VBN N
to TO N
investigate VB N
the DT N
session-by-session JJ N
variation NN N
in IN N
muscular JJ N
coordination NN N
patterns NNS N
during IN N
the DT N
training NN N
. . N

RESULTS VB N
The DT N
improvement NN o
in IN o
FMA NNP o
( ( o
shoulder/elbow NN o
, , o
wrist/hand NN o
) ) o
obtained VBN N
in IN N
the DT N
NMES NNP i
robot NN i
group NN N
was VBD N
more RBR N
significant JJ N
than IN N
the DT N
robot NN N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Significant JJ N
improvement NN o
in IN o
ARAT NNP o
was VBD N
achieved VBN N
in IN N
the DT N
NMES NNP N
robot NN N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
but CC N
absent NN N
in IN N
the DT N
robot NN N
group NN N
. . N

NMES NNP N
robot-assisted JJ N
training NN N
showed VBD N
better JJR o
performance NN o
in IN N
releasing VBG o
muscle NN o
co-contraction NN o
than IN N
the DT N
robot-assisted JJ N
across IN N
the DT N
training NN N
sessions NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
NMES NNP i
robot-assisted JJ i
wrist NN i
training NN i
was VBD N
more RBR N
effective JJ N
than IN N
the DT N
pure JJ N
robot NN N
. . N

The DT N
additional JJ N
NMES NNP N
application NN N
in IN N
the DT N
treatment NN N
could MD N
bring VB N
more JJR N
improvements NNS N
in IN N
the DT N
distal JJ N
motor NN N
functions NNS N
and CC N
faster JJR N
rehabilitation NN N
progress NN N
. . N

-DOCSTART- -X- O O

Loss NNP N
of IN N
tooth JJ N
substance NN N
during IN N
root NN i
planing VBG i
with IN N
various JJ N
periodontal JJ N
instruments NNS N
: : N
an DT N
in IN N
vitro NN N
study NN N
. . N

Ultrasonic JJ i
and CC i
power-driven JJ i
instrumentation NN i
is VBZ N
gaining VBG N
in IN N
significance NN N
as IN N
an DT N
acceptable JJ N
alternative NN N
to TO N
manual JJ N
periodontal JJ N
root NN N
treatment NN N
. . N

Some DT N
question NN N
whether IN N
they PRP N
do VBP N
not RB N
remove VB N
too RB N
much JJ N
tooth DT N
substance NN N
. . N

Various JJ i
ultrasonic JJ i
scalers NNS i
, , i
hand NN i
instruments NNS i
and CC i
two CD i
power-driven JJ i
systems NNS i
were VBD N
compared VBN N
by IN N
assessing VBG N
the DT N
loss NN o
of IN o
tooth JJ o
substance NN o
due JJ N
to TO N
root VB N
instrumentation NN N
. . N

Quantitative JJ N
analysis NN N
of IN N
this DT N
effect NN N
of IN N
the DT N
instruments NNS N
used VBN N
was VBD N
performed VBN N
on IN N
20 CD p
freshly RB p
extracted VBN p
, , p
non-periodontally RB p
involved VBN p
, , p
large JJ p
human JJ p
molars NNS p
. . p

In IN N
the DT N
first JJ N
study NN N
, , N
40 CD p
specimens NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
of IN N
treatment NN N
: : N
combined VBN N
use NN N
of IN N
ultrasonic JJ i
scaler NN i
and CC i
Periopolisher NNP i
diamond-coated JJ i
inserts NNS i
( ( i
US-POL NNP i
) ) i
, , i
hand NN i
instruments NNS i
( ( i
MANUAL NNP i
) ) i
, , i
Perioplaner-Periopolisher NNP i
system NN i
( ( i
PPL-POL NNP i
) ) i
and CC i
Periokit NNP i
ultrasonic-designed JJ i
scalers NNS i
( ( i
PERIOKIT NNP i
) ) i
. . i

The DT N
second JJ N
study NN N
involved VBN N
two CD N
treatment NN N
groups NNS N
, , N
ultrasonic JJ i
scaler NN i
alone RB i
and CC i
hand NN i
instruments NNS i
, , N
each DT N
allocated VBN N
with IN N
20 CD N
teeth NNS N
( ( N
small JJ N
root NN N
fragments NNS N
) ) N
. . N

An DT N
unpaired JJ N
two-tailed JJ N
t NN N
test NN N
was VBD N
carried VBN N
out RP N
for IN N
both DT N
studies NNS N
to TO N
compare VB N
the DT N
average JJ N
weight JJ o
loss NN o
of IN o
root JJ o
substance NN o
with IN N
the DT N
modes NNS N
of IN N
instrumentation NN N
. . N

The DT N
level NN N
of IN N
significance NN N
was VBD N
set VBN N
at IN N
p JJ N
< NNP N
or=0.05 NN N
. . N

The DT N
overall JJ N
results NNS N
of IN N
the DT N
first JJ N
and CC N
second JJ N
experimental JJ N
trials NNS N
did VBD N
not RB N
reveal VB N
obvious JJ N
differences NNS N
in IN N
weight JJ o
loss NN o
between IN N
the DT N
manual JJ N
, , N
ultrasonic JJ N
or CC N
power-driven JJ N
root NN N
treatments NNS N
. . N

Based VBN N
on IN N
the DT N
results NNS N
of IN N
these DT N
two CD N
comparative NN N
studies NNS N
, , N
the DT N
power-driven JJ N
inserts NNS N
or CC N
the DT N
various JJ N
ultrasonic JJ N
scalers NNS N
tested VBD N
did VBD N
not RB N
remove VB o
more RBR o
tooth JJ o
substance NN o
than IN N
conventional JJ N
hand NN N
instruments NNS N
. . N

They PRP N
may MD N
thus RB N
be VB N
a DT N
useful JJ N
alternative NN N
for IN N
the DT N
debridement NN N
of IN N
root NN N
surfaces NNS N
. . N

